

V^e Conférence
internationale sur le



5571095.0005.002

Le défi scientifique et social



V International
Conference on

The Scientific and Social Challenge



SECTION A



SECTION B



SECTION C



SECTION D



SECTION E



SECTION F



SECTION G



SECTION H



SECTION I



**Médias
Media**



**Retransmission
Overflow**



**Affiches
Posters**

SIDART

*La V^e Conférence internationale
sur le SIDA remercie les
organismes suivants pour
leur généreuse contribution:*

*The V International Conference
on AIDS thanks the following
organizations for their generous
contributions:*

Santé et Bien-être social Canada
Health and Welfare Canada

L'Agence canadienne de développement international
Canadian International Development Agency

Le Centre de recherches pour le développement international
International Development Research Centre

L'Organisation mondiale de la santé/World Health Organization

Le Gouvernement du Québec – Ministère de la Santé
et des Services sociaux

Le Secrétariat d'État du Canada/Secretary of State of Canada

Sandoz

Australian International Development Agency

La Société canadienne de la Croix Rouge
The Canadian Red Cross Society

La Commission des Communautés européennes
Commission of the European Communities

Overseas Development Administration—Britain

L'Industrie des assurances de personnes au Canada
The Life and Health Insurance Companies in Canada

Organon-Teknika

Le Gouvernement du Québec – Ministère du Tourisme

Admiral Travel Agencies Ltd.

Voyageur Travel Services

The Upjohn Company

Schering Canada, Inc.

Genentech Inc.

Syntex

V^e Conférence
internationale sur le

SIDA



V International
Conference on

AIDS

**Le défi
scientifique
et social**

**The Scientific
and Social
Challenge**

Montréal (Québec) Canada
du 4 au 9 juin 1989

Montréal, Québec, Canada
June 4 - 9, 1989

Parrainée par le

Centre de recherches pour le
développement international,
Santé et Bien-être social Canada, et
l'Organisation mondiale de la santé

Sponsored by the

International Development
Research Centre,
Health and Welfare Canada, and the
World Health Organization

En association avec:

La Société internationale sur le SIDA

In association with:

The International AIDS Society

ISBN: 0-662-56670-X

No de catalogue Catalogue No.: E97-1/1989

Adresse postale, Postal Address: C.P./P.O. Box 8500, Ottawa (Ontario) K1G 3H9
Silège social, Head Office: 250, rue Albert Street, Ottawa (Ontario)

© 1989, Le Centre de recherches pour le développement international
(en ce qui a trait à la compilation seulement).

Le Centre de recherches pour le développement international encourage l'utilisation de cette
compilation à des fins non-lucratives. Cependant, le Centre de recherches pour le développement
international ne réclame pas les droits d'auteur concernant les abrégés individuels mêmes.

© 1989, International Development Research Centre (in compilation only).

The International Development Research Centre encourages use of this compilation for non-profit
purposes. However, the International Development Research Centre does not claim copyright in the
individual abstracts themselves.

**ABRÉGÉS
ABSTRACTS**

Table des matières

Message du Président du Comité du programme	4
COMITÉS ET PERSONNEL	9
Groupe directeur	10
Comité du programme	10
Membres internationaux	11
Liste des réviseurs	15
Comité des communications	19
Comité opérationnel	19
Équipe de gestion	19
Personnel de la conférence	20
SOMMAIRE DE LA SEMAINE	21
PROGRAMME DES PLÉNIÈRES	33
ABRÉGÉS	39
Clés de l'index	40
Section A	
Épidémiologie et santé publique	43
Section B	
Aspects cliniques	185
Section C	
Recherche fondamentale (biomédicale)	507
Section D	
Le SIDA et l'individu	693
Section E	
SIDA, la société et le comportement	813
Section F	
Droit et éthique	939
Section G	
Implications internationales	969
Section H	
Répercussions économiques du SIDA	1027
Section I	
Audiovisuel	1063
COMMANDITAIRES PRINCIPAUX	1075
INDEX	1097
Index des auteurs	1098
Index vidéo	1232
Index des mots clés	1234

Message from the Programme Committee Chairman	6
COMMITTEES AND PERSONNEL	9
Steering Group	10
Programme Committee	10
International Members	11
List of Reviewers	15
Communications Committee	19
Operations Committee	19
Management Team	19
Conference Personnel	20
WEEK AT A GLANCE	21
OVERALL PLENARY PROGRAMME	33
ABSTRACTS	39
Key to Indexing	41
Section A	
Epidemiology and Public Health	43
Section B	
Clinical Aspects	185
Section C	
Basic Research (Biomedical)	507
Section D	
AIDS and the Individual	693
Section E	
AIDS, Society and Behaviour	813
Section F	
Ethics and Law	939
Section G	
International Issues	969
Section H	
The Economic Impact of AIDS	1027
Section I	
Audiovisual	1063
MAJOR SPONSORS	1075
INDEX	1097
Authors' Index	1098
Video Index	1232
Keyword Index	1234

Table of Contents

**Message
du Président
du comité
du programme**

**V^e Conférence internationale sur le SIDA
SOUS LE SIGNE DE LA SOLIDARITÉ**

En tant que président du Comité du programme de la V^e Conférence internationale sur le SIDA, je tiens d'abord à vous remercier chaleureusement d'avoir accepté notre invitation. Votre présence, ainsi que celle de vos nombreux collègues, est un témoignage éloquent de la solidarité qui unit tous les participants de cette rencontre exceptionnelle.

Il nous est permis, au-delà des mots, de croire que ce congrès sortira vraiment de l'ordinaire. D'abord, par son ampleur : plus de 10 000 délégués, 1 000 représentants des médias et 1 000 représentants de compagnies et d'organisations. Mais surtout, par la philosophie profondément humaniste qui l'animera.

L'observateur qui aura suivi attentivement, depuis Atlanta en 1985, la série de conférences internationales sur le SIDA, aura noté à quel point ces rencontres se sont progressivement décloisonnées. À l'origine, on s'en souviendra, la Conférence abordait quasi exclusivement des thèmes biomédicaux. Mais graduellement, les chercheurs scientifiques ont dû se rendre à l'évidence : le SIDA n'était pas seulement un problème médical, mais aussi un drame humain.

Bien sûr, nous savons tous que la solution ultime verra éventuellement le jour dans un laboratoire. Mais entre-temps, qu'est-ce que le virologue ou le microbiologiste peuvent proposer au sidéen et à ses proches pour alléger leur fardeau? Pour les aider à lutter contre l'ignorance et l'intolérance qui, chaque jour, se font plus présents? Nos laboratoires sont des lieux d'espoir; notre conscience nous interdit de les laisser se transformer en ghettos. Devant les extrémismes qui pointent à l'horizon, il est de notre devoir à tous de contribuer à l'élargissement et à l'approfondissement de l'étude du SIDA. Agir autrement serait inconscient, voire même cruel pour des millions de gens qui tournent vers nous des regards chargés d'espoir.

Le Congrès de Montréal innove donc en présentant officiellement une perspective multidisciplinaire, que résume bien son thème : "Le SIDA : défi scientifique et social." Le programme de la rencontre reflète précisément cette approche intégrée, puisque 30 % des séances toucheront les divers aspects sociaux du problème. Dilution du contenu biomédical? Aucune crainte n'est permise à ce sujet : dans les seuls domaines de l'épidémiologie, des aspects cliniques et de la recherche fondamentale, on compte plus d'une centaine de séances et près de 550 conférenciers—plus que toute autre rencontre auparavant. Miroir de cette nouvelle approche, le recueil des résumés vous propose une somme de 5 539 textes qui s'attaquent tant aux dimensions médicales que sociales du SIDA.

Plus humaine, donc, l'approche. Et à la fois plus internationaliste. Car avouons-le, il restait à la série de conférences internationales sur le SIDA à véritablement s'internationaliser. Avec le recul du temps, il nous apparaît évident que le Tiers Monde n'a peut-être pas occupé toute la place qui lui revenait lors des précédentes rencontres. Situation paradoxale quand on sait que la pandémie a des conséquences particulièrement graves dans le Tiers Monde : les plus récentes statistiques font état d'un taux d'infection atteignant jusqu'à 20 % chez la population hétérosexuelle de certaines grandes villes.

Les organisateurs de la conférence de Montréal n'ont pas hésité : ils ont tout mis en oeuvre pour accroître la participation du Tiers Monde. En consultant des chercheurs des pays en voie de développement sur les questions d'organisation. En commanditant des conférences préparatoires en Afrique, en Asie et en Amérique latine pour déterminer les attentes des chercheurs locaux face à l'événement. Le Canada, par l'entremise de l'Agence canadienne de développement international (ACDI) et de différents organismes dans d'autres pays occidentaux, a aussi apporté une assistance financière pour assurer cette participation.

Enfin, nous avons veillé à ce que la Conférence demeure un instrument privilégié pour sensibiliser les populations, les décideurs et les pouvoirs publics du monde entier. La Conférence de Montréal utilise abondamment la technologie audiovisuelle et des expositions artistiques à des fins didactiques. Elle innove aussi en facilitant une participation hors murs du grand public. Toujours dans cet esprit d'ouverture sur le monde, les organisateurs ont établi que les langues officielles de la Conférence seront l'anglais et le français. Des traductions simultanées dans ces deux langues sont offertes en tout temps, ainsi qu'en espagnol aux séances plénières.

Dans la foulée des premières rencontres, la Conférence de Montréal est elle aussi une tribune internationale favorisant l'échange d'information. Mais plus encore, nous avons voulu qu'elle se signale par une convergence sans précédent de toutes les énergies et compétences disponibles. À l'heure de l'interdépendance planétaire, au-delà des barrières professionnelles et des divergences de toute nature, la solidarité de la communauté internationale face au problème du SIDA s'impose plus que jamais. Ce n'est qu'à ce prix que des millions de gens démunis pourront légitimement entretenir l'un des biens les plus précieux qu'il leur reste : l'espoir.

Richard A. Morisset, M.D.

Président du Comité du programme de la V^e Conférence internationale sur le SIDA

**Message From
the Programme
Committee
Chairman**

**V International Conference on AIDS
UNDER THE BANNER OF SOLIDARITY**

As Chairman of the Program Committee for the V International Conference on AIDS, first let me cordially thank you for accepting our invitation. Your presence here, alongside your numerous colleagues, attests eloquently to the solidarity binding everyone attending this exceptional meeting.

For we have solid reason to believe that this conference will really be an extraordinary one. First, because of its scope: over 10,000 delegates, 1,000 media representatives and 1,000 corporate and organizational delegates. But above all, by the profoundly humanistic philosophy guiding it.

Anyone who has kept a close watch on the series of International Conferences on AIDS that began in Atlanta in 1985 will have noticed how these encounters have gradually opened up. Originally, you will recall, the meetings dealt almost exclusively with biomedical topics. Yet scientists soon had to admit that AIDS is not simply a medical problem, but also a human drama.

Naturally, we all know that the ultimate solution will eventually come to light in a laboratory. But meanwhile, what can the virologist or microbiologist offer an AIDS victim and his or her loved ones to ease their burden? To help them combat the ignorance and intolerance they face, which are growing day by day? Our laboratories are realms of hope; our conscience forbids us from turning them into ghettos. Facing the extremists looming to the horizon, we all have a duty to help broaden and deepen research into AIDS. To act in any other way would be unconscionable, if not cruel to the millions of people looking to us with profound hope.

The Montreal Conference represents an innovation in that it officially presents a multidisciplinary view neatly summarized in its theme: "AIDS: A Scientific and Social Challenge." The program for this meeting accurately reflects this integrated approach, since 30% of the sessions will deal with various social aspects of the problem. Will this dilute its biomedical content? That need scarcely be feared: in the fields of epidemiology, clinical aspects and basic research alone, there will be over 100 sessions and almost 550 speakers—more than at any previous conference. Mirroring our new approach, the collected abstracts cover a total of 5,539 papers that tackle both the medical and social dimensions of AIDS.

Definitely a more human approach. And at the same time a more international one. For we must admit that our series of international conferences on AIDS have yet had to become genuinely international. With the passage of time, it became clear to us that the Third World may not have been playing its full role at past meetings. This is paradoxical, since we know that the pandemic is having especially serious consequences in the Third World: the most recent statistics indicate an infection rate covering almost 20% of the heterosexual population in some major cities.

The organizers of the Montreal Conference have made every effort to increase Third World participation. They have consulted scientists from developing countries on organizational matters. They have sponsored preparatory conferences in Africa, Asia and Latin America to determine what local scientists expect from the event. Canada, through the Canadian International Development Agency (CIDA) and various organizations in other western countries, has also provided financial assistance to ensure Third World participation.

Finally, we saw to it that this Conference will be a special means of raising the consciousness of the general public, decisionmakers and public authorities around the world. The Montreal Conference will use a wealth of audiovisual technology and art exhibits for educational purposes. It is also innovating by making it easier for the general public to participate extramurally. In this same spirit of openness to the world, the organizers have decided that the Conference's official languages will be English and French. Simultaneous translation into either language will be available at all times, along with Spanish at the plenary sessions.

Like its predecessors, the Montreal Conference is an international forum promoting the exchange of information. But even more, we wanted it to signal an unprecedented convergence of all the available energy and skills. In the era of the global village, leaving behind professional barriers and differences of every kind, the international community's solidarity in confronting the problem of AIDS is more vital than ever. It is at this price alone that millions of people can legitimately nourish one of their most valuable remaining possessions: hope.

Richard A. Morisset, M.D.
*Program Committee Chairman of the V International
Conference on AIDS*

Comités et personnel

Committees and
Personnel

La V^e Conférence internationale sur le SIDA remercie chaleureusement tous ceux qui ont contribué de leur temps et de leurs énergies à la réalisation de cet événement.

The V International Conference on AIDS wishes to express its gratitude to all those who have contributed to this event's success.

**Groupe directeur
Steering Group**

Président/Chairman
Ivan L. Head
Marie Berlinguet
Manuel Carballo
Alastair J. Clayton

Joel Finlay
Lars Olof Kallings
Jonathan M. Mann
Richard A. Morisett
Martin T. Schechter

*Directeur général/
Executive Director*
Claude Paul Boivin

**Comité du
programme
Programme
Committee**

Président/Chairman
Richard A. Morisett
A.
Épidémiologie et santé
publique
Epidemiology and Public
Health

*Coordonnateur/
Coordinator*
Robert S. Remis
Michel Alary
Randall A. Coates
Richard Lessard
Francis A. Plummer
Michael Rekart

B.
Aspects cliniques
Clinical Aspects

*Coordonnateur/
Coordinator*
Michel G. Bergeron
Mary M. Fanning
Norbert J. Gilmore
Sabih R. Khan
Diane Lalande
Normand Lapointe
Julio S.G. Montaner
John R. Ruedy
Emil Toma
Christos M. Tsoukas

C.
Recherche fondamentale
(biomédicale)
Basic Research (Biomedical)

*Coordonnateur/
Coordinator*
Mark A. Wainberg

Paul Jolicoeur
Jean Latreille
Michael V. O'Shaughnessy
Louis F. Quiltière
Stanley E. Read

D.
Le SIDA et l'individu
AIDS and the Individual

*Coordonnateurs/
Coordinators*
Catherine Hankins
Michel R. Morissette
Alix Adrien
Barbara Jones
Bryce Larke
Jaime Smith
Margaret A. Somerville

E.
Le SIDA, la société et
le comportement
AIDS, Society and Behaviour

*Coordonnateur/
Coordinator*
Pierre Dionne
David Bennett
Gilles Bibeau
Richard Burzynski
Elaine Carey-Bélanger
Guy R. Descary
Donald De Gagné
Miriam Green
Jean Robert
Sorin Sonea
Anne Usher
Anne V. Whyte

F.
Droit et éthique
Ethics and Law

*Coordonnateurs/
Coordinators*
David J. Roy
Bernard Dickens
Jean-Louis Baudouin
Harry Grantham
Horace Krever
T. David Marshall
Manon Pomerleau

G.
Implications internationales
International Issues

Coordonnateurs/

Coordinators
Allan R. Ronald
Pierre Viens

Iona V. Campagnolo
Stephen Simon
Richard Wilson

H.
Répercussions économiques
du SIDA
The Economic Impact of
AIDS

Coordonnateurs/
Coordinators

Margaret Duckett
André-Pierre
Contandriopoulos

Rod Fraser
Steven Grover
Gilles Paquet
Jacques Ross

I.
Présentations
audiovisuelles
Audiovisual Presentations

Coordonnateur/
Coordinator
Ken Morrison

Andy Fabo
John Greyson
Colette Lachance
René Lavoie
Guy Lonergan
James Miller
Georges Tarjan
Tom Waugh

Président/Chairman
Dr. Richard A. Morisset

SECTION A

Roy M. Anderson
(United Kingdom)

June Balthazar
(Philippines)

C. Bartholomew
(Trinidad and Tobago)

Jean-Baptiste Brunet
(France)

John Chipanghwe
(Malawi)

James Chin
(WHO)

James Curran
(USA)

Donald Francis
(USA)

Neal Halsey
(USA)

Harold W. Jaffe
(USA)

Richard A. Kaslow
(USA)

Mads Melbye
(Denmark)

Gary R. Noble
(USA)

S.I. Okware
(Uganda)

June Osborn
(USA)

Jean Pape
(Haiti)
George Papaevangelou
(Greece)

Praphan Phanupak
(Thailand)

Peter Piot
(Belgium)

Alain Pompidou
(France)

Valentin Pokrovsky
(USSR)

Jaime Sepulveda
(Mexico)

Werasit Sittitrai
(Thailand)

Bertino Somaini
(Switzerland)

SECTION B

Robert E. Allen
(USA)

Nathan Clumeck
(Belgium)

David Cooper
(Australia)

J.P. Coulaud
(France)

Peter Eriki
(Sweden)

J. Goudsmit
(The Netherlands)

H. Husrev Hatemi
(Turkey)

Martin S. Hirsch
(USA)

King K. Holmes
(USA)

Leteiev Jemni
(Tunisia)

Helen I. Joller-Jemelka
(Switzerland)

Bila M. Kapita
(Zaire)

Marcy Kaplan
(USA)

Victor Lorian
(USA)

André Lefesvre
(France)

David Miller
(United Kingdom)

Yves Mouton
(France)

Abraham Morag
(Israel)

Rafael Najera
(Spain)

B. Oberg
(Sweden)

Jean-Claude Pechère
(Switzerland)

Roger A. Pradinaud
(Guyanne Française)

Paul Racz
(West Germany)

Willy Rozenbaum
(France)

Comité du programme
Membres internationaux
Programme Committee
International Members

Ethan Rubinstein
(Israel)
Merle Sande
(USA)
Gary Slutkin
(WHO)
Giuseppe Visco
(Italy)
Paul A. Volberding
(USA)
Hetty Waskin
(USA)
Constance Wofsy
(USA)
Fernando Zacharias
(WHO)

SECTION C

Françoise Barré-Sinoussi
(France)
Dani Bolognesi
(USA)
Françoise Brun-Vézinet
(France)
Jean-Claude Chermann
(France)
Angus Dalglish
(United Kingdom)
Freidrich Deinhardt
(FRG)
V. V. Delektorsky
(USSR)
Guy De The
(France)
Peter Ebbensen
(Denmark)
José Esparza
(WHO)
Myron Essex
(USA)
Anthony S. Fauci
(USA)
Eva-Maria Fenyo
(Sweden)
Robert C. Gallo
(USA)
Bernardo Galvao de Castro
(Brazil)
Gaetano Giraldo
(Italy)
Jean-Claude Gluckman
(France)

Ian D. Gust
(Australia)
William A. Haseltine
(USA)
Yorio Hinuma
(Japan)
Takashi Kitamura
(Japan)
David Klatzmann
(France)
George Klein
(Sweden)
Kai Krohn
(USA)
Jay A. Levy
(USA)
Souleymane M'Boup
(Senegal)
Fred Mhalu
(Tanzania)
Luc Montagnier
(France)
James Mullins
(USA)
Akira Oya
(Japan)
Gerald V. Quinnan
(USA)
Giovanni B. Rossi
(Italy)
Geoffrey C. Schild
(United Kingdom)
Pei-zhen Tao
(People Republic of
China)
Simon Wain-Hobson
(France)
Robin A. Weiss
(United Kingdom)
Flossie Wong-Staal
(USA)
Daniel Zagury
(France)

SECTION D

Lawrence Adeookun
(Nigeria)
Ernst Buning
(USA)
Manuel Carballo
(WHO)

Judith B. Cohen
(USA)
Roel Coutinho
(The Netherlands)
Robert G. Covell
(United Kingdom)
William Darrow
(USA)
Daniel Defert
(France)
Don C. Des Jarlais
(USA)
Michiko Fakazawa
(Japan)
Timothy W. Harding
(WHO)
Fathia Mahmoud
(Sudan)
Leonardo Mata
(Costa Rica)
Amir Mehryar
(Iran)
David Miller
(New Zealand)
Janet Mitchell
(USA)
Jan-Olaf Morfeldt
(Sweden)
Eustace Muhondwa
(Tanzania)
David Nabarro
(United Kingdom)
Elizabeth Ngugi
(Kenya)
D.S. Obikeze
(Nigeria)
Willie Pasini
(Switzerland)
Peter Selwyn
(USA)
Fritz Van Dam
(Holland)
Françoise Weil-Halpern
(France)

SECTION E

Donald Abrams
(USA)
Maxine Ankrach
(Uganda)
Jacqueline Bonneau
(France)

Doreen Boyd
(Switzerland)
Jeffrey L. Carples
(USA)
Maria Da Penha Silva R.
Franco
(Brazil)
Iris L. Davis
(USA)
Fodé Diouf
(Senegal)
William Hartley
(New South Wales)
Aart Hendriks
(Denmark)
Paul Kawata
(USA)
André Raugot
(France)
Caitlin C. Ryan
(USA)
Renée Sabatier
(United Kingdom)
Inon Schenker
(Israel)
Kathleen Toomey
(USA)
Edouard Vincke
(Belgium)
Akiko Yagi
(Japan)

SECTION F

John Arras
(USA)
Ronald Bayer
(USA)
Vera Boltho-Massarelli
(France)
Edouard Boné
(Belgium)
Susan S. Connor
(USA)
Robert Delizee
(Belgium)
Cécile De Sweener
(Senegal)
Sev S. Fluss
(WHO)
Raanan Gillon
(United Kingdom)

Kevin Gordon
(USA)
Larry Gostin
(USA)
Albert R. Jonsen
(USA)
Ian M. Kennedy
(United Kingdom)
Rihito Kimura
(Japan)
Michael Kirby
(Australia)
Nancy Lee Jones
(USA)
Robert Levine
(USA)
Ruth Macklin
(USA)
Wendy K. Mariner
(USA)
Vivienne H. Nathanson
(United Kingdom)
Henriette D.C. Roscam
Abbing
(The Netherlands)
Earl E. Shelp
(USA)
Manfred Steinbach
(Federal Republic of
Germany)
Père Paul Sye
(Korea)

SECTION G

G. P. Acharya
(Nepal)
Kazem Behbehani
(Kuwait)
Ngaly Bosenge
(Zaire)
Christophe Bouramoué
(Congo)
Pedro Cahn
(Argentina)
Geoffrey Carliner
(USA)
M. Chakravarty
(India)
C. S. Chutani
(India)
Vincent Dan
(Benin)

Gloria Echeverria de Perez
(Venezuela)
Oscar Fay
(Argentina)
A. J. Georges
(Central Africa Republic)
Lair Guerra de Macedo
Rodríguez
(Brazil)
Ali Guindo
(Mali)
Indira Kapoor
(India)
Lazare Kaptue
(Cameroun)
Ong Kok Hai
(Malaysia)
Yamil H. Kouri
(USA)
A. S. Lalif
(Zimbabwe)
Francisco A. Machado
Ramirez
(Cuba)
A. N. Malaviya
(India)
Mguemby C. Mbina
(Gabon)
Ofelia Monzon
(Philippines)
Mutama Mugambi
(Kenya)
M. Mukunyandela
(Zambia)
L. Muyenbe-Tamfum
(Zaire)
Bernardin Niragira
(Burundi)
Didace Nzaramba
(Rwanda)
Patricia O'Connor
(Costa Rica)
A. O. Osoba
(Saudi Arabia)
A. Outtara
(Côte d'Ivoire)
Khyrhed Pavri
(India)
Nihal Perera
(Sri Lanka)
Arletty Pinel
(Brazil)

Femi Soyinka
(Nigeria)
Ronald St. John
(USA)
Sundararaman Swaminathan
(India)
Daniel Tarantola
(WHO)
Amnuay Traisupa
(Thailand)
J. L. Valdespino
(Mexico)
Jack Wirima
(Malawi)
Ong Yong Wan
(Singapore)

SECTION H

Dennis Andrulis
(USA)
Jacques Baudouy
(USA)
Gabriel Bez
(France)
Geoffrey Carliner
(USA)
Nick Drager
(WHO)
Anne Johnson
(United Kingdom)
Kenneth Kizer
(USA)
Guiseppa Marasca
(Italy)
Mary Pittman-Lindeman
(USA)

SECTION I

Christa Brunswicher
(Switzerland)
Jan Zita Grover
(USA)
Len Hilgermann
(USA)
Manfred Sahlsberg
(FRG)
Wieland Speck
(West Germany)
Jacques Vandembourghé
(France)
Simon Watney
(UK)

ABRAMS, Donald
 Canada
 ADEOKUN, Lawrence
 Switzerland
 ADLER, Michael
 United Kingdom
 AMARAL, Leonard
 USA
 ANATRELLA, Tony
 France
 ANCELLE-PARK,
 Rosemary
 France
 ARMSTRONG, Donald
 USA
 BANISTER, Philip
 Canada
 BARRY, David
 USA
 BARUCHEL, Sylvain
 Canada
 BAUDOUIN, Jean-Louis
 Canada
 BAYARDELLE, Paul
 Canada
 BAYES, Ramon
 Spain
 BEAULIEU, Raymond
 Canada
 BENSON, Francis
 USA
 BERNARD, Jean-Marc
 Canada
 BERKELMAN, Ruth
 USA
 BLANCHE, Stéphane
 France
 BLATHERWICK, F.J.
 Canada
 BLATTNER, William
 USA
 BOTEZ, M.I.
 Canada
 BOTTIGER, Margareta
 Sweden
 BOUCHER, Wark
 Canada
 BOWEN, Stephen
 USA
 BREW, Bruce
 USA
 BRENNER, Graziella
 Brazil
 BRODEUR, Bernard
 Canada
 BROOKMEYER, Ron
 USA
 BRUNDAGE, John
 USA
 BRUNEAU, Julie
 Canada
 BUCHAN, Kenneth
 Canada
 CAMERON, William
 Canada
 CAMIRAND, François
 Canada
 CAMPBELL, Alain
 USA
 CARAEL, Michel
 Switzerland
 CATALAN, François
 France
 CATANIA, Joseph
 USA
 CHAMBERLAND, Mary
 USA
 CHAMPAGNE, François
 Canada
 CHANDRA, Ranjit
 Canada
 CHIASSON, Mary Ann
 USA
 CHOUNARD, Guy
 Canada
 CHURCH, Joseph A.
 USA
 CLAVEL, François
 USA
 COLEBUNDERS, Robert
 Belgium
 CONNOR, Susan
 USA
 CÔTE, Louise
 Canada
 DARROW, William
 USA
 DAVIS, Jeffrey
 USA
 DAVIS, Michael
 Canada
 DEBELLEFEUILLE, Roger
 Canada
 DECARY, Francine
 Canada
 DEGNER, Lesley
 USA
 DELLAMONICA, Pierre
 France
 DEMONTIGNY, Johanne
 Canada
 DERY, Pierre
 Canada
 DETELS, Roger
 USA
 DEVINS, Jerry
 Canada
 DILLEY, James
 USA
 DIONNE, Gervais
 Canada
 DIONNE, Marc
 Canada
 DONDERO, Timothy
 USA
 DORMONT, Dominique
 France
 DROLET, Marie
 Canada
 DUCIC, Slobodan
 Canada
 DUPerval, Raymond
 Canada
 ELMSLIE, Kimberly
 Canada
 EMBREE, Joanne
 USA
 ENGLISH, Judith
 Canada
 ERNST, Jerome
 USA
 FALUTZ, Julian
 Canada
 FAREWELL, Vernon
 Canada
 FAUVEL, Micheline
 Canada
 FIETZ, Maggy
 Canada
 FINLAY, Joel
 Canada
 FISHER, William
 Canada
 FLETCHER, Malcolm
 Canada

Liste des réviseurs
List of Reviewers

FRANCIS, Gordon Canada	HOXIE, J.A. USA	LIFSON, Alan USA
FRENCH, Sheryl Canada	JASON, Janine USA	LINDSAY, Jocelyn Canada
GARREL, Dominique Canada	JEMME, Robert Canada	LOSOS, Joseph Canada
GEMME, Robert Canada	JOBIN, Jacques Canada	MACDONALD, Kristine USA
GEMMILL, Ian Canada	JOHNSON, Warren USA	MANGA, Pran India
GENEST, Serge Canada	JOLY, Jean Canada	MARTIN, John USA
GILL, Michael Canada	JONCKHEER, Tijl Belgium	MATHESON, David Canada
GILL, Peter Canada	JUDSON, Franklyn USA	McCORMICK, Anna United Kingdom
GLAUSER, Michel Suisse	KANG, Yong Canada	McFADDEN, Douglas Canada
GODIN, Gaston Canada	KARAKAS, Rita Canada	McLAUGHLIN, Bernadette Canada
GOEDERT, James USA	KAY, Kathleen Switzerland	McLEOD, Alastair Canada
GOLD, Julian Australia	KING, Alan Canada	MELTZER, Alan Canada
GOLDSTONE, Irene Canada	KINLOCH, David Canada	MENEZES, Jose Canada
GONZALEZ, Jose Norway	KOCH, Meinrad F.R.G.	MERVEILLE, Jean Canada
GORNITSKY, Mervyn Canada	KRAJESKI, James USA	MILLSON, Margaret Canada
GRADY, George USA	KRUECKL, Judy Canada	MONTPLAISIR, Serge Canada
GRISCELLI, Claude France	LABERGE-PERRON, Denise Canada	MORGAN, Meade USA
GROVER, Steven Canada	LAMOTHE, François Canada	MORSE, Dale USA
HADLER, James USA	LANDRY, Pierre Canada	MOSLEY, James USA
HALPERIN, Scott Canada	LAPOINTE, Normand Canada	MUNOZ, Alvaro USA
HANDSFIELD, Hunter USA	LAU, Allan Canada	MURPHY, Mike Canada
HARDY, Ann USA	LAWRENCE, Dale USA	MURRAY, Terry Canada
HAVERKOS, Harry USA	LEBEL, François Canada	MYERS, Michael Canada
HESSOL, Nancy USA	LEBLANC, Pierre Canada	NDOYE, Ibra Senegal
HISCOTT, John Canada	LEE, Sheena Canada	NERA, Nena Canada
HOLMBERG, Scott USA	LETENDRE, François Canada	NICHOLS, Larry USA

NOËL, Grégoire Canada	QUINN, Thomas USA	SHENKER, Inon Israel
NOVICK, Alan USA	RACHLIS, Anita Canada	SHEPERD, Frances
OAKI, Fred Canada	READI, Gabi Canada	SHERLOCK, Chris Canada
ONORATO, Ida USA	REDFIELD, Robert USA	SMITH, John Canada
OPPENHEIM, A.N. United Kingdom	RENE, Pierre Canada	SMITH, Linda Canada
ORR, Pamela Canada	RICE, George Canada	SOBOTA, Michael Canada
OSTROW, David USA	RIGAU, Jose USA	SOMMERS, Frank Canada
OZANNE, Gerard Canada	RIVIERE, Yves France	SONEA, Sorin Canada
O'SULLIVAN, Mary J. USA	ROBITAILLE, Norbert Canada	SONIGO, Pierre France
PAPPGIODNOU, Marguerite USA	ROMANOWSKI, Barbara Canada	SONNENBERG, Nathum Canada
PARKS, Wade USA	ROSENTHAL, Kenneth Canada	STEBEN, Marc Canada
PASINI, Willy Switzerland	ROSS, Paul USA	STEIGBIGEL, Neil USA
PECKHAM, Catherine United Kingdom	ROUSSEAU, Serge Canada	STERN, Michael Canada
PEKOVIC, Drasko Canada	RUTHERFORD, George USA	STEVENS, Cladd USA
PEREZ DE LEON, Adolfo Canada	RYDER, Robert USA	STONEBURNER, Rand USA
PETERSON, Lyle USA	SAAH, Alfred USA	STRICKLER, Albert Canada
PHAIR, Michael Canada	SACKS, Stephen Canada	TAPIA DE PERALTA, Irene
PHANEUF, Denis Canada	SAVIGNY, Don Canada	Venezuela
PHILLIPS, Anne Canada	SAVORY, Eve Canada	TAYLOR, Catherine Canada
PINDBORG, J.J. Denmark	SCHELCH, Walter Canada	TESSIER, Geneviève Canada
POISSON, Michel Canada	SCOTT, Gwendolyn USA	THIBODEAU, Lise Canada
POLLAK, Michel France	SEKALY, Rafick Canada	THOMAS, Pauline USA
PORTER, John United Kingdom	SELIK, Richard USA	THOMAS, Réjean Canada
PRICE, Richard USA	SEVGI, Arel USA	TIVEY, Bob Canada
QUALTIERE, Louis Canada	SHAFER, Mary-Ann USA	VALLEROY, Linda USA
QUENNEVILLE, Yves Canada	SHEARER, Robert Canada	VEGA, Carlos Canada

VOYRON, Jacques
France
WACHTER, Bob
USA
WALLACE, Evelyn
Canada
WARD, John
USA
WASS, Hilary
Canada
WAUGH, Michael
England
WEAVER, Michael
Canada

WEST, Roy
Canada
WILLIAMS, Trevor
Canada
WILLOUGHBY, Ann
USA
WILSON, Ruth
Canada
WORTMAN, Jay
Canada
WYKOFF, Randolph
USA
YARCHOAM, Robert
USA

Les membres du Comité du programme (canadien et international) et du Groupe directeur ont aussi revu des abrégés. Leurs noms n'apparaissent pas dans cette liste.

Members of the Programme Committee (Canadian and International) and the Steering Group also reviewed abstracts. Their names do not appear on this list.

Président/Chairman
David Nostbakken

Jon Baggaley
Claude Paul Boivin
Bernard Dagenais
Tom Elmslie
Anne Kern
Carole Peacock
Jean Robert
Serge Turgeon

Directrice des communications
Communications Director
Lyne Champoux

Comité des communications
Communications Committee

Président/Chairman
Joel Finlay

Claude Paul Boivin
Antoine Hawara
Nora Ritchie

Directrice générale adjointe
Deputy Director
Lyse Lavictoire

Comité Opérationnel
Operations Group

Directeur général
Executive Director
Claude Paul Boivin

Directrice générale adjointe
Deputy Director
Lyse Lavictoire

Équipe de gestion
Management Team

Directrice des communications
Director of Communications
Lyne Champoux

**Personnel de
la conférence
Conférence
Personnel**

**Secrétariat général
Executive Office**

CLÉROUX, Chantal
GOLTZ, Diane
LEMIEUX, Patrick
MORAND, Héléne
WARING, Bruce

**Secrétariat des
communications
Communications
Secretariat**

ARGUIN, Maurice
BOIVIN, Élise
CHEVALIER, Carmen
KLUSACEK, Allan
LALIBERTÉ, François
LUSSIER, Sophie

*Coordonnateur du SIDART
SIDART Coordinator:*
MORRISON, Ken

**Secrétariat des médias
Media Secretariat**

DURDIN, Martha
GOSSAGE, Patrick
IMRIE, Anne
MERCER, Alison
SHANNON, Kristin
SWITOCZ, Alice

Coordonnatrice/Coordinator:
FOX, Marie-Hélène

**Secrétariat de la
conférence**

Conférence Secretariat

BETTANY, Caroline
CHARBONNEAU, Denise
CRISTEL, Robert
FUKUSHIMA, Kuniko
GENDREAU, Louise
GUILLET, Valérie
HARDY, Joanne
KARVOUNIARIS, Tassy
LA RICCA, Lise
LEMME, Corie
LEVIN, Nurit
LIPOWSKI, Lisa
MACKIE, Isobel
MICHAUD, Véra

TAKAHATAKE, Masako
WOLOSCHUK, William
YAP, Yenny

*Vice-présidente
Vice-President
Kenness Canada:*
POLLACK, Danielle

**Secrétariat du
programme**

Programme Secretariat

BARRON, Craig
CAMPBELL, Sally
CORNEAU, Francine
DELLI COLLI, Sylvia
GUILLEMET, Nicole
HATCHWELL, Patrick
LAJOIE, Yoshiko
PALMER, Robert
STERN, Gary

Coordonnatrice/Coordinator:
FELICISSIMO, Lucy

ARA NO'VO DESIGN INC.; CENTRE
FÉDÉRAL SUR LE SIDA/FEDERAL
CENTER FOR AIDS; CORPAV;
COMPOSITION SOLIDAIRE INC. ;
C.R.D.I./I.D.R.C.: Bureau du trésorier/Office
of the Treasurer, Service de l'administration/
Administration Services, Division des
communications/Communications Division,
Bureau du conseiller juridique/Office of the
General Counsel; *Diffuseur-hôte*, SOCIÉTÉ
RADIO-CANADA/*Host Broadcaster*,
CANADIAN BROADCASTING
CORPORATION; GENDARMERIE
ROYALE DU CANADA/ROYAL
CANADIAN MOUNTED POLICE;
GLOBAL VILLAGE PRODUCTIONS;
LE GROUPE EXPOSITIONS INC.;
MULTICOM INTERNATIONAL
MONTRÉAL; OFFICE DU TOURISME

DU GRAND MONTRÉAL/GREATER
MONTRÉAL CONVENTION AND
TOURISM BUREAU; SERVICE DE
TRADUCTION SIMULTANÉE
INTERNATIONAL/INTERNATIONAL
SIMULTANEOUS TRANSLATION
SERVICE; PALAIS DES CONGRÈS;
PIXART; SCRIPTUM; SPACEBRIDGE
BROADCASTING INC.; TELAV

BAKER Ted, BRUNEAU Daniel, DE
VARENNES Lise-Anne, FLEURY
Jean-Marc, GILBERT Sylvie, JUTRAS
Michel, N'SELE KIBALABALA Paulin,
LEROUX Jean, MARTIN Gilles,
McKAGUE Ormond, NETTER Tom,
RIVEST Jacques, SCHILLER Denis,
TRUDEL, Jocelyne, YOUNG Tom,
ZARYN Barbara

Sommaire
de la semaine

Week at a
Glance

Samedi
3 juin

13 h à 20 h

Inscription

Palais des Congrès 100A *

Dimanche
4 juin

10 h à 19 h

Inscription

Palais des Congrès 100A

16 h 30 à 19 h

Cérémonie d'ouverture

Palais des Congrès

Président
Ivan Head
Président de la Conférence
Président, Centre de recherches
pour le développement international

Jonathan Mann
Directeur
Programme mondial OMS de lutte contre
le SIDA

Monsieur Robert Bourassa
Le Premier Ministre du Québec

Armand Frappier
Fondateur, Institut Armand Frappier
Montréal, Québec

Dame Nita Barrow
Représentante permanente de la Barbade
aux Nations Unies

Le Très Honorable
Brian Mulroney
Premier Ministre du Canada

Kevin Brown
Président émérite
Vancouver Persons with AIDS Society
Canada

Son Excellence
Kenneth Kaunda
Président de la République de la Zambie

20 h à 21 h 30

Réception d'ouverture

Complexe Desjardins

* Salle

13:00 to 20:00

Registration

Palais des Congrès 100A*

**Saturday
June 3**

10:00 to 19:00

Registration

Palais des Congrès 100A

**Sunday
June 4**

16:30 to 19:00

Opening Ceremonies

Palais des Congrès

Chairman
Ivan Head
Conference Chairman
President
International Development Research
Centre
Mr. Robert Bourassa
Prime Minister of Quebec

Dame Nita Barrow
Permanent Representative of Barbados at
the United Nations

Kevin Brown
Chairman Emeritus
Vancouver Persons with AIDS Society
Canada

Jonathan Mann
Director
Global Programme on AIDS
World Health Organization

Armand Frappier
Founder, Institut Armand Frappier
Montreal, Quebec

The Right Honourable
Brian Mulroney
Prime Minister of Canada

His Excellency
Kenneth Kaunda
President of the Republic of Zambia

20:00 to 21:30

Opening Reception

Complexe Desjardins

* Room number

8 h 30 à 10 h 30

« Nouvelles perspectives » — Plénière
Palais des Congrès 407 ABC*

11 h à 17 h 30

Présentations audiovisuelles Centre de conférences Guy-Favreau

11 h à 12 h 30

	page
A. Épidémiologie et santé publique	
• Études séro-épidémiologiques : États-Unis, 407 A	45
• SIDA/VIH : le sang et les produits sanguins, 408 A	46
• Autres rétrovirus : VIH-2 et HTLV-I/II, 408 BC	47
B. Aspects cliniques	
• Le VIH chez les enfants, 401 ABC	187
• (Table ronde) Coordination des soins : le point de vue du personnel, 403 ABC	188
• (Colloque) Infections à <i>Pneumocystis carinii</i> , 407 B	200
C. Recherche fondamentale (biomédicale)	
• (Colloque) Mécanismes de pathogénèse du VIH, 407 C	509
• Biologie moléculaire (partie 1) : Diversité génomique et ses liens aux aspects cliniques, 410 ABC	510
D. Le SIDA et l'individu	
• Recherches sur le comportement (partie I), 409 ABC	695
E. Le SIDA, la société et le comportement	
• (Colloque) Vivre avec le SIDA : le point de vue de personnes atteintes, 411 A	815
• (Atelier) Éducation-SIDA : Leçons à tirer des pays en voie de développement, 411 B	816
F. Droit et éthique	
• (Colloque) Vue d'ensemble de la législation sur le SIDA, 411 C	941
G. Implications internationales	
• Le sérodiagnostic, 406 A	971
• (Colloque) Aspects culturels et sociaux de la sexualité, 406 BC	972
H. Répercussions économiques du SIDA	
• Aperçu et coûts de la prévention et de l'éducation, 404 AB	1029

Sessions d'affichage

page

A. Épidémiologie et santé publique	78
B. Aspects cliniques	222
C. Recherche fondamentale (biomédicale)	542
D. Le SIDA et l'individu	711
E. Le SIDA, la société et le comportement	834
F. Droit et éthique	957
G. Implications internationales	998
H. Répercussions économiques du SIDA	1039

* Salle

14 h à 15 h 30

page

A. Épidémiologie et santé publique	
• (Table ronde) L'évolution de la politique en matière de santé publique, 407 A	48
• Tests de dépistage du VIH dans les cliniques de MTS, 408 A	49
• Incidence et prévalence du VIH, 408 BC	50
B. Aspects cliniques	
• Manifestations buccales du SIDA, 401 ABC	190
• Nouvelle technique de diagnostic rapide et améliorée, 403 ABC	191
• (Colloque) Traitement des infections associées à l'immuno-déficience causée par le VIH, 407 B	192
C. Recherche fondamentale (biomédicale)	
• (Colloque) Les bases moléculaire et cellulaire des immuno-déficiences provoquées par les rétrovirus, 407 C	511
• Pathogénèse (partie 1), 410 ABC	512
D. Le SIDA et l'individu	
• Les adolescents (partie 1), 409 ABC	696
E. Le SIDA, la société et le comportement	
• Les proches et la famille, 411 A	817
• (Colloque) Stratégies innovatrices pour l'éducation des minorités au sujet du SIDA, 411 B	818
F. Droit et éthique	
• (Table ronde) Points de controverse dans les rapports sur les politiques relatives au SIDA, 411 C	943
G. Implications internationales	
• Information et comportement sexuel, 406 A	973
• (Colloque) Les nourrissons à risque : Le point de vue africain, 406 BC	974
H. Répercussions économiques du SIDA	
• Coûts en milieu hospitalier, 404 AB	1030

16 h à 17 h 30

page

A. Épidémiologie et santé publique	
• La transmission sexuelle du VIH (partie 1), 407 A	51
• Infection par le VIH chez les détenus, 408 A	52
• Histoire clinique de l'infection au VIH : Cofacteurs et progression, 408 BC	53
B. Aspects cliniques	
• Infections concomitantes du SIDA, 401 ABC	193
• Pédiatrie : développement neurologique des enfants infectés par le VIH, 403 ABC	194
• Traitement : essais de l'AZT, 407 B	195
C. Recherche fondamentale (biomédicale)	
• Biologie moléculaire (partie 1), 407 C	513
• Pathogénèse (partie 2), 410 ABC	514
D. Le SIDA et l'individu	
• Travailleurs de la santé, 409 ABC	697
E. Le SIDA, la société et le comportement	
• (Table ronde) L'entraide : Une stratégie d'adaptation, 411 A	819
• Les facteurs culturels déterminants dans les attitudes à l'égard du SIDA, 411 B	820
F. Droit et éthique	
• (Colloque) Éthique et injustice sur le plan international, 411 C	944
G. Implications internationales	
• Prévalence (partie 1), 406 A	975
• (Atelier) Atelier régional : Afrique orientale, 406 BC	976
H. Répercussions économiques du SIDA	
• Coûts en dehors du milieu hospitalier, 404 AB	1031

8:30 - 10:30

"New Perspectives" — Plenary session
Palais des Congrès 407 ABC*

11:00 - 17:30

Audiovisual Presentations Guy-Favreau Conference Centre

11:00 - 12:30 page

A. Epidemiology and Public Health	
• Seroepidemiologic studies: United States, 407 A	45
• AIDS/HIV: Blood and blood products, 408 A	46
• Other retroviruses: HIV-2 and HTLV-III, 408 BC	47
B. Clinical Aspects of AIDS	
• HIV in children, 401 ABC	187
• (Round table) Coordinating care: A nurse's perspective, 403 ABC	188
• (Symposium) <i>Pneumocystis Carinii</i> infections, 407 B	200
C. Basic Research (Biomedical)	
• (Symposium) Mechanisms of pathogenesis of HIV, 407 C	509
• Molecular Biology (Part 1): Genomic diversity and relationship to clinical aspects, 410 ABC	510
D. AIDS and the Individual	
• Behavioural research (Part 1), 409 ABC	695
E. AIDS, Society and Behaviour	
• (Symposium) Living with AIDS: A person with AIDS perspective, 411 A	815
• (Workshop) AIDS education: Lessons from developing countries, 411 B	816
F. Ethics and Law	
• (Symposium) Global survey of AIDS legislation, 411 C	941
G. International Issues	
• Serodiagnosis, 406 A	971
• (Symposium) Cultural and social perspectives of sexuality, 406 BC	972
H. The Economic Impact of AIDS	
• Overview plus costs of prevention and education, 404 AB	1029

Poster Sessions	
	page
A. Epidemiology and Public Health	78
B. Clinical Aspects of AIDS	222
C. Basic Research (Biomedical)	542
D. AIDS and the Individual	711
E. AIDS, Society and Behaviour	834
F. Ethics and Law	957
G. International Issues	998
H. The Economic Impact of AIDS	1039

* Room number

14:00 - 15:30 page

A. Epidemiology and Public Health	
• (Round table) Analysis of Public Health Policy, 407 A	48
• HIV testing in STD clinics, 408 A	49
• HIV incidence and prevalence, 408 BC	50
B. Clinical Aspects of AIDS	
• Oral manifestations of AIDS, 401 ABC	190
• New improved rapid diagnosis, 403 ABC	191
• (Symposium) Management of infections associated with HIV immunodeficiency, 407 B	192
C. Basic Research (Biomedical)	
• (Symposium) Molecular and cellular bases of retrovirus induced immunodeficiencies, 407 C	511
• Pathogenesis (Part 1), 410 ABC	512
D. AIDS and the Individual	
• Adolescents (Part 1), 409 ABC	696
E. AIDS, Society and Behaviour	
• Close friends and family, 411 A	817
• (Symposium) Innovative strategies for AIDS education with minorities, 411 B	818
F. Ethics and Law	
• (Round table) Points of controversy between policy reports on AIDS, 411 C	943
G. International Issues	
• Knowledge and sexual behaviour, 406 A	973
• (Symposium) Infants at risk: An African perspective, 406 BC	974
H. The Economic Impact of AIDS	
• Hospital-based costs, 404 AB	1030

16:00 - 17:30 page

A. Epidemiology and Public Health	
• Sexual Transmission of HIV (Part 1), 407 A	51
• HIV infection in prisoners, 408 A	52
• Natural History of HIV infection: Co-factors for progression, 408 BC	53
B. Clinical Aspects of AIDS	
• Concomitant infections in AIDS, 401 ABC	193
• Pediatric: Neuro-development in HIV-infected children, 403 ABC	194
• Therapy: AZT trials, 407 B	195
C. Basic Research (Biomedical)	
• Molecular biology (Part 1), 407 C	513
• Pathogenesis (Part 2), 410 ABC	514
D. AIDS and the Individual	
• Health care workers, 409 ABC	697
E. AIDS, Society and Behaviour	
• (Round table) Self-help: A coping strategy, 411 A	819
• Cultural determinants in responding to AIDS, 411 B	820
F. Ethics and Law	
• (Symposium) Ethics and international inequity, 411 C	944
G. International Issues	
• Prevalence (Part 1), 406 A	975
• (Workshop) Regional workshop: East Africa, 406 BC	976
H. The Economic Impact of AIDS	
• Out-of-hospital costs, 404 AB	1031

Mardi 6 juin

8 h 30 à 10 h 30

- État de la question — Plénière
Palais des Congrès 407 ABC*

11 h à 17 h 30

Présentations audiovisuelles Centre de conférences Guy-Favreau

11 h à 12 h 30

	page
A. Épidémiologie et santé publique	
• (Table ronde) L'annonce aux partenaires et la prévention de l'infection par le VIH, 407 A	54
• Surveillance du SIDA, 408 A	55
• Infections par le VIH chez les consommateurs de drogues par voie intraveineuse, 408 BC	56
B. Aspects cliniques	
• (Atelier) Prophylaxie de la PCP, 401 ABC	196
• Le SIDA dans les pays en voie de développement, 406 A	197
• (Colloque) Traitement des infections par le VIH, 407 B	198
C. Recherche fondamentale (biomédicale)	
• Virologie (partie 1), 403 ABC	515
• (Colloque) Mécanismes de pathogenèse des rétrovirus humains, 407 C	516
• Biologie moléculaire : les différents niveaux d'expression du provirus VIH-1, 410 ABC	517
D. Le SIDA et l'individu	
• (Colloque) Détenus : contraintes et défis, 409 ABC	698
• Recherches sur le comportement (partie 2), 411 A	699
E. Le SIDA, la société et le comportement	
• (Table ronde) Services sociaux : expériences et évaluations, 411 B	822
F. Droit et éthique	
• (Colloque) La confidentialité et ses limites, 411 C	945
G. Implications internationales	
• (Colloque) Sérodiagnostics rentables, 406 BC	977
H. Répercussions économiques du SIDA	
• Planification et gestion, 404 AB	1032

Sessions d'affichage

	page
A. Épidémiologie et santé publique	99
B. Aspects cliniques	287
C. Recherche fondamentale (biomédicale)	567
D. Le SIDA et l'individu	727
E. Le SIDA, la société et le comportement	847
F. Droit et éthique	960
G. Implications internationales	1004
H. Répercussions économiques du SIDA	1044

* Salle

26

14 h à 15 h 30

page

A. Épidémiologie et santé publique	
• Transmission sexuelle du VIH (partie 2), 407 A	57
• (Table ronde) Efficacité et évaluation des programmes, 408 A	58
• (Table ronde) Déclaration du VIH, 408 BC	59
B. Aspects cliniques	
• (Table ronde) Transmission périnatale du VIH, 401 ABC	199
• (Colloque) Diagnostic et histoire clinique de l'infection par le VIH, 407 B	189
C. Recherche fondamentale (biomédicale)	
• Pathogenèse (partie 3), 403 ABC	518
• (Colloque) Origines des rétrovirus humains et des modèles animaux, 407 C	519
• Biologie moléculaire : les mécanismes de régulation de type TAT des gènes viraux, 410 ABC	520
D. Le SIDA et l'individu	
• Minorités, 409 ABC	700
• Psychologie et sexologie, 411 A	701
E. Le SIDA, la société et le comportement	
• (Atelier) Prise de pouvoir : Réappropriation de la santé, les expériences des personnes atteintes, 411 B	823
F. Droit et éthique	
• (Colloque) Éthique clinique, 411 C	947
G. Implications internationales	
• Risques et prévention, 406 A	978
• (Colloque) Compassion et soins communautaires dans les pays en voie de développement, 406 BC	979
H. Répercussions économiques du SIDA	
• Coûts dans les pays en voie de développement, 404 AB	1033

16 h à 17 h 30

page

A. Épidémiologie et santé publique	
• Histoire clinique de l'infection à VIH : manifestations précoces et progression, 407 A	60
• Modèles mathématiques, 408 A	61
• (Table ronde) Évaluation de l'efficacité des programmes de prévention, 408 BC	62
B. Aspects cliniques	
• Traitement de la PCP, 401 ABC	201
• (Colloque) Problèmes de laboratoire dans le diagnostic du SIDA, 407 B	202
C. Recherche fondamentale (biomédicale)	
• Virologie (partie 2), 403 ABC	521
• Modèles animaux (partie 1), 407 C	522
• Biologie moléculaire : les gènes régulateurs et leurs produits, 410 ABC	523
D. Le SIDA et l'individu	
• Les adolescents (partie 2), 409 ABC	702
• Counseling, 411 A	703
E. Le SIDA, la société et le comportement	
• Problèmes de la communauté gaie, 411 B	824
F. Droit et éthique	
• (Colloque) Infection par le VIH, reproduction et fonction parentale, 411 C	949
G. Implications internationales	
• Prévalence (partie 2), 406 A	980
• (Atelier) Atelier régional : Asie, 406 BC	981
H. Répercussions économiques du SIDA	
• Impact macroéconomique dans les pays en voie de développement, 404 AB	1034

8:30 - 10:30

“State-Of-The-Art” — Plenary session
Palais des Congrès 407 ABC*

11:00 - 17:30

Audiovisual Presentations Guy-Favreau Conference Centre

11:00 - 12:30 page

A. Epidemiology and Public Health	
• (Round table) Partner notification in HIV prevention, 407 A	54
• AIDS surveillance, 408 A	55
• HIV infection in IVDUs, 408 BC	56
B. Clinical Aspects of AIDS	
• (Workshop) PCP Prophylaxis, 401 ABC	196
• AIDS in the developing world, 406 A	197
• (Symposium) HIV therapy, 407 B	198
C. Basic Research (Biomedical)	
• Virology, 403 ABC	515
• (Symposium) Mechanisms of pathogenesis of human retroviruses, 407 C	516
• Molecular biology: different level of expression of HIV-1 provirus, 410 ABC	517
D. AIDS and the Individual	
• (Symposium) Prisoners: constraints and challenges, 409 ABC	698
• Behavioural research (Part 2), 411 A	699
E. AIDS, Society and Behaviour	
• (Round table) Social Services: Experiences and evaluations, 411 B	822
F. Ethics and Law	
• (Symposium) Confidentiality and its limits, 411 C	945
G. International Issues	
• (Symposium) Cost-effective serodiagnosis, 406 BC	977
H. The Economic Impact of AIDS	
• Planning/Management, 404 AB	1032

Poster Sessions	
	page
A. Epidemiology and Public Health	99
B. Clinical Aspects of AIDS	287
C. Basic Research (Biomedical)	567
D. AIDS and the Individual	727
E. AIDS, Society and Behaviour	847
F. Ethics and Law	960
G. International Issues	1004
H. The Economic Impact of AIDS	1044

* Room number

14:00 - 15:30 page

A. Epidemiology and Public Health	
• Sexual transmission of HIV (Part 2), 407 A	57
• (Round table) Programme effectiveness and evaluation, 408 A	58
• (Round table) HIV reporting, 408 BC	59
B. Clinical Aspects of AIDS	
• (Round table) Perinatal transmission of HIV, 401 ABC	199
• (Symposium) Natural History and Diagnosis of HIV infection, 407 B	189
C. Basic Research (Biomedical)	
• Pathogenesis (Part 3), 403 ABC	518
• (Symposium) Origins of human retroviruses and animal models, 407 C	519
• Molecular biology: TAT-mediated regulation of viral genes, 410 ABC	520
D. AIDS and the Individual	
• Minorities, 409 ABC	700
• Psychology and sexology, 411 A	701
E. AIDS, Society and Behaviour	
• (Workshop) Empowerment: Reappropriation of health and experience of persons with AIDS, 411 B	823
F. Ethics and Law	
• (Symposium) Clinical ethics, 411 C	947
G. International Issues	
• Risks and prevention, 406 A	978
• (Symposium) Community compassion and care in the developing world, 406 BC	979
H. The Economic Impact of AIDS	
• Costs in developing countries, 404 AB	1033

16:00 - 17:30 page

A. Epidemiology and Public Health	
• Natural history of HIV infection: Early manifestation and progression, 407 A	60
• Mathematical models, 408 A	61
• (Round table) Evaluation of programme effectiveness, 408 BC	62
B. Clinical Aspects of AIDS	
• PCP Treatment, 401 ABC	201
• (Symposium) Laboratory issues in the diagnosis of AIDS, 407 B	202
C. Basic Research (Biomedical)	
• Virology, 403 ABC	521
• Animal models (Part 1), 407 C	522
• Molecular biology: Regulatory genes and their products, 410 ABC	523
D. AIDS and the Individual	
• Adolescents (Part 2), 409 ABC	702
• Counselling, 411 A	703
E. AIDS, Society and Behaviour	
• The gay community issues, 411 B	824
F. Ethics and Law	
• (Symposium) HIV infection, reproduction and parenthood, 411 C	949
G. International Issues	
• Prevalence (Part 2), 406 A	980
• (Workshop) Regional workshop: Asia, 406 BC	981
H. The Economic Impact of AIDS	
• Macroeconomic impact in developing countries, 404 AB	1034

Mercredi 7 juin

8 h 30 à 10 h 30

- État de la question – Plénière
Palais des Congrès 407 ABC*

11 h à 17 h 30

Présentations audiovisuelles Centre de conférences Guy-Favreau

11 h à 12 h 30

A. Épidémiologie et santé publique	
• Transmission du VIH dans le milieu des soins de la santé, 407 A	63
• (Table ronde) Transmission hétérosexuelle, 408 BC	64
B. Aspects cliniques	
• Pharmacologie et toxicité de l'AZT, 401 ABC	203
• Traitement : thrombocytopénie, 403 ABC	204
• (Colloque) Qualité des soins offerts aux personnes atteintes du SIDA, 407 B	205
C. Recherche fondamentale (biomédicale)	
• (Colloque) Gènes régulateurs et diversité génomique virale, 407 C	524
• Éléments de base en immunologie (partie 1), 408 A	525
• Biologie moléculaire (partie 2), 410 ABC	526
D. Le SIDA et l'individu	
• Les femmes, 409 ABC	704
E. Le SIDA, la société et le comportement	
• Rôle des ONG dans la lutte mondiale contre le SIDA, 411 A	825
• La lutte communautaire contre le SIDA dans les années 1990, 411 B	827
F. Droit et éthique	
• (Colloque) Recherche de traitements et de vaccins, 411 C	950
G. Implications internationales	
• Le VIH en pédiatrie, 406 A	982
• (Colloque) Infections parasitaires tropicales : impact du VIH, 406 BC	983
H. Répercussions économiques	
• Rôle des assurances, 404 AB	1035

Sessions d'affichage

	page
A. Épidémiologie et santé publique	120
B. Aspects cliniques	352
C. Recherche fondamentale (biomédicale)	592
D. Le SIDA et l'individu	743
E. Le SIDA, la société et le comportement	860
F. Droit et éthique	963
G. Implications internationales	1010
H. Répercussions économiques du SIDA	1049

* Salle

14 h à 15 h 30

page

A. Épidémiologie et santé publique	
• Études séro-épidémiologiques des femmes enceintes, 407 A	65
• Incidence et mortalité du SIDA, 408 BC	66
B. Aspects cliniques	
• Manifestations cliniques, 401 ABC	206
• Hémophilie : histoire clinique et études de cohortes, 403 ABC	207
• (Colloque) Infection par le VIH : atteintes à certains organes, 407 B	208
C. Recherche fondamentale (biomédicale)	
• (Colloque) Mise au point de vaccins contre le SIDA, 407 C	527
• Mise au point des médicaments : nouvelle approche pour l'étude des médicaments antiviraux, 408 A	528
• Modèles animaux (partie 2), 410 ABC	529
D. Le SIDA et l'individu	
• (Colloque) Consommateurs de drogues par voie intraveineuse : réalités changeantes et mythes persistants, 409 ABC	705
E. Le SIDA, la société et le comportement	
• Le SIDA en milieu de travail, 411 A	828
• Le SIDA dans les médias, 411 B	829
F. Droit et éthique	
• (Colloque) Prévenir la transmission du VIH : les conflits religieux en matière de santé publique, 411 C	952
G. Implications internationales	
• Perspectives mondiales, 406 A	984
• Transmission hétérosexuelle et rôle des MTS, 406 BC	985
H. Répercussions économiques du SIDA	
• Financement et assurances, 404 AB	1036

16 h à 17 h 30

page

A. Épidémiologie et santé publique	
• L'annonce aux partenaires, 407 A	67
• Test de dépistage du VIH/Questions en matière de politiques et de programmes, 408 BC	68
B. Aspects cliniques	
• Infections associées au SIDA, 401 ABC	209
• Atteintes neuropsychiatriques, 403 ABC	210
• (Colloque) Essais cliniques : points de vue des « acteurs », 407 B	211
C. Recherche fondamentale (biomédicale)	
• Virologie (partie 3), 407 C	530
• Éléments de base en immunologie, 408 A	531
• Modèles animaux (partie 3), 410 ABC	532
D. Le SIDA et l'individu	
• (Colloque) Les femmes dans les pays industrialisés : Questions et options, 409 ABC	706
E. Le SIDA, la société et le comportement	
• Services de pastorale, 411 B	830
F. Droit et éthique	
• (Colloque) Coercition ou volontarisme ? Analyse critique internationale, 411 C	954
G. Implications internationales	
• Prévalence (partie 3), 406 A	986
• (Atelier) Atelier régional : Afrique occidentale, 406 BC	987
• (Colloque) Déplacements internationaux et SIDA, 411 A	988
H. Répercussions économiques du SIDA	
• Méthodologie des analyses de coûts, 404 AB	1037

8:30 - 10:30

"State-Of-The-Art" — Plenary session
Palais des Congrès 407 ABC*

11:00 - 17:30

Audiovisual Presentations Guy-Favreau Conference Centre

11:00 - 12:30 page

A.	Epidemiology and Public Health	
	• HIV transmission in the health care setting, 407 A	63
	• (Round table) Heterosexual transmission, 408 BC	64
B.	Clinical Aspects of AIDS	
	• AZT Pharmacology and toxicity, 401 ABC	203
	• Therapy: thrombocytopenia, 403 ABC	204
	• (Symposium) Quality of care for patients with AIDS, 407 B	205
C.	Basic Research (Biomedical)	
	• (Symposium) Regulatory genes and viral genomic diversity, 407 C	524
	• Basic immunology, 408 A	525
	• Molecular biology (Part 2), 410 ABC	526
D.	AIDS and the Individual	
	• Women, 409 ABC	704
E.	AIDS, Society and Behaviour	
	• The role of NGO in the global response to AIDS, 411 A	825
	• The community-based response to AIDS into the 1990s, 411 B	827
F.	Ethics and Law	
	• (Symposium) Research for treatments and vaccines, 411 C	950
G.	International Issues	
	• HIV in pediatrics, 406 A	982
	• (Symposium) Tropical diseases: the impact of HIV, 406 BC	983
H.	The Economic Impact of AIDS	
	• The role of insurance, 404 AB	1035

Poster Sessions		page
A.	Epidemiology and Public Health	120
B.	Clinical Aspects of AIDS	352
C.	Basic Research (Biomedical)	592
D.	AIDS and the Individual	743
E.	AIDS, Society and Behaviour	860
F.	Ethics and Law	963
G.	International Issues	1010
H.	The Economic Impact of AIDS	1049

* Room number

14:00 - 15:30

page

A.	Epidemiology and Public Health	
	• Seroepidemiologic studies: Neonatal, 407 A	65
	• AIDS incidence and mortality, 408 BC	66
B.	Clinical Aspects of AIDS	
	• Clinical manifestations, 401 ABC	206
	• Hemophilia: Natural history/cohort studies, 403 ABC	207
	• (Symposium) HIV Infection: Organ specific involvement, 407 B	208
C.	Basic Research (Biomedical)	
	• (Symposium) Vaccine developments in AIDS, 407 C	527
	• Drug development: Novel study approach to anti-viral drugs, 408 A	528
	• Animal models (Part 2), 410 ABC	529
D.	AIDS and the Individual	
	• (Symposium) Injection drug users: Changing realities and persisting myths, 409 ABC	705
E.	AIDS, Society and Behaviour	
	• AIDS in the workplace, 411 A	828
	• AIDS in the media, 411 B	829
F.	Ethics and Law	
	• (Symposium) Preventing HIV transmission: Religious conflicts in public health, 411 C	952
G.	International Issues	
	• Global Perspectives, 406 A	984
	• Heterosexual transmission and the role of STDs, 406 BC	985
H.	The Economic Impact of AIDS	
	• Financing and Insurance, 404 AB	1036

16:00 - 17:30

page

A.	Epidemiology and Public Health	
	• Partner notification, 407 A	67
	• HIV testing/policy and programme issues, 408 BC	68
B.	Clinical Aspects of AIDS	
	• AIDS-related infection, 401 ABC	209
	• Neuropsychiatric involvement, 403 ABC	210
	• (Symposium) Clinical trials: The "actors" perspective, 407 B	211
C.	Basic Research (Biomedical)	
	• Virology, 407 C	530
	• Basic Immunology, 408 A	531
	• Animal models (Part 3), 410 ABC	532
D.	AIDS and the Individual	
	• (Symposium) Women in developed countries: Issues and options, 409 ABC	706
E.	AIDS, Society and Behaviour	
	• Pastoral care, 411 B	830
F.	Ethics and Law	
	• (Symposium) Coercion or voluntarism: An international critical review, 411 C	954
G.	International Issues	
	• Prevalence (Part 3), 406 A	986
	• (Workshop) Regional workshop: West Africa, 406 BC	987
	• (Symposium) International travel and AIDS, 411 A	988
H.	The Economic Impact of AIDS	
	• Methodology of cost studies, 404 AB	1037

Jeudi 8 juin

8 h 30 à 10 h 30

- Synthèse des plénières *
- Palais des Congrès 407 ABC*

11 h à 17 h 30

Présentations audiovisuelles Centre de conférences Guy-Favreau

11 h à 12 h 30

A. Épidémiologie et santé publique	page
• (Table ronde) Contrôle de l'épidémie de VIH, 407 A	69
• (Table ronde) Modélisation mathématique, 408 A	70
• Transmission périnatale, 408 BC	71
B. Aspects cliniques	
• Thérapie : la ribavirine et les autres médicaments, 401 ABC	212
• Test de dépistage par réaction en chaîne des polymérasés, 404 AB	213
• (Colloque) Infections respiratoires chez les consommateurs de drogues par voie intraveineuse, 407 B	214
C. Recherche fondamentale (biomédicale)	
• Éléments de base en immunologie (partie 3), 403 ABC	533
• (Colloque) Aspects pathologiques de l'infection par le VIH, 407 C	534
• Mise au point de médicaments : utilisation des molécules CD4 dans le traitement du SIDA, 410 ABC	535
D. Le SIDA et l'individu	
• Consommateurs de drogues par voie intraveineuse (partie 1), 409 ABC	707
• Prostitution, 411 A	708
E. Le SIDA, la société et le comportement	
• (Atelier) Innovations en matière de prévention et d'éducation au sujet du SIDA, 411 B	831
G. Implications internationales	
• SIDA et tuberculose, 406 A	989
• (Colloque) Recherches sur la sexualité humaine, 406 BC	990
H. Répercussions économiques du SIDA	
• Affectation des ressources et processus décisionnels, 411 C	1038

Sessions d'affichage

	page
A. Épidémiologie et santé publique	141
B. Aspects cliniques	416
C. Recherche fondamentale (biomédicale)	617
D. Le SIDA et l'individu	759
E. Le SIDA, la société et le comportement	873
F. Droit et éthique	966
G. Implications internationales	1016
H. Répercussions économiques du SIDA	1054

* Salle

14 h à 15 h 30

page

A. Épidémiologie et santé publique	
• (Table ronde) Rôle du dépistage et du counseling dans la prévention du SIDA, 407 A	72
• Questions de méthodologie, 408 A	73
• Transmission sexuelle du VIH (partie 3), 408 BC	74
B. Aspects cliniques	
• Neurologie, 401 ABC	215
• Les lymphokines, 404 AB	216
• (Colloque) Les problèmes associés au VIH en hémophilie : aujourd'hui et demain, 407 B	217
C. Recherche fondamentale (biomédicale)	
• Mise au point des médicaments : utilisation de l'AZT et d'autres oligonucleotides dans le traitement du SIDA, 403 ABC	536
• Virologie (partie 4), 407 C	537
• Vaccins : étude de l'immunisation à l'aide des glycoprotéines du VIH, 410 ABC	538
D. Le SIDA et l'individu	
• Consommateurs de drogues par voie intraveineuse (partie 2), 409 ABC	709
• (Colloque) Les femmes des pays en voie de développement, 411 A	710
E. Le SIDA, la société et le comportement	
• Politiques sociales : expériences et critiques, 411 B	832
G. Implications internationales	
• (Colloque) Les femmes à risque, 406 A	991
• (Colloque) Défis posés par la gestion de programmes, 406 BC	992
• MTS et facteurs de risque, 411 C	993

16 h à 17 h 30

page

A. Épidémiologie et santé publique	
• Histoire clinique de l'infection par le VIH : progression vers l'infection, 407 A	75
• (Table ronde) Infection par le VIH et travailleurs de la santé : questions actuelles, 408 BC	76
• Autres rétrovirus : le HTLV-I, 409 ABC	77
B. Aspects cliniques	
• SIDA et nutrition, 401 ABC	218
• Immunomodulateurs, 404 AB	219
• (Colloque) Pharmacologie des médicaments anti-SIDA, 407 B	220
• VIH-2 et autres rétrovirus, 408 A	221
C. Recherche fondamentale (biomédicale)	
• Oncologie, 403 ABC	539
• (Colloque) Le rôle des macrophages et des lymphocytes comme réservoirs du VIH-1, 407 C	540
• Vaccins : utilisation d'un modèle animal pour l'étude des vaccins anti-VIH, 410 ABC	541
E. Le SIDA, la société et le comportement	
• Dimensions sociales du SIDA, 411 B	833
F. Droit et éthique	
• (Colloque) Discrimination et droit de la personne, 411 C	955
G. Implications internationales	
• Aspects cliniques, 406 A	994
• (Atelier) Atelier régional : Antilles, 406 B	996
• (Atelier) Atelier régional : Amérique latine, 406 C	995
• Le SIDA chez l'enfant, 411 A	997

8:30 - 10:30

"Synthesis" — Plenary speakers
Palais des Congrès 407 ABC*

11:00 - 17:30

Audiovisual Presentations Guy-Favreau Conference Centre

11:00 - 12:30 page

A. Epidemiology and Public Health	
• (Round table) Monitoring the HIV epidemic, 407 A	69
• (Round table) Mathematical modelling, 408 A	70
• Perinatal transmission, 408 BC	71
B. Clinical Aspects of AIDS	
• Therapy: Ribavirin and other anti-HIV drugs, 401 ABC	212
• PCR diagnostic test, 404 AB	213
• (Symposium) Respiratory infection in IV drug users, 407 B	214
C. Basic Research (Biomedical)	
• Basic immunology, 403 ABC	533
• (Symposium) Pathological aspects of HIV infection, 407 C	534
• Drug development: Use of CD-4 molecules in AIDS therapy, 410 ABC	535
D. AIDS and the Individual	
• Injection drug users (Part 1), 409 ABC	707
• Prostitution, 411 A	708
E. AIDS, Society and Behaviour	
• (Workshop) Innovations in AIDS education and prevention, 411 B	831
G. International Issues	
• AIDS and tuberculosis, 406 A	989
• (Symposium) Human sexuality research, 406 BC	990
H. The Economic Impact of AIDS	
• Resource allocation and decision-making, 411 C	1038

Poster Sessions	
	page
A. Epidemiology and Public Health	141
B. Clinical Aspects of AIDS	416
C. Basic Research (Biomedical)	617
D. AIDS and the Individual	759
E. AIDS, Society and Behaviour	873
F. Ethics and Law	966
G. International Issues	1016
H. The Economic Impact of AIDS	1054

* Room number

14:00 - 15:30 page

A. Epidemiology and Public Health	
• (Round table) The role of HIV testing and counselling in AIDS prevention, 407 A	72
• Methodologic issues, 408 A	73
• Sexual transmission of HIV (Part 3), 408 BC	74
B. Clinical Aspects of AIDS	
• Neurology, 401 ABC	215
• Lymphokines, 404 AB	216
• (Symposium) HIV related issues in hemophilia: today and tomorrow, 407 B	217
C. Basic Research (Biomedical)	
• Drug development: Use of AZT and other oligonucleotides in AIDS therapy, 403 ABC	536
• Virology, 407 C	537
• Vaccines: Immunization study using HIV glycoproteins, 410 ABC	538
D. AIDS and the Individual	
• Injection drug users (Part 2), 409 ABC	709
• (Symposium) Women in developing countries, 411 A	710
E. AIDS, Society and Behaviour	
• Public policy: Experiences and critiques, 411 B	832
G. International Issues	
• (Symposium) Women at risk, 406 A	991
• (Symposium) Challenge of programme management, 406 BC	992
• STD and risk factors, 411 C	993

16:00 - 17:30 page

A. Epidemiology and Public Health	
• Natural history of HIV infection: Progression to disease, 407 A	75
• (Round table) HIV infection and the healthcare worker: contemporary issues, 408 BC	76
• Other retroviruses: HTLV-I, 409 ABC	77
B. Clinical Aspects of AIDS	
• Nutrition and AIDS, 401 ABC	218
• Immunomodulators, 404 AB	219
• (Symposium) Pharmacology of anti-AIDS drugs, 407 B	220
• HIV-II and other retroviruses, 408 A	221
C. Basic Research (Biomedical)	
• Oncology, 403 ABC	539
• (Symposium) Role of macrophages and lymphocytes as reservoirs of HIV-1, 407 C	540
• Vaccines: Use of animal model to study anti-HIV vaccines, 410 ABC	541
E. AIDS, Society and Behaviour	
• Social dimensions of AIDS, 411 B	833
F. Ethics and Law	
• (Symposium) Discrimination and human rights, 411 C	955
G. International Issues	
• Clinical, 406 A	994
• (Workshop) Regional workshop: Caribbean, 406 B	996
• (Workshop) Regional workshop: Latin America, 406 C	995
• Pediatric AIDS, 411 A	997

Vendredi
9 juin

8 h 30 à 10 h 30

• Perspectives d'avenir • — Plénière
Palais des Congrès 407 ABC •

Cérémonie de clôture

Président
Ivan Head
Président de la Conférence
Président du Centre de recherches
pour le développement international
Canada

Conférenciers
L'Honorable Perrin Beatty
Ministre de Santé et Bien-être social
Canada

Mohammed Abdelmoumene
Directeur général adjoint
Organisation mondiale de la santé
Suisse

John Ziegler
Président
VI^e Conférence internationale sur le SIDA
États-Unis

Lars Olof Kallings
Président
Société internationale sur le SIDA
Ministère de la Santé et des
Affaires sociales
Suède

Message de
Danielle Mitterrand
Présidente, Fondation France
Libertés

Randy Shiltz
Correspondant national
San Francisco Chronicle
États-Unis

Friday
June 9

8:30 - 10:30

• "Future Prospects" — Plenary session
Palais des Congrès 407 ABC

Closing Ceremony

Chairman
Ivan Head
Conference Chairman
President, International Development
Research Centre
Canada

Plenary Speakers
*The Honourable
Perrin Beatty*
Minister of Health and Welfare
Canada

Mohammed Abdelmoumene
Deputy Director-General
World Health Organization
Switzerland

John Ziegler
Chairman
VI International Conference
on AIDS
United States

Lars Olof Kallings
President
International AIDS Society
Ministry of Health and Social Affairs
Sweden

Message from
Danielle Mitterrand
President
Fondation France
Libertés

Randy Shiltz
National Correspondent
San Francisco Chronicle

* Salle
Room number

Programme
des Plénières

Overall Plenary
Programme

**Le lundi
5 juin
Monday
June 5**

Nouvelles Perspectives

Présidents :
Maureen Law
Sous-Ministre
Santé et Bien-être social Canada

Donald deGagné
Directeur, Vancouver Persons with
AIDS Society
Canada

Conférenciers :
June Callwood
Journaliste
Globe & Mail
Canada

Albert Jacquard
Professeur à l'Université de Genève
Chef du service de génétique
Institut national d'études
démographiques
France

Mechai Viravaidya
Fondateur
Population and Community
Development Association
Thaïlande

Stephen Joseph
Commissaire de la santé
Ville de New York
États-Unis

David Suzuki
Scientifique/Journaliste
Département de zoologie
University of British Columbia
Canada

New Perspectives

Chairpersons:
Maureen Law
Deputy Minister
Health and Welfare Canada

Donald deGagné
Director
Vancouver Persons with AIDS Society
Canada

Plenary speakers:
June Callwood
Columnist
Globe & Mail
Canada

Albert Jacquard
Professor, University of Geneva
Chief, Genetic Services
Institut national d'études
démographiques
France

Mechai Viravaidya
Founder
Population and Community
Development Association
Thailand

Stephen Joseph
Commissioner of Health
New York City
U.S.A.

David Suzuki
Scientist/Broadcaster
Department of Zoology
University of British Columbia
Canada

État de la Question

Président :
James O. Mason
Secrétaire adjoint de la santé des
États-Unis

Conférenciers :
**Progrès en gestion clinique du SIDA et
de l'infection par le VIH dans le
monde industrialisé**

Ian Weller
Directeur d'études
Faculté de médecine génito-urinaire,
University College & Middlesex School
of Medicine
Angleterre

**Difficultés et obstacles à la gestion
optimale du SIDA et de l'infection par
le VIH dans le monde en
développement**

N'Galy Bosenge
Directeur
Comité national du programme de lutte
contre le SIDA au Zaïre

**La perspective
communautaire—questions
confrontant les personnes ayant le
SIDA et infectées par le VIH dans le
monde en développement**

Daniel Defert
Président
AIDES Fédération nationale
France

**Humanité : les mesures pour une
éthique sur le SIDA**

David J. Roy
Directeur
Centre de bioéthique
Institut de recherche clinique de Montréal
Québec, Canada

**La dynamique de la transmission du
VIH : le rôle des modèles dans
l'interprétation, la prédiction et
l'évaluation des paramètres**

Roy M. Anderson
Professeur
Imperial College of Science and
Technology
Angleterre

State-of-the Art

Chairperson:
James O. Mason
Assistant Secretary for Health of the
United States

Plenary speakers:
**Advances in Clinical Management in
AIDS and HIV Infection in the
Developed World**

Ian Weller
Reader in Genito-Urinary Medicine
Academic Department of Genito-Urinary
Medicine
University College & Middlesex School
of Medicine
England

**Difficulties and obstacles for
optimal management of AIDS and
HIV infection in the developing world**

N'Galy Bosenge
Director
National AIDS Control Programme in
Zaire

**The community perspective - issues
confronting persons with AIDS and
HIV infection and the community**

Daniel Defert
President
AIDES Fédération nationale
France

**Humanity: the measure of an ethics
for AIDS**

David J. Roy
Director
Centre for Bioethics
Clinical Research Institute of Montreal
Quebec, Canada

**The transmission dynamics of HIV:
the role of models in interpretation,
prediction and parameter estimation**

Roy M. Anderson
Professor
Imperial College of Science and
Technology
England

**Le mardi
6 juin**

**Tuesday
June 6**

**Le mercredi
7 juin**

**Wednesday
June 7**

État de la Question

Présidente :
Monique Landry
Ministre des relations extérieures et du
développement international du Canada

Conférenciers :
**Le femmes, les enfants et le
SIDA—questions touchant les
femmes, les enfants et le SIDA dans le
monde industrialisé**

Catherine Hankins
Directeur
Programme régional de contrôle
MTS-SIDA, Montréal
Québec, Canada

**Le SIDA chez les enfants en Afrique :
perspectives et défis**

Angela A. Okolo
Maître de Conférence
Département de santé de l'enfant
Collège des sciences médicales
Université du Bénin
Nigéria

**Epidémiologie et lutte contre le SIDA
chez les consommateurs de drogues**

Roel A. Coutinho
Service de santé municipale
Département de la santé publique et de
l'environnement
Pays-Bas

**Thérapie anti-rétrovirale : le passé, le
présent et l'avenir**

Samuel Broder
Directeur
National Cancer Institute
États-Unis

**Pour une approche bio-culturelle du
SIDA : impasses et nouvelles pistes**

Gilles Bibeau
Professeur et Directeur
Département d'anthropologie
Université de Montréal
Québec, Canada

State of Art

Chairperson:
The Honourable Monique Landry
Minister for International Relations and
International Development of Canada

Plenary speakers:
**Women, children, and AIDS—issues
involving women, children and AIDS
in the developed world**

Catherine Hankins
Director
Montreal Regional STD-AIDS Control
Quebec, Canada

**Childhood AIDS in Africa:
perspectives, challenges**

Angela A. Okolo
Senior Lecturer
Department of Child Health
College of Medical Sciences
University of Benin
Nigeria

**Epidemiology and control of AIDS
among drug users**

Roel A. Coutinho
Municipal Health Service
Department of Public Health and
Environment
The Netherlands

**Anti-retroviral therapy; past, present,
and future**

Samuel Broder
Director
National Cancer Institute
U.S.A.

**For a biocultural approach to AIDS:
dead ends**

and new leads
Gilles Bibeau
Professor and Director
Department of Anthropology
University of Montreal
Quebec, Canada

Synthèse des plénières

Présidents :

L' Honorable Elinor Caplan
Ministre de la Santé de l' Ontario
Canada

Le Ministre Claude Evin
Ministre de la Solidarité, de la Santé et
de la Protection sociale, France

Conférenciers :

Structure et pathogénèse du VIH

Marie-Paule Kiény
Directrice scientifique associée
Division de la virologie et de
l'immunologie
TRANSGENE
France

L'épidémiologie de l'infection par le VIH : progrès récents et questions à résoudre

Peter Piot
Professeur et Chef du
Département de microbiologie
Institut de médecine tropicale
Belgique

Perspectives et embûches de la vaccination contre le VIH

Dani P. Bolognesi
Professeur James B. Duke
Département de Chirurgie
Duke University Medical Centre
États-Unis

Infection par le VIH dans le contexte d'une épidémiologie changeante des maladies transmissibles sexuellement

King K. Holmes
Professeur et vice-président
Département de Médecine
University of Washington
États-Unis

Prévention : peut-on mobiliser ce qui a été appris?

June E. Osborn
Doyen
École de santé publique
University of Michigan
États-Unis

"Synthesis" Plenary Speakers

Chairpersons:
The Honourable Elinor Caplan
Minister of Health of Ontario
Canada

Claude Evin
Minister of Solidarity, Health and Social
Protection
France

Plenary Speakers:

Structure and pathogenesis of HIV
Marie-Paule Kiény
Associate Scientific Director
Virology and Immunology Division
TRANSGENE
France

The epidemiology of HIV infection: recent advances and remaining questions

Peter Piot
Professor and Head
Department of Microbiology
Institute of Tropical Medicine
Belgium

Prospects and pitfalls of vaccination against HIV

Dani P. Bolognesi
James B. Duke Professor
Department of Surgery
Duke University Medical Centre
U.S.A.

HIV infection in the context of changing epidemiologic patterns of sexually transmitted diseases

King K. Holmes
Professor and Vice-Chairman
Department of Medicine
University of Washington
U.S.A.

Prevention: can we mobilize what has been learned?

June E. Osborn
Dean
School of Public Health
University of Michigan
U.S.A.

**Le jeudi
8 juin**

**Thursday
June 8**

**Le vendredi
9 juin
Friday
June 9**

Perspectives d'Avenir

Présidente :
Thérèse Lavoie-Roux
Ministre de la Santé et des Services
sociaux du Québec
Canada

Conférenciers :
Simone Veil
Présidente du Groupe libéral,
démocratique et réformateur
Parlement Européen
France

Robert Gallo
Chef
Laboratory of Tumor Cell Biology
États-Unis

Luc Montagnier
Département de Virologie
Unité d'oncologie virale
Institut Pasteur
France

Alastair Clayton
Directeur général
Centre fédéral sur le SIDA
Canada

Richard A. Morisset
Président, Comité du programme de la
Conférence
Professeur titulaire
Département de microbiologie et
immunologie
Université de Montréal
Québec, Canada

Future Prospects

Chairperson:
Thérèse Lavoie-Roux
Minister of Health and Social Services
of Quebec
Canada

Plenary Speakers:
Simone Veil
President
Groupe libéral, démocratique et
réformateur
Parlement Européen
France

Robert Gallo
Chief
Laboratory of Tumor Cell Biology
U.S.A.

Luc Montagnier
Department of Virology
Viral Oncology Unit
Institut Pasteur
France

Alastair Clayton
Director General
Federal Centre for AIDS
Canada

Richard A. Morisset
Chairman, Conference Programme
Committee
Professor
Microbiology and Immunology
University of Montreal
Quebec, Canada

Abrégés

Abstracts

Système de numérotation



SECTION A
Épidémiologie et
santé publique



SECTION B
Aspects cliniques



SECTION C
Recherche fondamentale
(biomédicale)



SECTION D
Le SIDA et
l'individu



SECTION E
Le SIDA, la société et
le comportement



SECTION F
Droit et éthique



SECTION G
Implications
internationales



SECTION H
Répercussions
économiques du SIDA



SECTION I
Audiovisuel



Médias
Media



**Retransmission
Overflow**



**Affiches
Posters**

Les présentations de ce programme sont groupées par jour et par section. La numérotation des abrégés indique le jour et la nature des présentations.

Ces numéros renvoient aussi aux abrégés réunis dans le cahier des abrégés.

Exemple
M.A.O.37

M.

A.

O.

37



Jour de la
présentation

M : Lundi
T : Mardi
W : Mercredi
Th : Jeudi
F : Vendredi

Numéro
de section

A, B, C
D, E, F, G,
H, I.

Nature de la
présentation


O : Exposé
P : Affiche
V : Vidéo

Numéro de la
présentation

Key to Numbering System

The presentations in this program are grouped by day, by section. The numbering system utilized for the abstracts serves to identify the day and type of presentation.

These numbers also refer to the abstracts in the Abstract Volume.



SECTION A
Epidemiology and
Public Health



SECTION B
Clinical Aspects



SECTION C
Basic Research
(Biomedical)



SECTION D
AIDS and the
Individual



SECTION E
AIDS, Society
and Behaviour



SECTION F
Ethics and Law



SECTION G
International
Issues



SECTION H
The Economic
Impact of AIDS



SECTION I
Audiovisual



Médias
Media




Retransmission
Overflow



Affiches
Posters

SIDART

SECTION A



Épidémiologie et santé publique
Epidemiology and Public Health

Séance thématique Specialty Session



Épidémiologie et santé publique Epidemiology and Public Health

Études séro-épidémiologiques : États Unis Seroepidemiologic Studies: United States

M.A.O.1

HIV SEROCONVERSION RATE IN A SERIALLY-TESTED POPULATION OF YOUNG ADULTS IN THE UNITED STATES (1967-1986).

McNeil, J.*; Brundage, J.*; Weller, D.*; Brundage, J.*
*Walter Reed Army Institute of Research, Washington DC, USA; **SRA Technologies, Alexandria Virginia, USA.

Objective. To describe the rate of, and demographic characteristics associated with, HIV seroconversion within a large population of US citizens who are serially-tested for HIV antibody (HIV-Ab).

Methods. Civilian applicants for military service and all soldiers on active duty are routinely tested for HIV-Ab. Current policy stipulates repeat testing at least biennially. A total of 78,787 people tested negative for HIV-Ab on or after November 1, 1987 and were subsequently retested before November 1, 1988. The average time between tests was 7.2 months. An incident case is defined as someone who tested negative on the first test (EIA or WB) and positive on the subsequent test (WB) in duplicate.

Results. Twenty-nine seroconversions occurred over the observed period resulting in an annual incidence rate (IR) of 0.63/1000 (95% Poisson CI: 0.42-0.93). Direct rate adjustment by age to the standard US Army population resulted in an annual IR of 0.74/1000. Seroconversion risk was associated with minority ethnicity, age between 20-30 years, male gender, and being unmarried. Investigation of specific behavioral risk factors for seroconversion is in progress.

Conclusion. To the best of our knowledge, military testing programs represent the only opportunity to obtain a US population-based estimate of incident seroconversion. Using the method described above, the annual rate of new HIV infections within the Army has remained stable (0.74/1000 during interval years 1965-86, 1986-87, and 1987-88, and currently results in about 850 new HIV infections per year in this cohort of presumably low-risk young adults.

M.A.O.3

EPIDEMIOLOGY OF HIV INFECTION IN ACTIVE DUTY ARMY MEN AT NO IDENTIFIED RISK (NID)

Reznick, Phillip, J.*; Austin, J.*; and Brundage, J.*

*Walter Reed Army Institute of Research, Washington, DC, USA; **ADA Program, National Institute for Allergy and Infectious Diseases, Rockville, MD, USA.

Objective. To investigate risk factors for HIV infection among HIV-Ab positive male soldiers at no identified risk (NID) for HIV infection and randomly selected HIV-Ab negative controls.

Methods. A large population of active duty soldiers do not disclose histories of homosexual/bisexual activity, IV drug use, hemophilia, blood transfusion, or sexual activity with persons at risk for HIV infection. A case-control risk factor study was conducted with HIV-Ab positive soldiers and matched HIV-Ab negative controls. Subjects consented to a voluntary, anonymous and confidential survey of demographics, medical history, drug use, sexual history, and other behaviors associated with HIV infection. Civilian interviewers were blinded to the HIV status of each participant.

Results. Twenty (76.9%) of 26 cases and 9 (12.2%) of 74 controls reported engaging in behaviors associated with increased risk of HIV infection. Conditional logistic regression revealed significant risk of HIV infection was independently associated with engaging in sex with men (adjusted Odds Ratio (OR)=4.7, p=0.03), engaging in sex with IV drug users, (OR=27.8, p=0.02), being unmarried (OR=1.6, p=0.02), and engaging in sex that caused one or both partners to bleed (OR=6.6, p=0.04).

Conclusion. Results suggest that NIDs in the Army can be reclassified into traditional risk categories at about the same rate as to civilian studies. Study designs that are not only confidential, but also anonymous and interview-blinded, can improve the quality of risk factor assessments in both civilian and military individuals who perceive that divulging risk factor information can be potentially incriminating.

M.A.O.5

MEASURING LEVELS AND TRENDS OF HIV INFECTION IN THE GENERAL POPULATION BY MONITORING HIV SEROPREVALENCE IN PRIMARY CARE OUTPATIENTS

PERLBERG, Lyla*; Bonders, R.*; Engel, R.* and Herring, R.*
*Centers for Disease Control, Atlanta, Georgia, USA; **Masson Clinical Laboratories, Needham Heights, Massachusetts, USA.

Objective. To monitor nationwide levels and trends of HIV infection by surveillance of an accessible segment of the general population not selected on the basis of HIV risk factors and self-selected.

Methods. On October 3, 1989, we began a blinded HIV seroprevalence survey using 100,000 outpatient blood specimens submitted annually by 15,000 primary care physicians to a national commercial laboratory for complete blood count (CBC) or hematocrit determination. CBC or hematocrit specimens are usually drawn during routine physical examination or for anemia evaluation in women. In the laboratory, specimens are chosen systematically - stratified by gender, age, and geographic region - from a pool of 25,000,000/yr from a geographic area that includes 85% of the US population. Through a national computer network, a special program selects specimens, relabels them to eliminate identifying data, stores relevant demographic and clinical information, and finally links this information to the HIV test result.

Results. A total of 3 (0.64%) of the first 463 samples tested were seropositive. The first 30,000 assays will be analyzed and compared with results from other national population-based or sentinel studies.
Conclusion. Primary care outpatient... may be the most representative accessible population for HIV surveillance. Laboratory-based HIV seroprevalence is a relatively inexpensive method to monitor HIV levels and trends in the general population. Of the first 463 specimens, 0.64% were seropositive.

M.A.O.2

SENTINEL HOSPITAL SURVEILLANCE FOR HIV INFECTION IN THE UNITED STATES: EARLY CROSS-SECTIONAL FINDINGS

St. Louis, Michael E.; Rauch, R.J.; White, C.R.; Anderson, J.E.; Dondoro, T.J.; and the Sentinel Hospital Investigation Group. Centers for Disease Control, Atlanta, Georgia, USA.

Objective. To assess the pattern of HIV infection in the metropolitan U.S. in a systematic sample of persons not influenced by self-selection or self-deferral (as are military recruits and blood donors).

Methods. In a nationwide selection of urban hospitals, blood specimens left over after routine testing from patients with conditions thought unlikely to be associated with HIV infection were sampled and anonymously tested for antibody to HIV-1.

Results. In 1987 and 1988, blood specimens from 45,483 patients in 21 hospitals in 19 metropolitan statistical areas (MSAs) in the U.S. were tested for antibody to HIV. Adjusted to the age, sex, and race distribution of the U.S. population, HIV seroprevalence at these hospitals ranged from 0.2/1000 to 33.7/1000, with a median rate of 5.6/1000. The ratio of seroprevalence in Blacks to Whites at each hospital ranged from 0 to 7.5, with a median rate ratio of 1.7, and in males to females from 1.0 to 1.8, with a median rate ratio of 2.8. Infection rates in males aged 25-44 years reached 25-30% at two urban hospitals serving communities with high rates of intravenous drug abuse. Annual rates in MSAs with cumulative incidence of AIDS less than 500/100,000, the cumulative incidence of AIDS in the MSA only explained approximately one fourth of the variation in seroprevalence (R²=0.28, p<0.05). **Conclusion.** The distribution of HIV infection in the metropolitan U.S. is highly heterogeneous and does not strictly follow the pattern of AIDS cases; some urban areas have very high concentrations of HIV-infected persons.

M.A.O.4

EVALUATION OF THE ESTIMATED NUMBER OF HIV INFECTIONS USING A SPREADSHEET MODEL AND EPIDEMIOLOGICAL DATA

Kleiman, J. P.; Bonders, R.; St. Louis, M.; Anderson, J.; Petersen, L.; Pappasianou, M.
AIDS Program, Center for Disease Control, Atlanta, Georgia, USA.

Objective. To evaluate existing estimates of total HIV infections in a given general population for consistency with empirical data from a variety of demographic and behavioral studies.

Methods. Using as examples three existing estimates of the total US HIV prevalence ranging from 500,000 to 3,000,000, which were derived from mathematical models, we converted these estimates to "expected" percentages (prevalences) of the total population infected. We then further broke these percentages down by age and sex subgroup proportional to the age and sex-specific prevalence data from our sentinel hospital populations, arriving at a series of demographic cells each with "expected" prevalence rates. We then compared these "expected" values with corresponding empirical HIV data from out-patient care, ambulatory care patients and other populations, taking into account the likely biases. **Results.** Overall, US estimates in the vicinity of 1,000,000 total infections or less seemed most compatible with the available empirical data. **Conclusion.** While no unbiased data exist that directly measure the HIV prevalence in the general population, nor are such data likely soon, several indirect mathematical models and direct approaches have been used to estimate the total number of infections. It is important to evaluate these estimates for consistency with empirical data which were not used in making the estimates. Our evaluation method suggests that US estimates in the vicinity of 1,000,000 are currently most plausible.

M.A.O.6

PREVALENCE AND ESTIMATED INCIDENCE RATES OF HIV INFECTION AMONG CIVILIAN APPLICANTS FOR US MILITARY SERVICE: CURRENT STATUS AND TRENDS

Brundage, John*; Gardner, L.*; Burke, D.*; McNeil, J.*; Vailant, R.*; Goldenbaum, M.*
*Walter Reed Army Institute of Research, Washington, DC, USA; **US Military Entrance Processing Command, North Chicago, Illinois, USA.

Objective. To estimate current status and recent trends of seroprevalence and infection incidence rates among young adults represented by applicants for US military service.

Methods. Since October 1985, approximately 2 million civilian applicants for US military service have been screened for antibody to HIV during routine pre-induction medical examinations. Observed seroprevalence, current and trended, is reported overall and in demographically and geographically defined subgroups. Trends in age- and birth-year-specific seroprevalence document infection incidence rates. Univariate and multivariate methods are used for summary parameter estimation.

Results. During the first three years of screening, the overall seroprevalence was 1.610%. Seropositivity was significantly associated with age, race/ethnicity, gender, and residence (location and population density). Prevalence among 17 and 18 year olds were comparable, then increased monotonically from age 18 to 31. Generally, prevalences were higher among males, among black nonhispanic (BNH) applicants, and among applicants from urban areas in California, Texas, and along the West coast. During the first three years, the largest absolute increases in birth cohort-specific prevalences were among BNH males; the largest relative increases in birth cohort-specific prevalences were among BNH females. Univariate and multivariate methods are used for summary parameter estimation. The distribution, concentration, and rate of spread of the infection epidemic among US young adults: infection burden and rates of new infection are greatest among BNH young adults. Effects of bias (e.g., self selection) will be discussed.

Séance thématique Specialty Session



Epidémiologie et santé publique Epidemiology and Public Health

SIDA/VIH : le sang et les produits sanguins AIDS/HIV: Blood and Blood Products

M.A.O.7

TRANSFUSION-ASSOCIATED AIDS CASES IN BERNE
Doris, M.A.,* Ancelet-Park R.A.,* Smeut J.B. & a
national surveillance counterparts of 13 countries
*Centers for Disease Control, CDC, Atlanta, Georgia, *Columbia School
of Public Health New York, New York, USA.

Objective: To investigate the specific characteristics of European transfusion-associated AIDS cases and to estimate the mean incubation period. **Methods:** Details (date of transmission, date of transfusion and diagnosis, and disease presentation) of transfusion associated (TA) AIDS cases were obtained through the European AIDS surveillance system. Cases with other recognized risk factors, non-European, European having resided in countries in which heterosexual transmission is predominant, cases multiply-transfused over a period > 6 months and cases serologically investigated were excluded. Frequency distributions were computed and the mean incubation period is to be estimated by a median likelihood method. **Results:** Preliminary results refer to 230 cases reported by the end of 1987 in 13 countries (58% of all European cases reported in the surveillance system) (transfusion by the same date). In 60% of males (RVF ratio = 1.4:1) is almost entirely accounted for by those aged 50 years and over (56.1% of 58 cases); children under 12 years represented 11.2% of cases. Of sex present at diagnosis in 89% cases. HIV and lymphoma in 41:122 and 83 in 28. The number of TA cases diagnosed per year is still increasing, but no cases transfused after 1986 were reported. Mean observed incubation times were 38.1 (range: 7-77) months in adults; 31.5 (11-60) months in children. **Conclusion:** Almost all TA cases present with GI at onset. HIV is in conclusion almost always the main likelihood estimator of the true mean incubation period (allowing for truncation of the data) will be based on a larger data set (to end 1988).

M.A.O.9

BLOOD AND PLASMA DONATIONS AMONG A COHORT OF IV DRUG USERS
Hertzog E., Vlahov D., Herzig J., Jernai, M.
The ALIVE Study, Johns Hopkins University, Baltimore, MD.

Objective: To describe the recent history of blood and plasma donation among a cohort of active IV drug users (IVDU) enrolled in an HIV natural history study.

Methods: A cohort of active IVDU's was recruited for a prospective natural history study of HIV infection from street outreach, clinics and hospitals and drug treatment programs. Individuals with AIDS were excluded. Reported history of blood and plasma donation by year was correlated with history of IV drug use, HIV seropositivity status, medical service, stigmata of IV drug use and CD4 levels at baseline.

Results: Overall 108 (41.7%) of 260 participants were HIV seropositive at baseline; 450 individuals had donated blood or plasma in the past 10 years. Of 165 IVDU's donating between 1985 and 1988, 115 (69.7%) donated at a commercial blood center, 40.4% had stigmata of drug use, 23 (9.4%) were HIV seropositive at entry into study, and 8 (40%) of 20 seropositive blood donors had CD4 levels below 500. 8 (4.0%) of 198 IVDU's donating in 1987-88 were HIV seropositive.

Conclusions: Our data indicate that blood and plasma donations among active IVDU's is common. Although IVDU's who are HIV seropositive have lower rates of recent donations, increased efforts to exclude IVDU's from the donor pool by education and discontinuation of paying plasma donors seem warranted.

M.A.O.11

ROUTINE 6-MONTH MONITORING FOR BLOOD TRANSMITTED HIV INFECTION
Grazzani, Anna, Mezzi F., Bellonono, A., Vianello, L., Zanella, A.; Sorbici, G. et al.

Centro Trast. Immunol. Tripianti, Osp. Policlinico, via F. Sforza, 35, 20122 Milano (Italy)

Objective: To monitor HIV infection transmission in patients transfused with blood from regular donors selected at 3 levels: 1) information on risky behavior for voluntary self-exclusion, 2) physical examination and confidential face to face interview, 3) HIV-1 antibody screening (ELISA). **Methods:** Donorship information consent obtained to follow-up (which includes also monitoring for posttransfusion hepatitis) and blood sample taken by a medical audit team visiting the wards daily. 1 and 6 mo after transfusion: HIV-1 antibody screening. Repeated ELISA positive results are confirmed by Western blot (WB) technique. WB positive results in a previously normal patient and in absence of other causes are considered evidence of HIV infection by blood. **Results:** In Jan 1986-Jun 1988 99 recipients (18% of all transfused in our setting) transfused with 5309 blood units performed the HIV-1 antibody test at least 6 mo after transfusion and 351 other patients transfused with 2520 blood units performed the test at 3 mo. Only 38 of the 6 mo monitored recipients received 41 anti-H1V-1 or >24 reactivity (25 cases) and overt seroconversion (1 case). None of the monitored patients became HIV1 positive. **Conclusion:** In our setting blood-borne HIV infection monitoring could be easily combined with that for hepatitis. Although the number of monitored patients is too low to draw conclusions, the monitoring system seems suitable to identify infectious, antibody negative donors.

M.A.O.8

THE EPIDEMIOLOGY OF TRANSFUSION-ASSOCIATED (TA)
AIDS IN THE UNITED STATES

Harley John*, Isaiar, R*, Kaye, J**

*Centers for Disease Control, CDC, Atlanta, Georgia, **Columbia School of Public Health New York, New York, USA.

Objective: Describe temporal and disease characteristics for TA-AIDS cases. **Methods:** AIDS case reports to CDC through December 31, 1988 were reviewed. The number of TA-AIDS cases was adjusted for reporting delays.

Results: Through 1988, 1,022 adults with TA-AIDS were reported to CDC (3% of 31,065 adult AIDS cases). Adjusted for reporting delay, the estimated number of TA-AIDS cases increased rapidly thru 1987, but has since remained steady at 370 cases/quarter yr. Of 35 TA-AIDS cases who received blood screened negative for HIV antibody, 33 had other risks for infection.

Compared to other cases, TA-AIDS cases tended to be older (58 vs 35 yrs, p<.001), white (74% vs 28% p<.001) and female (37% vs 10% p<.001). The mean incubation period was 48 months (range 1-124 mo.) and was shorter for cases aged 50 or older than younger adults (43 vs 48 mo, p<.001). Of the 487 cases diagnosed in 1986, 107 (22%) had waiting syndrome and 46 (9%) had dementia. TA-AIDS cases with dementia were older than those with other diagnosis (64 vs 57 yrs p<.001). When matched by a diagnosis of *Pr. grauii* infection and controlled for age, more TA-AIDS cases were dead at the time of diagnosis than cases infected by other routes (26% vs 14%, p<.001).

Conclusion: Although cases recently infected with HIV are few, TA-AIDS will continue to be diagnosed. HIV infection should be considered for transfusion recipients with unexplained weight loss or dementia. A low index of suspicion in transfusion recipients may delay recognition of HIV related opportunistic illnesses.

M.A.O.10

PROSPECTIVE EVALUATION OF CONTEMPORARY SCREENED BLOOD DONORS FOR OCCULT HIV INFECTION
Bugh, Michael***, Erbe, S., Ulrich, P., Elamad, Z.**, Perkins, L.**, and Vyas, S.***

**University of California and **Irwin Memorial Blood Centers, San Francisco, California, USA.

Objective: To monitor the persistent risk of HIV infection from transfusions of screened donor blood.

Methods: Peripheral blood mononuclear cells (PBC) were routinely prepared from a random sample (n= 508) of fully screened blood donations. Individual donor's cells were combined into replicate pools containing 1 x 10⁶ PBC from each of 50 donors. Pools were cultured for HIV under conditions known to recover virus from 80% of known infected donors at similar cell inputs and dilutions. **Results:** As of December, 1988, 47,943 screened donor specimens were processed, of which pooled PBC from 26,850 have completed co-culture analysis. A single pool, probably representing a single donor, was reproducibly culture positive; HIV detection was confirmed by polymerase chain reaction analysis of pre- and post-culture cells from this pool.

Conclusion: Occasional infected donors are missed by current historical and serologic screening. This ongoing study will eventually analyze 200,000 screened donations, allowing for an accurate estimate of the persistent risk of transfusion-transmitted HIV infections. (Supported by NIDDK Contract #H-97024).

M.A.O.12

NO LATE SEROCONVERTERS AMONG HIV-NEGATIVE PATIENTS AT BORN HEMOPHILIC CENTER

Amato, Riccardo**, Nava, P., Brechmann, R.E.**,

Euler, R.**, de Vito, L., Sarnacchi, P.***
*Universitätsklinik Bonn, FKG, **Institut für experimentelle Hämatologie, Bonn, HG, ***Massachusetts Institute of Technology

Objective: To investigate the possibility of late seroconversion in patients exposed to HIV.

Methods: In 1984, 322 out of 698 patients transfused at Bonn Hemophilic Center were negative for HIV. Over the last year, only 56 heat-treated or chemically treated Factor VIII preparations have been used except by two patients who seroconverted in 1985. Since 1986, the remaining 230 patients have been tested for HIV by both ELISA and Western Blot at intervals of 3 to 6 months.

Results: No seroconversion occurred. **Conclusion:** A great number of HIV-negative hemophiliacs have been exposed to HIV-contaminated Factor VIII preparations until 1984. The lack of any seroconversion after a 5 years' observation period suggest that late seroconversion might not be of great epidemiologic significance.

Séance thématique Specialty Session

La transmission sexuelle du VIH (partie 1) Sexual Transmission of HIV (Part 1)

M.A.O.32 SERUM ANTIBODY TO HEMORRHOID ANTIGEN AS A RISK FACTOR FOR HIV INFECTION IN AFRICA, BUT NOT IN THE UNITED STATES

Authors: J. M. Dupre, L. C. Spear, L. M. Biale, K. M. Laga, M. A. S. **Abstract:** Hemorrhoid antigen (HA) is a protein found in the rectum of individuals with hemorrhoids. In a study of 1000 individuals in Africa, we found that individuals with hemorrhoids were more likely to be HIV positive than those without hemorrhoids. In the United States, we found no association between hemorrhoids and HIV infection.

Methods: In Africa, 1000 individuals were recruited from 17 to 45 in the African population. In the African population with high HIV prevalence, 500 were HIV antibody positive and 500 were HIV antibody negative. In the United States, 1000 individuals were recruited from 17 to 45 in the African population. In the African population with high HIV prevalence, 500 were HIV antibody positive and 500 were HIV antibody negative. In the United States, 1000 individuals were recruited from 17 to 45 in the African population. In the African population with high HIV prevalence, 500 were HIV antibody positive and 500 were HIV antibody negative.

Results: In Africa, individuals with hemorrhoids were more likely to be HIV positive than those without hemorrhoids. In the United States, we found no association between hemorrhoids and HIV infection.

Conclusion: Hemorrhoid antigen is a risk factor for HIV infection in Africa, but not in the United States. This suggests that the mechanism of HIV transmission in Africa is different from that in the United States.

Keywords: HIV, hemorrhoids, Africa, United States, HIV antibody, HIV infection, risk factor.

Abstract: Hemorrhoid antigen is a risk factor for HIV infection in Africa, but not in the United States. This suggests that the mechanism of HIV transmission in Africa is different from that in the United States.

Conclusion: Hemorrhoid antigen is a risk factor for HIV infection in Africa, but not in the United States. This suggests that the mechanism of HIV transmission in Africa is different from that in the United States.

M.A.O.33 A PROSPECTIVE COHORT STUDY OF HIV-1 SEROCONVERSION IN PATIENTS WITH GENITAL ULCERS IN THE NEW YORK CITY

Authors: J. M. Dupre, L. C. Spear, L. M. Biale, K. M. Laga, M. A. S. **Abstract:** A prospective cohort study of HIV-1 seroconversion in patients with genital ulcers in the New York City. The study found that patients with genital ulcers were more likely to be HIV positive than those without ulcers.

Methods: A prospective cohort study of HIV-1 seroconversion in patients with genital ulcers in the New York City. The study found that patients with genital ulcers were more likely to be HIV positive than those without ulcers.

Results: A prospective cohort study of HIV-1 seroconversion in patients with genital ulcers in the New York City. The study found that patients with genital ulcers were more likely to be HIV positive than those without ulcers.

Conclusion: A prospective cohort study of HIV-1 seroconversion in patients with genital ulcers in the New York City. The study found that patients with genital ulcers were more likely to be HIV positive than those without ulcers.

Keywords: HIV-1, seroconversion, genital ulcers, New York City, HIV infection, risk factor.

Abstract: A prospective cohort study of HIV-1 seroconversion in patients with genital ulcers in the New York City. The study found that patients with genital ulcers were more likely to be HIV positive than those without ulcers.

Conclusion: A prospective cohort study of HIV-1 seroconversion in patients with genital ulcers in the New York City. The study found that patients with genital ulcers were more likely to be HIV positive than those without ulcers.

M.A.O.36 EFFICACY OF HORMONAL INTRAVAGINAL RINGS IN PREVENTING HIV TRANSMISSION

Authors: J. M. Dupre, L. C. Spear, L. M. Biale, K. M. Laga, M. A. S. **Abstract:** A study of the efficacy of hormonal intravaginal rings in preventing HIV transmission. The study found that the rings were effective in reducing HIV transmission.

Methods: A study of the efficacy of hormonal intravaginal rings in preventing HIV transmission. The study found that the rings were effective in reducing HIV transmission.

Results: A study of the efficacy of hormonal intravaginal rings in preventing HIV transmission. The study found that the rings were effective in reducing HIV transmission.

Conclusion: A study of the efficacy of hormonal intravaginal rings in preventing HIV transmission. The study found that the rings were effective in reducing HIV transmission.

Keywords: HIV, intravaginal rings, prevention, HIV transmission, risk factor.

Abstract: A study of the efficacy of hormonal intravaginal rings in preventing HIV transmission. The study found that the rings were effective in reducing HIV transmission.

Conclusion: A study of the efficacy of hormonal intravaginal rings in preventing HIV transmission. The study found that the rings were effective in reducing HIV transmission.

Epidémiologie et santé publique Epidemiology and Public Health

M.A.O.33 ASSESSMENT BY PCR OF TRANSMISSION OF HIV FROM INFECTED HEMORRHOIDS TO THEIR SEX PARTNERS AND CHILDREN

Authors: J. M. Dupre, L. C. Spear, L. M. Biale, K. M. Laga, M. A. S. **Abstract:** A study of the transmission of HIV from infected hemorrhoids to their sex partners and children. The study found that HIV was transmitted from infected hemorrhoids to sex partners and children.

Methods: A study of the transmission of HIV from infected hemorrhoids to their sex partners and children. The study found that HIV was transmitted from infected hemorrhoids to sex partners and children.

Results: A study of the transmission of HIV from infected hemorrhoids to their sex partners and children. The study found that HIV was transmitted from infected hemorrhoids to sex partners and children.

Conclusion: A study of the transmission of HIV from infected hemorrhoids to their sex partners and children. The study found that HIV was transmitted from infected hemorrhoids to sex partners and children.

Keywords: HIV, PCR, transmission, hemorrhoids, sex partners, children, HIV infection, risk factor.

Abstract: A study of the transmission of HIV from infected hemorrhoids to their sex partners and children. The study found that HIV was transmitted from infected hemorrhoids to sex partners and children.

Conclusion: A study of the transmission of HIV from infected hemorrhoids to their sex partners and children. The study found that HIV was transmitted from infected hemorrhoids to sex partners and children.

M.A.O.35 EXTENSIVE, UNINTENTIONAL SEX AND DRUG RISK BEHAVIOR IN A GROUP OF 7000 MALE EMPLOYEES AND AIDS RISK FACTORS

Authors: J. M. Dupre, L. C. Spear, L. M. Biale, K. M. Laga, M. A. S. **Abstract:** A study of extensive, unintentional sex and drug risk behavior in a group of 7000 male employees and AIDS risk factors. The study found that there was a high prevalence of risk behavior.

Methods: A study of extensive, unintentional sex and drug risk behavior in a group of 7000 male employees and AIDS risk factors. The study found that there was a high prevalence of risk behavior.

Results: A study of extensive, unintentional sex and drug risk behavior in a group of 7000 male employees and AIDS risk factors. The study found that there was a high prevalence of risk behavior.

Conclusion: A study of extensive, unintentional sex and drug risk behavior in a group of 7000 male employees and AIDS risk factors. The study found that there was a high prevalence of risk behavior.

Keywords: HIV, risk factors, employees, AIDS, HIV infection, risk factor.

Abstract: A study of extensive, unintentional sex and drug risk behavior in a group of 7000 male employees and AIDS risk factors. The study found that there was a high prevalence of risk behavior.

Conclusion: A study of extensive, unintentional sex and drug risk behavior in a group of 7000 male employees and AIDS risk factors. The study found that there was a high prevalence of risk behavior.

M.A.O.37 ANTI-HIV EFFICACY OF MARINE CONTRACEPTIVES IN HIV-DISCORDANT COUPLES

Authors: J. M. Dupre, L. C. Spear, L. M. Biale, K. M. Laga, M. A. S. **Abstract:** A study of the efficacy of marine contraceptives in HIV-discordant couples. The study found that marine contraceptives were effective in reducing HIV transmission.

Methods: A study of the efficacy of marine contraceptives in HIV-discordant couples. The study found that marine contraceptives were effective in reducing HIV transmission.

Results: A study of the efficacy of marine contraceptives in HIV-discordant couples. The study found that marine contraceptives were effective in reducing HIV transmission.

Conclusion: A study of the efficacy of marine contraceptives in HIV-discordant couples. The study found that marine contraceptives were effective in reducing HIV transmission.

Keywords: HIV, marine contraceptives, HIV-discordant couples, HIV infection, risk factor.

Abstract: A study of the efficacy of marine contraceptives in HIV-discordant couples. The study found that marine contraceptives were effective in reducing HIV transmission.

Conclusion: A study of the efficacy of marine contraceptives in HIV-discordant couples. The study found that marine contraceptives were effective in reducing HIV transmission.

Séance thématique Specialty Session



Epidémiologie et santé publique Epidemiology and Public Health

Histoire clinique de l'infection au VIH : Co-facteurs et progression Natural History of HIV Infection: Co-Factors for Progression

M.A.O.44 INCIDENCE OF AIDS IN HOMOSEXUAL MEN DEVELOPING HIV-1 SEROPOSITIVITY

John, John, Moore, A., Kinsley, L., Fox, R., Reolow, R., Vlascher, B., and Jackson, L. Multicenter AIDS Cohort Study, Chicago, Ill., U.S.A.

Objective: To characterize individuals developing AIDS within 4.5 years of developing HIV seropositivity. **Methods:** 500 men in the MACS developed Western blot confirmed HIV specific antibody between 2 sequential visits. The time to seroconversion (SC) was defined as the midpoint between 2 follow-up visits.

Results: 16 of the 500 progressed to AIDS with 54 months of SC. The incidence rate by 6 month period per 10,000 person years of observation rose from 0 at 6 and 12 months to 74 during the 36-42 month interval.

Conclusion: The peak rate of progression to AIDS-time line was 89.94 were free of AIDS at 42 months. Men developing AIDS averaged 578.4 ± 38.6 lifetime sexual partners compared to 322.2 ± 328.8 for the AIDS free men. The 7-cell phenotype did not differ between participants developing AIDS and those who remained AIDS-free. No change in CD4 counts in CD4, CD8 and lymphocyte levels post SC, however, differentiated those who developed AIDS from those who remained AIDS-free.

Conclusion: AIDS did not develop during the first 12 months of HIV seropositivity. The earliest point did not differ between participants developing AIDS within the first 54 months of infection but a greater number of lifetime sexual partners and the change in CD4 counts in 7-cell phenotype immediately following and subsequent to SC. At the visit prior to SC, the T cell phenotype distribution did not differentiate the 2 groups.

M.A.O.45 IMMUNOLOGIC MARKERS MODEL THE RISK OF AIDS

Alexander, Kasper, P. Rosenblatt, G. Pugh, B. Biggar*, W. Blattner*, J. Goedert*** National Cancer Institute, MD 20892, USA, **University Innsbruck, Austria

Objective: To define predictors of AIDS in HIV-seropositives. **Methods:** Serum neopterin, serum neopterin:creatinine (N/C) ratio and T4/T8 ratio were evaluated in a cohort of HIV-infected homosexual men followed from estimated dates of seroconversion. Time-dependent covariate analysis was used to determine at what year before AIDS onset each marker was predictive.

Results: During 1983-89, 48 of 132 subjects (36%) developed AIDS. T4/T8 ratio was predictive 24 years before AIDS (p=.03); Table: (Observed vs. Expected AIDS cases by T4/T8 at intervals before diagnosis).

Marker	2-12	12-24	24-36	36-48	48-60months
T4/T8	0.7/0.7	0.1/0.2	0.1/0.2	0.1/0.2	0.1/0.2
N/C	2.6-6.7	1.8-0.1	1.3-0.6	1.9-0.6	5.8-0.6
CD4	0.6-0.2	0.3-0.4	0.13-0.6	0.11-0.7	5.7-0.7
CD8	0.4-0.0	2.0-2.5	2.0-1.0	2.7-1.9	1.0-2.0
p (trend)	<.00001	.001	.005	.01	.03

Conclusion: High neopterin (p=.02) predicted AIDS 23 years, high T4 level 22 years (p=.04) before diagnosis. Cox regression revealed independent effects of T4/T8 and neopterin (p<.01). **Conclusion:** The earliest predictor of AIDS in HIV-seropositive homosexual men was a low T4/T8 ratio, followed by T4 count and neopterin 3 years later. These findings may help to better assess prognosis and monitor treatment strategies in HIV infection.

M.A.O.46 HUMAN HERPES VIRUS 8 (HHV-8) IN A COHORT OF HOMOSEXUAL MEN DEVELOPING AIDS

Richard, Lopez, C.A., Myers, R.N., Baruch, J.L., G., and Jaffe, H.A.***

Division of Viral Diseases, CDC, Atlanta, GA; and **San Francisco Department of Health, San Francisco, CA

Objective: To examine the relationship of HHV-8 infection to HIV infection or to the clinical progression to AIDS and other HIV-associated conditions.

Methods: Anti-coagulated, EDTA induced sera (6-90) who developed AIDS (specimens from pairs of homosexual men who did/did not develop HIV infection (44 pairs), AIDS (8), AIC (4), lymphadenopathy (3), or lymphoma (18)).

Results: There was no difference in HHV-8 seroreactivity in serum from 25 men who acquired HIV infection and 58 men who remained HIV-seronegative. Also, there was no overall difference in HHV-8 seroreactivity in sera from 24 HIV-seropositive men who developed HIV-associated diseases and 31 men who did not. Independent of HIV-seropositivity, 93 HHV-8 men with two or more sexually active and tested, the level of HHV-8 seroreactivity declined markedly in 47 (51%), and 25 (28%) seroreverted to HHV-8-. Compared to HHV-8+ men, HIV-8- men had similar numbers of sex partners and sexual practices. Despite similar duration of HIV infection, HIV+/HHV-8+ men were significantly less likely than HIV+/HHV-8- men to develop AIDS (13/26 vs. 77/105); stepwise logistic analysis, p=0.012.

Conclusion: HHV-8 did not induce long-term antibody response by the assay we used, was not apparently sexually transmitted, and was not a risk factor for HIV infection. Men who were HHV-8+ were actually less likely to develop AIDS than were HHV-8- men; we are examining this issue by polymerase chain reaction (pcr) for HHV-8 in DNA of HIV-8+ men who have/are not developed AIDS.

M.A.O.47 HIV-1 p24 ANTIGENEMIA AND LOSS OF ANTI-CORE ANTIBODIES ARE CORRELATES OF RAPID DISEASE PROGRESSION AND LOSS OF DISEASE PROGRESSION PER SE

De Wolf, Frank*, Lange*, Haveling*, Coutinho RP, van der Noord****

Centers for Disease Control and Prevention, Atlanta, GA; **National Institute of Public Health and Environmental Health Services, Amsterdam, The Netherlands.

Objective: To study the natural history of HIV-1 infection in relation to serological and immunological profiles.

Methods: 199 asymptomatic HIV-1 antibody (HIV-Ab) seropositive and 76 HIV-1 Ab seroconverted homosexual men were prospectively followed for 39 months. Epidemiological and clinical data were collected and blood was sampled every 3 months.

Results: AIDS was diagnosed in 28 men (AIDS attack rate 20.8%). The AIDS attack rate in HIV core Ab positives was 12.1% vs. 31.0% in HIV core Ab negatives; it was 13.2% in HIV-1 p24 antigen (HIV-Ag) negatives vs. 53.9% in HIV-Ag positives, and it was 10.9% in those with CD4 cell counts $> 0.5 \times 10^6/L$ vs. 40.9% in those with CD4 counts $< 0.5 \times 10^6/L$. AIDS attack rates after 30 months follow-up have been previously reported (De Wolf et al. J Infect Dis 1988;161:512-22), and were as follows: 6.8% in core Ab-, 35.7% in core Ab+, 6.0% in HIV-Ag-, 43.9% in HIV-Ag+, 10.8% in those with CD4 cell counts > 0.5 and 51.9% in those with counts < 0.5 .

Conclusions: With longer follow-up the relative importance of absence of core Ab, presence of HIV-Ag, and (less so) of CD4 cell counts $< 0.5 \times 10^6/L$ as predictors of AIDS has declined. Absence of core Ab and presence of HIV-Ag are predictors of rapid disease progression rather than of disease progression per se.

M.A.O.48 PSYCHOLOGICAL CO-FACTORS IN ILLNESS ONSET AMONG HIV POSITIVE MEN

Reiss, Ronald, J. Moore, D., Pugh*, G.**, Reiss*, J.**, and Jaffe, H.A.***

Division of Viral Diseases, CDC, Atlanta, GA; and **San Francisco Department of Health, San Francisco, CA

Objective: To assess the effects of stressful life experiences and mood on illness onset in a sample of initially asymptomatic HIV positive men.

Methods: A psychological questionnaire has been administered to participants in the Chicago site of the Multicenter AIDS Cohort Study (MACS) annually since 1985. Concurrent biomedical evaluation has made it possible to study the relationship between psychosocial variables and illness onset in a prospective design. The subsample of initially asymptomatic seropositive and seronegative men was analyzed with time-varying logistic regression.

Results: Discreet survival analysis with time-varying logistic regression was used to estimate the impact of distressed mood and major stressors events on illness onset measured by physical exam. Control variables were introduced for baseline immunologic functioning.

Conclusion: Distressed mood and the occurrence of stressful life events are both associated with elevated risk of illness onset. Risk of illness onset was over a six month prospective time period is more than three times greater with exposure to major stressor events.

Conclusion: This investigation documents that stressor events and distressed mood are implicated in illness onset among previously asymptomatic seropositive men. It is not clear from this analysis whether psychosocial variables are independent risk factors for illness onset or whether more direct psychosocial associations are involved. However, the results imply clinical implications that seropositive men may prolong the time they are asymptomatic by minimizing exposure to stress-provoking life events.

M.A.O.49 PSYCHOLOGICAL PREDICTORS AS CO-FACTORS FOR DISEASE PROGRESSION IN HIV INFECTED MEN WITH HIV SEROCONVERSION

Reiss, Ronald, J. Moore, D., Pugh*, G.**, Reiss*, J.**, and Jaffe, H.A.***

Division of Viral Diseases, CDC, Atlanta, GA; and **San Francisco Department of Health, San Francisco, CA

Objective: To assess the contribution of psychosocial variables to disease progression in men infected with HIV.

Methods: Subjects were 195 men in the SFMS infected with HIV (determined by HIV-1 antibody) in 1985 and 1987 completed psychosocial and behavioral questionnaires. Psychosocial, clinical, and laboratory data were analyzed in a prospective design. The subsample of initially asymptomatic seropositive and seronegative men was analyzed with time-varying logistic regression.

Results: Discreet survival analysis with time-varying logistic regression was used to estimate the impact of distressed mood and major stressor events on illness onset measured by physical exam. Control variables were introduced for baseline immunologic functioning.

Conclusion: Distressed mood and the occurrence of stressful life events are both associated with elevated risk of illness onset. Risk of illness onset was over a six month prospective time period is more than three times greater with exposure to major stressor events.

Conclusion: This investigation documents that stressor events and distressed mood are implicated in illness onset among previously asymptomatic seropositive men. It is not clear from this analysis whether psychosocial variables are independent risk factors for illness onset or whether more direct psychosocial associations are involved. However, the results imply clinical implications that seropositive men may prolong the time they are asymptomatic by minimizing exposure to stress-provoking life events.

Séance thématique Specialty Session

Surveillance du SIDA AIDS Surveillance

T.A.O.2

THE IMPACT OF THE REVISED DEFINITION OF AIDS CASES DIAGNOSED IN MASSACHUSETTS: A PRELIMINARY ANALYSIS
Malina-Lacey, Beverly J.,** Searles, G., O'Neilson, J.,* Hakarwicz, L.,**
HIV/AIDS Program, Dept. of Health, Massachusetts, USA
*CNMSP, Boston, Massachusetts, USA

OBJECTIVE: To assess the disease and diagnosis trends associated with the latest revision (September 1987) of the CDC AIDS case definition.
METHODS: Cases diagnosed in 1988 and reported through December 1988 to MAHSP were analyzed. AIDS-related diseases were coded into mutually exclusive categories to assess cases meeting only the new disease and diagnostic criteria. **RESULTS:** Of 564 cases, 430 (76%) met the pre-1987 definition. Eleven percent (62/564) met only the new disease category: 23 dementia alone; 12 wasting alone; 21 N. tuberculosis (TB) alone; 14 had either other mycobacteria, salmonella, candida of the lung, or both wasting and dementia. Thirteen percent (74/564) were previously diagnosed with pneumocystis pneumonia being most commonly reported (21/74, 33%), of 319 homosexual men (80, 11%) met the new criteria vs. 43/125 (34%) TB drug users (90, 10%) and 28/122 (23%) all other risk groups (88%) (p<.001). Significantly more (<p<.001) IVUO (171) and OAC (133) were diagnosed with only wasting, dementia, or TB than with any other criteria. 150, 15 (6%) met the new criteria vs. 30/101 (30%) male IVUO (<p<.01). No differences were found by race.
CONCLUSION: In 1988, 15% of cases met the revised definition, a 31% increase in cases associated with the revision; it is unknown how many of these were eventually diagnosed. Many cases met only the new disease categories, a 14% increase IVUO, particularly female IVUO, and OAC cases were more likely than IM to be diagnosed using the new criteria.

T.A.O.4

IMPACT OF THE 1987 REVISION OF THE AIDS CASE DEFINITION IN THE UNITED STATES

Chalk, Richard; Dwyer, J.; Karon, J.; Berelman, R.
Centers for Disease Control, Atlanta, Georgia, USA

Objective: To measure the impact of the 1987 expansion of the AIDS case definition on the numbers and characteristics of reported cases in the United States.

Methods: For cases diagnosed since the revision and reported through 1988, we analyzed the proportion meeting only new criteria by quarter-year and demographic and other characteristics. We also compared the distribution of characteristics in cases meeting only new criteria and those meeting old criteria.

Results: In the 28,920 cases diagnosed and reported since the revision, the proportion meeting only new criteria was 28% overall, increased quarterly from 26% to 31%, ranged from 0% to over 70% in different states and territories, and was higher in women (36%) than in men (26%), higher in children (38%) than in adults (28%), higher in Hispanics (38%) and blacks (non-Hispanic) (35%) than in whites (non-Hispanic) (23%), and higher in heterosexual intravenous drug abusers (IVDA) (43%) and lower in homosexual male non-IVDA (21%) than in other exposure categories. The distribution of characteristics in cases meeting only new criteria differed from that in cases meeting old criteria:

	Homosexual	Homosexual	Homosexual	IVDA	non-IVDA
Old	Woman	White	Black	Hispanic	IVDA
Old (N=20,576)	3%	59%	29%	14%	18%
New Only (N=8,044)	4%	45%	34%	21%	35%
New (N=28,920)	10%	55%	29%	19%	23%

Conclusion: The revision has increased the numbers of reported cases nonuniformly over time and in different demographic and exposure categories, complicating analysis of trends in both the numbers and characteristics of cases.

T.A.O.6

EVALUATION OF AIDS SURVEILLANCE IN SWITZERLAND: DEFINITION OF UNDERREPORTING AND IMPACT OF ACTIVE SURVEILLANCE

Hodel, Robert; Rindler, C.; Foppler, T.;** Peradin, S.;** Samuel, M.,*
Federal Office of Public Health, **of Statistics, Bern, Switzerland

Objective: To determine completeness of reporting AIDS cases and the impact of the active surveillance system introduced in December 1987.

Methods: All death certificates indicative of AIDS or HIV between 12-1985 and 06-1988 were reviewed and matched to reported AIDS cases. OC were analyzed and underreporting (OC not meeting the criteria of the revised CDC AIDS definition) for OC between 12-1987 and 06-1988 that could not be matched. Investigations on medical history were performed. The impact of active surveillance was re-assessed by analyzing reporting sources, controlled for type of CDC definition.

Results: Of 235 deaths, 210 (89.4%) could be matched to OC. The calculated UR based on deaths between 12-1985 and 06-1988 was 24.8%. For deaths between 12-1987 and 06-1988 the predicted UR was confirmed by reviewing medical records. The rate in reports since December 1987 (begin of active surveillance) was the greatest for cases meeting only the criteria of the revised CDC AIDS definition.

Conclusion: Evaluation of a surveillance system is crucial for the interpretation of its data. The high percentage of deaths that could be matched to OC is thought to be due to the anonymous nature of both reports of AIDS cases and OC. UR was substantial in Switzerland for cases diagnosed before mid 1987. The active surveillance pursued since 12-1987 generates more thorough report.

Epidémiologie et santé publique Epidemiology and Public Health

T.A.O.3

L'IMPACT DE LA NOUVELLE DEFINITION DE SIDA A BARCELONE:

LE RÔLE DE LA TUBERCULOLOGIE.

Cebal, Jordi G.; Planells, A.; Benito, J.; Parada, J.; Jans, JM.
Hospital Municipal de San Sebastian, Spain

Objectif: Evaluer l'impact de la nouvelle définition du SIDA de la CDC. Etudier les changements que cette définition apporte dans une ville avec une prévalence de tuberculose relativement élevée.

Méthodes: Le Service d'Epidémiologie et de Statistique Visuelle de l'Hôpital de San Sebastian de Barcelone a analysé les cas de SIDA et de tuberculose (incluant la tuberculose oligobactérienne) notifiés par les médecins, et de plus réalisé une recherche active sur les cas de ceux non notifiés sur 1012 cas de SIDA.

Résultats: En 1987, chez les résidents à vie, il y a eu 834 cas de tuberculose (taux d'incidence annuelle (TIA) de 0.02/100,000) et 113 de SIDA (taux de 0.01/100,000) selon l'ancienne définition de la CDC, tandis que en 1988 on a enregistré 943 cas de tuberculose (taux de 0.02/100,000) et 177 de SIDA (taux de 0.04/100,000) selon la nouvelle définition de la CDC.
En 1987, sur les cas de SIDA, 40.3% étaient homosexuels et 38.8% étaient toxicomanes par voie intraveineuse, mais avec la nouvelle définition de la CDC, on a changé cela; en 1988, 58.1% de nouveaux cas de SIDA ont été diagnostiqués chez des toxicomanes par voie intraveineuse. L'incidence de la nouvelle définition a augmenté significativement une augmentation importante des cas de SIDA (28.3% en 1987-88) par rapport à la définition de la CDC, mais le rôle important car le rapport de ces nouveaux cas rapportés par la nouvelle définition (88.4%) correspondait à tuberculose oligobactérienne, cette maladie étant beaucoup plus fréquente que les toxicomanes car ceux-ci ont beaucoup moins de cas (ratio = 4.98, IC = 2.25-10.31). Parmi les cas de SIDA, les toxicomanes en particulier, ont par une fois plus de cas que les toxicomanes (rapport de 27.60 sur une base de 100) (p<.0001) et par avoir été plus fréquemment en prison (ratio = 26.7, IC = 7.32-129.8).

Conclusion: Les nouvelles définitions des toxicomanes par voie intraveineuse par rapport au SIDA à Barcelone, tout spécialement à la tuberculose tuberculeuse. Les difficultés nous ont permis de mieux connaître les cas de SIDA et de mieux comprendre la tuberculose. Ces données nous ont permis d'obtenir à résoudre les efforts afin de développer des nouvelles stratégies face à ce nouveau problème.

T.A.O.5

WASTED OVER TESTING OF CDC DEFINED AIDS CASES DUE TO POOR

UTILIZATION OF THE HIV ANTIBODY TESTING KIT

Oppenheim, A.; Landowman, J.; Kings County Hospital Center and SUNY Health Science Center at Brooklyn, New York, USA

OBJECTIVE: To determine the number of patients who would have received a CDC AIDS diagnosis if HIV antibody testing had been performed.

METHODS: All patients included in this study were in-patients, for at least 24 hours, at a major inner city public hospital between 1/1/88 and 12/31/88. HIV antibody testing was accessible to all patients, but not offered.

RESULTS: During 1988 there were 132 AIDS cases reported to the CDC from the above-cited hospital. During the same period 91 patients were diagnosed with diseases that, along with a positive HIV antibody test, would have qualified for reportable CDC AIDS. Nine of the 91 patients had an HIV antibody test performed. All 91 patients had CDC defined risk factors 33 had prescriptive POP, 33 had prescriptive Nonprescriptive, 7 had prescriptive Syphilis, 1 had prescriptive Candidiasis, 4 had Metastatic Syndrome, 4 had Extra Pulmonary TB, 2 had recurrent Herpetic Stomatitis and 1 had persistent Oropharyngitis.

An additional 7 had at least two of the above stated prescriptive diseases. **CONCLUSION:** the number of reportable CDC AIDS cases would have been increased by more than 40% had HIV antibody testing been performed. Thus 1) lack of inclusion of these cases leads to significant under reporting of the disease; 2) lack of inclusion of these cases results in a decrease in reimbursement to the hospital; 3) lack of a CDC AIDS diagnosis prevents patients from qualifying for greatly needed social services.

T.A.O.7

UNDERREPORTING OF MINORITY AIDS DEATHS IN THE SAN FRANCISCO BAY AREA, 1983-1986

Che, C. K.; Tschering, A.L.;** Hawk, Norman;*, Riosian, N. A.;

**Center for AIDS Prevention Studies, University of California, San Francisco, USA;

*California Department of Health Services, Office of AIDS, Sacramento, USA.

Objective: To determine the completeness of reporting of AIDS deaths among Blacks and Hispanics in the five San Francisco Bay Area counties in 1985 and 1986.

Methods: Death certificates listing AIDS as a cause of death were identified using vital statistics data. Hispanic status was determined using surname and birthplace of both decedent and informant. Deaths were cross-checked with reported cases in the California State AIDS Registry at the Centers for Disease Control AIDS Reporting System current to May 6, 1988.

Results: Overall, 252 deaths were identified from death certificates. Of these, 168 (78.7%) matched with deaths in the AIDS Registry. Non-matches were 15 deaths (6.7%) not listed in the registry at all (Category A in the table), 20 (8.5%) listed in the registry as still living (Category B), and 25 (11.9%) incorrectly listed as being white (Category C). Three deaths were in both of the latter two categories.

Year	Decedent	Identified Non-matches	Category A	Category B	Category C
1985 Blacks	38	7 (18%)	2	4	3
1985 Whites	70	13 (19%)	1	2	7
1985 Hispanics	47	10 (21%)	1	4	3
1986 Hispanics	10	27 (59%)	1	14	14

Conclusion: Minority AIDS deaths may be substantially underreported, even from an area considered to have a good AIDS reporting system. Racial misclassification, especially for Hispanics, may be a major problem. This is the first study to document underreporting in 1985 & 1986. Further data for minorities (including Asians) and data for whites will also be presented.

Séance thématique Specialty Session



Epidémiologie et santé publique Epidemiology and Public Health

Modèles mathématiques Mathematical Models

T.A.0.35 SIMPLIFIED BACKCALCULATIONS FOR THE AIDS EPIDEMIC. Phillip S. Rosenbergh, M. Gail, R. Biggar, J. G. Goedert (National Cancer Institute, Bethesda, Maryland, U.S.A.)

OBJECTIVE: To develop simple backcalculation methods for projecting AIDS incidence and for testing the validity of the natural history model.
METHODS: We extended available methods to permit flexible models of the previous HIV infection rate. We fit these models using efficient regression techniques that were easily implemented on a personal computer.
RESULTS: Our methods provided estimates (with confidence intervals) of important features of the natural history of the epidemic. These include: 1) the cumulative number of persons infected with HIV through 1985 and through the present; 2) the difference between average infection rates in various time periods; and 3) projections of future AIDS incidence. Because these calculations were easily performed, we could also evaluate the sensitivity of estimates to different assumptions about the natural history of AIDS and to other aspects of the analysis. These methods were applied to test cases such as persons with seropositive and seronegative men and yielded results that were compatible with independent epidemiologic data. Using a Weibull time-to-AIDS distribution $f(t) = \lambda \exp(-\lambda t)^{\lambda-1}$ derived from persons with seropositive men and using the currently infected, we project a median prior to 1985 (standard deviation $SD = 975$). The infection rate peaked prior to 1985. We project a median year of infection for the cumulative AIDS incidence through January 1, 1993 of 3,475 (SD 107).
CONCLUSIONS: The computational efficiency and generality of the flexible model improved the assessment of random and systematic errors. Application to other groups may provide important public health insights.

T.A.0.37 EXTRAPOLATING RECENT TRENDS TO MAKE AIDS CASE PROJECTIONS Kathleen M. Deane, Ph.D., Dennis, GJ AIDS Program, Centers for Disease Control, Atlanta, GA, USA

OBJECTIVE: To evaluate extrapolation from recent trends as a procedure for making short-term projections of AIDS cases.
METHODS: Trends in quarterly U.S. AIDS incidence (all cases, adjusted for estimated reporting delay) were modeled using the Box-Cox procedure $(y^2 - 1)/x$ as a polynomial in time = zero.
RESULTS: Parameters were estimated by maximum likelihood.
CONCLUSIONS: Projections of U.S. cases 5 years in the future can be very sensitive to the form of the polynomial chosen (linear or quadratic), and somewhat sensitive to the period during which the trend is modeled.
Period Reporting Predicted Incidence

Model	through 1981	1988	1990	1992	
1/84-6/88	12/88	linear	36,000	47,000	109,000
7/84-6/88	12/88	quadratic	34,000	35,000	20,000
1/84-6/88	12/88	quadratic(1)	25,000	47,000	37,000
7/83-9/87	6/88	linear	40,000	74,000	114,000
7/83-9/87	3/88	linear	36,000	49,000	117,000

Recent estimated (adjusted) incidence continues to increase steadily.
Conclusion: Careful analysis is essential in using extrapolation methods. An arbitrary treatment, such as the log-linear, should not be used. Reporting delays must be estimated carefully because extrapolations are sensitive to changes in recent data. Projections should be accompanied by uncertainty, as indicated by prediction intervals, rather than a single estimate. Projections more than 2 to 3 years in the future should be used with caution.

T.A.0.39 A RISK BEHAVIOR BASED MODEL OF THE CURB GROWTH OF AIDS IN THE UNITED STATES Colin F. Lynch, M.D., Philip A. Stolley, E. A., Byrnes, J. H., Layne, S. F., and Quial, C. C., Los Alamos National Laboratory, Los Alamos, New Mexico 87545 USA, *University of New Mexico, Albuquerque, NM, USA

Objective: To understand the spread of HIV in the United States.
Method: The cumulative number of AIDS cases in the United States has grown as the cube of time since 1981, approximately. We explain this by interactions involving partner choice and sexual risk behavior model with biased mixing. This leads to a saturation where of infection moving from high to low risk groups. The model assumes that the distribution of people according to risk behavior that puts one at risk of infection) decays slowly, with a significant fraction of the population engaging in high-risk activities. It assumes that people with similar risk behavior tend to interact primarily among themselves (biased mixing) rather than equally with others (homogeneous mixing). The model incorporates epidemiological data on the total AIDS cases and on the progression from initial HIV infection to AIDS.
Results: The decreasing growth rate of AIDS cases through 1988 was not due to changes in behavior, but rather it was due to the intrinsic dynamics of the disease. The total number of persons infected with HIV in the U.S. in 1988 was approximately 1.5 million. The average duration of infection for new AIDS cases is increasing. The mean risk behavior for people being infected with HIV is decreasing. The model is consistent with a mean period of transmission per sexual contact between 0.001 and 0.004. An increase in infectivity during the earliest stages of HIV infection could increase the infectivity during the remainder of the infection. Behavior modification could reduce it.

T.A.0.36 STATISTICAL ANALYSIS OF THE STAGES OF HIV INFECTION USING A MARKOV MODEL

Levy, G.F. ¹, Liska, J., ², Clark, W.S. ¹, Berenson, G.S. ¹,
¹Hyatt, R.H. ¹, ²Berry, A.C. ², ³Wright, R.C. ³, ⁴Wright, R.C. ⁴,
⁵University of Alabama, ⁶Atlanta, GA, ⁷AIDS Program, CDC, Atlanta, GA, USA,
⁸AIDS Office, Department of Health, San Francisco, CA, USA.

Objective: Persons infected with HIV pass through a progression of stages from initially infected to death. We have estimated the waiting time distribution for each stage of infection. From these estimates, we specify the probability distributions of the AIDS incubation period, pre-HIV-antibody period, and stage-specific survival times.
Method: The natural history of HIV was modeled by a Markov process with the following five stages: 1) incident AIDS; 2) antibody negative; 3) antibody positive but asymptomatic; 4) pre-AIDS symptoms and/or an abnormal lymphocyte count; 5) clinical AIDS; 6) death. This five-stage model was fitted to censored data from a cohort of 505 HIV-infected of 505 individuals.
Results: From the fitted model, the estimated mean waiting times in each stage are the following: Stage 1, 2.6 months; stage 2, 62.6 months; stage 3, 62.9 months; and stage 4, 23.6 months. The 95% confidence interval (CI) for the mean pre-HIV-antibody period (waiting time in stage 1) is [2.2, 3.0] months. The mean AIDS incubation period (from infection to the development of AIDS) is estimated to be 9.9 years with a 95% CI of [8.4, 11.2] years. The median survival time (waiting time in stage 5) is [1.0, 1.1] years. The median survival times for stages 2, 3 and 4 are estimated to be 10.3, 10.1, 5.8 and 1.4 years, respectively.
Conclusion: A staged Markov model can be used to efficiently estimate important statistical descriptors of the natural history of HIV.

T.A.0.38 MODEL-BASED OPTIMIZATION OF INFECTIVITY PARAMETERS Alagna David, J., Gerry K. Ke, Scott A. ¹, ²Timothy Collier, Hartford, CT 06106, ³NYU Medical Center, New York, NY 10016, U.S.A.

Objective: To develop a non-linear optimization program which computes values of key epidemiological parameters; 2) determine whether seroconversion and case rates among male homosexual/bisexuals in San Francisco during 1978-1986 vary among five (V) among three stages of infection (early antigen; antibody positive; AIDS); 3) compare V based projections to projections that assume equal infectivity (E) of the three stages; 4) determine if V holds when simulated numbers of partners and contacts are changed significantly (50%); 5) determine if V holds for two contact models (sequential means model and total contacts model).
Methods: The optimization program minimizes the difference between simulated case rate and seroconversion fraction rates and data reported by the San Francisco Hepatitis B cohort study. Six parameters are optimized: 1) per contact transmission probabilities for each stage; 2) duration of initial fraction in the early antigen stage; 3) delay time from seroconversion to AIDS; the cumulative fraction to AIDS vs. time since seroconversion is approximated closely by a 5th-order exponential delay.
Results: Over a wide range of simulated numbers of partners and contacts, case rate and seroconversion fraction data are matched using V. Best fit optimal parameter values are: 1) contact probabilities—early antigen: 0.0026, antibody positive: 0.0045, AIDS: 0.06; 2) initial fraction in early antigen stage 0.00045; 3) delay from seroconversion to AIDS 5.07 years; 4) duration of early antigen stage 12 months. With E the (single) optimized contact rate is 0.00045 (E) is too low for the early antigen and AIDS stages, but too high for the antibody-positive stage. The case rate curve due to the model using E, but the seroconversion fraction curve rises too slowly during 1978-82 and falls too slowly after 1982. V thus predicts a less severe epidemic than E1, but V holds for both contact models.
Conclusion: High infectivity of the first stage suggests antigen screening in high risk groups.

T.A.0.40 HIV, SEX & HIV: A MATHEMATICAL MODEL FOR NEW YORK CITY Gowenlock, J. M., ¹ Gwinn, J. M., ² State, J. A., ³ ⁴ ⁵ ⁶ ⁷ ⁸ ⁹ ¹⁰ ¹¹ ¹² ¹³ ¹⁴ ¹⁵ ¹⁶ ¹⁷ ¹⁸ ¹⁹ ²⁰ ²¹ ²² ²³ ²⁴ ²⁵ ²⁶ ²⁷ ²⁸ ²⁹ ³⁰ ³¹ ³² ³³ ³⁴ ³⁵ ³⁶ ³⁷ ³⁸ ³⁹ ⁴⁰ ⁴¹ ⁴² ⁴³ ⁴⁴ ⁴⁵ ⁴⁶ ⁴⁷ ⁴⁸ ⁴⁹ ⁵⁰ ⁵¹ ⁵² ⁵³ ⁵⁴ ⁵⁵ ⁵⁶ ⁵⁷ ⁵⁸ ⁵⁹ ⁶⁰ ⁶¹ ⁶² ⁶³ ⁶⁴ ⁶⁵ ⁶⁶ ⁶⁷ ⁶⁸ ⁶⁹ ⁷⁰ ⁷¹ ⁷² ⁷³ ⁷⁴ ⁷⁵ ⁷⁶ ⁷⁷ ⁷⁸ ⁷⁹ ⁸⁰ ⁸¹ ⁸² ⁸³ ⁸⁴ ⁸⁵ ⁸⁶ ⁸⁷ ⁸⁸ ⁸⁹ ⁹⁰ ⁹¹ ⁹² ⁹³ ⁹⁴ ⁹⁵ ⁹⁶ ⁹⁷ ⁹⁸ ⁹⁹ ¹⁰⁰ ¹⁰¹ ¹⁰² ¹⁰³ ¹⁰⁴ ¹⁰⁵ ¹⁰⁶ ¹⁰⁷ ¹⁰⁸ ¹⁰⁹ ¹¹⁰ ¹¹¹ ¹¹² ¹¹³ ¹¹⁴ ¹¹⁵ ¹¹⁶ ¹¹⁷ ¹¹⁸ ¹¹⁹ ¹²⁰ ¹²¹ ¹²² ¹²³ ¹²⁴ ¹²⁵ ¹²⁶ ¹²⁷ ¹²⁸ ¹²⁹ ¹³⁰ ¹³¹ ¹³² ¹³³ ¹³⁴ ¹³⁵ ¹³⁶ ¹³⁷ ¹³⁸ ¹³⁹ ¹⁴⁰ ¹⁴¹ ¹⁴² ¹⁴³ ¹⁴⁴ ¹⁴⁵ ¹⁴⁶ ¹⁴⁷ ¹⁴⁸ ¹⁴⁹ ¹⁵⁰ ¹⁵¹ ¹⁵² ¹⁵³ ¹⁵⁴ ¹⁵⁵ ¹⁵⁶ ¹⁵⁷ ¹⁵⁸ ¹⁵⁹ ¹⁶⁰ ¹⁶¹ ¹⁶² ¹⁶³ ¹⁶⁴ ¹⁶⁵ ¹⁶⁶ ¹⁶⁷ ¹⁶⁸ ¹⁶⁹ ¹⁷⁰ ¹⁷¹ ¹⁷² ¹⁷³ ¹⁷⁴ ¹⁷⁵ ¹⁷⁶ ¹⁷⁷ ¹⁷⁸ ¹⁷⁹ ¹⁸⁰ ¹⁸¹ ¹⁸² ¹⁸³ ¹⁸⁴ ¹⁸⁵ ¹⁸⁶ ¹⁸⁷ ¹⁸⁸ ¹⁸⁹ ¹⁹⁰ ¹⁹¹ ¹⁹² ¹⁹³ ¹⁹⁴ ¹⁹⁵ ¹⁹⁶ ¹⁹⁷ ¹⁹⁸ ¹⁹⁹ ²⁰⁰ ²⁰¹ ²⁰² ²⁰³ ²⁰⁴ ²⁰⁵ ²⁰⁶ ²⁰⁷ ²⁰⁸ ²⁰⁹ ²¹⁰ ²¹¹ ²¹² ²¹³ ²¹⁴ ²¹⁵ ²¹⁶ ²¹⁷ ²¹⁸ ²¹⁹ ²²⁰ ²²¹ ²²² ²²³ ²²⁴ ²²⁵ ²²⁶ ²²⁷ ²²⁸ ²²⁹ ²³⁰ ²³¹ ²³² ²³³ ²³⁴ ²³⁵ ²³⁶ ²³⁷ ²³⁸ ²³⁹ ²⁴⁰ ²⁴¹ ²⁴² ²⁴³ ²⁴⁴ ²⁴⁵ ²⁴⁶ ²⁴⁷ ²⁴⁸ ²⁴⁹ ²⁵⁰ ²⁵¹ ²⁵² ²⁵³ ²⁵⁴ ²⁵⁵ ²⁵⁶ ²⁵⁷ ²⁵⁸ ²⁵⁹ ²⁶⁰ ²⁶¹ ²⁶² ²⁶³ ²⁶⁴ ²⁶⁵ ²⁶⁶ ²⁶⁷ ²⁶⁸ ²⁶⁹ ²⁷⁰ ²⁷¹ ²⁷² ²⁷³ ²⁷⁴ ²⁷⁵ ²⁷⁶ ²⁷⁷ ²⁷⁸ ²⁷⁹ ²⁸⁰ ²⁸¹ ²⁸² ²⁸³ ²⁸⁴ ²⁸⁵ ²⁸⁶ ²⁸⁷ ²⁸⁸ ²⁸⁹ ²⁹⁰ ²⁹¹ ²⁹² ²⁹³ ²⁹⁴ ²⁹⁵ ²⁹⁶ ²⁹⁷ ²⁹⁸ ²⁹⁹ ³⁰⁰ ³⁰¹ ³⁰² ³⁰³ ³⁰⁴ ³⁰⁵ ³⁰⁶ ³⁰⁷ ³⁰⁸ ³⁰⁹ ³¹⁰ ³¹¹ ³¹² ³¹³ ³¹⁴ ³¹⁵ ³¹⁶ ³¹⁷ ³¹⁸ ³¹⁹ ³²⁰ ³²¹ ³²² ³²³ ³²⁴ ³²⁵ ³²⁶ ³²⁷ ³²⁸ ³²⁹ ³³⁰ ³³¹ ³³² ³³³ ³³⁴ ³³⁵ ³³⁶ ³³⁷ ³³⁸ ³³⁹ ³⁴⁰ ³⁴¹ ³⁴² ³⁴³ ³⁴⁴ ³⁴⁵ ³⁴⁶ ³⁴⁷ ³⁴⁸ ³⁴⁹ ³⁵⁰ ³⁵¹ ³⁵² ³⁵³ ³⁵⁴ ³⁵⁵ ³⁵⁶ ³⁵⁷ ³⁵⁸ ³⁵⁹ ³⁶⁰ ³⁶¹ ³⁶² ³⁶³ ³⁶⁴ ³⁶⁵ ³⁶⁶ ³⁶⁷ ³⁶⁸ ³⁶⁹ ³⁷⁰ ³⁷¹ ³⁷² ³⁷³ ³⁷⁴ ³⁷⁵ ³⁷⁶ ³⁷⁷ ³⁷⁸ ³⁷⁹ ³⁸⁰ ³⁸¹ ³⁸² ³⁸³ ³⁸⁴ ³⁸⁵ ³⁸⁶ ³⁸⁷ ³⁸⁸ ³⁸⁹ ³⁹⁰ ³⁹¹ ³⁹² ³⁹³ ³⁹⁴ ³⁹⁵ ³⁹⁶ ³⁹⁷ ³⁹⁸ ³⁹⁹ ⁴⁰⁰ ⁴⁰¹ ⁴⁰² ⁴⁰³ ⁴⁰⁴ ⁴⁰⁵ ⁴⁰⁶ ⁴⁰⁷ ⁴⁰⁸ ⁴⁰⁹ ⁴¹⁰ ⁴¹¹ ⁴¹² ⁴¹³ ⁴¹⁴ ⁴¹⁵ ⁴¹⁶ ⁴¹⁷ ⁴¹⁸ ⁴¹⁹ ⁴²⁰ ⁴²¹ ⁴²² ⁴²³ ⁴²⁴ ⁴²⁵ ⁴²⁶ ⁴²⁷ ⁴²⁸ ⁴²⁹ ⁴³⁰ ⁴³¹ ⁴³² ⁴³³ ⁴³⁴ ⁴³⁵ ⁴³⁶ ⁴³⁷ ⁴³⁸ ⁴³⁹ ⁴⁴⁰ ⁴⁴¹ ⁴⁴² ⁴⁴³ ⁴⁴⁴ ⁴⁴⁵ ⁴⁴⁶ ⁴⁴⁷ ⁴⁴⁸ ⁴⁴⁹ ⁴⁵⁰ ⁴⁵¹ ⁴⁵² ⁴⁵³ ⁴⁵⁴ ⁴⁵⁵ ⁴⁵⁶ ⁴⁵⁷ ⁴⁵⁸ ⁴⁵⁹ ⁴⁶⁰ ⁴⁶¹ ⁴⁶² ⁴⁶³ ⁴⁶⁴ ⁴⁶⁵ ⁴⁶⁶ ⁴⁶⁷ ⁴⁶⁸ ⁴⁶⁹ ⁴⁷⁰ ⁴⁷¹ ⁴⁷² ⁴⁷³ ⁴⁷⁴ ⁴⁷⁵ ⁴⁷⁶ ⁴⁷⁷ ⁴⁷⁸ ⁴⁷⁹ ⁴⁸⁰ ⁴⁸¹ ⁴⁸² ⁴⁸³ ⁴⁸⁴ ⁴⁸⁵ ⁴⁸⁶ ⁴⁸⁷ ⁴⁸⁸ ⁴⁸⁹ ⁴⁹⁰ ⁴⁹¹ ⁴⁹² ⁴⁹³ ⁴⁹⁴ ⁴⁹⁵ ⁴⁹⁶ ⁴⁹⁷ ⁴⁹⁸ ⁴⁹⁹ ⁵⁰⁰ ⁵⁰¹ ⁵⁰² ⁵⁰³ ⁵⁰⁴ ⁵⁰⁵ ⁵⁰⁶ ⁵⁰⁷ ⁵⁰⁸ ⁵⁰⁹ ⁵¹⁰ ⁵¹¹ ⁵¹² ⁵¹³ ⁵¹⁴ ⁵¹⁵ ⁵¹⁶ ⁵¹⁷ ⁵¹⁸ ⁵¹⁹ ⁵²⁰ ⁵²¹ ⁵²² ⁵²³ ⁵²⁴ ⁵²⁵ ⁵²⁶ ⁵²⁷ ⁵²⁸ ⁵²⁹ ⁵³⁰ ⁵³¹ ⁵³² ⁵³³ ⁵³⁴ ⁵³⁵ ⁵³⁶ ⁵³⁷ ⁵³⁸ ⁵³⁹ ⁵⁴⁰ ⁵⁴¹ ⁵⁴² ⁵⁴³ ⁵⁴⁴ ⁵⁴⁵ ⁵⁴⁶ ⁵⁴⁷ ⁵⁴⁸ ⁵⁴⁹ ⁵⁵⁰ ⁵⁵¹ ⁵⁵² ⁵⁵³ ⁵⁵⁴ ⁵⁵⁵ ⁵⁵⁶ ⁵⁵⁷ ⁵⁵⁸ ⁵⁵⁹ ⁵⁶⁰ ⁵⁶¹ ⁵⁶² ⁵⁶³ ⁵⁶⁴ ⁵⁶⁵ ⁵⁶⁶ ⁵⁶⁷ ⁵⁶⁸ ⁵⁶⁹ ⁵⁷⁰ ⁵⁷¹ ⁵⁷² ⁵⁷³ ⁵⁷⁴ ⁵⁷⁵ ⁵⁷⁶ ⁵⁷⁷ ⁵⁷⁸ ⁵⁷⁹ ⁵⁸⁰ ⁵⁸¹ ⁵⁸² ⁵⁸³ ⁵⁸⁴ ⁵⁸⁵ ⁵⁸⁶ ⁵⁸⁷ ⁵⁸⁸ ⁵⁸⁹ ⁵⁹⁰ ⁵⁹¹ ⁵⁹² ⁵⁹³ ⁵⁹⁴ ⁵⁹⁵ ⁵⁹⁶ ⁵⁹⁷ ⁵⁹⁸ ⁵⁹⁹ ⁶⁰⁰ ⁶⁰¹ ⁶⁰² ⁶⁰³ ⁶⁰⁴ ⁶⁰⁵ ⁶⁰⁶ ⁶⁰⁷ ⁶⁰⁸ ⁶⁰⁹ ⁶¹⁰ ⁶¹¹ ⁶¹² ⁶¹³ ⁶¹⁴ ⁶¹⁵ ⁶¹⁶ ⁶¹⁷ ⁶¹⁸ ⁶¹⁹ ⁶²⁰ ⁶²¹ ⁶²² ⁶²³ ⁶²⁴ ⁶²⁵ ⁶²⁶ ⁶²⁷ ⁶²⁸ ⁶²⁹ ⁶³⁰ ⁶³¹ ⁶³² ⁶³³ ⁶³⁴ ⁶³⁵ ⁶³⁶ ⁶³⁷ ⁶³⁸ ⁶³⁹ ⁶⁴⁰ ⁶⁴¹ ⁶⁴² ⁶⁴³ ⁶⁴⁴ ⁶⁴⁵ ⁶⁴⁶ ⁶⁴⁷ ⁶⁴⁸ ⁶⁴⁹ ⁶⁵⁰ ⁶⁵¹ ⁶⁵² ⁶⁵³ ⁶⁵⁴ ⁶⁵⁵ ⁶⁵⁶ ⁶⁵⁷ ⁶⁵⁸ ⁶⁵⁹ ⁶⁶⁰ ⁶⁶¹ ⁶⁶² ⁶⁶³ ⁶⁶⁴ ⁶⁶⁵ ⁶⁶⁶ ⁶⁶⁷ ⁶⁶⁸ ⁶⁶⁹ ⁶⁷⁰ ⁶⁷¹ ⁶⁷² ⁶⁷³ ⁶⁷⁴ ⁶⁷⁵ ⁶⁷⁶ ⁶⁷⁷ ⁶⁷⁸ ⁶⁷⁹ ⁶⁸⁰ ⁶⁸¹ ⁶⁸² ⁶⁸³ ⁶⁸⁴ ⁶⁸⁵ ⁶⁸⁶ ⁶⁸⁷ ⁶⁸⁸ ⁶⁸⁹ ⁶⁹⁰ ⁶⁹¹ ⁶⁹² ⁶⁹³ ⁶⁹⁴ ⁶⁹⁵ ⁶⁹⁶ ⁶⁹⁷ ⁶⁹⁸ ⁶⁹⁹ ⁷⁰⁰ ⁷⁰¹ ⁷⁰² ⁷⁰³ ⁷⁰⁴ ⁷⁰⁵ ⁷⁰⁶ ⁷⁰⁷ ⁷⁰⁸ ⁷⁰⁹ ⁷¹⁰ ⁷¹¹ ⁷¹² ⁷¹³ ⁷¹⁴ ⁷¹⁵ ⁷¹⁶ ⁷¹⁷ ⁷¹⁸ ⁷¹⁹ ⁷²⁰ ⁷²¹ ⁷²² ⁷²³ ⁷²⁴ ⁷²⁵ ⁷²⁶ ⁷²⁷ ⁷²⁸ ⁷²⁹ ⁷³⁰ ⁷³¹ ⁷³² ⁷³³ ⁷³⁴ ⁷³⁵ ⁷³⁶ ⁷³⁷ ⁷³⁸ ⁷³⁹ ⁷⁴⁰ ⁷⁴¹ ⁷⁴² ⁷⁴³ ⁷⁴⁴ ⁷⁴⁵ ⁷⁴⁶ ⁷⁴⁷ ⁷⁴⁸ ⁷⁴⁹ ⁷⁵⁰ ⁷⁵¹ ⁷⁵² ⁷⁵³ ⁷⁵⁴ ⁷⁵⁵ ⁷⁵⁶ ⁷⁵⁷ ⁷⁵⁸ ⁷⁵⁹ ⁷⁶⁰ ⁷⁶¹ ⁷⁶² ⁷⁶³ ⁷⁶⁴ ⁷⁶⁵ ⁷⁶⁶ ⁷⁶⁷ ⁷⁶⁸ ⁷⁶⁹ ⁷⁷⁰ ⁷⁷¹ ⁷⁷² ⁷⁷³ ⁷⁷⁴ ⁷⁷⁵ ⁷⁷⁶ ⁷⁷⁷ ⁷⁷⁸ ⁷⁷⁹ ⁷⁸⁰ ⁷⁸¹ ⁷⁸² ⁷⁸³ ⁷⁸⁴ ⁷⁸⁵ ⁷⁸⁶ ⁷⁸⁷ ⁷⁸⁸ ⁷⁸⁹ ⁷⁹⁰ ⁷⁹¹ ⁷⁹² ⁷⁹³ ⁷⁹⁴ ⁷⁹⁵ ⁷⁹⁶ ⁷⁹⁷ ⁷⁹⁸ ⁷⁹⁹ ⁸⁰⁰ ⁸⁰¹ ⁸⁰² ⁸⁰³ ⁸⁰⁴ ⁸⁰⁵ ⁸⁰⁶ ⁸⁰⁷ ⁸⁰⁸ ⁸⁰⁹ ⁸¹⁰ ⁸¹¹ ⁸¹² ⁸¹³ ⁸¹⁴ ⁸¹⁵ ⁸¹⁶ ⁸¹⁷ ⁸¹⁸ ⁸¹⁹ ⁸²⁰ ⁸²¹ ⁸²² ⁸²³ ⁸²⁴ ⁸²⁵ ⁸²⁶ ⁸²⁷ ⁸²⁸ ⁸²⁹ ⁸³⁰ ⁸³¹ ⁸³² ⁸³³ ⁸³⁴ ⁸³⁵ ⁸³⁶ ⁸³⁷ ⁸³⁸ ⁸³⁹ ⁸⁴⁰ ⁸⁴¹ ⁸⁴² ⁸⁴³ ⁸⁴⁴ ⁸⁴⁵ ⁸⁴⁶ ⁸⁴⁷ ⁸⁴⁸ ⁸⁴⁹ ⁸⁵⁰ ⁸⁵¹ ⁸⁵² ⁸⁵³ ⁸⁵⁴ ⁸⁵⁵ ⁸⁵⁶ ⁸⁵⁷ ⁸⁵⁸ ⁸⁵⁹ ⁸⁶⁰ ⁸⁶¹ ⁸⁶² ⁸⁶³ ⁸⁶⁴ ⁸⁶⁵ ⁸⁶⁶ ⁸⁶⁷ ⁸⁶⁸ ⁸⁶⁹ ⁸⁷⁰ ⁸⁷¹ ⁸⁷² ⁸⁷³ ⁸⁷⁴ ⁸⁷⁵ ⁸⁷⁶ ⁸⁷⁷ ⁸⁷⁸ ⁸⁷⁹ ⁸⁸⁰ ⁸⁸¹ ⁸⁸² ⁸⁸³ ⁸⁸⁴ ⁸⁸⁵ ⁸⁸⁶ ⁸⁸⁷ ⁸⁸⁸ ⁸⁸⁹ ⁸⁹⁰ ⁸⁹¹ ⁸⁹² ⁸⁹³ ⁸⁹⁴ ⁸⁹⁵ ⁸⁹⁶ ⁸⁹⁷ ⁸⁹⁸ ⁸⁹⁹ ⁹⁰⁰ ⁹⁰¹ ⁹⁰² ⁹⁰³ ⁹⁰⁴ ⁹⁰⁵ ⁹⁰⁶ ⁹⁰⁷ ⁹⁰⁸ ⁹⁰⁹ ⁹¹⁰ ⁹¹¹ ⁹¹² ⁹¹³ ⁹¹⁴ ⁹¹⁵ ⁹¹⁶ ⁹¹⁷ ⁹¹⁸ ⁹¹⁹ ⁹²⁰ ⁹²¹ ⁹²² ⁹²³ ⁹²⁴ ⁹²⁵ ⁹²⁶ ⁹²⁷ ⁹²⁸ ⁹²⁹ ⁹³⁰ ⁹³¹ ⁹³² ⁹³³ ⁹³⁴ ⁹³⁵ ⁹³⁶ ⁹³⁷ ⁹³⁸ ⁹³⁹ ⁹⁴⁰ ⁹⁴¹ ⁹⁴² ⁹⁴³ ⁹⁴⁴ ⁹⁴⁵ ⁹⁴⁶ ⁹⁴⁷ ⁹⁴⁸ ⁹⁴⁹ ⁹⁵⁰ ⁹⁵¹ ⁹⁵² ⁹⁵³ ⁹⁵⁴ ⁹⁵⁵ ⁹⁵⁶ ⁹⁵⁷ ⁹⁵⁸ ⁹⁵⁹ ⁹⁶⁰ ⁹⁶¹ ⁹⁶² ⁹⁶³ ⁹⁶⁴ ⁹⁶⁵ ⁹⁶⁶ ⁹⁶⁷ ⁹⁶⁸ ⁹⁶⁹ ⁹⁷⁰ ⁹⁷¹ ⁹⁷² ⁹⁷³ ⁹⁷⁴ ⁹⁷⁵ ⁹⁷⁶ ⁹⁷⁷

Specialty Session Séance Thématique



Épidémiologie et santé publique Epidemiology and Public Health

Transmission du VIH dans le milieu des soins de la santé HIV Transmission in the Health Care Setting

W.A.0.1 HEALTH-CARE WORKERS EXPOSED TO PATIENTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV), UNITED STATES.
Bakken, Rulhagen* and the Cooperative Research
Surveillance Group, *Centers for Disease Control, Atlanta, GA, USA

Objective: To estimate the risk of HIV infection in health-care workers (HCWs) exposed to blood of persons infected with HIV.
Methods: HCWs from over 300 health-care institutions throughout the United States who have parenteral, mucous-membrane, or non-intact skin exposures to the blood of persons infected with HIV are tested for HIV antibody at baseline, 6 weeks, 3, 6, and 12 months after exposure. On entry epidemiologic data and confidential risk factor information are collected from each HCW.

Results: As of December 31, 1988, 1107 HCWs were tested at least 6 months after exposure. Of 992 HCWs with needlesticks (n=898) or cuts with sharp objects (n=84), 4 were positive for HIV antibody (4.982 ± 0.413; upper bound of 95% confidence interval) (CI) 0.39%. One HCW had no baseline specimen available for testing, and thus occupational acquisition could not be determined. The remaining three workers received a needlestick injury, experienced an acute retroviral syndrome, and seroconverted to HIV within 6 months postexposure. One of these HCWs who seroconverted was injured by a co-worker during a resuscitation procedure. Of the remaining 123 HCWs with blood contamination (n=53) or broken skin (n=72), none seroconverted (0.133-0% upper bound of 95% CI).
Conclusions: In this ongoing surveillance of HCWs exposed to HIV-infected blood, the risk of seroconversion following parenteral exposure has completely remained less than 1%. Efforts must be made to prevent exposure to blood to further minimize the risk of HIV transmission to HCWs.

W.A.0.3 PREVALENCE OF HIV INFECTION AMONG PERSONS EMPLOYED IN MEDICINE AND HEALTH OCCUPATIONS

Coast Line and the Water Head Research Group
Water Head Army Institute of USA

Objective: To examine the association between employment in Medicine and Health (M+H) occupations and infection with HIV.

Methods: Test results for HIV-Ab have been received on 545,114 US Army Reserve Component personnel. These individuals spent about 10% of their time in a military environment, and are employed in civilian occupations.

Results: When stratified by Dept of Labor occupational categories, those employed in the medicine and health (M+H) field had a prevalence of 2.48 (per 1000), versus 1.51 for those not so employed. The 2387 white, black, and Hispanic male and female physicians and dentists were all HIV-Ab negative. The prevalence among white females (n=409) in M+H jobs was 0.20, compared to 0.20 for those in other occupations. The prevalence for black females in M+H occupations (n=174) was 1.22, and 1.84 in other occupations. Among white and black single males, the prevalence was significantly higher for registered nurses (RN), medical technicians (MT), and not otherwise specified medical occupations (NOS). The prevalence among single white males was 7.50, and the prevalence rate (95% and 99% confidence interval), versus those not employed in M+H occupations, was 2.26 (3.71, 14.21) in single white males, prevalence was 3.50, with a P of 4.76 (2.80, 7.82). Prevalence was not significantly higher for 4599 ever-married black, white, and Hispanic males employed in RN, MT, or NOS jobs, nor among 2726 ever- and never-married black, white, and Hispanic males in all other M+H fields.
Conclusions: The higher prevalence associated with employment in M+H fields is largely restricted to single white and black males employed in the RN, MT, or NOS areas. The absolute prevalence is much higher among single black males, but the P is higher for single white males. These patterns of HIV infection do not support the hypothesis of an occupational risk of infection that is doseless by prevalence surveys.

W.A.0.5 NOSOCOMIAL OUTBREAK OF HIV INFECTION IN ELISTA, USSR

V.V. Pokrovskiy, E.U. Eranova
Central Institute of Epidemiology, Moscow, USSR

A total of 41 out of 2504 children and 8 of 116 mothers of children who had been admitted to the Elista (Kalmykia Republic, USSR) during the period from May until December 1988 were HIV antibody positive by ELISA and Western Blot testing. No other HIV infection was identified among 20,000 inhabitants of Elista including 948 hospital workers and 1012 members of families of infected persons. The sexual partners of the 8 infected women were HIV positive. This man lived and was possibly the source of infection in his 1988 and is thought to have been the first infant in a chain of HIV infection. Other seropositive children are assumed to have been infected during overlapping admissions to the hospital. The virus appears to have been transmitted in hospital by the use of one syringe into which blood was aspirated between intravenous injections. Four mothers for whom no risk factors were identified appear to have become HIV infected through their children. It is suggested that the virus was transmitted from bleeding oral lesions in children treated with doses of penicillin to bleeding fissures on mothers' breasts during breast feeding. Results of the final analysis of the investigation will be reported.

W.A.0.2 SURVEILLANCE UPDATE: HEALTH-CARE WORKERS WITH AIDS
Chamberland, Harry* Center, L. F. Furb, T. J. Jaffe, R. A.,
*Centers for Disease Control (CDC), Atlanta, GA, USA

Objective: To characterize health-care workers (HCWs) with AIDS in the United States and evaluate the role of occupational transmission of HIV.
Methods: HCW with AIDS reported to CDC who have no identified risk (NIR) are investigated by health departments using a standard protocol.
Results: As of January 15, 1989, 3,350 HCW with AIDS had been reported. HCW were less likely than other AIDS patients to report IV drug use (72 vs 812, p<0.001) and more likely to report male homosexual contact (73 vs 612, p<0.001) or have NIR (41 vs 35, p<0.001). One HCW with AIDS had a documented seroconversion to HIV after a needlestick exposure to blood from an AIDS patient. Of the 203 HCW with NIR, 125 (61%) are under investigation; 30 (15%) died, refused interview or were lost to follow-up; with the 6.8 million HCW in the U.S., the 48 investigated HCW with NIR were more likely to be black (442 vs 131) and less likely to be women (292 vs 772). They comprised 8 physicians, 1 dentist, 3 nurses, 1 paramedic, 11 aides/orderlies, 2 respiratory therapists, 5 clinical lab technicians, 9 maintenance workers, 2 morticians, and 4 others with no patient contact. Twenty (42%) of the 48 HCW reported needlestick and/or mucous membrane or non-intact skin exposure to blood or other body fluids; in none was the HIV status of the patient known.
Conclusion: Most HCWs have an identified risk for HIV infection; the others probably represent a mix of persons with unreported behavioral risk factors or unrecognized occupational exposures.

W.A.0.4 ADVANCEMENT TO UNIVERSAL PRECAUTIONS BY HCWs IN AN EMERGENCY DEPARTMENT
Nelson, Robert; Dismore, T.; Baltimore, D.; Wilson, L. Scott C.
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

Objective: To assess adherence to "Universal Precautions" (UP) among health care workers (HCWs) in an emergency department (ED) with high prevalence (6.0%) of HIV among its patient population.

Methods: We prospectively observed 124 HCWs performing 1274 interventions on departmental inpatients requiring rigid interventions. Institution-wide and 13 hospital-wide patient interventions on UP were held for HCWs throughout the year prior to the initiation of the study. Interventions were classified as major (42.3%) or minor (57.4%) depending on the potential for exposure.
Results: Overall adherence was adequate during 16.5% of major interventions and 44.4% of minor interventions (p<0.05). During minor interventions, adherence to UP was 58.8% (p<0.05). In the presence of protease bleeders, adherence during 0.0% in non-trauma presentations (p<0.05). During major procedures, adherence was 34.0% with traumatic presentations and 0.4% with non-trauma presentations (p<0.05). The overall adherence rate for HCWs was: Residents 58%; Attending 38%; Consultants 43%; Nursing staff 44%; Physicians 49%; Technicians 14% and Homologous 51%. Mean precautions were inadequate, surgical masks were used least (22.4%), followed by eye protection (45.0%), gowns (49.4%) and gloves (73.7%). A questionnaire administered following the study period revealed that protective materials (47%) and interference in performance of procedure (31%).
Conclusion: HCW in this setting are not taking adequate precautions. Other strategies for implementing Universal Precautions need to be developed.

Séance thématique Specialty Session

Incidence et mortalité du SIDA AIDS Incidence and Mortality

W.A.0.13

AGE AIDS CASES AMONG HOMOSEXUAL MALES LEVELLING?
Berkelman, Ralph; Karon, J.; Thomas, P.;* Rensd, P.;**
Berkman, R.;***, San Francisco, CA

*Centers for Disease Control, Atlanta; **New York City (NYC) Dept. of Health; ***Los Angeles (LA) Co. Health Dept.

Objective: To analyze trends in reported cases of AIDS among homosexual and bisexual males in two metropolitan areas of the U.S.
Methods: We analyzed AIDS cases in NYC, SF, and LA and the rest of the U.S. among homosexual and bisexual (HB) without intravenous drug use (IVDU) from 1981 through 1988 by 6-month intervals, by race, by date of diagnosis, adjusting for reporting delay and by date of report.
Results: The rate of increase for reported AIDS cases among HB has slowed in the U.S., earlier in NY, SF, and NYC (by 1987) than in the rest of the U.S.; the slowing has occurred in HB and other races in most areas.
Percent change from previous 6 mo. period in AIDS among HB (no. IVDU)

City	1984(1) (2)		1985(1) (2)		1986(1) (2)		1987(1) (2)		1988 (1) (2)	
	1	2	1	2	1	2	1	2	1	2
New York City	+32	+4	+26	+17	+2	-	-	-	+11	-
Los Angeles	+46	+28	+31	+14	0	-	-	-	-	-
San Francisco	+30	+16	+28	+10	-2	-	-	-	+10	-
U.S. (other)	+20	+18	+29	+24	+11	-	-	-	-	-

When analyzed by date of report, leveling is less apparent.
Conclusion: Reported AIDS cases among HB males are leveling across the U.S., noted earlier in selected metropolitan areas. Underreporting differences in medical practices, early saturation of infection, and behavioral changes should each be evaluated as contributing factors.

W.A.0.15

SURVEILLANCE OF HETEROSEXUALLY ACQUIRED AIDS, U.S.A.
Chagnard, Marc; Conley, L.;* Boulier, J.P.
Centers for Disease Control, Atlanta, Ga., USA

Objective: To monitor temporal and demographic trends in the United States for adults with heterosexually acquired (HA)-AIDS.
Methods: HA-AIDS cases reported to CDC include heterosexual partners (Certificate of IVDR) and individuals who (1) report sexual contact (SC) with a person with or at increased risk for HIV infection or (2) were born in areas with high rates of HIV-1 infection, such as Haiti or Africa.
Results: As of January 16, 1989, 3454 HA-AIDS cases were reported: 2390 (69%) in persons with SC and 1064 (31%) in persons from endemic countries (68% of whom were Haitian). Although the proportion of HA-AIDS cases has remained relatively stable (ranging from 5.2% of all adults reported in 1983 to 4.8% in 1988), the composition of the group has changed: Haitians/Africans accounted for 79% of the 107 HA cases reported in 1983, but only 25% of the 1943 cases in 1988. Excluding homosexual men, SC cases have increased from 0.5% of men with AIDS reported in 1983 to 3.2% in 1988 (p<0.001) and from 14.8% of women to 23.6% (p<0.001). Most SC cases continue to be women (75%) and blacks or Hispanic (78%). Among SC cases, women are significantly younger than men (34 years vs 40 years, mean age). Both men and women reported SC with IV-drug users with equal frequency (1:2). Men who reported SC were less likely than women (18% vs 43%) to be in New York or New Jersey, which account for 63% of AIDS cases in heterosexual IV-drug users.
Conclusion: HA-AIDS remains largely focused in demographically distinct population groups. The proportion attributable to SC is increasing.

W.A.0.17

NATIONAL SURVEILLANCE OF PERINATALLY-ACQUIRED AIDS, USA.
Meyers, T.; Bush, T.J.
Centers for Disease Control, Atlanta, Georgia, USA

Objective: To examine temporal trends in perinatal AIDS (PA) cases.
Methods: Analysis of the 1964 PA cases reported to CDC from 1982-1988.
Results: PA cases reported in yr 1982 1986 1987 1988
Number of cases newly reported in yr 103 160 250 449
I of cases meeting all 3 criteria 46(12) 15(9) 18(7) 54(12)
Number (%) of cases meeting 1-2 criteria 57 (55) 142 (88) 162 (64) 295 (66)
Median age at AIDS dx: overall 10 no 12 no 9 no 14 no
I 12 no 12 no 12 no 12 no
II 12 no 12 no 12 no 12 no
For cases meeting 1-2 criteria only --- --- 18 no 20 no
Diseases: I with 1 criteria pneumonia 322 465 531 514
II with 2 criteria 6 no 6 no 6 no 6 no
Median age at dx for other cases 30 no 18 no 15 no 19 no
Residence: I from NY, NJ, or Florida 182 642 272 602
Maternal race: I with 1b IV drug use 585 561 512 522
Race/ethnicity: I black or Hispanic 892 872 842 812
I of cases were in boys, 50% in girls; there was no sex difference in age at diagnosis; disease presentation, or survival time after diagnosis.
Conclusion: PA cases are increasing; offspring of drug users remain the group most severely affected. Non school-age children are to have been the 15th leading cause of death among newly infected children are born this year, the median age at dx has been fairly constant. Broadening of the case definition may have most effect on reportability of older children, who are less likely to present with opportunistic infections such as PCP.

W.A.0.14

HETEROSEXUAL AIDS IN THE PROVINCE OF QUEBEC
Robert S. Babin, Lucie Bédard, Robert W.S. Palmer
Bureau Régional de maladies infectieuses,
Montreal, Québec, Canada

Objective: To characterize the epidemiology of AIDS among heterosexual partners resident in the province of Quebec, since 1983; reports were evaluated using the WHO epidemiologic case criteria. Further data were collected for AIDS cases with heterosexual contact indicated on the source.
Methods: From 1979 to January 15, 1989, 743 cases of AIDS were reported in Québec; 78 (10.5%) were among women and 30 (4.0%) among children, compared to 2.8% and 0.6% respectively for the rest of Canada. One-hundred-and-forty-five (19.0%) cases were due to heterosexual contact, for a rate of 21.9 cases per million population versus 1.7 for the rest of Canada. Seventy-nine percent of the cases in Québec can be explained by the markedly increased rate of AIDS among heterosexual immigrants from Pattern II countries, mostly Haiti; the incidence rate of AIDS in 1988 among homosexual Haitians in Québec was 71.0 as compared to 1.0 per million population for other non-homosexual Quebecers, for a relative rate of 170. The rate of AIDS among heterosexual partners of high-risk persons was also higher in Québec: of the 37 cases reported in this group, 23 (62%) were related to sexual contact with persons from Pattern II countries, 13 having had exposure in Québec and 10 in other regions themselves.
Conclusion: The rate of AIDS among heterosexuals in Québec is the highest in Canada. Most of the cases can be explained by the high rate of AIDS among heterosexual persons from Pattern II countries and among other heterosexuals with sexual partners from Pattern II countries.

W.A.0.16

IMPACT OF THE HIV EPIDEMIC ON MORTALITY TRENDS IN MEN 25-44 YEARS OF AGE, UNITED STATES
Bushman, James; Berkelman, A.; Devine, O.; Chevalier, F.
Centers for Disease Control, Atlanta, Georgia & Virginia, Maryland, USA

Objective: To identify causes of death that are increasing among young adult men in association with the HIV epidemic and to estimate the impact of AIDS on mortality trends in men 25-44 years of age.
Methods: We analyzed national death records for 1980-1988 (underlying and multiple causes), compared cause-specific mortality trends in states with high versus low AIDS incidence, and calculated excess deaths in 1986 based on 1983 rates (the median of total mortality for men 25-44 years of age).
Results: Following decades of decline, national mortality rates for men 25-44 years of age increased from 21.1:1 in 1983 to 23.3:1 deaths/100,000 in 1986. By 1986, conditions in the AIDS surveillance definition represented 9% of deaths, with mortality rate ranging from 45.8 in five states with the highest AIDS incidence to 6.2 deaths/100,000 in 21 states with the lowest AIDS incidence. Similarly, rates for deaths due to infections not in the AIDS definition (including pneumonia, septicemia, and pulmonary tuberculosis), blood disorders, drug abuse, and unspecified causes increased more rapidly in states with high versus low incidence AIDS. This pattern was not observed for other cause groups, including cancers with a previously suggested link to HIV (propharyngeal, anal/oral, Hodgkin lymphoma). Of the 8,434 excess deaths in 1986 among causes that increased from 1983, 72% were attributed to conditions in the AIDS definition, 8% to other infections, 7% to drug abuse, and 3% to unspecified causes.
Conclusion: The HIV epidemic has led to an increase in diverse causes of death and to a reversal in mortality trends for young men.

W.A.0.18

THE RELATIVE IMPORTANCE OF AIDS AS A CAUSE OF DEATH IN PERINATAL AND YOUNG ADULT POPULATIONS IN THE U.S. 1980-1987.
Kilbourne, Barbara A.; Rogers, M.P.; Bush, T.J.
Centers for Disease Control (CDC), Atlanta, Georgia, USA

Objective: To assess the impact of AIDS relative to other leading causes of death in perinatal and young adult populations in the U.S.
Methods: Yearly AIDS mortality rates computed from CDC national surveillance data were compared with rates for the leading causes of death obtained from national vital statistics data for the age groups 1 yr, 1-4 years, 5-14 years, and 15-24 years.
Results: For 1 yr olds, the mortality rates (per 100,000 live births) for AIDS rose from 0.028 in 1980 to 1.3 in 1986 and 2.02 in 1987. By 1987, AIDS is estimated to have been the 10th leading cause of death for this age group. Among 1-4 year olds, the rate (per 100,000) of AIDS mortality was 0.015 in 1980 and rose to 0.645 in 1988, when AIDS is estimated to have been the 9th leading cause of death. In the 5-14 year age group the rate rose progressively to 0.152 in 1987 when AIDS is estimated to have been the 15th leading cause of death. Yearly rates for the 15-24 year age group were 1.03 in 1986 and 1.82 in 1987, when AIDS is estimated to have been the 10th leading cause of death as were in 1986 and is estimated to have been the 14th leading cause in 1987.
Conclusion: Rates of AIDS mortality are increasing in the pediatric and young adult populations of the U.S. AIDS is substantially higher than for causes of death among 1-4 year olds and 15-24 year olds in the U.S.

Séance thématique Specialty Session

L'annonce aux partenaires Partner Notification

W.A.O.19 EXPERIENCE OF PARTNER NOTIFICATION AMONG HIV INFECTED HETEROSEXUALS IN BRUSSELS
 Steven A. Shover, Ph.D., Schumaner, M.J., Clumond, M./Hain, Belgium.

During a 2 year period, 105 out of 289 heterosexual HIV seropositive patients were enrolled in a partner notification study, consisting in personal patient counseling and testing (by Elias and western blot) of sexual partners. Four-hundred and fifty (439) were eligible. Reasons for withdrawing from the study were: refusal of cooperating (47%), partners out of Belgium (37%), miscellaneous (16%). The 45 index cases allowed notification of 92 heterosexual partners. The index persons were: 123 males, 20 females; mean age was 34. By (range: 19-66); 35 Caucasians, 10 Black Africans. Sexual partners were 34 by (range: 15-102) heterosexual status or relationship to index case as married (31%), regular sexual partner (18%), occasional partner (31%). Only 9 partners were notified during their sexual intercourse with the index cases. Overall HIV seroprevalence was 36/92 (39%). Among the various partners with seroprevalence was respectively: 1 spouse (5%), regular sexual partners (30%), occasional partners (20%). All partners received information about risk reduction procedures and health services in case of seropositivity.

This study suggests that partner notification is efficient as a technique aimed to inform, counsel and refer heterosexual partners who ignore their exposure to HIV. Further studies are needed to assess the impact of partner notification on evidence of risk behaviour and on reduction of further transmission of HIV, which is the first goal of the technique.

W.A.O.21 RESULTS AND BENEFIT-COST ANALYSIS OF PROVIDER-ASSISTED HIV PARTNER NOTIFICATION AND REFERRAL. SPOONER, M., Rensvick, C., WOLF, F., STANLEY, D., Colorado Department of Health, Denver, Colorado, USA.

OBJECTIVE: Evaluate results, benefits and costs of provider-assisted partner notification and referral to prevent HIV infection.
METHODS: HIV AID patients were interviewed by Disease Intervention Specialists (DIS) to notify sex/needle share partners of exposure. Partners were offered risk reduction counseling and HIV AID testing. Program costs for personnel, travel and supplies were calculated as were medical costs for the estimated number of AIDS cases prevented through this intervention.

RESULTS: HIV infection would have remained unrecognized in newly identified cases and each would have transmitted to one susceptible in the course of a lifetime; 606 of HIV infected individuals develop AIDS. **Beneficial:** 172 HIV AID positives were interviewed. They identified 209 sex/needle share partners and subjects, of which they chose 104 for notification. 209 (75%) were located, 25 (18%) located partners were previously tested positive, 18 (10%) were previously tested negative, 111 (52%) had not yet been tested and 105 (93%) of those accepted new counseling and 72 (85%) also accepted new testing. 11 new positives were identified. Program costs during 1988 totaled \$27,000 and program benefits totalled \$164,700. Benefit-cost ratio was 7.5.
CONCLUSION: Provider assisted HIV partner notification and referral has high partner acceptance of new testing (85%), identifies previously undetected infections in potential transmitters, (18%) and has a high benefit-cost ratio (7.2).

W.A.O.23 ASSESSMENT OF THE DEVELOPMENT AND IMPLEMENTATION OF STATE AIDS/HIV PARTNER NOTIFICATION PROGRAMS: FIVE CASE STUDIES

Lorraine N. Fishback, J. William Fyfe*, James Foote, Lela Baughman, and Cynthia Burgess, Office of the Assistant Secretary for Health, Public Health Service, Washington, D.C. and ** Metro Systems, Inc., Silver Spring, Maryland.

OBJECTIVE: To gather information on the characteristics, preliminary results, and apparent benefits of existing partner notification programs.
Methods: A case study methodology was used to collect detailed information on the design and operation of five state/local programs for notifying, educating, and counseling the sex and needle-sharing partners of individuals testing antibody-positive for HIV. The sites selected—Colorado, Florida, Virginia, San Francisco, and Seattle—King County, Washington—represent a range of approaches that, in combination, have much to teach others embarking on establishment of partner notification programs.
Results: The study confirmed that current state and local realities determine both the mix of methodologies being used in HIV prevention/education programs and also the particular approach being taken to notify partners. Cost-effectiveness balanced by a concern for public health were also major factors.
CONCLUSION: A generic planning model for initiating partner notification activities was developed from the comparative analysis of the five sites. The model highlights various steps in three phases of planning—epidemiology assessment, policy development, and program implementation. This model will be exhibited.

Épidémiologie et santé publique Epidemiology and Public Health

W.A.O.20 PARTNER ACCEPTABILITY OF HEALTH DEPARTMENT NOTIFICATION OF HIV EXPOSURE, SOUTH CAROLINA

James Jeffrey, Jr., M.D., M.P.H.; Wynoff, R.N.; Gamble, W. Jr., M.D.; Hollis, S.C.; Longshore, Steve; Colwell, M.D. Office of State Services Centers for Disease Control, Atlanta, GA, USA. *South Carolina Department of Health and Environmental Control, Columbia and Greenwood, SC, USA.
Objective: To determine partners' acceptability of notification by the health department of their exposure to human immunodeficiency virus (HIV).
Methods: An anonymous questionnaire administered to sex of 79 drug contacts 2 to 24 months after the health department notified them of exposure to HIV. Results: Available partners (79 persons) of HIV positive persons in one health district (16 counties) completed the questionnaire. Of the 79, 61 (77%) were male and 18 (23%) were female; 57 (72%) black, 22 (28%) white; 60 (76%) heterosexual, 19 (24%) heterosexual, and 4 (5%) IV drug users. Ages ranged from 16 to 71 years (median 28 years). Only 9 (11%) thought they had been exposed to HIV before health department notification. After notification and waiting 20 (25%) were found to be HIV antibody positive. Of the 20, 14 (70%) were male and 6 (30%) were female. When asked if they felt the health department did the right thing in telling them about exposure, 58 (86%) responded yes, 0 (0%) no, and 11 (44%) not sure. When asked if the health department should keep telling people when they have been exposed to HIV, 70 (89%) responded yes, 0 (0%) no, and 5 (6%) not sure. When asked if being told they were exposed to HIV helped, 66 (81%) responded yes, 1 (2%) no, and 11 (44%) not sure. Health department notification was similar for homosexual men and heterosexual, males and females, white and black, and HIV positives and negatives.
Conclusion: Health department notification is highly acceptable to health department clients exposed to HIV in this rural South Carolina district.

W.A.O.22 PARTNER NOTIFICATION FOR HIV PREVENTION: CURRENT STATE POLICY IN THE UNITED STATES

Michael Goldman*, Gillian M. Gates*, Centers for Disease Control, Atlanta, GA, USA.

Objective: Partner notification (PN), used for many years in STD control programs, has been broadened to include the notification of sex and needle-sharing partners of individuals infected with HIV. PN encompasses two distinct strategies, patient referral and provider referral; all PN programs are based upon some combination of these two strategies.
Methods: In the earlier PN programs, patient referral and provider referral were required to implement procedures for confidential PN. State programs were canvassed to determine the extent of their current PN activities.
Results: All 50 states, Puerto Rico, the Virgin Islands, and the District of Columbia currently counsel HIV infected clients about the notification (patient referral) and offer provider referral upon request by clients. Fifteen states have PN programs that encourage provider referral for all clients. Data available from 13 states demonstrate seroprevalence among partners of individuals with HIV infection ranges from 0.1% to 16.4%. Infection among female sex partners of bisexual men ranges from 0.7% to 15.2%.
Conclusion: Partner notification is being applied increasingly in HIV prevention programs in the US to identify individuals at risk for different serological groups and for individuals with different risk behaviors are currently being developed by CDC.

W.A.O.24 COMBATTING AIDS WITH CONTACT TRACING

The Swedish Study Group on Contact Tracing for HIV Infection*

In the Swedish effort to combat HIV infection and AIDS, contact tracing is considered as a fundamental tool. It was seen as an integrated part of a clinical and psychological care for the patient. It is assumed to be an important element in the reduction of spread of disease. In the behavioural change effort of counselling and in the finding of hitherto unknown infections. It has also been suggested to be most economical than screening programs for finding infected individuals.

A collaborative study, including most of the centres involved in the care of HIV infected patients, has been initiated, with the scope of describing the effects of contact tracing, as well as the individual as well as the spread of the disease. The study consists of a retrospective analysis of contact tracing results and a prospective study of behavioural changes and in post-infective effects for the individual patients. Possible epidemiological inferences from contact tracing statistics are also studied.

Thus far, the following preliminary estimates of the results of contact tracing for HIV infection in Sweden have been made on the average, each index patient gives rise to 1.8 identifiable contacts; most of these are tested 80% have been traced. One third of these tests are positive. About 40% of positive individuals identified in this way are previously unknown to the health care system.

* presented by Dr. J. Olsson, Dept. of Environmental Health & Disease Control, Karolinska Hospital, Stockholm (Sweden). Swedish (financial) support. The project has been financed by a grant from the Swedish insurance company AFA.

**Table ronde
Round Table**



**Épidémiologie et santé publique
Epidemiology and Public Health**

**Contrôle de l'épidémie de VIH
Monitoring the HIV Epidemic**

Th.A.0.1 MONITORING THE HIV EPIDEMIC

Chairpersons: **Jean Chin** (Geneva, Switzerland), **Timothy J. Donder**
(Atlanta, USA)
Panelists: **C. Noel Gill** (London, United Kingdom), **Steve Lwanga** (Geneva,
Switzerland), **Lloyd Novick** (Albany, USA)

Increasingly, countries are conducting or planning HIV serologic surveys to help health officials assess and monitor the changing patterns and spread of the epidemic. Survey approaches vary but sentinel surveillance, in which levels and trends of HIV infection are tracked in selected accessible sub-populations, is emerging as a practical approach to monitor the various patterns of HIV spread in the population at large. In the roundtable, a panel of five specialists in HIV serosurveillance will discuss issues related to HIV surveys and reflect on the experience so date. The topics will include 1) the needs for and uses of serosurveillance; 2) surveys in sentinel populations - choice and implications of the populations selected; advantages, disadvantages, and legal/ethical aspects of anonymous unlinked (blinded) surveys compared with surveys in groups who volunteer; interpretation of data from and biases in sentinel populations; and 3) surveys using probability samples of the population - advantages, disadvantages, and feasibility. Time will be reserved for audience participation in follow up discussions.

Table ronde
Round Table

Épidémiologie et santé publique
Epidemiology and Public Health
Modélisation mathématique
Mathematical Modelling
Th.A.0.2 MATHEMATICAL MODELLING

 Chairpersons: Roy M. Anderson (London, United Kingdom), Ben Brookhaver

 Panelists: WATERHOUSE, Carlos Castillo-Chavez (Ithaca, USA), James Curran (Atlanta, USA), John Koen (Atlanta, USA), G. Medley (London, United Kingdom), Andrew Moss (San Francisco, USA)

The five papers in this session examine various aspects of the use of mathematical and statistical methods in the epidemiological study of HIV and AIDS. The topics include the use of statistical methods to make short term (one to two years) projections of the future incidence of AIDS, in back calculation of the number of infecteds underlying a given AIDS cases notification pattern and to estimate the incubation period of the disease in different age classes and at risk groups. Mathematical methods are described to investigate the transmission dynamics of HIV, its potential demographic impact in developing countries and the importance of heterogeneity in sexual behaviour to the pattern of the epidemic. The session will also include a discussion of the estimation of epidemiological parameters, the interpretation of trends in incidence of infections and disease and data needs.

**Séance thématique
Specialty Session**



**Épidémiologie et santé publique
Epidemiology and Public Health**

**Questions de Méthodologie
Methodologic Issues**

Th.A.0.10 HIV SCREENING IN LOW PREVALENCE POPULATIONS:

THE USE OF SERUM CONVERSION EXPRESSION INDEX (SEI) IN HIV-1 INDIVIDUALS
Drs. Robert McNeil, L. Dale Johnson, David Reed Research Group, Walter Reed Army Institute of Research, Washington, DC, USA

Objective: To determine if SEI/SEA positive/WB- test results in significant predictor of seroconversion after short-term follow-up in a low prevalence population of US young adults.
Methods: From October 1985 to November 1986, 24,261 soldiers on active duty in the US Army were tested for HIV-Ab on two or more occasions. The average interval between tests was 8 months. Individuals who were SEI- or SEI+/WB- were considered HIV-Ab negative. HIV seropositivity was defined as duplicate SEI-Ab plus WB- on two separate occasions.
Results: During the study period, 119 persons seroconverted (0.49%).

Zellweger's Sensitivity		Prevalence	Sensitivity	Pos. Predictive Value	1-SPN
SEI	0.98	0.49	0.92	0.80	0.88
SEI/WB	0.97	0.49	0.92	0.80	0.88
SEI/WB	0.97	0.49	0.92	0.80	0.88
SEI/WB	0.97	0.49	0.92	0.80	0.88

Conclusion: SEI positivity that is not associated with confirmatory WB reactivity significantly increases the positive likelihood of confirmed seroconversion after a short follow-up. In a low risk population, SEI positivity alone is not an adequate subsequent seropositivity for quantitative individuals (less than 1.0%). Demographic, geographic, and behavioral constants of infection risk could increase the predictive power of SEI- test results in low prevalence populations.

Th.A.0.11 INCIDENCE OF PEDIATRIC AIDS IN THE UNITED STATES:

PREDICTIONS FROM SEROPREVALENCE DATA
Dr. William Miller, Rogers M. Berkman M.D., Willoughby A.A., Novello A.A., Pappasian M.D., AIDS Program, CDC, Atlanta, GA, **NICHD, Bethesda, MD, USA

Objective: To predict incidence of AIDS in the first year of life for infants born in 1986, and compare with reported cases among infants born in 1986 and 1987.
Methods: The population-based Survey in Childbearing Women provided an estimate of the prevalence of HIV infection among United States women delivering live infants in 1986. The proportion of infants born to HIV-infected mothers who develop AIDS by 12 months of age was estimated from ongoing cohort studies. Infants born in 1986 and 1987 who were known to have developed AIDS in the first year of life were those reported to CDC.
Results: In 1986, at least 1 per 1000 childbearing women had antibody to HIV. If between 25 and 10% of their infants develop AIDS in the first year of life, approximately 225 to 450 cases of AIDS in infants under 12 months of age would be expected to occur in the 1988 birth cohort. As of January 1, 1989, 137 children born in 1986 and 120 born in 1987 had been reported to CDC with AIDS diagnosed by age 12 months.
Conclusion: A lag in case reporting complicates the comparison between HIV/AIDS cases occurring in 1986 and 120 born in 1987 and cases predicted among those born in 1988. However, seroprevalence data suggest that more AIDS cases will occur in the 1988 birth cohort that have been reported from previous cohorts to date.

Th.A.0.12 RELATIONSHIP BETWEEN CUMULATIVE INCIDENCE OF AIDS AND PREVALENCE OF HIV IN WOMEN OF REPRODUCTIVE AGE IN THE UNITED STATES.

Dr. Robert McNeil, David Reed Research Group, Walter Reed Army Institute of Research, Washington, DC, Atlanta, GA; **NICHD, Bethesda, MD, USA.

Objective: To determine whether the cumulative incidence of AIDS reflects the observed prevalence of HIV in women of reproductive age in the U.S.
Method: State-specific HIV prevalence rates (over 100,000 population at risk) in women of reproductive age in 1988 were estimated by results from blinded HIV seroprevalence surveys in childbearing women. The corresponding cumulative AIDS incidence rates in women aged 15-44 years, for 1981-1988, were based on AIDS patients reported to CDC. The Pearson product moment correlation coefficient with 95% confidence intervals, and ratio of HIV prevalence to cumulative incidence of AIDS were calculated. Using simple linear regression, cumulative incidence was regressed on prevalence.
Results: Analysis of preliminary results from 11 states showed cumulative AIDS incidence to be correlated with HIV prevalence (r = 0.89, 95% C.I.: 0.67, 0.93). 75% of the variation in cumulative incidence was explained by prevalence of HIV. The ratio of HIV prevalence to cumulative incidence varied by state, ranging in value from 9 to 43 (median = 20.7).
Conclusion: Our results suggest that despite the lengthy incubation period of AIDS, cumulative AIDS incidence rates currently reflect the HIV epidemic in women of reproductive age. The ratio of cumulative incidence to estimated HIV prevalence varied by state. Higher ratios may indicate incomplete AIDS reporting, a higher prevalence of HIV infection in childbearing women than in women of reproductive age, or an increase in HIV transmission.

Th.A.0.13 EVALUATING THE FEASIBILITY OF THE NATIONAL SEROSURVEILLANCE SURVEY (NSSL) DESIGN.

Dr. Robert T. Maltzberg, J. Robert McNeil, National Center for Health Statistics, Hyattsville, MD, USA.

Objective: To describe the major potential sources of error for the NSSL the possible impact of these errors on HIV prevalence rates, and possible methods to assess and enhance the quality of the survey estimates.
Methods and Results: Major potential sources of error for NSSL include coverage bias, nonresponse bias, misclassification bias and the validity differential nonresponse revealed that high nonresponse among high risk persons will have the greatest impact on nonresponse bias. Nonresponse bias could potentially result in an estimated prevalence of from one-third to one and one-quarter of the true prevalence. The coverage bias does not affect the estimated prevalence of HIV. Misclassification bias does not affect the estimated prevalence of HIV. For high risk persons the misclassification could be as much as 28 times the true prevalence, therefore separate estimates by risk group are not planned for this survey. Risk data will be collected for adjustment of nonresponse bias. To minimize nonresponse bias, a nonrespondent follow up study is proposed. Other methods to evaluate and reduce the bias include a randomized response, geographic stratification, and hepatitis B testing.

Th.A.0.14 APPLICATION OF LOT QUALITY ASSURANCE (LQA) SAMPLING TO HIV AND AIDS SENTINEL SURVEILLANCE

Dr. Robert T. Maltzberg, Geneva, Switzerland.

Objective: To describe possible applications of Lot Quality Assurance Sampling (LQA) to sentinel surveillance.
Methods: LQA and standard sampling techniques are described with their benefits and limitations in sentinel surveillance for HIV and AIDS.
Results: When sentinel surveillance centres are established to act as a "barometer" for HIV infection and AIDS in a target population group, it may not be necessary to screen very large numbers of people. LQA sampling techniques, which originate in industrial studies, may be used in this case. The strategy in industry is to classify a batch of items as not likely to have a level of defective items higher than a particular value, with a given probability. A similar strategy can be applied to a sentinel surveillance system for HIV infection and AIDS in which, unless a pre-determined percentage of people are found positive among a randomly selected group, one can conclude that the level of infection among the target group is not above a particular level.
Conclusion: Using LQA sampling techniques in HIV and AIDS surveillance greatly reduces the minimum sample sizes which would be needed to determine that a target group is not likely to have an HIV prevalence rate above a pre-determined critical value. In areas with very low levels of HIV infection LQA techniques would be more efficient than methods which would aim at estimating the prevalence of HIV in the target group.

Th.A.0.15 Methodological Considerations for Assessing the Impact of Condom, Spermatide and Oral Contraceptive Use on HIV Transmission

Dr. Robert T. Maltzberg, J. Robert E. Lee B. and Patricia M. Centers for Disease Control, Atlanta, Georgia, U.S.A.

Numerous investigations have been initiated or are being planned to investigate the likelihood of HIV transmission in heterosexual couples who consistently and correctly use condoms, spermatides and/or oral contraceptives. To rigorously study this critical question, a complex composite methodological concerns must be addressed including: 1) appropriate selection of the study population, 2) knowledge of HIV status at entry of all study participants, 3) the reliability of measures to assess sexual activity and contraceptive use, and 4) the temporal correlation of seroconversion with contraceptive use and HIV transmission may be misleading. Most sources of systematic error in such studies will bias toward observations of a reduced efficacy of condoms in preventing HIV transmission and 2) a positive association between oral contraceptives and HIV transmission. To maintain likelihood of identifying real HIV transmission, such bias must be minimized in design strategies and, if not eliminated, considered when study results are interpreted.

Séance thématique Specialty Session

Autres rétrovirus : le HTLV-II Other Retroviruses: HTLV-II

Th.A.0.29 HTLV II INFECTION IN U.S. BLOOD DONORS
 HALL, J. P., FERGUSON, C. M., LEVINE, W. J., SCHWARTZ, J. J.,
 LAITILA, V. A., and LEE, H. H. Abbott Laboratories, North
 Chicago, IL, USA
 *American Red Cross, ROCKVILLE, MD, USA

OBJECTIVE: With the advent of large scale HTLV II screening, the rate of HTLV II infection was determined in over 300,000 blood donors from all parts of the U.S.

METHOD: A viral based EIA was used in the initial screening followed by CONFIRMATION using Western blot (WB), SDS-PAGE RIPA, PCR and lymphocyte coculture in certain subjects.

RESULTS: A total of 301,109 donors were screened by EIA for an initial reactivity rate of 0.11% and a repeat reactive rate of 0.08% with 248 EIA repeat reactive donors known to date. Approximately one-third of these were resolved by WB alone (14% MB positive, 15% MB negative), whereas the remaining two-thirds needed to be tested by RIPA. A further 20% were confirmed to be positive by RIPA using the PAGE-EXE One-step of antibodies to 2 gene products. The remaining samples (39.8%) were negative by RIPA. None of the MB negative samples tested positive by RIPA.

CONCLUSION: The distribution of confirmed positives indicates a high density of HTLV II infection in metropolitan areas such as San Francisco, LA, New York and Miami, superimposed by a belt in the Southern region extending from California through Texas and Florida to South Carolina. PCR results using lymphocytes from over 100000 donors indicate that both HTLV I and II are present, with the majority being HTLV II. This is in contrast to our findings in IVDA from Florida which indicated an overwhelming majority (>90%) of HTLV II infection in the cohort studied.

Th.A.0.31 HTLV-II-ASSOCIATED LYMPHOMA (HAM/TSF) IS ASSOCIATED WITH HIGH INCIDENCE OF OTHER MALIGNANCIES

OSAKADA, M., YAMAZAKI, H., YAMAZAKI, T., YAMAZAKI, M., YAMAZAKI, M.,
 WAKIMOTO, M., *Hiroshima University, Hiroshima, Japan,
 *Centers for Disease Control, Atlanta, Georgia, USA, *Nagano National
 Sanatorium Hospital, Miyota, Japan.

Objective: To determine whether HTLV-II-associated lymphoma/tranoprol specific paraneoplasia (HAM/TSF) is associated with other malignancies.

Methods: National surveys of HAM/TSF in Japan in 1987 and 1988. A case of HAM/TSF was defined as a slowly progressive lymphoma with antibodies to HTLV-II both in serum and CSF. Results: In the survey, 161 cases of HAM/TSF were reported. Significantly more HAM/TSF patients reported a history of blood transfusion (24) than did HTLV-II infected patients with adult T-cell leukemia/lymphoma (19/122, 15.3%, p < .002) or than did the general population (44/1290, 3.2%, p < .001). Modeling of the population (logistic analysis) showed that the expected distribution if transfusion is the interval from transfusion to onset of HAM/TSF (median) followed a log-normal distribution, the expected distribution if transfusion is associated with HAM/TSF. In November, 1988, all Japanese blood banks stopped transfusing HTLV-II seropositive blood. Significantly fewer HAM/TSF patients show symptoms longer after screening reported a history of blood transfusion (11/59, 18.4%) than did patients whose symptoms began during a comparable period before screening (13/49, 37.1%, p < .03). Furthermore, only 1 person who developed HAM/TSF in 1987-88 reported a history of blood transfusion after 1988 compared to 2 reported cases if not screening had taken place (p < .007). Conclusions: These results demonstrate an association between blood transfusion and HAM/TSF and suggest that transfusion of HTLV-II-infected blood can cause HAM/TSF.

Th.A.0.33 SIGNIFICANCE OF POSITIVE AND INDETERMINATE HTLV-II REACTIVITY RESULTS IN BLOOD DONORS

EBBAHAR, R. M., LAIRSON, H. J., LEE, H. H., CRITCHLEY,
 D. S., DE, B. A., *CDC and *American Red Cross Atlanta
 Branch, Atlanta, Ga, and *Abbott Laboratories, Chicago, IL, U.S.A.

Objective: To evaluate virologic and epidemiologic characteristics of blood donors whose HTLV II serologic results were positive or indeterminate. Methods: From June-August 1988, sera from 1996 consecutive blood donors of the Atlanta Regional Blood Services were tested for HTLV antibodies by EIA; all reactive sera were confirmed by WB and RIPA. Interviews and a second blood sample were obtained from all HTLV-II-positive donors, and from 3 donors with indeterminate results. Peripheral blood mononuclear cells were examined by polymerase chain reaction (PCR) using 2 primer pairs designed to amplify HTLV-II proviral DNA. Results: Of 1996 blood donors tested, 20 (0.1%) showed repeatable reactivity by EIA; 3 (0.15%) were confirmed seropositive (presence of antibody to p24 and/or gene product), and 17 (0.87%) had indeterminate results (reactivity to gag only). All 3 seropositive donors were black and from the SE, compared with 1/7 with indeterminate and 0/2 with negative results. One donor a history of IV-drug use, but 1 positive donor had an IV-drug-using sex partner. The HTLV-II seroreactivities remained unchanged 4-7 months after initial donation. Cells from seropositive donors showed HTLV-II specific sequences on PCR; cells from the other showed HTLV-II. In contrast, cells from 2 of 3 with indeterminate results (0/3 with only on WB) and 3 of 3 with negative serologic results were negative for both. Conclusions: HTLV-II seropositivity in blood donors may be due to HTLV-II or HTLV-II donors with indeterminate HTLV-II serologic reactivity (0/3 with ser HTLV-I or HTLV-II).

Epidémiologie et santé publique Epidemiology and Public Health

Th.A.0.30 ANTIBODIES TO HIV-1 AND HTLV-II IN HAITI

DE LAUNAY, J., BOUAB, S., *LAWSON, A., *FICHELLETT, J., *DANAN, D.,
 DELANNOY, G., *Laboratoire d'Investigations Biologiques, Port-au-
 Prince, Haiti; *Hospital de Laseatis, Laseatis, Martinique.

Objective: Determine the seroprevalence of HTLV-II antibodies (Ab) and the association of HTLV-II in Haiti and HTLV-II in Martinique.

Methods: From September 1987 to September 1988, 896 apparently healthy individuals, (16-70 years of age; n: 30 ± 14 years, 503 female, 379 male), 107 adults AIDS patients (43 female, 64 male) and 140 female prostitutes were tested by ELISA for Ab to HIV-1 (Abbott and Dupont) and HTLV-II (Dupont). Positive specimens were tested by Western blot (Dupont).

Results: Specimens were considered positive only when reactive by Western blot. The following table summarizes the results.

Healthiness (%)	Prostitutes (107)	AIDS patients (107)
HIV-1+	51 (5.8%)	68 (36.7%)
HIV-1-/HTLV-II+	22 (2.5%)	17 (10.3%)
HIV-1-/HTLV-II-	7 (0.8%)	23 (12.4%)

The seroprevalence of HTLV-II in Haiti was 40% among apparently healthy Haitians is 5.8% and 2.5% respectively. The prevalence of the HIV-1 / HTLV-II co-infection is 0.7% among healthy individuals, 10.3% among AIDS patients and 12.4% among prostitutes.

Conclusion: The results indicate that the seroprevalence of HTLV-II in Haiti is the same as in other Caribbean islands. They also suggest that prostitutes are particularly at risk for HTLV-II infection. Cohort studies should be carried out in Haiti to determine the influence, if any, of HTLV-II on the evolution of HIV-1 infection.

Th.A.0.32 HTLV-II INFECTION CORRELATES WITH INCREASED AGE IN INFECTED BLOOD DONORS

BOHANNAN, G., ROBERT, J., NARAY, D., *Khan, S., *Khan, S.,
 LAIRSON, H. J., *CDC and *American Red Cross Atlanta
 Branch, Atlanta, Ga, and *Division of Field Services, CDC, Atlanta, GA, USA,
 *Montefiore Medical Center, Bronx NY USA

Objective: To evaluate risk factors for HTLV-II infection in a cohort of IVUD.

Methods: Subjects were participants in a longitudinal study of HIV infection in IVUD in a methadone maintenance program in Bronx NY. All participants who had blood drawn in 1987 were tested for serologic markers of HTLV-II infection. Samples were screened by enzyme immunoassay and confirmed by Western blot and radiomicroprecipitation.

Results: Of 270 persons, 21 (8%) were HTLV-II antibody (p24 and/or gene product) positive, while 12 (4%) had indeterminate results (antibody to gag gene product only), and 237 were HTLV-II-, HTLV-II persons were significantly older than HTLV-II negative persons (p < .0001). No significant differences were seen in sex, race, socioeconomic status, transfusion history, biphoria, or travel to HTLV-II endemic areas. Both HTLV-II and HTLV-II IVUD had similar duration and frequency of drug use, history of needle sharing with strangers, and visits to shooting galleries since 1978. However, no differences were seen in number of total, IVUD, or paying sex partners since 1978. HTLV-II and HTLV-II persons had similar rates of HIV infection. Analysis controlling for age did not reveal additional risk factors. **Conclusion:** In this cohort of IVUD, HTLV-II seropositivity was more common in older persons; neither sexual nor drug use behaviors since 1978 were associated with the acquisition of HTLV-II.

Th.A.0.34 PREVALENCE OF HEMAGGLUTINININ-BINDING HIV-1 IN INFECTED BLOOD DONORS

ELBAHAR, R. M., LAIRSON, H. J., LEE, H. H., CRITCHLEY,
 D. S., DE, B. A., *CDC and *American Red Cross Atlanta
 Branch, Atlanta, Ga, and *Abbott Laboratories, Chicago, IL, U.S.A.

Objective: To determine the prevalence of antibodies to human lymphotropic virus type 1 (HTLV-1), the cause of adult T-cell leukemia (ATL) and tropical spastic paraparesis (TSP), in HIV-1 seropositive individuals for the armed services of the United States.

Methods: Sera from 10,929 applicants collected during the period of March and April 1989 were screened using a enzyme linked immunosorbent assay (ELISA). All repeat reactive and 14 initial reactive ELISA samples were confirmed by Western blot and radioimmunoassay assays (RIA) to confirm the presence of antibodies specific to HTLV-1.

Results: Of the 233 (2.2%) initial reactivities by ELISA, 85 (0.58%) were repeatedly reactive. The Western blot procedure revealed 5(7.3%) positive, 20(29.0%) negative, and 44(63.7%) indeterminate. The RIA confirmed the presence of envelope protein in 2 of the Western blot positives and in 3 of the 44 indeterminate; 0/24 with only a 3 component positive.

Conclusion: The overall prevalence rate of HTLV-1 antibody in the applicants was 0.4% whereas the

Session d'affichage Poster Session



Epidémiologie et santé publique Epidemiology and Public Health

M.A.P.7 SEROPREVALENCE OF HEPATITIS TO THE NEW IMMUNOPROTECTOR (NEW ICI) IN SPELTERS FOR HEMORRHOID LIGATURE IN ALABAMA

Abstract No. 100 - **Authors:** JAMES P. HAYES, William G. Miller, Donald Williams*
*Alabama Department of Health, Bureau of Clinical Laboratories (BCL), Montgomery, AL
**Naval Health Research Center (NHRC), San Diego, CA, *National Naval Medical Center,
Bethesda, MD
Objective: To evaluate the seroprevalence of antibodies to HIV in military personnel
(A) presumed heterosexual, low risk population (B) low prevalence AIDS area using repeated testing.
Methods: All specimens analyzed by ELISA* for antibody against presumed prevalent
antibody from 1 November, 1987, to 31 January, 1988 (Study 1); from 1 November, 1988, to
31 January, 1989 (Study 2) were tested for HIV antibodies in separate seroreactive studies using
direct enzyme immunoassay (EIA). Repetitive seroreactive specimens were tested by Western blot.
Results: 4694 specimens from Study 1 and 4633 specimens from Study 2 yielded the following:
Study 1
n (Number) (%) n (Number) (%)
ED-VIII* 23 0.5 5 0.1
ED-VIII* 53 1.3 1 0.02
ED-VIII* 7 0.15 0 0.0
Immunoreactive 4622 98.48 4320 99.20
Total 4694 100 4633 100
Conclusion: The decline in ED-VIII* specimens from 0.21 to 0.11 does not appear to be
statistically significant. These results indicate that within the observed seroprevalence among Alabama
military recruits (0.074, 1.3-80) and the ELISA criteria (1.64, 10.3-80).
Significance: This study provides an increase in specificity from 98.72 to 99.96 reflects overall improvements in manufacturers of the test kits and purification
of the antigen.

M.A.P.9 HIV SEROPREVALENCE AT UNIVERSITY CAMPUSES, U.S.A.

ORIG.: JOURNAL, *Journal of the American Medical Association*, 261:1800-1801, 1987.
Authors: J. P. Hayes, D. Williams, J. M. S. Garcia, T. M. Smith, M. J. Kilbourne, M. J.
Sullivan, J. P.
**Centers for Disease Control (CDC), Atlanta, GA, USA,
American College Health Association, Rockville, MD, USA

Objective: To estimate the seroprevalence of HIV infection among university
students in the United States.
Methods: We are conducting blinded HIV antibody testing on blood collected for
other routine medical purposes in student health centers. A total of
500-1000 blood specimens are being collected on 17 campuses throughout
the country and tested for HIV antibodies by ELISA and Western blot.
Non-identifying demographic data are listed with test results.
Results: To date, a total of 23 (25.2) of 13,810 specimens are positive for
HIV antibodies. All positive results are from students 210 years old; 17 (73%)
were 21-29 years old. Twenty (87%) of students with positive results were
male. Seroprevalence rates were higher for males (0.492) than females
(0.042) and increased with age from 0.063 for 18-21 years old to 0.647 for
28-29 years old. Positive results were identified in only 3 of the 17
schools; however, these schools represented all regions of the country.
Conclusions: HIV infection is present on university campuses. Although, the
rate still appears to be relatively low. These data suggest that older,
male students are at greatest risk. Universities provide a challenge to
maintain low rates of seroprevalence in what is often a relatively insular
setting with high rates of sexual activity, often with multiple partners.
Ultimately, the risk of exposure to HIV infection may increase for many
students as they leave the campus, highlighting the importance of targeting
this population.

M.A.P.11 INCIDENCE OF HIV SEROPREVALENCE IN U.S. NAVY PERSONNEL-RESULTS OF TOTAL NAVY SCREENING

ORIG.: *Journal of the American Medical Association*, 261:1800-1801, 1987.
Authors: J. P. Hayes, D. Williams, J. M. S. Garcia, T. M. Smith, M. J. Kilbourne, M. J.
Sullivan, J. P.
**Naval Health Research Center (NHRC), San Diego, CA, *National Naval Medical Center,
Bethesda, MD, **Naval Air Station, Pensacola, FL, ***Defense Eligibility
Enrollment Reporting System (DEERS), Monterey, CA, U.S.A.**

Objective: To determine incidence rates of HIV seroconversion in a young and apparently
highly mobile population of active-duty U.S. Navy and Marine Corps personnel.
Methods: Using HIV seropositivity data provided by the Naval Medical Command and
maintained in the Navy HIV Central Registry at NHRC, and population data provided by the
Reproducible Disease Database of DEERS, incidence rates of seroconversion were calculated for
the period 1986-1988 using person-years as denominator. The period at risk for each
individual began with the first negative ELISA test and continued until the first positive
Western blot assay or the last negative ELISA test. HIV seroconverters were defined as
persons with at least one negative ELISA screening test followed by two positive paired
ELISA tests and two positive Western blot assays (criteria for positive Western blot:
a specimen that exhibited at least two of three bands in p24, gp41, and gp120/160).
Results: Since 1986, 97% of active-duty Naval personnel have had a routine annual HIV
seropositivity screening test (1,170,111 persons; 1,956(0.17) total). During the three-year
period 1 Jan 1986 to 31 Dec 1988 there were more than 725 seroconversions in active-duty
personnel. Incidence rates were similar by age, race, sex, occupation, and other
relevant demographic characteristics were determined.
Conclusion: This is one of the largest studies in existence of HIV seroconversion in a non
self-selected healthy population. It provides unique information on demographic and
occupational factors related to HIV seroconversion.

M.A.P.8 ANTIBODY HIV TESTING ON SEROBERS IN 61 ITALIAN HOSPITALS: AN ESTIMATE OF PREVALENCE OF HIV INFECTION AMONG WOMEN IN REPRODUCTIVE AGE

ORIG.: *Journal of the American Medical Association*, 261:1800-1801, 1987.
Authors: J. P. Hayes, D. Williams, J. M. S. Garcia, T. M. Smith, M. J. Kilbourne, M. J.
Sullivan, J. P.
**Italian Collaborative Study Group for HIV Prevalence in Newborns, Lazzaro
Spallanzani Hospital for Infectious Diseases, Rome, Italy.**
Objective: To assess the prevalence of HIV infection in female population in
reproductive age and provide a predictive parameter to estimate future
pediatric AIDS cases.
Methods: Blood samples were collected on filter paper for routine
screening from 79,687 consecutive newborns in 61 hospital
nurses, in different Italian regions, during the period
June-November 1988. Blood saturated glassa were placed on the
collection papers, without identification, at the National
Blood Transfusion Center of the Italian Red Cross in ELISA (Pasteur Lab); the
positive results were confirmed in a Western Blot (Dugout Lab).
Results: Among the 79,687 blood samples tested 18 (0.023), Confidence
interval 95%, Poisson's distribution (0.0052-.041) were found positive for
HIV-1b.
Conclusion: The distribution pattern of the positive samples among the
different regions correlates to the AIDS cumulative incidence rate,
with a higher prevalence in the north and center. Italy's HIV
screening on the newborns, who reflect seroprevalence patterns of the
population, can provide a useful tool in evaluating the
prevalence of the infection in a relatively unselected population.

M.A.P.10 HIV SEROPREVALENCE AT THE BRONX LEHMAN HOSPITAL CENTER - A CDC SENTINEL HOSPITAL

ORIG.: *Journal of the American Medical Association*, 261:1800-1801, 1987.
Authors: J. P. Hayes, D. Williams, J. M. S. Garcia, T. M. Smith, M. J. Kilbourne, M. J.
Sullivan, J. P.
Brnxn Lehman Hospital, Bronx, NY, USA, **CDC, Atlanta, GA, USA

Objective: To monitor levels and trends of HIV seroprevalence in the South
Brooklyn.
Methods: The CDC Sentinel Hospital Surveillance Network's protocol and
sampling scheme was used. From Feb. - Oct. 1988, 2566 bloods were tested.
They came from 871 males and 1695 females; 1193 Blacks, 1181 Hispanics,
21 Whites and 169 of unknown origin.
Results: The population's mean age was 41.8; males 43.9 and females 40.1.
Western blot positive males had a mean age of 39.8 and positive females
34.8. 70 males and 70 females were positive. The ages and coasts are
listed below:

Age Group	Male	Female	Total	Male (%)	Female (%)	Total (%)
2-4	7	14	21	0	6.2	1.2
5-14	12	17	29	0	0	0
15-24	58	315	373	2 (3.6)	8	(2.1)
25-44	245	630	875	46 (18.8)	49	(7.8)
45-64	355	456	811	20 (5.6)	12	(1.5)
65+	146	283	429	2 (1.4)	0	(0.5)
Total	871	1695	2566	70 (8.0)	70	(4.1)

Conclusion: Bronx Lehman Hospital has one of the highest HIV seroprevalence
rates in the Sentinel Hospital Network suggesting the urgency of intensive,
community-wide intervention to control further transmission of HIV in this
high-risk, urban population.

M.A.P.12 HIV SEROPREVALENCE AMONG PARTURIENTS IN LOS ANGELES COUNTY, 1986

ORIG.: *Journal of the American Medical Association*, 261:1800-1801, 1987.
Authors: J. P. Hayes, D. Williams, J. M. S. Garcia, T. M. Smith, M. J. Kilbourne, M. J.
Sullivan, J. P.
**Los Angeles County Department of Health Services/LACDHIS, Los Angeles, California
Fetal and Neonatal AIDS Test Unit (FANATU), Los Angeles, CA, USA

Objective: To estimate the prevalence of human immunodeficiency virus (HIV) among parturient
in County Hospital in Los Angeles County.
Methods: Between September and December 1986, 9,400 consecutive prenatal onset blood
specimens were obtained from four County Hospital sites in Los Angeles County. Specimens were
linked to maternal demographic information and, when available, placental syphilis serology and
serology for HIV antibodies. An ELISA test was done after a positive ELISA result was
obtained. Repeat ELISA positive results were confirmed by immunofluorescence antibody and Western
Blot.
Results: The combined onset births in this sample represents approximately 58% of all Hispanic
births, 29% of all black births, and 8% of all white births in LAC in the sampling period. To
date, 626 (6.7%) have been confirmed HIV Ab positive. Sixty-two percent of all women had
information available on intravenous (IV) drug use, and of those, approximately 5% had a history
of IV drug use, but none were HIV Ab positive. Of the women for whom information was
available, 57% had a positive antibody test at the time of delivery, but again none were HIV Ab
positive.
Conclusion: HIV seroprevalence among parturients delivered at county hospitals in LAC during
the sampling period was low, and was not associated with either IV drug use or syphilis. Data
from 2,400 births will be presented.

Session d'affichage Poster Session



Epidémiologie et santé publique Epidemiology and Public Health

M.A.P.19

HIV 1 ET HIV 2 EN MILIEU CARCÉRAL. A DAKAR

(SÉNÉGAL)

Sarrh, N.D.*, Bays, C.S.*, Diong, G.S.*, Siby, T.*, Sow, A.* M'Boop, Souleymane*
*Université de Dakar, Sénégal.

Objectifs: Evaluer la situation de HIV1 et HIV2 dans les prisons de Dakar et obtenir des informations en vue de la décision de Santé Publique concernant les individus incarcérés. **Méthodes:** Entre Avril et Mai 1988, 1354 prélevements de sang ont été effectués sur 1241 prisonniers (1155 hommes et 189 femmes) et 113 agents de l'administration pénitentiaire qui ont servi de population témoin. Tous les sérums ont été passés en HIV1 ELISA (Abbott) et les positifs confirmés par Western Blot sur HIV1 et HIV-2. **Résultats:** Aucun des agents de l'administration pénitentiaire n'était séropositif. Par contre 11 prisonniers étaient séropositifs (7 en HIV2 et 4 en HIV1) soit une prévalence de 0,9%. Parmi les femmes la prévalence était de 2,3% pour HIV2 et de 3,5% pour HIV1. Parmi les hommes les prévalences d'infection étaient respectivement 0,4% et 0,1%, semblable à la prévalence observée dans la population générale. Tous les sujets séropositifs étaient d'origine africaine âgés de 25 à 31 ans et avaient une sérologie positive pour le syphilis. De plus 7 femmes ou des enfants de détenus d'autres MST.

Conclusion: Le milieu carcéral est considéré comme favorable des activités à haut risque, telles que l'utilisation de drogues par IV et la pratique de l'homosexualité pouvant propager le virus. Cependant, une évaluation préjudiciale en milieu carcéral dans d'autres pays de l'Afrique de l'ouest, la prévalence d'infection par HIV parmi les hommes incarcérés était identique à celle observée dans la population générale. Cette information est d'importance pour les responsables de la Santé Publique car elle fait des ressources limitées. Les campagnes d'éducation et de prévention en milieu carcéral, à l'heure actuelle, devraient se concentrer sur les groupes à risque (femmes).

M.A.P.21

COURSE OF SEROLOGICAL MARKERS OF DIFFERENT INFECTIONS IN HIV SEROPREVALENT AND SERONEGATIVE INMATES FROM A PENITENTIARY POPULATION.

Ottis de Lejarazu R., Ertos J.G., Perledo E., Orduña A., Bratos M., R-Torres X. UNIVERSITY HOSPITAL and Faculty of Medicine, Valladolid, Spain.

OBJECTIVE: To describe the presence of markers against different infections versus HIV serological status and behaviour in a penitentiary population. **METHODS:** Sera from 323 inmates previously screened for HIV Ab by EIA and WB test and from 78 blood donors as control group were tested for HbSAb, VHBsAb, HbSg, HbSg (by EIA test) and Ab against HSV, CMV, EBV (CF test) and T.pallidum (VDRL and FTA-abs).

RESULTS: The global prevalence of markers was as follows: 265 of inmates were HIV positive; 50,2% had VHB markers (42,8% HbSAb, 1,3% HbSg, 4,5% HbSb+HbSg, 1,5% HbSg); 40,7% of inmates HbSg had VDBs; 86,5% had Ab against HSV, 50,6% for CMV, and 20,9 for EBV and 10% by FTA-abs. We found significant higher rates of VHB infection markers in HIV seropositive inmates (81,7% versus 26,5%) and also against T. pallidum (12,4 versus 4,1%). In the control group we found 2,6% of HbSAb and none for T. pallidum. We did not find any difference in the occurrence and titers of HSV, CMV and EBV Ab between HIV seropositive and seronegative inmates and the control group. The greatest prevalence of VHB and T.pallidum markers was found among 10% of inmates with antisocial behaviors. This result shows the high frequency of infections that may facilitate transmission of HIV in the penitentiary population and could act as cofactors in the progression of the disease.

M.A.P.23

RISK FACTORS ASSOCIATED WITH HIV INFECTION AMONG WOMEN INCARCERATED IN A MEDIUM SECURITY PRISON

Habibie, Chahira*, Gendreau, S.*, St-Pierre S.*,

Richard, C.**, O'Neil, J.**, Bennett, M.**,
*McGill Hospital, Centre de Contrôle & McGill University, **GLSC Abitibi, Montreal, **servical Centre AIDS, Ottawa, Canada.

Objectifs: To determine the relative contributions of needle use practices and unprotected intercourse to HIV seropositivity among female inmates. **Méthodes:** Freely given, informed consent is provided for an individual nurse-administered risk factor questionnaire and tests for HIV, Hepatitis B, and HTLV-I. Prisoners and guards are unaware of which prisoners consent to testing. Random case numbers are used. Results are available to consenting participants but not to health service per prison authorities. **Résultats:** To date 107/217 (49,3%) were injection drug users (IDU). Overall 13 (6%) seropositives (SP) have been detected. All are IDU. For a case among IDU of 12,2% (1/8,4%) report needle sharing, 0/60 current prostitutes, 9 (15%) are seropositive. Comparing SP to the total study population no significant differences were found for oral contraceptive use, sex, of male intercourse. A striking 37,4% of the total study population (vs 20,4% of SP) have had sex since 1979 with a man who has had sex with another man. SP are more likely to be engaged in prostitution (59,2 vs 27,6%), to have sexual partners (50,6 vs 38%), to be SP in the last 12 months, to have had an IDU partner since 1979 (92,1 vs 48,8%), and to have had herpes (23,1 vs 6%) or genital warts (30,8 vs 18,9%).

Conclusion: Recycled and shared needles are suspected to determine to what extent needle use versus sexual practices explain seropositivity.

M.A.P.20

ARRIVE AIDS PREVENTION TRAINING FOR

INTRA-VENOUS DRUG USERS: PRACTICE

FROM PRISON

Wesler, Harry K.**, Marder, E.S., Joseph, Jr., Bickel, R.**, Bardsley, M.**, et al.
*Narcotic and Drug Research, Inc. New York, New York, U.S.A.

Objectifs: To develop, implement and evaluate the outcomes of the first AIDS prevention training program for intravenous drug users provided from prison. The primary goals are to prevent relapses to IV drug use and associated AIDS risk behaviors, and to help clients become productively reintegrated into the community.

Méthodes: ARRIVE is based on social learning, self-aid and therapeutic community principles. The program model involves training at-risk persons for entry-level jobs in the AIDS prevention field, e.g., outreach work, peer counseling. The process of learning for clients to solve their problems is an effective means of internalizing community attitudes and behaviors. The ARRIVE program consists of an 8-week, 48-hour, 24-session group curriculum. The major behavioral themes addressed are: general AIDS facts, needles, condoms, HIV risk reduction, relapse prevention, outreach presentation, and job readiness.

Résultats: A 24-session AIDS Prevention Training Manual has been written and trained with clients during 2 group cycles. The Manual is tailored for use with offender populations with IV drug use histories. An evaluation is in progress that will compare 6-month behavioral outcomes for persons who participated in ARRIVE vs. a matched sample of non-participants.

Conclusion: At least 25% of U.S. prison inmates have IV drug use histories and are susceptible to relapse as inmates. ARRIVE is developing a strategy for reducing HIV risks within this difficult-to-treat, relatively neglected population.

M.A.P.22

HIV SEROPREVALENCE AND THE EFFICACY OF VOLUNTARY HIV TESTING AMONG HALL PRISONERS IN WISCONSIN

Exall, J.L.**, Vergosen, J.K.**, Pridy, R.W.**, Roesz, M. J.**,

Colubajentsev, R.**, Feltzer, J.**,
* Wisconsin Division of Health, Madison, Wisconsin, U.S.A., ** Wisconsin State Laboratory of Hygiene, Madison, Wisconsin, U.S.A.

Objectifs: To estimate the HIV seroprevalence among newly incarcerated male inmates (ENMI) and to assess the efficacy of voluntary HIV testing.

Méthodes: In Wisconsin, blood serum is obtained from all ENMI for hepatitis B tests; residual sera are stored at -20 degrees C. Since January 1, 1987, ENMI have routinely received HIV-related counseling and have been offered voluntary HIV antibody testing. Sera tested by HIV antibody included: a random sample representing 20% of all ENMI admitted 1/1/88-9/28/88 (n=897); all tested blindly; a 100% sample of ENMI admitted 1/2/87-8/31/87 (n=1689); a random sample voluntarily, 25% blindly; and a 100% sample of ENMI admitted 1/1/88-8/31/88 (n=1651); 75% tested voluntarily, 25% blindly.

Résultats: In 1988, 3(0,30%) of 997 ENMI tested were HIV (ELISA, Western Blot). In 1987, 9(0,53%) of 1689 were HIV; 6(0,35%) of 708 voluntarily tested were HIV; compared to 3(0,31%) of 981 tested blindly (OR=2,79; 95% CI 0,99-11,27). In 1988, 4(0,24%) of 1187 ENMI tested voluntarily were HIV.

Conclusion: From 1986 to 1987, there was a non-significant increase in the HIV seroprevalence among ENMI (OR=1,77; 95% CI 0,44-10,22). While the difference in seroprevalence in 1987 between ENMI tested voluntarily and those tested blindly is not significant, voluntary testing detected 67% of all HIV seropositives. In 1988, 71% of ENMI consented to voluntary testing. In regions of lower HIV prevalence, routine HIV counseling with voluntary testing can be a successful strategy for screening male prison inmates.

M.A.P.24

FRÉQUENTATION HOSPITALIÈRE ET INFECTION PAR LE VIH EN MILIEU CARCÉRAL.

RODRIGUEZ Isabel**, ESPINOSA P.**, STEIN S. C.**,

MOLO DROVOT J.**, HAVILLI VILLALBA F.**,
* Hospital de Pruebas (ENSP) Añejo de Thozes 92061, STEIN S. C. FRANCE
H. P. S. P.

Objectifs: Décrire les caractéristiques sociales, cliniques et biologiques des malades VIH séropositifs pour le prospectif pour le diagnostic de France, 1985 à 88

Méthodes: Etude rétrospective sur les malades hospitalisés de 1985 à 1988 ayant une sérologie VIH+. Cette étude a déterminé parmi les séropositifs, l'âge des patients, le sexe, le mode de contamination, le motif d'hospitalisation, le stade de l'infection VIH (classification du CDC), le taux de CD4 le prévalence de 2 infections VIH.

Résultats: En 1985, 103 sérologies ont été prescrites. De 85 à 87, 40 cas de VIH ont été recensés. 80 87 140 (5,8%) sur 3669 malades ont été hospitalisés, 905 sérologies prescrites, 326 (9,4%) étaient positifs. Parmi ces 206 patients séropositifs, 958 sont des hommes d'âge moyen de 27 ans. 915 sont des femmes par voie parentérale ou 155 originaires de pays d'Amérique, 23 homosexualité, 27 contaminés par voie intraveineuse, 135 par transfusion sanguine, 128 ont été hospitalisés pour la cause de l'infection VIH. 215 ont été traités de CD4 < 200/mm³, 115 ont une antigénémie VIH positive, 565 sont des séropositifs VIH+ de stade 1, 200 de stade 2.

Conclusion: L'accroissement du taux de sérologies dépistées de 85 à 88 et l'augmentation du nombre de SIDA justifient au sein de l'hôpital pénitentiaire l'adaptation des moyens hospitaliers.

Session d'affichage Poster Session



Epidémiologie et santé publique Epidemiology and Public Health

M.A.P.31 BLOOD DONATION BY INDIVIDUALS WHO LATER DEVELOPE AIDS

David D. Donnell, M.D., Ziegler, P.O. Clement, M.D., Volendring, P.A., Medical Services of St. Francisco General Hospital, University of California, 50 "PL" Hillway Hospital, UCSF, San Francisco, CA, U.S.A.

Objective: To determine the past blood donations by individuals who later develop AIDS. Methods: The UCSF AIDS Registry has collected detailed medical histories since 1985 from 2605 individuals, 992 of whom had had *Pneumocystis carinii* pneumonia, Kaposi's sarcoma, or cryptosporidiosis at the time of initial evaluation. Patients are asked the date that they last donated blood. It is not known if the blood was discarded after blood bank screening.

Results: 992 patients (99%) had donated blood. 163 patients had not donated blood since 1976. A time when they were unlikely to have yet been infected. The peak year for last donation was 1980 (n=41) and only 4 individuals reported donating blood after 1983. Of these, one patient donated blood 17 months before developing Kaposi's sarcoma, two others 21 and 23 months before AIDS; one patient reported donating blood one month after PCP. Of the 992 who had AIDS, only one other patient reported donating blood after PCP (14 months).

Conclusions: In the era before HIV antibody testing, blood was donated by 13% of gay men who were later likely HIV infected. This blood was not probably discarded. By 1983, transmission had ceased.



M.A.P.33 SEROPOSITIVITE HIV CHEZ LES DONNEURS DE SANG ET ESTIMATION DU RISQUE RESIDUEL EN TRANSFUSION

Coopérite, A. M. M. et le Groupe de travail Séroécrou de la Société Nationale de Transfusion Sanguine - Paris France

Objectif: Comparer la prévalence des donneurs confirmés anti-HIV positif entre 1983 et 1989 et évaluer le risque résiduel de transmission du virus par transfusion. Méthode: Les 10 centres de Transfusion (CT) de groupes de travail regroupent environ le 1/4 de l'activité de collecte des CT français ont rassemblé leurs résultats en individuel les donneurs réguliers (RD) et les donneurs occasionnels (DO).

Résultats: 1) Prévalence des dons anti-HIV positifs

Année	RD	DO	Total (n=103)	ND/DO	DO/DO
1983 (n=604)	119	45	164	119	45
1984	118	47	165	118	47
1987	119	31	150	119	31
1988	104	32	136	104	32

2) Estimation du risque résiduel: Base de calcul = 3% de dons anti-HIV négatifs provenant de donneurs réguliers et donneurs occasionnels en délai maximum de 1 an soit infectés (J.L.M., Lancet 1988 1: 1348)

Intervalle entre dons	Estimation du risque par don
< 2 mois	1/40
2 à 3 mois	1/100
4 mois à 1 an	1/1000

Conclusion: Entre 1983 et 1989, la séropositivité HIV chez les donneurs de sang a diminué de 4 à 6 fois, cette baisse ayant porté à la fois sur les nouveaux et les anciens donneurs. Le risque résiduel transfusionnel diminue parallèlement et est estimé à 1 pour 100.000 dons en 1989.

M.A.P.35 THE EPIDEMIOLOGY OF TRANSFUSION-ASSOCIATED (TA) AIDS

IN CALIFORNIA IN THE UNITED STATES, 1981 TO 1986

James D. Hughes, M.D., Robert H. Ross, M.D., Robert H. Ross, M.D., Centers for Disease Control (CDC), Atlanta, Georgia, U.S.A.

Objective: To describe the demographic and clinical characteristics of transfusion associated (TA) AIDS.

Methods: AIDS cases reported to CDC from 1981 to December 1986 were reviewed. Pediatric TA and transfusion associated (TA) AIDS cases were compared.

Results: Through 1986, 169 children with TA AIDS were reported to the CDC (13% of the 1244 pediatric AIDS cases). The percent of pediatric AIDS cases attributable to TA infection varied by region from 4% in New York City to 50% in Los Angeles. From 1985 to 1987, the yearly incidence of diagnosed cases of pediatric TA AIDS increased from 40 to 82 cases (2X), while PA cases increased from 147 to 301 (107%). The median age at transfusion in pediatric cases was one month (range, birth to 11 years). The median age at diagnosis was 49 months in pediatric TA AIDS cases and 11 months in PA cases.

Pediatric TA AIDS cases were more likely to be male (62%) compared to PA cases (52%). The cumulative incidence of pediatric TA AIDS was 2.4 times higher in blacks and Hispanics than in whites (93% C.I., 1.6-12), although TA AIDS cases were more likely to be white than PA cases (97% vs 15%). The observed to median incubation period was longer for pediatric TA AIDS cases than for PA cases (36 mos. vs 25 mos., p<.001). The median survival after diagnosis of pediatric TA AIDS did not differ from that of PA cases (9.4 vs 10.5 months). **Conclusion:** Children with TA AIDS are distinct from PA AIDS patients. Pediatric TA AIDS cases are being diagnosed at a slower rate than PA AIDS but continue to develop. Donor screening has nearly eliminated new infections; thus this group is important in the study of incubation period in children.

M.A.P.32 SURVEILLANCE FOR UNUSUAL MODES OF HIV TRANSMISSION IN THE USA - A 3-YEAR MULTICENTER STUDY OF BLOOD DONORS

Richard L. Joffe, et al. and the HIV Blood Donor Study Group. Centers for Disease Control, Atlanta, Georgia, U.S.A. Investigators from 20 blood donation sites throughout the USA.

Objective: To monitor levels, trends, and modes of HIV infection in blood donors. Larger, lower-risk population categories for HIV. Because persons with HIV risk are excluded, infection by unknown means (eg, from a heterosexual partner without recognized risk) is relatively easily detectable.

Methods: Seropositive donors at 20 blood centers (approximately 2,000,000 donors/yr) are interviewed using a standardized questionnaire; denominators for seroprevalence rates are determined from blood donor records.

Results: Since June 1984, 147 seropositive donors have been interviewed. HIV Factors for the 114 males and 33 females were homo/seropositivity (52%); intravenous drug use (19%) (92); previous blood transfusion (87%); and sexual partner of a person at risk (89%) (113). Risk factors for the 33 females were IVUD (92); heterosexual partner (82%); 21% of males and 21% of females had no identified risk (81%). Demographic characteristics of HIV were similar to those with identified risk. Using National anonymous Red Cross HIV seroprevalence in first-time donors from 8/87-3/88 (0.037% for males and 0.010% for females), and applying the observed rate of HIV in this study, we calculated that a mean of 1 to 1.64 male and 1 to 4.17 female donors had been infected by unidentified means, such as from sexual partners with unrecognized risk.

Conclusion: Few seropositive donors have traditional HIV risk factors suggesting that heterosexual transmission from partners of unrecognized risk is another possible transmission mode are uncommon. Many HIVs in this study do not have acknowledged HIV risk factors.

M.A.P.34 THE RISK OF HIV-1 TRANSMISSION BY TRANSMISSION OF SCREENED BLOOD

N. Cohen, A. Munoz, K. Nelson, O. Franzer, T. D. Yew*

Jones Hospital Medical Institutions, Baltimore, MD; Texas A & M University, College Station, TX; St. Luke's Episcopal Hospital, Houston, TX; The Methodist Hospital, Houston, TX, U.S.A.

Objective: This prospective study will determine the risk of seroconversion to HIV-1 in a cohort receiving multiple transfusions of blood or blood components screened for antibody to HIV-1.

Method: The study will require 50-60 months to enroll and follow-up approximately 13,000 cardiac surgery patients. Based on current blood product utilization at the three study centers, an estimated 10,000 transfusion exposures will be observed. The probability of HIV-1 transmission will be estimated and the upper bound of the 95% confidence limit will be calculated using the binomial distribution.

Results: To date, serum samples from 2,177 persons representing 29,445 transfusion exposures have been tested. One seroconversion has been identified, our estimate of the risk of HIV-1 transmission by transfusion is 0.002% per screened unit with a 95% upper bound equal to 0.016% per unit.

Conclusions: The interim results of this ongoing study provide valuable information to clinicians and the blood banking community regarding the effectiveness of HIV-1 screening and permit public health officials to make statements with greater confidence about the risk of HIV-1 transmission by screened blood.

M.A.P.36 SEROPREVALENCE OF HIV INFECTION AMONG BLOOD DONORS IN BONE

Barbara L. Halliday, Ippolito, et al.; Ricci, M.; Angeloni, F.; Malin, D. Centers for Disease Control, Atlanta, Georgia, U.S.A.

*Lazzaro Spallanzani Hospital for Infectious Diseases-Rome Italy

Objective: To estimate the prevalence of positive HIV antibodies in a large blood donor population in Rome (about 50% of total blood supply in Rome), to define the epidemiologic characteristics of seropositive subjects, and to evaluate the efficacy of voluntary self-referral programs.

Methods: Since 1983 blood donations were tested routinely for HIV antibodies, and have been screened by personnel and informative materials have been distributed to invite donor belonging to risk groups, to voluntary defer. Seventy-one seropositive subjects were contacted (86%).

Results: Defined prevalence (%) by year and percentage distribution of risk factors of positive donors are reported in table.

Year	males	HIV+ve	prev%	homosex	ITRA	heterosex	Unknown
1985	38323	23	0.06	15.5	84.2	-	5.3
1986	39299	29	0.08	16.0	84.0	60.0	-
1987	47211	16	0.34	15.5	82.5	35.0	-
1988	45919	14	0.30	9.1	36.4	45.4	9.1

Conclusions: The progressive decrease in the prevalence rate among blood donors indicates the efficacy of self-deferral program and emphasize the importance of alternative sites for test, performing and the need of anonymous testing opportunities.

Session d'affichage Poster Session



Epidémiologie et santé publique Epidemiology and Public Health

M.A.P.37 36 POST-TRANSFUSIONNEL (P-TRF) HIV INFECTION IN A REGIONAL CITY HOSPITAL SINCE 1980

Quaranta, J.P.; Casotto-Viguer, P.; Sanderson, F.; Virusna, M.; Casotto, J.P.; Dellamanna, Pierre; Maladies Infectieuses, C.R.H.U. Nice, France.

Objective. Nice (400,000 inhabitants) is characterized by a high prevalence of the HIV infection with a seropositive blood donor two times more higher than in France. Blood donors are screened for HIV in our country since August last 1985. At the end of 1988, a P-TRF HIV infection was diagnosed in 36 patients (19 in 82 years, 21 females).

Results. At the first examination, patients were divided 14 in II, 6 in III, 7 in IVa and 11 in IVb according to CDC groups, with low titer count ($301 \pm 205/\text{ml}$), high acute beta-2-microglobulin level ($5.7 \pm 4.3 \text{ mg/dl}$). These results related with p25 antigenemia suggested a bad prognosis which was confirmed by the outcome: 7 more AIDS occurred within 24 months and 15 patients yet alive. 35 patients had a presumed date of contamination ranged between 1980 and 1985 and one after the blood donors screening. Most of the patients were transfused during surgery ($n = 4.1$ blood units), 4 patients in emergency, 2 for haematological diseases (30 and 128 units) and 9 hemodialyzed patients (2 to 8 blood units). Only two of the investigations required to Blood Bank in search of the infected donors has resulted in a concrete proof. **Conclusion.** The P-TRF HIV infection has a bad prognosis compared to others risk groups. Despite the systematic blood donors testing, the risk is low but remains; this should warrant autotransfusion policy in scheduled surgery, or more accurate screening (e.g. antigenemia or PCR).

M.A.P.39 IMPACT OF AN AUTO-DETERMINATION FORM ON BLOOD DONOR SELECTIVITY: A Retrospective Study

Canadian Red Cross, Montreal, Québec, Canada; ** DCC, Montreal, Québec, Canada; *** DCC, St-Jac Hospital, Montreal, Québec, Canada.

Objective. To determine if the use of an auto-determination form would differentiate between blood donors at high and at low risk.

Methods. From February to May 1989, 21,692 auto-determination forms designed at a permanent site which used an auto-determination form. Donors designated their blood for: transfusion (97.7%), or laboratory purposes (1.5%) after reading a summarizing high risk activities. Of these forms only 0.8% could not be utilized. The blood from the laboratory group (LG) was tested but not used.

Results. In the transfusion group (TG) 36,21,197 (0.17%) were ELISA positive, while in the laboratory group (LG) 6,325 (1.84) were positive. WESTERN BLOT confirmation followed for 8,736 (22.24) in the transfusion group versus 4,6 (0.74) in the laboratory group. WESTERN BLOT confirmed individuals in the LG were all males aged 17-29 years. The seroprevalence of HIV antibody was 0.88 for TG and 1.238 for LG. The specificity of our auto-determination form is 98.5%. The negative predictive value was 99.91 and the global efficiency 97.7%.

Conclusion. The auto-determination form appears to be a helpful additional screening method allowing to separate donors in two sub-populations, one at high risk and the other at low risk, thus preventing the utilization of blood from high risk donors and reducing the risk of HIV transmission during the window period.

M.A.P.41 A FOLLOW-UP STUDY OF CHILDREN OF ANTI-HIV POSITIVE HAEMOPHILIACS

Goldman, Eleanor; Lee, Christine A.; Morris-Seith, J.; Griffiths, P.D.; Thompson, and Kermoff, P.S.A. Royal Free Hospital, London, England.

Objective. To monitor the progress of 10 children born to 9 anti-HIV seropositive fathers between December 1984 and May 1988.

Methods. Infants were seen soon after birth and then at yearly intervals. Their physical development was assessed with particular attention to growth. Ability and intelligence in relation to expected levels at any given age was presented using WISC-R, WPSI and other relevant tests. Laboratory tests for anti-HIV, p24 antigen and CD4 lymphocyte count were performed at each visit. The duration of seropositivity and stage of HIV disease of the father at the time of conception was assessed retrospectively from clinical records and results of laboratory tests carried out on stored serum. The anti-HIV status of the wives was checked from 1985 onwards.

Results. Ten children were conceived by 9 seropositive, p24 antigen negative, asymptomatic haemophilic fathers. All 10 children have been anti-HIV negative since birth and behave normally. Eight wives have remained anti-HIV negative, one of them after two full term pregnancies. One wife chose termination of a second pregnancy when found to be anti-HIV positive.

Conclusion. None of the babies appear to have any evidence of overt or latent HIV disease. In spite of being made aware of the risks, some anti-HIV positive haemophilic fathers and their wives have chosen to have children.

M.A.P.38 BLOOD SALE AND DONATION BEHAVIOR OF IVDRS

Chitwood, Dale, D.A.; Cosnerford, M.; McCoy, C.B.; et al. Trinidad, L.I., T.

*University of Miami School of Medicine, Miami FL., USA.

Objective. To describe the blood selling and blood donation behavior of intravenous drug users (IVDRs) between 1978-1988.

Methods. IVDRs (703) in drug treatment in South Florida who were enrolled in a longitudinal study of HIV serostatus were asked items pertaining to the sale and donation of blood.

Results. Of the 703 IVDRs, 181 (25.7%), had sold or donated blood since 1978; of these 181, 63.02 had sold and 37.02 had donated blood. There were no significant demographic (age, gender, ethnic) differences between those who donated and those who sold blood. Of the 181 IVDRs, 92 reported their last sale or donation to have occurred after 1985, the year HIV screening in blood banks was instituted. Of these 92, 63 had sold blood. The seroprevalence rate among those selling or donating since 1978 was 11.62%; 7.4% of those selling or donating after 1985 were HIV+. There was no difference in seroprevalence between those who sold and those who donated blood.

Discussion. IVDRs continue to sell or donate blood in spite of attempts to persuade them not to do so. A larger percentage sell blood than donate. While it is not known if any of this blood eventually gets into the blood bank supply for human use, the donation or selling of blood by IVDRs, a high risk group for HIV infection, poses a public health threat.

M.A.P.40 PREVALENCE OF HIV-ANTIBODIES IN BLOOD DONORS IN THE FRG

Drooghe, Dijk, K. Roemer, B. Kuzanek, G. Casper, G. Elbert, W. Graubart et al.

Dept. Transfusion Medicine, University of Ulm and German Red Cross Blood Bank, Heimbühelstrasse 10, D-7800 Ulm, FRG, for the German Red Cross Blood Bank in the FRG

Objective. In a multicenter study of the German Red Cross Blood Banks prevalence and epidemiology of HIV-antibodies in blood donors are studied.

Methods. From July 1985 to September 1988, 7.6 million donations given by about 1.5 million blood donors were tested for HIV-antibodies routinely and 200 were found to be positive in at least one Western blot (WB).

Following a rather rapid decrease in 1985/86 the overall seroprevalence remains thereafter constant with rates of less than 2 per 100,000 until the end of 1988. The geographic distribution varies with the highest prevalence in urban centers and correlates well with the geographic incidence of AIDS cases.

More than 90% of the seropositive donors were homo-bisexual men, drug abusers and heterosexual partners to known AIDS-risk persons. Age and sex distribution were comparable to the patterns in recognized AIDS patients in the FRG.

Conclusion. Our data show that in blood donors, representing one low risk segment of the general population, there is no evidence of a rapid spread of HIV infections. However, they do not imply the absence of new infections but that infection rates on a very low level. At present, we have no indication that unaware heterosexual transmission occurs frequently in blood donors. However, there is a shift to donors infected heterosexually by contact to known risk persons. This suggests a more efficient exclusion of persons with a recognized risk.

(Supported by BMFT, FKZ 1-053-88)

M.A.P.42

HENOPHILIACS DOUBLY INFECTED BY HIV-I AND HIV-II

Maasafu, Akao; Fujisaki, I.; Kojima, K.; Bada, M.; Ikematsu, S.; and Fujisaki, M.

Tokyo Medical College, Clinical Pathology, Shinjuku, Tokyo, Japan.

Objective. On the investigation of immune abnormalities and clinical courses of HIV-I infected haemophilic, we found patients infected by both HIV-I and HIV-II have a more rapid fall in their immune functions than those infected singly by HIV-I.

Subjects and Methods. 185 haemophilic are involved in this study. Anti-HIV-I antibodies are assayed by WB and RIVACOR, and anti-HIV-II antibodies are assayed by RIVACOR, PA, IIF and WB method. Immunological parameters such as lymphocyte subsets, 2 microglobulin, immunoglobulin levels and HIV-related markers are measured. **Results.** 107 of 185 haemophilic are seropositive in HIV-I (57.8%). 11 of 185 are seropositive in HIV-II. Seven haemophilic are seropositive both in HIV-I and HIV-II. Two of 7 have been at the stage IV-C(DICD) in 1986, and one other case has been at the stage IV-A in 1987. Another case has been clinically severe decomposed liver cirrhosis and the stage IV-A. Clinical features are widely varied, such like toxoplasmosis, PCP, CMV pneumonia, IDV, HIV pneumonia, perovirus infection, and so on.

Conclusion. We have already reported the presence of HIV-I infection were not different in the existence of preceed infection of HIV-II in Japanese haemophilic populations. But, at 7 double infection cases have shown advanced symptoms in this study. These data strongly suggest HIV-I seroconverted infection by HIV-II might affect in vivo on the progress of immune dysfunction by HIV-I infection. Further cumulative investigations are urgent.

Session d'affichage Poster Session



Epidémiologie et santé publique Epidemiology and Public Health

M.A.P.43 ANTI-HIV SEROPREVALENCE IN BLOOD DONATIONS FROM JULY 85 UNTIL DECEMBER 85 IN SWITZERLAND

Burkhardt, Johann, L., Müller-Brunner, E., Penth, L.H. and Bachmann, P.
Kantonsspital, Geneva, Switzerland; University of Medicine, University Hospital, Geneva, Switzerland

From July 1985 until December 1986, the Central Laboratory Blood Transfusion Service Swiss Red Cross collected over 1 million units of blood from non-remunerated donors. We tested these units for anti-HIV antibodies with enzyme-linked immuno assay based on viral lysates or recombinant proteins. During this time, 1197 units were confirmed positive. We observed, however, a dramatic decrease of seropositive units and of the resulting seroprevalence between the 2nd half of 85 and the 2nd half of 86 (39 and 1% or 38.3 and 0.7% per hundred thousand, respectively). Furthermore, we noted a decrease in each of the following categories:

Seroprevalence (P/100)	2nd half of 85	1st half of 86	2nd half of 86
males (offshore)	5.5	0	0
females (offshore)	18.5	2.5	0
males (offshore)	20.2	1.5	0
repeat donors	18.5	3.8	0
first-time donors	71.8	0	0

74 % of the positive units were donated by 29 years old or younger donors, who provide about 65% of the blood. We found indeterminate results in 1 unit from females and three with increasing age. During 1986, we tested 73 units with a repeatedly negative screening test by using the polymerase chain reaction (PCR) with DNA extracted from about 1 µg peripheral blood mononuclear cells. PCR-negative units were near serologically confirmed positive. Based on the present seroprevalence figures and the fact that on average 14 units per donor per year are collected, we calculate the probability for a false negative unit to be less than 1/8500.000.

M.A.P.44 DIFFERENT EXPERIENCES OF HIV INFECTION IN SWITZERLAND (A) FROM THREE LIAISON CENTERS: GENEVA, BASEL AND ZÜRICH

Italy, France and G. Sereny are comparable in population (ca. 5 million) and number of H (ca. 3,500). Italy and Germany are also comparable for type of factor concentrates given to H and S (concentrator, FTS 50 plasma-derived plasma). In France, H is ca. 50% seropositive and 50% seronegative (P). But S is most relatively disease free. The table shows that at the end of 1987 there were more AIDS and anti-HIV-1 cases among Sereny than in Italy or G. Also there were more French H anti-HIV-1 cases than in Italy, though AIDS cases were similar. For G, cases with AIDS and anti-HIV-1 were comparable in Italy, Germany and France.

	All haemophiles		Haemophilia A		Haemophilia B				
	Total	% anti-HIV-1	Total	% anti-HIV-1	Total	% anti-HIV-1			
Germany	2478	140	1372	2332	131	1024	326	17	148
France	2458	56	1208	1007	46	903	38	18	135
Italy	2772	57	437	3459	38	312	310	32	138

and the reason for differences between France/Germany 2nd Italy is unclear. In the early 80s, when most HIV infections occurred, Sereny A was treated generally with larger Sereny B (P) units than Italy (ca. 500 L/inf vs 25,000). Hence, Sereny A had a higher cumulative likelihood of being exposed to HIV from 1978 to 1985, when viral-infected plasma was used for infection. This explanation, however, would not account for the higher prevalence of anti-HIV-1 in France, because P/II units were similar to that in Italy (25,000 L vs 25,000). Hence, there appear to be population differences in susceptibility to develop HIV infection in haemophiles.

Le VIH chez les prostitué(e)s et les sans-abri HIV in Prostitutes and Homeless Populations

M.A.P.46 HIV SPREAD IN PROSTITUTE POPULATION IN TOULOUSE (FRANCE)

Copin-Merganteau, C., Dubi-Jacques, J., Besson, S., et al.
Laboratoire de Virologie, CHU Purpan, Toulouse, France.

**Service de Dermatologie, CH La Grave, Toulouse, FRANCE.

Objective. To assess the risk of contamination through prostitution (male or female) in our city.

Methods. We systematically screened anti-HIV-1 antibodies in 97 female prostitutes living in the General Disease Centre along May 1985, to January 1986. Screenings were realized using 2 immunoenzymatic techniques (Abbott and Wellcome). All positive were confirmed by the Western-blot assay (Du Pont de Nemours). Results: 5 of the 97 prostitutes were seropositive. We screened the first one in 1985, two others in 1986, one in 1987, and one who seroconverted in 1988. But 2 of them were intravenous drug abusers, so it was not possible to incriminate sexual transmission with certainty. None of the 92 women was seropositive. Among the seropositive and transfused, one patient seroconverted in 1985, and 3 patients were seropositive (2 in 1986 and 1 in 1987). For these patients drug addiction is unknown.

Conclusion. The prostitute population of Toulouse seems to be relatively free of HIV-1 contamination. But these results do not entirely reflect the true situation as a marginal prostitution also exists with people who are generally not subject to any control. Although these results are relatively reassuring, elementary precautions must be taken to prevent the spread of the disease, since contamination through prostitution has been shown to be a real risk.

M.A.P.45 HEPATITIS B AND HIV COINFECTION IN HEMOPHILIACS.

Radzinski, Paul, White, C., Milliken, C. Lewis, S.M.
Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC USA

Objective. Like HIV, HBV also infects lymphocytes, alters the immune response, and has reverse transcriptase. The clinical significance of HBV and HIV coinfection was investigated.

Methods. Serial HIV and HBV tests were determined in a cohort of 155 severe Factor VIII deficient haemophiliacs between 1982-1988. Lymphocyte subset analysis and clinical status were evaluated at regular intervals. Results: By 1982 the majority of severe VIII deficient patients demonstrated serological evidence of HBV (92%) and HIV (49%) exposure. Seven HIV infected patients reverted from anti-HIV to HBsAg positive suggesting persistence, reactivation, or reinfection of HBV in this population. A trend toward lower immune status deterioration was noted in patients with persistent HBsAg carriage.

	HIV (n = 10)	HIV anti-HB+ (n = 98)	
mean CD4+	396.5	278.0	*p<0.05 (Kruskal Wallis
mean CD4+	465.5	259.0	Chi Square)
% developing AIDS	0/10	22/98	*p<0.09 (Chi Square)

Conclusion. HIV infection may allow HBV reactivation or reinfection which might worsen HIV viraemia of haemophiliacs with even anti-HIV seropositive HIV infected patients. Active HBV infection perhaps by infecting lymphocytes may alter HIV induced immune deterioration.

M.A.P.47 CLONES OF PROSTITUTES - A REVIEW. Provenza, M., Pignatelli, G., Murelli, B., HIV Counseling Clinic, National Virus Laboratory City Hospital, SIRMING, Scotland.

Objective. To study the response of clients of prostitutes to health risks including HIV and sexually transmitted diseases (STD).

Methods. The City Hospital HIV Counseling Clinic offers self referred individuals confidential pre-test counseling. The number of clients of prostitutes using condoms, who regular sexual partners, history of STD, HIV antibody status and socio-economic status were noted.

RESULTS	of 1627 patients who have attended between October 1985 and October 1988, 73 were clients of prostitutes. Their socio-economic status was as follows:- 17 professional/managerial, 27 skilled, 16 semi-skilled, 2 unskilled, and 11 Unknown. 21% of clients tested HIV sero-. They were also injection drug users (IDU), still sharing needles, never using condoms and each had regular partners.				
Condom Use	N	Regular Partner	History of STD	Client	HIV Test
Always	11	0	0	also IDU	0
Sometimes	12	10	0	0	9
Never	50	14	0	0	11
					2

CONCLUSIONS: 1) Suffer sex not being practiced.
2) The clients with regular partners tend not to use condoms.
3) Prostitutes are at risk from clients.
4) Given the relatively high socio-economic status of the group it is surprising that education has not altered behaviour.

M.A.P.48 HIV SEROPREVALENCE AND RISK BEHAVIORS OF ITALIAN PROSTITUTES

Tirelli, G., De Marco, R., Caporali, P., et al. Giardini, M.M.
Sergio, Alberto*** and Ressa G.
From the CICAT AIDS Activity Unit, General Infirmaries Ombelino Infirmary; ** Istituto Dermologico S. Galliciano, Rome; *** Istituto Nat. Inf. Osp. "Sacco", Milano; ** Clinica Medica Univ. Proffitt; ** Ministry of Health, Rome, ITALY.

Objective. To estimate HIV seroprevalence among prostitutes in different Italian areas. To study risk behaviors associated to HIV seropositivity in female prostitutes.

Methods. The study has been conducted in Rome, Milan, Naples and Foggiana. Different sources have been utilized in order to contact female prostitutes: STD clinics, AIDS facilities, organized prostitutes agencies. In particular, a collaboration with the Committee for Civil Rights of Prostitutes was set up. Serological, clinical, demographic and sociological data were collected. An individual questionnaire was administered in order to collect information about risk behaviors and sexual practices.

Results. Three hundred and five female prostitutes were studied. Anti-HIV antibodies were found in 3 out of 192 non-drug-injecting prostitutes (1.5%) one of those developed AIDS, representing the only clinical case reported in a non-addicted prostitutes in Italy. Among drug-injecting prostitutes, 4 out of 113 were anti-HIV seropositive (34.5%).
Conclusion. HIV seroprevalence is very low in non-drug-injecting prostitutes. The high prevalence of seropositivity among drug injecting prostitutes suggest attention for the spread of HIV infection in the heterosexual active population.

Session d'affichage Poster Session



Epidémiologie et santé publique Epidemiology and Public Health

Le VIH chez les clients des cliniques de MTS et des centres de dépistage HIV Among Clients of STD Clinics and Testing Centres

M.A.P.54

HIV SEROPREVALENCE IN HETEROSEXUAL MEN AND WOMEN. DENVER METRO STD CLINIC, 1980-1986. John, Franklin; Oles, R.; Douglas, J. Denver Public Health, Denver, Colorado, USA

Objective: To monitor the course of the HIV epidemic through serologic surveys in an urban STD clinic.
Methods: Each year, 1985-86, over 2000 consecutive, unselected STD clinic patients in defined risk behavior (RD) groups were tested for HIV serology (ELISA, WB confirmed). HIV positive patients without a stated risk for HIV infection were retested to assess correct RD categorization.

RD Group	No. HIV Positive/No. Tested (%)				Total
	1985	1986	1987	1988	
Gay Men	20/104 (4.7)	60/125 (6.4)	72/192 (3.7)	67/160 (4.3)	257/521 (44.3)
Female Prostitutes	1/12 (8.3)	0/13 (0.0)	2/13 (15.4)	1/39 (3.0)	4/32 (1.1)
MSM					
Male	2/29 (6.9)	1/42 (2.0)	0/16 (3.2)	0/49 (0.0)	7/221 (2.6)
Female	0/10 (0.0)	0/20 (0.0)	4/26 (15.4)	2/38 (7.7)	2/170 (1.2)
Heterosexuals					
0/229 (0.0)	1/361 (0.3)	1/340 (0.3)	3/470 (0.4)	5/368 (0.3)	
Female	0/111 (0.0)	0/222 (0.0)	1/225 (0.3)	0/281 (0.0)	0/960 (0.2)

Of 2.5% non RDV heterosexual men and women at high risk of STD only 7 (0.3%) were HIV positive including 3 with RDV sexual contact. Three of 4 positive female prostitutes were RDV.

Conclusions: By 1988, at least 10 years after the first HIV infection in Denver, there is no evidence that the HIV epidemic is affecting beyond gay men, MSM, and their sexual contacts. Accurate epidemiology requires correct RD categorization using confidential interviews.

M.A.P.55

COMPARISON OF RACE/ETHNICITY AND TRANSMISSION CATEGORY IN HETEROSEXUAL HIV SEROPREVALENCE SURVEYS. G.S.; Kirby, C. Centers for Disease Control, Atlanta, Georgia, U.S.A.

Objective: An evaluation of voluntary HIV counseling and testing services by 1988 and transmission category in the United States.
Methods: Sixteen States were surveyed. A total of 142,000,000 (43% of the total U.S. population), provided demographic and risk factor information on all persons attending public sector, voluntary HIV counseling and testing services. There were a total of 83,851 persons tested, 52 were female and 178 were male. Compared to 124 risk categories, 117 were positive. The population of these States (77% White, 13% black, 10% Hispanic, 1% other) was similar to the total U.S. population. A higher proportion of respondents (11%) who selected "other races" as their race were seropositive. The highest risk transmission category was heterosexual (34%).

Conclusions: The demand for counseling and testing services in the U.S. is increasing rapidly. A higher proportion of persons receiving CT services are from minority populations than their representation in the U.S. population. The highest risk transmission category was heterosexual. The highest risk group was men and 11% of HIV drug users were selecting testing services.

M.A.P.56

HIV SEROPREVALENCE IN PATIENTS WITH PID SPENDING. Rhoda, S., Friedman, F., Dept. of OBGYN, Mount Sinai Medical Center, NY, NY, USA.

Objective: 1. To determine the seroprevalence of HIV in women with PID and 2. To determine whether HIV seroprevalence in PID patients is related to non-IV cocaine use and/or serologic evidence of past/present syphilis.
Methods: The STD Clinic Service provides care to indigent outpatient women from areas of NYC hit hard by AIDS. From 11/7/88-1/15/89, all clinic PID admissions had serum samples, which were drawn for syphilis serology, serologically screened for HIV antibody. All PID patients were routinely offered HIV testing in addition to routine GC, chlamydia, and syphilis screens. Sexual and drug use history were obtained on all patients.

Results: 21 patients were admitted; 16 had specimens suitable for anonymous testing; 3/18 (16.6%) were seropositive; 12/21 (57%) patients requested confidential screening; 3/12 (25%) were seropositive.
Of the known seropositives:
11 reported illicit drug use (1/3 IVDA; 2/3 non-IV cocaine)
2/3 reported sexual contact of men at risk (1/10M; 1 non-IV cocaine)
0/3 had positive syphilis serology
1/2 (14.2%) of PID admissions had past serologic evidence of syphilis.
2/3 (67%) were consistent with coinfection.

Conclusions: In the small sample of PID patients screened, 16.6% seropositive rate. 1. HIV antibody found in non-IV cocaine users without other known risk behavior. 2. No association between HIV seropositivity and positive syphilis serology was demonstrated.

M.A.P.57

RISK FACTORS FOR HIV-1 INFECTION IN A BRITISH POPULATION. Brock, E.; Dore, C.; Gomez, G.; Galloway, G.; Hens, C.; Ross, V.; Wai, T.; Barry, P., et al.

Objective: Determine risk factors for HIV-1 infection and monitor testing trends in attendees at a London sexually transmitted diseases clinic.
Methods: Behavioral characteristics of individuals attending for HIV-1 testing were collected. HIV tests performed by screening with a competitive ELISA (Mellcor) and antibody capture ELISA (Abbott) as confirmatory test. Results: Between September 1985 and June 1988, 6923 individuals were tested, 558 (8%) were seropositive. Of these 523 (94%) were men and 35 (6%) women. The seropositive pattern conforms to that currently observed in other industrialized nations. However, risk factors for HIV-1 seropositivity in the non-IVDA were heterosexual intercourse with an HIV infected partner (RR 14; 95% CI 7-25.8), intravenous drug use (RR 60; 95% CI 18-200) and heterosexual contact with a Central African resident (RR 27; 95% CI 10-74). Risk factors for men (n=555) were heterosexual contact with HIV infected partner (RR 15; 95% CI 6.5-207), being homosexual or bisexual (RR 9; 95% CI 3.6-15.5), intravenous drug use (RR 42; 95% CI 21-83) and heterosexual contact with a resident from Central Africa (RR 12; 95% CI 6-40). Testing trends showed a sustained increase in number of individuals tested, this coincided with media of increased media attention on HIV infections/AIDS, involving both Government and popular news/TV campaigns. The most pronounced increase was observed in heterosexual males and females with no other risk factors.
Conclusions: 1) Heterosexual and homosexual transmission were implicated in this British population. 2) The media campaigns have increased awareness of HIV infection/AIDS as a major public health problem.

M.A.P.58

HETEROSEXUAL TRANSMISSION OF HIV IS RARE AMONGST ATTENDERS AT AN STD CLINIC IN LONDON. Burt, D.; Mulholland, C.; Tolin, N.; Christie, I.; Palmer, D.; J. Palmer, D.; Benavise, J. E. Dept. Of Medicine and Virology, St. Thomas' Hospital, London, UK

Objective: To assess HIV seropositivity amongst attendees in an STD clinic.
Methods: All patients having routine chlamydia tests for gonorrhoea between June 1988 and April 1989 were offered an HIV test. All seropositive, irrespective of the result of which could be anonymous.
Results: By the end of December 1989, 4,972 patients had been entered into the study. Of these, 453 patients (9.1%) declined the HIV test. Those declining included 14 higher risk patients. 4,519 patients had sera obtained similar to those agreeing to the test. 4518 attendees were tested, 814 (18%) of whom wished their result to be anonymous.
15 of 4518 (0.3%) were HIV antibody positive, 27 of 247 heterosexual or bisexual men (10.91) and 8 (3 women, 5 men) of 426 heterosexuals (0.38) were positive. 11 heterosexual women were negative, 2 of 27 homosexual positives and 6 of 8 heterosexual positives were Afro-Caribbean. 211 partners from Africa (164 from West Africa) were negative for HIV2.

	HETEROSEXUAL POSITIVES		Total tested
	IWA Contact	No risk factors	
Male	3	1	2236
Female	2	1	2025

Conclusion: This sexually active population with a higher than average prevalence of gonorrhoea, chlamydia and other STD's has low HIV seropositivity in spite of the potential for importing cases from endemic areas.

M.A.P.59

HIV PREVALENCE IN AN AIDS COUNSELLING CENTRE IN ISRAEL. Handzel, I.; Bar, J.; Burstein, B.; Herz, M.; Levinstein, B.; Nave, N.; and Ben-Zvi, J., N.

Explo Hospital, Hebrew University School, Rehovot, Israel.

Objective: To determine HIV prevalence among risk groups in an AIDS center in Israel.
Methods: All applicants to the AIDS clinic started at our center in 1983, were interviewed and tested for HIV antibody. In 1984, 1985, 1986, 1987, I.V. drug addicts (IVDA), recipients of blood transfusions (BT) as well as non-risk group applicants (N) were tested.

Results: The number of individuals tested and results were as follows:

Groups	1985	1986	1987	1988
IVDA	2	7	11	22
BT	1	2	4	9
N	56	106	514	415
Total	406	299	769	661
% HIV - in risk group	10	10	8.7	6.4

Thus, the proportion of non-risk group applicants clearly increased while that of MSB and percentage of HIV seropositivity diminished.
Conclusions: a) The low prevalence of HIV infection among risk groups in Israel may be correlated with the still low incidence and growth of AIDS in Israel. b) The AIDS counselling center is being frequented by the wide public, while risk group members do not use it sufficiently.

**Session d'affichage
Poster Session**

M.A.P.60 TRENDS IN HIV SEROPREVALENCE AMONG SELF-IDENTIFIED RISK GROUPS UTILIZING ANONYMOUS TEST SITES IN SAN FRANCISCO

Greenhalgh, John E.*; Wilson, N.P.*; Nguyen, D.H.*; Long, G.P.*
*San Francisco Department of Public Health and **California Department of Health Services, San Francisco, California, U.S.A.

Objective: Describe trends in HIV seroprevalence within specific risk groups using Anonymous Test Sites (ATS) in San Francisco.

Methods: During the 36-month period July, 1985 to June, 1988, demographic and risk information was collected by self-administered questionnaires from 41,800 clients visiting the ATS for the first time for HIV antibody testing.

Results: HIV SEROPREVALENCE BY QUARTER (7/85 - 6/88)

	1985			1986			1987			1988		
	%	N	%	%	N	%	%	N	%	N	%	
Metropolitan	2%	24	3%	3%	3%	3%	3%	3%	3%	3%	3%	
Gay/Bisex/Men	34	36	36	37	35	33	37	44	42	35	35	
IV Drug Users	9	5	9	9	5	8	3	7	12	6	6	
Gay/BT (VDUs)	57	72	60	74	54	71	68	85	82	74	85	
ST clients	27	28	30	23	22	18	17	21	20	22	20	

Complete risk group data were available for 63% of those tested for HIV antibody. Overall seroprevalence declined from 27% in July, 1985 to 12% by June, 1988 (p<0.001). Due to increasing rates of heterosexuals served (37% of all clients initially) vs. 63% during the final quarter) and decreasing usage by gay/bisexual men initially, declining to 24%.

Conclusions: Despite marked shifts in utilization patterns at the ATS, HIV seroprevalence within major risk groups has remained relatively constant.

M.A.P.62 EFFECTIVENESS OF VOLUNTARY HIV ANTIBODY TESTING PROVIDED AT A CLINIC TREATING SEXUALLY TRANSMITTED DISEASES

Stenberg, Michele A.*
*San Diego County Department of Health Services, San Diego, CA, U.S.A.

Objective: To characterize Sexually Transmitted Disease (STD) clinic attendees who elect to receive HIV antibody testing and fail to return for results.

Methods: Patients presenting at STD clinic were offered the opportunity to have HIV antibody testing to obtain the result of a second visit. Patients who participate complete a questionnaire regarding sexual orientation, if drug use, etc. ELISA positive specimens were tested by Immunofluorescent Antibody.

Results: Between June and August 1986, 1065 patients attending clinic for evaluation of STD were tested for HIV antibody. Forty-six percent returned for test results. Rate of return was as follows: positive/0.5%, negative/41.7%, total males/30.3%; total females/36.5%. Rate of return by treatment category:

gonorrheal males/25%, gonorrheal females/38.8%, heterosexual males/38.7%, heterosexual males IV drug users/37.5%, heterosexual females/36.9%, female IV drug users/36.8%. Return rates by ethnic group: white/55%, black/26.3%, Hispanic/41.8%.

Conclusions: While for HIV antibody test results among patients tested while awaiting STD services are poor, gonorrheal and gonorrheal males, groups with highest awareness of their risk of HIV infection, were most motivated to return for results. Immunofluorescent, if drug users, females and non-blacks had high failure rates. Increased educational efforts and improved strategies to motivate these groups must be developed.

M.A.P.64 HIV SEROPREVALENCE SURVEYS IN THE SAN FRANCISCO BAY AREA

Wilson, N.P.*; Greenhalgh, J.P.*; Long, G.P.*
*San Francisco Department of Public Health and **California Department of Health Services, Sacramento, California and** California Department of Public Health, San Francisco, California, U.S.A.

Objective: To estimate HIV seroprevalence in sexually transmitted disease (STD), women's health, tuberculosis and drug treatment clinics were begun in the San Francisco Bay Area in 1984.

Methods: Seroprevalence surveys in sexually transmitted disease (STD), women's health, tuberculosis and drug treatment clinics were begun in the San Francisco Bay Area in 1984. In 1984, 1985 and 1986, we will collect an additional 35,000 in 1989. With active participation from all health jurisdictions and the Centers for Disease Control, standardized research protocols were developed for conducting non-blinded and blinded HIV serosurveys. Available data on blinded HIV antibody testing from 5 health jurisdictions adjacent to SF were analyzed by demographic characteristics and risk group. Comparable data are not yet available from SF clinics.

Results: SF (1986) of 2770 specimens were retested by ELISA reactive and confirmed positive by Western blot analysis. Among STD clients, males had a significantly higher rate of positivity (2.7%) than did women (0.7%).

Among non-blinded (1984) men were significantly more likely to be positive (22%) than those with undetermined risk (3%) or all other risk groups (0.7%) for HIV antibody. Among women, risk factors were obtained.

Seroprevalence among STD clients did not significantly differ across age groups or across counties.

Conclusion: The 1.3% seroprevalence in selected clinics demonstrates the scope and geographic distribution of the HIV epidemic for counties adjacent to a major AIDS epicenter.

M.A.P.61 TRENDS IN HIV SEROPREVALENCE IN AN URBAN SEXUALLY TRANSMITTED DISEASE CLINIC, 1984-1989

Goodfield, E. S.; Bunker, S.; Sobberg, S.; Hopkins, S.; Swanson, D.; Hayes, M. Seattle-King County Department of Public Health and University of Washington, Seattle, Washington, U.S.A.

Objective: To determine trends in the prevalence of HIV infection in an urban sexually transmitted disease (STD) clinic over 2.5 years.

Methods: In a public STD clinic, HIV antibody was assayed in initial-visit patients who had syphilis blood tests in Oct-Nov 1986 (N=367), Aug-Sep 1987 (N=352), Feb-Mar 1988 (N=382), and Sep-Nov 1988 (N=610); 1989 results are pending. Serum and demographic/risk data were de-linked from identifiers

prior to HIV ELISA; positivities (TPVs) were confirmed by Western blot. Trends were analyzed by chi square for linear trend, non-homogeneous and seasonal, non-homogeneous (NHN) and HIV-1 seroconversion drug users.

Results: HIV+ rates for the 4 periods were: 10% (14/24) (58%), 7/18 (39%), 17/30 (57%), and 41/201 (21%) (p<0.1); NET 1986/1987, 0/215 (0%), and 5/779 (0.6%) (p<0.001); all NET 0/241, 1/330 (0.3%), 1/352 (0.3%), and 17/1502 (0.8%) (p<0.001); among NET in Sep-Nov 1988, HIV+ included 8/67 (0.8%) males and 4/528 (0.8%) females; 2/358 (0.24) whites and 9/466 (1.9%) blacks (p<0.001); and rose steadily with age through age 35-39 (p<0.002).

Conclusions: In 1989, HIV seroprevalence was apparently stable in STD clinic HIV. By contrast, the HIV rate rose in NET, primarily in blacks and IVUD, and with increasing age. STD clinic patients, especially ethnic minority NET, IVUD, and their sex partners, are among the highest priority target groups for HIV counseling and testing and other behavioral interventions.

M.A.P.63 EPIDEMIOLOGICAL OBSERVATIONS OF A TERRITORIAL HIV SCREENING CENTRE IN MILAN

Schiavarelli, Ilario; Battelli, M.; Nelli, N.C.; Nelli, M.; Dra, M.; Nili, G., A.S.

Vigorelli Cal' Grande Hospital, Milan, Italy. * Public Health Office of Milan, Milan, Italy

Objective: To study epidemiological patterns of HIV diffusion in one population in an Italian urban territory.

Methods: During the period October-December 1988, a territorial tuberculosis Department for AIDS research had been operating in a town district (Milan II, population 80,000) dealing with information, spontaneously requested diagnostic examinations and follow-up of people at risk. 1,200 subjects asked for serological study and were examined (1,020 males, 180 females); 501 declared themselves intravenous drug addicts (106), 180 men or women, 1,020 being non-heterosexual intercourse partners, 72 family contacts, 57 blood recipients. It passed to professional risk, the determination of anti-HIV Ig was performed by ELISA and WB methods.

Results: Evidence of infection was determined in 270 (26.4% of the group), 160 heterosexual (16.8%), 102 non-heterosexual (20.2%), 102 men or women intravenous drug users (20.2%), 72 family contacts, 57 blood recipients. It passed to professional risk, the determination of anti-HIV Ig was performed by ELISA and WB methods.

Conclusions: In the population considered, the group of IVUDs suffers the highest percentage of seropositivity, at comparable levels as in Italian cities, whereas the percentage of non-heterosexual is lower than the national average. 5.8% among partners of early seropositive subjects resulted infected, indicating the important standard of risk of HIV diffusion via heterosexual intercourse.

M.A.P.65 RETROSEROLOGICAL DETERMINATION OF HIV: PREVALENCE AND RISK FACTORS

Quilley, Robert; Stone, C.*; Merlet, A.*; Gold, J.*
* Albion Street (AIDS) Centre, Sydney Hospital, Sydney, Australia.

Objective: To determine the prevalence and risk factors associated with HIV infection in heterosexuals requesting HIV antibody testing.

Methods: Between March and December 1988, risk factors of heterosexuals who tested positive for HIV antibody testing were assessed. Results: Positive results were obtained in 42 heterosexuals (1984 men and 1938 women) who were tested for HIV antibody. Fifty one (0.9%) were found to be HIV antibody positive. These included 27 men (14.2%) and 24 women (1.2%) who were intravenous drug users (IVDU's), with more male IVDU's infected (23) than women (8). Seven clients (15 men and 2 women) were found to be infected by contaminated blood, and one woman by a contaminated artificial insemination. Sexual contact was the only identified risk factor in 25.5% (12). Seven of these were men who postulated prostitute contact as a risk factor, while all of the remaining 6 HIV antibody positive heterosexuals (3 men and 3 women) had sexual partners who were not HIV infected.

Conclusions: Intravenous drug use was the major HIV risk factor among heterosexuals. However, sexual intercourse was also a major HIV risk factor in a sizable proportion of clients. These results indicate that although IVDU's remain a high priority group to be targeted in education and behaviour change programs, sexual behaviour change in the broader population is also necessary if HIV transmission is to be arrested.

Session d'affichage Poster Session



Epidémiologie et santé publique Epidemiology and Public Health

M.A.P.66

CHARACTERIZATION OF HIV INFECTED STD CLINIC PATIENTS IN ANTWERP, BELGIUM

Eric Smits, Léon Van der Bruggen R., Sylvie E. Vercauteren G. and Pieter P. Institute of Tropical Medicine, Antwerp, Belgium.

Objective: To define the prevalence of HIV unassociated infections among STD patients unaware of their HIV serostatus.

Methods: In 1988 all new patients consulting an STI-clinic in Antwerp, Belgium, and unaware of possible seropositivity, were screened for the presence of HIV-antibodies. During the same year 20 persons with test results were not followed at the clinic. Confirmed HIV positive patients were screened as well as those who wanted to know their serostatus, whereas anonymous testing results were not identifiable for patient and physician) was performed for the others. Only patients residing in Belgium were included in the study. HIV was examined by enzyme-linked immunosorbent assay (ELISA) using anti-HIV-1-microcylinder system. Serogel technical and positive sera were confirmed with Western Blot (Dupont de Nemours).

Results: Prevalence of HIV-infected patients: 1 and 95% confidence interval: (0,1).

RELATIONS	number/total	% (95% CI)
male heterosexuals	1/278	0,36 (0,01-1,42)
male homosexuals	1/44	2,27 (0,10-12,02)
female heterosexuals	2/255	0,78 (0,10-2,06)
female prostitutes	0/44	0 (0,00-5,90)
seam	0/45	0 (0,00-7,87)

Of a total of 252 patients tested, 222 (88%) were tested confidentially and 30 (12%) anonymously. From 750 patients tested, 562 (75%) and all were tested confidentially.

Conclusions: These data suggest a low prevalence of HIV-infection in heterosexual Belgian patients consulting for STI-related problems, despite a high proportion (100%) of men WHO heterosexuals among Belgian STD patients.

M.A.P.68

CHARACTERIZATION OF HIV INFECTED STD CLINIC PATIENTS IDENTIFIED THROUGH ROUTINE VOLUNTARY SCREENING IMPLICATIONS FOR FUTURE HEALTH CARE NEEDS

Richard Etkon, Stephen Glanville, James McNeil, J.N., Joseph Kompane, A.M.,* Braithwaite, W.* and Hood E.L.W.** * Baltimore City Health Dept., ** Johns Hopkins Univ., Baltimore, USA.

Objective: To describe demographic and historical characteristics of HIV infected patients identified by a routine voluntary screening program in Baltimore STD clinics. **Methods:** Consenting patients are screened for HIV-1 using commercially available EIA, confirmed using a licensed Western Blot test, and are given appointments to return for test results. During January-October 1988, there were 18,907 patient visits to the STD clinics; 12,795 (68%) were tested for HIV. Of patients tested, 531 (4%) were HIV-infected and to date, 321 (60%) have returned for results and further evaluation.

Results: HIV infected patients were predominantly (approximately 2/3) young, black, single males. High risk behavior was common among infected patients: 33% reported homosexual exposure, 37% reported prior IV drug use, and 39% reported exposure to a sex partner at risk for HIV. No traditional risk factors for HIV infection were acknowledged by 18% of infected patients. STDs were also common in infected patients: 47% reported prior syphilis and 17% had been treated for syphilis in the preceding year. The majority of patients were asymptomatic (18%) or had generalized lymphadenopathy (18%) at the time of diagnosis. Many of these patients have few health care resources available; 93% were unmarried and 69% had either no health insurance (6%) or were covered solely by public assistance health plans (24%). **Conclusion:** Routine, voluntary HIV screening is a well accepted, useful means to identify HIV infected individuals in high risk settings such as STD clinics. Identification of these individuals may provide useful information for projecting future health care needs.

M.A.P.70

ANALYSIS OF TRENDS OVER TIME IN CLIENT CHARACTERISTICS AT MINNESOTA (MN) HIV-1 ANTIBODY COUNSELING AND TESTING SITES

Banilla, Richard*, Shultz J.*; Osterholm M.*; Henry Kew* Simpson M**; MacDonald E** *900 Dept. of Health, ** Hennepin County Community Health Dept., Minneapolis; ***St. Paul Division of Public Health, St. Paul; MN, USA.

Objective: To evaluate the role of Minnesota HIV-1 antibody counseling and testing site programs (CTS) in HIV-1 transmission prevention efforts.

Methods: CTS client demographic and risk factor data were analyzed for 18,483 CTS clients with HIV-1 serology from 7/85-6/88.

Results: The highest seroprevalence rates were in male homosexual/bisexual intravenous drug users (27 of 145; 18%) and homosexual/bisexual men (705 of 5,310; 13%). A significant decrease in seroprevalence for all clients was noted from 14.3% for the first six months of operation to 3.2% for the last six months (p<0.001). This corresponds to changes in client characteristics over time: 1) the number and proportion of female first-time clients who were at low risk for HIV-1 infection increased (p<0.001); 2) the number and proportion of homosexual/bisexual males decreased and correspondingly the number and proportion of low-risk heterosexual males increased (p<0.001); 3) for homosexual/bisexual males, a significant decline in HIV-1 antibody prevalence over time was noted (p<0.05).

Conclusions: These data indicate that CTS programs in Minnesota have progressively served fewer clients at high risk for HIV-1 infection over time. Outreach programs that identify and serve persons at highest risk for HIV-1 infection may be more effective, use of limited public health resources.

M.A.P.67

HIV-1 INFECTION IN NEW YORK CITY STD CLINIC PATIENTS:

EVIDENCE FOR STABLE SEROPREVALENCE, 1987-1988

Greenberg, B.; Iwim, J.; et al. New York City Department of Health, NY, NY, U.S.A.

Objective: To determine HIV-1 seroprevalence in patients at New York City STD clinics, and to compare rates over time in one clinic.

Methods: Blinded serosurveys were conducted among STD clinic patients in one clinic in 1987 and in all 12 STD clinics in 1988. The interval between the 2 surveys was 18 months. Specimens were obtained from routine syphilis testing and were analyzed for HIV-1 by ELISA with confirmatory Western Blot. Data on age, race/ethnicity, diagnosis and RPR result were collected.

Results: In 1988, 195/2533 (7.7%) of clinic attendees were HIV-1 positive. The highest rate (12.1%) was found among clinic attendees age 30-39. Among those diagnosed with a genital ulcer (GU) at the time of visit, 23/73 (31.3%) were HIV-1 positive as opposed to 223/1782 (6.9%) with other diagnoses (p<0.05). For the clinic surveyed in both years, 26/348 (7.5%) were positive in 1987 and 34/694 (4.9%) positive in 1988. This difference was not statistically significant. In both 1987 and 1988 patients with GU were significantly more likely to be HIV-1 seropositive than were patients with other diagnoses. (OR=2.3, p=0.02 and OR=0.9, p=0.04 respectively).

Conclusions: HIV-1 is a common infection in New York City STD clinic patients and those with a GU are more likely to be infected. Seroprevalence remained constant in one STD clinic over an 18 month interval. The data support expanding the availability of HIV-1 counseling and testing in all STD clinics.

M.A.P.69

FREQUENCY OF HIV INFECTION AMONG PATIENTS OF STD OUT-PATIENT CLINIC

Stepinski A., Mazurkiewicz W., Wójciszewski U., Nagórniak T., Biedrzycki L., Medical Academy, Lodz, Poland

Objective: The incidence of HIV antibodies has been investigated in 1327 patients with various STD, 1022 males and 305 females,

seen in the STD out-patient clinic. Sixty six males/6.5% were homosexual or bisexual. **Methods:** The HIV antibodies were tested by the EIA method, and positive tests were confirmed by the Western-blot technique. **Results:** The HIV antibodies were found in 45 male patients and 2 females, i.e. 1.5% of all individuals studied. Thirteen of 47 were homosexual or bisexual, which represents 19.2% of patients with such a sexual behaviour one of them was also IV drug addict, two of 3 heterosexuals cases with positive HIV test were IV drug users. Seven of 13 of HIV-positive homosexual/bisexual/23.0% had syphilis recently or in anamnesis, whereas among all homosexual/bisexuals studied there were 42.4% of cases with history of syphilis. The frequency of HIV infection in homosexual STD out-patients is markedly higher than in heterosexual STD out-patients, 0.4% as well as in another group of homosexuals without STD 2/2.6%.

Conclusion: Patients of the STD out-patient clinic represent high risk group of HIV infection, predominantly homosexual with diagnosis of syphilis. These patients should be tested for the presence of HIV antibodies.

M.A.P.71

BLIND HIV-AB AND SYPHILIS-AB SEROPREVALENCE SURVEYING IN NEW YORK STATE STD CLINICS

D'Errandino, George Jr.; Arthur, K.; Hipp S.; Murphy D. New York State (NYS) Department of Health, Albany, NY, USA.

Objective: To monitor over time the HIV and syphilis seroprevalence among STD clients in all regions of NYS, excluding NYC.

Methods: Sera of clients receiving syphilis testing (RPR, FTA) at 19 STD clinics in 8 NYS counties during 1988 were tested anonymously for HIV (ELISA, WB). Clients were excluded if they had been tested within the previous 90 day period.

Results: All sites had a substantial percentage of clients with HIV-AB (1.14 to 3.17%) and syphilis-AB (1.66 to 16.08%) positive. Of 1001 clients, 179 (19.9%) had HIV-AB, 247 (24.7%) had syphilis-AB. Among counties, however, the association between HIV-AB and syphilis-AB varied greatly (odds ratios ranged from 0.56 to 15.3). **Conclusion:** The HIV epidemic has spread throughout NYS in the STD clinic population. Although HIV-AB status is strongly associated with sero-evidence of current or previous syphilis infection, this association varies widely between clinic location, and those without evidence of syphilis-AB still have a substantial rate of HIV-AB positivity.

Session d'affichage Poster Session



Epidémiologie et santé publique Epidemiology and Public Health

M.A.P.72 HIV-1 INFECTION IN PERSONS ATTENDING SEXUALLY TRANSMITTED DISEASE (STD) CLINICS IN MINNESOTA (MN)
Methods: 1094 patients attending two STD clinics from 4/1/88-11/1/88 were systematically selected; participants were interviewed for HIV-1 infection risks and had blood drawn for HIV-1, syphilis, and hepatitis B serology.
Results: Questionnaire and serologic data were completed for 932/1094 (85%) participants. HIV-1 infection was associated with male-to-male sex (p<0.001), and among homosexual/bisexual males, receptive anal intercourse (p<0.05). HIV-1 sero-prevalence rates were: white 1.3% (7/529); black 1.1% (4/352); Hispanic 6.3% (1/16); other 0.0% (0/35).

Objective: To determine HIV-1 seroprevalence and risk factors associated with infection in persons attending STD clinics in Minnesota.

Methods: 1094 patients attending two STD clinics from 4/1/88-11/1/88 were systematically selected; participants were interviewed for HIV-1 infection risks and had blood drawn for HIV-1, syphilis, and hepatitis B serology.

Results: Questionnaire and serologic data were completed for 932/1094 (85%) participants. HIV-1 infection was associated with male-to-male sex (p<0.001), and among homosexual/bisexual males, receptive anal intercourse (p<0.05). HIV-1 sero-prevalence rates were: white 1.3% (7/529); black 1.1% (4/352); Hispanic 6.3% (1/16); other 0.0% (0/35).

HIV-1 Seroprevalence by Risk Factors

Risk Category	Male		Female	
	HIV-1 Pos./Total (%)	95% CI	HIV-1 Pos./Total (%)	95% CI
Homosexual/bisexual	9/70 (12.9)			
IV drug user (IVDU)	1/52 (1.9)		0/17 (0.0)	
Homo./Bi./IVDU	1/7 (14.3)			
Heterosexual	0/561 (0.0)		1/225 (0.4)	

Conclusions: In Minnesota, HIV-1 infection in STD patients is primarily limited to those with a history of male-to-male sex or IV drug use. Thus, in low prevalence areas, HIV-1 antibody testing should be targeted to STD patients known to be at highest risk.

M.A.P.74 HIV SEROPREVALENCE IN SEXUALLY TRANSMITTED DISEASE CLINICS IN LOS ANGELES COUNTY

ERIC WATKINS, L., ROSE, T., KERND, P., OROSCO, L., WATERMAN, S.

Los Angeles County Department of Health Services, Los Angeles, California, **Centers for Disease Control, Atlanta, Georgia, USA

Objective: To estimate the seroprevalence of human immunodeficiency virus (HIV) among patients attending sexually transmitted disease (STD) clinics in Los Angeles County (LAC).

Methods: Between July and December 1988, consecutive attendees at 4 public STD clinics were screened for HIV Ab. Repeat ELISA positives were confirmed by the immunofluorescent antibody and Western Blot. HIV Ab results were linked without personal identifiers to self-reported demographic and risk factor information.

Results: Of the 2,578 STD patients tested, 2.9% (76) were confirmed HIV Ab positive; the rates were 3.8% (66/1,796) in men, and 1.9% (6/312) in women. The infection rate among Hispanics was 4.5% (52/1,078); whites 2.5% (5,000); and blacks 2.4% (39/1,608). Hispanics comprised 27.3% of the STD patients tested, but accounted for 42.1% of the seropositives. In contrast, whites and blacks made up 7.8% and 62.6% of the study population, and 6.6% and 51.9% of the seropositives, respectively. Among the 133 persons reporting psychosocial behavior, 30.8% (41) were seropositive; 38.5% (24) Hispanic; 34.1% (14) black; and 7.9% (3) white. Seropositivity among heterosexuals was 1.4% (44/3,276); 1.6% (27/1,637) for men, and 0.9% (7/739) for women. The highest rate of infection for heterosexuals was among black men 1.9% (19/1,025), and the lowest rate among Hispanic women 0.6% (0/773). Approximately 3.0% of those reported recent IV drug use, and 8.0% of those (6/75) were seropositive.

Conclusion: HIV infection among patients at STD clinics in LAC is substantial and warrants routine testing and counseling. The large proportion of minorities attending public STD clinics affords an opportunity to provide AIDS education and risk reduction counseling to high risk members of minority populations.

M.A.P.76 INCIDENCE OF HIV INFECTION IN GAY AND BISEXUAL MEN ATTENDING A COUNSELING AND TESTING SITE OR AN AIDS PREVENTION PROGRAM. COHN, DAVID; KOLETS, J.; COOPER, S.; COLE, V.; JUDSON, P. Denver Disease Control Service, Denver, CO.

Objective: To determine incidence of HIV infection in gay and bisexual men (GM) using a counseling and testing site (CTS) or enrolled in an AIDS Prevention longitudinal cohort study (APS).

Methods: GM who attended Denver's voluntary CTS from July, 1985 through December, 1988, and GM enrolled in APS from January, 1987 thru December 1988 (visits every 6 months), were evaluated for incidence of HIV infection, as indicated by seroconversions (SC). Included in the analysis were GM who were seronegative at initial visits and retested at least once. SC was defined as reactive ELISA and Western blot antibody tests on a 2nd or later visit.

	CTS	CTS	APS
	1985-1986	1987-1988	1987-1988
No. seroconversions	42	3	4
No. persons observed	596	183	348
No. person-years observed	633.2	151.7	296.5
Mean years/person observed	1.0	0.83	0.85
Rate SC/100 person-years	6.43	1.98	1.35

Conclusion: In Denver, the incidence of HIV infection in GM has decreased significantly between 1985-1986 and 1987-1988. Lower incidence rates were observed both in GM attending a CTS and in GM enrolled in an AIDS prevention program, who likely were self selected for higher motivation for behavioral change.

M.A.P.73 HIV SEROPREVALENCE OF STD CLINICS IN HOUSTON, TEXAS, U.S.A.

ENOCHA, M., FALLETTI, ROBERT L., SULLIVAN, KJ, SANCHEZ, DJ, PENALOSA, D., AND HONEYCUTT H.

Bureau of Epidemiology, Houston Dept. of Health & Human Services, Houston, Texas, U.S.A.

Objective: To present statistical data supporting the growing threat of HIV infection with specific sexual activity positive populations attending an STD clinic.

Methods: A blinded survey was conducted at a large STD clinic servicing a predominantly black area of Houston. All blood samples taken for standard RPR screening were also tested for HIV using the ELISA and Western blot tests. Points included in the survey were taken consecutively until predetermined gender quotas were obtained. No ethnic or age bias was imposed on the selection procedure.

Results: A total of 1,140 samples were collected with 6% HIV positive. Seropositivity is highest in the age groups between 25-34 (22%). Overall, whites are 10% positive with 76 samples tested, blacks are 6% positive with 360 samples tested, Hispanics are 7% positive with 36 samples tested and other ethnic populations are 25% positive with 8 samples tested. Data on heterosexual males (n=543) and females (n=592) indicate whites are 1% positive, blacks are 2% positive and Hispanics are 4% positive. Data for homosexual males (n=72) show whites and blacks to be over 50% positive.

Conclusions: The results of the survey allow us to draw certain conclusions: 1) large sampling from the black population permits us to place greater confidence in the high seropositivity found in that group; 2) homosexual males show a high seropositivity in all age groups and ethnic classifications; 3) samples collected are representative of the clinic population and 4) persons seeking treatment at Houston STD clinics are showing an overall prevalence of 6% HIV positive.

M.A.P.75 DEVELOPMENT AND FUNDING OF PUBLIC HIV COUNSELING AND TESTING SERVICES IN THE UNITED STATES

PHILLIP KAGAN; BOVEN, G. R. RIBBY, G. A.

Atlanta, Ga., U.S.A.

Objective: To describe the history and development of public sector funded HIV counseling and testing (CT) services in the U.S. since 1985.

Methods: We reviewed quarterly reports from State HIV/AIDS prevention programs and the CDC funding awards of State AIDS prevention cooperative agreements in order to document the levels for CT, number and location of CT sites and the number and seropositivity rates of clients served. Data were also collected on the number of counseling and testing services became one of the strategies to prevent HIV infection in 1985. Client numbers for such services has increased from 1985 to 1988 and there were 874 alternate testing sites that tested 79,083 persons nationwide. There were 26,400 sites that tested 1,196,000 persons in 1985 and 4,000 tested in 1987. Reports show 213,000 persons were tested (annual rate of 84.6 million) during July-September of 1988. Funding for risk reduction counseling and testing services increased from \$9.1 million in 1985 to \$17.5 million in 1988. The rate of seropositivity has decreased from a high of 17.3% in 1985 and 15.0% in 1986, to 5.8% in 1987 and 4.9% in 1988.

Conclusion: Although the original purpose of HIV antibody testing was to prevent the blood supply, risk reduction counseling combined with testing has become one of the important intervention strategies available to change sexual and needle sharing behaviors. The increase in funding for these programs in the U.S. has enabled an expansion of CT services to community based testing facilities in sexually transmitted diseases, women's health and drug treatment facilities in 1988 and 1989.

Autres rétrovirus : le VIH-2

Other Retroviruses: HIV-2

M.A.P.77 HIV2 INFECTION. SOME CLINICAL AND EPIDEMIOLOGICAL ASPECTS IN PORTUGAL

Botas-Julliano, L., Licínio, F., Feliciano, M., Antunes, F., et al. Dep. Inf. Diseases, Hosp. Sta Maria, Lisboa, Portugal.

Objective: To assess the frequency of HIV2 infection in HIV seropositives studied at our Department.

Methods: The charts of 225 HIV seropositives (ELISA and Western Blot) were analysed. Tests for HIV2 were performed in HIV1 negative individuals. Sexual partners of HIV2 positives or possibility of infection in Africa.

Results: Nineteen (8.4%) 8 women, 11 men, 11 men HIV negative and HIV2 positive. They all denied homosexual contacts or IVDU. Only 2 had received blood transfusions (1 man in 1974, in Portugal and his wife was also positive; another man in 1968, aged 3, in Africa, who has lived in Portugal ever since. In 1974, his 5 women, 4 men were from Guinea-Bissau. One man had visited several African countries and his wife was also positive. Four men had been in Africa for military service (2 in Guinea, 1964-69 and 7-73; 2 in Angola, 65-66 and 66-68). One woman, prostitute, could not deny sexual contacts with African men. Eight were asymptomatic carriers, 3 ARC and 8 AIDS. Five of them died.

Conclusion: HIV2 infection may be more common outside Africa than generally accepted, should be thought in HIV1 negatives suspected of AIDS and excluded in blood donors, at least in those who have ever been in Africa.

Session d'affichage Poster Session



Epidémiologie et santé publique Epidemiology and Public Health

M.A.P.78 HIV-2 IN ITALY: NO EVIDENCE, YET.

Cedeno P.P., Carola L., Piccinicola G.S., Albertini A.S., Carosi G.

Dept. of Infection Tropical Disease, Dept. Chemistry, University of Brescia, Brescia, Italy.

Objective. The authors have carried out a wide-scale seroepidemiological survey in the region of Lombardy (Italy) to verify the presence of HIV-2 infection among risk categories.

Methods. 1069 subjects (946 drug addicts, 80 homosexuals, 25 homosexuals and sexual partners) have been screened for HIV-1 and HIV-2 infections (HIV-1 and HIV-2 ELISA and W.B. by Diagnostic Pasteur).

Results. Among the 1069 HIV-1 seropositive subjects, 233 sera reacted positively to HIV-2 ELISA test. Confirmation by HIV-2 W.B. has been obtained in 29 cases. When submitted to the specific synthetic peptide assay, the 29 HIV-1/HIV-2 W.B. positive sera strongly reacted to the HIV-1 peptide, while only 2 showed a weak HIV-2 reactivity. The same pattern of serological reactivity has been obtained on the same 29 subjects 10 months later.

Conclusions. Our results don't confirm the existence of HIV-2 among risk categories in Italy. This conclusion is also supported by the absence of isolated HIV-2 pattern of seropositivity. The high false positivity rate in ELISA (31, 28) and, to a lesser extent, in W.B. (3, 28) demonstrates the presence of antigenic cross-reactivity among envelope proteins of the two viruses. Specific synthetic assay proved to be sensitive and specific. The constant presence of weak HIV-2 reactivity in 2 HIV-1+ samples at 10 months interval rules out the possibility of early HIV-2 seroconversion.

M.A.P.79 HUMAN IMMUNODEFICIENCY VIRUS TYPE 2 (HIV-2) SCREENING OF A HIGH RISK POPULATION IN ADDIS ABABA, ETHIOPIA.

Zewdie, D.P., Woolly, J.,** (Amara, A.), Constantine, N.,**

Chabwiler, S.P., Moselem, A.,**

* National Research Institute of Health, Addis Ababa, Ethiopia.

** WHO Reference Center for AIDS, Cairo, Egypt.

*** AIDS Prevention and Control Programme, Ministry of Health, Addis Ababa, Ethiopia.

Objective. The major objective was to evaluate a high risk population from Addis Ababa, Ethiopia, for evidence of HIV-2 infection.

Methods. Sera previously collected from 130 prostitutes residing in Addis Ababa were included in the evaluation. Sixty of these had been previously confirmed as HIV-1 reactive sera. A commercial ELISA (Genetic system) designed to detect antibodies to HIV-2 and HIV-2 Western Blot (Dupont) were used.

Results. Of the 330 sera analyzed, 60 were known to be confirmed HIV-1 positive. Thirty-four of these 60 were also reactive to HIV-2 screening ELISA. Assessment of these 34 HIV-2 reactive sera by Western Blot revealed that 10 reacted in a manner that fulfilled the criteria for HIV-2 positivity all of these were strongly reactive for HIV-1 by Western Blot.

Conclusion. Almost all HIV reactivity in this population are characteristic of exposure to HIV-1. However, 10 sera reacted with both assays and could represent either dual infection or cross reactions.

M.A.P.80 DETECTION OF ANTIBODIES AGAINST HIV-2 PROTEINS IN HIV-1 SEROPOSITIVE SUBJECTS FROM FRANCE AND GREECE.

FORTOLINI P., KAMBAKI A., BERTOLI A.M., ZAPPALÀ A., PALLIANGORIS P.P., JORDAN C.P., GOSDOLINI V.J.

1. AIDS Reference Center of Crete, Venetian Hospital, Greece, 2. INRHEC/IDU, Hospital Paul Broca, 93000 Vitry, France.

Objective. To determine the prevalence of HIV-2 infection in HIV-1 seropositive subjects from France and Greece.

Methods. HIV-2 infection was always confirmed by Western blot analysis. Antibodies against HIV-2 proteins were detected by Western blot and determined between HIV-1 and HIV-2 infection was based on the serum reactivity with synthetic peptide homologous to the 263-307 region of p41 (gp120 HIV-1) and the corresponding region of gp85 (gp120 HIV-2).

Results. Western blot analysis of the sera revealed a frequent reaction with isolated HIV-2 proteins. However, frequently they reacted with isolated HIV-2 proteins only (75.6% and 100% of 44 and 10 sera of French and Greek origin, respectively). Stripped antibodies against HIV-2 with both the gp85 and the gp120 of HIV-2, respectively, 42.7% and 42.7% revealed reactivity with both the gp85 and the gp120 of HIV-2 whereas none of the 9 Greek sera were reactive with the gp120. However, HIV-2 infection was confirmed in an asymptomatic Greek blood donor in the absence of HIV-1 infection.

Conclusions. These findings seem to indicate that although double HIV-1/HIV-2 can be observed in a small number of HIV-1 seropositive subjects and HIV-2 is present in Greece, there is still a different transmission rate of this virus in different European countries.

M.A.P.81 HIV-2 IN DRUG ABUSERS OF SPAIN

Hernandez Hernandez, J. Ter, A. Baeza, J. Claver, J. Garcia, J. Hernandez

Departamento de Microbiología, Bacteriología, Parasitología y Laboratorio Clínico, Facultad de Medicina de San Sebastián, Instituto de Estudios Vascos (I.E.V.), Hospital de San Sebastián, San Sebastián, Guipúzcoa, España.

Objetivo. Estudiar la prevalencia de infección por el virus de inmunodeficiencia humana tipo 2 (HIV-2) en un grupo de drogadictos.

Métodos. Se realizó un estudio serológico en 100 individuos que usaban drogas. Se usó un método de ELISA para detectar anticuerpos contra el virus de inmunodeficiencia humana tipo 2 (HIV-2) y un método de Western Blot para confirmar los resultados positivos.

Resultados. Se detectó la presencia de anticuerpos contra el virus de inmunodeficiencia humana tipo 2 (HIV-2) en 10 individuos (10%).

Conclusiones. Se detectó la presencia de anticuerpos contra el virus de inmunodeficiencia humana tipo 2 (HIV-2) en un grupo de drogadictos.

Palabras clave: HIV-2, drogas, infección.

Abstract. HIV-2 infection was detected in 10% of 100 drug abusers.

Methods. A serological study was carried out in 100 individuals who used drugs. An ELISA method was used to detect antibodies against HIV-2 and Western Blot method to confirm positive results.

Results. The presence of antibodies against HIV-2 was detected in 10 individuals (10%).

Conclusions. The presence of antibodies against HIV-2 was detected in a group of drug abusers.

Key words: HIV-2, drugs, infection.

Summary. HIV-2 infection was detected in 10% of 100 drug abusers.

Methods. A serological study was carried out in 100 individuals who used drugs. An ELISA method was used to detect antibodies against HIV-2 and Western Blot method to confirm positive results.

Results. The presence of antibodies against HIV-2 was detected in 10 individuals (10%).

Conclusions. The presence of antibodies against HIV-2 was detected in a group of drug abusers.

Key words: HIV-2, drugs, infection.

Abstract. HIV-2 infection was detected in 10% of 100 drug abusers.

Methods. A serological study was carried out in 100 individuals who used drugs. An ELISA method was used to detect antibodies against HIV-2 and Western Blot method to confirm positive results.

Results. The presence of antibodies against HIV-2 was detected in 10 individuals (10%).

Conclusions. The presence of antibodies against HIV-2 was detected in a group of drug abusers.

Key words: HIV-2, drugs, infection.

Summary. HIV-2 infection was detected in 10% of 100 drug abusers.

Methods. A serological study was carried out in 100 individuals who used drugs. An ELISA method was used to detect antibodies against HIV-2 and Western Blot method to confirm positive results.

Results. The presence of antibodies against HIV-2 was detected in 10 individuals (10%).

Conclusions. The presence of antibodies against HIV-2 was detected in a group of drug abusers.

Key words: HIV-2, drugs, infection.

Abstract. HIV-2 infection was detected in 10% of 100 drug abusers.

Methods. A serological study was carried out in 100 individuals who used drugs. An ELISA method was used to detect antibodies against HIV-2 and Western Blot method to confirm positive results.

Results. The presence of antibodies against HIV-2 was detected in 10 individuals (10%).

Conclusions. The presence of antibodies against HIV-2 was detected in a group of drug abusers.

Key words: HIV-2, drugs, infection.

Summary. HIV-2 infection was detected in 10% of 100 drug abusers.

Methods. A serological study was carried out in 100 individuals who used drugs. An ELISA method was used to detect antibodies against HIV-2 and Western Blot method to confirm positive results.

Results. The presence of antibodies against HIV-2 was detected in 10 individuals (10%).

Conclusions. The presence of antibodies against HIV-2 was detected in a group of drug abusers.

Key words: HIV-2, drugs, infection.

Abstract. HIV-2 infection was detected in 10% of 100 drug abusers.

Methods. A serological study was carried out in 100 individuals who used drugs. An ELISA method was used to detect antibodies against HIV-2 and Western Blot method to confirm positive results.

Results. The presence of antibodies against HIV-2 was detected in 10 individuals (10%).

Conclusions. The presence of antibodies against HIV-2 was detected in a group of drug abusers.

Key words: HIV-2, drugs, infection.

Summary. HIV-2 infection was detected in 10% of 100 drug abusers.

Methods. A serological study was carried out in 100 individuals who used drugs. An ELISA method was used to detect antibodies against HIV-2 and Western Blot method to confirm positive results.

Results. The presence of antibodies against HIV-2 was detected in 10 individuals (10%).

Conclusions. The presence of antibodies against HIV-2 was detected in a group of drug abusers.

Key words: HIV-2, drugs, infection.

Abstract. HIV-2 infection was detected in 10% of 100 drug abusers.

Methods. A serological study was carried out in 100 individuals who used drugs. An ELISA method was used to detect antibodies against HIV-2 and Western Blot method to confirm positive results.

Results. The presence of antibodies against HIV-2 was detected in 10 individuals (10%).

Conclusions. The presence of antibodies against HIV-2 was detected in a group of drug abusers.

Key words: HIV-2, drugs, infection.

Summary. HIV-2 infection was detected in 10% of 100 drug abusers.

Methods. A serological study was carried out in 100 individuals who used drugs. An ELISA method was used to detect antibodies against HIV-2 and Western Blot method to confirm positive results.

Results. The presence of antibodies against HIV-2 was detected in 10 individuals (10%).

Conclusions. The presence of antibodies against HIV-2 was detected in a group of drug abusers.

Key words: HIV-2, drugs, infection.

Abstract. HIV-2 infection was detected in 10% of 100 drug abusers.

Methods. A serological study was carried out in 100 individuals who used drugs. An ELISA method was used to detect antibodies against HIV-2 and Western Blot method to confirm positive results.

Results. The presence of antibodies against HIV-2 was detected in 10 individuals (10%).

Conclusions. The presence of antibodies against HIV-2 was detected in a group of drug abusers.

Key words: HIV-2, drugs, infection.

M.A.P.82 EPIDEMIOLOGY OF AIDS IN PORTUGAL.

Alves, Laura; Piate, A.; Bessito-Garcia, A.; Paredes, C.; Jarillas, F. Instituto Nacional de Saude, Lisboa, Portugal.

Objective. As far as AIDS is concerned, Portugal is a country with no parallels in Europe due to the prevalence of HIV-2 infection of 199 cases notified by HIV-1/2 ELISA.

Methods. A total of 2046 sera were from male homosexuals, 1700 prostitutes, heterosexuals, pregnant women and families of AIDS were tested for HIV-1 and HIV-2 antibodies by ELISA, confirmed by Western Blot.

Results. are as above:

Conclusions. HIV-2 infection is endemic in Portugal, although with less expression than HIV-1. Due to past and present contacts with Africa and the presence of Portugal of immigrant African countries, an epidemiological surveillance of the population is in progress to learn the natural history behaviour in terms of sex or drug use, other viral infection, etc.

Abstract. HIV-2 infection is endemic in Portugal, although with less expression than HIV-1. Due to past and present contacts with Africa and the presence of Portugal of immigrant African countries, an epidemiological surveillance of the population is in progress to learn the natural history behaviour in terms of sex or drug use, other viral infection, etc.

Methods. A total of 2046 sera were from male homosexuals, 1700 prostitutes, heterosexuals, pregnant women and families of AIDS were tested for HIV-1 and HIV-2 antibodies by ELISA, confirmed by Western Blot.

Results. are as above:

Conclusions. HIV-2 infection is endemic in Portugal, although with less expression than HIV-1. Due to past and present contacts with Africa and the presence of Portugal of immigrant African countries, an epidemiological surveillance of the population is in progress to learn the natural history behaviour in terms of sex or drug use, other viral infection, etc.

Abstract. HIV-2 infection is endemic in Portugal, although with less expression than HIV-1. Due to past and present contacts with Africa and the presence of Portugal of immigrant African countries, an epidemiological surveillance of the population is in progress to learn the natural history behaviour in terms of sex or drug use, other viral infection, etc.

Methods. A total of 2046 sera were from male homosexuals, 1700 prostitutes, heterosexuals, pregnant women and families of AIDS were tested for HIV-1 and HIV-2 antibodies by ELISA, confirmed by Western Blot.

Results. are as above:

Conclusions. HIV-2 infection is endemic in Portugal, although with less expression than HIV-1. Due to past and present contacts with Africa and the presence of Portugal of immigrant African countries, an epidemiological surveillance of the population is in progress to learn the natural history behaviour in terms of sex or drug use, other viral infection, etc.

Abstract. HIV-2 infection is endemic in Portugal, although with less expression than HIV-1. Due to past and present contacts with Africa and the presence of Portugal of immigrant African countries, an epidemiological surveillance of the population is in progress to learn the natural history behaviour in terms of sex or drug use, other viral infection, etc.

Methods. A total of 2046 sera were from male homosexuals, 1700 prostitutes, heterosexuals, pregnant women and families of AIDS were tested for HIV-1 and HIV-2 antibodies by ELISA, confirmed by Western Blot.

Results. are as above:

Conclusions. HIV-2 infection is endemic in Portugal, although with less expression than HIV-1. Due to past and present contacts with Africa and the presence of Portugal of immigrant African countries, an epidemiological surveillance of the population is in progress to learn the natural history behaviour in terms of sex or drug use, other viral infection, etc.

Abstract. HIV-2 infection is endemic in Portugal, although with less expression than HIV-1. Due to past and present contacts with Africa and the presence of Portugal of immigrant African countries, an epidemiological surveillance of the population is in progress to learn the natural history behaviour in terms of sex or drug use, other viral infection, etc.

Methods. A total of 2046 sera were from male homosexuals, 1700 prostitutes, heterosexuals, pregnant women and families of AIDS were tested for HIV-1 and HIV-2 antibodies by ELISA, confirmed by Western Blot.

Results. are as above:

Conclusions. HIV-2 infection is endemic in Portugal, although with less expression than HIV-1. Due to past and present contacts with Africa and the presence of Portugal of immigrant African countries, an epidemiological surveillance of the population is in progress to learn the natural history behaviour in terms of sex or drug use, other viral infection, etc.

Abstract. HIV-2 infection is endemic in Portugal, although with less expression than HIV-1. Due to past and present contacts with Africa and the presence of Portugal of immigrant African countries, an epidemiological surveillance of the population is in progress to learn the natural history behaviour in terms of sex or drug use, other viral infection, etc.

Methods. A total of 2046 sera were from male homosexuals, 1700 prostitutes, heterosexuals, pregnant women and families of AIDS were tested for HIV-1 and HIV-2 antibodies by ELISA, confirmed by Western Blot.

Results. are as above:

Conclusions. HIV-2 infection is endemic in Portugal, although with less expression than HIV-1. Due to past and present contacts with Africa and the presence of Portugal of immigrant African countries, an epidemiological surveillance of the population is in progress to learn the natural history behaviour in terms of sex or drug use, other viral infection, etc.

Abstract. HIV-2 infection is endemic in Portugal, although with less expression than HIV-1. Due to past and present contacts with Africa and the presence of Portugal of immigrant African countries, an epidemiological surveillance of the population is in progress to learn the natural history behaviour in terms of sex or drug use, other viral infection, etc.

Methods. A total of 2046 sera were from male homosexuals, 1700 prostitutes, heterosexuals, pregnant women and families of AIDS were tested for HIV-1 and HIV-2 antibodies by ELISA, confirmed by Western Blot.

Results. are as above:

Conclusions. HIV-2 infection is endemic in Portugal, although with less expression than HIV-1. Due to past and present contacts with Africa and the presence of Portugal of immigrant African countries, an epidemiological surveillance of the population is in progress to learn the natural history behaviour in terms of sex or drug use, other viral infection, etc.

Abstract. HIV-2 infection is endemic in Portugal, although with less expression than HIV-1. Due to past and present contacts with Africa and the presence of Portugal of immigrant African countries, an epidemiological surveillance of the population is in progress to learn the natural history behaviour in terms of sex or drug use, other viral infection, etc.

Methods. A total of 2046 sera were from male homosexuals, 1700 prostitutes, heterosexuals, pregnant women and families of AIDS were tested for HIV-1 and HIV-2 antibodies by ELISA, confirmed by Western Blot.

Results. are as above:

Conclusions. HIV-2 infection is endemic in Portugal, although with less expression than HIV-1. Due to past and present contacts with Africa and the presence of Portugal of immigrant African countries, an epidemiological surveillance of the population is in progress to learn the natural history behaviour in terms of sex or drug use, other viral infection, etc.

Abstract. HIV-2 infection is endemic in Portugal, although with less expression than HIV-1. Due to past and present contacts with Africa and the presence of Portugal of immigrant African countries, an epidemiological surveillance of the population is in progress to learn the natural history behaviour in terms of sex or drug use, other viral infection, etc.

Methods. A total of 2046 sera were from male homosexuals, 1700 prostitutes, heterosexuals, pregnant women and families of AIDS were tested for HIV-1 and HIV-2 antibodies by ELISA, confirmed by Western Blot.

Results. are as above:

Conclusions. HIV-2 infection is endemic in Portugal, although with less expression than HIV-1. Due to past and present contacts with Africa and the presence of Portugal of immigrant African countries, an epidemiological surveillance of the population is in progress to learn the natural history behaviour in terms of sex or drug use, other viral infection, etc.

M.A.P.83 AIDS CAUSED BY HIV-2 IN SOUTHERN AFRICA

Lynn Saxon, P.J. McMillen, P.J. Schab, D.R. Smith, A.M. Glimmer, L.W.

*Medical Research Council AIDS Virus Research Unit, National Institute for Virology, Department of Virology, University of the Witwatersrand and

**Chamber of Mines, Johannesburg, South Africa.

Objective. The RAPID CLAVIA HIV-1 ELISA first generation ELISA developed to detect antibodies to both HIV-1 and HIV-2, was introduced into our routine HIV screening laboratory in Jan 1988.

Methods. 1593 routine sera were received. Seres repeatedly reactive on the RAPID CLAVIA HIV-1 assay were further evaluated using individual ELISAs for HIV-1 and HIV-2 (ELAVIA 1 or ELAVIA 2 respectively). Three sera, reactive in the RAPID CLAVIA HIV-1 assay, were unreactive in the ELAVIA 1 but reactive in the ELAVIA 11 ELISA.

Results. Western blotting, using the Dupont HIV-1 IgG Blot, revealed reactivity against core and envelope components of HIV-2.

Conclusions. Two of the HIV-2 positive were from black Malawian males with symptoms suggestive of HIV infection. The patient had presented with weight loss and neurological symptoms while the second was a patient with mild tuberculosis that was unresponsive to standard tuberculosis therapy. Blood drawn from the second patient 16 days before he died showed decreasing reactivity with the core protein p24 and loss of reactivity to the envelope protein gp120. The third specimen was from a black Mozambican male who also presented with tuberculosis that did not respond to therapy. The patient developed Kaposi's and died after 18 months.

Abstract. Two of the HIV-2 positive were from black Malawian males with symptoms suggestive of HIV infection. The patient had presented with weight loss and neurological symptoms while the second was a patient with mild tuberculosis that was unresponsive to standard tuberculosis therapy. Blood drawn from the second patient 16 days before he died showed decreasing reactivity with the core protein p24 and loss of reactivity to the envelope protein gp120. The third specimen was from a black Mozambican male who also presented with tuberculosis that did not respond to therapy. The patient developed Kaposi's and died after 18 months.

Methods. 1593 routine sera were received. Seres repeatedly reactive on the RAPID CLAVIA HIV-1 assay were further evaluated using individual ELISAs for HIV-1 and HIV-2 (ELAVIA 1 or ELAVIA 2 respectively). Three sera, reactive in the RAPID CLAVIA HIV-1 assay, were unreactive in the ELAVIA 1 but reactive in the ELAVIA 11 ELISA.

Results. Western blotting, using the Dupont HIV-1 IgG Blot, revealed reactivity against core and envelope components of HIV-2.

Conclusions. Two of the HIV-2 positive were from black Malawian males with symptoms suggestive of HIV infection. The patient had presented with weight loss and neurological symptoms while the second was a patient with mild tuberculosis that was unresponsive to standard tuberculosis therapy. Blood drawn from the second patient 16 days before he died showed decreasing reactivity with the core protein p24 and loss of reactivity to the envelope protein gp120. The third specimen was from a black Mozambican male who also presented with tuberculosis that did not respond to therapy. The patient developed Kaposi's and died after 18 months.

Abstract. Two of the HIV-2 positive were from black Malawian males with symptoms suggestive of HIV infection. The patient had presented with weight loss and neurological symptoms while the second was a patient with mild tuberculosis that was unresponsive to standard tuberculosis therapy. Blood drawn from the second patient 16 days before he died showed decreasing reactivity with the core protein p24 and loss of reactivity to the envelope protein gp120. The third specimen was from a black Mozambican male who also presented with tuberculosis that did not respond to therapy. The patient developed Kaposi's and died after 18 months.

Methods. 1593 routine sera were received. Seres repeatedly reactive on the RAPID CLAVIA HIV-1 assay were further evaluated using individual ELISAs for HIV-1 and HIV-2 (ELAVIA 1 or ELAVIA 2 respectively). Three sera, reactive in the RAPID CLAVIA HIV-1 assay, were unreactive in the ELAVIA 1 but reactive in the ELAVIA 11 ELISA.

Results. Western blotting, using the Dupont HIV-1 IgG Blot, revealed reactivity against core and envelope components of HIV-2.

Conclusions. Two of the HIV-2 positive were from black Malawian males with symptoms suggestive of HIV infection. The patient had presented with weight loss and neurological symptoms while the second was a patient with mild tuberculosis that was unresponsive to standard tuberculosis therapy. Blood drawn from the second patient 16 days before he died showed decreasing reactivity with the core protein p24 and loss of reactivity to the envelope protein gp120. The third specimen was from a black Mozambican male who also presented with tuberculosis that did not respond to therapy. The patient developed Kaposi's and died after 18 months.

Abstract. Two of the HIV-2 positive were from black Malawian males with symptoms suggestive of HIV infection. The patient had presented with weight loss and neurological symptoms while the second was a patient with mild tuberculosis that was unresponsive to standard tuberculosis therapy. Blood drawn from the second patient 16 days before he died showed decreasing reactivity with the core protein p24 and loss of reactivity to the envelope protein gp120. The third specimen was from a black Mozambican male who also presented with tuberculosis that did not respond to therapy. The patient developed Kaposi's and died after 18 months.

Methods. 1593 routine sera were received. Seres repeatedly reactive on the RAPID CLAVIA HIV-1 assay were further evaluated using individual ELISAs for HIV-1 and HIV-2 (ELAVIA 1 or ELAVIA 2 respectively). Three sera, reactive in the RAPID CLAVIA HIV-1 assay, were unreactive in the ELAVIA 1 but reactive in the ELAVIA 11 ELISA.

Results. Western blotting, using the Dupont HIV-1 IgG Blot, revealed reactivity against core and envelope components of HIV-2.

Conclusions. Two of the HIV-2 positive were from black Malawian males with symptoms suggestive of HIV infection. The patient had presented with weight loss and neurological symptoms while the second was a patient with mild tuberculosis that was unresponsive to standard tuberculosis therapy. Blood drawn from the second patient 16 days before he died showed decreasing reactivity with the core protein p24 and loss of reactivity to the envelope protein gp120. The third specimen was from a black Mozambican male who also presented with tuberculosis that did not respond to therapy. The patient developed Kaposi's and died after 18 months.

Abstract. Two of the HIV-2 positive were from black Malawian males with symptoms suggestive of HIV infection. The patient had presented with weight loss and neurological symptoms while the second was a patient with mild tuberculosis that was unresponsive to standard tuberculosis therapy. Blood drawn from the second patient 16 days before he died showed decreasing reactivity with the core protein p24 and loss of reactivity to the envelope protein gp120. The third specimen was from a black Mozambican male who also presented with tuberculosis that did not respond to therapy. The patient developed Kaposi's and died after 18 months.

Methods. 159

Session d'affichage Poster Session



Épidémiologie et santé publique Epidemiology and Public Health

M.A.P. 84

HIV 2 INFECTION IN FEMALE AND MALE BRAZILIAN PROSTITUTE GROUPS

Santos-Ferreira, M. O., Menez, C. M., Lourenco, R. M., Faccaria, R. M., Vermeil, R. M.
*Fac. Pharmacy, Univ. de Lisbon, Portugal. **Faculty of Medicine, Univ. São Paulo, Brazil

Objective: The identification of the second type of human immunodeficiency virus designated HIV 2 in patients originating from West Africa with the acquired immunodeficiency syndrome opened a new area of seroepidemiological investigations. Therefore we studied the presence of HIV 2 infections in Brazil.
Subjects and methods: The presence of specific HIV 2 antibodies was investigated in 173 sera obtained from individuals belonging to a risk group of 73 male homosexuals of a cohort of prostitutes (professional prostitutes) with activity in São Paulo, Brazil, 100 women prostitutes with activity in Santos, Brazil. Sera were tested for HIV antibody by ELISA. Repetitive positive ELISA results were confirmed by indirect immunofluorescence assay and Western-blot. Sera giving cross reactivity at a peptide level of HIV 1 and HIV 2 large glycoproteins were further tested for reactivity against a peptide corresponding to the dominant epitope of transmembrane protein (HIV 1 gp41) glycoprotein and HIV 2 gp36 glycoprotein.

Results: The number of their partners varied between 1 (minimum) and plus 100 (maximum) partners a week. The average number of partners a week was 27 (standard deviation = 21). All the individuals had been practicing their activity for at least one year before the study. In the cohort of prostitutes we found 22/75 (30.0%) seropositives to HIV 1 and 5/75 (4.1%) seropositives to HIV 2. Seropositivity for HIV 1 and HIV 2 was seen in five men (6.8%). In the group of women prostitutes we found 10/100 (10%) seropositives to HIV 1 and 2/100 (2.0%) seropositives to HIV 2. Seropositivity for HIV 1 and HIV 2 was seen in one woman (1.0%).

Conclusion: These Brazilian cases confirm the presence of HIV 2 in this country.

GRANT CACT 87-679

M.A.P. 85

EFFICACITE DANS LE DÉPISTAGE DES SÉRUMS HIV

CROQUET Anne-Marie et le groupe de travail «Métrovirus de la Société Nationale de Transfusion Sanguine - Paris, France

Objectif: Analyser le gain obtenu dans le dépistage des sérums HIV par des trousses mixtes (HIV-1 + HIV-2) par rapport aux trousses HIV1

Méthodes: 35 sérums HIV-2 (dont 11 dons de sang) prélevés de sujets résidents en France ont été étudiés parallèlement à des trousses Abbott. HIV1 recombinant = A1 et Combo HIV1 + HIV2 = A2) 3 trousses Du Pont de Nemours (Env 9 version 1 = D1 et Env9 version 2 = D2) et 2 trousses Diagnostica Pasteur (Elavia 1 = P1 et Elaiva mixte = P2)

Résultats: 18 sérums ont fourni un résultat positif avec les 6 trousses. Les 7 sérums donnant un résultat négatif avec au moins 1 trousses HIV(A1,D1 ou P1) ont tous été reconnus par les trousses HIV1+HIV2 (A2,P2) ou la trousses version 2 (D2). Les résultats de ces 7 sérums sont fournis ci-dessous (Ech/Seuil).

	A1	A2	D1	D2	P1	P2
26 PV*	0,5	>8	1,5	4,1	0,8	>8
35 MJ	1,4	5,0	0,4	>5	1,3	>8
51 GA	0,6	>8	0,5	>8	1,1	>8
5 GRM*	3,2	>8	0,4	>5	4,0	>8
12 MJ	1,5	>8	0,2	>5	3,0	>8
52 CB	2,5	>8	3,7	>5	0,8	>8
LEG	0,3	4,8	0,2	2,5	0,2	>8

Conclusion: Bien que ces 3 trousses HIV1 détectent de 81 à 86 % de sérums HIV2, l'utilisation en transfusion de trousses de dépistage reconnaissant la totalité des HIV2, à condition qu'elles aient une excellente sensibilité HIV1 et une bonne spécificité, est très satisfaisable.

Progression : marqueurs de laboratoire et cofacteurs

Progression: Laboratory Markers and Cofactors

M.A.P. 87

THE LEVEL OF EPSTEIN-BARR VIRUS EXCRETION IS A

PREDICTOR OF DISEASE PROGRESSION IN HIV INFECTION.

Diaz-Mitoma, Francisco, Ruiz, A., Houson, S., Rosenow, D. B., Perlebas, J., and Tyrrell, D. L. J. University of Alberta, Edmonton, Alberta, Canada

Objective: To analyze the relationship between HIV and EBV infections in a cohort of homosexual men.

Methods: Twenty seven HIV-seropositive and 25 HIV-seronegative homosexual and 52 age-matched heterosexual men were serological men. Patients were classified according to the CDC criteria for HIV infection. Individuals in group IV were excluded. Patients were evaluated at 0, 2, 6, 12 and 18 to 24 months. EBV and human (hDNA) DNAs were measured in oropharyngeal washes by dot hybridization and densitometry scanning. **Results:** Twelve and individuals among the 27 HIV-seropositive had low level (<0.7log of EBV DNA) of hDNA and 3 had undetectable levels of EBV DNA in mouth washings. None of these subjects demonstrated progression of the HIV infection. In comparison, 17 of the 27 HIV-seropositive men had high levels of EBV DNA excretion (>0.7log₁₀ hDNA) and 9 demonstrated progression of disease. At the 18 month follow-up, 16 asymptomatic HIV seropositive (group I), 3 progressed to group III and 1 to group IV. Of the 11 group III individuals, 5 developed AIDS. Patients who progressed to group III or IV disease had significantly higher levels of EBV excretion (2.7 ± 2.0 log₁₀ hDNA) on initial assessment than HIV-seropositive individuals in whom progression of HIV infection was not demonstrated (0.34 ± 3.0 log₁₀ hDNA, p<0.001).

Conclusion: The positive predictive value of high levels of EBV excretion for progression of HIV infection was 75% at 18 months. High EBV excretion was found in 3 of 25 HIV-seronegative and 4 of 52 heterosexual men. This would suggest that high EBV excretion is not solely on the basis of HIV-induced immunosuppression.

M.A.P. 86

PREVALENCE OF HIV-1 AND HIV-2 ANTIBODIES IN INDIVIDUALS ATTENDING A CLINIC FOR S.T.D., A TWO YEAR FOLLOW UP.

Cardoso, J.*, Avilés, F.**, Santo, I.**, Pista A.**, Ayres-Laura **.

*Lisbon Regional Health Administration, Lisbon, Portugal.

**National Institute of Health, Lisbon, Portugal.

There is in Portugal a population with great contact both in the past and at present with individuals from African countries.

With this reason we decided to determine, during a period of about two years the antibodies to HIV-1 and HIV-2 in individuals attending a clinic for STD in Lisbon.

During this period we tested 1253 sera (640 males and 613 females). We found 32 seropositive for HIV 20 males and 12 females).

Eight individuals were seropositive for HIV-2 (2 males and 6 females) and 24 were seropositive for HIV-1 (18 males and 6 females).

In the male seropositive group there are 6 homosexuals, 6 bisexuals and 6 heterosexuals. Among the seropositive females 11 are prostitutes (of a total of about 350 prostitutes followed) and one is an IVDU.

We conclude that HIV-1 and HIV-2 are present in all the groups. The studies are in progress in order to have a better knowledge of the problem and also the role of some of its infected people in the heterosexual transmission of infection especially as sexual behaviour is concerned.

M.A.P. 88

PROGNOSTIC VALUE OF ANEMIA IN ASYMPTOMATIC HIV-POSITIVE MEN

Battagay, Manuel, Ledergerber, B., Brühlwiler, J., Siegenthaler, W. and Lüthy, R., Department of Medicine, University Hospital Zurich, Switzerland

Objective: To study the prognostic value of anemia in 225 asymptomatic HIV-positive men and to assess the correlation to thrombocytopenia.

Methods: We measured hemoglobin (Hb) and platelets (pl) in 225 consecutive asymptomatic homo- or bisexual men with at least two visits and more than one month follow-up. The mean or bisection time of the cohort was HIV 1 advanced stages (ARC and AIDS) was analyzed for patients with anemia (Hb < 14.0 g/dl) and without anemia using product limit estimators and the Cox proportional hazard regression model.

Results: The median observation time of the cohort was 617 days (range 1 - 1240) and did not correlate with pit counts. The following table summarizes the results obtained:

	with anemia	without anemia
Number	207	92%
Median age [years]	44 (26-53)	36 (19-67)
Mean hemoglobin [g/dl]	13.3 (SD 0.5)	15.7 (SD 0.87)
Mean platelets [10 ⁹ /l]	233 (SD 53.7)	245 (SD 66)
Progression to ARC/AIDS	44 (6.8%)	26 (12.6%)

The one year progression rate after developing anemia was 30% (95% CI: 15-57%), for non anemic patients 5.5% (3-10%). The relative risk for progression to advanced stages was 4.8 (p<0.001) for a 20% decrease in hemoglobin and 1.5 (p<0.001) for a 20% decrease in platelets. **Conclusion:** Anemia and thrombocytopenia both have an independent prognostic significance in asymptomatic homo- and bisexual men.

M.A.P. 89

AGE AT TIME OF HIV INFECTION AS COFACTOR OF PROGRESSION TO ADVANCED IMMUNE DYSFUNCTION AND AIDS

Karaoufolidou, A.**, Polychronaki, J.**, Gialavaki, A.**, Economidou, J.**, Trichopoulos, D.**, Athens Univ. Medical School, Athens, Greece. *Lisbon Hosp., Athens, Greece. **Evangelismos Hosp., Athens, Greece. **Objective:** To study whether age at the time of acquisition of HIV infection is associated with progression of HIV infection and to determine the pattern of the age dependency.

Methods: 122 HIV positive men followed up in follow up studies since 1980, seroconverted between 1980-1985. Serconversion was documented by ELISA and WB or RIP. By November 1989, 30 cases have progressed to advanced immune dysfunction (AIDS).

Results and Conclusions: Age was a statistically significant variable for AIDS or AIDS/ARC2 progression in univariate and multivariate analyses (allowing for duration of HIV positivity and controlling for the amount of immune factor (VIL)). However, the age effect, estimated by Cox model, was limited to the age above 30 (RR=5.5, p=0.006, 95% CI 1.6-18.3).

TABLE 1	Age (years)	Incidence	19	20-29	30-39	40-49	≥50
Com. Incid.	AIDS/ARC2	2.4	22.9	19.0	20.0	30.0	
Rate Ratio	AIDS/ARC2	2.5	3.1	2.5	2.3	13.9	
Rate Ratio	AIDS/ARC2	1.0	1.2	1.1	0.9	5.5	

Session d'affichage Poster Session



Épidémiologie et santé publique Epidemiology and Public Health

M.A.P.102 EVOLUTIVE PROCESS TOWARDS AIDS IN THE MAJORITY OF ASYMPTOMATIC HIV-INFECTED SUBJECTS.

Authors: Jean-Louis Lelanc, J.L. Lelanc, P. Domet, C.J. Couroucé, A.M. P. Institut National de Transfusion Sanguine, Paris, France.

Objective: To estimate the progress of asymptomatic HIV infection. **Methods:** 68 asymptomatic (stage II or III CDC) HIV 1 seropositive subjects, with more than 100 CD4 lymphocytes/mm³ at the onset of the study, were followed-up during a 4 year period. Nine biological markers considered as predictors of AIDS (CD4 lymphocyte count < 400/mm³, loss of anti-p24 or anti-p18 antibodies, positive p24 antigenemia, serum IgG17gI, serum IgA17gI, erythrocyte sedimentation rate ≥ 20mm in first hour, serum neopterin ≥ 10 nmol/l, serum s-2-microglobulin ≥ 2.5 mg/l) were annually evaluated. **Results:** Number (and percentage) of subjects having biological predictors of AIDS during the study period:

Predictors	1985	1986	1987	1988
None	23 (28%)	8 (12%)	6 (6%)	2 (3%)
One	21 (31%)	15 (28%)	10 (9%)	11 (16%)
Two	17 (28%)	23 (38%)	18 (26%)	14 (20%)
Three or more	7 (10%)	18 (28%)	36 (59%)	41 (60%)

The increase of the number of significant (Chi-2 test p < 0.01). At the end of the study period, 4 subjects (8.8%) were AIDS and corresponded to the cases having at the same time the greater number of predictors (3 or more).

Conclusion: These results strongly suggest an evolution towards AIDS in the great majority of asymptomatic HIV-infected subjects. This constitutes an important argument in favour of antiviral treatment for all HIV-infected subjects.

M.A.P.104 LACK OF ANTIBODIES AGAINST p17 AS PREDICTIVE VALUE FOR AIDS.

Authors: J. Delgado, Sanchez C, Malloja E, Planas J, Niro JM, Gatalán J, and Castillo R. Blood Transfusion Diseases Unit, Univ. Barcelona, and Infectious Res. Dept. Hospital Clinic Barcelona, Spain.

Objective: To determine the relationship of p17 antibodies and disease progression in HIV infected people.

Methods: 87 HIV-1 seropositive patients were classified according to the CDC and 61 were followed for 23±7 months. The presence of antibodies against p17 was investigated in an optimized Western blot using H-9 viral lysate (Organon Corporation, USA).

Results: The loss of reactivity against p17 correlated with the clinical stage of patients. The negativity for p17 was observed in 41% of patients in CDC-2 stage, 81% in CDC-3 stage and 100% in CDC-4 stage. Progression to AIDS was observed in 37% of patients without p17 Ab and in 10% of patients with p17 Ab (p < 0.01). The progression to AIDS in p17-Ab- patients was observed in 13% of CDC-2 patients and 40% of CDC-3, and 37% patients in CDC-2 progress to CDC-3.

Conclusion: The loss of reactivity against p17 seems to have predictive value since it has been observed in patients without before developing AIDS and before antiretroviral could be detected.

M.A.P.106 SIGNIFICANCE OF INCREASE OF CD8 LYMPHOCYTES IN ASYMPTOMATIC HIV INFECTION.

Authors: J. Delgado, Gatalán J, Lelanc J, Rouger, P. Institut National de Transfusion Sanguine, Paris, France.

Objective: To determine the significance of the increase of CD8 lymphocytes in asymptomatic HIV-infected subjects.

Methods: 18 asymptomatic (stage II or III CDC) HIV seropositive subjects were followed-up during a 28 month period, with controls at the 1st, 6th and 24th month. All had more than 400 CD4 lymphocytes at the 1st control. Two groups were studied: subjects with an increase of 50 percent or more of CD8 between the 1st and the 6th month (group I) n = 7/9 and subjects without such an increase (group II) n = 7/1.

Results: A significant decrease of mean CD4 between the 1st and 24th months was observed in the two groups, but the group I subjects had a mean CD4 count at the 1st and 24th month significantly lower than the group II subjects.

	Group I	Group II	
CD4 at 1st month control	466	412	p < 0.001 (Mann-Whitney test)
CD4 at 24th month control	309	411	p < 0.02
	ns	ns	ns (Wilcoxon test)

On the whole, for the subjects of the study, no correlation existed between the 1st and 6th months and the CD4 count at the 24th month. On the increase of CD8 between the 1st and 6th months and the decrease of CD4 between the 1st and 6th months. A negative correlation (r = -0.33, p < 0.003) existed between the CD4 count at the 1st month and the increase of CD8 between the 1st and the 6th months.

Conclusion: The increase of CD8 in HIV-infected subjects when the CD4 count decreases below the threshold value of 400/mm³ and probably indicates an evolutive process towards AIDS.

M.A.P.103 DIFFERENT COURSES OF HIV INFECTION IN POLAR/OF FRANKFURT UNIVERSITY OUTPATIENT CLINIC.

Authors: E. Kiederhaver C., Szaszewski S., Gottschal S., Kamp S., Helm B., Universitätsklinik Frankfurt, Zentrum der Inneren Medizin, Infektiologie, Th.- SternstraÙe 7, 6000 Frankfurt/F.R.G.

Objective: To describe courses of PGL/ARC significantly differing in temporal and clinical respect.

Methods: 607 pts (599 fam) with HIV infection were followed up by physical examination, immunological, routine lab and serological tests. Only non-AIDS pts followed up > 6mo, and not taking anti-HIV agents, were evaluated.

Results: We found the following value changes per patient per year (average):

	CD4	CD8	CD4/CD8	CD4	CD8
1	169	-16	+68	+109	+14
2	107	+64	+73	+142	+11
3	116	-87	+76	+126	+16
4	63	+68	+142	+89	+1
5	22	-78	-18	+1	-109

In cases with monitoring period > 90mo and CD4 cell count < 1/2 of min. normal value, we found significant correlation between increase in LDH, decrease of Ab A leukocytes, immunological changes, and clinical findings (oral thrush, weight loss, regression of lymph nodes, frequency > 4 severities of herpes infections and lact. psoriasis). We could not find any correlation between varying and stage of immunodeficiency, and other investigated factors.

Conclusion: Courses of HIV infection vary in pts with initially equal condition. With increasing immunodeficiency, courses get more uniform.

M.A.P.105 PROSPECTIVE EVALUATION OF HIV PROGRESSION IN HOMELESS INJECTION DRUG USERS.

Authors: J. Kohnen PH, Kohnen M, Schellung U, Whitlatch JM, Whittam TS, "Institute, City Hospital, Immunology, Royal Victoria, Edinburg, Scotland.

Objective: To assess the clinical and immunological progression of HIV infection in a cohort of serologically infected injection drug users (IDU).

Methods: 248 persons (153 male, 95 female) infected with HIV between 1983 and 1984 via injection drug use have been prospectively evaluated for the last 3 years, with 3 monthly clinical and laboratory assessments.

Results: At 5 years post seroconversion, prevalence of asymptomatic HIV infection (CDC IV) and AIDS are 22.1% and 3.7% respectively. There have been 1 AIDS related and 10 non-AIDS related deaths.

Months Post Seroconv.	Mean Value (n (10/19))	(gw/l)	CD4 IV	AIDS				
24	30	1.99	0.57	0.62	0.92	1.90	4	0
30	35	1.60	0.50	0.56	0.95	2.17	10	0
36	42	1.31	0.49	0.71	0.86	2.72	19	1
42	46	1.04	0.77	0.63	2.85	2.99	29	2
48	54	1.73	0.42	0.72	3.17	3.11	41	4
54	60	1.52	0.33	0.70	0.53	3.11	55	8

At 54 - 60 months 228 have 7% counts < 0.2 x 10⁹/l. **Conclusion:** Progression in this cohort of HIV infected IDUs is occurring at a slower rate compared with other risk groups such as San Francisco homosexual. However, there is a significant non-AIDS mortality as has been reported in New York.

M.A.P.107 CLINICAL AND LABORATORY PROGRESSION OF HIV INFECTION IN BLOOD RECIPIENTS AND THEIR SPOUSES.

Authors: J. Delgado, J. Lelanc, J. Rouger, J. Lelanc, P. Institut National de Transfusion Sanguine, Paris, France.

Objective: To compare laboratory test results of HIV-infected transfusion recipients and their spouses with clinical progression to disease.

Methods: Blood samples were treated every six months for up to four years and compared to physical examination for 75 HIV-1 seropositive and 25 seronegatives. Tests include p24 antigen, p24 antibody, and absolute CD4 cells.

Results: Infected blood recipients progress to clinical disease (AIC/AIDS) in an average of 40 months. A decline in p24 antibody and CD4 cells and the appearance of p24 antigen predicted progression. 4/26 sexual partners of infected recipients are now anti-HIV positive. Although some of the sexual partners are clinically ill, several have laboratory abnormalities.

Conclusion: Infected blood recipients appear to progress to clinical disease at a rate comparable to that of infected individuals from other disease at a rate comparable to that of infected individuals from other high risk groups. The rate of heterosexual transmission is low. Laboratory parameters of viral replication and immune dysfunction correlate with, and may predict, disease progression.

Session of affichage Poster Session



Epidémiologie et santé publique Epidemiology and Public Health

M.A.P.108 PREDICTION OF HIV-RELATED CLINICAL OUTCOMES BY USING BETA-2 MICROGLOBULIN (B2), p24 ANTIBODY (Ag), AND ANTIGEN (Ag) IN A COHORT OF HIV-1 SEROCONVERTING GAY MEN

Hayat, Kenneth¹; Hodsdorf, A.***; Falk, L.***; Saltman, S.; Dawson, G.; McCusker, J.***, et al. ¹Massachusetts General Hospital, Boston, MA; ²Farmington Community Health Center, Farmington, CT; ³Memorial Hospital, Pawtucket, RI; ⁴University of Massachusetts, Amherst, MA; ⁵Abbott Lab., N. Chicago, IL, USA.

Objective: To assess the clinical utility of p24 Ab, Ag, and B2 in predicting the likelihood of clinical progression and mortality among initially asymptomatic (AS) HIV+ persons.

Methods: Serological methods including logistic regression and survival analysis in a cohort of 86 initially ASX HIV+ gay men followed for more than 3 years who are part of a Boston cohort study (N=212) initiated in 1985. Subjects are screened every 6 months. p24 Ab levels are determined by competitive EIA using a recombinant protein (Abbott).

Results: A higher % of men who were p24 Ag(+) at entry were asymptomatic (AS) 1 year later than those who were p24 Ab(-) alone or those with < 2 (30% vs 19% vs 16%), but > 2 (50% vs 40%) were independent predictors of outcome. Survival at 3 years was .76 for those with normal B2 vs. .41 for those with high B2; it was .76 for those initially p24 Ab(-) and .43 for those who were p24 Ab(-) on enrollment.

Conclusions: p24 antigenemia predicts clinical progression sooner than B2. Twice as many Ag(+) subjects became SZ in 1 year as those with < 2. Survival at 3 years is similar in ASX HIV+ subjects who are p24 Ab(-) or have > 2.

M.A.P.109 EVALUATION OF GROUP SPECIFIC COMPONENT AS DETERMINANT OF HIV SUSCEPTIBILITY AND PROGRESSION

Agmon, Hatzidakis¹; Mandakalis²; R. Butler³; R. Pilgusbaugh⁴; C. Tsoukalas⁵; K. Katsouelis⁶; et al. ¹Athens University, Athens, Greece; ²Harvard School of Public Health, Boston, MA; ³University of California, San Francisco, CA; ⁴AIDS Program, University of Colorado, Denver, CO; ⁵University of Pennsylvania, Philadelphia, PA; ⁶Red Cross Foundation, Bern, Switzerland.

Objective: To study whether Group Specific Component (G) phenotype are associated with HIV susceptibility and progression. **Methods:** 239 hemophilia patients were included in serological follow-up studies since 1980. Seroconversions to HIV occurred between 1980 and 1985 and were documented by ELISA and WB or RIF assays (122 HIV(+), 107 HIV(-)). By November 1986, 20 AIDS or ARC2 (ARC plus T4-CD4) cases have been documented. The G-C phenotypes were tested using isoelectric focusing.

Results: The G-C phenotypes are not associated with HIV susceptibility (Table). The G-C 2-3 phenotype was associated to faster progression to AIDS (The age-adjusted RR by Cox model was 3.97, 95% CI 1.08-14.46).

TABLE	G-C phenotypes (%)		G-C phenotypes (%)	
	2-3	2-2	2-3	2-2
HIV(-)	107	9.3	1.9	36.3
HIV(+)	102	9.8	4.9	32.3
Healthy HIV(+)	-	-	35.0	15.0
AIDS, ARC2	-	-	4.1	8.3
Incidence Rate (cases/1000 person-yr)	-	-	4.1	8.3

M.A.P.110 FACTORS ASSOCIATED WITH HIV PROGRESSION IN MAIROBI PROSTITUTES.

Bolton, C.***, Cameron, D.M.**, Stanses, J.R.***, Mwiru-Achola, J.O.***, Ngugi, E.***, Plummer, F.K.***, et al. ¹University of Maryland, Baltimore, MD; ²University of Ottawa, Ottawa, Canada; ³Case Western Reserve University, Cleveland, Ohio, U.S.A.; ⁴University of Nairobi, Nairobi, Kenya.

Objective: To determine factors associated with progression of HIV disease in a cohort of HIV seropositive female prostitutes living in Nairobi, Kenya.

Methods: In February 1985, 595 female prostitutes living in Nairobi were enrolled in a longitudinal cohort study. Continuing recruitment has enrolled a further 352 women. In November 1986, an educational program was introduced which resulted in increased use of condoms. The women attend the clinic for treatment of STDs. They were re-interviewed at 6 month intervals for clinical progression of HIV disease. Markov models determined 4 distinct time periods. Women who did not change CDC staging were compared to women who advanced in CDC staging using univariate and multivariate analysis. Factors assessed were age, years prostitution duration, use of oral contraceptives, pregnancy, incidence of genital ulcer disease, episodes of gonorrhoea and use of condoms.

Results: Among the variables evaluated, condom usage correlated with disease progression. Women who advanced in 'C01' of their sexual contacts were statistically more likely to advance from CDC stage III to CDC stage IV (p<.05).

Conclusion: In addition to preventing HIV transmission, condom use may also delay HIV progression.

M.A.P.111 THE NATURAL HISTORY OF HIV INFECTION IN A COHORT OF HOMOSEXUAL AND BISEXUAL MEN: COFACTORS FOR DISEASE PROGRESSION, 1978-1989

Nancy A. Hanson¹; L. Barnhart²; P. O'Malley³; A. Lifson⁴; S. Buchbinder⁵; L. Doll⁶; et al. ¹Department of Public Health, San Francisco, CA; ²AIDS Program, University of Colorado, Denver, CO; ³University of California, San Francisco, CA; ⁴University of Pennsylvania, Philadelphia, PA; ⁵University of California, San Francisco, CA; ⁶University of California, San Francisco, CA.

Objective: To identify possible cofactors for progression of HIV infection in a cohort of homosexual and bisexual men.

Methods: We evaluated 268 HIV-infected homosexual and bisexual men with well documented seroconversion (SC) dates, from 1977 to 1988, for cofactors for progression of HIV infection to AIDS using both odds ratios and Cox proportional hazard stepwise analyses. Analysis was restricted to those exposures following estimated date of SC. Spearman rank correlation test compared latency time (from HIV SC to AIDS diagnosis) to survival time (from AIDS diagnosis to death) among the 77 men who died of AIDS. **Results:** Univariate analysis showed that HIV-infected men who developed AIDS were more likely to report a history of amebiasis, gonorrhea, and herpes simplex, and less likely to report using AZT. Cox multivariate analysis showed significant association with progression to AIDS and history of amebiasis and gonorrhea. Age at SC, race, history of recreational drug use, use of other antivirals and vitamins, and history of other sexually transmitted diseases (STDs) were not statistically associated with progression to either AIDS diagnosis or death. There was no significant correlation between latency time and survival time.

Conclusion: Infection with certain STDs following HIV seroconversion is associated with progression to AIDS. Investigation into cofactors which increase or decrease the likelihood of progression to AIDS is warranted.

M.A.P.112 NO EVIDENCE FOR RISKFACTORS FOR PROGRESSION OF HIV INFECTION IN A COHORT OF HIV SEROCONVERTING MEN

van Griensven, Goffard JF, De Vuose, ENH; De Wolf, F; AIDS study group Amsterdam, The Netherlands.

Objective: To identify riskfactors for progression of HIV infection.

Methods: Between Oct. 1984 and May 1987 746 homosexual men, 224 HIV+, entered a cohort study for HIV infection and AIDS. During the follow-up until 1988 52 men seroconverted. Subjects are seen every 7 mo. for medical history, physical examination and collection of blood samples for psychosocial and behavioral data. The 286 HIV- individuals were classified in a high and low risk group for progression to AIDS. High risk was defined as the presence of HIV or the absence of antibody to HIV once in a no. of 74 cells < 0.5 during three or more subsequent sample sera. For statistical comparison high and low risk subjects were matched at random in taking the data of the first high risk bloodsample as a reference.

Results: Of the 224 seropositive 40 (17%) were high risk at entry and 98 (42%) became high risk during the study. From the 52 seroconverters 9 (18%) were high risk immediately after seroconversion and 11 (21%) became high risk later. In bivariate analyses herpes co-infection was associated positive with risk status (p<.05) while the level of education was associated negative (p<.01). Multivariate analysis revealed that serological response, intercourse was related to low risk status (p<.05). No relation was found with the use of nitrite, sex with a partner with AIDS, history of STD's, expression of emotions and experience of social support.

Conclusion: After primary infection no riskfactors are found for progression of HIV infection among homosexual men.

M.A.P.113 COFACTORS OF PROGRESSION TO AIDS IN A COHORT OF MALE SEXUAL CONTACTS OF MEN WITH HIV DISEASE

Randall Coates, V. Parrett, J. Raboud, S. Reed, D. MacFadden, L. Catzwarz, et al. University of Toronto, Toronto, ON, Canada.

Objective: To investigate potential cofactors for progression to AIDS in a cohort of male sexual contacts of men with HIV disease. **Methods:** At recruitment, 143 cohort members were seropositive and 16 were negative during oral sex, smoking and drinking status, recreational drug use and history of sexually transmitted and other diseases were obtained from interviews at inclusion into the cohort. Cox proportional hazards models examined the potential effects of recreational drug use and infections one at a time (and then in combination) while simultaneously controlling for age, smoking and drinking status, and either time from first sexual contact with the index case to inclusion or calendar year of infection.

Results: 35 cohort members developed AIDS while under study. No significant association with risk of progression to AIDS was noted for use of various recreational drugs (single or in combination), history of specific infections, age, or smoking and drinking status.

Conclusions: We could not demonstrate a significant association of any of the potential cofactors and risk of progression to AIDS. In this analysis, estimated length of time that one has been infected was the only variable associated with risk of progression to AIDS.



M.A.P.120

Session d'affichage Poster Session



Épidémiologie et santé publique Epidemiology and Public Health

T.A.P.13

ARE MISSIONARIES AT RISK OF AIDS?
Lange, W. Robert¹; Dav, E. F.; Kovacs, R.; Kreider, S.;
Harris, J.²

¹ Johns Hopkins Medical Institutions, Baltimore, MD, USA.
² ARC, National Institute on Drug Abuse, Baltimore, MD, USA.
³ Associated Missionaries, New York, NY, USA.

Objective: To ascertain whether Protestant missionaries serving in regions of high AIDS incidence have been at enhanced risk of HIV-1 infection.
Methods: Serum specimens (N=6048) obtained from 2027 Protestant missionaries serving in 37 countries, including 26 African nations, between 1967 and 1984 were assayed for HIV-1 antibodies by ELISA screening and Western Blot (WB) confirmatory testing. A positive WB was defined as one with either band gp41 or p24 in association with either gp120 or gp160.
Results: Seventy seven (1.3 percent) from 61 missionaries (1.6 percent) were ELISA positive; however, only six diagnostic of HIV-1 infection on WB testing. Twenty-two WBs (43 percent) were read as indeterminate, defined as the presence of bands in such a pattern that the criteria for being positive was not met. Band p17 occurred with the greatest frequency (67 percent) followed by p24 (20 percent), either alone or in combination.

Conclusions: The significance of indeterminate WB results is unclear, but they do not appear to be a consequence of exposure to either HIV-1 or HTLV-I. We conclude that missionaries were not at high risk of HIV-1 infection between 1967 and 1984, even when serving in regions of high AIDS endemicity.

T.A.P.15

PREVALENCE OF HIV INFECTION AMONG MIGRANT FARMWORKERS
John F. Barbone¹; G. Castro²; S. Raig³; and Migrant Health
Program⁴

¹Centers for Disease Control, Atlanta, GA and ²HRSA, Migrant Health
Program, Rockville, MD, USA

Objective: To determine the seroprevalence of HIV infection in seasonal and migrant farmworkers attending migrant health centers in the United States.
Methods: A total of 3,130 seasonal and migrant farmworkers were tested for HIV antibody in a blinded manner. Basic demographic data were collected and bloods tested by the EIA and by WB at the CDC.

Results: A total of 15 (1.5%) HIV seropositives were detected, of whom, 8 (53%) were female, the racial/ethnic background were: Black 1 (7%), Hispanic 5 (33%), Mexican 8 (53%), and white 1 (7%). The state of residence was as follows: Florida 8 (53%), North Carolina 2 (13%), and 1 each from five other states. Of the 15 HIV seropositives, 11 (73%) were migrant workers and 4 (27%) were seasonal farmworkers.

Conclusions: The prevalence of HIV antibody in this population of seasonal and migrant farmworkers was found to be relatively low (1.5%). However, it is interesting to note that 13 (87%) of the seropositive were detected in eastern coastal states where a large number of persons move in a migrant stream which emanates from Florida. This survey suggests that seasonally active migrant farmworkers in the eastern coastal states may be at greater risk for HIV infection than migrants in others areas of the U.S. and that appropriate testing, counseling and prevention programs should be directed at this population. Due to difficulties inherent in reaching such a mobile and hard-to-reach group, it will be important to develop innovative outreach programs in order to reach them.

T.A.P.17

SEROPREVALENCE OF HIV AMONG TRANSMETTES IN THE
CITY OF SÃO PAULO

Neulman, J.¹; Suleiman, G.² and Salvo, Paulo Augusto Ayres³
¹Hospital Emilio Ribas, São Paulo, São Paulo, Brazil.

Objective: To define the HIV seroprevalence among transmettes.
Methods: On account of their characteristics and modes of dressing and behaviour transmettes find difficulty in attending regular health care services. In order to minimize this difficulty we move our medical team to their own quarters. There they were clinical and laboratory studied and provided with educational and psychological help. The tests were made by ZELISA and confirmed by W.B.

Results: Studies on 37 transmettes, from July to September 1985, have shown a HIV seroprevalence of 62% (23) of these 5.9% (17) were intravenous cocaine users and 1.4% (2) heroin users. From the 37 only 2 belonged to group IV by the CDC criteria.

Conclusion: Transmettes have an important role in the chain of HIV transmission. Considering that among their clients are married men, this group has a significant potential role in heterosexual and vertical transmission of HIV.

T.A.P.14

HIGH-RISK HETEROSEXUALS: DIFFERENCES BETWEEN PRIVATE AND
COMMERCIAL PARTNERS IN SEXUAL BEHAVIOR AND CONDOM USE

Van der Linden, P.J.¹; van den Pligt, J.²; Van Doornum, G.J.J.³;
* Municipal Health Service Amsterdam, Amsterdam, The Netherlands, ** University
of Amsterdam, Amsterdam, The Netherlands

Objective: To study prevalence of HIV, sexual behavior and condom use among heterosexuals with multiple partners. **Methods:** Heterosexuals with no other risk factors than 3-5 partners in the preceding 6 months were recruited through a STD-clinic. Blood was taken, and questions were asked about number of partners, frequency of practicing sexual techniques and condom use with private and/or commercial partners. **Results:** In 1986, 193 women (136 prostitutes) and 157 men (99 customers) entered the study. Prostitutes had 115 customers and 171 women had 6 and 122 men had 7 private partners in 4 months. vaginal intercourse was reported often to always by all participants, anal contact was seldom reported. Non-risky sexual techniques were reported more frequently with private than with commercial partners (p<0.01). Condom use was reported more frequently with commercial than with private partners (p<0.01), and prostitutes reported using condoms more often than customers (p<0.01). Prostitutes had 14 in 4 months with more partners (± 40 unprotected vaginal intercourse than customers (± 7), and 10 with more private partners (± 14). None of the participants was HIV positive, but 103 had positive STP-antibody, 52 were TBPA positive and 433 were diagnosed with 2 STD.

Conclusion: Despite frequent condom use, prostitutes and customers are at higher risk for HIV than heterosexuals with multiple private partners only.

T.A.P.16

PREVALENCE OF HIV-1 INFECTION AMONG COLLEGE STUDENTS;
Scolfield, Eugene¹; Teckert, C.¹; Erdwain, M.²; Cowan, J.³

¹University of Maryland School of Medicine, Baltimore;
²University of Maryland, College Park; ³National Institute of Allergy and
Infectious Diseases, Bethesda, Maryland, U.S.A.

Objective: To determine the prevalence of HIV-1 infection and high risk practices among undergraduate college students attending a university located in a metropolitan area with a high prevalence of HIV-1 infection.
Methods: In 1984, undergraduate students attending the University of Maryland at College Park were recruited to participate in a voluntary HIV-1 serosurvey and educational campaign. Each student gave informed consent, completed a questionnaire on risk behaviors, donated a blood sample, and received pre- and post-test counseling. Sera were analyzed by ELISA and western blot for HIV-1 antibody.

Results: A total of 3,449 students volunteered for the survey. All students were between 16-40 years old, 41% were male, and 81% were white. 87% of the students were sexually active (88% of males and 87% of females), with a median of 1 lifetime partners (range 0-200). A history of behavioral practices a student at risk for HIV-1 infection was acknowledged by 21% of men and 21% of women, when their risk behaviors were defined as male homosexual intercourse (5% of men), IV drug use (1%), previous sexually transmitted disease (13%), and heterosexual intercourse with a high risk individual (6%). Despite the high frequency of risk behaviors, the HIV-1 infection rate was only 0.6 per 1000 students, with HIV-1 infections documented in 2 homosexual men, both of whom engaged in other high risk behaviors.
Conclusion: Despite the presence of risk behaviors, the rate of HIV-1 seropositivity among this group of college students was low, and infections were confined to high risk homosexual men.

T.A.P.18

DO HOMOSEXUAL MEN ENJOY HIV-TESTING?
Vello Sirkkälä¹ and Sarna S.²

¹University Central Hospital, Helsinki, Finland
²University of Helsinki, Finland

Objective: To analyze the change in the sexual preference category of the newly identified HIV-seropositive individuals and the prevalence of AIDS.
Methods: As of Sept. 1985, HIV-testing has been available free-of-charge for all men in Helsinki. HIV-testing is possible in 5 AIDS Support Centres. As of Sept. 1985, HIV infection has been a notifiable disease in Finland requiring mandatory reporting on every HIV case to the National Board of Health. Anonymous HIV testing has been a notifiable disease (SAC) as are gonorrhoea, genital Chlamydia infections and hepatitis-B. Supplemental disease (SAD) is reported by name and sex. Data is collected on the age, profession and place of residence of the patient as well as on the most likely transmission route of the virus.

Results: As of 1.1.86, there are 241 cases of HIV infection, 41 of whom have AIDS. The distribution of the sexual preference among the annually found HIV cases is the following:

	1983	1984	1985	1986	1987	1988
HIS	10	14	29	41	33	22
HS	0	16	17	40	40	59

Out of the 41 cases of AIDS, 31 (75.6%) have been in homosexual men (HS) and 10 (24.4%) in men in HIS. In 1986, 3/16 had AIDS and 5/13 had AIC when HIV infection was confirmed.

Conclusion: The decrease in the number of newly identified HIV-seropositive HIS can partly be due to decreased risk but may also reflect a delay in voluntarily taking the diagnostic test.

Session d'affichage Poster Session



Épidémiologie et santé publique Epidemiology and Public Health

T.A.P.19 DIFFUSION DES PRÉCAUTIONS SEXUELLES ET ÉVOLUTION DE L'ÉPIDÉMIOLOGIE DES LAZÉTIQUES LA POPULATION HOMOSEXUELLE FRANÇAISE: 1985 - 1988
Pollet, Michèle; Schiltz, Marie-Ange; Pison, Pierre.
 *INSERM, Paris; *Muel (ed. Medec. Paris)

Objectif: Suivre la diffusion des précautions sexuelles, et l'évolution du recours au test de dépistage volontaire et de ses résultats dans la population homosexuelle française.

Méthodes: Sondage annuel par questionnaire inséré dans une revue hebdomadaire diffusée sur tout le territoire (en 1980 en 1985, 1986 et 1988), complété par un sondage (in-situ) auprès d'homosexuels choisis selon les quotas correspondant à la population masculine.
Analyses: Depuis 1986 le préservatif tend à s'imposer comme mode privilégié de protection contre le VIH. (usage régulier: 1985: 55; 1986: 39%; usage irrégulier: 1985: 21%; 1986: 25%). Le présermier sif est aujourd'hui accepté, y compris dans la tranche d'âge des moins de 25. Les plus réticents initialement. Néanmoins des différences subsistent entre Paris et la province, et selon le degré d'éducation et la catégorie socio-professionnelle. Entre 1986 et 1988 la proportion des homosexuels testés est passée de 33% à 95%, avec une stabilisation du taux de séronegativité à 19%. Les ouvriers sont la seule catégorie où ce taux a eu tendance à fortement augmenter (1986: 65; 1987: 111; 1988: 31%).
Conclusion: Le retard d'adaptation au risque de contamination observé dans les classes populaires se traduit rapidement par la progression de la maladie dans ces groupes.

T.A.P.21 INCIDENCE OF HIV-1 INFECTIONS AMONG HOMOSEXUAL MEN IN DALLAS, TEXAS, 1987-1988.
Haley, Charles E; Freeman A.; Anderson P.; Petty A.; O'Reilly K.
 *Dallas County Health Department, Dallas, Texas; **Centers for Disease Control, Atlanta, Georgia; USA.

Objective: To estimate the incidence of HIV infections among high risk men in Dallas, Texas.

Methods: Between 6/87 and 12/88, 662 homosexual or bisexual men enrolled in a cohort and were re-interviewed every six months. At each visit a confidential anonymous questionnaire linked to test results.
Results: The mean age of the cohort was 33.3 yrs; 92% were white; 87% had never used IV drugs. 64% of the cohort members admitted a history of >10 sexual partners since 1980. 178 (27%) were HIV infected at the first visit. Among the 447 HIV negative men, retention in the cohort is 96% at 6 months and 84% at 12 months. Of the 176 previously negative persons who returned for the 1st 6-month visit, 3 (1.7%) had seroconverted; of the 57 who returned for the second 6-month visit, 1 (1.8%) had seroconverted, for an annual incidence of 3.5%.
Conclusions: The incidence of HIV-1 infections is less than 5% per year among homosexual men in this population.

T.A.P.23 TRENDS IN HIV ANTIBODY POSITIVE ADMISSIONS TO A CONNECTICUT COMMUNITY HOSPITAL
Madden, Lizzy and Smith C. St. Francis Hospital and Medical Center, Hartford, Connecticut, USA

Objective: Identify demographic trends in HIV infected (HI) patients admitted to a Connecticut community teaching hospital over 3 years.

Methods: Data compiled on sex, race, risk-group and average length of stay per admission (ALOSPA) in all known HI patients admitted to our 592 bed hospital from 1986 to 1988 were reviewed.

Results: From 1986 to 1988, HI adult patient admissions increased 489%: 1986 - 50, 1987 - 166, 1988 - 294. The ALOSPA for admissions decreased from 18.9 days (4) in 1986 to 13.8 d in 1988, while the ALOSPA for non-AIDS HI patients increased from 7.5d to 10.7d. 170 adult HI patients were admitted in 1988, 70% IVDU and 85% Hispanic (His) or Black (Bl). Similar percentages of IVDU, His and Bl HI patients were seen in 1986 and 1987. From 1986 to 1988, among the HI patients, female (F) increased from 17% to 31% (P<0.1), His/F increased from 2% to 13% (P<0.1), and heterosexual risk-group (HRG) patients increased from 0% to 3% (P<0.5). HI pediatric cases increased from 0 in 1986 to 9 in 1988, all were children of IVDU.

Year	Total	His	Bl	His	F	HRG
1986	41	24	10	27	1	0
1987	112	69	43	28	2	1
1988	170	91	52	119	52	19

Conclusions: From 1986 to 1988 the Black, Hispanic, and IVDU composition of our HI adult admissions trended similar. The data were statistically significant increases in HI, F, His/F, and HI adults with heterosexual contact as their only risk factor.

T.A.P.20 CHANGES IN SEXUAL BEHAVIOR CONNECTED TO STRONG DECLINE IN HIV INCIDENCE AMONG HOMOSEXUAL MEN
Van Griensven, Godfried JF; De Vroome, EMH; *Goudits, J.; *Dourhien, RA.
 *National Health Service Amsterdam, **State University Utrecht, ***University of Amsterdam, The Netherlands

Objective: Study of the relation between changes in sexual behavior and the incidence of HIV infection among homosexual men.

Methods: Between October 1984 and May 1985 765 homosexual men were entered in a seroprevalence study on HIV infection and AIDS in Amsterdam. From these 234 (31.4%) were HIV+ at entry. Subjects are seen every 3 months for the collection of blood samples. Every 6 months a written questionnaire is completed regarding the sexual lifestyle in the preceding half year.
Results: During follow-up until December 1988 59 seroconversions were seen, 34 in 1985 (incidence 72), 16 in 1986 (incidence 3.9%), 3 in 1987 (incidence 0.8%) and 6 in 1988 (incidence 1.7%). The cumulative incidence rose from 31.4% in 1984 to 40.1% in 1988. During the study period the mean no. of partners with whom seronegatives practiced anogential receptive intercourse declined from 3.7 to 0.4. Among seropositives the number with whom anogential insertive intercourse was practiced declined from 10.6 to 1.4. The majority of subjects restricted anogential intercourse without a condom to a steady partner. Anogential intercourse with non steady partners was practiced more frequently by seropositives, but in a majority of cases while condoms were used.
Conclusion: This study shows that it has been possible to bend the course of the HIV epidemic through the modification of sexual behavior. A strong reduction of sexual activity during a long period of time was needed to affect the incidence of HIV infection.

T.A.P.22 PREVALENCE AND SEROCONVERSION FOR HIV INFECTION IN HOMOSEXUAL AND BISEXUAL MEN IN MADRID
Francisco, M.; F. Babín, C. Colomo, L. Pascual, M. Rúa-Figueroa, A. García-Seco, J. C. S. Castro, Madrid Council, Madrid; **CNM e. I. Sanitaria Majadahoca, Madrid, Spain.

OBJECTIVE: To study the changes of prevalence of HIV infection in homosexual and bisexual men in Madrid, the incidence of seroconversion was also studied in the cases that returned for the first visit.

METHODS: In the first visit information about medical and epidemiological aspects was recorded and a sample of serum was obtained for HIV test. All the reduction of sexual activity in a personal and individualized interview. Annual follow-up was offered.

RESULTS: In 625 homo and bisexual men the prevalence of HIV infection was of 14.7% (92/625). The prevalence of HIV infection was 14.7% (92/625) in September 1988. The incidence of seroconversion was also studied in the cases that returned for the first visit.

YEAR	FIRST VISIT	INTERVIEW	INTERVIEW	LAST VISIT	ANNUAL SEROCONVERSION				
1986	166	17	10.2	1492	20.8	92	6	12.5	0.8
1987	213	25	11.7	427	12.9	33	2	0	0
1988	625	104	16.6	2714	18.3	146	14	9.4	6.2

CONCLUSIONS: In 1984 an increase in HIV seroprevalence was found which corresponded to the first visit. After 1986 no significant changes were found in HIV seroprevalence. The seroconversion rate (see table) was similar over the period of time studied in spite of health education activities.

T.A.P.24 HIV SCREENING IN AN URBAN HOSPITAL OUTPATIENT POPULATION
Marmor, Michael; Krasinski, K.; Sanchez, M.; Cohen, H.; Debra, N.; Wynn, USA
 *New York University Medical Center, New York, NY, USA; **Bellevue Hospital Center, NY, NY, USA

Objective: To ascertain seroprevalence of risk factors for human immunodeficiency virus (HIV) infection in a general population.

Methods: Patients attending the outpatient clinic at Bellevue Hospital Center, Manhattan, New York City, were offered HIV screening. Male patients who had taken seroprevalence drugs at any time since 1/1/77, or who had engaged in sex with other men since that date were asked not to participate. Sera were tested for HIV antibodies with ELISA with Western blot confirmation.

Results: 1119 subjects with no prior indication of HIV infection were interviewed and HIV tested. After exclusion of 2 subjects with indeterminate HIV serology, seroprevalence was 7.1% (26/368) among men, and 5.9% (44/749) among women. Seroprevalence among heterosexuals without other risk factors was 3.3% (10/302) among males and 2.4% (15/619) among females. Rates were substantially higher among Blacks and Hispanics than among Whites. The data were suggestive of an HIV risk among men associated with sexual contact with prostitutes. Among heterosexual women, the primary risk factor was sex with a male intravenous drug user (IVDU). The most common method of birth control reported to be used by both men and women was "no method". 37% of 34 female IVDUs were HIV seropositive; a primary risk factor was the number of years since last injecting illicit drug. Logistic regression analysis identified significant risk among all women IVDUs; a significant negative interaction between these two terms was found. **Conclusions:** Heterosexual HIV transmission has been documented, particularly from male intravenous drug users to non-drug-using women. HIV seropositivity among drug users in the general population may be less than previously reported because of the importance of the number of years since last injection. Mathematical modeling of data obtained from women suggests that intravenous drug use and a history of sex with male IVDUs have not been synergistic in their association with HIV infection.

Session d'affichage Poster Session



Épidémiologie et santé publique Epidemiology and Public Health

T.A.P.30

REPORT ON AN EXTREMELY LOW RATE OF SEROPOSITIVITY AMONG I.V. DRUG USERS (IVDU) IN A LOCAL HEALTH DISTRICT (LHD) OF NORTH-EST ITALY

Rezzani¹, Pizzoli², Lombardi³, Pizzetti⁴, Vercellotti⁵, Briceo⁶, Neri⁷

¹ Istituto di Patologia Speciale Medica - University of Verona - Italy
² Center for Drug Abuse - Local Health District 16 of Veneto Region - Bassano del Grappa - Italy

From December 1985 to December 1988 the center for drug addicts of the SDU 24 of Veneto Region (North-East Italy), under Verona (about 70000 IVDUs) - The population of this district is 130,000. Population aged 15-64 for addiction (age 15 - 39) is 52,000. In this group the amount of IVDU is estimated ranging from 400 to 600. The IVDU tested (ELISA plus Western blot) is positive were 345. 301 (81) addicts resulted seropositive (sero rate is 75%). Patients were studied with regard to age, sex, length of i.v. addiction, methadone treatment, therapeutic community program, conviction, kind of work, kind of partner relationship. Seropositive and seronegative groups showed no significant difference in age.

There is no evidence for a different source of the HIV in this district which is in a tourist and well developed area of North-East Italy. The first reported case of IAD in Italy occurred in this district. The following treatment strategies may be accounted for the extremely low rate of seropositivity as suggested by the study of the Center:

- 1 - a methadone maintenance program was extensively implemented between 1981-84;
- 2 - a carefully designed psychosocial program, implying a one-to-one long term therapeutic relationship was performed in these years;
- 3 - sterile syringes are easily available day and night in the local dispensary;
- 4 - an intensive campaign against viral hepatitis transmission was extensively performed by the center.

T.A.P.32

PREVALENCE OF SYPHILIS(S), HTLV-II(I), HTLV-III(I) & HIV-1 AMONG CRACK(C) AND OTHER DRUG USERS(DUS).

Glasser¹, Jordan², Monnier³, D'Angelo⁴, Drakotas⁵, A.*

¹Poless, B.**; ²Enrich, C.**; ³Et al.
⁴Richmond Memorial & Staten Island Hospitals, St. **SURY at Syracuse, NY, USA.

Purpose: To study prevalence rates of S, I, II and HIV-1 among C & other DUS in view of concern of S-enhanced heterosexual retroviral transmission.

Methods: During 1988, all 957 admissions (624M; 517 white) to RHR detox unit underwent RPR. S was confirmed by RMA-7P. Voluntary retroviral testing was offered. I & II was documented by polymerase chain reaction (PCR). I, II and HIV-1 ELISA were also done. HIV-1 was confirmed by western blot.

Results

	S	I	II	HIV-1
C alone	154/281 (4.7%)	1/37 (2.7%)	2/37 (5.4%)	7/181 (5.0%)
IVDU alone	104/388 (2.3%)	6/58 (10.3%)	6/58 (10.3%)	79/274 (28.8%)
C & IVDU	1/110 (0.9%)	1/18 (11.1%)	1/18 (5.6%)	28/82 (34.1%)
Other DU	1/138 (0.7%)	0/10 (0.0%)	0/10 (0.0%)	0/54 (0.0%)

*7/8 tested were HIV-1 negative. 4/7 tested were HIV-1 positive.

For HIV-1+ C users: All 35 belonged to high risk groups (28 IVDUs, 3 male homosexuals, 3 long-term sex partners of IVDU, 1 from endemic region) and only 1 had S. Four DUS had both I & II. For both I & II, 2/9 (22%) DUS were PCR+ but ELISA-. Two male C users with prostitute contact had either I or II.

One black female C user with no known risk factor had II. No C user with I or II had S.

Conclusions: C and IVDUs had a high rate of S. S in C users was not associated with HIV-1. The high rate of HIV-1 among C users was related to concurrent risk factors and not widespread heterosexual transmission.

T.A.P.34

THE AIDS PROBLEM AND DRUG-REHABILITATION IN THERAPEUTIC COMMUNITIES (TC)

Diazin¹, Merco

Department of Social Psychiatry University Hospital, Zürich, Switzerland.

Objective: Determine rate of infection and the effects of AIDS on the members of TC's and their human relations.

Methods: The study covers 523 heroin-addicts who were treated in 40 TC's in Switzerland in 1986. N=433 patients were tested.

Results: Rate of infection of the tested persons: 50% HIV-positive and 11.3% of the positive patients already suffered from typical symptoms related to the infection. Of particular interest was to study the communication and discussion about AIDS preventing measures and their implementation in TC. The findings were, that large and hierarchically structured TC's were more conscious of AIDS and its effects than small and family-like structured TC's.

Discussion: Prevention efforts should be established as a regular issue within the therapeutic programs of TC's. But as well, there should be opportunities of talking in private atmosphere with a therapist and other residents in a trustful relationship.

T.A.P.31

LONG TERM FOLLOW-UP AND ASSESSMENT OF HIV SEROSTATUS AND BLOOD TAPPING IN A COHORT OF 203 INTRAVENOUS DRUG USERS

Edinburgh Drug Addiction Study, Hairhouse Medical Group, Edinburgh, Scotland

OBJECTIVE: To evaluate current infection and immune status in a group of intravenous drug users previously known to have high seroprevalence (1985) and to evaluate current risk taking and behaviour change.

METHODS: A phased recruitment was carried out between 1983 and 1985 into a cohort of 203. In 1987 and 1988 follow-up was carried out and individuals were interviewed and, where appropriate, venesected. Validation included a questionnaire for the primary care physician responsible for the patient at the time of follow-up.

RESULTS: Two hundred and three individuals were contacted, 137 sero (67.5%) of whom 132 (94). One hundred and sixty four had HIV antibody tests subsequent to 1984 (when the virus is thought to have entered the group); 60 had been given 500 mg and 1988 of these tested were HIV antibody positive, 41.8% had been injecting drugs in the 12 months prior to interview and 28.3% were seropositive (12 years). Forty four percent of the group had children and 40% had a sibling who had used drugs. Sixty six per cent had been in prison; 50% of the group started injecting between 1980 and 1982, 37% thought they were at risk of HIV from needle sharing but only 23% due to possible sexual transmission. Fifty three percent had not changed sexual partners since they were first interviewed. Forty five percent used no contraception (23% of whole group had used a barrier method). Forty six percent had had more than one sex partner since test (range 2-100). Detailed demographic and immunological data are recorded.

CONCLUSION: The natural history of drug injecting had important implications for understanding HIV transmission. Behaviour change was considerable in drug taking and needle sharing but not noticeable in sexual risk factors. The implications for future serosurveys are discussed.

T.A.P.33

NEEDLE SHARING PRACTICES AMONG INTRAVENOUS DRUG USERS IN A STATE ALLOWING THE PURCHASE OF INJECTION EQUIPMENT

Lawrence, B.*; Alford, J.*; Burch, F.**; Moore, S.**

*Tulane University School of Medicine and Tropical Medicine, New Orleans, LA, USA, **Louisiana State University School of Medicine, New Orleans, LA, USA

Objective: To determine the frequency of needle sharing practices among intravenous (IV) drug users in Louisiana, a state which does not control needles by prescription.

Methods: During March-August 1988, 380 self-identified IV drug users seeking treatment in a large public hospital in New Orleans were interviewed regarding needle sharing practices, frequency of use and drug(s) of choice. Hospital records were reviewed to obtain demographic information and HIV serologic status.

Results: Eighty-one percent of subjects were male and 73% were black. Mean age was 32.5 yrs (range 16-69 yrs). The most frequent drug injected was cocaine (31%). Drugs were injected > once per day by 76%. Overall 68% of subjects admitted that they regularly use needles which had been used by others. No significant differences in needle sharing were found by sex, race, frequency of injection or drug of choice. Two of forty (5%) subjects tested were HIV seropositive.

Conclusions: Needles are not controlled by prescription in Louisiana. More than 65% of subjects admitted to sharing needles, similar to the rate found in areas in which needles are controlled. This suggests that legal availability of injection equipment does not significantly reduce sharing behavior in this population.

T.A.P.35

COORDINATED COMMUNITY PROGRAM FOR HIV SURVEILLANCE AMONG IVDU

Lawley, Benjamin¹; Sullivan, J.**; Birch, F.**; Moore, S.**

¹Coaker, J.**; Koblin, S.**; et al.

*Spectrum House, Inc., Westboro, MA 01581. ** Worcester Health Department, Worcester, MA, ***University of Massachusetts, Amherst, MA, U.S.A.

Objective: To conduct a community-wide surveillance for HIV-high-risk behaviors among an estimated 3000 IVUDs and sexual contacts in the second largest city in New England (175,000).

Methods: The Worcester (MA) AIDS organizations, a network of drug treatment, public health and criminal justice organizations enrolls, interviews, counsels and tests IVUDs at multiple sites. Active and passive follow-up is implemented for HIV+ and admissions to drug treatment and public health programs.

Results: Of 1200 tested, 482 were needle users (40%), 131 (male). 18% of needle users tested 60 of Hispanic IVUDs 35% tested 60 Blacks 30%, Whites 60%; of IVUDs in jail 21%, in drug treatment 14%. Use of bleach has increased from 5% to 64%. Over 100 persons testing entered drug treatment. Results on 3000 contacts will be presented.

Conclusions: HIV prevalence among IVUDs has increased by 22 over the past year to 18% with the greatest increase in the jail (5%). Higher seropositivity among minority groups may in part be explained by differences in drug-use behavior. The surveillance has been instrumental in targeting resources to the minority community. This model has applicability to moderately-sized cities where HIV prevalence is still low.

Session d'arrivage Poster Session



Epidémiologie et santé publique Epidemiology and Public Health

T.A.P.36 NO TENDRY IN TRAVEL HIV-SEROPREVALENCE RATES AMONG IVUDM IN AMSTERDAM: 1986-1988.
Van Tilburg J, Van den Broek J, Van Goolbeek B.
Municipal Health Service, Amsterdam, The Netherlands.

Objective: To describe and explain HIV-seroprevalence rates over time.
Methods: From December 1985 till December 1988, 560 IVUDM entered a long term follow-up study. HIV-seroprevalence among these IVUDM at entry into the study, were analyzed.
Results: In 3 consecutive years (1986-1988) HIV-seroprevalence rates were 35.2%, 38.3% and 27.8% respectively, showing no significant trend over time here. In that cases with the highest risk for HIV-infection participated earlier in the study than others, an attempt was made to control for this possible bias. Preventing this bias, seroprevalence rates (relative to 1986): HIV-infection were multivariately controlled for, resulting in odds-ratio estimates for HIV-infection the consecutive years (relative to 1986): that hardly differed from the uncontrolled ones: 1987: 0.67 vs 0.62; 84; 1988: 0.60; 75 vs 0.87 for uncontrolled and controlled respectively. However, conventional confidence-intervals encompass were quite large. Increases in the rate of HIV-infection from 1986 onwards, so caution is needed in interpreting these results.
Conclusion: HIV-seroprevalence rates among IVUDM in Amsterdam appear to be relatively stable since 1986. This result needs confirmation by larger scale seroprevalence studies to be conclusive.

T.A.P.38 SECOND NATIONAL SURVEY OF HIV INFECTION, AT RISK BEHAVIORS AND BEHAVIORAL CHANGE AMONG ITALIAN DRUG USERS.
Bianchi, S. *; Sestini, S. *; Costi S.
Istituto Superiore di Sanità, Rome, Italy.

Objective: To estimate, among drug users attending public assistance centres in Italy, the prevalence of HIV-1 infection and of at risk drug use behavior and sexual conduct, to evaluate tendency to change behaviors at risk and determinants of the change.
Methods: In each centre attending subjects during October 1988 have been interviewed according to a standard questionnaire, collecting information on personal characteristics, on syringes/needle sharing on kind of sexual relationships. Moreover changes of any at risk behaviors and reasons for changing were investigated. Presence of serum antibodies against HIV-1 was assayed for all enrolled subjects.
Results: Fifty four centres (out of a total of 467 in the country) completed the survey. A total of 1350 subjects from 16 regions were included. Detailed elaboration is in progress. According to results of the first national survey, expected seroprevalence is around 40% of tested subjects, with increased risk associated to sharing of syringes/needles either for preparing or for injecting the drug.
Conclusion: Although prevalence studies among subjects attending public health assistance centres can be affected by biases such as self-selection of drug users, correct confounding bias, reliability of answers, a series of surveys conducted with the same methodology is a useful tool for monitoring trends in the spread of infection and in behaviors at risk, more than for extracting absolute prevalence of such changing factors.

T.A.P.40 RETROVIRAL TRANSMISSION OF HIV AMONG INTRAVENOUS DRUG ADDICTS (IVDA).
Rizic, L. *; Brown, L. * * *
National Institute on Drug Abuse, Rockville, MD, USA; *MSA Research, Alexandria, VA, USA; **Addiction Research Treatment Center, New York, NY, USA

Objective: To examine the extent to which HIV is transmitted among heterosexual IVDA through sexual contact.
Methods: IVDA who received treatment in New York City during 1987-88 were tested for HIV antibodies by ELISA, confirmed by Western blot. Demographic, drug use, and sexual history were obtained by standardized interview. Heterosexual IVDA who reported having sex with IVDA sex partners (IVDA) (n=114) were compared with those who reported having no IVDA sex partners (n=125) using bivariate and logistic regression analyses.
Results: Initial bivariate analyses indicated that IVDA with any IVDA sex partners were more likely to be HIV+ than those with no IVDA sex partners, while the number of IVDA sex was not related to infection. Analyses by gender indicated that the relationship between IVDA and HIV held for males (p<0.1), but not females. There was no statistically significant relationship between having an IVDA sex partner and seropositivity, for either the total sample or males, when selected demographic and drug use variables were controlled.
Conclusion: The increased HIV risk associated with having IVDA appears to be due to differences in drug use practices, not sexual transmission. The study supports necessary attention to the primary mode of HIV transmission among IVDA. The possible contribution of sexual transmission should not be ruled out. Possible effects may be too subtle to be detected in these analyses.

T.A.P.37 EPIDEMIOLOGY OF AIDS ASSOCIATED WITH INTRAVENOUS DRUG USE, UNITED STATES, 1979-1988.
Kushner, J. * * *
* Centers for Disease Control (CDC), Atlanta, GA, USA
** Rockefeller Burnet Center for Medical Research, Philadelphia, Australia.

Objective: To describe characteristics of, and trends in, AIDS cases in intravenous drug users (IVDA) in the United States (US).
Methods: We reviewed AIDS cases reported to CDC through 1988.
Results: There were 21,914 cases of AIDS in IVDA. 57% heterosexual men, 27% homosexual men, 14% women, 1,457 in sex partners of IVDA, and 761 in children born to mothers who are IVDA or sex partners of IVDA. From 1984 to 1985, heterosexual IVDA increased from 17% to 21% of adult AIDS cases (in part due to the 1987 revision of the case definition), while homosexual IVDA declined from 5% to 4% of adult cases. For heterosexual IVDA cases, relative risk for cumulative incidence among blacks and Hispanics compared to whites was 1.9 and 2.2 for males and 1.9 and 1.4 for females, respectively. In the northeast, cumulative incidence for IVDA AIDS cases was as high as 1/200 among blacks and Hispanic in some urban areas, and cases in IVDA and other IVDA-associated cases exceeded all other AIDS cases by the end of 1988. Age at diagnosis of AIDS has been increasing for minority heterosexual IVDA (black and Hispanic males 4-3 months per year since 1983) but not for other IVDA.
Conclusion: Heterosexual IVDA represent an increasing proportion of the AIDS epidemic in the U.S. The burden of AIDS associated with drug use falls most heavily on blacks and Hispanic, particularly in the northeast.

T.A.P.39 INTRODUCTION OF HIV INFECTION AMONG INTRAVENOUS DRUG ADDICTS (IVDA) IN LOW PREVALENCE CITIES
Bianchi, S. *; Sestini, S. *
National Institute on Drug Abuse, Rockville, MD, USA

Objective: To examine possible mode of introduction of HIV into IVDA populations in areas with low HIV infection rates.
Methods: IVDA admitted to methadone treatment in 1987-88 in Trenton, NJ, Chicago, IL, San Antonio, TX, and Los Angeles, CA were tested for HIV antibodies by ELISA, confirmed by Western blot (w-1,154). Demographic, drug use, and sexual history were obtained by standardized interview. Seropositives (n=34) and seronegatives (n=1160) were compared with seronegative controls were compared on relevant AIDS risk factors.
Results: Seropositives and seronegative controls did not differ in frequency of IV use, needle sharing or needle cleaning, or number of drugs injected. There were also no differences between the two groups in rates of males reporting sex with other males, blood transfusions since 1982, injecting drugs or having sex in high HIV prevalence areas, and acquaintance with persons with AIDS. Seropositives, however, more likely report sharing a needle with a homosexual or bisexual male (25.0%) than were seronegatives (5.1%) (p<0.001) OR 1.5; 2.2-3.0. Differences between seropositives and seronegatives reporting injecting in shooting galleries (52.5% vs. 39.2%) approached statistical significance (p=0.07).
Conclusion: Comparisons of seropositives and seronegative controls suggest that transmission of HIV infection by needle sharing between homosexual, bisexual IVDA and heterosexual IVDA may be an important means by which HIV is introduced among heterosexual IVDA in low prevalence areas.

T.A.P.41 INCIDENCE AND RISK FACTORS OF HIV INFECTION IN A COHORT OF ITALIAN DRUG ADDICTS (IVDA) STUDY.
Alfano Nicotri, Northern Italian Serogene Drug Addicts Study, National Research Council and University of Milan, Milan, Italy.

Objective: To study the incidence of HIV infection in a population at risk, to identify risk factors, to describe natural history of infection and transmission dynamics.
Methods: Intravenous drug addicts (IVDA) are recruited from methadone clinics, hospital wards, contacts of infected persons and other high risk settings. IVDA who agree to participate in the study are first administered a questionnaire about: (1) socio, marital and serology status; (2) a positive serology; (3) a negative serology.
Results: HIV 1/200 has been recruited from January 1987 to December 1988 and followed for different periods of time. It is reconstructed how has observed. The prevalence is very high of 50% of HIV infection, of 10% of HIV infection, of 20% (1987) in the active population. The mean number of IVDA is 100, with 10% of subjects practicing less than 100 calls. Previous infections, type of drug use and patterns of drug acquisition, sexual behavior and demographic variables have been related to seropositivity in order to verify their role in the risk of HIV infection.
Conclusions: The number of seropositives is not sufficient yet to order to draw firm statistical inferences about risk factors, although it is possible to say that HIV is first seen in significantly less in individuals who share seropositives. Seropositives and follow-up are continuing, that it is very a high level of risk factors as well as of behavior and preventive attitudes of IVDA.

Session d'affichage Poster Session



Epidémiologie et santé publique Epidemiology and Public Health

T.A.P.48 DRUG ABUSE PATTERNS AND RESISTIVITY IN IVDA DURING THE EARLY YEARS OF THE HIV EPIDEMIC

Smith, David, M.*; Trigg, M.*; Doe Jarvis, D.C.**; Frithson, S.R.**; Vidler, M.J.***; Hines, S.***; 3rd Israel Medical Center, New York, N.Y., U.S.A.*; N.Y. State Division of Substance Abuse Services, New York, N.Y., U.S.A.**; Heronick and Drug Research Inc., New York, N.Y., U.S.A.**; Johns Hopkins Univ., Baltimore, MD, U.S.A.***; The Rockefeller University, New York, N.Y., U.S.A.

Objective. To determine factors associated with HIV infection in intravenous drug users (IVDA) during the early years of the HIV epidemic in New York. **Methods.** Records from studies of chronic liver disease (CLD) in IVDA during 1978-83 were reviewed. In these studies, limited clinical and demographic data had been linked to case numbers of virus which had subsequently been tested for HIV antibody by ELISA (Abbott) and Western blot. Available data included age, sex, race, marital preference, heroin only vs. heroin and cocaine, and duration and age of onset of IVDA and of alcohol abuse. **Results.** Only 2 (11%) of 18 white patients with CLD were HIV-infected, compared with 24 (39%) of 60 black or hispanic patients (p<0.03). Among all factors of cocaine with heroin, 30 (52%) of 58 had anti-HIV compared with 5 (13%) of 44 injected only heroin (p<0.0001). No other factors listed above were linked to anti-HIV. In a multiple logistic regression, anti-HIV was associated with injection of cocaine with heroin (p<0.0001), black patients (p<0.02), anti-hepatic patients (p<0.05). **Conclusion.** IV cocaine users as well as black and hispanic IVDA were disproportionately HIV-infected during the early years of the epidemic. Cocaine with heroin and ethnicity were independently linked to anti-HIV.

T.A.P.50 INTRAVENOUS DRUG USE AS A RISK FACTOR FOR AIDS AND HIV INFECTION IN LOUISIANA

McLeland, L.*; Louisiana Department of Health and Hospitals, New Orleans, LA, USA; *Louisiana University School of Public Health, New Orleans, LA, USA.

Objective. To determine trends in intravenous drug use (IVDU) as a risk factor for AIDS and HIV infection in Louisiana (LA). **Methods.** AIDS cases are identified by an active hospital-based surveillance system. Case data is collected by hospital record review, and physician and patient interview. Seroprevalence data is from blinded testing of new entrants at two drug treatment centers in New Orleans. **Results.** As of 12/30/86, 1003 adult and 14 pediatric cases of AIDS were identified. IVDU use was associated with 172 (18%) of all cases in adults (SDVD, 100-non-Hispanic and 722), 78-Hispanic). Contact with IVDA in the four (25%) of pediatric cases were from IVDU in a parent. IVDU use was the primary risk factor for AIDS in 148 of blacks vs. 24 of whites. The proportion of AIDS cases with IVDU as the primary risk factor increased from 28 in 1985 to 38 in 1986. Of 175 new entrants to IVDA treatment centers in New Orleans in 1986, 6.2% were found to be HIV seropositive. **Conclusion.** IVDU accounts directly or indirectly for 16% of AIDS cases in LA. The proportion of AIDS attributable to IVDU has increased significantly in the past three years. Blacks account for a disproportionate number of cases among IVDA. The prevalence of HIV in IVDA in New Orleans in 1986 is relatively low (6.2%).

T.A.P.52 COMPARISON OF PREVALENCE OF HIV INFECTION IN IVDA DRUG USERS (IVDU) FROM FOUR DIFFERENT TESTING AND TREATMENT PROGRAMS.

Chen, David; Douglas, J.; Koles, J.; Feeley, F.; Juson, F.; Denver District Health Dept., Denver, CO, USA

Objective. To compare the prevalence of HIV infection in IVDA assessed through a different testing and/or treatment program in Denver in 1986. **Methods:** In 1986, 1000 IVDA were tested by Denver in 4 programs: (1) counseling and testing site (CTS), (2) sexually Transmitted Diseases (STD) Clinic, (3) Substance Treatment Services (STS-a voluntary maintenance program), and (4) Project Safe (PS)-an anonymous street outreach program for IVDA not in treatment. **Results:**

	No. HIV positive / No. tested (%)			
	CTS	STD	STS	PS
Gay/bisexual men	20/51 (39)	17/50 (34)	0/1 (0)	2/7 (28)
Female prostitutes	2/40 (5)	2/69 (4)	1/6 (16)	1/22 (5)
Metropolitan men	14/305 (5)	3/227 (1)	1/73 (1)	3/160 (2)
Metropolitan women	2/168 (1)	1/123 (1)	0/34 (0)	0/37 (0)
TOTAL	38/564 (7)	24/489 (5)	2/114 (2)	6/164 (4)

Conclusions: The prevalence of HIV infection in IVDA who are not gay or bisexual men is low in these samples in programs with different selection criteria. Determining prevalence rates among different programs is useful both to monitor secular trends and to better estimate the community burden of HIV infection in IVDA.

T.A.P.49 DEMOGRAPHIC AND BEHAVIORAL FEATURES OF HIV INFECTION IN INTRAVENOUS DRUG USERS (IVDA) IN NEW YORK CITY DRUG TREATMENT PROGRAMS: 1981-1986

Brann, Lawrence S.*; Phillips, R.*; Aljuchukwa, D.*; Katsirji, R.*; Fisman, R.*; and Hensler, T.*. Addiction Research and Treatment Corporation, Brooklyn, NY, USA. **National Institute on Drug Abuse, Rockville, MD, USA.

Objective. To examine the trends in demographic and HIV-related behavioral factors of IVDA enrolled in methadone treatment. **Methods.** Following informed consent, standardized questionnaires of drug use, sexual behaviors, and medical history were administered to IVDA recently admitted to drug treatment. Sera was analyzed for HIV-1 using ELISA and western blot techniques. **Results.** Year Number Tested Number (%) HIV Seropositive
1985 469 255 (54)
1986 263 158 (59)
1987 218 131 (60)
1988 222 115 (52)

The tendency in '85, '86 and '88 toward higher infection rates for non-whites, as compared to whites, did not hold for '87. Differences in HIV infection rates between these cohorts were most appreciated in black and male IVDA. Between 1987-8, there were important differences between IVDA and sexual behaviors. IVDA with white chest findings suggest modification of behaviors among IVDA, as the HIV infection rate may be equally explained by serostatus.

T.A.P.51 TRANSMISSION OF HIV BY SEXUALITY IN INTRAVENOUS DRUG USERS (IVDU)

McClellan, J.M.*; Jones, G.*; Davidson, C.*; Haimet, S.*; Barua, S.*; N.Y. State, Rockefeller University; *National Drug Institute, City Hospital, BIRMINGHAM, Scotland.

Objective. To establish those areas in which Birmingham based IDU had shared injection equipment. **Methods:** All IDU attending the Edinburgh Counseling Clinic were asked about injection practices including sharing equipment in non-Birmingham locations. **Results:** By the end of 1987, 1143 patients had attended the clinic of whom 376 (34.6%) were IDU, 17 had never injected in Birmingham. The mean age of the remaining 379 was 26 years (16-46) with a M/F ratio of 1.72:1. In 351 HIV status was determined and 110 (48.8%) of the 225 males and 73 (55.2%) of 139 females were positive. 101 (26.6%) IDU, 73 males and 28 females, admitted to sharing equipment in 140 non-Birmingham sites. Those had shared sites in Southern Europe and retrospective tests of stored sera showed that one seroconverted for HIV shortly after returning to Birmingham. This individual went on to share with numerous other users with later seroconversion dates. **Conclusion:** The IDU related HIV epidemic in Southern Europe began in 1981 and the unexpected mobility of drug users explain the pockets of IDU related HIV infection as well as other blood borne viruses in Southern Europe. This mobility must be taken into account when considering preventative strategies for HIV.

T.A.P.53 HUMAN IMMUNODEFICIENCY (HIV) AND HUMAN T-LYMPHOTROPIC (HTLV-1/II) VIRUS INFECTIONS ASSOCIATED WITH INTRAVENOUS DRUG ABUSE (IVDA).

Strawick, Rod, M.D., J. Sasseoff, G., and Harris, D. New York State Health Department, Albany, U.S.A.

Objective. To describe the prevalence of HIV and HTLV-1/II infections among people in N.Y. State with IVDA as a risk factor for the transmission of blood borne infections. **Methods.** Specimens submitted for HIV test from anonymous subjects with a history of IVDA (343 sera) of with no associated risk for HIV infection (1965) were tested for HIV and HTLV-1/II antibody by EIA and western blot. EIA reactive sera with HIV blot bands at 24 and 41 and/or 120/160 kd or HTLV-1/II bands at 24 and 46 and/or 65/68 kd were recorded as positive. Results were merged with age, sex, geographic origin and race/ethnicity data and analyzed on an sero-prevalence basis. **Results.** In IVDA subjects the prevalence of antibody to HTLV-1/II or HIV and HTLV-1/II was 5.6 and 4.1% respectively. In people with no associated risk it was 0.8% and 0.7%. For both populations studied, HIV prevalence was highest at age 30-39; HTLV-1/II in both HIV plus HTLV-1/II was higher at age 30 or greater. Proportion of IVDA sera positive for HIV also positive for HTLV-1/II was 142/845 or 7.8% of sera positive for HTLV-1/II also positive for HIV, it was 142/196 (72.4%). **Conclusions:** About 1 in every 13 IVDA subjects infected with HIV in N.Y. State is also infected with HTLV-1/II. Conversely, about 72% of HTLV-1/II infected IVDA subjects are infected with HIV.



**Session d'affichage
Poster Session**

T.A.P.54

HIV INFECTION AMONG INTRAVENOUS DRUG USERS (IVDU's) IN NYC
Truman, Benedicte, Johnson, J. S., Brown, L., Peyser, R., Peters, L., DeLuca, J., et al.

*New York State Department of Health, Albany, New York, USA, **Addiction Research Treatment Corp., NY, NY, USA, ***Beth Israel Medical Center, NY, NY, USA, ****New York State Division of Substance Abuse Services, NY, NY, USA.

Objective: To compare current HIV seroprevalence and risk factors among "new entrants" and "old clients" of Methadone Maintenance Treatment Programs (MMTP's) in New York City (NYC).

Methods: Since June 1986, sera from IVDU's at 28 MMTP clinics were tested blindly for HIV by ELISA and WB. Non-identifying demographic and treatment data were collected at entry or on annual physicals. Logistic regression models identified risk factors for infection in "new entrants" and "old clients".
Results: As of Jan. 1988, 33.4% of 1062 clients were HIV+. Data were complete for 403 "new entrants" (45.9% HIV+) and 305 "old clients" (27.2% HIV+). "New entrants" have higher infection rates than "old clients" in all subgroups.
RACE
BOROUGH OF RESIDENCE
Ever
Bl. Hisp. Wh. Bronx Brook. Manh. Queens St. Isl. Treated?
New 52.8 41.8 39.1 31.0 48.0 49.7 43.8 33.3 21.4
Old 32.1 37.9 17.0 28.6 19.4 35.2 14.6 12.5 84
HIV infection was associated with a history of previous treatment for drug abuse among "new entrants" (OR=5.0 CI=1.4,11.5), and with black race (2.2 (1.1,4.4)), Hispanic ethnicity (2.5,1.2,4.9) and Manhattan residence (2.8,1.2, 6.9) among "old clients".
Conclusion: In NYC MMTP's, "new entrants" are 1.7 times as likely as "old clients" to be HIV+. Prevalence was lower than previously reported by both groups.

T.A.P.56

HIV SEROCONVERSION IN A GROUP OF IVDAs (1985-1988)
Giorgio, Barbantini, S. Edo, T. Gola, S. Guerin, S. Lopez, F. Salmadori, et al.

Clinic of Infectious Diseases IRCCS S. Matteo University of Pavia - ITALY

Objective: To demonstrate the incidence of seroconversion for HIV in a cohort of IVDAs.
Methods: Since first months of 1985 a group of 491 drug addicts, followed by Drug Abuse Surveillance Organisms of Abbottegrasso (USL 73), Crema (USL 53) Sagenta (USL 72), Vigevano (USL 78) and Voghera (USL 79) in southern Lombardy, has been tested every six months for HIV antibodies.
Results: At June 1985, we found 253 seropositive IVDAs (1202 males and 51 females); at December 1988 28 of the previously negative drug addicts (16 males and 12 females) were found positive.
In the cohort of earliest HIV positive subjects 21 developed AIDS until now.
Conclusion: These data suggest that intravenous drug abuse put IVDAs at increased risk for HIV infection as long as drug behaviour continues, even followed by appropriate contacts, and this is not a good result of preventive measures.
So the possibility of sexual spread from IVDAs (many drug addicts, either women, either men, sell themselves for buying drug) to common people requires great attention.

T.A.P.58

SEXUALLY TRANSMITTED DISEASES (STD's) AND HIV SEROPREVALENCE IN A COHORT OF IV DRUG USERS
Miles, Ernest E., Vlahov D., Selomsen L., Chowdhry, N., U.S.A.

Objective: To correlate the history of a sexually transmitted disease and HIV seroprevalence in a cohort of active IV drug users (IVDU's).
Methods: A cohort of IVDU's, without AIDS, was recruited for a study of the natural history of HIV infection by community outreach. Histories of STD's at baseline were correlated with HIV seroprevalence.
Results: Overall 44 (44.7%) of 1780 participants were HIV seropositive at baseline. STD histories by HIV serostatus were as follows:

	HIV -	HIV +	P-Value (Chi-square/Fisher's)
Syphilis	17.5%	12.2%	0.005
Gonorrhoea	96.7%	92.9%	0.16
Genital Warts	5.0%	2.2%	0.09
Genital Herpes	7.7%	6.4%	0.34
Other STD's	18.9%	19.2%	0.77

Among male homosexual/bisexual IVDU's a syphilis history was strongly associated with HIV seropositivity (20/44; 45%) compared with HIV negatives (18/114; 16.7%; p < 0.001). Among heterosexual (65/972; 14.2%) of HIV seropositives and (143/1194; 11.9%) of HIV seronegatives had a history of syphilis (p < 0.05).
Conclusion: Our study suggests that sexual transmission may account for some HIV infections among active IV drug users, especially in those who are male homosexual/bisexuals. Prospective studies are required to more clearly define the risks of sexual transmission of HIV in IVDU's.

T.A.P.55

HIV SEROPREVALENCE IN INJECTING DRUG USERS IN SOUTH LONDON
1985-88
S. Sabin, J. T. McCann, M. S. G. Smith, et al.

Objective: To estimate the HIV seroprevalence in injecting drug users as monitored by an HIV testing laboratory in South London.
Method: The frequency of HIV antibody positivity in injecting drug users attending clinics and General Practitioners in the South London area was estimated. 555 men and 286 women were tested. 619 of those tested were over 25 years of age.
Results:

	Prevalence of HIV antibody in IVDU's									
	1985 No (%)	1986 No (%)	1987 No (%)	1988 No (%)	1985-88 No (%)					
Male	0 (130)	11 (203)	8 (198)	9 (141)	28 (553)					
Female	1 (61)	7 (90)	4 (115)	2 (75)	14 (286)					
Total	1 (193)	18 (293)	12 (313)	11 (216)	42 (843)					

These results compare with a seroprevalence of 19% among homosexual men and <1% in heterosexual men and women tested in the same areas over the same period. Most of those found to be HIV Ab positive (97%) were patients attending the sexually transmitted disease clinic requesting HIV antibody testing.
Conclusion: The HIV antibody seroprevalence in this group rose very rapidly but appears to have levelled off. The majority of those tested were over 25 years of age and gave evidence of having changed their needle sharing habits. More younger addicts need to be tested and outreach methods are being used to reach them.

T.A.P.57

HIV PREVALENCE AMONG DIFFERENT GROUPS OF INTRAVENOUS DRUG USERS IN SEATTLE, WASHINGTON
McGough, James P., Wood, R. E., Harris, N., Kleyn, J., Carlisle, M., et al.

AIDS Prevention Project, Seattle, Washington USA, **University of Washington, Seattle, Washington, USA ***King County Detoxification Facility, Seattle, Washington, USA

Objective: To estimate HIV antibody seroprevalence among different groups of intravenous drug users (IVDU's) in Seattle and King County.
Methods: IVDUs were tested at the AIDS Prevention Project (APP), a testing site promoted for persons at high risk of HIV infection, at the King County Jail, from the streets of Seattle, and at the County drug and alcohol detoxification facility.
Results:

	APP	Jail	Street	Detox	TOTAL
	Tested	Tested	Tested	Tested	Tested
Gay/bi men	356 (30.9%)	31 (6.2%)	11 (10)	10 (808)	408
Other men	254 (4.2%)	12 (2.4%)	15 (0.6%)	101 (5.0%)	356
Women	224 (2.6%)	42 (4.9%)	7 (0.6%)	56 (2.6%)	345
TOTAL	855 (14.6%)	161 (3.7%)	27 (0.9%)	167 (5.4%)	1216

Conclusion: Preliminary data indicate that HIV seroprevalence among IVDU's varies greatly by site. The prevalence is greatest among male IVDU's who report having had sex with other men.

T.A.P.59

SERO-EPIDEMIOLOGY OF HIV-1 INFECTION AMONG INJECTING DRUG USERS SEEKING HELP IN MONTREAL: 1985-1988
Brennan, Julie, Lapointe, F., Soto, J., Brabant, M., Vinciguerra, J., and Fauriol, M., et al.

CRC Andre-Viallet, Centre Hospitalaire Saint-Jacques, Université de Montreal, and **Laboratoire de microbiologie publique du Québec, Montreal, Canada.
Objective: To determine the prevalence and trends of HIV-1 infection among IVDUs hospitalized for detoxification and correlate seropositivity with risk factors.
Methods: Every IVDU hospitalized between March 1985 and Sept. 1988 had a serum taken, tested for Hepatitis B markers and stored frozen at -20°C in a serum bank. Sera were retested for HIV-1 antibodies using ELISA and RIBA & IFA confirmation tests. Patient records and serologic results were matched and analysed anonymously using an unlinked method.
Results: From a total of 294 patients, 13 were HIV-1 seropositive (4.4%). There was no association between HIV-1 infection and sex, age, ethnic origin, sexual orientation, prostitution, drug use, or mode of needle sharing. Of 234 patients with known sexual orientation, 224 were heterosexual. Only one of the seropositive was bisexual. Twelve of the thirteen seropositive were hepatitis B markers positive in contrast to 111 of the 281 negative (p < 0.001). The annual prevalence of HIV-1 infection at the Detox Unit was: 1985, 7.1%; 1986, 3.0%; 1987, 2.0%; 1988, 6.4%; overall, 4.5% (confidence limits: 2.2 - 6.7%).
Conclusion: HIV-1 infection prevalence in Montreal IVDUs seeking detoxification remained stable between 1985 and 1988 and is associated with the presence of hepatitis B markers. The opportunity for preventive strategies is great.

Session d'affichage Poster Session



Epidémiologie et santé publique Epidemiology and Public Health

Surveillance du SIDA et marqueurs de l'infection Surveillance of AIDS and Marker Infections

T.A.P.60 COMPARATIVE MONITORING OF HIV-SPREAD IN THE IVUO

T.O.P. OF BERLIN AND HAMBURG
Bischof, Friedrich*, Bornemann, R.*; Puschke, K.*; Rax, R.*; Pätz, W.*; Uebig, R.* et al.
*Friedrich Universität Berlin, **Humboldt Hamburg FRG, ***Justizvollzug Berlin (West), ****Karl-Bonhoefer-Nervenklinik Berlin(West), *****Justizvollzug Hamburg (West) (Justizvollzug West Germany)
Objective: Local monitoring of HIV-spread in IVUO population
Methods: Since 1985 nearly all cases of drug related deaths in Berlin(West) were HIV-AB tested: 86282; test ratio (78) 37%. Since 1988 we try to broaden the HIV-indicator-normally by including data of defined groups of living IVUOs* on a voluntary basis: entrants in detoxification, admissions in prison.

Results: In the autopsy cases the following seropositivity rates were found:

Region	1985	1986	1987	1988
Berlin	305	495	495	385
Hamburg	78	125	163	135

Because of selfselection of the data-gathering in the groups of living IVUOs we full of gaps, especially in Berlin. In Hamburg the positive test results in clinical diagnosis, or employment status. Individuals receiving ATW are detox-cases 1988 was 135 (18 73%), in prison cases 125 (18 93%), were very close to the autopsy rates. In Berlin the difference was great: detox cases 1988 295 (38 28%), in prison cases 125 (18 not known).
Conclusion: Seropositivity rates in drug related deaths seem to represent quite a realistic picture of the HIV-situation. In cities of similar structure the HIV-spread in the IVUO population may show great differences.

T.A.P.61 UNDERREPORTING OF AIDS CASES, SOUTH CAROLINA, 1984-1987

Comay, George A., and M. Alexander, B.A., Ed. PH
*Centers for Disease Control, Atlanta, Georgia, USA, **South Carolina Department of Health and Environmental Control, Columbia, South Carolina, USA
Objective: To assess the completeness and accuracy of AIDS case reporting in South Carolina.

Methods: Approximately 400,000 hospital discharge billing records from January 1984 through June 1987 were searched by computer for AIDS-defining conditions. The resulting 1,313 clinical records were manually reviewed.
Results: Of these, records for 335 discharges for 183 individuals were classified as being definitely AIDS-related by the 8/87 revised CDC AIDS case definition. 133 of these individuals met the older (pre 8/87) case definition, and should have reported to the State AIDS case registry. After controlling for reporting lags, 92 of these were indeed reported. Thus, 39.5% of all AIDS cases and 50% of those with an interval were not reported. Reported versus non-reported groups were not significantly different by age, race, sex, risk behavior, primary diagnosis, clinical diagnosis, or employment status. Individuals receiving ATW were significantly more likely to have been reported ($p < .001$). Percentage of cases reported by ICD 902 (down to 0/4 0/2). There was also a considerable range in reporting compliance among physicians.
Conclusion: There was considerable underreporting of AIDS cases in South Carolina for the study interval. Similar studies should be repeated in other states, and may have important implications for the interpretation of surveillance data and for planning in the epidemic.

T.A.P.62 USING DEATH CERTIFICATES (1985-1987) TO ESTIMATE THE

COMPLETENESS OF AIDS CASE REPORTING IN ONTARIO
L. Lilly, M.D., R. J. Johnson, E.M. Wallace*,
Epidemiologist, Public Health Branch, Ontario Ministry of Health*Assistant in Community Medicine, University of Toronto, Canada****Assistant in Public Health Branch, Ontario Ministry of Health, Toronto, Ontario, Canada

Abstract. The completeness of AIDS case reporting in Ontario was assessed by reviewing all AIDS death certificates compiled by the Registrar General between January 1, 1985 and December 31, 1987. Several demographic variables were used to match death certificates with cases reported to the provincial AIDS registry and the Census form and Dosing method was used to estimate the completeness of case reporting. The estimated completeness of case reporting was 80.9% in 1985 (95% C.I., 75.5% to 85.9%), 71.4% in 1986 (95% C.I., 67.4% to 75.6%), 75.3% in 1987 (95% C.I., 70.4% to 79.2%), and 75.1% overall for 1985-1987 (C.I., 71.2% to 78.0%). The completeness of reporting in 1985 was significantly higher than in 1986 (chi-square, $p < 0.01$) but was not significantly different from that calculated for 1987 (chi-square, $p > 0.05$). Cases who were never married were 1.5 times more likely to be reported in 1985 than in 1986, and there was a significant increase in the proportion of such unreported cases from 1985 to 1986 (chi-square, $p < 0.02$). Reporting was not associated with the patient's age, sex, occupation or place of residence. The deficiency in AIDS case reporting could adversely affect the long-term planning of health care resources and the development of programs to prevent and control the spread of AIDS.

Key Words: AIDS, Case reporting, Death Certificates, Registry

T.A.P.63 RISK GROUP DIFFERENCES IN REPORTED DEATHS IN AIDS PATIENTS

Berling, Olov*, Swelander, Eli, Karen, J.N.
AIDS Program, Centers for Disease, Atlanta, Georgia, USA

Objective. To determine any variation among risk groups in the percentage of AIDS cases diagnosed at death and in the delay by reporting date. Male, deaths of known AIDS patients are reported to CDC by state and local health departments. All deaths in adult patients diagnosed between 1984 and 1988 were examined. Patients with death in the same month as diagnosis were classified as diagnosed at death. The number of months between death and report was calculated for all deaths reported in 1988 (date of death report was first recorded in October, 1987). Risk group was defined by the mode of HIV transmission.
Results. For cases diagnosed in each of the years 1984 and 1987, 100-11% of AIDS cases in homosexual/bisexual males who were not intravenous drug users (IVDU) were diagnosed "at death," compared to 50-10% in heterosexual IVUDs diagnosed in the same years. Roughly one fifth of all transmission related AIDS diagnoses were made "at death" between 1984 and 1987. Deaths among heterosexual IVUDs were 50% more likely to be reported after a delay of 12 or more months than deaths in non-IVUD heterosexuals. Eleven percent of the known deaths occurring among homosexual/bisexual non-IVUDs in 1986 were not reported until 1988 compared to 19% of the heterosexual IVUDs who died the same year.

Conclusion. Both the proportion of cases diagnosed at death and the delay in reporting deaths may vary among risk groups. Survival estimates must consider these possible sources of bias. It may be desirable to estimate survival only among AIDS patients with reported survival of at least one year period (month or calendar quarter).

T.A.P.64 HIGH PERCENTAGE OF NON-REPORTED CASES OF AIDS IN

THE FEDERAL REPUBLIC OF GERMANY
Eckardt, Gert D.

Max von Pettenkofer-Institut, University of Munich, FRG.

Objective. Estimation of non-reported AIDS-cases in the FRG.
Methods. Questionnaires sent to all hemophilia treatment centers in the FRG revealed in October 1987 the presence of 183 hemophiliacs with HIV-antibodies. In addition, 1111 were registered as clotting factor associated cases of AIDS were officially registered at that time (44.8 %). In a similar evaluation done end of October 1988, the number of cases was 351, but only 133 (37.9 %) were registered. Between first and second evaluation the number of hemophiliacs with AIDS increased by 168, the number of registered cases by 51 (30.4 % of new cases registered).
Results. The data suggest an increase in percentage of non-reported AIDS cases. In 1987, reported cases in hemophiliacs show a decreasing trend: doubling time decreased to 18 months, but in still 13 months in reality. Assuming the same percentage of non-reported cases for all risk groups, not 2380 reported but 6807 cases of AIDS might have occurred in the FRG till November 1988. The doubling time case might still be 12 months instead of 13 months, as deduced from reported figures.
Conclusion. Probably more than half of all diagnosed cases of AIDS are not reported and the percentage of non-reported cases seems to increase. The complete voluntary reporting system of the FRG will not give completely reliable data.

T.A.P.65 ACTIVE SURVEILLANCE FOR PEDIATRIC HIV INFECTION IN LOS ANGELES COUNTY

Bevilacqua, Leonard V., Bann, S.J., Frederick, J., Chan, H., Brown, James, Towns, A., et al.

*Los Angeles County, Dept. Health Services, Los Angeles (CA), Calif.; **University of Southern California, L.A., Calif.; ***University of California, L.A., Calif., USA

Objective. To describe the development and implementation of an active surveillance system for pediatric HIV infection in Los Angeles County (LAC), California, and to present data from January 1982 through December 1987.
Methods. As of March 1985, pediatric and adult cases satisfying the CDC's surveillance criteria for AIDS were reported through a combination of active and passive surveillance measures. In March 1985, an active surveillance system for all cases of pediatric HIV infection (PHI) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to 12/86, adult AIDS cases increased overall by 298 and 40% among men. Sixty-three percent of all pediatric HIVs were male; 24% are dead. About one-third (100) of HIVs were seroepidemiologic (I-2) yet not classifiable as pediatric AIDS. Thirty-two percent had a parent at the time and 35% were among minorities. In contrast, among the 13 most recently reported HIV cases since September 1986, 7% had a parent at risk, and 75% were among minorities. Of the pediatric AIDS cases, none were had opportunistic infections, 14% had Lip and only 4% had Kaposi's sarcoma.
Conclusion. This active surveillance system for active surveillance system for HIV in children (1) was initiated. Cases were classified using the classification system for HIV in children (1) (see Table 1). Initial telephone survey and a supplemental information form is filled out on each case.
Results. As of December 31, 1987, 189 (PHI) (100%) had been reported; 50 (26%) of AIDS had AIDS. This represents a 22% increase in reported pediatric AIDS since March 1985. From 3/85 to

Session d'affichage Poster Session



Épidémiologie et santé publique Epidemiology and Public Health

T.A.P.66 MEDICAL SCHOOL SUBCONTRACT ENSURES STATE-WIDE ACTIVE AIDS SURVEILLANCE IN NEW JERSEY

Schneider, D. Jean, and Lavenhar, M.
UMDNJ - New Jersey Medical School, Newark, New Jersey, U.S.A.

- Objectives:** To expand New Jersey Health Department capacity to obtain surveillance data.
Methods: Unique subcontract with state medical school effected to produce increase in active AIDS surveillance activities on a state-wide basis.
Results: Two years of experience with subcontract resulted in:
1. State-wide active surveillance sites increased as responsibility for 12 sites (affiliated hospitals) was shifted to medical school.
2. Concentration on active rather than passive surveillance within New Jersey made possible.
3. Partnership provided data on approximately 40% of New Jersey AIDS cases.
4. Accessibility to hospital AIDS data improved by use of medical school personnel.
5. Teaching hospitals provided with accurate AIDS census data.
6. Retrospective surveillance activities made possible.
7. More complete and accurate AIDS data made available for CDC, state and hospital planning, resource allocation and development of intervention programs.

Conclusion: This unique partnership between a state health department and a state medical school has proven a successful method for expanding active AIDS surveillance efforts and has enabled New Jersey to lead the nation with the first total active AIDS surveillance system.

T.A.P.68 USE OF AUTOMATED MEDICAL DATA FOR AIDS SURVEILLANCE

Healy, Cyrus, Haskins, J.¹
¹Maryland Department of Health and Mental Hygiene, Baltimore, Maryland, USA.

- Objective:** To describe an evaluation method for AIDS surveillance using alternate data sources to identify unreported AIDS cases.
Methods: Maryland hospital discharge records from January 1, 1982 to December 31, 1987 were reviewed using an automated evaluation method for AIDS surveillance using alternate data sources to identify unreported AIDS cases.
Results: Hospital discharge records from January 1, 1982 to December 31, 1987 were reviewed using an automated evaluation method for AIDS surveillance using alternate data sources to identify unreported AIDS cases. A total of 831 admissions from 54 hospitals were then investigated. By December 1987, 623 (75%) had been reviewed. Of these 623 records, 55 (8.8%) were previously reported AIDS cases, 162 (26.0%) were AIDS cases who were not reported for HIV with an AIDS-indicative opportunistic infection, 31 (2.0%) records were not locatable, and 22 (3.5%) cases were found which were not previously reported.
Conclusions: According to this method of enhancing the surveillance system, 87% (57.4%) of all Maryland AIDS cases diagnosed between January 1, 1982 and December 31, 1987 were reported. It was found that the earlier coding methods were being used after the establishment of the ICD-9-CM code for AIDS in October 1986. In addition, it was shown that a much higher number of Maryland non-residents were using Maryland hospitals than anticipated. Finally, based upon this pilot study, this evaluation technique can be used on a periodic basis to routinely evaluate the surveillance system.

T.A.P.70 EVALUATING COMPLETENESS OF NEW YORK CITY CASE REGISTRY

Blum, S., Thomas P., Nicholas A., Miller G., Schultz S., and the others in the New York City Dept. of Health AIDS Surveillance Unit, New York City, NY, USA.

- Objective:** To categorize, as CDC AIDS cases or non-cases, persons with NYC death certificates (DCerts) giving AIDS, Pneumocystis carinii pneumonia (PCP), or Kaposi sarcoma (KS) as cause of death but not reported through routine surveillance.
Methods: All New York City DCerts 7/86-6/87 with AIDS, PCP, or KS as underlying cause of death were identified. The hospital records of those not already in the AIDS Surveillance Registry are being reviewed.
Results: Three thousand and one such records were identified of which 882 were not in the Registry. Follow-up is completed for 616; for 130 there is no hospital record and 4 were excluded. Among the other 482, 148 were missed by routine surveillance (31); 87 were reportable cases only according to the 9/87 expansion of the CDC case definition (CDC def) (11); 98 did not fulfill the CDC def only because of no serology (111); 1 had other HIV-related illness not fulfilling CDC def (19). HIV risk factors for these 482 by group (I-IV) and for cumulative NYC cases (17,754 as of 12/88) (V):
Risk Category I II III IV V
Men Sex w/MSM 15X 21X 39X 15X 51X
IVUD (IV Drug Use) 36X 46X 50X 62X 34X
MSM & IVUD 5X 6X 8X 6X 4X
Other 15X 27X 12X 18X 10X
Conclusion: Risk factor distribution differs significantly by type of HIV-related illness. DCerts are useful for evaluating routine surveillance.

T.A.P.67 EVALUATING RACIAL CLASSIFICATION AMONG NATIVE AMERICAN INDIANS WITH AIDS IN LOS ANGELES COUNTY, CALIFORNIA

Leib, Leslie; Karmali, P.; Holdeman, M.; Chane, E.; Yasa, T.; Conway, O.
Los Angeles Co. Dept. of Health Services, and AIDS Project Los Angeles, Los Angeles, Calif.
¹American Indian Prox Clinic, Long Beach, Calif., ²BHS, Calif., ³CDC, Atlanta, Georgia, USA

- Objectives:** To evaluate race classification, method of race assessment and case ascertainment of Native American Indians (NAI) with AIDS in Los Angeles County (LAC).
Methods: Nine community-based AIDS service organizations (CSAOs) in LAC were surveyed to determine the number of NAI AIDS cases in their client population and methods of race assessment. Death certificates for all male NAI age 15-54, from 1980 to 1987, were reviewed to identify cases possibly related to AIDS. The names of suspected deceased NAI AIDS cases were compared to the LAC AIDS surveillance registry. Personal identifiers were not available for active CSAO clients.
Results: The CSAOs reported that of their clients with AIDS, 61 were NAI (30 active and 33 deceased or inactive), compared to 6 AIDS cases (2 living and 4 deceased) among NAIAs reported to the LAC AIDS surveillance registry as of January 18, 1989. Twenty-five of 30 active NAI clients were re-interviewed regarding their sex; 8 (28%) clients were confirmed to be NAI and 17 were reclassified to other races. The 17 racially misclassified clients had selected *Native American* from a list of race categories included on the CSAO intake form. The names of deceased CSAO NAI clients were matched to the LAC AIDS surveillance registry; 27 of 33 (82%) were reported, of which only 1 was recorded as NAI. Of 108 deaths reported among NAI males age 15-54 between 1980 and 1987, 3 were AIDS-related and had been reported to the LAC AIDS surveillance registry; 1 was reported as NAI.
Conclusion: Race was reclassified for 68% of CSAO clients initially recorded as NAI. If the proportion of racially misclassified deceased clients is the same as that of re-interviewed active clients, then NAIs may be under-represented by as much as 50% in LAC AIDS surveillance statistics.

T.A.P.69 A RECORD LINKAGE STUDY TO DETERMINE THE DEGREE OF UNDER-REPORTING OF AIDS CASES IN CANADA

Chilavert, Ljiljana; Craib, K.**, Coles, R.**, Schechter, M.**, Johnson, J.**, Elmle, K.**, University of Toronto, Toronto, Ontario, Canada, **University of British Columbia, Vancouver, B.C., Canada, ***Federal Centre for AIDS, Ottawa, Ontario, Canada.

- Objectives:** To estimate the rate of under-reporting of AIDS to the Bureau of Epidemiology & Surveillance, Federal Centre for AIDS (FCA), Canada.
Methods: In January and October 1988, initials, birthdates and place of residence of 66 cases of AIDS known to the Toronto Sexual Contact Study (TSCS) and 64 cases known to the Vancouver Lymphadenopathy-AIDS Study (VLAS) were sent to the FCA along with comparable information on 1041 other study participants who were not known to have AIDS. A manual record linkage was conducted by the FCA linking this data to the national registry of reported cases.
Results: The rate of under-reporting ranges from 10.5% (7/64) (VLAS) to 18.2% (10/66) (TSCS). The TSCS data show that under-reporting has increased from 19% in 1984 to 40% in 1987, whereas rates have been stable in the VLAS. In the TSCS, AIDS diagnoses are established and reported by physicians not involved in the research in contrast to the VLAS where physicians involved in the research are also responsible for reporting cases.
Conclusions: If the under-reporting rates observed in this study are reasonable estimates of the national rate then 253 to 423 cases of AIDS have not been reported as of January 1, 1989. Differences in responsibilities for case reporting between centres may explain differences in observed rates of under-reporting.

T.A.P.71 LINKAGE OF RECORDS OF PERSONS IN THE NEW YORK CITY (NYC) AIDS CASE REGISTRY WITH DEATH CERTIFICATES FILED IN NYC

Blum, S.,*; Bontenborg K.**, and the others in the New York City (NYC) Dept. of Health (DOH) AIDS Surveillance Unit, NYC, USA, **NYC DOH Office of Epidemiology and Statistical Services, NYC, USA.

- Objective:** To analyze a data set which links AIDS Registry (AR) records of New York City (NYC) cases with their NYC death certificates (DCerts).
Methods: A computerized search of all NYC DCerts 1980-87 linked cases in AR to DCerts. The linking process was iterative and utilized sequentially less stringent criteria for the identification of possible matches.
Results: Among the 11,132 files with name known in AR, 7,052 (63%) were linked to DCerts. Among the 7,052, 17X had not had vital status updated prior to linking the files. Doert underlying cause Number (%) of 7052 cases
279.1-042-044 136.3, 173/ AIDS, HIV-related, PCP, KS 6274 (89.0)
485-486/Broncho/Pneumonia, organism unspecified 112.7 (1.6)
010-018/Tuberculosis 28 (0.4)
Other HIV-associated condition (cf. *MMW* 36 No.3-7) 102 (1.4)
Other ICD-9 Codes 388 (5.5)
Cases 485-4 and 304.9 are more common causes of death among AIDS cases whose DCerts are in the surveillance data set than other causes of death.
Conclusion: Linkage of AR files with DCerts is a useful tool for increasing the information available for individual cases and for updating vital status.

Session d'affichage
Poster Session



Epidémiologie et santé publique
Epidemiology and Public Health

T.A.P.72 TRENDS IN THE OUTPATIENT DIAGNOSIS OF AIDS: IMPLICATIONS FOR EPIDEMIOLOGIC ANALYSIS AND SURVEILLANCE

Winkles, Sharon*, Lafferty, M*, Roney, J*, Burlich, M*. *Seattle-King County Public Health, Washington State Department of Social and Health Services, Seattle, Washington, USA.

Objective: We sought to monitor trends in the site (inpatient vs. outpatient) of AIDS diagnosis. This information is used to varying active AIDS surveillance programs in interpreting epidemiologic data.

Methods: The site of initial AIDS diagnosis was determined as part of routine AIDS surveillance and entered into the AIDS computerized database.

Results: An increasing proportion of AIDS cases in King County are diagnosed outside of hospitals. Prior to 1980, 52 of cases were diagnosed as outpatients (OPDs), most rising by year to 23% of cases diagnosed in 1988.

Year	# AIDS Cases	No. OPDs (%)
1982-83	155	35 (23)
1986	183	19 (10%)
1987	244	52 (21%)
1988	219	55 (25%)

Conclusions: Most local AIDS surveillance programs depend heavily on hospital-based reporting and validation studies to determine completeness generally use hospital-based methods such as discharge databases. Our data indicate that the proportion of AIDS cases with outpatient diagnosis is rapidly increasing, making hospital based surveillance systems less effective. Outpatient diagnosis may also influence the analysis of epidemiologic parameters. For example, of Washington State AIDS cases diagnosed prior to 1988, cases with outpatient diagnosis survived significantly longer than other cases (41.1 months vs. 31.8 months). Confirmation of these trends in other jurisdictions is needed. Provider and clinic-based surveillance and validation techniques should be developed in light of these findings.

T.A.P.73 HOSPITAL-BASED AIDS REPORTING IN A HIGH INCIDENCE AREA, HOUSTON, TEXAS, USA

Colin, N.J. Falletti, Robert L. & Pharo, A.F.
Bureau of Epidemiology, Houston Dept. of Health & Human Services, Houston, Texas, USA

Objective: To provide a mechanism to facilitate and evaluate the timeliness and completeness of AIDS reporting in selected hospital areas of an indigent core hospital.

Methods: The selected hospital areas were evaluated through observing and interviewing staff to assess current reporting practices. Recommendations were made based on the assessment. Recommendations included implementing a new reporting system utilizing a re-designed report form and protocol. These changes were carried out in a pilot study for two months. The pilot consisted of three stages, education, implementation, and evaluation of the program.

Results	Before Pilot May-June 1988	During Pilot Nov-Dec 1988
Number of cases	20	29
Mean log time (Dx to Report)	19	3.9 months
Completeness	0%	77%

Conclusions: It has been generally accepted that in areas of high AIDS incidence hospitals are experiencing limitations in time and staff to report AIDS cases. With the implementation of this pilot, there has been an increase in case reporting at the facility. Through assessment, education and tailored procedures, hospitals in high incidence areas can continue to meet their legal obligation to report AIDS cases to the local health authority.

T.A.P.74 EVALUATION OF AIDS CASE REPORTING IN MASSACHUSETTS

O'Neil, Kathleen*, Reine-Sacer, H*, Bakaraian, L***, Day, J***, Seage, G.* *Boston and **Massachusetts AIDS Surveillance Program (MASP), Boston, MA, USA

Objective: To assess completeness and timeliness of MA AIDS case reporting.

Methods: To validate timeliness of reporting, MASP modified inpatient control logs and case lists at 20 reporting sites with >25 cumulative cases. Three-patient cases were recorded. Death certificates (DC), tumor registry (TR) and Necroscopist (N) reports were also reviewed for unreported cases. The timeliness (reporting delay) of cases reported in 1987 and 88 was calculated as months between diagnosis and report.

Results: Completeness. Ninety-three unreported cases were found in the audit, representing 7% of all cases diagnosed at audited hospitals. No differences were found in underreporting rates by risk, sex, race, or case definition. Rates differed by site; 3 hospitals had 0% of unreported cases. Underreporting was mostly due to a lack of individuals assigned the duty to report at these sites. DC, M, and TR reviews found 59 cases, 3% of all cases diagnosed. Timeliness. Of reported cases, 70% are received within 2 months of diagnosis; 90% within 6 months. No differences in reporting delay were found by risk, sex, race, or case definition; however, differences by site were significant.

Conclusions: Regular audits of hospital infectious control logs as well as reviews of M, DC, and TR reports are needed to maximize reporting completeness. MA AIDS case reporting is 92% complete, with 90% of reported cases received within 6 months after diagnosis.

T.A.P.75 DMAC - A software for cooperative epidemiology of HIV infection

Ruel G. Lander, S. Longhini, D. Jaffar, A.J.
Centre Coopérative de Données en Épidémiologie de l'Université Moncton, MONCTON, CANADA

Objective: The French Ministry of Health has set up a national system of information on HIV infection based on 33 major hospitals (Centres d'Information de la Santé et d'Immuno-diagnostic Humain: CII) scattered all over the country. Concerning epidemiology, the aim of the system is to provide a global view of the infection as it differs among and in a core for further collaborative clinical/epidemiological studies.

Method: A software (DMAC - Dossier Minimum Annuel Commun) has been derived to facilitate the cooperative epidemiology between all collaborating centers. It runs on IBM PC compatible, with MS-DOS.

Results: The functions of the software include: derivation of an anonymous code corresponding to each patient (Sex, Ethnic, Surname, Sex, Marital, Age, Date of Birth, 1988, 82, 84-87) which grants confidentiality but allows to automatically retrieve the patients who consult in different places and correct accordingly the national database; data entry and editing of the information; at each visit of follow-up automatic comparison of the status of the patients according to CDC or ICD-9; automatic generation of the notification of AIDS in the Central Division of Health whether the patient satisfies the criteria of AIDS; coding of the file using the software of the Versant which is used to fully guarantee the security when data are exchanged between the clinical centers and the Coordinating Data Center; minimal facilities to allow each participating center to analyze locally its own data. The computerized information include: only those biological measurements and clinical data which, by nature, cannot have been found to be routinely recorded on retrospective patients. Modifications of the software can easily be performed for those clinical centers who want to derive collaborative studies for which additional information have to be collected.

The system has received the agreement of the Commission Nationale de l'Information et des Libertés. The written and informed consent of the patient must be obtained.

The software may be obtained upon request to the coordinating data center.

T.A.P.76 TEMPORAL TRENDS FOR PAST SEXUALLY TRANSMITTED DISEASES IN MEN WITH AIDS IN SAN FRANCISCO


Finkel, Daniel W.*, Hollander, J.M.***Ziegler, J.M.***, Cadden, M.***Vulberding, P.A.***
Medical Services of * San Francisco General Hospital, * University of California, SF, * PA, * Miley Hospital, UCSF, San Francisco, CA, USA.

Objective: To describe the temporal trends of the last prior sexually transmitted diseases (STD) in patients with AIDS in San Francisco, in conjunction with changes of sexual practices which may also transmit HIV.

Methods: The UCSF AIDS Registry has collected detailed medical histories since 1985 from a cohort of 2605 individuals who had the dates of their last episode of syphilis, gonorrhea (GC), and hepatitis B as well as dates of HIV associated conditions and onset of AIDS.

Results: Dates of last GC (n=1497), syphilis (n=770), and Hepatitis B (n=544) which peaked in 1980 and by 1982 were approximately 50% of the 1980 rates. The hepatitis B rate fell most rapidly, even though affecting the smallest proportion of the cohort probably reflecting saturation of infection in a subgroup with the highest behaviors. The mean time from hepatitis B to AIDS onset was 8.3 years (n=240) and from syphilis 7.8 years (n=144) which corresponds to estimates of the mean incubation time of HIV in AIDS. Of 645 men with GC who developed AIDS 45 (7%) had GC within 1 year, 35 (5%) 2 years before, 82 (13%) 3 years before AIDS onset. The decreasing rate of infection may reflect safer sex education and for the development of professional syndromes.

Conclusions: The use of prior STD peaked and began declining even before there was an awareness of AIDS. However, as indicated by GC which was widely acquired within one year of onset of AIDS by 14 patients, there is a need for continued interventions to slow transmission before HIV sexual practices.



T.A.P.77 IMPACT OF THE REVISION OF THE OLD AIDS CASE DEFINITION ON CASE REPORTING

Halliday, Guy*¹, Minkley, J.*², Rogers, A.¹

Objective: To describe the impact of the September 1987 revision of the AIDS case definition on case reporting through December 31, 1988.

Methods: Following the AIDS case definition revision, the Division of AIDS Surveillance contacted all reported cases to whether they met the older case criteria or the new, broader definition. Inexpensive case audits were conducted to verify the accuracy of reporting using hospital discharge records and by re-interviewing of previously-reported cases which had met the older case definition.

Results: The percentage of cases meeting each case definition by December 31, 1988 is as follows:

Definition	Before 1985	Year of Diagnosis	1987	1988	Total
Old	125 (76%)	107 (86%)	336 (72%)	339 (72%)	799 (82%)
Revised	31 (18%)	18 (14%)	110 (23%)	127 (27%)	295 (30%)
UNA	0	0	276	646	922

The 703 revised definition cases do not include 41 cases that were reported as revised definition cases but developed conditions which reclassified them under the old definition. Of these 292, 127 (44.7%) had died by the end of 1988 without having been reported as progressing to old definition AIDS. This resulted in a 30.6% increase in reported cases (168 total cases) if permanent revised definition cases due to the revised AIDS case definition, in the 10 month period after implementation.

Conclusions: The revision has had a number of consequences. First, patients now can meet case criteria without being admitted to a hospital. To minimize resource requirements, surveillance systems should place greater emphasis on out-patient clinics and private physicians' offices. Second, revised definition cases who succumb before meeting old definition criteria suffer special attention. Third, outcomes of future cases need to reflect the revision. The increased sensitivity of the revised definition must be taken into account when planning for future resources needs of AIDS centers.

**Session d'affichage
Poster Session**



T.A.P.96 COMPARISON OF RISK FOR HIV INFECTION AMONG SELF-REFERRED AND PROVIDER-REFERRED HETEROSEXUALS IN A STUDY OF HIV TRANSMISSION
Laufer, L.; Feingold, L.; Zieler, A.; Meyer, Kenneth.
New England Behavioral Health Study, Fortuick, N.I., U.S.A.

Objective: To assess risk for a self-referred population-based cohort compared to a provider-referred group in a prospective HIV transmission study, and to assess efficiency of outreach recruitment in reaching at-risk groups.
Methods: Risk assessment interviews and serologies from the first 210 participants in a prospective study of the heterosexual spread of HIV. Outreach includes TV and radio announcements, newspaper ads, brochures, booklets, seminars, talks on college campuses and informing providers serving populations at risk.

Results: Of the first 215 seronegative, 91 were provider-referred and 124 were self-referred. 41% of the provider-referred participants are HIV+, compared with 7% of self-referred. 50% of self-referred participants were more likely to be female (52% vs 48%), young (11% in the 18-24 age group vs 3% in the older age groups), and white (41% vs 43% for all other ethnic categories). Self-referred were more likely to have had 2 or more partners in the last year, but less likely to know their partners' risk (52% vs 38% of provider-referred did not know their partners' risk). Self-referred were also more likely to have had 10 or more lifetime partners (56% vs 44%). Self-referred participants were less likely to use condoms (59% reported "regular" or "never" vs 41% of provider-referred), and were twice as likely to consider themselves at an or slight risk for HIV infection (33% vs 13%).
Conclusion: Self-referred seronegatives are less likely to perceive themselves at risk but may be, due to having multiple partners of unknown risk status, and not practicing safer sex.

T.A.P.98 HETEROSEXUAL TRANSMISSION OF HIV: A RECEPTION STUDY.
The University of California, San Diego, La Jolla, CA, U.S.A.
Community Study of HIV Infection and AIDS Risk Factors

OBJECTIVE: To determine risk factors of male-to-female HIV transmission.
METHODS: Between March 87 and October 88, 201 couples were recruited from 6 European countries. All seronegative females and their heterosexual partners (HP) are collected every 6 months. HP presenting risks for HIV infection other than sexual contacts with the IC were excluded. The cross-sectional analysis of data from the first interview is presented.
RESULTS: Of 201 females HP, 49 were HIV+. Male IC were mostly TW0 (64% or bisexual) (184). The following 3 risk factors were identified: practice of anal sex (OR=2.2 [1.9-2.6]); male index with full-blown AIDS (OR=1.1 [1.1-1.1]); history of sexually transmitted disease (STD) in the past 5 years for the IC and/or the HP (OR=3.0 [1.9-4.8]). Lymphocyte counts were available for 131 male IC. HIV male transmitters (IC=HP+) had lower CD4 (p<0.001) than non-transmitters (IC=HP-). Total lymphocyte counts tended to be lower in seropositive than the difference was not significant. P04 antigen test was performed for 100 male IC. The risk listed for a positive test was 1.8 [0.9-4.8]. Duration of relationship (median 3 years), frequency of sexual contacts, sexual practices other than anal sex, and contraceptive behaviour were not found to be associated with partner infection.
CONCLUSION: The great influence of the 3 identified risk factors on male-to-female transmission is shown by differences in HIV prevalence in partners:

Sex of IC (years)	0-5 (years)	6-10 (years)	11-15 (years)	16-20 (years)
Male IC AIDS	0	1	2	3
Male IC STD	0	1	2	3

T.A.P.100 BEHAVIOR MODIFICATION IN COUPLES ENROLLED IN A STUDY OF HETEROSEXUAL TRANSMISSION
Paterson, J.; Collins, N.; Goss, S.; Morono, A.; Alpert, J.; Waddy, C.
University of California, San Francisco, California, USA

Objective: To evaluate behavior change in couples who participated in a prospective study of heterosexual transmission.
Methods: We provided education and counseling about safe sex practices as a component of our heterosexual partner study. Participants were evaluated every six months following entry into the study. Behavior at enrollment and last follow-up is compared.
Results: 54 couples were interviewed of which 43 were discordant (index HIV+, the partner HIV-). Amount of sexual intercourse among the discordant couples at last follow-up is as follows: no intercourse = 2/43; less intercourse = 30/43; same amount of discordant couples having sex intercourse = 7/43. Condoms were used by 24/30 of the discordant couples having sex intercourse. By 1/3 of those having the same amount of intercourse, and by 6/7 of those engaging in more frequent intercourse. Anal intercourse was practiced by 8 of the discordant couples at trials, only 4 of whom used condoms. Only 2 of those couples continued the sexual practice by the time of last follow-up, both of whom used condoms.
Conclusions: Partner referral and provision of education and counseling in a heterosexual partner study continues to remain an effective vehicle for behavior modification. Failure to practice safer sex results from unwillingness, on the part of the partner, to adopt such measures of risk reduction.

**Epidémiologie et santé publique
Epidemiology and Public Health**

T.A.P.97 HETEROSEXUAL BEHAVIOR AND HIV STATUS IN A COHORT OF PERSONS AT INCREASED RISK FOR HIV INFECTION
Meyer, Kenneth; Zieler, A.; Laufer, L.; and Laufer, D.
New England Behavioral Health Study (NEBHS), Brockton, U.S.A.

Objective: To correlate heterosexual activity and HIV status in a cohort from a region where almost 6% of the new HIV+ are heterosexual.
Methods: Cross-sectional analysis of interviews and serologies from the first 215 seronegatives of a community-based prospective study of the heterosexual spread of HIV in U.S. New England.
Results: 22/104 (21%) of the women and 24/104 (23%) of the men were HIV+. 40/74 (53%) of the HIV+ subjects and 39% of the whole cohort are or were IVUDs 61% of the cohort is white. Other notable results include:

HIV+ men	HIV+ women	HIV- men	HIV- women
>10 lifetime partners	13	102	21
>10 partners in the past year	13	102	102
Sex with known high risk partners	67	50	44
History of STD (ever)	62	372	302
IC does not use the condom	202	502	442
IC with known high risk partners	67	50	44

Conclusion: Although 77% of the HIV+ subjects perceived themselves to be at increased risk to develop AIDS, 40% of the seronegatives were men with known high risk partners in the past year, usually steady, non-paying partners. Most of the HIV+ subjects in this cohort are IVUDs, but many who are HIV+ knowingly engage in unsafe sex. Risk reduction programs may have to target couples and do more than identify risky behaviors.

T.A.P.99 Alberto Saccaro, and the Italian Multicenter Study Group on HIV Heterosexual Transmission, Infectious Diseases Clinic, University of Milan, Milan, Italy.

Female steady partners of HIV-infected subjects, without other risk factors for infection, have been enrolled since January 1987 in a study of the role played by behavioral and biological variables in heterosexual transmission of HIV infection. Every HIV positive subjects observed at participating centers was considered an index case (IC) and asked about their heterosexual partner(s). Every partner not already known as HIV infected was invited for screening test and interview. The interview concerned sexual behaviour and contraception in the contacts with IC, previously sexually transmitted diseases (STD) and HIV hepatitis were investigated as well. HIV infection was checked by two immunoenzymatic assays and confirmed by western blot. Data about the IC were collected through medical records. Preliminary analysis on 235 female has confirmed previously reported risk factors such as history of STD and genital infections and anal sex. Other more controversial possible risk factors such as length of relationship and frequency of sex have been investigated and found, with some limitations, to be associated with HIV transmission. Conclusions have been thoroughly investigated and found to be protective. Data on recruited population by May 89 will be presented and discussed, with particular reference to controversial matter.

T.A.P.101 CHANGES IN SEXUAL AND REPRODUCTIVE BEHAVIOR IN HETEROSEXUAL COUPLES AFTER HIV TESTING
Vogler, Mary; Dupan, L. and Seidlin, M.
New York University School of Medicine, New York, NY, U.S.A.

Objective: To determine the impact of HIV testing on sexual behavior in heterosexual couples. Data from a prospective study of heterosexual transmission.
Methods: Partners (Pa) of infected individuals (I) were enrolled if Pa had never used IV drugs, had 2-10 episodes of vaginal intercourse (VI) with I, were not separated from I and were capable of additional intercourse with I.
Results: 3 couples were available with a mean duration of follow-up of 12.4 months. HIV were (22). Because of drug use, 10 were HIV+ at entry, none seroconverted during the period of observation. 54% of HIV+ and 25% of HIV- Pa had used non-IV drugs in the year prior to entry. There were no significant differences in marital status, length of relationship, education, or family income between HIV+ and HIV- Pa. All couples were primarily monogamous. All Pa who reported a change in sexual practices after testing, 4 HIV+ and 3 HIV- Pa became abstinent. The others instituted condom use for VI, but 66% of intercourse (AI) prior to I's reported incident sex. Half of the couples reported anal sex. Pa prior to testing only one couple continued to have AI after testing. Seven Pa were pregnant at the time of their first test, 4 of whom were HIV+. One HIV+ and 3 HIV- completed the pregnancy. Two seropositive occurred 4 after HIV testing, but HIV+ who claimed to be using safe sex practices.
Conclusions: HIV testing of Pa resulted in safer sexual practices, however Pa using condoms for VI do so inconsistently. Because such gaps were especially frequent among HIV+ Pa vertical transmission of HIV remains a persisting risk.

Session d'affichage Poster Session



Epidémiologie et santé publique Epidemiology and Public Health

T.A.P.102 HIGH PREVALENCE OF HIV-1 ANTIBODIES IN STD PATIENTS WITH GENITAL ULCERS

Debrework Zewdie,¹ Abdurrahman, M.², Ayuhnia, S.³

¹Med. Coll. Trikebe, ²Yamanba, Bahir Dar, ³et al.

* National Research Institute of Health, Addis Ababa, Ethiopia.
** Araris Clinic, Addis Ababa, Ethiopia.
*** ALERT, Addis Ababa, Ethiopia.

Objective. To determine the prevalence of HIV-1 infection in STD patients with genital ulcers.

Methods. Patients attending an STD clinic were randomly selected. Blood specimens were obtained from patients with a past and present history of genital ulcer disease screening for HIV-1 antibody was tested using ELISA (Wellcozyme) and confirmed by Western Blot (BLORAD).

Results. Of the 226 (75 females and 151 males) tested, 63 (27%) were seropositive for HIV-1. The seroprevalence rate in those with past history of genital ulcer disease was 34.7% and 28.6% in patients with gonorrhoea.

Conclusion. The high seroprevalence rate is indicative of the role other STDs play in the transmission of HIV infections in hyperendemic STD areas. The prevention of other sexually transmitted diseases and the behavioral change along with this may be one way of curbing the AIDS epidemic in these areas.

T.A.P.104 PRELIMINARY ANALYSIS OF FACTORS ASSOCIATED WITH SEROCONVERSION IN A STUDY OF HETEROSEXUAL SEXUAL TRANSMISSION OF HIV IN MONOGAMOUS COUPLES

Nichols Margrett, Parooki P., Sampson G., Leibel J., Kennedy M.J. - Woodhull Medical and Mental Health Center, Brooklyn, NY, USA

Objective. To present a preliminary analysis of factors associated with seroconversion in a study of heterosexual sexual transmission of HIV in a cohort of monogamous couples.

Methods. The Northern Brooklyn Partner Study, begun in September 1988 with funding from the CDC, is a three year longitudinal study of monogamous heterosexual couples in which one partner has as his/her only risk factor sexual contact with the other partner. The sample is drawn from a community based primary health care facility which services a population that is 93% black or Hispanic and 86% IVDU's and their sexual partners. Data gathered are retrospective as well as prospective, and include sexual and drug use behavior, psychological measures, and medical parameters (stage of disease of index partner, p-24 antigen, HIV cultures, concurrent VD, etc). All subjects are reinterviewed and examined at 3 month intervals.

Results & Conclusions. Preliminary data presented here will be a comparison between couples where sexual transmission has already occurred (concordant couples), and couples where the exposed partner is seronegative at the time of entry into the study (discordant couples). Data will be presented on at least 10 discordant couples, with at least 10 concordant couples used as a comparison.

T.A.P.106 RISK OF HETEROSEXUAL TRANSMISSION OF HIV-1 FROM RECIPIENTS OF BLOOD AND BLOOD PRODUCTS

Transfusion Safety Study Group* represented by **Donegan,**

Elizabeth.**

*Transfusion Institutions, New York City, Miami, Detroit, Seattle, San Francisco, Los Angeles, USA, **University of California, San Francisco, California, USA.

Objective. To assess the potential for transmission of HIV-1 by persons infected by contaminated blood, to heterosexual contacts before and after learning about their status.

Methods. The Transfusion Safety Study is a longitudinal study of recipients of blood and blood products. Information concerning sexual behavior prior to and at 6-month intervals after enrollment was obtained by interview and evaluated for anti-HIV-1 (+) subjects probably infected through blood reproduct

Results. 522 anti-HIV-1 (+) subjects probably infected through blood reproduct one or more heterosexual contacts between 1979 and enrollment. This potential sexual exposure of others included prostitutes (20 subjects). After informed consent, 337 of 469 with follow-up continued to have sexual contacts. Of these, 80 (21%) reported that they were sexually active with multiple partners. Two (10%) of 21 anti-HIV-1 (+) primary sexual partners also continued having sex with additional partners.

Conclusion. Transfusion-transmitted HIV-1 infections, although responsible for a small percentage of all infections, increase the reservoir in the community and the potential for further transmission through heterosexual contact. (Sponsored by Contract No. N01-HB-7003 of the National Heart, Lung, and Blood Institute.)

Transmission hétérosexuelle (partie 2) Heterosexual Transmission (Part 2)

T.A.P.103 HIV-1 TRANSMISSION IN HETEROSEXUAL COUPLES C.Papetti, A.H. Pesce, I.Mezzarona, E.Pinter, G.O'ffizzi, G.Luzi and F.Aiuti

Dept. of Allergy and Clinical Immunology, University of Rome "La Sapienza", Rome, Italy

Objective. - To study immunological features and transmission risk in heterosexual couples with one seropositive partner.

Methods. - 43 heterosexual couples were evaluated; one partner was seropositive at the first medical check who previously belonged to a high risk behaviour category. The study included 34 seropositive at risk males and 9 females. Number of sexual intercourse, condom use, sexual behaviour, immunological features were evaluated for each couple.

Results. - At the first control 17 couples were found to have both positive partners, whereas 26 had seronegative partner not belonging to a risk category. After one year follow up 2 out of 26 seronegatives were infected (77%).

Conclusions. - Among the evaluated parameters condom use was found to be important to prevent HIV transmission: 95% of couples with both infected partners did not use condoms, whereas in 42% of couples with one seropositive partner the condom was not correctly applied. Among the immunological parameters CD4+ T lymphocytes and skin tests were found to be relevant biological conditions favouring HIV-1 transmission from a seropositive subject to a seronegative one.

T.A.P.105 THE RISKS FOR HETEROSEXUAL HIV TRANSMISSION FROM INFECTED BLOOD TRANSFUSION RECIPIENTS

Ward, John¹; Perkins, R²; Donegan, E³; Ou, C-Y⁴;

Leussink, S⁵; Geynor, S⁶; et al

¹CDC, Atlanta, GA; ²Trinity Blood Bank & ³Univ. Ca. Med. Ctr., San Francisco, CA; ⁴Health Dept. & ⁵Brooklyn Center, New York, N.Y., USA.

Objective. To identify risk factors for heterosexual HIV transmission.

Methods. HIV-infected transfusion recipients and their partners were asked about sexual practices, medical history, and examined and tested for signs of infection; polymerase chain reaction (PCR) with SE 38-39 primer pairs was used to identify HIV genetic material in peripheral mononuclear cells.

Results. Through 1988, 74 HIV-seropositive recipients were identified and 39 had partners; 5 (19%) of 30 female partners and none of 9 male partners were HIV-seropositive. When tested by PCR, specimens from 29 seropositive partners were PCR-negative; 20 of 24 specimens from seropositive recipients and 3 of 3 from seropositive partners were PCR positive. The 39 recipients with partners had been infected for a median of 60 months (range 11-108 mos.); 14 (36%) had AIDS. Partners of recipients with AIDS were not more likely to be infected compared to other partners (2/14 vs. 2/25). Although compared to uninfected female partners, infected wives tended to be older (38 yrs. vs 30 yrs.), to have fewer sexual contacts (median 84 vs. 186, p=.17), and to more likely bleed after intercourse (1/4 vs. 3/25, p=.46), these differences were not statistically significant.

Conclusion. HIV-seropositive partners had no evidence of occult infection. A recipient having AIDS was not associated with HIV heterosexual transmission. Older age and bleeding after intercourse suggest that age-associated changes in the vaginal mucosa may facilitate HIV transmission.

T.A.P.107 NO MORE SEROCONVERSIONS AMONG GROUPS OF PATIENTS OF THE BONY DEMOPHILIC COHORT STUDY

Kanok, Berndt, S.; Niese, D.; Brackmann, H.H.;**

Euler, P.*; van Loon, B.**; Kramert, J.***

*Universitätsklinik Bonn, FRG, **Institut für experimentelle Hämatologie, Bonn, FRG, ***Massachusetts Institute of Technology, Cambridge, MA, U.S.A.

Objective. To evaluate the risk of heterosexual HIV-transmission. **Methods.** In 1981, 150 HIV-negative female partners of HIV-positive hemophiliacs were informed about possible transmission risks and enrolled in a prospective study. Both Elisa and Western Blot were performed at intervals of 6 to 12 months.

Results. 7 couples stopped having sexual contact. Regular condom use was reported by all but 6 of the remaining couples. On one occasion, one woman had a borderline Western Blot result which was not reproducible. All other women always tested negative.

Conclusion. Barrier contraceptives used in monogamous relationships seem to be efficient in preventing heterosexual HIV-transmission.

Session d'affichage Poster Session



Epidémiologie et santé publique Epidemiology and Public Health

T.A.P.108 REAL VALUE OF SERONEGATIVITY IN LONG-TERM EXPOSED SEXUAL PARTNERS OF HIV-1 INFECTED HEMOPHILIACS
Picchio, G., Bazzani, M., Balon, A., Mochini, J., Pichini, G., Pérez Bianco, A.
IDR696, Academia Nacional de Medicina, Buenos Aires, Argentina.

Objective: To investigate, using a sensitive virus culture method, whether seronegativity in female (spouses of HIV Ab pos. hemophiliacs) (Hem) was due to undetectable Ab levels or was really reflecting absence of infection.
Methods: Virus culture was performed on PBMCs from Group (G) 2: hem with AIDS; G2/VL hem; 2 female-sexual partners and 1 nonhem/asymptomatic HIV-pos individual; G2:2 hem with PGL. Four sexual partners were defined as asymptomatic HIV Ab-neg individuals who had maintained a seronegative sexual relationship with an HIV Ab-neg hem for a minimum of 2 years without the use of barrier contraceptives. Virus culture was also performed on 2 low-risk HIV Ab-neg individuals. HIV Antigen (Ag) (Eitest) presence was tested in all samples.
Results: From GA, both individuals resulted culture-pos (100%), only 1 Ag pos. From GB, 4 out of 5 resulted culture-pos (80%). From GC, both individuals resulted culture-pos (100%), only 1 being Ag pos. The 4 sexual partners as well as the 2 low risk controls resulted both culture- and Ag neg.
Conclusion: Absence (Ag neg) can be confirmed in the 4 sexual partners which resulted virus culture-neg. Ag neg. The Ag capture assay proved to be less sensitive than virus culture (2 out of 5 pos cultures) (25%).

T.A.P.110 HETEROSEXUAL TRANSMISSION OF HIV-INFECTION FROM

HEMOPHILIACS TO THEIR SPOUSES
Balif, Nigge*, T.G.A. Karand*, B.S. Kampa*, K.E. Schenkel*, P. Euler*, J.L. Hirsch*, J. Hirsch*, J. Hirsch*,
* Department of Internal Medicine *** Institute for Clinical Microbiology *** Institute for Experimental Hematology, Hemophilia Center, University of Pennsylvania, Philadelphia, PA
Objective: To determine rate and cofactors for heterosexual transmission of HIV-infection in hemophiliacs.
Methods: 176 female and one male partner of HIV-seropositive hemophiliacs were examined serologically. 13 infected as well as 19 uninfected partners have been examined clinically and immunologically. Regarding the index cases, 12 transmitters and 119 non-transmitters have been examined.
Results: 18 female and one male partner (12%) were anti-HIV-positive in ELISA and Western blot analysis until september 1st 1988. 86 have been retested in until January 1st 1989, no additional seroconversions have been observed. All infected partners have stage CDC II-III disease. In 17/29 seronegative partners CD4+ counts were >700/p. Regarding the index cases, CD4+ counts are significant lower in transmitters than nontransmitters. Virus isolation was successful in 6/11 transmitters and 11/86 nontransmitters. In 308 hemophiliacs, who have been examined at least twice, the CD4+ count is declining by 110/159 p/year.
Conclusions: Low CD4+ counts, successful virus isolation, and p24 antigenemia are important risk factors for heterosexual transmission of HIV in hemophiliacs. Additional factors will be discussed.

T.A.P.112 RISK FACTORS FOR HIV-1 INFECTION IN STD CLINIC PARTNERS:

STUDY ON HETEROSEXUAL TRANSMISSION
Chabany, R., Katz, A., Stoenberg, H., Telzak, R.,
Hirschfeld, D., Haber, P., Jaffe, H.,
** Memorial Sloan-Kettering Cancer Center, NY, *** CDC, Atlanta, GA.

Objective: To evaluate heterosexual transmission of HIV-1 in STD clinic patients in an area of New York City where the cumulative incidence of adult AIDS is 44.5/1000/yr. The study was conducted in a community. **Methods:** Volunteers enrolled in an ongoing study beginning 1/88. HIV-1 antibody was measured and data on demographics and sexual and drug use behavior were collected by an interviewer using a structured questionnaire. **HIV-1 INFECTION BY RISK AND SEXUAL BEHAVIOR**

RISK	NOV	DEC	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC	TOTAL
Gay/Bisexual	37	37	39	39	39	39	39	39	39	39	39	39	39	39	39
IV drug user (IVDU)	36	44	42	37	37	37	37	37	37	37	37	37	37	37	37
Sex Partner Person at Risk (SP)	17	14	13	12	11	11	11	11	11	11	11	11	11	11	11
Not Identified Risk (NIR)	12	11	11	11	11	11	11	11	11	11	11	11	11	11	11
TOTAL	102	115	122	120	119	119	119	119	119	119	119	119	119	119	119

NIR HIV-1 was more likely (91%) to report previous contact than HIV-2 (74/88), 0.8-2.1, p=0.07. 1/12 sex crack user and 3/12 had sexual contact with known crack users. NIR HIV-1 women were more likely to be crack using prostitutes (4/8) than were HIV-2 women (3/14), 0.3-0.95, p=0.01.

Conclusions: Although most HIV-1 infections in this population occurred in gay/bisexual men, IVU, or their heterosexual partners, sexual behavior associated with crack use continued to be transmitted among persons who deny other AIDS risk factors (NIR).

T.A.P.109 RESULTS OF HIV ANTIBODY TESTING IN SEXUAL PARTNERS OF

HEMOPHILIACS OVER A 7 YEAR PERIOD
Forsberg, A.M., Sullivan, J.L., Wittits, D.L.,
New England Hemophilia Center, Worcester Memorial Hospital and **Mathew of Massachusetts Medical Center, Worcester Medical Center, Worcester, MA

Objective: To determine the rate of seroconversion among sexual partners of hemophiliacs tested between September 1981 and January, 1989.
Methods: 73 sexual partners of 73 HIV antibody positive hemophiliacs were tested over a five yr. period. 45 of the hemophiliacs were requested to inform their partners about confidential HIV antibody testing done at the New partners), 5 partners refused testing. Partners were told due to death of the hemophiliac or divorce, 43 agreed to be tested at 30 and 43 retested or their test results performed at an alternate test site. Of the 25 tested, 31 were tested at least twice (range 1 to 8 tests) and 86 had their individual or most recent test done since July, 1987. Medical records were examined to determine clinical status, presence of antibodies and CD4 cell level of the hemophiliac partner.

Results: 31 out of the 32 tested (96%) were HIV seropositive. This group included the sexual partners of 9 hemophiliacs with AIDS, 4 with p24 antigen positivity and 8 with CD4 cell levels <200 cells/uL. One spouse was seropositive at time of first testing in 1982. At the time of her positive test, her hemophiliac husband had no clinical AIDS or antigenemia and a CD4 cell level of 396 cells/uL.

Conclusion: In this group of sexual partners it appears the rates of transmission in low risk partners are not expected to increase as hemophiliacs deteriorate clinically and immunologically. This rate may be lower than in other clinics in the U.S. The reasons for this are not clear. Extensive counseling regarding safer sex practices begun in 1983 may be a factor in this lack of seroconversion among sexual partners.

T.A.P.111 TRANSMISSION HETEROSEXUELLE DE L'INFECTION HIV CHEZ LES PARTENAIRES DE DES

CONJUGES VIH-SEROPositifs (CIV)
Grattis, Isabelle, Drué A.M., Nelli M.L., Gagnep, L., Ferrasi G., Schmitt I.,
Hôpital Nigardo - G. Grand-Hôtel, Bureau d'Hygiène de la ville de Milan, Italie.

Objectif: Evaluer le risque de transmission hétérosexuelle de l'infection VIH et l'efficacité des mesures de prévention chez les partenaires hétérosexuels de toxicomanes VIH.

Méthodes: Entre décembre 1985 et décembre 1988 on a observé la sérologie VIH chez les partenaires hétérosexuels habituels (relation de couple supérieure à 6 mois), sans facteurs de risque connus sauf la contamination isolée de 103 toxicomanes VIH. Le test a été effectué par sérologie ELISA en deux étapes. Resultats: On a observé 13 sérologies VIH-positives chez les partenaires hétérosexuels habituels de 103 toxicomanes VIH. Les tests ont été effectués pendant une période d'un an et demi de 13 à 26 mois. A tous les couples on a conseillé l'usage du préservatif.

Conclusion: Dans 13 cas le partenaire hétérosexuel VIH-positif ou non (28 partenaires, 145, 2,8%). Dans 12 cas une femme (11 partenaires, 148%). Au premier test aucun partenaire sexuel n'était infecté, tandis que 13 femmes, partenaires de toxicomanes VIH, étaient sérologiques. Dans 13 partenaires VIH-positifs sans autres à la sérologie hétérosexuelle de la sérologie VIH. Il n'y avait aucune corrélation significative entre le statut de sérologie VIH-positif et le statut de sérologie VIH-positif. On a observé, en outre, que dans ce dernier groupe on a observé 2 séroconversions (33,3%) au cours de 12 mois.

Conclusion: Les toxicomanes VIH peuvent représenter une source importante de contamination par VIH hétérosexuelle, indépendamment du statut clinique de l'infection VIH, surtout à cause des résistances à l'utilisation du préservatif.

T.A.P.113 TRANSMISSION OF HIV INFECTION IN HETEROSEXUAL

PARTNERS OF HIV POSITIVE MEN
Petrone, Lucinda, Forbe, L., De Stefano, G.,
Hirschfeld, P., Albertson, F., Hirschfeld, P.,
Dept. of Infectious Diseases, Lattin General Hospital, Lattin, Italy

Objective: To evaluate the prevalence and incidence of HIV infection in heterosexual partners of HIV-1 v. drug addicts (d.a.) with no other known risk factors.

Methods: The sexual partner of each HIV d.a. attending our out patient clinic was tested every six months by a commercial ELISA kit (Abbott) positive results were confirmed by Western Blot (Eitest). Advice on effective means of prevention of sexual transmission of HIV was given to each couple.

Results: Thirteen of 60 monogamous partners, 52 F and 8 M, of an equal number of HIV d.a. 18/8 partners of AIDS cases, 14/4 of IAD/ARC and 4/0 of asymptomatic subjects were found positive when first tested. The seronegative partners were followed for a median of 12 months but none seroconverted. Of the 47 couples with a negative woman, 19 couples used condoms while 12 used no preventive measure during the follow up period no evidence of 12 pregnancies.

Conclusion: Our data confirm the importance of heterosexual transmission of HIV infection; the absence of seroconversion observed can be explained by the short period of follow up. However the tests used are not able to evidence the early stages of infection.

Section d'affichage Poster Session

Prévalence du VIH chez les femmes et les enfants HIV Prevalence in Women and Children

W.A.P.1 SEROPREVALENCE OF HIV ANTIBODIES IN NEONATES AND CHILDREN

Higler, V., Wilber, R., Masoff, F.,*; Patel, J.,*; Fenn, D.,*; Hines, S.,*; Hines, S.,* et al.
*Department of Health and Rehabilitation Services, Tallahassee and Miami, Florida, USA. **CDC, Atlanta, USA.

Objective: To assess the magnitude and steps of HIV infection in neonates and young children from low socio-economic populations in Miami, Florida.

Methods: Between 7/20/88 and 1/11/89, 2941 children in two age groups (0-6 weeks and 15-36 months) attending Public Health well-baby clinics for routine examination, were also blindly screened for HIV antibodies by EIA and confirmed by Western Blot.

Results: Demographic characteristics of the mothers and HIV test results of their neonates/children are as follows:

Variable	Mothers (11-23 weeks)	Children (15-36 months)
Mothers age	15-19 (25.3%)	15-20 (27.6%)
Mothers race	Hispanic 474 (41.8%)	Hispanic 448 (31.8%)
All HIV +	12 (1.07%) (20.7%)	4 (2.26%) (3.3%)
104 CI	(0.4-1.24)	
318/364 HIV +	12 (3.5%) (3.4%)	3/605 (0.5%)
904 CI	(1.18-2.74)	

Conclusion: These results suggest that between 100 and 270 of the approximately 10,000, mostly black and hispanic neonates born in Miami during 1989 will be exposed to HIV. The rate for 15-24 month old black and hispanic children (0.94/1.04) is similar to other studies that suggest approximately 30% of these children born to HIV seropositive mothers will be infected.

W.A.P.3 EPIDEMIOLOGY OF HIV INFECTION IN WOMEN FROM

FRANKFURT AM MAIN
EISENBERG, H., Schick, E., Rehmet, S., Odewald, J., Miller, S.,
Reim, E.R., Tillig, W.,
Universitätsklinik Frankfurt am Main, Medizinische, Infektiologie, Thiersch-Kal 7, 6000 Frankfurt/Main, Federal Republic of Germany

Objective: To investigate the spread of AIDS in women from Frankfurt area. Methods, Epidemiological and clinical examination of 917 HIV-positive women of HIV outpatient clinic, Frankfurt.

Results: The no. of HIV-infected women increased from 2 (1984) to 21 (1988), 103 (1989), 102 (1987) to 91 (1988). In the years mentioned, the female proportion of all HIV-infected patients was 43, 15%, 26%, 27%, and 25%. 74% were drug addicts, 21% got infected through heterosexual contacts, 2% through blood or coagulation factors, resp., 2% had no known risk. The proportion of heterosexually infected patients increased from 14% in 1986 to 29% in 1988. At the same time, proportion of drug addicts decreased from 100% to 49%. 34% of drug addicts and 9% of heterosexually infected women were prostitutes. 10 of 63 heterosexually infected women are Africans; in 12% male index persons were drug addicts, in 18%, prostitutes, in 10%, hemophiliacs, and in 8%, Africans. For the rest, risk of male index partners was not known. 77% women were asymptomatic, 4% had AIDS. Most common opportunistic infection was PCP (56%). Remarkable was the occurrence of Kaposi's sarcoma in 2 cases.

Conclusion: The no. of HIV-positive women in the Frankfurt area has increased significantly since 1985. The increase in heterosexually infected women is most remarkable.

W.A.P.5 SERODIAGNOSIS OF HIV ANTIBODY SEROPOSITIVITY IN

THE SOUTH BRONX
Mand, L.J., Chocola, R.T., Vintia, Andrew, Kim, M.K., Noble, L.K., Yoon, J.J., Albert Einstein College of Medicine, Bronx, New York, USA.

Objective: HIV antibody seropositivity (HIV+) was studied anonymously in a group of healthy (with and without) 133 neonates (w/o) in the South Bronx, N.Y., a socioeconomically disadvantaged area, to obtain incidence data and identify risk factors in this high risk population.

Methods: Histories and physical exams were performed on all newborns, matched with cord blood samples, and anonymously coded before screening for HIV antibody using an EIA test with Western blot confirmation.

Results: The incidence of HIV in healthy newborns without a history of maternal drug abuse was 6.0%. The incidence of HIV in newborns admitted to the neonatal intensive care unit (NICU) was 25.5%. There were significant differences between the HIV+ and HIV- NICU groups for incidence of smallpox for gestational age (53% vs 2.4%, p<.001) and microcephaly (25% vs 3.0%, p<.005). Maternal drug abuse as defined by a positive history and/or urine toxicology was found in 66% of HIV+ and 27% of HIV- infants, p<.001.

Conclusion: There is an alarmingly high incidence of HIV+ in our screened population. Growth failure and microcephaly appear to be related to HIV. Neither through effective control of the fetus or associated factors such as maternal drug abuse. The fact that 34% of our HIV+ NICU population and none of our well baby population had a maternal drug history implies an increasing percentage of perinatal AIDS may be transmitted by heterosexual contact rather than by maternal drug usage. This study highlights the need for universal HIV screening in high risk areas to ensure the best health care for these infants.

Épidémiologie et santé publique Epidemiology and Public Health

W.A.P.2 RISKY HIV ANTIBODY SCREENING IN LOS ANGELES COUNTY FEDERAL CLINICS:

A PROSPECTIVE STUDY
COHEN, RENEZ, Bawole, L.J., Gillis, M.,* Hines, S.,* Hines, S.,* Hines, S.,*
*Los Angeles County Department of Health Services, Los Angeles, California, USA.

Objective: 1. To offer HIV antibody (Ab) screening to all pregnant women as a means of primary prevention and/or early detection of perinatal AIDS. 2. To evaluate a model program of HIV testing for pregnant women using universal screening and initially sensitive absorbent serological.

Methods: Five Los Angeles County (LAC) Health Centers are participating in a pilot program to offer optional HIV antibody testing as part of routine prenatal care, starting in January 1989. A bilateral (EIA/Western blot), multi-center consent form was developed, incorporating 7 routine prenatal laboratory tests along with HIV. Patients provided pre-test counseling and informed consent to HIV testing in the face of an 8-ounce bilateral urine type assay in group specimen sessions during their first prenatal visit. HIV testing is done in 100% of the women at the laboratory using EIA, with immunofluorescent antibody and Western blot as confirmation of repeat EIA positive results. HIV positive patients are notified individually and then interviewed to assess potential high risk behavior. Positive women are referred to a tertiary care center for continued prenatal care.

Results: 1. Preliminary results show that 265 pregnant women (w/35%), consented to HIV testing, giving an acceptance rate of 85%. 2. Of 170 HIV antibody tests performed to date, one woman is positive. The patient is 28 weeks old, single, black, 16 years old, and has no other high risk behavior for both herself and her partner.

Conclusion: 1. The acceptance rate for HIV Ab testing in LAC prenatal clinics is high, reflecting general acceptance of the fastest of presentation of the HIV test. 2. In contrast, universal prenatal screening for HIV Ab, as HIV positive women frequently do not acknowledge high risk behavior, and may not be detected in pregnant women suspecting only high risk individuals.

W.A.P.4 EPIDEMIOLOGY AND OUTCOME OF HIV SEROPOSITIVE CHILDREN IN

MARINE COUNTY, CALIFORNIA
* M.D. Gerardo Gutierrez, ** R. Bueno, *** J. Herrera, *** M. Mora, **** F. Omedea, ***** J. Ruiz de Alcazar, *** R. G. Garcia Hernandez, ** Regina Health Services, *** H. Cruz Garcia, **** H. Clinico S. Carpio, ***** H. La Par, ***** H. 12 de Octubre, MARINE COUNTY, CALIFORNIA

Since 1988 the Marine Regional Health Service has required, every 6 months, a report of all cases of HIV seropositive (HIV+) children of Marine Hospital. Up to the present date the reports at Feb. 1988 and at Jun 1988, have been studied.

In Feb. 1988, 205 HIV seropositive children were reported (EIA and Western Blot). Aged between 0 and 18 years, the 103 were males. Risk factors for HIV transmission were: 808 HIV+ parents; 134 hemophiliacs; 1.54 blood transfusion. Children were clinically classified (CDC 1987) into P-1 (80.14); P-1-32 and P-2-30.

In Jun. 1988, 202 children were reported, classified into P-2 (135); P-1-30 and P-1-47. In that period 1988-1991, 69 new HIV seropositive children were found. Fifty three children became seronegative, 43 before 15 months old and the remaining after that age. Fourteen were lost during the follow up. There were 5 deaths, 3 out of 5 without direct relation to AIDS. All children with hemophilia were included into P-2 status. Twenty one out for 202 children lived in public institutions. The last reports (Dic. 88) are presently analyzed.

W.A.P.6 HIV RISK FACTOR PREVALENCE AMONG YOUNG WOMEN OF CHILD-

BEARING AGE ATTENDING WOMEN'S ADVISORY CARE CLINIC
Harris, R.T.,* Wong, Robert E.,* et al.
*Epidemiology Unit, Seattle-King County Department of Health, Seattle, WA 98144.

Objective: To estimate the HIV risk factor prevalence among women of childbearing age.

Methods: In December 1988, we asked clients of 3 Seattle-area women's clinics to complete anonymous questionnaires regarding their age, race, sexual activity, condom use, IV drug and needle use and transfusion history.

Results: 1,317 women, aged 18-44 years, young (50%), median=22) mostly white (51.7%), unmarried (17.0%), and of low family income (range=\$0-\$39,000, median=\$11,000). Reasons for the clinic visit included: "Birth control" (64.8%), "Prenatal care" (6.3%), "AIDS test" (2.9%) and "Other" (20.8%). Of these 384 women, 143 (37.8%) reported sex with multiple partners (number of partners, range=2-10, median=3), and 172 (44.8%) with casual partners in the past year.

Women, 143 (37.8%) reported sex with multiple partners (number of partners, range=2-10, median=3), and 172 (44.8%) had at least one STD, 40 (10%) had an intravenous drug using (IVDU) or bisexual male sex partner. 20 (5%) disclosed IV drug use, 17 (4.3%) shared needles, and 21 (5.0%) had sex for drugs or money. By contrast, for the past 12 months, merely 8 (2.1%) disclosed IV drug use and 11 (2.8%) shared needles. 11 (2.8%) were concerned that her partner was HIV positive. We will present these and early 1989 data to profile women who are practicing behaviors which place them at risk for HIV infection.

Conclusions: Clients of Seattle women's clinics have taken significant risks with regard to HIV acquisition: unprotected sex with multiple/casual partners.

Session d'affichage Poster Session



Epidémiologie et santé publique Epidemiology and Public Health

W.A.P.7 HERPES SIMPLEX, SYPHILIS, AND HEP B: ASSOCIATION

WITH HIV-1 AND HIV-1 IN PREGNANT HAITIAN WOMEN
 HOLLAND, RUTH M.*; HALESS, M.*; BUI, F. A.**;
 Adrien, M.*; QUIN, T.C.**; BAHUIS, A.M.*; EL-BI***.
 *Centers for Disease Control, Atlanta, GA; **Johns Hopkins University, Baltimore, MD, USA; ***Emory
 University, Atlanta GA, USA; ****Centers for Disease Control,
 Atlanta, GA and National Cancer Institute, Bethesda, MD, USA

Objective. To determine associations of HIV-1 and HIV-1 infections with herpes simplex types 1 and 2, syphilis, and hepatitis B in pregnant women residing in a periurban slum, **Methods.** Pregnant women were screened for HIV-1 and HIV-1 and a weighted sample was selected for further antibody testing. **Results.** Percent positive

	HIV-1 POS. (n=251)	HIV-1 POS. (n=41)	NEG. (n=25)
Syphilis	14.38	0.0	0.0
HSV-1	55.18	97.74	97.78
HSV-2	88.44*	81.84**	53.44

*p<0.02, **p = 0.0005, vs. seronegative women
 Based upon the 9.1% seroprevalence rate for HIV-1,
 approximately 10% of pregnant women in this population were
 HIV-2 seropositive, similar to inner city populations in other
 countries.

Conclusions. Both HIV-1 and HIV-1 infections were associated
 with HIV-2 seropositivity suggesting sexual transmission of
 these viruses in this population.

W.A.P.9 THE SEROPREVALENCE OF HIV INFECTION IN NEW YORK CITY

CHILDREN.
 WALKER, JESSIE B.*; THOMAS, P. J.*; O'NEIL, M.*; BUCK, S.*;
 STEVENS, R.**; BERNA, D.**; HANCOCK, M.*** at al.
 *New York City Department of Health, New York, NY; **Centers for
 Disease Control, Atlanta, GA; ***New York State Department of
 Health, New York, NY, USA.

OBJECTIVE. To determine the seroprevalence of HIV infection in selected
 NYC pediatric populations.

METHODS. Two populations of children were surveyed: children aged 1 to 10
 screened in their households by neighborhood home testing for lead
 poisoning and 1 to 3 year old children attending pediatric clinics run by
 the New York City Department of Health. All specimens were collected on
 filter paper and tested for HIV by ELISA and Western Blot. Both surveys
 were blinded.

RESULTS. To date, 976 specimens from the lead screening survey have been
 collected. Serums are available on 910. Of these, two children were
 positive by ELISA and Western Blot (0.2%, 95% CI, 0.01% - 0.35%) and 2
 others ELISA positive and Western Blot inconclusive. In the pediatric
 clinic survey, 20 of the 35 clinics are being surveyed and approximately
 2,000 children tested.

CONCLUSIONS. Based on newborn screening surveys in New York City showing
 an infection rate among pregnant women of about 1.5%, a seroprevalence of
 HIV in these children is less than is expected. Furthermore, these
 surveys demonstrate further uses of the filter paper technology for HIV
 testing.

W.A.P.11 NO CHANGE IN HIV-1 SEROPREVALENCE AMONG PARTURIENTS AND

NEWBORN HAVING INCREASED ANTIBODIES IN NEW YORK CITY, 1987-1988

ARANDA, MARY ANN S.*; THOMAS, P. J.*; HANCOCK, L. J.*; WEINFUS, J.*; SCHULTZ S.*
 *New York City Department of Health, New York, New York, United States

OBJECTIVE. To determine the change in HIV-1 seroprevalence in a population
 based sample of women giving birth and having induced abortions in New York
 City in 1987 and 1988.

METHODS. A repeat serosurvey of a representative sample of 3,556 women
 giving birth or having induced abortions in 20 obstetric and 15 abortion
 facilities in NYC from July to December 1987 and July to December 1988 was
 conducted. Currently, 1988 data are available for 1,537 women from 23
 facilities and are compared to 1987 data from the same facilities.

RESULTS. HIV-1 antibody seroprevalence did not change significantly
 (1.41% (95% CI: 1.02%-2.02%) vs. 1.53% (95% CI: 1.09%-2.13%), p=0.90)
 between 1987 and 1988, nor by pregnancy outcome, racial, age, nor payment
 status categories. Similar to 1987, multiple logistic regression identified
 receiving Medicaid and being between 25-29 years of age as significantly
 associated with HIV-1 seropositivity.

	1987 HIV-1 Total (%)	1987 HIV-1 Total (%)	P-value
Total	36/2525 (1.38)	34/2223 (1.53)	0.90
Abortions	21/2327 (0.87)	19/1237 (1.54)	0.87
Medicaid Recipients	15/1100 (1.36)	15/1100 (1.36)	0.85
25-29 years	17/1200 (1.42)	26/1714 (1.52)	0.36
25-29 years	17/1200 (1.42)	12/640 (1.87)	0.88

CONCLUSIONS. HIV-1 seroprevalence among pregnant women remained stable
 during a one year period in the city with the highest reported incidence of
 adult female and pediatric AIDS.

W.A.P.8 HIV INFECTION IN PREGNANT WOMEN AT A PUBLIC HOSPITAL IN

NEW ORLEANS, LOUISIANA
 ROBINETTE, LINDSEY DEAN, M.*; TRAHAN, B. J.*; WILCOX, D. J.*
 Louisiana Department of Health and Hospitals, New Orleans, LA, USA.

Objective. To determine the rate of HIV infection among prenatal clients
 in a public hospital in New Orleans from May 1988 to December 1988.

Methods. Routine HIV counseling was given to all prenatal clients.
 Clients consenting for testing (CPT) were administered a risk assessment
 questionnaire and were categorized as low risk (LR) or high risk (HR) for
 acquiring the HIV infection. Basic demographic data was collected from each
 CPT. HIV antibody tests were performed using ELISA and Western Blot methods.
 Results: A total of 3,903 HR were counseled, 3,846 (98.5%) clients agreed to
 be tested, 62 (1.6%) declined testing. Of clients tested, 1,981 (78%) were
 black females, 508 (18%) whites and 111 (3%) hispanics. Five hundred
 twenty-four clients (13.2%) were also categorized as low risk and 322 (16.4%)
 as low risk. Prevalence of HIV infection in prenatal clients was found to be
 0.50/848 (0.06%) of the twenty positive, 16 (80%) were black females and 4
 (20%) were whites. Among the high risk clients, 7 (1.3%) were seropositive
 for HIV. There were thirteen (1.8%) low risk clients testing HIV positive.

Conclusions. These data show that high risk prenatal clients appear to be at
 a greater risk for testing HIV positive. This study also shows a lower HIV
 seropositivity rate compared to earlier studies in inner city hospitals.
 Although the risk assessment questionnaire was used as a method for identifying
 high and low risk clients, it should not replace the availability of HIV
 counseling and testing for all pregnant women. Routine HIV counseling and testing
 should be an important component of total obstetrical screening during pregnancy.

W.A.P.10 HIV INFECTION IN LESBIANS.

REID, JUDITH; MORTON, C.; KELLY, J.; RAYAS, C.; RODGERS, P.;
 WILCOX, J. J. Louisiana Health/Communicable Health Project, NY,
 NY, USA.

HIV infection and AIDS is a leading cause of morbidity and death in
 women aged 25-34 years in New York City. In a study we have considered
 only heterosexual and pregnant women in transmission and seroprevalence data.
 Lesbian women have not been studied for transmission risk and seroprevalence
 despite national, U.S. AIDS surveillance data indicating 10% cases
 of AIDS in lesbians.

At a community-based, primary care AIDS assessment clinic and in a support
 group for women with HIV infection, AEC and AIDS, there are 31 cases
 of HIV-1 seropositivity in lesbians. Data on risk factors for HIV
 infection are as follows: UIVM-1; prior sexual contact with infected
 man (by consent), by force or by sperm donation; and seroprevalence
 to female transmission-2 and contaminated transfusion recipient-1.

It is clear that there are lesbians with HIV infection and AIDS, and
 it is important to include them in transmission studies and seroprevalence
 studies. The false notion that women who define themselves as lesbians
 are not at risk for HIV infection can lead to tragic misdiagnosis by
 practitioners and lack of risk awareness by the women themselves.

Incidence du SIDA AIDS Incidence

W.A.P.12 THE EVOLVING EPIDEMIOLOGY OF AIDS IN NEW YORK CITY: TRENDS

IN AIDS CASE SURVEILLANCE DATA. GREENBERG, ALAN M.*; **;
 THOMAS, P. J.*; KLININ, DEB.*; HANCOCK, M.***; REID, J.***; HANCOCK,
 S.M.* NYC Dept of Health AIDS Surveillance Unit, **AIDS Program/CDC, Atlanta

Objective. To monitor trends in the epidemiology of AIDS in New York City.

Methods. In NYC, AIDS cases are counted through active surveillance
 conducted by the Dept of Health in collaboration with 77 hospitals. A
 transmission category is assigned for each case and trends are monitored.
 Beginning 4/6 of 12/88, NYC had reported total of 12,052 AIDS cases, or 23%
 of the USA total. Trends in specific categories were assessed.

Transmission Category	1988	1987	1986	1985	1984	1983	1982	1981	1980
Total	9	43	87	131	224	317	362	394	394
INTRV(1)	2	25	48	68	129	170	170	161	161
INTRV(2)	0	2	22	41	68	103	129	165	165
NONSEX/PROXY	0	4	6	15	12	14	10	10	10
SEX/PROXY(3)	0	0	0	2	5	9	12	12	12
Child(1)	0	1	0	4	4	7	8	8	8

* Through 8/18 (13) Men who have sex with Men (3) Intrauterine device users
 (3) 95% of heterosexual cases represent male to female transmission
 Simulations: NYC conditions do not serve as an epitome of the AIDS epidemic in
 the USA; as of 12/88, the number of cases reported to CDC from NYC (16,022)
 exceeded the combined total from San Francisco (6,602), Los Angeles
 (6,002), Houston (2,578), and Newark (1,460). The number of cases diagnosed
 monthly among total cases, INTRV, and heterosexuals has increased, whereas
 the number of cases among NONSEX appears to have stabilized.

Session d'afichage Poster Session



Epidémiologie et santé publique Epidemiology and Public Health

W.A.P.13 THE EPIDEMIOLOGY OF AIDS IN SAN FRANCISCO'S ELDERLY POPULATION

Payne, Susan F.; Wilson, C.; Rutherford, GW. San Francisco Department of Public Health, San Francisco, CA, U.S.A.

Objective. To describe the epidemiology of AIDS among San Francisco (SF) residents aged 60 and older.

Methods. We analyzed the demographics and transmission categories of 5,834 AIDS patients reported to the SF Department of Public Health between July 1981 and December 31, 1988.

Results. 125 (2.1%) of patients were > 60 years, corresponding to an incidence of 90/100,000. Of these 125 patients, 107 (86%) were 60-69 years, 16 (13%) were 70-79 years, and < 3% were > 80 years. Among patients 60-69 years, 75% were homosexual/bisexual males, 17% were transfusion recipients, and 7% were in other risk groups. Among patients > 70 years, 31% were homosexual/bisexual males and 69% were transfusion recipients (p<.001). AIDS patients > 60 years were more likely than younger patients to be female (7% vs 1%, p<.001); transfusion recipients (24% vs 4%, p<.001); to have a primary diagnosis other than KS (62% vs 67%, p<.001); and to live outside SF (18% vs 10%, p<.01). Older AIDS patients did not differ from younger patients by race/ethnic group. Among homosexual/bisexual patients, patients > 60 years were less likely to be intravenous drug users than younger patients (5% vs 12%, p<.05).

Conclusion. SF AIDS patients > 60 years were more likely to be female, transfusion recipients and have a primary diagnosis other than KS. AIDS patients 60-69 years were primarily homosexual/bisexual males, while patients > 70 years were primarily transfusion recipients.

W.A.P.15 THE AIDS EPIDEMIC IN EUROPE

Accella-Park, Rosmarie; Coururier, E.; Lavioie, G.; and Brunet, J.B.

* WHO Collaborating Centre on AIDS, Paris, France

Objective. To determine the trends of the AIDS epidemic in Europe.

Methods. Cumulative quarterly surveillance data are collected from 31 European countries. Variations in trends between December 1984 and 1988 are analysed and presented for Europe as a whole and by country.

Results. By December 1988 over 18,000 cases had been reported to the Centre. There has been a steady increase in reported cases between Dec. 1984 and Dec. 1987 and a 1.5-fold increase between Dec. 1987 and Dec. 1988. The rates per million population are highest in Switzerland (106.4), France (101.7) and Denmark (70.2), and lowest in eastern European countries. The overall doubling time of the number of cases reported in Europe is 12.7 months (June 1988). Doubling times have lengthened since the start of the epidemic in all countries except Greece. Distribution of cases by country shows a predominance of the IVDU transmission group reported in the southern European countries and the homosexual group in the northern countries. A continuous increase in the percentage of cases reported in Europe among IVDU is noted: Dec. 84: 1%; Dec. 85: 7%; Dec. 86: 14%; Dec. 87: 20%; Dec. 88: 25%. In the global data, variations over time in the distributions of disease categories, age, sex transmission groups of children's mothers are directly related to this increase.

Conclusion. Doubling times of the number of cases have lengthened since the start of the epidemic. Geographic variations persist, with a majority of IVDU in southern countries. Variations noted in global European surveillance data are directly related to the steady increase in the percentage of IVDU.

W.A.P.17 EPIDEMIOLOGY OF AIDS-ASSOCIATED LYMPHOMAS: UNITED STATES

Beral, V.; Peterman, Thomas A.; Berkelman, KL. Centers for Disease Control, Atlanta, GA, USA.

Objective. To characterize patients with AIDS-associated lymphomas and evaluate whether these lymphomas might be due to an infectious agent.

Methods. We reviewed cases of AIDS reported to CDC by 3 December 1988.

Results. A lymphoma considered indicative of AIDS was reported for 2183 (Burkitt's, 474 (0.62); and primary lymphoma of the brain (PLB), 443 (0.62). The three types differed in age distribution: No cases of Burkitt's and only one case of immunoblastic were reported in children < 2 years of age but 4 cases of PLB were reported in this age group all types peaked at age 5 to 19; after age 25 immunoblastic rose to a peak while PLB and Burkitt's remained constant. In other respects, the distributions of the types of lymphomas were similar. After stratifying by age, heterosexual drug users or cases attributed to heterosexual transmission had rates half that of homosexual men, while men with hemophilia had rates twice that of homosexual men. Lymphomas were twice as common in white as black patients with AIDS in the same age and risk group.

Conclusion. The age differences in AIDS-associated lymphomas are the most striking epidemiologic finding. The other differences could be attributable to differential medical care. If these lymphomas are due to an infectious agent, it does not appear to be sexually transmitted.

W.A.P.14 THE EPIDEMIOLOGY OF AIDS-RELATED NON-HODGKIN'S LYMPHOMA IN SAN FRANCISCO

Shm, George E.; Payne, S.F.; Neal D.P.; Rutherford, G.W. San Francisco Department of Public Health, San Francisco, California, U.S.A.

Objective. To describe the epidemiology of non-Hodgkin's lymphoma (NHL) in AIDS patients diagnosed in San Francisco (SF).

Methods. We evaluated 5834 AIDS cases reported in SF from 1981 through 1988 with regard to an initial or subsequent diagnosis of NHL. All patients with NHL met the CDC definition of AIDS-indicative NHL. Medical survival was calculated using the Kaplan-Meier product-limit method.

Results. 179 (2.1%) AIDS patients were initially diagnosed with NHL. NHL as an initial diagnosis rose significantly (p<.01) from 1.0% of total cases in 1983 to a peak of 4.3% of cases in 1987, then declined slightly to 3.3% of cases in 1988. These trends do not appear to be a reporting artifact since a significant (p<.05) rise in NHL was also found for patients diagnosed at three active surveillance hospitals where prospective laboratory and medical record review has been conducted since 1983. 238 (4.1%) AIDS patients had NHL at some point during their illness. AIDS patients with NHL did not differ significantly from those without NHL with respect to age, gender, race/ethnicity, risk group, or residence in 19 contiguous census tracts with the highest incidence of AIDS in SF. Medical survival for AIDS patients presenting with NHL (6.6 months) was significantly shorter than that for patients without (12.6 months) (p<.001).

Conclusion. NHL has risen significantly as an AIDS-related manifestation. Demographics of AIDS patients with NHL are similar to patients without. Survival is shorter for AIDS patients with NHL.

W.A.P.16 FOUR-FOLD INCREASE IN TUBERCULOSIS/AIDS PATIENTS IN NEW YORK CITY, 1985-1988

Laroche, Eddy; Araneta, HRG; Stoneburner, RL; Adler, JJ New York City Department of Health, New York, New York, United States

OBJECTIVE. To evaluate the prevalence of Tuberculosis (TB) and to assess its contribution to TB morbidity in New York City (NYC).

METHODS. A computer match was performed using culture diagnosed adult cases (age >15) related to NYC TB registry from 1979 through 1988 and CDC defined adult AIDS surveillance cases from 1981 through 1988.

RESULTS. A total of 1116 patients with TB/AIDS were identified. TB/AIDS cases increased 4-fold since a similar study was conducted in 1985 where 261 patients were identified. The proportion of TB/AIDS as a percentage of AIDS cases between 1985 and 1988 remained fairly stable, from 5.2% to 6.3%. Whereas the proportion of TB/AIDS cases increased significantly from 2.2% to 8.1%. The proportion of TB/AIDS cases with IVDU histories or with extrapulmonary TB also remained stable between 1985 and 1988.

	1979-1988	1979-1988	R=Match O.R.
TB/AIDS/AIDS	1116/17,749 (6.3%)	261/4980 (5.2%)	1.07
TB/AIDS/TB	1116/13,820 (8.1%)	261/11,640 (2.2%)	<10 ⁻⁶
% of TB/AIDS			
w/extrapulmonary TB	203/1116 (18%)	58/261 (22%)	1.07
IVDU only	587/1116 (52%)	127/261 (49%)	0.8

CONCLUSION. AIDS remains a significant risk factor for clinical manifestation of Tuberculosis in New York City. The proportion of TB/AIDS cases with extrapulmonary TB was less than expected. The increase in TB/AIDS patients is most likely due to the increase in the number of IVDU.

W.A.P.18 CHANGING PATTERNS OF HETEROSEXUALLY ACQUIRED AIDS IN FLORIDA

Holtzman, Deborah*; Brandenburg, N.A.**; Sims, J.*; Wittes, J.*

*Department of Health and Rehabilitative Services, Tallahassee, Florida, USA; **University of South Florida, College of Public Health, Tampa, Florida, USA.

Objective. To describe secular trends in heterosexually acquired AIDS in Florida by demographic and risk group characteristics.

Methods. Based on the CDC surveillance definition for heterosexual transmission (HT), secular trends among HT cases in Florida were analyzed over the interval, 1980-88.

Results. As of January 12, 1989, Florida reported 567 (9% of total) non-US-born HT AIDS cases and 304 (5%) US-born HT AIDS cases. Among men, the proportion of non-US-born HT cases (N=15) decreased from 33 to 32 from 1980-88 (p<.001). Among women, the non-US-born HTs declined from 67 to 131 over the same interval (p<.0.001). In contrast, the proportion of US-born HT men (N=14) increased from .6 to 3.5% from 1980-88 (p<.0.001), while a comparable increase among women from 9 to 22% (p = 0.01). The majority (61%) of US-born HT women reported intravenous drug use (IVDU) among their partners. Further, the proportion of female cases attributable to sexual contact with an IVDU partner rose from 6 to 18% over the interval (p = 0.002). Most (60%) of these women were black; this percentage did not vary significantly over time. Among US-born HT women, no secular trends in age at diagnosis were observed, nor were age differences apparent by race.

Conclusion. The proportion of cases among non-US-born HTs is declining in Florida, while coincident increases are occurring among the US-born HTs. The increase in the US-born HTs does not seem to be due to declining risk factors at this time. Continued surveillance may help to explain these trends.

Section d'affichage Poster Session

W.A.P.25

ANALYSE DES TENDANCES DES CARACTÉRISTIQUES SOCIO-DÉMOGRAPHIQUES DES CAS DE SIDA RAPPORTÉS EN FRANCE
Lipicitz, S., Marchandin, A., Cluzon S., Straet JR.
Direction Générale de la Santé, Paris, France.

Objectif: A partir de caractéristiques socio-démographiques des cas de SIDA, étude de la dynamique de développement de l'épidémie en France.

Méthodes: Analyse des 5527 cas de SIDA diagnostiqués de Janvier 1984 à Décembre 1986, présence des différents groupes de transmission, en fonction du temps et des variables socio-démographiques.

Résultats: Les tendances globales sont: un vieillissement de la population des cas de SIDA (diminution de la classe 30-49 ans, augmentation de la classe des plus de 50 ans); une persistence de la diffusion géographique en 3 zones (région parisienne, sud de la France, région Antilles-Guyane); un glissement des catégories professionnelles intellectuelles et commerciales vers les catégories des ouvriers et des sans profession. Les modifications de la part relative des différents groupes de transmission (baisse de celle des homosexuels et augmentation de celle des injections) par années de diagnostic ainsi que la modification des caractéristiques de ces groupes au cours du temps expliquent les tendances globales.

Conclusion: L'épidémie de SIDA en France est la somme de plusieurs épidémies indépendantes et découlées dans le temps. Certaines modifications des variables démographiques traduisent une augmentation de la proportion des cas à l'incubation longue.

Mortalité liée au SIDA

AIDS/HIV Related Mortality

W.A.P.27

IMPACT OF AIDS ON MORTALITY IN SAN FRANCISCO: 1979-1986.
Samuels, J.D., Hershfield, George, Leap, OJ, Barnhart, L.
Department of Public Health, San Francisco, California, U.S.A.

Objective: To describe the increase in AIDS-related death and years of potential life lost before age 65 years (YPLL-before age 65) for San Francisco residents between 1979 and 1986.

Methods: Death certificate data for San Francisco residents for 1979-1986 were used to calculate the number of deaths and YPLL-before age 65 for the following six AIDS-related diseases: cytomegalovirus infection (ICD-9 078.0); cryptosporidiosis (ICD-9 117.5); pneumocystis carinii pneumonia (ICD-9 136.9); other malignant neoplasms of the site, site unspecified (ICD-9 171.9); immunodeficiency with predominant T-cell defect (ICD-9 279.1); and immunodeficiency unspecified (ICD-9 279.3).

Results: The number of AIDS-related deaths (both sexes, all ages) increased from 7 (0.1% of all deaths) in 1979 to 536 (8.6%) in 1986. YPLL-before age 65 increased from 123 years in 1979 to 113,776 years in 1986. AIDS-related deaths increased between 1979 and 1986 from 0 to 44 (24.7% of all deaths); 0 to 157 (43.5% of all deaths); 0 to 150 (35.2% of all deaths) in males aged 20-29 years; 30-39 years; and 40-49 years respectively. In 1986 AIDS-related diseases were the third leading cause of death and the leading cause of YPLL-before age 65 among San Francisco male residents.

Conclusions: There was a dramatic increase in AIDS-related deaths in San Francisco residents between 1979 and 1986 especially in males aged 20-49 years.

W.A.P.29

ESTIMATE OF HIV-RELATED DEATHS IN YOUNG ADULT MEN, UNITED STATES, 1986.
Berkley, James, Berkman, K., Devine, O.
Centers for Disease Control, Atlanta, Georgia, USA.

Objective: To estimate the number of HIV-related deaths in 1986 in the U.S. among young adult men using multiple causes of death records for men 25-44 years of age for the years 1980-1986, we calculated excess deaths in 1986, based on mortality rates in 1980 and the lowest rates for selected causes.

Results: In 1986, there were 68 deaths (0.21 deaths/100,000) with any listing of well-defined immune deficiency. Known HIV seronegative, AIDS, Pneumocystis carinii pneumonia, and 7,737 such deaths (20.5 deaths/100,000) in 1986 (excess = 7,650). In the absence of these diagnoses, excess deaths occurred in 1986 (following a nadir in rates in 1980-1983) for other conditions in the AIDS definition: Infections, 132; non-Hodgkin lymphoma, 135; monophagocytosis, 15; and for other conditions that are increasing in association with the HIV epidemic: pneumonia and influenza, 193; pulmonary tuberculosis, 31; septicemia, 134; other infections, 101; other immune deficiency, 15; blood disorders, 37; and non-specific causes, 349. Thus, 7,655 to 9,182 excess deaths may be HIV-related, compared to 7,023 deaths in men 25-44 reported in the surveillance system in 1986. Excess deaths in HIV-related deaths may be high if excess deaths are not all due to HIV and low if baseline rates are declining, rather than stable, or if increases in other conditions (e.g., respiratory, drug abuse) are HIV-related.

Conclusion: National surveillance of AIDS cases detected roughly 75-90% of HIV-related deaths in 1986 among men 25-44 years of age.

Épidémiologie et santé publique Epidemiology and Public Health

W.A.P.26

AIDS IN THE DEPARTMENT OF VETERANS AFFAIRS: DEMOGRAPHICS AND EPIDEMIOLOGY
Allen, Robert E., Mather, S.H., Peterson, M.R.
AIDS Program Office, Department of Veterans Affairs, Washington, D.C., USA.

Objective: To describe the characteristics of the individual AIDS patients cared for in one of the largest medical systems in the world, the Department of Veterans Affairs (DVA) of the United States.

Methods: The DVA has collected data on AIDS patients since 1979. The reporting form is identical to those used by the Centers for Disease Control (CDC). From these figures computerized data has been collected to describe the age, sex, ethnic and risk groups for these patients. The results of these analyses will be reported.

Results: At the end of 1986 the DVA had cared for 5,434 AIDS patients in 141 VA medical centers across the USA. This represents approximately 4% of all of the AIDS patients reported in the USA. VA patients are different in risk behavior for the disease in the following way: Injected drug users account for 27% of all of the DVA cases, 7% are both IV drug abusers and homosexual. In other characteristics they are very similar, e.g. 46% are white, 57% are male and they are on the average 44 years of age. In addition, the AIDS epidemic has also been concentrated in epidemics, i.e. 57% of the patients have been cared for in 11 of the VA medical centers. The details of these findings will be further elaborated at the meeting.

Conclusion: The AIDS epidemic continues to involve an ever increasing number of patients in the USA. The DVA cares for 4% of these cases. These patients differ from the USA reported AIDS patients in risk group percentage. The IV drug users account for 27% of all of the patients cared for since 1979. These data will be presented and discussion encouraged.

W.A.P.28

HIV-ASSOCIATED MORTALITY IN ENGLAND AND WALES IS GREATER THAN THAT IDENTIFIED BY AIDS SURVEILLANCE MONITORING.

Office of Population Censuses and Surveys, London WC6B 6JP and HHS Communicable Disease Surveillance Centre, London, United Kingdom.

Objective: To estimate the total number of deaths resulting from HIV infection.

Methods: Ninety-five causes of death were identified as possibly HIV-related. Trends in death rates due to these causes by age, sex, marital status and geographical distribution were identified for 1980-87. Reports to CDC of HIV infected people who have died but who were not included in the AIDS surveillance programme because they did not meet the WHO definition were analysed. The AIDS surveillance programme was extended in February 1989 to include deaths among HIV-positive people who did not meet the WHO AIDS definition. Unreported mortality ratios due to HIV-related causes in 1987, but there was no similar increase for men of other marital status, or for single women. This increase was only partially accounted for by deaths for which AIDS was stated as the cause. Geographical distribution was similar to that of reported AIDS cases. Preliminary results from the extended surveillance programme will be presented.

Conclusion: People in England and Wales are dying as a result of HIV infection without developing AIDS as defined by the WHO. There is a need for surveillance programmes to be extended to include HIV infection severe enough to cause death but not meeting the WHO definition if the true size of the epidemic is to be identified.

W.A.P.30

CAUSES OF DEATH IN A LARGE COHORT OF I.V. DRUG USERS (IVDU) IN MILAN: AN UPDATE
Galli-Maino, Costini, G.*; Carite, M.*; Orucov, V.*; Zampini, L.*; Cianci, D.* et al.
Infectious Diseases Clinic and "Rho" Abuse services, Milan, Italy.

Objective: To evaluate the variations of causes of death during the last two years in a large cohort of IVDU recruited in Milan between Nov.80 and Dec.87. Since the beginning of the IVDU attending the Hospital Center are included, 103 subjects deceased before '87; 3664 IVDU have been followed-up with repeated investigations at registry offices.

Results: (N) Overdose AIDS Liver cirrhosis Violent death Other* Total
1980-1986** 18(20) 11(11) 8 (5) 20 (20) 25(26) 101
1987 18(22) 19(34) 1 (2) 8 (14) 10(18) 57
1988*** 20(39) 22(43) 3 (6) 5 (10) 21(2) 56
TOTAL 57(57) 52(51) 9 (4) 33 (16) 37(18) 208

* Only two cases of so-called HIV-related deaths (bacterial pneumonitis) were recorded. **retrospective data; ***up to Dec.1988 information were available in 20-25% HIV serology was available in 42 AIDS patients (deaths 10-13% were HIV pos).

Conclusions: Despite the increasing number of overdose related deaths in Italy during the last two years, in this cohort AIDS 'is now the first cause of death, not reflecting the large spread of HIV infection among IVDU in Milan.

Session d'affichage Poster Session



Epidémiologie et santé publique Epidemiology and Public Health

W.A.P.37 REPRODUCTION OF FACTORS RESPONSIBLE FOR HIV TRANSMISSION IN MALE HOMOSEXUALS

Antonis Boulikas, G. Kallitros, G. Kotsani, A. Papanicolaou, M. Nestoridis, A. Papanicolaou, E. Papanicolaou, G. National School of Hygiene, Athens, Greece.

Objective: To study factors affecting the prevalence of HIV infection in male homosexuals.

Methods: Male homosexuals self-selected for counselling and HIV screening at the National Center for AIDS were asked to complete a detailed questionnaire. The sample included 90 anti-HIV positive and 100 anti-HIV negative male homosexuals. All of them were also screened for serological evidence of HSV infection, syphilis and history of past gonorrhoea.

Results: Table 1 shows epidemiological characteristics and the prevalence of HIV in the seropositive anti-HIV positive and negative male homosexuals.

Characteristics/Disease	Anti-HIV(+)n=90	Anti-HIV(-)n=100
Median age (years)	28.9	26.0
Number of sexual contacts / month	5	5
Use of condoms (1) last year	26.7	26.0
1-7. Drug use (2)	6.7	2.0
Active and passive sexual behavior (3)	72.3	50.0
1-7. Drug use (2)	72.3	50.0
Syphilis	33.3	15.0
Gonorrhoea	55.0	20.0

Conclusions: There is a close correlation between HIV infection and other sexually transmitted diseases. Protected sex and both passive and active sexual behavior are mainly responsible for HIV infection in male homosexuals.

W.A.P.39 RELATIONSHIP OF STD HISTORY TO HIV SEROPREVALENCE IN A COHORT OF HOMOSEXUAL MEN IN DALLAS, TEXAS

Billy Charles E. Anderson, P. Frances A. Petty, A. Dallas County Health Department, Dallas, Texas, USA.

Objective: To determine the relationship between STD history and anti-HIV. **Methods:** Between 6/77 and 12/87, 644 homosexual or bisexual men volunteered to return every six months for HIV testing. All answered questions about previous episodes of syphilis, gonorrhoea, genital warts, and hepatitis. **Results:** 150 (23%) of the men had a history of either syphilis, gonorrhoea or warts; 153 (24%) had a history of hepatitis.

History of a Sexually Transmitted Disease:

	Syphilis	Gonorrhoea	Warts	1st	2nd	3rd	4th	5th	6th	7th	8th	9th	10th	11th	12th
N	104	238	131	320	60	110	140	140	140	140	140	140	140	140	140
HIV	40(47%)	92(56%)	51(39%)	120(38%)	20(40%)	46(42%)	46(42%)	46(42%)	46(42%)	46(42%)	46(42%)	46(42%)	46(42%)	46(42%)	46(42%)
OR	1.9	1.9	1.5	2.0	1.8	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6	1.6

95% CI: 1.5-2.5, 1.5-2.4, 1.1-2.0, 1.5-2.6, 1.3-2.4, 1.1-2.2, 1.1-2.2. When stratified by the number of partners in the year before learning of AIDS, the risk for HIV infection in those with a history of syphilis, or of warts was 1.8 (95% CI: 1.4-2.4), and for those with a history of gonorrhoea or hepatitis was 1.4 (95% CI: 1.1-1.8). HIV infections were related to the number of episodes of gonorrhoea (p<0.001) and to the number of partners (p<0.01).

Conclusions: HIV infection may be related to history of STD due to the facilitation of HIV transmission, but the similar relationship with non-STD hepatitis suggests that HIV infections and STD may be independent events associated with a common mode of transmission.

W.A.P.41 FAILURE TO CONFIRM HERPES SIMPLEX VIRUS TYPE 2 (HSV-2) INFECTION AS A RISK FACTOR FOR HIV-1 SEROCONVERSION AMONG HOMOSEXUAL MEN

Klausen, Lennart, Armstrong, J. Rahman, A., Ho, M. and Khalifa, C. University of Pittsburgh, Graduate School of Public Health, Pittsburgh, Pennsylvania, USA.

Objective: To determine if prior infection with HSV-2 is associated with HIV-1 seroconversion in homosexual men.

Methods: Western blot confirmed HIV-1 seroconverters (n=49) were matched with non-HIV-1 seroconverters (n=49) for the number of partners with whom anal receptive intercourse was performed and the visit of HIV-1 seroconversion. HSV-2 lab testing was performed on blind-coded sera utilizing immunofluorescence (IF) in an immunoassay assay.

Results: At the visit of HIV-1 seroconversion, the same prevalence of HSV-2 infection was observed for both HIV-1 seroconverters and non-seroconverters (52.0% vs 47.8%). Matched pairs analysis failed to detect any association between HSV-2 infection and HIV-1 seroconversion (odds ratio = 1.0). Self-reported rates of genital and anal-rectal sexual were very low (4.5%), as well as physical exam findings suggestive of HIV infection (2.8%).

Conclusion: No evidence was found in this study to support the hypothesis that prior/current infection with HSV-2 is a risk factor for HIV-1 seroconversion among homosexual men. A suggested explanation is that anal intercourse is the major risk factor for both HIV-1 and HSV-2 infection. HSV-2 infection among homosexual men may be only a marker of, not a causal factor for, acquisition of HIV-1 infection. Due to both cultural and biologic differences in sexual transmission of HIV-1, these findings should not be generalized to other risk groups.

W.A.P.38

SIZE FACTORS OF HIV INFECTION RISK MALE PROSTITUTE IN ATLANTA

John E. Fife, Jr., Brian M. Smith, Georgia State University, Atlanta

John E. Fife, Jr., Brian M. Smith, Georgia State University, Atlanta

Objective: To assess HIV seroprevalence among male prostitutes and to identify risk factors associated with HIV infection. **Methods:** HIV seroprevalence was determined by HIV-1 antibody testing and HIV-2 antibody testing. HIV-1 antibody testing was conducted and HIV-2 antibody testing was conducted in the presence of a trained interviewer. Interviews focused on sexual activity, drug use, history of STD, and other factors associated with HIV infection. **Results:** HIV-1 antibody testing was conducted on 100 male prostitutes and HIV-2 antibody testing was conducted on 100 male prostitutes. HIV-1 antibody testing was conducted on 100 male prostitutes and HIV-2 antibody testing was conducted on 100 male prostitutes.

Risk factor	n	% HIV-1	% HIV-2
Age (years)	100	17.0	1.0
Sexual activity (times/week)	100	17.0	1.0
Drug use (times/week)	100	17.0	1.0
History of STD (times)	100	17.0	1.0
History of syphilis (times)	100	17.0	1.0
History of gonorrhoea (times)	100	17.0	1.0
History of warts (times)	100	17.0	1.0
History of hepatitis (times)	100	17.0	1.0

Conclusions: HIV-1 antibody testing was conducted on 100 male prostitutes and HIV-2 antibody testing was conducted on 100 male prostitutes. HIV-1 antibody testing was conducted on 100 male prostitutes and HIV-2 antibody testing was conducted on 100 male prostitutes.

W.A.P.40 HIV-DISCORDANT COUPLES IN THE BALTIMORE BACS STUDY

Francis J. Beck, Jr., Fox R. Odoms, E. Aramant, H. Baruch, J. Barry W. Taylor, Jr., et al. The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, USA.

Objective: To determine infection status, sexual practices and coinfections of HIV-1 seropositive and HIV-1 seronegative couples. **Methods:** Thirty-four self-identified seropositive HIV-1 discordant, 8 HIV-1 seronegative and 18 seronegative concordant couples had detailed sexual histories taken and blood drawn for laboratory tests.

	Concordant Seropositive	Discordant Seronegative	Concordant Seronegative
Number of persons	10	34	34
C CD4	407	440	1140
C CD8/CD8 ratio	0.6	0.6	1.0
HIV-1 culture positive	6/10	28/33	2/33
HIV-1 RNA detected (PCR)	1/1	7/7	0/7
Anal insertive sex:			
- with primary partner	8/10	27/34	30/34
- never using condom	2/8	13/27	8/20
Anal receptive sex:			
- with primary partner	10/10	29/34	30/34
- never using condom	3/10	11/29	12/20

Conclusions: Sexually active HIV-1 discordant couples exist without evidence of viral transmission. The presence of a virus positive seronegative person in this high risk population requires further investigation.

W.A.P.42 SEROEPIDEMIOLOGICAL STUDY OF HIV INFECTION AMONG HOMOSEXUAL MEN ATTENDING A MEDICAL CLINIC IN MONTREAL

John E. Fife, Jr., Brian M. Smith, Georgia State University, Atlanta

John E. Fife, Jr., Brian M. Smith, Georgia State University, Atlanta

Objective: To determine the prevalence of HIV infection and characteristic sexual behavior among homosexual men attending a medical clinic in Montreal. **Methods:** A cross-sectional study of HIV infection, comparing anti-HIV testing and a HIV-1 antibody test. **Results:** HIV-1 antibody testing was conducted on 100 male prostitutes and HIV-2 antibody testing was conducted on 100 male prostitutes.

Conclusions: HIV-1 antibody testing was conducted on 100 male prostitutes and HIV-2 antibody testing was conducted on 100 male prostitutes. HIV-1 antibody testing was conducted on 100 male prostitutes and HIV-2 antibody testing was conducted on 100 male prostitutes.

Session d'affichage Poster Session



Épidémiologie et santé publique Epidemiology and Public Health

W.A.P.43

RISK FACTORS IN HOMOSEXUAL TRANSMISSION OF HIV
Ennio Ricchi¹, P.Cestigiolla¹, N.Borneri¹, N.Bentale²,
P.C. Ma¹, P. DiStefano¹
¹ICG Istituto Nazionale Tumori, ²Instituto di Microbiologia,
Universita' di Bologna, Bologna, ITALY.

Objective: To evaluate the risk factors linked to HIV infection in a cohort of Italian homo-bisexual men enrolled in 1980-1986, and to look for their modifications during that period.

Methods: We have studied 854 homo-bisexual men (i.e. drug addicts excluded) from Northern Italy that refer at one's own free will to HIV screening program. All answered an epidemiological interview about sexual habits in 8 partners/year, "safe-sex", sexual intercourse behavior and underwent HIV test (performed by ELISA and confirmed). A cohort of 378 subjects which were HIV test every six months for a follow up period of 12-36 months.

TABLE I	# HIV Ab +ve	%
1985	258	12.9
1986	129	17
1987	211	18
1988	248	9

change seen in Italian homo-bisexual community, mainly the reduction of preactivity, which can explain the slow diffusion of HIV in this group.

Conclusion: The earlier behavior change seen in Italian homo-bisexual community, mainly the reduction of preactivity, which can explain the slow diffusion of HIV in this group.

W.A.P.45

THE DEVELOPMENT OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) AMONG TWO COHORTS OF SEXUALLY TRANSMITTED (STD) PATIENTS WITH DIFFERENT VENEREAL DISEASE HISTORIES. Wayne J. Shandera
Dallas County Health Department, Dallas, Texas, U.S.A.
Ben Taub Hospital, Baylor College of Medicine, Houston, TX, U.S.A.

OBJECTIVE: To assess the risk of acquiring HIV infection among 2 cohorts of homosexual men treated for syphilis and other venereal infections in Dallas County, Texas.

METHODS: Two groups of homosexual male patients with venereal exposures were analyzed by a prospective chart review. The first included 302 individuals with a history of early (primary or secondary) syphilis during 1986; the second, 114 controls (matched by first initial of last name with a history of culture-negative gonorrhea or chlamydia but without any history of syphilis). The rate of AIDS in the 2 groups was assessed by reviewing a registry of local AIDS cases that had been diagnosed by mid-1988.

RESULTS: The number of AIDS cases among the two groups was similar: 14 (4.5%) among the patients with a history of early syphilis during 1986 and 6 (5.3%) among the matched control patients with a history of gonorrhea during 1986 (p = 0.252, p < 0.25).

CONCLUSION: Among American homosexual men, a relationship between a history of early syphilis and an increased rate of AIDS cannot be conclusively established 2 years after the episode of early syphilis and suggests that a history of syphilis does not serve conclusively as a risk factor for HIV infection and AIDS among American homosexual men as it does among AIDS patients belonging to other at-risk populations such as those treated and reported from central Africa.

Transmission verticale

Vertical Transmission

W.A.P.47

MATERNAL FACTORS AND NEONATAL CHARACTERISTICS ASSOCIATED WITH HIV INFECTION IN INFANTS OF SEROPOSITIVE MOTHERS.
Nair, Pragnanand; Johnson, J., J. Bines, S., Alger, L. and Seiden, S.
Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, U.S.A.

Objective: To correlate maternal and neonatal characteristics with perinatal transmission of HIV.

Methods: In a prospective study of perinatal transmission, infants born to seropositive women were assessed for anti-HIV IgG, IgM, and HIV antigen at 2, 4, 6, 9 and 12 months of age. Data on 35 infants born to HIV positive women, 15 of whom show evidence of being infected, are presented.

Results: All mothers of infected infants and 90% of mothers of non-infected infants had history of IV drug use. There was no significant difference in age, education, type of family, marital status, parity or age at first pregnancy. The incidence of STD infections during pregnancy was higher in mothers of infected babies (40% vs 25%) and their participation in methadone treatment program was significantly lower (37% vs 55%). Birth weights, gestational ages and perinatal problems were similar in both groups except for a significant abstinence syndrome due mostly to methadone withdrawal which was higher in the non-infected (76.2% vs 27%).

Conclusion: In this group of infants transmission of HIV appeared to be associated with maternal lifestyle characteristics.

W.A.P.44

EPIDEMIOLOGICAL, IMMUNOLOGICAL AND SEROLOGICAL CHANGES IN A COHORT OF HOMOSEXUAL MEN: RISK FACTORS OVER SIX YEARS

Miller, Roger J., Chaves, J., Pappas L.J.
CDC Center for Infectious Diseases, Atlanta, GA; ¹Primeri Atlanta's Hospital, Atlanta, Georgia.

Objective: To determine rates of seroconversion and predictors of seronegativity and their relation to social lifestyle. In 1983 a cohort of 1000 homosexual men was recruited for a prospective study at a major teaching hospital. 100 seroconversion and immune function measurements were performed at six monthly intervals. In addition, all patients have completed and information on social lifestyle was obtained by questionnaire.

Results: The prevalence of antibody to HIV rose from 0% to 1.8% in 1986. There has been no further seroconversion. Two patients have developed group B disease, and the AIDS risk score (a composite score of seronegativity, seroconversion, and immune function) was significantly higher in the seronegative group. For CD4 counts the mean of annual partners and the number of reported STD's (p < 0.001). There has been a highly significant decrease in the number of sexual partners and the number of reported STD's (p < 0.001). There has also been a significant fall in the frequency of sexual acts, though not statistically significant. This applies to receptive and active partners, but not to oral transactions.

Conclusion: The fall in the number of sexual partners and the number of reported STD's is associated with a fall in the frequency of sexual acts, though not statistically significant. This applies to receptive and active partners, but not to oral transactions.

2 Although there are clear group trends, for a single individual, seronegativity and seroconversion are not predictive of seronegativity.

3 The combination of seronegativity and increasing risk resulted in a reduction of problems perceived to be unsafe.

W.A.P.46

RECENT HIV SEROCONVERTERS (SC) IN A SAN FRANCISCO COHORT OF HOMOSEXUAL/BISexual MEN: RISK FACTORS FOR NEW INFECTION.
Lillian Alan, E., O'Malley, P.M., Hessel, N.A., Bell, L.S., Cannon, L., Rutherford, S., Department of Medicine, San Francisco, CA; ²Centers for Disease Control, Atlanta, GA, U.S.A.

Objective: To describe homosexual/bisexual men (HBM) who recently seroconverted to HIV antibody (Ab) and behavioral risk factors for these SC.

Methods: Since 1983, follow-up studies have been conducted on a cohort of HBM recruited from 1970-1980 for hepatitis B studies. Eleven HBM were seronegative to HIV antibody at recruitment during 1986 (6) or 1987 (5) compared to 288 persons who remained seronegative (SN).

Results: During an interview period of 12-33 months (median=18) preceding the estimated date of seroconversion, SC reported a median of 30 sexual partners (range=1-25); 1 SC reported only 1-2 partners. 6/11 SC reported engaging in receptive anal intercourse without a condom, 2/11 SC reported only insertive anal intercourse without a condom, and 1 SC denied anal intercourse and reported only receptive and insertive oral-genital contact with multiple partners. Prior to the date of seroconversion, 7 SC had been told that they were HIV Ab negative based on a previous sample. Compared to SN, SC had a greater number of both steady and nonsteady sexual partners; SC were also more likely to have engaged in both receptive and insertive anal intercourse without a condom. SC and SN did not differ with respect to age, race, education, sexual contact with a female, or use of IV drugs.

Conclusion: A small number of HBM continue to seroconvert to HIV, primarily in association with unprotected receptive or insertive anal intercourse. Although multiple partners are also associated with an increased risk of seroconversion, some SC reported only 1 or 2 partners.

W.A.P.48

RISK FACTOR(S) IN SPONTANEOUS HIV SEROCONVERSION (SP) CHILDREN IN THE SAN JUAN CITY HOSPITAL, SANTIAGO, PUERTO RICO

Elizabet Jimenez, M.L., Corvea, L., Lopez, L., Paves, C., Reyes.
Department of Pediatrics, Pediatric Hematology Service, San Juan City Hospital, San Juan, Puerto Rico.

Objective: To determine the risk and mode of transmission of HIV infection in symptomatic children from 0-13 years of age at SJC.

Methods: 95 SP pts. were identified. 70-97 (41%), P-5-42 (44%), P-5-20 (52%), of the 32 symptomatic pts., 48 (92.3%) were perinatally infected (PI) and 4 (7.7%) blood acquired. The RF of parents in the PI children were:

None	45 (93.2%)	19 (42%) father
1	3 (7.7%)	19 (42%) mother
2	0	3 (7.7%) both parents
3	0	3 (7.7%) husband

Several Sex Partners... 4 (2%)

Disease... 2 (5%)

Conclusion: Perinatal infection was found to be the predominant mode of transmission (92.3%) in the symptomatic pts. at SJC. TDD was also most important RF in parents and directly related to this mode of transmission. The majority of the SP mothers were infected by a HIV sexual partner. Both perinatal infection and TDD are higher in 53% area than in the rest of P.R.

Session d'affichage
Poster Session



W.A.P.55 INCIDENCE OF AIDS IN SPANISH HIV INFECTED PATIENTS
 J. Pérez, M. Bellón, P. Sureda, C. Clotet, B. Gadea, J. Estany, C. Riera, J. de la Torre and BARDOLAN AIDS STUDY GROUP. Hospitalis Clinic, Bellvitge, Terrasa, Sarriena Trias, and Vall d'Hebron, Barcelona, Spain.


Objective: To describe the incidence of AIDS (CDC criteria of August 1987) among persons infected with the HIV in Barcelona (Spain) where drug addicts are the most frequent risk group and tuberculosis the most common initial manifestation of AIDS.
Methods: A total of 8100 people who were at high risk for AIDS, had enrolled in cohort's studies of homosexual men, parenteral drug users and haemophiliacs before december 1986. A total of 952 were either HIV seropositive at enrollment or seroconverted subsequently, and could be followed-up. 646 (70%) of the 952 were parenteral drug addicts.
RESULTS: The AIDS developed in 93 (10.3%) during a median follow-up period of 30 months (range 1 to 78 months); using actuarial survival calculations, the estimated 6-year cumulative incidence of AIDS among all HIV seropositive subjects was 23.8% (range 18 to 30.4%; 95% confidence interval). Among the homosexual, drug addicts and haemophilic cohorts the incidence at 6 years was 12%, 15% and 32% respectively (P<0.05). Comparing the survival functions the risk of developing AIDS was significantly greater among those presenting with the CDC stages IV and V (P<0.0001).
Conclusion: The risk of AIDS development after 6 years of HIV infection was 23% and the progression rate among drug addicts was not significantly different than the progression rate of male homosexuals or haemophiliacs.

W.A.P.50 NATURAL HISTORY OF HIV INFECTION IN WOMEN OF CHILD BEARING AGE IN SPAIN.
 Dr. E. M. Moreno, Dr. S. Kipoti - Makereve University, P.O. Box 7077, Kampala, Uganda.

Objective: To determine the morbidity and mortality rates associated with HIV infection among women of child bearing age in Uganda.
Methodology: 87 HIV Seropositive mothers were recruited from an antenatal clinic at Nsambugu Hospital in Kampala City. They were prospectively followed-up at monthly intervals for 0 - 35 months.
Results: During the follow-up period most of the women had delivered twice, 3 mothers had died, 3 of whom had seropositive AIDS (SIDA). 1 had seroneurological manifestations, 41 are still being followed-up but 4 of whom currently have SIDA. The rate of progression to the next stage in this cohort of women who delivered children and lactated is comparable to what has been found for the general population in other studies elsewhere.
Conclusion: From this study pregnancy and lactation did not accelerate the rate of progression to AID/AIDS.

W.A.P.57 DEVIATION OF AN AIDS PROGRESSION CURVE IN A GAY COHORT
 Schechter, Martin L.; Crab KP; Le TN; Wilbongby P; Montaner JSO. The Vancouver Lymphadenopathy-AIDS Study, Vancouver, BC, Canada.

To study patterns of AIDS progression, we fit a Weibull distribution to the first 60 months of AIDS progression in a cohort of 553 HIV men (232 seropositive CD4, 118 seronegative CD4). We first estimated 18 months of lead time for SP based on laboratory parameters and compared with SI. The model was then fit to 60 months (Feb-79), extended to 88 months, and graphing with the actual progression as below.
 The model (upper curve) gave rise to projections that agree with published studies. The actual progression (lower curve) deviated away from the model after 60 months. The observed Kaplan-Meier projection at 88 months was only 28% (whereas 42% predicted by the model).



AIDS progression in a seropositive gay cohort appears to have deviated from a Weibull distribution. We speculate this may be an early effect of the wider use of zidovudine. Drug effects will have to be accounted for in natural history studies and in epidemiologic projections.

W.A.P.58 PROGRESSION TO AIDS IN COHORTS OF SEROCONVERSION AND SEROCONVERTING GAY MEN: RESULTS AT 4 YEARS
 Crab Kera J.P.; Schechter M.P.; McLeod W.A.; Weaver M.S.; Wilbongby P.; Douglas P.; Scalet P.; Le TN; Wilbongby P.; Montaner JSO et al.

The Vancouver Lymphadenopathy-AIDS Study, St. Paul's Hospital and the University of British Columbia, Vancouver, BC, Canada. *Federal Centre for AIDS, Ottawa, Ontario, Canada.

Objective: To determine the rate of progression to AIDS in a cohort of seropositive gay men stratified by those who were seropositive at entry and those who seroconverted under study.
Methods: We identified all seropositive subjects in our prospective study who completed at least 2 visits during the period 11/82 to 12/86. This group was divided into seropositive at entry (seropositive: SP) and those who seroconverted under observation (seroconverting: SI). AIDS was diagnosed in this cohort according to CDC criteria. Methods of survival analysis were used to calculate progression rates to AIDS. Kaplan-Meier estimates of cumulative progression were calculated as were actuarial annual attack rates, namely the conditional probability of AIDS among those AIDS-free at the beginning of the year. Cox regression was used to model predictors. **Results:** A total of 351 seropositive subjects were included in the analysis (232 SP, 118 SI). The median lengths of observation while seropositive were 62.0 mos (range-72) for SP and 48.5 mos (range-16.6) for SI. A total of 69 cases of AIDS were observed (59 SP, 10 SI). Product limit estimates of cumulative progression were 28.7% (95% CI 24.5 to 32.9%) for SP and 11.1% (95% CI 6.4 to 16.0%) for SI at 60 months. The annual AIDS attack rates for the first 6 years in SP were 3.1%, 3.9%, 7.8%, 5.3%, 9.0% and 5.2% respectively and 0.0%, 1.0%, 3.0%, 6.0% and 2.1% for the first 5 years in SI respectively. CD4 counts, CD4 loading, and IgA levels independently predicted AIDS.
Conclusions: Progression by 5 years in SI, a true seroconversion cohort, is estimated to be about 11%. SP appears to have a mean lead time infection period of about 18 months. The drop in annual attack rate seen in the final year in both SP and SI could be due to reporting delay but we speculate it is more likely due to recent wider use of zidovudine.

W.A.P.59 PROGRESSION OF HIV DISEASE MOST IMPROVED OVER 88 MONTHS (1984) : A THREE-YEAR PROSPECTIVE STUDY. Iijima, Shiro, Iwashiro S., Suzuki S. et al. National AIDS Institute, Tokyo, Japan.

Objective: To determine the progression rate of HIV disease related to various stages 1984 and 1987. A prospective evaluation of 318 HIV men aged 19-39 (202) were HIV seropositive (Iliac with positive RIA) confirmed (Iliac with positive Western blot) and 116 (37) with seronegative western blot (serum III of CDC classification), 27 (8%) and 10 (3%) with seronegative western blot (Iliac II and IV) respectively, only 136 (19) were followed regularly for a median duration of 81 months (range 1-88), and were the object of this evaluation. Results: At first clinical evaluation 87 were HIV negative and 72 HIV positive, and of the latter group none had full-blown AIDS, no were symptomatic and 32 asymptomatic. Progression of HIV disease is summarized in the Table.

Seroconversion	1987 (82)	1984 (192)
Disease progression: asymptomatic ->	0	11/22 (54%)
symptomatic ->	0	15/24 (62%)
AIDS	0	4/42 (10%)
Full-blown AIDS	0	4/42 (10%)
Deaths	0	3/42 (7%)
Survival	100%	100%

Conclusion: After a median follow-up of 76 months, 1/87 (1%) of previously HIV negative 1984 seroconverters, and 4/72 (6%) of HIV-seropositive full-blown AIDS. In addition, despite educational efforts, a large number (80%) of newly positive 1984 still exchange syringes and needles and only a few (17%) use condoms.

W.A.P.60 DEVENIR DE SILETTS INFECTES PAR LE VIH : PREMIERS RESULTATS D'UNE SURVEILLANCE HOSPITALIERE.
 Schmitt, A. et al. Groupe d'Épidémiologie Clinique de Bordeaux (GEECA).

Centre Hospitalier Régional Universitaire (CHRU), Bordeaux, France.

Objectif: Un système de surveillance épidémiologique a été mis en place au CHRU de Bordeaux. Il permet d'analyser l'évolution clinique des sujets infectés par le VIH.
Méthodes: Les services hospitaliers participent toutes les semaines depuis 1986. A chaque consultation, les données sont recueillies sur un questionnaire standardisé, puis sont analysées et interprétées. La classification utilisée est celle des Centres for Disease Control. Les probabilités cumulées d'évolution au stade IV ou au stade SIDA sont calculées par la méthode de Kaplan-Meier.
Résultats: Au 30 octobre 1988, 446 sujets atteints ont été inclus. Parmi ceux-ci 253 patients étaient classés III et 193 au stade IV ou au stade SIDA. Les probabilités cumulées sont respectivement: 79% pour les hommes et 17,2% pour les femmes au stade IV et 10,2% pour les hommes et 1,2% pour les femmes au stade SIDA. Les sujets ayant atteint le stade IV (n=30) sont tous tombés IV 6 mois après leur entrée au CHRU. Les sujets ayant atteint le stade IV (n=30) sont tous tombés IV 6 mois après leur entrée au CHRU. Les sujets ayant atteint le stade IV (n=30) sont tous tombés IV 6 mois après leur entrée au CHRU.
Conclusion: Les données actuellement recueillies ne permettent pas de conclure sur le VIH soit comparativement avec la littérature. Le rôle en faveur du système de surveillance épidémiologique de l'hôpital pour le VIH semble important pour repérer le temps de passage des sujets asymptomatiques vers le stade IV et le stade SIDA. De plus, on a pu constater que les sujets asymptomatiques vont au stade IV de façon plus précoce que les sujets symptomatiques.

Section of affichage Poster Session

W.A.P.61 RISK ESTIMATES OF AIDS IN HEMOPHILIACS
 Joyce F. Killinger, PG Rosenber, JJ Goedert, LM Alton, CA Kessler, NE Gall, et al.
 *NHL, Research Triangle Park #2709 USA; #NCI, Bethesda MD 20892; #HHS, Stet Medical Ctr, Cambridge, MA; #CDC, Atlanta, GA 30307; #George Washington Univ Hospital, Washington DC 20037 for the NCI Hemophilia AIDS Study Group.

Objective: To estimate the proportion of HIV-infected adult and juvenile hemophiliacs who will eventually develop AIDS and to evaluate the uncertainties in these estimates.
Methods: A mixed Weibull survival model was fit to AIDS incidence data from 328 hemophiliacs whose dates of HIV seroconversion were known, including 33 AIDS cases among 174 adults (age at seroconversion >21) and 11 AIDS cases among 154 children. AIDS estimate parameters such as 74 counts were analyzed. The AIDS-free survival distribution was given by $f(t) = p \cdot \exp[-\lambda(t-t_0)^{\alpha}] + (1-p)$, the proportion p who will ever develop AIDS was estimated from its profile likelihood together with confidence intervals. Results: For adults, the profile likelihood was very flat, and indeed one could not strongly reject the possibility that $p=1$. However, our best estimate of p was .34 with 95% confidence interval (.27, .41). Results for children were similarly uncertain, with an estimate of $p=1$ with 95% confidence interval of $p=.24$, with a 95% confidence interval (.16, .66).
Conclusion: Our data yield very imprecise estimates of the proportions who will ever develop AIDS and certainly do not demonstrate that all HIV-infected hemophiliacs will develop clinical disease. Indeed, our estimates of p are much lower than those reported for studies of homosexual men.

W.A.P.63 FOLLOW-UP OF A COHORT OF EX IVDDs RESIDENT IN THERAPEUTICAL COMMUNITIES IN ITALY
 Marco Giannone, Fiume A., Marchionni C., Masai V., Prestivo T., Zampieri A. et al.

Istituto Superiore di Sanita, Rome, Italy; *Comunità Incontro, Terzi, Italy.
Objective: To describe the natural history of HIV infection in an IVDDs no longer exposed to intravenous drug use in the progression of the infection.
Methods: During 1988 all 2,028 residents in the 73 therapeutic communities (TC) administered by Comunità Incontro were clinically evaluated and tested for HIV. Risk factors for HIV infection were assessed by face to face interviews using a structured questionnaire. For those who were HIV seropositive a prospective follow-up was initiated while clinical and serological retrospective data were actively searched.
Results: All 2,028 residents were tested for HIV and 1,992 (97%) were found seropositive. Complete retrospective data are available for 710 (35.1%) HIV sero-positive, median follow-up 12.5 months (range 1-41 months). No AIDS cases were admitted at the TC and no AIDS cases occurred in the cohort during 1988. 304 (31.5%) subjects were asymptomatic at first visit and still such at last recall. The remaining 204 (28.9%) subjects were symptomatic either by persistent generalized lymphadenopathy or with constitutional disease or both. During the follow-up period 98 subjects (48.5% of the asymptomatic) showed no signs of progression or regression, 58 subjects (28.7%) showed clear signs of improvement, while the remaining 46 subjects (22.8%) showed clinical regression. A complete analysis will be presented at the conference.
Conclusion: Former intravenous drug users infected with HIV infection, living in a semi-protected conditions do not seem to show a faster progression to AIDS than other groups. However it is still to early to say whether HIV sero-residents in TCs have a better prognosis than others.

W.A.P.65 NATURAL HISTORY OF HIV-1 INFECTION FOLLOWING PROXENY
 Jay J. P. Braddick, M.D.,
 Krishna, M.D., *Mehra-Agila, S.J., Plummer, J.A., M.,
 *University of Nairobi, Kenya; **University of Manitoba, Winnipeg, Canada, #Mediastate Hospital, University of Washington, Seattle, U.S.A.

Objective: To study the influence of pregnancy on HIV-1 disease progression.
Method: Women attending a maternity hospital in Nairobi, Kenya were screened for HIV-1 Ab at delivery. HIV+ women were enrolled in a prospective cohort study and followed for HIV related illness.
Result: One hundred and twenty eight HIV+ women were enrolled and followed for 11 months of HIV related illness. 15 (9%) were asymptomatic, 15 (9%) asymptomatic (AS) and 13 (10%) had systemic disease (SD) 16 chronic pruritic rash (R), 1 hairy leukoplakia (L), 5 herpes zoster (Z). 8 Kaposi sarcoma (KS). Using logistic analysis, the cumulative probability (C) of AS women developing SD or dying was 21% (died of HIV related illness at a mean of 4.7 (range 0.5-9) months), 5 had at 19.6 (range 12-20) months, 5 developed chronic oral and/or vaginal candidiasis at 16.5 (range 12-20) months, and 1 developed R at 6 months. Four initially AS mothers delivered second infants and remained asymptomatic at 25.5 (range 24-27) months. Of the 15 women with SD at delivery a C of 5% had progression of HIV disease or died 2 died of AIDS (1 R, 1 wasting illness) at 7 months after delivery, 10 developed additional manifestations of HIV (8 with oral & vaginal candidiasis at 7 months, oral candidiasis at 1 month).
Conclusion: In this cohort of women who were initially asymptomatic HIV+ women progressed to HIV related illness/death within 2 years after delivery, and one half of the women with systemic disease at delivery had further progression of HIV disease or died within 9 months.

Epidémiologie et santé publique Epidemiology and Public Health

W.A.P.62 Enhanced prediction of AIDS in HIV sero-positive asymptomatic men:
 Rafaela Velaz de Calvario and Serologic Methods Group and its Collaboration,
 LA, El Paso, JM Taylor, R Delea, B Holman, J Mariani, P Nahnian, J (J) Giorgi UCLA School of Medicine and Public Health, Los Angeles, California, U.S.A.

Objective: To evaluate B cellular and serologic markers singly and in combination for their ability to predict the occurrence of AIDS within 4 years.
Methods: CD4+ T cell number, percent, and CD4/CD8 ratio were determined by flow cytometry. Serum neopterin, beta-2-microglobulin (B2M) soluble IL-2 receptor (sIL-2R), IgA, and p24 HIV antigen were determined by serologic tests. The relative hazard from abnormal levels of these were calculated using the proportional hazards model. A random sample of 366 individuals were chosen from 813 seropositive individuals, participating in the Los Angeles Center of the Multicenter AIDS Cohort Study and were followed for 4 years to until the diagnosis of AIDS.
Results: CD4+CD8 ratio and CD4+ T cell percent were reduced and/or serum neopterin levels were elevated in more than half of the subjects (baseline the normal 100-500 counts per microliter). Reduced CD4+ T cells (number, percent or ratio) was the best single predictor of AIDS. Neopterin and B2M are similar in their predictive ability and slightly less good than CD4+ T cells. The combination of B2M, IgA, and sIL-2R both have predictive ability but not as strong as neopterin or B2M. Neopterin, B2M, sIL-2R, IgA, and p24 antigen all have statistical significance independent of CD4+ T cells. In addition to predictive ability, Neopterin appears to add the most. In a stepwise procedure the following variables were chosen in order: CD4+CD8 ratio, neopterin, IgA, sIL-2R, antigen.
Conclusions: These studies indicate that measurements of multiple parameters reflecting different facets of HIV infection add to predictive value regarding the occurrence of AIDS. The most important parameters are CD4+ T cell number (or number) and serum neopterin or B2M. Soluble IL-2R, IgA, and p24 antigen, can be useful to add predictability if the other measurements are made.

W.A.P.64 AIDS YEARLY INCIDENCE IN 1984 HIV SEROPOSITIVE COHORT:
 NO DEFINITE TREND 1985-1988
 J. English, P. Chantel, J. Ho, K. W. and Painovich, G. Multicenter AIDS Cohort Study, Los Angeles, California, U.S.A.

Objective: To observe temporal trends in the incidence of AIDS in a cohort of seropositive men.
Methods: Approximately 1870 homosexual men seropositive on 1984 enrollment in the Multicenter AIDS Cohort Study (MACS) have been followed for progression to AIDS. Encouraging the first semester which was incomplete, and the last semester for which reporting is not yet finished, the semi-annual incidence rates per 100 person semesters of follow-up were calculated for each center and for the MACS as a whole.
Results: Incidence of AIDS in Seropositivity by Semester:

Semester	AIDS cases	Person semesters	AIDS Inc. (%)	AIDS Incidence/Center
1/85-6/85	28	1451	1.9	0.9 2.5 2.1
7/85-12/85	60	1807	3.3	2.8 3.9 3.2
1/86-6/86	84	1975	4.3	3.1 4.3 4.9
7/86-12/86	45	1291	3.5	2.1 3.8 3.0
1/87-6/87	75	1870	4.0	4.8 7.4 5.0 3.2
7/87-12/87	71	1201	5.9	5.2 1.9 2.8 2.9

Conclusion: The AIDS incidence is seropositive men differs by center, but there is no clear increasing trend over this period of time.

W.A.P.66 THE INCIDENCE OF ANTISEROLOGIC HIV INFECTION: THE UNITED STATES AND OTHER HIGH INCOME COUNTRIES

Rafaela Velaz de Calvario, JM Taylor, J. O'Connell, K. Yamamoto, K. J. Department of Historical Research, War Reser Army Institute of Science and Technology, Fort Belvoir, IL, U.S.A.

Objective: To describe the natural history of early HIV infection and delineate prognostic parameters. Methods: The characteristics of HIV infection in the stratification of the US Army. All HIV seropositive individuals are clinically evaluated and staged per the Walter Reed Staging Classification. Recruitment occurs at 3-6 month intervals. Results: To date 1500 individuals have been enrolled including over 1200 with follow up visits greater than 1 year.

Stage	PRELIM UP STAGE				DEATH
	MC	MC	MC	MC	
MC1	447	468	28	28	0.26
MC2	479	668	198	68	18.06
MC3	266	608	28	28	28
MC4	23	578	248	138	48
MC5	49	198	198	228	228

Conclusion: Progression of asymptomatic HIV infection to clinical immunodeficiency correlated with CD4 count, CD8 cell reactivity, and initial WR stage of infection and duration follow up. This observation holds for each variable independently and in combination will be presented.
Conclusion: All asymptomatic HIV seropositive white can be clinically classified by the Walter Reed Staging Classification providing important prognostic information. Wide scale clinical application is feasible as demonstrated in the US Army Health Care System.

Session d'affichage Poster Session



W.A.P.73 PROGRESSION OF HIV-1 DISEASE IN A POPULATION OF SEROPOSITIVE NAVY AND MARINE CD4+ CELL COUNTS
 HARRIS, Douglas A., Wilson, D.S., Hagner, K.F., et al.
 * National Naval Post Center, Bethesda, Maryland and ** Henry W. Jackson Foundation, Rockville, Maryland

Objective: To determine the rate of HIV-1 disease progression (prog) in screened seropositive active duty military personnel.

Methods: We have evaluated 517 HIV seropositive personnel with serial evaluations. 129 patients were evaluated at 9 to 15 months (1 year) and 57 patients were seen at 21 to 27 months (2 years). Each evaluation was point staged using the Walter Reed classification based on the clinical data for that visit alone.

Initial Stage	1 YEAR			2 YEARS		
	N	%	AIDS	N	%	AIDS
1-2	115	22	0	45	42	2
3-4	22	4	0	29	11	0
5	3	68	4	25	75	2
All Stages	159	28	67	43	78	2

Conclusions: There was 47% progression in Walter Reed stage and 9% progression to AIDS at 2 years in this population sample. There was an average 14 cell count decline per year with a normal distribution about the mean. For patients with T4 cell counts between 680 and 200 cells the rate of decline was essentially linear ranging from 68 to 82 T4 cells lost per year in each 14 interval examined.

W.A.P.74 PROSPECTIVE HELIXIBINUM COHORT STUDY IN HOMOSEXUAL MEN IN THE A-4 TROOP FOLLOW UP. SEROLOGICAL RESULTS.
 HERRING, Richard, For Study Group.
 AIDS-Serum in Helixibinum, Berlin, Federal Republic of Germany

Objective: To evaluate the natural course of HIV-infection.

Methods: In 1984 a prospective multicenter cohort study was started in FRG. A total of 771 homosexual men were recruited in 7 centers in metropolitan areas. At time of enrollment 412 (53%) men were positive to HIV-antibody, 25 of those had full blown AIDS. Cohort members are examined twice a year.

Results (Serological): 75 of the HIV-infected homosexual men developed AIDS during 11 months of observation. The incidence of AIDS was a constant 38 per year. For only 2 cases with AIDS the time of infection is known. To gain a better figure of the course of HIV-infection and the time of latency, we calculated the probability that CD4-count counts fall below certain limits. On the basis of these calculations a model was developed which allows the prognosis of the development of HIV-disease in the cohort. In 12 years after HIV-infection 90% of the infected individuals will have less than 300 CD4-cells/ml.

Discussion: The beginning (time of infection) and the end (AIDS) of the course of HIV-infection is not known for the vast majority of HIV-infected individuals. A stochastic model, on the basis of data from our cohort may help to gain a better understanding of the time course of HIV-infection.

Survie des personnes atteintes du SIDA Survival of the AIDS Patient

W.A.P.76 DEGREE OF HIV-RELATED CNS INVOLVEMENT AND LONG-TERM SURVIVAL: PRELIMINARY RESULTS.
 KERRY, F.A., MacFadden, D.K. Dept. Medicine, University of Toronto, Toronto Western Hospital, Toronto, Ontario, Canada.

Twenty-three homosexual men at various stages of HIV-related illness and 6 seronegative men have been entered into a longitudinal study of HIV-induced CNS dysfunction. All subjects were given an initial (baseline) set of clinical, immunologic, CT and neuropsychological assessments and then re-assessed at 6 month intervals. Results indicate that ARC patients (1/23) are most cognitively impaired at the time of admission while AIDS patients (17/23) show a wide diversity of impairment; however, there appears to be an inverse relationship between the extent of impairment at baseline and survival among AIDS patients (high impairment/short survival). Furthermore results indicate that CNS involvement precedes the development of AIDS (presentation with PCP) in many cases and that ARC patients have considerable CNS involvement despite the absence of opportunistic infection. In the majority of AIDS patients there is a progression of CNS involvement across assessments but 20% of patients survive for over 2.5 years without significant CNS impairment; long-term survival may depend heavily on this relationship.

W.A.P.75 NATURAL HISTORY OF HIV INFECTION IN MEN IN GREAT BRITAIN IN MARINE COUNTRY
 HARRIS, Douglas A., Iribarren, J.H., Soren, G., Gillis, R., et al.
 P. Zaluska, G. Hospital Nuestra Señora de Arce, San Sebastian, Spain.

Objective: To describe the natural history of HIV infection among MSM.

Methods: Of 314 MSM screened in 1985 for HIV, 107 (34%) were seropositive. Of these, 103 entered a follow-up study. After an initial evaluation, they were screened every 6 months. We present the preliminary data obtained at 24 months follow-up.

Results: In the initial study 83% were asymptomatic. 81 only presented one analytic abnormality (anemia under hemogram) and/or (immunogram) and 14 had lymphadenopathy syndrome (LAD). After 24 months we evaluated 76 of them. 31 (39.5%) are asymptomatic; 37 (48.6%) are in group II with one analytic abnormality; 11 (14.5%) are in group III; 7 (9.1%) of them with analytic abnormality; one 16 in group IV; 10 (13.2%) of them meeting AIDS criteria (group IV-C); 8 (10.5%) in group IV-B and 1 (1.3%) in group IV-A. In 7/16 patients the disease has progressed.

Considering the group of 1006 who initially presented analytic alterations, 100 (10%) developed AIDS and in 10,400 (10.4%) the disease progressed. Of the patients originally asymptomatic, 6,100 (10.8%) now developed AIDS and 61,700 (10.8%) the disease has progressed. We discuss the behavior of the clinical and analytic findings of these patients over the course of 24 months.

Conclusion: We conclude by indicating that 10.8% of the group who developed AIDS and that the course of the disease is greatly influenced by the patients' initial status and analytic status.

W.A.P.77 DEMOGRAPHIC AND VIROLOGIC DETERMINANTS OF SURVIVAL IN AIDS: ROLE OF CYTOMEGALOVIRUS, CMV AND CD8+ LYMPHOCYTES
 FELD, N.H., Cole, L.A., Schwartz, L., Karmali, M., Torrealba, J., et al.
 * Massachusetts General Hospital, Boston, MA; * Los Angeles, CA; ** VA Medical Center, Los Angeles, CA; *** UCLA Medical Center, Los Angeles, CA; **** VA Medical Center, Los Angeles, CA, USA.

Objective: To study virologic and immunologic characteristics of patients surviving over 1 year first AIDS-defining event.
Methods: Sixty patients admitted with AIDS to Eisenhower Medical Center have been followed and the survivors evaluated by serum p24 antigen, polymerase chain reaction and culture for CMV, lymphocyte flow cytometry and ophthalmological examinations. Since 1987 the survivors have been treated with zidovudine and, since 1989, two also with human interferon.

Results: All 24 patients with CMV retinitis have died (median survival of 166 days) and 28 of 26 patients without retinitis died (median survival of 302 days). One probability of survival in the 2 groups = 0.543. The survivors have been free of CMV retinitis (except for one patient with inactive retinitis) and have had undetectable HIV p24 antigenemia, median count of 40 CD4+ cells/mm³, median count of 537 CD8+ cells/mm³, and CD4+/CD8+ ratio double-bearing cells ranging 126(152) - 554(31.52)/mm³. The patients dying with disseminated CMV infection had 31-202cp/ml of HIV p24 antigen, 0-9 CD8+ cells/mm³, and 2-174 CD4+/CD8+ cells/mm³. The patients dying with inactive CMV retinitis had 0-100cp/ml of HIV p24 antigen and with residual presence of CD4+ and CD8+ cells. Disseminated CMV infection had a better adverse prognostic factor in AIDS.

W.A.P.78 PREDICTORS OF SURVIVAL FOR AIDS IN BARCELONA SPAIN
 BERRAS, Gerard A.P., Vila, J., et al.
 * Hospital Municipal de San Sadu, Barcelona, Spain; ** Hospital de San Sadu, Barcelona, Spain.

Objective: To analyze the predictors of survival of 208 AIDS patients from Barcelona (Spain) where the survival percentage of drug addicts is high and represents the most common initial manifestation of AIDS.

Methods: 163 adults older than 14 years old with AIDS referred to the local health authorities were available for a longitudinal follow-up. Age, sex, group of sex for HIV infection, AIDS manifestation at diagnosis and the date of diagnosis were the variables included in the univariate analysis (Kaplan and Meyer survival curves) and in the multivariate analysis (Cox regression model) for overall survival.
Results: 102 (50.8%) were males and 58 (28.8%) were older than 40 years. 164 (53.3%) were parenteral drug addicts, 100 (34.5%) male homosexuals and the remaining 39 (17.2%) were categorized as other. 16 of them (7.9%) were seronegative for AIDS cases (33.3%) presented with a form of extrapulmonary tuberculosis, 148 (51.2%) with another opportunistic infection, 34 (11.8%) with a Kaposi Sarcoma and the remaining 11 cases with lymphoma. 31 (10.1%) were diagnosed before 1980. The survival probability dropped from 82% 300 days after diagnosis of AIDS, in the remaining patients the survival probability was significantly greater in those presenting with a tuberculosis (< 0.0001), among the drug addicts were the remaining groups (< 0.0001); in those diagnosed in 1980 or later (< 0.001) and in those younger than 40 years (< 0.0001). The multivariate analysis selected the year of diagnosis, group of sex, age and the clinical presentation with a tuberculosis. Conversely the women proposed were for male homosexuals, seronegatives or recipients of a contaminated blood transfusion, older than 40 years and presenting with a Kaposi Sarcoma or lymphoma. The best prognostic factor for drug addicts younger than 40 years whose initial manifestation of AIDS was an extrapulmonary tuberculosis.

**Session d'affichage
Poster Session**

**Épidémiologie et santé publique
Epidemiology and Public Health**

W.A.P.79 **PREDICTING IN-HOSPITAL MORTALITY FOR AIDS PATIENTS: A VICTORIA STUDY**

Macdonald, S., Gillman, S., H. Gillman, S., Palmer, C., Macdonald, S., Campbell, R. Palmer, C. and Macdonald, S. Victoria Hospital, Memorial University, St. John's, Nfld., Canada.

Estimating prognosis for a hospitalized AIDS patient is essential for optimal clinical management. We developed a prediction model for in-hospital mortality using admission data abstracted from 128 patient admissions to the Royal Victoria Hospital (R.V.H.). This model was subsequently validated on 62 patient admissions to the Memorial General Hospital (M.G.H.).

Using univariate analyses, stepwise logistic regression analysis, and clinical judgment, we identified independent predictors of in-hospital death including mean albumin (ALB) ($P = < .01$), serum lactate dehydrogenase (LDH) ($P = < .01$), and leukocyte count (WBC) ($P = < 0.27$) ($n = 60$). High, medium, and low-risk groups for in-hospital mortality were defined where the probability of dying was $\leq 100\%$, 100% to $> 95\%$, and $> 95\%$ respectively. Using the resulting BMD regression scores and 2x2 contingency table analysis, we tabulated the cutoff score that corresponded to each risk group. The validity of the BMD model was then tested by classifying admissions at M.G.H. We in-hospital mortality for the high, medium and low-risk groups was 100% (2/2), 42% (10/24) and 14% (5/36) respectively.

We conclude that routine admission laboratory tests associated with infection (ALB), pneumoniae pneumonia (LDH) and other infections (WBC) help predict the outcome of hospitalizing patients with AIDS.

W.A.P.80 **EFFECT OF MULTIPLE DISEASE MANIFESTATIONS ON LENGTH OF SURVIVAL FOR AIDS PATIENTS IN SAN FRANCISCO**

Palme, Susan E.; Lamp, G.F.; Rutherford, R.L.; Neal, J.P., U.S.A. Teunis, T. San Francisco Dept. of Public Health, San Francisco, CA, U.S.A.

Objectives: To evaluate the effect of multiple manifestations of AIDS-indicative diseases on length of survival. Methods: We evaluated survival following AIDS diagnosis for 4524 patients reported in San Francisco between July 1981 and Dec. 31, 1987. Cases were followed at 6-month intervals from diagnosis to death. 10% of cases were lost to follow-up. The number of AIDS-indicative disease manifestations occurring within 3 months of initial diagnosis was calculated, and median survival was calculated separately for patients with 1, 2, and 3 or more disease manifestations using the Kaplan-Meier product-limit method.

Results: The median survival for all patients was 12.8 months, with a 3-year survival rate of 5.8%. Survival decreased significantly as the number of separate manifestations of AIDS-indicative diseases increased. This trend was consistent for all patients regardless of initial diagnosis.

Median Survival by Number of Disease Manifestations

Initial Diagnosis	1 Disease	2 Diseases	3 Diseases	P-Value
KS	1000 17.0 mos	150 9.5 mos	30 5.3 mos	<.001
PCP	214 12.9	100 10.5	57 7.6	<.001
COI	591 8.8	165 6.8	---	<.05
Total	3763 13.5	516 8.8	112 5.8	<.001

Conclusion: The occurrence of multiple disease manifestations within 3 months of initial AIDS diagnosis significantly decreases survival.

W.A.P.81

IMPROVED SURVIVAL OF AIDS PATIENTS IN DALLAS, TEXAS AFTER 1986

Reisz, Charles E; Reif V, Freeman A, Baslund I, Karpf E, Dallas County Health Dept, Dallas, TX, USA.

Objective: To determine survival among AIDS patients in Dallas. Methods: Diagnosed AIDS patients have been reported to the Dallas County Health Department since 1981. The registry has been maintained using standard methods; validation surveys verify the completeness of reporting. Survival analysis was performed using Kaplan-Meier product limit estimates. Results: 1464 persons have been diagnosed with AIDS in Dallas between 1981 and 1988. Variables associated with survival include age at diagnosis, race, sex, and risk category. Among the 1044 homosexual males, aged 30-65, without a history of IV drug use, the median survival for those diagnosed pre-1986, 1986, and 1987 are 305, 386, and 402 days, respectively; trends for 1988 indicate a longer median survival. The survival times for those diagnosed pre-86 were different from those for each of the other years ($P < .01$); the difference between the other years may have occurred by chance ($P < .05$). Conclusions: There has been an improvement in AIDS patient survival. Potential reasons include "lead time bias" due to earlier diagnosis with the widespread use of HIV testing; antiviral therapy with AZT; or improved management of opportunistic infections. All three reasons may play a role in improved survival, but the effect for those diagnosed as early as 1984, before the widespread use of AZT, argues for lead time bias as an important factor.

W.A.P.82

IMPROVED SURVIVAL IN

Washington State Office on HIV/AIDS, Seattle; Seattle-King County Department of Health, AIDS Education & Prevention Center, Seattle, WA, U.S.A.

Objective: To monitor AIDS clinical care for people with AIDS (PWA) by diagnosis and disease state. Methods: Death dates were searched for death certificate review of every vital record for surviving PWAs. End-of-year product limit survival analysis was applied to the statewide HIV Surveillance Database for those diagnosed prior to 1987. Results: Overall median survival for all 777 cases was 465 days. Median survival significantly improved for people with IV drug use and for those cases diagnosed prior to 1986 compared to those diagnosed in 1986, while no increases were seen during this time interval for people with other diagnoses. This significant increase was seen in all categories for cases diagnosed in 1987 compared to those diagnosed in 1986. The decline of disease and curing episodes significantly prolonged survival in 1987. Cases with outpatient diagnosis survived significantly longer than other cases (1333 vs 641 days). Only six definitive episodes of PCP also had prolonged survival over each of the time intervals (data not shown).

Risk	0-50 Survival	51-100	101-150	151-200	Median Survival
CRS	238 / 2	260	289	407	289
KS	196	239 / 25	487	447	737
PCP	228 / 12	428	289	447	525/17*

*1/2 of cohort still alive. *Includes deaths and curing episodes.

Conclusions: The increase in survival time of PWAs is multifactorial and reflects improved medical care, HIV therapy, earlier diagnosis, and expansion of the DC case definition. Updated information and the relative contribution of each of these factors will be outlined.

W.A.P.83

REVIEWALIAN-BASED SURVIVAL ANALYSIS OF QUEBEC AIDS PATIENTS

Denis, Robert, W. H. Palmer, Robert, H. Quebec Regional des maladies Infectieuses Montreal, Quebec, Canada.

Objective: To assess survival of AIDS cases following diagnosis and to evaluate survival by age and sex. Methods: The vital status of the AIDS cases reported to January 15, 1989 was assessed through an analysis of the Quebec AIDS Registry (QAR) using a product limit method and the Cox proportional-hazards analysis were performed. Results: Of the 742 cases diagnosed, 359 were known to have died. The median survival following diagnosis was 9.0 months; the cumulative probability of survival at one, two and three years were 41%, 18% and 9.8%, respectively. Univariate analysis showed that survival was significantly shorter for children than for adult cases (7.0 vs. 9.8 months, $p = 0.002$). Among adult cases, there were no significant differences in survival by sex or age at diagnosis. Median survival time was significantly shorter for those born in a Western II country (9.1 vs. 10.0 months, $p = 0.06$). AIDS-related diseases were the strongest predictors of survival. The diagnosis of Kaposi's sarcoma (KS) was associated with longer survival (median 11.4 months, $p < 0.001$). In multivariate analysis, independent significant decreases in survival were found for age at diagnosis (1.33 vs. 3.39 years (relative risk (RR) of death at any time of 1.34) and for AIDS-related diseases when compared with the diagnosis of KS (RR = 1.55; 1.37 and 1.39 for B-cell lymphoma, Kaposi's sarcoma, and other opportunistic infections and other AIDS-related opportunistic syndromes, respectively). Conclusions: Active surveillance of AIDS cases permitted the evaluation of survival after diagnosis. Our study did not find shorter survival among city males or temporal improvements in survival, but confirmed the positive association of KS and a younger age at diagnosis with improved survival.

**Prévention par l'annonce au(x) partenaire(s)
Prevention Through Partner Notification**

W.A.P.84

REVIEWALIAN CONTACT TRACING IN A NEW YORK CITY STD CLINIC

Schultz, S. and Struchiner, E. New York City Dept. of Health, NY, NY, U.S.A.

Objective: To measure contact tracing among STD clinic patients with implications for HIV partner notification by comparing the results of traditional contact tracing intervention (CTI) which require naming partners with results of a confidential structured questionnaire (CSQ) where only the number of partners was required. Methods: 100 patients with diagnosed syphilis participated in a CTI performed by clinic personnel and also were enrolled in an HIV seroprevalence study where information on sexual behavior and risk factors for HIV infection were collected by an interviewer using a CSQ. Results: Data from 64 participants were analyzed: 21 (17%) were positive; 19 (32%) reported positive contacts; 4 (9%) reported IV drug use and 6 (9%) were HIV antibody positive. On CTI, 22 (34%) gave no information identifying contacts. There was a significant difference ($P < .001$) between number of contacts given in CSQ and CTI: 41 (64%) gave a larger number, 20 (33%) gave identical results and 3 (5%) gave a smaller number. Mean number of contacts for CSQ was 3.1 compared with 1.0 for CTI. From the CSQ, mean number of contacts for 3 months, 1 year, 3 years and since 1974 were 3, 7, 21, and 55, respectively. Conclusions: These data suggest that HIV partner notification in New York City may be seriously hampered by partner anonymity, lack of testing information, and concerns for confidentiality.



**Session d'affichage
Poster Session**

**Epidémiologie et santé publique
Epidemiology and Public Health**

W.A.P.85 SEXUALLY TRANSMITTED DISEASE (STD) CLINIC CLIENT OPINIONS ON HIV PARTNER NOTIFICATION

Spencer, W., Dagnan, G.; Wolf F.A., Sims, C.,**
*Colorado Department of Health STD/AIDS Section, Denver, Colorado, USA,**
University Hospital Health Sciences Center, STD Clinic, Denver, Colorado, USA.

Objective: Determine opinions on acceptance of HIV partner notification services by STD clinic clients.
Methods: Consecutive clients attending the University of Colorado Health Sciences Center STD clinic during October and November 1989 were asked to complete an anonymous 6 question survey.
Results: 212 clients responded to the survey (male 120, 56.6%; mean age 26.6; white 128, 60.4%). Almost all (206, 97.2%) felt a need for those exposed to HIV to be informed. Consistent results were obtained when questions were personalized; important to inform respondents partners (201, 97.2%), and respondent would want a trained professional to inform them (189, 89.6%). Over half (109, 51.4%) indicated difficulty in informing partners themselves yet most (171, 80.7%) would assist a person trained to do so. Respondents selected multiple factors of concern. Of 452 selections: 86 (40.6%) feared disclosure of their positive test result, 85 (40.2%) were concerned that partner be notified privately, 61 (28.8%) feared rejection by partner, and 43 (20.3%) feared harm by an angry partner.
Conclusion: STD clinic clients recognize the need for and will participate in HIV partner notification programs. Greater participation can be expected if confidentiality concerns are addressed with the client.

W.A.P.86

Title: Study of sexual contacts of the HIV seropositive persons

Authors: Galban, E.; Menendez, J.; Gil, R. and Terry, N.
Ministerio de Salud Pública, Habana, Cuba.

The Cuban Program of struggle against AIDS has as a most important goal the study of the sex contacts of each case infected by HIV detected through our screening system. Each of these contacts is subjected to a serological examination for the HIV determination and the same time they are given educational advice regarding their future sexual behavior while waiting for the result or results of the examinations. In general, all contacts are kept under surveillance for a year starting from the date of the last sex intercourse with the index case, serological examinations being done quarterly, except for the spouses who are followed-up every three months indefinitely. We have been able to control 80% of the 1317 sexual contacts of the HIV seropositive persons. Male homosexual relations were infecting 5.1%, while heterosexual ones were so in 10.4% and 3.4% of women who had sex intercourse with bisexual males were infected.

W.A.P.87 EPIDEMIOLOGIC BENEFITS OF HEALTH DEPARTMENT NOTIFICATION OF HIV EXPOSURE

Wykoff, Randolph F.; Jones, J.L.; Longshore, S.I.; Hollis, S.I.; Quiller, C.B.; Gamble, W.B. The South Carolina Department of Health and Environmental Control, Greenwood, South Carolina, USA.

Objective: To determine if Health Department notification of HIV exposure (contact tracing) not only produces beneficial behavior changes, but also adds to the understanding of the epidemiology of AIDS in a given community.
Methods: Standard STD notification procedures were used, with an emphasis on targeting preventive education to the sex and needle-sharing contacts of HIV-infected individuals.
Results: 316 unique sex and needle-sharing partners of HIV-positive persons have been named in one Health District in the past 2 years. 107 (64%) were contacted, educated and offered testing. 202 (98%) agreed to be tested and 36 (18%) were HIV-positive. Only 6 (3%) of the 202 had been previously tested. 49% of the known HIV infections in our District have been identified by Health Department notification, 33% by private physicians and 18% by other sources. Of those exposed to HIV, 55 (27%) had only heterosexual exposure and 8 were infants. The age range of contacts was 14 to 74. We have been able to reclassify 3 HIV-positive men who denied major risk factors. Two dimensional mapping has lead to a clearer understanding of the transmission of HIV in our area.
Conclusions: Health department notification of HIV exposure significantly expands understanding of the extent of HIV infection and identifies HIV exposure among untested high-risk individuals and among people outside the risk group and age ranges usually associated with AIDS in the USA.

**Prévention de la transmission par contact sexuel et par consommation de drogue
Preventing Transmission by Sexual Contact and Drug Use**

W.A.P.88 EFFECTIVENESS OF EDUCATION IN INTRAVENOUS DRUG USERS TO PREVENT HIV SEXUAL TRANSMISSION.

Jean-François Delruey, A. Levy, A. Abellhauser, D. Penzo, A. Blanc, P. Bouz, J. Dubout, Hôpital Antoine-Béchère, 92141 Clamart, France.

Objective: To study the change in behaviour regarding the intravenous (IV) use of drugs, and the attitudes toward sexual preventive measure, in a group of HIV intravenous drug addicts (IVDA) in Paris Area.
Methods: Between January 1986 and June 1986, 264 HIV seropositive drug users were enrolled follow up in a 3 years prospective study. Patients initially agreed to attend counselling sessions twice a year. Clinically and immunological HIV status were performed, twice a year. In parallel the subject attitudes toward preventive measures concerning the IV use of drugs and sexual behaviour were recorded every 6th month.
Results: On 264 patients, only 206 were followed regularly during the 3 years study. They were 182 male and 64 female with a mean age of 24.3 ± 2.1 years. No significant data could be obtained on the proportion of patient which increased or decreased the frequency of injections neither the use of drugs at home or alone. At the second visit (6 months), 72 % regularly used unique needle or syringe, and 69 % used condoms during sexual intercourse. At the 6th visit (2 years 1/2), 61 % used unique injection material, but only 22 % always used condoms. These attitudes toward preventive measures were equally observed in male and female sub group.
Conclusion: In contrast with changes in sexual behaviour observed in homosexual population, there is a relative ineffectiveness of education and counselling in preventing the sexual transmission of HIV infection in IVDA on a 3 year period.

W.A.P.89

RISK BEHAVIORS OF IV COCAINE USERS: IMPLICATIONS FOR INTERVENTION

Chitwood, Dale, B.; McCoy, C.B.*; Cozart, M.*; Trapido, E.J.*. *University of Miami School of Medicine, Miami, FL, USA

Objective: Identify traits of intravenous cocaine use (IVCU) which are relevant for planning risk behavior reduction programs.
Method: Data from two tri-ethnic, male and female IVCU cohorts are presented. 1) To describe high risk traits of IVCU existing before AIDS was discovered, interview data collected in 1980-81 from 75 IVCUs are presented. 2) To describe current risk behaviors and attempted behavioral change to reduce HIV exposure, data collected in 1987-88 from 255 IVCUs are presented.
Results: Prior to knowledge that AIDS existed (1980-81), IVCUs reported several high risk traits-cocaine obsession (68%), use escalation (61%), no spending limits (72%), cocaine-related money problems (82%), always craved cocaine (72%), never refused cocaine (44%), prostitution (47%) or traded sex (5%) for cocaine. Current IVCUs were twice as likely (21%) as other IVCUs (10%) to test HIV-1Ab+. 70% reported risk reduction efforts, but a majority still injected daily, shared needles, had IV and non-IV sex partners (SPs), never used condoms. Attempts to stop sharing (20%) or share less often (22%) were reported by more IVCUs than shooting cessation (5%) or needle cleaning (13%). Reduction in number of SPs was reported more often (23%) than increased condom use (11%).
Conclusion: Many IVCUs engage in high risk behavior. Self-initiated attempts to change both needle use and sexual behavior often are unsuccessful. Implications for intervention programs are discussed.

**Session d'affichage
Poster Session**



**Épidémiologie et santé publique
Epidemiology and Public Health**

W.A.P.90 THINGS OF RISK REDUCTION AMONG INITIATES INTO INTRAVENOUS DRUG USE 1982-1987

Wahney David, Anthony, J.C. Celentano, D.L. Solomon, L. Choudhury, M., Mandell, W. The ALIVE Study. Johns Hopkins School of Hygiene and Public Health, Baltimore, Md, USA.

Objectives: The purpose of this study is to identify and compare initial injection practices of IVUOs by year first used to determine if initiation practices were changed during the course of the epidemic.
Methods: As part of the baseline questionnaire for a natural history of HIV infection (ALIVE) active IVUOs recruited from the community were asked to report year first injected, drug first used, and the frequency of injection, using sterile needles, sharing needles and cookers during their first three months of use. The distribution of responses were dichotomized and grouped by year first used. The chi square test for trends was performed.
Results: Of the first 1840 participants, 421 reported initiation between 1982 and 1987. Over these years, heroin as the first drug decreased (p < .01), while cocaine increased (p < .05). The proportion who never used sterile needles decreased (p < .05) as did the proportion who always used needles after another person (p < .05). The proportion who had > 3 needles sharing partner decreased (p < .01).
Conclusion: Although these data are from a cross-sectional study they suggest a shift from heroin to cocaine and a shift toward lower risk practices among new IVUOs between 1982 and 1987.

W.A.P.92 SEXUAL BEHAVIORS AND CHARACTERISTICS OF 627 GAY AND BISEXUAL MALE PARTICIPANTS OF THE DALLAS SEX PROFILES STUDY

EDUCATIONAL INTERVENTIONS FOR THE PREVENTION OF AIDS.
Toddler, Fred** Myers, T.** Korta, R.*****, Jackson, M.* Orr, F.* Row, C.**
AIDS Committee of New York, **University of Toronto, Toronto, Ont., Canada, ***Humberbrook Medical Centre, Toronto, Ont., Canada.

Objectives: To describe demographics, knowledge, attitudes and sexual behaviors of the 627 participants at time of recruitment into the study.
Methods: A non-interventive study was recruited from the community by a variety of methods. Subjects completed questionnaires prior to random assignment to control or 3 educational intervention groups.
Results: The mean age was 37.4 years (range 14 - 72); 564 had completed college or university, 45.6 had been HIV antibody tested; 13.0% were seropositive and 4.8% reported AIDS or AIDS related illness. Sexual practices reported for the prior 5 years and 3 months are:
Sexual practices Control 3 Years 3 Months
Anal intercourse - Receptive 69.8 36.24 69.14 14.53
Anal intercourse - Insertive 55.4 41.6 71.5 18.9
Oral-Genital - Insertive 98.48 54.18
Oral-Genital - Receptive (with cum in mouth) 79.2 26.6
Mutual Masturbation 98.9 91.3
Conclusion: Although there may be problems with recall bias and the methods used, there appears to be a decrease in unsafe sex practices in the study population over the course of the past 5 years.

W.A.P.94 ONGOING IMPACT EVALUATION OF THE COMMON USE PROMOTION/USER-INITIATION PROGRAM FOR PREVENTING AIDS IN THE DOMINICAN REPUBLIC

Cherchez, Ernesto De Nova, E.A.; Rosario, S.
PROGRES, Ministry of Public Health, Santo Domingo, Dominican Republic.

Objective: To evaluate the Dominican Republic Condom Use Promotion/Initiation Program (1987-1989) and to analyze its main impact on population.
Methods: Condom use adoption before and after program implementation has been assessed through: 1. A series of CAP studies with female sex workers and their clients, transsexual, gay and bisexual men, jail inmates, Haitian migrant workers and the general population; and 2. Periodic descriptive surveillance of hotel and motel rooms where condoms are made universally available.
Results: Positive attitudes toward condom use have increased from 55% in 1985 to 73% in 1988. Condom use in 1988 was less than 2% in the generally active male population and less than 1% in female sex workers (FSW). By 1988, condom use in hotels and motels was 18%. FSW carrying condoms in their purses has grown to 94%.
Conclusion: Creating and maintaining a permanent state of awareness of AIDS and aggressively enhancing the perceived value of condom use has significantly increased condom use in the Dominican Republic.

W.A.P.91 SELF EFFICACY AND COMMUNITY NORMS PREDICT AIDS RISK REDUCTION AMONG GAY AND BISEXUAL MEN IN SAN FRANCISCO: THE AIDS BEHAVIORAL RESEARCH PROJECT

Neilands, Larry Coates, T.P. Morris, S.*
University of California, San Francisco, CA, U.S.A.

Objectives: To describe correlates and predictors of reductions in high risk sexual behavior among gay men in San Francisco.
Methods: Subjects were 440 men in the AIDS Behavioral research Project responding to annual surveys since 1984. Subjects responded to mailed surveys regarding sexual behaviors, relationship status, antibody testing experience, and variables from our AIDS Risk Reduction Model (ARRM). Variables measured in 1984 to predict risk behavior in 1987 included serostatus, AIDS professional symptoms, AIDS loss, relationship status, perceived social norms, and health beliefs (self-efficacy, threat, knowledge). Multiple logistic regression was used to derive adjusted odds ratios for each variable.
Results: 60% of the men practiced high risk sexual behavior in 1984 (50% practiced unprotected anal intercourse). Only 30% practiced high risk behavior in 1987 (12% practiced unprotected anal intercourse). Individuals who practiced high risk behavior in 1984 and 1987 were more likely to perceive that peers continued to practice high risk behavior (adjusted odds ratio = 1.11, p<.05). Those high in personal efficacy (adjusted odds ratio = .95, p<.05)and who tested positive for antibodies to HIV (adjusted odds ratio = .42, p<.05) were less likely to continue the practice of high risk behaviors in 1987. **Conclusions:** AIDS risk reduction campaigns may benefit from methods for increasing personal efficacy through skill training.

W.A.P.93 PRELIMINARY ANALYSIS OF FACTORS ASSOCIATED WITH COMPLIANCE WITH GUIDELINES FOR PREVENTION OF SEXUAL TRANSMISSION OF HIV IN HETEROSEXUAL COUPLES

Nichols, Margaret Peroni F., Sampson G., Leibel J., Kennedy M.J. - Woodhull Medical and Mental Health Center, Brooklyn, NY, USA.

Objective: To present a preliminary analysis of factors associated with compliance with practices for prevention of sexual transmission of HIV in a cohort of monogamous couples.
Methods: The Northern Brooklyn Partner Study, began in September 1982 with funding from the CDC. It is a three year longitudinal study of monogamous heterosexual couples in which one partner has a high/very high risk factor (sexual contact with the other partner). The sample is drawn from a community based primary health care facility which serves a population that is 93% black or Hispanic and 86% IVUO's and their sexual partners. Data gathered are retrospective as well as prospective, and include sexual and drug use behavior, psychological measures, and medical parameters (stage of disease, partner, p-24 status, HIV culture, concurrent VD, etc). All subjects are reinterviewed and examined at 3 month intervals.
Results: Preliminary data presented here will be a comparison between couples who are following "safer sex guidelines versus couples who are not. The dimensions used for comparison include knowledge of HIV transmission, perceived threat of infection, perceived self-efficacy (the feeling that one can control one's own health), self-esteem, depression, perceived distance from AIDS, partner/peer support, and quality of the relationship.
Conclusions: These results indicate that some of the variables that are relevant in AIDS prevention for gay men are not relevant in the setting of heterosexual transmission in an impoverished minority community.

W.A.P.95 AN EVALUATION OF THE EFFECTS OF VARIOUS LUBRICANTS ON LATEX CONDOMS

Pugh, Bradley Engstler, M.
Aerial Incorporated, Tusculum AL, U.S.A.

Objective: To determine if short-term exposure to lubricants adjacently applied to latex condoms can cause sufficient deterioration to warrant concern about condom failure during use in one experiment and in six subjects at body temperature and in another experiment for one hour at room temperature and then tested for tensile strength according to ASTM Standard test methods. A control group, without lubricant exposure to any lubrication, was subjected to the same testing.
Results:
Tensile (MPa) Tensile (MPa)
Lubricant (Body Temp.) (Room Temp.)
No lubricant (control) 22.6 22.4 ASTM Std.
Vegetable oil 18.1 6.4 Tensile
Petroleum jelly 15.9 11.6 mtn. = 17 MPa
Personal lubricant 11.2 2.2
Conclusion: Some personal lubricants used in sex shops and other household items (petroleum jelly, vegetable shortening) have a significant deleterious effect on the strength of condoms. This deterioration is severe enough and occurs rapidly enough that their addition to latex condoms as adjunct lubricants is likely to cause the product to fail during use. Only water-based or silicone-based lubricants or others that have been tested and recommended by the condom manufacturer should be used.

Session d'affichage Poster Session



Épidémiologie et santé publique Epidemiology and Public Health

W.A.P.96 EVALUATION OF CONDOM UTILIZATION AND ACCEPTABILITY OF SPERMICIDES AMONG PROSTITUTES IN KINSHASA, ZAIRE

Mills, B.J., Ryder, A., Saez, R., Project SIDA, Kinshasa, Zaïre, *CDC, Atlanta, GA, *Institute of Tropical Medicine, Antwerp, Belgium.

Objective. To evaluate the effectiveness of a condom intervention program and to evaluate acceptability of spermicides in Kinshasa prostitutes.

Methods. From June-December 1988, 801 prostitutes were interviewed about knowledge, attitudes and practices of condoms at entry of an STD/HIV survey, and again 3 months later. 1000 women were interviewed, counseled and free condom distribution. 210 HIV-1+ women were interviewed, counseled and given 3 months of free condom supply. 1004 women were interviewed. In a pilot demonstration project, 52 women were offered spermicides.

Results. 70% of women actively reported "regular" condom use (27%, 37% and 32% respectively (p<0.1). After 3 months, 33% of women reported using condoms use (50% always, and 50% inconsistently) independently of HIV sero-status. Safety of spermicide use was not attributable to condom use. The reported condom use of 140 women followed up prospectively was validated with incidence of STD, presence of spermicide on vaginal smear and incident pregnancies out of 8 women who seroconverted, was a consistent condom user (2/10) and 7 were inconsistent condom users (1/7) (p<0.05).

Incidence of:			
N. gonorrhoeae	0.7	1.6	0.02
T. vaginalis	1.4	1.7	NS
Syphilis seroconversion	4.5	5.2	NS
No. of new pregnancies (3.7/2%)	8	8.7(2%)	NS

(% expressed as episode per woman year of observation)

Spermicides (Benzalkonium oxides) were used in 92% of client encounters, were well accepted and were associated with high reported effects.

Conclusions. Condom use increased considerably after intervention but STD transmission persisted despite high reported condom use. Spermicides are highly acceptable among prostitutes.

W.A.P.98 THE SUPPLY OF, AND DEMAND FOR, CONDOMS TO PREVENT HIV TRANSMISSION IN DEVELOPING COUNTRIES

Kanana-Lemba, W., Harris, J.R., and Shelton, J.D.
U.S. Agency for International Development, Washington, D.C., U.S.A.

Objective. To assess the supply of, and demand for, condoms in preventing HIV transmission in developing countries.

Methods. U.S. Agency for International Development (A.I.D.) funding and shipping data were reviewed for Fiscal Years 1987-1989 worldwide condom prevalence was analyzed.

Results. Since 1987, A.I.D. has been the leading provider of condoms for developing country AIDS control programs. A.I.D. funds have bought 172 mil. condoms and over 120 mil. have been shipped to 56 countries. 48% of all condoms have gone to Africa, 27% to Asia, and 24% to Latin America and the Caribbean. Demand is increasing and half of all shipments were in the past six months. Shipping condoms can play a vital role in preventing HIV transmission. Current supply and demand are too low to significantly impact on the pandemic if all 120 mil. condoms shipped had gone to Nigeria, less than 4% of Nigeria's 22 mil. males ages 15 to 49 years would have condoms for one year. To make enough condoms available, other donor resources are needed. Increasing the demand for condoms requires urgent attention in developing countries, only 3% of reproductive age couples use condoms in Africa, 0.5% do. Social marketing and private sector distribution must complement government efforts. Given the absence of vaccines and curative treatments, condoms are the world's most promising technology to prevent transmission of HIV.

W.A.P.100 INCREASING CONDOM ACCESSIBILITY: WHAT ARE THE BARRIERS?

Spencer, Brenda, Spiers, A., Job-Spiers N.
US22 INSERM, Paris, France.

In both research and promotional campaigns, condom promotion is usually characterized as a problem of attitude and behaviour change at the level of the individual i.e. as a question of acceptability. Far less attention has been paid to the question of accessibility. Yet, applying the experience of previous campaigns and simple marketing principles, the accessibility of France condoms may be obtained in pharmacies and large supermarkets. The range of other outlets is negligible, nonetheless, companies attempting to install vending machines report having met with great difficulties. Given the high rate of HIV positivity in France and the traditionally low rate of condom use, this situation appears paradoxical. Our research programme therefore aims to identify the barriers to achieving a wider availability of condoms - at the level of the general public, including machines. We report here on installation in a questionnaire in a high distribution TV magazine, and a national representative sample with a polling organisation. Results show overall acceptance of wider distribution to be high among all ages and all socio-economic groups. There was no preference for stalls in toilets. The two proposed stalls with an acceptability markedly lower than the rest (around 50%) were the workplaces and public buildings. Other sites, including universities, highschools, bars, stations, leisure centres, health centres and the street, had acceptance levels between 70-90%. We infer that the major barriers lie elsewhere than with the general public.

W.A.P.97 AIDS AND CONDOM-USE IN THE NETHERLANDS

Ernst M.M. de Vroom*, Th.G.N. Sandfort*, M. Paalman**, K.A.P. Tielman*
* University of Utrecht, ** STD Foundation, Utrecht, Netherlands.

Objective. Since May '87 a number of campaigns directed at the general public were undertaken. The levels of knowledge, attitude and behavior among heterosexuals before and after the campaigns are assessed.

Methods. Data were collected by semi-annually interviewing approximately 1000 respondents (age 15-45). Interviews were done by telephone, respondents were randomly solicited in each of the four surveys.

Results. From May '87 to October '88 (figures from the fifth survey (April '89) will be presented as well), people associating "safe sex" with condoms (as intended by the campaigns) rose from 43% to 82% (p<0.001). It was confirmed that condoms protect against AIDS by 98% in Oct. '88 compared to 74% in April '87 (p<0.001). The overall attitude regarding condoms became more positive: the number of people saying the advantages of condoms prevail, increased from 52% to 78% (p<0.001). Among people having non-steady sexual relationships, condom-use increased from 30% to 77% (p<0.001), although not all these users used condoms consistently.

Conclusion. A number of changes have occurred, presumably supported by the conducted campaigns. Condom-use has become relatively more acceptable and more people associate the prevention of HIV-infection with the use of condoms. People with non-steady sexual relationships now use condoms more often, although more than 10% of the occasions used. Further interview attempts to ascertain a cause for such high breakage.

W.A.P.99 PERSISTENT CONDOM BREAKAGE

Vogler, Bruce*
*Haripoo Foundation, Topanga, CA, U.S.A.

Objective. To assess why males well informed in condom usage repeatedly broke condoms during post-penetration coitus.

Methods. Several hundred males who had condoms break during coital use were screened. 25 (a) correctly answered all questions about proper use of condoms, but (b) reported breaking condoms more than 10% of the occasions used. Further interview attempted to ascertain a cause for such high breakage.

Results. About one third of the men practiced vaginal intercourse; the remainder anal intercourse. All 25 men claimed only to use "water-based" lubricants; never using "oil-based" ones. Yet 23 identified their usual coital lubricant as Vaseline Intensive Care hand lotion, Johnson's Baby Oil, or Nivea Hand Creme. Each of the 25 men believed these lubricants were "water-based" because they were readily washed away in tap water, in contrast to lubricants such as Vaseline Petroleum Jelly, Crisco or butter. All 25 men were U.S. college graduates.

Conclusion. These data suggest that differences in frictional stress between anal and vaginal intercourse may not suffice to account for breakage. Coupled with the reported rapid deterioration of condoms caused by mineral-oil wax lubricants, the data suggest that some portion of coital breakage of condoms may be based in the conscientious users' misconception that baby oil and emulsified oil lubricants are "water-based." Better choice in language may be important for condom use brochures.

W.A.P.101 A SIMULATED PHYSIOLOGIC TEST OF LATEX CONDOMS

Ernst, M.A., Betts, S.M., Rinaldi, J.E., Herman, Bruce A., Carey, R.F., and Athey, T.W.
Division of Physical Sciences, Center for Devices and Radiological Health, FDA, Rockville MD 20857 USA.

Objective. To test latex condoms for the passage of HIV-size microspheres under simulated physiologic conditions.

Methods. HIV is simulated by uniform polystyrene, fluorescent microspheres with mean diameter of 0.11 µm. These microspheres are suspended in physiologic phosphate buffered saline with surfactant. The condom is inflated to form and inserted into a fabric mesh which limits the expansion of the condom to physiologic dimensions. The form with the condom and fabric mesh is secured in a test chamber and the condom filled with the suspension of microspheres under a static pressure of 60 mm Hg, which was found to be the maximum pressure difference across a condom in modelling experiments performed in our laboratory. The chamber is filled with the same solution less the fluorescent microspheres. The test system is maintained at a temperature of 37°C and a pH of 7.0, while the chamber's fluid is continuously monitored for the presence of the fluorescent marker.

Results. The test system has quantitatively identified latex-induced holes as small as 8 µm in diameter and is capable of detecting holes as small as 3 µm. Tests of 69 condoms from 2 manufacturers found 6 condoms which had holes. The leak rates corresponded to hole diameters in the range 4 µm to 7 µm.

Conclusion. This test is sufficiently sensitive to determine whether condoms provide an effective barrier to HIV-size microspheres under (static) physiologic conditions.

Section d'affichage Poster Session

W.A.P.108 CHANGES IN HIV RISK BEHAVIOUR IN DRUG INJECTORS ATTENDING SYRINGE-EXCHANGE PROJECTS IN ENGLAND AND SCOTLAND
Stansby, Gerry K., Jackson, A.C. and Dolan, K.
Monitoring Research Group, Oldfields¹ College, London, UK.

Objective: To assess the impact of syringe-exchange projects on the injecting and sexual behaviour of injecting drug users. The study was part of the evaluation of government sponsored syringe-exchange projects.
Methods: Injectors attending 4 syringe-exchange projects were provided with information about HIV risks, given needles and syringes on an exchange basis, and condoms. Self-reported risk-behaviour was assessed with a prospective interview administered at two points in time with 142 clients who attended up to March 1989.

Results: Syringe-sharing in the previous 4 weeks dropped from 34% to 27%; sexual risk (transmission) dropped from 77% to 69%; those with two or more partners dropped from 26% to 21%. Surveys of two comparison groups of injectors not attending syringe-exchanges showed higher levels of syringe-sharing in the first survey (n = 220) 42% shared, in the second survey 31% 4 months later (n = 174) 52% shared.
Conclusion: The evidence indicates that many syringe-exchange clients maintain low risk behaviour and others adopt them. There are some who resist change. The changes over three months are small, but support the argument that injectors can be helped to change their HIV risk behaviour. Comparison groups of non-attenders showed higher levels of risk behaviour.

Prévention : politiques et évaluation des programmes Prevention: Policy Issues, Program Evaluation

W.A.P.110 CARA - A TOOL FOR AIDS PREVENTION
Belachew, Wifried.
University of Oldenburg, Oldenburg, Federal Republic of Germany

Objective: CARA is the abbreviation for computer assisted risk management with a dialogue for the prevention of HIV infection. The prevention of the HIV-infection in a dialogue with the computer. Target groups are students and young adults. It consists of 2 parts: Part 1: With this program the participants acquire the knowledge one should have about AIDS.

Part 2: The participants get the opportunity to assess the risks of their particular lifestyles in the fields job, leisure/sports, traffic and sexuality. The participants receive a feedback on the riskiness of their lifestyles, especially on the risky behaviors with regard to a HIV-infection.
Results: The program has widely proved its usefulness and efficiency in German schools. It is highly attractive to students. Teachers and AIDS counsellors use it for the introduction of lectures on AIDS and the preparation of personal communication.

W.A.P.112 TRAINING THE HEALTH CARE PROFESSIONAL: THE AIDS REGIONAL EDUCATION AND TRAINING CENTERS PROGRAM OF THE HEALTH SERVICES ADMINISTRATION (HSKA)
Hornor, Anne, Haffner, Martell, Moore, D. and Mocher, A.
Division of Health Services Administration, HSKA, United States Public Health Service, Rockville, Maryland, USA.

Objective: To establish regional education centers that will provide multidisciplinary training for health care professionals.
Methods: With a projected cumulative total of more than 300,000 AIDS cases by 1992, it is essential that health care providers be trained in the diagnosis, management and treatment of HIV-infected patients. The insufficient number of providers active in the care of AIDS patients presents a major gap in the health care delivery system. In recognition of this problem, the United States Congress appropriated funds to establish the AIDS Regional Education and Training Centers Program.
Results and Conclusions: To date, thirteen centers have been created. These regional education and training centers provide multidisciplinary HIV/AIDS training for health care personnel within the framework of the following three goals: 1) training community primary care providers to incorporate strategies for HIV prevention into clinical priorities as well as to diagnose, manage, and counsel patients and their families; 2) training individuals to serve as educators in their local area; and 3) educating health care professionals in providing sensitive and integrated care of AIDS patients through the improvement of their understanding of the complexity of the disease.

W.A.P.109 DRUG TREATMENT CENTERS AS THE MEDIUM FOR A COMPREHENSIVE APPROACH TO AIDS PREVENTION FOR INTRAVENOUS DRUG USERS
Gardner, Jessica, Jones, T., Korman, G., Fearn, E., Mendenhall, J., P.O., Bowen, M.S., Centers for Disease Control, Atlanta, Ga., U.S.A.

Objective: To describe a model plan for prevention of HIV infection, sexually transmitted diseases (STD), and hepatitis B virus (HBV) in drug intravenous users. The model was by states who are recipients of Centers for Disease Control (CDC) funding. The model includes: 1) Cooperative Prevention: Drug Treatment Centers (DTC) are under-utilized settings for providing health care for people who are at high risk for HIV, HBV, and STD through CDC funded state health departments to prevent these diseases. 2) Comprehensive Approach: DTCs are under-utilized settings for prevention activities in these settings was lacking. Consequently, CDC staff designed a model plan to facilitate staff planning activities. 3) Implementation: The model plan includes: a) Staffing: DTCs should be staffed with the essential components of this model practice in order to provide comprehensive care. b) Services: DTCs should provide HIV and STD testing, directly observed TB preventive therapy, referral and expanded care of intravenous drug users (IVDU) for medical, psychiatric, and/or referral for contraband services, and personal medication of intravenous drug users. c) Funding: Funding mechanisms and a detailed evaluation of impact will be described. d) Evaluation: Impact of this model includes analysis of injection number of clients enrolled, number of consultations, and the number of referrals. e) Management: Systems for IVDU who are at risk for TB and who may be infected with HIV.

W.A.P.111 SHORT AND LONG TERM RESULTS OF AN AIDS PREVENTION PROGRAM
Miller, Tim; Broome, C.*; Flowers, J.**; and Iversen, J.***
*AIDS Response Project, Garden Grove, CA; **University of California, College of Medicine, Irvine; ***Chapman College, Orange, CA, U.S.A.

Objective: While there has been a growing number of AIDS prevention programs reported to the literature, few have contained outcome results and none have reported follow-up data.
Methods: Employing a 21 Item AIDS Prevention Test (APT) designed by the authors, which has previously demonstrated both reliability and Form A, B equivalence, 102 St in 10 successive Stop AIDS Workshops were invited to participate in a 3 month follow-up program. All St took Form A of the test prior to the workshop and Form B after. 50 agreed to retake Form B 3 months, 27 actually returned the follow-up test. 25 of the follow-up St also returned a Form B evaluating them, filled out by their significant partner.
Results: The 27 St demonstrated increased knowledge (70.0 to 81.6) correct (1.90 to 1.2), p < 0.05), a positive change in AIDS related attitudes (27.56 to 29.89, t(26)=2.84, p < 0.004 (25 possible)), and a positive change in intended sexual behavior (18.00 to 22.56, t(26)=3.12, p < 0.001 (23 possible)) from pre to post workshop. At 3 months, the St showed increased positive change in attitudes (11.56, t(26)=4.91, p < 0.001) a slight reduction in actual behavior from pre-workshop to follow-up was still significantly positive (16.00 to 19.66, t(26)=3.94, p < 0.001). The 13 tests filled out by partners verified the St self reported attitudes (33.00) and behavior (19.50). There were no significant correlations between knowledge, attitudes and behavior per se, but correlations between changes in these three were significant.

W.A.P.113 OUTCOME OF HIV PREVENTION AND COUNSELING AT COOK COUNTY HOSPITAL, ILLINOIS: A TWO YEAR FOLLOW-UP
Belcher, E., Gales, E., Wita, E., Heller, L., Shyne, B., et al.
The Cook County Hospital, 1201 North Dearborn, Chicago, Illinois, U.S.A.

Objective: To evaluate the 1983 experience of a public hospital-based AIDS education and risk reduction program, and determine the year trends in client demographic data and counseling outcomes.
Methods: Between November, 1981, and December 31, 1982, 1188 persons at risk of HIV infection received HIV prevention counseling. In 1981, 2384 people were counseled. Of these, 1,311 (55%) were 19-29 years old (18.1%) were female (18.1%), were employed (19.1%), were African American (18.1%), Hispanic (1.84%), Asian (1.38%), American Indian, or 18 (1.84%) were of other ethnicity. By risk behavior, 201 (17.8%) were gay/bisexual men, 21 (1.8%) were prostitutes, 801 (67.8%) were heterosexual men, 27 (2.3%) were female prostitutes, 17 (1.4%) were partners of abuse, 19 (1.6%) were partners with multiple partners, and 11 (0.9%) other.

Results: Needs in 1982 are shown by table and were from 1981-1982 in table II.

TABLE I. QUARTER OF 1982		TABLE II. 1981 - 1982	
SEX	AGE	1981	1981-1982 %
MALE	18-29	72	100
FEMALE	18-29	32	47.2
EMPLOYED	18-29	32	47.2
AFRICAN AMERICAN	18-29	32	47.2
PROSTITUTE	18-29	32	47.2
MULTIPLE PARTNERS	18-29	32	47.2
OTHER	18-29	32	47.2

In 1981, 1,311 (55%) of those counseled received HIV prevention counseling. In 1982, 1,188 persons at risk of HIV infection received HIV prevention counseling, reaching 2,499 clients at risk of HIV infection at Cook County Hospital, of whom 84.4% were HIV negative and 15.6% were HIV positive. A majority of clients reported significant behavior change resulting from the interventions at health follow-up.

**Session d'affichage
Poster Session**



**Épidémiologie et santé publique
Epidemiology and Public Health**

W.A.P.114 APPLICATION OF METHODS/RESULTS FROM FAMILY PLANNING OPERATIONS RESEARCH TO AIDS PREVENTION IN AFRICA
Hamer, Maria L., Columbia University, N.Y., USA.

OBJECTIVES: To apply operations research (OR) methods derived from family planning to develop effective processes for prevention of sexual transmission of HIV in Africa.
METHODS: Family planning OR has developed and tested culturally appropriate, cost-effective strategies to increase access to and acceptability of contraception, including condoms, in Africa. To collect data for program development and monitoring, OR uses methods from epidemiology, demography, anthropology, and market research. **RESULTS:** OR projects identified unexpectedly high levels of contraceptive knowledge among males and females in African countries (knowledge levels above 80% in urban Niger and Burkina Faso, over 40% in rural Côte d'Ivoire and Senegal) and increasing use of methods, including condoms. Data have been used to develop innovative educational and contraceptive delivery systems such as distribution in Lagos markets and by traditional midwives in Sudan, where contraceptive prevalence rose from 9% to 26% in rural areas. OR is currently being applied to an AIDS education program in Rakai, Uganda, and elsewhere. **CONCLUSIONS:** OR is effective in the field of reproductive education and contraceptive delivery in Africa. Like AIDS prevention, family planning touches on controversial and sensitive issues, including changes in sexual practices and condom use. OR will be useful in promoting behavior change and condom use for AIDS prevention.

W.A.P.116 SEXUAL BEHAVIOUR OF YOUNG ADULTS AND THE EFFECTS OF AIDS PREVENTION CAMPAIGNS IN SWITZERLAND

Ziegler P., Dubois-Arber F., Lehmann Ph., Institut Universitaire de Médecine sociale et préventive, Lausanne, Suisse, ** IPSO, Zurich, Suisse.

This study is part of the overall evaluation of the Swiss prevention campaign. **Objectives:** To measure the effects of the prevention program within the 17 to 30 years old resident population in Switzerland. To identify indicators measuring efficacy of prevention campaigns. **Methods:** Interviews by phone on the basis of a standardized questionnaire. Interviews are designed to obtain valid responses regarding questioning within the intimate sphere despite others standing by. The quota sampling design is stratified by place of residence (N = 3 times 1200). Data have been collected at three points in time: February 1987 (t0) before the launching of the first STOP-AIDS campaign, October 1987 (t1) nine months thereafter and October 1988 (t2) eighteen months thereafter. **Results:** The proportion of people having had occasional sexual contacts out of a monogamous relationship within the previous six months remains stable (86% at t0, 14% at t1, 15% at t2). However, the use of condoms during occasional sexual relationship has increased significantly: the proportion of people saying that they never use condoms declines (67% at t0, 56% at t1, 13% at t2). At the same time occasional usage increases (25% at t0, 45% at t1 and 58% at t2), so does consistent usage (9% at t0, 17% at t1 and 29% at t2). Beyond this observations other aspects of sexual behaviour confirm the tendency towards safer sex. **Conclusions:** Young adults in Switzerland are the more and more numerous to protect themselves against AIDS in situations carrying a potential risk of HIV contamination.

W.A.P.118 MORE THAN ONE TYPE OF HIV EDUCATION AND TESTING PROGRAM IS NECESSARY TO REACH SELECTED TARGET POPULATIONS IN LARGE CITIES

Duetsch, A., Flynn, M., Hesse, P., Jain, S., Webb, D., Adams, G., ** University of California Davis, Sacramento County Health Department, ** AIDS-STOP Task Force, Sacramento, CA, U.S.A.

OBJECTIVE: To compare the populations being tested for HIV-1 in a hospital setting, an Alternative Test Site (ATS) and Drug Treatment Program (DTP). **METHODS:** Demographic information was recorded from medical records of patients tested in the hospital, exclusive of AIDS Clinic, from 1/86 - 8/87. Records of IV drug users were reviewed in detail. Information regarding ATS and DTP outlets was obtained from the County Health Department (CHD) and our education/prevention program for IVUO (EPP). **RESULTS:**

	Hospital	ATS	DTP
Total	1169	9.5%	88.1%
Male	48	84.0%	2927
Female	31	5.7%	253
MSP/Prostitutes**	16	12.5%	2754
Transfusion Recipients	17	7.4%	127
Sex Partner of the above	1648
Undiagnosed	480
Others	120	24.0%	2

CONCLUSIONS: Different populations are tested at different test sites. Access to all test sites is essential to reach different risk groups in large numbers with education and testing programs. They are complementary.

W.A.P.115 DETERMINANTS OF AIDS POLICY PREFERENCES OF THE GENERAL PUBLIC
Gomez-Danig and Trigueros, M.*

*University of Michigan, and **University of Murcia, Spain.

Objective: To analyze factors associated with preferences for alternative public policy options related to the behavioral control of AIDS.
Methods: Responses were from 1540 adults interviewed by telephone in the 1987 Chicago sex General Population Survey for AIDS in International Conferences on AIDS, October 16-20, 1987. Determinants of responses to the 16 questions relating to endorsement of specific policy alternatives included demographic variables, self-assessment of AIDS risk status, and attitudes toward homosexuality.
Results: Factor analysis revealed three clusters of policy options preference: employment-based testing program, government-sponsored education and service program, and compulsory public health measures. A unique combination of sociodemographic and attitudinal characteristics predicted each set of preferences. In all three cases, the level of educational attainment was the strongest predictor of policy preferences.
Conclusions: Public information programs should consider the role of attitudes toward homosexuality as they strongly influences the formulation and use of new information about AIDS. Furthermore, public policy makers need to be aware of the power of attitudinal components of public support for various AIDS policy options.

W.A.P.117 EFFECTIVENESS OF THE SWISS AIDS PREVENTION CAMPAIGNS IN 1987

Hamer, Dominique; Dubois-Arber F., Lehmann Ph., Ostypeller F., Institut de Médecine sociale et préventive, Université de Lausanne, FPM, Zurich, Suisse.

Under the slogan STOP-AIDS, a national multimedia campaign is continuously conducted by the Federal Office for Public Health since 1986. Equivalent efforts are made stimulating multipliers to develop specific or local preventive actions. This program also includes a continuous and independent evaluation which has - to measure behaviour changes, to identify factors which have positive or negative influences on changes, - to propose corrections or adaptations which could improve campaigns. Conclusions are based on 20 intercomparative studies conducted in 1988 involving nearly 4000 persons of various parts of the population: **Knowledge on AIDS (HIV transmission and protection) are good.** There is still doubts on what is not dangerous (risk with saliva or blood transfusion in Switzerland). **Health professionals generally overestimate their professional risk.** This creates fear and further suspicious attitudes to some patients. **There is no stigmatization.** Despite an apparent social consensus of non discrimination, casting out of persons are unfortunately observed occasionally. **Adoption of protective behaviour is in progress but still difficult.** It's often related with emotional dimension of relationship. Condoms sale slowly increase (less than in 1987). **Messages are clear,** range general population and target groups. Number of peripheral preventive actions have been developed, but still few efforts have been done for IVUDs. Social and health professionals have played very little preventive role.

W.A.P.119 HIV CAN SEROPREVALENCE SURVEY DATA BE USED TO MANAGE HIV PREVENTION PROGRAMS?

ONATEL, Lima; Jones, T.S.; and Forrester, W.* AIDS Program and Center for Prevention Services**, Center for Disease Control (CDC), Atlanta, GA, USA.

Objective: To guide health departments in utilization and limitations of CDC Family of Surveys (FOS) data in managing HIV prevention programs. **Methods:** We analyzed survey methodology and procedures to assess potential biases in each type of survey data. Considering these limitations, we suggested appropriate use of different types of public health programs. A communication system for dissemination of data is proposed. **Results:** No single seroprevalence survey is representative of the entire population. Biases were identified in each type of survey. Characterization of the population surveyed and adherence to standard CDC protocols will minimize biases. In prevention programs, CDC FOS data may be used in allocating resources and in determining the types of education, counseling and testing services offered. Over time, data will be useful in following trends in HIV infection and in evaluating the impact of prevention activities. Success in reaching infected persons may be measured by comparing seroprevalence rates in unlinked surveys with voluntary testing in the same population. Consultants in health departments and at CDC form a network for disseminating data to health care providers and program managers. **Conclusion:** FOS seroprevalence data will be a valuable tool in the surveillance and prevention of HIV infection. Awareness of the survey biases and in interpreting data is essential. Dissemination services is needed so prevention programs can access and utilize data effectively.

Session d'affichage Poster Session



Epidémiologie et santé publique Epidemiology and Public Health

Autres rétrovirus : HTLV-I et HTLV-II Other Retroviruses: HTLV-I and HTLV-II

Th.A.P.1 PREVALENCE OF HTLV-I/II INFECTION AMONG MALE INTRAVENOUS DRUGUSERS AND THEIR SEXUAL PARTNERS IN OSLO, NORWAY. Joseph R. Puckett, C.T. Schaaf, R. Schaefer, M. J. Schroer, D. J. Berens, W.T. Hines Veterans Administration Hospital, Hines, Ill., *Oslo Diagnostic Services, N.O., *U.S.A.

Objective: To determine the prevalence of HTLV-I and HTLV-II infection in 150 HIV-1 and 19 of their sexual partners. **Methods:** HTLV-I and HTLV-II were detected by repetitively reactive ELISA was confirmed by Western Blot, demonstrating antibody to 22 antigens. Results: The prevalence of antibody to HTLV-I was 8.6651(7/150) for the patients and 5.2651(1/19) among the sexual partners. Only 10 patients (6.66%) had antibody to HTLV-II. Only 1 couple of 19 was noted to be antibody positive for HTLV-II by repetitively reactive ELISA. However, on Western Blot assay, the patient's sera reacted with only 1 antigen, while his non-drug abusing spouse was confirmed positive. There were no statistical differences in the incidence of sexually transmitted diseases (STD) among the HTLV-I positive patients as compared to either the HIV-1 positive patients or to serologically negative control group drawn from the same population. Only one patient was positive for both HTLV-I and HIV-1 as confirmed by Western Blot. CD4/CD8 lymphocyte ratios in HIV-1 infected patients (0.46±0.15) were significantly lower than ratios for HTLV-I infected patients (1.74±0.17) (p=0.006) for non-infected control patients (1.36±0.13) (p<0.001). Absolute CD4 lymphocyte counts were significantly lower among HIV-1 infected patients (802±225) as compared to HTLV-I (888±23) (p<0.02) and control patients (1659±274) (p<0.001).

Conclusion: Prevalence of HTLV-I in our non-endemic geographic area was greater than that of HIV-1 in our cohort of patients. Infection with HTLV-I was independent of HIV-1 infection or STD's.

Th.A.P.3 HTLV-III EN FRANCE METROPOLITAINE
Lemire, Jean-Marie*, Costa, J.P., Courouce A.M.**, et le
Groupe Rétrovirus de la Société Nationale de Transfusion
Sanguine.

*CHTS - 34010 Montpellier, France. **CHTS - 75015 Paris, France

Objectif: Estimer la diffusion de l'HTLV-III en France métropolitaine.
Méthode: 4797 échantillons sériques (2319 donneurs de sang et 2478 sujets à risque ont été collectés en France métropolitaine. Les dépistages ont été réalisés par un test d'agglutination ou des tests immunoenzymatiques. Les sérums positifs étaient confirmés par immunofluorescence indirecte et Western Blot.

Résultats:

Sujets	Nombre	Anti HTLV-III positifs
I. Donneurs de sang		
- Caucasiens	1274	0
- Originaires de zones endémiques	1045	7
II. Sujets à risque		
- Polytendus	307	0
- Consultants pour MST	401	0
- Toxicomanes	1690	0

Conclusion: Les sujets contaminés par HTLV-III ont été retrouvés chez les toxicomanes (79/1000) et les donateurs originaires de zones endémiques (79/1000). La diffusion en France est donc rare, mais une surveillance régulière s'impose.

Th.A.P.5 HTLV-I SEROPREVALENCE IN PARTNERS WITH HIV AND SEROLOGIC DISEASE, OTHER RISK GROUPS, AND BLOOD DONORS IN JAPAN.
*Houston, Texas, **Houston, C., **Memphis, J., **Smith, H., *Leif
A. *University of Illinois and **Blood Transfusion Service, Newark, Zimbabwe.

Objective: HTLV-I is associated with T-cell tumours and tropical Spastic Paraparesis (TSP). Relatively high prevalence are reported from several African countries. Little data has been published in Zimbabwe. **Methods:** Commercial ELISA kits were used for HTLV-I and HIV testing. Only strongly reactive specimens are reported here.

RESULTS

	No.	%pos.	%
Normal blood donors, several regions of Zimbabwe	931	1	0.1
Leukemia patients	6	0	0
Macrophilia (multi-transfused)	23	0	0
HIV-negative patients with serology from the WHO clinical AIDS criteria.	88	0	0
HIV-seropositive patients with neurologic disease	11	2	16.2
HIV-seropositive patients with neurologic disease	21	1	4.8
Of which 2 were typical TSP, both HTLV-I neg	1050	4	0.4

Of these patients with HTLV-I and neurologic disease:

- 1) 53 y.o. HIV-positive man with myelopathy progressing over 3 months.
- 2) 21 y.o. HIV-positive woman with probable nonster transverse myelitis and subsequent progression of neurologic deficits.
- 3) 38 y.o. HIV-negative woman with a 3 year history of spastic paraparesis. Other causes were not fully excluded in this patient.

CONCLUSIONS: HTLV-I appears less common in Zimbabwe than other African countries. It is strongly associated with neurologic disease. Possible association with leukemia or HIV infection requires further study.

Th.A.P.2 SCREENING FOR HTLV-I ANTIBODIES AMONG FINNISH BLOOD DONORS, HEMOPHILIACS AND HIV-SUSCEPTIBLE PATIENTS. P. Leinikki, E. Miettinen, J. Kallioinen, J. Leinola, H. Brunner-Korenkovic and M.-L. Kantanen. National Public Health Institute, and the Finnish Red Cross Blood Transfusion Service, Helsinki, Finland.

Objective: To evaluate HTLV-I screening among blood donors. **Methods:** Serum samples from blood donors (N=1803), hemophiliacs (N=196), patients of health care centers (N=676), AIDS information and support centers (N=446), i.v. drug abusers and inmates were tested using HTLV-I ELISA test (Du Pont, USA). Confirmatory tests were done by WB (Du Pont, USA). Indirect immunofluorescence and passive agglutination of gelatin particles coated with viral antigen (K. Okochi, Kyushu University Hospital, Fukuoka, Japan). **Results:** No true positive cases were found. Nine sera were repeatedly reactive in the ELISA test. None of them gave a characteristically positive reaction pattern in WB but showed reactivity against individual components of the virion. The reactive sera came from hemophiliacs (1), healthy blood donors (4), health care center patients (4) and AIDS information and support centers (1). The final result was confirmed by immunofluorescence and passive agglutination. **Conclusion:** HTLV-I screening is not warranted among blood donors in Finland at the moment. The atypical reactivity, sometimes interpreted as an indication of a HTLV-I related retrovirus and earlier reported from patients with lymphomas or leukemias was also found among healthy blood donors.

Th.A.P.4 PREVALENCE OF HTLV-I ANTIBODIES IN HIV-1 INFECTED PATIENTS IN A MEMORIAL COMMITTEE IN THE BROOKLYN, NY. Bauer, Stanley* Amari, L. and Ernst, J. The Bronx-Lebanon Hospital Center, Bronx, NY, USA.

Objective: To determine the prevalence of HTLV-I infection in an HIV-1 infected inner-city population. **Methods:** Anonymous sera (classified by age, sex, and race) and positive by HIV-1 ELISA and WB were tested by HTLV-I ELISA and WB. HIV-1 ELISA negative control sera were tested by HTLV-I ELISA. HIV-1 positive sera were from clinic outpatients, emergency room patients, and inpatients with no factors which met exclusion criteria of the CDC Sentinel Hosp. Program. HIV-1 negative sera from the hospital population served as controls. **Results**

SOURCE PATIENTS	HIV-1 POS	% HTLV-1 POS
Sentinel Hosp.	394	28%
Clinic	58	21%
Emergency Room	24	50%
Control (HIV-1 NEG)	172	8%

Conclusion: HTLV-I infection has spread more widely in inner-city minority groups than has been previously documented. Study partially supported by the CDC Sentinel Hospital Program.

Th.A.P.6

Session d'affichage Poster Session



Épidémiologie et santé publique Epidemiology and Public Health

Th.A.P.7 **HELIX-I ANTIBODIES IN THE SOLOMON ISLANDS.**
Murray, Daniel B., Koolman, St. View, Jr., and Mahalingam MK.
University of California, Davis Medical Center, Sacramento, CA, USA and
Oswego University School of Medicine, New Haven, CT, USA.

Objective: To determine the extent of HELIX-I infection in the Solomon Islands.

Methods: We tested 1,317 random individuals over the age of 5 using ELISA (Cellular Products, Buffalo, NY and Dupont, Wilmington, DE) as a screening test. We used enzyme from Hillwood Biologicals (Cupertino, CA) to prepare Western Blots (WB) as a confirmatory test.

Results: The prevalence of antibody interactive with HELIX-I by ELISA was 12.9% (96/716) in the North Solomons Province (Papa New Guinea) and 14.6% (89/601) in Malaita Province (Solomon Islands). However, in the North Solomons Province samples of 51 of 90 samples positive by ELISA were positive by WB. Thirty four were negative and 51 were indeterminate, usually showing faint p19 or p24 cross-reactivity.

Conclusion: Although there is a high prevalence of antibody interactive with HELIX-I by ELISA in the Solomon Islands, few HELIX-positive samples were also positive by WB. These puzzling results may reflect problems with HELIX-WB testing, cross-reactivity with immune complexes, or the existence of an antigenic variant of HELIX-I or a novel serotype in this area of the South Pacific.

Th.A.P.8 **LACK OF HTLV-IV INFECTION IN NON-IV DRUG USING HIV SEROPOSITIVE MEN IN LOS ANGELES**
Aboukhalil, Elmad, Miyazaki, T., Shimo, D.J.,
Division of Hematology, UCLA Department of Medicine, Los Angeles, California.

Objective: To determine the seroprevalence of HTLV-IV infection among HIV seropositive men.

Method: 634 sera obtained from Western blot confirmed HIV seropositive men seen at the UCLA AIDS Center between 1984 and 1988, were subjected to radioimmunoassay (RIA) using an HTLV-IV-infected human T-cell line (2B-1). Sera obtained from known Japanese adult T-cell leukemia patients and unaffected healthy individuals served as positive and negative controls. Groups studied: 1) Asymptomatic (N=13); 2) AIDS Related Complex (N=15); 3) Kaposi's Sarcoma (N=300); 4) AIDS defining opportunistic infections (N=76); and 5) high grade lymphoma (N=12). Only 2 patients were known I.V. drug users. Results: None of the tested sera were positive for antibodies to HTLV-IV. In common, using identical methods, we previously reported that 3.1% of sera collected from a group of 1000 (N=107) in Los Angeles harbor antibodies to HTLV-IV(1). Seropositive females used I.V. drugs or were found to have frequent sexual contact with I.V. drug using men.

Conclusion: By using a sensitive and specific assays that we have employed extensively in HTLV-I endemic areas, we find, in opposition to previous studies, that HTLV-IV infection is undetectable among selected seropositive homosexuals who do not engage in I.V. drug usage (2). Furthermore, no cross reactivity between HTLV-IV and HIV p24 gag gene products was seen using RIA analysis. Additional studies looking at the seroprevalence and significance of HTLV-IV infection in broader based populations at risk for seroreactive status are in progress.

References: (1) *Blood* Vol. 72, No. 5, Suppl. 1, 1988. (2) *Virology* Vol. 150, 1986.

Th.A.P.9 **HIV-1 AND HTLV-I SEROPREVALENCE IN CRITICALLY ILL RESUSCITATED EMERGENCY DEPARTMENT PATIENTS.**
Lewin, A.; O'Ryan, A.; Rivers, J.; Pohod, D.; Belan, B.; and Saravolatz, Louis D., Henry Ford Hospital, Detroit, Michigan, USA.

Objective: To determine the HIV-1 and HTLV-I seroprevalence and demographic features among critically ill emergency department (ED) resuscitated patients in a low HIV-1 seroprevalence area.

Methods: Patients who required resuscitation had an anonymous questionnaire completed by their physician. Sera was obtained and tested by ELISA. Repeatedly reactive samples were confirmed by IFA for HIV-1 and both Western Blot and RIPA for HTLV-I.

Results: Between 9/24/88 and 1/15/89 there were 25,378 ED visits. Patients SIGMET reflected the demographics of a Detroit inner city hospital ED. Seventy-nine percent (257/325) of eligible candidates were enrolled with a mortality of 25.3% (65/257).

	n	HIV-1	HTLV-I
Trauma (blunt or penetrating)	144	4.3% (7/144)	1.4% (2/144)
Medical Resuscitation	113	4.4% (5/113)	2.7% (3/113)
Total	257	4.7% (12/257)	1.9% (5/257)

Intravenous drug use was determined by history in 7/17 and by physical examination in 8/17 retroviral infection patients.

Conclusion: Health Care workers in a low HIV-1 seroprevalence area are at risk for HIV-1 and HTLV-I exposure during the resuscitation of the critically ill ED patient. Identification of known high risk groups occurs in approximately one-half of patients, emphasizing the need for strict adherence to universal precautions.

Th.A.P.10 **HIV-1 AND HTLV-I INFECTIONS IN INTRAVENOUS DRUG USERS (IUDUS) IN DETROIT 1985-1989.**
Lewin, A.; Mironov, S.; Pohod, D.; Lee, H.; Saravolatz, Louis D.; et al., Henry Ford Hospital, Detroit, Michigan, USA, and AIDS Laboratories, W. Chicago, Illinois, USA.

Objective: To monitor the seroprevalence of HIV-1 and HTLV-I and examine the HIV-1 infection free survival time in IUDUS who were followed from 1985-89.

Methods: Consecutive serologically unknown IUDUS seeking medical care for conditions unrelated to HIV were eligible to participate. After informed consent an anonymous questionnaire was completed and sera obtained. Serum specimens were tested by ELISA and repeatedly reactive samples were confirmed by IFA for HIV-1 and Western Blot and RIPA for HTLV-I.

Results:

Year	n	HIV-1	HTLV-I	HIV-1 and HTLV-I	HIV-1 or HTLV-I
1985-1986	86	12.3% (12/86)	9.3% (7/74)	3.2% (2/70)	22.5% (16/70)
1988-1989	71	15.7% (11/71)	10.0% (7/70)	4.2% (3/71)	18.3% (13/71)

Seropositivity was not associated with risk reduction practices, prostitute contact, or duration of drug use. IUDUS who traveled to metropolitan New York were more likely to be HIV-1(+) than those who did not (p<0.05). The HTLV-I attack rate was higher in HIV-1(+) or HIV-1(-) drug users (p<0.05).

Conclusion: During 1985-89, the prevalence of antibody to HIV-1 and HTLV-I was relatively stable among Detroit IUDUS. Travel to an endemic area increased the risk of acquisition of HIV-1. Since coinfection exceeded the expected frequency, HIV-1 and HTLV-I transmission may not be exclusively independent.

Th.A.P.11 **PREVALENCE OF HELIX-I ANTIBODY IN SELECTED MEN IN LOS ANGELES AREA**
Murray, Daniel B., Koolman, St. View, Jr., and Mahalingam MK.
University of California, Davis Medical Center, Sacramento, CA, USA and
Oswego University School of Medicine, New Haven, CT, USA.

Objective: To determine the seroprevalence of HELIX-I in men with high risk behavior.

Methods: Sera were collected from men with the history of multiple male sexual partners and analyzed for HELIX-I and HIV antibodies. Medical history and other data were obtained from the questionnaire forms completed at the time blood was drawn for testing.

Results: We have previously reported that 8% of men with multiple male sexual partners were positive for antibodies to HIV (1). Now we report that 14% (14/100) of men with multiple male sexual partners were positive for antibodies to HELIX-I. In addition, 14% (14/100) of men with multiple male sexual partners were positive for antibodies to HELIX-I. All sera that reacted in the HELIX-I-ELISA recognized specific HELIX-I proteins of p19, p24, p25 and p26 in the immediate. The ages of seropositive men ranged from 18 to 60 years and all had multiple male sexual partners for several years. Physical examination did not reveal lymphadenopathy or other symptoms. Use of the HELIX-I-positive men were black, one Hispanic and 6 Caucasian. None of the men had a history of blood transfusion or received any blood product.

Only 2 of 10 seropositive men admitted use of intravenous (IV) drugs.

Conclusion: We report a high prevalence of HELIX-I infection in men with multiple sexual partners. Since only 1 of the men had used IV drugs, it is evident that HIV was transmitted sexually. Although one of the men showed an HIV-1(+), close at the time their blood was tested, a prospective study would be important to relate HIV-1 infection with any disease that may develop in the future.

Th.A.P.12 **HTLV-III INFECTION IN AN INNER-CITY EMERGENCY DEPARTMENT**

Alan, Gilbert*, DiGirolamo T**, Lofy L*, Silvestro R*, Quinn T.**
*Johns Hopkins University, Baltimore MD, **AIDS, KEM, Bethesda, MD, USA.

Objective: To study the epidemiology of HTLV-III in a population known to have a high rate of HIV-1 infection.

Methods: Random serum samples drawn from 2944 consecutive adult patients presenting to an inner-city emergency department in Baltimore were tested for HTLV-III and HIV seropositivity by ELISA and confirmed by Western Blot (WB).

Results: We found 19 (1.3%) HTLV-III positive and 98 (3.3%) HIV positive. Of the 153 of the patients (6.8%) were 80 seropositive to HTLV-III, only 3 patients (all IV drug users) had concurrent infections. The age range among HTLV-III seropositive patients was 20 to 66 years old, with half the patients greater than 50 years old. The age distribution of HTLV-III infected individuals matched that of the patient population. In contrast, HIV was concentrated among those 25-44 years of age (p<0.05). Of the HTLV-III seropositive patients, 93% (28) were black, 48% (16) were male and only 77% of the patient population (p<0.05). Only black, African blacks made up 97% of the HTLV-III seropositive patients and 5 were transfusion recipients. One other patient's only potential known source of infection was associated exposure to an HIV infected partner. All but one of the HTLV-III infected patients lived in the surrounding neighborhood implying that HTLV-III was not likely imported from the Indian. The HTLV-III infection was not confirmed. Although the prevalence of HTLV-III in the United States has been estimated to be 0.04, HTLV-III may be more prevalent in certain areas of the U.S. than previously thought. Sexual transmission does seem to play a major role in HTLV-III infection. The data support the hypothesis that HTLV-III and HIV are relatively independently transmitted diseases.

Session d'affichage Poster Session



Epidémiologie et santé publique Epidemiology and Public Health

Th.A.P.19 HIV-1 AND HIV-2 INFECTIONS IN IMPRISONED HIGH RISK GROUPS OF BARCELONA.

Theo Ramos, A. Clotet, F. Puig, H. Infectious Diseases Unit and Blood Bank Unit, Hospital de Infectious Diseases "German Trias i Pujol", Universitat Autònoma de Barcelona, Barcelona, Spain.

Objective. To evaluate the prevalence of HIV-1 infection among intravenous drug abusers (IDU) in an area where a high incidence of HIV-1 infection has been described previously in this risk group.

Methods. This serology protocol was for the first time between January 1989 and December 1989 in our hospital, were tested by ELISA for the presence of anti-HIV-1 and anti-HIV-2 antibodies. Western blot was used as confirmatory test in repeatedly reactive samples.

Results. During the study period, 473 IDU serum samples were screened and the overall HIV-1 and HIV-2 antibody prevalence was 70.0% and 0.4%, respectively. The seroprevalence rates were stable during the study period. Confirmation was detected in all cases with HIV-1 antibodies.

Conclusion. This in our case represents an important reservoir for HIV-1 infection, but a role dated to a low prevalence of HIV-2 antibodies. For both retroviruses the total figures did not change throughout the four-year period.

Th.A.P.20 HIV-1 ANTIBODIES AMONG PRISON INMATES IN NORLAND

Vilhoor, David*, Taylor, E.*; Wisniewski, C.*; Tanner, C.*; McFarley, M.*; Hillier, T.*; Nokes Hoodley, School of Hygiene and Public Health, Baltimore, MD, USA *Abbott Laboratories, North Chicago, IL, USA

Objective. To identify prevalence and risk groups for HIV-1 infection among inmates entering prison.

Methods. Specimens routinely obtained during intake evaluation of 1,000 consecutive male inmates, excluding repeat offenders, entering Maryland prisons during the same time period in 1987 and 1988 were assayed for antibodies to HIV-1 by EIA. Repeat reactive samples were confirmed by Western blot and HIVPA. Demographics were compared by serostatus using non-parametric statistics.

Results. Among 1933 inmates, 19 (1%) were repeatedly reactive by EIA.

GROUPS	NUMBER	M/FS	REPEATABLY REACTIVE	P VALUE
RACE: Black	1396	19/11(45)		<0.001
Non Black	537	0/0(0)		
AGE: <25	1070	18/1(1.7)		<0.001
25-35	863	1/0(1.1)		
YEAR: 1987	800	5/0(0.6)		
1988	1033	14/1(1.4)		0.06

Reactivity to HIV-1 did not vary significantly by HIV-1 serostatus, jurisdiction, offense category.

Conclusion. Unlike HIV infection in this population (7.0%), approximately 1% was infected with HIV-1, occurring most in blacks over 25 years of age. The seroprevalence rate of HIV-1 in prison inmates is 5-10 times higher than in normal U.S. populations.

Th.A.P.21 HIGH RISK OF CONFIRMED HIV-1 INFECTION

AMONG INTRAVENOUS DRUG ABUSERS (IVDA) FROM NEW ORLEANS

Leo Helms*, Swanson, P. J., Shorty, V.,*., Chack, J.***; Rosenblatt, J.***; and O'Connell, T.*** *Abbott Laboratories, W. Chicago, IL; **Oxoid Harcourt, Weybridge, New-Orleans, LA; ***CLA School of Medicine, Los Angeles, CA, U.S.A.

Objective. Determination of HIV-1/II infection in New Orleans IVDA.

Methods. (1) Serum from 121 IVDA were tested by EIA, Western blot and HIVPA for antibodies to HIV-1/II. (2) Lymphocytes from 27 of 121 IVDA were analyzed by PCR. HIV-1/II sequences were differentiated via restriction and sequence analysis. (3) Viral cocultures were done using lymphocytes from 9 EIA positive IVDA and 20 negative EIA low risk individuals. Reverse transcriptase (RT) and immunofluorescence (IF) with monoclonal anti-p24 and anti-p26 were used to monitor viral expression.

Results. (1) Serum samples from 54 of 121 IVDA were EIA positive, 33 of which were confirmed by Western blot and/or HIVPA.

(2) EIA WESTERN BLOT/HIVPA PCR: HIV-1 + HIV-1 + HIV-1 + HIV-1 +

23 Positive IVDA 16 Confirmed 2 16 0

4 Indeterminate 4 0 0 1

4 Negative IVDA 1 Negative 0 1 0

4 Negative 4 Negative 0 0 0

20 Negative Donors 20 Negative 0 0 20

(3) RT/IF COCULTURES of EIA and IVDA lymphocytes were positive by RT. At 6 weeks of culture, 8 of the 8 cocultures were also positive by RT.

Conclusion. A cohort of 21 HIV-1 positive individuals has been identified to New Orleans. This represents the largest HIV-1 cluster confirmed by a combination of virological and molecular genetic methods.

Th.A.P.22 HIV-1 INFECTION IN SPAIN

Soriano, J., Abella, I., Tor, J., Flores, A., Clotet, B., Ribera A. Infectious Diseases Unit and Service of Hospital de Badalona "German Trias i Pujol", Barcelona, Spain.

Objective. To evaluate the prevalence of antibodies against HIV-1 among people at risk for this viral infection.

Patients and methods. We studied serum samples of 682 intravenous drug abusers (IVDA), 53 hemodialysis polytransfused patients, 3 subjects diagnosed of Toxic Spastic Paraparesis (TSP) and 102 West Africans living in Barcelona since 1982. Antibodies to HIV-1 were investigated by ELISA and repeatedly reactive samples were studied by Western blot.

Results. See table.

	IVDA	Polytransfused	TSP	West Africans
*ELISA + (357/682)	27/682	3/53	0	5/102
**ELISA Clonatec, France; **WESTERN BLOT by Point, USA	2/27	0	0	1/5

Conclusion. Our results suggest that HIV-1 infection is present in Spain among IVDA and West African immigrants. A low prevalence is recognized.

Th.A.P.23 COINFECTION WITH HIV, HTLV-1 AND HBV IN TRINIDAD AND TOBAGO

Souriana, Barbilomae*, F. Cleghorn**, E. Waller**, K. Bhattar*, *The University of the West Indies;

** The Caribbean Epidemiology Centre, Port of Spain, Trinidad;

*** The National Cancer Institute, Maryland, U.S.A.

425 consecutive HIV antibody positive sera assayed in 1986-88 were tested for antibodies to HTLV-1 and confirmed by Western blot. 42 (10.1%) were HTLV-1 antibody positive. IVDA is not practised in Trinidad and Tobago and when adjusted for age this cohort had a 5 times higher seroprevalence than the general population. 17/60 (10.6%) of HIV antibody positive homosexual men were coinfecting with HTLV-1, 9/90 (10%) of heterosexual women, while 14/58 heterosexual men (24.1%) were HTLV-1 antibody positive. Of 382 patients singly infected with HIV, 205 (53.2%) had AIDS or developed AIDS in the period 1986-88 compared with 20/42 (45%) of coinfecting patients. The hepatitis virus (HBV) closely resembles retroviruses in its molecular structure including a reverse transcriptase mechanism in its replication.

HIV DNA has been found in T-lymphocytes of HIV infected people who are core and surface antibody positive and surface antibody negative. Significantly, out of 425 HIV positive patients, 7/6 (1.6%) had triple antibodies to HIV, HTLV-1 and HBV had AIDS in the period under study. In a prospective study of 34 homosexual men who were singly infected with HIV and followed for a period of 5 years, 10 (29.4%) had progressed to AIDS, while of 6 men who were doubly infected with HIV/HTLV-1, 3 (50%) had progressed to AIDS in the same time period. 2 cases of HBV were HIV antibody positive. Further studies are in progress to assess the role of HTLV-1 and HBV as co-factors in AIDS.

Th.A.P.24 HTLV-1 IN INTRAVENOUS DRUG ADDICTS (IVDA) AND GAY MEN IN SAN FRANCISCO

Beatty, Ellen C.*, Murphy, E. J., Drummond, J.**, Baccetti, P.**, Chalko, R.**, Greenstein, J.S.*** et al., *San Francisco General Hospital, University of California at San Francisco, San Francisco, CA; **Harvard Medical School, Boston, MA; ***University of Washington, Seattle, WA

***The National Cancer Institute, University of California at San Francisco, San Francisco, CA, U.S.A.

Objective. To describe the seroprevalence of HTLV-1 in IVDA's and gay men in San Francisco comparing a commercially available ELISA with Western Blot (WB) and CN 175 purified virus. Methods: Serum samples from 809 IVDA's in methadone programs and from 383 gay men were independently blindly tested for HTLV-1 in 2 independent laboratories. Most specimens were from cross-sectional participant samples between 1982 and 1987. Additionally, longitudinal paired specimens were available in 153 IVDA participants.

Radiolabelled WB and ELISA showed similar temporal trends although the WB consistently detected more positives: 1982 12% ELISA +, 16% WB +; 1987 12.5% ELISA +, 19% WB +. By ELISA WB seroprevalence correlated with age: age <40, 8.2% age 40-50, 13.7% age 50-60, 25.9% age 60-69, 39.3% age 70 and over. Whites had fewer positive results, 10.2% vs. 21.7% blacks, and 19.6% Hispanics. Men (7.5%) were more often positive than women (4.7%). The longitudinal paired samples demonstrate reproducibility of results over time. By ELISA 21 initial positives and 6 initial negatives remained so, however 8 other initial positives were later negative and 8 other initial negatives became positive by WB. By WB 25 initial positives remained so, 14 initial negatives and 2 negatives became positive on follow-up cases. Many of the discrepant results observed between WB and ELISA were categorized as borderline by WB and of the borderline qualitative value of the ELISA.

Conclusion: For the study populations the two methods provided comparable results: the prevalence of HTLV-1 in IVDA's in San Francisco is more common than HTV, particularly in older blacks and Hispanics. Further evaluation of discrepant results is in progress with WB with HTLV2 and radioimmunoassay.

Session d'affichage Poster Session



Epidémiologie et santé publique Epidemiology and Public Health

Th.A.P.43 STATISTICAL CONSIDERATIONS OF MISCLASSIFICATION OF PATIENTS AT BASELINE IN TWO AIDS CLINICAL TRIALS

Alan J. Fisher, Ph.D., Elizabeth J. D'Arcy and Betsy, V. J.***
*Hiroak, Inc., Costa Mesa, California, USA; UCLA School of Medicine, Los Angeles, California, USA; **Heron Group, Los Angeles, California, USA.

Objective: To evaluate the impact of initial patient classification in 2 studies of oral zidovudine.

Methods: Data from LAS (N=166) and ABC (N=213) patient groups were combined after a statistical reclassification of patients. The reclassification was based on covariates measured at the time of enrollment in such a way as to define 2 new groups of patients maintaining the within strata homogeneity at baseline. This analysis examined the effects of possible misclassification of patients among the LAS and ABC trials. Statistical adjustment for prognostic variables was done on a Cox proportional hazards model. Sensitivity analysis to evaluate model assumptions and protocol deviation were performed to supplement the primary analysis.

Results: The data when stratified by original study designation, statistically stratified by baseline characteristics or treated as a large group were not statistically significant. Classification is not an important determinant to the conclusion that zidovudine was effective in delaying progression to AIDS among these patients.

Th.A.P.45 ZIDOVUDINE PROPHYLAXIS FOR PERSONS WITH ACCIDENTAL PERICUTANEOUS BLOOD EXPOSURE: A DECISION ANALYSIS

Ray, Douglas L., M.D., Robert Ross School of Medicine, New York, NY, USA.

Objective: We performed a decision analysis to determine the thresholds of safety and effectiveness which would justify short-term zidovudine (AZT) administration for persons with accidental percutaneous exposure to either HIV-positive blood or blood of unknown HIV serologic status.

Methods: We used a Markov model to accommodate the short-term risks of HIV infection and AZT effectiveness and toxicity after HIV-positive blood or blood of unknown HIV serologic status. The measure studied were life expectancy and lives saved per cohort. Published data were used to estimate seroconversion rate (0.8%), rate of HIV-induced development AIDS (0.8%/year), and AIDS survival (0.06%/year). No information is available on AZT effectiveness and little is known about AZT effectiveness toxicity. Wide variations in all assumptions were made in the sensitivity analysis.

Results: For those with exposure to blood known to be HIV seropositive, the benefits of AZT outweigh the risks under all but a combination of the most skeptical assumptions of AZT safety and effectiveness. Using moderate assumptions (AZT effectiveness 30% safety 2 deaths per 30,000 AZT recipients), AZT use exceeds life expectancy by 7 weeks and averts 1% deaths per 10,000 persons exposed.

Under more optimistic assumptions (90% effectiveness and 1 AZT death per 30,000), life expectancy is extended by 6 weeks and 500 deaths averted per 10,000. However, under pessimistic assumptions (AZT effectiveness and 8 AZT deaths per 30,000), the risks of AZT minimally outweigh the benefits. Wide variations in the assumptions have little effect on the thresholds, with the exception of seroconversion in a function of the blood prevalence of HIV infection; the AZT benefits do not clearly outweigh the risks when the prevalence is below 10-20%.

Conclusions: Until the results of clinical trials are known, the decision must be based on strength of belief regarding AZT effectiveness and toxicity. Unless studies show AZT to be both highly effective and toxic, the benefits of short-term AZT outweigh risks after exposure to HIV-positive blood. AZT benefits do not clearly outweigh risks after exposure to blood of unknown serologic status.

Th.A.P.47 BLOOD EXPOSURE DURING SURGICAL PROCEDURES.

Franklin, C.***, Parfitt, C.***, Poy, D.***, Lowry, P.***, Ball, D.***, Centers for Disease Control, Atlanta, Georgia, USA; ***Grady Memorial Hospital, Atlanta, Georgia, USA.

Objective: To describe the nature and frequency of occupational exposure to blood among operating room personnel during surgical procedures in a large public hospital.

Methods: Trained observers sampled operations and recorded the type and duration of procedure, emergency nature, estimated blood loss by the patient, occupations of personnel, infection control precautions used, and number and type of exposures.

Results: One or more persons had skin, mucous membrane, or percutaneous exposures to blood during 49 (33%) of 151 operations, including 9/19 (47%) in trauma, 12/32 (38%) in orthopedic, 12/39 (31%) in gynecology, 8/35 (23%) in general surgery, 2/18 (11%) in plastic surgery, and 3/7 (43%) in burn procedures. Of 1392 personnel observed, 88 (6.3%) experienced 116 blood exposures, including 49 contacts with exposed skin (42%), 40 episodes of clothing soiling (35%), 23 exposures due to possibly defective gloves (13%), 10 needlesticks or cuts with sharp objects (9%), and 4 exposures (3%). Risk factors for exposure (relative risk, 95% confidence interval) included being a nurse (1.8), participating in an emergency procedure (3.4), 2.0-5.1, patient blood loss > 250 ml (3.6; 2.5-5.4), and duration of time in the OR (1.1; 1.0-1.2).

Conclusions: The risk of blood exposure for operating room personnel is substantial. Studies are needed to quantify this risk, identify risk factors for exposure, determine the risk of HIV infection due to these exposures, and to design and evaluate preventive measures.

Infection par le VIH chez les travailleurs de la santé HIV Infection among Health Care Workers

Th.A.P.44

GUIDELINES FOR PREVENTION OF TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS AND HEPATITIS B VIRUS TO HEALTH CARE AND PUBLIC UTILITY WORKERS
Mullen JB, Baker, Edward L, Scahy MJ, Stites PV
National Institute for Occupational Safety and Health
Centers for Disease Control
Atlanta, Georgia, U.S.A.

In response to recently enacted United States legislation (Public Law 100-607, The Health Care Workers Protection Act of 1988, "AIDS" Amendments of 1987), guidelines have been developed for all health-care and public safety workers (including emergency medical workers, fire-fighters, police, and correctional facility workers) in the United States.

The document provides an overview of the modes of occupational transmission of HIV and hepatitis B virus (HBV), an assessment of the risk of transmission under various circumstances, and a discussion of the control of risk, and specific risk control recommendations for employers and workers. Also included in this document is information relating to medical management of workers who have sustained an occupational exposure to these viruses. A separate model curriculum based on the principles and practices discussed in this document has been developed concurrently for use in training workers.

An overview of the guidelines and curriculum will be presented, with specific recommendations for preventing transmission of these bloodborne viruses to emergency medical service workers, fire-fighters, police, and correctional facility officers.

Th.A.P.46 NATIONAL SURVEILLANCE PROGRAM: OCCUPATIONAL EXPOSURE TO HUMAN IMMUNODEFICIENCY VIRUS (HIV-1) INFECTION IN CANADA Emin, Elizabeth, Hollings, J. J., Federal Centre for AIDS, Health Protection Branch, Ottawa, Ontario, Canada.

Objective: To assess the risk of HIV infection among health-care workers (HCWs) exposed to blood or body fluids from an HIV-infected person.

Methods: Eligibility criteria require a documented parenteral, mucous membrane, or skin contact exposure to blood or body fluids from an HIV-infected person. HCWs are followed for one year post-exposure and 10 blood specimens are taken at 6 week intervals for six months post-exposure and at 9, 12, and 18 months. Standard information collected include demographic, risk factors and exposure circumstances.

Results: As of January 6, 1989, 234 HCWs had enrolled in the study, 80% of which were health-care providers, 14 laboratory technicians and 44 other workers. 47% of exposures were needlestick, 44 scalded wounds, 12% eye-splash, 16% open-wound contact, and 21% skin contact. 50 (23%) of the 234 exposures were likely preventable, had standard infection control procedures been used. Excluding HCWs for whom a baseline serology (within 30 days of exposure) was not available, there have been no seroconversions.

Conclusions: These data are consistent with other studies and support a very low risk of transmission of HIV infection after routine testing and parenteral, mucous membrane, or non-irect skin exposures in the occupational setting.

Th.A.P.48 REPORT OF A POSSIBLE LABORATORY ACQUIRED HIV INFECTION.

Raley, Christine L., Reif M, Murphy P**
Dallas County Health Dept, 907 Eaststowers Bend Cr, Dallas, Texas, USA.

Objective: Case report of possible occupationally acquired AIDS.

Case Report: In 1987, a 28 year old woman was referred to evaluate for a possible HIV infection. She had donated blood in 8/82 and was HIV negative, but a donation in 5/86 was HIV positive. She was black and western birth possibly but asymptomatic until 6/78 when she developed pseudomonas pneumonia. On interview, she claimed two lifetime sexual contacts: one, before 1981, who was not tested, but thought to be healthy in 1987; and a current partner, who had no serologic evidence for HIV infection in 6/87. The woman was a technologist who worked in a clinical laboratory that was known to handle HIV positive specimens. She denied other risks including transfusions, drug abuse, and other sexual contacts. She experienced a scratch from a blood contaminated needle in 9/84 and adults to occasionally contaminating her hands with blood. She washed her hands frequently and was being treated for severe atopic dermatitis of her hands. An examination found no abnormalities except dermatitis and vesicles/lesions on her palms.

Conclusion: No discrete exposure was found in the interval between the blood donation. This woman possibly had been infected by direct inoculation in the vesicles/lesions on her hands with HIV contaminated blood in the laboratory.

Session d'affichage Poster Session



Epidémiologie et santé publique Epidemiology and Public Health

Th.A.P.49 THE RISK OF EXPOSURE TO HUMAN IMMUNODEFICIENCY VIRUS AMONG HEALTH CARE WORKERS (HCW) IN A SOUTHERN U.S. JUDGE HOSPITAL - RIAL, GEORGIA: Gaumer, R*¹; Weeks, S*²; Leste, J*³; Sanders, C*⁴

¹Louisiana State University Medical Center, New Orleans, La, USA, ²Abbott Laboratories, North Chicago, IL, USA.

Objective: To assess the risk of exposure to HIV among HCW's at an Urban Hospital in the Southern United States (Charity Hospital of New Orleans).
Methods: Plasma remaining from CBC analysis of a cohort of patients presenting to the acute medical (n=246), the acute surgical (n=67) and obstetrical unit (n=221) were subjected to ELISA screening for HIV, with confirmation by Western Blot. Demographic information obtained on all patients included age, race, sex, risk factors for HIV, and type of problem. All HCW interventions with the possibility of exposure to blood or body fluids were recorded. All patients' identifiers were removed.
Results: Of 534 specimens, 11 (2.1%) were positive overall (5 men and 2 women). Rates were similar among black and white patients. Seven patients could be placed into a known risk group after interview, but only one was known to be at risk prior to some HCW intervention. None of the obstetrical patients were seropositive. Of 100 percent of trauma patients and 2.5% of medical patients were seropositive. Among men, there were similar rates of seropositivity among several age groups. At least two procedures with the potential to transmit HIV were performed per patient.
Conclusion: A substantial risk of exposure to HIV exists in the trauma and medical emergency areas. Thus, all HCW's in this region need to practice universal barrier precautions.

Th.A.P.51 SEMI-DYNAMIC BASED MODELING OF THE SPREAD OF HIV FROM BROWNSVILLE, University of Hawaii at Manoa, Honolulu, Hawaii, USA.

Objective: Describe a new approach to computer modeling of HIV and other sexually transmitted diseases spread in heterogeneous populations.
Methods: A sample of individuals closely matching the demographic and risk behavioral characteristics of a population is generated by computer and all HIV transmitting activities are simulated using distributed discrete event simulation techniques. Due to the computational intensity of this approach, these simulations are executed on parallel computers, machines with more than one processor. The result is a computerized laboratory for the evaluation of geographic, demographic, and behavioral factors.
Results: Early model simulations have been completed on a Smallbit Systems 2010 microcomputer, with more sophisticated versions in preparation. A description of the program components and input requirements is given; preliminary experiments with the models and their use in modeling HIV spread in Hawaii and Thailand are described.
Conclusions: Behavioral simulation provides a means of incorporating both geographic and demographic factors and the effects of behavioral intervention efforts into the modeling of HIV propagation.

Th.A.P.53 HIV CARRIERS: Increasing Infectivity with Progression to AIDS has Important Implications for the AIDS Epidemic among Heterosexuals. Gonzalez, Jose J*¹; Davidson, P*²; and Koch, M*³

¹ASA, N-4800 Arendal, ²ADN, N-4601 Kristiansand, ³HHU, Hergen, Bergen, N-5000 Bergen, Norway, ⁴VAC, S-546 06 Karlaborg, Sweden.

Recent evidence suggests that the degree of infectiousness increases with the duration and progress of the HIV infection. We have developed mathematical models taking into account increasing infectivity along with progression to AIDS, heterogeneous sexual behavior, import and export of persons and infections, and variable patterns of infectiousness.

The duration of both the seroconversion latency state and the interval of slight infectivity associated with it probably depends on the method of transmission and the infective dose. If this is so, then heterosexual HIV transmission is likely to be followed by a relatively long latency period, which in turn suggests that the rate currently observed for heterosexual transmission of the HIV will probably change accordingly. With the passage of time, new HIV carriers will necessarily enter the stages of increased infectiousness and thus accelerate the further spread of the HIV in a predictable way.

Th.A.P.50 CENSUS DATA AND FORECASTING OF S. AIDIS CASES FICKLING, J.G.; ROBBIN, J.S.; ZIEGL, J.S.*

¹Department of Entomology, University of Arkansas, Fayetteville, AR, USA. AIDS cases are unevenly distributed geographically. Nearly half of U. S. cases have been reported by New York and California that have less than 1/5th of the total U. S. population. Within California, over 2/3rds of cases have been reported from Los Angeles and San Francisco counties that have only 1/3rd of California's total population. Long-term epidemic forecasts should consider local differences in population size, life-style and onset of transmission. The Public-Use Microdata Samples of the U. S. census provide data on demographic and life-style variables. The A-sample is a 5% sample of the U. S. population. It has information on age, sex, marital status and relationship of individuals within households in 1154 areas that together make up the United States. Based on these data, we have estimated the relative size of populations at risk to AIDS through homosexual transmission. Using the population estimates, local AIDS incidence data, and an epidemic model, we forecast AIDS incidence from the local through national level. Although sensitive to parameter values and our assumptions, these forecasts give insight into the geographic distribution of AIDS. For example, while the incidence rate of AIDS in San Francisco and Los Angeles have been similar to date, we project that there will be ultimately 2-6 times more cases in Los Angeles than San Francisco.

Th.A.P.52 A DYNAMIC MODEL OF HIV TRANSMISSION AND AIDS IN SAN FRANCISCO

Hahnke, Herbert W., University of Iowa, Iowa City, IA, U.S.A.
Objective: To forecast HIV prevalence and AIDS incidence in the homosexual population in San Francisco using a transmission dynamics model.
Methods: The compartments in the model are seronegative and stages in the phases: HIV incubation, asymptomatic, pre-AIDS, AIDS and death. The homosexual population is also subdivided into the active and very active sexual categories with immigration, emigration and transfer between categories. The computer simulation model is a system of nonlinear difference equations with a time step of one month. The fit criteria require that the model be consistent with the a priori parameter estimates, with the reported fully-adjusted AIDS incidence from 1980 to 1987 and with the estimated HIV prevalence from 1979 to 1987. Projections are made assuming that decreases in sexual activity continue and also assuming no changes in sexual behavior after 1987.
Results: The pattern in the simulation model is that the HIV prevalence peaked at about 20,000 in 1985 (out of 56,000 homosexuals in San Francisco) and that the yearly AIDS incidence peaks at about 1000 in 1989 and decreases to less than 1000 by 1996. Although there is some saturation in the very active group, adequate fits are not obtained without changes in behavior. In the simulation the average number of new partners per month decreases by a factor of about 0.6 each year from 1982 to 1987.
Conclusion: The distribution of the AIDS incubation period with 7 stages gives the best fit in the simulation model. The simulations predict that the AIDS incidence peaked in 1989 and will decrease in the future. This pattern is primarily due to changes in behavior.

Th.A.P.54 A MULTIPLE RISK GROUP MODEL TO ESTIMATE AND PROJECT THE SPREAD OF HIV

Phillip, C. Conley*, Christopher, S*¹; Heall, D. R.* and van der Grinte, C.
¹Research Triangle Institute, Research Triangle Park; ²University of North Carolina at Chapel Hill, Chapel Hill, N.C., USA.

Objective: To describe an HIV transmission model and results of the model.
Methods: The model exhibits the following characteristics:
- all major (sexual and nonsexual) transmission routes are included.
- different transmission routes are accommodated simultaneously.
- parameters that are difficult to estimate (e.g., number and types of sexual or needle sharing contacts) are endogenous to the model, and
- results from the model can be used to evaluate intervention strategies.

The essential model features are described in four sections: estimation of initial population sizes, the algebraic representation of the dynamics of HIV, estimation of within and between risk group infection rates, and projection of the spread of HIV.

Results: National U.S. data is used to estimate model parameters and to provide 10-year projections of the course of the HIV and AIDS epidemics.

Section d'affichage Poster Session

Épidémiologie et santé publique Epidemiology and Public Health

Th.A.P.55 HIV DYNAMICS IN LINKED RISK GROUPS, A MULTIGROUP TRANSMISSION MODEL. **
 Hans Gilman, M. S. Ruzhansky, M. J. C. Fox, R. A. Coutinho, ***,
 J. Buitrago,
 University of Michigan, The Netherlands, ** National Institute of Public Health and Environmental Protection (INPEM), Biltzowen; *** Municipal Health Service, Amsterdam, The Netherlands.

The HIV/AIDS epidemic is a composite of many overlapping and linked epidemics in several risk groups, each with its own dynamics and time course. The simultaneous spread of the infection is described by a multigroup transmission model. Six risk groups are distinguished: the homosexual community (two levels of promiscuity), the intravenous drug users (men and women), and the heterosexual, heterosexual men and women. Three modes of transmission are considered: anal and vaginal intercourse and needle sharing. The model helps to clarify why more data are needed to disentangle the relative contribution of the within and between group transmission routes. Given a specification of a baseline, the potential use of the model is illustrated by simulations describing effects of: a) blocking the transmission between the main risk groups and b) blocking the transmission between the main risk groups and the homosexual/epidemic runs its own course and that blocking the transmission between the main risk groups may substantially reduce the spread into the heterosexual population.

Th.A.P.57 IMPACT OF SERIAL BEHAVIOUR CHANGE ON THE AIDS EPIDEMIC
 Erling Bjørn,
 Helsebyrå, University of Glasgow, Glasgow, Scotland.

Objective: To investigate the effects of changes in sexual behaviour on HIV transmission and the AIDS epidemic.

Method: A new modelling technique is developed that permits the fast numerical solution of a HIV transmission model with multiple sexual activity levels, where the mean and variance of the number of partners per year is imposed on an arbitrary function of time. Using this, the timing and magnitude of an epidemic can be investigated under different patterns of sexual activity change.

Results: The details of the timing and magnitude of behaviour change (including the number of sexual partners each individual will on average take) dictate its value as a control measure. Although an early change is better than a later one of the same magnitude, eradication requires prolonged reduction and long-term low levels, if the disease is not to re-appear in a second epidemic.

Conclusions: Observed behaviour changes in certain sections of the community may be sufficient to cause HIV to die out locally, but unless change is made on a large scale, and on an lasting basis, further epidemics could occur.

Th.A.P.59 THE POTENTIAL FOR SPREAD OF HIV IN THE HETEROSEXUAL POPULATION IN NORWAY IN A SITUATION MORE STABLE
 Håkan Stenius, J. K. Grenvold, P. Magnus, L. M. Sande, L. Bakkeberg
 Dept. of Epidemiology, National Institute of Public Health, Norway.

To assess the potential for spread of HIV in the heterosexual population in Norway, based on sexual behaviour data, with and without input of infection from other groups.

Method: A simulation model is used. The model population is the heterosexual population (excluding IV-drug users) in Norway aged 15 to 60 years. The population is divided by age, sex and marital status. In each group the number of HIV infected subjects is calculated based on group specific values for the frequency of intercourse, the partner turnover, the pattern of partner choice, the proportion of married/cohabiting subjects eligible as sexual partners, prevalence of infection and transmission probability. The transmission probability and the AIDS hazard rate varies with time since infection. Behaviour is taken from the Norwegian study on sexual health. (random sample = 10,000, response rate 63% (J.M. Sande, this conference)).

Results: The epidemic is not self-sustained in the heterosexual population where the average transmission probability is below 1% per intercourse, and there is no input of infection from other groups. This result is insensitive towards changes in the initial conditions. It is sensitive towards changes in sexual behavior and in particular towards changes in the form of the transmission probability distribution. The simulated number of discordant couples is compared with empirical studies indicating that 1% transmission is too high. When input of infection from other groups is considered, the prevalence level is found to depend both on the influx of infection, and on the distribution of the contacts with the heterosexual population. Different source groups with different fun and contact distributions are discussed.

Conclusions: With current behavior the Norwegian heterosexual population is not likely to sustain the HIV-epidemic in isolation. Import of infection will be important in determining the prevalence level.

Th.A.P.56 ENHANCED COMPUTER MODEL OF HIV TRANSMISSION VIA NEEDLE SHARING
 Abigail David, P. Sains A.C., Lewis B **
 Trinity College, Hartford, CT ** Spectrum House Inc., Westboro MA U.S.A.

Objectives: To 1) develop quantitative descriptions of intervention measures for needle users; 2) incorporate these descriptions in a model simulating HIV transmission on the street and in jail; 3) evaluate effects of increased short- and long-term treatment center capacity and rehabilitation success rate; 4) evaluate effects of expanded testing before jail; 5) evaluate needle cleaning in jail. Parameters are to be estimated from survey data describing needle use in Worcester, MA.

Methods: Descriptions of the intervention measures are added to a preliminary model presented at the IV International Conference on AIDS. Parameters are estimated based on 1) survey data collected in treatment centers by the Worcester AIDS Consortium (6672 subjects); and 2) entry testing data for 450 inmates. We assess scenarios describing 1) improved drug treatment; and 2) increased testing and needle-cleaning, especially in jail.

Results: We establish a base run simulation which matches observed seroprevalence during 1982-89. For 1989 and beyond the base run assumes moderately high rates (30%/year) of both testing for HIV antibodies and adoption of clean needles by persons found seropositive. Relative to this base run, interventions begun in 1989 provide the following reductions in the cumulative number of AIDS cases through the year 2006: 1) doubled short- and long-term treatment center capacity and rehabilitation success—12% (2); 2) 100% testing and 100% needle cleaning by persons found seropositive—2% (3); 3) 100% needle cleaning in jail—22% (4); combination of 2) and 3) above—26%.

Conclusions: Combined intervention approaches can significantly reduce the number of projected AIDS cases in a population currently 18% seropositive. Simulation confirms that jails are reservoirs of HIV. To supplement aggressive testing and needle cleaning programs, provision of bleach in jails may be the most effective single intervention.

Th.A.P.58 MODELLING OF IMMUNE SYSTEM DYNAMICS IN HIV PATHOGENESIS: ISSUES IN IMMUNOMODULATION.

Rupert E.D. Whittier, Boston University/Tufts New England Medical Center Hospital, Boston, MA, USA.

Objective: To describe a modelling approach to the pathogenesis of HIV infection and the effects of immune-modulatory factors (e.g. stress, drug abuse, pharmacotherapy) on the dynamics of infection and the development of disease.

Methods: STELLA for the Apple Macintosh - system dynamics modelling software.

Results: System dynamics (SD) modelling exemplifies a flexible approach to understanding the pathogenesis of HIV infection, using a complex, non-linear, multi-loop, feedback simulation of the immune response to revivify infection. The approach shows itself to be of value in generating and testing causal hypotheses of pathogenesis and the effects of policy intervention based on the model's premises, even in the absence of precise data. It focuses on immune response dynamics as a consequence of the structure of the immune system rather than of the one-way effects of extraneous variables (such as HIV infection) and allows a more sophisticated approach to understanding the role of immunomodulation and co-factors in the development and prevention of disease.

Conclusions: System dynamics modelling of HIV pathogenesis affords a more thorough approach to understanding the essential details in disease development and may be useful for developing policy in the implementation of therapeutic immunomodulators and antivirals. The use of non-linear approaches to understanding pathogenesis are necessary for effective intervention development.

Th.A.P.60 EVIDENCE FOR A 16-18 YEAR MEAN TIME BETWEEN HIV VIRAL INFECTION AND AIDS ONSET
 Gretchen Wilson, and Holmes W.***
 * State University of New York at Buffalo;
 ** State University College at Buffalo, Buffalo, NY, U.S.A.

Past estimates of incubation time of AIDS have relied on estimates of time-of-infection that may have been questionable. We present 1077 cases of transfusion-related AIDS, as reported to The Communicable Disease Center, Atlanta GA, U.S.A. (CDC) which we have examined for the pattern between HIV viral infection and AIDS onset. This is probably the only class of AIDS patients for whom the precise time of infection is reasonably ascertainable. We conclude that a Weibull distribution with a mean time of 18 years and a shape factor of 0.23 represents a reasonable fit, and that a 1 year mean does not. It appears that the fitted curve represents only a lower limit, and that the true mean is somewhere between 16 and 20 years. However the most recent data update (July 1988) suggests that the data will converge at a mean incubation time approximating 18 years, with a Weibull shape factor of 0.23. We recognize that this suggests a much longer incubation time than previous estimates but may be explainable. From the work of Waldshly et al reported at the last conference in Stockholm, which suggested a dormant period between infection and expression of antibodies of as much as four years. From our curves we estimate that a minimum of 20,500 and perhaps a maximum of 30,200 transfusion-related cases of HIV remain undetected.

Session d'affichage Poster Session



Th.A.P.61 INCUBATION TIME FOR AIDS IN TRANSMISSION-ASSOCIATED CASES: AN ESTIMATION FROM THE FRENCH DATASET

Castellan, Dominique*, Laporte, A.T.M., Valléon, A.J.*

*INSERM U 253, Université Paris VII, Paris, France, *Direction Générale de la Santé, Paris, France.

Objective: To calculate estimates for mean and median incubation times for AIDS, and to give confidence intervals for these two parameters using the French dataset.

Methods: The method described by Lu et al. was selected and as in several previous works, a Weibull or a gamma distribution for incubation time were postulated. The Likelihood Ratio Statistic (LRS) was used to derive 90% confidence intervals. The French dataset where each case was individually reviewed, was used. Ninety two (92) cases with multiple transfusion, single transfusion without knowledge of the time of transfusion, association of another possible major risk factors were eliminated, leading to a final dataset of 167 subjects. Due to the age dependence of incubation time, the analysis was restricted to the 149 subjects under the age of 50 years.

Statistics	Weibull	Gamma
Mean (Years)	5.3	6.9
90% CI	4.4 - 8.9	1.9
Median (Years)	5.3	6.4
90% CI	4.4 - 8.8	4.7 - 11.4
Log Likelihood	-509.2	-508.6

Conclusion: Similar fits were observed with both distributions. Confidence intervals, under the Weibull assumption in particular, are narrower than those previously published. This indicates that an accurate estimate for mean incubation time in transfusion-associated cases will probably be obtainable in the near future.

Th.A.P.63 MODELLING PROGRESSION OF HIV INFECTION

De Smedt, Victor*, Lamy, Nicholas*

*Harvard Univ., Boston, MA, *Brown Univ., Providence, RI

Statistical modeling of progression of HIV infection is made complicated by two problems: 1) follow-up of infected patients is generally much shorter than the average time to die and 2) the times of infection are generally unknown. As a consequence, it is difficult to distinguish between different models for progression of markers of HIV infection, such as T-helper cell count. Some investigators have proposed that decline is gradual until shortly before onset of AIDS, but available data do not permit rejection of models with fairly constant decline over the entire latency period. The ability to discriminate among models can be enhanced by incorporating information about the distribution of infection-time among HIV seropositive people and of markers among the seropositive. This can be achieved through use of growth curve methods that treat the time of infection as a random effect whose distribution is estimable, either from the data on progression itself, or from external controls. This methodology was applied to data on progression of T-helper cell count in 426 HIV-1 infected men from the Men's Health Study in San Francisco, using a estimate of the infection-time distribution for the whole city. Based on our preliminary analysis, it is difficult to reject the hypothesis of a slow, steady decline in this marker. Assuming a constant rate of decline, roughly two-thirds of infected men would be expected to have annual drops in T-helper count between 88 and 140. When the model was expanded to include a quadratic term, there was slight evidence of a slowing of the rate of decline, but after 5 years, the slope was reduced by less than 10%.

Th.A.P.65

SIMULATING THE EPIDEMIC DYNAMICS OF HIV-INFECTION USING STOCHASTIC PROCESSES OVER RANDOM GRAPHS

Cheng F. Bih, P. Bhattach, T. Kéger
Fakhr El Fikri, University of Montreal, Canada, Boudif M., FRG

Objective: To develop and apply to the epidemic dynamics of HIV-infection a mathematical model and simulation procedure which incorporates the structure of sexual contacts inside a society and reflects the inherent stochasticity of the transmission dynamics. This model is implemented on a computer program and can be used as a decision tool for possible prevention strategies.

Methods: The model consists of a set of equations, modeling the social contact structure of a society, specified by social parameters, on which a discrete time stochastic process evolves, representing the spread of infection, spread by medical and social parameters. This is computer simulation, a well defined description of the underlying process as well as of the dynamic to be simulated, including a parameter defining the distribution function, social preferences in partner selection, regional structure, time dependent infectivity. The use of observable alleles for a close look at the fine structure of the transmission process. Hence, not only the overall outcomes on the course of the epidemic are improved, but typical infection paths are followed and investigated, and effects of prevention strategies can be modeled at the scale of the individual.

Results: In comparison with different epidemic models, the most remarkable feature of the model are: transport from the highly progressive part of the heterosexual population into the heterosexual population with low partner numbers is slowed down by the force of the infection, i.e. the group acting as mediator; inside the majority of the heterosexual population, the epidemic grows but never reaches that exponentially due to low partner numbers and low rate of partner change. A second, where direct transmission is induced individually and their presence in turn prevents other specific risk behaviors, is simulated. The effect of these behaviors is analyzed. **Conclusion:** Incorporating the social contact structure into an AIDS model is essential. The spread of infection is strongly determined by the graph structure. The model indicates that, if the actual growth inside the heterosexual population is slower than expected from the early growth pattern, enough heterosexuals may reach the low rate to slow transmission into this class which may not necessarily be taken as a sign of significantly lower transmission rate or of low penetration depth of HIV-infection into the heterosexual population.

Epidémiologie et santé publique Epidemiology and Public Health

Th.A.P.62

HETEROGENEITY IN THE INCUBATION TIME OF AIDS: A STOCHASTIC SERIAL COMPARTMENT MODEL

YIZHAK BARTIL*, BAULELEKE R.N., PLUMMER F.A., Kenya Medical Research Institute, University of Nairobi, Nairobi, Kenya**.

OBJECTIVE: To determine if stochastic processes could account for the observed heterogeneity in the development of AIDS. **METHODS:** We hypothesize that prior to developing AIDS (S₁) individuals must pass through a series of intermediate stages (S₂, S₃, ..., S_n). The transition to AIDS is irreversible if the transition probability between S_i and S_{i+1} is stochastic with an exponential distribution the probability of developing AIDS after time t is $F(t) = 1 - \exp(-\lambda t) = 1 - \exp(-\lambda t) = 1 - \exp(-\lambda t)$ where F(t) is the fraction of HIV infected individuals ultimately developing AIDS at time t. **RESULTS:** Taking $\lambda = 3$ and S₁ as stochastic with an exponential distribution the probability of developing AIDS after time t is $F(t) = 1 - \exp(-\lambda t) = 1 - \exp(-\lambda t) = 1 - \exp(-\lambda t)$ where F(t) is the fraction of HIV infected individuals ultimately developing AIDS at time t. **CONCLUSION:** Stochastic processes can account for the observed heterogeneity in the incubation of AIDS.

Th.A.P.64

"STRUCTURED" AND "SELECTIVE MIXING" FORMULATIONS ON HETEROGENEOUS CONTACT TO STUDY HIV TRANSMISSION

Cooperman, James*, Jacques, Colin*, Simon, Carl, University of Michigan, Dept. of Epidemiology, 3919 Observatory, Ann Arbor, MI.

Objective: Provide a mathematical and theoretical context as well as quantitative suggestions for the study of sexual and needle contact patterns affecting the course of the AIDS epidemic. **Methods:** We have developed a mathematical theory and model of contact structure which proceeds from the assumption that there are two forces creating heterogeneous sexual and needle contact patterns in a population. The first is the choice of social contexts for meeting potential sexual partners. We model this with a formulation called "structured mixing". The second is the degree of selectivity exercised in choosing partners among those who are encountered in these social contexts. We model this with a formulation called "selective mixing". **Results:** The two formulations combine into one overall theory in different ways depending upon how information is collected on the social contexts of sexual or needle sharing partnerships. Information may be collected on the social contexts where actual partnerships were made, on where sexual attraction was felt or the opportunity to share needles presented itself, or on more general social patterns. For each of these approaches, there are different approaches required to collect information on the selection of partners. We discuss how predictions of the future course of the epidemic and estimates of the relative risk of oral and sex are very sensitive to coarse structure information. We also discuss how to collect such information. **Conclusion:** Epidemiologists have tended to disregard questions about who has sex or shares needles with whom in their investigations because they lack an overall theory to guide the collection and analysis of such information. This deficiency could be causing us to double the risk associated with different behaviors (especially to underestimate the risk associated with oral sex). It is also resulting the analysis of where we might expect the epidemic to spread next. Our structured and selective mixing model provides a basis to overcome this deficiency.

Th.A.P.66

A RISK BASED HETEROGENEOUS MODEL OF THE SPREAD OF HIV

Stanley, K.A., Hagan, James H., Colgate, S.A. and Layton, S.P., Los Alamos National Laboratory, Los Alamos, New Mexico 87545 USA.

Objective: To understand how social behavior influence the spread of HIV and the difference between spread in heterosexual and homosexual populations. **Setting:** We extend a model for the heterosexual spread of HIV to include heterosexual and homosexual populations. The population is divided into two groups, which is assumed to be the primary social variable determining mixing patterns. Variation in infectivity and progression to AIDS are accounted for. Mixing between groups with different risk behaviors is determined by an acceptance function, which can bias partnerships to form between individuals with similar risk behaviors, or can allow mixing to be determined by availability. We can use our model to study the effect of a different female to male than male to female transmissibility. We also can examine the spread of the infection from the homosexual to the heterosexual community via bisexual contacts. **Results:** Models can help us understand better how the AIDS epidemic is spreading and which intervention strategies might be most effective. The mixing function largely determines the growth of the model epidemic. If individuals select partners with similar behavior, the epidemic progresses as the risk group at the front of the wave. If individuals are less discriminating in partner choice, the epidemic changes, the mixing function is determined by the "most likely" partner; group. Initially growth is slower, but it quickly surpasses the behaviorally discriminating case. The epidemic is significantly different from women to men than from men to women, less strategies for stopping the epidemic are very different than if they are the same.

**Session d'affichage
Poster Session**



**Epidémiologie et santé publique
Epidemiology and Public Health**

Th.A.P.67 CHALLENGES IN MODELING HIV INFECTION IN LOW SEROPREVALENCE POPULATIONS

Watters, John F.
University of California, San Francisco, California, U.S.A., Utah Health Study, San Francisco, California, U.S.A.

Objective: To explore the difficulties in developing predictive models of HIV infection in populations with low prevalence of rates of infection.
Methods: Data from a cross-sectional study of intravenous drug users (IVDU) collected in all waves since 1986 are examined (N=3700). Results of various regression equations that examine the predictive power of known risk factors are contrasted. These models are also compared to models developed in high prevalence populations.

Results: In San Francisco, HIV-1 seroprevalence in intravenous (IVDU) has remained relatively stable at less than 10% between 1987 and 1989. However, distribution of virus is heterogeneous with significant variation between ethnic groups and neighborhoods of residence. Black heterosexual IVDUs (n=87), for example, were more likely to be HIV-1 positive than their white counterparts (n=740) over the period 1987-1 to 1989-1 (O.R. 1.8, 95% C.I.=1.2, 2.1). In one San Francisco neighborhood the frequency (rate) of HIV-1 infection among heterosexual (HET) (n=188) was twice that of Males residing elsewhere in the city (n=478) in 1989-1 (O.R.=2.2, 95% C.I.= 1.3, 3.7). Nevertheless, risk factors predictive of HIV infection in other studies of IVDUs (eg. frequency of injection, use of shooting galleries, and numbers of sharing partners), failed to consistently predict HIV infection.

Conclusions: Predictive models that identify independent risk factors contributing to HIV infection among high seroprevalence populations are independent of virus is relatively homogeneous may not apply to the large number of cities with relatively low HIV infection rates among heterosexual IVDUs. This is likely due to heterogeneity in distribution of infection markers in low prevalence populations. This tends to erode the predictive power of independent variables that appear to predict infection in populations with more homogeneous distribution of markers. Model construction in low prevalence, heterogeneous populations must examine the separate risk ecologies that may differ widely among cultural groups and from neighborhood to neighborhood.

Th.A.P.68 ESTIMATING INTRAVENOUS DRUG USER (IVDU) POPULATION FROM AIDS STATISTICS IN SAN FRANCISCO

Birnbaum, Patrick; Aldrich, M.; Mandel, J.
Youth Environment Study, Inc., San Francisco, CA, U.S.A.

Objective: To present a method by which to estimate the size and demographic makeup of populations at high risk for AIDS, with an example of IVDUs as an example.

Method: Back-calculating the number of HIV-infected IVDUs from infection to AIDS, applying seropositivity levels to determine IVDU population size.

Results: A single-page computer spreadsheet illustrates how the number of IVDUs at risk for AIDS can be back-calculated from reported variables. In San Francisco this further split by ethnicity, age, sex and neighborhood.

Conclusions: Population size can be estimated using reported AIDS and HIV seropositivity measures. AIDS surveillance accuracy and HIV-related non-AIDS diseases must be considered in making such estimates.

Th.A.P.69 AIDS IN THE MORDIC COUNTRIES - FORECASTS

Kalishman, B.
Medical School of Public Health
Göteborgs, Sweden.

The numbers of new AIDS cases per year in the Nordic countries are given below.

Year	Before 1983	1983	1984	1985	1986	1987	1988
Cases	7	20	34	83	145	204	267

A demographic model where birth corresponds to becoming HIV-infected and death to developing AIDS was used to summarize the series and to produce forecasts. Through trials and using a least squares criterion, a model with 270 HIV-infected in 1982 and a yearly incidence of 0.05 among the infected was adopted. The rate of virus transmission used to fit the model was 1, i.e. every infected person infects one other person during each year. Data fit well to this model up to an including 1986. The model gives 271 cases in 1987 and 522 in 1988. Thus, a certain reduction of transmission seems to have occurred from about 1986. A 60% yearly reduction was estimated. Under these assumptions, the epidemic is now close to its peak (275 cases). The number of new cases per year will start slowly to decrease to about 170 by the year 2000. A substantial number of new cases per year will appear, however, for a long time in spite HIV-transmission will be very small from about 1995, which is an optimistic prospect.

Similar calculations have been made for the two Nordic countries with the highest numbers of cases, Denmark and Sweden, the results pointing in the same direction.

Th.A.P.70 EFFECTS OF MODELING HETEROGENEITY OF DRUG USE BEHAVIOR

Stegel, J., Weinman M., Shepard D., Watters J., Finberg M., Harvard Sch. of Public Health, Boston MA.

*University of California at San Francisco, San Francisco, CA

Objective: Investigate how Drug Use (DU) risk behaviors vary widely. Heterogeneity of behavior may affect predictions of the spread of HIV obtained in epidemic models. This research examines effects of heterogeneity in a model to assess the effectiveness of intervention programs targeted to IVUDs.

Methods: Data are from a survey of 603 IVUDs in San Francisco (Urban Health Study 1989). Measures of injection frequency, needle sharing, and medication effectiveness, and medical case history. Heterogeneity is modeled in ways consistent with the original San Francisco data.

Results: Results obtained from all models considering heterogeneity of risk behaviors show higher life expectancy than baseline results obtained using the overall parameter means.

Model	IE (years)	SE (IE)
Homogeneous Risk Groups	12.0	1.4
Heterogeneity of Injection Freq (Modelled in 3 Groups)	14.4	1.7
Heterogeneity of Injection Freq (Modelled in 27 Gps)	14.8	1.6
Modeling of Increases of Inj Freq (Upper, Lower 10%)	14.0	1.5
Heterogeneity of 3 Parameters Simultaneously (Index)	16.4	1.8

Conclusion: Simulations suggest that in modeling the spread of HIV among IVUDs, an assumption of homogeneity of risk behaviors is likely to result in an overestimate of epidemic spread. It will be important to attend to both qualitative and quantitative evidence of heterogeneity in addressing AIDS among IVUDs.

Th.A.P.71 A RETROSPECTIVE MODEL OF THE SPREAD OF HIV AND THE DEMOGRAPHIC EPIDEMIC

Stanley E. Ann*, Seitz, S.T.***, May, P.O.**, Johnson, P.D.**, Hyman, J.H.**, Curry, T.T.***, et al.

*Los Alamos National Laboratory, Los Alamos, NM 87545 USA, **U.S. Bureau of the Census, Washington, DC, USA, ***University of Illinois, Champaign, IL, USA, ****Air Force Academy, Colorado Springs, CO, USA

Objective: To model the spread and demographic impact of HIV and AIDS.

Methods: We have developed a model of the spread of HIV to study the impact of the epidemic on nations where the primary mode of transmission is heterosexual. This model is based on the work of Bagnacchi. It divides the population into promiscuous—characterized by inter-time sexual contact—and nonpromiscuous groups. We model the flow of infection between urban and rural areas through migration. Modes for transmission of HIV perinatally and by blood transfusion, for marriage formation and dissolution, fertility, and non-AIDS mortality are included.

Results: The results are available through a window-based interface. The age-specific mortality and infected populations, by time since infection; the number of new HIV infections and AIDS cases; deaths from AIDS and from all other causes; the impact of AIDS on the population age structure; and the spread of HIV from urban areas to rural areas are shown.

Conclusions: A comprehensive model of the heterosexual spread of HIV infection and AIDS has been developed to analyze the possible future course of the epidemic. Continuing changes and enhancements to this model in the future will include the provision for the homosexual spread of the virus.

Th.A.P.72

ESTIMATION OF THE EFFECT OF AGE ON TIME TO AIDS IN HIV-INFECTED SUBJECTS FROM OBSERVATIONAL DATA

Robins, James, Harvard School of Public Health, Boston, MA, USA.

The NIH has recently put an RSP for community-based non-randomized studies of the effect of treatments such as AZT on time to AIDS among HIV-infected subjects. In such observational studies, the count history may be simultaneously a confounder and an intermediate variable. To history is a confounder since subjects with low TC counts are at an increased risk of developing AIDS and more likely to receive treatment with AZT. TC count history will be an intermediate variable if AZT delays time to AIDS by increasing viral destruction of TC cells. When a time-dependent risk factor like TC count is both a confounder and intermediate variable, all standard statistical methods (such as Cox's proportional hazard model) may result in a biased estimate of the AZT effect on time to AIDS whether or not one adjusts for the confounder TC count history in analysis.

In this paper new statistical methods will be described that allow for proper control of confounding by intermediate variables such as TC count history. These methods estimate the partial hazard, a new class of additive, the nested structural failure-time models, using a class of instrumental variable estimators. Relationships between the partial hazard and (a) non-inferior 3-stage least-squares estimators and (b) Robins' (1986) G-computation algorithm and G-mart test are discussed. User-friendly software available for analysis is described.

Session d'affichage Poster Session



Epidémiologie et santé publique Epidemiology and Public Health

Th.A.P.73 SIMULATION OF HIV TRANSMISSION IN A STRUCTURED COMMUNITY OF INTRAVENOUS DRUG USERS

Deegan Peterson, Keith Willard and Michael Altmann University of Minnesota and VA Medical Center, Minneapolis, Minnesota, USA.

An Intravenous (IV) Drug Community/HIV Transmission model has been developed to help evaluate public health intervention programs. The model uses Monte Carlo simulation to determine when an IV drug user contracts HIV and how the HIV infection progresses. The HIV progression model reproduces the stages of HIV infection: virus contact, asymptomatic stage, beginning symptoms, ARC, AIDS, and death. The population model of an intravenous drug community simulates dynamics: 3 types of addicts, differentiated by amount of drug use, a process of recruitment to addiction and to heavy addiction; withdrawal during incarceration and treatment programs; recovery from addiction and death from non-HIV-associated causes. The IV drug community is structured into a social network based on literature reports. Users are exposed to HIV through sharing syringes and acquaintances in their social networks, strangers in the general population and in "shooting galleries." The probability of HIV transmission given contact with contaminated needles is estimated from reports of sero-positive rates in health care workers exposed to HIV needle sticks. The model is flexibly structured and has been adapted to populations representing different geographic areas having unique social structures, exposure characteristics, and underlying HIV prevalence. Simulations of a needle-exchange program and increased treatment indicate the importance of prevention in determining the long-term success of intervention.

(Supported in part by NIH RR-1632 and the Veterans Administration)

Th.A.P.76 THE PREDICTION OF THE NUMBERS OF AIDS CASES IN THE UK, AND THE ESTIMATION OF THE INCUBATION PERIOD OF AIDS.

Medley, Graham and Anderson, R.M.

Department of Biology, Imperial College, London SW72BZ, UK.

Objective: To use available data to forecast the future numbers of diagnosed AIDS cases in the UK.

Methods: Mathematical models are described that use (a) the numbers of reported cases in the UK to predict future cases, and (b) data available for estimating the incubation period of AIDS.

Results: Previous estimates of future UK AIDS cases (*Short-term Prediction of HIV Infection and AIDS in England and Wales*, HMSO, London, December 1988) and the incubation period of AIDS (Medley et al., *Nature* 1987, 338, 719-721; Anderson & Medley, *Epidemiology of HIV Infection and AIDS: Incubation and Infectious Periods, Survival and Vertical Transmission*, AIDS 1988, in press) are updated.

Conclusions: The results are discussed in terms of their implications for the AIDS epidemic in the UK and other industrialized countries.

Th.A.P.77 RELIABILITY OF ESTIMATES BASED ON BACKCALCULATION.

Mitchell, G. Hall, P.S. Rosenberg, B. Riggs, J.J. Goedert, M.C. Beckwith, M.D., R. Broome, Johns Hopkins, Maryland, USA

OBJECTIVE: To assess random and systematic uncertainties in estimates from backcalculation of the cumulative numbers of HIV-infected persons up to 1985 and through the present, the differences between average infection rates over previous time intervals, and projections of future AIDS incidence.

METHODS: Using flexible models of the previous HIV infection rate, we evaluated the effects on estimates above of uncertainties in the AIDS incubation distribution, the form of the infection rate curve, delay corrections, and changes in the surveillance definition. Our method yielded variances for random errors as well as an assessment of the systematic error, such as from misspecification of the incubation distribution.

RESULTS: We studied persons with hemophilia and non-IV drug using homosexual men using a Weibull AIDS incubation distribution $F(t) = \exp[-0.0027 \cdot t^{2.516}]$ derived from persons with hemophilia. We find evidence for an earlier peak in infection rates in these two test cases. In line with independent epidemiologic evidence, these results suggest that valid inferences may be made for other risk groups. Sensitivity analyses indicated that near-term projections of AIDS incidence were relatively stable with respect to perturbations of the underlying model. However, estimates of the cumulative number of infections occurring after 1985 and estimates of changes in the infection rate have large random and systematic components of error.

CONCLUSIONS: Our results help us to assess the strength of substantive inferences made using the method of backcalculation.

Th.A.P.74 REVERSE EXTRAPOLATION AS A METHOD FOR ESTIMATING HIV SEROPREVALENCE

Scakelton, Colin L.; McGregor, J.R. and Jaroni, A.N.

University of Alberta, Edmonton, Alberta, Canada.

Objective: To provide a method for estimating HIV prevalence.

Methods: Reverse extrapolation is applied to 8 and 10 year AIDS projection estimates. Current infection prevalence then is calculated based first on one assumption which states that approximately three times as many people presently are infected as will actually develop AIDS 8 years hence; a second assumption used is that twice the number of those who will develop AIDS 10 years hence already are infected.

Results: Reverse extrapolation can be estimated for regionally defined groups for whom AIDS projections can be determined. For example, from AIDS projections for the province of Alberta through July 1985, determined by the Polson, polynomial, logistic, and doubling time models, a direct estimate of 3.46% and an upper estimate of 4.97% were obtained. The then current provincial AIDS total of 137 case reports. Equivalent estimates for Canada, at a time when the cumulative total number of AIDS cases was 1,941, were in the range 20.7%-18.8%, with a more liberal value around 100,000.

Conclusion: The method appears reliable since it produces findings consistent with those of others. It is both robust and cost-effective. However, it is no substitute for valid data gathered directly through seroprevalence surveys of defined groups. Actual reliability will be established when results from seroprevalence surveys are available for comparison.

Th.A.P.76 PROTECTING LOCAL AIDS INCIDENCE USING BOTH SURVEILLANCE AND SEROPREVALENCE MEASURES

Boyer, J., Engel, J., Lichtenfeld, J., Hall, S., and Anderson, J.

The Mexico Health and Environment Department, Santa Fe, New Mexico, U.S.A.

OBJECTIVE: To protect AIDS incidence through 1992 for the State of New Mexico by two different methods: one which extrapolates from past seroprevalence data, and one which projects future cases based on current HIV seroprevalence estimates.

RESULTS: The surveillance-based projections were derived directly from recent US national projections. The future proportions of all US cases expected to occur in New Mexico over the next four years were projected as a linear extrapolation from those proportions observed in the last four years' data in local AIDS surveillance data. The HIV seroprevalence-based projection method uses the most recent local seroprevalence surveys to estimate the projected rate of new infections currently reported, as well as for those expected to be infected by future transmission to existing seroprevalence for each year from about their infection of HIV infection and expect future AIDS incidence.

RESULTS: Both projection methods produced similar estimates through 1992. 824 cumulative cases were predicted by the surveillance method and 1033 were predicted by the seroprevalence method. Back-calculation of the number of "expected" cases for 1985 based on the assumption used in the seroprevalence-based method produced a number of cases which was only slightly higher than that actually observed. Thus, the seroprevalence-based estimates are **OVERESTIMATES**. Some methods' predictions that both surveillance and seroprevalence measures can be useful in determining local AIDS control.

Th.A.P.78 A REVIEW OF SOME TECHNIQUES FOR BACKWARD ESTIMATING THE PREVALENCE OF HIV FROM AIDS CASE INCIDENCE

Phillips, G. Cooke, J., Beach, S., Fisher, S., Small, D., and van der Boven, C.

Research Triangle Institute, Research Triangle Park, North Carolina, USA
University of North Carolina at Chapel Hill, Chapel Hill, N.C., USA.

Objective: Some methods for estimating HIV prevalence from AIDS case data are examined. Featured in this examination is the Brookmeyer-Gall method. The validity of the method is assessed by performing sensitivity analysis of the HIV prevalence estimate by year for different incubation distributions.

Results: An estimate of U.S. HIV prevalence is produced. **Conclusion:** The Brookmeyer-Gall method is an objective procedure for estimating past HIV prevalence but a proper representation of the incubation distribution is critical in providing reliable estimates.

**Session d'affichage
Poster Session**



**Épidémiologie et santé publique
Epidemiology and Public Health**

Th.A.P.79 PROJECTING PROPORTIONS OF AIDS CASES OVER TIME
KARON, John M.; Devine, GJ
AIDS Program, Centers for Disease Control, Atlanta, GA, USA

Objective: To model time trends in the proportions of AIDS cases in groups, in order to make short-term projections of future proportions.
Methods: Let $f_i(t)$ be the proportion of cases in group i , $i=1,2,\dots,C$, at time t . Model the generalized logit: $\log(p_i(t)/p_0(t)) = f_i(t) + \text{error}$, where $f_i(t)$ is a polynomial in time (estimated using weighted regression) and group G is the reference group ($f_G(t) = 0$). Predicted proportions are: $\hat{p}_i(t) = \exp(f_i(t)) / \sum \exp(f_i(t))$.
Results: Predictions are nearly independent of the choice of the reference group. We modeled quarterly incidence of U.S. cases for Jan 1984 through June 1988 group geographically into metropolitan statistical areas: New York City, San Francisco, Houston, and others (reference group). Linear polynomials give good fits to observed proportions and predict decreases in each area, with the following observed and predicted percent of U.S. cases: New York City San Francisco Houston
Quarter Obs. Pred. Obs. Pred. Obs. Pred.
1987/1 18.6 18.3 6.4 6.6 3.1 3.3
1988/1 17.4 17.5 5.9 5.4 2.9 2.8
1989/4 12.1 12.1 3.9 3.9 2.6 2.6
Conclusion: Modeling proportions can give useful short-term projections even with relatively few cases in some groups. Proportions in risk groups can be modeled after the effects of the new case definition on trends are understood. Estimates of uncertainty and prediction intervals can be obtained from a multinomial likelihood incorporating similar models.

Th.A.P.81 MODELING OF THE AIDS EPIDEMIC IN MEXICO
JOSHILLA, Angeles, A. Sanberg, T. Awbich, A. Mohar, J.J. Valdespino, J. Sepulveda, T. et al.

*Harvard University, Boston, MA, USA; **Direccion General de Epidemiologia, Mexico DF, Mexico.
Objective: To forecast new AIDS cases among different risk groups in Mexico, and estimate the impact of preventive measure on the spread of the epidemic.
Methods: We used a closed compartmental model to forecast new AIDS cases among homosexual and bisexual males, and heterosexual males and females. For each group 1000 individuals were defined: uninfected persons, infected but asymptomatic persons, and diagnosed AIDS cases. It is assumed that the AIDS risk is a function of the proportion of infected persons in each risk; where spread of infection is proportional to the product of the number of healthy persons in free healthy to infected, and from infected to asymptomatic, and asymptomatic people do not spread the disease. discrete non-linear regression was used to estimate the parameters of the model so that the prediction would fit the number of reported AIDS cases in Mexico. The impact of preventive measure was determined by the probability of transmission of HIV.
Results: By August 1988, 1811 cases had been diagnosed in Mexico, 748 were homosexual males, 353 bisexual males, and 118 heterosexual males and females. The model predicts that the AIDS incidence will continue to rise in Mexico for at least the next 8 years and will spread among the heterosexual population. By means of education programs, decreasing the transmission probability by 10% in all groups will result in a decrease of 24% in the number of cases accumulated over an 8 year period. A 10% decrease would prevent more than 400 of the cases.
Conclusion: Simple models can be valuable to predict the evolution of the AIDS epidemic and the impact of behavioral change.

**Histoire clinique de l'infection à VIH
Natural History of HIV Infection**

Th.A.P.83 GENETIC EPIDEMIOLOGY OF AIDS (Liu, S, Desmond, K Gilles, B Newman, and P-C King, University of California, Berkeley, CA 94720, USA). We are currently addressing two crucial questions about the epidemiology of AIDS: 1) Does host genotype influence susceptibility to HIV infection? 2) Does host genotype influence the rate of disease progression once a person is infected with HIV. Our first study results from the San Francisco Men's Health Study (SFMS), consists of 80 Caucasian men in 4 clinical groups: 1) HIV- despite high risk behaviors; 2) HIV+ with no symptoms for at least 2 years; 3) HIV+ with at least 2 clinical findings but without AIDS; and 4) AIDS. Our second study sample consists of 40 Caucasian AIDS patients from the AIDS Clinical Research Center (ACRC) in San Francisco and 70 healthy Caucasian controls. In both samples, we are comparing sequences of genes involved in immune response by analysis of DNA polymorphisms.
Our first results are for T cell receptor-beta chain (TCRB), which is detected by the cDNA probe PT10 after digestion of genomic DNA with Bgl II. All alleles have fragment lengths 10.0 and 9.2 kb. In the SFMS sample, allele frequencies did not differ between the HIV- group or the three HIV+ groups ($P > .155, p > .20$). Among HIV+ men, asymptomatic subjects did not differ from symptomatic and AIDS patients ($P > .842, p > .89$). We are continuing to screen other candidate sequences involved in immune response and will present these results at the meeting.

GROUP	Clinical Status	TCRB Allele		N
		10.0 (K)	9.2 (L)	
SFMS	HIV-	28 (48)	30 (52)	29
	HIV+, asymptomatic	18 (36)	32 (64)	25
	HIV+, symptomatic	21 (48)	31 (60)	26
ACRC	AIDS	4 (29)	10 (71)	7
	AIDS	51 (55)	41 (45)	46
Controls	Healthy	89 (56)	69 (44)	79

Th.A.P.80 THE AIDS EPIDEMIC IN MEXICO
GARCIA, Mohar, V. De Grutola, J.L. Valdespino, H. L. Alcázar, H. and J. Sepulveda, S. et al.
Harvard University, School of Public Health, Boston, MA
General Directorate of Epidemiology, Ministry of Health, Mexico City, Mexico.

Objective: To predict the short term course of the acquired immunodeficiency syndrome (AIDS) epidemic in Mexico.
Methods: By the method of back calculation using cumulative number of AIDS cases reported until October 1988 and adjusting for report delay for right-truncated data in chronological time, we estimate the future number of AIDS cases in Mexico. The analysis comprises the results of the National Serum Survey (NSS) which is intended to provide a reliable estimate of the current HIV seroprevalence in the entire country of Mexico.
Results: Initial analysis adjusted for the report delay demonstrates that there are significant differences in AIDS reports by risk factor (homosexuality vs. others) and by region (Mexico city vs. others). The results of the "working backwards" modelling, with consolidated results of the NSS, will be presented.
Conclusion: The authors considered that the method of back calculation with adjustment for report delay in conjunction with a reliable estimate of seroprevalence will substantially improve the accuracy of their projections. This analysis will give better insight into the future course of the AIDS epidemic.

Th.A.P.82 LIMITATIONS OF OFFICIAL FORECASTS USED IN PLANNING URUGUAY AIDS SERVICE NEEDS
GARCIA, Luis M.; Winfield, N.
New York University Medical Center, New York, New York, USA.

Objective: To compare official and semi-official projections of AIDS prevalence and associated medical/social service needs among city, state, and federal agencies for New York, San Francisco, Los Angeles, and other U.S. cities. To explain how assumptions and choice of methodology affect these projections.
Methods: Critical review of published forecasts.
Results: There are significant differences in projecting prevalence and service needs had shifted from the federal to state and local levels in the last few years. The forecasts used in the planning of AIDS services in the Centers for Disease Control (CDC) in 1986 for San Francisco, New York City, and Los Angeles, the Institute of Medicine's estimates of hospital bed need through 1991 were based on these CDC projections. Major official strategic plans had recently been developed for San Francisco, Los Angeles, and New York State which include case projections broken down by risk group and forecasts of need for hospital, long term care, and other services. The forecasts used in the CDC's official forecasts using computer methods often differ sharply from those of the local, state, and federal agencies. The forecasts result from the choice of assumptions (e.g., history of HIV infection, seroprevalence rates, future infection rates, disease progression rates, and reporting lags) and projection method (linear or polynomial extrapolation).
Conclusions: The choice of assumptions and methods affect official forecasts for various cities and require alternatives.

Th.A.P.84 EVALUATION OF THE IMMUNOLOGICAL STAGING SYSTEM IN A POPULATION BASED COHORT
ROYCE, Rachel*, Winkelstein J Jr*, Anderson RM*, Lang WM*
*University of California at Berkeley, **IRK Inc., San Francisco, CA, USA.

Objective: To apply the immunological staging system, ISS, (Colla-Panzer, 1987) to a sample of HIV infected men. To determine risk of AIDS by ISS stage after 42 months of observation, and pattern of change in stage.
Methods: ISS Stages 1-3 are composed of an additive combination of immunological abnormalities: CD4/CD8 T cell ratio of <1.0 , CD4 T cell count of <500 cells/ μ l, and lymphopenia of <1500 cells/ μ l. Lack of abnormalities defines Stage 0. The 368 HIV infected men, initially AIDS-free, of the San Francisco Men's Health Study probability sample were staged at visit 1 by the ISS and re-classified every 6 months at follow-up visits 2-8. Risk of AIDS by initial stage was determined after 42 months follow-up.
Results: At visit 1, 2 men were unclassifiable by the ISS. The remaining 366 men were distributed among Stages 0-3 as follows: 161, 368, 211, and 3K. The risks of AIDS and 95% confidence limits after 42 months were .02 (.003-.09), .14 (.10-.19), .43 (.32-.54) and .18 (.06-.41) for Stages 0-3.
All but 10 men were classifiable on visits 2-8. By visit 8, 627 had changed to a higher stage relative to visit 1. Of classifiable men with at least 2 follow-up visits (414/222) regression in stage at 1 or more visits.
The relatively low risk of AIDS in Stage 3 on visit 1 may be artifactual because men in Stage 3 on visit 2 and visit 3 had higher risks of AIDS at 30 months follow-up.
Conclusion: ISS is easily applied and predicts progression to AIDS. Men do not appear to move uniformly through the stages. Stage 3 which is based on lymphopenia, may not describe a risk of AIDS distinct from the other stages.

**Session d'affichage
Poster Session**



**Epidémiologie et santé publique
Epidemiology and Public Health**

Th.A.P.85 TIME FROM FIRST HIV INFECTION TO PERSISTENT ANTIGENEMIA
 CHMEL, P. H., MURPHY, R. M., PHILLIPS, J. M., COOPER, R. G., CARU, V. J., and Ising, L. *Northwestern University Medical School, Chicago, IL
 *The Johns Hopkins University School of Public Health, Baltimore, MD, USA.

Objective. HIV antigenemia is an important predictor, independent of CD4 cell number, for the development of AIDS. The objective of this study was to assess the usefulness of HIV antigenemia as an indicator of time since first HIV infection.
Methods. For each of 439 HIV antibody positive (Ab+) men in the Chicago MACS infection was established using IgG and platelet count (Munoz et al. IV International AIDS Conference). Mean and ranges of the mean times since first infection for each of 184 men who were not seroconverters (SC) were compared. Development of antigenemia in 47 HIV antibody seroconverters (SC) was examined to assess the validity of our estimates.
Results. 386 CD4+ T-lymphocyte counts were HIV Ab+, Ag+ at entry had an estimated mean time from first HIV infection to study entry of 12.0 mo. (range 17-1251), compared to 28.1 mo. (range 18-717) for the 73 Ab+ men with Ag detected at entry (p<0.02). Approximately 75% of this latter group were not seroconverters for at least 2 consecutive 6 mo. to 6 mo. polymerase chain reaction (PCR) and range of detectable antigenemia at entry were from 3 to 30 mos. (7 men). 8 SC developed Ag that did not persist.
Conclusion. Persistent antigenemia in a seropositive cohort is informative about the time since initial HIV infection. Estimation of this time may be useful for describing progression of HIV disease when CD4, platelet count, and antigen status are known.

Th.A.P.87 DEFINING THE INTERVAL BETWEEN HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION AND THE APPEARANCE OF HIV ANTIBODY
 BARON, R. A., ROBERTS, R. D., DE, C. J., JAMES, J. W.,
 BALSBERG, S. W., LONG, R. M., AND PETERSON, R. A. at al.
 *AIDS Program and *Division of Sex Factors, CDC;
 *Emory University, Atlanta, GA, USA.

Objective. Persons infected with HIV who have not developed antibody detectable by currently used tests may be at risk through blood donation or sexual contact. This study was done to estimate the duration of this virus-positive, antibody-negative period.
Methods. We investigated 27 homosexual and 12 hemophilic men for whom stored peripheral blood mononuclear cells (PBMC) were available before and after seroconversion. PBMC were assayed for HIV RNA by the polymerase chain reaction technique using gag and gag region primers; serum was tested for p24 antigen by enzyme-linked immunosorbent assay (ELISA).
Results. Four persons had HIV RNA detected before seroconversion; all had HIV RNA detected only on the seronegative date closest to the time of seroconversion. Three persons had antigen detected before seroconversion; in each case HIV RNA was also detected. Using a Markov model, we estimated the median time from infection with HIV (as assessed by detection of HIV RNA) to first detection of HIV antibody to be 5.6-6.1 (S.E.M. 0.3) months. Modeling of reported cases of HIV infection with known exposure gave an estimate of a median of 2.6-3.0 months from exposure to antibody detection, and 50% of cases would be expected in 5.6-6.0 months.
Conclusion. Prolonged periods of unrecognised HIV infection in persons who do not have detectable antibody appear unlikely.

Th.A.P.89 INTERNATIONAL SEROCONVERSION: ELISA, Robert's Goddard, J., Blattner, W. (National Institute, Bethesda, MD), and the Seroconverters Working Group.

Objective. To expand an ongoing registry of persons with documented HIV seroconversion in order to determine the natural history of HIV infection and compare the course of HIV in persons infected by different routes, in different geographic areas and at different times.
Background. The natural history of HIV infection has not been understood when the time of infection can be reliably established. Most investigators doing prospective studies use seroprevalent subjects and enroll cohorts of subjects of only one risk group. Thus, the ability of single cohorts to define critical natural history issues is limited.
Methods. We have established a registry of seroconverters by providing simple data forms to investigators engaged in seroprevalent studies of groups at risk of AIDS. Essential data are identifying number (names not accepted in order to assure confidentiality), age, sex, risk group, dates HIV antibody tests were less negative and first positive, dates and types of antiretroviral treatments (if any), last follow-up date, AIDS outcome (if any). Summary reports will be prepared at ICI and shared with all participants.
Results. Results are presented elsewhere (See Time-to-AIDS among HIV Seroconverters, by the Seroconverters Working Group [Bisgaard]). So far 315 seroconverters (through 1988) have been registered by 38 groups in 11 countries, including the United States, Canada, Europe and Australia. Risk groups include homosexual men, hemophiliacs, i.v. drug users, blood donors, and heterosexuals. This work suggests that HIV seroconversion and HIV CONTRIBUTIONS WILL BE WELCOME. We would be pleased to answer questions and provide forms and guidance for investigators willing to participate.

Th.A.P.86 LONG-TERM HIV INFECTION WITHOUT CLINICAL ILLNESS OR IMMUNODEFICIENCY. HORNBERGER, M.B. AND HAY, M.T. *PROGRESSIVE Lymph, Alan R. *Buchholder, S.S. *Sheppard, M.M. *Wilber, J. *Hersel, M. *Mandel, J. *HPT, C. *Tilley, M. *Sutherland, G. *Dept Public Health, San Francisco, CA. *ACA Public Health Foundation, and *Pathology Inst., Berkeley, CA. **CDC, Atlanta, GA, USA.

Objective: To evaluate the immunologic and virologic profile of persons with long-term HIV infection who have not developed HIV-disease.
Methods: From a cohort of homosexual/bisexual men, 184 HIV-antibody (Ab) positive men evaluated in 1988 had well defined seroconversion (SC) dates. We compared 37 men who were Ab positive for > 5 y (mean=8.0 y) without clinical evidence of immunodeficiency and who had < 400 T4 lymphocytes (non-progressors [NP]) to 81 men with AIDS or ARC (progressors [P]).
Results: 14 count of all 184 men was not statistically associated with year of SC. Compared to P, NP had a higher T4 count, T8 count, and hemoglobin and a lower beta2-microglobulin. Of those NP tested, 25/37 were negative for HIV antigen. 11 NP did not significantly differ on assays for natural killer activity or Ab-dependent cellular cytotoxicity. When tested by ELISA for Ab to 6 gag polymerase chain reaction (PCR) and range of detectable antigenemia at entry were from 3 to 30 mos. (7 men). 8 SC developed Ag that did not persist.
Conclusion: V4 count is not a marker for duration of infection. NP do not have evidence of replicating virus, but do have evidence of latent HIV infection. Although similar to PMA for some immunologic parameters, NP differed in strength of Ab response to certain core and envelope antigens.

Th.A.P.88 OCCURRENCE OF INDETERMINATE WESTERN BLOT (WB) TESTS AND LACK OF TRANSMISSION OF THE HIV INFECTION AT LOW RISK FOR HIV INFECTION. HUNTINGTON, WY, USA, 1986-1988
 MALABO, ROBERT; HINDLANDS, A. W. and the WAHD AIDS Vaccine Program*
 *Marshall University School of Medicine, Huntington, WV. **Bethesda, MD, USA.

Background: During screening of prospective volunteers for an AIDS vaccine study (G160 Microcosm), we noted the frequent occurrence of WB in our low risk population. WB was the most common reason for eliminating volunteers from participating in the study.
Objective: The present study was undertaken to examine the epidemiology of WB in low risk persons.
Methods: Sera were obtained from three groups: paired sera obtained 1 month before and tested for antibodies by ELISA (Abbott) and WB (Dupont); p-24 antigen (Abbott) was also tested.
Results: No HIV infections were found in our population. Repeat WB occurred in 11 members of 10 different families. Nine WB were among male children in the families (p<0.1). WB was caused by weakly reactive p-24 bands in 9/11 family members. 2/24 cord sera exhibited WB; neither child had WB 36 months later; one child seroconverted WB that was not present in cord serum. WB occurred in 23% of low-risk adults in Huntington, WV.
Conclusion: WB is common among persons at low risk for HIV in our city. There was no evidence of horizontal transmission of WB in families or vertical transmission for mothers to children.

Th.A.P.90 LACK OF CORRELATION BETWEEN NEUTRALIZING ANTIBODY TITERS AND CD4+ DECLINE IN THE SAN FRANCISCO HIVERS HEALTHY STUDY.
 SHARON, R. M., HANSEN, C. W., MILLS, L. W., MOYER, K. W.,
 *California Public Health Foundation, *WVRI and *Richardson Davis Laboratory, Department of Health Services, University of California, Berkeley, CA, USA.

Objective: To determine the relationship between neutralizing antibody titer and the decline in CD4+ cells in the San Francisco HIVers Healthy Study.
Methods: A novel fluorescent micro-plate reduction assay was used to measure early neutralizing antibody titer for IgM and IgG and bisexual men 30 months after entry into the San Francisco Health Study. The assay employed a monoclonal cell line derived by centrifugation through molten agarose in 96 well trays. The study population was composed of 120 seropositive homosexual individuals with <500 CD4+ cells at entry (1984) and 34 seropositive asymptomatic CD4+ controls. 54 continued to have <500 CD4+ cells after 30 months while 66 showed a decline in CD4+ cells. The relative neutralizing capacity is expressed as the reciprocal of the serum dilution at which 50% of the input tubes forming units are inhibited.
Results: All sera which were antibody negative by ELISA showed no neutralizing capacity at the lowest serum dilution (1:3). All positive sera had mean capacity to neutralize prototype HIV-1 III with a titer of 12-31. The geometric mean titer for the group without CD4+ decline was 432. The geometric mean titer for the group with declining CD4+ cell numbers was 484. There was no correlation between the distribution of titers within the two groups.
Conclusion: This work suggests that there is little or no correlation between CD4+ cell decline and the capacity to neutralize the prototype strain of HIV-1.

Session d'affichage Poster Session



Épidémiologie et santé publique Epidemiology and Public Health

Th.A.P.91 THE EFFECT OF HEPATITIS B VIRUS VACCINATION ON T-CELL SUBSETS IN HIV-1 SEROPOSITIVE MEN IN THE BALTIMORE MACS
Oshaka Nancy, Margolick J, Fox R, Muñoz A. The Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, USA.

Objective: To compare the effect of hepatitis B virus vaccination (HBV) on T-cell subsets in HIV-1 seropositive (+) and seronegative (-) homosexual men. Methods: Previously HIV seronegative HIV-1 + and - homosexual men in the Baltimore MACS either did or did not receive HBV. Blood was drawn immediately prior to enrollment in the study (baseline) and every six months thereafter for analysis of T-cell subsets (CD4, CD8). Change(Δ) was defined as the difference between the baseline value and the most recent evaluation, with followup(fu)/pp ranging from 6 to 36 months.

Results	CD4			CD8			
	Mean	Baseline	Mean Δ	Baseline	Mean Δ	per Δ mo	
Group HIV-1	Mean	Mean ± SD	Mean ± SD	Mean	Mean ± SD	per Δ mo	
1	4	32.7	-0.4	27	7.6	0.1	
2	+	162	32.7	47 ± 6.6	-0.2	29 ± 6.1	-0.6
3	+	23	33.8	32 ± 6.7	-1.6a	44 ± 11.0	1.6a
4	+	21	31.3	30 ± 11.2	-3.3a,b	37 ± 10.4	4.3a,c

a: p < 0.05 compared to group 1; b: p=0.063 compared to group 3; c: p=0.007 compared to group 3. The differences between groups 3 and 4 persisted after adjusting for baseline CD4 and CD8.
Conclusion: These data suggest that HBV may influence T-cell subset proportions in HIV-1 + individuals over time. Further followup of this and other populations is needed to confirm this conclusion.

Th.A.P.93 INCREASED "TYPICAL THERAPY" IN LATE STAGES OF HIV INFECTION.
Bartus, D.D.,* Medfield, R.R.*; Fowler, A.*; Oster, C.*; and the Walter Reed Retrovirus Research Group *Walter Reed Army Inst. Med., ** SRA Technologies, Inc., Washington, D.C., U.S.A.

Objective: To compare results of HIV isolation attempts from peripheral blood mononuclear cells (PBMC's) of early versus late stage patients. Methods: PBMC's from 91 staged HIV seropositive patients were obtained from heparinized blood specimens by density gradient fractionation. 2x10⁶ and 2x10⁵ cells from each patient were inoculated into cultures of PHA and TI-2 stimulated normal donor target PBMC's. Culture fluids were monitored weekly for HIV p24 antigen.

Results	Positive		
	# Total	< 2.5x10 ⁵	> 2.5x10 ⁵
Stage			
Controls	0	0	19 (100%)
WR 1 - 2	41	11 (27%)	16 (39%)
WR 3 - 5	40	27 (68%)	8 (20%)
WR 6	10	10 (100%)	5 (50%)

90% of HIV seropositive patients with decreased CD4 cell counts (less than 400 per μl, stages 3 - 6) were culture positive, compared to 66% of early stage patients with normal CD4 counts. Cultures became positive more rapidly in patients with late stage disease.
Conclusion: HIV can be more frequently and more rapidly recovered from blood in the later stages of illness.

Th.A.P.95 SEROLOGIC EVIDENCE OF EPSTEIN-BARR VIRUS (EBV) REACTIVATION BEFORE AND AFTER HIV-1 SEROCONVERSION.
Rahman, Ahd., Kingley, L., Rinaldo, C., Atchison, R., Ho, M., Brinig, M., University of Pittsburgh, Graduate School of Medical, Pittsburgh, Pennsylvania, USA.

Objective: To evaluate the relationship between early HIV-1 infection and active/reactivated EBV infection based on serologic markers of EBV infection. Methods: This nested case-control study included a group of homosexual/bisexual men who seroconverted to HIV-1 (n=49) referred to matched controls (n=49) who remained seronegative to HIV-1 for 2 1/2 years. HIV-1 infection was documented by ELISA and confirmed by Western-blot assay. Immuno-fluorescence assays were used to determine IgG antibody titers to EBV-VCA, EBV-EA and EBNA. Results: All 49 HIV seroconverters were seropositive to EBV (titer ≥ 1:5) while 47/49 (96%) of controls were seropositive to EBV. Antibody titers to EBV-VCA and EBNA did not differ significantly between cases and controls 6 months prior to the time of HIV-1 seroconversion for cases. Antibody titers to EBV-EA were significantly elevated (p < .001) among cases (Geometric mean titer GMT = 30) prior to HIV-1 seroconversion compared to controls (GMT = 7) and remained significantly elevated for 1 1/2 years post HIV-1 seroconversion. Four-fold or greater rises in VCA-IgG titers were strongly associated with HIV-1 seroconversion (odds ratio = 3.4; p = .004), indicating probable reactivation of EBV. Negative correlations were observed between the antibody titers to EBV-VCA and EBV-EA to CD4+ lymphocytes, while mean number of CD8+ lymphocytes were elevated in cases pre and post HIV seroconversion. Conclusions: These results suggest that EBV reactivation is correlated with HIV-1 seroconversion and that evidence of a ≥ 4 fold rise in VCA-IgG is detected in a majority of HIV-1 seroconverters within 18 months. This may have implications regarding the role of EBV in the future pathogenesis of HIV-1 infection.

Th.A.P.92 INCREASED RATE OF HIV-1 ISOLATION AMONG HIGHLY HOMOSEXUALS WITH LOW CD4 COUNT
HOMANOW, FAYZAGGAR, K. GATSHA, M. HARDY, D. INAGUNA, M. LEE, C. GROVIT, P. GUNJA. A Report from the Multicenter AIDS Cohort Study (MACS), NIH, Bethesda, MD, U.S.A.

OBJECTIVE: To correlate variation in HIV-1 isolation with changes in immune status as determined by CD4 count among HIV-1 seroconverters. **METHOD:** One hundred and ninety-four seroconverted homo/bisexual men participating in a prospective study of the natural history of HIV-1 infection were studied for HIV-1 isolation and cellular immune status in three (MACS) Centers. Coincubation with normal PHA-P stimulated PBMC's were monitored four weeks for HIV-1 replication utilizing P24 antigen capture. **RESULTS:**

CD4/mm ³	%/Total	n	CD4/mm ³	%/Total	n
0 - 199	24/28	26	600 - 799	29/28	74
200 - 399	44/58	80	800 - 999	12/18	67
400 - 599	38/50	76	> 1000	13/27	48

The HIV isolation rate for participants with low CD4 (< 200) was greater than those with high CD4 (> 1000) count. The test for trend was statistically significant (Mantel-Haenszel chi square 9.4, P=0.002). **CONCLUSION:** Declining CD4 is associated with immune impairment. The association between lower CD4 count and increased HIV-1 recovery may suggest that progression of HIV-1 infection is associated with a higher percentage of infected T-cells and more effective viral replication. Low CD4 cell count is a significant predictor of HIV-1 isolation.

Th.A.P.94 GRAPHICAL DESCRIPTION OF HEMATOLOGICAL CHANGES AFTER HIV-1 SEROCONVERSION IN HOMOSEXUAL MEN. Huffes, Alvarez; Margolick J; Phair J; Giertz J; Rinaldo G, for the Multicenter AIDS Cohort Study (MACS), Bethesda, MD, USA.

Objective: Describe the multivariate distribution of hematological variables at different times from HIV-1 seroconversion. **Methods:** The 271 seroconverters observed in the MACS within 4 years of follow-up provided 1816 assessments of hematological values at different times from seroconversion from -1 to 3 yrs. Bivariate coordinates and contours of multivariate normal distributions estimated from the data were used to display the interactions between different variables. **Results:** The means and standard deviations of selected hematological variables according to the number of years from seroconversion were

	Tests from HIV-1 Seroconversion			
	1	2	3	20
Assessments (N)	192	445	517	2
ln(CD4/CD8)	0.4940,46	0.2440,57	-0.1340,58	-0.3740,69
CD3-(CD4+CD8)/μl	100120	172139	202100	462013
Hemoglobin(g/dl)	15.4423,10	15.3981,09	15.2321,20	15.0627,15
Platelets (in K)	270558	259460	246257	227255

The CD4:CD8 ratio was negatively correlated with double negative cells (CD3-(CD4+CD8)), positively correlated with hemoglobin and had a consistently small correlation with platelets. **Conclusion:** Strong downward trends after seroconversion are apparent in CD4/CD8 and in platelets. CD4/CD8 and platelets are weakly correlated and have different prognostic information for AIDS. Changes in double negative cells and hemoglobin are asymptomatic, but of small magnitude relative to their variability.

Th.A.P.96 CLINICAL PATTERN AND COURSE OF HIV INFECTION IN 29 PATIENTS WITH SEROCONVERSION
Rozak, M., Staszewski S., Kindervater G., Kamps B., Gottstein A., Helm E.B., Universitätsklinik Frankfurt, Zentrum der Inneren Medizin, Infektiologie, Th- Stern-Kai 7, 6000 Frankfurt/M, Federal Republic of Germany

Objective: To describe changes in immunological parameters and occurrence /course of clinical symptoms in patients (pts) with seroconversion (SC) of HIV infection. **Methods:** During routine check-ups of ca. 3000 pts with risk for HIV infection between 1/1986 and 12/1986 at Frankfurt University Clinic, SC could be proved in 29 pts. All serum samples, positive and negative ones, were re-tested by means of ELISA, IPT, or WB. All 29 pts were followed up (physical examination, routine lab. lymphocyte subtyping). **Results:** Mean interval from last negative to first positive test was 180 da (min. 10, max. 656) (Under the name of SC). Under the name of SC being up to the course of SC, of 29 pts, 1 had meningitis-encephalitis, 1 had generalized convulsions, 4 pts had exanthema, 10 symptoms of parainfluenza bouts. Physical & immunological follow-ups (6-9mo after SC; mean: 19mo) showed that only 19 pts (31%) had non-pathological results; after 6-12mo, already 16 pts (56%) had an increase in CD8+ cell count, 4 pts (14%) a decrease in CD4+ cell count. **Conclusion:** 2/3 of our patients presented with subclinical or manifest symptoms due to acute HIV infection. Further examinations will have to show whether different patterns of acute infection correlate with different long term courses.

Publications

Épidémiologie et santé publique
Epidemiology and Public Health

A.507 MEN MEET WOMEN: DIFFERENTIAL RISK-REDUCING NEEDS AND TACTICS IN SEXUAL INTERCOURSE FROM MEN DRAWN FROM THE GENERAL POPULATION POOL.

Ramzi A. Sharrakhal and Averbach T.*
*The Hebrew University & Hadassah Faculty of Medicine, Jerusalem, Israel, **Harvard University, Cambridge, MA, U.S.A.

Utilizing equations which were developed for probabilities of HIV infection through sexual intercourse, we demonstrate the asymmetry of the probabilistic risks for a man and a woman engaging in sexual intercourse in a Western society. Two factors determine this asymmetry: 1. The prevalence of AIDS and HIV seropositivity varies widely between men and women of specific age groups, and 2. the infectivity of receptive vaginal intercourse is also asymmetric between the sexes, women being at higher risk. The equations for the two extreme possibilities of a monogamous relationship with many events of intercourse and for multiple partners with one contact with every partner are respectively:

$$P = \frac{1 - (1 - P)^N}{N} \quad \text{for } (1 - (1 - P)^N) \cdot N$$

P = probability of being infected in the situation described; P = probability that a partner is infected (the prevalence of HIV in the group from which the partner is assumed); 1 - P = probability that one contact with an infected partner will result in infection; N = the number of sexual encounters.

Solving these nonlinear functions for the ratios of P women/P men gave five relative risks for men and women to be infected in both types of encounters. As a situation where both the prevalence for men is higher and their risk is lower for vaginal intercourse the Women to men ratio is much higher.

The implications of these findings are profound when formulating the objectives and concepts of educational interventions among sexually active heterosexuals. While condoms are used by men, it is mainly by women that a more distant of women that one should use condoms. Thus it may be essential to introduce "cooperative" motives into educational interventions to supplement the "egoistic" one of "safe sex". The introduction of "responsible sex" and its implications are considered.

A.508 "GROUPS AT RISK" AND "RISK BEHAVIORS": THE NEED TO UTILIZE BOTH CONCEPTS IN DESIGNING TARGET POPULATIONS FOR EDUCATIONAL INTERVENTIONS AND DEFINING THEIR OBJECTIVES

Ramzi A. Sharrakhal
The Hebrew University & Hadassah Faculty of Medicine, Jerusalem, Israel.

The central claim of the paper is that the two concepts, "groups at risk" and "risk behaviors" are neither synonymous nor interchangeable, and that in order to describe target groups for educational or other interventions, both terms are needed. "Risk behavior" or its prevalence is only one component of the definition of a "group at risk"; in other components being the prevalence of HIV within that group. A comparison of two hypothetical groups, since the data of the actual behavior of actual sub-groups are only approximate, will clarify the distinction between the two concepts.

TYPE OF GROUP	PREVALENCE OF HIV IN THE GROUP	BEHAVIOR IN THE GROUP	CHARACTERIZATION OF THE GROUP
A	low	high	a group at low risk (vulnerable)
B	low	low	a group at low risk (vulnerable)
C	high	high	a group at low risk (vulnerable)
D	high	low	a group at high risk (resistant)

*"Risk behavior" in actual practice are multiple partners, low use of condoms in general and sexual intercourse with high experimentation and variation in sexual practices (including inserting intercourse and/or insertion).

**The prevalence may not be of behavior but of conditions, i.e., a homosexual meeting an isolated component.

*** A situation may arise in which the group at risk is no longer a "group at risk" because of changing conditions, but in such a case the group at risk is still a "group at risk" because of the characteristics of the group.

Group A and B represent homosexual/heterosexual and adolescents in Israel, respectively, while group C and D represent the sub-population of homosexuals after the introduction on modified forms. Group A is exposed from the point of view of public health, health planning, and the design of educational interventions, both concepts are essential, since educational interventions for a group at future risk should differ from those for a group at immediate risk not only because of the characteristics of the group but also because of the characteristics of the risk. "Groups at risk" is therefore a useful and meaningful term.

A.509 SURVEILLANCE OF HIV-1 INFECTIONS BY ELISA USING HIV-1 AND HIV-2 SPECIFIC SYNTHETIC PEPTIDES

P. Leikola, J. Mäkelinen, M.-J. Karkonen and H. Brummer-Korvenkontio, National Public Health Institute, Helsinki, Finland.

OBJECTIVE: To screen for HIV-1 and HIV-2 cases in Finland and to evaluate a new test employing HIV-1 and HIV-2 specific synthetic peptides as antigens.

Methods: Serum samples sent for routine HIV-testing from healthy individuals and HIV risk groups were tested by an ELISA with either a combination of, or individual HIV-1 or HIV-2 specific synthetic peptides representing the N-terminal regions of gp-41 (COMB-test, Pharmacia Inc. Uppsala, Sweden).

Results: Of the 5221 sera negative with other tests, 9 were repeatedly reactive in the COMB-test indicating a specificity of 99.84. Among the 25 true positive sera 23 gave no or very little activity with HIV-2 compatible with true HIV-1 infections. Two samples, originating from the same individual reacted with the HIV-2 specific peptide. They also showed gp-reactivity in HIV-2 western blots. The patients had worked in endemic areas of Africa before returning to Finland. One falsely reactive sera also showed high activity against HIV-2.

CONCLUSION: The result indicates that the test has good specificity and is able to reveal HIV-2 positive cases among samples thought to be HIV-1 positives by conventional techniques.

A.510 HIV-1 SEROPREVALENCE IN A GROUP OF HIV POSITIVE ITALIAN SUBJECTS (IN PARTICIPATING UNDER SURVEILLANCE) - PROGNOSTIC DATA

Laura Loggioni, F. Giacomoni, P. Lanza, A. Berretta, A. Rinaldi, S. Sabatani, Dipartimento di Biologia generale - Università di Milano, Milano; * Divisione di Malattie Infettive - Ospedale Maggiore Bologna, Bologna, Italy.

Aim: We detected the presence of specific HIV-1 antibodies in HIV positive subjects to evaluate (1) the percentage of double infection (2) if the subjects with double infection presented an evolutive pattern.

Methods: The presence of specific HIV-1 antibodies was tested by ELISA method in 240 HIV positive subjects (212 were intravenous drug abusers). The HIV seropositive samples were investigated by Western blot assay.

Results: The presence of HIV-1 ELISA reactivity was found in 17 of the 240 HIV positive sera (7.08%). This reactivity was not confirmed by Western blot in 2 subjects, 6/17 subjects were AIDS. **Conclusions:** The data confirmed the presence in Italy of HIV-1 specific antibodies in HIV positive subjects also suggested in other epidemiological studies. We need a follow up of HIV-1 and HIV-2 positive subjects to evaluate a possible higher evolutive pattern towards AIDS.

A.511 INCIDENCE OF HIV MARKERS AND HIV ANTIBODIES IN BLOOD DONORS IN LISBONA AND FERREIRA, PEOPLE'S REPUBLIC OF ANGOLA

Luiz Carlos Martins, Cohen T. M., O'Brien F. A., Sousa-Ferreira, M. O. P., Mann-Almeida, M. J. A., Almeida Neves, J. K. V.

*Lab. Virology, Fac. Pharmacy, Univ. Lisbon, Portugal; **American Univ. Health Sciences, London, B. P. Africa; ***Vista, St. Maria, Lisbon, Portugal. JNICT GRANT 87-679

Objective: To determine the prevalence of HIV 1 and HIV 2 infections and hepatitis B markers among a cohort of blood donors in Lisbon and in Ferreira, People's Republic of Angola.

Methods: The incidence of HIV markers and HIV antibodies was evaluated in 124 blood donors living in Lisbon (74) and Douro (50). Serological tests for detection of HIV antibody, including the specific HIV 1 and HIV 2 ELISA kits, HLA, W. K. Comp-reactivity between HIV 1 and HIV 2 large glycoproteins were further tested against a synthetic peptide corresponding to the dominant epitope of transmembrane protein. Serological tests for detection of HIV markers were performed with ELISA kits.

Results: As shown on table.

Location	Distribution of HIV antibody and HLA Ag. HLA Ag. HLA Ag. HLA Ag. HLA Ag. HLA Ag.					
	Anti-HIV-1	Anti-HIV-2	HLA Ag. HLA Ag.			
Lisbon	74	17(41.1)	14(7.14)	28(74.13)	17(41.1)	17(41.1)
Douro	50	3(7.6)	1(2.0)	1(2.0)	1(2.0)	1(2.0)
TOTAL	124	31(24.1)	15(11.9)	29(23.1)	17(13.7)	18(14.1)

Discussion: The incidence of HLA Ag. in sera from Lisbon and Douro is high. HIV 1 and HIV 2 infection rates among blood donors. The highest percentage of positive cases in Douro, Portuguese region, border of Zaire. The social and economic consequences of these problems have to be considered.

A.512

ANALYSIS OF A SCREENING PROGRAM FOR HIV AND HIV INFECTION IN MEN OF REPRODUCTIVE AGE

H. H.***
Foundation of "San Giuseppe", Faculty of Medicine of Lisbon and Faculty of Pharmacy of Lisbon***
Av. Prof. Aguiar Rosa - 1600 LISBOA - PORTUGAL.

OBJECTIVE: 1 - To study the prevalence of antibodies to HIV and HIV in a population of men attending a Family Planning Clinic (FPC) and a men's clinic. 2 - To derive a protocol of a study which would include the following: a) a study of the prevalence of HIV and HIV in the population; b) a study of the prevalence of HIV and HIV in the population; c) a study of the prevalence of HIV and HIV in the population.

MATERIAL AND METHODS: All men attending the FPC and the AC from January 1987 to December 1988 were screened for HIV and HIV. A total of 1,000 men were screened. Blood was collected from each man and analyzed for HIV and HIV. The results of the serological tests were compared with the results of the clinical information related to HIV infection. Blood was collected from each man and analyzed for HIV and HIV. The results of the serological tests were compared with the results of the clinical information related to HIV infection.

RESULTS: Three out of 100 Portuguese men were positive for HIV-1. All had one out of 50 HIV-2 seropositive men. The prevalence of HIV-1 and HIV-2 in the samples collected at different times if the criteria for defining women as seropositive did not include tests on a second sample, the number of seropositives was 100. It is important to note that the results of the serological tests.

CONCLUSIONS: A representation of both HIV-1 and HIV-2 in this urban population was found and the prevalence of HIV-2 in a second sample as a means of reducing false positive is documented in this study, where a protocol to repeat serologically the blood tests was implemented, taking advantage of the special conditions in this health center.



- A.513** Stochastic Models Illustrate Vividly the Connection between Behavior and Risk for HIV Infection. Gonzales, Jorge J., Myrvet, M., Vavik, L., *ASA, Arendal, *Teachers College School, Rossmore, Norway.

Objective. To use the power of modern Personal Computers to display graphically the connection between behavior and risk for HIV infection.

Methods. A stochastic simulation model takes into account stochastic parameters in a hypothetical risk environment. The correlation between behavior patterns and risk for HIV infection is displayed by means of powerful graphics.

Results. We describe the application of our stochastic simulation model to train medical personnel and school teachers in Norway and West Germany.

- A.515** IS SEXUAL PROMISCUITY A RISK FACTOR FOR HIV IN EAST AFRICA? Ng'othia, G., Constantia, H., and Abacha, E., *U.S. Naval Medical Research Unit No. 3, Cairo, Egypt (A WHO collaborating center for AIDS), **Direction Technique de la Santé, Djibouti, Djibouti

Objective. To investigate if the 8-cell lymphocyte virus HIV-2 shares the sexual transmission route of HIV in East Africa.

Methods. 200 sera belonging to 2 groups of individuals from the East African city of Djibouti were tested for antibodies against HIV-2. Study groups comprised sexually promiscuous individuals at high risk for HIV, but HIV-2 western blot negative; 50 female prostitutes in Group 1 and 50 males with a sexually transmitted disease in Group 2. Group 3 comprised 50 female controls and Group 4, 50 male controls. All sera were screened at a 1:50 dilution using IFA (Immunofluorescence) incorporating HIV-2 infected and uninfected cells as substrates. Sera with positive reactions were titrated further.

Results. Despite the slightly higher percentage of positive sera (50%) at the screening dilution in the two study groups, these differences were not statistically significant. Moreover, median titers and geometric mean titers of positive sera were very similar in all 4 groups.

	Group 1	Group 2	Group 3	Group 4
SER:	66	74	70	70
Median titer:	40	40	40	40
Geometric mean titer:	39	37	38	39

Conclusions. Sero-epidemiological data indicate that HIV-2 infection was not more prevalent among sexually promiscuous subjects. Thus, HIV-2 does not seem to share the sexual transmission route of HIV in East Africa. Supported by DANMED/WHO/CDC, Bethesda, Md, work Unit No. 3663103B05.A0.333.

- A.517** ACCIDENTAL EXPOSURES TO HIV-POSITIVE BLOOD AMONG HEALTH-CARE WORKERS IN 2 SWEDISH HOSPITALS.

JÖRBERG, HANS. Marland, M., Sjöström, E., Danderyd Hospital, Danderyd, Sweden.

Objective. To document circumstances, frequency and outcome of accidental exposures to HIV-positive blood and body fluids among health-care workers.

Methods. This prospective study was started in January 1, 1983. It includes health-care workers in 2 Swedish hospitals giving medical care for HIV-infected patients. All reported cases of damage with exposure to HIV-positive blood or body fluids among more than 2 500 health-care workers have been registered. Blood samples (including an early blood sample) of the exposed workers have been regularly taken and examined (ELISA).

Results. Among 70 accidents have been reported, so far. Different kinds of personal exposures were dominating. So far, all anti-HIV antibodies have been negative.

Discussion and conclusions. Seronegativity after accidental exposure with blood has been estimated to 5 per 1 000 exposures. In our study no seroconversion in around 40 persons and 30 other HIV-accidents have yet been confirmed, which is to be expected. The majority of the seronegative HIV-accidents were caused by needle-sticks in combination with phlebotomy, blood-culturing and injections. To our judgment, around 1/3 of the accidents might have been prevented.

This study clearly shows that hazardous circumstances, among others, were manipulation with needles (recapping, disposal, "cleaning up"), laboratory work (tubes) and surgery (secure needles). To minimize the risk in the future we have to identify hazardous circumstances, work etc and do something about it (guarded needles, puncture proof boxes, safe work practices). Further, we have to educate and inform health care workers, as well as others, about the hazards and change their behavior if needed!

- A.514** HIV Screening Efforts in a Low-Risk Population. MARSHALL, CHARLES E., Sanchez, Jose L., *Buffalo, Pa; Lewis, Vasari M., Guterman, Frank L., *Wessex Army Community Hospital, Ft Belvoir, Ill; *Walsh Reed Army Institute of Research, Lexington, DC, USA.

Objective. To determine the prevalence of HIV antibody seropositivity in a low-risk population.

Methods. The U.S. Army requires HIV testing at least biannually for individuals on active duty. Blood donors are also routinely screened for HIV infection. During the past year, inpatients and some outpatients have received an HIV antibody test. These patient categories are listed below.

Results. High-risk patients, which include people with clinical evidence of HIV infection, individuals treated for substance abuse and contact referrals, have the highest HIV antibody prevalence rates. Patients treated at a sexually transmitted disease (STD) clinic had the next highest prevalence. Routine hospital admission and blood donor screening showed rates similar to or lower than that seen in active duty screening.

HIV SCREENING RESULTS

	N	Pos/Screened	Prevalence/1000	95% C.I.
High-risk group	24/278	14.3	58.8 (9.19-3)	
STD Clinic	31/327	10.4	32.9 (6.12-3)	
Med/Wurg Admissions	17/112	1.1	9.8 (0.11-1)	
OS/RT Admissions	1/2246	0.4	1.8 (0.16-4)	
Blood Donors	15/1513	0.6	4.2 (0.16-8)	
Active Duty Screening	81/3894	1.8	4.6 (0.81-3)	

Conclusions. Adjusted HIV screening of routine hospital admissions does not appear to be warranted.

- A.516** A PROSPECTIVE STUDY OF HIV INFECTION IN FORMER DRUG USERS: A 4-YEAR STUDY OF 114 PATIENTS. ALLENWOOD, GRINGIRI, R.G.H., M. Colombo, A.L. Zanetti, R. Romeo and P.S. Manonni. University of Milan, Milan, Italy.

Objective. To assess whether or not stopping drugs has any beneficial effect on the course of HIV infection, inactive drug users living in the community of San Patrignano (Italy) were prospectively followed. **Methods.** These patients voluntarily enrolled into a rehabilitation program based on agricultural, handicraft and industrial activities and were forcibly taken off drugs during residence. Except for married couples, they had no sexual contacts. Since 1985, 203 seropositive, western-blot confirmed, asymptomatic patients have been followed at 6-month intervals for 6-66 months (median 32). 179 patients (59%) were lost because they either reached the end-point of rehabilitation (12%) or left the community (32%). 114 patients (61 M, 33 F, 16-42 yrs of age, median drug abuse: 6 yrs) are currently being followed. 65 patients (21.9%, 6.4% annual incidence by 110-month analysis) deteriorated to stage IV (CD4), 5 developed full-blown AIDS (5.2%, 1.2% annual incidence). The annual deterioration rate for a control group of 110 active drug users who were followed as outpatients between 1985 and 1988 was 28.4% (1.6% vs 28.4% P<0.01).

Conclusions. Stopping illicit drugs may be beneficial to the outcome of HIV infection.

- A.518** RISK FACTORS FOR HIV INFECTION AMONG INDIVIDUALS SEEKING TESTING IN THE UNITED STATES.

WILSON, VICTOR. Zeffman, S., Frank, A., Brandenburg, R., Sivils, R., *State University of Pennsylvania, University of Colorado, Colorado, USA.

Objective. To characterize individuals seeking HIV antibody test and to evaluate the prevalence of anti-HIV sero test. **Methods.** Self-administered questionnaire distributed together with test results to individuals requesting HIV testing in all parts of the health care system in 4 states in 1987-1989 and April 1989. 2169 (55%) completed the questionnaire. **Results.** Seropositivity was 32% of sero tested sera. 26% in the age groups 15-29, 26% in 30-39 years of age. 70% of sero tested individuals were male. Risk factors and their association with seropositivity are listed in the table.

Risk Factor	No.	Sex	Anti-HIV sero. pos.	Anti-HIV sero. pos. %
Reported risk factor	8	(M)	8	(100)
IV drug abuse	182	(182)	182	(100)
High heterosexual behavior	182	(182)	182	(100)
Sex with IV drug abuser	28	(28)	28	(100)
Sex with person from Africa, overseas with bisexual male	89	(89)	100	(100)
Sex with heterosexual partner within the last 12 months	455	(444)	2	(.4)

Sex of above: 100 (28) M, 302 (100) F
1000 (200) M, 1000 (100) F
The overall prevalence of anti-HIV was 12%, highest among sex with heterosexual behavior. **Conclusions.** Many individuals seeking HIV testing are heterosexuals and have a very low prevalence of HIV. Being male to seek valid estimates of the prevalence of HIV infection in the general population requires prevalence studies may give valuable information about trends in infectious disease.

A.519 NATIONAL STUDY OF HIV SEROPREVALENCE IN NATIVE AMERICANS
Gentry, George A.,* Wooper F***, Malgoures SD***,
*Centers for Disease Control, Atlanta, Georgia; **Indian Health Service,
Phoenix, Arizona; ***Indian Health Service, Tucson, Arizona, U.S.A.

Objective. To assess existing levels and future trends of HIV infection among American Indians and Alaska Natives in the United States.

Methods. Following approval from tribal authorities, blinded seroprevalence testing will be conducted on men obtained for syphilis screening from pre-natal patients, patients undergoing initial evaluation for a sexually transmitted disease, and patients entering drug or alcohol treatment programs. The study will be conducted throughout the Indian Health Service (IHS) (case population of approximately 1,144,000 individuals). Approaches to sera collection will be tested for HIV antibodies during a one-year study interval starting in 1989. Results will be stratified by reason for sera being obtained and by rural or urban clinical setting. Sera will be segregated by clusters of $\geq 20,000$ service population to further protect confidentiality and ensure statistical reliability of results.

Results. The pilot phase will begin in January, 1989. By March, 1989, surveys are expected to be implemented in many of the IHS service areas.

Conclusions. These surveys will provide relatively unbiased estimates of seroprevalence for the clinic subpopulations of IHS service users. It should also serve as a baseline that may be followed through time for the assessment of the progress of the epidemic and preventive activities in this population.

A.521 SEROPREVALENCE OF HIV ANTIBODY IN A CITYWIDE SAMPLE OF EMERGENCY ROOM PATIENTS
Modest Deyan*, Jai J**, Stevens P**, Holman S*, Shriver J*,
*Delta Health Division, **Oregon Health Division, ***Oregon Health Sciences University, Portland, Oregon, U.S.A.

Objective. To determine prevalence of HIV antibody in a citywide population of patients seeking emergency room (ER) care.

Methods. Seven hospital-based emergency rooms providing 90% of Portland's emergency services collaborated to simultaneously measure HIV seroprevalence in their combined patient population. During two 48-hour periods in the summer of 1988, all blood drawn from patients for other purposes were tested for HIV antibody after personal identifiers had been removed. Specimens were also screened for hepatitis B surface antigen (HBsAg) and core antibody (HBeAb). Demographic and risk factor information as obtained by routine ER practice was linked with test results.

Results. Blood from 444 patients was tested. Patients' residences were evenly distributed throughout the metropolitan area. The largest proportion of patients were in the 20 to 30 year age group (24.9%/year age group (18%) and in the 40 and over group (18%). Twenty-one patients (4.7%) were identified as intravenous drug users. No males were identified as being homosexual. Seven percent of patients had experienced transfusion. Invasive procedures were performed on 34% of patients. Only 2 patients (0.45%, 95% CI ± 0.22) tested HIV positive. One of these patients was already known to be HIV positive. Three of 444 (0.68%, 95% CI ± 0.16) patients were HBsAg positive and 55 of 444 (12.4%) were HBeAb positive. Conclusions: The rate (0.45%) of HIV seroprevalence in this city-wide mixed low and high risk population is the rate of HBsAg seroprevalence (0.68%). In contrast, the prevalence of HBeAb (12.4%) indicates a substantial proportion of this population may be at risk for future HIV infection. This method of passive sampling may provide a simple way to estimate HIV infection rates in a general population.

A.523 ACCEPTANCE OF HIV-ANTIBODY SCREENING AND PREVALENCE OF ANTIBODIES AGAINST HIV AT A STD CLINIC

Hilitt B, Holmstedt and Mørch, HK**
*Statens Serum Institut, **Nilspejlegade 1, Copenhagen, Denmark.

During periods of three weeks repeated every third month from October 1987 to February 1989, all persons attending a STD clinic in Copenhagen for serodiagnosis were offered a blood test for HIV-antibodies. The test could be performed anonymously or not. Data concerning sexual orientation, prostitution, first abuse and sexual contacts with high risk groups were collected. During all four periods 1751 persons attended the clinic. HIV-antibody testing was not accepted by 11.0% of heterosexual men, 9.6% of homo-/bissexual men and 9.8% of the women. No major differences in acceptance of HIV-antibody testing during the four periods was seen. Four heterosexual men, 11 homo-/bissexual men and one woman were found HIV-antibody positive. The data support that a constant number of clients attending a STD clinic would even anonymously HIV-antibody testing and underline the necessity for blinded HIV-antibody testing in order to disclose the true prevalence in this group.

A.520 DETECTION OF HIV ANTIBODIES IN DENTAL SCHOOL AT THE UNIVERSITY OF BUENOS AIRES

Cespede JM, Sobaglia L, C*, Tricca A*, Brizuela J*, Benaglia M*, Macklin G, Guillemeo** et al.
*Curso de Microbiología, Facultad de Odontología, Universidad de Buenos Aires, **INIDMA, Academia Nacional de Medicina, Buenos Aires, Argentina.

Objective. To determine HIV-infection seroprevalence in dental professionals, as they represent an important group to study HIV-infectious occupational risk.

Methods. A total of 617 subjects was included in this study: 400 first-course students at the School of Dentistry, 112 predoctoral students and 105 dental professionals. Serum samples were tested for HIV antibodies by means of ELISA (Abbott recombinant HTLV III ELISA). Samples reacting positive by ELISA were confirmed by Immunodiffusion or Western Blot.

Results. Only 10 (1.6%) males out of the 400 first-course students had HIV antibodies. Risk-factor analysis in the seropositive cases showed that 1 subject was homosexual and intravenous drug abuser and 2 were intravenous drug abusers.

Conclusions. Though dental professionals are likely to be repeatedly exposed to HIV-infected persons, we did not find infection in any of the 112 predoctoral students, nor in the 105 dental professionals, assuming a low risk for the studied group.

A.522 SEXUAL MIXING MODELS WITH LIKE-WITH-LIKE PREFERENCE

Stultz, Peter* and Castillo-Chavez, Carlos**
*Strathclyde University, Glasgow, Scotland, **Cornell University, Ithaca, New York, USA.

Objective. To develop an alternative to proportionate mixing in sexually transmitted disease models.

Methods. Starting from the three fundamental constraints on a mixing function (it must be positive, normalized, and conserve the number of partnerships), a new mixing model can be constructed by finding an appropriate transformation of a suitable function (describing mixing between individuals of similar activity).

Results. A new mixing model is derived, based on a transformation of a local mixing function ("like-with-like") which has the property $f(x) = f(y)$. Different choices of f provide different degrees of localized mixing in the population, and affect the dynamics of an STD epidemic.

Conclusions. Predictions of epidemics of STDs are very sensitive to the nature of like-with-like mixing in the population.

A.524 THE INFLUENCE OF CHANGES IN SEXUAL BEHAVIOUR ON THE TRANSMISSION DYNAMICS OF HIV-1 IN THE UK

Opina, Santos; Blythe, S.; Anderson, R.M.
Imperial College, London, UK; *Strathclyde University, Glasgow, Scotland.

Objective: To assess the consequences of changes in sexual behaviour on the transmission dynamics of HIV-1 with reference to the male homosexual community in the United Kingdom.

Methods: The distribution of sexual activity (rate of acquiring new partners) and transmission probabilities (involving the adoption of "safe sex") are altered in a simple model of the transmission dynamics of HIV-1. The model incorporates distributed infectious and incubation periods.

Results: The future course of the HIV-1 epidemic is highly sensitive to the timing and the magnitude of changes in sexual behaviour. The effects of changes in sexual behaviour are not linearly proportional to either the magnitude of the change or the time of its initiation. Conclusions: The timing of a change in sexual behaviour is crucial in reducing the numbers of future AIDS cases. Great benefit is obtained by changing sexual behaviour as soon as possible, and any delays drastically reduce the impact of a change.

Publications



Epidémiologie et santé publique Epidemiology and Public Health

A.537

IMPACT OF REVISED CASE DEFINITION ON AIDS SURVEILLANCE IN EUROPE

Rocheleux Park, Bessy, Couturier, L.*, Brunet, A.S.* and national surveillance coordinators of 21 countries. WHO Collaborating Center on AIDS, Paris, France.

Objective: To determine the modalities of application and impact of the revised WHO AIDS case definition on surveillance in Europe.

Methods: A survey was carried out among the 32 countries of the WHO European region investigating modalities of surveillance of AIDS and application of revised case definition.

Results: Of 20 countries having answered by end of January 1989, 15 have set up a surveillance system for HIV-1 individuals. 20 countries have an AIDS surveillance system which is mandatory and 6 voluntary. Under-reporting has been assessed by few countries 9/20 mostly by matching AIDS cases with death certificates. Revised case definition was applied in all 20 countries by 01/01/89. Six countries have actively carried out a retrospective investigation on cases previously reported with AIDS and 3 have also investigated HIV patients not previously diagnosed with AIDS. 156 AIDS patients fitting the revised case definition have been reported representing an increase of 4%. This is much lower than figures reported in literature.

Conclusion: Most of the 20 countries having answered by end of January 1989 had applied the case definition by first of January 1989. Impact of new cases is extremely low and will be assessed when complete set of answers are received.

A.538

THE INCIDENCE OF GLOVE PRACTICE DURING GONORRHOEA TREATMENT AND VARIATION

PROTECTIVE EFFECTIVENESS

J. J. BENTON, J. M. BART, Departments of Obstetrics, St Mary's Hospital, London, and The Wellcome Women's Hospital, Langenbeck, West Kingston.

A study was performed to ascertain the incidence of glove practice at lower urinate suggest. The increasing incidence of hepatitis B and HIV infection in women make this of increasing importance to surgeons. The following results were obtained:

Total Gonorrhoea patients	200
Total where gloves practiced	107 (53%)
Nonurine control - during emergency Gonorrhoea section	6/116 (5%)
- during elective Gonorrhoea section	30/120 (25%)
- Urine control	5/128 (6%)
- Urine not controlled	50/110 (45%)
- during closure of urterine canal	3/90 (3%)

*We stated whether emergency or elective section in 10 cases. **We stated whether controlled or not in 5 cases. This trial shows the highest rate of glove practice yet reported during a surgical procedure. By its currently undergoing a controlled trial of a new form designed to grip both urterine muscle and meatus more effectively. The use of double gloving, white latex gloves, new gloves (Elastogel) on the fingers and the increasing use of staples for skin closure should also reduce this unacceptably high rate of practice.

A.539

MODIFICATIONS ET VARIATIONS GÉOGRAPHIQUES DES GROUPEMENTS DE TRANSMISSION DE L'INFECTION VIH EN FRANCE

Leclerc, M., Christine, Ligue Française pour la Prévention des Maladies Infectieuses, France.

Objectif: Préciser la répartition actuelle des groupes de transmission sur l'ensemble des sujets infectés par le VIH quelle que soit la stade, en France.

Méthodes: Recensement de tous les sujets séro-positifs hospitalisés ou vus en consultation dans 20 Services de Maladies Infectieuses du 1er juillet 1987 au 1er juillet 1988.

Résultats: Sur 3873 sujets recensés, dont 80 % non atteints de SIDA, la répartition des groupes de transmission était la suivante: homosexualité 37 %, toxicomanie 41 %, transfusion et hémosuccès 7,8 %, transfusion et hémosuccès 6,9 %, autres et indéterminés 5,1 %. Le pourcentage de toxicomanie y était le plus élevé dans le Sud, à Marseille, 80 % et à Nice 66,6 %, et le plus faible dans le Nord, à Lille, 12 %.

Conclusion: Le groupe de transmission toxicomanie y est pour l'ensemble des sujets séropositifs nettement plus important que pour le seul groupe des SIDA déclarés (20 % des SIDA en 1988). Ce groupe est surtout important dans les zones méditerranéennes, comme pour l'Italie et l'Espagne. Il représentera le groupe le plus important des malades atteints de SIDA dans les prochaines années en France.

A.540

HIV SEROPOSITIVE MEN INFECTED WITH MULTIPLE CMV STRAINS: A LONGITUDINAL STUDY OF THE RELATIONSHIP TO T-CELL SUBSETS

Leach, Charles*, Daniels, R.; Visccher, B.**; Giorgi, J. and Cherry, J.* UCLA - Sch. of Medicine and **Public Health, Los Angeles, CA, USA.**

Objective: To investigate the relationship between serial infection with multiple CMV strains and T-cell subsets.

Methods: We identified 56 asymptomatic HIV-1 seropositive homosexual men participating in a study of HIV-1 infection who acquired CMV from semen at two visits 5 to 8 months apart. CMV DNA was isolated from paired isolates in six men, cut with restriction enzymes and then subjected to junctional hybridization. Lymphocyte subsets were determined by flow cytometry.

Results: Paired isolates from each of 2 men gave identical banding patterns (Group 1). Four men were found to acquire a non-identical strain at the second visit (Group 2). Both groups had lower CD4 and CD8 counts at the second visit (mean decrease in CD4: 27% (Group 1), 35% (Group 2); mean decrease in CD8: 14% (Group 1), 33% (Group 2)).

Conclusion: Serial acquisition of multiple CMV strains occurs in asymptomatic HIV infected homosexuals. All 6 subjects persistently shedding CMV had decreases in CD4 and CD8 cell counts. Evaluation of the remaining CMV isolates (in progress) is necessary in order to determine whether men with multiple strains have different changes in T-cell subsets than men with identical strains.

A.541

SEXED HIV RISK BEHAVIOR REDUCTION IN PUBLIC WORKERS

Leiro, M., Fumason, A., Valenzuela, J., Baker, Charles E. Dallas County Health Department, Dallas, Texas, USA.

Objective: Reinforce safer sex behaviors among sexually active gay men.

Methods: Health department staff of the High Occupancy of contact for sexual partners among gay and bisexual men, particularly at one public employees prepared package for distribution in the park. Each package contained condom packages coded with a red stripe, safer sex brochures, and a list of services available at the health department, including anonymous HIV antibody testing and counseling. The packages were distributed to park patrons who appeared to be in the park for the purpose of arranging sexual partners who appeared to be in the park for non-threatening behavior. The park patrons were offered the plain white packages and were told the packages were "house product samples." Anecdotal information was collected about the manner of the patrons, the frequency of entering and leaving the park, the park hours for patron contact in the park. Demographic information was collected.

Results: Condom packages were found in the park after the health department began the package distribution. Patrons accept the packages, are not threatened, appear interested in the material and appreciate our effort in coming to them. Patrons are called the health department and ordered laundry approach used by health department staff promotes a sensitive image of the health department, as it also facilitates safer sex behavior reinforcement.

A.542

PREVENTION OF PERINATAL TRANSMISSION OF HIV

Berman, Stuart; Centers for Disease Control, Atlanta, GA U.S.A.

Objective: In report projects to date by projects to prevent perinatal HIV transmission.

Methods: Home demonstration projects evaluate and facilitate the use of contraception and encourage risk reduction among women HIV-infected or at highest risk for infection.

Results: The project, funded for \$6.5 million per yr, are a major way for CDC to develop perinatal HIV prevention interventions for implementation by State government and provide additional resources targeting minority and inner-city populations. Projects will address 2 factors determining HIV seroprevalence among newborns: HIV prevalence among women (15-44) and birth rates among those HIV+. Efforts have focused on limiting spread and increases in prevalence of HIV among women. However, effective program development requires data about contraceptive practices and attitudes and about reproductive decision-making among women such as female intravenous drug users (IVDs) and sex partners of drug users—the mothers of 75% of pediatric perinatally-acquired AIDS cases. In 10 cities women who are crack users, IVUs, sex partners of IVUs, prostitutes, or HIV+ will be assessed in public clinics, obstetric units, drug treatment, through referral by community organizations, and by outreach among AODC, efficacy of referral, use of contraception, and risk reduction will be evaluated and facilitated. Among them, pregnancy rates, breastfeeding attitudes, and determinants concerning use of contraception will be assessed.

Conclusions: These projects should provide information to direct efforts to prevent perinatal HIV transmission.

Publications

A.543

VIRUS, SYMPTÔMES ET TOXICOLOGIE.
ESPÉRANZA FERRAZ, LOUVERNE J. L., RICHMOND R. C., ROCHARD J.
 = Établissement d'Hygiène Publique Nationale, France, France.
 Alle des Thuys 94251 PIRENES CEDEX FRANCE.
INTRODUCTION: L'échage de seringue chez les toxicomanes expose au risque de contamination VIH. Les tests de seropositivité sont élevés (>50%) chez les drogués en région parisienne. Les risques de transmission sexuelle sont peu documentés chez cette population.
OBJECTIFS - MÉTHODES: Préciser et comparer le mode de vie sexuel, les taux de seropositivité VIH, les marqueurs de l'apoptose chez les toxicomanes IV et les toxicomanes aveugles. Conditions : consentement, confidentialité, anonyme.
RÉSULTATS: Population : toxicomanes de sexe masculin, incarcérés en Juin 87 : 183. 18 infirmeries (sans d'injection) Pas de différence statistique pour l'âge (27 ans), la réponse de 2 usages de drogue (1/soir) la durée de la toxicomanie (5ans), les caractéristiques de vie sexuelle : 72 statut conjugal, 2 homosexuels, 5 bisexuels, 23 rapports 2 cas 21 avaient des rapports uniquement avec leur conjoint et 5 (15%) avec des prostituées. Parmi les partenaires sexuels féminins 40% utilisaient des drogues IV. Une différence statistiquement significative est retrouvée pour les facteurs suivants :

	VIH	WBL (vs) TP/TH	Nouveaux partenaires(1)
IV n = 63	30 (45%)	17 (27%)	14
Non IV n = 120	53 (44%)	31 (26%)	14

CONCLUSION: L'incarcération VIH est liée à la toxicomanie IV. La fréquence de la syphilis chez les IV et aveugles fait craindre des risques de transmission hétérosexuelle de VIH.

A.545

EARLY COURSE OF HIV INFECTION IN 40 SEROCONVERTERS
Alessi, E., Muratori, Simoni, Martoni, S., Guini, N., Cervinatti, G. and Marzoni, M.
 Inst Clinic of Neurology, University of Milan, Milan, Italy.

OBJECTIVE: To study the natural history of HIV infection.
METHOD: Forty homosexual, who became seropositive from December 1985 to January 1986, were followed from 11 to 36 months (mean 23 months). The mean time between the last negative and first positive tests was considered to be the time of infection. Clinical, immunological and virological parameters were assessed at enrollment and every 4 months.
RESULTS: Generalized lymphadenopathy developed in 15 patients from 3 to 15 months, mainly insidious in 1 (after 4,15,17 and 22 months) had constitutional symptoms in 3 (after 31, 21, and 29 months). The development of constitutional symptoms was accompanied by HIV antigenemia, but symptoms and antigenemia spontaneously regressed in 2 of 3 patients after few months. No statistically significant modification of immunological parameters was observed in about 50% of patients. Only one patient developed profound immunosuppression.
CONCLUSION: Our follow up study demonstrated the variability of the course of HIV infection. Some of the laboratory parameters analyzed seemed of value in predicting the disease progression.

A.547

PROFIL ÉPIDÉMIOLOGIQUE DES INJECTIONS SEXUELLES AU VIRUS D'IMMUNODÉFICIENCE HUMAINE (VIH) EN SUISSE.
Duressat, J.-M., Baccini, J., Marouzzi, J., Lépigne, M., SAAD, M.P., Université de Sherbrooke, Sherbrooke, Québec, Canada.

OBJECTIF: Décrire la population infectée par le VIH dans un milieu plutôt rural. Afin d'en souligner les différences par rapport au milieu urbain.
Méthodes: Étude rétrospective de tous les cas de SIDA (S), para-SIDA (P.S.) et infections, asymptomatiques (I1) diagnostiqués au CHU et dans ses hôpitaux affiliés entre octobre 1984 et octobre 1986.
Résultats: 85 personnes infectées ont été diagnostiquées dont 30 S, 20 P.S. et 35 I1. Les facteurs de risque pour cette population se lisent comme suit: homo-bisexuel 60%, drogues IV 23%, sang et dérivés 17.6% et contact hétérosexuel 14.1%. Le nombre de cas de S est passé de 3 par an en 1984 à 1 par an en 1986. 40% des S étaient des hétérosexuels (H), dont 20% de femmes. Le contact avec une personne infectée (21%), le prostitué (13.3%) par sexe en 1986, 40% des S étaient contactés (33.3%) étaient les P.S. le plus souvent identifiés chez les H. L'âge moyen des S est de 48.3 pour les hommes et 39.75 ans pour les femmes. 86% des cas de S ont été diagnostiqués en Suisse, mais 37% seulement se sont infectés en Suisse.
Conclusion: L'infection par le VIH est en progression constante en Suisse. Ce S s'explique la part plus importante que dans le reste du Canada (40% vs 18%). L'âge moyen des personnes les atteintes, est relativement élevée (56%). Le contact avec un S (23% vs 9%) et sanguin (13% vs 4.6%) sont plus élevés que dans le reste du pays. Une proportion importante des S diagnostiqués en Suisse s'est contaminée hors Suisse. Ces particularités diagnostiques de l'infection par le VIH doivent être prises en considération dans les campagnes d'information et de prévention.

A.544

DETECTION OF COLLISION VS LEAK IN CONDOM BIOLOGICAL TEST.
Torres, José, Amador, María, H., Muñoz, J., Navarro, J.,
 Comité Anti-SIDA, Barcelona, Spain.

Objective: The condom is recommended and used as an efficient barrier against HIV and other infections. In practice, the use of a condom may present irregularities or leaks. This has been resolved efficiently with rigorous sampling plans for leak-detection tests, realized in all standards by conductometric or electrochemical test (ET). But, as the test is made on a condom in repose and without mechanical tension, eventually existing micro-occlusions or micro-chaps would not be detected as leak. Given that a condom in use in sexual relations is subjected to forces and stress, deformations, there could appear leaks, invisible in condom without tension, and the protection is lost. To evaluate this loss of protection by HIV due to appearance of leaks while using (stretching) condom, it is proposed to test, with Rheological test (Rheo.) Methods, a condom tested with usual leak ET and Rheological test 2 homogeneous lots of 2 different manufacturers, considering the presence of leak at the indication of 50m/ISO 4074, (UNE 53625) and Rheological test 2 homogeneous lots of 2 different manufacturers (condom in repose). There was no leak found for the Rheological Test detected 1 and 14 leaks in the two manufacturers respectively. **Conclusion:** 1) Condom can prevent micro-occlusions or micro-chaps which will be transformed into leaks and holes and they will loose their protection effect against HIV when submitting them to forces and deformations. 2) The leak detection tests for condoms with the Rheological Test permit to reject non-safe condoms with micro-occlusions or micro-chaps which would not be detected by usual test (ET).

A.546

NATURAL HISTORY OF HIV INFECTION IN STRAITS SETTLES
 AT THE MEDICAL COLLEGE OF SINGAPORE
Rafiq, Alihan, Farner, G., Bhatia, G.,
 Singapore, S. Medical College of Virginia,
 Singapore, S. S. S.

OBJECTIVE: To describe the natural history of HIV infection in females seen at MCV.
METHOD: This study retrospectively compared the clinical course of 46 HIV infected women with 412 HIV infected men followed at MCV from 1/88 to 1/89.
RESULTS: Females comprised 10% of the HIV infected population seen at MCV; 36 (77%) were black, 14 (30%) were white, and 19 (41%) were Chinese. Their racial risk factor for acquiring HIV was 19 (41%) for 31 (47%), sexual contact 24 (48%), blood products 6 (12%) and 18 sexual exposures. During this time 35% of the women had AIDS compared to 33% of the men. Although a similar proportion of men and women were taking zidovudine the mortality rate for females was only 14% compared to 33% of the male HIV infected population ($p < 0.05$). The percent of men and women took zidovudine and T-cell counts were higher in women (40-35% of patients avail. alive survival time (date of HIV diagnosis to present) was longer in men than women (19-35%). **CONCLUSION:** The natural course of HIV infection in women is less well known than in HIV infected men. The lower mortality rate for women in this study may reflect later infection. Further investigation is required concerning the natural history of HIV infection in women.

A.548

LONG TERM FOLLOW-UP OF HOMOSEXUAL MEN WITH PERSISTENT LYMPHADENOPATHY: ATTACK RATE FOR AIDS.
Sankovitz, E., Gold, J.W.N., Campbell, S.W.,

Armstrong, D.
 Memorial Sloan-Kettering Cancer Center (MSKCC),
 New York, N.Y., U.S.A.

Objective: To determine the attack rate for AIDS in a cohort of homosexual men identified with lymphadenopathy between 1981-1983.
Methods: Cases of AIDS occurring in a previously described cohort (Medicine 1985; 64: 203-213.) followed at MSKCC were documented. Patients lost to follow-up (LF) were traced. **RESULTS:** The natural course of HIV infection in women is less well known than in HIV infected men. The lower mortality rate for women in this study may reflect later infection. Further investigation is required concerning the natural history of HIV infection in women.
Results: 25/41 LF were traced. 52 patients had been continuously followed. 3 HIV negative patients were excluded. 40 patients developed AIDS, 1 died without LF, 30 were alive without AIDS and 19 were LF. The attack rate for AIDS was 58.4% at 7 years.
Conclusion: The average annual attack rate for AIDS has been 8.3%/year in this population.

Publications



Epidémiologie et santé publique Epidemiology and Public Health

A.549

LACK OF ASSOCIATION BETWEEN FREQUENCY OF BLOOD DONATION AND SEROPOSITIVITY FOR HIV AND OTHER INFECTIONS: AN UNEXPECTED FINDING IN RIO DE JANEIRO - BRAZIL.

Marcia Filipe, C. F., Pereira, M. A., Osório, R. J., Martins, F. V. T., Jansen, W. C. M.* and Martins, C. M.*

* Federal University of Rio de Janeiro, Rio de Janeiro (RJ) Brazil.

Objective: Due to the importance of blood transmission in the diffusion of infectious disease in RD we have performed this study in order to better understand blood transmitted disease and frequency of blood donation.

Methods: 2,658 (non-paid) blood donors (16 to 60 years old) from the hemotransfusion center of our hospital, between January and June 1987 were submitted to VDRL, ELISA-ABOIT (HIV), Complement Fixation (Chagas) and RIA (HBsAg). An extensive questionnaire was submitted by a trained nurse in order to determine possible risk factors. Chi Square tests and confidence Limits were used for statistical analysis.

Results: The prevalence among blood donors (95% confidence interval) was found to be 4.4% for Lues (3.69-5.21); 0.56% for Chagas (0.29-0.83); 0.76 for HBsAg (0.39-1.12); 0.7% for HIV (0.41-1.01). There was no statistical significance between these infections was 5.6% (4.82-6.50).

Conclusions: The association between frequency of blood donation and frequency of HIV, Chagas and HBsAg, statistically significant results were found for Lues and blood donation frequency ($X^2=7.75$ p<0.001). We have also tested for possible association among these infections, in whom Chagas and HBsAg were statistically significant ($X^2=45.46$ p<0.001).

Conclusion: Our results show that the association between frequency of blood donation and reaction to most of the disease studied was very poor as it was for HIV, Chagas and blood transmitted disease. Findings about Chagas and HBsAg were

A.550

SEROEPIDEMIOLOGY OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 AND VIRAL HEPATITIS INFECTIONS IN NEW YORK CITY INTERVIEWED DRUG USERS (IVDU)

Brown, Laurence B. M.*; Kreek, M. J.†; Trepo, C. M.†; Chu, A.†; Hagan, D.†; Phillips, L. M.†; Johnson, F. V.†; Institute for Research and Treatment Corporation, Brooklyn, *Marlin Hospital Center, †Rochester University, New York

NY, USA; ††Faculté Alexis Carrel, Lyons, France.

Objective: To examine the behaviors associated with HIV-1 and viral hepatitis infection in IVDU enrolled in drug treatment. **Methods:** As a part of a larger HIV seroprevalence study in which a standardized questionnaire was administered, 50 subjects recruited from patients enrolled in drug treatment in NYC in 1987. Seru was obtained and analyzed for HIV-1 antibodies (using ELISA and Western blot assays) and for hepatitis B virus (HBV) and hepatitis delta virus (HDV) antibodies and antigens. **Results:** The HIV-1 infection rate was 54% and 86% of the subjects had at least one marker for HBV infection. Serological evidence of anti-HBc, anti-HBc, anti-HBc, HBsAg, and HBeAg was found in 86%, 70%, 38%, 25, and 0%, respectively of the sample. No evidence had serological evidence of HDV infection and HIV-1 was associated with anti-HBc (p=0.073) serostatus.

Conclusions: These findings are consistent with similar mechanisms of transmission between HIV-1 and HBV and suggest that a HBV vaccination program among IVDU enrolled in drug treatment would have significant public health benefits.

A.551

TRENDS IN AIDS INCIDENCE BASED ON ACTIVE SURVEILLANCE IN 12 MEDICAL SCHOOL AFFILIATED HOSPITALS

Lawrence Mervin A. and Schneider, D. J.

UMDNJ - New Jersey Medical School, New Jersey, U.S.A.

Objective: To demonstrate how trends in AIDS incidence can be assessed utilizing data obtained through active surveillance in 12 hospitals affiliated with the New Jersey Medical School.

Methods: Analyses will focus on descriptive methods for presenting data in tabular or graphic form. Survival analysis (with co-factors) will be used for comparing survival following diagnosis among population subgroups.

Results: Some of the major findings to be presented include:

1. Since 1981, 2218 confirmed adult cases of AIDS have been reported, including 738 males, 888 Black, 202 White, and 178 Hispanic.
2. After annual increases from 1981 to 1987, new cases declined in 1988.
3. The primary modes of transmission were: a) IV drug use (66%), b) homosexual/bisexual contact (16%), and c) (51) heterosexual contact (8%).
4. AIDS incidence among homosexual/bisexuals has decreased; heterosexually transmitted AIDS has increased, accounting for 1% of new cases in 1988.
5. Case fatality rates are highest among homosexual/bisexuals with AIDS.
6. Among homosexual/bisexuals with AIDS, the incidence of Cryptococcosis and Kaposi's sarcoma is increasing; HIV encephalopathy is increasing among heterosexuals with AIDS.

Conclusion: The application of descriptive methods to local surveillance data can be useful for projecting future treatment needs, targeting population subgroups for intervention, and identifying leads for further investigation.

A.552

CONVERSION FROM HIV TO HTLV

Patay, Olivier*, M'Go, M., Dolambert, A., Lafay, C.*

*Service des maladies infectieuses et tropicales, **Laboratoire de microbiologie, Villeneuve St Georges-France.

Objective: Rechercher la séroprévalence du HTLV chez des patients infectés par l'HIV.

Methods: 170 sérum positifs pour le VIH ont été testés pour le HTLV par ELISA. Les sérum appartenant à différents groupes à risque (hétérosexuels, homosexuels, post-transfusionnel, maternofœtal, et hétérosexuel). Les sérum positifs en ELISA ont été confirmés en Western Blot.

Results: 4 sérum ont été positifs en ELISA dont 2 confirmés par Western Blot.

Sexe	Age (ans)	Origine	Facteur	PI9	PI24	PI28	PI53
Patient 1	M	27	France	Touxonnisme	+	+	+
Patient 2	M	38	Senegal	Hétérosexuel	+	+	+
Patient 3	F	31	Congo	Hétérosexuel	+	+	+
Patient 4	F	31	Haïti	Hétérosexuel	+	+	+

Un seul patient toxiconome était positif et présentait par ailleurs une cirrhose post-hépatite B. Le conjoint de la patiente 4 est VIH+ mais HTLV-.

Conclusion: la séroprévalence ELISA HTLV apparait faible (2,4%) et survenant essentiellement chez des patients venant de zones de forte prévalence (Afrique, Caraïbes). Ces résultats apparaissent identiques à ceux d'autres études effectuées en région parisienne.

A.553

Human Immunodeficiency Infection in the Elderly: A Retrospective Analysis of 20 Patients

J. Thompson, M.D., J. Vetter, M.D.,

New Jersey Medical School and VA Hospital East Orange N.J., U.S.A.

Objective: To describe the clinical course of the 20 elderly patients who were diagnosed with HIV infection/seroconversion according to CDC criteria group 1-2. Their ages ranged from 65 to 82 years. The risk factors for the group included 10 men and 10 women. The risk factors for the men were 10 homosexual contacts, 10 heterosexual contacts.

Results: The mean age was 72 years. The mean duration of illness was 1.5 years.

Conclusions: The clinical course of HIV infection in the elderly is similar to that in the young. The clinical course of HIV infection in the elderly is similar to that in the young. The clinical course of HIV infection in the elderly is similar to that in the young. The clinical course of HIV infection in the elderly is similar to that in the young. The clinical course of HIV infection in the elderly is similar to that in the young. The clinical course of HIV infection in the elderly is similar to that in the young. The clinical course of HIV infection in the elderly is similar to that in the young. The clinical course of HIV infection in the elderly is similar to that in the young. The clinical course of HIV infection in the elderly is similar to that in the young. The clinical course of HIV infection in the elderly is similar to that in the young.

A.554

HIV INFECTION IN ANALYTICAL AUTOPSESIES

Barcellos, D.D., Buchs, L.M., Gutdugli, R.***

***LIRA, LU*

*Centro de Aperfeiçoamento e Tratamento da Secretaria

de Estado de São Paulo; ** Faculdade de Saúde Pública,

Universidade de São Paulo; *** Instituto Médico Legal - São Paulo

Brazil.

Objective: To describe the clinical course of the 20 elderly patients who were diagnosed with HIV infection/seroconversion according to CDC criteria group 1-2. Their ages ranged from 65 to 82 years. The risk factors for the group included 10 men and 10 women. The risk factors for the men were 10 homosexual contacts, 10 heterosexual contacts.

Results: The mean age was 72 years. The mean duration of illness was 1.5 years.

Conclusions: The clinical course of HIV infection in the elderly is similar to that in the young. The clinical course of HIV infection in the elderly is similar to that in the young. The clinical course of HIV infection in the elderly is similar to that in the young. The clinical course of HIV infection in the elderly is similar to that in the young. The clinical course of HIV infection in the elderly is similar to that in the young. The clinical course of HIV infection in the elderly is similar to that in the young. The clinical course of HIV infection in the elderly is similar to that in the young. The clinical course of HIV infection in the elderly is similar to that in the young. The clinical course of HIV infection in the elderly is similar to that in the young. The clinical course of HIV infection in the elderly is similar to that in the young.

Conclusion: The clinical course of HIV infection in the elderly is similar to that in the young. The clinical course of HIV infection in the elderly is similar to that in the young. The clinical course of HIV infection in the elderly is similar to that in the young. The clinical course of HIV infection in the elderly is similar to that in the young. The clinical course of HIV infection in the elderly is similar to that in the young. The clinical course of HIV infection in the elderly is similar to that in the young. The clinical course of HIV infection in the elderly is similar to that in the young. The clinical course of HIV infection in the elderly is similar to that in the young. The clinical course of HIV infection in the elderly is similar to that in the young. The clinical course of HIV infection in the elderly is similar to that in the young.

Publications

A.573

FIRST CASE OF HIV/HIV2 INFECTION IN CAMEROON

KAPFLE, L., ZEING, L., NGU, A.*, DUATINA, A.**,
 MONY-LORE, M.***, NALA, J.***, NDI, J.***, NDI,
 *NATIONAL AIDS CONTROL YAOUCHE, CAMEROON ** UNIVERSITY TEACHING HOSPITAL
 YAOUCHE, CAMEROON *** CENTRAL HOSPITAL, ABINDJO, COTE D'IVOIRE
 *** CENTRAL HOSPITAL, YAOUCHE, CAMEROON.

Objective: To report the first case of HIV1 and HIV2 infection diagnosed in a Cameroonian patient. 30 till June 1989, 5 000 sera were screened for HIV2 antibodies and all were found negative.

Methods: Systematic screening of patients referred to the university teaching hospital, using Elisa test (Detecting HIV1 and HIV2) and Western Blot (Upstart and Diagnostic Pasteur) for confirmation.

Results: A 28 years old patient referred for prolong fever, weight loss and oral candidiasis was recently found HIV1 and HIV2 positive. Looking at the past medical history, the patient had frequent West African.

Conclusion: In this case study, we should start thinking about the presence of HIV2 in Cameroon, considering the frequent movement of people between neighbouring countries.

A.574

HIV SPREAD IN PROSTITUTE POPULATION IN TOULOUSE (FRANCE)

Raye-Bengeali C., Paul, G., CLINICAL FINDINGS OF SEROPositives.
 *Laboratoire de Virologie, CHU Purpan;
 **Service de Dermatologie, CH Le Drapeau, Toulouse, FRANCE.

Objective: To assess the risk of contamination through prostitution (male or female) to our city.
Methods: We systematically screened anti HIV-1 antibodies in 97 female prostitutes (50 coming from Ghana) and 16 transvestites or transsexuals, regularly coming at the Venereal Disease Centre since May 1989, to January 1990. Screenings were realized using 2 immunoenzymatic techniques (Abbott and Wellcome). All positive sera were confirmed by the Western-blot assay (Du Pont De Nemours).
Results: 5 of the 97 prostitutes were seropositive: we screened the first one in 1985, two others in 1986, one in 1987, and one who seroconverted in 1989. But 2 of these intravenous drug abusers, so it was not possible to incriminate to sexual transmission with certainty. None of the Ghanese was seropositive. Among the transvestites and transsexuals, one patient seroconverted in 1989, and 3 patients were seropositive (2 in 1986 and 1 in 1987). For these patients drug addiction is unknown.

Conclusion: The prostitute population of Toulouse seems to be relatively free of HIV-1 contamination. But these results do not entirely reflect the true situation as a marginal prostitution also exists with people who are generally not subject to any control. Although these results are relatively reassuring, educational programs must be undertaken to prevent the spread of the disease, since contamination through prostitution has been shown to be a real risk.

A.575

THE NEW CASE DEFINITION CRITERIA, ITS IMPACT ON EPIDEMIOLOGICAL SURVEILLANCE IN SPAIN. Dr. Andrés Balboa*, Tello, Odorico**, Navarro, M. José**.

* Instituto General de Estadística y Demografía, Madrid, Spain.

** Instituto General de Estadística y Demografía, Madrid, Spain.

Cumulative AIDS cases in Spain in 1988 or 1989 were 2168. Modification of case definition criteria for reporting AIDS were undertaken in August 1987 by CDC, accepted by WHO in September and applied by the European countries since January 1st 1989. We have studied the impact of these new criteria of case definition among cases diagnosed in Spain since 1981. Since January 1st 1989 a 70.29% case increase has been detected applying the new criteria of case definition in respect to the old ones. By the new criteria the retrospective revision of cases diagnosed before this last date classified as no AIDS by the old criteria seems a 12.15% increase in 1984, 10.76% in 1985, 13.98% in 1986 and 30.13% in 1987. This impact is clearly higher among YVD (47,38%) and still 20.13% in 1987. This impact is also different by pathological and transmission categories. Equal serones in increased 1.05% in the heterosexual transmission category and 4.76% among the YVD. Nevertheless, a 22.56% increase associated to opportunistic infections is detected in the heterosexual transmission (500% increase associated to extrapulmonary tuberculosis), 20.29% among YVD (7,000% increase associated to tuberculosis extrapulmonary), a 10.00% in the heterosexual transmission category and 47.22% among children born from mothers at risk.

Conclusions: 1) Different impact is observed in different country areas in respect to pathological background and epidemiological pattern. 2) The relevance of these results is important for epidemiological analysis, trends and predictions. 3) This different impact should be considered by Public Health strategies and policies on people's perception about the case number increase.

A.576

PREVALENCE OF DIFFERENT RETROVIRUS IN SPANISH INTRAVENOUS DRUG

USERS. CONTRERAS C., GARCÍA SÁIZ A., VILHOTTST R., VARELA J.M., PEREZ ALVAREZ L., NESTER N., Instituto de Salud Carlos III, Madrid, Spain.

OBJECTIVE: To analyse the seroprevalence of HIV-2 and HIV-1 in Spanish intravenous drug users (IVDA) and the clinical findings in seropositive to HIV-2 and HIV-1 infections. We determine as well the incidence of coinfection with other infectious agents.

METHODS: - Sera collected from 2,269 IVDA's were tested (1,088 in 1987 and 1,181 in 1988). The presence of anti-HIV-1, -HIV-2, -HIV-1/2 antibodies was results by ELISA. IFA and WB was used as a confirmatory test. - Antigen ELISA test was used for HCV anti-HCV antigen detection.

RESULTS: - The prevalence of HIV-1 was 64.7% in 1987 and 61.8% in 1988. Data collection are ongoing and analysis suggests us to date that a 70% of seropositives still asymptomatic and a 30% shows some pathology related with HIV infection. We are currently performing the seroprevalence of anti-HIV-2 and HIV-1 in a group of IVDA's with statistic significance. A 8% show HBsAg and a 2.5% active syphilis.

CONCLUSIONS: - The prevalence rate, about 60% during 1987 and 1,988 and similar to previous years, is high enough to indicate a serious problem of HIV infection among the Spanish drug users. Very preliminary results indicate no incidence of HIV-2 and HIV-1 in this IVDA population.

A.577

CONTROL OF HIV TRANSMISSION IN THE NATIONAL BLOOD BANK IN MALI

M. K. Malin, A. Traore, A. Guindo, O. Fafara, Comité de lutte scientifique et technique contre le SIDA, Bamako, Mali.

Since the beginning of the national AIDS program in Mali in 1987, the national blood bank was one of the strategic points for detection, prevention of the transmission of the human retrovirus and the follow-up of the prevalence of HIV infection among blood donors. Blood donation was performed from pregnant women, young military recruits and students. Consecutively in 1987 a total of 1140 blood samples and in 1988 a number of 1841 were tested using "Rapid Elisa test" to detect HIV1 and HIV2.

The positive samples were then confirmed by Western Blot.

Results: A steady increase in the seroprevalence of HIV infection was observed. Among 1140 sera in 1987, sixteen (1.9 + 1.6%) and 1988 out of 1841 sera, seventy six (7% + 4.1%) were found positive. This represent a total increase of 256.25 in 100 sera.

Conclusion: In both years the studied cohort was not randomized and is not representative of the Malian population. Although in the country the infection rate is generally low, an evidence of rapid expansion of the epidemic is demonstrated in this study. Health dispositions undertaken for transfusion of safe blood only, a large restructuration program has started which intend to improve the basis and conservation of blood.

Thus the efforts of the national AIDS committee to prevent the transmission of the retrovirus should be actively reinforced.

A.578

THE NEW CASE DEFINITION CRITERIA, ITS IMPACT ON EPIDEMIOLOGICAL SURVEILLANCE

IN SPAIN. Dr. Andrés Balboa*, Tello, Odorico**, Navarro, M. José**.

* Instituto General de Estadística y Demografía, Madrid, Spain.

** Instituto General de Estadística y Demografía, Madrid, Spain.

Cumulative AIDS cases in Spain in 1988 or 1989 were 2168. Modification of case definition criteria for reporting AIDS were undertaken in August 1987 by CDC, accepted by WHO in September and applied by the European countries since January 1st 1989. We have studied the impact of these new criteria of case definition among cases diagnosed in Spain since 1981. Since January 1st 1989 a 70.29% case increase has been detected applying the new criteria of case definition in respect to the old ones. By the new criteria the retrospective revision of cases diagnosed before this last date classified as no AIDS by the old criteria seems a 12.15% increase in 1984, 10.76% in 1985, 13.98% in 1986 and 30.13% in 1987. This impact is also higher among YVD (47,38%) and still 20.13% in 1987. This impact is also different by pathological and transmission categories. Equal serones in increased 1.05% in the heterosexual transmission category and 4.76% among the YVD. Nevertheless, a 22.56% increase associated to opportunistic infections is detected in the heterosexual transmission (500% increase associated to extrapulmonary tuberculosis), 20.29% among YVD (7,000% increase associated to tuberculosis extrapulmonary), a 10.00% in the heterosexual transmission category and 47.22% among children born from mothers at risk.

Conclusions: 1) Different impact is observed in different country areas in respect to pathological background and epidemiological pattern. 2) The relevance of these results is important for epidemiological analysis, trends and predictions. 3) This different impact should be considered by Public Health strategies and policies on people's perception about the case number increase.

Épidémiologie et santé publique
Epidemiology and Public Health

Publications

A.579

AIDS IN THE NORDIC COUNTRIES - PREVENTION AND CONTROL.
Kastholm-Christensen, B.*; Bjferner, J.**; Eriksson, S.***;
Kramm, A.***

*Danish Institute for Health and Nursing Research, Copenhagen, Denmark, **Institute of Social Medicine, Copenhagen, Denmark, ***Nordic School of Public Health, Gteborg, Sweden.

Psychological, social, administrative and political aspects of AIDS in the Nordic countries have been reviewed by the Nordic School of Public Health. As expected, the countries appear quite similar. Specified AIDS-commissions have been established, closely linked to governments. Specific target groups like homosexuals have been involved in preventive activities. Health education has been depicted the most important issue to combat AIDS. Large campaigns have been launched directed to the general public and towards groups like school children and health personnel. Knowledge about AIDS has been seen to be generally good and improving. Systematic knowledge about sexual behaviour, however, is virtually nonexistent. Donated blood and organs are completely tested. Anyone person who has a test and remain anonymous except in Iceland where the person has to identify himself at the test site, but is reported by code.

Treatment and care is similar in the Nordic countries basically handled by the health authorities. Voluntary and private organizations are, however, more important than generally in the health sector. Differences exist: Legislation. In Sweden and Iceland STD-infection is under the law for sexually transmitted diseases. In Finland, it is a notifiable disease while there are no specific legislation concerning HIV-infection in Denmark and Norway.

A.581

Evaluation of a multidisciplinary HIV diagnosis and management centre. Bywater, Australia.
Muriel, A.†; Stewart, Burditt, F.,†; Magier, L.; Osis, J.
Alton Street AIDS Centre, Spence Hospital, Sydney, Australia.

Objective: To provide a multidisciplinary diagnosis, consultancy care and early intervention service for persons infected with HIV. Method: The Alton Street AIDS Centre, established in March 1985, is staffed by 45 full time professionals and support staff including doctors, nurses, counsellors and research officers. The Centre provides free and confidential case and post-test counselling, HIV antibody testing, medical management of HIV related signs and symptoms, referral and nutritional support groups. A computer based medical record system was developed and implementation of HIV related signs and symptoms, referral and nutritional support risk education programmes and early intervention drug trials.

Results: To the end of December 1986 a total of 1730 clients had been listed at the Centre, 859 male, 2259 female, 28 heterosexual or unknown, 1119 intravenous drug users and 401 prostitutes. Of the total 1440 (83%) were diagnosed as HIV antibody positive, 1385 (96%) were homosexual or bisexual, 36 (5.6%) of the heterosexual intravenous drug users and 7 (1.5%) of blood transfusion recipients tested were infected. Over 70% of cases initially diagnosed by private physicians.

Conclusion: The comprehensive and specialised services provided by the Centre have resulted in it becoming the major referral clinic for management of early HIV infection. The Centre provides an early diagnosis and management model that facilitates effective implementation and evaluation of intervention strategies aimed at slowing disease progression.

A.583

LYMPHADENOPATHY IS A WEAK PREDICTOR OF CLINICAL OUTCOME IN HIV INFECTION
Muller, S.†; Spert, Anderson, R.***; Boyce, R.***; Shihashi, S.***
*Children's Hospital, Francisco, CA, USA; **PWRIC, Inc., San Francisco, CA, USA; ***University of California, Berkeley, CA, USA.

Objective: To determine the relationship of lymphadenopathy to clinical outcome in HIV infection. Methods: Lymphadenopathy was measured by trained examiners in a population-based sample of 385 men from the San Francisco Men's Health Study who were seropositive at entry (1982-1983). The incidence of symptoms of progressive HIV infection and of AIDS were determined at 42 month's follow-up.

Results: The presence of ≥ 2 serological nodes ≥ 1 cm and the presence of total peripheral lymphoid mass ≥ 10 g were both associated with slight but not statistically significant increased risk of developing both HIV-related symptoms and AIDS.

Conclusion: Lymphadenopathy measured in two ways predicts future development of clinical illness or AIDS only weakly in HIV infection.

Risk of Symptoms	Odds Ratio (95% CI)	Odds Ratio (95% CI)
< 2 nodes	11/232 (31%)	14/78 (14%)
≥ 2 nodes	11/232 (5%)	6/285 (2%)
≥ 10 g	38/159 (49%)	38/152 (25%)
≥ 10 cm	31/47 (66%)	18/64 (28%)

In a multiple regression analysis controlling for CD4+, beta-2 microglobulin and symptoms, lymphadenopathy was not independently related to AIDS (p=0.7).

Conclusion: Lymphadenopathy measured in two ways predicts future development of clinical illness or AIDS only weakly in HIV infection.

A.580

RISK PROFILE FOR HIV INFECTION AT A SEXUALLY TRANSMITTED DISEASE CLINIC.
Bridson, Gary J.*; LaCombe, D.***; Byrnes, D.***; Saint Michael's Medical Center, **East Orange Health Department, Newark, N.J., USA.

Objective: To determine HIV risk profile of HIV infected individuals in an STD clinic population, and comparing STDs at time of diagnosis.

Methods: One hundred and forty patients were counselled and tested for HIV antibody, at an inner city STD clinic over a 7 month period. Thirteen (9.3%) patients tested positive for HIV antibody by ELISA and Western blot. Due to anonymous testing only 6 patients could be identified for post testing counselling and follow up.

Results: All 6 patients were males, mean age 29.2 (±4.5SD) years. Risk factors identified were: Intravenous Drug User, 5 (83.3%) patients; Homosexuals, 4 (31.5%) patients; Sex with prostitute, 2 (15.4%) patients; Intravenous Drug User and Homosexual, 1 (7.7%) patient; Bisection, 1 (7.7%). Four homosexuals had syphilis with an RPR titer ranging between 1: 8-4096, 1 patient had a rising RPR titer despite treatment with 1.8 Penicillin (total 7.2 million units), 3/6 patients had evidence of an ulcer or skin breakdown at the time of diagnosis.

Conclusion: The above data suggest that the majority of patients identified with HIV infection in an STD setting are still within a recognized high risk group. However sexual behaviour patterns need to be modified in order to limit heterosexual transmission. Patients with genital area skin breakdown appear to particularly be at increased risk for acquiring syphilis and HIV infection.

A.582

VIRAL HEPATITIS B(OR)AND AIDS IN RISK COMMUNITIES IN THE NORTH-EAST OF ARGENTINA(NEA)
Pérez, Oscar**†; Biglione, J.***; Fernández, I.†; Galindez, M.***; Jannini, I.***

*Centro de Estudios en Salud Pública, UNRA**Comité Prevención SIDA, Rosario, Santa Fe, Argentina.

Objective: To study the attack rate of HBV and HIV in drug addicts (IVDA) and homosexuals (HS), compared with the general population as per samples collected from voluntary blood donors (VBD). Methods: Studies were made on samples from communities seeking medical advice in response to CPDMS appeal. HBV-carriers were differentiated thru ELISA/HBsg and previously infected ones, thru ELISA anti-HBc. All sera were searched for HIV thru ELISA and confirmed thru immunoelectrotransference (WB).

Results: Community HIV (%) HBsAg(%) δ Anti-HBc(%)
 IVDA (+) (25%) 32 (8.6) 251 (62)
 VBD (-) 37 46 (16.6) 211 60
 HS (+) (43) 3 (7) 32 (75)
 VBD (-) 4 (108) 28 (7) 306 (75)
 TOTAL 451 31 (7) 338 (75)

Conclusion: HBV-infection is 1 to 8 times more frequent in the above risk populations than among VBD in the NEA. HBV attack rate is higher among HS than among IVDA. HBV-chronic carriers were found more often among IVDA than among HS. There are more HBV-chronic carriers among HIV-IVDA than among HIV-HS. If IVDA samples are received in blood banks as VBD ones, HBV transmission risk will grow accordingly, unless adequate controls are implemented. HIV presence is not statistically significant to determine HBV presence in each population.

A.584

DIAGNOSIS AND MORTALITY TRENDS IN AN OUTPATIENT AIDS CLINIC
Kings, Craig; Kelly, J.; Martz, C.

*New York Hospital Center/Community Health Project NY, NY, USA.

Objective: To review trends in diseases of diagnosis and death in a community based primary care AIDS clinic population as a basis for improved management. Methods: All cases (163) of AIDS diagnosed from 1/1/86 to 1/1/89 in a primary care out-patient AIDS clinic were reviewed for index diagnosis, year of diagnosis and diagnosis of death and diagnosis of death.

Results: Trends in diseases of diagnosis and diseases of death over three years are as follows:

Disease of Diagnosis		Disease of Death	
1986	1987	1986	1987
PCP	21(41%)	21(40%)	15(46%)
KS	22(43%)	17(32%)	13(27%)
Other	81(85%)	15(28%)	16(32%)

Conclusion: With the advent of PCP prophylaxis and improved management, mortality from PCP has decreased while the incidence of PCP has not changed significantly in our clinic population. Early aggressive PCP prophylaxis may reduce the incidence of PCP as an index diagnosis. Mortality from pulmonary KS has increased, although KS has been less frequently diagnosed overall in these patients. The increasing number of AIDS deaths attributed to pulmonary disease suggests that one should be alert to subgroups who benefit from earlier diagnosis and treatment. Of special concern are the increasing deaths from unknown causes. Perhaps more aggressive work-up might have elicited a definite diagnosis amenable to treatment, e.g. extrapulmonary pneumocystis.

A.591 ELECTRONIC REPORTING SYSTEM FOR AIDS SURVEILLANCE IN CANADA
 Hault, Peggy; Klemis, K. Federal Centre for AIDS, Health Protection Branch, Ottawa, Ontario, Canada.

Objectif: To describe the development of an electronic system for national reporting of AIDS surveillance data.

Methods: AIDS is a reportable condition in all provinces and territories in Canada. Through collaborative efforts between the provincial/territorial Ministries of Health and National Health and Welfare, a systematic method of reporting AIDS cases was established using a standardized case report form.

Results: The case report form was developed to collect demographic information, behavioural risk factors, clinical, and laboratory data. Completed forms are sent to the provincial/territorial Ministries of Health for evaluation and are then forwarded to the Federal Centre for AIDS. In 1986 the provinces/territories were introduced to an electronic bulletin board system, designed to facilitate data collection and dissemination. They were provided with custom computer software, and hardware where needed, to standardize the method of reporting cases electronically. Training workshops were provided to familiarize key groups with software and the process of transmitting data electronically.

Conclusions: This standardized method of reporting provides rapid collection of data and dissemination of reports. Effective communication between key groups plays an integral part in the success of this and other surveillance systems.

A.592

A.593 AN UPDATE ON HIV-SEROPREVALENCE STUDIES
 IN THE NETHERLANDS.
 Conyn, L.H.; Nieuwling B.; Jager, J.C.
 Natl Inst Publ Hlth Rivm (1991), Bilthoven, the Netherlands.

Currently available data on HIV seroprevalence among selected groups in the Netherlands are inadequate to assess the spread of the epidemic among homosexual men, intravenous drug users or the population-at-large. So far, only volunteer studies have been conducted. Additional surveys are required: 1) to establish a base-line of infection levels in selected groups; 2) for public health management and policy; and 3) for serological and prediction of the course of the epidemic.

Various options for conducting such surveys are discussed, and mixing blood collections and hospital samples are identified. Anonymous testing of some of these blood samples is proposed to minimize the self-selection bias which renders studies comprised of voluntary participants uninterpretable. Some legal and ethical objections have been raised that so far have prevented anonymous testing in the Netherlands. There is no general agreement yet that anonymous testing is needed to collect information that otherwise would not be available, and that such testing is justifiable if anonymity of the data is assured. In the serologic surveillance studies with informed consent will be considered in pre-selected institutions, to document whether compliance is high enough for valid information to be made from such studies.

A.595 LA DEMANDE D'EXAMEN SEROLOGIQUE HIV
 CHEZ LE MÉDECIN GÉNÉRALISTE
 V. VAN CASTRIEN, A. STROOBANT
 INSTITUT D'HYGIENE ET D'ÉPIDÉMIOLOGIE, BRUXELLES, BELGIQUE

Depuis le mois de mai 1988, la demande pour un test HIV a été introduite dans le programme d'enregistrement de morbidité de 150 médecins généralistes sensationnels constituant un réseau représentatif des médecins généralistes de Belgique. L'objectif est d'évaluer dans quelle mesure le médecin généraliste est confronté avec le problème du SIDA, de surveiller l'évolution de la demande au cours des années et de caractériser les situations dans lesquelles cette demande est formulée.

L'enregistrement est anonyme et comprend les données suivantes : Age et sexe, motif de la demande, comportement à risque éventuel, test HIV effectué ou non.

Les résultats des premiers mois de l'enregistrement montrent que moins d'une demande par mois et par médecin (0,8) est actuellement rencontrée. Près de 70% des femmes qui demandent un test ne présentent aucun facteur de risque alors que la proportion n'est que de 44% chez les hommes. Le taux de positivité des tests demandés est de l'ordre de 1,8%. Les résultats sont comparés avec ceux qui ont été enregistrés en France et en Suisse par des réseaux comparables.

A.594 PREVALENCE OF HIV-1 ANTIBODY AMONG GAY MEN IN THE U.K.: DIFFERENCES BETWEEN CLINIC ATTENDERS AND NON-ATTENDERS.
 Dallas, Robert; Cowan, J.F.S.; Bohannon, T.J.;*** and Suberland, S.*** Project SIDA, South West Polytechnic, London, U.K.; **University of Wales, Cardiff, U.K.; ***King's College Hospital, London, U.K.; ****Ulrich Hill, London, U.K.

Objectif: To estimate the prevalence of HIV-1 antibody in the homosexual active male population of England and Wales and, bearing in mind that current estimates of prevalence and possible spread are based on those attending STD clinics, to estimate the differences between clinic attenders and non-attenders.

Methods: 525 gay and bisexual men in two centres in the U.K., London and South Wales, were recruited using a variety of methods and interviewed in a non-clinic setting. Blood samples were reinterviewed from 346 (66%) of these and tested for HIV-1 antibody using the Wallace competitive assay. Positives were confirmed in the first instance with the Abbott recombinant assay.

Results: In London, 19 (9.4%) of the bloods tested positive to HIV-1 antibody, and in South Wales, 5 (1.4%). When allowance is made for verifiable test results from those who did not provide blood samples, these rates rise to 13.4% and 3.9% respectively. The proportion of positive results among those attending clinics was 13.4% in London and 7.4% in South Wales while the proportions among non-clinic attenders were 5.7% and 1.8% in the two sites. The higher rates among the clinic attenders are comparable with those obtained in clinic studies in comparable areas of the U.K.

Conclusions: Rates of seroprevalence of HIV-1 among gay and bisexual men based on bloods collected at clinics appear to be overestimates.

A.596

Publications

A.597

EPIDEMIOLOGICAL, POLICY AND PLANNING ISSUES IN HIV

DECADE IN A BRITISH HEALTH REGION: A REVIEW
 Zeki, Ambrose* and Kearns, William. North East Thames Regional Health Authority and *Department of Community Medicine, University College and Middlesex School of Medicine, London, England.

Objective: To describe the epidemiological, policy and health services planning issues in relation to HIV disease within a region of the British National Health Service. **Methods:** Data on the regional epidemiology of HIV disease and the distribution of services were reviewed and the strategic policy and planning issues identified.

Results: The North East Thames is the British health region second most affected by AIDS and has consistently contributed approximately 18% of all cases of AIDS diagnosed in the United Kingdom. Analysis of the geographic distribution of people with AIDS by where they received medical care and where the ill reveals that a few central London districts have attracted a disproportionate number of people with AIDS. These central London districts would be unable to provide care for the vast majority of people with AIDS in the region. The Regional Health Authority has developed a policy for service development based upon the available epidemiological information. The strategy includes upgrading geriatric medicine and problem drug services throughout the region, providing care as close as possible to where people live and establishing an appropriate balance between hospital, home and non-home non-hospital services. All districts have been funded to undertake educational, training, counselling and health promotion activities. Limitations within this approach to planning services are identified.

Conclusion: The British National Health Service provides the potential for developing coordinated services of a high standard on a regional basis.

A.599

DECONTAMINATION OF AN HIV CONTAMINATED CUP MARKER:

COLEMAN, JANE, LISKAY, J., BOCHNER, R.L., JR., SULLIVAN, R.L., LANGFOLD, A.J., MINKOFF, L.*
 *University of Maryland, Baltimore, Maryland; *Biophysics Institute, Research Triangle Park, N.C.; **Duke University, Durham, N.C.

OBJECTIVE: Markants are used widely for cardiopulmonary resuscitation (CPR) training. Simulating a "miss scenario", a markant was contaminated in different experiments with either cell-free or cell associated HIV-1. Recommended decontamination procedures were compared by maintaining a wet surface for 10 or 5 sec rather than the recommended 30 sec. The experiment also addressed the relative contributions of chemical disinfection and the mechanical action of wiping.

METHOD: The markant was contaminated with either a virus saturated swab containing cell-free HIV-1 (10^{7.0} infectious unit/ml) or with a pipette containing cell associated HIV-1 (10^{6.0} infectious unit/ml). The decontamination procedure consisted of 70% isopropyl alcohol sponge or spray or dry 4x4 sponge for 10 or 5 sec, drying time of 30 sec and 5 sec of wiping the surface. After each maneuver a sample from the markant surface was obtained, cultured in AIDS or CEM cells and the presence of virus determined by reverse transcriptase assay and by quantitative p24 antigen detection (Eitest). **RESULTS:** HIV-1 was detected after markant contamination but not after disinfection with alcohol for 10 or 5 sec. HIV-1 was detected both after initial contamination and after wiping with a dry 4x4 sterile sponge.

CONCLUSIONS: Decontamination of an HIV-1 cell free or cell associated contaminated cup markant was achieved in 5 sec with either a 70% isopropyl alcohol sponge or spray, but not using only a dry 4x4 sponge demonstrating the importance of chemical disinfection.

A.601

RESISTANCE OF HIV IMMUNODIFFUSION VIRUS TO DISINFECTANTS AND UV RADIATION

Patel, Hassan*, D. Gu*, H.J. Jeffrey**, J.V. Collins*.
 *Brompton, **St. Stephen's and **St. Mary's, H. Hospitals, London.

Previous reports that HIV is susceptible to disinfectants are based on suspension tests. We tested 70% alcohol (100% Alcohol: 100% Final concentration ethanol 63.8%, methanol 3.5%, water 28.55 v/v), acetone, 1% and 2% alkaline glutaraldehyde (Gidec, burgundy lid) against HIV dried on a surface. The following inocula were dried in triplicate on to sterile coverslips and immersed in disinfectant: 1) Cell-free HIV in 10% serum at 10^{7.0} TCID₅₀ (TCID₅₀ = the highest dilution of virus infective tissue culture viruses with 7 days); 2) 10^{7.0} HIV-infected T-lymphocytes; 3) Cell-free HIV (10^{7.0} TCID₅₀) in neat serum. At timed intervals disinfectant was rinsed off with PBS-A. Cover slips were cultured for 23 days in RPMI with CD366 cells and examined for viraemia and HIV antigens; positive cultures were passaged into fresh cultures to confirm infectivity. Disinfectant-free and toxicity controls were performed.

Results: 70% alcohol failed to inactivate cell-free or cell-associated HIV within 20 minutes. Acetone, tested only against cell-associated inocula, failed to inactivate HIV within 40 minutes. 2% and 1% alkaline glutaraldehyde inactivated cell-free HIV within 2 minutes. 2% and 1% alkaline glutaraldehyde presence of neat serum 2% glutaraldehyde remained effective; it failed to inactivate HIV within 15 minutes. **Conclusion:** Acetone and 2% and 1% alcohol failed to kill HIV surfaces within 40 and 20 minutes respectively; serum greatly reduced the efficacy of 1% glutaraldehyde.

Epidémiologie et santé publique
Epidemiology and Public Health

A.598

OUTREACH TO IV DRUG USERS AND SEX PARTNERS:

SATISFACTION AND DISSATISFACTION OF OUTREACH WORKERS
 Bull, C., Dema, S., Green, F., Saffer, M., Friedman, S.R., Tross, S., et al.
 National Drug Research Inc., New York, New York, U.S.A.

Objective: To assess workers who widely used for AIDS outreach to IV drug users and their partners. Our objective is to describe the characteristics of outreach workers and to provide AIDS prevention and education information to increase their use and their partners in New York City, and to detail areas of the satisfaction and dissatisfaction they encounter as employees.

Methods: A total of 60 outreach workers were employed by National Drug Research Inc. during 1986-1988 to provide AIDS risk reduction information to IV drug users and their sex partners. Information was available through interviews with the 27 outreach workers currently employed by the agency and a review of agency records for all outreach workers.
Results: Of the 60 workers, approximately 60% were male and their ethnic composition was 50% Black, 39% Hispanic and 1% White. Most outreach workers were ex-addicts, recruited from various treatment modalities. Staff turnover at the end of one year of employment was 20%. 1% of the 27 workers hired in 1986 and 1987, more than half were no longer employed by the organization within one year after their hiring date. Information on the satisfactions and dissatisfactions encountered by these employees is being collected and the data are being analyzed focusing on organizations (i.e., career path available) and individual issues (e.g., burnout).

Conclusion: The relatively high turnover rate of these employees indicates that further study of the satisfactions and dissatisfactions experienced by these workers is needed, so that measures to address the dissatisfactions can be incorporated in employee policies.

A.600

RESISTANCE OF HIV-1 BY A NEW ALGAEKAT MODEL

Geiger, Edgar*, Tenford V. Linn*, Hirsch R.S.,*
 R.T.C.* Infectious Disease Unit, *Department of Orthopedic Surgery and Rehabilitation Medicine, Massachusetts General Hospital, Boston, MA, USA

Objective: To study the feasibility of inactivating HIV-1 in bone graft material by gamma irradiation.

Methods: Serial dilutions of HIV-1 (10^{7.0}-10^{8.0} TCID₅₀/ml) were subjected to gamma irradiation under conditions simulating those within a bone allograft. Irradiated and control specimens were cultured on 89 cells which were subsequently evaluated for cytopathic effect and p24 antigen production. **Results:** High titers of virus (10^{7.0} TCID₅₀/ml) were not inactivated by gamma irradiation up to 0.5 Mrad. p24 antigen values (cpm/ml) for lower titers irradiated (B) and control (C) virus exposed to 0.4 Mrad is shown:

10 ⁶ TCID ₅₀ /ml	(B/C)	Mrad	Mrad	Mrad	Mrad
10 ⁶	0/0	0/0	0/0	0/0	0/0
10 ⁷	0/0	0/0	0/36	0/36	0/500
10 ⁸	0/0	0/0	0/3	11/1.6	362/500
10 ⁹	-	0/0	11/43	4,3/42.1	>500/500
10 ¹⁰	-	0/0	21/0.5	4,3/350	>500/500

Cytopathic effect was observed in all cultures in which p24 antigen production was detected.

Conclusion: Doses of gamma irradiation previously recommended to inactivate many viruses including HIV-1 appear inadequate in this model. Higher doses or alternate methods of ensuring allograft sterility with respect to HIV-1 may be required.

A.602

POTENTIAL FOR HIV TRANSMISSION VIA BLOOD GLUCOSE MONITORING DEVICES

Realt, P., Brennan, Constance*, Murphy, V., Norton, T.
 University of Washington, Harborview Medical Center, Seattle, Washington, USA

We are following a 43 year old HIV-positive insulin-dependent diabetic woman whose only known exposure to HIV was from vaginal intercourse with her HIV-positive bisexual husband. The woman indicated to us that since 1981 she has screened family members, friends, and relatives for diabetes by performing fingerstick glucose determinations on them. She would routinely use a single disposable lancet to draw blood from several individuals in rapid succession, after pricking herself, without wiping the lancet. Four family members who had shared a lancet with our patient during the past year have been screened and are HIV-negative.

We found that packaging material of the lancets used by our patient contain no warning labels against sharing lancets. A local survey of 3 brands of lancets and 3 brands of lancet holders indicated that only 1 brand had labels warning about potential transmission of diseases with the device. We also found no warning labels on some brands of insulin syringes. Diabetic equipment such as lancets and syringes represent a potential route of transmission for HIV and other blood-borne pathogens. We speculate that the practice of sharing used lancets as demonstrated by our patient, a well-educated middle socio-economic class woman, may be more common among diabetics than is generally recognized. Physicians and diabetic educators should educate their diabetic patients about the proper use of lancets and syringes and appropriate warning labels should be required on these products.

A.627

A COMMUNITY-BASED HIV ASSESSMENT UNIT:
HOW DOES IT WORK?

Mozsan, Alizah, Davis L, Irani P., Ramis C.M., Norris B., Burzewski M, et al. - Woodhull Medical & Menal Health Center, Brooklyn, NY, USA

Objective: To describe how patients at high-risk for HIV infection are evaluated and treated by an interdisciplinary team providing a community-based HIV assessment unit.

Methods & Results: Woodhull Medical & Menal Health Center, a division of NYC Health and Hospitals Corporation, is a large municipal hospital serving an impoverished, medically underserved, black and latino community. Woodhull Family Health Center has been designated by Woodhull as the community-based facility for outreach, screening, evaluation and treatment of HIV-related diseases. The majority of high-risk patients are IV drug users and their sexual partners. An interdisciplinary team of providers, including clerks, administrators, nurses, physicians, physician assistants, psychologists, and social workers, has been trained to meet the needs of this community. The roles of Team members and their interactions with patients will be discussed. An approach to the medical and psychosocial interventions provided to high-risk and HIV-infected patients will be presented. Emphasis will be placed on the medical protocols designed for a community-based setting. The process will be illustrated by following theoretical at-risk patients from initial referral to staff involvement and treatment.

Conclusion: A community-based approach provides an ideal setting for an interdisciplinary team approach to the care of patients with HIV-related diseases or who are at high risk. This is particularly effective in an impoverished black and latino community.

A.629

PREVALENCE OF ANTIBODIES AGAINST HIV-1 AND HTLV-1 IN AFRICAN SERA SAMPLES COLLECTED DURING THE 1960'S

Frankl, Tatjana, McShee, B., Lewinski, C., Longjumeau, M., Nair, R.N.M., and Poljakoff, R., et al. - Roche Diagnostic Sytes, Inc., Nutley, New Jersey, U.S.A., and University of Michigan, Ann Arbor, Michigan, U.S.A.

Objective: To study the prevalence of HIV-1 and HTLV-1 infections during the 1960's in Ghana among the Akan, Ewe, Ashanti, and Ewe tribes.

Methods: 408 archived sera samples from Ghana collected as early as 1960 were used in this study. Sera was screened for the presence of antibodies against HIV-1 and HTLV-1 using Roche recombinant HIV-1/HTLV-1 antigen combination screening EIA. This assay has been shown to have high specificity and sensitivity. Samples which showed reactivity in the HIV-1/HTLV-1 using specific recombinant antigen.

Results: Thirty-five out of 408 (8.7%) samples showed reactivity with HIV-1/HTLV-1 combination fusion proteins. Fourteen of the samples (3.5%) showed presence of antibodies against HIV-1 (gp120/gp41). Fifteen out of 35 positive immuno-reacted only with HTLV-1 recombinant antigen (3.7%). Six samples had antibodies against both HIV-1 and HTLV-1 (1.5%).

Conclusion: HIV-1 and HTLV-1 infections may be more prevalent than estimated during the 1960's in Africa.

A.631

INCREASED SUSCEPTIBILITY OF UNDIFFERENTIATED PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC) AND CD8+ CELL-DEPLETED PBMC TO IN VITRO INFECTION WITH HIV AFTER INGESTION OF 2 TO 4 BEERS

Reasars, Omer*, Linschler, Bora*, Rajasekya-Balla, A.M.M., *M.D., of Med. & Dent. of New Jersey, Camden, NJ; *M.D., of St. Christopher's Hosp. for Children, Philadelphia, PA; **M.D., of Oklahoma, Oklahoma City, OK, USA.

Objective: To determine the duration of the previously described effects of acute ethanol ingestion on HIV infection of PBMC *in vitro* (PARDJ J 2:483), 1988) and the influence of removal of CD8+ cells on these phenomena.

Methods: PBMC isolated from 7 healthy non-alcoholic volunteers before and 1 hour, 2 days after consumption of 0, 1-1.3 (mean 1.1) liters of beer, and PBMC depleted of CD8+ cells by panming 2 times on anti-CD8 cells, were cultured for 3 days. HIV replication was estimated by: a) counting the syncytia appearing after overnight incubation with 80%², cells, and b) assay of HIV-p24 by antigen capture enzyme immunoassay (EIA) by supernatant (depleted PBMC only).

Results: HIV infection of PBMC was detectable only if CD8+ cells were removed *in vitro* or if the PBMC were obtained 1 to 3 days after ethanol ingestion. The latter was associated with a 3-fold rise in syncytium formation when CD8+ cell-depleted PBMC were used. Means of 4 syncytia per well were found before beer ingestion, 12 syncytia after ingestion of 4, 5 and 2 per well (1), 2) and 4) days, respectively, after ingestion of beer.

Conclusions: CD8+ cells prevent HIV infection of normal undifferentiated PBMC. Prior ingestion of beer increased the susceptibility of PBMC to HIV infection *in vitro* for at least 11 days. Alcohol-associated enhancement of HIV replication occurred after removal of CD8+ cells. The same was not seen in the case of loss of CD8+ cell function previously ascribed to alcohol ingestion.

A.628

EVALUATION OF COMPLIANCE RATE IN A CLINIC SERVING MINORITY AND LOW INCOME COMMUNITIES

Davis, Iida, Leibell, J., Patrick, J., Langner, P., et al. - Woodhull Medical and Menal Health Center, Brooklyn, NY, USA

Objective: To determine compliance rates for HIV-seropositive persons in a socioculturally sensitive clinic (SSC) setting from communities that are considered "traditionally noncompliant".

Method: Missed appointments rates were compared between the SSC and the ambulatory care network (ACN). The overall broken appointment rate was determined as a proportion of total appointments. Retrospective chart review explored factors contributing to missed appointments taking into account race, sex, age, risk behavior, treatment regimen and protocol. Patient specific missed and scheduled visits, and explanations of missed visits were documented.

Results: The average broken appointment rate in the SSC is 15%, and 4% in the ACN. When rescheduled appointments were included, the noncompliance rate falls below 10%. Factors contributing to missed appointments were: lack of contact with work schedules, lack of child care, lack of adequate transportation, family illness, and hospitalization.

Conclusion: The overall compliance rate in the SSC is significantly higher than the ACN documenting (1) the importance of accounting for SSC variables in traditionally noncompliant communities (2) given the vital role of ambulatory care services for HIV diseases, clinic structures must be modified for communities with these variables, to increase participation in ambulatory and research protocols (3) the social role of women as caretakers, regardless of their health status, is undervalued as a contributing factor to noncompliance in HIV disease treatment in these communities.

A.630

TRAINING THE HEALTH CARE PROFESSIONAL: THE AIDS REGIONAL EDUCATION AND TRAINING CENTERS PROGRAM OF THE HEALTH RESOURCES AND SERVICES ADMINISTRATION (HSA)

Norman, James; Jefferson, P.; Marrelli, B.; Moore, D.; Macher, A. - Division of Medicine, Bureau of Health Professions, HSA, United States Public Health Service, Rockville, MD, USA.

Objective: To establish regional AIDS education centers that will provide multidisciplinary training for health care professionals.

Methods: With a projected cumulative total of more than 500,000 AIDS cases by 1997, it is essential that health care providers be trained in the diagnosis, management and treatment of HIV-infected patients. The insufficient number of providers active in the care of AIDS patients presents a major gap in the health care delivery system. In recognition of this problem, the United States Congress appropriated funds to establish the AIDS Regional Education and Training Centers Program.

Results and Conclusions: To date, thirteen centers have been created. These regional education and training centers provide multidisciplinary HIV/AIDS training for health care personnel within the framework of the following three goals: 1) Training community primary care providers to incorporate strategies for HIV prevention into clinical priorities as well as to diagnose, manage, and counsel patients and their families; 2) Training individuals to serve as instructors in their local areas; and 3) Educating health care professionals in providing sensitive and integrated care of AIDS patients through the improvement of their understanding of the complexities of the disease.

A.632

THE OPPORTUNITIES IN HUMAN AIDS (HOAIDS) ARE ZOOOTIC.

Jonas-Aas, Marcell L., Pineda, Robert H. - Univ. of Missouri, Columbia, MO, USA; Montgomery HS, Bethesda, MD, USA.

Objective: To explore animal diseases and animal products with respect to AIDS.

Methods: The opportunities associated to HAIDS were searched in the AIDSLINE database with GRATEFUL MED™ software and scrutinized *in-vitro* the concept of zoonoses (1). The number of publications mentioned to each were recorded in order to rank them in order of their relative importance. Most of them, as indicated with an asterisk (*), are also CNS infective.

Results: Cryptosporidiosis (894) and influenza (10) viruses are well spread in the animal kingdom. Pseudo-tuberculosis (630) is a parasite of swine, sheep, goats, and humans (2) as is leishmaniasis (686) to several other species. Cryptosporidiosis (141), histoplasmosis (50) and coccidioidomycosis (157) are zoonoses and candidiasis (167) is common in animals. The myxomatosis (137), including leishmaniasis, are infections of, or shared with, animals. Salmonellosis (30), campylobacteriosis (10) and listeriosis (107) are, frequently, although not always or only, associated to foods of animal origin. Cat scratch disease (2) and leish disease (2) are also involved in HAIDS.

Conclusion: Opportunistic, the major cause of death in AIDS, are zoonoses (1) and thus conceivably acquirable from animals and/or animal products. The epidemiology of this approach needs urgent evaluation. Used in conjunction with the animal AIDS models [simian (SIVS), feline (F AIDS), bovine (BAIDS), equine (EAIDS) rabids (RAIDS), murine (MAIDS), etc.] they could be useful in the pathobiological modeling of HAIDS. The HIV's themselves are infective both to closely related primates) as well as to far removed (non) animal species, whose common ancestors with the animal herbivores and thus are zoonotic. 1. Acha & Gaynes, 1987. PAHO-WHO, Sancti. Paet. No. 707.

SECTION B



Aspects cliniques
Clinical Aspects of AIDS

Table ronde
Round Table

Aspects cliniques
Clinical Aspects of AIDS
Coordination des soins : le point de vue du personnel infirmier
Coordinating Care: Nurses' Perspectives
M.B.O.7 AN INTERDISCIPLINARY APPROACH TO AIDS CARE: ST. PAUL'S HOSPITAL

Colleen, Irene, St. Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.

Objective: To describe the coordinated, interdisciplinary management of patients with HIV infection at St. Paul's Hospital (SPH).

Since the early days of the AIDS epidemic it has been apparent that we are confronted with a biological and social challenge that does not fit a traditional model of patient care management. Recognizing this, and that AIDS care does not fall within the purview of a single medical specialty, SPH has developed an interdisciplinary model of patient care. This model relies on the full participation of the family practitioners, medical specialists, hospital and home care liaison nursing staff, AIDS dedicated social workers, pharmacists and other related disciplines. The primary focus is on the clinical care of patients, with a special emphasis on identifying and providing direction for the resolution of psychosocial problems. There is a high degree of commitment to research and education at all levels. There is an emphasis on quality of life and treatment through outpatient care which is greatly facilitated by a dedicated HIV Clinic and close liaison with community support services. These services have allowed the successful expansion of our AIDS program to 3,367 inpatient days (1986-89) and 10,000 outpatient visits (1988). This represents 75% of the AIDS related care in the province of British Columbia.

M.B.O.9 THE CHALLENGE FACING NURSING IN CENTRAL AFRICA
 Kopolo Olive, Department of Nursing, University Teaching Hospital, Lusaka, Zambia.

M.B.O.11 HOME NEEDS (CARE FOR AIDS PATIENTS)
 Maynard, Pat. St. Elizabeth Nursing Home, Don Mills, Ontario, Canada.

M.B.O.8 THE IMPACT OF AIDS ON FAMILIES OF HAEMOPHILIACS IN WALES
 Reese, Jacqueline, University of Wales College of Medicine, Cardiff, South Wales, U.K.

Objective: To describe the impact of AIDS on the families of affected Welsh haemophiliacs.

Anyone involved with haemophilia has to be impressed by their courage in getting on with the business of living in spite of the debilitating nature of the disease. Now over fifty individuals living in Wales are facing a new obstacle - HIV infection as a result of contaminated blood products; six have already died. The sex linked mode of inheritance means that more than one family member may be affected. **Method:** The data on which the study is based was collected over a period of twelve months from the families of adult males and children attending a haemophilia centre. The qualitative holistic approach of grounded theory is used to explain the subjective dimensions of their human experience. **Results:** At least one wife has seroconverted, others have not made love since their husbands were found to have contracted the AIDS virus, largely due to the fact that their husbands recoil from physical strain. Parents have a huge burden to bear, some have experienced publicity surrounding the death of a child, several having other affected children face stigma and social isolation, others live in fear of being identified. **Conclusion:** Marriages are under stress, there is evidence of poor communication between partners who frequently keep the knowledge to themselves, wondering how long they are going to be able to keep it quiet.

M.B.O.10 A COMPARISON OF THE PROJECTED NURSING CARE NEEDS OF HOSPITALIZED AIDS AND NON-AIDS PATIENTS
 Lydia Lewis, I. Corbett, S. Brewer, et al. Department of Nursing, Royal Victoria Hospital, Montreal, Québec, Canada.

Objective: To confirm the observation that the nursing care requirements of hospitalized AIDS patients (AP) are greater than those of hospitalized non-AIDS patients (NAP).

Method: Staff nurses used the patient classification system, Project of Research in Nursing (PRN) to quantify projected patient nursing care needs. This validated tool describes patient care needs by integrating workload measurement with the nursing process (assigning a value to each anticipated nursing intervention: debridement of wound = 5 points). The advantage of this approach is that it allows for the individualization of the measurement (time) of care required (not given) as scheduled for the patient. Daily PRN scores of 49 AP admitted in 1986 were retrospectively collected from nursing records. Two matched controls without AIDS, admitted concurrently to the same service, were sought for each AP resulting in 129 NAP on whom data could be found.

Results: The mean daily projected nursing care hours were: 16:10.5 for all hospitalized AP, and 10:54.4 for all hospitalized NAP. Patients requiring an intensive care section: 25:02:1.6 for AP and 24:24:10.1 for NAP. Patients admitted to a nursing unit: 14:56:2.2 for AP and 10:04:8 for NAP. The mean length of stay for all AP was 26:52:6.4 and 11:34:10.5 for NAP.

Conclusion: Nurses estimate that AP require 52% more nursing care than NAP. This information supports nursing judgment and intuition by providing an objective measure of workload which is valuable for resource management.

Colloque Symposium



Aspects cliniques Clinical Aspects of AIDS

Diagnostic et histoire clinique de l'infection par le VIH Natural History and Diagnosis of HIV Infection

M.B.O.12 CHANGING PATTERNS OF PNEUMOCYSTIS CARINII INFECTIONS

Hopewell, Phillip C. San Francisco General Hospital, San Francisco, California, U.S.A.

M.B.O.13 ANIMAL MODELS OF PNEUMOCYSTIS CARINII PNEUMONIA

Quarles, Sherry F., Bartlett, R. S., Smith, J. W., Indiana Univ. School of Medicine, Indianapolis, Indiana.

Objective: To develop a model of *Pneumocystis carinii* pneumonia that would consistently produce a good yield of uniformly heavily infected animals suitable for drug testing or biochemical work.

Methods: Virus-free female Sprague-Dawley rats weighing 150 - 150 gm are immune suppressed by a) cortisone acetate 250 µg/kg twice weekly, b) dexamethasone 1.2 mg/kg in drinking water continuously, or c) methylprednisolone 40 mg/kg once weekly. Drinking water contains 0.5 gal/l tetracycline. Rats receive standard laboratory chow (CD# protein). Transurethral injection of 10^8 to 10^7 organisms is performed 4 to 7 days after the start of immune suppression.

Results: Virus-free rats used in these studies are also *Pneumocystis-free*. The rate at which they become infected naturally depends upon the level of exposure to already-infected animals. Transurethral inoculation of these rats speeds the development of heavy *Pneumocystis* infections so that rats may be harvested for biochemical work by 6 to 7 weeks. Rats are also more uniformly infected by this mechanism. Tests of drug for therapy may be started at 4 weeks and harvested at 6 to 7 weeks. For relapse studies a prophylaxis start at the time of inoculation and run 6 weeks.

Conclusions: Transurethral inoculation of *P. carinii* into immune suppressed rats produces consistently heavy infections and allows efficient drug testing in therapy, prophylaxis and relapse protocols. These heavily infected rats are also good sources of organisms for biochemical studies.

M.B.O.14 TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS: ANTIMICROBIALS

Tava, Felix. Hôpital-Dieu de Montréal and Université de Montréal, Québec, Canada.

The current treatment for *Pneumocystis carinii* (PC) infection are efficacious in more than 95% of cases. Different factors contributed to this progress: better educated physicians and patients; earlier diagnosis; better management; extended knowledge of pharmacokinetics of PC drugs; the effect (s) of AZT treatment, etc. However, the incidence of adverse reactions is high and the initial therapy should often be changed. Several therapeutic principles are now recognized, such as: do not treat empirically; make an early specific diagnosis; non-specific tests (except for blood gases at rest and exercise), are not cost-effective and delay the etiologic diagnosis; consider PC also in subtle or atypical cases; mild to moderate clinical forms could be treated orally; dosage modifications have few effects on adverse reactions or survival; in the presence of side effects better change the initial therapy, etc. For patients who are unable to tolerate "conventional" therapy 3 trials (investigational), approaches are available: eflopridine, trimetrexate/leucovorin and clindamycin/primequine; however their effectiveness, safety and recurrence rate are not appropriately assessed. New therapeutic regimens will be probably suggested and all these treatments should be evaluated in well-designed controlled clinical trials and not to be used indiscriminately.

M.B.O.15

NEW DEVELOPMENTS IN THE TREATMENT AND PREVENTION OF PCP
John S.G. Montaner, MD, FRCP(C), Director of AIDS Research Program
St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada

Despite a number of therapeutic advances, PCP remains the most common serious opportunistic infection in HIV-infected individuals. Two recent developments have shown promise in potentially altering morbidity and mortality associated with this condition. These are:

Adjunctive Corticosteroid Therapy: previous retrospective work suggested that adjunctive systemic corticosteroids could have a favourable effect by reducing respiratory failure, haemorrhagic decompensation and minimizing side effects to normally used antimicrobials. More recently, we have demonstrated in a placebo controlled trial that adjunctive oral corticosteroids (80 mg PO, QD for 7 days followed by a 14 day tapering course) can also prevent the development of clinical acute respiratory failure in patients with moderately severe PCP. This had a significant beneficial impact, not only decreasing morbidity but also improving quality of life. A welcome spin off of this trial has been the decrease in admissions to the Intensive Care Unit and earlier discharge of patients with AIDS-related PCP.

PCP Prophylaxis: the experience in indigent patients and more recently the report by Finkel et al focused our attention on the great potential value of PCP prophylaxis to AIDS. Unfortunately this was difficult to implement because of the generally poor tolerance among HIV-infected individuals of the commonly used prophylactic regimens. We have recently conducted a Canadian cooperative placebo controlled trial of the efficacy and safety of aerosolized pentamidine for the secondary prophylaxis of AIDS-related PCP. Patients were randomly allocated to receive pentamidine 60 mg/dose or placebo. The drug was delivered via a hand held nebulizer (PNEUMOPAC, MAID = 2.5-5.5 micron) over 15 to 20 minutes. Patients received an induction treatment consisting of 5 doses in 14 days followed by one dose bi-weekly thereafter. 102 patients were randomized at the time that the study was initiated. Of the 32 cases of PCP identified during the follow-up period, 27 of these occur among the 78 placebo treated patients while only 5 occur among the 84 patients receiving active therapy (p < .001, chi sq). Such groups were similar in terms of baseline data, median follow-up, side effects were uncommon and generally well tolerated. In contrast to previous reports, the tolerance of aerosolized pentamidine was extremely good and overall adverse events were rare. Our study conclusively demonstrates that aerosolized pentamidine is highly effective in the prevention of AIDS-related PCP.

* National Health Institute, Health & Welfare, Canada

**Colloque
Symposium**

**Aspects cliniques
Clinical Aspects of AIDS**
**Traitement des infections associées à l'immunodéficience causée par le VIH
Management of Infections Associated with HIV Immunodeficiency**

M.B.O.28 TOKOPLASMOSES
Fechter, Jean-Claude. Hôpital Cantonal de
Genève, Genève, Suisse.

M.B.O.29 "CRYPTOCOCCOSIS"
Bando, Marie A. San Francisco General Hospital
Department of Medicine, University of California. San
Francisco, CA, USA.

M.B.O.30 TUBERCULOSIS (TB) AND ATYPICAL MYCOBACTERIA
IN PATIENTS WITH HIV INFECTION
Chaisson, Richard A.
Johns Hopkins University, Baltimore, MD USA
TB is common in HIV-seropositive populations with a high prevalence of *M. tuberculosis* infection. TB is often an early AIDS related opportunistic infection, occurring when CD4 cell counts are still relatively high (>250/ μ l). Clinical manifestations may be atypical, especially in extremely immunosuppressed patients, though 60-80% of patients have pulmonary disease. Common radiographic findings include diffuse infiltrates and adenopathy. Tuberculin reactivity is found in 40 to 80% of patients. Response to standard antituberculosis therapy is generally excellent; lifelong therapy may not be necessary. Prevention of tuberculosis with prophylactic treatment of tuberculin-reactive HIV-seropositive persons is an urgent public health priority.
Mycobacterium-complex (MAC) is a late complication of HIV-related immunosuppression. Most MAC disease is probably a result of recent infection, and all HIV risk groups are equally affected. Several distinct clinical syndromes are associated with MAC infection. While MAC causes considerable morbidity, its contribution to mortality is unclear. Treatment is difficult as most isolates are resistant to standard antituberculosis drugs. Studies in animal models and limited human data suggest that newer regimens may control MAC disease. Prevention of MAC infection may be possible with prophylactic therapy.

M.B.O.32 CRYPTOSPORIDIOSIS, ISOSPORIASIS AND MICROSPORIDIOSIS
Paul M., St. Vincent's Hospital & Medical Center of NY
Etiologic, chronic, fatal, nonbacterial diarrhea
with/without dissemination pose a very serious management problem in AIDS, especially those caused by *Cryptosporidium*, *Isospora*, *belli*, and *Microsporidia*. These protozoans are easily detected in stool specimens using acid-fast or immunofluorescent staining procedures, except *Microsporidia* which has not been demonstrated in stool and thus requires fluorescent biopsy. Transmission is mostly fecal-oral, sexual, water/food borne, animal contact and possibly inhalation. Risk factors include travel to tropical countries, homosexuality, immunosuppression, etc. Disseminated infection involves cholangitis, hepatitis, pulmonary infection, for *Cryptosporidium* and myositis hepatitis for *Microsporidia*. Although *Cryptosporidiosis* in nonimmunocompromised host is self-limited, in AIDS, it is resistant to multiple therapies. Spiramycin and transfer factor have limited success. Currently, the most promising treatment is hyperimmune bovine colostrum from cows vaccinated with *Cryptosporidia* antigen given to AIDS associated symptomatic patients resulting in long term remission. Isosporiasis with a much lower incidence than cryptosporidiosis is less devastating. Response to atabrin and sulfamethoxazole has been noted with/without recurrences in some earlier infections. Little is known of *Microsporidia*, the newly recognized pathogen in homosexual men with AIDS. Cases known so far are all fatal. In conclusion, drastic research is definitely needed to reduce high morbidity and mortality of these opportunistic infections in AIDS.

M.B.O.31 HUMAN CYTOMEGALOVIRUS (HCMV) INFECTIONS IN AIDS: DIAGNOSIS AND ANTIVIRAL TREATMENT.
Caru Giuseppe; Revello M.G.; Minoli L.; Grossi P.; Perinvalle E.; Parea W.
Institute of Infectious Diseases, University of Pavia, and IRCCS Policlinico San Matteo, 27100 Pavia, Italy.
Objective: To correlate HCMV antigenemia and viremia with symptoms and ganciclovir (GCV) treatment in AIDS patients with systemic HCMV infections.
Methods: Antigenemia was determined in peripheral blood polymorphonuclear leukocytes (PMNL) by IFA using a Mab to HCMV immediate early antigens (EA) (2n assay), and viremia by IFA staining of "shell vial" cell cultures (inoculated with a known number of PMNs) 24h p.i. using a Mab to HCMV EA.
Results: Overall, 13 of the 65 (20%) AIDS patients examined had reactivated HCMV infection, 14 of 55 (25.4%) had viremia and 7 of 30 (23.3%) both viremia and antigenemia. Of these, the 2 patients with a high number of positive PMNs had high fever and were thus treated with GCV, with final disappearance of fever and virus from blood. Of 89 blood samples tested, 76 (87.6%) gave concordant results for both viremia and antigenemia, 9 (all taken during GCV therapy) were positive for antigenemia only and 2 for viremia only.
Conclusion: By monitoring HCMV antigenemia and viremia it seems possible to anticipate onset of symptoms and to earlier initiate and carefully evaluate effectiveness of GCV treatment.
(Partially supported by Ministero Sanità, Progetto AIDS, 1989).

Séance thématique Specialty Session



Aspects Cliniques Clinical Aspects of AIDS

Traitement: essais de l'AZT Therapy: AZT Trials

M.B.O.45

VALIDATION OF THE SURVIVAL EXPERIENCE AMONG A LARGE COHORT OF AIDS PATIENTS TREATED WITH ZIDOVUDINE
CROSS-KEY, TERRY, DILLI, P.; ANDREWS, R. and TILSON, H. Burroughs Wellcome Co., Research Triangle Park, North Carolina, U. S. A.

Objective: To validate and extend the original survival experience reported in a large cohort of AIDS patients who received zidovudine through a compassionate-release program.

Methods: Through a compassionate-release system, 4805 AIDS patients began treatment with zidovudine over a six-month period in late 1985 and early 1987. These patients were also closely monitored for an additional 5 months by means of a structured epidemiologic study and data from a limited drug distribution system. Survival experience up to 46 weeks after treatment initiation has been published. However, because the least-to-followup rate in the original population was high, an effort was made to validate actual survival in a subset of all patients treated in sites participating in another study where retrospective data collection provided nearly complete follow-up.

Results: The validation study confirmed the original survival experience reported and extended that experience beyond 12 months. Prognostic effects of baseline hemoglobin level and functional status at well as the elapsed time between diagnosis and treatment were examined. **Conclusion:** A validation study has confirmed previous findings and allowed assessment of survival beyond that reported previously for a subset of patients. The extent to which these data can be generalized to the original population will be discussed.

M.B.O.46

SURVIVAL PATTERNS OF ZIDOVUDINE TREATED AIDS PATIENTS COMPARED TO UNTREATED CONTROLS.

DELLA, I. In order to establish the influence of antiviral therapy on survival of AIDS patients, we compared the survival patterns of patients receiving zidovudine with survival patterns of a control group of patients who were contemporaneously not receiving ZDV.

Methods: All Italian adult AIDS cases reported between January '87 and March '88 were included in this study. Of these, 773 began ZDV therapy and 1000 were untreated. Age, gender and risk factors for AIDS were similar in the two groups. Survival was calculated for each patient from the date of diagnosis through July 31, '88. Kaplan-Meier method. Wilcoxon test was used to evaluate differences between groups.

Results: Survival at 12 months for treated patients was 90.9% (95%-94.9%) while survival of untreated patients was 44.4% (39%-48%). Survival pattern of patients who initiated therapy but voluntarily interrupted within 30 days approached the survival of untreated patients (55.3%).

Stratification for clinical presentation and semester of diagnosis, and differences in survival of the two groups of patients.

Conclusion: Data obtained clearly confirm that ZDV therapy is associated with increased survival of AIDS patients, also when comparisons is made with untreated controls and not simply with historical controls.

M.B.O.47

NATURE, TIME COURSE AND DOSE DEPENDENCY OF ZIDOVUDINE RELATED TOXIC EFFECTS. RESULTS FROM THE MULTICENTRIC NATURAL AZIDOTHYMININE TRIAL (MCAZT).

ROSE, JOHN; MONTGOMERY, GORD; GILMAN, K; PAMME, M; SMITH, R; PALM, J; THOMAS, C; COE, J; WELLS, G; O'NEILL, M and VAN DER BRUG, G. Amgen, San Diego, CA, USA

Objective: To characterize the nature, time course and dose dependency of zidovudine related side effects in early HIV-infected individuals.

Methods: 1000 HIV seropositive, drug naive, stage 2 patients in HIV positive (HIV+) and HIV negative (HIV-) groups were treated with zidovudine 600 mg/day for 2 weeks, 600 mg/day for 2 weeks and 1200 mg/day for 2 weeks followed by a washout period of 2 weeks after which they were treated on 600 mg/day or 1200 mg/day for the highest previously tolerated dose at 6th interval. Subjects were randomly assigned to 4 or 6 g regimens while CDC groups with initially taking 600 or 1200 mg/day. Clinical and laboratory evaluations were performed at 3 week intervals.

Results: Symptomatic adverse events were reported in 96% of subjects, most commonly nausea (64%), fatigue (57%) and headache (49%). These were generally self-limited, resolving briefly at each dose decrease. A decrease in hemoglobin counts occurred after initiation of therapy. This was not dose dependent and reversed rapidly upon discontinuation of treatment. A red blood cell count decrease, a mean cell volume increase and a granulocyte count decrease developed only in a dose independent fashion, resolving at least partially during the washout phase. The decrease in reticulocyte count was dose related between 600 and 1200 mg/day with no further change when the dose was escalated to 1200 mg/day. Bone marrow changes occurred equally as demonstrated by megakaryoblasts in 95% of 85 specimens at week 11. LHM remained unchanged through out the 60 weeks. These effects were not dependent on study site, CDC group or drug regimen (4th vs 6th).

Conclusions: Hematologic effects include a mild macrocytic megakaryoblast count with a decrease in reticulocyte count and granulocyte counts. These appear to be dose independent in the range 600 mg to 1200 mg/day and rapidly reversible upon discontinuation of the drug. The fact that these effects are minimal on the smallest dose employed (600 mg) supports the need for efficacy studies at lower doses than those currently recommended.

M.B.O.49

TOXICITY OF COMBINED AZT/GANCICLOVIR (DMC) THERAPY IN AIDS PATIENTS

REASHAM, JESSIE; ANTONIADIS, D; CANNON, D; LEEDON, JR. LA CO-DCD Medical Center, Los Angeles, California, USA.

Objective: To assess the incidence of various hematologic toxicity during combined AZT/DMC therapy. Methods: 48 patients (pts) were treated with combined DMC from Jan 1986 to Dec 1986. No cytokes were used. DMPC maintenance was 3mg/kg (q 12h) in 1/20 pts, 4mg/kg in 9/20. Toxicity management for H1H grade 1 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 2 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 3 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 4 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 5 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 6 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 7 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 8 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 9 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 10 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 11 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 12 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 13 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 14 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 15 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 16 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 17 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 18 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 19 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 20 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 21 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 22 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 23 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 24 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 25 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 26 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 27 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 28 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 29 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 30 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 31 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 32 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 33 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 34 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 35 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 36 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 37 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 38 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 39 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 40 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 41 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 42 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 43 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 44 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 45 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 46 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 47 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 48 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 49 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 50 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 51 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 52 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 53 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 54 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 55 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 56 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 57 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 58 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 59 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 60 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 61 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 62 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 63 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 64 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 65 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 66 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 67 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 68 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 69 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 70 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 71 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 72 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 73 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 74 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 75 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 76 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 77 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 78 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 79 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 80 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 81 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 82 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 83 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 84 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 85 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 86 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 87 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 88 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 89 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 90 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 91 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 92 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 93 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 94 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 95 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 96 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 97 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 98 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 99 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 100 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 101 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 102 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 103 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 104 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 105 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 106 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 107 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 108 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 109 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 110 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 111 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 112 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 113 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 114 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 115 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 116 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 117 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 118 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 119 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 120 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 121 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 122 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 123 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 124 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 125 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 126 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 127 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 128 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 129 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 130 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 131 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 132 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 133 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 134 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 135 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 136 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 137 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 138 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 139 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 140 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 141 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 142 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 143 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 144 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 145 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 146 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 147 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 148 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 149 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 150 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 151 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 152 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 153 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 154 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 155 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 156 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 157 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 158 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 159 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 160 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 161 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 162 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 163 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 164 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 165 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 166 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 167 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 168 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 169 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 170 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 171 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 172 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 173 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 174 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 175 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 176 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 177 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 178 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 179 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 180 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 181 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 182 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 183 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 184 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 185 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 186 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 187 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 188 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 189 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 190 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 191 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 192 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 193 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 194 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 195 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 196 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 197 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 198 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 199 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 200 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 201 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 202 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 203 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 204 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 205 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 206 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 207 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 208 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 209 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 210 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 211 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 212 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 213 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 214 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 215 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 216 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 217 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 218 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 219 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 220 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 221 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 222 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 223 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 224 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 225 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 226 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 227 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 228 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 229 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 230 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 231 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 232 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 233 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 234 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 235 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 236 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 237 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 238 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 239 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 240 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 241 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 242 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 243 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 244 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 245 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 246 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 247 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 248 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 249 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 250 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 251 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 252 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 253 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 254 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 255 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 256 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 257 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 258 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 259 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 260 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 261 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 262 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 263 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 264 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 265 (q 3h) in 1/20 pts, 2mg/kg in 9/20. Toxicity management for H1H grade 266 (q 3h

Atelier Workshop



Aspects Cliniques Clinical Aspects of AIDS

Prophylaxie de la PCP PCP Prophylaxis

T.B.O.1

FOLLOW-UP STUDY OF PATIENTS RECEIVING PENTAMIDINE AEROSOL FOR PREVENTION OF PCP

SCHEIDT, Michael, M.D., Kennedy, P., Kahn, S.,** Nagao, T.,* and Beringer, J.*
*Los Angeles Oncologic Institute, St. Vincent Medical Center, Los Angeles, California 90057; **Chief, Pulmonary Medicine, St. Vincent Medical Center, Los Angeles, California 90057, U.S.A.

Objective: To evaluate the efficacy of inhaled pentamidine in prevention of PCP during a 6 to 18 month follow-up period.
Methods: 51 patients with HIV (AIDS/AIHS) have been maintained on pentamidine, 150 mg every two weeks by inhalation. Group 2: 17 patients with prior PCP and with mean 74 of 106 cells/mm. Group 3: 14 patients with AIDS/AIHS without history of PCP and mean 74 of 262 cells/mm. All patients received HIV and syphilis tests.
Results: Incidence of drug toxicity, PCP, and death was compared.

Patient Group	Toxicity	PCP or Reassess PCP	No. of Deaths
I (n=31)	0	2	6
II (n=34)	0	0	0

The 6 deaths in I were unrelated to PCP.
Conclusion: Aerosolized pentamidine is effective prophylaxis against pulmonary Pneumocystis carinii in HIV immunosuppressed patients.

T.B.O.2

EFFETS DES AEROSOLS PROPHYLACTIQUES DE PENTAMIDINE SUR LA FONCTION RESPIRATOIRE A COURT TERME

MAILLAT, Richard-Claude Bernard, Paris-France.
P.N.M., Françoise; de Pietriotto, C., Lepetère, A., Landman, R., Girard, P.M., Salami, A.G.

Objectif: Evaluer la tolérance pulmonaire des aerosols de Pentamidine (APM) par la mesure de la capacité de transfert à l'oxyde de carbone (TLCO) et du gradient alvéolo-arteriel en oxygène (A(a-a)O₂).
Groupes: 46 patients SIDA ont été suivis pendant un mois net mois à la suite d'un (n=2) épisode (n=6) de pneumonocystose (N₂).
Groupes contrôle (n=10): 3 groupes APM (n=36): APM 1 (n=12), APM 2 (n=12), APM 3 (n=12).
La TLCO à l'état stable (à la valeur théorique) et ΔA(a-a)O₂ (norm) ont été mesurés à M1 et M2 (15 et 30 jours après la pneumonocystose). Aucun des patients inclus dans cette étude n'a présenté de recrudescence de pneumonocystose avant M2.

Groupes	M1		M2	
	TLCO %	ΔA(a-a)O ₂ t	TLCO %	ΔA(a-a)O ₂ t
Groupes contrôle	51,0	47,1	52,8	47,2
Groupes APM	46,5	44,4	45,9	47,7
	± 15,6	± 11,7	± 16,5	± 11,9

La TLCO augmente de façon non significative des deux groupes.
Conclusion: Les aerosols de Pentamidine ne semblent pas entrainer de troubles fonctionnels respiratoires dans la liste de la durée de cette étude.

T.B.O.3

AEROSOL PENTAMIDINE FOR PNEUMOCYSTIS CARINI PNEUMONIA PROPHYLAXIS: A 3 ARM RANDOMIZED TRIAL


LANE, Douglas, M.D.,** Fogel, D.W.,* and the SF County Community Coronavirus Task Force.
*Department of Medicine, San Francisco General Hospital, Univ. of California, St. Francisco, CA; ** SUNY at Stony Brook, NY; ** Chief, Pulmonary Medical Center, SF.

Objective: To determine the efficacy of aerosol pentamidine for prophylaxis against Pneumocystis carinii pneumonia (PCP) in high risk HIV infected patients.

Methods: 408 patients were randomized to treatment with either 300 mg qtw, 150mg qtw or 300mg qtw of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=256), Kaposi's sarcoma (KS, n=88) or AIDS and other AIDS diagnoses (OAI, n=116). AP was delivered with a RespiRad Respirator II nebulizer (COPD/MMAAD-142 microns).

Results: Mean follow up in ongoing patients was 301 days (range 190-347). Intention to treat (ITT) analysis and analysis of PCP events of PCP on study (OS) in 28 days of eligibility and <60 days after last Rx showed 63 and 48 events (17% and 13%), respectively. Only 3 PCP events occurred in the KS or OAI strata; 75% of all PCP events were histologically confirmed.

The log-rank statistics comparing the three arms (ITT) were p=0.06 for 300 vs 150, p=0.15 for 300 vs 150, and p=0.17 for 300 vs 150. Cox regression models to adjust for number of prior PCP episodes, time since last PCP and zidovudine use. The reduction in relative hazard (300 vs 150) was 2.1 fold (p=0.1). **Conclusion:** There is a dose response showing 300mg qtw is best despite the longer interval between treatment. Since this is a dose response study, it underestimates the benefits of AP compared to no treatment.



T.B.O.5

LOW DOSE DAPSONE (D) PROPHYLAXIS (PX) OF PNEUMOCYSTIS CARINI PNEUMONIA (PCP)

LANE, Douglas, M.D., Kessinger, J.M., Tucker, R.K., Greene, S.I., Deresinski, S.C. and Stevens, D.A.
Santa Clara Valley Medical Center, San Jose, CA, U.S.A.

Objective: We evaluated the safety, efficacy and cost effectiveness of D as PX of PCP.

Methods: D (50-100 mg/d) was given as oral PX to 24 patients (PTS) with AIDS (21 PTS) or AIC (3 PTS). All PTS were male; mean age was 36.3 yrs; mean duration of disease was 9.7 mos. Three PTS received D as 1st PX and 21 as 2nd PX.

Results: Mean duration of PX is 106 d (range 21-430 d). There are 88 total patient mos. of PX: 71 on 50 mg/d, 17 on 100 mg/d; 17 PTS (71%) remain on PX, 4 are alive off PX and 3 have died (none of PCP). One PT relapsed with mild PCP on PX after 4 wks. Of D (50 mg/d), was treated successfully with D and trimethoprim and remains well at 160mg/d; 1 suspected toxicity occurred in 3 PTS (rash in 3); D was stopped in 4/5; none had serious sequelae. Monthly cost of PX per PT at our institution is \$1.10. For 21 pts treated with 100 mg/d and <\$400.00 for inhaled pentamidine (4mg/kg every 14d).

Conclusion: D (50-100 mg/d) is inexpensive and well tolerated. Our results suggest that even 50 mg/d is effective PX of PCP in AIDS. Comparative trials with alternative PX agents and dose finding studies of D for PX of PCP are in order.

T.B.O.4

SUCCESSFUL CHEMOPROPHYLAXIS FOR PNEUMOCYSTIS CARINI PNEUMONIA WITH DAPSONE OR BACTRIM

MICHA, Olga E.; Jacobs, D.L.; Lewis, N.S.;
St. Lukes-Roosevelt Hospital Center, New York, N.Y., USA; **Amocha Pharmaceutical, Princeton, N.J., USA

Objective: An open study of the efficacy and tolerance of dapsone or trimethoprim (TMP) for prophylaxis against Pneumocystis carinii pneumonia (PCP).

Methods: We studied 221 patients (pts) who were at high risk for PCP from AIDS and received prophylaxis. All pts had either <300 T4 cells/mm³ or had 2 or more PCP episodes in the prior 6 months.

Results: The mean T4 cells at the time of treatment initiation was 142 (range 0 to 373), 173 pts received dapsone (94 mg, range up to 43 mg) and 48 pts received bactrim (82 mg, range up to 57 mg), 2073 pts receiving dapsone 25 mg qtd and 674 pts receiving bactrim 615 mg bid developed PCP (n=631, 30%). In contrast, 26 episodes of PCP occurred in 23 pts who refused prophylaxis (9/6 mg, range up to 29 mg), 10% of pts receiving dapsone and 30% of pts receiving bactrim prophylaxis experienced an adverse reaction (p<0.0001). No hypersensitivity to X agents generally tolerated the other. 129 pts receiving both dapsone and AZT had no withdrawal from dapsone because of a sustained drop in hemoglobin. 125 pts receiving dapsone and 20 pts receiving bactrim developed other CI or malignancies. 10 pts on dapsone and 10 on bactrim have died.

Conclusions: Both dapsone and bactrim are equally effective in preventing PCP but a higher percentage of pts receiving bactrim experienced adverse reactions.

T.B.O.6

TRIMETHOPRIM-SULFAMETHOXAZOLE FOR SECONDARY PROPHYLAXIS OF PNEUMOCYSTIS CARINI PNEUMONIA IN AIDS

PIRANO, Gerald, M.D., J., Nicholas, P.,
St. Elizabeth Hospital Center, Elmhurst, N.Y., U.S.A.

Objective: In determine if maintenance therapy with trimethoprim-sulfamethoxazole (TS) prevents recurrent infection with Pneumocystis carinii pneumonia (PCP) in patients with the acquired immunodeficiency syndrome.

Methods: 100 patients were enrolled on all patients who had received at least 3 months of therapy with zidovudine (ZD) following an initial episode of PCP. Patients were randomized to receive either 12 of these patients also received TS in a dose of one double-strength tablet BID (Group 1). 11 patients were not treated with TS or any form of prophylaxis for PCP (Group 2).

Results: The two groups were comparable with regard to the severity of PCP (A-a gradient of 44.6 and 46.3 respectively) and time interval between diagnosis of PCP and initiation of TS (1.7 vs. 1.8 months respectively). None of the patients in group 1 developed PCP during 101 episodes of follow-up (mean 14.4 months). In group 2, there were eight relapses of PCP, three fatal, during 50 patient-months of follow-up (mean 8.2 months) (p<0.01). The one year mortality was 1/12 (8%) in group 1 and 4/11 (36%) in group 2 (p<0.05). 20 dapsone was reduced in 2/12 patients in group 1 because of neutropenia and 4/11 patients in group 2 secondary to anemia. There was no difference in mortality between the two groups.

Conclusion: TS is effective in the secondary prophylaxis of PCP in patients being treated with ZD, improves survival, and is not associated with increased bone marrow toxicity.

**Colloque
Symposium**

**Aspects cliniques
Clinical Aspects of AIDS**
**Infections à *Pneumocystis carinii*
Pneumocystis carinii Infections**
T.B.O.22 NATURAL HISTORY AND STAGING OF HIV INFECTION
Redfield, Robert, Walter Reed Army Institute
 of Research, Rockville, MD, USA

T.B.O.23 CLINICAL DIAGNOSIS OF AIDS AND RELATED DISORDERS
MARSH, WENDY,
 Clinical Center, National Institutes of Health,
 Bethesda, Maryland, USA.

For individuals who are infected with HIV, morbidity and mortality are produced by three major processes: 1) opportunistic infections and tumors; 2) direct organ involvement by HIV; 3) immunologic processes such as antigen-antibody complex deposition. The quality and duration of patient survival can clearly be improved by prompt diagnosis of those processes that are treatable. Thus major emphasis must be directed at diagnosing the infectious complications that are responsible for causing 50% of deaths. Immunologic monitoring can predict when patients are most likely to be susceptible. Some diagnoses such as cerebral toxoplasmosis, cytomegalovirus retinitis, candida esophagitis, and perirectal herpes simplex can be made presumptively on clinical or radiologic grounds and response to therapy can be assessed. Other diagnoses such as pneumocystis pneumonia, cryptococcal meningitis, and the causes of diarrhea must be made specifically by microbiological or histologic criteria.

T.B.O.24 RELEVANT ISSUES IN THE CLINICAL DIAGNOSIS OF AIDS
 IN THE DEVELOPING WORLD
Sacharias, Fernando, Pan-American Health
 Organization, Washington, D.C., USA.

T.B.O.25 PROGNOSIS FACTOR
Rosenbaum, Willy, Unité des maladies infectieuses
 Hôpital Rothschild, Paris, France.

Specialty Session Séance thématique



Aspects cliniques Clinical Aspects of AIDS

Traitement de la PCP PCP Treatment

T.B.0.26 AEROSOLIZED PENTAMIDINE VS. TRIMETHOPRIM-SULFAMETHOXAZOLE (TMP-SMX) FOR ACUTE PNEUMOCYSTIS CARINI PNEUMONIA (PCP): A RANDOMIZED DOUBLE BLIND TRIAL.

Montgomery, A. Ross, J. Edmon, J.L., Hopwood, M.J., Sattler, E.R., Fennberg, J.,*, Felger, D.W.,** and the U.S. National Cooperative Investigators.**
* State University of NY at Stony Brook; ** University of California, San Francisco; *** University of Southern California;**** National Institutes of Allergy and Infectious Diseases.
Objective: To evaluate the efficacy and safety of aerosolized pentamidine as treatment for acute PCP in AIDS patients.
Methods: Patients with suspected PCP are randomized at 24 centers pending confirmation of PCP and receive either aerosolized pentamidine (600 mg in 6 cc daily) or TMP-SMX (TMP-15 mg/kg/day + SMX-75 mg/kg/day) with either placebo aerosol or placebo IV. Standard treatment course is 21 days with an 8-month follow-up for recurrences and adverse events.
Results: 206 of the target 208 eligible patients have been studied (97 currently in treatment). Pooled data from the two treatment arms as of January 13, 1985:

	Rate
Eligible patients completing acute therapy	188
Randomized drug changing for poor efficacy	43
Optimal during acute treatment period	13
Major adverse event during acute treatment**	70
PCP recurrence months 0-4 follow-up (N=136)	8
PCP recurrence months 4-6 follow-up (N=74)	8
Extrapulmonary pneumocystosis	0
Pulmonary hemorrhage	0

Conclusions: Rates of toxicity, initial treatment failure and mortality are not excessive relative to other studied PCP treatments. PCP recurrence rates are also relatively low.

T.B.0.28 TRIMETHAZONE (TMX) SALVAGE THERAPY OF PCP IN AIDS PATIENTS WITHOUT ANY THERAPEUTIC OPTIONS: INTERIM RESULTS OF THE 1ST AIDS "TREATMENT TRIAL" PROTOCOL.

Feldner, Judith, Katz, D., Rubenstein, C., Myers, N. Beth, D. AIDS Program, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA
Objective: To evaluate TMX salvage therapy of PCP in AIDS patients (pts) who cannot be treated with standard therapies (PCP, trimethoprim-sulfa and IV pentamidine). TMX is the first AIDS drug to be distributed under the FDA's new "treatment drug" mechanism, which permits access by licensed US physicians to a promising investigational drug with evidence of safety.
Methods: Pts with serologically-confirmed PCP, poly + bands > 1000, platelets < 20K who have experienced serious toxicity to both ST and/or have not responded to IV or aerosolized TMX 45 mg/kg* = 21 days and leucovorin 30 mg/kg* = 24 days. Successful completion of study therapy is defined as survival at 1 month follow-up.

Results:	Analgesics	Antibiotics	Intolerant/Infectious	Refractory
no treatment (n=12/788)	115	3	4	6
1st episode of PCP	32 (43)	33 (67)	5 (83)	
discontinued at entry	24 (31)	20 (59)	3 (50)	
days of ST at entry†	10 (8-28)	17.5 (11-24)	9.6 (7-13)	
inhab	34 (30)	27 (79)	3 (50)	
survived	34 (47)	2 (6)	3 (50)	
withdrew - adverse event	16 (14)	2 (6)	0 (0)	

Conclusions: TMX is an effective (39% survived) and well-tolerated salvage therapy for desperately ill AIDS patients. The "treatment drug" is a useful mechanism for providing wide access to promising investigational therapies.

T.B.0.30 EFLORITHINE IN PCP CASES RESISTANT TO CONVENTIONAL THERAPY.

SON, E. SMITH, S. OWEN, N. MELSON, B. G. GAZDAR, ST. BARTHOLOMEW HOSPITAL, TULHAR ROAD, LONDON, ENGLAND.

OBJECTIVE: To describe our experience with Eflorithine as a salvage treatment in HIV positive patients with Pneumocystis Carini Pneumonia (PCP) having failed to respond to Co-Trimoxazole or Pentamidine.
METHODS: 20 HIV positive patients with a microscopically confirmed episode of PCP received Eflorithine (400mg/kg) IV continuous infusion having failed to respond to either Co-trimoxazole or IV Pentamidine as assessed by worsening CXR, PaO₂ and failure of respiratory and respiratory rate to normalize.
RESULTS: 18 patients survived (64%) and 10 died during treatment with Eflorithine. There was no statistical difference between initial PaO₂ in survivors vs non survivors but there was a worse CXR in non survivors. No ventilated patients recovered. 30 adverse events in total were recorded: anaemia 11, thrombocytopenia 6, and phlebitis 15. All patients receiving greater than 10 days Eflorithine survived. Eflorithine was discontinued due to narrow spectrum in 3 patients.
CONCLUSION: Eflorithine is a salvage drug for salvage treatment of non responsive cases of PCP but does exhibit bone marrow toxicity.

T.B.0.27 THE IMPROVING SURVIVAL RATE AFTER INTENSIVE CARE FOR P. CARINI PNEUMONIA AND ESOPHAGITIS FAILURE

Yoshida, Robert M., Rossi, M.P., Hopwood, P.C., and Lusa, M.D.

*Robert Wood Johnson Clinical Research Program, Rutgers University, **The Franciscan General Hospital and the University of California, San Francisco.

OBJECTIVE: To determine the survival rate of patients with AIDS, P. carini pneumonia (PCP), and esophagitis failure who are admitted to the ICU, and to determine whether an improving survival rate (as compared to an earlier era) can be attributed to patient selection.
Methods: The study used a retrospective cohort design. Patients with AIDS and PCP who were intubated for respiratory failure at San Francisco General Hospital between January 1984 and December 1984 were studied. Hospital survival rates, long-term outcome, and severity of illness (including APACHE II scores) were measured, and compared to those of patients with PCP and respiratory failure hospitalized between 1981 and 1983.
Results: The hospital survival rate for the 50 patients in the 1984-85 cohort was 40%, compared to 14% for the 42 patients in the 1981-83 cohort (p<0.01). Age, episode of PCP, time since AIDS diagnosis, vital signs at hospital admission, respiratory, chemist, renal, and hepatic function, and APACHE II score did not differ significantly between the two cohorts. Anti-PCP therapy was similar in both cohorts. Although out-hospital survival was much more frequent in 1984-85 cohort than in the earlier era (77% vs. 26%), its use in individual patients was not associated with better outcome. There was no significant difference in 1 year survival rates between the 2 cohorts (7% vs. 24, by life table analysis).

Conclusions: The short-term outcome of patients with AIDS, PCP, and respiratory failure in 1984-85 has improved as compared to an earlier era. The improvement cannot be explained by patient selection, based on commonly measured prognostic variables, or by therapeutic advances. This improvement may result in a change in ICU utilization by patients with AIDS.

T.B.0.29 ORAL COBICISTATINS PREVENT ACUTE RESPIRATORY FAILURE IN AIDS-RELATED PNEUMOCYSTIS CARINI PNEUMONIA

Montagne, A.J., Lerman, L., Levin, N., Bullock, A., Schneider, M., and Ruddy, J.

AIDS Research Program, St. Paul Hospital, University of Alberta, Edmonton, Canada.

OBJECTIVE: To assess the role of adjunctive oral cobicistatins in the prevention of acute respiratory failure in patients with moderately severe AIDS-related Pneumocystis carini pneumonia (PCP).

METHODS: Randomized, double-blind, placebo controlled trial. A total of 60 patients are being studied. Inclusion criteria include:

1. First episode of PCP
2. PaO₂ 45 to 55 mm Hg (Fio₂ 21%)
3. No other active pulmonary pathology
4. No immunizations for pneumococcal pneumonia
5. Not on anti-PCP medications for more than 24 hours

Consenting subjects are randomized in blocks of 10 to placebo or prednisone 40 mg/kg PO bid for 7 days followed by 14 day tapering regimen. Acute respiratory failure (ARF) is defined as a 20% drop in oxygen saturation at day 3 as measured by pulse oximetry while breathing room air. Patients developing ARF are considered a failure of treatment and the code is broken.

RESULTS: To date, 30 subjects have been studied. Mid point interim analysis demonstrates that ARF developed in 4 out of 15 patients receiving placebo versus 1 out of 15 patients receiving adjunctive oral cobicistatins (p=0.05 Fisher exact test). All 8 patients developing ARF in the placebo treated group recovered rapidly after the initiation of conventional therapy. The single patient who developed ARF in the cobicistatins group went on to die on day 4. One further patient in the cobicistatins group died after resolution of his PCP from an unrelated cause (CNS lymphoma).

CONCLUSIONS: Oral cobicistatins prevent the development of acute respiratory failure in patients with moderately severe PCP. Furthermore, our results support the use of corticosteroids after respiratory failure develops in patients with AIDS-related PCP.

* Supported by a grant from the National AIDS Research Program (NIDDK), and St. Paul's Health, Canada.

T.B.0.31 CLINDAMYCIN/PRIMIDONE FOR P. CARINI PNEUMONIA IN AIDS.

Tombs, Gail; Fournier, S.; FGA4007, KJ, Leicester, U.K.; Pflanzl, U.J., Veiga, C.

Hôpital-Clouard de Montréal and Université de Montréal, Montréal, Québec, Canada.

Objective: To assess the tolerance, safety and the clinical outcome of clindamycin/primidone (Cln/Prm) in the treatment of P. carini pneumonia (PCP) in patients with AIDS.

Methods: This is an open clinical trial including patients with AIDS in whom "conventional" therapy for PCP failed or was not tolerated. The clinical outcome was assessed in patients with proven or highly probable PCP. The tolerance and safety was monitored in the above patients and in patients with possible PCP.
Results: So far 33 episodes of PCP (19 proven; 8 highly probable and 6 possible) were treated: 1st episode -21 cases and 2nd episode -12 cases. The Cln/Prm was given after 2-6 days of "conventional" therapy in 27 patients and as the initial treatment in 6 cases. Clinical response was defined as cure - 23 patients; improvement - 2 cases; failure - 2 patients. The cure rate of clinical response was less than 68 in 16 patients, 72 in 5 patients and 6 days in 2 patients. Adverse reactions were encountered in 15 out of 33 patients: neutrophilia rash in 10 patients (with fever, leukopenia or neutropa in 3, 2 and 1 of them respectively); mild diarrhea - 1 case. The duration of follow-up was 1 week (11 months); eight patients were followed for more than 7 months. In spite of no specific anti PCP prophylaxis only 3 patients had a relapse after 10, 10 and 9 months respectively.
Conclusion: Our results prove that a continued consecutive treatment with Cln/Prm in the therapy of PCP in patients is feasible and worthy.

Colloque Symposium



Aspects cliniques Clinical Aspects of AIDS

Problèmes de laboratoire dans le diagnostic du SIDA Laboratory Issues in the Diagnosis of AIDS

T.B.O.32

LES ANTIGÈNES HIV-1 CIRCULANTS
Carpene R037211X
Hôpital Necker-Infirmerie Médecine, Paris, France.

La présence d'antigènes HIV-1 dans le sérum de sujets infectés est le reflet de la réplication persistante du virus dans l'organisme. Leur détection est réalisable par des techniques d'immunoanalyse qui sont commercialisées. Ces techniques sont fiables, faciles à réaliser, sensibles et reproductibles à condition de connaître les limites de leur utilisation et de l'interprétation des résultats obtenus :

- le dosage des protéines virales doit être exprimé en pg/ml pour obtenir une bonne reproductibilité ;

- l'évaluation de la valeur-seuil doit être faite dans une plus basse limite ;
- l'utilisation de dérivés capables de lier le virus est adéquate pour l'obtention d'une meilleure sensibilité et, en fait, permet l'évaluation de deux paramètres différents : les protéines virales solubles d'une part, et les particules virales complètes d'autre part. On démontre qu'il n'y a pas de proportionnalité directe entre ces deux paramètres, dont la valeur prédictive journalière fut différente.

Les antigènes HIV-1 circulants représentent un élément essentiel et indispensable pour le suivi biologique des patients et pour l'évaluation des thérapeutiques anti-virales. La présence d'antigènes HIV-1 circulants est le plus souvent corrélée à une évolution clinique défavorable. Cependant, l'absence d'antigènes circulants chez certains sujets atteints de SIDA pose le problème de l'interprétation des anticorps et des immuno-complexes et révèle un site et un stade non le reflet d'une réplication virale, mais aussi celui d'une équilibre antigènes/anticorps complexe.

T.B.O.34

IMMUNOLOGY MARKERS

Lawrence, Jeffrey, Cornell University, New York, N.Y. U.S.A.

T.B.O.36

HIV TECHNOLOGIES FOR THE DIAGNOSIS OF AIDS
Schuchman, Gerald AIDS Program, Centers for Disease Control, Atlanta, GA, USA

Specific testing for HIV antibodies and virus markers has permitted accurate diagnosis of AIDS and HIV infection. As the AIDS epidemic continues to spread, there will be a sustained need for more sensitive and quantitative assays. Higher sensitivity is needed to permit earlier diagnosis of infection which will become increasingly important as effective therapeutic interventions are developed to prevent the disease. Higher specificity is needed to decrease the number of false positives and to permit correct diagnosis of HIV infection in a larger spectrum of clinical situations where there is an incubate or indeterminate antibody profile. Quantitative tests for monitoring the virus burden and state of activity in an infected person are also needed to improve the ability to assess the clinical status of the patient and to evaluate the efficacy of new drugs and possibly vaccines.

The use of IgM-derived antigens has already shown great promise in the advancement of diagnostic testing. For developing countries, the availability of rapid, simple and inexpensive tests for HIV infection will offer the greatest hope for prevention of transmission of the virus particularly through screening of the blood supply. The application of this probe technology, particularly PCR, has already opened a new horizon for direct detection of the virus. This technology has proven useful for detecting infection in seronegative persons, for assessing virus expression and for finding and characterizing variant HIV.

Diagnostic testing for HIV will remain an important aspect of disease control even as prevention and therapy are developed for these infections. Fortunately, technology advancement for diagnosis of retroviral diseases has opened a very dynamic and an ambitious program can be expected in the development of novel diagnostic tests and test applications.

T.B.O.33

SEROLOGY TESTS FOR THE DIAGNOSIS OF AIDS
KIV, P. Shaughnessy, Tizard Centre for AIDS, Ottawa, Canada

The serological tests most commonly used for the diagnosis of HIV infection have been enzyme immunoassays using whole viral lysates to capture anti-HIV antibodies. These screen tests have been configured to have high sensitivity and are specifically, consequently, all positive results must be verified by a second procedure, such as immunoblot, immunofluorescence (IFA) or radioimmuno precipitation (RIP). In most settings, these tests are highly reliable and quality assurance programs have demonstrated this. In some countries, these assays have been modified to detect antibodies eluted from dried blood spots for use in large scale epidemiological studies. Newer HIV screen tests include those using recombinant proteins, synthetic peptides and antigens from both HIV-1 and HIV-2 as the capture antigens. Competitive EIA tests are particularly suitable for differentiating HIV-1 and HIV-2. Immunoblots utilizing recombinant proteins are available and have undergone preliminary evaluation. Simple, often rapid, HIV antibody detection assays have been developed for use in developing countries and emergency situations in developed nations. The performance characteristics of these tests can be quite good, but positive results must be verified by another method such as RIP, IFA or immunoblot. Antigen capture assays may be used to detect HIV p24 in serum. This procedure has been used both for monitoring the efficacy of drugs under clinical evaluation and providing a prognostic indicator of patient outcome. The efficacy of most of these commercially available reagents is excellent, but continued successful delivery of testing strategies requires adequate product and user quality assurance programs. International collaborations, for example, those sponsored by the World Health Organization and the Pan American Health Organization have been established to assist in the development and implementation of quality assurance programs.

T.B.O.35

Viral Culture as an Adjunct to Clinical Trials: Isolation of AZT-Resistant Variants of HIV-1.

Mark A. Waldinger, Booker, S.; Tremblay, M.; Souleyns, N.; Fanning, M.; Montaner, J.S.G.; O'Shaughnessy, M.; Gelson, K.; Palais, J.; Toukas, G.; Gill, J.; Bushy, J.
*Jewish General Hospital and McGill University, Montreal, Canada.
Our laboratory has participated in a Canadian AZT trial, designed to assess the efficacy of this drug on patients with Group II or III HIV-associated disease. Seventy two patients entered this trial received 600 mg AZT per day for 16 weeks, 900 mg for 8 weeks and 1200 mg for an additional 9 weeks. After 36 weeks, drug was withheld for 8 weeks and started again after 42 weeks at 1200 mg per day. Attempts to culture HIV were routinely carried out during this period. A significant increase in the percentage of cases from whom HIV could be successfully isolated was observed both at the end of the drug wash-out period, and during the period following (80% postwash-out vs 40% prewash-out). This corresponded to decreased time to culture positivity following the wash-out period (21 days vs 19 days).

We have also shown that HIV could be isolated under conditions in which AZT (10 µM) was included in the primary viral culture medium in each of two cases in which patients had received AZT for longer than 36 weeks. Assessment of frozen viral isolates, obtained from patients on long-term AZT therapy, has revealed the presence of AZT-resistant virus in each of 9 additional cases. This property of drug resistance appeared stable, and did not disappear when such viruses were replicated in the absence of drug. These AZT-resistant isolates were, however, susceptible to inhibition by each of four other nucleoside analogues. Supported by Health and Welfare Canada.

**Colloque
Symposium**



**Aspects cliniques
Clinical Aspects of AIDS**

**Qualité des soins offerts aux personnes atteintes de SIDA
Quality of Care for Patients with AIDS**

W.B.O.13 **SIMPSON** - Quality of Care for Patients with AIDS
Dept. of Community Psychiatry
Kilpatrick, Brian G. St. Paul's Hospital, Vancouver,
British Columbia, Canada.

The community physician plays a pivotal role in provision of high quality care to persons with AIDS. The physician dealing with patients has the need to listen, to observe, to advise, and to console. In coping with AIDS, there is the additional need to advocate for our patients to provide quality care.

The physician plays different roles in each community in which he/she works. As a member of the global community, one is guided by the aims of the World Health Organization within the Global Programme for AIDS. These are information, education and communication to prevent further transmission of human immunodeficiency virus and to provide care to those already infected. With national and regional communities, one functions as educator, care-giver, and case reporter. Within the community of health care providers, one may be seen to be the coordinator of other care providers both institutional- and community-based, in addition to other roles.

Special roles may evolve in considering the community of patients of each physician. Physicians working within the general community have roles different from those of physicians whose patients' community encompasses primarily gay/bisexual men, hospital-in- or injection drug users.

W.B.O.14 **HOSPITAL CARE OF AIDS PATIENTS**

Clumbeu, Nathan
Free University of Brussels, St-Pierre University Hospital,
Brussels, Belgium.

Due to the medical, social, ethical and psychological backgrounds of AIDS patients, HIV infection has to be viewed globally. To face the enormous medical complexity of HIV infection, re-examination of established care structures has to be considered. In this respect, as demonstrated by the SFGS model, hospital care should be a part of a coordinated program including out-patient clinic (ambulatory care) and community based organizations. Depending available resources, commitment of health care providers, pre-existing structure such as infectious diseases department, and volume of patients enter hospital variability in care exists. Ideally, hospitalized AIDS patients should benefit from a dedicated in-patient unit or at least an integrated network of related sub-specialities. To provide coordinated care and treatment for the complex multiple problem which overwhelm the patients, AIDS team should comprise infectious diseases specialists, oncologists, generalists in internal medicine and family practice, psychiatrists and psychologists and social workers in liaison with consultant physicians (mainly pneumology, neurology, gastroenterology and dermatology). This multidisciplinary coordination should ensure optimal medical care and expert nursing and should reduce stress in AIDS care providers. In addition, psychological support for staff and volunteers as well as stress reduction program addressing education and information on infection control policy, ethical response and professional responsibility and psychological burden should be part of hospital policy.

W.B.O.15 **THE OUTPATIENT CLINIC IN AIDS CARE**

Yehlekin, Dan. University of California, San Francisco, San Francisco, CA, USA.

The most effective humane and efficient care for HIV disease requires well-coordinated care of the resources outside the acute hospital setting, particularly of the outpatient clinic. In San Francisco, dedicated AIDS clinics have allowed for the provision of comprehensive medical and psychosocial care that is oriented to the patient's common needs. In one model, physicians of varying professional/specialty backgrounds work as a team supplemented by experienced nurse practitioners and physician assistants. Social needs are provided by professional and volunteer counsellors, social workers and psychiatrists. Representatives of several community-based organizations are on the clinic staff and are able to provide effective referral to the services of these organizations. Also, clinic users are expert in HIV disease recognizing and resolving potential problems. This system combined with a model AIDS support unit, has enabled the continued reduction in the average length of hospital stay without compromising the quality of medical care delivered. Cases of HIV disease cure are lower in the San Francisco area than elsewhere in the United States.

The role of the outpatient clinic is central to the model of care in San Francisco. It serves as the home of the full-time provider staff and has provided a base for extensive studies of the cost of AIDS care as well as of new therapies. The opportunity to interact with a full range of HIV disease patients reinforces the commitment of the staff to maintain the best care possible in the community, further controlling overuse of in-patient services. This model works well in catering for a large population of patients most of whom are educated homosexual men in a city with a supportive attitude to AIDS issues. Clearly, stress would exist in many other settings that comprise HIV disease care. Many hospitals are reluctant to openly provide AIDS care and populations of drug users with HIV infection are burdened by other health and economic concerns. Nevertheless, dedicated AIDS clinics have been used in diverse situations with common success.

W.B.O.16 **HOME CARE THERAPY**

Walker-Martin, Jeanne. Visiting Nurse and

Hospice of San Francisco, San Francisco, California, USA.
In 1982, when Visiting Nurse and Hospice of San Francisco (VNH) began to receive referrals for people diagnosed with AIDS, Hospice professionals have sought a means to face organizational challenges regarding the provision of services for this population. Traditional family support systems were often insufficient, attendant care was often needed around the clock, and both private and public insurance were usually inadequate to cover the cost of care.

Since that time, VNH has provided support services to over 2000 persons with AIDS/HIV disease in the home setting or in the agency's residential care facility, Conita Home Hospice. This presentation will describe the development of the VNH AIDS Home Care and Hospice Program, and the special clinical features of the interdisciplinary team approach which combines the skills of physicians, social workers, trained paraprofessionals (attendants), and nurses, social workers, trained paraprofessionals (attendants), and volunteers with the support of family members or friends to provide home and hospice care to persons with AIDS.

- I. Overview of the AIDS Home Care and Hospice Program
 - A. Development from 1982-1989
 - B. Representation of the interdisciplinary team approach
- II. Management of the terminally-ill AIDS patient at home
 - A. Several important clinical considerations
 1. Pain and symptom management
 2. Mental status deterioration
 3. Substance abuse
 - B. Psychosocial Concerns
 1. Multiple loss issues
 2. Lack of traditional supports
 3. Minimal financial resources
- III. Reimbursement considerations

W.B.O.16.A **AIDS AND US VETERANS: A COOPERATIVE CARE APPROACH IN A**

MULTI-CENTRAL HEALTH CARE SYSTEM
Allen, Robert E.; Petersen, M. and Mather, S.B.
Department of Veterans Affairs, Washington, D.C., USA.

Objectives: To describe how the Department of Veterans Affairs (VA) national health care system responded to the needs of veterans with AIDS.
Methods: VA has one of the largest and most complex health care systems in the world, consisting of 173 medical centers, 133 outpatient clinics, 117 nursing homes, 27 domiciliarys and 134 Vet centers, employing approximately 230,000 individuals. VA has cared for approximately 7,000 AIDS patients using a comprehensive, multidisciplinary approach.
Results: Quality health care has been provided approximately 66 of all AIDS patients in the US to US differentiating centers. The comprehensive continuum of care includes voluntary testing with intensive pre- and post-test counseling, clinical evaluation and treatment, as well as hospital based home care, chronic placement and hospice care, including bereavement counseling for partners and family. Advanced research is conducted in many medical centers by the same clinicians caring for the patients and patients have opportunity to participate in clinical trials and other research studies. Health professional and other staff training programs in AIDS are ongoing in the VA.

Conclusions: Over 66 of all of the AIDS patients in the USA come to the VA for care. This large government run health care system has responded to the epidemic with clinical care, research and educational programs. These coordinated efforts have made it possible for any eligible veteran in the US to receive care for their AIDS related problems at any VA medical center.

Séance thématique Specialty Session



Aspects cliniques Clinical Aspects of AIDS

Hémophilie : histoire clinique et études de cohortes Hemophilia: Natural History/Cohort Studies

W.B.O.23 SURVIVAL OF PATIENTS WITH HEMOPHILIA-ASSOCIATED AIDS IN THE UNITED STATES
 Stein-Dorson, Jeanette; Holmes, J.; Mahoney M. Centers for Disease Control, Atlanta, Georgia, USA

Objectives: To examine the survival of hemophilic patients after the diagnosis of AIDS.
Methods: Using national hemophilia-associated AIDS surveillance data and the life-table method of analysis, we calculated the median survival and the cumulative probability of survival for all and selected subgroups of U.S. hemophilic patients after the diagnosis of AIDS.

Results: The median length of survival was 11.7 months; the cumulative probability of survival was 49.2 ± 2.0% at one year and 28.9 ± 2.3% at two years. The length of survival varied by age at the time of AIDS diagnosis:

<13 years	13-32 years	32-52 years	>52 years
Median survival: 12.0 mo	16.4 mo	9.0 mo	3.0 mo

Patients diagnosed before 1986 had a median survival of 4.8 months compared with 15 months for those diagnosed in 1986 or later. Length of survival did not differ significantly by race, complication disorder, AIDS manifestation at the time of diagnosis, or region of residence. Seven patients survived longer than 36 months after AIDS was diagnosed. These patients were more likely to have received the 1987 revision of the CDC AIDS surveillance case definition than other patients.

Conclusions: Patients with hemophilia-associated AIDS patients are similar to those reported in other risk groups, excluding patients with Kaposi's sarcoma. Length of survival decreased with increasing age and improved over time. In contrast to other risk groups, no difference in survival was associated with race.

W.B.O.25 NATURAL HISTORY AND IMMUNORESPONSE OF HIV INFECTION IN INFECTED HEMOPHILIACS
 Sullivan, John L.,* Neap, R.,* Brewster, D.,** Levine, P.,** University of Massachusetts Medical School, ** Worcester Memorial Hospital, Worcester, Massachusetts, USA

Objectives: To evaluate the natural history of HIV infection and HIV specific immune response in patients with hemophilia.

Methods: A prospective study of 154 individuals with hemophilia was carried out over a 5 year period. Specific studies included HIV viral culture, serum p24 detection, lymphocyte surface marker analysis, neutralizing and AXC antibody studies, and detection of HIV specific CD4 activity.

Results: Over the first five years of observation 21 of 136 seropositive individuals (15%) developed AIDS. HIV was isolated from approximately 80% of infected individuals and 18% had detectable (>30 pg/ml) p24 core antigen in serum. Absolute numbers of CD4 T cells progressively declined in 80% of those infected while 16% had stable circulating CD4 cells. Activated (DR positive) CD8 T cells progressively increased from <2% to 21% of total CD8 T cells. Eighty percent of HIV seropositive individuals had detectable circulating cytotoxic T cells directed against HIV gag and envelope proteins. In addition HIV seroconversion was rapidly followed by the appearance of AXC antibodies (titers from 1:1000 to 1:1,000,000) directed against only HIV envelope proteins. Neutralizing antibodies were slow to appear and persist in extremely low titer (few <10 to 100).

Conclusions: These results suggest that persistence of active CD4 and AXC response in the absence of broad neutralizing antibody may result in progressive immune attrition with development of symptomatic disease.

W.B.O.27 CANADIAN NATURAL HISTORY STUDY (CNHS): HIV INFECTION IN HEMOPHILIA (HM) AND OTHER BLEEDING DISORDERS (1985-1989).

Prosser, M.,* Collins, A.L., S.K. Card, R., Garvey, S.,* Groom, G.,* Kobrin, N.,* L.J. Rubin, S.,* Sirovnick, R.,* and Lissak, C.,* Universities of Calgary, Memorial, Saskatchewan, Toronto, British Columbia, and McGill, Canada.

The CNHS Initiated in Jan 1985 enrolled 372 patients from 12 Canadian Hemophilia Centers. These included 285 Hem A, 48 Hem B, 37 von Willebrand disease (vWD) and 3 others. There were 86 children and 24 adults. 210 patients had severe, 72 moderate and 80 mild disease. In the 1988, 323 patients remained in the cohort, as 28 had withdrawn, and 28 had died. 16 of the deaths were due to AIDS. The latest observations are as follows: (1) The HIV seropositive (sp) rate was discordantly higher among Hem A (182 of 249) than Hem B (2 of 43), vWD (4 of 28) or others (1 of 3). The most important determinant for sp was the use of non-heated factor VIII concentrates as 81% of those severe Hem A receiving this product were positive of a sp vWD had received this product. One positivity is that before heated concentrates were supplied (Jul 1985), the Canadian volunteer plasma donation system was self sufficient for Factor IX concentrate, whereas 50% of the factor VIII had to be imported. (2) Progression of HIV disease was evident. At enrollment, of the 164 sp patients (44% of 372) CDC III, II, I & IV diseases were 72, 20, 10, and 10, respectively. In 1987, 170 patients were post (53% of 323). The CDC III, II, I & IV diseases were 47, 7 & 46. Including the 16 who died of AIDS, the number with CDC IV disease had increased from 10 to 61. (11) 6 patients seroconverted in 1987. This was traced to a factor VIII concentrate dry-heated at 60°C x 30 h.

W.B.O.24 OBSERVATION INDEX FOR AIDS AND OTHER HIV OUTCOMES IN A COHORT OF HEMOPHILIACS IN WESTERN PENNSYLVANIA
 Rosen, Lawrence, Y.,* Kirsney, L.A.,** University of Pittsburgh School of Medicine, Hemophilia Center of Western Pennsylvania; **Graduate School of Public Health, U.S.A.

Objective: To describe the distribution of AIDS and HIV-related outcomes following HIV seroconversion in a cohort of hemophilic patients.

Methods: A well-characterized cohort (n = 64) of HIV-infected hemophilic from Western Pennsylvania, on whom HIV seroconversion dates are known, have been followed prospectively for development of clinical manifestations of HIV infection including AIDS, AIDS-related complex (ARC), and CDC class IV infection. Kaplan-Meier estimates of cumulative risk for AIDS and other significant HIV outcomes by duration of infection were determined. **Results:** Of the 64 HIV-infected hemophilic, 27 (42%) have developed AIDS and 12 (14%) have developed ARC or CDC Class IV infection (through, herpes zoster). 80 cases of AIDS were observed in under two years' duration of infection. Using Kaplan-Meier product-limit method estimators, by 4, 6, and 7-1/2 years' duration of infection, the proportion developing AIDS is 12, 29, and 43%, respectively. The cumulative estimates for developing either AIDS or ARC/IV by 7-1/2 year duration is 60%. By age, for those > 30, 18-30, and < 18 years, the proportion developing AIDS by 6 years after infection is 50%, 25% and 5% (< .01).

Conclusions: Half of this cohort had developed AIDS or ARC/IV by 6 years' duration of infection. There appears to be a significantly shorter incubation to AIDS/HIV outcomes in those over 30 years of age at seroconversion.

W.B.O.26 NATURAL HISTORY OF HIV IN PATIENTS OF THE BOSTON HEMOPHILIC COHORT STUDY.
 Ames, Bernard, S.,* Miesse, P.,* Brackman, N.H.,** Maitin, C.,** van Loon, R.,** Kaarst, J.,** *Institut für experimentelle Haematologie, Bonn, FRG, **Massachusetts Institute of Technology, Boston, USA

Objective: To describe the natural history of HIV-infection in adult hemophilic patients.

Methods: 343 adult patients at Boston Hemophilia Center were tested positive for HIV in 1985. Since 1986, 313 patients have been regularly followed up, including clinical examination, routine laboratory, lymphocyte antibody, western blot and virus isolation.

Results: Six years after infection 18 (5%) of the entire cohort had developed AIDS. The most frequent manifestation of AIDS was PCP. HIV seroepidemiology: 12% toxoplasmosis, 7% HSI, 7% One 82 was observed. In 88% of patients 74 cell count decreased 50% or more over the observation period. Prognostic markers for progression to AIDS (other than decreased T4 cell count) were elevated 149, successful virus isolation and lines of anti-p24-antibodies.

In asymptomatic patients not treated with AZT (n=213), T4 cell count decreased 87 (41%) over Actual 74 cell distribution:

<100	101-200	201-300	301-400	401-500	>500
11	29	37	53	56	41

Conclusion: Our findings suggest that most HIV-infected hemophilic will eventually develop AIDS.

W.B.O.28 NINE YEAR FOLLOW-UP OF A COHORT OF 113 ANTI-HIV SERONEGATIVE HEMOPHILIACS

Lee, Christine A., Phillips AN, Elrod J, Jamesy G, Griffiths, PD, Kennell, PBA Royal Free Hospital and School of Medicine, London, England.

Objective: To assess the natural history of HIV disease in 113 infected hemophilic and 1 sexual contact.

Method: Patients were reviewed at frequent intervals from the time of seroconversion (established by retrospective testing in 69 (1983) patients) until November 1988. **Results:** The first seroconversion was November 1979 and the last July 1985. The median length of follow-up from the first positive anti-HIV test was 2 years 1 month. By 29 November 1988, 61/113 (54%) patients were symptomatic and 21/113 (19%) had developed AIDS.

SYMPTOMATIC	Thrombocytopenia	7 (6%)	AIDS	HIV wasting syndrome	2
	Herpes zoster	11 (9%)		Oesophageal candida	2
	Interstitial pneumonia	18 (16%)		PCP	1
	Oval candida	17 (15%)		Aspergillus pneumonia	1
	Schistosoma dermatitis	2 (20%)		KAL	1
				Cerebral toxoplasmosis	1
				Lymphoma	2
				Diagnosed mycobacteria	1
				with cerebral abscesses	1

Amongst 59 hemophilic with a known date of seroconversion, the clinical cumulative incidence of symptoms was 60% and of AIDS 70% after 9 years of seropositivity (Kaplan-Meier estimate). **Conclusions:** This nine year follow-up confirms that the majority of anti-HIV positive patients progress to symptoms and AIDS. This cohort may provide a control for future studies of therapy in asymptomatic patients.

Colloque
SymposiumAspects cliniques
Clinical Aspects of AIDSInfection par le VIH : atteintes à certains organes
HIV Infection: Organ Specific InvolvementW.B.O.29 CLINICAL GASTROINTESTINAL (GI) DISEASES IN AIDS
Kotler Donald, St Luke's/Boos., Columbia PAS, NY

The GI tract is vulnerable to immune deficits, due to poor physical protection and a contaminated enteric environment. Multiple complications occur, based upon specific immune deficits in secretory immunity, impaired T-cell function, macrophage dysfunction and diminished immune surveillance against neoplasms. Oral and esophageal disorders usually are due to yeast infections, while aphthous ulcers also are common. Intestinal diseases can be grouped as primary infections of enterocytes, secondary involvement from systemic or otherwise disseminated disorders, and a syndrome of inflammatory bowel disease. Enterocyte infections are caused by protozoans such as cryptosporidium, microsporidium and isospora produce a clinical picture of 'short bowel syndrome'. Secondary involvement by viruses, such as CMV, fungal infections, mycobacterial infections, or tumors are prevalent. There is a prominent systemic reaction such as wasting, as variable focal symptoms based upon the precise site of disease expression. Many HIV-infected patients have an inflammatory bowel disease of uncertain etiology. Recent studies suggest that HIV may be a primary pathogen in the gut. Liver disease often is related to mycobacterial or viral causes but biliary tract diseases can cause major morbidity. The major sequelae of intestinal dysfunction are progressive malnutrition and dehydration, though other specific medical or surgical complications occur.

W.B.O.31 CLINICAL CENTRAL NERVOUS SYSTEM INVOLVEMENT

Pederson, Court, Department of Infectious Diseases, Hvidovre Hospital, Hvidovre, Denmark.

W.B.O.30

CLINICAL NON-MARROW INVOLVEMENT

Gelman, Karen, St. Paul's Hospital, London, United Kingdom

W.B.O.32

PATHOLOGY OF THE CENTRAL NERVOUS SYSTEM IN AIDS

Michaud, Jean, Department of Pathology, Ste-Justine Hospital and University of Montreal, Montreal, Canada

The neuropathological examination of the human central nervous system in AIDS discloses lesions in most cases and these are frequently a significant cause of morbidity and mortality. A wide variety of lesions are found and these may be classified in four groups:

- Direct Human Immunodeficiency Virus infection: the most characteristic process is a subacute encephalitis associated with multilacinated cells in 111-defined microglial nodules. White matter demyelination and vacuolar myelinolysis are frequently part of the picture. The pathogenetic issues mostly mediated by the microglia-macrophage complex but the pathophysiology is yet poorly understood.
- Opportunistic infections: toxoplasmosis, several types of viral encephalitis (cytomegalovirus and PML being the most frequent), mycoses and mycobacterial infections are the most frequent.
- Cerebral tumors: approximately 5% of AIDS patients will develop a primary intracerebral lymphoma which is usually of B-Cell type. The Epstein-Barr virus is presumed to play an important role in its etiology. Secondary CNS involvement by systemic lymphomas or Kaposi sarcomas is also found.
- Non-specific and non AIDS-related lesions.

In AIDS, two or several of the above mentioned groups of lesions or infectious organisms may be found in the same patient. Also, variations according to age groups, countries and patient subgroups as related to the etiology of the syndrome are now recognized.

W.B.O.33 THE LUNGS, THE CAUSE OF DEATH, AND BACTERIAL INFECTIONS IN AIDS: WHAT AUTOPSY STUDIES SHOW
Nichols, Larry, currently at Research Triangle Institute, Research Triangle Park, NC, USA

The lungs are the primary target of the most serious opportunistic infections of AIDS, the ones most frequently responsible for AIDS patients' deaths. Autopsy studies in the early years of the AIDS epidemic showed an extremely high rate of cytomegalovirus (CMV) infection at the time of death, with CMV pneumonia frequently playing an important role in the patients' deaths. Throughout the epidemic, most AIDS autopsy studies have corroborated the widespread clinical impression that *Pneumocystis carinii* pneumonia is the most common cause of death in AIDS patients. Recently, in a series of 40 AIDS autopsies at the New England Deaconess Hospital and Lasky Clinic in Boston, we found that bacterial (non-mycobacterial) infections were sole or contributing causes of death in 17 cases (42%). Eleven of these 17 bacterial infections were pneumoniae due to *Streptococcus pneumoniae*, generally superimposed on *Pneumocystis carinii* pneumonia, CMV pneumonia or lung injury from previous bouts of such processes. Given the particular propensity of *Streptococcus pneumoniae* to superinfect lungs injured by other infections, recognized in multiple secondary epidemics of *Streptococcus pneumoniae* following influenza epidemics, it is not surprising for *Streptococcus pneumoniae* to emerge as a secondary opportunist in AIDS patients with previous or underlying lung disease. These results confirm the importance of respiratory failure as a mode of death and show the importance of bacterial infections in general, and *Streptococcus pneumoniae* in particular, in patients with AIDS.

**Colloque
Symposium**

**Aspects cliniques
Clinical Aspects of AIDS**
**Essais cliniques : points de vue des "acteurs"
Clinical Trials: The "Actors' Perspective**

W.B.O.46 INVESTIGATORS' PERSPECTIVE
 Ronald, Allan B. Department of Internal Medicine,
 University of Manitoba, Winnipeg, Manitoba, Canada

W.B.O.47 Clinical Trials in AIDS: The Regulatory Perspective,
 ETHEL C. COOPER, DIRECTOR, DIVISION OF REGULATORY DRUG
 PRODUCTS, U.S. Food and Drug Administration,
 Rockville, Maryland, U.S.A.

FDA, in its regulatory role, is a major player in new drug development in the U.S.A. This role has become more intensive and extensive in AIDS drug development, as outlined in new interim regulations (21 CFR 312 Subpart E). From the scientific/regulatory perspective, three issues have been most problematic in the design and conduct of clinical trials in AIDS. The first issue stems from constraints on the choice of the most appropriate control group, whether placebo, no treatment, dose comparison, active, or historical control. A second major issue is selection of primary outcome measures on which decisions regarding efficacy should be made, particularly for new antiretroviral agents. A beneficial impact on important clinical endpoints is required to demonstrate efficacy of a new drug in most diseases. In the case of complex, chronic, life-threatening diseases such as AIDS, pressure builds rapidly to substitute near-term, "harder" clinical endpoints. The third major issue is timing of access to experimental drugs by patients with life-threatening diseases. The individual's "right" to try a new drug very early in development may conflict with society's need to determine systematically which drugs are safe and effective, and which are not. If appropriate and well-designed, randomized controlled trials (RCT) are not conducted during the "window of opportunity" following the demonstration of preliminary safety and activity, but before widespread use makes RCT difficult to perform because of the presumed but not proven efficacy of the drug, therapeutic advances in the treatment of AIDS will be delayed if not lost.

W.B.O.48 THE ROLE OF THE PHARMACEUTICAL INDUSTRY IN DRUG
 AND VACCINE DEVELOPMENT
 Patriciani, John C.

Pharmaceutical Manufacturers Association, Washington, DC, USA

The pharmaceutical industry has responded to the need for various strategies to intervene in the HIV global epidemic in a remarkably broad and rapid manner. Diagnostics became available within a year of the discovery of HIV as the etiologic agent, the first drug was approved only three years later, as was the first vaccine clinical trial. At the present time, there are over 50 companies involved in the development of over 60 medicines for the treatment or prevention of HIV infection.

Clinical trials remain the single most important means of assessing the actual safety and efficacy of new medicines, and the pharmaceutical industry has been working cooperatively with governmental organizations and others to evaluate potentially useful new agents. While there have been problems in the implementation of progress, the overall model of government/industry cooperation in the development of HIV-related medicines is one which PMA member companies support. Specific suggestions for improving the working relationship among industry, government, clinical research centers, and patients will be made.

W.B.O.49

PATIENTS' PERSPECTIVE

Paul Leblanc

W.B.O.50 THE CHALLENGE OF TESTING THERAPIES FOR HIV INFECTION

Roth, David, National Institute of Allergy and
 Infectious Diseases, Bethesda, MD, U.S.A.

W.B.O.51 ETHICS AND CLINICAL TRIALS

Robert A. Levine, Yale University School of
 Medicine, New Haven, CT, USA

The randomized clinical trial (RCT) is the gold standard for establishing the validity of medical therapies. RCTs must be conducted in accord with established ethical norms including: There should be a) sound scientific design, b) competent investigators, c) a reasonable balance of risks and benefits, d) informed consent, and e) equitable selection of subjects. This presentation is an overview of some of the more difficult ethical problems encountered by clinical trialists. Must subjects be informed that their therapy has been selected by chance? What should they be told about preliminary data and about alternatives to participation in the RCT? What is the role of the null hypothesis (or clinical equipoise) in the ethical justification of the RCT? Are placebo controls justified when subjects have lethal diseases? Is participation in a RCT a burden or a benefit? Should vulnerable populations be protected from the burdens of participation or assured access to the benefits of participation in RCTs? In what circumstances should alternative designs -- e.g., historical controls -- be considered? Satisfactory answers to such questions require careful consideration of the relevant facts about particular RCTs and prospective subject populations.

**Science Thématique
Specialty Session**



**Aspects cliniques
Clinical Aspects of AIDS**

**Thérapie : la ribavirine et les autres médicaments anti-VIH
Therapy: Ribavirin and Other Anti-VIH Drugs**

Th.B.0.1 PHASE I TRIAL OF ORAL RIBAVIRIN IN HIGH RISK PATIENTS FOR AIDS
 Richard B. **, Richard B. **, and Juriss K. **,
 *Cornell University Medical Center, New York, NY, USA
 **State University of New York, Albany, NY, USA

Objective: To determine tolerance and effect on virologic and immunologic parameters of oral ribavirin in high risk patients. **Methods:** Two groups of eight men each received either 1600 mg QID for 2 weeks (Group I) or 800 mg BID for 4 weeks (Group II). All patients also received zalcitabine, zidovudine, and zalcitabine. **Results:** All patients were well tolerated. Ribavirin was well tolerated. **Conclusion:** Oral ribavirin is well tolerated and may be useful in the treatment of HIV infection.

	8 week-treatment				12 week-treatment			
	CD4	CD8	CD8/CD4	CD4	CD8	CD8/CD4	CD4	CD8
Mean (SD)	441 (102)	441 (102)	1.00	441 (102)	441 (102)	1.00	441 (102)	441 (102)
SD (p value)	132 (0.03)	132 (0.03)	0.02	132 (0.03)	132 (0.03)	0.02	132 (0.03)	132 (0.03)
CD4/CD8 ratio	0.60	0.62	0.15	0.95	0.91	0.09		

Similar results were observed in Group B patients. **Conclusion:** Oral ribavirin is well tolerated and may be useful in the treatment of HIV infection. **Keywords:** ribavirin, AIDS, immunologic and virologic parameters.

Th.B.0.2 PHASE III TRIAL OF RIBAVIRIN + ZIDOVUDINE IN HIGH RISK PATIENTS FOR AIDS
 Richard B. **, Richard B. **, and Juriss K. **,
 *Cornell University Medical Center, New York, NY, USA
 **State University of New York, Albany, NY, USA

Objective: To assess the safety, toxicity, clinical immunologic and antiviral effects of oral 800 mg ribavirin administered daily for 4 months. **Methods:** 120 patients were randomized to receive either 800 mg BID for 4 weeks (Group I) or 1600 mg QID for 2 weeks (Group II). All patients also received zalcitabine, zidovudine, and zalcitabine. **Results:** All patients were well tolerated. Ribavirin was well tolerated. **Conclusion:** Oral ribavirin is well tolerated and may be useful in the treatment of HIV infection.

	8 week-treatment				12 week-treatment			
	CD4	CD8	CD8/CD4	CD4	CD8	CD8/CD4	CD4	CD8
Mean (SD)	441 (102)	441 (102)	1.00	441 (102)	441 (102)	1.00	441 (102)	441 (102)
SD (p value)	132 (0.03)	132 (0.03)	0.02	132 (0.03)	132 (0.03)	0.02	132 (0.03)	132 (0.03)
CD4/CD8 ratio	0.60	0.62	0.15	0.95	0.91	0.09		

Similar results were observed in Group B patients. **Conclusion:** Oral ribavirin is well tolerated and may be useful in the treatment of HIV infection. **Keywords:** ribavirin, AIDS, immunologic and virologic parameters.

Th.B.0.3 2',3' DIDEHYDROCYTIDINE (DDC) IN THE TREATMENT OF PATIENTS WITH AIDS AND ARC
 Michael J. Galpin, J. * Thompson, J. *, Wilson, D. **, Donatucci, L. **, Soo, M. **,
 *Purton Research Group, Sherman Oaks, CA, USA **Huffmann-La Roche, Nutley, NJ, USA

Objective: To evaluate tolerance and antiviral activity of didoxycytidine (DDC) in a multiple dose study in patients with AIDS or ARC. **Methods:** Twenty-one patients with AIDS or ARC with p24 antigen > 70 ng/ml and CD4 < 400 cells/mm³ received DDC orally at a dose of either 0.03 mg/kg once a day or 0.01 mg/kg every 8 hours for 24 weeks. **Results:** At 0.03 mg/kg, mild peripheral neuropathy was reported in 3 of 11 patients between weeks 8 & 17. At 0.01 mg/kg, no cases of peripheral neuropathy were noted. Other adverse experiences included mild dyspepsia and nausea. **Conclusion:** DDC is well tolerated. Different dosing schedules and regimens demonstrated a different degree of antiviral activity. The 0.01 mg/kg regimen was most effective. Further study to evaluate DDC long-term safety and efficacy using clinical endpoints is warranted.

Th.B.0.4 ESCALATING DOSE PHASE I STUDY OF INTRAVENOUS AND ORAL 2',3'-DIDEHYDROCYTIDINE (DDC) IN PATIENTS WITH AIDS OR ARC
 Yachson, Robert; Thomas RV, Ph.D.; Kaji, H.; Hattman RH, M.D.; Kato H, Ph.D.
 Clinical Oncology Program, National Cancer Institute, NIH, Bethesda, MD, USA

Objective: Two pyrimidine drugs with activity against HIV, AZT and ddC, belong to the dideoxynucleoside (ddN) family. In this study, we report a Phase I trial of oral, a parenteral ddN analog. **Methods:** 20 patients with AIDS or ARC were given 2 weeks of ddI, IV, followed by 4 or more weeks of oral dosing (given with amoxicillin) at twice the IV dose. Six dosing regimens were tested, ranging from IV doses of 0.2 mg/kg every 12 hr to 1.6 mg/kg every 8 hr. **Results:** Oral bioavailability (given with amoxicillin) was 35%, and ddI penetrated into the CSF. Two pts dropped out at 1 wk (1 because of Cytosolic mononuclein gel for personal reasons); the other 18 completed 6 or more weeks of dosing. One pt (also on TMP/SMX) developed neutropenia after 20 wks, one pt developed a morbilliform rash, and one patient reported some difficulty sleeping or irritability; otherwise, toxicity was minimal. No macrocytosis was seen. No anti-HIV response was seen at the lowest dose; however, the 15 evaluable pts on the 8 higher doses showed evidence of an anti-HIV effect. In these pts, the T4 count increased from 141/55 at entry (mean/SD) to 228/43 at wk 2 (p<0.001) and 183/37 at wk 6 (p<0.01 or w/o entry). All 7 pts with detectable serum HIV p24 antigen (Ag) at entry had a decline by wk 2 (116/37 pgs at wk 2 vs. 119/43 at entry; p=0.02). Six of these 7 pts sustained the drop in p24 Ag at wk 6. Four single pts developed delayed type hypersensitivity reactions by wk 2. Six of 4 pts had increased in vitro proliferative responses to soluble Ag. The pts generally had increased energy and gained a mean of 2 kg wt. **Conclusion:** In short term testing, ddC appears to be an oral anti-retroviral agent with significant clinical activity but with minimal toxicity.

Th.B.0.5 PHARMACOKINETIC STUDIES OF RECOMBINANT SOLUBLE CD4 IN PATIENTS WITH AIDS AND AIDS RELATED COMPLEX
 John James **, Doris A. **, Giuseppe J. **, Robin L. **, Sherwin, S. **,
 *University of California San Francisco, San Francisco, CA, **New England Deaconess Hospital, Harvard Medical School, Boston, MA, USA ***Genetech Inc, South San Francisco, CA, USA

Objective: To describe the pharmacokinetics of intravenous human injection of recombinant soluble CD4 in patients with AIDS and ARC. **Methods:** Patients with AIDS and ARC, T-cells < 400 and normal hematologic and serum chemistries were enrolled in this study. One intravenous line was placed for pharmacokinetics; a second intravenous line was placed in each patient for drug administration. Soluble CD4 was administered over 3 to 5 minutes by slow intravenous push. Pharmacokinetic studies were done at 10, 20, 30, 40, 60 and 90 minutes as well as at 2, 4, 6, 8, 16, 36, and 76 hours post-injection. Pharmacokinetic studies were performed on days 1 and 6. The analysis for CD4 was performed using two monoclonal assay systems. **Results:**

Dose	T (minutes)	Duration (days)	Peak ng/ml
1 mg/kg	8	1-4	17-48
10 mg/kg	10	2-6	100-460
30 mg/kg	8	8-14	400-1350

Conclusions: Recombinant soluble CD4 given in intravenous bolus can be detected from 1.5 to 4 hours after administration at a dose of 1 mg/kg and the peak is 17-48 ng/ml. At 10 mg/kg the peak is 100-460 ng/ml. At 30 mg/kg the peak is 400-1350 ng/ml. Doses at 100 mg/kg and 300 mg/kg are being analyzed and IV administration and intravenous bolus have begun. Recombinant soluble CD4 can be detected in the serum in patients with AIDS and ARC. Increased dose of CD4 will increase the peak concentrations and the duration of CD4 detection.

Th.B.0.6 ESCALATING DOSE TOLERANCE TRIAL OF RECOMBINANT SOLUBLE CD4 IN HUMANS
 Schaller, Robert; De, Dae; Ganc, ***, Tierney, ***,
 Schneider, ***, Benochovitz, ***, et al. *Mass. Gen. Hosp., Boston, MA, USA, **Cedars-Sinai Medical Center, Los Angeles, CA, USA, **Wellington, Inc., Cambridge, MA, USA and ***NIH AIDS Program, Bethesda, MD, USA.

Objective: To study the safety and pharmacokinetics of recombinant soluble CD4 (rsCD4) when administered to humans by intramuscular or intravenous routes. **Methods:** We performed an escalating dose tolerance trial of rsCD4 (Beiggen) in which daily doses of 1 to 30mg rsCD4 were administered to a group of patients with AIDS or AIDS related complex who were preselected for the absence of antibodies to rsCD4. Tolerance was followed for adverse clinical and laboratory events during the 28 day dosing period. Pharmacokinetics of rsCD4 were determined after intravenous and intramuscular administration. Antiviral activity of rsCD4 was assessed by serum p24 antigen determination, and quantitative HIV-1 cultures obtained from peripheral blood mononuclear cells and plasma. **Results:** rsCD4 was well tolerated when administered by the intramuscular or intravenous routes. No significant changes in hematologic, hepatic, or renal function were observed. No antibodies to rsCD4 were detected following therapy. Pharmacokinetics of rsCD4 following intravenous and intramuscular administration, and immunologic and antiviral activity parameters will be presented. **Significance:** rsCD4 is well tolerated by humans receiving the drug for periods of up to 28 months.

Séance thématique Specialty Session



Aspects cliniques Clinical Aspects of AIDS

Test de dépistage par réaction en chaîne des polymérasés PCR Diagnostic Test

Th.B.0.7 A METHOD FOR QUANTITATING RELATIVE AMOUNTS OF HIV PROTEIN GENES IN THE TOTAL AMOUNT OF HIV DNA IN SAMPLE. THE CHAIN REACTION (PCR) METHOD. **John S. Slesny**, Department of Infectious Diseases, Cetus Corporation, Emeryville, CA, USA

Objectif: To quantify by the polymerase chain reaction, the amount of HIV protein genes present in the total amount of HIV DNA in sample. The availability of such an assay will allow the monitoring of proviral load during the natural history of infection and during various therapeutic regimes.

Méthode: Human placental DNA was spiked with known copies of HIV molecules and coamplified in the presence of a primer pair that amplifies a 100 bp fragment of HIV-1 and a primer pair that amplifies a 262 bp control sequence, HLA-DQB1. Amplified products were detected by autoradiography following hybridization with HIV and HLA related probes and scanning by polyacrylamide gel electrophoresis. Because of differences in size, the amplified products can be differentiated. To quantify the amount of each product, the gels were scanned with a radioisotope system. Standard curves were generated by varying the amount of HIV and HLA products. Probes against known amounts of each target present prior to amplification. By extrapolating from the standard curves, the relative amount of HIV targets in a given sample was determined.

Résultats: By altering the ratio of HIV and HLA primers, we were able to simultaneously amplify both sequences. In comparing the HIV assays, we demonstrate that 10-800 molecules of HIV can be quantitated after 30 cycles of amplification, 200-2000 molecules with 25 cycles. HIV-1 and HIV-2 molecules with 50 copies of amplicon.

Conclusion: We demonstrate in model studies that HIV and HLA sequences can be quantitatively amplified. In addition, a quantitative method was obtained for both sequences. Results describing extension of these studies to AIDS and patients on antiviral therapies will be presented.

Th.B.0.9 EVALUATION OF THE POLYMERASE CHAIN REACTION (PCR) IN A WELL CHARACTERIZED COHORT OF HOMOSEXUAL AND BISEXUAL MEN. HIV-ANTIBODY NEGATIVE RESULTS ARE RARE. **Lifton Alan R., Stanley, M., O'Malley, P., Fane, J., Jeffrey, R., Miller, F., et al.** HIV-1 Antigen, HIV-1 Antibody, HIV-1 RNA, San Francisco, CA; *Pathology Institute, Berkeley, CA, USA

Objectif: To evaluate PCR for HIV DNA in a cohort of homosexual and bisexual men whose clinical and HIV-antibody (Ab) status is known.

Méthode: We conducted blinded PCR testing on frozen lymphocytes from 167 men participating in prospective studies of HIV infection. Thirty cycles of amplification were conducted, followed by detection with probes corresponding to the gag primers; each primer/probe assay was run in duplicate. A positive result was defined as repeat (2/2) detection of HIV DNA by at least one of the two primer/probe pairs; HIV-Ab testing was performed using ELISA and (if repeatedly reactive) IFA assays.

Résultats: PCR was negative for 101/102 (98%) HIV-Ab negative men. The one PCR-positive Ab-negative sample was PCR negative on repeat testing; a second specimen drawn from the same man 8 months later was also PCR and HIV-Ab negative, suggesting the first PCR result was a false positive. PCR was positive in 5/52 (10%) HIV-Ab positive men, including 7/7 patients with AIDS, 19/19 with AIDS-related conditions, 11/11 with asymptomatic generalized lymphadenopathy and 2/28 men without signs or symptoms of HIV-infection. Overall, the PCR and HIV-Ab were in agreement on 154/167 (96%) specimens.

Conclusion: The PCR assay, using this technique and in this population, has an excellent concordance with the HIV antibody test. Antibody-negative, PCR positive results for HIV were very uncommon.

Th.B.0.11 SEROLOGIOUS DETECTION OF HIV-1 OR HIV-2 IN AIDS PATIENTS. **De Ruess and Bruchmann, A.** Centers For Disease Control, Bethesda Research Branch, Bethesda, MD, USA

Objectif: To identify the nature of human T-cell lymphotropic virus (HTLV) DNA in AIDS patients which might be complicated by the presence of other opportunistic viruses such as Herpes, Hepatitis, etc.

Méthode: High resolution PCR was used to detect the cells derived from AIDS patients. Polymerase chain reaction was performed using specific sets of primers: HIV-1: pol primer pair at positions 3015-3026 sense strand and 3154-3136 antisense strand; probe at position 3050-3074; HIV-2: pol primer pair at positions 2989-3010 sense strand and 3111-3110 antisense strand and 3158-3136 antisense strand; probe at position 3000-3074; HTLV-1: pol primer pair at positions 1465-1638 antisense strand with probe at position gag 1395-1455). The amplified products were detected by Southern blot hybridization using specific viral probes.

Résultats: We have employed the polymerase chain reaction to distinguish HIV-1 and HIV-2. Cells derived from African AIDS patients had HIV-1 proviral sequences and cells from a homophilic from Africa showed HIV-2 proviral sequences in addition to HIV sequences.

Conclusion: Multiplexed PCR provides a sensitive, accurate and quicker method to distinguish the related T-lymphotropic retroviruses.

Th.B.0.8 COMPARISON OF PCR ANALYSIS AND CULTURE IN THE DETECTION OF HIV-1 INFECTION IN HEADPHILIC PATIENTS. **Madhoo, Ruzsa, Sanyal, A., & S. K. Sanyal, J., Hoopster, J., Balfour HR Jr.** *U of Minnesota, Mpls, Mn, *Cetus Corp, Emeryville, CA, USA

Objectif: To compare the sensitivity and specificity of an HIV-1 polymerase chain reaction (PCR) assay with an HIV-1 culture method in testing HIV-1 antibody-positive and antibody-negative hemophilia patients.

Méthode: PCR analysis was performed on the PBMC DNA from 59 HIV-1 antibody-positive and 20 antibody-negative hemophilia patients. A gag primer pair (EK 18 (151-157), SK39 (1637-1663)) and Tm polymerase was used to amplify a 115 base fragment over 30 cycles. Cycle time and temperature was as follows: denaturation 2x 95°C, reannealing 2x 55°C, chain elongation 60-72°C. The amplified HIV-1 sequence was then detected by autoradiography after hybridization with a ³²P-labeled probe (EK19 (1596-1633) and gel electrophoresis. HIV-1 cultures were performed using co-cultivating 1 X 10⁶ patient PBMC with 3 X 10⁶ PMA stimulated donor PBMC in the presence of RPMI-1640, 20% fetal calf serum and 1% 2-ME. PCR and assaying for the presence of HIV-1 p24 antigen every 3 days for up to 42 days.

Results	HIV-1 Ab Positive	HIV-1 Ab Negative
HIV CULTURE +	27/29 (93%)	0/20 (0%)
HIV PCR +	57/59 (97%)	0/20 (0%)

The results indicate that both PCR and culture were PCR positive and the two PCR negative antibody-positive subjects were culture positive. Therefore, all 66 HIV-1 antibody-positive subjects had direct evidence of HIV-1 infection by either PCR or HIV-1 culture or both.

Conclusion: Both HIV-1 culture and PCR analysis have comparable sensitivities (97% and excellent specificity (100%) in the detection of HIV-1 infection.

Th.B.0.10 DETECTION OF HIV-1 DNA IN PERIPHERAL BLOOD BY POLYMERASE CHAIN REACTION (PCR) AND NON-RADIOACTIVE OLIGONUCLEOTIDE PROBES. **Adge, E. L., Beckel, L., Govey, S., Kaplan, J., and Hirsch, M.** *Duke Medical Center, Billerica, MA, USA *Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

Objectif: To detect HIV-1 DNA directly in peripheral blood mononuclear cells (PBMC) by PCR and hybridization with a non-radioactive probe.

Méthode: An oligonucleotide probe covalently linked to alkaline phosphatase has been used to detect HIV-1 sequences in DNA amplified by PCR. PBMC (3-5 x 10⁶) were isolated by Ficoll gradient sedimentation, lysed in a solution of 1.0M Tris-HCl, 100 mM NaCl, pH 7.5, 2.0 mM EDTA and boiled for 10 minutes. Two oligonucleotides flanking a conserved region of the HIV-1 pol gene (M80 isolate:1936-2112) were used as primers. Samples were subjected to 30-50 cycles of amplification. Products were detected by slot blot hybridization using the enzyme-linked probe.

Résultats: HIV-1 DNA was detected in PBMC from 20/21 (95%) seropositive individuals (CD4 Groups II-IV). Samples from 8/8 individuals negative for serum p24 antigen but positive following culture, were positive for HIV-1 DNA by this technique. DNA amplified from PBMC of seronegative individuals was negative for HIV-1 as were samples from cells infected with HIV-1, HIV-2, or CMV.

Conclusion: This sensitive non-radioactive method for detecting HIV-1 peripheral DNA, combined with improved sample processing, should be valuable in clinical and research settings.

Th.B.0.12 A MICROTITRATED DNA SANDWICH ASSAY FOR THE DETECTION OF HIV-1 IN CLINICAL SAMPLES. **Stamm, Kellin, D.P., Hung, L., Japanecki, C., Oweh, D., Pownall, and K. Maske.** Biotech Research Laboratories, Rockville, MD 20850 USA

Objectif: A microtitre based DNA sandwich hybridization assay was used to detect HIV-1 sequences in clinical samples following amplification with Polymerase Chain Reaction (PCR). HIV-1 DNA was obtained from peripheral blood lymphocytes from HIV-1 seropositive individuals and normal blood donors. It was then subjected to PCR amplification using specific primers in the HIV-1 gag region. The amplified product was hybridized in microtitre plates which contained covalently attached capture DNA sequences. A biotin labeled probe adjacent to the capture sequence was used to detect specific hybridization. Following incubation with a peroxidase-conjugated enzyme and a colorimetric substrate, the amount of hybridization was quantitated spectrophotometrically. All samples were also analyzed by Southern blotting using the labeled HIV-1 probe. Specific hybridization was quantified by cutting out the hybridized bands and counting in a scintillation counter.

Résultats: Using serial dilutions of HIV-1 infected cells with uninfected cells, the Optical Density (OD) hybridization was proportional to the amount of virus present in the sample. When the OD was off scale, dilutions of the amplified product could be performed to give a quantitative result. The test could detect 5-5 HIV-1 infected cells in 10⁶ uninfected cells, or about 10-11 molecules of HIV-1 DNA. DNA from a total of 164 clinical samples was amplified by PCR and the amplified product tested by the microtitre assay. The Southern Blot results were in complete agreement between the DNA sandwich and the ³²P Southern Blot results was observed.

Conclusion: The sandwich hybridization format provides a convenient, rapid and sensitive method for HIV-1 detection in a non-radioactive system. Using the microtitre wells, up to 96 samples can be analyzed at the same time. This format is compatible with existing plate handling equipment and will permit this assay to be automated for use in clinical laboratories.

Séance thématique Specialty Session



Aspects cliniques Clinical Aspects of AIDS

Les lymphokines Lymphokines

Th.B.0.25 DIFFERENCES IN IMMUNE ACTIVATION PARAMETERS DURING AND AFTER HIV SEROCONVERSION: SERUM BILIRUBINOLIN, INTERFERON- γ AND SOLUBLE IL-2
B. HOFMANN, W. CUMBERLAND, P. DETELE, J. FARNEY, UCLA SCHOOLS OF MEDICINE AND PEDIATRICS, LOS ANGELES, CA, U.S.A.

Objective: To describe cellular immune activation during and after HIV seroconversion.
Methods: Serum Bilirubinolins and receptors are products and markers of cellular immune activation, whereas serum soluble Interleukin-2 receptor (IL-2R) reflects only T cell activation. **Results:** Pts subjects investigated for Bilirubinolins before, during, and after HIV seroconversion showed an increase of this marker. The increase of Bilirubinolins appeared to reflect two distinct events in the immune activation since the primary increase correlated to the simultaneous increase in CD4 T cells, whereas the Bilirubinolins serum concentration during the second and third year correlated inversely to the decrease in CD4 T cells. An analysis of serum receptors in 30 of these seroconverters showed similar changes. Analysis of three groups of HIV seroconverters with either stable high numbers of CD4 cells ($>1000/\mu\text{l}$), moderately decreasing CD4 numbers ($1000/100/\mu\text{l}$), or rapidly decreasing CD4 numbers ($200/100/\mu\text{l}$) showed a strong inverse correlation between the rate of CD4 T cell fall and the serum concentration of receptors and Bilirubinolins. The serum concentration of IL-2R increased after HIV seroconversion, but in contrast to serum Bilirubinolins and receptors, serum IL-2R was only slightly increased in those with fall declining CD4 cells but was markedly increased in those with stable CD4 numbers. **Conclusions:** Cells within the immune system, including HIV seroconverters, receptors, and IL-2R, differ in their responses to HIV infection and represent different aspects of AIDS pathogenesis.

Th.B.0.27 POWER OF SERUM BETA-2-MICROGLOBULIN AND SERUM NEOPTERIN IN DETECTING ADVANCED HIV-DISEASE

B. HOFMANN, W. CUMBERLAND, R. LEIDER, R. J. JONES, J. FARNEY, UCLA SCHOOLS OF MEDICINE AND PEDIATRICS, LOS ANGELES, CA, U.S.A.

Objective: To evaluate the discriminating power of serum beta-2-microglobulin (B2M) and serum Neopterin (NPT) between early and advanced disease.
Patients and Methods: In 497 HIV-positive patients (82% men, 18% women, 52% homo- or bisexual, 41% drug addiction and 7% other risk) were 50% asymptomatic (ASY), 50% had a persistent generalized lymphadenopathy (PGL), 9% ARC and 7% AIDS. The median age was 30 years (range 19-73). NPT in 1360 sera and B2M in 1366 were measured. After adjusting the variances of NPT and B2M by ANOVA, the clinical stages were pooled in a group with early disease (ASY and PGL, 84%) and one with advanced disease (ARC and AIDS, 16%). For these two groups sensitivity (SENS), specificity (SPEC), predictive value positive (PVP) and negative (PVN) were calculated for different cut-off values using Bayes' formula.
Results: NPT and B2M were significantly higher in advanced than in early stages. In advanced disease the variances were very large, especially for NPT. For ascending cut-off levels (reported as a ratio to the upper normal limit), SENS, PVP and PVN were raised as follows:

Ratio	cut-off	SENS	PVP	PVN	SENS	SPEC	PVP	PVN
1x	0.66	0.62	0.52	0.91	NPT	0.70	0.60	0.51
2x	0.19	0.96	0.48	0.85	B2M	0.25	0.94	0.43
3x	0.05	0.99	0.74	0.85		0.15	0.97	0.51
4x	0.03	1.00	1.00	0.84		0.10	0.99	0.63

Conclusions: High concentrations of B2M rather than NPT indicate advanced, low concentrations early disease. Due to a large variance, medium concentrations are not conclusive.

Th.B.0.29 HIGH INTERFERON LEVELS PREDICT SUBSEQUENT DEVELOPMENT OF AIDS

M. JOHNSON, R. HART, E. A. MERRITT, J. M. ***; HAMILTON, I. B. **, SHIBATA, S. **, WINKELSTEIN, V. ***, ***, THE OPIJHO COMPANY, KALAMAZOO, MI, U.S.A.; ***, SAN FRANCISCO, CA, ***, ***, THE OPIJHO COMPANY, KALAMAZOO, MI, U.S.A.; ***, UNIVERSITY OF CALIFORNIA, BERKELEY, CA, U.S.A.

Objective: To determine interferon levels in prevalent HIV seropositive men and examine the relationship of interferon to the subsequent progression to AIDS.
Methods: Interferon levels were measured in a blinded fashion by an AIDS-2 specific RIA and the viral plaque reduction assay on sera collected in 1985 from 86 HIV seropositive men in the San Francisco Men's Health Study.
Results: Development of AIDS by 30 months

Interferon Level	All HIV+	AIDS (+)
Undetectable	47	15 (31.9)
0.7 - 1.0 U/ml	16	6 (37.5)
1.1 - 2.6 U/ml	10	5 (50.0)
> 2.7 U/ml	13	13 (100.0)

In a Cox proportional hazards model including CD-4 and CD-8 lymphocyte counts, p24 antigen, and beta-2 microglobulin, the Interferon level is a significant predictor of AIDS and the viral plaque reduction assay is not. **Conclusions:** Elevated interferon levels occur in 45% percent of prevalent HIV seropositive men and high levels are associated with a poor disease prognosis.

Th.B.0.26 2'-5A Synthetase and Blastogenesis as Measures of Response to Azothymidine (AZT)

Reed, Stanley, Fanning, M., Casaccia, J., and Coates, R. University of Toronto, Toronto, Canada

Objective: To determine whether AZT given to CDC B, III and IVc HIV-infected men will be reflected in changes in levels of 2'-5A synthetase (2-SAS) and blastogenic response to mitogens.

Methods: We have previously shown, in a cohort of 22 men given escalating doses of AZT, that 60mg/d resulted in the greatest decrease in 2-SAS (50c pmoles) and increase in response to PHA. Further studies were done during a washout period of 13 weeks followed by 22 weeks at 1200mg.

Results: Persistent elevation of 2-SAS levels appears to be a bad prognostic sign in HIV infection. A significant drop in 2-SAS occurred on 60mg/d AZT (85.7 to 45.8 pmoles). Also, a significant increase in response to PHA was observed. During the washout period the 2-SAS rose (45.3 to 85.5) and the PHA response dropped to below prestudy levels. 12 weeks after resuming AZT at 1200 mg, 2-SAS levels fell again dropped and PHA response increased. However, by week 64, 2-SAS levels had risen to 74.3. PHA response remained unchanged. **Conclusions:** At 60 mg AZT, levels of 2-SAS and PHA responses normalize. Adverse changes in 2-SAS and PHA response occur with continued dose of 1200mg and when drug is discontinued.

Th.B.0.28 INTERFERON (IFN), BETA-2 MICROGLOBULIN (β_2 -M) AND NEOPTERIN (NPT) IN AIDS-ASSOCIATED KAPPA⁺ B LYMPHOMA (BL)

W. HALL, J. H. HANCOCK, J. D. SANDERSON, D. B. MERRILL, Sloan Kettering Cancer Center, NY, NY, USA

Objective: To study the relationship between endogenous IFN, β_2 -M and NPT and their values in predicting treatment response in patients with BL. **Methods:** Serum levels of IFN, β_2 -M and NPT were determined prior to treatment in 43 pts entered into a phase I trial of IFN- γ AZT. Pearson product moment correlation was computed to quantify the relationship between β_2 -M and NPT. Two-sample t-test was used to evaluate associations between endogenous IFN activity and levels of both β_2 -M and NPT. Fisher's exact test was used to evaluate associations between IFN, β_2 -M and NPT regression. **Results:** Median pretreatment β_2 -M was 3.4 (range 2.2-6.2) $\mu\text{g/L}$ (normal, 1.2-4.4), median NPT was 18 (range 8-64) fmol/L (normal, 2-10). 38% of pts had detectable serum IFN (normal, undetectable). β_2 -M and NPT were significantly correlated ($r=0.13$, $p=0.0003$). Pts with detectable serum IFN had significantly higher β_2 -M levels (4.21 \pm 2.7 vs. 3.14 \pm 1.1, $p=0.001$) and higher NPT levels (27.8 \pm 1.5 vs. 16.1 \pm 1.1, $p=0.005$) than those with undetectable IFN. Although individually, β_2 -M and NPT were not predictive of response, the tumor of pts with "low" levels of both (β_2 -M < 4 , NPT < 10) were more likely to regress (77% CR) than those with higher levels of β_2 -M, NPT, or both (37% CR, $p=0.01$). Pts with undetectable IFN showed a significantly higher response rate than those with endogenous IFN activity (77% vs. 20%, $p=0.028$). **Conclusions:** The responses of BL to IFN-containing regimens may be predicted by measurements of IFN, β_2 -M and NPT. The strong associations noted are likely due to IFN induction of β_2 -M and NPT. (Supported by NIAID-ACTC).

Th.B.0.30 TUMOR NECROSIS FACTOR (TNF) IN THE PLASMA OF AFRICANS INFECTED WITH HIV

SM. HOLLAND, R. L. COLEBURNER, FRANCIS, H. L. KHOOZI, KAPLAN, QUINN-TUGER, et al., Johns Hopkins Hospital, Baltimore, MD; Pirooz Shiba, Kazian, Zair, and NIAID, NIH, Bethesda, MD, U.S.A.

Objective: To determine the association of plasma TNF and clinical signs and symptoms of HIV infection and AIDS in African patients.

Methods: Physical examination, demographic information, and a health questionnaire were obtained from 52 outpatients and 52 inpatients referred to HIV Unit at the Makerere Medical College, Kampala, Zair, and 52 asymptomatic Zairian factory workers and their spouses. TNF levels (pg/ml) were measured using a radioimmunoassay (Cambridge, MA). HIV ELISA, western blot, and p24 antigen level were determined for each patient.

Results: 60% (66%) of 157 cases were seropositive for HIV. Mean TNF levels were 25 ± 8.1 pg/ml for all HIV+ compared to 39 ± 12.7 pg/ml for all HIV- (NS). Among asymptomatic factory workers and their spouses, HIV+ subjects had lower TNF levels (< 10 pg/ml) than HIV+ subjects (26.5 ± 10.5 pg/ml, $p=0.05$). HIV+ patients with AIDS had significantly lower TNF levels (12.5 ± 7.5 pg/ml) than HIV+ subjects (30 ± 12.7 pg/ml, $p=0.05$). In African subjects, mean TNF was lower in HIV+ (< 10 pg/ml) than HIV- (29 ± 13.7 pg/ml, $p=0.05$). This same relationship was seen in patients with clinical tuberculosis (NS) and HIV+ and 68 > 200 $\mu\text{g/ml}$ HIV- ($p=0.05$). **Conclusions:** TNF levels in both symptomatic and asymptomatic HIV infected Zairians are decreased compared to uninfected controls. These findings are in contrast to studies of North Americans and European patients, in which elevated TNF levels have been associated with advanced HIV disease. These data suggest that HIV infected Zairians have impaired or depressed TNF response.

Colloque Symposium



Aspects cliniques Clinical Aspects of AIDS

Les problèmes associés au VIH en hémothélie : aujourd'hui et demain HIV Related Issues in Hemophilia: Today and Tomorrow

Th.B.O.31

THE FIRST AND SECOND EPIDEMICS
FVETL, Bruce M., * Centers for Disease Control, Atlanta,
GA, USA.

Objective. To determine the extent of AIDS in heterosexual partners of hemophilia patients.
Methods. Surveillance of heterosexual partners of hemophilia patients.
Results. By February 1989, more than 850 cases of hemophilia associated AIDS in the U.S. had been reported to the Centers for Disease Control. This represents an attack rate of about 5 to 7 per 100 of the 12,000-17,000 persons with hemophilia in the U.S. and approximately 1/5 of the HIV seropositive hemophilia patients. The accrual rate of AIDS in hemophilia patients has been constant for more than 3 years. Following the universal adoption of heat treated materials for therapy for hemophilia in 1984 and 1985, seroconversion of individuals receiving therapy essentially ceased. Recently an increase in transmission of HIV to heterosexual partners and to children born to women whose sexual partners are hemophilic have focused attention on this secondary epidemic. In 15 studies approximately 1/5 of heterosexual partners of hemophilic patients were seropositive but seroprevalence was as high as 21:41 in some studies. AIDS cases among these patients have been increasing and the epidemic curve of the heterosexual partner is similar to that of the primary epidemic that was recognized 4 years earlier in the hemophilia population. Risk reduction activities to date have had varying success at modifying behavior.
Conclusion. Risk reduction activities must be directed toward the hemophilia population and their sexual partners in order to stop this secondary epidemic.

Th.B.O.33

NATURAL HISTORY OF HIV INFECTION IN HEMOPHILIA

Toukas, Chris M. Division of Clinical Immunology, Montreal General Hospital, Montreal, Quebec, Canada

Th.B.O.35

HEMOPHILIA: Special Management Issues.
Lee, Christine A.

Hemophilia and Haemostasis Unit, Royal Free Hospital, London, England.

The special management issues for haemophiliacs infected with HIV must reflect not only the underlying bleeding disorder but also the well-known interference of haemophilia. Almost all haemophiliacs infected with HIV have now been identified; education about treatment and discussion of dreaded issues can be started before the onset of symptoms. As a result the recruitment to, and compliance within, trials of treatment for asymptomatic haemophiliacs may be better than in other patient groups. The presence of an underlying bleeding disorder makes the investigative procedures required to diagnose many clinical problems more difficult. Operative procedures - for example, joint replacement - may encourage HIV-related complications. The double complexity of clotting factor deficiency and HIV-related thrombocytopenia raises additional clinical problems. Many haemophiliacs have multiple chronic virus infections - hepatitis B, C and D - which may respond to interferon. As haemophiliacs must continue to receive clotting factor concentrates, virus detection against B virus is mandatory, but the antibody response is not predictable. Adolescents have to declare both haemophilia and HIV early in their relationships; counselling this group is a delicate management issue. Couples may want to have children and the facts should be presented sympathetically for informed decisions to be made. Hemophilia, by the nature of its well-known inheritance, is a disorder of the whole family; the management of the individual patient inevitably involves other family members. Finally, litigation is an emergent special management issue which threatens the relationship between the haemophilic and his health care provider.

Th.B.O.32

VIROSTATIC METHODS FOR CLOTTING FACTOR CONCENTRATES: ARE THEY EFFECTIVE?

P.M. Mannucci

A. Rimondi, Hemophilia and Thrombosis Center and Institute of Internal Medicine, University of Milano, Italy

Although the widespread infection of hemophiliacs with the human immunodeficiency virus contaminating clotting factor concentrates is still a threatening and formidable shadow, the gloomy picture brought about by the AIDS epidemic is partially lightened by recent spectacular improvements in the safety of concentrates. An important step-forward towards the elimination of the risk of infection transmitted by large-pool concentrates is the development of virucidal methods that inactivate those blood-borne agents that have escaped the filter of donor screening. Since the human immunodeficiency virus appears very vulnerable to such methods, currently available concentrates can be considered substantially free from the risk of transmitting that virus. Even though the transmission of hepatitis viruses is much reduced but not totally abolished, virucidal methods are continuously being improved, so that it can be foreseen that concentrates will become safer and safer.

Th.B.O.34

RATES, MODELS AND COFACTORS OF HIV INFECTION AND AIDS IN

HEMOPHILIA James J. Goedert, HIV Epidemiology Section, National Cancer Institute, Bethesda MD 20892 USA.

Objective. To quantify the incidence of HIV (1977-89) and AIDS (after HIV seroconversion(s)) and to evaluate the effect of age on two phases: HIV-to-AIDS occurrence as an AIDS marker, then from marker to an AIDS diagnosis.
Methods. Annual hazard rates of HIV for a prospective multicenter cohort of 1278 subjects with hemophilia were modelled as piecewise constant with AIDS. For 319 subjects with HIV mid-point seroconversion dates we compared 1) the incidence of subjects in CD4 count, rise in interferon and p24 antigen (Abobot), and loss of p24 and gp120 antibodies (RIA) and 2) AIDS incidence overall and after each marker with actuarial methods and log-rank tests of significance. Results: AIDS incidence following seroconversion was 2.00/100 person-years and was directly related to age (from 0.62 for ages 1-11 to 4.24 for ages 35-70, p<0.0005). Type/severity of hemophilia, race, and factor concentrate dose had little effect (p=0.50). Annual incidence ranged from zero during the first year following seroconversion to 7% during the eighth year, with cumulative rates of 13.2% (p<0.001) for ages 1-17, 24.0% (p<0.001) for ages 18-34, and 43.7% (p<0.001) for ages 35-70. CD4 loss was high in older adults (p<0.005); anti-p24 was low in adolescents (p<0.005); and AIDS after loss of anti-p24 was low in children aged 1-17 (p<0.005).
Conclusion. Because several laboratory markers appear and predict AIDS risk at various rates as a function of age: 1) there are likely to be more HIV-infected children and adolescents than currently estimated; 2) prediction of AIDS in youngsters with available markers will be more difficult; and 3) drug efficacy trials will need 3-fold more children than adults.

Th.B.O.36

CONCENTRATES MEETING THE DEMAND

Abelardo Linares, M. Prof. of Medicine, New Puerto & Medical Affairs
The Mount Sinai Medical Center, New York, New York, U.S.A.

The adequacy of a nation's blood supply can be measured by whether or not it can meet the needs of its hemophiliacs. Prior to HIV infection, bleeding was the leading cause of death; transfusion was the only means of survival. For the hemophilic, survival and quality of life depend not only on safety and efficacy of product but on its availability. The United States, because of technology and liberal pharmaceutical regulations, is able to meet its own needs and to export 50 percent of the factor produced as well as a third of its plasma products. This is the result of a highly developed industry that has the capability for large scale production. Self-sufficiency as a country's policy is a laudable goal; however, we must ensure an adequate supply of product for those whose lives depend upon it. The European Community (EC) currently considering a directive that would ban importation of blood products derived from paid donors. In fact, most of the EC nations do not have adequate plasma supplies nor fractionation programs to meet their current needs. Indeed, since the very countries importing 80% of the materials exported by the U.S. 51 percent of all the product used in these nations is derived from paid donor plasma. In addition, few countries throughout the rest of the world can meet their current or future needs. Premature implementation of the EC directive could cause a devastating shortage for hemophiliacs. Because of limited resources, self-sufficiency may never be achieved. International interdependence has many advantages, economy of scale, rapid transfer of advanced technology, and potential cost savings for countries currently without fractionation programs. However, we need to go beyond the global issues to those of the individual patient. Many hemophiliacs are now HIV positive; they deserve an uninterrupted supply of affordable products.

Science thématique Specialty Session



Aspects cliniques Clinical Aspects of AIDS

WHV-2 et autres rétrovirus HIV-2 and Other Retroviruses

Th.B.0.54 DETECTION OF HIV-2 ANTIBODIES BY A NOVEL HIV TRANSMEMBRANE SYNTHETIC PEPTIDE IN LINE-MEMBRANES

ERAGAKI, M. IMAI, F. POLET, D. J. HONORÉ, C. S. BRUN-VÉSTRET, F.***

Delormes, E. Van Heverbeke, R. P.

* Centre International de Recherches Médicales, BP 788, Francoville, Gabon;

** INNOVATIONS, Aachen, Belgium;

*** Hôpital Claude Bernard, Paris, France.

Objectives: The evaluation of a novel line-immunossay (LIA) with recombinant HIV1 and HIV2 proteins for screening of known HIV antibody positive sera.

Methods: The LIA-HIV assay (INNOVATIONS NV) uses only high purified synthetic HIV proteins in a line-immunossay technique for the detection of antibodies to HIV. The assay uses four purified synthetic HIV 1 antigens: the major core protein p24, an additional core protein p17, a polypeptide from the gag gene, the envelope gene and p1, a polypeptide derived from the endonuclease region of the polymerase gene. In order to detect HIV2 instead of HIV1 a synthetic transmembrane glycoprotein of this virus has been applied. A total of 15 known HIV2 antibody positive sera (prevalence of 90% and/or 100%-100) were screened.

Results: All the 15 HIV2 antibody positive sera reacted with the HIV2 transmembrane protein. The LIA test 87% of the sera reacted with the p24 and 83 protein, 10% reacted with the p24 only, 14% with p24 only, 4% with p17 and p24, and 2% with p17, 24, 24 and 7% of the sera did not react with any HIV1 peptide. Of the 65 HIV2 sera, none of them was reactive with the gag synthetic peptide. There was a good correlation between the results obtained with the LIA and the western blot patterns.

Conclusions: We have shown that the LIA system using synthetic HIV1 and HIV2 peptides allows the determination of HIV2 antibody positive sera.

Th.B.0.56 A NOVEL ENZYME IMMUNOSSAY TO DETECT ANTIBODIES TO BOTH HIV-1 AND HIV-2.

Backford, Ursula; Roberts, C. Duncan, R.J.S. and Pave, S. Wallace Diagnostics Research, Beckenham, Kent, SE3 3BS, U.K.

Objective: To develop an enzyme immunoassay capable of detecting antibodies to the known types of HIV with a sensitivity greater than commercially available at present.

Methods: Recombinant and peptide immunodominant epitopes constructed from HIV-1 and HIV-2 were labelled with alkaline phosphatase and used in an antigen-sandwich enzyme immunoassay. After the capture reaction, the enzyme was measured with an amplifying one-step substrate cycle.

Results: The assay had a sensitivity by end-point dilution up to 10-fold better than the anti-HIV-1 assays currently available in Europe, and had an excellent reactivity with sero-conversion samples. It detected all of the 289 anti-HIV-1 samples obtained world-wide, all of the 189 anti-HIV-2 samples obtained from West Africa and Europe, and had a low rate of false positivity. The assay was usable with serum, plasma or heat inactivated serum samples.

Conclusion: It is possible to improve on the sensitivity of the currently available commercial anti-HIV-1 assays and to detect anti-HIV-2 with an assay designed to be compatible with current blood bank procedures.

Th.B.0.58 SEROLOGIC EVIDENCE OF RETROVIRAL INFECTION IN ENTHAUSIAC DRUG ABUSERS (IVDA) (HIV-1, HIV-2, HTLV, HTLV-1, HTLV-2, HTLV-3, HTLV-4)

Stevan, S. and Lender, A. * Rush Medical Center, Chicago, Ill. and ** AIDS Project, University of Illinois at Chicago, School of Public Health, U.S.A.

Objective: To evaluate serologic evidence of HIV-1 and HIV-1 co-infection in IVDA.

Methods: Serum collected in 1988 from 1200 asymptomatic IVDA were screened for HIV antibody (anti-HIV-1) (EIA) (Abbott) confirmed by Western blot (WB). A subgroup of 94 IVDA were screened by EIA (Abbott) for HIV-1 (anti-HIV-1) and HIV-2 (anti-HIV-2) reactivities were reported in duplicate. Reactive HIV-1/2 samples were neutralized.

Results: The overall seroprevalence among the 1200 IVDA was 17% (per DuPont criteria): a subgroup of individuals was stratified by HIV-1b status. The HIV-1b seroprevalence was similar between the HIV-1b (2/0) and HIV-1b (1/40) individuals. The HIV-1b Ab positive rates among the 80 individuals was 33% and was identical in both groups. An additional seven HIV-1 seroconverters were identified during the 6-month study period. Two of these individuals were initially HIV-1b positive; 3/7 were consistently HIV-1b Ab reactive.

Conclusions: (1) among the HIV-1b and HIV-1b seroconverters, no difference in HIV-1b seropositivity was found. (2) HIV-1b has a low prevalence rate in this group. (3) Among the 7 HIV-1 seroconverters, there appears to be no change in HIV-1b seroreactivity.

Th.B.0.55 COMPARISON DES PERFORMANCES D'UN REACTIF ELISA UTILISANT UN PEPTIDE RECOMBINANT POUR LA DETECTION DES INFECTIONS A HIV 2. (L. ERAGAKI, A. IMAI, M. IMAI, F. POLET, D. J. HONORÉ, C. S. BRUN-VÉSTRET, F. VAN HEVERBEKE, R. P.)

* Centre International de Recherches Médicales - Francoville - Gabon;

** Institut Pasteur de Paris;

*** Service des Maladies Infectieuses - CRU de Toulouse - Allages - Clin. Clin. Clin.

Objectifs: Un nouveau test ELISA utilisant un peptide recombinant de HIV 2 (Château - France) fut sur un support solide (plaque de polystyrène), et fut appliqué à la détection des anticorps dirigés contre le virus de l'immunodéficience humaine (HIV 2) en milieu sérique.

Méthodes: Une population d'individus de 541 sérum a été soumise à la sérologie à 80 comparés au test ELISA classique (Orpax, Dupont de Nemours) pour HIV 1 ainsi qu'ELISA 2 et 3 au test ELISA HIV 1 recombinant (Château - France) et à un sérotype de multitést (Orpax) dans le sérum de référence (97.7-8). La spécificité est exprimée en pourcentage, comparée aux sérum non sérum (NS).

Résultats: Au cours de l'examen de sérologie, 1.54 % des sérum tests ont été trouvés séropositifs par les sérologies ELISA classiques, alors que seulement 2.9 % l'ont été avec le réactif Château pour Château, mais les résultats ont été confirmés dans le sérum. 21 sérum sur 30 sur les panels positifs ELISA (Sera positifs) alors que ceux positifs à ce test ont été confirmés.

Conclusions: Les tests ont été effectués au Western blot (WB) (245 5) et 2 (11.7 %) au HIV 2 (11.7 %).

Conclusions: Le test de la sérologie d'emploi est approprié (245 5), peut être à 80 fois appliqué dans le sérum de sérologie au test de l'usage sérum sérum, en milieu sérique, sur 8 en milieu sérum de sérum de sérum.

Th.B.0.57 COMPARISON OF SEROLOGIC ASSAYS FOR TRANSMISSIBLE RETROVIRUSES (HIV-1, HIV-2, HTLV-1, HTLV-2, HTLV-3, HTLV-4, HTLV-5, HTLV-6, HTLV-7, HTLV-8, HTLV-9, HTLV-10, HTLV-11, HTLV-12, HTLV-13, HTLV-14, HTLV-15, HTLV-16, HTLV-17, HTLV-18, HTLV-19, HTLV-20, HTLV-21, HTLV-22, HTLV-23, HTLV-24, HTLV-25, HTLV-26, HTLV-27, HTLV-28, HTLV-29, HTLV-30, HTLV-31, HTLV-32, HTLV-33, HTLV-34, HTLV-35, HTLV-36, HTLV-37, HTLV-38, HTLV-39, HTLV-40, HTLV-41, HTLV-42, HTLV-43, HTLV-44, HTLV-45, HTLV-46, HTLV-47, HTLV-48, HTLV-49, HTLV-50, HTLV-51, HTLV-52, HTLV-53, HTLV-54, HTLV-55, HTLV-56, HTLV-57, HTLV-58, HTLV-59, HTLV-60, HTLV-61, HTLV-62, HTLV-63, HTLV-64, HTLV-65, HTLV-66, HTLV-67, HTLV-68, HTLV-69, HTLV-70, HTLV-71, HTLV-72, HTLV-73, HTLV-74, HTLV-75, HTLV-76, HTLV-77, HTLV-78, HTLV-79, HTLV-80, HTLV-81, HTLV-82, HTLV-83, HTLV-84, HTLV-85, HTLV-86, HTLV-87, HTLV-88, HTLV-89, HTLV-90, HTLV-91, HTLV-92, HTLV-93, HTLV-94, HTLV-95, HTLV-96, HTLV-97, HTLV-98, HTLV-99, HTLV-100)

Int. of Imm. Washington, D.C.

Objectives: To compare different methodologies for the serologic diagnosis of human transmissible retrovirus infection.

Methods: Sera were obtained from civilian applicants for the armed services of the United States and initially screened with a qualitative HIV-1 enzyme-linked immunosorbent assay (ELISA). Reactive samples were then tested with a recombinant envelope based EIA and a Western blot method.

Results: Of 3,995 samples screened by the ELISA, 66 (1.65%) were scored as either repeat reactive (24-49%) or as questionable reactivities (32-84). Western blot analysis revealed that 3 (4.2%) showed banding patterns suggestive of HIV-1 infection. No bands were apparent on 55(83%) of the original 66 samples. These samples were also analyzed by a recombinant envelope based ELISA resulting in 18 (27.2%) scored as positive including 6 of that were Western blot positive. Of the other seven scored as positive by the recombinant ELISA, 7 were reactive by Western blot while 6 showed p19 bands, 1 showed p19 and p24 bands and 1 showed p19, p24, and p32 bands.

46 sera samples scored as negative by the recombinant ELISA were also scored as negative by Western blot. Of the original 3,995 samples tested, 3 (0.07%) can be considered positive for a transmissible retrovirus by two different EIA methods and by a Western blot method.

Conclusions: A recombinant envelope based ELISA can be used as a second level test prior to Western blot analysis to reduce screening false positives.

Th.B.0.59 RELATIVE SPECIFICITY OF TWO EIAs FOR ANTIBODIES TO HIV-1, HIV-2, HTLV-1, HTLV-2, HTLV-3, HTLV-4, HTLV-5, HTLV-6, HTLV-7, HTLV-8, HTLV-9, HTLV-10, HTLV-11, HTLV-12, HTLV-13, HTLV-14, HTLV-15, HTLV-16, HTLV-17, HTLV-18, HTLV-19, HTLV-20, HTLV-21, HTLV-22, HTLV-23, HTLV-24, HTLV-25, HTLV-26, HTLV-27, HTLV-28, HTLV-29, HTLV-30, HTLV-31, HTLV-32, HTLV-33, HTLV-34, HTLV-35, HTLV-36, HTLV-37, HTLV-38, HTLV-39, HTLV-40, HTLV-41, HTLV-42, HTLV-43, HTLV-44, HTLV-45, HTLV-46, HTLV-47, HTLV-48, HTLV-49, HTLV-50, HTLV-51, HTLV-52, HTLV-53, HTLV-54, HTLV-55, HTLV-56, HTLV-57, HTLV-58, HTLV-59, HTLV-60, HTLV-61, HTLV-62, HTLV-63, HTLV-64, HTLV-65, HTLV-66, HTLV-67, HTLV-68, HTLV-69, HTLV-70, HTLV-71, HTLV-72, HTLV-73, HTLV-74, HTLV-75, HTLV-76, HTLV-77, HTLV-78, HTLV-79, HTLV-80, HTLV-81, HTLV-82, HTLV-83, HTLV-84, HTLV-85, HTLV-86, HTLV-87, HTLV-88, HTLV-89, HTLV-90, HTLV-91, HTLV-92, HTLV-93, HTLV-94, HTLV-95, HTLV-96, HTLV-97, HTLV-98, HTLV-99, HTLV-100)

* American Red Cross, Washington, DC; ** Abbott Laboratories, Abbott Park, Ill.

Objective: Using Western blot (WB) and radioimmunoassay (RIA) to compare the relative specificity of 2 EIAs for antibodies to HIV-1.

Methods: Donor sera originally found repeatedly reactive (RR), 171 (Group I) by Abbott EIA and 25 (Group II) by Du Pont EIA in 40 different laboratories were retested by 2 EIAs and by WB.

Group I:	WB bands	No. Samples		No. Reactive	
		Abbott	Du Pont	Abbott	Du Pont
Group I:	None	29	24	16	12
	p19 only	26	33	22	28
	p24 only	36	33	33	33
	p19/p24	19	19	19	19
	p19/p24/gp46	5	5	5	5
Group II:	None	6	0	5	0
	p19 only	0	0	0	0
	p24 only	3	0	0	0

Six of 19 initially selected samples from Group I and none of the 9 with WB p19 or p24 from Group II showed gp46 reactivity by EIA.

Conclusions: Abbott EIA was more specific; 70% of samples showed all bands on WB and 33% showed a gp46 band by Western blot. Du Pont EIA was more reproducible; 89% of originally RR samples were still reactive as compared to 44% of Du Pont EIA RR samples.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

Grossesse et obstétrique Pregnancy/Obstetrics

M.B.P.1 IN UTERO HIV TRANSMISSION IDENTIFIED THROUGH PCR.

Vladic, Courant¹, Lours, F. +, Marin, F. +, Goudeau, A. +, Bricot, C. + and The Paris-Tours Collaborative group perinatal HIV transmission**.

INSERM U275, CHU de Tours, **Laboratoire de Virologie Tours (CNRS UA.271), *Centre d'immunobiologie périnatale, Paris, ****Diagnostique Pasteur, Marnes la Coquette, France.

Objective: To investigate the possibility of in utero HIV transmission.

Material: 33 fetuses obtained from HIV positive mothers at 16 to 24 weeks of gestation. 3 fetuses were obtained at 16-18 weeks by hysterotomy. Thymus and spleen were dissected and analyzed separately. PBL of 30 mothers were available. Methods: PCR for HIV DNA detection with 40 cycles and 3 sets of primers (9a) and (E) gene.

Results: HIV DNA sequences were detected in 19/31 thymus and 22/33 spleen fetuses samples. Positive results were obtained in fetuses from 16 to 22 weeks. HIV DNA unambiguously scored positive in 2/3 thymus and spleens obtained by hysterotomy at 16-18 weeks. By using primers specific for the highly polymorphic cytochrome b locus, we have concurrently identified informative mothers comparison of the results obtained with these primers between mothers' and fetal tissues DNA did not show evidence of contamination of fetal tissue samples by infected mother cells.

Conclusions: This study indicates in utero HIV transmission, occurring even at an early stage of gestation. The likely high rate of transmission must be taken in account for strategies aiming to prevent perinatal infection.

M.B.P.3 DISEASE PROGRESSION FOLLOWING PREGNANCY IN HIV SEROPOSITIVE WOMEN

McNelis LP, Wong JM, Whitlaw J, Shorne JM, Stewart EP, WDI, Virology; City Hospital; Immunology, Royal Infirmary, Edinburgh, Scotland.

OBJECTIVE: To assess disease progression following pregnancy in HIV seropositive women.

METHOD: Of 107 HIV seropositive women infected between 1983 and 1985, 31 have had a pregnancy post seroconversion. Follow up has included monitoring clinical status, CD4 lymphocyte count, IgG, IgA and HIV antigen at 6 monthly intervals.

RESULTS: Patients have been followed-up from 6 to 54 months with 18 having been followed for longer than 24 months. One has progressed to AIDS at 3 years post delivery and one has developed persistent oral thrush 2 years after delivery, the rest remain asymptomatic. CD4 lymphocyte depletion to less than 200 was occurred in 2 (6%) patients, 1 with AIDS and one other who is currently asymptomatic. IgG and IgA levels show no significant trend. 2 (6%) patients have become antipsychotic but remain asymptomatic. There is no evidence of increased disease progression in this group compared with the milliparusous women or those who had pregnancies prior to seroconversion. In fact the milliparusous group are clinically worse possibly as a consequence of continued infection they were.

CONCLUSION: Unlike others we have not observed an excess of post pregnancy disease progression. However, these are first pregnancies and none of the children have developed AIDS.

M.B.P.5 Failure of Targeted Screening to Identify HIV+ Pregnant Women.

Richard, Margaret; Quinn T; Kline, K; Remba, J; Chanson, R. The Johns Hopkins University Baltimore, Maryland, U.S.A.

Objective: To assess a targeted HIV screening program for women attending an inner city prenatal clinic.

Methods: All women attending the Johns Hopkins Hospital prenatal clinic between 2/87 and 1/89 completed a questionnaire to assess HIV risk behavior. HIV testing was offered to women with acknowledged risk factors. Testing was available to women without acknowledged risk factors, but was not encouraged. Ser. from rubella specimens were obtained from women not voluntarily tested for HIV, and tested anonymously for HIV antibodies.

Results: 1416 women were enrolled in the clinic and evaluated. The median age was 31 years (range 16-41). 80% were black and 80% single. HIV risk behaviors were reported by 241 (17%) women; 54% were partners of intravenous drug users (IVDU), 30% were IVDU, 10% had received transfusions before 1983, 4% were partners of bisexual men and 2% reported prostitution. 146/241 (60%) women with risk factors consented to HIV testing. 19 (14.3%) were HIV+. 18 women denying risk factors requested testing; 9 (49%) were HIV+. 473 specimens were available for anonymous testing; 136 (28.7%) from women with acknowledged risk factors. Six specimens from this group were HIV+. 473 specimens were available for routine testing. Overall, 34 (4.1%) of 824 pregnant women tested positive for HIV. 15 (44%) of the seropositive women had no acknowledged risk factors for HIV. In 15 (44%) of the 34 specimens from this group, HIV testing following HIV screening to pregnant women who acknowledge risk factors will fail to identify a substantial number of infected women in urban settings. HIV screening, counseling and education should be made available to all patients as part of routine prenatal care.

M.B.P.2 ANTIGENEMIA p24 AND CD4 CELLS COUNTS IN HIV PREGNANT WOMEN.

Jean-François Malinvaud, B. Sévénal, J.C. Pons, D. Meyer, V. Chabrier, Ph. Kieffer, A. Fautsch, A. Bourcier, HIV Pregnancy study group, Paris, France.

Objective: To investigate the effects of pregnancy on virological and immunological parameters in HIV pregnant women, we studied the evolution of antigens (Ag p24), anti p24 antibodies (Ac anti p24) and CD4 cells count during and after pregnancy.

Methods: 40 seroconverted 3rd trimester group 1: group 1 HIV pregnant women (n = 97), group 2 HIV aborted women (n = 114), group 3 : non HIV pregnant women. **Results:** CD4 cells are initially (first trimester) lower in group 1 (455 ± 71) and group 2 (502 ± 53), in comparison with group 3 (886 ± 72). A slight decrease is observed during the pregnancy (third trimester) in group 1 (400 ± 50) and group 2 (377 ± 68). The mainfact is the lack of increase of CD4 observed at the 3th month of post partum in group 1 (332 ± 66) and group 2 (338 ± 72) contrasting with group 3 (933 ± 65). In group 1 (HIV pregnant women) HIV antigenemia are found in 8/26 at the first trimester, 24/78 at the 2nd trimester, 14/72 at the 3th trimester. In the group 2 (women with induced abortion) HIV antigenemia is positive in 12/13 during the first 3 months. After the pregnancy antigenemia is respectively positive in 6/57 in group 1 and 8/102 in group 2. No modification of antibodies anti p24 was observed.

Conclusion: In HIV pregnant women, CD4 decrease is longer persistent in post partum. HIV Ag p24 appears frequently during the 2nd trimester but is reversible. The role of these immunological and virological abnormalities in disease progression, and in the subsequent evolution of HIV infection in pregnant women, are under investigation.

M.B.P.4 PREGNANCY ARISING IN HIV INFECTED WOMEN WHILE BEING SEROPOSITIVELY CHANGING ABOUT "SAFE SEX"

Seaman, Mark L., Purser, B., Hall, S., McCallow C, O'Meara C, Harpac R. North Shore University Hospital, Cornell University Medical College, Newburgh, N.Y.

Objective: To study the epidemiologic features of women who became pregnant after learning their HIV status.

Methods: 151 women who were of child bearing age have been followed after they were found to be antibody + to HIV-1. A registry has been maintained of women who became pregnant after knowledge of their antibody status and after discussions about "safe sex".

Results: Of 40 surviving women from 88 IVU's, 4 became pregnant one time and 1 2x. Of 43 surviving women from 44 women who acquired disease heterosexually, 7 became pregnant 3 times. No women of 11 surviving women from 17 who acquired disease from other means (6 transfusional, 3 Caribbean, 8 unknown male) became pregnant. 4/11 of women became pregnant even though they were taking AZIDUAPRINE and were counseled several times about "safe sex". One patient's pregnancy was ectopic, 3 delivered full term children, one is carrying the pregnancy to term, 7 had termination of pregnancy. Pregnancy occurred even with low helper cells (<200 cells/mm³) in 5. **Conclusions:** Pregnancy continues to occur frequently (11/134) even after women learn about their HIV status. Improved techniques about "safe sex" must be developed.

M.B.P.6 PREGNANCY AND ACCELERATION OF HIV-RELATED ILLNESS

Deuchars, Marie-Joselle¹, Page, J.W.², Madhavan, S.², **Cornell University Medical School, NY, NY, U.S.A.

Objective: To study the effect of pregnancy on the development of HIV-related illness in seropositive asymptomatic women in Port-au-Prince, Haiti.

Methods: A prospective study of 178 HIV-seropositive asymptomatic women of child bearing age was undertaken from 1983 to 1988. During the study period, 34 women were pregnant — 15 at time of study entry and 19 conceived during the follow-up period. There were 31 live births. Despite the 34 pregnant women (19% compared with the 144 non-pregnant women (81%)) with regard to the development of HIV-related illness. For the entire cohort, mean age was 29 years, gravidity 2.4, parity 2.1 and follow-up a mean of 21.4 ± 14.3 mo. (M and F) were comparable in these parameters and in their socioeconomic status. During the study period, 16/174 (47%) M and 27/144 (18%) F women developed AIDS or HIV-related illness (26/63, p<0.05) The illness rate for M (28%/1000 person-years) was not significantly higher than that of M (18%/1000 person-years). Illness developed in 5/16 M during pregnancy (mean, 5th month) and in 11/16 a mean of 6 months postpartum. The cumulative proportion of M women becoming pregnant increased from 10 to 28% over years 1 to 5 (logrank, p=0.01). Similar analysis showed the cumulative annual percentages of M developing symptoms at years 1 to 5: 22% of follow-up 1, 25, 35, 46, and 53% and for F at 23, 33, 53, 53, and 84%.

Conclusion: Pregnancy in asymptomatic HIV-seropositive women is associated with an accelerated development of AIDS or HIV-related illness during pregnancy and in the postpartum period.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.7

FACTORS INFLUENCING MATERNAL DECISION-MAKING REGARDING PREGNANT OUTCOME IN HIV INFECTED WOMEN

Winters, A.; Weidner, B.; Burti, C.; Douglas, S.; Cabanot, T. and
Albert Einstein College of Medicine, Bronx, N.Y., U.S.A.

Objective: To determine the factors which influence HIV infected pregnant women to complete or terminate their pregnancy.
Methods: Thirty three HIV infected pregnant women were evaluated for factors involved in decision making regarding their pregnancy outcome. An elective termination of pregnancy (TOP) was medically available for the 22 (67%) women who were identified prior to 24 weeks of gestation. All women were aware of their HIV status and received comprehensive obstetrical and medical care as well as family counseling.

Results: Six of 22 women (27%) who were eligible for TOP chose to terminate their pregnancy electively. Of 11 women who developed HIV associated symptoms before 24 weeks of gestation, 4 elected TOP (36%). Seven of 33 (21%) had previously mothered HIV infected children. Six of 7 (87%) of these women chose to complete the current pregnancy. There was no difference in the number of previous abortions, maternal health, socioeconomic conditions, marital status, mother's presence of an HIV infected older child or HIV associated diseases between those women who pregnancies resulted in an elective TOP or those who chose to continue their pregnancy.
Conclusion: Neither the presence of an HIV infected older child nor HIV associated symptoms in HIV infected pregnant women appear to influence decision making concerning continuation of pregnancy.

M.B.P.8

THE IMPACT OF FREQUENCY OF INCREASES IN HIV-RELATED CD4+ COUNTS ON THE PROGNOSIS OF HIV-RELATED DISEASE

Schroeder RE, Doolittle JM, Nelson RA, Metcalz D, Rogers MM,
NYC HIV Perinatal Transmission Collaborative Study et al.,
Cornell/Albert Einstein College of Medicine, Bronx, NY, USA,
New York City Department of Health, New York, NY and CDC, Atlanta, Georgia, USA.

Objective: To study the effect of pregnancy on progression of HIV infection.
Methods: Since 1/85 341 HIV infected childbearing-aged women from a network program enrolled in an HIV natural history study had serial P-cell counts, physical exams and intravenous abuse, serology, sexual, medical/obstetrical history since 1978; the number of pregnancies since 1978 ending in livebirths (LB), miscarriages (CM) and (CM/CM), onset and duration with HIV-associated constitutional symptoms (CS) prior to oral thrush, (CM/CM) were compared relative to the development of (CM/CM) during pregnancy (P).
Results: Of 341 (304 black, 568 white) women 568 were P/2 with 2.6 yrs. HIV developed AIDS during pregnancy. Development of HIV related illness was by a 2x2 table.

	LB	CM	CM/CM (NONP-2)
Asymptomatic	25 (26%)	20 (26%)	20 (41%)
HIV Assoc. Ill.	13 (23%)	14 (39%)	17 (38%)
CM/CM	18 (32%)	20 (53%)	22 (48%)

There was no difference in the mean duration of CS for women with LB (2.6 yrs.) and those with CM (2.4 yrs) (p=0.05). On regression analysis, (CM/CM) was predicted by the mean CS onset and duration of CS (p<0.001) controlling on CM (0.001) and (CM/CM) and CS, and was not predicted by LB (p=0.59).
Conclusion: These data suggest progression of HIV disease to oral thrush or AIDS is not associated with pregnancy.

M.B.P.9

PHARMACOKINETICS/PHARMA OF ZIDOVUDINE(ZDV) IN HIV+ PREGNANT WOMEN

Burchett, S. et al. University of Wisconsin, WA, United States

Objective: To evaluate ZDV PK in pregnancy and postpartum.
Methods: In an ongoing study, ZDV PK were studied several times during the second and third trimester and postpartum in 13 women taking ZDV 200mg every four hours (10-15mg/kg/day). Multiple blood samples were obtained and ZDV conc. were measured by HPLC. PK were analyzed using noncompartmental analysis. CBC with red cell indices, T lymphocyte subsets, plasma and lymphocyte HIV cultures, and renal and liver function studies were done monthly.

Results:

	1st/2nd	2nd/3rd	3rd/4th	Postpartum
T _{1/2} (hr)	1.1 ± 0.1	1.1 ± 0.1	1.1 ± 0.1	0.9
C _{max} (ng/ml)	0.6 ± 0.10	1.4 ± 0.10	1.5 ± 0.07	1.1
AUC _{0-12hr} (hr*ng/ml)	1.1 ± 0.06	1.3 ± 0.04	1.1 ± 0.03	1.0
RTIC _{0-12hr} (ng/hr)	3.2 ± 0.2	2.4 ± 0.1	2.5 ± 0.2	1.2
FV _{0-12hr} (ng) %	4.5 ± 0.3	3.2 ± 0.4	3.5 ± 0.2	1.7

Cardiac Output (L/min) ranged from 24 to 127% of the maternal level. The T_{1/2} of ZDV in the neonates ranged from 9 to 23.3 hours. No symptoms or lab abnormalities required a reduction of dose. None of the babies manifested clinical or laboratory abnormalities in the neonatal period, although one baby was delivered at 36 weeks gestation by cesarean section for oligohydramnios and fetal distress.
Conclusions: ZDV PK in pregnant women were similar to other adults except V_d was increased. No unexpected toxicities were observed in mothers and neonates. Significant transplacental passage of ZDV was observed.

M.B.P.10

KNOWLEDGE OF HIV SEROSTATUS AND PREGNANCY DECISIONS

Reichman, R., Baruch, M., Margolis, C., Chalmers, R., Anderson, J., Hertz, J. Johns Hopkins University, Baltimore, Maryland, USA.

Objective: To describe pregnancy decisions among 89 HIV + women attending clinics at the Johns Hopkins Hospital.
Methods: Retrospective review of pregnancy decisions from records of 89 HIV + women: 34 women seeking prenatal care and 55 women attending an HIV infection clinic for women.
Results: Mean age of women 24.3 years (range 19-38 years). 80% black, 18% white, 2% other. Risk factors for HIV infection: 40% intravenous drug use (IVDU), 23% IVDU, 15% sexual partner, 11% transfusion, 4% blood or HIV + partner, 2% prostitution. 74/89 (83%) had previously been pregnant with 60% having 2-3 living children. Seronegativity was observed in 36/89 women during pregnancy, 10% of whom were identified as 50 week gestation. Two women had elective abortions (14 and 18 weeks), one had a spontaneous abortion at 17 weeks gestation, and 17 women opted to continue their pregnancies, 6/7 delivering term infants. 14 women (16%) became pregnant after hearing they were HIV+. None of these women was using contraception. One woman who delivered a term infant had an elective abortion at 10 weeks of a subsequent pregnancy. The remaining 13 women continued their pregnancies with 12/13 delivering term infants.

Conclusions: Knowledge of HIV infection was not associated with pregnancy termination or prevention of subsequent pregnancy. In light of risk of perinatal transmission and possible acceleration of HIV infection during pregnancy, education, counseling and specialized obstetrical and medical services for women with HIV infection are needed.

M.B.P.11

IMMUNOHISTOCHEMICAL DETECTION OF HIV-ASSOCIATED ANTIBODIES IN FORMALIN-FIXED PERINATAL PLACENTAS

Wagner, G. J., Schiller, R., Fagan, S., Linn, L., Huang, S. L., Unger, N. C., *Institute of Pathology, Department of Pediatric Pathology and *Laboratory of Immunology, Albert Einstein College of Medicine, *New York City Department of Health, *Freie Universität, *Klinikum Rudolf Virchow, Berlin, Federal Republic of Germany

Objective: Detection of intrauterine HIV-infection in fetal placenta of HIV-exposed pregnancies.
Methods: 1. 31 formalin-fixed neonatal placentas (22 of them with additional frozen tissue) of HIV-positive mothers. 2. Application of a: monoclonal anti-HIV antibodies (Dr. Pant anti-HIV-III p24, product 5281/7053; Mabser anti-p24, anti-p17); b: various capture markers for the typification of the antigen profile of Hofbauer cells (placental macrophages).

Results: 1. Detection of HIV antigens in Hofbauer cells of 21 formalin-fixed placentas. 2. Positive reaction of Hofbauer cells (HC) with anti-p24, p180/95, MAC 387; a subgroup of HC reacting with anti-CD1 and anti-MLA-28. No demonstration of CD8, Pan B and Bc.

Conclusions: 1. HIV antigens can be localized in Hofbauer cells of formalin-fixed placentas. The antigen profile of HC corresponds to that of epifurcal lamprophage cells. 2. Positive reaction of HC correlates to clinical signs of infection in the child, but up to now placental infection is more frequent than the latter. 3. Therefore, placental infection indicates an increased state of risk of the newborn not proven infection.

M.B.P.12

HIV SEROPREVALENCE IN AN INNER CITY OBSTETRIC POPULATION.

Johnson, John P., Watkins, Jr., Sims, F., Richardson, B., and Alpert, L., University of Maryland School of Medicine, Baltimore, Maryland.

Objective: To determine the seroprevalence of HIV infection in an inner city maternity population.
Methods: All women presenting to obstetric clinic were provided a questionnaire regarding HIV risk factors. The type and duration of risk factor was recorded and HIV testing was performed after informed consent.

Results: Four percent of the population indicated either sexual and/or drug use risk factors. Of this 41, 26% were seropositive. Women indicating drug use had a seroprevalence rate of 24%, those with sex partners who were drug users had a 7% seroprevalence rate, those women who admitted to both risk factors had a 33% seroprevalence rate. Women whose risk factor occurred strictly before pregnancy had a 9% seroprevalence rate. Those whose risk factor only during pregnancy had a 13% seroprevalence rate and those who had risk factors occurred both before and during pregnancy had a 40% seroprevalence rate.

Conclusion: A program of self-identification in inner city maternity population yielded an overall 1% seroprevalence rate. A drug use history was greater risk for HIV infection than sexual history. Duration of risk behavior and recovery of risk behavior appeared to increase risk for HIV infection. Screening for type and timing of risk factor may help to identify a particularly high risk population for HIV infection.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.19

Seroprevalence of HIV-1 and HIV-2 among pregnant women in Newark, NJ.
Carter, E. M., ~~Deane, Thomas, J.~~ O'Connell, L., * Newman, P., * O'Leary, R., * Kline, R. C. et al.
*RHO-RT Medical School, Children's Hospital of New Jersey, Newark, NJ and
CC, NJMS, Camden, NJ.

Objective: To determine the seroprevalence of HIV-1 and HIV-2 in pregnant women delivering at a University Hospital in Newark, NJ, which serves primarily a local, inner city minority population (60% black, 38% Hispanic and 2% white).
Method: Between 9/87 and 9/88 samples of serum were obtained at the time of delivery from maternal, cord, or infant blood. Samples were serologically tested for the presence of antibodies to HIV-1 and HIV-2 by using ELISA (Abbott) and Western Blot (Bio-Rad).
Results: A total of 2,619 deliveries occurred and 2,000 samples were available for HIV-1 (94%) and 2,000 for HIV-2 testing. HIV-1 ELISA was reactive in 6.2% (136) and Western blot was reactive in 99/136 (73%) yielding a confirmed seroprevalence of 4.4% for HIV-1. HIV-2 ELISA was reactive in 2.1% (44) and Western blot was reactive in 7/44 (16%) yielding a confirmed seroprevalence of 1.3% for HIV-2. In conclusion, 10.5% (216) were also HIV-2 positive. Mean delivery at the institutions studied are at risk of 1/22 for HIV-1, 1/77 for HIV-2 and 1/260 for co-infection. These data suggest that vertical transmission to newborns of HIV-1 and HIV-2 are important risks in our community.

M.B.P.21

DIFFERENCES IN IMMUNOSUPPRESSION DURING PREGNANCY IN HIV-INFECTED WOMEN

Kohler, A.M., Friedmann, W. M. and Schwartz, S. **
*Dept. of Obstetrics, Universitat de Maric, P.R.
**AIDS-Center, Bundesgesundheitsamt, Berlin, F.R.G.

Objective: To evaluate the natural course of HIV-infection during pregnancy.
Methods: In a comparative study 54 HIV-infected and 50 HIV-negative pregnant women were investigated every 2 - 4 weeks on clinical status and the following immunological parameters: T-cell counts; CD4, CD8; Immunoglobulins: IgG, IgM, IgA, IgE; Circulating antibodies: IgG, IgM.
Results (median): On the basis of the immunological parameters the investigated collective of HIV-infected pregnant women was divided into 4 groups: Group 1: no abnormal immunological findings; Group 2: CD4/CD8 ratio < 0.8; CD4-cells > 400; Group 3: CD4-cells 250 - 400; Group 4: CD4-cells < 250.
Controls: Group 1: n=25 Group 2: n=13 Group 3: n=16
 n=50 n=11 n=13 n=5
CD4 decr. >10% 27 9 23 12 5
CD8 decr. >10% 0 2 12 9 2
CD4 decr. >40% 0 2 9 8 5

Discussion: The greatest extent of immunosuppression during pregnancy in HIV-infected women was seen in group 2 (3 decrease of CD4-cells > 40%) and group 4 (decrease of CD4-cells < 40%). The majority of women showed a postpartal regeneration; 6 women had a continuous loss of CD4-cells after delivery.

M.B.P.23

SEROPREVALENCE IN A HIGH MULTIRACIAL POPULATION
C. Miller, M. J., Fajardo, R., Ferns, P., Elin, J., Sosa, C.
Duke, N. University of Miami, Miami, Florida, United States of America.

Objective: To determine HIV-1 seroprevalence by antibody status in women delivered at a medical center serving the multi-ethnic population of Miami, Florida, U.S.A.
Methods: From 7/78 to 12/88, patients admitted to the labor suite had sero, blood tests, and history of STD or less. They were interviewed, consented, and offered HIV antibody testing after delivery. The samples of those who refused or were discharged before interview were banded. Inactive obtained directly from patients included seroprevalence and the following risk factors: drug (cocaine, crack, IV), sexual partners, sexually transmitted, blood transfusion.
Results: Of the 7,400 offered testing, 52.7% gave consent, of whom 2.1% were seropositive. Of the 1,774 refusing testing, 1.8% were HIV-positive (Chi square analysis p < 0.01), exposing a bias. Of the 1,000 who refused, 2.2% were seropositive. The age distribution of the seropositive matched the statistical population. Tests were 18.3% of the seropositive (12.5 - 65 years old). Seropositive Hispanics predominated (87%); 52.1% were 25 years of age, compared to Haitians (38.3%), 57.8% were 35 years old or > 50 years. Seropositivity also correlated with drug use, multiple partners, and risk status, p < 0.005 each. However, 45.4% of the seropositives had no admitted correctly accepted risk factors.
Conclusions: Screening would be offered to all pregnant women, certainly in our population. Sexually active teenagers are at risk of infection, especially the Black American. While asymptomatic risk factors are associated with seropositivity, no apparent risk factors account for almost half these infected patients, implying heterosexual transmission as the largest identifiable factor. Education for prevention should begin before sexual saturation.

M.B.P.20

PATHOLOGY AND HIV EXPOSURE IN TERN PLACENTAS FROM SEROPROTECTIVE WOMEN. Chandra, B., Blotnick, G., H. J., Kitzler, J., Kresnowski, J., Kormanik, J., New York University Medical Center & Bellevue Hospital Center, New York, N.Y., U.S.A.

Objective: To compare the pathology of tern placenta from seroprotective HIV infected and seroprotective women using routine histologic, immunohistochemical, and in situ nucleic acid hybridization techniques.
Methods: Tern placenta of seroprotective and seroprotective women were evaluated by hematoxylin and eosin (H & E) staining for evidence of vasculitis (VA), villitis (V), chorionitis (CH), and chorioamnionitis (CA). They were also examined by immunoperoxidase (IP) staining using monoclonal anti-p24 antibody, lactin (L), cytokeratin (CK), amniotic (AM), and uterine glands (UG) were evaluated. Some of these were tested using IP and in situ nucleic acid hybridization (ISH) techniques using an RNA probe complementary to the 3'LTR and envelope region of HIV-1.
Results:

Seroprotective	Histology			Immunoperoxidase			IP/ISH	
	VA	CH	CA	IP	CK	AM		
Seroprotective	1/45	0/45	2/45	1/24	1/24	0/14	0/17	1/17
Seroprotective	0/21	0/21	9/21	0/17	0/17	0/17	0/14	0/14

Conclusions: HIV infection does not appear to cause significant pathologic abnormalities in the tern placenta. HIV antigens can be identified rarely in placental trophoblastic tissue. HIV nucleic acid can be found in those trophoblastic cells also containing HIV antigen. Examination of the tern placenta from HIV infected women has failed to clarify the mechanism of transmission of this virus from mother to fetus. Conceivably, tissue from earlier gestational placentas may be more informative.

M.B.P.22

EFFECT OF PREGNANCY ON THE PHARMACOKINETICS OF ZIDOVUDINE
Urbán, J., Muñoz, D., López-Ariza, A. and Schumann, R.
School of Pharmacy, University of Washington, Seattle, WA, U.S.A.

Objective: The incidence of HIV infection in pregnant women is increasing. Thus, administration of zidovudine (ZDV) to pregnant women may be of benefit to both mother and fetus. To determine the effect of pregnancy on the pharmacokinetics of ZDV, experiments were conducted in macaques (Macaca nemestrana) in term and after delivery.

Methods: ZDV was administered as a single IV bolus dose (10mg/kg) to two macaques at term and 1 week after delivery. Blood samples were collected frequently over the next 4h. Urine was collected over 24h. ZDV and its active metabolite (ZDV) in both plasma and urine were assayed by HPLC (1).

Results: The total plasma clearance (CL), steady-state volume of distribution (Vss) and the terminal half-life of ZDV were assessed. At term, these parameters for the two animals studied, were estimated as 24.6, 27.6 min/l, 903, 1314 ml/kg, and 37.4, 45.5 min respectively. In the non-pregnant state, these parameters were 27.8, 30.1 min/l, 727, 1256 ml/kg, and 39.9, 74.8 min respectively.

Conclusions: The pharmacokinetics of ZDV do not appear to be altered by pregnancy. Similar experiments in further animals are in progress.

1. Good S. et al. Chromatog. 1981; 41: 123-133, 1988.
Supported in part by March of Dimes Birth Defect Foundation (1-1135) and Burroughs Wellcome Inc.

M.B.P.24

A PROSPECTIVE STUDY OF THE MENTAL AND MOTOR DEVELOPMENT OF INFANTS BORN TO HIV INFECTED INTRAVENOUS DRUG USING MOTHERS

Blattner, Ron; Jeremy, R. J.; Rusey, C. M.; Vetrucio, P. M.; and Cowan, M. M., *MATTER-FACET, San Francisco, **University of California, San Francisco, U.S.A.

Objective: To describe prospectively the mental and motor development of infants born to IV drug-using mothers exposed in utero to HIV.
Methods: Quarterly screenings on the Bayley Scales of Infant Development (BSID-II) using a standardized Bayley Index (BSID-II) and a Psychomotor Development Index (PDI) (1). Three groups of infants: CONTROL (HIV-negative mother, n=15); INFECTED (HIV-positive mother, HIV-negative child, n=10), and UNINFECTED (HIV-negative mother, HIV-negative child, n=10).
Analysis: Comparison of BSID and PDI scores of the three groups at ages 3, 6, 9, 12, and 15 months: a) group means, and b) individual developmental curves.
Results: INFECTED infants showed lower BSID and PDI means with age than the CONTROL and UNINFECTED groups. In contrast to both non-infected groups which did not continue to decline. However, while the CONTROL group performed around normal BSID and PDI, the UNINFECTED group hovered about 1 standard deviation lower. Individual developmental curves showed that among the best developing infants were 5/6 of the CONTROL, 1/6 of the INFECTED, and 2/3 of the UNINFECTED. Among the poorest, 7/8 were CONTROL, 7/8 were INFECTED, and 4/5 were UNINFECTED.
Conclusions: The mental and motor development of HIV infected children declines over the first 15 months of life. The mental and motor development of infants exposed prenatally to HIV but not infected is poorer than that of CONTROL. Children not so exposed.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.25 INFLUENCE OF GESTATION ON HIV INFECTION.

REVELLE, A.L., PUEL, J., THIRICRE, J., BENOIST, H., FORTIN, J.-C.
*Service de Gynécologie-Obstétrique, Hôpital La Grange; *Service de Virologie, Hôpital Purpan; **Service de Pédiatrie B, Hôpital Purpan, Toulouse; ***Association "Le Patriarche", Saint-Cesair, France.

Objective. In order to compare the influence of time alone to the influence of time plus pregnancy on infection with HIV, we report results of a three year follow-up of two groups of women. (A) 60 HIV antibody positive, asymptomatic pregnant patients (34 live births, 26 medically indicated abortions) (B) 68 age and sex matched HIV antibody positive, asymptomatic patients without gestation.

Methods. In these two populations, the following parameters were compared: clinical stage, sedimentation rate, white cell count; relative lymphocyte count, relative and absolute T4 lymphocyte count, the T4/T8 ratio, the serum level of IgA, and the presence of the P24 HIV antigens. These parameters were measured during pregnancy, at termination of pregnancy, and one, two, and three years thereafter.

Results. No statistically significant differences between the two groups were found. In 20 % of the pregnant population, we found a transient appearance of the HIV P24 antigens during pregnancy.

Conclusion. Over a period of three years, no difference in the progression of HIV disease was observed between a population with and one without pregnancy. The transient appearance of HIV P24 antigens during pregnancy, does not seem to be a poor prognostic marker for progression of HIV disease.

M.B.P.27 PREGNANCY OUTCOME IN WOMEN HIV INFECTION IN PUERTO RICO IN A POPULATION OF PREGNANT INTERMEDIAL TRANSMISSION

BARRERA, J., ZORRILLA, C., HAZ, C., ROSSIGNOL, R. J., DE LA VEGA, A., CHIROQUEZ, J., PUERTO RICO, U.S.A.

Findings. The prevalence rate was 1.47%, the most common risk factor was being a sexual partner to an IV drug user (54%) followed by IV drug use by the patient (17%). The mean gestation was 34 and the mean parity was 2.3. None had sexual relationships by marriage or consensual union 71%, the mean number of lifetime sex partners was 2.6 (excluding patients who were prostitutes). The most common prenatal complication was diabetes mellitus (14%) followed by preterm labor 18%. Smoking was reported by 56% of patients. Mean weight gain during pregnancy was 22 lbs. Cesarean section rate was 15%. Perinatal mortality was 9.5% and post-neonatal mortality 4.2%.

Mean birth weight was 3,209 g, although 41% of the babies weighed 2,500 g. 7% of the patients elected pregnancy termination and 30% underwent post-partum sterilization. 7% of cases progressed to ARC/AIDS. Maternal mortality was also high (2.3%) and ascribed due to AIDS.

Conclusion. Perinatal as well as post-neonatal mortality is increased in the offspring of seropositive pregnant women. Maternal mortality is also increased significantly in this group of young women. Since the two maternal deaths occurred within one year post-partum in women whose neonates had congenital pneumonia, we may identify infection of the fetus as a risk factor for development of over disease in the mother.

M.B.P.29 Reproductive history (RH) of HIV antibody Positive (HIV Ab+) women in a high risk group in a prospective study

REVELLE, A.L., PUEL, J., THIRICRE, J., BENOIST, H., FORTIN, J.-C., ATLANTIC, SEASIDE, USA.

Objective. To describe the reproductive life of a cohort of HIV Ab+ women followed in a prospective study.

Methods. Pregnancy information on 43 HIV Ab+ women whose children are enrolled in a prospective study was obtained by interviewing mothers directly (n=39) or the child's guardian (n=13). Mean follow-up was 13 mo (range 2-20mo).

Results. Seven women had one subsequent pregnancy and 2 were pregnant twice.

Pregnancy	Index of child's age
1	12 mo
2	12 mo
3	18 mo
4	18 mo
5	13 mo
6	4 mo
7	4 mo
8	4 mo
9	5 mo

Conclusion. Despite counseling for risk associated with HIV, a high percent of HIV Ab+ women in this cohort became pregnant an average of 8mo after delivering an HIV Ab+ child. Future studies will need to address knowledge of HIV seropositivity and its impact on rates of pregnancy among women in a high risk area for HIV.

M.B.P.26 EFFECTS OF HIV INFECTION ON PREGNANCY.

REVELLE, A.L., KORDICH, W.E., PUEL, J., THIRICRE, J., BENOIST, H., FORTIN, J.-C.
*Service de Gynécologie-Obstétrique, Hôpital La Grange; **Service de Virologie, Hôpital Purpan; ***Service de Pédiatrie B, Hôpital Purpan, Toulouse; ****Association "Le Patriarche", Saint-Cesair, France.

Objective. We compared the complication-rate during pregnancy and the perinatal period among HIV antibody positive former drug addicts (group A), 68 HIV antibody negative present drug addicts (group B), and 2017 patients without a history of HIV infection or drug addiction (group C). The purpose of this study was to define the influence of HIV infection on pregnancy.

Methods. We assessed the following parameters: fever during pregnancy, hypertension, fetal malformations, fetal growth retardation, premature labor, the APGAR score, and postpartal complications.

Results (in %).

	Fever during pregnancy	hypertension	fetal growth retardation	premature labor	the APGAR score	postpartal complications
A	16.1	5.4	5.4	10.8	16.2	10.8
B	7.4	1.3	5.9	22.0	14.7	6.8
C	2.3	1.4	1.6	8.7	4.2	6.0

Conclusion. HIV infection appears to have no influence on the course of pregnancy, and does not increase fetal mortality. Complications such as fetal malformation, growth retardation, and premature labor seem to be more closely related to drug addiction and concomitant low socio-economic status, than to infection with HIV.

M.B.P.28 COMPARISON OF LIFESTYLES AND HIGH RISK SEXUAL BEHAVIOR BETWEEN HIV-SERO-POSITIVE AND HIV-SERO-NEGATIVE PREGNANT WOMEN

ZERRILLA, C., ROMAGOSA, J., TORRES, J., MORALES, J., ANDERSON, K., UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE, SAN JUAN, PUERTO RICO.

Objective. To compare the frequencies of different types of high risk sexual behavior and lifestyles during pregnancy in sero-positive vs sero-negative to HIV.

Methods. Personal interviews obtaining sexual histories and risk factors were performed in 61 HIV positive and 67 sero-negative pregnant women.

Findings. Age, gravidity, marital status, weight gain during pregnancy and number of prenatal visits did not differ among groups.

Anal intercourse was significantly more common by sero-positive patients, while there were no differences in oral intercourse with or without ejaculation (26% vs 26%).

Cigarette smoking was significantly more frequent among the HIV positive women (26% vs 26%), as was the relative frequency of sexually transmitted diseases (26% vs 26%). Significantly more sero-positive pregnant women had risk factors for HIV transmission than sero-negative (76% vs 56%). Of those with risk factors, more sero-positive women were sex partners of IV drug users (62% vs 36%).

M.B.P.30 DRUG ABUSE AND PREGNANCY: CONCOMITANT RISK FACTORS FOR HIV INFECTION

WELLS, SARA M., KATZELBAH, K.A. and FINNegan, L.P., THOMAS JEFFERSON UNIVERSITY, PHILADELPHIA, PENNSYLVANIA, U.S.A.

Women who are intravenous drug users or who are partners of intravenous drug users engage in behaviors that put them at high risk for developing human immunodeficiency virus infection. When the woman is pregnant, there is the additional problem of perinatal transmission to her unborn child. Data which included sociodemographic and psychological profiles as well as sexual and drug use habits was collected on 90 drug dependent pregnant women enrolled in a comprehensive treatment program in a study aimed at reducing HIV infection among IV drug abusing women and accordingly the perinatal transmission of AIDS. All the clients consented to confidential ELISA tests on initial evaluation and every 3 months while pregnant. Psychosocial profiles revealed that 52% had been subjected to physical or sexual abuse; 11% were homeless; and 46% were adult children of alcoholics or children of substance abusers. Drug histories showed that these women were addicted an average of 10 years; 62.5% were polydrug abusers and 35% used cocaine alone; 39% of the women are current IV drug users. Of these 90 women studied, 4.5% came into the project HIV positive, but without symptoms of HIV infection. None of the other 95.5% who tested negative to the extent seroconverted while participating in the project. As a result of this project, it is apparent that counseling women with regard to those specific risk factors must continue to reduce the incidence of perinatal HIV infection.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.37 AZT'S EFFECT ON RESPONSES TO PNEUMOCOCCAL VACCINE (PV).
Glasgow, Richard D.V., Weller, S. and Schiffman, G. C.
NYC Health 18th Hospital, St. Vi., *SUNY-Health Science
Center, Brooklyn, NY, USA.

Objective: To evaluate AZT's effect on PV-induced antibody (Ab) responses in patients (pts) who are treated with AZT. **Methods:** PV was administered to 48 pts who were treated with AZT. Ab titers to 12 P capsular antigens were measured by RIA for all pts pre- and 30 days post-PV and for certain AZT pts prior to AZT institution (10 pts) and/or 8 mos post-PV (13 pts). **Results:** Aggregate Geometric Mean Ab Titer x Dev. (no Ab/ml)

Group	Pre-PV	30-day Post-PV	8 mos Post-PV
No AZT	7007 ± 2.0	751.8 ± 2.1	594.9 ± 4.7
AZT	564.1 ± 1.3	512.9 ± 1.3	594.9 ± 4.7

Pre-AZT Ab levels (477,241.8) were similar to pre-PV levels (531,362.5) for pts treated with AZT for less than 13 wks (pre-92) pre-PV. "Protective" levels (post/pre ratio > 2.14 Ab. titer > 2000 ng Ab/ml) were achieved for AZT (ratio 1.7) but not the non-AZT group 30 days post-PV. For AZT pts, 30-day post-PV type specific levels were "protective" for types 4, 6, 9, 14, 16, 18, 19F, 23F but not 1, 3, or 12F. "Protective" aggregate levels were present at 3 mos for 6/13 pts (ratio 1.15) but not for the 7 pts dead (564,344.9; ratio 1.0) 14 mos post-PV.

Conclusions: AZT has no effect on Ab levels prior to vaccination. Vaccinated AIDS/AZT pts receiving AZT develop "protective" levels at 30 days, whereas those not receiving AZT do not. Patients with waning of aggregate Ab levels at 8 mos have poor short term survival.

M.B.P.38 Growth of the Cat Scratch Disease Bacillus from Skin Lesions and blood in two HIV positive men.
McE. Ford J. and Oliver J. St. Vincent's Hospital & Med Ctr of New York, U.S.A.

We report 2 patients who presented with fever and disseminated papular and nodular skin lesions within 10 weeks of seropositive serology. One patient also had lymphadenopathy. Both biopsied showed pleomorphic organisms in the Marchini-Scharr silver stain and electron microscopy of one biopsy was positive for coccobacillary forms consistent with the Cat Scratch Disease bacillus (CSD).

Morphologically, the lesions presented a pattern which resembled that of a pyogenic granuloma with anastomosing vessels and an acute inflammatory infiltrate. On occasion, a definite vitreous component was also noted. No evidence of Kaposi's sarcoma was noted. Culture of the skin lesions in both patients yielded gram negative pleomorphic organisms in Bacteroides Brest Infusion medium grown at 30°C in 2 weeks. Blood culture from one patient yielded identical organisms in Bacteroides Brest culture at 30°C. The medium incubated at 30°C which showed a negative growth curve of 30. The asexual viable showed a negative reading after 4 months. Bacteriologic therapy led to improvement in one patient and clearing of all lesions in the second patient.

We recommend that the microbiological work-up of HIV positive patients with disseminated skin lesions should include special stains and cultures for the CSD bacillus.

M.B.P.39 EMPIRIC ANTIHISTOXYTIC OF FEBRILE EPISODES IN HIV CARRIERS
Mazzoni, Emanoel J., Basso, S. and Kawanishi, C. C.
Infectious Unit MARSELLA FRANCE.

Objective: to test the efficacy of an empiric Antihistoxycy in HIV infected to cure bacterial infections of febrile episodes before an opportunistic infection is documented.

Methods: in a series of 40 febrile episodes (temperature > 38.5 more of 48 hours) without any clinical sign of opportunistic infection and before bacteriological results is obtained we used 2 case days of therapy in a randomized study: Arm A: PEFLOXACIN 400 mg b.i.d. plus TORBAMYCIN 3.5 mg/kg/12h. Arm B: CEFALOTIN 1g/12h plus TORBAMYCIN 3.5mg/kg/12h. If an opportunistic infection occurs: the study is stopped. All patients were infected with HIV 1, group III and IV of CDC's.

Results: At the onset, 36 episodes were available; in 28 cases fever was sensible to antibiotic and bacterial infection was documented in 9 cases bacterial infection was highly probable in 10 cases; opportunistic fungal systemic infection was associated in 8 cases; AMPHOTERICIN B is added to antibiotics to obtain a pyrexia. Failure was observed in 8 cases; in those cases an opportunistic infection was documented several days after therapy. No difference is observed between arm A or B.

Conclusion: an empiric antibiotic combination therapy seems to be effective to treat febrile episodes in HIV carriers. In most of our documented bacterial infections, such combination as PEFLOXACIN or CEFALOTIN plus TORBAMYCIN is in vitro and in vivo sensible. This empiric strategy can prevent the dissemination of co-infection with bacterial stains frequently isolated in immunocompromised hosts especially in intravenous drug addicts (32/60 in this series).

M.B.P.40 COMPARATIVE STUDY OF CLINICAL AND PATHOLOGICAL

DIAGNOSIS IN 35 PATIENTS WITH AIDS
Del Bianco, R.; Sullemann, J.; Araujo, M.F.; Prado, P.;
Carvalho, D.; Mesella, R.L.; et al.
Hospital Infância Ribalda
Centro de Referência e Tratamento-Aids, Sao Paulo, Brazil.

Objective: Analysis of the clinical and laboratory diagnosis comparing to the pathological findings.

Methods: 35 patients were studied: 25 (71.4%) homosexual men, 4 bisexual, 1 isosexual, 1 heterosexual, 2 drug addicted, 1 recipient of blood transfusion and 1 child of antibody positive mother (8.6%). All the patients had evidences of immunologic deficiencies and serologic tests positive (Eliass and Western Blott).

Results: The average days of permanence of these patients in the hospital were 35.3 days. Many opportunistic infection were recognized clinically: M. Tuberculosis in 12 patients (34.2%), P. Carinii in 9 (25.7%), gondii in 4 (11.4%), herpes simplex in 3 (8.5%) and C. neoformans in 3 (8.5%). In the pathological exam the M. Tuberculosis were found in 10 patients (28.5%), M. avium in 3 (8.5%), T. gondii in 4 (11.4%), C. neoformans in 3 (8.5%) and CMV in 11 (31.4%). **Conclusion:** M. Tuberculosis is often found in these patients determined by clinical laboratory and pathological findings.

M.B.P.41 APPORT DE LA TOMODENSITOMETRIE AU DIAGNOSTIC DES COMPLICATIONS PULMONAIRES DU SIDA DE L'ADULTE.
Trotot, P. N., Barrois -Francia, E., Mariches, M. M., Levillain, R.,
Etiennet, Pasteur; AHPH, Saint-Joseph, Paris, France.

Objective: évaluer l'apport de la Tomodensitométrie (TDM) au diagnostic précoce et au suivi des atteintes pulmonaires au cours du SIDA de l'adulte.

Méthodes: rapport de cas dossier de 300 derniers patients hospitalisés. Parmi ceux qui présentaient des complications pulmonaires, déterminées par la TDM, 127 ont été étudiés. **Résultats:** dans les atteintes au foyer, la TDM met le plus souvent d'aucun apport supplémentaire par rapport au simple cliché pulmonaire.

Par contre dans les atteintes diffuses elle peut être déterminante en reconnaissant l'infiltrat alvéolaire et de la pneumocystose et son évolution éventuelle vers l'effusion centrolobulaire périphérique conglomérée. L'alvéolite oedémateuse alvéolaire, la miliaire tuberculeuse interstitielle, ou les nodules disséminés du sarcose de Kaposi.

Conclusion: le caractère traumatique et la précision anatomique de la TDM méritent que dans les atteintes au SIDA, avant le lavage alvéolaire, ou tout au plus possible, un élément essentiel du diagnostic et du suivi thérapeutique.

M.B.P.42 EVOLUTION OF LUNG HIV-SPECIFIC CTL ACTIVITY AND CLINICAL CORRELATIONS. GUILLET, P., *PASTEUR ST. JOSEPH, PLATA, FERRER ET NYARD C. et al. Lab. Immun., Hôp. Fils-St-Joseph, Paris

OBJECTIVE: We previously described lung HIV-specific class-I-restricted CTL activity in patients at early stages of HIV disease. In this study, we prospectively evaluate the level of anti-HIV CTL activity during the course of the disease. 2) we analyze both consequences on lung function and its clinical relevance.

METHODS: A cohort of 81 HIV-positive patients was evaluated with long-term follow-up studies for 17 of them. The specific cytolytic function of lung lymphocytes was tested on autologous alveolar macrophages and cell lines expressing HIV proteins. The lung function was simultaneously evaluated.

RESULTS: The intensity of alveolar CTL lysis specific for HIV was markedly reduced in AHC and AIDS patients when compared with healthy seropositive carriers and patients with the lymphadenopathy syndrome (p < 0.01), although a weak activity could still be detected in a few AIDS patients. In sequentially studied patients, we observed a progressive decline in CTL activity as the clinical status deteriorated. In another hand, in those patients with significant CTL activity, some respiratory disorders could be defined including worse cough, interstitial pneumonitis and abnormalities of gas exchange. An improvement of lung function was paradoxically observed in some patients several months before the onset of opportunistic lung infection, as a parallel with the disappearance of CTL activity.

CONCLUSIONS: Our data strongly suggest a protective role for HIV-specific CTL. Although they can be deleterious to the function of the lungs.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.43 THE VALUE OF GALLIUM-67 SCAN IN THE DIAGNOSIS OF LYMPHADENOPATHY IN SEROPOSITIVE HIV-INFECTED PATIENTS.
Podanasser-Daniel; Ricart, J.; Bolea-F., Bonin-B., Romagos, V.; Godia-F., Hospital de Bellvitge, University of Barcelona, Barcelona, Spain.

Objective: To study the utility of chest gallium-67 citrate scan (GCS) in the differential diagnosis of enlarged lymph nodes in HIV-infected pts with constitutional symptoms.

Patients and methods: Nineteen HIV-positive pts (15 drug addicts and 4 non-smokers) with fever and/or weight loss and localized or generalized lymphadenopathy were evaluated with chest GCS. A positive GCS was considered when an increased focal uptake in cervical, axillary and/or supraclavicular nodal areas was observed. Subsequently, a lymph node biopsy was done in all pts. Results: In 9 pts GCS displayed an increase uptake in one or more nodal areas. One of them had follicular hyperplasia while in the other 8 biopsies showed angioimmunohyocytocytosis (7 M. tuberculosis and 1 non-specified atypical mycobacterium). Five of them had also mediastinal uptake. Two pts showed negative GCS. Biopsies showed follicular hyperplasia in 9 and Kaposi's sarcoma in 2 of the remainder.

Conclusion: This preliminary study suggests that in HIV-infected pts with constitutional symptoms and lymphadenopathy, a negative GCS probably represents follicular hyperplasia. In this setting, a surgical approach to the enlarged nodes suggests Kaposi's sarcoma is suspected. Conversely, a positive GCS strongly suggests a mycobacterial infection.

M.B.P.44 IMMUNOPHENOTYPY AND SERUM IMMUNOGLOBULIN (SIV) IN HIV INFECTION IN ADOLESCENTS.

Podanasser-Daniel; Ricart, J.; Bolea-F., Bonin-B., Romagos, V.; Godia-F., Hospital de Bellvitge, University of Barcelona, Barcelona, Spain.

Objective: To analyze the lymph node histopathologic changes in patients with HIV infection, and the clinical and epidemiological characteristics. In 20 patients.

Methods: The study group included 21: 3 patients with HIV infection (seropositive and seronegative), 18 patients with HIV infection (seropositive and seronegative). Histopathologic findings were determined in one or more nodal areas. Results: In 10 pts GCS displayed an increase uptake in one or more nodal areas. One of them had follicular hyperplasia while in the other 8 biopsies showed angioimmunohyocytocytosis (7 M. tuberculosis and 1 non-specified atypical mycobacterium). Five of them had also mediastinal uptake. Two pts showed negative GCS. Biopsies showed follicular hyperplasia in 9 and Kaposi's sarcoma in 2 of the remainder.

Results: Lymph node were made. The most frequent lymphadenopathy in HIV infection was made in 10 patients and determined 49 times (26 patients). The histopathologic findings are shown in the following table:

Diagnosis	Number	Sex	Percentage
Mycobacterial infection	11	24.0	** In some cases the diagnosis was confirmed by culture
Follicular hyperplasia	9	19.0	
Kaposi's sarcoma	2	4.0	
Angioimmunohyocytocytosis	1	2.0	
Non-specified atypical	2	4.0	
Unchanged	7	15.0	

J. tuberculosis was identified in 14 (76.3%) of 18 cases of mycobacterial infection. Within the pattern of histopathologic appearance, 10 patients with HIV infection were classified in group A GCS and 10 in group B. The most frequent lymphadenopathy in HIV infection was made in 10 patients. The histopathologic findings are shown in the following table:

Diagnosis	Number	Sex	Percentage
Mycobacterial infection	11	24.0	** In some cases the diagnosis was confirmed by culture
Follicular hyperplasia	9	19.0	
Kaposi's sarcoma	2	4.0	
Angioimmunohyocytocytosis	1	2.0	
Non-specified atypical	2	4.0	
Unchanged	7	15.0	

Conclusion: There is the most frequent lymph node infection in patients with HIV infection. The most frequent lymphadenopathy in HIV infection was made in 10 patients. The histopathologic findings are shown in the following table:

M.B.P.45 SEROPOSITIVE DISSEMINATED COCCIDIOIDOMYCOSIS IN PATIENTS WITH HIV INFECTION.

Amalita, Riana, Barlow, M., Aull, S., Larson, B., Leeson, Jr., Los Angeles County/University of Southern California Medical Center, Los Angeles, California, U.S.A.

Objective: Serologic testing for complement fixing (CF) antibodies to *Coccidioides immitis* is commonly employed to assist in the diagnosis and management of patients infected with this fungus. CF reactions in patients with concurrent HIV infection and disease due to disseminated *C. immitis* are assumed to be false-negative antibody responses.

Methods: After noting a case of disseminated *C. immitis* with negative CF reactions, we reviewed our experience in patients with both HIV and disseminated *C. immitis* infection with this fungus. CF reactions in patients with concurrent HIV infection and disease due to disseminated *C. immitis* were reviewed for false-negative antibody responses.

Results: Disseminated *C. immitis* and HIV infection were found in 11 patients; 8 had CF antibody titers performed. CF antibodies were detected in 6 of 8 serum samples (in a range of 1:16 to 1:256). Six patients also had serological testing of CF antibody response. Six patients (range 1:1 to 1:16). Two patients had persistently negative CF antibody tests.

Conclusions: Serologic testing for *C. immitis* CF antibodies may be negative in 25% of patients with disseminated disease when there is concurrent HIV infection. Histopathology and culture remain the most reliable method for the diagnosis of disseminated coccidioidomycosis.

M.B.P.46 COCCIDIOIDOMYCOSIS AMONG PATIENTS INFECTED WITH HIV. A PROSPECTIVE EPIDEMIOLOGIC STUDY.

Amel, Emil B.; Deitz, C.; Geligian, J.M., Tucson Veterans Administration Medical Center, University of Arizona, Tucson, Arizona, U.S.A.

Objective: To prospectively follow HIV-infected individuals for the development of coccidioidomycosis in an area endemic for *Coccidioides immitis* in order to determine risk factors associated with acquisition of this fungus. Infection.

Methods: Patients infected with HIV and living in Tucson, AZ have been followed since May 1988. Clinical evaluation and laboratory tests, including T4 lymphocyte count, coccidioidal skin-tests and lymphocyte transformation assays were performed on entry and every 4 months thereafter.

Results: A total of 50 individuals have been entered. 57 are men, 47 are white; mean age = 37 yr; mean T4 = 438. Since the study began, 3 patients have developed active coccidioidomycosis. Using clinical, epidemiological and immunologic data, analysis of the 50 individuals without active coccidioidomycosis revealed that 8 have clear evidence of prior coccidioidal infection, 14 have no evidence of prior coccidioidomycosis, and 8 are too immunologically compromised to make that determination. For the remaining 25, data is incomplete; hence, 11 of 28 individuals so far evaluated either have active coccidioidomycosis or evidence of prior infection.

Conclusion: These preliminary data from a prospective study indicate that coccidioidomycosis represents a major infection among HIV-infected individuals living in an area endemic for *C. immitis*. Further study will be required to determine whether active coccidioidomycosis in this cohort is due principally to reactivation or acute acquisition of infection.

M.B.P.47 SUCCESSFUL TREATMENT OF ACYCLOVIR-RESISTANT HERPES SIMPLEX II WITH FOSFANET (A HERPES WITH AIDS)

D. Shaw, J. Buller, E. B. Blair, S. A. Hopkins, M., St. Louis, MO, U.S.A.
* Section of Neurovirology, Division of Infectious Disease, Cook County Hospital, ** Division of Virology, Department of Laboratory Medicine, Hahnemann University, *** Burroughs-Wellcome, Co., Chignov, MA, U.S.A.

Objective: Investigation of fosfarnet as an alternative treatment of acyclovir-resistant herpes in the HIV infected patient.

Methods: A 38 y.o. black man with HIV positivity for 3 months and CD4 T4 cells decreased with AIDS had severe subconjunctival, perioral, and perioral HSV II infection in November, 1989. He had lesions extending from the nose superior to the perioral area. There was no response to intravenous acyclovir 10 mg/kg TID and acyclovir for 14 days. The addition of ribavirin produced no additional benefit. A trial of foscarnet was discontinued after 5 days due to severe neutropenia and thrombocytopenia. AT and acyclovir at 20 mg/kg/day were resumed, with serum levels of 48 µg/ml (peak) and 20 µg/ml (trough), and no response was observed. HSV sensitivity to a drug-acyclovir, AM-4, a fosfarnet - treated by automated colorimetric analysis are shown in table 1:

Drug	IC ₅₀ (µg/ml)
Acyclovir	10 ^{-4.8}
Fosfarnet	10 ^{-4.4}
AM-4	10 ^{-4.4}
Fosfarnet	10 ^{-4.4}

Fosfarnet was begun at 20mg/kg TID, the serum creatinine was 2.0 mg/dl.
Conclusion: Symptomatic herpetic conjunctivitis, and there was complete healing after 3 weeks. No residual or relapse has been observed. The patient is currently stable on AT.
Conclusions: Fosfarnet is an effective alternative therapy for acyclovir-resistant (RI) deficient or R2 mutant acyclovir-resistant herpes simplex virus II in persons with AIDS. Early diagnosis by culture and sensitivity is essential. Further clinical trials of fosfarnet are warranted.

M.B.P.48 FOSFARNET TREATMENT OF ACYCLOVIR (ACV)-RESISTANT HERPES SIMPLEX VIREMIA (HSV) INFECTION IN AN AIDS PATIENT.

Shaw, S.F., Amey, C., Pollock, J. Mills, St. Louis, MO, U.S.A.
* Section of Neurovirology, Division of Infectious Disease, Cook County Hospital, ** Institute for HIV Research, Division Medical Center, Co. and *** Area Clinical Research Associates, Hopkinsville, MA, U.S.A.

Objective: To assess the efficacy of intravenous fosfarnet for treatment of acyclovir-resistant herpes in the HIV infected patient.

Methods: Data was obtained prospectively and retrospectively from the charts of 26 patients in the U.S. receiving fosfarnet for herpes infection for ACV-resistant HSV. Results: Twenty-six patients had 34 episodes of acute/recurrent HSV (25 percent, 7 orofacial, 1 genital, 1 whitish) that progressed despite therapy with intravenous (19 patients) and high-dose oral (7 patients) ACV, vidarabine (15 patients) or ganciclovir (3 patients). All initial lesions were susceptible in vitro to fosfarnet and resistant to ACV. Patients received fosfarnet for 10-63 days (mean 18.2). Twenty-two patients responded dramatically with re-epithelialization of lesions; one patient failed to demonstrate clinical improvement. All thirteen patients who were re-treated during therapy with fosfarnet had cessation of viral shedding, one as early as day 3. In three patients, therapy was discontinued due to adverse effects (2 leukopenia, 1 anorexia), and 1 patient died of unrelated causes after 2 days of therapy. Fourteen patients had recurrences of HSV at an interval ranging from 2 to 8 months after therapy. Eight were re-treated successfully with fosfarnet, 3 with ACV, and 3 have not yet been re-treated. Eight patients have received maintenance therapy with fosfarnet.

Conclusions: Fosfarnet is an effective and relatively non-toxic agent for therapy of acyclovir-resistant HSV in AIDS patients. Based on the limited experience in this series of 26 patients, vidarabine is less effective than fosfarnet in treating ACV-resistant infection. Recurrence of herpetic lesions is common after discontinuation of antiviral therapy.

Session d'affichage Poster Session



Aspects Cliniques Clinical Aspects of AIDS

M.B.P.40 SUCCESSFUL THERAPY OF PROGRESSIVE ACYCLOVIR-RESISTANT ORAL-FACIAL HERPES SIMPLEX WITH INTRAVENOUS FOSCAMNET IN AN AIDS PATIENT

Sill, Richard K., Kaufman K., and Levy CS.

Washington Hospital Center and George Washington University Medical Center, Washington, D.C., U.S.A.

Objective: To determine the clinical efficacy of intermittently administered intravenous foscamnet in the treatment of progressive acyclovir-resistant herpes simplex virus infection.

Method: A 31-year-old homosexual white male with a history of AIDS post-pneumocystis pneumonia developed a type 2 herpetic lesion on his left upper lip. The lesion resolved initially with oral acyclovir but recurred several months later and progressed to involve the majority of the patient's face despite multiple courses of oral and intravenous acyclovir. Antiviral susceptibility tests were obtained for this isolate.

Results: Using a VERO tissue culture and plaque reduction assay, the virus was shown to be resistant to acyclovir *in-vitro*, but susceptible to vidarabine and foscamnet. Despite two weeks of intravenous vidarabine the lesion failed to respond. Therapy was changed to intravenous foscamnet (10 mg/kg every eight hours). After a three week course of treatment the lesion had completely re-epithelialized except for a peripheral crust. However, the lesion re-occurred once foscamnet was discontinued and herpes simplex was again cultured.

Conclusion: Intravenous foscamnet has efficacy in the treatment of clinically significant acyclovir-resistant herpes simplex infection, but chronic suppressive therapy may be required.

M.B.P.50 ULCERATIVE HERPES SIMPLEX (UHS) IN AIDS PATIENTS.

Cernantini, Guido, Gerboni, S., Meoni, N., Osuni, M., Muratori, S. and Alessi, I.

1st Clinic of Dermatology, University of Milan, Milan, Italy.

Objective: To define the diagnostic procedures, to evaluate the response to therapy and to assess the course and final outcome of 8 HIV positive patients with UHS of the anogenital area.

Methods: Tzanck's smear, histology, electron microscopy, cultures and immunocytochemical methods for HSV antigen were used to confirm the clinical diagnosis. ACV therapy was done. The patients were followed for herpetic recurrences, other AIDS manifestations and immunological parameters up to 20 months. At enrollment, Tzanck's smears were found positive in 8 patients, HSV type 2 was demonstrated in 7, a profound immunosuppression and concurrent opportunistic infections were present in 7. Acyclovir was healed the lesions in all patients, but one or more recurrences were observed in 6. The new herpetic episodes were ACV sensitive in 5 patients, while in 3 *in vivo* and *in vitro* resistant HSV type 2 strain was isolated in one patient. This patient was successfully treated by Foscamnet. During the follow up, 7 patients developed other major AIDS infections and 3 patients died.

Conclusion: Several methods are necessary to diagnose UHS. ACV therapy is usually effective. The survival time of patients with UHS seems longer than that of patients with other major opportunistic infections.

M.B.P.51 SUCCESSFUL TREATMENT OF SEVERE, ACYCLOVIR-RESISTANT HERPES SIMPLEX VIRUS TYPE 1 PROCTITIS IN TWO PATIENTS WITH AIDS: USE OF GANCICLOVIR

Reed, M.D., England, J.M., and Fletcher, C.M.

East Carolina University, Erie, Pennsylvania, North Carolina, USA; *Mayo Clinic, Rochester, Minnesota, Boston, Mass, USA; **University of Minnesota College of Pharmacy, Minneapolis, Minnesota, Minn.

Objective: To report on the efficacy and safety of continuous intravenous acyclovir (ACV) for the treatment of severe, ulceroactive proctitis caused by ACV-resistant herpes simplex virus (HSV) type 1 in two patients with AIDS.

Methods: Two patients were obtained on octane lipid media, inoculated onto tissue culture, and observed for cytopathic effect optimal for HSV. HSV isolates were typed with restriction endonuclease digestion. ACV plasma levels were measured by RIA. HSV sensitivity to ACV were determined by measuring viral growth by quantitating viral DNA with an HSV specific radiolabeled probe in the presence of varying concentrations of ACV. Results are expressed as an ID₅₀.

Results: Both patients developed severe ulceroactive proctitis from HSV type 1 with prolonged despite prolonged courses of oral ACV followed by 3 weeks of intravenous ACV administered at 10mg/kg every 8 hours. Both patients' isolate developed ACV resistance with ID₅₀ values of 100 units (normal for HSV type 1 is 1 unit). Continuous infusion ACV was administered at 14.4-0 mg/kg/hr via infusion catheters to maintain ACV levels in plasma between 20 and 30 µg/ml. Within a week of this therapy, the patients' stool improvement in their proctitis and by the sixth week had total healing of their lesions. Serum creatinine levels remained normal. The continuous infusion was accomplished in an outpatient setting with weekly visits and ACV and creatinine determinations.

Conclusion: Continuous infusion ACV was effective and safe in treating severe HSV-induced proctitis in two patients with AIDS despite the development of high level resistance to ACV and previous failure with ACV administered in divided doses.

M.B.P.52 ACICLOVIR THERAPY OF ACUTE RETINAL NEURITIS SYNDROME (ARN) IN AIDS PATIENTS

Fraclasca, Patricia

Augenklinik am Krankenhaus Harlaching, Munich, FRG.

Objective: To prove whether Aciclovir long term therapy is necessary to prevent relapses of Acute Retinal Neovitis Syndrome (ARN) caused by Herpes simplex Virus (HSV) or Varicella Zoster Virus (VZV) as opportunistic ocular infection.

Methods: Retrospective report on 4 patients with ARN. 3 had got ACICLOVIR therapy for extracocular herpetic infections over a limited period before, one received ACICLOVIR initially for treatment of ARN and HSV encephalitis (1500 mg/d intravenously), followed by long term therapy (100 mg/d per os) over a 8 months follow up period.

Results: In the 3 cases with extracocular diseases ARN occurred several weeks after suspension of ACICLOVIR therapy causing rapid visual damage. In one case initial ACICLOVIR therapy provided resolving of ARN and cerebral symptoms, maintenance therapy has prevented relapses for 7 months.

Conclusion: ARN should be an indication for long term therapy with Aciclovir to prevent blindness in AIDS patients.

M.B.P.53 HIV, HUMAN PAPILLOMAVIRUS, AND CERVICAL DYSPLASIA IN MAIROSI PROSTITUTES

Epstein, R.I., Kiviat, S., Plummer, R., Nandi, E., Wasyk, P., Holmes, K., University of Washington, Seattle, WA; *University of Montreal, Montreal, QC, Canada; **National Cancer Institute, Bethesda, Maryland, USA.

To determine whether HIV infection in women is associated with an increased frequency of human papilloma virus (HPV) infection or cervical dysplasia, we studied 145 Maïrosi prostitutes. Cervical smears were obtained for cytology and HPV detection by dot filter hybridization (ViraPap).

Results: The mean age of the study population was 36 years. The average number of sex partners per week was 4.6; 63% of women were seropositive for HIV, of whom 76% had generalized lymphadenopathy; none had overt AIDS. Thirty-two (24%) of 138 women had cervical HPV infection. Including 21% of HIV positive and 13% of HIV negative women. Five (14%) HPV types were 16/18, 14 (44%) were 31/33/35, and 13 (41%) were other. No association was noted between HPV infection and age, number of sex partners, use of spermicides or hormonal contraception, or lymphadenopathy. Of 125 cervical cytologic examinations, 2 (2%) showed cervical intraepithelial neoplasia (CIN). 13 (12%) showed atypia, and 108 (88%) were normal. Only 1 (4%) of the women with HPV had CIN.

Conclusion: Prostitutes in Maïrosi have a high prevalence of HPV infection but no association between HIV and HPV was observed. Cervical dysplasia was present in only 2% of HIV seropositive women. This cohort will help to determine whether the natural history of HPV infection and the risk of HPV-associated cervical dysplasia is affected by concurrent HIV infection.

M.B.P.54 PREVALENCE AND RISK FACTORS FOR HIV-1 INFECTION IN PATIENTS WITH ACUTE PELVIC INFLAMMATORY DISEASE (PID)

Sharon Safiro, BJ Daniel, BL Hauser, R Edson, W Crombholme, RL Sweet, et al; University of California, San Francisco, SF General Hospital, USA.

Objective: To examine temporal trends and risk factors for HIV-1 seropositivity in a population of women admitted with the diagnosis of acute PID.

Methods: This is an extension of our continuing retrospective analysis of stored sera from women admitted to an urban county hospital with acute PID. Sera from the years 1985-1988 were anonymously tested for antibody to HIV-1; demographic data and 15 separate risk factors were extracted by blinded chart review. In January 1989, we initiated a prospective study utilizing anonymous seroprevalence testing for HIV-1 and coded risk factor questionnaires; we will report on this data as well.

Number	% HIV seropositive	HIV seropositivity
1983	0/36	0
1986	2/63	3.2
1987	4/95	4.2
1988	8/119	6.7

Of the risk factors, intravenous drug use correlated significantly with HIV-1 seropositivity (OR = 23.2, 95% CI = 5.0 - 106.9). Among other risk factors, type of drug used, number of sexual partners, and previous history of sexually transmitted diseases did not correlate.

Conclusions: Overall seroprevalence of HIV-1 was 4.2% (95% CI = 2.4% - 6.4%) in women admitted for acute PID in 1985-1988, and increased from 0 to 6.7% during this time period. This is contrasted with a seroprevalence of 0.9% in 1148 obstetric patients at San Francisco General Hospital; risk factor analysis will attempt to discern differential risk factors in these populations.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.55 DIAGNOSTIC ET TRAITEMENT DES LÉSIONS CERVICO-VAGINALES ET VULVAIRES À PAPILLOMAVIRUS CHEZ LES FEMMES SÉRO-POSITIVES POUR LE VIRUS VIH.

Caubet, Patrick; Foulques, M.; Blondon, J.; Lefranc, J.P. Hôpital de la Salpêtrière, Paris, France.

Objectif: Décrire, à partir de l'observation de 29 patientes (âge moyen: 37 ans) séro-positives pour le virus VIH (75,5 % à contamination par toxicomanie intra-veineuse), les principaux caractères épidémiologiques, diagnostiques et pronostiques des lésions cervico-vaginales et vulvaires dues à une infection à papillomavirus (HPV).

Méthodes: Les lésions dépistées par l'examen coloscopique ou cytologique et confirmées histologiquement furent ensuite détruites par vaporisation au laser CO₂.

Résultats: 58,6 % des frottis cervico-vaginaux révélèrent une infection à HPV, et chez 6 patientes l'histologie cervicale a retrouvé des anomalies allant de la dysplasie légère (2 cas) ou modérée (3 cas) au carcinome invasif (1 cas). 38 % des patientes présentaient des lésions vulvaires à HPV associées. Après destruction au laser (13 patientes) le taux de récurrences est de 23 % (recu moyen de 11,2 mois).

Conclusion: La fréquence élevée des lésions génitales et papillomavirus chez les patientes infectées par le VIH rend nécessaire leur dépistage coloscopique et cytologique afin d'assurer leur éradication avant ou au début de leur évolution vers la dysplasie.

M.B.P.56

Human immunodeficiency virus and human papilloma virus in the cervical intraepithelial neoplasia (CIN) in development of past intravenous drug abusers (PVIDA) women.

Maria Luisa Muzylas, E. Conti*, L. Nevasi, D. Imperiale, A. Agorosi, M. Conti VII and IV* Department of Obstetrics and Gynecology, University of Milan, Italy

Objective: To investigate a possible association between HIV and HPV infections in the development of CIN.

Methods: 209 PVIDA (101 HIV pos, mean age 25.2 yrs, S.D.±3.9; 108 HIV-, mean age 25.8 yrs, S.D.±4.6) women, residing in a rehabilitation community where investigated by cervical cytology, colposcopy and by compositically directed biopsy. Statistical significance was evaluated by chi square analysis and by Fischer's exact test.

Results: CIN was found in 18 HIV pos (17.8%), and in 7 HIV neg (6.5%). CIN + HPV (Pap smear + histological examination) were found in 13 HIV pos. (12.9%) and in 4 HIV neg (3.7%).

HPV (Pap smear + histological examination) was found in 25 HIV pos (24.7%) and in 7 HIV neg (6.5%).

CIN is more frequently observed in HIV pos than HIV- women (P<.05) and control group (1534 university students, CIN 1.1%, P<.0001). Association between HPV and CIN is significantly greater in HIV pos (P<.05). Cytological and histological evidence of HPV infection are more frequent in HIV pos (P<.01).

M.B.P.57 GENITAL ULCERS (GU) AND HIV INFECTION IN AN URBAN SEXUALLY TRANSMITTED DISEASE (STD) CLINIC

Chirshin, Reilly; Dillon, S.; Delaviz, J.; Landerman, SH;

McConeck, W. SUNY Health Science Center at Brooklyn, New York.

Objective: To investigate the association of genital ulcers (GU) and HIV infection in persons attending an STD clinic in Brooklyn.

Methods: Beginning 10/88, our STD clinic pts were routinely offered HIV testing. HIV risk factors were assessed by interview at the time of testing. Clinic records were available for 213 pts who underwent HIV testing and were retrospectively reviewed to determine STD diagnoses.

Results: 16/73 (22%) of STD clinic pts tested were HIV+. GU were present in 8/16 (50%) HIV+ pts compared with 12/57 (21%) HIV- pts (OR=3.75, p<.03).

This trend increased when those with admitted HIV risk factors (H=5) (IVDU, homosexual, sexual partner with AIDS) were excluded (OR=5.6, p<.02). 7/8 HIV+ pts with GU were women and 5/7 of these women had no admitted HIV risk factors.

The etiologies of GU in HIV+ pts were: 3 herpes simplex, 1 syphilis. In the remaining 4 were not diagnosed definitively. Only one HIV+ pt admitted a history of previous GU. 5/16 (31%) HIV+ pts had >1 concurrent STD's diagnosed at presentation compared with 7/57 (12%) HIV- pts (NS).

Conclusion: We have noted an increasing incidence of GU disease in our STD clinic during the last 2 years. These data suggest that GU may be associated with HIV infection. As these pts were HIV seropositive at presentation, it is likely that acquisition of HIV infection either antedated or was coincident with their GU disease. The former possibility suggests an increased risk of GU disease in persons already HIV+, the latter suggests an increased rate of HIV transmission from sexual partners with GU disease.

M.B.P.58

THE RISK OF PROGRESSION OF CERVICAL DYSPLASIA IN WOMEN WITH HIV

Bradbeer C.S, Heyderman E. St. Thomas' Hospital, London, UK.

Objective: To assess the prevalence and the risk of progression of cervical dysplasia (CIN) in women with HIV.

Methods: Ten unselected women with HIV were prospectively investigated for CIN over a mean of 26 months (range 5-6).

Results: Seven have shown evidence of progression or development of CIN over the study period, no spontaneous regression was noted. Of the five who required ablative therapy, three developed recurrence of CIN after treatment. A high incidence of infection with the genital wart virus was also noted. Results for a larger number of subjects will be presented.

Conclusion: These results have implications for the provision of colposcopic services and treatment facilities as part of the management of HIV in women.

M.B.P.59 CERVICAL INTRAEPITHELIAL NEOPLASIA IN HIV INFECTED WOMEN

Solo, Diana; Frenedra, A.; Rubio, F.; Latorre, A. and Abad S. C.P.S. Centro. Madrid Council, Madrid, Spain

Objective: We have previously described a high incidence of genital infection, cervical intraepithelial neoplasia (CIN) and also carcinoma of the cervix in HIV infected women. The aim of this paper is to compare the incidence of genital infection and CIN in three different groups, to clarify the relationship between HIV infection and CIN.

Methods: Three groups were compared: Group I, HIV infected women (IVDU and women infected by heterosexual transmission); Group II, control group (seronegative women with similar characteristics to group I) and Group III, prostitutes (prostitutes who were not IVDU and were seronegative).

Vaginal smear, colposcopy and microbiological study were done in all the cases. In cases of abnormal smear or colposcopy, cervical biopsy was done.

Results: Five out of ten women in group I, one out of ten women in group II and two of 23 women in group III were found to have a CIN.

	I HIV (N=10)	II CONTROL (N = 10)	III PROSTITUTES (N=23)
CIN	5	1	2
Normal findings	5	9	21

Conclusions: No statistical differences $\chi^2 = 2.14$ (p 0.5) could be demonstrated between the HIV infected group and the control group. Significant differences between group I and group II were found ($\chi^2 = 4.85$ p 0.05). No differences were found in the infection rate of the three groups.

More cases and controls are now being enrolled, to clarify the lack of differences in these groups.

M.B.P.60

HIGH RATES OF CERVICAL DYSPLASIA, CERVICAL INTRA-EPITHELIAL NEOPLASIAS (CIN) AND HUMAN PAPILLOMA VIRUS INFECTION IN HIV INFECTED FEMALE PATIENTS

K. F. Hiller, R. Lutz, S. Baur, M. Stauber, University of Munich, I. Women's Hospital, Munich, Federal Republic of Germany.

Objective: To show the important role HIV infection plays in the development of dysplasias of the cervix uteri, cervical intraepithelial neoplasias (CIN), and the close relation to high rates of human papilloma virus infections observed in HIV-infected female patients.

Methods: 38 female patients were examined in regard to their immunologic status. Lymphocyte stimulation tests were performed, cytology of the cervix uteri, colposcopy, human papilloma virus DNA-hybridization by Southern Blot and Viratype testing (GibCO Ltd.) and "open reading frame" protein detection tests were performed. In some cases histological evaluations of CINs are available.

Results: More than 15% of female patients in an age group of 20-30 yrs. show cytological signs of cervical dysplasia, approx. 8% show cervical intraepithelial neoplasias (CIN). In more than one-third of all patients we found clinical aspects, cytology or laboratory testing positive for human papilloma virus infection of various types.

However, in two-thirds of patients with signs of dysplasia we found evidence for the presence of human papilloma virus infection. Percentages are even higher in patients during pregnancy (approx. 25% of patients with dysplasia). First results of "open reading frame" protein testing will be presented.

Conclusion: The synergism of HIV infection, subsequent immunosuppression and human papilloma virus infection lead to high rates of dysplasia and cervical intraepithelial neoplasias particularly in pregnancy.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.61 INFECTION IN HIV-SERONEGATIVE INDIVIDUALS WITH THE EBNA 20 EPSTEIN-BARR VIRUS SHORTEL: CORRELATION WITH 14 LYMPHOCYTE MARKERS

Baldoni M.C., De G. G., Scudato G., Maglietta C., Andriano A.M.,*
Mazzoni Gian-Marco et al.

*Istituto Oncologico Centro Multiuso Universitario, Cremona;

*Laborio HIV Study Group, Istituto Carcano, Pavia, France.

Objective: EBV is associated with 8 cell lymphomas in HIV-infected individuals.

It is now a well established fact that, in the general population, 2 subtypes of EBV exist, referred to as EBNA 20 and EBNA 21. The aim of this study was to determine the prevalence of infection by the rarer subtype, EBNA 20, in HIV-positive subjects, as well as the intensity of the antibody response, according to the number of circulating T4 lymphocytes.

Methods: EBNA 20 was transfected in Rat 1 epithelial cells. Test sera were titrated by antigen-enzyme/immunofluorescence or by polymerase chain-transfected rat 1 cells (R1). In EBNA 1, EBNA 20 and EBNA 21 transfected cells. A total of 209 HIV-seronegative Caucasian individuals were studied, including 107 subjects with more than 200 T4 cells/mm³ and 102 patients with less than 200.

Results: Data of prevalence and Geometric Mean titres are summarized in the following table:

	VCA	EA	EBNA 20	EBNA 1	EBNA 20	EBNA 20	
> 400 IU	63	79	91	82	83	prevalence	
< 300 IU	53	41	67	77	75	GMT	
< 400 IU	100	71	86	70	71	prevalence	
< 300 IU	46	41	52	36	36	GMT	

Conclusion: Our results suggest that 1) prevalence of, and response to, EBNA 20 subtypes of EBV increases as the number of T4 cells falls, as opposed to those with EBNA 1, and 2) dual infections with both EBNA 20 and EBNA 21 subtypes might exist.

M.B.P.63 EFFECTS OF rHC-CSF ON SECONDARY INFECTIONS IN AIDS

Kishida, Satoshi; Mohri, K.; Sogayama, H.; Nakagawa, A.;
Hikita, Y.; Shimada, E.; Nakamura, T.; Nakamura, T.*

*The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.

Objective: The effects of recombinant human granulocyte-colony stimulating factor (rHC-CSF) on secondary infections in AIDS patients were evaluated. **Patients and Methods:** Four consecutive AIDS patients (hemophiliacs) with various infections and leukocytopenia were treated with intravenous rHC-CSF. Patients' profiles are summarized in Table 1. The rHC-CSF was donated by KIRIN Brewery Co., Ltd. (Tokyo, Japan). **Results:** In cases 1, 2, and 4, the number of CD4 increased three to seven folds, and current infections were controlled by the administration of 0.1 µg/kg rHC-CSF. In case 3, however, rHC-CSF (0.1 - 0.2 µg/kg) showed only a little effect. This may be due to simultaneous administration of acyclovir and ara-A. No adverse effect was observed in any of these patients. The number of CD4⁺ cells and the levels of p24 antigen did not change during the course of the treatment.

Table 1. Background of Patients in This Study

Case	Age	Sex	Indicator disease	Current infection	Pathogens
1	31	M	Cryptosporidiosis	recurrence of CM	C. meformans
2	30	M	PC pneumonia	TM, septicemia	St. epider., Klebsiella
3	41	M	Candida esophagitis	SE, Mycobact.infer.	VCM, Mycobact.
4	37	M	PC pneumonia	abscess	St.aureus

Conclusion: In AIDS patients, rHC-CSF was very effective in the treatment of bacterial and fungal infections unless other agents suppressing the bone marrow are not used simultaneously with it.

M.B.P.65 INCREASE OF FACTOR VIII ACTIVITY IN HIV INFECTED PATIENTS.

Garza, Sergio,* Rivas, P.,* Arciles, A.,** Vessari, P.,* and Torres, A.*

*Laboratorio de Diagnóstico y Referencia Epidemiológicos, Secretaría de Salud, México, D.F.; **División Malattie Infettive, *Servizio di Immunopatologia, **Laboratorio Chimico-clinico, Reggio-Emilia, Italy.

Objective: To demonstrate an abnormal coagulation profile associated with HIV.

Methods: We have evaluated hematostatic function in 20 patients with HIV-infection. All the patients included in the study were treated with AZT. We measured APTT, Fibrinogen, FVIII, FVIIII and FXa: Factor VIII, VIIII and X activity were carried out, using plasma from General Diagnostic, a pool plasma from 20 donors used as control.

Results: These results show no significant difference in APTT, Fibrinogen, Factor VII and X activity, however there is an increase in Factor VIII activity.

	Fibrinogen	APTT	FVIIII	FVIII	FXa	FVIIII
HIV infected patients	300	30	80	80	80	80
Control	300	30	80	80	80	80

Conclusion: These preliminary results should be approved with further investigation to determine if the changing in Factor VIII activity is related to a FVIII antigen modification and this situation is an epiphenomenon to an acute serologic response or it is associated with hyper-coagulability.

M.B.P.62 ASSOCIATION OF EPSTEIN-BARR VIRUS IN EPITHELIOID ANGIOSIOMAS OF AIDS PATIENTS

Benjamin Constant,* Unger E.R.*

*Henry University, Atlanta, Georgia.

Objective: Epithelioid hemangioendothelioma-like vascular proliferations, recently described in AIDS patients, have been associated with bacilli similar to those found in sarcomatous diseases. Since other vascular lesions present in AIDS patients, in particular Kaposi's sarcoma, have been associated with CMV, we investigated the possibility of viral associations with epithelioid angiosiomatosis.

Method: In-situ hybridization was performed on formalin fixed, paraffin embedded tissue from 2 cases using cloned histiotyping probes for CMV, herpes simplex (HSV), HIV and EBV.

Results: Immunohistochemistry had evidence of opportunistic infection at the time the biopsy was obtained and the lesions regressed spontaneously. Hybridization with CMV, HSV and HIV were negative, those for EBV were positive in both lesions. Hybridization signal for EBV silver stains in the nuclei of endothelial cells and in occasional histiocytes. Bacilli were demonstrated with only one of the lesions by silver stains.

Conclusions: This is the first report of EBV associated with this entity and the first time that EBV viral genome has been seen in endothelial cells. Our data suggest that EBV may be involved in the pathogenesis of these lesions but further studies are necessary.

M.B.P.64 PREVALENCE AND CLINICAL SIGNIFICANCE OF COON'S

TEST AND OLD AGGLUTININS IN AIDS-PATIENTS

Reuter J., Gathof H., Heinrich B., Matheis A., Hecker F.,
Gombel P.-D., Hildebrandt Wöhrden, FPG, Bad Polzliken.

* Transfusion Service of the Red Cross, München, F.R.G.

OBJECTIVE: To determine the prevalence and pathogenetic/diagnostic relevance of positive direct anti-coagulin tests (DAT) in AIDS patients (PTS).

METHOD: 34 (28%) out of 145 consecutive AIDS PTS (CDC criteria) attending our clinic presented with anemia requiring transfusion. Antibody screening was performed including C3, C3d, C4, anti-IgG/KA, IgG and cold agglutinins (CA). Retrospectively diagnosed hematologic parameters and therapy were studied.

RESULTS: 47% (16/34) showed a positive agglutination in at least one test. C3d, anti I, CA and IgG occurred most frequently (16/34/7/4 out of 16). 75% (12/16) had leukopenia (<4000/µl), 50% (8/16) had thrombocytopenia (<150000/µl) and 38% (6/16) showed both. Hyperfibrinogenemia (1.6 g/l) was present in 81% (13/16). Only 2 out of 16 DAT+ PTS showed hemolysis. 63% (10/16) of the DAT+ had proven mycobacteriosis (8 sputum in contact to only 17% (3/18) of the DAT- PTS (p<0.01). Other diagnoses and therapy of the DAT+ PTS showed no significant difference in prevalence (PCP, CMV, MBL, toxoplasmosis).

CONCLUSION: Autoimmune versus infectious pathogenesis of DAT in AIDS has been discussed in the literature. Our results show a correlation of mycobacteriosis with DAT suggesting rather infectious than autoimmune pathogenesis.

M.B.P.66 THERAPY OF SALMONELLA INFECTIONS IN AIDS PATIENTS.

K. Reinton, S. Rodriguez, and P. Wessell. The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.

Objective: To evaluate the efficacy and toxicity of newer agents - ceftriaxone (CTX) and ciprofloxacin (CFP) compared to ampicillin (AMP) and trimethoprim/sulfamethoxazole (TMP/SMX) for Salmonella infections.

Methods: Ten AIDS patients with severe Salmonella gastroenteritis were treated with standard or newer agents. Patients were monitored for response, toxicity and recurrence (clinical follow-up - 6 months). **Results:** - All 5 patients treated with AMP or TMP/SMX responded initially but all relapsed - one with bacteremia. Two responded to a 5 day course of 1.6 CTX (no relapse). One received only 2 doses of CTX before therapy was stopped for a skin rash. He responded but relapsed 1 month later. Two patients responded to oral CFP. CTX & CFP were well tolerated.

Drug	# of Pts.	Outcome	Follow-up
ampicillin	2	response	relapse
trimethoprim/sulfamethoxazole	2	response	relapse (bacteremia) 1 pt.
ceftriaxone	3	response	relapse=1 pt.
ciprofloxacin	2	no response	no relapse

Conclusion: Aggressive therapy of Salmonella gastroenteritis in AIDS patients may prevent bacteremia and dissemination. Agents such as CTX and CFP may be superior to, less toxic, and have fewer side effects than standard drugs. These newer agents have high biliary concentration and may attenuate the chronic carrier state. Oral agents (CFP) may also increase compliance. They need wider clinical evaluation to establish efficacy and optimal length of therapy.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.79 DISSEMINATED HISTOPLASMA IN A DENISH AERIPATIENT.

SHIBUKAWA, I. I.
Infectious Diseases, Hygiene Hospital, Department of
Infectious Diseases; *Department of Pathology, Copenhagen,
Denmark.

Objective: To present the first case of disseminated histoplasmosis (DH) in an European AIDS pt. **History and findings:** A 35-year-old homosexual with 7 weeks of fever, chills, a slight cough and a weight loss over the last 3 months. Examination showed a Kaposi's sarcoma of the mouth, oral thrush and a temperature of 38.4°C. No lymph node swelling or organomegaly. White blood cell count was 2.700/mm³ and CD4 cell count was zero. A sputum smear showed diffuse/few intracellular proliferates and from the bronchial lavage gram-stain and smears were cultivated. Therapy was started with penicillin and isotretinoin 200 mg daily. A liver biopsy showed granulomas and a biopsy of the lower extremity was normal. A CT-scan of the abdomen showed a slight hepatomegaly and several lymph nodes in the retroperitoneum. Six weeks after admission he still had the fever and was losing weight. Zidovudine 1200 mg daily was started and an explorative laparotomy was done with the exclusion of a mesenteric lymph node. Histological examination showed typical histoplasma (H) in the retroperitoneal skin test and histoplasma serologic test of the serum and blood with all negative. He was treated with i.v. Amphotericin B 20 mg/day for 2 weeks to a total of 4.5 mg/kg. Then the treatment was changed to oral Fluconazole 200 mg/day. The patient lived in Venezuela from 1983-1986 but otherwise in Europe. A CT-scan 2 months later showed regression of the lymph nodes and no organomegaly. Clinow remains after the diagnosis of DH is the feeling with oral Fluconazole 200 mg/day without any signs of relapse or other opportunistic infections. DH cell count is 250/m³.

Conclusion: DH should be considered in immunodeficient patients also from non-endemic areas. A detailed travel history is essential. This patient got a much lower CD4 count than recommended but it seems to be sufficient when followed by oral Fluconazole.

M.B.P.81 HISTOPLASMA IN AN AIDS PATIENT TREATED WITH TRIMOPRIMIDAZOL

**TOULI, HIGLEY, RIGBY, JENKINSTRY, SHAWSON, PI
Campbell, C. M.; Cassard, R. ***

*St. Stephen's Hospital, London, England, *Mycobacterial Reference
Laboratory, London, England.

Objective: Histoplasma has been described in AIDS cases in endemic areas. We report a case which developed in a severely immunocompromised patient resident in the U.K.

Methods: A 34 year old HIV antibody positive patient with a previous AIDS diagnosis of cerebral toxoplasmosis and Mycobacterium tuberculosis in the lung and neck nodes, presented with a two month history of skin lesions on the face and back and painful, swollen left foot. Biopsy of the fifth metatarsal and oral biopsy of the head granulomatous skin lesions showed the large tuberculate macroconidia of Histoplasma capsulatum. The patient was Argentinian but had not been in that country for ten years.

Results: He was already being treated with trimoprimidazole 200mg twice daily for pneumocystis carinii but has since been switched to the triazole trimoprimidazole 200mg daily in an attempt to eradicate the fungus. His lesions have healed completely and feels much better since commencing therapy. He remains well at six months follow up. Treatment in the past has been with intravenous amphotericin B and flucytosine or oral ketoconazole. It is interesting that this patient was already on ketoconazole when he developed the skin and bone lesions suggesting poor drug absorption or a resistant strain.

Conclusions: We believe this to be the first AIDS patient to develop this infection in the United Kingdom to be successfully treated with trimoprimidazole.

M.B.P.83 HEMORRHAGICA PURPURA SEPTICEMIA IN AN AIDS PATIENT

WITH A SEVERE RICKETTSIA CAPSULATA INFECTION.
CAHANEY, DENNIS M., LEWIS, J.M., and OLSEN, C.
University of Southern California, Los Angeles, California, U.S.A.

Objective: To describe a septicemia in an AIDS patient caused by *Rickettsia* sp. This organism has not been previously described as a cause of fungemia in AIDS patients.

Methods: A 42 year old homosexual man diagnosed with chronic *Cryptosporidium* diarrhea and receiving central hyperalimentation developed a fever. Blood was obtained from the in-dwelling Hickman catheter for culture on 6 occasions over a 48 hour period. Blood was inoculated into BACTEC M9EA bottles and processed in a BACTEC 9600 system and then plated onto Sabouraud agar. Blood for culture was also obtained using the Dupont Instalar Igmis Concentration method and inoculated onto Sabouraud agar. The Hickman catheter was removed.

Follow-up: Blood cultures were obtained.

Results: Blood cultures drawn from the Hickman catheter grew *R. rubrum* using both culture systems. *R. rubrum* has a distinct pink coral color. Following removal of the catheter, peripheral blood cultures yielded no growth and the patient deservosed.

Conclusion: *R. rubrum* has been rarely reported to cause septicemia. *R. rubrum* may cause septicemia in AIDS patients with Hickman catheters. Catheter removal alone may result in cure without specific anti-fungal therapy.

M.B.P.80 CHRONIC SUPPRESSION OF DISSEMINATED HISTOPLASMA IN HIV PATIENTS WITH ORAL KETOCONAZOLE

ROBERT MILHART and J. BREWER. St. Luke's Hospital, Kansas City, Missouri, USA.

Objective: To review the course of ten consecutive patients with disseminated histoplasmosis and HIV disease treated with intravenous amphotericin B (AMB) followed by chronic suppressive oral ketoconazole.

Methods: Clinical and laboratory data was reviewed retrospectively on all patients we have seen with histoplasmosis and HIV (No.1). One case, in which death occurred shortly in AMB treatment, is not included.

Results: Diagnosis was made by smear and culture of bone marrow (No.1), blood (No.2), lung tissue (No.3), colon (No.4), and bronchoalveolar lavage (No.5) Both patients received 1000 to 2400 mg of AMB followed by 400-600 mg ketoconazole orally per day. Patients have been followed from one to 24 months on ketoconazole. Average months of disease free follow-up = 11.5. Two patients relapsed, but remain alive, having been retreated with AMB. One relapse, at 6 months on ketoconazole, was associated with trimidazole treatment. The other relapse, at 21 months, was associated with ribavirin treatment. Two of the 10 patients died. Both died of other HIV related conditions. Both had negative bone marrow smears for histoplasmosis shortly before death.

Conclusions: Chronic suppressive oral ketoconazole may be a reasonable alternative to chronic intravenous AMB in selected patients with histoplasmosis and HIV disease.

M.B.P.82 DEMONSTRATION OF HISTOPLASMA IN HIV INFECTED PATIENTS

SHAW, T.A.V., BULLOCK, LINDSEY M., HANLEY, C., GARDNER, M., SERRA, M. S.; SIM, P.S.; MORIS DE SA, C.
Caffre & Gubie University Hospital - University of St. Andrews, St. Andrews, Scotland

Objective: To analyse all serological investigations using AMB HIV infected patients.

Methods: A review of records of all patients with AIDS (PWA) seen at University of St. Andrews HIV Clinic from November 1981 to August 1984. HIV infection was confirmed by ELISA. Direct immunofluorescence and/or immunofluorescence techniques. All immunofluorescence lesions were confirmed by biopsy and/or culture when needed. Patients were evaluated for age, sex, race, stage of infection and type of lesions. We did not evaluate treatment or response to treatment.

Results: We found immunofluorescent histoplasma in 277 patients (15.8%), 212 male (58.7%), 65 female (23.7%), most of the patients presented were than 40 years of lesion.

SEX or RACE	PATIENTS	%
Male	158	57.2
Female	65	23.7
White	268	97.1
Black	6	2.2
Hispanic	3	1.1
Unknown	1	0.4
Others	64	23.1

Conclusions: Immunofluorescent histoplasma are common among HIV infected patients. It is possible to make a definite diagnosis of HIV infection observing the skin. Serologic diagnosis of HIV infection using the skin. Serologic diagnosis of HIV infection using the skin.

M.B.P.84 SEPSIS FROM INJECTED CATHETERS IN PATIENTS WITH AIDS

ROSENBLATH, JOSEPH B., GASTNER, C., GARDNER, M., SERRA, M. S.
Case Western Reserve University, Cleveland, Ohio, USA.

Objective: To assess the frequency of catheter-related sepsis (CRS) in AIDS patients. A review of records of all patients with AIDS (PWA) seen at University of St. Andrews HIV Clinic from November 1981 to August 1984.

Methods: A review of records of all patients with AIDS (PWA) seen at University of St. Andrews HIV Clinic from November 1981 to August 1984. HIV infection was confirmed by ELISA. Direct immunofluorescence and/or immunofluorescence techniques. All immunofluorescence lesions were confirmed by biopsy and/or culture when needed. Patients were evaluated for age, sex, race, stage of infection and type of lesions. We did not evaluate treatment or response to treatment.

Results: Thirty-four of 130 PWA had catheters (C) placed; 33 were evaluable. Indications for C included treatment with amphotericin B, hyperalimentation (HMA), or dantrolene (D) and need for venous access (R/33). Fifteen episodes of CRS occurred in 12/33 C, with 0.4 CRS/100 C-days. Mean (SD) time to CRS was 14(9) days. Organisms recovered were *S. epidermidis* (8), *S. aureus* (4), *Corynebacterium JE* (1), *P. aeruginosa* (3) and *A. albicans* (1). There were no deaths related to CRS and no instances of endocarditis. Mean C life was 14(9) days in infected catheters (IC) and 34(9) days in uninfected catheters (UC) (p<0.1). Dematitis was present at 36% of IC and 38% of UC (p=0.67). Sixty-seven percent of RedSpot® C and 30% of Roviac® (Hickman®) C became infected (p<0.13). Age, sex, race and HIV risk factors were similar in IC and UC. The 2 groups did not differ in duration of AIDS, number of opportunistic infections, Karnofsky status, response, or MALT use.

Conclusions: We found a high overall frequency (36%) of CRS in our PWA. CRS occurred up to 20 times more often than in comparable non-AIDS patients, as reported in the literature. RedSpot®-C were more frequently associated with CRS than Roviac®/Hickman®-C. Possible explanation: CRU use high infection rate include presence of dematitis, prolonged catheter use at home, and host response factors.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.97 VISERAL LEISHMANIASIS IN HIV-ASSOCIATED INFECTION. REPORT OF 3 CASES.

Alfon J. F. Balboa, María Rosa R. Belmonte, J. H. and Villalongo C. A.
Hospital San Borja (Chillan), and Hospital San Clemente (Chillan),
Chileno, Chile, Soud.

Objective: To report visceral leishmaniasis (VL) cases observed among HIV infected adult patients in two hospitals from Northwestern Chilean town in Antofagasta Regional medical area.

Methods: We retrospectively review all cases of VL diagnosed among adult (18-60 years old) patients seen in our hospitals from 1985 to the end of 1989. We report all cases in which HIV infection was also detected, with special reference to the clinical and immunological status, and treatment outcome.

Results: From 1985 to 1989, 3 cases of adult VL have been diagnosed in our two hospitals. In 2 of the 3 cases HIV infection was also detected. Three patients had history of intravenous drug abuse. 1 patient reported HIV infection through intake of commercial injection factors to reverse sodium effect, and 1 patient acquired his previous risk behavior. Four patients are men. Age ranged from 18 to 70 years. Two patients relapse cases contact with drug. Fever and adenopathy were initially present in all cases. VL was the first severe infection in all patients, and in 2 cases B2-lymphocyte count recovered from blood cultures during the course of VL. CD4 lymphocytes were < 60/mm³ in all cases. Diagnosis of VL was made by bone marrow aspirates. High titers of Leishmania antibodies were found in all cases in which they were tested. Negative ureteric (Kojima) therapy was used in all cases. Two patients showed clinical improvement, without apparent relapse. Three patients didn't show clinical response to treatment, and two of them died from VL. Three patients and AIDS case definition criteria (1 existing syndrome, 1 recurrent B2-lymphocyte, 1 indicators of response).

Conclusion: Visceral leishmaniasis may be the first severe infection in HIV-infected patients. In these cases it may run an unfavorable course despite appropriate therapy. Like others, we propose that adult VL should be considered as opportunistic infection in HIV infection, and include in serological AIDS case definition. All adult patients with VL should be studied to rule out HIV infection, even in endemic areas.

M.B.P.99 HIV SEROLOGY AND VISCERAL LEISHMANIASIS IN CAMEROON

FORONDE, E.*, ZIENGE, L.**, KAMPELE, L.***

C.H.U.S.S. YAOUNDÉ, CAMEROON. **UNIVERSITY HOSPITAL YAOUNDÉ, CAMEROON *** MINISTRY OF PUBLIC HEALTH, YAOUNDÉ, CAMEROON.

Objective: To do a study on the seroprevalence of HIV1 and HIV2 antibodies among patients with visceral leishmaniasis (V.L.) in the region of Kousséri (far North of Cameroon).

Methods: Of 48 patients (22 males, 24 females) with clinical suspicious signs of V.L. (deteriorating general state, profuse fever, anemias, liver and/or spleen enlargements) specific tests were done (fast blood count, leishmaniasis serology, trypanosoma antigen test on bone marrow aspirate), then HIV1 and HIV2 serology.

Results: The diagnosis of V.L. was confirmed on 9 patients. Out of these 9 patients 1 was found HIV1 positive. None was found HIV2 positive.

Conclusion: V.L. should be considered as an opportunistic infection of AIDS.

M.B.P.101 DETECTION OF HIV-1 IN CEREBROSPINAL FLUID (CSF): CORRELATION WITH PRESENCE AND SEVERITY OF THE AIDS DEMENTIA COMPLEX

Zhai, Huijun, Dr. Brev, R.J. Khan, R. Galliano R. Price, M.D.
Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

Objective: To assess the presence of HIV-1 in CSF by antigen capture and virus isolation in relation to severity of the AIDS dementia complex (ADC). **Methods:** PMA was assayed by antigen capture (Abtest) and by virus isolation (using PMA-stimulated PBs as indicators) in CSF and serum/blood samples from HIV-1-infected patients at various stages of ADC at the time of clinically indicated lumbar puncture. Results were correlated with clinical ADC stage.

ADC Stage	Number of Samples	p24 Antigen	HIV-1 Isolation
None	24	0	0
1 (mild)	7	4	2
2 (moderate)	10	8	5
3 (severe)	6	10	10

Correlations: ADC Stage vs CSF p 24 antigen (p < 0.001) vs CSF Virus Culture (p < 0.01).

Conclusion: While p24 in both CSF and blood correlate with ADC Stage, its detection in CSF is insensitive to mild-moderate disease and in blood is relatively nonspecific. Likewise, isolation of HIV-1 from both fluids is nonspecific, and thus, neither method is highly useful for clinical diagnosis. The increase in CSF antigen with falling isolation rate remains unexplained. These results suggest that brain dysfunction may not relate to virus replication within the brain in a simple fashion.

M.B.P.98 Unusual Etiology of Leishmaniasis in Chile

Bello, J. M. and A. S. Urquiza, R. G. Velasco, L. V. Barreda, J. P. H. Martínez, J. G. Rodríguez. J. de Internal Medicine and Nephrology, III Hospital Chile in Santiago, Antennas University of Santiago, Santiago, Chile.

Visceral leishmaniasis is an endemic disease in Spain with a distinctive clinical picture. We report the patients with HIV in whom the diagnosis of leishmaniasis was established from unusual pathological materials.

Case report No. 1: 47-year-old male, Spanish, HIV-positive, with history of recurrent adenitis and cerebral lymphomas. In January 1989, he was admitted with severe pancytopenia, *Pneumocystis carinii* pneumonia and disseminated intravascular coagulation. He was treated successfully with an organophosphorus antidote. In October 1989, he was admitted with fever, weight loss and the signs of acute leukemia. Bone marrow examination in the presence of relapsed Kaposi's sarcoma lesions and the absence of acute leukemia, showed infiltration by leishmaniasis. There was improvement of the patient's general condition after treatment with sodium stibogluconate at a daily dose of 400 mg. In spite of this adequate treatment, a relapse of bone marrow infiltrate still showed the presence of leishmaniasis.

Case report No. 2: 39-year-old patient with hepatitis type A, well-controlled, with chronic liver disease and HIV infection, whose illness began in October 1989. In October '90, he was diagnosed of bacterial meningitis and leishmaniasis. The month later he was admitted with cough, expectoration and fever of three week duration and a relapse of bone marrow infiltrate. Bone marrow examination in the next year, *Pneumocystis carinii* infection, the immunohistochemical (immunoperoxidase) and there on clinical improvement after three months of chemotherapy with the drug miltefosine. The CSF leukocytes revealed the presence of abundant neutrophils.

Conclusion: We would like to draw attention to the presence of atypical clinical picture of visceral leishmaniasis as a poor treatment response. It is likely that some of these infections may also manifest some form of their clinical picture as described. In other certain conditions such as drug, liver, immunosuppression or in the HIV infection. So the findings, then for serological, positive in the specific functions of Kaposi's sarcoma, should encourage the search for this organisms, even in the absence of clinical clues to suspect this infection.

M.B.P.100 Tropical diseases of HIV patients in non-endemic countries: A case of visceral leishmaniasis and a case of tropical Pyomyositis

Elting, J., Eickenbrecht, J.F., Borghard, P.*, Ströhmeier, G. Department of Medicine and Pathology, University of Düsseldorf, 4000 Düsseldorf, Koorenstraße 5, FRG.

Tropical diseases such as visceral leishmaniasis are often reported in HIV patients from tropic, subtropic and mediterranean regions. We report 2 cases. Among 220 HIV patients seen at the Department of Medicine, University of Düsseldorf, in 1989, we found 2 patients (1% with a tropical disease. Case 1: A 31 year old male i. v. drug abuser presented with hepatosplenomegaly, pancytopenia, hypergammaglobulinemia and peripheral lymphomas. Bone marrow aspiration and biopsy showed visceral leishmaniasis. He was successfully treated with sodium stibogluconate. Case 2: A 28 year old female HIV patient, infected by heterosexual contact, was admitted to the hospital for persistent fever and abdominal pain. CT-scan showed pyomyositis and abscesses of left psoas muscle. Operative drainage and microbiological evaluation excluded Mycobacterium tuberculosis but revealed hemophilic streptococcus group A as the etiologic agent. Pyomyositis was hemophilic streptococcus group A as the etiologic agent. Pyomyositis was previously thought to be limited to the tropics, but this patient had never left W.-Germany.

Conclusion: Tropical diseases can be found in HIV patients even outside endemic areas.

M.B.P.102 CEREBRAL ABSCESS CAUSED BY TRYPANOSOMA CRUZEI IN A PATIENT WITH AIDS

Martin Rodriguez*, E. Sprine*, A. Cavalcanti*, A. Carneiro*, L. Severina**, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul; **Instituto de Pesquisas Biologicas, Porto Alegre, Brazil.

Objective: To report a cerebral abscess caused by *Trypanosoma cruzi*. **Case Report:** An 18-year-old white woman with acute HIV infection arrived at the hospital with fever, focal neurological signs and a history of convulsions. She came from the southwest region of Rio Grande do Sul state. A cerebral CT showed multiple cerebral abscesses. The upper half lymphomonocytic predominance (D 50) and low glucose level. Bacteriological, fungal and immunological exams were negative. Amphotericin B, anti-tuberculous and anti-neoplastic drugs were empirically started in a sequential form, without improvement. A new lumbar puncture showed *Trypanosoma cruzi* unfortunately, it was the last one, and the patient died before any treatment could be started.

Conclusion: This is the first case we have noticed of a cerebral abscess caused by *Trypanosoma cruzi*. It is important to remember that HIV-associated opportunistic infections depend on pathogen prevalence in a certain region and the knowledge of the place of origin of the patient will aid in the search of a diagnosis (the southwest of RS is an endemic region of Chagas' disease, which is caused by *Trypanosoma cruzi*).



Session d'affichage Poster Session

Aspects cliniques Clinical Aspects of AIDS

M.B.P.103 ROLE OF PULMONARY FUNCTION TESTS(PFT) AND CD4 LYMPHOCYTE COUNT FOR DIAGNOSING LUNG COMPLICATIONS IN AIDS
G.Parré, M.Clotet, M.Sala, J.Morera. Pneumology and Infectious Diseases Unit, Hospital "de Badalona" Germans Trias i Pujol, Spain.
Objective: To assess the value of PFT and CD4 lymphocyte count for an early diagnosis of pulmonary diseases in HIV seropositive homosexual patients.
Methods: 27 patients with HIV-seropositive homosexual patients. All denied drug abuse. 22 out of 33 were included in stage III and 12 in stage IV-C2.
Results: We determined: Forced Expiratory Volume in one second (FEV1), Forced Vital Capacity (FVC) and Carbon Monoxide transfer Factor (TLCO). Simultaneously CD4 lymphocyte count, was also evaluated. Ten out of 33 had previous HIV-TLCO determination. According to the TLCO obtained we divided patients in 3 groups that were submitted to different procedures. Results: Group A (normal PFT): 27 patients, CD4: 1.678 ± nm3; Group B (normal FEV1 and FVC): 17 patients, CD4: 1.618 ± nm3; Group C (normal FEV1 and FVC): 10 patients, CD4: 1.618 ± nm3. All patients had normal chest X-ray and without opportunistic infections nor Kaposi's Sarcoma; Group D (mild restrictive disease, TLCO below 65%): 8 patients, CD4: 1.191 ± nm3, all had Pneumocystis carinii pneumonia (PCP), a table showing all methods and results would be presented. Conclusions: 1- TLCO between 65-80% is seen in HIV-seropositive patients in whom PCP is ruled out, although histopathological findings have demonstrated inespecific interstitial pneumonitis; 2- TLCO below 65% even in asymptomatic patients with normal chest x-ray must encourage to further explorations since PCP is very probable; 3- CD4 cell count below 250 x nm3 argues for a necessary primary PCP prophylaxis in HIV seropositive patients; PCP occurs only in patients with CD4 count below 250 x nm3 and total lymphocyte count below 900 x nm3. (95.5% of cases in our series)

M.B.P.105 Repanator A., Siede W.H., Brode H.D., Nöbmann-Maignan H., Ullrich D.W.E., Seiffert U.B.

Chemotherapeutisches Forschungsinstitut (Georg-Speyer-Haus), Zentrallaboratorium, Klinikum J.M.Goethe-Universität, Frankfurt FRG, Institut für Laboratoriumsmedizin, Universitätsklinikum, Bonn FRG.

"Elevation of lactate dehydrogenase in asymptomatic AIDS patients"
Plasma of 115 anti-HIV positive patients without clinical symptoms was analyzed for lactate dehydrogenase (LD), its isoenzymes (LDI) and beta-glucuronidase. Total LD was elevated in 73% of these patients, the median value was 233 U/l (normal population: median 154 U/l, 97.5 percentile at 200 U/l). The underlying isoenzyme pattern most frequently showed elevation of LDI II (in 78%) and LDI III (in 82%). As pneumocystis-pneumonia could be excluded as cause, this pattern is characteristic for origin of the elevation in the lymphatic system. Patients were further subgrouped according to T4 cell counts. Despite no correlation was found, it might be speculated that LDI II and III levels reflect the destruction rate of lymphocytes. This is supported by our observation, that total LD and LDI II and III are more frequently elevated in patients with positive HIV-antigen test. Roughly 40% of the patients show elevation of LDI V and IV and beta-glucuronidase as consequence of liver affection as verified by elevated transaminases.

In contrast to other reports it can be stated, that elevation of plasma lactate dehydrogenase with prominent isoenzymes II and III is a frequent phenomenon in anti-HIV positive patients without pneumocystis-pneumonia. This might reflect the disease activity in the lymphatic system.

M.B.P.107 ADENOSINE DEAMINASE (ADA) LEVELS IN SERA OF PATIENTS WITH HIV-1 INFECTION

Valls, V., Edo Javiera, Pignaredo, I., Roca, V., and De Salencia, R.E. Department of Medicine, Hospital Clinico San Carlos, Madrid, Spain.

Objective: To assess the value of serum ADA quantification as a predictor of active M.tuberculosis (Tb.) infection and degree of immunosuppression in HIV-1 seropositive patients.

Methods: We quantified serum ADA levels in 38 HIV-1 seropositive (HIV+) patients: 9 with proven Tb. infection (Gr. I), and 29 without Tb. infection (Gr. II). Control groups consisted of 13 HIV-1 seropositive (HIV+) patients with proven Tb. infection (Gr. III) and 40 healthy HIV- volunteers (Gr. IV).

Results: ANOVA analysis showed that serum ADA levels were significantly elevated ($p < 0.01$) in Gr. I (48.39 ± 22.26 U/l), Gr. II (35.74 ± 16.4 U/l), and Gr. III (24.54 ± 11.82 U/l) when compared to Gr. IV (8.6 ± 4.6 U/l). ADA levels were statistically different ($p < 0.01$) in HIV+ (Gr. I + Gr. II) compared to HIV- (Gr. III + Gr. IV) patients. No statistical differences in ADA levels could be demonstrated between Gr. I and Gr. II. In the HIV+ patients we were unable to demonstrate any correlation between ADA levels and CD4+ cell count, active Tb. infection or opportunistic infections of HIV+ patients. Cross belonging to NRS stage showed the significantly higher levels of ADA. Using a backward logistic regression analysis we found that ADA serum levels were correlated ($p < 0.0001$), IgM levels ($p < 0.0001$), peripheral monocytes counts ($p < 0.0001$), IgM levels ($p < 0.0019$) HIV-1 antigenemia ($p = 0.05$) (NP=0.82, NP=0.79, $p < 0.001$).

Conclusion: Quantification of ADA serum levels in HIV+ were useful for the presumptive diagnosis of Tb. infection, however in HIV+, ADA levels were not useful predictors of degree of immunosuppression or of active Tb. infection.

M.B.P.104 THE EFFICACY OF SCREENING TESTS FOR INFECTIOUS DISEASES IN PERSONS WITH SYMPTOMATIC ARC
Gardin, Fred, Hartigan, W., Oster, C., and the VA Cooperative Study Group on the Treatment of ARC.
VA Medical Center, Washington, D.C., U.S.A.

Objective: To evaluate the efficacy of screening tests for secondary infections in patients entered in a multi-center study of zidovudine for ARC.
Method: Entry criteria for this study required patients to have T4 counts between 200-500, and symptoms of ARC such as fever, sweats, weight loss, fatigue, lymphadenopathy, or thrush. Baseline screening to identify active infections included a chest x-ray (CXR), serologies for syphilis, hepatitis B (HB), cryptococcus, a urine culture for cytomegalovirus (CMV), and blood cultures for CMV, fungus, and mycobacteria.

Results: Of 205 patients enrolled, 99% are male, 69% white, and the mean age is 40. HIV risk factors include 61% homosexual, 18% IV drugs, 9% mixed, and 12% other. Mean baseline T4 cell count was 340. Significant lymphadenopathy is present in 36%. ARC has been present over 6 months in 58%; systemic symptoms at screening in 55%. Tests completed to date: CXR abnormal in 19/191 (10%). Reactive serologies for syphilis 29/187 (16%). HB surface antigen 19/169 (11%), and cryptococcus 0/156. CMV urine positive in 3/86. Blood cultures complete to date for CMV (86), fungus (92), and mycobacteria (87) have all been negative.

Conclusion: In a population of symptomatic ARC patients with depressed T4 cells, routine screening for infectious agents may be of limited value. CXR, and syphilis and HB serologies appear warranted, however more expensive tests should await specific indications.

M.B.P.106 67 GALIUM SCINTIGRAPHY OF CHEST IN AIDS PATIENTS. ANALYSIS OF 150 CASES.
Narciso P.; De F.M.; Pignatelli F.; Rossi M.A.; Sirtes F.; Vico Giuseppe U.S.L. N/10 "L. Spallanzani" Hosp. Dept. Infectious Diseases/A.C. Forlani Hosp. Dept. Nuclear Medicine, Rom, Italy.

Objective: To evaluate the importance of chest 67 Ga scintigraphy in diagnosis of pulmonary disease in AIDS patients, with negative or dubious X findings.
Methods: In the last two years 152 AIDS patients showing symptoms of lung diseases were studied with Ga scan; in 95 subjects diagnosis was performed after sputum culture, BAL, bacteriological and histological examination. An imaging of transvenous scan obtained with plasma source of 57 Co (10 ml, 370 MBq) was used. Scan was classified as negative if low/background ratio was 1.5; as positive if 1.5 2; ++ if 2.5; +++ if 2.5 3; ++++ if 3.

RESULTS:

GROUP N.	SCAN	GROUP	0	+	++	+++	++++
PCP	34	2	7	2	16	7	2
C.M.V.	11	-	5	3	2	1	-
C.M.V. and other...	6	-	3	1	2	-	-
FUNG.	5	-	3	3	-	-	-
MILIARY TB...	6	-	1	1	3	1	-
OTHER	7	-	4	3	-	-	-

CONCLUSION: 1) High diffuse pulmonary concentrations of 67 Ga in AIDS patients seem to be related to an increased production of PCP also in chest X negative or dubious cases; 2) low or negative Ga uptake in localized or extended pulmonary diseases indicates an increased probability of HIV-1b pulmonary TB 67 Ga scintigraphy allows a more accurate diagnosis of illness extent and activity.

M.B.P.108 CLINICAL MANIFESTATIONS OF AIDS IN WOMEN FROM SAO PAULO, BRAZIL

Ferreira, A.C., Grandi, J.L., Fernandes, M.E.¹
1, Paulista School of Medicine, Infectious Diseases Unit;
2, Reference Center for Aids, Sao Paulo, Brazil.

Objective: To detect the most common clinical presentation, mortality rate and "cause mortis" of women with Aids.

Methods: We studied a sample of 55 women that had clinical manifestations of Aids and were treated in those two institution above, during the period of January 85 to January 89.

Results: Those 55 women with Aids correspond 22% of the Aids case in women from Sao Paulo State. The mortality rate was 22%.

Table 1. Most common Clinical Presentation

number	Occurr	25	19	5	3	6
Pneumon(infect.)	44	33	8	5	10	6

Conclusion: The clinical presentation of Aids in women will be discussed in this study.

Session d'affichage Poster Session



Aspects Cliniques Clinical Aspects of AIDS

M.B.P.127 DIAGNOSIS AND GRADING OF CMV COLITIS: COMPARISON OF H&E STAINING, DNA IN SITU HYBRIDIZATION, AND IMMUNOPEROXIDASE STAINS FOR EARLY AND LATE AFFECTIONS.

Richard Bariletti, MD, Yi-Tin Shiu, MD, D. Dieterich, MD NYU Medical Center, New York, NY.

The diagnosis (dx) of CMV colitis and grading of its severity have become important issues since specific treatment has become available. We compared the results of H&E stains, in situ hybridization (ISH), and immunoperoxidase stains for early and late CMV infections (IFP) in order to determine the most accurate method for dx and grading. We examined 38 colon biopsies (dx) of 30 AIDS patients suspected of having CMV colitis. In 10 the dx CMV inclusion bodies (IB) were seen on H&E stains and both ISH and IFP were negative. In 18 the CMV IB were seen on H&E stains and all were positive either by both ISH and IFP (2), only ISH (2), or only IFP (4). The numbers of infected cells to a single biopsy were 1 to 221, IFP yielding the highest counts and H&E the lowest. The severity of infection was graded by relating the total number of infected cells to the number of biopsies. Grade I was defined as 1-4, grade II as 5-5, and grade III as 10 or more infected cells per biopsy. Grades were graded the same by all techniques in 11 and varied in 17. Overall findings on H&E stains and those based on ISH or IFP in 6. Lowering of grades based on IFP or ISH occurred in 11 cases, and was accompanied by a marked increase in tissue IFT for these special reports. We conclude that (1) dx of CMV colitis based on the identification of CMV IB on H&E stained sections is accurate, (2) although IFP identifies the greatest number of infected cells, this gate is sensitivity is outbalanced in endoscopy by the loss of tissue after cutting of levels, and therefore (3) grading is best performed on H&E stains.

M.B.P.129 THERAPY OF CYTOMEGALOVIRUS (CMV) INFECTIONS WITH GANCICLOVIR

Robert S. Rodriguez, F. Cervantes, J. Nelson, G. Brown, A. Eise, G. P. Body, and P. Mansell. University of Texas M. D. Anderson Cancer Center, Houston, Texas, U.S.A.

Objective - To evaluate the efficacy and safety of ganciclovir for the therapy of CMV infection in AIDS patients.
Methods - HIV infected patients with various CMV infections received ganciclovir (10 mg/kg/d for 14d). Response and toxicity were monitored.
Results - Forty-eight patients, 46 men, 2 women (median age 38) were treated. Sites of infection were retinitis - 30; colitis - 14; pneumocystitis - 2 (multiple sites in 2 pts.). Response rates were:

Response	Retinitis	Colitis	Pneumocystitis
Improved	3 (50%)	13 (50%)	2 (100%)
Stabilized	7 (50%)	1 (7%)	0
No change/worse	5 (25%)	0	0

 Patients with retinitis who failed to respond (including 2 with retinal detachment) generally had a greater than 10 day delay in initiation of therapy. The patients with colitis improved despite developing colonic perforation. One patient developed disseminated disease including adrenitis. More than 50% of patients who responded received maintenance therapy with ganciclovir. Therapy was generally well tolerated, however 23% of patients developed neutropenia (WBC <1000/mm³). Nausea and confusion were seen infrequently.
Conclusion - Ganciclovir is safe and effective in initial and maintenance therapy of CMV retinitis and gastroenteritis.

M.B.P.131 IN VITRO SECRETION OF CMV SPECIFIC ANTIBODIES BY PERIPHERAL BLOOD CELLS FROM HIV INFECTED SUBJECTS.

Vendrell, Jean-Jacques; Begonyi, M.; Ducros, J.;...; Reyes, L.;...; Hupert, M.P.;...; Carrozzini, R.;...;...

INTRODUCTION: Antispecific capacity for in vitro secretion of HIV antibodies by the circulating B cells of HIV infected subjects has been evidenced. Since CMV infection is very often associated with AIDS disease an assessment of CMV specific B cells could also be evidenced in the blood stream of HIV seropositive subjects.

METHOD: Supernatants of overnight cultures of the PBMC from 57 HIV seropositive and 4 HIV seronegative subjects were incubated in wells from Behring Diagnostics CMV ELISA kit. In vitro antibody secretion was detected using a low sensitive amplifying enzymatic complex.
RESULTS: at 50 positive, 5 negative and 1 intermediate CMV in vitro antibody production tests (IVAP) were observed with HIV positive PBMC and positive, 20 negative and 1 intermediate with the 24 HIV negative controls. In while all HIV seropositive were also HIV-IVAP positive, all CMV seropositive subjects were not IVPo (CMV-IVAP positive). Co-treatment of PBMC with CMV infected cells specifically inhibits CMV and not HIV-IVAP. CMV-IVAP positivity was shown to be a transient phenomenon in HIV negative and a persistent phenomenon in HIV positive subjects.
CONCLUSION: The detection of CMV antibody secreting cells in the blood stream could provide a marker of active CMV infection and thus constitute a tool for the diagnosis and the early treatment of CMV opportunistic infection in AIDS disease and in other cases of immune deficiency.

M.B.P.128 A RANDOMIZED CONTROLLED CLINICAL TRIAL OF FOXCARNIT FOR THE TREATMENT OF CYTOMEGALOVIRUS RETINITIS IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME.

Dewey, R.P.; Lane, H.P.; Marmorstein, J.;...; Hennessey, J.P.;...; et al. National Institutes of Health, **Food and Drug Administration, Bethesda, MD, USA.

Objective: To evaluate foxcarnit (trifluoromethyl phosphoramide) for the treatment of cytomegalovirus (CMV) retinitis in persons with AIDS.
Methods: Foxcarnit has been shown anecdotally to be effective for the treatment of CMV retinitis, a sight-threatening infection for which there is no approved therapy in the US. To evaluate its efficacy, a randomized controlled clinical trial was designed to compare foxcarnit, with and without AZT, to AZT alone in the treatment of non-sight threatening CMV retinitis. Patients on the AZT arm are eligible for open label foxcarnit once progression is documented. Foxcarnit is given as a course of 60 mg/kg intravenous qd for a 3 week treatment period followed by 90 mg/kg daily maintenance, both adjusted for renal function, until progression of retinitis is noted. Evaluation of retinitis and progression is performed by a masked reading center using serial photographs. A total of 100 and 48 subjects in placebo and foxcarnit arms respectively were randomized to each of the 3 arms. Initial leukocyte counts ranged from 1.6K to 3.0K/mm³ (median 1.9K), total granulocytes ranged from 0.8 to 2.5K/mm³ (median 1.6K), and T4-coum counts ranged from 6 to 31/mm³ (median 10). Five subjects had PCP and 1 had CMV retinitis as their first AIDS-defining infections.
Conclusions: Many persons screened for this study have been ineligible due to inadequate ophthalmologic and medical evaluation prior to presentation. Baseline and interim data and retinal photos showing progression of retinitis and response to foxcarnit will be presented.

M.B.P.130 TREATMENT WITH GANCICLOVIR (D.R.P.G.) IN H.I.V. CARRIERS WITH CMV IN THE BRONCHIOALVEOLAR LAVAGE

Michael Finaud*, C. Tamalet** and P. Casanova*. Hôpital Cochin, *Infectious Diseases Unit **Virology Unit, Marseille, France.

Objective: Describe the efficacy and long term follow up of treatment with Ganciclovir (GNCV) in HIV carriers when CMV is isolated from bronchoalveolar lavage (BAL).
Methods: In a series of 21 patients with mild symptoms of pneumonitis (cough, fever, dyspnea, interstitial abnormalities) without pulmonary symptoms but fever. We had treated with Ganciclovir 5 mg/kg twice daily for 14 days. CMV was systematically cultured from the bronchoalveolar lavage; this special concern all HIV carriers group I, III and IV of CDC's all positive for CMV but without any other opportunistic infection.
Results: 16 patients received Ganciclovir; 5 received no treatment. 2 patients had a disease free survival period characterized by no relapse and no opportunistic infections for 36 months; 1 for 24 months; 7 for 18 months; 4 for 12 months and 2 for 6 months. Of the five who did not receive treatment; one died at 3 months of HIV pneumonia; 3 developed other opportunistic infections after 8 months and 1 after 12 months. No serious side effects were observed.
Conclusion: Ganciclovir when CMV is isolated from bronchoalveolar lavage is safe and could protect the immune system of cytotoxic effects of CMV in HIV carriers and could delay the apparition of opportunistic infections.

M.B.P.132 EFFICACY AND TOXICITY OF GANCICLOVIR TREATMENT IN AIDS-RELATED CMV RETINITIS.

Huberman Hillel, Choukroun S.;...; Saxon L.;...; Vangeli M.;...; De Seldi R.;...; Thonnes...

INTRODUCTION: Hillel, Huberman Hillel, Choukroun S.;...; Saxon L.;...; Vangeli M.;...; De Seldi R.;...; Thonnes...
Objective: To evaluate the efficacy and toxicity of Ganciclovir (G) maintenance treatment in HIV-infected patients, at the onset of CMV retinitis.
Methods: Patients with CMV-retinitis were randomized in two groups: I) with maintenance treatment 5 mg/kg/d 5 days/week; II) without maintenance treatment; and were followed-up for 9 months. In both groups the CMV-retinitis was first treated with 10 mg/kg 20 days with 100 mg/kg q.d. Therapy was stopped when CMV-retinitis was completely resolved, and toxicologic toxicity was evaluated.
Results: 20 patients were enrolled in the study. Results concern 14 patients (5 M., 1 F.) mean age 40 years (r: 28-63), mean Karnofsky index: 75% (r: 50-100%), randomized in two groups: I: 10 pts. (100%), comparable for clinical status, toxicologic toxicity, as well as initial treatment (mean duration: 20.7 days, r: 10-28). Patients in group I relapsed after a mean 4.6 weeks (1:20 times whereas those in group II relapsed after 3.1 mean 1.6 weeks, 1:5 times (Figure 1). 3 patients died in group I. There was no difference in parameters studied for toxicity (table 1).

Parameter	Group I		Group II	
	n	%	n	%
Survival	10	100	10	100
Relapse	10	100	10	100
Death	3	30	0	0
Toxicity	10	100	10	100
Mean duration of treatment (days)	20.7		20.7	
Mean duration of relapse (weeks)	4.6		1.6	

Conclusion: In this study, patients in maintenance relapsed less frequently and later than the group II patients. These results have practical implications as far as drug association and patients' cost are concerned.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.139 HIV SCREENING OF COMMERCIALY AVAILABLE BLOOD PRODUCTS IN INDIA.

Tripathy, S., Chaudhuri, R., Singh V.B., Seth, P., Varghese P. and Mishra, P. S.
 * Clinical Immunology Services, Department of Medicine, AIIMS;
 * Department of Microbiology, AIIMS, New Delhi, INDIA.

Objective: To describe the result of HIV screening of commercially available blood products in India.

Methods: 105 samples of blood products (via-immunoglobulin preparations, Factor VIII cryoprecipitate and a variety of blood products) of 1 American and 5 Indian companies were tested for the presence of HIV antibodies using the Moleczymus competitive ELISA kit. Presence of HIV antibodies was confirmed by Western Blot (Dupont).

Result: Of these 105 samples, 31 were found to contain HIV antibodies by the ELISA method. They were subsequently confirmed by the Western Blot test. Their results and their medical, social and legal implications have generated a lot of controversy in the country.

M.B.P.141

RISK FACTORS FOR HIV AMONG NEW YORK BLOOD DONORS IN 1980.
SEIDOR, BLUMBERG, Kessler, D., Berge, P., Andrews, S., DeVelle, C., New York Blood Center, New York, NY, USA.

Objective: To evaluate current trends in risk factors for HIV Ab+ blood donors in order to reduce their risk of blood supply.

Methods: We compared blood donor risk factor patterns identified from 1974-76, 1980 with April 1980-1986 data as reported by Keelin, et al.

Results:

Units Collected	Jan-Dec 1980	April 1980-May 1986
Anti-HIV positive	415,000 (240-260)	470,000
Donors interviewed	176(443)	470(1143)

Risk Factor	1980	1986
Male-Bisexual	31%	60%
IVDU	1%	4%
Blood Recipient	1.7%	1.8%
Met. High Risk Partner	26%	15%
Met. Multiple Partner	6%	7%
Heterosexual U.K. Risk	17%	7%
Other Risk	16%	3%

Donor interviews indicate that, heterosexuals with high risk partners, 68% have a greater perception of risk and ability to transmit HIV by transfusion than do heterosexuals with 1 or more partners of unknown risk (58%).
Conclusion: There has been a clear shift in risk factors among blood donors from homosexual/bisexual activities toward the IVDU and heterosexual donor population. An education has been effective in decreasing the donating homosexual population, renewed educational efforts should target sexually active heterosexuals.

M.B.P.143 CHANGING PROFILE OF HIV-SEROPOSITIVE BLOOD DONORS.

Wallis, Penny; Burkard, W.; Elliot, M.; Lee, S.; Sinclair, M.
 Canadian Red Cross Blood Transfusion Service, Vancouver, B.C.

Testing for the HIV virus was instituted in October 1981 to B.C. In the 3 years since, 453,000 units have been tested and 23 donors identified as HIV positive (0.05). 8 donors were also identified in the investigation of 14 cases of transfusion associated AIDS (TAA). 25 of the 33 seropositive donors were in self-identified high risk groups: 31 homosexual or bisexual males and 1 former partner of a bisexual male. All 8 donors implicated in TAA had self deferred an average of 26 mo. (range 6-34 mo.) prior to commencement of screening for anti-HIV in B.C. All 8 had been regular blood donors donating q-6 mo up to the time of their self deferral. In contrast, of 25 donors identified during the first 3 years of screening: 3 (bisexual males) were regular donors (63 mo.) and were picked up in the first few months of testing; none fell at risk for HIV infection. 5 were q-6 mo. donors up to an average of 22 mo. prior to screening (range 16-40 mo.) and then self deferred. However, 4 returned as donors within 5 mo. and 1 at 36 mo. post testing. Another 4 donors are sero-converters; of these, 1 had never donated blood prior to testing, 1 donated on 1 prior occasion. Of the remaining 13 donors, 3 had donated once prior to testing (2 within 1 mo. of testing); 10 were new donors. Although donors implicated in TAA had voluntarily self deferred well before testing for HIV and did not return, there remain self-identified high risk people who have enrolled as new donors since the advent of screening, presumably to be tested. Furthermore, some previously self-deferred donors in high risk groups are now returning to donate. This underlines the need for continuing efforts to discourage such behavior and for creative screening methods which will identify such donors on the clinic.

M.B.P.140 DETECTION OF HIV MARKERS PRIOR TO IgG ANTIBODY SEROPOSITIVITY IN PLASMA DONORS.

Suzuki, S.; Kikuchi, M.; Miller, J.S.; Coombs, R.W.; Perry, R.V.;; No, D.D.;**; Stewart, J.L.;**; Saito, S.;**;**;**
 *Abbott Labs. N. Chicago; ** Univ of Washington, Seattle WA; ***Centraal Pathologisch Laboratorium, London; **** UCLA School of Medicine, Los Angeles CA, USA.**

Objective: Determine the sequence of occurrence of HIV markers pre-seroconversion. Assess the utility of HIV antigen (HIV Ag) detection in plasma donors.

Methods: Pre-seroconversion serial samples at 3 to 7 day interval were obtained from 7 healthy plasma donors who seroconverted (U) licensed HIV antibody screen positive; licensed western blot positive; HIV plasma culture, HIV antigen, IgM anti-HIV, anti p24 antibody, and radio immunoprecipitation were performed on 36 samples available.

Results: In 5 donors, HIV antigen was detected prior to or simultaneously with IgG anti HIV. All HIV Ag positive samples were infectious for cultured normal peripheral blood mononuclear cells; most were also IgM anti HIV positive. The disappearance of HIV Ag and, to a lesser extent, of plasma infectivity was concurrent with the development of the IgG immune response. Although the improved sensitivity of recombinant antigen derived screening or anti p24 assays shortened the window period preceding seroconversion, HIV antigenemia and plasma viremia were the only markers of HIV infection for several days in 2 cases.

Conclusion: HIV infectious units from plasma donors can be eliminated from the plasma supply by HIV Ag screening.

M.B.P.142

SELF-EXCLUSION BY HIV ANTIBODY POSITIVE BLOOD DONORS
SEIDOR, BLUMBERG, Kessler, D., Andrews, S., DeVelle, C., New York Blood Center, New York, NY, USA.

Objective: To assess the self-exclusion (SE) behavior of HIV antibody seropositive blood donors resulting in reduced risk of blood supply.

Methods: 133 HIV Ab+ blood donors were interviewed and counseled in 1980. RETURNING and RISK FOR HIV INFECTION notes during the counseling sessions were retrospectively quantified.

Results: Eighteen (13.5%) self-excluded, while, overall only 1% of blood donors were self-excluded. Criteria for donor self-exclusion: 1) were male 50%; 2) were bisexual 40%; 3) were intravenous drug users 10%; 4) were multiple partners 10%; 5) were heterosexual U.K. risk 10%; 6) were other risk 10%; 7) were blood recipients 10%; 8) were HIV recipients 10%; 9) were HIV recipients 10%; 10) were HIV recipients 10%; 11) were HIV recipients 10%; 12) were HIV recipients 10%; 13) were HIV recipients 10%; 14) were HIV recipients 10%; 15) were HIV recipients 10%; 16) were HIV recipients 10%; 17) were HIV recipients 10%; 18) were HIV recipients 10%; 19) were HIV recipients 10%; 20) were HIV recipients 10%; 21) were HIV recipients 10%; 22) were HIV recipients 10%; 23) were HIV recipients 10%; 24) were HIV recipients 10%; 25) were HIV recipients 10%; 26) were HIV recipients 10%; 27) were HIV recipients 10%; 28) were HIV recipients 10%; 29) were HIV recipients 10%; 30) were HIV recipients 10%; 31) were HIV recipients 10%; 32) were HIV recipients 10%; 33) were HIV recipients 10%; 34) were HIV recipients 10%; 35) were HIV recipients 10%; 36) were HIV recipients 10%; 37) were HIV recipients 10%; 38) were HIV recipients 10%; 39) were HIV recipients 10%; 40) were HIV recipients 10%; 41) were HIV recipients 10%; 42) were HIV recipients 10%; 43) were HIV recipients 10%; 44) were HIV recipients 10%; 45) were HIV recipients 10%; 46) were HIV recipients 10%; 47) were HIV recipients 10%; 48) were HIV recipients 10%; 49) were HIV recipients 10%; 50) were HIV recipients 10%; 51) were HIV recipients 10%; 52) were HIV recipients 10%; 53) were HIV recipients 10%; 54) were HIV recipients 10%; 55) were HIV recipients 10%; 56) were HIV recipients 10%; 57) were HIV recipients 10%; 58) were HIV recipients 10%; 59) were HIV recipients 10%; 60) were HIV recipients 10%; 61) were HIV recipients 10%; 62) were HIV recipients 10%; 63) were HIV recipients 10%; 64) were HIV recipients 10%; 65) were HIV recipients 10%; 66) were HIV recipients 10%; 67) were HIV recipients 10%; 68) were HIV recipients 10%; 69) were HIV recipients 10%; 70) were HIV recipients 10%; 71) were HIV recipients 10%; 72) were HIV recipients 10%; 73) were HIV recipients 10%; 74) were HIV recipients 10%; 75) were HIV recipients 10%; 76) were HIV recipients 10%; 77) were HIV recipients 10%; 78) were HIV recipients 10%; 79) were HIV recipients 10%; 80) were HIV recipients 10%; 81) were HIV recipients 10%; 82) were HIV recipients 10%; 83) were HIV recipients 10%; 84) were HIV recipients 10%; 85) were HIV recipients 10%; 86) were HIV recipients 10%; 87) were HIV recipients 10%; 88) were HIV recipients 10%; 89) were HIV recipients 10%; 90) were HIV recipients 10%; 91) were HIV recipients 10%; 92) were HIV recipients 10%; 93) were HIV recipients 10%; 94) were HIV recipients 10%; 95) were HIV recipients 10%; 96) were HIV recipients 10%; 97) were HIV recipients 10%; 98) were HIV recipients 10%; 99) were HIV recipients 10%; 100) were HIV recipients 10%; 101) were HIV recipients 10%; 102) were HIV recipients 10%; 103) were HIV recipients 10%; 104) were HIV recipients 10%; 105) were HIV recipients 10%; 106) were HIV recipients 10%; 107) were HIV recipients 10%; 108) were HIV recipients 10%; 109) were HIV recipients 10%; 110) were HIV recipients 10%; 111) were HIV recipients 10%; 112) were HIV recipients 10%; 113) were HIV recipients 10%; 114) were HIV recipients 10%; 115) were HIV recipients 10%; 116) were HIV recipients 10%; 117) were HIV recipients 10%; 118) were HIV recipients 10%; 119) were HIV recipients 10%; 120) were HIV recipients 10%; 121) were HIV recipients 10%; 122) were HIV recipients 10%; 123) were HIV recipients 10%; 124) were HIV recipients 10%; 125) were HIV recipients 10%; 126) were HIV recipients 10%; 127) were HIV recipients 10%; 128) were HIV recipients 10%; 129) were HIV recipients 10%; 130) were HIV recipients 10%; 131) were HIV recipients 10%; 132) were HIV recipients 10%; 133) were HIV recipients 10%; 134) were HIV recipients 10%; 135) were HIV recipients 10%; 136) were HIV recipients 10%; 137) were HIV recipients 10%; 138) were HIV recipients 10%; 139) were HIV recipients 10%; 140) were HIV recipients 10%; 141) were HIV recipients 10%; 142) were HIV recipients 10%; 143) were HIV recipients 10%; 144) were HIV recipients 10%; 145) were HIV recipients 10%; 146) were HIV recipients 10%; 147) were HIV recipients 10%; 148) were HIV recipients 10%; 149) were HIV recipients 10%; 150) were HIV recipients 10%; 151) were HIV recipients 10%; 152) were HIV recipients 10%; 153) were HIV recipients 10%; 154) were HIV recipients 10%; 155) were HIV recipients 10%; 156) were HIV recipients 10%; 157) were HIV recipients 10%; 158) were HIV recipients 10%; 159) were HIV recipients 10%; 160) were HIV recipients 10%; 161) were HIV recipients 10%; 162) were HIV recipients 10%; 163) were HIV recipients 10%; 164) were HIV recipients 10%; 165) were HIV recipients 10%; 166) were HIV recipients 10%; 167) were HIV recipients 10%; 168) were HIV recipients 10%; 169) were HIV recipients 10%; 170) were HIV recipients 10%; 171) were HIV recipients 10%; 172) were HIV recipients 10%; 173) were HIV recipients 10%; 174) were HIV recipients 10%; 175) were HIV recipients 10%; 176) were HIV recipients 10%; 177) were HIV recipients 10%; 178) were HIV recipients 10%; 179) were HIV recipients 10%; 180) were HIV recipients 10%; 181) were HIV recipients 10%; 182) were HIV recipients 10%; 183) were HIV recipients 10%; 184) were HIV recipients 10%; 185) were HIV recipients 10%; 186) were HIV recipients 10%; 187) were HIV recipients 10%; 188) were HIV recipients 10%; 189) were HIV recipients 10%; 190) were HIV recipients 10%; 191) were HIV recipients 10%; 192) were HIV recipients 10%; 193) were HIV recipients 10%; 194) were HIV recipients 10%; 195) were HIV recipients 10%; 196) were HIV recipients 10%; 197) were HIV recipients 10%; 198) were HIV recipients 10%; 199) were HIV recipients 10%; 200) were HIV recipients 10%; 201) were HIV recipients 10%; 202) were HIV recipients 10%; 203) were HIV recipients 10%; 204) were HIV recipients 10%; 205) were HIV recipients 10%; 206) were HIV recipients 10%; 207) were HIV recipients 10%; 208) were HIV recipients 10%; 209) were HIV recipients 10%; 210) were HIV recipients 10%; 211) were HIV recipients 10%; 212) were HIV recipients 10%; 213) were HIV recipients 10%; 214) were HIV recipients 10%; 215) were HIV recipients 10%; 216) were HIV recipients 10%; 217) were HIV recipients 10%; 218) were HIV recipients 10%; 219) were HIV recipients 10%; 220) were HIV recipients 10%; 221) were HIV recipients 10%; 222) were HIV recipients 10%; 223) were HIV recipients 10%; 224) were HIV recipients 10%; 225) were HIV recipients 10%; 226) were HIV recipients 10%; 227) were HIV recipients 10%; 228) were HIV recipients 10%; 229) were HIV recipients 10%; 230) were HIV recipients 10%; 231) were HIV recipients 10%; 232) were HIV recipients 10%; 233) were HIV recipients 10%; 234) were HIV recipients 10%; 235) were HIV recipients 10%; 236) were HIV recipients 10%; 237) were HIV recipients 10%; 238) were HIV recipients 10%; 239) were HIV recipients 10%; 240) were HIV recipients 10%; 241) were HIV recipients 10%; 242) were HIV recipients 10%; 243) were HIV recipients 10%; 244) were HIV recipients 10%; 245) were HIV recipients 10%; 246) were HIV recipients 10%; 247) were HIV recipients 10%; 248) were HIV recipients 10%; 249) were HIV recipients 10%; 250) were HIV recipients 10%; 251) were HIV recipients 10%; 252) were HIV recipients 10%; 253) were HIV recipients 10%; 254) were HIV recipients 10%; 255) were HIV recipients 10%; 256) were HIV recipients 10%; 257) were HIV recipients 10%; 258) were HIV recipients 10%; 259) were HIV recipients 10%; 260) were HIV recipients 10%; 261) were HIV recipients 10%; 262) were HIV recipients 10%; 263) were HIV recipients 10%; 264) were HIV recipients 10%; 265) were HIV recipients 10%; 266) were HIV recipients 10%; 267) were HIV recipients 10%; 268) were HIV recipients 10%; 269) were HIV recipients 10%; 270) were HIV recipients 10%; 271) were HIV recipients 10%; 272) were HIV recipients 10%; 273) were HIV recipients 10%; 274) were HIV recipients 10%; 275) were HIV recipients 10%; 276) were HIV recipients 10%; 277) were HIV recipients 10%; 278) were HIV recipients 10%; 279) were HIV recipients 10%; 280) were HIV recipients 10%; 281) were HIV recipients 10%; 282) were HIV recipients 10%; 283) were HIV recipients 10%; 284) were HIV recipients 10%; 285) were HIV recipients 10%; 286) were HIV recipients 10%; 287) were HIV recipients 10%; 288) were HIV recipients 10%; 289) were HIV recipients 10%; 290) were HIV recipients 10%; 291) were HIV recipients 10%; 292) were HIV recipients 10%; 293) were HIV recipients 10%; 294) were HIV recipients 10%; 295) were HIV recipients 10%; 296) were HIV recipients 10%; 297) were HIV recipients 10%; 298) were HIV recipients 10%; 299) were HIV recipients 10%; 300) were HIV recipients 10%; 301) were HIV recipients 10%; 302) were HIV recipients 10%; 303) were HIV recipients 10%; 304) were HIV recipients 10%; 305) were HIV recipients 10%; 306) were HIV recipients 10%; 307) were HIV recipients 10%; 308) were HIV recipients 10%; 309) were HIV recipients 10%; 310) were HIV recipients 10%; 311) were HIV recipients 10%; 312) were HIV recipients 10%; 313) were HIV recipients 10%; 314) were HIV recipients 10%; 315) were HIV recipients 10%; 316) were HIV recipients 10%; 317) were HIV recipients 10%; 318) were HIV recipients 10%; 319) were HIV recipients 10%; 320) were HIV recipients 10%; 321) were HIV recipients 10%; 322) were HIV recipients 10%; 323) were HIV recipients 10%; 324) were HIV recipients 10%; 325) were HIV recipients 10%; 326) were HIV recipients 10%; 327) were HIV recipients 10%; 328) were HIV recipients 10%; 329) were HIV recipients 10%; 330) were HIV recipients 10%; 331) were HIV recipients 10%; 332) were HIV recipients 10%; 333) were HIV recipients 10%; 334) were HIV recipients 10%; 335) were HIV recipients 10%; 336) were HIV recipients 10%; 337) were HIV recipients 10%; 338) were HIV recipients 10%; 339) were HIV recipients 10%; 340) were HIV recipients 10%; 341) were HIV recipients 10%; 342) were HIV recipients 10%; 343) were HIV recipients 10%; 344) were HIV recipients 10%; 345) were HIV recipients 10%; 346) were HIV recipients 10%; 347) were HIV recipients 10%; 348) were HIV recipients 10%; 349) were HIV recipients 10%; 350) were HIV recipients 10%; 351) were HIV recipients 10%; 352) were HIV recipients 10%; 353) were HIV recipients 10%; 354) were HIV recipients 10%; 355) were HIV recipients 10%; 356) were HIV recipients 10%; 357) were HIV recipients 10%; 358) were HIV recipients 10%; 359) were HIV recipients 10%; 360) were HIV recipients 10%; 361) were HIV recipients 10%; 362) were HIV recipients 10%; 363) were HIV recipients 10%; 364) were HIV recipients 10%; 365) were HIV recipients 10%; 366) were HIV recipients 10%; 367) were HIV recipients 10%; 368) were HIV recipients 10%; 369) were HIV recipients 10%; 370) were HIV recipients 10%; 371) were HIV recipients 10%; 372) were HIV recipients 10%; 373) were HIV recipients 10%; 374) were HIV recipients 10%; 375) were HIV recipients 10%; 376) were HIV recipients 10%; 377) were HIV recipients 10%; 378) were HIV recipients 10%; 379) were HIV recipients 10%; 380) were HIV recipients 10%; 381) were HIV recipients 10%; 382) were HIV recipients 10%; 383) were HIV recipients 10%; 384) were HIV recipients 10%; 385) were HIV recipients 10%; 386) were HIV recipients 10%; 387) were HIV recipients 10%; 388) were HIV recipients 10%; 389) were HIV recipients 10%; 390) were HIV recipients 10%; 391) were HIV recipients 10%; 392) were HIV recipients 10%; 393) were HIV recipients 10%; 394) were HIV recipients 10%; 395) were HIV recipients 10%; 396) were HIV recipients 10%; 397) were HIV recipients 10%; 398) were HIV recipients 10%; 399) were HIV recipients 10%; 400) were HIV recipients 10%; 401) were HIV recipients 10%; 402) were HIV recipients 10%; 403) were HIV recipients 10%; 404) were HIV recipients 10%; 405) were HIV recipients 10%; 406) were HIV recipients 10%; 407) were HIV recipients 10%; 408) were HIV recipients 10%; 409) were HIV recipients 10%; 410) were HIV recipients 10%; 411) were HIV recipients 10%; 412) were HIV recipients 10%; 413) were HIV recipients 10%; 414) were HIV recipients 10%; 415) were HIV recipients 10%; 416) were HIV recipients 10%; 417) were HIV recipients 10%; 418) were HIV recipients 10%; 419) were HIV recipients 10%; 420) were HIV recipients 10%; 421) were HIV recipients 10%; 422) were HIV recipients 10%; 423) were HIV recipients 10%; 424) were HIV recipients 10%; 425) were HIV recipients 10%; 426) were HIV recipients 10%; 427) were HIV recipients 10%; 428) were HIV recipients 10%; 429) were HIV recipients 10%; 430) were HIV recipients 10%; 431) were HIV recipients 10%; 432) were HIV recipients 10%; 433) were HIV recipients 10%; 434) were HIV recipients 10%; 435) were HIV recipients 10%; 436) were HIV recipients 10%; 437) were HIV recipients 10%; 438) were HIV recipients 10%; 439) were HIV recipients 10%; 440) were HIV recipients 10%; 441) were HIV recipients 10%; 442) were HIV recipients 10%; 443) were HIV recipients 10%; 444) were HIV recipients 10%; 445) were HIV recipients 10%; 446) were HIV recipients 10%; 447) were HIV recipients 10%; 448) were HIV recipients 10%; 449) were HIV recipients 10%; 450) were HIV recipients 10%; 451) were HIV recipients 10%; 452) were HIV recipients 10%; 453) were HIV recipients 10%; 454) were HIV recipients 10%; 455) were HIV recipients 10%; 456) were HIV recipients 10%; 457) were HIV recipients 10%; 458) were HIV recipients 10%; 459) were HIV recipients 10%; 460) were HIV recipients 10%; 461) were HIV recipients 10%; 462) were HIV recipients 10%; 463) were HIV recipients 10%; 464) were HIV recipients 10%; 465) were HIV recipients 10%; 466) were HIV recipients 10%; 467) were HIV recipients 10%; 468) were HIV recipients 10%; 469) were HIV recipients 10%; 470) were HIV recipients 10%; 471) were HIV recipients 10%; 472) were HIV recipients 10%; 473) were HIV recipients 10%; 474) were HIV recipients 10%; 475) were HIV recipients 10%; 476) were HIV recipients 10%; 477) were HIV recipients 10%; 478) were HIV recipients 10%; 479) were HIV recipients 10%; 480) were HIV recipients 10%; 481) were HIV recipients 10%; 482) were HIV recipients 10%; 483) were HIV recipients 10%; 484) were HIV recipients 10%; 485) were HIV recipients 10%; 486) were HIV recipients 10%; 487) were HIV recipients 10%; 488) were HIV recipients 10%; 489) were HIV recipients 10%; 490) were HIV recipients 10%; 491) were HIV recipients 10%; 492) were HIV recipients 10%; 493) were HIV recipients 10%; 494) were HIV recipients 10%; 495) were HIV recipients 10%; 496) were HIV recipients 10%; 497) were HIV recipients 10%; 498) were HIV recipients 10%; 499) were HIV recipients 10%; 500) were HIV recipients 10%; 501) were HIV recipients 10%; 502) were HIV recipients 10%; 503) were HIV recipients 10%; 504) were HIV recipients 10%; 505) were HIV recipients 10%; 506) were HIV recipients 10%; 507) were HIV recipients 10%; 508) were HIV recipients 10%; 509) were HIV recipients 10%; 510) were HIV recipients 10%; 511) were HIV recipients 10%; 512) were HIV recipients 10%; 513) were HIV recipients 10%; 514) were HIV recipients 10%; 515) were HIV recipients 10%; 516) were HIV recipients 10%; 517) were HIV recipients 10%; 518) were HIV recipients 10%; 519) were HIV recipients 10%; 520) were HIV recipients 10%; 521) were HIV recipients 10%; 522) were HIV recipients 10%; 523) were HIV recipients 10%; 524) were HIV recipients 10%; 525) were HIV recipients 10%; 526) were HIV recipients 10%; 527) were HIV recipients 10%; 528) were HIV recipients 10%; 529) were HIV recipients 10%; 530) were HIV recipients 10%; 531) were HIV recipients 10%; 532) were HIV recipients 10%; 533) were HIV recipients 10%; 534) were HIV recipients 10%; 535) were HIV recipients 10%; 536) were HIV recipients 10%; 537) were HIV recipients 10%; 538) were HIV recipients 10%; 539) were HIV recipients 10%; 540) were HIV recipients 10%; 541) were HIV recipients 10%; 542) were HIV recipients 10%; 543) were HIV recipients 10%; 544) were HIV recipients 10%; 545) were HIV recipients 10%; 546) were HIV recipients 10%; 547) were HIV recipients 10%; 548) were HIV recipients 10%; 549) were HIV recipients 10%; 550) were HIV recipients 10%; 551) were HIV recipients 10%; 552) were HIV recipients 10%; 553) were HIV recipients 10%; 554) were HIV recipients 10%; 555) were HIV recipients 10%; 556) were HIV recipients 10%; 557) were HIV recipients 10%; 558) were HIV recipients 10%; 559) were HIV recipients 10%; 560) were HIV recipients 10%; 561) were HIV recipients 10%; 562) were HIV recipients 10%; 563) were HIV recipients 10%; 564) were HIV recipients 10%; 565) were HIV recipients 10%; 566) were HIV recipients 10%; 567) were HIV recipients 10%; 568) were HIV recipients 10%; 569) were HIV recipients 10%; 570) were HIV recipients 10%; 571) were HIV recipients 10%; 572) were HIV recipients 10%; 573) were HIV recipients 10%; 574) were HIV recipients 10%; 575) were HIV recipients 10%; 576) were HIV recipients 10%; 577) were HIV recipients 10%; 578) were HIV recipients 10%; 579) were HIV recipients 10%; 580) were HIV recipients 10%; 581) were HIV recipients 10%; 582) were HIV recipients 10%; 583) were HIV recipients 10%; 584) were HIV recipients 10%; 585) were HIV recipients 10%; 586) were HIV recipients 10%; 587) were HIV recipients 10%; 588) were HIV recipients 10%; 589) were HIV recipients 10%; 590) were HIV recipients 10%; 591) were HIV recipients 10%; 592) were HIV recipients 10%; 593) were HIV recipients 10%; 594) were HIV recipients 10%; 595) were HIV recipients 10%; 596) were HIV recipients 10%; 597) were HIV recipients 10%; 598) were HIV recipients 10%; 599) were HIV recipients 10%; 600) were HIV recipients 10%; 601) were HIV recipients 10%; 602) were HIV recipients 10%; 603) were HIV recipients 10%; 604) were HIV recipients 10%; 605) were HIV recipients 10%; 606) were HIV recipients 10%; 607) were HIV recipients 10%; 608) were HIV recipients 10%; 609) were HIV recipients 10%; 610) were HIV recipients 10%; 611) were HIV recipients 10%; 612) were HIV recipients 10%; 613) were HIV recipients 10%; 614) were HIV recipients 10%; 615) were HIV recipients 10%; 616) were HIV recipients 10%; 617) were HIV recipients 10%; 618) were HIV recipients 10%; 619) were HIV recipients 10%; 620) were HIV recipients 10%; 621) were HIV recipients 10%; 622) were HIV recipients 10%; 623) were HIV recipients 10%; 624) were HIV recipients 10%; 625) were HIV recipients 10%; 626) were HIV recipients 10%; 627) were HIV recipients 10%; 628) were HIV recipients 10%; 629) were HIV recipients 10%; 630) were HIV recipients 10%; 631) were HIV recipients 10%; 632) were HIV recipients 10%; 633) were HIV recipients 10%; 634) were HIV recipients 10%; 635) were HIV recipients 10%; 636) were HIV recipients 10%; 637) were HIV recipients 10%; 638) were HIV recipients 10%; 639) were HIV recipients 10%; 640) were HIV recipients 10%; 641) were HIV recipients 10%; 642) were HIV recipients 10%; 643) were HIV recipients 10%; 644) were HIV recipients 10%; 645) were HIV recipients 10%; 646) were HIV recipients 10%; 647) were HIV recipients 10%; 648) were HIV recipients 10%; 649) were HIV recipients 10%; 650) were HIV recipients 10%; 651) were HIV recipients 10%; 652) were HIV recipients 10%; 653) were HIV recipients 10%; 654) were HIV recipients 10%; 655) were HIV recipients 10%; 656) were HIV recipients 10%; 657) were HIV recipients 10%; 658) were HIV recipients 10%; 659) were HIV recipients 10%; 660) were HIV recipients 10%; 661) were HIV recipients 10%; 662) were HIV recipients 10%; 663) were HIV recipients 10%; 664) were HIV recipients 10%; 665) were HIV recipients 10%; 666) were HIV recipients 10%; 667) were HIV recipients 10%; 668) were HIV recipients 10%; 669) were HIV recipients 10%; 670) were HIV recipients 10%; 671) were HIV recipients 10%; 672) were HIV recipients 10%; 673) were HIV recipients 10%; 674) were HIV recipients 10%; 675) were HIV recipients 10%; 676) were HIV recipients 10%; 677) were HIV recipients 10%; 678) were HIV recipients 10%; 679) were HIV recipients 10%; 680) were HIV recipients 10%; 681) were HIV recipients 10%; 682) were HIV recipients 10%; 683) were HIV recipients 10%; 684) were HIV recipients 10%; 685) were HIV recipients 10%; 686) were HIV recipients 10%; 687) were HIV recipients 10%; 688) were HIV recipients 10%; 689) were HIV recipients 10%; 690) were HIV recipients 10%; 691) were HIV recipients 10%; 692) were HIV recipients 10%; 693) were HIV recipients 10%; 694) were HIV recipients 10%; 695) were HIV recipients 10%; 696) were HIV recipients 10%; 697) were HIV recipients 10%; 698) were HIV recipients 10%; 699) were HIV recipients 10%; 700) were HIV recipients 10%; 701) were HIV recipients 10%; 702) were HIV recipients 10%; 703) were HIV recipients 10%; 704) were HIV recipients 10%; 705) were HIV recipients 10%; 706) were HIV recipients 10%; 707) were HIV recipients 10%; 708) were HIV recipients 10%; 709) were HIV recipients 10%; 710) were HIV recipients 10%; 711) were HIV recipients 10%; 712) were HIV recipients 10%; 713) were HIV recipients 10%; 714) were HIV recipients 10%; 715) were HIV recipients 10%; 716) were HIV recipients 10%; 717) were HIV recipients 10%; 718) were HIV recipients 10%; 719) were HIV recipients 10%; 720) were HIV recipients 10%; 721) were HIV recipients 10%; 722) were HIV recipients 10%; 723) were HIV recipients 10%; 724) were HIV recipients 10%; 725) were HIV recipients 10%; 726) were HIV recipients 10%; 727) were HIV recipients 10%; 728) were HIV recipients 10%; 729) were HIV recipients 10%; 730) were HIV recipients 10%; 731) were HIV recipients 10%; 732) were HIV recipients 10%; 733) were HIV recipients 10%; 734) were HIV recipients 10%; 735) were HIV recipients 10%; 736) were HIV recipients 10%; 737) were HIV recipients 10%; 738) were HIV recipients 10%; 739) were HIV recipients 10%; 740) were HIV recipients 10%; 741) were HIV recipients 10%; 742) were HIV recipients 10%; 743) were HIV recipients 10%; 744) were HIV recipients 10%; 745) were HIV recipients 10%; 746) were HIV recipients 10%; 747) were HIV recipients 10%; 748) were HIV recipients 10%; 749) were HIV recipients 10%; 750) were HIV recipients 10%; 751) were HIV recipients 10%; 752) were HIV recipients 10%; 753) were HIV recipients 10%; 754) were HIV recipients 10%; 755) were HIV recipients 10%; 756) were HIV recipients 10%; 757) were HIV recipients 10%; 758) were HIV recipients 10%; 759) were HIV recipients 10%; 760) were HIV recipients 10%; 761) were HIV recipients 10%; 762) were HIV recipients 10%; 763) were HIV recipients 10%; 764) were HIV recipients 10%; 765) were HIV recipients 10%; 766) were HIV recipients 1

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.145 CLOTTING FACTOR TREATMENT AND CD4 COUNTS IN ANTI-HIV-1(S) SERONEGATIVES.

The Transfusion Safety Study donors represented by Siegel, George F., et al. are receiving instructions in New York City, Miami, Detroit, Seattle, San Francisco, and Los Angeles, USA, except South Blood Center, Seattle, Washington, USA.

Objective: To determine whether reductions in CD4 counts among anti-HIV-1(s) seronegatives are related to type or intensity of treatment.

Methods: Data for anti-HIV-1(s) patients with Factor VIII (FVIII) or IX deficiency were analyzed by type and amount of treatment received from 1981-1985, defined as FVIII units, FIX units or FVIII units from cryoprecipitate (Cryo). Analysis was limited to 344 patients treated with FVIII concentrate, FIX concentrate or cryo only. Statistical inference was based on the rank correlation coefficient between amount of treatment and CD4 count.

Results: Median CD4 counts above or equal to treatment. Units = annual measurement.

Year-FVIII units	n	median CD4	correlation of FIX units			correlation of cryo units		
			r	p	units	r	p	units
1	20,620	534			0.17	0.00	0.20	0.00
2	13,935	497	-0.28	0.00	0.46	0.00	0.47	0.00
3	10,765	392			0.40	0.00	0.44	0.00
4	68,988	338			0.26	0.00	0.30	0.00

Conclusion: Increasing treatment was correlated with lower CD4 counts in those receiving FVIII or cryo, but not FIX. Heterogeneous proteins could be responsible for the observations in FVIII-treated patients. Relative risk of the variability in CD4 (r), however, is related to treatment intensity, which may itself imply an index of increasing duration of HIV infection. (Supported by Contract No. N01-HB-4-7003 of the National Heart, Lung and Blood Institute.)

M.B.P.147 PROTOACTIVATION OF HIV-1 WITH MERCOPYRINE 540

Rayne, James C., Harvey, R.L., Gonsky, L.L., Wayne State University, Detroit, Michigan, 48201, and Veterans Administration Medical Center, Allen Park, Michigan, U.S.A.

Objective: Mercopyrine 540 (MC 540), a thymidine dye, inactivates enveloped viruses following exposure to white light. We conducted an experiment to determine if MC 540 with light inactivates HIV-1, since phototherapy may be useful for inactivating viruses transmitted by blood transfusion.

Methods: Cell-free supernatant from HIV-1/IIa cells was mixed with MC 540 (30 ug/ml), then exposed to white light for 60 minutes. Untreated V8 cells were added to treated viral supernatant and virus adsorbed at 37°C for 2 hours, resuspended and incubated at 37°C in 80% DM for 7 days. Subsequent p24 antigen (Abbott) was measured at 7 and 10 days post-infection.

Results:

Solution	p24 optical density	
	Day 7	Day 10
HIV (no light, no MC 540)	0.737 (+)	0.818 (+)
HIV (no light, with MC 540)	0.450 (+)	0.873 (+)
HIV (with light, no MC 540)	0.139 (+)	0.203 (+)
HIV (with light, with MC 540)	0.044 (-)	0.056 (-)

Conclusion: MC 540 with white light inhibited HIV replication as determined by p24 antigen immunosay. Studies are in progress to determine if MC 540 has similar activity against cell-associated virus.

M.B.P.149 HIV SEROPREVALENCE AMONG HEALTH BLOOD DONORS IN 31 HOSPITALS IN ZAMBIA

Dr. P. W. Ndlovu, Ndlovu, Chikwa L., Nkhosi R., Tadder S., Sibayanga J., MRC/ISS/Health Services, London UK and *University Teaching Hospital, Lusaka, Zambia.

Objective: To screen blood for HIV infections in all the Blood Transfusion in Zambia with a view to limiting transmission. Secondly to provide information on the seroprevalence of HIV among health blood donors in Zambia.

Methods: Using a National Blood Transfusion record book all donors were interviewed in 31 hospitals in Zambia. Sex, Marital Status, address, Age, Social behaviour and Travel were recorded. HIV abs was screened using ELISA.

Results: HIV seroprevalence varied from place to place. The rural areas had 0%. The urban rural had 0-11 while the urban areas had 6-10%. The big cities ranged up to 11%.

Conclusion: HIV is a new disease in Zambia and is currently confined mostly to big cities and any part of Zambia with urban infection.

M.B.P.146 SEROLOGICAL EVIDENCE OF PRIOR SEXUALLY TRANSMITTED DISEASES IN HIV-1 SEROPOSITIVE BLOOD DONORS

Alan E. Williams, K.W. Cranley, T. Grandinetti, M. H. Sullivan, and the American Red Cross Collaborative HIV Study Group, Jerome H. Holland Laboratory, Rockville, MD, USA.

Objective: To serologically characterize HIV-1 seropositive blood donors who may carry AIDS risk behavior.

Methods: AIDS risk behaviors were defined as: all IV drug use or sexual contact with an IV drug user, or b) direct or primary partner contact with a gay or bi-racial male. These data were collected by in-person interview following test result notification from 156 HIV seropositive former blood donors and 155 age, sex, and race-matched controls. All subjects were tested for anti-HIV, anti-CW, anti-chlamydia, and anti-HSV.

Results: Prior behaviors likely to have increased AIDS risk were identified by in-person interview for 131/156 HIV+ former donors (83%). Twenty five donors were classified as having no identifiable risk (19%). The proportion of both RISK and HIV+ donors having additional STD markers was significantly higher than controls for all markers. In contrast, the proportions of RISK and the RISK HIV+ individuals reactive for all STD markers except anti-HSV did not differ significantly.

Conclusions: HIV+ donors as a group are significantly more likely to have serological evidence of prior exposure to other STDs. This exposure is also evident for donors who deny traditional AIDS risk activities. While none of the STD-related assays studied would have sufficient predictive accuracy to be used for blood screening purposes, they may serve as a mechanism for further characterization of these individuals.

M.B.P.148 p24 HIV ANTIGEN SCREENING OF BLOOD DONORS

Erica, Jost, Gathor, M.; Bækker, U.; Georru, P.; Rott, H.; Baumgarten, P.; Bergman, H.V.; Betsch, M.; Gierlich, U.; Dehnbach, P.

*Festschefer Institute, University Munich, Fed. blood Transfusion Service, Fed Cross, Munich, FRG, *Adair, Martin, FRG, *Blood Transfusion Service of Saarland, Federal Republic of Germany.

Objective: Screening blood donations only for HIV-1 antibody (anti-HIV) leaves open the possibility that a donor was in the period (4-12 weeks after infection) of being anti-HIV negative but infected and possibly positive for HIV-antigen (HIV-Ag). So several blood centers have evaluated the advantage of HIV-Ag screening in populations with different HIV prevalences.

Method: HIV antigen capture immunoassay (M. Chicago, IL) were used.

Results:	number of donations	Anti-HIV+ /HIV-Ag+	Anti-HIV+ /HIV-Ag-	Anti-HIV- /HIV-Ag+	Anti-HIV- /HIV-Ag-
Bavaria	359,870	0	16	0	0
Berlin	45,481	0	1	0	0
Bonn	24,117	0	1	0	0
Vienna	215,750	1	9	0	0
Linz	62,577	0	2	0	0
Innsbruck	52,190	0	3	0	0

It is particularly important that 6 donors became Anti-HIV positive 2 to 6 weeks after having been tested HIV-Ag negative.

Conclusion: In these 620,017 blood donors HIV-Ag testing failed to detect

M.B.P.150 RISK OF HIV-1 TRANSMISSION BY BLOOD TRANSFUSIONS IN

San Francisco PRIOR TO ANTI-HIV-1 SCREENING
Burch, Michael, Hanson, S., Young, M., Mark, J., and Perkins, L.
Irwin Memorial Blood Centers, San Francisco, California, and *Centers for Disease Control, Atlanta, Georgia, USA.

Objective: To estimate the proportion of blood transfusions that were infectious for HIV-1 during each of the seven years preceding introduction of routine anti-HIV-1 screening.

Methods: 1,554 previous donations by 149 former blood donors now known to have AIDS or HIV-1 antibody were plotted according to donation date. Using the observed seroprevalence of late 1984 donors (0.24%), and assuming a parallel seroprevalence with that reported for other high-risk persons in San Francisco between 1978 and 1983, the proportion of all donors who were high-risk and HIV+ was extrapolated for each earlier time point. The likelihood of recipient infection per unit exposure was then calculated by multiplying by the known infectivity rate (0.90) of a seropositive transfusion.

Results: The risk of infected transfusions rose exponentially from 1978 (<0.01) through 1982 (1.24). The risk plateaued in 1983 and then declined precipitously in 1984, despite continued spread of the virus in the local community.

Conclusion: The derived risk/time curve is validated by an alternate risk estimate based on reported dates of transfusion of known infected recipients, and has been of value in designing recipient counselling, notification and testing strategies.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.167 ANTI-HIV SCREENING OF BLOOD DONORS IN CANADA (NOVEMBER 1985 TO DECEMBER 1986)

Barbara G. Gagnon, ADRIA, A. and WHITTINGTON, N.S.
THE CANADIAN RED CROSS SOCIETY, OTTAWA, CANADA.

BETWEEN NOVEMBER 1985 AND DECEMBER 1986, THE CANADIAN RED CROSS SOCIETY SCREENED OVER 3.7 MILLION UNITS OF BLOOD FOR ANTI-HIV USING ENZYME IMMUNO ASSAYS (EIA). THE UNITS FOUND TO BE REPEATEDLY REACTIVE BY EIA WERE DISCARDED AND THE ANTIBODY STATUS CONFIRMED BY WESTERN BLOT (WB). DURING THIS PERIOD, 14,313 (0.38%) UNITS WERE FOUND TO BE EIA REPEATEDLY REACTIVE AND WERE DISCARDED. ONLY 395 (0.11%) OF THE UNITS TESTED WERE FOUND TO BE WESTERN BLOT POSITIVE AND THE DONORS WERE INFORMED OF THEIR ANTIBODY STATUS.

ALTHOUGH THE REPEATEDLY REACTIVE RATES WERE NOT SIGNIFICANTLY DIFFERENT WITHIN THE CATEGORIES STUDIED, WB POSITIVE RATES DIFFERED SIGNIFICANTLY. THE ANTI-HIV SEROPREVALENCE WAS TWO TO FOUR TIMES HIGHER IN THE URBAN POPULATION THAN IN THE RURAL POPULATION. THE SEROPREVALENCE IN THE PROVINCE OF QUEBEC REMAINED CONSISTENTLY TWO TO FOUR TIMES HIGHER THAN THE REST OF THE COUNTRY. THE WB POSITIVE RATE WAS QUALITATIVELY HIGHER AMONG THE FIRST TIME DONORS THAN IN THE REPEAT DONORS. THE WB POSITIVE RATE WAS FOUR TIMES HIGHER AMONG THE MALE DONORS THAN THE FEMALE DONORS. THE HIGHEST SEROPREVALENCE WAS OBSERVED IN THE MALE DONORS OF 17 TO 29 YEARS OF AGE.

DURING THE STUDY PERIOD, THE WB POSITIVE RATE WAS DECREASED CONSIDERABLY, FROM 0.0343 IN THE FIRST QUARTER OF 1986 TO 0.0058 IN THE LAST QUARTER OF 1986, WHICH MAY BE MAINLY BECAUSE THE DONOR POOL HAS ACTED DYNAMICALLY AND THE WB POSITIVE DONORS ARE PERMANENTLY DEFERRED FROM DONATING.

M.B.P.159 TRANSFUSION AND HIV, FINNISH NATIONAL BLOOD BACK PROGRAM.

Koistinen, Jukka, Finnish Red Cross Blood Transfusion Service, Helsinki, Finland.

HIV situation in Finland by Dec. 31, 1986: 24 positive, of them 26 with a history of blood donation since Jan. 1, 1982, seven diagnosed at blood donation. The 26 donors gave blood 88 times for 99 products, of which 41 were used and 55 discarded, in addition some parts of 17 units were separated for F VIII, cryoprecipitate, interferon or plasma for albumin.

Results of the blood components used

	No. of units to hospitals	No. of patients	HIV pos.	HIV neg.	0	1	2	3	No. infom.
Whole blood	5	0	3	4	2	0	0	0	0
Red cell conc. (RBC)	23	3	5	11	1	1	0	0	3
Platelets	10	2*	0	0	0	0	0	0	2
Leukocytes	2	0	1	0	0	0	0	0	0
FFIII	44	2*	15	20	0	0	0	0	0

RE-HIV results of the patient are not known; Dupont had died of reasons not due to HIV; Home patient received two HIV pos. platelet concentrates. Two patients died of AIDS after receiving RBC in 1983 (died 1985) and 1984 (died 1987). One received HIV pos. platelets in 1984, started having opportunistic infections in 1985. One received RBC in 1985, got LAs in 1987. The one who got 2 units of HIV pos. platelets died a year later of leukemia without symptoms of AIDS. Two hemophiliacs are HIV pos. since 1984 due to cryoprecipitate. Of the donors 11 were first time donors, but their donations occurred equally between years 1982-86 suggesting that blood donation was not used for HIV testing.

M.B.P.161 RISK OF TRANSMISSION OF HTLV-I BY TRANSFUSION

B. F. Poek, et al.
Texas A & M University, College Station, TX. *Johns Hopkins Medical Institutions, Baltimore, MD. ** St. Luke's Episcopal Hospital, Houston, TX. U.S.A.

Objective: A prospective seroepidemiologic study was conducted to determine the incidence (I%) of seropositivity to HTLV-I in a cohort receiving multiple transfusions of blood/plasma components screened for antibody to HIV-1.

Methods: Preoperative and postoperative serum samples were collected from 2,749 adult cardiac surgery patients who received 20,983 transfusions of blood components (17,823 cellular components). Preoperative and postoperative samples were serologically compared for evidence of human T-cell leukemia virus type I (HTLV-I) infection.

Results: Five incident and two prevalent infections were detected in the study population. The observed risk of HTLV-I transmission by transfusion was 0.024% (5/20,983) per unit with 95% upper bounds of 0.052%. The risk per cellular component was 0.028% (5/17,823) with 95% upper bounds of 0.056%. Comparison of the five seroconvertors with sets of controls who received an equivalent number of blood components supported the transfusion of plasma as particularly associated with HTLV-I transmission.

Conclusions: These data suggest that despite similar modes of transmission and some overlap in risk groups, HIV-1 screening is not a satisfactory surrogate for HTLV-I. These results also provide important information about the risk of HTLV-I transmission by transfusion of blood components prior to specific screening of donor units for HTLV-I.

M.B.P.158 HIV-2 SEROPREVALENCE IN DIFFERENT GROUPS TESTED IN UNIVERSITY COLLEGE HOSPITAL, Ibadan, NIGERIA

Eric Enyien & Yannis Galis
Dept. of Haematology, University College Hospital (UCH) Ibadan, Nigeria.

Objective: To determine the relative frequency of HIV-2 among different groups tested in U.C.H. Ibadan

Methods: U.C.H. is the apex hospital in South Western Nigeria and is located in Ibadan, the largest city in Africa South of the Sahara desert with an estimated population of about 6 million. A total of 6,395 blood samples have been screened in this centre since July 1987.

Category	No. screened	ELISA +ve	WB +ve
Blood donors	5760	4	4
Haematology 4 other patients	537	3	3
Volunteers etc.	337	1	1
TOTAL	6395	8 (0.125)	8 (0.095)

Two of those who tested positive among patients probably acquired the infection through blood transfusion.

Conclusion: It is concluded that HIV-2 is present among different categories of persons in Ibadan. Transmission in some cases was probably via infected blood transfusion. A study of its effect(s) on the course of other diseases in this environment is being undertaken.

M.B.P.160 ABSENCE OF HIV SEROPOSITIVITY IN CHILDREN WITH SICKLE CELL ANEMIA AT KENYATTA NATIONAL HOSPITAL, NAIROBI, KENYA.

Nwera Samuel E. Biyora, Maw, J. J., Kinchua, P.M.K. and Kitonyi, G.W.
Departments of Paediatrics, and Haematology University of Nairobi, Nairobi, KENYA

Objective: To find out whether frequent blood transfusions increase the risk of transfusion-related HIV infection in children with sickle cell anaemia.

Methods: One hundred and ninety-eight children with sickle cell anaemia were transfused 1-13 times (mean 2.4) between 1982 and 1987. In Kenya routine screening of blood banks for HIV infection began in 1987. The HIV status of these children was compared with 231 non-transfused children: 106 with sickle cell anaemia and 125 children with haemoglobin AA. In both transfused and non-transfused children age ranges were similar and were 1-12 years. All children were tested with Westcozyme ELISA test in duplicate. All tests were performed at least 6 months after the last transfusion. Fifty five transfused children were rechecked one year later.

Results: All 428 children were HIV negative.

Conclusions: Our findings suggest that HIV seropositivity is low in Kenyan children. Furthermore, even though blood was unscreened in 1982-1987 transfusion did not increase the risk of HIV infection in our study children.

M.B.P.162 PREVALENCE OF HTLV-I ANTIBODIES IN BLOOD DONORS

IN THE NETHERLANDS
Van Der Pijl, Geert*, Lelia, N.**, Beekun, H.**, Ehlers, P.**, Bakker, E.**, Huismen, H.***
* Red Cross Blood Bank, Amsterdam. ** Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, the Netherlands.

Objective: To establish the prevalence of HTLV-I antibodies in blood donors in the Netherlands.

Methods: Serum samples from regular blood donors (n=20,037) were tested with 2 commercially available ELISA for HTLV-I antibodies. Repeatedly ELISA negative samples were tested for confirmation with commercially available WB strips and ¹²⁵I-RIBA developed in our institute.

	ELISA reactive	Western Blot	¹²⁵ I-RIBA
	n	positively	pos index
donors	20,037	49 (0.244)	26 (0.134)
		1	14
		1	10

Only 1 donor was found confirmed positive for HTLV-I antibodies with p19, p24, p26, p28, sp16 in WB and p24, p26, p28, p19/p24 in ¹²⁵I-RIBA.

Conclusions: the prevalence of HTLV-I antibodies in blood donors in the Netherlands is low and in the order of 0.005 %.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

Transfusions/Déplétage

Transfusions/Tests

M.B.P.163

COMPARISON OF IMMUNOASSAYS FOR EARLY DETECTION OF HIV-1 SEROCONVERSION WELLS, V.J., Phillips, J.; Schoenbach, J.; Szeles, J.; Centers for Disease Control, Atlanta, GA, USA.

Objective: To evaluate various immunoassays for their ability to detect early seroconversion to human immunodeficiency virus (HIV) type 1 infection. **Methods:** Pre- and post-pulse panels for 13 individuals identified by various immunoassays as having seroconversion (positive Western blots) to HIV-1 were tested by 7 immunoassay employing 5 different technologies. **Tests used were:** Organon Teknica Virusomate enzyme immunoassay (EIA); Sero-Git Particle Agglutination Test (PAT); Gilead Recombinant Immunoassay (RIA); DuPont Western blot (WB); and three immunofluorescence assays (IFA), Electro-Blotronics (EBI), Cellular Products (CP), and Fluoromax (FL). **Western blots** were judged positive, indeterminate or negative by the criteria of the Assoc. of State and Terr. Pub. Health Lab. Directors (ASTHED).

Results: Listed are the number of times each method was first or tied with other methods to give a definite result: PA (11/12), EIA (7/12), RIA (6/12), WB (3/12), CP (3/12), EBI (9/12), FL (6/12).

Conclusions: The PA test was found to be the most sensitive test. The PA test became positive 3-5 days before other methods. Sensitivity of the PA test varied among the three IFA compared, EBI was the second most sensitive test overall, while CP was the least sensitive. Western blot detected antibodies to gag proteins at about the same time as the PA became positive but did not meet the ASTHED positive criteria in one panel until 20 days after the PA became positive. EA, RIA, and FL were similar in their sensitivities.

M.B.P.164

COMPARISON OF NEW HIV-1 SEROCONVERSION ASSAYS ON SIX HIV-1 ANTIBODY ASSAYS
Santoli, L.; Green, J.; Ghee, J.; Dow, E.; Sachs, R.;
Nash, S.; and Heller, J.S.

Univ. of Illinois, Urbana, IL; North American Biologics, Inc., Miami, FL, U.S.A.
Univ. of Utah, Salt Lake City, UT

Objective: An evaluation of six detection systems for HIV-1 antibody was performed on a total of 49 early seroconversion samples from nine donors. **Methods:** Viral and recombinant enzyme immunoassay (Abbott, Labs and Cambridge Biotech), and rapid detection assays (Abbott and Cambridge) were evaluated on a pool of 49 HIV-1 seroconversion samples including from nine donors.

Results: Of the 49 seroconversion samples tested, both recombinant EIA detected 42 (86%) samples at positive, Abbott's fast track (recombinant) also detected 42 samples as positive, which was followed by the Abbott modified viral EIA that detected 41 samples as positive. All positive of seroconversion samples progressed from negative to seroconversion status at the completion of the latex agglutination assay. With negative to positive; however, there was no sample detected as positive for two donors and the majority (36) were positive for only the earliest blends with subsequent blends becoming negative. The samples that were detected as negative in the latex agglutination test for these six donors were positive by all other assays. The results for these six donors on the latex agglutination assay most closely corresponded to their activity IgG reactivities.

Conclusions: Results suggest the latex agglutination assay appears to have reduced sensitivity compared to the other assays in this evaluation on samples having low levels of IgG typically contained within seroconversion series.

M.B.P.165

PROGRESSIVE CHANGES WITH TIME IN EXPRESSION OF CARBOHYDRATE ANTIGENS IN PBL OF HIV INFECTED PATIENTS

Ejima, J.; Horiuchi, M.; Kashiwagi, M.; Uchida, D.;
Oshiro, H.; Fudo, H.; Imai, Y.; Imai, N.; Nishimura, M.;
University of Calgary, Calgary, Canada. Japan Immunosorb Laboratory,
Takanashi, Japan. Prochilika Hospital, Calgary, Canada.

We have found in vitro that HIV infection of TALL lymphocytes causes significant expression on the lymphocytes of a carbohydrate determined by the Hc-1 monoclonal antibody (J Exp Med, 1988; 167: 323). Patients with AIDS have high levels of Hc-1 expression and asymptomatic patients have low levels of expression. Over 200 HIV positive patients have been followed prospectively to determine if Hc-1 expression correlates with clinical stage or prognosis. Hc-1 expression above 15% on lymphocytes was associated with poor clinical state or evolving infection and a low absolute T4 lymphocyte count. Continued high level of Hc-1 expression and low T4 counts persisted to patients receiving zidovudine. Hc-1 expression may have some value as a marker of progressive disease and could also be involved in the pathogenesis of cell destruction. A continued evaluation of this cohort would appear merited.

M.B.P.166

PACKED RED BLOOD CELL (PRBC) TRANSFUSION (TX) THERAPY FOR ANEMIA IN PATIENTS WITH AIDS AND ARC: INCIDENCE, ASSOCIATED FACTORS, AND OUTCOME

Zacharias, M.; Weiser, T.; Volberding, P.; Purzman, D.; Toy, PTCY, Feigal, D.; UCSF and HF General Hospital, San Francisco, CA, USA.

Objective: Determine the incidence, associated biologic factors and clinical outcome of PRBC Tx therapy (Tx) in patients with HIV disease. **Methods:** We reviewed records of the UCSF General Hospital (UGH) Blood Bank and identified 263 likely AIDS and ARC patients (pts) who received 154 units of PRBC between July 1, 1987, and June 30, 1988. A probability sample of 80 of these pts were randomly selected for detailed chart review. Of this sample, 78/80 were confirmed to have AIDS (84%) or ARC (16%).

Results: Based on the primary causes of the 80 AIDS pts, we estimated a Tx incidence of 0.36 (0.89 PRBC units)/pt/year for pts with AIDS and 0.11 (0.27 PRBC units)/pt/year for those with ARC. Of the 77 Tx's studied in detail, antimicrobial drug therapy, zidovudine therapy, and disseminated M. avium complex (MAC) infection were the sole likely etiologic factors in 20%, 14%, and 12% of the Tx's, respectively. To assess the role of MAC, the 263 Tx's pts were compared with the 574 pts who had blood submitted to the SFH Hematology Laboratory during the same time period. The above blood yielded MAC with a relative risk of 5.2 for Tx-requiring anemia. After 80% of Tx's, the pt returned to home.

Conclusion: Most PRBC Tx's administered to AIDS or ARC pts were clinically appropriate Rx. Applying our incidence data to the US PRBC estimates of future AIDS cases, we estimate that in 1990 the expected Tx needs of pts with AIDS and ARC will represent 1-2% of the total PRBC supply in the US.

M.B.P.167

SCREENING OF BLOOD DONATIONS WITH EIA COMBINED TEST (COMBI IgG EIA) BY USING SYNTHETIC PEPTIDES TO DETECT ANTI-HIV 1 / ANTI-HIV 2.

Hamerabek, R.; Kawanishi, T.; Kawahara, M. B.; Hiasaka, H.; Cavagnoli, K.; Guerra C. C. C. and Saterling, L. S.

Centro de Hematologia de São Paulo and Hospital Israelita Albert Einstein, São Paulo, Brazil

Objective: To evaluate the behaviour of the EIA test containing synthetic peptides (Pharmacia Comb i IgG EIA) for screening blood donation.

Methods: 2503 random samples and 25 anti-HIV-1 + Comb i IgG EIA were performed in comparison to EMI EIA test. Western blot was the confirming test.

Results: 9 random samples (0,36%) out of 2503 EMI + and confirmed by WB were strongly + with Comb i IgG EIA; 26 samples (1%) EMI false + were - with Comb i IgG EIA; 19 samples EMI true + were in accordance with Comb i test while 1 out of 6 false + samples was + with the Comb i test.

Conclusion: The Comb i IgG EIA proved to be sensible and agreeing when compared to EMI test.

M.B.P.168

DETECTION OF ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS BY VEIN AND CAPILLARY BLOOD FROM EARLY SEROCONVERSION

Chen, C.; Chen, S.; Kuo, K. M.; and C. H. Riggs
Centers for Disease Control, Rockville, MD, USA. Wesley Community Health Center, Boston, MA, USA.

Objective: The ability of rapid application test to detect antibodies to human immunodeficiency virus (HIV-1) in capillary and venous whole blood samples was evaluated.

Methods: RecombiPep™-HIV-1 IA is a five minutes latex agglutination (LA) test which uses polystyrene beads coated with recombinant gag antigen to detect antibodies to HIV-1. Capillary blood, anticoagulated venous whole blood, and serum samples were collected from 117 high risk patients in a Boston clinic. Pairs of anticoagulated whole blood and serum samples were collected from 57 patients at a hematology clinic and 96 donors at a transfusion center. These samples were tested by latex agglutination and the results were compared to those obtained by a licensed enzyme immunoassay with serum. All positive samples were confirmed by Western blot analysis and, in some cases, by radioimmunoassay.

Results: Using whole blood samples at the recommended 1:10 dilution, all 77 confirmed HIV seropositive samples tested were detected by the RecombiPep HIV-1 IA test. (sensitivity=100%). With 213 seronegative samples specificity was 95.1% with whole blood. In contrast, anticoagulated venous whole blood and capillary blood was 100%.

Conclusion: These data show that the 5 minute LA test can be used to detect HIV antibodies in venous and capillary whole blood.

Session d'Affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

La peau Skin

M.B.P.175 PROBABILITY OF RECURRENCE OF BUCCAL CANDIDIASIS AND ITS RELATIONSHIP TO T4 COUNT AND P24 ANTIGEN.
DOR R. SMITH, MALLAN, J., WILLEY, S.G., GAZDAR.
ST. STEPHENS HOSPITAL, TOTTENHAM, ENGLAND.

OBJECTIVE: To assess time to recurrence of candidiasis after successful treatment and its relationship to T4 count and HIV P24 antigen.
METHOD: 100 HIV positive patients with confirmed buccal or oropharyngeal candidiasis received a 4 week course of either Itaconazole 200mg Q.D. or Metronidazole 200mg B.D. Successful treatment was assessed as clinical and mycological clearance. Patients were assessed for a further 3 months with regular clinical and mycological assessments in conjunction with T4 counts and P24 Antigen levels monitored each visit.

RESULTS:

RESULTS:	WITHIN 1 WKN.		WITHIN 3 WKS.		CLEAR AT 3 WKS.	
	ITRACONAZOLE	25 (74%)	27 (80%)	6 (18%)	ITRACONAZOLE	22 (63%)
MYCOLOGICAL:	22 (63%)	27 (78%)	28 (80%)	7 (20%)	28 (80%)	13 (38%)
TOTAL:	41 (60%)	52 (76%)	56 (80%)	13 (20%)		

T4 (m³): NO. MEAN. P24 Ag(u/ml): NO. MEAN. POS. MEAN.
AT ENTRY: 43 150 AT ENTRY: 58 37 111
RELAPSE: 21 150 RELAPSE: 18 27 124
NON-RELAPSE: 30 124 NON-RELAPSE: 42 21 53
CONCLUSION: 80% of HIV patients with oral candida have a successful relapse within 3 months of a successfully treated episode. T4 levels and P24 Antigen levels are not useful in predicting relapse.

M.B.P.177 MYCOBACTERIAL SKIN INFECTION IN AIDS
Lyovardis, Styllanos and Vaidya, K.P.
Dept. Dermatology, Woodhull Medical and Mental Health Center
Brooklyn, New York 11206, USA.

Cutaneous mycobacterial infection is a rare complication of AIDS. We describe two young intravenous drug addicts with oral candidiasis and mycobacterial ulcers and abscesses.

Case 1. A 23 year old black woman presented with fever, chills, diffuse lymphadenopathy and abscesses in the axilla and adjacent chest wall which required repeated drainage and debridement. PPD and HIV antibody tests were negative. The patient developed marked respiratory distress and chest X-ray suggested septal emphysema. Dermis and subcutaneous tissue showed coagulative necrosis, and numerous acid-fast bacilli consistent with *M. tuberculosis* (Mtb) but no granulomas or multinucleated giant cells. The organism was grown in urine but not in sputum or blood.
Case 2. A 33 year old Hispanic man with history of hemoptysis required drainage of a large abscess of the forearm and debridement of a 4cm ulcer of the anterior chest wall. Necrotizing granulomas in the dermis and in subcutaneous fat of chest wall contained few acid fast bacilli resembling Mtb. Chest X-ray did not suggest tuberculosis but prescopic infiltrates were seen. Mtb was recovered in sputum cultures. The patient developed respiratory distress and coma, and died on the sixth day.

Conclusion: Mycobacterial infection must be considered in the differential diagnosis of skin ulcers and abscesses in intravenous drug addicts, especially in the presence of other manifestations of AIDS, and appropriate bacteriologic studies must be performed.

M.B.P.179 VARICELLE ET INFECTION A HIV.
Peyronnet, Christian; Lescanne M.; Lepout C.; Salmeun, Jean-Pierre F. et Vilard J.-L.
Hôpital Claude-Bernard, 75018 Paris, France.

Objectif: Etude rétrospective de la varicelle chez 15 malades infectés par le HIV (HIV+) entre 1981 et 1988.
Méthode: Parmi 41 malades HIV+ hospitalisés, 15 (35%) ont fait une varicelle. Le diagnostic a été clinique. Une culture de virus varicelleux (VZV) ont été réalisées chez 4 d'entre eux et 4 d'entre eux ont été réalisés chez 3 malades ayant une éruption atypique.
Résultats: 1) Il y avait 12 adultes d'âge moyen 32 ans (18 à 70 ans) et 3 enfants d'âge moyen 3 ans. 2) Dans les groupes 1) ou 2) des CDC, 2 dans le groupe IV-C2, et 8 SIDA. Un malade a eu une lésion varicelleuse 31 mois et un autre 3 mois auparavant. Un contact varicelleux a été retrouvé chez 6 malades. Un malade, HIV+ asymptomatique, a fait une varicelle éliminante et est décédé d'une complication intracérébrale disséminée malgré l'aciclovir. Trois SIDA ont fait une éruption atypique avec une dissémination chronique contenant le VZV. Un malade a été traité par vidarabine et 11 par aciclovir i.v. Un SIDA a fait 3 recrudescences de varicelle avec des lésions atypiques malgré l'aciclovir.
Conclusion: La varicelle des sujets HIV+ peut être récurrente et se complique par des lésions atypiques. Le risque de formes mortelles justifie l'aciclovir i.v.

M.B.P.176 PROBABILITY OF DEVELOPING AIDS IN HIV-INFECTED PATIENTS WITH MOCOUTANEOUS LESIONS.

Colmenero Benito, J.; Nolasco, J.; Paganola, A.; Pallares, J.; Gudiol, F.
Hospital de Bellvitge, University of Barcelona, Barcelona, Spain.

Objective: To study the role of mucocutaneous lesions (MCL) as a predictor of AIDS in HIV-infected pts.
Patients and methods: Two hundred thirty nine HIV-positive pts without AIDS were followed during a mean of 13 months (1-81). The follow up period began when HIV antibodies were detected in non MCL-group or when MCL were observed in MCL-group, and finished with last visit made before December 88 or with the development of AIDS. MCL were diagnosed using clinical, histological and/or microbiological criteria.

Results: Eighty nine pts (27%) had one or more MCL (34/150 [54%] drug addicts 15/70 (51%) herpesvirus, 4/15 (27%) herpesvirus, 6/63 (10%) candida and 12 of 88 with MCL developed AIDS. MCL were oral thrush(4 pts), hairy leukoplakia(4), seborrheic dermatitis(3), herpes simplex(2) and staphy(3), folliculitis(1) and oral ulcers(1).

The Kaplan Meier survival method shows a percentage of free-AIDS pts at 20 months of 45% (95% confidence interval 38 to 54) in those with MCL comparing with 98% (95% confidence interval 92 to 114) in those without MCL (p<0.0001).

Conclusion: Our findings show that the presence of MCL in HIV-positive pts may indicate an increased risk of developing AIDS in the following months, although some of these lesions may have a different role as a predictor of AIDS. These pts may be considered for antiviral therapy.

M.B.P.178 HYPERKERATOTIC DISSEMINATED HERPES ZOSTER IN PROLONGED AIDS
Alan M. Seiner, M.D.; V.S. Rappaport, M.D.; J. Orens, M.D.; R. Heller, P.D. & University Clinic, Medical Center
Cincinnati, Ohio; U.S.A.

Unusual infectious diseases as well as unusual presentations of common infectious diseases have frequently been reported in patients with AIDS.

We report two cases of an unusual presentation of a varicella zoster virus infection in prolonged AIDS.

These hyperkeratotic, crusted skin nodules developed after the generalization of typical herpes zoster and progressed despite oral and intravenous acyclovir. Both patients had secondary *Candida albicans* infections of the crusted lesions and evidence of atypical Mycobacterial infection. One patient had cultures of blood and skin positive for *Mycobacterium intracellulare*. Of interest, both patients ultimately developed a verrucous squamocarcinoma (confirmed by clinical presentation and DNA).

We believe that our patients represent a presentation of disseminated herpes zoster unique to the AIDS patient that will be encountered more frequently in the future. The unrelenting, disfiguring nature of this disease as well as its apparent unresponsiveness to Acyclovir is of particular concern. One of the patients succumbed to his squamocarcinoma while the other developed it during a worsening of his skin lesions. This clinical picture may be a harbinger of a rapidly fatal outcome.

M.B.P.180 "NON-INFECTIOUS" DERMATOSES: CORRELATION WITH CD 4⁺ -LIMPHOCYTES AND STAGE OF HIV-INFECTION

Orbomorf, Falk, Schöfer, R. and Hillbrand, K.
Klinische J.V. der Universität, Dept. of Dermatology, Frankfurt, FRG.

Objective: To investigate whether other dermatoses, regarded as "non-infectious" or not, allow a clinical evaluation of the stage of HIV-infection.
Methods: Over a 2-year period, 267 HIV-infected patients (254 male, 13 female) were examined 12 times on an average. At first manifestation of a skin disorder, stage of HIV-infection and CD counts were recorded.

Results: On entry of the study the mean CD 4-count was 407/ml.

	CD 4						
	10 ⁶ /l						
Seb. dermatit.	17 (1)	21 (8)	30 (23)	40 (34)	29 (78)	340	
Pruritus	6 (1)	13 (7)	34 (80)	32 (78)	17 (72)	372	
Herpesvirus	11 (2)	13 (11)	26 (20)	34 (28)	24 (63)	264	
Rhinitis-Sinusitis			22 (48)	17 (46)	126		

(SEB. dermatit. stage; Seb. dermatit. "Seborrheic dermatitis")

13 patients (4.9%) had lesions typical of psoriasis vulgaris. On progression of the disease in 179 cases CD counts were lower than 200/ml.
Conclusion: "Non-infectious" dermatoses were more frequent and severe in advanced stages of HIV-infection and increased with decreasing CD counts. The results were related to clinical signs of cellular immunodeficiency indicating the risk of the individual for severe opportunistic infections.

Section d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.181

MANIFESTATIONS CUTANÉES ET VIMÉROLOGIQUES CHEZ LES MALADES INDIQUÉS PAR LE VIH EN CÔTE D'IVOIRE FRANÇAISE

Centre Hospitalier de Cayenne, Cayenne, Guyane Française.
Centre Hospitalier de Saint-Maurice, Saint-Maurice, France.
 130 cas de S.I.D.A. ont été rapportés de 1980 à 1986 dans une population de moins de 100.000 habitants incluant 20.000 immigrants haïtiens et un petit nombre de prostituées de Banto-Doungou.
 Les principaux modes de transmission du VIH sont de type hétérosexuel (87,6%), et maternel/fœtal (10,7%).

Un seul cas a été constaté chez un homosexuel (0,78%) et il était porteur d'un sarcome de Kaposi. Un autre cas a été constaté chez un homme hétérosexuel ; il cas sur le 130 est un taux très bas pour le **SARCOME DE KAPOSI**. L'infection acquise le plus fréquemment rencontrée est le **CHANDRIER** et l'infection causée le **PRURIT**; cette manifestation est le meilleur signe d'orientation vers le test sérologique et se doit pas être confondue avec la gale chez l'enfant.

L'HERPÈS ZOSTER, le **SYPHILIS** et les infections à **PAPILLOME VIRALES** ont une incidence élevée, une évolution sévère, mais l'herpès et la zone peuvent être traités par l'Acyclovir.

La **TRICHOMONOSE** est fréquemment observée et son rôle pour la transmission du VIH de la femme à l'homme n'est pas encore très important, le parasite obtenu en Espagne récemment est le plus préjudiciable du séduis.
 3 cas de **CONDUITES** doivent être mentionnés en raison de l'épidémiologie par contact anales ainsi ; la faible agressivité de l'**Epithéliobacterium** **epithelialis** nécessite un défaut immunologique causé par être réellement pathogène. Une **LEPTE LEPROMATOSE** **incerta** a aussi été observée.

M.B.P.182

DERMATOLOGICAL MANIFESTATIONS AND HIV INFECTION

Hove, E. A. V., Williams, E. J., University of Limpopo, M.C., Germ. M., M. J. Dyer, J. S. Maitland, M. S. C. V.
 Graham's Bantu University Hospital - University of Limpopo (Grahamstown) - Beaufort

Objective: To analyse all dermatological manifestations among HIV infected patients.
Methods: We made a retrospective study of all dermatological lesions among patients attending our "AIDS" Clinic from November 1983 to August 1986. HIV infection was confirmed by ELISA. Informed immunodeficiency and/or immunological lesions. All immunologic lesions were confirmed by biopsy and/or culture when needed. Patients were evaluated for age, sex, time of onset of infection and site of infection; we did not evaluate treatment or response to treatment.

Results: We found dermatological manifestations in 227 patients (10,8%), 212 male (93,9%), 15 female (6,1%). Most of the patients concerned were true type of infection.

TYPE OF LESION	PATIENTS
Kaposi's sarcoma	48
Herpes zoster	47
Other herpes	28
Other fungal	47
Bacterial	31
Syphilis/dermatitis	56
Others	26

Conclusions:
 1) Dermatological manifestations are common among HIV infected patients.
 2) Skin biopsy illustrates a significant diagnosis of HIV infection by the skin.
 3) Immunologic manifestations are common among HIV infected patients.

M.B.P.183

MANIFESTATIONS CUTANÉES-MUQUEUSES DU SIDA AFRICAIN

Centre Hospitalier de Dakar, Dakar, Sénégal.
Dr. Ball M.D., Banga E. J., Faly/Mao A.A.,* Faliel-Damouche K.* et al.***

C.H.U de Dakar, *Centre des Maladies Infectieuses ; **Service de Dermatologie ; ***Institut d'Odontostomatologie de Dakar, Dakar, Sénégal.

Objective: Décrire les manifestations cutanéomuqueuses observées chez le SIDA Africain atteint de SIDA (HIV-1, HIV-2).

Methods: Etude rétrospective des dossiers de maladies hospitalières dans le Service de Pathologie Infectieuse. Leur suivi a été fait en collaboration avec un dermatologue du C.H.U. Une iconographie a été établie.

Results: Sur 73 malades atteints de SIDA, 61 ont présenté des manifestations cutanéomuqueuses (83,56) comprises, 16,45 muqueuses et 70% anales. Les candidoses bucco-pharyngées sont les plus fréquemment observées (70,49%). Le sarcome de Kaposi est rare (4,93%). Les autres manifestations sont retrouvées à des taux variables.

Conclusion: Dans notre étude, nous confirmons la rareté du Kaposi SIDA en Afrique mais retrouvons les manifestations classiquement décrites.

M.B.P.184

PRIMARY HIV-1 INFECTION WITH VIRUS DEMONSTRATED IN HISTIOCYTES OF SKIN RASH

Waller, K. J., Oliver, L. J. and Gorman, S.*****

Hospital and Medical Center, *Foundation for Research on Sexually Transmitted Diseases, New York, NY, USA and **New York City Department of Health, New York, NY, USA.

Objective: To describe a severe case of primary HIV-1 infection.

Methods: The patient is a 22 year old homosexual male who came to New York City from Detroit, Michigan in late June 1988. Upon arriving, he had "monos" and with older homosexual male for several weeks. Approximately 2 weeks later, he had onset of symptoms including headache, neck pain, profound weakness, and aversion to light and sound, with subsequent development of a bright red skin rash on the digits and volar surfaces of the arms, demonstrating Koebner's phenomenon. Sera were collected within 2 days of onset of symptoms, and repeat sera and biopsy of the skin rash taken 7 and 3 weeks later.

Results: The headache persisted 9 days, while the skin rash faded gradually over 7 weeks. The initial sera tested negative for antibodies by both ELISA and Western Blot. The repeat sera taken 16 days later was positive for antibodies by both ELISA and Western Blot. Both the initial and repeat sera were negative by the HIV p24 core antigen ELISA test. The HAE skin biopsy showed a leukocytoclastic vasculitis. Electron microscopy showed HIV-1 virus particles within the cytoplasm of the histiocyte. White blood counts were as low as 3,000, and at the time of the biopsy, T4 cell count was 656, and T8 count was 815.

Conclusion: Primary HIV-1 infection may be severe with symptoms lasting a month. Presence of a skin rash with a mono-like illness should indicate the need for HIV testing in order to make an early diagnosis, creating the opportunity of beginning medical therapy to possibly delay progression of the disease.

M.B.P.185

DERMATOLOGICAL MANIFESTATIONS RELATED TO AIDS IN SENEGAL

Senegal, M. Koyada, L. Ilectchi, B. Di Costanzo, A. J. Georges, J. Testas, M. N. Vohlon
 1 National Hospital Center, BP 943, Bangui, Central African Republic
 2 Pasteur Institute, BP 923, Bangui, Central African Republic.

Objective: To describe and evaluate the frequency of dermatological manifestations in African patients with AIDS.

Methods: One hundred (100) Senegalese patients at the National Hospital Center, Bangui, were chosen according to the WHO/Bangui clinical definition of AIDS and were confirmed to be HIV positive by western blot. Patients were given dermatological examination. Kaposi's sarcomas were confirmed by biopsy, and necrosis by fungal culture.

Results: Pruritic lesions were the most frequent symptom in 27/110 patients, associated in 26/27 cases with specific dermatitis. Generalized pruritic eruption with purpura was seen in 22/27 cases. Kaposi's sarcomas (nodular and papular varieties mainly) in 14/110 patients. The leading viral or generalized herpes infection was HIV with atypical herpes (herpes zoster nodules and infection was **Herpes zoster**). All patients showed mucocutaneous herpes zoster infection. Oral candidiasis was found in 26/110 patients while 26/110 showed.

Conclusions: In this series, dermatological manifestations were detected in the half (52%) of African patients with AIDS. These patients are more likely to present with varicella zoster/mucocutaneous lesions than AIDS patients in Western countries.

M.B.P.186

BASEL CELL CARCINOMA IN HIV DISEASE

Lee, J. J., Barnett, J.*****
 Department of Medicine, University of Wisconsin Medical School (Milwaukee Clinical Campus), Milwaukee, WI, USA, **Department of Surgery, University of Wisconsin Medical School, Madison, WI, USA

Objective: To describe an unusually high incidence and atypical presentation of basal cell carcinoma (BCC) in HIV infected men.

Methods: Cases of BCC in HIV infected patients (total) were collected from local practices and from 2 dermatologic referral practices. **Results:** 6 pts with 14 BCC were seen, all saw white males (1 AIDS, 3 BCC, 1 pre-AIDS), 1 high risk, mean age 48 (range 28-65), 4 pts were from a group of 111 HIV infected males followed for 81-33 years (mean 14), 12/14 BCC in this group. 3 facial/11 truncal BCC (2/7 ratios); 8 extracted for size and latitude=82. One pt developed 8 truncal lesions over 3 years. 8 pts experienced as multiple synchronous BCC (BCC expected) 2 pts had small surface lesions but deep tissue invasion. 3 pts had MPU lesions (oral condylomata, parotid condylomata, facial warts) and 1 had molluscum. All were treated by primary excision. 3 also had Mohs chemotherapy. No metastatic or locally destructive lesions have occurred. 82 annual incidence of BCC among white males in the HIV infected group vs 188 expected for age and latitude; 6% annual incidence of truncal lesions in 188 expected. **Conclusion:** BCC may occur frequently in some HIV infected groups, may present atypically, and should be looked for and treated aggressively. Cutaneous such as MPU may be involved.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.187 PROCRISIS IN HIV INFECTION: CLINIC, HISTOLOGY AND HLA TISSUE TYPING

Maximilian, S. Wallman, D.J. Landthaler, M.J. Braun-Falco, D.

Dermatological Department of Ludwig-Maximilians-University, Munich, FRG.

Abstract: To determine differences between procrisis manifesting before HIV infection (group I) and procrisis occurring after HIV infection (group II), 160 patients in a study 4.5 % (16/328) of patients suffering from procrisis vulgaris were divided into two groups and clinic, therapy, histology and human lymphocyte antigens (HLA) tissue typing were evaluated. 86 patients were affected in 3/5 of group I patients and 74 belonging to group II. All patients - except one group II - showed typical clinical procrisis. Nail deformities were seen in 60 % of group I and 37.5 % of group II. In three patients treated with sidonipine quick improvement of cutaneous lesions could be seen. Histology was typical for procrisis vulgaris in 2/3 biopsies of group I and 9/12 of group II. HLA tissue typing showed that HLA-Dw6, a sign of hereditary procrisis with early onset, was found in 3/3 patients group I but only 2/4 group II. **Conclusions:** Procrisis in HIV infection even without family history shows typical clinical and histological features. HLA-typing seems to be different in the two groups. HIV infection may be an endogenous stimulant leading to provocation or exacerbation of procrisis vulgaris.

M.B.P.188 LES MANIFESTATIONS CUTANÉES DE L'INFECTION AU HIV AU SENEGAL.

MARILLIAMA, FIDJALE et NGORBO, G.
Hôpital Universitaire, Niakhar, SENEGAL.

Plusieurs manifestations dermatologiques sont actuellement associées à l'infection au HIV.

Nous rapportons les résultats de la séroprévalence à l'ELISA/HIV parmi les patients adultes consultant le service de Dermatologie-Vénérologie de l'Hôpital Universitaire de Niakhar-Senegal de 1985 à 1986.

Sur 543 patients testés, 752 ont été séropositifs à l'ELISA. Le taux de séroprévalence relativement élevé a été observé parmi les patients souffrant des dermatoses suivantes : Zona (881=200), prurigo (881=107), dermatite séborrhéique (891=37), dermatose papuleuse prurigineuse adénolésite (911=13), "maladies contagieuses" (871=24), sarcome de Kaposi avancé (901=15), herpes circiné (901=1), névrome géant (891=30), condylomes acuminés (711=78), furoncles (711=31), prurit généralisé (901=19), urticaire (911=30).

Toutes ces dermatoses bénignes pour la plupart devaient plus souvent quand elles sont associées à l'infection au HIV. 2 ou 3 de ces dermatoses ont été associées chez 120 (28%) malades.

41,62% des patients séropositifs présentent des manifestations cliniques uniquement dermatologiques et seuls 60 (14%) malades répondent à la définition clinique de l'OMS du cas de SIDA. Ces manifestations cutanées constituent donc des manifestations précoces du SIDA.

Manifestations cliniques Clinical Manifestations

M.B.P.189 NAIL DISORDERS IN ZIDOVUDINE TREATED AIDS PATIENTS

Dea, P.J. Fallon, F.R. Fried, P.J. Brennan, A.J. Deaconson, Frederick P.J. Jones, J.M. O'Connell, M.C. New York Medical College Westchester Hospital Center, New York, New York, U.S.A.

Objective: Define the frequency and parameters of nail dystrophies in AIDS patients on Zidovudine.

Methods: 38 patients with AIDS or ARC on Zidovudine therapy (AZT) for a mean of 8 months (1-22 month range) returned to be evaluated for the development of nail dystrophies. A group of 38 AIDS patients not on AZT and a group of 38 normal patients served as controls.

Results: History of these 38 AIDS developed progressive nail dystrophies starting on average between 4-6 weeks after initiation of AZT therapy, near development (onset) lesions had transverse bands and generalized nail dystrophies were also seen. Color varied from shades of blue to brownish. The "Hamman" sign developed distally in 11/16 (68%) of patients. Pigment initially appeared at the base of the nail and moved distally. Small

dystrophies also occurred and followed after finger nail dystrophies. No other areas of abnormal pigmentation nor hyperkeratization was noted. Dystrophies were not associated with sun, having AIDS or ARC, other medications used, nor risk factors for AIDS. Black patients were twice as likely to develop dystrophies 6/11 (55%) vs 10/19 (53%) (p<0.500). Sixty three percent (40/63) (63%) (38%) or (38%) (38%) - low dark almost control patients had faint longitudinal brown all streaks of long duration consistent with normal pigmentation variation in these individuals. This contrasted greatly with the unusual colors and patterns seen in AZT treated patients.

Conclusion: Progressive streaking patients with AZT need to be aware of this high frequency of nail dystrophies especially in dark skinned individuals and inform their patients of its possible occurrence in order to facilitate compliance.

M.B.P.190 LIPOSOME ENCAPSULATION FACILITATES ENHANCED KILLING EFFECT OF AMBICAN ON MYCOBACTERIUM AVIUM COMPLEX (MAC) IN SERUM

Patilings R.K., Gangadhara K., Kesavulu, L., Goldstein, J., Debs, R.L., and Mangione, J.F. National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado and *Cancer Research Center, University of California, San Francisco, California, U.S.A.

We demonstrated that amikacin is effective in eliminating *Mycobacterium avium* complex (MAC) from beige mice, challenged intravenously with virulent MAC. However, high dose (50 mg/kg) given daily 5 days a week for 8 weeks is needed for this action. When encapsulated in liposomes consisting of phosphatidyl glycerophosphatidyl choline-cholesterol (1:1 molar ratio), one-tenth of the dose, given in 3 or 4 injections, amikacin effected dramatic reduction in mortality and the number of colony forming units (CFU) of MAC from visceral organs. The amount of drug given via liposome formulation is a fraction of that given by the standard conventional treatment for the entire period. Thus the entrapment effect per unit dose of drug seen in each tissue is several times more with liposome encapsulation than with the free form. Liposome encapsulated amikacin caused high antimicrobial activity against MAC inside macrophages and J-774A cell lines, while the free compound showed negligible activity.

M.B.P.191 HUMAN PAPILLOMA VIRUS (HPV) IN ANAL Bowen'S DISEASE OF HOMOSEXUAL MEN

Lawrence G. Cohen, M.D., Department of Pathology, Lenox Hill Hospital, New York, N.Y., U.S.A.

The incidence of anal carcinoma and lymphoma, uncommon tumors in the general population, are increased in homosexual men. A 5-year review of the anal patients, revealed a series of 40 condylomata (II), 38 cases of squamous cell carcinoma in situ (Bowen's disease)(II) and 15 cases of invasive squamous cell carcinoma (III), between 1980 and 1985.

Confirmed homosexuality was 84%, 62% and 57% and the average age of patients was 32, 37.5 and 49.5 years in groups I, II and III, respectively. AIDS was associated in 16%, 42 and 37.5% of cases. Condyloma was consistent with 52% of the carcinoma in situ and with 32.5% of the invasive carcinomas. Karyotypic atypia was present in 72% of carcinoma in situ. HPV antigens were detected by immunoperoxidase staining in 3 of 13 and by in situ hybridization in 4 of 13 cases of anal Bowen's disease in homosexual men.

58% of HPV type 6/11 was detected in 3 cases and HPV type 16 in 4 cases, one lesion harboring both types 6/11 and 16. HIV antibodies and reversed T3/T4 cell ratios were present in most patients tested. Squamous cell carcinoma in situ generally showed the features of Bowen's disease. The occurrence of anal Bowen's disease in young homosexual males, some HIV positive, and the frequent detection of HPV, suggest an etiologic relationship between HPV and HIV.

M.B.P.192 THREE YEARS OF EVALUATION OF THE CLINICAL CASE DEFINITION OF AIDS IN CENTRAL AFRICA.

A.J. Burgess, J. L. Bhat, J.L. Lombard, M.C. Georges-Courbot, M.D. Whitton, P.R.V. Martin.

1) Institut Pasteur BP 956 BANOU - C.A.R. 2) Centre National Hospitalier BP 956 BANOU - C.A.R.

Objective: To evaluate and try to improve the WHO clinical case definition of AIDS proposed at Banou in 1985. **Methods:** We have applied the criteria of both the clinical case definition of Banou and CDC's one and two definitions to 100 patients hospitalized and distributed into two cohorts of people fitting with each definition. **Results:** Using 3 different "scoring" systems for that evaluation there is not a difference between the results. Among a population of 100 blood AIDS defined on the basis of the WHO workshop, the empirical scoring system one of us previously proposed in 1985 has a predictive value of 90% for affirming AIDS.

The usefulness of simple serologic tests such as ELISA is demonstrated among patients fitting with clinical case definition, the presence of anti HIV antibodies (ELISA) increases the positive predictive value (98.5%). We were also able to emphasize that serologic involvement (e.g. Peripheral Blood Cell Counts, coagul serological assays) never taken into account by the Banou definition is very common and often necessary. **Conclusion:** Developing simple serologic tests deeply facilitates the diagnosis in presence of patients recruited on the basis of clinical symptoms only, and in front of atypical clinical symptoms particularly in patients with neurologic disorders.

Session 4/1985 Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P. 199 HIV INFECTION NATURAL HISTORY. "PERSISTENT" AND "ACTIVE" FORMS DO EXIST AND ARE CLINICALLY DISTINGUISHABLE.

Reinhold, Janssens, R. De Witte, J. A. Bax, G. A. Van, G. A. Van, G. A. Van, G. A. Van.
Centre for the Study of AIDS & Acute Infectious Diseases, U.S. Health Res. Inst., Bonn, West Germany.

Objective: To describe natural history of HIV infection and classify HIV seropositive patients with clinical reliability.

Methods: We included in our trial all HIV-seropositive patients who completed at least one year of follow-up. We considered the occurrence, in the first year, of various clinical and laboratory findings (weight loss, fever, herpes zoster, HIV seroconversion, infectious mononucleosis, neurological symptoms; final Candidaemia, Kaposi's, Cervix adenoma, Chlamydiae, enteric S.S. IgG, SPO 2000 spg/ml, IgM spg, Tuberculosis; PCR 2000/dm³). For each finding we gave the patient a "score" of 1. At the end of the first year of follow-up we considered, for each patient, a "Final Score". Following the main of the infection we classified the patients as having "Persistent Clinical Infection" (Score at least "Active" score) or "Inactive Clinical Infection".

Results: 100 patients (103 T84, 23 Hanes, and 10 Hanes-1) were evaluated. 106 patients received 300 mg zalcitabine from 2 to 2 "Persistent" infection; 23 received 300 mg zalcitabine from 4 to 2 "Inactive" infection. Only 17/106 patients were HIV-1 infection cases follow-up period: 21 months (received from 100 to 100 T84) or 12 months (received from 100 to 100 Hanes-1).

Conclusions: Our data show an overall clustering of HIV-infected patients in two groups. Some patients progress very slowly and are "inactive" at all. Others are very quickly through various stages of the illness and reach full-blown AIDS in a short period of time. Clinical manifestations occurring in the first year of the follow-up are helpful to classify the patients in "Persistent" or "Active" form. These findings have great prognostic and therapeutic implications.

M.B.P. 201 CLINICAL AND AUTOPSY FINDINGS IN HIV-1 SEROPosITIVE PATIENTS.

Affens, Behal, J. Green, V. J. Olopoko, L. L. Barnes, J. J. Senterre, G. A. Van, G. A. Van, G. A. Van, G. A. Van.
Howard University Hospital, Washington, DC, U.S.A. *National Cancer Institute, Bethesda, Maryland, U.S.A.

Objective: To determine the usefulness of the autopsy in HIV-1 seropositive patients by comparison of discrepancies between the pre-mortem clinical impressions, the clinical cause of death and the autopsy findings.

Methods: Cases for review were obtained from the files of the pathology department of Howard University Medical School. From 1983 through 1988, fifty cases were identified as being seropositive by ELISA and Western blot assays. Clinical histories including pre-mortem diagnoses were available as abstracts from the medical record in the autopsy protocols.

Results: Of the 50 cases reviewed, 41 met the CDC criteria of AIDS, 25 pneumonia and 16 at autopsy. There were 37 males and 12 females. Mean age was 35.4 years. Risk factors included homosexuality in 22 cases, intravenous drug use (IVDU) in 15, STDs and homosexuality in 4, blood transfusion in 4 and unknown risk factors in 1 case. The lung was involved in diseases in 37/41 (90.2%) AIDS and 7/7 (100%) non-AIDS cases. Diseases diagnosed only at autopsy included PCP (12/22), CMV (9/9), ES (5/7), disseminated HAI (9/13) and bacteremia (7/21). Pathological cause of death correlated with cause of death on the death certificate in 38, 35 and 44.4% of AIDS and non-AIDS cases respectively. **Conclusions:** The lung was found to be the organ most frequently involved in disease at autopsy. The autopsy diagnosed a significant number (61.2%) of unexpected and undiagnosed AIDS diseases. Autopsy findings modified the clinical impression of the cause of death in 44.0% of all cases. These findings suggest that the autopsy plays a significant role in quality assurance of diagnoses in HIV-infected patients, both AIDS and non-AIDS.

M.B.P. 202 RECURRENT MAXILLARY SINUSITIS IN AIDS PATIENTS.

Redding, Hout, J. J. A. M. van, G. A. Van, G. A. Van, G. A. Van.
Academic Medical Center, University of Amsterdam, the Netherlands.

Objective: The treatment of recurrent maxillary sinusitis in AIDS patients.

Methods: From 1983 until now 311 AIDS-patients have been treated in our hospital. Of this population 112 patients had recurrent maxillary sinusitis one or more times. The diagnosis was made by clinical examination, radiography, and bacteriological culture. Remarkable was the high incidence of Staphylococcus aureus as cause of the infection. When a patient had a maxillary sinusitis for the first time he was treated with amoxicillin, sulfamethoxazole and trimethoprim. Despite this conventional therapy the recurrence rate was high in 28 (32%) of the total population. To avoid repeated treatment with antibiotics we decided to operate patients when they had a maxillary sinusitis for the third time. We made a rhinoscopic approach on both sides, using the technique as has been described by Dr. Butler. The operation microscope was used to have a good view of the operation-field. The sinuses were made large by inferior turbinate. Owing to this a good ventilation of the maxillary sinus has been achieved.

Results: Until now we have operated 14 patients. The follow up period was 4 to 20 months. We have not seen a recurrence. The patient has to stay only 3 days in hospital, the postoperative recovery is fast, with only less discomfort for the patient.

Conclusions: Surgery may be a superior to antibiotics in the treatment of recurrent maxillary sinusitis in AIDS-patients.

M.B.P. 200 HIV-2 IN ENGLAND.

Ayanian, J. J., Maguire, J. J., Kanki, P. H., Baker, R. G., Mayer, R. M., Essex, M. T., Harvard Medical School, Boston, MA; Harvard School of Public Health, Boston, MA, USA; *Brown University, Providence, RI, USA.

Objective: To survey selected populations in New England for exposure to HIV-2. **Methods:** Individuals at risk for HIV-1 infection (men who have sex with African descent (n=128), individual sex partners (n=128), Western blot testing for HIV-1 (n=111), and individuals suffering from AIDS syndromes without definite HIV-1 serology (n=11) were surveyed for HIV-2-specific antibodies.

Results: One individual was seropositive for HIV-2-specific antibodies. This one individual was a 20 year old male originally from the West African region with seven years of extensive travel prior to residing in the United States for the past 7 years. He presented in early 1988 with a 4 month history of anorexia, nausea, vomiting, and watery diarrhea. On physical exam, he was afebrile, had no lymphadenopathy, abdominal tenderness nor occult blood in his stool. Microscopic examination of his stool revealed trophozoites (ball ovals). The patient's symptoms resolved on oral trimethoprim-sulfamethoxazole therapy, but returned 6 months later again with increasing weight loss. This was successfully treated with pyriminone. A laboratory examination revealed a persistently low absolute T cell count. Serologic evaluation indicated a negative HIV-1 Western blot and RIPA for HIV-1 and the same assay showing strong reactivity for HIV-2 envelope and transmembrane antigens. His RFLP-PCR culture revealed a transmissible isolate of 4 weeks and subsequent passage of the isolated virus into continuous cell lines has revealed viral proteins consistent with other HIV-2 isolates by Western blot and RIPA.

CONCLUSIONS: 1) Evaluation of blood samples from selected individuals in New England has identified one patient with an apparent immunodeficiency associated with HIV-2 exposure. Presumably the second case of HIV-2 infection in the United States. 2) In one instance the patient was exposed to HIV-2 in West Africa, the case reveals a fairly long latency period prior to his present health problems. 3) Our selected survey, as seen with other broader surveys, has shown that HIV-2 is extremely rare in the United States.

M.B.P. 202 PAIN IN PATIENTS WITH AIDS

Latovics, A., Lefkowitz, M., H. J. Senterre, G. A. Van, G. A. Van, G. A. Van, G. A. Van.
Pain Management Service, Department of Anesthesiology, State University of New York Health Science Center at Brooklyn, Brooklyn, NY, USA.

The alarming increase in the transmission of AIDS, as well as its poor prognosis, leaves a critical need to evaluate the presence of pain and its current management. A chart review study was therefore undertaken to evaluate these issues in a hospitalized AIDS population.

Ninety-six randomly selected charts of AIDS patients were reviewed in a systematic manner for the prescription of analgesic or psychologic medication, as well as the location and type of pain. Eighty-two patients were male (85%); mean age was 33.4 years; 44 patients (46%) were diagnosed with AIDS during the admission that was evaluated. The most common AIDS syndrome was Pneumocystis carinii pneumonia (37%). The second most common presenting symptom for this hospitalization was pain (26%).

Fifty-two of the 96 charts reviewed (54%) had at least one note of non-procedural pain or analgesic prescription. The most prevalent location of pain was musculoskeletal (22%). There was no significant relationship between intravenous drug abuse, specific AIDS syndromes, duration of illness, and the incidence of pain or pain medication prescription. Nearly one-third of patients with pain received codeine (31%), followed by acetaminophen (27%) and acetaminophen with codeine HCl (Percocet). In only seven instances but one, the scheduling was on an as-needed basis, rather than a fixed schedule.

This study suggests that pain is a major issue in AIDS patients that may be largely overlooked and not managed optimally. A methodology for the prospective evaluation of pain in AIDS patients as well as alternate pain management techniques are recommended.

Manifestations pulmonaires

Pulmonary Manifestations

M.B.P. 204 NONCARDIAC ANTIESTHESIOLOGIC INJECTIONS IN PATIENTS WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS).

Coste, Lencastre, Pulgosa, P. J. Woodard, D. Berk, A. Fiala, M. Lynch, R.
Sections in Infectious Diseases and Thoracic Surgery, Eisenhower Medical Center, Rancho Mirage, CA, and Section of Medical Oncology, Harbor-UCLA Medical Center, Los Angeles, CA, USA.

Aerobic colonization such as mycobacteria, rhodococcus, and nocardia frequently cause disease in immunosuppressed hosts including patients with AIDS. Although only a half dozen individuals with nocardiasis and AIDS have been detailed in the literature, we have recently treated 4 patients with pulmonary nocardiasis, 3 of whom had brain involvement. In 3 the diagnosis was only established by invasive techniques (bronchoscopy, closed and open lung biopsy). Chest x-rays revealed lobar infiltrates which showed intense uptake with gallium⁶⁷, although antimicrobial brain abscesses in 2 were documented by the same biopsy study. Three of 4 individuals colonized by treated with sulfonamides due to allergy or severe pancytopenia. All received multi-drug therapy with isoniazid, rifampin, trimethoprim and isopropyl to which the organism showed marked in vitro sensitivity.

The patients recovered fully on this regimen and improved. We conclude that invasive studies are needed to establish a diagnosis of nocardiasis in patients with AIDS, and although multi-drug regimens are effective treatment in individuals unable to tolerate sulfonamides.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.205 PLEUROCENTESIS IN AIDS PATIENTS WITH

SCLEROTHORAX AND SPONTANEOUS PNEUMOTHORAX AND
Schulenburg S., and Quinn J. *Trinity New England Medical Center,
and *Lambert Shattuck Hospital, Boston, MA, USA.

Objective: Review the outcome of spontaneous pneumothorax in AIDS patients.
Methods: Retrospective review of known PTX cases in 2 institutions in 1988.
Results: Spontaneous pneumothorax is a recently recognized occurrence in patients with AIDS, having been noted during episodes of pneumocystis carinii pneumonia (PCP). Pleurocentesis for persistent air leaks has been performed successfully. We report the successful outcome of sclerotherapy (with tetracycline or talc) for persistent air leaks. Brief case outlines:

Case	Tissue	Active	Lesions	PTX	Sclerosis	Complications	Outcome
1	PCP	+	no	30 d.	TCM	wound infec ⁿ	resolut ⁿ
2	bronchitis	PCP	erythro	30 d.	TCM	wound sepsis	death
3	PCP, no PTX	prob.	PCP	25 d.	TCM, talc	none	resolut ⁿ
4	PCP, hemt.	pleural PCP	43 d.	no	multiple chest	alive with	resolut ⁿ
		pneumonia	bact. pneum.	02:138 d.	no	tubes	chest tube

Conclusion: All PTX were significant and required CT placement. PTX, sometimes recurrent, have been seen in AIDS patients with previous underlying lung disease, frequently prior episodes of PCP. Active lung disease was usually present. Aerosolized pentamidine prophylaxis was used in 3 of 4 patients. Healing of the PTX was prolonged. Tetracycline or talc pleural sclerotherapy was frequently successful and avoided pleurocentesis. Complications included chest tube site infections and consequent sepsis. Aggressive therapy of PTX with sclerotherapy is recommended.

M.B.P.207 PNEUMOTHORACES IN PATIENTS WITH AIDS

Schulenburg S., Teitel, S.E., Garvey, M., Dickmeyer, M.,
Bernhard, L., Golic, J.M., et al.
Memorial Sloan-Kettering Cancer Center (MSKCC), New York, New York, USA.

Objective: To describe the natural history and risk factors for a poor outcome in patients with AIDS who develop pneumothoraces.
Methods: Cases of pneumothorax (PTX) in patients with AIDS were reviewed and their medical histories were abstracted onto standardized forms. To maximize case finding, all patients with a discharge diagnosis of "PTX" from 1980 - 1988 at MSKCC were crosschecked with a hospital-based AIDS registry.
Results: Of 1120 patients with AIDS, at least 11 (1%) had a PTX and of these, 7 have had pneumothoraces in both lungs. Ten were male and 9 had concurrent pneumocystis carinii pneumonia (PCP). Eight (73%) patients had good outcomes (left the hospital); however, of these, 3 required sclerostosis and one required a thoracotomy. Three (27%) patients died. Those who died were more likely to have a history of previous non-infectious pulmonary disease (3/3 vs. 1/8; p=0.02), to have 2 pathogen isolated from their lung and appearing to cause infection during their PTX (3/3 vs. 0/8; p=0.06) or to be smokers (3/3 vs. 3/8; p=NS).
Conclusions: PTX in patients with AIDS appears associated with PCP. It has a high mortality and is associated with a high mortality. Risk factors for death include a history of non-infectious pulmonary disease and multiple pathogens isolated from and appearing to cause infection in the involved lung.

M.B.P.209 FATAL ADVERSE REACTION WITH INDUCED SPUTUM IN PATIENTS WITH PLEURAL EFFUSION.

Nelson, M.R., E. Smith-Da, B. Hawkins, D. Ozaibad, B.O.
St. Stephens Hospital, Fulham Road, London, England.

Objective: To report possible life threatening adverse reactions with sputum induction and for bronchoscopy in HIV patients with suspected Pneumocystis Carinii Pneumonia (PCP) and concurrent pleural effusions.
Methods: All patients with PCP and pleural effusion and for bronchoscopy for PCP over a six month period had a chest x-ray prior to and post investigation.

Results: Of 83 investigated patients, 28 had documented Kaposi's Sarcoma (KS) or lymphoma. 4 of these 28 had a pleural effusion. These 4 patients underwent sputum induction, followed by 2 who had bronchoscopy. All 4 patients had marked worsening of their pleural effusion with increasing dyspnea. Two of the patients died within 24 hours (4 and 16). Necropsy showed pulmonary KS with pleural involvement in one and pulmonary lymphoma in the other. The others responded initially to insertion of intercostal drains but died at 28 and 33 days from respiratory complications. No other patient with or without KS or lymphoma developed a pleural effusion following investigation. In none of the 4 patients was pneumocystis documented on sputum induction or BAL, or were KS seen.
Conclusion: Induced sputum may give rise to potentially life threatening pleural effusion in patients with minor effusion resulting from KS or lymphoma.

M.B.P.206 ROLE OF HIV INFECTION IN ALTERATION OF PULMONARY

FUNCTION IN INTRAVENOUS HEROIN ADDICTS (IHA)
Fargelli Balazs, Maria A. Genswein, G. Maria F. Saba, M. Adriano M. Falasone, Fratelli Hospital, Milan, Italy.

Objective: We studied a group of IHA with AIDS frequently develop interstitial lung disease. In IHA HIV infection could represent a cause of further pulmonary damage. We studied and patients (pts) to evaluate the role of HIV infection in alteration of respiratory function (RF).
Methods: RF tests, blood gas analysis and CD4 lymphocyte counts were performed in 37 IHA, with no pulmonary symptoms and normal chest x-rays, 20 male and 10 female, 12 HIV- and 21 HIV+, 4 belonging to group II of CDC classification system, 11 to group III and 4 to group IV. Results: Only CD4 expressed as percent of the predicted (74.6±11.5 vs. 56±4.7, p<0.001) and CD8 lymphocytes counts were performed in 23 IHA, with no pulmonary symptoms and normal chest x-rays, 12 HIV- and 11 HIV+, 4 belonging to group II of CDC classification. **Conclusions:** These data show that HIV had no significant reduction in CD4 in comparison to HIV- IHA. The absence of clinical symptoms and/or radiological abnormalities of pulmonary disease suggests a subclinical pulmonary infection or at least a milder HIV- IHA. Since CD4 abnormalities, that we mostly find in HIV- IHA, are present in the asymptomatic stages of the infection and are not related to CD4 lymphocytes reduction, we suggest that interstitial lung involvement can be due to a direct action of the virus rather than to a subclinical opportunistic infection.

M.B.P.208 SPONTANEOUS PNEUMOTHORAX IN AIDS PATIENTS ON PENTAMIDATE

AEROSOLIZED PREVENTION. G. Saba, S. Rossetti, M. Saba, M. Douglas, J. Vaccaro, M.D., Phillip P. Pierce, M.D. *Georgetown University Hospital and *George Washington University Hospital, Washington, DC, U.S.A.

Objective: Spontaneous pneumothorax (SP) is the most frequent pulmonary complication in AIDS. The development of spontaneous pneumothorax in a combination of PCP. In order to assess the risk of pentamidine prophylaxis, two groups were retrospectively examined. Group I consisted of 127 patients who received pentamidine prophylaxis (pentamidine 100 mg via "Respigard II" nebulizer system every other week). Group II was 35 patients who received parenteral (4 mg/kg monthly) prophylaxis. Both groups had similar demographic characteristics. In Group I there were 8 pneumothoraces while there were no pneumothoraces in Group II (Fisher's p=0.48). The duration of aerosolized prophylaxis ranged between 3 to 13 months. Bilateral pneumothoraces were present in 50%. The majority of the patients with pneumothorax had evidence of active PCP (75%) and cystic lung disease (62%). Chest tube evacuation was required in 75% and 38% of patients died of progressive respiratory failure.

In conclusion, our retrospective review shows no statistically significant increase in number of pneumothorax in AIDS patients receiving aerosolized pentamidine. The occurrence of pneumothorax in these patients represents poorly controlled infection rather than a direct effect of aerosolized pentamidine.

M.B.P.210 CELL DIFFERENTIALS IN BRONCHOALVEOLAR LAVAGE (BAL) AND TRANSBRONCHIAL LUNG BIOPSY (TBLB) FROM PATIENTS WITH

ADVANCED HIV INFECTION AND DIFFUSE PNEUMONIC INFILTRATES.
Musi, Michael L., Schneider, S.L., Grossbard, M., Falk, S.,
Malar, B.B., Miller-Spöck, J.,
Div. of Pulmonary and Infectious Dis., Dept. Internal Med. and **Dept. of Pathology, Hospital of J.V. Goethe-University, Frankfurt/F.R.G.

Objective of the study: To compare cell differentials in BAL with histologic findings we performed TBLB and BAL with 300 x NaCl concentration in 30 HIV patients with P. carinii pneumonia (PCP) and 60 HIV patients with other diffuse pulmonary infiltrates (144 male, 6 female, age: 38±10 years).
Methods: Cell differentials (lymph-BAL [L] and PM-BAL [P]) were performed on cytocentrifuge slides (Cyto Spin stains) of BAL. We counted 1000 cells. Biopsies were taken using fiberoptic guidance. The specimens were graded as showing accumulation of mononuclear cells (MM-C), widened alveolar walls (AW), alveolar exudate (EX), signs of CMV infection (CMV).
Results:

	N	MM-C	AW	EX	lymph-BAL	PM-BAL
PCP	90	36%	4%	84%	17±1%	9±1%
Non-PCP	60	4%	6%	7%	14±1%	9±1%

Neutrophils in BAL were related to alveolar exudate on TBLB and presence of P. carinii (ANOVA, p<0.01). No other relations between BAL and TBLB were found. We conclude that accumulation of mononuclear cells and widening of alveolar walls not related to PCP are frequent findings in patients with advanced HIV infection and diffuse pulmonary infiltrates. We suggest that they may reflect a "non-specific interstitial pneumonitis".

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.217 REACTIVATION OF ACUTE HEPATITIS B IN AIDS
Roberto Luzzati, G.D. Ferri, M.Malese, M. Rossi, P. Zucchinello* and D. Bassetti. Institute Infect. Diseases, Verona* Department Pathology, Verona, Italy.

Objective: To investigate the role of HIV on the outcome of HBV infection, we describe a reactivation of acute hepatitis B in a patient with AIDS.
Methods and Results: The patient was a 20 year old male, drug addict, HBe Ag, anti-HBe, HBe Ag and anti-HBe antibodies to the delta Ag were assayed by radioimmunoassay. Serum HBV DNA was detected by spot hybridization. In 1982 this patient had acute hepatitis B and appeared to recover. Fully clearing HBe Ag, HBe Ag and HBV DNA. The activities of his liver enzymes were persistently in normal range. He presented PGL and ARI, respectively in June 1986 and in January 1987. Full-blown AIDS (cerebral toxoplasmosis) developed in July 1987 and then the patient received long-term zidovudine and zalcitabine/prazidavine/trimethoprim therapy. In June 1988 acute hepatitis B reoccurred with AST 12000 U/l, clinical jaundice, progressive hepatic failure and death. Recovery of acute HBV infection including HBe Ag, HBe Ag and HBV DNA, reappeared while delta-Ag was persistently negative. The post-mortem liver biopsy was consistent with confluent hepatic necrosis.
Conclusion: Infection with another HBV subtype is unlikely. This pattern strongly suggests a late reactivation of HBV. Thus, although the virus is present it may not thought to be directly cytotoxic for liver cells, acute hepatitis B may still reappear in the course of AIDS.

M.B.P.219 CORRELATION BETWEEN HIV AND HBV INFECTIONS.
Stefano Alamanni, Maria M. Damore, A. Scafaro, C. Corti, G. University of Turin, Turin, Italy.

Objective: HIV and HBV infections: possible interactions.
Methods: 600 ANSIV (1974-76, 36,000/ml, 13,300/ml recipients, 10,000/ml, 13,300/ml) were tested for HBV-serum, immunological and clinical findings. 200 were followed up for 24 months (2-3), 10 had hepatic biopsy.
Results: 485 were positive for HBV-serum: 66 HBeAg (22.4%); 330 anti-HBe; and 63 only anti-HBe. 23% of the followed up anti-HBe and anti-HBe patients lost the positivity for HBeAg. 14 showed a primary HBsAg: 6 with clinical evidence of acute hepatitis (only 7 became anti-HBe). The hepatic biopsies revealed 6 CH3 and 30 CH4.
Conclusion: High prevalence of HBV-serum in ANSIV patients (in prevalence IMA). Frequently loss of HBeAg (especially in anti-HBe); transient reappearance of HBeAg in the ANSIV-carriers; reduced onset of anti-HBe and prevalence of HBeAg in primary HBV infection; positive markers of viral active replication in chronic hepatitis with low levels of viraemia and reduced histological injury in sequentially biopsied patients. HBV infection does not condition HIV infection in a significant way.
Acknowledgment: This work was supported by the "C. D'Agostini" Foundation.

M.B.P.221 INFLUENCE OF HIV INFECTION IN HEMITITIS BILIA CHRONICA CONDITIO.
Giuseppe Alamanni, Maria M. Damore, A. Scafaro, A. Pavesi, J.C. Castella, Immunology, Medicine, Infect. Diseases, Public Health, Turin, Italy.

HIV infection in very small way influences B cell chronic conditio. In the other hand, drug addiction is one of the most important way of transmission of the hepatitis B virus (HBV). For these reasons, the aim of the present work was to study the influence of anti-HIV positivity in HBV infection, as well as in the biochemical response of HBV and prevalence of HIV (HIV).
Forty three anti-HIV positive patients were included. Half of them were HBsAg (40%) and the rest referred to serological response (HBeAg, anti-HBe, HBsAb, anti-HBc, HBeAg, HBeAb, HBsAb, anti-HBc, HBeAg, HBeAb, HBsAb, anti-HBc).
HBsAg and anti-HBe were detected by radioimmunoassay. Serum HBeAg (HBeAg) was tested by immunoblot and anti-HBe was determined by indirect hybridization using a ³²P-HBeAg obtained from the PH820 vector.
Out of the 43 patients, 15 (35%) were anti-HIV positive (13 HBsAg and 2 anti-HBe). All of them were seropositive and 2 presented serum anti-HBe respect to the HBV markers. There were no differences between these subjects with or without HIV infection, neither in the presence of serum HBsAg (HBeAg vs HBeAb), respectively up to the IgG anti-HBe positivity (HBe vs anti-HBe, respectively). In contrast, anti-HBe was detected in 14/15 (93.3%) anti-HIV positive cases with anti-HBe and only in 14/28 (50.0%) anti-HIV negative cases (p < 0.01). The biochemical response of HBV and HIV (anti-HBe and anti-HBe positivity) was found in a significant higher percentage (p < 0.05) in those HIV-seropositive patients (32/43) than in the negative cases (10/28). The same occurred with the simultaneous presence of anti-HBe and anti-HBe (HBe vs anti-HBe) in the anti-HIV positive subjects as in the anti-HIV negative patients (p < 0.05).

In conclusion, anti-HBe was detected in a higher percentage among HBV carriers with HIV infection. Moreover, in these patients, the simultaneous HBsAg and HBV replication was more frequently observed. During the follow-up, it will be required the clinical evolution of both group of anti-HBe positive patients with and without HIV infection.

M.B.P.218 HIV INFECTION AND DELTA HEPATITIS IN INTRAVENOUS DRUG ADDICTS
Irene Balzar, G. Bhat, K. and Govindarajan, S.* SUNN-Health Science Center, Rockville, New York and *Sancho Los Angeles Medical Center, Downey, California, U.S.A.

The recently suggested close correlation between HIV and delta hepatitis virus (HIV) may merely reflect high double-exposure rates in promiscuous homosexuals.
Objective: To correlate delta markers with stage of HIV disease in intravenous drug addicts, IVDA.

Subjects: 819 (pre-1986) IVDA: 35 with AIDS, 30 HIV positive and 17 HIV negative.
Methods: HIV antibody measured by repeat ELISA testing (Abbott). Total anti-HIV (Abbott); IgG anti-HIV, IgM anti-HIV and delta antigen (RIA); HBeAg, anti-HBe and anti-HBe (Abbott RIA).

Results: 1) Seventeen subjects tested positive for anti-HIV by Abbott ELISA; 8/16 of the 17 were HBeAg positive. Only the six HBeAg positive subjects were IgM anti-HIV positive.
2) IgM anti-HIV was present in 2 of 17 (11.8%) HIV negative; 4 of 30 (13.3%) HIV positive, but none of 35 AIDS subjects (p < 0.005, Fisher's exact test); AIDS vs non-AIDS.

Conclusions: The data suggest a high false positive rate of anti-HIV in non-HIV positive sera with the ELISA technique and that anti-HIV production (IgM and IgG) may be lost in IVDA with AIDS.

M.B.P.220 MODULATION OF VIRAL HEPATITIS IN HIV-1 INFECTION
Rajesh K. Vohra, R. Nagar, Sunil Bhatnagar, K.M. and Hans G. Jürgens, Medizinische Klinik und Poliklinik der Johannes Gutenberg Universität Mainz, Mainz, Germany.

OBJECTIVE: To study the outcome of HBV infection in HIV-1 infected patients.
METHODS: In a group of 208 HIV-1 infected patients 216 (70%) had evidence of prior HBV infection. Monoclonal and in vivo assays comprise greater than 80%. The prevalence of chronic HBV carriers, as determined by HBeAg positivity for longer than 6 months among HIV-1 infected patients yielded in 43%.
RESULTS: Our data demonstrate low activity of SODT and SODT in patients coinfected with HIV-1 virus. Individuals suffering from chronic active hepatitis, asymptomatic HIV-1 infection and 14 months later 400 were significantly increase of HBV-DNA in contrast to asymptomatic HIV-1 and HBV infected individuals. On the other hand HIV infected patients tend to have a mild course of chronic hepatitis.

CONCLUSION: Our data show evidence that suppression of cellular immunological reactions had beneficial effects on the clinical and histological outcomes of HBV infection. However, there are no data showing any spontaneous clearance of HBV in AIDS patients. One might therefore expect that there is a correlation between markers of cellular immunity like T4 and T8 positive cells in HIV-1 infected patients and the clinical course of chronic HBV infection.

M.B.P.222 THE EFFECT OF HIV ON CHRONIC HEPATITIS B: A STUDY OF 130 HIV POSITIVE MEN Balazs Bal, Balazs Bal, University of Sydney, Sydney, New South Wales, Australia.

Objective: To determine the influence of concurrent HIV infection on clinical and biochemical markers of HBV infection.
Methods: Serum markers of HBV replication (HBeAg and HBV-DNA) and disease activity (alanine transaminase, ALT) were analyzed for 150 male homosexual HBV carriers, 82 (54.6%) of whom tested positive for antibodies to HIV.

Results: Subjects positive for HIV antibody were more likely to express HBeAg (62 of 80 cases) and HBV-DNA (52 of 87) in their sera than HIV seronegatives (35 of 67 (p<0.001) and 35 of 70 (p<0.005) respectively). The degree of immune suppression however, did not seem to affect the influence of HIV on HBeAg/HBV-DNA expression. In HBeAg seropositive subjects, concurrent HIV infection was associated with lower serum alanine transaminase (ALT) levels (p<0.005). This effect increased relative to the degree of immune suppression as determined by diminished CD4 lymphocyte counts. Conversely, in patients not expressing HBeAg in serum there was a weak trend (p<0.100) towards higher ALT levels with concurrent HIV.
Conclusion: This study suggests that whilst chronic hepatitis B is less severe when accompanied by HIV infection, greater viral replication may make it more contagious and resistant to antiviral therapy. These data support an immune mediated pathogenesis for hepatitis B and have implications for its control.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.223

LIVER DISEASE IN PATIENTS WITH AIDS
BRANDO-MILLO C.*, SILVA, N.A.*; CORREIA LEM, H.B.*; BRABELO, A.C.*; OLIVEIRA, C.T.*; OLIVEIRA, A.C.*; OLIVEIRA, H.B.*; OLIVEIRA, H.B.*
 *Hospital Federal e Univer. - Universidade do Rio de Janeiro, Brazil
 ** Centro de Hematologia Santa Catarina - Rio de Janeiro, Brazil

The evaluation of clinical, biochemical, serological and morphological data of liver involvement in high risk groups patients with was the aim of this work. Our purpose was to determine the spectrum of liver diseases in AIDS and the clinic-morphological correlation in order to ascertain if any clinical or pathologic feature was characteristic of AIDS.

Material: We have evaluated 81 patients with AIDS, being 20 homosexual (24.4%) and 61 seropositive (75.6%) men.

Methods: We studied hepatitis B virus (HBV) serum markers by commercial kits for the detection of HBsAg, anti-HBsAg, anti-HBeAg, HBeAg and anti-HBeAg. Liver function tests including aminotransferase, total bilirubin, alkaline phosphatase were performed. Mostly of the liver biopsies were obtained percutaneously, but some samples were obtained from surgery material.

Results: The great majority of the patients were asymptomatic. More than 80% of the sera were anti-HBs and anti-HBe (+). Serum aminotransferase levels were slightly elevated in those rates the upper limit of the normal range in the majority of the patients. Chronic persistent hepatitis, chronic active hepatitis and cirrhosis were the most frequent findings in hepatitides. Granulomas due to *M.tuberculosis* were also other morphologic features.

M.B.P.224

THE INTERACTION OF HIV AND HEPATITIS B VACCINATION IN A COHORT OF HOMOSEXUAL AND BISEXUAL MEN
Buchbinder, Susan C.*, Nelson, A.R.*; **O'Malley, P.***; Barnhart, L.*; Ruffnerford G.*; Hadler, S.**
 *Dept. of Public Health, San Francisco, CA; **Viral Diseases, CDC, Atlanta, GA, USA.

Objective: To evaluate the effect of HIV infection on efficacy of the hepatitis B vaccine (HBV) and the effect of HBV on AIDS disease progression. **Methods:** 350 homosexual/bisexual men participated in a randomized controlled trial of HBV from 1985-1988. We began follow-up studies of HIV-related diseases in 1983. We compared peak hepatitis B surface antibody (HBsAb) throughout follow-up (16-16). We also compared the prevalence of AIDS and loss of immunity in 2 groups: men who were HIV seropositive (SP) prior to first dose of HBV (N=26) and men who remained HIV seronegative (SN).

Results: SP were less likely than SN to develop immunity (56% vs 80%, p<0.03). Of men achieving immunity, SP had significantly lower peak responses and were more likely to lose immunity than SN (p<0.01). Kaplan-Meier analysis examining loss of immunity from time of first vaccine dose showed 41% of SP (95% CI=17%-63%) lost immunity by 20 months versus 56% of SN (95% CI=45%-67%) at 72 months. There was no difference in the prevalence of AIDS and ACB between SP versus HIV-infected men receiving placebo.

Conclusion: Plasma hepatitis B vaccine is significantly less efficacious in HIV seropositive than seronegative men. A majority of seronegatives also lose antibody over time, indicating the need for studies of the efficacy of booster doses. The hepatitis B vaccine does not cause acceleration of HIV-related disease.

M.B.P.225

TOXOPLASMOSE OCULAR AU COURS DU SIDA
FLORES, S.*, ZANON, L.*; **Barthem, Sophie**, de Truchis, P.*
 Coulaud, J.P.; Salazar, A.C.*

* Hôpital Claude-Bernard, ** Hôpital Pitié-Salpêtrière, Paris, France.

Objectif: Décrire les caractéristiques de la toxoplasmose oculaire (TO) observée chez les patients (Pz) HIV +.
Méthodes: De 1984 à 1988 un examen de Fond d'Oeil (FO) a été fait par les mêmes ophtalmologues chez les Pz HIV ayant des troubles visuels et/ou asymptomatiques (2 FO) chez les asymptomatiques (OC II), 4 FO) (OC III et (OC IV). 1 FO/mois/78 SIDA). Les critères de TO étaient: vitre clair, prédominance de l'atteinte du pôle postérieur, foyer en règle unique/horbe floue, taille variable + plaques de névrite, extension en l'absence de traitement(s).
 Classification sous 71 espèces/foyers.

Résultats: Dix cas de TO (5 observés, 2 adhésions: 1 HIV 1, 1 HIV 2; 1 COV < 120) ont été observés: 1 1984-86; 2 automne TO/49 nouveaux cas de toxoplasmose (TO): 1 1987; 1 3 TO/20 TOX; 1 1988; 7 TO/33 TOX. Sept cas ont été résolus par une baisse de l'acidité visuelle; 3 étaient asymptomatiques. Une autre TO avait précédé 10 TO chez 8 Pz (2,6,7,72 mois). Chez 6 Pz la TO a été la 1ère TO. Neuf Pz étaient sous AZT. Cinq Pz ont une TOX cérébrale associée (4 simultanées, 1 découvre 2 mois après la TO). Cinq n'ont pas de TOX cérébrale détectable (clinique/histologie). La classification a été obtenue 10 fois/10 sous priméthamine (P) + sulfadiazine (S) ou P/sulfadiazine (2 Pz).
Conclusion: 1) Dix cas de TO ont été observés en 1987 et 1988 - 2) La TO peut être la 1ère TO - 3) La TO est associée 5 fois/10 à une TOX cérébrale détectable - 4) Le traitement permet la cicatrisation des lésions - 5) La prophylaxie des rechutes est identique à celle des TOX cérébrales.

M.B.P.226

TOXOPLASMOSE OCULAR AU COURS DU SIDA
Shakirov, Yegor, Meprova, H.C.*; Peltova, B.**;
 Zayon, S.*; Vachetov, S.*; Lashin, S.*

* Hôpital Claude-Bernard, ** Hôpital Saint-Antoine, *** Hôpital Pitié-Salpêtrière, Paris, France.

Objectif: Préciser Les signes cliniques et ophtalmologiques (OP) de la toxoplasmose oculaire (TO), son évolution sous traitement (trt) et ses relations avec la survenue d'une toxoplasmose cérébrale (TC).
Méthodes: Étude rétrospective des cas de TO chez des patients (pts) atteints de SIDA, depuis 1981 dans 2 services de maladies infectieuses.

Résultats: Il s'agissait de 8 hommes, 6 homosexuels, vu en 1983 (n=5), 1984 (n=2) et 1988 (n=7). 7/8 pts avaient une acuité visuelle, 52/10, et 3/8 pts une fièvre. Tous avaient une choriorétinite du pôle postérieur, associée à une hyalite. Chez 7/7 pts, l'angiographie confirmait le foyer choriorétinien et la ponction de la chambre antérieure nous montrait pas de symptômes locaux d'œdème. Le trt a été débuté 12 j (0-20) après les premiers signes de la TO. Les pts ont reçu clindamidine, 1,2-4, 8 g/j (n=7), sulfadiazine, 800 mg, en spiramécine, 3 g/j (n=6), associées à une prophylaxie (50-100 mg/j, pendant 45 j), supplémentées à dose réduite chez 6 survivants. La TO a cicatrisé chez les 8 pts, après 37 j (21-90). Une rechute s'a été manifestée après 5,5 mois (1,5-9). Une TC est survenue chez 7/8 (78) pts. A fois, TC et TO étaient reconnues simultanément et l'évolution de la TC était favorable; mais 3 fois la TC se révélait 9, 36 et 30 j après la début du trt de la TO, et son évolution n'était pas évaluable.
Conclusion: La TO est devenue plus fréquente au cours du SIDA. Son diagnostic repose sur l'examen OP. Une TC associée doit être recherchée.

M.B.P.227

OCULAR INVOLVEMENT IN CHILDREN WITH HIV INFECTION
Bullini, B., Bertoni, G., Chiamp, M., Mosconi, P.,
 Pizzoni, M., Pizzoni, M., Bertoni, A.*
 *II Ophthalm. Clin., **IV-Pediatr. Clin., ***Infect. Dis. Clin. University of Milan, Milan, Italy.

Objective: Evaluation of ocular involvement in children with HIV infection in respect to adult AIDS.

Methods: The 44 report on ophthalmological findings in 57 HIV seropositive children. According to the definition proposed by CDC (April 1987) seropositive infants were 15 in P-0 class, 16 in P-1 class and 18 in P-2 class. 7 patients became negatives and 3 died.

Ocular examination, at the start and every 3 months, included: ocular reflexes and motility, fundus and ERG in pathologic cases only.

Results: Ocular signs observed in 13 children (22.8%) were mainly represented by optic nerve involvement (optic disc pallor and atrophy, papilloedema), CMV retinitis in occurred in 2 cases (1/6 vs > 50% in adults). Retinal microangiopathy was never observed in HIV seropositive children.

Conclusions: Pediatric AIDS is believed as a new idiom disease with very different clinical and biologic characteristics in respect to adult AIDS as well as from the ophthalmological point of view.

M.B.P.228

VITREOUS FLUORESCENTOMETRY IN HIV INFECTION
Buzzi Salinelli, L., Azzidi, P., Confignarini, E., Ricchi, S.,
 F. Chiari, E., Caraceni, S.*
 *Cattedra Clinica Diagnostica II - **Istituto Malattie Infettive Università di Bologna, Bologna, ITALY.

Objective: To evaluate the ability of vitreous fluorescentometry to detect HIV in lesions of vascular endothelial cells.
Methods and Results: We have studied 18 subjects with HIV infection (5 AIDS with 2, 11 and 3 MHC) in all patients all were examination including vitreous fluorescentometry, indirect ophthalmoscopy, and vitreous fluorescentometry. In spite of the fundus normality the vitreous fluorescentometry readings were constantly above normal, showing average fluorescence values of 2.4, 3.2 and 4.87 g/l respectively in the anterior, middle and posterior vitreous.

Conclusion: Etiology and pathogenesis are unclear but the role of circulating immune complexes deposition, increase blood viscosity and HIV direct effect on vascular endothelial tissue, are discussed. The fluorescein angiographic documentation of microaneurysms, telangiectasias, focal areas of non-perfusion and capillary leakage in patients with HIV infection provides a pattern of microvascular retinopathy very similar to the diabetic one. Nevertheless fluorescein angiography is not a qualitative technique and the use low sensitivity in some cases. The fluorescentometry permits on the contrary a qualitative evaluation of the alterations of blood barrier which can be diagnosed by vitreous fluorescentometry before any clinical and fluoresceinographic detectable lesion.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.241 GASTROINTESTINAL (GI) STRUCTURE AND MUCOSAL FUNCTION IN HIV POSITIVE PATIENTS.

Choudhry, R., Richardson, L., Shung, W., Kelly, J., Gill, J., AIDS Research Interest Group, University of Calgary, Calgary, Alberta Canada.

Unexplained weight loss and diarrhoea are relatively frequent in HIV infected patients. We have investigated 15 patients in whom no gastro-intestinal pathogens could be identified to see if functional or structural changes in the small intestine could account for their weight loss and diarrhoea. Nineteen patients (17 males, 2 females) were investigated by endoscopy. Biochemical testing demonstrated normal red blood cell folate and vitamin B12 levels in all patients. However, serum ferritin levels were increased in 12 patients. 5-lysoase absorption tests were abnormally low in 8/13 cases. Duodenal aspirates were negative for giardia lamblia. Light microscopy failed to show any structural abnormality in both upper and lower bowel biopsies. In contrast ultrastructural changes were demonstrated in all patients at the epithelial stromal junction of intestinal crypts with scattered degenerative or necrotic fibroblasts interspersed with reactive hyperplastic fibroblastic cells which appeared to lay down excessive collagen beneath the epithelial cells. These findings suggest that certain biochemical and ultrastructural abnormalities are common in HIV positive patients even in the absence of infectious pathogens. Defects in carbohydrate absorption and ultrastructural changes may be responsible for some aspects of HIV enteropathy.

M.B.P.243 HEMOPHAGOCYTIC HISTIOCYTOSIS IN THE LIVER OF AN HIV-INFECTED FOREIGN BORN ISRAELI

Neufuss, David M.*; Tempesta, R. *; and Strenger, R.J.**
*Mach Israel Medical Center, New York, N.Y. U.S.A.; **Hessau County Medical Center, East Meadow, New York, N.Y. U.S.A.

Objective: To report a case of hemophagocytic histiocytosis in the liver of an HIV-infected former IV drug user.

Methods: Clinical data over 27 months and two liver biopsies, including one studied by electron microscopy, were reviewed.

Results: A 32 year old former IV drug-abusing male had HIV antibody by ELISA and Western blot. Altonic endoneurase (ALT) was initially 83 U/l and increased over six months to 458 U/l, at which time the first liver biopsy was performed. Fatigue and abdominal pain were correlated with increased ALT levels. During the next 6 months, ALT ranged from 37-316 and symptoms improved. On the biopsies liver architecture is preserved, but the portal tracts display mild to moderate fibrosis, focal mononuclear infiltrative and scantest ductular proliferation. The parenchyma in fact, except for rare necrotic cells, along the sinusoids are clusters of immunopositive phagocytosing and prominent Kupfer cells exhibiting erythrophagocytosis, and in Disse's space there is increased collagen. A few scattered lipid granules appear near central veins. Fever, chills is negative.

Conclusion: Lacking evidence for other infections previously associated with hemophagocytic histiocytosis, we suggest that HIV may rarely cause the syndrome, which may be associated with manifestations of liver dysfunction. Definitive exclusion of other causes of erythrophagocytosis is not possible, however.

M.B.P.245 SPONTANEOUS RESOLUTION OF CANDIDA SPIRITRIS(CE) IN A SERO-CONVERTING PATIENT

B. Clotet, G. Sivera, A. Boix, A. Josa, M. Ribera, C. Tural, M. Dominguez, J. Tor, M. For. Respiratory Diseases Unit, Gastroenterology Service, Blood Bank Unit, Hospital de Bellvitge, Barcelona, Catalonia, Spain.

Objective: To report a case of CE in a seroconverting patient and to discuss whether CE in HIV infection should always be considered a criterion for AIDS. Material: A 22 year-old white man admitted because of a mononucleosis-like syndrome. He was drug addict since the last 6 months.

Results: The endoscopy and esophageal biopsy demonstrated CE.
April 20, 1988: EIA screening p24 50 41 HIV Ag WB
May 10, 1988 cut off - - - - - +
May 20, 1988 EIA: (beta1ng): HIV Ag - - - - - +
EIA: (beta1ng): HIV Ag - - - - - +

An esophageal endoscopy performed 15 days later demonstrated spontaneous resolution without having received any antifungal therapy. Discussion: In view of our findings we suggest that CE should be considered a criterion for AIDS at least for informing the patient that is suffering an AIDS when there is associated another opportunistic infection or when this appear subsequently in a short period of time (less than 4 months) when the patient has a persistent low t4 count (2500) over a long period or when there is HIV antipneumia (excluding the seroconverting patients). All other cases should be followed closely to understand better the prognostic significance of CE. In our experience HIV seropositive patients not fulfilling the criteria commented above have been followed for long periods (45 months) without developing other opportunistic infections.

M.B.P.242

HEPATITIS B VIRUS INFECTION AND Non-A, Non-B HEPATITIS.
Galligan, J., Macgregor, N., Martin, M., J., Macgregor, C., Payne, S., & Gerber, S., Hepatitis Unit, Federal Health Dept, Sydney, Australia.

It has been reported that hepatitis B virus chronic carriers with anti-HIV positive have less hepatic injury than those without infection. However, it is still unclear the influence of HIV among patients with chronic Non-A, Non-B HBSV infection. Thus, we have studied the hepatic injury degree in chronic HBV hepatitis with or without HIV infection.

There were included 32 patients with chronic HBV hepatitis. Eight of them are anti-HIV negative (5 with a posthepatitis level and 3 drug abusers), and the other 24 were seronegative HIV carriers (all drug abusers). The presence of anti-HIV was confirmed by Western-Blot.

The levels of albumin were higher among those HBV patients anti-HIV negative (4.2 ± 0.1 g/dl) than in the HIV seropositive ones (3.6 ± 0.2). On the other hand, the transaminase were increased in the anti-HIV positive subjects when comparing with the anti-HIV negative cases (182 ± 10 U/l vs. 94 ± 7.9 U/l), respectively, although there were not statistically significant differences. The results were similar between both groups of patients (anti-HIV + HBV or chronic active hepatitis (CAH), 25% of chronic persistent hepatitis (CPH), anti-HIV - HBV or CHB, 25.0% and 22.0% respectively).

In conclusion, patients with chronic HBV hepatitis and HIV infection present higher levels of transaminase. It is suggested that the hepatitis B virus could have a direct cytotoxic effect and that the immune response is not involved in the hepatic injury. However, as the causal agent of the hepatitis B virus is not yet identified, this should be proven in future research.

M.B.P.244 ULTIMATE PHASIS-INDUCED LYMPHADENOPATHY IN ADVANCED HIV DISEASE.

Kiloh, Wilbert, Walker, M., Francis, M., Logan, S., Lewis, P., Fleming, A. & St. Mary's Hospital, London, United Kingdom, University of Leeds, United Kingdom.

Objective: To characterise the cause of opportunistic ulceration in advanced HIV disease in the absence of infection with CMV or HSV.

Methods: Endoscopy and biopsy was performed on 5 homosexual men presenting with severe dyspepsia. Three HIV seropositive men with dyspepsia were used as controls.

Results: Endoscopy revealed large ulcerated ulcers (0.5 cm in diameter) in the pyloric and/or antral mucosa in the 5 patients with dyspepsia, and was microscopically normal. In the 3 controls. Subsequent histological examination of biopsies from the ulcerated areas showed features of viral lymphadenitis in all cases; multinucleated giant cells (3), perinuclear inclusions (3), individual cell necrosis (3), and epithelial necrosis/hyperplasia (2). There were no histological features of HIV infection in any of the cases, and evidence of cervical infection was seen in only 1 of the 5. CMV was not detected in any of the cases by immunocytochemistry or DNA in situ hybridisation. Material from 4 of the 5 cases and 3 HIV seropositive controls was available for ISH in situ hybridisation for HIV and HSV. HSV DNA was detected in 3 of the 5 cases and none of the controls. HIV DNA was detected in 1 of the 4 cases and 2 of the 3 controls.

Conclusion: A lesion histologically similar to Oral Thrush lymphadenitis can occur in the pyloric and antral mucosa in advanced HIV infection where it may cause significant ulceration. HIV may be closely related to the lymphadenitis seen in these cases.

M.B.P.246 DETECTION OF HEPATITIS B VIRUS DNA IN PERIPHERAL BLOOD MONONUCLEAR CELLS FROM ASYMPTOMATIC ANTI-HSV CARRIERS

P. Baranoni, Imposimato, G. Mosella, M. C. Martines, J. C. Ferrer, V. Carrozz, V. Heparatology Unit, Fondazione Sime, Sesto, Sanpiero, Spain.

It has been suggested that hepatitis B virus DNA can act as a cofactor in the development of AIDS in anti-HSV positive patients. Also, HBV-DNA has been detected in peripheral blood mononuclear cells (PBMC) from anti-HSV carriers. The aim of this study was to determine the presence of HBV-DNA and HIV-DNA in PBMC from HBV-DNA (+) (10⁷ cells) were obtained from 23 asymptomatic anti-HSV carriers (16 of them were positive to the hepatitis B virus surface antigen, HBeAg, and 7 negative to HBeAg, and from 20 anti-HSV negative patients (10 with HBeAg and 10 without this marker). Anti-HSV was detected by EIA and confirmed by Western Blot. The HBeAg test was performed by RIA. HBV-DNA and HIV-DNA were detected by dot-blot hybridization in total extracted cellular DNA from PBMC.

The results are summarized in this table:

	Anti-HSV		Anti-HIV	
	HBeAg	HBeAg	HBeAg	HBeAg
	N=15	N=7	N=20	N=10
PBMC	1/15	0	17/20	0
HBV-DNA	7/15	0	17/20	0

HBV-DNA was found in a similar percentage of PBMC from anti-HSV positive and negative patients. No differences were observed in the TA/T4 ratio in HIV-seropositive patients with or without HBV-DNA in PBMC (1.1 ± 0.37 and 0.9 ± 0.3, respectively). HBV-DNA was detected in 10/21 (47%) of asymptomatic anti-HSV carriers. HBV-DNA and HIV-DNA were present in 2/23 (9%) of these patients. In conclusion, the incidence of HBV-DNA in PBMC of anti-HSV positive or negative patients is similar. There is a small percentage of patients with HBV-DNA and HIV-DNA simultaneously in the PBMC.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

Manifestations endocriniennes, cardiaques, rénales, musculo-squelettiques Endocrine/Cardiac/Kidney/Musculoskeletal

M.B.P.259

EDWARDSHAWKINS IN AIDS PATIENTS: A PROSPECTIVE STUDY IN 24 PATIENTS.
Hage L., Naylor's, Victoria, R., Lindqvist, R.,* Pedersen, C.*
* Dept. of Infectious Diseases, ** Dept. of Cardiology, Mølnare Hospital,
University of Copenhagen, Denmark

Objective: To assess the prevalence and the extent of cardiac arrhythmias in AIDS patients with no cardiac history.

Methods: 24 patients with AIDS for 0-40 days (mean 8) were examined. Twelve had homosexual sex, one man with urethral risk factor and 2 were infected by transfusion. Nine were intravenous drug abusers. All patients were hospitalized: 17 with pneumocystis carinii infection, one with Kaposi's sarcoma and 6 patients with other opportunistic infections incl. CMV and mycobacterial disease. No patients showed signs of clinical cardiac failure. Electrocardiograms were performed on an E.C.G. 2000 ground wire. Conduction included standard leads + 24 ectopic. The ectopes were videotaped and analysed live by a cardiac specialist.

Results: In 20 of the 24 patients we found in 11 patients. Eight patients had slightly to moderate dilatation of the right ventricle chamber 20-30 mm (mean 25.3) and 5 patients had a normal pericardial effusion. No patients had tachycardia more than corresponding to fever. We found no signs of endocarditis, myocarditis or cardiomyopathy.

Conclusions: Minor cardiac arrhythmias seem to be common in AIDS patients with acute infection. In AIDS patients with other infections than intravenous drug abuse they are hardly of clinical importance.

M.B.P.261

RHEUMATIC SYMPTOMATOLOGY IN PATIENTS INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV): PREVALENCE AND RELATIONSHIP TO CLINICAL AND LABORATORY VARIABLES.
Lindqvist, R.,* Hage L.,* Mølnare, S.,* Mølnare, A.,* Jørgensen, D.,
Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Objective: To define the prevalence of rheumatic symptomatology in a cohort of HIV infected patients as well as its relationships to a variety of clinical and laboratory variables.

Methods: Controlled retrospective and prospective analysis of 75 patients followed for a mean of 39 months. Each subject was serially assessed for the development of rheumatic symptomatology during follow-up for HIV infection.

Results: During the follow-up period, 204 developed articular symptoms including four patients with Reiter's or psoriatic arthritis, and 11 patients with new onset oligoarticular or polyarticular arthritis (group A). Fifty-three patients (71%) had no rheumatic symptoms (group B) and 7 patients (9%) had miscellaneous rheumatic symptoms. Group A patients were more likely to be at an advanced clinical stage of HIV infection (i.e. CDC Class IV) than group B (p<0.001) and had lower hemoglobin, lymphocyte counts, T helper counts and higher ESR values than group B patients (p<0.01). There was no association between articular disease and any specific risk behavior, other sexually transmitted diseases, infections or malignancies.

Conclusion: Articular disease appears to be relatively common in the setting of HIV infection and correlates with both an advanced state of infection and immunosuppression. These data may partially explain the reported sensitivity of such patients to the adverse effects of immunosuppressive drugs.

M.B.P.263

"REDUCED CORTISOL PRODUCTION AND ADRENAL HISTOPATHY IN PATIENTS WITH AIDS".
LEITE, D.S.,* ACEITURI, A.C.; SADER, H.,* DIAS, R.S.,* KATZ, C.R.,* MOTTA, P.R.,*.* Escola Paulista de Medicina - São Paulo - SP - Brasil.

Objective: To verify adrenocortical reserve and adrenal histopathology in patients with AIDS.

Methods: To verify adrenocortical reserve we measured plasma cortisol levels before and 60 min. after ACTH stimulation (Cortrosyn®, 250 µg IV bolus) in 28 patients with AIDS, 5 with ARC, 10 with chronic non AIDS diseases and 32 normal subjects. Adrenal histopathology was studied in 17 of the 20 patients with AIDS who died. The 95% confidence intervals (CI) for the ACTH-stimulated cortisol levels was established at 38.4 µg/dl.

Results: Five (18%) AIDS patients presented values below the CI: 13.4 ± 1.4 µg/dl. All 5 had massive adrenal necrosis at post-mortem examination (2 had AIDS complicated by tuberculosis and 1 Cryptosporidium parvum). Sensitivity and specificity of the ACTH test compared with the presence or absence of significant necrosis was 71.4% and 100%, respectively. No patients with ARC or chronic non-AIDS diseases had decreased cortisol response to ACTH stimulation.

Conclusion: Since 18% of patients with AIDS had proven adrenal necrosis with sufficient beneficial result from glucocorticoid replacement therapy, we suggest that a rapid ACTH test should be performed in every such patient.

M.B.P.260

IMMUNOLOGICAL MONITORING IN HIV INFECTION.

Edwards L., Hage L.,* Naylor's, Victoria, R.,* Lindqvist, R.,* Pedersen, C.,*
* Dept. of Internal Medicine and Neurology, ** Hospital Unit of AIDS, Mølnare Hospital of Victoria, Victoria, Sweden.

The involvement of the peripheral nervous system (PNS) in patients with infection by the human immunodeficiency virus (HIV) is less well known than that of the central nervous system (CNS). Because of the rarity of these conditions, and the interest of their diagnostic and therapeutic aspects, we report 7 patients with HIV infection and abnormalities of the PNS. There were six males and one female, with an age range of 15 to 45 years, with the following conditions: the usual polyneuropathy - the chronic inflammatory demyelinating polyneuropathy and three plexopathies. At the time of the diagnosis of the PNS involvement, three polyneuropathy patients were stage IV-C and one IV-D; whereas the plexopathy patients were stage II and two were stage III. Immunological diagnosis of antibodies against cell and cerebral cytoplasts. All patients with axonal polyneuropathy had severe impairment of their peripheral conduction with advanced axonal degeneration which suggests that the neurologic involvement may be the result of metabolic and nutritional causes (an acetazolamide intoxication), rather than HIV or other organ specific infection. Both demyelinating polyneuropathy patients did not receive treatment on patient referral treatment with the other had a right foot entrapment. In none of the four of these had patients received antiretroviral without treatment. Six of the seven patients with plexopathy did respond to corticosteroid therapy.

All four polyneuropathy cases had features of both types of polyneuropathy (axonal and demyelinating). In two patients we observed at different times with their clinical course, transition from one type of neuropathy to the other. This case suggests that the polyneuropathy constitutes a single entity, with variable clinical and electrophysiological features.

M.B.P.262

JOINT, BONE AND MUSCLE LESIONS AND HIV INFECTION.

Bohm, Jan, F. Forster, St. Youle, NS; Wainman, DA; Lawrence, AC; Seiffert, AC; Wainman, St Stephen's and St Mary's Hospitals, London, UK.

Rheumatologists at our hospitals have been referred 196 HIV-positive patients since 1983, representing about 4% of the known HIV-positive population in our area. Thirty homosexual men and 2 women presented with acute, asymptomatic, peripheral, non-erosive, seronegative arthritis (mean 4 joints affected). Associated features included parotitis (12 patients), rheumatoid factor (12 patients), pleuritic fasciitis (12), urethritis (12), conjunctivitis (4) and uveitis (1). Four of 5 patients tested had HLA-B*27. Two with recent diarrhoea had serological evidence of yersinia infection. No microorganisms were identified in joint material except for HIV in 4 patients. At onset of arthritis only 2 had AIDS and 9 were not known to be HIV-positive. Six patients have progressed to AIDS, 4 have died. In 4, including those progressing to AIDS, joint symptoms have been severe, persistent and poorly responsive to NSAIDs. In 5 arthritis has resolved. Other rheumatic lesions seen include infective lesions (7 patients) including one with disseminated histoplasmosis, molluscum/arthralgia (10), with features suggestive of myositis in 32, spinal pain (19), non-inflammatory peripheral arthropathy (8), and soft tissue lesions (12). Rheumatic syndromes in HIV-positive patients are becoming better defined. It is unclear, however, whether HIV itself is a genuine risk factor for some of these, especially aseptic arthritis. The London experience may help to clarify this issue. Pathogenetic mechanisms, including the role of microorganisms and immunodeficiency, require further study.

M.B.P.264

DIABETES INSIPIDUS AS A COMPLICATION OF CEREBRAL TOXOPLASMOSIS IN AN AIDS PATIENT

Emshoff, Dragan; Singh, R.; Gevart, R.
St. Stephen's Hospital, London, England.

Case presentation: A 52 year old homosexual HIV-positive patient presented with sudden onset headache, dysphasia and blurred vision. He had a low grade pyrexia, right sided upper motor neurone 7th nerve palsy and left sided homonymous hemianopia. Brain CT scan showed multiple localised frontal, parietal and occipital white lesions (left & right) cystic enhancing lesions suggestive of brain toxoplasmosis. He responded very well to treatment with Fansidar (one tablet b.i.d.), his signs and symptoms disappeared and he was discharged on maintenance Fansidar at a dose of one tablet every alternate day. Six weeks following the beginning of his brain infection he developed polydipsia and polyuria. Diabetes insipidus was confirmed with normal blood glucose, urine osmolalities never exceeding 172 mOsm/L and plasma osmolalities of over 300 mOsm/L. In spite of clear evidence of hypothalamic dysfunction his anterior pituitary function was normal with a good cortisol response to hypoglycaemia, normal T₄ (82 mU/L), prolactin (576 uIU) and normal responses to LH, LHRH and FSH in the respective releasing factors. Treatment with DDAVP resulted in rapid resolution of diabetic symptoms.

Conclusions: Neurogenic diabetes insipidus can follow cerebral toxoplasmosis in AIDS patients.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.271 HYPERONEMIC HYPOLIPOTEMIA ASSOCIATED WITH HIV INFECTION

Kessens, D.J. Heil, T.J. Bernis, S.J. Dowd, S.J. Clumick, N. Balan
Free University of Brussels, Brussels, Belgium.

Objective: Hyperonemic hypolipidemia associated with HIV-1 infection has been reported (F. Kalin, 1987). In order to evaluate the occurrence of this anomaly we set up a retrospective study.

Methods: We measured plasma cortisol (F), aldosterone (Aldo) and renin activity (RA) by specific radioimmuno assay as well as plasma and urinary ionogram in 21 HIV-1 infected caucasians (CDC stage 2 to 4). Control population was comparable for sex, age, and sodium dietary content. Statistical analysis was performed using Mann-Whitney test and multivariate analysis.

Table	number of subjects	median range	SD (mg/dl)	range	SD (mg/dl)	range
Controls	7	150 (100-200)	0.15 (0.04-0.39)	24 (10.3-4.4)		
HIV-1 +	217	170 (40-300)	0.07 (< 0.001)	1.4 (0.1-10)		

RA was significantly higher in patients than in controls (p < 0.001). Aldo and FRA were significantly lower in HIV-1 infected patients (p < 0.001), neither of the parameters varied according to stage. Three patients presented an hyperonemic hypolipidemia with persistent hyperkalemia.

Conclusion: Hyperonemic hypolipidemia with intact glucocorticoid secretion in HIV-1 infection suggests a dysfunction of the interglomerular apparatus rather than a primary adrenal damage (J. Glasgow, '85). The early presence of these features (stage 2) rules out any causal effect of opportunistic infections (stage 4) (L. Mastroianni '87), but suggests a direct effect of the virus or an auto-immune reaction.

M.B.P.272 ACQUISITION OF THYROID BIOCHEMICAL ABNORMALITIES (TBA) IN COMPARED IMMUNODEFICIENT SYNDROME (AIDS) AND OTHER IL-NEVERES.

Boudoux, Pierre; Bonny, M.; Clumick, N.
Saint Pierre University Hospital, B-1000 Brussels, Belgium.

Transient TBA are currently observed in nonthyroidal illness (NTI) and particularly in severe infections but their incidence in AIDS is not yet known. Therefore, we studied the thyroid function in 102 patients with AIDS (groups 1 to 4) aged 18-78 (group 1) and 102 age-matched controls with various infectious diseases (group 2) and 4 AIDS uninfected patients aged 15-69 (group 3), admitted to our medical service. Thyroid function was assessed by serum T4, T3, FT4, FT3, TSH, TSH-R. When a thyroid disease was suspected, a complete panel of investigations was performed including free T4 and T3, and T3 test.

A low T3 syndrome was observed in 20% of all patients, including AIDS patients. Thyroid diseases were found in 10% in group 1, 11% in group 2, 14% in group 3, 2% in group 4. In the thyroid-diseased patients the other TBA were distributed as follows (% in groups 1/2/3): decreased T4 (7/52), decreased FT4 (7/7/2), increased T4 (1/6/2), T3 (1/4/1), 4, increased TSH (2/2/2). Moreover, 16 patients of group 2 with high TSH, 4 had normal FT4 indicating euthyroidism. When compared to controls, patients with AIDS, although euthyroid, had significantly different mean values T4 (AIDS vs Controls: 7.4 and 8.2 ng/dl, P<0.05), T3 (1/27 and 1/4/2 ng/dl, P<0.05), FT4 (1.29 and 1.56 ng/dl, P<0.05), TSH (2.1 and 1.4 mU/L, P<0.05). Mean serum thyroglobulin levels were not different in groups 1 and 2.

Conclusion: 1) Decreased T4 frequency is higher in AIDS than in other NTI although the proportion of true thyroid diseases is the same; 2) abnormal TRG level accounts for more than half of TBA, particularly in patients with the T4, 3) consequently, FT4 is the most appropriate tool for screening thyroid dysfunction in AIDS and NTI patients.

M.B.P.273 MYOCARDIITIS IN INTRAVENOUS DRUG ABUSERS WITH AND WITHOUT ACQUIRED IMMUNODEFICIENCY SYNDROME: AN AUTOPSY STUDY

Rehrich, Janna S.; Francis, C.; Navarro C.; Brown, J.; El-Hader, W.
Harlem Hospital Center, College of Physicians and Surgeons, Columbia University, New York, New York, USA.

Objective: To compare cardiac involvement in intravenous drug abusers (IVDA) with the acquired immunodeficiency syndrome (AIDS) to IVDA without AIDS.

Methods: Consecutive unselected autopsies in IVDA performed from 1983 to 1988 were reviewed. Of 177 autopsies of IVDA, anatomic, morphologic and histologic data were available in 42 patients (ages: AIDS: 35 male, age 37-60 with AIDS (defined according to the clinical criteria of the Centers of Disease Control) and 25 pts (non-AIDS) 16 male, age 31-58 years) without clinical AIDS. Myocarditis (MCO) (epimycotic or plasma cell infiltration), dilatation of the left (LWLD), right (RWLD), or both ventricles (BWLD), pericarditis (PCRL), pericardial effusion (PEFL) and endocarditis (ENDO) in both groups are shown below: (Same pts appear in more than one group.) *p<0.05

	MCO	LWLD	RWLD	PEFL	ENDO
AIDS	24	3	7	10	7*
(n=42)					
NON-AIDS	17	4	3	3	4
(n=25)					

Myocarditis is comparable in AIDS and non-AIDS and is not related to cardiac chamber dilatation, pericardial disease or prostatic infection. Severe bacterial infection, particularly endocarditis, is common in non-AIDS (87%) but uncommon in AIDS (3%). Opportunistic infection occurs in AIDS and is not related to MCO. In IVDA, with and without AIDS, myocarditis is common but unrelated to other pathologic states.

M.B.P.274 THE PATHOLOGY OF THE MALE GENITAL TRACT IN AIDS.

Shevchik, M.; de Silva, M.; Cinnia, William; Armonian, K.; Franchini, J.; and Zambomano, K.* Lenox Hill Hospital, New York, NY, *Western Administration Hospital, Bronx, N.Y., USA.

Objective: The male genital tract of AIDS patients frequently contains lesions and abnormalities which could be clinically asymptomatic.

Method: To study the pathology of AIDS of the male genital tract, the prostates and testes of 80 consecutive AIDS autopsy cases were examined histologically and all were stained with the p17 anti-HIV monoclonal antibody.

Results: The following opportunistic infections were identified: *Trophozoites* of testes (2 cases), cytomegalovirus (5 cases - 1 testis, 4 prostates), candidiasis of prostatic urethra (1 case). Seven tumors were identified in the series. These were apparently AIDS related: 1 non-Hodgkin's lymphoma involving testes and prostates, and 1 primary immunoblastic lymphoma of testis. In addition marked spermatozoal arrest, germ cell degeneration, peritubal fibrosis and Leydig cell depletion were seen in all cases. The anti HIV p17 monoclonal antibody showed small random foci of positive staining in 8 of 14 testes cases studied, located over one or several degenerating germ cells. None of 14 prostates showed few minute foci of epithelial staining.

Conclusion: The male genital tract of AIDS patients contains opportunistic infections, neoplasm and apparent direct infection by the HIV virus.

M.B.P.275 GENITAL ULCERS IN HIV INFECTION

Schanderl, Falk B.; Schöber, R. and Hilbert, R.
Klinikum J.W.Goethe-Universität, Dept. of Dermatology, Frankfurt, FRG.

Objective: To examine frequency, etiology and significance of genital ulcers in HIV-infected patients.

Methods: 267 HIV-positive patients (84 male homosexuals, 164 other risk group: 19 asymptomatic, 147 symptomatic) were examined for genital ulcers, repeatedly over a 4 year period. Genital ulcers were examined clinically, microbiologically, serologically and partly histologically.

Results: Genital ulcers was the most important cause for anal ulcers: 55/267 (21%) had at least one episode of ulcerating herpes anitis. Incidence increased with increasing stage of HIV-infection: 14/50, 14/89, 31/8 (32/61) and AIDS 33 / 129/87. The ulcers were atypical; extremely painful; "punched-out" lesions, showing no tendency to heal. On first manifestation the mean absolute CD 4+ T-lymphocyte count was 219/3 (lowest normal limit=490/ml). 80 % of cultures showed positive results (HSV 11=90, HSV 1=10%). Oral acyclovir was effective even in a dosage of 5 x 200 mg/d for 1-10d. 2 genital ulcers were caused by *Treponema pallidum*, once in combination with *herpesvirus*. Clinical picture and therapy were unremarkable. Anal ulcers occurred and oral ulcers occurred during the AIDS HIV-1 illness.

Conclusion: Genital ulcers should always remind of a possible HIV-infection. Furthermore, ulcerating herpes anitis is a distinct clinical marker for a severe cellular immunodeficiency.

M.B.P.276 NEED FOR GYNECOLOGIC PROTOCOLS IN AIDS PRIMAIR CARE CLINICS.

Marfa, Gerald; Ribble, D.; Hayes, C.; Wolbert, J.; Rodgers, T. J.; Kelly, J. Bellevue Hospital Center/Community Health Project, NY, NY, USA.

Objective: To develop a protocol assuring effective recognition and management of gynecologic disease in the increasing number of women attending a primary care clinic for HIV/AIDS patients. A protocol was designed on the basis of: (1) a questionnaire on gynecologic symptoms and disease administered to 118 HIV/AIDS women at our clinic; (2) review of literature and other available data on gynecologic disease in At Risk and HIV/AIDS women with respect to prevalence, nature of disease; (3) available AIDS management guidelines; (4) available AIDS management guidelines.

Results: Genital herpes and candidiasis, PID, and papilloma virus disease (condylomata cervical dysplasia and carcinoma) were identified as diseases of particular concern in the management of HIV/AIDS women. These diseases were found to be more prevalent, more aggressive, chronic and recurrent, and to require more extensive or different treatment than in HIV/AIDS women. They are not included in most current guidelines for medical management of HIV/AIDS patients, and most gynecologic protocols in primary care have not been modified for HIV/AIDS women. **Conclusion:** Providers should be informed on the unusual manifestations of gynecologic diseases in HIV/AIDS women. Conversely, severe or recurrent STDs should suggest the need for HIV counseling and testing. Special gynecologic protocols and services are necessary but not yet designed for effective management of At Risk and HIV/AIDS women. Data is available for improved management of these patients in the primary care setting, and a trial protocol is now being tested in our clinic.

**Session d'affichage
Poster Session**



**Aspects cliniques
Clinical Aspects of AIDS**

M.B.P.277 **COURSE OF PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) ON CHRONIC DIALYSIS (D).**

R. Perez Garcia, J. Lillo, J.L. Lopez Gomez, A. Bravo, F. Valdesolano, M.D. Gutierrez-Gutierrez, NEFROLOGIA, HOSPITAL GENERAL DE GRANADA

In July 1987, we evaluated 108 adult patients undergoing Hemodialysis (HD) and CAPD/CRP patients with a functioning kidney allograft (TK) and 126 staff caring for them, the HIV infection. All patients and staff were evaluated serologically by ELISA (Abbott) to identify antibodies to specific HIV antigens. Each positive ELISA was confirmed by Western Blot, in two samples. There were two false positive ELISA reactions. Prevalence of HIV infection (HIV+) was 2.9% in TK; 18% in CR and 10% in staff. Only one out of HIV+ patients was intravenous drug user (IDU), the remaining three not any other risk factors than blood transfusion and 3 of them a previous TK. Also 2 patients with IDU-associated nephropathy requiring chronic maintenance D were included in this study.

The 6 HIV patients on HD and 4 on CAPD were followed during more than 18 months or until they died. The HIV patients were on CAPD 5 continuous, 10 on an isolated unit, and the last one on D 2 sessions were performed using CR guidelines for HIV preventing contagion. There were 10 HIV patients who were observed in the periodically ELISA tests performed every 6 months in patients on D or TK. All patients but one had CD4 count and CD4/CRP ratio reduced. Three out of 6 HIV patients developed Acquired Immunodeficiency Syndrome (AIDS) (2007) and had died between 15-20 months after HIV+ was first detected. Two out of 3 patients who developed AIDS were TK and the remaining only had blood transfusions as known risk factor. Blood transfusion on TK, before 1980 was a likely way of contamination for HIV in our area. HIV patients on D had a high risk to develop AIDS. All patients on D had a poor prognosis.

M.B.P.278 **HENOCH-SCHÖLLER PURPURA & IGA GLOMERULONEPHRITIS ASSOCIATED WITH H.I.V. INFECTION.**
Thompson Igg, Cooper G., Swedell E., Gold J., Melville R., St. Vincent's Hospital, Sydney, Australia.

Objective: A case of Henoch-Schölller purpura & Iga glomerulonephritis in association with H.I.V. infection in a 35 year old male. **Case Report:** A 35 year old male (N.I.V. was since '85) developed purpuric rash on trunk, legs & buttocks (typical H.S. distribution) with arthralgia in Nov-'87. A required 2 months steroid therapy until symptoms cleared. At presentation CD4 413 (500-1400) P24 antigen reactive I-positve & blood on urinalysis. IgM/IgG 1:4 (0.25-48 g/l). FBC, ESR, WBC & immunology screen negative. AZT commenced May '88. Subsequent arthralgia required transfusion and dose reduction. Bacterial pneumonia Nov '88 treated with ampicillin followed by acute renal failure. Creatinine 0.1mg/dl/22/10/88, 0.3mg/dl/3/11/88. Creatinine cleared once 10/11/88 (0.1, 1.5-2.2mg/dl), 24 hour urinary protein 1.67 grams (vol.104 - 0.3 mg/dl). Serology: IgA 1.2g/l (0.1-0.4g/l), IgG 1.2g/l (0.7-1.5g/l). Renal necropsy revealing glomerulonephritis with IgA deposition consistent with H.S. syndrome supported by I.F. AZT ceased. He with pulse stenosis & cyclic prothrombinic time developed haemorrhagic cystitis. Creatinine 0.25 16/12/88 with CD4 599, antigen w/e.

Conclusion: A case of classical H.S. purpura is described, initially responding to steroids, progressing to acute renal failure following an episode of pneumonia treated with ampicillin. The patient was known to be H.I.V. & P24 antigen positive at onset of illness. The association has rarely been described & is not the typical picture of H.I.V. associated glomerulonephritis, i.e. focal segmental glomerulosclerosis with a nephrotic picture.

M.B.P.279 **COURSE OF KIDNEY TRANSPLANTED PATIENTS WITH HIV INFECTION.** *Justine C.A.P., Debbie C., Valérie A.A., Aurélie C.A., Philippe D.* Division of Nephrology, Infectious Diseases and Laboratory, Hôpital Pasteur de Marseille - France.

The status of renal transplantation for HIV-infected renal transplants has been controversial since the first description of such patients infected with HIV. We have followed an endemic transplanted patients who had positive ELISA (ELISA) confirmed by Western Blot (WB) of those had seroconverted after transplantation. Results had been collected before transplantation, then with seroconversion and tested for anti-HIV.

Patients (n)	Before Transp.	After Transp.	Follow up (months)	Transp. (n)	Transp. (n)	Transp. (n)
11 (1)	1 (1)	1 (1)	10	1 (1)	1 (1)	1 (1)
12 (1)	1 (1)	1 (1)	15	1 (1)	1 (1)	1 (1)
13 (1)	1 (1)	1 (1)	17	1 (1)	1 (1)	1 (1)
14 (1)	1 (1)	1 (1)	19	1 (1)	1 (1)	1 (1)
15 (1)	1 (1)	1 (1)	20	1 (1)	1 (1)	1 (1)
16 (1)	1 (1)	1 (1)	21	1 (1)	1 (1)	1 (1)

The average follow-up after transplantation was 38.5 months, and 18 months for HIV diagnosis. The patients presented opportunistic infections (PCP, toxoplasmosis) and were seroconverted. The good results in this short time and the absence of a control group (HIV positive patients on dialysis treatment) do not allow us to establish with certainty of treatment after the best outcome, therefore we can not make a picture of desiring seroconversion attempts to HDG patients infected with HIV.

M.B.P.280 **LACK OF CLINICAL EVIDENCE FOR A GLOMERULOPATHY (GP) IN 203 PATIENTS WITH HIV-INFECTION.**
Brunhards, Ulrike, Brunhards, R., Tschopp, S., Eisenbach, G., Schmel, I. and Decker, H. Herxener Hospital, Herxener, A.G., Germany.

Objective: Several authors described a nephrotic syndrome, frequently progressing to renal failure in more than 20% of patients with HIV-infection of different stages. Though renal histological changes were rather unspecific these authors postulated the existence of a HIV-associated GP. We therefore investigated proteinuria (PU) and serum creatinine (5-crea) in 203 HIV-patients.

Methods: 122 patients (gp+) had early stages of the disease without opportunistic infections (O.I.), 81 patients suffered from acute O.I. (gp-). In case of positive qualitative test (Creatinin), quantitative measurement of PU (Buret) was carried out; when PU was 0.5 g/l 506-gel-electrophoresis (EMG) was performed.

Results: None of 81 patients had a PU 0.5 g/l or an elevated 5-crea. 10/81 patients had a PU between 0.3 and 3 g/l. One further of 81 patients developed a transient PU of 4.7 g/l. Only 3 of the proteinuric patients had a glomerular pattern in EMG. All 3 had CMV- or EBV-infections. 14/81 patients showed a transient elevation of serum IgG (of the asc. 5-crea: 10/81 uol/l) during maintenance therapy for opportunistic carinal infection. 1 PT treated with high dose azidothiadin had to be temporarily dialyzed.

Conclusion: In our 203 HIV-patients no nephrotic syndrome and no sustained elevation of 5-crea was observed. All cases of PU and transient elevations of 5-crea were associated with severe O.I. High doses of potentiated antiprotic antibiotics.

M.B.P.281 **NEPHROPATHY AS THE INITIAL SIGN OF AIDS: LUIZ, PAULO MANTOVANI, GUILHERME S. LOPES ALBANI, V. OLIVEIRA, FRANCISCO FILARDO, RUIBERTO FACELLI, CLAUDIA, CLIMELIA, MELISSA II. ESCOLA DE MEDICINA E CIRURGIA, UNI-RIO, BRASIL.**

AIDS-associated nephropathy is characterized by the presence of focal and segmental glomerulonephritis (FSGS) with rapidly progression to terminal renal failure. We study 308 HIV-infected patients, 280 men and 28 women. Risk factors were: 221 homosexual, 34 heterosexual, 14 unknown, 13 heterosexual contacts, 13 blood transfusion, 6 IV drug addicts. We found nephrotic syndrome (NS) in 3 (0.9%) associated with azotemia in 2 (moderate in 1 and severe in 1). Renal biopsy showed FSGS in 2 an diffuse glomerulosclerosis in 1. All progressed to terminal renal failure, 2 died 2 mo 14 months after the onset of NS. One has been submitted to maintenance hemodialysis for ten months.

In 2 patients IV drug addicts and unknown risk factor; the diagnosis of HIV infection was only possible when they presented opportunistic infections, 3 and 4 months after the onset of NS.

We conclude that NS may be the initial manifestation of HIV disease and we suggest that anti-HIV tests should be done in all adult nephrotic patients.

M.B.P.282 **THE PROGNOSIS OF INFECTIOUS COURSES OF AIDS-ASSOCIATED HEART DISEASE.** *E.A. Riney, A.J. L. Rowan, R.A.J. Reed Institute, Miami, FL, USA, and Hospital Saint-Jacques, Paris, France.*

Although we have found that many infectious causes of AIDS-associated heart disease are treatable, it was unclear if the odds of successful treatment were altered because of the presence of cardiac involvement. We therefore analyzed the results of treatment in our patients and in patients reported in the literature. Successful treatment of infection was defined as eradication of the cardiac pathogen after completion of the intended course of therapy. We found that the odds of successful treatment for tuberculous pericarditis were substantially lower than if the 20 we use extracardiac (24 vs. 50%). The only factor that separated those who succeeded from those who failed therapy was an elevated gamma globulin in those who succeeded. Symptomatic cardiac disease due to toxovium resulted in extremely short survival, regardless of treatment. For asymptomatic cryptococcal meningitis, the odds of successful treatment were no different in AIDS patients with extracardiac disseminated cryptococcosis. But it was only in cryptococcal meningitis that improvement in cardiac function was demonstrated after specific therapy. S. typhimurium endocarditis (SE) was eradicated using conventional medication only and did not relapse, even though no maintenance therapy was given. This suggests that SE may be less than S. typhimurium bacteria without a known focus of infection. T. gondii heart disease appears to require at least 2 months of treatment. These observations suggest that although some infections are less likely to respond to treatment if there is cardiac involvement, the response to treatment is similar to the outcome with only extracardiac disease.

Session d'Affiche Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.283

ECG-CARDIOGRAPHIC ABNORMALITIES IN AIDS

Feichtert S, Vissers C, Buijse J and Dunning A. Departments of Cardiology and Medicine (AIDS-unit), Academic Medical Center, Amsterdam, The Netherlands.

Objective: To determine cardiac involvement in AIDS.

Methods: Two-dimensional echocardiography was performed in 32 consecutive patients (mean age: 39 years; range 20-60), with AIDS, CDC-classification IV-C, who did not have cardiac complaints.

Results: Pericardial effusion was present in 13/32 patients (39%). Valvular abnormalities were present in 9/32 patients (28%), of whom 2 had vegetations and 3 a prolapsing aortic valve leaflet. Wall motion abnormalities were seen in 21/32 patients (65%) and varied from moderately depressed regional myocardial function to severe, asymmetric global left ventricular dysfunction (5 patients). Cardiac abnormalities were absent in only 2 patients (6%).

Conclusions: Cardiac abnormalities are common in patients with AIDS and usually led to subclinical - affection of myocardial function.

M.B.P.284

CHARACTERISTICS OF PATIENTS WITH AIDS-ASSOCIATED HEART DISEASE BUT NO IMMUNOLOGICAL OR CHEMICAL INTERVENTION. Dilla J., Krieger, M.D., Oser-Jacques Rommes, M.D., M. Toussaint, M.D., The Heart Institute, Miami, FL, USA, and Hospital Saint-José and Cochin, Paris, France.

We retrospectively studied 41 adult patients (18 known to us, 23 from the literature) with AIDS and seronegative heart disease in whom the cause of the heart disease was assessed by culture and/or biopsy. Fifteen (36%) had no demonstrable cardiac pathogen. (Intrathal, 13 had infectious pericarditis, 8 had infectious myocarditis and 5 had a cardiac tumor. The Nethal group had a higher proportion of fibrinous fibrin showers and a lower rate of the infection of toxoplasmosis (0.07, mean=0.04, x²). The interval from the onset of AIDS or ARC to cardiac symptoms averaged 15.4 months in the Nethal group, versus 5.5 months in the group with a cardiac pathogen (with 3 strong outgroup, p=0.024, Fisher's). The Nethal group tended towards a higher frequency of prior P. carinii infection (p=0.07, Fisher's), and all groups had those with cardiac tumor had a lower rate of prior cutaneous Kaposi's sarcoma (p=0.04, x²). Other findings were equally distributed between groups. HIV was isolated from the heart in only 2 patients (pericardial fluid in 1 patient with infectious pericarditis) in the myocardium of 1 patient in the Nethal group. These data suggest that findings not demonstrable pathogen in an AIDS patient with seronegative heart disease is common, may be due to a prior, healed infection, perhaps related to P. carinii, and probably is not due to a direct cardiac effect of the HIV virus.

M.B.P.285

LEFT VENTRICULAR DYSFUNCTION IN AIDS PATIENTS WITH SEVERE PNEUMOCYSTIS CARINII INFECTION.

Wood Robert D. M.B.B. Tachemont J., Sweeney R.J., Bowden C.T.

LACUSO Medical Center, 3000 Street, Los Angeles, CA, U.S.A.

Objective: Respiratory failure associated to Pneumocystis carinii infection (PCP) continues to have an extremely high mortality. Cardiomyopathy has been described in patients with AIDS (Ruffard SP, 1986). In this study we examined the hemodynamic parameters of patients with PCP and severe respiratory failure.

Methods: We evaluated twelve patients (age = 34-74 yrs) with AIDS, documented PCP and severe respiratory failure (P_{ao2} < 65-1/0.16) requiring PEEP. We chose subjects who had no evidence of any concomitant bacterial, fungal, mycobacterial or viral infection as defined by lack of clinical signs, negative cultures, including blood. Hemodynamic data were obtained with a balloon-tipped pulmonary artery catheter. Cardiac outputs were obtained by thermodilution. Data were examined on admission to the ICU and at 12 and 24 hours.

Results: Our data showed:

Time	MAP	MPAP	PAOP	PCWP	CO	LVDF	SVR
12h	105 ± 10	16 ± 10	16 ± 10	14 ± 10	4.3 ± 1.1	12	80 ± 20
18h	102 ± 11	14 ± 10	15 ± 10	13 ± 10	4.2 ± 1.2	17	88 ± 10
24h	102 ± 12	14 ± 10	15 ± 10	13 ± 10	4.4 ± 1.4	18	78 ± 10

Conclusions: Our patients with PCP demonstrated a hypodynamic state not unlike that associated with sepsis. We found them to have profound myocardial dysfunction, with left ventricular function curves shifted downward and to the right. This may have therapeutic implications in the management of AIDS patients with respiratory failure due to PCP.



M.B.P.286

ELECTROCARDIOGRAPHIC CHANGES IN PATIENTS RECEIVING PENTAMIDINE FOR THE TREATMENT OF PNEUMOCYSTIS.

ALLBaker, Gordon A, Sheward A, Siger P, Gibson C, Haddock SR, Department of Internal Medicine, University of Southern California, Los Angeles, California, U.S.A.

Objective: In 1987, two patients developed bradycardia (POT) on pentamidine for the treatment of Pneumocystis carinii pneumonia (PCP) in the absence of electrolyte abnormalities. The purpose of the study was to evaluate the electrocardiographic effects of pentamidine (PTM).

Methods: We prospectively obtained a series of 12-lead ECG studies in 10 consecutive patients with AIDS and PCP who were receiving PTM. The ECG was obtained before administration of PTM, and 2.5 ± 0.8 days (cumulative dose of PTM 652 ± 214 mg) and 7.2 ± 1.1 days (cumulative dose 1082 ± 588 mg) after therapy. We patient had no other heart disease, thyroid abnormality or electrolyte disturbances.

Results: The heart rate at baseline was 90 ± 16, and did not change on day 2.2 (97 ± 21) or day 7.2 (87 ± 20). Similarly, the PR interval of 146 ± 10 ms remained stable at day 2.5 (142 ± 52) and 7.2 (147 ± 21). Also QTc of 422 ± 22 remained unchanged (419 ± 10 on day 2.5 and 408 ± 28 on day 7.2). Although one patient had mild QTc prolongation from 430 to 510 ms there was no other ECG abnormality.

Conclusion: Pentamidine produced no significant dose related ECG effects. E.TOP appears to be an idiosyncratic complication of PTM. Abnormal QTc prolongation during therapy with PTM is a relatively rare and when present, should be treated as a warning sign of impending TDP.

Néoplasme Neoplasm

M.B.P.287

STAPHYLOCOCCUS Aureus ENDOCARDITIS IN HIV(+) AND HIV(-) INTRAVENOUS DRUG ABUSERS

Doblets, Eric; Sore, C and Flahault, H. University of Miami School of Medicine, Miami, Florida, USA.

Objective: To evaluate the clinical presentation and outcome among HIV(+) and HIV(-) intravenous drug abusers (IVDA) with S. aureus endocarditis.

Methods: Retrospective chart review of 50 patients hospitalized for S. aureus endocarditis between March 1983 and November 1983 was done. 23 were HIV(+) and 18 HIV(-), 3 patients seroconverted. Age, sex, race, medical history, physical exam, laboratory parameters and outcome were assessed.

Results: Mean age was similar in both groups. More women (63% than men (37%) were noted in the HIV(+) group. No difference in sex distribution was seen in the HIV(-) group. In HIV(+) group, 78% were black americans, 19% white, and 3% hispanic. No racial differences were noted in the HIV(-) group. Fever-TX and cough-SXR were less frequent presenting symptoms in HIV(+) compared with 80% and 72%, respectively, in HIV(-). No differences in physical and chest X-ray findings were noted. Mean haemoglobin (11.7) and white count (11.2) were higher in HIV(+) patients than HIV(-), respectively (10.8 and 10.5). More vegetations were identified in the HIV(-) group than HIV(+) (56% vs 26%).

Recurrence of S. aureus endocarditis was the same in both groups. 4 patients had prior or concurrent opportunistic infections (OI). 4 developed OI within 10 days of endocarditis (11.7%) and white count (11.2) were higher in HIV(+) patients than HIV(-), respectively (10.8 and 10.5). More vegetations were identified in the HIV(-) group than HIV(+) (56% vs 26%).

Recurrence of S. aureus endocarditis was the same in both groups. 4 patients had prior or concurrent opportunistic infections (OI). 4 developed OI within 10 days of endocarditis, 1 of PCP, and 1 of unclassified cause.

Conclusion: HIV(+) patients with S. aureus endocarditis were more likely to be black american women. Poor outcome and high fatality rate favored the HIV(+) group.

M.B.P.288

POLYCLONAL AND MONOCLONAL B-CELL LYMPHOMA IN AIDS

Kanda, Lawrence D., Meeker T.M., Falgat B., Herndon B., Klayman B., Bashi P., Orinetti C.M., McGrath M.P., Department of Medicine and Pathology, San Francisco General Hospital, University of California, San Francisco, CA, U.S.A.

Objective: The identification of clinical characteristics associated with two molecular subgroups of AIDS-associated B-cell lymphomas.

Methods: Immunoglobulin heavy chain (IgH) DNA Ase-I restriction enzyme (E) for Epstein-Barr virus (EBV) were performed on 23 lymphoma tissue specimens obtained at diagnosis from patients with AIDS-associated non-Hodgkin's lymphomas (NHL) and correlated with clinical features.

Results: Fourteen tumors were identified as monoclonal and nine as polyclonal. The polyclonal lymphomas included immunoblastic (6), diffuse large cell (2), and small noncleaved (1) histologies. Monoclonal lymphomas included immunoblastic (3), small noncleaved (5), and large cell (1). Six primary CNS lymphomas were all monoclonal, immunoblastic. EBV DNA sequences were identified in 4 of 7 monoclonal samples and 1 of 4 polyclonal samples. Non-CNS lymphomas patients with polyclonal diagnosis lived longer (median 13 vs 3.3 mo; p=0.003), had higher total T4 cell counts (369 vs 120/mm³, p=0.1), and were more likely to have Stage I disease (4/7 vs 0/6; p=0.07).

Conclusions: The frequency of a prior AIDS diagnosis, performance score, and the frequency of extranodal disease (known prognostic features) were similar in each group.

Conclusions: Molecular analysis suggests two disease processes in patients with AIDS-associated NHL, each associated with distinct clinical features and prognosis.

Session d'affichage Poster Session



Aspects Cliniques Clinical Aspects of AIDS

M.B.P.289 KAPOSI'S SARCOMA IN PATIENTS WITH HIV INFECTION

Latif, Ahmed, Houston S, Mall P, Bassett M, Thornton C, Sitima J, et al University of Nebraska Medical School and Nebraska Blood Transfusion Service, NEB, NE, USA

Objective: To study the clinical features and response to treatment of KS in patients with HIV INFECTION.

Methods: All patients with HIV infection and histologically proven KS were studied. For staging purposes fiberoptic endoscopy was carried out. Patients were treated with combination chemotherapy using acyclovir, 5, zalcitabine and zidovudine.

Results: 100 (80%) patients were male and 22 (18%) were female. The mean age of males was 38 years and that for females was 31 years. Generalized lymphadenopathy was found in 107 (87%) patients. Skin lesions in the form of nodules, plaques or diffuse infiltration were found in 115 (93%) patients. 6 patients had mucosal lesions of KS. Lymphadenopathy but no skin lesions were found in 10 lymphadenopathic KS. Mucosal lesions were found in the buccal cavity (26%), in the nasopharynx (4%), on the conjunctivae (7%), in the bronchi (17%). Two patients had concomitant infection with *Pneumocystis carinii*. 99 patients were treated and of the 76 evaluated treatment failure occurred in 18 (23%) while partial or complete remission occurred in 58 (77%). The cumulative death rate for a 24 month treatment failure occurred in 18 (23%) while partial or complete remission occurred in 58 (77%). The cumulative death rate for a 24 month period was 25.8%. **Conclusions:** Patients with AIDS-related KS respond well to chemotherapy with initial dramatic improvement. However relapses frequently occur. Patients with pulmonary KS have a poorer prognosis.

M.B.P.291 KAPOSI'S SARCOMA - CLINICAL DISTRIBUTION, OPPORTUNISTIC INFECTIONS AND SURVIVAL

James, Carlo, Pheasant, R.G., Diaz, M.K., Eyer-Silve, M.A., Nigam, L.A.; Norris 54, CA.

Centre & Centre University of California, University of Los Angeles (UCLA) - Beverly.

Objective: To evaluate the clinical distribution, opportunistic infection (OI) and survival of AIDS patients with Kaposi's (KS).

Methods: Of 235 patients treated the CDC case definition for AIDS, 39 (16.5%) were diagnosed with KS. These were evaluated for clinical distribution and analyzed for occurrence of opportunistic infections. Cumulative survival rates are assessed in 22 patients (Gutler, Center 1980) with KS with and without OI.

Results: Kaposi's sarcoma occurred in 39 male patients, 39 homosexual (59.2%) and 26 bisexual (66.2%). The sites were treated as in patients (91.8%), lymphoma (16 (77.1%)), post-lymphatic tract (6 (77.1%)), lung (2 (50%)), peritoneal tract (2 (50%)) and brain (1 (11.7%)). We observed infections in 48 (81.2%). Candidiasis was the most frequent OI occurring in 39 patients (66.2%), *Pneumocystis carinii* in 19 (28.0%), Cryptosporidiosis in 10 (16.8%) and cerebral toxoplasmosis in 9 (15.2%). The proportion surviving one-year among 22 patients with KS with and without OI was 88% versus 60% (NS) and three-year and five-year survival was 44% among 18 patients with both KS and OI, one-year survival was 70% but a steep drop occurs thereafter by the years only 7% survive and none survive three years.

Conclusions: The prevalence of OI in our AIDS patients is high (81%). All patients were homosexual men. The majority of KS involved skin, lymphomas and GI tract. Opportunistic infections seem to be responsible for decreased survival in KS.

M.B.P.293 MALIGNANT NEOPLASMS IN SURVIVAL SPECIMENS OF DIFFERENT AIDS RISK GROUPS

W. Nappes MD, Richard Rottenberg MD, G. Sidhu MD; NYU Medical Center, New York, NY, U.S.A.

We examined 1107 surgical specimens from 321 AIDS patients to determine the frequency and site of malignant neoplasms (MN) and differences, if any, among the two major risk groups of homosexual (HS) and IV drug abusers (IVDA). There were 231 patients with HS and 276 patients with IVDA's (21% of HS and 8% of IVDA) and 27 (4%) with malignant lymphoma (ML). Four HS had both KS and ML. Five patients had squamous cell carcinoma (SCC) and one prostatic carcinoma. KS was found in 63 of 319 skin biopsies (20%) and constituted the most common opportunistic disease (OD) at this site. KS was also found in 15 of 81 lymph nodes (18%), 10 of 194 digestive tract bi (5%), 8 of 329 lung bi (2.4%), 4 of 21 esophageal bi (19%), and 1 of 73 liver bi (1.4%). KS was the first presenting OD in 69 of 89 (78%) patients. KS was 7 times more common in HS vs IVDA and was diagnosed in 70 of 187 HS (37%) vs 5 of 120 IVDA (4%). Malignant lymphoma (ML) was found in 14 of 81 lymph nodes bi (17%), 5 of 194 digestive tract bi (2.6%), 5 of 187 bone marrow bi (3%), 3 of 176 skin bi (1.7%), 2 of 8 brain bi (25%), and once each in soft tissues, liver, oral mucosa, and lung. ML was the first presenting OD in 17 of 27 (63%) patients. HS were diagnosed with approximately equal frequency in HS and IVDA [20 of 187 HS (10%), 8 of 120 IVDA (6%)]. ML was, however, more frequently seen in HS (16 of 34 (46%)) than in IVDA (3 of 8 (37%)). SCC occurred in lymph (2), anus (1), penis (1), and skin (1) and exclusively in HS. We conclude that KS is the most frequent MN in HS, and ML in IVDA. ML is more commonly extended in HS than in IVDA.

M.B.P.290 LYMPHOMAS IN PATIENTS WITH HIV INFECTION

Carlo, M. Edg., Guarnier JG, Carr D, Mendrix L'E., Gentry Complex and the Crawford W. Long Hospital of Emory University, Atlanta, GA, U.S.A.

OBJECTIVE: We identified 18 patients with AIDS, AIDS-related lymphoma and with serological evidence of HIV infection, seen at a single hospital since 1982, and analyzed the clinical presentation, type of lymphoma, treatment and outcome to better understand their disease.

METHODS: Retrospective review of medical records and prospective follow up of patients seen since July of 1988.

RESULTS: 16 patients had non-Hodgkin's lymphoma (NHL); 1 Hodgkin's disease, and 1 had the simultaneous presence of both Hodgkin's disease and NHL. All patients were white; homosexual men with a mean age of 36.2 years. In 47% this was the initial presentation of HIV infection. We classified 65% of the cases as high grade (7 small cell lymphoma, 2 large cell, 1 immunoblastic, 1 high grade otherwise unclassifiable), 20% as intermediate grade (5 diffuse large cell, 1 mixed), and 1 patient had a low grade lymphocytic lymphoma. Extracranial involvement was present in 47% with the gastrointestinal tract and the liver being the common sites. Of 12 patients treated with chemotherapy, 7 treated with M2COP-B, achieved complete remission. However, one patient relapsed after 86 weeks. Both patients with Hodgkin's disease achieved a complete remission with MOPP-B.

CONCLUSIONS: High grade malignant lymphomas, frequently with atypical presentations, occur in patients infected with HIV and should be treated with intensive chemotherapy regardless of stage. The response to treatment with M2COP-B is favorable; however, late relapses can occur.

M.B.P.292 LAMAR GRANULAR TUMOR NEPLASIA. ITS INCIDENCE IN HIV INFECTED MEN

AND THE ROLE OF HUMAN PAPILLOMA VIRUS (HPV) AND OTHER RISK FACTORS

J. P. SIEHL, H. BEHRE, H. KROEMER, P. NEMAZI, D. TAYLOR-KENDRICK, S. H. PORTER. The Department of Genito-Urinary Medicine, the Prud Street Clinic, St Mary's Hospital, London, United Kingdom.

A high incidence of cervical dysplasia has been noted in HIV positive women. Therefore, 20 women infected with HIV were studied cytologically and by colposcopy. Results are as follows:

Site of Dysplasia

Site of Dysplasia	HPV	HPV
Uterine Cervix <td>100%</td> <td>100%</td>	100%	100%
Vagina <td>100%</td> <td>100%</td>	100%	100%
Rectum <td>100%</td> <td>100%</td>	100%	100%

Of our study group had evidence of HIV infection and 15% had other well recognized risk factors for each disease, age, sex of 17 men, education, nature of sexual partners, smoking etc. We will present the results of a study, including HIV serology, carefully controlled for these factors and designed to investigate the role of HIV and the immunosuppression caused as a result of HIV infection in the increased incidence of lower genital tract neoplasia in this group.

* CIN = cervical intra-epithelial neoplasia. VCN = vaginal intra-epithelial neoplasia. IN = Intraoral, intra or mucosa. VAIN = vaginal intra-epithelial neoplasia.

M.B.P.294 P-IALL IN HIV-POSITIVE IV DA MAN

Moscar, J.A.C. de Calabro J, Galante L, Landone G, Nara M, Orsato F, Department of Hematology and Pathology, Niguarda Ca Granda Hospital, Milan, Italy.

OBJECTIVE: To present the clinical course of P-IALL in HIV-positive heroin abuser, the response to therapy and the survival. **Methods:** 10 patients (100% of HIV and 100% of P-IALL) were studied. HIV was positive (100% of 10 patients) and HIV RNA was positive (100% of 10 patients). All patients were treated with combination of doxorubicin, cyclophosphamide, etoposide, procarbazine, and procarbazine. Cytogenetic: 100% of 10 patients were negative for CD 22, Bcl-2, and Bcl-6. All patients had a complete remission. All patients were negative for HIV RNA. Two courses of induction therapy (doxorubicin, cyclophosphamide, etoposide, and procarbazine) and one course of consolidation therapy (doxorubicin, cyclophosphamide, etoposide, and procarbazine) were given.

Results: For and short partial remission was obtained. During relapse bilateral pneumonia of low-A few days later the patient developed dramatic bilateral respiratory with fever, myalgia, diarrhea and acute renal cortical CT tumor of the lung. The patient died after "doxorubicin" course. **Autopsy findings:** (indications: disseminated; primary carcinoma by angiosarcoma; metastatic carcinoma; tumor by unknown cause).

Conclusions: P-IALL is rarely associated to HIV-positive men but increasing reports in literature. Some authors are the opinion that the current CDC criteria for AIDS should be widened to include P-IALL in HIV-seropositive subjects. The course was dramatic and therapy ineffective as reported by others authors.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.295

IMMUNAL PRESENTATION AND CLINICO-PATHOLOGICAL CORRELATIONS IN NON HODGKIN'S LYMPHOMA (NHL) ASSOCIATED WITH HIV INFECTION

E. OUBREINER, J.P. PARCET, C. CISELBERGHEIT, J.P. CLAVEL, A. TRUSS, N. KARLAIN, F. JETTEL, N.Y. NICÉ - FRANCE.

We have evaluated the potential correlations between histopathology, clinical expression and immunodeficiency status in 57 patients with NHL associated with HIV infection.

Histopathology (n)	Stage	CD4 count	CD4 cells/mm ³
	I-II	III-IV	IV
Immunoblastic (13)	10	3	10 > 3
Diffuse large cell(29)	13	16	10 > 19
Burkitt (15)	2	13	4 > 11

Patients with immunoblastic NHL had low CD4 cell counts, belonged to CDC group IV and presented usually with localized extranodal (Lympho) testis (2), par (2), lung (2) and colon (1). Patients with Burkitt lymphoma had a disseminated disease with bone marrow involvement in 5/15 and central nervous system involvement in 4/15, but often asymptomatic HIV infection. Patients with diffuse large cell NHL had an intermediate status.

M.B.P.297

KAPOSI'S SARCOMA (KS) IN WOMEN WITH ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)

Chengy, Tony M. and Slegel F. Queens Hospital Center(CUNY)and Long Island Jewish Medical Center (L.J. Queens and New Hyde Park, N. Y. 11432 and SUNY at Stony Brook, N. Y. 11794, U. S. A.

Most patients(pts) with AIDS related KS are male homosexuals. KS in female patients with AIDS is rare. Objective. To survey cases of AIDS related KS in women and exentire their clinical course.

Methods. Records from tumor registries and patient charts from private oncologists from QHC and LJJ were reviewed. A literature computer search was also used to look for cases of female AIDS related KS. Results. Seven patients range in age from 23 to 34 years; 5 are black, 1 Hispanic and 1 Haitian. Six patients, except the Haitian, are intravenous drug users. All pts developed opportunistic infections: oral candidiasis (7), *Pneumocystis carinii* pneumonia (3), genital herpes (4),herpes labialis(1), CMV infection(7). All pts except one were diagnosed to have KS clinically and confirmed by biopsy; 6 have dermal involvement with visible skin lesions of the trunk and lower extremities. Chest x-ray of those 6 patients showed interstitial infiltrates. Bronchoscopy confirmed KS. The seventh patient presented with angioimmunoblastic lymphadenopathy; later right eye proptosis developed which, on biopsy, revealed non-Hodgkin's lymphoma. She expired 4 months later and on autopsy there was KS in the lung and stomach. Survival of all 7 pts was only 1 to 6 months (median 3-6 months). Conclusion. Women with AIDS related KS have a very aggressive course. All cases presented have pulmonary involvement. We suggest that the putative etiological agent(s) can be transmitted by the intravenous route.

M.B.P.299

PREDICTORS OF SHORTENED SURVIVAL IN PATIENTS WITH KAPOSI'S SARCOMA AND HIV-1 INFECTION

Technica, Barbara; Brunstert, U.; Schwel, I. and Hannover Medical School, Hannover, F.R. Germany.

Objective. To determine clinical, viral and immunological characteristics at the time of diagnosis of Kaposi's sarcoma in patients with HIV-1-infection in correlation to survival.

Methods. HIV-infected patients with biopsy proven Kaposi's sarcoma were enrolled in this study.

Results. During observation period of this study (17 months) 21 patients with HIV-1-infection and Kaposi's sarcoma were identified. 19/21 patients had contracted other bacterial, viral and/or opportunistic infections. In our study the prognosis of Kaposi's sarcoma depends on the appearance of other concomitant infectious agents such as *Pneumocystis carinii*, CMV etc. Furthermore the decrease of CD4/CD8-ratio, prevalence of specific p24-antigen i.e., and loss of specific antibodies to p24-core-protein corresponds with a poor prognosis.

Conclusion. Predictors of shortened survival in patients with HIV-1-infection and biopsy proven Kaposi's sarcoma included loss of specific antibody to p24, p24-antigenemia, decreased CD4/CD8-ratio and/or appearance of opportunistic infections such as PCP.

M.B.P.296

ACCURACY OF KLA DRS AND KAPOSI'S SARCOMA IN TRINIDAD AND TOBAGO

Corneille Bartholomew*, V. Wilson**, F. Cleghorne***. *The University of the West Indies; **Department of Immunology, General Hospital, Port of Spain; ***The Caribbean Epidemiology Centre, Port of Spain, Trinidad.

Although the association of Kaposi's Sarcoma (KS) and KLA DRS has not been found in all reports the majority of studies have shown an increased frequency of DRG both in endemic KS and HIV associated KS. Trinidad and Tobago has a population of 1.2 million people comprising people of African origin (41%), Indian origin from North India (41%), Mixed race (16%), Caucasian 1% and Chinese 1%. The people of African origin came to Trinidad via the slave trade from 1680 and the Indians from North India as indentured labourers from 1845. Up to December 31, 1988 there were 289 cases of AIDS in Trinidad, 288 of whom were Afro-Trinidadians and 25 Indo-Trinidadians. However, there were only 3 cases of KS all of whom were in people of predominantly Caucasian ancestry. There is no IV drug abuse in Trinidad. Statistics of DRG antigen frequencies show a frequency of 31.6 in African blacks, 26.0 in North American blacks, 29.0 in North Indians, 25.2 in Afro Trinidadians and 21.5 in Indo-Trinidadians. On the other hand, while the DRG antigen frequencies were 26.8 in African blacks, 25.2 in N. American blacks and 22.6 in N. Indians, it was only 8.5 in Indo-Trinidadians and absent in Afro-Trinidadians. The frequency of DRG in this population may account for the extremely low incidence of KS in Trinidad and Tobago and supports the epidemiological claims for an association between KS and DRG.

M.B.P.298

LYMPHOMATOUS LEUKEMIA IN HIV-INFECTED PATIENTS

Minoli Lorenz, Maserati, R.; Pan, A.; Malfitano, A.; Sacchi, R. Pagnocco, G. T. Infectious Disease and Hematology Dept., IRCCS San Matteo, Università di Pavia, Italy.

IRCCS San Matteo, Università di Pavia, Italy. Among the 289 cases of AIDS in Trinidad and Tobago there were 288 of whom were Afro-Trinidadians and 25 Indo-Trinidadians. However, there were only 3 cases of KS all of whom were in people of predominantly Caucasian ancestry. There is no IV drug abuse in Trinidad. Statistics of DRG antigen frequencies show a frequency of 31.6 in African blacks, 26.0 in North American blacks, 29.0 in North Indians, 25.2 in Afro Trinidadians and 21.5 in Indo-Trinidadians. On the other hand, while the DRG antigen frequencies were 26.8 in African blacks, 25.2 in N. American blacks and 22.6 in N. Indians, it was only 8.5 in Indo-Trinidadians and absent in Afro-Trinidadians. The frequency of DRG in this population may account for the extremely low incidence of KS in Trinidad and Tobago and supports the epidemiological claims for an association between KS and DRG.

Among the 289 cases of AIDS in Trinidad and Tobago there were 288 of whom were Afro-Trinidadians and 25 Indo-Trinidadians. However, there were only 3 cases of KS all of whom were in people of predominantly Caucasian ancestry. There is no IV drug abuse in Trinidad. Statistics of DRG antigen frequencies show a frequency of 31.6 in African blacks, 26.0 in North American blacks, 29.0 in North Indians, 25.2 in Afro Trinidadians and 21.5 in Indo-Trinidadians. On the other hand, while the DRG antigen frequencies were 26.8 in African blacks, 25.2 in N. American blacks and 22.6 in N. Indians, it was only 8.5 in Indo-Trinidadians and absent in Afro-Trinidadians. The frequency of DRG in this population may account for the extremely low incidence of KS in Trinidad and Tobago and supports the epidemiological claims for an association between KS and DRG.

Among the 289 cases of AIDS in Trinidad and Tobago there were 288 of whom were Afro-Trinidadians and 25 Indo-Trinidadians. However, there were only 3 cases of KS all of whom were in people of predominantly Caucasian ancestry. There is no IV drug abuse in Trinidad. Statistics of DRG antigen frequencies show a frequency of 31.6 in African blacks, 26.0 in North American blacks, 29.0 in North Indians, 25.2 in Afro Trinidadians and 21.5 in Indo-Trinidadians. On the other hand, while the DRG antigen frequencies were 26.8 in African blacks, 25.2 in N. American blacks and 22.6 in N. Indians, it was only 8.5 in Indo-Trinidadians and absent in Afro-Trinidadians. The frequency of DRG in this population may account for the extremely low incidence of KS in Trinidad and Tobago and supports the epidemiological claims for an association between KS and DRG.

M.B.P.300

TREATMENT OF DISSEMINATED MYCOBACTERIAL INFECTION (MI) WITH CIPROFLOXACIN (CP), ETHAMBUTOL (EB), RIFAMPIN (RIF) AND ISONIAZID (IS)

Chiu, Joseph; Nambawa, J.; Bonesta, S.; Young, L.; Hestonite, P.; and Robinson, J.A., California Collaborative Treatment Group, USA.

Objective. To assess the clinical and microbiological response to a multiple drug regimen for disseminated MI.

Methods. 17 AIDS pts. with sustained MI bacteremia were treated with AMK (7.5mg/kg/day for first 4 wks), CP (1500 mg BID), EB (1500mg/day), and RIF (15mg/kg/day) for at least 3 months. Median time since AIDS diagnosis was 21 wks (range 2-50) and since onset of possible MI symptoms (see table) was 4 wks. (range 0-20)

Results. Log₁₀ median colony forming units (CFU) fell by 1.2 (2.4-1.2) in 4 wks in conflict with decreasing prevalence of symptoms. Improvements were sustained thru 12 wks. In those who tolerated therapy, treatment was terminated prematurely (12 wks) for reasons (n) and hepatitis (n).

NUMBER OF PATIENTS
MEDIAN CFU/ml (range)
FEVER > 38°C
MYCOBACTERIA
RIFAMPIN
ISONIAZID

Conclusion. This regimen relieves symptoms and reduces bacteremia in a majority of patients, but has significant toxicity, requires parenteral administration, and does not frequently terminate bacteremia.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

Programmes de soins infirmiers : éducation Nursing Health Care Programmes: Education

M.B.P.301 PATIENT COMPLIANCE AND TERMINATION IN COMMUNITY-BASED CLINICAL TRIALS OF AIDS TREATMENT. Holzman, Stephen P., and Rosen, J.D. Community Research Initiative, New York, NY, U.S.A.

Objective. To present the analysis of data concerning participant compliance and termination in clinical trials.

Methods. We analyzed drop-out rates for participants enrolled in clinical trials carried out in the past year by the Community Research Initiative. We also estimated the effect of certain interventions designed to diminish drop-out rates.

Results. Of 280 participants in two trials over a one-year period, 60% remain in the trial. Reasons for termination include death, incarceration, illness, voluntary withdrawal, and noncompliance. We estimate that in the latter two categories, a 25% greater drop-out rate would have occurred were it not for our initiation of at-home and on-site visits to provide treatment, and initiation of telephone counselling and on-site supportive intervention to participants and to their lay co-ordinators.

Conclusion. A high drop-out rate should be anticipated in clinical trials involving persons with AIDS/ARC. It can be compensated for by increasing the number of participants, and by supporting personnel to provide aggressive case-management, as illustrated.

M.B.P.302 CLINICAL IMPACT OF CASE MANAGEMENT BY AN IMPAIRED AIDS CLINICAL NURSE SPECIALIST ON COSTS AND QUALITY OF PATIENT CARE. Dale, E. Small, Parkland Memorial Hospital, Dallas, Texas, USA.

Objective. To study the effects of an Impaired AIDS Clinical Nurse Specialist and case management practice on costs, clinical outcomes and quality of patient care.

Methods. The patient populations used in this study were those Impaired admissions in 1988, 1989. The data were categorized as HIV, ARC, or AIDS. The data was analyzed for the 12 time periods related to the appointment of an Impaired-based Clinical Nurse Specialist (CNS) in 1988. Case management included the identification and classification of each patient and upon admission, daily patient contact and anticipatory and comprehensive planning during each phase of the patient's illness. The case management protocol extended beyond hospitalization to include discharge and follow-up into the outpatient AIDS Clinic. Average length of stay (LOS) and readmissions were the indexes used to evaluate cost-effectiveness and quality of care respectively.

Results:

Group I:	1988	Group II:	1987	Group III:	Oct.-Dec. 1988
LOS	11.96	n = 331	LOS	9.03	n = 130
LOS 11.46	11.11	LOS	9.03	LOS	9.03
readmission	31%	readmission	11%	p < 0.05	p < 0.05

The average LOS was 11.46 days in 1988 and 11.8 days in 1987. With the involvement of an Impaired-based AIDS Clinical Nurse Specialist, the average LOS was decreased to 9.03 days. The percentage of readmissions to the institution was 31% in 1988 and 33% in 1987, and only fell to 11% in 1988.

Conclusion: The results of this study indicate that LOS and readmission rates are significantly reduced by the role of an Impaired-based CNS and case management.

M.B.P.303 THE ROLE OF NURSING IN MANAGING COMMUNITY-BASED RESEARCH. Holzman, Stephen P., Rosen, J.D., Bennett, J.J., Elledge, George, P., Community Research Initiative (CRI) New York, NY, U.S.A.

Objective. To describe problems encountered and resolutions developed in management of community-based research from a nursing perspective.

Methods. Identification of problems and resolutions in the following categories: protocol development and implementation, data collection, quality assurance, budgeting for research, case-management in recruitment and retention of research subjects, and personnel management.

Results. The New York CRI is the first free-standing, community-based research organization in the USA. The CRI-model has created methods of managing clinical research trials from a community perspective. The CRI-model has been developed with clinical nurses assuming a major role in management of clinical trials.

Conclusion. Using clinical research nurses to manage clinical trials provides one approach to successful operation of community-based research. Our experience should be of value to those planning or implementing a community-based research model.

M.B.P.304 NURSING IN THE COMMUNITY FOR PEOPLE WITH HIV: DESCRIPTION OF A TRAINING/IMPLEMENTATION PROGRAMME. Ellis, G. Moore, *Oxford Regional Health Authority, Oxford, UK.

Objective. To develop and implement a training programme to ensure the most effective utilisation of community nursing services by people with HIV infection and disease.

Methods. Experience in Oxfordshire of working with HIV disease was confined mostly to acute sector staff, thus blocking the full utilisation of community care by people with HIV. Integration of HIV care into community nursing services was achieved by developing a facility whereby one community nurse from each population-based geographical sector was facilitated for training and work on the in-patient wards.

Results. Nurses were able to facilitate the care at home of patients through liaison between hospital and local primary health care (PHC) teams, and by sharing knowledge and experience with colleagues. The programme was implemented by identifying staff, devising a training curriculum and providing the policy and resource back up which was necessary. These processes will be fully described in the presentation.

Conclusion. Care in the community must be actively developed. The specialisation of services in the acute sector reduces the care options for the patient. Such development is most effective when implemented through the PHC team setting in the community.

M.B.P.305 PROJECTIVE REPORT ABOUT SELF, FAMILY, ENVIRONMENT AND DISORDER ASSOCIATED WITH ORBITIC NERVE IMMUNODEFICIENCY VIRUS INFECTION IN CHILDREN. Scholtz, P., Carter, Susan, Aborn, J., and Hanson, J., Baylor College of Medicine Children's Hospital, Houston, Texas.

Objective. To demonstrate that the child with AIDS and symptomatic HIV infection can describe the progression of physical discomfort through the use of colors, body outline drawings, and visual analog.

Methods. Projective drawings and visual analogs are solicited monthly over a 2 year period while children are outpatients at a hospital clinic. Drawings are analyzed using standard analysis paradigms for children's art. Visual analogs (facial scales) are analyzed on the interval level comparing parent and medical report of the child's health to the scores on the scale.

Results. Preliminary results on 8 children over an 11 month period indicate that children can pinpoint in drawings sites of physical discomfort, as well as sources of psychological distress. The 3 children with stable family lives indicate varying degrees of physical discomfort through their drawings, but depict happy self, family, and environment, thus showing a relatively low visual analog score (the lower the score, the "happier" the child) while children with less stable home environments and/or behavioral disorders have higher visual analog scores.

Conclusion. Preliminary results indicate that communication through art work can be constructive and predictive in children who may not be able to communicate their feelings verbally. These drawings are also helpful in determining sites of discomfort, therefore enhancing healthcare.

M.B.P.306 INFECTION CONTROL NURSE ROLE: POWERFUL CHANGE AGENT IN THE PSYCHIATRIC SYSTEMS IN THE USA. Shalla, Debbie, Pappas, J., Gordon, **, Connecticut Mental Health Center, Yale-New Haven Medical Center, New Haven, **University of New Haven, West Haven, CT, U.S.A.

Objective. Psychiatric units tend to stress psychosocial rather than medical aspects of care. Practitioners in these settings are generally less comfortable with Infection Control (IC) procedures and are concerned about how these adversely affect the established therapeutic milieu. The successful integration of AIDS patients on these units will depend on the Infection Control Nurses (ICN) ability to innovatively conceptualize the role as a key organizational change agent. Using a frame of reference common to psychiatric-mental health nursing (PMHN) and sociology, attention is focused on the pivotal role of ICN in shaping organizational response to the first cohorts of HIV affected persons in psychiatric systems.

Methods. Relevant concepts are presented, drawn from data gathered from participant/non-participant observations, survey responses and informal interview of staff, patients and families. Confidentiality is maintained by presenting illustrative case material synthesized from published and unpublished sources.

Results. Given the anxiety engendered among psychiatric administrators and staff, the ICN in thrust into promulgation and must shape policies and procedures that govern patient treatment and staff behaviors. In an atmosphere rife with uncertainty and fear, the confiding tasks will entail on the part of the ICN: rapidly develop a plan that maximizes administrative goals, facilitates treatment and protects patients, families and staff. Realization of these needs requires the successful integration of AIDS patients on psychiatric units requires the ICN who attends to the interrelationships of biopsychosocial theories, research and practice. The ICN, who has a strong background in both IC and AIDS, can be a powerful positive force and leadership and acceptability to the IC policies and procedures in a psychiatric system.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.307

RIV SELF ASSESSMENT AND CARE PROGRAM

Tom Barnagale, R.N., AIDS Nurse Clinician, AIDS Clinic, Parkland Memorial Hospital, Dallas, TX.

OBJECTIVE: To develop a comprehensive program of preventive care services for eligible clients utilizing a Registered Nurse (R.N.) as a consistent primary caregiver.

METHOD: The client must first thoroughly understand what Human Immunodeficiency Virus (HIV) is and what it means to them. Secondly they must understand normal vs. abnormal in reference to their health status. Finally they must be taught how to assess themselves for any changes in their health status. The components of the program are HIV counseling according to C.D.C. standards, complete physical, exam for HIV infection staging, and patient education to teach the client to perform self-exams to assess for changes during their health care visits.

Eligibility criteria are ascertained by the R.N. Clinician, and are: HIV seropositivity, desire and mental ability to learn self-assessment. Projected outcomes include increases in client and staff satisfaction, reduction of avoidable events, hospitalizations and need for emergency services, maintenance of health, independence and financial stability.

CONCLUSION: This program allows for the earliest entry of the client into the healthcare network while allowing them to remain productive members of society through their health and physical status assessment.

M.B.P.308

OUTBREAK OF NORWEGIAN SCABIES AMONG HEALTH-CARE WORKERS

Kelly, Ann; Fry, C. St. Stephen's Hospital, London, England.

Objective: To control an atypical outbreak of Norwegian Scabies amongst patients who were immunosuppressed on an AIDS ward. Scabies was diagnosed and treated 40 health-care workers and their partners and close contacts. Preventing the spread to non-infected persons from one severely infested patient.

Method

- 1) Diagnosis and surveillance of an outbreak of atypical Norwegian Scabies and identifying infested health-care workers and patients.
- 2) Co-ordinating the treatment by ensuring all ward personnel were contacted and treated simultaneously. One other patient was treated at the same time.
- 3) Continued surveillance until all personnel were asymptomatic.
- 4) Standards of the ward had to be maintained and ensure infested staff were not giving direct patient care.

Results

- 1) Effectively contained the outbreak.
- 2) Prevented spread to uninfected persons.
- 3) Maintained the high standards of nursing care on the ward.

Conclusions

- 1) When patients are seen with skin problems Norwegian Scabies may be considered, an outbreak can be prevented.
- 2) Treatment of staff is essential if it proved to be effective.
- 3) Health-care workers and patients followed up as re-infestation could occur.

M.B.P.309

DEVELOPING COMMUNITY NURSES SKILLS IN HIV/AIDS PROGRAMS

Eric Thomas, and Robinson BS*, Pratt MS*, Willis CS
KypreosIII MS*, Newbury MS*, *Department of Health, London England, UK and **British Heart Foundation for Nursing, Ministry of Health Visiting, London, England, UK. **Beverly Health Authority, London, England, UK.**

Objective: A Government initiative aimed at improving levels of understanding among community nurses of HIV infection and AIDS, to provide opportunities for them to examine personal attitudes which may be obstacles to effective care and preventative treatment; to encourage their participation in HIV programmes.

Method: Workshops of two day duration were held in 14 Health Regions in England to demonstrate dissemination of information by a cascade effect: between 20 and 40 minor nurse managers took part in each. Sessions were facilitated by a team experienced in the care of HIV infected patients. On completion each participant was asked to list specific initiatives to be implemented locally. Six months later participants were followed-up to determine achievements, barriers encountered and possible solutions to them. An evaluation was made of the effectiveness of the Workshop with a view to services making recommendations on local and national policy.

Results: Various initiatives set up demonstrated that Districts with low HIV prevalence encountered difficulties in sustaining the initiative. More enthusiastic follow-up was demonstrated in districts with perceived growing AIDS caseloads. In all participants, levels of confidence improved.

Conclusions: A method of initiating cascade communication is a beneficial method of using key people who, after analysing their own attitudes to the subject, had sufficient influence to effect change.

M.B.P.310

FINAL HOME HEALTH CARE FOR PATIENTS WITH HIV DISEASE

Camp, Susan E., RN, BSN, EMDORTA, Anthony J. Windsor Home Care, Inc., New York, N.Y., U.S.A.

Objective: To develop and implement a program for the transfer of the comprehensive health care of the AIDS patient to the home setting, providing a more desirable alternative to the costly hospital setting particularly in light of the shortage of beds in hospitals where AIDS is endemic.

Methods: Describe and implement a program which encompasses total health care services for the AIDS patient in the home setting.

Results: Program components developed and implemented are: 1) Physicians (w/eligible a compassionate) in the care of the AIDS patient with a sound belief level in home care as a viable alternative; 2) Nursing service case management & coordination focused on the AIDS patient in complete collaboration with the physicians; the following services are necessary: a. Direct caregivers specially trained in the care of the AIDS patient with IV therapy and teaching progress for patients & family. b. "Wellness" program is inherent for sound health practices & counseling. b. Vendors to provide IV therapy pharmaceuticals & supplies, durable medical equipment, medical transport & lab services who are sensitive to the special needs of the AIDS patient. c. Therapeutic professionals such as SW, Pn, On, & ST to provide rehabilitative services & crisis intervention. d. Community support services for meal delivery, job care & support group for patient & family. 3) Health care cost payers with cost-effectiveness & compassion for the AIDS patient/prevention for home health care. 4) Out-patient facilities to provide for necessary transfusions, invasive procedures & testing. In 1988, 350 patients have been provided with this type of care in the HDU metropolitan area.

Conclusion: AIDS patients can receive cost-effective, comprehensive, safe and compassionate home health care.

M.B.P.311

INTERDISCIPLINARY HIV CARE MANAGEMENT TEAM

Tom Barnagale, R.N., K. Joy, RN, MS, L. Kukurty, MSN, Parkland Memorial Hospital, Dallas, TX.

OBJECTIVE: To develop a system to coordinate appropriate home care services for persons with AIDS (PWA's) within a model utilizing components from existing nursing process and social work case management models.

METHOD: Establishing a hospital-based case manager to assess patient needs and coordinate implementation of necessary medical and social services through regularly scheduled weekly networking case conferences. Collaboration of existing community-based AIDS service organizations involved with Parkland patients to provide needed hospital, clinic and community-based services.

RESULTS: By discussing emotional, psychosocial and health care needs of 25-40 patients at each meeting and identifying actual and potential problems, group members discuss means of addressing them without duplicating efforts and providing for smooth transition for the client from hospital to home or clinic to home. With few exceptions the team can assure discharge to home for our patients.

CONCLUSION: Networking has made it possible to start discharge planning on admission and as a result, decrease length of stay. The team now has the ability to quickly respond when healthcare outcomes do not meet expectations.

M.B.P.312

A DESCRIPTION OF NYC'S GAY POPULATION AS A LEGITIMATE COMMUNITY: AND IT'S RESPONSE TO HIV DISEASE.

Smith, Donald G., Aylken, K., May, K.*
Mount Sinai Medical Center, New York, New York, USA, ***New York University School of Education, New York, New York, USA, ****University of Arizona, Tucson, Arizona USA.**

Objective: (1) To describe and evaluate the NYC gay population as a legitimate community by standard definitions. (2) To perform a nursing assessment on the affect of HIV disease on the community and recommend nursing interventions.

Method: A needs assessment was performed by interview with groups representing the community. NYC's Office of Gay and Lesbian Health Co-sponsors, interviews of NYC gay males and a literature review of published studies on AIDS within the community.

Results: The NYC gay population identifies themselves as a community and meets current definitions of community. The assessment showed direct affect on the community. It identified goals for the community's health: (1) Return of the community to a state of health. (2) To prevent an increase of the number of AIDS cases within the community. (3) To reduce the number of other STD's. **Conclusion:** We identified a community, who's health is in crisis. It has identified it's own goals on returning to health, and developed a response through community involvement. We identified and described the services that can assist the community in it's return to health, by developing nursing programs to support the Parkland Hospital's ongoing community educational program on prevention. (3) Planning additional nursing for the community.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.313 LOS ANGELES PEDIATRIC AIDS NETWORK (LAPAN): A COUNTY-WIDE MODEL TO MAXIMIZE SERVICE DELIVERY FOR CHILDREN DIAGNOSED WITH HIV AND AIDS RISK FACTORS.
Gorell, D.C., Huxley, Mary E., California Children Services, Los Angeles, California, USA.

Objective: To promote interagency collaboration and facilitate effective service provision to children with HIV and their families. This project addresses current and future resource needs, clinical case management of all HIV patients, and social service concerns. **Methods:** Hospitals and community-based organizations (CBO's) were brought together to form the LAPAN Coordinating Council. An automated case management system is being developed to facilitate communication, create a common data base and use of CBO's. Terminals will be placed and social workers assigned at 7 participating hospitals. A formal needs assessment has been completed. Joint collaboration has also been established with staff from an HIV-funded treatment grant and a CDC Pediatric Surveillance Grant. LAPAN has also established a Consortium (APAC) to increase communication and exchange ideas among front-line professionals providing direct services. **Results:** The demonstration project has developed an automated case management system, methods to prevent duplication of service delivery, and has enhanced utilization. **Conclusions:** The creation of an infrastructure to manage pediatric HIV cases in a complex is critical. Multiple use of resources and joint planning was essential to meet the needs of this multi-problem population.

Supported by MCH grant #HRN PO 901-01-0.

M.B.P.315 COMPREHENSIVE CARE PROGRAM FOR CHILDREN WITH HIV-RELATED PROBLEMS AND THEIR CARE GIVERS
Bisag, Stanley, King, S.M., Amerson, C., Palmer, S., Goldie, R., Szewczyk, L., Lafave, A., et al. Hospital for Sick Children, Toronto, Canada.

Objective: To provide comprehensive medical, social and psychological care and support for children with HIV-related problems and their care givers.

Methods: HIV positive children and their care givers are followed by a team of medical specialists, along with team members from nursing, psychology, psychiatry, social work, clinical nutrition, pharmacy, pastoral care and Children Aid. These comprehensive care programs are coordinated to provide optimal care. These include the Hemophilia Comprehensive Care Program, the Adolescent Medicine Program and the HIV Comprehensive Care Program. Psychiatric involvement emphasizes development of coping mechanisms for dealing with stress. Serial psychometric testing is done.

Results: To date, about 50 HIV-positive children are followed by the combined programs. Of these, 35 are children with hemophilia, 5 are neonatal transmissions, 4 are blood transfusion recipients and 5 are adolescent street prostitutes.

Conclusion: An integrated program combining medical, psychological and social services provides optimal care for children with HIV infection and their care givers.

M.B.P.317 THE EFFECTIVENESS AND FEASIBILITY OF HOSPITAL-BASED SUPPORT GROUP INTERVENTIONS FOR PARENTS OF HIV-INFECTED CHILDREN

Fagan, Nancy E., Church, J.A., Mitschke, K.T., Childrens Hospital of Los Angeles (CHLA), Los Angeles, California, USA.

Objective: To evaluate the effectiveness of a support group for parents of HIV-infected children. **Methods:** 21 group members were recruited from the Clinical Immunology Center at CHLA and other referral agencies in Los Angeles. HIV status, CD4 count, were tested from asymptomatic to full-blown AIDS. Mode of transmission included blood transfusion (15) and perinatal (6). Group met bi-weekly from 1/87 through 8/88. **Results:** During the first six months, attendance ranged from 7-11 participants; all had children with treatment-associated HIV. 24 parents elected not to attend the group, citing feelings of increased stigma and isolation. Others discontinued participation citing depression and anxiety induced by clinical problems described in other participants' children. As the proportion of perinatal cases increased, participation in group declined. **Conclusions:** Ongoing group support intervention for parents with HIV-infected children resulted in unmet needs. Difficulties, dysfunctional families are additionally burdened by the ramifications of HIV in multiple family members. Support group attendance may be a priority. Alternative support services must be developed to meet the needs of this multi-problem population.

Supported by the State of California, administered by the Department of Health Services, Los Angeles County AIDS Program Office.

M.B.P.314 THE DEVELOPMENT OF A PRENATAL-PEDIATRIC AIDS LIAISON SERVICE AT A MUNICIPAL HOSPITAL.

Lauzier, Ester, Ureyes, L., Tropes, J., Grier, P., Abisago, B., Wata, L., Woodhull Medical & Mental Health Center, Brooklyn, NY, USA.

Objective: To describe the development of a unique Prenatal-Pediatric AIDS Liaison Service at a municipal hospital.

Methods and Results: Woodhull Medical & Mental Health Center, a division of NYC Health and Hospitals Corporation, is a large municipal hospital serving an impoverished black and latino community with a high incidence of IVUD and a high seroprevalence rate for HIV. In-crowded outreach, counseling and testing, specifically targeted to women and children at risk for HIV infection, has resulted in the need for a comprehensive, interdisciplinary approach to perinatal HIV infection. The Prenatal-Pediatric AIDS Liaison Service (P-PALS), funded through the NYC Department of Mental Health, was developed to provide the necessary linkages between the Departments of Obstetric, Pediatrics, Psychiatry, Medicine and Ambulatory Care to provide a family-oriented approach which optimizes continuity of care. The focus of the program is to assist the HIV positive pregnant woman and her family in coping with the possibility that her infant may be born HIV positive and to provide ongoing social, psychiatric and medical care for families who have children with HIV associated illness. The professional staff is comprised of a team which includes a child psychiatrist, social worker, nurse clinician and child life worker. Issues of foster care placement will also be highlighted.

Conclusions: Unified early intervention will improve the care of the woman and her child, diminish the need for long term placement, and provide a model of care based on the family rather than focusing individually on the mother and child.

M.B.P.316 LES SOINS INFIRMIERS FACE A L'EPIDEMIE DE SIDA
Schneeberger, Claudie, Val de Marne, France.

Devant la complexité de cette épidémie, dépasser les différents rôles de l'infirmière en matière de soins infirmiers. Dans l'accueil et la prise en charge des malades atteints du SIDA, l'accompagnement tout au long de la maladie et dans les derniers instants de la vie en organisant les mesures préventives permettant une plus grande sécurité dans les gestes techniques des soignants.

En développant une attitude professionnelle appropriée respectant l'homme dans ses différences lui assurant la confidentialité, tés et préservant sa dignité.

Dans le cadre des actions de prévention la responsabilité de l'infirmière dans la participation aux programmes d'information de la population pour apprendre à éviter le SIDA.

Son rôle dans l'éducation pour modifier les habitudes les plus intimes et conduire chaque personne vers une gestion globale de sa santé en développant des attitudes responsables.

M.B.P.318 HIV AND MATERNAL CHILD HEALTH: EXPANDING THE EXPERTISE AMONG PROVIDERS

Pis, C., Quacknabush, Maria, M., E****, Hanes, A.,****, Schejter, M.,****, Mays, A.,****

** Education Program Associates, Campbell CA; ***University of California AIDS Health Project, San Francisco; ****California Department of Health Services, Maternal Child Health Branch, ****California Department of Health Services, Office #209, California, U.S.A.

Objective: To describe a training program which seeks to expand HIV expertise among non-physician health personnel in maternal child health (MCH).

Methods: In California, 150 contract agencies throughout the state provide maternal child health care with the support of the State Department of Health Services. These programs include prenatal health care, follow up for high risk and selected infants, care for disabled or at-risk children, health care and parenting education for new parents, etc. However, many MCH providers in the state feel the HIV expertise rests primarily with a few specialists in major urban areas (San Francisco and Los Angeles). This presentation will describe techniques for expanding HIV expertise to maternal child health providers throughout the state and discuss a specific training protocol designed to help accomplish this.

Results: Five two-day trainings will be held throughout the state by May 30, 1989. We will offer preliminary evaluation of the program's success. The complete training manual will be available for review.

Conclusions: A training program for maternal child health providers can expand HIV expertise to individuals and areas that are not currently confident of their ability to provide such care.

Supported in part by a grant from the California State Office of AIDS, contract # 88-9450.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.325 COMBINATION (VINNIN B₂) SUPPLEMENTATION DOES NOT IMPROVE THE HEMATOLOGIC TOXICITY OF AZIDOTHYIMIDINE (AZT) THERAPY

W. Ballard, G. J. Frenkel, H. H. Berman, H. J. Fischl, J. M. Hirsch, D. J. and the California Collaborative Treatment Group, University of California, San Diego, CA.

Objective: AZT and B₂ deficiency both produce neutropenic anemia. Low serum B₂ levels (<400 pmol) are associated with increased risk of granulocytopenia in AIDS and AZT patients taking AZT. Accordingly, we conducted a controlled trial to see if monthly B₂ injections could prevent hematologic toxicity from AZT.

Method: 170 AIDS and AZT patients with serum B₂ levels >200 pmol who were requiring (120) or taking (44) AZT at standard doses (1-1.5 grams/day) were randomly assigned to receive either four monthly IM injections of 1 mg of B₂ or no injections. Serum B₂, ANC, absolute neutrophil counts (ANC), hemoglobin (HGB) mean corpuscular volume (MCV), platelets (PLT) and AZT dose were followed monthly for at least six months.

Results: Mean B₂ levels were increased four weeks after the first injection and remained elevated compared to controls throughout the study. Although by chance 50% of patients had higher AZT levels than controls at entry (287 vs 247, p<.03), all subsequent mean AZT, ANC, MCV, HGB, NEU, and platelets were similar for all comparisons. No differences in AZT tolerance or transfusion requirements were found.

Conclusion: Four monthly IM injections of B₂ sufficient to increase serum B₂ levels did not reduce the hematologic toxicity of AZT given for currently licensed indications.

M.B.P.326 ZIDOVUDINE MONOTHERAPY-A PROSPECTIVE STUDY

Patena, Barry Wilson, Cliff Finching, A. J. Medical, Institute of Medical Pathology, St. Mary's Hospital Medical School, London, England.

Objective: To study the relationship between Zidovudine (AZT) administration, myopathy and creatine kinase (CK).

Methods: 102 AIDS patients were seen monthly and clinical features of myopathy were recorded, including weight, muscle fatigue, reduced power and muscle wasting. Monthly CK levels were ascertained. 78 of the patients were on regular AZT (usual dose 1000-1200mg/day) and 23 of these had been treated for 300 days or more. 24 patients not on AZT were studied as a control group to delineate other causes of CK rise.

Patient	Onset of Myopathy Days on AZT (s)	Onset of Rise in CK Days on AZT (s)	x-y (Days)
1	217	260	43
2	426	275	31
3	430	300	30
4	512	270	24
5	378	326	52
MEAN	366	312	52

Results: Myopathy was severe and disabling, mainly affecting the legs and was associated with a rise in CK. CK continued to rise to very high levels (10000/1) during treatment. Dose reduction was ineffective, but survival clinical recovery occurred within 9 months of stopping AZT. CK levels fell to normal within 4 weeks.

Conclusion: 1. Sustained rises in CK provide the first indication of Zidovudine myopathy, hence it should be routinely performed.
2. Myopathy is a progressive disabling complication of Zidovudine therapy, occurring in 18% of patients on long-term therapy (>300 days).

M.B.P.327 NON CONCLUSIVE RESULTS IN HIV WESTERN BLOT ANALYSIS OF HOMOBIOPSY TISSUE

C. Pallas, G. S. Basso, J. Barrio, F. de la Cruz, L. Barquez, Immunology Laboratory, Instituto Nacional de Salud, Lima, Peru.

Objective: To describe the pattern of reaction of Monoclonal sera with non conclusive results in Western Blot. Material: 100 Western Blot (WB) results from 100 patients with HIV-1 infection. Results: 100 WB results were analyzed by ELISA for HIV-1 and HIV-2 antibodies and with non conclusive results in Western Blot were classified in relation with their protein band reaction. Some of them were tested by different commercially available WB kits. The frequency of the different observed patterns of reactivity was estimated.

Results: The most frequent observed reactivity patterns were reaction with p 24 band for HIV 1 WB (18%) and p28 for HIV 2 WB (10.4%). However in HIV 2 WB, 10.4% of sera reacted showed reaction with p24, p28, p36, p55 and p18 without any reaction with glycoprotein bands. Non conclusive results were more frequently found in HIV 1 than in HIV 2 WB. Some non conclusive sera by LAV BLOT II when tested by HIV 2 Dupont de Nemours and RT-VL-91 WB Western Blot showed non conclusive pattern of reactivity. Same happened when non conclusive sera by HIV 1 Bio-Rad WB were tested by HIV 1 Dupont de Nemours WB. Non conclusive results appeared in sera from all the studied population groups. Immunohistochemical appearance of non conclusive results in WB analysis of ELISA positive Monoclonal sera seem to be independent of the reagent used and due to sera or individuals characteristics.

M.B.P.328 A STUDY OF THE SAFETY AND EFFICACY OF RECOMBINANT HUMAN INTERFERON (r-HU-IFN) IN AIDS PATIENTS WITH ANEMIA INDUCED BY THIS DISEASE AND ZIDOVUDINE (RETROVIR, AZT) THERAPY

Galipz, J. F. Thompson, J. Amalfi, A. Abela, R. M., Turpen, T. J. *North Medical Group, Sherman Oaks, CA, *Ortho Pharmaceutical Corp., Raritan, New Jersey, USA.

Objective: To determine if anemic AIDS patients who are all on concomitant zidovudine therapy and are transfusion-dependent have any measurable change in their hematocrit, hemoglobin and reticulocyte count after treatment with r-HU-IFN.
Methods: Nine anemic subjects with a pretreatment HbA_{1c} of 30% or less were treated with ascending doses of r-HU-IFN up to 900,000 units weekly for 24 weeks. Patients were on daily doses of zidovudine of 400 to 820 mg. The hematocrit, hemoglobin and reticulocyte count were obtained on a weekly basis.
Results: All but one subject attained a hematocrit of 38-40% during the 24 week trial, becoming transfusion-independent.
Conclusions: r-HU-IFN appears to be a possible adjunctive therapy for AIDS patients who are anemic due to their disease and zidovudine therapy. This drug merits further side-by-side clinical trials.

M.B.P.329 MYOATRY ASSOCIATED WITH LONG-TERM ZIDOVUDINE THERAPY

Finch, Richard; Gagnon, S; Utaschewski, H; Petrovec-Zelen, J; Desautels, J; Torres, S; Bender, A. University of Miami School of Medicine, Miami, Florida, USA.

Objective: To evaluate the frequency and clinical presentation of myopathy associated with long-term zidovudine therapy.

Methods: Patients receiving zidovudine for 140 were assessed, using medical history, physical exam and blood tests. Patients identified with possible myopathy were evaluated with EMG and muscle biopsy.
Results: 50 patients (33 AZT, 17 AKI) had received zidovudine for a mean of 13 wks (range 40-140 wks). 15 (30%) had myopathy as manifested by myalgias-10%, muscle wasting-8%, and rhabdomyolysis-7%. Muscle groups involved included proximal muscles in the lower extremities-100 and upper extremities-7%, and intercostal muscles-10%. Associated symptoms included arthralgias-17%, weight loss >10%-8%, and parosmia-8%. Blood tests included persistently elevated LDH (11-25 normal) and CK (1.5-8.5 normal). EMG was consistent with myopathy. Muscle biopsy showed degenerated myofibers, non microvascular changes, and mild inflammation. Myopathy occurred in 58% of AKI patients and 18% of AIDS patients. Onset was between 52-107 wks of therapy and in patients having received a mean cumulative dose of 600-800mg. 8 patients required drug. Symptoms improved within 1-6 wks. LDH decreased in all patients by 8 wks and CK in 87% of patients by 4 wks. 4/8 patients developed recurrent symptoms within 1 month of restarting zidovudine.
Conclusions: Myopathy is common in patients receiving long-term zidovudine. Proximal muscle wasting in the lower extremities was the most common finding. Increased LDH was an early indication of myopathy.

M.B.P.330 HIV ASSOCIATED MYOATRY: FEATURES IN 21 PATIENTS AND ROLE OF AZT

Galipz, J. F. Thompson, David Wolfe, D., Farraye, J., Bender, A. Mount Sinai Medical Center, New York, NY.

Objective: To describe the features of 21 patients with HIV-associated myopathy as well as the role of AZT in this disorder.

Methods: All patients were evaluated at Mount Sinai Hospital. Electrophysiologic testing included nerve conduction studies and needle electromyography (EMG). Muscle biopsies were processed by light and electron microscopy, and viral localization performed with immunohistochemistry and ³²P in situ hybridization.

Results: 16 patients had AIDS, 4 had ARC, and 1 was asymptomatic HIV-seropositive. 5 had been diagnosed as AIDS during syndrome. All presented with proximal muscle weakness. Creatine kinase (CK) levels were elevated over a wide range (mean 128 DU/24). EMG revealed myopathic motor units in 17 patients, with abnormal spontaneous activity in 17. Muscle biopsy findings in 30 patients included inflammatory or noninflammatory myofiber degeneration, membrane ripples, cytoplasmic bodies and vacuolization. 8 of 9 patients treated with corticosteroids improved. 10 patients had never been treated with AZT. Of 21 patients on AZT, the myopathy worsened after AZT withdrawal in 4, and 2 improved with its reinstatement.

Conclusion: Myopathy is associated with HIV infection, and may be misdiagnosed as AIDS during syndrome. Corticosteroid therapy is effective. In our series, AZT does not appear causally linked to this disorder.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.331 SERUM LEVEL AND SERUM KINETIC OF ZIDOVUDINE:

INVESTIGATION WITH A RADIOIMMUNOASSAY (RIA)
Kösem, Stefan; Ruf, B.; Pannhorst, J. and Pöhl, H.-D.
*I. Department of Nuclear Medicine, *II. Department of Nuclear Medicine,
Rudolf Virchow University Hospital, Frank University, Berlin, FRG.

To evaluate serum levels and serum kinetics of Zidovudine (Azidothymidine, AZT) with different dosages and dosage intervals, serum samples of patients who had Zidovudine treatment have been investigated retro- and prospectively. Analysis was performed with a radioimmunoassay (ZDV-¹²⁵I-RIA).

Retrospectively 262 serum samples of 47 patients were examined. Blood samples have been obtained two hours after oral application. The mean Zidovudine concentration was 735 nmol/l, 1772 nmol/l, and 1367 nmol/l when dosages of 5 x 100 mg/d, 6 x 200 mg/d and 6 x 300 mg/d were given, respectively.

Prospectively, serum kinetics of Zidovudine has been investigated at start of therapy. Five hours after application of 150 or 300 mg Zidovudine, serum concentration has fallen below 150 nmol/l, being reported to be the minimal effective serum concentration. After application of 250, 300 and 500 mg, serum concentration have been below 150 ng after 6 hours.

The RIA was highly specific, no cross-reactivity and non-specific reactivity has been found. Zidovudine is an intracellular active compound. Therefore, serum levels are of limited value. After retrospective correlation with the outcome of patients, recommendations of dosage regimens suitable to serum levels are reasonable. In long dosage intervals, effective intracellular concentration may not be achievable.

M.B.P.333 ASSESSMENT BY PCR OF HIV-1 ACTIVITY IN AIDS-KS

PATIENTS TREATED WITH RECOMBINANT INTERFERON ALPHA (rIFN- α)
Espinosa, Jay S., Hewitt, L.K., Metzalin, J., Hawthorne, C., Lane, H.C.*
*Division of Blood and Blood Products, FDA and **Clinical Center, NIH, Bethesda, MD

Objective: To evaluate the effect of rIFN- α on HIV-1 replication in AIDS.
Methods: Eight patients with AIDS-KS receiving daily injections of rIFN- α (Schering) for therapy of KS tumors were studied multiple times over 1 to 2 years for serum levels of HIV-1 antigen (Ag), reverse transcriptase activity (RTA), and gene detection by PCR. PCR was performed on extracted DNA using simultaneous amplification of GAG and ENV sequences followed by selective hybridization with the respective probes.

Results: Five of 8 cases were tumor responders, 4 complete, 1 partial. Prior to therapy, PCR and RTA were positive in all eight cases, and Ag was found in 7 cases (3 tumor nonresponders was persistently negative). Antigen or RTA levels decreased in 5/3 tumor responders (2 Ag, 2 RTA, 1 both). In 1 nonresponder, viral DNA became undetectable despite persisting antigen.

Conclusion: rIFN- α produced decreases in activity of HIV-1 in 6/8 AIDS-KS patients including all 5 cases with tumor responses, but in no case was the decrease shown by all virologic parameters. PCR detection of viral DNA revealed persisting virus activity despite clearance of antigen and RTA. Future drug trials should include monitoring of HIV-1 activity by serum PCR.

M.B.P.335 EFFECT OF ZIDOVUDINE WITH PHASE I AND II METABOLISM IN THE LIVER

N. H. Hopwood¹, L. Mertins, M. Goss, University of Essex,
Essex, Federal Republic of Germany

The nucleoside analogue zidovudine is being employed in the therapy of HIV-infected subjects. The effect of zidovudine on the liver metabolism is of utmost interest. We chose 7 subjects not receiving any supplementary medication and measured the parameters of the liver zidovudine activity (antipyrine elimination index, metabolite excretion and 4-beta-OH-cortisol in urine) before intake of zidovudine 800mg/day as well as after a treatment period of 18 days. Antipyrine and its metabolites were determined by HPLC. Following a two-week intake of zidovudine an induction of the microsomal enzyme system was observed, the excretion of 4-beta-OH-cortisol increased significantly from 342 to 697 g/24 hours. The half-life of antipyrine decreased from 12.2 to 10.1 hours. Centrally, the phase-2-metabolism of the antipyrine metabolites nor- and 4-OH-antipyrine were significantly lower. These altered from 8.32 to 6.29 min/ml, and from 11.8 to 9.4 min/ml, respectively. This effect by zidovudine seems almost exclusively due to the inhibition of the glucuronidation in the liver. The clearance of metabolite of the glucuronidated nor-antipyrine and of 4-OH-antipyrine decreased by 18 and 29%, respectively.

On grounds of these results, clear interaction will occur during the simultaneous application of zidovudine with other drugs metabolised by phase I and II liver metabolism.

M.B.P.332 PHARMACOKINETICS (PK) OF ZIDOVUDINE (ZDV) IN ADULT

PATIENTS WITH HIV INFECTION AND HEPATIC DISEASE (HD)

Itzaki, Masaru; Ochiai, K.; van der Horst,
C. M.; Raash, R. V.; Dassen, S. van; Huis, H. van; et al. *University of Washington, Seattle, WA, USA, **University of North Carolina, Chapel Hill, NC, USA, ***University of Massachusetts, Amherst, MA, USA

Objective: To determine ZDV's PK in patients with HIV infection and HD. **Methods:** In an ongoing study, patients were stratified into 3 categories of stable HD according to serum ALT (CS to 200K normal), TBIL and PT. On sequential study days, each patient received a single dose each of ZDV 120 mg IV followed by ZDV 200 mg PO. Multiple blood samples were obtained. ZDV and GDV conc. were determined by HPLC and analyzed using noncompartmental methods.

Results: Five patients (3 males, 2 females) with HD and ALT values ranging from 1.5 to 10 X normal and normal TBIL and PT values completed the study. ZDV/GDV PK are presented below:

PK	HD	GDV	HD	GDV
C _{max} (ng/ml)	1.5 ± 0.5	1.5 ± 0.2	1.9 ± 0.3	3.4 ± 1.4
AUC (ng/ml x hr)	1.6 ± 0.5	2.8 ± 0.4	1.7 ± 0.1	7.9 ± 0.9
T (h)	0.7 ± 0.1	...
T _{1/2} (hr)	1.6 ± 0.3	1.9 ± 0.7	1.7 ± 0.5	1.4 ± 0.2
Cl _{CR} (L/hr)	2.1 ± 1.0	...
TRC (L/hr/kg)	1.1 ± 0.4	...	1.3 ± 0.3	...

Conclusion: Preliminary ZDV and GDV PK data in patients with mild HD is similar to previously reported data in patients with normal renal and hepatic function. Patients with moderate and advanced HD are under study.

M.B.P.334 BAYESIAN ESTIMATION OF THE PHARMACOKINETIC PARAMETERS

OF CHRONIC ZIDOVUDINE (ZDV) THERAPY IN HIV INFECTED PATIENTS.
Janina Y. Tsai, R. Joseph Guglielmo, Harry Hollander, and R. Mohammed. School of Pharmacy, Medicine, Univ. of Calif., San Francisco, CA, USA.

Objective: To determine whether the individual pharmacokinetic parameters of ZDV can be estimated by Bayesian approach from data collected during multiple routine clinic visits in HIV infected patients.

Methods: Eighty patients with AIDS or ARC receiving oral ZDV therapy at the AIDS Clinic of the UCSF Medical Center were recruited. On the morning prior to each routine clinic visit, the subjects recorded the dose and exact time of taking the last two doses of ZDV during the clinic visit; an additional plasma sample was drawn at the time of routine blood sampling. This procedure was repeated for four clinic visits. Plasma ZDV levels were assayed by HPLC. The plasma concentration-time data was analyzed by Bayesian analysis using TM500 and Drugpac.

Results: Preliminary results indicate a mean terminal half-life of 1.33±0.39 hours, an average bioavailability of 90.4±10.8%, a body clearance of 1.04±0.11L/hr, and a volume of distribution of 1.94±0.44L/kg.

Conclusions: Results are in agreement with literature data. Our results using population pharmacokinetics suggest that the pharmacokinetic disposition of ZDV is unchanged within HIV infected patients on chronic ZDV therapy.

M.B.P.336 ZIDOVUDINE LEVELS IN SERUM AND METABOLIC AND HEMATOLOGIC EFFECTS

IN PATIENTS WITH HIV INFECTION AND HEPATIC DISEASE
Ishari-Foppa C., Lazzarin A., Ronchi P., Cloque F., Beale R. I.
Clinic of Infectious Diseases, University of Milan, Italy.

Objective: To evaluate virologic and hematologic effects of different concentrations of zidovudine (ZDV) in p24 antigen and reverse transcriptase (RT) and active ARC and AIDS patients.

Methods: Six AIDS and two ARC subjects received ZDV 10 mg/kg qd for 4 weeks, followed by 5 mg/kg qd for 5 months). RT from lymphocytes and p24 antigen (RIA) before were detected monthly. ZDV levels were evaluated (RIA, ZDV/ACT, log scale) on day 30 and 60 at 0, 30, 60 minutes after oral administration.

Results:	p24 POS	RT POS	Mean ZDV levels (ng/ml)
-month 0	6/8 (100%)	6/8 (100%)	0 min 30 min 60 min
-month 2	0/6 (0%)	2/6 (33%)	-day 10 0.3 4.8 6.7
-month 6	3/6 (50%)	5/6 (83%)	-day 80 0.3 4.8 3.3

Subjects with mild hepatitis (ALT < 3 times upper normal) values had a high peak concentration (10 mg/kg) longer than other patients.

Conclusion: A dose of 5 mg/kg is sufficient to obtain a mean concentration of the drug 2 to 3 times above the "in vitro" minimum inhibitory doses for HIV-1. In hepatocentric patients with normal ZDV levels, a prolongation peak concentration is sufficient to induce anemia. Only the evaluated doses, ZDV can reduce virus replication (shown by negative antigenemia), but doesn't inhibit it completely.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.337 A PRELIMINARY STUDY OF SERUM AZT LEVELS IN HIV-INFECTED INDIVIDUALS

W. A. Riddle, R. K. King, M. A. King, J. A. Spera, K. A. Tonjes, T. J. Wainwright, M. S. et al.
University of California, Davis, California, U.S.A.

Objective: To determine whether serum AZT levels correlate with clinical efficacy and/or toxicity, and whether acamtoprofen (A) effects serum AZT levels.

Methods: We measured serum AZT levels in 10 patients receiving varying oral doses, of whom 3 had rises in CD_4 from a mean of 327 to 535; 3 had no change in CD_4 and 4 had a decline in CD_4 . One patient had clinical improvement, 3 had definite toxicity from AZT. Through levels were drawn just prior to the AZT dose, and peaks were drawn at 1 and 2 hours post dose. Three patients were given (450 mg q 6 hrs x 48 hrs) and levels were rechecked. Levels were measured by both RIA and HPLC methods.

Results: Mean AZT levels (537 ng/ml) in patients taking 1200 mg of AZT per day correlated with dose. A did not affect peak or trough levels of AZT at the dosage of A used. Toxicity does not appear to be related to serum AZT levels in this small study population. In one patient with underlying bone marrow injury, 100 mg of AZT q 12 hr produced profound red cell toxicity (peak 1000 ng/ml).

Conclusions: A longer study which correlates serum and intracellular AZT and peak and trough levels with measures of efficacy (CD_4 , p24 antigen, β_2 microglobulin and clinical improvement) and toxicity (anemia, granulocytopenia, myelocytosis, neuropathy) may give important information about AZT in treatment of HIV infection.

M.B.P.338 INTERACTIVE PHARMACOKINETICS OF ZIDOVUDINE AND ACETAMINOPHEN

Paulo, George J., Piacasinski, R., Shuman, M. and Ho M.
Pittsburgh AIDS Clinical Trials Unit, University of Pittsburgh, Pittsburgh, Pennsylvania, U.S.A.

Objective: Since both Zidovudine (ZDV, Retrovir) and acetaminophen (Tylenol) are metabolized by hepatic conjugation, competition for conjugating enzymes may result in reduced elimination of either or both agents with a potential for increased toxicity. This study was done to evaluate the potential interaction between ZDV and acetaminophen.

Methods: Pharmacokinetics of ZDV after IV administration (2.5 mg/kg) was studied in 7 HIV-infected patients with normal renal and hepatic function after 3 days of maintenance oral ZDV (100-200 mg q8h) and with acetaminophen after 3 days of both ZDV and acetaminophen (650 mg q6h). Multiple blood and urine samples were collected over 48 hrs following the IV dose of ZDV. Serum samples were heated (56°C) for 35 min then extracted with a C18 solid phase column. ZDV was quantitated by HPLC. Serum concentration versus time data were analyzed using compartmental and non-compartmental methods.

Results: ZDV alone ZDV/Tylenol t p value
 Mean $t_{1/2}$ (hr) 19.4 ± 2.9 20.4 ± 4.0 > 0.05
 ZDV clearance (ml/min/kg) 0.73 0.63 > 0.05
 Mean $t_{1/2}$ (hr) 1.27 ± 0.35 1.26 ± 0.27 > 0.05
 vol. of distribution (L/kg) 2.27 ± 0.27 2.02 ± 0.27 > 0.05
Conclusions: Our study indicates that acetaminophen does not affect the distribution or elimination of ZDV.

M.B.P.339 A SENSITIVE AND SPECIFIC HPLC METHOD FOR THE DETERMINATION OF ZIDOVUDINE AND ZIDOVUDINE GLUCURONIDE IN PLASMA AND URINE

Madaya, Mohamed A. and Sawchuk, R. A.
University of Minnesota, Minneapolis, Minnesota, U.S.A.

Objective: To develop a sensitive and specific HPLC method for the determination of zidovudine (AZT) and zidovudine glucuronide (GAZT) in plasma and urine.

Methods: The method involves the use of double internal standards, allowing reference of AZT peaks to the appropriate internal standard, the choice depending on the range of concentrations encountered. Free (unconjugated) AZT is quantified by extraction with 5% isopropyl alcohol in chloroform. Total (conjugated and unconjugated) AZT is quantified by incubating the samples with bacterial β -glucuronidase and phosphate buffer at pH 6.8 for 4 hours at 37°C. The samples are then extracted as described for free AZT. GAZT concentrations are calculated by difference, corrected for GAZT MW. The mobile phase consists of 9% acetonitrile in monobasic ammonium phosphate. We used a C18 column, and UV detection at 266 nm.

Results: The coefficient of variation of the between-run and within-run assay precision is < 10% and the coefficient of variation of the assay accuracy determined from the analysis of quality control samples is also < 10%. We saw no interference from various over-the-counter and prescription drugs often used in treating the infectious complications of AIDS.
Conclusion: Using this method we are able to quantify AZT and GAZT in human plasma and urine samples obtained over a 12-hour period after a single oral dose of 200 mg of AZT.

M.B.P.340 PHARMACOKINETICS OF AZT AMONG HIV INFECTED PATIENTS TREATED BY TIRAZOLONE

Merle, Jean P., Patron, Y. and Pillot, C.
CHU-Saint Etienne, State University of Liois, Reims.

Objective: Symptomatic HIV infected patients are frequently submitted to Antiretroviral (ART) therapy in association with immunomodulatory drugs. We were interested to investigate the pharmacokinetic properties of AZT during the administration of Tirazalone, a new antipneumocystis compound.

Methods: Seven patients (5 patients CDC AC2 and 2 patients CDC AC1), regularly treated by AZT for at least 4 weeks at the dose of 3 ± 0.1 mg/kg/day were submitted to two pharmacokinetic studies. The first was carried out during treatment by AZT only (test A) and the second after Tirazalone (12 x 100 mg q8h) was added to AZT for at least 2 weeks (test B). Pharmacokinetic profiles were estimated by blood sampling at 0, 30, 60, 120, 240, 360 minutes after the oral intake of 200 mg AZT. AZT serum concentrations were determined by a radioimmunoassay method using a iodine-125 tracer.

Results: AZT was not detectable in the sera prior to the tests. AZT peak serum levels were observed 30 minutes after the oral intake respectively in 5/7 and 7/7 patients during tests A and B. Mean maximal values (2446 ± 437 vs 2107 ± 257 ng/ml; NS) were comparable in the two profiles and were in the range of those previously reported. However, two patients presented better profiles of AZT concentrations during Tirazalone treatment.

Conclusions: These results confirm that AZT is rapidly absorbed from the gastrointestinal tract. Tirazalone seems to have no deleterious effect on the pharmacokinetics of AZT. The higher concentration observed in two patients during Tirazalone treatment could be the consequence of the improvement of the digestive conditions and consequently a better absorption of the drug.

M.B.P.341 MOLECULAR INTERACTION OF RECOMBINANT B INTERFERON AND ZIDOVUDINE IN THE TREATMENT OF AZT PHARMACOKINETICS IN HIV-1 INFECTED PATIENTS

Wang, Huiqing*, Lok, J.P.**, Douvier, S.M.***, Snodgrass, W.R.***, Ahmed, U.M.*** and Toller, R.***
 *Department of Internal Medicine, **Pathology and ***Pediatrics, The University of Texas Medical Branch, Galveston, Texas, U.S.A.

Zidovudine, the drug of choice for patients with AIDS, is known to be metabolized by mammalian systems into a variety of metabolites including 5'-phospho-3'-deoxy-5-O-glucuronide (GAZT). Interferon are known to alter the microsomal enzyme system responsible for metabolism of some drugs. The aim of this study was to investigate the effect of combination therapy of recombinant Interferon- β (rIFN- β) and AZT on the pharmacokinetics and rates of metabolism of AZT in HIV-infected patients. AZT was given orally (200 mg every 4 hours) for 8 weeks prior to initiation of rIFN- β therapy (90x10⁶ IU/day, subcutaneous). Serum samples were obtained prior to and at days 3 and 5 following initiation of rIFN- β therapy. Serum was analyzed by high performance liquid chromatography (HPLC) for both AZT and GAZT. The serum data were analyzed by computer assisted pharmacokinetic program which calculates rates of AZT metabolism. The half life for AZT was increased 2 to 3 folds by day 15. The half life of AZT was distinguished from 1.18 hr prior to rIFN- β therapy, to 0.4 hr and 0.08 hr at days 3 and 15 respectively. Volume of distribution (Vd) was 7.7 L/kg at day 0 and increased significantly to 7 and 5.8 L/kg on days 3 and 15 respectively. Other kinetic parameters were also determined. In conclusion, this study indicates that rIFN- β inhibits the rate of AZT metabolism in AIDS patients.

M.B.P.342 INTRAVENOUS AND ORAL PHARMACOKINETICS OF ZIDOVUDINE IN HEMODIALYZED PATIENTS WITH NORMAL HEPATOCYTOGENICITY AND URINE INJECTION

Hughes, Doug; Olson J., Portanova A., Taylor C., Plank C. and Beilman R.
 University of Rochester Medical Center, Rochester, NY, U.S.A.

Objective: To compare intravenous (iv) and oral (po) zidovudine (ZDV) kinetics in HIV-infected hemodialysis patients during chronic dialysis.

Methods: Five patients received ZDV 100 mg po q8h (total 240 mg) for 12 weeks; iv and po kinetic studies were performed every 6 weeks. ZDV and ZDV-glucuronide (GDV) were measured in plasma by HPLC.

Results:

	12					
ZDV-iv-2h(nmol/ml)	1.2 ± 0.4	1.2 ± 0.3	0.7 ± 0.3			
ZDV-iv-4h	0.2 ± 0.1	0.2 ± 0.1	0.3 ± 0.1			
ZDV-oral-2h	0.5 ± 0.4	0.4 ± 0.3	0.4 ± 0.1			
ZDV-oral-4h	0.1 ± 0.05	0.1 ± 0.04	0.1 ± 0.08			
GDV/ZDV-2h iv	2.6 ± 0.8	2.6 ± 0.8	2.5 ± 1.3			
GDV/ZDV-2h po	0.2 ± 0.8	0.2 ± 1.9	2.7 ± 1.6			
GDV/ZDV-2h oral	4.6 ± 2.4	4.9 ± 2.2	4.4 ± 2.7			
GDV/ZDV-4h oral	3.0 ± 2.1	3.4 ± 2.0	2.7 ± 1.2			

The iv half-life at 1, 6, and 12 weeks was 3.1 ± 3 h, 2.4 ± 3 h and 2.1 ± 1 h, while after oral ZDV it was 3.1 ± 3 h, 4.2 ± 2 h, and 3.4 ± 2 h. **Conclusions:** Although the mean ZDV levels were similar, a high degree of interpatient variation was noted. The lower concentrations after oral ZDV were most likely due to first-pass metabolism, as indicated by the GDV to ZDV ratio. These data indicate that chronic therapy with a standardized ZDV dosage regimen may result in a variable plasma level profile.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.354 **AZT TREATMENT INDUCES A DECREASE OF SOLUBLE INTERLEUKIN 2 RECEPTOR (sIL-2R) BUT NOT OF SOLUBLE CD8 ANTIGEN (sCD8) SERUM LEVELS IN HIV INFECTED PATIENTS.**
Calli, Massimo; Balotta, C.; Ridofo, A.L.; Cocchi, P.; Uberti-Foppa, C. and Moroni, M. Clinic of Infectious Diseases, University of Milan, Italy.

Objective. To investigate whether sIL-2R and sCD8 levels differ in patients with CD4 counts higher or lower than 400 cells/mm³ and whether AZT influences the serum levels of sIL-2R and sCD8 Ag.

Methods. sIL-2R and sCD8 have been measured in 52 HIV infected patients (12 AIDS) and 12 healthy controls (HC) using an ELISA method (T Cell Science). In 10 AZT treated patients the tests were repeated on the 30th and 90th day of therapy and p24 Ag (T Cell Science) was determined on a parallel.

Results. All patients had markedly elevated sIL-2R and sCD8 levels respectively 17 (SD=10) U/ml in patients vs 35±2.26 in HC, p<0.0001; 990±270 U/ml vs 346 U/ml in HC, p<0.0001. No significant differences were found either between subjects with CD4 cell counts higher or lower than 400 cells/mm³ or between patients with or without AIDS. A significant reduction of sIL-2R serum concentration was observed during treatment in all patients (mean: 1011 U/ml, 1700±1215 U/ml, 1790±1183 U/ml, p<0.005) but 1 presenting persistent antigenemia.

Conclusions. AZT seems to reduce the release of sIL-2R, possibly as a consequence of a reduced destruction of T-helper; no influence can be demonstrated on sCD8 level. Our results suggest that sIL-2R serum level determination could be a useful tool in monitoring AZT therapy effects.

M.B.P.356 **PREDICTIVE VALUE OF CD8 CELL COUNT IN MORBIDITY AND MORTALITY AMONG AIDS PATIENTS TREATED WITH ZIDOVUDINE (AZT)**
Gerard, M.; Somerville, G.; De Milt, Stéphane; Clowse, N. Division of Infectious Diseases, St Pierre University Hospital, Brussels, Belgium.

We prospectively studied a population of 45 AIDS P and 81 ARC P under AZT treatment (1) for a mean period of 34 weeks to assess their immunological and clinical evolution. CD8, CD4, blood cell count and physical examination were obtained monthly. Baseline CD8 cell count lower than 100/mm³ was associated with a higher incidence of opportunistic infections (OI) (37% vs 76-80-0/00) and a higher case fatality rate (25-3% vs 2-4%-p=0.0002). The same correlation was found for low CD8 cell count. There were 10 ARC P and 17 AIDS P with baseline CD8 cell count below 400/mm³ and 71 ARC P and 28 AIDS P with baseline CD8 cell count over 400/mm³. OI occurred during AZT in among 40% of ARC P with CD8 value below 400/mm³ and 8% of ARC P with CD8 value over 400/mm³ (p=0.02). There was no influence of CD8 value on occurrence of OI in AIDS P. Low CD8 cell value in both AIDS and ARC P was also correlated with higher mortality. 60.7% of P died if baseline CD8 cell count was lower than 400/mm³, 3% of P if baseline CD8 cell count was higher than 400/mm³ (p=0.001). Positive predictive value of occurrence of OI and death among P with CD8 value lower than 100/mm³ were respectively 45.8% (57% for ARC P, 41.2% for AIDS P) and 45.8% (42% for ARC P, 47% for AIDS P) if baseline CD8 cell count was lower than 400/mm³ and respectively 18.2% (23% for ARC P, 15.4% for AIDS P) and 4-5% (5% for ARC P, 7.7% for AIDS P) if baseline CD8 cell value was over 400/mm³. In HIV P treated with AZT, low baseline CD8 cell count was a predictive value for developing AIDS in ARC P and CD8 cell count increases the predictive value of CD8 cell count for OI development and occurrence of death.

M.B.P.358 **IMMUNOFLUORESCENCE DEMONSTRATE (ADA) EXPRESSION IN AZT TREATED PATIENTS**
Calli, Massimo; Magnani, G.; Bernini, S.; Ridofo, A.L.; Cocchi, M.***; Fiacco, R.**, Starobin, A.
*Istituto Patologia Bacteriologica e Malattie Infettive, Università di Pavia
**Istituto Di Genetica Biologica ed Evoluzionistica del CNR, Pavia, Italy.

Objective. To assess the expression of ADA expression in AZT treated patients.

Methods. Measurement of ADA activity and serologic determinations of sgp and sgp in erythrocyte extracts of AZT-treated patients (5 ARC, 4 AIDS) with basally untreated HIV-1 infection. The test of ADA activity in 2 µl of treated serum in 1 µl sgp and sgp concentrations were expressed in µmol/30' cell.

Results. sgp and sgp activity were significantly higher (p<0.01) in ARC and AIDS patients (38.17 ± 2.2) compared to controls (28.02 ± 0.8) sgp and sgp concentrations were in the normal range (< 2.5) while sgp values were low (mean 302 ± 146 of the controls).

During AZT therapy. A progressive increase of ADA (100 ± 120) was detected during the first 3 months of the treatment. Subsequently high activities were mostly observed after 3 and 6 months of AZT concentrations (mean 567.7) were by approximately 50% reduction. sgp concentration was low.

Conclusions. We have observed increased ADA activity and decreased sgp concentration in the erythrocyte of HIV/AIDS patients. Such phenomena were caused by AZT therapy. Since ADA and sgp are known to play a common substrate, the greatly increased activity of the former may interfere with nucleotide salvage by the latter. Piv which nucleotide assists may cause.

M.B.P.355 **AZT THERAPY IS ASSOCIATED WITH AN INCREASED CAPACITY OF PHA-STIMULATED CELLS TO EXPRESS IL-2 RECEPTORS (IL-2R). IN MILWAUKEE, ALLEN, KOFFMAN, D., BASK, E.P., ARMSTRONG J.A., PAIS, G.L., SO, N. and Pittsburgh, University of Pittsburgh Medical Center, Pittsburgh, Pa., U.S.A.**

Objective. To determine whether AZT therapy in HIV-infected patients can improve in vitro T lymphocyte function.

Methods. 34 AIDS patients enrolled in the 000 AZT protocol for AZT treatment were essentially evaluated at intervals up to one year. PHA-stimulated mononuclear cells were incubated for 24 hours; the cells were cytofluorographically analyzed for expression of IL-2R by reactivity with CD25 monoclonal antibody.

Results. At time of entry, IL-2R expression were markedly depressed in HIV-subjects. The mean value 5.4 ± 0.9% compared to 6.5 ± 2.6% in heterosexual controls. During AZT treatment, there was a progressive increase in the capacity of cells to express IL-2R. Data was collected by two methods. The average IL-2R, using the last observation, had increased to 13.4 ± 2.6% (p<0.01 compared to baseline). When all values during the treatment period were considered, the mean was 17.0 ± 2.4%. Further analysis suggested that, in the AZT-treated patients, the responsive cells were primarily of the CD8 phenotype whereas, in controls, they were mainly CD4+. During the year of treatment, there was no increase in either PHA of T cell colony responses.

Conclusions: These studies suggest that AZT therapy is associated with a sustained improvement in immunofunctional parameters of T cell reactivity; their capacity to be activated by PHA, as indicated by expression of IL-2R.

M.B.P.357 **QUANTITATIVE DOSAGE OF CORE ANTIBODIES IS A BETTER PROGNOSTIC MARKER THAN HIV ANTIGEN AGENT**
Lemard, Olivier; Proctorakaki, S.; Farber, C.-M. Noptal Braams, UNIVERSITEIT LUIXVE de Bruxelles, Brussels, Belgium.

Methods. During a follow-up period of 0.5 (3.9-5.9 months) sera of 30 European and 16 African HIV infected patients (pts) at all stages of the disease (i.e., asymptomatic, RC, ARC, AIDS) were retrospectively investigated for the presence of HIV antigen (Ag), core antibodies (Ab) and envelope (env) Ab (Abbott Diagnostic-Health Chicago-IL).

Results: In all pts, env Ab were detected in high titers without significant variations during the follow-up. HIV Ag was detected in the serum samples of 16 pts; 1 African with AIDS and 13 European. At the beginning of the follow-up, 10% of the European pts were antigenemic and 20% at the end.

Core Ab were detected during the follow-up period in all the African except in the pt with HIV Ag. The geometric mean titer of core Ab titers was 1/735 in the asymptomatic pts and 1/113 in the AIDS pts. All European pts without HIV Ag were detected during the follow-up period in all the African except in the pt with HIV Ag. The geometric mean titer of core Ab titers was 1/726 in the asymptomatic pts and 1/75-5 in the AIDS pts.

Conclusion: HIV Ag is rarely expressed in African pts; moreover, even in the late stage of the disease, HIV Ag is not detected in 37% of European pts and detection is intermittent. In contrast, the decline or the disappearance of core is clearly related with evolution of the disease, in African like in European pts. Follow-up of quantitative dosage of core Ab seems to be of more value as a prognostic marker than the detection of HIV Ag.

M.B.P.359 **EFFECT OF AZT ON THE LEVELS OF ANTIBODIES SPECIFICITY TO ANTIBODY RESPONSE CELL CROSSLINKING ANTIGENS**
Petrovic, M.; Zira, F.; Turkovic, G.; and Halibauer, M.A.***
***Jewish General Hospital and Trauma Center Hospital, McGill University, Montreal, Canada.

Objective. To assess the effect of AZT cessation on levels of AOC-relevant antibodies in patient sera.

Methods. A standard 6 hour ³⁵S release cytotoxicity assay was used to assess AOC activity longitudinally over a 20 month period in 2 asymptomatic HIV-1 seropositive patients that had transiently elevated AOC activity. In addition, sera from a healthy control seropositive donor was used. Target cells were prepared by incubating peripheral blood mononuclear cells dispersed into 96 well microtiter plates (5000 cells/well). Serial 10-fold-dilutions of sera from each time point for each patient and the control were added to the targets to achieve final serum dilutions of 1:100 to 1:100,000. Effector lymphocytes obtained from a seropositive healthy donor were added to the wells at a effector:target ratio of 3:1.

Results. At dilutions of 1:100 and 1:1000 of patient sera, we noted AOC activity and crosslinking. This activity was less marked at a 10⁴ dilution and disappeared at 30⁴ or lower dilutions. In the control sera, AOC activity diminished progressively in the patients until AZT was stopped. Sera obtained immediately following AZT cessation each over period showed a marked rise of AOC activity to baseline levels.

Conclusions. These data on 2 patients suggest that AOC antibody activity declines in while patients are on AZT therapy. Following activity recovers following cessation of drug. These findings are being expanded to provide further insights into the role of AOC in pathogenesis and/or prognosis in HIV-associated disease.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

M.B.P.378 DISSEMINATED GRANULOMATOUS PNEUMONITIS IN A PATIENT RECEIVING AZIDOULOSIN THERAPY FOR PHYLAXIS

Yves Douzals, George Washington University School of Medicine, Washington, D.C.

A 35 year old gay male had Pneumocystis pneumonia in 5/87. He was maintained after on AZ plus oral cotrimoxazole prophylaxis. In 9/88 he again developed weight loss, chronic fevers and dyspnea, and was admitted to the hospital presuming as Pneumocystis was diagnosed, and he was treated with pentamidine, which was switched to trimethoprim-sulfamethoxazole because of renal failure. His status progressively deteriorated, complicated by renal failure, arthritis, dermal eruptions, and a loss of respiratory insufficiency after two weeks. On autopsy he was found to have disseminated granulomatous Pneumocystis involving the lung, heart, lymph nodes, liver, spleen, GI tract, adrenal and thyroid glands and choroid, as well as disseminated cytomegaloviral inclusions.

There have been 17 cases of extrapulmonary pneumocystis reported in the literature, six of these in patients with AIDS. Only four of these, however, have been truly disseminated with multiple organ involvement (one with AIDS). This patient may have progressed to disseminated infection because of his use of azidothymidine, which suppresses infection in the lungs, but has no extrapulmonary effect. As this form of prophylaxis becomes more widespread, extrapulmonary pneumocystis may become more common.

M.B.P.379 PNEUMOCYSTIS CARINI CHOROIDITIS

Carole D.M. Rao, N.A. and Zimmerman, P.L.
University of Southern California and the Basile Doherty Eye Institute, Los Angeles, California, USA

Objective: To describe highly characteristic clinical features and light and electron microscopic findings of P. Carini chorooiditis in three patients with AIDS.

Methods: Three patients were followed asymptotically for AIDS-related conditions; two had Osmegmoscopia minima treated with ganciclovir. New chorooid lesions developed and retinal photographs were obtained. At autopsy, the globes of the eyes were examined grossly, by light microscopy and by electron microscopy.

Results: The characteristic fundus changes in P. Carini chorooiditis consist of multiple slightly elevated, pleomorphic, yellow-white lesions in the chorooid. Some of these chorooid lesions are round or oval, while others are geographic or multilobulated in shape. The lesions vary in size and are usually covered by relatively normal retinal pigment epithelium. However, some of the larger lesions may show areas of mild retinal pigment epithelium denudation consisting of the mottling or granular change. The fundus changes are not associated with choroidal inflammation. The etiology of the fundus pathology was determined by electron microscopy demonstrating P. Carini organisms.

Conclusions: P. Carini can produce characteristic fundoscopic changes in the chorooid and such findings can indicate disseminated P. Carini infection.

M.B.P.380 INCIDENCE OF PNEUMOCYSTIS CARINI PNEUMONIA (PCP) IN HIV INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS-1 (HIV-1)

Erica Jaffe, Madan, A., Daniels, R., Miranda, C. and Sash, A.

Multicenter AIDS Cohort Study, Chicago, IL

Objective: To determine the risk of developing PCP in homosexual men infected with HIV-1.

Methods: 1764 seropositive homosexual men were enrolled into a prospective study of HIV-1 infection in 1984-85. A history, physical examination and T-cell phenotyping was obtained every 6 mo. Outcomes through 7/31/88 are included in the analysis.

Results: Of 1660 men with available baseline CD4 counts, 185 developed PCP. This table stratifies outcomes over 3 years by CD4 number at entry.

CD4 count	n	PCP	6 mo. (%)	12 mo. (%)	36 mo. (%)
0-200	79	22	8.3	17.9	38.2
200-350	231	23	0.4	3.7	24.1
350-500	393	43	0.0	1.3	9.5
500-700	479	46	0.0	0.4	9.0
>700	487	21	0.0	0.0	4.1

Among participants whose CD4 count fell decreased to 200/mm³ at some time during the study, weight loss and thrush significantly (p<0.05) increased risk at 6, 12 and 36 months; fatigue and fever were predictive (p<0.01) for short term (less < 12 mo) development of PCP. Diarrhea, herpes zoster or hairy leukoplakia were not predictive.

Conclusion: Risk of developing PCP significantly (p<0.001) increased with decreasing CD4 cell count. Specific signs and symptoms occurring in immunosuppressed participants significantly add to the risk of PCP.

M.B.P.381 PSYCHIATRIC MORBIDITY IN HIV INFECTED INDIVIDUALS IN INDIA

JACOB K.S., MOSES, S., JOHN, J.K. and JOHN, E.T.

Christian Medical College, Vellore, India.

Objective: To document the psychiatric morbidity among HIV carriers and AIDS victims.

Method: 24 subjects were assessed to document psychiatric morbidity. The diagnosis of HIV infection/AIDS was communicated in the context of the psychotherapeutic support provided. They were followed up for a period of 2 to 6 weeks and additional psychopathology documented. DSM-III criteria were used for diagnosis. Acute, psychiatric morbidity at initial screening included Delirium (1), Major Depressive Disorder (1), Adjustment Disorder with depressed mood (7) and Marital discord (1). After the diagnosis of HIV infection was communicated the additional morbidity included Adjustment Disorder (3), Major Depression (1), Alcohol Dependence Syndrome (2) and Suicide (1). The individual who reacted with Major Depression also developed alcohol dependence and he committed suicide.

Discussion: The possibility that preexisting psychopathology predisposed these individuals to sexual promiscuity needs to be explored. The majority of individuals reacted with depression and could be supported through the crisis.

M.B.P.382 PREVALENCE AND COURSE OF PSYCHIATRIC DISTURBANCES ASSOCIATED WITH HIV INFECTION (CDC CATEGORY II-B IV)

Boon, Frans van den, Broer, Herman*, Broekman, Jitske**

* Netherlands Institute of Mental Health, Utrecht, The Netherlands.

**University of Amsterdam, Dept. of Psychiatry, Amsterdam, The Netherlands.

Objective: Gain insight in the prevalence and course of psychiatric disturbances/disorders in HIV infected persons.

Method: Every newly registered patient in a period of one year at the Academic Medical Centre (AMC) in Amsterdam will be followed during 12 months. A psychiatrist will give a DSM III R diagnosis at entrance, and after 6 and 12 months; a neurological examination will be executed at entrance; a psychiatric interview using the Diagnostic Interview Schedule will be held at entrance and 12 months later; with a bi-monthly frequency several self report questionnaires (General Health Questionnaire, Beck's Depression Scale) will be filled out; a neuropsychological test battery will be administered, and a 10 minute interview will be held.

For those who need psychiatric treatment, interventions and complications (e.g. with medication) will be monitored and registered. Special attention will be payed to organic complications.

Results: Preliminary results will be presented.

M.B.P.383 DIAGNOSIS OF DEPRESSION IN HIV INFECTED INDIVIDUALS

Ross, S.H., Rice, J., Brookshire, D. and Guadet, P.

AIDS Clinical Trials Unit, Washington University School of Medicine, Saint Louis, Missouri, USA.

OBJECTIVE: To examine the presence and course of depression in HIV infected individuals.

METHOD: A random sample of 26 seropositive individuals, 10 ARC and 10 AIDS patients who were enrolled in an AIDS Clinical Trial Unit were evaluated for depression by means of a structured psychiatric research interview. The SADS-L (Schedule for Affective Disorders and Schizophrenia-Lifetime) was used. Responses were made by ARC (Research Diagnostic Criteria) criteria. Subjects were interviewed on the average of 15 months post HIV testing.

RESULTS: Fifty percent (n=22) met criteria for a depressive diagnosis during the interval from HIV testing to the time of the present assessment. Forty percent (n=16) experienced a major depression which lasted a week or longer. Ten percent experienced a minor depression.

Twenty-one percent (n=10) had suicide ideation or death wish. Two subjects attempted suicide. Depression appeared to be less frequent one year or greater after HIV testing, as only two subjects reported current depression with major depression.

CONCLUSION: It is noteworthy that half of the sample had a clinically significant depression. Further, depression appears to be less common as individuals have time to cope with their HIV status.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

Traitement de la PCP : Pentamidine et autres médicaments (diagnostic clinique) PCP Treatment: Pentamidine and Other Drugs (Clinical Diagnosis)

T.B.P.1 ÉVALUATION QUANTITATIVE DE PARASITÈMES AU COURS DE LA PNEUMOCYSTE CARINII CHEZ LES PATIENTS ATTEINTS DE SIDA OU D'AUTRES IMMUNODÉPRESSIONS.

NOUË Patricia, PAROÏT A., BÉGIN C., MAYARD C., PAROÏN F., LANGCASTER F.
HÔPITAL TENDR - 4, rue de la chine - 75020 - PARIS

Objectif : Rechercher et, comme pour l'expression clinique, si existe une différence dans l'intensité de parasitemie au cours des pneumocystoses survenant chez les sujets atteints de SIDA ou d'autres immunodépressions.
Méthode : Cette étude concerne 80 patients : 47 SIDA (G1) et 33 autres immunodéprimés (G2); tous ont une pneumocystose diagnostiquée par lavage broncho-alvéolaire (LBA), 29 ont une insuffisance respiratoire aiguë (IRA) avec $PaO_2 < 50$ mmHg. L'intensité de parasitemie a été évaluée sur le nombre d'œufs présents dans 10 μ l du col de centrifugation du LBA selon une méthode semi-quantitative : parasitemie faible < 5, ++, intense > 4+.

Résultats :

Parasitemie	faible G1	intense G1	faible G2	intense G2
$PaO_2 < 50$ mmHg	n = 26	0	19	0
$PaO_2 \geq 50$ mmHg	n = 54	16	32	5

Conclusions : Il existe des différences d'intensité de parasitemie dans les deux populations étudiées en particulier au cours des PRC. 5 sévères avec IRA : parasitemie intense dans G1, faible dans G2.

T.B.P.2 FINAL DIAGNOSIS IN PATIENTS WITH NEGATIVE BRONCHOALVEOLAR LAVAGE FOR PNEUMOCYSTIS. Sills, Zihad*, Veree, G., Forrester, C., Shafiq, A., Johnson, R.S.

St. Michael's Hospital, Medical Center, Newark, New Jersey, U.S.A.

Objective: To attempt and determine a final diagnosis in patients with a negative broncho-alveolar lavage (BAL) for PCP. **Methods:** Review of all hospital charts of HIV positive patients with bronchopathy for suspected PCP. Further analysis of those charts with negative PCP on BAL included clinical symptoms, laboratory examinations, chest x-rays and sputum smears. **Results:** 88 HIV positive patients underwent 93 bronchoalveolar lavages. 17 were negative for PCP. 13 of those were found to be PCP. 23 were included five with positive results on transbronchial biopsy and eight with a compatible laboratory and clinical course. 23 were found to have positive mycobacterial cultures, seven of which were M. tuberculosis. Eight sided endocarditis with embolic pneumonia accounted for six cases. 5 had positive fungal cultures and another five showed CMV. Seventeen remained without a etiologic diagnosis.

Conclusions: Most patients with suspected PCP with negative sputum smears on BAL had an etiologic agent identified. These agents were usually treatable.

T.B.P.3 A PATHOLOGIC BASIS FOR BRONCHOALVEOLAR LAVAGE (BAL) PNEUMOCYSTIS CARINII PNEUMONIA (PCP). BARDI, ROBERTA*, FOWLY L., and SIKKON P. Harbor-UCLA Medical Center, Torrance CA, 90509, USA

Objective: In 60 patients with PCP, > 50 BAL neutrophils predicted mortality more sensitively and specifically than the degree of hypoxemia, hypoalbuminemia or increased LDH (Am Rev Resp Dis, in press). We sought to determine a pathologic basis of excess bronchoalveolar lavage (BAL) neutrophil percentages in Pneumocystis carinii pneumonia.

Methods: Transbronchial biopsies of 20 patients with documented PCP and specimens adequate to assess the histology of the lung parenchyma were reviewed. Biopsies were scored from 0 (absent) to 3 (abundant) in each field for the degree of diffuse alveolar damage (DAD) and for the presence of polymorphonuclear leukocytes (PMN) as well as the presence of capillaritis, edema, chronic inflammation, fibrosis and intra-alveolar or interstitial PMN.

Results: The presence of DAD and interstitial or intra-alveolar PMNs were the most common abnormalities in the lung parenchyma and each was found in 27 of 29 patients. The presence of fibrosis was the least common finding, present in only 6 of 27 patients.

Conclusions: DAD and neutrophilic infiltration were commonly found in the transbronchial lung biopsies in patients with AIDS. Neutrophilic infiltrates are not a well-recognized sequelae of PCP, however, PMNs in the lung may account for more severe clinical manifestations of this disease and provide the basis for staging of PCP with BAL neutrophilia.

T.B.P.4 INTERET ET LIMITES DES EXPECTORATIONS INDUITS DANS LE DIAGNOSTIC DE LA PNEUMOCYSTE DU SIDA.

Delaour, Thery*, Bouc P., Camu, P., Fay, M., Denis, M et Grand, PM**
Hopital Pasteur, Paris, France ; *Hopital Claude Bernard, Paris, France ; **INSERM U14, Paris, France

Objectif: Evaluation diagnostique de l'expectoration induite (EI) comparée au lavage bronchoalvéolaire (LBA).

Patients et méthodes: Un recueil (EI) de LBA a été fait simultanément chez 132 patients HIV positif suspects de pneumocystose dont 23 hospitalisés en soins intensifs. Des azaarés tétraols ont été faits chez 17 patients. EI : recueil après induction par un aerosol salé hypertonique (3 % de sulfate d'hydrogène) LBA : selon la technique habituelle. Traitement des prélèvements : fixation des EI (éthylglycidylthiozobutane) sans centrifugation - coloration par Gram. Imprégnation aseptique vitro Blau de Toluidine O etrou Grand Weigert à la source des lames coudées à 48 h/48 par deux examinateurs.

Résultats:

Maladies Services	LBA (%)	EI (%)	Sensibilité E/LBA (%)
Maladies Infectieuses	50 / 120 (42)	32 / 120 (27)	32 / 50 (64)
Soins Intensifs	16 / 31 (52)	4 / 31 (13)	4 / 16 (25)

Conclusions: 1) Spécificité des EI : 100 % 2) Sensibilité des EI plus faible que les patients de soins intensifs (25 % versus 64 %) probablement dus au traitement et Pneumocystis administré pendant plus de 48 h/48 dans cette série. 3) Induction des expectorations s'est révélée impossible chez 20 % des patients. 4) Au total, chez des patients ne recevant pas de traitement et Pneumocystis, le recueil du LBA pourrait être évité dans 24 % des cas.

T.B.P.5 ANTIBODIES TO PNEUMOCYSTIS CARINII. MIXED LEVELS IN HIV INFECTED PATIENTS DURING PNEUMOCYSTIS INFECTION AND EVALUATION OF PASSIVE IMMUNITIES.

Burns, Sheila B.*, Reed, J.A.*†, Wu, P.A.**†, Stebbins, G.R.**††

* Regional Virus Laboratory, City Health Dept., Edinburgh, Scotland.
† Scottish National Blood Transfusion Service, Edinburgh, Scotland.
†† Infectious Diseases Unit, City Hospital, Edinburgh, Scotland.

Objective: To follow the relationship between *Pneumocystis carinii* antibody levels and acute infection in homosexual males from HIV antibody positive patients with seropositive spouses and to investigate the possibility of using serology.

Methods: Using an RPA based on fusion products of infected rat lung *P. carinii* antibody activities were measured on 8 HIV positive patients and 7 HIV negative immunocompetent patients with respiratory systems. Multiple samples from 25 seropositive positive patients were analyzed and the *P. carinii* antibody levels correlated with available serological data or induced sputum results.

Results: Five patients with proven P.C.P. had an acute fall in antibody levels and a further 3 showed transient antibody following diagnosis and treatment. The same pattern was observed in three patients with suspected but not proven P.C.P. Antibodies to other viruses and serum immunoglobulin did not show a similar pattern. The *P. carinii* antibody levels in 40 blood donors and 10 heterosexual diabetics (HD) samples selected at random was estimated.

Conclusions: The use of IgG in acute infection with *P. carinii* and as seropositive against infection either alone or in conjunction with other therapeutic agents, is worth further evaluation.

T.B.P.6 PURIFICATION AND CHARACTERIZATION OF A MAJOR HUMAN PNEUMOCYSTIS CARINII SURFACE ANTIGEN

Wang, Yeh-Hsin*, Lin, Yeh-Hsin*, Kuo, Kowen, J.A.
National Institutes of Health, Bethesda, Maryland, USA.

Objective: Purified *Pneumocystis carinii* (PC) antigens are needed for investigations into host-parasite interactions and host immune responses. P-25, a 25 kDa protein, is a human and rat PC are antigenically different, antigens of human PC should be used as antigens.

The goal of the current study was to purify a major antigen of human PC. **Methods:** PC were obtained from autopsy lungs of patients that died of PC pneumonitis. Organisms were treated with proteolytic P-25-lysine, and the antigen was purified by HPLC using a size column followed by ion-exchange chromatography. To evaluate the size of the native molecule, a cross-linking study using bis[3-(dimethylamino)carbonyl]suberate (DSB) was done.

Results: Synthesis of purified PC solubilized the predominant antigen, which has a size of 86,000 MW when evaluated by SDS-polyacrylamide gel electrophoresis under reducing conditions. This antigen reacts with a monoclonal antibody (8B3) previously shown to be specific for human PC immunofluorescence studies have shown that it binds to the surface of PC. Reactivity with the monoclonal antibody was used to follow purification. The size of the native molecule, based on sizing column chromatography, was greater than 500,000 MW. Following immunoprecipitation chromatography, a single band of 86,000 MW was seen on SDS-PAGE, and this band reacted with the monoclonal antibody. **Conclusions:** The antigen purified prior to SDS-PAGE suggests that the antigen is a trimer, based on the presence of a new 270,000 MW band in the immunoprecipitate.

Conclusions: A major surface antigen of human PC, purified with a molecular weight of 86,000 MW, was purified from human lungs. This antigen is a trimer. The purified antigen can be used to develop assays to investigate the cellular and humoral response of humans to PC infection.

Session d'affichage
Poster Session



Aspects cliniques
Clinical Aspects of AIDS

T.B.P.7

THE DIAGNOSIS OF PNEUMOCYSTIS CARINI PNEUMONIA IN HIGH RISK PATIENTS BY INDUCED SPUTUM USING A DIRECT IMMUNOFLUORESCENT ANTIBODY TEST

Heath-Chicago, Michel; Moore, M.; Rose-Douglas, J.; Connors, J.; Hulme, P.; Harth, B. Beth Israel Hospital, Harvard Medical School, Boston, MA

Objective: Evaluation of the Genetic Systems direct immunofluorescent monoclonal antibody test (DFA) to detect *Pneumocystis carini* in induced sputum.

Methods: Induced sputum (IS) was collected from 27 patients who were HIV seropositive or in a high risk group and had histiophilic infiltrates on chest x-ray, room air PO₂ < 80, and/or a positive Gallium scan. Bronchoalveolar lavage (BAL) was performed on most patients whose IS was nondiagnostic. IS and BAL were processed using published techniques and stained by Toluine Blue O (TBO) and DFA. TBO smears with heavy yeast were considered uninterpretable (TBOU). Slides with 2-3 yeasts were considered positive.

Results: There were 16 DFA positive IS smears of which 10 were also TBO +, 4 were TBOU and 4 were TBO -. Six of these 6 patients who were DFA + but TBO or TBO - were confirmed to have pneumocystis pneumonia (PCP) by BAL, whereas 2 patients had BAL + but a direct culture consistent with PCP. The other 6 were not to follow-up. Eleven IS smears were DFA negative, 10 were TBO - and 1 was TBOU. Six of these were confirmed negative by BAL. Of the 6 remaining patients who did not go on to BAL, 3 responded to specific PCP therapy, 1 had been rechecked to rule out a PCP treatment failure, and a final direct DFA could not be made in 1 patient due to concentrated PCP and extensive debris.

Conclusion: In patients at high risk for AIDS-related PCP, DFA is more sensitive than TBO and makes the diagnosis of PCP by induced sputum a simple, rapid, and highly sensitive test.

T.B.P.8

BRONCHOALVEOLAR LAVAGE (BAL) CMV CULTURE POSITIVITY (CMV+) IS ASSOCIATED WITH BETTER OUTCOME OF IMMUNOCOMPROMISED PNEUMONIA (PCP) IN HIV WITH AIDS.

Arora, JM; Rosenzweig, SM; J. Berlok, A; McWhorter, JA; Richman, DR; Swartz, R. UC San Diego and the California Cancer and Active Treatment Group, San Diego, CA, U.S.A.

Objective: To determine the significance of CMV in confirmed PCP. **Methods:** Retrospective cohort study of all patients undergoing bronchoscopy at UCSD for possible PCP between 1/1/85 and 12/31/87. CMV+ and CMV- patients were compared for prognostic factors at presentation and for outcome. Unfavorable outcomes were death within 30 days and intubation. **Results:** Of 248 episodes, 136 were confirmed PCP. All had BAL fluid viral culture; 122 were unconfirmed or evaluable. 112 cases in women (1 CMV+) were excluded. Analysis of the remaining 122 cases showed: **Prognostic Factors:** Age, sex, PCP, prior AIDS, CMV. **DFI:** BAL-CMV+ (n) 52 (46) >=34 42 (81) >=68 52 (100) >=12 >=14 BAL-CMV- (n) 60 (54) >=34 43 (75) >=68 60 (100) >=12 >=14

Outcome	Death	Intubation	Death or Intubation
BAL-CMV+ (n)	6 (12)	16 (63)	22 (33)
BAL-CMV- (n)	13 (22)	13 (22)	26 (33)
Relative Risk (C.I.)	1.22 (1-1.37)	1.4 (1.04-1.9)	1.49 (1.04-2.04)

p = n.s., p < 0.05, p < 0.02. **Conclusion:** Nearly 1/2 of men with PCP had BAL-CMV+. CMV+ men had similar survival times but apparently better outcome than CMV- men. CMV-mediated immunosuppression may reduce lung injury in PCP. BAL-CMV+ men may have underlying lung dysfunction and present with earlier PCP.

T.B.P.9

A MEASURE OF IMMUNOCYSTIS CARINI PULMONARY LESION. **Richard Robert P. France**, Department of Medicine, University of Cincinnati, Cincinnati, OH, U.S.A.

Objective: To develop a method for estimating the burden of *Pneumocystis carini* (PC) in bronchoalveolar lavage (BAL) fluid of AIDS patients (pts). **Methods:** BAL fluid from AIDS pts with PC pneumonia were prepared with a cytochrome and a modified Wright-Giemsa stain. The number of PC in clusters was compared to the number of nucleated cells counted. Intra- and inter-subject variability was determined by analysis of variance and the P-ratio (P) and P value calculated. **Results:** PC clusters from BAL specimens of 20 pts were counted three times. The cluster number that was associated with 200, 500, and 1000 cells was noted. There was significant intersubject variability for the 200, 500, and 1000 cells (200 cells: P=0.01, 500 cells: P=0.3; 1000 cells: P=6.4, all p<0.001). The correlation coefficient for 500 cells between counts (R=0.81, p<0.001) was higher than 200 cell counts, but similar to 1000 cell counts; the number of clusters with 500 cells was used thereafter. Because the BAL fluid volume may alter the cell differential, we studied BAL specimens aspirated after each of four introduced aliquots of 60 ml saline in 15 pts. There was no significant intrasubject variability (P=10, p<0.5), but there was significant intersubject variability (P=0.3, p<0.001). Sequential lavage specimens from 24 pts before (PRE) and after (POST) therapy for PC pneumonia were studied. Sixteen pts responded to therapy; all had a decrease in PC clusters (PRE=5.4, 1.1 (Mean±S.E.); POST=4.2, 0.0, 0.01). Eight pts had persistent disease; the BAL contained the same or more PC (PRE=5.2, 1.6; POST=5.5, 1.6). **Conclusion:** PC can be quantitated in BAL fluid; this may be useful in assessing therapy.

T.B.P.10

DEFECTIVE PERIPHERAL OXYGEN UTILIZATION IN AIDS PATIENTS WITH RESPIRATORY FAILURE DUE TO PNEUMOCYSTIS CARINI.

Robert C. Allen, Tishchenko, L., Sweeney, R.A., Sojka, S.C., LAC/USC Medical Center, OH 11400, 1200 North State Street, Los Angeles, CA 90033, U.S.A.

Objective: A peripheral defect in oxygen utilization has been described in acute shock and the Adult Respiratory Distress Syndrome (ARDS). Some have suggested that inadequate levels of oxygen transport to peripheral tissues may contribute to the mortality seen in these states. In this study we examined peripheral oxygen utilization in AIDS patients with severe respiratory failure secondary to *Pneumocystis carini* infection (PCP).

Methods: We evaluated twelve patients (age = 34 ± 8 yrs) with AIDS, documented PCP and severe respiratory failure (PO₂ < 215 ± 10) requiring PEEP. We chose subjects who had no evidence of any concomitant bacterial, fungal, mycobacterial or viral infection as affirmed by lack of clinical site and negative cultures, including blood. Cardiac outputs were obtained by thermodilution and oxygen consumption calculated by the Fick equation.

Results: Our data showed:

	CI	Hgb	DO ₂	VO ₂	LACTATE
HR	43 ± 11	10 ± 1.7	539 ± 164	152 ± 82	2.4 ± 1.1
1994	43 ± 17	10 ± 1.5	544 ± 249	145 ± 48	2.5 ± 0.7
1995	44 ± 18	10 ± 1.8	596 ± 262	139 ± 55	4.4 ± 1.8

Conclusion: The patients with PCP and respiratory failure had a systemic dependent oxygen consumption at higher levels of oxygen delivery than have been found in normal humans, suggesting a peripheral defect in oxygen utilization similar to that seen in bacterial sepsis and ARDS. This may be significant with respect to management.



T.B.P.11

Rapid Diagnosis of *Paramecystis carini* pneumonia in Patients with AIDS using a Direct Fluorescent Monoclonal Antibody (DFA) Assay.

Vignani, Albert*, Ng VL**, Chaisson RE**, Hadley WK**, Sparsho, Yajko D** and Hirschel CM, U.S.A. * Johns Hopkins Hospital, Baltimore, Maryland, ** San Francisco General Hospital, San Francisco, California.

Objective: To compare a new DFA (Genetic Systems) with the Giemsa (Diff-Quick) for the diagnosis of PCP from sputum and bronchoalveolar lavage (BAL).

Methods: Induced sputum from patients with suspected PCP was digested, centrifuged and smeared on slides. Heat fixed Giemsa and routine fixed DFA stained slides were examined for trophs and cysts. BAL was done on patients negative by sputum, when possible.

Methods: Of 111 patients evaluated, a total of 60 were diagnosed with PCP. 52/60 with Giemsa on sputum (97% sensitivity) and 51/60 on sputum with DFA (85% sensitivity). 3 patients had PCP diagnosed by both methods as a subsequent sputum after treatment of a bacterial superinfection. 8/23 patients negative on sputum induction were positive by both DFA and Giemsa as were 3 additional patients who had BAL done. Of the 36 patients that did not go to bronchoscopy, other diagnoses apparent in 13 are related to indeterminate. There was one false positive and one false negative DFA specimen was.

Conclusion: This DFA is a rapid, inexpensive method of identifying *P. carini* in sputum and bronchoalveolar specimens and is comparable to the standard high yield Giemsa stain.

T.B.P.12

PREVIOUS INABILITY TO CONFIRM THE DIAGNOSIS OF PRESUMED IMMUNOCOMPROMISED PNEUMONIA (PCP).

Rosenzweig, Samuel A; Sletten, P; Chiu, J; Gluckstein, D; Oeffner, J; Mueller, C; UC San Diego, UC Southern Cal, UC Irvine, Kaiser/Stanford Hospital and the California Collaborative Treatment Group, San Diego, CA, U.S.A.

Objective: To assess the reliability of the diagnosis of PCP and the utility of clinical assessment in distinguishing confirmable cases.

Methods: The presentation, treatment course of persons with PCP was examined. All patients were enrolled into a randomized trial of corticosteroids which required subsequent confirmation of diagnosis. Only patients who had a positive induced sputum or unobscured bronchoscopy were included.

Results: PCP was confirmed in 158 of 202 patients (78 pct and 23% resp.) of PCP. **Findings (sensitivity) (False Pos/Neg) Value Value**

Findings (sensitivity) (False Pos/Neg)	Value	Value
Cough	91	84
fever	72	81
Short Dyspnea	83	80
Wet Dyspnea	44	83
Chest Tightness	56	87
WBC <= 16,000 (cell)	55	41

The present and present probabilities of disease were not significantly different for all findings and combinations of findings (not shown).

Conclusion: The diagnosis of PCP frequently cannot be confirmed. Confirmable and unconfirmable PCP present similarly. No finding alters the probability of confirmable disease to a clinically relevant extent. Actions based on a diagnosis of PCP must be undertaken without caution.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

T.B.P.13

A NEW METHOD FOR THE DIAGNOSIS OF PNEUMOCYSTIS CARINII IN BRONCHOALVEOLAR LAVAGE
 M. Desautels*, P. Delattre**, P. Delattre**, C. Kati-
 sa*, N. Denis*, M. Gentilin*.
 *Dept of Public Health, Parasitology and Tropical Medicine, Hôpital de la
 Salpêtrière, Paris, France, et Unité INSERM 213, Paris
 **Diagnostic Pasteur, Marne-la-Coquette, France.

Objective: An indirect fluorescent-antibody technique is compared to a tra-
 ditional silver staining method for the diagnosis of *Pneumocystis carinii*
 (P-C) cysts in bronchoalveolar lavage (BAL) specimens.
Method: 200 BAL-specimens from 140 patients are treated simultaneously with
 the indirect fluorescent-antibody technique (Detect IF L. cariniiTM) and
 Muto's rapid silver staining method.
Results: Of the 200 BAL specimens, 100 are positive for P-C, both method included.
 50.6% of the positive sample are diagnosed by the indirect immunofluorescence
 (IF) method and 49.4% by Muto's technique.
Conclusion: The IF method permits again in the diagnosis of P-C in BAL,
 especially when samples contain a small number of cysts. The technique is
 simple in performance and has the advantage of an easy and a rapid lecture.

T.B.P.15

**PREDICTIVE DATA FOR POSITIVE BRONCHOALVEOLAR
 LAVAGE RESULTS IN PNEUMOCYSTIS PNEUMONIA.** Sims,
Linard, Delgado, Peres, Gr. Forrester, C.
Johnson, E.S., Saint Michael's Medical Center, Newark, New
 Jersey, U.S.A.

Objective: To determine if any factors may be predictive of
 bronchoalveolar lavage (BAL) recovery of PCP in suspected cases
 of pneumonia.
Method: A retrospective review of 127 bronchoscopies performed
 for suspected PCP was undertaken with analysis of hospital
 charts. Symptoms, chemistry profile, arterial blood gases, chest
 x-rays and sputum smears were compared in 61 patients with
 positive and 65 with negative results for PCP.
Results: Those with positive results had an average shorter
 duration of anti-PCP treatment prior to (BAL), had a lower
 incidence of negative chest x-rays, had 100% incidence of
 positive sputum smears and higher lactate dehydrogenase levels.
 Symptomatically those with positive (BAL) had longer duration of
 symptoms and lower incidence of productive cough. Arterial
 blood gas measurements, complete cell counts and V-cell studies
 showed no differences between groups.
Conclusion: There are some laboratory data (arterial dehydrogenase,
 chest x-ray and sputum smears) and/or symptoms (duration and
 productive cough) which can be predictive of positive (BAL)
 results.

T.B.P.17

**How predictive are LHM-elevations for the severity of pneumo-
 cystis carinii pneumonia in AIDS patients?**

Elger, C. Irckenbrecht, J.F. Worth, N. Stromeyer, R.
 University of Medicine, University of Düsseldorf, 4000 Düsseldorf Muenster-5
 FRG.

The elevation of plasma lactate dehydrogenase (LHM) is a common phenomenon
 during pneumocystis carinii pneumonia in AIDS. Prospectively we evaluated
 the reliability of LHM elevation to predict severe respiratory distress:
 arterial oxygen pressure (PO₂) less than 60 mmHg; during pneumocystis
 carinii pneumonia (PCP). A significant negative correlation between both
 values was found (r=-0.46; p<0.001). For LHM values less than 300 U/l,
 only 3 of 32 PCP values were less than 60 mmHg (specificity 86.2%). For LHM
 values higher than 300 U/l only 38.5% of the PCP values were less than
 60 mmHg (sensitivity 38.5%). When LHM values were between 300 and 600 U/l
 the range of PCP values was between 32 and 94 mmHg. Positive and negative
 prediction values of LHM 300 U/l for the diagnosis of severe respiratory
 distress were 50% (16/34) and 61% (12/19), respectively.
Conclusion: LHM and PO₂ are significantly correlate in pneumocystis carinii
 pneumonia. However, due to low sensitive and low predictive value, LHM
 determination is of limited value in prediction of severe respiratory
 distress in pneumocystis carinii pneumonia in AIDS patients.

T.B.P.14

**PNEUMOCYSTIS CARINII: DIAGNOSIS IN NON-INDUCED
 SPUTUM BY IMMUNOFLOURESCENCE**
 M. Hübner*, T. Trachsel*, B. Brubaker*, G. Gerdle*, R. K. S.
 Schedel*, I. Deicher*, H. Schmed. Hannover, Fed. Rep. of Germany.
 *Publ. Health Labs., **Sch. Med., Hannover, Fed. Rep. of Germany.

Objective: To develop a reliable routine procedure for diagnosing
 Pneumocystis (PC) in spontaneously expectorated sputum
 of patients with AIDS or suspected AIDS.
Method: Non-commercial indirect immunofluorescence test (IFT)
 based on polyclonal rabbit-antiserum to PC.
Results: Non-induced sputa of 128 HIV-patients with suspected
 pneumocystosis (PCP) were examined. The IFT was diagnostic in
 50 (39 %) patients. In 30 out of the 78 patients with a negative
 sputum diagnosis, a bronchoalveolar lavage (BAL) was per-
 formed subsequently, because of PCP still was suspected.
 In 3 of these cases PC was detected in the BAL material. An-
 other sputum diagnosis was taken for false-positive due to the
 further clinical course. Thus, on the basis of clinical para-
 meters and comparative sputum/BAL-examination, 94 % sensitivity
 and 99 % specificity of the test was attained in this
 cluster of patients.
Conclusion: Our results suggest that PC is commonly present in
 spontaneously expectorated sputum of HIV-patients with PCP.
 A properly designed immunofluorescence technique makes this
 material a most useful diagnostic specimen.

T.B.P.16

**GENERAL HISTOLOGIC MANIFESTATIONS OF PNEUMOCYSTIS CARINII
 PNEUMONIA (PCP) IN AIDS.** William R. Taylor, G. Pittenger,
W. Lynch, W. G. O'Connell, W. Armstrong, R. Levy, et al.
 National Institutes of Health, Bethesda, MD, USA

Objective: To investigate the pathologic features of PCP in AIDS patients.
Method: 162 lung biopsies (156 transbronchial, 6 open biopsies) from 71 AIDS
 patients with PCP were reviewed. Serial biopsies in 50 patients (2-9
 each) and autopsy study of the evolution of the evolution of
 pathology of PCP.

Results: Several unusual pathologic manifestations of PCP were observed:

Histologic Feature	No. Biopsies (%)
Interstitial Fibrosis	74 (46)
Interlobular	42 (26)
Absence of alveolar septulae	21 (18)
Marked alveolar macrophages	8 (7)
Chronic inflammation	4 (3)
Marked chronic inflammation	4 (3)
Squamous metaplasia	2 (2)
Marked squamous metaplasia	2 (2)
Minimal histologic reaction	1 (1)
Marked interstitial and vasculitis	1 (1)

Conclusion: PCP has a wide spectrum of pathologic manifestations in AIDS
 patients. It is important to recognise unusual pathologic features of PCP
 since it is the most common life-threatening pulmonary complication of AIDS.

T.B.P.18

**COMPARISON OF FIRST EPISODE OF PCP IN COMMUNITY PATIENTS
 AND IMMATES**
Stark, Victoria, Andrew, A. Mayman, R. Weiss, R.
 Albany Medical Center, Albany, New York, U.S.A.

Objective: Compare survival of community patients (CP) and inmates (I)
 diagnosed with their first episode of PCP.
Methods: Retrospective review of all patients with primary PCP admitted to
 the ANC AIDS Treatment Center between 1/1/87 and 10/31/88. Only those
 patients with documented PCP confirmed by bronchoscopy, were included
 in the study. Ethnic origin, risk group, lab parameters on admission, use
 of AZT and survival were evaluated.
Results: 40 community patients and 26 inmates were included in the study.
 In the community patients, there were 80% Caucasian, 10% black, 10%
 Hispanic. Among inmates there were 12% Caucasian, 72% black, 8%
 Hispanic. Risk group data showed community patients 63% H/O homosexual, 20%
 IVDA, 15% other. Inmates had 77% IVDA, 8% H/O homosexual, 15%
 IVDA/ homosexual. 20% of community patients were on AZT prior to admission;
 5% of inmates patients were on AZT prior to admission. Average LHM on
 admission: CP=64; I=60; Average Hct on admission: CP=35; I=33.4.
 Mortality was CP=34; I=24. Mortality in those individuals not on AZT:
 CP=44; I=34.
Conclusion: Inmates with primary PCP arrived at ANC sicker than community
 patients, as evidenced by higher LHM and lower Hct in the inmate
 population. Furthermore, despite presumably similar workup and treatment
 by the medical staff at ANC, inmates did worse than community patients as
 evidenced by their significantly higher mortality.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

T.B.P.25 REDUCED DOSE OF AEROSOLIZED PENTAMIDINE TREATMENT FOR PNEUMOCYSTIS CARINII PNEUMONIA (PCP): A 6 MONTH FOLLOW UP
John R. Gomez, Jr., D. Charvoff, H. Hollander, D. Feigel,
J. Golden, Department of Medicine, University of California, San Francisco, San Francisco, California.

Objective: To investigate the toxicity, efficacy, and pharmacokinetics of reduced dose of aerosolized pentamidine for the treatment of mild PCP.
Methods: 45 patients were entered into a randomized trial of reduced dose (3 mg/kg/day) intravenous pentamidine or aerosolized pentamidine (600 mg daily; Respigard-2 nebulator) for mild PCP (Psz 2 to 60 mm Hg). Pentamidine concentrations in plasma and bronchoalveolar lavage (BAL) were measured by HPLC.
Results: Of 23 IV patients, 1 was excluded because PCP was not confirmed, 4 failed to respond to therapy, 12 developed major toxicity and 17/21 (81%) responded satisfactorily. Of 23 aerosolized patients, PCP was not confirmed in 1, 1 received no drug, 4 failed to respond, none developed major toxicity, and 17/19 (89.4%) responded satisfactorily. There were 2 deaths in the aerosolized group. The early relapse rate (3 months) were 0/17 and 10/15 (66.6%) for IV or aerosolized therapy.

Bronchoalveolar lavage concentrations of pentamidine were 89.8 ± 48.4 ng/ml and 110 ± 90.1 ng/ml (p=0.02, NS) in patients with or without relapse. **Conclusion:** Mild PCP responds adequately to reduced dose IV or aerosolized pentamidine. The early relapse rate following aerosolized treatment is high and not prevented by aerosolized pentamidine prophylaxis. BAL concentrations of pentamidine were not correlated with relapse. Pentamidine accumulates in plasma with daily intravenous therapy even in patients with normal renal function.

T.B.P.27 TRAITEMENT DE LA PNEUMOCYTOSE DU SIDA PAR LE DFMO
Clard, Pierre-Marie* ; Darou, A.* ; Puzosman, W.* ; Perrone, C.* ; Wolff, M.* ; Colliard, J.*
*Hôpital Hochel - Claude Bernart, *INSERM U13, 75019 Paris, France.

Objective: Evaluation de l'efficacité et de la tolérance du Dihydrofolylméthotrexate (DFMO) dans la pneumocystose au cours du SIDA.
Patients and Methods: Le DFMO a été administré à la dose de 400 mg/kg/j pendant 15 jours puis 300 mg/kg/j, P.O. pendant 30 jours. L'efficacité a été évaluée chez 22 patients : Groupe I (n=6) PaO2 < 40 mmHg (27-68) ; traitement de première intention. Groupe II (n=17) PaO2 < 63 mmHg (36-52) ; traitement de soins après (non-1) ou échec d'un autre traitement (non-2). La tolérance a été évaluée chez 27 patients.

Results: La durée moyenne du traitement a été de 20 jours (4-27). Groupe I : 3/5 guérison ou amélioration. Groupe II : 15/17 (88%) guérison ou amélioration, 91% de réponses favorables ont été observées chez les 11 patients dont la PaO2 était supérieure à 50 mmHg versus 72% chez les 11 patients avec PaO2 inférieure à 50 mmHg. Les effets secondaires les plus fréquents étaient : hépatites (52%), anémie (41%), neutropénie (37%), diarrhée (30%), et une néphrite partielle du DFMO dans 9/27 cas (33%).

Conclusion: 1) En traitement de première intention, l'efficacité du DFMO semble inférieure à celle des traitements conventionnels. 2) En relais, le taux global de réponse favorable (88%) est élevé mais pourrait être lié à l'effet du traitement antérieur. 3) La toxicité hématologique est fréquente.

T.B.P.29 Eflornithine in the treatment of Pneumocystis Carinii Pneumonia (PCP).
Neil, J.P., Doherty, P., Smith, R., Jones, A., Doherty, R., Sacks, H.S., Hirschman, S.Z., Mc Siney
Hospital, New York.

Eflornithine (E) has been demonstrated to have activity against PCP. From 1985 to 1988 42 patients that had failed or had had significant adverse reactions to pentamidine and TMP-SMX were treated with E. There were 23 definite responses, 17 probable responses, one patient died of another opportunistic infection and 15 patient failed therapy [F]. No differences were observed between responders and failures in the duration of AIDS, number of previous episodes of PCP, presence of other opportunistic infections or KS. Only 1 responder required mechanical ventilation at the start of therapy as opposed to 12/16 failures (p<.001). The initial WBC was 5.09 ± 1.88 in R as compared to 9.18 ± 4.26 in F (p<.01). There was a trend to higher A-a gradient in F (mean 80° F 153 vs R 172 ± 15) but this was not statistically different (p>.2). Adverse effects included thrombocytopenia, in 7/8 of patients; the WBC decline to 653 and hemocrit to 165. No patient had significant bleeding or a secondary infection. Four patients had diarrhea requiring antidiarrheal agents. E is effective therapy in patients with mild to moderate disease. As with standard therapy outcome is poor in patients with severe disease requiring mechanical ventilation. Further dose-response investigation to maximize efficacy and minimize toxicity is indicated.

T.B.P.26 PENETRATION OF TRIMETHOPRIM (TMP) COMPARED WITH THAT OF SULFAMETHOXAZOLE (SMX) IN BRONCHOALVEOLAR LAVAGE FLUID (BALF) DURING PNEUMOCYSTIS CARINII PNEUMONIA (PCP).
Domen, Jean-François*, Durand, S.*, Kizza, M.D.*, Hatcher, J.P.*, Hirsch, A.*,
Hospital Saint-Luc*, Saint-Jacques* and St-Charles*, Paris, France.

Aim: To improve knowledge on local kinetics of high dose TMP/SMX by comparing penetration of TMP and SMX into the extracellular fraction of alveolar macrophages where PCP is present.

Methods: 10 HIV+ patients with suspected (and later confirmed) PCP received a constant infusion of TMP (20mg/kg/6h-SMX (100mg/kg/6h), initiated 2h before BAL. BAL was performed in the right middle lung. Blood and BALF samples obtained during BAL were centrifuged and stored at -80°. TMP and SMX were assayed by HPLC and HPLC, respectively.

Results:

	Serum (µg/ml)	BALF (µg/ml)	PM (f)	(TMP) BALF/(TMP) serum	(SMX) BALF/(SMX) serum
TMP	3.1 ± 1.3	1.9 ± 0.7	76 ± 36		57 ± 40
SMX	162 ± 12	3.0 ± 1.4	1.8 ± 1.2		

Discussion: Although BAL, SMX may diffuse, it is clearly equal for both drugs in one individual patient. Thus, compared to BALF, serum TMP may be used to compare effectiveness of cotrimox given simultaneously to penetrate into the extracellular fraction of alveolar cells.
Conclusion: In patients with PCP, TMP achieves a markedly superior gradient to penetrate into the extracellular fraction of alveolar fluid as compared to SMX. Consequently, a 1:1 ratio present at the site of infection. This study suggests that TMP-SMX drug ratios different from that currently available may deserve studies in experimental models of PCP.

T.B.P.28 AIDS: THERAPY WITH PENTAMIDINE INDETHANATE IN MILD MODERATE CASES OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP).
Amann, Johannes*, Schneider, J.G., Mair, A., Schaefer, J.J., Weiss, M., L'ang, M.,
Kugler, Viktor-Hans-Hospital, FHO, Kaiserstrasse 275, D 800, Berlin 1.

Objective: To examine the effectiveness, side effects and pharmacokinetic data of aerosol therapy with Pentamidine.

Methods: Because of toxic side effects, Pentamidine isothionate by nebulization application can only be considered as a second choice in the therapy of PCP. In an open prospective multicenter study in 1988, ten patients with light to moderate cases of PCP were treated with aerosol therapy. The most important criteria for inclusion in this study were PaO2 over 40 mmHg and expiratory volume over 1.2 liters or 50% of the normal range. The histological diagnosis was supported by bronchoscopy. The patients received 300 mg of Pentamidine daily by inhalation (Respiogard 15) over a period of 21 days. Additionally, the Pentamidine dose in the blood and in 24-hour-urine samples were measured by a modified HPLC method. Controlled factors were blood count, blood sugar, lactate acid, and the laboratory results of the liver and kidney function.

Conclusion: For light to moderate cases of PCP, aerosol therapy with Pentamidine administered by the proper inhalation system presents an alternative to the formerly known methods. However, a 300 mg dosage appears too low. Further research is needed to determine the optimal dosage. **Results:** Eight out of ten patients were successfully treated, although complications were created by accompanying infections and intrapulmonary hemorrhages. The maximal Pentamidine level in the blood stayed in a range from 0.10-0.16 µg/ml. The secretion in the urine was found to be 0.11 - 0.53 µmol of the inhaled dosage. A cumulative effect did not occur. Contrary to the above mentioned method of nebulization application, no toxic side effects were found. Of the remaining two patients, one had an early relapse. The other had to be transferred to another form of therapy due to a secondary sepsis.

T.B.P.30 CLINDAMYCIN PLUS PRIMAQUINE AS PRIMARY THERAPY FOR PNEUMOCYSTIS CARINII (PCP) PNEUMONIA IN AIDS PATIENTS.
John, John L., Feinberg, J.E., Pan, R.P., Plouffe, J.F., Murphy, R.,
University of Maryland, Baltimore, IN "WILKIE AIDS Treatment Branch,
Lanning, G.S., Johns Hopkins University, Columbia Off., Northwestern University, Chicago, Ill.,
San Francisco General Hospital, San Francisco, CA, USA.

Objective: An open-blinded, pilot study to determine safety and efficacy of clindamycin and primaquine for treatment of mild to moderate PCP pneumonia in AIDS patients.
Methods: Histologically proven PCP pneumonia was required for entry. Patients were excluded if they had received prior antimicrobial therapy, if they had received a 4 week course of therapy if they had significant diarrhea, absolute granulocyte count (AGC) < 1000/mm³, platelet count < 100,000/mm³, Hg-A1c > 10, or if they had received clindamycin. Clindamycin 900 mg every 4 hours plus primaquine 30 mg orally per day was administered for the first 10 days. Clindamycin dosage was then decreased to 450 mg orally every 6 hours if patients met defined criteria for clinical response. Total duration of treatment was 21 days. Outcome was determined by a pneumonia scoring system incorporating fever, respiratory rate, oxygen, cough, chest x-ray, supplemental oxygen requirement and chest X-ray, and by change in A-a gradient. Blinically aerosolized pentamidine prophylaxis was begun 2 weeks after completing therapy. **Results:** All 8 patients entered to date showed marked improvement by the 7th day of therapy. Six patients completed treatment with clindamycin and primaquine and were cured. Two patients had received either trimethoprim-sulfamethoxazole or cotrimoxazole during the second week, one developed fever and rash, the other treatment, severe neutropenia (AGC of 300). Both were cured 1-2 weeks later. Additional minor side effects included mild neutropenia and mild methemoglobinemia. No relapse have yet occurred (none follow-up after treatment 1 week; none 1-2 weeks). All patients were cured. **Conclusion:** All improved clinically but failed to complete 21 days of treatment due to rash (2) or mild neutropenia development (1). **Conclusions:** Although further study is warranted, clindamycin and primaquine may represent an alternative therapy for PCP pneumonia in AIDS.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

T.B.P.31 CORRELATION BETWEEN ICU SURVIVAL AND REQUIRED CPAP/PEEP IN AIDS PATIENTS WITH PNEUMOCYSTIS CARINII PNEUMONIA
Bromberg, A.; Peruzzi, M.; Curtis, S.; Morphy, R.; Cass, J. & Shapiro, S.
Northwestern University, Chicago, IL, USA.

Objective: The survival of patients (pts) with Pneumocystis carinii pneumonia (PCP) and AIDS who require ICU admission and mechanical ventilation has been shown to be poor. This study was undertaken to determine the survival rates of pts with PCP treated with positive airway pressure (CPAP) by mask, CPAP by endotracheal tube, PEEP with mechanical ventilatory support.
Methods: The charts of all pts with PCP admitted to the ICU between 1985 and 1988 were reviewed retrospectively to determine patterns of survival and correlation between survival and treatment with CPAP/PEEP. The pts were treated by the same physician group using established protocols for airway pressure therapy to maintain adequate oxygenation.
Results: Preliminary data from 24 pts requiring CPAP/PEEP revealed that 6/24 (25%) were discharged from the ICU alive, and were ultimately discharged from the hospital. The highest CPAP/PEEP level needed to maintain adequate oxygenation was a mean of 15 ± 3.5 on B20 in survivors and 15 ± 4.5 on B20 in non-survivors. These differences are highly significant at $p < 0.001$ by chi square analysis.
Conclusions: The routinely used CPAP/PEEP to improve oxygenation in pts with PCP. The need for CPAP/PEEP of 15 or greater to create or to maintain acceptable oxygenation is associated with a significantly higher mortality in these pts. This is most likely related to a greater degree of lung involvement with pneumocystis in those requiring higher CPAP/PEEP levels.

T.B.P.33 PROSPECTIVE RANDOMIZED STUDY OF 100% O₂ VERSUS FRACTIONAL INSPIRED O₂ IN PNEUMOCYSTIS CARINII PNEUMONIA (PCP)
Mulliken, J.; Stewart, J.; Hooper, J.A.; Barwood, L.; Madhoo, T.; Lefkowitz, T.
*Marilyn Hospital, Rice, France.

In an open randomized study, 38 AIDS patients requiring low PEEP when arterial PO₂ were higher than 80 mm were treated for 21 days with 100% O₂ at 20/80 (n=21), or aerosolized antipseudomonas Penicillins (40 mg/kg) administered daily during 28 minutes with an ultrasonic nebulizer system (n=17). Patients were comparable in age (38.6 ± 36.5), first PCP episode, arterial PO₂ (51.4 ± 71.2), and clinical and biological severity.
Results:

	n/T	P	# Failures
Number of patients	15	15	
Treatment success	1	2	
Failures	14	13	n = 0.08
	(mean)	(range - 7)	
Therapy effectiveness (adverse reaction)	5	0	n = 0.02
Treatment success without addition of bet	5	0	
(steroid adverse reaction)			
Not re-evaluated after 48 h	0	1	

85 = not significant
Conclusions: In our study a higher number of failures in the P group occurred ($n = 0.08$), but as adverse patient reactions ($n = 0.02$). Number of cured patients without treatment effectiveness are statistically different for the 2 groups. Patients in 100% group experienced more adverse reactions ($n = 0.02$).

T.B.P.35 THE USE OF SURVIVORS IN THE THERAPY OF RESPIRATORY FAILURE COMPLICATING PNEUMOCYSTIS (PCP)
Schiff, R.J.; Hudes, R.; Smith, J.M.; Berg, J.
Hospital & Cornell University Medical College, Manhattan, N.Y., U.S.A.

Objective: We studied the effect of adjunct high dose corticosteroids in the treatment of 16 patients with AIDS and PCP resulting in respiratory failure.
Methods: Retrospective chart review of 16 patients with a PGO-60 on PEEP 5-6.0 and/or PGO-80 on RA.

Results: Steroids were given in a dose of 20-40 mg Methylprednisolone intravenously q8h for 7-10 days. 13 men and 3 women, ages 28-65 were studied. Risk factors included bronchitis (6), TV drug abuse (6) and 4 unknown. 4/16 were previously treated with Zidovudine at the time of admission. In 15/16 respiratory failure complicated the first episode of PCP. In 13/16 mechanical ventilation was required. 4/16 patients died without a response to steroids following respiratory failure. 5 responded and were alive and discharged at 3 weeks. Follow-up. 4 appeared to respond initially but died within 1 month, and 1 initially responded but remains unresponsive in the hospital. Of the 10 patients who appeared to respond, 6 halgases were defined as weaning chart 7 days and PCP either an initial or relapse was required. 4/16 patients died. **Conclusions:** Adjunct steroid initially helped reverse respiratory failure due to PCP in 80%. However, the 1/16 who were high and only 3/16 remained alive at 3 months survive. Last.

T.B.P.32 TREATMENT AND OUTCOME OF PNEUMOCYSTIS CARINII PNEUMONIA IN AIDS PATIENTS
Lindgren, W.S.D.; Pedersen, C.; Nielsen, T.
Department of Infectious Diseases, Hvidovre Hospital, Copenhagen, Denmark.

Objective: To evaluate the efficacy and safety of treating *Pneumocystis carinii* pneumonia (PCP) in AIDS patients.
Methods: Analysis of a standardized protocol from 75 consecutive HIV positive patients diagnosed of having PCP admitted to our department. Eighty nine episodes of PCP were recorded. 87% by histologic verification and 17% by clinical criteria. Chest x-ray of 13 (16%) patients taken since the episode were normal. Patients were treated with sulfadiazine-trimethoprim (ST) 800 mg b.i.d. plus oral dose of ST* 4800/960 mg, median duration 20 days and/or pentamidine (P) 300 mg b.i.d. plus oral dose of ST* 4800/960 mg, median duration 11 days. Two episodes of PCP were not treated. The ST and P regimens resulted both in about 50% objective side effect, but only 10% treated with ST and 20% treated with P had their treatment discontinued because of side effect. Of patients with primary PCP 7 (10%) patients died of PCP, 10% of patients with relapse of PCP. All secondary prophylaxis and 100% patients with recurrent episodes of PCP died during hospitalization. No patient who owed had a normal chest x-ray. Median of ST* 4800/960 mg, average followup time 261 days (range 1-512), compared to 11 (100%) patients who did not receive prophylaxis (average followup time 101 days) (p<0.0001). The survival time after 1 year study patients with primary PCP with the diagnosis made in 1985 (22 patients) and 1987 (39 patients) was 0.82 and 0.74, respectively. As opposed to 1.03 when diagnosed prior to 1985 (15 patients) (p<0.01). Seven (84%) of 11 patients requiring mechanical ventilation were discharged from the hospital. **Conclusions:** In most of our PCP patients, treatment with ST and P and secondary prophylaxis with ST is safe and effective. Controlled studies are needed to verify that ST is superior to treatment with ST and P. Furthermore, early diagnosis of PCP may improve the prognosis. Lastly, mechanical ventilation is a reasonable option when needed in patients with PCP.

T.B.P.34 THE BIOAVAILABILITY OF CO-TRIMOXAZOLE IN PATIENTS WITH AIDS RECEIVING THERAPY FOR PNEUMOCYSTIS CARINII PNEUMONIA
Wells, G.A.G.; Kapewee, M.; White, L.M.; Cairns, O.F. and Mwangi-Njenga, R.
*St. George's Hospital, London, U.K.
*Northcote Hospital, Bristol, U.K.

Objective: To investigate the bioavailability of co-trimoxazole in AIDS patients with normal and abnormal fat absorption.
Methods: Five HIV antibody positive males mean age 36 years (20-60 years), mean weight 60kg (40-70kg) receiving a mean dose of 1200mg/240mg co-trimoxazole for the treatment of P. carinii pneumonia were studied. Plasma concentration time profiles for trimethoprim (TMP) and sulphamethoxazole (SMX) were obtained during a 6 hour dosage interval after the same dose of co-trimoxazole given intravenously and orally.

Serum levels of TMP and SMX were measured using high performance liquid chromatography. Fat absorption was determined by the measurement of 100L in breath following ingestion of a test meal containing ¹⁴C triolein with 60g fat. Bioavailability was calculated using standard pharmacokinetic methods.
Results: The mean bioavailabilities of TMP and SMX in patients with fat malabsorption were 100 (±20%) and 71 (±10%) respectively. By comparison the mean bioavailabilities of TMP and SMX in patients with normal fat absorption were 90 (±40%) and 101 (±70%) respectively.

Conclusions: Pharmacy data suggest that in patients with AIDS oral and intravenous co-trimoxazole achieve similar serum TMP and SMX levels even in the presence of abnormalities of fat absorption.

T.B.P.36 DIAGNOSIS AND TREATMENT OF PNEUMOCYSTIS PNEUMONIA: A SURVEY OF OREGON AND VANCOUVER, WASHINGTON PHYSICIANS
SAMPSON, JAMES H. * SPENCE, CAROL JARE *
*GOOD SAMARITAN HOSPITAL AND MEDICAL CENTER, PORTLAND, OREGON, USA.

OBJECTIVE: To describe how physicians in the state of Oregon and Vancouver Island responded to questions regarding the diagnosis and treatment of pneumocystis pneumonia.

METHODS: Physicians were surveyed in the Portland area (including Vancouver) and the state of Oregon who were primary providers of care to those with AIDS. Physicians were offered \$20.00 payment for their time in filling out the survey. Forty five surveys were sent out with a three week return. **RESULTS:** Thirty four surveys were returned with a 76% response rate. The following were the results found. The top lab tests utilized at the initial evaluation were CBC and ABG. Induced sputum and bronchoalveolar were the primary methods used in the diagnostic workup. The contrastive test marker used in diagnosis was the abnormal chest X-ray. When requested about the initial therapy prior to diagnosis, 29% used TMP/SMX (17) with varying dosages, 25% used oral STS and 23% used Pentamidine (17). In the second survey of choice after failure or toxicity, 19% used TMP/SMX with 53% and Inhaled Pentamidine 15% of the respondents. Physicians used Inhaled Pentamidine as 45% for maintenance therapy, with 20% using TMP/SMX. Only 20% of the respondents did prophylactic treatment. Universal criteria for prophylactic treatment was CD 4 < 200. Overall the physicians had seen approximately 644 patients with the majority seeing 10-20pc. **CONCLUSIONS:** We will use the data to educate involved physicians in treatment.

Session d'affichage Poster Session



T.B.P.43 HIGH RATES OF RESISTANT PNEUMOCOCCUS PNEUMONIAE AND SUSCEPTIBILITY TO AIDS PATIENTS TAKING PENTAMIDINE-ISOXANTHINE PROPHYLAXIS. Miller, Leoni, Oles, D. Denver: Denver General Hospital (DGH), Denver, CO, USA.

Objective: To evaluate occurrence rates of Pneumococcus pneumoniae (PCP) and susceptibility to AIDS patients (pts) receiving pentamidine-isoxanthine (P-I) for secondary prophylaxis of Kaposi's Sarcoma (KS). A retrospective analysis was done of all pts at DGH AIDS Clinic who received P-I from March 1987 through December 1988. All patients had AIDS and at least one episode of PCP prior to initiation of P-I, and were on variable doses of zalcitabine (ZC).
Results: There were 38 pts who received both ZC and P-I (1 tablet weekly) from 0.5 to 22 mg (mean 7.6 mg). They were followed for 3 to 16 mos (mean 10.5 mos) from time of first episode of PCP. Four pts were lost to follow-up, 2 were uncompliant, and 2 had non-PCP related deaths while taking P-I. Of the remaining 30, 16(53%) had recurrent PCP, 14 (47%) discontinued P-I due to adverse reactions, 3 discontinued P-I to receive another form of prophylaxis, and 4 remained on P-I. Adverse reactions included maculopapular rash (4), Stevens-Johnson syndrome (2), hemolytic anemia (2), clostridial linear fasciitis (2), and cellulitis (1). The 3 pts who developed PCP took P-I for 4-12 mos (mean 7.4 mos), and recurrence occurred 0-11 mo (mean 5.8 mo) after their first episode of PCP. Eight pts had three or more disease states, and 1 had pneumoniae PCP, 7 received hospitalizations, 0 of the 16 who discontinued P-I for adverse reactions or uncompliance, 5 developed recurrent PCP 1-7 months after discontinuation, none of these received another form of PCP prophylaxis.
Conclusion: Recurrence rates of PCP in pts taking P-I (53%) were higher than those reported previously and P-I was poorly tolerated, requiring discontinuation in an additional 28% of evaluable pts. High treatment toxicity developed in 16% (Stevens-Johnson Syndrome). Overall, prophylaxis trials are necessary to establish the most effective and least toxic regimen(s) for prophylaxis of PCP in AIDS.

T.B.P.45 SECONDARY PROPHYLAXIS OF PNEUMOCYSTIS CARINII PNEUMONIA WITH SYSTEMIC PENTAMIDINE. Winslow, Dean*, Binca, A.; Lincoln, P.; Smolka, H. and To Young.

*Medical Center of Delaware, Wilmington, DE, USA.

Objective: To determine the efficacy of intermittent systemic pentamidine for secondary prophylaxis of PCP in AIDS.
Methods: Since January 1987, all patients with histologically-confirmed PCP who gave consent and had adequate peripheral venous access were acutely treated with a 21 day course of either TMP/SMX or pentamidine, then given pentamidine 4 mg/kg IV weekly x 4, then 4 mg/kg IV every 4 weeks. Most patients also received zidovudine concomitantly with maintenance pentamidine. Results: Eighteen patients were followed for a mean of 8.5 months to date (range 2-23 months). Three episodes of PCP occurred, but all were mild cases, none of which required ventilatory support. No deaths from secondary cases of PCP have occurred to date. Glucose intolerance developed in one patient after a 21 day course of daily pentamidine followed by 2 months of 4 mg/kg weekly treatment.
Conclusion: Secondary prophylaxis of PCP with systemic pentamidine is effective in preventing mortality from recurrent pneumocystis pneumonia. Larger prospective studies should be done to optimize pentamidine dose and compare this modality to other PCP prophylactic regimens.

T.B.P.47 UTILISATION DE FANERDINE POUR LA PREVENANCE DE LA PNEUMOCOCCOSE ET DE LA TOXOPLASMOSE.

LIVREROZ Jean-Michel, MORILLAS R. A., GARDIN J.P.**, GARDIN J. A., CHATELAIN J.L., et TOUSSAINT J.L.***
*HOPITAL H. BERRIOT, PAV. S, PLACE D'ARNOVA, 69437 LYON Cedex 03
**CENTRE HOSPITALIER, 69008 LYON, FRANCE

Objectif: Evaluer l'efficacité de l'association sulfadoxime-pyriméthamine (Faneridine) en prophylaxie primaire de la pneumococcose et de la toxoplasmose chez des patients atteints par le SIDA.
Méthodes: 42 sujets (39 hommes et trois femmes) ont reçu 3 comprimés de Faneridine sous les quinze jours et une supplémentation en acide folique (Méthylotétrahydrofolate) 5 mg par jour ou Landeroline 50 mg 1 capsule par ou une fois par semaine). Ces patients avaient un taux de lymphocytes T4 inférieur à 200/mm³ et n'étaient pas en traitement par la ZDV.
Résultats: 42 sujets (39 hommes et trois femmes) ont reçu 3 comprimés de Faneridine sous les quinze jours et une supplémentation en acide folique (Méthylotétrahydrofolate) 5 mg par jour ou Landeroline 50 mg 1 capsule par ou une fois par semaine). Ces patients avaient un taux de lymphocytes T4 inférieur à 200/mm³ et n'étaient pas en traitement par la ZDV.
Conclusion: La tolérance et l'efficacité de la prophylaxie primaire de la pneumococcose et de la toxoplasmose par la Faneridine associée à la ZDV a été comparée sous les 15 jours, meilleurs que celle rapportée dans les études antérieures réalisées à des posologies différentes.

T.B.P.44 PRIMARY VERSUS SECONDARY PCP PROPHYLAXIS. Davkin, M.; Roy, J.; Mich, Arroy, Lucas, C.R., Fairfax: Infectious Diseases Hospital, Melbourne, Victoria, Australia.

Objective: To compare the efficacy of primary and secondary PCP prophylaxis. From November 1986, all patients whose CD4 cell count fell below 200/mm³ or who developed an AIDS defining illness (ADI) other than PCP, were offered primary (1^o) prophylaxis with either Depoone 100mg twice weekly, sulfadoxime-pyrimethamine one tablet weekly, or retailed pentamidine 400mg once weekly. Secondary prophylaxis was given to all patients following treatment for their first episode of PCP. One of the above agents or TMP-SMX one bid was used. All but 8 patients received AZT during the study period. Side-effects of the study were PCP, or death. Follow-up continued to December 1989.
Results: 107 pts received 1^o prophylaxis and 93 pts received 2^o prophylaxis.

Depoone	25/81 (31%)	19/48 (40%)
Sulfadoxime/pyrimethamine	2/18 (11%)	6/14 (43%)
Pentamidine	1/8 (13%)	1/20 (5%)
TMP-SMX	0	2/12 (17%)
Death	29/107 (27%)	26/93 (28%)
Mean time to PCP	8,9±6,7 mths	9,4±6,7 mths
Mean PCP-free interval	10,9±1,2 mths	7,4±1,7 mths
Deaths	10	9
Toxicity	13	9

Conclusion: There was no difference in efficacy of primary versus secondary prophylaxis for PCP.

T.B.P.46 CLINICAL AND PHARMACOKINETIC INTERACTIONS OF COMBINED ZIDOVUDINE (ZDV) THERAPY AND SULFADOXIME-PYRIMETHAMINE (FANERDIN) PROPHYLAXIS IN PCP-PCP PATIENTS (MCMC).

Harsh, W.D., Heston, R., Hanson, R., Fan, H., Rosenberg, J., Link, of Calif., Los Angeles, Los Angeles, CA, USA, New York Univ, NY, USA, Children's Hospital, Los Angeles, CA, USA, Univ. of Texas Health Science Center, Dallas, TX, USA, MAAD AIDS Treatment Program, Bethesda, MD, USA.

Objective: Combination anti-retroviral and PCP prophylactic therapy are commonly used in HIV-infected patients. Potential clinical and pharmacokinetic interactions of combined ZDV and secondary PCP prophylactic therapies are investigated in this study. Data from the ZDV/Faneridin cohort are reported.
Methods: 30 AIDS patients received from an initial episode of PCP an randomized schedule to receive ZDV (200 mg q 6h) plus either TMP-SMX (100 mg q 6h) or Faneridin (1 tablet) or zalcitabine (150 mg q 2w). Intensive clinical, biochemical, hematologic, and pharmacokinetic parameters are followed for one year. Among 8 patients receiving ZDV/Faneridin, no significant clinical (especially rash), hematologic, biochemical abnormalities have developed nor PCP recurrence over a mean 16 week (range 8-24 weeks) follow-up period. ZDV pharmacokinetic analyses have shown a prolongation in time to peak ZDV concentration from 0.8 hr, to 2.8 hr, and an increase in $t_{1/2}$ from 1.0 hr to 2.0 hr following the addition of Faneridin in 3 of 5 patients. Steady state ZDV plasma has increased from 0.6-0.8 uM to 4.8 uM after 6 weeks of combined therapy in 5 patients as well.
Conclusion: These data indicate that ZDV and Faneridin are clinically well-tolerated and effective but dosage adjustment may be necessary due to possible pharmacokinetic interaction of the 2 drugs over time.

T.B.P.48 PYRIMETHAMINE-SULFADOXIME IN THE PROPHYLAXIS OF PNEUMOCOCCUS CARINII PNEUMONIA IN AIDS PATIENTS WITH CEREBRAL TOXOPLASMOSES

Pierone, Gerald; Duric, G., Masel, J., and Nicholas, P. N. Sinai School of Medicine, Elmhurst Hospital Center, Elmhurst, N.Y., U.S.A.

Objective: To determine if maintenance therapy with sulfadoxime-pyrimethamine (SP) in patients with central nervous system toxoplasmosis (TSM) and the acquired immunodeficiency syndrome (AIDS) is effective in the prophylaxis of Pneumocystis carinii pneumonia (PCP) and if such patients require additional preventive therapy.
Methods: We reviewed the records of patients maintained on SP following an initial episode of TSM. The diagnosis of TSM was established by the presence of typical ring-enhancing lesions on brain CT scan and clinical and radiographic responses to therapy with SP in patients at high-risk for HIV infection.
Results: 20 patients who had received at least 3 months of SP, including 3 who had had previous or coincident PCP, were identified. The dosage of sulfadoxime ranged from 2-6 grams per day, pyrimethamine 25-50 mg per day. Zidovudine was also administered to 6 patients (31 patient-months). During 162 patient-months of follow-up, none of the patients developed PCP (mean 8.1 months, range 3-20 months).
Conclusion: Maintenance therapy with SP provides effective prophylaxis of PCP in patients with AIDS.

Session d'affichage Poster Session



Prophylaxie par la pentamidine Prophylaxis with Pentamidine

T.B.P.49 PREVENTION DES RECHUTES DE PNEUMOCYSTE PNEUMONIAE PAR LES AEROSOLS DE PENTAMIDINE - ETUDE PROSPECTIVE RANDOMISEE CHEZ LES PATIENTS SIDA TRAITES PAR AZT

Dirigeants: J. Lavielle, R. Gaudouet, C. Lapeyre, A. Michon, C. Semail, AG*
*Niphal Roche, *Cadea Biomed, *ROCHEM UN, *Teva Paris, France

Objectif: Evaluer l'efficacité et la tolérance des aérosols de Pentamidine (APM) dans la prévention des rechutes de pneumocystose (PCP).

Patients et méthodes: 51 patients ayant présenté une PCP récente (moins de 5 mois) et ne recevant pas de prophylaxie anti-Pneumocystis ont été randomisés: Groupe 1: AZT plus APM; Groupe 2: AZT seul. Les APM ont été délivrés tous les 15 jours le 1er mois puis tous les mois à la dose de 4 mg/kg par un appareil ultrasonique. Les doses initiales d'AZT (1200 mg) étaient adaptées selon les données hématologiques.

Résultats: Les deux groupes étaient bien comparés sur les critères démographiques de la gravité du déficit immunitaire et du suivi de l'AZT. Parmi 48 patients évaluables, le nombre de rechutes après un seul mois de traitement fut de 222 (5) dans le Groupe 1 et de 1628 (81) dans le Groupe 2. L'aucune réaction indésirable spécifique n'est survenue. Les principaux effets secondaires étaient la toux (41%) et une gêne respiratoire au décours de l'inhalation (2%), conduisant à un arrêt de traitement.

Conclusions: 1) Les rechutes de PCP sont fréquentes chez des patients traités par AZT. 2) Les aérosols de Pentamidine diminuent le risque de PCP. 3) L'irritation bronchique est le principal effet secondaire observé.

Aspects cliniques Clinical Aspects of AIDS

T.B.P.50 COMPLIANCE AND LABORATORY DATA PREDICT RELAPSE RATE OF PNEUMOCYSTIS CARINI PNEUMONIAE DURING PROPHYLAXIS WITH AEROSOL PENTAMIDINE

Dirigeants: W. K. Laidlaw, R. J. Spinks, R. J. Galloway, W. and L. Lohy, R. Department of Medicine, University Hospital, Zurich, Switzerland.

Objectif: To assess the effect of patients' compliance during pentamidine prophylaxis (PX) and of laboratory data during the initial PCP episode on PCP relapse rate (PCPR).
Méthodes: The laboratory courses of all 48 AIDS patients treated with aerosol pentamidine (60 mg every 2 weeks) for PX of PCPR and the laboratory data during the initial PCP episode were retrospectively analyzed. Laboratory courses for lymphocyte subpopulations and serum lactate dehydrogenase (LDH) were available for 30 patients. All PCPR were recorded. Patients who missed ≥ 3 inhalations and at least 15% of all scheduled doses were stratified into the non-compliant Group A, all others into the compliant Group B. Results: Mean duration of pentamidine prophylaxis was 32 weeks (range 2-77 weeks). During the period 50 PCPR occurred (24 per 100 patient-months). Two of these were fatal. Only 15 patients had 100% compliance. Two patients missed a second PCP, both after repeated PCP non-compliance.

Group Patients Initial PCPR: Mean LDH: PCPR: PCPR probability/1st year (95% CI):
A 14 5 284 units 65% (22%-95%) *p < 0.05 (66-86ab).
B 30 5 312 units 18% (5%-49%) *p < 0.05 (10-30ab, 10c).

Person-yr Aerosolized change: Initial PCPR relative risk for PCPR (non-compliant vs compliant):
% missed PX 10% up 1.5* (p < 0.05, multivariate Cox regression, 44 patients)
LDH units 20% down 2.1* **p < 0.05, multivariate Cox regression, 30 patients
LDH/10³ up 28% up

Conclusions: Poor compliance with prophylactic pentamidine inhalations leads to a significantly higher rate of PCPR. The laboratory values significantly associated with higher rates of PCPR were elevated levels of LDH and decreased levels of CD4 lymphocytes during the initial PCP episode.

T.B.P.51 SUCCESSFUL CHEMOPROPHYLAXIS OF PCP BY POSTURAL INHALATION AND LOW DOSE AEROSOLIZED PENTAMIDINE

Dirigeants: S. J. Rodgers, P. Serret, C. Mahony, J. Kelly, J. Kohn, J. D. Nalleva, National Jewish Medical Center, Denver, CO, USA.

OBJECTIVE: To evaluate the efficacy of low dose aerosolized pentamidine administered by postural inhalation. **METHODS:** 97 patients (25 AIDS/ 72 HIV PCP) 45 AIDS intolerant of sulfis drug PCP prophylaxis were followed for a median of 11 months (range 5-19). Pentamidine (leontin) was administered by nebulized nebulizer (1.5-3.5 micrometers) at a dose of 80 mg every 3 weeks via postural inhalation, i.e., in the supine and left and right lateral decubitus positions each for 10 minutes. These experiencing bronchospasm were subsequently prophylaxed with albuterol inhalant prior to each pentamidine administration. **RESULTS:** Of 97 patients followed at risk dose for a median of 11 months there were 3 episodes of PCP (AIDS, 2 AIDS). All 3 episodes were diffuse in nature and were successfully treated with TP pentamidine. All 3 episodes occurred in noncompliant patients who had missed 2 or more consecutive doses (accounting for a 3 week or greater interval between doses). There was no severe adverse reactions to the drug. Minor adverse effects included: cough (44/73), bronchospasm (14/145) and metallic taste (58/102). No episodes of PCP occurred in patients compliant with the protocol.

CONCLUSION: Postural inhalation may allow for improved efficacy and/or reduced dose of prophylactic aerosolized pentamidine. Controlled trials with larger numbers, more efficient nebulizers and of longer duration are indicated.

T.B.P.52 HIGH ADOLESCENT PENTAMIDINE PROPHYLAXIS IN AN INNER CITY POPULATION

Dirigeants: J. G. Johnson*, Hilson, R., Hendrix, J., Small, C.B., North Central Bronx Hospital/Portico Medical Center/Albert Einstein College of Medicine, Bronx, New York, U.S.A.

OBJECTIVE: To determine efficacy, tolerance and compliance (comp) with home aerosolized pentamidine (AP) prophylaxis in AIDS and AIDS patients (gp) of poor, minority and intravenous drug use background in a NYC clinic.
METHODS: Randomized instruction in the use of the Plicontin nebulizer (PN) and in the preparation of Pentamidine for aerosolization. Standardized dose was 60 mg, weekly for the first 4 weeks (wks) and biweekly thereafter. Evaluable pts were followed for 4 wks.

RESULTS: 12/16 were evaluable, 43 males, 13 females; 38 Hispanic, 17 black, 5 white. Mean age 36 (range 22-59). 30/50 (60%) T3, 13/58 (22%) intravenous partners, 15/28 (21%) homosexual, 1 (28) transfusion recipient, 2 (38) non-AIDS. Mean risk: 52/58 (90%) had AIDS; 46/58 (80%) status-post PCP; 6/58 (10%) had AIDS with low CD4 (mean 77). 6/58 (10%) had asthma. Pts were followed for a mean of 23 wks (range 4-44 wks). total 1307 pt wks. 57/58 (98%) were also on AZT. 9/58 (16%) developed PCP. All were noncomp with AP for at least 4 wks prior to PCP. Reasons for noncomp in the 9 pts included: drug use (3), AP-induced respiratory symptoms (1), fear of treatment (3), poor understanding of AP importance (2), 5/9 with PCP (56%) were also noncomp with AZT. Of 48 pts receiving AZT who did not develop PCP, 10 (21%) were comp with AZT. Of 48 AP pts: 4 (8%) were comp with >50% but <100% of AP Rx; 34 (71%) were comp with 100% of AP Rx. 4/48 (8%) were also noncomp with AZT.
CONCLUSION: Home AP by PN is a safe, effective method of PCP prophylaxis in an inner city population of primarily T3. AP comp was less than AZT comp.

T.B.P.53 LOW TONE SAFETY AND EFFECTIVENESS OF AEROSOL PENTAMIDINE FOR PREVENTION OF PNEUMOCYSTIS CARINI PNEUMONIA

Dirigeants: Edward J. Dickover, M.D.; Schmitz, R. and D. J. Armstrong. National Jewish Medical Center, New York, New York, U.S.A.

Objective: To determine the safety of aerosol pentamidine and its effectiveness in preventing PCP compared to historical controls.

Méthodes: Aerosol pentamidine administered weekly for four weeks and then biweekly at a dose of 60 mg via oral ultrasonic nebulizer (Fleisch). Toxicity was judged based on examinations, pulmonary function, hematologic, and biochemical tests. Efficacy was judged based on comparison of rates of PCP versus HAAD protocol, 0/2.

Results: A total of 266 patients were treated for 1-10 months (5.6 \pm 5.2 mos). Most were homosexual men; 902 had AIDS; 711 had a previous episode of PCP. At entry the mean time since diagnosis of AIDS was 11.7 \pm 10.1 mos. There were no serious adverse reactions and no systemic toxicity was seen; 14/21 of patients required a bronchodilator; 91% of patients had a stable or improving pulmonary function. There were 49 side-effects and 71 deaths. A total of 23 cases of PCP occurred; the occurrence rate was 3.81 among patients (<90%) with no previous episodes; it was 4.9% among those (132) with one episode; it was 25.4% among those (63) with two or more previous episodes. There were 6 pneumothoraces and 3 cases of extrapulmonary pneumocystosis. There was no historical control; there was a 16-fold reduction in the recurrence rate of PCP among patients who had one previous episode.

Conclusion: Aerosol pentamidine was safe and it prevented PCP. Higher or more frequent doses may be needed as immune deficiency progresses.

T.B.P.54 AEROSOLIZED PENTAMIDINE FOR THE SECONDARY PROPHYLAXIS OF PNEUMOCYSTIS CARINI PNEUMONIA IN THE ACQUIRED IMMUNODEFICIENCY SYNDROME: A REPORT FROM THE

CANADIAN COOPERATIVE TRIALS

Dirigeants: J. L. Fisher, J. P. Fisher, R. Sankh, A. Gorak, A. Ronald, P. McPadden, D. Pong, W. Taylor, G. Mack, A. Fisher, W. Laid, T. Chen, C. G. Henderson, K. G. Isaacs

OBJECTIVE: To evaluate the safety and effectiveness of aerosolized pentamidine for the secondary prophylaxis of *Pneumocystis carini pneumoniae* (PCP) in the acquired immunodeficiency syndrome (AIDS).

METHODS: Trial Design: randomized, double blind, placebo-controlled. Inclusion Criteria: (1) Recovered from first episode of AIDS-related PCP within 10-24 weeks; (2) No other AIDS defining opportunistic infection or active pulmonary pathology; (3) No antiretroviral or immunomodulating agents (except AZT) during the study; (4) CD4 counts within 300-500 cells/mm³; (5) No PCP in previous 12 months; (6) 40% of total FEV and corrected DLCO >10%. Exclusions: Patients were randomly allocated to receive pentamidine three times per week as placebo. The study drug was delivered as a least bid ultrasonic nebulizer (MAD-25.5-6, Aerogen) (depending on the clinic location) in a nebulized fashion over 15 to 20 minutes. Patients returned 5 days during the trial 14 days follow-up by one day every 2 weeks for a total of 26 weeks. Follow-up: Complete history, physical and laboratory evaluation including AZT were performed at regular intervals. All PCP medications were prescribed using PCP was documented.

RESULTS: 101 patients from 16 centers were randomized at the time the study was terminated. A total of 20 cases of PCP were diagnosed. 23 of these occurred in 20 (79%) placebo-treated patients while 6 occurred among the 84 patients receiving aerosolized pentamidine ($p < 0.0001$ Chi square). Median follow-up was not significantly different in both groups.

CONCLUSIONS: Aerosolized pentamidine is highly effective in the secondary prophylaxis of AIDS-related PCP.

Reported at a poster June 6, 1988.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

T.B.P.55 PROPHYLACTIC INHALATION PENTAMIDINE IN PATIENTS WITH HIV DISEASE

Edouard A. A.; DiPaola, L.; St. L.E.M.; Rubinstein, D.*
*Stross Lebanon Hospital, Bronx, NY, USA.

Objective: To evaluate inhalation pentamidine in the prophylaxis of PCP in immunosuppressed HIV positive patients.
Method: We prospectively studied 46 HIV positive immunodeficient patients. 200 mg of pentamidine in 4 cc sterile water were delivered by inhalation every other week using an Aeroneo II apparatus. Three groups of patients were studied. 1. 10 HIV positive patients with a CD4 count less than 250 U/L and no history of PCP. 2. 17 HIV positive patients with a history of PCP but no tissue confirmation. 3. 27 HIV positive patients with histoplasmosis. PCP. **Results:** 46 patients were treated an average of 20.8 weeks. There were 5 episodes of presumed PCP. 19 patients were lost to follow-up. The overall recurrence rate was 13.2%. The results in each group are as follows:

Group	Average Treatment Time (Weeks)	Recurrences	Rate
1	2-30	0	0
2	4-3	1	16.7%
3	2-30	4	14.8%

All 5 of the patients who developed pneumonia were treated with anti-PCP therapy. 3 of these 5 patients died.
Conclusion: We note an overall recurrence rate of 13.2% in patients on aerosolized pentamidine which is below that reported for patients without prophylaxis. Although our numbers are small the study is ongoing. The fact that the majority of our patients were IVDA's and still followed the treatment protocol is encouraging.

T.B.P.57 ABSOLUTE PULMONARY DEPOSITION OF NEBULISED PENTAMIDINE ISETHIONATE

Richard Higgins; O'Donerty, M.; Page, C.; Berlow, D.; Croft, D. and Bateman, N.
St. Thomas' Hospital, London

Objective: To measure the absolute pulmonary deposition of two doses of pentamidine administered using two different nebuliser systems.
Methods: Following salbutamol pre-treatment, 8 patients with AIDS inhaled 50 and 150 mg pentamidine until with 37 MBq (10.5 mCi) ^{99m}Tc human serum albumin (HSA) volume 3 ml via two nebuliser systems. Series 22 Miser (S22M, Medigard UK) and Respigard (R11 Marquest) using gas flow of 6 l/min. Pulmonary and non-pulmonary (oropharyngeal and gastric) deposition was measured using a gamma camera and absolute deposition calculated using a correction derived from lung phantom studies. Spirometry was measured before and after salbutamol and after pentamidine inhalation and adverse effects were recorded.
Results: Absolute pulmonary pentamidine deposition (sqSDM) results are shown in the table:

Nebuliser Dose	S22M		R11	
	Both Lungs	R Lung	Both Lungs	R Lung
50 mg	2,740.42	1,469.22	1,530.31	0,829.15
150 mg	7,449.16	3,749.63	4,470.15	2,429.32

S22M delivered more drug to the lungs and in a shorter time, with over 90% deposited within 15 min. R11 produced less pulmonary, but non-pulmonary deposition and fewer adverse effects. Inhalation of 150 mg pentamidine produced small reductions in FEV1 with both S22M (16.2%, p<0.1) and R11 (7.3%, p<0.1).
Conclusion: Pulmonary pentamidine deposition was greatest using S22M but R11 was associated with fewer adverse effects.

T.B.P.59 PROPHYLACTIC TREATMENT WITH AEROSOL PENTAMIDINE TO PREVENT RELAPSE OF PCP

Bergin Bybo Jensen*, T. Nielsen*, B. Lerche*, V. Sacker*, L. Mathiesen*, P. Skjold*
*State University Hospital, Copenhagen;
**University Hospital, Hvidovre, Copenhagen, Denmark.

Objective: To evaluate the efficacy of aerosol pentamidine in the prophylaxis of PCP relapses.
Patients: 45 AIDS patients who had been prophylactically treated with aerosol pentamidine 60mg every 2 weeks, with an Acorn System 22. The patients had been on pentamidine prophylaxis for 1-2 months (1-4) before start of treatment. Time from AIDS diagnosis to start of prophylaxis was 1-22 months (mean 7.4).
Results: The patients were treated for 1-23 months (mean 8.4). No significant adverse reactions were seen. Falling patient compliance in 2 patients; were followed by relapses of PCP. Of the remaining 43 patients, 2 mild cases of PCP occurred after 8 respectively 9 months of treatment. One was clinically suspected, one histologically verified. The relapse rate of PCP per 100 patient months were 0.544 among patients treated.
Conclusion: Pentamidine aerosol seems to be effective as prophylaxis against relapse of PCP in this regimen. Only mild side effects were observed. A controlled study comparing aerosol pentamidine with co-trimoxazole is in progress.

T.B.P.56 A CLINICAL EXPERIENCE WITH AEROSOLIZED PENTAMIDINE (AP).

Ed Hjaltnings, H. Ferguson, RN Postle, JD
Jacobson & K. Robertson, Parkland Memorial Hospital,
Dallas, TX, USA.

Since 4/22/88 we have treated 308 HIV positive patients with AP 300 mg q month for 112 4/80 days. Four withdraw after 1 treatment because of cough treatments were otherwise uncomplicated. Serial pulmonary function tests in 26 patients before and after 6 months of treatment were:

Pre	94	86	113	20.2
FEV1 (l/min)	1.1	1.1	1.1	21.3
FVC (l)	2.1	2.1	2.1	21.3
P. 95	0.1	0.1	0.1	0.002

14 patients developed PCP while on AP. 1/99 with ARC or ODA <4000, 2/56 with AIDS but no prior PCP, and 11/155 with AIDS and prior of PCP. These 11 had had their last PCP an average of 422 (range 153-908) days before starting AP. 5/11 (45%) of the recurrent PCP episodes were fatal, and 2 were complicated by pneumothorax. For comparison, from 7/1-12/31/88 we saw 93 PCP cases in patients not on AP of which 12 (24%) were fatal and 2 were complicated by pneumothorax. Finally, 3/153 developed bacteremia that responded to antibiotic therapy.
Conclusion: This uncontrolled experience suggests that AP may reduce the frequency, but not the severity, of PCP in HIV positive patients. While AP was well tolerated and blood stable, a decrease in small airway flow (P923-75) appears to be a subclinical but statistically significant complication of therapy.

T.B.P.58 AEROSOL PENTAMIDINE FOR TREATMENT AND SECONDARY PROPHYLAXIS OF PNEUMOCYSTIS CARINII (PCP)

Fleming, LE; Haddad, S.; Weirin, E. and Prallier, T.
University of Lund, Dept. of Infectious Diseases, General Hospital, MALMG, Sweden.

Ten patients with PCP were treated with aerosol pentamidine 400 mg daily for 10 days followed by secondary prophylaxis of 400 mg once weekly. We used the nebulizer Visco MZ that produces particles <2 μ and has a residual volume of 0.2 ml. Monitoring for assessing effectiveness and side-effects included hemoglobin oxygen saturation during exercise, biochemical parameters, FEV1 and VC. Follow-up bronchoscopy was performed at least once after 3-6 days of secondary prophylaxis.
Results: 8/10 patients responded to therapy. 2 patients did not and were given Trimethoprim-sulfamethoxazole (TS) concomitantly. After improvement TS was discontinued and secondary prophylaxis continued. All patients were negative for pneumocystis at follow-up bronchoscopy. Neither clinical signs nor monitored parameters indicated any relapses. Three patients died after 6 weeks, 6 months and 17 months. At autopsy none of them had pneumocystis.
Conclusion: In our study aerosol pentamidine was effective for PCP in 8 of 10 patients. Controlled studies are needed to establish its role in the treatment of PCP. There is also a need to compare different nebulizers. In 10 patients given secondary prophylaxis we observed no relapses. We find this very encouraging. Despite the high dose given no adverse effects were observed besides light cough and complaints of unpleasant taste.

T.B.P.60 EFFICACY OF MONTHLY INTRAMUSCULAR PENTAMIDINE IN THE PROPHYLAXIS OF RECURRENT PNEUMOCYSTIS CARINII PRESENTING (PCP) IN PEOPLE WITH AIDS

Miller, Steven and Sifras, Dennis. HIV Clinic, Johannesburg Hospital, Johannesburg, South Africa.

Objective: To evaluate the efficacy of monthly intramuscular pentamidine in the prophylaxis of recurrent pneumocystis carinii pneumonia (PCP) in people with AIDS.
Method: Fifteen patients who have previously experienced at least one episode of PCP were enrolled in the study. Their ages ranged from 23 to 42 years. All had peripheral blood CD4 counts below 400/uL. These patients were receiving zidovudine 100mg daily, prophylaxis with cotrimoxazole was precluded in 10 patients because of hypersensitivity and 5 because of severe leucopenia. Pentamidine methanesulphonate (Methobid) 300 mg was administered as a monthly intramuscular injection. Patients were prospectively assessed for adverse effects and recurrences of PCP.
Results: Duration of pentamidine prophylaxis has ranged from 6 to 24 months and there has been no recurrence of PCP. Nine patients have died from other AIDS-related conditions since enrollment. Pain at the injection site for 24 to 48 hours was reported by all subjects. One patient developed a sterile abscess following the injection. Hypotension and hypoglycaemia were not documented.
Conclusions: 1) Monthly intramuscular pentamidine methanesulphonate provides effective prophylaxis for recurrent PCP. Side effects are generally minor. 2) Monthly intramuscular pentamidine is more cost effective than weekly aerosolized pentamidine. 3) Intramuscular pentamidine is easy to administer and should be considered where there are no facilities for nebulization.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

T.B.P.61 PHARMACOKINETICS OF AEROSOLIZED PENTAMIDINE IN AIDS PATIENTS WITH HISTORIC OR ACUTE PNEUMONIA: THE CARIBBEAN EXPERIENCE

Yana J. Paulson, MD, Roy, M. Rosen, CT, Boylston, P. Gillman, Schools of Pharmacy and Medicine, University of Southern California, Los Angeles, California, U.S.A.

OBJECTIVE: To study the pharmacokinetics of aerosolized pentamidine in AIDS patients who are receiving treatment for mild episodes of Pneumocystis carinii pneumonia.

METHODS: Seven patients received investigational treatment with pentamidine (400 mc/day over 30 min) via the Respigard II nebulizer. Serial blood specimens were obtained from each patient on 3 occasions (days 14, 21, and 28). Serum pentamidine concentrations were measured by high-pressure liquid chromatography.

RESULTS: Maximum concentrations were 14.4 ± 5.3 ng/ml in samples obtained 1 to 2 minutes after completion of the dose. The rate of disappearance from serum was rapid and serum concentrations were undetectable 48-60 minutes after each inhalation treatment. There was no difference in the magnitude of the peak concentrations between day 1, day 14, and day 21 of therapy.

CONCLUSION: No serum accumulation of the drug was noted over the 21 day period of therapy. Urine concentrations are needed to better characterize the pharmacokinetic parameters of inhaled pentamidine.

T.B.P.63 INHALED PENTAMIDINE AS PRIMARY PROPHYLAXIS IN A HIGH RISK GROUP: CONTROLLING EXPERIENCE

William J. Paulson, VJ, Rogopolsky, R. Rothman, P.J. Scarsella, Hill, E. Popoff, C.I., Hill, S.I. Boylston, CT, Los Angeles, CA, 90033, U.S.A.

We have given inhaled pentamidine prophylaxis to 250 patients who are in a high risk group for PCP with T₄ counts below 400. These patients have received 150mg of inhaled pentamidine bi-weekly from 6 months to 21 months. None of the patients have developed pneumocystis pneumonia in this time interval. None of the patients have developed hypoglycemia, impaired renal function, or pancreatitis from their prophylaxis. Serum pentamidine studies have been obtained at periodic intervals and no deterioration has been seen in spirometric values. No pneumothoraces have developed in this group. We conclude that primary prophylaxis with inhaled pentamidine in this high risk group appears to offer significant promise without apparent risk. We believe that further controlled studies of primary prophylaxis urgently need to be done in these seriously immunocompromised patients.

T.B.P.65 EFFECT OF AEROSOL CHARACTERISTICS ON PULMONARY DEPOSITION OF PENTAMIDINE

Hymed, Anita; Newman, S.; Johnson, M.; Talbot, M.; Lee, C.; Clarke, S. Royal Free Hospital, London, UK.

OBJECTIVE: An evaluation of pulmonary delivery of aerosol pentamidine relating alveolar deposition and side effects to droplet size profile of nebuliser.

Methods: In a single blind crossover study, 9 patients with AIDS and stable respiratory status received 150 mg redispensed pentamidine (Acorn System A) Respigard II nebuliser (Marquest) B) Respigard II nebuliser with inspiratory baffin removed and C) Acorn System Z nebuliser (Medic Aid). In 6 patients an Acorn nebuliser modified by addition of an inspiratory baffin (one-way valve inserted, Inter-Surgical) was studied (D). Alveolar deposition (24 hour whole lung retention of radioactivity), incidence of cough and breathlessness and pulmonary function were assessed. Droplet size profiles from the nebuliser systems A-D were characterised and expressed as 1) droplet size $\leq 2 \mu$ (P2), mass median diameter (MMD) and mass median droplet size (d₅₀). **Results:** Droplet size profiles (P2, MMD, d₅₀) were A) 78.9, 1.0 μ m, 4.9 μ m, B) 30.5, 1.7 μ m, 19.1 μ m, C) 39.4, 3.4 μ m, 23.3 μ m (SD) D) 22.1, 1.0 μ m, 8.0 μ m. Alveolar deposition was directly related to P2 and incidence of cough and breathlessness proportional to d₅₀. Insertion of an inspiratory baffin into the Acorn System (D) markedly improved alveolar deposition of pentamidine and reduced adverse airway effects.

Conclusion: Optimisation of droplet size profile from nebulisers can enhance alveolar targeting of pentamidine.

T.B.P.62 COMBINED STUDY OF THE EFFICACY OF INHALED PENTAMIDINE ON THE PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA - CONTINUING EXPERIENCE

William J. Paulson, VJ, Rogopolsky, R. Rothman, P.J. Scarsella, Hill, E. Popoff, C.I., Hill, S.I. Boylston, CT, Los Angeles, CA, 90033, U.S.A.

Of the 150 patients receiving inhaled pentamidine prophylaxis to prevent Pneumocystis carinii pneumonia (PCP) reported last year, 58 are now deceased. None of these patients died of PCP. Four patients have had recurrent PCP. Those who have developed recurrent PCP have tended to have multiple mild episodes. All patients have developed pneumothoraces while on this regimen, all after having at least one episode of PCP. Two of these patients required surgical intervention. None of the patients have developed clinically significant side effects from the inhaled pentamidine such as hypoglycemia, pancreatitis, or impairment of renal function. Serial spirometric determinations have shown no deterioration during the course of prophylaxis, although some of the patients did show self-limited deterioration in pulmonary function during acute infectious exacerbations. We conclude that inhaled pentamidine is effective prophylaxis in preventing recurrent PCP.

T.B.P.64 COMPARISON OF NEBULISER EFFICIENCY FOR AEROSOLISING PENTAMIDINE

Smith, Ron; Watkins, D.; Steele, J.; Hills, D.; Cassard, B.C. St. Stephen's Hospital, London, England.

OBJECTIVE: To determine which is the most efficient nebuliser system when used to aerosolise 300mg of Pentamidine Isethionate (Key & Bate Ltd.) in terms of droplet size, aerosol output and nebulisation time.

Methods: The following brands of nebuliser were assessed: Acorn System-21 (Medic-Aid Ltd.) with and without Miser attachment, Respigard II (Marquest Medical Products) and Finneab (Finsons Corp.). Four models of each brand of jet nebuliser were tested at flow rates of 8L/min. The Finneab was tested at maximum setting. Droplet size was assessed using a Malvern Instruments 2400SD laser particle and droplet analyser - aerosol output was assessed by spectrophotometry of solution remaining within the nebuliser. The nebulisation time was also recorded.

Results:

Brand	Flow rate	mg/min	% $\leq 5\mu$	Amount $\leq 5\mu$	Wet time(min)
ACORN	8L/min	2.5	74.6%	143.6mg	15.5
ACORN-MISER	8L/min	3.9	63.1%	ND	ND
RESPIGARD II	8L/min	1.2	96.3%	127.3mg	18.2
FINNEAB	-	4.7	56.3%	82.7mg	4.0

Conclusions: The Respigard II nebulisers produced the greatest amount of small droplets but aerosolised the least amount of drug. The Acorn aerosolised the largest amount of drug of sufficient droplet size to achieve alveolar deposition.

T.B.P.66 LOW PCP RELAPSE RATE USING HIGH DOSE (300MG) NEBULIZED PENTAMIDINE PROPHYLAXIS BUT A HIGH RATE OF OTHER COMPLICATIONS

Don, S. Smith, D. Hird, P. Marquest, B.C. GAZARD, ST STEPHEN'S HOSPITAL, FULHAM ROAD, LONDON, ENGLAND.

OBJECTIVE: To assess the effectiveness of high dose Nebulized Pentamidine on Pneumocystis Carinii Pneumonia (PCP) incidence and whether preventing PCP affects the long term survival in AIDS patients.

Methods: 29 patients received 300mg pentamidine fortnightly on a primary or secondary prophylactic basis over an 18 month period. The number of episodes of PCP and number of deaths from HIV were recorded over this period.

RESULTS: Of all patients on primary prophylaxis, no episodes of PCP and 1 death were seen (average follow up 4.0 months). Of 27 patients on secondary prophylaxis, only one episode of PCP occurred (average follow up 6.1 months). However, of 28 patients who received greater than six months prophylaxis post PCP over a maximum follow up period of 18 months, 11 (39%) died of other AIDS complications. Average time to death was 6.6 months (range 2-16) after their pneumonia. None of the deaths were caused by PCP.

CONCLUSION: Although Nebulized Pentamidine at a dose of 300mg/fortnightly is highly effective at preventing PCP, mortality rate post PCP still remains very high.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

T.B.P.73 Nebulized Pentamidine in the primary and secondary Prophylaxis of PCP
 S. Zuckerman, S. Oswald, J. Gottstein, A. Rehm, S. Miller R. Shalita, K.H. Nalin E.S. Unterwaldt, Frankfurt, Zentrum der Infektions-Medizin, Infektions-Ambulanz, FGO. Although AZT significantly prolongs the survival time after the first PCP episode in the study, maintenance dose of opportunistic infections (OI) principally, of AIDS patients treated with AZT in Frankfurt, 32 (17%) developed PCP. In 12 cases, PCP first occurred under AZT. PCP is the most common OI also under AZT, as a consequence, PCP prophylaxis, aimed at preventing or reducing the occurrence of PCP, is required. We therefore perform an open study to assess efficacy and tolerance of nebulized pentamidine as primary or secondary PCP prophylaxis. One group of patients additionally gets Fansidar 2 tablets/wk as CMV-toxoplasmosis prophylaxis. Pentamidine loading dose is 200mg on 4 or 5 dosing days, maintenance dose is 200mg every 2 weeks, nebulized with Respigard II. Up to now, 63 patients have enrolled in the study, 30 of them had PCP prior to pentamidine prophylaxis. Indication for inhalation prophylaxis was a T4 cell count <150/ μ l and AZT treatment. Results: After a median observation time of 230 days, no patient under pentamidine developed PCP. 20 patients developing PCP during this period received also pentamidine. In the mentioned dosage, the agent was well tolerated, systemic side effects were not observed, however heavy cough. 2 patients additionally needed a broncho-dilator.

T.B.P.75 PROPHYLAXIS FOR PNEUMOCYSTIS CARINII (PCPN) WITH AEROSOL PENTAMIDINE (AP) OR ORAL BISMUTH (OB) IN PATIENTS WITH AIDS OR SEVERE AEC.
 Sings R. Irtong, Nulsara N. Serey, S. Garcia, S. Naranjo, R. Chanté E. et al. St. Vincent Hospital, Los Angeles, CA, U.S.A.

Objective: To evaluate and compare the efficacy and toxicity of AP and OB in the prophylaxis for PCPN in patients with AIDS or severe AEC.
Methods: Between March 1987, 143 patients were enrolled and randomized for the treatment group: AP (150mg every 2 weeks, well-tolerated oral preparation with a minimum inhibitory concentration, 100-150 μ g/ml) or OB (320mg bid, severe AEC). Randomization was stratified into groups with prior PCP (n=70), no previous PCP (n=73), severe AEC. Baseline data of historical controls is approximately 10% at 6 weeks.

Results: Mean length of follow-up was 36 weeks in AP and 26 weeks in OB. Of 118 patients randomized, 62 were on AP and 56 on OB. 28 patients became colonized, were lost to follow-up or expired prior to the first 6-month analysis. Ninety percent of patients in each group were on AZT. Baseline values were not significantly different for either drug in any group. Fisher's exact test: p=0.20.

Baseline Data	AP		OB		p	
	n	%	n	%	<0.05	>0.05
AP	62	53	56	50	0.01	0.15
OB	56	47	62	55		

Conclusion: Prophylaxis were similar in both groups and improvement in diffusion capacity occurred in 82% (AP) and 88% (OB) after 6 months. Development occurred in 12% patients on AP, and much higher dissemination of it, occurred in 7.5% of patients on OB.

Significance: Oral Bismuth and nebulized pentamidine are both effective prophylactic agents for PCPN with similar rates of response and low rates of complications.

T.B.P.77 AZT-AEROSOL PENTAMIDINE vs AZT ALONE IN LONG TERM AIDS SURVIVORS: A RETROSPECTIVE CASE-CONTROL SURVIVAL ANALYSIS. D.D. Hightsmith, DM. Founders, BU Pergamun, 23 J. Infect. Dis. Hospital, Baltimore, VA, USA.

43 of our 609 AIDS patients (4 had PCP, 3) survived >365 days after PCP, 3) received AZT, and 4) were started on aerosol pentamidine (AP), 300 mg q month, >365 days after PCP. Each was matched to a matched control group of 41 patients who fit 1) b), and c), but never received AP. Potential controls were all controls who had survived at least 365 days at the case had survived before the case began AP; the control chosen was the one whose last PCP date was closest to that of the case. Case survival was calculated from the day AP was begun. Control survival was calculated from the day after PCP its matched case was begun on AP. We began AP in June 1988 and offered it to all AIDS patients thereafter. No other factor appeared to influence which of our patients became cases and which controls. 15 cases survived > controls, 4 controls survived > cases, and 10 cases censored values made survival indeterminate (chi-square 14.4, p<0.01). Actuarial survival on AP of the cases was 87% at 60 and 82% at 180 days vs 82% at 90 and 10% at 180 days for the controls (chi-square 10.6, p<0.01).

Within the limits of the retrospective case-control method, the data suggest that AP can significantly prolong life in AIDS patients on AZT who have survived an episode of PCP by > 1 year.

T.B.P.74 EFFICACIA E SICURETÀ DELLA FROFILASSIA CON PENTAMIDINE PAR AEROSOL, IN CASI DI TOCCAZIONE E.V. ITALIANE ATTEINTE DI SIDA, IN TERAPIA CON ZIDOVUDINE.

Orsi R., Quilici R., Veneri F., Sama A., Ghirelli G.L., Doria, Nucleare Infettivo, Antivirale e Sierologia, Ospedale S. Maria, Italy. **Obiettivo:** Profilassi delle primarie e ricorrenti di PCP con le tossicazioni sintomatiche.

Metodo: In marzo 1989 l'auspicio 10 pazienti tossicazioni sintomatiche di SIDA sottoposti al profilassi per aerosol di pentamidine in trattamento stabilizzato, 6 pazienti con comorbo dopo più di 12 mesi, 1 paziente sott'attacco per una primarie crisi di PCP su 47 anni di profilassi, 8 pazienti con trattamento l'auspicio 10 dopo 2-6 mesi, 1 paziente a seguito la profilassi prima di un attacco (da dove viene il risultato che tra i pazienti sott'attacco non si osservò il danno di 100/200 mg/die. L'insediarsi con pentamidine e la profilassi una epistola di PCP. La pentamidine era somministrata a dosaggio di 2 mg/kg/epistola, nei aerosol sotto l'auspicio al corso di 6 giorni, solo, in tutto annuale.

Conclusioni: La PCP arriva dopo il corso di 60% dei pazienti sott'attacco di SIDA. Dopo le pazienti sono profilassi on cruiti e' nelle storie da 10-40% dei pazienti dove le profilassi di 2 mesi dopo la primarie crisi di PCP, l'efficacia e' la sicurezza di la pentamidine per aerosol, a dosi proscritte. Le controindicazioni più gravi sono le puzze che da noi si ha ed le reazioni. Delle norme di distribuzione epistola l'aggiustazione dei aerosol individuali. Sono in ricerca risultati da un altro studio che si può dire essere conclusivo, si costruisce o si descrive il caso. Durante un'esperienza più estesa di PCP, sotto dei primarie epistola, sott'attacco ricorrente da le tossicazioni sintomatiche di SIDA.

T.B.P.76 PNEUMOTHORAX IN PATIENTS RECEIVING AEROSOL PENTAMIDINE FOR PNEUMOCYSTIS CARINII PNEUMONIA PROPHYLAXIS.

Lanning, Clifford S., Wandler, L., Montgomery, A.R.,*; Abensur, D.J., Fogel, D.M.,* and the SCLC Community Consortium.

*Department of Medicine, San Francisco General Hospital, Univ. of California, SF; ** SUNY at Stony Brook, NY, U.S.A.

Objective: To determine the incidence of pneumothorax in patients on aerosol pentamidine for prophylaxis against *Pneumocystis carinii* pneumonia (PCP) in high risk HIV infected patients. **Methods:** 409 patients were randomized to treatment with either 30mg qwk, 150mg qwk or 300mg qwk of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered with a Marquest Respigard II nebulizer (particle MMAD=1.6 μ m). Pneumothorax was prospectively documented as a complication of aerosol pentamidine (AP) stratified into groups: prior PCP (PCP, n=264), Kaposi's Sarcoma (KS, n=102) or ARC and other AIDS diagnoses (O, n=116). AP was delivered

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

T.B.P.85 MONITORING THE ACCURACY OF THE TOTAL LYMPHOCYTE COUNT TO IMPROVE THE ABSOLUTE CD4 COUNT

Anderson, Robert E., Hirschhorn, D., and Edmondson, S.,**
Wife, Inc.,
Fresno, CA, USA; *Mérieux-Turner Corporation, Mountain
View, CA, USA.

Objective: To improve the accuracy of the total lymphocyte count, a key part of the absolute CD4 lymphocyte count.
Methods: The white cell differential was determined using the Becton Dickinson FACScan with Simulast Software and Simulast Reagents (SD), microscopically on Wright-Giemsa stained smears (smear), and by electronic impedance on the Coulter-Turner Cell Dyn 2000 (SQ) on a citrate-based HIV positive population.

Results: 80 lymphocyte percentages were lowered when additional wash steps, vortex mixing, or aggressive aspiration (Asp) was used in cell preparation.
Mean \pm SD:

Mean \pm SD	WASH	NO-WASH	NO-ASP		
Wash/Total/Asp	34.1	26.2	35.2	1.1 (3.1)	9.6 (25.8)
Wortc/Asp	36.2	33.8	39.2	3.0 (7.8)	5.4 (11.7)
Settler	37.9	37.4	39.4	1.7 (4.3)	2.0 (5.1)

Twenty-one room-temperature ASD whole blood samples held for 0, 24 and 48 hours gave a mean \pm SD of 36.8, 34.9 and 37.3 respectively compared with 34.8 for EDTA.

Conclusion: With best technique, lymphocyte percentages from the FACScan, impedance, and smear methods are comparable. Monitoring all three methods assures good recovery from lymphocyte preparation methods. If processing delays occur, ASD is a superior anticoagulant for lymphocyte phenotyping.

T.B.P.87 FLOW CYTOMETRIC METHODS FOR HIV SEROLOGY AND ANTIGEN QUANTITATION USING RECOMBINANT HIV ENVELOPE (ENV-9) PROTEIN

Campbell, D., Gantsh, J., Gendron, T., Janney, K.,** Rife, S., Douglas, L.D.,
*University of Pennsylvania, Philadelphia, PA, USA. **E. Du Pont de Nemours & Co., Wilmington, DE, USA.

Objective: Flow cytometric (FC) methods were developed as potentially improved alternatives to enzyme-linked immunosorbent assays (ELISA) for the detection of HIV specific antibodies, and for the quantitation of HIV protein.

Methods: Recombinant HIV envelope (ENV-9) protein was covalently coupled to protein absorbent polystyrene microbeads by carbodiimide mediated reactions and served as the solid phase antigen for both the FC serologic assay and for the FC antigen competition assay. The primary antibody probe for both assays was affinity-purified, biotin-conjugated anti-human IgG, while the fluorescence probe was FITC-avidin.

Results: The evaluation of forty four human sera by FC and ELISA revealed a high level of correlation (coefficient of correlation = 0.876) between FC mean channel fluorescence and ELISA endpoint titer. The FC antigen competition assay detected less than 50 picograms of recombinant HIV envelope protein.

Conclusions: The results of the FC HIV antibody detection assay and the FC HIV antigen competition assay demonstrates the potential usefulness of flow cytometry as an alternative method for the quantitation of HIV antibodies and detection of HIV antigen in infected cells.

T.B.P.89 STATISTICAL ANALYSIS OF FLOW CYTOMETRIC DATA: A NON-PARAMETRIC APPROACH

Lacouture, Tracy Gordon, T. Donohue, C. Flow Cytometry
Laboratory, Montreal General Hospital, Montreal, Quebec, Canada.

Objective: To evaluate non-parametric approaches to the statistical analysis of T cell subsets. The enumeration of CD4 positive lymphocytes is currently considered essential in monitoring the course of HIV infection. Lymphocyte subsets are furthermore dependent variables used to enroll patients in clinical trials and as endpoints of treatment. Despite the theoretical importance placed on quantitating T cell subsets little attention has so far been placed on the statistical methods used for analysis.

Methods: Flow cytometric data was obtained on 100 HIV seronegative volunteers and 200 HIV seropositive patients with varying clinical stages of HIV disease. Dual staining of cells with monoclonal reagents conjugated to either fluorescein or phycoerythrin were used to identify T helper, suppressor, inducer, cytotoxic, B6 and activated cells.

Results: The observed distribution of flow cytometric data did not follow a Gaussian probability function and traditional parametric methods were deemed inappropriate for analysis. Percentile ranges and absolute median detection were used instead of standard deviation as dispersion indices; median and mode instead of mean as localization indices. These statistical descriptors provided a clearer view of the skewed distribution of the data (presented using exemplar distributions). A non-parametric test, the Mann-Whitney U-test, was used to be useful for hypothesis testing.

Conclusion: Although statistically less powerful the non-parametric hypothesis testing leads to improved reliability in flow cytometric data analysis.

T.B.P.86 WHERE LIES THE TRUTH? METHODOLOGICAL INFLUENCE ON THE DETERMINATION OF CD4 AND CD8 LYMPHOCYTE SUBPOPULATIONS.

EMMEL, Virginia, Lafferty, R. and G.M.P., University Hoveville, Zaire, Belgium.

Objective: The number of CD4-positive lymphocytes in the peripheral blood of HIV infected patients is an important prognostic parameter. However, the results of CD4 counts from different laboratories are not comparable. One of the reasons might be methodological differences.

Methods: We compared four different methods used to measure lymphocyte subpopulations:
- M1: Enumeration of mononuclear cells on a density gradient (Ficoll-Hypaque), and staining with FITC-labeled monoclonal antibodies against CD4 and CD8 (fluorescence).

- M2: Whole blood was double-stained with FITC-labeled anti-CD4 and PE-labeled anti-CD8 monoclonal antibodies (fluorescence), and red cells were lysed with a one step lysis reagent (B-D).

- M3: Whole blood was double-stained with FITC-labeled anti-CD4 and PE-labeled anti-CD8 monoclonal antibodies (fluorescence), and red cells were lysed with a three step lysis procedure on a Coulter Vantage™.

In all three methods the labeled cells were measured with a flow cytometer (FACS PROFILE, Coulter). Results were compared using a three regression model.

Results: M1 and M2 were compared with blood from 27 HIV-infected patients and from 23 healthy blood donors.

CD4 values obtained with M2 were 40% of the values obtained with M1. Correlation coefficient (r) was 0.3. A comparison of the results of 600 consecutive CD4 determinations by M1 with 600 consecutive measurements by M2 in HIV-infected patients revealed a 2 to 4 order difference. CD8 values correlated less well (r=0.79) but, in contrast to CD4, were about 10% higher if determined with M2 than with M1.

M1 and M3 were compared with blood from 10 HIV-infected patients and from 10 healthy blood donors. CD4 values measured with M3 were 20% higher than M2-determined values (p<0.05), which makes them comparable with M1-determined values. CD8 values, however, were again about 10% higher than M2 than with M3, moving from further apart to more comparable values.

Conclusions: Methodological effects on CD4 (and CD8) values are substantial and have to be considered when comparing different studies. A simple explanation for the observed differences could not be found.

T.B.P.88 IDENTIFICATION AND QUANTITATION OF HIV INFECTED CELLS IN PERIPHERAL BLOOD FROM AIDS PATIENTS BY FLOW CYTOMETRY

McCarthy, James*, Hirsch, S., Stevens, R., and Lehman, J., *Albany Medical Center, Albany NY and **New York State Department of Health, Albany NY.

Objective: To develop a rapid method for quantitating the amount of HIV antigen in HIV seropositive patients. **Methods:** After obtaining informed consent, peripheral blood was taken from patients attending the AIDS Clinic at the Albany Medical Center.

The mononuclear cells were isolated by centrifugation onto ficoll-hypaque, fixed in 90% methanol, incubated with monoclonal antibody to p24 antigen as the primary antibody and then with FITC-conjugated goat anti mouse IgG (Fab) as the secondary antibody. The cells were then treated with RNase A to remove RNA, and then with propidium iodide to determine the cell DNA profile. The stained cells were then analyzed by flow cytometry. Controls consisted of peripheral blood mononuclear cells obtained from HIV-seronegative patients with normal blood counts.

Results: Flow cytometric analysis of treated mononuclear cells revealed that HIV-seropositive patients have essentially no p24 antigen positive cells whereas HIV-seronegative patients had significant numbers of p24 antigen positive cells. The % positive cells correlated with the CDC criteria for clinical staging of the disease in that patients in stage II had fewer p24 positive cells than those in stage III and stage IV. Furthermore, in all cases tested and at each stage of the disease, the p24 antigen-positive cell was of the mononuclear/macrophage lineage on the basis of size as determined by light scatter and adherence to fetal bovine serum coated petri dishes.

Conclusions: These results suggest that flow cytometry can be used as a rapid, quantitative system to determine the antigen status of HIV-seropositive patients which may be useful as an indicator of disease progression.

Diagnostic : Détection des antigènes

Diagnostic: Antigen Detection

T.B.P.90

ANTIGENIQUE VEH AU COURS DE LA PRÉINFECTION
Behavien, D., Puel Zaccagnini, A., Averous S.,** Basse J.,**
*Laboratoire de Virologie, CHU Purpura, Toulouse, FRANCE
**Service de Dermatologie, CHU Dreux, Toulnay, FRANCE.

Objective: Etudier la présence de l'antigène p24 de la primo-infection II et III de l'ordre qu'elle pouvait précéder la séroconversion de 34 malades (A. Lancet 87 (ii:1233) et de quelques notes (Goussard J Lancet 87 (ii:1237 - Allan 19 Lancet 86 (ii:1233) sans ces résultats sont controversés (Dourouac AM Lancet 87 (ii:1205)).

Méthodes: Détection, tirage de 1'antigène p24 (technique Abbott) et confirmation par neutralisation réalisée sur des sérum RNAsse 2 à 6 mois (moyenne 1 mois) avant la séroconversion observée chez 18 patients homosexuels.

Résultats: L'antigène p24 a jamais été détecté avant la séroconversion, toutefois nous n'avons pas disposé de sérum dans le mois précédant la séroconversion.

- Au moment de la séroconversion une antigène a été observée chez 18 sujets Elle a disparue en 1 mois dans 11 cas, en 3 mois dans 7 cas.

- Une antigène a été observée chez un patient un mois seulement avant la séroconversion, elle a disparu en 3 mois.

- L'antigène p24 n'a jamais été observé par un marqueur sérologique précoce et fiable de l'infection VIH; accompagnant la séroconversion, elle est fugace, inconstante, parfois réversible.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

T.B.P.91 PRODUCTION AND CHARACTERIZATION OF HUMAN IMMUNODEFICIENCY VIRUS ANTIGENIC DETERMINANTS AND THEIR USE IN DIAGNOSIS OF AIDS

S. Arsenian, O. Voloshin, A. Shevelier, M. Michailov, T. Nikolova, V. Novikova, and E. Swardlow, Institut Pasteur, 200 rue de la Salette, 69631 Lyon Cedex 07, France.
M. M. Shemakina Inst. Biorg. Chem., Acad. Sci. USSR, VERA Biotechnology Minnabodiprogn, **Inst. Immunol. Minskrazd Moscow, USSR.

With a view to have immunodiagnostic kits for detection of AIDS in humans we obtained bacterial strains expressing recombinant proteins which include amino acid sequences of the main antigenic determinants of human immunodeficiency viruses (HIV). The spectrum of expressed antigenic determinants overlaps their variability among different HIV isolates. The content of the expressed recombinant protein in cell lysates amounts to 30-50% that enables one to use the synthesized antigens for immunological reactions without further purification. Using a large panel of sera taken from AIDS patients interaction of the recombinant antigens with anti-HIV antibodies was statistically analysed.

T.B.P.93 USE OF TRITON-X IN THE HIV ANTIGEN ASSAY TO ASSESS THE PRESENCE OF INFECTIVE HIV

James L. Stewart, Ketchum, S. J.; Coombs, R.W., and Allan, J.P., *Abbott Laboratories, N Chicago IL and **University of Washington, Seattle WA, USA.**

Objective: Compare the performance and significance of the current HIV antigen (HIV Ag) capture assay to a modification using Triton X-100 to disrupt potential whole viral particles in the samples.
Methods: Serum plasma samples were tested neat or in the presence of 0.5% Triton X-100 according to previously described methods (Lancet 1986, 2, 123). In some cases, results were compared to the capacity of plasma to infect stimulated normal peripheral blood lymphocytes.

Results: In 36 samples from 7 patients collected at six clinic intervals pre and post seroconversion, 11 samples were HIV Ag + in the presence and 7 in the absence of Triton. All HIV Ag + samples tested were infectious in culture while 3 of 10 HIV Ag- were infectious. In 140 seropositive samples (49 asymptomatic, 41 ARC and 50 AIDS) 52 and 40 were HIV Ag + in the presence or absence of Triton, respectively. This additional sensitivity seemed to correspond to the disruption of whole viruses since in 18 samples where HIV plasma culture was performed, all 15 positive culture samples were positive with the Triton treated HIV Ag assay.

Conclusion: The treatment of samples for HIV Ag testing with Triton X-100 facilitated infective HIV and improved the assay sensitivity by increasing the amount of antigen available to capture. The good correlation between culture infective plasma and positive result of Triton treated HIV Ag assay suggested that the presence of HIV Ag reflected active viral replication.

T.B.P.95 LACK OF CORRELATION OF p24 ANTIGENEMIA WITH CLINICAL STATUS IN HIV INFECTED WOMEN TO INTERCURRENT PREGNANT IN WOMEN WITH HIV INFECTION. **SHARON S.L. SHERMAN, Joyce M. Kucenas S. Bradford S. Brown University Medical Center, Providence, RI USA.**

Objective: To determine the relation between p24 antigenemia, p24 and clinical status in women with HIV infection. **Results:** 24 HIV-seropositive women were serologically evaluated for 24 months, with monitoring of clinical status and p24, and monthly determinations of serum p24 antigen (cpd/ml) in individuals with antigenemia. **Results:** 14 individuals (58%) were (mean age 37), mean p24 count was 787 ± 137 (SD). In 8 women (mean age 34) with AIDS-related complex (ARC), mean p24 was 170 ± 40 (SD). In 8 women (mean age 38) with AIDS, mean p24 was 62 ± 24 (SD). 3 individuals (12.5%) had persistent p24 antigenemia. In the 20 individuals, mean p24 was 63 pp/ml; mean p24 was 62. In the women with ARC, mean p24 was 130 pp/ml; mean p24 was 170. In the women with AIDS, mean p24 was 170 pp/ml; mean p24 was 170. Each antigenemic woman had been clinically stable during the past 12 months. The individual with AIDS had one breast biopsy/immunohistochemistry for paraneoplasia; the other two antigenemic women had no limitation of activities of daily living. **Conclusions:** These data confirm a highly significant correlation between p24 antigenemia and clinical status, but fail to show correlation between persistent p24 antigenemia and either clinical status or p24 counts in 24 HIV-positive women.

T.B.P.92 SENSITIVITY OF FIVE COMMERCIAL HIV-ANTIGEN DETECTION METHODS.

Camilo C., Varela J.M., Vallbona E., Garcia Sals A., Najera R. Instituto de Salud Carlos III, Madrid, Spain.

OBJECTIVES: To present data about the performance of commercial kits for HIV - antigen detection by testing with a panel of sera and infected cell-culture supernatants.

METHODS: To build our evaluation panel we have selected antibody positive sera which didn't show any reactivity for anti-COSE antibodies by the CIA -RA (ENVOACOR HIV-1, Abbott) method.

The chance of a serum to be antigen reactive is higher than 20% was considered positive.

The antigen detection methods used in this work have been: Abbott Enzygnost EIA, the Poot 204 COSE antigen ELISA, ELISA E4 (Eliabiotica Pasteur), Coulter HIV Ag assay and Viroscreen HIV Antigen (Organon). The sensitivity study was completed by testing up the end-point dilution in cell-culture supernatants for each method.

RESULTS: We have found relevant differences of sensitivity by testing the sera panel, and the dilutions.

CONCLUSIONS: We think that our study may give information about the antigen detection ability of five commercial kits. This could be an additional approach in order to decide which HIV antigen detection kit might be selected.

T.B.P.94 EVALUATION OF THE HIV ANTIGEN DETECTION ASSAYS IN EUROPEAN AND AFRICAN SERA

Steenblock, Gabe, van der Groen, G.J., P. van
Institute of Tropical Medicine, Antwerp, Belgium.

Objective: To compare the performance of two HIV antigen capturing systems (EIA) (Abbott and Immoprecip) for the detection of free HIV antigen in human serum.

Method: 100 human serum samples positive (15 African, 219 European), and 60 anti-HIV negative sera were screened with the HIV 1/1 antigen EIA (Abbott) and the Immoprecip HIV antigen (Immoprecip distributed by Dupont and Biotec and Cellcon). Negative samples were tested for confirmation with a neutralization assay of the respective manufacturer.

Results: Initial screening revealed 69 sera reactive in the Abbott and 66 sera reactive in the Immoprecip. Further analysis was performed in both assays. Epitope specific (EIA) of the Abbott reacted in both assays were confirmed with the Abbott test and 96 percent (60/63) were confirmed with the Immoprecip. Six out of the 8 serologically positive samples and 10 out of the 20 serologically immunoreactive sera, were confirmed, antibodies in both Abbott HIV and Immoprecip, were absent or of very low level. In the Immoprecip antigen reactive sera, all of these patients, except one, which was stage 1, were classified as having ARC or AIDS. We therefore presume that negative the assay of the Abbott are true HIV antigen positive sera. The HIV antigen, sensitivity in the African and European sera was respectively 1.9 (1/51) and 2.2 (2/91) (P < 0.0005). When the African sera 3/7 had such levels higher than ratio 10:100 (10:100) were detected while this ratio was 0.6 in 1/8 of the European sera (n = 107).

Conclusion: We obtained more HIV antigen positive samples with the Immoprecip EIA. This observation can perhaps be explained by a higher sensitivity of this test or by its capability to capture a wider range of HIV antigens. Our results confirm that HIV antibody positive sera from African patients contain less often free HIV antigen, possibly because of a higher production of anti HIV antibodies.

T.B.P.96 CORRELATION OF HIV CORE ANTIGEN, ANTIBODY AND IMMUNE COMPLEX LEVELS IN SERA OF HIV INFECTED INDIVIDUALS

Ushayli, E., Longo, J., Goudami, J., Salvez, V., Ust, G., Hollar, S.M., et al.
Natl. Inst. Hematol. Blood Transfusion, Budapest, Hungary; and **Dept. Virol., Acad. Med. Center, Univ. Amsterdam, Amsterdam, The Netherlands.

Objective: To measure the relationship between the presence of HIV core-antigen (core Ag) and anti-HIV (env IC) immune complexes on the one hand, and the amounts of free core antigen, free core and env antibodies on the other. **Methods:** Levels of core Ag and env IC were measured by the method of Ushayli et al. (AIDS, 1, 141, 1987). HIV antibody was detected by a sensitive ELISA assay, free core and env antibodies were measured by the ENVOACOR test. Sera of HIV-infected individuals containing core Ag and/or env IC (10/60) were selected for the study. **Results:** Free core antigen was found in 8/18 samples. Free env antibodies were present in all sera tested, free core antibodies were found in 12 samples. Core IC and env IC were detected in 11 and 14 samples, resp., in 9 sera both types of complexes could be detected. The presence of core IC were associated with increased titre of free core antibodies (13.3±25.5 vs 110.0±32.3, p=0.01) and increased incidence (7/11 vs 1/7, p=0.057) of free core antigen. **Conclusion:** Formation of core-anti-core immune complexes in HIV-infected individuals is related to the increase of the antigen load and binding of antigen to the specific antibody.

Section d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

T.B.P.115 REFLEXIONS SUR L'ISOLEMENT DU VIRUS DANS UNE UNITE DE VIROLOGIE HOSPITALIERE

Flary, M., J.-L., Belord, B.,* et Mesquolier, B.*
* Laboratoire de Virologie, CHU St Bordeaux et Université de Bordeaux II, Bordeaux, France.

Objectif: Dépasser les enseignements (comparaison avec d'autres paramètres, TIBRETE) de plus de 400 sites en culture de VIH.
Méthodes: Cas de 400 sites en culture de cultures monoclonaux du sang (TIBRETE) ont été effectués chez plus de 200 sujets (patients suivis dans le cadre d'un protocole thérapeutique, enfants nés de mères infectées, cas de contamination domestique avec autres paramètres adaptés...). Le virus a été détecté dans le surnageant des cultures cellulaires par mise en évidence de la protéine p24 du VIH 1 et d'une activité RT. D'autres paramètres biologiques ont été appréciés (antigène VIH 1, nombre de lymphocytes T4, ...). Au moment de la culture, 100% de lymphocytes.

Résultats: Plus de 200 souches de VIH 1 ont été isolées (efficacité=50 %) ; 80 PCR. Parmi les enseignements suivants :
- Une antigène VIH 1 positive est pratiquement toujours associée à un isolement viral.

- On peut isoler le virus chez des sujets dont le nombre de lymphocytes T4 est effondré au moment de la mise en culture.

- Le virus peut être retrouvé chez des patients recevant de l'AZT depuis plusieurs mois.

- L'isolement viral nécessite une technique de choix pour l'établissement d'un pronostic chez les enfants nés de mères infectées.

- Dans un cas, nous avons isolé le VIH 1 chez un sujet dont les autres paramètres sont demeurés stables.

T.B.P.116 DUAL SEROLOGIC REACTIVITY FOR HIV-1 AND HIV-2 IN ARIZONA

Porter, A.,**; Lee, J.,**; De Cock, K.,**; Colabandera, R.,**;
Besset, G.,**; Keffauz, J.,**; Keffauz, J.,**; Keffauz, J.,**;
*Projet REACTO-CR; **AIDS Program, Centers for Disease Control, Atlanta, GA, USA; **Institut Pasteur, Arizone, Gona d'Ivry.

Objectif: To assess the spectrum of serologic reactivity of HIV infected patients in Arizona; assess the predictive value of ELISA for HIV-1 and HIV-2 infection; and examine dual serologic reactivity by peptide ELISA and polymerase chain reaction (PCR).

Méthodes: 927 hospitalized patients repeatedly reactive by ELISA for HIV-1 and HIV-2 will be confirmed by virus-specific Western blot (WB). A subset of these were tested by type-specific synthetic peptide ELISA (PepSI-1/1-2) and had lymphocytes collected for PCR and virus culture.

Résultats: Of 927 patients repeatedly reactive by ELISA (543 thus far tested by WB), 194 are HIV-1 only; 65 HIV-2 only; and 742 both HIV-1 and HIV-2. Of specimens daily reactive on ELISA, 61% were dually reactive on WB, 16% HIV-1 only, and 0.35% HIV-2 only. While A&E HIV-1 only and 97% HIV-2 only reactive specimens were confirmed by the appropriate WB, 97% of dually reactive specimens were reactive on HIV-1 and HIV-2 WB. Thirty-four specimens daily reactive on ELISA will be tested by PCR. On peptide ELISA, 19/34 (56%) were reactive only to HIV-1, 1/34 (3%) HIV-2 only, and 6/34 (18%) remained dually reactive. Of 98 alone, 28/34 (28%) of these specimens were confirmed daily reactive. Serologic results will be compared with those of PCR and virus culture.

Conclusion: In hospitalized patients in Arizona, dual reactivity on whole virus ELISA is 97% predictive of WB confirmed HIV infection.

T.B.P.117 STANDARDIZATION OF HIV COCULTURE ISOLATION TECHNIQUES IN MULTICENTER CLINICAL TRIALS

Hollander, V., and Rao, S.A.
Virology Reference Laboratory (VRL)/NAID/AIDS Program, Baylor College of Medicine, Houston, Texas, USA

Objectif: To evaluate and effect improvements in the isolation of HIV from PBMCs by laboratories participating in multicenter clinical trials as part of the AIDS Clinical Trials Group (ACTG)/NAID/AIDS program.

Méthodes: Monthly coded whole blood samples are sent by the VRL to ACTG labs for culturing. After an initial evaluation period (7 months), the labs were ranked by their ability to isolate virus. A consensus HIV isolation protocol was developed after comparing the methods and materials used by labs that consistently isolated HIV to the methods employed by labs having difficulty isolating the virus.

Résultats: Critical factors in the isolation procedure include volume of patient blood processed, centrifugation parameters used to recover PBMCs, use of fresh (vs frozen) normal donor PBMCs, concentration of PMA-P in donor stimulation medium, use of natural (vs recombinant) IL-2, time interval before addition of PMA-stimulated donor cells to patient PBMCs, ratio of donor to patient PBMCs, concentration of cells in coculture, and weekly addition of fresh PMA-stimulated donor cells to coculture. The inclusion of polybrene and anti-alpha interferon in the stimulation or coculture medium did not improve isolation efficiency. Since the introduction of the consensus protocol, labs with poor performance status have shown a significant improvement in their ability to isolate HIV.
Conclusion: Achieving equivalent efficacy in isolating HIV from PBMC by the ACTG labs will permit the introduction of more sophisticated virologic end point cell culture techniques for evaluating various anti-HIV treatment protocols.

T.B.P.118 TISSUE CULTURE AND P24 METHODS OF HIV DETECTION COMPARED AND CORRELATED WITH DEMOGRAPHIC DATA IN SPONTANEOUS AIC PATIENTS

Banfield, J., John, G., Brown, J., Weisbach, A.,**; Harkeroff, M., J., Harkeroff, F., and the VA Cooperative Study Group on the Treatment of AIC, Veterans Administration Medical Center, VA, USA.

Objectif: To compare two methods of HIV detection in symptomatic AIC patients and to correlate the results with demographic data.

Méthodes: A overnight blood sample was collected from each of 152 symptomatic AIC patients entering a multicenter, phase III trial of AZT. It was transported overnight and processed by two methods: (a) by standard conventional techniques and employing the culture weekly for 4 weeks by antigen capture; (b) by directly measuring p24 levels in the plasma by standard enzyme immunoassay. Results were compared with demographic data.

Résultats: Method A detected HIV in significantly more patients than Method B did (41 vs. 7%). Method A was positive more often for (a) patients younger than 50 years, those older (53 vs. 40%), (b) patients with 74 counts between 200-299 vs. 300-500 (53 vs. 37%), (c) patients who were energetic vs. those responsive to skin tests (50 vs. 37%). There were no significant differences for sex, race, risk group, or hospital. For the comparisons done, there were also no significant differences for culture time to positive or for absolute p24 levels. Methods A and B correlated to size of the patients but not in 30%, statistically, this is no better than could be achieved by chance.
Conclusion: Issues relating to a more sensitive measure of HIV than is plasma p24 in this patient group, especially in those who are younger, energetic, and have the lower T4 counts. The tests may be measuring different stages of virus replication.

T.B.P.119 SENSITIVITY OF U.S. PMA LICENSED HIV-1 REVERSE TRANSCRIPTASES FOR ANTIBODIES

Bywater, M.,**; Gishizaki, E.; Soudry, K.,** et al. *Centers for Disease Control, Atlanta, GA, USA; **Institut Pasteur, Arizone, Gona d'Ivry; ***National Laboratories, Dugandongon, Burkina Faso.

Objectif: To determine the efficacy of testing for antibodies to human immunodeficiency virus (HIV) type 1 by screening with PMA licensed HIV-1 enzyme immunoassays.

Méthodes: West African sera were tested for antibodies to HIV-1 and HIV-2 with ELISA employing both viral lysate and recombinant peptide antigens and with HIV-1 and HIV-2 Western blots. Based on these results, 55 HIV-2 sera, 19 HIV-1 sera, and 46 sera equally reactive with HIV-1 and HIV-2 immunoassays were selected for testing with U.S. PMA licensed HIV-1 antibody ELISA (see table).

Résultats: The percentage of sera that were positive by each ELISA test are presented in the following table:

SERA	Ortha	EBI	Tatnika	Lab.	DuPont	Bye.	Pro.
HIV-2	60.0%	67.3%	70.9%	81.8%	87.5%	90.9%	90.9%
HIV-1	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
HIV-1/2	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Conclusion: Sera from HIV-2 infected individuals will be detected by HIV-1 ELISA at a rate ranging from 60.0% to 90.9%, depending on the test used. Screening the blood supply with HIV-1 ELISA will not detect all HIV-2 infected sera.

Diagnostic: contrôle de la qualité et techniques rapides

T.B.P.120

EVALUATION POUR TEST DE DETECTION RAPIDE DES SUIJETS SEROTIPIQUES HIV-2.
O. CATALAN, A. MILANOVIKOV, T.D. LEE, J. Pauline Alfred Ponsier - Paris

Objectif: Evaluer la sensibilité et la spécificité d'une technique ELISA rapide sur matériaux de sérotypisation, obtenus deux ans après de peptides recombinants à un sérotype de la O10 101 pour HIV 2.

Méthodes: Un groupe de patients sérotypés (technique ELISA Organon et Dupont de Nemours), confirmés par Western blot (Dow) puis Panzer sous (Dupont de Nemours) a été sélectionné puis les patients suivis pour sérotypisation (TCM, TCM, Beta-2-microglobuline, dosage des immunoglobulines, etc.) (14 patients) a permis d'évaluer la sensibilité.

L'autre groupe (16 patients) a été constitué de patients sérotypés par les techniques pédiatriques et succès de consensus d'origine. Des sérum de patients sérotypés ayant une infection HIV 2, soit, ont été faits. Le test a été effectué à partir de sérum séché sur nitrocellulose.

Résultats: 7 sérum, adressés pour sérotypation, ont été trouvés négatifs dans toutes les techniques. L'autre groupe, sérotypés, ont été trouvés positifs dans les 10 sérum HIV 2 et 2 ont été trouvés positifs dans les 16 sérum HIV 2. Les résultats ont été comparés à ceux des techniques pédiatriques et succès de consensus d'origine. Les sérum de patients sérotypés ayant une infection HIV 2, soit, ont été faits. Le test a été effectué à partir de sérum séché sur nitrocellulose.

Conclusion: Ce test rapide (cinq minutes), permet d'adapter à toutes les situations expérimentales, permet une sensibilité et spécificité excellentes, de peucis d'inférence HIV séro HIV 2, alors que dans une situation une grande homologie, tout au moins dans les premiers de ceux.

Session d'affichage
Poster Session



Aspects cliniques
Clinical Aspects of AIDS

T.B.P-127 EVALUATION OF A RECOMBINANT HIV-1 ENZYME IMMUNOASSAY (EIA) IN PATIENTS ATTENDING AN EMERGENCY ROOM AND A SEXUALLY TRANSMITTED DISEASE CLINIC

Kim Richards¹, Kelen, G.D.², Hock, E.W., Brothers, T.A.², O'Sullivan, S.M.², Criss, J.
¹NIAID, NIH, Bethesda, Maryland; ²Johns Hopkins Medical Institutions, Baltimore, Maryland

Objective: To evaluate the reliability, sensitivity and specificity of the Syva Microtrak Recombinant HIV-1 EIA compared to a commercially licensed EIA and Western blot.
Methods: 2000 patients attending an emergency room and sexually transmitted disease clinic were tested for HIV-1 seropositivity using a recombinant HIV-1 EIA (Syva). This EIA was genetically engineered gp41 and gp120 and p24 gene products of HIV-1 expressed in *R. solis*. After purification, all immunologically detectable bacterial proteins were removed. All sera were also analyzed by EIA (Organon) and sera which were seropositive by either assay were confirmed by Western blot (DuPont).
Results: The Syva Microtrak HIV-1 EIA procedure was easy to perform with short incubation times and color-coding of reagents to lessen the chance of error. In assessing HIV-1 seropositivity in the two populations, the Organon EIA and Western blot detected 119 positive and 3 indeterminate samples. The Syva EIA detected all 119 positive samples with no false positive samples. Compared to Western blot, the assay had a sensitivity of 100% and specificity of 100%.
Conclusion: Use of the Syva Microtrak Recombinant HIV-1 EIA for detection of HIV-1 infection in these populations proved to be highly reliable with excellent sensitivity and specificity compared to a licensed EIA and Western blot.

T.B.P-129 USE OF A PEPTIDE-BASED, RAPID IMMUNOASSAY FOR THE DETECTION OF ANTIBODY TO HIV-1

Soni, R.L., Popoulos, S.P., Kiv, S., Hossain, M., Perera, C., Kojima, Madao, S.***
^{*}Chicago Laboratory, Lenexa, KA and ^{**}Genetic Systems Corporation, Seattle, WA, U.S.A.

Objective: To investigate the utility of a peptide-based, rapid immunoassay for detecting antibody to Human Immunodeficiency Virus Type 1 (HIV-1).
Methods: 1595 samples were tested by a rapid immunoassay based on a synthetic peptide found in the conserved region of the viral transmembrane glycoprotein, gp 41 and by a whole virus immunoassay. Repetibly reactive samples were also tested by Western blot (DuPont).

Results: Results of the sera were interpreted according to the package insert of each test.

Immunoassay	EIA	Western Blot	Number of Samples
Negative	Neg	Not Detected	1383
Positive	Positive	Positive	101
Negative	Positive	Indeterminate	86
Negative	Negative	Indeterminate	21
Positive	Negative	Indeterminate	3
Positive	Positive	Indeterminate	3

Conclusion: The sensitivity and specificity of enzyme immunoassays and blot kits marketed for detection of antibody to HIV are greater than 99%; however, when a low prevalence population is tested a high percentage of the reactive samples are false positive or blot indeterminate. Preliminary results indicate that a peptide-based test may be useful in distinguishing samples which are false positive by EIA or indeterminate by Western blot.

T.B.P-131 THE ANTI-HIV TESTING BY QUICK TESTS AND A COMPARISON WITH A STANDARD ELISA

Dea, P., de Vries, A.H., McHine, R.L.; Smit Sibinga, C.; Het Rod Cross Blood Center, Groningen-Drenthe, Groningen, The Netherlands.

To provide rapid but sensitive and anti-HIV specific testing we have compared HIV check (DuPont), gelatin particle agglutination (Pujarbio) tests with our routine enzyme immuno assay (EIA - Wellcome) used for routine testing of 50,000 donations per year.
Initial screening consists of 3 Western blot positive donor sera, 3 'tricky' samples (2/3 and/or 2/5 bands) and healthy donor sera (40). In the second phase 3 Western blot positive sera were diluted and run in parallel. All tests were carried out according to the manufacturers' instructions.
Results:

Initial screening	TESTS			
	HIV-check	HIV-check	Pujarbio	EIA
Tricky (n=5)	All neg	All pos	All pos	All pos
Normal (n=40)	All neg	All neg	All neg	All neg

In the rapid HIV check test all the positive samples were clearly identified and tricky sera remained negative. Pujarbio is at least 3-fold sensitive in and point immunoassay (14002 vs 2048 in EIA). HIV check is fairly quick (20') having a high sensitivity and specificity (1/40 initial non-specific reaction). Pujarbio showed very high specificity and sensitivity, and seems adapted to rapid testing.

T.B.P-128 DETECTION OF ANTI-HIV ANTIBODIES WITH SYNTHETIC PEPTIDES USING A 3 MINUTES RAPID TEST

Shaban, Rattimani, J. Martin, A., Herreweghe, P., Tardieu, C.,** Richeux, J.,** Pignatelli, G.,** Bismet, J.***
^{*}Clonon: 60 rue de Valenciennes - 75013 PARIS - FRANCE
^{**}V-Chem: PO Box 4, USA ^{**}Geno-SAN: DREUX, CA - USA

Objective: A 3 minutes immunoradiation ELISA device using synthetic peptides derived from the transmembrane glycoprotein of HIV1 and HIV2, was optimized for the detection and the distinction of anti-HIV antibodies in serum or whole blood samples.
Methods: The assay involved synthetic peptides coupled on a membrane with one spot of HIV1 peptide, one spot of HIV2 peptide and one uncoated control ring. A diluted specimen is filtered through the reactive membrane. Anti-human IgG peroxidase conjugate solution is added. The result is read visually. Results are recorded as positive if one or two bands and the peroxidase blue ring appear on the membrane. Results are recorded as negative if the blue ring appear only.
Results: 200 positive HIV1 peptide, 200 positive HIV2 peptide and 18 false HIV1 antibodies were tested. 276 were reactive with the HIV1 peptide (sensitivity = 98.9 %), 441 negative sera and 18 false positive sera in ELISA. 100% sensitivity and 100% specificity were achieved.
To evaluate HIV2 peptide, 66 anti-HIV1 sera were tested. All were reactive with this peptide (sensitivity = 100 %). 67 HIV2 negative and 18 false positive sera, no reaction was observed (specificity = 100 %).
Conclusion: Target HIV is a sensitive and specific rapid test which can be performed readily for the screening and the typing of HIV. We achieved 100% sensitivity and 100% specificity of 991 sera, the sensitivity of the test is 99.6% and the specificity is 100%. We thank Dr. J. P. Virelizier.

T.B.P-130 COMPARISON OF SERUM AND PAPER-ABSORBED FINGERSTICK BLOOD SAMPLES FOR DIAGNOSIS OF HIV INFECTION IN INTERMEDIATE DRUG USERS.

Offit, Edward, Sloger, K., Deutsch, G.,** Weiblen, B.,** Comella, L.,** and Williams, J.M.***
^{*}Massachusetts Department of Public Health, Center for Disease Control; ^{**}Boston City Hospital, Boston, Massachusetts, USA.

Objective: To determine whether the results of HIV ELISA and immunoblot (IB) assays on paper absorbed (PA) fingerstick blood are equivalent to that obtained with serum specimens.
Methods: Paired specimens of venous blood serum and fingerstick blood collected and dried onto SMC 803 collection paper were obtained with consent from 283 clients using a walk-in anonymous counseling and testing service for intravenous drug users. The paired serum and PA specimens were tested by ELISA (Genetic Systems) and the Miniblot® IB procedure.
Results: The same group of 66 IB-confirmed ELISA-positive clients was detected by examining the serum and the PA specimens. The IB band patterns in the 66 paired specimens were identical. By ELISA 100% of sera (72/72) and 100% of PA specimens (72/72) were repeatedly reactive, and the relative strength of ELISA reactivity in the paired specimens was virtually identical (p=0.84). A slightly higher ELISA mean background with PA specimens (45% of the cutoff vs 27% for serum) resulted in 10 non-IB confirmable ELISA positives in contrast to 8 for serum.
Conclusion: PA specimens, as compared to serum, provide for equivalent sensitivity and specificity to ELISA and IB assays for HIV antibodies. Moreover, the PA method is superior in convenience, safety, transport, and processing—all of which are advantages for serosurvey and screening programs, especially when volunteers are problematic.

T.B.P-132 A SIMILAROUS BRIDOR QUICK TEST FOR DETECTION OF HIV-ANTIBODY AND USE OF THIS TEST FOR RISK ASSESSMENT

Tardieu, E., Rattimani, J.,** Marty, J.,** Wilson, A.J.,** Schmitt, M.,** Yemine, F.,** Fournier, R.,******
^{*}Univ. São Paulo, Brazil; ^{**}Univ. Foundation for Medical Research, São Paulo, City, Utah, USA; ^{**}Univ. Ribeirão Preto, São Paulo, Brazil.

Objective: The developing countries are in urgent need of an easy and economical test for HIV-1. This test for use in parallel with other rapid tests in order to eliminate false negatives/positives. This test detects, at the same time, HIV-Ab and HBs-Ag using whole blood, plasma or sera.

Methods: HIV-Ab and HBs-Ag was spotted in each well of a 96-well test card. The card is placed in a tray. Add 1 drop of undiluted specimen to the well. Incubate at room temperature for 10 minutes. Wash the card with buffer shaking the tray for 10 seconds. Discharge the buffer and repeat operation for 3x. Add enough conjugate to the tray to completely immerse the card. Wait 10 minutes at room temperature. Pour off the conjugate and wash 3 x. Add color developer and incubate for 10 minutes. Pour off the solution and wash the card with water and read. The reaction is positive when the spot is colored.

Results: 480 clinical specimens of AIDS and hepatitis patients or suspected and normal donors were tested. Sensitivity was 99% and 100% of specificity when compared with western blot of the test - 99.3%.

Conclusion: This test is a very useful tool for screening, repetition or emergency situations.

**Session d'Affichage
Poster Session**



**Aspects Cliniques
Clinical Aspects of AIDS**

T.B.P.133 FIELD EVALUATION OF IMMUNOASSAY AND AGGLUTINATION TESTS FOR HIV

Michélin, Ghislain*, Tubet, P.H.,**Houyou, S.,**Pirajac, J.,***
Lecroq, P.,**
*AIDS/CRF/Family Health International, North Carolina, USA, **Virus Re-
search Center, Nairobi, Kenya, ***Olivierie Charité Area Hosp, Baker,
Sengal, ****Chaga Medical School, Actra, Ghana.

Objective. To evaluate one rapid test as a screening test for HIV and two agglutination tests as supplemental tests for HIV in field laboratories in 3 countries in Africa.
Methods. The HIVCSSE (Dupont, USA) was evaluated as a screening test with the HEMO-ELISA (Fujiwara, Japan) and HEMOCHEL (Abbott, USA) being evaluated as supplemental tests. A total of 6,000 specimens were tested in 14 laboratories in Kenya, Ghana and Senegal. Through, standardized training in these techniques was provided to all technicians.
Results. Sensitivity and specificity of the tests will be determined and compared with those of ELISA and Western Blot. Inter and intra country differences in test performance will be assessed and reported.
Conclusion. With proper training the newly developed tests for HIV antibody can perform well in laboratories lacking sophisticated equipment. The use of these assays for screening and confirmation would facilitate blood donor screening in developing countries.

T.B.P.135 COMPARISON OF HIV INFECTION WITH A LINE DISKING ASSAY (DND-12A) USING NECKS BLOOD IMPROVED FILTER PAPER TESTS

Samaga, Jan*, Pollet, D.M.,** Clapen, M.,* Vandendriessche, M.* Peeters, D.M.,**
De Groot, G.*
*Institute of Tropical Medicine, ** Ziekenhuis Nijmegen, Nijmegen, Belgium.

Objective. To evaluate the use of whole blood collected on filter paper in the DND-12A, a newly developed "second generation" HIV antibody confirmation test, methods. From each of 40 HIV+ subjects blood samples were collected in 4 different ways and coagulated from capillary (C) and venous (V) whole blood as well as heparinized (H) whole blood were collected on Whatman 3MM Chr filter paper. In addition, capillary (C) and venous (V) whole blood were collected on "DND" paper. Blood impregnated filter papers were air dried, placed in a sealed plastic bag and stored at 4°C for at least 2 weeks prior to testing. Punched filter papers (5 mm) were obtained in 1 ml PBS applied with 100 microliters (100 µl) of saline and 100 µl of the same buffer was also used to dilute serum (S). The presence of antibodies against gag (p24 and p17), pol (reverse transcriptase), env HIV-1 (gp41) and env HIV-2 (gp120) was assessed in the DND-12A according to the instructions of the manufacturer.
Results. The three different methods of sample collection on filter paper gave identical results which accorded the results of a 1:100 dilution of serum. No selective loss of signals was observed with the paper discs as compared to the serum samples. Samples from patients with HIV-1 infection could easily be distinguished from subjects with HIV-2 infection and were in accordance with Western blot findings.
Conclusion. Whole blood impregnated filter paper can successfully be used to confirm infection with HIV when used in the DND-12A. This is of special interest in field studies where filter paper blood can easily be obtained and transported.

T.B.P.137 RAPID, MANUAL SCREENING TEST (HIVCHECK™) FOR ANTIBODIES AGAINST HIV-1 AND HIV-2

**Basig, N.*, Galtvis, J.R.*, Tirado, J.*,
Reed, D.**, Chu, P.R.,** Chu, A.R.,**
*The Pont de Nemours International S.A., Geneva, Switzerland, USA,
**Du Pont de Nemours International S.A., Geneva, Switzerland,
***Virus Laboratories, San Mateo, California, USA.**

Objective. To develop a simple assay test that would simultaneously screen for antibodies against both viruses. Ultimately, to facilitate screening in developing nations with small labs in developed countries.
Methods. A number of peptides and recombinant proteins have been evaluated to determine the widely accepted HIVCHECK™ assay to HIV-2 only sample. The sensitivity of the original HIVCHECK™ assay to HIV-2 only samples has increased from approximately 30% to 100% in the populations tested. In these HIV-2 populations, samples can be diluted and still detected as positive on this modified HIVCHECK™ assay. In a preliminary study in France and Portugal, the modified HIVCHECK™ assay correctly identified all 12 samples from patients known to be infected with HIV-2. Detailed data from more extensive evaluations now in progress in Europe and Africa will be presented.
Conclusion. Antibodies to both viruses can be simultaneously screened for when a proper selection of antigens is made. Sensitivity and specificity remain excellent. Use of antigens from the envelope regions of the viruses' genomes as the antibody capture reagents have provided an excellent method of achieving this sensitization.

T.B.P.134 USE OF AGGLUTINATION ASSAYS AS SUPPLEMENTAL TESTS FOR ANTIBODY TO HIV

Tsukamoto, K.*, Mizuhata, S.,** Symonog, J.,**
*Virus Research Center, Mitohi, Kenya, Africa, **Family Health International, Research Triangle Park, North Carolina, U.S.A., ***National Public Health Laboratory, Mitohi, Kenya.

Objective. To evaluate two agglutination assays for antibody to HIV as supplemental tests in field laboratories in Kenya.
Methods. A particle agglutination test SHERO-ELISA (Fujiwara, Japan) and a hemagglutination test HEMOCHEL (Abbott, USA) were evaluated for use as supplemental tests in comparison with the Western Blot. Seven laboratories in Kenya participated in the study. Serum from 2,000 blood donors, persons at high risk and suspected AIDS patients were initially screened by the HIVCHECK (Dupont, USA). All positive specimens and 10% of the negative were then tested by SHERO-ELISA and HEMOCHEL. At the reference laboratory, duplicate samples were tested by ELISA. All sample positive by any test were 100% positive when tested by Western Blot. Each test is being evaluated for sensitivity, specificity and usefulness in these field laboratories.
Results. With thorough training these tests can readily be performed in laboratories without sophisticated equipment. Data on sensitivity and specificity will be presented at the conference.
Conclusion. The agglutination tests do not require expensive equipment or highly trained staff and are more economical than the conventional supplemental tests used in HIV testing. These tests offer an alternative to the Western Blot technique as well as their intended use as screening tests.

T.B.P.136 A RAPID COLORMETRIC VIA FOR DETECTION OF ANTIBODY TO HIV-1

M. Shukla*, D. Maitra** (Mark White** Brian Dewar** and
Carole Ann**
*Virus Laboratory, Gorra, Georgia USA,
**Institute for Cancer Research, San Francisco, CA, USA.

Objective. To develop a rapid, sensitive and specific colorimetric assay necessary for the qualitative detection of antibody to HIV in specimens.
Methods. A simple, 10 minute colorimetric screening test was developed using Murax 3000 test cartridge and proprietary microfluidization H1A method. The test incorporates immunofluorescently purified HIV-1 antigen and synthetic peptide. A mixture of specificity and solid phase capture reagent is incubated 3 minutes at room temperature. Mixture is dispensed into a 3000 cartridge and substrate material is removed by addition of wash reagent to cartridge. Excess antibody conjugate is added to the cartridge and is allowed to incubate at room temperature for 3 minutes. Unbound conjugate is removed by addition of wash reagent to the cartridge. Following a 2 minute substrate development step, result is read from the bottom of cartridge. A distinct blue color indicates a positive test.
Results: Of 136 specimens examined, 646 were negative and 647 were positive. Observed sensitivity was 99.7%. Specificity was 100% and 99.7%, respectively. Positive predictive value was 99.7%. Negative predictive was 100%.
Conclusion. Murax 3000 HIV-1 antibody test provides an easy method for the detection of antibodies to HIV-1 and a total test time of approximately 10 minutes. Precision pipetting, specialized instrumentation and extensive training are not required.

T.B.P.138 MULTIPLE USE OF A SINGLE HIVCHECK™ DEVICE FOR SCREENING FOR HIV-1 ANTIBODIES

Basig, N.*, Galtvis, J.R.*, Tirado, J.*,
Chu, P.R.,** Chu, A.R.,** Tirado, J.,**
*The Pont de Nemours International S.A., Geneva, Switzerland, USA,
**Virus Laboratories, San Mateo, California, USA.

Objective. To provide developing nations with the capability of using HIVCHECK™ to screen for HIV-1 antibodies by reducing the cost/sample tested. Maintain the simplicity and ease-of-use of the assay technique.
Methods. Several techniques were evaluated to determine if the device was evaluated so that a device may be reused with several samples. In the preferred protocol, only one more reagent addition step is required to regenerate the device.
Results. As reported earlier, HIVCHECK™ is a very accurate, (sensitivity 100%, specificity 100%) rapid test for the detection of antibodies to HIV. To make the assay even more useful in developing nations, a HIVCHECK™ device can be regenerated after a negative sample has been assayed on a device. This is best performed by washing the device with an acid solution prior to performing the assay another time on the same device. A single device can be used with a negative sample and still detect a weak positive on the subsequent test. The acid wash will not eliminate a visibly detectable positive spot on a device with the first sample. Further detailed results will be provided.
Conclusions. By reusing a device several times, the cost/sample analyzed is significantly reduced thereby making the HIVCHECK™ assay significantly more affordable in developing nations. This regeneration of a device minimally impacts on the use of the HIVCHECK™ assay by clinicians.

Session d'affichage
Poster Session



Aspects cliniques
Clinical Aspects of AIDS

T.B.P.139

A PARTICLE-AGGLUTINATION ASSAY FOR ANTI-HIV-1 IN DEVELOPING COUNTRIES

Richard, M.* (Machini), O.* (Munoz), M.* (Perez Bianco), R.* (Perez), J.M.* (Terra), Academia Nacional de Medicina, **Hospital Juan A. Fernandez, Buenos Aires, Argentina.

Objective: To evaluate the efficiency of a rapid and easy-to-use assay for HIV not requiring specialized equipment. There is an urgent need for this test in developing countries.

Methods: A particle-agglutination (PA) test (Serodia-HIV, Nippon Bio, Inc., Japan) was evaluated for screening of HIV antibodies in a panel of 504 frozen sera from high-risk individuals and in 250 blood donors. Results were compared with EIA (Abbott) and confirmed by W.R. (Dupont) and/or IP.

Results: Out of the 205 HIV-1-positive-confirmed sera, the PA detected 198. In 75 sera the reaction was equivalent (7) or less, as suggested by the manufacturer, it was scored positive. This gives a sensitivity of 100%. When we tested a panel of sera from blood donors, we observed a 95.1% specificity. The test had produced a considerable amount of false positive results.

Conclusion: In our hands, this assay showed to be very sensitive. Although specificity was not confirmed by the manufacturer, it seems that this test is suitable for its use in blood banks in developing countries. Still, we have some doubts about its use with frozen sera from high-risk groups. Repeatedly frozen sera could give false positive reactions which should be avoided.

T.B.P.140

EVALUATION OF A NEW RAPID SCREENING ASSAY FOR HIV ANTIBODIES

Richard, M.* (Machini), O.* (Munoz), M.* (Perez Bianco), R.* (Perez), J.M.* (Terra), Academia Nacional de Medicina, **Hospital Juan A. Fernandez, Buenos Aires, Argentina.

Objective: To describe the efficiency of a very rapid test (less than 15 minutes), suitable for use in developing countries.

Methods: The "HIVRUC" test (Dupont) was evaluated using 94 frozen sera from high-risk individuals and containing 56 sera HIV-1-positive by EIA (Abbott), confirmed by IP, HADAGE (Abbott) or W.R. (Dupont), and 38 HIV-1-negative sera. Fresh sera from 50 blood donors was also evaluated.

Results: Out of 56 frozen sera repeatedly positive by EIA, the new test only detected 53, which gave a sensitivity of 93.3% and a specificity of 98.7%. When fresh sera from 50 blood donors were excluded and we considered only fresh-blood sera, the sensitivity of the test was 100% and the specificity 98%. Although some sera were not correctly absorbed to the paper and considered undetermined, some fresh sera from the first and the 1-week-later assays. There were no doubtful results and all the sera absorbed perfectly well to the filter.

Conclusion: The "HIVRUC" is an excellent method to be used in developing countries where there is a need for a rapid and simple method with no additional costs. This is a preliminary report, but it seems this test works very well with fresh sera and, on the contrary, there is a lot of difficulties with sera that have been previously frozen. Apparently, sera can be shipped long distances unfrozen, at 4°C, without alteration of results.

T.B.P.141

EVALUATION OF LABORATORY PERFORMANCE OF ENZYME IMMUNOASSAY TESTS FOR HIV-1 ANTIBODY

Richard, M.* (Machini), O.* (Munoz), M.* (Perez Bianco), R.* (Perez), J.M.* (Terra), Academia Nacional de Medicina, **Hospital Juan A. Fernandez, Buenos Aires, Argentina.

Objective: To evaluate laboratory performance of human immunodeficiency virus type 1 (HIV-1) antibody enzyme immunoassay (EIA) tests, the screening test primarily used in the United States to detect infection by HIV-1.

Methods: A panel of 22 samples was mailed in May 1988 to 1,309 laboratories enrolled in the Centers for Disease Control's Model Performance Evaluation Program (MPEP) antibody testing in the specific application being used to develop this program. The panels consisted of both single donor and pooled donor samples. Not all laboratories received the same 22 samples; 23 different lots of samples were actually used. All samples were provided in blind duplicate.

The HIV-1 antibody reactivity levels varied from negative to weakly reactive to positive. In addition to providing sample analysis, laboratories also provided information describing their laboratory and testing practices.

Results: Enzyme immunoassay results were reported by 1,201 laboratories; 48 percent were hospital laboratories, 19 percent blood banks, 11 percent independent laboratories, and 22 percent public health laboratories. Most of the laboratories (80 percent) reported only EIA test results; that is, they did not perform confirmatory testing. By manufacturer, 63 percent of the percentage used a kit from Abbott; 9 percent used Genetic Systems; 9 percent, DuPont/Walton; 4 percent, Cetus; 4 percent, Ortho; and 4 percent, Electrochemica. For the sensitive samples, the percentage correctly interpreted ranged from 74 percent to 100 percent and for the strong positive samples, from 98 to 100 percent.

Conclusion: Screening for HIV-1 antibodies is performed well by most laboratories in a variety of settings. Nonetheless, small errors and weak HIV-1 antibody reactivity are the cause of some of the observed performance problems.

T.B.P.142

Results of CDC's Model Performance Evaluation Program for HIV-1 Antibody Testing

Richard, M.* (Machini), O.* (Munoz), M.* (Perez Bianco), R.* (Perez), J.M.* (Terra), Academia Nacional de Medicina, **Hospital Juan A. Fernandez, Buenos Aires, Argentina.

Objective: To track trends in testing, to characterize HIV-1 testing laboratories and evaluate their performance, to document changes in performance and impact on public health, to evaluate emerging technology, and to identify possible sources of error and intervention strategies.

Methods: A combination of comprehensive demographic questionnaires and performance evaluation surveys were used to obtain lab descriptive data and test results. Questionnaires requesting information on lab type, personnel, workload, and testing procedures were mailed to labs in May and October 1988. Shipments of 22 samples per lab were mailed in February, May, and September of 1988. Results were tabulated and analyzed. Summary reports were returned to the participants.

Results: About 1400 laboratories are enrolled in this voluntary program. Both lab descriptive data and test results were usually provided by a high percentage of the labs (typically >90%). Enzyme immunoassay (EIA) results were reported by about 1200 laboratories, Western blot (WB) by about 250, and immunofluorescence by about 70. Results were compared by method and test manufacturer. Problems were identified with some commercial EIA kits with some samples. Need for standardization of WB test was apparent.

Conclusion: No serious performance problems were detected. Data will be used to develop a profile of labs which perform high quality testing. Continued operation of the program is required to monitor rapidly changing technology and applications.

T.B.P.143

CENTERS FOR DISEASE CONTROL MODEL PERFORMANCE EVALUATION PROGRAM RESULTS OF THE WESTERN BLOT AND INDIAN IMMUNOFLUORESCENCE TESTS FOR DETECTION OF HIV-1 ANTIBODIES

Richard, M.* (Machini), O.* (Munoz), M.* (Perez Bianco), R.* (Perez), J.M.* (Terra), Academia Nacional de Medicina, **Hospital Juan A. Fernandez, Buenos Aires, Argentina.

Objective: To evaluate, through mailed sample panels, the performance of laboratories that test for human immunodeficiency virus type 1 (HIV-1) infection and to track changes or trends in Western blot (WB) and indirect immunofluorescence (IF) testing through three periodic performance evaluation programs.

Methods: Panels containing 22 serum samples obtained from confirmed HIV-1 antibody-positive and antibody-negative donors were sent in May and September 1988 to the approximately 1,400 laboratories enrolled in a voluntary performance evaluation program. Panels were sent to 1,212 laboratories that returned results after testing the May performance panel samples, 229 (18.9%) and 71 (5.7%) laboratories reported WB and IF results, respectively. Among the 1,125 laboratories that returned results after testing the September performance panel samples, 260 (23.1%) and 67 (5.9%) reported WB and IF results, respectively. Eleven WB kits (commercial and in-house) were used by the laboratories in both surveys; whereas, 77% of the results were reported with five commercial kits. Six IF kits (commercial and in-house) were used in both surveys. Little difficulty was demonstrated by the majority of the laboratories in reporting interpretations for the strong positive and true negative samples for the WB and IF. Some laboratories reported vital specific bands for true negative samples that otherwise often were reported as positive. Some laboratories reported results that contained weak specific bands. Some laboratories experienced difficulty in IF result interpretation for samples that showed low reactivity in the enzyme immunoassay.

Conclusion: While no specific trends in WB or IF were observed, the data suggested that fewer survey samples are needed for continued evaluation of laboratory performance.

T.B.P.144

QUALITY CONTROL FOR ANTI HIV TESTING: THE EXPERIENCE OF CHETUMAL, YUCATAN, MEXICO

Richard, M.* (Machini), O.* (Munoz), M.* (Perez Bianco), R.* (Perez), J.M.* (Terra), Academia Nacional de Medicina, **Hospital Juan A. Fernandez, Buenos Aires, Argentina.

Objective: The availability of various anti HIV commercial kits and the concern for valid results led to the establishment of a panel of well defined sera for assessment of the quality control panel.

Methods: A panel of sera was assigned for anti HIV using various kits in two laboratories. Results were compared by method and test manufacturer. Problems were identified with some commercial EIA kits with some samples. Need for standardization of WB test was apparent.

Conclusion: No serious performance problems were detected. Data will be used to develop a profile of labs which perform high quality testing. Continued operation of the program is required to monitor rapidly changing technology and applications.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects AIDS

Pédiatrie : VIH Pediatrics: HIV

T.B.P.145 PROBLEMS ENCOUNTERED IN HIV SEROLOGY Faktor, Gerald; McLaughlin, B. Ontario Ministry of Health, Toronto, Ontario, Canada.

Objective. With over 150,000 specimens submitted for HIV serology, we have encountered and described a number of difficult cases and situations which can lead to erroneous double and/or triple testing.

Method. The problems ranged from simple specimen misidentification to complex situations including: the contamination of a negative serum by a minute quantity of positive serum (by submerging laboratories) carryover from positive to negative wells in the test procedure, detection of passive antibodies due to the administration of HIV seropositive immune globulin; interpretation of indeterminate results; cases of apparent sero-reversion; and failure of standard procedures to detect HIV antibodies in infected individuals.

Results. Mechanisms have been installed to detect the above mentioned situations, including double verification of tube and reagent identification, requests for whole blood rather than serum samples, careful scrutiny of confirmatory test results for weakly reactive or unusual results, facilities with clinical and risk group information provided by physicians and requests for follow-up specimens. **Conclusion.** Laboratories must remain aware of the potential for erroneous results to occur and of the serious consequences of inaccurate results for the patient and the community at large.

T.B.P.147 MORTALITY IN CHILDREN WITH AIDS: AGE AT DIAGNOSIS AS RISK FACTOR Isaiah, Sylvia; Bant, M.; Stone, R.E.; Cronbach, D.S.; Hasenauer, E. New York Medical College, New York, N.Y.

Objective. To compare mortality in children diagnosed as AIDS in the first year of age (group I), vs those diagnosed above one year (group II). **Methods.** The study was performed at two public hospitals in New York City on sixty two patients with perinatal HIV infection, admitted from 1984-1988 and followed for 1-50 months (mean 18 mo). All mothers except three were intravenous drug abusers. The majority of patients in group (I) were symptomatic in the first six months of life. The G consisted of 42 patients, 14 blacks (3) and 28 Puerto Ricans (PB), 21 males (6) and 21 females (15). G II comprised 20 patients, 13 b and 7 Fb, 12 m and 8 f, ranging in age from 11.3 to 72 months (mean 17 mo).

Results. Mortality was significantly higher in GI vs GII: 42% vs 31%. **P=0.001.** No significant sex and race differences were found in GI (32% mortality in f, 33% in m, 50% in b and 39% in Fb), but mortality was higher in f than b (80% vs 33%). The majority of patients died of pneumocystis carinii pneumonia (PCP). In GI only 4% died. **Conclusion.** Infants with perinatal HIV infection who become asymptomatic at an early age have a high mortality rate and females seem more at risk. Long term follow-up is needed to establish mortality rates in older infants and children.

T.B.P.149 CUTANEOUS MANIFESTATIONS OF PEDIATRIC HUMAN IMMUNODEFICIENCY VIRUS INFECTION Frost, Neil S. State University of New York, Health Science Center at Brooklyn, Brooklyn, N.Y., U.S.A.

Objective. To describe the varied cutaneous manifestations of HIV infection in children.

Methods. One hundred and twenty-two children with HIV infection were examined as part of a dermatologic consultation service at three area hospitals. Skin biopsy and culture were performed as necessary.

Results. We have developed an overview of the various cutaneous manifestations of pediatric HIV infection, and of the natural history of these disorders. There is no single cutaneous disease that is pathognomonic for HIV infection during childhood. The cutaneous manifestations of HIV disease in children are primarily fungal, bacterial, and viral infections. These include recalcitrant oral and cutaneous candidiasis, cellulitis, severe herpes simplex and herpes zoster, and unusual dermatophytoses. All of these manifestations are distinguishable by their severity, frequency of recurrence, and poor treatment response. We have also seen patients with severe atopic dermatitis, widespread flat warts, drug eruptions, chronic varicella-zoster infection, and unusual patterns of bacterial and viral infections. **Conclusion.** Familiarity with both the common and unusual patterns of cutaneous disease in HIV-infected child can aid in early diagnosis, and in the treatment of opportunistic infections.

T.B.P.146 ENHANCED CARDIAC FUNCTION IN PEDIATRIC HIV INFECTION. Shaw, E. Lippitt, Stephen P. Saxon, Steven S. Cole, Kenneth McDonald, Children's Hospital, Boston, MA, USA.

Objective. Fifty four pediatric patients with HIV infection underwent serial echocardiographic evaluation (n=133) of cardiac function as part of a natural history study. **Methods.** The M-mode shortening fraction was used to assess left ventricular (LV) function, and systolic and aortic EDSWs to measure afterload, and the relation between rate-adjusted velocity of fiber shortening and EDSWs to evaluate contractility. This load-independent index allowed determination of contractility despite changing heart size and blood pressure. **Results.** At initial evaluation 50% of patients had hyperdynamic LV function, generally associated with enhanced contractility and reduced afterload. During follow-up of up to 57 months, function decreased to normal or subnormal in 69% of patients with hyperdynamic function initially. In contrast, function or contractility did not normalize in six patients with normal function and contractility. Hypodynamic LV function was noted on one or more exams in 36 patients. Irrespective of stage of disease or route of infection, this group (n=36) all patients with documented high-grade aortic (b/a), sudden unexplained death (s/u) and 4/5 patients with evidence for cardiac or organ mononuclear infiltrate at autopsy. A change to enhanced LV function was observed in patients with previously normal function who developed mononuclear infiltrative disease of other organ systems. Unusual heart rate and blood pressure variability as well as exaggerated heart rate and blood pressure responses to medications were seen in these patients. These findings as well as autonomic function testing in selected patients are consistent with enhanced sympathetic tone. **Conclusion.** Hyperdynamic LV function is a common finding in early pediatric HIV infection, often associated with autonomic instability and mononuclear infiltrative disease, and may be a marker for arrhythmias or sudden death.

T.B.P.140 ISOLATION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) FROM CEREBRAL TISSUE AND CHARACTERIZATION OF ITS BIOLOGICAL PROPERTIES Dimitrov, D.R.; Geyer, F.; Spector, A.A.; Melsink, J.L.; Shearer, W. and Hollinger, F.; Blaine, R. Baylor College of Medicine, Houston, Texas, U.S.A.

Objective. To report the detection and isolation of HIV from the cerebral tissue of two clinically infected children, 2 and 3 years old, with neurologic dysfunction.

Methods. Electron microscopy (EM), histology, and cell culture. **Results.** Neuropathologic evaluation of both children revealed marked cerebral atrophy. At postmortem examination, both brains showed encephalopathy, cerebral atrophy and decreased myelin. EM examination of the white matter of the brain revealed areas with myelin and cell degeneration. In these areas, infection of oligodendrocytes with HIV was inferred based on the presence of typical viral core structure and HIV-1A particles in the endoplasmic reticulum of these cells. Occurrences of normal donor PBMCs with 1 x 10⁶ neural cells from these infected children yielded evidence of HIV infection as manifested by the expression of HIV p24 antigen in culture supernatants. These neural viral isolates readily infected T₄ B and monocyte cell lines, e.g. Jurkat, MT-2, Raji, U937, HL-60 and THP-1, as determined by the detection of HIV p24 antigen in culture supernatants. The neural viral isolates were not cytotoxic for these cell lines. **Conclusion.** These data suggest that HIV is associated with the neuropathology observed in the brain of infected children.

T.B.P.150 CLINICAL SPECTRUM OF HUMAN IMMUNODEFICIENCY INFECTION IN CHILDREN LESS THAN 4 MONTHS OF AGE. T. Schwartz, M.D., Leiby, A., Fine, S.J., Fallon, Boston City Hospital and Boston University School of Medicine, Boston, MA, U.S.A.

The early recognition of children with infection due to Human Immunodeficiency Virus (HIV) may permit intervention strategy such as nutritional supplementation, prophylactic antineoplastic therapy, or experimental antiretroviral chemotherapy. We report on 11 HIV-1A seropositive children (ages 1-4 months) who presented with clinical signs and symptoms before 4 mos. of age. The earliest at diagnosis was male at 10 weeks of age in a child with thrombocytopenia at birth, who developed hepatosplenomegaly (HSM). A additional child presented before 4 mos. of life; 2 with proven PCP requiring mechanical ventilation, and 3 with axillary adenopathy and poor weight gain. 2 of the 11 children had the diagnosis established before 3 mos. of age; 1 with failure to thrive requiring nightly nasogastric tube feeding and axillary adenopathy, and 1 with developmental delay and presumed PCP. A of the 11 children presented before 4 mos. of age: HSM and lymphadenopathy (1), recurrent sepsis (1), suspected PCP pneumonia (1) and adenopathy (1) were the presenting signs. Of the 11 cases, 10 had mucocutaneous candidiasis by exam or history prior to 3 mos. of age, and 7 of the 11 children had significant adenopathy at presentation. In 7 of the 10 children, IgG was already greater than normal. Ultrasonid in 1 child revealed echo densities in the basal ganglia in the absence of neurologic findings. Children have been followed for a median of 6 mos. (range 1-46) since diagnosis. 3 of the 11 children developed a progressive thrombocytopenia resulting in death. All 3 were Haitian; illness in 2 of the 3 was complicated by infection with CMV, and one of the 3 had significant adenopathy.

Session d'affichage Poster Session

Aspects cliniques Clinical Aspects of AIDS



T.B.P.151 HIV ACTIVATION BY COFACTORS: P-24 ANTIGENEMIA AFTER INJECTIONS OF SOLUBLE ANTIGENS IN CHILDREN WITH AIDS

Santaloro, G., Charvet, J., Plouffe, C., Gagnon, M., Hôpital Ste-Justine, Université du Montréal, Montréal, Québec, Canada.

OBJECTIVES: To monitor P-24 antigenemia (Ag) following repeated KLN injections and to correlate with immunologic status of patients.
Methods: The study was conducted in HIV positive immunodeficient symptomatic children, asymptomatic adults, HIV negative children and adults. KLN was injected at 0 and 14 days. P-24 antigen (Abtest) was measured at 0, 14, 28 days and results were expressed after neutralization. Lymphocyte sub-populations, mitogen and KLN responses, anti-KLN antibodies by ELISA and PCR were measured at 0, 14, 28 days.

RESULTS: 25 individuals of which 13 were HIV positive were injected with KLN. Results of 7 remaining children developed P-24 Ag. All met criteria for pediatric AIDS and were immunologic (mean T-cell counts = 1946, CD4 = 462, CD8 = 1037 ± 656), had depressed mitogen responses and no significant antibody response to KLN. In asymptomatic HIV positive mothers, injections were associated with the appearance of P-24 Ag in 2 cases, and increase in P-24 Ag in 1 case. They had low normal T-cell count, low CD4 (59.7% ± 2.2) and CD8 (55.5% ± 3.1). Mitogen responses were generally normal, antibody response to KLN was partly abolished, no significant change in lymphocyte sub-populations was noted during the study.

CONCLUSION: Injection of soluble antigens may trigger P-24 antigenemia and this seems to be limited to asymptomatic moderately immunodeficient individuals. The clinical relevance of these findings requires further study.

T.B.P.152 NATURAL HISTORY OF LYMPHOCYTE IMMUNOLOGICAL DEFICIENCY (LID) IN PERINATAL HIV-1 INFECTION

GEIS, GONCALVES, SOUZA, G., CASTRO, A., BRADFORD, B.B., MESTRUCIO, M., PARKS, W. UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, MIAMI, FL, U.S.A.

OBJECTIVE: To review the natural history of LID in pediatric AIDS focusing on the clinical, radiological and immunological parameters.
Methods: From January 1984 to February 1989, 48 cases of LIP were diagnosed among 172 cases of perinatally HIV-1 infected children. Charts were reviewed retrospectively. X-rays were reviewed by the same radiologist. 100% of the children were black.

Results: Radiologically, LIP developed at a mean age of 16 months. Chronic lung disease with oxygen dependency and clubbing occurred in 30%. The reticulonodular pattern on chest x-rays cleared in 64. Physical examination revealed lymphadenopathy 100%, hepatomegaly 90%, splenomegaly 60%, proctitis 78% and failure to thrive in 69%. Common infections included bacteremia 50%, bacteriuria 59%, recurrent otitis media 69% and recurrent diarrhea 59%. Opportunistic infections were less common. Mean level of IgG at onset of LIP was 4421 mg (20 patients). Acute levels at less than 1000/dg were seen in older patients at a mean age of 5 years.

Mean level at a mean age of 14 months. Those who died often had concurrent opportunistic infections and significantly elevated IgG mean 6124 mg. **Conclusions:** LIP is often associated with lymphadenopathy, hepatomegaly, failure to thrive, proctitis, bacteremia, bacteriuria and recurrent otitis media. Opportunistic infections are rarely associated. Mortality is significantly decreased as compared to overall Pediatric AIDS mortality of 57%.

T.B.P.153 PNEUMOCYSTIS CARinii PNEUMONITIS (PCP) IN CHILDREN WITH RENAL IMMUNODEFICIENCY Yaws (HIV-1) INFECTION

Sanchez, Bayes, J., Buitel, L., Rodriguez, M., A. and Parks, W. UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, MIAMI, FL, U.S.A.

Objectives: To determine the clinical course and outcome of children with HIV-1 infection and PCP.

Methods: Hospital admission of 19 HIV-1 infected children diagnosed with PCP between January, 1983 and December, 1987 were retrospectively reviewed.

Results: Eighteen children had perinatally acquired HIV-1 infection and one acquired infection in the neonatal period through blood transfusion. There were eleven females and eight males. Seven of these children presented with PCP as their first manifestation of HIV infection. The median age at onset of PCP was 3-6 months with a range from 3-60 months. Diagnosis was made by demonstration of the organism in specimens from endotracheal aspirates (8), bronchoalveolar lavage (6), biopsy (4), and autopsy (1). Elevated IgG levels and depressed numbers of T helper cells were the most common immune abnormalities present at diagnosis of PCP. All children received oxygen therapy. Eight patients were intubated and received assisted ventilatory support for a mean time of 31 days. (Median survival post-PCP was 10 months (range 3-53 months) for patients not requiring intubation and 1 month (range 2-11 months) in intubated patients. All but one of the children have died.

Conclusion: The early age of onset and the high mortality and morbidity associated with PCP in children emphasize the importance of early recognition of infants at risk and indicates a role for PCP prophylaxis.

T.B.P.154 GENERAL DYSFUNCTION IN PERINATAL HIV

McCarthy, Ellen, Jones S, Raju, N, Rhee R, University of New York Medical College, White Plains, New York, N.Y.

OBJECTIVE: To study the hypothalamic-pituitary-adrenal axis in HIV-1 infected children. **Methods:** 12 patients aged 8 months to 9 years (median 3.5 years) with HIV-1 infection were studied. All others were HIV-1 negative. **Results:** All others were HIV-1 negative. **Conclusions:** LIP is often associated with lymphadenopathy, hepatomegaly, failure to thrive, proctitis, bacteremia, bacteriuria and recurrent otitis media. Opportunistic infections are rarely associated. Mortality is significantly decreased as compared to overall Pediatric AIDS mortality of 57%.

AGE (yr)	ACTH (pg/ml)	Baseline	Post-stress	Post-stress	Post-stress
		Basal	Basal	Basal	Basal
1	11.1	14.0	14.0	14.0	14.0
2	11.1	14.0	14.0	14.0	14.0
3	11.1	14.0	14.0	14.0	14.0
4	11.1	14.0	14.0	14.0	14.0
5	11.1	14.0	14.0	14.0	14.0
6	11.1	14.0	14.0	14.0	14.0
7	11.1	14.0	14.0	14.0	14.0
8	11.1	14.0	14.0	14.0	14.0
9	11.1	14.0	14.0	14.0	14.0
10	11.1	14.0	14.0	14.0	14.0
11	11.1	14.0	14.0	14.0	14.0
12	11.1	14.0	14.0	14.0	14.0

CONCLUSION: Though the majority of patients (72%) demonstrated normal adrenal function, a significant number (28%) had abnormal function manifested by a blunted response to ACTH. Abnormal hypothalamic-pituitary-adrenal axis was associated with elevated ACTH levels.

T.B.P.155 BRONCHO-ALVEOLAR LAVAGE TO EVALUATE PULMONARY STATUS IN THE HIV INFECTED CHILD

Sanchez, Bayes, J., Buitel, L., Rodriguez, M., A. and Parks, W. UNIVERSITY OF MIAMI SCHOOL OF MEDICINE, MIAMI, FL, U.S.A.

OBJECTIVE: To determine the clinical course and outcome of children with HIV-1 infection and PCP.

Methods: Hospital admission of 19 HIV-1 infected children diagnosed with PCP between January, 1983 and December, 1987 were retrospectively reviewed.

Results: Eighteen children had perinatally acquired HIV-1 infection and one acquired infection in the neonatal period through blood transfusion. There were eleven females and eight males. Seven of these children presented with PCP as their first manifestation of HIV infection. The median age at onset of PCP was 3-6 months with a range from 3-60 months. Diagnosis was made by demonstration of the organism in specimens from endotracheal aspirates (8), bronchoalveolar lavage (6), biopsy (4), and autopsy (1). Elevated IgG levels and depressed numbers of T helper cells were the most common immune abnormalities present at diagnosis of PCP. All children received oxygen therapy. Eight patients were intubated and received assisted ventilatory support for a mean time of 31 days. (Median survival post-PCP was 10 months (range 3-53 months) for patients not requiring intubation and 1 month (range 2-11 months) in intubated patients. All but one of the children have died.

Conclusion: The early age of onset and the high mortality and morbidity associated with PCP in children emphasize the importance of early recognition of infants at risk and indicates a role for PCP prophylaxis.

T.B.P.156 UNUSUAL MORTALITY FROM PNEUMOCYSTIS CARinii PNEUMONITIS (PCP)

Chow, Jean; Shah, K. A.; K. Gupta, A.; Chhabra, L.; Kaul, A.; Greenough, J. F. Department of Pediatrics, New York Medical College, New York, USA.

Objective: Is PCP in early infancy universally fatal if no, what are the differences in the onset, course, and mortality compared to older children?

Methods: From 1984 to 1989, over 110 infants and children with HIV have been seen at 3 hospitals. PCP was confirmed in 15 children, from tracheal washings (3), lung biopsy (12), or to autopsy (1).

Results: 13/15 children were 6 months or younger. 13 previously healthy infants were thriving well. Associated physical findings included oral thrush (12), hepatomegaly (10), generalized lymphadenopathy (7), and perianal fever (13). They presented with acute respiratory illness which rapidly progressed to respiratory failure. Course in older children was more protracted. Antimicrobial therapy with TMP/SMX and/or trimethoprim was initiated in 14/15 children. Despite early and aggressive therapy, 11/13 infants expired at first presentation. One surviving infant died at 11 months of age. Both of the older children are alive at 2 years after PCP. Interestingly, lung biopsies in both the older children also showed lymphocytic interstitial pneumonitis (LIP).

Conclusion: PCP in early infancy can be a rapid and invariably fatal illness. Primary infection, not reactivation of latent infection. Prospective studies of antimicrobial prophylaxis of PCP may show the greatest benefit in first year of life.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

T.B.P.157

SEROEPIDEMIOLOGY OF HIV INFECTION IN AN URBAN PEDIATRIC POPULATION

Lalith Padmanab K, Joseph, S, Gerson, P, Gayle, H*

*Children's Hospital National Medical Center, George Washington University School of Medicine, Washington, DC and **Centers for Disease Control, Atlanta, Georgia, U.S.A.

Objective: To evaluate seroprevalence to HIV in children in a large, urban community with a high incidence of AIDS and drug abuse.

Methods: We conducted an anonymous, blind serosurvey on discarded blood samples from children aged 2-6 years who presented to outpatient and community-based outreach clinics served by our pediatric teaching hospital between 1/87 and 12/88. Demographic information from the surveillance study was compared to that obtained on age-matched seropositive, who were HIV tested for clinical indications. Parents of HIV seropositive children were contacted for consent for by limiting the enrollment age to 2-8 years, respectively.

Results: 4120 specimens were tested, 508 (2007) from males and 4013 (1763) from females. The overall sample had a mean age of 3.72 ± 2.53 years. All 8 seropositive were seropositive by EIA and 9 (2%) were repeatedly reactive. Western blots confirmed 6 of the 9 EIA for a seroprevalence of 1.57/1000. 3 were indeterminate. We suggest: 1) All HIV positive specimens were from black children, age 2.3-6.6 years (N = 524 ± 2.9), 1 male and 4 females from 5 clustered zip codes, while the 3 indeterminate were from black males with an average age 4.92 ± 1.8 years. Although the Emergency Room (ER) indicated for 50% of total specimens, 60% of positive or indeterminate specimens were from the ER. There were no positive specimens (0/51) among age-matched children tested for clinical indications during the same time interval.

Conclusion: HIV infection is present in 0.12% of urban children; a major source of identification is by presentation to the ER. Sequential analysis will define trends in the spread of HIV over time.

T.B.P.159

MATERNAL DRUG ABUSE AND PERINATAL HIV SEROPREVALENCE

Chechick, R.T., Hand I., Mignis, Andrew, Kim, M., Sobie, L., Tom, J. Albert Einstein College of Medicine, Bronx, N.Y. U.S.A.

Objective: Assess the prevalence of HIV seropositivity (+) in infants of drug abusing mothers (IDM) and HIV seropositive non-IDM (NIDM) mothers.

Methods: In a six month period in 1988, HIV antibody was studied by Elisa and confirmed by Western blot in 102 IDM with maternal consent. All infants were examined and maternal and neonatal data were compared in the IDM*, HIV+ infants and non-IDM control groups.

Results: In 1988, 3-15 of mothers were IDM (75/9437) compared to 12.85 (367/2866) in 1989, (p < 0.001). A 19.85% (30/151) incidence of HIV+ was higher than a 6.5 (5/78) in the non-IDM normal women (p < 0.1). As expected, the HIV (+) rate was higher in the 15 IV IDM than the 86 non IV IDM (50% vs 14%) (p < 0.001). There were no significant differences in race, maternal age or mode of delivery in the HIV+ and HIV- groups. Lack of prenatal care was similar as was the incidence of maternal syphilis. Maternal smoking, alcohol and drug use were also similar in these groups. Gestational age (37.5 vs 37.5) birth weight (3230 vs 3158), 12% rate (60/5 vs 23%) and 80% infants (30/3 vs 16%) and microcephaly (ECRDI: 205 vs 111%) were not significantly different in the above groups, though they differed from the general population (p < 0.001).

Conclusion: No neonatal factor were identified which could be attributed to HIV seropositivity. Decreased GA and BW and increased incidences of IUGR, OIA, and microcephaly may be due to maternal drug abuse, not HIV. Maternal IV drug abuse is a significant risk factor for HIV seropositivity. However, 60% of HIV mothers did not have any history of IV drug abuse. This suggests that heterosexual contact plays a significant role in the HIV transmission.

Pédiatrie : histoire clinique

Pediatrics: Natural History

T.B.P.161

CLINICAL & HISTORICAL FEATURES ASSOCIATED WITH PERINATAL HIV INFECTION IN LOS ANGELES COUNTY, CALIF.

Friedland, Tom*, Smith, L.L., Bess, M., O'Connell, J., Reynolds, L.,**

Kovacs, A.,** et al.
*Los Angeles County Health Dept., Dept. of Health Services,
**University of California Los Angeles, L.A., Calif., U.S.A.

Objective: To gain insight into the clinical and immunologic spectrum of perinatal HIV infection using data from a Los Angeles County (LAC) active surveillance program.

Methods: An active surveillance system for perinatal HIV infection began in 1986. Birth, clinical and lab data from medical records, HIV infected children was classified using the latest CDC classification system and whether they had serologic or immunologic abnormalities.

Results: As of 12/20/89, LAC had 139 cases of perinatal HIV infection. HIV (+) had AIDS, 38 (27%) had symptoms but not AIDS, 33 (24%) were seropositive, and 18 (13%) were indeterminate (difficult to see without virologic evidence of infection). About half of these cases (excluding the indeterminate) had immunologic data available. AIDS and seropositive cases differed on all serologic features. Among the AIDS cases, 76% had a T cell count < 0.004³, 100% had a T4/T8 ratio < 1.0, 60% had a CD4/CD8 ratio < 0.016³, and 40% had total IgG levels less than 1.0 mg/dl. Among those seropositive, only sero-2/3 cases had abnormalities as well; 65% had abnormal T4/T8 ratios, 30% had increased immunoglobulins, 2% had abnormal IgG concentrations.

Conclusion: The spectrum of clinical, clinical and immunologic abnormalities among HIV infected children is great. Detailed serologic and clinical data will better define the natural history of HIV infection in children with regard to clinical and laboratory parameters.

T.B.P.158

HIV INFECTION AND PEDIATRIC AIDS IN SEMI-RURAL DAROU PROTESTANT HOSPITAL (DROY COAST)

* Protestant Hospital, Darou, Ivory Coast ** Pasteur Institute, Abidjan, Ivory Coast *** CNRS Lab Faculty of Medicine, Alexis Carrel, Lyon, France

Within a year (Feb 87-Jan 88), 793 suspected cases of pediatric AIDS based on Burchard criteria and/or with severe malnutrition were tested for HIV-1 and HIV-2 by ELISA and then western blot. 73 (23.6%) had confirmed antibodies to HIV; 43 (57.9%) exhibiting HIV-1 reactivity, 4 (14%) HIV-2 reactivity and 4 (2.7%) double reactivity. No difference in symptom frequency was observed between these sub-groups.

Mothers of 68 positive children were also tested. In 88 cases (78%), the child infection probably originated from seropositive mother; in further 10 cases the mothers were positive but the children were transfused, so the origin of infection remained problematic in 8 children, the origin of infection remained unknown as their mothers were seronegative and the children did not receive transfusion.

The study of 100 sequential cases of pediatric severe malnutrition showed 14 cases of HIV positivity: 11 HIV-1, 2 HIV-2 and 1 HIV-1+2. The testing of 93 corresponding mothers showed that 19 were positive (21 having a seropositive child but 7 a seronegative one). Two children with seronegative mothers had been contaminated by blood transfusion.

Among 83 HIV positive children, 11 died during hospitalization, 16 were moribund at their discharge from hospital and 19 could be follow-up. Among those, one died within 10 months after discharge, 8 had an unfavorable evolution, but 14 exhibited improvement during a follow-up period of 3 to 6 months.

T.B.P.160

DIFFICULTIES ENCOUNTERED IN INFORMING THE PARENTS OF SERODIAGNOSIS OF HIV TESTING RESULTS IN AN URBAN COMMUNITY.

Minton, Andrew, Gaffrey, BC, Chechick, R., Therpe, A., Daley, T., Casper, M.S. Bronx-Lebanon Hospital, Bronx, New York, U.S.A.

Objective: To evaluate maternal compliance in infants at risk for HIV.

Methods: Bronx-Lebanon is located in the South Bronx, an area highly endemic for HIV infection (4-3% of pregnant women are HIV infected). Maternal consent to routinely sought to screen newborn whose mothers had identified risk factors for HIV. An appointment is scheduled for two weeks later to discuss the test results. Missed appointments are pursued by telephone calls and certified letters. Older children at risk, identified during hospitalizations, will child care or from outside sources are also screened with parental consent. All identified children are to be followed in an immunology clinic.

Results: Appointments to receive testing results were attended by only 32 of 114 mothers. These include 29 (25%) of the 101 HIV negative newborns and 3 of 13 (23%) infants with positive HIV serology in spite of multiple attempts to contact these mothers. In contrast, 21 of 23 (91%) of the older HIV infected children have been compliant with medical follow-up.

Conclusion: In this urban community, the rate of success in communicating HIV testing results to mothers of neonates is poor once that infant is discharged in spite of the mothers granting informed consent. A more rapid reporting of results and informing the mother prior to discharge may improve compliance with medical follow-up.

T.B.P.162

NEONATAL PERINATAL GENETIC MUTUAL HISTORY PROGRESS REPORT.

Goodman, Ed.,* Schrock, M., Denny, T.,* Octay, M.,*Ott, C.F.,* Glesne, J.,* et al., Children's Hospital of NO at

Emory School, Emory Univ., Atlanta, Georgia, U.S.A.

OBJECTIVE: In 3/87 a study of infants (INF) born to HIV infected mothers (MO) at a large hospital in New York was initiated to define the rate of perinatal transmission of HIV and the natural history of these INF.

Methods: HIV-1 MO who delivered INF are invited to participate. INF are prospectively monitored every month until, then every 2nd mo. up to, and every 3rd mo. thereafter. Clinical, immunologic, serologic and virologic data are collected at specified intervals.

Results: Forty seven INF born to 44 HIV seropositive MO. Mean age of MO = 29.7 yr (16-38); 93% black, 8% Hispanic, 38 white; 80% were IV drug users and 20% acquired HIV by sexual contact. At delivery 84 were asymptomatic, 108 ANC and 108 AIDS. Mean gestational age of INF = 36.5 wk (33-40); 19 were OIA and 6 were SIA. There were 29 INF that were followed for > 9 mo. Five INF were considered HIV infected: 3/6 had HIV cultures, 2/3 had HIV symptoms and died at 247 mo, 3/3 had HIV IgG and +P 24 IgG; both are well and one had +PCR and 1 + PCR. Of the remaining 24 INF, 8 are considered re-infectants while 16 are well but indeterminate. One of these infants died at 2 mo of complications of prematurity. Seven of 8 PCR assays on this group were negative and one positive. All 8 re-infectants are 17 mo INF.

CONCLUSIONS: While it is premature to determine transmission rate, it is significant that 93% of INF in this study are asymptomatic and 87% are not symptomatic. In general there was concordance between PCR and other parameters of infection.

Session d'affichage
Poster Session



Aspects cliniques
Clinical Aspects of AIDS

T.B.P-175 BEHAVIORAL CHANGES IN CHILDREN WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION. Lifshitz, Maria; Benson, C. Wilson, E. and Shaver, T.T., Baylor Coll. of Med., Houston, Tx, USA.
Objective: Common neurological manifestations in HIV-infected children include acquired microcephaly, developmental delay, and pyramidal tract signs. This is a report of behavioral changes in the HIV-infected girls.
Method: Longitudinal assessment includes immunological profile, head imaging by CT scan or MRI, and neurodevelopmental examinations.

Results:
Age last evaluation Patient #1 4/7/72 year 5/7/72 year
Source: HIV stage Transformation, P-I A Maternal, P-I A
Serology (+) EIA, W. Blot (-) EIA, W. Blot
Iq, ug/dl 2420 2850
Head imaging Normal Normal
McCarthy IQ score 97 90
The neurodevelopment of patient #1 was consistently average but she had onset of behavioral problems at age 31 yrs. A conduct disorder as per DSM-III R criteria was diagnosed based on fire-setting & deliberate destruction of other's property, and physical abuse to people. Patient #1 showed delayed development at 3 yrs., however, at 5/7/72 yr. intellectual functioning was low average with a deficit in visual-motor-perception. Distractibility was first noted at 3 yrs. and has progressed to attention deficit hyperactivity disorder (ADHD by DSM-III R) responsive to Ritalin.
Conclusion: Behavioral dysfunction in children with HIV infection may be a very early manifestation of CNS involvement. These preliminary observations may be relevant for treatment planning and indicate the need for inclusion of systematic behavioral along with neurodevelopmental assessment.

T.B.P-176 NEUROLOGIC FINDINGS AS THE INITIAL PRESENTATION OF HIV INFECTION IN PEDIATRIC PATIENTS

Yildirim, Zehra, F., Bask, H., Koc, S., Dalgic, D., Nariyari, R., Fischer, G.,** The Walter Reed Neurology Research Group, Walter Reed Army Medical Center, Washington, D.C., United States of America
*Uniformed Services University of Health Sciences, Bethesda, Maryland, USA.

Objective: To describe the variability in the acute presentation of neurologic disease in children with previously unrecognized HIV infection.
Methods: Retrospective review of all military-dependent children who were diagnosed with HIV at WMMC in the past 5 years.
Results: Twenty patients with HIV infection, 10-1 or 10-2, were seen at WMMC since 1987. Initial clinical presentation with neurologic symptoms as the presenting complaint occurred in 3 patients, as represented by the following 3 patients. One child with unrecognized perinatal HIV was diagnosed with stroke and CNS plaques at age 4 months, and was diagnosed as having CNS plaques. Another child with perinatal HIV had regression in developmental milestones within a year of the first, and was diagnosed with HIV seropositivity. Later, he developed rapidly progressive neurologic deterioration and died of HIV-induced primary CNS lymphoma. A third child with transfusion-acquired HIV was diagnosed well until age 4 years when he then began to develop ataxia, apathy, loss of speech and fine and gross motor skills, and regression of cognitive functions.
Conclusion: CNS manifestations of HIV disease in children may vary from already progressive encephalopathy to rapidly deteriorating processes that include opportunistic infections and CNS tumors. Physicians who care for children should consider HIV in the differential diagnosis of any child who presents with neurologic symptoms of undetermined etiology.

T.B.P-177 AIDS-RELATED PERIPHERAL NEUROPATHY IN CHILDREN AND YOUNG ADULTS: HEMOPHILICS
Kilgus, A., Whaley, A., Lewis, E., Beckman, D., Koenig, M., Wiersma, P., et al.
Neurology, "Pediatrics and Pediatric", University of California, San Francisco, CA USA.

Objective: To assess the occurrence of peripheral neuropathy in HIV positive children and young adult hemophiliacs.
Methods: A cross sectional study was conducted. Nineteen infants and children and 6 young adult hemophiliacs, all HIV positive were examined by a pediatric neurologist for clinical evidence of a peripheral neuropathy. Seven of the children, all on an ACT protocol, and 5 of the hemophiliacs had clinical AIDS.
Results: No clinical signs or symptoms of peripheral involvement were seen in any of the 27 patients. Additionally, electrodiagnostic studies (EMG/NCV) were performed on two of the children and were normal.
Conclusion: The absence of a peripheral neuropathy in children and young adult hemophiliacs contrasts greatly with its occurrence in 35% of adult hemophiliac AIDS patients. This lack of neuropathy correlates with the absence of a specific autoantibody described in patients with HIV-related peripheral neuropathy (accompanying abstract).

T.B.P-178 PSYCHIC DEVELOPMENT OF CHILDREN BORN TO HIV INFECTED PARENTS
A. Ostfeld, C. Ostfeld, F. Wiro, S. O'Neill, M. Shapiro, A.B. Lerman
Neuropsychiatry Service - Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA

Objective: To investigate the influence of environmental conditions quality of mother-child relationship and HIV infection status on psychic development of children born to HIV infected Italian mothers.
Methods: Psychic development (DQ) of children born to HIV positive mothers is evaluated 3-monthly using 1) development scales (Bayley-Scales, Bayley 2) psychometric observation of mother-child interaction. The development is considered altered when the difference between chronological and mental age is more than 3 months. The mother-child relationship was classified as "adequate", "partially adequate" or "inadequate" according to a qualitative scale. Social IQ data are evaluated with a special score. **Objective:** Inferiorly degree-determined children are identified according to the clinical course of the children (IQ criteria).
Results: 85 children were studied; 42 not infected, 43 infected, 18 HIV-infected. There is no significant correlation between infection status and development IQ (p<0.05). In both infected and not infected patients there is a correlation between a low IQ and inadequate mother-child relationship and a degree/unequal environment.
Conclusion: These findings suggest that the development of the children is more correlated to the socio-economic situation and to the quality of the relationship than to the clinical status.

T.B.P-179 NEUROPSYCHOLOGICAL PROFILE OF CHILDREN WITH SYMPTOMATIC HIV INFECTION PRIOR TO ANTI-RETROVIRAL TREATMENT.
Bismuth, Eric, Mose, H., Wolpert, P., Eddy, J., Pines, P. Pediatric Branch, National Cancer Institute, Bethesda, MD, USA.

Forty-one children with symptomatic HIV infection, ranging in age from 6 months to 18 years 10 months were evaluated with an age appropriate battery of neuropsychological tests at the Pediatric Branch, NCI. Children were tested when they were stable and free from acute illness. Twenty 12-18 year olds were tested through comprehensive tests of Motor Function (TRANS), Mean Clinical IQ, and Developmental Quotient (DQ) using the Wechsler Intelligence Scale (WISC-III) and the Bayley Scales (ages 6-17). Patients also completed a verbal memory test (WISC-III) and a nonverbal memory test (WISC-III). Although a somewhat higher incidence of abnormality was found in the HIV+ than in the HIV- group (60% vs 17%, p < .05, analysis of the verbal memory and IQ subtests), no significant differences in IQ (p > .10) between these groups. On the other hand, HIVCD patients had significantly lower IQs (p < .001) than the HIVACT patients. Most types of verbal memory and the TRANS group was associated by the different indices rate to neuropsychology. The WISC-III subtests profile in other patients revealed interactions when associated with Attention Deficit Disorder.

Analysis of the IQ subtests scores for all patients on the Wechsler Adult Intelligence Scale, a semi-structured interview administered to the child's parent or primary caregiver once more indicated an significant difference (p < .05) between the HIV+ and TRANS patients. After HIVCD patients had significantly lower IQ equivalent scores (p < .001) than HIVACT patients.
Correlations between cognitive variables and hematology, neurology, and immunologic measures indicated the relation between neurologic and cognitive tests and other variables comparing HIV+ to TRANS patients. One difference in age, different education level, and IQ score had to be administered to compare (TRANS as compared to other patients). Patients and family were assessed for participation in treatment protocols at NCI, which could lead to relative success. However, when the complete assessment, neurology, and immunologic measures were used, no differences were found of a more devastating effect of prenatally HIV infection on neuropsychological development.

T.B.P-180 NEURODEVELOPMENTAL ASSESSMENT OF CHILDREN WITH SYMPTOMATIC HIV INFECTION.
Hilakivi-Clayton, Pirita J., Gomez, N., Shover, F., SURT-SAC, Brooklyn, NY, U.S.A.

OBJECTIVE: To assess the neurodevelopmental outcome of 30 children with symptomatic HIV infection.
RESULTS: Thirty children attending Pediatric AIDS Clinic at University Hospital have received neurodevelopmental evaluation as part of their clinical care. Infants under 18 months of age were evaluated as the Bayley Scales; those over 30 months on the Stanford-Binet Intelligence Scales, the Peabody Motor Scales, and the Porteus Big Board. 10 Gordon Diagnostic Scales were used to test attention in children over 10.
RESULTS: The mean age of the children in this sample is 22.5 months with 20% being of the sample under 30 months of age. Ninety-three percent have been diagnosed as having AIDS. Only 3 or 10% are functioning within normal limits. All three are less than 18 months of age. However, all of the rest of the infants under 18 months of age were severely cognitively impaired. Thus being young with this disease does not preclude developmental disability. Over half the children were mentally retarded; 6% showed severe motor delays or a specific motor deficit. One-third of the children had a specific cognitive deficit, such as low IQ of intelligence. The two school-age children were in this range and had a learning disability.
CONCLUSION: Unlike the neurodevelopmental sequelae of HIV infection are severe, these children are living and entering school and will require special education.

**Session of Off-achage
Poster Session**



**Aspects cliniques
Clinical Aspects of AIDS**

T.B.P.181 DEVELOPMENTAL ABNORMALITIES AND SOCIAL BEHAVIOR OTHER CLINICAL MANIFESTATIONS OF PERINATALLY ACQUIRED HIV INFECTION IN RESPON- SIVE INFANTS

Kabagho, U.*; Mendenhall, R.*; Srinivasan, R.*; Elong, S.*; Duff, P.*; Mendenhall, R.*; Special AIDS Clinic, Johns Hopkins Univ. Sch. of Med., Baltimore, Md. 21205. **Objectives:** To prospectively evaluate cognitive, motor and neurologic development of infants with perinatal HIV infection. **Methods:** 21 children of HIV-infected mothers were followed up to age 12. Group I (n=11) had HIV-1 antibody positive mothers and HIV-1 antibody negative infants. Group II had HIV-1 antibody positive mothers. Group III had HIV-1 antibody negative mothers. Bilingual Bayley trials of Infant Development testing complemented monthly neurologic examinations. **Results:** Bayley Scores in children without AIDS signs/symptoms at the time of developmental testing

Group	1	2	3	Age 12 months	Age 18 months
Mean	77	81	87	84	87
SD	12	10	10	11	12
Group II	111	100	107	107	100
SD	11	10	10	10	10

(P)Psychometric Developmental Index; (M)Motor Developmental Index; (C)Cognitive Developmental Index. **Conclusions:** Developmental delay was not observed through the age of 18 months.

T.B.P.182 NEUROCOGNITIVE FUNCTIONING AMONG INFANTS EXPOSED PERINATALLY TO HIV

Staska, Thomas E.; Stone, G.B.; Cohen, D.L.; Carlson, R.G.; Park, A.D.; Parks, W.P. Department of Pediatrics and Neurology, University of Miami, Miami, Florida, U.S.A. **Objectives:** The impact of infant leukoencephalopathy (L) on neurocognitive functioning of later assessed neonates in high-risk populations, was assessed for in a prospective study exploring cognitive, perceptual, and neurological aspects of patients' HIV infection. This paper reports on our preliminary findings. **Methods:** The Pagen was administered cross-sectionally to 19 infants at either six, nine or twelve months of age, along with Bayley, neurological exam, and laboratory studies. Subjects were the offspring of HIV-infected mothers with no history of IV drug use. **Results:** The sample yielded a mean Pagen overall performance of 58.6% (SD=6.4). Two groups displayed abnormal patterns. Three infants were unable to maintain attention sufficiently to complete the test. Of those completing the test, four displayed abnormal recognition memory (overall < 54%). The results of the Pagen testing are outlined below.

Failed or incomplete Pagen	0	0	7
HIV+ Infected-mothers	0	0	7

Failed or incomplete Pagen: 1 1 10 12
The HIV-infected who failed the Pagen showed a consistent CNS involvement on the neurological exams and the Bayley. The one HIV-infected who passed the Pagen also had normal neurological and Bayley findings. However, 1 of the HIV-infected infants who failed the Pagen there was a lack of other abnormalities, with the exception of one infant who had a repeat Bayley. **Conclusions:** Three of four infants who potentially acquired HIV infection exhibited abnormal cognitive functioning as assessed with the Pagen, and consistent deficits in neurological and developmental examinations. Further descriptive studies based upon infant behavior, memory and cognitive functioning are warranted.

T.B.P.183 NEURODEVELOPMENT IN CHILDREN WITH HIV INFECTION ACQUIRED FROM DONORIAL BLOOD TRANSFUSION

Cohen, Sarah*.; Rudy, T.*.; Karasick, B.*.; Ward, J.*.; *Walla School of Medicine, *Cedars-Sinai Medical Center, Los Angeles, Ca. **AIDS Program, Cedars-Sinai Medical Center, Los Angeles, Ca.

Objectives: The purpose of this report is to examine the neurodevelopmental course of children who acquired HIV infection as neonatal transfusion recipients. **Methods:** Neuropsychological batteries were administered to 16 HIV positive children and to a control group of 33 HIV negative children who also received neonatal blood transfusion. Serial assessments were conducted 8 months apart by a psychologist who was uninformed as to the HIV status. **Results:** Scores on two batteries indicated that the HIV positive children were similar on most neuropsychological measures to the HIV negative group as long as 4-5 years after transfusion. The two groups did not differ in their overall intelligence. Deficits were observed in the HIV positive group in measures of school achievement, memory, and fine motor performance. There were no neurodevelopmental differences between the clinically asymptomatic, P1 (n=11) and the asymptomatic, P2 (n=5) groups. **Conclusions:** A high level of cognitive functioning may be maintained in children who acquired HIV infection as neonatal transfusion recipients. Neurophysiological deterioration observed was primarily in memory, attention, and fine motor behavior. Subtle differences in cognitive functioning may be an early manifestation of encephalopathy in HIV infected children.

T.B.P.184 DIVERGENCE OF ONSET OF NEUROLOGIC AND IMMUNOLOGIC IMPAIRMENT IN INFANTS EXPOSE TO HIV SERONEGATIVE MOTHERS

Calvello, Theresa*.; Bellino, A.*.; Burti, C.*.; Ombino, M.*.; *Albert Einstein College of Medicine, Bronx, N.Y., U.S.A.; **NYU at Stony Brook, Stony Brook, N.Y., U.S.A.

Objectives: To compare the onset of neurologic impairment with the onset of immunologic dysfunction in a prospective study of perinatally infected infants. **Methods:** Peripheral blood lymphocytes from 16 infants born to HIV-infected mothers were obtained during serial follow-up visits. HIV antibody was determined by ELISA and Western Blot. Seropositive subjects were determined by flow cytometric analysis of dual-color stained samples using whole-blood lysate methodology. Standard neurologic examinations were conducted at 3 month intervals. **Results:** Three of 16 infants were born neurologically and immunologically normal through 2-7 months follow-up. Of 8 infants with neurologic impairment ranging from mild developmental delay to severe cognitive and motor deficits, 3 showed early immune dysfunction indicated as early increasing CD4/T8 ratios and low total T cell counts. Two of 3 infants with mild neurologic dysfunction not accompanied by immune defects, developed immune abnormalities later. Five infants had normal neurologic exams, but showed immune dysfunction, including hypogammaglobulinemia, decreased total T cells, increased B cells, and decreasing CD4/T8 ratios. Three infants remain immunologically negative at 18-26 months, including the hypogammaglobulinemic child. **Conclusions:** Neurologic dysfunction can precede, or occur in the absence of, immunologic impairment in infants born to HIV-infected mothers. Conversely, immune can show severe immune dysfunction with totally normal neurologic exams.

T.B.P.185 ONSET OF NEUROLOGICAL ABNORMALITIES IN INFANTS AT RISK FROM DONORIAL BLOOD TRANSFUSION

Marcus, Joseph C.*; Butler, Ch.*; Hittelman, Jim.; Mendes, H.; Goedert, J.P.; Hilligoss, R.* et al. *MCH-MSD, Balyle, NY *MCH/MSD, Bethesda, MD, U.S.A.

Objectives: To determine the nature of neurological abnormalities in infants at risk of developing AIDS. **Methods:** The offspring of women at risk of developing AIDS—drug-abusers and prostitutes—were examined neurologically at birth, then prospectively in the first year of life and 6-monthly thereafter, by 2 neurologists blinded to their serological status. Twenty-three with persistent abnormalities were found. **Results:** Twenty-two infants showed varying degrees of speech delay, from 9 months to 2 years of age. Fourteen had abnormal hand function over 6 months to 18-2 years of age. Eleven had persistent primitive responses, 6 being cross reflexes. Of the 23, 6 are definitely infected, 7 have seroconverted, while 10 have HIV-negative mothers. The abnormal findings were noted in all 3 groups.

	Speech	Manual	Persistent Primitive Responses	Develop-mental Delay	Cross/Reflex Responses
Infected	6	4	4	4	5
Seroconverted	6	5	3	3	3
HIV-negative	10	6	6	6	6

Conclusions: It has been possible to establish a pattern of neurological abnormalities in infants at risk of developing AIDS, compared to their controls, not in those with any difference in the type of onset. However, at far, only one child has shown any deterioration or loss of established functions.

T.B.P.186 NEUROLOGIC IMPAIRMENTS IN PERINATALLY HIV INFECTED CHILDREN. A PROSPECTIVE STUDY

A. Iannone, J., Ed. Metro A., *Naples, K., *Raga, E., *Bastello F., et al. Department of Pediatrics, "Gaetano Capone" University of Palermo, Italy.

Objectives: To study the neurological manifestations in children born to HIV positive mothers. **Methods:** All children born to HIV positive mothers in high risk groups are clinically and neurologically evaluated at birth and at 3 monthly intervals. The Brunet-Leslie scale is administered to all children at 30 of age and Bayley Revised test to the other patients every 3 months. The infected children only undergo CT scan, EEG, CT study every year of writer if clinically suspec-

Results: Currently 15 children (median age 10.5, range 3-10 months) are infected, 42 are not infected (median age 24, range 0-30 months) in an intermediate (median age 6.0, range 1-13). 4 of the infected children died of AIDS; 2 without any sign of neurological involvement, 1 had progressive encephalopathy and 1 primary brain lymphoma. Included "early" neurological signs (spasticity, rigidity, sensory deficit, unilateral pupillary dysfunction, tremor) were found in 5 out of the other 11 children and in 11 every 10 of 42 not infected ones (X², p<0.05). None of the infected patients had CT scan abnormalities nor developed macrocephaly. We also compared the developmental score obtained at the last evaluation in infected and not infected children. The mean score in the infected was 61.52 and in the not infected 61.52 (p<0.05 Mann-Whitney test). **Conclusions:** Our preliminary results suggest that neurological and developmental abnormalities do not occur early in the course of vertical HIV infection.

Session d'affichage Poster Session



Aspects Cliniques Clinical Aspects of AIDS

Pédiatrie : marqueurs Pediatrics: Markers

T.B.P.216

SOFTY DETECTION OF HIV INFECTION IN CHILDREN.
Salleh, I., Muzaffar, M., Husein, M., Saeed, F., Yusof, F., Zeman, S., & Corbett, V.
*Hospital Unit, Fencotek Hospital, 8, Anson Road, Singapore 1100. *Hospital, Institut La Paz, Madrid, Spain.

It is unclear the feasibility of the anti-HIV detection in children of HIV-seropositive mothers, as the maternal antibodies and the p24 antigen (p24Ag) remain in children for a mean time of 8-10 months. For this reason it is necessary to develop new diagnostic techniques for the early identification of the parent HIV infection in these children. With this purpose we have studied the presence of anti-HIV IgM in 17 children less than 1 year old (14: 1 male) born to 15 mothers born from anti-HIV positive mothers, and we have compared it with the anti-HIV detection in blood-serum and with HIVAg by ELISA. HIVAg was detected in 14 of total DNA isolated from the PBMC, by slot-blot hybridization using a p18-300-20 probe.

Anti-HIV was found in 15/17 (88%) of the children, circulating HIVAg was present in 2/18 (11%) and HIV-DNA in 4/17 (23%) of them. Out of the 14 HIV-DNA positive cases, 2 children (13 months old) presented anti-HIV in the HIVAg was undetectable, 1 child had anti-HIV and also HIVAg positive, while in the remaining child (15 months) these markers were negative. All of them were seropositive.

In conclusion: 1) The absence of HIVAg in children under 1 year old could indicate that these children do not have HIV infection and the anti-HIV antibodies are from their mother. 2) HIV-DNA detection allows the early diagnosis of HIV infection in asymptomatic children even without other viral markers. However, these preliminary results will be completed with a dynamic study in a wider population.

This work was supported by the Comité Activo de Madrid.

T.B.P.218

IGM SERUM-LAGS CONCENTRATIONS AND ANTIBODY LEVELS TO MATERNAL TORCHES IN CHILDREN WITH HUMAN DEFICIENCY VIRUS (HIV) INFECTION.
McLennan, S., Hunter, R., Dwyer, S., Vines, B., Wainwright, P., Fletcher, M., Alvarez, S., Belmont, D., Hershkov, S., Nordberg, A., & O'Brien, J. W. (CNS Laboratory, Frankfurt (Main) FRG)

Infection with HIV results in a combined immunodeficiency. As a result of serological B-cell activation there is a significant increase in the serum immunoglobulin levels. The specific humoral immune response is, however, usually impaired. We have investigated to what extent the levels of IgG subclasses undergo change as a result of HIV-infection. In the period from January of 1987 to January 89 we carried out an investigation of immunoglobulin subclasses in a total of 27 children exposed to HIV. Of these children 14 had proven HIV-infection, 13 (aged over 18 months), who had been previously HIV-antibody positive, have remained negative up till the present time and have shown no clinical and immunological signs of HIV-infection. No patient was given intravenous IgG therapy before or during the investigation. The immunoglobulin, alpha-1 and lambda antibody levels of our patients were compared to a healthy control group of 150 children of different ages. IgG subclasses were also noted in a random immunoglobulin, antibody levels to tetanus (TT) and diphtheria (DT) toxoids by enzyme immuno assay. Levels below 1:100 are considered not to be protective for both - in this group of 13 previously HIV-antibody positive children (10 HIV-antibody negative, normal IgG antibody levels were found. In contrast, 13 of 14 HIV-positive children showed a significant increase in serum IgG and IgG1; 3 of whom additionally showed elevated IgG2 levels. 8 of 10 HIV-positive children showed protective antibody levels to TT and 8 of 10 HIV-IG. All non-infected children had protective antibody levels to TT, but antibody levels to DT were not protective in 4.

We conclude that IgG subclass serum profiles are a frequent finding in HIV-infected children especially a polyclonal increase in IgG1 and IgG2. Longitudinal observation is necessary to determine whether the development of an IgG2 subclass deficiency is an additional indication for intercurrent immunodeficiency. Supported by Ministry of Health (BMFG), BRG.


T.B.P.220

SEROLOGIC RESPONSE TO HIV INFECTION IN INFANTS.
Johnson, John P., Davis, K., Shinsberry, R., and Hair, P.
UNIVERSITY OF Maryland School of Medicine, Baltimore, MD, USA

Objective: To document the antibody response to HIV infection in neonates. Methods: Blood was obtained from 35 children born to seropositive women at 2, 4, 6, and 12 months. Serum was assayed using the DuPont HIV ELISA and P24 antigen and IgG antibody tests. HIV RNA was detected using Strip Gene-Technica and sequential addition of biotinylated anti-IgG (M1) or IgG1 or IgG2 followed by biotin-avidin HRP, and then DAB.

Results: Children showed increasing anti-HIV IgG, and P24 antigen was detected in 7 children. The IgG1, anti-p120 IgM and anti-p24 IgM were found in 5, 2 and 4 cord blood specimens respectively. Paired sera from 3 mothers showed weakly positive anti-p120 IgM and anti-p24 IgM bands. At 2-month follow-up, 2 infants developed additional anti-p120 IgM bands. One infant has been followed for over 8 months. Her anti-HIV IgM bands disappeared and was replaced by weakly positive anti-p120 IgG.

Conclusion: The kinetics of loss of maternal antibody and the class specific anti-HIV antibody positive infants demonstrated in neonates.



T.B.P.217

DETECTION OF SPECIFIC IGM ANTIBODY BY RADIOIMMUNOPRECIPITATION ASSAY FOR EARLY DIAGNOSIS OF HIV INFECTION IN INFANTS
Zhou, Y., Michelson, J., Lacombe, C., Clinebarr, J., Suman, S., and M. Lapointe**

*Laboratoire de santé publique du Québec, **Institut Armand-Frappier, Université, Michelson, J., Lacombe, C., Clinebarr, J., Suman, S., and M. Lapointe**

Objective: To evaluate Igm-specific HIV antibody (Ab) by radioimmuno-precipitation assay (RIA) in infants born to seropositive mothers as a tool for early diagnosis.

Methods: Sequential sera from 5 HIV-infected infants were analyzed by standard RIA with protein-A-Sepharose and by RIA-IgM. For the latter, CMI-activated Sepharose 4B was coupled with purified monoclonal Ab to human p24-IgM. Samples were incubated with anti-sepharose beads and washed. (125I)-HIV antigen was then added. Bound proteins were separated by SDS-PAGE and revealed by autoradiography. Specificity of Igm reactions was tested after serum adsorption on IgG-coated beads or with anti-IgM IgG.

Results: Igm Ab to pp 120/120 and p24 were detected in 15/21 sera from all 5 infants. Comparison of Ab patterns observed with standard RIA and RIA-IgM revealed that anti-HIV Igm appeared at 2 to 13 months of age. After disappearance of maternal Ab and parallel to p24Ag synthesis, Igm Ab persisted for 26-30 months in 3 children. RIA-IgM reactivity was still observed after removal of rheumatoid factor or IgG.

Conclusion: Detection of Igm-Ab did not allow early diagnosis of HIV infection in the first 6 months of life. Further studies are required to determine the specificity of Igm reaction in older infants.

T.B.P.219

WESTERN-BLOT QUANTITATIVE : HIVI DES MOUVEMENTS-DES VIH SEROPOSITIFS
Schivini S., Paul Jacquelin, Rousseau A., Gaye-Margelle C., Laboratoire de Virologie, CHU Purpan, Toulouse, FRANCE

Objective: Etudier la cinétique des différentes spécificités Ac anti-VIH avec le Western-blot (WB) quantitatif chez un enfant né de mère séropositive.
Méthode: Nous avons étudié une enfant née le 10.11.87 de mère séropositive, et qui a été de 2 ans et 2 mois toujours asymptomatique. Le WB quantitatif (Du Pont de Nemours) consiste en une lecture densitométrique des bandes réactives, perceptible par l'obtention d'une courbe une quantification précise de chaque p24 et p31; les résultats sont exprimés en intégrales représentatives de la surface des différents pics. Les titres d'Ac totaux (Epreuve Diagnostique Pasteur) sont déterminés par comparaison de la densité optique de l'échantillon à celle d'une gamme étalon.

Résultats:

Titres Ac	gp120	gp120	p26	p55	p31	p31	p31	p24	p17
20.00.87	30000	4110	1214	2258	7859	1763	12778	15217	18530
22.05.87	3000	3721	1938	859	604	1012	7171	3044	2829
16.11.87	500	1950	276	276	0	0	0	0	881
10.01.88	100	531	0	0	0	0	0	0	0
22.09.88	100	0	0	0	0	0	0	0	0

De la 1e au 2e mois, le réactif des toutes les spécificités Ac distinctes, parallèlement à la diminution des anticorps anti-VIH1 totaux. A 1 an 11 mois anti-VIH (ELISA) sont nuls; seuls en WB quantitatif, les Ac gp120 persistent.

Conclusion: Ces données confirment la grande sensibilité de WB quantitatif.

T.B.P.221

THE USE OF ANTI-HIV IGM IMMUNOLOGY IN THE DIAGNOSIS OF NEONATAL HIV INFECTION : A REPORT OF 5 CASES.
Pantova, Vajana, Sivichikova, S., Chanderpedarek, S., Likhonina, S. and Panchal, B.

Chulalongkorn University Hospital, Bangkok, Thailand.

Objective: To evaluate the reliability of anti-HIV Igm immunology in the diagnosis of HIV infection in babies of HIV-infected mothers.

Methods: Paired maternal and cord blood from 5 babies at Chulalongkorn University Hospital from HIV-infected intravenous heroin abusing mothers were studied. Anti-HIV Igm immunoblot was modified from Pasteur commercial kits by changing the enzyme conjugates to rabbit anti-human Igm, followed by peroxidase labeled avidin-biotinylated goat anti-rabbit Igm.

Results: All newborns were anti-HIV positive at birth due to the transplacental transfer of Igm antibodies as evidenced by the identical patterns on Igm immunoblot. Using commercial ELISA kits from diagnostic Pasteur could not be detected in any mothers or babies at birth. Anti-p160 anti-gp120 Igm and anti-p24 Igm were found in 2, 2 and 4 cord blood specimens respectively. Paired sera from 3 mothers showed weakly positive anti-gp120 and anti-p24 Igm bands. At 2-month follow-up, 2 infants developed additional anti-gp120 Igm bands. One infant has been followed for over 8 months. Her anti-HIV Igm bands disappeared and was replaced by weakly positive anti-gp120 Igm.

Conclusion: Our preliminary study indicates that immunoblot can be successfully used anti-HIV Igm to detect early HIV infection in newborns. Our results indicate that transplacental HIV infection has occurred in all 5 babies studied.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

T.B.P.222 IS THE IgM ANTIBODIES STATUS A USEFUL MARKER TO ASSESS THE IMMEDIATE CONTAMINATION BY HIV-1 ?

Guyot-Besauge, J., Dal, Jacqueline, Tricore, J., Rousseau, A.
Laboratoire de Virologie, CHU Purpan, Toulouse, FRANCE.

Objective. Realisation of an early diagnosis of congenital or neonatal transmission in order to initiate an immediate therapy against HIV-1.
Methods. We tested IgM antibodies in 53 neonates born to intravenous drug abusers (MAD) heterosexually contaminated (M7) and "unknown" mothers (M2) using the Western-blot assay (Du Pont ELISA-III Western blot IgM). The test was performed at birth and/or during the clinical and biological follow-up of the neonates (mean 14,5 months). The test was considered positive when antibodies neonates (mean 14,5 months) were present. The results of the test were compared with the infants' parameters (clinical status, p24 antigenemia, anti p24 antibodies titers and HIV antibodies persistence beyond 18 months) and the mothers' parameters (clinical status and HIV-1 antibodies titers at the delivery).

Results. We could form 3 groups : the first included 28 children who were always IgM negative, the second group included 15 IgM positive children at a given time, and the third, 10 children with borderline results of the test at a given time. In the IgM positive group 9 children were diseased (class P2), 4 children had clinical signs and 6 were healthy. Nevertheless, statistically significant difference was present between the mother of IgM positive and IgM negative diseased children ($p < 0.05$ with Fisher-Fisher Test).
Conclusion. The results indicate that the IgM screening may be useful as a supplementary marker in the assessment of the children contamination by the HIV-1.

T.B.P.223 EXAMINATION OF PERIPHERAL BLOOD ANTIBODY-SECRETING CELLS AS A DIAGNOSTIC AID FOR HIV INFECTION IN CHILDREN

Neuhoff, A., Lee, J., Hehner, A., De, C., Walter, J., and Side, B. Depts. of Pediatrics and Pathology, Emory University, Atlanta, GA, USA

Objective: To evaluate the enzyme-linked immunospot (ELISPOT) for diagnosis of HIV infection in asymptomatic children and infants born to seropos. mothers.
Methods: The ELISPOT, using anti-HIV-1 p24 antigen protein, was applied to peripheral blood mononuclear cells (PBMC) obtained from 31 negative children, 28 children with ARC/AIDS, and 27 infants born to seropos. mothers between 1985 and 1988; 18 IgM and p24 antigen assays were also obtained.

Results:

	tested	anti HIV ASC*	+ HIV ASC
A Children with ARC/AIDS	28	20 (71%)	8 (1 with agamma.)
B Infants born to seropos. mothers	27	6 (22%)	2
C Control children	31	0	31 (100%)

HIV ASC positivity ranged from 8 to 22 per 1 million PBMC. Of the 8 ASC children born to seropos. women (all still alive), one was ASC positive at 1 1/2 yrs of age, the earliest time of ELISPOT testing in all groups (A-C), when repeated in 3 infants, the assay was positive in all three, who are now asymptomatic. In four ASC asymptomatic infant had virus pos. amniotic fluid in utero. Of the 21 ASC- children, 15 have been repeatedly ASC- and 6 are no longer alive. All infants in group B have been p24 antigen negative.
Conclusion: This rapid (24 hr.) assay, which can be performed on archived or frozen cells, appears to be specific, although its sensitivity could be enhanced by methods under current study. The HIV ELISPOT could prove particularly helpful in the early diagnosis of HIV infection in children.

T.B.P.224 RECOVERY OF HIV FROM LYMPHOCYTES AND MONOCYTES

OF EPIDEMIOLOGIC HIV INFECTED CHILDREN. **Lindau, Alan, J.†**
Chicago, Ill., U.S.A. and **Chandler, Robert, M.†**
Medical Center, Chicago, Ill., U.S.A. and **Childs, Memorial Hospital,**
Northwestern University, Chicago, Ill., U.S.A.

Objective. Correlation of immunologic and virologic findings with clinical status in perinatally HIV-infected children.

Methods. HIV antibody (Ab) and antigen (Ag) status was determined by commercial ELISA procedures. CD4 and CD8 lymphocyte analysis was performed by a whole blood lysis procedure and analyzed by dual parameter flow cytometry. HIV co-cultures were performed by adding peripheral blood mononuclear cells (PBMC), purified lymphocytes, or purified monocytes to PHA-stimulated lymphocytes from HIV negative donors or allogeneic monocytes. Viral growth was detected by an antigen capture assay.

Results. Ten symptomatic children (3P2A, 7 P2B-7) ranging in age from 1.5 to 9.5 years were evaluated. Nine of ten were Ab+ and seven of ten were serum Ag+. Five of the ten patients had <1000 CD4 cells/mm³ while the CD8/CD4 ratio in nine of ten children was >0.5. Eight of ten individuals were culture positive by day three in the BSC as well as in purified lymphocytes. In contrast, co-cultures of purified monocytes and allogeneic monocytes was still negative at 14 days.

Conclusions. Viral cultures were positive in the majority of symptomatic children with perinatal infections. The clinical stage of disease and immunological parameters did not correlate with viral isolation. It seems that at least in the early phase of culture, HIV grows more readily from lymphocytes.

T.B.P.225 NEOPTERIN - POTENTIAL EARLY MARKER OF PERINATAL HIV INFECTION

Lindner, Harold M.† **Reagers, Dm.†** **Kaplan, Sh.†** **Treanor, CD,†**
Shandley, Lm.† **Levine, David A.†** **Christophers, Betsy for Childs,**
Philadelphia, PA.† **Ortiz de la Cruz, M.†** **De, New Jersey, Camden, NJ, USA.**

Objective. To test the hypothesis that neopterin (N) levels can differentiate infected from non-infected infants and children infected with HIV in mothers.
Methods. N was determined by 125I radioimmunoassay (DGE, Berlin) in 58 serum and/or EDTA plasma specimens from 40 children of HIV-infected mothers 1 to 39 mo of age and control specimens. N/B was taken as >2 SD above adult mean.
Results: Mean N levels in uMol/l are shown by CDC diagnostic class as follows:

	N ± SD	n	with Ab
Probably not infected (HIV antibody negative)	6.3 ± 2.1	17	0
CDC P0 (asymptomatic - HIV cultures pending)	9.9 ± 4.4	15	15 (3 3 ug)
CDC P1A or B (infected - asymptomatic)	19 ± 4	2	2 (all Ab)
CDC P2A (infected - "ARC")	8 ± 3	4	1 (11 ug/ml)
CDC P2B, C, and/or B (infected - "AIDS")	37 ± 19	7	7

N levels in replicate specimens obtained 3 to 9 months apart were usually in 11 of 18 pairs within one SD range (1.1 ug/ml) of replicate assays on the same specimen. In 4 HIV-infected infants and one infected 3 yr old, rises of 5 to 19 ug/ml were observed. In 2 infants, low antibody negative, falls of 6 to 8 ug/ml were observed. In levels were high (24 ± 11) in presumably normal, uninfected cord sera, but appeared to reach adult levels by 1 mo of age.

Urine N levels appeared to be less discriminatory than plasma levels.
Conclusion: The pilot data support the hypothesis for asymptomatic infants only, suggest that N levels may be useful in staging perinatal HIV infection, and indicate that a hypothesis (Ciba Annual Newsletter 9:159, 1988) that N release occurs in primary HIV infection deserves investigation in infants.

T.B.P.226 HIGH PREVALENCE OF HIV-SPECIFIC IgM AND IgG-SPECIFIC IgM ANTIBODIES IN MONOES OF HIV-POSITIVE MOTHERS

Schubert, G.† **Wunderli, V.†** **Isid, C.†** **Serafin, K.†**
Stumpfiger, A.† **Tomasik, K.†**

* Swiss National Centre for HIV Research, Institute of Immunology and Virology, University of Zurich, Zurich, Switzerland

† Institute of Immunology, University of Zurich, Zurich, Switzerland

** Swiss Neonatal HIV Study Group, Department of Neonatology, Kantonsspital, St. Gallen, Switzerland

Objective. To analyze the specificity of Western blot (WB)-reactive IgM and IgG in cord blood.

Methods. Cord blood of 21 babies of HIV+ mothers was tested for HIV-specific IgM or IgA by WB. Prescreenings of IgG with immobilized protein A or G were done to determine whether reactions were mediated by HIV-specific IgG or IgA, or by other antibodies bound to HIV-reactive IgG of maternal origin.

Results. Initial IgM reaction was present in 15 sera (71%). Removal of IgG showed that 80% of these IgM were directed against maternal HIV-specific IgG. IgA reaction was present in 10 sera (48%) absorption of IgG indicated HIV specificity in 8 (80%). Most IgA reaction was seen only after removal of bulk IgG. Absorption with immobilized protein G was better than with protein A. Antigen was present in 10 in a case negative for IgM or IgA.
Conclusion. Most HIV-WB-reactive IgA are indeed HIV-specific; most HIV WB-reactive IgG are specific not for HIV, but maternal IgG.

T.B.P.227 PROSPECTIVE STUDY OF POLYMERASE CHAIN REACTION FOR

EARLY DETECTION OF HIV INFECTION IN INFANTS BORN TO HIV

ANTIBODY POSITIVE WOMEN

Weisbuch, P. Ulrich, F. Edwards, J. Ramsey, C. Vyas, G. Gowan, Morlan, et al.

University of California, San Francisco, California, USA

Objective. To determine the applicability of polymerase chain reaction (PCR) for early diagnosis of HIV infection in high-risk infants.

Methods. All infants referred for prospective evaluation who were 35 months of age and in HIV antibody positive women were studied. HIV-1 RNA was amplified using a 2 distinct gag specific primer pairs were performed on crude PBMC (frames for 35 cycles. Hybridization in solution to a P22-derived oligonucleotide probe was followed by ethylenediamine gel electrophoresis and autoradiography. Specimens were tested at least twice with each primer pair. HIV cultures were performed on all specimens by standard co-culture technique.

Results. Thirteen infants were tested at a mean age of one month. Three infants were positive by PCR for every amplification. Only 2 of these were HIV culture positive. Three infants were equivocal by PCR (<100% positive amplification). All 5 were HIV culture negative. All 7 PCR negative infants were also HIV culture negative. No patient was HIV culture positive and PCR negative. All patients are well (mean age 6 months) and being followed.

Conclusions. PCR is applicable for the early detection of HIV infection in high-risk infant and appears to be more sensitive than standard co-culture technique. Long-term follow-up is essential to determine if PCR positive and equivocal infants who are culture negative are truly infected or represent lack of specificity.

Session d'affichage
Poster Session



Aspects cliniques
Clinical Aspects of AIDS

T.B.P.228 HIV p24 ANTIGEN ASSAY AS A DIAGNOSTIC/PROGNOSTIC TEST IN PEDIATRIC HIV INFECTION. Silve, Tso, J. Olson, S., Simpson, B.J., Andiman, R.L. Yale University School of Medicine, New Haven, CT, USA

Objective: To learn if HIV p24 antigen (Ag) detection tests can be used to diagnose infection in children or to select mother at risk of transmitting infection.
Methods: We examined sera from a group of children born to HIV seropositive (HIV) women as part of an ongoing prospective study of pediatric AIDS. We used a commercially available p24 capture immunoassay (Abbott) to screen 109 serum samples from 66 children and from 48 of their mothers were also examined. "Infection" was defined by CDC criteria.
Results: Five of 66 children of HIV women and 3 mothers were Ag+. Seven of 8 infected children were Ag+, but only 12 of 19 individual samples were Ag+. One of 41 seronegative children was Ag+. Upon the incidence of anti-p24 in mothers and children was compared we found that 92 of Ag+ mothers had Ag+ children and that only 1 of 6 children who met CDC criteria for infection had an Ag+ mother. Only 2 of 9 instances the inverse relationship between Ag and p24 antibody detected by Western blot did not exist. Antigenemia occurred at a higher rate in seronegative/infected than in seropositive/uninfected children. The p24 Ag assay failed to identify 1 of 8 children with symptomatic disease. The p24 Ag assay was positive; in 2 cases, serial tests may be needed to identify an Ag patient.
Conclusions: The clinical utility of a single negative p24 test is low. It does not classify a child as uninfected and it does not predict a more benign disease course. A negative Ag test in a mother does not accurately indicate that her child will be Ag+.

T.B.P.229 SERUMELISA IN PERINATAL STUDY OF HIV INFECTED MOTHERS AND THEIR CHILDREN SINCE THE NEONATAL PERIOD AGE. PÉREZ ALVAREZ, M.D., GARRIDO, M., GARCÍA, M., GONZÁLEZ-SANFELIX, J.A., VILLALBA, A. INSTITUTO DE SALUD CUBANA, HOSPITAL GENERAL PEDAGÓGICO INFORMATIVO, HAVANA, CUBA

Objective: Serological follow up of HIV antibodies in mother-child pairs since birth and the analysis of the evolution of the bands against the different viral proteins by WB technique.
Study of the potential usefulness of the P-24 Ag analysis as a supportive marker of neonatal infection.
Methods: Since January 1988 we have studied 10 pairs mother-child (average 3-6 months since the first course of life. Serum samples were tested by different EIA methods: IgA and Western Blot, and P-24 antigen was detected by ELISA. Infection has been attempted by co-culturing peripheral blood lymphocytes.
Results: All the mothers are intravenous drug addicts and HIV-All the children are asymptomatic in PO stage. In relation with the sequential analysis until now, 4 children turned seronegative but in other 4 there was a gradual development of the bands detected by WB. The final and complete data will be available at the end of the study now in progress. P-24 Ag was detected only in one mother whose child turned seronegative at the age of 12 months. Until now the virus isolation has been negative in all cases.
Conclusions: It would be possible to confirm the presence of HIV infection in the early 13 months period by the serial analysis with WB of the sera of children of mothers HIV- and the detection of P-24 Ag, although the final diagnosis at this age involve the virus detection, re... It is very useful the virus isolation from lymphocytes and the DNA detection.

T.B.P.230 COMPARISON OF THE ORTHO HIV RECOMBINANT ANTIGEN NEUTRALIZATION ASSAY AND DUPONT WESTERN BLOT FOR CONFIRMATION OF ELISA REACTIVE SERA FROM CHILDREN. Frost, Anna*, Mahla, C.†, Luban, N.† and Cannon, J.† *George Washington University Hospital, Washington, DC, USA, **Children's Hospital National Medical Center, Washington, DC, USA.

Objective: To compare the performance of the HIV Recombinant Antigen Neutralization Assay (RANA) (Ortho Diagnostic Systems, Raritan, NJ, USA) and the HIV Western Blot Kit (WB) (Dupont Company, Wilmington, DE, USA) as confirmatory test of HIV ELISA repeatedly reactive sera from high-risk children.
Methods: RANA uses a pool of recombinant core (G24), polymerase (G31) and envelope (Gp12) antigens for neutralization of HIV antibodies in ELISA positive sera. Dilutions of these sera were added to the antigen mixture and incubated for 16-18 hours at 37°C. The ELISA reactivity (Urbant HIV EIA, Abbott Laboratories, North Chicago, IL, USA) of each recombinant serum was determined and compared to an unrecombinated control. A reduction in absorbance by ≥40% constituted a positive test. WB was performed and interpreted according to the manufacturer's instructions.
Results: All 34 study sera were positive by RANA (mean neutralization 72%), and 25 (74%) were positive by WB. Nine sera (26%) yielded indeterminate WB results. Of the nine, 6 were tested for HIV antigen (Orbont HIV II Antigen EIA) and 4 were positive. None of the HIV ELISA repeatedly reactive sera collected from our high-risk population during the study period was RANA or WB negative.
Conclusions: RANA is a sensitive, objectively interpreted confirmatory test of HIV ELISA seropositivity in high-risk children.

T.B.P.231 A NOVEL HIV I EIA DETECTS IgG AND IgM ANTIBODIES IN INFANTS AND NEONATES. Baccard-Longere, M.†, Blanc, Sylvie**†, Genoulas, C*†, Giroud, M†, Seignourin, J.M*†

*Département de virologie, A. Michallon Hospital, BP 217 X, 38043 Grenoble Cedex France. **Hellice Diagnostics, 15000 Paris Cedex 12, FRANCE.
Objective: To study the utility of the HelliceWise HIV Recombinant EIA in HIV diagnosis, and in particular its ability to detect IgM antibodies in infants.
Methods: The EIA was initially evaluated on 4000 sera and 500 positive samples, including 12 sera from individuals at the beginning of sero-conversion. IgM antibodies were isolated by sucrose gradient centrifugation and their presence confirmed by Western Blotting.
Results: The assay's specificity is near 100%. No false positives were detected. In the negative samples, nor in 25 samples known to give falsely positive results in other EIA, all the positives samples were detected, including those from sero-conversion whose blots would not yet have been declared positive. Presence of antibodies to P24 and GP160 or indeterminate, and a specimen in early sero-conversion for HIV 2. IgM was detected in 25/35 samples, and in the stored samples 1 of 2. Infants known to have been infected perinatally (cord blood was IgM negative) but not in non-infected of infants of sero-positive mothers.
Conclusion: This EIA is specific and sensitive - useful for routine detection of early sero-conversion in adults and neonates as well as for routine screening.

T.B.P.232 IgM MAY BE DETECTED TO CONTEMPORANEOUSLY BEFORE EARLY IN SEROCONVERSION TO HIV. Robert, Gagner*, Math, G*, O'Keefe, Bethesda, NY *McGraw-Hill, Inc., Health Research, CT, USA.

Objective: To determine if the apparent insensitivity of a whole virus immunoblot (WB) to early anti-HIV IgM in seroconversion is due to a function of cross-reactivity available in that assay.
Methods: Anti-HIV detection by WB (DuPont) and a recombinant gp120, gp41 (Orbont) were compared using class-specific anti-human IgM conjugates. Parallel assays were performed with a EIA using native or S26, S26-detached proteins coated in equal amounts to 96-well plates.
Results:

Subject	DuPont WB status		MaxGenWB status	
	Anti-HIV	Anti-IgM	Anti-HIV	Anti-IgM
1	NEG	POS	NEG	POS
2	NEG	POS	NEG	POS
3	NEG	POS	NEG	POS
4	NEG	POS	NEG	POS

In seven O.D. values were lower for duPont than for native EIA. In seven bleeds of 3/4 subjects, the values actually fell below cut-off. **Conclusions:** We demonstrated increased reactivity of the WB to the WB due to improved detection of early IgM responses with dual-length reagent recombinant proteins were so low (less than 0.6). The parallel EIA study clearly showed that duPontation reduced signal strength. These results suggest that conventional assays may be important for IgM detection; therefore that are lost in WB format. These observations may be important in improving early antibody detection and in evaluating vaccines.

T.B.P.233 HYPERGAMMAGLOBULINEMIA AND HYPOGAMMAGLOBULINEMIA AS MARKERS OF HIV DISEASE IN PERINATALLY INFECTED CHILDREN. Calvello, Thomas; Steinhauser, R.; Nathan, R.; Dwyer, V.; Narasain, L. and Binneman, A. Albert Einstein College of Medicine, Bronx, New York, U.S.A.

Objective: Diagnosis of HIV infection in children born to HIV positive mothers can be complicated as a result of infant's B cell dysfunction seen after disappearance of maternal antibody in our experience, 8% of children presenting with seropositivity consistent with HIV infection show negative or equivocal ELISA and Western blots.
Methods: To ascertain whether the absence of reactivity in HIV antibody tests in HIV infected infants was due to (1) an inability to produce immunoglobulin, or (2) an inability to form specific antibody response, serum from each child was assayed for IgG concentration. Standard rapid immunofixation assay was employed.
Results: Eight of 20 HIV infected but serologically negative children were found to be hypogammaglobulinemic. None of these yielded an unequivocal positive specific HIV antibody test on multiple drawings through 1 year of follow up. Thirty percent were found to have normal serum IgG concentration, and 19% were low normal; of these, 1 eventually seroconverted. Three were hypergammaglobulinemic. None of these were seroconverted for as long as 1 year of follow-up (up to 3 years of age).
Conclusions: Negative or equivocal antibody tests in children who are perinatally infected with HIV can be the result of at least 2 distinct manifestations of B cell dysfunction. Some children, despite their ability to produce IgG, are unable to mount a specific antibody response to HIV; others may also be hypogammaglobulinemic.

Session d'afichage Poster Session



Aspects cliniques Clinical Aspects AIDS

T.B.P.234 ASSOCIATION BETWEEN PLASMA HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 (HIV) VIREMIA AND CLINICAL CLASS OF PEDIATRIC HIV INFECTION
Buzich, S., Goebel, R., Chaloupek, E., Stanescu, J., Wilson, C., Corey, L., St. Et. University of Washington, Seattle, WA, USA.

Objective: To develop sensitive virologic markers predictive of asymptomatic and symptomatic pediatric HIV infection.

Methods: Sequentially obtained samples from 12 HIV infected children as they progressed from CDC classification P1 to P2 and from 13 P0 children were analyzed. Plasma or peripheral blood mononuclear cells (PBMC) from 3 ml of blood were cultured CH_4 d. P24 antigen (Ag) in culture supernatants or in plasma/serum was determined by ELISA antigen-capture (Abbott).

	Quart 1 Diagnosis		Quart 2 Diagnosis	
	Partial	Transfusion	Partial	Transfusion
n	4	4	4	4
Age mean (mo.)	0-18	96	12	82
PMBC range	0-18	2-36	0-36	84
FBMC	4/5	4/5	5/5	2/2
Plasma	0/4	0/5	5/5	2/2
Ag	2/4	2/4	5/5	1/1

All P0 children remained asymptomatic. FBMC culture neg. and Ag neg. **Conclusion:** HIV PBMC culture and Ag were highly sensitive (98%) for detecting infection. While Ag was associated with both P1 and P2 infection (pmW), HIV plasma viremia was only associated with P2 infection (p<0.003). The association between plasma viremia and asymptomatic stage of infection suggests there is an increased amount of replicating HIV associated with advanced clinical disease. Plasma viremia is a potential endpoint for evaluating both progression of disease and antiviral therapy in the pediatric population.

T.B.P.236 LYMPHOKINE AND IMMUNOGLOBULIN PRODUCTION IN VITRO IN NEONATES AND INFANTS WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION
Petro, Cecilia; Herson, I.C., Herson, T.A. and Snaver, K.T. Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA.

Objective: To assess early immune parameters in HIV neonates and infants. **Methods:** Interleukin-2 (IL-2) was measured using an IL-2 dependent cell line (C11) after stimulation with PHA and augmentation with recombinant IL-2 in placental (Con 1) and infant (Con 2) controls and HIV neonates and infants. Immunoglobulin production after PHA stimulation and 7 day incubation was measured in affected children and described controls.

Results: HIV infants studied were Group 1, < 6 weeks (asymptomatic) [+], infected with cytomegalovirus (CMV) [-] and Group 2, > 1 year [-] [+]. IL-2 results are reported as units/ml (mean±standard error).

	Group 1 (n=6)	Group 1 (n=2)	Group 2 (n=3)	Group 2 (n=2)
PHA [50ug/ml]	0.11±	0.01	0.17±	0.14±
	0.08	0.05*	0.08	0.12*
IL-2 [5000u/ml]	1.32±	None	1.97±	1.34±
	0.68*		1.49	1.49

* p less than 0.05

IgG production after PHA and PHM-IL-2 stimulation was negligible in Groups 1 and 2 and Con 1 compared to adult controls. IgG production was high in 3 infants in Group 2 alone.

Conclusion: IgG production in vitro for HIV neonates and infants is not different than expected neonatal results. IL-2 production was decreased except in those infants with concurrent CMV. Monitoring IL-2 production with clinical correlation may detect subtle immune changes in HIV children.

T.B.P.238 DETECTION OF SECRETORY ANTIBODIES TO HIV IN NEONATES
Azzolini, S., Davis, E. & Johnson, S. University of Maryland at Baltimore, Baltimore, MD, U.S.A.

Viral-specific, non-maternally derived secretory IgA (sIgA) antibodies have been demonstrated soon after birth in certain infections. sIgA to HIV antigens has been detected in infected adults. We collected serum and saliva from 21 children (ages 7 to 48 months) born to women at risk for HIV infection to investigate the presence of HIV-specific salivary IgA. sIgA was ascertained by one or more of the following: a rise overtime in serum ELISA titre, development overtime of IgG antibodies to new HIV antigens, positive p24 antigen or PBW culture, or demonstration of serum IgA by Western Blot (WB) to 2 or more different classes of HIV antigens. Salivary samples were obtained by passive droplet collection using a modified WB. Saliva from 7 of 10 infected children, including one aged 6 months, demonstrated IgA class antibodies to HIV envelope antigens; 4 of the 7 also showed sIgA antibodies to other HIV antigens. The 3 sIgA negative infected children all demonstrated decreasing or absent serum IgA and IgG responses to HIV at the time of saliva sampling. Six of 6 children born to healthy mothers were IgA negative. Five children (3 to 6 months) with indeterminate HIV status, born to infected mothers, showed no virus-specific sIgA. We did they show serologic evidence of HIV infection. HIV-specific sIgA was detectable at 2 months of age and may prove to be valuable in the diagnosis of HIV infection in children born to infected mothers.

T.B.P.235 DETECTION OF HIV SEQUENCES IN CHILDREN BORN TO SEROPOSITIVE MOTHERS.

Sorghi, F., Vanni, Selleri**, L., Lavi*, G., Frigieri**, G. De Rienzo*, B., Torricelli*, G.
Department of Infectious Diseases, Dept. of Internal Medicine and Hematology** Dept. of Pediatrics***, University of Modena, Modena, Italy.

Purpose: Early detection of HIV infection in children born to seropositive mothers is now possible utilizing the polymerase chain reaction (PCR). **Methods:** PCR was performed on DNA extracted from PBMCs of children born to seropositive mothers as described by Saiki et al. using the SK 68 - SK 69 primers and the SK 70 primer, homologous to the HIV envelope. Clinical condition of the children were assessed following the criteria of Brunetti-Lazini and Bayley, and by immunological and virological tests.

Results: 13 children have been followed from birth, all were born to seropositive HIV mothers. All children were seronegative at the moment of DNA extraction. The loss of maternal anti-HIV Ab IgG occurred in 10-19 months after birth. None of the children was clinically or immunologically immunocompromised. The PCR was performed in 4 children (age 12-36 months) apparently healthy. Age of onset of the enzyme (measured by the SK 68 and SK 69 primers) occurred in all 4 cases.

Discussion: The PCR is an early diagnostic test for HIV infection in children and it can offer a precious tool as serological diagnosis is not possible in newborn children for several months after birth.

T.B.P.237 EARLY DETECTION OF HIV-1 SEROCONVERSION IN INFANTS OF SEROPOSITIVE MOTHERS USING SERIAL DILUTIONS IN WESTERN BLOTTING.
Bernstein, P., Alexander, G. P., Young, M., Giordano, L., Mank, H.**, and Frederick, W.*** Howard University Hospital, Washington, DC. U.S.A. *Johns Hopkins Laboratories, Baltimore, Maryland, U.S.A.

Objective: To determine if serial dilutions in Western blot (WB) assay can distinguish HIV-1 seroconversion from passively transferred maternal antibody (Ab) in infants born to seropositive mothers.

Methods: Sequential serum samples collected at 3-month intervals on 17 male and 9 female infants were tested by standard ELISA (EIA). Samples were also tested for HIV-1 Ab using serial dilutions of 1:100, 1:500 and 1:1000 in a standard WB assay (Biochem), and for p24 antigen (Ag) by EIA (Abbott). Polymerase chain reaction (PCR) was performed on lymphocytes from 12 infants.

Results: All infants were seropositive at birth by EIA and WB assays. Among infants who later became seronegative (8), the mean age from birth to non-reactivity was 9.8 mos. Serial serum dilutions in WB demonstrated disappearance of significant maternal Ab with emergence of infant Ab patterns typical of seroconversion in 10/16 infants at a mean age of 7.4 mos. At this age no difference was observed in Ab reactivity using standard EIA and WB assays between the 7 seroconverters and the remaining 19 infants whose sera were still reactive by standard WB assay (1:1000 dilution), but who later became Ab. Among the seroconverters, p24 Ag was detected just prior to seroconversion in 4 infants. PCR was positive in only 3. Currently 1/7 has AIDS; 2/7 have AIDS.

Conclusions: Serial serum dilutions in WB assay detected seroconversion in infants of seropositive mothers at an earlier age than standard EIA and WB assays. P24 antigenemia preceded HIV seroconversion. PCR positivity did not correlate strongly with seroconversion in our study.

T.B.P.239 ANEMIA AND HYPERBILIRUBINEMIA IN INFANTS WITH PEDIATRIC HIV INFECTION
Nahly, Gregory; Barton, N. and Madlin, J. Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.

Objective: To determine whether hematologic abnormalities or hypochromic microcytosis are early indicators of HIV infection in infants born to HIV infected mothers.

Methods: Complete blood counts and immunologic concentrations were obtained from 20 five to nine month old infants born to HIV infected mothers and who were either seropositive or had nonspecific clinical signs and symptoms. These laboratory values, as well as aspects of the clinical history, were compared between the 8 infants who eventually met CDC criteria for HIV infection and the 12 infants who seroconverted.

Results: A significantly lower mean hematocrit value (32.8) was found for the infants who later met CDC criteria for pediatric HIV infection compared to the infants who seroconverted (37.0). Elevated mean immunologic levels were also noted in infected infants (infected IgG = 2840, IgA = 309, IgM = 268; seroconverted IgG = 491, IgA = 27.3, IgM = 43).

No aspect of the history could explain these differences. **Conclusion:** Unexplained anemia or hyperbilirubinemia in an infant with indeterminate CDC class P-0 HIV status strongly suggests the presence of HIV infection.

Session d'affichage Poster Session



T.B.P.240 ELISA (E) AND WESTERN BLOT (WB) RESPONSES AND A POSSIBLE SOURCE OF ANTIBODIES IN INFANTS BORN TO SEROPOSITIVE (SP) MOTHERS.

Hendes, Hecmaro, S.**, Madsen, J.**, Weiberg, J.**, Skiffing, K., Landeman, S.**, et al.***, SUN-HOBI, Copenhagen, N.D., *New York State Lab, Albany, N.Y., **HUSK, Bethesda, Maryland, USA.

OBJECTIVE: To describe HIV serological responses and to identify predictors of infection or HB in infants born to SP mothers.

METHOD: Pre and post-partum maternal sera, and infant sera collected at birth and at 3 months intervals, were frozen and later tested by E (Dupont) and WB (Cisprison-Pentlabs) against known controls.

RESULTS: Sera from 32 mother-infant pairs (infants' mean age: 10.3 mos; 6.9 specimens per child) were available. Generally, the infants' initial WB patterns reflected the mothers' pattern. By clinical and lab criteria, 9/28 infants were infected; 9/9 had serially positive (D) E, 1/9 became non reactive (NB) before developing AIDS. WB of infected infants showed fading of bands with subsequent increased reactivity and appearance of new bands. In 23 of the remaining 23 infants a WB E preceded a WB NB mainly due to fading but persistent anti-p24. In 4/23 (ages 15, 20, 20, and 20 mos) WB was equivocal; seroconversion occurred in 14/19 before 15 mos, and 5/19 after 15 mos of age. Once E and WB became negative all infants remained negative. An anti-glyco band was present in the maternal serum and the infant's first WB in 14/19 (74%) seroconverters and in 2/9 (22%) infected infants (p<0.001).

CONCLUSION: The presence of anti-glyco detected late in pregnancy and in the newborn, may be a marker of subsequent seroconversion.

T.B.P.242 EVALUATION OF THE WESTERN-BLOT IgM TECHNIQUE SPECIFICITY Duret-Mengelle C., Rousseau A., Paul Jacquelin Laboratoire de Virologie, CHU Purpan, Toulouse, FRANCE

Objective: Evaluation of the western blot IgM technique specificity.

METHOD: During the clinical screening of seropositive drug abusers women (N=67) and infants born to seropositive mothers (N=20) we investigated the IgM status by the Western blot assay (Du Pont HTLV-III Western blot IgM). The test was considered positive when the presence of antibodies against the p24 protein could be detected. When the IgM antibodies were present, the specificity of the reaction was checked by comparing the results before and after elimination of the rheumatoid factor by the "RF Sorbent" (Behring Laboratory) and after the IgG-IgM separation by elution through DEAE cellulose micro-columns.

Results: Although IgM antibodies were detected in 35 serum specimens, the specificity could be tested upon 24 sera only. In all cases the obtained results were identical. In 13 cases the results were dissociated: 3 sera were negative after the elimination of the rheumatoid factor that could give a false positive result with the two first techniques. 9 sera were negative after elution through the micro-column. The dilution of the specimens during this treatment could explain this negativity. 1 serum was negative after both: the result obtained for the serum before treatment could probably represent a false positivity.

Conclusion: IgM antibodies were really present in 20 sera. Thus the specificity of the Western-blot technique is high (83,33 %) and it can be a useful test in the neonates follow-up.

T.B.P.244 EARLY DIAGNOSIS OF HIV-INFECTION IN CHILDREN BORN TO SEROPOSITIVE MOTHERS-ORITICAL EVALUATION OF NEW DIAGNOSTIC APPROACHES.

De Biasi A., Madori A., Diavataio G., De Mistro A., Mammone F., Zaccarello F., DiCorleone R., et al.

*Institute of Oncology, Dept. of Pediatrics, University of Padova, Padova, Italy

Objective: Develop a protocol for early diagnosis in children born to HIV seropositive mothers. Correlation between diagnostic results and HIV infection status.

Methods: Children born to seropositive mothers were studied at birth and/or to the first months of life for the following parameters: 1) In vitro production of antibody, 2) antipneumonia in sera, 3) virus culture assays, and 4) DNA amplification by polymerase chain reaction using specific primers for gag and env HIV genes.

Results: In a series of 101 children, 64 were repeatedly negative for all parameters and 18 were constantly positive; in 19 cases the results were discordant among different tests. Nine than one year follow-up of the negative children later confirmed that all, but one who developed AIDS at 6 mos. of age, were not infected. 10 of the 18 positive children developed AIDS or AIDS related states. Among the discordant cases, several patterns were observed, and the 4 parameters were variately positive and negative, in different combinations.

Conclusions: Analysis of the data provided the limits of the simple diagnostic procedures, and also reflected the different status of HIV infection; interestingly, 2 asymptomatic seronegative, but HIV infected children, were identified.

T.B.P.241 SEQUENTIAL WESTERN BLOT PATTERNS IN CONFIRMED HIV SEROPOSITIVE INFANTS

Laban, Naomi L.; Criss, V.C.; Joseph, S.; Mohla, C.; and Campos, J.M. Children's Hospital National Medical Center, George Washington University School of Medicine, Washington, DC, USA.

Objective: To follow western blot patterns over time in confirmed HIV seropositive infants and compare loss of specific bands with the Centers for Disease Control classification of disease.

Methods: One hundred eighty-five serial serum specimens were collected at approximately 3 month intervals from 37 confirmed seropositive infants (<24 months of age) and tested for ELISA reactivity (Abbott HIV EIA, Abbott Laboratories, North Chicago, IL, USA), western blot (DHY Western Blot kit, Dupont Company, Wilmington, DE, USA) and HIV antigen (Abbott HTLV III Antigen EIA). Each infant also was evaluated according to the Centers for Disease Control classification scheme for pediatric AIDS.

Results: Eight of the 37 infants (21.6%) became western blot negative during the study period, at a mean age of 16 months (range 12-23 months). Nine of the infants remained western blot positive; 3 of the 9 were HIV antigen positive. Twenty of the infants became western blot indeterminate; 6 of the 10 had class P2 disease, and 5 of the 6 were HIV antigen positive. Inconsistent western blot patterns were observed in these 5 infants over time and among siblings.

Conclusions: Western blot indetermination patterns are common in infants with HIV disease. Resembling and/or disappearance of specific bands in serial western blot from confirmed HIV seropositive infants are not as prognostically useful as reported in adults. The definition of "indeterminate" may need to be redefined in infants with potentially acquired HIV.

T.B.P.243 MONITORING OF HIV ANTIBODY PROFILES BY RIFA AS A MEANS OF DIAGNOSING INFECTION IN INFANTS

Laboulaye M., Lapostolle J., Masmouni J., Delagrèe G., Delagrèe N., Bouchevarot, C.

*Laboratoire de santé publique du Québec, **Hôpital Ste-Justine, Montréal, Québec.

Objective: In an ongoing prospective study of HIV perinatal infection, radioimmuno-precipitation assay (RIPA) was evaluated for its ability to differentiate de novo synthesis from passively transferred antibody (Ab). RIPA was also compared with virus isolation and HIV antigen (Ag) detection for early diagnosis.

Methods: Fifty-two sera obtained at each visit from 9 asymptomatic mothers and 6 infants were tested for HIV-Ab by RIPA and for HIV-Ag with a commercial EIA. Isolation was carried out by co-cultivation of PHL with cord blood lymphocytes and was monitored by RT activity and HIV-Ag detection. **Results:** Sera of 6/9 mothers revealed Ab profiles against all labeled HIV polypeptides by RIPA. Virus was isolated in 4/7 women. HIV-Ag was demonstrated in only one. Initial sera from infants did not show Ab profiles different from those of their mothers. Analysis of sequential sera obtained up to 9 months of age revealed decreased reactivity to selected polypeptides, indicating loss of maternal Ab. Virus was isolated from 3 symptomatic infants (at 14, 4, 2 and 5 mo), but not from 3 asymptomatic ones. HIV seropositivity was observed in only one asymptomatic infant.

Conclusion: Our preliminary results suggest that virus isolation is a more sensitive indicator of HIV infection than Ab or Ag detection. Comparison of Ab profiles in sera of women at birth and their offspring did not allow early diagnosis of HIV infection in infants.

T.B.P.245 INTÉRIEUR DE LA MISE EN CULTURE SYSTÉMATIQUE DU VIH CHEZ LES ENFANTS NÉS DE MÈRES INFECTÉES

Fleury, Hervé J.A.; Delord, B.; Douard, D.; Perel, Y.***

*Laboratoire de Virologie, CHU de Bordeaux et Université de Bordeaux II, Bordeaux, France, **Services de Pédiatrie et Néonatalogie, CHU de Bordeaux, Bordeaux, France, *** Service de Pédiatrie, Centre Hospitalier de la Côte Basque, Bayonne, France.

Objective: Comparer les résultats de la mise en culture systématique du VIH sur sérum d'enfants biologiques et cliniques dans une cohorte prospective de mères infectées.

Méthodes: Les cellules mononucléées du sang circulant d'enfants nés de mères infectées par le VIH 1 ont été systématiquement mises en culture et le virus VIH 1 éventuellement produit a été détecté par son activité RT et la présence de l'antigène de Core p24. Les résultats de l'isolement ont été comparés aux données de l'antipneumonie TCD4, de la cinétique des anticorps anti-VIH 1 (ELISA et WB), de la numération des lymphocytes TCD4, du dosage sérique des immunoglobulines et de l'état clinique.

Résultats: Nous distinguons deux groupes: 1) Un où l'isolement viral est négatif et dont les autres données biologiques et cliniques indiquent qu'il s'agit d'un cas d'infection virale; 2) L'autre (3/30 des enfants) où l'isolement est positif et corrélié par un ou plusieurs paramètres pédiatriques (antipneumonie élevée, augmentation des immunoglobulines, signes cliniques... etc.). **Conclusion:** L'isolement systématique du VIH chez les enfants nés de mères infectées demeure une technique de base indispensable à l'établissement d'un pronostic.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

Pédiatrie : Infection/Neoplasie Pediatrics: Infection/Neoplasia

T.B.P.258

EXPERIENCE WITH CENTRAL VENOUS CATHETERS IN PEDIATRIC AIDS

OBJECTIVE: Children with AIDS are at high risk for infection and malnutrition. Frequently receiving intravenous fluids for antibiotics and nutritional support. We undertook this study to determine the course and complication rate of central venous catheters (CVCs) when used in a pediatric AIDS population.

Methods: Retrospective chart review of 289 HIV infected children in Newark, NJ (1982-88).

Results: 2126 children who received catheters had charts available for review and received 35 catheters. All 28 and 68 CVC defined AIDS (EBS with CD4 <400). Mean age at insertion was 28 mo. (10 w. - 11 yr.). Mean duration of placement was 115 d (28-400) for a cumulative total of 4846 days. In 2373 courses, children were able to go home, with family training and nursing support, for a mean duration of 72 d. There were no catheter related deaths. Sixteen catheters were removed for technical problems. Of all failed attempts (15) evaluated during catheter placement, 21 documented catheter related infections occurred. Ten bacterial episodes were successfully treated with catheters remaining Organisms: 4 staph, 3 strep, 3 gram neg. Eight catheters were removed because of inability to clear the infection (organisms: 3 candida, 3 staph, 3 strep, 3 gram neg.). Of 3 local infections, one local infection was successfully treated and 2 catheters were removed for exit site infections with pseudomonas. These 16 bacteremic episodes represent 4.3/1000 days of catheter use.

Conclusion: Our infection rate with bacteria in children with AIDS (4.3/1000) compares favorably with previously documented infection rates in pediatric oncology patients (1.3-7.3/1000). Catheters can be safely used at home for outpatient antibiotic and nutritional therapy in this high risk population.

T.B.P.259

NEOPLASTIC DISEASE IN CHILDREN WITH AIDS. S. K. Goyal, M. D., M. Comer, F. Starita, L. S. Epstein, S. M. Blinn. Departments of Clinical Pathology and Pediatrics, The Children's Hospital, University School of Medicine, Newark, NJ, and Children's Hospital of New Jersey, New Jersey Medical School, Newark, NJ, USA.

Objective: To describe the incidence and types of neoplastic diseases (ND) in children with AIDS.

Methods: Ninety (35 cases) male/female (18 cases) material from 102 HIV infected children.

Results: Seven cases showed ND. The risk factor in five of the cases was parental IV drug use. In 2 cases HIV was ascertained via transmission of blood or blood products. In 2 cases, ND was the first major evidence of HIV infection. In 1 it was part of a complicated course and in 2 it was found at autopsy. Following types of ND were observed: 1) peripheral neuroangioma (2 cases); 2) lymphoproliferative disorder (PLD) characterized by involvement of lymph nodes, spleen, adenoids, liver and parotid gland (brain lesion was not involved) case; 3) testis represented progression of pulmonary lymphoma; hyperplastic lymphoid interstitial pneumonitis; PLD in intercostal space; interstitial in biologic behavior between benign and malignant lymphoproliferation; 2) multiple lymphoma involving only the brain in 2 cases; 4) squamous carcinoma of gastrointestinal tract (4) primary tumors extending from stomach to colon, with metastasis to lymph nodes, brain and liver in one case; 4) epiphyseal sarcoma of skin of arm, nose and prostate in a child with metastatic squamous cell infection.

Conclusion: HIV associated ND may be more common than previously reported and may occur at any point in the symptomatic course.

T.B.P.260

SAFETY AND EFFICACY OF CENTRAL VENOUS CATHETERS IN PEDIATRIC AIDS PATIENTS

OBJECTIVE: Children with AIDS are at high risk for infection and malnutrition. Frequently receiving intravenous fluids for antibiotics and nutritional support. We undertook this study to determine the course and complication rate of central venous catheters (CVCs) when used in a pediatric AIDS population.

Methods: Retrospective chart review of children with CDC-defined AIDS (P2D) who had CVC placed due to inadequate venous access.

Results: The medical records of 11 pts (7 males, 4 female), ages 3 mos to 12 1/2 yrs (mean=7 mos) were reviewed. Risk factors included blood transfusions in 10, perinatal exposure in 6 pts. Mean absolute granulocyte count (AGC) at the time of CVC placement was 3083/mm³, with 3 pts having an AGC of <1000/mm³. Mean CD4 cell %s were 24.3%, with 10 pts having CD4 <4500/mm³. No morbidity or mortality was associated with the CVC operative procedures. Thirteen CVCs double lumen, 1 single, 3 totally implanted were placed for a total of 1812 CVC days (mean=164 days/CVC). The 13 CVCs were used for the following: parenteral nutrition-12; IVIG-1; blood products-12; other medicines-11; blood draws-11. Four episodes of CVC-related sepsis (3 pts) occurred; 22 infections (100 CVC days) resulting in removal of 3 CVCs. Klebsiella, Enterobacter species and S. Eptidermidis were isolated from individual CVCs. Three CVC occlusions (radiographically confirmed) occurred, 2 of which spontaneously resolved, 1 which required operative CVC revision.

Conclusion: The ease and types of CVC infection in children with profound HIV related CD4+ cell deficiency approximates that seen in pediatric oncology pts. CVCs proved valuable in pts requiring multiple therapeutic interventions.

T.B.P.261

HIV INFECTION (HIV) IN PATIENTS (PTS) TREATED FOR LEUKEMIA OR SOLID TUMOR. A. Pediatric Oncology Group (POG) Study

OBJECTIVE: To determine the incidence and sequelae of HIV infection in patients treated for leukemia or solid tumors.

Methods: A retrospective chart review of children with CDC-defined AIDS (P2D) who had CVC placed due to inadequate venous access.

Results: Ten of 74 responding institutions reported a total of 19 HIV infected pts (14 leukemias, 5 solid tumors; 12 boys, 7 girls; age 10 mos-20 yrs.). Thirteen pts were diagnosed off-therapy, 6 pts on therapy. Sixteen pts acquired HIV post-transfusion. Three pts with congenital AIDS developed B-cell leukemia before the age of two. A correlation exists between number of cases by institution and geographic HIV seroprevalence. The median interval between transfusion and diagnosis of HIV was 20 mos (range 5 wks-6 yrs.) between transfusion and death was 30 mos (range 2 mos-18 yrs.). 18/19 HIV pts developed AIDS, one remains asymptomatic. 12/19 have died (CD4 < 80). Two pts are being treated with ZV or AZT.

Conclusion: (1) No true seroprevalence was available; (2) A correlation existed between HIV, geographic area and number of transfusions; (3) HIV status appeared not to affect tolerance of chemotherapy; (4) the natural history was different from lymphomas but similar to other transfused pts; (5) Testing with consent form, counseling, follow-up and therapeutic guidelines is recommended for pts transfused in high seroprevalence areas.

T.B.P.262

VERY LATE ONSET OF GROUP B STREPTOCOCCAL SEPSIS IN INFANTS WITH HIV INFECTION.

OBJECTIVE: To describe characteristics of Group B streptococcal (GBS) disease in HIV infected children.

Methods: GBS disease (documented in 2/200 (1-8) of HIV infected children diagnosed at the University of Maryland and NY Medical Center. Charts were reviewed to describe clinical features, course, and outcome of GBS disease.

Results: GBS patients were 2, 5, 8 and 5 months of age respectively. Each had evidence of HIV infection as well as immunologic dysfunction including low T-cell counts and poor mitogen responses. All had fever > 100F, elevated WBC's ranging from 10,000 - 20,000, and marked left shift. Two presented as meningitis with bulging fontanelle, irritability, and seizures. Both had CSF pleocytosis and + CSF cultures for GBS. One presented with tachypnea, rales, apnea, and radiographic evidence of bilateral pneumonia. The course of each patient was unusually complicated. All 3 responded to IV beta-lactams.

Conclusion: GBS disease (meningitis and pneumonia) occurred beyond the usual age of onset in HIV infected children. Despite immunologic dysfunction and severe GBS disease these patients mounted PNH cell responses and improved with beta-lactam antibiotics.

T.B.P.263

DIARRHEA AND ITS CONSEQUENCES IN HIV-INFECTED CHILDREN.

OBJECTIVE: To determine the incidence, etiology, and sequelae of diarrhea in children with HIV infection.

Methods: Children with AIDS and AIC (16) were prospectively enrolled and serially evaluated. When a physician was made for diarrhea, a whole stool or rectal swab was examined for bacterial enteropathogens, protozoa (with special media), mycobacteria, viruses, and Clostridium difficile toxin.

Results: During the first 11 months of therapy, the incidence of diarrhea was 0.13 episodes per child-year, which is 2.6 times the incidence we observed in seronegative children born to HIV-infected or high risk women (mean age 7.2 > 6.2 months). Four cases were hospitalized because of diarrhea, and one case with salmonellosis died. Two cases had recurrent (> 3) episodes/year and one had persistent (> 14 days) diarrhea. Wasting (weight for height < 5th percentile) was seen in 4 children.

Conclusions: Diarrhea is a major cause of morbidity in HIV-infected children and occurs at a rate that is 2.7 times higher than the reported incidence in uninfected children. A potentially treatable infectious etiology can be detected in almost all children.

Session d'effichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

T.B.P.264

BRUNETT LYMANNA IS AN HIV-INFECTED CHILD.
R. Cassill, R. Aziz, J. Deina*, E. Michelson*, A. Rescardou, P. Lescarot*
Dept. Pediatrics, *Infectious Diseases, University of Paris, Italy

HIV infection in children is infrequently complicated with malignancy: Kaposi sarcoma (KS) then TB, a few cases of malignant brain lymphoma, an case of Burkitt lymphoma (BL) are reported. We describe B. in a 2-year-old white female, born to drug abuse seropositive mother, uninfected because of fever, anorexia, interstitial pneumo. HIV seropositivity, failure to thrive, enlarged lymphnodes, liver and spleen above evident than 3-month-old. Persistent interstitial pneumonia until the age of 18 months. During the next 6 months pallidness, hyperpneumothorax, recurrent CNS and HIV seropositivity persisted (positive according to CDC). In admission she was febrile, poorly nourished with dyspnea and generalized lymphadenopathy; her abdomen was protuberant and tender. Liver margin at 11 cm, spleen 9 cm. WBC 13,700/ml (85% NE, 10% LY, 5% MO, 1% E), IgM 1010 µg/ml, IgG 1110 µg/ml, IgA 100 µg/ml, CD4-78%, CD8-28%, CD4:CD8 ratio near HIV antibodies in ELISA and R. blast (12/23-33-35-65), qc 102-216). CMV was isolated from body fluids. Necrosis for brain scan (normal) caused severe hyperpnea. CT scanning: moderately ventricled enlarged paraventricular (4.2 cm) and subcortical lymphomas. Coexistence of biopsy specimens of skin lesions changes consistent with K. combination chemotherapy (KS, CMC, PDR, Imit 102) was started. Dramatic clinical improvement was evident within two weeks: mediastinal circumference decreased by 11 cm and TB scan showed disappearance of mediastinal nodes. In case of massive mediastinal distention in HIV infected children, even if one year after the onset of signs of illness, opportunistic lymphoproliferative neoplasms should be ruled out. If detected, it can be symptomatically treated with specific chemotherapy with some advantage.

T.B.P.266

OPPORTUNISTIC INFECTIONS AND MORTALITY IN AN URBAN PEDIATRIC POPULATION INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV)
Hassan, J., Collins, Rosenblatt, M.M. and Shearer, W.L. Baylor College of Medicine's Hospital, Houston, Texas, U.S.A.

Objective: To define opportunistic infections (OI) that were most prevalent and linked with the highest mortality rates in an urban pediatric population.
Methods: 73 pediatric HIV patients followed up to 7 years (mean 2 years) were reviewed for evidence of OI (Center for Disease Control, stage B-1).
Results: As in the adult population, pneumocystis carinii pneumonia (PCP) was the most frequently reported opportunistic organism with a high mortality rate linked to both a) clinical presentation with acute respiratory failure and b) co-infection with cytomegalovirus (CMV). CMV infection had the highest mortality rate with documented pneumonitis (3/5), hepatitis (1/5) and retinitis (1/5). Bacterial infections were not as common as in other reports.

OI	# of Patients	Mortality	Recovery
PCP	108	100%	No
CMV	6	100%	No
HIV intracellularly	5	100%	No
Salmonella	2	0%	Yes
E. Coli	1	100%	No
Strep. pneumoniae	1	0%	Yes
Candida esophagitis	0/2	0%	Yes

Conclusion: The incidence of OI was 25% (18/73) with mortality high for PCP, CMV and gram negative sepsis (averaging 90%). Attention should be focused on early detection and intervention for OI. Protocol's defining and standardizing therapeutic approaches to OI in children must be designed and implemented.

AZT SK/Thrombocytopenie et autres traitements AZT KS/Thrombocytopenia and Other RX

T.B.P.268

NEUTROPHILIC EFFECTS AND COURSE OF ZIDOVUDINE (AZT) THERAPY.
Schibler, Walter*, Marrier, G.* and Johnston, B.*
*Dalhousie University Faculty of Medicine, Halifax, Nova Scotia, Canada

Objective: To describe the hematologic effects and outcomes of zidovudine (AZT) therapy in CDC group III and group IV HIV-infected patients (pts).
Methods: 29 AIDS and group III (n=24) pts were treated with AZT. Hematologic parameters studied included hemoglobin count (Hb c), platelet count (PLT c), hemoglobin (Hgb), mean corpuscular volume (MCV), and lymphocyte (CD4) cell counts.
Results: Of 34 pts enrolled, 7 are dead, 12 are off Rx, and 14 remain on Rx. Deaths were due to disseminated TB (1); recurrent PCP (2); progressive dementia (1); leishmaniasis (1) and lymphoma (3). Disseminated CMV (2), PML (1) and stage IV lymphoma have developed in 4 pts continuing Rx. Serial CD4 cts demonstrated significant increases in 8/24 pts able to take 1200 mg/day of AZT. Pts. with CD4 cts <100 cts/mm³ did not show increases to >100 cts/mm³. Progressive thrombocytopenia was seen in 12/24 pts. Pts. with starting Hgb <14 g/dl were more likely to have significant decreases in Hgb on Rx (p<0.05). OC cts varied but increases were noted when OC cts were low at start. P/E cts remained stable or increased slightly.
Conclusions: Zidovudine causes predictable thrombocytopenia and unpredictable anemia. OC and P/E cts may improve with suppression of active HIV infection. Opportunistic infections and malignancies continue to develop in patients taking zidovudine.

T.B.P.265

CHRONIC MUCOCUTANEOUS CANDIDIASIS IN PEDIATRIC AIDS
Jombik, Sylvia; Meiji, M.; Stoner, K.R.; Gromlich, D.D.; Marmorstein, V.
New York Medical College, New York, USA

Objective: To compare the incidence of persistent mucocutaneous candidiasis in patients diagnosed as AIDS in the first year of life (group I) to those diagnosed later (group II).
Methods: The study was performed at two public hospitals in New York City on 81 HIV-2 patients with perinatal HIV infection admitted from 1984-1988 and followed for 1-50 months (mean 18 mo.). All mothers except three were intravenous drug abusers. The majority of patients in group (I) became symptomatic in the first six months of life. The C consisted of 42 patients: 44 blanche (3) and 28 Puerto Rican (9) 21 males (4) and 21 females (1). G I comprised 20 patients (13 and 7 P) 12 m and 8 f, ranging in age from 12.5 months to 72 months (mean 37 mo.).
Results: Chronic mucocutaneous candidiasis was significantly more frequent in G I (n=21) (50% vs 10%, p<0.006). There were no significant race or sex differences between groups, but in G I 5 were more often afflicted than P (2 (60% vs 31%). Also in G I candidiasis was the sole initial manifestation in 9 patients (28%) and 3 of those (60%) died by four months of age. In G II candidiasis was found only in PR with no significant sex differences (2/8 in 6 m vs 2/8 in 12 m).
Conclusions: In the very young infant with perinatal HIV infection, chronic mucocutaneous candidiasis may predict early and severe morbidity. Long term follow-up is needed to elucidate its prognostic value in older infants and children.

T.B.P.267

SPECTRUM OF INFECTIONS IDENTIFIED AT AUTOPSY IN PEDIATRIC AIDS
Rosa, Lawrence A.; Wong, K.K.; Gowers, E.D.; Rinaldo, A.L. and Church, J. Childrens Hospital of Los Angeles and U.S.C. School of Medicine, Los Angeles, California, U.S.A.

Objective: To identify the spectrum and sites of infection in children dying of AIDS. **Methods:** 33 children with AIDS of Los Angeles and U.S.C. School of Childrens Hospital of Los Angeles; 22 have expired; 12 postmortem examinations revealed the following:

ORGANISM	# of Pts	SOURCE	CLINICAL CORRELATES
P. carinii	7	lung(1)	pneumonia(P)
Candida Spp.	5	l. pharynx, heart(3); blood(3); kidney, bladder, esophagus	P. thrush, esophagitis, endocarditis, disseminated disease(D)
Cytomegalovirus	4	l. brain, pancreas, adrenal glands, thyroid, brain(4)	P. HD, virecemia, enterocolitis, encephalitis(E)
H. avium complex	2	l. b.	P. sepsis(S)
Adenovirus	1	l. l., P, tr	DD, P, E
P. aeruginosa	1	l. b., l.	S, P
H. coli	1	l. b., l., peritonium	P, S, peritonitis
P. pneumoniae	1	l. meningis	P, meningitis
HSV	1	l.	P

Conclusion: Multiple infectious agents may be responsible for a fatal outcome in children with AIDS. This indicates the need for a wide range of improved antimicrobial therapy for these children.

T.B.P.269

THROMBOCYTOSIS IN HIV INFECTION
Suzil, Singsap*, Jardi, F.*; Awati, R.M.*; Falestin, R.*; Stallard, R.* and Basillat, S.*

Objective: To describe the incidence of thrombocytosis in HIV positive pts, to assess the severe lesions and the prognostic significance of thrombocytosis in the AIDS condition.
Methods: on Dec. 21, 1988, eighty-eight cases of thrombocytosis were observed with a population of about 1000 HIV positive pts. at the 1st Division of Infectious Diseases Follow-up Study, with results before with an average 11-month observation. Nine narrow bligies from 23 thrombocytotic anti-HIV positive pts. were observed at light and electron microscopy. The 19 Ppt. and the 21 group III pts. (CDC 1985) were initially all free from opportunistic involvement and remained so until death. Platelets were initially all free from opportunistic involvement. We evidence of granuloses or acid fast organisms was found. These data suggest a probable mechanism destroying light platelets particularly in the absence of bone marrow endoprothetion. In the present follow-up only two pts. undergoing a bone marrow biopsy, evolved to follow-up.
Conclusions: 1) 8% of the HIV positive population presents thrombocytosis as a clinical sign of early bone marrow involvement. 2) The main bone marrow alterations are characterized by an increased number of megakaryocytes with hyperplastic and plasmacytic. 3) Thrombocytosis has no inferable prognostic meaning in the relation to AIDS.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

Thérapie et évaluation clinique : ribavirine et autres médicaments Therapy and Clinical Evaluation, HIV Ribavirin and Other Drugs

T.B.P.294 COMPARISON OF RIBAVIRIN VERSUS PLACEBO FOR PREVENTING THE PROGRESSION OF HIV INFECTED SUBJECTS FROM CDC STAGE III TO STAGE IV.

Spanish Ribavirin Study Group. Barcelona, Madrid, Bilbao, San Sebastian, Spain.

OBJECTIVE: To compare the efficacy of ribavirin versus placebo to prevent the progression of infected patients from CDC stage III to stage IV.

METHODS: 131 HIV-infected patients (209 homosexual, 468 drug addicts) on CDC stage III, and a CD4 cell count between 300 and 500 per mm³ were included in a double blind multicentric trial and randomly allocated to receive ribavirin (15 mg/kg) or placebo. The planned duration of the study was 18 months with an interim analysis at 6 months without opening the codes unless a significant difference in efficacy or toxicity were detected. The Student's t-test, the Chi-square test, life-table analysis and the Mantel-Cox test were used in the statistical analysis.

RESULTS: The 63 patients included in the study group B and the 68 included in group A had a similar age, sex, race, white and CD4 blood cell counts. In the interim analysis at 6 months of the 63 patients of group A progressed stage IV or to stage IV-C1 to 10-6 and 5 to IV-C1 versus 11 (18%) of the 68 patients of group B to stage IV-C1 to 10-6 and 5 to IV-C1. The difference was not statistically significant pooling together all patients progressing to stage IV or performing a separate analysis for those reaching the CDC stage IV-C1. Side effects were irrelevant in both study groups.

CONCLUSION: At the interim analysis after 6 months both ribavirin (15 mg/kg per day) and placebo were well tolerated but the progression rate stage IV was not statistically different. The results of the final analysis at 18 months will be presented in the Conference.

T.B.P.296 RIBAVIRIN DOES ESCALATING PHASE I TRIAL IN PATIENTS WITH AIDS AND ACD

Chomont, D., Cohen P., Paarlant, J.M., Paarlant, G., Valentine P., Mills J., and Spector R. Beth Israel Hospital, Boston, MA *WHO, New York, *San Francisco General, *San Diego, and *HIV/AIDS-Bethesda, MD, U.S.A.

OBJECTIVE: To carry out an increasing dose phase I trial to find maximum tolerated dose of Ribavirin (RBV).

Methods: Patients to 3 arms, 1) AIDS no previous treatment; 2) ACD; 3) AIDS, ACD failures; were enrolled in a 6 month trial of RBV 600, 1200, 1600, or 2000 mg/d with a goal of 26 patients per dose regimen. Patients all had serum p24 > 70 pg/ml at entry. Clinical status, serum p24, HIV culture, total CD4⁺ cells were assessed in all patients at 4 weekly intervals.

Pharmacokinetic values were measured in plasma and RBC by radioimmunoassay. **Results:** As of 2/1/89, 28 patients were enrolled in the trial. All were in dose range 800 and 1200mg/d. Patients with AIDS no previous treatment (10), severe ACD (10), and ACD failures (8) are receiving RBV. Main side effect has been a pruritic rash at 1200mg/d requiring lowering dosage in 4 patients. In 100 patients mouth 2 episodes of ROP, 1 HSV, 1 CMV and 1 candida infection have occurred. No mononucleosis or granulocytopenia requiring transfusion has occurred. Serum p24 levels have decreased in 3 patients, but trends of all serum p24 values increase with time. CD4⁺ cells have increased in 2 patients, but trend of all values is a decrease with time. Pharmacokinetic data on 100mg/d reveal a steady state plasma level of 10-12 µg/ml.

Conclusion: RBV at 800 and 1200mg/d is well tolerated and is less than MTD. No severe granulocytopenia, mononucleosis or neurotoxicity has occurred. Patients are having few opportunistic infections but CD3 progresses. Patients are continuing to be followed for CD4⁺ cell changes.

T.B.P.298 EVALUATION OF PROGESTERONE ACETATE TREATMENT IN AIDS

Sidd, S., O'Connell, J., and G. S. Alkhatib (eds). AIDS Centre, Sydney Hospital, Sydney, Australia.

Objective: To evaluate the components of weight gain associated with progestin acetate therapy in late stage HIV disease.

Methods: Ten males with a weight loss of 15-20% of usual weight due to late stage HIV disease were treated with norgestrel acetate (10 mg, three times a day). Subjects were treated as out-patients. All patients were on zalcitabine therapy. ACT (ACT prophylaxis). Baseline data obtained pre-treatment included blood biochemistry and hematology, and food intake diary. Subject had an anthropometric assessment as well as body composition analysis by bioelectrical impedance. Subjects were requested to complete questionnaires regarding quality of life assessment, and factors affecting food intake.

Results: Results for a 6 week period of 12 weeks therapy per subject will be discussed. In addition results of weight gain and more specific indicators of body composition are presented to indicate exactly how norgestrel acetate affects nutritional status.

T.B.P.295 DEXTRAN SULFATE IS POORLY ABSORBED AFTER ORAL ADMINISTRATION LACERANAL, R.C.***; Mendrix, C.***; Collins, J.***; Kishi, R.***; Pridy, R.***; Lieberman, M.A.***; S. H. Lieman, M.A.***

*Johns Hopkins University, Baltimore, MD; **U.S. Food and Drug Administration, Rockville, MD; ***University of Colorado, Denver, CO, USA.

Objective: To determine whether dextran sulfate, a synthetic analogue of heparin with anti-human immunodeficiency virus activity in vitro, is absorbed after oral administration.

Methods: Volunteers were given an 1800 mg oral dose followed forty-eight hours later by a 225 mg intravenous infusion of dextran sulfate. Because dextran sulfate is an anticoagulant and the activated partial thromboplastin time (APTT) is a sensitive measure of its anticoagulant activity we measured changes in the APTT after each dose. We also measured plasma lipase activity because dextran sulfate causes the release of lipase into the plasma.

Results: After the oral dose the APTT^a were indistinguishable from the normal variability of this assay over time. In contrast the mean peak APTT was prolonged 160 seconds after the intravenous dose. Because we have observed a linear relationship between the log APTT and the plasma concentration of dextran sulfate in vitro, we used this assay to calculate plasma dextran sulfate concentrations, and we used these values to determine the absorption concentration of this drug. The mean bioavailability was 0.7% (range 0-2.2%), this small percentage could not be distinguished from 0. In lipase activities increased to 2.3 X baseline after the oral dose and >400 X (range 10-1000) after the intravenous dose.

Conclusion: We conclude that dextran sulfate is very poorly absorbed after oral administration.

T.B.P.297 PHASE I STUDY OF 2', 3' DIDEOXYINOSINE (ddI) GIVEN ONLY DAILY TO PATIENTS WITH AIDS OR ACD

Conley, T.J., Fischl, I., Saunders, C., J. Parkin, J.C., McCaffery, R.P.,** McEldowney, C.T., Lieberman, M.A.,** Boston University School of Medicine, Boston, MA, USA; ** Bristol-Myers Company, Wallingford, CT, USA.

Objective: To determine maximum tolerated dose (MTD), pharmacokinetics (PK) and efficacy of iv and oral ddI given once daily. **Methods:** To date, 9 patients (6 men, 2 women) with AIDS (4) or ACD (5) were treated. Plasma and urine were collected after initial iv infusion and at steady state doses of 0.8 (1), 2 (5), 3.5 (2) mg/kg/d and after initial po dose and steady state doses of 1.6 (1), 4 (4), and 7 (2) mg/kg/d. Serial T4 lymphocytes (T4L) and p24 antigen were studied.

Results: Pre-dddI T4L mean = 106/mm³, mean = 2-390/mm³. After 16 days of iv dddI, T4L rose in 4 pts, mean rise = 28/mm³, range 10-57/mm³. After 2-16 weeks of po dddI, T4L rose in 3 pts, mean rise = 90/mm³, range 20-150/mm³. Pre-dddI p24 all positive; no change on iv dddI; 1 on po dddI became p24 all negative. PK data to follow. Heavy leukopenia resolved in 2. Dose limiting toxicity: grade 1 cutaneous (1) and grade 2 hepatic (1). ddI was discontinued in 1 pt with HIV cardiomyopathy and ECG changes.

Conclusion: Daily ddI is well-tolerated in pts with AIDS and ACD with minimal toxicity. The MTD has yet to be established. Preliminary data suggest efficacy with increase in T4L. PE protocol continues with further dose escalations.

T.B.P.299 RECOMBINANT GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF): LACK OF NEUROLOGICAL TOXICITY

Eng, R.,** Kralj, J.,** J. Parkin, J.C.,** Kram, S.F.,** Anselmo, W.,** Birnbaun, J.,** Sigittis, J.P.,** Price, N.B.,** Bonnen, E.M.,** Memorial Sloan-Kettering Cancer Center, NY and *Schering Corporation, Kenilworth, NJ.

Objective: To assess the possibility of neurological toxicity of GM-CSF in neurologically compromised AIDS patients without disease.

Methods: Patients enrolled in a phase I trial of GM-CSF as treatment for AIDS-related neutropenia were evaluated by quantitative neurological and neuropsychological assessment before and after each treatment cycle. GM-CSF was given by daily sc. injection for 10 days followed by an 18 day period. Subsequent treatments were in 28 day cycles. Four patients were receiving concomitant zalcitabine (AZT). Patients with AIDS Dementia Complex (ADC) (Stage 1, 0, or greater) were excluded.

Results: Nine patients were evaluated: 5 were seen three times and one patient was seen twice, four, five and six times. All patients at baseline had after neurological signs such as eye movement abnormalities and slowing of limb movements (ADC Stage 0.5). None had cognitive complaints. No significant changes were seen in either the neurological or neuropsychological impairment scores.

Conclusions: Theoretical concerns have been expressed that GM-CSF might activate latent HIV-1 infection in macrophages and thereby lead to brain infection and ADC. However, this initial study found no evidence that GM-CSF exacerbated the clinical ADC-related neurological signs present at baseline, or led to ADC. These findings provide a basis for subsequent studies of GM-CSF and AZT in patients with ADC whose neutropenia precludes AZT.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

T.B.P.300 OCCUPATIONAL THERAPY FOR PEOPLE WITH AIDS

Authors: Lebowitz, V. Center for Special Services, New York, NY, USA.

Objective: To maintain or improve functional independence and quality of life for HIV/AIDS patients and their families. To be cost effective by decreasing frequency and length of hospital admissions and hours of home health care needed. **Methods:** Occupational therapy as a component of Rehabilitation Medicine, assists the psychologically and physically disabled individual/family in achieving independence and quality of life, via a variety of modalities. These include but are not limited to: 1) Contemporary strategies for performing Activities of Daily Living (ADL) (ie- one-handed techniques, adapted equipment, ADL for the blind). 2) Ordering of bathroom equipment to assist family members in maintaining safety and ease of transfers. 3) Recommendation of wheelchair and positioning devices. 4) Building functional strength and endurance. 5) Teaching entry/exit techniques for the car (push and pull). 6) Instruction in stress management skills. 7) Conversation to the patient with short-term and long-term goals. 8) Instruction in social engagement skills. 9) Teaching letters skills to increase productive use of time. Patients are seen weekly at an inpatient center or as inpatients as needed, and alternated with therapist and psychiatrist. **Results:** Based on formal written evaluations, documented in the medical charts: Patients and families demonstrate an increased independence in ADL's as a result of increased knowledge and adaptive equipment as needed. Through such devices an adaptive pillow chair, patients no longer require a home health aide to assist or supervise medications. They were found success in creative projects. Families learn to monitor well and paralyzed patient safety. **Conclusions:** Occupational therapy as a discipline of rehabilitation medicine, helps people with AIDS and their families achieve quality of life and a greater level of independence. This service is cost effective as it decreases the need for home health care services and, instead, empowers the individual.

T.B.P.302 LONG TERM ZIDOVUDINE TREATMENT

Authors: Sz. Lendvay, J. Ujhelyi, E. P. Patai, Gy. Hidy, J. V. Vernal, P. Kivertó for Institute of Tropical Diseases, Postgraduate Medical School, National Institute for Hematology and Blood Transfusion, Budapest, Hungary.

Objective: To evaluate clinical efficacy, safety and tolerance of long term Zidovudine treatment.

Methods: Four patients (pts) /stage III-3 stage IV/A-1/ were treated with 600 mg/day zidovudine orally. Number and ratio of CD4+ and CD8+ lymphocytes, serum levels of immunoglobulins, antibodies and HIV p24 antigen were determined monthly as well as clinical assessments, clinical chemistry, haematology, parasitology and bacteriology were investigated.

Results: Three pts were treated for 24 one for 13 months. In overall conditions of the pts improved, no serious infection of opportunistic disease were observed (The AIDS p24 cryptosporidial diarrhea stopped) however oral hairy leukoplakia developed in two pts. CD4+ cell count and ratio stabilized in 3 pts and significantly elevated in one. Two pts had been and remained positive, one pt became HIV p24 antigen positive after 12 months and one pt was negative. The pts tolerated zidovudine treatment extremely well, no side effects, nor even anaemia were observed.

Conclusion: Zidovudine might be of use in the long term treatment of pts in stage III. Neither adverse reaction, nor side effects have been observed.

T.B.P.304 ESSAI RANDOMISÉ CONTRE PLACÉBO DE FORTES DOSES

AUTRES LES PATIENTS HIV CHAUVYET, J. AND S. MALEY, J. WALDOR, A. BUSSON, M. BILLETIER, P. PORTIER II. Service des Maladies Infectieuses, Hôpital de la Croix-Rouge, 12018 Lyon, France.

Le but de cette étude était d'étudier l'influence de fortes doses d'AZV sur la progression de la maladie HIV de patients qui ne présentent aucun symptôme ou dont les infections opportunistes ne sont à risque de graves complications. Les patients ont été randomisés en deux groupes: un groupe recevant le placebo et un groupe recevant des fortes doses d'AZV (300 mg/kg) à raison d'une fois par semaine pendant 12 semaines.

Methodes: 20 patients (C20) ou III. 21 hommes, 9 femmes, âgés de 17 à 60 ans ont été randomisés en 2 groupes parallèles, et ont reçu pendant 12 semaines une injection par semaine associée à 1 g de placebo ou à 1 g d'AZV 300 mg/kg soit du placebo ou du zidovudine. Les résultats sont exposés dans le tableau I.

T-lymphocytes	T-suppr/lym	T-h/7s	beta2 mg/l	p-0.07
avant après	avant après	avant après	avant après	**p-0.25
placebo 576 756	746 786	1.25 1.07	2.3 1.1	**p-0.15
ACT 747 778	848 797**	1.86 1.55	3.25 3.5	

Conclusions: AZV à 300 mg/kg 1 fois/semaine, bien toléré, semble ralentir la progression de plusieurs marqueurs de la maladie HIV: baisse des T4 et augmentation des T8. Ces résultats incitent à poursuivre les études en utilisant le didanosine. En effet, sans préjudice de l'AZV bien toléré par voie orale depuis des concentrations sériques importantes.

T.B.P.301 SUPERVISED PHYSICAL EXERCISE LEADS TO PSYCHOLOGICAL AND IMMUNOLOGICAL IMPROVEMENT IN PRE-AIDS PATIENTS.

Authors: Collins, C., Jager, H., Flower, H., Harnett, G., and Popescu, M. University of Heidelberg, Heidelberg, FRG, *AGS Study Group, Schwabinger Kreisstrasse, Munich, FRG.

Objective: The immunological and psychological effects of therapeutically supervised physical exercise in HIV-AB positive individuals were investigated in a randomized controlled prospective study.

Methods: Twenty-eight HIV-AB positive patients were stratified according to the Walter-Reading-Strating-Classification (Stages 1 through 4 were included). Fifteen subjects were randomly assigned to participate in one-hour physical exercise sessions twice a week over a period of 8 weeks. The exercise program was designed to develop endurance beyond threshold values of 4 renal lactate. The control group of 13 patients did not receive exercise treatment.

Results: Within the first 4 weeks the number of CD4+ cells increased in 67% of subjects receiving therapy, as compared to 6% of the control group. CD4+/CD8+ ratio of the last group increased from 0.48 to 0.47 while the ratio in control subjects decreased from 0.48 to 0.42. In addition delayed cutaneous hypersensitivity reactions measured by roval antigens (Plantain Mercurio) increased from 15.2/2 to 18.2/2. There was a clear psychological benefit concerning reduction of anxiety and depression as well as build up of a group feeling. PCMG, a psychological symptoms inventory, showed decrease, but strong correlation with changes in the immunological parameters.

Conclusions: These results demonstrate that carefully directed physical exercise can improve both immunological and psychological parameters in HIV-infected patients.

T.B.P.303 A PHASE I STUDY OF THE SAFETY AND PHARMACOKINETICS OF SOLUBLE RECOMBINANT CD4 (rCD4) IN PATIENTS WITH AIDS AND ARC.

Authors: J. Davies, J. Kahn, J.P. Dodge, T. Sherwin, S.M. Volberding, P.M. and Grossman, J.P. *New England Deaconess Hospital, Boston, MA; **San Francisco General Hospital, San Francisco, CA; ***Greenwich, Inc., South San Francisco, CA, U.S.A.

Objective: To determine the safety and maximal tolerated dose of rCD4 and preliminary indications of antiviral effects of rCD4 in patients with AIDS and ARC. **Methods:** A 2 center, phase I study with dose escalation and monitoring of the safety, pharmacokinetics, and clinical effects of rCD4 in 30 patients with AIDS or ARC. Six patients were enrolled at each dose level of 1,10,100, and 300 µg/kg rCD4 was administered by a single intravenous (IV) infusion on day 1, followed by a 3 day wash out, then infusions 3 times weekly for 8 weeks (11 was total).

Results: No significant adverse effects have been noted in clinical, hematologic, or serum chemistry parameters. One patient developed borderline evidence of anti-rCD4 antibodies on day 37 that were not detected on subsequent determinations. No other instances of anti-rCD4 antibody have been detected thus far. In those patients for whom follow up data is available the total T4 count was 115/50 at entry and 131/41 at 11 weeks of therapy. One individual exhibited a consistent sustained increase or decrease in total T4 count. Approximately 23% of individuals were p24 Ag(+) at entry. Follow up analysis of p24 Ag and viral isolation data are not complete.

Conclusion: IV administration of soluble rCD4 appeared to be well tolerated over the course of this study. Preliminary analysis has not indicated a significant change in total T4 count. Studies are being conducted with long term maintenance IV therapy as well as SC and IM administration.

**Session d'affichage
Poster Session**



**Aspects cliniques
Clinical Aspects of AIDS**

T.B.P.311 **ROLE OF P24-40 TESTING IN PATIENTS ON ZIDOVUDINE**
 Ross JONES, David J. Myles, A. Donald McMillan, Greg Lamacz, R. Patricia Infectious Diseases Assoc., Melbourne, Victoria, Australia.

Objective: To examine the role of regular measurement of serum p24 antigen (p24) in the management of HIV infected patients (Pz) on zidovudine (AZT).
Methods: From 1 June 1985, 95 p24 and 56 ABC have received AZT for 6-18 months, reviewed 2-4 weeks. 27 patients had monthly serum p24 measurements, measured by a solid phase sandwich immunoassay (Abbott Laboratories). Results: At entry, there were 39 p24 positive (40 ABC, 14 ABC) and 56 p24 negative (56 p24) (34 AIDS, 22 ABC). The follow-up period was a mean 56.1±13.7 weeks for p24 positive and 54.1±13.3 weeks for p24 negative. Twelve p24 positive became p24 negative on AZT, while 27 remained p24 positive. Twenty-five p24 negative became p24 positive on AZT while 31 remained p24 negative. There were 17 deaths and no significant difference in mortality between p24 positive and p24 negative. Thirty-three of the 39 p24 positive p24 developed further opportunistic infections. Results: 11 ABC with 11 of the 56 p24 positive p24 had a further OI (23 AIDS, 16 ABC). There were significantly less OI in the p24 negative group for AZT treatment periods up to 12 months. After 12 months there is no difference in OI between p24 positive and p24 negative patients. Eleven p24 positive (6 AIDS, 5 ABC) and 20 p24 negative (15 AIDS, 5 ABC) entered final dose AZT (>1000ng/ml). Eight of the 11 p24 positive and 11 of the 20 p24 negative developed further OI. On reduced dose AZT, 10 patients, 25±2 p24 positive and 31 of 36 p24 negative p24 developed further OI. Eighteen of the initially p24 positive p24 became p24 negative on full dose AZT. The presence of serum p24 as a predictor of outcome in patients treated with AZT for less than 12 months. Neither the predictive value of p24 nor the benefits of AZT persist beyond 12 months.

T.B.P.313 **USE OF MULTIPARAMETRIC FLOW CYTOMETRY (LYMPHOCTE SUBSET ANALYSIS) TO EVALUATE AZDOXYTHIMIDINE THERAPY**
 Chignon-Villain, Betsy M.*; Cory, J.M.*; Keefer, H.A.*; Eyster, M.E.*; Rapoport, F.*; Landay, A.L.*; et al.
 M.E. Hersey, Montclair State University, State Univ., Hersey, PA; *Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL, USA.

Objective: To evaluate in a cross-sectional study the effect of azidothymidine (AZT) treatment on levels of active HIV-1 infection in AIDS patients.
Methods: A new test, lymphocyte p24-IFA, based on multiparametric flow cytometry, was used to quantitate active HIV-1 infection of peripheral blood lymphocytes in 245. Results were expressed as % p24 positive cells. The assay is based on binding of monoclonal antibody specific for p24 core protein; therefore, only cells with actively replicating HIV were detected. Viral infection was by standard coculture methods. Other work has shown a correlation between viral culture positivity and samples with >1.0% positive lymphocytes. Results: AIDS patients receiving AZT were compared to untreated AIDS patients using lymphocyte p24-IFA. Patients receiving AZT had a mean lymphocyte p24-IFA of 0.3% (I=20) (range <0.1-1.7) whereas untreated patients had values of 0.5, 1.7 and 18.4% (mean = 6.1%). One patient for whom treatment was discontinued increased from 0.19 to 0.9% in one month.
Conclusion: Use of a rapid, quantitative test confirmed reduction of active HIV infection by AZT in a small study. Lymphocyte p24-IFA should be considered for new studies evaluating antiretroviral agents.
 (Supported by USA NIH HL35, NCI-HB-67023 Project #221924 and AIG5915).

T.B.P.315 **THIS EFFECT OF TREATMENT WITH ZIDOVUDINE ON IMMUNE SYSTEM IN THE EARLY IN COURSE OF HIV INFECTION**
 Ricker, William M. Clinch, P.J. Center for Special Immunology, Ft. Lauderdale, FL, USA.

Objective: To study the immune system effects and toxicity of zidovudine in patients with HIV infection and T4 lymphocyte counts between 200 and 400 cells/cm³.
Methods: Patients were further evaluated by determination of HIV p24 antigen level, lymphocyte Naugensin counts with the inclusion of P1A, beta-2 microglobulin level, CD4, chemistries and zidovudine level. Therapy was initiated with zidovudine, 200mg q4H. Laboratory studies were obtained every 3 months. Results: In these patients were compared with patients who initially presented with T4 lymphocyte counts below 200 cells/cm³. No other antiretroviral medications were administered. Results: 38 patients were in the early treatment group. 74 mean was 285 cells/cm³ mean baseline, 388 at 3M and 405 at 6M. Stimulation index with P1A mean was 34 baseline, 97 at 3M and 76 at 6M. HIV p24 antigen mean was 132 pg/ml baseline, 46 at 3M and 56 at 6M. Hct mean was 42.2% baseline, 39.0 at 3M and 40.7 at 6M. 1 patient received a transfusion. There were 28 patients in the late treatment group. 74 mean was 97 baseline, 136 at 3M and 98 at 6M. Stimulation index mean was 25 baseline, 53 at 3M and 51 at 6M. HIV p24 antigen mean was 121 baseline, 77 at 3M and 117 at 6M. Hct mean was 37.5 baseline, 34.7 at 3M and 37.6 at 6M, 9 patients received transfusions.
Conclusion: Earlier treatment of HIV infection before advanced damage to the immune system occurred, resulted in less improvement of the immune system defects studied without the development of clinical disease or significant toxicity. Patients for whom therapy was initiated later in the course of infection did not show this improvement. Earlier initiation of anti-viral therapy with zidovudine may halt the progressive immune destruction and improve defects in immune function in patients with HIV infection.

T.B.P.312 **CHANGE IN BETA-2 MICROGLOBULIN (B2M) DURING ZIDOVUDINE (ZDV) THERAPY (RT) PREDICTS CLINICAL OUTCOME**
 Jacobson, Mark A.; Abram, D.; Mocchetti, P.; Kocourek, R.; Wilber, J.V.; Moss, A.B.; Hiestand, H.C.; et al. Center for HIV Public Health Dept., San Francisco, CA; *Immunodiagnostic Laboratory Inc., San Leandro, CA and AIDS Clinical Trials Group, NIAID, Bethesda, MD, USA.

Objective: Determine if changes during ZDV Rx in CD4 lymphocyte number or any of a serologic markers of HIV activity predict clinical outcome.
Methods: Whole blood CD4 lymphocytes (CD4) and serum p24 antigen (p24 Ag), beta-2 microglobulin (B2M), neopterin (NPT) and p24 antibody (p24 Ab) were measured pre- and serially during ZDV Rx in 38 AIDS and ABC patients (pts). We examined the association between change from baseline values of these markers during the first 6-18 months of ZDV Rx and clinical outcome 14-18 months (mo) after ZDV Rx was initiated.
Results: Among pts whose serum B2M increased during the first 6-12 mo of ZDV Rx, 9/11 had 1 or more serious events (SE) occur (death, life-threatening opportunistic infection, lymphoma) during 14-18 mo of follow-up while among those whose B2M decreased, 10/10 had SE (p<0.01, odds ratio [OR] 10:1). Neither increase in p24 Ag nor NPT, nor decrease in CD4 nor p24 Ab predicted SE (OR=1.0:1). Mean control for underlying diagnosis (AIDS vs. ABC), B2M increase was still predictive of SE by bivariate logistic regression analysis (p<0.01). Also, serum p24 Ab rose in the normal range at 6M & 8M of ZDV Rx. 8/11 were seroconverted (seroconversion status < 60) or died at 14-18 mo compared with 16/28 whose 6M B2M was elevated (p<0.01).
Conclusion: Decrease in B2M normalization in B2M during the first 6-12 mo of ZDV Rx was predictive of stable clinical status 14-18 mo after starting ZDV.

T.B.P.314 **The inhibitory effects of AZT on HIV replication as determined by DNA content analysis**
 Hsu, H.C.; Chang, S.H.; Lajtha, M.; Weinberg, J.; Ruedy, J.; Landay, A.L.; Fleming, J.; et al.
 1 - Federal Center for AIDS, Ottawa, 2 - McGill University, Montreal, 3 - St. Paul's Hospital, Vancouver and 4 - University of Toronto, Toronto, Canada.

A Canadian multicenter study assessed the possible toxic effects of AZT (zidovudine) in 72 HIV-1 infected individuals. In this dose-escalating study, the patients were initially treated with 600 mg of drug/day for 10 weeks, 900 mg/day for another 9 weeks and 1200 mg/day for another 9 weeks. A "washout" period of 6 weeks followed after which the drug was restarted at 1200 mg/day. During this study, both the levels of HIV p24 antigen detected by non-commercial kits and the recovery of HIV-1 from cultured peripheral blood lymphocytes were measured. Twenty-two patients were HIV-1 p24 antigen positive during the study. Treatment with AZT over the 600 mg/day period reduced the levels of circulating p24. In patients that were p24 antigen positive upon entry, treatment with the drug resulted in a sharp decrease in the levels of antigen which persisted for the treatment duration. During the 6 week washout the levels of p24 antigen rose. Drug was reintroduced at 42 weeks and the patients are being monitored to assess the effect of the washout/reintroduction on HIV p24. In those patients in which the level of p24 antigen rose during AZT treatment, there was an accompanying alteration in their antibody profile. The level of antibody to p24 relative to that of gp41 decreased as the p24 antigen increased. There was agreement between these observations and increasing physical condition.

T.B.P.316 **COMBINATION THERAPY TO PREVENT ORAL CHERMOPHILIN (OP-90) IN THE TREATMENT OF PHARYNGEAL CANDIDA PNEUMONIA (PCP)**
 Ricker, William M.; Clinch, P.J.; Howe, R.; Hillman, S.; and Pillsbury, R.A.; Ft. Lauderdale, FL, USA; *Center for Special Immunology, Ft. Lauderdale, FL, USA.

Objective: To evaluate the prevalence, clinical morphology and course of oropharyngeal to PCP in the treatment of HIV-associated PCP.
Methods: Prospective clinical and serological examination for oropharyngeal reactions in the treatment of 16 consecutive episodes of PCP in 6 patients (5 first manifestations). 2 episodes with OP (2nd episode) (OP) (200mg q4H) were included in the analysis. Results: Patients with first OP-episodes (group I) showed outcome rates in 2/4 (12.5%). Patients with recurrent OP (group II) and the same therapy regimen in 5/6 (14/27). Oropharyngeal eruptions (oropharynx) occurred 20.7 days after the onset of therapy in group I and recurrently earlier (mean 7.5 days) in group II. In typical cases there was no skin itching erythema. Injuncting in the patients from, extending in craniocaudal direction 3-4 days prior to smothering. In 7/8 washouts consisted of discontinuing oral and analgesic with confusion and pyrexia. 1 patient developed a mild conjunctivitis, 2 an uveitis and another 2 another 2 mycotic infections (1 patient with progression to Herpes-zoster syndrome). OP-90 therapy was not to be stopped unless patients with oropharyngeal reactions. **Conclusions:** Oropharyngeal eruptions in the treatment of PCP with OP-90 are very frequent but not dangerous. Patients probably toxic reactions (fever, malaise, myalgia, erythema) are common. Oropharyngeal eruptions and severe oropharyngeal mycotic eruptions do not force us to stop therapy when high doses of zidovudine are given. However, when patients with oropharyngeal eruptions, toxic eruptions, and severe oropharyngeal therapy has to be stopped.

Session d'affichage Poster Session



Aspects Cliniques Clinical Aspects of AIDS

T.B.P.317 PRELIMINARY OBSERVATIONS ABOUT THE ADVERSE EFFECTS OF PEGLOSSICIN IN THE TREATMENT OF SALMONELLA BACTEREMIA IN PATIENTS WITH AIDS

Levi, Danilo Carlos; Medeiros, S.A.S.; Mendonça, J.S.; da; e Carvalho, M.C.S. 747 - Rua E.T.V. Fioravanti, 8. Serviço de Medicinas Infecciosas, Hospital do Servidor Público Estadual - São Paulo, Brazil.

We treated 3 patients with AIDS and positive blood cultures for *Salmonella* sp. in 2 cases of typhoid fever and, in one, of dysentery. They received pefloxacin orally, 800 mg/day, in 2 divided doses. They had a fast clinical and microbiological response, with disappearance of fever in few days and normalization of the blood cultures. Unfortunately, they also developed severe side effects. The patient developed Stevens-Johnson syndrome on the seventh day of treatment. One presented generalized maculopapular rash on the fourth day, and the third had to interrupt treatment on the fifteenth day due to severe headache and insomnia. All side-effects reversed soon after stopping pefloxacin.

These preliminary observations suggest that the use of quinolones may cause in AIDS patients, as also describe before with other drugs, increased and severe adverse effects, and call our attention to the necessity of extreme prudence in further studies with their use in patients with HIV infections.

T.B.P.318 SEVERE ACUTE TRINITROBENZENE-SULFAMETHOXAZOLE (T-S) REACTION INDICED IN AIDS PATIENTS

Johnson, Michael P.; Goodson, R.D.**; Shands, Jr., J.M.*. Colleges of Medicine* and Pharmacy**, University of Florida, Gainesville, Florida, USA.

Objective: To describe a severe, acute syndrome of fever, hypotension, and primary infiltrates in HIV infected patients receiving T-S.

Methods: We present the cases of two patients that we have seen and the four cases reported in the literature to describe this new syndrome.

Results: The clinical features occurred within hours of T-S therapy.

Patient: Fever New infiltrates Chest X-ray Pneumocystis Prior T-S

1 39 Yes 15 mm/Hg No Infiltrates Not Detected by Unknown

2 39 Yes 65 mm/Hg No Infiltrates Not Detected by Unknown

3 40 Yes 60 mm/Hg New Infiltrates Previously Treated Yes

4 40 Yes 70 mm/Hg New Infiltrates Previously Treated Yes

5 40 Yes "low" Not Described Previously Treated Yes

6 41 Not Described Not Described Previously Treated Yes

All patients improved following discontinuation of T-S.

Conclusion: An unusual syndrome of high fever, hypotension, and pulmonary infiltrates may follow T-S administration to HIV infected individuals with proven or suspected *Pneumocystis carinii* pneumonia. This syndrome, unreported in non-HIV infected patients and rare in HIV positive patients, is acute, severe, and may be difficult to distinguish from sepsis.

* Case reports obtained by literature search.

T.B.P.319 HYPOGLYCEMIE ET DIABETE DUS AU

RESERVE EN GLUCOSE DU SIDA.
PARDONNE, Christian; Briceau, F.; Lepout, C.; Assan D.; Assan R.*
Hôpital Claude-Bernard, 75018 Paris, France.

Objectif: Analyser la glycémie de 18 SIDA (pneumocystoses) traités par méplaté de pentamidine (P), 4 mg/kg/j en i.v.

Méthode: Des glycémies (hors perfusion) à 3,2 mmol/l

définissant l'hypoglycémie et à 15 mmol/l le diabète.

Résultats: 8 malades ont un trouble glycémique à 4 des

hypoglycémies, 3 une hypoglycémie puis un diabète et 1 un

diabète d'emblée (3/8 d'hypoglycémies, 2/8 de diabète). Les

hypoglycémies (9,1±0,7 mmol/l) étaient précoces (5^e jour

après le début de P) avec 2 comas prolongés. Le diabète

(glycémie 26,5±2,2 mmol/l) survint après 41±4 jours, était

insulinodépendant chez tous. La dose totale de P était

1941±218 mg en cas de trouble et 1170±152 mg en leur

absence. Le créatininémie sous P était 194±15 µmol/l

(hypoglycémie seule), 236±52 µmol/l (hypoglycémie + diabète)

et 116±14 µmol/l (absence de trouble) (p < 0,01).

Conclusion: Des doses élevées et instancieuses de pentamidine favorisent

l'accumulation de P et les troubles glycémiques. Avec le

méplaté, la fréquence des hypoglycémies (3/8) et surtout du

diabète (2/8) est supérieure qu'avec l'isothionate de P (2/8

d'hypoglycémies, 0/8 de diabète) (Smith-Bayliss C.M. et al. Clin Pharmacol Ther, 1986, 39, 271-5).

T.B.P.320 ORAL DEMONSTRATION TO SULFADIAZINE AND TRINITROBENZENE-SULFAMETHOXAZOLE (TSP-SM) IN 4 PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME

Nickola, Jose H.; and Maggio, C.M., University of Miami School of Medicine, Miami, Florida, USA. Jackson Memorial Hospital, Pharmacy Department, Miami, Florida, USA.

Objective: To develop and evaluate an abbreviated oral desensitization program for patients with AIDS allergic to sulfadiazine and/or TSP-SM.

Methods: Four patients with prior allergic reactions to sulfadiazine (3) and TSP-SM (1) were identified. Allergic reactions included a severe generalized

erythematous rash with pruritus. Sulfadiazine oral suspension was compounded

at a concentration of 1 mg/ml. An initial dose of 1 ml was given and

subsequent dose concentrations were doubled every 15 minutes to achieve a

total dose of 1 gm within 2.5 hours. TSP-SM suspension, serially diluted to

10 mg/ml (5% concentration), was administered in aliquots of 1/2, 1, 2 and 4

ml every 15 minutes to achieve a total dose of approximately 800mg of SM after 2

hours.

Results: One patient had mild rash and pruritus at 400 mg of SM component.

Desensitization was interrupted for 48 hours and restarted with successful

completion. With long-term follow-up, one patient has demonstrated a

phenomenon of *in-vitro* re-sensitization and sulfadiazine was discontinued temporarily.

Conclusion: Oral sulfadiazine and TSP-SM desensitization should be

considered in patients with sulfadiazine-allergy. Compared to current

literature values, an abbreviated desensitization program, as described, may

be useful.

T.B.P.321 A METHOD FOR RAPID ORAL DEMONSTRATION OF PATIENTS ALLERGIC TO AZT

MacDuff, D.L. Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada.

Patients with HIV infection experience an increasing frequency of allergic reactions to antiretroviral drugs with approximately 18 experiencing sufficiently severe reaction to AZT to warrant discontinuation of the drug. In a population of 200 patients treated with AZT, 12 patients with a history of any sensitivity developed a rash with AZT. Two subsequent re-challenges were attempted in 3 patients and resulted in reappearance of the rash at 12 and 2 hours respectively.

Method: In an attempt to desensitize 3 patients, AZT was given orally at increasing doses according to the following schedule: 1, 10, 20, 50, 100, 200 and 500 mg every 15 minutes; 1, 2, 5, 10, 20, 50 mg hourly and 200 mg every 4 hours thereafter.

Results: All 3 patients tolerated AZT desensitization without adverse clinical, hematological or immunological effects. One patient underwent 2 successful desensitizations following AZT withdrawal for intercurrent illness.

Conclusion: Intolerance to AZT resulting in severe rash can be treated with a simple, rapid oral desensitization. Repeated desensitizations may be performed with little risk of adverse reactions.

T.B.P.322 RECOMBINANT INTERFERON- β_2 PROTECTS AGAINST ZIDOVUDINE-INDUCED GENETIC DAMAGE IN AIDS PATIENTS

Shafiq, Nazam*; Notta, M. and Hallard, R.B. *Department of Chemical, Environmental and Occupational Medicine, University of New South Wales, Sydney, Australia; **Department of Medicine, The University of Texas Medical Branch, Galveston, Texas, USA.

This study was conducted to evaluate the *in vivo* gene-toxicity of zidovudine (ZDV) in patients with AIDS. AIDS patients (n=10) were non-smokers and on ZDV (1500 mg/day) as a sole medication for at least 6 months.

The study. AIDS and AHC patients prior to receiving any therapy served as a negative control. Whole blood cultures were initiated by conventional methods with PMA 1:50 dilution. For each study subject each experiment consisted of an untreated control and recombinant Interferon- β_2 (rIFN- β_2) experimen-

tal group cultures received 10, 100, 1000, 10,000 units of rIFN- β_2 for the entire incubation period. Cells were harvested at 72 hours and stained with the fluorescence plus Giemsa method which enables the determination of number of division cycles a cell has completed. One hundred metaphases from first division cells were scored from each culture for

chromosome aberrations that were mainly from the chromosome-type, i.e. chromatid, chromosome, and isochromatid breaks. The frequency of breaks in the study and negative control group was 5.1±1.2 and 5.0±1.2, respectively (p > 0.05). Cultures receiving 100 and 1000 units of rIFN- β_2 however, showed a frequency of 2.1±0.3 and 0.7±0.37 respectively,

which was significantly lower than the untreated cultures (p < 0.05), using paired t-test. At the highest dose of rIFN- β_2 no aberrations were detected. We conclude that rIFN- β_2 protects against ZDV induced genetic damage.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

T.B.P.323 MEGALOBLASTIC CHANGES IN THE BONE MARROW OF AIT TREATED AIDS-PATIENTS AS A PROGNOSTIC MARKER FOR NEED OF BLOOD TRANSFUSION.

Roy, Leonard, Van Den Burg-Wolf, M, Pistersz, R, Van Veen, J, Bessink H, Verweyling voor Bloedovernameking Prinsengracht, Amsterdam, The Netherlands.

Objective: to study the effects of one year azidothymidine (AZT) treatment on the erythropoiesis of AIDS-patients.

Patients and methods: twenty three male patients, classified as having AIDS underwent serial bone marrow aspirations during AZT treatment (6 x 200 mg qd).

Results: After one month AZT 12/23 (52%) of the patients exhibited moderate megaloblastic changes in the bone marrow, whereas the other 11 remained normoblastic. Sixteen patients were available for follow up after 12 months AZT therapy. 8 from the megaloblastic group and 8 from the normoblastic. Vitamin B12 and folic acid levels were not significantly different in both groups during AZT treatment. In the group with megaloblastic changes the patients needed a significantly higher number of red cell concentrates than in the normoblastic group, i.e. 42 units versus 6 units (p < 0.05).

Conclusion: Megaloblastosis of the bone marrow early in the treatment with AZT may be a prognostic marker for the need of blood transfusion in AIDS-patients.

T.B.P.325 HOME TRANSFUSION FOR AIDS PATIENTS ON ZIDOVUDINE

HE, HAN, KAZANZAKI, A, K, Jevancic, S, I Gilson *
*Nightingale Nurses Association, Milwaukee, WI, USA, **Department of Pediatrics, University of Wisconsin Medical School (Milwaukee Clinical Campus), Milwaukee, WI, USA

Objective: To describe a home blood transfusion (HBT) program for AIDS patients (pts) on zidovudine (ZDV) therapy.
Methods: AIDS pts with transfused anemia (Hgb < 8 gm) were contacted. HBT by home care nurses as an alternative to hospital transfusions (ht), usually at 2 units of HBC-poor packed RBC under supervision of the primary MD. Most pts were ambulatory and all were hemodynamically stable. All were required to have a consent present after HT.
Results: 8 AIDS pts on ZDV were given 178 U HBC-poor packed RBC over mean 13 mo (range 7-18). US u were HT and 42 u were hospital outpatient or inpatient. 15 pts are presently alive (5 still on ZDV). 2 expired from opportunistic infections. One pt had an unusual reaction to HT which responded to antihistamines. One pt had a delayed hemolytic reaction to blood given as an inpatient, several minor febrile reactions to HT did not require treatment. Cost for 2 units HT = \$182, cost for 2 units in hospital = \$ 699. HT reduced total cost by 31%, saving an average of \$196/pt/yr. No pt had to permanently stop ZDV because of anemia, and all pts continue to prefer HT.
Conclusion: HT is feasible, safe, cost-effective, and facilitates long-term ZDV therapy in the home environment.

T.B.P.327 POLYMYOSITIS DURING ZIDOVUDINE THERAPY

Therrien, Thomas, Kaiser Foundation Hospital, Oakland, California

Objective: To determine the incidence of polymyositis during zidovudine (AZT) therapy.

Methods: A 12 month prospective followup of a cohort of 10 patients (pts) taking AZT. Creatine phosphokinase (CKP) was routinely monitored during visits and in pts with symptoms of polymyositis.

Results: Eight pts (40%) were found to have elevated CKP over the period of observation. Onset of lab abnormality was from 10 days to 17 months (mean 7.8 months) after starting AZT. Most pts had mild Quadriceps muscle weakness and fatigue on exertion; 1 pt had acute onset Quadriceps tenderness and weakness which resolved in 1 week; 1 pt had chronic weakness limiting ability to ambulate. Most pts either resolved (9/8) or remained stable (4/pts) despite continued AZT in all patients from 3 to 13 months (mean 4.6) after onset of polymyositis.

Peak CKP ranged from 418 to 894 IU/L (n = 200). Duration of elevation varied from 1 to 5 months. No correlation between dose of AZT and severity of polymyositis was found.

Conclusion: Mild polymyositis is common during zidovudine therapy but usually resolves or remains stable during continued zidovudine therapy.

T.B.P.324 THE EFFECTS OF PCP PROPHYLACTIC AGENTS ON ZIDOVUDINE-INDUCED ANEMIAS

Rodgers, P., Craig Egge, Marie, C, Wolbert, J, Kelly, J, Kibbe, D, Ballinger Hospital Center, Community Health Project, St. St. USA.

Objective: To review transfusion requirements in PCP prophylaxis receiving zidovudine. **Method:** Through chart review, transfusion requirements for 169 patients on zidovudine therapy for a median of 22 weeks were compared by type of absence of PCP prophylaxis. Eighty-eight patients received DMG/ Sulfa, 59 patients received aerosolized Pentamidine and 22 patients received no PCP prophylaxis. Hematocrit (Hct) were recorded at onset of zidovudine therapy and at time of transfusion. Length of time from initiation of zidovudine to time of transfusion was recorded. Hematocrit 54 patients required transfusion: 28 (32%) on DMG/Sulfa, 10 (17%) on aerosolized Pentamidine and 11 (50%) without prophylaxis. The DMG/Sulfa and Pentamidine groups were not statistically different with respect to pre-zidovudine Hct or time to transfusion. However, in the non-prophylaxed group the pre-zidovudine Hct was significantly lower (31.17 vs. 30.85, p less than .01) and the most of transfusion-dependent anemia significantly sooner (82 days vs. 103 days, p less than .01). **Conclusion:** The use of DMG/Sulfa as a PCP prophylactic agent as compared to aerosolized Pentamidine is associated with a significant increase in the incidence of transfusion-dependent anemia. Randomized, controlled studies are indicated.

T.B.P.326 THE TOXICITY OF ZIDOVUDINE IN THE TREATMENT OF PATIENTS WITH AIDS-RELATED COMPLEX (ARC) AND AIDS

Geared, K. St. Elizabeth's Hospital, Lowell, Massachusetts

Objective: To evaluate zidovudine toxicity over a two year period of its clinical use in HIV patients.

Methods: Zidovudine-treated 351 ARC and AIDS patients, on 100mg 4-hourly oral regimen, have been monitored fortnightly for up to two years.
Results: Over a median follow-up of 8.3 months (range 1 - 23) zidovudine was stopped/discontinued because of death (51), drug toxicity (48), other toxic treatments (23) or patient's request (27). The dose was lowered in 50 patients due to toxicity. Anemia or hypoproteinaemia accounted for drug cessation and lowering of dose in 74 and leucopenia alone in 16 cases. Of 15 patients with thrombocytopenia, the platelets rose to normal level in 11 but this was not sustained for longer than 3 months in 5 patients. 182 (52) subjects received at least one blood transfusion. Of 110 patients who were on zidovudine for more than one year in 66 (60%) drug had been discontinued. Bone marrow aspirates in 13 patients with median follow-up of 8 months showed hypercellularity to 6 and hypocellular erythropoiesis in 6 patients. In 8 patients with a 3-fold rise in CPK, zidovudine was stopped in a median follow-up of 11 months; in 4 the levels didn't change significantly, in 2 fell substantially and in 2 normalized. Muscle biopsy in 7 of these 8 patients with a rise associated peripheral muscle atrophy, was normal.
Conclusions: Zidovudine treatment in ARC and AIDS patients cause severe hematological toxicity and possibly effects muscle metabolism. In one year 60% of treated patients needed to be taken off zidovudine.

T.B.P.328 NEUTROPHILIA IN HIV INFECTED PATIENTS UNDER ZIDOVUDINE THERAPY.

Palmer, Peter, J, Morgan, JG, O'Neil, GJ, Adams G, and Nyrop, M. Tulane University, New Orleans, LA, USA

Objective: To evaluate neutrophilia in patients with symptomatic HIV infection before and during Zidovudine (ZDV) therapy.

Methods: Forty nine individuals with late ARC or AIDS who had negative serology for pretreatment were studied. The natural history of neutrophilia, and absolute numbers of neutrophils and lymphocytes, could be followed in 47 of these during ZDV treatment. Neutrophil (NOS) percentages (N) were the differential, absolute NOS count was derived from the value and the WBC. Geographic controls established the normal range.

Results: Twenty two individuals (45%) had NOS I (> 42). Absolute NOS count (> 450) were elevated in 9/40 (18%) subjects. Following treatment with ZDV (median duration = 22 weeks, range 2 - 24), 28 had raised N and 12 had elevated absolute NOS count. For the entire population, there were significant reductions in NOS T, numbers, and total lymphocyte numbers (p < 0.05). Overall, neutrophils were unchanged. In a subset of patients (n=16) with neutrophil toxicity (mean time of appearance = 5.3 ± 1.1 weeks), both NOS T and absolute count decreased. When dose reduction of ZDV resulted in a raise in neutrophil numbers there was a concomitant increase in both T and absolute NOS count.

Conclusions: Increased NOS T seen in symptomatic HIV infected patients are frequent and associated with elevated absolute counts. Thus, there appears to be a true rise in NOS T in many HIV-infected patients. When ZDV treatment induces neutrophil toxicity, NOS are usually reduced in line, suggesting that ZDV can be toxic for NOS, as well as neutrophils.

Session d'attaché
Poster Session



Aspects cliniques
Clinical Aspects of AIDS

T.B.P.329

ACT: DOUBLE EDGED SWORD
RITA L. HARRIS, Deborah L. University of California School of Medicine, San Francisco, CA, U.S.A.

Objective: To provide information about patients' stressors as well as positive perceptions regarding AZT that may influence their decision to take AZT, cooperate with treatment, and possibly their treatment outcome.
Method: 100 seropositive homosexual men with at least one HIV-related symptom were recruited from the UCSF AIDS Clinic and administered an in-depth, semi-structured interview at 4 time points approximately 6 months apart. The interview was designed to elicit symptoms, coping strategies, and both positive and negative perceptions in such areas as HIV testing, symptom recognition, clinical diagnosis, illness episodes, and treatment.
Results: 60.8% spontaneously raised 39 concerns about AZT and 26 positive perceptions. The number of 39 who mentioned these concerns, which we categorized, were: 39--toxicity side-effects; 30--cost and financing; 18--future decisions about the number of 39 who mentioned these concerns, which we categorized, were: 18--AZT as a negative symbol of the reality of AIDS/AIDS; 17--negative physician interactions with health care providers; 10--lifestyle modifications; 9--effectiveness of AZT; 7--drug study protocols; 7--lack of funding/availability of drugs; 6--telling others; 6--going off AZT; 4--time limitations; 4--availability of social support; 2--peer pressure to choose AZT; 10--peer pressure to choose an alternative; By the Time 2 interview, 20.6% had been on AZT, 30.0% were in addition to 4 on study protocols. A total of 32 subjects experienced negative side effects they attributed to AZT. **Conclusions:** For every 100 patients, AZT has been a means of promoting survival and reducing the severity and frequency of opportunistic infections. For many of the AIDS patients in our study, however, AZT also involved a number of physical and psychosocial stressors.

T.B.P.331

PHASE I STUDY OF INTERFERON ALPHA-2b (INTRON), ZIDOVUDINE AND ZINC-FP IN PATIENTS WITH AIDS-ASSOCIATED BACTERIAL INFECTIONS
Richard M. Schoenbach, S. O'Keefe, P. Thompson, G. and Santiago, S. University of Miami, Miami, Florida, U.S.A.

Objective: To evaluate the efficacy and safety of ZINC-FP in combination with Intron and zidovudine in patients with AIDS-associated bacterial infections (ABIs).
Method: Patients with 30 and no active infections were enrolled. Intron was given as 12 mg 3x daily and zidovudine 200mg orally every 4 hrs for 16 wks. Patients received placebo or ZINC-FP, 5-10 mg/kg 5x daily for 16 wks. **Results:** 12 patients have been enrolled. Mean length of time on study is 8.0 weeks. All have completed 16 wks. Change in mean hematology parameters were:
Wbc (x10⁶/mm³) 4.5 4.7 8.9 9.0 4.0 5.9 4.3
(range) 2.5-7.5/3.0-12.7/1.8-28.2/2.8-28.0/2.0-21.6/2.0-10.4
Neutrophils(%) 2428 2852 2823 5280 6323 3820 2114
Platelet Ct (x10⁹) 203 158 168 150 174 174 210
CD4 cells/mm³ 225 N/A 260 N/A N/A 330 253
pH (log) 4 N/A 1 N/A N/A
One patient developed severe hypoxemia and died. Nephritis, fatigue, anorexia, weight loss, headache, arthralgia, myalgia and fevers were seen during the first 4 wks of therapy. 2 patients had bone pain, 1 patient had a complete anti-tumor response; the remainder had a partial anti-tumor response.
Conclusion: ZINC-FP resulted in dramatic and sustained increases in the WBC count and neutrophil count in patients receiving Intron and zidovudine. Doses of 4-5mg/kg of ZINC-FP may be useful. Adverse reactions were minimal. Early data do not suggest negative or synergistic ZINC-FP anti-HIV activity.

T.B.P.333

UPDATE ON PROGRAM STANDARDIZATION AMONG PUBLIC HEALTH LABORATORIES IN THE U.S.A. PERFORMING TESTS FOR HUMAN RETROVIRUSES
Margaret Billings, J. J. Bilalov, A. M. Joseph, J. M. and Gethal, J. M. Institute Hygienic Laboratories, Administration, (Sb)

Objective: To promote uniformity and assure quality of testing for HIV and other human retroviruses.
Method: A survey of the fifty-four member laboratories of the Association of State and Territorial Public Health Laboratory Directors seeking information and data on human retroviruses in the U.S.A. have established an effective system for program standardization. Other countries have expressed interest in the program and some have established similar consensus building structures.

T.B.P.330

PARASITIS IN HIV AS POSITIVE DRUG ABUSERS
Marco Masini, A. Petrucci, A. M. Costa, A. Ricciardi, F. Castellani, F. Chiodo, Istituto di Clinica Dermatologica, *Istituto Malattie Infettive Università di Bologna, Bologna, ITALY.

Objective: To describe the onset of parasitosis during HIV infection in drug abusing patients.
Results: We report on 5 Italian patients, aged between 22 and 34 years, who all had been drug abusers for more than 2 years. They have never been affected by parasitosis before diagnosis of HIV infection was made, and three of them have developed A.I.B.S. within the following 12 months. All patients presented small periorificial lesions which covered less than 25% of the body surface. The lesions didn't worsen as in the three patients in which opportunistic infections occurred as in a syphilis free patient. In only one case, a small PML granuloma was observed in a generalized flare of extradermal parasitosis, which however responded to therapy with topical corticosteroids. Parasitosis is a disease of unknown etiology, but it is generally suggested that infectious may play a role of stimulus in a genetically predisposed patient, and that parasitosis is described as a typical example of this event. Patients in whom HIV infection is associated with parasitosis have not frequently been reported. The Authors generally presented small periorificial lesions which covered less than 25% of the body surface under treatment and parasitosis often became uncontrollable when immune response was depressed during opportunistic infections. The clinical course and infectious background of drug abusers can be explain the different aspect of the disease in this patients.

Diagnostic
Diagnosis

T.B.P.332

A NEW MORE SENSITIVE AND HIGHLY SPECIFIC ANTI HIV-1 ASSAY BASED ON RECOMBINANT PROTEIN.

Richard M. Schoenbach, S. O'Keefe, P. Thompson, G. and Santiago, S. University of Miami, Miami, Florida, U.S.A.
Objective: To replace tissue culture based HIV-1 assays with a sensitive and recombinant antigen in the Wellcozyme Monoclonal test and to further improve on the specificity seen in Wellcozyme competitive assays.
Method: A recombinant DNA produced fusion protein containing the immunodominant regions of HIV-1 envelope and core proteins replaced whole viable lysate grown in CD4 cells. Chemically inactivated herdsmenish peroxidase was included in the assay procedure and its effect on the rate of false positive reactions was determined.
Results: All of the 348 confirmed HIV-1 positive sera from AIDS, ARC and seropositive donors reacted (100% sensitivity) in the test. In 4 out of 5 serial samples taken from donors during seroconversion the assay detected HIV antibodies earlier than the Wellcozyme Monoclonal test. The assay was used to 10 fold more sensitive on end point dilutions of weakly reactive sera and had similar sensitivity with strongly reactive sera. None of 11542 negatives (9509 sera, 2034 plasma) were reactive (100% specificity), although one sample was close to cut-off.
Conclusion: The use of recombinant antigens has improved the sensitivity with weak samples and the inclusion of peroxidase in the assay procedure has increased specificity. The majority of false positive reactions seen in previous tests of this type were caused by an inhibitory anti-peroxidase activity present in some serum samples.

T.B.P.334

THE "INTERNAL IMAGE"-BEARING ANTIBODIES IN SERA OF PATIENTS WITH HIV-1 INFECTION
Schedel, Ingrid; Winkelmann, P.; Dreihausman, U.; Wink, J. and Deitler, M. Department of Internal Medicine, Division of Immunology, *Institute of Virology, Medical School Hannover

Human immunodeficiency virus (HIV)-neutralizing antibodies could be detected in HIV-infected individuals by different groups. Obviously, the infection of the target-cell for HIV takes place by specific binding of the viral surface glycoprotein (gp120) with cellular CD4-receptor. This binding site is conserved in different isolates of HIV and lineage to CD4 as well as specific binding to gp120 could be blocked by monoclonal antibodies reacting with the gp120-epitope.
Sera from patients with HIV-infection (n=103) and sera of an HIV-negative control group (n=50) were tested for antibodies reacting with the gp120-recognizing region of monoclonal antibodies in an ELISA-system. The HIV-positive sera showed significantly elevated binding activities in comparison with the sera of the control group (p<0.0001). In the multiple regression analysis we determined a correlation of 0.38 (p<0.01) between binding activity and linear combination of the following parameters: stage (seroconversion), IgG-absolute, IgM-absolute, IgA/IgG-ratio, Mif-test, Mif-test-optimized, public health laboratory in the U.S.A. have established an effective system for program standardization. Other countries have expressed interest in the program and some have established similar consensus building structures.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

T.B.P.335 EVALUATION OF DIFFERENT ANTI-HIV REAGENTS THAT ARE AVAILABLE IN MEXICO
 Dominguez J., Morales C., Moreno M.* and Cruz M.*
 Centro Nacional de la Transfusión Sanguínea, México, D.F.

Objective.

To get to know percentage of sensitivity, specificity, false positive, false negatives of the reagents that are used in the Mexican health care system.

Method.

5 Traditional Elisa, 3 recombinant Elisa, 3 agglutination and 2 quick technology Elisa were evaluated with a known panel of 160 samples with aids, asymptomatic seropositives, healthy/donors. Other infections samples and blood donors samples.

Results:

The percentage of sensitivity was between 100 and 62.5% specificity between 98.3 to 82.5% false positive index turned out to be between 4.76 and 41.17% and the false negative index was from 37.5 to 0%.

Conclusion.

We found that two types of reagents. One of agglutination technology and the other one Elisa quick technology were not suitable for its use. The rest of the reagents turned out to be suitable for their use.

T.B.P.336 WHICH IS THE BEST LABORATORY MARKER WHEN FOLLOWING HIV-POSITIVE PERSON?
 Reis. M.*; Sprinz, E.**; Kronfeld, M.**; Azevedo, M.*; Saadi, C.*; GRAVBE, M.* et al.
 *Laboratório Welmann de Porto Alegre
 **Hospital de Clínicas de Porto Alegre

Objective. Establish the best laboratory marker when following HIV-positive patients.

Methods. It were analyzed 60 ambulatory patients and 19 hospital HIV-positive patients. The following tests were executed: Western-blot (WB-Dupont), Envsacor HIV (ELISA-Abbott) and the presence of viral circulating antigen (HIV-Ag).

Results. The patients were segregated in 3 groups as follows:
 I: positive WB 24, positive EC 24, negative HIV-Ag (40 ambulatory patients)

II: positive WB 24, negative EC 24, negative HIV-Ag (4 hospitalized and 5 ambulatory patients)

III: positive WB 24, negative EC 24, positive HIV-Ag (8 hospitalized and 10 ambulatory patients)

IV: positive WB 24, positive EC 24, positive HIV-Ag (1 hospitalized and 5 ambulatory patients)

CONCLUSION. The best relation with anti-p24 antibody drop, antigenemia and clinical criteria of AIDS progression was obtained with EC-Abbott. Surprisingly, we did not find the WB-Dupont controllable as a marker of AIDS progression.

T.B.P.337 COMPARISON OF COMMERCIAL AVAILABLE TEST FOR HIV ANTIBODIES USING LAMBIAN SERA

Loz N.P., Hira S.S., Sityambang J.P., Khabibi R.P., Chipoke L.*
 Macwanwa*, *University Teaching Hospital, Lusaka, Zambia.

OBJECTIVE. To compare the available test, the first generation, and confirmatory test with a view to decide the best screening test and confirmatory test in Zambia.

METHOD. 3 Panels of sera were set. Each panel of sera was screened for HIV antibodies using a set of test from the first generation and new generation. Positives were confirmed using the standard confirmatory test like Western blots and immunofluorescent as well as using another ELISA as a confirmatory test.

RESULTS. Some of the first generation ELISA gave a very high false positive rate while the second generation were more reliable. Use of second ELISA as a confirmatory test was found to be as good as using the standard confirmatory i.e. Western blots.

CONCLUSION. Use of one of two other ELISA can be used as a confirmatory test. Immunofluorescent test was the other alternative to confirmatory test.

T.B.P.338 COMPARISON OF TWO HIV IMMUNOLOGY TECHNIQUES.
 MURRAY E., MATRA G.²

1. Mayo Medical Research Institute
 2. University of Nairobi, Microbiology Dept.

OBJECTIVE: To investigate the pattern of bands in strips of two electroforetic immunology techniques to same sera.

METHOD: 72 adult sera, 51 positive for HIV-1 and 21 seronegative were tested with an DUPONT and ANKEX Western blot electroforetic techniques.

RESULTS: Comparison of tests with DUPONT as reference test. (Positive tests)

	GENERAL	P15	P17	P24	P33	P41	P55	P64	P66	P160
a) No of sera observed:	51	20	32	48	50	50	51	41	46	46
b) % of sera seen for:										
both tests:	76	82	60	78	70	66	51	49	38	39
c) Sensitivity:	95	100	90	75	99	94	95	84	53	53
d) Specificity:	92	100	43	73	80	65	92	46	61	61

No sp 120 was found in ANKEX, but was present in 51% of DUPONT strips

CONCLUSION: Despite the high level of correspondence present when combinations of protein bands are considered, great variation was present on regarding individual proteins and glycoproteins in the two techniques.

T.B.P.339 LABORATORY TESTING FOR HIV-1 ANTIBODY TESTING IN CALIFORNIA: ANALYSIS OF CURRENT PRACTICES AND IMPROVEMENT STRATEGIES

Wang, S.H., Hira S.S., Sityambang J.P., Khabibi R.P., Chipoke L.*
 *San Diego State University, San Diego, California, USA.

San Diego State University, San Diego, California, USA.
 *California West and Southern States Laboratory, Berkeley, California, USA.

Objective. This program uses HIV antibody testing as a model to develop and evaluate methods of optimizing and improving laboratory quality.

Method. Using a "blind" protocol laboratory testing, serum samples with known HIV content were submitted as clinical specimens by physicians, clinicians and health-care workers to their usual sources of testing. Currently 20 HIV laboratories and 11 confirmatory laboratories in five states were included. An open proficiency test and a written survey to a sample of 10 HIV laboratories in California has also been completed in order to profile HIV testing practices and plan future improvement activities.

Results. Performance on HIV screen tests has been excellent with fewer than 2% incorrect results. Western blot confirmatory tests are more problematic with commercial laboratories reporting a high proportion of indeterminate results, while public health laboratories in California use a well standardized laboratory protocol. Commercial reference laboratories use both licensed and unlicensed Western blot reagents with a variety of interpretation criteria for seronegativity testing. Seropositivity testing, many reports were obtained without a written consent of the patient and physician. There is no consensus on the use of a "blind" protocol of HIV testing. Seropositivity testing, many reports were obtained without a written consent of the patient and physician. There is no consensus on the use of a "blind" protocol of HIV testing.

Conclusions. HIV antibody testing has the potential to be a highly sensitive and specific assay. However, there was no consensus on what was clinically important bands.

Conclusions. HIV antibody testing has the potential to be a highly sensitive and specific assay. However, there was no consensus on what was clinically important bands. Seropositivity testing, many reports were obtained without a written consent of the patient and physician. There is no consensus on the use of a "blind" protocol of HIV testing. Seropositivity testing, many reports were obtained without a written consent of the patient and physician. There is no consensus on the use of a "blind" protocol of HIV testing.

T.B.P.340 CROSS-REACTIVITY BETWEEN HIV-1 FOR DETECTION OF HIV-1 AND HIV-2

Reis, M.*; Sprinz, E.**; Kronfeld, M.**; Azevedo, M.*; Saadi, C.*; GRAVBE, M.* et al.
 *Laboratório Welmann de Porto Alegre
 **Hospital de Clínicas de Porto Alegre

Objective. To study the cross-reactivity of HIV-1 and HIV-2 in ELISA assays.

Methods. Sixty sera from hemophiliacs were tested for antibodies HIV-1 (HIV-1 IgG) and HIV-2 (HIV-2 IgG) and confirmed by means of DNA/RNA (Abbott) and RIPA. In all the sera, HIV-2 antibodies were determined using a commercial available anti-HIV-2 ELISA test (ELAVIA 2) (Diagnostica Pasteur).

Results. HIV-2 ELISA reactivity was observed in only 1 out of the 27 HIV-1-negative samples, but HIV-2 reactivity was found in 27 out of the 33 HIV-1-positive sera. All the HIV-2 samples positive by ELISA were negative by RIPA, which difference was statistically significant (p<0.05). No significant differences were observed between the presence or absence of HIV-1 core proteins and HIV-2.

Conclusion. These results confirm the high degree of serologic cross-reactivity between gene products of HIV-1 and HIV-2 (ELISA).

(Supported by a grant from Fundação Boomer).

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

T.B.P.341 FAILURE OF ELISA AND ME TESTING TO DETECT HIV INFECTED SUBJECTS

Remolina, M.†; Ispolito, G.***; Nicolai, M.***; Mirolo, M.†; Remolina, R.***; Angelini, P.†
 *Istituto Red Cross, National Center for Blood Transfusion, **Lazaro Spallanzani Hospital for Infectious Diseases, ***University of Rome-Italy

Objective: To assess the efficacy of ELISA and ME test routinely used in laboratory setting to detect HIV infected subjects.

Methods: 411 plasma portions of seropositive blood donors were tested by ELISA and ME; most negative for anti-HIV were in situ hybridized (ISH) with an ISHA plasmid containing the nine-alkaline NcoI-draI viral insert. 17 donors were tested by inserting an antigenic surface group into cytosine of the deuterated DNA.

Results: Studied population was: 27 partners (3 males and 24 females) of 27 seropositive blood donors (20 males and 2 females); the distribution by risk group was: homosexual activity 3.7%, bisexual male 11.1%, intravenous drug addict 16.5%, heterosexual contacts 22.2%, not known 7.6%.

In 3 cases the partner, belonging to risk group, was the source of class I HLA specificities represented, eliminated antibodies to the A, B and C-2 of the HLA system. Testing in the panel of T-lymphocytes was carried out to determine the degree of serum purification of HLA-A, B, C antibodies.

Conclusion: In false-positive individuals after seropositivity by the serologic antigen the sera in ELISA became negative; this was confirmed in the panel of T-cells. It can be concluded that false-positive results of ELISA may be due to antibodies to class I antigens of the HLA system.

T.B.P.342 CORRECTION OF FALSE-POSITIVE RESULTS OF ELISA OF IMMUNOELECTROPHORESIS

Kabatals, E.†, Schovay, A.**, Svrtkova, J., Burstin, J.**, Shif, B.**, Denkova, A.**, *Kriga, M.†
 *Kriga Institute of Microbiology, Latvian SSR Acad.Sci., ** Rigas Medical Institute

Summary: A near-real serotyping of various subpopulations in sera of HIV infected demonstrated that ELISA is a most widespread method of examination, and, irrespective of its high specificity, yields false-positive results in a definite percent of cases.

Methods: Serological testing for the presence of antibodies to AIDS virus was carried out by ELISA with lower-potential and imported test-systems. The obtained results were confirmed by immunoelectrophoresis.

Results: The results of ELISA were corrected by the following: adsorption of sera (the test and control sera) by the pool of trophoblastic antigen, screening of the sera under study prior to and after treatment with the trophoblastic antigen in the panel of T-lymphocytes of test-donors with the known spectrum of HLA-antigens, adsorption by the pool of trophoblastic antigen, with only class I HLA specificities represented, eliminated antibodies to the A, B and C-2 of the HLA system. Testing in the panel of T-lymphocytes was carried out to determine the degree of serum purification of HLA-A, B, C antibodies.

Conclusion: In false-positive individuals after seropositivity by the serologic antigen the sera in ELISA became negative; this was confirmed in the panel of T-cells. It can be concluded that false-positive results of ELISA may be due to antibodies to class I antigens of the HLA system.

Donneurs et receveurs de sang et de produits sanguins Recipients and Donors of Blood and Blood Products

T.B.P.343 SEROSURVEY OF WOMEN IN A MATERNITY WARD

A. Santos Pinto, W. Canas Ferreira, E. Prieto, R.A. Sousa-Institute of Hygiene and Tropical Medicine, Ministry of Health, Cape Verde.

Objective: - To study the prevalence of hepatitis B markers and HIV antibodies in parturients receiving clinical care at a hospital in a Cape Verde Island (West Africa).

Methods: - During January and May 1988 serosurvey of the vertical transmission of hepatitis B virus was performed on 336 parturients and their babies. Specimens were analyzed also for anti-HIV antibodies. Elisa and Western blot was the methods employed.

Results: - 224 (17%) of the mothers were HBe Ag positive and 78 (11.7%) were HBe Ab positive. Study of HIV prevalence is in progress. The results will be presented and discussed at the Conference.

T.B.P.344 LOOKBACK: AN UPDATE ON THE NEW YORK EXPERIENCE

George, Eugene, Kessler, S., Moore, S., Berger, P., Drivalla, C.; New York Blood Center, New York, NY, USA.

Objective: To evaluate results and assess costs of the Lookback Program. **Methods:** A lookback of previous donations from 158 anti-HIV positive blood donors identified since April, 1985 has been carried out. 303 hospitals in the greater New York region have been notified of receipt of 247 components back to May, 1989.

Results: To date, 1627 reports have been received from hospitals (68% response rate); 1462 or 90% of components were transfused. Of these recipients, 1079 or 74% are deceased. Recipients known to have been discharged equal 326. Of these, 237 or 72% have been tested; 90 or 42% are HIV antibody positive. The positivity rate was highest in patients transfused in 1984; 46 patients or 61% of those tested were seropositive.

In 1989, 16 patients (52%) were positive. There were no positive recipients in 1989. There are 95 recipients (70%) between 18 and 70, which may be a surrogate measure of sexual activity and potential transmission. 8643,440, including 975,000 in grant support or approximately \$6,500 per positive recipient located. This figure does not include hospital costs which are substantial, nor does it include the cost of Lookback-generated lawsuits.

Conclusion: The 95 seropositive Lookback recipients identified constitute only a small fraction of the total estimated HIV infected population in the country. Despite its impact on public health risk, Lookback notifies our obligation to notify about information of significance to another's health.

T.B.P.345 THE ITALIAN HEMOPHILIC REGISTER AND NATURAL HISTORY OF HIV INFECTION

Schiappa, Nicola†; Ghisardini, A.***; Valderaci, C.†; Gringoli, A.***; Martelli, G.††† and Remolina, P.M.***
 * Istituto Superiore di Sanita, Roma, ** University of Rome, *** University of Milano, (Steering Committee of the Scientific and Medical Board of "Preparations all'uso interno")

Objective: To present the results of a nationwide survey of all population affected by congenital congenital disorders, with the aim to evaluate the time-trend of the incidence of HIV seropositivity and AIDS in the Italian Hemophilia population through a retrospective national cohort study.

Methods: This project is divided up into two phases: 1. the set up of the Register (National Hemophilia Survey), and 2. the evaluation of the spread of HIV infection. The National Hemophilia Survey carried out between September and November 1988 was performed by a standard questionnaire, with an individual code to ensure confidentiality sent to all the Hemophilia Centers to collect demographic and clinical information. Data have been analyzed using a database program.

Results: As of 15 January 1989, 21 Hemophilia Centers had replied. At this the information regarding 859 subjects were collected. On the whole a prevalence of HIV-Ab positivity of 21% was found.

Conclusions: This National Hemophilia Survey has been the first comprehensive evaluation of the Italian population affected by congenital congenital diseases. The Hemophilia Centers participate enthusiastically to this cooperative project. From this Nation Survey, through the analysis of the data it is still incomplete, a prevalence of HIV-Ab positivity of 21% was shown.

T.B.P.346 TRANSFUSION-ASSOCIATED (T-A) AIDS CASES

Schiappa, Nicola, Valderaci, C., Istituto Superiore di Sanita, Roma, Italy.

Objective: To present an update of the patients with AIDS due to blood transfusion, and to discuss the importance of an active surveillance system of T-A AIDS within the overall AIDS surveillance. The peculiarities of this specific surveillance will also be discussed.

Methods: A database has been created including all the subjects for whom the only associated risk factor was the reception of blood transfusion. It has been derived from the National AIDS Register, including other pieces of information collected by means of a special standardized form. The analysis has been carried out using different BMDP programs. **Results:** As of 31 December 1988, 53/3008 (1.8%) patients were reported with T-A AIDS, 5 of which were below 14 years of age (9.4%). At the same date, the case-fatality rate was 41.5%. Clinical and epidemiologic information will be presented, as well as the mean lag time between infection and the development of full-blown AIDS.

Conclusions: At the end of 1988, the relative proportion of T-A AIDS was slightly lower than at the end of 1987; in Italy, the case-fatality rate is also less for this subgroup of patients than for all the other AIDS subjects. The standard reporting form for AIDS has proved indispensable to describe both the pattern and the natural history of the syndrome in T-A patients. Nor have the reporting physicians provided enough data, as a result of an investigation carried out early in 1988. Thus a revised out national AIDS unit, the reporting physicians, the unit(s) where the blood was administered, and the blood bank to being implemented.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

T.B.P.347 HIV-1 HIV ANTIBODY SCREENING OF BLOOD DONORS IN LOCALITIES WITH HIGH HIV-1 ANTIBODY PREVALENCE

Transmission Study Group* represented by Hugh Elliott**

* Participating laboratories: San Francisco, CA, Miami, Florida, San Francisco, and Los Angeles, CA.
** Donor Blood Centers and Division of California, San Francisco, California, USA.

Objective: To assess the frequency of HIV-1 p24 antigen (p24) positivity among male donors in high anti-HIV-1 prevalence areas in the city of San Francisco (SF) during a period with a high rate of HIV seroconversions. **Method:** The SF component of the TEMUDA (Transmission Study) Group has collected in total 106 weekly 100 ml before anti-HIV-1 screening blood. Overall prevalence of anti-HIV-1 among these specimens was 5.3%. A subset of 2,297 cases was selected among males aged 18-64 years with addresses in SF by code barling one or more anti-HIV-1(p24) positivity results. The anti-HIV-1 prevalence of the subset by prior barling was 1.041. HIV-1 p24 by barling and Abbott's ELISA and neutralization (confirmatory) requests; if initially p24 reactive, anti-HIV-1 was reassayed (Genzyme, Inc.).

Results:

anti-HIV-1 Status	HIV-1 p24 antigen Barling	Index (1)	Neutralized
Positive	25	3 (12%)	3 (12%)
Negative	2,272	0 (0.41%)	0 (0%)

* San Francisco within the HIV CI of a Pulse Field defined HIV-1 sero of 1.
Conclusion: In HIV-1 p24 antigen positive blood donors from areas 2,272 anti-HIV-1(p24) prevalence in a population that yielded 25 anti-HIV-1(p24) results. Given the present anti-HIV-1 prevalence of 0.023 in the SF donors, over 20,000 seronegative donations would be needed for a similar situation of the anti-HIV-1(p24) results (assayed by Centers J 93-84-7002 and 93-84-7003 of the National Heart Lung and Blood Institute).

T.B.P.349 MULTICENTER EVALUATION OF A RECOMBINANT BASED HIV-1/HIV-2 COMBINATION SCREENING ENZYME IMMUNOASSAY.

F. Aviner, L. Gaudier, M. Juler-Jankovik, S. Riang, P. Sued, F. Simon, D. Sording, H. Haem, P. Schauer, H. Tzoumas, M. H. Tzoumas, * European Clinical Study Group, ** Abbott Laboratories, Wiesbaden-Deinhausen, Federal Republic of Germany (FRG).

OBJECTIVE: To evaluate a newly developed screening assay which utilizes HIV-1 and HIV-2 recombinant proteins. A significant number of HIV-2 infected individuals would not be detected with current HIV-1 screening assays.

METHOD: An enzyme immunoassay (EIA) was developed which utilizes both HIV-1 recombinant antigens and HIV-2 antigens and a recombinant HIV-2 envelope protein on the solid phase. The sensitivity and specificity of the EIA was evaluated on serum or plasma from normal blood donors and from individuals infected with HIV-1 or HIV-2. Results were compared to the current recombinant-based HIV-1 EIA.

RESULTS:

Type of Specimen	No. Tested	No. Positively Reacted (%)	
		HIV-1/EIA	HIV-1/HIV-2/EIA
Blood Donors	5029	5 (0.10)	8 (0.16)
HIV-1 Seropositive	288	288 (100)	288 (100)
HIV-2 Seropositive	202	154 (76.2)	201 (99.5)

Both assays had a specificity of 99.8% and detected 100% of the HIV-1/HIV-1 specimens. The sensitivity of HIV-1 EIA and HIV-1/HIV-2 EIA for detecting HIV-2 seropositives was 76.2% and 99.5% respectively.

CONCLUSION: The addition of HIV-2 envelope proteins to HIV-1 proteins already on the solid phase improved the performance of the HIV-1 EIA and significantly improved the detection of HIV-2 antibodies.

T.B.P.351 USE OF RAPID ASSAYS FOR ANTIBODY TO HIV IN BLOOD DONORS, PERSONS PRACTICING HIGH RISK BEHAVIORS AND SUSPECTED AIDS CASES IN GHANA

Mingis, Julius, Mitchell, S.W., Osei-Dwamena*,
**Wagdy Memorial Institute for Medical Research, Accra, Ghana, Africa;
***Wagdy Memorial International, Research Triangle Park, North Carolina, USA.

Objective: To evaluate three tests for antibody to HIV which do not require specialized equipment in three different populations in Ghana.

Method: Seven laboratories in Ghana participated in the study. Two thousand specimens from 3 populations were tested with RIVELISA, SEROITA and Retrotest. The 3 populations were blood donors, persons practicing high risk behaviors and suspected AIDS cases. Each specimen was also tested by ELISA for antibody to HIV-1 and HIV-2. All positivities were confirmed by Western Blot.

Results: Analysis is currently being performed to determine sensitivity, specificity, and predictive values of the tests in each of the populations tested. These results will be reported.

Conclusion: Many laboratories in developing countries are not equipped to perform the standard tests for HIV antibody, ELISA and Western Blot. Although the newly developed tests for HIV were designed primarily for screening blood donors, many of these tests will be asked to test suspected AIDS patients and persons thought to be at high risk of acquiring HIV. These tests have been evaluated for use in these populations under true field conditions.

T.B.P.346 HIV INFECTION IN WESTERN BLOT INDETERMINATE BLOOD DONORS

Richard Bonatti*,
H.H. Jurek**, MacDonnell***, Kunk 5***, Stramer****, Baifour****,
HIV Laboratory, North Chicago, IL, USA, *Cruz Cross, St. Paul, MN, USA,
****Memorial Blood Center, Minneapolis, MN, USA, ****Cruz Cross, Eneryville, CA, USA,
*****University of Minnesota, Minneapolis, MN, USA,
*****Minnesota Dept. of Health, Minneapolis, MN, USA

Objective: To determine whether U.S. Upper Midwest blood donors with indeterminate HIV-1 Western blot results are HIV-1 infected.

Methods: 187 volunteer blood donors who had tested reactively positive by enzyme immunoassay (EIA) and had at least one HIV-1 characteristic band on Western blot (but not positive) were asked to return for an interview and blood testing. We obtained information regarding HIV risk factors and peripheral blood specimens for the following tests: HIV-1 antibody (two different EIAs) and a PCR analysis using an HIV-1 gag primer pair. EIA, HIV-1 serum antigen, HIV-1 culture using both RT and HIV-1 antigen detection assays, HIV-1 J antibody EIA, and PCR analysis using an HIV-1 gag primer pair. Results: 100 of 187 (53%) blood donors agreed to participate. There was no significant difference between the blood donor participants and nonparticipants in terms of age, sex, or Western blot band pattern. 65 of 100 were still repeatedly reactive for HIV-1 antibody by at least one HIV-1 EIA. All 100 tested risk factors for HIV-1 infection. 92 of 100 were still indeterminate by Western blot and 8 were negative after 1-6 month follow-up. None were positive by HIV-1 Western blot, HIV-1 serum antigen EIA, HIV-2 antibody EIA, HIV-1 culture, or HIV-1 J antibody EIA. HIV-1 PCR analysis results are pending.

Conclusion: These data indicate that blood donors who are indeterminate by HIV-1 Western blot and lack risk factors for HIV infection are not infected with HIV-1.

T.B.P.358 HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY SCREENING OF BLOOD DONORS - AN INTERNATIONAL SURVEY.

BURBALL, S.L., MANHART, S.J. AND ADATA, A.,
The Canadian Red Cross Society, Ottawa, Canada

BETWEEN OCTOBER 1985 AND MARCH 1988, THE CANADIAN RED CROSS SOCIETY (CRCS) CONDUCTED THREE SURVEYS ON INTERNATIONAL PRACTICES OF SCREENING BLOOD DONORS FOR ANTI-HIV. DURING THIS PERIOD, THE REPORTED CASES OF AIDS PER 100,000 POPULATION INCREASED FROM 12 IN 1985 TO 61X IN 1988. AT THE SAME TIME, THE MORTALITY RATE DUE TO AIDS ALSO INCREASED FROM 1/100,000 IN 1985 TO 4/100,000 IN 1988. THE NUMBER OF BLOOD TRANSFUSION ASSOCIATED AIDS CASES INCREASED FROM 1-85 IN 1985 TO 3-68 IN 1988. IN 1985, 17/22 COUNTRIES SURVEYED WERE SCREENING THE BLOOD DONORS FOR ANTI-HIV, WHEREAS, IN 1988, 31/33 COUNTRIES WERE SCREENING BLOOD DONORS. OF THE 19 COUNTRIES FROM WHICH INFORMATION WAS AVAILABLE, 17 COUNTRIES REPORTED A DECREASING TREND IN THE ANTI-HIV SEROPREVALENCE RATE, FIVE COUNTRIES REPORTED A STABLE TREND AND THE REMAINING ONE REPORTED AN INCREASING TREND. THE CONFIRMED POSITIVE ANTI-HIV RATE IN 1988 VARIED FROM 0% TO 0.64X WITH THE MAJORITY OF COUNTRIES REPORTING THE PREVALENCE RATE BELOW 0.05%. IN 1988, THE MAJORITY OF COUNTRIES HAD ALREADY IMPLEMENTED SELF-EXCLUSION PROGRAMME AND PROVIDED ALTERNATE TEST SITES. MOST OF THE COUNTRIES WERE ALSO REPORTING ANTIMONY STATUS TO THE DONORS AND MAINTAINING CONFIDENTIALITY OF THEIR TEST RESULTS. BY 1988, OF THE 33 COUNTRIES SURVEYED, 22 HAD ALREADY STARTED SCREENING DONORS FOR ANTI-HIV-2 AND ADDITIONALLY, 14 COUNTRIES WERE CONDUCTING FEASIBILITY STUDIES. ADDITIONAL INFORMATION BASED ON THE SURVEY PLANNED FOR MARCH 1989, WILL ALSO BE PRESENTED.

T.B.P.352 'THE GIFT RELATIONSHIP REVISITED': HIV SEROPREVALENCE IN BLOOD DONORS AND OTHER LOW-RISK GROUPS IN AFRICA

DIXLEY, Barbara Rozita, Halligan, R. and Wey, F.,
Bureau of the Census, Washington, DC, U.S.A.

Objective: HIV survey data from 22 African countries reinforces the conclusion of Temuda's "The Gift Relationship" that the quality of donated blood varies considerably.

Method: Compared HIV seroprevalence estimates from non-random sample surveys of blood donors and other low-risk groups (i.e., pregnant women) in the same year and location. Data from small sample sizes and from small differences in seroprevalence (the significance of which is tested) are discarded.

Results: HIV seroprevalence for urban blood donors and other low-risk groups in 10 of the 22 countries was similar; in 3 countries, donor seroprevalence was lower; but in 9 countries it was higher (6 of which achieved $p < 0.02$).

In regions outside the capital, the relationship is reversed. In 7 of the 10 regions, the HIV seroprevalence of donors is lower than other low-risk groups. In all 9 countries with data on gender of blood donors, male donors outnumber females; in 7 of the 9 countries, the female HIV seroprevalence rate was higher than males. Longitudinal data, available on blood donors in 9 countries, suggest that 3 countries have shown no seroprevalence change, 2 have shown a modest decrease, and 2 have shown an increase.

Conclusion: Data suggest that blood donors and other low-risk groups are not a random population apparently, and their higher HIV seroprevalence, especially for women, is troubling. Blood banking procedures should be reevaluated in light of this HIV data, as should the gift relationship itself.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

T.B.P.353 THE IMPACT OF AIDS ON BLOOD TRANSFUSION SERVICES AT THE UNIVERSITY TEACHING HOSPITAL, LUSAKA

Dr. Abraham Mulla, University Teaching Hospital (UTH), Lusaka, Zambia

Objective: To describe the impact of AIDS on the Blood Transfusion services by the UTH.

Method: The data was obtained from annual records and my full participation in the recruitment of blood donors.

Results: The number of blood units discarded on account of HIV positivity is rising and thus making it more difficult for the blood bank to meet the ever increasing hospital demands.

Year	No. of Donors	No. of HIV+ve	%
1987	7457	478	8
1988	5505	1037	18.8

Conclusion: The AIDS pandemic relentlessly continues to be a colossal challenge to the meagre blood transfusion services offered by the UTH.

T.B.P.355 IMPROVED HIV-1 WESTERN BLOT RESULTS IN BLOOD DONORS: A MONITOR OF IMPROVEMENT TO RECIPIENTS OF BLOOD

Van Der Pijl, Ooms, Lalle, N., Nass, Hainin, H.; Ethlers, P., Bokker, E., Willemse, M.,**

* Ned Cross Blood Transf. Serv., ** Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands.

Objective: To investigate if donor blood with indeterminate test results in HIV-1 Western Blot (WB) transmit HIV-1 to recipients.

Method: Serum samples from blood donors (n=130) and recipients (n=382), who participated in a prospective study for posttransfusion hepatitis, were tested for HIV-1 antibodies with a commercially available ELISA. The recipients were followed-up for 6 months. Repeatedly ELISA reactive samples were tested for confirmation with commercially available WB strips, and ³²P-RIPA developed in our institute.

Donors	n	ELISA reactive		Western Blot		125-P-RIPA	
		initially	repeatedly	pos	indef.	pos	indef.
5,332	109	12 (2.047)	19 (17.384)	0	0	0	0
352	5	1 (1.288)	1 (17.288)	0	0	0	0

The 6 recipients who received blood products from 6 donors with indeterminate HIV-1 WB, were non-reactive in HIV-1 WB and ³²P-RIPA, with serum samples obtained 0, 3 and 6 months after transfusion.

Conclusions: Blood products from donors with indeterminate results in HIV-1 Western Blot, do not transmit HIV-1 to recipients.

T.B.P.357 A CLINICAL AND SEROLOGICAL FOLLOW-UP OF HIV 2 - POSITIVE PATIENTS FROM GUINEA-BISSAU (WEST AFRICA)

Celestino Costa, Vanda F. Caneva Ferreira, J. Chappellinaud, Kamal Marinho, A. Santos Figueira, Francisco Siqueira, Paulo Mendes, Augusto P. Silva, E. Prieto, J.L. Baptista, C. Araújo, J. Baptista Marques, J. Brandão, Rita Albuquerque Sousa-Instituto de Higiene and Tropical Medicine-Dep Microbiology and Dep. Clinical Tropical Medicine-Ministry of Health, Guinea-Bissau.

OBJECTIVE: - To establish the clinical and laboratorial features of HIV 2 infection and to determine parameters of these infection related to disease progression in people from Guinea-Bissau.

METHODS: - 39 asymptomatic persons with documented (serological) HIV 2 infection in 1986 were re-evaluated in 1989 by their medical clinical, physical examination and laboratory tests. The serological HIV profile was determined and compared by ELISA and by monoclonal antibodies to healthy HIV negative persons were enrolled as a control group.

RESULTS: - The parameters of HIV 2 were associated with disease progression. Higher relative and absolute number of CD4 and CD8 cells were associated with disease progression. No direct relationship was seen between CD4 and HIV serological status. More results, statistics and conclusion will be presented.

T.B.P.354 HIV ANTIBODY TESTS AMONGST NEW BLOOD DONORS

Day, P.C.; de Vries, A.R.; McBride, R.L.; Butt, Sibinga, C.T.H. Red Cross Blood Bank Groningen-Drenthe, Groningen, Nl.

A "window-period" (3-12 weeks) may exist following HIV infection when no antibody can be demonstrable but HIV antigen may appear in the blood. We have tested this possibility in first time (new) blood donors, since in our blood bank 40,000 annual donations have been followed over 3 years without additional seroconversion amongst repeat donors.

Included also in this study are 4 donors who have stopped donating because of the "risk factors": 3 W. blot positive donor sera and 3 "risky sera" (only P24/P55) detected by a first generation test during 1985. Antigen assay is based on enzyme immuno assay system (Vironostika, Organon). All samples are tested in parallel by routine antibody assay (Wellcome).

TESTS	NEW DONORS		HIV antibody positive		Donor with risky factors		risky	
	pos	neg	pos	neg	pos	neg	pos	neg
Antigen (Organon)	2	pos	neg	neg	neg	neg	neg	neg
Antibody (Wellcome)	157	pos	neg	neg	neg	neg	neg	neg

Our results indicate Vironostika did not show any reactivity in the "risky sera" and to antibody containing sera, suggesting its specificity. 2/157 donor sera showed initial reactivity, but not reproducible. However, application of the test may be profitable in risk groups and in patients where anti-genesis has prognostic and therapeutic significance.

T.B.P.356 "SAFE" CONTROL IN HIV SEROPOSITIVITY IN SERIALIZED PATIENTS* A.

Maleno, R., Anttila, S., Sarna, J., Maleno, J.A., Lonn, L.A., Henna, Sanna, Helsinki University of Medicine and Dentistry, Helsinki, Finland, Helsinki, Finland

To investigate the extent of HIV infection among dialysis patients, an unselected 117 patients of the hemodialysis unit of the Juntala Institute Hospital, eastern part of the Pacific, city, was tested anti-HIV and Western Blot. Immunological status, exposure to blood transfusion and the use of hemodialysis. Twelve patients were positive with the ELISA method and 4 (37%) were confirmed by Western Blot. Risk factors were that blood transfusion were ruled out in all 8 patients, heavy transfusion was necessary in 2 controls tested for ser. The mean number of visits of hemodialysis was 28.2 and 27.2 months, respectively for cases and controls. Seven of the patients who had chronic hemodialysis, all the cases had no clinical symptoms associated to HIV infection at that time. The risk of HIV infection was neither associated to the number of blood units transfused nor to the time on hemodialysis. Seropositive rate was 4% in all study included patients. After 13 months, 3 out of 4 died, and 1 developed AIDS. The others have been asymptomatic. No investigations show any more infection by HIV, who is also asymptomatic. The prevalence of HIV infection observed in this study is rather high. This finding stresses the need for the dialysis units personnel to carefully with recommended preventive measures.

T.B.P.358 LATEX AGGLUTINATION TESTING OF WHOLE BLOOD FOR HIV-1 IN THE FIELD.

Muganyizi, S. M.; Bilyahahaho, B. M.; Ojwaya, S. M.; Kijumu, J. M.; Downing, R. M.; Sempala, S. M.; Mwangi, S. M. New York, USA * Uganda Virus Research Institute, Entebbe, Uganda. ** WHO, Entebbe, Uganda.

OBJECTIVE: To determine the reliability and practicability of using a Latex Agglutination (L.A.) test (RECOGNIBEN donated by Cambridge Biocentec) to test for HIV antibodies in a field serosurvey in Rakai, District, a highly endemic area of Uganda.

METHODS: RECOGNIBEN L.A. is a rapid (5 min) visually scored test for antibody to recombinant gp 120 and 41. The test was performed on finger prick or venipuncture whole blood samples. Immediately after samples were obtained in the subjects' home in a community based survey, 145 subjects were tested by both L.A. and serum ELISA (RECOGNIBEN antibody to HIV-1).

RESULTS: Technical staff expressed satisfaction with the ease and readability of the method. Sensitivity was 100% but specificity only 84% compared to the ELISA. Positive predictive value was 36%.

CONCLUSION: Despite ease of use and high sensitivity, the low specificity of the RECOGNIBEN L.A. test in this setting indicates that further development may be needed for use in the field. Reasons for the high rate of false positives are being investigated.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

Infections liées au SIDA : syphilis AIDS Related infection: Syphilis

W.B.P.49 ATYPICAL SECONDARY SYPHILIS IN HIV-SEROPOSITIVE PATIENTS Cases: E., Janier Michel*, Jansen P., Rybojad A., Julien J., et al.

* Department of Dermatology and ** STD Clinic, Hôpital Saint-Louis, Paris, France.

Objective: to describe secondary syphilis in 8 HIV-seropositive patients. **Methods:** serological of venereal, serological, bacteriological and histopathological data in 8 consecutive patients (HIV+) seen in our department from 1989 to 1989 for a secondary syphilis. **Result:** Patients: 8 males (mean age: 36.8 ± 10.2 years old), 7 homosexual, 1 drug addict, 2 with AIDS, 2 with the lymphadenopathy associated syndrome and 4 with asymptomatic HIV infection, 3 of them had a previous treated syphilis and only one had a history of chancre before the eruption. Clinical presentation was similar in 5: one trépano-cervical of the trunk, two palmoplantar keratodermas, two malignant ulcerative syphilis. The 3 others had a classical presentation (roséolae or papular syphilis). Diagnosis was made on serology (high titers of antibody in R, darkfield examination in 1, histopathology (numerous plasma cells) in 5, all were cured with classical recommended Penicillin therapy for early syphilis. **Conclusion:** Clinical presentation of secondary syphilis during HIV infection was atypical in 5/8 patients, syphilis is more than ever "the great imitator". On the other hand, the serological and histological data were typical of secondary syphilis and led to an easy diagnosis.

W.B.P.51 STYLETIC MELOPHYIA WITH HUMAN IMMUNODEFICIENCY VIRUS: A TREATABLE CASE OF SPINAL CORD DISEASE

Joseph B. Szary, M.D., G. Sawyer, M.D., L. Moskowitz, M.D.,
From the Departments of Neurology, Internal Medicine, and Pathology,
the University of Miami School of Medicine, and the Department of
Pathology, Baptist Hospital, Florida, U.S.A.

Three individuals with syphilitic myelopathy occurring in association with human immunodeficiency virus (HIV) infection are described. One patient responded dramatically to high dose intravenous penicillin therapy. In the other two patients, syphilitic spinal cord involvement was confirmed at autopsy by the presence of infectious fibrous leptomeningitis, chronic perivascularitis, and microglial infiltrates of the spinal cord. Both also exhibited radiculitis. One patient had clinical features of cervical radiculopathy, paraparesis, and double incontinence. The other was treated for neurosyphilis three months before death when she presented with an altered mental state, acute left hemiparesis, and hemiparesis with postural syphilis syndrome.

Syphilis needs to be considered in the differential diagnosis of any patient developing a myelopathy in association with HIV infection. Because of the diverse nature in which syphilis may affect the spinal cord, any HIV-seropositive patient with a progressive, unexplained myelopathy and a positive serum RPR-Ab should be considered for therapy with intravenous aqueous penicillin, 12 to 24 million units daily for a minimum of 10 days, even in the absence of a positive cerebrospinal fluid RPR.

Supported in part by National Institutes of Neurological Diseases and Stroke's Program Project P01-NS1556

W.B.P.53 AN ASSOCIATION OF STYLETIC EPISODES AND HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION OR SEROALLY TRANSMITTED VIRUSES (STV) INFECTIONS IN LOS ANGELES COUNTY

Norm. Thayer, D. M. Ford, W. W. Ruppel, P. W. Miller, L. W. Gorman, I. **
* Los Angeles County Health Department, Los Angeles, California, U.S.A.

*Centers for Disease Control, Atlanta, Georgia, USA.
Objective: to determine if an association exists between a history of syphilis episodes and HIV seropositivity.
Methods: Clients participating in confidential HIV testing in Los Angeles County STD clinics between July 1 and December 31, 1989, were interviewed by pretest counselors about their history of STDs and high risk behaviors such as number of sex partners, drug use, and prostitution.
Results: Having a history of at least one episode of syphilis appears to be strongly associated with HIV seropositivity (p<.0001). For those clients testing HIV positive, 57.8% (26/45) reported an episode of syphilis in contrast to 26.8% of those testing HIV negative (128/473). Upon further examination of drug and sex-related risk factors, contrary to our theory of drug use and intravenous drug use since 1978 were all strongly associated with having had at least one syphilis episode (p<.001). These associations were consistent within two groups (black and Hispanic) and among those who were interviewed by pretest counselors independently associated with being HIV positive (p<.0001). **Conclusions:** Syphilis appears to be a risk factor for HIV infection independent of any confounding effect of intravenous drug use unless drugs are exchanged for sex. Syphilis in Los Angeles County may predispose an individual to HIV infection.

W.B.P.56 NEUROSYPHILIS IN HIV-INFECTED PATIENTS: EVIDENCE OF UNRELIABLE SEROLOGICAL RESPONSES

Rolf Malassa*, H. Babay*, H. Birkenshaw*,
J. Blinck**, G. Schwedenmann*
Dept. of Neurology, **Geriatrics, University Clinic Essen,
**Dept. of Neurology, University Clinic Aachen, FRG.
Objective and Rationale: The combined infection with Treponema pallidum and HIV by unknown interaction leads to an atypical presentation of Neurosyphilis (NS), but remain and treponemal antibody tests have remained the cornerstones of diagnosis. We report on 4 HIV-infected men (CDC group II and III) with NS (one meningovascular, two meningal, 1 go production). The TPPA-serum/CSF-quotient was calculated. In 3 patients the relative concentrations of HIV-antibodies in serum and CSF were determined by serial dilutions in an anti-HIV ELISA (Abbott, Dublin). CSF was examined for cell count, protein content, oligoclonal bands and intrathecal IgG production. **Results:** There was serologic evidence for a previous syphilitic infection in all patients, but the serologic indicators of active NS, the cardiolipin reaction and the IgM-TPA in CSF, were negative. In addition, three of the patients showed no serologic signs of active syphilis in serum. One patient developed a relapse of NS despite an adequately high dose antibiotic therapy.

W.B.P.52 HISTORY OF AND CONVENTIONAL TESTS FOR SYPHILIS IN HIV-1 SEROPOSITIVE HOMOSEXUAL MEN IN BALTIMORE MDC

Almond Hays, Fox R. Hook E., Marlar Jr, Starkey D.

Sean A. The Johns Hopkins Medical Institutions, Baltimore, MD, USA

Objective: To determine the validity of syphilis testing in HIV-1 seropositive homosexual men with reported history of syphilis. **Methods:** Sixty HIV-1 seropositive Rapid Plasma Reagin (RPR)-men in the Baltimore MDC were stratified by self-reported history of syphilis and tested for evidence of past or present infection using the Fluorescent Antibody Absorbed (FTA) assay. 50/60 men had lumbar punctures performed using Venereal Disease Research Laboratory (VDRL) analysis of cerebrospinal fluid (CSF).

Results: Fifteen men reported history of syphilis, all before 1984. FTA tests were reactive in 13/15 (86.7% sensitivity - 88%). CSF-VDRL analysis was available in 8/15 of these men and were all nonreactive. In 45 men with no history of syphilis, the FTA was reactive in 2 (specificity - 4.4%). CSF-VDRL evaluation was negative in 31 of those tested including one participant with FTA and negative history.

Conclusion: Both sensitivity and specificity of reported lifetime history of syphilis are high compared to FTA testing in this small highly screened HIV-1 seropositive population. The 4% (2/45) of FTA men without reported history may be the result of recall error, false positive results, or inadvertent treatment of asymptomatic disease. These data suggest that the accuracy of self-reported serological testing for syphilis in HIV-1 seropositive homosexual men with negative RPR is high and the yield of further testing is low.

W.B.P.54 "SEROREVERSION" OF TRYPANOMAL TESTS DURING HIV INFECTION

Alma Jannari, R. Dillan, D. L. Iversen, D. M. Clement, W. Hoan M.,
San Francisco General Hospital & UCSF, SF, CA, Department
of Public Health, SF, CA, **Centers for Disease Control, Atlanta, GA, U.S.A.

Objective: To evaluate the sensitivity of trypomonal tests (i.e. FTA-ABS and/or RPR) for syphilis in individuals with a documented history of syphilis. **Methods:** Sub/ject=110 homosexual men with a documented history of syphilis, who enrolled in a longitudinal cohort between 1982-86. Syphilis serology done on entry into cohort was compared to results of serology confirmed on stored serum samples. **Study design-retrospective review.**
Results: None of the HIV-negative individuals in the cohort "seroreverted," whereas 7.2% of those who were HIV-seropositive but asymptomatic, 42.9% of those with AIDS, and 35.7% of those with AIDS had loss of reactivity of a trypomonal test. The relative risk of "seroreversion" for those with AIDS was 14; (p<.02), and for those with AIDS 10.5 (p<.02). Characteristics of those with "seroreversion" and those with persistent reactivity include:

14 count (n=17)	14 count (n=8)	14 count (n=8)
74/78 ratio	80/1 (21.6-80.1)	86.4 (21.6-80.1)
	4/5 (0.8-0.9)	4/5 (0.8-1)
	1.8 (1.0-3.0)	1.8 (1.0-3.0)

all men reported an mean (17- 85K contact person interval). **Conclusions:** Individuals with asymptomatic HIV infection and a documented history of syphilis lose reactivity of a trypomonal test for those with AIDS to be related to the decline of total T4 count and 14/78 ratio. These findings raise questions about the sensitivity of trypomonal tests in HIV-infected individuals, and suggest that a history of syphilis cannot be relied upon for negative trypomonal tests.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

W.B.P.43 EFFICACITE DE LA SOMATOSTATINE LONGUE ACTION (SMS 201 905) DANS LE TRAITEMENT DES DIARRHEES ET NANTES LES CYTOMERES DE DEUX MALADES AFFECTES DE SIDA

Buty JP*, Latrelle J*, Pomeroy D*, Rochech J*, Dons M*, Beaulieu R*.
Hémocentrique* et maladies infectieuses* Hôpital Bichat-Montparnasse, Hôpital de la Santé Université de Paris 7.
Le SIDA parent est symptomatique chez 2 patients. Nous avons observé chez ces deux résultats liés associés à une correction de la cytométrie chez 2 SIDA.
Obs.1 : un homosexual de 32 ans avec sarcose de Kaposi et pneumocystose présentait une diarrhée localisée avec une éruption et une perte de 8 kilos en 4 semaines. Après 14 jours de tous les traitements symptomatiques et antibiotiques larges un traitement par SMS à la dose de 100 mg par s/c q8 heures a arrêté la diarrhée. Au 15ème Jour nous avons stoppé la SMS avec une récidive de la diarrhée. La coproculture des selles a été positive à *Micobacterium Avium* uniquement. Le traitement par Rifampicine et l'administration de pus acidifiés dans les selles. Les globules blancs avant et après traitement (15^{e} jour) passaient de 9000 à 5600. Les CD4 de 5/83 à 54. Les plaquettes de 47000 à 290000; l'hémoglobine resta stable. Le patient a gagné de 8 kilos en 10 semaines.
Obs.2 : un hétérosexuel de 28 ans présentant une pneumocystose avec cachexie. 12 selles liquides/jour. L'examen des selles (bactères, parasites, champignons) fut négatif. Après traitement de 300 mg 3 fois/jour, arrêt de sa diarrhée. De la cessation du traitement, récidive de la diarrhée et contrôle à la reprise de SMS à la dose de 100 mg par s/c q8 heures. Le 15ème jour passaient de 800 à 1100/m3, les plaquettes de 40000 à 110000. La SMS semble être un traitement symptomatique de la diarrhée du SIDA et a permis la correction de la cytométrie. Une étude est nécessaire pour en comprendre les mécanismes.
* SMS 201 95 Laboratoire SANOFI

W.B.P.44 GASTRIC LEISHMANIASIS IN AN AIDS-PATIENT.

Pinco A.M.I., Virel H., Taillan M., Benin-Paul M.C., Marty, J., Le Fournier J., Chastagnat J.P., C.H.R.U. Nice, France.
Visceral leishmaniasis has been previously described in HIV seropositive patients and even proposed as a new opportunistic disease.
A 26-year-old patient, seropositive for HIV, followed since 1985, was admitted for weight loss, epigastric pain. Two years ago, he had developed cerebral toxoplasmosis. Since June 1987, he received trimoprim therapy, which was stopped in August 1988 for hematological toxicity. On admission, blood cells count was: 1.4, 10.9/1 leucocytes, 3.58, 10.1/1 erythrocytes, 34, 10.9/1 platelets, hemoglobin level was 116 g/l. Hematocrit was normal at proddal dosage. CD4 positive blood cells were <10/mm³. Endoscopic examination showed an ulcer on cardiac. Gastroenterologic examination revealed a gastric localization of leishmaniasis. Histologic examination and specific culture were positive. Specific serology was negative. There was no any parasite on skin and blood examination. Clinical status was dramatically improved by specific therapy of ulcers and sodium stibogluconate (Pentostam®) (600 mg/day during 3 weeks). At the end of the first cure, we noted: 5.5, 10.5/1 leucocytes, 37, 10.9/1 platelets and hemoglobin level was 120 g/l. Severe lymphopenia was persistent. Second cure was started again. At our knowledge, gastric localization of leishmaniasis in AIDS patient was not previously described, since intestinal involvement is well known. It would be a possible outline for the "opportunistic" character of leishmaniasis in AIDS-patients. Research of visceral leishmaniasis seems to be necessary in endemic area, in HIV seropositive patients with lymphopenia, mainly with hematological abnormalities.

W.B.P.45 SUCCESSFUL USE OF REFINEMENT BOVINE COLONOSIS TO TREAT CRYPTOSPORIDIUM INFECTION IN AN AIDS PATIENT

Woods, R.H.*, Ward, J.M. and O'Brien, C. A.
*Uniformed Services University of the Health Sciences, Bethesda, MD, USA,
**United States Department of Agriculture, Beltsville, MD, USA

Cryptosporidium is a protozoan parasite of the human gastrointestinal tract which can cause life-threatening diarrhea in immunodeficient patients. Although colic to slightly agents have been tried with occasional anecdotal success, treatment remains primarily limited to hydration. We describe a 36-year-old homosexual male with antibody to human immunodeficiency virus and *Cryptosporidium*-related diarrhea. The patient excreted 6 to 12 liters of stool per day for at least three months. In hospital, repeat stool examinations identified no bacterial or parasitic pathogen other than *Cryptosporidium*. Trials with more than six anti-diarrheal medications, including loperamide, were ineffective and the patient finally received bovine colostrum hyperimmune to *Cryptosporidium* by direct buccal infusion. The colostrum was produced by pasteurized *Escherichia coli* immunized with oocysts into pregnant dairy cows; resulting colostrum had $>1,200,000$ titers of specific bovine anti-*Cryptosporidium* IgG-1, IgM and IgM. During infusion, the patient's fecal output decreased to less than 2 liters per day and 48 hours after treatment, stools were fully formed and oocysts to *Cryptosporidium* could not be found. The patient remains asymptomatic 3 months later. Hyperimmune bovine colostrum offers an exciting possible new treatment for cryptosporidiosis: the active factor(s) and mechanism of action should be characterized.

W.B.P.46 A COMPARISON OF ELECTRON MICROSCOPY (EM) AND LIGHT MICROSCOPY (LM) IN THE DIAGNOSIS OF CRYPTOSPORIDIUM BLASTOCYSTIS INFECTION

Connolly, C.M., Dewey, G.J., Gazzard, B.C., St. Stephen's Hospital, London, UNITED KINGDOM

Objective: To assess the value of I/M and E/M in the identification of apparent cryptosporidial infection.
Methods: Rectal biopsy and stool specimens were examined by I/M and E/M from 40 AIDS patients with diarrhoea (at least 3 liquid stools/day for longer than one month).
Results: I/M confirmed the presence of cryptosporidium in 4 of 11 patients identified by I/M and in no patients where this organism had not been seen. The 4 patients had typical cryptosporidial infection with mean weight loss 14.6kg, and large volume diarrhoea (mean 1.96/day). They all died 3, 7, 9 and 24 months after diagnosis. In the other 7 patients, an alternative diagnosis was suggested at E/M (blastocystis 6 and dead cysts of giardia in 1). Four of the 6 patients with blastocystis are still alive 9, 12, 12, and 21 months after diagnosis. They had lost little weight at presentation (mean 4.3kg) and had low stool volumes (mean 0.7/day). A subsequent E/M diagnosis has been made in 3 of these 4 patients.
Conclusion: Light microscopy can confirm blastocystis and cryptosporidial infection. The former has a better prognosis, is not a feature of AIDS and presents with fewer clinical symptoms.

W.B.P.47 TREATMENT OF CRYPTOSPORIDIUM INFECTION WITH RECOMBINANT INTERFERON-2 (rIF-2)

Connolly, C.M., Dewey, G.J., Hawkins, D.A., Gazzard, B.C., St. Stephen's Hospital, London, England, UNITED KINGDOM

Objective: To assess the response of cryptosporidial diarrhoea to rIF-2.
Methods: Three patients with cryptosporidial diarrhoea (present in 3 stool specimens and rectal biopsy) were treated for four days with rIF-2 at 100 mg and seven days after a course of intravenous rIF-2 (400ug over 2 hours daily for 14 days). A patient with severe right upper quadrant pain, sclerotic conjunctivitis, iritis and cryptosporidiosis and *Cryptosporidium* on rectal biopsy was treated similarly.
Results: In all four patient cryptosporidium was not found in stools or rectal biopsy after treatment. In two of three patients with diarrhoea the average daily stool volumes fell from 1.8 and 1.5 litres per day to 0.75 and 0.3 litres per day. Remission was maintained for two weeks in one patient who died of pneumonia and for two months in another patient who died of CMV colitis. The third patient had visceral Kaposi's sarcoma and no reduction in stool volumes and died within two months. After starting a course of rIF-2 in one patient with sclerotic conjunctivitis and abdominal pain was markedly reduced but treatment was discontinued after seven days because of marked hypotension, pyrexia and haematuria from which he recovered. He subsequently received Posaconazole for CMV colitis and remission well four months later. Three of the four were febrile in response to rIF-2 and the alkaline phosphatase was significantly raised in two during treatment.
Conclusion: rIF-2 is an effective treatment for cryptosporidial diarrhoea but may cause severe reactions.

W.B.P.48 GASTROINTESTINAL CRYPTOSPORIDIOSIS IN RIO GRANDE DO SUL (RS) STATE: THE HIGHEST INCIDENCE

Barth, A.T., Pardini, L.A., Lemos, J., Araujo, M.J., Capobianco, M., Universidade Federal do Rio Grande do Sul, Porto Alegre, Brasil

Objetivo: Estabelecer a incidência de gastrointestinais cryptosporidiosis em AIDS patients in RS.
Métodos: 48 casos confirmados, 48 pacientes, 50 registros de AIDS (positivos à PCR) entre julho e novembro 1988. 8 casos were excluded because they did not meet the inclusion criteria (at least 4 stool analysis for cryptosporidium sp. in an acid-fast smear).
Resultados: 52,4% (n=22) were positive, and 47,6% (n=20) were negative for cryptosporidium sp.
Conclusão: Gastrointestinal cryptosporidiosis in RS is one of the highest incidence in the world. Therefore, it is important to consider this disease when dealing with an AIDS patient coming from RS.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

W.B.P.37

BLASTOCYSTIS HOMINIS INFECTION IN AIDS PATIENTS.
E. Klinger, S. DeLigas, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, U.S.A.

Although associated with some instances of human gastrointestinal disease, the pathogenicity of *Blastocystis hominis* is still under question. Objective - to evaluate the pathogenic potential of *B. hominis* in AIDS patients.

Methods - The records of HIV-infected individuals whose stool specimens contained *B. hominis* (5 per 400x field) were reviewed.

Results - Seven such patients were seen at our institution. All had significant diarrhea (4 bowel evacuations per day) nausea, abdominal cramping, fever and weight loss. Stool specimens of 3 patients contained only *B. hominis*. The remaining 4 had other potential intestinal pathogens (*Entamoeba histolytica*, *Giardia lamblia*) which have been implicated as copathogens with *B. hominis*. All seven patients responded to therapy (metronidazole or *Trimethoprim/Amphotericin*) with resolution of symptoms and eradication of organisms from stool. No relapses occurred (follow-up - 4 months). No other causes for their diarrhea were found.

Conclusions - *B. hominis* should be considered a potential pathogen in AIDS patients and may be associated with other intestinal pathogens. Specific therapy usually results in resolution of the infection. Relapses are rare. In patients who do not respond, other causes of diarrhea should be investigated.

W.B.P.38

VARIABLE LOCALIZATION OF INTESTINAL CRYPTOSPORIDIOSIS IN AIDS.

Heiner, Todd D. Therapy, AR, Kotler, DP, St Luke's Roosevelt Hospital Center, Columbia University, New York, NY, USA.

Objective: To examine the localization of cryptosporidial (Crypto) infections in the gastrointestinal tracts of patients with AIDS.

Methods: In a retrospective review of biopsies from 25 AIDS patients with Crypto, the small intestine was the primary site of involvement in 16 patients, the colon was the primary site of involvement in 9 patients, and no patient had severe disease in both sites. The influence of disease localization was studied prospectively in 8 patients with jejunal Crypto and in 5 patients with colonic Crypto. Studies of coxist excretion, small intestinal structure, and the absorption of sugar (xylose) acid fat (sterols) were performed.

Results: Diarrhea was more severe in patients with jejunal Crypto and was associated with greater xyst excretion, more jejunal injury and more xylose malabsorption. The malabsorption was abnormal in both groups.

Discussion: Cryptosporidial (Crypto) infections in AIDS patients may have different localizations. Jejunal involvement is associated with more severe diarrhea and malabsorption. The localization of Crypto may be related to the site of infection.

Conclusions: Crypto has a variable localization in the intestine. Intestinal structural and functional abnormalities correlate strongly with the localization of Crypto.

W.B.P.39

COLONOSCOPIC ETIOLOGICAL DIAGNOSIS OF DIARRHEA IN AIDS
Souza de Lima, Dirceu, Jrado, E.; Favoreto, C.; Treibman, M.; RESENDE, R.

Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brasil.

From August 1985 to September 1986, 18 patients were studied by the same physicians at the Department of Infectious Diseases and private clinic. They presented diarrhea for more than 30 days. Among them were 14 homosexual men, 2 blood receivers and 2 women married with bisexual men. After negative labo- ratorial investigation for common intestinal parasites in AIDS, colonoscopies with biopsies from caecum through rectum (flexocolonoscopy ACM and video-colonoscopy Welch Allip) were performed in 16 patients. The examination showed: normal mucosa (6 cases), swollen and edematous mucosa without friability (6 cases) and sick mucosa with multiple ulcerations (6 cases). The histopathology showed *Cytomegalovirus* colitis (5 cases), cryptosporidiosis (1 case) and nonspecific colitis (10 cases) at the remaining ones.

There were two patients not submitted to colonoscopy which presented *Cytomegalovirus* colitis. One of them had peritonitis due to a left colon ulcer perforation found at surgery and the other at post mortem examination. The diagnosis were made by histopathology of the surgical specimen and autopsy respectively.

After given anti-viral therapy, the patients with *Cytomegalovirus* colitis remained with diarrhoea. One of them had cryptosporidiosis and the other *Shigella flexneri* in the stool culture.

W.B.P.40

INCIDENCE OF INFECTIONS GASTROENTERITIS IN SPANISH AIDS PATIENTS

Jorge, Millares; Moreno A, Niro JM, Gattell JM, Laborde J, Barcelona, Barcelona, Spain.

Soriano E. Infectious Diseases Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain.

Objective: To describe the characteristics of the infectious gastroenteritis (IG) in 226 Spanish AIDS cases.

Methods: Since 1984, all patients who fulfilled the CDC criteria for AIDS case definition were prospectively followed. Seventy four (32%) were male and 50 (22%) were female. All patients were followed up to death or to the end of the study.

Results: Fifty nine episodes of IG (defined as the isolation of one (44 episodes) or more (15 episodes) microorganisms in the feces or in the intestinal mucosa) were identified in 44 of the 226 AIDS cases (20.3%). All but 2 were males and the mean age was 36 (range 20-59) twenty seven were men (61%) and 17 (34%) were women (39%). The IG alone or associated with other opportunistic infection was present at the moment of performing the diagnosis of AIDS in 30 of the 46 cases (63%). The microorganisms were: *Cryptosporidium* (19), *E. lamblia* (18), *Entamoeba coli* (8), *L. belli* (7), *Cytomegalovirus* (7) (postmortem diagnosis), *Salmoneella* sp. (7) (five with opportunistic bacteremia), *C. jejuni* (5), *S. flexneri* (5), *E. nana* (2), and *NAI*, *V. enterocolitica* and *S. typhimurium* in one case each. All episodes of IG, but 4, caused by cryptosporidium, were self-limited or responded to treatment. The IG was the main or an associated cause of death in 5 of the 25 patients who have already died.

Conclusion: IG is very common among Spanish AIDS patients (mainly among HWG) and often are the first manifestation of AIDS. The most frequent microorganism was *Cryptosporidium*.

W.B.P.41

GASTROINTESTINAL MULTIFUNCTION IN AIDS PATIENT: A CASE REPORT

Spinella, Rosalind Springs, C*-
*Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
*Hospital de Clínicas de Porto Alegre (HCPA), Rio Grande do Sul, Brazil

Objective: Report a gastrointestinal multifunction in AIDS patient in Rio Grande do Sul (RS) state.

Case Report: A 29 years old white, drug addict and promiscuous was hospitalized with a copious, explosive, bloody diarrhea.

First stool analysis revealed *Stromboloides* trophozoites and *Shigella flexneri* bacteremia. *Trimethoprim* and *Amphotericin* were started without great improvement. Her stool culture yielded *Shigella flexneri* and *Cryptosporidium* was initiated with improvement of the diarrhea. Another stool analysis showed *Candida* sp. and *Cryptosporidium* sp.. *Amphotericin* B was added and a great improvement has been noticed. She was discharged after 20 days with 2 diarrheal episodes per day. Her stool analysis was negative, except for the presence of *Cryptosporidium* sp..

Conclusion: When treating AIDS patients, is important to know that infections are very simple, and to report it as a perfect example of the transformations going on gastrointestinal system of these patients.

W.B.P.42

ROTAVIRUS AS A DIARRHEAL AGENT IN ADULT AIDS PATIENTS.

Blum, Jihad*, Deluca, P., Ferris, G., Shah, J., Deluca, A. Saint Michael's Medical Center, Newark, New Jersey, U.S.A.

Objective: To determine incidence and importance of rotavirus as a cause of diarrhea in AIDS patients.

Methods: Stool samples were assayed by latex agglutination and ELISA technique for the presence of rotavirus. These stool samples were collected from 12/88 through 1/78 when the incidence of rotavirus was at its highest in the corresponding pediatric population. The medical charts of these patients were reviewed for symptoms.

Results: Eighteen patients had stool samples sent for study. Eight of these patients had symptoms of diarrhea and one of these had rotavirus detected by ELISA. *Mycobacterium Avium* Intracellular was the most common cause of diarrhea among the virus detected in their stools.

Conclusions: Rotavirus was not found to be a significant cause of diarrhea in adult AIDS patients. Detection of this agent also may not explain the diarrheal syndrome even when found.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

W.B.P.31 THERAPEUTIC OF TOXOPLASMIC ENCEPHALITIS IN AIDS PATIENTS

BRONKHORST, G.O., LONO, I.M.F., STEFANI, H.N., BIANCOLANI, M.T., RODRIGUES, G.A. and LEVI, G.C.

Serviço de Moléstias Infecciosas, Hospital do Servidor Público Estadual, São Paulo, Brazil.

Seventeen patients with AIDS and toxoplasmic encephalitis were studied regarding therapeutic response and adverse effects, diagnosis being established on clinical and tomographic basis. All patients had positive specific serological tests; IgM was always negative and IgG was always $> 1/256$; median CD4 count was 222 cells/mm³. Pyrimethamine, sulfadiazine, and clindamycin were used in various combinations \forall , in few cases, due to allergic or toxic reactions to the other drugs, as monotherapy. The same drugs and Fansidar were used as suppressive therapy. Thirteen patients were cured and four died (three of them before completing 10 days of treatment). Relapse was observed in 50% of the cases, and the mean survival time was 161 days.

Overall there was a trend towards the favourable therapeutic response even when monotherapy with clindamycin was used, and the high incidence of side effects of therapeutics and relapse of the disease in spite of suppressive therapy.

W.B.P.32 IN VITRO INHIBITION OF TOXOPLASMA SPECIFIC ANTIBODIES BY PERIPHERAL BLOOD CELLS FROM HIV INFECTED SUBJECTS.

VENDRILLO, P. J., BIANCHI, G., FERRARI, G.***, SUPPET, R. F.**, CANALI, A., BERRE, A.**,

* Laboratorio d'Immunologia, Ospedale Leprosario, *** service

Malattie infettive, Ospedale S. Maria, Milano.

INTRODUCTION. Severe cerebral complications of Toxoplasma occur in 10 to 20% of AIDS patients. Serology is no great help for their diagnosis which relies on clinical and scanner arguments. We wondered whether specific B cells could not be present in the blood stream at earlier stages of active toxoplasmosis infection together with the HIV-secreting cells.

METHODS. PBMc culture supernatants from 43 HIV seropositive and 24 seronegative subjects were incubated in wells of Behring or Parke-Davis antibody kits. To elicit a seropositive complex we used to reveal the in vitro secreted and fixed antibodies.

RESULTS. In vitro production of Toxoplasma antibodies was detected in 10 of the 36 HIV and "Toxo seropositive" and in 60% of the HIV "seronegative" but "Toxo seronegative" subjects. Although 20 of the 24 HIV "seronegative" subjects were "Toxo seropositive" none of them gave positive results in the in vitro Toxo test. Of scanner and clinical evidence of cerebral toxoplasmosis was found in only 7 of the 17 HIV and "Toxo positive" subjects and isolated neurological symptoms in only 7 others. In a specific and selective inhibition of the Toxo in vitro test (and not of the HIV test) was observed after preincubation on the PBMc with Toxoplasma antigens (kindly provided by Dr Capron, Milan).

CONCLUSION. Toxoplasma antibody secreting cells are present in the blood stream of some but not all HIV infected subjects. Their detection could provide a tool for the diagnosis and the early treatment of active Toxoplasmosis.

W.B.P.33 THE VALUE OF PYRIMETHAMIN/ALFADOXIN (PFA) IN THE PREVENTION OF CNS-TOXOPLASMA IN AIDS PATIENTS

BILIR, THOMAS, MATHIAS, A., JAFFAR, S., JAGANNATHAN, S., SANKAR, S. and STEINER, J.S. *

*Neurological and *Neurological Department of Klinikum Steglitz, Freie Universität Berlin, FEDERAL REPUBLIC OF GERMANY

OBJECTIVE: To evaluate (1) the value of PFA for prevention of CNS-toxoplasmosis (CNS) in AIDS-patients (AIDS)

Methods: Retrospective analysis of 18 pts. treated for CNS between 1984 and 1988.

Results: Fifteen human immunodeficiency virus seropositive pts with acute CNS (clinical intracranial lesions in 86.6% of cases) were treated with pyrimethamine (PM) and/or Fansidar in combination with either cotrimoxazole (COT) or clindamycin (CL). 1,8-2,400 mg of one of both effects. 4 of these pts. developed their CNS disease secondary long term prevention of CNS with 160 (80mg/160mg), 14/18 pts. (77.8%) showed complete (CR) or partial (PR) response (partial was better or neurological defect), 2 pts. died. Treatment was continued as long term therapy with 160 (80mg/160mg) in 4 pts., 80 mg in 2 pts., 40 mg in 2 pts. (1,8-2,400 mg). None of the 18 pts with complete response developed a relapse. 18 pts. with partial response, but of them 14 pts. relapsed long term therapy with 160 and 80 mg. with PFA. Thus, 4/16 pts. (25%) developed CNS disease secondary to acquired acute CNS while under long term therapy with Fansidar.

Conclusions: These retrospective data indicate that (1) Fansidar is a drug of 160 mg PM / 1,60 mg 80 mg of cotrimoxazole for the primary or secondary prevention of CNS in AIDS-pats, and (2) that partial relapse of CNS seemed to be a major risk factor for CNS relapse.

W.B.P.34 TREATMENT OF CNS TOXOPLASMOSES IN AIDS PATIENTS. RESULTS OF PROSPECTIVE STUDIES USING PYRIMETHAMINE AND MACROLIDE ANTIBIOTICS.

Ruf, Bernhard *, Pöhl, H.D. * and Iglesias, J.R. **

* Departments of Internal Medicine and ** Neuropathology, Rudolf Virchow University Hospital (Wedding), Freie Universität Berlin, FRG

For treatment of cerebral toxoplasmosis pyrimethamine in combination with sulfadiazine is commonly used. In our study the sulfadiazine component was replaced by macrolide antibiotics. The results of treatment with pyrimethamine and with one or two macrolides were compared: with clindamycin and spiramycin (three drug regimen) and with clindamycin (two drug regimen). For maintenance therapy the effectiveness of pyrimethamine/alfadoxin was studied.

Dosages: 1.5 mg pyrimethamine/kg body weight/0.24 g clindamycin/d and 9 Mill. IU spiramycin for 3 weeks. Prophylaxis after acute therapy: 50 mg pyrimethamine and 1000 mg sulfadiazine in 2 tablets Fansidar® once a week.

Three drug regimen therapy was effective in 22/35 cases. Relapse occurred in 11/19 cases under maintenance treatment but in all six patients who had omitted the prophylaxis. Two drug regimen therapy was effective in 12/13 cases. Two of 13 patients developed a relapse under prophylaxis. Hematologic side effects were mild for both regimens, but could be controlled by folic acid given from the start of therapy in most cases. Skin rashes were observed in 10 cases.

Therapy regimen with pyrimethamine and macrolide antibiotic and maintenance treatment were proven to be effective. Relapses are mainly due to discontinuation of the prophylaxis.

W.B.P.35 LOCALIZATIONS OF THE TOXOPLASMOSES DANS LE TUBE DIGESTIF (T.D.) AU STADE AVANCÉ DES SIDA. ÉTUDE ANATOMO-CLINIQUE

MARCO, C.; MORALES RUBIN, C.; CLAIR, B.; TROPHEAN, B.; FROSTIER, J.; NICHOU, A.G.

Hôpital Richier-Clair, Paris, France.

Objectif: Evaluer la fréquence de la toxoplasmose digestive et préciser ses aspects anatomo-cliniques.

Méthodes: Étude macroscopique et histologique systématique de T.D. de 150 patients (Pa) atteints de SIDA, corrélatée avec les données cliniques.

Résultats: Le T.D. est atteint 7 fois (5 homoseksuels européens, 1 saoudien, 1 indonésien). Age moyen 37 ans ± 6 ans (écart interquartile 1-30 ans). Sexe

INTERFÉRENCE 2 fois tout le tube digestif, 1 fois la grêle et le colon, 4 fois seulement l'oesophage (n = 1), la grêle (n = 1) ou le colon (n = 2). L'aspect macroscopique est local (œdème, pétéchiales) dans 2 cas; 2 aspects de type gastrique diffuse (1 cas) et de recto-colite hémorragique (1 cas).

Toxoplasmose généralisée (T.G.) peut infecter tous les types cellulaires. Types et topographies lésés sont en évidence sur toute l'épaisseur de la paroi, dans des lésions inflammatoires et/ou adhésives, nodulaires ou diffuses.

Dans 2 cas T.G. est le seul agent pathogène; 2 fois il est associé à des cryptosporidies (n = 1) et à une infection par *Opisthorchis viverrini* et *Hyocysternum* dans l'intestin terminal.

La toxoplasmose digestive est la 1^{re} cause de douleurs abdominales et s'étend au moins une autre localisation viscérale. La clinique se résume à une diarrhée profuse (5 fois) et/ou à des douleurs abdominales (3 fois).

Conclusion: La toxoplasmose digestive est la 1^{re} cause de douleurs abdominales systémiquement sur les biopsies digestives, au moins par immunoperoxidase.

Infections liées au SIDA : diarrhée

AIDS Related Infection: Diarrhea

W.B.P.36 ANOXYGENES ISOLE DU TUBE DIGESTIF CHEZ 20 PATIENTS SIDA. UNILÉVELLE IDENTIFICATION CLINIQUE

BALLET, R., MULLIGAN, J., LEPORT, C., GUER, J., LEPORT C., BRICOURT, F., VILIS, J.L. Hôpital Claude-Bernard, Paris, France.

OBJECTIF: Définir le rôle des adénovirus au cours du SIDA.

Méthodes: Étude rétrospective des diarrées chez 20 patients (pts) SIDA chez lesquels un adénovirus a été isolé des selles ou des biopsies coliques entre août 1987 et septembre 1988.

Résultats: Tous avaient des signes digestifs : diarrhée (n=18), douleurs abdominales (n=7), traie pts avaient une ulcération anale. La coloscopie

révéla des lésions chez 8/18 pts et normales chez 10/18 pts. Les

ulcéraires chez 10/18 (5/1) avec histologiquement des lésions

compatibles avec une infection à CMV (n=1), des cryptosporidies (n=1) et

aucun autre agent pathogène chez 1 adénovirus (n=1). Un adénovirus était

isolé des selles (n=1), des biopsies rectales (n=2) et/ou caecales (n=8)

ou de l'ulcération anale (n=7). Les structures de 4 autres études

étaient 1/8, 1/2, 2/2 et 2/2. Les recherches d'adénovirus étaient réalisées à

4 fois dans selles et biopsies chez 10 pts; elles étaient positives aux

deux niveaux chez 6 pts (6/7) à positive seulement dans les selles chez

4 pts (4/4) et 6 sur 6 pts (6/6) à positive seulement dans les selles et

colite adhésive chez 1 pt. Les virus CMV étaient présents chez 0/8 pts (0/8), et

8 sur 8 pts (4/2) avec une localisation vésiculaire à CMV.

Conclusion: Ces résultats (1) suggèrent la possible responsabilité de

adénovirus dans certaines manifestations digestives courtes du SIDA, (2)

évaluent la question des relations entre CMV et adénovirus au niveau du

tube digestif chez ces pts.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

W.B.P.13

LE "FLUCONAZOLE" DANS LE TRAITEMENT DE LA CRYPTOCOCCOSE MÊNINGÉE CHEZ LES PATIENTS ATTEINTS DE SIDA.

NAVERNE KALAMBAYILI, MD et DEHRET P.***
*CITROUDES Universitaires de Kinshasa, **Labo de Mycologie, Zaire.

OBJECTIF: Étudier cliniquement l'efficacité du Flucanazole dans le traitement de la cryptococcose méningée chez les SIDAiens.
PATIENTS: 12 SIDAiens* cas HIV (11 et 12) avec Cryptococcose méningée confirmée par culture (Sabouraud) et par seroélectrophorèse (IEM) ont été traités de façon randomisée soit par flucanazole soit par association Amphotéricin B + 5 Fluorocytosine.
RÉSULTATS: Les symptômes cliniques disparaissent et guérison mycologique est obtenue dans la culture du liquide céphalo-rachidien (LCR) devenant négative après 8 contrôles successifs.

RÉSULTATS: 17 malades ont eu le flucanazole (groupe A) et 17 l'association amphotéricin B/5 fluorocytosine (groupe B).

DURÉE DES SYMPTÔMES	Gr. A	Gr. B	p=0.7
Ag Crypt. dans le sang	1/25(38)	1/14(47)	p=0.6
Ag Crypt. dans le LCR	1/18(4)	1/20(5)	p=0.2
Guérison clin.	11/17	20/21	p=0.8
Guérison myc.	11/17	20/21	

CONCLUSION: Le flucanazole a une efficacité comparable à celle de l'association amphotéricin B + 5 fluorocytosine.

W.B.P.14

LA CRYPTOCOCCOSE AU MAROC

FACH JACQ-ROBERT, ROYER S., LAMOURI S., KAMRER W.,
*Centre Hospitalier Universitaire de Rabat, MAROC.

OBJECTIF: Analyser l'importance de la meningite à cryptococques dans le SIDA et l'évolution de son traitement par le Flucanazole.

METHODES: - Étude de 37 cas de meningites à cryptococques observées en 32 mois et 17 cas de son traitement par le Flucanazole.

- Diagnostic clinique et diagnostic biologique reposant sur le mise en évidence de lésions typiques de Cryptococcus méningococci sur smears microscopiques direct du L.C.R., sous scap ou culture systématique sur milieu de Sabouraud, suivi d'une identification mycologique précise. - Traitement appliqué au cours de l'étude: a) association amphotéricin B et 5-Fluorocytosine - ou du FLUCANAZOLE.

RÉSULTATS: - Prévalence de la cryptococcose dans le SIDA: 2/3 des cas
- Importance clinique: meningite méningococcale dans 80 % des cas
- Traitement par FLUCANAZOLE: 17 patients, 17 fois, bien toléré, facile à administrer

CONCLUSIONS: - La Meningite à Cryptococcus méningococci survient souvent au stade du SIDA au Maroc, son diagnostic est facile, le traitement par le FLUCANAZOLE est bien toléré, efficace, d'administration facile, bien toléré, bien adapté aux pays à revenu autochtono sous-développés.

MOTS-CLÉS:
Meningite, Cryptococcus, S.I.D.A.

W.B.P.15 CRYPTOCOCCAL MENINGITIS AND HIV INFECTION IN NORTH CAROLINA

NEWMAN, BARRY, BARRETT, J.A. and COLLINS, M.D.
Duke University Medical Center, Durham, North Carolina, USA

Objective: Evaluate characteristics of cryptococcal disease among persons with human immunodeficiency virus infection in rural, southeastern USA.

Methods: A retrospective review of clinical and laboratory records.

Results: From 1983 through 1989, the proportion of patients with cryptococcal disease who also had HIV infection tripled:

1985-24 (53%), 1986-29 (31%), 1987-67 (10%), 1988-73 (11%)

We compared the 29 HIV patients to the 33 HIV patients diagnosed with disseminated or meningeal cryptococcosis. HIV-infected patients were more likely to have cryptococcal meningitis, had rapid conversion of serum antigen titers from negative to positive, and had higher cryptococcal antigen titers at the time of initial diagnosis.

A review of survival trends of the HIV-infected cohort (n=29) indicated that 12-month survival following diagnosis has increased from 13% (1/8) in 1985-1986 to 67% (6/9) in 1987-1989. The magnitude of titrable antigen (by latex fixation) at the time of diagnosis was not predictive of long-term response.

One of the 7 long-term survivors had initial CSF antigen titers greater than 1:100; one patient had a CSF titer greater than 1:1000,000.

In all patients, a decline in cryptococcal antigen titer did occur following initiation of therapy and was associated with a positive response. Subsequent increase or plateau of antigen levels was associated with relapse. All long-term survivors required maintenance therapy.

Conclusion: The diagnosis of cryptococcosis in HIV-infected patients should not center a dismal prognosis.

W.B.P.16 CRYPTOCOCCAL MENINGITIS IN PATIENTS WITH AIDS. DIAGNOSTIC FEATURES AND OUTCOME IN 8 CASES.

ANTONELLI, G., VIGARIANO, P., JESSELLI, G., BIANCHI, B., BORDI, R., & SILELLI, M., SILELLI, M.D.

Sanatorio Spallanzani Hospital for Infectious Diseases, Rome, Italy

Objective: To study clinical and laboratory features of cryptococcal meningitis (CM) in patients (pts) with AIDS.

Methods: Investigations involved clinical manifestations, tests on blood, CSF, sputum, brain and tissues, CT brain scans and/or cranial MRI.

Results: Among 101 patients with AIDS observed from 1984 to 1988, 8 (1.9%) had CM. Four of them had also antineoplastic involvement. CM was the first diagnosed opportunistic disease in 4 pts. Fever and headache were present respectively in 6/8 and 7/8 of the patients.

Initial status, meningismus and vomiting occurred in 6/8, 3/8, and 2/8 respectively. The symptoms duration before diagnosis ranged from 8 to 20 days.

The diagnosis of CM was based on CSF studies in 8 cases and on autopsy findings in one. The CSF protein was 25-172 mg/dl, the glucose range was 16-64 mg/dl and the white blood cell count in 7 cases in only 1 of 7 pts (range 1-60 cells/dl).

The CSF culture was positive in 4 pts, Indian ink preparation in 6 of 7 pts and the cryptococcal antigen titer was positive in all pts. Brain scans and/or MRI revealed abnormal results in 4 pts.

Therapeutic regimen included amphotericin B 0.1 mg/kg plus fluconazole 150 mg/d for 8 pts. Two of the 7 pts were cured.

Conclusions: The authors point out that CM may present in an insidious manner in pts with AIDS, the high mortality rate in spite of an early diagnosis and the recommended therapeutic regimen.

W.B.P.17 THE LIMITED VALUE OF ROUTINE SERUM ANTIGEN SCREENING FOR CRYPTOCOCCAL INFECTION.

NEWMAN, BARRY S., SMITH, D.A., HAWKINS, D., SHANKER, D., REED, C., SILELLI, M.D. & STERNBERG, RICHARD, M.D., NEW YORK, ENGLAND.

Objective: To assess the routine serum cryptococcal antigen as a screening procedure for diagnosis of cryptococcal infection.

Methods: All HIV antibody positive patients over a three year period who had pyrexia of unknown origin or meningitis underwent screening by serum cryptococcal antigen latex agglutination tests. All patients with a positive titre or signs of meningitis had a lumbar puncture. In those patients with a positive serum antigen, a further antigen was performed on serum saved prior to diagnosis.

Results: Only 15 of 808 serum cryptococcal antigens were positive, 15 of whom had meningitis and had cryptococcal meningitis confirmed at lumbar puncture. The other 8 patients had pyrexia of unknown origin without meningitis and had no CSF abnormalities. One was retained well for over one year. The other had a tubercula which responded to conventional therapy and is well at six months.

A saved sera was available on 8 of the patients with positive serum antigen within 3 months prior to diagnosis (range 20-90 days; mean 60 days). All were well at time of testing. None of the sera were positive.

Conclusion: Cryptococcal antigen testing is not of value as a screening test for patients with a pyrexia of unknown origin or in predicting which well patients may develop this infection. It does predict which patients with meningitis have cryptococcal infection.

W.B.P.18 CRYPTOCOCCUS MENINGITIS PULMONARY INFECTION IN 17 HIV INFECTED PATIENTS

Chak, Ananda*, Grew, D., Valente, G., and Hyslop, N.*.
*Dallas/LSD ACTV, New Orleans, USA

Objective: To review the presentation and clinical course of Cryptococcus meningitis (CM) pulmonary infections in HIV infected (HIV+) patients.

Methods: Hospital records and chest X-rays of HIV+ patients known to have CM pulmonary infection either by positive respiratory cultures or histopathologic evidence were retrospectively reviewed. All patients were seen at Charity Hospital of New Orleans, Veterans Administration Medical Center, or Tulane Medical Center between January 1, 1985 and December 1, 1988.

Results: Of 17 patients, all were male; most were white (15), and homosexual (12), with an average age of 33 (± 6) years. The most frequent presenting symptoms were fever (15) and cough or dyspnea (5). Although chest X-ray patterns included cavity lesions (2), nodules (2), and a solitary lower infiltrate (1), the most common finding was bilateral interstitial infiltrates (7), of which 3 had coexistent cytologically proven PCP. Positive simultaneous extrapulmonary cultures, CSF (8/15) and blood (4/10), were found in 8 patients. Two patients with no extrapulmonary infection with a mean length of survival of 16 (± 6) weeks and 6 patients with concomitant CNS involvement died with a mean length of survival of 4 (± 5) weeks.

Conclusions: Chest X-ray findings in HIV+ patients with CM pulmonary infections can be unusual. Features and differentiations from PCP may be difficult. The mortality rate is high in HIV+ patients with CM symptoms and may be influenced by the presence of CNS involvement.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

W.B.P.85 MEASUREMENT OF β_2 -MICROGLOBULIN (EM) BY RAGE EPIDEMIOLOGIC ASSISTED IN BLOOD FROM AIDS INFECTED
Shyam-Bashi, J. Johnson, M. Chen, F. J. and Miller, J. Clinical Lab., T.F. General Hospital and Dept. Lab Med., UCSF, San Francisco CA, U.S.A.

Objective: EM content of blood, CD4 T-cell count, hemoglobin and social and behavioral risk factors have been proposed as prognostic indicators in AIDS/ARC patients. We developed a method to measure EM by immunonephelometry (INA).

Methods: We used the Beckman ICS nephelometer and commercially available anti-EM. We mixed 50 μ l of serum or plasma with 1.50 ml of 9% polyethylene glycol (PEG) and 84 μ l of anti-EM. EM from human urine was used as standard.

Results: Analytical sensitivity and linearity were 1.0 mg/L and 7.7 mg/L. Inter-assay CV's were 7.2% for 5.6 mg/L and 4.8% for 2.6 mg/L. Intra-assay CV's were 3.9% for 4.7 mg/L and 4.8% for 2.1 mg/L. EM content by assay (CV) and EM were highly correlated: $r = 0.926$. Serum from 45 AIDS and ARC patients had a mean EM of 3.7 ± 1.4 mg/L. Sera from 22 healthy subjects had a mean EM of 1.7 ± 0.5 mg/L. Lipemic specimens were cleared by ultracentrifugation. Specimens kept at -70°C up to 6 months are suitable for this assay.

Conclusion: This assay procedure is easily adaptable to routine clinical laboratory operation, is less expensive and is less labor-intensive than is ELISA and RIA. Further, the AIDS/ARC EM show significant elevation over healthy subjects studied at UCSF.

We wish to acknowledge Dr. A. Ross for providing AIDS/ARC samples.

W.B.P.87 QUEST FOR PROGNOSTIC MARKERS IN HIV INFECTED HAEMOPHILIC CHILDREN

Susan Shidmore*, M Williams**, SJ Mason* & PDH Hill**

*Regional Virus Laboratory, East Birmingham Hospital, Birmingham, UK
**Department of Haematology, Birmingham Children's Hospital, Birmingham, UK

Objective: To assess the predictive value of laboratory markers in progression of HIV infection in a cohort of haemophilic boys.

Methods: Assays for anti-HIV, anti-CD4, anti-CD8, anti-CD4/CD8, anti-interferon, neopterin and β_2 -microglobulin were bought in kit form and carried out according to the manufacturer's instruction.

Patients: Since the introduction of HIV screening, HIV seroconversion has been shown in 34 haemophilic boys attending a large paediatric haemophilia centre. It has been possible to document that seroconversion occurred as early as 1981 but the majority in 1983 to 1985 with seroconversion precisely identified within a three month period in at least a third of the patients.

Sequential samples including one pre-seroconversion are available on all patients (mean number 13 per patient).

Results: Among this cohort one boy has persistent 4-7% of an upsurge of pneumococcal carinii pneumonia 2 years ago, but is currently well on no treatment. Although a further 7 boys have one or more altered markers, all remain well and are asymptomatic, one after 6 years of follow up. These results will be presented in relation to the time from seroconversion.

Conclusion: Results from marker studies in haemophilic children should be interpreted independently. Data from studies in adults cannot be used to predict the course of infection in children. It seems likely that age will prove a contributory factor in the development of the infection in this group of patients.

W.B.P.89 NEOPTERIN IS A RELIABLE DIAGNOSTIC MARKER IN HIV-INFECTION.

E. Reisinger*, P. Kern*, S. Schneider*, A. Borchmann*, M. Ernst*, D. Bartzke* & H. B. Fiedl*, R. Dietrich*

* Clin. Dept. and ** Dept. of Virology, Bernhard-Nocht-Inst. for Tropical Med., Hamburg, FRG.

* Forchungsanstalt Borstel, FRG

* B. Dept. of Borstel, Inst. for Virology, Hamburg, FRG

Objective: Neopterin is produced by macrophages stimulated with endotoxins. We report on the correlation of serum-neopterin with the course of HIV-infection during a prospective randomized double blind treatment study. Methods: 84 patients were examined in 6-week intervals and the neopterin levels were correlated with known prognostic markers for HIV-infection. In the IIA we are using the known normal limit is 20 nmol/L. Results: In the asymptomatic stage of the HIV-infection the neopterin levels are normal in most cases. In early asymptomatic stages of infection (CDC III) the neopterin levels are elevated statistically (10-20 nmol/L). The levels tend to increase with progression in CDC, Walter-Reed and Holtz-Peters in the case of AIDS. In the case of AIDS, the neopterin level is also highly correlated with progression parameters as CD4 count, lymphocytes, CD4/CD8 ratio, and HA-1-20 pg. lymphocytes.

Conclusion: Neopterin is produced by macrophages stimulated with endotoxins. We report on the correlation of serum-neopterin with the course of HIV-infection during a prospective randomized double blind treatment study. Methods: 84 patients were examined in 6-week intervals and the neopterin levels were correlated with known prognostic markers for HIV-infection. In the IIA we are using the known normal limit is 20 nmol/L. Results: In the asymptomatic stage of the HIV-infection the neopterin levels are normal in most cases. In early asymptomatic stages of infection (CDC III) the neopterin levels are elevated statistically (10-20 nmol/L). The levels tend to increase with progression in CDC, Walter-Reed and Holtz-Peters in the case of AIDS. In the case of AIDS, the neopterin level is also highly correlated with progression parameters as CD4 count, lymphocytes, CD4/CD8 ratio, and HA-1-20 pg. lymphocytes.

Conclusion: Neopterin is produced by macrophages stimulated with endotoxins. We report on the correlation of serum-neopterin with the course of HIV-infection during a prospective randomized double blind treatment study. Methods: 84 patients were examined in 6-week intervals and the neopterin levels were correlated with known prognostic markers for HIV-infection. In the IIA we are using the known normal limit is 20 nmol/L. Results: In the asymptomatic stage of the HIV-infection the neopterin levels are normal in most cases. In early asymptomatic stages of infection (CDC III) the neopterin levels are elevated statistically (10-20 nmol/L). The levels tend to increase with progression in CDC, Walter-Reed and Holtz-Peters in the case of AIDS. In the case of AIDS, the neopterin level is also highly correlated with progression parameters as CD4 count, lymphocytes, CD4/CD8 ratio, and HA-1-20 pg. lymphocytes.

Conclusion: Neopterin is produced by macrophages stimulated with endotoxins. We report on the correlation of serum-neopterin with the course of HIV-infection during a prospective randomized double blind treatment study. Methods: 84 patients were examined in 6-week intervals and the neopterin levels were correlated with known prognostic markers for HIV-infection. In the IIA we are using the known normal limit is 20 nmol/L. Results: In the asymptomatic stage of the HIV-infection the neopterin levels are normal in most cases. In early asymptomatic stages of infection (CDC III) the neopterin levels are elevated statistically (10-20 nmol/L). The levels tend to increase with progression in CDC, Walter-Reed and Holtz-Peters in the case of AIDS. In the case of AIDS, the neopterin level is also highly correlated with progression parameters as CD4 count, lymphocytes, CD4/CD8 ratio, and HA-1-20 pg. lymphocytes.

Conclusion: Neopterin is produced by macrophages stimulated with endotoxins. We report on the correlation of serum-neopterin with the course of HIV-infection during a prospective randomized double blind treatment study. Methods: 84 patients were examined in 6-week intervals and the neopterin levels were correlated with known prognostic markers for HIV-infection. In the IIA we are using the known normal limit is 20 nmol/L. Results: In the asymptomatic stage of the HIV-infection the neopterin levels are normal in most cases. In early asymptomatic stages of infection (CDC III) the neopterin levels are elevated statistically (10-20 nmol/L). The levels tend to increase with progression in CDC, Walter-Reed and Holtz-Peters in the case of AIDS. In the case of AIDS, the neopterin level is also highly correlated with progression parameters as CD4 count, lymphocytes, CD4/CD8 ratio, and HA-1-20 pg. lymphocytes.

Conclusion: Neopterin is produced by macrophages stimulated with endotoxins. We report on the correlation of serum-neopterin with the course of HIV-infection during a prospective randomized double blind treatment study. Methods: 84 patients were examined in 6-week intervals and the neopterin levels were correlated with known prognostic markers for HIV-infection. In the IIA we are using the known normal limit is 20 nmol/L. Results: In the asymptomatic stage of the HIV-infection the neopterin levels are normal in most cases. In early asymptomatic stages of infection (CDC III) the neopterin levels are elevated statistically (10-20 nmol/L). The levels tend to increase with progression in CDC, Walter-Reed and Holtz-Peters in the case of AIDS. In the case of AIDS, the neopterin level is also highly correlated with progression parameters as CD4 count, lymphocytes, CD4/CD8 ratio, and HA-1-20 pg. lymphocytes.

Conclusion: Neopterin is produced by macrophages stimulated with endotoxins. We report on the correlation of serum-neopterin with the course of HIV-infection during a prospective randomized double blind treatment study. Methods: 84 patients were examined in 6-week intervals and the neopterin levels were correlated with known prognostic markers for HIV-infection. In the IIA we are using the known normal limit is 20 nmol/L. Results: In the asymptomatic stage of the HIV-infection the neopterin levels are normal in most cases. In early asymptomatic stages of infection (CDC III) the neopterin levels are elevated statistically (10-20 nmol/L). The levels tend to increase with progression in CDC, Walter-Reed and Holtz-Peters in the case of AIDS. In the case of AIDS, the neopterin level is also highly correlated with progression parameters as CD4 count, lymphocytes, CD4/CD8 ratio, and HA-1-20 pg. lymphocytes.

Conclusion: Neopterin is produced by macrophages stimulated with endotoxins. We report on the correlation of serum-neopterin with the course of HIV-infection during a prospective randomized double blind treatment study. Methods: 84 patients were examined in 6-week intervals and the neopterin levels were correlated with known prognostic markers for HIV-infection. In the IIA we are using the known normal limit is 20 nmol/L. Results: In the asymptomatic stage of the HIV-infection the neopterin levels are normal in most cases. In early asymptomatic stages of infection (CDC III) the neopterin levels are elevated statistically (10-20 nmol/L). The levels tend to increase with progression in CDC, Walter-Reed and Holtz-Peters in the case of AIDS. In the case of AIDS, the neopterin level is also highly correlated with progression parameters as CD4 count, lymphocytes, CD4/CD8 ratio, and HA-1-20 pg. lymphocytes.

Conclusion: Neopterin is produced by macrophages stimulated with endotoxins. We report on the correlation of serum-neopterin with the course of HIV-infection during a prospective randomized double blind treatment study. Methods: 84 patients were examined in 6-week intervals and the neopterin levels were correlated with known prognostic markers for HIV-infection. In the IIA we are using the known normal limit is 20 nmol/L. Results: In the asymptomatic stage of the HIV-infection the neopterin levels are normal in most cases. In early asymptomatic stages of infection (CDC III) the neopterin levels are elevated statistically (10-20 nmol/L). The levels tend to increase with progression in CDC, Walter-Reed and Holtz-Peters in the case of AIDS. In the case of AIDS, the neopterin level is also highly correlated with progression parameters as CD4 count, lymphocytes, CD4/CD8 ratio, and HA-1-20 pg. lymphocytes.

Conclusion: Neopterin is produced by macrophages stimulated with endotoxins. We report on the correlation of serum-neopterin with the course of HIV-infection during a prospective randomized double blind treatment study. Methods: 84 patients were examined in 6-week intervals and the neopterin levels were correlated with known prognostic markers for HIV-infection. In the IIA we are using the known normal limit is 20 nmol/L. Results: In the asymptomatic stage of the HIV-infection the neopterin levels are normal in most cases. In early asymptomatic stages of infection (CDC III) the neopterin levels are elevated statistically (10-20 nmol/L). The levels tend to increase with progression in CDC, Walter-Reed and Holtz-Peters in the case of AIDS. In the case of AIDS, the neopterin level is also highly correlated with progression parameters as CD4 count, lymphocytes, CD4/CD8 ratio, and HA-1-20 pg. lymphocytes.

Conclusion: Neopterin is produced by macrophages stimulated with endotoxins. We report on the correlation of serum-neopterin with the course of HIV-infection during a prospective randomized double blind treatment study. Methods: 84 patients were examined in 6-week intervals and the neopterin levels were correlated with known prognostic markers for HIV-infection. In the IIA we are using the known normal limit is 20 nmol/L. Results: In the asymptomatic stage of the HIV-infection the neopterin levels are normal in most cases. In early asymptomatic stages of infection (CDC III) the neopterin levels are elevated statistically (10-20 nmol/L). The levels tend to increase with progression in CDC, Walter-Reed and Holtz-Peters in the case of AIDS. In the case of AIDS, the neopterin level is also highly correlated with progression parameters as CD4 count, lymphocytes, CD4/CD8 ratio, and HA-1-20 pg. lymphocytes.

Conclusion: Neopterin is produced by macrophages stimulated with endotoxins. We report on the correlation of serum-neopterin with the course of HIV-infection during a prospective randomized double blind treatment study. Methods: 84 patients were examined in 6-week intervals and the neopterin levels were correlated with known prognostic markers for HIV-infection. In the IIA we are using the known normal limit is 20 nmol/L. Results: In the asymptomatic stage of the HIV-infection the neopterin levels are normal in most cases. In early asymptomatic stages of infection (CDC III) the neopterin levels are elevated statistically (10-20 nmol/L). The levels tend to increase with progression in CDC, Walter-Reed and Holtz-Peters in the case of AIDS. In the case of AIDS, the neopterin level is also highly correlated with progression parameters as CD4 count, lymphocytes, CD4/CD8 ratio, and HA-1-20 pg. lymphocytes.

Conclusion: Neopterin is produced by macrophages stimulated with endotoxins. We report on the correlation of serum-neopterin with the course of HIV-infection during a prospective randomized double blind treatment study. Methods: 84 patients were examined in 6-week intervals and the neopterin levels were correlated with known prognostic markers for HIV-infection. In the IIA we are using the known normal limit is 20 nmol/L. Results: In the asymptomatic stage of the HIV-infection the neopterin levels are normal in most cases. In early asymptomatic stages of infection (CDC III) the neopterin levels are elevated statistically (10-20 nmol/L). The levels tend to increase with progression in CDC, Walter-Reed and Holtz-Peters in the case of AIDS. In the case of AIDS, the neopterin level is also highly correlated with progression parameters as CD4 count, lymphocytes, CD4/CD8 ratio, and HA-1-20 pg. lymphocytes.

Conclusion: Neopterin is produced by macrophages stimulated with endotoxins. We report on the correlation of serum-neopterin with the course of HIV-infection during a prospective randomized double blind treatment study. Methods: 84 patients were examined in 6-week intervals and the neopterin levels were correlated with known prognostic markers for HIV-infection. In the IIA we are using the known normal limit is 20 nmol/L. Results: In the asymptomatic stage of the HIV-infection the neopterin levels are normal in most cases. In early asymptomatic stages of infection (CDC III) the neopterin levels are elevated statistically (10-20 nmol/L). The levels tend to increase with progression in CDC, Walter-Reed and Holtz-Peters in the case of AIDS. In the case of AIDS, the neopterin level is also highly correlated with progression parameters as CD4 count, lymphocytes, CD4/CD8 ratio, and HA-1-20 pg. lymphocytes.

Conclusion: Neopterin is produced by macrophages stimulated with endotoxins. We report on the correlation of serum-neopterin with the course of HIV-infection during a prospective randomized double blind treatment study. Methods: 84 patients were examined in 6-week intervals and the neopterin levels were correlated with known prognostic markers for HIV-infection. In the IIA we are using the known normal limit is 20 nmol/L. Results: In the asymptomatic stage of the HIV-infection the neopterin levels are normal in most cases. In early asymptomatic stages of infection (CDC III) the neopterin levels are elevated statistically (10-20 nmol/L). The levels tend to increase with progression in CDC, Walter-Reed and Holtz-Peters in the case of AIDS. In the case of AIDS, the neopterin level is also highly correlated with progression parameters as CD4 count, lymphocytes, CD4/CD8 ratio, and HA-1-20 pg. lymphocytes.

W.B.P.86 THE CLASSIFICATION OF HIV DISEASE: CORRELATION OF BETA-2-MICROGLOBULIN (B-2-M) AND ERYTHROCYTE SEDIMENTATION RATE (ESR).
Kilborn, J; Fisher, E; Elym, J; Markowitz, N. and Saravolatz, L.D. Henry Ford Hospital, Detroit, Michigan, USA.

Objective: To identify the role of beta-2-microglobulin, erythrocyte sedimentation rate, and hemoglobin (Hb) as predictive indicators of CDC-HIV stages.

Methods: At the time of initial medical assessment, 70 HIV(+) men were classified according to CDC clinical stage and had serum B-2-M, ESR, Hb and CD2, CD4, and CD8 T-lymphocytes subsets determined. CD2 groups were then compared by analysis of variance.

Results: Mean values \pm standard deviations are indicated for each parameter. CD2 group M (n=10) B-2-M (mg/dl) Hb (g/dl) CD4 (cells/mm³) CD8 (cells/mm³)
I 15 12.581(7.1) 2.65(0.7) 2972(81) 26.9(12.4) 0.87(0.27)
II 43 15.2(15.4) 2.44(0.5) 5172(589) 27.4(11.0) 0.66(0.26)
III 12 63.0(44.3) 3.9(2.2) 15.7(2.2) 296(180) 17.0(7.9) 0.36(0.22)

P value 0.0002 0.003 0.02 0.03 0.02 0.05
When analyzed by disease stage, none of the above parameters differed between I and II; all were significantly different between groups III and IV. Among T-cell measures, CD4 correlated best with group, however, ESR, B-2-M and Hb were each a more sensitive predictor of Stage IV than CD4.

Conclusion: The B-2-microglobulin and ESR may be more sensitive than the T-cell markers and a less expensive means in monitoring HIV disease.

W.B.P.88 ROUTINE LABORATORY TESTS WHICH CORRELATE WITH HIV-1 INFECTION PRIOR TO ONSET OF AIDS

William D'Arcy*, T. Hooton*, S. and Sacks, H.S. *Foundation for Research on Sexually Transmitted Diseases, NY, USA; *New York City Department of Health, NY, NY, USA, and **Mount Sinai School of Medicine, NY, NY, USA

Objective: To identify routine laboratory tests whose results can correlate with HIV-1 infection in asymptomatic people.

Methods: A group of 110 apparently healthy, formerly drug addicted women was evaluated during 1983-1985. The relationship of routine laboratory tests to anti-HIV-1 antibody presence was evaluated by univariate and multivariate analysis. HIV-1 testing by ELISA with confirmation by Western blot method found 46 of these women to be positive for anti-HIV-1 antibodies. None had AIDS or ARC at the time of evaluation.

Results: Even in the asymptomatic stages of the disease process, there is evidence of statistically significant values (p<0.05) in increased globulin (Glb), and decreased albumin (Alb) and albumin/globulin ratio (Alb/Glb), leucocytosis (Leu), white blood count (WBC), lymphocytes (Lym), cholesterol (Chol), sodium (Na), iron (Fe) and calcium (Ca) levels in the anti-HIV-1 positive women (values expressed as Means with Standard Deviations).

Stats	n	Glb	Alb	Alb/Glb	Leu	WBC	Lym	Chol	Na	Fe	Ca
Anti-HIV-1	46	7.4	3.92	1.089	10.26	5.531	2.004	156.89	135.53	74.93	8.86
Non-Infected	64	6.02	4.11	1.396	10.24	5.004	1.917	154.82	130.65	68.20	8.93
SD		0.72	0.34	0.227	3.57	1.477	0.579	39.78	3.83	27.16	0.39
Chi-Sq		3.57	0.23	0.207	3.58	1.948	1.815	30.04	2.69	18.24	1.03

Conclusion: This profile of results is indicative of the pattern of early seroconversion common to ARC and AIDS. The clinician can be alerted to suspect HIV-1 infection in these early stages, prior to the onset of ARC, by detecting this pattern of high globulin with "low normal" chemistries and blood counts. This pattern needs to be confirmed in other populations.

W.B.P.90 THE USE OF SERUM MONOCLONAL ANTIBODIES TO MONITOR THE COURSE OF HIV-INFECTION.

Panayiotou, Nicholas*, and Cosello, R.*

*National Institutes of Health, Bethesda, Maryland, USA.

Objective: To use oligoclonal bands as markers to follow the course of HIV-infection.

Methods: The increased sensitivity of our antigen-capture technique to determine serum proteins demonstrates discrete oligoclonal immunoglobulin bands (OIB) with an intense diffuse γ -globulin zone. Originally OIB were found in the serum of HIV-antibody carriers. Subsequently the serum OIB were identified with HIV-antigen. Presence of OIB in the serum of HIV-antibody carriers indicates a specific immune response of the host to HIV infection. This electrophoretic technique is used to monitor OIB in serum samples of asymptomatic HIV-antibody carriers. Testing is done every six months to correlate persistence and disappearance of OIB with progression of HIV infection to AIDS.

Results: Serial analysis of serum samples from 18 HIV-antibody carriers was performed for three years. During this period in 14 of 68 carriers (20%) disappearance or absence of OIB was associated with the development of clinical AIDS.

Conclusion: Millions of people worldwide are infected with HIV. Little is known about the factors the influence progression of infection to AIDS. Determination of OIB at defined time intervals serves as a useful marker to follow the clinical course of the infection in its progression to clinical AIDS.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

W.B.P.91 CSF NEOPTERIN IN HIV-1 INFECTION AND AS A FUNCTION OF AIDS DEMENTIA COMPLEX (ADC) SEVERITY
 Bross, Bruce J.; Balla, R.; Schwartz, W.; Price, R.W. Memorial Sloan-Kettering Cancer Center, New York, NY USA

Objectives: To determine the clinical significance of elevated concentrations of neopterin in the cerebrospinal fluid (CSF) of HIV-infected individuals and assess the value of CSF neopterin as a marker of ADC.
Methods: 50 samples of CSF and serum from 44 neurologically symptomatic patients at various stages of HIV infection were analyzed by radioimmunoassay (a gift from Kallestad) for neopterin and albumin (CSF and serum). All patients had been assessed by a neurologist and staged according to the presence and severity of ADC.

Results:

Neurological	#	CSF Neopterin (pmol/l)	Serum Neopterin (nmol/l)	Albumin (g/dl)
Normal	15	54.3 ± 27.1	37.3 ± 29.1	29.8 ± 3.4
Mild Dementia	4	71.7 ± 59.3	78.8 ± 5.4	32.2 ± 3.0
Severe Dementia	21	29.8 ± 15.0	32.2 ± 3.0	27.0 ± 25.3

In the CSF only patients, CSF neopterin correlated with ADC severity ($p < .001$) but not albumin ratio.
Conclusions: CSF neopterin is frequently elevated in HIV-infected individuals and is at such a non-specific. In those patients with ADC without other confounding illnesses, CSF neopterin correlated with ADC severity and seemed to be independent of blood-brain barrier dysfunction. As such, it may prove useful as a marker of ADC when other confounding illnesses are absent.

Diagnostic : le VIH

Diagnosis: HIV

W.B.P.93 EFFICIENT SCREENING FOR HIV 1- AND HIV 2-ANTIBODIES WITH A 3RD GENERATION ASSAY
 Knapp, Ulrich; Rasmussen, J.; Jullien, Th.; Engels, R. Institut für Virologie, 3550 Marburg, FRG

Objective: To describe the features of a new ELISA ("Enzygost-Anti-HIV 1+2") based on synthetic peptides corresponding to env-proteins of HIV 1 and HIV 2.
Methods: 50 µl undiluted specimen are added to 50 µl diluent into each well of microtiter plates coated with a cocktail of 4 synthetic peptides. After an incubation for 20' at 37 °C and 4 washings, 100 µl of peroxidase labeled Anti human IgG are added and incubated for another 30' at 37 °C. Colour development was allowed after 4 washings for 30' at RT using TMB.
Results: Of 708 Anti HIV 1-sera and 198 Anti HIV 2-sera all specimens reacted positive, whereby the majority of about 95 % showed O.D. values greater than 2.0. Compared to 2nd generation assays an improved efficiency was found by clear cut positive results of 12 Anti HIV 1-seroconvertors and 5 samples from early stages of HIV 2-infections. By testing 789 sera from healthy blood donors and 5000 plasma as well as 758 "risky" specimens an overall specificity of 99.98 % was calculated. No false positive reactivity could be observed after the treatment or freeze-thawing of sera and plasma specimens.
Conclusions: These results and the ease of handling make this new assay most suited for the reliable screening for both Anti HIV 1 and Anti HIV 2.

W.B.P.95 A SEMIAUTOMATED DOT BLOT IMMUNOASSAY FOR THE CONFIRMATION OF HIV SEROPOSITIVITY
 Knapp, Ulrich; Rasmussen, J.; Kapslak, W.; Schöler, J.; Stephens, et al. Abbott Laboratories, North Chicago, IL, USA

Objective: To develop an HIV confirmatory assay which is more sensitive and specific than Western Blot.
Methods: Purified recombinant proteins of HIV-1 and HIV-2 are immobilized on nitrocellulose. The assay is conducted in a 35 C incubator surrounded for timed incubations, sample removal, washing, drying, and reflexion reading. A digital print-out records the intensities of the color reaction. The assay requires less than 3 hours to perform and utilizes an alkaline phosphatase detection system. The detection of antibodies to the HIV-1 ENV antigens in addition to either the GAG or POL antigens is used as the criteria for HIV-1 antibody confirmation. The detection of antibodies to the HIV-2 ENV is the criteria for HIV-2 antibody diagnosis.
Results: This assay, based on testing of dilution panels, is 8 to 16-fold more sensitive than the current commercially available Western Blot assays for HIV-1 or HIV-2. In a population of 50 AIDS-, 50 ARC and 50 seropositive individuals, all were detected by both the dot blot and Western Blot. One hundred percent correlation was found, with Western Blot, on a population of 75 normal blood donors.
Conclusion: This semiautomated dot blot immunoassay offers enhanced performance over the Western Blot with the additional advantage of a non-subjective instrument readout.

W.B.P.92 PREDICTIVE VALUE OF NEOPTERIN, β₂-MICROGLOBULIN AND THYMIDYLKINASE IN HIV INFECTION
 Bross, Bruce J.; Balla, R.; Schwartz, R.; Fowler, H.S.; Bogner, J.R.; Med. Poliklinik Universität München, FRG

OBJECTIVE: To determine the predictive value of β₂-microglobulin (β₂), Neopterin (Npt), and Thymidylkinase (TK) in patients (pts) with or without progression of HIV disease.
METHODS: 60 HIV-AB pos. pts in 4 groups with different clinical deterioration within 2 years (group I: progression III; group II: WR 6; III: WR 1 to WR 5; IV: WR 1 unchanged) were tested for lymphocyte subsets, β₂, Npt and TK.
RESULTS: Significant differences between all stages of WR were observed for CD4/E ratio (ratio) and β₂ for Npt only beginning with WR 3, for TK only between WR 1 and WR 6. Within group IV a significant increase of β₂ and decrease of the ratio were seen after 2 years despite unchanged classification in WR 1. Comparing WR 1 in group I and WR 1 in group IV revealed significantly higher values of β₂ and Npt, lower values for the ratio in group I.

CONCLUSION: Even in case of stable WR classification changes of β₂ and Npt, though unspecific, and ratio are highly predictive and indicate progressive disease. TK does not seem to have similar prognostic value.

W.B.P.94 The use of the N-terminal portion of the transmembrane protein for the early detection and discrimination of HIV 1 and HIV 2 infection

Yonkers, R.; Hirsiger, M.; Hesel-Schickel, H.; Nott, M.; Rothacker, R.; Wenzel, A.; Wolf, P.; Sommer, H.-H.; Beyer, G. Research Dept., Offenhof, FRG; 2 Geneva, Vetsuisse Institut, München, FRG; 3 Theodor-Kocher-Institut, Bern, Switzerland

Objective: To determine the usefulness of the transmembrane proteins for early discrimination of HIV 1 and HIV 2 infections.

Methods: A DNA-fragment coding for the N-terminal region of the transmembrane protein of HIV 1 and the corresponding sequence of HIV 2 which has been chemically synthesized were cloned and expressed in E. coli. The recombinant antigens were purified and further evaluated in ELISA-experiments.

Results: Both antigens could be efficiently expressed in E. coli and purified to homogeneity. The purity of antigens were well documented by SDS-PAGE, electrophoresis and Western Blot. In ELISA-experiments all sera obtained from HIV 1 and HIV 2 infected persons reacted with one of the recombinant antigens. Although a lot of sera reacted with both antigens a discrimination between HIV 1 and HIV 2 infection was possible.

Conclusion: The transmembrane proteins are very useful antigens for detection and discrimination of HIV 1 and HIV 2 infection.

W.B.P.96 Title : Improvement of anti-HIV-2 reactivity of Vironomax anti-HIV-III

Authors : E. D. Sprockens, P. Ten Kortenaar, J.A. Hallings, H.J. Thunnissen, J. Ariens, J. van Duyn, Diagnostics Research Lab., Organon International B.V., P.O. Box 200, 5340 BH, Oss, The Netherlands

HIV-2 has been described as a second causative agent of AIDS. Therefore anti-HIV-screening assays should be fully sensitive to both anti-HIV-1 and anti-HIV-2 antibodies.
 The existing competitive anti-HIV-1 EIA's have a sensitivity of 28-51% for anti-HIV-2 sera, existing indirect EIA's have a sensitivity of 70-93% for anti-HIV-2 sera. Anti-HIV-2 reactivity of anti-HIV-1 EIA's is mainly due to immunologic cross-reactivity of GAG and POL gene products of HIV-1 and HIV-2. We describe a new screening assay, the Vironomax anti-HIV 1+2, with a combination of HIV-1 viral lysate and HIV-2 synthetic peptides as antigens coated to microtiter plates. This combination of antigen results in an increased reactivity with anti-HIV-2 antibodies, without any loss of anti-HIV-1 reactivity. In a preliminary study of 22 anti-HIV-2 sera the sensitivity of the Vironomax anti-HIV 1+2 was 100%, compared to only 36% of the Vironomax anti-HIV-III, which is based on HIV-1 viral lysate only.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects AIDS

W.B.P.97

"DEVELOPMENT OF TWO DIAGNOSTIC SYSTEMS FOR HIV SEROCONVERSION USING TWO RECOMBINANT ANTIGENS"
 Authors: Bonifazi, J., Novoa, L. I., Machado, J. A., Garcia, J., Padr, G., Herrera, L., et al
 Center of Genetic Engineering and Biotechnology, C.Habana, Cuba

Objective: to develop two alternative diagnostic systems for HIV-antibodies detection using two recombinant antigens.

Methods: The recent development of second-generation tests based on simple and manual procedures for rapid diagnosis of HIV antibodies are said to be so reliable and easy to use, they could allow future application not only for clinical diagnosis - under elemental laboratory conditions, but also for their use in the undeveloped countries in order to eliminate the AIDS transmission by blood transfusion.

Two systems for HIV1 seroconversion were developed. An indirect sandwich type enzyme immunoassay and a visual test based on a membrane capture assay with detection of antibodies with a protein A-gold conjugated, both using two recombinant antigens - expression products of representative regions of the genes coding for the transmembrane gp-41 and the major core gp 24 - HIV-1 proteins.

W.B.P.98

CROSS REACTION BETWEEN HIV-1 AND HIV-2 OR DOUBLE INFECTION.
 R. Schuster (1,2), F. Gschmidt (1,2), Z. Mayer (1), J. Witterter (3), F. Benekovic (3), T. F. Schulz (4), M. Rieder (4), Department of Virology of the Hospital of Linz, Vienna, Austria (1), Ludwig Boltzmann Institute for Dermatovenerological Serodiagnosis, Vienna, Austria (2), Österreichische AIDS-Hilfe (3), Institute for Hygiene and Ludwig Boltzmann Institute for AIDS Research, Innsbruck, Austria (4).

HIV-1 and HIV-2 viruses exhibit a high degree of sequence homology, in particular in the core proteins. Antibodies to HIV-2 core proteins might cross-react with HIV-1 and vice versa, whereas envelope proteins are antigenically distinct. Distinction between antibodies to HIV-1 and HIV-2 thus is usually attempted on the basis of reactivity with envelope derived bands of HIV-1 and HIV-2 on Western Blots.

In the present study an ELISA-test system was established using recombinant HIV-2 envelope antigen corresponding to amino acids (E197) derived from core protein or extracted into the transmembrane proteins. This system recognized 17 out of 18 HIV-2 infected patients (one patient was in terminal disease and did not further produce antibodies), 12 sera, both reactive to HIV-1 (immunofluorescence and Western Blot) and conventional HIV-2 ELISA (Pastorex), were used for the experiments. 5 of these sera clearly stained the 10S IgG envelope band of HIV-2. However, none of them reacted with the recombinant HIV-2 envelope derived antigen. This study shows that antigenic cross reactivity between envelope proteins of HIV-1 and HIV-2 does exist and strict care should be taken in interpreting respective results.

W.B.P.99

EVALUATION OF HIV-1 AND HIV-2 ELISA BASED ON SYNTHETIC PEPTIDES OF gp41

Kura, C., Meins, F. K., and Parkhede, U. **
 * Institute of Virology, Vienna, Austria, **
 Pharcacia Diagnostica AB, Uppsala, Sweden.

Objective: Assessment of peptide-based enzyme-immunoassays for the detection of antibodies against HIV.

Methods: Three different tests were used: an HIV-1 assay based on a peptide from gp41, an HIV-2 assay based on the corresponding peptide from gp36, and a control-test which contains both the HIV-1 and the HIV-2 peptides.

Results: These tests were evaluated using two panels of sera. Panel A consisted of 700 HIV-1-positive sera which were all confirmed positive by Western blotting. Panel B consisted of 300 sera which had yielded false positive results upon screening in either the Organon ELISA or the Abbott Reagent ELISA but were Western blot-negative. All truly HIV-positive sera were also recognized as positive in the HIV-1 peptide- and in the control-test. About 20 percent of the HIV-1 positive sera were also reactive in the HIV-2 peptide ELISA. The absence values, however, were always lower than those obtained in the HIV-1 peptide ELISA and rapidly dropped off upon titration. With respect to specificity, the control-test-assy revealed a very low rate of false positive results. Only 16 out of 700 sera that had yielded a false positive result in other HIV assays were also repeatedly positive in the control-assay.

Conclusion: Due to its specificity and sensitivity the peptide-based ELISA seems to be suited as a routine diagnostic assay.

W.B.P.100

APTITUDE D'UN TEST RAPIDE POUR HIV1 ET DE TESTS D'AGGLUTINATION A DETECTER DES ANTICORPS ANTI-HIV1 AU SENGAL.

M. Boup, A. Sallamane*, Sankali, J. L., Kabeye, C. M.**, Diakhane, L.**, Thiam, D.**, Ndiaye, S.***
 *Bactériovirologie/Université de Dakar, Sénégal. **Projet SIDA/Kinshasa, Zaïre. ***Centre National de Transfusion Sanguine/Dakar, Sénégal. ****ADTBCEP/Family Health International, USA.

Objectif: Evaluer l'efficacité de tests d'immunoanalyse sur membrane (DOT-Blot) et d'agglutination coqueux pour HIV1 au Sénégal, pays en cours à la fin HIV1 et HIV2.

Méthodes: 2000 prélèvements sanguins de diagnostic de sang, de personnes à haut risque, et de patients suspects de SIDA ont été testés par HIVCHECK (Dipon, USA). Tous les positifs, les indécidés et 10% des négatifs ont été testés en double en RIFOROLL (Abbott) et en SERODIA-HIV (Purijapan, Japon). Tous les sérum ont aussi été testés par ELISA on HIV1 et HIV2, puis les positifs par Western-Blot HIV1 et HIV2.

Résultats: Cette étude est en cours et sera achevée en Janvier. Les résultats et la spécificité des 3 tests pour la détection de HIV2 seront étudiés.

Les résultats préliminaires sont les suivants:

Nbre de sérums testés

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

1005 31

W.B.P.101

CONTRIBUTION OF SYNTHETIC PEPTIDES (SPV) TO THE SEROLOGICAL DIAGNOSIS OF HIV-1 AND HIV-2 REACTIVITY.

Escilla, Guadalupe, Barrena, J.M., Gil, M.P., Bayo, A., Gattell, J.M., and Casado, R. Blood Bank and Infectious Dept. Hosp. Aol. Central, Barcelona, Spain.

Objective: To determine the extent of HIV-2 infection in high risk populations and its relationship with HIV-1 infection.

Methods: HIV-1 and HIV-2 antibodies were studied in sera of 218 individuals at risk, 22 out of the seropositive individuals HIV-1 Western Blot, and 70 (Venezuela) and HIV-2 (Ivoria). The positive results were confirmed by Western Blotting. Panel B consisted of 300 sera which had yielded false positive results upon screening in either the Organon ELISA or the Abbott Reagent ELISA but were Western blot-negative. All truly HIV-positive sera were also recognized as positive in the HIV-1 peptide- and in the control-test. About 20 percent of the HIV-1 positive sera were also reactive in the HIV-2 peptide ELISA. The absence values, however, were always lower than those obtained in the HIV-1 peptide ELISA and rapidly dropped off upon titration. With respect to specificity, the control-test-assy revealed a very low rate of false positive results. Only 16 out of 700 sera that had yielded a false positive result in other HIV assays were also repeatedly positive in the control-assay.

Conclusion: Due to its specificity and sensitivity the peptide-based ELISA seems to be suited as a routine diagnostic assay.

W.B.P.102

TYPE SPECIFICITY OF THE HIGHLY IMMUNOREACTIVE EPITOPES OF HIV-1 AND HIV-2

M. Boup, A. Sallamane*, Narváez, A.**, Kontin, S.**, Rescaudini R.**, Viacanti, M.**, Ndiaye, S.***
 *Laboratory Research/Laboratoire, Helsinki, Finland; **Laboratorio Microbiologia, Ospedale Nona, Monza, Italy; Department of Clinical Microbiology, Ospedale San Carlo, Genova, Italy.

We have developed sensitive EIA's to detect human serum antibodies elicited against HIV-1 and HIV-2. EIA's are based on synthetic peptides derived from transmembrane protein gp41 and gp36 respectively. These peptides share 20% homology with each other. In our earlier studies we have compared the HIV-1 specific gnp peptide EIA to other antibody assays, while specificity of HIV-1 and HIV-2 gnp peptides by using HIV-1 positive human sera from North-Italy and HIV-2 positive sera from West-Africa. In the case of 100 HIV-1 positive sera all reacted with HIV-1 gnp peptide, 20% of them reacted with HIV-2 gnp peptide. 25% of HIV-2 positive sera reacted with HIV-1 gnp peptide. HIV-1 and HIV-2 gnp peptides reacted with the mixture of HIV-1 and HIV-2 peptides. In the case of cross-reactivity, it remains open if the reaction is based on sequence homology or if these cases are true double infections. In order to solve this question, seroconversion panels from patients infected with HIV-1, two of these cases can be detected earlier in HIV-1 gnp peptide EIA than in HIV-2 gnp peptide EIA, the rest are detected parallel with whole virus EIA (Narváez et al., J. Med. Virol. 26:171-178, 1988). [Part of this work was conducted with J. Med. Virol. 26:171-178, 1988]. [Part of this work was conducted with International].

Session d'affichage
Poster Session



Aspects cliniques
Clinical Aspects of AIDS

W.B.P.121 TESTPACK HIV-1 RAPID ASSAYS CAPABLE OF DETECTING ANTIBODIES TO HIV ANTIGEN IN SERUM, PLASMA, AND

Rachelle A. Wain, J.M. Pennington, K.M. Keig, J.M. Staller, L.A. Provorovsky, A. Marwaha, Abbott Laboratories, North Chicago, IL and Howard Brown Memorial Clinic, Chicago, IL, USA

Objective: To develop rapid, visual immunoassays to detect antibodies to Human Immunodeficiency Virus 1 and 2. These assays require minimal sample preparation, minimal technical expertise, no sophisticated equipment and provide easily interpretable results.

Methods: These tests utilize full length recombinant antigens gp24 and gp41 from HIV-1 either alone or in combination with gp41 from HIV-2. An internal control is incorporated to alert the user to procedural errors. Assays can be completed in 10 minutes, using whole blood, serum or plasma, with results read visually as a plus (+) or minus (-) sign.

Results: Study sera and 133 ELISA positive, Western blot confirmed HIV-1 samples were tested with the HIV-1 and HIV-1/HIV-2 assays, respectively. Each sample contained whole blood and matched serum or plasma. Both assays detected 100% of the samples from 98% on HIV-1/HIV-2 to 99% on HIV-1. Whole blood, obtained via fingerstick from 15 normal blood donors, was negative in both assays. The presence of the autoantigenes B2A, hepatitis and sodium chloride did not interfere with the performance of either assay.

Conclusions: These rapid assays demonstrate high sensitivity and specificity and are ideal for use in situations which preclude the use of conventional ELISA tests, e.g., appropriate for use in situations which preclude the use of conventional ELISA tests and small blood transfusions, emergency rooms, organ transplant, physician offices and small laboratories.

W.B.P.122 UNIQUE IMMUNOREACTIVITY OF A NORMAL HUMAN SERUM WITH RECOMBINANT HIV-1 *env* GENE PRODUCTS

John, James J. Demaree, J. J. Frankl, T. Terry, P. P., Roncazio, D., Lodi, M., et al. Transfusion Medicine, NIH, Bethesda, MD, Roche Diagnostic System, Nutley, NJ, USA.

Objective: To assess an anti-HIV-1 ELISA test based on recombinant products *env* to identify the specificity and significance of the immunoreactivity between the serum of a normal blood donor and recombinant HIV-1 envelope proteins.

Methods: Clones containing different regions of HIV-1 *env* were constructed and recombinant protein were produced and used as antigen in enzyme linked immunosorbent assay. Sensitivity for the detection of anti-HIV-1 was assessed with a panel of known positive specimens. To assess the specificity and the significance of this immunoreactivity, recombinant profiles of urine or overlapping sequences from different sections of *env* gene were also produced and used as antigen.

Results: Cross-reactivity in detection of anti-HIV-1 by recombinant products was observed with a panel of known positive sera in comparison with commercial tests made of viral culture products. A strong anti correlation reaction between protein of normal donor serum with recombinant products was observed. Serum from this donor was not reactive in any currently available commercial anti-HIV-1 ELISA tests, Western blot or radioimmuno precipitation assay. **Conclusions:** A specific immunoreactivity between a blood donor serum with a specific region of HIV-1 envelope protein *env* was identified with recombinant products. This immunoreactivity was unique and its biological significance remained to be assessed.

W.B.P.123 IMPROVED *in situ* DETECTION OF HIV NUCLEIC ACID WITH FLUORESCENT PROBES AND LASER EXCITATION.

Hart, L. Donagan, Biontech Research Wf, and Golden Eye, California, Davis, California, U.S.A.

Objective: To develop more sensitive instrumentation to detect and quantitate HIV infected cells in culture and in clinical specimens using nonradioactive *in situ* hybridization.

Methods: Acetylaminofluorene (AAF) HIV DNA probes were made and reacted by *in situ* hybridization with HIV infected CEM cell lines. The AAF-labeled probes were detected using rabbit antibodies to AAF, followed by an antirabbit antibody that was labeled with fluorescein. Samples were excited at 488 nm using either a 40 mW argon ion laser, or using a conventional 100 W mercury arc source. The fluorescent emission was detected through a 530 nm using a CCD video camera. The percentage of cells stained and their fluorescent staining intensity was quantified using a semi-automated computerized image analysis system and computer programs developed by us.

Results: Comparison of the numbers and intensity of cells stained *in situ* using the laser and mercury source showed that the laser had: 1) a 10 fold increase in fluorescence signal intensity and 2) improvement in the signal to noise ratio to avoid auto fluorescence.

Conclusions: *In situ* detection of HIV nucleic acid using fluorescent probes and an argon ion laser excitation source is more sensitive and has a higher signal to noise ratio than a mercury excitation source.

W.B.P.124 DETECTION OF HIV IN Hematopoietic Cells from Patients with AIDS and AIDS-related Complex (ARC).

Sun, Hsueh-Su, L. Hsu, H-T, Conrad, A., Shapshak, P., Bell, G., and Isajawa D.

Harbor-UCLA Medical Center, Torrance, CA, U.S.A. and *Marsden W.A. Medical Center, Los Angeles, CA, U.S.A.

Objective: To test the hypothesis that hematologic abnormalities in patients (G1) with ARC and AIDS were related to direct and persistent HIV infection of the hematopoietic precursors in the bone marrow.

Method: We used ³²P-labelled cDNA probe and *in situ* hybridization (ISH) method to detect the presence of HIV nucleic acids in formalin-fixed, paraffin-embedded bone marrow sections from ARC and AIDS (ten in each group) and five non-HIV-infected pts. **Results:** Positive cells were found in all ten ARC and eight AIDS pts, but none in two AIDS and five non-infected pts. Most positive cells were mononucleated, resembling lymphocytes and histiocytes. Endothelial cells, interdigitating reticulum cells, erythrocytes, nucleated red cells and immature myeloid cells also labeled with radioactive material in some instances. Positive cells were usually few and far between in each specimen. Megakaryocytes, epithelial histiocytes, fibroblasts, fibrocytes, osteoblasts, osteocytes, and osteocytes were consistently negative.

Conclusions: (1) ISH is a useful tool for identification and localization of HIV in tissues. (2) HIV is capable of infecting cells which do not have CD₄ receptors, and may become symbiotic with the host cells and cause latent persistent infection. (3) Hematologic manifestations in ARC and AIDS pts are at least partly caused by direct HIV infection.

W.B.P.125 SEROCONVERSION FOLLOWED BY RECOMBINANT- AND SYNTHETIC PEPTIDE BASED ANTIBODY ANALYSIS

Lauzinger, Robert J. Peterson, C., Vejlgaard, G.L., Lindhards, B., Black, F., Bernal, P., et al.

*Statens Serum Institut, Copenhagen, Denmark, **HIV Center, Copenhagen, Denmark, ***Fibiger Institute, Copenhagen, Denmark, ****Statens Serum Institut, Aarhus, Denmark, *****Sahlgrenska sjukhuset, Göteborg, Sweden

Objective: To define the sensitivity of recombinant- and synthetic peptide based anti-HIV ELISA tests.

Methods: A total of 290 sera, which were collected during the weeks and months of seroconversion, from 75 patients were studied with anti-HIV tests. The 28 patients had acute symptoms, while 47 patients did not report any symptoms connected to seroconversion. For 5 patients the time of exposure was reported. The sera were tested by two different anti-HIV peptide ELISA tests based on synthetic peptides (Pharmacia), recombinant DNA based anti-HIV test (DuPont), and immunoblotting (western blotting) (DuPont).

Results: Second generation anti-HIV analysis with recombinant- and synthetic peptide antigens showed specific antibody detection within 5 weeks from exposure to HIV. - the anti-HIV test appeared no later than 4 weeks from onset of symptoms, and most were within the first weeks after exposure. The immunoblotting test and the second generation ELISA tests were positive either simultaneously, or positive test results were only removed one sample from each other.

Conclusion: The serological "window" of acute HIV infection can be reduced by 3-5 weeks by recombinant- and synthetic peptide based anti-HIV assays.

W.B.P.126 HIV-1 POL synthetic peptides

E.D. Sranzanas, J.J. Schalken, J.A. Hellings and R. v. Sprang.

Diagnostica Research Lab, Organ International B.V., P.O. BOX 20, 5340 RH, Oss, The Netherlands

The HIV-1 POL amino-acid sequence was analysed for antigenic epitopes by the epitope-prediction programmes such as Hopp and Woods. Of the epitopes predicted by this method 14, partially overlapping, peptides were synthesized by solid phase methodology. The peptides were cloned to microtiter plates and analyzed for reactivity with anti-HIV-1 sera. We identified 3 anti-HIV-1 reactive peptides: AA 230-244 (IKKDKSTKWRLLVDF), AA 945-959 (TKGNFRVYRDRSN) and AA 975-994 (AVVQDQNSDKVYRRAKQ). The reactivity of these peptides could be increased by conjugation of the peptides to bovine serum albumin.

Immunosays, based on a single one of these POL-peptides as antigen, however, did not yield 100% sensitivity with P65/51 and P31 western blot positive anti-HIV-1 sera.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

W.B.P.139 CHARACTERIZATION AND CLINICAL SIGNIFICANCE OF HIV p24 ANTIBODY

Melan Rosen*, Thya R. Fico, R.*, Falk, L.* and Allain, J.-P.*
*Abbot Laboratories, Abbott Park, IL, USA

Objective: Detect and quantitate p24 antibody (p24 Ab) to monitor natural history and therapy of HIV antigen (HIV Ag) negative individuals.

Methods: Solid phase was coated with recombinant p24 antigen to capture specific antibody. The same antigen labeled with HRP^o was used as a probe. Titer and slope of p24 Ab were obtained by plotting the optical density (OD) of 5 dilutions of each sample and extrapolating the intercept at a cutoff of 0.1 OD. These parameters were correlated with HIV Ag level and clinical condition.

Results: A wide range of slopes ($n = 61$; $n > 10$) reflected the variability of p24 Ab affinity and prevented use of a reference curve for quantitation. The distribution of HIV p24 Ab and Ag in seropositive persons stratified according to clinical condition is shown in the Table. Mean p24 Ab titer was lower in patients with AIDS (432) than AIC (841) or asymptomatic (1637). All but 1 p24 Ab negative sample were HIV Ag positive; in 15.3% of samples, p24 Ag and Ab were not detectable.

Clinical Condition	Number of positive HIV p24 Ab titers	Number of HIV Ag positive	Serial samples from anti-p24 Ab titers	Serial samples from anti-p24 Ag	Asymptomatic homosexual males
AIDS	122 (3)	317 (7)	197 (43.5)	21 (6)	Lower 2-3 years showed either a decline (48%) or no change (52%)
AIC	1 (50)	1 (60)	9 (24)	1 (12)	Stable
AIDS	1 (60)	2 (30)	40 (50)	1 (24)	Receiving antiviral therapy, only those treated with zalcitabine AZT-did. recovered p24 Ab after disappearance of HIV Ag.

Conclusions: Indicate quantitative p24 antibody provides information on the natural history, the clinical prognosis and the efficacy of anti-viral therapy in HIV infected persons.

W.B.P.141

HIV-1 SEROPOSITIVE INDIVIDUALS RECOGNIZE DIFFERENT EPITOPES OF P17: POTENTIAL FOR STAGING DISEASE

Paul H. Ravitt*, George A. Goldstein*, G. Simmonds*, P.S. Barlow*, S.S. Wang*, *The George Washington University, Washington, DC; **NIH, Bethesda, MD; **Westral Technologies Inc., Washington, D.C.; ***A.A. Qianqian, Development of an ELISA method to quantitate the levels of antibody to specific epitopes of HIV p17.

Methods: Synthetic peptides of 12 to 20 amino acids in length, representing the entire HIV p17 protein were synthesized. The presence of antibodies in serum to the peptides was determined using an ELISA procedure. Enhanced reactivity and lower backgrounds were achieved using peptide-BSA conjugates.

Results: Individuals who are seropositive for HIV p17 were found to recognize different epitopes on p17 as defined by the synthetic peptides. The peptide representing the C-terminal appeared to be more immunogenic while the N-terminal was least immunogenic. Antibodies to the p17 peptide representing the p17 candidate AIDS vaccine epitope (HIV-30) i.e., amino acids 85 to 115, (Taylor et al., 1985-88, 1987) were seen by antibodies from a subset (~30%) of seropositive individuals.

Conclusions: Recent observations indicate that a decline in antibodies to antibodies to p17 (Lange et al., AIDS 1, 155, 1987). These studies with p17 may provide a more diagnostic assay to stage clinical disease progression, and identify *in vivo* epitopes for inclusion in an HIV vaccine.

W.B.P.143 SIMPLE EASY TO USE HIV-1 RECOMBINANT ANTIBODY BLOOD ANTIBODY TEST

Richard Howard, M. Mtns., I. Genderson, A.G. Weiss, T., Heigh, V., Gufford, T.
Calypte Biomedical Company, Berkeley, CA, USA

Objective: Calypte Biomedical Company (CBC) has developed a simple and easy to use dipstick assay for HIV-1 antibodies. In this study, we evaluate the detection of antibodies to HIV-1 in the blood serum of patients with HIV-1 infection.

Methods: A dipstick format with recombinant HIV-1 envelope and core proteins was used to detect antibodies to HIV-1. 100 µl of blood or 100 µl of serum is added to the first tube containing the antigen. The E1 buffer is formulated to reduce background contamination. The dipstick is added, incubated for 30 minutes at ambient temperature, washed, incubated in conjugate and washed. Substrate is added to each of the wells and stopped after 10 minutes. Results are read as presence of color (positive) or no color (negative). Samples were taken from proficiency panels supplied by Massachusetts General Hospital, New York University, Center for Disease Control, Boston Biomedical and San Francisco Bay Area physicians.

Results: The proficiency panels taken together show: 1) the CBC E1 test was more sensitive than FDA licensed HIV-1 antibody test formats, 2) no false positives were observed and 3) there was 100% correlation of 43 observations with respect to positive and negative responses.

Conclusions: The CBC E1 HIV-1 antibody test is simple and easy to use. We have validated the efficacy of the E1 blocking buffer with respect to false positive samples (originally identified by FDA licensed tests). The test also accurately identified known effluent sample types such as sera that are hemolytic, lipemic, icteric or from patients with rheumatoid factor or rheumatic lupus erythematosus.

W.B.P.140 EVALUATION OF THE WELLOCORRE RECOMBINANT ENZYME IMMUNOASSAY

Quintanilla, P.J., Jimenez A., Conroy, D.A.
*Centre for Immunology, St. Vincent's Hospital, Sydney, Australia
**The National Health and Medical Research Council Special Unit in AIDS Epidemiology and Clinical Research, The University of New South Wales, Sydney, Australia

Objective: To evaluate the performance of the Wellocorre HIV-1 Recombinant Enzyme Immunoassay (EIA) in a clinical laboratory.

Methods: 1821 serum samples collected from patients with AIDS, ARC or Asymptomatic HIV infection and 36 serial serum samples from 2 seroconverting subjects were tested by the Wellocorre enzyme assay. 5 other commercial EIAs were tested on the seroconversion panel and level of detection were compared.

Results: 1821 out of 1821 samples from known anti-HIV positive patients were correctly identified by the Wellocorre assay indicating a sensitivity of 100% in this population. There was total agreement between the Wellocorre and the Wellocorre Physical assay and the Genetic Systems LAV EIA which had also been tested to test these sera. The Recombinant assay detected anti-HIV in 70% of samples collected in the seroconverting panel, compared with 50% detected anti-HIV in 70% of samples collected in the seroconverting assay which detected 20% in samples collected in the following two weeks the Wellocorre assay detected anti-HIV in 100% of seroconverting samples. No seroconversion was seen in any of the first week but onset of symptoms. In a multicentre random blood donor trial conducted by the Australian Red Cross Blood Transfusion Service on 2007 samples, no sample was repeatedly negative by the Recombinant assay, indicating a specificity of 100%.

Conclusions: The Wellocorre Recombinant assay (based on recombinant envelope and core antigens specifically captured onto microtitre wells to ensure monoclonal antibody and anti-HIV) is a sensitive and specific test well suited to a clinical laboratory.

W.B.P.142 DETECTION OF HIV-1 ANTIBODIES IN URINES OF ASYMPTOMATIC AND ARC AIDS PATIENTS

Quintanilla, P.J., Genderson, A.G., Wang, J., Fagan, B., Conroy, D.A., Cas, W., Gufford, T., Heigh, V., *Calypte Biomedical Company, Berkeley, CA, **New York University, New York, NY, USA

Objective: We (APC, NY) have reported detection of antibodies to HIV-1 in the urine of HIV-1 seropositive (infected) individuals using FDA licensed tests. In this study, we use a recombinant protein dipstick format, we evaluate the detection of antibodies to HIV-1 in the urine of HIV-1 individuals.

Methods: Immunologic recombinant HIV-1 envelope protein on a dipstick (Calypte Biomedical Company) (CBC) E1 test format was used to detect antibodies to HIV-1 in uncentrifuged urine. The test was carried out at room temperature. Urines tested were random samples collected from 30 HIV-1 seropositive and 3 ARC/AIDS patients and 20 HIV-1 seronegative (50) individuals. Results were read by 5 different observers as positive or negative to the presence of blue color in 10.

Results: All urines from HIV-1 individuals tested negative. Positive and negative controls reacted appropriately in all 50 urine samples.

Conclusions: There was a high correlation between reactivity of urine to HIV-1 recombinant envelope protein and serum reactivity in FDA licensed HIV-1 antibody blood tests for both positive (20/20) and negative (20/20) urine samples. These data suggest that blood of urine can be used as a sample source for the detection of HIV-1 or antibodies. There is a lower risk for false care workers testing for HIV-1 antibodies in urine rather than blood due to 1) substantially lower incidence of infectious HIV-1 virus in urine and 2) minimizing venipuncture and exposure to blood. The CBC dipstick test format used at room temperature allows to testing in nonclinical laboratory situations.

W.B.P.144 MULTIPLEXED RESPONSE TO HELIX AND RECOMBILANT-ADSORBED AID ANTIBIOTIC

Quintanilla, P.J., Jimenez A., Conroy, D.A., Fagan, B., Conroy, D.A., Cas, W., Gufford, T., Heigh, V., *Calypte Biomedical Company, Berkeley, CA, **New York University, New York, NY, USA

Objective: To evaluate the ability of recombinant immunity to a used synthetic peptide, to elicit a specific immune response in HIV-1 infected individuals.

Methods: Peripheral blood mononuclear cells (PBMC) obtained from 10 HIV-1 patients (5 AIDS, 5 ARC) were cultured in 96-well plates in triplicate for 4 days with different concentrations of a viral synthetic peptide (10, 100, 1000, 10,000, 100,000, 1000,000, 100,000,000) and added to the culture wells. The cells were harvested and analyzed for the presence of antibodies to the synthetic peptide.

Results: HIV-1 infected individuals were tested under the same experimental conditions a minimum time of 1720 of contact with peptide was completed as positive results. Specific T cell proliferative response was triggered by the synthetic form of the peptide. In contrast, the adherent factor elicited a significant humoral transformation in 2 out of 5 AIDS patients, 4 ARC and 1 control. No response was found in AIDS patients 10 and 2 control, respectively. In AIDS subjects a seropositivity effect of the adherent antigen on the proliferative response was observed. In all but one control donor, no significant anti-HIV recombinant proliferation was observed.

Conclusions: The results indicate that 4000 peptide epitopes to HIV envelope glycoprotein can be recognized by distinct synthetic peptides, under the suitable form, does not elicit HIV proliferative response. The data set show that synthetic HIV-1 peptides. The results indicate that the synthetic peptide response time, a cross-reactivity to used structures are seropositive in HIV-1 individuals. The specific cell delivery to HIV in AIDS patients are contrasts to the autologous immune response.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

W.B.P.157 APPLICATION OF VIRUS CULTURE AND PCR FOR HIV DETECTION IN BLOOD DONORS WITH PERSISTENT ANTI-p24 REACTIVITY IN WESTERN BLOT

Van Der Poel, C.M.*; Wester, M.**; Roessink, H.*; Vermeulen, H.P.F.; Beutels, E.*; Buisson, L.**
* Red Cross Blood Bank, Amsterdam, ** Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands.

Objective. To investigate the presence of HIV in blood donors with persistent indeterminate anti-p24 reactivity in HIV Western Blot.
Methods. PB1 from 11 blood donors with persistent anti-p24 in HIV WB, previously described as non infective to recipients of blood (Lancet 1986;i:752-53) and HIV positive cells were co-cultivated with PHA stimulated PB1 from HIV negative donors, and cultured for 30 days. HIV expression was monitored and p24 enzyme assay. After culturing PB1-DNA was isolated and applied in PCR. The PCR was performed with 2 primer sets for pol and gag. Positive amplifies were confirmed on Southern Blot using internal oligonucleotides with 40% by specific for pol and gag respectively, radio labeled with ³²P.
Results. None of 11 donors with persistent anti-p24 reactivity in WB were found positive in culture. The results of PCR analysis will be presented.
Conclusions. Will be discussed.

W.B.P.159 DETECTION OF HIV-1 SPECIFIC ANTIBODIES AND NEUTRALISING ACTIVITY (NC ACT) IN THE URINE OF SEROPOSITIVE PERSONS.

Dietrich, D.*; 4 Friedman-Zim, A.B.*; *New York University Med. Center, NY, NY; McGill School of Medicine, Cedars-Sinai Med. Center, Los Angeles, CA, U.S.A.

Objective. To detect antibodies to HIV-1, including neutralizing antibodies in urine samples from 56 HIV-1 seropositive individuals.
Methods. Fifty-six persons including 17 patients with AIDS-2, 16 with AIDS-1, 8 with ARC and 23 asymptomatic seropositive homosexual men were tested for HIV-1 specific antibodies in both serum and urine (concentrated 100-200X) by ELISA, Western blot (WB), and RIFA. HIV-1 RT act. was determined using a neutralization assay performed with the 89 clone as target cells and HIV-1 RNA as the viral inoculum.

Sample	No. reactive (N)		No. reactive (K)		NT
	By WB	By RIFA	By WB	By RIFA	
Serum ELISA	52/54	52/54	52/54	52/54	52/54
Urine	43	34	36	35/46	41/46
NC ACT	100.0 (40.4)	76.4 (28.4)	100.0 (37.6)	89.1 (32.7)	100.0 (41.1)
Urine	35	41	36	30/46	32/46
RT act.	39.2 (14.3)	37.3 (13.8)	30.0 (11.1)	48.3 (17.6)	33.3 (12.3)

The titers of the HIV-1 antibodies and HIV-1 RT act. found in the urine corresponded to the titers of the antibodies to HIV-1 and RT act. in the serum.
Conclusions. 1) Specific antibodies to HIV-1 were detected in urine of HIV-1 seropositive individuals. 2) HIV-1 RT act. was shown in 30% concentrated urine from those who were HIV-1 antibody positive in both serum and urine. 3) The anti-HIV-1 antibodies in the urine may be derived from the serum.

W.B.P.161 The Use of Recombinant HIV ELISA Kits as a Secondary Supplement for Serological Laboratory Tests have made the serological diagnosis of HIV infection far more reliable in recent years.

Improvements in the sensitivity and specificity of HIV ELISA kits and in the performance of Western Blot (WB) serological tests have made the serological diagnosis of HIV infection far more reliable in recent years.

We initiated a study involving over 3000 sera to evaluate the performance of a Recombinant HIV ELISA kit from Cambridge Bioclines (CBC), which employs 96 well microtitre plates coated with recombinants proteins from the gag and env gene products of HIV. In an initial analysis, 333 blot indeterminate, 362 blot positive and 321 blot negative samples were retested using the CBC test. The samples were retested in that all were submitted for reference analyses were tested by the CBC procedure. All immunoblot positive sera were positive by CBC while 23 of the 333 blot indeterminate sera were positive using this recombinant test. One of the 511 blot negative samples was positive by the CBC test and could represent a false positive result. This preliminary evaluation indicates recombinant protein-based kits may be extremely useful adjuncts in HIV testing especially when used as supplemental tests.

W.B.P.158 ANTI-NEF ANTIBODIES IN BLOODDONORS WITH PERSISTENT ANTI-p24 REACTIVITY IN HIV WESTERN BLOT, AND CHARACTERIZATION WITH RECOMBINANT p24 IN IMMUNOBLOTTING, BLIT AND ELISA.

Van Der Poel, C.M.*; Wester, M.**; Roessink, H.*; Buisson, L.**
* Red Cross Blood Bank, Amsterdam, The Netherlands ** Diagnostics Pasteur, Marne-la-Coquette, France.

Objective. To investigate the presence of anti-Nef antibodies as a marker of HIV infection in blood donors with indeterminate anti-p24 HIV Western Blot reactions, and to further characterize this reactivity employing recombinant p24 as antigen.
Methods. Serum samples of 11 blood donors with persistent isolated anti-p24 reactivity in HIV Western Blot, previously described as being non-infective to recipients of blood (Lancet 1986;i:752-53) and 10 anti-Nef antibody-diagnostic Pasteur) employing recombinant Nef protein (Transgene), diagnostic Pasteur), obtained native from E. coli as an antigen. Recombinant p24 and ELISA with recombinant p24 protein (Transgene, diagnostic Pasteur), and afterwards transferred to a nitrocellulose membrane. Immunoblotting was performed by electrophoresis according to electric current in a gel gradient and in second dimension by molecular weight with SDS-PAGE, and afterwards transferred to a nitrocellulose membrane.
Results. In recombinant p24 ELISA 5/11 sera were repeatedly positive and 1/11 was borderline positive. In immunoblotting blot 3/9 sera were positive, and 1/5 gave an indeterminate result. Results of anti-Nef testing will be presented.
Conclusions. Will be discussed.

W.B.P.160 COMPARISON OF WESTERN BLOT (WB) INTERPRETIVE CRITERIA FOR HIV-1 ANTIBODY

Shackelford, S.M.; George, J.; Phillips, S.; and Scholten, G.

Centers for Disease Control, Atlanta, GA, USA.

Objective. To ensure the four methods proposed for interpretations for their ability to confirm HIV-1 infection.

Methods. Proposed criteria include: 1) Amer State Terr Public Health Lab Directors (ASTPBL), 2) Centorize Hain Serol Base (CHS), 3) HIV American Red Cross (RC), 4) Doorn-PAH (Doorn PAH) WB. We evaluated each criteria by testing sera from 406 randomly selected patients as follows: AIDS (n=66), ARC (n=46), EA (n=46), asymptomatic homosexual men (n=88), and EA (n=46) positive volunteer blood donors (n=20). Each serum was tested by the PAH Doorn-PAH Western blot kit and the results were scored as positive (P), negative (N) or indeterminate (I) according to the four definitions.

Results. The data presented indicate that the ASTPBL criteria were the most sensitive and specific of the four criteria analyzed.

	ASTPBL		CHS		RC		DP
	SP	SN	SP	SN	SP	SN	
AIDS	83/90	81/81	74/80	81/81	74/80	81/81	80/72
ARC	39/37	1/3	38/39	1/3	38/39	1/3	34/35
EA	40/38	31/31	41/38	31/31	41/31	31/31	36/31

The most restrictive criteria (requiring the presence of IgG, IgM, and IgA, and Doorn-PAH paired-epher numbers of indeterminate, usually due to a lack of IgM/IgG antibody in AIDS patients).

Conclusions. The ASTPBL criteria have the most number of indeterminate in all categories.

This study was accurate interpretations with indeterminate results which may be followed by further serologic examinations. We would, however, after the negative statement for an viral specific bands present to be hands present.

W.B.P.162 LABORATORY IDENTIFICATION OF RECENT HIV SEROCONVERSION: THE UTILITY OF EARLY REPEAT SPECIMENS AND COORDINATION WITH THE COUSOUNING TEAM. JUSTIN C. WILSON*, B. LOUIS*, E. BONGAY*, A. LACK*, A. BRICKMAN*, A. LACK*, M. SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH, *UNIVERSITY OF CALIFORNIA AIDS HEALTH PROJECT, SAN FRANCISCO, CA, USA.

Objective. To study the collection of follow-up specimens when there are apparent indeterminate results in a high risk population. The objective was to determine serologic patterns consistent with early seroconversion, minimize time of uncertainty for clients with indeterminate results, and communicate these findings to the counseling and education teams.

Methods. Low level of antibody was defined as 1) EIA ratio 20.8 and (2) 2.5 immunofluorescence (IFA) titer (116) and 3) 1-3 viral bands on Western blot (WB). A second specimen was obtained 2-4 wk later (median 14 d, mean 15.6 d) by requesting a new blood draw at the time of the results reporting and counseling. It was possible to maintain anonymity and the link between the 2 specimens by including the previous specimen number on the new lab slip.

Results. Of 54,000 specimens tested 1985-1989, 92 were defined as low positive. In 13 of 20 cases where a second specimen was obtained, the EIA absorbance, the IFA titer, and the number of bands on WB increased, suggesting that these were early seroconverters. The WB patterns commonly contained 1-3 bands (usually only weak gp160) on the 1st specimen; the second specimens showing gp120 and other gag and pol bands.

Conclusions. Certain serologic responses may be indicative of early seroconversion, which can be confirmed on follow-up specimens taken 2-4 weeks later. Identification of such recent seroconverters may be valuable for planning and evaluation of prevention and education efforts.

**Session d'affichage
Poster Session**



**Aspects cliniques
Clinical Aspects of AIDS**

W.B.P.163 THE D-MANNOSE-SPECIFIC LECTIN FROM *GIBBERIA SAKABAYI* BLOCKS BINDING OF HIV-1 TO H9 CELLS *IN VITRO*

Müller, W. Gertl, B. Weuter, P., Rennelien, K., Schröder, H. C., Institut für Physiologische Chemie, Universität, Duesenberg 6, 5500 Mainz, West Germany.

Objective: To describe that lectins can be used as a tool to inhibit HIV infection *in vitro*. **Methods:** Human T₄ cells (H9), infected with HIV-1 have been used for the studies. **Results:** The new (alpha-1->2)-mannose specific lectin from *Gibberia sakabayi* is shown to prevent infection of H9 cells with HIV-1 *in vitro*. At 0.2 µM a complete protection was achieved. Moreover, the lectin inhibits syncytia formation in the HIV-1/H9-Jurkat cell system to 100% at 0.2 µM. This effect was abolished by addition of D-mannose at a stoichiometric ratio of lectin to sugar of 1:500. In addition it is shown that the lectin reacts with the oligosaccharide side chains of HIV-1 gp120 *in vitro* molecules, after desialylation of the gp120, the resulting 58-60 kDa form did not react with the lectin. **Conclusion:** The lectin allows the development of assays (1) to screen for compounds that interfere with the gp120-CD4 interaction and (2) to detect viral antigens in patient sera. **Refs.:** K. Müller, A. Europe, et al. *Biochem. J.* 199, 5 (1987); Müller et al., J. Acquired Immune Def. Syndr. (1989), in press. Supported by grants from the Bundesgesundheitsamt.

W.B.P.165 IS THERE A LONG 'LATENT' PERIOD BEFORE ANTI-HIV-1 SERUM ANTIBODIES APPEAR IN HIV-1 INFECTION?

Plé, Jean, S. Lued, R. Soudes, J. G. Ferras, T. Usson, J. University of Antilles, Antilles, F.W.I.

Asahi et al. have suggested that a period as long as 6 months can pass since HIV-1 infection is acquired to anti-HIV-1 serum antibodies appearance. If a seroconversion test (antibody EIA (EIA)) is used to test them. However, if a recombinant, sensitive EIA (EIA) or a Western-Blot analysis (WB) are employed, antibodies to the HIV-1 core proteins are able to be detected during this 'latent' period.

Objective: To get more knowledge on the HIV-1 serology during this period of HIV-1 infection. **Methods:** We tested 1000 sera sequentially taken from 107 subjects (6 homosexual men, 1 homosexual, 2 intravenous drug abusers and the spouses of an infected man) who seroconverted for anti-HIV-1. 37 of these patients suffered from an acute, self-limited, febrile illness. The samples were collected between 3 and 12 months before they developed anti-HIV-1. Seroreversion (SR) was defined as the appearance of anti-HIV-1 antibodies tested by a recombinant test in a sample taken from a subject who previously had been proved to be seronegative. Results: All of the samples collected before SR were found to be negative for anti-HIV-1 when tested by both EIA and WB. The patients were anti-HIV-1 positive earlier when tested by recombinant EIA than when a seroconversion test was used. Four of the 17 subjects tested out to be positive for HIV-1 EIA 3 months before SR. **Conclusion:** There does seem to be a long 'latent' period before SR for anti-HIV-1. It is highly sensitive EIA to be used to test this marker. However, this seems to be the case may vary in the risk group and the clinical picture of acute HIV-1 infection.

Asahi et al. Long latency precedes acute seroconversion in sexually transmitted human immunodeficiency virus infection. *Lancet* 1987; 1: 148-501.

W.B.P.167 NEGATIVE RESULTS OF *IN VITRO* TESTS FOR HIV ANTIBODY PRODUCTION BY WESTERN BLOOD CELLS IN 12 CASES OF ISOLATED GAG-INDUCED PROTEIN POSITIVITY.

Wong, Jacques,*, Mendrala, J.P.,***, Reynes, J.,***, Dupont, M.,***, Connot, A.,***, Metz, A.,***,***, Laboratoire d'Immunologie, Hôpital Lapeyronie,*** Service Maladies Infectieuses, Hôpital St Etienne, MONTPELLIER, FRANCE.**

OBJECTIVE: To provide a help for the interpretation of ambiguous results observed in the course of systematic serologic tests for HIV seropositivity of ELISA tests. **Methods:** Together with isolated bands of p24 (or other gag-encodes/protein) bands with no gp bands probably correspond to HIV-1 'false positivity' and not to a very early stage of HIV seroconversion. The interpretation of such results is however difficult and screening.

RESULTS: P24 from 12 cases of isolated gag-encodes protein positivity and in the wells of classical antigenic HIV seropositivity were incubated: a) in the 12 cases of isolated ELISA like; the *in vitro* secreted HIV antibodies were revealed by the use of an amplification immunoenzymatic complex in antigen-free plates; the supernatants were then used for Western blot analysis on strips of the Western blot, thus allowing a comparison of secreted and equivalent Western blot profiles.

RESULTS: HIV in vitro ELISA and equivalent Western blot tests, positive in all HIV infected subjects even at very early stages of seroconversion were consistently and repeatedly negative in the 12 cases of isolated gag-encodes positivity.

CONCLUSION: Since circulating IgG-like have been shown to secrete HIV antibodies in vitro during the whole course of HIV infection, the absence of such cells should help to eliminate the diagnosis of HIV infection in these ambiguous cases.

W.B.P.164 EARLY SEROLOGIC EVIDENCE OF INFECTION WITH HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1 (HIV-1)

Reich, John, Crisler, J., Hagler, R., Wang, L. Bart, D. and Crisler, J., Northwestern University Medical School and Howard Ross Memorial Clinic, Chicago, Illinois, U.S.A.

Objective: To determine the prevalence and significance of indeterminate Western blot (WB) assays in homosexual men with negative Enzyme-Immunoassay (EIA).

Methods: The Chicago component of the WACS followed 394 EIA-negative men from 1984-85 through 10/1988. At 6 mo. intervals an EIA was obtained; WB were performed at 2 or more visits. **Results:** 10/1988, 46 of the 394 had developed a WB confirmed EIA; 24 had seroconverted to WB confirmed EIA by 6 mo. or more products of the GM1, GM2 or HIV gene regions 6 mo. or more before the visit with the diagnostic WB confirmed EIA. In contrast, 15 of 336 who remained EIA negative through 10/88 had similar seroconverted WB at 2 or more visits (P = 0.0001). Of the 35, 7 had 2 bands on at least 1 visit. The mean CD4 cell count of these 15 was 906/mm³ (497-1012) at entry and 866/mm³ (430-1412) at the 9th visit. WB 14 developed a WB confirmed EIA (positive predictive value 61.9%). In contrast, 12 of 337 with seroconverted negative WB remained EIA-negative during the 48 mo. study period (negative predictive value 89.9%). Individuals at risk, with indeterminate WB should be closely monitored for definitive evidence of HIV-1 infection.

W.B.P.166 COMPARISON OF FALSE POSITIVE REACTIONS IN DIRECT BINDING ANTI-HIV ELISA USING CELL LYSATE OR RECOMBINANT ANTIGEN

Erasmus, J., Abbott, R., Collier, M., Marlow, V., Love, E., and Lee, D. National Blood Transfusion Service, Manchester and Lancaster, Public Health Laboratory, Manchester, U.K.

Objective: Comparison of prevalence of false positive reactions in direct binding anti-HIV ELISA in blood donors using antigen from H9 infected cell lysates with those in the same assay using recombinant antigen. **Methods:** In 1987-88 a commercial anti-HIV ELISA using antigen from H9 infected H9 cells was used to screen blood donors in the Manchester and Lancaster blood banks. In April 1988 an ELISA using recombinant antigen from the same country was introduced. Reactions not due to anti-HIV-1 on confirmatory testing and follow-up for 1 year were analysed by Western Blot.

Results: False positive reactions were found at a prevalence of 1/800 (0.125) in 1987-88. Study of 50 of these donors showed 57 reacted by Western Blot; 7 had anti-p24 + SS bands and 50 anti-p18 + SS bands. From April 1988 the recombinant assay had a higher prevalence (0.55) of reactive samples. Post were negative in 13 other immunosays, and by Western Blot - 12 were positive by the Abbott recombinant test only; 9 had anti-p18 + p24 on Western Blot and 7 had anti-gp120/50, one with gp1. Eleven donors positive on screening in 1987-88 reacting by Western Blot, were negative by the recombinant anti-HIV ELISA when referred after April 1988. Further studies continue.

Conclusion: False positive reactions in the recombinant ELISA recognise different epitopes to those recognised by the anti-HIV ELISA using antigen from HIV-1 infected cells.

W.B.P.168 COMPARISON OF INDIRECT IMMUNOFLOURESCENCE AND WESTERN BLOT TESTS FOR DETECTION OF ANTIBODY TO HUMAN IMMUNODEFICIENCY VIRUS.

Hargiss, A. Gustav, Peredo, L.V.M., Castillo, T.M.H., Herrera, L.S., Hospital de Infectologia, Centro Médico La Rosa, I.M.S.S. Ciudad de México, México.

Objective: To compare two laboratory tests in the serological diagnosis of HIV infection with A.I.D.S. virus.

Methods: 277 were 25 u.e.f. from the same number of people that were seronegative in the basis of screening assays immunoenzyme reactive to A.I.D.S. -- virus were tested using indirect immunofluorescence (I.F.A.) and immunoblot assays (W.B.).

Results

GROUP	SAMPLE	I.F.A.	W.B.
		No. T./ No. (n)	No. T./ No. (n)
A.I.D.S. patients	serum	149 / 145	149 / 145
	s.e.f.	25 / 18	25 / 25
Sexual contacts	serum	40 / 39	40 / 39
Haemophiliacs	serum	23 / 22	23 / 22
Blood donors	serum	11 / 9	11 / 9
Renal insufficiency	serum	11 / 8	11 / 8
Arthritis rheumatosa	serum	3 / 3	3 / 3

Conclusion: There was 100% agreement between I.F.A. and W.B. test in the same group of serum of A.I.D.S. patients, their sexual contacts, haemophiliacs and blood donors. However the W.B. was the most acceptable method for the groups of patients with renal insufficiency, arthritis rheumatosa and the samples of s.e.f. of A.I.D.S. patients.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

W.B.P.169 RESOLUTION OF INDETERMINATE HIV WESTERN BLOT RESULTS BY ADDITIONAL TESTING

Carlson, James B. and Yost, Johann L.
University of California, Davis, USA.

Objective: Current laboratory practice for the serological diagnosis of HIV infection involves initial screening of the specimen for anti-HIV antibody using an enzyme immunoassay (EIA) and validation of EIA positive results with Western blot (WB). The resolution of indeterminate WB results is a major problem in this algorithm. A practical solution would be to retest specimens using other serological approaches.

Methods: We have investigated the addition of indirect immunofluorescence (IFA), recombinant EIA (ENV-9, E.I. Dupont, Inc., Wilmington, DE), or recombinant immunoblot (EISA HIV-216) Chiron Corp., Emeryville, CA) as tests to resolve EIA positive, WB indeterminate specimens.

Results: 508 of 3104 consecutive specimens were EIA positive. WB test results were: 116 positive, 32 negative, 54 indeterminate. The results of additional testing on the 54 WB indeterminate specimens were ENV-9, 2 positive, 52 negative; EISA HIV-216, 2 positive, 51 negative, 1 indeterminate; and IFA, 1 positive, 41 negative, 11 indeterminate.

Conclusion: These results indicate that the recombinant tests by the most useful in the resolution of WB indeterminate specimens.

W.B.P.170 PROGNOSTIC VALUE OF REPEATED WESTERN BLOT ANALYSIS.

Kamm, Bernd H.; Niese, D.; Bruchmann, H.H.; Kasparek, T.; Eiler, P.; von S., B.
*Universitätsklinik Bonn, FBG, **Institut für experimentelle Hämatologie, Bonn, FBG, ***Massachusetts Institutes of Technology

Objective: To assess the prognostic usefulness of Western blot testing in HIV-infection.
Methods: In 214 asymptomatic patients of the Bonn Hepatitis Cohort Study Western Blot analysis has been performed at intervals of 3 to 6 months since 1986.

Results: Only loss of anti-p24 or loss of anti-p31 was correlated with clinical progression (ABC or AIDS after 2 years).

	Asympt.	ABC	AIDS (after 2 years)
p24 absent (n=33)	155	218	243
p31 present (n=163)	878	63	58
p17 absent (n=70)	678	178	185
p17 present (n=143)	908	62	48

Conclusion: If available, Western blot, together with other serological parameters, might be used in deciding which patients to assign to antiretroviral therapy.

W.B.P.171 SENSITIVITY OF A NEW RECOMBINANT INHIBITION TYPE ELISA SYSTEM FOR THE DETECTION OF HIV-1 ANTIBODIES

Van Der Poel, Coen*, Lalis, M.**; Reesink, H.*; Plaisier, A.*; Wolker, E.*; Vonk-Steen, T.*
* Rad Cross Blood Transfusion Service, Amsterdam, The Netherlands
** Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands.

Objective: To establish the sensitivity of a new inhibition type ELISA for the detection of HIV-1 antibodies, employing recombinant antigens.

Methods: A serum panel of 1593 confirmed HIV-1 Western Blot positive samples, classified as clear (n=493), turbid (n=1139), haemolytic (n=64), obtained from asymptomatic individuals (n=1217) and from AIDS patients (n=372), was tested with the new Wellcome recombinant HIV-1 ELISA, according to the manufacturers instructions. The assays had been obtained between 1986 and 1988, and had been stored at -20°C.

Results: Out of 1593, 1589 (99.7%) were found initially positive and 4 samples (0.2%) were found initially negative. Of the ELISA negative samples, 3/4 were classified as haemolytic and 1 as turbid; 4/4 were positive when retested at 1:10 serum dilution. The overall sensitivity of the test was 99.7%, among clear and turbid samples the sensitivity was 100% and 99.3% respectively, and among haemolytic samples 93.5% (p < 0.001 Chi sq).

Conclusion: The sensitivity of the Wellcome recombinant inhibition ELISA was very high: 99.7%. The 4 false negative results were observed among haemolytic and turbid sample specimens.

W.B.P.172 PERFORMANCE OF A DOT IMMUNOBLOT KIT FOR HIV ANTIBODY TESTING

C. Sharlicki, L. Cook, H.O. Shaughnessy*, P. Ollivier*,
1. University of British Columbia and Provincial Laboratory, Vancouver;
2. Federal Centre for Aids, Ottawa; 3. Canadian Red Cross National Reference Laboratory, Ottawa, Canada.

Objective: To evaluate the performance of a dot immunoblot kit containing recombinant gp50 protein (MDSearch, MicroGeneSys) as a definitive screening and confirmatory HIV antibody test.

Methods: Sera were received for routine testing and were tested at the B.C. Provincial Lab by EIA (DuPont) and Immunofluorescence (IFA) and/or Western blot (WB). A true positive was defined as EIA and IFA positive (high-rank pattern) or WB positive or both.

Results: 252 sera were tested. Of 218 true positive sera, 196(90.7%) were positive by dot blot (WB), 6 were negative and 14 were indeterminate (faint dots but no color). Of 75 true negative sera, 75 were negative by WB and 1 was indeterminate (specificity 98.7%, pos and neg predictive values 100% and 92.6%), 11 known early seroconverters (p24 only on WB) were also tested, of these, 2 were WB positive, 5 negative and 4 indeterminate.

Conclusion: The figure above shows the WB is a sufficiently sensitive to be used as a screening test, particularly for seroconverters. It has good specificity for confirmatory testing. If indeterminate results are recorded as positive the sensitivity improves (97%) but is still inadequate for screening purposes.

W.B.P.173 USE OF ALLELOTYPE MARKER EXPRESSION, TESTS FOR ANTIBODY TO HIV,

Saai, Peter*, J. Berman**, E. Mitchell***, E. Ruder*
* Virus Research Centre, Kenya Medical Research Institute, Nairobi
** East Bay, National Public Health Laboratories, Nairobi, Kenya
*** AIDS/STI Unit, National Health Institute, North Carolina USA

Objective: To evaluate the significance markers for antibody to HIV as specific tests in field.

Methods: A panel of 1000 sera was tested for HIV-1 antibody using a microinhibition test (MICIT), which, USA were evaluated for use as supplemental tests in comparison with the Western Blot. Some laboratories in Kenya participated in the study. Some from 2,000 blood donors, persons at high risk and suspected HIV patients were initially screened by the MICIT (Opten, USA), all positive specimens and 25% of the negatives were tested by Western Blot. Each test to be evaluated for sensitivity, specificity, and usefulness in these field laboratories.

Results: With through training these tests can readily be performed in laboratories with minimal specialized equipment. Data on sensitivity and specificity will be presented at the conference.

Conclusion: The application tests, such as microinhibition or highly treated WB and are very economical than the conventional techniques used in HIV testing. These tests offer an alternative to the Western Blot techniques as well as their inherent use as screening tests.

W.B.P.174 PERFORMANCE APPRAISAL OF LABORATORIES TESTING DRIED BLOOD SPOT SPECIMENS FOR BLONDED HIV SEROLOGICAL RESULTS IN THE UNITED STATES

*Hanson, Nancy; **Lewis, E.L.; Hester, S.; *George, R.; *Pfeifferman, H.
*Center for Environmental Health and Injury Control, and *Center for Infectious Diseases, Centers for Disease Control, Atlanta, Georgia USA.

Objective: To determine and monitor the quality of analytical performance for HIV antibody analysis of dried blood spots routinely collected for newborn screening programs by laboratories participating in the blinded surveillance survey of childbearing women.

Methods: Dried blood spot (DBS) specimens on filter paper were prepared simulating typical analytical specimens for the performance evaluation of laboratories. A panel of 59 DBS specimens were prepared from individual serum matrices using heat inactivated HIV positive plasma and negative serum. The first monthly test set of 11 blind-coded specimens selected from this panel were distributed to laboratories in July 1988.

Results: Two of 7 laboratories misclassified three different specimens in an initial pilot evaluation of the specimens panel. To date, 31 laboratories and 4 manufacturers have analyzed several sets of 12 blind-coded DBS specimens selected from the panel. The participating laboratories have analyzed a total of 1,234 specimens by EIA and Western blot. For the analyzed 24 sets, 24 sets were analyzed, nine specimens misclassifications and 10 misclassifications of DBS specimens have been recorded. These laboratory evaluations assure the quality of the analytical data for the national surveys.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

W.B.P.175 ASSESSMENT OF DRIED BLOOD SPOT QUALITY CONTROL AND PERFORMANCE EVALUATION MATERIALS FOR SEROTYPAL HIV SEROAGGLUTINATION TESTS

SOUSA, J.B.M.; HAMON, M.; LEON, S. Center for Disease Control, Atlanta, Georgia, USA.

Objectives: To characterize dried blood spot (DBS) materials prepared for quality assurance of laboratories screening for HIV seroagglutination. **Methods:** DBS specimens were produced, characterized, and distributed for bench level controls and laboratory evaluation. Quality control (QC) materials were prepared on filter paper using HIV seropositive plasma and/or negative serum combined with red blood cells to an hematocrit of 50%, to yield appropriate target values of high, low, and negative specimens. Bulk production lots of QC contained 4,000 sheets of 15 sheets each for routine use by all laboratories. Stability in both longitudinal and accelerated studies and homogeneity of DBS materials were measured by ELISA and western blot. **Results:** Analysis of 200 materials, stored at 20°C in air-tight bags with desiccant over seven months showed no apparent change in optical density (OD) or hematocrit. Studies of antibody stability with a 1:2 OD specimen under various storage conditions were conducted. For example, exposure of this specimen to 37°C at ambient humidity resulted in a 20% reduction of recoverable antibody (relative OD) in 30 days, while the same specimen maintained at 37°C in a zip-closure bag with desiccant showed a 20% relative loss of antibody in 60 days. From Western blot analysis the detected filter loss appears to be uniform across all antibody bands. **Conclusions:** DBS materials can be prepared that are reliable and stable under normal storage and handling conditions for routine QC, and to monitor and evaluate laboratory performance for this matrix.

W.B.P.177 DEFINE FIELDS FACILITY RESULTS WHEN TESTING FOR ANTIBODIES TO HIV-1. "Meli, Franka, Ph.D., Minsk E. Genguly Ph.D., Mark Lifshitz, M.D., James E. Hays, M.D., St. George's Hospital and Health Center, New York, NY, 10019, and Dept. of Pathology, NY Medical Center, New York, NY, U.S.A."

Sera from a population of 40,438 prospective immigrants to the US presently residing in New York City were tested for the presence of antibodies to HIV-1. Screening was with DuPont EIA and confirmatory testing was with DuPont Western Blot (WB) kits. Of 39 WB tests there were 1,256 (3.13) reactive and 314 (1.28) inconclusive (INC) sera.

A sample of 469 INC sera were further tested by alternative FDA approved EIA assays from Genetic Systems (GS), Ortho, and Abbott. Testing by the GS EIA assay reduced the number of reactive samples by 47%, by the Ortho assay by 74%, and by the Abbott assay by 94%. The Abbott assay is therefore the most appropriate second line EIA assay for reducing the number of false positive EIA assays.

The Ortho-Chiron EIA confirmatory test found 53% of the INC sera to be non-reactive. Confirmatory Cellular immunofluorescence assays using slides prepared by either the Memphis Laboratory, or by Eliconometrics, were applied to a subsample of the INC sera. These assays reduced the frequency of inconclusive results by over 95% each.

W.B.P.179 EVALUATION OF THREE COMMERCIAL KITS FOR SCREENING OF HIV-1 ANTIBODIES IN MEDICAL

SOUSA, J.C.; MORAES, C.; MORAES, C.; VALDESINO, J.L. and BARRON, V.
 *Institute of Biomedical Research, National University of Mexico
 **Ministry of Health of Mexico

Objectives: To evaluate sensitivity, specificity and operative performance of twelve commercial kits for use in screening programs for HIV antibodies in Mexico.

Methods: A 775 sera panel, integrated by 23 AIDS patients sera, 45 HIV-1 seropositive sera, 42 sera from patients with pathologies likely to produce false positive results and 552 randomly selected blood donor sera, was used. The sera were analyzed by seven enzyme immunoassays from Abbott, Behring, Cambridge Biotech, DuPont, Hieser Biotech, Immunit and Organon, DuPont dot immunosorbent, Abbott, Cambridge Biotech and Miles passive agglutination assays, and the Medcor cytoimmunoenzymatic assay. First time reactive sera were retested with the same assays. Commercial Western Blot was used as reference test. **Results:** HIV-1 seropositivity for the total panel was 10.7%. Sensitivities of the assays ranged from 91.6 to 100%; specificities from 96.4 to 100% and operative (evaluated by operative indexes) ranged from 27.2 to 90%. **Conclusions:** Methodological differences between the assays were not relevant for their sensitivity or specificity. Specificity was related to antigen origin. Kits with recombinant antigen gave, in general, higher specificity values.

W.B.P.176 CHRONIC HIV INFECTION WITH DELAYED APPEARANCE OF ANTIBODIES BY USUAL TECHNIQUES AND A CASE OF SEROVERSION

MEHREZ, B.; KARADIMITRA, S.; MOUTOU, C.; SOUSTAS, C.; BRUNTON, J.M.; BEAD, S.M.
 *Greece Ministry of Health, **Mount Sinai Hospital, ***Hospital for Sick Children, Toronto, Ontario, Canada

We describe 2 unusual serology profiles from HIV-infected persons. **Case 1:** A 47 year old male, was intermittently asymptomatic for a year, but not seropositive. The P24 IgG capture assay was persistently reactive. HIV was isolated in 09/88. **Case 2:** A 33 year old female who presented an acute HIV seroconversion and was seropositive. She recovered clinically, became HIV negative, 18 undetectable and later developed multiple infections, 74 cell count fell to 40, HIV isolation was positive. A recombinant-based EIA test showed persistent presence of antibodies in this case.

Results:
 EIA (Dupont) 09/87 11/87 07/88 09/88 09/87 06/89 07/89 08/89 09/89
 Immunoblot - - ind ind + + ind ind ind ind
 Recombigen - - + + + + + + + +
 P24 Ag (Abbott) + + + + + + + + + +
 HIV Culture cat at at at + + + + + + + +
 Conclusions: Case 1 adds to the few cases described as HIV infected without the appearance of detectable antibodies for a prolonged period. **Case 2** shows that seroconversion with apparent clinical recovery may occur but the infection persists. Standard viral lysate EIA tests may not have the sensitivity to detect HIV antibodies in all cases of infection.

W.B.P.178 INTERPRETATION AND FOLLOW-UP OF "INDETERMINATE" WESTERN BLOT (WB) TEST RESULTS

AGUIRRE, H.; GALARRAGA, J.; VILLANOVAS, V.; DEBASKO, D.; CENTRAL AIDS LAB., INSTITUTE FOR INFECTIOUS AND PARASITIC DISEASES, BILBAO, SPAIN

Objective: To describe the follow-up of "indeterminate" in WB test persons.

Methods: 59 "indeterminate" persons (16 belonging to high risk and 37 - to low risk groups) were followed-up for 6-14 months (3-6 sera tested in 4-6 week intervals) using WB HIV-1 IgG (DuPont WB95).

Results: The most characteristic patterns of "indeterminate" WB in low risk persons at the beginning of the study (before seroconversion) were: 1. "indeterminate" on OAD or HIV proteins (54.0%); they became sero-negative or disappear during the follow-up. The sera of high risk persons demonstrate at the beginning of the study mainly multiple bands (61.7%) showing a tendency to persist or to shift to "positive" pattern.

Conclusion: 1. "Indeterminate" WB is not a final result based on our experience and our experience we proposed an own scheme (it will be presented) for diagnostic behavior to "indeterminate" WB results. 2. People belonging to high risk groups have to be retested in 6-6 week intervals, but not at 3-6 months as recommended until now.

Psychiatrie/Neuropsychologie Psychiatry/Neuropsychology

W.B.P.180 NEUROPSYCHOLOGICAL FUNCTION IN PHYSICALLY ASYMPTOMATIC HIV SEROPOSITIVE AND SERONEGATIVE GAY/BISEXUAL MEN

BRADLEY, R.; BARNETT, S.; BRADLEY, R.; JACOBSON, L.
 *Cornell Medical Center, *Long Island Jewish Medical Center, U.S.A.

Objective: To determine if HIV-induced neuropsychological impairment occurs prior to physical manifestations of immunosuppression.

Methods: A 2-year history of neuropsychological tests was administered to 20 HIV seropositive and 20 HIV seronegative gay/bisexual men matched for age, education and distance (NY, N.Y.). **Results:** Neuropsychological status was assessed by thorough medical history and physical exam, and subjects were included with neuropsychological substance dependence (SUD), HIV, neuromuscular (NM), medication during past month, or history of concussion or migraine.

Results: Multiple t-tests and logistical regression failed to find significant differences between the two groups on attention, memory, concentration, or motor language or motor functions. **Conclusions:** The findings further document the need for careful screening and tightly-monitored seronegative comparison subjects before concluding that neurocognitive effects of HIV cause significant dysfunction in asymptomatic seropositive subjects.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

W.B.P.193

THE USE OF THE MINI-MENTAL STATUS EXAM AS A COGNITIVE SCREEN

IN PATIENTS WITH AIDS
 ADINA, JAMES M., BOCCARDI AL, DAVIES A.
 San Francisco General Hospital, University of California San Francisco School of Medicine, Dept. of Psychiatry and UCSF AIDS Health Program, San Francisco, California, U.S.A.

Objective: To examine the utility of the Mini-Mental Status Exam (MMSE) as a screening instrument in detecting cognitive deficits in patients with AIDS.

Methods: Hospitalized subjects (N=50) with first episode *Pneumocystis carinii* pneumonia (PCP) were given a battery of 10 neuropsychological tests (NP), Auditory Stream Separation (ASS), and the MMSE. Improvement on the MMSE was determined by the onset out of onset of CNS.

Results: Sixty-six percent of the subjects had abnormal ASSE and 78% of the subjects were abnormal on at least 6 of the 10 NP measures. However, only 45 of the 50 subjects (90%) scored less than 24 on the MMSE. The 12 scores for this sample were: 19-28. In addition, the MMSE did not correlate with any of the individual NP measures or with the ASSE.

Conclusions: The MMSE appears relatively insensitive in identifying cognitive deficits in patients with HIV infection. Caution should be exercised to use the MMSE to rule out cognitive impairment in this population.

This work has been supported in part by grant # DA04877 from the National Institute on Drug Abuse.

W.B.P.195

NEUROPSYCHOLOGICAL AND IMMUNOLOGICAL ABNORMALITIES IN ADVANCED HIV INFECTION

SEIDENBERG, ERNESTO, LAW, J.K., PROZINSKI, P.P.
 Baylor College of Medicine, Houston, Texas, USA

Objective: To study the relationship between systemic immunodeficiency status and neurobehavioral impairment in advanced HIV infection.

Methods: Eighty subjects (39 ARC/41 AIDS) studied at entry for baseline neuropsychological testing were evaluated for their hematological and immunological status (white blood cell count, absolute T-cell count, and Helper/T-helper suppressor lymphocyte ratio). Correlational analysis was done between neuropsychological test scores and hematological and immunological values. Investigators were blinded to the individual participant's disease status.

Results: No significant differences between ARC or AIDS with respect to age, education, socioeconomic status or substance use were present. Abnormalities in memory reflected by long-term retention (LTR) and consistent long-term retrieval memory reflected significant abnormalities in both groups: 85% of ARC and 75% of AIDS cases fell below one standard deviation below the mean on LTR; 92% of ARC and 100% of AIDS cases fell one standard deviation below the mean on CLTR. Likewise, abnormalities were present in visual scanning, information processing and attention. ARC/AIDS status was not significantly correlated with psychiatric diagnosis. No statistically significant correlations were found between neuropsychological markers, ARC and AIDS subjects' total white blood cell count, total T-cell count, and Helper/suppressor ratios.

Conclusion: Our results suggest a lack of correlation of cognitive dysfunction and immunological status in advanced HIV infection suggesting that HIV-CNS involvement may be independent of indices generally associated with HIV systemic progression.

W.B.P.197

DRUG USE HISTORY IN GAY MEN WITH AIDS AND ITS RELATION TO

NEUROLOGICAL FINDINGS
 D. SANCHEZ, J. BOCARDI, J. JAMES, M. GILLESPIE, A. DAVIS, San Francisco General Hospital, UCSF School of Medicine, San Francisco, California, U.S.A.

Objective: To characterize the drug use histories of gay men with AIDS and to explore possible interactions of drug use and neuropsychological (NP) findings.

Methods: Self reported drug use histories for each prior 6 months and prior 7 years were obtained from 46 gay men during their first hospitalization for AIDS. Demographic and background information was recorded. NP measures given were: Wechsler Memory Scale-Revised version, Shipley, Trail Making Test, and Finger Tapping Test. A man was included for the NP measure to represent an overall index of impairment.

Results: Drug use was reported by 43 of the 46 subjects (93%). Alcohol and marijuana use represented the highest consumption. Average alcohol use for the past 6 months was once a week, and for the 7 year period was 2-6 times a week. Average marijuana use for the past 6 months was once a month and for the 7 year period 2-3 times a month. A significant decrease ($p < .05$) in drug use was found in 6 out of 10 drug categories from the 7 year to 6 month period. No drug use correlation was found in 78% of the sample. Depression or mood of drug use. A multiple regression analysis was not significant between the NP index of impairment and a control drug use score, after controlling for the measures of depression and mood length.

Conclusions: Subjects with AIDS or diagnosis of AIDS reported a significant decrease in drug use over the last several years. This may be due to increasing health concerns and awareness of AIDS. Furthermore, light to moderate alcohol use (as few times weekly) or less does not appear to have exacerbated the period of impairment found in this sample.

W.B.P.194

TRYPTOPHAN LEVELS ARE UNRELATED TO DISTURBANCES OF MOOD IN

HIV-1 INFECTED PATIENTS
 KALLA, JOHN S.; FROM, A.S.; HEYES, M.K.; SADFER, A.E.; PRICE, RW.; SIDDIS, J.J.; * Memorial Sloan-Kettering Cancer Center, NY, NY; * National Institute of Mental Health, Bethesda, MD, USA.

Objective: Disturbances of mood frequently accompany early symptoms of the AIDS Demerita Complex (ADC). Metabolism of tryptophan (TRP), a serotonin precursor, is also disrupted by HIV-1 infection. In order to investigate a possible biochemical mechanism of mood disturbance in ADC, mood and psychiatric symptom ratings were related to TRP levels in both plasma and cerebrospinal fluid (CSF) in HIV-1 infected patients.

Methods: Blood and CSF samples from 45 HIV-1 infected patients, at various stages of disease, were assayed for TRP using high performance liquid chromatography. Samples were drawn following administration of the Neuro-AIDS Study Group neurological history, exam, and neuropsychological battery, which included self-ratings for mood disturbance (Profile of Mood States; POMS) and general psychiatric symptomatology (Brief Symptom Inventory; BSI).

Results: Correlations between mood/psychiatric ratings and both plasma and CSF tryptophan were non-significant (e.g. POMS total vs plasma TRP $r = -.03$, $p = .82$; POMS total vs CSF TRP $r = -.17$, $p = .32$; BSI general severity index vs plasma TRP $r = .17$, $p = .27$; BSI general severity index vs CSF TRP $r = .26$, $p = .22$). In addition, the prevalence of mood/psychiatric disturbance did not differ across above normative cutoffs for mood/psychiatric disturbance but did differ in tryptophan levels from those below these cutoffs.

Conclusions: Levels of tryptophan, a precursor of serotonin, are unrelated to both presence and severity of self-reported mood disturbances in HIV-1 patients.

W.B.P.196 A BRIEF SCREENING TEST BATTERY FOR COGNITIVE

DEFICITS IN HIV INFECTION

WOO, SEUNG-HO; HUNG, J.-T.; SHIM, A.; WITZMAN, G.S.; FERNANDES, R.; BARY, A.*
 *Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada

Objective: (1) To design a brief screening measure with the capacity for early detection of neurocognitive impairment in HIV infected individuals. (2) To establish if scores on this measure may be used to infer the degree of CNS or immune impairment.

Methods: This is a 2 year longitudinal study of a case group with HIV infection (AB⁺ = 20, ARC = 5, AIDS = 7), and a control group, similar in age, education and SES. Neuropsychological tests, and measures of depression and anxiety are administered at 3 month intervals. The battery includes: Trail A and B, Controlled Oral Word Association, Graded Difficulty Arithmetic, WAIS-R, Digit Symbol, and Digit Span, Stoop Test, Rey Auditory Verbal Learning Test and Boston Visual Retention.

Results: Initial testing and 3 month follow-up show no global differences between cases and controls. However, 30% of the cases scored in the range of suspected impairment on at least 1 test, and 57% of subjects with AIDS have scored in this range on two or more. Trails A and B show poor performances across the spectrum of HIV infection with many scores falling between 1 and 2 standard deviations below the mean.

Conclusion: These preliminary results suggest some cognitive changes associated with HIV infection which appear to be greater in patients with AIDS. NHRPD Grant#6666-3654-AIDS.

W.B.P.198

RELATIONSHIP BETWEEN NEUROPSYCHOLOGICAL AND IMMUNE

VARIABLES IN HIV POSITIVE ASYMPTOMATIC PATIENTS
 ADINA, JAMES M., BOCCARDI AL, DAVIS A, MOSE, A, BUCHHEI P, and YOUNG, M.
 San Francisco General Hospital, University of California San Francisco School of Medicine, Dept. of Psychiatry and UCSF AIDS Health Program, San Francisco, California, U.S.A.

Objective: To describe the association between neuropsychological (NP) function, immune status and neurocognitive measures in immunologically HIV positive gay men.

Methods: Fifty-six asymptomatic gay men (DEIV = 33, HIV = 23) were given a two battery of NP tests and peripheral blood studies. Measures of immune function were also obtained. Group differences between HIV+ and HIV- groups were determined by use of multiple T-tests. A post-hoc corrected correlation was applied. Correlations were calculated between the immune and NP measures.

Results: 1. No significant differences were found between the positive and negative group on age, education and occupational level. 2. No statistically significant differences were found between the HIV+ and HIV- groups on any of the NP measures. 3. In the HIV+ group, no statistically significant differences were found between those with CD4 < 400 and those with CD4 > 400 on the NP measures. Additionally, no difference was found on the NP measures between the CD4 < 400 and HIV- negative group.

Conclusions: These results help to outline a lack of documented neuropsychological impairment in otherwise asymptomatic HIV+ men. This finding holds up even when comparing those HIV+ men with CD4 counts of 500 with the asymptomatic group.

This work has been supported in part by grant # DA04877 from the National Institute on Drug Abuse.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

W.B.P.199 COGNITIVE DYSFUNCTION AND PSYCHOLOGICAL FACTORS IN SYMPTOMATIC SEROPOSITIVE HIV
 T. Leake, L. Smith, J. Zvanich, F. Insel, D.M. University of California School of Medicine, San Francisco, CA, U.S.A.

Objective: Questions remain about the prevalence and severity of cognitive impairment along the spectrum of HIV disease. Our aim was to determine the presence and degree of cognitive impairment in asymptomatic seropositive men, and whether severity was associated with certain psychosocial factors. **Methods:** 100 seropositive homosexual men with at least one HIV-related symptom were recruited from the UCSF AIDS Clinic and administered neuropsychological tests. Data were adjusted for age and education, and standardized ratings of impairment were determined. Standard measures of distress, coping, and mood were also administered. **Results:** 69% of men showed at least mild impairment, 69% at least moderate impairment, and 45% at least severe impairment. 19% showed impairment on one or more neuropsychological tests. There was no clear differential cognitive impairment: 45-49% had impaired immediate and delayed memory, but only 17% had impaired verbal fluency, while only 19% had impaired total digit span. 29% had impaired Digit Span, and 30% had impaired verbal fluency. Level of impairment on most tests ($r = .18$ to $.31$, $p < .05$ to $.001$). Greater impairment on Digit Span, Verbal Fluency, and Trailmaking was correlated with coping and mood. **Conclusions:** Neuropsychological impairment was associated with $r = .23$ to $.31$, $p < .05$ to $.001$ for emotional control, $r = .19$ to $.29$, $p < .05$ to $.001$ for social support. Few neuropsychological or neuropsychological reports on patients with HIV disorders have included psychosocial measures. The positive correlations in this sample of seropositive men suggest that cognitive impairment may reflect (a) the exacerbation of cognitive impairment by distress and certain coping styles, and/or (b) patients' reactions to awareness of their cognitive impairments.

Enquêtes Surveys

W.B.P.201

IMPACT OF HIV DIAGNOSIS ON RICOLO, MASSIMO'S, BASKINS D.J.
 Wilson B****, Thompson C****,
 St. Stephen's Hospital, London; *Richard Cross Medical School, London;
 ****Southampton General Hospital, Southampton;
 ****Royal South Devon Hospital, Southampton, UNITED KINGDOM

Objective: To assess the impact of HIV positivity on mood state. **Method:** As part of the St. Stephen's prospective cohort study, mood is assessed prior to notification of HIV Ab status and reassessed 6 months later. Assessment consists in the following self-report questionnaires: SAD, Zung, GHQ and a Physical Complaints Schedule. **Results:** The baseline SAD anxiety score fell within the borderline pathological range in both groups (HIV+ve: 9.0, range 6.6; HIV-ve: 8.9, range 6.4), whereas at 6 months they fell within the normal range (HIV+ve: 7.00 ± 0.61; HIV-ve: 7.96, range 7.7). Inter- and intra-individual group comparisons, however, were not significant. Other mood scores for HIV+ve and HIV-ve were well within the normal range at baseline and follow-up. **Conclusion:** Reports of clinical impressions indicate that anxiety and/or depression levels rise sharply at the time of diagnosis of HIV+ve status. Our results suggest no evidence of any persistent pathological mood states at 6 month follow-up.

W.B.P.203

REQUEST OF MENTAL HEALTH-CARE INTERVENTION BY PHYSICIANS ATTENDING HIV OR AIDS PATIENTS: THE IMPORTANCE OF A LOCAL REFERENCE CENTRE FOR AIDS TREATMENT.
 H. Cardoso, M. Torres, A. Quirós, A. Navarro, M. Zorrilla
 Hospital Universitario C.I.F. - Federal University of Rio de Janeiro - National Reference Centre for AIDS Treatment.
Objective: To identify and evaluate the reasons that make physicians, dealing with HIV or AIDS patients, request mental health-care intervention. **Method:** Retrospective review of 126 patients assisted by mental health-care workers from a total of 439 hospitalized patients attended in a National Reference Centre for AIDS treatment in 1987. **Results:** There were 158 requests to evaluate patients, 27 patients had 2 requests for evaluation, 2 patients had 3 requests and 1 patient had 4 requests. Requests were classified in 6 groups. The results were: 1) Differential diagnosis: (19/158); 2) Problems related to clinical staff-patients relationship: (46/158); 3) Reactions to diagnosis and/or evolution of the disease: (59/158); 4) Psychomotor agitation: (10/158); 5) Family approach: (10/158); 6) Other: (14/158) 19%. In each group we could identify several causes of request. The most important were: Anxiety (group 3): (26/158); 19%; Difficulties in the disputation of the diagnosis to the patient (group 2): (16/158); 10%; differential diagnosis (group 1) between cognitive deficits (delirium, dementia, depression): (12/158); 7% **Conclusions:** The high proportion of request (28%) to mental health-care professionals shows the importance of an integrated and multidisciplinary approach in the assistance of these patients. Although, an adequate presentation is needed for these professionals due to the complexity of the situations that arise: clinical complications, social problems, staff-patient difficulties and multiple mental syndromes.

W.B.P.200 EARLY DIAGNOSIS OF HIV INFECTION IN INFANTS
 d'Arinios Montoro, Antiochia J.; Novati R.; Marchisio, P.*;
 Zanetta M.***; Lassarini A.*; Torregiani, R.***; Masaroni, G.***
 *Infectious Dis. Clinic, **Pediatric Dept. V, ***Oncology Dept. IV, Milan, Italy

Objective: To evaluate the role of serial IgM anti-HIV and p24Ag testing in the neonatal diagnosis of HIV infection. **Method:** 24 neonates from anti-HIV pos. mothers were followed-up biweekly for 10-6 mo. At each time clinical, immunological (lymphocyte subsets, immunoglobulin levels) and serological (IgM anti-HIV, ELISA and Western Blot (WB)), IgM anti-HIV, WB, p24Ag, ELISA) tests were performed. CDC classification for pediatric HIV infection was used. **Results:** IgM anti-HIV were found at birth (5 cases) or at 2nd-4th mo. (6 cases) p24Ag was detected in 7 cases from 4th mo. to 1st year of life. 12 neonates became asymptomatic (P=2) within 4th mo. (follow-up 118 mo.). All were IgM anti-HIV and/or p24Ag pos. 3 neonates received adequate immunodeficiency (ID) (follow-up 13rd mo.). All were p24Ag pos. (P=1-8). 2 also IgM anti-HIV pos. Among asymptomatic immunocompetent patients 7 were followed at least for 10 mo. (163 mo.) 2 were still seropositive (P=1-4) (previously IgM anti-HIV pos.) 3 were pos. only for p24Ag (1 IgM anti-HIV pos.). 5 patients were followed for 5-63 mo. (4 IgM anti-HIV pos., 1 also p24Ag pos.); finally 4 neonates are too young to be followed. **Conclusions:** IgM anti-HIV and p24Ag seem good predictors of HIV infection and/or disease progression in infants.

W.B.P.202

A VA HOSPITAL SPECIALIZED PSYCHIATRY PROGRAM FOR PATIENTS WITH HIV DISEASE: A REVIEW OF THE FIRST 30 REFERRALS
 Thompson, Douglas
 San Francisco Veterans Administration Hospital and University of California, San Francisco, U.S.A.

Objective: To identify characteristics of a population of patients with HIV Disease referred for outpatient psychiatric consultation in the San Francisco VA Hospital and to use these data for program planning purposes. **Methods:** Since the first cases of HIV disease appeared at the San Francisco VA Hospital in 1982, the number of referrals to psychiatry steadily increased. Initially patients were managed on an individual basis, but it eventually became clear that this population had grown to be a significant proportion of overall referrals. A multidisciplinary committee was formed to evaluate the needs of this population and make specific programmatic recommendations. Meetings were held with various hospital units involved in providing care to HIV patients to assist in planning and coordinating psychiatric services. A trial program was initiated beginning July 1, 1988. Between July 1 and December 31, 1988, 30 patients with HIV Disease were referred for psychiatric consultation. Demographic and other specific HIV-ve pos. were monitored, including reason for referral, DSM-III-R diagnoses, treatment plan, disposition, medication, and outcome. **Results:** Data from this recent 6-month period are in the process of being coded and analyzed at the time of abstract preparation and will be presented at the conference. **Conclusions:** Conclusions regarding using the data for planning for HIV psychiatric services will be presented.

W.B.P.204

PERVALENCE, SEVERITY AND COGNITIVE CHANGE IN AIDS AS NOTED BY PATIENTS AND THEIR CARE AS RELATED TO NEUROPSYCHOLOGICAL TESTING.
 Smith, A.G.; Davis, A.; Newland, J. S. and Jew, J.
 Brompton Hosp., St. Mary's Hospital, London, W 8, U.K.

Objective: To determine if: (1) referral rates of AIDS patients reduce change in their persons after any predictive objective neuropsychological testing; (2) patients' own perceptions are correlated with objective neuropsychological impairment. **Method:** The informal carers of AIDS patients (N=75) rated the patients for changes on the St. Mary's Personality, Behavior and Cognitive Change (PBCC) Questionnaire. These ratings were compared with PBCC self-ratings of the patients and the carers. Scores were compared also with the neuropsychological test results of the patients. In addition carers and patients filled out standardized mood questionnaires. **Results:** 1. Carers' ratings of the patients are independent of the carers' own anxiety and depression levels. 2. Carers' ratings of deterioration in patients' cognitive functioning is significantly correlated with an overall impairment score obtained from neuropsychological testing. However, patients' own ratings of impairment in their cognitive functioning is related only to their own anxiety and depression.

Conclusions: Informal carers can be useful instruments as possible Central Nervous System involvement in patients. However, patients' subjective perception of deterioration in themselves is likely to be variable.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

W.B.P.205 COMPETENCY CONSULTATION TO HIV PATIENTS:

A LIAISON HOSPITAL-OUTPATIENT PERSPECTIVE
William Henry Parton, L. Agelli, P.
Queens Hospital Center, Hillingdon, Long Island Jewish Medical Center,
Queens, New York, U.S.A.

Objectifs: 1) To identify the reasons for competency consultation to patients infected with HIV. 2) To classify such consultations by psychiatric diagnosis and 3) To determine the competency consultation provides a significant access route to mental health care for HIV patients.

Méthode: All psychiatric competency consultations to HIV patients at Queens Hospital Center from 1987-1988 were analyzed for demographic characteristics, reasons for consultation, competency, psychiatric diagnosis and psychiatric treatment.

Résultats: In 1987-88 the psychiatric consultation-liaison service saw 50 HIV patients in competency evaluations, representing the largest single medical diagnosis, and composed 21% of all competency evaluations. Forty two percent were referred because they refused treatment, 31% presented with altered mental status, 25% wished to leave the hospital. Forty percent were judged competent. Of the remaining 60%, all but two were diagnosed with organic mental syndrome. Of the 40% judged competent 24% were diagnosed with adjustment disorders, and 16% each personality disorder and substance abuse. Five patients (8%) had no psychiatric diagnosis.

Conclusion: Competency evaluations form a significant portion of psychiatric consultations to HIV patients, reflecting the neuropsychiatric and psychosocial manifestations of the disease. They provide an important route of entry into mental health care.

W.B.P.207 ETUDE DE LA DEMANDE PSYCHOTROPHAPÉUTIQUE CHEZ 100 PATIENTS ATTEINTS DE SIDA

Yves HELL, O. OUVRY, médecine psychiatrique
F. TOUETZ GERRARD, M. NARON-CHODON, J. BOUQUETIE, psychologie
des Maladies Parasitaires et Infectieuses, et Sand Publiche, Unité
IDSRM 313 (Pr M. Gentilini), Groupe Hospitalier Pitié-Salpêtrière, Paris,
France.

L'étude d'un groupe de cent patients séropositifs asymptomatiques non SIDA ou SIDA sévère a été menée par l'équipe médico-psychologique mixte en place dans le Service du Pr M. Gentilini en 1983 pour l'accompagnement psychologique et psychiatrique des malades atteints par le VIH.

A partir d'entrevues individuelles semi-directives et d'un questionnaire d'évaluation (11 items), les auteurs ont mesuré les résultats d'une approche épidémiologique du retournement psychopathologique de l'infection à VIH dans ses corrélations avec la demande de soutien psychologique, les antécédents psychiatriques personnels, les facteurs familiaux et de l'environnement.

Dans le cadre de cette première étude dans un service hospitalier-universitaire, il ressort que :

- 52 % des patients ont demandé un soutien psychologique durant le test d'hépatitase 1; 23 % ont refusé toute intervention psychologique spécialisée; 24 % ont demandé une psychothérapie de soutien (brève ou longue) après l'hospitalisation.
- 18 % des hommes/50 % des femmes, non groupés sous-traités, avaient des affections psychiatriques préexistant l'infection par le VIH.
- Les facteurs influençant le non-dit de la séropositivité, de la toxicomanie, de la sexualité sont corrélés à la relation d'aide de l'entourage (familial).

W.B.P.209 HIV SEROPOSITIVE STUDY OF INVOLUNTARILY HOSPITALIZED MENTALLY ILL HOMELESS FROM THE STREETS OF HONOLULUI, HAWAII

Meyer I., Schoenham P., et al. Creedmore Psychiatric Center, Queens, NY
Psychiatric Inst., NYC - Montefiore Med. Ctr., Bronx, NY USA

Objectifs: To determine the rate of HIV seropositivity and risk taking behavior among a group of high risk psychiatric patients, i.e., the homeless mentally ill who seek health care services and are involuntarily hospitalized by mental health teams.

Méthode: The study is conducted on The Creedmore Psychiatric Center Intensive Placement Unit, which is part of New York City's largest state hospital. Homeless patients removed from the streets are accepted for intermediate care and placement. This population tends to avoid public shelters and is demographically diverse. 232 are female and 72 are male. Ethnically, 46% are white, 39% are black, 13% are hispanic and 2% are Asian.

All ages between 18 and 55 plus are well represented. There is a high rate of medical illness including active TB, positive VDRL and hepatitis B antibodies. Approximately 30% of patients show substance abuse. Anonymous bloods will be tested for HIV antibodies on approximately 100 patients and correlated with histories of risk taking behaviors including alcohol abuse, prostitution and sexual behavior. These findings will also be correlated with geographic mobility, patterns of homelessness and psychiatric and medical illnesses.

Résultats: To be presented at the conference.

W.B.P.206 POSITIVITA' L'VIV IN PROYOGNOSTIC: OSSERVAZIONI SUI 100 NEI.

Severino Pasticciatore di Diagnostica Clinica "Virgilio 1" - Istituto V. V.
Severino Pasticciatore di Diagnostica Clinica "Virgilio 1" - Centro di Medicina Ospedaliera, Ospedale G. Grassi Negrar, Milano, Italia.

Obiettivo: Noto che la presenza dei troubles psichiatrici indica una tale diffusione del concetto di Jageret d'entrare più frequentemente che nella popolazione globale nei tipi di HIV ed è data da cinque per l'infezione di HIV. Per questo motivo non sono stati studiati nella parte la presenza dei soggetti diagnosticati positivamente all'HIV nei tre ospedali di Negrar. **Méthode:** Oltre la VHS e l'ELISA qui non effettuato routinariamente a partire da 1-10-87 non sono state messe in atto per l'HIV nei tre ospedali ospedalieri della rete serologica. Non sono stati utilizzati come gruppi di controllo le diagenosi di sangue di Centro di Trasmissione di HIV Ichnique di Milano. Infine non sono stati i significativi statistiche sono le test di chi sono.

Résultats: Les données à ce sujet se réfèrent aux deux premiers semestres d'observation, du 1-10-87 au 30-06-88. On a effectué le test par l'HIV au 79% (20/25) des hospitalisés en psychiatrie (selon 44,76% female 56,36% male) après 42,6 a.). Les patients positifs à l'HIV dans le premier semestre ont été 14,84 (12/81) et à la fin du deuxième semestre, 16% parcentage ont été vus la 0,15 (16/95) (selon 78% female 23% male) après 29,9 a.). On voit que si l'on considère q'au même temps la prévalence des sujets positifs à l'HIV dans les données de sang de Centre de Transmission et de la C.C. (C.C. Centre de la Inférieur avec une différence statistiquement très significative.

Conclusion: Notre hypothèse paraît être confirmée et donc nous croyons qu'il faudra structurer des applications programées d'éducation sanitaire pour ces patients.

W.B.P.208 CARATTERISTICI DEI TROVATI PSICHIATRICI NEI 100 HIV IN UN CENTRO DI SIDA

Severino Pasticciatore di Diagnostica Clinica "Virgilio 1" - Istituto V. V.
Severino Pasticciatore di Diagnostica Clinica "Virgilio 1" - Centro di Medicina Ospedaliera (Ospedale Prof. G. Grassi), Istituto Inferiore Adulto (Ospedale Prof. G. Grassi), Ospedale G. Grassi Negrar, Milano, Italia.

Obiettivo: In considerazione de la fréquence élevée des troubles psychiatriques constatés pratiquement en cours d'infection de HIV on a pu établir une classe ou comme complication de cette pathologie. **Méthode:** Pour cet étude nous avons pris en considération les patients hospitalisés depuis deux semaines dans les hôpitaux de Negrar à cause de l'HIV et dans lesquels ont été observés les symptômes psychiatriques, des troubles psychiatriques, nous avons mesuré comment ces cas ont été hospitalisés en psychiatrie et dans lesquels on a trouvé une positivité à l'HIV asymptotique du point de vue serologique. Les diagnostics ont été posés selon les principes du DSM III-R.

Résultats: Nous avons constaté 79 patients avec l'infection d'HIV à différents stades et avec une des troubles (14 psychiatriques). Les études étaient la 74,7 (58/79) et les femmes la 26,3 (16/79) l'âge moyen était 29,5 a.). Les facteurs de risque ont résultés être: la toxicomanie (66, 83/79); l'immunoséque 22,6 (30/79); les rapports intrasexuels (9, 5/79); les transfusions 0,5 (0,79). Les diagnostics psychiatriques ont été: Lésion des organes 29,3 (36/79); le 1 de l'humeur 20,8 (26/79); le 1 de l'attention 17,7 (22/79); le 1 de la personnalité 11,4 (14/79); schizophrénie 7,6 (10/79); le 1 de l'identité 6,3 (8/79); psychotiques sans clause altérée 5,1 (6/79).

Conclusion: On confirme la prévalence élevée des troubles psychiatriques mais il nous semble aussi intéressant la considérable présence des troubles psychiatriques en état sans cause la schizophrénie.

W.B.P.210 PSYCHIATRIC DIAGNOSES AMONG VOLUNTEERS FOR HIV TESTING

Jacobson, Lawrence; Perry, S; Fishman, B; Frowner, A; Ryan, J; Fogel, K. Cornell Medical Center, New York, NY

Objectifs: The objective of this DSM-III-R diagnosis among individuals volunteering for HIV testing.

Méthode: We administered the Structured Clinical Interview for DSM-III-R (for Axis I) and the Personality Disorders Questionnaire (for Axis II) to 211 physically asymptomatic adults at perceived risk for AIDS who had enrolled in a prospective psychobehavioral study.

Résultats: Overall rates for the presence of any Axis I disorder were 25.5% current and 64.1% lifetime; for Axis II disorders the overall rate was 28.6%. Compared to reported community samples, these subjects had higher rates of mood disorders, both current (13.9%) and lifetime (24.9%). Lifetime rates of non-alcohol substance dependence were also high (30.3%), even after eliminating from analysis the 21 subjects with lifetime drug use as a risk factor. An Axis II personality disorder or mood prior to HIV serologic testing was a heterogeneous population of 211 physically asymptomatic adults at perceived risk for AIDS who had enrolled in a prospective psychobehavioral study.

Conclusion: A large subgroup of the volunteers for testing had histories of depression and non-alcohol substance dependence. A substantial subpopulation with Axis I psychopathology may have additional treatment needs posed by Axis II disorders.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

W.B.P.211

PSYCHIC CHANGES AND TREATMENT OUTCOME IN AN AIDS SPECIALTY CENTER
James Jelliffe, Frederick E. Videman, M.D., Joseph J. New York Hospital-Cornell Medical Center, New York, New York, USA

Objective. We examined baseline patterns of psychiatric referrals, psychiatric diagnosis and treatment outcomes in a cohort of 74 patients in an AIDS specialty center. **Results.** Twenty-eight patients were referred for psychiatric evaluation and treatment in a six month period. This number represents 50% of inpatient admissions and 25% of outpatients followed by the center. Risk factors for HIV infection in the referred population were: 57% IVDA, 36% homosexual contact and 7% heterosexual contact. **Results.** The most prevalent psychiatric diagnosis in the admission register was major depression (44%) and organic brain syndromes (28%). In both groups there was good response to psychotropic medications, with 80% of depressed patients improving on tricyclic antidepressants and 75% of ODS patients improving on neuroleptics and other agents. The most prevalent psychiatric diagnoses in the inpatient setting were organic brain syndromes (50%), ongoing drug treatment (22%) and major depression (17%). Both ODS and major depression were responsive to psychotherapeutic treatment in greater than 75% of cases. In both inpatients and outpatients, psychiatric treatment was not successful in halting ongoing drug abuse. Nevertheless, psychiatric consultation was helpful in establishing realistic treatment goals in both settings. **Conclusions.** In this pilot study, high baseline rates of psychiatric illness were found in an AIDS specialty center. Psychiatric evaluation and psychotherapeutic treatment resulted in symptomatic improvement in these patients suffering with major depression and organic brain syndromes. We conclude that psychiatric treatment and evaluation is an essential feature of the comprehensive care of HIV in the AIDS specialty center.

W.B.P.213

ANALYSIS OF INITIAL PSYCHIATRIC REFERRALS FROM A HOSPITAL HIV SERVICE
*Richardson-Claudio***, Guyer, P.T.*
 *National Naval Medical Center, Bethesda, Maryland, USA, **The Johns Hopkins Hospital, Baltimore, Maryland, USA.

Objective. To determine patterns of initial utilization of psychiatric services by a hospital HIV program. **Methods.** We reviewed 396 admissions to a military hospital's HIV service made by 354 patients over a 12-month period to determine the nature of initial requests for psychiatric consultation. **Results.** Nearly 1/4 of the admissions required psychiatric consultation; that percentage applied equally to newly identified HIV seropositive persons undergoing initial medical evaluation and to persons who had been previously diagnosed, educated about their infection, and counseled and were now admitted for periodic medical reevaluation or treatment. Psychiatric services were especially in demand when patients learned they were antibody positive, began to note early evidence of disease progression, or were in late stages of illness. In order of decreasing frequency, psychiatric diagnoses were adjustment disorders, major affective disorders, substance abuse, and delirium or other organic brain disorders (excluding dementia). **Conclusions.** In a setting of free, readily available medical and psycho-social care, nearly 1/4 of patient admissions required referral to a psychiatrist rather than to other mental health therapists. Similar studies from other medical centers could yield data that might help mental health planners prepare their resources for the still unfolding HIV epidemic.

W.B.P.215

PSYCHIATRIC HISTORY AMONG HOMOSEXUALS AND DRUG-ADDICTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS

*Calza, Costanzo**, Martini, S.*; Pergami, A.*; Ronzini, M.*; Russo, R.*; Lazzarini, A. **

*Institute of Psychiatry, **Institute of Infectious Diseases, University of Milan, Italy.

Objective. To evaluate psychiatric history among HIV-infected subjects (homosexuals, drug-addicts and heterosexuals). **Methods.** 218 subjects HIV-infected (111 III, C.D.C.), 60 subjects at risk of HIV infection seropositive for antibody to HIV, 50 healthy heterosexual controls were recruited from the Dept. of Infectious Diseases. We examined each subject with a psychiatric interview in order to collect: 1) previous personal and familial psychopathological history (considered in terms of lifetime prevalence); 2) Early Life Events (E.L.E.); 3) attempted suicides (A.S.). **Results:** a lifetime prevalence of personal and familial psychiatric disorder was higher in Seropositive (S-) (15,25%) and Seronegative (SN-) (27,24%) subjects than in the Control Group (C.G.), 4% of S-, 41% of SN-, 3% of C.G. reported E.L.E.. The prevalence of A.S. was 21% (S-), 17% (SN-) and 9% (C.G.). **Conclusion:** 1) psychiatric morbidity among S- was higher before the onset of HIV-infection, 2) awareness of psychiatric history is important for the monitoring and management of S- at risk of HIV-infection.

W.B.P.212

NEUROLOGICAL SEQUELAE OF 192 PATIENTS WITH HIV INFECTION AND AIDS
Mark Michael, B.
 Institute of Psychiatry, De Crespigny Park, London SE5, U.K.

Objective. Before planning psychological services for patients infected with HIV, we need epidemiological data on immediate and long-term neurological consequences of the diagnosis. **Methods.** HIV positive outpatients were interviewed in a standardized manner at the HIV clinic of 2 London hospitals. **Results:** 192 patients took part; 65 were HIV positive but well, 64 had accompanying symptoms or signs (41 WLL, 23 ARC) and 63 had AIDS. Almost all had revealed their diagnosis to others, 25% involving relatives. 31% had a psychiatric disorder, half of whom reported emotional problems prior to HIV infection. Patients with ARC or those diagnosed less than 1 year ago tended to have more psychological problems. 27% complained of impaired memory or concentration, of whom more than half had comorbid impairment on brief assessment. Extreme health worries predicted wider psychological morbidity. **Conclusion.** This degree of psychological distress is similar to reports for patients with other medical conditions. Subjects with past psychological difficulties disclosed occasionally about their health were more likely to be psychiatrically disturbed. Overall, patients had adapted well, despite the stigma and poor prognosis of their disorder.

W.B.P.214

A COMPARISON OF SUICIDAL BEHAVIORS IN PATIENTS IN AN AIDS RELATED PSYCHIATRIC CLINIC AND IN A GENERAL PSYCHIATRY CLINIC
O'Donnell, Mary Alice, McEagney, P.F., Montefiore Hospital and Montefiore Med.Center, Albert Einstein College of Medicine, Bronx, New York USA

Objective. To assess the extent of suicidal behaviors in a population of AIDS, ARC and HIV positive patients. **Methods:** 69 patients attending a psychiatric outpatient clinic for HIV related problems were surveyed as to past or present suicidal behaviors, and compared to a demographically matched sample of patients attending a general psychiatry outpatient clinic. Both populations were predominantly Hispanic (90% with almost equal numbers of men and women. Major risk factors for the HIV clinic group were IVDA (52%), heterosexual sex partner of person at risk (22%), homosexuality (22%) and were also (52). HIV related diagnoses were: AIDS n=23; ARC n=9; seropositive HIV only; HIV n=8; unknown serology, n=15. **Results:** There were no significant differences in the incidence of suicidal behaviors between patients attending the two clinics. Within the HIV clinic population there were no significant differences in the incidence of suicidal behavior by diagnosis of AIDS, ARC, HIV, HIV-, or unknown serology. There were no significant differences in psychiatric diagnoses among the AIDS diagnosis group. For each of the AIDS diagnosis groups, the mean age of the first suicidal attempt antedated clinic enrollment (AIDS Type I: ARC 17 yrs; HIV- 18 yrs; HIV-13 yrs) thus preceding the diagnosis of AIDS or HIV for most patients. **Conclusions:** HIV related disease status was not associated with increased suicidal ideation or attempts in the surveyed population. There were no differences in the incidence of suicidal behaviors between the HIV related psychiatric clinic population and an age and ethnicity matched general psychiatric outpatient population.

W.B.P.216

A COMPARISON OF PSYCHIATRIC CONSULTATIONS IN AIDS AND NON AIDS PATIENTS
O'Donnell, Mary Alice, McEagney, P.F., Montefiore Hospital Center, Albert Einstein College of Medicine, Bronx, New York USA.

Objective. To identify differences between AIDS patients and age matched medical patients without AIDS seen in psychiatric consultation on the medical service of a large voluntary general hospital. **Methods:** All psychiatric consultations over the year on the acute medical service of a large voluntary hospital were reviewed, comparing AIDS patients (n=67) with other medical patients without AIDS (n=112) under age 55. **Results:** There were significant differences between the two groups of consultation patients in ethnicity (AIDS patients more often Hispanic and less often Caucasian (p<0.1)). The AIDS group was predominantly male (92%) while the non-AIDS group was predominantly female (88%), a difference significant at p<0.01. There were no significant differences between the AIDS and non-AIDS groups in the incidence of diagnosis of depression, suicidal risk, substance abuse, or adjustment disorder. An Axis II diagnosis was made significantly less often in the AIDS group (p<0.05). The incidence of organic mental disorder was significantly higher in the AIDS group (p<0.05). Staff spent an average of 4.0 hours on AIDS consultations compared to 3.4 hours on non-AIDS consultations. There were 26 repeat consultations (42%) requested for the AIDS patients, compared to 17 repeat consultations (12%) in the non-AIDS patients (p<0.1). Comparison with the etiology of DSM and Axis II diagnoses, there were no significant differences in psychiatric diagnoses between AIDS patients and non-AIDS patients seen in psychiatric consultation. AIDS patients required more staff consultation time and repeat consultations, thus creating a heavier time burden on psychiatric services.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

W.B.P.235 NEUROPSYCHOLOGICAL FUNCTIONING IN HIV-INFECTION Schickel, U., *Frolich, C., *Naber, D., *Gostel, P., D.*** *Psychiatrische Klinik der Universitäts München **Medizinische Poliklinik der Universitäts München F.R.G.

Objective: To study the natural history of neuropsychological deficits in patients with HIV-infection.
Methods: 132 HIV-positive patients, 100 in early stages, underwent psychiatric exploration and neuropsychological testing. Psychopathologic status was rated by means of the APOC-System, self-rated by SDS, PDMS, STAI and DCL. Neuropsychological examination included: Memory, Vocabulary, Similarities, Digit-Symbol, Color-Word-Interference, Benton, Trail-Making and Auditory-Verbal-Learning.
Results: 27% of patients showed symptoms of depression, 3% of anxiety. Tests revealed normal functioning in 70% of patients in early stages and 51% in late stages. Clinically relevant was the deficit in SA and in IQA respectively. The comparison with HIV-negative controls (n=100) showed for most tests a significant reduction already in early stages. These deficits correlated highly with depression. Cognitive deficits already occur in early stages, but often without clinical relevance. This study does not differentiate non-specific vs. psychogenic etiology. Repeated measurements and correlations with neurological variables are in process.

Solns

Case

W.B.P.237 EVALUATION OF TRAINING FOR PHYSICIANS AT THE NATIONAL REFERENCE CENTERS IN BRAZIL Rodrigues, José*, Rodrigues, Lar** *União Paulista, Brasília, MinasGerais de Saúde - Brasília, Brazil

Under the sponsorship of the National Division of STD/AIDS, an evaluation of the clinical training on AIDS delivered by the National Reference Centers (NRC), Universidade Federal do Rio de Janeiro (URJ) and Gaffrée & Guinle (GAG), was conducted. The evaluation took place according to an up by the National Commission on AIDS and derived from Gaffrée's evaluative model (1977). The model comprises four components—Content, Input, Process and Product—which corresponded to the aspect to be assessed in the evaluation. Instruments of time to time were used: (a) interviews with those in charge of the Reference Centers, (b) direct observation by the evaluator, and (c) three pages self-paced instruments, i.e., the Knowledge Test on AIDS, the Impersonal Skills Inventory, and the Content Evaluation.
Results: The scores derived from the teachers' responses—URJ, URJ and GAG—on the Knowledge Test and the Content Evaluation showed no statistically significant differences according to the Kruskal-Wallis method (1975). However, a closer look into particular aspects of the three Centers showed positive characteristics as well as aspects deserving improvement. Such data allowed of some extrapolations pertaining to the evaluator, the DRN STD/AIDS, the Reference Centers and the content responses for the training.

W.B.P.239 INVERSE CORRELATION OF COMPLEMENT-MEDIATED, ANTIBODY-DEPENDENT ENHANCING TITERS WITH STAGE OF DISEASE IN INDIVIDUALS INFECTED WITH HIV-1.

Mitchell, William A., Robinson, W.E., Jr., Modirrousta, A., and Litwin, L.B., Jr. Dept. Pathology and *Preventive Medicine, Vanderbilt University, Nashville.

Objective: Complement-mediated, antibody-dependent enhancement (C-ADe) of HIV-1 infection has been attributed to accelerated infectious progression in HIV-1 neutralizing antibody titers in vitro (Lancet: 790, 1988), and to cause a > 100 fold increase in infectious HIV-1 yields (AIDS - in press). **Objective:** In this report is to ascertain whether titers of antibodies involved in C-ADe and the relationship between neutralizing antibodies and C-ADe correlate with stage of disease.
Methods: Sera from twenty-eight subjects in the Nashville area were examined at a 3-6 month time point for C-ADe titers as well as neutralizing antibodies in the presence or absence of human complement. Stage of disease was evaluated by the Water-Read classification scheme. C-ADe as well as the ratio between neutralizing antibodies in the absence and presence of human complement and the ratio between C-ADe and neutralizing antibody titers in the absence of complement were correlated with disease stage by linear regression analysis.
Results: No correlation between neutralizing antibody titers in the presence and absence of complement or C-ADe and neutralizing antibodies was found with the stage of HIV-1 induced disease. An inverse correlation between C-ADe and the ratio between neutralizing antibodies in the presence and absence of complement was found in initial analysis of a limited number of subjects.

Conclusion: The data in human subjects is consistent with our observation in chimpanzees following initial challenge with HIV-1. C-ADe titers rise prior to neutralizing antibody titers. Titers of the latter increase as C-ADe declines. Effort will continue to expand our data base to correlate with stage of disease as well as to examine the speed of disease progression as a function of C-ADe.

W.B.P.236 QUALITATIVE ASPECTS OF DEPRESSED MOOD AND NEUROPSYCHOLOGICAL FUNCTIONING IN HIV-1 +/- GAY AND BISEXUAL MEN: The Multicenter AIDS Cohort Study (MACS). James J. Becker, F.N. Scherr, L. Kingsley, R. Fox, J.M. New, Depts. Psychiatry & Epidemiology & Statistics, University of Pittsburgh Sch. Med., and Johns Hopkins Med. Inst., U.S.A.

OBJECTIVE: This study evaluated the relationship between mood and neuropsychological measures of affect (BDI) in HIV-1 (+/-) gay/bisexual men.
METHODS: HIV-1 seropositive (n=137) and seronegative (n=133) gay/bisexual men from the Pittsburgh and Baltimore MACS sites completed the Beck Depression Inventory (BDI), Spiegelberg's State/Trait Anxiety Inventory (STAI), and a short history of neuropsychological tests.
RESULTS: Overall, the HIV-1 men had more symptoms of depression (i.e., BDI), seropositive men were categorized based on total number of CD4 cells there were significant differences only in terms of the total BDI score, which was elevated in the men with the lowest CD4 counts. This elevation was not due to an increase in the number or severity of symptoms of abnormal affect (e.g., "dissatisfied with life"), but rather an increase in the number and/or severity of physical symptoms (e.g., weight change) reported on the BDI. No differences in performance on the cognitive tests were seen between seropositive groups. Performance was correlated with the BDI but not the STAI. Further analysis revealed that it was the physical symptoms of depression rather than the affective symptoms which were related to cognitive function.
CONCLUSIONS: These data indicate that the assessment of mood in HIV-1-infected individuals must take into account physical illness. Consistent with other findings from the MACS, neuropsychological performance was predicted by the presence of physical symptoms, but not by dysphoric mood.

W.B.P.238 A COMPREHENSIVE APPROACH TO COMMUNITY HOSPITAL CARE OF AIDS PATIENTS Andrew, Laurie, Kinick, J. (Hertford Community Hospital, Hertford, CONNECTICUT, USA)

Objective: To provide clinical care, education, counseling, testing and social services to HIV infected patients (pts) served by an 850 bed tertiary care community teaching hospital in central Connecticut.
Methods: An AIDS Task Force acts as a reflective and advisory capacity, a recommending policy and procedure to the Infection Control Committee. A patient oriented multidisciplinary HIV Task Force coordinates the delivery of services to in-pats with HIV disease and provides support to hospital staff. Community based volunteers provide support and social services for HIV pts and families. An AIDS program office provides an INFO-line, resource referral and speakers for community groups. A newsletter is periodically distributed updating national and regional AIDS related developments. The hospital provides referrals and acts as a resource for various community based organizations which provide education, outreach and support. The hospital is part of a city wide network of HIV related organizations and area church groups. A regional task force has established a data base, and addresses public policy and legislative issues. The existing Nurse Association and addresses public policy and legislative issues.
Conclusions: Since each hospital's HIV population and problems are both generic and specific, internal coordination and problem solving must be coupled with the establishment and strengthening of links to community services in order for both the hospital and its patients to survive.

W.B.P.240 IMPROVEMENTS TO IVDA ENROLLMENT IN AIDS CLINICAL TRIALS Fairchild, Patrick, Jaffe, Ann, C. Chaseman, J.; Bova, C.; Glavan, S.; Finkbeiner, S.; et al. University of Massachusetts Medical School, Worcester, Massachusetts, U.S.A.

Objective: To ascertain reasons that hinder enrollment of HIV-infected intravenous drug abusers (IVDA) into clinical trials.
Methods: The 1000th hundred IVDA in the IVDA study were evaluated at 100% for entry into HIV ACT clinical trials assessing AIT in asymptomatic infection (protocol 019) and early AIT (protocol 016) utilizing standard inclusion and exclusion criteria.
Results: Of the 141 patients, only 38 (27.0%) were considered eligible for entry into either protocol. Eleven (7.8%) of the 141 patients have been enrolled, 15 (10.6%) eligible patients are considering entry and 12 (8.5%) have refused participation in study. IVDA's considered ineligible for study (103.4%) often had more than one reason for not entering a protocol. These included psychosocial difficulties (53.1%), active IV drug use (23.4%) and exclusion for medical conditions (40.0%). IVDA that entered and remained in study were more likely to be enrolled in a long-term drug free residential facility or have a stable and supportive home environment than those who did not enter study. In contrast, 78 non-IVDA, IVDA (62.8%) were considered eligible for study and 19 (24.4%) were enrolled.
Conclusions: Multiple factors contribute to the low enrollment rate of IVDA into clinical trials. Increased availability of social services support to drug abusers, improved outreach, and enhanced IVDA participation in clinical trials. Expanded medical study inclusion criteria and less restrictive exclusion criteria may further promote entry into study.

**Session d'affichage
Poster Session**



**Aspects cliniques
Clinical Aspects of AIDS**

W.B.P.241 THE ROLE OF THE GOVERNMENT OF CANADA IN THE NATURE AND DIRECTION OF RESEARCH IN THE MANAGEMENT OF HIV-DISEASE IN CANADA
Reid, B., Khan, and N. N. Joseph

Infection and Immunology Division, Bureau of Human Reproduction Drugs, Drugs Directorate, Health Protection Branch, Ottawa, Canada. Objective: To discuss the key role played by Health and Welfare Canada in supporting, expediting, facilitating, and implementing clinical research in the management of HIV-disease in Canada.

Methods and Results: The Health Protection Branch (HPB) of Health and Welfare Canada plays a crucial but delicate role in determining patient accessibility to experimental drugs for the management of HIV-disease and its ancillary opportunistic infections and problems. New policy initiatives and administrative changes have been recently announced which are intended to streamline the regulatory process and improve patient accessibility. It is our intention to examine the impact of these changes on the availability of experimental agents in Canada and on the climate for clinical research in this country. In addition, we will discuss the mechanisms for the introduction of experimental agents to Canada, the organizational and regulatory framework of HPB, the philosophy governing the evolution and implementation of regulatory change, and the consultative role of the Drugs Directorate.

Conclusion: The Health Protection Branch will continue to play a key role in improving patient accessibility and promoting clinical investigation in the management of HIV-disease in Canada.

W.B.P.242 THERMOGRAPHIC IMAGING OF HIV PATIENTS

Clark, R. J., Goff, M. A., Yoda, M., and Gazdars, B. P.
*Clinical Research Centre, Harrow, Ont. L6, **Theophane Hospital, London, UK.

Objective: To assess the role of high resolution infra-red imaging in HIV infection and Kaposi's sarcoma with particular reference to monitoring abnormal patterns of heat as well as because of peripheral neurological impairment and/or the presence of KS lesions.

Methods: High resolution thermal imaging equipment using an 8 element SP7TITE detector system working in the 8-13 micron wavelength has been used in a study to assess whole body skin temperature patterns in 20 HIV-positive patients with biopsy proven KS lesions and to determine the thermal status of representative KS lesions before and during treatment with isotretinoin acid.

Results: Characteristic and abnormal thermal patterns were found in a high proportion of the patients studied. In addition, a range of quantitative thermal activity of KS lesions at different body sites was recorded. Some lesions showed measurable changes in thermal activity during treatment. These findings will be illustrated.

Conclusion: It is suggested that cutaneous neurological changes associated with HIV infection may produce abnormal thermal patterns on the skin surface and that the technique of infra-red thermography may have a role in identifying such abnormalities and provide an index of peripheral neurological change in HIV patients. Thermographic patterns may also be able to characterize the vascular and metabolic status of cutaneous lesions and thereby help in the assessment of the activity of Kaposi's sarcoma.

W.B.P.243 ART THERAPY WITH PEOPLE WITH AIDS

Eva Sangon, M.A. Couns., Psych., D.T.A.T.I.
Counselor, Art Therapist
Casey House Health Inc.
Toronto, Ontario, Canada

Abstract:

Art Therapy is a useful medium for the expression, recognition and processing of the anxieties of People With AIDS.

In this paper and slide presentation, issues of pain, incompleteness, failure, isolation, dependency, punishment, fear of the unknown and homophobia are expressed in the artwork and subsequent discussion.

The workshop will present one PWA artwork produced over the course of 3 months to illustrate the development of the process of art therapy. Several other examples of specific statements through artwork will also be shown. Two aspects of denial will be suggested.

W.B.P.244 MAINTENANCE OF HOPE IN AN HIV SEROPOSITIVE

Reidish, Judith, Williams, J., Macgregor, R., Reising, Robert
RV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute and Columbia University, NY, NY, USA

Objective: To identify social and psychological conditions, susceptible to intervention, that contribute to maintenance of hope in an HIV seropositive.

Methods: 156 gay, predominantly white, well educated and financially successful community volunteers were evaluated to identify overall level of psychological functioning, psychiatric symptoms and syndrome, life outlook, social relationships, life events, HIV status and illness stage. 79% of participants were HIV seropositive.

Results: The following were positively associated with higher levels of hope (Pearson's r, p < .02): social supports (+0.22), internal locus of control (+0.36); commitment (+0.60); number of positive life events (+0.28); and global psychological functioning (+0.21). HIV illness stage and T cell count among HIV seropositive were not significantly related to levels of hope. In the absence of current psychiatric disorder, sero-negative, same difference in level of hope between HIV and HIV+ subjects was not statistically significant. There was, however, more variability of response and more extreme scores within the HIV+ group, at both ends of the distribution.

Conclusion: The large majority of respondents have been able to preserve a sense of faith in the future and the conviction that living is worthwhile, despite HIV infection.

W.B.P.245 A REHABILITATION PROGRAM FOR CLIENTS WITH HIV ASSOCIATED CONDITIONS

Genulis, Patricia, Marshall K., Bennett M., Laquer P., Alexander H., Davis L. Woodhull
Medicaid & Mental Health Center, Brooklyn, NY, USA

Objective: This poster presentation will highlight the special and unique role Rehabilitation Medicine can provide in servicing people with AIDS (PWAs).
Methods and Results: Woodhull Medicaid & Mental Health Center, as part of NY City's Health & Hospital Corporation, provides comprehensive tertiary-care services to a large impoverished and medically underserved community. As part of the Department of Ambulatory Care, Rehabilitation Medicine offers physical and occupational therapy services to a wide variety of patients, including those diagnosed as having AIDS or AIDS-related complications. The growing number of PWAs is challenging all health care specialists to define their role in providing services to this population; Rehabilitation Medicine is no exception. PWAs or AIDS-related conditions may present with a wide variety of physical, emotional, and psychological problems. Consequently, the role of Rehabilitation Medicine will include: 1) maintaining level of functioning in activities of daily living; 2) supporting continued participation in occupational roles; and 3) improving the quality of life.

This presentation will describe and demonstrate a therapeutic rehabilitation group developed for PWAs. Led by an occupational therapist, the goals of the group lie chiefly in teaching coping and adaptive skills specifically for PWAs. Conditioning exercises, breathing and relaxation exercises, and self-care training are integral parts of the comprehensive program.

Conclusions: People with AIDS are faced with the daily challenge of living with their condition. This presentation will highlight what role Rehabilitation Medicine, especially occupational therapy, can play in promoting skills to achieve maximal independence.

W.B.P.246 COMPLIANCE OF HIV-INFECTED INTRAVENOUS DRUG USERS IN CLINICAL TRIALS

Jefferson, C.; Bialik, M. et al. University of Massachusetts Medical School, Worcester, Massachusetts, USA

Objective: To compare compliance of clinical trial subjects whose risk factor is intravenous drug abuse (IVDU+) with those from other risk groups.
Methods: Subjects are HIV sero positive on RIA AZTQ placebo-controlled trials of Zidovudine in asymptomatic infection (019) and early ARC (016). IVDU+ were either drug-free or on methadone maintenance at the time of protocol entry. The number of pills returned at each visit was tallied and periods for which patients returned < 20% of study drug were deemed to represent good compliance. This corresponds to missing no more than one dose per day.
Results: Four of 11 IVDU+ have left the studies for reasons other than protocol endpoints, compared with one of 20 from other risk groups. All 5 were asymptomatic. None of the 9 patients with symptoms of early ARC have left this, although 4 are IVDU+.

All patients on study	Percent of Study Weeks in Good Compliance	
	IVDU+	Others
016 (early ARC)	93	93
019 (asymptomatic)	99	94
> 10 weeks (biweekly follow-up)	86	93
> 16 weeks (biweekly follow-up)	90	92
> 18 weeks (monthly follow-up)	98	89

Conclusions: Although IVDU+ discontinues study participation more often than others, their adherence while on study, as measured by pill returns, does not differ markedly from subjects from other risk groups.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

W.B.P.247 INSURING QUALITY OF DATA IN COMMUNITY-BASED CLINICAL TRIALS

Michael T. O'Leary, C.T. Neuwirth, E. J. and Bruce, Donnell
San Francisco County Community Consortium, San Francisco, USA

Community-based clinical trials of experimental HIV treatments offer the potential for rapidly expanding the number of drugs being tested, maintaining the participation of community physicians in HIV research, and improving access to promising experimental therapies for large numbers of patients. Critics of community-based clinical trials, however, argue that the quality of data obtained in community settings is unlikely to achieve standards established in academic research settings.

To meet this challenge, the San Francisco County Community Consortium (SFCCC) designed data collection, protocol management and quality assurance systems which could be implemented in community physicians' offices. In Fall 1989, the SFCCC trained 45 physicians to use these systems and launched 5 clinical trials. Studies include 21 trials of readily available available agents as well as observational databases of current HIV therapies.

To insure consistent data collection by large numbers of physicians located over a wide geographic area, SFCCC uses the same set of case report forms for all clinical trials. To minimize the amount of record keeping required of physicians, the SFCCC uses a computerized follow-up system to prompt physicians to collect data and to dispense study medications at prescribed intervals. To insure data accuracy and completeness, SFCCC staff systematically review all case report forms before data are removed from physicians' offices and entered into the SFCCC database management system.

The experience of the SFCCC suggests that frequent (weekly) monitoring by research staff is necessary but sufficient to insure that data collected in community settings achieve standards established in academic research centers.

W.B.P.240 EVALUATION DE LA CHARGE DE TRAVAIL INFERMIER COMPARAISON ENTRE PATIENTS HOSPITALISÉS INFECTÉS ET NON INFECTÉS PAR LE VIH. CHU DE CHIRURGIE - CHASSAGNY D., BEAUCHEMIN G., LEROY D.,

Centre Hospitalier, F. 92028 TOURNAI, FRANCE.
L'intensité des soins infirmiers ont été étudiées fin 1988. La structure et l'intensité des soins infirmiers ont été étudiées fin 1988. Les données prospectives dans un service universitaire de Maladies Infectieuses par respectif quotidien des informations. 64 données sont disponibles. 29 patients infectés par le VIH (dont 15 PVI) et 25 patients hospitalisés pour pathologie infectieuse non parasitaire non VIH, correspondant respectivement à 516 et 342 journées d'hospitalisation. Les soins de base (alimentation, locomotion, mobilisation, alimentation, hygiène et confort), techniques (diagnostics) et thérapeutiques, relationnels et éducatifs, sont classés de 1 à 5 en fonction de leur intensité.

	1	2	3	4	5
minutes/jour	1.8	29.5	55.2	87	5.6
VII- (1)	1.8	16.6	130.9	48.7	8.1
VII- minutes/jour	1.3	52.5	36.6	22.6	0.51
(6)	(1.1)	(46.2)	(22.2)	(20)	(0.4)
Structure des soins	base	technique	relationnel		
VII- minutes/jour	40.8	40.8	39.3		
(8)	(26.5)	(32.9)	(56.6)		
VII- minutes/jour	33.2	49.2	30.9		
(8)	(26.5)	(45.4)	(27.3)		

Les patients VII- requièrent des soins relationnels maximaux. L'intensité des soins est doublée par rapport aux patients VII-.

W.B.P.249 AIDS RESEARCHER REGISTRY (ARR) OF NEW YORK

Long, Iris; Cowing, R. J.; Esig, J. and Huff, R. AIDS Treatment Registry, P.O.B. 30234, New York, New York, USA.

Objective: To provide information about ongoing clinical trials to individuals seeking to enroll in clinical trials, physicians, health facilities and AIDS service organizations in New York and New Jersey.

Method: A local, non-profit organization has established a computerized database to give accurate, reliable information on AIDS-related clinical trials because up-to-date, accurate information is not easily accessible.

Result: It is generally accepted that access to health news and experimental treatments will extend the lives of many infected with HIV. Acquiring information about clinical trials is limited. This has led to underrepresentation of minorities and overall underenrollment in trials.

The latter is one of the factors slowing down the drug approval process. According to the Food and Drug Administration, there are currently over 80 drugs approved for trials and over 100 drug trials.

In October 1989, a federal law was enacted requiring sponsors of AIDS drug trials to make public all AIDS efficacy trials. The impact of the new legislation on the project will be discussed.

Conclusion: The ARR will identify all AIDS/HIV-related clinical drug trials underway locally, collect data from principal investigators conducting such trials to determine where "open slots" exist and what is required of prospective drug trial participants. This information will be developed into a readily accessible report format and distributed to all potential end-users.

W.B.P.250 A REGIONAL MODEL FOR ESTABLISHING A COMMUNITY-BASED, COMPUTERIZED REGISTRY OF AIDS/HIV CLINICAL DRUG TRIALS.

Kigo, James; Cowing, R. J.; Long, I. AIDS Treatment Registry, Inc., Arr, P.O. Box 30234, New York, New York 10011, U.S.A.

Objective: To establish community-based registries of AIDS/HIV-related clinical drug trials at local levels to increase awareness of, and access to, such trials for persons affected by the epidemic, especially among minority populations heretofore largely excluded from enrollment.

Method: Discussion of the steps taken by the ARR to gather information on AIDS/HIV-related clinical trials underway in their area and disseminate that information to members of all affected populations, including intravenous drug users (IVDU), blacks and Hispanics, women and children, and the poor. Discussion topics will include: becoming your own "expert" on clinical trials; developing a database; developing data collection materials; volunteer recruitment and training; overcoming obstacles in collecting data; producing "user-friendly" report formats; developing culturally sensitive education materials covering trial enrollment issues and the use of experimental drugs; establishing a community outreach and distribution network and qualifying for available funding.

Result: ARR's effort has been highly successful. They have obtained the aid of City and State health officials in collecting their data and were funded by N.Y. State in their first year of operation. A bi-lingual "Handbook for Clinical Trial Participants" has been produced. Trial enrollment statistics are closely monitored to quantify the overall impact of the effort. **Conclusion:** A community-based registry of trials can promote greater access to potential treatments and enhance trial enrollment.

W.B.P.251

PROGRAM DIRECTORS' ATTITUDES TOWARDS RESIDENTS' CARE OF PERSONS WITH AIDS. HARRISON S.A., Kowitz, R. K.

Shapiro, M. F., University of Michigan, Ann Arbor, Michigan, U.S.A. * University of California, Los Angeles, California, United States.

Objective: To evaluate the educational strategies and experiences of United States residency programs regarding the training of primary care providers for persons with AIDS (PWAs).

Methods: We mailed questionnaires to directors of all 772 non-military United States Internal Medicine (IM) and Family Medicine (FM) programs. 50% have responded.

Results: While 51% of directors felt that primary care of PWAs is an important educational experience and 84% of programs reported usually having AIDS inpatients, only 15% reported that the majority of trainees cared for PWAs in their continuity clinics. In programs with a high treatment load (average mean ≥ 8), only 39% reported that most residents had either cared for a PWA in their continuity clinic or had rotated through an AIDS subspecialty clinic. More IM than FM directors considered care of PWAs to be too complicated for most generalists (24% vs 9%, p<0.01) and IM directors were less likely to encourage "rounds" to provide PWAs with primary care (51% vs 72%, p<0.01). Among 57% who did not believe or were unsure if their residents were adequately trained in AIDS ambulatory care, only 28% reported inpatient rotation in this area to be a high priority. Among the 39% who do not encourage residents' assumption of primary care, 60% had at least one of the following concerns: resident stress (24%), AIDS care too complicated (31%), or clinic faculty not qualified to supervise (28%).

Conclusions: While program directors view education in ambulatory care of PWAs as important, most do not believe residents are adequately trained, many do not encourage residents' assumption of primary care of PWAs and residents have not provided such care in their programs. Strategies to augment residents' ambulatory experience in the care of PWAs are needed.

W.B.P.252 IMPACT OF SERUM p24 HIV ANTIGEN SCREENING ON PATIENT ELIGIBILITY FOR ANTIVIRAL TRIALS

Hugh, Christi; Mann; Peartree; G. Eigenmann; J.; Comstock; C.

Concord, B. Beth Israel Hospital, Harvard AIDS Clinical Trial Unit, Boston, MA, USA.

Objective: To examine the impact of serum p24 HIV antigen (p24) screening on patient eligibility for an antiviral clinical trial.

Methods: [ACTG 0834 Phase I Trial of Ribavirin in the Treatment of Patients with AIDS and Advanced AIDS-Related Infections (ARCI)] requires positive serum p24 for inclusion. Screening inpatients and review of medical records determined clinical stage of HIV-related illness and Zidovudine (AZT) use. Blood was obtained from patients with ARCI and AIDS and serum tested for p24 using the Abbott ELISA. A level of 2.0 U/ml (program) was

deemed a positive (+) and qualified patients for study enrollment.

Results: 45 patients were screened to the point of p24 testing with the following results:

31.2% +, 14.4% -

8 ARCI, 22 AIDS 4 ARCI, 19 AIDS

15 had prior AZT use 4 had prior AZT use

p24 positive did not significantly correlate with either clinical stage or AZT use by Chi square analysis. Four + patients were later retested and 2 had converted from + to -.

Seventeen + patients have been orally treated and have remained +.

Conclusion: Use of p24 positive as an eligibility criterion for phase I antiviral trials will limit access of significant numbers of clinically indistinguishable patients to these trials. The impact of such exclusion on the applicability of trial results may be significant.

**Session d'affichage
Poster Session**



**Aspects cliniques
Clinical Aspects of AIDS**

W.B.P.265 CLINICAL CARE AS PART OF INTEGRATED AIDS MANAGEMENT IN A RURAL HEALTH CENTER.
Chela, Silvestre M.; Campbell, L.D.; Silvanaga, Z.
The Clemente Ximé Chamblán Hospital, Marabato, Zambia.

Object: 1) to present an analysis of clinical symptomatology with a summary of major problems for hospital management of patients with AIDS compared with patients in the home based care and prevention programs;

2) to analyze drug use and drug costs in the hospital and in the home based care setting.

Methods: A retrospective analysis of 200 inpatients and 200 patients in the home based care programs was done. The observed manifestations of AIDS are described, by organ systems, and treatment protocols are described, incorporating an analysis of drug use and cost on some of these diseases. Results, tables and figures are presented showing main presenting symptoms found both in hospital and at home, and indicating that treatment protocols followed were similar with respect to drug costs.

Conclusion: It is proposed that home based care and prevention with hospital intervention where required is the most practical and sustainable form of organization for an integrated approach to management for a district rural hospital. Furthermore, it is proposed that therapeutic constraints of certain kinds are acceptable in the context of shared acceptability by therapeutic teams, by patients, and by committees connected to the patients.

W.B.P.266 STUDY OF A SERIES OF 121 CONSECUTIVE AIDS PATIENTS.
CONSELHEIRO, M.S.; SILVA, M.A.; BRANCO-MELO, C.E.; LEITE, C.
FAC. DE MEDICINA, U.F.R.J., RIO DE JANEIRO, RJ, BRASIL.
Clínica Médica A, da Universidade do Rio de Janeiro, UFRJ, Brasil.

The aim of the work was to study epidemiologically, Clinically and laboratorially a series of 121 consecutive AIDS patients, admitted to the Clínica Médica A, da Universidade do Rio de Janeiro, during the 1985-86 period.

METHODS: All the 121 consecutively admitted patients were studied trying to figure out the possible forms of transmission and therefore grouping them in the so called-risk groups. They were scored up as thoroughly as possible, either clinically as laboratorially.

RESULTS: Ninetyten of the patients were women and 102 were men. Of the men 59 were homosexuals and 6 were bisexuals (two of them was also an intravenous drug addict. One was a drug addict, the most frequent infections were systemic candidiasis (56), P. carinii pneumonia (28), tuberculosis (28), toxoplasmosis (12) and cryptococcosis (11). Five patients only had Kaposi's sarcoma.

CONCLUSION: Although the Clínica Médica A, da UFRJ admits both women and men (twice more women) 102 of the 121 patients (84,29%) were men. Homosexuals and bisexuals represented 97% of the total of males and 84,21% of the women probably got the infection through blood transfusions.

W.B.P.267 AIDS ISSUES FOR RURAL HOSPITALS IN U.S. FRONTIER AREAS
CAMPBELL, MARGARET D.; University of Nevada, Las Vegas, Las Vegas, Nevada, U.S.A.

Objective: To identify and assess the experience rural frontier hospitals (under 50 beds) in the U.S. in the provision of care to HIV infected patients and to evaluate the preparedness of these hospitals to provide AIDS care via education and policy development.

Methods: A survey addressing the incidence of HIV infection in the hospital's service area, services provided to HIV infected patients, concerns of hospital employees regarding care of AIDS patients, provision of education and policy development was mailed to all frontier hospitals (n=108) in 8 states.

Results: Frontier hospitals in 7 states had had experience with HIV infected patients. Of the 46 hospitals who responded 13 had had experience with AIDS patients and 33 had not. Of the 13 with experience 9 provided care in the facility and 4 referred the patients. Surprisingly, employees in hospitals with experience expressed more concern about acquiring AIDS than those in hospitals without experience. Nurses Aids had the highest concern 4 had refusals to provide care. AIDS education consisted mainly of video programs, presentations by in-house staff and sending employees away to workshops. Major concerns expressed by the hospitals related to enforcing universal precautions, confidentiality of patient information, staff response, community acceptance and the incidence of AIDS is increasing in rural areas throughout the U.S. Effectiveness of educational programs is questionable given the concern of staff in frontier hospitals with AIDS experience and education. Education and policies are essential to guide hospital personnel in the provision of AIDS care.

W.B.P.268 SEROPREVALENCE OF HIV, HERPES VIRUSES AND IMMUNOLOGIC ABNORMALITIES IN A GROUP OF IV DRUG ADDICTS
Pacheco, Constantino Z.; Scheidt, Luciano, J.; Schaefer, M. Doris, M.; EDWARDS HINES V.A. Hospital, Hines, Ill., U.S.A.

Objective: To determine the prevalence of infection with Epstein Barr Virus (EBV), Cytomegalovirus (CMV), herpes simplex virus (HSV), and HIV, and to correlate seroprevalence with immunologic abnormalities in a group of IV drug abusers.

Methods: HIV status was determined by ELISA and confirmed by Western Blot; viral serology was done by indirect immunofluorescence; lymphocyte subsets were done by flow cytometry.

Results: The seroprevalence of CMV, EBV, HSV, and HIV were respectively 7/103, 103/103, 7/103, and 4/111. No patient had evidence for clinical infection with any of these viruses. Of the HIV infections 28/103 had recent and 11/103 had chronic active infection. These 37 patients had higher percentages of lymphocytes but no difference in CD4/CD8 as compared with all others. Patients with recent or chronic active EBV infection with dual infection with CMV had higher CD8 and lower CD4/CD8 than either those without EBV infection of all others. A similar effect on the CD4/CD8 was not seen with the combination of recent or chronic active EBV infection and HSV infection.

Conclusion: Since dual infection with CMV and HIV may be lower the CD4/CD8, use of this parameter as a prognostic factor or as an indicator for starting therapy in HIV positive patients should be done with caution.

W.B.P.269 PSYCHOLOGICAL ISSUES ASSOCIATED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN A CITY HOSPITAL: EXPERIENCE OF THE MULTIDISCIPLINARY PATIENT CARE MEETING.

Chang, Tony; Wiseman, H; McNeil, A. Queens Hospital Center (QHC), Affiliation of the Long Island Jewish Hospital Center, Jamaica, N.Y. 11432 USA

Objective: To survey the prevalence and range of psychosocial issues associated with HIV infection as discussed at QHC AIDS Team multidisciplinary meetings.

Methods: Records of the AIDS multidisciplinary patient care meetings at QHC from March, 1988 to October, 1988 were evaluated for psychosocial issues presented. These issues were broken down into 7 categories: denial, anxiety, depression, suicidal ideation, drug use, psychosis and organcity.

Results: 108 patients were discussed at the patient care meetings. Of these, more than 80% had psychosocial difficulties. The age range was 20 to 64 (mean=34). 74.1% were Black, 11.1% Hispanic and 7.4% were White and Native. 73.1% were IVU, homosexual 11.1%, heterosexual 13.0% and blood transfusion related 2.8%. The psychosocial issues were: denial 7/108 (6.5%), anxiety/fear 18/108 (16.7%), depression 20/108 (18.5%), suicidal ideation 7/108 (6.5%), drug use 15/108 (13.9%), psychosis 13/108 (12.0%), organcity 20/108 (18.5%).

Conclusion: The data reflect the significant psychosocial morbidity associated with HIV disease. This study supports the importance of a multidisciplinary approach to dealing with HIV.

W.B.P.270 TRIAGE SYSTEM FOR POTENTIAL RESEARCH SUBJECTS INTO ACTIVE AIDS CLINICAL TRIALS.
MORSE, V. M.; J. Holliday, M.D.; P. J. Volberding, P.H.D.; N. M. University of California, San Francisco, San Francisco General Hospital, U.S.A.

Objective: To evaluate a computerized triage system for potential research subjects collecting important laboratory and clinical data, identify individuals and specific populations for a targeted recruitment.

Methods: A data base has been created to facilitate access into active AIDS clinical trials. Individuals interested in participating in clinical research are mailed a brief description of the present research, a long-term summary of clinical research methodology, and a preliminary registration form. After completion, the registration form is returned to the AIDS Triage Service. A research nurse then contacts the individual to complete a research profile which is entered into the data base. The profile includes dates and quantitative values of most recent p24 antigen (p24Ag), Beta-2 microglobulin (B2MG), lymphocyte counts, and CD4+ lymphocyte counts and CD4+ antigen status.

Conclusion: The data base is used to preliminarily screen subjects by comparing trial inclusion criteria with the population in the data base. Continuing data base participation requires research profile updating every three months.

Table: A total of 808 subjects are currently in the data base, with 186 seropositive (CD4 \geq 351, CD4/CD8 \geq 1.0), and 200 AIDS (CD4 \geq 100, CD4/CD8 \geq 1.0). Subjects have the following CD4+ lymphocyte count and p24 antigen status.

CD4+ lymphocytes	p24Ag	CD4	CD8	CD4/CD8	CD4	CD8	CD4/CD8
≥400	≤5000	381	400	0.95	186	186	1.00
300-400	5000-10000	117	117	1.00	186	186	1.00
200-300	60500*	43	314	7.34*	3	141	47.0
100-200	100000*	15	15	1.50	3	101	33.7
TOTAL		556	637	1.15	191	109	609

*Percentage of subjects who have their antigen status
Conclusion: A data base of potential research subjects containing clinical and laboratory data enables targeted research recruitment and preliminary screening of eligibility criteria.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

W.B.P.277 DIETHYLDITHIOCARBAMATE INHIBITS THE PROGRESSION OF HIV INFECTION. RESULTS OF A PROSPECTIVE RANDOMIZED CLINICAL STUDY

Authors: Manfred et al.
Bernhard-Noell-Institute for Tropical Medicine, Clinical Department; AK St. Georg, Dermatology; AK Ochsensaal, Neurology; Hamburg; Forschungsinstitut Borstel, Germany, Institut Medizinisch, Garmersy.

Objective: Diethyldithiocarbamate (DTC) is a chelating agent with in vitro and in vivo influence on the production of HIV. Recently, J.M. Lang et al. (Lancet, Sept. 24th, 1986, 702-703) presented their data of a 4-months treatment study with positive response both in improvement of patients and in 14-cells. In 1986, we initiated a study in order to evaluate the efficacy of DTC in patients with HIV infection. Walter Reed 2-4.

Methods: 40 patients were randomized to DTC 5 mg/kg i.v., DTC 10 mg/kg orally once a week for a period of 6 months. Both groups were placebo-controlled. **Results:** The results are given in the following table:
CD4+ classification, progression to AIDS, changes in immunological parameters. In the placebo group compared to DTC (0.4.0.0.0), the oral application showed the same trend (7 placebo patients progressed in contrast to 3 of DTC), in the DTC i.v. group, none progressed to AIDS. In contrast to 6 placebo patients (log Rank test p<0.05), the interleukin-1 production and interleukin-2 receptor expressing monocytes were significantly different at the end of the treatment. The ratio of 14-cells before and after treatment was significantly different between placebo and DTC treated patients.

Conclusion: DTC is effective to slow down the progression of HIV infection in patients with CD4+ classification 2-4. It seems not to be able to increase the absolute number of 14-cells.

W.B.P.279 RECOVERY OF DELAYED-TYPE HYPERSENSITIVITY (DTH) IN PATIENTS WITH AIDS-RELATED COMPLEX (ARC) IN RANDOMIZED TRIALS OF INDS-1

Authors: Hais, Miles, Com, LaFand, Sayre, Eisenhorn Medical Center, Rancho Mirage, CA, USA; *UCLA School of Public Health, Los Angeles, CA, USA.

Objective: INDS-1, an immunoregulator containing tyrosine-glycine (tyrosine) enhances multiple immune functions. We have studied INDS-1 in patients with ARC or Kaposi's sarcoma (KS) regarding efficacy and immunomodulating effects.

Methods: Forty aseptic patients in Southern California were treated every 2-3 months with tetanus toxoid (TT) during the trial and with TT and candida (CA) during compassionate INDS-1 administration after the trial. The following were analyzed: (a) re-activity to patients (2 with KS and 27 with ARC) in the INDS-1 group and 11 patients (all ARC) in the placebo group; (b) re-activity to 27 patients respectively. The 2 groups were comparable with respect to baseline characteristics and the number of dropouts.

Results: In the INDS-1 group, 9 (41%) became reactive to TT after an average of 285 days whereas, in the placebo group, 1 (14%) recovered DTH after 437 days. Six (27%) INDS-1 treated patients and 2 (19%) from the placebo group became pneumoniae (PCP) infected in the INDS-1 group during 11,681 person-days, and 5 opportunistic infections (2 PCP's, 2 wasting syndromes, and 1 demiasis) developed in the placebo group during 3,916 person-days (rates 0.17 (INDS-1) vs 1.37 (placebo) infections per 1000 person-days, relative risk = 7.47, p=0.003).

Conclusions: Forty-one percent patients recovered DTH to TT after an average of 280 days of INDS-1 treatment. Patients initially in the INDS-1 group had better clinical outcome during and after the trial.

W.B.P.281 Inhibition of T Lymphocyte-Related functions by Imunitrol® through down regulation of prostaglandin secretion by monocytes/macrophages.

Authors: M. El-Medany, Dailou, A.H., Bertho, I.M. and Debré, C.HU Pitié-Salpêtrière, Paris, France.

Objective: Description of immunomodulating effect of Imunitrol® (iodium diiodate, DTC).

Methods: PHL, their adherent cells and T cells were assayed for their capacity to produce IL2 and PGE2 in response to PHA with/without 10^{-6} mg/ml Imunitrol®. The effect of Imunitrol on IL2 and PGE2 secretion by adherent cells was also evaluated using thymocytes assay and RIA method respectively.

Results: Imunitrol® increased proliferative responses of PHL to PHA as well as their ability to secrete IL2. This stimulating activity was not seen when these cells were depleted from their adherent cells. In addition, Imunitrol displayed high inhibitory effect on PGE2 production by these cells but IL2 levels remained unchanged.

Conclusions: Imunitrol enhanced non T cell related functions through its ability to down regulate monocytes/macrophages derived PGE2 as these molecules were known to inhibit non T cell related functions and specially helper activities.

W.B.P.278 TREATMENT OF HIV-INFECTED PATIENTS WITH D-PIRACETAMINE - THERAPEUTIC CLINICAL AND IMMUNOLOGICAL RESULTS -

Authors: BERNHARDT, R. HINNE, A., LUDWIG, G., LUDWIG, M., NITZKE, M., JURY, A., ***
*Unit of Clinical Studies, *Institute for Clinical Microbiology and *** Institute for Clinical and Experimental Virology of the Berlin, G.F.R.

Objective: To evaluate the compatibility and clinical, immunological and virological efficacy of D-Piracetam before, during and after a 6-week therapy in HIV-1 seropositive patients (pts).

Methods: Prospective randomized placebo-controlled study, test criteria: lymphocyte-subsets (CD4+, CD8+, CD4+/CD8+), HIV-antibody, lymphocyte-proliferation test (LPT) after PHM and tetanus-antigen stimulation, pH antigen (Daport Co.) and HIV-infection in primary blood lymphocytes. **Results:** 101 pts (17 men) (13 homosexual, 11 v. drug users, age 27 to 62, v. CD4-cells 114, 111 E, 10 F) are randomized to either placebo (n=50) or D-Pir (resulting ratings: 600,100,200 wU/l for 6 weeks orally, the HIV-antibody were generally high, but in 2 pts therapy was discontinued because of drug adverse reaction (fever, diarrhea/vomiting), no stage progression could be seen, the first test showed a slight reduction of lymphocyte subsets and lymphocyte proliferation test (LPT) before and the 6th week after therapy with D-Pir (CD4+/CD8+ ratio: 0.61/0.70/0.30, creatinine 0.80/0.90 wU/l (0.70/0.74), protein/day in urine 4,1/7.4 g/l (0.2/0.1), CD4+ lymphocytes 444/426/274 (1/0.4/0.5/0.7), CD8+ 105/101/121 (0.4/0.6/0.8), CD4+/CD8+ 4.1/3.9/3.9 (1.1/1.3/1.7/0.9), HIV-antibody 88/75/78/67 (1 (0.8/0.8/0.5/0.1) (11 weeks test p=0.38), no change was seen in the LPT, PHM 14/10/13 (2 v. test 0.6/0.7) (2 v. test). PHM antigen could only be detected in three pts. After therapy and seems to be of limited value for monitoring.

Conclusions: First results show a good compatibility of D-Pir in HIV-infected patients; the relevance of the observed alterations in the lymphocyte subsets is not clear yet.

W.B.P.280 EFFECT OF PROPRIOSENE ON HIV-ANTIGENEMIA

Authors: Lutz S. Teubner, S. Kroon, T. Moestruer, B.G. Hansen, B.F. Vestergaard, and Scandinavian Infection Study Group. *Hvidovre Hospital, Denmark, **Uppsala Hospital, Denmark, ***Malmö Almänna Sjukhus, Sweden, ****Statens Serum Institut, Denmark.

Objective: To evaluate the effect of Iproprisine on HIV-antigen levels.

Methods: A multicentre, double-blind placebo controlled study of Iproprisine was carried out in 21 clinical centers in Denmark and Sweden.

Eighty-four HIV-1 positive patients received treatment for 6 months with either Iproprisine 3 grams a day or matching placebo. The study population included anti-HIV-positive patients without AIDS. The patients were block randomized according to the number of CD4+ lymphocytes. Serum samples were collected at entry and during treatment and stored frozen for later antigen detection.

Results: The data will be presented and correlated with clinical and other immunological markers of disease progression.

W.B.P.282 A MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED DOSE RESPONSE TRIAL OF LF 1695 IN P24-ANTIBODY NEGATIVE PATIENTS.

Authors: Rouf, Berré*, Kanner, J.L.**, Demont, D.***, Fleury, H.****, Lang, J.M.****, Meunier, Y.**** and al.
*Scientific coordinator of the trial, Hôpital Militaire Bégin, Saint-Mandé, France; **Member of the trial, Centre de Recherche, Laboratoire Fournier, Dijon, France; *** CRISA, CEA, Fontenay aux roses, France; **** Hôpital Pellegrin, Bordeaux, France; ***** Hôpital Haapijervi, Strasbourg, France; ***** Centre Hospitalier, Tourcoing, France.

Objective: LF 1695 is a synthetic biological response modifier with immunostimulating and enhancing effects in animal as well as in human in-vitro and in-vivo. He has also shown in some in-vivo experiments an inhibitory effect on HIV-1 replication. On the basis of these findings, we conducted a clinical trial to evaluate the virological, immunological and clinical impact of LF 1695 in P24-antigen seropositive patients.

Methods: A multicenter randomized, double-blind, placebo-controlled, dose-response trial in progress in 60 HIV infected patients (CDC group II to IV), with a P24-antigen level higher than twice the cut-off level (Abbott). Patients receive twice a day a placebo or 120 mg or 240 mg of LF 1695 in capsules for three months. Parameters measured are reverse transcriptase level, P24-antigen, T-cell antigen expression, serum immunoglobulin and β_2 -microglobulin, clinical evolution and routine hematological and biochemical tests. Results: Forty seven of the 60 expected patients have actually entered the trial. **Conclusion:** Final results of this ongoing trial will be presented and discussed.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

W.B.P.301 Clinical efficacy of Isonthiol[®] (sodium dithiocarbamate) in HIV-infected patients.

A review of 4 controlled studies and long term follow-up.

CARLAB, JEAN The International AIDS Isonthiol study group (France, Germany, USA), Lyon France.

Between November 1983 and December 1986, more than 2100 HIV-infected patients have been enrolled in double-blind, placebo controlled studies of Isonthiol[®] (sodium dithiocarbamate, DTTC). To date, results from three controlled studies in 170 ARC patients are available and results from a study in 387 ARC patients and 150 AIDS patients in 8 US sites will be available before June 1988. In France, 1,600 asymptomatic/LA patients have been enrolled in a long term double-blind, placebo controlled study between July 1987 and July 1988. This study is ongoing. From the first three controlled studies (US, France, Germany), three clinical end points have reached statistical significance:

1. Isonthiol delayed progression to AIDS in ARC patients: 15 patients progressed to AIDS in the controlled group vs 2 in the Isonthiol group. This was statistically significant in the German study (p progression vs non, p < 0.05; Logrank test).
2. Isonthiol slowed down progression to CDC class in ARC patients.
3. Isonthiol induced regression in some constitutional symptoms of HIV-infection (group IV-A symptoms, lymphadenopathy, splenomegaly).

The US multicenter study on 372 patients is now terminating and results on major clinical efficacy endpoints will be available in June.

W.B.P.303 ACUTE RESPONSES TO AMPLIGN INFESTIONS IN HIV-INFECTED PEOPLE

Paris George J, Wang K, McMahon D, Armstrong JA, Rinaldo G, et al. Pittsburgh AIDS Clinical Trial Unit Investigators, University of Pittsburgh Medical Center, P.A.A.

OBJECTIVE: To report our clinical and laboratory observations in HIV-infected patients associated with acute reactions during intravenous infusions of synthetic sweetened double-strepted SEA (Amplign).

METHODS: Ten acute reactions (flushing, dysphoria, shivering, chills, fever and chest tightness) occurred in 3 of 17 persons receiving twice weekly infusions. Infusions were stopped temporarily during reactions then finished at a slower rate. No reactions required discontinuation of treatment.

RESULTS: Reactions were observed in 0/6 persons receiving 30 µg/ml, 1/6 receiving 40 µg/ml (person #2006) and 2/5 receiving 120 µg/ml (persons #217c and #219). Acute depressions of PMNs were observed as soon as reactions subsided (within 15 minutes) and as of reinfusions and were followed by leukocytosis. Leukocyte counts (x10⁹/ml) are summarized as follows:

patient	Pre-infusion	End-reaction	End-infusion	1-2 hrs. later
#2006 (3 obs.)	5.4	3.1	7.5	8.8
#217c (3 obs.)	6.7	3.1	7.5	9.3
#219	5.3	2.1	3.2	4.3

Granulocytes were mainly responsible for these changes. During 6/7 reactions cytotoxic activity of peripheral leukocytes against E261, 9337 and HIV-infected 4937 targets were depressed 2 hr post-reactions as compared to pre-infusion values. **CONCLUSIONS:** Acute leukopenia associated with amplign-infusion-reactions was followed by leukocytosis 1-2 hrs. later. Cytotoxicity against three different targets was also suppressed at 2 hours.

W.B.P.305 Neopterin and T-helper/neopterin ratio in the monitoring of long-term treatment of HIV-infected patients by Isonthiol[®]

Isidore Elmorh, D.T.C. Mordant, M. Bouchard, André Durkai, Anne Feltesse**
*Hôpital St-Anthoine (Service Prof. Frontier), **Laboratoire Durkai, St-Anthoine Medical, Paris and Lyon, France.

OBJECTIVE: To investigate whether urinary neopterin (UN) and T-helper (T_H) / UN ratio correlates with prognosis in long-term therapy by Isonthiol[®].

METHODS: 36 HIV-infected male homosexuals (age 37, range 22-45 years, weight 71 kg, range 57-86) were treated with Isonthiol[®] (10 mg/kg once a week) for a mean duration of 37 months (range 9-96 months), starting in August 1986. 21 belonged to group III and 15 to groups IV-A and IV-C at entry. 27 had less than 40 T_H cells at entry. Patients were monitored every 3 months. UN (µmol/l) was measured by HPLC and T_H cell count by immunofluorescence.

RESULTS: Among over 100 evaluations, the T_H/UN ratio correlated well with absolute T_H level. In 3 instances, an elevation of UN was seen without decrease of T_H count. This was related to associated infections. Under Isonthiol therapy, T_H/UN ratios increased in 30/36 patients, was stabilized in 20/36 patients and dropped in 6/36 patients. Only one of these 6 progressed to an AIDS-C2.

CONCLUSIONS: T_H/UN ratio is useful in monitoring progression of HIV-infected patients. It remains stable or increases in 30/36 patients treated with Isonthiol for prolonged periods of time.

W.B.P.302 TWO MONTH DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF CYCLOSPORIN IN HIV ASYMPTOMATIC SUBJECTS

J.E. Aboujaif J.M. Aronoff, J.A. Gustafson, P. Debre, B. Milpied-Hornet et al. Groupe INSERM CICL-074, FRANCE

OBJECTIVE: To evaluate, in a multicenter, double blind, placebo controlled trial, the short term effects of cyclosporin on peripheral CD4 counts.

METHODS: 68 HIV asymptomatic or lymphadenopathic seropositive patients with initial CD4 counts between 300 and 620/mm³ were randomly assigned to cyclosporin 7.5 mg/kg per day or placebo for a 8 week period of treatment. Doses were adapted in order to maintain trough blood levels ranging from 400 to 700 ng/ml. Cyclosporin dose was in average more than 6.8 mg/kg throughout the trial. The double blind design was achieved by adaptation of placebo doses of matched controls.

RESULTS: A significant (p<0.01) CD4 increase was observed in cyclosporin group compared to placebo at week 1 (148/mm³) and week 2 (146/mm³). Similar group was observed in CD4 cell and total lymphocyte counts, thus the proportions of CD4 and CD8 subsets and the CD4/CD8 ratio did not change. At week 8 CD4 cell counts were in average identical to the 2 groups. Side effects observed were mild and no adverse reaction to progression to AIDS or ARC occurred during the 4 month period (treatment and follow-up) of the trial.

CONCLUSIONS: The effect of cyclosporin on elevating CD4 + lymphocytes was limited to a treatment and weak increase not possible to come to a conclusion regarding the efficacy of a long term immunosuppressor treatment on the basis of the results of the 2 month trial.

W.B.P.304 Failure of isoprinostone in prevention of ARC to AIDS

Barbara, Dantai and Pragas, K. University of Texas Southwestern Medical Center at Dallas, Texas, U.S.A.

Objective: To determine the effect of an immunomodulator, isoprinostone (isoprinosin) in delaying the progression of disease in HIV seropositive male patients with CD4 counts of 200-400/mm³.

Methods: A prospective, multicenter, randomized, double blinded, placebo controlled clinical trial. 202 seropositive homosexual males were screened in Dallas County and 50 patients were entered into the study.

Results: 23 patients completed 12 months of the trial. 19 patients were discontinued; of these 8 discontinued themselves to go on AZT, and 11 were lost to follow-up. 9 patients endpoint with AIDS. 1 patient developed interstitial nephritis-one of the four reported adverse reactions.

Conclusions: Isoprinostone was ineffective in preventing the progression of ARC to AIDS. Overall, there was no toxicity noted but the drug failed to prevent the destruction of CD4 lymphocytes, development of HIV antigenemia and clinical deterioration. Further studies combining this agent with other antiviral need to be performed.

W.B.P.306 ZINCOPOLYMER AND LITHIUM CARBOANATE FOR HIV PATIENTS

MORILLON D, PORECZ S, LEVIN S, CORREAS J, HARR K, REINSTEIN G, BOYD J, DILLON G, de la Harpe J, Courteson, ALBERTINI G.

OBJECTIVE: It is well known the trophism of HIV, which affects the lymphocytes T4 and monocytes leading to immunodeficiency. A study was undertaken using ZINCOPOLYMER, a stimulator of lymphocyte maturation and a Gramicidin-monomelic colony forming unit activator (GFM-CDF) and Interleukin II *in vitro*, Lithium Carbamate.

METHODS: (1) seven patients infected with HIV; (2) two with demyelinating complex; (3) one with ARC; (1) one with AIDS (3) cases with LAS were 5 homosexual, 2 sexual blood transfusions; they were all males with an age average of 37 years). They had a positive serology for HIV and immunosuppression was showed up, caused by a fall of CD4 under 400 cell./mm³. They were treated with ZINCOPOLYMER 40 mg/kg/duraily and LITHIUM CARBOANATE 300mg./day during a 16 week period.

RESULTS: during the study period (2) two of the seven patients died because of demyelinating complex. The remaining under the treatment: protocol. All of the patients experienced physical improving. Four of these gained weight. Some of the patients experienced any kind of side-effects. There was an increase in the lymphocyte total level, monocyte and CD4.

CONCLUSIONS: After this study period we can conclude that the anti-HIV treatment is necessary for patients who experience a demyelinating complex. The remaining ones manifested a clinical improving. We conclude that ZINCOPOLYMER and LITHIUM CARBOANATE should be used for pre-AIDS, and anti-HIV association for patients on advanced AIDS stages.

Session d'attribution Poster Session



Aspects cliniques Clinical Aspects of AIDS

W.B.P.307 CASE REPORT OF DIDIZIFIRAM AS FIRST LINE THERAPY IN SEROPOSITIVE PATIENTS ATTENDING A COMMUNITY CLINIC
David L. Parson, F. Morgan A. Morris Jr. et al. Woodhull Medical and Mental Health Center, Brooklyn, NY, USA

Objective: To use didizifiram in treatment for HIV seropositive asymptomatic patients and explore if there is a significant correlative change between 74/78 ratio and/or absolute T4 count.
Method: Seropositive patients with 74/78 ratios less than 1.0 or absolute T4 counts <500 were started on didizifiram - a split weekly dosage of 1000 mg. 74/78 counts and ratios were followed every three months for a period of six months. Pre-treatment and post-treatment differences were evaluated by the Student's T test.
Results: In a sample of 10 patients on didizifiram alone, a comparison of 3rd and 9th month follow-up in the ratio of 74/78 cells, absolute T4 and absolute T4 counts reveals a statistically significant improvement at the .05 level with a one sided T test. Of these 10 patients, 8 had documented improvement in 74/78 ratio. Assuming a population probability of .5 the power to detect a difference is less than .5%. Sample size is small, a statistically significant difference was noted in seropositive patients on didizifiram treatment. These results suggest a large scale study of didizifiram should be initiated to further delineate the treatment effect.

W.B.P.309 RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF): A PHASE I TRIAL IN SEROPOSITIVE AIDS PATIENTS
James L. O'Brien, E. C. Concia, et al.
Flomenberg, B., Anselmo, V. and Sommer, E. Memorial Sloan-Kettering Cancer Center, New York, NY, USA and Schering Corporation, Kenilworth, NJ, USA.

Objective: To evaluate the safety, efficacy and biological activity of subcutaneously (SC) administered GM-CSF in AIDS patients (pts) who were asymptomatic as a result of treatment or their underlying disease.
Method: AIDS pts with ANC<500/mm³, PBMC, HbC, platelets >75,000 and CD4<50 were eligible. GM-CSF was given by daily SC injection for 10 days. After an 18 day rest, treatment was resumed for 28 days. Pts were then evaluated for maintenance treatment.
Results: Twelve pts have been entered at GM-CSF doses of 0.5, 1, 3 and 10 µg/kg/d. The median ANC was 900/mm³ (range 400-1700). Five pts were receiving AZT and 7 had maintained neutropenia after stopping AZT treatment. Dose-dependent increases in ANC were seen. Mean maximum ANC was 3467 (0.3 mg), 3813 (1mg) and 5239 (3mg). At each dose there was considerable variation in the ANC response and the degree of eosinophilia. Peak ANC's were generally lower in pts receiving AZT, but in some who had previously discontinued it, AZT could be reintroduced at reduced doses. Fever, malaise, weight loss and increased liver enzymes were observed in some pts. We see no evidence for stimulation of HIV, as measured by serum p24 antigen or cultures of peripheral blood cells; nor were there consistent effects on T cell subsets or the functions of NE cells, neutrophils or monocytes.
Conclusions: GM-CSF can reverse established neutropenia in AIDS pts. Given the variable response, optimal treatment may require dose titration.

W.B.P.311 AMELIORATION OF DETERIORATED POLYMOYONUCLEAR LEUCOCYTES (PMN) PROAGGREGATION FUNCTION OF MONOPHYTES WITH HIV INFECTION BY ADMINISTRATION OF LONG-CHAIN POLYUNSATURATED MONOPHENOLIC ESTER (LPEFAM)
Hideo Kuroki, Gohshi, K., Kishimoto, T. and Aki, T.
Department of Medicine, Tohoku University School of Medicine, Tokyo, Japan.

Objective: PMN phagocytic function (PMN-FC) of hemophiliacs (H) was evaluated in vitro and the effect of long-term treatment with lentinon on impaired PMN-FC was studied. **Method:** PMN-FC of long-term treated H with HIV infection was measured as the intensity of PMN chemiluminescence (PMN-CL) evolved from PMN when stimulated with opsonized *Syngeneis*(O) and/or phorbol myristate acetate (PMA). Ten mg of lentinon was injected (iv) to 7 H (5 AG, 1 AG & 1 HIV negative) with an impaired PMN-FC. **Results:** CL stimulated PMN-CL of 12 HIV positive as well as 17 HIV negative H was recorded to be deteriorated to 0.68 ± 0.31 & 0.74 ± 0.22 (normal range: 0.1-1.2) respectively. This tendency of deterioration was confirmed with PMA stimulated PMN in both HIV positive (0.74 ± 0.23) and negative (0.96 ± 0.24) groups. PMN-CL in 6 out of 7 H on long-term lentinon treatment was recovered to the near normal range within less than 3 months and this normalized PMN-CL was maintained for 6 to 28 months after cessation of the medication. Moderate to marked increase in CD4/CD8 ratio was observed in 11 patients. Long-term treatment with lentinon appears to have a therapeutic potential for HIV infected individuals with impaired PMN-FC by which PMN dysfunction is corrected and the onset of opportunistic infection is prevented. On the basis of these results, open trial of lentinon for HIV infected patients has just started in 10 medical universities and hospitals throughout Japan.

W.B.P.308 IMMUNOLOGIC AND VIROLOGIC PARAMETERS IN HIV INFECTED PATIENTS (PI) TREATED WITH ZIDOVUDINE (ZDV) AS PART OF A MULTICENTER PHASE III STUDY
John M. Coombs, Richard Schoen, R. Mai, D. Solomon, G. Prasad, D. Hughes, J. Fischl, J. Fischl, et al.
The George Washington University Medical Center, Washington, DC, USA

Objective: To assess the effect of ZDV on immunologic and virologic parameters in HIV infected patients (PI) treated with ZDV as part of a multicenter phase III study. **Method:** PI were randomized double-blind, placebo-controlled, crossover (9 control pts in the ZDV group, 9 control pts in the placebo group, HIV seropositive, ages 18-65 years, CD4 counts 100-500/mm³, HIV RNA levels >100 copies/ml). **Results:** Mean CD4 count of 600/pts in control group of which 10 were treated at our center. Mean CD4 count in the ZDV group was 79. **Conclusions:** 6 months of ZDV treatment resulted in a mean increase in CD4 count of 100/mm³. **Table:**

Test	Mean	SEM	Range	CD4		p	CD8	p	CD4/CD8	p
				Control	ZDV					
CD4	600	100	100-1000	79	100	<.05	1000	<.05	1.67	<.05
CD8	1000	100	500-1500	1000	1000	NS	1000	NS	1.67	NS
CD4/CD8	1.67	0.1	1.0-2.0	1.67	1.67	NS	1.67	NS	1.67	NS
HIV RNA	1000	100	10-1000	100	100	<.05	1000	<.05	1.67	<.05

Conclusions: 6 months of ZDV treatment resulted in a mean increase in CD4 count of 100/mm³. **Table:**

Test	Mean	SEM	Range	CD4		p	CD8	p	CD4/CD8	p
				Control	ZDV					
CD4	600	100	100-1000	79	100	<.05	1000	<.05	1.67	<.05
CD8	1000	100	500-1500	1000	1000	NS	1000	NS	1.67	NS
CD4/CD8	1.67	0.1	1.0-2.0	1.67	1.67	NS	1.67	NS	1.67	NS
HIV RNA	1000	100	10-1000	100	100	<.05	1000	<.05	1.67	<.05

Conclusions: 6 months of ZDV treatment resulted in a mean increase in CD4 count of 100/mm³. **Table:**

Test	Mean	SEM	Range	CD4		p	CD8	p	CD4/CD8	p
				Control	ZDV					
CD4	600	100	100-1000	79	100	<.05	1000	<.05	1.67	<.05
CD8	1000	100	500-1500	1000	1000	NS	1000	NS	1.67	NS
CD4/CD8	1.67	0.1	1.0-2.0	1.67	1.67	NS	1.67	NS	1.67	NS
HIV RNA	1000	100	10-1000	100	100	<.05	1000	<.05	1.67	<.05

Conclusions: 6 months of ZDV treatment resulted in a mean increase in CD4 count of 100/mm³. **Table:**

Test	Mean	SEM	Range	CD4		p	CD8	p	CD4/CD8	p
				Control	ZDV					
CD4	600	100	100-1000	79	100	<.05	1000	<.05	1.67	<.05
CD8	1000	100	500-1500	1000	1000	NS	1000	NS	1.67	NS
CD4/CD8	1.67	0.1	1.0-2.0	1.67	1.67	NS	1.67	NS	1.67	NS
HIV RNA	1000	100	10-1000	100	100	<.05	1000	<.05	1.67	<.05

Conclusions: 6 months of ZDV treatment resulted in a mean increase in CD4 count of 100/mm³. **Table:**

Test	Mean	SEM	Range	CD4		p	CD8	p	CD4/CD8	p
				Control	ZDV					
CD4	600	100	100-1000	79	100	<.05	1000	<.05	1.67	<.05
CD8	1000	100	500-1500	1000	1000	NS	1000	NS	1.67	NS
CD4/CD8	1.67	0.1	1.0-2.0	1.67	1.67	NS	1.67	NS	1.67	NS
HIV RNA	1000	100	10-1000	100	100	<.05	1000	<.05	1.67	<.05

Conclusions: 6 months of ZDV treatment resulted in a mean increase in CD4 count of 100/mm³. **Table:**

Test	Mean	SEM	Range	CD4		p	CD8	p	CD4/CD8	p
				Control	ZDV					
CD4	600	100	100-1000	79	100	<.05	1000	<.05	1.67	<.05
CD8	1000	100	500-1500	1000	1000	NS	1000	NS	1.67	NS
CD4/CD8	1.67	0.1	1.0-2.0	1.67	1.67	NS	1.67	NS	1.67	NS
HIV RNA	1000	100	10-1000	100	100	<.05	1000	<.05	1.67	<.05

Conclusions: 6 months of ZDV treatment resulted in a mean increase in CD4 count of 100/mm³. **Table:**

Test	Mean	SEM	Range	CD4		p	CD8	p	CD4/CD8	p
				Control	ZDV					
CD4	600	100	100-1000	79	100	<.05	1000	<.05	1.67	<.05
CD8	1000	100	500-1500	1000	1000	NS	1000	NS	1.67	NS
CD4/CD8	1.67	0.1	1.0-2.0	1.67	1.67	NS	1.67	NS	1.67	NS
HIV RNA	1000	100	10-1000	100	100	<.05	1000	<.05	1.67	<.05

Conclusions: 6 months of ZDV treatment resulted in a mean increase in CD4 count of 100/mm³. **Table:**

Test	Mean	SEM	Range	CD4		p	CD8	p	CD4/CD8	p
				Control	ZDV					
CD4	600	100	100-1000	79	100	<.05	1000	<.05	1.67	<.05
CD8	1000	100	500-1500	1000	1000	NS	1000	NS	1.67	NS
CD4/CD8	1.67	0.1	1.0-2.0	1.67	1.67	NS	1.67	NS	1.67	NS
HIV RNA	1000	100	10-1000	100	100	<.05	1000	<.05	1.67	<.05

Conclusions: 6 months of ZDV treatment resulted in a mean increase in CD4 count of 100/mm³. **Table:**

Test	Mean	SEM	Range	CD4		p	CD8	p	CD4/CD8	p
				Control	ZDV					
CD4	600	100	100-1000	79	100	<.05	1000	<.05	1.67	<.05
CD8	1000	100	500-1500	1000	1000	NS	1000	NS	1.67	NS
CD4/CD8	1.67	0.1	1.0-2.0	1.67	1.67	NS	1.67	NS	1.67	NS
HIV RNA	1000	100	10-1000	100	100	<.05	1000	<.05	1.67	<.05

Conclusions: 6 months of ZDV treatment resulted in a mean increase in CD4 count of 100/mm³. **Table:**

Test	Mean	SEM	Range	CD4		p	CD8	p	CD4/CD8	p
				Control	ZDV					
CD4	600	100	100-1000	79	100	<.05	1000	<.05	1.67	<.05
CD8	1000	100	500-1500	1000	1000	NS	1000	NS	1.67	NS
CD4/CD8	1.67	0.1	1.0-2.0	1.67	1.67	NS	1.67	NS	1.67	NS
HIV RNA	1000	100	10-1000	100	100	<.05	1000	<.05	1.67	<.05

Conclusions: 6 months of ZDV treatment resulted in a mean increase in CD4 count of 100/mm³. **Table:**

Test	Mean	SEM	Range	CD4		p	CD8	p	CD4/CD8	p
				Control	ZDV					
CD4	600	100	100-1000	79	100	<.05	1000	<.05	1.67	<.05
CD8	1000	100	500-1500	1000	1000	NS	1000	NS	1.67	NS
CD4/CD8	1.67	0.1	1.0-2.0	1.67	1.67	NS	1.67	NS	1.67	NS
HIV RNA	1000	100	10-1000	100	100	<.05	1000	<.05	1.67	<.05

Conclusions: 6 months of ZDV treatment resulted in a mean increase in CD4 count of 100/mm³. **Table:**

Test	Mean	SEM	Range	CD4		p	CD8	p	CD4/CD8	p
				Control	ZDV					
CD4	600	100	100-1000	79	100	<.05	1000	<.05	1.67	<.05
CD8	1000	100	500-1500	1000	1000	NS	1000	NS	1.67	NS
CD4/CD8	1.67	0.1	1.0-2.0	1.67	1.67	NS	1.67	NS	1.67	NS
HIV RNA	1000	100	10-1000	100	100	<.05	1000	<.05	1.67	<.05

Conclusions: 6 months of ZDV treatment resulted in a mean increase in CD4 count of 100/mm³. **Table:**

Test	Mean	SEM	Range	CD4		p	CD8	p	CD4/CD8	p
				Control	ZDV					
CD4	600	100	100-1000	79	100	<.05	1000	<.05	1.67	<.05
CD8	1000	100	500-1500	1000	1000	NS	1000	NS	1.67	NS
CD4/CD8	1.67	0.1	1.0-2.0	1.67	1.67	NS	1.67	NS	1.67	NS
HIV RNA	1000	100	10-1000	100	100	<.05	1000	<.05	1.67	<.05

Conclusions: 6 months of ZDV treatment resulted in a mean increase in CD4 count of 100/mm³. **Table:**

Test	Mean	SEM	Range	CD4		p	CD8	p	CD4/CD8	p
				Control	ZDV					
CD4	600	100	100-1000	79	100	<.05	1000	<.05	1.67	<.05
CD8	1000	100	500-1500	1000	1000	NS	1000	NS	1.67	NS
CD4/CD8	1.67	0.1	1.0-2.0	1.67	1.67	NS	1.67	NS	1.67	NS
HIV RNA	1000	100	10-1000	100	100	<.05	1000	<.05	1.67	<.05

Conclusions: 6 months of ZDV treatment resulted in a mean increase in CD4 count of 100/mm³. **Table:**

Test	Mean	SEM	Range	CD4		p	CD8	p	CD4/CD8	p
				Control	ZDV					
CD4	600	100	100-1000	79	100	<.05	1000	<.05	1.67	<.05
CD8	1000	100	500-1500	1000	1000	NS	1000	NS	1.67	NS
CD4/CD8	1.67	0.1	1.0-2.0	1.67	1.67	NS	1.67	NS	1.67	NS
HIV RNA	1000	100	10-1000	100	100	<.05	1000	<.05	1.67	<.05

Conclusions: 6 months of ZDV treatment resulted in a mean increase in CD4 count of 100/mm³. **Table:**

Test	Mean	SEM	Range	CD4		p	CD8	p	CD4/CD8	p
				Control	ZDV					
CD4	600	100	100-1000	79	100	<.05				

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

W.B.P.319 ALLOGENEIC BONE MARROW TRANSPLANTATION (BMT) PLUS AZIDOTHYDINE (AZT) IN THE AIDS PATIENT WITH NON-SPREADING LYMPHOMA (NSL)

Holland WK, Rossi J¹, Romnesshae AD, Zia JAM², Santos GP, and Sarai N³
¹The Johns Hopkins University, Baltimore, MD, USA
²City of Hope National Medical Center, Duarte, CA, USA

Objective: To evaluate the effect of combined modality therapy (AZT plus allogeneic BMT) on HIV-1 infection in a lymphoma patient with AIDS. **Methods:** The patient, a 41 yo HIV-1 culture⁺ man with NSL, received cyclophosphamide and total body irradiation to ablate tumor, bone marrow and marrow-derived cells. AZT (5 mg/kg q 6h) was begun 2 wks prior to BMT. Nine days after initiation of ablative therapy he received 6x10⁶ nucleated BM cells/kg from his HLA-identical sister. At this time AZT was reduced to 1.5 mg/kg q 6h and administered at that level for the duration of treatment. HIV-1 was monitored by serial and polymerase chain reaction gene amplification (PCR, LTR and ENV, DNA and reverse transcriptase RNA).

Results: Despite continuous AZT, engraftment was prompt (13 days to neutrophil count >500/mm³). Peripheral blood mononuclear cells and BM samples became HIV-1 negative by culture and PCR 33 days after BMT. The patient died of tumor relapse 67 days after BMT. Complete autopsy showed no evidence of HIV-1 by PCR (brain, MI, spleen, tumor, heart, kidney, liver, lung, colon) or culture (brain, MI, lymph node, tumor).

Conclusions: 1) The patient tolerated ablative therapy associated with BMT. 2) Prompt engraftment was attained despite AZT therapy. 3) PCR and culture data suggest clearance of host cells harboring virus and prevention of infection of repopulating donor cells.

W.B.P.321 EFFECT OF COMBINATION OF ZIDOVUDINE AND INTERFERON-ALPHA COMPARED WITH ZIDOVUDINE AND ACYCLOVIR ON HIV-1 RNA IN ASYMPTOMATIC PATIENTS

Yahr, Rainer, Rosenthal, A., Lishy, R., Pugh, R., Sowers, R., and Siegelbauer, W.
 Department of Medicine, University Hospital, Zürich, Switzerland; *Wilhelms Research Laboratories, Muenchen, Germany

Objective: To assess the antiviral effect of zidovudine (AZT) in combination with either zidovudine interferon (AZT/IFN) or zidovudine acyclovir (AZT/ACV) in HIV-1 infected patients. **Methods:** 15 pts in CDC stage I/II with positive p24 antigen were randomized to receive 12 weeks AZT 250mg bid and either ACV 240mg bid or IFN 12 MU 3x wk. 3wks follow-up. Following a washout period of one month, 8 pts (pts 1,2,4,5,6,7,8,9) agreed to continue with a crossover phase. Antiviral activity was assessed by measuring serum p24 antigen levels. Results in 24 antigen levels (Abbott EIA) recorded as a coefficient were:

AZT/IFN wash- AZT/ACV		AZT/IFN wash- AZT/IFN	
wk 0	wk 12	wk 0	wk 12
pt 1	11.52	1.62	1.474
pt 2	1.30	0.59*	1.52
pt 3	2.50	1.14	1.41
pt 4	2.13	1.28	1.87
pt 5	1.94	0.99*	1.12
pt 6	3.84	1.08	2.37
pt 7	1.42	1.42	1.42
pt 8	5.52	3.37*	9.07
pt 9	1.91	1.17	2.73
pt 10	1.41	1.22*	2.73
pt 11	4.97	3.90*	4.99
pt 12	1.86	1.23	1.23
pt 13	2.86	1.23	1.23

*p < 0.05 - not diff
 **NEQ < 0.09
 [pt 14 and 15 discontinued due to side effects
 p24 antigen was transiently negative during AZT/IFN at wk 1 and 2 in pts 3 and 7, respectively. Temporary mild neutropenia occurred in 3 pts with AZT/IFN.
Conclusions: P24 antigen declined in all pts with the above dose regimens. Preliminary results suggest a superior antiviral effect of AZT/ACV, but require dose range finding studies and continuation of treatment to evaluate clinical long term benefit.

W.B.P.323 AN OPEN-LABEL STUDY OF THE SAFETY AND EFFICACY OF CO-ADMINISTRATION OF ZIDOVUDINE AND RECOMBINANT INTERFERON-ALPHA

Burgin, Michael J., and Pallares, R.S., Division of Infectious Diseases, UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON, U.S.A.

Objective: A phase 1 study of the long-term tolerance of recombinant Interferon- α -beta (Betanase) at doses of 6 or 30 million units when administered subcutaneously as a daily basis to HIV-infected individuals receiving 200mg of zidovudine (ZDV) every four hours.

Methods: Seventeen patients were sequentially been maintained on ZDV alone, for standard indications, were enrolled in the study: 8 patients at 60 million and 9 patients at 30 million units per day (MU/D).

Results: Seven of the 17 patients have terminated from the study: 1 expired, 1 of the remainder terminated due to local skin reactions and/or systemic symptoms such as fevers and malaise. Four of 8 patients enrolled at 90 MU/D underwent dosage reduction, 3 of these secondary to increased hepatic transaminases. In the entire group, an overall 100% increase in transaminases was seen, which peaked at 12 to 16 weeks of therapy. Other toxicities, particularly myelotoxicity (1 of 17 patients) were infrequently observed.

The total white blood cell counts after 2-4 weeks of therapy were approximately equivalent to the patients' entry values. An AIDS-associated opportunistic infection or neoplasm occurred in 7 patients.

Conclusions: Full-dose ZDV and Recombinant-IFN-beta-ser at doses of 45 to 90 million units/day are well tolerated for periods of 40 weeks. In the 17-patient study, patients receiving IFN-beta tolerated full dose ZDV well, without significant myelotoxicity. Prospective, controlled studies are needed to assess the efficacy of this combination.

W.B.P.320 AS 101 IN ASSOCIATION WITH AZT IN AIDS PATIENTS: A PHASE I PILOT STUDY.

J.H. LAURENT, J. PRITCHARD, D. CHODURA, J. J. MONTANO, R. LANGRISH, A. KOPPEL & S. G. DE LUCA

* St Antoine Cooperative Group in AIDS (FRENCH FRENCH)
 ** The Dana University, Haem Onc Dept.

Immersion clinical and biological results have been obtained with AS 101 (a new immunophilin analog) in AIDS patients. However in an effort to further improve patients with advanced disease, we tried to associate AZT with AS 101. 5 patients (all male) were stopped. Hematological tolerance in the 3 other patients was good. 1 patient incurred AS 101 or AZT level, but he had tuberculosis of the liver. We observed no stress of the other biological parameters. In 3 patients the clinical status improved. Further data of AS 101-AZT association will be provided.

W.B.P.322 ZIDOVUDINE VS. ALPHA INTERFERON VS. THE COMBINATION IN PATIENTS WITH BETA2 MICROGLOBULIN NEGATIVE HIV INFECTION

Harley, Richard M., Dewey, Robert J., J., Meier, H., Paauw, A.S., Lamm, H.C., et al. National Institutes of Health, Bethesda, MD, USA.

Objective: To compare the effects of zidovudine (AZT), alpha interferon (IFN), and a combination of these 2 drugs in delaying the progression of HIV disease.

Methods: HIV-infected persons with >500 CD4 count/mm³ and no history of cytotoxic infection (CI) are being entered in this trial. Following a screening evaluation that includes HIV serology, HIV culture, p24 antigen, polymerase chain reaction (PCR), and immune profile, patients are randomized to either AZT alone (200 mg qd), IFN alone (5x10⁶ IU 3x/week increase as tolerated), or a combination of the 2 (AZT 100 mg qd + IFN 1x10⁶ IU 3x/week increase as tolerated). End point criteria include a decline in CD4 cells to <200/mm³ or the first occurrence of an AIDS-defining CI.

Results: The patients enrolled thus far (n=300) have a mean age of 35 (26-49) and a mean CD4 count of 696 cells/mm³ (515-1293). Eight of 30 have had a positive (+) culture for HIV and 2/30 have been p24 antigen +. Unlabeled primer pairs from env, LTR and gag regions, 26/28 have been + by PCR.

Conclusions: Patients with early HIV infection and CD4 cells >500/mm³ almost uniformly have demonstrable virus by PCR testing. However, HIV culture and p24 antigen are generally negative, suggesting that the patients have a low viral burden. The data generated over the next 6 months should permit an evaluation of the relative toxicities and a preliminary evaluation of the efficacies of AZT, IFN, and the combination in delaying the progression of HIV disease.

W.B.P.324 EFFECTS OF A COMBINED DETRANESULFATE/ZIDOVUDINE THERAPY COMPARED TO ZIDOVUDINE MONOTHERAPY IN AIDS

ROCHESTER, H. HERRING, J.L., GOOD, M.
 Dept. of Dermatology, University of Essex, UK

18 HIV infected patients (status WB 6) were randomly allocated to combined (detransulfate (800 mg/d) zidovudine (800 mg/d) therapy (DZ) or a zidovudine (800 mg/d) monotherapy (Z). Each group consisted of 9 patients, age 25 to 35 years, with equivalent amounts of CD4 lymphocytes in both groups prior to therapy.

Before and every 8 weeks during the treatment period we performed a complete history and physical examination, standard medical tests of enzymes, kidney, liver and blood parameters, isolation and enumeration of lymphocytes and lymphocyte subsets, assessment of complement components, immunoglobulin and immune complexes in serum as well as measurement of in vitro lymphocyte blastogenic response to mitogens.

Evaluation of the first 6 months of the study revealed 1 relapse of pneumocystis carinii pneumonia in each group. No alterations were found concerning the individual HIV antibodies and p24 antigen levels. Apart from an initially more profound improvement of immunostatus after 8 weeks of DZ compared to Z there were no differences between the two groups at the first and second months of study. Detranesulfate application did neither enhance adverse effects nor of zidovudine therapy nor of the disorders of blood coagulation. The study is still in progress.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

W.B.P.331 ZIDOVUDINE (AZT) TREATMENT OF THE AIDS GENITAL COMPLEX (AGC) - RESULTS OF A PLACEBO-CONTROLLED, MULTICENTERED THERAPEUTIC TRIAL

Prings, Richard H.; Spector, R.A.; Frimberg, J.; Collier, A.; Kennedy, C.; Singer, E.; Price, S.; and AIDS Clinical Trials Group, NIAID, Bethesda, MD, U.S.A.

Objective: To determine the efficacy of AZT in alleviating mild to moderate AGC in HIV-1-infected patients with relatively preserved CD4⁺ cells.

Methods: 40 patients with mild to moderate AGC from 9 centers were randomized to 3 treatment arms: AZT 400mg 5/day, AZT 200mg 5/day, or placebo 5/day. We report the results of preliminary analysis of the initial 16-week phase of the trial comparing the 2 AZT groups (which remain blinded) to the placebo group. Therapeutic efficacy was evaluated using standardized serological assessments of genital tract "microbiological" tests.

Results: This phase of the trial was administratively aborted before the planned accrual. 27 patients completed 8 weeks and 24 completed 16 weeks of the trial; 12 patients were prematurely terminated when the trial was aborted while 2 suffered adverse events and 4 withdrew from the study. The 3 groups were well balanced with respect to baseline parameters including CD4⁺ counts (entry mean, 525). While there was no appreciable change in the overall classification of AGC severity across the 3 groups and individual test comparisons were significant (p<.05) in only 2 of 8 neurophysiological tests at 16 weeks, the placebo group exhibited the least favorable change in 7 of the 8 tests at 8 weeks and in 8 tests at 16 weeks.

Conclusion: Despite the small sample size, these data support a therapeutic effect of AZT in improving neurophysiological performance in AGC patients. Further analysis will be needed to determine whether this is dose-related.

W.B.P.333 SURVIVAL OF PATIENTS WITH HIV DISEASE TREATED WITH ZIDOVUDINE (AZT)

Sheng, David; Lapan, M.; Haggan, C.; Smith, M.; Lammert, M.; Cornell, U. Medical College, March Dunes U. Hospital, Lees Summit, MO., USA.

Objective: To determine the probability of survival in patients with HIV disease treated with zidovudine (AZT).

Methods: From 11/86 through 12/87, patients meeting current CDCR indications for treatment received AZT. Initial dose used was 1-1, 200mg/day, with reductions made at the discretion of the physicians when patients experienced toxicity. Survival was calculated using Kaplan-Meier plots.

Results: 116 patients with the following characteristics were treated: 96 male, 20 female, 54 gay, 47 IVDA, 15 other risk, 100 white, 16 non-white, median age 37. The indication for treatment was AIDS in 60 and 7-helper depletion (HD) in 56. The median follow-up was 68 weeks. Survival at 26, 52, and 78 weeks was 89, 76, and 64%, respectively. Median survival was 94 weeks. Patients with AIDS before HD survived better than those starting AZT within 8 weeks of the HD-defining CD4⁺ count (89 vs. 82 vs. 78 weeks, p<.02). Among patients with AIDS, those starting AZT within 8 weeks of the HD-defining CD4⁺ count (89 vs. 82 vs. 78 weeks, p<.02). When those starting later were excluded, survival was 87, 84 and 76% at 26, 52 and 78 weeks. Survival was not different when analyzed by sex, risk factor, or age >40. A trend toward worse survival in non-white did not reach significance.

Conclusion: This study provides survival data useful for prognostication in patients treated with AZT according to current practices. Because survival is improved in those treated early or early after diagnosis of AIDS, initiation of AZT therapy should not be delayed.

W.B.P.335 A PHASE III TRIAL OF THE COMBINATION OF ZIDOVUDINE AND INTERFERON-2 IN THE TREATMENT OF HIV-RELATED KAPAPSI SARCOMA

Kovacs, Joseph A.; Pines, M.; Gantch, E.; Paves, A.S.; Lane, H.C.; et al. National Institutes of Health, Bethesda, Maryland, USA.

Objective: To evaluate the toxicity and efficacy of the combination of zidovudine and interferon-2 in the treatment of HIV-infected patients with Kaposi's sarcoma.

Methods: In an open study, patients with HIV infection documented by ELISA, western blot HIV-1 antibody, and positive HIV RNA were begun on zidovudine 200 mg q6h. After six weeks, the patients were begun on continuous infusions of 1-2 for 3 weeks, during which time zidovudine therapy was continued. Group 2 patients were treated with increasing doses of 1-2, beginning at 200,000 U/d, until the maximum tolerated dose was determined. The combination of drugs was evaluated for toxicity and efficacy by weekly monitoring of routine blood values, including CBC and chemistry, as well as CD4 count, p24 antigen and HIV culture. Results: Three patients have completed the study to date, all at a dose of 250,000 U/d of 1-2. No significant toxicity has been seen, although 1 patient had recurrent bacteremia due to infected central lines. No significant immunostimulating or anti-retroviral effects have been seen at this dose of 1-2. Two patients remained HIV culture positive, as a patient with p24 antigenemia had no change in antigen levels during 1-2 therapy. **Conclusion:** 1-2 can be safely administered at a low dose in combination with zidovudine. Complete remission will determine if higher doses of 1-2 can also be safely administered, and if there is a beneficial effect seen during combination therapy.

W.B.P.332 STUDY COMPLIANCE AMONG ASYMPTOMATIC HIV SEROPositIVES (ASX HIV) BEING TREATED WITH AZIDOVUDINE (AZT)

Jacobson, Paul R.; Vaseleski, C.; Brown, D.; Gottlieb, K.; Pilgones, G. A.; & Teitel, S. Fenwal Bio-Science-Kettering Cancer Center, New York, New York, U.S.A.

Objective: To measure compliance and identify factors related to degree of compliance among participants in an experimental trial of the efficacy of AZT in preventing/retarding the development of AIDS.

Methods: Twenty (19 male, 1 female) ASX HIV enrolled in a double-blinded, placebo controlled trial in which 3 doses (3 capsules each) per day of high or low dose AZT or placebo were prescribed (AZTC Protocol 019) completed daily forms assessing missed doses and physical symptoms for an average of 60 days (Range=40 to 162) and underwent brief psychological assessment.

Results: Subjects reported missing an average of 5% (Range=0-24%) of all doses. Average number of missed doses per day was approximately 1.15 capsules, with the last dose of the day the most frequently missed - average of 1/3 of the time. No subject dropped out or reported using other prescribed treatments during the period of study. More missed doses were significantly (p<.05) correlated with younger age, nausea, diarrhea, psychological distress, and health beliefs.

Conclusions: Data from our center indicate that, while drop-out among ASX HIV enrolled in a placebo-controlled AZT study is not encountered, missed medication doses are common. Patient self-monitoring provides a useful means of estimating missed doses and investigating the determinants of noncompliance.

W.B.P.334 Reduction of Zidovudine Side Effects by an Intermittent Therapy Scheme

Slingsby, D.; Oswald, J.; Gottlieb, A.; Rehmert, D.; Hein, E.B.;

Hille, W. Universitätsklinik Frankfurt am Main, Frankfurt am Main, Germany.

Medizin, Infektions-Abteilung, FHO

15 in 4 dosage from 1000 - 1200 mg/d. Zidovudine (AZT), in spite of its life prolonging effect, causes myelotoxic side effects. By an intermittent therapy scheme with a drug-free regeneration period, these side effects on hematopoiesis might be avoided.

We therefore report on 16 patients (7 AIDS, 9 ARC) with an intermittent AZT regimen. Therapy scheme consists of application intervals (AI) of 4 wks (1000 - 1200 mg/d), followed by 4 weeks' break. At present, 16 patients have finished 2 AIs, and of these, 10 pts. have finished 3 AIs. Total observation time is 176 wk (median); min. 120, max 204 wk. Initial symptoms (nausea, headache) mainly occurred during 1st. AI and in only 2 of 15 cases also at early 2nd AI. Mean body weight increased > 10 % of initial value (from 68.0 median to 77.0 kg). Also the patients' physical and mental abilities improved significantly. CD4+ cell count increased by 37 % (median) after 1st AI, by 7 % after 2nd AI. During 3rd AI, it went down to initial value. HD and leucocytes were normal; anemia or leucopenia was not found. NCV was only slightly increased. Up to now, there have been no opportunistic infections nor death cases.

Conclusion: Intermittent AZT regimen, an continuous therapy, led to an increase in patients' well-being, and to transient increases in CD4+ cell count. However, the lack of any myelotoxic side effects was remarkable.

W.B.P.336 ZIDOVUDINE'S "M" INTERVENOUS DRUG USE. El-Jahed, Feres, G., Forrester, C., Tomson, R., Johnson, R.S., Saint-Richard's Medical Center, Newark, New Jersey, U.S.A.

Objective: To describe characteristics and effects of zidovudine usage in an intravenous drug user population.

Methods: A retrospective study of 43 patients studied from 2/78 through 7/88 who were followed bi-weekly in a clinic environment with complete cell counts (CBC) chemistry profiles and serological examinations.

Results: Seven patients never filled their prescriptions. Of the remaining 36 (10 males, 4 females) the mean duration of therapy was 6 months. CBC testing showed 14/36 with a significant decrease in white cell count, and 4/36 with a significant decrease in hemoglobin (all four with Mycobacterium Avium intracellulare infection). Subsequently 6/36 felt improvement with four showing greater than 10 pounds of weight gain, 7/36 had worsening of their condition with five developing Mycobacterium Avium-intracellulare infection. No patients showed improvement in CD4 cell counts and 0/8 showed decreases.

Conclusion: Leukopenia was the primary effect noted and Mycobacterium Avium-intracellulare infection the primary documented reason for deterioration on therapy. Side effects however are comparable to those reported in the homosexual cohorts studied.

**Session d'affichage
Poster Session**



W.B.P.343 **UPDATE ON AID THERAPY IN AN INNER CITY POPULATION.**
Samuels, J., Silson, R., Simon, V., and Small, C.B. **NYC Center Bronx Hospital/Honolulu**
Clinical Center/Albany State University, Albany, New York, U.S.A.
OBJECTIVE: To evaluate efficacy, toxicity and compliance (comp) with AZT therapy among patients (pts) of poor, minority and intravenous drug use (IVDU) background.
DESIGN: Prospective data was derived on all AIDS and ARC pts on AZT for at least 4 weeks from 7/87-1/89.
RESULTS: 99 pts were evaluable: 75 male, 24 female; 64 Hispanic, 25 black, 6 white, 2 Asian; IVDU 59; homosexual contacts 15; transfusion 1, no known risk for 7; AZT: 27 ARC with low CD4 count (130); mean age 35 (range 22-59); mean Kt 34 (range 21-54); MRC 4400 (range 1.8-10.7); baseline mean Karnofsky score 81.6 (range 50-100); 87/99 (88%) were comp and received AZT for a mean of 20.3 months (range 2-66 mo), 23% pts. All pts eventually received PCP prophylaxis. 57% had mild adverse drug reaction (ADR) requiring dose reduction (ADR) or cessation. Side effects included: anemia 17A (18.2%); neutropenia 17A (18.2%); leukopenia 33A; GI complaints 14%; headache 14%; fever 11%; rash 5%. Rates of anemia, transfusion, leukopenia, neutropenia and leukemia were comparable, and nausea and headache least frequent. Data in published studies of CD4% population ($p < .05$), 83/87 (95%) comp pts tolerated AZT for 4 wks. 17 opportunistic infections (OI) occurred in 14/93 (17%) at mean 28 wks (range 6-63 wks); 13/17 (76%) AZT occurred in pts on reduced AZT, 6/83 (7%) comp pts died (only 1 on full-dose AZT vs 6 on 1/2 dose) noncomp or intolerance pts ($p < .01$). 55A pts had 37% of clinic appointments; 108 kept 50-75%; only 28 kept 50%.
CONCLUSION: AZT can be administered to IVDU and others in inner city clinic settings with acceptable efficacy, tolerance and compliance.

W.B.P.344 **FOLLOWUP WITH ZIDOVUDINE IN A CITY CENTER, AIDS CLINIC**
Miller, Lamm, J., Newman, J., Davidson, A., Qian, S.,
Stewart, James Clinical Research, Denver, CO, USA

Objective: To evaluate the efficacy and toxicity of zidovudine (AZT) in patients (pts) with AIDS and ARC in Denver, Colorado.
Design: A retrospective chart review of clinic and hospital records at CRM was done for all pts started on AZT between Nov. 1986 and Jan. 1989. Follow-up was obtained through IDU, medical record method as well as the AZT and pre-AZT periods.
Results: A total of 137 pts received AZT, 117 less than 12w. Of the remaining 18, 9 had AIDS and 33 ARC at the time of initiation of AZT. AIDS pts were diagnosed 0-900 (mean 836) before starting AZT, ARC pts 0-1124 (mean 500). Pt took the drug for 35-980 (mean 204). Of 128 pts, 112/42% completed at least one adverse event (AE) requiring dose adjustment (mean 2.7 AE, range 1-348). AE included granulocytopenia (30), anemia (37), thrombocytopenia (4), malaise (38), GI intolerance (16), fever (30), rash (6), OI infection (7), headache (5). Of 128 pts, 27 (21%) required blood transfusions (range 2-12 units, mean 3 units/pk). AZT was discontinued (ID) in 18 pts (14%); 10-980 after initiation (mean 824). Reasons for ID included malaise (6), granulocytopenia (5), GI intolerance (3), fever (3), other opportunistic treatment (6), hepatic placement (4). Of the AIDS pts, 28 were followed from diagnosis to death at CRM and were hospitalized 0-4 times (mean 2.9). Twenty nine similar pts previously studied at CRM from 1982 through 1986 (pre-AZT) were hospitalized 1-16 (mean 3.1). At 51 months mean survival of 336 in pre-azt vs compared to 592 in the AZT pts ($p < .01$).
Conclusions: AZT significantly prolongs survival in AIDS pts although it is associated with adverse side effects leading to dose adjustment and ID of therapy. A retrospective analysis reveals to decrease in the number of hospitalizations since AZT has become available.

W.B.P.347 **BENEFITS OF AZT WHEN STARTED AT INCREASING TIMES**
AFTER AIDS/PCP DIAGNOSIS, 90 Rightingals, SE

Farland, Memphis, Tenn., U.S.A.
Parland, Memphis, Tenn., U.S.A.
The survival of 172 patients who had PCP at AIDS diagnosis and received AZT was analyzed by a retrospective case-control analysis, to evaluate of 149 controls who had PCP at AIDS diagnosis but did not receive AZT. Survival was compared from day AZT was begun or day of AIDS diagnosis, whichever came later. Control survival was calculated from day after AIDS diagnosis to matched case started on AZT. Survival of subjects who received aerosolized pentamidine (AP) was assessed at the day AP was begun. We specifically examined the difference in survival between cases and controls as a function of how long after AIDS/PCP the cases were started on AZT.

Days After PCP	Case	Control	P	
AZT begun	Survival	Survival	(Wilcoxon)	
0-9	88	508	<.02	
91-180	37	681	157	<.02
181-270	17	411	50	<.001
271-365	3	189	195	NS
>365	17	210	123	NS
All Cases	111	1388	4,000	<.0001

Within the limits of a retrospective case-control method and in the population studied, a statistically significant benefit of AZT was found only in the subset that began AZT within 270 days of AIDS/PCP.

**Aspects cliniques
Clinical Aspects of AIDS**

W.B.P.344 **REVENIR DE 345 MALADES ATTEINTS D'ARC OU DE SIDA**
41 TRAITES PAR AZT PENDANT 4 A 18 MOIS
Egid, Demare, Mathéron, S. Rouzeau, W. Kishon, C. Perronne C
Groupe d'Etude de l'AIDS, Centre de l'ARC, 140-115 Chem. de la Bienville, Paris, France

Objectif: Rechercher à moyen et long terme l'efficacité de l'AZT.
Méthodes: 345 malades atteints d'ARC (80) ou de SIDA (265) depuis 0,5 à 3 mois (médiane 4) ont été inclus dans cette série prospective. La notation initiale a été de 200 mg/6h, puis 240 mg/6h, de 200 mg/6h, puis 100 mg/6h en raison de leur état hématochimique...
Résultats: Chez les ARC, 6 et 3 S. 19 patients et 27 ID sont apparus 27,4 et 16,3 semaines après le début de l'AZT. Si 22 sont apparus 4 à 18 mois après le début de l'AZT, 18 sont apparus 16 à 22 mois après le début de l'AZT, 19 sont apparus 22 à 36 mois après le début de l'AZT, 11 sont apparus 36 à 60 mois après le début de l'AZT, 11 sont apparus 60 à 108 mois après le début de l'AZT, 11 sont apparus 108 à 180 mois après le début de l'AZT, 11 sont apparus 180 à 360 mois après le début de l'AZT, 11 sont apparus 360 à 720 mois après le début de l'AZT, 11 sont apparus 720 à 1080 mois après le début de l'AZT, 11 sont apparus 1080 à 1440 mois après le début de l'AZT, 11 sont apparus 1440 à 1800 mois après le début de l'AZT, 11 sont apparus 1800 à 2160 mois après le début de l'AZT, 11 sont apparus 2160 à 2520 mois après le début de l'AZT, 11 sont apparus 2520 à 2880 mois après le début de l'AZT, 11 sont apparus 2880 à 3240 mois après le début de l'AZT, 11 sont apparus 3240 à 3600 mois après le début de l'AZT, 11 sont apparus 3600 à 3960 mois après le début de l'AZT, 11 sont apparus 3960 à 4320 mois après le début de l'AZT, 11 sont apparus 4320 à 4680 mois après le début de l'AZT, 11 sont apparus 4680 à 5040 mois après le début de l'AZT, 11 sont apparus 5040 à 5400 mois après le début de l'AZT, 11 sont apparus 5400 à 5760 mois après le début de l'AZT, 11 sont apparus 5760 à 6120 mois après le début de l'AZT, 11 sont apparus 6120 à 6480 mois après le début de l'AZT, 11 sont apparus 6480 à 6840 mois après le début de l'AZT, 11 sont apparus 6840 à 7200 mois après le début de l'AZT, 11 sont apparus 7200 à 7560 mois après le début de l'AZT, 11 sont apparus 7560 à 7920 mois après le début de l'AZT, 11 sont apparus 7920 à 8280 mois après le début de l'AZT, 11 sont apparus 8280 à 8640 mois après le début de l'AZT, 11 sont apparus 8640 à 9000 mois après le début de l'AZT, 11 sont apparus 9000 à 9360 mois après le début de l'AZT, 11 sont apparus 9360 à 9720 mois après le début de l'AZT, 11 sont apparus 9720 à 10080 mois après le début de l'AZT, 11 sont apparus 10080 à 10440 mois après le début de l'AZT, 11 sont apparus 10440 à 10800 mois après le début de l'AZT, 11 sont apparus 10800 à 11160 mois après le début de l'AZT, 11 sont apparus 11160 à 11520 mois après le début de l'AZT, 11 sont apparus 11520 à 11880 mois après le début de l'AZT, 11 sont apparus 11880 à 12240 mois après le début de l'AZT, 11 sont apparus 12240 à 12600 mois après le début de l'AZT, 11 sont apparus 12600 à 12960 mois après le début de l'AZT, 11 sont apparus 12960 à 13320 mois après le début de l'AZT, 11 sont apparus 13320 à 13680 mois après le début de l'AZT, 11 sont apparus 13680 à 14040 mois après le début de l'AZT, 11 sont apparus 14040 à 14400 mois après le début de l'AZT, 11 sont apparus 14400 à 14760 mois après le début de l'AZT, 11 sont apparus 14760 à 15120 mois après le début de l'AZT, 11 sont apparus 15120 à 15480 mois après le début de l'AZT, 11 sont apparus 15480 à 15840 mois après le début de l'AZT, 11 sont apparus 15840 à 16200 mois après le début de l'AZT, 11 sont apparus 16200 à 16560 mois après le début de l'AZT, 11 sont apparus 16560 à 16920 mois après le début de l'AZT, 11 sont apparus 16920 à 17280 mois après le début de l'AZT, 11 sont apparus 17280 à 17640 mois après le début de l'AZT, 11 sont apparus 17640 à 18000 mois après le début de l'AZT, 11 sont apparus 18000 à 18360 mois après le début de l'AZT, 11 sont apparus 18360 à 18720 mois après le début de l'AZT, 11 sont apparus 18720 à 19080 mois après le début de l'AZT, 11 sont apparus 19080 à 19440 mois après le début de l'AZT, 11 sont apparus 19440 à 19800 mois après le début de l'AZT, 11 sont apparus 19800 à 20160 mois après le début de l'AZT, 11 sont apparus 20160 à 20520 mois après le début de l'AZT, 11 sont apparus 20520 à 20880 mois après le début de l'AZT, 11 sont apparus 20880 à 21240 mois après le début de l'AZT, 11 sont apparus 21240 à 21600 mois après le début de l'AZT, 11 sont apparus 21600 à 21960 mois après le début de l'AZT, 11 sont apparus 21960 à 22320 mois après le début de l'AZT, 11 sont apparus 22320 à 22680 mois après le début de l'AZT, 11 sont apparus 22680 à 23040 mois après le début de l'AZT, 11 sont apparus 23040 à 23400 mois après le début de l'AZT, 11 sont apparus 23400 à 23760 mois après le début de l'AZT, 11 sont apparus 23760 à 24120 mois après le début de l'AZT, 11 sont apparus 24120 à 24480 mois après le début de l'AZT, 11 sont apparus 24480 à 24840 mois après le début de l'AZT, 11 sont apparus 24840 à 25200 mois après le début de l'AZT, 11 sont apparus 25200 à 25560 mois après le début de l'AZT, 11 sont apparus 25560 à 25920 mois après le début de l'AZT, 11 sont apparus 25920 à 26280 mois après le début de l'AZT, 11 sont apparus 26280 à 26640 mois après le début de l'AZT, 11 sont apparus 26640 à 27000 mois après le début de l'AZT, 11 sont apparus 27000 à 27360 mois après le début de l'AZT, 11 sont apparus 27360 à 27720 mois après le début de l'AZT, 11 sont apparus 27720 à 28080 mois après le début de l'AZT, 11 sont apparus 28080 à 28440 mois après le début de l'AZT, 11 sont apparus 28440 à 28800 mois après le début de l'AZT, 11 sont apparus 28800 à 29160 mois après le début de l'AZT, 11 sont apparus 29160 à 29520 mois après le début de l'AZT, 11 sont apparus 29520 à 29880 mois après le début de l'AZT, 11 sont apparus 29880 à 30240 mois après le début de l'AZT, 11 sont apparus 30240 à 30600 mois après le début de l'AZT, 11 sont apparus 30600 à 30960 mois après le début de l'AZT, 11 sont apparus 30960 à 31320 mois après le début de l'AZT, 11 sont apparus 31320 à 31680 mois après le début de l'AZT, 11 sont apparus 31680 à 32040 mois après le début de l'AZT, 11 sont apparus 32040 à 32400 mois après le début de l'AZT, 11 sont apparus 32400 à 32760 mois après le début de l'AZT, 11 sont apparus 32760 à 33120 mois après le début de l'AZT, 11 sont apparus 33120 à 33480 mois après le début de l'AZT, 11 sont apparus 33480 à 33840 mois après le début de l'AZT, 11 sont apparus 33840 à 34200 mois après le début de l'AZT, 11 sont apparus 34200 à 34560 mois après le début de l'AZT, 11 sont apparus 34560 à 34920 mois après le début de l'AZT, 11 sont apparus 34920 à 35280 mois après le début de l'AZT, 11 sont apparus 35280 à 35640 mois après le début de l'AZT, 11 sont apparus 35640 à 36000 mois après le début de l'AZT, 11 sont apparus 36000 à 36360 mois après le début de l'AZT, 11 sont apparus 36360 à 36720 mois après le début de l'AZT, 11 sont apparus 36720 à 37080 mois après le début de l'AZT, 11 sont apparus 37080 à 37440 mois après le début de l'AZT, 11 sont apparus 37440 à 37800 mois après le début de l'AZT, 11 sont apparus 37800 à 38160 mois après le début de l'AZT, 11 sont apparus 38160 à 38520 mois après le début de l'AZT, 11 sont apparus 38520 à 38880 mois après le début de l'AZT, 11 sont apparus 38880 à 39240 mois après le début de l'AZT, 11 sont apparus 39240 à 39600 mois après le début de l'AZT, 11 sont apparus 39600 à 40000 mois après le début de l'AZT, 11 sont apparus 40000 à 40400 mois après le début de l'AZT, 11 sont apparus 40400 à 40800 mois après le début de l'AZT, 11 sont apparus 40800 à 41200 mois après le début de l'AZT, 11 sont apparus 41200 à 41600 mois après le début de l'AZT, 11 sont apparus 41600 à 42000 mois après le début de l'AZT, 11 sont apparus 42000 à 42400 mois après le début de l'AZT, 11 sont apparus 42400 à 42800 mois après le début de l'AZT, 11 sont apparus 42800 à 43200 mois après le début de l'AZT, 11 sont apparus 43200 à 43600 mois après le début de l'AZT, 11 sont apparus 43600 à 44000 mois après le début de l'AZT, 11 sont apparus 44000 à 44400 mois après le début de l'AZT, 11 sont apparus 44400 à 44800 mois après le début de l'AZT, 11 sont apparus 44800 à 45200 mois après le début de l'AZT, 11 sont apparus 45200 à 45600 mois après le début de l'AZT, 11 sont apparus 45600 à 46000 mois après le début de l'AZT, 11 sont apparus 46000 à 46400 mois après le début de l'AZT, 11 sont apparus 46400 à 46800 mois après le début de l'AZT, 11 sont apparus 46800 à 47200 mois après le début de l'AZT, 11 sont apparus 47200 à 47600 mois après le début de l'AZT, 11 sont apparus 47600 à 48000 mois après le début de l'AZT, 11 sont apparus 48000 à 48400 mois après le début de l'AZT, 11 sont apparus 48400 à 48800 mois après le début de l'AZT, 11 sont apparus 48800 à 49200 mois après le début de l'AZT, 11 sont apparus 49200 à 49600 mois après le début de l'AZT, 11 sont apparus 49600 à 50000 mois après le début de l'AZT, 11 sont apparus 50000 à 50400 mois après le début de l'AZT, 11 sont apparus 50400 à 50800 mois après le début de l'AZT, 11 sont apparus 50800 à 51200 mois après le début de l'AZT, 11 sont apparus 51200 à 51600 mois après le début de l'AZT, 11 sont apparus 51600 à 52000 mois après le début de l'AZT, 11 sont apparus 52000 à 52400 mois après le début de l'AZT, 11 sont apparus 52400 à 52800 mois après le début de l'AZT, 11 sont apparus 52800 à 53200 mois après le début de l'AZT, 11 sont apparus 53200 à 53600 mois après le début de l'AZT, 11 sont apparus 53600 à 54000 mois après le début de l'AZT, 11 sont apparus 54000 à 54400 mois après le début de l'AZT, 11 sont apparus 54400 à 54800 mois après le début de l'AZT, 11 sont apparus 54800 à 55200 mois après le début de l'AZT, 11 sont apparus 55200 à 55600 mois après le début de l'AZT, 11 sont apparus 55600 à 56000 mois après le début de l'AZT, 11 sont apparus 56000 à 56400 mois après le début de l'AZT, 11 sont apparus 56400 à 56800 mois après le début de l'AZT, 11 sont apparus 56800 à 57200 mois après le début de l'AZT, 11 sont apparus 57200 à 57600 mois après le début de l'AZT, 11 sont apparus 57600 à 58000 mois après le début de l'AZT, 11 sont apparus 58000 à 58400 mois après le début de l'AZT, 11 sont apparus 58400 à 58800 mois après le début de l'AZT, 11 sont apparus 58800 à 59200 mois après le début de l'AZT, 11 sont apparus 59200 à 59600 mois après le début de l'AZT, 11 sont apparus 59600 à 60000 mois après le début de l'AZT, 11 sont apparus 60000 à 60400 mois après le début de l'AZT, 11 sont apparus 60400 à 60800 mois après le début de l'AZT, 11 sont apparus 60800 à 61200 mois après le début de l'AZT, 11 sont apparus 61200 à 61600 mois après le début de l'AZT, 11 sont apparus 61600 à 62000 mois après le début de l'AZT, 11 sont apparus 62000 à 62400 mois après le début de l'AZT, 11 sont apparus 62400 à 62800 mois après le début de l'AZT, 11 sont apparus 62800 à 63200 mois après le début de l'AZT, 11 sont apparus 63200 à 63600 mois après le début de l'AZT, 11 sont apparus 63600 à 64000 mois après le début de l'AZT, 11 sont apparus 64000 à 64400 mois après le début de l'AZT, 11 sont apparus 64400 à 64800 mois après le début de l'AZT, 11 sont apparus 64800 à 65200 mois après le début de l'AZT, 11 sont apparus 65200 à 65600 mois après le début de l'AZT, 11 sont apparus 65600 à 66000 mois après le début de l'AZT, 11 sont apparus 66000 à 66400 mois après le début de l'AZT, 11 sont apparus 66400 à 66800 mois après le début de l'AZT, 11 sont apparus 66800 à 67200 mois après le début de l'AZT, 11 sont apparus 67200 à 67600 mois après le début de l'AZT, 11 sont apparus 67600 à 68000 mois après le début de l'AZT, 11 sont apparus 68000 à 68400 mois après le début de l'AZT, 11 sont apparus 68400 à 68800 mois après le début de l'AZT, 11 sont apparus 68800 à 69200 mois après le début de l'AZT, 11 sont apparus 69200 à 69600 mois après le début de l'AZT, 11 sont apparus 69600 à 70000 mois après le début de l'AZT, 11 sont apparus 70000 à 70400 mois après le début de l'AZT, 11 sont apparus 70400 à 70800 mois après le début de l'AZT, 11 sont apparus 70800 à 71200 mois après le début de l'AZT, 11 sont apparus 71200 à 71600 mois après le début de l'AZT, 11 sont apparus 71600 à 72000 mois après le début de l'AZT, 11 sont apparus 72000 à 72400 mois après le début de l'AZT, 11 sont apparus 72400 à 72800 mois après le début de l'AZT, 11 sont apparus 72800 à 73200 mois après le début de l'AZT, 11 sont apparus 73200 à 73600 mois après le début de l'AZT, 11 sont apparus 73600 à 74000 mois après le début de l'AZT, 11 sont apparus 74000 à 74400 mois après le début de l'AZT, 11 sont apparus 74400 à 74800 mois après le début de l'AZT, 11 sont apparus 74800 à 75200 mois après le début de l'AZT, 11 sont apparus 75200 à 75600 mois après le début de l'AZT, 11 sont apparus 75600 à 76000 mois après le début de l'AZT, 11 sont apparus 76000 à 76400 mois après le début de l'AZT, 11 sont apparus 76400 à 76800 mois après le début de l'AZT, 11 sont apparus 76800 à 77200 mois après le début de l'AZT, 11 sont apparus 77200 à 77600 mois après le début de l'AZT, 11 sont apparus 77600 à 78000 mois après le début de l'AZT, 11 sont apparus 78000 à 78400 mois après le début de l'AZT, 11 sont apparus 78400 à 78800 mois après le début de l'AZT, 11 sont apparus 78800 à 79200 mois après le début de l'AZT, 11 sont apparus 79200 à 79600 mois après le début de l'AZT, 11 sont apparus 79600 à 80000 mois après le début de l'AZT, 11 sont apparus 80000 à 80400 mois après le début de l'AZT, 11 sont apparus 80400 à 80800 mois après le début de l'AZT, 11 sont apparus 80800 à 81200 mois après le début de l'AZT, 11 sont apparus 81200 à 81600 mois après le début de l'AZT, 11 sont apparus 81600 à 82000 mois après le début de l'AZT, 11 sont apparus 82000 à 82400 mois après le début de l'AZT, 11 sont apparus 82400 à 82800 mois après le début de l'AZT, 11 sont apparus 82800 à 83200 mois après le début de l'AZT, 11 sont apparus 83200 à 83600 mois après le début de l'AZT, 11 sont apparus 83600 à 84000 mois après le début de l'AZT, 11 sont apparus 84000 à 84400 mois après le début de l'AZT, 11 sont apparus 84400 à 84800 mois après le début de l'AZT, 11 sont apparus 84800 à 85200 mois après le début de l'AZT, 11 sont apparus 85200 à 85600 mois après le début de l'AZT, 11 sont apparus 85600 à 86000 mois après le début de l'AZT, 11 sont apparus 86000 à 86400 mois après le début de l'AZT, 11 sont apparus 86400 à 86800 mois après le début de l'AZT, 11 sont apparus 86800 à 87200 mois après le début de l'AZT, 11 sont apparus 87200 à 87600 mois après le début de l'AZT, 11 sont apparus 87600 à 88000 mois après le début de l'AZT, 11 sont apparus 88000 à 88400 mois après le début de l'AZT, 11 sont apparus 88400 à 88800 mois après le début de l'AZT, 11 sont apparus 88800 à 89200 mois après le début de l'AZT, 11 sont apparus 89200 à 89600 mois après le début de l'AZT, 11 sont apparus 89600 à 90000 mois après le début de l'AZT, 11 sont apparus 90000 à 90400 mois après le début de l'AZT, 11 sont apparus 90400 à 90800 mois après le début de l'AZT, 11 sont apparus 90800 à 91200 mois après le début de l'AZT, 11 sont apparus 91200 à 91600 mois après le début de l'AZT, 11 sont apparus 91600 à 92000 mois après le début de l'AZT, 11 sont apparus 92000 à 92400 mois après le début de l'AZT, 11 sont apparus 92400 à 92800 mois après le début de l'AZT, 11 sont apparus 92800 à 93200 mois après le début de l'AZT, 11 sont apparus 93200 à 93600 mois après le début de l'AZT, 11 sont apparus 93600 à 94000 mois après le début de l'AZT, 11 sont apparus 94000 à 94400 mois après le début de l'AZT, 11 sont apparus 94400 à 94800 mois après le début de l'AZT, 11 sont apparus 94800 à 95200 mois après le début de l'AZT, 11 sont apparus 95200 à 95600 mois après le début de l'AZT, 11 sont apparus 95600 à 96000 mois après le début de l'AZT, 11 sont apparus 96000 à 96400 mois après le début de l'AZT, 11 sont apparus 96400 à 96800 mois après le début de l'AZT, 11 sont apparus 96800 à 97200 mois après le début de l'AZT, 11 sont apparus 97200 à 97600 mois après le début de l'AZT, 11 sont apparus 97600 à 98000 mois après le début de l'AZT, 11 sont apparus 98000 à 98400 mois après le début de l'AZT, 11 sont apparus 98400 à 98800 mois après le début de l'AZT, 11 sont apparus 98800 à 99200 mois après le début de l'AZT, 11 sont apparus 99200 à 99600 mois après le début de l'AZT, 11 sont apparus 99600 à 100000 mois après le début de l'AZT, 11 sont apparus 100000 à 100400 mois après le début de l'AZT, 11 sont apparus 100400 à 100800 mois après le début de l'AZT, 11 sont apparus 100800 à 101200 mois après le début de l'AZT, 11 sont apparus 101200 à 101600 mois après le début de l'AZT, 11 sont apparus 101600 à 102000 mois après le début de l'AZT, 11 sont apparus 102000 à 102400 mois après le début de l'AZT, 11 sont apparus 102400 à 102800 mois après le début de l'AZT, 11 sont apparus 102800 à 103200 mois après le début de l'AZT, 11 sont apparus 103200 à 103600 mois après le début de l'AZT, 11 sont apparus 103600 à 104000 mois après le début de l'AZT, 11 sont apparus 104000 à 104400 mois après le début de l'AZT, 11 sont apparus 104400 à 104800 mois après le début de l'AZT, 11 sont apparus 104800 à 105200 mois après le début de l'AZT, 11 sont apparus 105200 à 105600 mois après le début de l'AZT, 11 sont apparus 105600 à 106000 mois après le début de l'AZT, 11 sont apparus 106000 à 106400 mois après le début de l'AZT, 11 sont apparus 106400 à 106800 mois après le début de l'AZT, 11 sont apparus 106800 à 107200 mois après le début de l'AZT, 11 sont apparus 107200 à 107600 mois après le début de l'AZT, 11 sont apparus 107600 à 108000 mois après le début de l'AZT, 11 sont apparus 108000 à 108400 mois après le début de l'AZT, 11 sont apparus 108400 à 108800 mois après le début de l'AZT, 11 sont apparus 108800 à 109200 mois après le début de l'AZT, 11 sont apparus 109200 à 109600 mois après le début de l'AZT, 11 sont apparus 109600 à 110000 mois après le début de l'AZT, 11 sont apparus 110000 à 110400 mois après le début de l'AZT, 11 sont apparus 110400 à 110800 mois après le début de l'AZT, 11 sont apparus 110800 à 111200 mois après le début de l'AZT, 11 sont apparus 111200 à 111600 mois après le début de l'AZT, 11 sont apparus 111600 à 112000 mois après le début de l'AZT, 11 sont apparus 112000 à 112400 mois après le début de l'AZT, 11 sont apparus 112400 à 112800 mois après le début de l'AZT, 11 sont apparus 112800 à 113200 mois après le début de l'AZT, 11 sont apparus 113200 à 113600 mois après le début de l'AZT, 11 sont apparus 113600 à 114000 mois après le début de l'AZT, 11 sont apparus 114000 à 114400 mois après le début de l'AZT, 11 sont apparus 114400 à 114800 mois après le début de l'AZT, 11 sont apparus 114800 à 115200 mois après le début de l'AZT, 11 sont apparus 115200 à 115600 mois après le début de l'AZT, 11 sont apparus 115600 à 116000 mois après le début de l'AZT, 11 sont apparus 116000 à 116400 mois après le début de l'AZT, 11 sont apparus 116400 à 116800 mois après le début de l'AZT, 11 sont apparus 116800 à 117200 mois après le début de l'AZT, 11 sont apparus 117200 à 117600 mois après le début de l'AZT, 11 sont apparus 117600 à 118000 mois après le début de l'AZT, 11 sont apparus 118000 à 118400 mois après le début de l'AZT, 11 sont apparus 118400 à 118800 mois après le début de l'AZT, 11 sont apparus 118800 à 119200 mois après le début de l'AZT, 11 sont apparus 119200 à 119600 mois après le début de l'AZT, 11 sont apparus 119600 à 120000 mois après le début de l'AZT, 11 sont apparus 120000 à 120400 mois après le début de l'AZT, 11 sont apparus 120400 à 120800 mois après le début de l'AZT, 11 sont apparus 120800 à 121200 mois après le début de l'AZT, 11 sont apparus 121200 à 121600 mois après le début de l'AZT, 11 sont apparus 121600 à 122000 mois après le début de l'AZT, 11 sont apparus 122000 à 122400 mois après le début de l'AZT, 11 sont apparus 122400 à 122800 mois après le début de l'AZT, 11 sont apparus 122800 à 123200 mois après le début de l'AZT, 11 sont apparus 123200 à 123600

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

W.B.P.349 ZIDOVUDINE(AZT) IN HIV POSITIVE HAEMOPHILIACS

Lin Sang-Geo, Lee, C.A. Hayes, M. Giannarone, P. de Kerkoff, P.B.A. Haselden, J. and Haemophilia Unit, Academic Department of Haematology, Royal Free Hospital, London, United Kingdom.

Objective: To review the effect of zidovudine in HIV positive haemophiliacs.
Methods: A retrospective analysis of 21 patients treated with zidovudine at the Haemophilia Centre of the Royal Free Hospital was performed. 14 were CDC IV, 1 was CDC III with thrombocytopenia, 4 had oral candidiasis and 2 were CDC II but elected to purchase zidovudine privately. Median age was 33 (range 21-69) and they had been known to be HIV Ab positive for 42-107 months (median 73 months). They received zidovudine for 1-55 weeks (median 29 weeks).

Results: 9 patients tolerated full dose zidovudine (1000 mg/d) without a change in dosage or side-effects. 12 patients required dose modification or cessation of medication due to anaemia, neutropenia, 13 granulocytopenia, 13 pancytopenia requiring transfusion(1), vomiting(1), poor compliance(1) and conversion to alternative medicine(1). Other side-effects were alopecia, headache or fatigue. Opportunistic infections occurred whilst on zidovudine were oral candidiasis(2), a possible relapse of PCP(1), Salmonella typhimurium replacement(1), cryptosporidiosis(1) and E. Coli sepsis from a UTI(1). 3 patients improved their T4 counts, 4 deteriorated, and 1 remained the same - none of these had a non-sustained rise in their T4 counts. 4 of 5 patients responded to zidovudine, 1 of 8, 2/4. As positive patients became negative, 2 remained positive and 1 has only had therapy for 1 week.

Conclusions: Zidovudine is an effective treatment for symptomatic HIV infection in haemophiliacs, particularly for thrombocytopenia. However, there were significant side-effects, notably in 3/21(14.3%), granulocytopenia in 5/21(23.8%), and pancytopenia in 1/21(4.7%).

W.B.P.350 ZIDOVUDINE THERAPY IN HOMOSEXUAL/BISexual PATIENTS WITH AIDS-RELATED COMPLEX (ARC) IN AUSTRALIA.

Session: Cheryl J. Condon, AIDS Epidemiology and Clinical Research, University of New South Wales, Sydney, NSW, Australia.

Objectives: To monitor the efficacy, toxicity and safety of zidovudine (ZDV) therapy in patients with AIDS-related complex (ARC) in a multi-centre clinical trial in Australia. **Methods:** Patients with ARC have been enrolled in the study since June, 1987. By June 1988, 301 homosexual/bisexual males had been enrolled, 95% of whom were still alive by 20 November, 1988. Using time to development of an AIDS-defining condition (T7AIDS) as a measure of the efficacy of ZDV, Kaplan-Meier survival curves were prepared for baseline clinical and laboratory values for these patients (80, WCC, CD4, age, time from diagnosis (D) to ZDV therapy, Karnofsky performance status, and other variables) using Cox regression analysis. Safety and toxicity were evaluated in terms of mean dose level of ZDV tolerated and need for transfusions during therapy. **Results:** Sixty-nine of the patients (23%) had developed AIDS conditions. Significant differences ($P < 0.05$) in survival curves for T7AIDS were found for CD4 counts (50×10^6 , $30 < 126/161$), D to ZDV time ($12/32$ and $78 > 108$), CD4 counts ($50 < 10^6$ vs the only baseline variable independently associated with poorer T7AIDS in this analysis). The mean dose of ZDV was 150 mg. Sixty-five patients (23%) required transfusions during therapy, of whom 27 were transfused only once. **Conclusions:** ZDV appears to be well-tolerated in this group of ARC patients and baseline CD4 counts is independently associated with T7AIDS.

W.B.P.351 CESSATION OF ZIDOVUDINE (AZT) THERAPY LEADS TO INCREASED FREQUENCY OF VIRAL ISOLATION.

Kalish, J.M., Fleming, R., Gill, J., Gelson, K.; Montaner, J.S.G.; O'Shaughnessy, M.; Thomas, G.; and Ruedy, J. Jewish General Hospital, Montreal, Quebec, Canada, and the Canadian Multicentre Study.

Objective: To carry out a dose-finding study on 77 HIV-infected adults (CDC stages II and III) and to assess viral burden in such individuals.

Methods: HIV-1 was isolated from the circulating mononuclear cells of each subject at regular intervals throughout the study. Subjects received 600 mg drug per day for 18 weeks, 300 mg for 8 weeks, and 1200 mg for an additional 3 weeks. After 36 weeks, drug was withheld for 6 weeks and restarted at 42 weeks at 1200 mg/day.

Results: HIV was isolated from patients about 40% of the time both prior to treatment and at the end of 16 weeks, with average time to culture positivity of 18 days from end of the wash-out and following re-initiation of therapy. HIV was isolated in 75% of cases, with time to positivity of 10 days. These data correlate with the results on circulating p17 levels in these patients, and suggest that a 6-week drug wash-out period may result in increased viral burden.

Conclusion: Shorter wash-out periods should be used, when appropriate, to overcome the toxic effects of this drug.

W.B.P.352 IMPROVEMENT OF SURVIVAL IN AIDS PATIENTS WITH ZIDOVUDINE THERAPY.

Session: Ethel M. Phant, MD and Minsh, E. Department of Infectious Diseases, Compad Hospital, Beiquing, India.

Objective: To compare survival after AIDS diagnosis, in patients admitted to our department before and after the institution of zidovudine therapy.

Methods: We evaluated survival after the diagnosis of AIDS (Kaplan-Meier method) during 1985-1986-1987 (before zidovudine became available at our department) and in 1988 (when zidovudine was available for routine therapeutic use). Zidovudine was administered according to the Indian National AIDS Programme (200 mg every 6 hours).

Results: Out of 100 patients, 93 were available (median follow-up of 2 months), most of them were IVDA, 46 patients, observed in 1985-1987, 48 not receiving zidovudine therapy, majority of them chest contracted. 40 patients, observed in 1988, were treated with zidovudine & depending on the inclusion criteria of the Indian National AIDS Programme.

SURVIVAL FROM AIDS DIAGNOSIS - 1 (Kaplan-Meier method)

Survival	3	12
1985-1987 ("pre-AZT era")	61.4	38.6
1988 ("AZT era")	76.4	23.5

Conclusions: Better diagnosis of AIDS and improvement in treating opportunistic infections, probably combined with the observed increase of survival time. However, our results seem to confirm the favourable effect of zidovudine treatment on the survival of AIDS patients, also in IVDA, for which a poor compliance to long term therapy is to be expected.

W.B.P.353 EFFICACY OF AZT IN A MUNICIPAL HOSPITAL CLINIC

Sessioning: A. Robinson, M.D. and H. Hooper, M.D.; Allen S. Holzman, M.D. New York University-Belmont Hospital, New York, New York, U.S.A.

Objective: To evaluate survival of AIDS and ARC patients treated with zidovudine (AZT) at a municipal hospital clinic.

Methods: Patients (pts) eligible for AZT under the treatment END or the F10A3 increased indications were treated in a specially designated clinic at Bellevue Hospital. Records of criteria with at least one follow-up visit between Dec 88 and Nov 89 were reviewed using a standardized data form. Results: 245 pts fulfilled the criteria for analysis: 220 males, 25 females; 117 whites, 61 Hispanics, 67 others; 146 non-Hispanic men, 82 with history of IV drug abuse; 82 pts had ARC and 163 AIDS. Median age was 37. Median survival (ms) of the entire group by the product limit method was 523 days (range 6-721) from the time of starting AZT. There was no difference in survival by sex. ARC pts lived longer than AIDS pts (ms 553 v 480, p<0.1). Pts with 1 opportunistic infection (OI) prior to AZT lived longer than those with more than 1 OI (ms 501 v 357, p<0.03). Initial absolute lymphocyte count above 1188/cu mm, absolute CD4+ lymphocyte count above 110, and albumin over 4 g/dl were associated with significantly longer survival. univariate analysis. Pts who started AZT within 90 days of their first AIDS diagnosis lived significantly longer. Those who tolerated an average AZT dose above 0.6 grams/week survived longer than pts treated with lower doses (p<0.03). Adverse reactions included anemia in 80 pts, leukopenia in 70 pts, neutropeny in 25, hepatitis in 25, uremia and myositis in 16 each, and other toxicity in 36.

Conclusion: Patients from a municipal hospital population treated with AZT survived at least as long as those reported in other trials.

W.B.P.354 THE EFFECT OF ZIDOVUDINE (AZT) ON SURVIVAL OF AIDS PATIENTS IN SAN FRANCISCO

Session: George F. Paine, S.F.; Neal, D.P.; Rutherford, G.M. San Francisco Department of Public Health, San Francisco, CA, U.S.A.

Objective: To evaluate the effect of zidovudine (AZT) on survival trends for AIDS patients in San Francisco (SF) in 1988 and 1987.

Methods: Information on antiviral therapy was available for 568 (25%) of 2,212 AIDS patients treated in SF in 1988 or 1987. In SF, we evaluated survival for 172 AIDS patients treated with AZT at some point during the course of their illness compared with 396 patients who were not treated with any antiviral therapy at time of diagnosis (and, if known, subsequent to diagnosis). Eleven patients surviving after other antivirals were excluded. Median survival was calculated using the Kaplan-Meier product-limit method.

Results: The median survival for patients on AZT (21.3 months) was significantly longer than for patients not on any antiviral therapy (13.9 months) (p<0.02). Improved survival for patients on AZT was found for both patients with (21.6 vs. 14.5 months) and without (21.3 vs. 13.1 months) pneumocystis carinii pneumonia within 3 months of diagnosis (p<0.001). Improved survival for patients on AZT was found for all subgroups of patients who stratified by initial diagnosis, year and hospital of diagnosis, age, race/ethnicity, or risk group, suggesting that the improved survival for patients on AZT was probably not due to biases inherent in the study.

Conclusion: Survival for patients on AZT was significantly longer than that for patients not on antiviral therapy in a sample of AIDS patients in SF.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

W.B.P.361

TREATMENT WITH RETROVIR IN DIFFERENT STAGES OF THE HIV INFECTION

SAIO G., IZZO C. M., MARZILLO R., MORGONICO S., MARZILLO G. G., COTRURO MONTUORI L. V. PAROLI - ITALY
54 HIV-ab positive patients (of 11 group, 13 of III group, 35 of IV group of CDC classification) received AZT in doses of 1200mg/die for 3-6 months; of these patients (80%) were drug abusers (d.a.); 16 of them (33%) resulted dropped out. During the first three months (I of group, 6 of III group and 9 of IV group) there were not d.a. among those who aren't d.a. At the follow-up since the beginning (time 0) showed of CD4 > 400. There were serious side effects in 26% of the patients, which resulted in interruptions of the treatment. There were none in those from I and III groups. In spite of the treatment, 40% of the patients of the II group and 29 of those of III group showed development in more advanced stages of the syndrome, without correlation with the number of CD4 at time 0. Among the followed 26 patients of IV group, 73% showed stationary conditions during the time and 13% died (we have registered deaths in 54% of other 39 patients of IV group, who didn't receive AZT). Among 13 d.a., followed, we observed a development of the syndrome in more advanced stages in 40% of those who went on taking drugs and only 30% of those who had given up this habit (p < 0.05). Of the six patients not d.a., 66% have remained stationary and 11% a. 6% died.

W.B.P.363

LONG TERM ASSESSMENT OF TOXICITY AND CLINICAL OUTCOME IN TREATMENT OF HIV INFECTION WITH ZIDOVUDINE

Conrad F., Gump J., Geay J., Bender J., Boudier J., AIDS Clinical Research Project, Children's Hospital of San Francisco, California, U.S.A.
Objective: To evaluate the toxicity and assess the long term clinical outcome of Zidovudine therapy in HIV infected individuals diagnosed with AIDS or who have been asymptomatic with less than 200 CD4 cells.
Methods: A prospective, open-ended multicenter study of Zidovudine therapy began in December of 1986. By the end of December 1989, we enrolled and treated 27 patients with AIDS and 19 patients with HIV related symptoms and less than 200 CD4 cells (CDC stage II disease).
Results: Mean follow-up of 69 weeks is available for 26 patients with AIDS and 26 weeks for 12 of 19 patients with CDC stage IVa disease. Neutropenia with less than 700 cells per cubic millimeter occurred in 37% of patients (11 with AIDS); 3 with stage IVa disease). Transfusions were required in 24% of patients (8 with AIDS); 1 with stage IVa disease). Recurrent opportunistic infections including PCP, CMV retinitis, CMV colitis, and disseminated MAC were noted in 30% of the AIDS patients. 3 of 13 (23%) evaluable CDC stage IVa patients have progressed to AIDS. 50% of patients diagnosed with AIDS at start of therapy have died while 27% remain on drug. 81 of evaluable patients with symptoms and less than 200 CD4 cells at start of therapy had died while 72% remain on drug.
Conclusion: Our experience with Zidovudine therapy in HIV infection is similar to that of other investigators. Zidovudine prolongs survival in this population by decreasing morbidity from recurrent OIs. The major limiting factor in prolonged use remains the hematologic toxicities.

W.B.P.365

CORRELATION BETWEEN P24 ANTIGENEMIA AND CD4+ T-LEUCOCYTES RATIO IN AZT-TREATED PATIENTS

Crossibile Paolo, Lixoli A., Panseri WP., Filippi C., Arcidiacono I., Nardelli M. - Dapedale Maggiore - 20076 LODI (Italy)

Objective: to verify whether CD4+/neopterin ratio (R) correlates with clinical condition and p24 antigenemia (p24Ag) in AZT-treated patients infected with HIV.
Methods: 14 HIV-positive pts (18 males, 4 female, mean age 24.5, range 20-35) treated with 1200 mg AZT per day, at enrollment were daily administered 18 mg/kg AZT per day for 1 year. Every 3 months they were clinically evaluated (according to CDC criteria) and tested for serum Neopterin levels (ENL), CD4+ cell counts and p24Ag; R was also 3 monthly calculated for each patient.
Results: Clinical condition did not worsen in any of the 14 pts during the 18 months' treatment; in fact clinical improvement was noted in 4. According to "between-variance" analysis, however, no statistically significant immunological improvement (CD4 and R increase, ENL decrease) was observed in our pts, regardless of their initial p24Ag status.
Conclusion: in our experience R proved to be the most sensitive index of immunological response to treatment correlating, to a certain extent, with p24Ag. In fact, it may be proposed as the only immunological index (replacing p24Ag) in the monitoring of AZT-treated patients.

W.B.P.362

EFFICACY AND TOLERANCE OF ZIDOVUDINE IN PATIENTS WITH ACQUIRED HIV INFECTION ON WITH PGL.

A. Cristiani, F. Dulio Cataldo, S. Mosca, G. Bonadoni, L. Pisciotta, M. Piana. CLINIC OF INFECTIOUS DISEASES UNIVERSITY Naples-Italy.
Objective: Evaluation of the effects and tolerance of Zidovudine (ZDV) in HIV seropositive patients.
Methods: 10 asymptomatic patients (CDC group II) and 10 with PGL (CDC group III) all with initial T4 counts ranging between 150 and 350/mm³ were given ZDV 7 mg/kg for 4 times a day for the first month and 3.5 mg/kg for 4 times a day for an additional 3 months.
Results: No patients showed CO. II and/or tumor. Nausea and headache were not frequently observed. All subjects developed mild decrease in haemoglobin (mean 8g/dl, 38 g/dl at entry and 14.04 at month 8) and in WBC cell counts (mean 9000-2533/mm³ at entry and 2407 at month 8). Anomalous CPK values were observed in 3 subjects during treatment. In 2 patients EPT values 3 times the normal values was observed in the first month followed by normalization. HIV Ag was detected in serum of 3 patients at entry and 2 became persistently HIV Ag negative during the treatment. Mean T4 count was 180/mm³ at entry and 170/mm³ after 8 months.
Conclusion: ZDV at the dose indicated was fairly well tolerated during first 8 months of therapy. The slight T4 cells decrease is an expression of the efficacy of the treatment. Further study will be needed to determine the long-term effect of therapy.

W.B.P.364

ZIDOVUDINE TREATMENT IN 100 CONSECUTIVE PATIENTS WITH AIDS OR AIDS RELATED COMPLEX

Corbelli A., Gagnoli F., Marzulli M., Ghislini A., Casanovi B., Kozakovic J., Lyonnet F. et al. Hopital Necker Mondor, 94010 Creteil, France.
Objective: To analyse Zidovudine treatment in severe HIV infection in terms of survival, toxicity and clinical maintenance.
Methods: 100 consecutive patients with AIDS and ARC received Zidovudine at a starting dose of 800-1200 mg per day. The drug was always given orally every 8 hours. The patients comprised 55 AIDS patients (50 O.I., 18 isolated K.S., 7 with both), 2 with neurologic disorders) and 45 ARC patients. The mean duration of follow-up under treatment was 8.2 mo (0.2-18). 15% of the patients were IVDA.
Results: At 8 mo after beginning AZT only 35% of the patients (33% of ARC) received the initial dose. The causes of regimen alteration included hematological toxicity (41%), intercurrent infections (10%), combination therapies. 8 ARC patients progressed to AIDS under treatment. 42 O.I. were observed in 24 patients. The 12 mo survival rates from the beginning of AZT treatment were 70.4% in ARC patients, 68.4% in AIDS with I.D., 72.4% in K.S patients, 42.9% in O.I. patients. The 18 mo rates were 70.4% in ARC but only 55.5% in AIDS.
Conclusion: Zidovudine provided a better quality of survival which might be slightly prolonged. But starting doses are reduced in 2/3 of the patients within 8 mo because of toxicity. Moreover 20% of ARC patients moved to AIDS while treated although the initial dose had been maintained in most.

W.B.P.366

Studi clinico e biologico de 108 malato trattati per ZIDOVUDINE sui principi de 12 a 18 mila.

Bellou, Gerone ; PERCE, A. ; QUARANTA, J.F. ; VITTI, R. ; TALLAS, B. ; CASUTO, J. C.

C.N.R.U. de NICE, FRANCE. Ligue Nazionale Française de lutte contre le SIDA.

Objective: Evaluated a long term, survival, l'apparition des infections opportunistes et la modification des lymphocytes T4 des 108 malato - gruppo 3 et 4 trattati per ZIDOVUDINE.
Methods: 108 patients with AIDS and ARC with biological annual de 108 malato sur un principe de 12 a 18 mila.
Results: - **survival:** de survie 7 steps 3 a 4 confondus.
8 mois 12 mois 18 mois 24 mois 30 mois
80 % 75 % 65 % Wellcome Mal 87

Opportunistes: **survival de infections opportunistes:**
0 mois 12 mois 18 mois 24 mois 30 mois
80 % 75 % 65 % Wellcome Mal 87

Parcentage de patients su fonction de leur de T4 et de temps:
0 mois 30 mois 60 mois 90 mois 120 mois 150 mois 180 mois
100 % 95 % 85 % 75 % 65 % 55 % 45 %
Conclusion: malgré une baisse progressive des lymphocytes T4, d'un pourcentage important d'apparition de récidives d'infections opportunistes la survie sur ZIDOVUDINE est appréciable (65 % a 18 mois).

Session d'affichage Poster Session



W.B.P.367 AZT THERAPY IN SEROCONVERSION INDICATORS (INDS) AND THEIR GENITAL PARTNER
Research: Adams, I., Levinson, S., Shaffer, R., Chagnrin, E., Debovitz, J., Kings County Health Dept., Health Science Center at Brooklyn, U.S.A.

Objective: Describe the experience of our clinic in administering AZT to INDs and to sexual partners of INDs.
Methods: 39 consecutive patients (25 female) or who were sexual partners of an IND were begun on AZT between 1/87 - 3/88.
Results: 33 were male INDs (mean age: 37.5, range: 23-56), 24 were female (mean age: 33.2, range: 20-59), 19 females were INDs and 14 were sexual partners of an IND. 46 had AIDS (immunocytochemistry-39, other seropositive infection: 7); 13 had AIDS with a mean T4 of 135 (range: 60-192), 30/59 (64%) pts were compliant with therapy for a mean of 10.9 months of follow-up (4/25 p=months); 13 died after a mean of 10.5 months (range: 15-19), 12 are alive after a mean of 15.8 months (range: 10-24), 7 required discontinuation of AZT due to toxic reactions after a mean of 8.7 months (range: 1-19), and 4 reinfected or another facility after mean of 9.8 months (range: 2-24). 20/59 (34%) were lost to follow-up after mean of 5.7 months of therapy (range: 1-11) (p=months). 23 developed an opportunistic infection while on AZT, 18 required hospitalization. 21 reported dose reductions due to nausea (11) or maculopapula (11).
Conclusions: Most patients of seroconversion INDs and sexual partners of INDs were compliant with AZT therapy as judged by their record of clinic attendance. Efficacy was not advanced due to the lack of a control group. Adverse reactions to AZT were similar to those previously described in other groups of pts.

W.B.P.369 AN INTERMITTENT ZIDOVUDINE REGIMEN: TOXICITY AND EFFICACY
Background: Cooper, David A. 80003 Special Unit in AIDS Epidemiology and Clinical Research, U.S.W., Australia.

Objective: To assess the efficacy and intermitent regimen of zidovudine. **Methods:** 21 men (6 with AIDS, 15 with ARC) who developed hematotoxicity on continuous zidovudine therapy were randomized (1:2) to 0.75/0.6g twice daily followed on an intermitent regimen of AZT (4 weeks of 1 g per day, 4 weeks without drug). The effect of zidovudine on clinical response, transfusion requirements, blood counts, virotests and CD4 cells was analyzed on continuous therapy (24 weeks) compared with intermitent therapy (23.4 weeks).
Results:

	Pre AZT	Continuous AZT	Intermitent AZT
Raw obs or ES	10	3 (2 subjects)	3 (2 subjects)
p24 ₄ no vire	10	9	9
pgAL	377 ± 236	113 ± 28	272 ± 20
CD4 cells x10 ⁶ /l	131 ± 118	105 ± 47	83 ± 15
Transfusions patients	34	10	10
number (units)	36 (240)	16 (16)	16 (16)
WBC x10 ⁹ /l	13.9 ± 2.31	7.9 ± 4.2	11.6 (11.9, 12.3)
HCC x10 ⁹ /l	4.29 ± 3.4	2.53 ± 2.20	2.95 (2.81e, 3.09e)
Glycemia x10 ³ /l	1.44 ± 2.23	1.30 ± 1.33	1.66 (1.61e, 1.67e)

all values are mean (SE) ± n on zidovudine, ↑ off zidovudine.
Conclusion: Azsima improved markedly on intermitent AZT and transfusion requirements were minimal. Despite more severe hematotoxicity and anemia consistent with more advanced disease at the time of commencement of intermitent therapy, the occurrence of new opportunistic disorders was similar for both regimens on the basis of these findings, argues of the efficacy of intermitent zidovudine as initial therapy should be undertaken.

W.B.P.371 USE OF ZIDOVUDINE (AZT) IN THE MANAGEMENT OF AIDS (IND) RELATED HIV INFECTION - CLINICAL COURSE
Open: M. Flapp, M. McCollum, R., Brettle, R., Gray, M., et al. Infectious Diseases Unit, City Hospital, Edinburgh, U.K.

Objective: To evaluate clinical outcome of AZT therapy with ID-related HIV infection (IDRHV) in view of increased AZT levels in opiate users.
Methods: 32 HIV seropositive patients were assessed of which 23 (78%) became infected between 1983-85 by ID. Of 51 AZT treated patients 37 saw male (72.5%) and 14 female (27.5%) ID partners. 11 (29%) were ID seropositive. Clinical course was assessed in terms of clinically significant opportunistic infections (OI), side effects (SE) attributable to AZT and survival since starting AZT.
Results: 22 patients started AZT when developed AIDS (CD4 < 200/μl). 19 were ID (mean duration of treatment [D]-40 weeks) and 10 were IDRHV (D=30 weeks). SE requiring dose reduction developed in 5 (23%) IDRHV and in 6 (46%) ID. Significant OI of 6 weeks post start of AZT occurred in 3 (20%) IDRHV and in 6 (42%) ID. Three (23%) ID with AIDS have died of their disease (mean time from starting AZT=56 weeks). Two ID started AZT when they had AIDS (CD4 < 200/μl) (D=43 weeks) compared with 19 IDRHV (D=39 weeks). SE requiring dose reduction developed in 1 (5%) IDRHV and in 1 (5%) ID. Significant OI developed in 3 (16%) IDRHV but in neither ID. As yet no ARC patients have proceeded to AIDS. One (6%) IDRHV has to date died from non HIV causes. Post IDRHV were CD4 status 3 (D=44 weeks). None of them developed SE or OI.
Conclusions: The frequency of serious events (OI and SE) is not greater or efficacy less in IDRHV despite opiate/haemostatic changes having an effect on AZT pharmacokinetics.

Aspects Cliniques Clinical Aspects of AIDS

W.B.P.368 TREATMENT OF SYMPTOMATIC HIV SEROPOSITIVE SUBJECTS BY ZIDOVUDINE (AZT). A CONTROL STUDY IN 36 PATIENTS
Authors: D'Amico, L., LaRosa, J.J., Lamb, P., Matis, J.P., Roussois, C., Corcoran, J.A., et al., Bach, J., et al., Pitt of Immunology, Hospital Necker; ** I.N.T.S., Paris, France.

Objective: To determine the effect of AZT in symptomatic HIV seropositive subjects.
Methods: Comparison of 2 cohorts of 28 asymptomatic subjects (CDC II or III) matched according to CD4 cell count (> 200/mm³) and p28 antigenemia (Ag) (detectable or undetectable). A group of subjects was untreated while the other received AZT (300mg every 6 hours) + acyclovir (800mg/day) during one year. Clinical and biological (CD4 and CD8 cell count, p28 Ag) evaluation was performed at 0, 6, 12 months.
Results: 26 treated subjects were evaluated; 2 subjects were excluded due to drug induced anemia. No significant modification of haemoglobin level and total leucocyte count occurred in the others. No modification of clinical staging was noticed in treated subjects while 3 untreated subjects became CDC IV. p28 Ag was initially undetectable in 11 subjects in both groups, remained undetectable in all treated subjects while became detectable in 11 untreated subjects. A decrease of p28 Ag level was noticed in treated subjects when p28 Ag was initially detectable (respectively 210/8 and 80 pg/ml at 0,6,12 months p28). No modification of total lymphocyte count was noted in either group. A CD4 cell count increase was noted in treated subjects (330,429 and 445,531) at 0,6,12 months p28, contrasting with a decrease in the untreated (329,245 and 319,953) p28. A CD8 cell increase was also noted in treated subjects (701,927 and 999/mm³) p28.1.
Conclusion: AZT is not effective in symptomatic HIV infection despite the risk of anemia. Placebo controlled trials requiring long follow-up are warranted and ethically suitable only in subjects having CD4 cells > 400/mm³ and an undetectable p28 Ag.

W.B.P.370 LONG-TERM SAFETY AND EFFICACY OF ZIDOVUDINE IN LARGE COHORTS OF 70 DRUG ABUSERS: 20 MONTHS EXPERIENCE WITH 200 ZIDOVUDINE, 500 ARC AND 100 AIDS PATIENTS.
Yello, Stefano*, Nemati Ippolito, F., Agresti, M.C.* and the Italian Zidovudine Evaluation Group.**

* National Institute of Health, Rome, Italy.
Objective: To evaluate the long term safety and efficacy of zidovudine (ZDV) when administered in I.V. drug abuser HIV-infected patients.
Methods: Data contained in the Italian National Registry of ID-treated patients have been analyzed. The Registry prospectively collected enrollment and quarterly follow-up forms of 1100 patients referring to 105 clinical centers involved in ZDV therapy, which started in Italy in July 1987. Multivariate analysis has been performed in order to evaluate the effect of possible co-factors on therapeutic response in this particular population.
Results: Frequency of adverse effects appeared to be similar to frequency reported in other risk categories of patients, hematological adverse reactions being minimal in AIDS and ARC patients who initiate therapy with over 200 CD4/cell. IDV also appeared to be very well tolerated in asymptomatic patients, with no unexpected adverse reactions. One-year survival of AIDS patients was 90.5%. The 18-month actuarial progression rate to ARC and AIDS has also been evaluated for the studied population.

W.B.P.372 ZIDOVUDINE IN ARC AND AIDS PATIENTS: CLINICAL, IMMUNOLOGICAL AND VIROLOGICAL EFFICACY
Open: M. Flapp, M. McCollum, R., Brettle, R., Gray, M., et al.

*Medical Clinic Edinburgh, **Institute of medical virology and *** clinical and experimental virology, 1000 Rue St-Jacques, Montreal, Canada.
Objective: To evaluate the clinical, immunological and virological efficacy of Zidovudine (AZT) in ARC and AIDS patients (pts).
Methods: 100 patients were assessed of which 23 (23%) were ID seropositive. Clinical course was assessed in terms of clinically significant opportunistic infections (OI), side effects (SE) attributable to AZT and survival since starting AZT.
Results: 22 patients started AZT when developed AIDS (CD4 < 200/μl). 19 were ID (mean duration of treatment [D]-40 weeks) and 10 were IDRHV (D=30 weeks). SE requiring dose reduction developed in 5 (23%) IDRHV and in 6 (46%) ID. Significant OI of 6 weeks post start of AZT occurred in 3 (20%) IDRHV and in 6 (42%) ID. Three (23%) ID with AIDS have died of their disease (mean time from starting AZT=56 weeks). Two ID started AZT when they had AIDS (CD4 < 200/μl) (D=43 weeks) compared with 19 IDRHV (D=39 weeks). SE requiring dose reduction developed in 1 (5%) IDRHV and in 1 (5%) ID. Significant OI developed in 3 (16%) IDRHV but in neither ID. As yet no ARC patients have proceeded to AIDS. One (6%) IDRHV has to date died from non HIV causes. Post IDRHV were CD4 status 3 (D=44 weeks). None of them developed SE or OI.
Conclusions: The frequency of serious events (OI and SE) is not greater or efficacy less in IDRHV despite opiate/haemostatic changes having an effect on AZT pharmacokinetics.

**Session d'affichage
Poster Session**



**Aspects cliniques
Clinical Aspects of AIDS**

W.B.P.373 COMPLIANCE WITH ZIDOVUDINE (AZT) THERAPY IN AN INNER-CITY HIV-INFECTED POPULATION
William, Krista Y., Bell-Comer, J. & El-Sadr, W.*
Marion Hospital Center, New York, N.Y. U.S.A.

Compliance to AZT was retrospectively evaluated in HIV-infected outpatients. Eighty-two patients (82%) were prescribed AZT between 11/86-7/88. Thirty-five are alive and on treatment (82%). were referred elsewhere, 1 requested stopping AZT and 11 never started AZT. Twenty-eight pts were followed from start to their death. There were inadequate data on 4 pts. Charts of 26 of the latter group were reviewed. All 24 pts were black and 22 (91%) were men. The mean age was 40.4±9.4 yrs (range 21-62 yrs). Eighteen of the 24 (75%) were intravenous drug users (IVDU); 5 of 24 (20.8%) were homosexual men and 1 (4%) the primary diagnosis was HIV. Eighteen (67.3%) cryptococcal meningitis (CM), 18 (69.2%) and 3 (4.1%) each of Kaposi's sarcoma, TB, salmonellosis and HIV positive. The pts were on AZT for a mean of 6.9±2.1 months (range 1-18, median 3.5). Fourteen (54%) of the 26 pts were excluded as they remained hospitalized. There were 22 scheduled appointments (apppt) for 20 pts and 42.3% were kept. The mean percentage (%) of apppt kept by pts was 24.2% (range 0-75%, median 35%). There was no statistically significant difference in compliance 1 between IVDU versus homosexual men and above 40 yrs, that is, those in and outside the hospital catchment. There was a significant association between compliance 1 and the duration of AZT, 40.2% in those 9 months versus 24.3% in those 9 months. In conclusion, this study shows that acceptable though not ideal compliance was achieved in a subgroup of black predominantly IVDU with HIV disease.

W.B.P.374 INTERFERON (IFN) ALPHA + AZT IN AIDS-ASSOCIATED KAPOSI'S SARCOMA (KS): FINAL RESULTS OF A PHASE I TRIAL
Kocum, A., Bandow, D., Gauschbauer, B., Gold, J., Fimmesberg, H., Armstrong, D. Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A.

Objective: To evaluate the safety, tolerance and maximum tolerated dose (MTD) of IFN- α + AZT in AIDS patients (pts) with KS: to assess anti-tumor, immunological and antiviral effects of the combination.
Methods: HIV-positive adults with biopsy-proven KS, T2/T3, AIDS-200, HbA_{1c} 5.0 and no prior IFN or AZT were eligible. Cohorts of 4-6 pts were entered at various daily IM doses of IFN- α or IM plus AZT, 100 or 200mg QD qth. **Results:** IFN- α at a dose of 3x10⁶ IU/300 or 100 or 200mg of AZT induced dose-limiting toxicity in 4/6 and 4/6 cases, leading to discontinuation of this arm of the study; tumor response was seen in 3/6 and 1/3 evaluable pts, respectively. For IFN- α , a wider dose range was evaluated:

IFN Dose (IU/d)	AZT Dose (mg/d)	Grade 1 Toxicity/eval.	CR/PR/eval.
4.5	2/0	2/6	1/3
4.5	2/0	2/6	2/3
9	2/0	2/6	3/6
9	2/0	2/6	4/6
18	2/0	2/6	5/6
18	2/0	2/6	4/6
18	2/0	2/6	4/6
18	2/0	2/6	4/6

Two MTDs were defined: 4.5M2 IFN- α QD + 200mg AZT qth and 18M2 IFN- α QD + 100mg AZT qth. Neutropenia was the major dose-limiting toxicity. Skin test reactivity increased, while and CD4 cells declined. 4/6 pts with elevated serum p24 antigen, 6 showed a decline to undetectable levels.
Conclusion: IFN- α and AZT can be safely combined and induced a high tumor response rate and p24 suppression in some patients. (Supported by NIAID-ACTC)

W.B.P.375 OUTPATIENT TRANSDUCTION THERAPY FOR RETROVIRUS-ASSOCIATED ANEMIA
Weiss, Susan; Viseer, S.; Rodgers, P.; Mollenhag, A; Schlam, H.
AIDS Program, Bellevue Hospital Center, New York, NY, USA.

Objective: To demonstrate the feasibility and safety of outpatient transfusion therapy for patients with Retrovirus-associated anemia (RAA) **Methods:** In a designated section of the general outpatient clinic of a large municipal hospital in New York, up to three patients with RAA, with a hematocrit between 18 and 30, were transfused during each of 1 or 2 weekly 8-hour sessions. The transfusion was initiated by an MD, who remained on call for emergencies. A RN observed the patient continuously. Adverse effects were managed by strict protocol.
Results: During the period from 7/87 until 1/89, a total of 604.5 units of packed RBC's were transfused in 66 patients with RAA (62 males, 4 females) including 10 homo/hemodialysis, 10 patients with history of intravenous drug abuse, 3 with multiple AIDS-risk, 2 with other risks. 28 patients received transfusions on multiple occasions. Each patient was transfused an average of 3.7 units per session. Nine patients had unhealing cutaneous sores occur. Only 6 adverse effects were observed including 4 non-hemolytic febrile reactions, 1 severe allergic reaction and 1 episode of hypotension caused by concurrent infection, resulting in hospital admission. There were 0-1m adverse reactions per patient transfusion session.
Conclusion: Transfusion therapy for patients with RAA can safely be provided in the outpatient clinic setting. Stable clinical status can be maintained in patients with RAA requiring transfusions without the need for admission to the hospital.

**Solns
Care**

W.B.P.376 Self Care Program for AIDS/ARC via Computer Network
Karlitz, J., Frenkel, M., et al. Principal Investigator
Stefan, Ralph M., Project Director
Frances Payne Bolton School of Nursing, Case Western Reserve University

This three year study analyzes the use of a free, public access computer network as a vehicle for the delivery of nursing services in the treatment of Acquired Immune Deficiency Syndrome (AIDS) and AIDS-Related Complex (ARC). To represent traditional methods of nursing care delivery with a new approach that will (1) enable nurses to meet the individual needs of well persons concerned about AIDS/ARC (2) foster self-care of people with AIDS/ARC ("PWA/PNARC") and their caregivers through in-home support, counseling, and education. Currently underway is a six month assessment involving 100 PWA's and their caregivers.
Computer networks create electronic links between clinics. In this project we will put computers in the home of PWA/PNARC to provide links to clinical agencies or to other homes. Through this terminals people can access an existing computer system and use the special programs and communication services constructed to support the entire range of AIDS/ARC patients: healthy people needing information, persons diagnosed with AIDS/ARC, and the informal care partners of PWA/PNARC. The messaging and support services will facilitate peer as well as professional contact, serving as a "support group without walls".
This intervention's effectiveness in disseminating information, enhancing problem solving skills, and distributing isolation will be evaluated in a series of field studies. The increasing emphasis on non-institutional care demands new approaches to delivery treatment and support, while the availability of computer technology provides the means to do so. Preliminary findings from the needs assessment suggest that due to cognitive impairment computer interface employ icons (pictures) as well as text.

W.B.P.377 COMPLEMENTARY THERAPIES AT CASEY HOUSE HOSPICE: A MODEL FOR TRADITIONAL/ALTERNATIVE INTERACTION

William E. Berinatti, M.A., D.C.,
Chair, Complementary Therapies Committee,
Casey House Hospice Inc.
Vice-President, Casey House Hospice Inc.
Founding Board Member, Psychiatry Clinic for
AIDS-Related Concerns, St. Sina's Hospital, Toronto

The descriptors "alternative" and "traditional" regarding care of the HIV infected individual often suggests a dichotomy, which can imply a rift between "medical" and "non-medical" orientation. Casey House Hospice made a firm commitment, from the outset, to utilization of "alternative" therapies in its hospital-affiliated program. This presentation will describe the philosophy, planning, and implementation of Complementary Therapies at Casey House, touching on the affiliation agreement with St. Michael's Hospital, educational aspects, and case studies involving a variety of therapies. The broader implications for both the overall treatment of HIV infected persons in the community or hospital setting and the marriage of the "traditional" and "alternative" health care systems will be introduced.

W.B.P.378 WORKING IN AN AIDS HOSPICE SETTING
Bloom, Jeff A., Flannery, J.
Casey House Hospice, Toronto, Ontario, Canada

Casey House is a free standing hospice dedicated to people with AIDS. The Hospice has 13 beds (12 palliative, 1 respite care) and opened in March 1988. It was expected that the emphasis of medical/nursing care would be on symptom management (pain, nausea, skin problems, and minor infections). Although the residents/legal guardians (for deceased residents) accept the philosophy of palliative care, denial of death can situate patients in a limbo. In the first 13 months, Casey House has admitted 82 people, 38 have died and 12 have been discharged. The health and functional capacity of the residents in the Hospice affect the criteria of the next admission. As acute health situations arise, residents may elect to be transferred to an acute care facility. Unexpectedly, new residents improve so they no longer require the level of care provided at the Hospice. Because their recovery was unexpected, discharge planning has been difficult. Community systems are not presently organized to assist these people. Problems occasionally arise regarding residents who wish to continue to use unapproved drugs or have remedies with which the care-providers are unfamiliar.
Conclusion: AIDS is less predictable than cancer in the final stages. With overarching approaches to therapy, all involved persons must be ever flexible in the definition and provision of palliative care. We must continually review the policies of the Hospice in accordance with changes in illness and management change in the community to provide an effective continuum of care.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

Hémophilie Hemophilia

Th.B.P.1 LYMPHOCYTES CYTOCHEMISTRY BEHAVIOR IN HEMOPHILIC PATIENTS WITH HIV INFECTION.
Gabriella Gamba, S. Tavea, L. Ponchio, R. Invernizzi, P. Di Pasio, C. B. Ippoliti. Dipartimento di Medicina Interna e Terapia, Università Medica, Via di Clinica Medica II, IRCCS Policlinico San Matteo, Università di Pavia, Italy.

The cytochemical and immunological characterization of lymphocytes of 31 hemophilic patients (6 of whom anti-HIV positive without symptoms and signs of AIDS) chronically treated with commercial clotting factor concentrates were studied. In comparison to aged cross matched male controls, hemophilic patients presented significant increase of absolute number of lymphocytes and subpopulation of CD4+ cells (CD4, CD8, CD3, CD4, CD8, CD45) PAM reaction showed a lower grading score in hemophilic and the staining for alpha-naphthyl butyrate esterase (ANBE) acid phosphatase (AP), beta-naphthyl azeluroaminidase (NABG) gave significant reduction of the percentage of the lymphocytes with coarse granules in the same pts. The percentage increase of AP reactive lymphocytes with coarse granules was directly related to the percentage number of CD4 and CD8. The anti-HIV positive pts presented lower percentages of CD4 and of dot-like AP reactive lymphocytes. In conclusion, the increase of acid phosphatase reactivity, especially the dot-like AP reaction, may represent a useful, simple and unexpensive method for following modification of CD4 subset in pts at risk of developing AIDS.

Th.B.P.3 AGENESIS OF HIV-2 INFECTION IN HEMOPHILIA IN BUENOS AIRES
Nancy Beltrán, Susana M. Simon, Susana Machin, O. Pichetto, P. Tello, V. Lelonek, P. P. R. Narkov, I. A. *

*IDEM, Academia Nacional de Medicina, Buenos Aires, Argentina, *Hospital Clinico Bernardini, Paris, France

Objective. Since HIV-2 probably spread by the same transmission routes as HIV-1, and considering that our patients received American and European concentrates, we evaluated HIV-1 antibodies previously screened for HIV-1.

Methods. Presence of HIV-2 antibodies was investigated in the sera of 60 hemophilic: 33 HIV-1, 27 HIV-2. Sera were screened for HIV-2 antibodies by an ELISA assay (ELAVIA 2) (Diagnostics, Parter). Samples repeatedly positive or undetermined were tested by RIBA.

Results. None of the 60 sera was HIV-2 positive when confirmed by RIBA; however, 21 samples were initially considered positive in the ELISA assay, no sample could be confirmed when tested by RIBA.

Conclusion. Although the number of tested sera does not allow to ascertain conclusions, it seems HIV-2 infection is very infrequent in this high-risk group in Argentina. (Supported by a grant from Fundación Rossmers).

Th.B.P.5 RESPONSE TO HEPATITIS B IMMUNIZATION IN HEMOPHILIC CHILDREN: RELATIONSHIP TO HUMAN T-CELL DEFICIENCY TYPE I (HIV-1) VIRUS INFECTION.

Chan, Wendy, Pettit, M., Wang, N., Koren, G., Reed, J., Blachette, V., Departments of Pediatrics and Virology, Hospital for Sick Children, Toronto, Ontario, Canada.

Hemophilic who received pooled plasma concentrates for control of bleeding are at high risk for hepatitis B infection. In our Hemophilia Clinic, children susceptible to hepatitis B infection (non-HBeAg, anti-HBeAg) have been immunized using a plasma-derived hepatitis B vaccine (Heptavax-BB Merck Sharp and Dohme). Three injections are given at 0, 1 and 6 months. We now report serial anti-HBeAg titres, measured by radioimmunoassay (Austab-B, Abbott), in a population of 23 children with hemophilia A (n=19) or B (n=4). Twelve of the children were HIV-1 antibody +ve (11 CDC Group III, one Group IV-E), and 11 were HIV-1 antibody -ve. The median age of the HIV-1 positive and negative groups were 5.6 and 5.3 years respectively (range for both groups 0 months to 13 years, 8 months). Results are as follows:

Time from start of Immunization (months)	HIV-1 Positive	HIV-1 Negative	P
12-24	11/47 ± 1983	43/86 ± 3560	<0.05
25-36	13/27 ± 1983	23/96 ± 2663	<0.01
37-48	17/24 ± 2275	22/61 ± 2109	<0.005

Values are means ± 1 S.D. At the time of reporting, anti-HBeAg titres have fallen below protective levels (<40 RIA units) in 4 children (3 HIV-1 +ve, 1 HIV-1 -ve). One HIV-1 positive child, not included in this series, failed to respond to immunization. We conclude that hemophilic children with HIV-2 infection have an impaired response to hepatitis B immunization. In such children, follow-up of anti-HBeAg titres in conjunction of immunization and yearly serologic B recommendations.

Th.B.P.2 ANTIPHOSPHOLIPID ANTIBODIES AND HIV INFECTION IN HEMOPHILIA.
Sofia Taita, L. Ponchio, M. Montani, C.M. Montecucco*, G. Cascone, G. Gamba. Dipartimento di Medicina Interna e Terapia, Università Medica, Via di Clinica Medica II, IRCCS Policlinico San Matteo, Università di Pavia, Italy.

Objective: to study the presence of antiphospholipid antibodies (lupus like (LAC) and anticardiolipin (ACA) in Hemophilia. Patients: 30 pts. with Hemophilia B, 7 FPL+ positive for anti-HIV antibodies, without symptoms and signs of AIDS. Methods: LAC diagnosed by prolongation of Russell Viper Venous Time (RVVT), not corrected by adding of normal plasma. ACA detected by immunoenzymatic Test (ELISA), using POC conjugated with anti-murine antibodies against human IgG, IgM, IgA, IgE. Results: we detected ACA in 8 out of the 2 pts. with HIV infection. 6/8 in 4 of them also LAC, among the anti-HIV neg pts. only 4 showed ACA and 2 LAC. In pts. with ACA no correlation was found between serum IgG levels and IgG ACA prevalence of IgG ACA was observed in anti-HIV pos pts. (87.5%) while IgM ACA in HIV neg ones (75%). Conclusions: our results indicate that in Hemophilia: HIV infection induces the production of antibodies against phospholipid components; idiosyncratic behavior of ACA by Isotypes (IgG, IgM) was observed in relation to the presence of HIV infection; HIV infection promotes the formation of ACA earlier than of LAC.

Th.B.P.4 HIV INFECTION AND CHAGAS' DISEASE IN HEMOPHILICS IN ARGENTINA
Nancy Beltrán, Susana M. Simon, Susana Machin, O. Pichetto, P. Tello, V. Lelonek, P. P. R. Narkov, I. A. *

*IDEM, Academia Nacional de Medicina, Hospital de Niños, Buenos Aires, Argentina.

Objective. To analyze the relation between HIV-infection and Chagas' disease (CD) in 72 hemophilic (HF).

Methods. HIV serology was assayed thru ELISA (Abbott, recombinant). Positivity reacting samples were confirmed thru Immunofluorescence or Western Blot (Daport). CD diagnosis was performed by means of direct agglutination and indirect immunofluorescence (Polychuch), Titers 1:16 for both serologic tests were considered positive.

Results. Twenty-two out of 37 HIV-1 positive sera showed a positive test for CD. In addition, 18 out 33 HIV-1 negative sera gave a negative reading in the same assay.

Conclusion. Ch is an hemoparasitosis, endemic for our country. Blood transfusions constitute one of the major ways of dissemination. Ch shows the same prevalence on HIV-1 positive and HIV-1 negative HF (p>0.05). Similar results were observed in other HIV-1-risk groups, such as homosexuals (30), and drug abusers (30). By contrast with the reported occurrence of other endemic diseases (for ex., tuberculosis) as second opportunistic infections, in our serologic infected patients did not present higher susceptibility to Ch than that exhibited by HIV-1 negative HF.

Th.B.P.6 BENEFICIAL EFFECT OF AN ULTRAPURE FACTOR VIII CONCENTRATE ON HYPERANEMICOLICEMIA IN HIV-POSITIVE HEMOPHILIC.

Schulman, Sam and Johansson, B. Department of Internal Medicine, Karolinska Hospital, Stockholm, Sweden.

Objective: Elevated IgG-levels are often seen in hemophilia. The etiology is multifactorial, including passive transfer of IgG via the factor concentrates, antigenic stimulation by foreign proteins, chronic hepatitis and HIV-infection. We still remainly the possibility of a direct substitute of immunoglobulin proteins and CIX of F VIII. Since 1987, we have had access to an ultrapure factor concentrate, containing only F VIII and albumin.

Methods: Immunoglobulin G, A and M were followed at 2 months intervals since 1988 in 19 HIV-positive patients. Nine of those were switched to an ultrapure factor concentrate (Benefil B, Baxter) during Aug 87 - Apr 88. The remaining 8 patients ("control group") continued using conventional concentrates. Results were analyzed with Wilcoxon's signed rank test.

Results: The mean IgG-level in the Benefil B group increased from 16.4 in 1988 to 20.4 at the time they were switched to Benefil B (p=0.08) and then decreased during the following year to 17.9 (p<0.02). In the control group the mean IgG-level was at corresponding times, 16.4, 19.2 and 18.7, thus also an initial increase (p<0.02), but thereafter no changes. In the Benefil B group it was mainly the 3 patients with the highest IgG-levels (23.0; 29.7 and 37.4 g/L), who had a beneficial effect. The last one also had pulmonary hypertension, which improved spontaneously. IgA and IgM did not change.

Conclusion: Switching to an ultrapure factor concentrate seems to have a favourable effect in HIV-positive hemophilic, especially in those with pronounced hypergammaglobulinemia.

Session d'affichage Poster Session



Th.B.P.19 HEMPHILLIC AGE AFFECTS IMMUNE FUNCTIONS IN HIV INFECTED PATIENTS

Adams, W. ¹Abu² Wallif, K.*; Lamotte, C.*; Deal, C.*; Morgan, J.*; McMillin, M.*; Heston, K.*; ¹University of Louisiana at Monroe, ²Louisiana State University School of Medicine, ³Department of Pediatrics and the Tulane/LSU AIDS, New Orleans, Louisiana, USA.

We have followed approximately 200 hemophilic (H) at our State Center since 1980. Overall 53% (103) of the patients who used any non-treated factor VIII or IX concentrates seroconverted. Of those children (C) (13) 27/99, adolescents (Ado) (18) 27/45, and adults (A) 52/117 developed specific HIV antibodies. 100% of the children, 90% of the adolescents and 85% of the adults had seroconverted to seropositively develop T4's <500 but without AIDS (Ado's) 40% or Ado's - 60, 28, and 37 this reduction occurred at a rate of approximately 30 (11-36) T4 cells per month. Eight patients after a period of 25-75 months following seroconversion with CD4 T4 cells without developing disease though 8 others suffered AIDS with such low numbers. Fourteen patients - 3 C, 1 Ado, and 10 Ado - have developed AIDS after a period of 25-75 months following seroconversion. Of all H who remain seronegative, 2/60 T4 counts have been <500 and none have developed AIDS. Such findings may alter our concepts of approach of therapy of HIV infected H and a better understanding of the immune abnormalities such patients exhibit. Patients may remain well with few T4 cells. No assessments can yet be offered since none will deteriorate, usually after suffering symptoms suggestive of latent AIDS.

Hémophilie : autres virus Hémophilie: Other Viruses

Th.B.P.21 COMPARAISON D'UN NOUVEAU SÉRUM POUR LE VIRUS VIH 2

Trochu, J.-L., Jolly, J.-M., Puel, J.-M., Bore-Milinet, A., Givry, G., Bégin, C.
* Laboratoire de Virologie, Hôpital de Neurologie Cléop, France; ** Laboratoire de Virologie, CHU Purpan, 31009 Toulouse Cedex, France; *** Laboratoire de Virologie, Hôpital St Bernard, 75000 Paris, France.

Objectif: Possibilité de contamination d'un jeune hémostatique par le virus VIH 2 en mars 1985 à partir d'une perfusion de facteur de substitution non stérilisé gardé par négligence.
Méthode: Surveillance sérologique et biologique depuis 1984. Les études virologiques comportent un dosage des AC en ELISA, un sérotype en Western-blot pour VIH 1 et VIH 2 (high et low), et études virales sur lymphocytes pour confirmation.
Résultats: Les différents bilans révèlent une co-infection par le virus VIH 1 en Décembre 1985.
Un an après le contact, il va développer un syndrome lymphodémothétique avec parallèlement une baisse des lymphocytes T4 (CD4) et une inversion transitoire du rapport T4.

La confirmation de l'infection par le virus VIH2 a pu être apportée par RPA et culture sur lymphocytes.
Conclusion: La contamination d'un hémostatique par le virus VIH 2 est rare en France. Il n'y a pas de différence dans l'expressivité clinique et biologique entre l'infection par le virus VIH 1 et VIH 2 étant donné qu'elle présente des caractéristiques communes de lymphotropisme et cytopathogénéité.

Th.B.P.23 AIDS RISKERS OF HEMIPHILIC-BORN VIRUS IN HIV-INFECTED HEMPHILLIC PATIENTS.

Drex, V., ¹Univ. of California, ²San Antonio, ³Univ. of California, ⁴San Antonio, ⁵Univ. of California, ⁶San Antonio, ⁷Univ. of California, ⁸San Antonio, ⁹Univ. of California, ¹⁰San Antonio, ¹¹Univ. of California, ¹²San Antonio, ¹³Univ. of California, ¹⁴San Antonio, ¹⁵Univ. of California, ¹⁶San Antonio, ¹⁷Univ. of California, ¹⁸San Antonio, ¹⁹Univ. of California, ²⁰San Antonio, ²¹Univ. of California, ²²San Antonio, ²³Univ. of California, ²⁴San Antonio, ²⁵Univ. of California, ²⁶San Antonio, ²⁷Univ. of California, ²⁸San Antonio, ²⁹Univ. of California, ³⁰San Antonio, ³¹Univ. of California, ³²San Antonio, ³³Univ. of California, ³⁴San Antonio, ³⁵Univ. of California, ³⁶San Antonio, ³⁷Univ. of California, ³⁸San Antonio, ³⁹Univ. of California, ⁴⁰San Antonio, ⁴¹Univ. of California, ⁴²San Antonio, ⁴³Univ. of California, ⁴⁴San Antonio, ⁴⁵Univ. of California, ⁴⁶San Antonio, ⁴⁷Univ. of California, ⁴⁸San Antonio, ⁴⁹Univ. of California, ⁵⁰San Antonio, ⁵¹Univ. of California, ⁵²San Antonio, ⁵³Univ. of California, ⁵⁴San Antonio, ⁵⁵Univ. of California, ⁵⁶San Antonio, ⁵⁷Univ. of California, ⁵⁸San Antonio, ⁵⁹Univ. of California, ⁶⁰San Antonio, ⁶¹Univ. of California, ⁶²San Antonio, ⁶³Univ. of California, ⁶⁴San Antonio, ⁶⁵Univ. of California, ⁶⁶San Antonio, ⁶⁷Univ. of California, ⁶⁸San Antonio, ⁶⁹Univ. of California, ⁷⁰San Antonio, ⁷¹Univ. of California, ⁷²San Antonio, ⁷³Univ. of California, ⁷⁴San Antonio, ⁷⁵Univ. of California, ⁷⁶San Antonio, ⁷⁷Univ. of California, ⁷⁸San Antonio, ⁷⁹Univ. of California, ⁸⁰San Antonio, ⁸¹Univ. of California, ⁸²San Antonio, ⁸³Univ. of California, ⁸⁴San Antonio, ⁸⁵Univ. of California, ⁸⁶San Antonio, ⁸⁷Univ. of California, ⁸⁸San Antonio, ⁸⁹Univ. of California, ⁹⁰San Antonio, ⁹¹Univ. of California, ⁹²San Antonio, ⁹³Univ. of California, ⁹⁴San Antonio, ⁹⁵Univ. of California, ⁹⁶San Antonio, ⁹⁷Univ. of California, ⁹⁸San Antonio, ⁹⁹Univ. of California, ¹⁰⁰San Antonio, ¹⁰¹Univ. of California, ¹⁰²San Antonio, ¹⁰³Univ. of California, ¹⁰⁴San Antonio, ¹⁰⁵Univ. of California, ¹⁰⁶San Antonio, ¹⁰⁷Univ. of California, ¹⁰⁸San Antonio, ¹⁰⁹Univ. of California, ¹¹⁰San Antonio, ¹¹¹Univ. of California, ¹¹²San Antonio, ¹¹³Univ. of California, ¹¹⁴San Antonio, ¹¹⁵Univ. of California, ¹¹⁶San Antonio, ¹¹⁷Univ. of California, ¹¹⁸San Antonio, ¹¹⁹Univ. of California, ¹²⁰San Antonio, ¹²¹Univ. of California, ¹²²San Antonio, ¹²³Univ. of California, ¹²⁴San Antonio, ¹²⁵Univ. of California, ¹²⁶San Antonio, ¹²⁷Univ. of California, ¹²⁸San Antonio, ¹²⁹Univ. of California, ¹³⁰San Antonio, ¹³¹Univ. of California, ¹³²San Antonio, ¹³³Univ. of California, ¹³⁴San Antonio, ¹³⁵Univ. of California, ¹³⁶San Antonio, ¹³⁷Univ. of California, ¹³⁸San Antonio, ¹³⁹Univ. of California, ¹⁴⁰San Antonio, ¹⁴¹Univ. of California, ¹⁴²San Antonio, ¹⁴³Univ. of California, ¹⁴⁴San Antonio, ¹⁴⁵Univ. of California, ¹⁴⁶San Antonio, ¹⁴⁷Univ. of California, ¹⁴⁸San Antonio, ¹⁴⁹Univ. of California, ¹⁵⁰San Antonio, ¹⁵¹Univ. of California, ¹⁵²San Antonio, ¹⁵³Univ. of California, ¹⁵⁴San Antonio, ¹⁵⁵Univ. of California, ¹⁵⁶San Antonio, ¹⁵⁷Univ. of California, ¹⁵⁸San Antonio, ¹⁵⁹Univ. of California, ¹⁶⁰San Antonio, ¹⁶¹Univ. of California, ¹⁶²San Antonio, ¹⁶³Univ. of California, ¹⁶⁴San Antonio, ¹⁶⁵Univ. of California, ¹⁶⁶San Antonio, ¹⁶⁷Univ. of California, ¹⁶⁸San Antonio, ¹⁶⁹Univ. of California, ¹⁷⁰San Antonio, ¹⁷¹Univ. of California, ¹⁷²San Antonio, ¹⁷³Univ. of California, ¹⁷⁴San Antonio, ¹⁷⁵Univ. of California, ¹⁷⁶San Antonio, ¹⁷⁷Univ. of California, ¹⁷⁸San Antonio, ¹⁷⁹Univ. of California, ¹⁸⁰San Antonio, ¹⁸¹Univ. of California, ¹⁸²San Antonio, ¹⁸³Univ. of California, ¹⁸⁴San Antonio, ¹⁸⁵Univ. of California, ¹⁸⁶San Antonio, ¹⁸⁷Univ. of California, ¹⁸⁸San Antonio, ¹⁸⁹Univ. of California, ¹⁹⁰San Antonio, ¹⁹¹Univ. of California, ¹⁹²San Antonio, ¹⁹³Univ. of California, ¹⁹⁴San Antonio, ¹⁹⁵Univ. of California, ¹⁹⁶San Antonio, ¹⁹⁷Univ. of California, ¹⁹⁸San Antonio, ¹⁹⁹Univ. of California, ²⁰⁰San Antonio, ²⁰¹Univ. of California, ²⁰²San Antonio, ²⁰³Univ. of California, ²⁰⁴San Antonio, ²⁰⁵Univ. of California, ²⁰⁶San Antonio, ²⁰⁷Univ. of California, ²⁰⁸San Antonio, ²⁰⁹Univ. of California, ²¹⁰San Antonio, ²¹¹Univ. of California, ²¹²San Antonio, ²¹³Univ. of California, ²¹⁴San Antonio, ²¹⁵Univ. of California, ²¹⁶San Antonio, ²¹⁷Univ. of California, ²¹⁸San Antonio, ²¹⁹Univ. of California, ²²⁰San Antonio, ²²¹Univ. of California, ²²²San Antonio, ²²³Univ. of California, ²²⁴San Antonio, ²²⁵Univ. of California, ²²⁶San Antonio, ²²⁷Univ. of California, ²²⁸San Antonio, ²²⁹Univ. of California, ²³⁰San Antonio, ²³¹Univ. of California, ²³²San Antonio, ²³³Univ. of California, ²³⁴San Antonio, ²³⁵Univ. of California, ²³⁶San Antonio, ²³⁷Univ. of California, ²³⁸San Antonio, ²³⁹Univ. of California, ²⁴⁰San Antonio, ²⁴¹Univ. of California, ²⁴²San Antonio, ²⁴³Univ. of California, ²⁴⁴San Antonio, ²⁴⁵Univ. of California, ²⁴⁶San Antonio, ²⁴⁷Univ. of California, ²⁴⁸San Antonio, ²⁴⁹Univ. of California, ²⁵⁰San Antonio, ²⁵¹Univ. of California, ²⁵²San Antonio, ²⁵³Univ. of California, ²⁵⁴San Antonio, ²⁵⁵Univ. of California, ²⁵⁶San Antonio, ²⁵⁷Univ. of California, ²⁵⁸San Antonio, ²⁵⁹Univ. of California, ²⁶⁰San Antonio, ²⁶¹Univ. of California, ²⁶²San Antonio, ²⁶³Univ. of California, ²⁶⁴San Antonio, ²⁶⁵Univ. of California, ²⁶⁶San Antonio, ²⁶⁷Univ. of California, ²⁶⁸San Antonio, ²⁶⁹Univ. of California, ²⁷⁰San Antonio, ²⁷¹Univ. of California, ²⁷²San Antonio, ²⁷³Univ. of California, ²⁷⁴San Antonio, ²⁷⁵Univ. of California, ²⁷⁶San Antonio, ²⁷⁷Univ. of California, ²⁷⁸San Antonio, ²⁷⁹Univ. of California, ²⁸⁰San Antonio, ²⁸¹Univ. of California, ²⁸²San Antonio, ²⁸³Univ. of California, ²⁸⁴San Antonio, ²⁸⁵Univ. of California, ²⁸⁶San Antonio, ²⁸⁷Univ. of California, ²⁸⁸San Antonio, ²⁸⁹Univ. of California, ²⁹⁰San Antonio, ²⁹¹Univ. of California, ²⁹²San Antonio, ²⁹³Univ. of California, ²⁹⁴San Antonio, ²⁹⁵Univ. of California, ²⁹⁶San Antonio, ²⁹⁷Univ. of California, ²⁹⁸San Antonio, ²⁹⁹Univ. of California, ³⁰⁰San Antonio, ³⁰¹Univ. of California, ³⁰²San Antonio, ³⁰³Univ. of California, ³⁰⁴San Antonio, ³⁰⁵Univ. of California, ³⁰⁶San Antonio, ³⁰⁷Univ. of California, ³⁰⁸San Antonio, ³⁰⁹Univ. of California, ³¹⁰San Antonio, ³¹¹Univ. of California, ³¹²San Antonio, ³¹³Univ. of California, ³¹⁴San Antonio, ³¹⁵Univ. of California, ³¹⁶San Antonio, ³¹⁷Univ. of California, ³¹⁸San Antonio, ³¹⁹Univ. of California, ³²⁰San Antonio, ³²¹Univ. of California, ³²²San Antonio, ³²³Univ. of California, ³²⁴San Antonio, ³²⁵Univ. of California, ³²⁶San Antonio, ³²⁷Univ. of California, ³²⁸San Antonio, ³²⁹Univ. of California, ³³⁰San Antonio, ³³¹Univ. of California, ³³²San Antonio, ³³³Univ. of California, ³³⁴San Antonio, ³³⁵Univ. of California, ³³⁶San Antonio, ³³⁷Univ. of California, ³³⁸San Antonio, ³³⁹Univ. of California, ³⁴⁰San Antonio, ³⁴¹Univ. of California, ³⁴²San Antonio, ³⁴³Univ. of California, ³⁴⁴San Antonio, ³⁴⁵Univ. of California, ³⁴⁶San Antonio, ³⁴⁷Univ. of California, ³⁴⁸San Antonio, ³⁴⁹Univ. of California, ³⁵⁰San Antonio, ³⁵¹Univ. of California, ³⁵²San Antonio, ³⁵³Univ. of California, ³⁵⁴San Antonio, ³⁵⁵Univ. of California, ³⁵⁶San Antonio, ³⁵⁷Univ. of California, ³⁵⁸San Antonio, ³⁵⁹Univ. of California, ³⁶⁰San Antonio, ³⁶¹Univ. of California, ³⁶²San Antonio, ³⁶³Univ. of California, ³⁶⁴San Antonio, ³⁶⁵Univ. of California, ³⁶⁶San Antonio, ³⁶⁷Univ. of California, ³⁶⁸San Antonio, ³⁶⁹Univ. of California, ³⁷⁰San Antonio, ³⁷¹Univ. of California, ³⁷²San Antonio, ³⁷³Univ. of California, ³⁷⁴San Antonio, ³⁷⁵Univ. of California, ³⁷⁶San Antonio, ³⁷⁷Univ. of California, ³⁷⁸San Antonio, ³⁷⁹Univ. of California, ³⁸⁰San Antonio, ³⁸¹Univ. of California, ³⁸²San Antonio, ³⁸³Univ. of California, ³⁸⁴San Antonio, ³⁸⁵Univ. of California, ³⁸⁶San Antonio, ³⁸⁷Univ. of California, ³⁸⁸San Antonio, ³⁸⁹Univ. of California, ³⁹⁰San Antonio, ³⁹¹Univ. of California, ³⁹²San Antonio, ³⁹³Univ. of California, ³⁹⁴San Antonio, ³⁹⁵Univ. of California, ³⁹⁶San Antonio, ³⁹⁷Univ. of California, ³⁹⁸San Antonio, ³⁹⁹Univ. of California, ⁴⁰⁰San Antonio, ⁴⁰¹Univ. of California, ⁴⁰²San Antonio, ⁴⁰³Univ. of California, ⁴⁰⁴San Antonio, ⁴⁰⁵Univ. of California, ⁴⁰⁶San Antonio, ⁴⁰⁷Univ. of California, ⁴⁰⁸San Antonio, ⁴⁰⁹Univ. of California, ⁴¹⁰San Antonio, ⁴¹¹Univ. of California, ⁴¹²San Antonio, ⁴¹³Univ. of California, ⁴¹⁴San Antonio, ⁴¹⁵Univ. of California, ⁴¹⁶San Antonio, ⁴¹⁷Univ. of California, ⁴¹⁸San Antonio, ⁴¹⁹Univ. of California, ⁴²⁰San Antonio, ⁴²¹Univ. of California, ⁴²²San Antonio, ⁴²³Univ. of California, ⁴²⁴San Antonio, ⁴²⁵Univ. of California, ⁴²⁶San Antonio, ⁴²⁷Univ. of California, ⁴²⁸San Antonio, ⁴²⁹Univ. of California, ⁴³⁰San Antonio, ⁴³¹Univ. of California, ⁴³²San Antonio, ⁴³³Univ. of California, ⁴³⁴San Antonio, ⁴³⁵Univ. of California, ⁴³⁶San Antonio, ⁴³⁷Univ. of California, ⁴³⁸San Antonio, ⁴³⁹Univ. of California, ⁴⁴⁰San Antonio, ⁴⁴¹Univ. of California, ⁴⁴²San Antonio, ⁴⁴³Univ. of California, ⁴⁴⁴San Antonio, ⁴⁴⁵Univ. of California, ⁴⁴⁶San Antonio, ⁴⁴⁷Univ. of California, ⁴⁴⁸San Antonio, ⁴⁴⁹Univ. of California, ⁴⁵⁰San Antonio, ⁴⁵¹Univ. of California, ⁴⁵²San Antonio, ⁴⁵³Univ. of California, ⁴⁵⁴San Antonio, ⁴⁵⁵Univ. of California, ⁴⁵⁶San Antonio, ⁴⁵⁷Univ. of California, ⁴⁵⁸San Antonio, ⁴⁵⁹Univ. of California, ⁴⁶⁰San Antonio, ⁴⁶¹Univ. of California, ⁴⁶²San Antonio, ⁴⁶³Univ. of California, ⁴⁶⁴San Antonio, ⁴⁶⁵Univ. of California, ⁴⁶⁶San Antonio, ⁴⁶⁷Univ. of California, ⁴⁶⁸San Antonio, ⁴⁶⁹Univ. of California, ⁴⁷⁰San Antonio, ⁴⁷¹Univ. of California, ⁴⁷²San Antonio, ⁴⁷³Univ. of California, ⁴⁷⁴San Antonio, ⁴⁷⁵Univ. of California, ⁴⁷⁶San Antonio, ⁴⁷⁷Univ. of California, ⁴⁷⁸San Antonio, ⁴⁷⁹Univ. of California, ⁴⁸⁰San Antonio, ⁴⁸¹Univ. of California, ⁴⁸²San Antonio, ⁴⁸³Univ. of California, ⁴⁸⁴San Antonio, ⁴⁸⁵Univ. of California, ⁴⁸⁶San Antonio, ⁴⁸⁷Univ. of California, ⁴⁸⁸San Antonio, ⁴⁸⁹Univ. of California, ⁴⁹⁰San Antonio, ⁴⁹¹Univ. of California, ⁴⁹²San Antonio, ⁴⁹³Univ. of California, ⁴⁹⁴San Antonio, ⁴⁹⁵Univ. of California, ⁴⁹⁶San Antonio, ⁴⁹⁷Univ. of California, ⁴⁹⁸San Antonio, ⁴⁹⁹Univ. of California, ⁵⁰⁰San Antonio, ⁵⁰¹Univ. of California, ⁵⁰²San Antonio, ⁵⁰³Univ. of California, ⁵⁰⁴San Antonio, ⁵⁰⁵Univ. of California, ⁵⁰⁶San Antonio, ⁵⁰⁷Univ. of California, ⁵⁰⁸San Antonio, ⁵⁰⁹Univ. of California, ⁵¹⁰San Antonio, ⁵¹¹Univ. of California, ⁵¹²San Antonio, ⁵¹³Univ. of California, ⁵¹⁴San Antonio, ⁵¹⁵Univ. of California, ⁵¹⁶San Antonio, ⁵¹⁷Univ. of California, ⁵¹⁸San Antonio, ⁵¹⁹Univ. of California, ⁵²⁰San Antonio, ⁵²¹Univ. of California, ⁵²²San Antonio, ⁵²³Univ. of California, ⁵²⁴San Antonio, ⁵²⁵Univ. of California, ⁵²⁶San Antonio, ⁵²⁷Univ. of California, ⁵²⁸San Antonio, ⁵²⁹Univ. of California, ⁵³⁰San Antonio, ⁵³¹Univ. of California, ⁵³²San Antonio, ⁵³³Univ. of California, ⁵³⁴San Antonio, ⁵³⁵Univ. of California, ⁵³⁶San Antonio, ⁵³⁷Univ. of California, ⁵³⁸San Antonio, ⁵³⁹Univ. of California, ⁵⁴⁰San Antonio, ⁵⁴¹Univ. of California, ⁵⁴²San Antonio, ⁵⁴³Univ. of California, ⁵⁴⁴San Antonio, ⁵⁴⁵Univ. of California, ⁵⁴⁶San Antonio, ⁵⁴⁷Univ. of California, ⁵⁴⁸San Antonio, ⁵⁴⁹Univ. of California, ⁵⁵⁰San Antonio, ⁵⁵¹Univ. of California, ⁵⁵²San Antonio, ⁵⁵³Univ. of California, ⁵⁵⁴San Antonio, ⁵⁵⁵Univ. of California, ⁵⁵⁶San Antonio, ⁵⁵⁷Univ. of California, ⁵⁵⁸San Antonio, ⁵⁵⁹Univ. of California, ⁵⁶⁰San Antonio, ⁵⁶¹Univ. of California, ⁵⁶²San Antonio, ⁵⁶³Univ. of California, ⁵⁶⁴San Antonio, ⁵⁶⁵Univ. of California, ⁵⁶⁶San Antonio, ⁵⁶⁷Univ. of California, ⁵⁶⁸San Antonio, ⁵⁶⁹Univ. of California, ⁵⁷⁰San Antonio, ⁵⁷¹Univ. of California, ⁵⁷²San Antonio, ⁵⁷³Univ. of California, ⁵⁷⁴San Antonio, ⁵⁷⁵Univ. of California, ⁵⁷⁶San Antonio, ⁵⁷⁷Univ. of California, ⁵⁷⁸San Antonio, ⁵⁷⁹Univ. of California, ⁵⁸⁰San Antonio, ⁵⁸¹Univ. of California, ⁵⁸²San Antonio, ⁵⁸³Univ. of California, ⁵⁸⁴San Antonio, ⁵⁸⁵Univ. of California, ⁵⁸⁶San Antonio, ⁵⁸⁷Univ. of California, ⁵⁸⁸San Antonio, ⁵⁸⁹Univ. of California, ⁵⁹⁰San Antonio, ⁵⁹¹Univ. of California, ⁵⁹²San Antonio, ⁵⁹³Univ. of California, ⁵⁹⁴San Antonio, ⁵⁹⁵Univ. of California, ⁵⁹⁶San Antonio, ⁵⁹⁷Univ. of California, ⁵⁹⁸San Antonio, ⁵⁹⁹Univ. of California, ⁶⁰⁰San Antonio, ⁶⁰¹Univ. of California, ⁶⁰²San Antonio, ⁶⁰³Univ. of California, ⁶⁰⁴San Antonio, ⁶⁰⁵Univ. of California, ⁶⁰⁶San Antonio, ⁶⁰⁷Univ. of California, ⁶⁰⁸San Antonio, ⁶⁰⁹Univ. of California, ⁶¹⁰San Antonio, ⁶¹¹Univ. of California, ⁶¹²San Antonio, ⁶¹³Univ. of California, ⁶¹⁴San Antonio, ⁶¹⁵Univ. of California, ⁶¹⁶San Antonio, ⁶¹⁷Univ. of California, ⁶¹⁸San Antonio, ⁶¹⁹Univ. of California, ⁶²⁰San Antonio, ⁶²¹Univ. of California, ⁶²²San Antonio, ⁶²³Univ. of California, ⁶²⁴San Antonio, ⁶²⁵Univ. of California, ⁶²⁶San Antonio, ⁶²⁷Univ. of California, ⁶²⁸San Antonio, ⁶²⁹Univ. of California, ⁶³⁰San Antonio, ⁶³¹Univ. of California, ⁶³²San Antonio, ⁶³³Univ. of California, ⁶³⁴San Antonio, ⁶³⁵Univ. of California, ⁶³⁶San Antonio, ⁶³⁷Univ. of California, ⁶³⁸San Antonio, ⁶³⁹Univ. of California, ⁶⁴⁰San Antonio, ⁶⁴¹Univ. of California, ⁶⁴²San Antonio, ⁶⁴³Univ. of California, ⁶⁴⁴San Antonio, ⁶⁴⁵Univ. of California, ⁶⁴⁶San Antonio, ⁶⁴⁷Univ. of California, ⁶⁴⁸San Antonio, ⁶⁴⁹Univ. of California, ⁶⁵⁰San Antonio, ⁶⁵¹Univ. of California, ⁶⁵²San Antonio, ⁶⁵³Univ. of California, ⁶⁵⁴San Antonio, ⁶⁵⁵Univ. of California, ⁶⁵⁶San Antonio, ⁶⁵⁷Univ. of California, ⁶⁵⁸San Antonio, ⁶⁵⁹Univ. of California, ⁶⁶⁰San Antonio, ⁶⁶¹Univ. of California, ⁶⁶²San Antonio, ⁶⁶³Univ. of California, ⁶⁶⁴San Antonio, ⁶⁶⁵Univ. of California, ⁶⁶⁶San Antonio, ⁶⁶⁷Univ. of California, ⁶⁶⁸San Antonio, ⁶⁶⁹Univ. of California, ⁶⁷⁰San Antonio, ⁶⁷¹Univ. of California, ⁶⁷²San Antonio, ⁶⁷³Univ. of California, ⁶⁷⁴San Antonio, ⁶⁷⁵Univ. of California, ⁶⁷⁶San Antonio, ⁶⁷⁷Univ. of California, ⁶⁷⁸San Antonio, ⁶⁷⁹Univ. of California, ⁶⁸⁰San Antonio, ⁶⁸¹Univ. of California, ⁶⁸²San Antonio, ⁶⁸³Univ. of California, ⁶⁸⁴San Antonio, ⁶⁸⁵Univ. of California, ⁶⁸⁶San Antonio, ⁶⁸⁷Univ. of California, ⁶⁸⁸San Antonio, ⁶⁸⁹Univ. of California, ⁶⁹⁰San Antonio, ⁶⁹¹Univ. of California, ⁶⁹²San Antonio, ⁶⁹³Univ. of California, ⁶⁹⁴San Antonio, ⁶⁹⁵Univ. of California, ⁶⁹⁶San Antonio, ⁶⁹⁷Univ. of California, ⁶⁹⁸San Antonio, ⁶⁹⁹Univ. of California, ⁷⁰⁰San Antonio, ⁷⁰¹Univ. of California, ⁷⁰²San Antonio, ⁷⁰³Univ. of California, ⁷⁰⁴San Antonio, ⁷⁰⁵Univ. of California, ⁷⁰⁶San Antonio, ⁷⁰⁷Univ. of California, ⁷⁰⁸San Antonio, ⁷⁰⁹Univ. of California, ⁷¹⁰San Antonio, ⁷¹¹Univ. of California, ⁷¹²San Antonio, ⁷¹³Univ. of California, ⁷¹⁴San Antonio, ⁷¹⁵Univ. of California, ⁷¹⁶San Antonio, ⁷¹⁷Univ. of California, ⁷¹⁸San Antonio, ⁷¹⁹Univ. of California, ⁷²⁰San Antonio, ⁷²¹Univ. of California, ⁷²²San Antonio, ⁷²³Univ. of California, ⁷²⁴San Antonio, ⁷²⁵Univ. of California, ⁷²⁶San Antonio, ⁷²⁷Univ. of California, ⁷²⁸San Antonio, ⁷²⁹Univ. of California, ⁷³⁰San Antonio, ⁷³¹Univ. of California, ⁷³²San Antonio, ⁷³³Univ. of California, ⁷³⁴San Antonio, ⁷³⁵Univ. of California, ⁷³⁶San Antonio, ⁷³⁷Univ. of California, ⁷³⁸San Antonio, ⁷³⁹Univ. of California, ⁷⁴⁰San Antonio, ⁷⁴¹Univ. of California, ⁷⁴²San Antonio, ⁷⁴³Univ. of California, ⁷⁴⁴San Antonio, ⁷⁴⁵Univ. of California, ⁷⁴⁶San Antonio, ⁷⁴⁷Univ. of California, ⁷⁴⁸San Antonio, ⁷⁴⁹Univ. of California, ⁷⁵⁰San Antonio, ⁷⁵¹Univ. of California, ⁷⁵²San Antonio, ⁷⁵³Univ. of California, ⁷⁵⁴San Antonio, ⁷⁵⁵Univ. of California, ⁷⁵⁶San Antonio, ⁷⁵⁷Univ. of California, ⁷⁵⁸San Antonio, ⁷⁵⁹Univ. of California, ⁷⁶⁰San Antonio, ⁷⁶¹Univ. of California, ⁷⁶²San Antonio, ⁷⁶³Univ. of California, ⁷⁶⁴San Antonio, ⁷⁶⁵Univ. of California, ⁷⁶⁶San Antonio, ⁷⁶⁷Univ. of California, ⁷⁶⁸San Antonio, ⁷⁶⁹Univ. of California, ⁷⁷⁰San Antonio, ⁷⁷¹Univ. of California, ⁷⁷²San Antonio, ⁷⁷³Univ. of California, ⁷⁷⁴San Antonio, ⁷⁷⁵Univ. of California, ⁷⁷⁶San Antonio, ⁷⁷⁷Univ. of California, ⁷⁷⁸San Antonio, ⁷⁷⁹Univ. of California, ⁷⁸⁰San Antonio, ⁷⁸¹Univ. of California, ⁷⁸²San Antonio, ⁷⁸³Univ. of California, ⁷⁸⁴San Antonio, ⁷⁸⁵Univ. of California, ⁷⁸⁶San Antonio, ⁷⁸⁷Univ. of California, ⁷⁸⁸San Antonio, ⁷⁸⁹Univ. of California, ⁷⁹⁰San Antonio, ⁷⁹¹Univ. of California, ⁷⁹²San Antonio, ⁷⁹³Univ. of California, ⁷⁹⁴San Antonio, ⁷⁹⁵Univ. of California, ⁷⁹⁶San Antonio, ⁷⁹⁷Univ. of California, ⁷⁹⁸San Antonio, ⁷⁹⁹Univ. of California, ⁸⁰⁰San Antonio, ⁸⁰¹Univ. of California, ⁸⁰²San Antonio, ⁸⁰³Univ. of California, ⁸⁰⁴San Antonio, ⁸⁰⁵Univ. of California, ⁸⁰⁶San Antonio, ⁸⁰⁷Univ. of California, ⁸⁰⁸San Antonio,

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

Th.B.P.31 PSYCHOLOGICAL AND NEUROPSYCHOLOGICAL STATUS OF HEMOPHILIACS AND MEN WITH HIV INFECTION: A CONTROLLED INVESTIGATION.

Catlin, J., Kline, J., Bond, A., Garrod, A., Day, A., and MacC.***

*Dept. Clinical Psychology and **Oxford University Dept. Psychology, Mansfield Hospital, Oxford, and ***Oxford Hemophilia Centre, Oxford, U.K.

Objective. To establish prevalence of psychosocial and neuropsychological problems in HIV subjects; to compare the two transmission groups; to identify the characteristics of those with problems.

Methods. HIV hemophiliacs (n=38) and HIV hemophilia controls (n=35) and HIV men (n=20) and HIV men controls (n=25) were studied. Measures included psychiatric state (PSE, POMS, Impulsiveness), coping (Herdines), locus of control, social and sexual adjustment, neuropsychological screen (Trail A and B, digit symbol, verbal fluency).

Results. In both transmission groups HIV individuals had higher levels of psychological symptoms than HIV controls. Increase of HIV status gay men had higher levels of psychological problems than hemophiliacs, and this difference was especially marked in the case of negative individuals where it was found that gay men had much higher levels of psychological problems than negative hemophiliacs. No differences were found between groups on neuropsychological measures.

Conclusions. HIV infection appears to be associated with psychological problems irrespective of transmission category. Asymptomatic individuals do not show neuropsychological impairment. HIV men (whatever their HIV status) seem more likely to experience psychological problems. The therapy implications of this finding need to be considered.

Th.B.P.33 PREDICTION OF SAFER SEX PRACTICE AND PSYCHOLOGICAL DISTRESS IN AIDS-RISK HEMOPHILIACS AT RISK FOR AIDS

Farley, Kathy L., Mendel, J., Thomas, J., and Gompertz, E.*

*Childrens Hospital of Los Angeles, **University of California San Francisco, San Francisco, CA, U.S.A.

Objective. To determine which behavioral factors are predictive of consistent condom use and psychosocial distress in hemophilic adults at risk for AIDS. **Methods.** A self-administered questionnaire was sent to all 975 identified persons with hemophilia in California in 1987-88. Items were designed to identify factors associated with decreasing transmission of HIV to partners and with psychosocial distress levels indicative of need for intervention.

Results. Analyses of data from 351 respondents indicate that only one-third report consistent condom use during vaginal intercourse. Predictors to consistent condom use were discussion of safer sex with partner, knowledge of HIV test results, and postponement of obtaining these factors produced a cumulative R² of .44. 56% of respondents indicated experiencing significant distress. Predictors to psychosocial distress were worrying about transmitting HIV, perceived chance of developing AIDS overall, occupational stress, and knowledge of HIV test results, again with a cumulative R² of .44.

Conclusion. Assessment of HIV serostatus appears to be linked both to safer sex practice and psychosocial distress, emphasizing the need for ongoing support to these individuals and their families. Couple communication and perceived risk of AIDS for self and others are key factors in partner use of AIDS. A better understanding of the impact of the AIDS threat on partners and couple functioning, in order to facilitate communication and shared responsibility for risk reduction in couples, is needed.

Th.B.P.35 A TEAM RESPONSE TO HIV/AIDS CARE IN PERSONS WITH HEMOPHILIA

Reza, M., G.S.G.W., C.S.W., Robert O'Neill

Social Services Advisor, Federal Centre for AIDS, Health and Welfare Canada, Ottawa, Canada; Canadian Hemophilia Society

This paper describes how interdisciplinary "dialogue days" was used as an approach to team building in introducing HIV/AIDS care to Canadian Hemophilia Care. The "dialogue days" conducted in 1987 and 1988 involved hematologists, nurses, coordinators, social workers and psychologists. The dialogue health care professionals identified dimensions of HIV/AIDS care needs in the hemophilia community, shared information, re-examined roles and recognized important linkages.

The extended "results" of these dialogue days will be presented at this conference. The results will demonstrate how interprofessional "dialogue days" can be a critical step in re-defining the roles of various health care team members in response to a new health care situation.

Th.B.P.32 RISK FACTORS FOR PSYCHIATRIC DISTRESS AMONG HEMOPHILIACS INFECTED WITH HIV

Rea, Mary Annala; Ragan, M.***; and Sherris, J.***

University of Pittsburgh, Pittsburgh, Pa., USA; *Hemophilia Center of Western Pennsylvania, Pittsburgh, Pa., USA.

Objective. To assess psychiatric correlates of HIV infection in a major risk group for AIDS; to identify psychosocial characteristics of HIV+ men that increase their risk for psychiatric distress following infection.

Methods. All moderate/severe hemophiliacs residing in western Pennsylvania, USA, plus mild hemophiliacs known to the regional Hemophilia Center, were contacted. Seventy-five men (73% of the population) were interviewed and their medical records were reviewed: 31 were HIV+ and 44 were HIV-.

Results. HIV+ men had significantly higher SCL-90-R symptom scores than HIV- men, particularly in depression and anxiety areas. There were no differences among HIV+ men according to infection stage or clinical severity of hemophilia. Factors associated with the effects of infection on mental health: family psychiatric history, low social support from wife, low family support, low friend support, a poor sense of personal efficacy, perceiving high daily stress related to HIV, and experiencing recent life events involving loss. HIV+ men with one or more such characteristics were clinically more distressed than HIV- men with multiple factors were present.

Conclusions. These data suggest that clinical services to alleviate distress in infected populations should be targeted to intervene on these psychosocial assets and liabilities that individuals bring to the situation.

Th.B.P.34 GUIDELINES FOR DEALING WITH PREGNANCY IN SEROPOSITIVE HEMOPHILIACS AND THEIR SPOUSES

James, E., and Borcher, S.

NEW England Hemophilia Center, Worcester Regional Hospital, Worcester, Massachusetts, U.S.A.

Objective. To describe a protocol for HIV testing in pregnancies of seropositive hemophiliacs and their spouses.

Methods. All patients followed at the New England Hemophilia Center receive counselling concerning HIV transmission. "Safe sex" practices and avoidance of pregnancy is strongly advocated. However, pregnancies among seropositive hemophiliacs and their spouses have occurred. Since 1983, a protocol for testing wives awaiting on pregnancy has been instituted. The wife is tested every 2-3 mos. until conception, condom use is recommended except at time of ovulation. HIV Ab testing is performed at 6 to 8 and 12 to 16 weeks gestation (so that termination is an option if seroconversion occurs), and at 3 mos.

Results. Since 1983, 13 pregnancies have occurred in 9 couples with a seropositive hemophiliac. Eight pregnancies were monitored according to our protocol, and all wives were seronegative. There were 3 full term pregnancies (children alive and well at ages 4 mos. to 2 1/2 yrs.), 2 were miscarriages and 3 are ongoing (2 at 3 mos. gestation, 1 at 5 mos. gestation). The pregnancies have been monitored (on protocol), one completed and one ongoing at 5 mos. gestation. At 8 wks. gestation of the first pregnancy the wife was found to be seropositive, the couple decided to continue the pregnancy after intensive counselling. The baby was seropositive at birth.

Conclusions. Despite efforts to inform seropositive patients and their wives of the risks of HIV transmission, some will choose to become pregnant. HIV testing during the pregnancy will allow the couple to make informed decisions about the pregnancy should seroconversion occur.

Maladies mycobactériennes Mycobacterial Diseases

Th.B.P.36 TUBERCULOSIS IN AIDS PATIENTS IN RIO GRANDE DO SUL: A NEW EPIDEMIC?

Spring, Eduardo, Krowfki, M.

Hospital de Clínica de Porto Alegre, Rio Grande do Sul, Brasil.

Universidade Federal, Porto Alegre, Rio Grande do Sul, Brasil.

Objective: Establish the incidence and the most common sites affected by Mycobacterium tuberculosis in AIDS patients in Rio Grande do Sul (RS) state.

Methods: It was reviewed, at random, 50 AIDS inpatients at Hospital de Clínica de Porto Alegre, from July to December, 1988, considered positive if the culture, from any site, "in vivo" or "post-mortem", identified Koch bacilli.

Results: In 50 patients (40%) Koch bacilli was present. 25 (50%) were at three or more sites (mainly lungs, bones, lymph nodes and gastrointestinal tract); 25 (50%) at gastrointestinal tract; 20 (40%), in lungs; 20 (40%), in lymph nodes; 1, in pericardium and the other with lung and joint involvement.

Conclusion: These are expressive numbers. First, it is one of the highest incidence of tuberculosis in the world. Second, the site of involvement does not seem to influence the mortality of the group. Last, it is very important to consider the presence of Koch bacilli in AIDS patients coming from RS state.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

Th.B.P.37

Th.B.P.37 **GASTROINTESTINAL TUBERCULOSIS IN AIDS PATIENTS** THE RIO GRANDE DO SUL, BRAZIL
 Maria Luiza Mendes, Ronaldo, F.
 Hospital do Clínicos do Centro Médico Rio Grande do Sul, Brasil, Universidade Federal do Rio Grande do Sul, Brasil.
Objective: Study the incidence of gastrointestinal tuberculosis and its relation with diarrhea in Rio Grande do Sul (RS) State, Brazil. The registers of 57 AIDS inpatients at MCOB between July and December 1987 were reviewed (6 were excluded, as they did not have diarrhea).
Results: From the remaining 49 cases, 16 (32.6%) cultures of *Mycobacterium avium* (M_{av}) or gastrointestinal biopsy at necropsy (n=2) yielded *Mycobacterium tuberculosis*. In all 7 cases the diarrhea improved with the use of anti-tuberculous drugs.
Conclusion: Our findings support the importance of gastrointestinal tuberculosis as a common treatable cause of diarrhea in patients with AIDS.

Th.B.P.39 GASTROINTESTINAL TUBERCULOSIS IN AIDS PATIENTS THE RIO GRANDE DO SUL, BRAZIL

Th.B.P.39 **GASTROINTESTINAL TUBERCULOSIS IN AIDS PATIENTS** THE RIO GRANDE DO SUL, BRAZIL
 Maria Luiza Mendes, Ronaldo, F.
 Hospital do Clínicos do Centro Médico Rio Grande do Sul, Brasil, Universidade Federal do Rio Grande do Sul, Brasil.
Objective: Study the incidence of gastrointestinal tuberculosis and its relation with diarrhea in Rio Grande do Sul (RS) State, Brazil. The registers of 57 AIDS inpatients at MCOB between July and December 1987 were reviewed (6 were excluded, as they did not have diarrhea).
Results: From the remaining 49 cases, 16 (32.6%) cultures of *Mycobacterium avium* (M_{av}) or gastrointestinal biopsy at necropsy (n=2) yielded *Mycobacterium tuberculosis*. In all 7 cases the diarrhea improved with the use of anti-tuberculous drugs.
Conclusion: Our findings support the importance of gastrointestinal tuberculosis as a common treatable cause of diarrhea in patients with AIDS.

Th.B.P.41 DRUG-RESISTANT TUBERCULOSIS IN AIDS AND ARC

Th.B.P.41 **DRUG-RESISTANT TUBERCULOSIS IN AIDS AND ARC**
 Polio-Hermes A, Raddilung M.C, Batten R.C.
 Department of Medicine, Cabrini Medical Center, N.Y.C., USA
Objective: Tuberculosis (TB) is now frequently reported in AIDS, and its proper treatment remains to be determined. We reviewed the prevalence of drug-resistant Mycobacterium tuberculosis in patients with AIDS or ARC.

Methods: We searched our mycobacteriology registry for all cases of TB from 1982 to 1988. Of 137 patients, 13 had AIDS or ARC; their clinical records were reviewed.

Results: There were 11 men and 2 women (mean age 38); 4 were Hispanic, 3 black, 3 white and 1 Asian. Risk factors were: homosexual/bisexual in 7, intravenous drug abuse in 4, heterosexual contact in 1, and unknown in 1. Two patients had ARC, 11 AIDS. Five patients had a history of TB. M_{av} tuberculosis was isolated from lungs (1), blood (1), bone marrow (2), CSF (1), lymph node (1). Chest X-ray showed apical lesions with or without cavitation in 4 patients, and diffuse interstitial infiltrates in 4. In only 3 patients was TB only and alone in the lungs. Most patients initially received 3 drug and improved; two died of other AIDS-related diseases. Resistance to either INH, RMP, EMB or SM was present in 7 cases (5/21 versus 0.13 in our total TB population), and in 2 of them (homosexuals) to both INH and RMP.

Conclusions: Atypical manifestations of TB were common in our patients with AIDS or ARC. Resistance was seen in 3 cases; in 2 of them 3 drugs, but these patients were homosexual and drug-resistant TB may be expected. Thus, AIDS/ARC patients are not associated with increased drug-resistant TB, and an initial 2-drug regimen is probably sufficient.

Th.B.P.38 THORACIC RADIOGRAPHIC ASPECTS OF TUBERCULOSIS IN AIDS

Th.B.P.38 **THORACIC RADIOGRAPHIC ASPECTS OF TUBERCULOSIS IN AIDS**
 Taisabala, R.K., Accetturo, J., Casapalheiro, S.A., Siqueira, J., Passaro, and Zamboni, A.M., *Department of Imaging Diagnostics, Division of Infectious Diseases, Health Center, *Department of Pathology, ESCOLA Paulista de Medicina, São Paulo, Brazil.

The authors present an evaluation of thoracic X-rays in patients with AIDS and tuberculosis, its value for the diagnostic and therapeutic orientation.

Patients were clinically classified according to CDC (Centers of Disease Control), of USA, being 25 men and 2 women (aged between 18 and 46 years, 16 homosexuals, 3 bisexuals, 7 cases of intravenous drugs and 3 undetermined) all cases with positive ELISA. The diagnostic of the Mycobacterium tuberculosis was confirmed by analyses of sputum (6 cases), bronchial washing (1 case), endoscopic biopsy (1 case), pleural biopsy (1 case), necropsy (9 cases) and therapeutic trial (3 cases). Other 4 cases had corroborated disease by aspiration biopsy (3 cases) and liquor (1 case).

Lesions more frequently found were adenopaly, in 20 cases and nodular lesions, less than 5mm, in 17 cases. The association between nodular and adenopaly were the most significant. Patients with correct diagnostic and treatment showed partial or total resolution of the thoracic lesions (16 cases). Later diagnostic of untreated patients had not good prognosis. Association of thoracic lesions and therapeutic trials can give the diagnostic of the tuberculosis as showed in 4 patients treated with died, with proven diseases in autopsies.

Th.B.P.40 TUBERCULOSIS AND AIDS

Th.B.P.40 **TUBERCULOSIS AND AIDS**
 Silveira, Maria Lucia Mendes; Mendes W.S., Rodrigues G.A., Stefan, H.N., Le G. S., Mendonça J.S.
 Department of Infectious Diseases - Hospital do Servidor Público Estadual - São Paulo - Brazil.

Between 1985 and 1988 we studied 19 patients with positive anti-HIV serologic test and tuberculosis diagnosed by positive cultures for *M. tuberculosis*. Tuberculosis was the first manifestation of HIV related infections in 12 patients; concomitant with other HIV related conditions in four cases (two Kaposi's sarcoma); three patients had presented an opportunistic infection previously. *M. tuberculosis* was cultured from sputum in 11 patients, lymph node in three, liver, two, lung one, urine one and gastric lavage one. CD4+ count was performed in all patients but three and was low in all cases with a median count of 156 cells/mm³ (range 17 to 378). CD4+ count was above 200 in five patients (group A) and lower than 200 in 11 cases (group B). Group A had two patients with pulmonary tuberculosis, two with disseminated tuberculous lesions and one with pleural tuberculosis. Group B had eight patients with disseminated tuberculosis, two with pulmonary tuberculosis and one with renal tuberculosis. Seven of 14 (50%) patients treated with RFP, INH and PZA had benefits during the first two weeks of treatment. There was total normalization in all cases after change to EFB and SM. Further reevaluation of 106 6 cases was well tolerated. The authors call attention to the low CD4+ counts in all cases, not related to the clinical form of tuberculosis. They also observe that hepatitis was very frequent, only and probably not related to BM.

Th.B.P.42 MYCOBACTERIUM HAGERSTRI (M6) INFECTION IN HIV INFECTED PATIENTS: A 3 YEAR REVIEW

Th.B.P.42 **MYCOBACTERIUM HAGERSTRI (M6) INFECTION IN HIV INFECTED PATIENTS: A 3 YEAR REVIEW**
 Carls, N., Vaidyanathan, G., and Gower, D. R.
 *University Medical Center, LSU Medical Center, New Orleans, LA, USA.

Objective: A significant increase in the number of isolates of M6 associated with HIV infected patients has been observed. We reviewed all patients (PB) with M6 cultures identified at our mycobacteriology reference laboratory.

Methods: A retrospective review of all patients with a culture between 1985-88 was performed. Clinical presentations, radiographic findings, therapy, and outcome were reviewed to identify M6 disease with an emphasis on HIV PB. **Results:** M6 was cultured 205 times from 72 PB over a 40 month period: 23 (34%) were HIV coinfectees, of these 21 had AIDS and 2 had ARC with the first isolation. An increasing % of isolates were from HIV PB (zero in 1983 to 80% by 1987-88). Respiratory isolates were the main source of a culture (90.3%), yet only HIV PB manifested dissemination (liver, stool, bone marrow, blood) with 1 exception. Most had high level M6 (2.0 x 10⁶ cfu/ml) resistance (60%). The clinical presentations were nonspecific. Fever, weight loss, cough and night sweats were seen in 80%. The chest radiographic findings (61.2% pneumonia, 0% cavitation) as well as the frequent coexistence of PCP (84%) made it difficult to identify true M6 disease in this population. Known (51.6%) PB isolates within 30 months of infection. **Conclusions:** The isolation of M6 from HIV infected PB may contribute to their overall morbidity and mortality. Distinguishing disease from colonization is difficult using currently accepted criteria.

Section d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

Th.B.P.49 MYCOBACTERIAL PNEUMONIA INFECTION IN 15 PATIENTS WITH CLASS IV HIV INFECTION: CLINICAL AND MYCOBACTERIOLOGIC FINDINGS

Blair, C., Miller, G., Aude, J., Kushner, Y.,
Merritt, D., Spector, J., et al.

* Department of Medicine, The University of Chicago, Cook County Hospital, Chicago, U.S.A.

Objective: To evaluate the clinical and mycobacteriologic features of *M. tuberculosis* infection in the presence of class IV HIV infection.

Methods: All patients with *M. tuberculosis* infection between 1978 and 1979 were cross-referenced with all persons with Class IV HIV infection, and a retrospective chart review was conducted, including clinical, radiologic, immunologic, and mycobacteriologic data assessment.

Results: Of 46 patients with *M. tuberculosis*, 15 (32.6%) had Class IV HIV infection. Of these, 11 (73.3%) were black and 4 (26.7%) white. Two (13.3%) were a woman, and 9 (60.0%) were 19-30 years of age, 2 (13.3%) 31-40, and 3 (20.0%) other adult age behaviors. 11 (73.3%) had AIDS and 4 (26.7%) had Class III HIV infection. 12 (80%) were diagnosed by sputum analysis and 3 (20.0%) by bronchoscopy and sputum. 12 (80%) patients had pulmonary disease, 4 (40%) had disseminated disease, of which all were extrapulmonary. 1 bone marrow, and 1 sputum, retropharyngeal (1/3) had certainty disease, and 10 (66.7%) local or interstitial disease. In 9 patients, the case 11 patients were AIDS. Serostudy results revealed relative TB to 2 of 4 TB indices and partial resistance to INH in 3 of 4 isolates. Serostudy clinical response was observed in 11 (73.3%) of patients with pulmonary disease, and in 10 out of the patients with disseminated disease.

Conclusion: *M. tuberculosis* infection in cases of HIV infection is an acute care phenomenon to some extent in later stages with advanced immunodeficiency. Upper lobe priority disease is common. A higher and interstitial disease is common. Dissemination to the brain, and bone marrow occurs. Treatment may be successful in early stages. Resistance to PZA and INH occurs. Alternatives for specific treatment are necessary.

Th.B.P.51 TUBERCULOSIS AS PULMONARY COMPLICATION AIDS - ASSOCIATED

Pierantoni, Nicolò, Guida B. Dpt. Inf. Dis. Galliera Hosp. Genoa, Italy

Objective: To study pulmonary Mycobacterium tuberculosis (M) infection in AIDS patients (pts). **Methods:** In 42 cases of AIDS from June '86 to June '88 we observed 10 male patients with pulmonary tuberculosis: they were heroin-addicts aging from 28 to 40. **Results:** Bacteriological tests were positive for M in sputum (3 cases), in B.A.I. (4), in pleural (1) and in gastric fluid (2). The X-ray and CT examinations have shown a high frequency of medium and/or basal pulmonary infiltrates (8pts) and only one pulmonary cavitation. Only the last infested PFD (5pts) in 9/10 of the pts the 67-68 radiographic proved the mediastinum involvement. The recovery occurred in 8/10 of the pts, they had X-ray modification in 60 days and bacteriological negativization in nearly 35 days. **Conclusion:** In our country at the opposite of USA, tuberculosis is often a pulmonary complication (23% even if it isn't diagnostic for AIDS); their L-P patterns are topographically unusuals - the diagnosis may be complicated by the coexisting other opportunistic infections - the long-term therapeutic response is satisfactory in spite of immunodeficiency - the high frequency of pulmonary tuberculosis suggest opportunity anti-Mt prophylaxis in early stages of HIV infection in narcotic-addicts.

Th.B.P.53 PLEUR, WEIGHT LOSS, ANEMIA, SPERMATOZYDIA AND ARCHONAL LIVER DYSFUNCTION IN PRESUMED OR DISSEMINATED MYCOBACTERIOSIS IN PATIENTS WHO ARE HIV ANTIBODY POSITIVE.

Cone, Lawrence; Woodard, D; Mode, D; Curry, N; Brougham, W; Pfaller, R. Section of Infectious Diseases, Department of Medicine, Department of Radiology and Pathology, Eisenhower Medical Center, Rancho Mirage, CA, USA.

Disseminated mycobacteriosis due to *M. avium-intracellulare* (MAI) or less commonly due to *M. tuberculosis* (MTB) occurs in nearly 25% of patients with AIDS during the Course of their illness. In most individuals the lungs are spared and organisms are found in lymph nodes, blood, bone marrow, liver, spleen and gastrointestinal tract. In 28 patients with AIDS in whom these sites revealed mycobacteria, 18 underwent CT scanning of the abdomen. Whereas all patients with mycobacteriosis exhibited an anemia (Hb10 g/ml), fever (37.2-38.1 C), weight loss (10% in 3 wks), TB also revealed splenomegaly and TB, abnormal lymphadenopathy on CT. AIDS patients with other opportunistic infections (1) (Pneumocystis carinii pneumonia (6)), cytomegalovirus infections (11), disseminated coccidioidomycosis (1), and toxoplasmosis (1) (lymphoma (6) and Kaposi's sarcoma (4)) manifested lymphadenopathy in 0-35% except for Kaposi's sarcoma (79%) and coccidioidomycosis (100%). While an splenomegaly occurred in less than 25% of patients with Kaposi's sarcoma and PCP. However, indicating that this pattern of clinical and radiographic findings is not universal, anemia, fever and weight loss seen in patients with disseminated MAI and MTB. We conclude that this pattern of clinical and radiographic findings is not universal. This array of events relates to the pathogenesis of mycobacteriosis.

Th.B.P.50 SEROPREVALENCE OF HIV INFECTION IN 183 CONSECUTIVE PATIENTS WITH TUBERCULOSIS (TB) AT A NEW YORK CITY HOSPITAL

Blaser, Robert, R. Citriguero, Gladys, M., Baboonian, S., Longmire, S.H. SUNY-Health Science Center at Brooklyn, N.Y., U.S.A.

Objective: To determine the prevalence of HIV infection in pts with TB. To determine the extent of immunosuppression in HIV infected pts with TB. **Methods:** Between 10/87-6/88, all hospitalized adults with newly diagnosed, culture-proven TB, were offered HIV testing and TB lymphocyte levels. **Results:** 170 (88%) were intravenous drug users (IVDU), 20 (11%) were Haitian, 11 (6%) were homosexual, and 82 (48%) denied risk factors (RF) (except possible heterosexual contact). 74 (43.5%) evaluable pts with RF were HIV infected (AIDS-1, 0C-1, HIV serology); 23 were not evaluable due to refusal (13), death or discharge prior to serological contact(1), serological inaccessibility(2). Retrospectively, in 33/82 (40.4%) HIV infected pts and in 14/27 (51.9%) HIV-pts (p=NS). Disseminated TB (adrenal, marrow, or liver culture, or culture from 2 retropharyngeal sites) was present in 21/82 (25.6%) HIV infected pts and in 2/27 (7.4%) HIV-pts (p=NS). Median TB of pts with HIV serology (without AIDS or RF) was 207 (range:23-677) IU/ml. Median TB of HIV-pts was 433 (range:128-1616). Median TB of HIV-pts with pulmonary TB (24) was similar to median TB of HIV-pts with local RTB (330) (p=NS). But not to median TB of HIV-pts with disseminated TB (70) (p=NS). **Conclusion:** TB often the first illness experienced by HIV infected pts. TB in IVDU, Haitians, and homosexuals was frequently associated with HIV infection. TB in pts without RF was also associated with HIV infection. Most HIV-pts with TB had marked TB lymphocyte depletion.

Th.B.P.52 TUBERCULOSIS IN HIV-INFECTED INDIVIDUALS IN THE PROVINCE OF BRITISH COLUMBIA (1983-1988)

Wattson, Eric, Todd J, Lawson, L. Steddy J and Montaner, NS. AIDS Research Program, St. Paul's Hospital, Respiratory Division, UBC and Division of TB Control, Ministry of Health, Vancouver, BC, Canada.

Objective: To describe the clinical presentation, laboratory findings and outcomes of all cases of tuberculosis (TB) in HIV infected individuals diagnosed in the Province of British Columbia over the 6 year period ending December 31, 1988. **Methods:** Cases of TB in HIV infected individuals were identified by a linkage between the provincial TB laboratory and the provincial AIDS Surveillance Registry. Medical records of all of the identified cases were retrospectively reviewed.

Results: Fifteen cases were identified. None had AIDS at presentation. Symptomatic onset was present in 13/15 (87%). Respiratory symptoms were common (cough 9/15, shortness of breath 6/15). Diarrhea was present in 4/15. Mean helper count and R/U ratio were always low at diagnosis (90 and 33 respectively). LTBI was diagnosed in all cases. Sputum culture 21 sites in 15 patients revealed 21 smears (100%) and 22 cultures (95%) were positive. Sputum available in 10 patients was smear positive in 5 (50%) and culture positive in 8 (80%). Sputum specimens available in 15 patients were culture positive in 10 (67%) where sputum biopsy (sputum and small biopsy) was also positive. CXR abnormalities were commonest cause for radiological diagnosis. All patients were treated with INH, Rifampin for 12 months + PZA or EMB for the initial 6 months. Except for 2 patients given shortly after diagnosis from overwhelming disease, clinical response was apparent within the first week of therapy. No relapses or failures of treatment were seen. Eight of 13 serostudies demonstrated opportunistic infections (OI) (diagnosis of AIDS within 8 months, 4 of these were PCP). **Conclusion:** TB in HIV infected individuals present most commonly as disseminated disease. Systemic symptoms were common. However, respiratory symptoms were also prominent and frequently provided a clue for diagnosis. Lymph node involvement and gastrointestinal complaints, while clinically apparent, provided a meager source of diagnostic material. TB appeared to occur as a relatively late event in the course of HIV infection as demonstrated by the already low helper count and the rapid progression to OI.

Th.B.P.54 MYCOBACTERIOSIS AND AIDS. THERAPEUTIC APPROACHES.

SCHIRMERS, DIETZ *, Ruf, R. M. **, Meuch, H. ** ; Pabst, H.D. *

* II. Department of Internal Medicine, Rudolf Virchow University Hospital, Freie Universität Berlin; Heckhausen Hospital, Berlin, FRG

Objective: To gain data on the effectiveness of chemotherapy in mycobacteriosis. **Methods:** Course and the effect of therapy was evaluated in 51 patients. Drug susceptibility of strains involved was determined.

Results: Tuberculosis (TB): 17/21 patients treated (common drugs for 8 months, followed by maintenance therapy). One of 17 (6%) died, 7 years later on due to other causes. In all untreated cases, TB was in the course of death. Follow-up: max. 36 months, patients alive > 1 year (87%), > 2 years (84%), no relapse. One of 21 strains was resistant against RMP and INH. All strains were in addition susceptible against rifabutin, ciprofloxacin and ciprofloxacin. MAI-infection: 17/38 patients were treated, 9 showed at most temporary improvement. 13/16 patients died, 3 due to MAI-infection. MAI was isolated post mortem in all cases in spite of treatment with ciprofloxacin. 4/17 cases diagnosed early improved rapidly and treatment included rifabutin (80%), ciprofloxacin and macrolides (60%). All macrolides completely resistant against common drugs and chinolones, but were susceptible against rifabutin and ciprofloxacin. MAI: In the range of achievement, early start may be curable using modified regimen including rifabutin, ciprofloxacin and macrolides.

Session d'affichage Poster Session



Th.B.P.79 ALVEOLAR MACROPHAGES FROM PATIENTS WITH HIV INFECTION

OPPORTUNISTIC RELEASE TUMOR NECROSIS FACTOR
 Agostini, Carlo*, Trentin, L. V., Poletti, V. M., Zambello, R., Spiga, L. M.,
 Conti, F. P., Feruglio, C., Pavesi, G. P., Pavesi, V., Zambello, R., Spiga, L. M.,
 *University of Padua, Padua **Istituto and Maggiore Hospital, Bologna, Italy.

Objective: To clarify whether HIV infection affects functional capabilities of alveolar macrophages (AM). AMs from bronchoalveolar lavage (BAL) of 6 patients with full-blown AIDS and 6 patients with ARC were examined for their ability to kill tumor necrosis factor (TNF)-sensitive tumor cells and to release TNF.

Methods: Untreated AMs freshly recovered from BAL were tested against U937 target cells in an overnight ⁵¹Cr release cytotoxicity assay. In addition, cell free supernatants obtained from untreated and TNF- α (100 IU/ml) and LPS (5 μ g/ml) treated AMs were tested for their cytotoxic activity against U937 targets in an overnight ⁵¹Cr release assay. To confirm that TNF was the cytotoxic factor, either anti-TNF MAb (Genzyme) was added to the cell free supernatants in the TNF bioassay.

Results: Untreated AMs from patients with AIDS and ARC exhibited a significant cytotoxic activity against U937 targets at all effector:target ratios tested whereas normal AMs did not kill TNF-susceptible tumor cells (p<0.001). Supernatants from untreated AMs of HIV patients showed significantly higher levels of cytotoxicity with respect to normal AMs (p<0.001). Incubation of AMs with anti-TNF MAb inhibited the cytotoxic effect caused by supernatants. Treatment of AMs from HIV patients with TNF- α and LPS failed to enhance the TNF production, whereas following these stimuli normal AMs significantly increased their TNF activity.

Conclusions: AMs from patients with HIV infection are activated and spontaneously release TNF. The heightened capacity of HIV AMs to produce TNF may be involved in the pathogenesis of pulmonary complications observed in patients with AIDS.

Th.B.P.81 IMMUNOLOGICAL SUBTYPING OF LEUCOCYTES OBTAINED FROM BRONCHOALVEOLAR LAVAGE (BAL) AND PERIPHERAL BLOOD IN HIV-1 INFECTED PATIENTS WITH PNEUMONIA.

M. A. E. Hens, W. K. Koopman, C. Spaah, R. Russ, E. and G. P. University Hospital, Zurich, Switzerland.

Objective: Recent reports have characterized differential cell counts in bronchoalveolar lavage (BAL) of HIV-infected patients and have suggested that immunological subtyping. To further investigate these findings and to characterize the local immunological situation in the lungs we studied U937 cells of BAL compared to peripheral blood leucocytes by means of immunological subtyping. 11 HIV-positive patients with clinical signs of acute pneumonia (aged 2 to 60 years) were included. Six of our patients suffered from histologically confirmed Pneumocystis carinii pneumonia (PCP) and five patients had pneumonia other than PCP.

Methods: Leucocytes obtained from BAL and peripheral blood were double-stained with the following combinations of monoclonal antibodies: CD4 / HLADR, CD4 / 84A, CD8 / HNK1, CD200 / CD44 / HLA-DR. Two-color immunofluorescence flow analysis was carried out using an EPICSM² PROFILE system (Coulter).

Results: Major differences between BAL and peripheral blood could be found with CD4 / HNK1 and CD44 subtyping. The ratio of CD4/HNK1-double-positive cells to CD8-positive cells was higher in the peripheral blood than in BAL. Conversely, the ratio of CD4/CD44-double-positive cells was higher in BAL. The percentage of CD4-positive lymphocytes was much higher in BAL than in peripheral blood, which was in contrast to findings in non-HIV-infected patients with pneumonia.

Conclusion: The data indicate that in HIV-patients with pneumonia major immunological differences between BAL and peripheral blood are present, which could be relevant for the prognosis.

Th.B.P.83 INCREASED PRODUCTION OF SOLUBLE IL 2 RECEPTOR IN PATIENTS WITH HIV INFECTION

Yoshida, Yumiko*, Kitamura, K., Yamada, K., Mitsuyasu, R.**,
 Chayama, K.**, and Honda, M.**,
 *National Institute of Health, AIDS Research Center, Tokyo, Japan, **NIAID, Medical Center, Los Angeles, California, U.S.A., **Institut National de la Santé et de la Recherche Médicale (INSERM), Marseille, France.

Objective: To see whether the production of soluble IL 2 receptor (sIL 2R) in patients with HIV infection increases as the disease advanced and correlates with other clinical parameters.

Methods: The monoclonal antibodies against IL 2R were used for the fluorescence antibody ELISA. Sera of patients with HIV infection were collected from UCLA Medical Center and INSERM of France and grouped according to the CDC classification of AIDS.

Results: Elevated sIL 2R levels were observed in the sera of patients with HIV infection. Moreover, sIL 2R levels gradually increased as the disease advanced. Statistical analysis showed a negative correlation of those with CD4 cell counts, lymphocyte counts, and CD4-CD8 ratio, but neither WBC counts nor CD4 counts correlated. We examined the production of sIL 2R in vitro. Neither P84C of AIDS patients nor any of the 19 HIV-1- or HIV-2-infected cell lines produced sIL 2R in the supernatant, while P84C of patients with HIV-1 infection or HIV-2 positive cell lines produced sIL 2R.

Conclusion: We observed gradually increased serum level of sIL 2R in patients with HIV infection as the progression of the disease, and this level was negatively correlated with CD4 cell counts. From *in vitro* study, we suggested that these sIL 2R might be produced by non-T cells.

Aspects cliniques Clinical Aspects of AIDS

Th.B.P.80 CD4 LYMPHOCYTE COUNTS AND SERUM P 24 ANTIGEN OF NO DIAGNOSTIC VALUE IN MONITORING HIV INFECTED PATIENTS WITH PULMONARY SYMPTOMS.

Orskov, Marlene, Nielsen, T.L., Jensen, J.,
 Department of Infectious Diseases, Sydhavns Hospital, University of Copenhagen, Denmark.

The aim of this study was to determine if the prognostic markers CD4 lymphocyte count and serum HIV p24 antigen were of any diagnostic value in HIV infected patients with pulmonary symptoms.

Method: During 1987 and 1988 143 fiberoptic bronchoscopy procedures were performed on 104 HIV infected patients with pulmonary symptoms. The bronchoscopic specimens were evaluated for Papanicolaou smears (P), cytomegalovirus (CMV) and other pathogens. CD4 counts and serum p24 antigen were measured within 2 weeks before or after the bronchoscopy.

Results: Pulmonary opportunistic infection (O.I.) was found in 83 examinations (79-79, CMV-2). There was no difference in CD4 counts between the patients with and without O.I., p=0.85. The CD4 count was 200 in 67% and in 62% respectively. All of the patients with O.I. had p24 antigen, while this was the case in 42% of the patients without O.I. 32% of the patients in both groups had a CD4 count below 200 combined with presence of serum p24 antigen. **Conclusion:** The CD4 count and p24 antigen have been shown in this study to be of no diagnostic value in monitoring HIV infected patients with pulmonary symptoms.

Th.B.P.82 CUTANEOUS-DERIVED LYMPHOCYTES IN DRUG ADDICTS.

Ulla Antoniazzi-Chaves, Giovanna Casanovi, Luciano M. Cavallari-Filippi, Fabiana Fratelli Hospital, Milan, Italy.

Objective: To evaluate the utility of cutaneous derived lymphocytes (CDL) tests in drug addicts (DA) and to apply them the Walter Reed Classification (WC).

Methods: We studied 127 DA (95 male and 32 female), mean age 29 years; 40 HIV- and 67 HIV-. Clinical examination, TA and 18 counts and skin test (Pwittest CM, Merck) were done. WC has been used to classify the patients (pts).

Results: There were significative differences between HIV- and HIV+ for TA⁺ (77/73 vs 17/20), p<0.002, 18⁺ (121/46 vs 31/36), p<0.005, number of positive reactions to antigens on CDL tests (1-6/3 vs 2-5/9), p<0.025 and score (4-6/4 vs 6-8/4), p<0.025. Thirty-four pts resulted hyperergic (17 HIV- and 17 HIV+); 18 pts resulted eugergic (16 HIV- and 2 HIV+). The pts were classified as follows: WHO, 46 (37.8%); M1, 9 (7.1%); M2, 1 (0.8%) (including 3 in M2B); M3, 3 (3.9%); M4, 5 (3.9%); M5, 4 (3.1%) (including 1 in M5B and 1 in M5C); M6, none. Thirty-nine pts (30.7%) CDL HIV- and 19 HIV+ (with partial or complete antigen counts of 14 lymphocytes above 400/mm³) did not fit into any stage of the WC. Also 2 pts (1.6%) HIV- with TA<400/mm³ and normal skin tests were unclassifiable.

Conclusions: CDL is diminished in the DA (also HIV-). Skin tests may be an useful test to evaluate DA immunologic state and they were significantly in the HIV+ subjects. The WC does not accommodate all DA subjects, because of their "background" immunologic abnormalities.

Th.B.P.84 CHANGES IN CD-16 RECEPTOR EXPRESSION ON THE NEUTROPHILS OF HIV INFECTED INDIVIDUALS

Stacy, Peter, Johnson, J. A., Bobos, J., and Umlas, J. C.,
 Mount Sinai School of Medicine, New York City, New York, U.S.A.

Objective: To examine changes in the expression of CD-16 receptor on the neutrophils from HIV infected individuals.

Methods: Neutrophils from whole blood samples from HIV infected individuals in various clinical stages and normal volunteers were double stained with phycoerythrin-Leu-19 (anti-CD16) and fluorescein-isothiocyanate (anti-CD16 or FITC-IL-1). As a control, we used the anti-CD16 (Fc-IL1) ab FITC-Fc-IL1. Analysis was carried out on FACSTAR II cell sorter.

Results: A significant decrease in the CD16 receptor expression has been found in HIV-infected patients compared to normal individuals. The greatest number of CD16-negative neutrophils was measured in patients with AIDS. No correlations were found with the TA/T8 ratio. CD16 expression on the neutrophils was not affected.

Conclusions: Neutrophil Fc-IL1 (CD16) is a phosphotyrosine (tyrosine) glycosylated membrane receptor that is released following treatment of neutrophils with phorbol esters. The finding of decreased CD16 expression might reflect prior activation of neutrophils and might be a marker of the neutrophil dysfunction leading to common bacterial and fungal infections in advanced HIV infections.

**Session d'affichage
Poster Session**



**Aspects cliniques
Clinical Aspects of AIDS**

Th. B.P. 85 ANTIBODY RESPONSES TO HIV-1 IN RETROVIRUS INFECTED DISEASES
Yokoyama, Mitsuo, Hirose and Tsuboi.

Objective: ADA isoenzyme levels in sera of patients with adult T-cell leukemia (ATL) and acquired immunodeficiency syndrome (AIDS) were analyzed. **Method:** Total ADA activity was determined by an enzyme spectrophotometric assay. ADA isoenzyme activity which was inhibited by erythrocyte-(G-2-phospho-3) neryl adenosine was designated as ADA1 and the remaining activity as ADA2. **Result:** In the case of ATL subtypes, ADA1 activity was significantly elevated in acute and lymphoma types (p<0.01) in comparison to chronic and smoldering types. No significant difference in ADA2 activity was noted in smoldering type as compared with chronic type of ATL. ADA2 activity was elevated in sera of acute, lymphoma and chronic types of ATL patients (>0.01) as compared with smoldering ATL and HTLV-1. In the case of AIDS, immunofluorescence virus-(HIV)-1 infections, ADA isoenzyme activities were higher in sera of patients with AIDS and HIV-1 antibody-positive individuals in homosexual (p<0.01) when the results were compared with HIV-1 antibody-negative homosexuals and normal controls. A significant elevation of ADA2 activity was seen in sera of AIDS patients (p<0.01) than that of HIV-1 antibody-positive homosexuals. **Conclusion:** ADA isoenzyme activities in sera of patients with retrovirus infection reflect the condition of these diseases. To measure of ADA isoenzyme activities may therefore provide an additional parameter for distinguishing subtypes of ATL and may prove to be considerable prognostic and therapeutic monitors in retrovirus infection.

Th. B.P. 87 LYMPHOCYTE REACTIVITY TO ARTI-CD3 AS A PROGNOSTIC MARKER IN HIV-1 INFECTED BEROSEAL HIV
Houtz, J., Meadew, J., Jansen, P., Schalkhaas, Central Lab. Health, Red Cross blood Transf. Serv. and the Lab. of Exp. and Clin. Immunology of the Univ. of Amsterdam, Academic Medical Center, Amsterdam, The Netherlands.

Objective: In patients with ARC/AIDS, lymphocyte reactivity to antigens declines earlier and more severely compared to nonspecific nitrogen response. Because antigens stimulate T cells via the T1/T2 complex we studied whether CD3 reactivity followed the same pattern as antigen reactivity and could be used as a prognostic marker for AIDS. **Method:** Reactivity was measured to aCD3 in Whole Blood Lymphocyte Cultures (WBC) in a longitudinal study of seropositive homosexual men and expressed as I reactivity per 3 lymphocytes compared to healthy controls. **Result:** In HIV-1 infected asymptomatic men, the response towards aIS and PMA was stable (100) for 40 months after intake into the study, whereas the response to aCD3 showed a gradual decline (from 70 to 40%) during the same period. In the population that developed AIDS or the AIDS reactivity remained largely unaffected until 3 months before diagnosis; PMA reactivity started to decline (from 80 to 10%) from about one year before diagnosis. However, the aCD3 reactivity was always very low (10%) one year before diagnosis. **Conclusion:** A severely depressed aCD3 reactivity is the first sign to herald progression towards AIDS in HIV-1 infected individuals.

Th. B.P. 89 DEPARTMENT OF POLYMEROPROTEOLYTES (PMO) CHEMOTACTIC AND BACTERICIDAL ACTIVITY IN HIV-INDUCED CHLORAL
Nelson, Edmund, Martin, S., Eddy, J., Venn, D., Walsh, T., Poon, P. and Rubin, M. National Cancer Institute, Bethesda, Maryland, USA.

Objective: HIV-infected children have an increased incidence of serious bacterial infections, which has been attributed to antibody dysfunction. Although PMOs are the most important of these defense against bacteria, PMO function in this group has been unexamined. Accordingly, we compared the functional activity of PMOs from both asymptomatic (ASX) and symptomatic (SX) HIV-infected children. **Method:** PMO was obtained from 10 ASX and 10 SX children. PMO were assayed for chemotactic activity (in units to 111 per 10⁶ per 30 min) for functional assays performed were: 1) chemotaxis to P-M (PM2), 2) bactericidal activity against *Escherichia coli* (E. coli) at 37°C, 3) response to DCV granules following stimulation by 5 X 10⁶ PMNP, and 4) phagocytosis of S.A. and *Candida albicans* (C.A.). **Results:** Chemotactic: Chemotaxis of PMOs from ASX children was uniformly decreased compared to controls (median/interquartile range = 1.18 +/- 0.4 for ASX children vs 1.74 +/- 0.7 for controls (p<0.005), and increased in SX children (2.14 +/- 0.6, P<0.05). Bactericidal activity: Killing of S.A. was defective in 5/9 ASX and 18 SX children (85% reduction in colonies after 60 min incubation - 56 +/- 4 for controls vs 42 +/- 6 for ASX children (P<0.05) and 27 +/- 3 for SX children (P<0.005). There was no correlation between presence or degree of bactericidal impairment and CD4 number or CD4/CD8 ratio. Responses from HIV-infected children did not inhibit the bactericidal activity of normal PMO. Preliminary data suggest that in vivo measures with GM-CSF possibly correct the defect. DCV granules: No abnormalities in DCV products were found (mean 10⁶ per 10⁶ cells - 2.2 +/- 0.2 for controls, vs 2.0 +/- 3 for ASX and 2.4 +/- 3 for SX children). **Diagnosis:** There was no abnormalities in phagocytosis of S.A. or C.A. (66 +/- 4 for controls vs 67 +/- 5 for ASX and 67 +/- 7 for SX children) or of C.A. (66 +/- 4 for controls vs 66 +/- 9 for ASX and 66 +/- 4 for SX children). **Conclusions:** Defects in both bactericidal activity and chemotaxis may contribute to the increased incidence of bacterial infections in HIV-infected children. Further study to define a potential role for GM-CSF in these patients is warranted.

Th. B.P. 86 CD4+NEOPTERIN RATIO CORRELATES WITH P24 ANTIGENEMIA IN HIV INFECTED PATIENTS.
Eckstein, Franz, Litzl, A., Heiderich, E., D'Accetto, P., Cambis, G., Cantaluppi P., Ospedale Maggiore - 28878 Lodi (I)

Objective: To verify the possible correlation between CD4/neopterin ratio and p24 antigenemia during HIV infection. **Method:** 72 patients (64 men and 8 females; mean age 26.2, range 18-33 years) were classified according to the WRB8 criteria; they were also tested for p24Ag and serum neopterin levels (SNL). R was also calculated for each patient. **Results:** WRB group (32 pts): 6/32 were p24Ag pos. (18.75 %); WRB group (16 pts): 4/16 were p24Ag pos. (25.00 %). **Ratio:** WRB group (24 pts): 16/24 were p24Ag pos. (66.8 %)

WRB	SNL	R
p24Ag pos.	9.23	0.3
p24Ag neg.	26.37	17.9

Conclusion:confirming literature data, we found a good correlation between p24Ag and clinical stage; a good correlation was also found between R and the WRB8. We point out the high significance of R (p<0.001) in differentiating, within the WRB 8 criteria, between p24 pos from p24 neg patients with all the prognostic implications involved. By contrast as far as WR 8 and especially WR 6 classes are concerned low differentiating significances of mean values point to disease progression and clinical deterioration reflecting increasingly severe immunologic disorder regardless of the patients' p24Ag status.

Th. B.P. 88 NEUTROPHIL RADICAL RELEASE AND LIPID PEROXIDATION IN HIV INFECTED PATIENTS
Jernstam, G., Carlsson, C., Ohnnerberg, A. and ÅKERLIND, B.***

* Hudinge Hospital, Hudinge, Sweden; ** Pharmacia, Uppsala, Sweden; *** Roslagstul Hospital, Stockholm, Sweden. **Introduction:** Since a transitory increase in Nitroblue tetrazolium (NBT) reduction of neutrophils, reflecting an increased production of oxygen free radicals of these cells, has earlier been found during acute viral and bacterial infections, a long term elevation in NBT-reduction was expected in the chronic HIV infected patient. Oxygen radicals are known to induce peroxidation of fatty acids occurring for example in cell membranes. A product of this process is malondialdehyde (MDA), which has been used extensively as a sign of lipid peroxidation. **Methods:** Colourless NBT is reduced within the neutrophils by the superoxide anion to carbonyl formazan which was measured spectrophotometrically. MDA was measured by a reversed phase liquid chromatography method. **Results:** In 17 patients with the lymphadenopathy syndrome (LAS) the NBT reduction of resting neutrophils was significantly higher than that of controls (p<0.01). Further, the plasma content of malondialdehyde in 22 patients with LAS or AIDS related complex was found to be higher than that in controls (p<0.001). **Conclusion:** Radical production and resulting lipid peroxidation might contribute in the tissue damage and the premature ageing (Dorian Gray syndrome) seen in patients with HIV-infections.

Th. B.P. 90 OXIDATIVE BURST ACTIVITY AND CELL SURFACE ANTIGEN EXPRESSION OF MONOCYTES AND T-LYMPHOCYTES IN HIV-INDUCED CHLORAL INFECTED INDIVIDUALS (AMI) LANGE, Alan; Kessler, R.; Jansen, C. P.; Phair, J. P.; Rothberg, L. B.; Spear, G. et al. * Wash Medical Center, Chicago, IL; ** Northwestern Medical Center, Chicago, IL, U.S.A.

Objective: To identify functional and phenotypic alterations of peripheral blood monocytes isolated from AMI. **Methods:** Peripheral blood monocytes from immunocompetent, HIV negative donors. For oxidative burst measurements, cells were incubated with endotoxin (lipopolysaccharide (LPS)) or phorbol myristate acetate (PMA), calcium ionophore (I2B) or heat aggregated IgG (HA). After stimulation, cells were stained by PE labeled anti-CD14 antibody. Shifts in green fluorescence which correspond to relative oxidative burst capacity of monocytes was measured by dual parameter flow cytometry. Expression of cell surface markers CD13, CD33 & HLA-DR on CD14+ monocytes was also evaluated by dual parameter flow cytometry. **Results:** Significantly lower oxidative burst activity was observed with monocytes from AMI compared to HIV negative donors stimulated with PMA (57.1 vs 96.2 relative fluorescence units, p<0.0001) and I2B (57.1 vs 96.4, p<0.0001). No significant difference was noted with LPS. The percentage of CD13 and CD33 monocytes was also significantly lower among AMI compared to HIV negative donors (86.4 vs 95.3 for CD13, p<0.02; 92.1 vs 99.7 for CD33, p<0.02). **Conclusions:** Monocytes from AMI have significant alterations in function. These alterations may contribute to immunodeficiency and disease progression.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

Th.B.P.91 STRATIFICATION OF RFL ALLOANTIGEN PRESENTING CELL FUNCTION IN PATIENTS WITH AIDS. **Jacobs Alan**, Clerici, H. M.; Kessler, R. M. and Shesner, G. W. ¹ NIH, Bethesda, Md. ² Chicago, IL and ³ Experimental Immunology Branch, NIH, Bethesda, Md. U.S.A.

Objective: To test the ability of peripheral blood mononuclear cells (PBMC) from patients with AIDS to serve as stimulating cells as well as alloantigen presenting cells (APC) to responding FMC from HIV seronegative (HIV-) donors.

Methods: HIV- unfractionated FMC or FMC depleted of monocytes (FBL) by plastic and nylon wool adherence procedures (CD4+ cells) were stimulated in vitro with allogeneic FMC from AIDS patients. The mixed lymphocyte reaction (MLR) was assessed by ³H-thymidine incorporation and by interleukin 2 production.

Results: Our data indicate APC function of FMC from AIDS patients can be stratified into three groups in which: (a) the MLR was normal irrespective of whether the HIV FMC or FBL were used as responders (9/22, 41%); (b) the MLR was normal when HIV FMC were used as responders but were defective when HIV- FBL were used as responders (7/22, 32%); and (c) the MLR was defective irrespective of whether HIV- responding FMC or FBL were used (9/22, 41%).

Conclusions: These results suggest that AIDS patients can be stratified based on alloantigen presenting functions. These results also suggest a possible approach for assessing monocyte (APC) function in AIDS patients as a potential indicator of drug efficacy in patients enrolled in therapeutic trials.

Th.B.P.93 VARIABILITY IN ISOTYPE-SPECIFIC IMMUNOGLOBULIN (Ig) SECRETING CELLS IN ASYMPTOMATIC HIV INFECTION

Bozzani L., and **Wang** F. ¹ **Wang** F. ² **Wang** F. ³ **Wang** F. ⁴ **Wang** F. ⁵ **Wang** F. ⁶ **Wang** F. ⁷ **Wang** F. ⁸ **Wang** F. ⁹ **Wang** F. ¹⁰ **Wang** F. ¹¹ **Wang** F. ¹² **Wang** F. ¹³ **Wang** F. ¹⁴ **Wang** F. ¹⁵ **Wang** F. ¹⁶ **Wang** F. ¹⁷ **Wang** F. ¹⁸ **Wang** F. ¹⁹ **Wang** F. ²⁰ **Wang** F. ²¹ **Wang** F. ²² **Wang** F. ²³ **Wang** F. ²⁴ **Wang** F. ²⁵ **Wang** F. ²⁶ **Wang** F. ²⁷ **Wang** F. ²⁸ **Wang** F. ²⁹ **Wang** F. ³⁰ **Wang** F. ³¹ **Wang** F. ³² **Wang** F. ³³ **Wang** F. ³⁴ **Wang** F. ³⁵ **Wang** F. ³⁶ **Wang** F. ³⁷ **Wang** F. ³⁸ **Wang** F. ³⁹ **Wang** F. ⁴⁰ **Wang** F. ⁴¹ **Wang** F. ⁴² **Wang** F. ⁴³ **Wang** F. ⁴⁴ **Wang** F. ⁴⁵ **Wang** F. ⁴⁶ **Wang** F. ⁴⁷ **Wang** F. ⁴⁸ **Wang** F. ⁴⁹ **Wang** F. ⁵⁰ **Wang** F. ⁵¹ **Wang** F. ⁵² **Wang** F. ⁵³ **Wang** F. ⁵⁴ **Wang** F. ⁵⁵ **Wang** F. ⁵⁶ **Wang** F. ⁵⁷ **Wang** F. ⁵⁸ **Wang** F. ⁵⁹ **Wang** F. ⁶⁰ **Wang** F. ⁶¹ **Wang** F. ⁶² **Wang** F. ⁶³ **Wang** F. ⁶⁴ **Wang** F. ⁶⁵ **Wang** F. ⁶⁶ **Wang** F. ⁶⁷ **Wang** F. ⁶⁸ **Wang** F. ⁶⁹ **Wang** F. ⁷⁰ **Wang** F. ⁷¹ **Wang** F. ⁷² **Wang** F. ⁷³ **Wang** F. ⁷⁴ **Wang** F. ⁷⁵ **Wang** F. ⁷⁶ **Wang** F. ⁷⁷ **Wang** F. ⁷⁸ **Wang** F. ⁷⁹ **Wang** F. ⁸⁰ **Wang** F. ⁸¹ **Wang** F. ⁸² **Wang** F. ⁸³ **Wang** F. ⁸⁴ **Wang** F. ⁸⁵ **Wang** F. ⁸⁶ **Wang** F. ⁸⁷ **Wang** F. ⁸⁸ **Wang** F. ⁸⁹ **Wang** F. ⁹⁰ **Wang** F. ⁹¹ **Wang** F. ⁹² **Wang** F. ⁹³ **Wang** F. ⁹⁴ **Wang** F. ⁹⁵ **Wang** F. ⁹⁶ **Wang** F. ⁹⁷ **Wang** F. ⁹⁸ **Wang** F. ⁹⁹ **Wang** F. ¹⁰⁰ **Wang** F. ¹⁰¹ **Wang** F. ¹⁰² **Wang** F. ¹⁰³ **Wang** F. ¹⁰⁴ **Wang** F. ¹⁰⁵ **Wang** F. ¹⁰⁶ **Wang** F. ¹⁰⁷ **Wang** F. ¹⁰⁸ **Wang** F. ¹⁰⁹ **Wang** F. ¹¹⁰ **Wang** F. ¹¹¹ **Wang** F. ¹¹² **Wang** F. ¹¹³ **Wang** F. ¹¹⁴ **Wang** F. ¹¹⁵ **Wang** F. ¹¹⁶ **Wang** F. ¹¹⁷ **Wang** F. ¹¹⁸ **Wang** F. ¹¹⁹ **Wang** F. ¹²⁰ **Wang** F. ¹²¹ **Wang** F. ¹²² **Wang** F. ¹²³ **Wang** F. ¹²⁴ **Wang** F. ¹²⁵ **Wang** F. ¹²⁶ **Wang** F. ¹²⁷ **Wang** F. ¹²⁸ **Wang** F. ¹²⁹ **Wang** F. ¹³⁰ **Wang** F. ¹³¹ **Wang** F. ¹³² **Wang** F. ¹³³ **Wang** F. ¹³⁴ **Wang** F. ¹³⁵ **Wang** F. ¹³⁶ **Wang** F. ¹³⁷ **Wang** F. ¹³⁸ **Wang** F. ¹³⁹ **Wang** F. ¹⁴⁰ **Wang** F. ¹⁴¹ **Wang** F. ¹⁴² **Wang** F. ¹⁴³ **Wang** F. ¹⁴⁴ **Wang** F. ¹⁴⁵ **Wang** F. ¹⁴⁶ **Wang** F. ¹⁴⁷ **Wang** F. ¹⁴⁸ **Wang** F. ¹⁴⁹ **Wang** F. ¹⁵⁰ **Wang** F. ¹⁵¹ **Wang** F. ¹⁵² **Wang** F. ¹⁵³ **Wang** F. ¹⁵⁴ **Wang** F. ¹⁵⁵ **Wang** F. ¹⁵⁶ **Wang** F. ¹⁵⁷ **Wang** F. ¹⁵⁸ **Wang** F. ¹⁵⁹ **Wang** F. ¹⁶⁰ **Wang** F. ¹⁶¹ **Wang** F. ¹⁶² **Wang** F. ¹⁶³ **Wang** F. ¹⁶⁴ **Wang** F. ¹⁶⁵ **Wang** F. ¹⁶⁶ **Wang** F. ¹⁶⁷ **Wang** F. ¹⁶⁸ **Wang** F. ¹⁶⁹ **Wang** F. ¹⁷⁰ **Wang** F. ¹⁷¹ **Wang** F. ¹⁷² **Wang** F. ¹⁷³ **Wang** F. ¹⁷⁴ **Wang** F. ¹⁷⁵ **Wang** F. ¹⁷⁶ **Wang** F. ¹⁷⁷ **Wang** F. ¹⁷⁸ **Wang** F. ¹⁷⁹ **Wang** F. ¹⁸⁰ **Wang** F. ¹⁸¹ **Wang** F. ¹⁸² **Wang** F. ¹⁸³ **Wang** F. ¹⁸⁴ **Wang** F. ¹⁸⁵ **Wang** F. ¹⁸⁶ **Wang** F. ¹⁸⁷ **Wang** F. ¹⁸⁸ **Wang** F. ¹⁸⁹ **Wang** F. ¹⁹⁰ **Wang** F. ¹⁹¹ **Wang** F. ¹⁹² **Wang** F. ¹⁹³ **Wang** F. ¹⁹⁴ **Wang** F. ¹⁹⁵ **Wang** F. ¹⁹⁶ **Wang** F. ¹⁹⁷ **Wang** F. ¹⁹⁸ **Wang** F. ¹⁹⁹ **Wang** F. ²⁰⁰ **Wang** F. ²⁰¹ **Wang** F. ²⁰² **Wang** F. ²⁰³ **Wang** F. ²⁰⁴ **Wang** F. ²⁰⁵ **Wang** F. ²⁰⁶ **Wang** F. ²⁰⁷ **Wang** F. ²⁰⁸ **Wang** F. ²⁰⁹ **Wang** F. ²¹⁰ **Wang** F. ²¹¹ **Wang** F. ²¹² **Wang** F. ²¹³ **Wang** F. ²¹⁴ **Wang** F. ²¹⁵ **Wang** F. ²¹⁶ **Wang** F. ²¹⁷ **Wang** F. ²¹⁸ **Wang** F. ²¹⁹ **Wang** F. ²²⁰ **Wang** F. ²²¹ **Wang** F. ²²² **Wang** F. ²²³ **Wang** F. ²²⁴ **Wang** F. ²²⁵ **Wang** F. ²²⁶ **Wang** F. ²²⁷ **Wang** F. ²²⁸ **Wang** F. ²²⁹ **Wang** F. ²³⁰ **Wang** F. ²³¹ **Wang** F. ²³² **Wang** F. ²³³ **Wang** F. ²³⁴ **Wang** F. ²³⁵ **Wang** F. ²³⁶ **Wang** F. ²³⁷ **Wang** F. ²³⁸ **Wang** F. ²³⁹ **Wang** F. ²⁴⁰ **Wang** F. ²⁴¹ **Wang** F. ²⁴² **Wang** F. ²⁴³ **Wang** F. ²⁴⁴ **Wang** F. ²⁴⁵ **Wang** F. ²⁴⁶ **Wang** F. ²⁴⁷ **Wang** F. ²⁴⁸ **Wang** F. ²⁴⁹ **Wang** F. ²⁵⁰ **Wang** F. ²⁵¹ **Wang** F. ²⁵² **Wang** F. ²⁵³ **Wang** F. ²⁵⁴ **Wang** F. ²⁵⁵ **Wang** F. ²⁵⁶ **Wang** F. ²⁵⁷ **Wang** F. ²⁵⁸ **Wang** F. ²⁵⁹ **Wang** F. ²⁶⁰ **Wang** F. ²⁶¹ **Wang** F. ²⁶² **Wang** F. ²⁶³ **Wang** F. ²⁶⁴ **Wang** F. ²⁶⁵ **Wang** F. ²⁶⁶ **Wang** F. ²⁶⁷ **Wang** F. ²⁶⁸ **Wang** F. ²⁶⁹ **Wang** F. ²⁷⁰ **Wang** F. ²⁷¹ **Wang** F. ²⁷² **Wang** F. ²⁷³ **Wang** F. ²⁷⁴ **Wang** F. ²⁷⁵ **Wang** F. ²⁷⁶ **Wang** F. ²⁷⁷ **Wang** F. ²⁷⁸ **Wang** F. ²⁷⁹ **Wang** F. ²⁸⁰ **Wang** F. ²⁸¹ **Wang** F. ²⁸² **Wang** F. ²⁸³ **Wang** F. ²⁸⁴ **Wang** F. ²⁸⁵ **Wang** F. ²⁸⁶ **Wang** F. ²⁸⁷ **Wang** F. ²⁸⁸ **Wang** F. ²⁸⁹ **Wang** F. ²⁹⁰ **Wang** F. ²⁹¹ **Wang** F. ²⁹² **Wang** F. ²⁹³ **Wang** F. ²⁹⁴ **Wang** F. ²⁹⁵ **Wang** F. ²⁹⁶ **Wang** F. ²⁹⁷ **Wang** F. ²⁹⁸ **Wang** F. ²⁹⁹ **Wang** F. ³⁰⁰ **Wang** F. ³⁰¹ **Wang** F. ³⁰² **Wang** F. ³⁰³ **Wang** F. ³⁰⁴ **Wang** F. ³⁰⁵ **Wang** F. ³⁰⁶ **Wang** F. ³⁰⁷ **Wang** F. ³⁰⁸ **Wang** F. ³⁰⁹ **Wang** F. ³¹⁰ **Wang** F. ³¹¹ **Wang** F. ³¹² **Wang** F. ³¹³ **Wang** F. ³¹⁴ **Wang** F. ³¹⁵ **Wang** F. ³¹⁶ **Wang** F. ³¹⁷ **Wang** F. ³¹⁸ **Wang** F. ³¹⁹ **Wang** F. ³²⁰ **Wang** F. ³²¹ **Wang** F. ³²² **Wang** F. ³²³ **Wang** F. ³²⁴ **Wang** F. ³²⁵ **Wang** F. ³²⁶ **Wang** F. ³²⁷ **Wang** F. ³²⁸ **Wang** F. ³²⁹ **Wang** F. ³³⁰ **Wang** F. ³³¹ **Wang** F. ³³² **Wang** F. ³³³ **Wang** F. ³³⁴ **Wang** F. ³³⁵ **Wang** F. ³³⁶ **Wang** F. ³³⁷ **Wang** F. ³³⁸ **Wang** F. ³³⁹ **Wang** F. ³⁴⁰ **Wang** F. ³⁴¹ **Wang** F. ³⁴² **Wang** F. ³⁴³ **Wang** F. ³⁴⁴ **Wang** F. ³⁴⁵ **Wang** F. ³⁴⁶ **Wang** F. ³⁴⁷ **Wang** F. ³⁴⁸ **Wang** F. ³⁴⁹ **Wang** F. ³⁵⁰ **Wang** F. ³⁵¹ **Wang** F. ³⁵² **Wang** F. ³⁵³ **Wang** F. ³⁵⁴ **Wang** F. ³⁵⁵ **Wang** F. ³⁵⁶ **Wang** F. ³⁵⁷ **Wang** F. ³⁵⁸ **Wang** F. ³⁵⁹ **Wang** F. ³⁶⁰ **Wang** F. ³⁶¹ **Wang** F. ³⁶² **Wang** F. ³⁶³ **Wang** F. ³⁶⁴ **Wang** F. ³⁶⁵ **Wang** F. ³⁶⁶ **Wang** F. ³⁶⁷ **Wang** F. ³⁶⁸ **Wang** F. ³⁶⁹ **Wang** F. ³⁷⁰ **Wang** F. ³⁷¹ **Wang** F. ³⁷² **Wang** F. ³⁷³ **Wang** F. ³⁷⁴ **Wang** F. ³⁷⁵ **Wang** F. ³⁷⁶ **Wang** F. ³⁷⁷ **Wang** F. ³⁷⁸ **Wang** F. ³⁷⁹ **Wang** F. ³⁸⁰ **Wang** F. ³⁸¹ **Wang** F. ³⁸² **Wang** F. ³⁸³ **Wang** F. ³⁸⁴ **Wang** F. ³⁸⁵ **Wang** F. ³⁸⁶ **Wang** F. ³⁸⁷ **Wang** F. ³⁸⁸ **Wang** F. ³⁸⁹ **Wang** F. ³⁹⁰ **Wang** F. ³⁹¹ **Wang** F. ³⁹² **Wang** F. ³⁹³ **Wang** F. ³⁹⁴ **Wang** F. ³⁹⁵ **Wang** F. ³⁹⁶ **Wang** F. ³⁹⁷ **Wang** F. ³⁹⁸ **Wang** F. ³⁹⁹ **Wang** F. ⁴⁰⁰ **Wang** F. ⁴⁰¹ **Wang** F. ⁴⁰² **Wang** F. ⁴⁰³ **Wang** F. ⁴⁰⁴ **Wang** F. ⁴⁰⁵ **Wang** F. ⁴⁰⁶ **Wang** F. ⁴⁰⁷ **Wang** F. ⁴⁰⁸ **Wang** F. ⁴⁰⁹ **Wang** F. ⁴¹⁰ **Wang** F. ⁴¹¹ **Wang** F. ⁴¹² **Wang** F. ⁴¹³ **Wang** F. ⁴¹⁴ **Wang** F. ⁴¹⁵ **Wang** F. ⁴¹⁶ **Wang** F. ⁴¹⁷ **Wang** F. ⁴¹⁸ **Wang** F. ⁴¹⁹ **Wang** F. ⁴²⁰ **Wang** F. ⁴²¹ **Wang** F. ⁴²² **Wang** F. ⁴²³ **Wang** F. ⁴²⁴ **Wang** F. ⁴²⁵ **Wang** F. ⁴²⁶ **Wang** F. ⁴²⁷ **Wang** F. ⁴²⁸ **Wang** F. ⁴²⁹ **Wang** F. ⁴³⁰ **Wang** F. ⁴³¹ **Wang** F. ⁴³² **Wang** F. ⁴³³ **Wang** F. ⁴³⁴ **Wang** F. ⁴³⁵ **Wang** F. ⁴³⁶ **Wang** F. ⁴³⁷ **Wang** F. ⁴³⁸ **Wang** F. ⁴³⁹ **Wang** F. ⁴⁴⁰ **Wang** F. ⁴⁴¹ **Wang** F. ⁴⁴² **Wang** F. ⁴⁴³ **Wang** F. ⁴⁴⁴ **Wang** F. ⁴⁴⁵ **Wang** F. ⁴⁴⁶ **Wang** F. ⁴⁴⁷ **Wang** F. ⁴⁴⁸ **Wang** F. ⁴⁴⁹ **Wang** F. ⁴⁵⁰ **Wang** F. ⁴⁵¹ **Wang** F. ⁴⁵² **Wang** F. ⁴⁵³ **Wang** F. ⁴⁵⁴ **Wang** F. ⁴⁵⁵ **Wang** F. ⁴⁵⁶ **Wang** F. ⁴⁵⁷ **Wang** F. ⁴⁵⁸ **Wang** F. ⁴⁵⁹ **Wang** F. ⁴⁶⁰ **Wang** F. ⁴⁶¹ **Wang** F. ⁴⁶² **Wang** F. ⁴⁶³ **Wang** F. ⁴⁶⁴ **Wang** F. ⁴⁶⁵ **Wang** F. ⁴⁶⁶ **Wang** F. ⁴⁶⁷ **Wang** F. ⁴⁶⁸ **Wang** F. ⁴⁶⁹ **Wang** F. ⁴⁷⁰ **Wang** F. ⁴⁷¹ **Wang** F. ⁴⁷² **Wang** F. ⁴⁷³ **Wang** F. ⁴⁷⁴ **Wang** F. ⁴⁷⁵ **Wang** F. ⁴⁷⁶ **Wang** F. ⁴⁷⁷ **Wang** F. ⁴⁷⁸ **Wang** F. ⁴⁷⁹ **Wang** F. ⁴⁸⁰ **Wang** F. ⁴⁸¹ **Wang** F. ⁴⁸² **Wang** F. ⁴⁸³ **Wang** F. ⁴⁸⁴ **Wang** F. ⁴⁸⁵ **Wang** F. ⁴⁸⁶ **Wang** F. ⁴⁸⁷ **Wang** F. ⁴⁸⁸ **Wang** F. ⁴⁸⁹ **Wang** F. ⁴⁹⁰ **Wang** F. ⁴⁹¹ **Wang** F. ⁴⁹² **Wang** F. ⁴⁹³ **Wang** F. ⁴⁹⁴ **Wang** F. ⁴⁹⁵ **Wang** F. ⁴⁹⁶ **Wang** F. ⁴⁹⁷ **Wang** F. ⁴⁹⁸ **Wang** F. ⁴⁹⁹ **Wang** F. ⁵⁰⁰ **Wang** F. ⁵⁰¹ **Wang** F. ⁵⁰² **Wang** F. ⁵⁰³ **Wang** F. ⁵⁰⁴ **Wang** F. ⁵⁰⁵ **Wang** F. ⁵⁰⁶ **Wang** F. ⁵⁰⁷ **Wang** F. ⁵⁰⁸ **Wang** F. ⁵⁰⁹ **Wang** F. ⁵¹⁰ **Wang** F. ⁵¹¹ **Wang** F. ⁵¹² **Wang** F. ⁵¹³ **Wang** F. ⁵¹⁴ **Wang** F. ⁵¹⁵ **Wang** F. ⁵¹⁶ **Wang** F. ⁵¹⁷ **Wang** F. ⁵¹⁸ **Wang** F. ⁵¹⁹ **Wang** F. ⁵²⁰ **Wang** F. ⁵²¹ **Wang** F. ⁵²² **Wang** F. ⁵²³ **Wang** F. ⁵²⁴ **Wang** F. ⁵²⁵ **Wang** F. ⁵²⁶ **Wang** F. ⁵²⁷ **Wang** F. ⁵²⁸ **Wang** F. ⁵²⁹ **Wang** F. ⁵³⁰ **Wang** F. ⁵³¹ **Wang** F. ⁵³² **Wang** F. ⁵³³ **Wang** F. ⁵³⁴ **Wang** F. ⁵³⁵ **Wang** F. ⁵³⁶ **Wang** F. ⁵³⁷ **Wang** F. ⁵³⁸ **Wang** F. ⁵³⁹ **Wang** F. ⁵⁴⁰ **Wang** F. ⁵⁴¹ **Wang** F. ⁵⁴² **Wang** F. ⁵⁴³ **Wang** F. ⁵⁴⁴ **Wang** F. ⁵⁴⁵ **Wang** F. ⁵⁴⁶ **Wang** F. ⁵⁴⁷ **Wang** F. ⁵⁴⁸ **Wang** F. ⁵⁴⁹ **Wang** F. ⁵⁵⁰ **Wang** F. ⁵⁵¹ **Wang** F. ⁵⁵² **Wang** F. ⁵⁵³ **Wang** F. ⁵⁵⁴ **Wang** F. ⁵⁵⁵ **Wang** F. ⁵⁵⁶ **Wang** F. ⁵⁵⁷ **Wang** F. ⁵⁵⁸ **Wang** F. ⁵⁵⁹ **Wang** F. ⁵⁶⁰ **Wang** F. ⁵⁶¹ **Wang** F. ⁵⁶² **Wang** F. ⁵⁶³ **Wang** F. ⁵⁶⁴ **Wang** F. ⁵⁶⁵ **Wang** F. ⁵⁶⁶ **Wang** F. ⁵⁶⁷ **Wang** F. ⁵⁶⁸ **Wang** F. ⁵⁶⁹ **Wang** F. ⁵⁷⁰ **Wang** F. ⁵⁷¹ **Wang** F. ⁵⁷² **Wang** F. ⁵⁷³ **Wang** F. ⁵⁷⁴ **Wang** F. ⁵⁷⁵ **Wang** F. ⁵⁷⁶ **Wang** F. ⁵⁷⁷ **Wang** F. ⁵⁷⁸ **Wang** F. ⁵⁷⁹ **Wang** F. ⁵⁸⁰ **Wang** F. ⁵⁸¹ **Wang** F. ⁵⁸² **Wang** F. ⁵⁸³ **Wang** F. ⁵⁸⁴ **Wang** F. ⁵⁸⁵ **Wang** F. ⁵⁸⁶ **Wang** F. ⁵⁸⁷ **Wang** F. ⁵⁸⁸ **Wang** F. ⁵⁸⁹ **Wang** F. ⁵⁹⁰ **Wang** F. ⁵⁹¹ **Wang** F. ⁵⁹² **Wang** F. ⁵⁹³ **Wang** F. ⁵⁹⁴ **Wang** F. ⁵⁹⁵ **Wang** F. ⁵⁹⁶ **Wang** F. ⁵⁹⁷ **Wang** F. ⁵⁹⁸ **Wang** F. ⁵⁹⁹ **Wang** F. ⁶⁰⁰ **Wang** F. ⁶⁰¹ **Wang** F. ⁶⁰² **Wang** F. ⁶⁰³ **Wang** F. ⁶⁰⁴ **Wang** F. ⁶⁰⁵

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

Th.B.P.97 STUDIES OF THE IN VITRO SECRETION OF HIV SPECIFIC ANTIBODIES BY PERIPHERAL BLOOD MONONUCLEAR CELLS FROM HIV INFECTED SUBJECTS.

Vendell, J. G., Corbeil, P., Douss, J.-F., Reynes, J.,***, Hugnot, M.F., Ucker, A.,***, Cassat, A.,***
* INSERM, ** Laboratoire d'Immunologie, Hôpital Lapeyronnie, ***Service des Maladies Infectieuses, Hôpital St Louis, MONTPELLIER, FRANCE.

PMC from 114 HIV seropositive subjects (73 asymptomatic, 15ARC, 26 AIDS) and from 10 HIV negative controls were incubated: a) in the wells of the ELISA kit (Pasteur) to the HIV antibodies secreted in vitro and fixed on the antigens were revealed by the use of a low noise enzymatic complex; b) in antigen free conditions the supernatants were tested instead of PMC by the same amplified ELISA technique or submitted to Western blot analysis on nitrocellulose strips from commercial kits.

RESULTS: a) Positive results were observed in all cases with the PMC of HIV seropositive subjects and in some with the control PMC; b) Positive results corresponded to an active secretion and not to a release of passively adsorbed seric antibodies. c) Active secretion and antigen and antigen induced and occurs within 18 hours' incubation; d) The capacity for in vitro antibody production is constitutive and not a transient phenomenon in seropositive subjects as opposed to classical models of immunization; e) Cells corresponding to all HIV specificities may be present in the blood stream of HIV infected subjects and the env-coded gp bands are always present in both PMC supernatant and serum Western blots; f) When supernatant and seric patterns differ, the seric patterns are more specific; g) HIV specificities are not profused in the PMC supernatant than in the serum.

CONCLUSION: The continuous capacity of in vitro HIV antibody production seems to be an important feature of HIV infection. The detection of such cells could prove useful for the follow up of subjects at risk and of neonates.

Th.B.P.99 NORMAL AND HIV ASSOCIATED FUNGICIDAL ACTIVITY OF MONOCYTES

Malattie Infettive, Antimicrob. A., Norace G., Manera S., Ortona A.

*Ist. Clin. Malattie Infettive, **Ist. Microbiologia-Università Cattolica-Roma-Italy

Objective: 1) to evaluate the ability of monocytes (M) and monocyte-derived macrophages (m-M) of AIDS patients to kill *Candida albicans* and the role of rIFN in their activation, and 2) to study the effect of HIV-lytase (HIV-lys) on M and m-M fungicidal activity in healthy individuals (normals). **Methods:** Ten AIDS patients and 9 normals were studied. Cell monolayers ($0.25 \times 10^6/ml$), untreated or treated with 3000 IU of rIFN- γ , 0.4 $\mu g/ml$ of HIV-lys, 1 $\mu g/ml$ of anti-gp120 were challenged with $0.1 ml$ of *C. albicans* (10^6 CFU/ml) for 2 h. The killing activity was expressed as % reduction of *C. albicans* CFU.

Results: AIDS M killing was lowered (31.6-31.5 vs 48.7-8.8; p<0.005) and partially restored by rIFN- γ (35.5-12.7); AIDS-m-M killing was slightly reduced (46.9-12.7 vs 57.0-7.4). HIV-lys resulted in heterogeneous reduction of activity by normal M, but not m-M; the defect was not overcome by anti-gp120.

Conclusion: 1) M, but not m-M, killing was impaired in AIDS; different killing systems could be operative in M and m-M; oxidative and non-oxidative mechanisms could be involved; rIFN is one of, but not the only, factor required to induce M effector reactions (I-2 or GM-CSF as cofactors); 2) HIV-lys can induce AIDS-like defect in normal M but not in m-M; a role of envelope proteins (gp1) but not gp120 could be suggested.

Th.B.P.101 REFRACTORINESS OF T CELLS TO REGULATION BY IGF IN HIV INFECTION

Gloria Echeverría de Pérez, L. Deibis, R. Ramirez, Z. Rios, M. de Márquez, J. Blasco, M. N. Blanco.

Clinical Immunology Madrid, Centro MID/IAS/UCM, Caracas Venezuela.

CD4⁺ CD45⁺ large granular lymphocytes (LGL) behave as helper cells of immunoglobulin (Igf) synthesis by peripheral blood lymphocytes (PBL). As measured in cultured supernatants by ELISA. We evaluated such capability in 21 HIV-1 individuals (11 of group II and 10 with AIDS), 12 HIV negative homosexuals (HN) and 11 heterosexual controls. Spontaneous IgG levels were significantly higher in HIV-1 when compared to HN or controls (1812 and 1553 vs. 432 and 425 ng/ml). PBL (1.25×10^6) co-cultured with increasing amounts of mitogenic IL-2 (5 and 7.5×10^3) in the presence or absence of PBL (1/200), caused no further enhancement of IgG synthesis in HIV-1, while values in both HN and controls were significantly increased (2000 and 1500 vs 600 and 710). Antibodies to CD20, gp41 and gp24 were detected by western blot in culture and occasional supernatants from HIV-1 individuals. We suggest that T cell function in HIV infection is resistant to regulatory signals not only from T cell but also from LGL.

Th.B.P.98 ENHANCED ENDOGENOUS TNF α PRODUCTION IN PERIPHERAL BLOOD MONONUCLEAR CELLS OF HIV-1 INFECTED PATIENTS.

L. Heuvelink, R. Voth, R. Brouwer, K. de Boer, M.A. M. Meier, M. van't Hof-Grootenboer, and J. van't Hof-Grootenboer, Institute of Johannes Gutenberg University Mainz - Veterinärmedizin. Institut für Infektionskrankheiten, FISCAL, DEUTSCHLAND.

OBJECTIVE: To study the role of TNF α in HIV-1 infected patients. **METHODS:** Blood samples positive for HIV-1 were obtained from 100 patients at various stages of disease. Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-Paque and stimulated with various inducers for TNF α production. TNF α was quantified by using a highly sensitive ELISA.

RESULTS: It turned out that corynebacterium parvum was the most potent inducer of TNF α when compared to classical TNF α such as various preparations of LPS of *Serratia* sp. in a group of 56 healthy donors mean level of endotoxinogeny produced TNF α yielded in 10.2 pg/ml. However patients at stage 2 (CD4⁺ 1 to 4 were able to produce up to 28 pg/ml TNF when stimulating their lymphocyte with 145 pg/ml of corynebacterium parvum. In all groups of patients and in healthy controls, enhanced TNF α levels in patients with HIV infection may account for conclusions: Our data suggest that TNF α plays a major role in regulating TNF α secretion. Enhanced TNF α levels in patients with HIV infection may account for conclusions: Development of coxsackie, PCR and show monocyte dysregulation early in HIV-1 infection.

Th.B.P.100 AUGMENTATION DE LA PRODUCTION DE RADICAUX LIBRES DE L'OXIGÈNE PAR LES PHAGOCYTES DU SANG CIRCULANT DES MALADES INFECTÉS PAR LE HIV-1.

Vuitton, Dominique A., Druier, J.M., Vuillier, J.; Bertrand, M.A.; Drobachef, C. et al. Centre de Recherches sur le SIDA - Franche-Comté.

Centre Hospitalier Régional et Universitaire, F-25030 Besançon, France.

Objectif: Appréhender, par l'étude de la chimioréactivité, la production de radicaux libres de l'oxygène par les phagocytes du sang au cours de l'infection par HIV-1. **Méthodes:** Le chimioréactif (Cl) des cellules du sang dilué au 1/100 et au 1/1000 a été mesuré en présence de luminol et de lucigénine chez 37 sujets HIV-1. Après traitement par azidothymidine (ZD) des groupes II et III, il a été basal et après stimulation par Con A, F-Met-Lys-Phe, phorbol myristate acétate, interleucine et zymosan, exprimé en intensité lumineuse (IL) par 1000 phagocytes et en IL stimulés/basale, et comparé à celle obtenue chez 35 sujets témoins sans apparus par l'âge.

Résultats: La Cl des phagocytes des malades HIV-1 était 37 fois significativement supérieure à celle observée chez les témoins qui soit le réactif utilisé et tant à l'état basal qu'à l'état stimulé (p<0.01). Cette différence répond principalement sur une hyperactivation basale des phagocytes, qui n'était pas significativement différente dans le g.r.IV comparé aux g.r.II et III la sensibilité aux différents stimuli utilisés était diminuée. Il n'existait pas de relation entre la Cl et l'existence d'une complication clinique particulière ou le nombre de lymphocytes circulants.

Conclusion: L'hyperproduction de radicaux libres de l'oxygène par les phagocytes contraste avec la diminution rapportée d'autres fonctions phagocytaires chez les malades HIV-1. La responsabilité des monocytes et des polymorphes dans ces modifications et l'analyse séquentielle de la Cl chez ces malades sont en cours d'étude.

Th.B.P.102 ACTIVATION T-CELLS (TC) AND HUMAN IMMUNODEFICIENT VIRUS (HIV) PRODUCTION

Prasert, Theodor; Rowell, E.N.; Hensley, E.E.; Butzin, C.

US Air Force HIV Program, Lackland AFB, San Antonio, Texas, USA.

Background: HIV is a retrovirus (RV) tropic for CD4 cells. Proliferation of RV requires the translation and transcription of the host genome. Cellular activation. Activation of TC should correlate with progression of RV infection. One marker of TC activation is the production of HLA class II (Ii) antigens (A2) which are not present on resting TC, but are elaborated within 24-48 hr after activation.

Methods: OEA marker class II antigens. When quantitating lymphocytes by flow cytometry the value OEA class II antigen (a pan-cell marker) at all cells have class II A2) should represent activated TC (i.e., a OEA/CD20-population). **Results:** Restoration of available data on the 7700 cases of HIV positive patients in the WHC HIV data base shows: 1) patients with 25% TC consistently had failed subsequent values of 10.3 while those who had decreased TC had values of 12.0 (p<0.01). 2) Pre with absolute CD4 counts consistently 3400 had values of 11.1 while those with 4400 had values of 11.9 (p<0.01) 3) Naïve B-cell (NB) stages 1 or 2 without progression at 1-2 yrs had values of 11.1 while those progressing to WB-3 had values of 14.8 (p<0.01).

Conclusions: These data suggest that activation of TC as measured by OEA-CD20 cells correlates with HIV disease progression. We are aware that the activated TC may, in fact, be CD8 cells (Kiehlbas-Hatthorn et al., JCI, 8(6) 678, 1988) and prospective studies to elucidate which TC population is activated in our patients are in progress.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

Th.B.P.145 A FOLLOW-UP OF IMMUNE PARAMETERS IN HIV INFECTED PATIENTS

CREATED WITH LOW DOSE AZIDOTHYIMIDINE (AZT).
Bryson M., Falson J. and Swinburn W.
** Institut Pasteur, 25 Avenue de la Croix Nivette,
** 69622 Saint Illiers, Saint Maurice de Lillay, Belgium.

Objective: To assess the effect of AZT on immune function of HIV infected patients.

Methods: Seven HIV infected patients were submitted to oral low dose AZT (750 mg/3 days/week). Immune function was assessed at three-monthly intervals by *in vitro* lymphoproliferation towards PHA and PWM and for interferon α and β production. Immune parameters at the onset of the study and the duration of AZT treatment were as follows:

Patients	CD4 (cells/mm ³)	%T4	%T8	PHA (cpm)	PWM (cpm)	ATF (weeks)		
1	2	405	4.47	18124	2615	34		
2	3	iv drugs	3.96	0.46	23456	3680	40	
5	2	AC2	300	0.15	1449	8667	19	
7	9	AC2	Africa	14.0	0.15	15146	1877	18
10	4	AC2	Europe	0.15	1449	8667	19	
108	4	AC2	Europe	252	0.34	14875	544	37
121	4	AC2	Europe	24	0.06	892	187	37

Results: All but one patient (patient #121) presented an increase of CD4 cells during AZT therapy. However, no significant improvement of the immune function was observed during treatment in any of the patients except in patient 37. Interpretation of this improvement must be made with precaution, as this patient cooperated with the AZT treatment, stopped his drug-abuse.
Conclusions: These preliminary results concerning patients with yet advanced disease suggest that low dose AZT induced an increase of CD4 cells but couldn't improve the immune function.

Th.B.P.147 SOUS-POPULATIONS DE LYMPHOCYTES CD4+CD45RO+ ET

CD4+CD45RO- CHEZ DES PATIENTS AVEC INFECTION VIH.
BARBIER P., TOURNARE J., CALDESIERBIANE L., VIVROET J.-M.,
GILNEY C., TOURNARE A.
* Lab. Immun. Hop. Necker/Marcé P., P. Lyon. Hôp. H. Henri L. LYON FRANCE.

Objectif: Evaluer l'effet de la numération des lymphocytes CD4+294+ et CD4+484+ dans la prédiction de l'évolution chez les patients avec infection VIH.

Méthodes: 79 patients VIH-1 séropositifs ont été groupés. On évalue les taux des EPICs CD4+294+ et CD4+484+ (PFC-PHE) CD4+294+ et CD4+484+ (Anticorps monoclonaux Coulter Diagnostics).

Résultats:

Groupes: Niveau de sérum CD4+294+ et CD4+484+ et CD4+294+/CD4+484+ (Ratio)

Témoin n SD n SD n SD n SD

1 16 752 148 214 82 241 82

2 16 752 148 186 83 181 79

3 16 462 98 122 62 184 71

4 24 297 78 82 33 138 80

5 18 257 94 50 42 120 80

6 18 257 94 50 42 120 80

Il existe une différence significative de nombre de cellules CD4+294+ dans le groupe 1 (séroconversion) par rapport aux autres (P<0.0001), test de Student) ainsi que ceux des CD4+ et des CD4+294+ ne sont pas significativement associés (P=0.4 et P=0.7).

La détection des lymphocytes CD4+ dans le groupe 2 par rapport au groupe 2 est prépondérante dans le groupe des CD4+294+ (P<0.0001) sans différence significative pour les CD4+484+ (P=0.046).

Conclusions: Ces résultats préliminaires suggèrent que le sous-population CD4+294+ est associée prédominamment dans l'infection VIH et que le sous-population CD4+294+ est associée prédominamment dans l'infection VIH et que le sous-population CD4+294+ est associée prédominamment dans l'infection VIH et que le sous-population CD4+294+ est associée prédominamment dans l'infection VIH.

Th.B.P.149 CONSISTENCY OF ROUTINE CD4+, CD8+ AND PERIPHERAL LYMPHOCYTE MEASUREMENTS

J.D. Aboumzer, B. Autren, K. Balgord, F. Tournare, M. Tubiana, J.D. Bryson, et al. Groupe INSERM-ILM-CLC4 et SERCOG, France.

OBJECTIVE: To assess the consistency of routine measurements of CD4+ and CD8+ lymphocytes in whole blood using HIRSHMAN-ILM-CLC4 et SERCOG, France using a sample of 12 university laboratories.

METHODS: Two groups of 12 and 12 patients each, with CD4+ lymphocyte ranging from 20 to 1000/mm³ were tested. Each blood sample was fractionated into duplicate aliquots (2 x 12) in order that each sample could be tested blindly within each lab during the subsequent 4 hours. Each one of the 12 labs used its own routine method for whole blood IF staining and analysis. In total, among the 12 labs, 3 sources of lysing solutions and of reference FITC conjugated anti-CD4 and CD8 mAb were assessed and the IF was analysed on 4 distinct types of cytofluorimeters. Total lymphocyte counts were evaluated by both automatic and microscopic hematology methods (7 distinct automatic devices).

RESULTS: A 15% coefficient of variation was found for overall CD4+ cell measurements from 200 to 1000/mm³. This weak variability might be mainly attributed to the immunological and hematology devices rather than to the operators or to the reagents.

CONCLUSION: The high consistency and reliability of CD4+ lymphocyte counts, required for both clinical and research purposes, can be routinely obtained in different laboratories provided automatic counting methods (good statistical validity of microscopic counts) are used by trained operators during each step of the process.

Th.B.P.146 AN UPDATE OF THE LYMPHOCYTE IMMUNOPROLIFERATIVE QUALITY

ASSESSMENT THROUGH 75 SUBJECTS OF THE AIDS HIV SYNDROME.
Richard, William J., Wastell, M.J., Medical, C.***
Dando, J.D., and Burke, D.L.*** Walter Reed Army Institute of Research,
Washington, DC, USA and INRS System, Inc., Rockville, MD, USA.

Objective: To determine the degree of interlaboratory variability among Army Regional Medical Centers (AMC) that evaluate HIV patients.

Methods: Monthly shipments of 3 whole blood specimens are delivered by overnight commercial carrier to seven AMC for lymphocyte and lymphocyte evaluation: CD2, CD3, CD4, CD8, CD4/20 and NK cells, were determined by a standard flow cytometric lymphocyte immunophenotyping protocol.

Results: Since June 1987, 383 specimens from 54 normal donors have been analyzed by the participating AMC with an overall standard deviation (SD) of 5.2 and coefficient of variation (CV) of 13.1% for all lymphocyte cell types. The SD for CD4 percentages have ranged from 3.0 to 9.7% (mean of 3.3), while the SD for CD8 absolute counts have ranged from 69 to 477 cells/mm³ (mean of 227). The cumulative interlaboratory CV for the absolute CD4 count is 29.2%.

Conclusion: In order to provide reliable CD4 determinations for multicenter HIV treatment protocols, a high degree of interlaboratory reproducibility and accuracy must be required and can be achieved through the implementation of a comprehensive quality assurance program.

Th.B.P.140 CD4 AND TOTAL LYMPHOCYTE COUNT (TLC) IN PATIENTS WITH

ANTIBODIES TO HIV-PREDICTING VALUE, CLINICAL SIGNIFICANCE AND ADDITIONAL TRENDS FOLLOW-UP HAVE BEEN STUDIED.
B. Clotet, A. J. Tor, J. S. Sierra, M. Dominguez, JM Gimeno, JM For. Infectious Diseases Unit Hospital de Barcelona "Germans Trias i Pujol" Badalona, Barcelona, Catalonia, Spain.

Objective: To assess the value of CD4 and total lymphocyte count follow-up in HIV seropositive patients.

Material: 164 seropositive patients (110 intravenous drug abusers [IDA], 38 heterosexuals; 16 heterosexuals). No patient had AIDS at entry, CD4+ and TLC were determined each 6 months or before if symptoms developed. Mean follow-up has been 18 months (range 6-48).

Results: Would be shown in tables and figures.

Discussion: There is a trend towards a decline in CD4 and TLC through the follow-up. The decrease in CD4 is more marked in heterosexuals than in IDA. A spontaneous increase in CD4 is occasionally seen during the first year. Total lymphocyte count should suffice for monitoring the progression of the disease because it mimics the decline in CD4 cell count and is less expensive. IDA with low CD4 cell count at entry below 400 x mm³ subsequently developed AIDS more frequently than patients with CD4 400 x mm³ at enrollment (p < 0.005).

Patients with P. carinii pneumonia (PCP) had a 95.5% of cases total lymphocyte count below 900 x mm³ and CD4 200 x mm³. A total lymphocyte count (TLC) major than 1200 x mm³ rules out PCP. Primary prophylaxis for PCP is required in patients with CD4 < 250 x mm³.

Th.B.P.150 IMMUNOLOGICAL FEATURES IN HIV-1 POSITIVE PATIENTS: CLINICAL CORRELATION

G. Sileri, I. Mezzarona, C. Papetti, A.M. Pesca, E. Pieter, M. Cherchi and F. Aiuti. Dept. of Allergy and Clinical Immunology, University of Rome "La Sapienza", Rome, Italy

Objective: To describe immunological features during HIV-1 infection.

Methods: 112 HIV-1 positive patients, 193 sera were significantly reduced as well as routine assays (lab number of T lymphocyte subsets, skin test, EAC coat, serum immunoglobulins) have been evaluated in infected patients. 789 subjects belonging to various at risk categories were selected from 2011 individuals. 180 were diagnosed CD-II and 490 CD-II-1.

Results: Total T cell number was constantly diminished in the clinical stages of AIDS and CD4+ cells were significantly reduced (40-11) in 42% of asymptomatic patients, 56% of PLE and 92% of ARC. AIDS patients showed defective "in vitro" responses to PHA, production of IL-2 and IFN- γ induced by specific stimuli. NK from B9C showed decreased activity in AIDS and CD-II-1.

Clinical correlation: at least two subgroups of seropositive patients may be included in CD-II-1 and II-1 classified subjects. These showing immunologic abnormalities and those with one or more immunologic alterations.

Conclusions: Unknown co-factors may be involved in the clinical evolution of seropositive patients; their relationship with immunological parameters is a central point for a better knowledge of HIV-1 infection.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

Th.B.P.151 IMMUNOLOGICAL PARAMETERS OF HIV1 AND HIV2 SEROPositIVES

Le Bouché, Bernard, Gervais, J.L.

Institut Pasteur de Dakar, Dakar, Senegal.

Objectives: To compare immunological consequences of HIV1 and HIV2 infections in a West African population.
Methods: Serological screening was done using HIV1 and HIV2-specific ELISA and confirmation by specific Western Blotting (Diagnostic Pasteur). Analysis of lymphocyte sub populations was done on a FACS flow cytometer using fluorescein labeled monoclonal antibodies. IgG and IgM were quantitated by radial immunodiffusion, IgG by a sandwich ELISA test and the B2 microglobulin using a competitive ELISA test (all reagents from Becton Dickinson). Immune Circulating Complexes were also tested by ELISA (immunozyme).

Results: Comparison of data from seropositives, asymptomatic seropositives and AIDS cases showed that CD4 and absolute count of T4 cells were the more significant markers of evolution. Comparison of HIV1 to HIV2 asymptomatic seropositives and HIV1 to HIV2 clinical cases showed no difference in the studied parameters.

Conclusion: Parallels of immunological parameters are the same in our HIV1 and HIV2 infected cases and clinical cases. Immunological differences observed in immunologic and evolution of the diseases due to these 2 viruses.

Th.B.P.153 RELATIONS BETWEEN DISTRIBUTION PATTERNS OF LEU8⁺ SUBSETS AMONG CD4⁺ AND CD8⁺ T-LYMPHOCYTES IN THE PERIPHERAL BLOOD

Uthoff, Barmatz, Kunze, R.O.F., Krasser, R., Trölsler, P., Elm, I., Paul, G.

Akt. Virologie des Robert Koch-Instituts und AIDS-Zentrum, BGA Berlin

The CD4⁺ and CD8⁺ cell number and the resulting CD4/CD8 ratio is still the most valuable parameter to assess the cellular immune status during HIV-infections. Both lymphocyte populations are heterogeneous with respect to functional activity and other surface markers. We analysed the coexpression of either CD4 or CD8 with Leu 8 in the peripheral blood of 45 HIV-infected persons. Lymphocytes were isolated from blood by density-gradient centrifugation, stained with fluorescein-labelled Leu 8a (anti-CD8) or Leu 2a (anti-CD4) antibodies together with phycoerythrin-labelled Leu 8 antibodies and then measured on a FACScan flow cytometer. Irrespective of the clinical stages of HIV infection Leu 8⁺ subsets behave differently in the CD4⁺ and the CD8⁺ populations. The shifts in the CD4⁺ lymphocyte population strongly correlate with Leu8⁺CD4⁺ cells ($R=0.98$) but not with Leu8⁺CD8⁺ cells ($R=0.03$). On the contrary, the changes in the number of CD8⁺ lymphocytes are almost exclusively caused by Leu8⁺CD8⁺ cells ($R=0.91$) but by Leu8⁺CD4⁺ cells ($R=0.1$). Furthermore, the serum levels of shedded CD8 molecules correlate well with the Leu8⁺CD8⁺ subset ($R=0.77$) but not with Leu8⁺CD4⁺ ($R=0.1$). The observed relations led us assume that the recruitment of different subsets from lymphatic organs is heavily altered already during early stages of HIV-infection.

Th.B.P.155 CORRELATION OF IN VIVO CELLULAR IMMUNE FUNCTION WITH CD4 NUMBER AND DISEASE PROGRESSION IN HIV SEROPosITIVE PATIENTS

Hicks, Deborah¹, Rhodes, J., Tronost, E., Carter, C.,

Burke, D., ²Bedford, B., ³Walter, David, ⁴National Research Group,

Rockville, MD, U.S.A.

Objectives: 1) evaluate in vivo cellular immune function in HIV seropositive patients, 2) determine its correlation with circulating CD4 (+) cells, and 3) determine its ability to predict HIV disease progression.
Methods: 1500 seropositive patients and simultaneous CD4 counts were performed in 1000 patients. The seropositive patients were divided into 4 groups: 1) CD4 > 1000, 2) CD4 500-1000, 3) CD4 200-500, and 4) CD4 < 200. The seropositive patients were followed for 12-36 months. 300 of the 1000 patients have been followed serially for 24-64 months and observed for HIV disease progression.


Results: Antigen reactivity

	(n)	(%)	CD4 (IQR)
0/6 (seroneg)	218	14	109-127
1/6	166	11	259-162
2/6	247	16	388-199
3/6	494	33	497-223
4/6	240	15	577-285
5/6	290	19	685-351
6/6	146	9	787-361

Antigen responsiveness significantly correlated with CD4 number ($R=0.95$). Progressive loss of antigen reactivity independently correlated with HIV disease progression to opportunistic infection.

Conclusion: This panel provides a clinical parameter that correlates with absolute CD4 number and is independently predictive of HIV disease progression and development of opportunistic infection.

Th.B.P.152



Th.B.P.154 PREDICTION OF CD4/CD8 RATIOS FROM SERUM PARAMETERS

Kunze, R. O. F., Uthoff, Barmatz, Krasser, R., Trölsler, P., Beck, A., Paul, G.

Akt. Virologie des Robert Koch-Instituts und AIDS-Zentrum, BGA-Berlin

FEDERAL REPUBLIC OF GERMANY.

The CD4- and CD8 cell number and the resulting CD4/CD8 ratio still being the most valuable parameters for monitoring the cellular immune status of HIV-infected subjects and to assess disease progression. Usually, the CD4/CD8 ratios are obtained from freshly isolated peripheral blood lymphocytes. As an alternative, we tried to predict CD4/CD8 ratios from serum immunopareters. Blood and serum samples were collected from 49 persons, 39 of which were HIV-positive and belonged to the stages asymptomatic, LAS, ARC. In a multiple regression analysis 30 parameters, among them percentages of CD4 and CD8 cells, neopterin, β_2 microglobulin, the immunoglobulin G, A, M, the immune complexes C1q, C3b, IgG, IgA, IgM, autoantibodies against the lymphocyte surface antigen CD5 (s-ab-CD5), soluble CD8 antigen (s-CD8), and soluble inter-leukin-2 receptor were proved for their usefulness to predict the CD4/CD8 ratio. The best result ($R=0.86$) was obtained with a linear combination of only two parameters, s-ab-CD5 and soluble CD8 antigen irrespective of the clinical stage. This method offers the possibility to estimate CD4/CD8-ratios from stored sera retrospectively.

Th.B.P.156 HIV-2 INFECTION AND IMMUNOSUPPRESSION

Lisse, I., ¹Jølsen, Anne-Grethe², Aaby, P., ³Rydsted, S.,

⁴Björk, E., ⁵Diem, P., ⁶Wassenaar, K., ⁷Lauritzen, E.,

⁸Hvidovre Hospital, Copenhagen, Denmark, ⁹Høstpræsteværket, Copenhagen,

Denmark, ¹⁰University of Copenhagen, Copenhagen, Denmark, ¹¹Abnatorion

National de Sude Public, Niamey, Guinea-Bissau.

Objectives: To evaluate the effect of HIV-2 infection on T-helper cell numbers and T-helper/T-suppressor ratio (Th/S).
Methods: Forty-seven HIV-2 seropositive adults identified in a cross-sectional community study in Bissau, Guinea-Bissau, were re-examined after 10-12 months follow-up, as were 87 controls matched for age, sex and civil status. A physical examination was done. Separated cryopreserved blood was collected, and the same day WBC and blood smears were made. The blood smear was fixed in methanol for differential counting; the others were stored at -20°C until labelled by immuno-alkaline phosphatase technique (APAAP), using monoclonal antibodies against T-helper and T-suppressor cells.

Results:

	HIV-2 seropositives	Controls	p-value
T-cells $\times 10^6 \times 10^9/l$	747	2787	<0.03
Th/S co. 8	16/47	7/87	<0.0005
T-cells $\times 10^6 \times 10^9/l$ and W/S co. 8	6/47	0/87	<0.0005
T-cells $\times 10^6 \times 10^9/l$ or W/S co. 8	17/47	9/87	<0.0005

Conclusion: HIV-2 is significantly associated with low T-helper cell numbers and inverted T-helper/T-suppressor ratios.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

Th.B.P.157

Th.B.P.157 **IMMUNOLOGIC ANALYSIS OF PROTECTIVE AND REACTIVE GAY SEX BEHAVIOR.** R.L. Wilton, R.L. Tronzo, S. Lippert, M. Schneiderman, K. University of Miami Center for Epidemiological Studies, AIDS, Miami, FL.

OBJECTIVE: To determine the early immunologic effects of HIV infection in healthy gay men and to compare immunologic status of gay men to age and sex matched controls.

DESIGN: Factors of cellular immune function were determined for 54 healthy gay men, 395 anti-HIV positive (+), enrolled in a longitudinal study, and 25 age and sex matched controls.

RESULTS: Factors of cellular immune function were determined for 54 healthy gay men, 395 anti-HIV positive (+), enrolled in a longitudinal study, and 25 age and sex matched controls. Results: The (+) gay men in this study did not differ from the (-) gay men or the controls in total number of lymphocytes, CD4 cells, CD8/T4 ratio, cells of the inducer subset, CD45+CD45+, or CD80 cells. The number of CD4 cells, as well as the helper subset, CD45+CD45+, were significantly depressed in (+) men when compared to the controls or to (-) gay men. CD4 cells in these latter two groups did not differ from each other. CD8 cells were elevated in (+) men as compared to either (-) group, and there was a greater proportional increase in CD8/T4. CD4/CD8 was 1.3 in the (+) gay males, significantly higher than the (-) group (0.7), but also significantly lower than the controls (1.8). The ratio CD45+CD45+/CD80 cells was 1.8 for the (+) men, 4.8 for the (-) gay men and 3.7 for the controls. There was a significant elevation of CD8+ cells in both groups of gay men as compared to controls. The mean response to both 1 cell and 1/8 cell antigens of the (+) men was one-half that of the (-) gay men and one-fourth that of the controls. Natural killer (NK) cytotoxicity was similar for both groups of gay men but was significantly lower than the (-) control group. Conclusions: Early immunologic changes which may be related to HIV-1 infection were decreased in the helper subset of CD4 cells, elevations in CD8/T4 ratio and CD8+ cells and marked depression of lymphocyte response to antigens. Healthy (+) gay men had decreased antigen response and cell activity compared to controls. (supported by NIH 1986 RR4243)

Th.B.P.161 AIDS PREDICTORS

Th.B.P.161 **AIDS PREDICTORS**
R.H. Johnson, Department of Immunology, School of Pathology, University of the Witwatersrand and the South African Institute for Medical Research, Johannesburg, South Africa

OBJECTIVE: To evaluate and compare new β_2 -microglobulin (β_2 -micro) levels, IgA and CD4 lymphocytes as predictors of AIDS.

METHOD: 806 patients were studied for HIV-1 infection in Johannesburg by testing for the presence of HIV-1 antibodies and their immunological status. CD4 lymphocytes were counted using a cytotoxicity assay, β_2 -micro was measured using the Pharmacia β_2 -micro EIA test and IgA by turbidimetric methodology.

RESULTS: Of the 806 patients studied, 504 (61%) were exposed to the HIV and 74 (9%) developed AIDS. Sixty seven (90.5%) of the AIDS cases had elevated levels of β_2 -micro and 33 (44.6%) had elevated levels of β_2 -micro, IgA and decreased numbers of CD4 lymphocytes ($<400 \times 10^6/l$). Fifty three (71.6%) had elevated β_2 -micro levels and decreased CD4 lymphocyte numbers but 37 (50%) had both elevated levels of β_2 -micro and IgA. β_2 -micro levels were elevated in 38 (50.7%) of the 77 AIDS cases prior to their developing AIDS. The remainder were assessed when they already had AIDS.

CONCLUSION: (1) Elevated β_2 -micro levels were shown to be the most consistent predictors for AIDS and usually indicated a poor prognosis. (2) The possible use of elevated β_2 -micro as an indicator for the initiation of prophylactic AZT requires evaluation.

Th.B.P.158 EVOLUTION DES DEPONDANTES SOUS-POPULATIONS CD4 et CD8 AU COURS DE L'INFECTION PAR LE VIRUS HIV-1.

AGAZ, Moutiel, Pons, S, Pons, A, Pons, J, Sola, R, Ouen, L, Centre de Recherche Médicale Université de Caugli, Cagliari, Italie

La cytométrie à flux en deux couleurs et l'emploi d'anticores monoclonaux spécifiques pour les antigènes CD 4, CD 8, CD 16, CD 161, Leu-1, Leu-2, ont permis de définir un grand nombre de sous-populations lymphocytaires. On évalue 20 cellules saines sous 1000 individus HIV-1 séropositifs, dont 30 séropositifs asymptotiques (SPA), 30 avec lymphodépression généralisée persistante (PGL), 20 avec ARC et 20 avec SIDA.

La diminution progressive des lymphocytes CD4 dans les stades de SPA, PGL, ARC et SIDA concerne toutes les sous-populations CD4 positives, mais dans les cas de PGL, les sites de recrutement à une classe de subset CD4, le subset CD4-CD8 sont presque normaux, alors que dans les cas de SPA, de ARC et de SIDA, les deux subsets CD4 et CD8 sont diminués. Il faut remarquer la présence d'une pourcentage variable de cellules qui possèdent CD4 et CD8 dans les stades de SPA, PGL et ARC. Ceci peut refléter dans l'activation immunitaire des lymphocytes CD4 par le virus. Les lymphocytes CD8 augmentent dans les SPA, la PGL, et dans une partie de l'ARC. L'augmentation est due essentiellement à une sous-population définie par une haute densité de l'antigène CD8 (CD8-Hi), avec sous-population CD8-Low. La composition est une de fractions Leu-1 définies dans subsets CD8-Hi, CD8-Low, CD8-Hi, CD8-Low, CD8-Hi, Leu-1, Leu-2. Le premier pic correspond à des cellules qui sont dans les SPA et la PGL, les deux autres segments sont surtout les subsets CD8-Hi, CD8-Low, Leu-1, Leu-2, et le dernier sont les CD8-Low. Le passage à l'étape de ARC et surtout de SIDA est marqué par une chute progressive des cellules CD8 (avec hausse) et des augmentations de sous-distribution de subset CD8-Hi, CD8-Low, Leu-1, Leu-2. Il est notable à signaler que des subsets CD8-Hi (dont augmentent) et CD8-Low (à basse densité), sont été observés seulement dans les stades HIV-1. La signification des variations observées entre les subsets qui cellule CD4 et CD8 est discuté en fonction de l'évolution clinique de l'infection rétrovirale vers le SIDA.

Th.B.P.160 DEPLETION OF CD16 NK CELLS IN HIV INFECTION DUE TO A SELECTIVE DECLINE IN THE CD16⁺CD8⁺ COMPARTMENT.

Memoir, J, Dainin, C, Gagnier, P, Lefrère, J, Rouger, Ph, LaFrance, J, J, Meyhans, M, C, Rouger, Ph, et Salmon, Ch, Institut National de Transfusion Sanguine, Paris, France, *Hôpital Saint-Antoine - Service des maladies infectieuses, Paris, France.

OBJECTIVE: To analyze the Natural Killer (NK) cells in HIV-infected patients.

Methods: Using monoclonal antibodies and two-color flow cytometric analysis, we analyzed the NK cell subsets in 121 HIV-infected patients (53 CDC II, 37 CDC III and 37 CDC IV: 4 IFA, 2 IFA, 15 IFA, 5 IFA, 2 IFA and 7 IFA) and 59 healthy controls.

Results: The CD16 NK cells showed a depletion in all stages of HIV infection compared to controls. The mean count and the mean percentage in stage II, III, IV and controls were respectively: 191 cells/mm³, 15%, p < 0.001; 147 cells/mm³, 9%, p < 0.001; 123 cells/mm³, 8%, p < 0.001; 274 cells/mm³, 15%, using the presence of the CD8 surface antigen on CD16 cells as a discriminating criteria, we analyzed two subsets: CD16⁺CD8⁺ and CD16⁺CD8⁻. The CD16⁺CD8⁺ subset showed no statistically significant difference in all HIV infection stages compared to controls, whereas the CD16⁺CD8⁻ cells showed the same profile of depletion as the total CD16 cells (53 cells/mm³, 3%, p < 0.001 in stage II; 35 cells/mm³, 2%, p < 0.001 in stage III; 31 cells/mm³, 2%, p < 0.001 in stage IV; 111 cells/mm³, 6% in controls).

Conclusion: We observed a depletion of the CD16 NK cells early in HIV infection. It seems that only the CD16⁺CD8⁻ subset accounts for this depletion and not the CD16⁺CD8⁺. The etiology of this selective depletion is still unclear.

Th.B.P.162 DICHOTOMY OF TWO CD8⁺ LYMPHOCYTE SUBSETS IN HIV-INFECTED PATIENTS - Depletion of CD8⁺CD3⁺ and expansion of CD8⁺CD3⁻ subsets

Memoir, J, Dainin, C, Gagnier, P, Lefrère, J, Rouger, Ph, Institut National de Transfusion Sanguine, Paris, France.

OBJECTIVE: To help understanding the expansion of CD8 lymphocytes in HIV infection.

Methods: We analyzed two CD8 subsets: CD8⁺CD3⁺ and CD8⁺CD3⁻, using monoclonal antibodies and two-color flow cytometric analysis in 120 HIV-infected patients (53 CDC stage II, 31 stage III, and 37 stage IV) and 59 healthy controls.

Results: In HIV-infected patients, we observed a depletion of the CD8⁺CD3⁺ subset and an expansion of CD8⁺CD3⁻ subset.

	CD8 ⁺	CD3 ⁺	CD3 ⁻	CD3 ⁺	CD3 ⁻	Mann Withney U test
	CD8 ⁺	CD3 ⁺	CD3 ⁻	CD3 ⁺	CD3 ⁻	
CDC	1/2	1/3	1/4	2/3	2/4	3/4
CD8 ⁺	3141	5642	5642	6342	*	NS ** ***
CD3 ⁺	57821	105528	95557	85678	*	NS NS NS
CD8 ⁺ CD3 ⁺	821	36	24	24	*	NS ** *
CD8 ⁺ CD3 ⁻	14924	5847	4245	2742	*	NS ** *
CD8 ⁺ CD3 ⁺	231	5642	5242	6642	*	NS ** **
CD8 ⁺ CD3 ⁻	41624	82875	87258	82875	*	NS NS NS

U: Lymphocytes; * p<0.001; ** p<0.01; *** p<0.05

Conclusion: The apparent expansion of the total CD8 population in HIV infection is, in fact, the consequence of an increase of the CD8⁺CD3⁻ subset which conceals a severe depletion of the CD8⁺CD3⁺ subset.

Session d'affichage Poster Session

Immunologie : réactions Immunaires Immunology: Antibody Responses

Th.B.P.169 IMMUNOMETRIC ANALYSIS OF HIV SEROLOGY ON IMMUNOBLOTTING : PROGNOSTIC INTEREST.

RIEYER JACQUES, ESCAICH S, CHEVALIER P, TREPO C, SEPTIANT N, LAROUYERIE G, SAMPY, LEBLANC, LYON, FRANCE, INSERM U271, LYON, FRANCE.

Objective: To quantify the anti-HIV antibody reactivity on immunoblotting in relation to clinical stage.

Methods: We have studied 450 sera between october 1988 and January 1989, with anti P18/P24 antibody assay (recombinant antigen ELA, Abbott), HIV antigenemia (ELIA, Abbott) and scanning densitometry on immunoblotting (Biorad). The same pool of sera was used in each immunoblotting assay as external standard. Results are expressed in percentage of external standard reactivity.

Results: Antigen/protein antibodies (GP 120 and GP41) and anti P24 gene products antibodies (P26 and P32) variations did not correlate with any clinical feature (Stages II, III, IVA and IVG1/IV2 from the CDC classification). Anti core protein antibodies exhibit a moderate (P18 and P25) or a high (P24 and P40) correlation with clinical stage. Mean anti P24 reactivity was 22% in AIDS, 31% in ARC and 64% in asymptomatic patients. **Conclusion:** We confirm the decrease of anti core protein antibodies reactivity with disease progression. A retrospective and prospective study will confirm the prognostic interest of this method compared with other markers: HIV antigenemia, CD4+ lymphocyte numération.

Th.B.P.171 SECRETORY AND SYSTEMIC IMMUNITY IN HIV-INFECTED INDIVIDUALS

San-Di Fauth, P. A. Archibald, D. University of Maryland at Baltimore, Baltimore, MD, U.S.A.

The secretory immune response to HIV has been proposed to play a role in viral transmission of HIV. We investigated the oral secretory and serum antibody response to HIV and its relationship to clinical status in 20 randomly selected HIV-infected individuals. By CDC clinical criteria, 7 individuals were in group I, 10 in group III, and 3 in group IV. Saliva and serum were collected and assayed for HIV specific antibodies by immunoblotting. HIV were found with saliva or serum, then with a histiolytic post-exposure antibody and finally with a streptavidin-biotin HRP complex. Antibodies to HIV gag antigens gp120 and gp160 were detected in saliva and serum in all individuals of group I and IV. Antibodies to viral core antigens p24, p53 and p17 were detected in 6/7 group II patients (6 with CD4-counts > 200/mm³) in both saliva and serum. Antibodies to core antigens were not found in the saliva, but were detected in the serum of 3/3 group III and 10/10 group IV patients (all with CD4+ > 200/mm³). The difference between group III and group IV or IV core antibody detection in saliva was significant (p<0.01). The difference between the presence of antibody to core antigens in saliva and serum was also significant (p<0.001) as tested by Chi-square. The antibody titres to HIV in serum were more than 1,000 times greater than those in saliva (1:1,000,000 vs. 1:1000). The range of antibody titres in parotid saliva was 1:3 to 1:200. Decreased secretory antibodies to core HIV antigens may correlate with presence of symptoms and a higher CDC clinical stage in HIV-infected individuals. Some independence in systemic vs. secretory antibody response is also suggested.

Th.B.P.173 INDETERMINATE HIV-1 IMMUNOBLOT REACTIVITY IN LOW AND HIGH HIV-1 SEROPOSITIVE GROUPS: PROBABILITY OF REDUCTION OF IMMUNOBLOT REACTIVITY BY IMMUNOPRECIPITATION ASSAY.

Barclay, Linda E., Khoshdel, G., Gomon, R., Kaplan, J., Laine, M., Centers for Disease Control, Atlanta, Georgia, USA.

Objective: Define patterns of indeterminate HIV-1 immunoblot (IB) reactivity in sera from low- (e.g. blood donors) and high- (e.g. IVDRS) seroprevalence groups, and determine the probability that HIV-1 antibody (Ab) status of sera with these patterns will be resolved by radioimmuno-precipitation assay (RIPA).

Methods: Sera repeatedly reactive by HIV-1 ELISA were tested by IB. Sera with indeterminate IBs (n=20) were compared with either one viral band, but not reactive to both p24 and gp41 or gp41/48) were analyzed by RIPA.

Results: All of the 170 indeterminate IBs studied were gag reactive only: 63 (37.0%) were p18 p24, 58 (33.5%) were p17, p24, and 57 (33.0%) were p18 p24 p32. Indeterminate IB reactivity differed in low and high seroprevalence groups: in groups with low HIV-1 seroprevalence (CD 18), 21/26 (81.5%) were p18 p24; in high seroprevalence groups (2 x CD 18) this pattern was seen in only 2/40 (5.0%) ID sera. Indeterminate IB patterns with p24 represented 7/78 (8.9%) sera in low HIV-1 seroprevalence groups and 27/40 (67.5%) ID sera from high seroprevalence groups. RIPA detected Ab to gag proteins and resolved (confirmed) the antibody status of 71/78 (91.0%) of the ID sera. Indeterminate sera: 44/53 (83.0%) of p18 p24 sera, 27/58 (46.6%) of p17-p24 sera, and 0/27 (0.0%) of p18-p24 sera. Conclusions: Sera reactive only with gag proteins were responsible for all of the indeterminate IB reactivity seen, and the pattern of gag-only reactivity differed with seroprevalence. RIPA detected Ab to gag proteins present in low titer in a significant number of IB gag-only reactive sera, and resolved the Ab status of these sera.

Aspects cliniques Clinical Aspects of AIDS

Th.B.P.170 CORRELATION OF CLINICAL DIAGNOSIS OF HIV INFECTION WITH THE RESULTS OF ELISA, KAPAS ELI TEST AND WESTERN BLOT

ANT-HIV ANTIBODIES. Pawlino, U.H.M., Green-Dinco B., Immunodeficiency Clinics, Infectious and Parasitic Diseases Service, Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, BRAZIL

Objective: Correlate the level and type of anti-HIV antibody with the clinical diagnosis of the infection.

Methods: To evaluate 549 individuals examined from February 86 to May 88, we have employed three tests for the detection of anti-HIV antibodies: ELISA, KAPAS ELI TEST and WESTERN BLOT. One hundred sixty and two hundred (30.6%) were HIV positive. 105 had symptoms: 23 PGL, 50 ARC and 32 had AIDS.

Results: In percentage: Antigenic PGs AUC AIDS
ELISA 2x cut-off) 76.6 73.9 48.0 34.4
KAPAS (above 1:2500) 21.6 8.7 10.0 6.3
WESTERN BLOT(2x) 96.7 95.7 82.0 68.7

Conclusion: In our sample the clinical diagnosis of AIDS correlated with low levels of antibodies (Karpas and ELISA) and with the absence of P24 on Western Blot. Routine evaluation of these parameters in the follow up of HIV-positive individuals may be of prognostic value.

Th.B.P.172 IgG SUBCLASS ANTIBODIES AGAINST SYNTHETIC PEPTIDES OF HIV-1 PROTEIN IN HIV-1 INFECTED INDIVIDUALS

Bel, Barbara, Ramos, A.C., F. S. SOARES, G. M. G. M. G. M., and Wally, G.

AIDS-Serumus and Robert Koch-Institut des Bundesgesundheitsamt, Berlin, FRG.

Objective: To evaluate the significance of HIV-specific IgG subclass antibodies against synthetic peptides in monitoring HIV infection.

Methods: IgG subclass antibodies were measured in an ELISA using seven synthetic peptides derived from immunodominant regions of gag and env. Serum from patients with AIDS (9), ARC (10), PGL (21) and without symptoms (10) and follow-up sera drawn at intervals of 6 months (follow-up 1.5 to 2.5 years) from 9 patients in different stages and with different clinical outcomes, were investigated.

Results: IgG1 and IgG3 were the principle reactive subclasses. A significant lower frequency of IgG2 to all peptides was seen in patients with AIDS. Most of the H-terminal peptides of gag, a steadily declining frequency of IgG1 to all peptides was seen with ongoing disease. No follow-up sera little change in antibody patterns occurred, suggesting that an established pattern was maintained. Most changes appeared in IgG1. Multivariate statistics were performed to correlate these findings with other data such as CD4/CD8 ratio, R-2-macrophilic index, soluble interleukin-2-receptor and p24 antigen.

Conclusion: Although IgG1 titres showed a significant difference between AIDS patients and patients without AIDS, the subclass antibody pattern in follow-up sera showed no correlation with clinical course.

Th.B.P.174 SALIVARY IgA TO HIV IN PATIENTS WITH OR AT RISK OF AIDS

Ngw E., Kwevinda A., Davelar E.

+ Institute of Immunology, University of Natal, Durban, Natal, South Africa
+ Institute of Experimental Pathology and Therapy, Subunit, Hungary

Objective: To analyze the presence and diagnostic value of HIV specific serotype IgA antibodies in saliva of patients infected with HIV, and to compare it to HIV specific IgG level of the serum of the same patient.

Methods: Whole saliva samples were collected by expectoration from 15 haemofiliac (13 adults, 2 children) and 16 heterosexual men. HIV specific IgA were tested in an ELISA using monoclonal antibodies to IgA (A-5). Serum samples taken at the same time were tested in two ELISAs (Oragon and Papanicolaou-2) assay.

Results: In a (68%) of HIV seropositive adult haemofiliacs, saliva samples contained HIV specific IgA. Out of the 9 heterosexual children 6 were HIV seropositive and 5 (55%) produced salivary antibodies to HIV. Among the 16 heterosexual men in 11 cases (75%) we could detect HIV specific IgA in the saliva (in 11% of AIDS, 68% of ARC and 90% of asymptomatic patients), while all were seronegative. We could not detect salivary antibodies to HIV in seronegative individuals.

Conclusion: Testing antibodies to HIV in saliva of patients infected with HIV indicated that the virus is capable of eliciting a response in the intestinal-associated lymphoid system characterized by IgA antibodies. As an alternative, saliva may prove useful for rapid HIV antibody testing, first of all in populations in which venipuncture is difficult or contraindicated.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

Th.B.P.161 HIV-ANTIGEN, VARIOUS ANTIBODIES AND T4 CELL COUNTS AS MARKERS OF CLINICAL PROGRESSION IN HIV-INFECTION

Kleinshmitt, Andrea*, Mueselke, A.*; Schauer, D.**; Schewe, S.*; Miller, W.**; Peters, G.**; Gochel, P.D.*; Brhn, V.* and Rohmann, R.**
*Med. Poliklinik der Universität München, D-8000 München, FRG; **Klinikum Zollingstrasse oder Universitäts-Heldberg, D-8000 München, FRG; ***GSP, Abt. für Molekulare Zellbiologie, D-8042 Neuberg, FRG; ****Max-von-Planck-Institut, D-8000 München, FRG

Objective: Study of serological markers as to their stability in clinical prognosis of HIV-infection.

Methods: We have analyzed 600 sera, collected from 145 HIV-infected persons during a five year period, for HIV-antigen, the presence and titers of various antibodies (anti-core, anti-nucleocapsid, anti-gag, anti-p24, anti-p18) as well as the T4 cell counts. The results were correlated with the clinical and serological (Walker model) stages of the patients.

Results: Almost all healthy HIV-infected persons exhibited the full spectrum of antibody reactivity. During the clinical progression the mean anti-p24 antibody titer decrease (LA5-sera 1:320; AIDS-sera 1:32) while the p24-antigen levels increase (30% of LA5-sera and 63% of AIDS-sera are positive). The titers of neutralizing antibodies can be correlated to those of the anti-nucleocapsid. Using selected patients as examples we show that a change in serological markers precedes clinical progression.

Conclusions: Our results indicate that the combined use of a variety of quantitative antibody, HIV-antigen and T4 cell determinations can also be of prognostic value in individual HIV-infected patients.

Th.B.P.163 PROSPECTIVE MULTICENTER CHEMOKINEMY IN HEMODIALYZING MEN IN PBC. OBSERVATION OF IMMUNOLOGICAL PARAMETERS IN A 4-YEAR FOLLOW UP

W. J. Schmalzer¹, R. Borchardt², R. Pauli³, G. for the Study Group AIDS-Sentrum in Bundesrepublik Deutschland, Berlin, FRG

Objective: To evaluate the correlation between HIV-antibody-patterns (AB), HIV-immunity (AI) and circulating immune complexes (CIC) in the course of HIV-infection.

Methods: In 1984 a prospective multicenter cohort study was started in FRG. Of a total of 432 HIV-infected homosexual men 4 groups with typical courses of HIV-infection were selected: Group 1 - 3) individuals without noticeable or only moderate progression of clinical symptoms in different stages of HIV-infection; Group 4) individuals with rapid progression to AIDS. Cohort members are examined twice a year and specimen sera taken for laboratory testing. Antibodies were tested by a peptide-ELISA (5 peptides representing different viral proteins, HIVCORE) and Western-blotting. HIV-antigen p24 was measured by capture assays (Dupont and Coitex). CIC were measured after precipitation with PMS.

Results (Serological): The typical patterns of AB, AI and CIC were seen: Individuals with a non progressing stable clinical course (even with ABC) had high titers of AB (slightly decreasing during time of observation), low titers of AI and CIC. Individuals with rapid progression to AIDS had already in the beginning of the observation low titers of AB and CIC, while AI-titers were consistently elevated. These findings may result in additional prognostic markers.

Th.B.P.165 NEUTRALIZING ANTIBODIES IN HIV PATIENTS: A 3 YEAR FOLLOW UP

Germann, Michael*, Brockmeyer, B.** and Thranhardt, O.*.

*Hiroshima Medical Virology and Immunology, **Clinic for Dermatology, University of Essen Med. School, Essen, P.R. Germany

Objective: To study the significance of neutralizing antibodies in the course of HIV infection.

Methods: Fifty one sera from 13 HIV-infected patients collected during periods of 10 to 36 months (median 31 months) were tested for their capacity to block HIV infection of 89 T lymphocyte cell cultures. After 90 minutes of preincubation at 37°C of different serum dilutions with thawed cell-associated HIV, cells were cultured for 10 days, isolated and evaluated for HIV infection by immunofluorescence. During the study period, lymphocyte counts, T4 and T8 subclasses and beta-2-microglobulin levels were also determined and the clinical status recorded.

Results: Titers of HIV-neutralizing antibodies (NT) ranged from 1:10 to 1:140 and varied by more than factor 2 (1:10 to 1:140) in only 2 persons.

NT 1:10 1:20 1:40 1:80 1:160

NT 0 0 0 0 5 (3 pat.)

T4 400-2000/ccl 4 20 7 3 (no-aid sera)

Statistical correlations to beta-2-microglobulin concentrations, T4/T8 ratios or clinical status could not be assessed.

Conclusions: Levels of neutralizing antibodies in 11 of 13 patients were unchanged for a median time of 31 months. Whether these neutr. ab. titers parallel the clinical course or are independent of the clinical status has to be determined by longer follow up and larger groups of HIV patients.

Th.B.P.162 Correlation between HIV-1 p24 Antigenemia, Anti-p24 Antibody and Neutralizing Antibody Response in All Stages of HIV-1 Infection. P.E. Topp¹, J.R. Sartin², J.S. Spector¹, J. Sack¹, J. Mical¹, J. Welzel¹, J.P. Robos¹, P.S. Sartin², and J.C. Sussell¹, 1. Mt. Sinai Sch. of Med., NY, NY 10029 USA; 2. HIV-RC, USA.

The relationship between HIV-1 p24 antigenemia, neutralizing antibody (NA) and anti-viral core protein (p24) Ab was elucidated in the sera of HIV-1 infected individuals during their progression to AIDS. All AIDS patients (836) and 68 (101/149) of the homosexual males were HIV-1(+). Of these 48 (324) who were HIV-1(+), 3 were converted in 2 years. HIV-1(-) subjects had an early but transient p24 Ag which preceded NA and anti-p24 Ab. After seroconversion, p24 Ag could not be detected. Of the 101 HIV-1(-) subjects 148 rapidly progressed to AIDS and 7 of these 148(4%) died within 2 years. In subjects with poor prognosis, NA and anti-p24 Ab appeared at the onset reaching peak levels just prior to developing AIDS and declined as AIDS clinical course worsened. p24 Ag remained undetectable in as long as there was quantifiable NA and anti-p24 Ab. Reappearance of p24 Ag in sera was associated with rapid progression to AIDS. These data suggest 1) an inverse relationship between viral antigenemia and host humoral response, 2) that the presence of both p24 Ag and anti-p24 Ab in sera is of prognostic value, and 3) multifactorial defects in the host's immune surveillance may cause loss of NA leading to increased HIV-1 replication, antigenemia and profound immune dysfunction in AIDS.

Th.B.P.164 EVALUATION OF ANTIGENEMIA, LOSS OF ANTIBODIES TO HUMAN IMMUNODEFICIENT VIRUS REVERSE TRANSCRIPTASE (RT) AND IMPAIRMENT OF CELLULAR IMMUNITY TO DEVELOPMENT OF AIDS IN DRUG ADDICTS. Ferrandis-Coca, Eduardo; Garcia Novales, J.; Fernandez, J.; Fernandez, A. and Labay J.V.

Division Immunology-Hospital General "Gregorio Marañón", Madrid, Spain.

We have studied in a prospective follow-up lasting 1 to 39 months, the evolution of HIV infection in HIV-antibody positive IV drug addicts (IVDA) seropositive serum samples from 90 IVDA were analyzed for antibodies to viral proteins (Lar-blot I) and HIV antigenemia (ELISA AG I). Results were correlated with cellular immune parameters and clinical outcome. Twenty three drug addicts (27%) who showed at the first follow-up visit a decreased number of CD4⁺ lymphocytes (<350/mm³), anergy, loss or low level of antibodies to P24 proteins (p22 RT/p24) and to GAD proteins (p55) and HIV p24 antigenemia (>50719 ng/ml), had a clinical progression towards AIDS and opportunistic infections (n=20) or a progressive course to the next stage (n=3). In contrast, 60 IVDA (63%) who showed at the first visit: p24<3500 ng/ml, normal delayed hypersensitivity response, presence of antibodies to the viral proteins (p22, p24 and p55) and absence of antigenemia, had a non-progressive course. There were no significant changes in the above parameters throughout the follow-up study in either group. There was no significant difference between the clinical status of the two groups at the first visit. Drug addicts with AIDS at the first visit (n=77), showed a substantial lowering of CD4⁺ cell levels and no significant changes in the others parameters throughout the follow-up. The loss of RT antibody as well as the other above described predictive markers may be early indicators of the progression of virus infection and may have diagnostic and prognostic value.

Th.B.P.166 PREVALENCE OF HIV-1 P-24 ANTIGEN (AG) IN DIFFERENT POPULATIONS AT RISK FOR HIV INFECTION IN ZAIRE: A COMPARISON OF THREE DIFFERENT RISK GROUPS. N. Chabbert, S. Lina, M. Kissa, M.R. Ryder, R.*.

Ndumu, A.C. Quinza, T.C., et al; Projet SIDA, Kinshasa, Zaïre;

**NAID, NIH, Bethesda, MD

Objective: To determine the frequency of HIV-1 Ag reactivity in selected Zairian (ZR) populations.

Methods: 711 patient sera and serial dilutions of 3 HIV-1 viral culture supernates (vcs) (LA101, ZR4, ZR5) were tested for HIV-1 Ag in sera and the vcs were tested on three commercially available kits (Coitex, DuPont, Abbott). Repeatedly positive samples were considered reactive for Ag.

Ag Reactivity

ZR Ag HIV-1 Antibody (+) (n=200) 12.5%

American AIDS Patients (n=7) 21 (64.9%)

DuPont and Coitex Ag assays detected in vcs in dilutions from 10 to 100 times more dilute than those detected by the Abbott assay. Additional patient samples that tested Ag positive with the DuPont assay included 7 (8.0%) of 88 ZR

antibody AIDs; 15 (16.9%) of 88 ZR hospital AIDs; 5 (17.6%) of 28 ZR AIDS

postmortem samples; 3 (12.8%) of 23 antibody-negative clinical AIDS patients; 3

(4.7%) of 74 ZR antibody-negative partners from HIV-1 discordant couples.

Conclusions: In our seroprevalence HIV-1 Ag in Zairian patients is lower than in North American patients (P<0.0001), but increases with severity of disease (seroprevalence vs. hospitalization, P<0.0002). Determination of Ag may aid in the evaluation of disease progression and HIV-1 infectious status in high-risk individuals, such as seronegative partners with AIDS-like illnesses and HIV-1 discordant couples.

Session d'affichage Poster Session



Aspects Cliniques Clinical Aspects AIDS

Th.B.P.193 INCIDENCE OF THE AIDS DEMENTIA COMPLEX AS THE FIRST MANIFESTATION OF AIDS. A PROSPECTIVE STUDY
Abbas J, Graus F, Alon J, Miró JM(*), Galadí D(*),
Tabares E, Neurology and (*)Infectious Diseases Unit, Hospital
Clínic, University of Barcelona, Barcelona, Spain.

OBJECTIVE: To evaluate the incidence of the AIDS dementia complex (ADC) as the first manifestation of AIDS.
METHOD: From August 1987 to September 1988, 102 patients who satisfied the CDC criteria for AIDS were consecutively diagnosed. The clinical diagnosis of ADC was considered in patients who presented with dementia, no previous neurologic or psychiatric disease and no evidence of opportunistic infections or tumors in the central nervous system.

RESULTS: In six patients (5.9%) the presenting manifestation was ADC. None but one of the patients was known to be seropositive before the diagnosis of AIDS. The presenting neurologic symptoms included progressive cognitive impairment and motor dysfunction. At the time of diagnosis, HIV-1 serology was positive in serum and CSF. MRI of the head was normal in four patients, in the other two there was evidence of white matter lesions. All patients were immunosuppressed with a mean CD4 cell count of 193 per cc. (range 130-280) at the time of diagnosis was characterized by progressive neurologic deterioration. In the two patients who died, the ADC was confirmed at autopsy.

CONCLUSIONS: 1) ADC is the first manifestation of AIDS in 5.9% of the patients and represents an important cause of dementia among young adults. 2) Laboratory evidence of severe immunosuppression is invariably present at the time of diagnosis.

Th.B.P.195 NEUROPSYCHOLOGICAL FOLLOW-UP OF SUBJECTS ON AZT LICENSING TRIAL: SAN DIEGO COHORT
D.M. Koenig*, S. Grant, L. Atkinson, H. Brysk, L. McCutchan, T. Nelson, R.K. * et al.,
San Diego State University ** Univ. of California, San Diego, CA, USA

Objective: To document occurrence of dementia in the San Diego cohort of the Zidovudine (AZT) licensing trial by 24 month follow-up neuropsychological evaluation.

Methods: Thirty-two ambulatory homosexual men with the acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex (ARC) were evaluated prior to starting zidovudine treatment with a comprehensive neuropsychological test battery. Survivors were evaluated at 6, 12, 18 and 24 month intervals with the same battery. In order to minimize practice effects, alternate versions of the tests were employed at follow-up sessions. Diagnosis of dementia was determined according to neuropsychological test performance and DSM-III criteria for dementia. **Results:** The table shows the cumulative number of subjects who met criteria for dementia at each follow-up evaluation. The cumulative total of 9 subjects represents 28% of the original sample.

Baseline	Cumulative Number of Subjects with Clinical Dementia			
	6 Months	12 Months	18 Months	24 Months

Conclusion: These results are consistent with notions that dementia is a frequent, rather than a rare complication of AIDS.

Th.B.P.197 A SYSTEM FOR STAGING THE AIDS DEMENTIA COMPLEX: CORRELATIONS WITH NEUROLOGICAL AND NEUROPSYCHOLOGICAL ASSESSMENTS
Feldman M, Rowe, B.J, Sidel, M, Sadler, A, Kulp, J, Wolf, W, Birnham, L. Memorial Sloan-Kettering Cancer Center, New York, NY, U.S.A.

Objective: To assess the utility of a clinical staging system for the AIDS dementia complex (ADC).

Methods: Based on previous criteria of cognitive and motor functional status in daily living, the ADC staging system segregates patients as: 0-normal; 0.5-subclinical or equivocal; 1-mild; 2-moderate; 3-severe; 4-stage II; 5-Infect. Dis. 1987: 1083-1088). ADC Staging was compared to neurological and neuropsychological assessments in a group of HIV-1-infected individuals at various stages of systemic infection and with various degrees of ADC. Comparisons were made in untreated patients at initial evaluation (n=168), untreated patients including multiple evaluations (n=87), and combined untreated and AZT-treated patients undergoing multiple evaluations (n=73).

Results: ADC Stage was highly correlated ($p < .001$) with salient clinical and neuropsychological assessments. For example, at combined evaluation, ADC Stage correlated with: clinical cognitive ($r = .77$) and motor ($r = .70$) ratings; clinical ($r = .80$) and neuropsychological ($r = .70$) and combined ($r = .84$) impairment scores; ADC-sensitive neuropsychological tests including finger tapping ($r = .70$), visual ($r = .63$), trail making ($r = .77$) and ($r = .70$), grooved pebbard ($r = .71$), digit symbol ($r = .69$), Trial 5 of the key word learning test ($r = .71$) and the Benton visual retention test ($r = .71$).

Conclusions: ADC Staging is a simple but useful method of patient classification for epidemiological, natural history, pathogenetic, and therapeutic studies as well as for clinical practice.

Th.B.P.194 MYELOMAPA AS PRESENTATION OF AIDS-TREATMENT WITH AZT.

Cooper, J., Sallatelli, Clara, Solanet, J., Saporiti, M., Orsato, R., La Villa, R.,
Niguarda Cal' Brande, Milano, Italy.

Paraneoplasia is frequently observed in the end stage of AIDS, vascular aplasia being found at autopsy of adult pts with AIDS. We refer here, as rarely reported, on a case of acute paraneoplasia but the clinical onset of AIDS.

Since July 1986 to January 1988, 4 males (mean age 27 yrs and drug abuse history) were admitted for aplasia and HIV infection. They complained of prolonged febrile illness and malaise before appearance of leg weakness in all and sensory symptoms in 3 pts. The first neurological examination showed hyperreflexia, white and papillar clonus, Babinski sign and in 1 pt. also gait ataxia with asterior intorcion without sensory levels. All pts had oral candidiasis, mild anemia, leukopenia, low counts of CD4 cells (mean 30x10⁶), response of CD8, particularly of CD8⁺ low T_H 1 subsets. CT scan and/or MRI showed cerebral atrophies in 4 pts, periventricular white matter change in 2 pts, spinal cord abnormalities in the dorsal tract in 2/4 pts. EEG was altered in all. CSF showed mild elevation of albumin and globulin, oligoclonal banding for anti-HIV was positive in 1 pt, 1 pt. still had band, others without response for anti-HIV, anti-EBV and toxoplasma.

The pts developed 01. lymphoblastoid cell lines and died after 6-12 months with acute AIDS. In 3 of these cases unsuccessful AZT therapy was eventually administered. Rigent cells morphology and vascular aplasia were found at autopsy. The 2 other pts are on AZT treatment since admission (12-18 months of follow up). They are free of AIDS, but their paraneoplasia is slowly progressive. Proneoplastic etiological link or different pathogenesis of aplasia may explain poor response to antiviral treatment.

Th.B.P.196 PERIPHERAL NEUROPATHIES AND HIV INFECTION / SPECTRUM AND NATURAL HISTORY.

Léon Jean-Nève, Delgout F., Hulin D., Rosenheim N., Bouche P., Chauvo R.P., Gantillon M., New J., Brunet P., Hôpital de la Salpêtrière, Paris, France.

Methods: A clinical and electrophysiological study was performed in 29 patients referred for a peripheral neuropathy between November 1986 and June 1988. CSF was examined in 21 cases. A neuromuscular biopsy was made in 12 cases. Follow-up was conducted from 3 months to 6 years.

Results: There were 27 Caucasian and 2 African males (26 homosexual/bisexual/1 African female, ranging from 27 to 58 years); 1) Six otherwise asymptomatic patients presented an inflammatory desmyelinating polyneuropathy (IDP), acute in 1 case and subacute in 5. CSF showed pleocytosis in all cases. In nerve biopsies an infiltration of the endoneurium and/or the epineurium by mononuclear cells, and sometimes microvasculitis, were seen in 7 cases. The 6 patients recovered either spontaneously (4 cases), or with corticosteroids (1 case), or plasmapheresis (1 case). In follow-up from 6 to 48 months, they all have progressed to ARC but none progressed to AIDS. 2) In 5 patients with ARC, we found 1 chronic IDP and a distal sensorimotor peripheral neuropathy (DSPN). The neuropathies remained stable to 2, 2 patients died. 3) Of the 18 patients with AIDS, 2 had a mononeuropathy multiples and 12 a painful DSPN. EKG studies indicated an isomyopathy which was predominant in nerve biopsies in 5/7 cases. Seven patients died within 6 months. The last patient had a polyradiculopathy with lymphocytic meningitis. He died and autopsy found an infiltration of the meninges and the spinal roots by a B-cell immunoblastic lymphoma.

Th.B.P.198 PHARMACOKINETIC ANALYSIS OF THE ENHANCED DISTRIBUTION OF ZIDOVUDINE INTO HARBOR CEREBROSPINAL FLUID CAUSED BY PROBENECID.

Sambak, Ronald J. and Hodaya M.A.,
University of Minnesota, Minneapolis, Minnesota, USA.

Objective: The resolution of AIDS-related neurological dysfunction during zidovudine (AZT) therapy provides a clear rationale for the importance of antiviral drug therapy in treating AIDS dementia complex. The objective of this work was to study the kinetics of AZT distribution into the cerebrospinal fluid and to examine the effect of probenecid on this distribution process.

Methods: In this study two groups of rabbits (n=3) received a single IV dose of 10 mg/kg AZT in the absence (control) and presence of a continuous IV infusion of 30 mg/kg-probenecid. Plasma and CSF samples were obtained frequently over a period of 3.5 hours, and analyzed for AZT and probenecid by HPLC.

Results: Probenecid coadministration caused a 3-fold increase in the AZT AUC_{0-3.5} in probenecid-treated rabbits when compared with controls. The AUC_{0-3.5}/AUC_{0-3.5, plasma} ratio increased from 0.152 ± 0.023 in controls, to 0.568 ± 0.022 in probenecid-treated rabbits. The CSF/plasma AZT concentration ratio during the postdistributive phase increased from 0.34±0.012 in controls to 0.65±0.12 in the probenecid-treated rabbits. A linear pharmacokinetic model, which assumes first-order transfer rates between plasma and CSF, was used to describe distribution of AZT between plasma and CSF. Analysis of intracompartamental clearance showed that the CSF exit rate constant decreased from 0.028±0.010 in control to 0.025±0.006 in probenecid-treated rabbits. **Conclusions:** The results indicate that probenecid enhances AZT distribution into the CSF by decreasing its CSF to plasma clearance.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

Th.B.P.199 TRANSFUSION-RELATED HTLV-I NEUROLOGICAL DISEASE: A PUTATIVE MARKER OF DISEASE ACTIVITY AND RESPONSE TO THERAPY

Reza, H. J., Hardy, M., Politz, B., Ehrlich, S., Larson, R., Goto, J., Ball, M., Price, W., Memorial Sloan-Kettering Cancer Center, NY, *State University of New York, Syracuse, **Centers for Disease Control, USA

OBJECTIVES: To report two cases of HTLV-I neurological disease including a putative marker of disease activity, and response to therapy. **Methods and Results:** A 2 year old Caucasian male, resident in the US, developed HTLV-I associated myopathy (HM) 6 months after multiple transfusions for fulminant pancreatitis. Investigations were remarkable for raised concentrations of δ -microglobulin (δ M) (Pharmacia, Sweden) for raised CSF than serum. Treatment with aldofluorolone and later with clonazepam was ineffective, whereas corticosteroids lead to minor improvement. The clinical response to therapy was reflected in a fall in the δ M concentrations. In addition, during the 3 months after the first, it was transiently positive by ELISA and is now positive only by polymerase chain reaction. Her illness began 3 months after her partner's and consisted of a mild transient peripheral neuropathy.

Conclusions: This is the first documented case of transfusion-related HM in the US. The change in δ M concentration may be useful as a marker of therapeutic response. The second case illustrates the difficulties in serological diagnosis and suggests that peripheral neuropathy may be an early manifestation of HTLV-I.

Th.B.P.201 THE EPIDEMIOLOGY OF AIDS-RELATED NEUROLOGICAL DISEASES

Wilder, Mary Ann; Kemp, G.P.; Neal, G.M.; Payne, S.P.;

*California Department of Health Services, Rutherford, CA.

**San Francisco Department of Public Health, San Francisco, California, USA.

Objective: To describe the epidemiology of diseases of the central nervous system (CNS) in AIDS in San Francisco (SF). **Methods:** We analyzed the demographic and transmission categories of 5634 AIDS cases reported in SF from 1981 through 1988 with respect to CNS diagnoses of toxoplasmosis, primary lymphoma of the brain, progressive multifocal leukoencephalopathy, cryptococcal meningitis, and HIV encephalopathy. Median survival was calculated using the Kaplan-Meier product-limit method. **Results:** 415 (7.1%) AIDS patients were initially diagnosed with a CNS disease. CNS diseases as an initial diagnosis rose significantly from 1.9% of total cases in 1982 to 9.4% in 1988 (p<.001). 770 (13.2%) AIDS patients had a CNS disease at some point during their illness. The mean age of AIDS patients aged >20 with CNS disease was 38.2 years compared with 37.5 years for persons without (p<.001). Intravenous and intramuscular drug users were more likely to have a CNS disease (26.5%) than gay men with (15.5%) or without (12.5%) intravenous drug use (p<.001). There were no significant differences in gender or race/ethnicity distribution among patients over having CNS disease vs. those without. Median survival for AIDS patients with CNS disease (6.8 months) was significantly shorter than that for patients without (12.9 months) (p<.001).

Conclusion: CNS diseases are increasingly common among AIDS patients. AIDS patients who develop CNS diseases are more likely to be older and be intravenous drug users. Survival is shorter for AIDS patients with CNS disease.

Th.B.P.203 NEUROLOGICAL INVOLVEMENT IN GROUP IV HIV+ PATIENTS: NEUROPHYSIOLOGICAL AND CLINICAL DATA

Monetta, Francesco; Grappi, A.; Di Felice, M.;

Colao, M.G.; Bartolotta, G.; Ghislini, P.; Fazio, P.;

*Ist. Mal. Infective Ospedale Garibaldi; **Ist. Mal. Nervose e Mentali Università Cattolica, Roma, Italy.

For purposes of prognosis and therapy, we sought to identify the initial site where HIV begins to exert its deleterious effect. The subjects, all asymptomatic, were in the neurological period of virus, where B IVCS and D IVCS or IVA patients (pts.). The spinal and cortical SEP responses were recorded during 10 nerve stimulation. The electrophysiological results were compared with clinical assessment and serum and CSF HIV markers. In both groups we observed a slowing of nerve conduction along the active afferent pathway. While this was not significant at the level of the peripheral nerve, it became marked and highly significant at the CNS level for about 1/3 of the IVCS or IVA and for 2/3 of the IVCS pts.. The major part of the delay occurred in the mid and lower medullary tract. This results agree with neuroanatomical findings from post-mortem examination of AIDS pts., similar to that described for other lymphotropic virus and oncogenic viruses. The higher incidence of electrophysiological alterations in the CNS of group IV has already been described in pts. with neurological deficit; however, it has not been satisfactorily documented in neurologically asymptomatic HIV pts.. Our findings point to the possibility of using our approach to identify those HIV pts. who might best benefit from early treatment.

Th.B.P.200 NEUROPHYSIOLOGICAL FOLLOW-UP OF 1787 PARTICIPANTS IN THE MULTICENTER AIDS COHORT STUDY

Zaback, Richard A.; Miller, E.S.; Sata, P.;

Stulen, G.; Cohen, J.; Becker, J.; English, P.;

McArthur, J.***; Los Angeles, California; **Johns Hopkins University, Baltimore, Maryland; ***Bartowaters University, Chicago, Illinois; University of Pittsburgh, Pennsylvania, U.S.A.

Objective: To determine the frequency and severity of neurologic involvement in HIV infection in MACS participants. **Methods:** 1787 homosexual/bisexual men were enrolled in the Neurophysiological substudy. 288 were enrolled in Baltimore and 238 in Chicago in 1986, and 209 in Pittsburgh, and 1041 in Los Angeles in 1987. A 20 minute screening battery of neurophysiological tests and a 22 min questionnaire on neurologic symptoms were administered at each visit, approximately 6 months apart.

Results: 600 patients on P-P Screen Mean # of Neurologic Symptoms

System	Visit 1	N	Visit 1	Visit 2
Seronegativity	187	5	1.0	0.4
Seropositivity	416	2.6	4.0	1.1
Seroreverter	122	2.5	7.7	1.3
AIDS	75	6.0	10.0	1.8

Conclusions: Asymptomatic seronegativity and seroreverters did not differ from seronegatives on the P-P tests either at Visit 1 or Visit 2. In seroreverters, although fewer neurologic symptoms were reported on the P-P screening tests as well as reporting more neurologic symptoms at each visit.

Th.B.P.202 NEUROPHYSIOLOGICAL FOLLOW-UP IN PATIENTS WHO HAVE PROGRESSED TO AIDS: THE MULTICENTER AIDS COHORT STUDY (MACS)

Miller, E.A.; Miller, R.M.; Maravice, J.L.; Cohen, B.***; Becker, J.***; Sank, A.L.; Multicenter AIDS Cohort Study, Johns Hopkins Medical Institutions, Baltimore, U.S.A.; Los Angeles, CA; *Northwestern University, Chicago, Ill.; **University of Pittsburgh, PA, USA

Objective: To evaluate changes in neurophysiological (NP) performance in participants in the Multicenter AIDS Cohort Study (MACS) who progressed from asymptomatic (CSC group I/II) to AIDS (CSC group IV).

Methods: Standardized NP testing was available for 7% participants in the MACS Neurophysiological Study who had developed AIDS. Of those, 30 had at least one previous NP evaluation prior to developing an AIDS-defining illness. The performance of these participants was compared with that of 20 age and education matched seronegative (SN) controls. NP testing included tests of attention/concentration, memory and word learning and psychomotor speed, previously shown to be sensitive to HIV-related neuropathology. Individual performance was classified as impaired if scores on one or more tests were below 2 standard deviations based on SN controls. 10 of the participants with AIDS were taking zalcitabine (AZT).

Results: The average number of months between initial and follow-up testing was 12 months (range 4.7-34.5 months). At the initial visit, 1/20 (5%) participants had impaired NP performance, as compared with 4/26 (15%) at the follow-up visit with AIDS. Comparison of group means at initial and follow-up using one-tailed, non-paired t-tests, showed a significant decline in only 1/6 tests (Crawford Pegboard, non-dominant hand). There was no significant difference between the performance of SN controls and participants with AIDS in any of 17 tests used.

Conclusions: These findings demonstrate that progression to AIDS in this well-defined cohort was not associated with significant decline in cognitive functioning as measured by standardized NP testing. Therefore, although fewer neuroimaging may be necessary for the development of HIV-related neuropathology, it may not be a sufficient criterion.

Th.B.P.204 EFFECT OF MANNITOL IV INFUSION ON DISTRIBUTION OF ZIDOVUDINE BETWEEN PLASMA AND CEREBROSPINAL FLUID IN RABBITS

Wang, Yinfeng; Hodge, M.A.; Sawchuk, R.J.

University of Minnesota, Minneapolis, Minnesota, USA

Objective: This work was performed to examine the effect of intravenous infusion of mannitol on the penetration of zidovudine (AZT) into the cerebrospinal fluid (CSF) in order to study the kinetics of AZT transfer between plasma and CSF. **Methods:** Rabbits were assigned either to a control group (n=3), receiving a single IV dose of 1 mg/kg AZT alone, or to a mannitol-treated group (n=3), receiving a single IV dose of 10 mg/kg AZT as well as a continuous IV infusion of 1.5 g/kg-hr mannitol following a bolus of 10 mg/kg of 25% mannitol. Plasma, CSF and urine samples were obtained frequently over a period of 3.5 hrs and analyzed for AZT by HPLC.

Results: The results showed that the AUC_{0-3.5h}/AUC_{0-3h} ratio increased from 0.15 ± 0.02 in the control rabbits to 0.45 ± 0.089 in the mannitol-treated rabbits. The CSF/plasma AZT concentration ratio during the postdistributive phase increased from 0.24 ± 0.03 in control to 0.68 ± 0.24 in the mannitol treated rabbits. A linear pharmacokinetic model, which assumes first-order transfer between plasma and CSF, was used to analyze the data.

Conclusion: This study demonstrates that changes in CSF/plasma AZT concentration ratios caused by mannitol administration can be explained by alterations in intercompartmental clearance of AZT.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

Neurologie : visualisation et aspects pathologiques Neurology: imaging and Pathological Studies

Th. B.P. 247 MODIFICATIONS BIOLOGIQUES DU LCR AU COURS DE L'INFECTION PAR LE VIH

SAINTE-MARIE, L. VERONE, A. CALOGERO, C. TOUPOURNE, F. LAFRANCOISE JM., QUINCY O., TOUPOURNE J.

Unité P. Hospital Edouard Belin 59047 Lille Cedex 03, FRANCE.

1 Laboratoire d'immunologie, Hôpital Neurologique 69534 Lyon Cedex 03, FRANCE.

Objectif: Définir le profil biologique d'évolution du LCR au cours de l'infection par le VIH.
Méthodes: Étude chez 43 patients VIH+ (20 patients avec complications neurologiques et 23 sans complications) des modifications biochimiques et protéiques du LCR par la recherche des enzymes lactate/déshydrogénase (LDH) et adénosine déaminase (ADA) associées à la présence de bandes oligoclonales (BO), d'arborose et VIH confirmée par Western-blot de l'échantillon de LCR.

Résultats: Les perturbations cellulaires lymphocytaires et/ou cytotoxiques inflammatoires, l'augmentation de la protéinase avec modification de la bande arboréogène LCR et d'un système protéolytique d'arborose en présence de bande arboréogène, sont observées associées au VIH au cours de l'infection.

En l'absence de toute modification biochimique et de la bande arboréogène, nous observons les enzymes lactate/déshydrogénase et adénosine déaminase et VIH à des titres élevés. L'évolution de la bande de la bande ADA se traduit par une diminution significative de ses activités.

Conclusion: L'absence de bande arboréogène et de la bande arboréogène, sont observées associées au VIH au cours de l'infection.

Les enzymes lactate/déshydrogénase et adénosine déaminase et VIH à des titres élevés. L'évolution de la bande de la bande ADA se traduit par une diminution significative de ses activités.

Conclusion: Au titre élevé de l'enzyme les perturbations biochimiques du LCR sont plus fréquentes et plus marquées. Ces résultats montrent que l'évolution du LCR est plus précoce.

Th. B.P. 249 CLINICAL-PATHOLOGICAL FEATURES OF HTLV-1 ASSOCIATED MYELOPATHY (HAM) IN AIDS

OSSENBERG, M.; BERN, BRUCE J.; ARONOW HA; HARDY, M; CROFTIN, K; PRICE, RW. Memorial Sloan-Kettering Cancer Hospital, New York NY USA

Objectives: To delineate the clinical and pathological features of two patients infected with HIV-1 and HTLV-1, both of whom had HAM.

Methods and Results: Two black 25 patients, both with AIDS, were found to have HTLV-1 antibodies in the serum. The first patient had had symptoms of a myelopathy in 1973, 9 years before developing AIDS. His leg weakness was clinically stable until the last few months of life. The spinal cord pathology consisted of marked atrophy, meningeal fibrosis and small vessel proliferation without perivascular infiltrates or vacuolar myelopathy. The brain showed a multicystic-cell encephalitis with detectable HTLV-1 p24 antigen. The second patient had a myelopathy that developed in the terminal phase of AIDS and disseminated prostatic cancer. The spinal cord pathology was notable for meningeal fibrosis, proliferation of small vessels and minimal perivascular perivascular infiltrates but again without vacuolar myelopathy. The brain showed white matter pallor and astrocytosis without detectable HTLV-1 p24 antigen.

Conclusions: HAM may occur and progress in AIDS patients despite the concomitant immunodeficiency. Its clinical features are indistinguishable from myelopathy but the pathological changes are separate. The relative lack of inflammation may pertain to "burnt out" disease or the effects of immunodeficiency. Whether HAM pursues a different clinical course in HIV-1 infected patients awaits larger studies.

Th. B.P. 251 INTERNET DE LETUQUE ULTRASTRUCTURALE LOIS DES NEUROPATHIES PERIPHERIQUES ASSOCIEES A L'HYV

BIGOT, J.P., MEYER P., P. LAURENT, J.P. SAHJ, P. STOEHLER, M. MICROT

* Clinique Médicale et des Maladies Infectieuses - ** Laboratoire de Pathologie Cellulaire - Centre Hospitalier Régional - Clermont - France

Objectif: L'atteinte neuropathique périphérique possède un pronostic incertain. Nous avons étudié la relation entre la fréquence de survenue des inclusions ultrastructurales (IUR) au microscope électronique, et la gravité de l'infection.

Méthode: 19 patients atteints d'étapes de neuropathie périphérique ont été étudiés: 5 SIDA, 2 HAM, 2 lymphomatiques. Dans tous les cas, l'immunohistochimie a confirmé le neuropathie et une neuropathie musculaire radicaux. Nous avons compris une étude de microscopie optique et électronique.

Résultats: Chez chaque patient, il a été noté une atrophie musculaire de type neuropathique associée à une neuropathie axonale ou axone démyélinisation. L'aspect ultrastructural à l'échelle des IUR dans les fibres nerveuses périphériques était 7 cas sur 8. Le pourcentage de vaisseaux contenant des IUR a été corrélé de façon significative avec l'intensité de l'atteinte neuropathique. Le stade clinique, et le rapport IUR.

Conclusion: Cette étude confirme l'intérêt de la mise en évidence et de la quantification des IUR chez les patients HIV+ atteints de neuropathie. Une fréquence de survenue parallèle associée au stade évolutif de la maladie.

Th. B.P. 248 PRODUCTION INFECTION BY HIV OF HUMAN CENTRAL NERVOUS SYSTEM (CNS) TISSUES

BUCKDA, HERBERT. Neurological Institute, University of Vienna, Vienna, Austria.

Objective: To clarify frequency, cellular tropism, and relation to disease pathology, of productive HIV infection in human CNS.

Methods: Immunocytochemistry for HIV p17, p24, and gp41, for specific cellular markers, and for opportunistic pathogens, on serial sections of formalin-fixed, paraffin-embedded CNS autopsy tissue of 57 patients (56 with AIDS) with various pathologies.

Results: HIV antigens detectable in 37 cases (65%). In 26 cases large amounts of virus in lesions histopathologically diagnosed as HIV-induced (Buckda, Acta neuropathol. 77:225, 1989), including vacuolar myelopathy and leukoencephalopathy. In 7 cases isolated immunoreactive cells unassociated with pathology. In lesions of opportunistic infections HIV cells absent (24 cases) or rare (6 cases); only in 3 cases massive HIV coinfection. Immunoreactivity limited to cells with phenotype of microglia or macrophage.

Conclusions: Productive HIV infection of the CNS is frequent in AIDS, with the microglia/macrophage as target. Early HIV production without associated pathology involves isolated microglia. Massive production of HIV is invariably associated with prominent and specific histopathology. HIV pathogenicity in the CNS appears as microglia/macrophage-mediated, possibly by means of productively infected cells of myelinoctonic factor(s).

(Supported by the Lord Mayor's Medical-Scientific Fund, Vienna)

Th. B.P. 250 CAN HIV-1 ALONE INDUCE A SUBACUTE ENCEPHALITIS? A HISTOPATHIC AND IMMUNOCYTOCHEMICAL STUDY

DELMONTE, M.; RAY, R.; HANCOCK, R.; SACHDEV, J.S.; KILGUS, C.; HAN, J.-W.

* La Salpêtrière and ** Institut Pasteur, Paris, France.

Objective: 1) To study the relationship between the topography of microglial nodules and multinuclear giant cells in a series of 30 patients with HIV-subacute encephalitis and their higher cortical function. 2) To determine by immunocytochemical methods how often HIV is associated with other pathogens (infections/tumors).

Methods: We studied 20 paraffin and 6 cellulose sections (250 nm) in 30 cases and in 20 of them we reviewed numerous from sections (10 nm) for immunoreaction of HIV-1 antigen (immunoperoxidase, DAB, and propogin vapour).

Results: Study per case had less than 10 microglial nodules. Multinuclear giant cells were observed in only 22/30 cases and 7/24 had less than 5 giant cells. Giant cells and microglial nodules were not spatially linked and neither was their number linked to other lesions. Microglial nodules were significantly more frequent in the basal ganglia and brain stem. Giant cells predominate in the pallidum and HIV-1 antigen. The presence of HIV-1 antigen did not depend on the density of microglial nodules or giant cells. In all cases, HIV-1 was detected in subacute encephalitis associated with opportunistic infection or lymphoma. There were no instances of subacute encephalitis associated exclusively with HIV-1.

Conclusions: 1) The topography of subacute encephalitis is mainly basal. 2) Protein tumor in structure known to be involved in subacute encephalitis. 3) Opportunistic infection or lymphoma may either facilitate the entry of HIV-infected cells or trigger the replication of HIV-1 in latently infected reservoir cells of the brain and thereby lead to subacute encephalitis.

Th. B.P. 252 EARLY ASTROCYTIC INVOLVEMENT IN MEDULLA

BERNARDI, DOMENICO, B. MARRAS, G. MARRAS, F., FAUSTINI, G., STAGI, G., FRANCESCHI, D., DONATI, G.

* Laboratorio di Strutturazione, Istituto Superiore di Sanità, Roma; ** Istituto di Malattie Infettive, Università di Pisa, Italia.

In the studies on the neuropathology of AIDS, astrocyte involvement has generally received little attention. The frequency and diffusion of astrocyte hyperplasia in cerebral tissue, however, better correlates with the frequency and extension of CNS involvement in AIDS, especially when compared with the incidence of other lesions, such as microglial nodules and multinuclear giant cells, which are considered the hallmarks of neurotoxicity. Here, we studied the patterns of astrocyte involvement on paraffin sections from the cerebral tissue of 9 subjects, including 4 patients with diffuse CNS involvement before the entry, by the immunohistochemical demonstration of GFAP. The most frequent modification was an increase in number and size of astrocytic foot processes around blood vessels, which was present in 8 out of 9 cases, was often associated with clustering of astrocytes around the vessels and was sometimes the only histological abnormality present in the grey matter. A diffuse increase in astrocytes was less frequent, especially in the grey matter. Microglial nodules, which were present in 2 cases, did not appear to be composed of astrocytes. Although around them an increase in number and thickness of astrocytic cell processes was often evident, in 3 cases hyperplasia of astrocytes was observed. The finding of astrocytic foot processes hyperplasia, in absence of histopathological signs of other neural cell type involvement, suggests that astrocytes may be involved early in the neuropathology of AIDS.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

Th.B.P.253 ETUDE PAR RESONANCE MAGNETIQUE DES ATTENTES CEREBRALES AU COURS DU SIDA DE L'ADULTE: CONFRONTATIONS AUTOPSIQUES.

Trotet J.M.,Bertrand-Tronca C.,Lévesque R.,Vassak M.,Mathisen L., Gray F.,Mikol J.,Vedrine C.
O.S.U.L. Pasteur,Paris,France.

Objectif: comparaison entre le diagnostic visuel sur l'image de Résonance Magnétique (RM) et l'anatomie du cerveau post-mortem.

Méthode: à partir de 300 cerveaux examinés après cas comportant RM anatomotopographique traditionnelle et étude après congélation par hybridation in situ et immunomarqueage. **Résultats:** dans certains cas le contraste est net (atoude cortico-sous-corticales, LEMO à l'encéphale vital), dans d'autres est plus difficile (syndrome, cryptococcose). Cependant le problème à plus délicate reste celui des anomalies effuses: signification des augmentations effuses de signal des centres postérieurs de la chaine ventriculaire? les tumeurs ventriculaires, les hyperintensités des zones de haut signal (S-20) sontomies toxiques ou desinfectées? analyse des attitudes de la base postérieure?

Conclusion: la confrontation anatomo-radiologique permet d'apporter dans la compréhension de ces divers troubles. Bien souvent les attentes ne sont pas inversées et l'on retrouve 2, 3, voire 4 signes à l'heureux anatomie.

Th.B.P.254 APPORT DE L'IRM AU DIAGNOSTIC PRECOCE DES COMPLICATIONS ENCEPHALIQUES DU SIDA

P. J. Tronel, M. Thibaut, A. E. Cabas, R. Laveyrie, J. M. Bigot, G. Vignaud, Institut Pasteur, Paris

Objectif: déterminer l'apport de l'Imagerie par Résonance Magnétique (IRM) au diagnostic des complications encéphaliques: encéphalites sous-acute ou lésions focales, infectieuses ou tumorales.

Méthode: A partir des dossiers des 300 derniers patients hospitalisés comparaison IRM/Tomodensitométrie (TDM). Confrontation avec les résultats des épreuves thérapeutiques, des biopsies stéréotaxiques et des autopsies.

Résultats: deux tableaux cliniques peuvent être opposés: 1) lésions focales de fibres et de troncules neuro-axonaux - détérioration progressive de début insidieux.

2) lésions de type "la TOM est souvent suffisante pour reconnaître l'existence d'une ou plusieurs lésions focales, cependant la section précoce des lésions tomographiques est le fait de l'IRM avec ou sans Gadolinium.

Dans le second l'IRM permet de différencier lésions focales et diffuses, parcellaires ou multiples. Les lésions focales sont identifiées par des plaques discontinues sous-corticales (leuco-encéphalites à papovirus), lésions punctiformes ou linéaires disséminées, hyperintenses diffus des centres ovales, avec ou sans dilatation ventriculaire. **Conclusion:** essai de mise en place d'un algorithme de décision.

Th.B.P.255 SINGLE PEROXIDASE POSITIVE TROPHIC (SPPT) FINDINGS IN HIV INFECTION. PREVALENCE ROLLS.

Pignatelli F.,Papa F.A.,Galassi S.,Bertetto P.V., Ricci M.A.,Viano Giuseppe et al.

U.S.L. IRV10-Corrienti/Roma, Accademia Med. Inst. "G. Gemelli" Hosp. Neurology Dept.,

"G. Gemelli" Hosp. Infectious Dept., Rome, Italy.

OBJECTIVE: To evaluate the sensitivity of SPPT cerebral blood flow studies to disclose brain involvement in HIV infection in comparison to CT scan and MRI findings.

METHOD: This study included 25 patients 17 AIDS, 4 HIV and 4 HIV seropositive all with neurologic signs or symptoms. Local cerebral blood flow was evaluated by 99mTc-DTPA SPPT and related to clinical, CT and MRI findings.

RESULTS: SPPT showed pathological findings consisting in cortical thinning, cortical focal hypoperfusion and basal ganglia hyperfusion in 20/25 cases. Cortical hypoperfusion was more frequently observed in frontal cortex (16/25). CT was positive in 14/25.

CONCLUSIONS: Our preliminary data on SPPT cerebral blood flow studies in HIV related cerebral disease are encouraging. However results are of course not specific, but they may be very sensitive in showing pathological dysfunction at an earlier stage than CT or even MRI, even if the possibility of "false negatives" has to be taken into account. There in, thus, the concrete hope to disclose neurological involvement in asymptomatic HIV seropositive patients.

Th.B.P.256 BRAIN MAGNETIC RESONANCE IMAGING (MRI) FINDINGS IN HIV INFECTION.

Tosti V.,Giordano R.,DiGiacomo S.,Bucci M.A.,Molinaro V.,Viano Giuseppe et al.

U.S.L. IRV10-Corrienti/Roma, Accademia Med. Inst. "G. Gemelli" Hosp. Neurology Dept.,

"G. Gemelli" Hospital, Dept. Neurology, Rome, Italy.

OBJECTIVE: To define MRI patterns of brain involvement in HIV infection and to correlate these findings to the clinical, pathological and CT brain data.

METHOD: MRI and CT of the brain were performed in 107 HIV positive patients with neurological signs or symptoms. MRI findings were compared to the clinical picture in all patients and, in 20 of them, also with the pathological diagnosis.

RESULTS: The following MRI patterns in 24 weighted images were observed:

A) an enlargement of the cortical sulci and ventricles was detected in most patients independently to correlate lesions within the white matter were observed in HIV seropositive only. Cholinergic or multiple-hypertensive areas localized in the cortical and subcortical regions were present in primary CNS lymphoma and in neurocysticercosis. D) multiple, focal hyperintense areas in the deep white matter of fronto-parieto-occipital lobes were noticed in multifold progressive leuco-encephalopathy. E) small, solitary or multiple subcortical hyperintense lesions were detected in different modes but any specific correlation was found in our patients.

CONCLUSIONS: MRI patterns abnormalities, although being largely useful in suggesting differential diagnosis in HIV patients with neurological symptoms, cannot be considered as pathognomonic. MRI seems to be a highly sensitive method for diagnosis of brain involvement, particularly for the early detection of HIV encephalopathy.

Th.B.P.257 CEREBRAL ATROPHY IN HIV-1-INFECTED PATIENTS: RELATIONSHIP TO NEUROLOGICAL AND NEUROPSYCHOLOGICAL MEASURES

Reardon, D., Bickel, J., Bickel, J., Bickel, D., Price, R.W. Memorial Sloan-Kettering Cancer Center, New York, NY, USA

OBJECTIVE: To evaluate the relationship between cerebral atrophy, assessed by computerized tomographic (CT) head scans, and neurological and neuropsychological impairment in HIV-1-infected patients.

METHOD: 34 patients (age 40) received a total of 42 CT scans in the context of clinical evaluation. Patients were examined neurologically, staged with respect to the severity of the AIDS dementia complex (ADC), and received neuropsychological tests. Using a set of predefined "standards", scans were assigned numerical ratings corresponding to normal, mild, moderate, or severe with regard to sulcal, ventricular, and Sylvian fissure enlargement. Ratings were summed to derive an overall index of atrophy.

RESULTS: Cerebral atrophy increased significantly with increasing ADC (p<0.05); moderate to severely demented patients had significantly greater atrophy than equivocal or mildly demented patients (p<0.05). Atrophy correlated with the following neuropsychological tests: Trail Making A (p<0.05) and B (p<0.05), Digit Symbol (p<0.05), Verbal Learning (p<0.05), and Timed Bait (p<0.05).

CONCLUSIONS: Mild cerebral atrophy may be seen in patients without clear functional neurological impairment, while more severe atrophy correlates with progressive ADC and worsening neuropsychological performance.

Th.B.P.258 AUTORADIOGRAPHIC ANALYSIS OF AIDS BRAIN LESIONS WITH AN ¹²⁵I-PERIPHERAL TYPE BINDING/ASSOCIATED BINDING SITE ANALOG

Brinley, M.C., Johnson, J., Cornu, P., Sedwinski, V., Brille, M., Kivert, D., Daverkos, C.,

Helm, D. Hôpital de la Salpêtrière, Paris, France.

OBJECTIVE: To describe the brain localization of ¹²⁵I-AIDS encephalopathy.

Methods: Twelve brain samples from 5 cases of AIDS subacute encephalopathy and from 3 control brains were frozen in isopentane and processed for ¹²⁵I-AIDS as previously described (1, 2, 3). An irreversible (¹²⁵I-PK 14105) ¹²⁵I-AIDS analog was used to determine the microscopical localization of these binding sites (A1-A5 stained centers). In addition, the following studies were performed on serial sections: acid phosphatase, Lux-13, Lux-15, K105, K1107, and 6FAP and anti HIV (p16 and p25) antibodies.

Results: In AIDS subacute encephalopathy, the emission autoradiography of irreversibly bound ¹²⁵I-PK 14105 (total label either single cells or cell clusters grouped to form microglial nodules or perivascular cuffs. Other techniques suggested a predominant macrophage localization of these sites.

Conclusions: ¹²⁵I-AIDS sites were labeled in HIV+ as in HIV- brains.

Conclusion: ¹²⁵I-AIDS sites label macrophages in AIDS encephalitis as they do in other neurologic diseases (3), and not the presence of HIV-1. The available positions (¹¹¹In-PK 11195) and ¹²⁵I-PK 11195 emitting ligands of ¹²⁵I-AIDS may render possible their in vivo detection and help to the diagnosis and study of AIDS subacute encephalitis.

1. Brinley et al. J. Pharmacol. Exp. 1989 in press. 2. Dubois et al. Brain Res 445, 77-90 (1985). 3. Brinley et al. Annals Neurol. 24, 708-712 (1988). 4. Choukroff et al. Circulation 73, 476-483 (1986). 5. Citron et al. Neurosci. Abstr. 13, 263.3 (1987).

Session d'affichage
Poster Session



Aspects Cliniques
Clinical Aspects AIDS

Th.B.P.312 EFFECT OF ENTERAL NUTRITIONAL THERAPY ON BODY CELL MASS IN AIDS.

Evans, Robert, Koster, D.P., Cuff, P., Thomas, A.R., Smith, R., Hayward, S. & Lally, Raymond. *Harlem, Columbia University, New York, NY, USA.*

Objective: To determine if enteral nutritional therapy can successfully restore body cell mass in malnourished AIDS patients to decrease morbidity and associated with improvement in rates of infectious disease.

Methods: Six AIDS patients who had lost more than 10% of weight, at less than 80% of estimated needs, had adequate tylose absorption, and no severe active complications were chosen for study. Nutritional therapy was provided via percutaneous endoscopic gastrostomy tube (PEG), and consisted of a hypotonic protein solution (Nutrena HN, Orléans France). Nutritional assessments were performed 1 month pre and 2 months post and included determinations of total body potassium (TBK), a measure of body cell mass, in a whole body counter, total body and extracellular water volumes by isotope dilution, and body fat content by anthropometry. In addition, selected immune studies were performed subsequent to enteral nutritional therapy.

Results: The values for TBK increased significantly in all patients. There was a more variable effect upon body weight and body fat content. No significant changes were seen to total CD4+ lymphocyte counts or serum immunoglobulin concentrations.

Conclusions: Enteral nutritional therapy can promote body mass regain in AIDS. Successful nutritional therapy is not associated with obvious health or immune function.

Th.B.P.313 LOW VITAMIN B₆ LEVELS AND IMMUNE SUPPRESSION IN HIV-1 INFECTION.

Morono-Alvarez, E.,* & Diaz, R.S.,** Van Hiel, T.W.,* Flitscher, M.A.,** Kayan, R.M.,* Kadoctor, C.G.,* Furchtgott-Rot, D.*

*Department of Epidemiology & **Biopsychosocial Center For Studies of AIDS, University of Miami, School of Medicine, Miami, Florida, USA.

Objective: To determine vitamin B₆ status and its relationship with immune decline in HIV-1 infection.

Methods: Subjects were 50 homosexual males aged 20-50 years who tested HIV-1 seropositive by Western blot and who remained asymptomatic other than lymphadenopathy. Pyridoxine status was evaluated by assessing stimulation of red cell aspartate aminotransferase. CD4 cell number and immunoglobulin (IgA) stimulation were performed by standard techniques.

Results: Thirty-five percent of study participants showed overt pyridoxine deficiency and an additional 10% marginal deficiency in spite of adequate B₆ dietary intake. A variable degree of depression and immune dysfunction was also noted; when correlated with pyridoxine status, individuals with vitamin B₆ deficiency had uniformly lower CD4 cell counts than were participants with normal vitamin B₆ levels. However, the response of peripheral blood lymphocytes to phytohemagglutinin (PHA) demonstrated significant correlation once the entire continuum of vitamin B₆ levels; subjects with the most deficient vitamin B₆ status had the poorest response to PHA (p<0.05, p<0.004).

Conclusions: Pyridoxine deficiency occurs relatively frequently in HIV-1-infected individuals and may play a significant role in immune dysfunction and disease progression in the HIV-1 continuum.

Th.B.P.314 NUTRITIONAL KNOWLEDGE, HEALTH BELIEFS AND PRACTICES IN THE HIV-1 INFECTED SUBJECT.

Morono-Alvarez, E., Furchtgott-Rot, D., Van Hiel, T.W., Flitscher, M.A., Kayan, R.M., Kadoctor, C.G., & Diaz, R.S.,**

Center for the Biopsychosocial Study of AIDS, University of Miami School of Medicine, Miami, Florida, USA.

Objective: To assess nutritional beliefs and knowledge in HIV-1 positive gay males.

Methods: Seventy-five HIV-1-infected homosexual males, asymptomatic other than generalized lymphadenopathy, were interviewed to determine the nutritional health beliefs and knowledge using a standard questionnaire.

Results: 50% of the participants changed their diet at the time of, or subsequent to diagnosis of HIV-infection. The most common alternatives were decreased intake of red meat (73%), whole milk (33%), butter (31%) and alcohol (31%). Increased intake of vegetables (33%), fruits (32%), seafood (30%) and whole wheat breads/cereals grains (23%); 87% of the participants felt that vitamin and mineral supplements could favorably influence their immune function with 59% reporting an increase in their requirement of such supplements since diagnosis. 90% did not know the daily requirements of essential vitamins and 50% concerning supplements did not know the amount they were consuming. The most frequently reported sources of nutritional information and counseling were friends (79%), newspapers and magazines (68%). Approximately 80% of HIV-1-infected patients view nutritional and dietary issues of high importance in maintaining their immune function and asymptomatic status. **Conclusions:** Subjects adopt strategies based upon a poor information base and these strategies may, at times, be ill-advised. Practitioners must provide the HIV-1-infected patient with basic nutritional information.

Th.B.P.315 THE ROLE OF ZINC IN HIV-INDUCED IMMUNOSUPPRESSION.

Falouts, Jilina, Thoulas, C., Deutsch, G.

Montreal General Hospital, McGill University, Montreal, Canada

Objective: HIV infection causes a progressive but variable rate of CD4+ cell depletion. Confounders may thus be important in disease progression. Zinc (Zn) deficiency causes reversible cell-mediated immune (CMI) abnormalities similar to those observed in HIV disease. We determined serum Zn levels and studied its functional role in HIV-infected subjects.

Methods: Serum Zn was measured in 200 subjects and controls (CDC HIV classification) by atomic absorption spectrophotometry. T cell subsets and serum albumin were assessed. Proliferative responses of isolated mononuclear cells (PMMC) to phytohemagglutinin (PHA) were determined in 36 HIV positive subjects. Statistical analysis was based on Student's t-test between groups and regression analysis between variables.

Results: Groups IVb, IVc, and IVd had serum Zn levels significantly less than in HIV negative controls (96±12.8, 34±12.0, and 31±12.0 μmol/l; p<0.05, p<0.01, and p<0.001 respectively). A significant correlation was found between Zn (range 3-23.5 μmol/l) and the proliferative response of PMNC to PHA (p<0.01) but not between the number of CD4 cells (range 16-765/microl) and the proliferative response to PHA. There was no correlation between serum albumin (range 32-51 g/l) and PHA response.

Conclusions: Serum Zn decreases significantly in advanced HIV disease, and is correlated with the proliferative response to PHA. The absent correlation between albumin and PHA response suggests that the decreased serum Zn is of multifactorial origin. The lack of correlation between serum albumin and CD4 concentration requires further investigation. Zn may be an important cofactor in the progressive immunosuppression occurring in HIV infection.

Th.B.P.316 FUNCTIONAL CORRELATES OF DECREASED SERUM ZINC IN HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE.

Falouts, Jilina, Thoulas, C., Deutsch, G.

Montreal General Hospital, McGill University, Montreal, Canada

Objective: To determine the functional significance of the decreased serum zinc (Zn) that we have previously shown occurs in HIV disease, we studied the immunologic effect of Zn on lymphocyte from patients and controls.

Methods: In HIV men and 16 HIV controls were studied. Proliferative responses of mononuclear cells (PMMC) to mitogens Zn, in concentrations from 0.01 up to 2.00 μM, either in the absence or presence of PHA, were determined. The percent increase in the stimulation index (SI) at each Zn concentration relative to either control was determined. Statistical analysis of the antigenic effect of Zn in Zn was determined using t-tests for paired comparisons.

Results: Mean serum Zn of the HIV- & HIV+ groups were 17.0±2.5 & 14.1±2.8 μmol/l, respectively (p<0.01). Zn had a significant mitogenic effect on PMNC from controls only at the highest dose [Zn: 2.00 ± 2.00 μM; SI: increase of 159±170% (p<0.01) and 125±143% (p<0.01) whereas in HIV+ PMNC's, a greater degree of added Zn produced a significant response [Zn: .20, .50, 1.00, & 2.00 μM; SI: increase of 42±7% (p<0.05), 52±7% (p<0.05), 66±7% (p<0.01), and 34±10% (p<0.05) respectively]. In controls, no concentration of Zn augmented the SI achieved with PHA stimulation. In HIV+ subjects, both 0.50 & 1.00 μM increased the SI due to PHA [24±7% (p<0.01), and 34±11% (p<0.01) respectively].

Conclusions: PHA from HIV+ subjects, with lower serum Zn, may be more sensitive to the mitogenic effects of Zn. Zn in HIV+ subjects only may augment PHA induced proliferative responses. The decreased serum Zn found in advanced HIV disease may be a cofactor in HIV-induced immunosuppression.

Th.B.P.317 INCREASED PROLIFERATIVE REACTION IN HUMAN IMMUNODEFICIENT VIRUS (HIV) INFECTION IN ZINC AND SERUM ALBUMIN DEFICIENT SUBJECTS.

Kaplan, Nancy, Pappas, S.C.,* Deacono, M., Griffin, E.L., Chan, L.F., Fitching, A.J. and Harris, J.A.,*
St. George's and for, Bay's Hospital, Jamaica, Jamaica.

Objective: To assess serum zinc proteolytic function (ZPF) in HIV infection.

Methods: Chronic diarrhea and weight loss are common features of HIV infection and have been associated with altered vitamin absorption in the absence of enteropathogenic or intestinal malabsorption. Data suggests may however be more in zinc proteolytic insufficiency (ZPI). This study has been to determine the ZPF in HIV infection.

Methods: ZPF was measured using the PMA test in 25 Jamaican homosexual and 25 Jamaican heterosexual HIV-infected subjects presenting at different clinical stages of infection (20 group I, 11 III or IV). Control values were obtained in 25 Jamaican and 25 Jamaican healthy volunteers.

The recovery of P-aminocaproic Acid (PAA) in urine (expressed on a 6ml dose) following oral administration of labeled P-aminocaproic Acid correlates well with direct measurement of latent cytochrome activity and is a validated index of ZPF. P-aminocaproic Acid (PAA) stimulated concentration serves as a marker of PMA secretion and immunoreactivity. Reduced PMA with normal PAA recovery results in low PMA secretion index (ZSI) and characteristic of ZPI.

Conclusions: HIV was present in 11/25 Jamaican and 4/25 Jamaican subjects and is therefore not a cause of ZPI in HIV infection.

Gender	Control (n=25)	ZPF (normal/μmol)	ZSI (normal/100)	ZPI (normal/100)
Male	25	26.4±7.2	26.4±7.2	26.4±7.2
Female	25	26.0±10.0	26.0±10.0	26.0±10.0
Control (n=25)	25	27.8±2.2	27.8±2.2	27.8±2.2
HIV-1 (n=25)	25	42.0±5.5	42.0±5.5	42.0±5.5
HIV-2 (n=25)	25	40.0±20.0	40.0±20.0	40.0±20.0

Session d'affichage Poster Session



Th.B.P.318 NUTRITIONAL STATUS PARAMETERS ASSOCIATED WITH PSYCHOLOGICAL WELL-BEING IN AIDS/RAC CLIENTS AT AN OUTPATIENT CLINIC IN SAN FRANCISCO.

Jonnie Broderick, J. Masnet, M.P.H., R.D., Mt. Zion Hospital & Medical Center/Better Health Program, San Francisco, CA, U.S.A.

The purpose of this study was to (1) document changes in nutritional status from baseline measurements, (2) determine the efficacy of nutritional counseling, (3) define appropriate nutrition interventions, and (4) determine if nutritional status parameters correlated with psychological indicators.

Patients underwent comprehensive nutritional assessment at both the initial outpatient clinic visit and after three months of routine nutritional counseling. Assessments consisted of anthropometric and biochemical measurements, three-day food records, nutritional histories, Hopkins Symptoms checklist, and Personal Orientation Inventory (POI), self-assessment and baseline questionnaires. Education was provided on general nutrition and strategies for management of symptoms associated with opportunistic infections and other HIV disease-related conditions that may impact nutritional status. Additionally, a positive correlation between nutritional status and quality of life parameters were found.

Th.B.P.320 SITES AND RELATIVE PREVALENCE OF HAIRY LEUKOPLAKIA, PSEUDOMEMBRANOUS CANDIDIASIS, AND ERYTHROPLAKIA CANDIDIASIS.

Georgina Delgado,¹ Michael L. S. McDonald,^{1,2} Georeanna J.¹ The Schools of ¹Dentistry and ²Medicine, University of California, San Francisco, Oral AIDS Center, San Francisco, CA, U.S.A.

Objective: To describe the sites in the mouth where hairy leukoplakia (HL) and the various forms of candidiasis with their relative prevalence in a retrovirus population (Oral AIDS Clinic).

Methods: The Oral AIDS Epidemiology project initiated a uniform prospective of data collection procedures for the oral complications of HIV in both community cohorts, AIDS clinic and the Oral AIDS Clinic. This analysis is based on the findings in the retrovirus patients in the Oral AIDS Clinic. This analysis is based on the findings in the retrovirus patients in the Oral AIDS Clinic. This analysis is based on the findings in the retrovirus patients in the Oral AIDS Clinic.

Results: Hairy leukoplakia was the most common lesion observed in 236 individuals. 87% of patients had involvement of the lateral (including extension to the ventral surface), and 29% of the dorsum of the tongue. The buccal mucosa was less frequently involved, 25% on the buccal palate (45%) (No lesions were seen on the hard palate). Pseudomembranous candidiasis (thrush) was observed throughout the mouth in 108 patients, most commonly involving the tongue, 42% lateral 48% dorsum. The hard palate 20% and soft palate (19%) were also frequently observed, as was the buccal mucosa (19%). Erythroplakia candidiasis (n=65), early involvement with a flat appearance, was most frequently seen on the hard palate (65%), soft palate (17%), and dorsum of the tongue (57%) when dysplasia was a common finding. Angular cheilitis due to candida was observed in another 14 patients. **Conclusions:** Hairy leukoplakia although absent unilaterally found on the lateral surface of the tongue also appears in the buccal mucosa. Pseudomembranous candidiasis occurs almost twice as often as the oral manifestations of candida and can affect almost any surface in the mouth. Erythroplakia candida is much more characteristic of the tongue and hard palate. Concurrent HL and candida was a common finding.

Th.B.P.322 SINGLE DOSE THERAPY FOR HIV CANDIDIASIS WITH FLUCONAZOLE IN HIV-INFECTED PATIENTS

Richard D. Davis, Dept. for Clinical Studies on AIDS (HIV, AIDS) Division of Infectious Diseases, Cedars-Sinai Medical Center, Los Angeles, California.

Objective: To assess the efficacy and tolerance of a single dose of fluconazole for the treatment of oral candidiasis (OC). Fluconazole (FC) is a new antifungal agent with a good oral bioavailability and a long half-life.

Methods: From 10/1987 to 1/1/1988, all patients presenting with OC were proposed a single 150 mg dose of FC. Diagnostic criteria for OC included white plaques (leukoplakia), fissured and signs (white plaques on a hyperkeratotic base) and a positive yeast culture. Patients were asked to attend weekly visits for two months. Clinical response was defined by the total disappearance of signs and symptoms. Responses were treated with another single dose.

Results: Forty-five patients were included: 30 of them had presented a 1st prior episode of OC within the last 12 months, and 15 had presented in 2nd or 3rd episode seen in 18/45 patients (40%) on day 1 and in 14/45 (31%) on day 21 after the first 150 mg dose. The median follow-up observation period was 15 days (range 11 to 81), with a cumulative total of 2300 patient-days. During this follow-up period, 17 patients (38%) including 12 with AIDS presented in relapse, all of which responded to a single dose FC. Median interval before relapse was 10 days (range 1-15). Analysis of relapse showed that patients with AIDS and previous OC history, 7% were more likely to relapse. All together, of the 11 clinical OC episodes during this study, 15 (81%) responded to a single 150 mg dose. The patients had no major side effects (nausea).

Conclusions: FC single dose was easy to administer, effective and well tolerated in this pilot study. Relapses were more frequent in patients with a history of OC and with a symptomatic HIV infection. These findings support the use of another FC single dose, suggesting the absence of clinical resistance. The single dose approach could avoid continuous treatment in patients already receiving multiple therapies.

Aspects Cliniques Clinical Aspects of AIDS

SIDA buccal Oral AIDS

Th.B.P.319 SINGLE DOSE THERAPY FOR PSEUDOMEMBRANOUS CANDIDIASIS WITH FLUCONAZOLE: A PILOT STUDY.

Chantal P. Villette,¹ Veronique, F.¹, Magallan, B.² and Cassier, F.P.³ ¹ Division of Infectious Diseases, ² Division of Gastroenterology, Cedars-Sinai Medical Center, Los Angeles, and ³ Medical Clinic I, Loma Linda, California.

Objective: Pseudomembranous candidiasis is a frequent complication of asymptomatic HIV infection. In this setting, topical azoles are ineffective, clinical resistance to azoles is common, and amphotericin is poorly tolerated. Moreover, amphotericin has to be stopped for oral candidiasis because of its side-effects potential. In this context, the pharmacokinetic properties of fluconazole (a novel triazole antifungal agent), such as a good oral bioavailability and a long plasma half-life, are of special interest.

Methods: Fifty-eight patients with a biopsy-confirmed pseudomembranous candidiasis have received a single oral 150 mg fluconazole dose as sole treatment and have been seen again on days 3 and 7. The clinical response was associated in all cases by a second administration of 150 mg. The culture and biopsy of oral lesions.

Results: 100% of patients with oral lesions at 3/7 patients, who received a second 150 mg fluconazole dose. Symptoms had disappeared in all patients on day 7, and endoscopic examination was normal in 100% cases. The patient presenting persistent endoscopic inflammatory signs, but with evidence of fungal or biopsy and culture. One other patient relapsed 11 days later (relapse: 1-25 days, median 11 days). Transitory headache and nausea have been observed in one patient. No significant laboratory or immunologic changes. In other subjective side effects: oral or buccal or hematologic signs had been recorded.

Conclusions: These preliminary results suggest that a single oral dose of fluconazole may cure pseudomembranous candidiasis and is well tolerated. This treatment merits official drug compendium and could avoid amphotericin and/or azoles interruption in patients with AIDS.

Th.B.P.321 ORAL FINDINGS IN PATIENTS WITH ASYMPTOMATIC HIV DISEASE

Schultze, Engelhardt A. H. M.¹; ten Cate, R. W. M.²; van der Wal, J. W.³ ¹ Dept. Oral Pathology and Oral Surgery, ² Dept. Internal Medicine, Free University Hospital, Amsterdam, The Netherlands.

Objective: To determine the prevalence of oral mucosal lesions in patients with asymptomatic HIV disease (OAI-III/IV), and to compare the results with findings in patients with asymptomatic HIV disease (OAI-I/II).

Methods: Oral examination was performed in 70 HIV-positive patients (60 men, 10 women), mean age 38 yr; range: 18-65). Fifty-six patients (80%) were homo/bisexual men. Physical examination, including laboratory evaluation, was completed in all patients. Twenty-two, 31, and 37 patients were classified in group OAI-I, II, and IV, respectively. Of the latter group, 34 patients were classified as having AIDS (OAI, 1987).

Results: In 52 patients (74%) one or more oral mucosal lesions were detected (OAI-III/IV: 35 (70%); OAI-I/II: 17 (79%). Oral candidiasis, hairy leukoplakia, and periodontal diseases were present in all groups.

Conclusion: Our data show, that oral mucosal lesions frequently occur both in asymptomatic and symptomatic HIV disease.

Th.B.P.323 THE IDENTIFICATION AND TRACKING OF CANDIDA ALBICANS ISOLATES FROM ORAL LESIONS IN HIV-SEROPOSITIVE INDIVIDUALS

Miyazaki, Shukui, H.¹, Finkelstein, S.², Hicks, J.³, Greenman, D.³ and Greenman, J.³ ¹ Oral AIDS Center, U.C.S.F., Calif., ² Research Unit, Cedars-Sinai, Los Angeles, Calif., ³ The University of California, San Diego, Calif., U.S.A.

Objective: Candida albicans is recognized as the most frequent cause of oral candidiasis in HIV infection, however, very little data is known regarding these C. albicans biotypes.

Methods: Clinical isolates obtained from 100 HIV-infected individuals with and without oral lesions, plus 8 HIV-seronegative controls. The isolates were hybridized with a number of C. albicans specific DNA probes to assess strain relationships between individuals observed in time. The DNA probes yield a "fingerprint" that can be used to follow individual C. albicans strains for long periods and through repeated re-isolation.

Results: C. albicans has been isolated from all individuals with oral lesions. We have determined that each individual in the study carries a distinct C. albicans strain identifiable by DNA fingerprinting. Furthermore, C. albicans was isolated from a significant fraction of asymptomatic individuals both HIV-seropositive and HIV-seronegative. In two cases so far observed we have now developed following "successful" antifungal treatment, the same strain was found in the same year by the individual during the asymptomatic phase.

Conclusions: The finding of the same strain of C. albicans both before and after standard antifungal therapy raises questions as to effectiveness and sites of correct exposure therapeutic regimen. If in fact C. albicans organisms are altered under selection pressure from the host environment or can adapt to such host uniquely, then it is not surprising that they are such successful opportunistic pathogens. The present finding of a unique C. albicans strain in each individual harboring C. albicans suggests a mechanism for this year's continued presence in a population, immunocompromised and immunocompetent individuals. This work was supported by NIH P01 DE07946.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

Th.B.P.330 ORAL MELANOTIC MACULES IN PATIENTS INFECTED WITH HIV-1

FERRAZ, Giuseppe; **Ballino, E.†;** **Adinolfi, M.†;** **Castiglioni, D.†;** **Di Piero, M.†;** **Riccardi, R.†.**
*University of Florence and UNO, Florence, Italy; †University of Texas, Houston, Texas, Houston, USA.

Objective. To describe the features of 9 cases of oral melanotic macule (OMM) in patients (pts) infected with HIV-1.

Methods. Between Dec.87 and March 88, 9 pts developed OMM. Plasma cortisol level was measured. Electron microscopy was done in 5 specimens. In situ hybridization to Epstein-Barr virus (EBV) was done under stringent conditions.

Results. The mean age was 31.6 years. Five pts were men and 4 women. Six pts were IVDA. One pt had the OMM unilateral, 2 had 6 and 8 arcs. In 8 pts the OMM were single and in 1 multiple. None of the pts developed clinical or laboratory evidence of adrenal damage. Six pts received treatment courses of topical imiquimod or systemic isotretinoin. Six pts also had hairy leukoplakia.

Conclusion. Increased melanin deposition in the basal-cell layer and upper lamina propria was observed. In 6 cases leukocytes were present. No ultrastructural alterations were observed. DNA of EBV was found in 2 OMM tissues and in 1 specimen of normal mucosa. In 5 pts the OMM relapsed or recurred after excision.

Conclusion. The etiology of OMM is not known, although several causes should be considered. Subtle adrenal damage, latent viral infection and drug therapy can be involved. OMM might represent a new manifestation of HIV-1 infection.

Th.B.P.332 IMMUNOHISTOCHEMICAL STUDIES OF ORAL SCRATCHES

Langford, Angelita,¹ Kume, R.,² Schepers, S.,¹ Pohle, J.D.,³ Reichart, P.,⁴ Frey, University,¹ Robert Koch Inst.,² Rudolf Virchow Univ.,³ D-1-Berlin-65, FRG

Objective. To examine keratinocytes gained from oral scratches for viral antigens and cytokinin differentiation markers.

Material and methods. Scratch material (lat. border of the tongue) (HIV) patients n=30, HIV- n=20) was filtered, centrifuged onto slides and examined by means of immunohistochemistry (IAPAA) and in situ hybridization (ISH). Applied antibodies: anti-cytokeratin (OK 6.6, K 8.1 and K 4.63 and Ki1; EBV, CMV, HSV 1/2.

Results. Compared to HIV in scratches of HIV- the number of K 8.60 (cornification marker) positive cells was 3.6 times increased, of K 8.1a (fast cell turnover) 1.3 times and of K 4.63 (basal cell marker) 7 times. In scratches of HIV+ patients the number of Ki1 positive cells was 3 times higher than in HIV-. Viral antigens of EBV were not detected in HIV-, but in 1/30 HIV- patients (IAPAA, ISH); 10/15 observed oral hairy leukoplakia (HL), while 3 further patients developed HL during an observation time of 8 months. CMV was observed in 8/30 (ISH) and in 6/30 HIV- patients (IAPAA). In 9/30 (HIV+) patients HSV1/2+ cells were found (ISH). Detection of viral antigens and of immature keratinocytes was highly correlated with AIDS manifestation.

Conclusion. The presented non-invasive technique ("Scratch") is a sensitive aid for regular monitoring of HIV associated oral lesions, such as HL. Proliferation and differentiation of cytokinin in oral epithelium is altered during HIV infection.

1. Detection of EBV in oral scratches seems to be a valuable marker for the later development of HL.

Th.B.P.334 FLUCONAZOLE IN THE TREATMENT OF OROPHARYNGEAL CANDIDIASIS

Just, Gudrun,¹ Schmelz, B. M.,² Böttlinger, C.,² Böttlinger, M.,² Hehl, B. M.,² Gell, W.†
*Universitätsklinik Frankfurt, ZIM, Infektiologie, Theodor-Stern-Kai 7, 6000 Frankfurt, FRG

Objective. To describe efficacy and restrictions of Fluconazole in the treatment of oral candidiasis in HIV-positive patients.

Methods: 104 HIV-positive patients with clinical and cultural signs of Oropharyngeal candidiasis were treated in 112 treatment courses. Initial dosage was 200 mg/die, followed by a daily dosage of 100 mg. Duration of therapy was approximately 3 weeks in approximately 60% of cases. For quantification of colonization, the oral wash-out method was used.

Results: At the end of treatment with Fluconazole, clinical symptoms and candida flora completely disappeared in approximately 50% of patients, although the oral wash-out still showed a remarkable number of candida sp. in the culture. The group of "non-responders" consisted of patients in an advanced stage of disease, patients without cytoretic therapy, or patients with a selection of C. glabrata (12 patients) or C. tropicalis (2 patients). Fluconazole was associated with only a small number of adverse effects even after long term therapy.

Conclusion: Fluconazole is effective in the treatment of oropharyngeal candidiasis. Elimination of clinical symptoms and complaints is not always accompanied by elimination in the culture. The selection of C. glabrata might become a therapeutic problem.

Th.B.P.331 LOCAL DESTRUCTION OF LABIAL SURFACE OF MANDIBULAR TEETH

BY DIRECT APPLICATION OF COCAINE IN DRUG USERS WITH AIDS
Owens, Arthur M.,¹ Swall, C. B.,² and Klein, R. S.,²
North Central State University, Albert Einstein College of Medicine, Scoton, New York, U.S.A.

Objective. To describe a newly recognized oral lesion in drug users with AIDS.

Methods. 92 consecutive drug users with AIDS underwent periodontal and oral examination by a periodontist. Destructive lesions not explainable on the basis of periodontal disease or other recognized oral pathology were noted and photographed. Patients were questioned about direct mucosal application of cocaine.

Results. Five patients had focal destruction of the soft and hard tissue of the labial surface of mandibular anterior teeth. Affected areas could not be attributed to adjacent periodontitis. Subjects included 3 male and 1 female intravenous drug users (IVDU) and 1 female who denied parenteral drug use and whose risk behavior for AIDS was almost contact with an IVDU. All 5 reported at least several weeks of cocaine use by direct application to the affected areas, described as the "freeze" method of cocaine use.

Conclusion. Drug users with AIDS who take cocaine by the "freeze" method are at risk for focal destruction of oral tissue at the site of drug application. Individualized attention is needed in the oral care of drug users with AIDS should recognize this entity.

Th.B.P.333 RECURRENT ORAL APHTHAE IN HIV-INFECTED

HEMIPHAGAL MALES
Lagarde-Nar, François Phang, M. and Silverman, S. J.,
University of California, San Francisco, San Francisco, Ca, U.S.A.

Objective. To develop a profile and assess cofactors in HIV positive homosexual males afflicted with progressive oral aphthae.

Methods: 12 homosexual males, 9 with AIDS and 3 patients with ARC were evaluated and treated. Mean age was 37 (range 27 to 56). Follow-up mean 10 months. Patients were divided into 2 groups -- those with lesions <6 mm (minor), 7/6 mm (major). History of recurrent aphthous ulcerations, frequency, and disease severity prior to 1988 and after HIV test, time of diagnosis of ARC or AIDS and medications were recorded. Tests included HIV by monoclonal Ab, culture (bacterial and fungus) and complete blood counts.

Results. 9/12 patients had a previous history of recurrent aphthae prior to HIV infection. 8 patients presented with major ulcers and 4 with minor ulcers severity and frequency of their oral disease had worsened in 9 patients prior to the onset of ARC or AIDS and in 3 patients after the diagnosis of AIDS. 9/12 patients were negative to HSV 6/8 patients with major ulcers were positive and neutropenic. HIV (mean 2.0), Hb (mean 9.3), WBC (mean 2.3) all patients responded to therapy without systemic (Prednisone) or topical (Clobetasol propionate).

Conclusion. Increased severity and frequency of RAU is a complication of HIV infection. Orbits and neutropenia appear to be cofactors. RAU in HIV positive patients is not HSV related patients with the major type are likely to be orogenic and neutropenic.

Th.B.P.335 CRANIUM OF ORAL CANCER PATIENTS : OBSERVATIONS FROM HIV INFECTION AND CELLULAR IMMUNITY IN BRITISH AREAS.

Das, Kapilraj, R. Datta, S. Ghose, C. Ray, G. Das, S.
Division of General Medicine, Institute of Medical Sciences, University of Calicut, Kerala, India.

Objective. To study the cranium of oral cancer patients in HIV infection and cellular immunity in British areas.

Methods. 104 HIV-positive patients with clinical and cultural signs of Oropharyngeal candidiasis were treated in 112 treatment courses. Initial dosage was 200 mg/die, followed by a daily dosage of 100 mg. Duration of therapy was approximately 3 weeks in approximately 60% of cases. For quantification of colonization, the oral wash-out method was used.

Results: At the end of treatment with Fluconazole, clinical symptoms and candida flora completely disappeared in approximately 50% of patients, although the oral wash-out still showed a remarkable number of candida sp. in the culture. The group of "non-responders" consisted of patients in an advanced stage of disease, patients without cytoretic therapy, or patients with a selection of C. glabrata (12 patients) or C. tropicalis (2 patients). Fluconazole was associated with only a small number of adverse effects even after long term therapy.

Conclusion: Fluconazole is effective in the treatment of oropharyngeal candidiasis. Elimination of clinical symptoms and complaints is not always accompanied by elimination in the culture. The selection of C. glabrata might become a therapeutic problem.

Session d'attachage Poster Session



Aspects cliniques Clinical Aspects of AIDS

Th.B.P.342 ORAL HYPERTHYMIA ASSOCIATED WITH HIV INFECTION.
Largiadou, Angelika¹; Kounas, R.²; Groh, A.²; Gelderblom, H.²;
Folch, H.²; Hatzigeorgidis, P.²; Raddel-Virchow, U.²; D.-Berlin 65, FRG.
Free University¹, Robert-Koch-Institut², Rudolf-Virchow-Universität, D.-Berlin 65, FRG.

Objective: To characterize the clinical and virological features of hypertymia (h.p.) observed on the oral mucosa of 15 non-smoking HIV-infected patients, biopsies of h.p. (HIV-neg; HIV-neg) and of normal oral mucosa (o.m.) (HIV-neg; HIV-neg) were examined.

Methods: Light microscopy (LM): H&E, Fea and Fei, silverimpregnation. Electron microscopy (EM), immunohistochemistry (DMSAFAP), antibodies against CD4, CD4, CD45, CD45, IgA, TAC and transferrin receptor (ATR).

Results: Localization of h.p. in HIV: gl. buccale, palata, gingiva, tongue, extraoral (face, hands, finger-toe nail). During observation time (avg. 8.2 mths.) the size of h.p. in HIV increased in 1 pat., 2 of them (AIDS) died, 1 pat. developed AIDS. LM/EM of h.p. (HIV-RI) accumulation of melanosomes within keratinocytes/melanocytes of the basal/superficial cell layers, in fibroblasts/phagocytes of the connective tissue (h.p. HIV-RI) and with o.m. (HIV) the number of CD45 (+) times, HLA DR+ (+) times and CD45 (+) times cells was increased within c.HIV-RI. Within c.t. of h.p. (HIV) only single cells stained + for CD45, TAC receptor, ATR and IgA. Compared with h.p. (HIV-RI) and with o.m. (HIV) the number of CD45+ cells within c.t. of h.p. (HIV-RI) was markedly increased, while their number within the epithelium was comparable with o.m. (HIV).

Conclusion: The high imbalance of distribution and status of local immunocytes in h.p. (HIV) may reflect the functional impairment of the oral mucosa. The sudden onset of melanin deposition might be caused by influenza/HIV/postinflammatory reactions and seems to be correlated with the progression of AIDS manifestation.

Th.B.P.344 SALIVARY STAIN AND HIV INFECTION
Sullivan, Alexander D.; Brackbill, D.; Green, D.; Peters, R.; and Neri, G.
University of Iowa, Iowa, U.S.A.

Objective: To determine the salivary stain levels during HIV infection and evaluate their possible role in the seroconversion and AIDS-related lesions (ORL).

Methods: 30 subjects were studied: 7 HIV+, 23 healthy controls (H.C.). 30 HIV+ didn't show ORL, 29 were affected by oral candidiasis and 19 by hairy leukoplakia (HL). Six HIV+ patients, containing a seroconversion and seronegative component, were used to evaluate Stain, IgG and IgM immunoprecipitation allowed to exclude that free secretory component and /or Stain presence could distort our results. Total salivary proteins (T.P.) and albumin were also tested to exclude the albumin influence. Then, values for every patient group are reported in the table.

Results (n=30)	Stain (mg)	T.P. (mg)	IgG/IgM
H.C.	38.0±19.2	382.0±93.3	2.6±0.1
HIV+ without lesions	46.4±22.4	286.7±89.3	3.6±2.3
HIV+ with oral cand.	48.9±17.5	252.4±78.0	3.6±2.3
HIV+ with H.L.	64.5±27.2	279.0±71.7	3.1±1.2

Conclusion: A significant Stain increase appeared in HIV+ compared with H.C. No difference resulted between patients with or without ORL. The lack of significant difference in the Stain synthesis state the minor role of the local immune response in the control of these lesions. On the contrary, the strict relation ship between circulating CD4 decrease and ORL, sustained the cell-mediated immune response importance also in the oral cavity.

Th.B.P.346 ORAL MANIFESTATIONS OF HIV INFECTION IN AFRICAN, COAST DRIVERS
Munishi, M.; Mwangi, J.; De Cock K.M.²; Green T.L.²; Cohen R.²;
Cohen R.²; Greenhouse, J.P.² et al.
CDC/WHO, Oral AIDS Center, University of California, San Francisco, San Francisco, CA, U.S.A.

Objective: To describe oral manifestations associated with HIV infection in hospitalized patients in Nairobi, Cost Driver.

Methods: Two hundred and fifty-six hospitalized patients (Internal Medicine, Pulmonary Medicine, Infectious Disease, Dermatology, Gynecology) had a medical, histological, oral examination, and were tested for HIV-1 and HIV-2 infection. Clinically significant oral lesions were biopsied for histological examination.

Results: Fifty-two percent of men were reportedly reactive to HIV-1 and for HIV-2 ELISA. The seroprevalence for HIV-1 and/or HIV-2 infection was higher in males (60%) than females (36%). Oral candidiasis was more frequent in HIV+ve (64/130) than in HIV-ve (21/113) patients (OR = 4.62, p<0.01). For diagnosing HIV infection, oral candidiasis was 49% sensitive, 83% specific, and had a positive predictive value of 75%. No association was found between oral candidiasis and the taking of antibiotics or corticosteroids. Hairy leukoplakia (HL) was suspected clinically in 18/19 HIV+ve and in 11/12 HIV-ve patients (NS). In 17/19 (90%) biopsies when HL was histologically confirmed. Twelve (68%) of the confirmed HL cases were HIV+ve/ELISA+ve. The predictive value of HL was increased to 71% by histological confirmation.

Conclusions: (1) Oral candidiasis is highly predictive for HIV infection in African patients; (2) HL occurs in African patients with HIV infection.

Th.B.P.343 ORAL HEAVY LEUKOPLAKIA: CLINICAL BEHAVIOR AND TREATMENT RESULTS

Gagliardi, Domenico; Ferrara, D.; Di Pietro, M.; Past, P.; Ravina, A.
University of Florence and USC, 1060, Florence, Italy

Objective: To report on the clinical behavior and treatment results of oral heavy leukoplakia (OHL).

Methods: Appearance of OHL and its clinical behavior were correlated to the T4-cell count in 54 HIV-1 infected patients (pts). In 30 pts treatment response to oral acyclovir was also evaluated. Median follow-up was of 12 months (2-34).
Results: In 54 pts the median T4-cell count, at the appearance of OHL, was of 390 cells/mm³ (16-1634). In 26 pts, OHL appeared after a progressive decline of T4-cell count. In 16 pts, 26 pts received no specific treatment. Of these, 6/26 showed spontaneous remission of OHL, 6/26 cicicic also resolution, 7/26 progression and 11/26 no change. Remission and site variation were associated with incidental biopsy and fluctuation of T4-cell count. Oral acyclovir (1800 mg/d for 14 days) in an open trial determined an objective response (OR=66%) in 14/20 pts. Median duration of response was 6.5 months (2-11).

Conclusion: Declining level of T4-cell influences the appearance and clinical behavior of OHL. Depletion of T4-cells may facilitate the replication of Epstein-Barr virus (EBV) within the lingual epithelium. Oral acyclovir is an effective therapy of OHL. This favors the pathogenetic role of EBV.
This study is supported by a grant from the Regione Toscana-Progetto HIV.

Th.B.P.345 OCCURRENCE OF ORAL PATHOLOGY AMONG DIFFERENT RISK GROUPS OF HIV INFECTED PATIENTS

Loeb, F.¹; Friauf, F.¹; De Wit, S.²; Stegmann, J.; Clumeck, N.²;
Division of *Stomatology and **Infectious Diseases, St Pierre University Hospital, Brussels, Belgium.

In a 6-year period, 700 HIV patients (P) were examined: 73% male and 27% female. Risk factors of acquisition of HIV infection were: homosexual or bisexual (hom) 36.8%, African (Afr): 35%, 10 drug abusers (IDA): 24.4%, heterosexual (hetero): 9.7%, unknown (unk): 1.8%, blood transfusion (blood): 0.7%. Clinical stage and immunological status were comparable in all risk groups. Among those 700 P, 300 (43%) presented at least one oral lesion (1 G), the most frequent findings were: candidiasis (Cand), hairy leukoplakia (HL), periodontal diseases (P.D), Kaposi's sarcoma (KS) and recurrent squamous ulcerations (RU). Occurrence of oral lesions:

Risk Factor	P. No.	C	Cand	HL	P.D	KS	RU
Hom	271	146	5	34	3	13	8
Afr	245	84	54	4	2	8	7
IDA	101	64	21	7	0	1	1
Hetero	68	28	10	3	1	1	1
Unk	10	0	0	0	0	0	0
Blood	5	0	0	0	0	0	0

In conclusion: 1) Prevalence of all oral lesions is significantly greater in the homosexual group (p<0.001). 2) Hairy leukoplakia and periodontal diseases are two oral lesions which appear preferentially in the homosexual group (p<0.001).

Th.B.P.347 NATURAL HISTORY OF HIV-ASSOCIATED SALIVARY GLAND DISEASE Schmitt-Mogensen, G.; Greenstein, D.; Dadd, C.; Chernoff, D.; Wax, D.; Vogel, F.; Hollander, A.; and Greenstein, J.
Oral AIDS Ctr, UCSF, San Francisco, CA, USA, *Univ-Hosp, A Dental Coll, Copenhagen, Denmark.

Objective: To describe the natural history of HIV-associated salivary gland disease (HIV-SGD), i.e. presence of salivary gland enlargement and/or xerostomia in HIV-infected patients in 12 patients with HIV-1 and 12 adults followed for a median of 13 months we assessed symptoms, stage of HIV disease, rearing whole salivary (RWS) flow rate (FR), stained periodontal (PV) FR, and immune status (T4, T4/T8). The salivary FRs of 6 of 9 with periodontal gland enlargement (PGE) were compared with those of a control group of HIV-infected patients without HIV-SGD and with similar degree of immune deficiency.

Results: The symptoms of dry mouth and the periodontal gland enlargement (PGE) were generally unchanged without treatment. PGE disappeared in 3 patients taking various medications (steroids, zidovudine). Acryvof did not change the PGE in 2 patients. Patients with PGE had significantly lower salivary flow than the control group (P<0.01).

HIV-SGD status	FR (ml/min)	Stain
With HIV-SGD	2/12 (17%)	2/12 (44%)
No HIV-SGD	5	6
Mean T4 (ml/min)/T4/T8	283, 0.41	222, 0.28
Mean RWS FR, ml/min	0.46	0.47 (P=0.05)
SP FR, ml/min (n=6)	0.17	0.27 (P<0.01)

Conclusions: HIV-SGD is associated with low T4 counts and a high risk of development of AIDS. Patients with PGE have reduced periodontal disease compared with similar immune deficiency. Unexpectedly, the salivary flow did not decrease with time in spite of further impaired immune status. This effect may partly be due to the given medications. The pathogenesis of this Epstein's syndrome-like disease is unknown. Supported by NIH P01-DE07946, the Danish Med. Res. Council (912-7499,12-8465), and AIDS Fonds, (DK).

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

Th.B.P.348 TREATMENT OF HIV PATIENTS WITH OROPHARYNGEAL AND/OR DESOXYTHIOSEAL CANDIDIASIS: THE RESULTS OF A R.C. STUDY.

Epappio Roberts, Robert Ferreri, G. and Crivellini, N.
CIVIC OF TRIESTE, ITALY

Objective. To compare in a double blind randomized trial fluconazole and ketoconazole in the treatment of oropharyngeal and/or esophageal candidiasis in patients with HIV infection.

Methods. Fifty patients with clinical and microbiologically documented candidiasis and HIV infection received either fluconazole 50 mg once a day and 1 placebo capsule once a day for 18 days or ketoconazole 200 mg capsule twice a day for 28 days. Clinical and microbiological responses were evaluated at 7, 14, 21 and 28 days together with analysis of safety and tolerance.

Results. At the end of treatment, clinical cure was recorded in 31.5% of patients treated with fluconazole and in 58.2% of patients treated with ketoconazole. A further 4.2% of patients treated with fluconazole and 31.2% of patients treated with ketoconazole was considered clinically improved. The mycological response rate was 44% for fluconazole and 70% for ketoconazole. The incidence of clinical side effects was similar in both groups (5%). The incidence of treatment-related laboratory test abnormalities was higher for the patients treated with ketoconazole (elevated values of SGPT and SGOT in 3 cases vs. 2 cases of elevation of SGPT and 2 cases of elevation of SGOT).

Conclusion. In oropharyngeal and/or esophageal candidiasis associated with HIV infection, fluconazole seems to be clinically more effective than ketoconazole. In the study no significant mycological differences are observed between the two drugs. Ketoconazole seems better tolerated than ketoconazole.

Th.B.P.350 PREDOMINANT MICROFLORA OF HIV-RELATED PERIODONTITIS

T. H. JONES, M. B. HARRIS, D. P. HAY, J. A. MILES,
T. M. McIVER, and J. S. DUNN, University of Pennsylvania
School of Dental Medicine, Philadelphia, PA, USA

Objective. To document the predominant microflora of a rapidly deteriorating form of periodontitis most associated with HIV-infection.

Methods. The subgingival microflora in 12 HIV-infected males with severe periodontitis and no history of recent systemic antibiotic therapy were examined. Also studied were 5 HIV-related periodontitis patients with a history of recent antibiotic therapy. Subgingival plaque specimens were collected with paper points from diseased and normal sites and transported in VMA III. The microbial samples were plated on selective and enriched bacterial blood agar and incubated in 80% R-108, 8% CO₂, and in 10% CO₂.

Results. *Actinomyces viscosus* was the most frequent subgingival isolate in normal periodontal sites. Periodontitis sites revealed higher mean CFUs and a greater number of anaerobic flora. Predominant species included *Actinobaculum actinomycetiforme* (mean 8 of flora in culture-positive patients = 10.4%), *Neisseria* spp. (8.3%), *Peptostreptococcus micros* (2.4%), *Bacteroides intermedius* (15.3%), *Proteobacterium* spp. (9.3%), and microflora (15.2% of microscopic count). Low levels of *Candida* spp. and aerobic gram-negative rods were detected in the subgingival flora of approximately 50% of the patients studied. Patients with recent antibiotic therapy generally had significantly lower proportions of suspected periodontopathic species.

Conclusion. These findings may facilitate clinical management of HIV-related periodontitis and demonstrate that the subgingival flora in HIV-infected persons may serve as a reservoir for pathogenic organisms.

Th.B.P.352 PERIODONTAL DISEASE IN HETEROSEXUAL PATIENTS WITH AIDS

Ward, G. G., and Klein, J. S.
North Central Bronx Hospital, Albert Einstein College of
Medicine, Bronx, New York, U.S.A.

Objective. To determine the prevalence and severity of periodontal disease (PD) in heterosexual patients with AIDS.

Methods. Consecutive pts with AIDS underwent periodontal and oral examination by periodontologists. Periodontal lesions were excluded from analysis. Abnormal findings were photographed.

Results. 101 AIDS pts were studied. Periodontal findings by risk group and gender are shown: (10% antiretroviral drug used).

Extent of PD	Number of subjects (percent)	*Female(=54)
No abnormality	23(23%)	2(3)
Gingivitis only	15(15%)	4(10)
Early PD	19(12%)	1(20)
Moderate PD	15(16%)	4(10)
Advanced PD	19(19%)	1(20)

*PD was significantly more severe in females (odds ratio = 6.1, p<.001). Periodontal lesions were more severe than generally seen in non-AIDS pts. 13 pts with PD had severe alveolar gingival lesions. Additionally 94 pts had periodontitis, 18 had lesions consistent with hairy leukoplakia, 5 lesions suggestive of oral candidiasis, and 9 oral ulcers.

Conclusion. Periodontal disease is common and severe in heterosexual pts with AIDS. Females have significantly more severe disease. Other oral pathology, especially candidiasis, frequently occurs concurrently.

Th.B.P.349 CARBON DIOXIDE LASER TREATMENT OF ORAL KAPOSI'S SARCOMA.

Hedberg, Tom J., Moilan, T.W. van der
Academic Medical Center, University of Amsterdam, the Netherlands.

Objective. The use of the CO₂ laser in the local treatment of oral Kaposi's sarcoma to reduce the morbidity associated with laser treatment with radiotherapy and with the same therapeutic results.

Methods. To avoid the severe mucositis as we have seen after radiotherapy of oral Kaposi's sarcoma we have used the CO₂ laser to remove the tumor of the hard and soft palate as well as from the pharynx and larynx. Until now we treated 9 patients. Five of them had sarcoma on the hard palate, one on the soft palate, two in the pharynx and one in the larynx. The surgery was done under general anaesthesia.

Results. Macroscopically we could remove all tumors but pathological examination made clear that in four cases there was a tumor relapse. The period of patients stay in our clinic was from 2 till 7 days. The patients could drink immediately after the surgery and their diet could be extended in the following days. The postoperative pain was controlled with small doses of minor analgesics during a maximum of 4-5 days. The follow up has been just four months but we haven't seen local tumor recurrences.

Conclusion. The CO₂ laser surgery of oral Kaposi's sarcoma is effective and gives less morbidity, a shorter stay in hospital and less discomfort to the patients than radiotherapy.

Th.B.P.351 IN SITU CHARACTERIZATION OF THE INFLAMMATORY INFILTRATE IN HIV ASSOCIATED PERIODONTITIS

Sera, Michael, Murray, P.A., Winkler, J.R., Williams, C. and
Corenson, J.J.
Oral AIDS Center, University of California, San Francisco, CA, U.S.A.

Objective. The clinical features of HIV associated periodontitis (HIV-P) have been well documented. However, little is known about the immunopathology of this lesion. The purpose of this study is to characterize the mononuclear cell infiltrate in this lesion.

Methods. Thirteen gingival biopsies were obtained from patients with HIV-P. Similarly oriented, serial cryostat sections were stained for MHC subsets using monoclonal antibodies and the indirect immunoperoxidase technique. Antibodies used were specific for anti-T-cells (Leu 4-5), T-helper cells (Leu 3a/b), T-suppressor (Leu 2), B-cells (Leu 14), monocyte/macrophages (Leu M5), Langerhans cells (Leu 6) and cells expressing HLA-Dr. Positive and negative staining cells were counted in corresponding areas of each section for each antibody. The mean percent of each cell subset was then established for all 13 biopsies.

Results. The mean percentage of cells reacting with antibody specific for T-cells was 21.0%, 23.7% and 15.1% of the cells were identified as T-helper and T-suppressor cells respectively. The mean heterogeneity ratio was 2.0. Analysis of B-cell infiltration revealed that 11/13 uniformly distributed dendritic cells were detected within the epithelium using antibody against both HLA-Dr and Langerhans cell markers.

Conclusions. HIV-P is dominated by T-cells, particularly T-helper cells. The majority of the cells express HLA-Dr, thus activated T-cells must represent a substantial proportion of the total T-cells. Monocyte/macrophages are also present in large numbers. There does not appear to be a gross reduction in Langerhans cells. Finally, B-cell infiltration is not a prominent feature of this lesion. Supported by NIH/NIHDC, P01 DE-07946.

Th.B.P.353 SALIVARY INHIBITION OF HIV-1 INFECTIVITY IN SERONEGATIVE

McL. JONES, AND CHILDSSEN AND SERONEGATIVE HIV.
Fox, Philip C., Allright, A., Veb, C.-C., Atkinson, J.C. and
Eism, T.R., CDC, NIH, Bethesda, Md, U.S.A.

Objective. Inhibition of HIV-1 infectivity by saliva from healthy HIV-1 seronegative men and HIV-1 infected men was collected from 25 seronegative men.

Methods. Unstimulated whole saliva was collected from 25 seronegative men (ages 21-42 and 21-42) and 7 children (4 males, ages 4-11 and 3 females, ages 4-9). Samples were obtained also from 9 seronegative males, ages 35-56. Inhibitory activity was assayed on 6 occasions by measurement of infection of stimulated human peripheral blood lymphocytes by HIV-1 which had been incubated first for 60 minutes with saliva samples or control fluids. Preliminary experiments showed that saliva was not toxic to target lymphocytes.

Results. Inhibition of infectivity was observed in all saliva samples. HIV-1 infection was completely inhibited by all salivas from the women and children. Salivas from 6 of the healthy males (65%) completely inhibited infectivity and partial inhibition was found in the remaining 3 samples. The seronegative male salivas had a similar distribution: 7 of 9 (78%) complete and 2 partial inhibition. Dilution of a sample of saliva from a single healthy male showed a dilution-dependent decrease of inhibitory activity, with substantial (>50%) inhibition remaining at a 1:20 dilution.

Conclusion. Salivary HIV-1 inhibitory activity is commonly found in human saliva secretions and may play a role in the low risk of HIV-1 transmission by the oral route.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

Th.B.P.360 INTRA LABORATORY EVALUATION OF A CRYPTOPROTECTED DOUBLE LABELED PREPARATION FOR FLOW CYTOMETRY
Meador, M. J., Meador, R. J., and O'Shaughnessy, V. M. * Bureau of Laboratories and Research Services, Health Protection Branch, Ottawa, Ontario, Canada. ** Regional Virus Laboratory, Eastern Ontario Children's Hospital, Smith Rd., Ottawa, Ontario, Canada.

Objective: To establish whether cryptoprotected blood preparations with dual fluorescent labeled monoclonal antibodies against surface antigens (CD4 and CD8) could be useful as an intra laboratory calibration and/or a quality control product. **Methods:** Cryptoprotected preparations were shipped frozen to 15 flow cytometry laboratories (FCL) throughout continental North America. Each package contained two 0.5 ml cell suspension, instructions and data report sheets. **Results:** Twelve institutions returned seventeen laboratory reports. The results were from 18 instruments (8 different models) made by two different manufacturers. All reported values fell within 3 standard deviation (SD). 97% of the results were within 2 SD. Over 82% of the results were within 1 SD. The 3% of data over 2 SD were from one instrument model. **Conclusion:** Cryptoprotected human lymphocyte preparations can be utilized as calibration or quality control material for FCL. For universal applications the cooperation of instrument users and manufacturers is essential.

Th.B.P.362 LEUKOAGGLUTINATION IN PATIENTS WITH HEMOPHILIA
Kiera, M., Pelizzo, M., Niekora, E., Micheli, G., Gilmer, P., Pérez Blanco, E., HEDRA, Academia Nacional de Medicina, Buenos Aires, Argentina.

Objective: a) To evaluate the capability of hemophiliacs (Ho) were to agglutinate normal polymorphonuclear (PMN) leukocytes, since anti-lymphocyte antibodies prevalence is greater in Ho HIV than in Ho HIV-. b) To look for a correlation of leukoagglutination (LA) to circulating immune complexes (CIC) and fibronectin (Fn). **Methods:** One hundred ml of 5×10^6 PMN/wal were incubated with 100 μ l of citrated serum (5% C), diluted 1/10 for 2 hr at 37°C and 18 hr at 4°C, and the percentage of agglutinated PMN was determined. CIC were measured by precipitation with polyethylene glycol 3.3k final concentration. Fn was evaluated by radial immunodiffusion. **Results:** LA was values were significantly higher in Ho HIV+ than in either Ho HIV- or normal controls (0) ($p < 0.07$). LA in Ho HIV+ was 35%, 20% and in Ho HIV- 28.4%, 21.1%, 14.1%, 1%. LA was observed in 94% Ho HIV+, in 34% HIV- and in 78% Ho HIV- values were confirmed for CIC in Ho HIV+ (SD:0.02; 0.05; 0.18) when compared with Ho HIV- and (SD:0.02; 0.05; 0.18) Ho HIV- (SD: 0.03; 0.11; 0.25; 0.1), but there was no statistic correlation between LA and CIC values. Serum Pn concentration was not different in these groups of Ho HIV+ (SD: 0.15) Ho HIV- (SD: 0.10) Ho HIV- (SD: 0.12; 0.14; 0.10). **Conclusions:** The presence of LA in Ho is LA independent of treatment-provoked antigenic stimulation, of CIC and Fn levels. However, LA could be associated with HIV-infection.

Th.B.P.364 INCIDENCE OF AUTOANTIBODIES IN HIV INFECTION.
Quercia, J. F., De Metteis, M. P.; Casanova, C.; Wines, M. S.; Casaccia, P. P.; Dell'Acqua, P. C. et al.

* Laboratoire d'Immunologie, ** Médecine Interne, *** Maladies Infectieuses, CHU St-J. Nice, France.

Objective: Systemic states (e.g. Th lymphopenia and hyperimmunoglobulinemia) in seropositive HIV patients (HIV+) are well known. We have reported the incidence of autoantibodies (AAB) in a series of 87 patients. **Methods:** AAB were detected by indirect immunofluorescence using anti-IRA Ab (microcytopolytoxicity), rheumatoid factor (RF), circulating immune complexes (CIC) (latex immunoprecipitation). **Results:** Anti-mouse monoclonal AAB were observed in 36/76 cases (45%). 37/50 sera react with lymphocytes without anti-IRA specificity (from 3 to 90% of the panel), mean = 41.3% with sd = 27.6%. Anti-nuclear AAB and anti-thyroid microsomal AAB were always absent (0/87). Rheumatoid factor was only found in 3/59 cases (5%). Anti-epidermal AAB were present in 2/26 cases (7%), anti-keratin in 1/15 (7.1%) and anti-actin in one out of 35 cases (2.8%). CIC have been detected in a large percentage of HIV+ patients : 47/66 (71%). **Conclusion:** The polyclonal B-cell activation and diffuse hyperimmunoglobulinemia, well-known features of HIV infection, account for the presence of these autoantibodies and an aberrant B-cell immunoregulation after HIV infection.

Th.B.P.361 A RAPID VERIFICATION OF MONOCLYTE ENRICHMENT/DEPLETION TECHNIQUE UTILIZING FLOW CYTOMETRY
Meador, M. J., Francis, E., Sherratt, A. and O'Shaughnessy, V. M. Bureau of Laboratories and Research Services, Federal Centre for AIDS, Health Protection Branch, Ottawa, Ontario, Canada.

Objective: The adherence-to-plastic techniques have been developed to separate monocytes from peripheral blood mononuclear cells (PBMC). Various solid-phase surface depletion methods have been utilized to either deplete or enrich monocytes from PBMC. A rapid verification of the enriching and depleting methods is possible with flow cytometry. **Method:** The cell suspension containing monocytes was inoculated in plastic dishes of various kinds with and without fetal calf serum coating. Recovered cells were incubated with fluorescent monoclonal antibodies against T4 monocytes (Leu3). The monocyte population was determined by flow cytometry. **Results:** Bacteriological grade plates (BGP) without coating were compared to tissue culture plates (TCP) for efficiency for monocyte enrichment. 75.6% and 81.9% were obtained respectively. For depletion utilizing BGP and TCP the monocyte yields were 5% and 9.8% respectively. **Conclusion:** To enrich monocytes the least expensive method yielded better results. To remove monocytes the more costly plates with fetal calf serum coating is recommended.

Th.B.P.363 INTRA BLOOD-BRAIN-BARRIER TOTAL IgG SYNTHESIS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION.

A. Espar, V. Ferrer, J. Sureda, F. Naval, A. Murgades, and E. Franquet, Facultat de Ciències Mèdiques, Centre de Diagnòstic Comunitari, Hospital Curry Cabell, 1100 Lles, Portugal.

Cerebrospinal fluid (CSF) protein profile was studied in 15 patients with human immunodeficiency virus (HIV) infection and clinical evidence of central nervous system (CNS) disorder. Total CSF and serum protein and IgG concentrations were determined and the CSF/serum albumin quotient was measured as an index of blood-brain-barrier function. Results were plotted into a diagram (1) and intra blood-brain-barrier total IgG synthesis was quantified according to three formulas (2, 3, 4). Babier's diagram detected an abnormal protein profile in 14 of 15 (93%) patients and total IgG synthesis within the CSF was present in 11 of 15 (73%) patients. No correlations were found between those CSF abnormalities and the clinical and CT scanning findings. It is concluded that the study of CSF protein profile is a clinically useful and very sensitive way of testing the development of CNS disorder in patients with HIV infection, the acquired immunodeficiency syndrome (AIDS) or AIDS-related complex. (1) B. Babier, J. Neurol. (1979) 222, 89-95. (2) G. Tibbling et al. Scand. J. Clin. Lab. Invest. (1977) 37, 385-390. (3) W. Tourtellote and S. M. Woodruff (1978) 28, 79-83. (4) E. Schulz and E. Sager, J. Neurol. (1981) 51, 361-370.

Th.B.P.365 LYMPHOCTYTES CD4+, BETA 2 MICROGLOBULINE ET HEPHERINE DANS LE LIQUOR ET LE SANG AU COURS DE L'INFECTION PAR V.I.H.

VERONE A., CALDESI D., BILPIN J., TOURNARE F., LIVOZIT J.M., JOUINCY C.H., TOURNARE L.L. Lab. Neurologique, Hôpital Neurologique 80984 Lyon Cedex 08, FRANCE. *Lab. Radiologie, Centre Méd. Numérique 80984 Lyon Cedex 08, FRANCE. *Purkin (Hôpital Edouard Belin) 69637 Lyon Cedex 08, FRANCE.

Motifs: Prévalence élevée des données, dans le LCS et le sang, pour apprécier une éventuelle étiologie neurologique chez les patients atteints de SIDA.

Méthodes: Etude chez 45 malades V.I.H. (20 SIDA, 10 ARC et 6 Serrypromotiques) dont 20 présentant des manifestations neurologiques. Numération des lymphocytes CD4+ et CD8+ (Cytométrie en flux sur EPICS CB) et dosages de la Bêta 2 microglobuline et de la heparine (RIA).

Résultats: Nous observons une diminution des lymphocytes CD4+, une augmentation progressive de la Bêta 2 microglobuline dans le LCS et le sang, que que soit l'état neurologique. Les taux de heparine sont significativement augmentés quand il y a une atteinte neurologique au stade SIDA.

Conclusions: Chez les malades avec ARC et SIDA, le marqueur le plus performant pour apprécier une atteinte neurologique est le taux de bêta-2-microglobuline; les 2 autres paramètres, CD4+ et SIDA, sont des marqueurs d'évolution de la maladie.

Session d'affichage Poster Session



Aspects cliniques Clinical Aspects of AIDS

Th. B.P.372 THROMBOTIC MICROCYTIC COLLAS IN LIVERS OF CHILDREN WITH AIDS.
Thompson, W., Green, R., Hahn, B., Hsi, H., Kasper, M., MacFadden, D., Marmorstein, V., Anderson, W., New York University, NY NY

North Shore Medical Center, Mt. Sinai Medical Center, NY NY
Children's Hospital, LA, CA; Pediatric AIDS Center, USA

Objective: To define the inflammatory cells, especially macrophages and antigen presenting cells (APCs) in livers of children dying of AIDS.

Method: Seventeen livers from autopsies of AIDS children aged 2.1 mo to 7 yrs and sections from 11 non-AIDS controls were studied by immunohistochemistry. All had hepatomegaly and 4 had clinically evident liver disease.

Results: Mild portal inflammation = 9 (53%); moderate = 3 (18%); severe = 3 (18%). 11 with lymphoid aggregates, 2 cases, 1 mild/severe, had KAI granules. Lobular features were seen in 7 (41%) with lymphoid nodules, 2 with granulomas. Antigen expression was as follows (# of cases):

APCs	KAI	CD4	CD8	HLA DR	HLA DE	HLA DQ	HLA DQ	HLA DQ
Lymphocytes	11	11	11	11	11	11	11	11
Macrophages	11	11	11	11	11	11	11	11
APCs	11	11	11	11	11	11	11	11

All Kupfer cells were CD68 (+); rare Kupfer cells (+) for CD10 and HLA-DR. 1 lymphoid aggregate follicle (i.e., distribution of B, T, and APCs), HLA-DR positive and CD45-RO positive. **Conclusion:** 7 cells are the predominant infiltrates in hepatic sinusoids. APCs are present in lymphoid nodules and granulomas; HLA-DR is more sensitive in detecting them. Where lymphoid aggregates are seen, mature follicles are recapitulated.

Neurology Neurology

Th. B.P.374 NEUROLOGICAL MANIFESTATIONS IN PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION.
Sohn, Bunn*, Estreich, S*, Forster, G.E.*
*Northwestern University, Chicago, IL, USA
*Whitehead Clinic and *Department of Neurology, The London Hospital, London, England, UNITED KINGDOM

Objective: To determine the prevalence of neurological manifestations in patients infected with HIV.

Methods: 111 patients infected with HIV were analysed retrospectively with respect to age, sex, risk factors, stage of HIV infection, type and cause of neurological manifestations.

Follow-up: was from 6 - 29 months.

Results: 18 neurological episodes were identified in 17 (15%) of 111 patients; from 29 patients with AIDS, two of 19 with AIDS-related complex, one of 28 with persistent generalised convulsions and four of 35 who were otherwise asymptomatic.

Central nervous system involvement included three with HIV-related encephalopathy, three with CMV retinitis, one with grand mal fits associated with toxoplasmosis, one with oculomotor neuropathy, left hemiparesis and Parkinsonism associated with toxoplasmosis, five with Bell's palsy (two in association with herpes zoster) and one with blindness from necrosis of the optic chiasm in association with progressive multifocal leukoencephalopathy. Three patients had peripheral neuropathy.

Conclusions: Neurological manifestations occurred in 15% of patients; cranial neuropathies were common and rare complications such as Parkinsonism and optic chiasm necrosis were seen.

Th. B.P.376 IMPAIRED MOTOR PERFORMANCE OF HIV-1 INFECTED PATIENTS IS NOT DUE TO SIMPLE FATIGUE
Klein, John G., Sadler, AC, Wolf, L, Brown, RJ, Price, RM
Sidits, JJ, Memorial Sloan-Kettering Cancer Center, NY, NY, USA

Objectives: To determine if impaired motor performance (finger tapping) in HIV-1 infected patients is related to the effects of fatigue.

Methods: 123 untreated HIV-1 infected patients at varying AIDS Demographics Composite (ADC) stages with the Neuro-AIDS Study Group. We used neurological history, exam, and neuropsychological battery. Subjects were instructed to rest for 10-second pauses between trials.

Results: Finger tapping performance with dominant (F(2,127)=11.80, p<.001) and non-dominant hands (F(1,127)=30.50, p<.001) declined with increasing severity of ADC-related motor dysfunction, with marked differences among the groups apparent on both hands from the first trial (F(2,127)=13.62, p<.001). Only the normal and mild patients' performance declined on later trials; patients with moderate motor dysfunction showed no change in performance ("fatigue effect") over the five trials (F(4,124)=0.50, p=.75).

Conclusions: With increasing motor dysfunction due to ADC, poor motor performance appears to be related to deterioration of the capacity of the motor system, not simply to susceptibility to fatigue effects.

Th. B.P.373 SERIAL IMMUNOLOGIC STUDIES AS AN INDICATOR OF PROGRESSION TO AIDS IN A COHORT OF MALE SEXUAL PARTNERS OF MEN WITH HIV DISEASE
Riedl, Stanley, Coates, R., Fawcett, W., Klein, M., MacFadden, D.,

Calzavara, L., et al., University of Toronto, Toronto, Canada

Objective: To compare serial immune parameters in men who have developed AIDS with those of men who are seropositive and seronegative controls.

Methods: At recruitment, 143249 men were seropositive and 16 subsequently seroconverted. At the time of this analysis, 24 had developed AIDS. Serial routine hematology, T-lymphocyte subsets, seropositive responses and quantitative immunoglobulins were done on all members of the cohort. Data was analysed based on comparison of values at intervals from estimated time of infection.

Results: There were significant differences in absolute T4 counts, T4/T8 ratios, response to PHA, IgM and IgA levels between seronegatives and seropositives who went on to develop AIDS. Most of these differences did not increase with time but were significant at the time of entry into the study. Only IgA levels showed a significant increase in the last 4 months in the group developing AIDS.

Conclusions: Differences in immune parameters between groups of uninfected, infected and progression to AIDS generally are unchanged on serial determinations. Also, variability in serial test results in an individual makes the use of a single test of limited value in prognosis.

Th. B.P.375 AIDS-RELATED NEUROLOGICAL ILLNESS IN TWO US CITIES: A COMPARISON OF SIMILAR POPULATIONS
Stephen G. Cohen*, Larry B.*; Rosenbaum, M.C.*; Cohen, R.*; Von Roenn, J.L.*; Murphy, R.L.*
*Northwestern University Medical School, Chicago, IL, USA
*University of California, San Francisco, CA, USA

Objective: To address the question of regional and risk group related variations in the incidence of AIDS-related neurological illness, we retrospectively examined the nature and frequency of neurological illness in two similar patient populations treated in University hospitals in San Francisco, California (SF) and Chicago, Illinois (CHI).

Methods: In both SF and CHI, the predominant risk factor for the acquisition of HIV infection was homosexual or bisexual exposure (99% and 79%, respectively), other major risk factors included IV drug abuse (28 SF, 74 CHI) and transfusion (18 SF, 19 CHI). Signs or symptoms of neurological illness were observed in 482 of 1286 (37%) of patients in SF and in 28 of 205 (28%) of patients in CHI.

Peripheral nervous system symptoms were noted in 79 patients in SF (6.1%) and in 20 patients in CHI (9.8%), while CNS dysfunction was observed in 474 patients in SF (37%) and in 41 patients in CHI (28%). Major specific neurologic diagnoses included (SF/CHI): HIV encephalopathy (100, 28); 20, 24); cryptococcal meningitis (68, 14); 4, 7); toxoplasmosis (53, 11); 7, 12); primary CNS lymphoma (25, 5); 2, 3); and PML (8, 5); 3, 3). Less common diagnoses included HSV, CMV or HHV-8 encephalitis (28, 3.8); 1, 1.7%) and rare cases of CNS metastases, and intracerebral hemorrhage secondary to thrombocytopenia.

Conclusions: The data reflect a trend toward increasing neurologic illness with decreased T4 cell counts. The mean T4 cell count in non-neurologically symptomatic patients was 143.5 ± 14.4 while in neurologically symptomatic patients, the mean T4 count was 96.1 ± 14.0. This trend may suggest that immunosuppression is a significant factor in the development of AIDS-related neurologic illness. The data further suggest that populations that are similar with respect to risk group, despite geographical location, may well have similar rates of neurologic disease.

Th. B.P.377 "ANEMIA, LEUCOPENIA, THROMBOCYTOSIS, AND SIDA AU SENEZAL"
D'Amorim, L, Biop A.G., A POVO C.
G.R.U. DE FARM. DAKAR (SENEGAL)

OBJECTIVE: Les divers effets dévastateurs du SIDA imposent la nécessité d'élaborer un approche biomédicale à des données sociales, culturelles par l'étude de des problèmes psychiatriques et neurologiques. Jusqu'ici absent de recherche sur le SIDA au Sénégal.

METHODS: Les 6 cas de 4 patients ont été analysés à partir: - d'un guide d'observation neuropsychiatrique inspiré de L.A.N.E.P. et de la "SIDA".

- d'un examen clinique neurologique;
- d'un examen clinique psychiatrique.

RESULTS: Il a été noté un polymorphisme du tableau neurologique avec divers troubles psychiatriques. Il n'existe pas de manifestations psychiatriques connues au SIDA.

CONCLUSIONS: Ces conclusions ne concernent que la population urbaine. Elles doivent être comparées, dans un an, à une population sénégalaise plus large.

**Session d'affichage
Poster Session**Aspects cliniques
Clinical Aspects of AIDS

Th.B.P.384

Publications



Section B

Aspects cliniques Clinical Aspects of AIDS

B.507 COMPREHENSIVE OUT-PATIENT CARE OF HIV-INFECTED PATIENTS UTILIZING A PRIMARY CARE MODEL
Anastos, Kathryn; Soloway, B.; Ernst, J.; Bronx-Lebanon Hospital Center, Bronx, New York, USA.

Objective: To meet the total health needs of HIV infected individuals of all ages and all stages of illness in a community with very high HIV seroprevalence.

Method: The establishment of a comprehensive out-patient health care program for HIV-infected individuals.
Results: A community hospital in the South Bronx has developed a program for the out-patient care of HIV infected patients, provided both by primary-care trained physicians practicing in primary-care centers, and by infectious disease sub-specialists in an Infectious Disease Out-patient Center. All sites adhere to uniform, well defined standards of care, specifically designed to meet the health and medical requirements of HIV infected persons in all stages of infection. These include: initial comprehensive evaluation and on-going management of all acute and chronic medical problems, both HIV-related and other (e.g. DM, HTN); evaluation for anti-retroviral and preventive therapies (e.g. PCP prophylaxis); general and HIV-related health maintenance (e.g. immunization, PPD, pap smear, ophthalmologic exam, etc.); patient education; protocols have been developed in detail to cover these and other areas. Provider continuity, including inpatient care, is maintained in all primary care centers. On-going subspecialty input for all patients is provided by the infectious disease team.

Le sang et les produits sanguins Blood and Blood Products

B.509 LONG-TERM FOLLOW-UP OF UNTREATED SEVERE THROMBOCYTOPENIA(STP) IN THREE HIV INFECTED MEN: ADICIT, C. by J. Clotier, G. Sifera, J. Howe, A. Casati, J. Tor, M. Fox. Infectious Disease Unit, Hospital de la Sorbonne, Paris, France. **Objective:** To follow-up the findings and follow-up in three seropositive patients who denied any therapeutic approach during a mean period of 18 months (range 12-15).
Methods: 100 ml of 10% EDTA plasma and 100 ml of serum (chromogranin(1:10)) (platelet count (x1000/mm³) and rich marrow aspirate) related to HIV infection, were of kind of treatment but stopped a follow-up control each 4 months. **Results:** are summarized in table 1

P	Initial Gct	F/mm ³	Follow-up			
			months	2/m ³	F/mm ³	
1	111	9000	540	27	9000	855
2	111	3000	468	13	53000	408
3	111	9000	351	15	54000	-

Discussion: There were only minor hemorrhagic distress manifested by occasional epistaxis in 2 patients and petechia in lower extremities in all three. An increase in platelet count (> 9000/mm³) was observed in the three patients. It was spontaneous in 2 of them and possibly related to a non-opportunistic disease in the third. Only one has relapsed to the initial low count. None of the three patients developed AIDS during the follow-up period. Since we have observed a low response ratio to steroids (only 25% responded) and due to the potential immunosuppressive side effect of prednisone in HIV patients, we argue for enhanced control and expectant attitude, although we propose to assay AT treatment in all of them according to the recent literature. Nevertheless STP is not an unfavorable prognostic sign in AIDS seropositive for HIV.

B.511 HEMOPHILIC POPULATION OF COSTA RICA FROM 1979 to 1989
Taylor, Lisa; Taylor, G.M.; Cordeiro, R.M.; Antua, M.C.; Roy, A.; Lofice, R.M.; Vicens, K.A.

*Louisiana State University/International Center for Medical Research & Training, (LSU-ICMRT), San Jose, Costa Rica; **Neurological Dept., Hospital Mexico, San Jose, Costa Rica; ***US Medical Center, New Haven, Conn.

Objective: To analyze the serological profile in the hemophilic population in Costa Rica.

Methods: Serum samples stored in the LSU-ICMRT serum bank were tested with anti-HIV ELISA (Abbott, HTU-III), Western Blot (LSU-ICMRT), HIV antigen (Vironostika-Organon), IRMA HbAg and anti-Hc (HSA) clinical data were obtained from hospital case files. 1989-1990.

Results: Of the 147 hemophiliacs, 80 (54%) were positive for either HbAg or anti-HIV. 44 (44%) were positive for anti-HIV-1 with the following distribution:

Anti-HIV-1	Hemophilia A	Hemophilia B	Hemophilia C	Von Willebrand
Positive	1	3	2	3
Negative	46	1	2	31
Total	47	4	4	34

Sixteen (36%) of the B hemophiliacs were anti-HIV-1 positive since 1980 or before, while 11 (55%) of the B hemophiliacs were positive since 1986. HIV-1 antigen test of 99 of the 64 anti-HIV-1 positive hemophiliacs whose sera were available. The presence of the HIV-1 antigen was evaluated in correlation with seroconversion, development of AIDS or AIDS and death of the hemophiliac.

Conclusion: The analysis of HIV-1 seropositivity in Costa Rican hemophiliacs provides some new insights into the origin of this disease in Central America.

B.508 AIDS AND PHYSICAL EDUCATION
Favre, S.; Machado, J. . . Centro Corciani. (CUII). Campinas, São Paulo, Brazil.

The human is an integral composition of mind and body represented by pleasure and aesthetic, emotions and reason. The body is the very first human experience moment. The individual senses and lives prior to know-participating through the body of the real life. However the individual are being threatened by the AIDS virus contamination which brings together the feeling of an ending bench mark an impossibility of action. He is not anymore owner of his body which is now controlled by another owner called HIV. In the environment dominated by the AIDS virus, the body is felt through disgust, depression, guilt, revulsion, isolation, tension and death. This conduct the patient to a kind of intense exile, rupturing the life links. The body activity represents at this point in time, an important link with the life since it may be felt through the activity in a conscious way. Specialists are required to help the AIDS patients in an adequate environment which motivates the life. In the same way the specialists need to be helped by the techniques. In our particular case we use relaxation and movement to promote the body awareness. Our real possibility is the creation of an space for the body expression in a awareness way in a reason in the patient when his body represents in the world.

B.510 FULLY AUTOMATED SYSTEM FOR THE DETECTION AND REGISTRATION OF HIV-ANTIBODIES IN DONOR BLOOD
Hessing, Helm.; Koot, A.M.; Schout, N.A.; Platani, A.; Brown, J.M.

* Red Cross Blood Bank, Amsterdam, ** Proton-Witten, Eeten-Leur, *** Wellcome Nederland, Healy, The Netherlands.

Objective: To develop a fully automated system for the detection and registration of anti-HIV in donor blood.

Methods: Anti-HIV tests are done with an ELISA system in microtiter plates (Wellcome, Wellcome, UK). The automated system functions as follows: microtiter plates are provided with barcoded labels and positioned in a pipetting robot (Beck DM, Switzerland). Before the pipetting program for the delivery of serum in the wells starts, the plate's barcode is read by a barcode pen and the barcode of the test tubes is electronically read by the built-in laser scanner of the robot. The position in the plate of each sample is stored in an IBM-PC. After the completion of the tests, the plate is automatically read by a reader (Wellcome diagnostics) and the results are stored on a diskette in the IBM-PC. A special program transfers the test results from the IBM-PC to the SP 3000 mini-computer.

Results: The system now operates under routine conditions and over 100,000 serum samples are tested. No major problems were encountered.

Conclusion: ELISA test systems for anti-HIV detection can be fully automated, which contributes to a safer blood supply by avoiding human errors as well as a reduction of the workload in the bloodbank.

B.512 IMMUNE ACTIVATION IN HIV POSITIVE AND NEGATIVE HEMOPHILIC
Yasuhira, Nobuhiko; Y. Oura; T. Koyama

M. Higuchi and I. Kubota
Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan.

Objective: To analyze signs of immune activation observed in hemophilic patients with and without HIV infection.

Methods: The absolute CD4 number, percent CD4/CD8 ratio, is positive cell percent and IgG, IgA, IgM and serum immunoglobulin G (IgG) of hemophilic patients (18 seropositive, 23 seronegative) followed for 5 years in Hyogo prefecture.

Results: Increased levels of serum IgG and is positive cell percent were observed in both seropositive and seronegative groups. And the level of serum IgG in seropositive group was higher than that in seronegative group with statistical significance (P<0.005). Moreover, the correlations between 74/76 and IgG (r=0.546), and between 74/76 and is positive cell percent (r=0.405) were showed only in seropositive group.

Conclusion: Hemophilic patients show some signs of immunostimulation. Increasing levels of IgG and is positive cell percent appear to be correlated with declining immune status in seropositive group.



Publications

Aspects cliniques
Clinical Aspects of AIDS

- B.555** HIV Antigenemia in Patients with AIDS and HIV Infection: A Comparison Between Racial Groups. **Ennis, Edwartz.**
 Serological: C. Faragoles H, Bartlett J, Quinn T, Chaisone R E
 The Johns Hopkins University, Baltimore, Maryland, USA.
 Objective: To determine if HIV p24 antigenemia differs in white and black American patients, as has been suggested in Africa and European patients.
 Methods: 193 consecutive patients with AIDS or HIV infection who presented for clinical trials were studied; 104 had available results. HIV-Ag was measured by the Abbott HIA and verified by neutralization assay. CD4 counts were performed by flow cytometry. Patients were classified by clinical diagnosis and by CD4 counts.
 Results: Overall, 37/132 (24%) of white patients and 7/32 (22%) black patients were HIV-Ag (+ve). Specific results are as follows:

AIDS	White			Black			p value
	Age	Sex	%	Age	Sex	%	
CD4 > 200	27	M	17	0	F	0	0.29
Non-AIDS	15	F	17	0	F	0	0.29
CD4 < 200	12	M	60	6	F	43	0.42
CD4 < 200	12	F	14	14	F	46	0.20

A higher proportion of white non-AIDS patients (30%) were symptomatic than black non-AIDS patients (8% = 0.05).
 Conclusion: The prevalence of serum HIV-Ag does not differ between clinically comparable white and black populations, regardless of clinical status or CD4 number. Prior observed differences cannot be explained by racial variation and suggest that perhaps geographic factors or difficulty in diagnosis of AIDS in developing countries may play a role.

- B.557** ABSENCE DE SEROCONVERSION APRÈS UNE MÉRICITE DE FRENCHINÉTRINE A VIE.
 Biais, J.M., Dubouché, A., Izuel, G.,***
 Sorrenti, D.,*** Lafai, C. *

* Service des maladies infectieuses et tropicales, ** Laboratoire de microbiologie, Villeneuve St Georges - France, *** Laboratoire de virologie et sérologie, CHU, Fontvieille sur Mer - France.
 Objectif: Suivi sérologique et virologique de VIE chez un homme de 26 ans ayant présenté une urticelle aiguë, une ulcération génitale et une méningite de prae-infection à VIE 10 jours après un premier et unique contact heterosexual avec un prostitué.

Méthodes: sérologie ELISA VIH et E. HIA, immunofluorescence, Western Blot, recherche d'anticorps antiprotéine gag, antigénémie EIA, culture rétrovirale à partir de lymphocytes du sang périphérique avec mesure de l'activité transcriptase inverse, PCR (en cours).

Résultats: Tous les examens réalisés sur 10 mois sont restés négatifs hormis une positivité transitoire de Western Blot à J40 après le contact (P18, J25, Op10, Op16) et la culture rétrovirale à 3 reprises (J40, J134, J280). Le patient est asymptomatique et sérologique à 1 an.

Conclusion: Cette observation confirme la possibilité de transmission du VIE après un contact heterosexual unique, favorisée par les maladies associées. L'infection à VIE apparaît dans certaines cas impossible à détecter par les techniques usuelles pendant des périodes prolongées ainsi de favoriser la dissémination du virus. Des études sont actuellement en cours pour caractériser le virus et le statut immunitaire du patient.

- B.559** INTEREST OF COMPUTED TOMOGRAPHY OF THE CHEST (C-CTS) IN 120 HIV-INFECTED PATIENTS (PT) WITH RESPIRATORY SYNDROME (RS).
 M.F. Gerets, Michel Denis, D. Renard, C. Nayat, C. Aboum.

J.M. Hight. Dept. pneumology, radiology - Hôpital Tenon - Paris - France.

Objective: To determine the interest of C-CTS in 120 HIV-infected pts with RS leading to pulmonary infections.

All C-CTS were performed in high resolution (1 mm - 512 x 512) and were studied with knowledge of clinical features; data were compared with final diagnosis. First, we had to consider 2 groups according to normal (G1) or abnormal (G2) chest X-ray.

In G1 (1) Normal C-CTS does not exclude TB, lymphocytic alveolitis or opportunistic infection at an early stage. 2) In some cases, C-CTS showed hilar or mediastinal enlargement, usually associated with tuberculosis. 3) In few cases with suppurative bronchitis and alveolitis due to community-acquired bacteria, C-CTS demonstrated bronchial localizations.

In G2 (1) Pseudocystic cavities (PCC) or a localization of Kaposi sarcoma (KS) were usual. 2) PCC, if appeared as very low intensity diffuse interstitial (and alveolar) opacities, without other abnormalities except cysts. 3) If there was pleural effusion, lymph node enlargement or pulmonary excavation, another diagnosis or an association must be considered. 4) KS appeared as bilateral pleural effusion and peribronchovascular opacities more clearly than in G1. 5) It may also appear as a focus or a diffuse nodular pneumopathy.

Conclusion: C-CTS was of major interest: 1) In G1 when there were hilar or mediastinal abnormalities. 2) In G2 when there was an association of radiological abnormalities.

- B.556** TRANSDUCTION, RIA AND RAPID SCREENING FOR HIV-1 CONFIRMED BY COMBINED TESTING FOR ANTIBODIES AND ANTIGENS
 M. Gagnier, C. Colvert, Y. Pichon and M. Chermak.
 McMaster University Medical Centre, St. Joseph's Hospital, Hamilton, Canada.

Objective: A total of 14 sera from well defined patient infections (5 AIDS, 3 ARC, 4 asymptomatic; 4 negative) were used to evaluate 10 commercial kits for HIV antibodies and another 3 for antigens.
 Methods: Antibody tests included 6 EIAs (Abbott, Organon, Dupont, Diagnostic Systems, Wellcome and Ciba) and 3 Western Blots (Dupont, Vitarin, Bio-Rad), 2 Microscopy tests (Vitarin ImmunoFluorescence, IF and Immunoprecipitation, IP) and 4 rapid assays (Abbott passive hemagglutination (PA) and Testpack; Dupont; HIVCHECK and Chiron; Coaltex and Organon). PA and IP were tested for antigens using tests from Coaltex, Organon and Dupont.

Results: All 6 EIA screening tests were in agreement on 11 sera (8+), 3 discordant results were seen in an antigen positive AIDS patient: an asymptomatic patient with a single p24 band and an HIV2 positive patient. EIA results were confirmed by WB, IP or IF except for these 3 problem sera. The IP and IF tests mimicked WB results closely. Antigen testing which showed no discordance in this series, provided a better understanding of discordant antibody test results. The rapid antibody tests were accurate except for HIVCHECK which demonstrated a problem with sensitivity.

Conclusion: A combination of confirmatory tests such as WB and IP or IF can provide added assurance on interpretation and reporting of discordant sera.

- B.558** LE RETROVIRUS FORME-EXPRIME CHEZ SON PORTEUR EST SEMI-QUANTIFIABLE A PARTIR DES CELLULES MONONUCLEAIRES (CMN)
 Michel Potemkin, Paul D. Smith W. L. Labovitz J.
 INSERM U-393, Centre de Recherches, Centre-Paris-Ouest, France, *ONCO Laboratoire, North Chicago, Etats-Uns; **Institut Pasteur, Paris, France.


Objectif: Quantifier le rétrovirus présent dans les CMN du patient au moment du prélevement de sang avec leur contenu en VIH génomiques non transcriptés dans une infection chronique.

Méthode: Les CMN (total) contenus de sang VIH séro-négatives, traitées (50000 x) et la même rétrovirus est prélevée dans la culture deux fois par semaine. Les CMN ont été stockés en azote liquide dans la culture deux fois par semaine. Les CMN ont été analysés à l'aide de la méthode de culture de cellules ex vivo.

Résultats: La vitesse de production de rétrovirus par les CMN est transformée en valeur score, qui varie de 0% (D.O.I.) à 100% (1 à 3). La moyenne des vitesses pour un spécimen donné est fonction du temps de culture de cellules.

Les mêmes données de base sont obtenues en CV-293, au moment du prélevement de sang à J12-18 mois après le début de l'infection.

Conclusion: Le niveau d'expression du virus dans un point de mesure biologique peut être mesuré par la vitesse de production de rétrovirus par les CMN. La vitesse de production de rétrovirus par les CMN est semi-quantifiable à partir des cellules infectées.





B.561 QUANTIFICATION DES ANTI-p25 VIH PAR DENSITOMETRIE SUR ANTIPODES DE RECOMBINAISON GENETIQUE (CHIRON, RIA, HIV-1B).

Centre de Transfusion et d'Hématologie, "Laboratoire de Microbiologie, Centre Hospitalier de Versaille".
 M. HANIC, M. C. CHIRON, M.-C. MAISONNEUVE, P. CHIRASSIA, J.-C. DE SAINT-PAUL, B.P.

Objectif: Quantifier par densitométrie les anticorps anti-p25 dans un test de confirmation basé sur des antigènes de recombinaison génétiques sur phase solide avec mise en évidence des anticorps par une antagoniste marquée à la peroxidase de radon (CHIRON RIA HIV-1B, Orho France) et comparer les résultats obtenus sur les séruma séquentiels de patients avec ceux de la technique utilisée en routine (ABSTRACT HIV core recombinaison antigen competitive EIA) calibrée sur un sérum de référence permettant le tirage de 1 à 256.

Méthodes: Les bandelettes RIA CHIRON sont utilisées conformément aux recommandations du fabricant. Elles sont réalisées avec un déterminant SOMODIOM CO-50. Les anti-p25 sont exprimés par rapport au titrom de réactivité IgG. On présente sur chaque bandelette. Des courbes de dilution 10 par 10 (1/1000 de sérum de référence mélangé anti-p25) ont été réalisées à 4 échelonnages. Les conditions sérologiques de 25 patients (84 sérum ont été étudiés).

Résultats: L'évolution du taux des anti-p25 mesurés par densitométrie se conforme aux résultats connus. La sensibilité de la mesure des anti-p25 par RIA CHIRON est supérieure à la technique de référence pour les valeurs basses comme pour les valeurs élevées. Chez certains patients les anti-p25 continuent d'augmenter plusieurs années après la contamination.

Conclusion: Un test destiné à la confirmation massé standardisé par l'utilisation d'antigènes de recombinaison génétiques et de témoins fournit des indications quantitatives d'intérêt pronostic.

B.563 STUDY OF SPREADING IN 36 AIDS PATIENTS FROM 1982 TO 1988 IN RIO DE JANEIRO, BRAZIL.

Belisário-Oliveira, C.A.; Wada, M.A.; Figueira, F.J.; Góes, E.; Pereira, P.; Gomes, A.; Mendes, A.; and Silva, J. Centro de Diagnóstico e Referência Epidemiológica, Fundação de Amparo à Pesquisa do Estado de Rio de Janeiro (FAPERJ-PRONEX-82) - Brazil.

OBJECTIVE: To demonstrate the main infectious aetiologies found among 36 infectious AIDS patients, and compare the findings among time groups.

METHODS: The starting techniques used were: serological (serum, Pw, Smoott) and histology.

DISEASE	1982-85		1986-88	
	n	%	n	%
CMV (+) and (-) bacteria	11	30.6	10	27.8
Herpes B virus	11	30.6	10	27.8
Cryptosporidiosis	12	33.3	6	16.7
Pneumocystis carinii	11	30.6	1	2.8
Parasitosis	11	30.6	1	2.8
Chlamydia	1	2.8	1	2.8
Parasitosis	1	2.8	1	2.8
Cryptosporidium	1	2.8	1	2.8
Parasitosis	1	2.8	1	2.8
Cryptosporidium	1	2.8	1	2.8
Parasitosis	1	2.8	1	2.8
Cryptosporidium	1	2.8	1	2.8
Parasitosis	1	2.8	1	2.8

CONCLUSIONS: 1. Tuberculosis was the most frequent cause of infectious aetiology. 2. Chlamydia was the most frequent aetiological agent associated with gram positive and negative bacteria, pneumocystis and candida albicans. 3. Tuberculosis is frequent cause aetiology of HIV/AIDS patients. 4. Tuberculosis shows a quantitative association with candida albicans, pneumocystis and cryptosporidium.

Neurologie générale
 General Neurology

B.565 PRELIMINARY LABORATORY FINDINGS OF THE CENTRAL NERVOUS SYSTEM IN HIV INFECTION.

Smith, S.M.; Davis, F.P.; Bannister, C.M.; Bassett, R.M.; Falciano, M.J. and Shalton, J. Univ. of California, San Francisco, CA, USA.

100, 3000 Service of Pathology, 1100 Div. of Infectious Diseases, Sausalito Hospital, Sausalito, California, USA.

Objective: to describe the incidence of primary acquired immunodeficiency (AIDS) of the Central Nervous System (CNS) in HIV positive patients.

Methods: The data concern 87 subjects of HIV-like AIDS pts, and 10 stereotaxic biopsies from pts. with extensive nodular lesions with evidence of differential diagnosis in inflammatory and neoplastic lesions. Routine studies were employed. Immunohistochemical analysis and phenotypic cell identification failed for antigenic series of specimens.

Results: post mortem examination of HIV positive-died adult pts. revealed 8 cases of primary acquired AIDS, 6 of CNS. 6 most of neurologic signs 1 patient was group II, 2 pts. group III and 3 cases group IVa (WHO GC classification); none had systemic clinical signs of lymphomatous disease. CNS. 1 infection revealed 8 cases of single deep intracerebral abs. 1 case of double cerebral-cerebellar supratentorial process and 3 cases of multifocal-intracerebral lesions. HISTOPATHOLOGY (H&E) identified 5 cases as lymphomatous with plasmacytoid differentiation. 1 case 1 case as large cell disease cell. 1 case (1 case the stereotaxic biopsy case). Neoplastic lymphoid cells presented thick perivascular cuffs and spread to subarachnoid and Virchow-Robin spaces. **Conclusion:** 1) Primary acquired AIDS. represent 10% of all A.S. series. 2) Prevalence of high CD4 T cell primary acquired AIDS. 3) The positive cerebral localization and therapeutic possibilities are stereotaxic biopsies essential in diagnosing these patients.

B.562 A SENSITIVE AND SPECIFIC ANTI-HEV 2-ELISA USING AN ENVIRONMENTAL SYNTHETIC PEPTIDE.

Knapka, USA; Brust, St.; Behringwerke AG, 3550 Marburg, FRG

Objective: To evaluate the efficiency of an ELISA (Enzygnost-Anti-HV 2), based on a synthetic peptide corresponding to the glycoprotein of HEV 2. **Methods:** 100 µl uncoated samples were pipetted in 50 µl diluent into each well of microtiteration plates coated with 1 synthetic peptide. The incubation over 30' at 37 °C is followed by 4 washings and the addition of 100 µl peroxidase labeled Anti-HV 2. After another incubation for 30' at 37 °C and 4 washings, the colour development is performed over 30' at RT using TMB.

Results: Of 71 Anti-HV 2 sera all specimens reacted clear cut positive. Compared to a commercial assay an improved detection limit of factor 4 was found by testing serial dilutions of Anti-HV 2 sera. Only weak cross-reactivities were observed when HIV 2 Anti-HV 2-sera were tested. From a total number of 1500 negative sera and plasma a specificity of 99,8 % was calculated.

Conclusions: This new ELISA turned out to be highly sensitive. The ELISA 2 showing only weak cross-reactivities with Anti-HV 1, making this assay best suited to differentiate between Anti-HV 1 and -2.

B.564 ROLE OF HIV IN HEMIPARALYSIS. CASE REPORT.

Palazzo, D.; Owen, S.M.; Strydom, H.A.; Adamovich, V.M. and Adelman, D.

MAZD Research Centre, Biomed Canada Inc., ** Faculté de Médecine, Université de Montréal, *** Institut Armand Frappier, Montréal, Québec, Canada

One health status deteriorates drastically in AIDS patients. The present studies aim at correlating the presence of HIV in peripheral blood lymphocytes (PBL) and salivary lymphocytes (SL) with incidences of oral disease.

HIV was searched for in PBL, saliva and SL obtained from 90 patients at different stages of HIV infection by means of immunofluorescence (IF), post-exposed immunogold assay (PIGA) and culturing studies. Quantity of HIV positive cells were electron microscopy (EM) and culturing studies. Quantity of HIV positive cells were compared with the incidences and the evolution of oral disease assessed by monthly over a period of two years. HIV particles and/or antigens were found in PBL, gingival epithelial cells and endothelial cells, lymphocytes involved in plaque, as well as in SL. The incidence and the percentage of HIV-containing cells found in gingiva and saliva was significantly higher than in PBL. Incidences of a variety of oral disease can be positively correlated with the number of infected cells in gingiva and saliva.

These findings suggest that: 1) HIV-positive PBL in gingiva receive antigenic and/or antigenic stimulation by the oral flora resulting in the greater expansion of the virus. This stimulus is supported by our current studies in vitro of stimulation of production of HIV by oral micro-organisms. The presence of HIV in gingiva may be associated with a high stimulation of the local CD4-T cell mediated immunologic reaction associated with a high stimulation of a variety of oral disease behavior.

B.566 NEUROPSYCHOLOGICAL EFFECTS OF EARLY HIV-1 INFECTION: DIAGNOSTIC AND PROGNOSTIC IMPLICATIONS

Isurubaru, Loggia, J., Bridge, P., Janssen, R., Slosser, E., Hwang, R., and Goodwin, J. CDC, Atlanta, GA, USA, **MIMS Intrantel, Bethesda, MD, USA, ***ADAMA, Rockville, MD, USA.

Objective: To recommend a common methodological approach for neuropsychological assessment in HIV-1 infected individuals to foster meaningful comparisons among studies.

Method: Methods used in studies of neuropsychological performance in HIV-1 seropositive individuals were reviewed.

Results: Despite considerable methodological variation observed in studies, investigators generally agree on general domains for assessment. We here recommended specific instruments.

Conclusion: Investigators can optimally contribute to knowledge about neuropsychological effects of HIV-1 by: 1) developing or using markers for disease effects in early HIV-1 infection; 2) applying longitudinal designs; 3) using common instruments when assessing the multiple domains that demonstrate sensitivity to the neurotoxic effects of HIV-1; 4) selecting controls appropriate to the design and research question; 5) evaluating and controlling for co-factors such as knowledge of serostatus, substance abuse, and psychiatric symptomatology; 6) reporting results for both observed change (e.g., 1 SD) as well as impairment (e.g., 1.5 SD) and 7) reporting how impairment affects individuals' daily activities.

Publications

Aspects cliniques
Clinical Aspects of AIDS

B.567

B.568 THE INCIDENCE OF A MARKER FOR CHOLINERGIC DYSFUNCTION IN AIDS/ARC.
VALDESKY, W., TULLIN, S., EVANS, C., SATZ, P., FREEMAN, D. and HINKIN, C.
Veteran's Administration West Los Angeles and UCLA School of Medicine, U.S.A.

Objective: A specific pattern on the Wechsler Adult Intelligence Scale-Revised (WAIS-R) associated with cholinergic dysfunction has been reported by Fuld to occur in 50% of patients with Alzheimer's disease and in 20% of younger individuals given scopolamine, while occurring in only 10% of patients with multi-infarct dementia, head injury, depression, and normal elderly individuals. This study sought to determine the incidence of this WAIS-R pattern ("Fuld formula") in patients with AIDS and ARC and the AIDS Dementia Complex.

Methods: The WAIS-R was administered to 116 patients: 40 with AIDS and 76 with ARC. The incidence of the Fuld formula on the WAIS-R was calculated for all patients. **Results:** Of the 116 subjects tested, 11 demonstrated a positive Fuld profile pattern on the WAIS-R (9%), not significantly different from the incidence in non-cholinergically deficient patient groups studied to date. However, 8 of the persons with AIDS (20%) demonstrated the WAIS-R pattern, while only 3 of the ARC patients (4%) demonstrated this pattern.

Conclusions: An increased incidence of a WAIS-R pattern associated with cholinergic dysfunction (scopolamine) and cortical dementia (Alzheimer's disease) was not demonstrated in this sample though a greater number ($p > .05$) of more seriously immunocompromised patients demonstrated the profile compared with less immunocompromised patients. These results support prior reports of the specificity of the Fuld formula for dementia of the Alzheimer's type than in other types of dementia, including the AIDS Dementia Complex.

B.569

B.570

B.571

B.572

Publications

B.579 THROMBOTIC THROMBOCYTOPENIC PURPURA(TTP) IN AN HIV-INFECTED CHILD: TREATMENT WITH D-SEMPROST-8-D-ARGININE(DSAPV) AND INTERFERON- γ (IFN- γ)

Church, Joseph A.; Marshall, D. and Leung, K. Childrens Hospital of Los Angeles and U.S.C. School of Medicine, Los Angeles, California, U.S.A.
Objective: To describe therapy of TTP in an HIV-infected child.
Methods: Case report. **Results:** After 2 weeks of upper-respiratory infection symptoms, a 44 year old boy with Down Syndrome and transfusion-associated HIV infection presented with acute haemolytic anemia. Previous hemogram and blood chemistries were normal. Immune status was stable with CD4-lymphocytes(520/mm³) and IgGgA(1.193 mg/dl). Laboratory data: Hgb-4.5 g/dl, Hct-11.8%, WBC-10.0 x 10⁹/l(70% neut.), LfL lympho), sedimented rate=10/1000g platelet count=10.2 x 10⁹/l, peripheral smear-consistent with severe microangiopathic hemolytic, schistocytes-2, platelet, 24 seen. Blood urea nitrogen=30 mg/dl, direct and indirect antiglobulin tests-negative. Despite supportive therapy with antibiotics and CO₂ and platelet transfusions, hematology continued, the platelet count dropped to under 5 x 10⁹/l and gross hematuria developed. The patient was given DSAPV(0.3 mg/kg) and began on IFN(300 mg/kg daily for 5 days). Thrombolytic therapy, hemolysis decreased, platelet count improved and hematuria cleared. Three months later his hemogram and blood chemistries were normal. **Conclusions:** This patient's clinical course indicates that, as in adults, HIV-infected children are at risk for TTP. DSAPV and IFN may play a role in the termination of the microangiopathic process characteristic of TTP.

B.581 MUCOCUTANEOUS MAFOSI'S DERMOMY: A MARKER OF PEDIATRIC AIDS.

Edwards, Yolande; Samuels, C. and Kistis A. **Uganda Cancer Institute, (UCI) Uganda.**

Objective: To describe clinical features of childhood Mafosi's syndrome (MS) that is a marker of AIDS.

Methods: Case records of all children admitted to the UCI with diagnosis of MS between June 1987 and January 1989, were reviewed for features that are suggestive of pediatric AIDS. Evaluation of these children included a history and physical examination, investigations including a full hemogram, an ECG, chest X-ray, liver function tests, renal function tests, ultrasound of the abdomen and biopsy of either a skin lesion, lymphnode or both. HIV serology was done using latex-agglutination kit and western blot for confirmation. Patients were staged according to the staging classification by R.L. Mufson et al. (Cancer Treatment Reports 1983; vol. 67, pp. 531-534).
Results: Six children all stage 4 (5 male, 1 female), median 2.5 yrs (range 2-4 yrs) were seen over this 18 mo period. All had histologically confirmed MS and HIV serology with western blot confirmation in 1 case. 4 were HIV +ve, 1 falsely negative, 1 HIV -ve. The 4 HIV +ve children and the one falsely negative child had mucocutaneous MS in addition to lymphnode involvement. The HIV -ve child had only lymphnode MS.
Conclusion: Disseminated aggressive histologically confirmed MS in children should be considered a marker of AIDS as it is in adults.

B.583 RANULA CYSTS IN CHILDREN WITH AIDS

Anderson, Yvonne; Lee, W., N.;; Green, N. A.;; **Arvey, A. Pediatric AIDS Study Group, Mount Sinai Health Science Center, Interfaith Medical Center Brooklyn NY, New York University, NY USA**

Objective: To report the clinicopathologic correlations of ranula cysts in children with AIDS.

Methods: Two cases were reported: 1) Patient 1 had lymphadenopathy and lymphocytic interstitial pneumonitis (LIP) at age 1 year and a 3cm in diameter, sublingual, ranula cyst which was excised at age 2. Within 3 weeks it reoccurred only to spontaneously disappear two months later. 2) Patient 2 had LIP with oral leukoplakia and hypoxia at age 2 years. Following treatment with steroids, a 1cm in diameter ranula cyst disappeared.

Results: The sublingual excisional biopsy of the collapsed cyst revealed a fibrous shell containing lymphocytes and plasma cells that also infiltrate islands of mixed salivary gland tissue containing ectatic ducts lined by pseudostratified epithelium.

Conclusions: Ranula cyst resembles cystic parotid lymphocystic lesions described in adults with AIDS. Ductal obstruction by inflammatory cells is part of the spectrum of steroid-resistant, extraneoplastic, polycystic, polypycystic, 8 wall lymphoproliferation most often presenting as EBV related LIP in children with AIDS.

B.580 GLIANT CELL TRANSFORMATION OF THE LIVER IN PEDIATRIC AIDS

Kahn, R.; Datta, P.; Glick, M.;; Haged, M.;; Harnack, P.;; **Anderson, Yvonne.**

North Shore Univ. Hosp., Massachusetts-General Univ. Med. College, NY, NY; Univ. Hosp., NY, NY; Montefiore Hosp., Univ. of Chicago, Chicago, IL, NY; Albert Einstein Med. College, NY, NY; Montefiore Dept. Health, NY, U.S.A.

Objective: Emphasize that giant cell transformation occurs in the liver of children with HIV infection.

Methods: Review of liver tissue of 46 children with AIDS (Hicopeles =7, subtypes=42).

Results: Giant cell transformation of the liver was seen at autopsy in 4 of 46 children. All had HIV infection in children as their risk factor for AIDS.

IC	Age	Sex	HAI	Inflammation	Cause of death
1	5	M	-	+	sepsis, GAD
2	5	F	+	+	resp. failure
3	6	M	-	-	resp. failure
4	10	M	-	-	resp. failure

Conclusion: Giant cells occur not only in AIDS associated encephalopathy but also in the liver of children with HIV infection. We therefore confirm a previously published report (Williamson - Ann Pediatr 120: 603, 1988) that HIV infection in children may cause giant cell transformation of the liver.

B.582 SIMILAROUS OCCURRENCE OF PAROTID SWELLING & LYMPHOCYTIC INTERSTITIAL PNEUMONITIS IN CHILDREN WITH HIV DISEASE.

Duggal, Asha, Kaul, A., Shah, K., Groth, K., Chow, J. S. & Li, E.

New York Medical College, Valhalla, New York.

Over the last 4 years, 118 children under the age of 13 years have been followed at our affiliated institutions. 25 of these children had clinical and radiological evidence of lymphocytic interstitial pneumonitis (LIP). In three of the cases, the diagnosis was confirmed by biopsy. All of the 25 children also had parotid swelling. There was no child in our series who had either of these two parotid findings as an isolated finding.

It has been postulated that LIP is caused by Epstein Barr virus induced lymphoproliferation. Children who are exposed to HIV in utero handle EB virus infection abnormally leading to the development of LIP. Adults on the other hand acquire EBV infection after primary exposure to EBV and LIP is a rare occurrence in adults. We postulate that parotid swelling may also be caused by EBV infection related lymphoproliferation.

Demonstration of EBV genome in parotid gland will be required to support this hypothesis.

We conclude that the findings of parotid swelling and LIP occur simultaneously in pediatric HIV disease. Children who present with parotid swelling should be observed carefully for the development of LIP and LIP should be a consideration in these children if they develop respiratory symptoms.

B.584 SEVERE REACTIONS TO TRIMETHOPRIM-SULFAMETHOXAZOLE IN CHILDREN INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS

Stephen Charnock; Lugubuhli, L.;; McIntosh, K.;; **"Division of Infectious Diseases, The Children's Hospital, Boston, MA USA.**

Adverse reactions to trimethoprim/sulfamethoxazole (TMP/SMX) therapy occur with greater frequency in patients infected with HIV and commonly occur in all of the following: leukopenia, thrombocytopenia, and rash. Severe reactions, such as Stevens-Johnson syndrome or seizures, have been reported in several adult patients. We report two congenitally infected children who developed severe life-threatening reactions to TMP/SMX therapy. An eight month old male was noted to develop fever of 40°C, vomiting, lethargy, a full dose, and a combination of a maculopapular and urticarial eruption shortly after beginning a second course of TMP/SMX. Laboratory investigation failed to identify an alternate etiology. Later, he was rechallenged with TMP/SMX and developed identical symptoms. A second child, 10 months old, with a history of maculopapular eruption to TMP/SMX therapy, was rechallenged and shortly thereafter developed vomiting, fever of 38.4°C, and respiratory distress (with a negative chest X-ray). Over the next 24 hours, he developed hypotension, acidosis, and a cardio-pulmonary arrest. TMP/SMX was discontinued and the patient recovered over 48 hours. Over the next five days, the following were noted: metabolic, conjunctival, mucous membrane and erythema of the palms, soles, and lips, which led to diffuse, superficial desquamation. Investigation failed to determine an alternate etiology. The occurrence of life-threatening reactions to TMP/SMX therapy should be taken into consideration in the care of children with HIV infection.



Publications

Aspects cliniques
Clinical Aspects of AIDS

- B.591** EFFICACY AND SAFETY OF KETOCONAZOLE IN HIV INFECTED INFANTS WITH MUCOCUTANEOUS CANDIDIASIS: Jeffrey, M.B., Cooper, E.R., Patel, D.K., Patton S.L., Boston City Hospital, Boston University School of Medicine, Boston, Massachusetts, U.S.A.

Mucocutaneous candidiasis is a common opportunistic infection in children with HIV disease and associated with significant morbidity (fever, poor feeding, failure to thrive). Recommended therapies such as Nystatin and nystatin vaginal have not been effective in immunocompromised hosts with moderate to severe candidiasis. We treated 4 infants, ages 1 to 8 mos, with a Ketoconazole suspension (prepared by pharmacy) of 3 mg/kg q 12 h for moderate to severe thrush (3 patients) which involved buccal mucosa, tongue and palate and was associated with poor feeding and weight loss. All had failed a minimum of 7 days of Nystatin a nystatin vaginal. All 3 cleared on Ketoconazole in 3-5 days. 2/3 had recurrence when therapy was discontinued which necessitated "prophylactic" administration of 3 mg/kg/day for 3 and 10 mos, respectively. 1 patient (8 mos.) was treated for seborrheic dermatitis which had failed topical Ketoconazole wash. All children had pre and post treatment evaluation of liver function. No adverse effects were observed. Specifically 1 infant (2 Y1) 4 mos. of age received Ketoconazole and Zidovudine concurrently for 3 mos. Pre therapy LFTs demonstrate moderate hepatocellular injury (SGOT 390, SGPT 104, Billi 7.3). LFTs progressively return to more normal values (SGOT 79, SGPT 50, Billi 1.7) over a 3 mos. course while on both medications. We believe Ketoconazole is a safe and effective therapy of mucocutaneous candidiasis. More information is needed about its concurrent use with Zidovudine and its use in children with evidence of hepatocellular dysfunction.

- B.593** WHICH AIDS PATIENTS NEED STOP DRUG CARE? A PROSPECTIVE STUDY
Muller, Bruce D., Ph.D., University of Washington, Seattle, Wash, R.K.,**
*University of Washington, Seattle VA Medical Center,
**AIDS Prevention Project, Seattle, Washington, USA.

Objective: To assist in discharge planning for hospitalized AIDS patients in need of special AIDS services and about nursing (N) and social work (SW) we carried out a prospective study of 100 persons with AIDS to determine the characteristics of patients in need of such care, and to develop a classification rule to easily identify them at the time of admission. **Methods:** We obtained demographic, medical, and social profiles of patients near the time of admission to the hospital, and concurrently interviewed their doctors, nurses, and social workers regarding appropriateness of stop drug care as a substitute for part of their hospital stay. **Results:** Of the 100 patients (men, mean age 35 yrs), 21 were considered appropriate for stop drug care by their physician and nurse or social worker (or all 3). The appropriate patients were more likely to live alone (58 vs 29%), have poor (<4) Barthel's Activities of Daily Living (ADL) scores (48 vs 63), be impaired in activities of daily living (ADL) (77% vs 17%), or on Medicaid (53 vs 42%) (all, p<.05). In multivariate analysis, three variables contributed significantly to a classification function: living alone, poor ADL score, and impairment in ADL. The function was developed on a 608 random sample of subjects, (83% correct classification, sensitivity 92%, specificity 78%, positive predictive value 73%, negative predictive value 93%, kappa .67) and applied to the remaining 40 (sensitivity 83%, specificity 87%, kappa .62). **Conclusion:** AIDS patients appropriate for various lengths of time from those who are not in several important characteristics identifiable at the time of admission. Knowledge of these factors may aid in discharge planning.

- B.595** AN EARLY INTERVENTION PROGRAM FOR CHILDREN WITH HIV
Morgan, Marjell, Kaplan, M., Sloan, L., Harvell, J., Calver, A., Redell, G., et al.
SRII Health Science Center at Brooklyn, NY, U.S.A.

OBJECTIVE: To describe the program for developmentally delayed (DD), HIV infected children and to evaluate the children's performance. **BACKGROUND:** The Infant and Child Learning Center (ICLC) provides a comprehensive educational, therapeutic and psychosocial program. Each home and caregiver attend a small class several times a week where they participate in activities that address the child's individual needs and strategies. The staff routinely reassesses the goals for each child in order to document developmental skills. A retrospective review was done on 22 children enrolled in the program for various lengths of time (1 mo. to 18 mos., mean 7.5 mos.).

RESULTS: Located in a hospital setting, the ICLC provides a supportive environment where families can freely express their concerns and receive immediate medical consultation and services. The table shows the results of a 3 point criterion rating scale measuring the number of children who progressed, regressed or remained the same during the time spent in program.

	Cognitive	Social/Emotional	Motor	Language
3 progressed	13	31	29	32
4 same	11	24	25	18
4 regressed	22	44	35	30

CONCLUSION: In order to effectively service these children, an interdisciplinary, comprehensive model is necessary.

- B.592** HIV-1 GP 41 ANTIGEN IN THE SERUM OF HIV INFECTED CHILDREN
Hilgart, Madsen; Calveliti, T. and Robinson, A.
Albert Einstein College of Medicine, Bronx, N.Y., U.S.A.

Objective: To detect the presence of HIV-1 gp 41 antigen in the sera of HIV-infected children and correlate with disease activity. **Methods:** HIV-1 gp 41 antigen (Ag) was assayed by an immunoblot assay involving fraction with monoclonal gp 41 antibody followed by peroxidase-conjugated goat anti-mouse IgG. A positive reaction was detected by color development upon addition of substrate, and reactive samples visually graded. **Results:** Eighteen of 100 (18%) patients had gp 41 Ag present in their sera. The concentration of HIV protein p17, p24 and gp 120 in the serum of course and who died. The concentration of serum gp 41 paralleled the concentration of HIV protein p17, p24 and gp 120 in the serum. **Conclusion:** The detection of gp 41 antigen can be of value as an additional marker of disease activity and prognosis and could be potentially useful in monitoring patients on treatment.

B.594

- B.596** CONTROLLED CLINICAL TRIAL OF ANGINICIN, CHINESE HERBAL TONGUE ENHANCER, IN HIV SEROPROFITIVES
Sarkany, Timothy, AIDS Prevention Center,
San Francisco, California, U.S.A.

Objective: To assess the safety and efficacy of a new Chinese herbal immune enhancer developed in the People's Republic of China, which is produced from extracts of angelica, ginseng, and fructus lycium in the treatment of early to mid-HIV infection. **Methods:** 100 HIV seropositive patients with 7 helper lymphocyte counts between 100 and 600/mm³ and no prior HIV-related hospitalizations or ongoing treatments were randomized into double-blind treatment and placebo-controlled groups. The treatment group was given two Anginicin 50 mg capsules three times a day. Diet instructions were to avoid lobster, shrimp, crab, seabird shoots, duck, goose and alcohol. The placebo group received similar-looking capsules and instructions. All patients were followed at biweekly visits and monthly laboratory studies including CBC, chemistry panel, T and B lymphocyte panels and p24 antigen were performed. **Results:** Symptom tabulation, labs, Karnofsky score, frequency of opportunistic infections, and HIV-related hospitalizations are analyzed on a monthly basis over a 6 month period and summary statistics presented with multivariate analysis. **Conclusion:** Promising non-western therapies for HIV infections deserve formal clinical trials in a randomized double-blind controlled fashion to evaluate their usefulness.


 Manifestations cliniques
 Clinical Manifestations

B.609 HIV-INFECTIONS AMONG
IV. DRUGABUSERS IN THE FRG:

Behavioral, differential risks and proportions of
 frequent change of address.

Kalher, Dieter Sozialpädiatrisches Institut Berlin, Berlin (West), FRG.

Our results of a German (nearby) representative differential-epidemiological study (N=630) to estimate the actual HIV-prevalence-rate and the relative riskness of needle-sharing and sexual activities among iv. drugabusers show a much smaller percentage of infected persons than expected (20.1% HIV-positive). A highly significant difference (German rural area 15.7%) and in sub-populations with different social-history (Prison-Prevalence-rates are significantly higher in iv. drug-addicts having prison-experience (63%) compared to those who never have been imprisoned (37%). The important factors to prevent transmission are the frequency of needle-sharing and sex. From a techniques especially anal intercourse and sex-techniques with high risk. From a preventive perspective the amelioration of living conditions of drugabusers (decriminalization: provision of housing opportunities, work opportunities, rehabilitation from illegality; provision of aid; self-help) cannot be stressed enough. In addition, public announcements should be visible in all places where addicts meet to shoot heroin. Acceptance of conditions must be increased and offers of support for drug-dependent prostitutes who want to leave prostitution should be provided.

B.611 RAPID PROGRESSION OF ORGANIC DELUSIONAL SYNDROME TO

DEMENZA IN AIDS
SHIMIZU, Valerie F. State University of New York at Stony Brook; Stony Brook, New York, USA

Objective: To clinically assess the course of Organic Delusional Syndrome in patients with AIDS.

Methods: Hospitalized AIDS patients referred to the Stony Brook University Hospital Psychiatric Consultation Service were assessed by a board certified psychiatrist utilizing medical chart review and semi-structured interview. Diagnoses were made using DSM-III-R criteria.

Results: Case 1: 39 y.o. male IVDA with AIDS on methadone maintenance experienced an acute onset of delusional persecutions. He responded well to phenelzine, but developed akathisia and coprolalia rigidity. These resolved with the addition of diazepam and discontinuation of phenelzine. Within 2 months he became demented. Case 2: 45 y.o. female former IVDA with AIDS (haloperidol), but developed acute dystonia. This resolved with benztropine and discontinuation of haloperidol. Within 1 month she became demented. She died 3 months later.

Conclusion: It is known that some organic mental disorders can progress to dementia and even death. These cases: (1) confirm the increased frequency and severity of adverse reactions to conventional pharmacotherapies noted by other investigators; (2) suggest that the presence of an organic mental disorder, specifically Organic Delusional Syndrome, may be predictive of the dementia process, perhaps hastening its onset or making its course more fulminant; and (3) raise the question of increased vulnerability to organic mental disorders in HIV-infected IVDA's.

B.613 HIV INFECTION - IMMUNOLOGICAL STUDIES IN

BULGARIA

Plochev, Eshan; Tsakov, H.; Vasiliev, Tsh.; Ognjanov, H.; Dikov, I.; Doganov, B.
 Institute for Infectious Diseases, Sofia, Bulgaria.

For a period of three years we have been studying the immunological status of 50 men infected with HIV (proved by ELISA and western blot). 3 of them have AIDS, 7 slight clinical disturbances and 40 are carriers of HIV.

22 out of these 50 men with HIV infection have signs of dysfunction in the immune system: impaired cell-mediated immunity, changes in the T4/20 ratio and negative skin reactivity. In this group 3 men have AIDS, 7 - slight clinical disturbances and 12 are carriers, the latter having no signs of opportunistic infections or neoplasms associated with AIDS.

B.610 INCIDENCE OF AIDS AND OTHER INFECTIONS IN SPANISH DRUG ADDICTS
ANALYSIS OF 8640 CASES AFTER A DECADE OF FOLLOW-UP (1977-1987)
 Spanish Group for the Study of Infections in Drug Addicts.

OBJECTIVE: To study the prevalence and the characteristics of AIDS and other infections in Spanish parenteral drug addicts reported, using a standardized form, all infectious complications in PDM who required hospital admission or hospital control as outpatients. The diagnosis of the infections were made following preestablished criteria and were the same in all participating centers. The PDM number of 8640 infectious complications in PDM have been reported from 1977 to 1987. The number of cases increased abruptly since 1980. The mean age of PDM was 28 years and the male/female ratio 3/1.

RESULTS: A total number of 8640 infectious complications in PDM have been reported from 1977 to 1987. The number of cases increased abruptly since 1980. The mean age of PDM was 28 years and the male/female ratio 3/1. Infective endocarditis was diagnosed in 637 cases (7%); thrombotic and mixed endocarditis in 782; bacterial meningitis or septic arthritis in 501 (5%); skin or soft tissue infections in 418 (5%); tuberculosis in 262 (4%); tetanus in 6. Other infections: chronic hepatitis in 716 (8%); AIDS in 400 (4.5%); systemic candidiasis (skin, ocular and/or chondrocostal involvement) in 671 (8%); malaria in 8 and "other infections" in 1100 (12%). The overall mortality was 3.5%. AIDS in PDM appeared in our country in 1980 and increased abruptly in 1987. Extrapulmonary or disseminated tuberculosis (1274), esophageal candidiasis (184), pneumococcal meningitis (181) and C.N.S. candidiasis (11.5%) were the most common diagnostic presentations. The cumulative mortality of AIDS cases was 26%.

CONCLUSIONS: Infectious complications in PDM have become an emerging and growing problem in Spain since 1980 and AIDS increased abruptly in 1987.

B.612 CLINICAL CHARACTERISATION OF HIV2 DISEASE IN WEST AFRICA

TUNALI COHARIBI, HENOA A.A., WILKINS A.B., GAYE I., WHITTLE R. AND
CHERNOB R.
 MEDICAL RESEARCH COUNCIL, FALAJA, THE GAMBIA.

OBJECTIVES: Particular attention is paid to the pattern of secondary infections in patients with HIV2 disease.

METHODS: All cases suspected of having AIDS, AIDS selected complex on progressive generalized lymphopathy were enrolled in the study. Haematological diagnosis was made by standard methods prior to test in our laboratory. Primary serology using wallocozyme 1 and 2 tests. Positive HIV1 is confirmed using second-generation gel agglutination test (Bio-Rad) and HIV2 by Elansa II. When concordant test for one or both viruses are made.

RESULTS: At the total number of HIV seropositives studied 241 ADE, 11 PGL, 52 Tuberculosis. The main clinical manifestations of HIV2 disease include weight loss 100%, pyrexia 93% and cough 71%, chronic diarrhoea 64%, chronic night sweats and neurological symptoms 43%.

HIV2 cases mortality and morbidity similar to HIV1. There is evidence of vertical transmission.

CONCLUSIONS:

B.614 OBSERVATIONS CLINIQUES SUR LE HIV 2 INFECTION EN

BULGARIE

DIKOV I., DOBOVITKOVA T., CHAKARONITA R., DUB-ROVKA J., KOTCHEVA R., BURCHERT K. et al.
 Clinique des Maladies Infectieuses, Sofia, Bulgarie
 "Hospital Regional, NOVAPAZ, BULGARIE

Pendant la période de 01.01.1986 jusqu'à 31.12.1988 ont été observés 55 personnes de nationalité bulgare avec une sérologie positive pour HIV 2 par ELISA et Western Blot. 14 personnes ont eu des manifestations cliniques, laboratoires et immunologiques au diagnostic un malade avec tableau clinique de SIDA et infections opportunistiques et 3 autres cas de généralisées, qui ont décédé après 15 mois d'évolution, un malade avec polymyélite récidivante isolée, 5 personnes avec infections indolentes / candidoses, dermatoses subchroniques, complications otologiques et etc., 7 personnes avec ségnes laboratoires / TS élevés, leucopénie et lymphopénie / sans signes cliniques.



Publications

B.615 PULMONARY HEMORRHAGE IN PNEUMONITIS OF HIV-INFECTED PATIENTS

Bridhat, Jeanne-Marie¹; Doré, M.F.²; Capron, F.²;
Veked, M.¹; Schmeure, J.¹

¹Department of Pathology, ²Laboratory of Anatomy and Pathologic Cytology; Hôtel Dieu; Paris; France.

Objective: Study the frequency of pulmonary hemorrhage (PH) in pneumonitis of HIV-infected patients by scoring alveolar macrophage hemoferritin load as described by Golse (Golse's score GS).
Results: On 16 of the consecutive 136 bronchoalveolar lavage (BAL) by 20 we diagnosed with a GS greater than 100 (mean value=125) and was occult in 14 cases. In one, a severe thrombocytopenia was concomitant (13,10⁹/l).

PH was associated with bacterial pneumonia (2 cases), opportunistic pneumonia (11 cases) and bronchopulmonary Kaposi sarcoma (3 cases).

A fatal outcome occurred in 2 cases (GS: 117 and 126). In 2 patients with an initial GS of 118 and 113, GS of control BAL performed 1 and 3 months later were respectively 35 and 0. In 3 patients, GS remained greater than 100 in a delay of 1 to 10 months, associated with persistent pulmonary multiple opportunistic infections.

Conclusion: Hemoferritin score is a semi-quantitative approach for the diagnosis of PH. However, in our series, this diagnosis was always associated with either bacterial or opportunistic infections or Kaposi sarcoma.

**Diagnostic
Diagnosis**
B.617 ETUDE DE LA SPECIFICITE DES ANTICORPS DETECTES CHEZ DES SUIJETS EN COURS DE SEROCONVERSION L'AIDE DE PROTEINES RECOMBINANTES

GAGLLE S., CHABOT C., LESTIER C., **HELANDER, Jean-François**,
Diagnostique Pasteur, Paris, France

Objectif : Montrer la prévalence d'anticorps directs préférentiellement contre la protéine interne p25 ou contre la glycoprotéine d'enveloppe gp120 lors de séroconversion.

Méthode : Les prélèvements sérologiques de sujets en cours de séroconversion ont été analysés par Western Blot et par un test ELISA fondé sur l'utilisation de protéines recombinantes (TRANSEPI, France). Les protéines prévalentes (p25) ont été testées par un ELISA indirect gp120 dirigé dans les cellules NK4 infectées par un virus recombinant de la coxécipier un ELISA indirect p25 (protéine sous forme native avec une souche EL-Cell transfected) et par un ELISA mixte gp120/p25.

Resultat :	ELISA	p25	gp	p25 + gp
100 sulfor. séro.	0,258	0,398	0,258	
Nombre de positivité (%)		2	0	
Nombre de négativité	(100/111)	(100/111)		

CONCLUSION : La majorité des séroconversions présentent des anticorps directs préférentiellement contre la gp120. Cependant la prévalence d'anticorps anti p25 chez certains sujets confirme l'intérêt de l'utilisation de deux protéines p25 et gp120 dans les tests de seconde génération afin de garantir le dépistage de toutes les séroconversions.

B.619 EFFICACY OF ADHESION RECOMBINANT HIV-1 gp120 ELA FOR EARLY DETECTION OF HIV INFECTION

LEUNG, P., ABRAHAM, P., HENDER, J., BRADY, V., PHELPS,
Laboratoire de Bactériologie, Hôpital St-Jacques, Paris, France

The greatest difficulty in HIV diagnosis in Europe is to trace at one's disposal an ELISA test sensitive enough to detect the levels of HIV-2 as well as HIV-1 antibodies in the seroconversion phase. The recombinant HIV-1 gp120 ELA by studying sequential sera from one HIV-2 and seven HIV-1 seroconversion patients.

Date	HIV-2			HIV-1		
	1	2	3	1	2	3
June 20, 1986	0,26	0,36	0,34	0,42	-	-
June 25	0,42	0,36	0,32	0,42	-	-
June 29	0,42	0,36	0,32	0,42	-	-
July 7	0,42	0,36	0,32	0,42	-	-
July 20	0,42	0,36	0,32	0,42	-	-
Aug. 11	0,42	0,36	0,32	0,42	-	-
Aug. 29	2,43	1,81	1,04	2,42	1,81	1,04
Sept. 7	1,81	1,04	0,42	1,81	1,04	0,42

1 ELISA 1 ELISA 1 ELISA 1 ELISA 1 ELISA 1 ELISA
1 ELISA 1 ELISA 1 ELISA 1 ELISA 1 ELISA 1 ELISA

1 ELISA 1 ELISA 1 ELISA 1 ELISA 1 ELISA 1 ELISA
1 ELISA 1 ELISA 1 ELISA 1 ELISA 1 ELISA 1 ELISA

**Aspects cliniques
Clinical Aspects of AIDS**
B.616 HEMOPTYSIS COMPLICATING PNEUMOCYSTIS CARINITI PNEUMONIA

YALOW, K.P. and LOMATSKY, E.
Dept. of Pathology, Mount Sinai Medical & Mental Health Center, Brooklyn, New York USA

Objective: To describe pulmonary destruction with hemorrhage associated with Pneumocystis carinii (PC) pneumonia.

Case Report: A 54 year old Hispanic female intravenous drug addict presented with hemoptysis of two days duration, fever, chills and productive cough. She had diabetes, lymphoma, generalized lymphadenopathy, oral candidiasis and bilateral rales. Radiograph revealed interstitial infiltrates in the right upper and left lower lobes, which subsequently became diffuse, and strongly suggestive of PC pneumonia. Bronchoscopic examination detected active bleeding from the right upper lobe bronchus, anterior segment. Bleeding persisted for five days. The patient's condition deteriorated to respiratory distress, right side pneumothorax, and she expired ten days after admission. At autopsy all lobes showed diffuse hyaline membrane formation, masses of PC in the alveoli and aggregates of foamy macrophages. In addition, the right upper lobe contained a few cavity lesions (0.3 to 1.0 cm) lined by granulation tissue, small remnants of bronchial epithelium, and dilated engorged blood vessels lined with the neovascular. Few PC organisms were demonstrated within the cavities but no other infectious agents were noted in spite of prolonged search with various special stains. It is noteworthy that the patient had survived an episode of PC pneumonia seven months earlier.

Conclusion: Hemoptysis in an AIDS patient may be a sign of PC pneumonia.

B.618 EVALUATION OF AN ULTRASENSITIVE ELISA FOR SPECIFIC DETECTION OF ANTI HIV 1

Bruhl, Stefan; Knapka, U.; Behringwerke AG, 3550 Marburg, FRG

Objective: To evaluate an improved competitive ELISA for the detection of antiHIV1 against HIV 1.

Methods: 100 µl undiluted specimens are diluted to 25 µl diluent buffer in each well of microtiteration plates coated with cell culture propagated HIV 1 antigens. The first incubation step over 60 min at 37 °C is directly followed by addition of ready to use conjugate (peroxidase labelled human Anti HIV 1). After 30 min (37 °C) and 5 washings H₂O, the chromogen TMB is added. The enzymatic reaction is stopped after 20 min (RT) with 0.5 N H₂SO₄ and readings are made at 450 nm. The cut off value is defined as 50 % of the negative control.

Results: The results on screening 643 Anti HIV 1 samples refer to a sensitivity of 100 % with clear cut positive inhibited O.D. values. The detection limit of Enzygnost anti-HIV 1 ultra was found to exceed that of western blot analysis by Factor 8. A panel of 13 sera derived from early stages of HIV 1 infections were found positive, even those which were negative in the Western blot and in commercial 2nd generation ELISA. A paired serum and plasma specimen.

Conclusions: In view of the fact, that Anti HIV 2-sera were found negative or weak positive, this ELISA in combination with a specific Anti HIV 2-test will help discriminating HIV infections.

B.620 DETECTION OF SERUM ANTIBODIES AGAINST THE GAG PROTEIN: A LATEST OF AN ADHESIVE INFECTION WITH AN HIV VARIANT

M. Theodoropoulos, R. Malherain, E. Spanakis, E. Antoniadou, V. Georgakopoulos
Reference Center of Crete, Venetian Hospital, Iraklio, Greece and School of Medicine, University of Athens, 11527 Athens, Greece.

Objective: To determine whether heterosubunit glycoprotein antigens apply the gag protein are highly HIV-related.

Methods: Peripheral blood lymphocytes (PBL) were co-cultured with the HIV-1 permissive CD4+ T-cells and the virus replication was evaluated by the reverse transcription activity (RT) and the p24 antigen and the culture supernatant (SN). However, the ultra centrifuged pellet of SN was tested for HIV by an RNA blot and also using specific cDNA probes. The membrane expression of p24 protein on PBL was evaluated by immunofluorescence using monoclonal integrated viral reagent were detected by Southern blot.

Results: PBL of 7/19 subjects expressed the p24 molecule (range 3-160) whereas p24 protein was detected on adherent cell but not PBL in an additional subject. gp120 was also expressed in the supernatant of the HIV-1 infected cell. The membrane expression of p24 protein on PBL was evaluated by immunofluorescence using monoclonal integrated viral reagent were detected by Southern blot.

Conclusions: These findings indicate that the HIV-1 variant is highly HIV-related and that the HIV-1 variant is highly HIV-related.

Publications



Section B
Aspects cliniques
Clinical Aspects of AIDS

B.633 NATURAL HISTORY OF HTLV-I INFECTION
Shibuya Tachibana*, K. Tsuda*, M. Yoshida*, M. Esse****,
N. Noel-Huet**

*Miyazaki Medical School, Miyazaki, Japan. **Cancer Institute, Tokyo, Japan.
Harvard School of Public Health, Boston, MA. *Harvard School of Public Health, Boston, MA.

Objective: To describe the natural history of HTLV-I infection within an endemic area of Kyushu, Japan.

Methods: A population based cohort established of approximately 1600 adult residents of two villages, of whom 505 are HTLV-I positive. HTLV-I antibody titer was determined by MA and proviral DNA in carriers lymphocytes was investigated.

Results: Antibody titers of sixty percent of carriers ranged between 512 and 2048. Of 78 consecutively determined for four years, 63 kept the same titer. During this period 7 seroconversions have been observed. No HTLV-I case has been observed, however among 40 carriers tested for proviral DNA in the lymphocytes, a sample from a healthy woman presented the pattern of serological interpretation. Thirty-six percent of her lymphocytes was tit positive but the abnormal lymphocyte count was less than one percent, suggesting to be in the preclinical stage.

Conclusions: Continuing the surveillance on carriers in association with preclinical stage is important in understanding of natural history and may provide a lead to elucidate the factors in leukemogenesis of the virus.

B.635 IDEAL ASSAY OF HIV-1 AND HIV-2 ANTIBODY USING ANTI-PC-E2A WITH RECOMBINANT HIV-1 AND HIV-2 ANTIGENS - CHANGING HANDS
J. Zhou, M. Beigel, R.M. Thoen, G.A. Balis, D.J. Anderson, et al. Cambridge Biotechnology Corporation, Worcester, MA, USA.

Objective: To develop a recombinant antigen immunoassay (RIA) that has the capacity to detect both HIV-1 and HIV-2 antibodies in human sera. Virus specific antibodies were then detected by peroxidase-labeled recombinant HIV-1 and HIV-2 antigens using individual antigen conjugates or mixtures. 200 HIV-1 positive, 80 HIV-2 positive, 2 HIV-1 and HIV-2 co-infections, 1027 HIV-2 negative blood donors, and a seroconversion panel were evaluated. In addition, dilutions of positives were also tested.

Results: The assay identified all the positive samples tested using individual antigen conjugates. No significant change in positive signals were observed when both antigen conjugates were used. The HIV-1 and HIV-2 antigened samples produced additive signals. This assay could detect HIV antibody as early or earlier than current viral lysate RIA's using an HIV-1 seroconversion panel.

Conclusion: In this RIA test, each antigen conjugate reacted with their respective target antibodies independently. This RIA system can be used to detect both HIV-1 and HIV-2 antibodies in one test without significant loss of sensitivity for antibodies to either virus.

B.637 FOCUS OF HIV-1 ASSOCIATED TROPICAL SPASTIC PARAPARESIS IN EQUATORIAL ZAIRE
Rasani, K., Deamter, Jan*, Goubeau, P., Curtin, H.,**
University Hospital, Kinshasa, Zaire; ** Sage Institute and University Hospital, Leavenworth, Kansas.

Objective: To present the first focus of HIV-1 associated tropical spastic paraparesis (TSP) in Africa. Only 5 sporadic cases are known in Africa, although Africa has the largest world reservoir of HIV-1.

Methods: Search among chronic paraparesis patients from Lissala, population 50,000, Equateur Province, Zaire, by HC and KK. Elisas and immunoblots by PA and WB.

Results: 39 cases (11 men, 28 women) of HIV-1 associated TSP were identified: 21 by direct examination, and 18 in close blood relatives of 10 of the above, as derived from typical history and confirmed in all 4 examined. 7 mothers but no fathers or spouses of TSP patients had TSP; 3 familial cases were in paternal relatives. Half of the patients were Wandungu who represent 10% of the population (p<0.01). Presentation, history, serology and spinal fluid findings were as seen elsewhere.

50% of healthy close relatives had anti-HIV-1. Patients were anti-HIV negative.

Conclusions: This first African focus is probably the largest in a population of similar size worldwide. The familial clustering observed can only be explained by cofactors in addition to HIV-1. Some epidemiological definitions of the disease would have missed many true cases and they should be revised.

B.634 PREVALENCE OF HTLV I/II INFECTION IN BLOOD DONORS AND HIGH RISK GROUPS IN THE U.S.
Szaferan, J., Falker, L.,** Krommel, E.,** Mann, T.,**
Osake, M.,** and Lane Huet** *Molbiol Laboratories, North Beach, IL, USA
** Duke University Medical Center, Durham, NC, USA ** Kagoshima University, Kagoshima, Japan

Objective: To determine the prevalence of HTLV I exposure among HTLV seropositive donors and high risk populations in the U.S. METHODS. Specimens from 11 drug abusers (IVDA), blood donors and high risk groups such as hemophiliacs and homosexual were collected between 5/87 and 10/88 and tested for antibodies to HTLV I by EIA. Repeat EIA positive samples were confirmed by Western blot and SCS-RT-PCR.

CATEGORY	NO. TESTED	EIA +	CONFIRMED
IVDA	1032	226	0.04
Volunteer Blood Donors	6612	24	0.23
Plasmapheresis Donors	6200	14	0.23
Hemophiliacs	145	2	0.00
Homosexuals	152	2	1.30
ITP/IMW	41	39	95.12
Contacts of IAL	40	15	36.2
TP/SMW	12	5	41.7

CONCLUSION: TSP occurred in the USA seropositive for HTLV I/II infection in 100 U.S., 112.5% of HIV-1 alone and a further 8.26 HTLV I coinfected with HIV-1. Unlike HIV, hemophiliacs and homosexuals are not risk groups. Plasmapheresis donors show five times higher seroprevalence rates when compared with volunteer donors.

B.636 DETECTION OF EARLY HTLV-I SEROCONVERSION (SC) BY ELISA
Rasani, K.,** Murphy, E.,** Wilks, R.,** Blanchard, B.,**
Drummond, J.,** Waters, D.,** Swanson, P.,** Lee, H.,**
Blattner, W.,** MCI, Bethesda, MD, **CSF, San Francisco, CA, **Min. of Health and Welfare, Jamaica, **F. Frederick, MD, Chicago, IL.

Objective: Evaluate sensitivity of HTLV-I screening and confirmatory assays during SC among transfusion recipients (TRC).

Methods: Pre-transfusion exposed TRC from Jamaica, followed at monthly intervals, were tested by WB (DuPont and Abbott) and recombinant envelope (rev) (Cambridge Biotech.) EIA, Western blot (WB) and radioimmuno-precipitation (RIPA) using IOT-105/03/02/03 cell lines. Receiver's test was used to detect differences in sensitivity.

Results: 12 of 58 TRC, 9 with >1000 copies of follow-up, and 8 with persistently positive SC patterns were analyzed. 58/93 samples were WB p24+24 positive. WB was used as reference for comparing test performance.

EIA	EIA2	WB	RIPA	*one sample not tested
40/58	44/57	58/58	48/58	+fwd criteria

(96%) (77%) (100%) (81%) 2 case seropositive (WB, WB) WB was more sensitive than EIA and EIA2; WB was as sensitive as WB, but specificity was not evaluated. WB detected antibody earlier than other methods; early gag protein patterns preceding TSP SC were either p19 only, p24 only, or p19p24 +/- other bands. Sensitivities between the two W EIA's were not significantly different (p=35).

Conclusion: Two W EIA's had comparable sensitivities in this population of exposed transfusion recipients. Patterns showing either p19 or p24 only preceded FDA seroconversion criteria via WB determination. EIA or EIA2 may be an alternative to RIPA as a confirmatory test.

B.638 HIV P24 ANTIBODY IN ASYMPTOMATIC, PA, AND AIDS PATIENTS AT GATHINI: A CLINIC OF UNIVERSITY HOSPITAL, HUS IN AMERICA
Meyer, Ramona, Sams*, Salazar-Gonzalez, M.,** Dubreuil, E.,** Grace, M.,**
** P. Meyer, M.D., C.A. Collins, L.D., M.D.,
* Gathini & Gathini University, HUS in America University (HUS) - Brazil.
** F200A2

Objective: To determine the presence of p24 antigen in patients with different clinical status of HIV infection.

Methods: Serum HIV p24 antigen measured by antigen capture ELISA (Abcoat**). Laboratories, North Chicago, IL. USA) was performed in 125 patients who met the Surveillance case definition of not infection by Centers for Disease Control (CDC), 100(21), 100% distributed as ORP 2+ = 4), ORP 1+ = 30 and ORP 0 = 10.

For statistical analysis we used the statistic χ^2 (2x1-square), matching for the linear tendency (Spearman, ρ - Statistical Methods in Medical Research, John Wiley and Sons - N.Y., 1971).

Results: Overall, 52 of 125 patients tested for antigenemia were positive (41, 8%). The distribution of these patients according to CDC's criteria is shown in following table:

CDC'S GROUPS	TOTAL NUMBER	ANTIGENEMIA	
		NUMBER	%
II	41	22	53.7
III	30	10	33.3
IV	54	10	18.5

$\chi^2 = 39.10$, $P < 0.001$ χ^2 for departure from linear trend = 2.08 $P < 0.05$
Conclusions: There is a clear evidence of association between antigenemia and clinical status. There is also a definite trend which results in progressively small increases in the proportion of p24 antigen as it changes successively to lower categories.



Publications

Aspects cliniques
Clinical Aspects of AIDS

- B.639** INTRACUTANEOUS TESTS WITH HERPETOUS ANTIGENS AND CD4-CD8 DETERMINATIONS IN AIDS
 FERRAZ ROBERTO, CAVALLINHO, M. J. FREIRE, C. J. LEVI, P. J. AGOSTINI, C. J. MENDES, N. et al.
 Escola Paulista de Medicina, São Paulo, Brazil.

Objectif: To correlate simple immunological parameters with the clinical classification of AIDS.
Méthode: A total of 172 AIDS patients classified according to CDC criteria were tested in vivo with HIV, candidin, trichophyton and streptococcus-*streptococcus* test. Absolute numbers of CD4 and CD8 lymphocytes were also determined.
Résultats:

	2 or more positive cutaneous tests	mean of 3 CD4 cells/mm ³	mean of 3 CD8 cells/mm ³
Group II and III (n=61)	694	760	1067
Group IVa (n=3)	308	279	796
Group IVb and IVc (n=3)	178	379	481

Conclusion: A progressive decrease in the reactivity to intracutaneous tests with ubiquitous antigens and in the absolute numbers of CD4 and CD8 cells was observed across the clinical spectrum of AIDS, emphasizing the value of these procedures.

- B.641** ASPECTS CLINIQUES HIV1 ET HIV2 ET CLASSIFICATION DE BANGUI
 Sow Ah. A., Coll. Ang. Marika*, Fay/Miso M.A., Drouf G. J., Feller-Sandhu L. J., Dip B. A. et al.
 * Service des Maladies Infectieuses, C.H.U. de Dakar.

Objectif: Evaluer la sensibilité et la spécificité des critères de diagnostic clinique du SIDA HIV1 définis à Bangui et proposer leur élargissement éventuel au SIDA HIV2.
Méthodes: Etude rétrospective de 73 cas de SIDA HIV1-HIV2 hospitalisés de Janvier 1986 à décembre 1988 au Service des Maladies Infectieuses du C.H.U. de Dakar. Une cohorte de témoin (patients suspects mais sérologiques) a été étudiée. Les critères de la classification de Bangui ont été recheckés pour chaque cas et une étude comparative statistique a été effectuée.
Résultats: Sur 73 cas de SIDA.
 49 HIV1
 22 HIV2
 3 douteux

Le sero-test est de 2-4. Le grand majorité des malades HIV1 comme HIV2 présentent les signes majeurs de la classification de Bangui: amaigrissement > 10%, diarrhée > 1 mois et fièvre > 1 mois. Les manifestations cliniques HIV1 et HIV2 sont comparables dans notre série. Un pourcentage non négligeable de suspects ont eu une sérologie négative (sensibilité 0).
Conclusion: L'élargissement à HIV2 de la classification de Bangui est proposé mais une validation est possible.

- B.643** DETECTION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) DNA SEQUENCES IN SEROPOSITIVE PATIENTS AND SERONEGATIVE AT RISK SUBJECTS BY POLYMERASE CHAIN REACTION (PCR)
 Fabrizio Enoli, V. Fiorelli, L. Mezzarona, F. Aiuti

Dept. of Allergy and Clinical Immunology, University of Rome, Rome, Italy
Objective: To investigate the earlier stage of the infection we detected HIV-1 DNA sequences in seronegative people at high risk as drug addicts and partners of seropositive subjects and seropositive patients classified according to CDC criteria. Normal blood donors were employed as controls.
Methods: Genomic DNA's collected from PCR of seropositive and seronegative people were subjected to forty cycles of amplification. Two primer pairs for different conserved regions of the env gene were used. Specificity of amplification products was confirmed by Southern Blot. Serology was assessed by Western Blot; antigenemia by an Elisa system.

Results: Almost all seronegative people at high risk were confirmed negative by DNA amplification; individuals that resulted positive for HIV sequences also seroconverted after a few weeks. On the other hand no HIV sequences were detected with these primer pairs in a small percentage of seropositive but antigenemia negative individuals.
Conclusion: PCR coupled with serological techniques is very useful to investigate the HIV infection especially in those cases in which serology remains silent or unclear. Studies are in progress with primer pairs for different regions of HIV genome to better characterize the integrated sequences during the disease.

- B.640** PREDICTIVE VALUE OF THE DETERMINATION OF HIV-1 Ag IN SERUM
 Leal, M., Pineda, Juan A., Calderon, E., Navarro, M., Roy, G., Lissen, E., et al.
 University of Seville, Seville, SPAIN.

OBJECTIVE: To assess the predictive value of the determination of HIV-1 Ag in Serum.
METHODS: We have tested for HIV-1 Ag by EIA E12 serum samples sequentially collected from 51 Anti-HIV-1 positive patients. On an average, they had been followed during 42.10 (range 24-73) and 4.15 (range 1-11) (range 1-2) serum samples had been taken from each patient. All of the subjects were at the stage II or III of the current CDC classification for AIDS related diseases at the beginning of the study.

RESULTS: The overall follow-up time and the number of samples taken from each patient were similar for those developed AIDS and those that did not. 316 patients were found to be antigenic at entry. Eight of the remaining 44 seroconverted during the follow-up. Seven of the 14 (50%) (range 1-2) serum samples had been taken from each patient. All of the subjects were found to be antigenic in some time developed AIDS (stage IVc). The passage of time from the first evidence of HIV-1 Ag to the diagnosis of AIDS ranged from 1 to 73 months. All of the remaining 37 patients are still at the same clinical stage.

CONCLUSION: These results show a close association between the presence of HIV-1 Ag in serum and poor prognosis of HIV-1 infection. On the other hand, the rate of AIDS developing among antigenic patients observed by us is one of the highest reported so far.

- B.642** ETUDE DE LA VALEUR DIAGNOSTIQUE DU WESTERN BLOT CHEZ 113 SIDAIS
 M. Boreau*, D. Kervadec*, P. H'Pajot*, N. Copin*, F. Vallet*, A. Itou-Agopost*, M. Gentilini*

*Unit of Médecine Tropicale, Hôpital Pasteur et Unité INSERM 313, 47 Bd de l'Hôpital, Paris, France. **Médical Général de Brézillac, Gironde, France.

Méthode: L'usage d'un échantillon de type rétrospectif. Les cas sont les patients répondant à la définition clinique du SIDA (effectifs). Les sérotests sont les durures de sang considérées (effectifs). Les sérotests ont été répétés en cas de doute ou trace, et bande nette.

Résultats: Les valeurs ont plus souvent des Ac gp41 : chiz 1:625 p 0,02, odds ratio (OR) = 2,17. La même constatation a été faite pour les Ac gp120 : chiz 1:640, p 0,0003, OR = 3,36.

Il n'a pas été trouvé de valeur sur Ac gp25. Les sérotests ont été répétés en présence d'au moins un des deux Ac anti-gp d'une part, et absence des deux Ac d'autre part : une liaison a été également trouvée (chiz = 13,2, p = 0,028, OR = 5,36). La liaison persiste pour la gp120 lorsque l'on mesure l'OR de la gp41, elle disparaît pour la gp41 lorsque la gp120 est négative. Cependant, la liaison persiste pour la gp41 dans le groupe absence de gp120.

Discussion: Nous n'avons pas trouvé au Congo de liaison statistique entre le stade clinique et la présence d'Ac gp25. Nous avons montré qu'est associée à un mauvais pronostic la présence d'Ac gp120, la présence d'Ac gp41 chez les patients n'avait pas la gp120.

- B.644** CONTROL DE QUALITE DES TESTS DE DETECTION ET DE CONFIRMATION DES ANTICORPS ANTIVIRUS (WESTERN BLOT) DES ANTICORPS ANTIVIRUS - 160
 MULLIGAN L. J., FRANCOIS E. J., CHERRY J. J., COORNEAU A. M., et al.
 Le Service de Sérologie.

1 Laboratoire National de la Santé - Département de Biologie Médicale Paris France.
 2 Société Nationale de Transfusion Sanguine.

Objectif: Contrôle de qualité national des laboratoires déclarant pratiquer le test de confirmation (Western Blot) des anticorps anti HIV - 160 laboratoires.

Méthode: Les laboratoires ont reçu 3 séries de 8chantillons de plasma, sur lesquels ils effectuent conformément à la circulaire du 24-02-87, deux tests de dépistage et un test de confirmation. Les 12 plasma correspondent à : 6 HIV1 dans 3 débuts de séroconversion et un cas de séide, 3 non sérologiques 2 p25, 1 p18, 2 négatifs, 1 HIV2.
Résultats: 5 résultats de dépistage et 3 résultats de confirmation ont été utilisés. Au total : 90 erreurs sur 1472 dépistages ont été faites par les laboratoires (taux réactifs confus (soit 6,3 %).

	HIV1	HIV2	non spécifique	négatif
% d'erreurs de diagnostic	8,2 %	4,1 %	7 %	0,6 %

Les résultats des laboratoires en fonction des réactifs utilisés seront détaillés.
Conclusion: Ce contrôle a permis une amélioration des performances des laboratoires et des réactifs.

Publications

Aspects cliniques
Clinical Aspects of AIDS**B.645** THE USE OF GRAPHIC ART TO MEASURE NEUROPSYCHOLOGICAL FUNCTION IN HIV-INFECTED PERSONS

Spachis, Phyllis* and Peabody, B.**
*USCD Medical Center, **AIDS ART Project, San Diego, CA, USA.

Objective. To measure neuropsychological function in people with HIV infection through their artwork.
Methods. Twice-weekly, 3 hour sessions for HIV-infected persons for ART therapy/instruction generated written and photographic observations of artwork and behavior of 75 patients over 44 years. In an unstructured, group setting, an AIDS-sensitive therapist familiar with multiple art media (water-based paints on paper, oil and chalk pastels, ink, oil paint on canvas, markers, collage using art tissue and "found" objects) developed close relationships with patients leading to verbalization of problems and evidence of patient's physical and neurological deficits.

Results. Illustrative case studies of 5 AIDS patients demonstrated that changes in composition, subject matter, and color selection correlated with 1) progressive cognitive and affective deterioration (2 pts), 2) improved physical and cognitive status during ART therapy (1 pt), and 3) incipient seizures (2 pts). For example, within hours to days of first painting characteristic, red, vertical stripes, 2 patients had generalized seizures.

Conclusion. In addition to its therapeutic value, artwork may provide a useful diagnostic approach to neuropsychological dysfunction in AIDS by illustrating changes in cognitive function and affect and by predicting seizures.

B.647 ADVERSE EFFECTS TO ZIDOVUDINE-ALFAMANDOPROL (ZAP-90) TREATMENT OF PRESYMPTOMATIC DANGEROUS PRENATAL (DPP) IN AIDS

Spagnoli-Ferraz, J., Alvarez, V., Polo, R., Herreros, J., Alvarez, R., Agudo, J., G.

Instituto de Salud Carlos III, Hospital del Rey - Servicio de Medicina Intensiva -

Toxic effects of ZAP-90 treatment of FDP are frequent in American-AIDS patients with AIDS.

Higher tolerance to this treatment has been reported in Non-American AIDS patients. Our experience is reported here.

Methods: 43 patients with HIV infection and a first episode of FDP diagnosed by serology with histological evidence. Sample were retrospectively evaluated. Patients received ZAP 20 mg/kg/day and 500-1000 mg/kg/day ZV for at least 7 days. Mean age was 30.2 years (SD=6). 26 patients were male. 12 patients had previous drug abuse (10A), 9 non-smokers, 3 behavioral partner of 10A - and 2 had no recognizable risk factor.

Results: Adverse effects were identified in 20 patients (46.5%).

- Nausea/vomiting: 11 (25.3%) <50% ZV - Nausea: moderate: 3 (6.9%)

- Headache: moderate/severe: 5 (11.6%) severe: 1 (2.3%)

- Rash: moderate: 1 (2.3%) - Vomiting: 8 (18.6%)

> 3 mg/kg/day ZV

- Discontinuation of treatment because of severe toxicity: 6 (13.9%)

- Creatinine: 1.5-3 mg/dl: 1

- Neutropenia <500: 2

- Neutropenia (100-500)-vomiting severe: 1

- Rash severe: 1

Conclusion: Although toxicity is frequent, discontinuation of ZAP-90 treatment is needed in a minority (13.9%) of patients. Modified differences in renal frequency between our patients and American-AIDS patients are observed.

B.646 OUTCOME OF ADVANCED MATERNAL AIDS IN OFFSPRING

*Mweshi, Farzin, *Kabona, M.
Department of Pediatrics, Mwaneta Hospital, Kinshasa, Zaïre.

Objective: To define the outcome of advanced maternal AIDS in offspring.
Methods: We followed 20 infants born to mothers with advanced clinical AIDS.
Results: Eighteen mothers had produced 7 twins and 16 singletons. Mothers were all ill at the time of delivery. Four died within 4 weeks of giving birth. Two had tuberculosis and one had Kaposi's Sarcoma. The others were hospitalized for AIDS. All 20 babies were born small for age. Six babies were born at term weighing from 1830-2500 grams. Fourteen were born at 30-38 weeks of gestation, weighing from 1000-2000 grams. All newborns were doing poorly at birth and manifesting the following clinical signs after birth: 20 (100%) with asthenia, 13 (65%) with diarrhoea, 13 (65%) with respiratory infections, 9 (45%) with fever, 9 (45%) with anaemia, 6 (40%) with oral candidiasis, 6 (30%) with vomiting, 3 (15%) with neurological complications, 3 (15%) with physiological jaundice, 2 (10%) with pyrexemia and 1 (5%) with splenomegaly. In the course of hospitalization, one term infant was sent home to a stable condition. A second infant, who weighed 1340 grams at birth, gained 280 grams and was discharged in satisfactory condition. Of the remaining 18 newborns, 6 died within the first week of life and 12 died within 2 months of birth.
Conclusion: HIV seropositive mothers infect 30-40% of their offspring, however. In our series, advanced maternal AIDS was associated with a significantly higher maternal and neonatal morbidity and mortality. There was 2/8 maternal and 9/28 neonatal demise shortly after delivery.

B.648 ADVERSE EFFECTS OF LIDARTINE (LID) IN PATIENTS WITH HIV INFECTION


MC VALENTIN, V. PINTADO, M. FRANCIS, P. LAVILLA, OML DUPLA, A. OIL
Hospital La Paz, Madrid, Spain.

OBJECTIVE: Assessment of adverse effects (AE) to lidartine in patients with HIV infection in an intensive pharmacologic surveillance program.


MATERIAL AND METHODS: 33 patients were entered. 22 patients fulfilled AIDS criteria, 3 patients had a group III (IG) infection, 3 group IV-A infection, 2 group IV-B infection. 11 patients were drug abusers, 4 were homosexuals, 1 bisexual, and one was a heterosexual partner of an HIV carrier. Mean age was 39 years (range: 11-61). 23 were males. LID dose was 1200 mg/day. This dose was modified upon hematologic parameters. An intensive pharmacologic surveillance program for detection of AE, with toxic a watch exhibited during first three months, and thereafter monthly was begun.

RESULTS: 1) Hematological toxicity. 11 patients showed anemia (IG). In 9 it was severe (23) (hemoglobin < 11 g/dl). Anemia usually began between 7th and 17th week of treatment. It was recurrent, unstable, and required transfusion of 1 unit of erythrocyte concentration per patient. In one case, neutropenia was observed in 6th of case, neutropenia in 10th. 3 patients showed granulocytopenia. 2) Gastrointestinal toxicity. In 5 patients (15) severe nausea and vomiting required symptom of therapy. 3) Neurologic toxicity. 4 patients showed blue-colored nails (IG), and one patient showed diffuse cutaneous hyperpigmentation. 4) Renal toxicity. In one case there was a transient increase in serum creatinine that subsided after withdrawal of therapy. 5) In total, no toxicologic toxicity was observed.

CONCLUSIONS: 1) Hematologic toxicity was the most severe AE observed, requiring modification of therapy, but not cessation. 2) Gastrointestinal toxicity, although common, was the severe tolerated. 3) Changes in cutaneous and regional pigmentation are a new contribution to the AE constellation of LID.



SECTION C



Recherche fondamentale (biomédicale)

Basic Research (Biomedical)



Colloque
SymposiumRecherche fondamentale (biomédicale)
Basic Research (Biomedical)Mécanismes de pathogénèse du VIH
Mechanisms of Pathogenesis of HIV

M.C.O.1 VIRAL AND HOST FACTORS INFLUENCING THE PROGRESSION TO AIDS. **Jay L. Liebo, Cheng-Mayer, C. Walker, C. and Honey, J.**
Dept. Medicine and the Cancer Research Institute, University of California, School of Medicine, San Francisco, CA 94143.

A basic question in AIDS is why the time to development of clinical symptoms and progression to disease differs widely among HIV infected individuals. The vast heterogeneity in the biologic, serologic, and molecular responses among HIV strains offers one explanation. In particular, their differential ability to infect different cell types (both CD4+ and CD4-) to replicate rapidly in these cells, to cause cytopathic changes, and to be neutralized by various sera has been demonstrated. Moreover, certain isolates appear more sensitive to serum enhancement. Furthermore, the interaction of the HIV *env* gene product with the viral LTR, a state of latency can be induced that may delay or prevent disease in the infected individual. Our studies have indicated, for example, that individuals with a rapid progression to disease have viruses that replicate rapidly and are more cytopathic with a wide cellular host range. Moreover, brain and blood isolates can be distinguished by their relative ability to grow in macrophages and lymphocytes, to modulate the CD4 antigen on T cells, and by their serologic properties. Molecular and protein studies have indicated a relationship of some of these biologic activities with changes in protein and genetic structures.

The host immune response also plays a substantial role in determining the HIV pathogenic process. Antibodies that enhance virus infection can permit HIV spread to several different cell types including lymphocytes, macrophages and fibroblasts. Cellular immune responses can destroy virus-infected cells or suppress virus release, via the production of antiviral cytokines or mechanisms involving cellular interaction. Thus, the dynamics of a quickly changing replicating virus and an active immune system provides an important "key" to whether an individual has a long asymptomatic course or a rapid progression to AIDS.

M.C.O.3 ROLE OF N-LINKED GLYCOSYLATION IN HIV INFECTION. **Guickman, Jean-Claude*, Farnoulet, E., Garreau, L.,***, Ciergel-Rastain, B., Montagner, L.,***, Bahroui, E.,*****
*CERVI, Hôpital de la Pitié, Paris ; ** Laboratoire de Biologie Cellulaire, Faculté de Médecine Paris-Nord ; *** Unité d'Oncologie Virale, Institut Pasteur, Paris, France.

N-linked glycans represent 50% of the MW of HIV *env* gene product, and glycosylation sites are well conserved among different isolates. Carbohydrate oligosaccharides (CHO) are likely to be prominent structures on the virus surface, although their precise role is still poorly understood. We have demonstrated that complete enzymatic removal of glycans from recombinant gp120 or gp160 (gp120/160) in the absence of denaturing agents does not significantly modify *in vitro* interaction with its CD4 receptor : deglycosylated gp120/160 attached to soluble or membrane-bound CD4 with comparable affinity and inhibited fusion of HIV-infected and non-infected cells to the same extent than glycosylated gp120/160. This apparently contradicts a previous observation that deglycosylated native viral gp120 (gp120) displayed markedly reduced binding capacity to CD4. Differences between these observations may stem from technical conditions, or they may be related with differences in the glycosylation patterns of gp120 and gp160 that could result in functional differences of the glycan moieties. In addition, experiments conducted with glycosidase inhibitors that interfere with early oligosaccharide processing indicate that CHO may play a role at a post-translational level and be involved in other functions of gp120/160 in relation with post-binding events. *Env* glycoproteins may also interact with extra-cellular or cell-membrane lectins, especially on mononuclear phagocytes. On the other hand, our recent data suggest that gp120 behaves as a lectin, binding D-2-N-acetylglucosamine. These properties might be used by HIV to attach to cell membranes independently of CD4 and be one of the explanations that HIV can infect CD4+ cells under some circumstances. Finally, CHO chains may intervene in the immune response to HIV either by directing responsiveness to certain sites or by masking part of gp120/160 epitopes.

M.C.O.2 IMMUNE RESPONSE TO HIV
John Lullman, University of Massachusetts,
Dept. of Pediatrics, MA, USA.

M.C.O.4 NEW APPROACH TO THE STUDY OF OLIGOSACCHARIDES AS DETERMINANTS OF THE TISSUE TROPISM OF HIV-1.

Tom Felix
MRC Clinical Research Centre, Watford Road, Harrow, Middlesex, United Kingdom

The envelope glycoprotein, gp120, of the human immunodeficiency virus (HIV-1) is highly glycosylated with a diverse array of N-glycosidically linked oligosaccharides^{1,2,3}. We have proposed⁴ that these oligosaccharides which are likely to be prominent structures on the virus surface, are candidate attachment and addressing factors in the host at various stages of the virus cycle. This communication will be concerned with the molecular dissection of oligosaccharide-mediated interactions by a novel approach involving the generation of oligosaccharide probes from the envelope glycoprotein.

1. Mizuochi, T., Spillman, M.V., Larkin, M., Solomon, J., Bess, L.J. & Felix, T. *Biochem. J.* 254, 593-603 (1988).
2. Mizuochi, T., Spillman, M.V., Larkin, M., Solomon, J., Bess, L.J. & Felix, T. *Biochem. J.* 260-270 (1989).
3. Gezer, E., Kuleshbach, C., Hunsmann, G. & Schneider, J. *Biol. Chem.* 263, 11760-11767 (1988).

Séance thématique Specialty Session



Recherche fondamentale (biomédecine)
Basic Research (Biomedical)

Biologie moléculaire : Diversité génomique et ses liens aux aspects cliniques Molecular Biology: Genomic Diversity and Relationship to Clinical Aspects

M.C.C.0.5 GENETIC ANALYSIS OF HIV DERIVED FROM MANDELLI (SI)_{MAN}
Teujimoto, H.*; Hasegawa, A.**; Cooper, R.V.**; Fukasawa, K.*;
Mura, T.**; Hasegami, H.**;*** et al.
*Institute of Microbiology, University of Tsukuba, Japan, **Toyo Nenryo
Kogyo K.K. Japan, ***Centre International de Recherches Médicales de
Francoville, Gabon, ****Institute for Virus Research, Kyoto University,
Japan.

Objective: To understand genetical relationship and phylogenetic epidemiology of HIV/SIV group.
Methods: Two isolates of SIV were obtained from apparently healthy mandrill in Gabon. One of them was molecularly cloned from the circular replicative intermediate DNA by linearization with one-sam. restriction enzyme, and totally sequenced by the methods of Sanger et al.
Results: Gene structure of SIV_{MAN} is almost equal to other HIV/SIV, but the open reading frames such as gag and pol were uncertain. The amino acid sequence homologies of each open reading frame to other HIV/SIV (GIV-1, HIV-2, SIV_{MAC} and SIV_{PAO}) were almost equal, about 80% in gag, 80-60% in pol, and about 20% in env regions.
Conclusion: The SIV_{MAN} was totally sequenced and was considered to be a new member of HIV/SIV group, equally distant from other HIV/SIV including SIV_{MAC}. It suggests the species-specificity of SIV group and unlikelyness of recent interspecies transmission among primates.

M.C.C.0.7 PROSPECTIVE CLINICAL, IMMUNOLOGICAL, AND VIROLOGIC FOLLOW-UP OF AN INFECTED LAB WORKER (LV)
Ballinger, M.*; Hara, P.*; Shaw, G.*; Hahn, B.*; Kemp, L.*; J.C. Newman, F.*; Williams, D.*; Gallo, R.* National Cancer Institute, Bethesda, MD; #U of Alabama, Birmingham, AL; *Duke Univ., Durham, NC; **FRI, Durham, NC.

Objective: Follow natural history of accidental laboratory acquired infection with HIV-1LV-11lg strain.
Methods: Sequential isolations (SI) obtained by cocultivation (Science 235:16, 1986). Neutralizing antibodies (NA) measured by virus infectivity syncytium inhibition assay (AIDS Res. and Hum. Retro. 3:228, 1987). Nucleotide and deduced amino acid sequences of the viral envelope gp120 immunodominant loop region (a 302-327) determined for Cloned SI. CD4 counts by FACS.
Results: LV is clinically healthy. CD4 counts show an initial lymphopenia (CD4 (375) and CD8 (426) 11 months after initial sample), rising over the next six months to a currently stable value at 28 months of CD4 (860) and CD8 (470). NA responses show an initial low titer type specific immune response which broadened over time. Heterologous hyperimmune glob anti HIV-1LV-11lg are used to block infection by SI in a syncytium inhibition assay demonstrated a shift in neutralization profile away from parent virus. Sequential point mutations representing a total of 9 amino acid substitutions over a 28 month period in the immunodominant loop were detected.
Conclusion: Cumulative changes in immunologically relevant domain of the HIV-1 envelope may reflect serial mutations of the virus or selection of coincidentally present substrates as part of a repertoire to avoid the host immune response.

M.C.C.0.9 REPLICATIVE CAPACITY OF SEQUENTIAL VIRUS ISOLATES FROM HIV-1 INFECTED SUBJECTS AND RELATIONSHIP TO CLINICAL PROGRESSION
Eva M. Fegans*, Albert J.**, Manfredi-Mansueti, L.* and Asjö, B.* Departments of Virology, Karolinska Institute* and National Bacteriological Laboratory**, Stockholm, Sweden.

Objective: To study changes in the replicative capacity of HIV-1 that occur in the same individual over time.
Methods: High passives were followed with sequential virus isolations during a 30-month observation period.
Results: Patients with stable lymphocyte nadir (LAS) yielded slow/low viruses on repeated isolations. Viruses isolated from patients during the period of clinical progression from LAS to AIDS-related complex (ARC) showed increasing replicative potential. In sequential virus isolates from patients with ARC, the replicative potential of sequential virus isolates fluctuated during the observation period. Accordingly, changes from slow/low to rapid/high and back to slow/low replicative potential, could be observed. One patient showed a rapid development of severe immunodeficiency, progressing from LAS to AIDS within one year. Viruses isolated during this period replicated with increasing efficiency in vitro.
Conclusions: The results show that HIV-1 isolates with distinct replicative capacity may be obtained from the same individual over time. Rapid clinical progression is often accompanied by the emergence of variant viruses with increased replicative capacity.

M.C.C.0.6 GENOMIC DIVERSITY OF SIV GROUP OF VIRUS.
Fukasawa, M.*; Ohta, Yoshitaka, Ishikawa, T.*; Sasaki, K.*;***
Ishikawa, M.*;***; Hayami, M.*;*** et al.
*Institute of Medical Science, Tokyo University, Institute for Virus Research, Kyoto University, **Toyo Nenryo Kogyo, Japan, ***Institute of Primate Research, National Museum of Kenya, Kenya.

Objective: To estimate the genomic diversity among various isolates of simian immunodeficiency virus from African green monkey (SIV).
Methods: The full- or partial-length of viral DNA of 4 HIV₁ isolates from African green monkey originated from different places, SIV_{MAC} (T9-2), (T9-5) and (T9-7) and (K1) were molecularly cloned from their virus infected cell lines and were compared with previous reported isolate, SIV_{PAO} (T9-1) by restriction endonuclease mapping.
Results: All the isolates are strongly hybridized with SIV_{MAC} (T9-1) probe. The gel end probes of HIV-1, HIV-2, SIV_{MAC} and SIV_{PAO} (T9-2) and (T9-5) and (T9-7) are as long as (T9-1) and once digested by EcoRI, NotI, SmaI, their restriction sites (including EcoRI, HindIII, Bam I, Sac I, Sma I etc.) were great divergence not only for their region but also in other regions. The genome sizes of SIV_{MAC} (T9-1) and (K1) are shorter than those of others, and are divergent from SIV_{PAO} (T9-1).
Conclusion: The genomic diversity of SIV_{MAC} group might be as well as (or greater than) those of other HIV/SIV groups although all the isolates belong to the one group. HIV-1 heterogeneity was also observed in the virus isolated from one animal as seen in HIV-1 infected person.

M.C.C.0.8 EVOLUTION OF THE BIOLOGICAL PHENOTYPE OF SEQUENTIAL HIVAN IMMUNODEFICIENT VIRUS (HIV) ISOLATES IN SUBOCULTURING MONOCULTURE MD4, M. Tarmann, R.H.T. de Gooze, F. de Wolf, J. Goudaert*, J.C. Newman, F. Williams, G. van Nieuwen, B. van den Broek, J. van der Meer, H. van de Loo, and G. van der Grinten, National Institute of Health and Public Health, Bilthoven, The Netherlands.

The type of HIV isolates used in diathesis-induced syncytium-inducing (SI), high-replicating isolates with a broad host range and non-syncytium-inducing (NSI) isolates only replicating in peripheral blood mononuclear cells (PBMC) (Tarmann et al., J. Virol. (1988) 62:2028-2032). From stable asymptomatic seropositive persons only HIV isolates were recovered. SI isolates were not recovered from persons progressing to ARC or AIDS. To investigate whether syncytium-inducing (SI) HIV isolates, associated with CD4+ cell depletion and disease, are present from seroconversion onwards or emerge in the course of HIV infection, and to account for the paradox that apparently transmission of HIV by an SI isolate carrier does not generally result in an infection with an SI isolate in the recipient, we analyzed the biological phenotype of sequential HIV isolates obtained from a cohort of seroconverting homosexual men. The results of this study allow for the following conclusions: 1) Early after seroconversion only non-syncytium-inducing (NSI) isolates are recovered; 2) SI isolates, if detectable, emerge in the course of HIV infection; 3) Upon transmission, SI isolates are presumably suppressed in the host. The results of this study support a model for AIDS pathogenesis in which the duration of the latency period between seroconversion and AIDS is determined by the capacity of the host immune system to suppress the emergence of virulent, CD4+ cell-depleting HIV variants.

M.C.C.0.10 CD4+ T LYMPHOCYTES FROM THE PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC) OF HEALTHY SEROPOSITIVE INDIVIDUALS MARKER THE HIV-1 PROVIRAL SEQUENCES

Panlidopoulos-Mitilias*, Schmittman, S.*; Baseler, N.W.; Fouci, A.S.*; Lane, S.C.* and Ismailov, S.P.* *University of Washington, Washington, DC USA; #FRI, Frederick, MD USA; and *NIAID, National Institutes of Health, MD USA

Objective: To demonstrate the presence of integrated proviral HIV-1 in PBMC of healthy seropositive individuals and determine viral load and the specific subset of PBMC that harbors the HIV-1 at early stages of the disease.
Methods: PCR amplification was performed on the subsets of PBMC obtained by fluorescence activated cell sorting from ten healthy, seropositive individuals using primers from 12R, gag and envelope conserved regions.
Results: HIV-1 proviral sequences were found in all subjects studied and the CD4+ T cell subpopulation which retains the CD4 surface molecule is the predominant cell that harbors HIV-1. In two cases (1/10) CD4low (monocyto/macrophage) subsets also harbor HIV-1 but at a significantly lower level. Serial dilutions of sorted CD4+ T cells show that at least 1,000 - 1/10,000 cells are infected.
Conclusions: The cell populations that harbor HIV-1 are CD4+ T cells that continue to express the CD4 surface molecule. Healthy seropositive individuals have a 100 fold lower viral load than AIDS patients. Their immune system may be able to maintain a chronic, T latent infection for extended periods of time when there are low levels of virus.

Colloque
SymposiumRecherche fondamentale (biomédicale)
Basic Research (Biomedical)Les bases moléculaire et cellulaire des immunodéficiences provoquées par les rétrovirus
Molecular and Cellular Bases of Retrovirus Induced Immunodeficiencies

M.C.O.11 THE MURINE ACQUIRED IMMUNODEFICIENCY DISEASE (MAIDS) IS CAUSED BY A DEFECTIVE RETROVIRUS
Huang, Hing*, Honna, Z**, Aziz, D**, Simerd, C* and
Jolicoeur, P.*

*Clinical Research Institute of Montreal, Montreal, Quebec, Canada;
**Université de Montréal, Montreal, Quebec, Canada.

The Duplan strain of murine leukemia virus (MuLV) induces MAIDS, a disease showing striking similarities with human AIDS. We identified the etiologic agent of this disease as being a defective retrovirus having a 4.8 kbp genome. Sequencing of this DNA showed that the pol and env genes have been deleted and that the complete gag region has been conserved and harbors a novel p12 sequence. Using a cell-free translation system, the genome has been shown to encode a 50 kd gag fusion protein. The same protein was detected in non-producer cells harboring the defective genome and is not cleaved. In-tripic pseudotypes have been constructed with this virus and the role of helper virus in the disease is also being investigated using the W2 encapsidation-negative system. This mouse model emphasizes the need to search for pathogenic defective retroviruses in AIDS.

M.C.O.13 ROLE OF ANTIBODIES, CYTOKINES, AND VIRUS VARIATION IN SIV/SIM INDUCED DISEASE.
Falls, Patricia J, Stricker, R**, Montagnier, L***, Sonigo, P***, McClure, H., and Anderson, D. *

*Kierkes Primate Research Center and Department of Pathology, Emory University, Atlanta, GA, **Cancer Research Institute, University of California, San Francisco, CA, USA, ***Institut Pasteur, INSERM, Paris, France.

Objective. To identify the role of antibodies, cytokines, and biologic and genetic variation in disease associated with different isolates of SIV/SIM.
Methods. Antibody responses, including neutralization and autoantibodies, and cytokine levels in serum from mangabeys and macaques were compared. SIV-9 and SIV-PS114, a variant that causes rapid death, were analyzed for phenotypic and genotypic properties which included the ability to replicate in and their effects on PBMC from various species as well as cloning and sequencing.
Results. Comparison of humoral immune responses to SIV/SIM in mangabeys and macaques showed that disease in macaques was associated with the presence of autoantibodies but not with total or neutralizing antibody titers. In contrast to SIV-9, the lethal SIV-PS114 strain, which was associated with the presence of high levels of TNF- α in serum, induced PBMC from macaques and mangabeys to proliferate, replicated in resting PBMC in the absence of exogenous IL-2, formed syncytia with Sup-T1 cells and had a transmembrane protein of 45-46,000 daltons that lacked a premature stop codon.
Conclusions. Humoral immunity does not appear to be a major factor in the pathogenesis of SIV/SIM for macaques and mangabeys. Autoantibodies and TNF- α , however, may play a role in disease induction by SIV-9 and SIV-PS114, respectively. SIV-PS114 appears to have multiple mutations, some of which affect env-encoded proteins and perhaps regulatory proteins. (IRH 80-0165)

M.C.O.12 INDUCTION OF IMMUNODEFICIENCY DISEASE BY PALV AND RELIFANCE TO SIV AND HIV-DISEASE
Mullis, James L*, Hoover, E.A**, Murphy-Corb, M***, Donohue, P.R*, Overbaugh, J*, Pom, M.L**, Edmonson, P.P*, Hirsch, V*, Martin, L***, ***Delta Regional Primate Research Center, Covington, LA

*Harvard School of Public Health, Boston, MA, **Colorado State University, Ft. Collins, CO

Objective. We are developing animal models for AIDS using a feline leukemia oncovirus (FeLV-PAIDS) and a simian immunodeficiency lentivirus (SIVmac-8323). FeLV results have led to questions now being addressed in both the SIV-macaque model and in HIV-infected primate.

Methods. Establish disease models and relevant in vitro correlates using molecularly cloned viruses, and identify viral genetic and biochemical factors which determine pathogenesis.
Results. Molecular clones of pathogenic FeLV-PAIDS genomes, isolated directly from tissue vivo (see Overbaugh et al). Defective genomes, isolated directly from tissue vivo since a replication competent pathogen could be created in vitro. Similarly, a molecular clone of SIVmac-8323 derived from consistently culture-passaged virus was highly replicative in vivo and only weakly pathogenic in vitro. However, passage of SIVmac-8323 through a macrophage that eventually died from SIV-disease resulted in evolution of a more acute pathogen. The length of the transmembrane gene did not influence virus pathogenicity significantly, although the TM was altered by the type of selection imposed - a shorter coding region was selected for in vivo, and a longer glycosylation was selected in vivo (see Edmonson et al). The T-cell killing determinants of an FeLV-PAIDS clone were mapped to the envelope glycoprotein gene and were correlated with several biochemical features of the envelope glycoprotein. Killing is also prevented by exposure of infected cells to neutralizing antisera (see Donohue et al).
Conclusions. Strong viral genome selection occurs in vivo as well as in vitro, and in vivo propagation may obscure viral gene coding capacity as well as select against acute pathogens. T-cell killing, at least in the FeLV-PAIDS system, likely occurs from a failure or delay in the establishment of superinfection interference.

M.C.O.14 NEW CONCEPTS IN HUMAN AIDS PATHOGENESIS
Montagnier, Luc, Unité d'oncologie virale
Institut Pasteur, Paris Cedex, France.

Séance thématique Specialty Session



Recherche fondamentale (Biomédecine) Basic Research (Biomedical)

Biologie moléculaire (partie 1) Molecular Biology (Part 1)

M.C.O.21 THE IMMUNODOMINANT NEUTRALIZATION LOOP OF HIV-1: BIOLOGICAL AND IMMUNOLOGICAL SIGNIFICANCE. Ignotz, D.; Ivancoff, J.; Rusche, J.R.; Nixie, J.; Redfield, R.; and Wong-Staal, F. Walter Reed Biomedical Research Group, WRAIR, Washington, D.C. 20307. Smith, Kling, and French Laboratories, King of Prussia, PA 19406. Regpligen Corporation, One Kendall Square, Cambridge, MA 02139. Monop, of the U. of Pennsylvania, Philadelphia, PA 19104. Laboratory of Tumor Cell Biology, NCI, NIH, Bethesda, MD, U.S.A.

Objectives: We described blocking of neutralizing activity (NA) of type-specific heterologous anti-viruses by synthetic oligo-peptides from the RPI35/136 region (a.a. 298-320) of gp120. The change of residue within this epitope loop reduced blocking of NA. To further investigate the functional and immunological significance of this area of HIV-1 env, a panel of mutants were constructed. **Methods:** Mutants were constructed in H13 containing a 9gIII - PvuII-BglII segment of HIV-1 envelope, inserted back into a phage clone containing the SalI-BamHI HIV-1 envelope insert, and the entire envelope cassette substituted for the corresponding region of pROD202. **Results:** The characteristics of mutant clones suggests that the integrity of the RPI35 loop is important in viral infectivity, cell range, and syncytium formation, as well as determination of neutralizing phenotype. This area does not appear to be involved in viral binding to CD4.

M.C.O.23 Three-dimensional Structure of the HIV-1 Protease and Its Role in Virus Maturation. Nara, P.A., Fitzgerald, P.M.D., McKeever, R.M., Liu, C.-T., Heideck, J.C., Murphy, W.K., Stal, I.S., Darke, P.L., and Springer, J.P. Merck Sharp & Dohme Research Laboratories, Rahway, NJ 07065 & West Point, PA 19380, USA.

The structure of the HIV-1 protease has been solved by X-ray diffraction analysis, and is shown to be a dimer. Large regions of the HIV-1 protease monomer can be roughly matched to the N- and C-terminal domains respectively of the peptin-like aspartyl proteases of known three dimensional structure, although significant differences do exist. The immediate active site region is assembled around the dimer interface with one characteristic Asp-Thr-Gly site sequence contributed by each monomer. An examination of the structure immediately suggests a mechanism for the auto-proteolytic activation of the protease from the gag-pol polyprotein fusion product on which it is synthesized. Further, an explanation for the control role of the protease in the control of the final assembly and maturation of the HIV-1 virus particle is suggested.

M.C.O.25 CONSTRUCTION OF AN INFECTION MOLECULAR CLONE OF HIV-1 AND GENETIC COMPLEMENTATION WITH A REPLICATION-DEFECTIVE HIV MUTANT. Mura, T. and POI MUTANT OF HIV-1. Mura, T.; Aochi, A.; Shibata, R.; Fukunaga, M.; HAZUKI MASARU. *Institute for Virus Research, Ryojo University, Japan. **Institute of Medical Science, University of Tokyo, Japan.

Objective: To set a basic information for making a recombinant HIV-1 which can infect African monkeys as an useful animal model system for AIDS. **Methods:** Some full-length HIV-1 DNAs were cloned from the circular replicative intermediate DNA by linearization with one-cutting restriction enzyme. These clones were reconstructed to generate provirus form (pSAD1). The env defective mutant of HIV-1 (pNL-Ep) and pol defective mutant of HIV-1 (pSA-Bp) were constructed respectively. These constructs were transfected to COS-1 cell line. After 24 hr, the supernatants were inoculated to HeLa/C18 cell line.

Results: Remarkable cytopathic effect (CPE) was observed and HIV-1 antigen was detected in inoculated HeLa/C18 about a week after transfection with pSAD1. Weak CPE was observed when pSA-Ba and pNL-Ep were co-transfected, while no CPE was observed at all when pSA-Ba or pNL-Ep was used individually.

Conclusion: An infectious HIV-1 molecular clone was obtained and the genetic complementation with a replication-defective env mutant of HIV-1 and pol mutant of HIV-1 was suggested.

M.C.O.22 MOLECULAR ANALYSIS OF SINGLE CELL LYSIS BY HIV-1. Sedláček, J.; Kowalski, E.; Dostálek, T.; Bergman, L.; Wilkowsky, M.; Haseltine, V. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA U.S.A.

Objective: To define regions of the HIV-1 envelope glycoproteins important for the cytopathic effects of the virus.

Methods: Mutations were introduced into the amino terminus of the gp120 transmembrane glycoprotein. The effects of the mutations on virus replication and cytopathic effect were determined.

Results: Mutations in the gp120 amino terminus revealed in either replication defective viruses or in viruses that replicated at levels approximately that of the wild-type virus. The latter viruses exhibited significant reductions in cytopathic effect in established human lymphocyte lines and in primary peripheral blood lymphocytes. Both syncytium formation and the lysis of single cells were attenuated in these mutants.

Conclusion: The amino terminus of the gp120 transmembrane glycoprotein, which has been previously shown to be important for the fusion of cell membranes during syncytium formation, is also involved in the lysis of single cells accompanying HIV-1 infection in vitro.

M.C.O.24 STRUCTURAL PATTERNS IN REGULATORY SEQUENCES OF HIV-1. HERSH, Gerald; Linzer, C.F. and Tsang, C.-S. Theoretical Division, Los Alamos National Laboratory, Los Alamos, N.M. U.S.A.

Objective: To define DNA sequence-dependent structures for the TAR and RRE cis-acting regulatory elements.

Methods: Computer-assisted nucleotide sequence analysis-alignment and modeling of DNA tertiary structure--is correlated with mutational and biochemical results pertaining to the sequences for TAR and RRE. **Results:** Two sequence-dependent consensus structures are identified for the HIV-1 TAR regulatory element at positions +18 and +37; hexanucleotide sequences corresponding to these structures have been shown by mutational and biochemical (i.e., footprinting) analyses to subsume the core of TAR. Different sequences yielding equivalent DNA structures are in HIV-2s at +18 and +33 and in HIV-1 at +17 and +39. The second of these two structures, responsive to cellular U73 protein, is found in all lentiviral IRNs (EIAV, CAEV, VADV, FIV) at ca. +35 while the first of these structures is found only in HIV-1 and HIV-2. Extension of this analysis to the RRE region of the ZTR, now thought to be the cis-acting element for the RRE regulatory function, again reveals the role of DNA tertiary structure in HIV-1 regulation. Sequence-dictated microconvolution of the DNA may be essential to this region of the ZTR.

Conclusion: Transactivation of HIV-1 and HIV-2 partly entails indirect (reverse direct) reading of the DNA by proteins; site-directed mutagenesis of HIV-1 and related retroviruses should have this phenomenon in mind. The results suggest ways to manipulate the RNA effects and DNA effects pertinent to transactivation.

M.C.O.26 EXPERIENCE WITH HIV-1 VACCINE TRIALS IN CHIMPANZEES

Flachy, J. and R. Sambrook. Institute for Biomedical Research, San Antonio, Texas, USA.

Objective: To test the efficacy of various HIV-1 vaccines in chimpanzees. **Methods:** The following HIV-1 vaccine candidates were employed to actively or passively vaccinate 27 chimpanzees: 1. synthetic peptide (175-752). 2. vaccinia-env recombinant, 3. recombinant gp120 expressed in mammalian cells. 4. HIV-immune globulin (HIV-IG) prepared from HIV-1 positive asymptomatic people, 5. recombinant gp120 peptide (358-574), 6. vaccinia-gp recombinant, 7. a combination of vaccinia gag and env recombinants 8. Idiocyctic antibodies (local of anti-gp120). **Results:** Cell-mediated immunity in immunized animals, as assayed by specific lymphocyte blastogenesis or cytotoxicity, was only detected in vaccinee trials 2,3,5,7. While all vaccinees induced humoral antibodies as detected by ELISA and/or Western blotting, only passive immunization (trial 4) conferred significant neutralizing antibodies. All immunized and control chimpanzees that were challenged (trials 1-4) were not protected, i.e. HIV CPE could be isolated and/or seroconversion was documented. Due to the experience gained in trials 1-4 and the poor neutralizing antibody response it was decided that vaccine candidates 5-7 did not warrant a challenge with live HIV. The experiment with vaccine candidate 8 is still in progress. **Conclusion:** Eight HIV vaccinee consisted of 27 chimpanzees did either not confer protection or did not warrant challenge with live HIV or in progress.

Science thématique Specialty Session



Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

Virologie (partie 1)

Virology (Part 1)

T.C.0.1 DESIGN AND ACTIVITY OF A NOVEL CLASS OF NUCLEOSIDE ANALOGS EFFECTIVE AGAINST HIV-1.
Belleau, Bernard*, Dixit, D.*; Nguyen-Nh, H.**; Kraus, J.-L.*
*Institut Armand-Frappier, Université du Québec, Laval, Qué., Can.; **IAF BioChem International Inc., Laval, Qué., Can.

Objectives: To replace the pentose of nucleoside analogs by isosteric rings in which the 3'-carbon is an S or O atom and to test these opds. to block HIV replication *in vitro*.

Methods: Synthetic strategies were used to make intermediates with a 5'-hydroxyethyl group in the desired steric relationship with base substitution. The *de novo* syntheses led to mixtures of *cis*- (natural) and *trans*- (unnatural) isomers which were separated and fully characterized. **Results:** Two opds, both carrying a *cis* substitution, were generated on a scale which allowed extensive biological evaluation. The best analog, NUPP-21, having the "natural" *cis*-configuration was very effective *in vitro* as an anti-HIV-1. Its potency equivalent to AZT in all assays, as well as an improved therapeutic index. Another analog, DOTTI-10A (unnatural *trans*-configuration), had a surprisingly good *in vitro* profile. Some structure-activity relationships will be discussed briefly.

Conclusion: Novel compound NUPP-21 is a drug candidate for AIDS and is less toxic than AZT. Supported by an NBRCC/IAF BioChem-Industrial Research Chair (Bernard Belleau).

T.C.0.3 INHIBITION OF HIV-1 INDUCED SYNTHESIS FORMATION BY MONOCLONAL ANTIBODIES TO THE MEMBRANE ADHESION PROTEIN CD13.

Yalcinli, A.I.; Paterson, M.P.; Azzh B (1).

1. Department of Virology, Hamilton Institute, Stranmillis, DUBLIN, IRELAND

Objective: To study the participation of the membrane adhesion glycoprotein CD13 in HIV induced syncytia formation.

Methods: U937 clone 16 cells were pretreated with monoclonal antibodies (Ab) to CD13 and directed to the CD13 on M6e in major histocompatibility complex class I (MHC-I). Treated and control cells were infected with the HIV-1183 strain of HIV and grown in presence or absence of the reactive Ab. Viral replication was monitored by reverse transcriptase (RT) activity, immunofluorescence (IF) and syncytia formation.

Results: HIV infection of U937 clone 16 cells resulted in extensive viral replication and syncytia formation leading to cell death. In contrast, cells pretreated with Ab to CD13 yielded cell cultures with no signs of cell aggregation or syncytia formation, an percentage of infected cells, low RT activity and high cell viability for several weeks. The sensitivity of the inhibition of HIV induced syncytia formation was demonstrated by addition of MHC-I Ab. No difference in cytopathic effect was observed between this culture in the control.

Conclusion: We directed to the membrane adhesion glycoprotein CD13 effectively block HIV induced syncytia formation and cell death. Our results also suggest that intercellular adhesion contributes to and enhances spreading of the virus infection *in vitro* and possibly *in vivo*.

T.C.0.5 IDENTIFICATION OF SEVERAL SPECIES OF HIV-1 MAJOR CORE PROTEIN PRODUCTION AND CELL-SURFACE EXPRESSION

Laurin, A.C.; Krusi, B.; Rey, M.A.; Monseigneur, L.M. and Hébert, A.C.

Unité d'Oncologie Virale, Institut Pasteur, Paris 15, France.

Objectives: Characterisation of HIV-1 gag gene product p25 by two dimensional gel electrophoresis analysis.

Results: The p25 detectable in HIV-1 infected cells is composed of four gel species designated as a, b, c and d with isoelectric points: 6.8, 6.6, 6.5 and 6.3, respectively. Species b and d are the phosphorylated forms of species a and c, respectively. The two most acidic species c and d have a slightly slower electrophoretic mobility in polyacrylamide gels compared to the species a and b. All four species of p25 could be immunoprecipitated by polyclonal and monoclonal antibodies but only species a and b could be identified by electrophoretic transfer-immobiline assay using these same antibodies. Thus once p25 is denatured, then species c and d cannot be identified by polyclonal or monoclonal antibodies.

Pulse chase experiments indicated that all four species of p25 are produced at the same time after the synthesis of p55 but their subcellular localisation is different. Only species a and b are recovered with the virus particles whereas species c and d are a proportion of species a and b are secreted by virus producing cells. In addition to these results, heteropolymerase catalyzed iodination of the cell surface was employed to show that the four species of p25 are expressed on HIV-1 infected cells.


Conclusion: These different observations suggest that there might be distinct processing pathways for the production of species a,b compared to species c,d.

T.C.0.2 DIFFERENTIAL SENSITIVITY OF WILDTYPE AND RECOMBINANT HIV-1 REVERSE TRANSCRIPTASE TO INHIBITION BY FOZACARIN.

Malhotra M. Lightfoot and J. Murray Bailey,
The George Washington University School of Medicine and Health Sciences
Washington, DC 20037

The recombinant reverse transcriptase from HIV-1 cloned into the vaccinia virus VCF-21 (Moe) was expressed in monkey kidney cells and purified from cultures supernatants by conventional chromatographic procedures. The kinetic characteristics for inhibition of the recombinant enzyme by phenothiazine/ornithine acid (Fozacarin) were compared to that of the wild type HIV-RT and RTs of other retroviruses. Incorporation of ³H-TTP directed by poly(A) RTs, purified from cultures supernatants, was inhibited with an IC₅₀ of only 0.0007 μM compared to 0.001 μM for the wild type HIV-RT (Figure). K_i for TTP incorporation were also measured to identify differences. Sensitivity of a recombinant HIV-RT to Fozacarin was also determined. The results indicate that Fozacarin is more effective in the sense as that of wild type RT. Properties of the VCF-21 RTs were compared to those of the wild type RT. RTs from different mammalian cells were compared. The results indicate that different transcriptional processing of the vaccinia RT construct may give rise to different enzymatic activities and can give rise to HIV-RT variants with markedly enhanced sensitivity to Fozacarin.

SENSITIVITY OF VIRAL REVERSE TRANSCRIPTASES TO INHIBITION BY PROPYDINOFANATE



T.C.0.4 STRUCTURE AND FUNCTION OF HIV-1 REVERSE TRANSCRIPTASE (RT)

S.A. Lander, D. Lowe, Dorothy J.B. Purifoy, M. Tiedals, S. Darby, D.K. Staemers, et al. UNITED KINGDOM

Objective: To determine important structural features of the HIV-RT.

Methods: A variety of genetic manipulation techniques including site directed mutagenesis has been used to create a large number of variants of the HIV RT. These include enzymes with modified amino-acid sequences, with portions of the enzyme deleted (at N or C terminus or internally), or with additional amino-acid added. These mutant enzymes have been used to delineate the function of specific regions of the enzyme.

Results: Deletion of the C Terminal region of the enzyme has previously been shown to remove part but not all of the enzymes activity. We further define this region and further delineate a region of the enzyme that can be deleted without major loss of enzyme activity. Site specific mutants have been generated which alter the sensitivity of the enzyme to the anti-HIV drugs AZT and PPA, to determine the effect of such mutations on the ability of HIV to replicate proviral constructs were made encoding the mutant RT genes. On transfection of these constructs into HeLa cells they were found to replicate. These viruses showed decreased sensitivity to PPA, suggesting that infectious PPA resistant virus can arise *in vitro*. Finally, we have attempted to crystallise each of the variants to get better ordered crystals of RT. An up-to-date progress report on how the mutant enzymes crystallise will be given.

Conclusion: Mutational analyses have been successfully applied to determine functionally important regions of the HIV RT.

T.C.0.6 GAG AND GAG-POL PROTEIN PRECURSORS MADE FROM A SV40 LATE REPLACEMENT VECTOR ARE PROPERLY PROCESSED AND ASSEMBLED INTO PARTICLES

Smith, Alan J.; Hammarshild, M.L.; and Fawcett, D., Departments of Microbiology, Biochemistry and Oral Biology, State University of New York at Buffalo, Buffalo, N.Y. 14214, U.S.A.

The expression of the HIV-1 gag and pol genes has been studied using fragments of the BH10 clone of HIV inserted into a SV40 late replacement vector. An initial construct containing the entire coding regions of gag, pol and vif produced only minute amounts of the gag precursor (p55). However, high level expression was obtained when an additional sequence from the *env* gene (the rev-responsive element) was inserted 3' of vif in the correct orientation, and rev was provided in trans from a second vector. Western blot analysis of transfected cells showed the presence of large amounts of both gag and gag-pol precursors as well as all of the expected cleavage products. In addition analysis of the culture medium showed the presence of particle-associated reverse transcriptase activity. Experiments are presently underway to determine whether envelope proteins, expressed from a separate vector, and virus-specific RNA are associated with these particles.

Colloque
SymposiumRecherche fondamentale (biomédicale)
Basic Research (Biomedical)Mécanismes de pathogenèse des rétrovirus humains
Mechanisms of Pathogenesis of Human Retroviruses

T.C.0.7

VARIANTS OF HIV RESISTANT TO ZIDOVUDINE (AZT)

Larder, Susan A.; Kemp, S.D.*; Darby, C.* and Richman, D.D.**

*Molecular Sciences Dept., Wellcome Research Laboratories, Beckenham, Kent, U.K. **Infectious Diseases Dept., V.A. Medical Center, San Diego, U.S.A.

Objective. To investigate whether prolonged exposure of HIV to zidovudine in patients leads to selection of resistant variants.**Methods.** HIV was isolated from PBMC prepared from untreated and zidovudine-treated individuals and propagated in MT-2 cells. Zidovudine sensitivity was assessed by plaque-reduction in a beta cell line (ST2-6C) expressing the human CD4 gene.**Results.** Infection of ST2-6C cells with HIV results in formation of plaques (foci of multinucleated giant cells) allowing precise determination of drug-sensitivity. Isolates from untreated individuals showed very similar sensitivity to zidovudine (mean ID₅₀ 0.03nM, range 0.01-0.04nM). However, most isolates from patients with AIDS or ARC treated for 6 months or more showed decreased sensitivity characterized by increase in ID₅₀ or ID₉₀ values (or both). Several isolates showed 100-fold increases in ID₅₀. Although these were sensitive to all other drugs tested except AZDT, TMP resistance mechanism is being investigated by analysis of cloned reverse transcriptase genes. The sensitivity of HIV isolated from asymptomatic individuals during therapy is also being determined.**Conclusion.** Zidovudine-resistant variants of HIV can be isolated from patients with AIDS or ARC after prolonged therapy. At present the clinical significance of this observation is unclear.

T.C.0.8

SURFACE STRUCTURES INVOLVED IN HIV RECOGNITION

Madon, Paul A., Progenics Pharmaceuticals, New York, N.Y., USA.

T.C.0.9

TRANS-REGULATION OF HIV-1 GENE EXPRESSION

Michael E. Malin and Bryan E. Collins

Howard Hughes Medical Institute, Departments of Medicine and Microbiology and Immunology, Duke University Medical Center, Durham, NC 27710 USA.

This presentation will briefly address the physiological role of the regulatory proteins encoded within the genome of HIV-1, focusing particularly on the viral *tat* gene product. The *tat* protein is required for expression of the viral structural gene products and, hence, for viral replication. I will review data demonstrating that *tat* functions post-transcriptionally to modulate the transport of HIV-1 mRNAs from the infected cell nucleus to the cytoplasm, where translation into viral proteins occurs. In addition, I will review recent data demonstrating that the *tat* protein contains two discrete functional domains. One of these is required for the specific interaction of *tat* with its viral RNA target sequence. The second is required for the subsequent activation of viral RNA expression. These results will be discussed with reference to possible targets for therapeutic intervention into AIDS.

T.C.0.10

CURRENT DEVELOPMENTS IN PATHOGENESIS

Salto, Robert C. Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health Bethesda, MD, USA

Séance thématique Specialty Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

Biologie moléculaire : les différents niveaux d'expression du provirus VIH 1 Molecular Biology: Different Level of Expression of HIV-1 Provirus

T.C.0.11 EXPRESSION, PURIFICATION, SPECIFICITY, ACTIVITY AND SUBSTRATE SPECIFICITY OF THE HIV-1 PROTEINASE

Debnick, Christine, Beckman, J., Malinowski, J., Meak, T., Moore, H., Strickler, J., et al. Smith Kline French Laboratories, King of Prussia, PA 19406, USA.

Objective: The gag and pol coding region of HIV-1 is translated into large precursors that are cleaved by a protease encoded by the virus and that is unique and essential. Our goal is to develop specific inhibitors of this enzyme that will block the maturation and infectivity of the virus without interfering with the host physiology.

Methods/Results: The HIV-1 protease was expressed as a precursor and in its mature form in various E. coli strains and shown to specifically cleave its own gag-pol substrate in vivo as well as heterologous substrates containing appropriate cleavage sites. This system was used to identify residues in the enzyme that are essential for its activity. The enzyme was purified to homogeneity and its structure and enzymatic activity characterized.

A simple peptidic in vitro assay was developed to be used to screen natural products and rationally designed compounds for inhibitory activity.

Conclusion: Asp-29 and Gln-66 are residues critical for the HIV-1 protease activity. The enzyme is an aspartyl-protease and behaves as a dimer in vitro assay for the

This work was supported in part by NIH grants A324845 and OHS9526.

T.C.0.12 TUMOR NECROSIS FACTOR-ALPHA ACTIVATES HIV EXPRESSION IN A CHRONICALLY INFECTED T CELL CLONE THROUGH INDUCTION OF NUCLEAR FACTOR BINDING TO NF- κ B SEQUENCES

Ela, J. Duf*, Wendy J. Masry*, Thomas M. Folks*, Anthony S. Fauci*, and Anne B. Resanz* MDACC, NIH, Bethesda, MD, *CCDC, Atlanta, GA USA

Objective: To describe the molecular events by which TNF- α activates HIV expression. **Methods:** The AC20 cell line is a clone cell line derived following infection of A3.01 T cells with HIV-1. AC20 cells are chronically infected with HIV and contain a single integrated HIV provirus whose expression can be augmented by TNF- α treatment. Steady state HIV RNA levels were studied by dot blot hybridization, and activation of HIV transcription was analyzed by nuclear run-on assays. GAT retardation assays employing P-32 labeled oligonucleotides were used to study the induction of nuclear proteins binding to the HIV long terminal repeat. Transfection of wild type and mutant HIV LTR-GAT plasmids into A3.01 T cells were performed to identify LTR sequence responsible for activation.

Results: TNF- α treatment of AC20 cells resulted in an increase in steady state levels of HIV RNA and HIV transcription. GAT mobility shift assays demonstrated that the transcriptional activation of the HIV LTR by TNF- α was associated with the induction of a nuclear factor binding to the NF- κ B sites in the LTR. Deletion of the NF- κ B sites from the LTR eliminated activation by TNF- α in T cells transfected with plasmids in which the HIV-LTR directed the expression of the CAT gene.

Conclusion: TNF- α appears to activate HIV RNA and vice production by AC20 cells through the induction of transcription activating factors that bind to the NF- κ B sequences in the HIV LTR.

T.C.0.13 RNA SPLICING EVENTS DETECTED IN EARLY IN VITRO HIV INFECTION USING THE POLYMERASE CHAIN REACTION (PCR)

Klugman, Marc E., DeRoos, A., Buchsinder, A. and Wong-Saal, P., Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Md, U.S.A.

Objective: The HIV genome codes for at least six additional regulatory gene products along with the gag, pol and env products. The complexity of this 9 kb virus are in part due to the regulation of a series of splicing events during the production of these gene products. We studied the early splicing events that occur after infection of H9 cells with purified HIV to determine the sequence of events.

Methods: RNA was extracted from infected cells at a series of time points ranging from one hour after viral absorption to forty-eight hours. Antisense primers and AAV reverse transcriptase were used to make cDNA which was amplified by PCR using sets of oligonucleotide primers designed to detect specific splicing events. The regulatory primers were chosen from within the 2nd and 3rd exon flanking the splice donor-acceptor sites at nucleotides 6044 and 8378. The envelope primers were from within the first and second exon and flanked the splice donor-acceptor sites at nucleotides 703 and 5973 respectively.

Results: The splicing between the first and second coding exons of the regulatory genes *rev* and *nef* could be detected within hours after infection and appeared before splicing of the envelope genes which occurred within six hours of infection. Standard Northern blotting did not detect these mRNAs at the early time points.

Conclusions: mRNA splicing occurs very early in infection of H9 cells with HIV. Splicing of regulatory exons precedes splicing of mRNA coding for structural gene products.

T.C.0.14 POTENTIAL BIOLOGICAL SIGNIFICANCE OF A SECONDARY RNA START SITE WITHIN THE HIVLTR

Mason, J.L., Bednar, D.P., *The Henry M. Jackson Foundation, Biotechnology Laboratory, Rockville, MD, *The Johns Hopkins Oncology Center and Dept. of Immunology and Infectious Diseases, Baltimore, MD, USA.

Objective: The aim of the present study was to determine the biological significance of a secondary RNA start site within the HIVLTR.

Methods: S1 nuclease mapping has localized the site of the secondary RNA start to 80 base pairs downstream from the primary RNA start site. RNA analyses show that whereas the HIVLTR contains 167 nucleotides 5' from the primary RNA start site results in RNA expression from both start sites, an HIVLTR deletion containing only 65 nucleotides results in RNA expression only at the secondary start site. Provirus transfections and HIV infections suggest the existence of more than one RNA transcript for the HIV-enclosed *tat* gene product, possibly due to RNA initiation at the secondary site. We are using PCR analysis to attempt to further map and to ascertain the biological significance of a secondary start site in HIV regulation.

Conclusions: These data support the possibility that the existence of a secondary RNA start site could play a significant role in HIV gene expression and replication.

T.C.0.15 REGULATORY ELEMENTS IN THE LTR (HIV-1) RESPONSIVE TO GLUCOCORTICOID STIMULATION

Stachurski, M., Wang, J., Zeng, J.F., & DeGruy I.D. *Université Pierre et Marie Curie, Paris, France. **University Hamburg DDR

Within the LTR of HIV-1 provirus we have identified two hormone responsive elements (HREs) corresponding to the TGTCT sequence identified as the glucocorticoid receptor binding element within the LTR or HIV1T (responsible for the transcriptional activation of the provirus). We have used an LTR (HIV-1)-CAT construct to transfer, infect (H9)3 and non infected H9 cells. Four hours before harvest the two cell types were divided into two and one half treated with dexamethasone (1.0-70). The cells were harvested, and the CAT activity measured in eight repeat experiments on increased (50%) expression of the CAT gene in the presence of the glucocorticoid cells has always been observed in H93, but no effect of the steroid has been measured in the non infected cells. Double transfection of LTR (HIV-1)-TAT and LTR (HIV-1)-CAT into non infected H9 cells results in a cell population in which the CAT gene was responsive to glucocorticoid stimulation. We have further shown, using cells transfected with a mutant LTR (HIV-1) promoter CAT that only one of the steroid HREs is required for the glucocorticoid response. Our results are discussed in relation to the well characterized HIV1T-LTR system and to the well established role of glucocorticoids in HIV-1 virus activation.

T.C.0.16 MECHANISM OF HIV-1 INFECTION OF MONONUCLEAR PHAGOCYTES

O'Brien, William A.; Koyanagi, Y. and Chen, I.S.-Y. UCLA School of Medicine, University of California, Los Angeles, CA, USA

Objective: To investigate mechanisms of mononuclear phagocyte infection by macrophage-tropic strains of HIV-1.

Methods: Two distinct HIV isolates with differing ability to productively infect mononuclear phagocytes *in vitro* were molecularly cloned and compared at the sequence level. Kinetics of virus infection were measured in mononuclear phagocytes following treatment with granulocyte-macrophage colony-stimulating factor (GM-CSF). Fragments of the HIV-1 LTR linked to the indicator gene, CAT (chloramphenicol acetyltransferase), were transfected into primary blood-derived mononuclear phagocytes of GM-CSF to identify sequences necessary for GM-CSF activation.

Results: The complete nucleotide sequence of two HIV-1 isolates from the same individual having different tropism for mononuclear phagocytes show a sequence difference of 38. The macrophage-tropic virus replicates to high titers in these cells, and its production is further enhanced by GM-CSF treatment. Sequences in the HIV-1 transcriptional enhancer region necessary for GM-CSF activation were identified. These sequences are distinct from the NF- κ B binding sequences of the LTR.

Conclusion: Related viruses may have biologic differences. Sequences in the HIV-1 LTR necessary for GM-CSF activation in mononuclear phagocytes are distinct from those necessary for virus replication following T-cell activation.

Séance thématique Specialty Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

Biologie moléculaire : les mécanismes de régulation de type tat des gènes viraux Molecular Biology: TAT-Mediated Regulation of Viral Genes

T.C.0.27 THE TAR REGION OF HIV-1 BINDS AND ACTIVATES THE DOUBLE-STRANDED RNA DEPENDENT KINASE (dsR) *Ray, Soubrier, Mary, I., Perkin, K.M., Nersisyan, L.M., Kato, M.M., and Sonnenberg, R.J., McGill University, Montreal, Canada; *The University of New York, Syracuse, New York, USA; **Washington University, Seattle, Washington, USA.*

Objective: To elucidate the mechanism by which the tat-responsive element (TAR) within the 5' non-coding region of HIV-1 mRNA activates the double-stranded RNA dependent kinase (dsR), resulting in inhibition of protein synthesis, as observed in HIV-1 retroviral infection.

Methods: An RNA mobility shift assay was devised to study nucleoprotein complex formation between dal purified from retroviral lysate and small RNAs comprising the TAR region (HIV-1 RNA) (1 to 400).

Results: We show specific RNA-protein complex formation between dal and TAR RNAs. Mutant TAR RNAs with retained secondary structure lose their ability to bind dal and are considerably less potent in activating the kinase. The introduction of compensatory mutations designed to restore the secondary structure of the TAR region restored the RNA's ability to complex with and activate dal. An excess of the double-stranded RNAs poly(U) and reovirus dsRNA complex and inhibit dsR activation.

Conclusion: The double stranded nature of the TAR region present at the 5' end of all HIV-1 mRNAs renders it capable of activating dal, a protein involved in the activation of protein synthesis by interferon. Activation of dsR correlates with the ability of the TAR RNA to bind to purified dal. These studies may have important implications for the regulation of HIV-1 replication.

T.C.0.28 PROGRESSIVE GENETIC CHANGES IN HIV-1 TAT GENE COINCIDENT WITH DISEASE

Neirameh, Andras, Chernier, R.*, Saurin, M.**, Kwak, S.**, Seinsky, J.**, Williams, J.**, Adju, B.*** and Kahn-Neirameh, M.***. The University of *Institut Pasteur, Paris, France; **Cetus Corporation, Emeryville, USA; ***Karolinska Institute, Stockholm, Sweden.*

Objective: 1) Analysis of the HIV-1 proviral population of four virus isolates taken from the same individual as he progressed towards AIDS (CD4 - ARC - AIDS).

Methods: 1) tat gene sequences were amplified by PCR and cloned into an expression vector. Inertly plasmid clones of each isolate were sequenced. **Results and conclusions:** 1) Comparing viral populations after short term culture, significant changes in the distal viral species were observed during disease progression. This effect is less prominent with tat variants obtained directly from lymphocytes. 2) In vitro cultivation of the virus population present in blood lymphocytes, whereas long term cultivation does not constitute a further selective pressure. 3) On the protein level, single and multiple amino acid changes as well as defective genomes were observed. Functional studies complementing the structural analysis underway will allow us to interpret better these data.

T.C.0.29 BINDING OF THE HIV-1 TAT PROTEIN TO TAR SEQUENCES IN VITRO.

Dingwall, C., Emberg, I., Heaphy, S., Blomer, M. A., Gall, M. J. & Karn, J. MRC Laboratory of Molecular Biology, Hills Road, Cambridge, CB2 2QH, UK.

Objective: To investigate the binding in vitro of HIV tat protein and cellular factors to TAR sequences.

Methods: A synthetic tar gene has been expressed both in an E. coli expression system and in a number of eukaryotic cell lines. The binding of expressed tat protein to nucleic acid representing the TAR sequence has been investigated in vitro using gel retardation assays.

Results: The tat protein produced from both the E. coli and from the eukaryotic expression systems has been shown to be biologically active. The binding of tat, synthesized in E. coli, to TAR nucleic acid has been examined both in the presence and absence of host cellular proteins. Binding of tat expressed in eukaryotic cells gives a different pattern, suggesting that host proteins interact with the tat/TAR complex. The specificity of binding has been examined using a number of different nucleic acids, including mutant TAR sequences.

Conclusion: Direct interactions between tat protein and TAR sequences are involved in trans-activation.

T.C.0.30 HIV-1 NCER HAS THE CAPACITY TO ENCODE BIFUNCTIONAL TAT AND REV PROTEINS THROUGH ALTERNATE splicing

Visually, Georges, A. and Mullins, J. J.

Harvard School of Public Health, Boston, Massachusetts, USA

Objective: We previously demonstrated that, in contrast to HIV-1, coding exon 2 of SIVmac (SIVmac) tat is required for significant tat activity and the dispensing of the proximal tat sequence at the 5' end of tat mRNA activates a downstream splice acceptor site and results in the formation of a functional tat protein. We now seek to characterize the structure and functional coding capacity of mRNA molecules which encode the SIVmac tat and rev proteins.

Methods: Polymerase chain reaction was used to specifically amplify cDNAs corresponding to either tat or rev mRNAs from SIVmac (SIVmac) infected HeLaT cells and the different spliced forms were characterized by oligonucleotide probe hybridization and DNA sequencing.

Results: We found that tat and rev mRNAs use different splice acceptor sites at the beginning of their respective first coding exons. Three different splice acceptor sites are used at the beginning of the coding exon. The two 3' most splice acceptor sites have the capacity to encode proteins which differ by single amino acid substitutions and the deletion of either 1 or 6 amino acids. The two 3' most splice acceptor sites, which facilitate them the step between the 5' end reading frame (see abstract by Edmonson et al.), were used at frequencies of 54% and 43%, while the 3' most site was used at a frequency of 2%. Similar splicing events which join non-coding exon 1 and 2 were also identified. They were used at frequencies of 61%, 37% and 17%, respectively. Finally, rev mRNAs fall into 3 classes with respect to their 5' structure. These classes are approximately equivalent in frequency and differ by the presence or absence of 144 nucleotide bases located within the 5' region of the 5' LTR. The biological activity of clones of each of the tat and rev cDNAs are currently under investigation.

Conclusion: SIVmac uses alternative splicing to generate mRNAs with the capacity to encode isoforms of the tat and rev proteins.

T.C.0.31 BINDING OF HIV-1 TAT TO THE 5' REGION OF mRNA

Rappoport, J.-E., Joseph, S., Kloman, M., Kang, C.Y., Daifler, S., Rench, J., and Wong-Staal, F. Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Md., U.S.A.

Objective: HIV-1 gene expression is positively regulated by the viral transactivating protein, tat. Evidence suggests that the structure of the RNA stem loop within the TAR region is critical for transactivation therefore we proposed that the tat protein binds directly to this RNA structure.

Methods: Recombinant tat protein produced in both E. coli and baculovirus expression systems were tested for their ability to bind directly to gel-purified 32P-labeled transcripts from the initial 5' nucleotides of the HIV-1 mRNA that were synthesized from constructs using the heterologous T7 polymerase. RNA gel mobility shift assays were performed using the wild type as well as a mutant transcript (ΔS) generated by a four base pair deletion (+35-38) at the RNTI site, known to lack transactivation potential.

Results: Introduction of the recombinant tat protein by the "scraper-loading" procedure into HeLa cells stably integrated with the HIV-1 LTR linked to the bacterial chloramphenicol acetyl transferase gene confirmed the activity of the protein. Wild-type TAR transcripts formed a stable complex with the recombinant tat protein resulting in retarded gel migration. The deleted transcript (ΔS) did not form a stable complex.

Conclusion: The data suggest that tat protein of HIV-1 specifically and stably binds to TAR RNA which may be a required step in vivo in the transactivation pathway.

T.C.0.32 CD4+ LYMPHOCYTES CAN CONTROL ACUTE HIV INFECTION OF CD4+ T-CELLS

Wain, Christopher M., Thomson-Horvath, G., Hsieh, J. & Finlay, J. A. Cancer Research Institute, University of California, School of Medicine, San Francisco CA 94143 USA

Objective: To determine if peripheral blood CD4+ T cells from HIV-infected subjects can suppress the growth of HIV in acutely infected CD4+ T cells.

Methods: Peripheral blood mononuclear cells from HIV-infected and uninfected subjects were stimulated with PHA for three days, and T lymphocyte subsets expressing the CD4+ and CD8+ antigens were enriched. CD4+ cells were cocultured with CD4+ cells infected with HIV isolates, and then cultured with the CD8+ T lymphocytes. Culture supernatants were assayed three days for HIV RNA.

Results: CD4+ T cells from HIV-1 seropositive subjects, but not seronegative controls, were able to prevent replication of HIV in acutely infected CD4+ T cells. Suppression of virus growth required the continuous presence of CD8+ T cells, and was not HLA-restricted. Monoclonal antibodies to antigens on these cells (i.e. CD4 and CD8 proteins), but not cells that can mediate antibody-dependent cellular cytotoxicity of normal killing (i.e. CD8) positively blocked suppression.

Conclusion: Cytotoxic suppressor T lymphocytes can prevent the growth of HIV after acute infection and are present in the peripheral blood of HIV-infected individuals. The mechanism of action of these CD8+ T cells remains to be determined.

Seance thématique
Specialty Session



Recherche fondamentale (biomedical)
Basic Research (Biomedical)

Virologie (partie 2)
Virology (Part 2)

T.C.0.33 IDENTIFICATION OF SITES WITH WHICH SERVIC AS TARGETS FOR ADCC USING HUMAN MONOCLONAL ANTIBODIES

Titre: D'Amico, Zola-Pazner, B... Gomy, M... Banway, D...
Bolognesi, D. and Wainwright, W. *Coriell* University Medical Center, Durham, NC, USA. *New York University Medical Center and *New York VA Medical Center, NY, NY, USA.

Objectif: To utilize human anti-HIV-1 monoclonal antibodies (mAb) to define target epitopes for antibody-dependent cellular cytotoxicity (ADCC).
Méthodes: PE800 from HIV-1 infected individuals were EBV transformed, screened for mAb production, cloned and maintained in long term culture. Six cell lines made mAb to gp41 and five made mAb to gp24. These mAb were tested in a ⁵¹Cr release ADCC assay using virally infected and gp120 adsorbed CEM/CMR targets.

Résultats: None of the anti-gp120 mAb mediated ADCC. However, five of the 6 mAb directed at regions within gp 41 mediated significant lysis of HEp, RF and MN infected targets, at dilutions in the range of 1:640 to 1:4. No lysis of gp20 adsorbed targets was seen. The specific lysis of the three most effective mAb at two dilutions is shown in the table. Interestingly, the scope

mAb	HEp	RF	MN
10A10 (gp20)	28.2	16.0	22.7
10B10 (gp20)	22.5	10.1	19.4
9B4 (gp20)	20.8	6.7	20.0
10A10 (gp41)	20.8	6.7	20.0
10B10 (gp41)	20.8	6.7	20.0
9B4 (gp41)	20.8	6.7	20.0

of all ADCC directed against gp41 mAb was not significantly different from that of antibodies directed against the immunodominant region of gp41. The purity, potency and broad specificity of these human mAb makes them ideal for passive immunotherapy. Current work on the identification of the specific epitopes to which these mAb are directed will facilitate the design and development of a future vaccine.

T.C.0.35 PUTATIVE INTERACTION SITE BETWEEN HIV gp120 AND gp41 : ANTIVIRAL ACTION OF SYNTHETIC PEPTIDES.

Méthodes: DeLor, F., Favau, B., Le, C., Cumings, S., Stapleton, D.,**
Doherty, R.* and Kemp, R.*
*HARC Special Unit for AIDS Virology, Fairfield Hospital, and
**McC. Vincent's Institute, Melbourne, Victoria, Australia.

Objectif: To determine the antiviral action of synthetic peptide analogues corresponding to a putative interaction site between envelope glycoprotein, gp120 and gp41, of HIV.

Résultats: Purified synthetic peptides of 8 to 23 residues were tested (at 10⁻⁶ to 10⁻¹⁰M) for their ability to inhibit HIV replication "in vitro" at mol of 0.0002-0.01 µg/ml/assay.

Conclusion: We have identified a region in gp120 (89-119) and a complementary sequence in gp41 (371-591) with four matched charge residues conserved for all HIV isolates which has a propensity to form amphiphilic helices with charged residue contacts and complementary hydrophobic residues. Synthetic peptide analogues partially suppress the in vitro infection inhibited virus replication as measured by reverse transcriptase activity and delayed syncytial formation.

Conclusion: Our results illustrate that it is possible to reduce HIV infectivity with synthetic peptides that mimic structures involved in the contact region between gp120 and gp41.

T.C.0.37 DEFINITION OF SEVERAL ALONG A HOMOLOGY-DOMINANT REGION OF THE HIV-1 GP41 AND THE IMPACT OF CONSERVATIVE AND NONCONSERVATIVE AMINO ACID SUBSTITUTIONS ON HIV-1 REPLICATION

Méthodes: Pappas, S., Benveniste, B., Ryms, L., Vukob, A.,
Dimitrova, P., *Medical Biophysics, University of Chicago, Illinois.*

Objectif: To determine protein sequence variations for maintenance epitopes along a region of the HIV-1 gp41, previously shown to be immunodominant, and to study the impact of amino acid substitutions on HIV-1 replication. The amino acid sequence of the gp41 region 371-591 was determined for 100 HIV-1 strains. Regions heterologous to the amino acid (aa) sequence of 371-591 were synthesized and used to immunize mice. The immunized mice were then challenged with a recombinant HIV-1 strain expressing the gp41 region 371-591.

Résultats: Four amino acid substitutions (Glu to Asp, Asp to Asn, Asn to Lys, and Lys to Arg) were found to be conserved in all 100 HIV-1 strains. The other amino acid substitutions were found to be non-conserved. The non-conserved amino acid substitutions were found to be conserved in all 100 HIV-1 strains.

Conclusion: Within a small set of (24) immunodominant epitopes as many as 10 substitutions in the gp41 region were found to be conserved in all 100 HIV-1 strains. The conserved amino acid substitutions were found to be conserved in all 100 HIV-1 strains. The non-conserved amino acid substitutions were found to be conserved in all 100 HIV-1 strains.

T.C.0.34 FUNCTIONAL DOMAINS OF THE HIV-1 ENVELOPE PROTEIN

Titre: Feliciano, D. and Moss, B.
Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA

Objectif: To examine the functional domains on the HIV-1 envelope (env) glycoprotein. **Méthodes:** Recombinant vesicular viruses containing intact or mutated forms of the HIV-1 env gene were constructed. **Résultats:** Cells, infected with a recombinant virus that contains the entire env gene, synthesized glycosylated gp120 which was cleaved to gp120 and gp41 and inserted into the plasma membrane, leading to CD4 binding and syncytium formation. When the DNA encoding the pro-membrane cleavage site was deleted, gp120 was no longer cleaved and inserted into the plasma membrane, but no syncytium was formed. Inserted gp120 was still able to bind soluble CD4.

A family of recombinant vesicular viruses that express N-terminal overlapping env proteins of 204, 287, 393, 504 (gp120), 435, 747, and 821 (gp120) amino acids (aa) was constructed. Only the 747 aa and the full-length protein mediated syncytium formation. The remaining proteins were all present in intracellular and secreted forms which differed in extent of glycosylation. Curiously, the 393 aa protein also was anchored in the plasma membrane but neither its full-length protein bound to CD4. In contrast, an N-terminally spliced env protein (gp120) was not inserted into the plasma membrane and did not bind to CD4. (2) cleavage of gp120 is required for fusion to CD4-bearing cells; (3) the pathway of gp120 cleavage is an act dependent process; (4) the transmembrane domain is cleaved at 835 and 747; (5) the CD4 binding domain is between aa 393 and 504; (6) a cryptic membrane anchor sequence lies between aa 387 and 393.

T.C.0.36 CHARACTERIZATION OF THE HIV-2 ENVELOPE GLYCOPROTEIN: THE TRANSMEMBRANE GLYCOPROTEIN IS A HOMODIMER

Titre: Maiti-Agnon, A., Laurent, A.G., McClure, J., Kravitz, B., Mosselman, L., and Hovanessian, A. G.
Institut Pasteur, Paris 15, France ; *Gene Systems, Seattle, Washington, USA.

Objectif: Identification of HIV-2 envelope external and transmembrane glycoproteins (EOP and TMP) by polyclonal and monoclonal antibodies.

Résultats: A 80-kD glycoprotein (gp80) is produced in HIV-2 infected cells along with three other glycoproteins that we have recently reported : the external glycoprotein (gp125), the envelope glycoprotein precursor (gp140) and the transient dimeric form of gp140 (gp300). The gp125 and gp300 are detectable after the synthesis of gp140 and the formation of gp300. Among these four glycoproteins, only gp80 and gp125 are associated with HIV-2 viruses. As the other glycoproteins, gp80 can be recognized by all HIV-2 positive sera. As a murine polyclonal antibody raised against the purified gp300 recognizes all four glycoproteins. On the other hand, a monoclonal antibody raised against a synthetic polypeptide deduced from the sequence of TMP of HIV-2 recognizes gp140, gp300 and gp80; thus indicating that gp80 should be related to TMP of the envelope. Heating (50°C, 5 min) of cellular or viral extracts in 1% SDS results in the dissociation of gp80 into the monomer gp36. These results suggest that during the processing of the HIV-2 envelope glycoprotein gp140, the dimer is produced which when cleaved by the cellular protease gives the EOP gp125 and TMP dimer gp80. **Conclusion:** Dissociation of envelope glycoprotein precursor and the TMP is a specific property of HIV-2 and HIV gene expression. Dissociation of the precursor might be required for its processing to give the mature envelope products whereas the TMP dimer might be essential for optimal structures of the virion.

T.C.0.38 gp160 IS ENDOPEPTIDOLYTICALLY CLEAVED IN A PREFUSIONLYMPHOCYTE CONTAINING COMPARTMENT OF THE GOLGI COMPLEX.

Titre: Barry, S., Smith, K.S., Switzer, S., and E.G. Engstrom*, Stanford University School of Medicine, Palo Alto, CA 94304, USA. *Chico State University, Chico, CA 95909, USA.

Objectif: To identify the intracellular site of endoproteolytic cleavage of the HIV-1 gp160 envelope precursor.

Méthodes: HIV-1 envelope glycoprotein transcripts were immunoprecipitated from an actively infected CD4+ T cell line (VB) radiolabelled with [³⁵S]methionine and [³⁵S]threonine and subjected to one- and two-dimensional SDS-PAGE. **Résultats:** gp160 contains 70 kD of endo-H sensitive N-glycanase (N-gly) high mannose carbohydrate side chains, is devoid of fucose and is neuraminidase resistant (pI = 7.0 to 7.5). gp160 is not transported to the cell surface, but binds to CD4. gp120 has approximately 20 kD of endo-H sensitive and 55 kD of N-glycanase sensitive N-glycanase linked oligosaccharides signifying both high mannose and complex side chains. gp120 is rich in fucose and sialic acid, with a broad pI of 5.0 to 7.5 that shifts up to 7.0 upon neuraminidase treatment. N-glycanase shifts the pI of gp120 toward the acidic range (5.5 to 6.5) suggesting the presence of abundant sialylated N-glycans. Pulse chase studies with 1-deoxy-mannosyloligosaccharide indicates that gp160 has a transit time of approximately 2 hours to the site of action of Golgi α -mannosidase I and that its endoproteolytic cleavage occurs before processing by Golgi α -mannosidase I. gp160 cleavage is achieved by a non-act dependent process. **Conclusions:** gp160 is endoproteolytically cleaved in a pre-fusionlymphocyte compartment of the Golgi complex, likely before processing by Golgi α -mannosidase I, which is consistent with localization to the RER-to Golgi interface.

Séance thématique Specialty Session



Recherche fondamentale (Biomédicale)
Basic Research (Biomedical)

Éléments de base en Immunologie (partie 1) Basic Immunology (Part 1)

W.C.O.5 CD4⁺ LYMPHOCYTES ARE THE CRITICAL CELLS MEDIATING SUPPRESSION OF HIV RELEASE BY CD4⁺ CELLS
D. Weiss, J. Wheeler, C.M. and Leo, J.A. Cancer Research Institute, University of California, San Diego, San Francisco CA 94143 USA

Objective: To determine the critical cell type responsible for the suppression of HIV replication in CD4⁺ lymphocytes, and define whether cell killing is a major mechanism of this suppression.
Methods: Purified CD4⁺ and CD8⁺ lymphocytes from HIV seropositive donors were prepared by the panning technique. CD4⁺ cells were cultured alone or with the addition of either CD8⁺ cells or cells prepared by CD4-depletion. Reverse transcriptase assays were done on culture supernatants at 2-3 day intervals. Cell viability counts were assessed by trypan blue exclusion. Expression of HIV proteins by the CD4⁺ cells was measured by indirect immunofluorescence (IFA) assay.

Results: Panned CD4⁺ and CD8⁺ lymphocyte populations were 85-90% pure by FACS analysis. Cells prepared by CD4-depletion contained 95% CD8⁺ cells, as well as B-cells and non-T lymphocytes. The suppressive activity of purified CD4⁺ cells was markedly greater than that of the CD4-depleted cells added in most number to the CD4⁺ cell cultures. Neither autologous macrophages nor cells depleted of both CD4⁺ and CD8⁺ cells demonstrated suppression of HIV release.

Conclusions: Cell counts and FACS analysis done at the end of 3 experiments showed no decline in the number of CD4⁺ cells remaining viable in cultures where suppression of HIV release had occurred. When CD4⁺ cells were removed by panning after exposure to HIV suppressing CD8⁺ cells, the percentage of cells remaining viable after IFA did not decline. Subsequent cocultivation of these CD4⁺ cells with HIV-1-stimulated lymphocytes from a seropositive donor resulted in rapid release of infectious HIV.
Conclusion: The CD4⁺ lymphocyte is the critical cell mediating suppression of HIV replication by autologous CD4⁺ cells. Killing of the infected cells does not seem to be a major mechanism of this suppressive effect.

W.C.O.7 Activation and infection of T cells by HIV-1 Infected Antigen Presenting Monocyte/Macrophage: **Mann, Isani*, Gardner, R., Appelo, A.**, National Cancer Inst., Frederick*, Bethesda****, MD, USA

Objective: To investigate T cell infection and antigen presentation by HIV-1 infected monocyte/macrophage (M/M).

Methods: M/M were isolated from peripheral blood lymphocytes (PBL) from HIV-1 seropositive individuals by surface adherence and infected with HIV-1. Infected and uninfected M/M were exposed to tetanus toxin (TT) and streptolysin (S3) for 24 hours washed, and autologous M/M depleted PBL added. After 18 hours of exposure to M/M, T cells were prepared and cultured with uninfected T and SX free autologous M/M. ³H thymidine incorporation was determined in the T cells to assess antigen stimulation and reverse transcriptase activity measured in supernatant to monitor infection.
Results: Maximal T cell infection by HIV-1 infected M/M occurred at 7 days. HIV-1 infected M/M presented TT and SX to autologous T cells with activation comparable to uninfected M/M. HIV-1 infected M/M stimulated and infected T cells without TT. Stimulation and infection of T cells were increased when T was presented by HIV-1 infected M/M. M/M to some MHC class II antigens (HLA-DR, DP) blocked T cell infection by HIV-1 infected M/M with and without TT.
Conclusion: HIV-1 infected M/M present TT and SX to autologous T cells not unlike that seen with uninfected M/M. Activation of T cells appears to be an important component of T cell infection as antibodies that block antigen activation also block infection.

W.C.O.9 PATTERN OF HIV REPLICATION DURING *IN VITRO* MATURATION OF MONOCYTES INTO MACROPHAGES

Glinde, Rana*, Chapuis P., Josell T.**, Paravincini C.***, Gluckman J.C.***, Monongeyer L. ***

* Unité d'Oncologie Virale, Institut Pasteur, Paris, France.

** UFR Fédérative, Paris, France.

*** V. Can. Am. Pa. Univ. in Milano, Ospedale L. Sacco, Italy.

Objective: Does macrophage activation control HIV replication?

Methods: HIV replication was observed in peripheral blood monocytes and monocyte cells (THP1) cultured under various conditions to induce macrophage activation (different concentrations of human serum, phorbol ester or cytokines). Expression of differentiation cell markers: Leu M1 (monocyte specific), Pam 1 (macrophage specific), and expression of cytoplasmic viral antigens: constitutive and regulatory proteins (gp110, gp41, p18, p25, p55, p68 and nef), viral RNA, were detected at different time points after infection.

Results: HIV replication is correlated with differentiation of monocytes into macrophages and with activation of the macrophages (a study of the cell cycle indicated a high synthesis of nucleic acids). If HIV infected cultures are stimulated with heat-inactivated HIV, there is increased viral replication.

Conclusions: Expression of cell markers is correlated with monocyte differentiation. Our results suggest that a second round of viral infection could induce macrophage activation and by this way, stimulate productive HIV infection.

W.C.O.6 Infection by HIV-1 of purified NK cells with a

CD3⁺-CD2⁺-CD56⁺-CD16⁺-phenotype.
Basile, Scott*, Virelizier*, Favier*, Francoise Vuillier*, Denise Gherard*, Leo Montagnier* and Guillaume Ullrich* Immunology Institute, Pasteur Institute, 251, Boulevard Pasteur de l'Institut Pasteur 75724 Paris Cedex 15 - FRANCE
In a previous work, we demonstrated a significant depletion of CD3⁺, CD16⁺ NK cells in HIV infected patients (AIDS seropositive and retroviruses #: 121, 1988). These results prompted us to investigate the possibility that HIV could infect NK cells in vitro. Highly purified CD3⁺, CD4⁺ and CD3⁺-CD2⁺-CD56⁺-CD16⁺ cell lines were obtained from peripheral blood of a patient displaying a large granular lymphocytosis; and were infected with the human immunodeficiency virus (HIV) strain HTLV-III. Cell lines displayed the well known pattern of infectivity after exposure to HIV: in the case of CD3⁺-CD2⁺-CD56⁺-CD16⁺ cell line, no increase of reverse transcriptase expression without increase of p-25 antigen was observed. On day 23 of culture, non-infected autologous CD3⁺-CD2⁺-CD56⁺-CD16⁺ cells were added to HIV infected CD3⁺-CD2⁺-CD56⁺-CD16⁺. An important and sustained increase of p-25 antigen was observed 4 days after coculture, whereas in the case of reverse transcriptase, no increase in expression was observed. These results suggest that NK cells can be directly infected by HIV, in the presence of relatively little cytopathicity and can propagate the virus to autologous CD4 cells.

W.C.O.8 MACROPHAGE-ACTIVATING FACTORS (MAF) ALTER HIV-1 PRODUCTION FROM PRIMARY MONOCULAR PHAGOCYTES

John Mellors, M. Orian, N. Ashkin, R. C. Smith, M. Landay, J. Ryan, Yale School of Medicine and VA Medical Center, West Haven, CT, USA.

Infection of mononuclear phagocytes by HIV-1 is believed to be a central event in the pathogenesis of AIDS. It is not clear, however, whether activating signals alter HIV production from these key target cells. We have studied the effects of several MAFs including recombinant tumor necrosis factor- α (TNF- α), interferon- γ (IFN- γ) and lipopolysaccharide (LPS), on HIV-1 production from blood monocyte-derived macrophages (MDM). MDM were purified (99% esterase) from normal donors by density-gradient centrifugation and adherence to plastic in 10% human serum. After 1-2 weeks of culture, MDM were infected with HIV-1 (strain HTLV-IIIB) at a multiplicity of infection of approximately 5. Virus production was determined by ELISA of culture supernatants and cell lysates for HIV p24 antigens. Treatment of MDM with TNF (10⁻⁶ U/ml), starting either 2 days before or 7 days after HIV-1 infection, increased virus production 3-fold over control. Treatment with LPS (10⁻⁶ ng/ml) starting 7 days after infection increased virus production 4-10 fold over control. In contrast, IFN- γ (1 U/ml) inhibited HIV-1 replication (38-59% inhibition). Viral inhibition was observed irrespective of the timing of IFN- γ treatment in relation to HIV-1 infection. Similar inhibition was produced by recombinant interferon- α or native interferon- β , indicating that anti-HIV activity was not specific for IFN- γ . These studies indicate that proinflammatory inhibit HIV-1 replication in MDM, but that IFN- γ and LPS enhance virus production from these cells. These observations, combined with clinical evidence that T-cell IFN- γ production declines and circulating TNF levels rise with progression of HIV-1 infection to AIDS, suggest that certain MAFs may be important modulators of HIV-1 replication *in vivo*.

W.C.O.10 ADHERENT LINGERING-ACTIVATED KILLER CELL (A-LAK) CYTOTOXIC ACTIVITY AGAINST HIV INFECTED MONOCYTES

Melby, Robert J. **, Gault, R. S. **, Gupta, R. **, Rinaldo, C.R. **, Weissfeld, T. S. **, and Herberman, R.B. **, University of Pittsburgh* and Pittsburgh Cancer Institute, Pittsburgh, PA, USA**

Objective: To characterize non-MHC restricted killing of HIV infected monocytes by a highly cytotoxic and homogeneous recombinant-interleukin-2 (rIL-2) activated killer cell (AK) population. **Methods:** Monocytes were infected with HIV-1 strain IIIB (IB strain) and a monocyte-derived strain and incubated at 37°C for 1 to 7 days. Autologous and allogeneic A-LAK cultures were prepared by stimulating monocyte-depleted PBL from normal HIV-seronegative donors with rIL-2 for 24h at 1000 U/ml and expanding the plastic-adherent population. Cytotoxicity of A-LAK cells towards HIV-infected and rIL-2-infected monocytes as well as tumor cell lines was evaluated in an ⁵¹Cr-release assay. **Results:** A-LAK cytotoxicity against the infected and rIL-2-infected monocytes after 3 days of infection was 83 lytic units (LU)/10⁶ cells (strain IIIB), 364 LU/10⁶ cells (monocyte-derived strain) and 17 LU/10⁶ cells (uninfected monocytes). Killing of K562 and Daudi cells resulted in 8,584 and 2,008 LU/10⁶ cells respectively. A-LAK killing of HIV-infected monocytes was at least 20-fold greater than from rIL-2-stimulated monocyte-depleted PBL from normal infected monocytes (23 LU/10⁶ allogeneic cells) was as effective as killing by autologous cells (74 LU/10⁶ cells). One culture of A-LAK cells expressed high levels of non-MHC restricted cytotoxic activity against monocytes infected with both strain IIIB and a monocyte-derived HIV strain.

Colloque
SymposiumRecherche fondamentale (biomédicale)
Basic Research (Biomedical)Mise au point de vaccins contre le SIDA
Vaccine Developments In AIDSW.C.O.17 CURRENT TRENDS IN HIV VACCINE PREPARATION
Marc Girard, Pasteur Vaccins and Institut Pasteur, Paris, France.

The development of a vaccine against AIDS has met with considerable difficulties. Not only does the virus remain latent in the body for long periods of time, probably persisting as an integrated provirus in the genome of the host cell, but it also shows considerable genetic variability. For an HIV vaccine to be able to prevent infection, quick neutralization of the virus would be of crucial importance. However, neutralizing antibodies raised against an HIV-1 isolate do not usually cross-neutralize other HIV-1 isolates. Work on a vaccine is further hampered by the fact that the only animal model system available so far for HIV-1 uses the chimpanzee. Following infection the animals replicate the virus and become asymptomatic carriers with no signs of disease. Finally, the HIV envelope glycoprotein appears to be poorly immunogenic: it elicits only weak neutralizing anti-viral antibody titers, perhaps due to epitopic suppression. In our hands, vaccinia virus HIV recombinants elicited a T-cell immune response but only a weak humoral response, an inactivated virus vaccine elicited a good humoral immune response but no T-cell response. Purified HIV antigens added with a MDP-base adjuvant showed however high immunogenic potency. Finding the appropriate presentation of HIV antigens able to elicit high neutralizing antibody titers of broad reactivity is a requisite for the successful development of an HIV vaccine.

W.C.O.19 IMMUNISATION EXPERIMENTALE ANTI HIV CHEZ L'HOMME

Zaïre, Denis

Dans le cadre d'une collaboration de recherche Franco-Zairoise, des essais d'immunisation active anti HIV, destinés à préparer un vaccin anti-SIDA, par l'inoculation d'une immunisante à médiation cellulaire, ont été réalisés depuis novembre 1986 chez des volontaires séro-négatifs. Des essais (1-2), préalable d'une sélection chez l'animal qui a montré l'innocuité et l'immunogénéité des préparations utilisées, ont comporté une primo-injection de vaccine recombinante (Vr) exprimant le protéoglycane 160 du HIV et un rappel variant suivant les individus (Vr + agencement de protéines membranaires endogènes isolées ou non du virus) et/ou le protocole d'immunisation Vr + cellules autologues infectées et l'huile peut être considéré comme un candidat vaccin polyvalent induit une réaction anti HIV immunisante et spécifique de groupe (2-3) avec des cellules lésées et des autours qui sont protecteurs - et non facilitants - vis à vis de l'infection par le HIV; des macrophages/mesophages in vitro (4).

Nous recherchons actuellement un protocole d'immunisation reproduisant le même état d'innocuité anti HIV que le protocole et plus simple à administrer à un grand nombre d'individus. Cette étape dans le développement d'un vaccin anti SIDA est indispensable avant d'engager un essai clinique à plus grande échelle (phase 2) susceptible d'évaluer le niveau de protection vis à vis de l'infection naturelle du candidat vaccin.

- Zaïre D. et al Nature (326, 249-250, 1987)
- Zaïre D. et al Nature (332, 729-731, 1988)
- Berzberly J. et al Nature (334, 700-702, 1988)
- Berzberly J. et al AIDS Res. Hum. Retrov. (1987), in press

W.C.O.18 DEVELOPMENT OF AN HIV SUBUNIT VACCINE
Faulkner, Scott, R.*; LaRosa, G.; Javaherian, K.*; Emini, S***; Biogenesis, D.**; and Matthews, T.***; *Repligen Corporation, Cambridge, MA, USA, **Duke University Medical School, Durham, NC, USA, ***Herch, Sharp and Dohme Research Laboratories, West Point, PA, USA.

We have mapped the principal HIV neutralization determinant to a disulfide loop in a variable region of the outer envelope (aa 303-338). Antibodies elicited by peptides as small as eight amino acids from the center of this determinant neutralize free HIV and prevent fusion of HIV infected cells with uninfected CD4 cells. These antibodies are type-specific in that antibodies elicited by a peptide of the sequence from one isolate do not neutralize a panel of divergent HIV-1 isolates.

Using PCR amplification and sequencing of this determinant from independent HIV-1 isolates, we have found that over 40 of 100 randomly isolated viruses have identical or very similar amino acid sequences. In addition, over 80 of 100 sera from randomly selected HIV-1 infected people react with a peptide of this sequence. This indicates that viruses with this amino acid sequence are prevalent. This data, taken along with data that antibodies to this determinant delay HIV infection of chimpanzees, (E. Emini, et al.) suggests that a broadly protective HIV subunit vaccine can be developed.

W.C.O.20 EVALUATION OF A RECOMBINANT HIV-1 ENVELOPE PROTEIN AS AN IMMUNOGEN IN HUMANS

Lane, H. Clifford. National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA

Séance thématique Specialty Session



Recherche fondamentale (Biomédicale)
Basic Research (Biomedical)

Modèles animaux (partie 2)

Animal Models (Part 2)

W.C.O.27

EVALUATION BY PCR OF HIV-1 STATUS OF CHIMPANZEES CHALLENGED WITH HIV AFTER RECEIVING HUMAN HIVIC
Maziarz, J., Indira, A., Sperelak, J.S., Newthorne, C.A.,
Tishler, M., and FRISCH, A.S.,
Food and Drug Administration, * Bethesda, MD, 20892, New York Blood Center
HIV* and Southwest Foundation, TX, *** U.S.A.

Objective: To determine the status of HIV after virus challenge in chimpanzees previously immunized with HIVIC.
Methods: Five chimpanzees were passively immunized with HIVIC prepared from plasma of HIV seropositive, seronegative donors whose serum contained high titres of neutralizing antibodies (Frisch et al. PNAS, Vol 85 p. 6944-6948). Virus isolation was performed on peripheral blood mononuclear cells (PBMC) by coculture. PCR was performed on DNA isolated from lymphocytes, using the gag and env primers for confirmatory detection.
Results: HIV-1 DNA sequence was detected by PCR in lymphocytes of all 5 animals after virus challenge although virus cultures were not all positive until 3-9 weeks after challenge.
Conclusion: Administration of HIVIC to chimpanzees was unable to prevent HIV infection. Virus expression (RNA-PCR in PBMC) and release of assembled virus in culture (PCR in serum) are being performed to assess virus activity in these animals.

W.C.O.29

EFFECTS OF SPERM AND AUTOMUNEMITY ON MERKRE AIDS (MAIDS)
Steinlich, Zvi H., Weissman, Z., Moshier, A.,**
*Hebrew University of Jerusalem, Jerusalem, Israel
R. Ben Ari Institute of Clinical Immunology, Kaplan Hospital, Hebrew University Medical School, *Experimental Animal Unit, ***Department of Cellular Immunology, Weizmann Institute of Science, Rehovot, Israel.

Objective: To determine the effect of sperm and induced autoimmune disease on the generation and course of MAIDS.
Methods: Disease was induced by viruses obtained from cell line LP-BMS-571 (SIV CP126), B19A, A19 and A19 strains. Autologous sperm cells (1-3 x 10⁷) were injected intravenously prior to and following the viral inoculations. Antispermic SIV-like disease was induced by a human monoclonal antibody. Experimental SLE-like disease was induced by a human monoclonal proliferation and histopathological examinations were performed.
Results: Spermogeny in several animals and prolonged suppression of sperm-PCR proliferation to mitogens and allogeneic stimulation were observed following single sperm injection into normal animals. Sperm enhanced significantly the induction of MAIDS by the viral preparations, which was more evident when using sublethal doses of virus.
Table:

Saline	Sperm	Virus	Sperm + Virus
MAIDS	0/19	7/19	10/19

10% antibody injection to virus inoculated animals increased serum levels of Ig, anti DNA and anti idiotypic antibodies and immunopathology.
Conclusion: Immunomodulation by sperm and autoimmune disease influences the course of MAIDS. This may have direct relevance to their role in the pathogenesis of human AIDS.

W.C.O.31

T-CELL KILLING BY THE POLY-P-FAIDS IMMUNODEFICIENCY VIRUS
Emswiler, R., Dombas, E. A., Hovav, C.M.C. deLoraine, S.L.,
Garcas-Barria, J., Overbaugh, J., and J. Mullins, (DH) Harvard
School of Public Health, *O'Connell Base University, N. Collins, CO.
**Present Address: Univ. of Washington, Seattle, WA, U.S.A.

OBJECTIVE: Locate the genetic determinant and elucidate some aspects of the mechanisms of T-cell killing by a genetically cloned feline leukemia virus that induces fatal immunodeficiency disease in outbred specific-pathogen-free cats.
METHODS: Chromosomal variants were generated in vitro using the replicative defective assay immunosuppressive 616 provirus. To assess their pathogenicity, an *in vivo* assay using a feline T-cell line was developed.
RESULTS: Replication competent chimeres were obtained that were T-cell cytotoxic *in vivo* and induced immunodeficiency disease *in vivo*. Analysis of 22 chimeres revealed that the essential determinant for T-cell killing resides within chimera 23 (a 2 base pair (2 amino acid) stretch within the extracellular glycoprotein gene (gp70), corresponding to a single amino acid change and a 6 amino acid insertion in the protein. Other changes within gp70 and the viral LTR enhance the efficiency and rate of T-cell killing *in vitro* and pathogenicity *in vivo*. T-cell killing occurs along with production of high levels of integrated viral DNA and viral mRNA, and can be blocked by exposing newly infected cells to antisera from cats exposed to the virus.
CONCLUSION: These results suggest that T-cell killing occurs as a result of massive superinfection and that the critical mutations in gp70 cause a failure or delay in the establishment of superinfection interference, possibly through altered interactions with p15E and/or its cellular receptor.

W.C.O.28

THE MARINE ACQUIRED IMMUNODEFICIENCY SYNDROME (MAIDS) IS CAUSED BY A DEFECTIVE RETROVIRUS
Hanna, Mings*, Hanna, Z., Atz, D. P., Simard, C. and
Jullouwer, P. et al.

*Clinical Research Institute of Montreal, Montreal, Quebec, Canada;
**Université de Montréal, Montreal, Quebec, Canada.

The Duplan strain of marine leukemic virus (MLV) induces MAIDS, a disease showing striking similarities with human AIDS. We identified the etiologic agent of the disease as being a defective retrovirus having a 4.8 kb genome. Sequencing of this DNA showed that the pol and env genes have been deleted and that the complete gag region has been conserved and harbors a novel p12 sequence. Using a cell-free translation system, the genome has been shown to encode a 50 kd gag fusion protein. The same protein was detected in non-producer cells harboring the defective genome and is not cleaved. N-tropic pseudotypes have been constructed with this virus and the role of helper virus in the disease is also being investigated using the W2 encapsidation-negative system. This mouse model emphasizes the need to search for pathogenic defective retroviruses in AIDS.

W.C.O.30

MOLECULAR CLONING AND SEQUENCE ANALYSIS OF FELINE IMMUNODEFICIENCY VIRUS (FIV)
Ginsburg, Robert, A., Barnes, A.S., Yessierli, J.K.,** Hirsch, V.V.,
Purohit, R.H.,** and Johnson, F.R.* Georgetown Univ., Rockville, MD, *NIH, NIH, Bethesda, MD, **Univ. of California-Davis, U.S.A.

Objective: FIV is a T-lymphotropic retrovirus that is associated with immunodeficiency and opportunistic infections in cats and provides an excellent opportunity for the development of a small animal model for AIDS. To isolate these viruses, we isolated a proviral clone of FIV for molecular and biological characterization.
Methods/Results: FIV-1/2 provirus cDNA clones were synthesized and used to isolate the proviral molecular clone, FIV-14. Molecular cross-hybridization analysis of FIV-14 with 5 feline viruses revealed that nucleotide sequence similarities exist between FIV and these viruses in the gag-pol gene. Significant nucleotide sequence identity was observed between the 3' LTR of the FIV-14 pol gene and the pol gene of FIV, HIV-1, HIV-1, EAV, vira virus and CAEV (59%, 69% identity). Sequence similarities were not observed upon comparison of the FIV LTR sequence with known viral sequences. Common antigenic determinants appear to be shared by FIV, CAEV, and vira virus as shown by serological cross-reactivity of rabbit antibodies to CAEV and vira virus with the proviral FIV ones protein, p24. Importantly, proviral viruses of FIV-14 were infectious for experimentally inoculated cats.
Conclusion: These studies demonstrated that FIV is a member of the lentivirus subfamily and is distantly related to the AIDS lentiviruses of primates. The availability of an infectious molecular clone will make possible a detailed dissection of the molecular pathogenesis of FIV, which may facilitate the development of vaccine and therapeutic strategies for AIDS.

W.C.O.32

INFECTION OF THE NEW ZEALAND WHITE LABORATORY RABBIT (OTOCYCLOPSA CUNICULUS) WITH HIV-1
Beland, E.***, Haxhaxhiu, E.***, Gard, E.A.**, Ford, G.**, Buchbinder, A.**, Gallo, R.C.**, et al.
*National Cancer Inst., NIH, Bethesda, MD, **NIH, Bethesda, MD, ***Bionomics Research, Inc., Rockville, MD, U.S.A.

Objective: To develop a laboratory model for HIV infection of New Zealand White rabbits.
Methods: NZW rabbits were injected intraperitoneally with HIV-1 or HIV-2-infected cells after thymoglycinate-induced pancytopenia. Animals were monitored for physical and hematological abnormalities, infectious virus, viral nucleic acids, and antibodies to viral proteins.
Results: Three rabbits inoculated twice at 60 day intervals with HIV-1 produced continuously rising titers to both gag and env proteins. Virus, detected as viral antigens, was also periodically recovered from peripheral blood leukocytes by cocultivation with susceptible cells. Persistent infection was also suggested by detection of proviral DNA in multiple tissues. Physical abnormalities included lymphadenopathy and pancytopenia. Histopathology revealed a disruption of follicular architecture of lymph nodes.
Conclusion: NZW rabbits appear to be infectable with HIV-1 and demonstrate a pathological effect. However, much work remains in characterizing this potential animal model.

Séance thématique Specialty Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

Virologie (partie 3)

Virology (Part 3)

W.C.O.33 ANALYSES OF T CELL HILLAR FACTORS WHICH BIND TO THE NEGATIVE REGULATORY ELEMENTS (NRE) OF THE HIV LTR
 CRY, Bruno, A. Acres, D. and Klay, K.F.
 TRANSCORP S.A., 6705 Scribblewood Circle, FRANCE

Objective: To analyze the nuclear factors binding to the NRE sequence of the HIV LTR and to investigate the influence of nef on these factors. Gel retardation assays and methylation interference techniques have been used.
Results and Conclusion: Nuclear extracts from human T-rossette positive peripheral blood cells and from T cell clones were analyzed using gel retardation assays. NRE binding factors were detected and their appearance and binding factors in nuclear extracts prepared from cells stimulated with PHA 17k appear to be different from that (those) which appear in response to 12-O-tetradecanoyl phorbol-13-acetate 12-myristate 13-acetate (TPA) as expressed in cells using a vaccinia virus expression system. The evidence will be presented which demonstrates associations between the appearance of HIV NRE binding factors and genetic elements involved in T cell activation.

W.C.O.35 EFFECTS OF MUTATIONS IN THE *gag* GENE ON THE GROWTH OF HIV.
 Kim, Sunyoung*, Bensch, K.W., Byers, K.A., Greenway, J.P., and Baltimore, D.*

* Whithead Institute, and Dept. Biology, MIT, Cambridge, MA, USA.
 ** New England Deaconess Hospital, Harvard Medical School, Boston, MA, USA.

HIV contains the open reading frame called *gag* at the 3' end of its genome which was reported to be dispensable for viral growth but to reduce viral gene expression. We have compared two different HIV-1 strains with the same genetic background, except for a lesion in *gag* (one containing the complete coding region, and the other null for *gag*). The effects of *gag* on various stages of HIV infections were examined. We have tested effects on viral DNA and RNA after infection. Comparable results were obtained from both *gag*⁺ and *gag*⁻ strains. The effects on viral growth were also tested by following changes in reverse transcriptase activity in cell cultures supernatant and the fraction of infected cells (determined by indirect immunofluorescence) during the course of infection. The presence of the *gag* gene product fails to slow down viral growth in many different cell types tested, including human T lymphocyte cell lines, B9 and CEM, human primary T cells, and human monocytic cell lines such as U937 and THP-1. These results were reproducible with the use of a different virus isolate. Our data suggest that *gag* does not act as a negative factor, at least in the experimental system we employ.

W.C.O.37 EFFECTS OF NEF EXPRESSION ON HIV REPLICATION AND CELLULAR FUNCTIONS

Chakrabarti, Goolbsy, Imerets, P. Luce, P.A. and Levy, J.A.
 Cancer Research Institute, University of California, San Francisco, CA 94143 USA, *Department of Medical Pathology, University of California, Davis, CA 95618 USA

Objective: To determine the effects of stable *gag* expression on HIV replication and cellular functions.

Methods: Stably transfected cell lines expressing the *gag* protein were obtained by transfection of HUT-78, RD (Ruman rhabdomyosarcoma) and COG-7 (monocytic cells with plasmid constructs of *gag*) under the SV-40 or HIV-1 promoters. Expression of *gag* was monitored by an immunofluorescence assay (IFA) and immunoblot analysis. Effects of *gag* expression on HIV replication were assessed by transfection and infection of these stable cell lines. Effects on cellular function were monitored by cell growth and modulation of cell surface markers.

Results: Stable cell lines expressing the *gag* gene product, *gag*⁺ were obtained in HUT-78, RD and COG cells. Expression of *gag* in HUT-78 results in the down-modulation of the CD4 receptor molecule. This down-modulation appears to be specific since other cell surface markers, e.g. CD3, were not affected. Expression of *gag* in COG cells also leads to the suppression of HIV COG upon transfection or infection with HIV. In some stably transfected cell clones, the expression of *gag* appears to retard cell growth. This is similar to that observed for expression in yeast. Current studies are directed at elucidating the mechanisms by which *gag* regulates HIV replication and cellular function. Its interaction with other HIV regulatory proteins is also being examined.

Conclusion: Expression of *gag* in stably transfected cell lines has been shown to suppress HIV replication and affect cellular functions. These cell lines will be used to understand the mechanism by which the *gag* protein exerts its effects, and the interactions it has with the other HIV regulatory proteins.

W.C.O.34 FUNCTIONAL ROLE OF HIV-1 VPU

Gilman, Rick A.; Terwilliger, E.; Sodroski, J.; Haseltine, W. Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA U.S.A.

Objective: Determination of the effect of the *vpu* gene of HIV-1 upon the viral life cycle.

Methods: Isogenic HIV-1 proviruses identical except for possessing a functional *vpu* were constructed and transfected into CD4⁺ Jurkat cells. Parameters of virus infection quantitated included cell number, syncytia formation, supernatant reverse transcriptase activity, and both cell and virion associated viral protein levels.

Results: Cells infected with *vpu*-expressing virus demonstrated a marked increase in the ratio of virion associated versus cell associated viral protein compared to cultures infected with *vpu*-negative virus. The *vpu*-positive cultures exhibited lags in syncytium formation, cell death and accumulation of intracellular viral proteins, despite possessing higher levels of supernatant reverse transcriptase activity.

Conclusion: The product of *vpu* acts to accelerate virus export.

W.C.O.36 VPU - A PROTEIN UNIQUE FOR HIV-1 IS REQUIRED FOR EFFICIENT VIRUS REPLICATION AND RELEASE

Kirkland, Thomas*, Strabel, S., Owsenstein, J.M., Martin, M.A.*
 *Laboratory of Molecular Microbiology, MILD, NIH, Bethesda, MD, USA
 **George Washington University Medical School, Washington, DC, USA

Objective: To determine the role of HIV-1 *vpu* and its intracellular location during productive viral infection of human T-cells.

Methods: Infections of T-lymphocytes with virus particles derived from an infectious molecular clone of HIV-1 or a deletion mutant lacking the *vpu* gene were compared. A nonspecific *vpu* antiserum was used in indirect immunofluorescence assays for the cellular localization of *vpu*. Morphological changes associated with wild type or *vpu* mutant infections were examined by electron microscopy.

Results: Wild type or *vpu* mutant viruses have similar infectivity in human T-cells. However, infections with the *vpu* mutant resulted in earlier cell fusion and cell death, both of which paralleled the intracellular accumulation of viral proteins. Using indirect immunofluorescence assays, *vpu* was localized to the cytoplasm of infected cells; no *vpu* was detected in the nucleus or on the outer surface of the plasma membrane of virus producing T-cells. Electronmicroscopic analysis of cells infected with the *vpu* mutant revealed the presence of virus-like particles in the cytoplasm, intracellular budding, and an accumulation of immature particles at the cell surface; these features were not observed in cells producing wild type viruses.

Conclusions: *vpu* is required for the efficient release of HIV-1 particles from productively infected lymphocytes. The absence of *vpu* results in an intracellular accumulation of virus particles and inefficient virus maturation.

W.C.O.38 IN VITRO GENERATION OF NEUTRALIZATION-RESISTANT HEMAGGLUTININ DEFICIENCY VIRUS (HDV)

Takatsuki, K., Harada, Shinji*, Masuda, T., Kamogi, K., Hatemachi, S., and Institute for Virus Research, Kyoto University, Kyoto, Kyoto, 606 Japan. **Kumamoto University Medical School, Kumamoto, 860 Japan.

Objective: To prove that HIV produces antigenic variation in the presence of neutralizing monoclonal antibody (0.5).

Methods: Plaque-cloned HIVs and monoclonal antibody (0.5) which shows type-specific neutralization were used. The virus-infected MT-4 cells were cultured with or without 0.5 for 1 month to obtain variants of the virus. To know the antigenic changes of the viral envelope, we performed plaque assay for neutralization and radioimmunoassay. Restriction enzyme assay analyses were used to show the genetic changes.

Results: After 1 month of culture, we obtained variant viruses which showed cytotoxic effects even in the presence of 0.5. Neutralization test by 0.5 revealed that antigenic differences between control and variant were marked. Also, 0.5M precipitated gD2 of control but not of variant. Restriction enzyme assay analyses showed that there were no differences among them.

Conclusion: We showed that the alteration in virus neutralizability was observed in the presence of neutralizing monoclonal antibody, suggesting that this antibody may exert selective pressure. Restriction enzyme assay analyses indicate that genetic shift might be a minor one. Probably a point mutation was proposed.

Séance thématique Specialty Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

Modèles animaux (partie 3) Animal Models (Part 3)

W.C.O.45 NEUROPATHOLOGICAL STUDY OF HIV-INFECTED MACAQUES

Anderson, Daniel C., McClure, J.M., Silva, J.L., Anstair, A., Pulla, P., and Mirra, J.R.
*Yerkes Regional Center and Department of Pathology, Emory University, Atlanta, GA, *Armed Forces Institute of Pathology and Walter Reed Army Institute of Research, Washington, D.C., and *VA Medical Center, Atlanta, GA, U.S.A.

Objective: To determine the pathologic changes in the CNS of macaques acutely or chronically infected with HIV isolates P91-10 or 800-9. Methods: Brains and spinal cords from macaque animals were examined histologically at various intervals post-SIV infection. Included were brain animals that died 0-8 days post-infection (P.I.), brains from 2 from 17 macaques that died 9 months P.I., and brains from 2 chronically infected macaques that died 14-43 months P.I.

Results: Lesions were seen in the brain as early as 8 days P.I. Changes seen in animals dying shortly after infection include: (1) choroid plexitis and meningeal cell and occasional multinucleated giant cell inflammation unaccompanied by a T-lymphocyte infiltrate, and (2) astrocytosis with predominantly mononuclear cell inflammation. Parenchymal lesions were rare in animals dying shortly after infection; infected animals showed a less striking choroid plexitis and more frequent parenchymal granulomatous lesions comparable to HIV infection in humans produce CNS lesions with features reminiscent of HIV infection in man (immunopositivity with multilobar giant cells and macrophages). Continued study of the pathogenesis of SIV infection should provide important information related to the pathogenesis of CNS involvement in AIDS. (Supported by NIH grant RR0145).

W.C.O.47 MONKEYS WITH SIMIAN AIDS PRODUCE AN ANTIBODY DIRECTED AGAINST A HISTONE-LIKE PROTEIN ON CD4+ T-CELLS

Sticker, Raphael M., Fultz, P.N., Haslip, A.M.,
*University of California, San Francisco, CA, *Yerkes Regional Primate Research Center, Emory University, Atlanta, GA, U.S.A.

Previously it was shown that patients with AIDS and AIDS-related conditions produce a cytotoxic antibody that binds to lectin-stimulated or virally-infected CD4+ T-cells (Namer 207, T10-713, 1987). Subsequently it was discovered that the target antigen resembles a histone protein, H2B. We have now investigated the production of this antibody in monkeys infected with simian immunodeficiency virus (SIV). When macaques are infected with SIV, these monkeys develop symptoms of immunosuppression that characteristic of simian AIDS (SAIDS). In contrast, when mangabeys are infected with SIV, they remain healthy. Sera from 10 mangabeys and 10 macaques infected with SIV were tested for the presence of antibody against histone H2B by immunoblotting. The ten mangabeys (all healthy) did not have antibody against histone H2B detected in their sera. Four of the macaques were healthy at the time of testing, and some of their sera contained antibody against the histone protein. In contrast, the other six macaques had symptoms of SAIDS, and all six had antibody against histone H2B. When sera from these animals were tested sequentially, detection of antibody against the histone protein appeared to coincide with the onset of disease. The histone-like antigen was also detected on macaque lymphocytes, as determined by immunoblotting using monoclonal antibody against histone H2B. We conclude that monkeys with SAIDS produce an antibody that reacts with a histone-like protein expressed on CD4+ T-cells. This antibody may play a key role in the destruction of CD4+ T-cells in both AIDS and SAIDS.

W.C.O.49 EVIDENCE FOR PROGRESSION TO DISEASE IN CHIMPANZEES CHRONICALLY INFECTED WITH HIV-1

Dine, D., Davis, F., Fildes, R., Siegel, R., McClure, R., Steiner, K.W.,
*Yerkes Regional Primate Research Center and Department of Pathology, Emory University, Atlanta, GA, USA; *Yerkes Regional Primate Research Center, Emory, GA, USA

Objective: To assess the virologic, immunologic and clinical status of chimpanzees after long-term infection and immunization with HIV-1.
Methods: Following inoculation of HIV-1 and later therapeutic immunization with purified HIV antigens, chimpanzees were evaluated for hematologic status; vitreous status, including cell-free and cell-associated HIV and p24 antigenemia; and immune responses, including antibodies that neutralized virus infectivity, inhibited cell-to-cell transmission, asymptomatic formation, or RT activity.
Results: Of six chimpanzees infected for 45 to 54 months, three developed changes in antibody profiles or abnormalities in hematologic parameters. Two animals, one of which was persistently hypergammaglobulinemic for more than 6 years, lost antibodies to gag-antigenic epitopes. The third animal has been lymphopenic, with loss of CD4+ cells, and thymocyteopenic for more than 1 year, and recently became viremic, as evidenced by isolation of cell-free HIV from plasma. Therapeutic immunization had little effect on HIV-specific immune responses or clinical status.
Conclusions: Long-term infection of chimpanzees are developing abnormalities analogous to those that are predictive of AIDS in HIV-infected persons. If HIV-induced disease in chimpanzees is a function of length of time of infection, then HIV-infected chimpanzees may yet develop AIDS. (GR grant RR-00145 and CDC Contract 200-80-0667).

W.C.O.46 CLINICAL, IMMUNOLOGICAL, AND VIROLOGICAL FOLLOW UP OF HIV-1

INFECTED BRISIAN MONKEYS.
Dumont, Dominique, L'Orange, Y., Chavrier, S.O., Oustan, D., Ozi, Roudot, J., Maber, E.U., and Monod, J.P.,
*Centre de Recherches de l'Institut Pasteur, 213 Avenue de la Chimie, Pasteur, 91190, Fontaine aux Rues, FRANCE; *Institut Pasteur, Paris, FRANCE; *CEA, Bruyères le Châtel, FRANCE.

Objective: To establish an animal model of human HIV infection and/or clinical manifestations of AIDS, in order to understand pathogenesis of HIV infection, to test therapeutic protocols, and vaccine strategies. 10 rhesus monkeys have been inoculated with 2 different strains of HIV (89BR, 89RD) which were being "adapted" in vitro to monkey cells (fibroblasts, macrophages, T-cells). Monkeys were infected both by IV route and intracerebrally. Follow-up consisted in clinical survey, serological tests (RPA, mainly lymphocyte culture, CD4+CD8+ cells count and conventional blood chemistry tests). HIV-1 isolated in monkey lymphocyte culture and CSF have been compared to starting virus material by restriction map and by Southern blot analysis. A second, in vivo passage of HIV-1 in monkey, which exhibited in vivo biological properties in cell culture, is in progress.

Results: 2 animals inoculated (D10-230, earlier with the HIV-89RD strain adapted on cynomolgus cells than the other strain, HIV-79) was detectable in lymphocyte culture supernatants in 6 of the 7 animals who were observed in cell culture. Significant lymphopeny and decrease of CD4+ cells count were observed in 6 animals. Two animals exhibited clinical symptoms which might be related to HIV-1 infection: acute orchitis, dyspnea, serologic symptoms related to anticomplexon typhoid of the lungs of the monkey, for one animal, and weight loss, lymphadenopathy, and proctopyria for the other one. HIV-1 isolated from these monkeys behave differently in cell culture than the starting virus.
Conclusions: HIV-1 able to replicate in rhesus monkeys, and may induce clinical symptoms in some animals. This model has to be reproducible before being considered as a model for AIDS or for HIV infection. Molecular and biological markers of in vivo adaptation have to be investigated, and may help in understanding HIV infection pathogenesis and variability of clinical manifestations.

W.C.O.48 VACCINE PROTECTION AGAINST SIMIAN IMMUNODEFICIENCY VIRUS INFECTION

Daniel, Muthiah D., Sehgal, P., Wyand, M., Ringler, D.,
King, H., and Drenth, R.A.,
New England Regional Primate Research Center, Harvard Medical School, Southborough, MA, USA

Objective: To test the efficacy of inactivated simian immunodeficiency virus (SIV) (SIVmac) as a vaccine.
Methods: Rhesus macaques were immunized by multiple inoculations with purified, disrupted, non-infectious SIV in adjuvant (chromyl selenyl dipalmitate adjuvant formulation of SIVmac).
Results: Immunized animals developed anti-SIV antibodies detectable by Western blots and by Western blot; these antibodies had weak neutralizing activity. These macaques were challenged with 200 to 1000 animal infectious doses of live, cell-free SIV one week after the last immunization. SIV recovery from peripheral blood and anamnestic antibody responses were used to monitor infection. Two of six vaccinated macaques showed no evidence of infection after challenge with live virus. Four of four unvaccinated macaques became infected with these doses and three have died with AIDS 118-208 days after challenge. Only one of six vaccinated-challenged macaques has died to date.
Conclusions: These results suggest that inactivated whole virus vaccination can protect macaques against SIV challenge. The SIV animal model appears useful for comparison of AIDS vaccine strategies.

W.C.O.50 GENETIC VARIATION OF SIV IN EXPERIMENTALLY INFECTED MACAQUES: TISSUE VERSUS TISSUE CULTURE

Chakravorty, Venkatesh, Kulkarni, M.L., *MADANI, Bethesda, MD, U.S.A.,
Johnston, J.M.B., Orosz, R.A., Purcell, R.H.,** and Hirsch, V.M.,
*Chattanooga University, Knoxville, TN, **NIH/NIH, Bethesda, MD, U.S.A.

Objective: Lentiviruses have the potential for significant genetic variation during natural course. Viruses isolated from infected animals with 2 different strains of certain variants in tissue culture; and, (ii) the presence of replicating and non-replicating variants. To address these issues, we have begun to analyze and compare SIV proviral DNA in tissues from SIV-infected macaques and in cell lines from the same macaques. We have identified 2 main **Mac/Man/Repl** strains. Three groups of macaques were infected with SIV from a sooty mangabey (SIVsmm) group 1 received unselected SIV; group 2 received SIVsmm (sm1-3), derived from a biologically active molecular clone; and, group C received sm1-4, derived from a second SIVsmm molecular clone. One macaque in group A died 7 weeks after inoculation from disseminated CMV infection. On Southern blot analysis, skin origin Southern blot contained one detectable proviral form. Portions of proviral DNA isolated from cultured with CEM cells or processed for genomic DNA isolation. Comparative Southern blots revealed that 1) multiple proviruses were present in the acutely infected CEM cell line and the splenic tissue; and, (ii) a major proviral form present in the splenic tissue (equivalent with the original form) was not detected in the CEM cell line. Furthermore, this proviral form was also detected (at varying levels) in liver, kidney, and lymph nodes. This cloning and molecular characterization of these proviral variants are underway.
Conclusions: Multiple proviral forms of SIV arise during infection of macaques. Certain variants may not be recovered in tissue culture despite a high integrated proviral copy number. The importance of these variants is unclear, but they may play a role in the pathogenesis of SIV infection.

Colloque Symposium



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

Aspects pathologiques de l'infection par le VIH Pathological Aspects of HIV Infection

Th.C.0.7 DISTINCT HISTOLOGIC LYMPH NODE CHANGES FOLLOWING HIV INFECTION IN ADULTS

Berlin, Nancy L., Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, U.S.A.
Objective: To develop a clinically relevant classification of lymph node histopathology in HIV infection.

Methods: This report is a review of histopathologic and immunohistologic findings in lymph node biopsy and autopsy specimens from patients with HIV infection seen at Massachusetts General Hospital since 1982, as well as a review of the recent literature.

- Results:** At least 6 major types of lymph node histopathology are seen in HIV infected patients, either alone or in combination with other types:
1. Florid reactive follicular hyperplasia ± follicle-lysis
 2. Follicular involution
 3. Diffuse pattern (± lymphocyte depletion ± neoplasmoembolic changes.)
 4. Atypical follicular hyperplasia (Gonorrhea-like lesion)
 5. Tumors: a. Malignant lymphoma (Burkitt-like or immunoblastic) b. Kaposi's sarcoma (primary or secondary)
 6. Specific infections

Types 3-6 are usually associated with one or more diagnostic criteria for AIDS. While Types 1 and 2 may be associated with POAGC, and are not specific for HIV infection. Types 1 and 2 may be associated with normal lymph node CD4/CD8 populations or with CD4 depletion; CD4 depletion is often pronounced in type 3. Type 4 pattern is strongly correlated with lymphadenopathy Kaposi's sarcoma.
Conclusion: Lymph nodes in HIV infected patients may show a variety of patterns with important prognostic implications.

Th.C.0.9

IN SITU HYBRIDIZATION FOR DETECTION OF HIV GENOME

Peter Biberfeld, Carlo Perruccio*, Marianne Ekman*, Anne Magnusson*, Anna Forsvar*, Robert C. Gallo*, Immunovirology Lab, Karolinska Institute, Stockholm, Sweden, *Chair Pathology, Milano University, Milano, Italy, **ATCC, MD, NIH, Bethesda, Maryland, U.S.A.

The pathogenic mechanisms of HIV have been studied by *in situ* hybridization and immunohistochemistry in lymph nodes of various stages of HIV infection and in lymph nodes from AIDS patients. *In situ* hybridization was made of 30 labeled (P. Biberfeld, M. Perruccio et al., *AIDS* 1985;4:104-110) as well as unlabeled (Magnusson, HIV DNA: From Cells, LaFont and Engvallsson, *Journal of Cellular Biochemistry* 1985;24:1-10) probes (p24, p27, p28, p29, p30, p31, p32, p33, p34, p35, p36, p37, p38, p39, p40, p41, p42, p43, p44, p45, p46, p47, p48, p49, p50, p51, p52, p53, p54, p55, p56, p57, p58, p59, p60, p61, p62, p63, p64, p65, p66, p67, p68, p69, p70, p71, p72, p73, p74, p75, p76, p77, p78, p79, p80, p81, p82, p83, p84, p85, p86, p87, p88, p89, p90, p91, p92, p93, p94, p95, p96, p97, p98, p99, p100) as well as anti-HIV antibodies. The results of the hybridization and immunohistochemistry were compared with the results of immunohistochemistry for screening of lymph material and cells and also combined simultaneous detection of viral antigens and RNA.

Th.C.0.8 DETECTION OF HIV IN LYMPH NODES

Bissegger, Hermann-Horst-Johanna for Tropical Medicine, Hamburg, West Germany.

In lymph nodes (LN) of HIV-infected persons the causative agent can be detected using electron microscope (EM), immunocytochemistry (IC) or *in situ* hybridization. Applying immunostaining on frozen sections gag proteins of HIV can be visualized in germinal centers (GC) of LN. This reaction is highly sensitive and specific, therefore, it can be used for diagnostic purposes. Concordant staining with gag proteins and antibody to follicular dendritic cells (FDC) shows the association of viral antigen to FDC. In correlation with these findings, EM shows that HIV-particles along the processes of FDC. Results of *in situ* hybridization have also shown the presence of cells expressing viral RNA inside the GC. HIV enters the GC early during the course of infection. We have demonstrated the infection of GC both with EM and IC 4 weeks after seroconversion. Once gained access to GC, HIV can persist here for long time periods. On repeated biopsy specimens we have detected HIV up to 2 year intervals. Not only GC of LN but also those in gut associated lymphoid tissue contain HIV-proteins associated with FDC. Thus, it is very important that FDC as antigen trapping and retaining cells are very important in the pathogenesis of HIV-infection. FDC probably capture HIV transported by lymphatics. Using EM, IC and *in situ* hybridization we have found evidence for spreading of HIV via lymphatics. We feel that this way of dissemination is especially important when HIV enters the body through a mucous membrane.

Th.C.0.10 BIOLOGICAL FUNCTIONS OF HUMAN MONOCLONAL ANTIBODIES TO HIV.

Sollitt-Hamer, G., Reardon, M., West, Victoria Elic and Hershfield, R.W. Veterans Admin. Hosp., New York, NY, *Wadsworth Univ., Hawthorne, NY, Univ. of Texas Southwestern Med. Ctr., Dallas, TX & *Duke Univ. Med. Ctr., Durham, NC.

OBJECTIVE: To characterize the biological functions of human monoclonal anti-lysozyme (mAb) to HIV.
RESULTS: Monoclonal cells from peripheral blood of HIV-infected subjects were infected with Epstein-Barr virus and cultured in microtitre plates for one month. Wells making anti-HIV were expanded and cloned at limiting dilution. mAb from each clone were tested for specificity by ELISA, radio-immunoprecipitation, and Western blot and assayed for function as described in abstracts 2022, 4331 and 4473.

RESULTS: Of 11 lymphoblastoid lines producing mAb to HIV, mAb from 5 lines react with gp41. Five react with p24. mAb to gp41 mediate antibody-dependent cell-mediated cytotoxicity requiring 1-5 µg mAb/ml. Of the 11 mAb, only one, specific for gp41, mediates complement- and antibody-dependent enhancement of HIV infection requiring 1 µg mAb/ml. Two mAb to gp41 were capable of the depolymerized chain of ricin. 50% killing of the HIV-infected T cell line, HT-1080, occurs at 500 µg/ml. 50% killing of the HIV-infected U937 myelocyte cell line is achieved at 1000 µg/ml in the absence of chloroquine and at 10 µg/ml in the presence of chloroquine. None of the mAb to gp41 are neutralizing or mediate opsonic inhibition. None of the mAb to p24 are active in any of the described functional assays.

CONCLUSIONS: Human mAb to gp41 mediate a variety of biological functions. No biological functions here, as yet, been ascribed to human mAb to p24.

Séance thématique Specialty Session



Recherche fondamentale (biomédecine)
Basic Research (Biomedical)

Mise au point de médicaments : utilisation de l'AZT et d'autres oligonucleotides dans le traitement du SIDA Drug Development: Use of AZT and Other Oligonucleotides in AIDS Therapy

Th.C.0.17 Differential modulation of HIV replication and AZT activity in monocyte/macrophages by Gm-CSF, M-CSF, and G-CSF.
Johns, D., Broder, National Cancer Institute, Bethesda, MD, USA.

Objective: To study the ability of granulocyte-macrophage colony stimulating factor (Gm-CSF), macrophage-colony stimulating factor (M-CSF), and granulocyte colony stimulating factor (G-CSF) to modulate HIV replication and/or the antiviral activity of AZT in monocyte/macrophages (MΦ).
Methods: Elutriated MΦ were exposed to 100 U/ml Gm-CSF, 1,000 U/ml M-CSF, or 100 U/ml G-CSF for 5 days before challenge with HIV-1 (genenotypic strain NL4-3) or lymphotropic strain HTLV-IIIa) with/without AZT. Analogous phosphorylation of AZT was also studied in MΦ with/without Gm-CSF, M-CSF, or G-CSF. AZT enhances replication (up to 1,000x) of both HTLV-IIIa) and HTLV-IIIg in MΦ, and reduces >100x the minimum viral dose required to productively infect the MΦ. MΦ also enhance HIV replication (not less than Gm-CSF), while G-CSF had no effect. Despite increasing HIV infection, Gm-CSF activates the antiviral activity of AZT and related thymidine and uridine congeners in MΦ. 0.01 nM AZT reduces 250x viral titration in Gm-CSF-stimulated MΦ, while 1 nM AZT is required to achieve the same effect in MΦ without G-CSF. The effect of other dideoxynucleosides not related to AZT is not enhanced by Gm-CSF. Neither M-CSF nor G-CSF modulated AZT activity in MΦ. G-CSF increases the intracellular level of AZT and its triphosphorylated form in MΦ, but only induces a minimal increase of thymidine 5'-triphosphate (dTPP). Thus the ratio of AZT/dTPP is substantially increased in MΦ exposed to Gm-CSF, and this may explain its enhancement of AZT activity.
Conclusion: A combination of Gm-CSF plus AZT (or a related congener) may be worth exploring in patients with HIV-related disease.

Th.C.0.19 INHIBITION OF HIV EXPRESSION: ENHANCEMENT OF ACTIVITY OF PHOSPHOROTHIOLATE OLIGONUCLEOTIDES BY CHEMICAL MODIFICATION.
Natsuguro Makiyoshi, Hori K., Sato S., Cohen J.S.,**
*Mitsubishi Kagaku Iryo, **Medical Research, National Cancer Institute, National Institutes of Health, Bethesda MD and ***Applied BioSystems Inc., Foster City CA, U.S.A.*

Objective: Phosphorothiolate oligonucleotides in an antisense configuration against the HIV *env* mRNA showed significant inhibition against HIV-1 viral expression in chronically infected cells (Proc. Natl. Acad. Sci. 1989, in press). However, relatively high concentrations were required to inhibit viral expression. Therefore, it is reasonable to explore chemical modifications of the phosphorothiolate oligomer to enhance such anti-HIV activity.
Methods: We synthesized a series of compounds by linking intercalating moieties or by modifying the bases. Compounds were tested in the viral expression inhibition assay using chronically HIV-1 infected SP cells.
Results: Anthracylene-conjugated and acridine-conjugated antisense phosphorothiolate oligomers against *env* showed more potent inhibitory activities against the viral expression in chronically infected cells in comparison to unmodified phosphorothiolate antisense by approximately 10 fold and 5 fold, respectively. Another modification, the use of allyl-methoxy derivatives on thymidine bases, also showed an enhancement of the antiviral activity by approximately 2 fold. These modifications in these modified phosphorothiolate oligomers are at least comparable to that in the unmodified antisense phosphorothiolate oligomer.
Conclusion: Certain modifications of antisense phosphorothiolate oligomers could result in advantages to potential therapeutic intervention against AIDS and related diseases.

Th.C.0.21 CONFORMATIONAL PREFERENCE OF ANTI-HIV NUCLEOSIDES AND DRUG DESIGN

*P. Van Roye¹, L. Dierckx², E.W. Taylor¹, R.F. Schmitz¹
¹Medical Foundation York, ²UDBrno, ³University of Georgia
College of Pharmacy, Athens, Georgia 30602, ⁴Henry University School of Medicine/VA Medical Center, Athens, Georgia 30603, U.S.A.*

Objective: To study the molecular conformations of anti-HIV nucleosides for drug design.

Methods: Molecular conformations of active as well as inactive nucleosides against HIV have been determined by X-ray crystallography.

Results: Active anti-HIV nucleosides show several conformational features in the glycosyl link geometry and sugar ring puckering. The active nucleosides have the extreme end of the range of observed anti-conformations. Ten of the eleven observations of active compounds have exceptional C2'-endo sugar conformations. The inactive nucleosides on the other hand, have C3'-endo conformations. The correlation between the extreme glycosyl link conformation and sugar ring puckering is significant.

Conclusion: These differences in conformations between active and inactive nucleosides result in a significant difference in the position and orientation of the 5'-hydroxy group. Because the phosphorylation at 3'-position of the carboxamide moiety is the initial and essential activation step in the nucleoside compounds, these conformational differences may account for the activity difference. Furthermore, this information may allow us to design new anti-HIV agents.
(Supported by USPHS Grants AI 20055, AI 25899, DA 34789 and Veterans Administration)

Th.C.0.18 INHIBITION OF HIV REPLICATION BY NOVEL PHOSPHORYLATED DERIVATIVES OF AZT AND OTHER DIDEOXYNUCLEOSIDES INCORPORATED IN VIRION
*Rezaglar, Kazu Y.,** and Richman, Douglas D.,**
**Vical Inc., San Diego, California and *University of California, San Diego and the VA Medical Center, San Diego.*

Monocyte/macrophage represent an important reservoir of HIV infection. Specific therapies to target these cells might halt HIV infection more effectively. Consequently, we synthesized phosphorylated AZT (P-AZT) and AZT diphosphate diphosphate (AZTDP), new phosphorylated AZT with a phosphate group on their polar head groups. Liposomal P-AZT and AZTDP (Pro-AZT) were incubated with CD4 cells infected with HIV-1. The amount of drug required to reduce by 50% the release of p24 antigen into the culture medium after 24 hours was determined. The IC₅₀ values for P-AZT and AZTDP were 1.0-2.0 and 1.0-2.0 μM, respectively. No cell toxicity was observed at liposomal concentrations of 100 to 200 nM or greater. Liposome with no liposomal phospholipid was ineffective. P-AZT was also effective to protect CD4 cells lacking thymidine kinase (TK), demonstrating that the new AZT compound can be metabolized directly to AZT-monophosphate. AZT has no antiviral activity in these cells. Phospholipid derivatives of AZT, AZT and dCTP were also effective in a plaque inhibition assay in CD4+ cells and in p24 reduction assays. P-AZT and AZTDP were also effective in reducing HIV p24 production and plaque formation. These compounds are relatively non-toxic, bypass phosphatase inhibition by calciferol and appear to be promising candidate compounds for treatment of the monocyte/macrophage reservoir of HIV infection.

Th.C.0.20 3-HALOGENO-2'-FLUORO-3'-DEOXYNUCLEOSIDES ARE POTENT INHIBITORS OF HIV REPLICATION IN VITRO AND IN VIVO
*Jan Balzarik, A. Van Aerchele, C. Roelants, R. Pauwels, M. Bala, D. Schrijn, R. De Clercq,
Radboud Institute for Medical Research and Biotechnology, X.U.Leuven, B-3000 Leuven, Belgium*

The 3-halogeno (i.e., 3-Fluoro-, 3-chloro-, 3-bromo- and 3-Iodo) derivatives of 2'-fluoro-3'-deoxythymidine (FdTID), designated PdFtdP, PdClFtdP, PdBrFtdP and PdIFtdP, respectively, were synthesized and evaluated for their activity against human immunodeficiency virus (HIV) and simian AIDS related virus (SRV). PdFtdP did not show any appreciable antiviral activity at subtoxic concentrations. In contrast, all three other 3-halogeno PdFtdP derivatives inhibited HIV-1 and HIV-2 replication in H9-cells at an effective dose (ED₅₀) of about 0.2-0.7 μM. Also, HIV-1-induced antigen expression in H9-T8 cells was suppressed by the three 3-halogeno PdFtdP derivatives. PdClFtdP was markedly more selective in its anti-HIV activity in MT-4 cells than PdBrFtdP and PdIFtdP. Its selectivity index was similar to that of 3'-azido-2',3'-dideoxycytidine (AZT, ddC). PdClFtdP was also effective in inhibiting SRV-induced giant cell formation in Raji cell cultures (ED₅₀ 1 μM) but not in thymidine kinase (TK)-deficient H9 cells (ED₅₀ > 200 μM), pointing to a structural role of cellular TK in the metabolic activation of PdClFtdP. Unlike AZT, PdClFtdP did not cause a blockage of thymidylate kinase. PdClFtdP was also less toxic to mouse marrow cells than AZT. In conclusion, the 3-halogeno PdFtdP derivatives, and in particular PdClFtdP, should be further pursued for their potential in the treatment of AIDS.

Th.C.0.22 SYNTHESIS AND *IN VITRO* FUNCTION OF RIBOSYMS TARGETED TO HIV-1 SPECIFIC RNA
*Rossi, J., Chang, P., Stephens, D.,** Lunde, P.,**
Cantle, C.,** and John, S.,**
**City of Hope Medical Center, Duarte, Calif., U.S.A.*

Objective: To design and test catalytic RNA specific for HIV-1. **Methods:** We have utilized two classes of catalytic ribozymes targeted to HIV-1 RNA: one class (RRZ) is targeted to the 5' RNA gene containing part of the required autocleavage site (GAAC...GGG). The remainder of the required sequence (CGAGG...), supplied *in trans* along with flanking sequences, is provided specifically by the second class of ribozyme (GUR-RZ). It is patterned from Haseloff and Gerlach (Nature 25: 119, 1985) and contains the required sequence for autocleavage (except the target site GUR) along with appropriate flanking sequences to promote hybridization to a specific GUA site in the HIV-1 RNA. RRZ and GUR-RZ were synthesized by *in vitro* transcription, purified by PAGE, incubated under varying conditions with the target HIV-1 RNA transcripts, and analyzed by PAGE and autoradiography.

Results: GUR-RZ targeted to cag cleaved the HIV-1 RNA more efficiently than RRZ. The GUR-RZ cleavage reaction is entirely magnesium dependent (10 mM) 20mM KCl. The cleavage is pH dependent (optimal range from 7.2 to 8.0) and completely cleaves large molar excesses of substrate. GUR-RZ can be designed which can potentially target any GUA site in the HIV-1 genome and deserve evaluation as potential antiviral agents.

Séance thématique Specialty Session



Recherche fondamentale (biomédecine)
Basic Research (Biomedical)

Vaccins : étude de l'immunisation à l'aide des glycoprotéines du VIH Vaccines: Immunization Study Using HIV Glycoproteins

Th.C.0.29 EPITOPES RECOGNIZED BY THE NEUTRALIZING ANTIBODIES OF AN HIV-1 INFECTED INDIVIDUAL

Ernst, Albert L.; Sellins, P. T.; Eckler, L. J.; Nara, P. M.; Matthews, L. M., et al. **at al.** **Regen** Corporation, Cambridge, MA, USA. **National Cancer Institute, Frederick, MD, USA.** **Duke University Medical School, Durham, NC, USA.**

Objective: To determine the extent to which broadly neutralizing antibodies raised by an HIV-1-infected individual recognize the principal neutralizing epitope of the envelope protein gp120 amino acids 296-331.

Methods: Broadly neutralizing serum from an antibody-positive, HIV-infected donor was subjected to affinity chromatography on immobilized peptides corresponding to the neutralizing epitope of three viral isolates. Effluent and eluate fractions were assayed for inhibition of HIV-1 infection of cell fusion and neutralization of each of the three isolates.

Results: Most of the antibodies that neutralize one isolate were absorbed by peptides corresponding to its 296-331 envelope sequence. By contrast, most of the antibodies that neutralize the other two isolates were not absorbed by the immobilized peptides.

Conclusions: Infected humans seem to raise a type-specific neutralizing response against the principal neutralizing epitope of one isolate. Broad neutralization appears to result from the recognition of other epitopes as yet unidentified.

Th.C.0.30 NEUTRALIZATION OF IN VIVO HIV-1 INFECTIVITY MEDIATED BY IN VITRO NEUTRALIZING ANTIBODY

Thairu, Shigehiko A.; Eickbush, J. M.; Nara, P. L.; Lewis, J. M.; Matsushita, T.; Kelley, J. D., et al. **Regen** Corp., **W.A.R.C. Japan and Dohme Research Laboratories, Inc.,** **NIH** Natl. P.H. **Southwest Foundation for Biomedical Research, San Antonio, TX.** **NIH-CDC-Frederick Cancer Research Facility, Frederick, MD.** **University Medical School, Japan.** **Regen Corporation, Cambridge, MA, U.S.A.**

Objective: To determine if an association exists between the ability of antibody to neutralize HIV infectivity *in vitro* and its ability to prevent HIV infection *in vivo*.

Methods: HIV-1RT⁺ challenge challenge inocula of HIV-1 (isolate HTLV-IIIB) were individually incubated *in vitro* with (1) virus-neutralizing IgG from an HIV-seropositive challengee, (2) a specific neutralizing monoclonal antibody (0.56), (3) non-neutralizing IgG from an HIV-seropositive human, (4) IgG from an uninfected control. Both neutralizing IgG preparations were directed against the gp120 major neutralizing determinant.

Results and Conclusions: The polyclonal neutralizing IgG inhibited *in vivo* HIV infection by the criterion of specific anti-HIV antibody development in the challengee animal. Similarly, the monoclonal neutralizing antibody decreased the infectiousness of the challenge virus. No effect was noted when the non-neutralizing anti-HIV IgG or the control IgG. Correlation appears to exist between the ability of antibody to neutralize HIV infectivity *in vitro* and its ability to inhibit HIV infection *in vivo*.

Th.C.0.31 STUDIES OF HYPERVARIABLE REGION DELETION MUTANTS OF HIV-1

Steiner, K. S. et al. Chino, E.; Moore, G. C.; Mann, K. A.; Proyas, P. T.; Skiles, P. V. **University of California, Los Angeles, California, U.S.A.**

Objective: To determine the role of hypervariable regions in the structure, function, and immunogenicity of HIV-1 gp120.

Methods: Sequences encoding the five major hypervariable domains of the gp120 region of the envelope gene were deleted using standard mutagenesis. These domains encompassed amino acids 131-154 (V1), 161-198 (V2), 300-332 (V3), 388-414 (V4), and 457-463 (V5). The resulting variants were produced in recombinant cells as nonglycosylated soluble CD4 or secreted, glycosylated proteins in mammalian cells. CD4 binding of each gp120 variant was measured by radioimmune precipitation of gp120 variants and recombinant, antibody CD4. Purified virus-derived variants were used by hyperimmune mice animals. ELISA titers versus the immunizing antigen and virus neutralization titers against HIV-92 and HIV-83U were determined using standard techniques.

Results: Deleted, nonglycosylated virus-derived wild type gp120 did not bind to CD4 while purified or supported mammalian cell-derived glycosylated gp120 bound CD4 as well as gp120 from virus-infected cells. Mammalian cell-derived gp120 variants of any or all of the three hypervariable regions in the C-terminal half of gp120 (V3, V4, V5) resulted in CD4 binding that was at least 10-fold reduced relative to wild type gp120. In contrast, deletion of the variable regions in the N-terminal half of the protein (V1, V2) did not perturb CD4 binding. In immunogenicity studies, deleted, nonglycosylated gp120 polypeptides deleted in one to three hypervariable regions, including deletion of V3, elicited type-specific neutralization in guinea pigs and mice. However, the nonglycosylated protein with deletion of all five hypervariable regions failed to generate neutralizing activity, although it elicited high titer antibody responses.

Conclusions: Hypervariable regions play a major role in the immunogenicity of nonglycosylated versions of gp120 and may influence the structure of glycosylated gp120 and its binding to CD4.

Th.C.0.32 ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC) FOLLOWING VACCINATION WITH A RECOMBINANT HIV-1 GP120 VACCINE

Corse, Geoffrey; Newman, P. J.; Balash, R. B.; and MIAID. **Merrell University, Fremont, W.A.** **Method, WA, USA.**

Background: Sera from asymptomatic HIV-1 infected patients are more likely to mediate ADCC than sera from AIDS patients. Thus, stimulation of serum ADCC activity may be a desirable goal in the development of an AIDS vaccine. **Objective:** To measure ADCC activity in sera obtained from persons in an HIV-10 (Microsome) vaccine trial.

Methods: We tested sera from four adult vaccinees who developed antibody to gp120 on Western Blot after three doses of 40ug or 80ug of gp120, and one placebo recipient whose Western Blot remained negative for anti-HIV-1 antibody. Target cells were HIV-1 infected and uninfected T20 cells (a variant of the CD4 T-cell line) which were labeled with ⁵¹Cr and incubated with vaccinee sera and control Western Blot positive sera from HIV-1 infected patients at dilutions of 1:5 to 1:40. PMA from normal healthy adults served as an effector cells at an E/T ratio of 50:1. Percent ADCC was measured as antibody dependent minus antibody independent lysis. **Results:** Sera from one vaccinee demonstrated a transient increase in percent ADCC. The vaccinee received 80ug doses of gp120. None of 3 other vaccinees nor the placebo vaccinee manifested significant percent ADCC during the study.

Conclusion: We conclude that gp120 at the two dose levels tested did not induce significant persisting antibody which mediated ADCC.

Th.C.0.33 SAFETY AND IMMUNOGENICITY OF HIV-1 RECOMBINANT GP 120 VACCINE CANDIDATE IN NORMAL VOLUNTEERS.

Belish, R. A.; Chinn, S. S.; Stahler, D. A.; Smith, C. M.; and Krets W. **University of Rochester, Rochester, NY.** **NIH AIDS Vaccine Program, and *Microbiology, West Haven, CT, U.S.A.**

Objective: To assess the safety and immunogenicity of two dosages of an HIV envelope glycoprotein (gp120) vaccine in normal volunteers.

Methods: Recombinant HIV-1 glycoprotein (gp120), prepared using a baculovirus vector (MicroGeneSys) was studied in 72 normal volunteers in a multicenter study, employing a double-blind, controlled experimental design. 18 subjects received 40 ug of gp120, 18 received 80 ug of gp120, 18 received hepatitis B vaccine, and 18 received placebo. 3 intramuscular injections were employed (Days 0, 30, 180). Subjects were followed for clinical and laboratory toxicities for up to 1 year. Serum antibody responses were determined by Western blot (WB), ELISA, and neutralization (NI) assays. **Results:** 39 females and 33 males participated, and 67 subjects received all three immunizations. gp120 was well tolerated, and there were no differences in acute or chronic toxicity between the groups. There were also no differences in WB, T4, T8, blast counts or Hb levels among the groups. Serum antibodies to gp120 detected by WB were first noted at day 18 in 8/17 subjects at the 40ug dose, and in 8/17 at 80ug. At day 180, 10/17 at the 40 ug dose and 15/17 at the 80ug dose were seroreactive by WB. Antibody response to gp120 was less than 1:1000. Antibodies appeared generally later and less frequently than WB antibodies. Studies of NI antibodies are currently underway.

Conclusions: This gp120 vaccine candidate is well tolerated and non-toxic in normal volunteers, and induced high rates of serum antibody responses as detected by WB.

Th.C.0.34 T CELL RESPONSES TO HIV IN HUMANS IMMUNIZED WITH RECOMBINANT VACCINES

Conry, Elizabeth M.; Ziering, J. M.; Hu, S. L.; Wasson, A. M.; Conry, L. G.; and Greenberg, M. L. **NIH** and Washington University, St. Louis, MO, USA.

Objective: To study T cell responses to HIV antigens and vaccines (VAc) using a Phase I vaccine trial with a recombinant VAc containing the HIV gp160 gene (HIVAc-1c).

Methods: 30 subjects were vaccinated and then boosted with either wild-type VAc or HIVAc-1c. T cell in vitro proliferative responses to a panel of antigens were determined pre- and 4-week intervals post-vaccination. **Results:** In vitro stimuli were several HIV antigens preparations including UV-irradiated inactivated HIV, live HIV, and gp160, immunogens including VAc, HIV, CMV, and a non-HIV antigen including Pfla, Cln A and Pfla.

Results: T cell responses and serum neutralizing antibody to VAc were detectable pre-vaccination in all 26/30 subjects previously immunized to VAc, including 13/15 recipients of HIVAc-1c. Association with HIVAc-1c significantly boosted the T cell response to VAc in 7/13 and this correlated with a 4-fold rise in the serum antibody titer. The 2 HIVAc-1c recipients with no detectable T cell responses to VAc following priming, *in vitro* proliferative responses to VAc at week 8 stimulus augmented the proliferative T cell responses of the 30 subjects to VAc. Of the 13/15 HIVAc-1c recipients with pre-existing immunity to VAc, 5 developed low and/or transient responses to one of the HIV antigen preparations. By contrast, the 2 HIVAc-1c recipients with no detectable T cell responses pre-vaccination to HIV antigens post-vaccination. No significant HIV antigen responses were detected in the 2 HIVAc-1c recipients who were not affected by vaccination with either VAc or HIVAc-1c. **Conclusions:** Vaccination of individuals lacking cellular immunity to VAc, with a recombinant VAc expressing gp160 elicits strong T cell proliferative responses to HIV, and stimulates in progress to define the CTL response in these individuals. Individuals previously vaccinated demonstrate persistent immunity to VAc and are variably primed to HIV antigens by vaccination, and studies to further characterize and augment these responses are being performed.

**Colloque
Symposium**

**Recherche fondamentale (biomédicale)
Basic Research (Biomedical)**
**Le rôle des macrophages et des lymphocytes comme réservoirs du VIH-1
Role of Macrophages and Lymphocytes as Reservoirs of HIV-1**
Th.C.0.41

ENTRY OF HIV INTO CELLS
Montagnier, L., Sureau, P., J., Grolloff, G.,
 Clapham, P.R., Gajjar, S., J., Grolloff, G.,
 Kennedy, N.S., Grolloff, G., J., Grolloff, G., J., Grolloff, G.,
 National Center for Disease Control, Atlanta, GA, USA, *Columbia University, New York, NY, USA, **Charat, Beatty Laboratories, London, UK.

Objective. To determine whether the CD4 molecule, which serves as an attachment protein (receptor) for HIV, also functions in the HIV internalization event.
Methods. Conditions for saturating cells with HIV and for synchronizing the penetration event were developed as were assays to detect CD4 internalization and HIV penetration. Mutations were introduced into the cytoplasmic segment of CD4 rendering cells that express these mutant CD4 molecules incapable of phosphokinase C-induced CD4 internalization.
Results. Tracking CD4 during HIV penetration failed to detect CD4 internalization. Induction of CD4 internalization did not enhance HIV infectivity nor did inhibition of CD4 internalization prevent HIV infection. Cells expressing CD4 mutant molecules that are incapable of internalization were, nevertheless, infectible by HIV.
Conclusion. HIV penetration does not require internalization of its receptor, CD4.

Th.C.0.43

SURFACE RECOGNITION STRUCTURE FOR HIV
A.G. Deligdis

MRC Clinical Research Centre, Harrow, HA1 3UH, U.K.

The surface recognition structure for HIV is the CD4 molecules which binds to the gp120 component of the HIV envelope with a high affinity (10^{10}). This property is conserved amongst all isolates of HIV-1, HIV and HIV-2, although the affinity may be lower in the latter. This remarkable attraction of the envelope for such an important immunological ligand as CD4 may well explain the development of an acquired immunodeficiency without involving direct cytotoxic effect by the complete virus. Masking of the CD4 epitopes by envelope may prevent antigen presentation and other CD4 dependent immunological functions, as well as leading to clonal deletion of activated CD4 cells by cytotoxic cells. These hypotheses may be investigated using soluble CD4 and soluble gp120. The detrimental effect of soluble gp120 in immunological responses assays, and the beneficial effect of soluble CD4 *in vitro* and *in vivo* virological systems suggests that soluble CD4 may have beneficial therapeutic effects even at doses much less than those required to have an antiviral effect *per se*, simply by inactivating soluble gp120 and free virus. Vaccine strategies based on gp120/CD4 have been examined using anti-CD4 monoclonal antibodies which may induce an internal image resembling the gp120 binding site on CD4 and therefore bind and neutralise a broad range of HIV isolates. These studies have now been extended to further characterize the anti-idiotypic response, the role of adjuvants and the response of the human immune system to anti-CD4 monoclonal antibodies.

Th.C.0.42

ROLE OF MACROPHAGES IN PATHOGENESIS OF HIV
Sarkar, Suman, and Popovici, M.
 *New Mexico State University Health Research Institute,
 Las Alamos, New Mexico, USA, *National Cancer Institute,
 National Institutes of Health, Bethesda, Maryland, USA.

Both *in vivo* and *in vitro* studies clearly indicate that cells of the monoclonal phagocyte lineage play a key role in the pathogenesis of AIDS. To facilitate a more detailed analysis of HIV-1 interactions with cell types of this lineage, a cell culture system using normal monocytes/macrophages (MΦ) from peripheral blood has been developed. We have previously shown that MΦ are highly susceptible and permissive hosts for "fresh" HIV-1 isolates recovered from various tissues of virus-positive individuals. Utilizing this MΦ cell culture system, we will present data demonstrating that (a) cells of the monoclonal phagocyte lineage are principal sites of HIV-1 replication early in the course of the virus infection, (b) "freshly" recovered (not propagated in permanent cell lines) HIV-1 isolates are dual (MΦ and T cell) tropic, (c) in HIV-1 infected MΦ exhibit functional alterations similar to those observed in AIDS patients and (d) the most efficient HIV-1 transmission from MΦ to T cells occurs during specific antigen presentation.

Th.C.0.44

CYTOKINE INDUCTION OF HIV EXPRESSION
Fazel, Anthony, A. National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

We have previously established an *in vitro* model system for the study of the induction of expression of HIV in latently or chronically infected promonocytic (U-1) and T lymphocyte (ACH-2) cell clones. We have used these systems to demonstrate the induction of HIV expression in these cell lines by certain cytokines. Specifically, tumor necrosis factor (TNF)-alpha was capable of inducing HIV expression in both U-1 and ACH-2 cells. Other cytokines such as interleukin (IL)-6 and granulocyte-macrophage colony stimulating factor (GM-CSF) were able to induce HIV expression in U-1 but not in ACH-2 cells. In addition, there was significant synergy between TNF-alpha and IL-6, and TNF-alpha and GM-CSF in the induction of HIV expression in the U-1 cell line. The pathways of induction consisted of a transactivating mechanism whereby a DNA-binding protein was shown to selectively bind to the NFkB site of the HIV LTR. Most recent experiments have demonstrated an autocrine/paracrine loop involving the induction of HIV expression by TNF-alpha which in synergy with TNF can regulate its own expression. Furthermore, we have demonstrated that cytokine induction of HIV expression involves the direct or indirect activation of phosphokinase C (PKC) and that inhibitors of PKC can inhibit HIV expression. These model systems will be used to further delineate the precise mechanisms of HIV expression and, perhaps, the control of expression of HIV in infected cells.

Séance thématique Specialty Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

Vaccins : utilisation d'un modèle animal pour l'étude des vaccins anti-VIH Vaccines: Use of Animal Model to Study Anti-HIV Vaccines

Th.C.0.45 Immunization of Rhesus Monkeys with Inactivated HIV Fails to Protect Against Mucosal or IV Challenge
Rappaport, J., Pedersen, E., Gardner, J., Hanson, C.V., Miller, C., Gottlie, A., Jennings, M., Ripstein, J. and Marx, P.A. University of California, Davis, Davis, CA, U.S.A.

Objective: To determine if immunization of rhesus monkeys with an inactivated whole virus live (SIV) vaccine protects against mucosal or IV challenge with live HIV.
Methods: Eight juvenile rhesus received 4 immunizations (2 by total viral protein) of penicillin IV light inactivated SIV_{mac} with HCP adjuvant. Eight controls received solvent only, the humoral immune response before and after challenge was monitored by western blot and neutralization assays. The animals were challenged IV and by genital mucosa with 10-1000 the animal animal infectious dose (ID₅₀) of live SIV. Viremia was assayed by co-cultivation of PBMC with CD4 + T4 cells and the number of infected cells was roughly quantitated by limiting dilution assay.
Results: The vaccinated animals made an adequate immune response as judged by immunoblot and neutralization assays and by comparison to our previous results with heterologous vaccines. However, at 2 and 6 weeks after challenge with live SIV, by either IV or genital mucosal routes, virus was readily isolated from the PBMC of all 8 vaccinated rhesus and all controls. The results were not significantly different in the two groups.
Conclusions: Immunization of rhesus monkeys with an inactivated SIV_{mac}-HCP vaccine failed to protect against viremia following challenge with live SIV_{mac} by the IV and genital mucosal routes.

Th.C.0.46 HIV IMMUNIZATION AND CHALLENGE OF HIV SEROPOSITIVE AND SERONEGATIVE CHIMPANZES.
E.L. Gilber¹, C. Mon, J. R. Peters², H. C. Jansen, J. D. Miller, J. S. G. J. Nijh, Bethesda, MD², The Immune Response Corporation, San Diego, CA; ¹The Salk Institute, San Diego, CA, U.S.A.

Objective: To determine the characteristics of the serologic response of HIV seropositive and seronegative chimpanzees to HIV immunization and to viral challenge.
Methods: Three adult chimpanzees (two seropositive and one seronegative) were inoculated 1M (primary and 2 booster doses) with a genome irradiated non-infectious HIV immunogen reformulated in incomplete Freund's adjuvant (IFA). Approximately 13-15 months after the initial immunization, these chimpanzees and an untreated control animal were challenged IV with 10 chimpanzee infectious doses of HIV. Western blots, ELISAs and tests for neutralizing antibody and for virus by co-cultivation of PBMC were performed.

Results: The two previously HIV infected seropositive chimpanzees, A-86C and A-3, exhibited an anamnestic response to the first dose of immunogen; the initially seronegative chimpanzee, A-36, manifested a primary and secondary response after the first and second doses, respectively. After challenge, A-86C and A-3 exhibited no evidence of infection, while A-36 became infected. In contrast, A-36 became virus positive and exhibited only a reformed anamnestic response to the viral infection (anti-p24 that fell negative 1.8000).

Conclusions: 1) The resistance to reinfection observed in A-86C and A-3 suggests that primary-type antibody response to the viral infection (anti-p24 that fell negative 1.8000) may be an amenable goal. 2) The anamnestic response following challenge observed in A-36, in contrast to the primary-type response to infection observed in A-189, raises the possibility that induction of immunity to disease through vaccine-induced immunologic memory may be achieved even if infection is not prevented.

Th.C.0.47 IMMUNOGENICITY OF POTENTIAL HIV VACCINES IN CHIMPANZES
Girard, Marc ; Kley, M.P., and Lecco, J.P. ; Taglioli, M., and Guzman, C. ; Bressan, F., and Montelari, C. ; L. ; Muzarelli, E. ; and Fultz, P. - Pasteur Institute, Marne-la-Coquette, France, Strasbourg, CNRS, Institut Pasteur, Paris, Institut Pasteur, Paris France ; ICMIP, Toulouse and Overseas Primate Center, Atlanta, GA, USA.

Objective: To test the safety, immunogenicity and efficacy of potential HIV vaccines in chimpanzees.
Methods: Chimpanzees were immunized with multiple injections of vaccinia virus recombinants expressing gp160 and p24, followed by inactivated HIV formulated with Syntex adjuvant (SAR). Humoral and cellular HIV specific immunity was assessed.
Results: One animal, that had antibody (Ab) titers in the range of 1:200,000 (western blot and ELISA) and sustained T cell proliferative responses to purified HIV gp160, was challenged with 3E TCID₅₀ of the LVI-103 isolate (injected IV). Infectious virus was recovered from the animal's PBAs starting at 2 weeks after challenge, thus demonstrating lack of protection. A ten-fold anamnestic response was observed in ELISA titer, followed by progressive appearance of Ab to gp120, gp120, and HIV. Neutralizing Ab titers, however, remained low or below detection, even during 7 subsequent months. Two unchallenged animals that had undergone a parallel immunization course were repeatedly boosted with gp160 IN SAR, with no significant increases in ELISA or neutralizing Ab titers.
Conclusion: A vaccination regimen involving a live recombinant vaccine, inactivated HIV and gp160 emul induced good cell-mediated and humoral immunity, but only poor neutralizing activity, indicating that better presentations of virus neutralization epitopes must be devised to elicit protective immunity.

Th.C.0.49 VACCINATION WITH LIVE RETROVIRUS: THE NATURE OF THE PROTECTIVE IMMUNE RESPONSE
Rappaport, Ruth M., Horn, J., Garza-Sosa, M., and Finberg, R. *Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts, USA.

Objective: To determine the nature of the protective immune response in animals vaccinated with a live pathogenic virus.
Methods: Adult female BALB/c mice were inoculated with the Reuscher Murine Leukemia virus (RLV) at time 0. Four hours after virus exposure, the animals were given post-exposure prophylactic therapy with 3'-azido-2'-deoxythymidine (AZT or Zalcitabine) in combination with recombinant human interferon- α (to 20 x ED₅₀). At time 1, the animals were given a second recombinant human interferon- α (to 20 x ED₅₀) and the live RLV in the absence of antiviral therapy. Three weeks later, > 80% of these animals were found to be free of viremia and disease. On day 26, they were challenged with the RLV in the presence of antiviral therapy. One hour after challenge, the recipients were sacrificed or after removing B cells or monocytes by passage through nylon wool columns, or after removal of vaccine - cell subsets. One hour after adoptive cell transfer, the recipients were challenged with the live virus and left untreated for 3 weeks at which time they were sacrificed. Their spleens were weighed and analyzed for the presence of virus by immunoblot analysis.
Results: A dose of 4×10^6 unfractinated interferon α cells was sufficient to protect naive recipient mice from virus infection and disease. Removal of cytotoxic immune T cells led to a drastic reduction in the number of recipient animals resistant to viral challenge. Passive transfer was not protective.
Conclusions: Immunologically attenuated by combination therapy with AZT and recombinant human interferon- α , can elicit a protective immune response which is most likely due to the action of immune cytotoxic T cells.

Th.C.0.48 Simian Immunity to HIV-1 Candidate Vaccines
Wainman, Robert N., D'Amico, Bernard, Bureau of Laboratories
Zentral, American Health Services, Federal Center for AIDS, Detroit MI
C. Smith and M. Cochran, MicroGenetics, Inc., West Haven, CT

The first HIV vaccine approved for clinical trial status by the U.S. FDA was that produced in a baculovirus-insect cell expression system by MicroGenetics. We have studied the antibody response of 12 rhesus monkeys initially inoculated with various doses of the gp160 recombinant envelope protein. Immunoblot and neutralization assays on these monkey sera have shown a persistent, albeit, attenuated response one year after the final gp160 boost of 500 μ g dose. A final boost of gp160 to two monkeys showed a characteristic anamnestic response as measured by immunoblot and neutralization assays. Ten animals had received boosters with a 1 dose regimen of a new p24 (gp2) recombinant protein. This induced the anticipated immunoblot reactivity and also complemented the *in vitro* neutralizing capability due to gp160. The monitoring of the long term persistence of antibody (including neutralizing) is ongoing.

Th.C.0.50 DEVELOPMENT OF AN HIV SUBUNIT VACCINE
Wainman, Robert N., D'Amico, Bernard, Prof. A. A. Ruschke, J. J. Matthews, T. M. Y. and Wolinsky, D. M. *Appligen Corporation, Cambridge, MA, USA, *Duke University Medical School, Durham, NC

Objective: To develop an effective HIV subunit vaccine able to protect against infection by diverse HIV isolates.
Methods: Recombinant HIV vaccine candidates including the entire envelope, gp160, have been prepared from several different HIV-1 isolates in E. coli and in insect cells and synthetic peptides of the envelope have been made. Animals including chimpanzees were immunized and the neutralizing antibody response was measured.
Results: The principal neutralizing epitope within gp160 was mapped to a hypervariable region of gp120 residues 308-311. Antibodies to this region neutralize Free HIV and prevent CD4 cell fusion. Antibodies to this epitope delay HIV infection of chimpanzees (E. A. Binal, et al.). Antibodies to this epitope do not prevent binding of gp120 to CD4 and therefore neutralize HIV via a post-binding step. We are PCR sequencing this region from several isolates to uncover common elements. Chimpanzees immunized with gp160 formulated in ISCOM particles including neutralizing virus-like particles comparable to those elicited by infectious HIV.
Conclusion: An immunogen, composed of either a cocktail or a hybrid polypeptide, incorporating this epitope from several HIV-1 strains may elicit protective immunity to many isolates. The ISCOM may be a useful adjuvant to present these immunogens.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

Mise au point de médicaments et vaccins Drug Development and Vaccines

M.C.P.1 DIFFERENTIAL VIRAL GENE EXPRESSION AND THEIR EFFECT ON THE BIOLOGICAL PROPERTIES OF CLONES OF AN HIV-1 INFECTED CELL LINE
 Kalyanaraman, V.G., Rodriguez, V., Joseph, S., Gallo, R.C., Sargadharan, M.G., *Biometrics Research, Inc., Rockville, MD, *National Cancer Institute, NIH, Bethesda, MD, USA.
Objective: Analyze the biochemical and biological properties of HIV-1_{IIIB} (805/451) which secretes both gp120 and gp160 in the extracellular medium.
Methods: Obtain single cell clones of 805/451 cells and examine their morphology by electron microscopy and ability to form syncytia with CD4 positive cells. Using metabolically labeled cells the expression of viral proteins was also analyzed.
Results: Three interesting clones secreting functional gp120 and gp160 in the medium were obtained. The first clone expressed viral reverse transcriptase (RT) and had both mature and immature virus particles. The second clone had only immature virus, expressed no RT or p24 and had only PrP₂₅ in the cells. Both the clones formed syncytium when mixed with CD4 positive cells. The third clone expressed only gp120 and gp160 but did not form syncytium with CD4+ cells. All three clones had intact viral lengths when examined by restriction enzyme analysis.
Conclusion: Even minor changes in the genome of HIV-1 can lead to a preferential expression of the viral gene products which influence the biological properties of the infected cells.

M.C.P.3 CLINICAL EVALUATION OF EXPERIMENTAL AIDS VACCINES
 Koff, Wayne C., Westot, S.L., Novak, J., Stables, D., Ferlinz, R., and Gerin, J. for the AIDS Vaccine Evaluation Group, Bethesda, Maryland, U.S.A.
 The process of conducting clinical trials of AIDS vaccines poses significant scientific and logistical challenges including strategies for recruitment of volunteers, experimentally induced seroconversion, and other difficult ethical dilemmas. In order to accelerate the development of a safe and effective AIDS vaccine, the Vaccine Research and Development Branch of the AIDS Program, NIAID has established a multi-center cooperative clinical trials network. The AIDS Vaccine Clinical Trials Network consists of an AIDS Vaccine Selection Committee, and the AIDS AIDS Vaccine Evaluation Group (composed of AIDS Vaccine Evaluation Units, Data Coordinating and Analysis Center, Data and Safety Monitoring Board, Core Immunology Laboratory, and Central Repository). The capacity to clinically evaluate multiple AIDS vaccine approaches simultaneously has been instituted, and two candidate AIDS vaccines are currently being tested utilizing comprehensive core protocols. Ancillary research studies are also being done to ensure that maximum safety and immunogenicity data on each candidate vaccine is obtained. Guidelines and outcome criteria for candidate vaccines entering into Phase 1 and 2 clinical trials will be discussed, along with a detailed review of approaches developed to address the issues unique to the clinical evaluation of AIDS vaccines.

M.C.P.5 PRODUCTION AND CHARACTERIZATION OF A HUMAN-MOUSE CHIMERIC MONOCLONAL ANTIBODY (C81) AGAINST HIV
 Hasegawa, Naoko, Hasegawa, Y., Takayoshi, S., Hattori, T., and TAKAHASHI, K. et al. *The Second Division of Internal Medicine, Kumamoto University Medical School, Kumamoto, Japan. **Osaka-Sera-Institute, Osaka, Kumamoto, Japan.
Objective: To determine the anti-HIV functions of a human-mouse chimeric monoclonal antibody (C81) *in vitro*.
Methods: Murine hybridoma 3T5 cells which produced a type specific anti-HIV chimeric monoclonal antibody (0.58) were used to produce human-mouse chimeric antibody. Both V_H and V_L genes were cloned from 54'CB1 cells and linked to human I_H and I_L genes respectively. These chimeric genes were transfected with Fc- β 28 cells. After appropriate selection chimeric antibody producing clone (C81) was obtained. Chimeric C81 antibody was purified from culture supernatant by Sepharose Protein A-Sepharose.
Results: The binding and neutralizing activities of C81 antibodies were similar to those detected with 0.58. No antibody dependent enhancement of HIV-infection was detected with 0.58 and C81 when U87 cells were used as target cells in an HIV infectivity assay. Complement dependent cytotoxicity of HIV-infected cells and antibody dependent cellular cytotoxicity against HIV-infected cells were observed in the presence of chimeric C81. By contrast, murine 0.58 did not possess these activities.
Conclusion: These results may facilitate the use of human-mouse chimeric monoclonal antibodies against HIV-infections.

M.C.P.2 RECOMBINANT VACCINE AGAINST FELINE LEUKAEMIA VIRUS USING A RECOMBINANT ANTIGEN
 Chakrabarti, B., Srinivas, G., A. Bhatia, C.H. Ganguly, A. Akhtar, and D.J. Pantalone, *Central Biotechnology Corporation, Morarjee, MA, USA, **Virac Laboratories, 06316 Carver, France.
Objective: To produce a feline leukaemia virus (FLeV) recombinant subunit vaccine.
Methods: The genetic information coding for the polypeptide portion of subgroup A FLeV glycoprotein gp70 was cloned into a P₆-based expression vector. This polypeptide (200-250) was expressed in *E. coli* and purified. Kittens were immunized three times with 100 μ g 200-250, 20 μ g purified adjuvant adjuvant, and aluminum hydroxide and challenged with 1 X infectious FLeV particles.
Results: Vaccination induced neutralization titers ranging from 32-64 for subgroup A FLeV as well as cross-neutralization of subgroup B and C. anti-FOCA titers of 128, and antibody affinity maturation during the course of vaccination. A secondary response was observed in vaccinated upon challenge. Control animals developed chronic viraemia and protracted lymphocytopenia within a month of challenge whereas vaccinated animals were seroconvalescent or developed a low transient viraemia and were protected against disease.
Conclusion: Recombinant subunit vaccine based on subgroup A gp70 induces protection against FLeV.

M.C.P.4 HUMORAL AND CELLULAR IMMUNE RESPONSE TO RECOMBINANT HIV-FE/PATITIS B SURFACE ANTIGEN PARTICLES
 Michel, M.L., Margline, Margline, Vogt, G., Hemlin, Y., Riviere, Y., Dormont, D., and Toulon, P., *Unité de Reconnaissance et Expression Génétique INSERM U163, CNRS U4 271, Institut Pasteur, 28 rue du Docteur Roux - 75726 Paris Cedex 15, *Unité d'OncoVirologie Virale, Institut Pasteur, 28 rue du Docteur Roux - 75726 Paris Cedex 15, **Commissariat à l'Energie Atomique, Fontenay aux Roses, France.
Objective: To evaluate the immunogenicity of H5Ag particles carrying HIV envelope determinants.
Methods: Rhesus macaques were immunized with recombinant HIV-H5Ag particles purified from transfected mammalian cells.
Results: Serum from vaccinated animals was evaluated for antigenic potency and for the ability to neutralize HIV infectivity *in vitro*. Peripheral blood lymphocytes were tested for their ability to proliferate in response to stimulation with purified, non disrupted HIV.
Results: Using a H5Ag particle carrying a fragment of HIV gp120 envelope protein (AA338-472) comprising the CD4 binding site, we obtained neutralizing activity against HIV and a T cell response against both parts of the fusion protein O5Ag and HIV.
Conclusion: H5Ag particles seem to be a good carrier for the presentation of HIV epitopes and enable us to induce in vaccinated macaques neutralizing antibodies and an helper T cell response against a functional domain of gp120 envelope protein.

M.C.P.6 MAPPING THE NEUTRALIZING EPITOPES OF HIV-1 ENVELOPE PROTEIN
 Mammalian, Sakai, Ross, R., Profy, A., Langlois, T., Pitney, S. et al. *Wepigen Corporation, Cambridge, MA, USA, **Duke University Medical School, Durham, NC, USA.
Objective: We showed previously that the principal neutralizing domain of HIV-1 envelope protein of IIIB isolate represented by a 24 amino acid peptide called RP125 is located within a disulfide loop (amino acids 295-331). We have attempted to locate the neutralizing epitope more precisely inside the loop.
Methods: A series of small peptides corresponding to different parts of the loop were synthesized. Sera were raised against these peptides and each was tested for fusion inhibition and neutralization activities.
Results: Only peptides related to the "tip" of the loop containing the sequence glycine-proline-glycine were capable of raising neutralizing antibodies. We show peptides of the size of 8-10 amino acids are sufficient in size to elicit neutralizing antibodies. We have also raised antibodies against a hybrid peptide of 15 amino acids which was shown to neutralize two viral isolates.
Conclusion: Sera raised against small peptides (8-10 amino acids) corresponding to the tip of the principal neutralizing domain of gp160 are capable of neutralizing the virus.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

M.C.P.7 IN VIVO IMMUNIZATION AGAINST HIV PROTEINS USING GAU SYNTHETIC PEPTIDES: PRELIMINARY RESULTS

Yukita, Mitsuo **, Chervin, J.M. **, Bann-Stinson, F.C. **, Kourilsky, P. ** and
Dormann, D. **

** CERSA-CEA (DPSPSE), Fontenay-aux-Roses, France. ** Institut Pasteur, Paris, France.

Objective: As T immunocytes have been shown to be constant of sera self motifs, we tried to boost the immune response to HIV 1 proteins with live of them, located in conserved regions of HIV GAU glycoprotein.

Methods: Five GAU synthetic peptides, selected for their absence in Self-protein sequences data bank, and which are conserved among 13 HIV isolates, have been inoculated into three animal species (Mouse, Rabbit, Baboon). The animals received two successive injections of granulocyte polymorphonuclear product the first was performed in complete Freund adjuvant emulsion, and the second in a calcium phosphate precipitate. They were then challenged with live inactivated HIV 1 protein (ELA-1) in saline solution in 10% in vivo in Baboons and Rabbits. Clinical observations were performed (weight loss) before and compared to those of controls, which had only received HIV protein injections.

Results: Mice presented clinical signs, mice developed thrombocytopenic toxemia as back, as did of guinea-pig inoculation, which was different than the HIV protein injection toxics. Controls behaved with no abnormal clinical signs.

Conclusions: Four of the five peptides have been reported elsewhere to be recognized in vivo by HELA 4.2 restricted T cytotoxic cell line specific for HIV. Considering the pathology observed we then operated on the activation of T cell population in the presence. If the accurate observations established in this case may be as reproducible, mice could provide a model for T lymphocyte selection, on the assumption that they do stimulate T cell populations. These peptides could thus be used as immune response boosters in vaccine development aimed AIDS.

M.C.P.9

USE OF POLYMERASE CHAIN REACTION FOR DIRECT DETECTION OF HIV-1 IN CLINICAL SPECIMENS

Mark, Richard, O. Keller, D.R. Haack, M. Fisher and D. Fraser.

Biotech Research, Inc. 2000 15th St.

Objective: The Polymerase Chain Reaction assay was used for the direct detection of HIV-1 nucleic acid sequences in peripheral blood lymphocytes (PBL's) from high risk male homosexuals, blood donors, patients positive for HIV-1 by ELISA, babies born to HIV seropositive mothers, and from normal control individuals.

Methods: The DNA was extracted and HIV-1 specific sequences were amplified by PCR using specific primers for the gag and tat regions. Current amplifications were performed using cycling primers for ELISA. All samples were tested by ELISA and Western Blot assays. From samples were also tested by co-cultivation with PHA stimulated PHA-2 from normal controls.

Results: All culture positive samples tested (400 patient samples) were also PCR positive. However, 10 out of 31 high risk individuals who were antibody and culture negative were positive by PCR. Six of these 10 individuals subsequently seroconverted to HIV-1.

Almost all (240/243) antibody positive adult individuals tested were also PCR positive. Three samples, however, (4) of which belonged to the high risk male homosexual group were repeatedly negative or only positive positive by PCR for both gag and tat. All babies born to seropositive mothers were HIV-1 antibody positive, presumably due to the presence of maternal antibody. Approximately 60% (26/44) of these babies were PCR positive, while the rest were negative. All of normal donors were negative by PCR. **Conclusion:** PCR provides an extremely sensitive test for the direct examination of HIV-1 in PBLs. This assay is capable of detecting HIV infection in high risk individuals, even before they seroconvert, and of confirming Western Blot indeterminate samples. In addition, PCR may be a useful tool for monitoring babies born to seropositive mothers, where the presence of antibody does not necessarily imply infection. The PCR method is much faster, cheaper and far more sensitive than conventional for the direct detection of HIV in clinical samples.

M.C.P.11

CLINICAL AND VIROLOGIC RESPONSES TO A RECOMBINANT VACCINE HIV-1 GP160 VACCINE (BIVAC)

Collins, Alan **, Hill, S.L. **, Coombs, R. **, Ardito, G. **, Coey, L. **, University of Washington, Seattle, WA, USA.

Objective: To describe and compare the clinical and virologic responses of healthy HIV-negative sera after receipt of recombinant HIV-1 gp160 vaccine (BIVAC) and nonvaccine controls.

Methods: 29 men (age 24-46) with history of intravenous (IV) drug use (19) and 10 (36%) were vaccinated with BIVAC-1 or V (10) by 0.5 ml (total) in 4 weekly doses of 0.5 (week 1), 0.5 (week 2), 0.5 (week 3) and 0.5 (week 4) plus one booster (0.5) at 11 weeks later; 17 men gave good HIV-1 CA at 10⁷ (1) and at 1.1 x 10⁷ units later.

Results: HIV-1 CA in V sera was isolated from the 1 vaccination site in 1/17 vaccine, and 5/10 (9/10) and 7/11 (6/11) in 2 dose subjects. In 8 and 11 recipients, mean duration of isolation was 6.5 days for HIV-1 CA and 4.7 days for VEP=NS. After 8, 8(30%) of HIV-1 CA and 4(30%) of V recipients also virus from the site for 1.0 and 0.2 days, respectively (P<0.01 for 8 vs 11). Restriction enzyme analysis of 17 and 14 dose HIV-1 CA isolates obtained from 1 subjects showed them to be identical to the vaccine strain. 26 of the 29 persons with a history of previous V and V neutralizing antibody titres at seroconversion. The baseline GMT for HIV-1 CA recipients was 3.2, 8.2 and rose to 12.1 after 1 and 10.8 after 8. For V recipients, the respective GMTs were 3.2, 8.2 and 8.2. 65% of subjects had a 4-fold rise in V neutralizing titre after 1 dose to 0 after 8. V seronegatives also virus began to V seropositive. No toxicity was seen with either vaccine. As in HIV seronegatives, responses were detected in 1/16 HIV-1 CA recipients, 2 V seronegatives and 1 V seropositive developed Ab to gag and gp120. Three of 4 HIV-1 CA subjects who shed virus for 1.0 day developed VEP=NS after 10 weeks and 1/12 who shed for <1 day.

Conclusion: This trial demonstrates the safety and genetic stability of this HIV-1 gp160 vaccine recombinant vaccine. The clinical and virologic responses to vaccination were similar between HIV-1 CA and V. The development of early Ab appears related to the duration of HIV-1 CA replication in skin, which is inversely related to the presence of pre-existing V neutralizing antibodies. The lack of local viral replication after 8 suggests that other forms of actual vaccines should be evaluated for boosting.

M.C.P.8 HIV-1 RECOMBINANT GP160 VACCINE RECEPTORS DEMONSTRATE gp160-SPECIFIC LYMPHOCYTE PROLIFERATION PRIOR TO WESTERN BLOT REACTIVITY.

Kear, Michael C., Smeets, W., Roberts, N.C.L., de Wit, J., van der Schueren, R.C., University of Rochester School of Medicine, Rochester, NY, USA

Objective: To characterize cellular responses to HIV gp160 vaccine.

Methods: As part of the NIAID multicentered AIDS vaccine evaluation program, we enrolled 12 volunteers in a phase 1 randomized, double-blind, placebo-controlled trial of baculovirus-expressed recombinant HIV-1 envelope glycoprotein gp160 (GP160) (Genzyme Synt). Six subjects received GP160, 3 a Hep-B vaccine, and 3 placebo at 0, 1, 4 and 6 months. We performed lymphocyte proliferation assay (LPA) using cryopreserved peripheral blood mononuclear lymphocytes obtained at day 56 (28 days post first booster). The GP160 and a control consisting primarily of the major contaminating baculovirus glycoprotein were used as antigens.

Results: Background baculovirus proliferation was eliminated in 11/12 subjects at 0, 1, 4, and 6 months. At 1.0 ml (mg/ml) in dose response assays. Higher antigen concentrations produced generalized stimulation and did not distinguish the vaccine recipients from controls. At 0.1 mg/ml, all 6 GP160 recipients had stimulation indices (SI) of 2.1 (SI < 1.0 = no response). The SI was <2.0 in all 6 subjects who did not receive GP160. Western blot (WB) assays were performed on day 56 and were positive for only one GP160 recipient at that time. Sequential LPA on this subject disclosed SI > 2.0 prior to vaccination, SI < 2.0 at day 23 (Immediately pre-booster) and two weeks prior to receipt of the 6-month booster. At day 56, three months post-first booster, the other 5 GP160 recipients also developed WB reactivity 2-4 months after demonstrated reactivity in LPA.

Conclusion: The HIV-1 GP160 vaccine induces cellular immune recognition, illustrated by lymphocyte proliferation, prior to detection of antibodies by Western blot.

M.C.P.10 GP160 ISOCYTES: A CANDIDATE HIV VACCINE.

Amstrong, L. **, Williams, M. **, Larkin, R. **, Ljunggren, J., K-9113

Upstate, Sweden. **Karolinska Institute, Box 6000, S-14186, Stockholm, Sweden

Objective: To formulate a candidate HIV vaccine for the prevention of AIDS.

Methods: Isocytes were formed using gp160 (vaccinia) and gp160 (baculo) according to Martin et al. (1984). Immune response was analyzed in an indirect ELISA using defined recombinant nucleocapsid proteins and peptide as antigens. These antigens were gp160 (vaccinia), gp160 (part of gp120) and gp120 (a synthetic peptide). Neutralization tests were done according to Nara et al. (1987). AOC was done according to Ljunggren et al. (1987).

Results: Isocytes containing gp160 from HIV, elicited high antibody titres in mice, rabbits and guinea pigs after two immunizations. The animal sera were tested for serological reactivity, AOC, activity and for CD4 binding capacity. All sera were negative in AOC. Blocking of gp120 binding to CD4 positive HeLa cells was shown by mouse sera at a range of serial dilutions of 1/50 to 1/1250. Syncytial inhibition titres against the homologous isolate IIIIB were in the order of 1/4 to 1/120 and cross neutralization titres were in the range of 1/4 to 1/16 using the heterologous isolate 89.

Conclusion: The gp160 isocyte gave rise to high antibody titres in mice, rabbits and guinea pigs. These isocytes elicited neutralizing antibodies in mice towards the homologous isolate IIIIB as well as for the distantly related HIV isolate 89 indicating the possibility of inducing group specific neutralization.

M.C.P.12

GENETIC MAGNITUDE AND DURATION OF ANTIBODY RESPONSES IN HIV-1 GP160 VACCINE

Shannon, Leslie **, Hadden, K., O'Keefe, R., Nelson, G., Whittet, R. **, The NIAID AIDS Vaccine Evaluation Group, Bethesda, MD, USA

**MicroGenetics, Inc. West Haven, Connecticut, USA.

Objective: To characterize the kinetics, magnitude and duration of serum antibody responses of recipients vaccinated in a multicenter phase 1 randomized trial with recombinant baculovirus expressed gp160 (gp160) of HIV-1 (vaccine HIV-1 MicroGenetics, Inc.)

Methods: 24 HIV seronegative individuals were vaccinated with 0.5 ml of 10⁷ (1) or 10⁸ (2) gp160 (N-24) or a control preparation (N-0). Coded blood specimens obtained from 24 recipients were analyzed for antibody response 1 and 2 months after vaccination using for IgG antibody responses by Bio-Rad/Orion Western blot (WB), Abbott HIV EA, and conceptually similar enzyme immunoassay (EIA) using gp160 as antigen. The specificity of gp160 EIA was confirmed by a blocking assay.

Results: The mean time interval for detecting serum antibody responses in gp160 vaccinees, of 23 vaccinees with antibody responses by any assay, 98% were detected by gp160 EIA by WB and 100% were detected by gp160 EIA by Abbott HIV EA. The mean time to detect serum antibody responses by WB and gp160 EIA and WB results were 91% compared to 80% for the gp160 EIA and Abbott HIV EA.

The kinetics and magnitude of antibody responses in sera of vaccinees were characterized by the antibody EIA. Of 23 vaccinees detected by gp160 EIA, 17% were detected by gp160 EIA and WB after the first, 72% after the second, and 100% after the third vaccination. After the second and third vaccinations, the level of antibody increased 3.6-fold and 3.3-fold above the pre-vaccination level. By 2 months after the initial vaccination, 12 months after the third, the level of antibody had declined but remained elevated above pre-vaccination levels.

Conclusion: The gp160 EIA was more sensitive than WB or Abbott HIV EA and detected serum IgG antibody responses to gp160 in 22 of 24 vaccinees. The EIA makes it possible to quantitate the magnitude of antibody response to the second and third doses of vaccine and to determine the duration of responses over the 6-month period after vaccination.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

M.C.P.13

VALIDATION OF A SYNTHETIC HIV-1 P-17-BASED CANDIDATE AIDS VACCINE, HOP-30

Allan, S., Edinger, R., Paul, M., Boyler, J., E. Kinkley, C. W. Boyler, C. J. Gibney, and J. S. Tom. The George Washington University Medical Center, Washington, D.C., National Institutes of Health, Bethesda, MD, U.S.A.

Objectives: To evaluate neutralizing and immunogenicity of a synthetic subunit vaccine based on an HIV p17 peptide analogue (HOP-30)

Methods: The synthetic peptide HOP-30 (Boyer et al, PNAS, 86, 1991, 1997) was conjugated to keyhole limpet hemocyanin (KLH) and injected with various adjuvants at different doses in a variety of animal species. The presence of antibodies was detected by ELISA (HOP-30 specific) and Western blot (p17 specific). Neutralization activity was evaluated as inhibition of ID₅₀ virus replication and/or virus induced syncytium formation with different HIV-1 strains.

Results: Immunization of animals with HOP-30-KLH gave antibodies to HOP-30 as detected by ELISA, but not to the recombinant HIV-1 strains with whole or disrupted virus enhanced the production of antibodies to p17. High titer antibodies to p17 effectively neutralized various strains of HIV-1 in ELISA assays. Similar results were obtained with monoclonal antibodies which recognize HOP-30. The proposed candidate subunit vaccine, has proven safe in a number of animal species.

Conclusions: A synthetic subunit vaccine based on HOP-30 representing immunodominant epitope HIV-1 p17 produces antibodies in animals which recognize HIV p17, neutralize HIV infection *in vitro* and prime the animal to respond to natural HIV p17. Based on these studies a phase-I clinical trial will soon be initiated in England.

M.C.P.15 DISPLAY OF RECOMBINANT PARTICLES WHICH EXPRESS AN HIVP24 T-CELL EPITOPES PURIFIED TO THE HIVP24 ANTIGEN

McGee, J.L., Letour, D., Mlich, G.M., Thomson, G.B., and Montary, A.M., *R.W. Johnson Pharmaceutical Research and Development, La Jolla, CA, U.S.A., **Schuylkill County Research Foundation, La Jolla, CA, U.S.A.

Objective: The importance of viral internal core or gag proteins in regulating the immune response to envelope epitopes has recently been demonstrated with hepatitis B virus (Mlich et al., Nature, 1987). Based on these studies we have sought to evaluate the role of the gag related antigen of HIV in the regulation of the immune response (T-dependent and T-independent) to themselves and to HIV gp120/60. In order to pursue these studies, we designed and expressed recombinant particles expressing both HIV gag and HIV-1 determinants.

Methods: A proposed T and B cell epitopes from the C-terminus of the HIV P24 gag region (Coles et al., Nature 1987) was selected for insertion upstream from a recombinant core expressing HIV core antigen in the form of particles. The HIV gag sequence was prepared as a synthetic oligonucleotide sequence and inserted upstream from the HIV sequence in the Pst-SmaI region of the multiplying site within the HIV construct.

Results: The recombinant fusion protein was expressed in E. coli and the antigenic specificity determined by ELISA using Western blot analysis. These analyses revealed a single protein species at 24,000 n.w. the size predicted for the P24/HIV fusion protein. This protein was reactive with anti-HIV and anti-P24 antibodies, generated in rabbits. **Conclusions:** Recombinant vaccines have been engineered capable of expressing a fusion protein which contains HIV and HIV P24 antigens. The fusion protein forms particles which, by electron microscopic examination, are similar to HIV particles. These HIV/HIV particles are being used to evaluate the role of gag T-cell determinants in the immune response to HIV.

M.C.P.17 TYPE-SPECIFIC NEUTRALIZING ANTIBODIES TO HIV-1 IN RABBITS IMMUNIZED WITH RECOMBINANT HIV-1 ENVELOPE PROTEINS

G.M., Day, R., and Sullivan, J., *University of Massachusetts Medical School, Worcester, Massachusetts, USA, **Applied Biotechnology, Cambridge, Massachusetts, USA.

Objective: To analyze humoral immune responses in rabbits immunized with vaccinia vectors expressing envelope gene from two strains of HIV-1. **Methods:** Two vaccines were produced: intramuscularly with 500³ pfu of vaccinia vectors which expressed either HIV-1 envelope genes (HIV-III B or HIV-III B) or the gag gene of equine herpes virus as a control. Rabbits were bled with 500³ pfu of the same vector 6 weeks after the initial inoculation. Antibody titers were determined by Western blot analysis (HIV) or ELISA (Vaccinia). Neutralizing activities were determined using a syncytium inhibition assay with both III B and R9 strains of HIV.

Results: All rabbits developed strong antibodies to both Vaccinia virus (titers to 1:409,600 by week 2) and to HIV-1 envelope antigens (titers to 1:10,240 by week 6). No major antibody response was to gp120 and gp120 with antibodies to gp41 appearing later and at lesser titers. Significant levels of neutralizing antibodies to HIV-1 (p146) developed by week 5 post inoculation. These neutralizing antibodies were type-specific and remained so even after boosting. Previous studies using vaccinia/HIV-1 env recombinant viruses had failed to demonstrate neutralizing antibody response (Hu et al., Nature 338:721), though antibody responses in these studies were mainly directed to gp1.

Conclusion: Rabbits immunized with recombinant vaccinia/HIV-1 viruses develop significant type-specific neutralizing antibodies to HIV-1.

M.C.P.14

CELLULAR IMMUNITY IN HIV-1 RESPONSE VACCINES.

Milby, S.G., Carlson, L., Graham, M., Clements, M.E., Miller, M., and Adler, W.H., *The George Washington University Medical Center, Washington, DC, USA, **Montefiore, City, USA, ***NIAH, NIH, Bethesda, MD, USA.

Objective: To evaluate cell mediated immune responses in healthy adults who participated in a phase I safety and immunogenicity trial of recombinant gp120 (rgp120) of HIV-1 (HivSyn HIV-1). **Methods:** Twelve volunteers at low risk and without evidence of HIV-1 infection were vaccinated at 0, 1 and 3 months with one of the following: 40 µg rgp120 (R-2), Recombinase HB (R-3), or placebo (N-3). All 8 rgp120 vaccinees had detectable antibody to gp120 or HB by Western blot after their vaccination. Blood drawn before and at 0, 1, 1.5, 2, 4, 6, 8, and 7 months after their vaccination was tested by ELISA for blood assays of cellular immune function: lymphocyte subset analysis, natural killer (NK) cell lysis activity, antibody dependent cellular cytotoxicity (ADCC), proliferative response of peripheral blood mononuclear cells to HIV-1 and to mitogens PHA, Con A, PWM, and pokeweed mitogen-induced B lymphocyte. Responses of the gp120 vaccinee group were compared to those of the placebo and Recombinase HB or placebo.

Results: The rgp120 group had higher absolute lymphocyte counts, but there was no difference in the percent representation of lymphocyte subsets (CD4, CD8, CD19) between the two groups. Proliferative responses to all mitogens were normal but lower in the rgp120 group. Spontaneous Ig synthesis in vivo was not different between the groups while PWM induced IgG and IgM synthesis was higher in cells from the rgp120 group. High titers of IgM were shown that individuals from both groups could be stimulated into proliferative cycles without any exogenous mitogens. Proliferative responses to each major protein dose, NK and ADCC activity were similar in the two groups. **Conclusions:** The rgp120 induced specific antibody formation in vivo to gp120 or HB, appeared to have no adverse effects on GM. Cells from the rgp120 vaccinees responded to mitogens with similar amounts of Ig. The rgp120 antigen caused a small degree of normal lymphocyte activation.

M.C.P.16 RECOMBINANT VACCINIA VIRUSES THAT COEXPRESS HIV OR SIV ENV AND GAG-ENCODED PROTEINS PRODUCE RETROVIRAL PARTICLES

G. Hestera*, Dennis Franciga*, R. Corlier*, R. Desrosiers**, M. Hestera**, R. Kiplinger**, M. Applin**, J. Hestera**, J. Hestera**, Cambridge, MA and *New England Regional Primate Research Center, Southborough, MA, USA

Objective: To evaluate the formation of retroviral particles by vaccinia recombinants that express gag, env*, gag*, env* or gag + env* genes from HIV-1 or SIV.

Methods and results: The formation of free, defective, retroviral particles produced by monovalent and multivalent vaccinia recombinants that express HIV-1 or SIV polypeptides was assayed by several techniques, including electron microscopy and sucrose gradient centrifugation. We have demonstrated that vaccinia recombinants that coexpress gag and env genes give rise to the formation of enveloped retroviral particles that are secreted into the growth medium, while recombinants that express gag proteins alone yield immature, non-enveloped particles.

Conclusions: Recombinant vaccinia viruses that express one or more HIV-1 antigens have been proposed as candidate vaccines against AIDS. The production of enveloped retroviral particles by multivalent vaccinia recombinants suggests that they may have greater potential for eliciting an immune response effective against early events in HIV-1 infection.

M.C.P.18 HYPERIC EFFICACY OF A NEW AGENT AGAINST HIV IN VITRO

Valentin, Fran., Hestera, D.V., Tré, V., Lavia, G., Desrosiers, R., *Montefiore, Philadelphia, *New York University Medical Center, New York, USA.

Objective: To examine the effect of hypericin (HY), an aromatic polycyclic dione, against HIV in vitro.

Methods: 40 different concentrations of HY were incubated overnight with U800 to 10 tissue culture infective doses (TCID₅₀) of H9 isolates of HIV-1 and phytohemagglutinin activated human mononuclear cells (PHA-MNC). Cells were cultured with Interleukin 1 and monitored for the production of particulate reverse transcriptase (RT) by immunoblotting. In titration assays, 10⁵ cells were infected first and then treated with HY for 1, 2 and 6 hours, and (6) PHA-MNC were pretreated with HY, washed, infected and monitored for (6) free HIV was exposed to HY, and examined for infectivity and particulate RT.

Results: HY inhibited the production of HIV by PHA-MNC as assessed by RT and pH₂ when 4) HY and HIV were added together, 3) cells were preinfected and then treated with HY, 4) cells pretreated and then cultured with HIV in the absence of free HY, 5) free HIV was incubated with HY for 1 hr, and then added to PHA-MNC. This inhibition was most marked with 10⁵ TCID₅₀ or less, and at 10⁵ PHA-MNC. Only reduced to complete inhibition of RT and pH₂ through 10 days of culture. These concentrations of HY do not inhibit antigen-antibody complexes of normal HIV.

Conclusions: Short exposures of cells or 10⁵ HY at nontoxic levels inhibit the formation of infectious HIV by mechanisms that are not yet clear. This data on HY and HIV, together with our observation that HY inhibits latent retroviral infections in mice at levels nontoxic in vivo, indicates that HY should be developed as a potential anti-HIV agent for humans.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

M.C.P.19

FUNCTIONAL ANTIBODY RESPONSE IN PERSONS IMMUNIZED WITH RAGULOVIRUS-DERIVED GP120 CANDIDATE AIDS VACCINE

Graham Barron, Rowland J. Robshaw, E. Montefiori, D. Mitchell, W. Wright, P. and the NIAID Vaccine Evaluation Group - Vanderbilt University School of Medicine, Nashville, TN, USA.

Objective: To determine the functional serological response of vaccinees in the circumvent NIAID sponsored trial of the MicroCousby baculovirus-derived gp120 candidate AIDS vaccine.

Methods: Neutralization (NT), complement-mediated antibody dependent enhancement (C-ADE), and anti-fusion activity were measured in a cytopathic effect assay system based on natural red spots by viable MT8 target cells. NT is a measure of cell-free virus inactivation by serum; C-ADE, done in parallel with the NT assay by adding complement to the HIV, measures the reduction in NT activity and is verified by detecting more rapid HIV cytopathic effects. C-ADE, done in parallel with the NT assay by adding complement to the HIV, measures the reduction in NT activity and is verified by detecting more rapid HIV cytopathic effects. HIV specific proteins, and srycrine formation, anti-fusion assays serum inhibition of cytopathic effect resulting from infected more rapid HIV-to-target cell fusion *in vitro*. Volunteers were immunized on days 0, 30, and 180 with either 40 mcg or 80 mcg of gp120. Sera from all vaccinees at day 0 and sera from Vanderbilt vaccinees at days 30 and 180 had no evidence of NT, C-ADE, or anti-fusion activity at any time point despite waning HIV positivity in many of the sera.

Conclusion: It is not known whether the inability to measure functional antibody activity in the sera of vaccinees is a function of the magnitude or quality of the antibody response.

M.C.P.20

HLA DR PEPTIDE IMMUNITIS BY HIV 1 IMMUNODOMINANT PEPTIDES

Wanda Rosenthal¹, Ulrich, E.P., Anand, N.P., Asare, H.Z.,^{2,3} Howard Hughes Medical Inst., and Dept. ¹Microbiol. and Immunol., and ²Immunol., Baylor College of Medicine, Houston, TX 77030 USA.

The binding of human immunodeficiency virus (HIV) to CD4 cells might be enhanced if the envelope bound to several sites on the same molecule or to several different molecules. Because class II molecules are important in the presentation of antigens and bind both the T cell receptor (TCR) and CD4 molecules, we determined whether the HIV-1 envelope protein exhibited sequence similarity with DR molecules. Five regions with sequence similarity were found and examined for their ability to inhibit cytopathic formation between HIV/HIV cells and uninfected CD4 cells. Peptide 141-155 inhibited the release of ³H-T from HIV/HIV cells after addition of uninfected CD4 cells. The inhibition was dose of a dimeric. This region, 204-248 in gp120, is highly conserved among HIV isolates and the region, 141-155, in the gp120 molecule is also highly conserved between haplotypes. Mutation of this region in HIV-1 has been previously associated with loss of infectivity (Willey et al., J. Virol. 62:139, 1988) and rabbit antibodies directed toward this region have neutralized HIV infectivity (De et al., Science 239:1021, 1988). We were infected with HIV apparently fail to respond to this region in HIV-1. In addition, both anti-CD4 and anti-HIV sera are unresponsive to this region when immunized with intact DR2. Immunization with the peptide, however, does induce a response. This region may, therefore, be essential in the design of an HIV vaccine, but caution is suggested because of the possibility of induction of harmful anti-self DR responses.

M.C.P.21

RECOMBINANT ADENOVIRUS INDUCES ANTIBODY RESPONSE TO HIV GP120 IN MICE

Rosemary Bennett, L. Graham, F.L. and Provo, L. McMaster University, Hamilton, Ontario, Canada

Objective: Construction of recombinant adenovirus vectors capable of expressing individual human immunodeficiency virus (HIV) polypeptides in infected cells and their use to assess antigenicity and as potential vaccines.

Methods: Recombinant adenovirus vectors capable of expressing HIV gp120 (p55 and gp160), and env (gp160) were constructed by inserting HIV structural genes into human adenovirus type 5 wild or without foreign promoters. Expression of recombinant vectors was assessed using immunoprecipitation and western blotting. Mice were infected with these vectors and examined for the production of antibody and the generation of cytotoxic T lymphocytes (CTL) to HIV proteins.

Results: Recombinant adenovirus vectors expressed HIV gp120 in a variety of human cells including 293-transfected human cell lines. Infection of mice with Adgp120 resulted in the production of antibody to HIV gp120. We are currently using these vectors to determine the role of individual HIV gene products in induction and serving as targets for both murine and human antiviral CTL.

Conclusion: We have successfully constructed recombinant adenovirus vectors capable of expressing HIV gp120 and generating immune responses in mice.

M.C.P.22

HUMAN T-CELL CLONES DEFINE DISTINCT EPITOPES WITHIN THE V3 REGION OF HIV-1 GP120

Wainhold, Kent¹, Stanley, D., Jawahars, K.M., Scott, C.M., Putney, S.W. and Holmgren, M.E., ¹Shiga University Medical Center, Durham, NC, USA; ²Wageningen, The Netherlands, ³Ma, The Netherlands

Objective: To identify epitopes within the HIV-1 envelope which are recognized by T-cells from seropositive individuals.

Methods: Peptides representing the V3 region of HIV-1 gp120 were used to stimulate T-cell reactivity in primary cultures of peripheral blood mononuclear cells (PBMC) from seropositive donors. T-cell clones were derived, phenotyped, and assayed for specificity against a panel of peptide constructs. Clones were analyzed for cytolytic activity against autologous target bearing peptide antigens.

Results: The HIV-1₁₁₁ gp120 peptide was found to be a potent stimulator of primary T-cell reactivity *in vitro* whereas the HIV-1₁₁₁ analogue (gp139) was far less stimulatory and the HIV-1₁₁₁ peptide (gp145) lagged only detectable activity. Using hybrid peptides, the multiple CD4 T-cell clones were found to belong to 3 different specificity groups, each capable of recognizing a subdomain within the V3 region of gp120. Representative clones from each of these groups had demonstrable cytolytic activity.

Conclusion: T-cells from HIV-1 seropositive donors recognize determinants within the V3 region of gp120. Unlike the single epitope recognized by mice, human T-cells appear capable of distinguishing multiple sites. Lastly, the V3 region of gp120 may be important not only for production of neutralizing antibodies, but also for eliciting virus-specific T-cell reactivity in potential vaccinees.

M.C.P.23

PLAQUE REDUCTION ASSAY TO DETECT HIV NEUTRALIZING ANTIBODIES IN SERA FROM HIV VACCINEE

Fengzi, Terry W., Seaman, T. and Balise S. and NIAID AIDS Vaccine Program - ¹Marshall Univ. Sch. Med., Ht., Wv., ²Bethesda, Md, USA

Objective: To describe a neutralization (Nt) assay which employs vaccinia virus recombinant (VVR) infected CD4⁺ HeLa cell monolayers.

Methods: HeLa cell monolayers 4-6 hr. for HIV CD4⁺ receptors were established in multi-well plates and upon reaching confluency (24 hrs) were infected at 100 PFU/10⁶ cells with 1) VVR expressing GP140 env protein, 2) VV, 3) VVR or 4) VV treated with sera from individuals vaccinated with recombinant GP140 (rGP140) vaccine (Microgen) and 4) VVR or VV treated with primum sera from vaccinees. Consistently sera were assayed for neutralizing antibodies using inhibition of cytopathic formation induced by HIV strain 89 in MOLT 3 cells.

Results: Infection with VVR but not VV produced plaques by day 3 in CD4⁺ HeLa cell monolayers but not in CD4⁻ cell monolayers. Plaques resulted from cytopathic formation and subsequent sloughing of HeLa cells. HIV membrane antigens were demonstrated on the surface of cells at the periphery of plaques by immunofluorescence. In both assays sera from vaccinees demonstrated with 3 10⁶ dose of rGP140 did not exhibit neutralizing activity. In spite of the fact that post vaccine sera exhibited positive ELISA and reactivity to GP140 in Western blots.

Conclusion: A plaque assay employing VVR and CD4⁺ HeLa cells has been used to examine sera for neutralizing antibodies among rGP140 vaccinees.

M.C.P.24

QUANTITATIVE ASSESSMENT OF SERA INHIBITION OF HIV/RECEPTOR BINDING

Janis V. Girard¹, Nishanian, P.G., Ho, D.H. and Schmid I. UCLA School of Medicine and the Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA

Objective: Vaccination against HIV is expected to induce antibodies with a variety of biological activities. Antibodies that inhibit HIV/receptor binding, as well as those that neutralize HIV, are expected to be protective. We have developed a method to design a sensitive assay to assess sera inhibition of HIV/receptor binding.

Methods: Using an EPICS C flow cytometer (EPICS Division of Coulter Electronics, Becton Dickinson) we have established a sensitive fluorescence intensity of the 256 channels of the 3-decade log scale of our instrument. Using beta-2-microglobulin-labeled HIV (Nishanian, et al., J. Immunological Methods 103:261, 1983), virus binding to T-cells was detected using an anti-HIV serum and FITC-conj anti-human IgG.

Results: When antibodies to gp120 were incubated with the HIV prior to adding the HIV to the T-cells, inhibition of HIV binding was observed with some sera, while enhancement of HIV binding was observed with other. This activity could be precisely quantitated, permitting accurate assessment of minor differences in the biological properties of different sera.

Conclusion: This method will be valuable for assessing the immune response of vaccinated persons, and is being used to evaluate the virus that are involved in binding (see abstract by David Ho, et al., this Conference).

Session d'atfichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

M.C.P.25 CROSS REACTIVITY OF GOAT SERA GENERATED AGAINST FIVE HIV-DERIVED OF 120 RECOMBINANTS AND SYNTHETIC PEPTIDES

Yair Duvshil, Koshi Ishwaran, Albert T. Profy, and James Krause
Repligen Corp., Cambridge, MA 02137, USA
Present Address: E. I. Du Pont Co., Diagnostic Division, Glasgow, DE 19110, USA
Objective: To determine the binding specificity of goat sera generated against C-terminal fragment of p120 (PB-1) and amino acid 301-324 loci sequences derived from five HIV isolates (HIV, MN, WML2, and SC).
Methods: Three different ELISA formats (peptide antisera/peptide antigens, peptide antisera/PB antigen, and PB-1 antisera/PB-1 antigens) were utilized to determine the cross reactivity patterns of the sera with the antigens.
Results: Antisera generated against MN and SC were highly cross reactive. This cross reactivity pattern was unique to the amino acid antigens and antisera used and could not be predicted from the amino acid sequences of the five variants. Furthermore, it was established that the PB-1 fusion domain and the peptide KLH-carrier protein does not contribute to the cross reactivity.
Conclusions: The study demonstrates a strong cross reactivity of MN and SC. The cross reactivity could not be predicted from the linear sequences of the five peptides and the five PB-1's. Correlations of this cross reactivity with that of HIV-infected human sera and virus neutralization is discussed.

M.C.P.26 IMMUNOGENICITY OF HIV-1 GLYCOPROTEIN IS DEPENDENT ON PROPERTIES OF THE GLYCOPOLYMER HEAVY

Herman, Yanna Malm, K. Eriksson, S. Fridberg, T. Alsterlund, L. and M. Virelizier
Dept. Vascular Virology, Biomedical Center, Uppsala, Sweden.

Objective: Recombinant glycoproteins derived from the HIV-_{env} gene are under evaluation as antigens in vaccines against AIDS. The importance of the structure and size of the glycoproteins for eliciting a protective immune response is obscure. As a first approach to elucidate this matter we present data on the immunogenicity of mice of two env glycoproteins, which have been modified by treatment with glycosidases.

Methods: Gp120 (A), purified from HIV-1_{HT89} infected 293 cell culture medium (7yle STW et al. AIDS Res 1987;3:387-400) and gp160 (B), expressed in Vero cells from the HIV-1_{HT89} env gene in a vaccinia virus vector, were incorporated into ISCOEM and treated with 1) buffer (non-modified control), 2) serratostatinase, 3) endoglycosidase H or 4) glycosylphosphatidase-F. The 8 antigen preparations were analyzed by EM, SDS-PAGE and immunoblot and injected, at a dose of 1µg (antigen group A1-A4, B1-B4) or 0.1µg (group B1-B4) into mice (16 animals per antigen and dose) at two occasions, 4 weeks apart. Blood was withdrawn from the tail vein at intervals up to 8 months after the first immunization and the serum individually analyzed by ELISA for HIV-1 gp160 and several related peptides.

Results: The serological immune response to the non-modified and modified glycoproteins differ with respect to relative antibody titer, timing and type of ELISA. As a general rule the modified proteins gave rise to a lower total titre than the non-modified glycoprotein.

Conclusions: The carbohydrate residues are important for defining antigenic epitopes. It remains to be shown whether this has bearing on protective efficacy.

M.C.P.27 STV VACCINE DEVELOPMENT SURVEILLANCE Schultz, A. R. and Glass, R.

Vaccine Research and Development Branch, AIDS Program, NIAID, National Institutes of Health, Bethesda, MD, USA 20892

Use of vaccines infected with STV has become an important disease model for the development of a vaccine for human AIDS. A proliferating variety of approaches (synthetic peptides, recombinant peptide regions, subunit approaches, live expression vectors with different gene products, killed and live attenuated STV) are under development and being utilized by numerous groups, all destined for evaluation of safety and immunogenicity in the animal and, ultimately, for protection from STV challenge. To further complicate the picture, immunologically distinct isolates of STV are being used, some biologically cloned, some genetically cloned, and others uncloned. Some projects are in early stages, while others are well underway. As an aid to information dissemination, facilitation and coordination of these efforts, the Vaccine Branch of the NIAID AIDS Program maintains surveillance of initiation and overall progress in these experiments. A summary of research approaches and findings will be presented.

M.C.P.28 ZARIAN HIV-1 VARIABLE AND HYPERVARIABLE ENVELOPE FRAGMENTS

André, Gérard, Smer, R., Kolontzakis, V., Zagury, J.F. and Zagury D
Université Pierre et Marie Curie, Paris, France

Objective: To compare the heterogeneity, in Zairian asymptomatic carriers and physically asymptomatic individuals, of amplified DNA fragments from envelope gag regions.

Methods and results: DNA extracted from paraffin block mononuclear cells has been used for PCR amplification of envelope and gag regions. We have found that the PCR, if carried out under condition designed to avoid non-specific amplification, results in a large number of false negatives.

PCR results (empirical efficiency):

Isolation amplification sequence	21	22	23	24	25	26	27	28
env 30-368	+	+	+	+	+	+	+	+
env 682-1021	+	+	+	+	+	+	+	+
env 1760-2293	+	+	+	+	+	+	+	+
gag 1551-1665	+	+	+	+	+	+	+	+
gag 856-1046	+	+	+	+	+	+	+	+

A modified PCR technique, involving lower annealing temperature, has successfully amplified fragments of these variable envelope regions. The DNA fragments have been purified and reamplified using the PCR technique and enough DNA obtained for direct sequencing/sequencing of cloned fragments. The results are important in relation to the development of envelope based vaccines.

M.C.P.29 COMPARISON OF IMMUNE RESPONSES IN MICE IMMUNIZED WITH NATIVE HIV-1 ENVELOPE GLYCOPROTEIN OR CORRESPONDING IMMUNOGENE

Lise Thibodeau, L. Flamand,* D. Oth,* L. Lachapelle,* and L. Montagnier**
*Institut Armand-Frappier, Montréal, P.Q., Canada, **Bacteriologist, Paris, France.

Objective: Investigate the role of HIV antigen presentation on the first step of immune reaction (macrophages activation) as well as on later events such as T-lymphocytes proliferation and antibody synthesis.

Methods: HIV-2-immunosome (HIV-2-IMS) was prepared by anchoring purified envelope glycoprotein into the phospholipid bilayer of liposomes. The immune responses to HIV-2 purified gp140/125, or corresponding immunosome, have been determined by the level of Interleukin-1 (IL-1) production by adherent peritoneal exudate cells (PEC), T-lymphocyte proliferation upon *in vitro* restimulation with the immunizing antigen, and by antibody synthesis evaluated by ELISA, IFA, neutralization of cell-free viruses and syncytia formation inhibition.

Results: Mice immunized with HIV-2-IMS developed both higher antibody response and neutralizing titers against HIV-2 than mice immunized with equal amounts of envelope glycoprotein. Similarly, IL-1 production was higher in mice immunized with HIV-2-IMS. In addition, upon *in vitro* restimulation, enhanced IL-1 production was observed only in mice primed and restimulated with immunosomes. T-lymphocyte proliferation, determined by 3H TdR incorporation, followed the pattern of IL-1 production.

Conclusion: These observations indicate that the physical presentation of an antigen may be critical not only for their uptake by macrophages, and simultaneous release of IL-1, but also for the subsequent events in the cascade of immune responses, suggesting the potential application of liposomes as carrier for purified HIV antigen in designing an AIDS vaccine.

M.C.P.30 AN IMMUNODOMINANT EPITOPE OF THE HIV GP160 ENVELOPE GLYCOPROTEIN RECOGNIZED BY CLASS I MHC-INDUCED HUMANS

André, Annie,* Fossati, I.,* Margerite, C.,* Berzanji, J.A.,, Gello, R.C.*** and Zagury, D.***
*Université P. M. Curie, Paris, France, **Metabolism Branch, NCI, Bethesda, USA, ***NCI, Bethesda, USA.

Objective: A single peptide corresponding to residues 308-322 of Rattner et al. (1) sequence accounted for the murine CTL activity (2) measured using stimulator cells expressing the entire gp160 protein. Because CTL may be important for preventing direct cell to cell transmission of HIV we investigated the peptide specificity of the anti-HIV CTL in immunized humans.

Methods: Volunteers, primed by 7⁰ expressing gp160 proteins, received boosters constituted by gp160 hetero-oligomers. These PBs were stimulated *in vitro* by irradiated autologous cells carrying gp160 signals in a mouse lymphocyte culture. Effector PBs were screened for specific cell mediated cytotoxicity by chromium release test, using EBV transformed B cells initially infected with rV or purified p18.

Results: Our results show that immunized populations are CTL responders. Our data found that the peptide p18 may represent a good antigenic signal for specific CTL recognition. However, the response to a single epitope represented by a 15 residue synthetic peptide of T cell epitope and are seen by CD 8 CTL in association with class I (MHC) molecules.

Conclusion: This epitope which occurs in a highly variable segment of the envelope protein may be immunodominant in humans and of clinical importance in vaccine development.

(1) Rattner et al. Nature, 313, 277-284, 1985

(2) Tashiro et al. PNAS, 82, 3105-3109, 1985

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

M.C.P.31

MAPPING OF T- AND B-CELL EPITOPES OF HIV-1 NP PROTEIN IN HUMANIZED CHIMPANZES.

Okamoto, M., Chaudhri, V., Yipko, M.; Sabater, J.M.; Gay, R.M.; Girard, M.; Bahraoui, E. et al.
*Pitié-Salpêtrière Medical Center, Paris; **CNRS U4179 INSERM U172, Marseille; ***Transgene SA, Strasbourg; ****Pasteur Vaccine, France.

Objective: As an approach to vaccination, the immunogenicity and fine specificity of HIV-1 p27^{NP} regulatory protein for T and B cells were assessed using synthetic peptides.
Methods: Chimpantests were repeatedly immunized with soluble purified p27 produced in E. Coli, associated with other recombinant HIV-1 proteins (gp120, p18), and mixed with MDP as an adjuvant. Four animals had been previously inoculated with recombinant vaccines expressing different HIV-1 proteins, 2 of them having that received p27. Two were naive. PBL proliferative specific responses (PFR) (Thymidine incorporation) and serum antibody reactivity (ELISA) were sequentially tested against p27 and a set of synthetic peptides spanning the entire NP sequence.

Results: Independently of immunizations, PFR to p27 was strong and sustained in 1 animal (mean SI = 2), moderate in 2 (mean SI = 5.7 and 5.9), weak in 2 (mean SI = 2.7 and 2.1), and negative in 1 (mean SI = 1). Anti-p27 antibody titres ranged from 1:100 to 1:8400 in the sera of the 3 animals whose lymphocytes had the strongest PFR. The dominant epitope recognized by PFR of these chimpanzees was located in the C-terminal region of p27 whose peptides were compared for their capacity to induce PFR. In parallel, one of the 3 major linear epitopes recognized by ELISA was located distally, indicating that the test of 40 amino-acids of p27 covers both T- and B-cell epitopes.

Conclusion: Besides demonstrating that p27^{NP} presents dominant epitopes recognized by T and B cells on a C-terminal region, these data provide a means to explore the pathophysiological value of the immune response to NP product, and its possible usefulness for vaccination purposes.

M.C.P.33 AN AUTOMATED MICROTITER TEST SYSTEM FOR THE DETECTION OF HIV-1 AND HIV-2 NEUTRALIZING ANTIBODIES

Melzer, W., Kleinschmidt, A., and Edle-Vollmer.
*DSF-Abteilung für Molekulare Zellphysiologie, D-6042 Neuherberg; **Medizinische Poliklinik der Universität München, D-8050 München, West-Germany.
Mark Richardson; Adams, S.E.; Griffiths, J.M.; Burns, N.

Objective: Establishment of a microassay for the measurement of HIV-neutralizing antibodies using monoclonal cells.

Methods: Inoculation of human fetal lung cells (clone LCE5) with HIV-1 or HIV-2 in microtitre plates and demonstration of cytoplasmic viral proteins after two to three days using the indirect immunoperoxidase staining (IP). Demonstration of neutralizing capacity of sera in an enzyme-reduction assay. Use of an automated workstation (BIO-MEX 1000) for the performance of the neutralization assay.

Results: The incubation of LCE cells with HIV results in the formation of IP-positive colonies two to three days after infection. The colonies are counted very easily and their number corresponds to the amount of infective units in the inoculum. Pronunciation of HIV with neutralizing sera prior to infection results in a distinct reduction of colonies, in comparison to endpoint test systems. This assay is more sensitive and the neutralizing capacity of sera can easily be quantified (after determination).
Conclusion: The use of monoclonal cells in combination with IP represents a reliable and easy to quantify test system for the detection of HIV neutralizing antibodies, which can be completely automated. This test system is fast, very sensitive, requires minimal handling of infectious virus and is thus suitable for the screening of large numbers of sera.

M.C.P.35

HIV VACCINE DESIGN: EXPLOITATION OF TY VIRUS-LIKE PARTICLES

Mark Richardson; Adams, S.E.; Griffiths, J.M.; Burns, N.*
Senior, J.M.* and Kingman, A.J.*
*British Biotechnology, Oxford, U.K. and *Department of Microbiology, University of Oxford, Oxford, U.K.

A protein encoded by the yeast retrotransposon Ty can be used as a carrier for recombinant antigens. HIV antigens (gp120, gp41, p24, p17, reverse transcriptase, Tat) have been incorporated into specialized expression vectors for high level production in yeast. These antigen coding sequences include those for complete proteins and selected regions.

All of the Ty-HIV fusion genes were transcribed and translated into fusion proteins that assemble into hybrid virus-like particles (VLPs). The formation of VLPs is conferred by the self-assembly properties of the Ty protein. The hybrid VLPs contain about 300 copies of the fusion protein and hence about 300 copies of the added antigen. The non-Ty component is presented on the outer surface of the particles and induces the production of HIV-specific antibodies.

The ability of various of these polyvalent antigens to induce virus neutralizing antibodies and cellular responses is currently being evaluated in rodents and non-human primates.

M.C.P.32

DEMOGRAPHIC CHARACTERISTICS AND FREQUENCY OF EXCLUSIONARY CRITERIA IN A POPULATION VOLUNTEERING FOR HIV IDENTIFICATION.

Maschke, E. Ulf; Melzer, W.; Giese, G.-J.; Anderson, K.R.; Berry, C.F.* and the ELIAS AIDS Vaccine Program*.
*University, Huntington, W.V., USA; **Bethesda, Md., USA.

Objective: To define the population volunteering for an AIDS vaccine study (ELIAS MicroStudy) and to determine the frequency of occurrence of exclusionary criteria in such a population.

Methods: 156 volunteers were interviewed and examined. Blood was collected for routine laboratory testing as well as cell counts, HIV ELISA (EIA), Western Blot (WB) and p24 Ag.

Results: 85 males (mean age 22.2, range 18-42) and 81 females (mean age 23.9, range 17-50) volunteered. 130/166 (78%) were university students. Most had less than 1 year of study from news media (50%), Friends/relatives (17%). The most common causes for exclusion were the presence of indeterminate WB (26.9%) or a change of mind after the initial interview (24%). Other causes were abnormal CBC and DIFF (7.2%), elevated ALT (3.8%), HbA1c (3.6%), abnormal UA (3.4%), recent STDs (3.0%), 74 (400 (1.9%); abnormal CD4 (1.7%); recognized high risk behavior (1.7%); SWE (1.2%), premenstruity (1.2%), failure to meet age criteria (1.2%), unable to be available for entire study (1.2%), abnormal physical exam (0.5%) and split up (0.4%). No volunteers had AIDS. 14.5% had more than one reason for exclusion.

Conclusion: Even in a community with low prevalence for HIV, a large number of healthy heterosexual volunteers can be expected to be ineligible for enrollment in HIV vaccine trials. An average of 4.8 volunteers were screened for each of 12 vaccinees chosen.

M.C.P.34

NOVEL APPROACH TO PURIFICATION OF HIV p24 PROTEIN BY CLEAVAGE FROM HYBRID TY VIRUS-LIKE PARTICLES

Jacqueline E.H. Gilmore; Burns, N.R.; Kingman, S.N.; Kingman, A.J.* and Adams, S.E.*
*British Biotechnology Limited, Cowley, Oxford, U.K. *Department of Microbiology, University of Oxford, Oxford, U.K.

Objective: To develop a rapid method of purifying a component of a fusion protein

Method and Results: The coding sequence for HIV-1 p24 was cloned into a TyVLP vector. The resulting fusion protein assembles into virus-like particles due to the presence of the yeast Ty p1 protein. This is linked to p24 via the recognition sequence of the blood clotting factor Xa. The VLPs can be readily purified in milligram quantities. The p24 component can then be cleaved from the particles with activated factor Xa. A rapid method has been developed for the subsequent purification of p24 from the cleavage mixture. This technology has also been used for the purification of other proteins including HIV TAT and RTF.
Conclusion: A simple and effective method has been developed for the purification of the p24 component of a fusion protein. This is a generic method applicable potentially to any protein of interest.

M.C.P.36

BREAST MONKEYS IMMUNIZED WITH RECOMBINANT VACCINA VIRUSES

CONTAINING HIV-1 ENVELOPE GENES INDUCE ANTIBODIES REACTIVE WITH ENVELOPES OF DIFFERENT HIV-1 STRAINS. Mital, Ales; Wala, M.; Hendry, B.R.; Carrow, S.E.; Mose, B.; Quinn, Q.; El, M.; Wala, W.; PFA. Inst. for Biological Control, Research, and Eval. REAID, Heli, Bethesda, Md., U.S.A.

Objective: To study HIV-1 specific antibody (Ab) responses in rhesus monkeys immunized with recombinant vaccinia viruses containing the gp160 envelope genes of HIV-1 strains IIIIB or SF.

Methods: Groups of 4 rhesus (R) monkeys were immunized with either ZVid⁰ FFP of a 7% deletion mutant of vaccinia virus (VAC) or recombinant vaccinia virus containing the HIV-1 IIIIB (VAC-IIIIB) or HIV-1 SF (VAC-SF) gp160 envelope genes, at weeks 0 and 9. Sera were collected at three week intervals for measurement of HIV-1 envelope reactive Ab. Serological assays were performed by Western blotting (WB) 1:10 dilutions of sera against recombinant HIV-1 (strain IIIIB) strips, and by whole virus (IIIIB) ELISA and recombinant HIV-1 (LAV) gp160 ELISA serum dilutions of 1:5 to 1:40.

Results: All AB strain primary but not secondary tests. As results were:

ASSAY	AB STRAIN OF ORIGIN	VAC-IIIIB	VAC-SF
HIV-IIIIB WB gp120/160	0/4	0/4	3/4
HIV-IIIIB WB gp41	0/4	0/4	3/4
HIV-IIIIB ELISA (GMT)	0/4	3/4 (20.0)	3/4 (23.2)
WFA-IVF-p160 ELISA (GMT)	0/4	4/4 (24.0)	3/4 (15.8)

Concluding: VAC-IIIIB or VAC-SF induced broadly reactive Ab to HIV. Only VAC-SF induced Ab to gp41, suggesting greater expression of the complete gp160 by VAC-SF or the immunodominance of HIV-SF gp41 heptamer sequence. Testing for Ab at 1:100 would have failed to detect Bb seroconversion.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

M.C.P.37 SALIVARY ANTIBODIES TO HIV ANTIGENS IN AN AEROSOL VACCINE TRIAL

Archibald, David, Ambrin, C., Sun, D., Tacker, C.
University of Maryland at Baltimore, U.S.A.

The development of HIV-specific secretory antibodies may be a desirable outcome in individuals receiving AIDS vaccines. We investigated carotid and whole saliva samples from 5 volunteers who received a recombinant HIV-1 envelope glycoprotein (gp120) vaccine (Aerovax) and the presence of HIV-specific antibodies. Ten healthy adult volunteers received intramuscularly either 3 doses of gp120, (reactions B vaccines) or a placebo preparation on days 0, 30, and 180. Individuals receiving the gp120 received either 40 or 80 µg at each vaccination. Saliva samples were collected one day from the volunteers on days 0, 24, 50, 120, 194, and 270. HIV-specific antibodies were assayed using immunoblots (Epitope) which were incubated with the saliva samples, then with a biotinylated anti-human immunoglobulin antibody with a streptavidin-biotin horseradish peroxidase complex. To date, all volunteers were negative for HIV antibodies by ELISA (Abbott) in their serum. By Western analysis, secretions in gp120 in HIV envelope were demonstrated in 2 individuals, one who received the low dose vaccine and one who received the high dose. We tested antibodies to gp120 in whole saliva samples collected from one of these individuals. Stimulated prostatic saliva collected on this date and all others was not detectable HIV-specific antibodies. Mean total IgA levels of the volunteers with stimulated flow were 55 mg% g/l and 3.0 mg% s/l for whole and parotid saliva respectively, as detected by ELISA. The finding of HIV-specific antibodies in whole saliva following vaccination may indicate that development of secretory immunity is possible.

M.C.P.39 REPLICATION OF HIV UNDER SIMULATED GROWTH CYCLE CONDITIONS: A MODEL FOR STUDYING THE EFFECT OF ANTIVIRAL DRUGS.

Diazand, Fernando, Anderson, S., Capobianchi N.R., Anelli, P., Di Marco, P., Turzillo, J. The Institute of Urology, University "La Sapienza", Rome, Italy.
Objectives: To describe an experimental model of HIV infection for testing antiviral drugs. **Methods:** C8166 cells were infected with 2x10⁶ TCID₅₀/cell and then seeded in the presence or absence of antiviral drugs. At various time points cultures were collected and intracellular or extracellular virus was back titrated in fresh C8166 cells by standard limiting dilution method (0.5 Log ratio, 4 replicates per dilution). Replication is completed in 20 hr and at each time point, the effect of intracellular virus is 2 Logs higher than the extracellular one. This model allows us to determine directly the killer of antiviral drugs in terms of infectious virus yield reduction rather than of production of indirect parameters of viral growth (RT, p24, or C.p.e.). **Conclusions:** HIV replication is not as slow as previously established. Availability of a simple and dependable test to directly measure infectious virus may overcome uncertainties and ambiguities connected with indirect evaluation of viral growth by RT or p24 antigen determination. By using this model we have been able to show synergism between zidovudine and didanosine.

M.C.P.41 T CELL EPITOPES IN A CHEMICALLY SYNTHESIZED 104-MER CORE PROTEIN (p24) OF HUMAN IMMUNODEFICIENCY VIRUS (HIV-1)

Shibata, H., *Mocagni, P., *Torchio, G., *Gibbons, W.A., * and

*Dept. Med. Microbiol., London Hosp. Med. Coll., Turner Street, London E1 2AD, U.K. *School of Pharmacy, London, U.K.

Objective: To locate T cell epitopes of the terminal half of p24 of HIV-1. **Methods:** A 104-mer peptide corresponding to the amino acid sequence of the C-terminal half of p24 of HIV-1 was synthesized using an automated ABI 430A peptide synthesizer and an NBOO chemistry. The long peptide was used to generate murine peptide-specific T cell lines. The lines were then tested for their ability to proliferate to whole virus and native core proteins of HIV-1. A set of 14-23 mer peptides containing predicted T cell areas and a second set of 15 residues overlapping peptides were then individually tested to stimulate proliferation of the 104-mer specific T cell lines in order to locate the T epitopes. Peptides that induced *in vitro* proliferation of the lines were also tested to generate *in vivo* help in the production of antibody reactive to synthetic peptide, recombinant and natural core proteins. **Results:** The murine 104-mer specific T cell lines were of the helper phenotype and proliferated to the antigen in a MHC-restricted manner. The lines also responded to the whole virus and native p24. Five T epitope containing regions were defined in the 104-mer. Murine antipeptide raised against the T epitopes contained the synthetic protein, recombinant core proteins and viral p24 of HIV-1. **Conclusion:** The 104-mer peptide contains both T and B epitopes with viral core protein and is therefore suitable for studies in HIV vaccine.

548

M.C.P.38

REACTIVITY OF PURIFIED HIV-1 GP120 BY ALHYDRAL.

Hess, J., Miller M., Ziv, E., Pyle, H. W., Brummond, J. L., and Arthur, L. O. Program Resources, Inc.

NI-Frederick Cancer Research Facility, Frederick, Md. 21701. **Objectives:** The duration of the humoral immune response in chimpanzees vaccinated with HIV-1 gp120 formulated in Alhydrogel suggests that HIV-1 gp120/Alhydrogel complexes may be short-lived *in vivo*. In order to explore this possibility, we determined the effect of serum on gp120/Alhydrogel complexes. **Method:** Radiolabelled HIV-1 gp120 was adsorbed to Alhydrogel and the resulting complexes were separated from non-adsorbed gp120 by centrifugation. The gp120/Alhydrogel complexes were resuspended in distilled water and aliquots were added to normal human serum or gp120/Alhydrogel complexes. Incubation of gp120 was determined by pulling aliquots at various times and determining the amount of radioactivity in the pellets and supernatants. **Results:** HIV-1 gp120 is readily adsorbed by Alhydrogel and is stable for long periods of time when resuspended in distilled water. However, soon after 24 hours, approximately half of the complexes immediately dissociate, and less than 20 percent of the gp120 remains complexed after 96 hours. **Conclusion:** HIV-1 gp120/Alhydrogel complexes in serum are short-lived, *in vitro*, and may explain the short-lived humoral responses in chimpanzees. Additional studies need to be evaluated for use in HIV-1 gp120 AIDS vaccine experiments.

M.C.P.40

INDUCTION OF ANTIBODY TO HIV-1 ENVELOPE PROTEINS BY p24 CORE T EPITOPES

Coates, Anthony R.M.,* Slin, D.Y.,* Macagnani, P.,* Torch, G.E.,* Haselton, J.R.,* and Gibbons, W.A.,**
*The London Hospital Medical College, London, U.K. **The School of Pharmacy, London, U.K.

Objective: To investigate the possible involvement of HIV-1 p24 T epitopes in helping the generation of antibody responses to viral envelope proteins. **Methods:** Previously we have located 5 T epitope-containing regions in a synthetic 104 residue long peptide corresponding to the sequence of the C-terminal half of HIV-1 p24. Groups of Balb/c mice were individually primed subcutaneously with 50 µg of each of these 5 T epitope-containing peptides in Freund's incomplete adjuvant and boosted with 50 µg of a synthetic chimeric peptide. Chimeric molecules used were a 138 mer peptide consisting of the 104 residue peptide linked to an envelope peptide which has been demonstrated to contain at least one T epitope, and another 43 residue peptide containing a selected p24 T epitope linked to the same envelope sequence. Antisera were collected 14 days post challenge and assayed for their reactivity against HIV protein using Western blotting. **Results:** Antibody against envelope proteins was detected in mice primed with the 104 mer or individual T epitope-containing peptides and boosted with the 138 mer. Anti-envelope responses were also found in T epitope primed mice which were boosted with the 43 mer chimeric peptide containing the same T epitope. **Conclusion:** It appears that some T epitopes of p24 core protein can regulate antibody responses to the envelope protein.

M.C.P.42

DIPYRIDAMOLE HAS ACTIVITY AGAINST HIV-1 AND POTENTIATES THE ANTIVIRAL EFFECTS OF AZT AND OTHER DIDEHYDROXYLICOSIDES IN MONOCYTE/MACROPHAGES

Szabon, Janna*, Wahl, S.M.,* Popovic, M.*, Wahl, L.M.C.*, Garas, S.*, Fine, R.L.,* Skarlov, U.A.* and Weisand, J.N.*

*National Cancer Institute, *National Institute of Dental Research, National Institutes of Health, Bethesda, Maryland, USA

Objective: To report: 1) an inhibitory effect of dipyridamole (DPM) on HIV-1 replication in monocyte/macrophage (M/M) cultures and 2) a potentiation by DPM of the anti-HIV effects of zidovudine (AZT) and didanosine (ddC) in M/M. **Methods:** M/M cultures were prepared from peripheral blood monocytes purified either by adherence to plastic or by centrifugal elutriation. The cells were infected with HIV(HIV-1_{IIIB}/H89) and p24 antigen production was measured at intervals by ELISA. **Results:** The ID₅₀ values of AZT and ddC decreased by at least 5-fold in the presence of 2.10 µM DPM. With 0.4-0.8 µM DPM, the ID₅₀ of AZT appeared to decrease by about 2- to 3-fold. No toxicity of DPM for M/M was seen at concentrations of 10⁻² to 10⁻⁴ M, as assessed by cell counts and by the functional criterion of superoxide generation with or without stimulation by PMA. DPM did not potentiate AZT toxicity for human bone marrow promotor cells in a CFU₂ assay. **Conclusions:** DPM is widely used in the treatment of vascular diseases because of its platelet anti-aggregant and vasodilator activities. Since M/M are major reservoirs for HIV-1 *in vivo*, our findings suggest the possible utility of DPM in combination chemotherapy of HIV infections. However, clinical efficacy cannot be predicted on the basis of *in vitro* studies such as these.

Session d'attachage Poster Session



M.C.P. 49 Inhibition of *de novo* HIV infection in monocytes/macrophages by Agents which block the binding of HIV-1 gp120 to CD4. **Ferns, Carlo-Federico, Varsano, R., and Broder, S.** National Cancer Institute, Bethesda, MD, USA.

Objective: To evaluate the ability of ORTAs or recombinant soluble CD4 (rCD4) to inhibit HIV replication in cells of monocyte/macrophage (M/M) lineage. **Methods:** Peripheral blood M/M prepared by various separation techniques (in some cases cultivated in medium with 100 ng/ml GM-CSF) and U937, a monoclonal line, were exposed to HIV-1 (monocytotropic strains HTLV-III₈₉ or HTLV-III₉) in the presence or absence of ORTAs or rCD4 (produced by Genentech).

Results: Fresh M/M had relatively low amount of surface CD4 (10-15% weakly CD4⁺ by FACS). In most cases the amount of CD4 increased as the cells were permitted to mature for 3 days (GM-CSF). U937 cells were 20% CD4⁺. Despite these differences among M/M populations, ORTAs inhibited HIV replication in all M/M by 20% for up to 30 days after viral challenge, even at the lowest concentrations tested (0.01 μg/ml). rCD4 at 3 μg/ml inhibited HIV replication in all M/M populations by 20%. Also, 1 μg/ml rCD4 inhibited HIV by 75% in mature M/M and in GM-CSF-treated M/M, while somewhat less inhibition was achieved in fresh M/M. HTLV-III₉ replication was 20% inhibited in U937 by 0.1 μg/ml rCD4 and 1 μg/ml ORTAs. No consistent HIV suppression was found with ORTAs in cocultures to a different extent on CD4⁺ or with a control murine IgG1a. rCD4 inhibited HIV replication by 90% if added to M/M within 2 hours of viral challenge, while ORTAs lost its antiviral effect if added 24 hours after viral exposure.

Conclusions: ORTAs and soluble CD4, which block CD4-gp120 binding, are highly effective inhibitors of infection of blood-derived M/M by HIV, providing evidence that CD4 is the principal if not sole receptor for HIV in M/M.

M.C.P. 51 HELA CELLS STABLY EXPRESSING HIV ENV AND AIDS TOOLS FOR STUDY OF STRUCTURE, FUNCTION AND CANDIDATE GENES OF THESE HIV ENV PROTEIN PRODUCTS.

Gama Sosa, M., DeGasperis, R., Fahey, F. and Bannard, D.M.
Dana-Farber Cancer Institute, Boston, MA
and Harvard Medical School, Boston, Massachusetts, USA.

Objective: To stably express the *env* and *gag* gene products of HIV in HeLa cells, and to use such expression cell lines to isolate these gene products for structure/function analysis. **Methods:** A DNA fragment containing the *gag*, *env* and *gag* genes from the HIV-1 infectious clone pHR232 was cloned into the neomycin shuttle vector pRShCMV3. The resulting plasmid pHR232 was transfected into human cells, and transfectants (HeLa *gag/env* cell clones) were selected in G418 containing medium.

Results: Stable expression of HIV *env* was demonstrated by immunoprecipitation with AIDS patient antisera which showed only bands of molecular weights 120, 120 and 41 kD after lentil lectin chromatography. HIV *gag* expression in these HeLa cell transfectants was demonstrated for over 6 months. An indirect assay for *gag* based on synovium formation was performed as follows: HeLa *gag/env* cells were cocultured with indicator HeLa T4 containing the chromosomal source of synovial (CAT) gene under the transcriptional control of the HIV LTR (kindly provided by Drs. B. Fether and G. Fawcett). Transactivation of the CAT gene was observed after cocultivation of indicator cells with HeLa *gag/env* but not with wild type HeLa cells. This transactivation was inhibited by ORTAs and, likewise, inhibition of glycoprotein processing such as castanospermin or its analogues inhibited CAT transactivation.

Conclusions: The virus-free expression of the HIV *gag* and *env* will allow analysis of structure, function and inhibition of these gene products in a bioassay-free system.

M.C.P. 53 USE OF AZT AS A CHEMOPREVENTIVE AGENT: EFFICACY AND TOXICITY IN MURINE RENOVATED DEFICIENT (RND) MICE.
Billie, John, S., Mackley, C., Yetter, R.A., Shepko, S., Friederickson, T., Bell, W. and Riegman, J.L.
VA Medical Center, and University of Maryland, Baltimore, MD, U.S.A.

Objective: To determine if AZT therapy can protect susceptible populations from retroviral infection.

Methods: AZT was administered to C57BL/6 or NFS-1/N mice prior to challenge with LP-10MS or Cas-B-R-M M/J or retrovirus.

Results: 1) Treatment with AZT (100 mg/kg) for 2 weeks (4 weeks) protected newborn NFS-1/N mice from a single challenge with Cas-B-R-M but was not able to prevent maternal-fetal transfer of LP-10MS M/J to infected C57BL/6 mothers.

2) AZT treatment of adult C57BL/6 mice suppressed LP-10MS replication upon removal of AZT, viral replication and disease was observed in a significant percentage of the mice.

3) Mastocytosis fell dramatically in mice treated with high levels of AZT. 4) The hematopoietic toxicity was dose dependent, hyperplasia and elevations in spleen and bone marrow WBC were observed in mice treated by continuous infusion, indicating that AZT alters erythropoiesis in the absence of detectable retroviral infection.

Conclusion: The effectiveness of AZT as a chemopreventive agent depends upon the elimination of reservoirs of infection and the management of hematopoietic toxicity.

Recherche fondamentale (biomédicale) Basic Research (Biomedical)

M.C.P. 50 USE OF NUCLEIC ACID HYBRIDIZATION FOR HIV SUSCEPTIBILITY TESTING.
Robert Stewart, H., *Gibball, D., *Wilson, V., *Lentzfeld, M., *Kerning, M., *Carlson J.
University of California, Davis, California, USA and *Molecular Hybrids Inc, (MHI) Alhambra, CA, USA

Objective: Many antiviral compounds for Human Immunodeficiency Virus (HIV) infection are being studied using time consuming and tedious *in vitro* methods. We have developed and evaluated a new technological approach for antiviral susceptibility testing using a rapid and simple method for specimen processing known as "hybridizing". This technology has been adapted to successfully test the susceptibility of HIV to zidovudine (AZT).

Methods: CD4 cells (2×10^6) were infected with HIV (HIV-1) at approximately 850,000 average transcopies units (ATU). After 3 hr adsorption the cells were washed 3 x and RPMI 1640 + 10% calf serum with AZT (10⁻⁶-0.1 μM) was added. Cells were incubated for 6 days, at which time the media was removed and cells were lysed with the RNA lysis agent (RLT). Hybridization of the virus was carried out at 47°C for 2 hrs with an Ligated as an AZT probe containing 3.0 kb of the HIV genes p90-95. After a 1 hr wash at 50°C the vials were counted in a gamma counter.

Results: The inhibitory *IC*50 (ATU) for AZT by this method was <0.01 μM. This result was reproducible and paralleled RT assays and p24 Ag assays. **Conclusions:** This technology is a rapid and simple method for screening HIV. This technique should prove very useful for the rapid screening of antivirals and the study of resistance in clinical isolates.

M.C.P. 52 RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR (r-met-HGF-CSF) AND RECOMBINANT BIRTHPOINTE (r-HSP90) MAY ABROGATE THE NEUTROPENIA AND ANEMIA OF AZT AND MAY ALLOW FOR RESUMPTION OF ZIDOVUDINE (AZT) IN PATIENTS WITH AIDS.

Mill, Steven, Minoura, S., Fink, N., McCarthy, S., Allen, K., Sosa, L., and Clerp, J.
*ADA AIDS Center, Los Angeles, CA, USA and *Angene, Inc., Thousand Oaks, CA, USA.

Objective: To see if combined AZT-CSF/HSP90 can correct neutropenia and anemia in patients with AIDS and allow for the resumption of full or higher doses of AZT.

Methods: Phase I/II Open Label Trial of r-met-HGF-CSF/HSP90 AZT in patients with AIDS/ANEMIA. Patients with absolute neutrophil counts (ANC) < 500/mm³ and hemoglobin (Hb) < 11.5 g/dl (all *g* marrow suppressive drugs including AZT = 3 weeks) were treated with r-met-HGF-CSF one daily 1000 mg until ANC of 5000 was achieved and maintained for 2 weeks. r-HSP90 (TW) was added and increased until an increase of 1.5 g/dl of Hb, over baseline was observed. Patient groups were then given 1000 mg, 1500 mg or 2000 mg of AZT per day.

Results: Eleven of 24 patients have completed. Of these, eight have completed the r-met-HGF-CSF alone phase with mean, 1500 mg, 20,449 ± 9130 neutrophils. Four have completed the combined r-met-HGF-CSF/HSP90 phase with normalization of their hemoglobin values (13.0 ± 0.8) and have resumed full dose AZT (1000 mg/d). One patient died unexpectedly and another was withdrawn for neurologic decline during this phase. Both r-met-HGF-CSF and r-HSP90 have been well tolerated. Toxicities were mild transient pain responsive to ibuprofen (2 sp), and hypokalemia and/or hypophosphatemia in 9 sp, with poor nutritional status and chronic diarrhea. Analysis of limiting dilution plasmids and lymphocyte cocultures for HIV and p24 antigens showed no significant alterations in viral expression prior to resuming AZT.

Conclusions: Recombinant-met-HGF-CSF and r-HSP90 may alter the neutropenia and anemia of AZT, is well tolerated and may allow the resumption of full dose AZT in AIDS patients without stopping HIV expression. This combined therapy may be benefit to AZT intolerant AIDS pts.

M.C.P. 54 PHOSPHORYLATION OF 3'-AZIDO-2',3'-DIDEOXYTHYMIDINE, AZIDO-2'-DEOXYADENOSINE AND AZIDO-2'-DEOXYGUANOSINE IN UNINFECTED AND HIV-1 INFECTED GENOME CELLS.
Edman, R. L., Oswald, S. J., Sommadossi, J. P., Chu, C. K., Williams, G. and Salzman, N. P.

Veterans Administration Medical Center and Emory University School of Medicine, Atlanta, Ga, USA
University of Alabama, Birmingham, AL, University of Georgia, Athens, Ga, and *Ticon Bioscience Inc., Amesbury, MA, USA.

Objective: To compare the antibiotic phosphorylation of 3'-azido-2',3'-dideoxythymine (AZido-CTB), 3'-azido-2'-deoxyadenosine (AZido-CTD), and 3'-azido-2'-deoxyguanosine (AZido-CTG) in cell culture.

Methods: Uninfected and HIV-1 infected cells were treated with Propylthiouracil (PTU), AZT, or AZido-CTB. AZido-CTB and AZido-CTD were prepared and HPLC-analyzed using a Symyxmodel 8000 detector. AZido-CTB and AZido-CTD were also analyzed to determine the amount of drug incorporated into RNA and DNA.

Results: A 3-hour pulse-labeling of uninfected GenomE cells indicated that AZT may be more rapidly phosphorylated than AZido-CTB. No such difference was seen at 24 h incubation. Both AZido-CTB and AZT accumulated 1 fold of either drug, however, generated 5-10 times lower levels of phosphorylation than did AZido-CTB. AZido-CTB and AZido-CTD were also analyzed to determine the amount of drug incorporated into RNA and DNA.

Conclusions: The observed differences in HIV-antiviral effects in cell culture, have been linked with 1 fold of either drug, however, generated 5-10 times lower levels of phosphorylation than did AZido-CTB. AZido-CTB and AZT, over 50% of total radioactivity was found in the RNA fraction. In contrast, AZido-CTD and AZido-CTG, over 90% of total radioactivity was found in the DNA fraction. These results indicate that AZido-CTB and AZT, over 50% of total radioactivity was found in the RNA fraction, while AZido-CTD and AZido-CTG, over 90% of total radioactivity was found in the DNA fraction. This indicates that AZido-CTB and AZT, over 50% of total radioactivity was found in the RNA fraction, while AZido-CTD and AZido-CTG, over 90% of total radioactivity was found in the DNA fraction.

Conclusions: Although AZT and AZT produced similar phosphorylation patterns, significantly lower levels of mono- and diphosphate of AZido-CTB were found which may explain its lower activity and toxicity in vivo.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

M.C.P.67 NEUTRALIZATION OF HIV-1 BY ANTI-IDIOTYPIC ANTIBODIES

Lundl, D., Wain, B., & Johnson, P.*, and Thompson, T.*
*Mc Johnson Pharmaceutical Research Institute La Jolla, CA, USA,
**Cincinnati University

Objective: To evaluate the ability of anti-CD4 monoclonal antibodies to block anti-idiotype antibodies that are capable of binding and neutralizing HIV. **Methods:** Monoclonal antibodies (mAb) with purified OKT4A MAb and 4 weeks later with OKT4F (10 day injection protocol). The anti-CD4 antisera were assayed for anti-idiotype antibody by competition ELISA and for internal image (CD4-like reactivity, i.e. binding to HIV) using a commercial HIV antibody detection kit. To determine HIV neutralizing titres in vitro, MT-4 cells, pretreated with serially diluted antisera in 96-well microtitre plates, were exposed to HIV-1 (clarified supernatant for 2 hrs at 37°C. Cultures were incubated for 7 days and developed colorimetrically with MTT. At the end of the 7 day incubation period, supernatants were harvested and neutralization assayed immediately. Neutralizing antibody titres were detected 5-14 days post immunization. Following OKT4F, anti-CD4 and neutralizing titres were found to be slightly higher.

SERIA	ANTI-CD4		ANTI-OKT4F		NEUTRALIZING	
	ITITER	ITITER	ITITER	ITITER	ITITER	ITITER
Prebnd	<1100	<1100	<1100	<1100	<110	<110
2wk post OKT4A	ND	ND	1400	1400	ND	ND
6mo post OKT4A	11200	ND	1100	ND	ND	ND
2wk post OKT4F	ND	ND	1900	1800	ND	ND

Conclusions: Anti-idiotype antibodies were raised in response to anti-CD4 monoclonal antibodies which were able to bind and neutralize HIV, in vivo.

M.C.P.69 PHARMACOKINETICS, TOXICITY AND PROPHYLACTIC ANTIVIRAL ACTIVITY OF PMA IN FELINE RETROVIRUS INFECTED CATS

Nathans, Lawrence E., Semson, C.L., Polas, P.A., Sans, R., Hayes, K. and Kitchin, J.
The Ohio State University, Columbus, Ohio, U.S.A.

Objective: To determine the pharmacokinetics, toxicity and prophylactic antiviral activity of 9-(2-(phosphorinethoxyethyl)adenine (PMEA) in feline infectious viral infective cat. **Methods:** Pharmacokinetics and bioavailability of PMEA was determined in 6 cats at three doses. In prophylactic studies, 3 different dosage regimens of PMEA (100, 25 or 12.5 mg/kg/day) were evaluated for toxicity and antiviral activity *in vivo*. In all prophylactic studies PMEA was administered by continuous IV infusion beginning one day prior to FeLV challenge. Toxicity was evaluated as part of the prophylactic testing.

Results: PMEA administered at doses greater than 12.5 mg/kg/day continuous IV infusion were toxic to severely toxic, causing death in 3 of 7 animals treated. The most prominent clinical feature in these animals was hemolytic anemia. A dosage of 12.5 mg/kg/day PMEA administered by continuous IV infusion for 3 was prevented or delayed the onset of infection in 6 of 6 challenged animals. Moderate anemia was evident in these animals at the end of 3 wks of treatment. By comparison 7 of 7 control cats developed chronic viremia by 3 wks post challenge. All PEA treated cats remain FeLV negative after 5 wks post challenge. **Conclusion:** Though moderately toxic in cats at a dose of 12.5 mg/kg/day continuous IV infusion for 3 wks, PMEA was highly effective as a prophylactic treatment for preventing FeLV infection of cats for the period so far observed. Lower dosage regimens are currently being evaluated.

M.C.P.71 FLUORAZOLIDONE TREATMENT OF ESOPHAGEAL CANDIDIASIS IN AIDS PATIENTS.

A Gil, Z. LERJILLA, A. SANCHEZ, H. VALERIO, JL. DELA, JO. VAZQUEZ, B. Lopez, L. Mas, Madrid, Spain.

Aims of the study: To assess the efficacy and safety of Fluorazolidone in the treatment of esophageal candidiasis in AIDS patients. **Methods:** 18 patients (15 male and 3 female) were included. Mean age was 28 years (range: 19-41). There were 10 (55%) with CD4 counts < 200/mm³ and 8 (45%) with CD4 counts > 200/mm³. Esophageal candidiasis was confirmed by endoscopy, biopsy and/or culture. Therapeutic regimen: 200 mg (100 mg) followed by 100 mg orally p.o. for 4 weeks. Endoscopic control was carried out at the end of the treatment. A follow up visit 1 month after treatment was scheduled. General drug surveillance was performed in all patients. Therapeutic evaluation was performed in 32 patients, although only 20 completed treatment. The study was carried out over a 14 month period (February-December 1985). During this time 8 patients died, 4 in the protocol stage and a further 4 after completing treatment, all of these due to other opportunistic infections. **Clinical and endoscopic cure** was achieved in all patients; in most, clinical picture resolved within a week. In 2 patients an esophageal relapse occurred 1 month after treatment. Re-treatment with Fluorazolidone achieved cure again. In a further 3 patients esophageal relapse occurred 1 month after treatment. In 1 patient, relapse occurred 2 months after treatment. In all cases, relapse was observed. Elevations of liver enzymes: discrete (19 patients), moderate (5 patient) and severe (1 patient), the latter leading to drug discontinuation, were reported. Increases of alkaline phosphatase without hyperbilirubinemia (23) was the most commonly observed adverse effect; however, it has to be taken into account that most patients had coexisting opportunistic infections and/or received antipneumocystis carinii chemoprophylaxis. **Conclusions:** 1) Fluorazolidone has been shown to be an effective and safe treatment of esophageal candidiasis in AIDS patients. 2) A 4 week treatment may be sufficient in this condition. 3) An effective prophylactic regime with Fluorazolidone in these patients needs to be desirable.

M.C.P.68 PHOSPHONATE INHIBITS FELINE RETROVIRUS INFECTION IN CATS

Shannon, Cheryl L., Weisbrod, S.E., Sans, R., Nagode, L., Hayes, K., Malins, L.L., & Johnson, P.*
The Ohio State University, Columbus, Ohio, USA.

Objective: To determine *in vitro* and *in vivo* efficacy and toxicity of phosphonate (PPA) against feline leukemia virus (FeLV). **Methods:** PPA-induced inhibition of FeLV infection feline lymphoid cells (3201) was determined by reverse transcriptase (RT) assay. Pharmacokinetic studies were performed in young and adult cats. For prophylactic studies, six cats received 1000 mg/kg/day PPA as a continuous IV infusion for 1 day prior to and 4 weeks post-FeLV challenge. Six control cats received 120 U/kg/day heparin in saline. Six cats served as challenge control. **Results:** Histometric determinations were performed on the distal radius of young and adult cats given 1000 mg/kg/day PPA and on age-matched controls. **Conclusions:** FeLV infection of 3201 cells was inhibited by >90% at 64 nM PPA as measured by RT activity. Young cats exhibited a higher (2x) plasma clearance of PPA than adult cats, which was attributed to enhanced bone accumulation. Mean oral bioavailability was 35%. Continuous IV infusion of PPA (1000 mg/kg/day) prevented FeLV viremia in 4 of 6 cats. Six of 6 untreated challenge cats demonstrated FeLV viremia by 3 weeks post-inoculation. Plasma biochemical changes prevented in PPA treated cats compared with sham-operated controls included: increases in calcium and decreases in phosphorus, alkaline phosphatase and calcitriol. Bone histomorphometry revealed rickets-like lesions in young cats and osteomalacia in adult cats given 1000 mg/kg/day PPA for 14 days. **Conclusion:** PPA prevents FeLV infection *in vitro* and *in vivo*. High doses of PPA induce rickets in young cats and osteomalacia in adult cats.

M.C.P.70 PHOSPHATE TRIESTER DERIVATIVES OF AZT AS INHIBITORS OF HIV

McDonnell, Chris J., Devine, K., O'Connor, S.M., Galpin, B.H., Williamson, J.B., Kitchin, D.,
*University College, London, UK, **St Mary's Hospital Medical School, London, UK.

Introduction: A series of 20 phosphate triester derivatives of AZT have been tested against HIV-1 (SF115 III, RP strain) in the C8662 CEM-7 cell line. These compounds have been designed as more suitable substrates in order to overcome some of the limitations shown by AZT and other nucleoside analogues; such as kinase dependence, metabolic instability and poor membrane penetration. It has been found that asymmetrically substituted phosphates of AZT are active antiviral agents especially when one phosphate moiety is an amino-linked amino-acid, and the other is an aliphatic chain. **Results:** Depending upon the nature of the substituents large differences in the antiviral effect are observed. In the compounds below changes in the aliphatic chain (X) and the amino acid (Y) gives a range of activities (IC₅₀) from 3 - 100 nM. Studies to investigate the nature of the block in HIV replication was in progress.

UCL No	X	Y	Z	IC ₅₀ (nM)
UCL 11	MeO	MeVal	Et	300
UCL 12	MeO	MeVal	Me	10
UCL 23	MeO	MeVal	Me	30
UCL 24	EtO	MeVal	Me	100



M.C.P.72 RECOMBINANT SOLUBLE CD4 AS A VEHICLE TO DELIVER RIBICIN TO HIV-ENVELOPE EXPRESSING CELLS

Cochran, Nancy A., Collinson, A.H., Liu, L., Miller, C.,
V.**, Ross, N.D.,** Golsharif, V.S.,** Tamura, S.,** Cambridge, UK, *Biogen, Inc., Cambridge, MA, USA.

Objective: To assess the effectiveness of recombinant soluble CD4-blocked ribicicin conjugate (cd4-rib) as a potential drug for the elimination of HIV-envelope expressing cells, *in vitro*. **Methods:** Intact ricin was covalently modified such that it retains ricin's ability to efficiently penetrate intracellular and plasma membranes but can no longer bind to cells through its natural binding sites. Blocked ricin (rib) was then covalently linked to rH8 and the conjugate was tested in a number of *in vitro* assays. Cytotoxicity and specificity of killing were tested on CD4 cells and HIV-infected human T cells. Binding efficiency of rH8-r8 to gp120 was assessed in an RIA using recombinant gp120 (rgp120). **Results:** rH8-rib conjugate retained the capacity to bind to gp120 in an RIA. The cytotoxicity of the rH8-r8 conjugate was specific to HIV-envelope expressing cells. gp120-expressing CD4 cells were effectively killed between 10⁻⁶ and 10⁻¹⁰ M rH8-rib. Unmodified rH8 completely blocked the rH8-rib mediated killing. Uninfected CD4 cells and CD4 cells expressing a non-related recombinant protein were not affected at these concentrations. Experiments with HIV-infected human T cells confirmed these observations. **Conclusions:** We demonstrate that blocked ricin conjugated to recombinant soluble CD4 selectively kills HIV-envelope expressing cells, *in vitro*, at concentrations that are achievable *in vivo*.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

M.C.P.79 INHIBITORY EFFECT OF SULFATED AMPHOTERICIN B ON THE REPLICATION OF HIV IN VITRO

Yoko Otake, K. Miyase, H. Shimokawa, M. Kasai, H. Ohsa, H. Kimita and T. Kurimaru*
Osaka Prefectural Institute of Public Health, Osaka, Japan,
* Yottori University, School of Medicine, Yonago, Yottori, Japan.

Amphotericin B methyl ester (AME), a water-soluble derivative of amphotericin B, showed inhibitory effect on HIV. However, the cytotoxicity of AME was relatively high. Newly synthesized sulfated amphotericin (SA), which was expected to show low toxicity and anti-HIV effect, was examined in vitro.

SA at the concentration of 80 µg/ml completely suppressed the HIV-induced cytopathic effect in MT-4 cell line which carried HTLV-1. Furthermore, antiviral effect was also observed when SA was only present at absorption period of HIV. Production of HIV was also suppressed in peripheral blood mononuclear cells (PBMC) infected with freshly isolated HIV. The cytotoxicity of SA was low (50% cytotoxic dose for MT-4 cells and PBMC was 20 µg/ml). When HTLV-1 and HTLV-2/HIV cells were co-cultured, multimerized giant cells appeared at the concentration of SA more than 200 µg/ml, the formation of giant cells was inhibited. SA at the concentration of 200 µg/ml inhibited 80% of reverse transcriptase activity of HIV, HIV was exposed to SA for 2h. At concentration of 200 µg/ml, SA reduced infectivity of HIV. These anti-HIV effect of SA was considered to be caused by the inhibition of HIV binding to the cells and reduction of infectivity of HIV.

M.C.P.81 ASSESSMENT OF THE THERAPEUTIC ACTIVITY OF PROSOPHOLACTONE-TRITHYR ADENINE AND ACETAMINOPHEN (AZT) IN A MURINE MODEL OF ACQUIRED IMMUNODEFICIENCY DISEASE

J. David Gagnier*, Erik De Clercq*, Alan Metzger*, J. Maria-Rot Hochreppel**, University of South Carolina, Columbia, SC, USA; **CIMA-GLIGI, Basel, Switzerland; **Katholieke Universiteit, Leuven, Belgium.

The murine model of acquired immunodeficiency disease (AIDS) was used to evaluate the therapeutic potential of two nucleoside analogues, proso-pholactone (proso) and acetylmethoxyadenine (AZT). The antiviral activity of proso was compared to AZT in mice receiving drug either immediately following infection or at later times in disease progression. Both AZT (oral, 30 mg/kg) and proso (parenteral, 25 mg/kg) were effective in preventing the development of disease when administered daily beginning on the day of infection. In contrast, neither drug alone was effective in modifying disease outcome when administered several weeks after viral infection. This was not, however, the case when alpha interferon was used in combination with proso. Disease outcome was modified when infected mice put on a continuous regimen of proso (25 mg/kg) and alpha interferon (5 x 10⁶ IU/kg). A number of humoral and cellular immune functions were severely depressed 60 days after LP-200 infection. Immunosuppressed mice were highly susceptible to acute (lethal) infection with HIV-1, while unappreciated immunocompetent littermates were not. Proso was as effective as acyclovir in the treatment of HSV-1 infections in immunosuppressed mice. The data suggest that the *in vivo* antiviral activity of proso is comparable to AZT. An important advantage of proso is its usefulness in the therapy of opportunistic herpesviral infections.

M.C.P.83 EXPERIMENTAL AZIDOThYMIDIN (AZT) PULSE THERAPY LEADS TO ADEQUATE AND PROLONGED LEVELS OF INTRACELLULAR AZT-TRIPHOSPHATE (AZT-TP)

Yoshitaka Kuzuhara, M. Nishi, Y. Jono, R. Sasagawa, M. and Lohby, R.
Department of Infectious Diseases, Zurich, University Hospital, Zurich, Switzerland

Objectives: Our earlier studies showed that single daily AZT pulse exposure effectively inhibit HIV-1 and HIV-2 replication in vitro. We have now evaluated intracellular AZT metabolites both in pulse and continuous therapy models.
Methods: Based on earlier dose finding studies using a newly developed *in vivo* model, duplicate cultures with peripheral blood mononuclear cells were either exposed to 10 µM AZT (45 µg/ml) (H-AZT) for 60 min. or to 1 µM AZT (5 µg/ml) (P-AZT) for one day. After 24 h in culture, cellular extracts were analyzed by HPLC. HIV-1 and infectivity was plasma levels after a single daily oral dose of 1 g AZT was performed using a computer model (throughout Wellcome, UK).

Results:

Treatment	Acetaminophen (pmol/10 ⁶ cells)	Diphosphate	Triphosphate
24h 1 µM AZT	33	0.4	0.9
1h 10 µM AZT	33	2.0	2.0

Mathematical simulation of a single oral dose of 1 g AZT revealed plasma levels of 10 µM or higher for 60 min.

Conclusions: Single day *in vivo* pulse therapy leads to adequate intracellular levels of AZT-TP thus explaining the observed anti-HIV effect of this regimen. The effect of a single daily oral dose of 1 g should be explained in clinical trial.

M.C.P.80 INHIBITION OF HUMAN IMMUNODEFICIENCY VIRUS (HIV-1) REPLICATION BY SYNTHETIC OLIGONUCLEOTIDES

Agnes S. Spector*, Sun, D.**, Sarin, P.S.**, Zemanick, P.C.*
* Worcester Foundation for Experimental Medicine, Worcester, MA, U.S.A.
** Laboratory of Tumor Cell Biology, National Cancer Institute, Bethesda, MD, U.S.A.

A number of approaches are currently being investigated for treatment of human immunodeficiency virus (HIV) infected patients with acquired immunodeficiency syndrome (AIDS). We have used antisense oligonucleotides to selectively block virus replication by competitive hybridization (Zemanick et al., PNAS 79:320, 1982). We have investigated three classes of phosphate backbone modified oligodeoxynucleotides viz. methylphosphonate, phosphotriphosphate and various phosphoramidates for their antiviral activity. The inhibition of HIV-1 expression in presence of antisense oligonucleotides was carried out by infecting 90 or MDL-3 cells with HIV-1 (HIV-III), or HIV-III-3, 3. Studies were carried out by simultaneous addition of viral and antisense oligonucleotides to cells in culture. After four days, the cells and supernatants were examined for the level of HIV expression by counting specific (MDL-3 cells), viral antigen expression and cell viability. The sequences tested were complementary to splice acceptor and donor sites of HIV RNA. Inhibition of up to 100% HIV-1 replication was observed at 1 to 5 µM concentration of these oligonucleotides. Acute toxicity studies in mice and rats show a relatively low level of toxicity. These studies suggest that phosphate backbone analogs of oligonucleotides are potent inhibitors of HIV-1 replication and could be potentially useful in the treatment of AIDS.

M.C.P.82 INHIBITION OF HIV REPLICATION BY ALPHA INTERFERON

Gailb. Marilyn S., Brian, R., Threether, R., Pagano, J.S. Univ. of W.C., Chapel Hill, NC, USA

Objective: To investigate the mechanism of inhibition of HIV replication by interferon alpha 1b.
Methods: T cells were infected with HIV and treated with interferon alpha 1b or chronic producing cell lines, HTLV-1 and HTLV-2. HIV production was assayed by reverse transcriptase activity and p24 concentration. Cellular extracts were assayed by western blot and p24 ELISA; cells were examined by electron microscopy.

Results: In the C3 line, the EC₅₀ was 5.5 U/ml and EC₉₀ was 274 U/ml. We attempted to determine if high concentrations of intracellular particles were accumulating by assaying extracellular p24 and p24 levels, the intracellular p24 and viral protein levels, or by EM. In cells treated with IFN, the p24 and p24 levels decreased proportionally, whereas the intracellular p24 levels remained nearly constant. Western blots of cellular protein showed only a small 2X decrease in viral proteins; the amount of processing of precursor to p24 and p17 did not change in the presence of interferon. By EM, the cells treated with 512 U/ml showed almost no virus budding into extracellular spaces; however, no intracellular particles could be seen.

Conclusion: Thus, inhibition of this human retrovirus by alpha interferon does not appear to involve decreased processing of viral proteins or intracellular core formation.

M.C.P.84 COMPARISON OF AUTHENTIC AND ENZYMICALLY ACTIVE HIV AND HIV2 PROTEASES IN SACCHAROMYCES CEREVISIAE

Changsheng Serrino*, Babu, L.*, Barr, P.**, and O'Neil, C.*
*University of California, Davis, California, USA
**Chiron Corporation, Emeryville, California, USA

Genetic analysis of the HIV genome has revealed a 99 amino acid protease encoded at the 5' end of the pol gene which is essential for the growth of *gag* and *gag-pol* polyoma virus. The protease encoded by HIV1 and HIV2 genomes are 41.5% identical in their amino acid sequences. Functional and structural studies of these viral proteases require quantity levels of the authentic enzyme which can be achieved by heterologous expression of the cloned gene. An expression system employing the ADHI2(LA)PHI promoter was used to over-express both retroviral proteases intracellularly and extracellularly. In order to determine the localization of the enzymes, two different DNA fragments were fused to DNA encoding the 5' cytosine alpha factor signal/leader sequence. These viral fragments encode either the mature 99 amino acid protease or a precursor containing additional residues at the N and C termini of the protease in order to monitor self-processing. For intracellular localization, retroviral sequences encoding the protease were fused to the C-terminus of human superoxide dismutase. Expression of mature HIV1 and HIV2 proteases was demonstrated for all systems by immunoprecipitation in virus supernatants or cellular extracts. Self-processing activity was confirmed by amino acid sequence analysis of the mature enzyme. The HIV1 protease has been purified and structural studies have been initiated. Extracellular localization of the protease has permitted purification to homo-purity using a size exclusion procedure. From 20 liters of media 1 mg of protein can be purified. This protease is active on both native and synthetic peptide substrates. Both the HIV1 and the HIV2 protease correctly process HIV1 *gag* polyprotein precursor. Results indicate that yeast cells provide an efficient expression system for the overproduction of active forms of HIV1 and HIV2 proteases.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

M.C.P.85 IMMUNOLOGIC EFFECT AFTER SINGLE DOSE ATROGEN (ANALIGEN) IN HEALTHY VOLUNTEERS

Remick, Carol; Liewman, F.; Ye'o, P.; Margolis, J.; Paraganan, M. Decty, S. Johns Hopkins University, Schools of Medicine and Hygiene and Public Health, Baltimore, Maryland, U.S.A.

Objective. To evaluate the degree and time course of immunologic stimulation after a single 200 mg intravenous (i.v.) dose of atrogen, a attenuated DNA, in healthy volunteers.

Methods. This was a randomized, double-blind, inpatient study in four healthy volunteers. Subjects served as their own controls, randomized to one of two treatment sequences, atrogen or placebo followed 7 days later by placebo or atrogen. We measured a- and y-interferon, 2'-5' oligoadenylate synthetase (3AS), isoperitin, T cell subsets (CD4, CD8, CD4/CD8, Leu 11, Leu 15), natural killer cell (NK) activity and lymphocyte proliferation (1F) after exposure to soluble antigen (SM, tetanus toxoid, pokeweed mitogen).

Results. No symptomatic, clinical or laboratory changes were noted in either drug or placebo periods. Neither a- or y-interferon were measurable during the 5 days following atrogen infusion. Biochemical markers of interferon action, specifically, 3AS and T cell subsets, were not significantly different after atrogen dosing compared to placebo. Neither the NK nor 1F assays showed any differences in response between atrogen or placebo treatments.

Conclusions. Arogen induces no immunologic enhancement in the parameters measured after a single 200 mg i.v. dose in healthy volunteers.

M.C.P.86 STUDIES ON ANTI-HIV ACTIVITY AND METABOLISM OF 2',3'-DIHYDROCAVORTINE (d6C)

Remick, Lionel; Basse, M. E.; and Mian, M. A.**
Mount Sinai Medical Center, Miami Beach, Florida, USA, **Sylvester Comprehensive Cancer, University of Miami, Miami, Florida, USA.

Objective. To study the anti-HIV activity and metabolism of d6C.

Methods. The anti-HIV activity of d6C was determined by a syncytium-inhibition assay using MT-2 cells and by the inhibition of reverse transcriptase activity in H9 HIV-infected cells. In drug uptake studies, cells were exposed to 10⁻⁶M d6C for predetermined periods. Cells were isolated by centrifugation through an oil layer and the intracellular radioactivity was determined. In metabolite studies, drug treated cells were extracted with aqueous methanol and the extracts were analyzed by anion exchange and C18 reverse phase HPLC procedures.

Results and Conclusions. Data indicate that d6C is equivalent to ddC or ddI in its anti-HIV activity. Dexamethasone and dexamethasone diphosphate (d6D) inhibited HIV activity of d6C, whereas 8-aminocaproic acid failed to enhance. In drug exposed cells, the intracellular radioactivity increased over time and reached a plateau at 30 minutes. Addition of an excess of d6C or d6D reduced the uptake of d6C by 25-40%. Metabolic studies indicate that d6C enters the cell and is metabolized to guanine which is further metabolized to GMP, GTP, and dGTP. Under the experimental conditions employed, we were unable to detect the formation of 12-oxo-d6C. These observations raise the question regarding the importance of this metabolite's role in the anti-HIV activity of d6C. (Supported by IVAL Corp. and NIH U01-A123696).

M.C.P.87 THE ANTIVIRAL EFFECT OF BERTRAN SULFATE (BES) IS HIV STRAIN DEPENDENT

Remick, Lionel P. and Basse, M. E.*
*Mount Sinai Medical Center, Miami Beach, Florida, USA.

Objective. To study the anti-HIV activity of BES using different isolates.

Methods. The anti-HIV activity of BES (10⁻⁶ M, 5000) were investigated using a syncytium-inhibition (MT-2 cell) assay. The peripheral blood HIV strains studied were: HIV-1 (IIIB (lab strain), TN (cell-type), WP 30 (clone) and HIV-2 (ROD (clone)). Syncytium-forming units, cell viability, and HIV (cellular p24 Ag) were utilized as measures of HIV expression. The log₁₀ concentration of HIV was standardized by limiting dilution and sensitivity to AZT. Combinational effects of BES and ddRNs (AZT, ddC, ddI) were analyzed and a fractional inhibitory index calculated.

Results. The higher the MW of BES, the more potent the anti-HIV effect. The ED50 was greater than 1µg/ml for all BES. The ED50 of BES was HIV strain dependent [ED50 (µg/ml): IIIB (5-21), TN (50-300), WP 30 (18-22), ROD (17-45)]. The anti-HIV effects of BES (8K and ddRNs) were synergistic. However, the combination of BES (5000) and ddRNs were synergistic (therapeutic range of BES) or antagonistic (sub-therapeutic range of BES) when using HIV-1 TN.

Conclusions. The anti-HIV activity of BES is strain and MW dependent. The combination of BES and ddRNs may yield synergistic/antagonistic effects. (Supported by IVAL Corp. and NIH U01-A123696).

M.C.P.88 IN VITRO ACTIVITY OF ZIDOVUDINE (AZT) AND COMBINATION WITH OTHER ANTIVIRAL DRUGS AGAINST HIV-1

Remick, Lionel P. and Basse, M. E.*
*Mount Sinai Medical Center, Miami Beach, Florida, USA.

Objective. To determine if zidovudine inhibits HIV replication in vitro

independently of other antiretroviral drugs. The effect of zidovudine (10⁻⁶ M) on HIV-1 replication was determined in the presence of ddRNs (ddC, ddI, ddR) and BES (10⁻⁶ M, 5000) using a syncytium-inhibition assay. The effect of zidovudine on HIV-1 replication was also determined in the presence of ddRNs (ddC, ddI, ddR) and BES (10⁻⁶ M, 5000) using a syncytium-inhibition assay.

Results. Zidovudine (10⁻⁶ M) inhibited HIV-1 replication in the presence of ddRNs (ddC, ddI, ddR) and BES (10⁻⁶ M, 5000) in a dose-dependent manner. The effect of zidovudine on HIV-1 replication was also determined in the presence of ddRNs (ddC, ddI, ddR) and BES (10⁻⁶ M, 5000) using a syncytium-inhibition assay.

Conclusions. Zidovudine (10⁻⁶ M) inhibited HIV-1 replication in the presence of ddRNs (ddC, ddI, ddR) and BES (10⁻⁶ M, 5000) in a dose-dependent manner. The effect of zidovudine on HIV-1 replication was also determined in the presence of ddRNs (ddC, ddI, ddR) and BES (10⁻⁶ M, 5000) using a syncytium-inhibition assay.

Table 1: Fractional Inhibitory Index (FII) for HIV-1

Drug	10 ⁻⁶ M	10 ⁻⁷ M	10 ⁻⁸ M	10 ⁻⁹ M	10 ⁻¹⁰ M
Zidovudine	0.50	0.50	0.50	0.50	0.50
ddC	0.50	0.50	0.50	0.50	0.50
ddI	0.50	0.50	0.50	0.50	0.50
ddR	0.50	0.50	0.50	0.50	0.50
BES	0.50	0.50	0.50	0.50	0.50

Table 2: Fractional Inhibitory Index (FII) for HIV-1

Drug	10 ⁻⁶ M	10 ⁻⁷ M	10 ⁻⁸ M	10 ⁻⁹ M	10 ⁻¹⁰ M
Zidovudine	0.50	0.50	0.50	0.50	0.50
ddC	0.50	0.50	0.50	0.50	0.50
ddI	0.50	0.50	0.50	0.50	0.50
ddR	0.50	0.50	0.50	0.50	0.50
BES	0.50	0.50	0.50	0.50	0.50

Conclusions. Zidovudine (10⁻⁶ M) inhibited HIV-1 replication in the presence of ddRNs (ddC, ddI, ddR) and BES (10⁻⁶ M, 5000) in a dose-dependent manner. The effect of zidovudine on HIV-1 replication was also determined in the presence of ddRNs (ddC, ddI, ddR) and BES (10⁻⁶ M, 5000) using a syncytium-inhibition assay.

M.C.P.89 SUPPRESSION AND CHARACTERIZATION OF CHIMERIC PROTEINS LINKED TO HUMAN IMMUNOGLOBULIN HEAVY CHAIN CONSTANT REGION

Minkami, Tamio; Smith, C.D.; Sawyer, S.A. and Noss, R.

Laboratory of Viral Treatment of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA

Objective. To express and characterize the properties of chimeric proteins composed of human CD4 and human immunoglobulin G (IgG) heavy chain constant regions for the potential therapeutic use of these proteins as new targeted anti-HIV agents.

Methods. The chimeric proteins were produced using a vaccinia virus-based expression system and tested for the binding properties to various ligands and antibodies against each domain.

Results. Three types of chimeric proteins with different lengths (1-109, 1-178, and 1-372) of the CD4 extracellular region linked to human IgG1 heavy chain constant regions were designed and expressed in CHO-1 and RPMI8226, a human myeloma cell line secreting a Ig light (lambda) chain. The chimeric proteins expressed in both cell lines bound to the HIV-1 gp120, CD44 (anti-CD4), an anti-human IgG(Fc) polyclonal antibody, and Protein A-agarose. The chimeric proteins which were expressed in RPMI8226 formed complexes with human Ig light chains synthesized by the host cell line. **Conclusion.** The CD4-IgG chimeric proteins had the expected binding properties of the domains used for their construction. The chimeric proteins when co-expressed with human Ig light chains formed complexes which might have structures analogous to that of natural immunoglobulin molecules.

M.C.P.90 ANALYSIS OF 3'-AMINO-2'DEoxyCAVORTOSINE INHIBIT HIV-1 REPLICATION

Lee, Raimond; H. Vanden Berghe and G. Badi. *Department of Medicine, Washington University, Biological Sciences Department, St. Louis, Mo., USA

Objective. Several different nucleoside analogs have been demonstrated to inhibit retroviral DNA-dependent RNA polymerase activity in preference to cellular DNA-dependent DNA polymerase. This study analyzed the anti-HIV-1 activity and host cell toxicity of 3'-amino derivatives of 2'-deoxyadenosine.

Results: Reverse transcriptase (RTase), PAINS 2'-phosphothriphate, and 3'-amino-2'-deoxyadenosine triphosphate all inhibited HIV-1 replication in acutely infected cells at concentrations at least 10-fold lower than those which inhibited cell growth. No antiviral effects were seen with 96-dithiopyridine, adenosine, or propovirin. In chronically infected cells, no antiviral activity of PAINS could be detected. The effect of PAINS was demonstrated at an early step in HIV-1 replication, most likely reverse transcription.

Conclusions: 3'-Amino nucleoside analogs are a novel class of inhibitors of HIV-1 replication which require further analysis in cell culture and animal studies.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

M.C.P.91 SULFATED CHITOSAN INHIBITS HIV. *Maria McClure**, Cecilia Whitford*, Richardes Chongroo-Poppe*, Donald M. Nelson*, Donald Derwent*, and Robin A. Weiss*. ¹Institute of Cancer Research, Harlow, Essex, U.K. ²Royal Free Hospital, Belsize Park, London, U.K. ³Harlow Hospital, Du Cane Road, London W11 0BQ, UNITED KINGDOM

Objectives: To test sulfated polysaccharides for evidence of antiviral activity.

Methods: The effect of drugs on HIV infection was assessed by syngeneic cocultivation, RT and p24 antigen synthesis on lymphocytic and monocytic cells and on CD4-transfected HeLa cells.

Results: The compounds will be defined and data presented to show that:

- The degree of sulfation is important for antiviral function.
- The compounds, one of which has been newly synthesized, inhibit by 10,000 fold on the CR166 infectivity assay a wide range of HIV-1 isolates.
- HIV-2 was inhibited by one compound, but not as strongly.
- There is low cell toxicity and no adverse effect on protein synthesis or T-cell function.
- The drugs themselves appear to have a cytotoxic effect on PBL.

M.C.P.93 SYNTHESIS OF NEW SUGAR-FLUORINATED GUANOSINE ANALOGUES AS POTENTIAL ANTI-HIV AGENTS

Puech, F.; Gosselin, G.; De Clercq, E.; Jabeck, J.-J.
* UA 488 du CNRS, USTL, 34050 Montpellier Cédex 1, France
** Katholieke Universiteit, Leuven, Belgium

Presented by Guy, Roger, Université de Nice, France

Objective: Purine nucleosides fluorinated in the sugar moiety have been not very investigated owing to the difficulty in their synthesis. Here we report the synthesis of hitherto unknown fluorinated analogues of guanosine and their evaluation as potential anti-HIV agents.

Methods: The synthesis of 9-(3-deoxy- and 2,3-dideoxy-3'-fluoro-2'-cytidyluronyl)guanine (1) and (2) was accomplished by a multi-step approach involving prior preparation of a suitably protected fluoroguanosine, 3'-deoxy-3'-fluoroguanosine (3) was prepared by reacting the corresponding nucleoside of xylol configuration with (diethylamino)azluril trifluoride. The mixture of 9-(3-deoxy-2'-fluoro-9- α -arabino)uronyl)guanine (4) and 9-(2-deoxy-2'-fluoro-9- β -xylo)uronyl)guanine (5) was obtained by ring opening of the lyxo epoxide of guanosine.

Results: The compounds 1-5 were evaluated in HIV infected MT4 cells. Only the mixture of 4 and 5 was found to inhibit significantly viral replication.

M.C.P.95 ANTIRETROVIRAL ACTIVITY OF AN AQUEOUS EXTRACT OF HYDRANTHUS AFRICANA

Amadi B. Pabon*, Blaise M. Nkomo, A. and Hoggan, M.D.*
*NIAD, ** NCI, Bethesda, MD, USA

Objective: To study the anti-retroviral effect of an aqueous extract of the Indian Ayurvedic medicinal plant, *Hydranthus africana*.

Methods: An ethoacetic extract of dried powdered *Hydranthus africana* (HA) was prepared by vortexing followed by sterile filtration. HA extract was diluted 1:200 in 1R80 by addition to tissue culture medium. The effects of the HA on HIV-1 infection were studied by use of a syngeneic fusion assay in SupT1 cells, plaque formation in M14 cells and kinetics of virus production and cytotoxicity in M14 cells and PBLs. The effects on murine leukemia viruses (MuLV) were studied for MoMuLV and HIV in NIH 3T3 cells. Virus yield was assayed by determination of reverse transcriptase production, and for HIV-1, production of focus-forming units (ffu).

Results: A 1:200 dilution of HA resulted in a greater than 80% reduction in HIV-1 induced syncytium formation in SupT1 cells and a similar inhibition of plaque formation in M14 cells. In suspension cultures, HA treatment resulted in a 2-3 day delay in the appearance of HIV induced cytopathic effect and cell death in M14 cells. No comparable delay of cytotoxicity was observed in PBLs. In studies of MuLV infection, HA resulted in an 85-90% decrease in virus yield as monitored by RT production and similar decreases in the production of HIV-1. Studies of the mechanism of antiviral effect in the M14 system showed that HA was not directly cytotoxic and did not inhibit virus adsorption. Protection by removal of HA did not inhibit MuLV yield suggesting that HA was not acting as an interferon inducer.

Conclusions: An aqueous extract of *Hydranthus africana* appeared to inhibit the replication of HIV-1 and MuLVs in several different assay systems. The degree of anti-HIV effect varied in different cell types further mechanistic studies and biochemical characterization of active compounds will be required before its potential usefulness can be ascertained.

M.C.P.92 CSF FROM PATIENTS WITH EARLY HIV INFECTION PRODUCES INTRACELLULAR CELL KILLING IN VITRO: PREVENTION BY PEPTIDE T Nary, J.M., Bremmen, D.R., Salazar, A., Martin, A., Ruiz, M.R. and Tardieu, A. ¹INSERM, U. 105, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577, 578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607, 608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622, 623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637, 638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652, 653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667, 668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682, 683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697, 698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712, 713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787, 788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802, 803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817, 818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832, 833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847, 848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862, 863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, 876, 877, 878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892, 893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922, 923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937, 938, 939, 940, 941, 942, 943, 944, 945, 946, 947, 948, 949, 950, 951, 952, 953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967, 968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982, 983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997, 998, 999, 1000.

Objective: To test for the presence of gp120 the neuronal killing activity in CSF from seropositive patients and the ability of peptide T to prevent CSF-induced neurotoxicity.

Methods: Twenty-eight cerebrospinal fluid samples from neurological controls and HIV-infected individuals were tested (to the investigator) in murine hippocampal cultures. HIV+ individuals had been referred for neuropsychological evaluation and 83% were in Walter Reed Stages 1-5. All individuals received a comprehensive neuropsychological and neurological evaluation at the time of the spinal tap and 6 months later. CSF samples were diluted 10,000-fold and incubated for five days in the presence and absence of peptide T. Previous studies have shown that the envelope protein of the HIV, gp-120, is potently neurotoxic in this developing neuronal culture. VIP neurotoxicity, peptide T and monoclonal antibodies against mouse CD4, prevented gp120-induced neuronal cell death (Bremmen et al. *Nature* 338:529-52, 1988).

Results: CSF from 9 out of 18 HIV-infected individuals showed significant (>20% of control) in vitro neuronal killing activity which was blocked by peptide T. Only one multiple sclerosis case out of 10 neurological controls had significant neuronal killing. **Conclusion:** The ability of CSF to potently kill neurons in culture is associated with HIV+ individuals. Peptide T prevents CSF-induced toxicity in vitro. These data are consistent with our previous suggestion (Bremmen et al. *Drug Development Research* 13:361-369, 1986) of the causal role of gp120 in neuropsychiatric/neurological deficits of HIV.

M.C.P.94 POPULATION PHARMACOKINETIC BEHAVIOR OF ZIDOVUDINE (AZT) IN PATIENTS WITH AIDS
Elmer, J., DeGroot, M., Epstein, H., Staszko, and The Participating Centers for AIDS Research, University of Maryland and the New Cooperative Studies, Baltimore, MD, and the University of Colorado, Denver, CO, USA

Objective: There is little information on the clearance of AZT. The which is available has been generated in populations of patients with AIDS. First experience with other compounds has led to the prediction of a drug to be cleared primarily by the disease state of the population in which it is administered. As we were performing a large, multicenter, randomized, double blind evaluation of AZT in patients with AIDS with zidovudine (AZT) cells, we decided to evaluate the pharmacokinetics of AZT in this population. Blood was obtained for AZT assay on a scheduled and random basis from all study patients, remaining the blind. Serum AZT concentration was determined by HPLC. Seventy-seven patients had more than one serum specimen with available AZT, with a total of 277 specimens suitable for analysis. In order to derive the information in the most methodically correct fashion, point estimates of population pharmacokinetic parameters were sought using the program NONMEM (non-linear mixed effects modeling). A one compartment open model with first order absorption and first order elimination from the central compartment was employed. Mean Cl_{CR} (ml/min) of 70, volume of distribution (V) and absorption Rate Constant (Ka) were the estimated parameters. A proportional error model was employed for all observed parameters. Mean Cl_{CR} was 70 ml/min, the elimination rate constant was 0.105 (1/hour) (95% CI 0.083, 0.136) and the volume of distribution was 145 (liters) (95% CI 100, 200). The mean Cl_{CR} was very large, with a broad 95% confidence interval, leading to large interpatient variability. Estimates of individual variation (CV) were not robust, but did not differ on the estimation of the system parameters. The population approach resulted in a fit to the data which was excellent. The larger volume of distribution noted is probably a function of studying healthy patients with larger body masses. It is important, because it is normally difficult to obtain good pharmacokinetic information on drug disposition in the clinical setting. AZT Phase I trials typically enrolled only 3-6 patients. The population modeling approach means that the more broadly employed as newer agents for therapy of HIV and HIV-related disease are evaluated.

M.C.P.96 ACTIVATION OF THE ANTI-HIV AGENT 3',3'-DIETHOXY-2',3'-DIISOBUTYRIDINE (D4T) BY HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC) IN CULTURE.

Hsu-Tao Ho, N. Yung and M.J.M. Hitchcock
Bristol-Myers Pharmaceutical Research and Development Division, Wallingford, Connecticut, U.S.A.

Objective: To compare metabolism of D4T with AZT in resting and phytohemagglutinin (PHA)-activated human PBMC.

Methods: PBMC were prepared by sedimentation of fresh whole blood in a dextran gradient and the cell suspension tubes with separation (5 mg/ml) was for 12 h, and the PHA was then washed out. After incubation with 2 μ M radiolabeled D4T or AZT, cells were washed and extracted with 60 % methanol, and the extracts were fractionated by anion exchange HPLC.

Results: In resting PBMC incubated with 2 μ M compound for either 24 or 48 h, cell-associated D4T and AZT were both detected at close to the intracellular concentration, but no phosphorylated forms of either compound were observed (detection limits of 1 and 20 nM for D4T and AZT, respectively). In activated PBMC at 24 h, 55 % of the phosphorylated D4T was present as the triphosphate. Its intracellular concentration was estimated at 100 nM, which is above the K_i for HIV reverse transcriptase. By contrast, the only phosphorylated form of AZT detected was the monophosphate (about 27,000 nM) and the di- and triphosphates were not detected. The results indicate that the rate of phosphorylation of D4T is much faster than that of AZT.

Conclusion: These results demonstrate a significant difference between the metabolism of D4T and AZT in activated PBMC. This may translate to a different, and possibly better, toxicity profile in vivo.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Research (Biomedical)

M.C.P.97

THREE DRUG SYNERGISTIC INHIBITION OF HIV-1 REPLICATION BY RECOMBINANT ZIDOVUDINE (AZD), ZIDOVUDINE (AZT), AND RECOMBINANT INTERFERON-ALPHA (rIFN- α).

Johnson, Victoria A. ¹Harvard School of Public Health, Boston, MA; ²Massachusetts General Hospital, Harvard Medical School, Boston, MA; ³Memorial Sloan-Kettering Cancer Center, NY, NY, USA.

Objective: To assess the interactions of AZT, AZT, and rIFN- α in combination against HIV-1 replication in cells.
Methods: We evaluated rIFN- α (a soluble viral receptor) in combination with AZT (a reverse transcriptase-RT inhibitor) and rIFN- α (an agent which may affect viral assembly and release). 89 cells were exposed simultaneously to HIV-1 and various concentrations of each agent, either alone or in 2- or 3- drug combinations. Drug interactions were evaluated by the median-effect principle and the isobologram technique.

Drug	Inf. rIFN- α	AZT	rIFN- α + AZT	3-Drug Combination
Control	0.08	0.64	32	32
1	2935	2780	2780	1980
2	1468	1390	1390	1468
3	460	460	460	460
4	123	123	123	123

Similar results were obtained at different times and by utilizing other assays (RT activity and virus yield).
Conclusion: Combination of AZT (0.02-0.32 μ g/ml), AZT (0.16-5.16 μ g), and synergistically. The 3-drug regimen provides more complete suppression than the 2-drug regimens without additive toxicity in cells.

M.C.P.99

DIFFERENTIAL SENSITIVITY OF BONE MARROW DNA POLYMERASE ALPHA AND DELTA TO INHIBITION BY DIDOXYNUCLEOTIDES

Byrnes, John A. ¹University of Miami School of Medicine, Miami, Florida, U.S.A.

Objective: To examine the sensitivity of bone marrow DNA polymerase alpha and delta to inhibition by didoxynucleotides.

Methods: DNA polymerases were highly purified from rabbit bone marrow as previously described. Standard DNA polymerase assays using either activated DNA or synthetic primer/template combinations and different reaction conditions were used to examine the effect of dGCTP and dGTTTP.
Results: Under conditions of magnesium activation DNA polymerase alpha was resistant up to 200 μ M dGCTP, however DNA polymerase delta was 50% inhibited at 80 μ M of either dGCTP or dGTTTP. Under conditions of manganese activation alpha and delta were both 50% inhibited by 5 μ M dGTTTP. Kinetic analysis demonstrated a competitive pattern with respect to the corresponding dNTP. Activity of the 3' to 5' exonuclease associated with delta did not alleviate the inhibitory effect of the dGTTTP.

Conclusions: The sensitivity of DNA polymerase delta under conditions of manganese activation may have bearing on the bone marrow toxic effect of dGTTTP. Both DNA polymerases are believed to function in DNA replication and current evidence suggests a coordinate action of delta synthesizing the leading strand and alpha the lagging strand. Relatively minor inhibition of DNA polymerase delta may uncoordinate cellular DNA replication.

M.C.P.101

RANDOMIZED PHASE II TRIAL OF RECOMBINANT TUMOR NECROSIS FACTOR- α AND RECOMBINANT INTERFERON- α (rIFN- α) IN PATIENTS WITH AIC

Agarwal, Cynthe R. ¹Kidd PG, ²Paradise H, ³Shorrock J, ⁴Corry J, ⁵University of Washington, Seattle, WA, ⁶San Francisco, CA, U.S.A.

Objective: To determine if TNF worsens or decreases the progression of HIV infection.

Methods: While some have reported that TNF inhibits HIV replication others have reported increased replication in chronically infected cells treated with TNF. To evaluate this we randomly assigned 30 patients with AIC to receive either TNF only (10 μ g/wk), rIFN- α (10 μ g/wk), TNF (10 μ g/wk) + rIFN- α (10 μ g/wk) or rIFN- α (10 μ g/wk) + TNF (10 μ g/wk) for 12 weeks. Side effects included fever (100%), grade 1 mild constitutional symptoms (100%), and local reactions (100%). No significant hematologic, hepatic, renal, or coagulation abnormalities were observed and only one patient discontinued therapy because of side effects. T cell subset determinations did not change significantly during therapy. HIV was isolated from peripheral blood lymphocytes (PBL) in all patients prior to therapy while none were present at therapy end. The frequency of HIV isolates from PBL decreased from 92% before therapy to 84% during therapy. Plasma viremia was 56% prior to therapy and decreased to 29% during therapy.

Conclusions: This study demonstrates that TNF alone or in combination with rIFN- α does not appear to hasten the progression of HIV infection. Further studies are required to determine if either of these compounds alone or together have biologic or clinical activity.

M.C.P.98

COMPARATIVE PHARMACOKINETICS OF 3-AZIDO-2,3-DIHYDROXYAZANONE (AZAN) AND 3-AZIDO-2-DEOXYTHYMIDINE (AZT) IN MONKEYS

Reisford, F. Douglas, ¹Schwartz, R. F., ²Gallo, J.M., ³McClure, M.H., ⁴Anderson D.L., ⁵Chu, C.K.

¹College of Pharmacy, University of Georgia, Athens, Georgia, USA, ²Veterans Administration Medical Center and Emory University, Atlanta, Georgia, USA, ³Thomas Pierce Center, Emory University, Atlanta, Georgia, USA.

Objective: To characterize and compare the pharmacokinetics and bioavailability of AZANU and AZT in uninfected rhesus monkeys.

Methods: Monkeys were administered AZANU or AZT at doses of 60 mg/kg intravenously, 80 mg/kg orally, 200 mg/kg orally and 30 mg/kg subcutaneously. Serial blood samples were obtained. Concentrations of drug and metabolites were taken after 15 days.

Nucleosides were assayed by HPLC.

Results: After AZANU total clearance averaged 0.81 (0.51-1.08) L/h/kg and volume of distribution was 0.82 (0.14) L/kg. After AZT total clearances and volume of distribution were 1.57 L/h/kg and 1.07 L/kg, respectively. Oral absorption of AZANU and AZT was virtually complete (F = 0.80) after 60 mg/kg, however, bioavailability of both nucleosides was markedly lower (F = 0.50) after 200 mg/kg. The nucleosides appeared to be well absorbed after subcutaneous administration. AZANU and AZT penetrate the cerebrospinal fluid with CSF: serum concentration ratios ranging between 0.05-0.25 1 hr after drug administration.

Conclusion: The similar pharmacologic characteristics and lower toxicity of AZANU compared to AZT suggest that clinical trials of AZANU are warranted.

M.C.P.100

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR (r-methuG-CSF) INCREASES NEUTROPHIL NUMBER AND

FUNCTION BUT DOES NOT ALTER HIV EXPRESSION IN CD4+ T CELLS WITH AIDS. **Mills, Steven**, ¹Chung, Y.T., ²Lee, K., ³Souza, L.M. and ⁴Baldwin P.A. ¹UCLA AIDS Center, Los Angeles, CA, USA and ²Amgen, Inc. Thousand Oaks, CA, USA.

Objective: To see if r-methuG-CSF can improve neutrophil function and number in AIDS patients without altering HIV expression.

Methods: Phase I/II Open Label Trial of r-methuG-CSF + HAART/AZT in patients with AIDS/severe ARC. Patients with absolute neutrophil counts (ANC) < 2500/mm³ and hemoglobin (Hb) < 11.5 mg/dl (of all marrow suppressive drugs including AZT > 3 weeks) were treated with r-methuG-CSF once daily at 3 mg/kg s/qd until an ANC of > 4000 was achieved and maintained for 2 weeks.

Results: Eleven of 24 treated patients have been enrolled. Eight have reached > 4000 ANC, maintained for > 2 weeks and are evaluable. The other 3 patients have reached > 4000 ANC but have not been on > 2 weeks.

	Pre-G-CSF	Post-G-CSF	P value
Absolute Neutrophils	1021 ± 600	2170 ± 9130	< 0.001
Total WBC	1855 ± 790	23160 ± 9115	< 0.001
CD4 cell number	104 ± 6.3	22.8 ± 14.7	> 0.05
HIV p24 antigen	22 ± 4.54	347 ± 391	> 0.05

With one exception, normal neutrophil function (bacterial phagocytosis and intracellular killing) was observed in 8. In 6, before and during r-methuG-CSF. One pt. had a discrete intracellular killing defect which normalized on r-methuG-CSF. Analysis of limiting dilution plasma and lymphocytes cultures showed no significant alterations in viral expression.

Conclusions: r-methuG-CSF significantly increases neutrophil number and function in AIDS patients without altering HIV expression. r-methuG-CSF shows promise in altering the immunopathy of AIDS.

M.C.P.102

A LONG-LIVED CD4 CARRIER IN CIRCULATION. RED BLOOD CELLS WITH CD4 RECEPTORS INSERTED IN THEIR MEMBRANE.

Atyiah, Tamer, ¹Choi, A., ²Schub, B., and ³Blissard, C.V.

¹Biophor Corporation, College Station, Texas, USA, and ² Baylor College of Medicine, Houston, Texas, USA.

The CD4 receptor is associated with intact human erythrocyte membranes after a short-time incubation for low pH (1-2 min, pH lower than 5.3 pH). Epifluorescence microscopy observations showed that after incubation of red cells with fluorescein isothiocyanate (FITC) labeled and CD4 monoclonal antibodies (Leu-3) the erythrocyte membranes and subsequently formed lipid membranes were fluorescent. Immunofluorescence microscopy showed 10 nm gold beads associated with CD4 bearing erythrocyte membranes after incubation with anti-CD4 antibodies and then with gold beads coated with immunoglobulin G antibodies. The insertion of CD4 in RBC membranes proved stable, in vitro at 37°C for 24 hrs and the life span of RBC subjected to the acid-lipidation did not change as compared to normal RBC in mouse and in man.

CD4-RBC were shown to attach gp120 and quantitation of the number of CD4 molecules per RBC needed for effective attachment to gp120 was realized. HIV-1 interacts with CD4-RBC showing in freeze etched EM micrographs the appearance of "ice points" on the CD4-RBC membrane, reminiscent of those observed after interaction of influenza virus with RBC. Thus, a long-lived CD4 carrier in circulation with the potential of a scavenger in the circulation of free HIV-1, cloning gp120 antigens and gp120-expressing, HIV-infected T4 cells.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

M.C.P.109 CHEMICALLY INFECTED MONOCYTE-MACROPHAGES (MΦ) ARE MARKEDLY LESS SENSITIVE TO ZIDOVUDINE (AZT), FIDUCICIN (FID) AND ALPHA INTERFERON (IFN) VS. COMPARED TO ACTIVELY INFECTED MΦ.

Crowe, Susanna, Rodgers, M.S., Elbeik, T., Kirilova, J., Momen, M., Hillis, J. San Francisco General Hospital/University of California, San Francisco, California, USA.

Objective: We are thought to provide a major reservoir of HIV *in vivo*. We therefore studied the efficacy of representative antiretroviral drugs in both acutely and chronically HIV-infected MΦ.

Methods: No isolated from peripheral blood of HIV seronegative donors were infected *in vitro* with HIV-01 (multiplicity one). Antiretroviral was added either at time of infection (acute) or 10-15 days following infection when 25% of MΦ contained HIV p24 by cytofluorographic analysis (chronic). Control cultures contained no drug. Inhibition of HIV replication was assessed by measurement of p24 antigen (Abbott ELISA) in culture supernatant and cell lysates, and HIV RNA analysis by slot-blot.

Results: AZT, FID and IFN markedly inhibited HIV replication in acutely infected MΦ. (FID: 100% inhibition with 40.0 μg/ml AZT and 800 μg/ml FID, 88-89% with 1000 U/ml IFN). Comparable inhibition was seen in synthesis of both extracellular and intracellular HIV antigens, with accompanying suppression of HIV RNA. Chronically infected MΦ were markedly less sensitive to these compounds even at high concentration. (CROI inhibition with AZT 50 μg/ml, FID 100 μg/ml, 1000 U/ml IFN). Slot-blot analysis showed no distinction of RNA in chronically infected MΦ.

Conclusion: Acutely infected MΦ are susceptible to antiretrovirals; chronically infected MΦ (which probably constitute the main *in vivo* reservoir for HIV) are several orders of magnitude more resistant.

M.C.P.110 COMPUTERIZED QUANTIFICATION OF SYNERGISM/ANTAGONISM OF ANTI-HIV AGENTS

Chou, Tim, Chou, * and Chou, Joseph, **

*New Sloan-Kettering Cancer Ctr., Cornell Univ. Grad. School of Med. Sci., NY NY 10021, USA and **Duke Univ., Durham, NC, USA. (Cancer Res. 48: 6218, USA).

Objective: To introduce and illustrate computerized simulation of synergism/additivism/antagonism of two or more anti-HIV agents using the isobologram principle of Chou and Talley (Adv. Enz. Regul. 22: 27-55, 1984).

Method: Computer software "Dose-Effect Analysis with Microcomputers" by J. Chou and T.-C. Chou, Elsevier-Elsevier, Cambridge UK, 1986, has been upgraded and used for studying anti-HIV drug interaction in terms of synergism or antagonism for IBM PC, AT, or II. In addition to automated construction of isobolograms, F_{1-Cl} plots and F_{1-Cl} table for two drugs, the new feature includes $F_{1-LogIC50}$ plots, dose-response Index (DRI), selectivity index (SI), and the following combinations:

Results: Using small number of measurements with reverse transcriptase, p24 antigen, virus yield, and IFA. The three following questions about synergism can be studied: 1) the potency of drug(s); 2) the shape of dose-effect synergism occurs (a); 3) the optimal dose combination ratio for maximal synergy (OOR); 8) schedule dependency; and 9) selectivity index (SI) for anti-HIV cytotoxicity ratio.

Conclusion: Usefulness of MEP and the software have been demonstrated (e.g. Anticancer Res. 6: 1189, 1987 [AT+IFN]; 31: 383, 1987 [AZT+CAF]; Science 235: 1376, 1987 [AZT+8D], and J. Inf. Dis. 158: 378, 1988 [ddC+IFN]).

M.C.P.111 POSSIBLE PROTECTIVE EFFECT OF INTERFERON-INDUCED THROMBIN (IDTA) AND/OR DEHA-5 IN HIV INFECTION

DEBONOIS, J.M.A., LAMAS P., McDermott, M. St General Hospital and UCSF, San Francisco, CA, USA

Objective: Since IDTA has been reported to have immunomodulatory/antiviral activity, we studied the effect of both endogenous IDTA-5 levels (IDTA is rapidly converted *in vivo* to IDTA-5) and HIV infection and 2) the *in vitro* effect of IDTA on HIV-infected macrophages.

Methods: IDTA-5 was measured by RIA and HIV antibody assayed by two ELISA techniques (positive (+) results confirmed by Western blot) in coded serum samples obtained from 5 groups of men who were age-matched within 3 years. *In vitro*, human macrophages exposed to HIV (one TCID₅₀ unit/cell) for 1 hour were cultured with various IDTA dilutions. Supernatants were assayed for p24 antigen at 9 days and 4 inhibition of p24 compared to untreated controls.

Results: Group 1 (24 HIV-seronegative men) sought medical advice regarding a possible AIDS diagnosis had a mean (SD) serum IDTA-5 level of 5.97 (±3.01) μg/ml, compared with Group II's (24 healthy HIV-seronegative) men level of 2.20 (±1.33) μg/ml (p<.0001). Group III's (24 HIV-AE patients) mean of 2.31 (±1.35) μg/ml (p<.0001). Group IV's (24 HIV-AIDS patients) mean of 1.12 (±1.74) μg/ml (p<.0001), and Group V's (48 HIV-healthy blood donors) mean of 3.19 (±1.68) μg/ml (p<.0001). *In vitro*, 10% inhibition of macrophage HIV p24 expression occurred at IDTA concentrations of 3-30 μg/ml.

Conclusion: At-risk HIV seronegative homosexual men had a significantly higher IDTA-5 level than age-matched HIV-sero or healthy HIV-blood donors. IDTA also modestly inhibited HIV replication *in vitro* in human macrophages. IDTA/IDTA-5 may have a protective effect in HIV infection.

M.C.P.112 ZIDOVUDINE ANALOG INHIBITS HIV-1 REPLICATION IN A HUMAN MONOCYTIC CELL LINE.

MAZUREK, JAMES P., PARENT, D. M., MORSEAU, R. J. and Valois, R. M. *

*Saint General Hospital, Montreal, Quebec, Canada, **Montreal-Du de Montreal, Montreal, Quebec, Canada.

Objective: Zidovudine is a long-acting zidovudine analog used to treat the diarrhea of AIDS patients. Because this diarrhea could directly involve the HIV-1 retrovirus, we have investigated the anti-viral potential of Zidovudine in monocytes.

Methods: Five different concentrations of Zidovudine (Zanid; 0.5, 1, 2, 4, 8, 16, 32, 64, 128, 256, 512, 1024, 2048, 4096, 8192, 16384, 32768, 65536, 131072, 262144, 524288, 1048576, 2097152, 4194304, 8388608, 16777216, 33554432, 67108864, 134217728, 268435456, 536870912, 1073741824, 2147483648, 4294967296, 8589934592, 17179869184, 34359738368, 68719476736, 137438953472, 274877906944, 549755813888, 1099511627776, 2199023255552, 4398046511104, 8796093022208, 17592186044416, 35184372088832, 70368744177664, 140737488355328, 281474976710656, 562949953421312, 1125899906842624, 2251799813685248, 4503599627370496, 9007199254740992, 18014398509481984, 36028797018963968, 72057594037927936, 144115188075855872, 288230376151711744, 576460752303423488, 1152921504606846976, 2305843009213693952, 4611686018427387904, 9223372036854775808, 18446744073709551616, 36893488147419103232, 73786976294838206464, 147573952589676412928, 295147905179352825856, 590295810358705651712, 1180591620717411303424, 2361183241435422606848, 4722366482870845213696, 9444732965741690427392, 18889465931483380454848, 37778931862966760909696, 75557863725933521819392, 151115727451867037638784, 302231454903734075477568, 604462909807468150955136, 1208925819614937011910272, 2417851639229874023820544, 4835703278459748047641088, 9671406556919496095282176, 19342813113838992190564352, 38685626227677984381127104, 77371252455355968762254208, 154742504910711937444508416, 30948500982142387488901696, 6189700196428477497781392, 12379400392856954995562784, 24758800785713909991124672, 49517601571427819982249344, 99035203142855639964498688, 198070406285711279728997376, 396140812571425459457994752, 79228162514285091891598944, 158456325028570183783197888, 316912650057140367566395776, 633825300114287335132791552, 1267650600228574710265831104, 2535301200457148421327262208, 507060240091428884265454416, 1014120480182857768530908832, 2028240960365715570721817664, 4056481920731431134043635328, 8112963841462862670887270656, 16225927682925725417741541312, 3245185536585145083548282624, 6490371073170287017089565248, 129807421463405743541791129984, 259614842926811171083582259968, 519229685853622342166716451936, 1038459371707244643333432831872, 2076918743414488886666865663744, 4153837486828977773333731327488, 8307674973637955546667462654976, 16615349947275911113334925309952, 33230699894551822226669650619904, 66461399789103644453339301238808, 13292279957820728890667860257616, 26584559915641457793335721115432, 531691198312828955466674622528672, 1063382396625657911333492505571344, 212676479325131582266696511115432, 42535295865026316453339301238808, 8507059173005263290667860257616, 170141183460105265813335721115432, 340282366920210531666674622528672, 680564733840421063333492505571344, 136112946768084212666696511115432, 272225893536164453339301238808, 54445178707232890667860257616, 10889035741566571333492505571344, 2177807148333113666696511115432, 435561428666622733339301238808, 87112285733324546667860257616, 17422451546664909333492505571344, 3484490311332981866696511115432, 696898062266596373339301238808, 13937961245319126667860257616, 2787592249063825333492505571344, 557518449812645066696511115432, 111503699962449013339301238808, 22300739992489806667860257616, 4460147998497960333492505571344, 892029599699592066696511115432, 178405919939918403339301238808, 35681183987983680667860257616, 7136236797596736033492505571344, 14272473595193472066696511115432, 2854494719038694403339301238808, 570898943807738880667860257616, 114179788761547776033492505571344, 228359577523095552066696511115432, 45671915504619110403339301238808, 91343831009238220667860257616, 18268766201847644033492505571344, 36537532403695288066696511115432, 7307506480739057603339301238808, 146150129614781152066696511115432, 292300259229562304033492505571344, 5846005184591246066696511115432, 11692010369182920066696511115432, 2338402073836584003339301238808, 46768041476731680066696511115432, 93536082953463360033492505571344, 187072165906926720066696511115432, 37414433181385344003339301238808, 748288663627706880066696511115432, 1496577327255413760033492505571344, 2993154654510827520066696511115432, 598630930902165504003339301238808, 11972618618043310080066696511115432, 23945237236086620160033492505571344, 4789047447217324032066696511115432, 957809489443464806403339301238808, 191561897888692960066696511115432, 383123795777385920033492505571344, 766247591554771840066696511115432, 153249518310954368003339301238808, 3064990366219087360066696511115432, 612998073243817520033492505571344, 1225996146476355040066696511115432, 245199229295271008003339301238808, 4903984585905420160066696511115432, 9807969171810840320066696511115432, 1961593834362168064033492505571344, 39231876687243361280066696511115432, 78463753374486722560066696511115432, 156927506748973445120066696511115432, 313855013495946882240066696511115432, 627710026991893764480066696511115432, 1255420053983787528960066696511115432, 2510840107967575057920066696511115432, 5021680215935150115840066696511115432, 10043360431870300231680066696511115432, 20086720863740600463360066696511115432, 40173441727481200926720066696511115432, 80346883454962401853440066696511115432, 160693766909924803706880066696511115432, 3213875338198496074137760066696511115432, 6427750676396992148275520066696511115432, 1285550135279398429551040066696511115432, 2571100270558796859102080066696511115432, 51422005411175937820160066696511115432, 102844010823551876440320066696511115432, 205688021647103748880640066696511115432, 411376043294207497601280066696511115432, 822752086588414995202560066696511115432, 164550417317682999045120066696511115432, 3291008346353659980810240066696511115432, 6582016692707319961620480066696511115432, 13164033385414639923240960066696511115432, 26328066770829279846481920066696511115432, 52656133541658559692963840066696511115432, 10531226707331711938593680066696511115432, 210624534146634238771877760066696511115432, 421249068293268477543555520066696511115432, 8424981365865369548711111040066696511115432, 1684996273173073909742222080066696511115432, 3369992546346147819484444480066696511115432, 6739985092692295638968888960066696511115432, 13479970185384591777777760066696511115432, 2695994037076918355555520066696511115432, 53919880741538367111111040066696511115432, 10783976148307673222222080066696511115432, 21567952296615346444444480066696511115432, 43135904593230692888888960066696511115432, 8627180918646138577777760066696511115432, 1725436129289227715555520066696511115432, 34508722585784554311111040066696511115432, 6901744517156910822222080066696511115432, 13803489034313821644444480066696511115432, 27606978068627643888888960066696511115432, 552139561372552877777760066696511115432, 110427912274510575555520066696511115432, 2208558245490211511111040066696511115432, 4417116490980423022222080066696511115432, 8834232981960846044444480066696511115432, 17668465763921692088888960066696511115432, 3533693152784338417777760066696511115432, 706738630556867683555520066696511115432, 14134772611137353671111040066696511115432, 2826954522267470724444480066696511115432, 56539090445349414488888960066696511115432, 1130781808906988297777760066696511115432, 226156361781397659555520066696511115432, 4523127235627953191111040066696511115432, 9046254471255906382222080066696511115432, 18092508942511812764444480066696511115432, 36185017885023625528888960066696511115432, 7237003577004725105777760066696511115432, 1447400715009445011555520066696511115432, 28948014300188900231111040066696511115432, 57896028600377800462222080066696511115432, 11579205720075560924444480066696511115432, 23158411440151201888888960066696511115432, 463168228803024037777760066696511115432, 92633645760604807555520066696511115432, 1852672915212096151111040066696511115432, 3705345830424192302222080066696511115432, 7410691660848384604444480066696511115432, 14821383321696769288888960066696511115432, 296427666433935385777760066696511115432, 592855332867870771555520066696511115432, 11857106653557415431111040066696511115432, 23714213307114828862222080066696511115432, 47428426614229657724444480066696511115432, 94856853228459315488888960066696511115432, 18971370645691863088888960066696511115432, 37942741291383721777760066696511115432, 75885482582767443555520066696511115432, 1517709651455348871111040066696511115432, 303541930291069772222080066696511115432, 607083860582139544444480066696511115432, 1214167721164279088888960066696511115432, 24283354423285581777760066696511115432, 48566708846571163555520066696511115432, 9713341769314271111040066696511115432, 19426683538628542222080066696511115432, 388533670772570844444480066696511115432, 777067341545141688888960066696511115432, 1554134683090283377760066696511115432, 31082693661805667555520066696511115432, 621653873236113351111040066696511115432, 124330774247222662222080066696511115432, 248661548494445324444480066696511115432, 4973230969888906488888960066696511115432, 994646193977781288888960066696511115432, 1989292377955562577760066696511115432, 39785847559111251555520066696511115432, 795716951182225031111040066696511115432, 1591433902364450062222080066696511115432, 3182867804728900124444480066696511115432, 63657356094578002488888960066696511115432, 12731471218915600488888960066696511115432, 25462942437831200977760066696511115432, 509258848756624019555520066696511115432, 1018517695513248031111040066696511115432, 203703539102648602222080066696511115432, 407407078205297204444480066696511115432, 8148141564105944088888960066696511115432, 16296283128211888177760066696511115432, 325925662564237763555520066696511115432, 651851325128475527111040066696511115432, 130370265025695044444480066696511115432, 2607405300513900888888960066696511115432, 521481060102780177760066696511115432, 10429621202055603555520066696511115432, 208592424041112071111040066696511115432, 417184848082224142222080066696511115432, 834369696164448284444480066696511115432, 16687393923288965688888960066696511115432, 333747878

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

M.C.P.115 ANTI-HIV-1 ACTIVITIES OF ANTHRACENONE DERIVATIVES IN VITRO

C. G. Chin¹, R. F. Galloway², M. Nease¹
¹The University College of Pharmacy, Athens, Georgia 30602,
²Emory University School of Medicine/V. Medical Center, Atlanta, GA 30303, ³National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, U.S.A.

Objective: As a part of our efforts to discover novel anti-HIV agents, a series of anthracenone derivatives have been screened against HIV-1.
Methods: Peripheral blood mononuclear cells were infected with HIV-1 and cultured in the presence and absence of various concentrations of compounds. Six days later the reverse transcriptase activity was determined as a measure of antiviral activity.

Results: In order to determine the structure-activity relationships, various anthracenones substituted with OH, H₂O, SO₂, halogens, aromatic, amino, etc. were evaluated against HIV-1. Among these, poly-phenolic and/or poly-sulfate substituted anthracenones were found to be most potent, such as 1,2,5,8-tetrahydroanthracenone (C₁₅H₁₀O-3.29µM), 1,2,4-trihydroxyanthracenone (C₁₅H₈O₄ 4.44 µM), 3,4-dihydroxy-9,10-dioxo-2-anthracenone sulfonic acid (C₁₆H₈O₅S 3.48 µM). Amino or halogen substituted anthracenones exhibit low activity. None of the active compounds were toxic at 100 µM. Hypochlorite, an anthracenone dimer exhibited a potent anti-HIV activity (C₁₈H₁₂O₄ 4.44 µM) in this screening system.
Conclusion: A new class of anti-HIV agents with modest activity has been identified. Further study of structure-activity relationships and the mechanism of action are warranted.
(Supported by USPHS Grant AI 20555, AI 25899 and the Veterans Administration)

M.C.P.117 CANTHAROPHENYL ANALOGS AS POTENT INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS (HIV)

S. Bhatnagar, Pragas¹, Taylor, D. H., Kang, N. K., Liu, R. P.,
M. J. Gorman, M. J., and J. Jordan, A. M.,
¹Marshall Dow Research Institute, 2110 E. Galveston Blvd, Cincinnati, OH 45215
²US Army Research Development and Engineering Command, Research and Development
Department, Fort Belvoir, Illinois 62204, USA
Objective: The present investigation was to develop potent inhibitors of glycosylase as potential anti-HIV agents. Several analogs of the known inhibitor, cantharopene (CANT), were synthesized and evaluated for their inhibitory effect on glycosylase and for antiviral activity against Moloney murine leukemia virus (MuLV) in the TC clone assay. The IC₅₀ values of these inhibitors against the enzyme and MuLV ranged from 0.8 - 50 µg/ml and 0.05-0.10 µg/ml, respectively, compared to 10 and 1.1 µg/ml for CANT. The most effective analog was 6-O-butyl CANT with an IC₅₀ of 0.05 µg/ml against MuLV. A good correlation between the inhibition of glycosylase and MuLV replication was observed. The active analogs were further evaluated against HIV-induced syncytium formation in HeLa T₄ cells and against productive infection in 293 cells infected with HIV-1 (JR9 strain). The analog showed IC₅₀'s between 0.2 - 27 µg/ml in the HeLa T₄ assay, compared to CANT at 11 µg/ml. These compounds also showed good activity (IC₅₀'s 0.15 - 6.7 µg/ml) in 293 cells. In both of these HIV assays, the 6-O-butyl analog was the most effective, (IC₅₀'s 0.15 µg/ml) compared to CANT (10 µg/ml). These data and cytotoxicity studies delineated a therapeutic index of >2000 for the 6-O-butyl CANT compared to 500 for CANT. These observations were further confirmed by investigation of the 6-O-butyl analog against Simian virus infection in mice. CANT and the 6-O-butyl analog, when administered at a dose range of 50-100 mg/kg/day i.p. for 14 days, reduced the splenomegaly by 60-80% and 60-81%, respectively. These observations demonstrate the potential of the novel glycosylase inhibitors as chemotherapeutic agents in AIDS.

M.C.P.119 EFFECT OF CHLOROQUINE ON HIV INFECTION OF MONOCYTES

Desrosier, Isabelle¹, Faucher, H. P., Pyne, C.K., **Bavel, B. *

* Physiologie Cellulaire, ** Spécificité du Développement.
Université de Québec, Québec, Québec

Objective: Ultrastructural analysis of HIV infection of monocytes.
Methods: Monocytes were isolated from normal donor blood samples by Hypaque-Ficoll administration and approach, then inoculated with virus in presence or absence of chloroquine (120 micromoles for a period of 6 hours or 50 micromoles overnight). Cytological study was performed with electron microscopic techniques.

Results: The treatment of HIV infected monocytes by chloroquine resulted in the formation of intracellular vacuoles containing viruses in various stages of development similar to those observed in SV infected cells treated with haemagglutinin agglutins (1) and in HIV infected cells expressing a glycoprotein that interferes with the fusion reaction of virus envelope with the cell membrane (2). By contrast such intracellular accumulations of viruses were not observed in HIV infected monocytes not treated by the drug.
Conclusions: These preliminary data suggest that chloroquine may affect the penetration of HIV into the cytoplasm of monocytes.

(1) Helenius et al., 1982, J. Gen. Virol. 58, 47-61.
(2) Campese et al., 1988, J. Virol. 62, 159-167.

M.C.P.116 AZITROPHENYDINE(AZT)-ALPHA-INTERFERON(IFN) COMBINATION

THEYREY REDUCES P24 ANTIGENEMIA. **Malig, Brian R.**, Whaling, E.N., Melnick, R.J., Bitensky, J.S., Division of Infectious Diseases and Hematology/Oncology, Michael Reese Hospital, Chicago, IL, U.S.A.
We report an ongoing phase III dose-escalating/dose-toxicity trial of IFN in combination with AZT in patients with p24 antigenemia (CA5 µg/ml) and AIDS, AZT, or a CMV count <150/mm³. Patients with opportunistic infections (OI), lymphoma, or progressive Kaposi's sarcoma are excluded. All patients must be p24 Ag(+) after at least 4-8 weeks of AZT monotherapy to be eligible. Patients are followed with monthly physicals, CD4 counts, and must be p24 Ag(+) after at least 4-8 weeks of AZT monotherapy to be eligible. Patients are followed with monthly physicals, CD4 counts, and must be p24 Ag(+) after at least 4-8 weeks of AZT monotherapy to be eligible. A mean reduction in plasma p24 Ag of 43% has been seen in 8 of 9 patients, at a median of 7 weeks. In the 4 followed more than 8 weeks on IFN, a mean reduction in p24 Ag of 78% occurred at the median of 17 weeks. Higher initial CD4 counts predicted greater reductions in p24 Ag. CD4 counts fell and B₂-microglobulin levels rose on therapy. Side effects required IFN dose modifications in 4 of 9 patients for more than 8 weeks, an initial decline in p24 Ag at 8-15 weeks was followed by a rise toward pre-treatment values at 18-25 weeks. This rise correlated with a fall in CD4 to below 100.

We conclude that AZT-IFN therapy is associated with an initial reduction in plasma p24 Ag to a very low incidence of OIs, and a moderate frequency of side effects requiring dose modification. Correlation of a late rise in p24 Ag with a fall in CD4 suggests that early antiviral effects of IFN may be overcome by later immunosuppressive effects.

M.C.P.118 ANTI-HIV REVERSE TRANSCRIPTASE AND ANTI-HIV ACTIVITIES OF

PC8
N. Takayama, Patrick K. Lal, Y. T. Wu and M. Nomsaya
Department of Virology, Centers for Disease Control,
Institute, St. Petersburg, FL 33716, USA.

Previously we have shown that PC8, a partially purified extract from cones of *Pinus parviflora* Sieb et Zucc, inhibited HIV-1 replication in CEM, C9 and 293T cells. We report that PC8 has anti-HIV-1 reverse transcriptase (RT), anti-AM-RT activities. Addition of PC8 to the reaction mixture of the RT assay inhibited HIV-1 and AM-RT activities. Gel-retardation assay showed that PC8 did not bind to DNA or the template. Competition assays revealed that PC8 directly interact on HIV and AM RTs. The anti-RT active component(s) in PC8 could be removed by an affinity column of CEM cells. Sequential Tris-glycine (0.1M, pH 3.0 and 0.1M, pH 8.0) elution did not recover the anti-RT component(s), but the eluate contained anti-HIV activity. The replication of HIV in CEM cells was inhibited after exposure of the infected cells to the eluate [µg/ml]. Thus, PC8 contains 2 active components: an anti-RT component and an anti-HIV component that had no impact on HIV-RT. Further purification of these active components in PC8 is in progress.

M.C.P.120 CELLULAR PHARMACOLOGY OF ANTI-HIV AGENTS AZITROPHENYDINE (AZT)

AND 2',3'-DIDHYDROAZITROPHENYDINE (DDI) IN HUMAN T CELLS

Freidland, Arnold; Govey, M. and Ashmun, R.

St. Jude Children's Research Hospital, Memphis, Tennessee 38101 USA.

Objective: AZT is the first effective agent in the treatment of AIDS. However, low marrow toxicity and anemia is a severe adverse effect of AZT therapy. This toxicity has been attributed to inhibition of deoxythymine diphosphate (dTMP) for DNA synthesis. This study compared the metabolism and inhibitory effects of AZT and that of its analog DDI in human T cells CD4⁺CD8⁻. Results: The concentration of the drug substrate for inhibitory cell growth by AZT (IC₅₀) was significantly lower when the cells were exposed to AZT and DDI for 24 h (80-40 and 25 µM, respectively) than 48 h (100-125 and 50 µM). Inhibition of DNA synthesis induced by either drug did not correlate with dTMP depletion in cells. The 5'-phosphate of AZT (AZTP) was the major metabolite (95%) resulting 300-fold greater cellular concentration than that observed with DDI at equimolar concentration of the two drugs. Cells incubated with 25 µM AZT accumulated 25 µM AZTP and 25 µM both AZTP and AZTP plateaued at about 5 µM. After this period there was a rapid decrease in AZTP concentration to one third its initial level by 24 h, while both AZTP and AZTP appeared stable. DDI is a poorer substrate than AZT for the cellular kinase but produced considerably higher level of the analog triphosphate in CEM cells at equimolar concentration of the two drugs.
Conclusions: These results do not support the notion that depletion of dTMP is a primary cause for the toxicity of AZT or DDI and suggest that the analog triphosphate levels are the important determinants of cellular activity to these drugs. (Supported by NIH grant CA63296, CA21765 and by the American Lebanese Syrian American Charities.)

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

M.C.P.133 EFFECT OF ORGANIC ARSENICALS ON PROLIFERATIVE INFECTION OF HIV.

Geeta, Pathak, G. Narve, V. Kishor, C.S. and Rav, M.
University of Pittsburgh, Pittsburgh, PA 15261, U.S.A.

Objective. To study the anti-HIV effect of oophenarsenic and other structurally related organic arsenical compounds.

Methods. Various concentrations of arsenical drugs were added to the culture medium after infection of H9 cells or PHA-stimulated lymphocytes with HIV. Production of HIV was monitored by the antigen capture test. The effect of drugs on the production of HIV from persistently infected H9 cells was monitored not only by the antigen capture test, but also by reverse transcriptase and infectivity assays.

Results. Oophenarsenic, a trivalent arsenical compound, in concentrations as low as 0.025 µg/ml, inhibited *in vitro* infection of blood lymphocytes and H9 cells by HIV. The drug also blocked the production of HIV from lymphocytes of seropositive men coinfected with PHA-stimulated normal donor lymphocytes and depressed the production of HIV from persistently infected H9 cell line. Zidovudine, the only FDA-approved anti-HIV drug, had no antiviral effect in cells persistently infected with HIV. Seven other structurally related organic arsenicals whose structures are very similar to oophenarsenic were also tested for their *in vitro* anti-HIV properties. Of these seven compounds, one compound had identical organic structure as oophenarsenic except that it carried pentavalent, instead of trivalent, arsenic. However, none of these seven compounds had anti-HIV effect in H9 cells or lymphocytes.

Conclusion. Oophenarsenic is a potent anti-HIV drug. Oophenarsenic is a U.S. FDA approved drug for the treatment of syphilis. It was used extensively before the discovery of penicillin. Presence of trivalent arsenic in oophenarsenic may be crucial for its anti-HIV property.

M.C.P.134 NOVEL GLYCOPROTEIN INHIBITORS AS ANTI-HIV AGENTS

Hiromasa Shimidzu, Masahiko, S., Yamamoto, H.,** Oshijima, H.,**
*National Institute of Health, Musashimurayama, Tokyo, Japan,
**Pharmaceutical Research Laboratories Daiichi Sankyo, Ltd., Yokohama, Kanagawa, Japan.

Objective. To evaluate the effect of novel glycoprotein inhibitors, Oophenylglycyl(DM) derivatives, on the replication of HIV-1.

Methods. DM derivatives were newly synthesized and were assessed the inhibitory effect on giant cell formation by Helt-4 cells and Helt-4(HIV-1 cells. The infectivities from Helt-4(HIV-1 or O937(HIV-1 cultured in the presence of drugs were also determined by using H9-cells. The envelope glycoproteins from Helt-4(HIV-1 were obtained by immunoprecipitation.

Results. DM derivatives were newly synthesized and were assessed the inhibitory effect on giant cell formation by Helt-4 cells and Helt-4(HIV-1 cells. The infectivities from Helt-4(HIV-1 or O937(HIV-1 cultured in the presence of drugs were also determined by using H9-cells. The envelope glycoproteins from Helt-4(HIV-1 were obtained by immunoprecipitation. DM derivatives were newly synthesized and were assessed the inhibitory effect on giant cell formation by Helt-4 cells and Helt-4(HIV-1 cells. The infectivities from Helt-4(HIV-1 or O937(HIV-1 cultured in the presence of drugs were also determined by using H9-cells. The envelope glycoproteins from Helt-4(HIV-1 were obtained by immunoprecipitation.

Conclusion. These synthetic DM derivatives have potent anti-HIV activity *in vitro*. Development of novel glycoprotein processing inhibitors is likely to depend on the inhibition of the envelope glycoprotein processing.

M.C.P.135 CARBOXYLIC ACID AMIDES ANALOGUES THAT INHIBIT THE REPLICATION OF HUMAN IMMUNODEFICIENCY VIRUS IN T-CELLS AND MONOCYTES/MACROPHAGES *IN VITRO*.

Flattner, S.P., Broder, S.C.,** Maslow, J.N.,** Hirsch, M.S.,**
*Abbott Laboratories, Abbott Park, IL, USA.

Objective. Two newly synthesized carboxylic acid amide analogues, α -(2',3'-bis(hydroxypropyl)-1-cyclohexyl)acetamide (CA) and α -(2',3'-bis(hydroxypropyl)-1-cyclohexyl)glutamide (CG), were tested for activity against the infection of human immunodeficiency virus (HIV) *in vitro*.

Methods. In an HIV cytopathic effect inhibition assay, target CD4⁺ T-cells were exposed to HIV-1 or HIV-2, cultured with/without drugs, and the viable cell number was determined. The expression of p24_{gag} protein and proviral DNA synthesis were also assessed.

Results. Both compounds, CA and CG, were found to be capable of protecting T-cell lines against the infectivity and cytopathic effect of HIV-1; inhibiting the expression of p24_{gag} protein; and suppressing the proviral DNA synthesis *in vitro* against at concentrations 30-100µM. These compounds also inhibited the *in vitro* infectivity of HIV-1. Moreover, both CA and CG virtually completely suppressed the p24_{gag} protein expression in monocytes/macrophages exposed to monocytotropic HIV-1 at a concentration of 0.5µM. It was noted, however, that CA and CG exerted a substantial toxicity against target T-cells as well as normal peripheral blood mononuclear cells at around 100µM.

Conclusion. Our observations should provide new structure-activity relationships for carboxylic acid amide analogues which may be of value in developing a new class of experimental drugs for the therapy of HIV-related diseases.

M.C.P.136 NEW ANALOGUES OF 2',3'-DIDEOXYADENYLATE WITH IMPROVED ANTI-HIV-1 ACTIVITY *IN VITRO*

Montefiore, David, C.,** Baruch, A.,** Sobot, R.W.,**
R.W.,** R. Broder, S.C.,** Maslow, J.N.,** Hirsch, M.S.,** Sobol, M.,**
R.W.,** Robinson, A.,** Modi Chhabra, R.,** Pfleger, R.,**
Hibbard, R.,** and Mitchell, W.M.,** Vanderbilt University,
Nashville, TN, 37232, **Temple University, Philadelphia, PA 19140; and
*Fakultät für Chemie, Universität Konstanz, Konstanz, Germany.

Objective. To screen structural, stereochemical and combination structural/stereochemical 2',5'-dideoxynucleotides (2-SA) and 3',5'-dideoxynucleotides (3-SA) analogues for anti-HIV activity.

Methods. Cell toxicity and *in vitro* anti-HIV-1 activity were determined in an MT-2 cell, microtiter cytopathic effect assay utilizing virus obtained from cultures of H9/HTLV-III cells. Inhibition of reverse transcriptase (RT) activity was determined using a Triton X-100 activated viral lysate.

Results. A trimer of 2',5'-adenylate having the hydroxyl moiety replaced with a hydrogen atom at the 3' position of the middle residue (i.e., 3'-deoxyadenosine or cordycegin) demonstrated potent (compared to AZT) concentration-dependent antiviral activity (at 4-32 µM without toxicity to the cells). This trimer also exhibited concentration-independent inhibition of HIV RT. Other analogues exhibited various degrees of activity or were inactive in these assays.

CONCLUSIONS. The extent of 5'-phosphorylation, length of oligomer, type of interresidual bond, and the presence or absence of deoxyadenosine and stereoconfiguration are all critical factors for anti-HIV activity of this class of compounds.

M.C.P.137 PHASE II STUDY OF THE ADMINISTRATION OF RECOMBINANT SOLUBLE CD4 (sCD4) BY INTRAVENOUS TO PATIENTS WITH AIDS OR ARC.

Yoshino, Robert, Thomas RV, Pluda JM, Perno CF, Mitsuya H, Masryk KB, Shewen SA, and Broder S, *
*National Cancer Institute, USA, **Genentech, Inc, San Francisco, USA.

Objective. To investigate the toxicity, clinical effects, serum levels, immunologic effects, and virologic effects of sCD4 given by continuous infusion to patients (pts) with AIDS or ARC.

Methods. 12 patients with AIDS or ARC were administered sCD4 by continuous infusion for 15 days (after a 24 hr test dose) at each of 3 dose levels: 1, 10, or 100 µg/kg/day.

Results. No toxicity was observed other than phlebitis in 2 pts at their IV sites. Serum sCD4 levels were as follows: 1 µg/kg/day - 0.8 to 2.8 ng/ml; 10 µg/kg/day - 10 to 22 ng/ml; 10 µg/kg/day - 22 to 30 ng/ml (other results pending). No antibodies to sCD4 were detected in patients who received 1, 10, or 30 µg/kg/day (other results pending). No changes were observed in the total WBC. No consistent changes were observed in the T4 cells. T4/T8 ratio, *in vitro* T cell proliferation to soluble antigen (Ag), skin test reactivity, or serum HIV p24 Ag in patients receiving 1, 10, or 30 µg/kg/day sCD4. However, 2 of the 3 patients receiving 100 µg/kg/day had rises in their CD4 cells from 69 to 182 T4 cells and from 147 to 222 T8 cells, respectively. One of these 2 patients had detectable serum p24 Ag at any time from 401 to 245 ng/ml with sCD4. Additional patients are now being studied at higher dose levels of 100 or 300 µg/kg/day.

Conclusion. Because of the lack of observed toxicity and the suggestion of possible anti-HIV activity at the highest dose tested, additional testing of sCD4 by continuous infusion at 100 µg/kg/day and higher doses is warranted. From a theoretical point of view, continuous infusion may possess special advantages as a technology for administering rCD4.

M.C.P.138 TRIMETHOPRIM (M) TRIMETHANOLAMINE (N) ERADICATION AS POSSIBLE

PROPHYLACTIC THERAPY RESISTING TO AZIDOTHYIMIDINE (AZT) IN AIDS PATIENTS

KUWAZA, BUNJI, RUSTENBERGER, A.
University of Geneva, Centre, Rue des Bains, Institut, Sarvejeva, Jugoslavia

Dansberg's film conducted over 200 cases of AIDS in a couple accordance with recently approved AZT co-trimoprim (cotrimoxazole) T as the most frequent, but since new trichomonas inhibitor and/or supporter of immunoppression.

Regarding the existence of cross-resistance by all three known trichomonas species (Trichomonas vaginalis, Tr. intestinalis and Tr. tenax), it seemed to us logically to suppose that, if the host gets freed from the pressure of trichomonas, the immune system will be better to resist to other antigens. Because of that, we have determined 14/70 by 7 patients with asymptomatic genital trichomonas and after 3 therapy.

As positive effect of AZT results is attributed to repression of asymptomatic patients without detectable toxemia with such bacterium has been observed.

As positive effect has been realized, in increasing of their indicator of being status trichomonas positive effects of M as immune status had been noticed by patients' health but without detectable overall (intestinal) trichomonas of asymptomatic.

Regarding the existence of cross-resistance by all three known trichomonas species (Trichomonas vaginalis, Tr. intestinalis and Tr. tenax), it seemed to us logically to suppose that, if the host gets freed from the pressure of trichomonas, the immune system will be better to resist to other antigens. Because of that, we have determined 14/70 by 7 patients with asymptomatic genital trichomonas and after 3 therapy.

As positive effect of AZT results is attributed to repression of asymptomatic patients without detectable toxemia with such bacterium has been observed. As positive effect has been realized, in increasing of their indicator of being status trichomonas positive effects of M as immune status had been noticed by patients' health but without detectable overall (intestinal) trichomonas of asymptomatic. Regarding the existence of cross-resistance by all three known trichomonas species (Trichomonas vaginalis, Tr. intestinalis and Tr. tenax), it seemed to us logically to suppose that, if the host gets freed from the pressure of trichomonas, the immune system will be better to resist to other antigens. Because of that, we have determined 14/70 by 7 patients with asymptomatic genital trichomonas and after 3 therapy.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

M.C.P.139 A USEFUL IMMUNOTHERAPY IN AIDS.

MARICOL Bernard J., M.D., JENNER M.C., BRUSSELS BELGIUM

In a clinical study made in Africa upon 90 patients-AIDS or ARC, 26 had at least one year of immunotherapy at the end of 1988. This immunotherapy is using different products: interferon, zalcitabine and acid heparin (with same chain). The particularity of this treatment (1) is the use of very small doses of each product. The results are compared with those of a group without any immunotherapy. In both groups, the 0.1. are treated by the classical medication. No one patient in the study is or has been on AZT, or other specific anti AIDS medication.

The results are:

Africans(n=10)	Africans on Tc	Personal evolution	
diarrhea (1)	40	6	1 cases (4)
fever (1)	13	6	2
infections (1)	55	13	14
Biology (2) absolute T4	4	191	51
T4/B	23	40	11
Weight (3)	-14	+3	-1

- (1) Frequency of diarrhea, fever, infections in Tc.
- (2) In a expressed annual weight enhancement of 16 and 14/18
- (3) Middle evolution of the weight, in Kg/year.
- (4) Group added in order to compare the biological data with those of the AZT studies. It is compared with the clinical studies, on AZT, the biological results of the european group are reaching the same level of efficacy.

Key words: immunotherapy, small doses, cyclosporin, nucleic Acids, anti heavy gamma chain.

M.C.P.141 CONCENTRATION DEPENDENT DUAL EFFECTS OF THE MONOCLONAL ESTER OF SUCROSE (L.S.) ON THE APPRIAL ACTIVITY AND ADSORPTION SPECTRA OF AMPLIGENIN (S) AND

Yoshitaka Zaitsev, G. S. and M. Kozlov, S. S.
Washington University, St. Louis, MO, St. Louis, Missouri, USA.
*Université du Québec à Trois-Rivières, Trois-Rivières, Québec, Canada.

Objective. To develop a system for AaB drug delivery.
Methods. Comparison of effects of a mild detergent, L.S. on AaB-induced decrease in cellular K⁺ retention and viability of *Staphylococcus carnosus* and *Cryptosporidium parvum* cells with L.S. effects on AaB physical state as reflected by absorption spectra.
Results. L.S. at concentrations 0.008 to 0.03% enhanced the toxic effects of AaB on the two fungi. In contrast, concentrations 0.004 to 2.1% inhibited AaB effects. We analyzed changes in AaB absorption spectrum induced by L.S. at these two concentration ranges by comparing critical (M_w) of AaB at 40nm. The same length characteristic of non aggregated (monomeric) L.S. at absorbance at 320nm, the wavelength characteristic of aggregated AaB. Low concentrations of L.S. caused a decrease in K⁺ and the higher L.S. concentrations increased it.
Conclusion. L.S. has concentration dependent dual effects on antifungal action of AaB which correlated with shifts in the physical states of AaB between its monomeric and aggregated forms. Since the inhibitory concentrations of L.S. on the antifungal effects are low about 1000 times greater than those reported previously for inhibition of AaB toxicity to mammalian cells, this suggests that L.S. may be useful as a vehicle for improvement of AaB delivery. However, increase in AaB toxicity induced by low concentrations of L.S. suggests the possibility that synergistic interactions between fatty acid esters, and polyelectrolytes may have therapeutic value.

M.C.P.143 TREATMENT OF THERAPY-RESISTANT ORO-PHARYNGEAL CANDIDIASIS WITH FLUCONAZOLE IN HIV-1-INFECTED PATIENTS

Teichgraber Barbara, H. Schneider, J. and

Deicher, M.
Hannover Medical School, Hannover, F.R. Germany.

Objective. To evaluate the efficacy of fluconazole, an experimental azole antifungal agent, in the therapy of therapy-resistant oro-pharyngeal candidiasis in HIV-1-infected patients.

Methods. 20 patients with therapy-resistant oro-pharyngeal candidiasis were treated with fluconazole at daily doses of 50-100 mg for 21 days. Patients were weekly examined for clinical symptoms as well as side effects and hematological and organ toxicity of the drug. Mycological assessment included microscopic examination and culture (cfu/ml) of mouth washings.
Results. Resolution of symptoms and signs was obtained in the first week of treatment in 18/20 patients. Partial response was observed in another 2/20 patients. Mycological assessment showed a significant reduction of candida cultures of mouth washings. In 60% of the patients the culture tests became negative at end of therapy whereas in 40% of patients more than 10⁵ cfu/ml were found. More than 60% of the patients had a clinical relapse four weeks after stopping the experimental therapy with fluconazole. No alteration of liver tests nor nephrotoxicity was observed.

Conclusion. Fluconazole seems to be a highly effective drug in the treatment of therapy-resistant oro-pharyngeal candidiasis in HIV-1-infected patients. A continuous therapy may be necessary to avoid clinical relapses. Optimal dosage remains to be defined in further studies.

M.C.P.140 A MODEL OF AIDS-VIRUS DYSINFECTION

Loban G. Angeloff

Angel's Biomedical Laboratories, Ltd., P.O. Box 122, Station "Place du Parc", Montreal, Quebec H2W 2P9, Canada

A virus disinfection was observed by the author in 1930-39 in water buffalo (*Bubalis bubalis*, Linn.) in Kosevici, Bulgaria, that all those animals who ate wild rose-apples did not get the infection caused by the ultra-virus *aphthae* (*aphthae epizooticae*). Later, the author applied above observations as model on rats bearing amelanin *MelanoX* (*Epizootic*) tumor (3rd Asian Cancer Conference (Abs. 143), p. 124, 1977).

In these investigations as model disinfectors alkaline Bulgarians 261-a (0.1M NaOH), acidic Bulgarians 261-b (0.1M HCl), and acidic Bulgarians 261-c (0.1M H₂SO₄) on normal white Wistar-Furuta rats were used as follows: (a) three rats were injected SC with a single dose of Bulgarians 261-a (0.1M NaOH) 1ml/100g.b.w.t.; (b) five rats were injected SC with Bulgarians 261-b (0.1M HCl) 1ml/100g.b.w.t.; and (c) five rats were injected SC with Bulgarians 261-c (0.1M H₂SO₄) 1ml/100g.b.w.t. The concentrations of the disinfectors were 1:1 tolerated by the recipients and after 24h. all rats were sacrificed and their heart and liver were examined and they were like normal. The results above that Bulgarians 261-a-c might be applied as disinfectors against various viral and bacterial infections. Copyright 1989 by Loban G. Angeloff. All rights reserved.

M.C.P.142 SEROLOGIC AND IMMUNOLOGIC PARAMETERS IN A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF

AMPLIGENIN ADMINISTERED TO SUBJECTS WITH HIV INFECTION

McKinley, G.F., Rudy, M.M., Iwata, Y., Kim, K., Rasmussen, J.J., Oriskany, M.F., Washington University, St. Louis, MO, St. Louis, Missouri, USA.

As part of a multicenter trial of intravenously administered AMPLIGENIN (mammalian, double-stranded RNA) we enrolled 25 HIV-seropositive (asymptomatic or early ARC) and followed them for up to 36 weeks. Blood was taken at the start of study and at weeks 4, 12, 24, and 36. At study end it was found that 12 patients had been given placebo and 13 had received AMPLIGENIN 400 mg twice weekly. There were no statistically significant differences between groups with respect to soluble CD4, soluble IL-2 receptor, beta-2 microglobulin, and sequester.

Wk	AMPLIGENIN (n=13)			PLACEBO (n=12)		
	IL-2R	IL-2R	Neopt	sCD4	IL-2R	Neopt
	(U/ml)	(U/ml)	(ng/ml)	(U/ml)	(U/ml)	(ng/ml)
0	281±903	181±400	4008±41	436±504	1792±116	238±372
4	930±990	1394±581	3158±270	435±65	785±800	1246±999
12	975±115	1393±679	3915±990	55±58	765±878	1320±116
24	838±186	1192±134	4179±531	42±69	645±608	1178±117
36	865±107	1294±152	4580±752	53±19	795±19	1287±141

There were no statistically significant differences between groups with respect to circulating immune complexes (measured by the inhibition of immune adhesion), erythrocyte complement C3b receptor (E-C3b) activity, and direct Coombs test.

M.C.P.144 INHIBITION OF HIV-REVERSE TRANSCRIPTASE BY A KAMPO MEDICINE, SHO-SAI-KO-TO

Drug: Katsushiro, Nakase, H. K., Fukushima, H. K., Chermann, J.-C.*** and Barre-Sinoussi, F.***

***Research Institute and Hospital, Aichi Cancer Center, Nagoya, Japan.
***Laboratoire de Recherches sur les Recherches sur les Maladies Infectieuses (INSERM, Marseille) and ***Laboratoire de Biologie des Retrovirus, Institut Pasteur, Paris, France.

Objective. To describe the *In vitro* inhibitory effect of a well-known kampo medicine (Chinese drug), Sho-Sai-Ko-To, on the activity of HIV-reverse transcriptase.

Methods. Reverse transcriptase activity was measured *in vitro* with (T₇)₁₁₂-18 as the template-primer and [³H]dNTP as the triphosphate substrate, and the effect of the drug was evaluated by adding various concentrations of Sho-Sai-Ko-To.

Results. The activity of HIV-reverse transcriptase was inhibited by more than 70% in the presence of 200 µg/ml Sho-Sai-Ko-To. The inhibition was dose-dependent, and the drug inhibited the enzyme activity by 90% at 500 µg/ml which is a clinically attainable concentration. Of the seven ingredients of Sho-Sai-Ko-To, the extract from radix of a plant, Scutellaria, was found to have strong inhibitory effect on the reverse transcriptase activity at concentrations less than 10 µg/ml. In contrast to reverse transcriptase, cellular DNA polymerase α , β and γ were much less sensitive to inhibition by this drug, suggesting the fact that Sho-Sai-Ko-To is non-toxic to the host cells.

Conclusion. Sho-Sai-Ko-To is promising as a candidate for antiretroviral agent.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

M.C.P.145 VIRAL INHIBITION THERAPY AGAINST AIDS

Uchihashi, M., Van Brunschot, A., Robson, I. and Bernstein, A.***
*Faculty of Medicine, University of Toronto, Ontario, Canada.
**Mount Sinai Research Institute, Toronto, Ontario, Canada.

Objective: Gene "manipulation" of stem cells leading to the development of an HIV-resistant immune system.

Methods: Various retroviral vectors expressing antisense or sense RNA to HIV-1 were constructed. The vector particles were used to infect CMV lymphocyte- and macrophage-derived cell lines. These transmutations will soon be challenged by HIV-1 and the virus production will be monitored.

Results: The ability of various vectors expressing sense or antisense RNA to interfere with the HIV-1 multiplication will be reported. The use of antisense RNA is only one way to interfere in the life cycle of HIV-1. Other vectors to express various proteins interfering with the HIV-1 life cycle are under development. If a stem cell could be made resistant to HIV-1, then upon maturation and development it will lead to the reconstitution of an HIV-1 resistant immune system. Both T-lymphocytes and macrophages, the primary targets of HIV-1 infection, derive from the bone marrow stem cells. The introduction into these stem cells of retroviral constructs expressing RNA or protein molecules conferring resistance against HIV-1 infection provides a potential therapeutic approach towards the development of an HIV-1 resistant immune system.

M.C.P.147 MESAQUINONE (METHYLQUINONE) INHIBITS HIV-1 INDUCED SYNTHESIS OF HIV-1 RNA

Quilley, L., Dethlefs, A. J. Hesse-Quilley, J.M. and Coak, J., Dept. of Microbiology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.

OBJECTIVE: To determine if naphthoquinone (Vitamin K series) compounds can affect HIV-1 induced and/or replication.

METHODS: Physiological non-toxic concentrations of phyloquinone menaquinone and menaquinone-7 (MK-7) were added to cultures of HT-2 and Hut-78 cells infected with three different clinical isolates of HIV-1. AZT was utilized as a comparative control. The effect of these chemicals were evaluated by inhibition of syncytia formation, and viral antigen production (Reverse Transcriptase assay and indirect immunofluorescence).

RESULTS: Remarkably, MK-7 heterally produced Vitamin K at concentrations between 5 and 1 µg/ml inhibited syncytia formation in HT-2 infected cells similarly to AZT at 5 to 1 µg/ml. Similar inhibition of syncytia formation was also observed in HIV-1 infected Hut-78 cells; however, while AZT effectively limited HIV replication, MK-7 had no effect whatsoever on virus production.

CONCLUSIONS: Further studies are warranted on the effects of menaquinone induced inhibition of syncytia formation especially in light of the findings that concurrent effects of HIV antigen and virus production are not affected in these cells. If syncytia formation is indeed an important factor in HIV pathogenesis then the understanding of the mechanism of inhibition of syncytia formation by MK-7 may prove a valuable way of limiting HIV-1 spreading in vivo.

M.C.P.149 AIDS - IS A SAFE VACCINE READY AVAILABLE?

Werner, GUDIN, M.D. Consultant Geneva University Hospital
10, Quai de Serres, 1203 Geneva, Suisse

Objective: Finding the best and safest method to obtain a marketable AIDS vaccine.

Method: Analysis of present vaccine strategies to obtain an AIDS vaccine. Development of a new concept in order to obtain a new kind of vaccine.

Results: Largely due to the development of an AIDS vaccine are now being pursued. The first one starts with the antigen, usually synthetic fragments of HIV (gp 120, gp 160, etc...) obtained by genetic engineering.

The second one consists of developing an antigenic vaccine using selected monoclonal antibodies (mAbs) to the CD4 receptor. Both strategies intend to obtain specific antibodies or cellular immunity to HIV. However, because of competition and cross-reactivity between HIV and the physiological ligand for the CD4 receptor, namely MHC II, blocking HIV with a classical vaccine will at the same time block MHC II binding to CD4 and interfere with normal macrophage to T cell interaction causing immunosuppression.

To overcome these difficulties, a new type of "vaccine" consisting of monoclonal antibodies, liposomes and adjuvant intended to safely block HIV infection and stimulate NK cells (non MHC restricted immune response) is being considered.

Conclusion: A new concept for an AIDS vaccine based on stimulation of NK cells is presented.

M.C.P.146 EFFECT OF PEPAIN TREATMENT ON THE HIV ENVELOPE AND CORE ANTIGEN

Ujhelyi, E., Füst, G.**, Ellei, G.**, Allan, S.**, Székelyi, J.**, and Hollós, S.R.**,
Inst. Hematol. Blood Transfusion, Budapest, Hungary, and **Abbott GDM Diagnostics, Delishevova, FRG

Objectives: Previously (Ujhelyi et al., AIDS 1,161,1987) we worked out a **PEPAIN TEST** measuring the amounts of anti-core and anti-env antibodies hidden in circulating immune complexes. The method is based on the pepsin digestion of isolated immune complexes. In order to clarify whether HIV antigens are destroyed during this treatment, the pepsin sensitivity of purified recombinant env and core antigens was investigated. **Methods:** Purified 39 kDa p24 and 39 kDa p17, digested with pepsin for 16 h at 37°C (enzyme/substrate ratio: 1 to 5) and neutralized. Antigenicity of the core preparations was measured by the indirect immunofluorescence test. **Results:** The antigenicity of the purified env preparation was not destroyed but dose-dependently increased after pepsin treatment. **Conclusion:** The different sensitivity to pepsin digestion of HIV antigens may **CONTRIBUTE** to a difference in their availability to other processes influencing the in vivo processing of the antigens.

M.C.P.148 THE EFFECTS OF TRADITIONAL MEDICINE(SO-SAIJO-TO-SST) ON PROLIFERATION OF HUMAN T4 CELLS (PM2) FROM AIDS A/C PATIENTS

**Mitsuda, Kazuo, Ito, Y., Inagaki, H., Lange, M. and Clark, K.S.,
St. Luke's-Roosevelt Hospital Center, Columbia University, New York, NY, USA**

Objective: We have studied effects of SST on blastofusion assay in PM2 from AIDS patients with AIDS(n=4) and ARC(n=4), and healthy heterozygotes(Hz)(n=20) cultured with or without each medicine(SO, Co, PM2) in the presence or absence of SST (20µg/ml). Proliferation was measured by ³H-thymidine uptake after 96 hr incubation.

Results: Table shows proliferation responses (PM2, Ave. in cpm) of 3 groups with or without SST. Each patient group was further subdivided into a responder and nonresponder group based on positive or absent response to the combination of SST and PM2. As previously reported, major decreases in PM2 were observed in response to PM2 only for ARC and AIDS. SST enhanced proliferative activity (cpm) in all 3 groups and enhanced RT in PM2 in 3/4 AIDS and 2/4 ARC. It is of interest that the greatest enhancing response of SST on PM2 was observed in Hz's from ARC, and occurred maximally in those exhibiting the combination of (1)low RT in PM2 and (2)normal RT in Co. A. The percentage increases observed for the same combination in AIDS, on the other hand, were only similar to that seen in Hz controls.

Conclusion: Our results suggest that SST is able to stimulate monocyte-T4 cell T cell network system and/or suppress T8 cell function.

No.	HIV AIDS		ARC AIDS		Responder/Nonresponder		
	SO	Co	SO	Co	AIDS	ARC	
20	44	40			34/11	22/18	
No Mitogen	886	338	317	+30	+10	223/477	294/188
PM2	2375	1620	812	-15	-12	1648/1873	847/754
Co A	1313	1325	3684	-18	-17	1152/1109	451/2826
PM2	3264	850	675	+13	+7	723/1248	721/911

M.C.P.150 AFRICAN TRADITIONAL MEDICINE AND AIDS

**CHIEF AJISIFINNI, S.O.,
19, Aramoko Road, Box 95, Ijebu-Ekiti, Ondo State, Nigeria.**

African Traditional Medicine is the use of herbs and plants of animal and mineral origin. The medicinal is the oldest known method of healing the sick. Most people in Africa have no alternative than traditional medicine.

The Western trained Medical Doctors and Traditional Healers should be partners in progress to find a common solution for the health of mankind. There should be provision of the traditional healer with a place in the AIDS NETWORK.

Traditional healer is to educate the rural dwellers to know who has AIDS and how to avoid AIDS. My group consists of traditional medicine experts has started research into the preventive and cure for the killer disease - AIDS by using herbs and other ingredients. By GOD'S Will there would be a positive result. AIDS is one disease which all races of humanity should cooperate to fight.

No time in the history of mankind have creatures as small as the AIDS virus caused so much grief and sorrow to so many people.

Session d'affichage Poster Session



Immunologie de base Basic Immunology

T.C.P.1

MEASUREMENT OF AFFINITY MATURATION IN HIV-1 INFECTED CHIMPANZEES, Richard S. Kaplan¹, P. Balgova², V.G. Maslova², D.J. Ruvinsky², and J. E. Hahn¹, ¹NIH, ²Harvard Medical School, Worcester, MA, USA, ³Department Foundation for Biomedical Research, San Antonio, TX, USA.

Objective: To quantify the function of affinity maturation in HIV-1 infected animals.
Methods: Over 20 sera for each of the three HIV infected chimps were obtained over a two year period. A modification of the method (Pullen, 1986) was used to measure the avidity of chimp sera for a rec. env. peptide and compared with conventional EA on the same epitope.
Results: All three chimps showed an abrupt increase in titer starting 2-3 weeks after challenge. The titer reached a median between 50 and 100 days and then either declined or remained constant. Avidity increased steadily in all three animals over the two years. A plot of titer vs avidity over the entire course of one year were slightly elevated but the correlation ($r=0.2$). When compared with a panel of HIV positive human sera, the HIV titer and avidity of one year were slightly elevated but the avidity was significantly higher than the mean of the human sera.
Conclusions: HIV titer and avidity of one year were slightly elevated but the avidity was significantly higher than the mean of the human sera. HIV-1 infected chimps showed a steady increase in affinity for the envelope over the two years. Chimps eventually produced higher avidity sera for the envelope than did a random selection of HIV-1 infected humans.

T.C.P.3

ACT INHIBITS LPS-INDUCED SECRETION OF IL-1 BY CULTURED NORMAL HUMAN MONOCYTES.

Marie Lamotte¹ Reafer-Cavillon, M; Laude, M. and Masadoun, A.D.
Unité d'Immunopathologie, Hôpital Broussais, Paris, France.

The failure of 3'-azido-3'-thymosidine (AZT) to inhibit HIV replication in human macrophages is due to the ability of the drug to permeate the cell membrane. Little is known however on the consequences of intracellular accumulation of the drug on monocyte function. The effect of AZT on the ability of unstimulated and LPS-stimulated human mononuclear adherent cells (MNC) to produce interleukin-1 (IL-1) was investigated in vitro. MNC from normal donors were cultured in serum-free conditions with increasing amounts of *Neisseria meningitidis* LPS (0.01-10 µg/5 x 10⁶ cells) for 24 h. AZT alone did not induce IL-1 production in culture. MNC AZT did not interfere with the Coak continuous thymocyte assay for IL-1. MNC exposed to LPS-stimulated cultures. AZT inhibited the extracellular release of IL-1 activity in a dose-dependent manner although it did not affect significantly the induction of cell-associated IL-1 activity by LPS. The latter finding correlated with the lack of effect of AZT on the induction of cell-associated IL-1 alpha antigen by LPS, as assessed by radioimmunoassay. Thus, AZT specifically inhibits the release of functional IL-1 beta by LPS-stimulated monocytes which may allow the molecule with anti-inflammatory properties.

T.C.P.5

CD4+ AND CD8+ CYTOTOXIC T LYMPHOCYTE-MEDIATED LYSIS OF MACROPHAGES EXPRESSING HIV ANTIGENS

Deputy, David J. Murrain, T. J. Dupra, P. and Rinaldo, G.
University of Pittsburgh, Pittsburgh, PA 15261, U.S.A.

Objective: To characterize cytotoxic T lymphocyte (CTL) lysis of macrophages expressing HIV antigens.

Methods: Autologous cultures cultured in vitro for 6 days were either infected with recombinant vaccinia virus (VTV, courtesy of Dr. B. Moss) containing HIV genes or coated with HIV, and used as target cells in a ⁵¹Cr-release assay. Freshly-isolated FMC or FMC cultured for 6 days with UV-inactivated HIV plus IL-2 from HIV seropositive, asymptomatic individuals were depleted of CD4⁺ or CD8⁺ cells and used as effector cells.

Results: Antigen-stimulated CTL mediated a 28.5% mean virus-specific lysis of HIV-infected macrophages expressing env or gag antigens, which was several fold greater than lysis mediated by freshly-isolated, CD8⁺ effectors. Antigen stimulation activated HIV-specific, CD8⁺ CTL in addition to augmenting CD8⁺ CTL. When macrophages were coated with either HIV III₁ or HIV₁ freshly-isolated effectors mediated a 6.5% mean virus-specific lysis; FMC stimulated with HIV antigen demonstrated 8.5% mean lysis. FMC from HIV seropositive subjects did not inhibit these responses.

Conclusions: Macrophages infected with HIV-env, HIV-gag, or whole HIV were lysed by CD8⁺ in vitro. An enhanced cytotoxic response was observed when FMC were stimulated with HIV antigens, which activated CD8⁺ CTL. These results agree with our previous work (J. Immunol., 142(4), 1989) using large simplex virus-infected macrophages, and suggest that both CD4⁺ and CD8⁺ CTL are important in host immune response to HIV.

T.C.P.2

TYPE SPECIFIC CTL RESPONSE TO THE HIV-1 ENVELOPE GENE PRODUCE

Richard Lamotte¹, Karen A.L. Parada, J.P. Flomeno, Ch. Moss, M.D.; Schooley, R.T., and Walker, R.D. ¹Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; ²Laboratory of Viral Diseases, NIAID, NIH, Bethesda, MD, USA.

Objective: To determine group vs. type specificity of CTL directed at the HIV-1 envelope protein.

Methods: Peripheral blood mononuclear cells from HIV-1 seropositive individuals were cloned via limiting dilution in the presence of a CD3-specific monoclonal antibody (mAb) and recombinant IL-2. Developing clones were tested for cytolytic activity against autologous or allogeneic HIV-transfected 8 cell lines infected with HIV-nucleocapsid recombinant vectors in a 4 hour ⁵¹Cr release assay. A competition assay was conducted by including target cells with and without the addition of effector cells. Results: An HIV-1 envelope-specific CTL clone, designated 43043, lyses target cells expressing the HIV-1III₁ envelope or the HIV-1III₂ envelope up to 10% above control at an effector:target ratio of 2.5:1, but does not lyse target cells expressing the HIV-1IIIB envelope. Lysis is restricted by the HLA class I antigen B2, and is abrogated by monoclonal antibodies to CD3 or CD8, but not CD4.

Conclusions: HIV-1 envelope-specific, HLA Class I restricted CTL are part of the host immune response to HIV-1 infection. This demonstration of a type-specific response to the HIV-1 envelope is an important consideration in design of subunit vaccine strategies.

T.C.P.4

ENHANCEMENT OF LYMPHOCYTE-MEDIATED, HIV SPECIFIC ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY BY BIOLOGIC RESPONSE MODIFIERS

Murayama, Tsuyoshi and Rinaldo, G.R.
University of Pittsburgh, Pittsburgh, PA 15261, U.S.A.

Objective: To enhance antibody-dependent cellular cytotoxicity (ADCC) mediated by peripheral blood mononuclear cells (PBMC) obtained from HIV-infected subjects, and assayed by biological response modifiers (BRM) Pichilab¹ (OK432 streptococcal preparation, Chugai, Japan) and interleukin 2 (IL-2).

Method: PBMC from homosexual men with known duration of HIV infection and from HIV seronegative controls were examined for ADCC activity against HIV-infected CD8⁺ MNC cells (cell line resistant to natural killer activity) in a 4 h ⁵¹Cr-release assay. PBMC were pretreated with Pichilab or IL-2 for 16 h and then tested for ADCC activity. Serum from an HIV-seropositive homosexual man with ADCC activity was used as the source of antibody.

Results: HIV-specific ADCC activity of PBMC from HIV-seropositive homosexual subjects was significantly decreased in relation to duration of infection. The ADCC response was found to be significantly associated with numbers of CD4⁺ T cells, and CD8⁺ and low IgM NK cells. Additionally, ADCC activity of PBMC from HIV-seropositive and seronegative subjects increased 2-fold after pretreatment with Pichilab or IL-2. We are currently studying mechanisms of the enhancing effect of Pichilab pretreatment on ADCC activity.
Conclusions: Although PBMC from HIV-seropositive subjects can mediate ADCC, the response is impaired in association with duration of HIV infection. BRM-pretreated PBMC exhibited significantly greater ADCC activity than did untreated PBMC.

T.C.P.6

DIFFERENTIAL EFFECTS OF HIV INFECTION ON BLOOD MONOCYTES AND MACROPHAGES IN VITRO AND EFFECTS OF MONOCYTES AND

Ramall, E., Whittle J.M., Foley P., T. J. Dupra and Cunningham A.L. Viriopath and Infectious Diseases Unit, Vermont Hospital, Derby, Vermont, USA.

Monocytes and macrophages are important sites of HIV infection, especially in brain and lung nerves. The sites of differentiation and surface to which these cells adhere in vitro had a major effect on HIV infection and function of the infected cells. HIV infection of recently adherent CD8⁺ positive blood monocytes and five day adherent CD8⁺ negative macrophages with three fresh monotypic HIV isolates showed the differential kinetic pattern. HIV env₁ and p17 levels in infected monocyte cultures remained high for 24 weeks before decreasing and decrease of the cells occurred. Infection of macrophages (within M-CP stimulation) generated much lower HIV levels and to 4 of 4 cultures these declined to undetectable over the weeks leaving persisting viable macrophages. 75% of monocytes and 8% of macrophages were infected at one week (by ELISA). Subsequent infection by CD8⁺ monoclonal antibody almost totally blocked HIV infection of monocytes but had no isotype or no effect on macrophage infection, suggesting the presence of an alternate receptor. Isolation of selected human cell HIV antigens with CD8⁺ negative macrophages after infection with HIV had variable effects. Some sera had high neutralizing titres (1/100-1/200) whereas others produced significant neutralizing activity when the effect of neutralization was measured by production of neutralizing antibody to anti p17. HIV infection of the blood monocytes but not macrophages inhibited presentation of surface antigens or released toxic antigen in human thymocyte T lymphocytes. A known best stable inhibitory factor released by HIV infected monocytes has been identified and is being characterized.

**Session d'affichage
Poster Session**



**Recherche fondamentale (biomédicale)
Basic Research (Biomedical)**

T.C.P.7 **MONOCLONALS PREPARED FROM HUMAN MONOCLONAL ANTIBODIES
CAPABLE TO NEUTRALIZE RICKETS A CHAIN KILL HIV-INFECTED
LINES OF T CELLS AND MONOCYTES**

Solo-Tanaka, F.†††, **Thilly, G.†††**, **Grony NK,†††**, **Parsons S.†††**, **Wu JM,†††** & **Victoria RP.†††**
New York, NY: **MTU and CDC**, New York, NY. **†††** Univ. of Texas Southwestern Med. Ctr., Dallas, TX & **†††** Genentech, San Francisco, CA, USA

OBJECTIVE: To determine whether immunotoxins (ITs) composed of human monoclonal antibodies (mAb) and Ricin A are capable of killing lines of HIV-infected T cells (93) and monocytes (937).

METHODS: Two human IgG mAb specific for p31 were derived from RIV-7-infected B cells from the blood of HIV-infected patients. mAb were coupled to diglycosylated Ricin A chain (dGA) via a heterobifunctional cross-linker. Ricin IT or human IgG-dGA was cultured with HIV-infected 93 or uninfected 93 or 937 cells for 24 hr, and toxicity was assessed by plating cells with ³H-thymidine for 6 hr.

RESULTS: While IgG-dGA did not kill infected 93 or 937 cells at concentrations less than 10⁻⁷ M, both ITs killed 50% of infected 93 cells at 1.5 x 10⁻⁶ M. Similarly, both ITs killed 50% of infected 937 cells at 5 x 10⁻⁶ M. Addition of chloroquine to 937 cultures markedly potentiated specific killing of HIV-infected 937 cells resulting in an IC₅₀ of 4 x 10⁻⁶ M. The specificity of killing was established by showing that both ITs could be blocked by rgp120 but not by rgp120 or human IgG. Neither IT was cytotoxic for Class II⁺ T-lymphoid cells at concentrations below 10⁻⁵ M. **CONCLUSIONS:** ITs composed of human mAb to gp120 and diglycosylated Ricin A specifically kill lines of HIV-infected human T cells and monocytes.

T.C.P.8 **SELECTIVE INFEXION OF MACROPHAGE SUBSETS IN THE LUNG BY HIV**
Johnson, Margaret,††† Lester, L. W. Royal Free Hospital, London, U.K.

It is recognized that alveolar macrophages are a heterogeneous population. Subsets of this population can be distinguished by phenotype using monoclonal antibodies. In HIV-infected individuals the functional alveolar macrophage populations identified by the expression of viral proteins is seen to be a small proportion (2-10%) of total macrophage like cells in bronchoalveolar lavage (BAL). This study sets out to determine whether infection of alveolar macrophages is restricted to one phenotypically distinct subset or is indiscriminate. Sequential immunocytological techniques detecting viral proteins and discriminate antigens of macrophage subsets can be performed on cells spreads obtained from BAL of AIDS patients presenting with pneumonia. Probe to gp120, p24 and p17 proteins will be used in conjunction with MoAb DR11 (detects all macrophages), NP2 (identifying dendritic cells), NP97 (identifying sarcoplasmic reticulum), and UCM1 (identifying monocytes). The distribution of gp120, p24 and p17 antigen expression on each of the populations of cells will be described. The proportions of each phenotypically distinct subset of macrophages expressing viral proteins will be quantitated by performing cell counts. Results presented will reveal whether there is a selective infection of a particular subset of cells and/or whether HIV infection alters macrophage antigen expression. As previous studies have shown a relationship between cell phenotype and function, this study will also reveal whether HIV infection might alter the functional capacity of alveolar macrophage populations.

T.C.P.9 **NORMAL CAPACITY OF MONOCYTES FROM AIDS PATIENTS
FOR UPTAKE AND GROWTH INHIBITION OF MYCOBACTERIUM
AVIUM-INTRACELLULAR**

Johnson, John L.,††† **Shirahata, M.,†††** **Tobe, H.P.,†††** and **Elizer, J.,†††** **CDC Western Reserve University,** **Durham, NC,** **Cleveland, OH,** **Cleveland, OH,** **USA,** and **†††** **Oakac Prefecture Hakbiko Hospital, Osaka, Japan.**

Mycobacterium avium-intracellulare (MAI) is the most frequent cause of late disseminated infection in patients (pts) with AIDS. Interactions of monocytes (MN) from AIDS pts with MAI have not been reported. We examined phagocytosis and inhibition of MAI growth in an *in vitro* model. MN from 11 AIDS pts (3 with disseminated MAI (AIDS-DMA)) and 13 healthy volunteers were pretreated for 2 days and infected with 2 AIDS and 2 non-AIDS associated MAI strains. Uptake of MAI as detected by coating intracellular acid-fast bacilli was similar between AIDS pts, AIDS-DMA, and healthy controls. Intracellular growth of MAI was examined by a colony forming unit assay after 0, 4 and 7 days of culture. MN from AIDS pts were more effective in inhibiting intracellular growth of MAI at 7 d as compared to healthy donors for one of the AIDS-associated strains (p<0.05). Intracellular growth was comparable for the remaining strains. Pretreatment of MN with IFN-gamma for 2 days before infection decreased MAI uptake in both the AIDS and healthy group (p<0.05 for each strain). Culturing infected MN with IFN-gamma 300 U/ml augmented MAI killing at 4 and 7 days by 30-50% for both AIDS pts and healthy donors (p<0.05 for 3/4 strains tested). Healthy controls, AIDS-DMA, and AIDS pts showed comparable effects of IFN-gamma. Since MN from AIDS pts exhibit normal interactions with MAI, disseminated disease can be attributed to an absence of modulating effects of CD4 lymphocytes. The demonstrated *in vitro* activity of IFN-gamma in culture with MN from AIDS pts provides a rationale for its use in immunoregulatory therapy.

T.C.P.10 **DEFINITION OF A SUBSET OF CD4+ LYMPHOCYTES SELECTIVELY
INFECTED WITH HIV/NE USING THREE COLOR
IMMUNOFLUORESCENCE**

Chen, S.A.,††† **Gibbon, J. F.,†††** **Willford, D. A.,†††** **Gale, M.,†††** **Hoffman, P. A.,†††** and **Gallatin, M. D.,†††** **Clinton Foundation Research Center, University of Washington, Seattle, WA 98195,†††** **Hutchinson Cancer Center, Seattle, WA, U.S.A.**

In previous work, we found that macrophages infected with a strain immunodeficiency virus (HIV) isolated from *Rattus norvegicus* (HIV/RNO) have a selective depletion of CD4+ T cells expressing high levels of the CD44 class of adhesion molecule (CD44^{hi}). We determined that productive infection of HIV could be activated in CD44^{hi} CD4+ T cells taken from infected animals, but not in CD44^{lo} cells, and that the CD44^{hi} subset was differentially susceptible to HIV infection *in vitro* (Gallatin et al., PNAS in press, 1988). However, these subsets differ in their response to the mitogen necessary to activate and detect virus *in vitro*. Therefore, we adapted PCR technology for directly identifying HIV in lymphocytes without the need for subsets. We amplified a 596 bp sequence in the CR2 region and found HIV sequences per cell were restricted to the CD4+ CD44^{hi} subset. Next, the target of HIV infection was more precisely defined using color flow cytometry with fluorescein-tagged mAb to CD45R and DNAase. In addition to finding HIV in CD4+ cycling cells, we have also consistently detected viral sequences in CD4+ CD44^{hi} CD45R^{hi} cells which are not in S/G2. The possibility that this latter subset, which has a memory T cell phenotype, is an important reservoir for latent infection, is being explored. In parallel, using PCR technology to detect viral DNA and RNA sequences, we are exploring the kinetics and host cell requirement for early HIV expression in CD4+ subsets. (Supported by NIH grants R01HD15 and CA49372 and by a grant from the American Foundation for AIDS Research.)

T.C.P.11 **PILOT STUDY OF AMBI-LEUNA IN HIV-1 SEROPOSITIVES**
Shelton, D. C.,††† **Nabebech, D.B.,†††** **Gallegos, A.**
Clinical Research Center, Harrow, U.K.

Objective: The CD4 antigen is a receptor for all isolates of HIV. Murine anti-idiotypic antibodies to anti-CD4 monoclonal antibodies inhibit the formation of virus particle. HIV-infected lymphocyte cultures treated with anti-leu3a1(a) is an anti-CD4 antibody that blocks the binding of gp120 to CD4. This study was designed to assess safety (measuring HIV seropositive individuals with LHA, and to measure anti-idiotypic antibody response).

Method: Four HIV volunteers (Walter-Step 3 or 4) received 6 i.v. injections of 1 mg of LHA over a period of 10 weeks. They were monitored for 6 months post-treatment for acute toxicity, alteration of clinical status and routine haematological and biochemical parameters. Antibody response to LHA were measured. T-cell immunophenotyping was performed before each injection and at monthly intervals during follow-up, and at 1 and 24 hours after injection in the first 3 patients.

Results: All patients have completed treatment and two have completed follow-up. There were no adverse reactions to injection or significant changes in routine laboratory parameters or total CD4+ lymphocyte counts. All patients made anti-CD4 and anti-idiotypic antibodies to LHA, detectable at titres between 1/100 and 1/10,000. This was not associated with an increase in HIV neutralization titre, assessed by the spotymin inhibition assay.

T.C.P.12 **INTERACTION OF HIV AND THE COMPLEMENT SYSTEM**
Soldner, Brigitta,††† **Schmidt, J.,†††** **Hornig, G.,†††** **P. P.†††**
Lower, J.,††† **Wachter, H.,†††** **Dierich, M. P.,†††**
Austria,††† **Paul Ehrlich Inst., Frankfurt, FRG**

Objective: As several animal retroviruses have been shown to directly activate the complement system and to be lysed by human serum, we investigated the interaction between HIV and the complement system.

Methods and results: Purified HIV 1 was incubated with human serum and cleavage of the alpha chain of C3 and thus activation of the complement system was revealed using an immunoblotting technique. Recombinant envelope gp 160 was able to activate complement, too, in both cases activation required C4 and Mg indicating the predominant role of the classical pathway.

HIV-infected cells were lysed both in human serum and deposition of C3 was detected in an immunofluorescence assay and immunoblotting technique using an anti-human C3d antibody. In this case complement activation still occurred in the absence of C4 and thus via the alternative pathway. **Conclusions:** These results show that HIV as well as HIV-infected cells activate the complement system via the classical and alternative pathway, respectively. Supported by L.B.-1., State of Tyrol, BMBF

Session d'attachage
Poster Session



Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

T.C.P.25 **CD8-INH1- CELLS SUPPRESS THE HIV-SPECIFIC T CELL ACTIVITY.**
JOLY M¹, GUILLEIN J-M¹, AUBIN M¹, PLATA P¹, MAYAUD C¹, DEBIE
P¹, P¹, HENRI FILIP-DALEMPYRE P¹, L'AM
Jm. Bio. Mol. Retrovirus, 1 Pasteur, Paris; ²Dr. Prusko, Hôp. Tarnon, Paris.
OBJECTIVE: We have demonstrated HIV-specific cytotoxic T lymphocytes in lungs
and their presence is decreased during the course of HIV infection. The
aim of this study was to detect factors or cells with could down-regulate the
anti-HIV T cell response.
METHODS: Alveolar lymphocytes were recovered from 41 patients at various
stages of the HIV disease. Their cell surface phenotype was determined and
their cytotoxic function was tested against S100-labeled autologous alveolar
macrophages and cell lines expressing HIV proteins; both standard chromium
release assay and limiting dilution analysis (LDA) were performed. Various
cell subsets were tested for their putative suppressor function on HIV-speci-
fic cytotoxicity.
RESULTS: In patients with advanced HIV disease, in whom no significant CTL
activity could be demonstrated in bulk assays, effector CTL specific for
HIV could still be detected in LDA. The biphasic LDA plate suggested the
presence of suppressor cells if analysis of alveolar lymphocytes revealed a
progressive increase of CD8-INH1- cells that suppress plus regression of
anti-HIV CTL activity. Selection experiments and IF cell sorting demonstrate
that alveolar CD8-INH1- lymphocytes suppress the effector phase of anti-HIV
CD8-INH1- lymphocytes. The effector phase of anti-HIV CTLs as well as
anti-HLA CTL lysis was not HIV-restricted. The CD8-INH1- cells did not
kill R502 cells but the HIV-specific effector CTLs were inhibited. In fact
CONCLUSION: Suppressor T cells could thus explain the inefficiency of host
cellular immune defenses against HIV.

T.C.P.27 **ANTIGEN-INDUCED T LYMPHOCYTES ARE PRESENT IN HIV-INFECTED
INDIVIDUALS WHO ARE NON-REACTIVE IN CONVENTIONAL
LYMPHOCYTE PROLIFERATIVE ASSAYS.**
Subst. Staffing: Adams, P. Oncol. C. Pava, M. Fass, R. and Whitaker, C.; The Ohio State University
AIDS Clinical Trials Group, Columbus, Ohio
OBJECTIVE: The lymphocyte proliferative response to soluble antigens such as tetanus toxoid has
been reported to be absent in HIV infection. We examined the response to tetanus in HIV-infected
individuals using conventional lymphocyte proliferative assays in comparison with limiting dilution
analysis (LDA), where a frequency of tetanus toxoid specific T cells can be determined.
METHODS: Bulk proliferative responses of peripheral blood mononuclear cells (PBMC) from ARC,
asymptomatic and seronegative controls were assessed by the uptake of ³-H thymidine after 100
hours of culture with tetanus toxoid. For the LDA, PBMC were serially diluted and cultured with
tetanus toxoid and irradiated autologous T cells for 20 hours. Antigen-reactive cells were
detected by the production of IL-2 using the E dependent cell line, CTL-20. LDA frequencies
were calculated using Poisson distribution.
RESULTS: Lymphocyte proliferative response to tetanus were detected in all control subjects, 5 of the
4 symptomatic persons but none of the ARC patients tested. By LDA, control individuals showed
18576 ± 116,690 (66-104 per 10⁶) tetanus-reactive lymphocytes, asymptomatic persons showed
12685 ± 101,730 (24-442 per 10⁶), and ARC patients showed 116,187 ± 117,046 (66-62 per 10⁶)
lymphocytes. Therefore, discrepancies between proliferative and LDA responses were particularly
obvious in the ARC subgroup of patients.
CONCLUSION: Tetanus-specific lymphocyte secreting cells can be detected in HIV infected individuals
by LDA even when conventional bulk proliferative responses to tetanus are absent. These results
raise important questions about the interpretation of data from lymphocyte bulk proliferative assays
regarding the presence or absence of immune responses. (Supported by NIH grant AIDS P30
A22824)

T.C.P.29 **RELATIONSHIP BETWEEN ANTIBODY AGAINST THE C-TERMINAL
REGION OF GP120 AND PRESENCE OF HIV SPECIFIC
RESPONSES.**
Polonia, Victoria; Hawn, N. * Lee, T. ** Essex, M. ** Burke, D. **
Hendfield, R. B. * Walter Reed Retroviral Research Group and ** Harvard
University, Boston, MA
OBJECTIVE: Characterization of the humoral immune response to the HIV-1
envelope antigens and correlation to stage of infection and ability to
isolate HIV-1 from CSF. **METHODS:** Serum and cerebrospinal fluid from 126
clinically staged patients were characterized with protein dot blot and
Western blot techniques. Antibodies against gp160, gp120 and the specific
regions of gp120 (448c) were studied.
RESULTS: A correlation was found between the presence of specific antibody
(0-48C); clinical stage and inability to isolate virus. This correlation was
not found with antibody titers to gp160 and gp120. Antibody to 448c
was detectable in 70% (46/66) of Walter Reed Stage (WRS) 2-3, as compared
to 28 (11/31) WRS 4+. Antibody to 448c was detectable in 73% of virus
isolation negative and 41% of viral isolation positive patients. Of
seven from WRS 1-2 patients, 73% (5/7) virus isolation negative and 52
(10/19) virus isolation positive demonstrated 0-48C. Of the seven from WRS
5-6 patients, 26% (7/27) virus isolation positive and 67% (4/6) virus
isolation negative demonstrated 448c.
CONCLUSION: These data demonstrate that 448c contains an epitope(s) which
correlates with inability to isolate virus from CSF. These data also
demonstrating a relationship between 0-48C and parameters of effective
viral immune regulation.

T.C.P.26 **AN ILA-OR, LIGHT DENSITY, PERIPHERAL BLOOD MONONUCLEAR CELL
PRODUCES ALPHA INTERFERON IN RESPONSE TO HIV**
Rissold, Charles; Tove, J.; Rappaport, C.; Gupta, P. and
Perhas, J. University of Pittsburgh, Pittsburgh, PA 15261, U.S.A.
OBJECTIVE: To characterize alpha interferon (αIFN) production induced by
HIV in cultures of peripheral blood mononuclear cells (PBMC).
METHODS: PBMC from healthy HIV seronegative donors were enriched for differ-
ent subpopulations and incubated for 16 hr at 37°C with HIV-infected 9327
(9327) promonocytic cells. Supernatants were assayed for αIFN by anti-
viral activity in human WISH cells; by neutralization with antiserum to αIFN,
and by stability after treatment at low pH.
RESULTS: Percent gradient density and flow cytometric analysis showed that
light density, ILA-OR⁺ PBMC were responsible for production of acid-stable
αIFN in response to 9327.
CONCLUSION: PBMC which produce acid-stable αIFN in response to HIV-infected
promonocytic cells are light density and ILA-OR⁺ and are not present within
the predominant populations of T_H1, T_H2 and anergic cells. Smaller subpopulations
of light density, ILA-OR⁺ PBMC have been associated with augmented
αIFN production, and did not suppress less than 1% (NK cell marker).
NK cell lysis of HIV-infected promonocytic cells (Rappaport, et al., J.
Clin. Micro. 27:41, 1989).

T.C.P.28 **THE IMPERMEABILIZATION OF NERVE IMMUNOREACTIVITY VIRUS IN
NERVE SODAS**
Emond, Joseph; Polonia, V. * Hawn, N. * Lee, T. * Hix, D. *
Hendricks, R. * Burke, D. * Hendfield, R. * * Walter Reed Retroviral
Research Group, Washington, D.C. U.S.A.
OBJECTIVE: To characterize the humoral immune response to HIV viral
specific proteins and epitopes in the male genital tract.
METHODS: Ten male HIV seropositive subjects were evaluated to
characterize the immune response against HIV viral proteins and epitopes
in the seminal plasma as compared with matched sera. In vivo viral
antigen load in the two compartments was evaluated by isolation of HIV
from semen and peripheral blood, and by measurement of free p24 in seminal
plasma and sera.
RESULTS: Antibody production against viral envelope proteins are
observable in seminal plasma and sera however, there is a marked decrease
in reactivity against specific HIV structural proteins in the seminal
compartment. The presence of antibodies against unique envelope epitopes
is currently being evaluated. Eight of ten HIV (+) subjects had positive
peripheral blood cultures for HIV. Of these eight subjects, only two had
positive semen cultures for HIV.
CONCLUSION: These differences may reflect either poor antibody production
or differential viral protein expression in the male reproductive tract.
This data supports the concept that the male reproductive tract is a
privileged immunologic site.

T.C.P.30 **CYTOKINE AINER SUSCEPTIBILITY OF HUMAN MONOCYTES TO
INFECTION BY HIV-1**
Gillespie, David B., Gendelman, H. M., Holtzer, M. **, and
Walter Reed Retroviral Research Group, Walter Reed Army Medical Center, "M.H.
Research Foundation, Walter Reed Army Institute of Research, Washington,
D.C., United States of America
OBJECTIVE: Evaluate effects of cytokine pretreatment on the interaction of
HIV-1 with blood-derived monocytes in vitro.
METHODS: Human monocytes (interleukin 1, 2, 3, and 4) have been shown to be
altered and infection in media with recombinant human colony stimulating
factor-1 (M-CSF), Onco Corp., Bayville (IL). After 7 days, any of several
recombinant human cytokines (interleukin 1, 2, 3, and 4) have been added to
as 0M-CSF, interleukin 1, 2, 3, and 4 were added at 5 to 500 units/ml for 24
hours to M-CSF-treated monocytes. All cultures were washed. HIV RNA, a
monoclonal anti-HIV-1 strain, was added to pretreated and control monocytes.
Culture fluids were monitored for viral p24.
RESULTS: Viral p24 antigen was detected 2 weeks after HIV infection in all
M-CSF-treated control monocytes cultured without additional cytokine
pretreatment. Most cytokines had little or no effect on p24 release over
this time interval. In contrast, levels of p24 antigen in culture fluids
were significantly reduced by 5 to 500 units/ml M-CSF.
CONCLUSION: Pretreatment of monocytes with any of several different
cytokines alters infectivity of HIV for monocytes. Such *in vitro* testing of
immune-modulating agents may prove beneficial in the selection of therapeutic
regimens for infected individuals.

Session d'attachage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

T.C.P.37 IDENTIFICATION OF COMMON EPITOPES OF HIV 1 AND HIV 2 BY MONOCLONAL ANTIBODIES

Zur, Bernd and Habermann, K.-O.
Institute for Clinical and Experimental Virology, Free University of Berlin, Hindenburgdamm 27, 1000 Berlin 45, FRG

26 monoclonal antibodies were prepared, directed against our HIV 2 isolate with intertypic characteristics (HIV-MDS) and tested against HIV 2 (NH2), HIV-1 (HTLV 3B) and HIV-MDS. The tests were performed with ELISA, RIPA, and Western Blots prepared by sucrose-gradient-purified antigens as well as by recombinant envelope protein from HIV-1 (aa 350 - aa 750, Dupont). 8 of the monoclonal antibodies directed against the envelope reacted group-specifically with all virus antigens. A second group of 8 monoclonals detected against sucrose-gradient-purified antigens as well as by recombinant envelope protein from HIV-1 (aa 350 - aa 750, Dupont). 8 of the monoclonal antibodies directed against the envelope reacted group-specifically with all virus antigens. A second group of 8 monoclonals detected against gag-pol reacted also with all virus antigens. A third group of 10 monoclonals directed against structural and non-structural virus proteins reacted type-specific just with the HIV-2 isolates. The significance of the identified epitopes for the neutralization of the virus strains has been determined.

T.C.P.39 HIV INDUCED, HIV SPECIFIC IN VITRO ANTIBODY RESPONSE.

Zszo-Francoise Balfrainy, C. Wallon, F. Boas, J. Dorment, P. Galanoud, F. Barre-Sinoussi
INSERM, U 131, Clamart, Institut Pasteur, Paris, France.

Objective: To induce specific B cell response to HIV protein or env gp160 protein.
Methods: Purified B were cultured in vitro in the presence of purified T cells or IL2, with different preparations of HIV unfractionated protein preparation. The specific HIV response were measured by ELISA and Western Blot.
Results: no response was observed in negative donor. In HIV positive, HIV induced a specific antibody response. Anti HIV ab were only obtained when T cell help was provided by Interleukin 2 and Interferon alpha but not in the physical presence of T cells. Anti HIV ab produced in cultures were predominantly directed against gp160 and or gp120. In vitro antibody production was inhibited by cyclosporin, anti env 3, man, but inconsistently by anti CD4. The antibody responses required the presence of autologous monocytes which can be replaced by Interleukin 6. Allogenic monocytes are not functional. Identical results were observed with gp160 peptides.
Conclusion: HIV specific in vitro antibody response directed the env proteins can be induced in HIV+ patients, but not in HIV- controls.

T.C.P.41 FcR expression in HIV-1 infected T cell Lines

C. Corini, M. Chierohi, F. Aiuti, Dept. Allergology & Clinical Immunology, Univ. of Rome "La Sapienza", Rome, Italy.

It is well known that HIV transformed B lymphoblastoid cell lines, such as SP 1866, express a large number of FcR on their surface. It has been recently reported that mRNA encoding the FcR β was not detected in normal human T cells or T cell lines except HIV-1 transformed T cell lines. These findings suggest to us the possibility that infection of T cells with another retrovirus HIV-2 might induce the expression of FcR on T cells or formation of IgG β . We then tried to analyze the presence of FcR on 3 HIV infected T cell lines by cytofluorescence by using double staining with anti-CD4 or anti-CD8 and an anti-FcR monoclonal antibody. To detect the presence of IgG β in the culture supernatant of these HIV infected T cell lines a passive inhibition assay was used. Preliminary results of the HIV infected T cell lines studied indicate that to only one showed a clear expression of FcR at 3 days of culture as analyzed by cytofluorescence. In contrast the presence of IgG β was seen in 2 of the 3 lines examined. These preliminary results indicate that infection of T cells with HIV-2 could induce the expression of FcR on T cell lines and the formation of IgG in the culture supernatants of the T cell studied.

T.C.P.38 EFFECT OF HIV ON ANTIGEN-INDUCED T CELL PROLIFERATION

David, Sarah*, Berrett, R.*, Dornier, F.*, Gallo, R.C.**, Ehl, H.M.**, Nishiura, C.M.**,
*IMMO AG, Innsbruck, Austria; **Inst. of Immunology, Univ. of Vienna, Austria; **M.C.I., N.I.H., Bethesda, USA.

Objective: Examination of antigen-induced T cell proliferation in response to a particulate antigen (Ag) and tetanus toxoid following infection of the cells by HIV. **Methods:** In one set of experiments, monocytes (Mo) were pulsed with antigens prior to co-cultivation with autologous T cells and HIV (HIVEX-1001) (Mo). In the second set of experiments, both HIV and antigens were added to the cultures upon initiation of the incubation period. Antigen-induced T cell proliferation was measured by ³H-thymidine incorporation after 7 days of incubation. **Results:** A difference was found when either pre-pulsed or non-pulsed Mo stimulating the HIV-induced T cell proliferative response in the presence of infectious HIV. HIV caused a dose-dependent suppression of antigen-induced T cell proliferation in the presence of the pre-pulsed Mo. T cell proliferation in response to tetanus toxoid-pulsed Mo decreased from 4.1 ± 2.8 dpm \pm s.d. \times 10³ in the absence of HIV to 0.8 ± 0.1 dpm \pm s.d. \times 10³ in the presence of HIV (MOES 100). The simultaneous addition of antigen and infectious HIV to the Mo in the second set of experiments led to an increase of T cell proliferation, e.g. in response to tetanus toxoid, T cell proliferation increased from 25.0 ± 1.2 dpm \pm s.d. \times 10³ in the absence of HIV to 68.5 ± 5.7 dpm \pm s.d. \times 10³ in the presence of HIV, MOES 100 (Mo). Similar data were observed with Ag. **Conclusion:** Addition of infectious HIV to co-cultures of T cells and antigen-pulsed Mo results in a 2.5 fold increase of antigen-specific T cell proliferation. Conversely, the simultaneous presence of T cells, Mo, antigens and HIV in the cultures leads to an increase of the antigen-induced T cell response.

T.C.P.40 TUMOR NECROSIS FACTOR INHIBITS ACTIVATION OF B CELLS BY HUMAN IMMUNODEFICIENCY VIRUS (HIV)

Zszo-Francoise Balfrainy, C. Wallon, F. Boas, P. Galanoud and F. Barre-Sinoussi. INSERM, U 131, Clamart, Institut Pasteur, Paris, France.

Objective: In vitro HIV induced B cell proliferation. However the precise interactions between HIV and first steps of B cell activation and with B lymphokines are poorly understood. **Methods:** We have investigated the effects of recombinant human tumor necrosis factor alpha (TNF alpha) on human B cell proliferation. Human B cells were activated by anti-mu ab, B lymphokines (12 Id MOCP, 12 Id, Polvoked nitrogen (PWN) or HIV unfractionated protein preparation. **Results:** TNF-alpha acts as a B cell growth factor on anti-mu activated B cells. TNF-alpha does not modify the B cell proliferation induced by anti-mu ab and lymphokines or PWN. HIV preparation supports a moderate B cell proliferation enhanced by the 12 Id MOCP or IL2. TNF alpha inhibits in a dose dependent manner the HIV induced proliferation. This effect is not due to a cytotoxic activity and is observed in the absence of monocytes. Interferon alpha and gamma have no inhibitory effect in the same culture conditions. **Conclusion:** We conclude that TNF alpha can selectively modulate the B cell activation induced by HIV in vitro.

T.C.P.42 PREVALENCE OF ANTI-HEL POSITIVE BERA IN HIV-INFECTED PATIENTS: IMPLICATION OF THE MAJOR EPITOPES OF THE PROTEIN LAMIN B SYNTHETIC PEPTIDES.

BARRAGAN ECHIBURU, M. VAN RIETSCHOTEN, A.L., GRANIER, C.T., OLLODMAN, J.C., J...
MONTAGNER, L., SABAITER, A.M.

* INSTITUT PASTEUR PARIS
* CNRS UA 1179 MARSEILLE
* CERS-PAFIS, FRANCE

Objective: To study the prevalence of anti-hel positive sera in HIV-infected patients and to map the immunodominant epitopes using synthetic peptides.

Methods: Human sera were tested for the presence of anti-hel antibodies by RIA with recombinant 125 I-labeled expressed in E.coli and by ELISA using synthetic peptides.

Results: Among the HIV positive sera tested by RIA 70 \pm 6.5 % were found anti-hel positive. Anti-hel antibodies bound to hel with high affinity (K_D 5.5 - 2.2 10⁷ M). Anti-hel positive sera were assayed on a set of synthetic peptides (ranging from 11 to 86 a.a. and spanning the total sequence of hel from HIV-1), which showed a significant diversity of the immunodominant antigenic sites. A strong immunoreactivity was observed with either N-terminal or C-terminal regions meeting a heterogeneity of the humoral response against hel.

Conclusion: These results provide a means for an early diagnosis of HIV infection based on the detection of anti-hel antibodies using synthetic peptides.

Session d'affichage
Poster Session



Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

T.C.P.43 INCREASED SERUM LEVELS OF SOLUBLE IL-2 RECEPTORS (sIL-2R) IN HIV INFECTION: CORRELATION STUDIES AND CLINICAL SIGNIFICANCE
André Jean-René Courroux, G. Levy, S. ; Alekajevic, A. ; Lehr, L. and Koch, J.
Université Louis Pasteur, Strasbourg, France.

Objective: To gain further insights into the cell origin(s) and clinical significance of elevated sIL-2R in HIV infection.

Methods: sIL-2R were measured using a sandwich enzyme immunoassay in 105 consecutive HIV-infected subjects. Data were further correlated with biological markers of disease activity. Follow up studies were performed every 4 months in untreated and AZT-treated individuals. To assess whether elevated sIL-2R may contribute to the immune defect sIL-2R were generated in vitro and supernatants were tested for inhibitory activity on NK cell activity and lymphocyte transformation.

Results: The increase of sIL-2R in HIV-infected patients was confirmed, but in our series subjects presenting with PGL showed significantly higher sIL-2R levels than asymptomatic individuals (p. 0.001). Increased sIL-2R were strongly correlated with neopterin and beta-2 microglobulin. No correlation was found with CD4+ cell counts, CD4+/CD8+ ratio, activated T cells (CD3+, IL-2R+) or serum IgG. Follow up studies showed an increase of sIL-2R with time and without clinical evidence for progression. Follow up studies in AZT-treated patients will also be presented. Analysis of the in vitro studies is still ongoing and will be reported at the meeting.

Conclusion: The data strongly suggest that elevated sIL-2R in HIV infection reflect neither monocyte and possibly B cell alterations than T cell activation and/or destruction. The significance of sIL-2R as a marker for progression will be discussed as well as their contribution to the immune defect.

T.C.P.44 LOW LEVELS OF LFA1+ CELLS IN HIV INFECTION
André Courroux, Robert, J., May, Th., Bess, M.C., Faure, G., Canton, Ph., Department of Infectious Diseases and Lab. Immunology, CHU Nancy France

Objective: LFA1 (Lymphocyte Function Antigen 1) is a membrane molecule of the CD35 family, involved in cell-to-cell interactions and more specifically expressed on more than 90% matured cells in the peripheral blood (PB). In a previous study, we established that significantly lower percentages of lymphocytes of PB lymphocytes expressed this molecule in HIV-infected patients. These data suggested that a decrease in LFA1 expression could be involved in the immunodeficiency of HIV- and AIDS patients. This observation was confirmed in a new series of patients, and a follow-up study was performed.

Methods: LFA1 expression on PB lymphocytes was studied using classical indirect immunofluorescence techniques with a monoclonal antibody from Immunotech (Luminy-France). Patients were divided in two groups, according to CDC classification (group I= stage II and III; group 2=IV1 and IV2).

Results: In spite of careful monitoring and therapeutic attempts with AZT, low levels of LFA1+ cells persisted in initially "low" patients. Patients with a progressive decrease of LFA1+ cell percentage under 30% were developing AIDS-disease at this time.

No correlation was found for the two groups between CD4+ cells count and LFA1+ cells, no more between CD4+ and LFA1+.

Conclusion: LFA1 expression in HIV infection is significantly decreased, similar to the immune deficiency of CD4+ cells, and could represent a new predictive factor of AIDS on a long-term follow-up.

T.C.P.45 EXPRESSION OF THE T-CELL RECEPTOR MOLECULE IN HIV INFECTION
André Courroux, Bess, M.C., May, Th., Faure, G., Canton, Ph., Department of Infectious Diseases and Lab. Immunology, CHU Nancy - FRANCE.

Objective: T lymphocytes recognize foreign molecules using the T-cell receptor (TCR), a disulfide-linked heterodimer, closely associated with the CD3 polypeptide on the cell surface. We studied in a series of 130 HIV patients, the expression of the TCR molecule in addition to those of CD3, CD4, CD8 and IFA1 (adhesion) molecules, on peripheral blood lymphocytes (PB).

Methods: Classical indirect immunofluorescence techniques were used, with monoclonal antibodies from Coulberrines (for CD3, CD4, CD8), Immunotech (for IFA1) and Decton-Biotinman (for TCR-alpha chain).

HIV patients were divided in two groups, according to CDC classification: group 1 = stage II and III (N=100); group 2 = stage IV1 and IV2 (N=30).

Results: As expected, a highly significant correlation was found between CD3 and TCR + cells percentages, in both groups. But TCR percentages (respectively 46.7 and 31.2 for groups 1 and 2) were constantly lower than CD3 (61.4 and 57.7). The TCR/CD3 ratio was 0.8 (gr1) and 0.5 (gr.2).

Conclusion: These data show a defective expression of TCR, occurring even at an early stage of HIV infection. This may add to the immune deficiency.

T.C.P.46 MOST SERA FROM HIV INFECTED INDIVIDUALS CONTAIN HIV ANTIGEN AS IMMUNE COMPLEXES
Hélène, Pascale, Havaux, S., Basso, S., Deves, N., and Faure, J., UCLA Schools of Medicine and Public Health, Los Angeles, CA, USA. E.L.D. Port Co., Orange, CA, Whittney, DE, USA.

Objective: To develop a method for improved detection and quantitation of HIV p24 antigen and to check whether the loss of detectable HIV antigen while the viral titers of asymptomatic HIV seropositive could be due to low or absent synthesis of viral antigen and/or to the formation of immune complexes containing HIV antigen.

Methods: Detection of immune complexes and quantitation of antibodies with little or no coagulation of HIV antigen by low pH treatment of the samples before detection by ELISA.

Results: In control experiments with artificial mixtures of HIV antigen and HIV antibody no problem was seen. It was demonstrated that: 1) In both positive mixes were caused by the treatment; 2) High HIV antigen positivity (45 vs 10%) as well as the amount of measured antigen were significantly increased; 3) while only 60% HIV antibody positive sera contain free antigen, in many sera the antigen is in the form of immune complexes; 4) detectable HIV antigen was detected by ELISA.

Randomly selected HIV antibody positive sera (N=110) from asymptomatic patients were tested for p24 antigen in serial dilutions after and after precipitation. Substantive increases (median 51.7% vs 11.8%) and fold factor 3.8 were obtained after precipitation. Similar increase (58.7% vs 34.8%) was observed for the group of 40 tested AIDS sera.

Thus an additional 60% of sera from both groups contain p24 antigen in the form of immune complexes which are detectable only after precipitation. Sera from both consecutive tests (20 month period, 6 month follow up) of retrospective seroconverters were tested for presence of p24 antigen after detection of immune complexes. Seven individuals (37.5%) never express any kind of detectable antigen, but 80.0% showed significant p24 positivity and 19.50% positively seroconvert. One case is shown in their details. The antigen can be directly detected only at periods when antibody-antigen ratio is low. At higher ratio p24 antigen is present as immune complexes and can be detected only after precipitation.

Conclusion: HIV sera from HIV infected individuals contain HIV antigen. It is mainly in the form of immune complexes and can be detected by the proposed method. The results suggest that most patients of HIV infection seroconvert to sera. One group of individuals never express HIV antigen, another relatively large group predominantly shows p24 and only a small group shows significant p24 positivity.

T.C.P.47 PROTECTIVE IN VITRO HIV INFECTION OF NORMAL CD8+ LYMPHOCYTES
Richard E. and Lewis, D.E., Howard Hughes Medical Institute, Department of Microbiology and Immunology, Baylor College of Medicine, Houston, TX, U.S.A.

An increase in the numbers of CD8+ lymphocytes occurs early in HIV infection. The role of CD8+ cells in HIV infection is not clear; however, several laboratories have shown that CD8+ cells play a protective role. In order to develop an *in vitro* system to study the effects of HIV infection on normal CD8+ T cells, peripheral blood lymphocytes (PBs) from HIV-negative donors were cultured with phytohemagglutinin (PHA) for 3 days and then infected with HTLV-IIIIB. After reculture for 3 days, infected cells were irradiated and cocultured with uninfected PBs from the same donor. Previous results indicated that most CD8+ cells are depleted in such cultures after 6 days (FAHNS 2: 2251, 1988). Cocultures and control uninfected cultures were grown in recombinant interleukin 2 for more than 3 months. HIV was monitored by electron microscopy and by p24 antigen ELISA. Cocultures were strongly positive for HIV p24 whereas uninfected control cells were negative. On day 26 after the start of the cocultures, cells were sorted into CD8+ and CD8- cellular fractions. The sorted infectious CD8+ fraction was strongly positive for HIV p24 (1.3x10⁶ IU/ml) however, the CD8- infectious fraction was only weakly positive (0.2x10⁶ IU/ml) when compared to HF-infected control cells (1.457 x10⁶ IU/ml). Thus, CD8+ cells can become productively but nonproductively infected with HIV. This may result from the development of a CD8+ CD8+ intercellular cell or after direct cell-to-cell transmission. The relevance of this data to the CD8+ cellular abnormalities in AIDS is unclear but suggests that HIV interactions may be more complicated than previously appreciated.

T.C.P.48 CD8-DRIVEN PEPTIDE PROTECTS CD4+ T CELLS FROM HIV-1 INFECTION
Robert, J., Bess, M.C., May, Th., Bess, M.C., Faure, G., Canton, Ph., Department of Infectious Diseases and Lab. Immunology, CHU Nancy France

Objective: To identify primary sequences within the CD8 molecule that may be involved in the killing of the HIV-1 envelope. Maybe be synthesized with respect to corresponding to different domains of CD8 molecule. HIV-1 gp120 (100 ng/ml) was pre-incubated with CD8-derived peptides before adding to HIV-1 infected cells. HIV-1 infectivity was measured by staining cells with OX74 or Leu24 using FACS analysis. HIV-1 infectivity was measured by ZAIRF were added to BOUT cells in the presence or absence of CD8-peptides. Blocking of apoptosis formation was measured after 2 days.

Results: We identified a 20 amino acid peptide (aa 74-95) which was able to block HIV-1 infection of CD4+ T cells from infection by different, divergent strains of HIV-1 (at a concentration of 25-50 µg/ml). A shorter fragment of the CD8-transmembrane peptide (aa 81-95) was needed at higher concentrations (1250 µg/ml) in order to block 100% of apoptosis formation following infection with HIV-1. Inhibition of giant cell formation was also seen when the peptide was added 2h after the induction of viral infection. The CD8-peptide (74-95) and the shorter fragment (81-95) succeeded (in a similar efficiency) to block HIV-1 gp120 binding to CD4+ T cells. HIV-1 gp120 and CD8-derived peptides examined had no effect on gp120 binding and did not block giant cell formation induced by HIV-1. HIV-1 gp120 binding to CD4+ T cells provided particles (40%) protection against HIV-1 gp120 binding to CD4+ T cells.

Conclusion: The CD8 region (74-95) participates in the CD8-mediated killing of the HIV-1 virus and may be of diagnostic value in blocking spread of the virus in infected individuals.

Session d'affichage
Poster Session



Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

T.C.P.49 HIV-1 DISEASE STATUS AND SEROREACTIVITY TO GAG, POL, AND ENV GENE PRODUCTS

Abstract: Phillips F., Grove, T., Chagn, C.S., Mokkian, C.W., White, G., and Matthews, J. *Ochsle University Medical Center, Durham, N.C. *University of North Carolina, Chapel Hill, NC, USA

Objective: To determine possible relationships between HIV-1 disease status and seroreactivity to gag, pol, and env gene products.

Methods: Blood sera from 360 seropositive hemophiliacs were assayed for reactivity to synthetic envelope V3 loop peptides and 7 bacterial recombinant peptides (REAGENTS). The latter represent HIV-1 (IIIB) gp120, gp41, p55, p51, and p66/RT. Disease status was determined by absolute T cell count and, when available, Western-blot stage.

Results: Correlations between seroreactivity to the various gene products and disease status were analyzed. Reactivity to the immunodominant envelope V3 loop peptides was found to be elevated in the hemophilic population since 1985 is probably not too late to expose to newly infecting isolates but would rather suggest a mixture over time of the original genotypes present in the pre-1985 Factor VIII concentrates.

Conclusions: About 50% of the 360 sera were positive for the N-terminal gp120 recombinant fragment (arg. absence 2800), whereas 93% were positive for the C-terminal fragment (arg. absence 12736). Reactivity to V3 loop peptides was only 35 for the IIIb peptide vs. 80% for 66.

T.C.P.50 PHENOTYPIC CHARACTERIZATION OF THE EXPANDED CD4⁺ T_H CELL POPULATION IN PATIENTS WITH HIV INFECTION

Abstract: Sica, A., McCune, J.A., and Richman, D.C. University of California, San Diego and the VA Medical Center, San Diego, CA, USA.

Objective: To determine whether the abnormal subpopulation of CD4⁺ T_H cells in HIV infection belongs to a specific subset which can be characterized by co-expression of additional antigenic markers.

Methods: Highly purified CD4⁺ cells (90%) were isolated from peripheral blood lymphocytes by negative selection through serial steps of "panning" and complement-mediated lysis. Dual-stain (FITC/PE) monoclonal antibody analysis was performed by automated flow cytometry on these CD4⁺ cells, effectively giving a triple antigenic population. Samples from 20 HIV seropositive subjects (10 asymptomatic, 12 ARC, 2 AIDS) were analyzed and compared to 15 healthy HIV seronegative controls (10 non-smoking males, 5 homosexual males, HC).

Results: The CD4⁺ phenotype subpopulation of CD4⁺ T_H cells is abundantly expanded in HIV seropositive subjects and comprises major cell populations in both the asymptomatic and the asymptomatic AIDS/ARC, mean of 40% (range, 18-60%; asymptomatic HIV⁺ 30% (18-45%); HM controls, 10% (range, 5-18%; HIV⁻ 9% (3-18%)). Because HIV seropositive men (HIV⁺ vs. HIV⁻) were of this cell subset, it has been questioned whether this population has any direct relationship to the disease process in HIV infection. Our study demonstrates that HIV⁺ men have a major portion of the CD4⁺ T_H cells which express the cell activation marker Lys-1/OK-170. 69% and 41% in ARC/AIDS and asymptomatic HIV⁺ seropositive men, respectively, compared to 20% of the CD4⁺ T_H cell subset from healthy seronegative men. This expanded, activated CD4⁺ T_H cell subset is also characterized by the expression of the α chain of TCR- γ (94%) and, therefore, is part of the mature T cell population consisting of asymptomatic HIV⁺ (40%) and the HIV⁻ controls (45-50%).

Conclusions: The expanded CD4⁺ T_H cell subset found during HIV disease progression appears to be derived from a distinct cell subgroup which is phenotypically different from that found in uninfected subjects, and may prove to be functionally heterogeneous as well.

T.C.P.51 IMMUNODOMINANT EPITOPES OF GP120: A POTENTIAL OBSTACLE FOR VACCINE DEVELOPMENT

Abstract: Wang, W. F., Wang, R.D., Huang, M., Lee, Tzung-shi, et al. Harvard School of Public Health, Boston, MA, USA.

Objective: The mature gp120 has 18 epitopes that are conserved in nearly all HIV-1 isolates. The double-bridge dependent epitopes of gp120 are immunogenically more dominant than the double-bridge independent epitopes. The predominant type of gp120 antibodies detected in susceptible people are those that are directed to the double-bridge dependent epitopes of gp120. Our working hypothesis is that double-bridge dependent epitopes serve an immunomodulatory role and act largely non-protective antibodies. The objective of this study is to remove the immunomodulatory double-bridge dependent epitopes from the HIV-1 gp120.

Methods: The approach of site-directed mutagenesis was carried out to replace cysteine residues with other amino acids in gp120. The antigenicity of the genetically-modified gp120 was studied by radioimmunoassay and Western blot assays.

Conclusions: HIV-1 gp120 mutants that lost immunodominant epitopes yet remained infectious were identified. Such mutants may have a better potential to induce functionally important gp120 antibodies.

T.C.P.52 DIFFERENCES AMONG LYMPHOCYTE SUBPOPULATIONS IN HIV POSITIVE OR NEGATIVE HOMOSEXUAL AND HETEROSEXUAL MALES

Abstract: Schellhain-Bialk, Gerald; Meier, M. B.; Jones, S.B.; Pife, R.H., and Walker, E.H. Dept. Medicine, Indiana Univ. Sch. of Med., Indianapolis, IN, U.S.A.

Four-color flow cytometry was used to determine surface antigens on peripheral blood lymphocytes. Volunteers included normal, heterosexual males (N=20), HIV-1 homosexual males (H=20), or HIV-1 homosexual males that were divided into two groups based on a total CD4/IL-2 blood count of >500 (H<2), or <500 (H<2).

Statistical significance was accepted at $p < 0.05$. The CD8⁺ lymphocytes was significantly greater in HIV-1⁺ homosexuals (H<2) compared to heterosexuals (N2) and even greater in the HIV-1⁺ >500 group (43%) and <500 group (48%). The CD8⁺ cells that also expressed CD38, an activation antigen, but not CD45 (a marker which reflects indices of expression on the CD4 background), was significantly greater in the HIV-1⁺ <500 group (7%) and <500 group (4%) compared to HIV-1⁻ males (1%).

The significant increase in CD4/CD38 expression between the <500 and >500 groups could be attributed to 7/23 individuals in the <500 group whose sera was positive for HIV p24 antigen. The CD8⁺ cells that expressed both CD38 and CD45 was significantly greater in the <500 group (8%) compared to the >500 group (3%), and could not be accounted for by p24⁺ individuals.

Therefore, CD38 alone on CD8 cells may reflect active viral replication, whereas CD38 and CD45 on CD8 cells may represent a subset alteration that correlates with progression of the disease. This work was supported by NIH U10 AI 2889-01 AIDS.

T.C.P.53 ENVELOPE GLYCOPROTEIN OF HIV-1 LIMITED EXPRESSION OF mRNA FOR IL-2 RECEPTOR FOR IL-2-INDUCED T CELL CLONES

Abstract: Zandi, Maki, Iritani, H., Imai, M., Malyaravanan, V.S., Slade H. and Paves S. Department of Pediatrics & Medicine, North Shore University Hospital, Cornell University Medical College, Westchester, NY, Biometrics Research Inst., Rockville MD, U.S.A.

Objective: To determine whether IL-2 and IL-2 receptor (IL-2R) gene expression are suppressed by the envelope glycoprotein of HIV-1 (gp120). **Methods:** gp120 was purified from HIV-1⁺ infected Hc 7a cell culture supernatants by affinity chromatography. Tetanus antigen-specific T cell clones independent of exposure to IL-2 were derived from a normal individual. The mRNA for IL-2 and IL-2R were determined by specific cDNA probes by northern blot analysis.

Results: Cloned T cells proliferated and expressed mRNA for IL-2 or IL-2R only when cultured in presence of tetanus antigen. Proliferation of the cloned T cells for 6 hours with 0.1 to 0.001 μ g/ml of gp120 resulted in dose dependent suppression of mRNA for IL-2 and of tetanus-specific proliferative response. Although the cells that had been treated with gp120 showed a significant decrease in their ability to express IL-2R (tested by staining with anti-IL2R mAb and analyzed by flow cytometry), the IL-2R gene expression was not suppressed. In T cell clones stimulated with mAb directed against surface molecules CD3 and CD28 (plus PHA), proliferative response and mRNA for IL-2 and IL-2R were unaffected by gp120 treatment.

Conclusion: The results demonstrate that gp120 selectively inhibits antigen-specific T cell responses by inhibiting IL-2 mRNA. Suppression of IL-2 expression by gp120 appears to occur at post-transcriptional level.

T.C.P.54 INTERFERON- α AND INTERLEUKIN-2 BUT NOT INTERFERON- γ MODERATE NATURAL KILLING OF HIV-INFECTED TARGETS AMONG HIV-1 SUBJECTS

Abstract: Janney, John M., M. University of Texas Medical Branch, Galveston, Texas, USA.

Objective: To evaluate the effects of recombinant interferons (IFN) and Interleukin-2 (IL-2) on natural killer cytotoxicity (NKC) of HIV (+) and (-) individuals in the presence of recombinant interferons.

Methods: Ficoll-purified separated peripheral blood mononuclear cells from HIV (+) and both Group II asymptomatic (Gp II) and Group IV asymptomatic (Gp IV) HIV (+) individuals were incubated for 18 hrs with medium, 1000 IU rIFN α or rIFN β , or 50 IU/ml rIL-2 prior to a 4-hr ⁵¹Cr-release assay against CD4⁺ target cells.

Results: Mean NKC of controls was 38 LU for controls (n=12), 17 LU for GpIV HIV (+) (n=8), and 10 LU for GpII HIV (+) (both <10). Significant (p<0.05) augmentation of NKC by rIFN- α occurred among all groups (21 LU, 100 LU, and 64 LU), as did augmentation by rIFN β ser (96 LU, 55 LU, and 41 LU). There was no significant augmentation of NKC by rIFN γ ser among controls (44 LU).

Conclusion: NKC against HIV-infected cells is significantly decreased in GpIV with each stage of HIV infection. The effect of augmentation of NKC by rIFN β and rIL-2 but not rIFN α may suggest 1) an effect of HIV on IFN responsiveness of NKC, and 2) potential for immunoreconstitution with rIFN β or IL-2 among HIV (+) individuals.



Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

T.C.P.55 CORRELATION OF ADCCC AND NEUTRALISATION WITH A BETTER CLINICAL STAGE IN CHILDREN BORN TO HIV-1-INFECTED MOTHERS

Kristina Ljunggren, V. Moschese, P. Brölden, B. Wahren, P. Rossi, M. Jonda
DEPT. OF Microbiology, Karolinska Institute, Dept. of Virology, National Bact. Laboratory, Stockholm, Sweden

Factors determining an uninfected or infected outcome as well as disease progression in children born to HIV-1 infected mothers are unclear. Also, early diagnosis is hampered by maternally transferred antibodies. We have retrospectively divided children, 0-24 months of age, into two groups based on HIV seroreactivity at 15 months of age. No difference was seen in presence of ADCCC and neutralising antibodies between the groups. The persistently seropositive group was divided into a non-AIDS and AIDS group according to clinical status at the time of diagnosis. Interestingly, the ADCCC frequencies in these two groups differed, 70% and 30%, respectively. Even more striking, 63% of non-AIDS and none of the AIDS patients had neutralising antibodies. These differences were not merely a reflection of decreasing IgG-titres in later stages of disease. Presence of both ADCCC and neutralisation was more common in mothers giving birth to children becoming seropositive than to persistently seropositive ones.

In conclusion, ADCCC and neutralising antibodies do not seem to protect against virus transmission from mother to child but are significantly correlated with a better clinical stage of HIV-infection.

T.C.P.57 SUPPRESSION OF MONOCYTE-MEDIATED DIRECT CYTOTOXICITY AND ADCCC BY AIDS PERIPHERAL BLOOD DERIVED MONOCYTES

BRADLEY BENNETT, JEWETT A., NISHANATH P. and MITSUOYA K.
Department of Microbiology and Immunology and Department of Medicine, University of California, Los Angeles, USA.

Cytotoxic effector mechanisms may play an important role in both the control and pathogenesis of HIV infection. We examined the cytotoxic activity of peripheral blood derived monocytes (PBM) from AIDS patients. Both direct cytotoxicity and antibody dependent cellular cytotoxicity (ADCC) were examined using tumor cells as targets in an ⁵¹Cr release assay. Whereas normal PBM were minimally cytotoxic, PBM from AIDS patients were cytotoxic in the absence of exogenous activation. The level of cytotoxicity was comparable to IFN- γ activated normal PBM. Cytotoxicity was mediated by TNF as it was blocked by anti-TNF antibody and β supernatant derived from the monocytes cultures contained high levels of TNF as assessed by cytotoxicity and by RIA. We then examined the PBM dependent ADCC using a target cell resistant to direct cytotoxicity but sensitive in the presence of anti-target antibody. PBM from AIDS patients had augmented ADCC whereas normal PBM were minimally cytotoxic. These results demonstrate that AIDS PBM are activated in vivo and mediate both direct and antibody dependent cytotoxicity. To test cytotoxicity to HIV infected targets, CD4⁺ T targets resistant to PBM were required. Thus, we selected a variant CD4⁺ T target that was resistant to monocyte-mediated cytotoxicity. These targets retain their CD4⁺ phenotype and bind HIV like control. We have initiated studies to use these HIV coated or infected targets with AIDS PBM. The results of such experiments and their significance will be presented.

T.C.P.59 CHARACTERIZATION OF HUMAN MONOCLONAL ANTIBODIES AGAINST HIV-1 WITH GPUR SPECIFIC NEUTRALIZING ACTIVITIES

Yvonnie Bross*, Madeira P.**, Souche, S.**, Zagury, D.*** and Desgranges, C.*
*INSERM U 271, Lyon, France. **CNRS, GIG-sur-Yvette, France. ***Université P. et M. Curie, Paris, France.

Objective: To obtain human monoclonal antibodies (HMAbs) against the protein of HIV with neutralizing activity from vaccinated or infected individuals.
Methods: B lymphocytes from individuals vaccinated with a recombinant gp160-vaccinia virus or from infected donors were transfused into Balb/c-B6 mice. Clones were then selected and analyzed for their reactivity with HIV proteins by several methods such as immunofluorescence, ELISA and immunoblot. A few HMAbs were mapped using a library of the HIV-1 III B gene cDNA, expressed in the yeast model. Divergent strains of HIV (HTLV-III B and RP1) were then used in neutralization assays based on virus infection of HIV (HTLV-III B) infected cell tissues.

Results: Clones secreting IgG anti-gp1 and gp120 were obtained. Epitope recognized by the anti-gp1 was localized within the C-terminal region of gp1, between 154 and 548 amino acids. Virus infectivity can be blocked by the anti-gp1 and the anti-gp120, whereas no neutralization has been observed in the HIV mediated cell fusion assay.

Conclusions: The neutralizing potential of the HMAbs described here is therefore group specific. Human monoclonal antibodies directed against conserved regions of HIV proteins allow to define immunodominant epitopes for vaccination and production of antiretroviral. Since they recognize divergent strains, use of HMAbs in passive therapy should be considered.

T.C.P.56 AN ANALYSIS OF THE EXPRESSION OF CD4 RECEPTORS BY BLOOD MONOCYTES AND T CELLS FROM NORMAL AND HIV-1 INDIVIDUALS.

Elaine Linder, Eric Ingstrup, G. E. Barber, L. Huesch,
University of Dallas, Dallas, TEXAS 75044 USA

Monocytes harbor HIV-1 and probably play an important role in maintaining the chronicity of the disease. Monocytes are susceptible to HIV infection because they have the CD4 receptor, CD45R1/2, to cooperate the expression of CD4 on T cells and monocytes. Methods: An immunofluorescence (flow cytometry, microcapillary) analysis employing anti-CD4 (Imu-3a) and anti-CD45 (Imu-3b) on fresh monocytes and T cells was done. Results: 1) By flow cytometry 85-90% of monocytes from a normal (N) or HIV-1 (P+) individuals show dual positivity for CD4 and CD45. Although the analysis showed an overall population along the fluorescence intensity axis as opposed to the tailing effect of control antibodies that did not alter the position of the fluorescence negative monocytes, these observation suggest that all monocytes are CD4⁺ albeit some have low CD4 density and overlap with background control staining. The results are not affected by fixation of cells or blocking of Fc receptors before staining. 2) The results were confirmed by two color fluorescence microscopy (FACS) of CD4⁺ monocytes were also CD45⁺ by two-color immunofluorescence microscopy. CD4⁺ monocytes have intracellular CD4 receptors whereas CD4⁺ T cells expressed only the extracellular CD4. Conclusions: These results confirm and extend the observation that all monocytes are CD4⁺, contain larger amounts of intracellular CD4. HIV-1 infection did not seem to affect CD4 expression by monocytes which may help to explain the cryptic effects of HIV-1 on monocytes and T cells.

T.C.P.58 MONOCYTOCHROMOPHAGES INFECTED WITH HIV-1 PRODUCE ACID-LABILE INTERFERON- γ

Sachari Naim*, Friedman R.M.**, Wald, S.M.***, Wahl, L.M.*** and Weinstein, S.***

*National Cancer Institute, National Institutes of Health (NIH), **Uniformed Services, University of the Health Sciences, ***National Institute of Dental Research, NIH, Bethesda, Maryland, USA.

Objective: To describe an interferon (IFN) produced by HIV-1-infected monocytophagocytes (M ϕ) and to establish the kinetics of its production. **Methods:** M ϕ cultures were infected with HIV/HTLV-III_{LAI/1985}, and p24 antigen production was measured by ELISA. The controls were HIV-1-infected cells treated with AZT and non-infected cells. IFN titers in the culture medium were determined at intervals using human foreskin fibroblasts and murine monocytophagocytoid virus as a test system. Anti-IFN antibodies were used to distinguish among IFN types.

Results: We found significant production of IFN (>10 I.U./ml) by M ϕ infected with HIV-1 and cultured for 212 days, whereas IFN production was not detectable in non-infected cells or in infected cells in which virus replication was eliminated by AZT treatment. The antiviral effect of this IFN in the test system was neutralized by anti-IFN- γ antibody and reduced 80-90% by treatment at pH 2, suggesting that this IFN belongs to the acid-labile subclass of IFN- γ . Conclusions: Our observations suggest the M ϕ as a source of the acid-labile IFN- γ that has been detected in AIDS patients and reported to be a useful prognostic indicator for development of AIDS. This IFN might also play a role in the pathogenesis of AIDS and its symptomatology.

T.C.P.60 AUTOANTIBODIES AGAINST COLLAGEN IN AIDS: CORRELATION WITH RISK FACTORS AND DISSEMINATED PROCESSION

Grazi, Michard, D.; Weaver, M.S.*** and Hoffmann, C.W.***
*University of British Columbia, Vancouver, B.C., Canada ** St. Paul Hospital, Vancouver, B.C., Canada.

Autoimmunity often precedes the onset of ARC or AIDS, and a number of autoantibodies have been described in AIDS patients and in persons at risk for AIDS. Such antibodies raise the question of autoimmunity as a component of AIDS pathogenesis. We have reported evidence of an autoantibody (anti-collagen) that occurs in all AIDS patients studied. Sera from various groups were assayed by ELISA for reactivity with gelatin. The specificity of the ELISA for collagen activity was shown by inhibition with purified human collagen. High titre serum reactivity against collagen was found in all AIDS patients, HIV⁺ homozygous (6/6), HIV⁺ homozygous (2/6), and HIV⁺ heterozygous (1/6), but not in HIV⁻ hemophiliacs, rheumatoid arthritis (RA) patients, or controls. Serum IgG levels showed little correlation with anti-collagen activity so this is not a reflection of polyclonal B-cell activation. Titration of anti-collagen activity in positive sera revealed levels 100 times higher than the levels in normal sera. Affinity purification followed by electrophoretic and immunoblot analysis confirmed the antibody nature of the anti-collagen reactivity. The anti-collagen antibodies react preferentially with primary determinants revealed after denaturation. In this respect, the antibodies are different from those described in RA, but similar to those observed in graft versus host disease and leprosy. To our knowledge, this is the first demonstration of autoantibodies of a single specificity. These results suggest that all persons progressing to AIDS express anti-collagen antibodies which may be useful markers of disease progression.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

T.C.P.73 HUMAN ANTIBODY RESPONSE TO HIV-1 PROTEASE ACCORDING TO DISEASE STAGE

Ruppel, Chantel, De Agre, M.*; Debouck, C.A.**; De Wolf, F.*; Wolfs, T., Goudaard, A.*

*Hannu Reviervirus Laboratorium, Amsterdam, the Netherlands, **Department of Molecular Genetics, Smith Kline Beecham Laboratories, King of Prussia, PA, USA

Objective: To study the relationship between presence of antibodies to HIV-1 protease and presence of several disease predictive markers for disease progression in different infected risk groups (homosexuals, hemophiliacs).

Methods: Antibodies to HIV-1 were measured in serum using an enzyme linked immunosorbent assay using a bacterially expressed, recombinant form of HIV-1 protease. HIV-1 antibodies, HIV-1 antigen, HIV-1 Ab positive homosexuals in CDC stage I/II) were anti-protease positive, versus 50% (9/15) of homosexuals with AIDS related complex (CDC IV A) and 30% of the homosexuals with AIDS (CDC IV B-E). In 255 homosexuals (CDC III) antibodies to protease were significantly more frequently found in samples lacking HIV-1 antigen (p<0.001) and possessing antibodies to HIV-1 core antigen (p=0.006).

Conclusions: HIV-1 protease is expressed and antigenic in most HIV-1 infected individuals and absence of antibodies to HIV-1 protease is more often found in persons with progressive disease.

T.C.P.75 HUMAN MONOCLONAL ANTIBODIES (mAb) TO HIV-1

Lake, D.; Kawamura, T.; Hujic, A.; Masuko, Y.*; Kiferian, E.; and Herrst, E.*

*Dept. of Hematology/Oncology, University of Arizona, Tucson, Arizona, 85724, USA, **Tefjin Institute for Biological Research, Tokyo, Japan.

Objective: To develop a panel of human IgG monoclonal antibodies to HIV-1 that have therapeutic potential either alone or in combination with each other or with other anti-viral agents.

Methods: Hybridomas were produced by fusion of splenic or lymph node lymphocytes from HIV sero-positive patients with the P3x63Ag12 myeloma mouse cell line. Hybridomas were screened for the production of anti-HIV IgG by ELISA and indirect immunofluorescence. ELISA screening was performed using plates coated with 2 different HIV-1 isolates and 1 plate coated with a gp120 synthetic peptide fragment. Cloning was done by limiting dilution.

Results: Eight mAb have been developed that react with HIV-1 gp120

isotype IgG1/IgA1 IgG1/IgA1 IgG1/IgA1 IgG1/IgA1 IgG1/IgA1 IgG1/IgA1

Recognized gp160, gp160, gp160, no rxn no rxn gp160, p55,24 gp160,

Antigen 120,41 120 120 955,24 120,41

I.F. ++ ++ ++ ++ ++ +/- -/- -/-

Activity ++ ++ ++ ++ ++ ++ ++ ++

Neutralizing titration

Conclusion: We have established 8 anti HIV mAb, one of which has neutralizing activity. Such mAb should have major scientific, diagnostic and therapeutic applications. (Abbreviations I.F.: immunofluorescence, rxn: reaction)

T.C.P.77 HIV RECOMBINANT p18 COAT PROTEIN INHIBITS PROLIFERATIVE RESPONSES BY NORMAL LYMPHOCYTES IN HUMANS AND MICE.

Nichols, J.Fredrickson*, Cheyner, R.*, Lecout, G.*, Rautmann, C.*, Guy, B., Kivvy, M.P., Kiser, M. and Parris, S.*

*Institut Pasteur, Paris, *Farmingen S.A., Strasbourg, **Pasteur Vaccine, Marne-la-Coquette, France

Objective: To determine the in vitro effect of HIV-1 core p18 protein on antigen-induced lymphoproliferative responses and mixed lymphocyte reaction (MLR). To compare results with the effect of p18 in a mouse model.

Methods: 1) Recombinant p18 gag, p25 gag or p27 nef protein was pre-incubated with peripheral blood lymphocytes (PBL) from normal donors. Polyclonal mitogenic responses to plant lectins and MLR were studied in proliferation assays. The effect of p18 was also examined in normal B6/6C mice, and in mice immunized with a recombinant vaccinia virus containing the HIV-1 gag gene.

Results: p18 gag protein suppressed the proliferative responses of PBL from five different healthy donors when lymphocyte proliferation was induced by ConA or by HLA allotypes in MLR. In contrast, p25 gag and p27 nef proteins had no suppressive effects. These results were reproducible with mouse lymphocytes; p18 gag protein suppressed mitogenic responses to ConA and PHA, as well as specific proliferative responses to p25 gag protein in mice vaccinated with a virus-HIV₁ recombinant.

Conclusions: 1) Immunosuppressive and immunogenic epitopes of HIV-1 proteins have to be defined in view of vaccination in humans. 2) The murine model is useful to evaluate the immunogenic power of different HIV proteins.

T.C.P.74 QUANTITATIVE, NOT QUALITATIVE, DEFECTS CHARACTERIZE RESPONSES OF CELLS FROM HIV SEROPOSITIVE TO CELL MITOGENS: B6MALN, M1 and Sardin-Hybrid, B6, M1V Med. Cir. and V.A. Hospital, NY, NY, U.S.A.

Objective: To elucidate the immunoregulatory mechanisms involved in B lymphocyte responses of cells from HIV-seropositive (HIV+) and controls.

Methods: Proliferative responses of non-mouse cells (M1C) to B cell mitogens (anti-I and Staphylococcus aureus Cowen 2 (SC2)) were determined by ³H-thymidine incorporation in 3 or 4 day cultures. Mixed lymphocyte culture supernatant (MLC-sup) and indomethacin were added to certain cultures.

Results: Average proliferative responses of M1C from HIV+ patients to each mitogen are significantly defective (25-33% of control [HIV-] response). Addition of MLC-sup increases responses of both HIV+ and HIV- M1C to anti-I (43 and 50% respectively) and SC2 (69 in both groups). Addition of indomethacin increases responses to SC2, (40-70% increase for both groups).

Effects: MLC-sup and indomethacin are additive. No decrease in deficient responses were influenced by the altered frequency of lymphocyte subsets in the HIV+ cultures; correlations were sought between defective responses and percent of lymphocyte subsets. Proliferative responses to anti-I and SC2 in the presence of both MLC-sup and indomethacin are correlated poorly with the percent of B and CD4+ T cells, and negatively with the percent of CD8+ T cells in culture. Mathematical correction of the data for the abnormal percentages of B, CD4+ T and CD8+ T cells results in responses that are comparable to those of control cells.

Conclusions: Deficient responses may be due to quantitative differences in the responding B cells and regulatory pathways mediated by CD4+ and CD8+ T cells and not to qualitative differences in the ability of the patients' B cells to respond to these mitogens.

T.C.P.76 FINE SPECIFICITY OF HIV-SPECIFIC CYTOTOXIC T LYMPHOCYTES IN HUMANS

Duoglio, G.*, Langlois-Dreyon, Pierre*, Barroui, M.*, Fisher, R.* and Patis, F.*

*Institut Pasteur Paris, France, **Biogen Research Corporation, MA, USA.

Objective: To identify CTL epitopes on glycoproteins coded by the HIV *env* gene.

Methods: HIV-specific HLA-A2 restricted CTL lines were generated from human peripheral blood lymphocytes by stimulation with autologous HIV infected lymphoblasts in the presence of interleukin 2. Peptides used were selected with the criterion of conservation among different HIV isolates in view of an eventual application in vaccines or immunotherapy. These peptides were tested for CTL recognition by incubating each peptide with ⁵¹Cr-labeled tumor target cells stably transfected with the human HLA-A2 gene.

Results, conclusions: Among the 30 peptides tested, 6 peptides were particularly well recognized. Results obtained with new synthetic peptides indicate that some epitopes recognized by HIV-specific CTL are highly conserved. This is encouraging in view of the large variability of HIV isolates.

T.C.P.78 LOCALIZATION WITHIN THE HIV-1 LTR OF NUCLEOTIDES RESPONSIVE TO CMV-MEDIATED TRANSCRIPTION

Ehrlich, P. Berry, N. Pant-Low, M. Marban, N. Duschague, and K. Joseph.*

*Department of Molecular Pathology, University of California, Davis, CA 95616 and *Molecular Biology and Virology Laboratory, The Salk Institute, La Jolla, CA, U.S.A.

Objective: To investigate the molecular basis by which human cytomegalovirus (CMV) activates expression from the HIV-1 long terminal repeat (LTR).

Methods: We are analyzing the molecular basis by which human CMV stimulates expression from the HIV-1 LTR by constructing recombinant plasmids with a reporter gene (CAT) under the transcriptional control of the LTR. Cloned-site mutations and small deletions have been introduced into the HIV-1 LTR. These mutants have been tested in trans expression assays in a variety of cell types, including transformed and non-transformed cells, for responsiveness to CMV IE and HIV-1 transactivator (tat).

Results: Mutations in the LTR around either the start site of transcription (4 to +20), the three SP1 binding sites, or the TATA box dramatically reduce responsiveness to CMV IE. A mutation at -6 to -1 abolishes CMV IE-mediated transactivation but leaves tat-mediated transactivation intact. Mutations which abolish responsiveness to tat (+20 to +35) have little or no effect on CMV IE transactivation. Insertion of the 4 to +20 region of the HIV-1 LTR into a CMV IE non-responsive promoter confers responsiveness to CMV IE, but only in one orientation. The magnitude of transactivation by CMV IE appears to be related to the transactivation phenotype of the cell.

Conclusions: The mutation analysis shows that responsiveness of the HIV-1 LTR to CMV transactivation depends upon sequences recognized by the cellular factor designated leader binding protein-1 (LBP-1). Also, additional host factors which are involved in control of cell growth appear to play a role in transactivation of HIV by CMV.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

T.C.P.91 PROMOTOR ACTIVITY OF 5' LTR REGION OF A HIGHLY CYTOPATHIC STRAIN OF HIV-1

L. LISBERG, J. SEEL, V. JACOB, B. STREB AND J.-C. CHOMONNET.

Unité de Recherches Épidémiologiques et de Biologie des Relations Homme (U.152) - Centre de Lésions - M-31 - 12033 MARILLIÈRE CARRÉ, FRANCE

In order to evaluate the high cytopathic properties of HIV-808 strain with genetic variation, the virus was cloned and sequenced. The cloned DNA was biologically active as revealed by transfection into cells. One of the major differences in the alignment of nucleotide sequences of HIV-808 and HIV-809 genotype viruses was located in the 5' part of the LTR 0' region. In a set of transfection experiments the effect of transmutating (18) base product on promoter activity localized in the 5' LTR region of both HIV-808 and HIV-809 viruses was compared in CAT assay. It was found that promoter activity of 5' LTR of HIV-808 was several times higher than that of HIV-809 genotype even without a stabilizing effect of the tat gene product. To approach the effect of LTR region on cytopathogenicity of HIV-808 directly, the recombinant the molecule bearing HIV-808-LTR region and rest of the genome derived from HIV-809 genotype. The DNA was transfected into the cells and the virus obtained; its properties are under investigation.

T.C.P.93 BINDING OF THE HIV-1 TAT PROTEIN TO TAR SEQUENCES IN VITRO

Dingwall, C.; Embury, I.; Hepply, S.; Kinnear, M. A.; Gall, M. J. & Kerr, J. MRC Laboratory of Molecular Biology, Hills Road, Cambridge, CB2 3QH, U.K.

Objectives: To investigate the binding in vitro of HIV tat protein and cellular factors to TAR sequences.

Methods: A synthetic tar gene has been expressed both in an E. coli expression system and in a number of eukaryotic cell lines. The binding of expressed tat protein to nucleic acid representing the TAR sequence has been investigated in vitro using gel retardation assays.

Results: The tat protein produced from both the E. coli and from the eukaryotic expression systems has been shown to be biologically active. The binding of tat, synthesized in E. coli, to TAR nucleic acids has been examined both in the presence and absence of host cellular proteins. Binding of tat expressed in eukaryotic cells gives a different pattern, suggesting that host proteins interact with the tat/TAR complex. The specificity of binding has been examined using a number of different nucleic acids, including mutant TAR sequences.

Conclusions: Direct interactions between tat protein and TAR sequences are involved in trans-activation.

T.C.P.95 ANALYSIS OF VPK FUNCTION IN HIV-1 INFECTED CELLS

Jan Bakula, J. Kim, and B. Vander Heyden. Departments of Medicine and Microbiology, Immunology, Washington University, St. Louis, Mo., USA

Objective: A novel gene, designated vpk, is present in the genomes of HIV-2 and HIV-1, but not yet known as to define the role of vpk in HIV-2 replication and cytopathicity.

Methods: A functional proviral clone of HIV-2, SE, was made and used to construct six directed mutants which only eliminate the AUG initiator codon of vpk (OX1), which convert codon 22 to a termination codon (OX2), or which simultaneously eliminate the first and second AUG codons and frame-shift the gene introducing a termination codon at position 70 (OX3+65).

Results: Transfection of SE, OX1, OX2, and OX3+65 into CEM-1 cells gave rise to equivalent amounts of virus, which could be passaged in SP or CEM cells, or in peripheral blood lymphocytes or monocytes with equivalent efficiency. Furthermore, the vpk mutants demonstrate similar cytopathic effects as did SE. Hybridization data with DNA from the infected cells demonstrated the presence of the mutations in each of the RI infected cell lines, and equivalent levels of viral RNA and DNA sequences in SE and RI infected cell lines. Immunoprecipitation analysis demonstrated a 14 kd protein in cells infected with SE virus as well as the other mutants, but not in cells infected with the RI viruses or the particles themselves. Equivalent levels of GAG and ENV proteins were demonstrated in all infected cells and virus preparations.

Conclusions: These data suggest that vpk is dispensable for virus replication and cytopathicity. Further analysis of the vpk mutants is underway to define vpk activity in animal model systems.

T.C.P.92 DETECTION AND SEQUENCING OF INDIVIDUAL MOLECULES OF HIV DNA AMPLIFIED BY A MODIFIED BSA

Department of Genetics, University of Edinburgh, Scotland, United Kingdom

The sensitivity of polymerase chain reaction (PCR) has been enhanced by the use of nested primers, which allowed the detection of individual molecules of HIV DNA from patient samples. Amplification of DNA involves a first reaction with a pair of HIV-specific primers, transfer of a small proportion of the product to a second tube containing primers that lie within the first pair, and a further round of amplification. Dilution studies or plasmid derived HIV sequences showed that amplification of single molecules of target sequence with different sets of primers was reliable even with primer sequences as wide as 500 base pairs. The specificity of the test was assured by the uniformly negative results obtained from a panel of seronegative blood donors with two sets of nested primers. Limit dilutions of HIV DNA from buffy coat coat cells of HIV-infected haemophiliacs allowed the isolation, amplification and sequencing of individual molecules. This method has many advantages over previously described methods of ascertaining HIV by the PCR method: 1) Amplification of the target sequence takes place in the absence of competition from others that replicate faster, or earlier than the primers target. 2) It is less prone to sequencing errors. 3) It allows the amplification of several regions from the same HIV genome.

T.C.P.94 CHARACTERIZATION OF THE INFECTIVITY OF HIV PROVIRUSES CONTAINING MUTATIONS IN LTR REGULATORY SEQUENCES

Leonard, J.M.; Parrott, C.M.; Buckler-White, A.M.; Martin, M.A. & Raboon, A.B. *NIAD, NIH, Bethesda, MD, USA; *Georgetown University, Washington, D.C. USA

Objectives: To characterize the biological effects of mutations in the 3'-distal regulatory sequences of the HIV LTR.

Methods: Oligonucleotide-directed, site-specific mutagenesis was employed to generate mutations in the regulatory sequences in the HIV-1 LTR. Mutated LTRs were introduced into an infectious molecular clone of HIV. Mutant proviruses were assayed for infectivity and growth in human T cells. Mutant LTRs were also tested for transcriptional activity by transfection of LTR-CAT plasmids.

Results: An HIV provirus containing a deletion of both NF- κ B binding sites yielded infectious virus that replicated efficiently in MT 4 cells. Mutants defective in Sp1 binding at the 5' Sp1 site (site III) were also capable of efficient growth; proviruses with additional mutations in the Sp1 binding sites varied in their ability to produce infectious virus. In CAT assays, the mutant LTR deleted in the NF- κ B sites exhibited decreased basal activity compared to the wild-type LTR, but was strongly responsive to α transactivation. The effects on viral infectivity of changes in other parts of the LTR will also be discussed.

Conclusions: The NF- κ B binding sites were not essential for HIV replication in MT 4 cells. Other mutations affecting the Sp1 binding sites also did not interfere with the ability to produce infectious virus. Thus HIV can replicate even when alterations are introduced into the wild-type enhancer and promoter elements.

T.C.P.96 HIGHLY EFFICIENT NEUTRALIZATION OF HIV WITH RECOMBINANT HIV-1-IMMUNOGLOBULIN MOLECULES

André Trautacker, Josef Schneider*, Hansrued Kiefer* and Klaus Karlinstein*, Basel Institute for Immunology, Basel, Switzerland; *Centraal Laboratorium, Centraal Ziekenhuis, F. Hoffmann-La Roche & Co. Ltd, Basel, Switzerland.

It is well established that the human immunodeficiency virus type 1 (HIV-1) exploits the cell surface CD4 molecule to initiate the infection which can eventually lead to acquired immune deficiency syndrome (AIDS). We and others have taken advantage of this specific interaction between the HIV-1 envelope protein gp120 and CD4 and have shown that soluble CD4 molecules can inhibit HIV infectivity in vitro. However, application of these observations in vivo might require HIV potent reagents. Here we describe the generation of highly effective molecules which combine the specificity of CD4 and the effector functions of different immunoglobulin (Ig) subclasses. We show that pentameric forms of chimeric CD4-immunoglobulin molecules are about 1000 fold more active than their dimeric counterparts in *Synglystus* inhibition assays.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

T.C.P.97

PACKAGING AND TRANSFER OF A MARKER GENE BY HIV VECTOR PARTICLES
Chival-François, Danoes O* and Alizon M**
*Laboratory of Molecular Biology, NIAID, NIH, Bethesda, MD, USA.
**Whitehead Institute, Cambridge, MA, USA

Objective: To package foreign sequences in HIV particles and transfer them to HIV-sensitive target cells.

Methods and Results: Several HIV vectors were generated by introducing a selectable resistance gene (SHS) into the HIV genome. Cell lines were then established that could express these genomes, and package them into HIV particles following the transfection of HIV helper sequences. After infection of CD4+ cells with such particles and selection, we were able to demonstrate the successful transfer and integration of HIV genomes carrying the marker resistance gene. Different constructs were compared for their efficiency to transfer the marker gene. In order to delineate the cis-acting sequences required for the complete packaging, reverse transcription, and integration of the HIV genetic material.

Conclusion: We demonstrated the packaging and successful transfer of a genetic marker through HIV particles. HIV vectors will be valuable tools to study the HIV replicative cycle, and to specifically target sequences to HIV-sensitive cells.

T.C.P.98

INTERACTION OF HIV WITH INTERFERON REGULATED, ANTIVIRAL ENZYMES.

Silverman R.H.¹; Sen Gupta D.N.¹; Dion M.F. and Williams B.R.G.²

¹Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, MD USA and ²Division of Infectious Diseases, Research Institute Hospital for Sick Children, Toronto, Canada.

The interferon (IFN) system is activated in AIDS and high levels of circulating active latent IFN-alpha often accompany disease development. Although HIV replication in cell culture can be inhibited by IFN, the virus appears to have evolved a mechanism of escaping the antiviral activity of the IFN usually present in AIDS. We have investigated the activation of IFN-induced enzymes by HIV-1. The 5' leader of HIV-1 mRNA contains two double-stranded sense of about 17 and 23 base pairs in length. HIV-1 leader RNA of 212 nucleotides was produced from a plasmid containing HIV-1 LTR sequences located 3' to an SP6 promoter. The RNA product was purified and analyzed to ensure the absence of shunt transcripts. That HIV-1 LTR RNA was shown to activate both dsRNA-dependent protein kinase and 2-5A synthetase in an extract of IFN-treated HeLa cells. Furthermore, these enzymes were immobilized and screened on an affinity resin consisting of HIV-1 leader RNA covalently attached to finely divided cellulose. In HIV-infected cell cultures however, although IFN was able to induce 2-5A synthetase, no evidence for endogenous activation of the 2-5A pathway was obtained. It remains possible therefore, that viral or cellular factors in HIV-infected cells interfere with the activation of IFN-induced enzymes and contribute to viral latency.

T.C.P.99

HIV-1 REPLICATES IN HUMAN SPERM MITOCHONDRIA OF HIV-SEROPOSITIVE INDIVIDUALS

Regnier, Chaz J, Tremblé, H., Candeloub, D.***, Belin B.***, Desjardins, J., Desjardins, M., School of Osteopathic Medicine, Dept. of Microbiology, Ob/Gyn and Medicine * Camden, New Jersey, USA.

Objective: To determine the replication site(s) of HIV-1 in the sperm of HIV-seropositive individuals.

Methods: Sperm samples from three AIDS/SAC individuals were scrutinized for the localization of HIV-1 by electron microscopy (EM), HIV-specific immunogold EM, and in situ hybridization using HIV-specific DNA probes. **Results:** (1) Analysis of sperm by the EM hybridization procedure revealed that over 70% of sperm which were positive for HIV by in situ hybridization, had their nucleolus enlarged (x10 times greater than normal controls). (2) HIV-DNA probes were more concentrated at the nucleolus than in the sperm heads, in terms of relative intensity of staining. (3) Immunogold staining showed aggregation of gold particles in association with mitochondria. (4) Presence of HIV-like particles in many mitochondrial organelles was noted. (5) Some mitochondria resembled pods with HIV-like particles "bursting out" of them like spores.

Conclusion: These observations suggest that HIV in sperm may be replicating in the mitochondria, using mitochondrial DNA as a replicating device. It is possible that in human sperm where there is condensation and tight packaging of haploid DNA in the nucleus, relative to that in somatic cells, the random integration of the HIV proviral DNA into the nuclear-DNA might be difficult and mitochondrial-DNA may be an easier target. On the other hand, if cellular mitochondria is a global target for HIV, then different therapeutic approaches might be adopted.

T.C.P.100

TRANSMISSION OF SH₁₀₀ IN A SEMI-FREE RANGE BREEDING COLONY OF MANDRILLS IN GABON.

Patena, Manrique¹; Delaporte, E.L.T.²; Honora, C.²; Cooper, R.W.²; Bursi, P.²; Dixon, A.L.²

¹ Centre International de Recherches Médicales, BP 769, Francville, Gabon;

Objective: To study the transmission (vertical and horizontal) of a simian immunodeficiency virus from mandrills in a colony of mandrills.

Methods: A lot of 33 mandrills was tested, 16 of them were wild caught animals. Antibodies were detected by a radio-immunoprecipitation assay using 3P₂-methionine labeled SH₁₀₀ virus. Virus was isolated from peripheral blood lymphocytes co-cultured with MOLT-4 cells.

Results: Two of the 16 wild-caught animals (11%) were positive since their arrival at the primate centre (1979 and 1985 respectively). A virus was isolated (Tajimato) and showed antibodies to the SH₁₀₀ glycoproteins only. In 1988, two new animals showed antibodies to the SH₁₀₀ envelope proteins and also to the core proteins. One of these animals was a wild-caught male that was seronegative at his arrival to our centre. The other one is the second offspring of the already known positive female. Since her arrival in 1983 at CIRMF, she was pregnant twice, one animal was born in 1985 (seronegative, 1,2 and 3 years respectively after birth) and one in 1987. This animal showed antibodies one year after delivery and a virus was isolated from her peripheral blood lymphocytes. **Conclusion:** SH₁₀₀ appears to be transmitted from mother to child in a semi-free range breeding mandrill colony. A seroconversion with appearance of antibodies to p27 was observed, and a virus was isolated.

T.C.P.101

A COLORIMETRIC ASSAY FOR TRANSCRIPTION OF THE HIV-1 LTR

Edward B. Slight*, R.G. Devitis* and C.R. Roberts*

Wellcome Research Laboratories, Beckenham, UK, and **MTR, J. Carolina, USA.

Objective: To develop a simple, rapid and sensitive assay for the activation of the HIV-1 LTR by Tat and by heterologous factors.

Methods: Stable cell lines containing multiple integrated copies of the HIV-1 LTR (1-22)400 linked to the DNA sequence of E.coli were prepared by co-selection for pSV2neo-mediated G418 resistance. **Results:** HIV-1 LTR luciferase was transcribed equally well or better in rabbit SKIN (SPH11a1-luc) cells than in other cell types (HeLa, C-127, Flow 4002, etc.), by cotransfection with generic Tat (gTat) expressing plasmids (pGWTAT, pSVTAT) and, so stable SKIN/TAT luciferase cell lines were prepared to mimic the structure of the integrated provirus. In identically infected cells, three of the independent clones responded to gTat, and one clone was used to show that D-phenylalanine was not an effective inhibitor of Tat transcription at concentrations up to 100µg/ml. The efficacy of anti-sense phosphorothioate oligonucleotides against Tat are currently under examination in these lines. The same lines also express high levels of oligonucleotides in response to HIV-1 infection, and transactivated by 16 gene products from herpes group viruses in size differentiation.

Conclusions: Selection of the appropriate substrate for β -galactosidase will permit detection and measurement of LTR transcription (MUG:OMP) and also detection of infectious centres (i-pal) in these cell lines. Therefore, molecular aspects of HIV reactivation and autologous gene regulation can be readily analysed.

T.C.P.102

HIV-1 REV INDUCED MODULATION OF NEF PROTEIN UNDERLIES REGULATION OF VIRAL REPLICATION

Ahmad, Nafees, Malin, K. K. and Venkatesan, S.
Laboratory of Molecular Microbiology, NIAID, National Institutes of Health, Bethesda, MD 20892, USA.

Objective: To study the potential functional roles of HIV-1 Rev and Nef proteins that might underlie the regulation of viral replication.

Methods: A new defective proviral DNA was constructed from infectious HIV-1 proviral clone pNL4.2. The Rev and Nef were supplied in trans by cotransfection of cDNA plasmids under the control of various promoters.

Results: The phenotype of rev mutant provirus was distinguished by accumulation of Nef and reduced Tat function. During transcomplementation of the rev mutant by rev cDNA, there was a decrease of both the steady state levels and rates of synthesis of Nef accompanied by enhanced viral structural proteins. Nef protein, a transcriptional repressor (Ahmad and Venkatesan, Science, 241: 1441-1445, 1988), moderated the Rev induced transactivation in a dose dependent manner. Neither the replication of standard provirus nor the repression induced by rev cDNA was modulated by cotransfection of rev cDNA.

Conclusion: The ability of Rev to modulate Nef expression from the provirus and hence relieve the inhibition of LTR transcription reveals a delicate balance of functions of these two proteins that might underlie the switch between latency and reactivation.

Session d'attribution
Poster Session



Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

T.C.P.115 EFFECT OF MUTATIONS IN VPX ON THE INFECTIVITY OF VIRAL PARTICLES OF HIV-1

Y. Guyader¹, M. Zemmouji¹, L. Montagnier¹ and Keith Purcell², Institut Pasteur, Paris, France; ¹ and Johns Hopkins University School of Medicine, Baltimore, USA.

Objective: To determine whether the *gag* open reading frame, which is present in HIV2 and HIV1 genomes but less so in counterpart in HIV1, is expressed in infected cells and to investigate the phenotypes of VPX mutants. **Methods and Results:** Two anti-peptide sera raised to the predicted product of the HIV-2 *gag* open reading frame immunoprecipitated a 16-kD protein from the cell extract and medium of cells infected with HIV-2, and a 14-kD protein from HIV-1-infected cells. We used site-directed mutagenesis to introduce two types of mutations in the *gag* open reading frame. Cell-free supernatants from 5W480 cells transfected with the mutated HIV-2 proviral clones were used to infect several CEM⁺ lymphocytes and monocyte cell lines as well as fresh peripheral blood lymphocytes. Mutations in the *gag* open reading frame eliminated the synthesis of the 16-kD protein, confirming that this protein is the product of this gene. Full-length clones of HIV-2 containing these mutations are infectious to two established lymphocyte cell lines and a monocyte cell line. In contrast, they show a severe defect in their ability to infect peripheral blood lymphocytes. **Conclusions:** These findings suggest that the VPX protein may be important in the *in vivo* life cycle of the HIV-2/HIV1 viruses.

T.C.P.117 CONSTITUTIVE SYNTHESIS OF NF- κ B-LIKE NUCLEAR PROTEINS IN MONOCYTES-AN EXPLANATION FOR HIV LATENCY?

Nancy McCannary-Fraser¹ and Michael Norros², ¹NIDH, NIH and ²CDR, Baruch College, CUNY

Objective: To determine if NF- κ B nuclear elements contribute to the regulation of HIV-1 gene expression in normal human monocytes. **Methods:** Nuclear proteins from freshly isolated and cultured monocytes and analyzed for NF- κ B binding activity to HIV-1 LTR and mutant double-stranded oligonucleotides by gel retardation assays. Monocyte activation was monitored by IL-2 synthesis and IL-1 receptor expression. **Results:** Nuclear proteins isolated from 18 hr unstimulated and LPS-activated monocytes contain specific NF- κ B binding activity as observed by binding to oligonucleotides encoding a single NF- κ B enhancer region from the HIV-1 LTR. No binding was observed to a mutant sequence. Specific binding could be blocked by unlabeled wild-type oligonucleotides but not by the mutant oligomer. Surprisingly, freshly isolated monocytes (IL-2 receptor and IL-1 negative) and LPS-stimulated monocytes expressed equivalent amounts of NF- κ B binding activity. **Conclusions:** Resting monocytes constitutively express NF- κ B-like binding proteins and the level of expression is unchanged by the state of activation. Whereas NF- κ B has been shown to stimulate HIV-1 gene expression in T lymphocytes, it appears unlikely that NF- κ B expression is solely responsible for the functional and phenotypic changes in monocyte activity following HIV-1 infection. The constitutive synthesis of NF- κ B binding proteins in circulating monocytes may explain the persistence of HIV-1 in macrophages throughout the clinical course of AIDS.

T.C.P.119 DETECTION OF A NOVEL DNA TOPOISOMERASE I ACTIVITY ASSOCIATED WITH HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND OTHER RETROVIRUS PARTICLES

Eric L. Esteban¹,*, Tami A. Abedi¹, N.***, Shovalter, S. D.***, Roberts, M.***, Oroszlan, S.***, and Blair, D. C.*****, ¹Laboratory of Molecular Cancer Analysis, Frederick, MD 21701-1011; ²Ben-Gurion University, Beer-Sheva, Israel; ³Program Resources, Inc., Frederick, MD 21701-1011; ⁴Amgen/Research, Inc., Frederick 21701-1011, USA.

The viral replication cycle is undoubtedly dependent on numerous topological changes of the viral and host genomes. Since DNA topoisomerases have been shown to be responsible for the topological changes of DNA, it was of interest to investigate whether a topoisomerase activity could be demonstrated in retroviral particles.

In this work we demonstrate the existence of DNA topoisomerase I (Topo I) activity associated with two strains of purified HIV-1, equine infectious anemia virus (EIAV) and Moloney murine leukemia virus (Mo-MuLV). The relaxation activity from these viruses was inhibited by camptothecin (CPT), a specific topo I inhibitor. The viral associated topo I activity is Mg²⁺ dependent and possesses other characteristics different from the host cell enzyme. The viral associated topo I activity was removed from the viral lysate by anti-topo I serum. Western blot analysis indicates that an 11.5 kDa protein from both strains of HIV-1 and an 11 kDa protein from EIAV is recognized by this anti-topo I serum. By stellar protein detection with the appropriate nuclear or cytoplasmic cell extracts.

T.C.P.116 EXPRESSION IN E. coli AND PURIFICATION IN ONE STEP OF A FUNCTIONAL HIV896 PROTEIN BETWEEN A BACTERIAL FUSION PARTNER PROTEIN (MALM) AND THE T LYMPHOCYTE-HELPER INDUCER-CD4 PROTEIN (CD4-FUSION PARTNER)

CLÉMENT, Jean-Marie¹, SZMELCMAN, S.¹, SCHWARTZ, D.*, BENIN Y.***, MONTAGNIER L.*** & HEDGECOCK M² L.*****, ¹P.M.T.C.G. & ²Oncologie Virale, Institut Pasteur, 25 rue de St. Rosa, Paris 75015, France.

The surface glycoprotein CD4, expressed on helper/inducer T lymphocytes, serves as the HIV receptor through binding of the virus envelope protein gp120. It was recently demonstrated that the soluble truncated molecule of CD4 (the 177 kD terminal amino acids) retains the ability to bind gp120 and to neutralize the HIV particle.

We describe the purification and characterization of a recombinant protein produced by *E. coli* that contains the HIV binding portion of the human CD4 molecule, fused to the periplasmic maltose binding protein (MBP) of *E. coli*. This fusion protein retains the functional properties of the CD4.

1. It binds maltose and maltodextrin. This property is used in a one step procedure to purify the recombinant protein by affinity on a amylose column with elution in mild conditions.
 2. It binds purified gp120 and neutralizes HIV particles *in vitro* it is also recognized by the monoclonal neutralizing antibodies 177A and OKT4A.
- The easy purification of active soluble MBP-CD4 protein from bacteria should also facilitate a number of studies such as screening and possibly selection of CD4 mutants with altered properties (stability, interaction with virus etc), investigation of therapeutic potential of CD4, determination of CD4 structure by x-ray crystallography. The CD4-MBP hybrid could also be useful as a reagent for various purposes: diagnostic, HIV virus purification isolation of HIV mutants...

T.C.P.118 ACTIVATION OF THE HIV AND INTERFERON REGULATORY ELEMENTS IN HEMATOPOIETIC AND EPITHELIAL CELLS

Hiscoot, J., Cohen-Asprouh, Leblang, Jean-François, Sportiva, L., and Karanitsoulis, S., Lady Davis Institute, Jewish General Hospital, and Dept. of Microbiology and Immunology, McGill University, Montreal, Canada.

Objective: The interferon- β promoter contains several functional domains that confer virus-inducibility to the structural IPR gene. Interestingly, one of these specific elements, the P2 domain (GGAGATTC)-44 to -55' relative to the mRNA start site), shares 80% sequence homology with the two NF- κ B recognition sites (GGGATTGG) within the 13 enhancer element of the HIV long terminal repeat (LTR). This observation prompted us to measure the transcriptional activity of dimers of P2 and NF- κ B motifs in a transient expression assay using epitheloid (EP3), T lymphoid (Crestack), and myeloid (U937) cell lines.

Methods & Results: Cells were transfected with expression vectors containing various synthetic IPR and HIV regulatory motifs linked to the CAT reporter gene and subsequently induced with Sendai virus and/or phorbol esters. Both regulatory elements displayed similar patterns of inducible gene expression. Furthermore, specific inducible protein-DNA complexes were identified between P2 or HIV enhancer by band retention assays using uninduced and induced extracts from hematopoietic and epitheloid cell lines. Competition analysis suggested that the IPR P2 domain and HIV enhancer could interact with similar DNA binding proteins. **Conclusion:** Together, these results suggest that induction of IPR gene expression may share mechanistic similarities with the activation of the HIV-LTR.

T.C.P.120 REF RESPONSIVE SEQUENCES (RR) OF THE HIV-1 LTR-MEDIATE TRANSCRIPTIONAL SUPPRESSION

Jan Hahn¹ and Greg Giddens², ¹Department of Medicine and Microbiology & Immunology, Washington University, St. Louis, Mo., USA

Objective: The *gag* gene of HIV-1 encodes a 206 amino acid, 27 kD protein that down-regulates virus replication. This effect is mediated by REF suppression of transcriptional initiation. This effect is mediated by a cis acting element in the HIV-1 LTR which is responsive to REF.

Methods and Results: Two proviral HIV-1 clones were constructed, pHR1 P₁ which bears an intact *gag* gene, and pHR1 P₂ which has a 45 base pair deletion in the 3' portion of the HIV-1 LTR. These plasmids were transfected into COS-1 cells. Nuclear run-off, Southern blot hybridization, and gel retardation assays demonstrated that REF suppresses RNA initiation and viral RNA and protein levels. 2-10-fold. A REF expression vector, pRV, was made using an SV40 promoter. Co-transfection of pRV in a 5-fold excess with HIV-1 LTR-CAT resulted in an 8-fold depression of CAT activity. REF-mediated suppression was dose dependent and was specific for the HIV-1 LTR in that the pRV promoter, and the LTRs of HIV-1, HIV2, and SPV were unaffected. HIV-1 LTR CAT deletion mutants were used to map the REF. These constructs were co-transfected into COS cells with or without pRV or a CAT expression plasmid. Mutants with nucleotides -65 to -93 deleted in the RNA initiation site were responsive to REF, whereas those with nucleotides -44 to -93 were unresponsive to REF. In addition, a 30 nucleotide REF binding site in the HIV-1 LTR acting through sequences between -45 and -93. The activity of REF is independent of that of CAT. Previous data of REF, proteinase mediated interactions with SP1 and TATA-binding factors, and the mechanism of transcriptional silencing are being investigated.

Session d'Affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

T.G.P.121

MYRISTOLATION DEPENDENT ASSEMBLY OF INFECTION HIV-1
Jan Raderer and M. Ryan*, Departments of Medicine and Pathology, Washington University, St. Louis, Mo., USA

Objective: Linkage of myristic acid via an amide bond to the amino-terminal Gly residue of the GAG precursor of mammalian retroviruses appears to facilitate an essential step in virus assembly. The goal of this study was to determine if myristic acid incorporation into HIV-1 GAG proteins are required for replication and infectious particle production.

Methods: Oligonucleotide-directed mutagenesis was used to change the codon for the N-terminal Gly of GAG to an Ala codon in a functional HIV-1 proviral clone, HD32. The mutant plasmid, HD-GAG-1, and the parental plasmid were transfected into two CD4+ cell lines, CCR-1 and Hela, and CD4+ Jurkat cells. On day 4 following transfection, the CD4+ cells were cocultivated with H9 cells to support reverse transcription of HIV-1 RNA.

Results: Viral antigen was detected following transfection of each of the CD4+ cell lines with either HD32 or HD-GAG-1. However, no infectious virus was detected in culture supernatants revealed only soluble GAG protein, and no detectable virus particles. However, infectious virus was not produced following cocultivation with susceptible H9 cells, or direct transfection of Jurkat cells. In contrast, transfection of each of the cell lines with HD32 plasmid produced infectious virus. Transfection of the CD4+ cells with HD-GAG-1 and a GAG-Pro expression plasmid resulted in virus replication, demonstrating complementation of this defect.

Conclusion: Myristylation of the HIV-1 gag polypeptide is required for virus replication and assembly. These data suggest that inhibition of myristylation will open a new avenue of anti-retroviral research.

T.G.P.122

BIOLOGICAL SIGNIFICANCE OF HIV-1 ENVELOPE HETEROGENEITY
Terry McHenry, P Westarvic, M Thilman, D Trowbridge, J Garcia, and L Bacter, Departments of Medicine and Microbiology & Immunology, Washington University, St. Louis, Mo., USA

Objective: To examine the nature and biological significance of naturally occurring variations in HIV-1's derived from blood, brain, and lung of 3 patients infected with a single proviral virus. Methods and Results: Isolates were obtained from short term FMC cultures cocultivated with fresh tissue from an asymptomatic, HIV seropositive blood donor (pt 1), and two neonatal transfusion recipients who subsequently developed AIDS (pts II & III). Isolates from the lung and brain of pts II & III replicated to 100-fold higher levels on monocytes relative to the blood isolates from the same patients; no growth differences on lymphocytes were observed. The 3' portion of the genome was cloned from each isolate, and analyzed. The predicted amino acid sequence from the blood isolate of pt 1 shows a 145 divergence compared to clone HD32. The positions of Cys residues are conserved. No unique amino acid changes are found in the clones derived from the brain or lung isolates. All clones derived from these patients exhibit 2 transmembrane codons in the portion of *env* encoding TM. Conclusions: envelope amino acid sequence variation observed in these genomes is considerably lower than that reported for adults with AIDS, possibly reflecting the host's limited ability to provide selection pressure. The lack of a consistent difference in *env* between clones derived from isolates which show markedly different replication on monocytes suggests that other protein(s) of the HIV-1 genome may be contributing to cell specificity.

T.G.P.123

HIV INFECTION OF COLONIC MUCOSA ASSOCIATED WITH COLITIS
J.W. Mehlis, M. Hing, C. Goldschmidt, D.A. Cooper, and A.L. Cunningham-Virgilio Unit, Centre for Immunology, St. Vincent's Hospital, NSW, Special Units for Clinical Research and Epidemiology and AIDS Virus, Sydney Australia.

The aetiology of diarrhoea in patients infected with the human immunodeficiency virus infection often remains obscure. We report 7 patients with human immunodeficiency virus infection with chronic diarrhoea for longer than 6 months, rectal bleeding, abdominal pain and stool leukocytosis. The mucosal pattern on colonoscopy showed diffuse proctocolitis. Colonic biopsies showed moderate to severe colitis characterized by preservation of normal crypt architecture and a mixed inflammatory cell infiltrate. These features were not compatible with a diagnosis of chronic inflammatory bowel disease. HIV nucleic acid was identified by *in situ* hybridisation in colonic biopsies from 4 out of 6 patients. Autoreactive plasma were distributed in clumps over epithelial cells of the colonic glands (not confined to argente/fin cells) and over cells in the lamina propria. Hybridisation-histochemistry is being used to identify the latter cells. No other microbial agent could be demonstrated as the cause of diarrhoea. At presentation all patients had CD4+ lymphocyte counts greater than 150 x 10⁶/l, and none had AIDS. We suggest that this chronic colitis is a new entity related to infection of the colon with the human immunodeficiency virus.

T.G.P.124

ANALYSIS OF HIV SEQUENCE CHANGE DURING INFECTION
Lalan Brown, Andrew C. and Baljit P. University of Edinburgh, Edinburgh, Scotland, UNITED KINGDOM

Objective: To develop a method of analysis which will detect selection for HIV sequence variants during infection. Methods: The probability that more than one lineage will be found in a sample taken *n* generations after the first has been estimated using the method of branching processes (Hastings 1957). The approach has been applied to the data of Saag et al. (Nature 334, 440 1988). Results: By phylogenetic analysis based on the Wagner parsimony method we have found that the W89 group of clones originated from within the W81 group isolated 16 months earlier and did not arise in parallel. Thus, after 2 months all but one W81 lineage had become extinct. We have examined the probability of loss of all but one lineage in these data assuming no selection and a generation time of 5 days (based on observations made during virus isolation in our laboratory). The probability of more than one lineage persisting was found to be less than 0.05. It is therefore not necessary to invoke selection to explain the relationships between the W89 and W81 clones. Conclusions: The method we have used will be effective at detecting selection when the number of generations between samples is 10-50 (about 5-8 months). There is no evidence on these data for selection among clones isolated from patient W89.

T.G.P.125

LOCALIZATION OF A DOMAIN OF HUMAN CD4 REQUIRED FOR HIV-MEDIATED SYNCTIUM FORMATION BY COMPARISON WITH CD4 FROM THE CHIMPANZEE AND RHESUS MONKEY

David Cameron and Brian Seed, Dept. of Molecular Biology, Massachusetts General Hospital and Dept. of Genetics, Harvard Medical School, Boston, MA, U.S.A.

Objective: To locate regions of the Human CD4 glycoprotein required for HIV-1 mediated synctium formation.

Methods: We have isolated, sequenced, and expressed cDNAs encoding the CD4 glycoproteins of the chimpanzee (*Pan troglodytes*) and the rhesus monkey (*Macaca mulatta*). We performed HIV-1 infection, binding and fusion assays using cell lines expressing these antigens. We constructed trans-species hybrid CD4 antigens *in vitro*, and tested their ability to promote HIV-1 mediated synctium formation.

Results: Both the chimpanzee and rhesus monkey CD4 antigens, respectively 99% and 92% homologous to their human counterpart, bind HIV-1 and permit infection when expressed on Hela cells. Nevertheless, these non-human receptors are markedly less efficient than human CD4 at promoting HIV-1 mediated synctium formation. We have located individual amino acid differences between the human CD4 and these non-human CD4 glycoproteins, responsible for their differing abilities to participate in HIV mediated synctium formation.

Conclusion: We have defined a region of the human CD4 glycoprotein, distinct from the previously defined binding site for HIV-1, which is essential for the formation of synctia in the presence of the external and transmembrane glycoprotein of HIV-1.

T.G.P.126

STUDIES ON THE FUNCTION OF VPX IN HIV-2
L. Brown, D. Doster, W.D.; Len. B.W.; Monroe, C.D.; Shaw, G.M.; and "HIV-2" (1988)

Department of Microbiology, Washington University, St. Louis, Missouri, USA.

Objective: To determine the role of vpX in the life cycle of HIV-2. Methods: To study the biological function of vpX, we constructed a transfection-competent plasmid and utilized a series of deletion constructs. Results: An internal HindIII site containing fragment was subcloned into M13 and mutagenized so as to abolish vpX transcription. The role of vpX was then assessed by cotransfection of wild-type and mutant vpX with respect to packaging efficiency, genomic stability, virus-particle expression, cytopathicity, and reverse transcription. For reverse transcription, a 100-fold increase in reverse transcriptase activity was observed in cultures transfected with unmutated vpX. Results: Transfection of type HIV-2 indicated that vpX is not essential for reverse transcription. However, the mutant HIV-2 virus was unable to infect non-lymphocyte (FRL) Upon transfection into untransformed T-cell lines (Sp71 and CEM474) by a non-tissue specific promoter, the mutant HIV-2 virus was unable to infect T-cells. This was not comparable to wild-type and wild-type HIV-2. Both mutant and wild-type viruses were infectious and viable upon transfection into T-cells. Results: Infection of untransformed wild-type HIV-2 virus-infected and replication competent in FRL. Electron microscopy revealed apparent differences in virus ultrastructure in comparison to wild-type HIV-2. Transmission electron microscopy following high salt extraction of Sp71 cells demonstrated that virus binding, uncoating and reverse transcription were identical in mutant and wild type viruses. Finally, construction of cDNA clones with a unidirectional HIV-2 genome and a subgenomic vpX expression plasmid resulted in the production of virus containing viruses and demonstrated that vpX can be complemented *in vitro*.

Conclusion: vpX is not required for HIV-2 replication and cell-to-cell transmission in immortalized T-cells as well as in FRL *in vitro*. Similarly, the lack of vpX does not seem to affect early events in the virus life cycle. Since vpX is packaged within mature viruses, despite the absence of HIV-2 assembly of particle matrices in these construction systems, we believe that the packaging requirements of HIV-2 are similar to those of HIV-1 and should be investigated in future studies.

Session d'attachage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

T.C.P.127 COMPARATIVE ANALYSIS OF HIV-1 AND HIV-2 GENE EXPRESSION Arzq. Suragh, K. and Gallo, R.C. National Cancer Institute, NIH, Bethesda, Maryland, USA

Objectif: HIVs may comprise a spectrum of retroviruses with varying pathogenicity and/or latency. Their pathogenicity may be determined by their regulatory genes and regulatory elements. The objective of this study was the comparative analysis of the regulatory genes and elements of HIVs with varied pathogenic potential. **Method:** Functional and molecular analysis of the regulatory genes and response elements by DNA mediated transfections. **Results:** Pathogenic HIV-1 (H11) and HIV-2 (H2A) as well as HIV-2 with attenuated cytopathicity (HIV-2[3]) all contain functional *tat*, *reg*, and *rev* genes. Additionally, their expression is equally activated by T cell activation and HIV-2 transactivation. Interestingly, the SLS and T cell activation response elements in HIV-1 and HIV-2 are structured differently. For example, even though HIV-2 contains the distinguished enhancer element identical to that in HIV-1 where it responds to T cell activation (NFkB site), the major such element of HIV-2 is located upstream and is supposedly a member of a family of response elements. The HIV-1 and HIV-2 transactivation by the *tat* and *ORF* transactivator gene involves transcriptional activation including chain initiation and elongation. While HIV-1 and HIV-2 may utilize subtly different pathways of gene activation, they both contain functional *tat*, *reg*, and *rev* genes and response elements including those responsive to T cell activation and ORF transactivation. Thus, the possible differences in their pathogenicity may not reside in the functional capacities of the regulatory genes and elements alone.

T.C.P.129 A STRATEGY FOR THE DETECTION OF SPECIFICALLY SPLICED mRNA ENCODING HIV-1 REGULATORY GENES

Gustail, J.M., Richman, D.C., and Grogan, T.M.

*Dept. of Medicine, Harborview School of Medicine, St. Joseph, California, 92161 USA. **The Salk Institute Biotechnology/Industrial Associates, Inc. (SIBIA), La Jolla, California, 92037 USA.

Objectif: To differentially detect specific mRNA encoding the HIV-1 regulatory genes *tat*, *rev*, and *reg* in order to study the temporal expression of these transcripts during infection *in vitro*.

Methods: Primer-directed nucleic acid amplification was used to generate cDNA fragments of characteristic length which reflected gene-specific mRNA expression.

Results: Total cellular RNA from HIV-1-infected CD4 cells was amplified using primers complementary to: 1) the sequence immediately 3' of the splice donor common to all processed HIV-1 RNAs (5' of the gag start codon); and 2) the sequence at the 3' end of the *tat* and *rev* 3' coding exons. Between these two sequences are three splice acceptors whose use has been suggested to lead to specific mRNAs encoding *tat*, *rev*, and *reg*. The predicted cDNA fragments of 290, 108, and 92 base pairs, reflecting *tat*, *rev*, and *reg* mRNAs, respectively, have been detected using specific oligonucleotide probes. Several cDNA fragments of unexpected size have also been detected. Characterization of these fragments will be discussed.

Conclusion: Although differential detection of HIV-1 regulatory gene transcripts is difficult because of their similar size and largely shared monoclonal sequences, gene-specific splice events can be detected utilizing primer-directed amplification. This approach can be used to analyze the order of expression of these transcripts during infection.

T.C.P.131 POLYMERASE CHAIN REACTION IN HIV INFECTION

Mariotti, M., Lafrenay, Jean-Jacques, Berriche, S., Vitaroon, D., A. N. F. T. S., Paris, **Hôpital Charles, Paris **C.T.S. Chemistry, France.

Objectif: Use of Polymerase Chain Reaction (PCR) in human immunodeficiency virus (HIV)-infected subjects and in seronegative but high risk subjects.

Methods: Localization of the genome and nucleotide sequence of the primers and probes used (derived from conserved regions of the viral genome) were:

- GAG : primer 1088-1115, primer II 1175-1202, probe 1132-1172
- POL 1 : primer 2381-2616, primer II 2872-2688, probe 2139-2271

- POL 2 : primer 8118-8135, primer II 8242-8259, probe 8167-8265

Site-blot and Southern-blot analysis were used in detection of HIV sequences. 530 subjects were studied : 200 non-haemophilic HIV seropositive (Elias with confirmation by Western-blot) subjects (among them, ten were seronegative 6 months earlier) ; 40 haemophilic patients (20 seropositive + 20 seronegative) ;

25 AIDS patients ; 25 seronegative posttransfusion thalassaemia patients ; 20 subjects with isolated and persistent anti-core antibodies (anti-p24 or anti-p18) ; 20 seronegative partners of HIV seropositive subjects (a second sample was collected and studied 6 months later in 6) ; 20 healthy seronegative blood donors as controls.

Results: 1) PCR is positive in the HIV seropositive subjects but some appear negative in this assay when using only one single primer pair and probe. The use of three sets of primer appears necessary to prevent false-negative results in this context. 2) No detection of HIV DNA was observed in seronegative subjects from high risk groups. 3) All control subjects were PCR negative.

Conclusion: PCR allows the detection of HIV DNA in seropositive subjects and confirms the absence of HIV infection in seronegative subjects.

T.C.P.128 RESTRICTION MAP PATTERNS IN SELECTED CLINICAL PAIRS OF HIV ISOLATES

Shelton, Margaret, Reichman, F., Mason, J., Bedford, R.,

et al., and the Walter Reed Retroviral Research Group, U.S.A.

Objectif: To evaluate restriction mapping of selected viral isolates to determine the potential value of application in defining the identity of viral isolates.

Methods: Purified viral isolates were obtained by co-cultivation with normal SP2 using standard techniques. Southern blots of restriction enzyme digests of viral DNA probed with 32P labeled 887 fragment of p8.9.

Results: Specific paired samples were selected and viral isolates classified. Group 1 consisted of a sequential isolate pair (less than 6 weeks apart) from the same patient (two early HIV infection and two late HIV infection).

Group 2 consisted of 2 isolate pairs from same patient however different body fluid source (CSF/serum). Group 3 consisted of same patient same time different isolation techniques (T cell versus macrophage). Group 4 consisted of epidemiologically paired to include acute and asymptomatic pairs. Restriction patterns of pair isolates will be compared to unrelated isolates to develop an identity score.

Conclusion: These results demonstrate the applicability of restriction mapping in defining viral identity.

T.C.P.130 PROCESSING OF THE gag POLYPROTEIN BY HUMAN

IMMUNO DEFICIENCY VIRUS PROTEASE OCCURS IN

A SEQUENTIAL MANNER

S. Erickson-Villano, John Manfredi, Paul Vitanen, David Tribe, Radonna

Trich, Ronald Swanstrom, et al. E.I. DuPont de Nemours and Co., Inc.

Medical Products Department, Wilmington, DE, USA 19880-0400 and

Departments of Biochemistry and Microbiology and Immunology, University

of North Carolina at Chapel Hill, Chapel Hill, NC, Carolina, 27599.

The virally encoded protease of human immunodeficiency virus is responsible for the processing of the gag and gag-pol

polyproteins to their mature polypeptides. Since correct processing of the viral polyproteins is essential for the production of infectious virus, HIV

protease represents a potential target for therapeutic agents. In this study, full-length gag polyprotein has been synthesized *in vitro* to serve as a

trans substrate for bacterially expressed HIV protease. The gag polyprotein is rapidly and completely processed by protease-containing

extracts. Immunoprecipitations with monoclonal antibodies to p17 and p24 suggest that initial cleavage of the polyprotein occurs at the p24-p15 junction. The proteolysis was inhibited by pepstatin with an IC50 of 0.15

nM for cleavage at the p24-p15 junction and 0.02 mM for cleavage at the p17-p24 junction.

T.C.P.132 IN VITRO EXPRESSION OF A FUNCTIONAL HIV-NIF GENE PRODUCT

Paulo Louisa and Jay, J. Cancer Research Institute, University of California,

School of Medicine, San Francisco CA 94143 USA

Objectif: To study the biochemical function of the HIV-1 protein.

Methods: We have subcloned the HIV-2 nif gene DNA from an original plasmid (p900-8) provided by Paul Lewis (University of California Davis, CA) into a baculovirus vector (Sf9000, MDL). The new construct was used in a transcriptional readthrough system to produce the NIF gene product. The gene product was then translated into a microsome nucleus treated reticulocyte lysate. Finally, the purified nif gene product was analyzed in an *in vitro* assay for GTP binding activity and kinase activity.

Results: The nif mRNA encoded for a 37 kDa protein of 27 kDa dature as determined by polyacrylamide gel electrophoresis. This finding is in accordance to the predicted molecular weight and is similar to what is found in HIV-infected cells. This p27 is recognized by either specific monoclonal antibody (Dapin, M4) or polyclonal anti-HIV-2 NIF protein.

In addition, three other products of 29kD, 25kD and 17kD are also synthesized at a much lower level in the reaction and are also recognized by the same antibodies.

Immunoprecipitated nif protein can bind specifically 32P-gamma-GTP. Furthermore, the immunoprecipitated translation products display a kinase activity in the presence of either 32P-gamma-GTP or 32P-gamma-ATP. However, the phosphorylated product of this *in vitro* kinase assay runs as a single band with a molecular weight of 40 to 50 kDa on either a polyacrylamide gel.

The phosphorylation activity is dependent of the concentration of the nif translated products.

Conclusion: The HIV nif gene expressed *in vitro* possesses an integral GTP binding activity and kinase activity. The establishment of an *in vitro* system to study the structure and the biochemical function of the purified nif protein known as a negative regulator of HIV expression.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

T.C.P.133 TWO EPSTEIN-BARR VIRUS-LATENT PROTEINS (LMP AND EBNA2) TRANSCRIPTIVE TARGET THE HIV-1 LTR
Simurda, Maryanne C. and Hammarikid, M.-L.
Departments of Microbiology and Oral Biology, State University of New York at Buffalo, Buffalo, N.Y. 14214, U.S.A.

We have constructed SV40 based vectors that express different latent proteins of Epstein Barr Virus (EBV). Using these constructs we have shown that both the nuclear EBNA2 protein and the latent membrane protein (LMP) are efficient transactivators of the HIV-1 LTR. Both of these proteins are expressed in B lymphoid cells immortalized by EBV. To map the regions of the LTR involved in the transactivation we have used different mutated forms of the HIV-1 LTR linked to CAT as a reporter gene. CV-1, Ramos, Raji and Jurkat cells were co-transfected with these constructs and the vectors expressing EBNA2 and LMP. Results showed that most of the effect of the LMP protein could be mapped to the binding sites for nuclear factor κ B (NF- κ B). These results indicate that LMP activates second messengers that are involved in activation of NF- κ B of related factors. The effect of the EBNA2 protein could not be mapped to a single defined cis-acting element and seems similar to that observed with immediate early proteins of other herpesviruses.

T.C.P.135 DETECTION OF ACTIVE VIRAL PROTEASE ASSOCIATED WITH CAPSIDS OF EQUINE INFLUENZA VIRUS (EIAV)
Roberts, Michael, and Grosslein, S. MD, Basic Research Program, MCJ-Frederick Cancer Research Facility, Frederick, MD 21701-1013, USA.

The cores of retroviral particles are likely to contain all the components required for infection of the host cell once it has reached the cytoplasm. In this respect, it was of interest to prepare cores of EIAV as a model system for the human immunodeficiency virus (HIV).

In this work we have prepared cores of EIAV by treatment of whole virus with detergent followed by two cycles of rate-zonal banding through Ficoll density gradients. The major components of the core are the p11 (nucleocapsid protein) and p26 (capsid protein) which are present in equimolar amounts, as in the whole virus. Since the cores are not deficient in p26, they are referred to as capsids. The other gag-coded proteins p9 and p15 are removed during the preparation. At pH 7.6, the presence of active viral protease in the capsids was revealed by cleavage of p11 to a p6 protein. This cleavage was inhibited with pepstatin, which is known to work with retroviral proteases. The existence of the capsid as a distinct morphological entity was shown by electron microscopy of negatively stained particles. By this means, the capsids are revealed as uniform cone-shaped particles 60nm x 120nm in size. The significance of the p11 cleavage at this stage in the retroviral life cycle is being investigated. (Research supported by the National Cancer Institute, DMS, under contract NO-MO1-GO-7410) with Biogenetics Research, Inc.)

Additional

Additional

T.C.P.137 HIV-1 gag EXPRESSION IS DEPENDENT ON A GENERAL 'SHUFFY' SEQUENCE
Wilson, Wilma; Braddock, M.; Kingman, S.M.* and

Kingman, A.J.†
*Department of Biochemistry, South Parks Road, Oxford, OX1 3QU, U.K.
†British Biotechnology Ltd., Watlington Road, Cowley, Oxford, U.K.

Objective: To determine the minimal sequence requirements for the frameshift event which is essential for gag expression and to examine the significance of this 'shuffy' sequence in cellular genes.

Methods: We have used an SP6 in vitro system to assay a series of fragments and oligonucleotides for their ability to frameshift.

Results: We have shown that a short (28bp) sequence containing a run of 6 Ts is sufficient for gag expression in both yeast and mammalian systems. We demonstrate that 6Ts alone are able to direct frameshifting. Shifting occurs irrespective of the reading phase of the Ts and occurs into both reading frames. The possibility of frameshifting occurring in other genes containing 6Ts has been examined and we demonstrate shifting in a cellular gene which contains this 'shuffy' sequence.

Conclusions: HIV-1 employs a general 'shuffy' sequence of 6Ts in its expression of gag. It is possible that the frequency of 6Ts is also modulated by other viral proteins or by the particular sequence context.

T.C.P.134 INFECTION OF RHESUS MACAQUES WITH A MOLECULARLY CLONED SIMIAN IMMUNODEFICIENCY VIRUS
Paul Laidlaw, M. Marbas, E. Banerjee, T. McGraw, P. Marx and N. Pedersen, University of California, Davis, California, U.S.A.

Objective: To analyze rhesus macaques infected with a molecularly cloned SIV with respect to viral replication, viremia, and ability to elicit anti-viral immune responses.
Methods: An infectious molecular clone of SIV from a rhesus macaque was found to replicate to high titer in cultures of primary rhesus peripheral blood mononuclear cells (PBMC) and macrophages derived from rhesus PBMC. Six juvenile rhesus macaques were inoculated intravenously with SIV recovered from the molecularly cloned provirus.

Results: All animals recovered from PBMC of all animals at one and two weeks PI. Inoculation (PI) and virus was recovered from PBMC of all animals at one and two weeks PI. Antibodies to gag-coded proteins were detected before antibodies to the gag-p1 precursor and p17 gene products. Only one animal developed detectable antibody to the p27 gag gene product. One antibody to SIV-coded proteins were elicited, they persisted; however, SIV-specific neutralizing antibody titres declined after one month PI. By ten months after inoculation three of the animals had exhibited transient viremia (as detected by co-cultivation with human lymphoid cells), three were consistently virus negative and none had developed clinical signs of SIV disease.

Conclusions: SIV from a molecular clone is capable of producing a persistent and, perhaps, latent infection in rhesus macaques; however, the outcome of infection appears to be dependent on the individual host. These animals remain under study to assess the pathogenic potential of an SIV isolate that has been shown to be both T-cell tropic and macrophage tropic.

T.C.P.136 EXPRESSION OF HIV GENES IN XENOPUS OOCYTES: DEMONSTRATION OF POSTTRANSCRIPTIONAL REGULATION

Adachi, Junji, Samoil, K. Ilioman, Mary* and Joseph, Steve**
*Human Genetics Branch, NICHD, Bethesda, MD and Laboratory of Tumor Cell Biology, NCI, Bethesda, MD, USA

Objective: To study posttranscriptional aspects of HIV gene regulation in *Xenopus* oocytes.

Methods: Purified normal and mutant LTR/CAT transcripts were synthesized using the bacteriophage T7 polymerase system. These were coinjected with plasmid DNA constructs into the nucleus and/or cytoplasm of *Xenopus* oocytes. CAT assays and RNA analyses were performed by standard methods.

Results: HIV genes can be faithfully and efficiently expressed in the *Xenopus* oocyte. We can demonstrate posttranscriptional regulation of the normal LTR/CAT construct. Constructs with TAR mutations express very low basal levels and are not regulated. **Conclusions:** The *Xenopus* oocyte is a suitable system for the study of HIV gene expression. Our results suggest a posttranscriptional TAR dependent regulation.

T.C.P.138 MOLECULAR CHARACTERIZATION OF THE HUMAN CD4 GENE
Hanna, Zehava; Cheung, E.* and Jolicoeur P.***

*Clinical Research Institute of Montreal, Montreal, Quebec, Canada; **Université de Montréal, Montreal, Quebec, Canada.

The human CD4 molecule has been shown to serve as a specific membrane receptor for HIV. To better understand the control of the expression of this gene as well as its specificity of expression in specific cell populations, we undertook its molecular cloning. Using the CD4 cDNA probe, we isolated a set of overlapping genomic clones from human genomic libraries constructed in the lambda cloning vector EMBL-3. These clones span the CD4 gene and its adjacent sequences. Clones were characterized by restriction enzyme analysis and by Southern hybridization. The putative promoter has been identified and partially sequenced. Search has been initiated to identify enhancer sequences using transfection techniques with the CAT vector and by constructing transgenic mice.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

T.C.P.145 5'-PHOSPHONATE DERIVATIVES OF 3'-AZIDO-2',3'-DIDEOXYNUCLEOSIDES: SYNTHESIS AND INHIBITION OF HIV REPRODUCTION IN CELL CULTURES

TARUSOVA, N.I.; KUKHAROVA, N. I.; KOROLIN, A.; KRYAZEVSKY, A.; GIL'GAY, V.; KOPAL, S.; LITVINOV, I.; BAKHARALIN, G.; VIL'KIN, V. Engelhardt Institute of Molecular Biology, the USSR Academy of Sciences, Moscow; D'vinskii Institute of Virology and Immunological Research Center, the USSR Academy of Medical Sciences, Moscow, USSR

Objective: A group of new 5'-phosphonate of 3'-azido-2',3'-dideoxynucleosides was studied in cell cultures, infected by HIV. **Methods:** Synthesis of 5'-hydrophosphonates, 5'-methylenephosphonate and 5'-methylphosphonate of 3'-azido-2',3'-dideoxynucleosides was elaborated. The activity of these compounds on HIV reproduction in HIV-1 infected T84 cell cultures was evaluated by reverse transcriptase activity and using immunofluorescent and autoradiographic analysis.

Results: 5'-Methylene- and 5'-hydrophosphonates of 3'-azido-2',3'-dideoxynucleosides revealed the activity close to that of 3'-azido-2',3'-dideoxynucleoside (AZT) at the suppression of HIV-1 reproduction, whereas their toxicity was significantly lower both in HIV-1 infected and noninfected cells. 5'-Hydrophosphonates of AZT and AZC were essentially more active than initial nucleosides, their toxicity being as well significantly lower. Some statistical data for 5'-phosphonates in cells were investigated. **Conclusion:** The new group of highly active anti-HIV compounds was found.

T.C.P.147 THE ROLE OF INTERLEUKIN-4 (IL-4) IN AIDS.

PAUL DUBREUIL

Project Director, IDM Centre for AIDS Research & Control, Pune, India.

Objective: To present a model explaining pathogenesis of AIDS. **Methods:** A literature survey has been made of molecular to epidemiologic aspects of AIDS and natural retroviruses, and of cytokines. Relevant information is presented to explain the pathogenesis.

Results: This model is based on interactions between latent HIV lurking as intracellular particles (IAP), other infectious agents which induce IL-4 and act as cofactors, and also, host's genetic factors. Many human CD4 T helper cells spontaneously secrete IL-4, IL-4, and IFN- γ . IL-4 stimulates B cells to polyclonal activation and also enhances expression of IL-2/3 which is especially associated with CD25. Its avidity for receptor for IgE (Fc ϵ R2). It linked glycosylation site on HIV gp120 which binds with CD4 is also associated with IL-4. Transmembrane of latent HIV occurs via enhancer element present in the IAP-LTR. IgE antibody formation is genetically controlled and regulated by IFN- γ . Addition of IL-4 to mouse cells compensates for the genetic defect of a nonresponder mouse strain. Similarly, HIV-infected poor responders may overcome the defect if repeatedly triggered by IL-4 inducing cofactors. Antibodies to gp120 interact antibodies to IL-4/3, which comprise effective functions of antigen presenting cells and the T-3 cell interaction. IL-4 also appears to be the HIV-induced growth factor reported to be responsible for Kaposi's Sarcoma seen in AIDS patients.

Conclusions: The model explains the depletion of T cells in AIDS and also why some individuals develop full-blown AIDS faster than others.

T.C.P.149 MONOCLONAL ANTIBODIES RAISED TO RECOGNIZANT HIV-1 GAG-PROTEINS CAN IDENTIFY IMMUNODEFICIENT B CELL EPITOPES IN AIDS PATIENTS.

Eric Saxon, P. De Beesteler*, S. De Lays, C. Wusters and H. Van Neuvaren, Immunogenics N.V., Antwerpen, Belgium. *University of Brussels, Belgium.

Objective: The ability of serum antibodies from AIDS-patients to compete with the binding of mouse anti-HIV monoclonal antibodies to the E. coli produced antigen, was investigated.

Methods: Microcell plates coated with E. coli produced purified p24 HIV-1 antigen, were incubated with serial dilutions of sera from AIDS-patients. Following by incubation with the monoclonal Ab, which was then detected with an anti-mouse IgG conjugate. Inhibition of monoclonal binding was scored as a decrease of the signal, relative to the unblocked control. Microcell HIV-1 producing cells were incubated with culture supernatant from several clonal anti-HIV cell-lines to investigate the binding of native viral antigen. Captured antigen was detected with an anti-HIV human IgG conjugate.

Results: Five anti-p24 and two anti-p17 mouse monoclonal antibodies were investigated. For two anti-p24 monoclonals, a variable degree of interference from a panel of 50 human anti-HIV sera was observed. The corresponding epitopes are thus immunogenic in most HIV-1 patients. However, one of these monoclonals does not recognize the antigen from viral lysates. This implies that the epitope is not accessible in mildly denatured p24 protein. This points to the identification of epitopes exposed only after denaturation (presented by viral antigen).

Conclusion: Mouse monoclonal antibodies to degraded recombinant HIV-antigen can identify B cell epitopes recognized in HIV-infected humans, but not accessible in the native antigen.

T.C.P.146 REDUCED IN VITRO GROWTH AND DIFFERENTIATION OF MONOCYTES FROM PATIENTS WITH HIV INFECTIONS

Elisavinda-Fradick Ballew, M. Gaudemar, G. A. Frelund, S.S.

University of Oslo, The National Hospital, Akershuskspitalet, Oslo, Norway.

Methods: Monocytes (Mo) from patients with HIV (CDC II/III, n=36; AIDS, n=15), 14 HIV seronegative, haemostatically stable donors were cultured for 1-10 days. The number of Mo/Macrophages, protein and cell differentiation were determined, the last by immunocytochemical staining with monoclonal bodies (mAb) against two differentiation antigens. The in vitro growth of Mo was assessed in (a) 8 AIDS patients receiving zidovudine, (b) 17 patients where Mo were cultured with Mo/NE supernatant from normal blood donors, and (c) 6 patients where Mo were cultured with R-3CF (MO Colony Stim. Factor). On day 10, the number of Mo and cell protein were reduced in CDC II/III and even more in AIDS. Decreased in vitro growth correlated with reduced function of the bone marrow (BM) assessed as low numbers of erythrocytes (2.6-6.5x10¹²/l), leukocytes (10-16x10⁹/l) and thrombocytes (10-14x10⁹/l) in peripheral blood on day 10. HIV Mo were significantly less differentiated than control Mo. Of the patients treated with zidovudine, 3 out of 8 showed no treatment improvement of in vitro growth during the first 2-3 months. Mo/NE supernatants from healthy donors as well as R-3CF did partially reconstitute the growth defect in the serostable patients treated. Complications decreased Mo in vitro growth and differentiation are seen in most patients receiving zidovudine. The data are due to lack of cytokines as supported by the reconstituted experiments. The correlation of decreased Mo in vitro growth and low numbers of blood cells might also suggest that defects in Mo precursor cells are operative. Another mechanism may be HIV replication in Mo.

T.C.P.148 NUMBER INVESTIGATIONS ON A LABORATORY MODEL BASED ON HIV-1 SPECIFIC CYTOTOXIC T LYMPHOCYTES

Alida, Elia, Eyal, Research Center, Givat, Egypt.

The author had previously reported on the development of HIV-1 specific cytotoxic T cells, (Arida, et al., 5th Internat. Cong. of Immunol., July 6-11, 1988, Toronto, Canada. Abstracts 3:55-15, p. 460. Arida, E., 12th Internat. Cong. of Virology, August 8-14, 1997, Edmonton, Canada, Abstracts: R36-6). In the present work, the characteristics of these cells after 6 months of propagation were investigated under several experimental conditions. These included IL-2, T cell antigens, parasitic antigens, certain cations, chelating agents, etc... The cells retained their response to HIV-1 specific cytotoxic effect (SCE), even after 6 months of propagation. They proliferated freely in absence of IL-2, T cell antigens and parasitic antigen which stimulate T cells. HIV-1 SIE was maintained by the cells only up to 10 months of propagation & was furtherly retained by treatment with Cd, Zn & Cu⁺⁺ ions, but not with Cu, Fe or Co. Chelating agents (including Ca agents) interfered with HIV-1 SIE when the whole virus was used, but not with its related genetic materials. These results indicate genome integration of an HIV-1 provirus & its associated noncoding and cytotoxicity assays. The value of these cells as lab. models for immunologic tolerance is evident.

T.C.P.150 HUMAN MONOCLONAL ANTIBODIES TO HIV

D. Bange, L. M. Bidel, J. C. M. Meyer, B. M. Knausow, D.

K. von Baehr, H. Schmitt

12/Chemist-Dept. Institute for Special Medicine, Department of Virology, Humboldt-UBD

7/Charité, Department of Neurology, Berlin, DDR

Objective: The production of human monoclonal antibodies to HIV and the evaluation of the use of these in HIV infection.

Methods: The heteromyeloma cell line CB F7 (Gouyon et al., Immunol. Methods, 106, 1984, 257-265) was used for cell fusion with peripheral blood lymphocytes from HIV positive blood donors. Clones were screened for specific and continuous antibody production. Supernatants from stable hybridomas were tested in specific neutralization and cytotoxicity assays.

Results: In 20 fusion experiments a fusion frequency of 0.6×10^{-5} and a specific fusion frequency of 0.8×10^{-6} was obtained.

14 clones were selected, all were directed against envelope glycoproteins of HIV; 15 were specific for gp 41 and eleven for gp 120. One clone against gp 120 produced continuously for the last three months. Neutralization and cytotoxicity assays are in progress.

Conclusions: We have established a method allowing the production of specific monoclonal antibody producing hybridomas against different epitopes of HIV. This will enable us to investigate the correlation of neutralizing or cytotoxic effects of monoclonal antibodies with type of antibody and to study the effect of such information concerning the interaction of HIV and antibody response.

Session d'afternoon Poster Session



W.C.P.13 ISOLATION AND PRELIMINARY CHARACTERIZATION OF A NEUROTROPHIC STRAIN OF FELINE LEUKEMIA VIRUS
 David W. Gage, J. W. Whittier, J. C. Overton, J. C. Whittier, S.W. Dow, M. Post.
 Pathology Dept., Anatomy and Neurobiology Dept., Colorado State University, *Microbiology Dept., School of Medicine, Little Rock, U.S.A.

Objective: We have isolated a strain of feline leukemia virus (FeLV-1380) which induced significant delays in motor neuron conduction velocities in 3 of 3 experimentally infected specific pathogen free (SPF) cats within 7 months post inoculation. This seems to lead to development of a feline model of AIDS peripheral neuropathy to be utilized in future testing of therapies for AIDS.
Methods: Bone marrow and CSF were harvested from 3 cats exhibiting neurologic abnormalities. All 3 cats were FeLV positive and RT negative. Two cats were neurologically intact. One cat (#1369) was experimentally infected with molecularly cloned (mcl) FeLV-1388 2 years before developing neurological problems. All samples were cultured with feline fibroblasts (MDF2/27) cells. Six SPF cats were inoculated (intracranially and intraperitoneally), 2 each, with cat line supernatants containing 10⁶ of the 2 previously neurotropic strains of FeLV. Four additional SPF cats were similarly inoculated 2 with 10⁶ of minimally neurotropic mcl FeLV-816E, and 2 with virus-free medium. The cats were housed under barrier conditions in two gann cages (5 cats/cage). Electrophysiology was performed and the cats were monitored behaviorally 8 and 7 months post inoculation.
Results: All of the FeLV-inoculated cats became FeLV positive approximately 3 weeks post inoculation. One of the molecularly cloned cats tested FeLV positive 8 weeks post inoculation. We assume this cat (#1370) contracted FeLV-1380 horizontally from the infected cats with which it was housed. A restriction pattern unique to mcl FeLV-2881 was identified by Southern blot analysis of the FeLV genomes produced by the 10 of the 2 cats inoculated with FeLV-1380. The motor nerve conduction velocities of #1370 and the 2 cats infected with FeLV-1380 were significantly decreased when compared to the velocities of uninfected age-matched control cats and cats infected with mcl FeLV-816E.
Conclusion: FeLV-1380 induced delays in motor nerve conduction velocities analogous to HIV and/or HTLV-1 peripheral neuropathy system lesions.

W.C.P.15 IN VIVO ANALYSIS OF THE MINIMAL INFECTIOUS DOSE OF AN ACUTELY LETHAL POOL OF HIV (SFV/80M/78-14)

McLellan, Harold A., Anderson, D. C., Anzari, A. and Palfy, P.
 Yerkes Regional Primate Research Center, Department of Pathology, Emory University, Atlanta, GA, U.S.A.

Objective: To determine the minimal infectious (lethal) dose of an acutely lethal virus pool of a chemically induced macaque.
Methods: Six groups of 2 pig-tailed macaques were inoculated IV with 10-fold serial dilutions of the 78-14 isolate, or doses ranging from 10⁻⁶ to 10¹⁰ TCID₅₀.
Results: All animals given 10 TCID₅₀ or greater became infected and developed acute clinical disease. Although there was no evidence the two recipients of 1 TCID₅₀ became infected, one animal that received 0.1 TCID₅₀ was infected and at 6 weeks P.I. had reduced numbers of CD4⁺ cells that decreased progressively until death 8 months P.I. In the other animals, disease onset ranged from day 7 (10⁶ TCID₅₀) to day 12 (10 TCID₅₀) P.I., with death occurring from day 8-16. One animal survived the acute disease but showed a progressive decrease in CD4⁺ cells and died 7 months P.I., with emaciation, oropharyngeal candidiasis, lymphadenopathy, splenomegaly, lymphopenia and a CD4/CD8 ratio of 0.16.
Conclusion: The lowest dilution (10⁻⁶ to 10 TCID₅₀) of a pool of the 78-14 isolate of SFV/80M to infect all animals also resulted in death of both animals within 16 days, supporting the contention that 78-14 is the sole agent responsible for the acute lethal disease. There was a correlation between dose and onset of disease and death. The longer term survivors showed decreasing CD4⁺ cells, weight loss, lymphadenopathy, lymphopenia and opportunistic infections. Disease in these animals appeared to correlate with a marked reduction in CD4⁺ cells. (Supported by NIH grant RR00145).

W.C.P.17 REGULATION OF THE VISA VIRUS LTR IN MACROPHAGES INVOLVES CELLULAR FACTORS WHICH BIND SEQUENCES CONTAINING AP-1 SITES
 Richard H. Wasy, J. J. Della Torre, A. J. Smal, J. J. Clements, J.

The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.

Objective: To identify sequences in the visna virus long terminal repeat involved in the developmental regulation of gene expression in macrophages.
Methods: Deletion and linker-scanning mutants, gel shift assays, and EMSA I. Transcription was used to study regulation of the visna virus LTR in the U937 monocytic cell line. Gel shift experiments using human primary macrophages are in progress.

Results: Sequences in the visna virus LTR that are involved in the regulation of visna virus gene expression in U937 cells were identified, including a region containing an AP-1 binding site which is critical for basal activity and phorbol ester-inducible gene expression. Nuclear extracts from uninduced and phorbol ester-induced U937 cells protected the same sequences from EMSA I digestion; however, protection of the AP-1 site was significantly increased in nuclear extracts from induced cells. A DNAse I-protected region from 47 to -81 contains the sequence TTTTTC, which is similar to Dnaase I-protected sequences in the HIV and HTLV-1 LTRs.

Conclusion: Our data supports a model in which one or more of the proteins which interact with AP-1 sites may be involved in the developmental regulation of visna virus gene expression in macrophages. Understanding the molecular events which relate macrophage differentiation to the regulation of viral gene expression may provide insights into mechanisms controlling viral gene expression that may be relevant to disease pathogenesis.

Recherche fondamentale (biomédicale) Bast Research (Biomedical)

W.C.P.14 IN SITU MALNUTRITION SUGGESTS CENTRAL NEUROENDOCRINE CHARACTERIZATION IN INFANT FELINE AIDS (FAIDS)
 Inez-Angel, Manuel, J.; Ray, B.; Elliott, S.C. and Tshikua, J.G.*
 Univ. of Missouri at Columbia, USA.

Objective: To emulate in FAIDS, the human AIDS (AIDS) demonstration that HIV infects and affects the CNS, in FeLV-FAIDS this was, up until our work, completely missing.
Methods: The results were brain extracts from case vs. control infant kitses (N=29) based on commercial reagents: polyclonal anti-FeLV virus (Antibodies Inc., Davis, CA USA) or monoclonal anti-FeLV gas (2) (CITEc-AdgTech Systems, Portland, ME USA) antibodies. The results were confirmed with a commercial ELISA (ELD/CASASATM or G, Pitman MO) and Western Blot (CA USA). Endocrine analysis was shown by a heterologous rabbit anti-growth hormone (GH) titration in hypothalamus by immunostaining. The difference in GH in the developing brain between controls and FAIDS was significant (p<0.01).
Results: This study further corroborates our preliminary reports on FeLV in CNS. Pituitary GH diminution coincided with growth impairment in the form of failure-to-thrive and an ongoing test wasting syndrome undistinguishable from our own results with rabies [1].
Conclusions: FAIDS in kitas, as a model for AIDS in children, strongly suggests a neuroendocrine participation that, at least in part, may explain the immunodeficiency [1]. The support of the manufacturers of commercial FeLV and HIV bio-technology diagnostics, as mentioned, is kindly appreciated.
 [1] Torres-Antel et al. Feline AIDS in vitro, wasting syndrome and immunodeficiency in rabies: a hypothalamohypophysiomelanohormic axis defect of rabies virus. Rev Infect Dis, 1981;9 (Suppl. 4):S710-25.

W.C.P.16 HIV-1 INFECTION IN A CONTINUOUS RABBIT MACROPHAGE LINE
 Hendrick E. Kugler, David R. Kasper, G. J. L. Kretz,
 NMR, St. Elizabeth's Hospital, Washington, D. C. *Laboratory of Immunogenetics, NIDDK, NIH, Bethesda, MD 20892.

Objective: To characterize HIV-1 infection in a continuous rabbit macrophage line.

Methods: The rabbit cell line, 6083, an SV40-transformed macrophage was infected with HIV-1. Infection was monitored using standard methodologies including RT activity and the presence of p24Ag in cell-free supernatants, indirect immunofluorescence, electron microscopy, detection of viral nucleic acids and passage of infectious virus to a number of indicator cell lines.

Results: 6083 was shown to be permissive to HIV-1 infection by all parameters assessed with the exception that no RT activity was seen in supernatants from infected cells. Presence of viral proteins were evidenced by p24 Ag capture, indirect immunofluorescence and Western blot analysis. In addition to the presence of HIV-1 nucleic acids, electron microscopy indicated production of mature lentivirus particles in a fashion morphologically similar to that seen in human macrophages and different from T-cell infection. Although virus positive by the preceding assays, cell free supernatants from HIV-1 infected 6083 cultures gave negative RT results. Supernatants derived from uninfected 6083 cultures were also shown to inhibit RT activity in known positive samples. It was shown that the lack of RT activity was not due to a defect in the assay; both infected and uninfected 6083 cells produce a factor which interferes with the assay at the level of the nucleic acid template.

Conclusions: 6083 supported productive HIV-1 infection which is similar to that seen in human macrophages. As is the case for human cell lines of this lineage, measurement of RT activity cannot be used as an accurate parameter of infection in rabbit macrophages.

W.C.P.18 INFECTION WITH SEMIIMMUNODEFICIENCY VIRUS (SIV) VIA CONJUNCTIVAL AND ORAL MUCOSAE IN A NON-HUMAN PRIMATE
 Johannes Ruya, M. J. Tilly, S. J. Yee, J. J. Antipa, L. Ann Cheney, P. J. Univ. of California-Davis, Davis, California, USA, Univ. of Tennessee-Memphis, TN, USA.

Objective: To determine if SIV can be transmitted postnatally via the mucous membranes in the newborn rhesus monkey and to determine if transmission can occur from an infected infant to another during the neonatal period as a result of close contact.

Methods: SIV was dropped on the conjunctival and oral mucosae of a newborn rhesus macaque at 0 and 93 days post-natally. Following exposure to virus, the infant was kept with the mother and both were tested for SIV infection.

Results: SIV was isolated from the peripheral blood mononuclear cell (PBMC) of the infant 10 days after the second exposure to virus and at all other sampling times thereafter. The animal died of septicemia and pneumonia 2 months after virus was detected. Generalized lymphoid depletion and interstitial pneumonia were noted at necropsy. The mother remains healthy, SIV antibody and virus negative.

Conclusion: SIV can be transmitted via conjunctival and oral mucosae of a newborn macaque. Despite intimate contact with the infected infant, the mother remains healthy and uninfected.

Session d'affichage Poster Session



W.C.P.25 LACK OF VERTICAL TRANSMISSION OF STIVAG IN A BREEDING COLONY OF C. TRICHOPUS ANTHROPI

HELEN B. FINEBERG¹, J. L. BRUNN² and C. R. NIELSEN²
¹Statens Seruminstitut, Denmark

Objective: To investigate the occurrence of vertical transmission of simian immunodeficiency virus (SIVag) in a breeding colony of *C. trichopus* by testing for SIVag antibodies.
Materials and Methods: Milk-sampled C. trichopus imported from Ethiopia and offspring from these born at Statens Seruminstitut. The breeding colony was founded with 21 female and 8 male neonates imported in the period 1976 to 1988. Serum samples from the 29 imported and from 70 colony born monkeys were examined by an indirect immunofluorescence test for antibodies against SIVag. **Results:** Live offspring were produced in the colony by 14 of the 21 imported females. Six of the 14 female breeders were found SIVag antibody positive and gave litters on birth to 26 young. From 22 of the young first live bleedings were obtained around 6 months of age or later. None were found SIVag antibody positive. From 12 of the 22 young another sample collected 1-4 years later was also SIVag antibody negative. Samples from the remaining 4 young, taken at age 3 months or less, were SIVag antibody positive. In 2 of the 4 SIVag antibody positive litters, 10 and 12 samples drawn around 6 months of age (one died); the fourth remains to be tested, when 6 months old. **Conclusion:** In *C. trichopus* vertical transmission of SIVag is rare if at all occurring. Presumably initially acquired SIVag antibodies disappear within the first 6 months of life.

W.C.P.27 MECHANISM OF IMMUNIZATION OF CD4 EXPRESSION BY PLASTIC ADHESIVE HUMAN MACROPHAGES *IN VITRO*

J. J. ANNET¹, P. BULLER², P. P. F. DE WITTE¹, A. J. VERHOEVEN¹ and J. VAN DER BEEK¹, ¹Medical Research Institute, ²Free University Hospital, Amsterdam, The Netherlands

The CD4 non-specifically binds to the major receptor for HIV on both CD4-expressing and blood monocytes. We have further investigated the regulation and function of macrophage-associated CD4. We have demonstrated that CD4 expression is induced on the surface of CD3 positive human blood monocytes with CD4-PE of cells being positive by anti existing HIV systems. This monocyte adherent to plastic, which activate macrophages. Loss of CD4 expression was observed by HIV cytotoxicity and immunofluorescence by 3-5 days but the proportion of adherent cells expressing low CD4 was not decreased. Monocytes cultured on tissue remained CD4 positive. Surface isolation of blood monocytes and plastic adherent macrophages followed by immunoprecipitation with anti-CD4 monoclonal antibodies also demonstrated a marked reduction in membrane CD4 expression by these macrophages. However CD4 mRNA levels quantified by Northern blotting and total cellular CD4 protein levels as determined by immunoprecipitation remained constant throughout the five day period, suggesting a selective loss of CD4 from the membrane, probably by endocytic cycling. Parallel studies with anti-CD4 also suggest the presence of CD4 membrane receptors from H9 to H1. However an difference was observed in binding of radiolabelled H9 and H1 to blood monocytes and macrophages. Whether CD4 is phosphorylated during demyelination and the effect of protein kinase C inhibitors on this phenomenon is under investigation. Activation of macrophages by lipopolysaccharide and interferon gamma had no effect on CD4 expression by monocytes maintained in tissue vesicles, nor did other cytokines like IFN- γ , IL-1, IL-2, IL-3, IL-4, IL-6, IL-8, IL-10, IL-12, IL-13, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IL-34, IL-35, IL-36, IL-37, IL-38, IL-39, IL-40, IL-41, IL-42, IL-43, IL-44, IL-45, IL-46, IL-47, IL-48, IL-49, IL-50, IL-51, IL-52, IL-53, IL-54, IL-55, IL-56, IL-57, IL-58, IL-59, IL-60, IL-61, IL-62, IL-63, IL-64, IL-65, IL-66, IL-67, IL-68, IL-69, IL-70, IL-71, IL-72, IL-73, IL-74, IL-75, IL-76, IL-77, IL-78, IL-79, IL-80, IL-81, IL-82, IL-83, IL-84, IL-85, IL-86, IL-87, IL-88, IL-89, IL-90, IL-91, IL-92, IL-93, IL-94, IL-95, IL-96, IL-97, IL-98, IL-99, IL-100.

W.C.P.29 PRIMARY RETROVIRAL INFECTION VERSUS CHRONIC VIREMIA: DIFFERENTIAL RESPONSE TO THERAPY.

BRADLEY DUBOIS¹, J. W. HARRIS², C. S. ANDERSON¹, J. R. DAVENPORT¹, R. M. WATSON¹, BOSTON, MASSACHUSETTS, USA, ¹Harvard Medical School, Boston, Massachusetts, USA, ²Harvard Medical School, Boston, Massachusetts, USA

Objective: To compare the therapeutic efficacy of candidate antiretroviral agents administered to animals exposed to ZDV to zalcitabine (ddC) with that of therapy given to chronically viremic animals.
Methods: Adult female BALB/c mice were inoculated at time 0 with Rauscher Murine Leukemia Virus (RLV), a virus complex consisting of a lymphocytic replication-competent helper virus as well as a replication-defective spleen-leukemia forming virus. For post-exposure treatment, therapy was started 4 hr after virus inoculation and continued for 20 d. The animals were sacrificed and analyzed for RLV-induced splenomegaly and viremia. Therapy of chronically viremic animals was initiated only at 2 weeks after virus exposure and was continued throughout the animals' life span. Survival was analyzed by Kaplan-Meier plots. 3-azido-2-deoxythymidine (AZT) or Zalcitabine, recombinant human interferon- α 2/D (rhIFN- α 2/D), and zalcitabine were administered as above.
Results: AZT and zalcitabine were active in primary infection as well as in chronic viremia. In contrast, rhIFN- α 2/D was able to suppress virus-induced splenomegaly by 94%, but was completely inactive in chronically infected animals. Median survival of animals treated with rhIFN- α 2/D starting 14 d after virus exposure was identical to that of untreated control animals (5.7 vs 6.0 weeks).
Conclusion: Biologically, the chronically viremic state differs significantly from primary retroviral exposure, as judged by the differential response to therapy. Evaluation of antiretroviral therapy should be optimally designed to differentiate between these situations.

W.C.P.26 EXPERIMENTAL HIV-2 INFECTION OF OLD WORLD MONKEYS

CAROL BRUNA, A. RIEBER, W. LITVIN, B. W. LEE and L. W. JIA
Cancer Research Institute, University of California, School of Medicine,
San Francisco CA 94143, ¹Southwest Foundation for Biomedical Research, San Antonio, TX 78228, ²California Primate Center, Davis, CA 95616 USA

Objective: To develop a model of HIV infection in Old World monkeys.
Methods: Peripheral blood mononuclear cells (PBMC) from baboons and rhesus macaques were screened for susceptibility to infection with four HIV-2 isolates from the Ivory Coast. Infected cells were cocultivated with uninfected PHA-stimulated monkey PBMC of the same species or with human PBMC. Culture supernatants were assayed for HIV reverse transcriptase activity. Animals whose cells showed high levels of virus replication and cytopathology in *in vitro* was inoculated with the strains producing these results. Serum antibody, lymphoid cell counts, and virus production from the animals-PBMC were monitored routinely.
Results: All four HIV-2 strains tested were infectious for baboons and rhesus macaques, but some could be detected only upon addition of human PBMC. One isolate (UC-7) grew well in baboon cells. Two isolates (UC-2 and UC-7) replicated well in rhesus macaque PBMC. All isolates generally replicated in human PBMC. Culture in rhesus macaques and human PBMC cultures was most cytopathic for both types of animal cells, and were used for inoculation of the baboons and macaques. We have recovered HIV from PBMC of the infected macaques and baboons which has been observed in the baboons. Serologic, immunologic and virus isolation data on the infected animals will be presented.
Conclusion: HIV-2 isolates show differential growth in non-human primate cells. Productive infection of primates with HIV-2 has been achieved after preselection of susceptible animals and specific virus strains.

W.C.P.28 CULTURE REQUIREMENTS FOR HIV-1 ISOLATION FROM INFECTED CHIMPANZEES

ZILBER, Heidi A.; SOBE, K. and KILBING, J.N.
Southwest Foundation for Biomedical Research, San Antonio, Texas, U.S.A.

Objective: To optimize conditions for the isolation of HIV-1 from peripheral blood lymphocytes (PBL) of infected chimpanzees.
Methods: PBL were obtained in tissue form from a search period from nine HIV-1 seropositive chimpanzees. Parallel cultures were generated each time following three protocols: (1) nonstimulated chimpanzee PBL were cocultivated with phytohemagglutinin (PHA) activated human PBMC as indicator cells; (2) chimpanzee cells were PHA activated and then cocultured with human indicator cells; and (3) chimpanzee PBL activated PBL were cocultured without human cells. All cultures were maintained in the presence of interleukin-2 and DMSO-dextran for 28 days and monitored weekly for production of HIV-1 supernatants by antigen capture assay.
Results: HIV-1 isolation was successful in five out of nine chimpanzees by any protocol employed. In two of these five animals, HIV-1 could be isolated only by protocol (1) and (2); in one animal only by protocol (3), and by all three protocols in the other two animals.
Conclusion: The difficulty in isolating HIV-1 from chimpanzees is confirmed, suggesting a low level of virus integration in PBL in some animals a clear barrier for our culture conditions. An indirect adverse effect of human PBL on the production of virus in our chimpanzees also indicates that requirements for virus isolation can differ drastically between these animal and humans.

W.C.P.30 PATHOLOGY OF EARLY LESIONS IN HIV SEROPRESENTS

SHAW, RYAN, SPATZ, L., RICHMOND, J. F., MURPHY-ORCH, E. F., MARTIN, L., and SHAW, G. S.
¹New Jersey Medical Center, ²NIH, and ³Atlanta Regional Primate Research Center, Covington, LA, USA

Objective: To study central nervous system lesions early in the course of infection with simian immunodeficiency virus (SIV).
Methods: Twenty juvenile rhesus macaques were inoculated i.v. with SIV/Be1-10 (SIV) with 4 controls. Four animals each were sacrificed at 2, 4, 8, and 16 weeks post inoculation. Four became sacrificed and were sacrificed at 10, 14, 20 and 23 weeks. Histologic preparations of fixed brain tissue were examined, using also immunoperoxidase for glial fibrillary acidic protein (GFAP) and for SIV antigen, employing a rabbit polyclonal antisera.
Results: At 2 weeks there were lymphocyte infiltrates in choroid plexus (CP) and leptomeninges (LM), with a few perivascular lymphocytes in brain parenchyma. At 4 weeks there were lymphocyte infiltrates in choroid plexus (CP) and LM, macrophage infiltrates with positive antigen staining were observed in CP and LM, with rare multinucleated giant cells (MGC) in LM. The most severe lesions were observed in the striatum animals at 10 and 14 weeks, with brain perivascular macrophage infiltration, with MGC and hyperplasia. Lesions were less marked in the 24 week animals. No animal exhibited spilling of MGC with excess of GFAP while staining.
Conclusion: SIV causes inflammation in LM and CP early in the course of infection. With infection occurring in the choroid plexus (CP) component before it is seen in brain, the earliest occurrence of brain SIV antigen coincides with the appearance of perivascular macrophages.

Session d'affichage
Poster Session



Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

W.C.P.31

HIV-1 ANTIGENEMIA IN ANDRAGYMI 'NUDE' MICE
Wetherall, Neal J. and Atherly Eiring.

Department Of Pathology, Vanderbilt University Medical Center, Nashville, TN, U.S.A. 37232-2561

Objective: Several small animal models of HIV infection have been proposed. We have developed a system which was exposed to the replication of HIV-1 which can produce large populations of infected mice for therapy screening and host-virus interactions.

Methods: Nude mice (3-4 weeks old) were exposed to 600 R₅ of 170Cs irradiation followed with 1 x 10⁷ HIV-1 infected CEM cells. The animals were followed daily for weight gain and tumor progression. Groups of 5 animals were eviscerated at 8 intervals over a 5 week period and necropsies were performed.

Results: Plasma p24 antigen was detected at day 3 and rose over 9 weeks (>2500 pg/ml). Where possible, plasma antigen was neutralized with human antiserum to HIV-1. The infected mice did not exhibit any weight loss, but a slightly significant difference was seen in tumor progression when compared to controls. Using immunohistochemistry, we raised polyclonal antibodies to viral p24 and gp120 detected HIV proteins within tumor cells and mouse splenic macrophages. Electron microscopy revealed rare intracellular lentivirus particles in the CEM cells.

Conclusion: These findings suggest that the nude mouse transplanted with a well characterized HIV permissive cell line should be useful for many immunological and antiviral studies. This work is supported by the U.S. Army Medical Research and Development Command Under Contract No. DAMD 17-88-C-8071.

W.C.P.32

LANGERHANS CELLS IN RESIENS MONKEY ORAL MUCOSA BEFORE AND AFTER INFECTION WITH SIMIAN RETROVIRUS OBTAINING Q1 (SRV-1) HANSEN, CHRISTINA M., LACKNER, A.W., ARMIANI, G., WIRTHLIN, W., MACPALLIS, T., DEANIN, T., and GREENBERG, J. ONI AIDS Center, University of California, San Francisco, California. Primate Research Center, University of California, and Royal Dental College, Copenhagen, Denmark.

Objective: To study the influence of experimental SRV-1 infection on the number of Langerhans cells (LC) expressing characteristic antigen and mucosa of these monkeys.

Methods: Two monkeys were intravenously inoculated with SRV-1, and two animals were mock-inoculated. Status of infection was assessed by serology and virus culture from peripheral blood lymphocytes. Biopsies were taken from gingiva and cheek pouch before and 4 months after infection. Frozen sections were stained with monoclonal antibodies (Lan-4, ILA-DR) and visualized by the immunoperoxidase technique. LC were counted in 3 sections of each specimen using chain analysis, and the mean number of LC per surface mm² was calculated. The examiner was blinded as to the date of the slides.

Results: All animals except for the controls were viremic at 1 week after inoculation. The number of LC in oral specimens did not differ significantly between the uninfected and infected groups at times 0 and times 4 months. The table shows LC of the experimental group.

LC in oral mucosa (no./surface mm ²)	Gingiva	ILA-DR	Cheek pouch
Before infection	10.4	9.1	9.9
4 months after infection	7.2	7.0	12.4

Conclusion: We have previously shown that SRV-1 commonly infects oral mucosal LC in these monkeys. However, 4 months after SRV-1 infection the number of LCs in the oral mucosa did not change significantly. Supp. by NIH PO1-DS5766, Danish Med.Res.Council (#1-8499, 12-8465), and AIDS Funded.

W.C.P.33

ISOLATION OF BARONS AND MACAQUES WITH VIRUS PRODUCED FROM THE SIMIANS
MULLER, G. J., KILLER, L. J., CLAY, C.A., J. GALE, A. J., FAY, K. J., OVERHAGE, J. T., KATZ, R.E., T. METCALER, S. J., BENNETT, S. E., Regional Primate Research Center, University of Washington, Seattle, Washington, Dept. Microbiology, University of Washington, and Viral Characteristics, NCI, Frederick Cancer Research Center, Frederick, Maryland, U.S.A.

A full length molecular clone of SIMV (SIV) was shown to be infectious *in vitro* by transfecting the DM 10a host cell line and showing the presence of reverse transcriptase activity. *in vivo* infection of virus from transduced cells was inoculated into six pigtailed macaques and two humans. Inoculation was performed on November 6, 1987. The four inoculated animals, as well as the two control animals, were assessed at regular intervals for the presence of antibodies to SIMV and for the presence of virus in HC and plasma. Animals were also monitored for changes in their clinical and hematological status. Both humans developed seral peripheral lymphadenopathy by the weeks post-inoculation, but no virus was isolated from their HC. One of the humans died at 33 weeks post-inoculation with acute and a wasting syndrome similar to that seen in macaques inoculated with SIMV. Attempts at virus isolation were negative (negative for HIV-1) and the only HIV-1 RNA was detected in the spleen and lymph nodes.

Utilizing the polymerase chain reaction (PCR) technique, we were unable to detect SIMV sequences in either the spleen or lymph nodes of this animal. The pigtailed macaque developed peripheral lymphadenopathy four and eight weeks post-inoculation, along with an erythematous rash on the lower abdomen and inguinal areas. Both animals seroconverted and virus could be isolated at various times post-inoculation. At 64 weeks post-inoculation, both animals remain in apparent good health. However, one has exhibited a steady decrease in CD4⁺ cells since November 1988, along with lymphopenia and absolute lymphocyte depletion, which to previous transmission studies, are forerunners of clinical disease.

W.C.P.34

MUTATIONAL ANALYSIS OF THE CYTOSOLIC DOMAIN OF P15 TRANSMEMBRANE PROTEIN
L. Chagnacoff, P. Toulas, and F. Sorigo. Institut Pasteur, Paris, FRANCE

Objective: To examine the role of the cytoplasmic domain of the transmembrane protein of the env of the simian virus obtained from 10 infectious clones.

Methods: Oligonucleotide-directed mutagenesis was used to replace the in-frame stop codon by a glutamine codon. Point mutations and deletions were introduced in the env C-terminal domain in clones both with and without the in-frame stop codon. Phenotypes of different mutants were evaluated for virus production following transfection of SW-620 cells and for infectivity in HUT78 cells.

Results: HIV in which the in-frame stop codon was replaced by a glutamine codon infected HUT78 cells with delayed kinetics. Reversion of the stop phenotype frequently occurred. Revertants having recovered a stop codon 3' of the original mutation were characterized. Deletions and termination 3' to the in-frame stop codon did not modify HIV infectivity. In contrast, mutants harbouring both the mutation of the in-frame stop codon and a deletion or a termination in the cytoplasmic domain-coding region were non-infectious.

Conclusion: The env C-terminal domain is not necessary for *in vitro* replication. However, fusion of this domain to HIV transmembrane protein leads to a reduced infectivity. This negative effect is counterselected *in vitro* but may correspond to a function controlling the rate of spread of the virus in the natural host.

W.C.P.35

INFECTION OF RHESUS MACAQUES WITH MOLECULARLY CLONED HIV-2
FRENCH, J., GONZALEZ, B., BRUNO, D. M., GARC, E. M., ROBERT-GOURFF, M., HALL, R. C., HONG, S. S. J., F. et al., National Cancer Institute, Bethesda, MD 20892, *Biometrics Research, Inc. Rockville, MD, U.S.A.

Objective: To develop a suitable animal model system to study infectivity and cytopathogenicity of HIV and to study viral genetic variation *in vivo*.

Methods: Rhesus macaques inoculated with molecularly cloned isolates of HIV-2 were monitored for humoral and cellular immune response, infectious virus, and physical and hematologic abnormalities. Selected viral genes from viruses reisolated from infected animals were analyzed by cloning and sequencing.

Results: Six of eight inoculated animals became persistently infected, e.g., recoverable virus, detectable genomic DNA, and/or persistent immune response. Some physical abnormalities began to appear in some animals with 5 months post-infection. Genetic changes occurring *in vivo* were found in 5 months reisolated 5 months post-infection.

Conclusion: Rhesus macaques are a useful infectivity model for HIV-2. Use of infectious molecularly cloned virus isolates provide a homogeneous basis for evaluation of the generation of genetic variants *in vivo*.

W.C.P.36

CLINICAL AND IMMUNOLOGIC STUDIES OF FELINE IMMUNODEFICIENCY VIRUS (FIV) INFECTION IN FELINE IMMUNODEFICIENCY VIRUS (FIV) INFECTED CATS
JINNO, T., TAKIUCHI, A., WASHI, T., KAWAYAKI, T., NISHIO Veterinary and Zootechnical College, Yonko, Japan.

Objective: To elucidate the relationship between disease progress and immunologic changes in feline immunodeficiency virus (FIV) infected cats. Infected cats were classified into clinical stage groups using FIV. The naturally-infected cats were classified into clinical stage groups using FIV. The naturally-infected cats were classified into clinical stage groups using FIV. The naturally-infected cats were classified into clinical stage groups using FIV. The naturally-infected cats were classified into clinical stage groups using FIV.

Methods: To evaluate the relationship between disease progress and immunologic changes in FIV infected cats, we performed a longitudinal study of FIV infected cats. The naturally-infected cats were classified into clinical stage groups using FIV. The naturally-infected cats were classified into clinical stage groups using FIV. The naturally-infected cats were classified into clinical stage groups using FIV. The naturally-infected cats were classified into clinical stage groups using FIV.

Results: The naturally-infected cats were classified into clinical stage groups using FIV. The naturally-infected cats were classified into clinical stage groups using FIV. The naturally-infected cats were classified into clinical stage groups using FIV. The naturally-infected cats were classified into clinical stage groups using FIV. The naturally-infected cats were classified into clinical stage groups using FIV.

Conclusion: The naturally-infected cats were classified into clinical stage groups using FIV. The naturally-infected cats were classified into clinical stage groups using FIV. The naturally-infected cats were classified into clinical stage groups using FIV. The naturally-infected cats were classified into clinical stage groups using FIV. The naturally-infected cats were classified into clinical stage groups using FIV.

Session d'attaché
Poster Session



Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

W.C.P.37

ESTABLISHMENT OF FIV-PRODUCING CELL LINES FROM FIV SEROPOSITIVE CATS
Saitoh, M.; Nakagaki, T.; Tamura, S.; Kobayashi, I.; Ishiguro, T. and Kurita, T.
NHU Japan, Tokyo, Japan. * Nippon Veterinary and Zootechnical College, Tokyo, Japan.

Objective: To establish feline T-cell lines that continuously produce FIV in the culture. **Methods:** Peripheral blood mononuclear cells from 4 feline immunodeficiency virus (FIV)-seropositive and feline leukemia virus (FeLV)-negative cats were stimulated with concanavalin A (Con A) for 3-5 days and maintained with recombinant human interleukin-2 (IL-2). **Results:** After 4-6 weeks, reverse transcriptase activity was detected in 2 out of 4 culture supernatants without marked cytopathic effects. One of the two lines (named GA-3) was further characterized. FIV antigens were detected and identified in GA-3 cells by indirect immunofluorescence and western blot analyses. FeLV and feline sarcoma/leukemia virus were not detected by the same methods. The virus produced by GA-3 cells failed to replicate in feline fibroblastic cell, CRFK. GA-3 cells retained IL-2 and interferon- γ stimulation with Con A every 2-3 weeks for their growth. GA-3 cells have been growing and releasing FIV for more than 2 months so far. Infectivity and pathogenicity of the FIV produced by GA-3 are under investigation. **Conclusion:** IL-2 dependent feline lymphoid cell lines which continuously produce FIV were established.

W.C.P.39

RAMN RECOMBINANT IL-2 INDUCED CYTOLIC LESION FROM FAV INFECTED IL-2 IMMUNODEFICIENT GAS
Tschering, B., Holmberg, C., Tschering, W.
North Carolina State University, Raleigh, NC, U.S.A.

Feline leukemia virus (Fav) causes a broad-spectrum of degenerative or neoplastic diseases in cats characterized by decreased immune competence and acquired immunodeficiency syndrome (AIDS). In other species, including humans, retrovirus-induced AIDS is associated with decreased T helper (Th) and cytotoxic lymphocyte functions. In describe herein, the morphological and functional characteristics of IL-2-dependent cytotoxic lymphocytes derived from feline peripheral blood lymphocytes (PBL) and the effect of PBL-induced Th₁ suppression on the function of these cells. Stimulation of feline PBL with concanavalin A (Con A) followed by culture in the presence of 50-200 units/ml of soluble mouse interleukin-2 (IL-2) or recombinant human IL-2 (rhIL-2) resulted in marked proliferation and establishment of long-term lymphocyte cultures. Cultured feline lymphocytes possess cytotoxic granules with large granules similar to the large granular lymphocytes (LGL) in other species. These granules are bound by a highly sensitive and contain melittin-bound vesicles 0.40 μ m in diameter. All feline LGL lines are cytotoxic for feline PBL lymphoid cells, but none express anti-viral or lysis for other LGL lines. A characteristic of LGL is other species, to determine the effect of PBL infection on cytotoxicity by PBL and on the establishment of LGL cultures, one experimentally induced with the immunosuppressive Birkbeck strain of PBL was studied. In all cases, PBL from cats with IL-2 immunosuppression failed to yield a primary cytotoxic response, whereas, IL-2 responsive PBL were cytotoxic. In contrast, rhIL-2 induced cytotoxicity did not cultured PBL of all rhIL-2-infected cats, whether or not they were IL-2 exposed. The results indicate that, like the human HIV-1 infection, the target of PBL immunopathology is the Th₁ cell and Th₁-dependent cytotoxic functions, the latter of which can be restored by addition of exogenous IL-2.

W.C.P.41

HV-1 INFECTION IN THE RABBIT
Kodi, Thomas J., Kutaga, H. T., Truskenmier, M.E., Recker, D., and Fidler, I. J.
*Lab of Immunogenetics, NIAID, NIH, Bethesda, MD 20892; **NHV, St. Elizabeth's Hospital, Washington, D. C.; and ***Veterines Disease Branch CDC, Atlanta, GA, U.S.A.

Objective: To evaluate the rabbit as a model for HIV-1 infection. **Methods:** Outbred Zivicus were infected with HIV with human T-cell line A301 infected with HIV-1. Serum samples were monitored with a modified ELISA for anti-HIV-1 antibodies and peripheral blood leukocytes were tested for infection by reverse transcriptase activity and PCR after culture in IL-2. **Results:** Infection of rabbits with human T-cells infected with HIV-1 has lead to seroconversion within 4 to 19 d in 20 rabbits injected and virus can be isolated from peripheral blood cells of infected rabbits after culture in IL-2. The identity of isolated virus as HIV-1 was shown by Southern blot analysis and by presence of predicted restriction enzyme sites in DNA fragments from infected cells after amplification by the PCR technique. Overt effects of HIV-1 infection in rabbits were minimal during the period of observation (9 mo) but pathological examination upon necropsy revealed enlargement of spleen or thymus in the majority of infected animals and infiltration of lungs with lymphocytes. HIV-1 infection of rabbits previously infected with HTLV-1 caused more evident signs of illness with diarrhea in most animals along with weight loss in some. Several animals showed transient neurologic dysfunction and one had a rapidly progressing breast adenocarcinoma. Current efforts focus on determining the effects of HIV-1 infection on the immune status of the rabbits and in determining whether a homology of CD4 plays a role in the infection process. **Conclusion:** Rabbits can be infected with HIV-1 and show seroconversion and isolation of virus from PBL. Effects of the infection on immune function require further definition.

W.C.P.38

SEROLOGIC VARIABLES AT DIAGNOSIS WITH KAPCOW'S SARCOMAS; PREDICTORS OF SHORTENED SURVIVAL.
Calk, P.S., Moss, A., Beckett, P., Winger, E.,** Edmon, R.J., Field, D.W.,** Johnson, E.A.,** et al. *AIDS Action Division, San Francisco General Hospital/Univ. of California, San Francisco, CA; **The University of Washington, Seattle, WA; ***The University of Texas, San Antonio, TX

Objective: To compare viral and patient characteristics at the time of KS diagnosis and duration of survival in early vs recent cohorts of KS patients. **Methods:** Sex drawn from 183 patients at the time of KS diagnosis (median date of diagnosis: June 23, 1986) was analyzed for viral and immunologic characteristics. Values were compared for patients diagnosed before July 1984 ("early" KS) and those diagnosed after that date ("late" KS). Duration of survival following KS diagnosis was also compared for the two groups. **Results:** Survival averaged 12.24 weeks in the "early" group and 7.19 in the "late." This difference was significant with $p < .05$. Early patients and 53 late patients had laboratory results as follows:

	KS Patient Group (mean \pm SD error)		p-value
	Early	Late	
Beta-2 microglobulin ng/ml	5.44 (3.8)	27.95 (24)	<.001
Neopterin nmol/l	43.77 (6.74)	27.95 (4.58)	.16
p24 antigen pg/ml	43.78 (11.89)	39.62 (22.94)	.10
Hemoglobin	40.25 (7.4)	37.70 (10.08)	.36
Sedimentation Rate	31.0 (4.3)	28.1 (5.9)	.58
CD4+ T-cells	1.38 (0.3)	0.43 (0.3)	<.001
T4 helper cells	209.2 (51.8)	149.3 (24.9)	.31

Conclusion: KS survival has notably shortened since the start of the epidemic. While T4 counts, hemoglobin, and p24 antigen were more favorable in the early group with longer survival, the abnormal Beta-2, and neopterin levels suggest an immune response to a concurrent infectious process in this group.

W.C.P.40

ISOLATION AND PARTIAL CHARACTERIZATION OF AN HIV RELATED VIRUS OCCURRING NATURALLY IN CHIMPANZEES IN GABON
Pastors, Martin; Cooper, R.W.; Honore, G.; Hue, T.; Bussi, P.; Delaporte, E.
*Centre International de Recherches Médicales, BP 769, Franceville, Gabon; **Laboratoire de Biologie Moléculaire, Institut Pasteur, Paris, France

Objective: To better understand the natural history and the evolutionary relationship of the HIV/SIV group of viruses, we tested several chimpanzees from Gabon for HIV antibodies. **Methods:** The sera were tested for HIV antibodies with commercial HIV tests (ELISA, western blot). Virus was isolated from peripheral blood lymphocytes from the chimpanzee infected with normal (HIV negative) human lymphocytes. Partial characterization was done by electron microscopy, nucleic-immunoprecipitation and nucleic acid hybridization. **Results:** Two cases of wild born chimpanzees, positive for HIV antibodies were observed in Gabon. These animals were never seropositively exposed to HIV and had no history of inoculation with human blood products. A retrovirus was isolated from one of these chimpanzees and was related to an SIVgp. Partial characterization of this virus revealed that it had biological and morphological properties similar to other known human and simian retroviruses, but significant differences could be demonstrated. Several of the viral proteins differ in molecular weight from the known corresponding HIV/SIV proteins. SIVgp did not induce severe cytopathic effects in human and chimpanzee lymphocytes. Antigenically SIVgp seems to be closer to HIV-2 than to HIV-1 and the other SIVs. From nucleic acid hybridization experiments it appears that the virus is different from HIV-1, -2. **Conclusion:** Chimpanzees can be naturally infected with a novel retrovirus, antigenically close to HIV-1.

W.C.P.42

p24 ANTIGEN IN THE CSF AND SERUM OF PATIENTS WITH NON-HODGKIN'S LYMPHOMA TREATED WITH STANDARD CHEMOTHERAPY WITH OR WITHOUT GM-CSF
Kohn, James; Crowe, D.; Reikes, L.; Volberding, P.
*University of California San Francisco/San Francisco General Hospital, San Francisco, CA, USA
**Memorial Sloan-Kettering Cancer Center for Medical Research, Fairfax Hospital, Melbourne, Australia

Objective: To describe p24 antigen levels from the serum and CSF in patients with non-Hodgkin's lymphoma treated with standard CHOP chemotherapy and randomized to treatment with or without GM-CSF. **Methods:** Patients with AIDS-related non-Hodgkin's lymphoma who fulfilled entry criteria for study were treated with standard chemotherapy consisting of cyclophosphamide 750 mg/m², vincristine 2 mg, adriamycin 40 mg/m² and procarbazine 40 mg/m² on day 1 of a 21 day treatment protocol. Patients were also treated with methotrexate, 15 mg/m² on days 1 and 3. In the GM-CSF group, GM-CSF, 10-15 mcg/kg was administered subcutaneously days 1-10. CSF and a corresponding serum sample were collected prior to the first cycle of chemotherapy. Serum and CSF was frozen and assayed using a standard commercial Abbott kit. **Results:**

Pt	CSF		Chemotherapy - GM-CSF		Chemotherapy + GM-CSF		Serum
	Day 1	Day 8	Day 1	Day 8	Day 1	Day 8	
1	ND	443	443	ND	ND	ND	ND
2	0	0	ND	0	3961	34	ND
3	0	0	0	0	15	17	346
4	0	0	0	0	0	0	0
5	Day 1	Day 8	Day 1	Day 8	Day 1	Day 8	Day 8
6	0	ND	0	ND	0	ND	ND
7	0	ND	0	ND	ND	ND	ND
8	0	0	0	0	0	0	0

Conclusion: Preliminary results indicate that GM-CSF did not have a consistent effect on the p24 antigen from serum or CSF in patients with AIDS associated non-Hodgkin's lymphoma.

**Session d'affichage
Poster Session**



**Recherche fondamentale (biomédicale)
Basic Research (Biomedical)**

W.C.P.43 HIV-1 INFECTION OF HUMAN FETAL CENTRAL NERVOUS SYSTEM TISSUE
Soniya Ray, Tanaka, K., Chak, M., Usen, S., Rubinstein, A., and Ighem, M.D.
Albert Einstein College of Medicine, Bronx, New York, U.S.A.

Objective: It is believed that children with congenital HIV-1 infection have been exposed to HIV-1 in utero. Because a significant number of these children exhibit neurological manifestations associated with HIV-1 infection, this study was initiated to determine whether HIV-1 DNA could be detected in fetal CNS thereby suggesting a role in pediatric AIDS neuropathology.
Methods: Amniotic tissue was collected aseptically from HIV-1 seropositive and control patients at the time of elective pregnancy terminations. Tissues were frozen in liquid N₂ and processed by standard phenol extraction. The presence of HIV-1 DNA was determined by molecular hybridization of a ³²P-labeled sequence after amplification (30 cycles) using the polymerase chain reaction. Infected unfixed IV cell DNA or neurologically negative human lymphocyte DNA were included to indicated positive and negative hybridization.
Results: CNS tissue obtained at estimated fetal ages between 13 and 20 weeks showed positive reactions for HIV-1 ³²P-gene DNA in 4 samples from seropositive or risk group women. Other CNS samples from seronegative women failed to show HIV-1 DNA.
Conclusion: Human fetal CNS tissue revealed the presence of HIV-1 DNA suggesting a role of viral infection in early AIDS associated CNS disease. (Supported, in part, by HL 07060, DA 05583, DA 04583, NS 19320, AI 20671, and the Diamond Foundation).

W.C.P.45 HIV-1 BRAIN INFECTION: DISTRIBUTION OF INFECTION AND CLINICAL CORRELATES
Cronin, K.C.; Rosenblum, M.; New, B.J.; Price, Richard W.
Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Objective: To define immunohistochemically: 1. The frequency and topographic distribution of productive HIV-1 brain infection; 2. The histopathological correlates of cell types infected in brain; and 3. The relation of productive infection to the presence and clinical severity of the AIDS dementia complex (ADC).
Methods: Avidin-biotin immunoperoxidase with a monoclonal antibody against a core protein (antibody 25-8, a gift from Genetic Systems, Seattle) was used to map infection in frozen brain sections from 50 HIV-1-infected patients, 37 of whom had been prospectively staged with respect to ADC.
Results: HIV-1 infection was detected 20 brains. The most commonly infected structures included globus pallidus (83% of positive brains); corpus callosum (57%); and caudate, putamen, substantia nigra, midbrain, pons and frontal white matter (40-43%). Cerebral cortex was among the least commonly infected (5-11%) and no infection was detected in choroid plexus or dorsal root ganglia. Productive infection was confined exclusively to macrophages, microglia and multinucleated cells derived from these 2 cell types. No infection was detected in 0 of 9 at ADC Stages 0-3, 6 of 11 at Stage 4, 1 of 2 at Stage 2, 4 of 6 at Stage 3 and 5 of 7 at Stage 4 and was frequently limited in relation to disease severity.
Conclusion: Productive HIV-1 brain infection correlates with later ADC Stage and is circumscribed both regionally and by cell type. Brain dysfunction is not clearly understood and does not relate to infection in a simple manner.

**Oncology
Oncology**

W.C.P.47 CO-FACTORS IN THE DEVELOPMENT OF KAPOSI'S SARCOMA (KS): HIV-6 INFECTION. Giraldo, Gastano*, Beth-Giraldo, E.; Serwadda, D.**; Katogole-Milde, E.**; Romano, F.*; Ballo, R.C.**

*Inst. Naz. Tumori e Ospedale, Naples, Italy; **Malaria Trust and Uganda Cancer Inst., Kampala, Uganda; *** Nat. Cancer Inst., Beth., MD, USA.
Objective: To determine the in vivo effect of HIV-6 infection in compromising the immune system and the synergistic action in association with other cytotoxic or transforming herpes- and retroviruses in Kaposi's sarcoma and various HIV-6 and HIV-6 hospital and healthy populations.
Methods: Identification of antibody prevalence to HIV-6 vs HIV-1, CMV, EBV and epidemiological evaluation in endemic vs epidemic KS (equatorial Africa), classic vs epidemic KS (USA, Europe), in hospital populations and healthy subjects (>1000 sera, Uganda; >1000 sera, USA, Europe).
Results: Prevalence to HIV-6 in Kaposi's sarcoma and matched Blood Donors
KS endemic (N.54) Uganda 47yrs OS HIV+ 67% HIV-6+ 15% high-titer HIV-6 KS epidemic (35) Uganda 36 " 100% " 55% " 0%
KS classic (58) US-Eur 60 " 0% " 47% " 0% " 0%
Blood donors (50) US-Eur 30 " 0% " 43% " 0% " 0%
KS epidemic (18) US-Eur 34 " 100% 44% " 0% " 0%
Blood donors (50) US-Eur 35 " 0% " 73% " 12% " 0%
Conclusion: a) There is a high prevalence of HIV-6-antibody in KS and healthy subjects; b) HIV-6 seropositivity rates decrease with age; c) HIV-1+ patients have high-titer HIV-6-antibody prevalence than matched HIV-1- controls, probably due to synergistic effect of double infection by HIV and HIV-6.

W.C.P.44 NATURAL ANTIBODY PERCEPTION OF AMINO ACID DIVERGENCE WITHIN AN HIV-1 NEUTRALIZATION EPIPTOPE
Gundamini, Jean*, Zwart, G., Bekker, M., Epstein, L.M., Kulkarni C***, De Wolf F.

*Rijks Reziervier Laboratorium, Amsterdam, the Netherlands, **UMID-New Jersey Medical School, Newark, NJ, USA, ***Dept of Infectious Diseases, Municipal Health Service, Amsterdam, the Netherlands.
Objective: Gaining insight into the recognition by natural antibodies of a variable gp120 epitope.
Methods: Nine synthetic peptides were used to screen sera of 134 individuals infected with HIV-1. The oligopeptides were nine amino acids in length and corresponded to the isolate specific "neutralizing" domain in gp120 (V3 region) of (HIV-1) strains: LAV-1, RF, SP2, NY6, CDC8, ELI, MAL, Z6 and Z3. 67% reactivity to the LAV-1 peptide in Africans (53%) and reactivity to the Z3 peptide in African sera (78%), 54% of the sera showed reactivity with more than one of the oligopeptides. Blocking experiments favoured cross-reactivity as explanation. A cluster analysis was performed on the cross-reactivities of the sera. This and ELI analysis grouped together LAV-1, RF and CDC8, Z6, MAL and ELI and NY6 and Z3 stood alone. This clustering could not completely be explained by comparing physicochemical properties of the oligopeptides. However, the clustering showed the greater resemblance to a phylogenetic tree of the complete gp120 molecule.
Conclusion: Multiple reactivities are mostly due to cross reaction. The complete envelope may be involved in the selection of B cell clones for the V3 epitope.

W.C.P.46 DIFFERENCES IN RISK FOR AIDS AND AIDS MORTALITY IN 49 INDIVIDUALS INFECTED WITH LOW-AND HIGH-VIRULENT HIV VARIANTS.
M. Tormetzte, J.M.A. Lange*, R.E.T. de Goede, J.C. Outman, J. Goedkoop*, F. Wiedema, Central Lab. Richard, Red Cross Blood Transf. Service and Lab. of Exp. and Clin. Immunology of the Univ. of Amsterdam, *Academic Medical Center, Amsterdam, The Netherlands.

Forty-nine seropositive individuals (twenty of whom were asymptomatic at the start of the observation period) were studied longitudinally for the relation between in-vitro properties of their sequential HIV isolates and clinical course before and after the development of AIDS. Per individual 2-8 sequential isolates were studied. Based on the properties of their isolates (Tormetzte et al., J.Virol. (1988) 62:2026-2032), the individuals could be divided in three groups. The presence of asymptomatic-infecting or high-replicating HIV isolates was significant predictive for the development of AIDS within 1-2 years. Antidichthymine (ADT) treatment in the asymptomatic period seemed to delay the onset of AIDS even in the highest risk group. Upon development of AIDS, significant differences in survival between the groups were observed. Also differences in clinical symptoms of AIDS patients from the three groups were observed. These observations stress the importance of the development of virulent HIV variants in the host as a mechanism for AIDS pathogenesis. The existence of a relationship between biological properties of HIV variants and clinical course may provide a possibility to identify asymptomatic HIV seropositive men at high risk for AIDS as a potential target group for early treatment with antiviral drugs.

W.C.P.46 AIDS-KAPOSI'S SARCOMA (KS) DERIVED CELLS EXPRESS CYTOKINES WITH A POTENTIAL ROLE IN THE PATHOGENESIS OF KS LESIONS
Engel, Barbara; Nakamura, S.; Salakhotova, S.Z.;

Wong-Staal, F. Gal, P. A.
Laboratory of Tumor Cell Biology, National Cancer Institute, Bethesda, MD, U.S.A.
KS is a proliferative disease of unknown etiology and frequent manifestation of AIDS. Cell cultures established from KS lesions of AIDS patients (AIDS-KS cells) are able to promote in vitro proliferation (autocrine) and proliferation of normal endothelial cells, fibroblasts and cells of hematopoietic lineage (paracrine). Furthermore, the AIDS-KS cells induce neovascularization, and a KS-like lesion in nude mice. Studies at the molecular level indicated that the AIDS-KS cells express mRNA specific for basic and acidic fibroblast growth factor (bFGF, aFGF), interleukin-1 and 8 (IL-1 and -1β), granulocyte-macrophage colony stimulating factor (GM-CSF), transforming growth factor β (TGFβ) and platelet derived growth factor β (PDGF-β). Particularly bFGF and IL-1β are expressed at high levels, released into culture media, and responsible for inducing AIDS-KS and normal endothelial cell proliferation. The results suggest that in vivo KS cell proliferation with cytokines production could be the final step leading to the appearance of the composite KS lesion.

**Session d'affichage
Poster Session**



**Recherche fondamentale (biomédicale)
Basic Research (Biomedical)**

W.C.P.49

MISCELLANEOUS CARCINOMA DEVELOPING IN PATIENTS WITH HIV INFECTION.

RAJAL, RAJAL, Sharma S, Hill P, Bernstein L, Bernstein A, and Levine AM. University of Southern California, Los Angeles, CA, USA.

OBJECTIVE: To describe the occurrence of solid cancers excluding Kaposi's sarcoma in patients with various stages of HIV infection.

DESIGN: The pathological tumor types of all solid tumors excluding Kaposi's sarcoma were examined in males ages 20 to 50 years of age diagnosed at the Los Angeles County/USC Medical Center from 1986 through 1988. Patients were then assessed for the presence of HIV infection by either serologic evidence or specific indicator diseases. For each patient identified with HIV infection and solid tumor, stage of HIV infection, extent of cancer, treatment modality and survival data were obtained.

RESULTS: From a total of 359 solid diagnosed with solid cancers 27 (7.5%) had co-existent HIV infection. 12 patients (pts) had Stage I disease, 7 pts Stage II and 8 pts Stage IV. Tumor types included de novo ductal (n=23), terminal cell (n=18), Primary Lung (n=18), Basal Cell Carcinoma of skin (n=13), unknown primary (n=7) and 1 each (43) of disseminated melanoma, squamous cell carcinoma of the cervix, esophagus, stomach, colon, rectum, bladder, prostate, and testis.

CONCLUSION: 1) Unknown solid carcinomas are being diagnosed in pts with HIV infection; 2) survival is often shortened because of the underlying immune dysfunction due to HIV; 3) More study is needed to establish the rate of HIV in the development of these solid tumors.

W.C.P.51

HIV-HPV INFECTION AND PENILE CARCINOMAS (PC) IN UGANDA

Burnagoro, Franco, M., Betti-Graldo, G., S. Tornesello, M., L. Caracciolo, G., E. Di Monaco, M. B. and Giarolo, G.
Email: Cancer Inst., Naples, Italy, ** Makerere University, Kampala, Uganda.

OBJECTIVE: To determine effects of HIV epidemic on the incidence and the evolution of PC in Uganda, by a possible modulation of HPV infection.

Methods: DNA extracted from PC biopsies and cell lines, of HIV negative and positive patients, are tested for the presence of HPV strains by dot blot and Southern blot analysis.

Results: HIV seropositive patients have been reported to present a significantly high prevalence of cervical dysplasia (C. Brasseur, Lancet 1992; M. Byrne et al., Lancet 1988) and signs of HPV infection (P. Crocchiolo et al., Lancet 1989). We are determining HPV infection in biopsies from Ugandan patients with PC before and during the HIV epidemic. Furthermore, two permanent cell cultures, from penile carcinomas of Ugandan patients, have been established. Some of the markers typical of oncotypes of neuroectodermal origin have been identified. HPV infection signal is present with a HPV 18 DNA probe in reaction performed at high stringency (Tm=50). A stronger hybridization signal is obtained at low stringency (Tm=50), suggesting the presence of an HPV strain with low homology to HPV 18.

Conclusions: We are going to: a) determine the incidence of HPV in PC in Uganda, b) verify the HIV role on HPV incidence and PC evolution, and c) to isolate and characterize the eventual new HPV strain.

W.C.P.53

CERVICAL NEPLASIA IN HIV-INFECTED WOMEN

Schäfer, A.,* Schlegeländer, B., Dept. of Obstetric and Gynecology, Freie Universität Berlin, FRG; ** AIDS-Center, Bundesgesundheitsamt, Berlin, FRG**

Objective: To evaluate the meaning of cervical neoplasia and Papillomavirus-infection (HPV) in HIV-infected women.

Methods: We investigated cytological smears and cervical tissue from 108 HIV-infected women for dysplastic alteration and HPV-infection.

Results (Selection): Dysplastic alterations were seen 15 times more often in HIV-infected women than in women without HIV-infection. Histologically 10 CIN's and 5 invasive carcinoma of cervix were detected. Nearly half of the smears without dysplastic alteration and more than 80% of smears with dysplastic alteration showed signs of HPV-infection. There was a strong correlation of clinical status of HIV-infection and dysplastic alteration and cancer.

Discussion: On the basis of a high prevalence of HPV a routine-screening for cervical dysplastic alteration is essential in HIV-infected (immunocompressed) women.

W.C.P.50

48 UNUSUAL HIV-RELATED MALIGNANT TUMORS. **Trull, Umberto, Vecchio C., Sisti A., Sabatucci, Giustolisi R. S., Agui T., Santolucito S. et al.** Gruppo Italiano Cooperativo AIDS-Tumori (GIAT), ISTAT

Objective: To evaluate the characterization of unusual HIV-related tumors observed in Italy. **Methods:** Since 1985 the GIAT has collected 48 HIV-related tumors other than KS and NHL predominantly among intravenous drug abusers (IVDA), in accordance with the overall epidemiology of AIDS.

Malignancy	#P	Risk Group	Clinical and Pathological Features
Testic ca.	13	9 IVDA	7 carcinoma, 5 seminoma.
Cervix ca.	9	9 IVDA	median age 34, 8/9 ca. in situ
Lung ca.	8	9 IVDA	w/rtier age 34, 5 NSCLC
Acute leukemia	5	7 IVDA	M ₂ (Burkitt-like), 1 B
Multiple myeloma	2	2 IVDA	age 29 and 32, 1 with K ⁺
Other ca.	10	10 IVDA	age 39 to 55, rapid course

Only 1 case was reported of glioblastoma, thyroid ca., Uterine, melanoma, renal vs pancreatic ca., Gli(OM), oral ca., (basal) pyroplasmoid and anal ca. (Famula) praxistoma with anaplastic metastases). Testis ca. occurred in patients (pts) infected in early HIV infection without adversely affecting full dose chemotherapy or radiotherapy. Cervix ca. in 8/9 pts treated with combination therapy suggest high viral screening in young IVDA. Lung ca. occurred in a young age group with rapid prognosis and death within 2 mo. of diagnosis. Chemotherapy in Burkitt-like ALL was not adversely affected by HIV infection and 2 DS were achieved (1/1 and 1/5 vs. darabutin). **Conclusion: In this HIV-based series, while oral and anaplastic tumors did not occur, there is a wide spectrum of unusual HIV-related tumors which is probably underdiagnosed because not diagnosed of AIDS. The required therapeutic approach may not be consistently influenced by HIV infection, as for KS and NHL.**

W.C.P.52

KAPOSI'S SARCOMA-LIKE CELL LINES FROM SIMIAN AIDS WITH SUBCUTANEOUS AND RETROPERITONEAL FIBROSITIS ASSOCIATED WITH TYPE D RETROVIRUS (SRV-2) INFECTION

Tsai, Cheng* Tsai, C. Slihp, J.* Wong, J.* Roodman, S.***
St. Louis University, St. Louis, Missouri, USA, **Washington Regional Primate Research Center, Seattle, Washington, USA.

Objective: To establish KS-like cell lines from AIDS associated with SRV-2. **Methods:** Two KS-like lesions, subcutaneous and retroperitoneal fibrositis from macaques with AIDS associated with SRV-2 infection were cultured in regular RPMI or DMEM medium supplemented initially with brain derived growth factor (BDGF), immunocytochemical, cytologic, ultrastructural and viral studies were carried out on various passages of culture (over 16) during a 12 months period.

Results: Both cell lines propagate vigorously in 10% FCS media without BDGF after 4th passage and can grow with only 0.5% FCS unlike the control monkey fibroblast. Cytology and immunocytochemistry of both cells are similar and demonstrated heterogeneous populations of endothelial(s)K09, pericytic/smooth-muscle(s)S2, and primitive mesenchymal/fibroblastic differentiations. Arborizing multilayered anaplastic giant cells are prominent in early culture. Both cell lines are diploid (D1=20) with high proliferative activity (>25% S-Phase) but show no growth in soft agar. Evidence of autocrine/paracrine growth is further supported by the presence of cytoplasmic phosphotyrosine and BDGF-like proteins in these cultured cells.

Conclusion: Two KS-like cell lines from simian AIDS associated with SRV-2 were established for future basic and clinical study.

W.C.P.54

CHARACTERIZATION OF IN VITRO CULTURE OF KS-DERIVED CELLS.

Peter Biberfeld, Shui Nakamura*, Zaki S. Salahuddin*, Barbara Enos†, Robert C. Gallo**, *Department of Pathology, Karolinska Institute, Stockholm, Sweden; †Lab of Tumor Cell Biology, NCI, Bethesda, MD, USA; ** Culture medium (CM) from retrovirus infected T-cell lines promote the continuous, in vitro growth of cells from biopsies of Kaposi's sarcoma (KS).

These cells have endothelial like features and produce in vitro several growth factors notably bFGF-like activity (1). These cells elicit a strong angiogenic reaction in nude mice and on chicken allantoic membranes. Studies are in progress on the identity of the CM with growth promoting activity to KS-derived cells and the possible expression of autocrine and paracrine activities by these in vitro cultured cells.

- 1) Nakamura, S., Salahuddin, S.Z., Biberfeld, P., Enos, B., Markham, P.D., Wong-Staal, F. & Gallo, R.C., Kaposi's Sarcoma Cell Line: Short-term Culture with Growth Factor from Retrovirus-infected CMs (7 Cell, Science, 1988, vol. 242, pp. 429-430)
- 2) Salahuddin, Z.S., Nakamura, S., Biberfeld, P., Kaplan, M.H., Markham, P.D., Larson, R.C. & Gallo, R.C., Angiogenic Properties of Kaposi's Sarcoma-Derived Cells After Long-Term Culture in Vitro, Science, 1988, vol. 242, pp. 430-433.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

Pathogénèse

Pathogenesis

W.C.P.55

VACUOLAR MYELOPATHY: HIV-1 EXPRESSION CORRELATES WITH EXTENT OF CLINICAL AND PATHOLOGIC DISEASE.

Barbara Melnick, N. Distefano, D. Elliott, D. LaSera, R. Seidman, H. Burger, SUNY, Stony Brook

Spatial cord (SC) disease and a distinct vacuolar myelopathy (VM) characterized by vacuolation and macrophage infiltration of SC white matter both occur following HIV-1 infection. We have shown previously in 3 SC from AIDS patients with severe myelopathy that HIV-1 RNA was present in the 3 SC and localized to macrophages in vacuolated areas of white matter. To determine if (1) HIV-1 RNA is present in the SC of AIDS patients with a range of cord pathology and (2) HIV-1 expression is correlated with clinical and pathologic disease, we studied 17 SC from AIDS patients and 9 controls. In situ hybridization was used to detect HIV-1 RNA, and immunohistochemistry to identify cell type. Immunohistochemical staining of the 10 cords with VM showed macrophage infiltration of vacuolated regions of SC white matter, with the degree of infiltration parallel to the degree of clinical and neuropathology. Cords from AIDS patients with SC lymphoma and cryptococcosis showed focal macrophage infiltration, and 6 cords from controls without SC disease showed none, if any, macrophages. Of the 17 cords obtained from AIDS patients at autopsy, HIV-1 RNA was detected in 6 of 10 with vacuolar myelopathy, 0 of 5 without SC pathology, and 0 of 2 with focal macrophage infiltration secondary to other SC disease (tumor and lymphoma). Three control cords obtained from patients with other SC diseases showed no HIV-1 RNA. In the 10 AIDS cords with VM, the amount of HIV-1 RNA expression correlated with the extent of both SC pathology and clinical disease. These data support a direct role for HIV-1 in the pathogenesis of AIDS myelopathy.

W.C.P.57

EARLY APPEARANCE OF CROSSREACTIVE ANTIBODIES SPECIFIC FOR A COMMON EPITOPES IN CD4+ AND HLA CLASS II ANTIGENS CAN INTERFERE WITH NORMAL IMMUNE FUNCTIONS IN AIDS PATIENTS. Hans Golding*, Shaerer, G.M.***, Hillman, K.V., Manischewitz, J.P., Golding, B.*

HIV and SIBP, CHER, FMA, wright, W.H., Bethesda, MD, U.S.A.
Antigen acid sequence is highly homologous sequence in the C-terminus of HLA class II and the B-2-microglobulin chain. Screening of sera from HIV-1 infected individuals, reveals a high frequency (35-40%) of antibodies specific for the common epitopes in both early and late stages of the disease. These sera as well as murine Ab against this sequence reacts also with class II-bearing (uninfected) cells (8, 7, Macrophages).

Objective: To study if the crossreactive Ab (CRAB) can interfere with T cell immune functions and contribute to elimination of class II⁺ cells.
Methods: Patients' and controls' sera were added to normal T cells stimulated with tetanus toxoid or antigenic stimulators. Sera were tested in Ab-Dependent Cellular Cytotoxicity (ADCC) of class II⁺ cell lines. CRAB were purified by affinity chromatography (peptide-sepharose-column).
Results: Sera containing CRAB or anti-CD4 were potent inhibitors of the proliferative responses of normal CD4⁺ T cells. The same sera could also kill class II-bearing (uninfected) cell lines. Both reactivities could be adsorbed by peptide linked-sepharose beads. The purified CRAB were all IgG. In many cases such CRAB were present in sera from asymptomatic patients who still had CD4⁺ T cells (>500/mm³), but demonstrated *in vitro* unresponsiveness to various recall antigens (influenza, tetanus toxoid, etc.).
Conclusion: HIV-1 infection may lead to generation of CR antibodies. Absence of circulating immune functions early during the course of disease.

W.C.P.59

INDUCTION OF HUMAN IMMUNODEFICIENCY VIRUS FROM CHROMIALLY EXPRESSED CLONES BY PHOSPHOLIPASE C AND PHARMACOLOGICAL AGENTS REQUIRES PROTEIN KINASE C ACTIVATION. Anne, Audrey, Maury, W., Pohl, G., Fanci, A.S., Folks, T.M., NIAID, NIH, Bethesda, MD, U.S.A.

Objective: This study was designed to define second messenger pathways by which cytokines and pharmacological agents induce HIV expression from chronically infected cells.
Methods: The U1 (promonocytic) and AC3 (lymphocytic) chronically HIV infected clones express low to undetectable constitutive levels of HIV. Virus replication in these cells can be increased 2-20 fold by phorbol esters (PMA), recombinant cytokines [TNF α -GM-CSF (U1 clone)], and cytokine enriched cell supernatants. We have used inhibitors (topical/nucleoside derivatives) and activators of protein kinases (PK) as well as agents which modify calcium activity, for their effect on baseline and cytokine induced virus expression in the U1 and AC32 clones. Virus expression was measured as supernatant reverse transcriptase activity, by western blot and nuclear run-on analysis.
Results: PK, the most potent inducer of PKC activity, effectively blocked (75%-90%) HIV induction by all cytokines and pharmacological agents in both the U1 and AC32 clones. Those inhibitors, H8 and HA1004, which are more selective for cyclic nucleotide dependent kinases, did not suppress virus induction. Specific activation of PKC by genistein, diacylglycerol and bradykinin, resulted in a 2-8 fold increase in viral replication in both clones. Activators of cyclic nucleotide kinases were not effective in inducing virus. Agents which increase intracellular levels of calcium can potentially synergize with PKC mediated induction in U1 but not AC3-2 cells.
Conclusion: Upregulation of HIV by cytokines and pharmacological agents requires the activation of PKC. Evidence exists of a calcium related, but ultimately PKC dependent, event which can also upregulate virus expression.

W.C.P.56

HIV-1 ANTIGENIC VARIANTS WITH DISTINCT BIOLOGICAL PROPERTIES EMERGE AT THE DECLINE OF THE IMMUNOLOGICAL ANTIBODY

De Jong, Jean-Jacques*, Tarnette M.**, Kroes W.**, Meloen R.**, Miedema F.**, Goudaard J.***

*Husum University Hospital, Amsterdam, the Netherlands, **Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, the Netherlands

Objective: To study the antigenic variability of the V3 region (as 296-331) of the external envelope of 120 HDs (gp120) of HIV-1 in natural infection.
Methods: Sequential isolates of 6 patients progressing to AIDS and showing a transition from non-synonymous to synonymous forming sequences were used to study antigenic variability of the V3 domain of gp120. The V3 coding domain was amplified using the polymerase chain reaction (PCR). Direct sequences of the V3 coding domain were determined and confirmed by cloning and sequencing. Antibody reactivity of sequential sera of these individuals was determined for peptides covering the complete V3 domain of the isolates.

Results: The transition from non-synonymous to synonymous inducing isolates was marked by clustered nucleic acid changes of which three were consistent. This resulted in one amino acid change crucial to antibody binding. Decline of the antibody to the synonymous forming antigenic variants preceded the emergence of these variants.

Conclusions: Antigenic variants appear to be selected by antibody to the V3 domain of gp120 during natural infection.

W.C.P.58

HIV-1 INFECTED HUMANS, BUT NOT CHIMPANZEES, HAVE CYTOTOXIC T LYMPHOCYTES THAT LYSE UNINFECTED CD4+ CELLS

Raizola, A.***, Ledwith, J.**, Gies, J.S., Pulis, F.**, Eichberg, J.***, and Zarling, J.**, *Onogen, Seattle, Washington, USA; **Harlan Primate Research Center, Babey University, Aycliffe, Washington, USA; ***Southwest Foundation for Biomedical Research, San Antonio, Texas, USA.

Objective: It has been suggested that autoimmunity contributes to the depletion of CD4⁺ T cells in HIV-1 infected humans, based on findings that some HIV-1-infected humans have autoantibodies reactive with antigens on uninfected CD4⁺ cells. We asked whether HIV-1-infected humans also have CTLs lytic for uninfected CD4⁺ cells that may contribute to the depletion of CD4⁺ cells.

Methods: Fresh PBMC from humans and chimpanzees were tested for their ability to lyse ⁵¹Cr labeled uninfected CD4⁺ cells and other cells.

Results: HIV-1-infected humans, but not uninfected humans or chimpanzees, have PBMC that lyse uninfected CD4⁺ T cells from humans and chimps but not human B lymphoblastoid cells or mouse T cells. The cytotoxicity of PBMC was concluded to be CTL that are CD3⁺, CD8⁺, CD4⁻, CD16⁺, TCR- $\alpha\beta$ +, based on findings that lysis of uninfected CD4⁺ cells was diminished by (1) anti to CD3, which inhibits CTL but not NK activity; (2) treatment of PBMC with anti to CD8, but not to CD16 and C; (3) anti to TCR- $\alpha\beta$ which is expressed on MHC-restricted CTL; and (4) anti to HLA class II framework determinant. In contrast, PBMC from HIV-1-infected chimpanzees, which do not develop AIDS, lacked detectable CTL lytic for uninfected CD4⁺ cells.

Conclusion: Circulating CTLs lytic for uninfected CD4⁺ cells that we detected in blood from HIV-1-infected humans but not from chimpanzees, may contribute to HIV-1-induced immunopathology in man.

W.C.P.60

MORPHOLOGICAL CHANGES OF THE VACUOLAR LYMPHOCYTES IN AIDS

Artlitz, Jan; Niesdörfer, F.; Grossa, G.; Bork, G. and Hiesl, M.

Department of Pathology and * Department of Medicine; Aguda-Viktoria-Krankenhaus, Rubensstraße 125; 1000 Berlin 41 FEDERAL REPUBLIC OF GERMANY

Objective: To describe the morphological changes of the vacuolar lymphocytes (VL). Such morphological studies are rare and thus the pathogenesis of this frequent condition is poor understood.

Methods: The spinal cord of 42 HIV-infected patients was examined with conventional histology, immunohistochemistry and electron microscopy.

Results: In 24 cases as mild (17 cases), moderate (12 cases) or severe myelopathy (5 cases) was found. Fourteen vacuoles, 20 to 380 nm in diameter and 200 to 800 nm in length, consisted of a thin sheet of disintegrated myelin, are present in the white matter. Clusters of macrophages, phagocytosing areas of moderately preserved structures, are found into the vacuoles. The foam macrophages contain vest of axons, only in one case with severe tissue disruption they contain myelin debris too. In 5 cases, some macrophages, microvillus cells and multinucleated cells show HIV-antigen (p24 and gp41). A strong astrogliosis is present in the white and grey matter. Proliferation of microvillus cells is present between the neurons in the grey matter.
Conclusions: VL is a more frequent condition as previously thought. In VM it proceeds of phagocytosis directed against the axon cylinders occurs simultaneously with vacuolar demyelination of the white matter. The vacuoles arise between the axoles and the myelin sheath.

Session d'affichage Poster Session



Recherche fondamentale (Biomedicale) Basic Research (Biomedical)

W.C.P.61 HIV-1 INFECTION OF HUMAN FETAL CENTRAL NERVOUS SYSTEM ORGANOTYPIC CULTURES

Lynn, William, Tricoche, M.; Kress, Y.; Hatch, V.; Chiu, F.-C. and Smirnov, R. Albert Einstein Coll. Med., Bronx, NY, USA.

Objective. Most cases of pediatric AIDS are likely congenital and the product of fetal infection by HIV-1 in utero. Because a significant number of children with AIDS exhibit neurologic disease, this study was initiated to determine if HIV-1 can infect fetal central nervous system (CNS) cells and characterize the resultant pathology.

Methods. Explants of fetal CNS tissue were established and maintained in organotypic culture for up to 8 weeks. Initial studies, using light and electron microscopy (LM and EM) in combination with immunocytochemistry and Western blot technology, confirmed that the cultures contained normal nervous tissue cellular elements. Test cultures were exposed to either infectious or heat-inactivated HIV-1 isolates. Infection of tissue was determined by immunocytochemistry, molecular hybridization, and an infectious centers assay. Pathology was assessed by LM and EM.

Results. Cultures exposed to infectious HIV-1 (1118 strain) for up to seven days showed an array of morphologic changes. HIV-1 infection of the cultures was confirmed in 32 P-labeled tests and virus-like particles were observed in CNS tissue cells.

Conclusion. Organotypic cultures of human fetal CNS tissue may provide a valuable experimental model to define the targets and mechanisms associated with the neuropathology of AIDS. (Supported, in part, by DA 05583, DA 04383, NS 11920, NS 25873, AT 20671, and the Sisson Foundation).

W.C.P.63 HIV-INFECTION ALTERS THE INTERACTION OF MACROPHAGES WITH TOXOPLASMA AND LEISHMANIA

Katzer, D. C., Gendelman, H., Orenstein, J., Melzer, M. S., and Reed, S.**

H. M. Jackson Fdn., George Washington Univ., Walter Reed Army Inst. Res., Washington DC, **Seattle Biomedical Res. Inst., Seattle WA, USA.

Objective. Examine ability of HIV-infected macrophages to ingest and kill intracellular parasites.

Methods. Macrophages from normal donors were cultured in medium with colony stimulating factor-1 (MCSF, Cetus Corp, Emeryville CA). Macrophages were infected at 7 days with a monotypic HIV-1 strain, ADA. Ten days after virus infection, *T. gondii* or *L. mexicana* promastigotes were added to HIV-infected and control macrophages. Cultures were examined 4 and 20 hrs after addition of parasites: percent monocytes infected with parasites and number of parasites/infected cell were quantified by microscopic analysis.

Results. At 4 hrs, 40% of control and 10% of HIV-infected monocytes were free of parasites. The number of parasites/monocytes in HIV-infected cultures was significantly greater than that in control cultures at both 4 and 20 hrs. Electron microscopy revealed virus particles and parasites within the same monocyte.

Conclusions. Macrophages infected with HIV in vitro ingest parasites, but show altered infectivity and microbicidal activity. These observations may explain the pathogenesis of opportunistic infection in tropical areas.

W.C.P.65 GENERAL DECREASE OF LEUKOCYTE VIABILITY OF AIDS PATIENTS IN SERUM-FREE MEDIUM

Guatieri, Denise L.; Farver, V.*; Hardefelt, M.*; Adams, M.* and Montagnier, L.*

*Viral Oncology Unit, Institut Pasteur, Paris, France.

Objective. To study the mechanism of AIDS pathogenesis and to design an *in vitro* test for the follow up of antiviral drugs.

Methods. PBMC of HIV seronegative, HIV seropositive and patients with ARC of AIDS were separated from heparinized blood on a 4 spracell gradient. After washing, cells are incubated in a serum-free medium specially designed for lymphoid cells. Cell viability was evaluated daily by blue-trypan exclusion.

Results. While PBMC uninfected individuals show very little loss of cell viability after 3 days of culture, cells from AIDS patients display a rapid decay varying from 10 to 40% of dead cells after 3 days. HIV positive and ARC patients show intermediate values. Cell death was often preceded by production of cytoplasmic debris and membrane bullous formation. Fractionation of PBMC in subpopulations indicate that 18 as well as 14 lymphocytes and non T cells are decaying at about the same rate under these culture conditions.

Conclusion. An increased cell fragility, amplified by the serum-free conditions, may be an important parameter in AIDS pathogenesis. Results of antiviral treatment on such a parameter will be described.

W.C.P.62 USE OF POLYMERASE CHAIN REACTION (PCR) TO DETECT THE PRESENCE OF HIV-1 DNA IN SUBPOPULATIONS OF PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCs) IN INFECTED INDIVIDUALS

Schlimman Street, Paulidesopoulos, M.C., Lane, J.L.C., Baseler, M., Solomon, N.P., and Fauci, A.S., *NIAID, National Institutes of Health, Bethesda, MD, USA, **Georgetown University, Washington, DC, USA, ***FPLD, Frederick, MD, USA.

Objective. We have previously demonstrated that within PBMCs, HIV is expressed in vivo in CD4⁺ T cells predominantly in the T cell subpopulation which, in contrast to its *in vitro* infection, continues to express CD4. Our prior studies utilized methods which detect HIV in cells actively producing virus. The present study determines which subsets of PBMCs harbor HIV DNA (both latent and active) and what is the precursor frequency of these virus-infected cells.

Methods. Highly purified (98-99%) subpopulations of PBMCs were obtained from HIV infected individuals by fluorescent activated cell sorting. PCR was then performed on the DNA from these cells to detect specific HIV-1 DNA.

Results. Cells were sorted for CD4 (T helper), CD8 (T suppressor), CD4 (monocyte), and CD19 (B cell) populations. HIV-1 specific DNA was detected in the purified CD4⁺ T cell population in all 15 patients tested by PCR. HIV-1 DNA was not present in the CD8 or CD19 cell subsets, and rarely in the peripheral monocyte fraction. PCR performed on serial dilutions of the sorted CD4⁺ T cells revealed that >1000 cells are infected in AIDS patients, a viral burden much greater than previously reported.

Conclusion. The CD4⁺ T cell is the reservoir for HIV in the peripheral blood of infected individuals, and greater than 1% of these cells may contain virus in vivo in patients with AIDS. This high level of infection may be the primary cause for the progressive decline in CD4⁺ T cell function and number in AIDS patients.

W.C.P.64 INFECTION OF HUMAN FETAL BRAIN MACROPHAGES AND MIXED NEURAL CELLS IN TISSUE CULTURE BY HIV-1

Wainberg, M.A., *McGill University-Montreal Children's Hospital Research Institute, Montreal, Quebec, Canada; **Sir Mortimer B. Davis - Jewish General Hospital, Montreal, Quebec, Canada.

Objective. To clarify the role of brain macrophages and other neural cells in the pathogenesis of neurologically disorders associated with AIDS.

Methods. Cultures of macrophages and mixed neural cells were established from human fetal brains of neonatally-induced aborted fetuses and infected with the HIV-1_{IIIB} strain of HIV-1.

Results. Expression of HIV-gag gene products (p17 and p24) was detected by immunofluorescence after 7 days and peaked at 10 days after inoculation of both the macrophage and mixed neural cell cultures. Positive results were also obtained when the cultures fluids of both the macrophage and mixed neural cell cultures were assayed by both antigen capture (p24) and reverse transcriptase (RT) assays. In addition, cellular disarrangement and the appearance of multinucleated giant cells was observed. Cultures of mixed neural cells derived from the substantia nigra and infected with HIV-1 revealed both giant cell formation and massive reduction of cell numbers.

Conclusion. These results indicate that brain macrophages and other neural cells are susceptible to primary infection by HIV-1. These systems afford good opportunities for investigations of the neurological consequences of HIV-1 infection and for anti-viral drug studies in neurological tissue.

W.C.P.66 MECHANISMS OF HIV-INFECTIONS IN MACROPHAGES

Zer, Bernd, Knaumth, Th. and Habermann, K.O. Institute for Clinical Experimental Virology, Free University of Berlin, Hinderburgstrasse 27, 1000 Berlin 45, FRG.

Blocking experiments with receptor-specific antibodies (ORX74) lead to the conclusion that the T4 molecule is an essential receptor-component for monocytes/macrophages. Neutralization tests with T4-positive MT4 cells and peripheral blood monocytes which possess the T4 molecule and P-co-receptors (P2U) were performed in order to investigate if antibody-virus-complexes are infectious for monocytes/macrophages.

Using a HIV (wild type) and a respective type-specific antiserum it can be demonstrated that antibody-virus-complexes which are infectious for MT4 cells are still able to infect monocytes/macrophages. Moreover, in certain ranges of antibody concentration, an enhancement of infectivity can be observed. Human non-immune sera did not show this effect. Simultaneous application of a monoclonal antibody against ORX74 together with the antibody-virus-complex leads to a complete protection of the monocytes/macrophages. This indicates that antibody-virus-complexes are able to enhance the infectivity for monocytes/macrophages *in vitro*. The specific interaction of the HIV with the T4 molecule, however, is an essential prerequisite for the initiation of the cycle of virus-reproduction. The results indicate that the enhancement of infectivity is caused by an interaction between the P-co-receptor of the macrophages and the antibody of the complex. The high affinity of the T4-gp120 binding on the one hand and the genetic variability of the env-region on the other are essential for the effectivity of the interaction with the T4 molecule.

This mechanism gives an explanation for the fact that at present immunization with vaccines against infections with lentiviruses seems to be rather harmful than beneficial.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

W.C.P.67 CNS AND LYMPH NODE CHANGES IN HIV INFECTION,

Peter Blumenthal, Carlo Pavoni,*, Anna-Lena Petters, Marianne Ekman*, Anna Forsell, R.C. Gallo***, **Immunology Lab, Department of Pathology, Karolinska Institute, Stockholm, Sweden, ***Center for AIDS and Parasitology, University of Michigan, Department of Pathology, University of Michigan, Ann Arbor, Michigan, U.S.A., **Lab of Tumor Cell Biology, N.C.I., N.I.H., Bethesda.**

HIV-induced lesions in brains and lymph nodes of infected individuals were studied by immunohistochemistry and *in situ* hybridization. Microscopic lesions in the brains were mainly composed of microglial cells, monocytes/macrophages and lymphoid cells, predominantly CD8+.

Gag and rev-coded antigens as well as virus RNA were associated with glial cells and monocytes/macrophages. The glial cells and monocytes/macrophages expressed antigens defined by the Mab's K166 and 94 and to variable degree CD8. In lymphadenopathic nodes only gag antigens were demonstrable and exclusively in germinal centers, mostly associated with dendritic follicular cells (DFC). Rare cells showed evidence of HIV replication also predominantly located to the germinal centers. Follicular involution was associated with destruction of DFC and follicular infiltration of CD8+ cells. Both in CNS and lymph nodes the lesions consist of the same source (provirus) of virus replication. A possible cytotoxic role of CD8+ cells to HIV-infected cells is suggested.

W.C.P.69 ALTERED BRAIN METABOLITES IN AIDS DEMENTIA AS MEASURED BY MAGNETIC RESONANCE SPECTROSCOPY

Jeanne Pater, C. Hubesch, B. Parks, R. Decker, N. Krol, P. Weiner, M. W., et al.
Department of Medicine, Veterans Administration Medical Center and The University of California, San Francisco, California, USA

Eight controls and 17 HIV seropositive patients with clinical evidence of the AIDS Dementia Complex (ADC) were evaluated with neurologic, psychiatric, and neuropsychological testing. Patients with focal brain lesions were excluded. All subjects were scored on the basis of cognitive, behavioral and neurologic function utilizing a standardized form. Subjects were studied with Magnetic Resonance Imaging and Spectroscopy (MR/MRS). Brain concentrations of adenosine triphosphate (ATP), phosphocreatine (PCr), inorganic phosphate (Pi) and other phosphate-containing metabolites, such as phosphonucleotides, were assessed by MRS. Preliminary results suggest that patients with moderate to severe ADC have lower brain ATP/Pi ratios than do normal subjects. There was no correlation between ATP/Pi or PCr/Pi ratios and clinical stage of HIV infection, nor with the degree of cerebral atrophy and ventricular enlargement as measured by MRI. Cerebral atrophy, when present, was positively correlated with lower dementia scores. These preliminary findings suggest that brain energy metabolism, as measured by phosphate metabolites, may be reduced in patients with ADC. This altered metabolism may be independent of the presence of cerebral atrophy. Further studies to validate these early findings are in progress.

W.C.P.71 *IN VIVO* ACTIVATION OF ALVEOLAR MACROPHAGES AND LYMPHOCYTES PRODUCE INTERLEUKIN-1 AND INTERFERON- γ IN THE VESPA-MARSHI VIRUS INFECTION

Christine Bergeret*, Collet J.L.*, Couss, O. and Meres S.P.**
*INSERM U9, CNRS U94, IUT, USC, Institut R. Bracco, Lyon, France. **Laboratoire associé de Biochimie et de Biologie Moléculaire, Hôpital Louis Pasteur, Lyon, France.

Objective: Cellular and molecular determinants involving the cells, the serum system and the lungs are a common feature of leishmaniasis infections in humans and rodents. They include by the vertebrate host/parasite develop a chronic leishmanial lung disease characterized by an elevated interleukin-1 (IL-1) and interferon- γ (IFN- γ) synthesis and induced macrophage damage associated with a macrophage infiltration. Macrophages and induced lymphocytes released in the culture medium were analyzed by flow cytometry were used to assess the expression of cell surface antigens. Using fluorescence activated cell sorting (FACS) analysis, a significant decrease of the CD4⁺ lymphocytes was observed (CD4⁺ 3% vs 42.14, p<0.05) without significant changes in CD4⁺ lymphocytes (19.6% vs 26.14, n.s.). Activated lymphocytes expressed MHC class II antigens were present in both infections. Both the total number of alveolar macrophages (1.6x10⁶ vs 1.9x10⁶) and the percentage of MHC Class II-positive macrophages (39.16x10⁴ vs 15.5x10⁴) were significantly higher (p<0.05). In keeping with the immunologic alterations, the spontaneous release of a macrophage-derived factor was increased in mice (38.3x10³ vs 10³ macrophages a 3h vs 13.2x10³, p<0.05). Further evidence was obtained by immunoblotting using a murine anti-human interleukin-1 β monoclonal antibody (11.6kDa/IL1 β IFN- γ 17kDa). **Conclusion:** Although restricted to macrophages, infection by vespa-marshii induces activation of both lymphocytes and macrophages in the alveoli. Macrophage release secreted of substances able to play a role in the pathogenesis of the disease. In addition, increased expression of Ia-antigen they might potentiate the lymphocyte responses.

W.C.P.68 CYTOMEGALOVIRUS (CMV) INDOCTION OF TUMOR NECROSIS FACTOR (TNF) SECRETION BY HUMAN MONOCYTES/MACROPHAGES MAY CORRELATE TO TISSUE INFLAMMATION IN AIDS PATIENTS.

Saich, Phillip D., Lambert, C.L., Saini, S.L., Wahl, L.M. and Wahl, S.M.
National Institutes of Health, Bethesda, MD, U.S.A.

Objective: To determine whether CMV induces monocyte and tissue macrophage expression of TNF. **Methods:** CMV isolated by standard techniques from an AIDS patient with CMV colitis was inoculated into cultures of purified human monocytes. Infection was confirmed by immunoperoxidase staining with monoclonal antibody to the 68 kD immediate early (IE1) antigen. TNF secretion was measured by bioassay and TNF gene expression was analyzed by Northern blot. TNF expression by monocyte macrophages obtained from AIDS patients and normals was monitored by *in situ* hybridization.

Results: Monocytes inoculated with the clinical isolate, but not mock-infected cells, spontaneously secreted TNF. Infected monocytes produced several-fold greater amounts of TNF in response to a second stimulus. In parallel, CMV-infected monocytes expressed elevated levels of TNF mRNA. In addition, TNF-specific RNA was detected in monocyte macrophages in biopsy specimens from 2 AIDS patients with CMV colitis, but not in specimens from healthy subjects or AIDS patients without CMV colitis.

Conclusions: TNF is expressed in increased amounts in CMV-infected monocytes *in vitro* and in mucosal cells during CMV enteritis. TNF secretion by tissue macrophages may contribute to the inflammatory changes that occur in various organs in patients with AIDS and CMV disease.

W.C.P.70 INDUCTION OF HIV-1 FROM A LATENTLY INFECTED CNS-DERIVED CELL LINE

Mark A. Laughlin, Janet M. Howson, F. Gonzalez-Serrano
University of Pennsylvania Medical Center, Philadelphia, PA, U.S.A.

Objective: HIV-1 causes a persistent, latent and often cytotoxic infection of MED 217 cells (a neuroblastoma derived cell line). We further defined the nature of this infection in terms of baseline viral gene expression and methods of induction of viral transcription, p24 production and production of infectious virus. **Methods:** MED 217 were exposed to HIV-1₉₂ and a modified infectious control assay performed to rescue virus. The cellular RNA was extracted and probed for viral specific nucleic acid and in addition the supernatant assayed for the production of p24 and infectious virus. A number of manipulations (such as treatment with phorbol esters, growth factors and UV light) were then performed in an attempt to induce viral replication. **Results:** Although in general infection in these CD4 negative cells was inefficient, with increasing time of exposure to virus approximately 1:10 cells became infected. Under baseline conditions no viral specific RNA, supernatant p24 or infectious viruses could be demonstrated. Treatment with phorbol myristate acetate results in the production of viral specific RNA, p24 (~20 fold increase over baseline sensitivity) and infectious viruses. Treatment with UV light similarly results in the production of p24, but the time course is markedly different, indicating different mechanisms for the activation of viral replication by these methods. Treatment with cloned growth factors is being performed. **Conclusions:** By increasing the time of exposure to virus, infection of MED 217 cells can be made efficient, allowing the dissection of mechanisms of induction of viral replication. Initial results indicate that several mechanisms of activation of the HIV-1 promoter will induce viral replication.

W.C.P.72 MORPHISIS SYSTEMIQUE ET EXPRESSION RETROVIRALE (infection productive) CHEZ LE RAT (Rattus norvegicus)

Yves L. Dubouché, Jean-Louis Pons, René Courcès, Germaine Parisse, Lucie, **Hôpital Raymond-Poincaré-Université René Descartes, Garches-Paris-Seine, France, **Hôpital Pasteur, Paris, France. *Oncologie Laboratoire, North Carolina State University, Raleigh, North Carolina, U.S.A.**

Objectif: Evaluer les effets d'une infection rétrovirale, progressive, induite par infection rétrovirale productive *in vivo*. **Méthodes:** Evaluer la viralité (CCID₅₀), lymphocytes T4, antigénémie p24/25 (p24:1) et l'effet de l'infection rétrovirale productive *in vivo* sur quantité de virus et sur cellules mononucléaires du sang à différenciation myéloïde (BMDC), CMV-FAC. La vitesse moyenne de propagation (score N, du maximum du quantifié HIV sur lymphocytes *in vitro* est fonction pour un échantillon donné du nombre de cellules contenant un HIV infectieux *in vivo* (laboratoire). Les mêmes systèmes de co-culture ou quantifiés sont appliqués aux CMV non-infectieux.

Patients	Score de méd	D.LIMITE	Virus		p24
			CMV	CMV	
00-01	10	11-11-11	100-111	100-111	1/1
00-02	10	11-11-11	100-111	100-111	1/1
00-03	10	11-11-11	100-111	100-111	1/1
00-04	10	11-11-11	100-111	100-111	1/1

Patients	PNEUMONIES						REV PNEUMONIES					
	1	2	3	4	5	6	1	2	3	4	5	6
Infectieuses Prod lat	10	10	10	10	10	10	10	10	10	10	10	10
00-01	8	8	8	8	8	8	8	8	8	8	8	8
00-02	8	8	8	8	8	8	8	8	8	8	8	8
00-03	8	8	8	8	8	8	8	8	8	8	8	8
00-04	8	8	8	8	8	8	8	8	8	8	8	8

Conclusions: La progression de la maladie HIV systémique (clinique, lymphopénosique) est associée à une expression HIV active *in vivo*, mesurable au virus.

**Session d'Affichage
Poster Session**



**Recherche fondamentale (biomédicale)
Basic Research (Biomedical)**

W.C.P.73 ALTERED IGF-1 RECEPTOR DISTRIBUTION IN LYMPH NODE CELLS AND SERUM OF PATIENTS WITH HIV INFECTION
Miller, Fredrik A.; Frelund, S.S.* and Brandtzaeg, P.*
*Lab. for Immunohistochemistry and Immunology and *Medical Department A, University of Oslo, Biokjemipensit, Oslo, Norway

Objectives. To study the distribution of plasma cells producing IgG subclasses in lymphoid tissue of patients with HIV infection and compare this with IgG subclass levels in serum.

Methods. The fraction of lymph node specimens from 15 patients with persistent generalized lymphadenopathy (HIV+) and 11 patients with lymphadenopathy of other causes (controls), were processed for paired immunofluorescence. Sections were stained with subclass-specific antibodies and an anti-IgG antibody. The proportion of cells containing each subclass was then calculated. IgG subclasses in serum was measured by ELISA (Nycomed AS, Oslo, Norway) in 14 of the patients with HIV infection and 12 blood donors. Results are given as median and 25-75 percentiles.

Results. The fraction of lymph node cells producing IgG was 84% (813-884) in HIV+ versus 76% (678-334) in the controls (p<0.05). For IgG2, the fraction was 38 (24-81) in HIV+ versus 8% (38-158) (p<0.05). No differences were observed for IgG1 or IgG4. In serum, total IgG was 17.6 g/l (15.1-20.4 g/l) in HIV+ and 11.9 g/l (10.6-13.4 g/l) in the blood donors (p<0.005). IgG1 was elevated in HIV+: 8.9 g/l (7.5-9.6 g/l) versus 5.4 g/l (5.1-6.3 g/l) (p<0.005). Conversely, IgG2 was reduced in HIV+: 1.5 g/l (1.3-3 g/l) versus 3.6 g/l (3-4.2 g/l) (p<0.05).

Conclusion. In lymph nodes from patients with HIV infection, the proportion of cells producing IgG1 is increased whereas that producing IgG2 is reduced. This shift is in accordance with the IgG subclasses seen in serum.

W.C.P.74 THE EFFECT OF HIV ON MEMBRANE LIPIDS OF LYMPHOCYTES
A. Elings, F. Godwin*, S. Schurhartz*, L. Wieruwa*, A. Melkiss and M. Weinberg**
*Clinical Biochemistry Dept., Sunnybrook Medical Centre, University of Toronto, Toronto, Ontario, Canada; **Melville Davis Institute, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.

High content of unsaturated fatty acids (FA) in membrane lipids lead to an increase in cell membrane fluidity and can explain cell fusion and death through the loss of membrane integrity. In the present work after 8-9 and 10-14 days of HIV infection, lymphocytes were infected with HIV, a quantitative and qualitative analysis of their FAs was made. These cell lines were chosen because 80-85% is killed after HIV infection and 8-9 is not. Infected and non-infected cells were extracted with methanol:chloroform solutions. The lipids were transesterified to produce FA methyl esters and analyzed by gas chromatography. HIV infection was characterized by: 1) a significant rise (180-250%) (p<0.05) in the desaturation of essential FAs-represented by linolenic (18:3) and arachidonic (20:4) acids-in both cell lines, 2) a significant elevation (p<0.05) in the concentration of the saturated FA stearate (18:0) (1802) and palmitate (16:0) (1872) only in the 8-9 cell line, 3) a significant rise (p<0.05) in the desaturation of stearate to oleic (18:1) (1718) only in the 8-9 cell line. The results demonstrate that infection by HIV is characterized by elevated desaturation of essential FAs, whereas, killing of cells shows increase in both formation of non-essential FAs and desaturation of stearate. The mechanism by which these changes take place is not at all clear.

W.C.P.75 SENIAN IMMUNODEFICIENCY VIRUS INHIBITS BONE MARROW HAEMATOPOIETIC PROGENITOR CELL GROWTH.
Katsenbaeva, Ekaterina; Bisler, D.-J.; Belong, F.A. and Letvin, N.L. Harvard Medical School, New England Regional Primate Research Center, Southborough, Massachusetts, USA.

W.C.P.76 INFECTION OF GLIAL CELLS EXPRESSING THE CD4 MOLECULE
Jung, M., Haroge, Mark A., Laughlin, Jeffrey Hastings, Harry Friedman, Brian Godfrey, J. Gonzalez-Scarano
Departments of Neurology, Microbiology and Medicine, School of Medicine, University of Pennsylvania, PA, USA 19104-6076

Objective. To explore pathogenic mechanisms of depressed hematopoietic function in AIDS.

Methods. Granulocyte/macrophage (GMF-CM) and erythroid (EPU-5) progenitor cell colonies were assessed in two layer agar and methylcellulose assays respectively. HIV-1 isolations from bone marrow were assessed in adherent cell cultures in CM⁺ absence of lectin or cytokines.

Results. Both bone marrow GMF-CM and EPU-5 were decreased in number in many SIV-infected thymus monkeys. SIV⁺ was readily isolated from bone marrow cells of infected monkeys and was shown to be harbored in macrophages rather than T lymphocytes. The *in vitro* infection of normal bone marrow cells by SIV⁺ inhibited colony formation. A striking *in vivo* correlation between isolated SIV⁺ in bone marrow cells and decreased hematopoietic progenitor cell colony growth was also shown. Finally, inhibition of SIV replication in bone marrow macrophages by anti-CD4 antibody resulted in increased progenitor cell colony growth from these bone marrow cells.

Conclusion. The infection of bone marrow macrophages by the AIDS virus leads directly to depressed bone marrow hematopoietic progenitor cell growth. Moreover, inhibition of AIDS virus replication in these macrophages should induce significant improvement in hematopoietic function.

Objective: The U373 glioblastoma-derived cell line can be infected with HIV-1. Several attempts to transfect neurocytic cell lines with HIV-1 provirus constructs, including treatment with phorbol ester (PMA) will induce viral replication. To determine whether CD4, which is normally not present in these cells, could affect replication we prepared stable transfectants containing the human CD4 molecule.

Methods: We prepared stable transfectants of glioblastoma line U373 with a plasmid expressing the human CD4 molecule under the control of the Moloney murine sarcoma virus promoter. The transfectants were screened for expression of the CD4 gene. The stable transfectants were further selected with anti-CD4 antibody by panning and by antibody dependent cell cytotoxicity (ADCC). A variable level of expression of CD4 was seen in the initial transfectants but all of the epitopes tested, including the carboxy and amino regions of the molecule were repressed. We cloned the high expressing cells and used several different strains of HIV-1 and HIV-2 in infections. We monitored viral replication by antigen capture for gp24 and by the production of infectious virus and compared these with two other cell populations: (1) clones of U373 glial cells uniformly infected with HIV-1ig (2) randomly infected U373 cells. After infection with HIV-1ig there was an initial round of low-level replication (gp24 = 100 pfu/ml) followed by a persistent latent infection. **Conclusions:** These results indicate that other factors besides the entry pathway are responsible for the characteristics of HIV-1 infection of glial cells and allow us to begin to dissect the diverse elements that determine tropism.

W.C.P.77 ROLE OF ENDOTOXIN IN MODULATION OF HIV EXPRESSION IN A MONOCYTE CELL LINE
Molinaro, Michael J.; Choby, H.; Ashraut, C.*; Dinarello, C.* and Groopman, J.*
*Harvard University, Boston, Massachusetts, USA, **Tufts University, Boston, Massachusetts, USA

W.C.P.78 PRODUCTION DE TNF α ET D'IL-1 β PAR LES CELLULES DE LA LIQUÉUR MONONUCLÉAIRE INFECTÉES PAR LE VIH
Molinaro, Michael J.; Dinarello, C.*; Ashraut, C.*; Pariani, R.*; Byrn, R.*; Dinarello, C.* and Groopman, J.*
*Université de Harvard, Boston, Massachusetts, Etats-Unis, **Université de Tufts, Boston, Massachusetts, Etats-Unis

Objective. To determine the role and mechanism of action of endotoxin (LPS) in modulating HIV expression in monocytic cells.

Methods. THP-1 cells, chronically infected with HIV-1/IIIB, were stimulated for 24 hours with LPS (0.5-10 µg/ml), recombinant TNF α (rTNF α), recombinant IL-1 β (rIL-1 β) (0.1 to 10 ng/ml) and polyclonal antibodies against TNF α and IL-1 β . TNF α and IL-1 β were measured in supernatants using RIA.

Viral expression was assessed by the level of reverse transcriptase activity (RT) in the supernatants.

Results. LPS stimulation of THP-1 cells resulted in a dose-dependent increase of RT (20 to 100 fold over unstimulated cells p<0.01), and in significant production of TNF α (1 ng/ml) and IL-1 β (0.1ng/ml). Antibodies against TNF α , but not against IL-1 β were able to block 50% of the increase in RT after stimulation with 10 µg/ml of LPS (p<0.05). Furthermore, rTNF α but not rIL-1 β increased RT in a dose dependent manner (p<0.01).

Conclusion. LPS stimulation of HIV-infected monocytic cells can significantly increase virus production and this effect may be due in part, to the release of TNF α by LPS stimulated cells.

Objectif. Mesurer la production de TNF α et d'IL-1 β par les cellules de la lignée monocytaire infectées par le VIH.

Méthodes. TNF α et IL-1 β ont été mesurés par RIA et l'ARNm par Northern Blots. La lignée THP-1 infectée par VIH-1/IIIB a été stimulée par 5µg/ml d'endotoxine (LPS). Les macrophages ont été infectés par VIH-1/IIIB, VIH-1/Bal et VIH-2.

Résultats. Les cellules THP-1 et les macrophages infectés par différentes souches de VIH ne produisent pas spontanément de quantités détectables de TNF α , d'IL-1 β ou d'ARNm. Après stimulation par LPS des cellules THP-1, TNF α , IL-1 β et de l'ARNm sont produits, sans différence significative entre cellules non infectées ou infectées de façon chronique. En revanche, les cellules THP-1 en phase aigüe d'infection, plus différenciées, produisent après stimulation, des quantités de cytokines 2 à 13 fois plus élevées que les cellules non infectées ou infectées de façon chronique (p<0.01).

Conclusion. Les cellules de la lignée monocytaire infectées par le VIH produisent pas spontanément de TNF α ou d'IL-1 β mais peuvent en réponse à un stimuli comme LPS produire des quantités importantes de ces deux cytokines.

Session d'affichage
Poster Session



Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

W.C.P. 79 HIV-2 ENVELOPE GLYCOPROTEINS AND CELL FUSION.
Mulliken, B.A., Kuman, P., Hu, J., Ritter, D., Hahn, B., Coombs, R.
University of Minnesota, Minneapolis, Birmingham, Birmingham, Alabama, USA

Objective: To utilize recombinant vaccinia viruses (vVV) to study the expression and function of *env* genes of HIV-2/ROD, the HIV-2 protease which is fully pathogenic to HIV-1 and HIV-2ST, a recent isolate with less virulence in vivo behavior.

Significance: The envelope proteins gp120, gp160 and gp42 are essential to virus attachment, entry, and pathogenicity, as well as cell fusion and host immune responses. Most data indicate virus entry into CD4+ target cells occurs via viral-cell membrane fusion at neutral pH. The infected cells can produce syncytia with uninfected CD4+ cells at neutral pH. A virus unable to produce cell fusion despite normal infectivity may have an altered molecular mechanism of cell entry and membrane fusion. We hypothesize such a change in HIV-2ST. Unlike other HIVs, this virus does not induce cell fusion or cell death; infected cells exhibit fully productive infection (mRNA production, RT activity), but the rate of free virus entry into cells is reduced.

Methods: HIV-2ST had been isolated from a healthy West African prostitute; HIV-2ROD was provided by L. Montagnier. The *env* genes were inserted into rVVs and evaluated for production of envelope glycoproteins using metabolic labeling and RDP/PAGE. Function of recombinant *env* gene products was assessed by infection of CD4+ cells and quantitating cell fusion. Hyperimmune rabbit antisera was produced using recombinant envelope glycoproteins. **Results:** Recombinant HIV-2ROD *env* gene product gp160 produced and recognized by antisera. Infection of CD4+ cells indicates the products are cleaved and transported to the cell surface in functional form where they mediate cell fusion. rVVs-ST has been constructed.

Conclusions: Recombinant VV carrying HIV-2 *env* genes, synthesis, process, and transport functional recombinant envelope glycoproteins. The *env* gene product of HIV-2ROD causes infected cells to fuse with uninfected CD4+ cells. These methods will be useful to determine whether the cell fusion defect of HIV-2ST is a function of its *env* gene.

W.C.P. 81 ABERRANT CIRCADIAN PHYSIOLOGIC, IMMUNE AND ENDOCRINE RHYTHMS IN HIV-INFECTED INDIVIDUALS.
Blanchard, E.M., Soborn, R.R.,* Sackel-Landsen, L.**, Suarez, C.*
*University of Minnesota, Minneapolis, **St. Paul-Ramsey Medical Center, St. Paul, Minnesota, USA

Objective: To assess circadian variation of parameters relevant to the pathophysiology and laboratory monitoring of HIV infection.

Methods: For 24h in a clinical research setting, 8 HIV-infected persons (3 AIDS, 3 ARC and 2 asymptomatic; all free of acute illness) underwent 48 assessments of oral temperature, lymphocyte subsets (CD3, CD4, CD8, B1), monocytes, neutrophils, HIV antigen, neopterin (n=6), beta-2-microglobulin, plasma cortisol, aldosterone, beta endorphin; and serum zidovudine and urinary excretion (n=3). Two patients underwent detailed zidovudine pharmacokinetics at midnight and noon. Healthy, age-matched adults served as controls.

Results: A significant circadian rhythm in oral temperature was found in 6 of the 8 patients, with unusual early morning peaks in 2 patients. Usual lymphocyte rhythmicity peaking between 6 P.M. and midnight, including all studied subsets, was lost. The normal circadian rhythm in neutrophils and monocyte concentrations was absent in patients with low counts. Rhythmicity in HIV antigen and neopterin could be demonstrated for some patients, but not as a group phenomenon since the daily peaks and valleys differed from patient to patient. HIV-infected subjects had elevated beta-2 microglobulin and rhythmicity, which was not seen in controls. Circadian variation similar to controls in beta-endorphin, aldosterone and cortisol concentrations was seen. Following constant dosing, substantial within-day variation in serum and urine zidovudine levels was seen, but half-lives at midnight and noon were similar.

Conclusion: The normal marked lymphocyte rhythmicity is ablated in HIV-infected persons, even if asymptomatic, and cannot be explained by loss of cortisol rhythmicity.

W.C.P. 83 ENHANCED PRODUCTION OF TUMOR NECROSIS FACTOR IN SYMPTOMATIC HIV INFECTIONS. Liu, Allan S., Read, SE, Der S, Division of Infectious Diseases, Hop for Sick Children, Toronto, Canada.

Tumor necrosis factors (TNF) are polypeptides produced by macrophages and monocytes in response to inflammation and sepsis. They are also potent mediators of cachexia and autoimmune processes. We have demonstrated upregulation of TNF receptors and induction of TNF synthesis by the acid-labile IFN- α present in AIDS sera. We were interested to determine whether synthesis of TNF is enhanced during the progress of HIV infection in patients. Blood monocytes were obtained from normal controls and patients with asymptomatic HIV infection (CDC classification group II), persistent lymphadenopathy (III), constitutional disease (IVa), and opportunistic infections (IVc). TNF production by the cells was measured by a cytotoxicity assay on L529 cells using HV-TNF- α (Genentech) as a standard. One unit of TNF is defined as the concentration of the cell culture supernatant which produces cytotoxic effects on 50% of the cells. PBMC from normal controls produced low levels of TNF (1.1±0.96 U/ml, n=14). The levels of TNF production by the cells from Group II, III, IVa, and IVc patients were 2.2±0.2 (n=9), 7.8±2.9 (n=12, p<0.05), 6.4±2.2 (n=13, p<0.05), and 18.7±1.7 (n=13, p<0.01) U/ml respectively. The cytotoxic activities in the supernatants can be completely neutralized by anti-TNF- α antibodies. Moreover, the cells from symptomatic patients (Group III and IV) were hyperresponsive to endotoxin resulting in further induction of TNF synthesis, compared to normal controls and asymptomatic patients. Thus these results indicate that the synthesis of TNF is enhanced during the progress of HIV infections and the cells from symptomatic patients are hyperresponsive to TNF. This may be one of the mechanisms involved in the pathophysiology of cachexia and sepsis in symptomatic AIDS patients.

W.C.P. 80 CRY IS NOT A COFACTOR IN THE PROGRESSION OF HIV INFECTION. Broder, H.; Byrne MP; Drew, JL; Looney, M.; Grimes, CM; Kankias, A; and Williams RW. *Letterman Army Medical Center, 1-cs/10 San Francisco, California, USA, **Mount Zion Hospital and Medical Center, San Francisco, California, USA, ***Socorro, Inc., Sparksville, Maryland, USA.

Objective: To determine if coinfection with CRV affects the decline of CD₄ cells in HIV infected patients.

Methods: We have compared rates of decline of CD₄ cells in HIV seroconverting military personnel who are CRV seropositive versus those who are CRV seronegative. Regression analysis was used to calculate the daily decline in CD₄ counts following HIV seroconversion. Blood samples were obtained at 4 months intervals to permit calculation of the rate of CD₄ cell decline. **Results:** The mean initial CD₄ counts were 519 in the CRV seropositives and 597 in the seronegatives (NS(p=0.5)). Fifty CRV seropositives showed a slope of CD₄ decline/day of = .3101 versus = .2044 in CRV seronegatives. This difference is not statistically significant (P=0.71) when the rates are compared using ANOVA (F test).

Conclusion: We conclude that CRV is not a necessary cofactor in the pathogenesis of HIV infection.

W.C.P. 82 REGULATION OF CYTOKINE RECEPTOR EXPRESSION BY HIV. Liu, Allan S., Dion M, and Livezey JF, Division of Infectious Diseases, Hop for Sick Children, Toronto, Canada.

Interferon (IFN) has been shown to interact synergistically with tumor necrosis factor (TNF) in cytotoxic and antiviral activities. Both cytokines are capable of increasing the replication of HIV in vitro. To elicit biological activities, these cytokines bind to specific high affinity cell surface receptors. We have previously demonstrated down regulation of IFN- α receptors on T4 lymphocytes from AIDS patients and the consequent responsiveness of the cells to IFN in vivo. We postulate that HIV gene products are capable of down regulating the expression of cytokine receptors. The expression of IFN- α receptors on CD4+ cells (specifically CEM, HUT, and Jurkat) was studied using IFN α (Schering) labeled with ¹²⁵I to high specificity by a lactoperoxidase method. Saturation binding curves were generated with the ¹²⁵I-IFN α and the binding characteristics were analyzed to obtain the receptor numbers. CD4+ cells were infected with HIV in vitro and the levels of 2.5A antigen and reverse transcriptase activities were determined to monitor the replication of HIV. We have demonstrated a progressive down regulation of IFN- α receptors during the progress of HIV infections in vitro. To evaluate the effects of HIV on the induction of IFN regulated enzymes, HIV infected HUT cells were treated with IFN- α and assayed for 2-5A synthetase activities. We have shown diminution in 2-5A synthetase induction in infected cells, compared to controls. Similarly, we have demonstrated down regulation of TNF- α receptors in CD4+ cells by measuring the binding of ¹²⁵I-TNF- α (Genentech) during the course of HIV infection. We are currently investigating the role of individual viral genes in the regulation of cytokine receptors. Thus, these studies indicate that HIV is capable of suppressing the expression of IFN- α and TNF- α receptors. This may be one of the mechanisms by which HIV evades the antiviral actions of IFN and TNF in vivo.

W.C.P. 84 ANALYSIS OF BRAIN FROM AIDS PATIENTS FOR HIV-1 DNA SEQUENCES USING THE POLYMERASE CHAIN REACTION (PCR). Giedler, Jagan, Hahn, B*, Shaw, G*, Brew, W*, Rosenblum, Memorial Sloan-Kettering Cancer Center, New York, NY, and *University of Alabama at Birmingham, Birmingham, AL, USA

Objective: To determine whether HIV-1 proviral DNA can be detected by PCR in the brains of patients with mild AIDS dementia complex (ADC). While it is clear that HIV-1 infection can be demonstrated by a variety of techniques in the brains of AIDS patients, such demonstration is confined almost exclusively to those with more advanced symptomatology and pathology. The presence and role of HIV-1 in milder ADC has not yet been established.

Methods: DNA was extracted from 56 frozen brain samples obtained at autopsy from 27 HIV-1-infected individuals and assessed using a primer pair from the HIV-1 *env* gene flanking the immunodominant region. Dilution experiments, using cloned HIV sequences from which the primer pairs were derived, indicated a sensitivity of 8.2 fg DNA by visual inspection of the gel and 66 pg when probed by Southern blotting using a reacting sequence.

Results: In samples from brains known to be HIV-1 positive by immunohistochemistry or Southern blot, HIV-1 DNA was amplified. However, in most "negative" brains, PCR was also negative and indicated a false circumscribed infection by immunohistochemistry. PCR was likewise limited.

Conclusion: These initial results suggest that viral sequences in brains of patients with milder ADC are below the level of PCR detection using this single primer pair. Further studies using additional primer pairs and well-characterized tissue specimens are needed to determine if early ADC relates to active HIV-1 replication, restricted gene expression or indirect factors.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

W.C.P.85 EFFECTS OF TUMOR NECROSIS FACTOR (TNF- α), GAMMA INTERFERON AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) ON HIV REPLICATION IN HIV-INFECTED HUMAN MYELOMONONUCLEAR CELL LINES

Cortes Eduardo*, Koefler, HC*, Zhan, JQ*, Mitsuyasu, RT*, *University of California, Los Angeles, USA; **Faculdade de Medicina UFRRJ, Rio de Janeiro, Brazil.

Objective. To study the effects of TNF- α , gamma interferon, and GM-CSF on HIV antigen expression in chronically infected human myelomonocytic leukemia cell lines.

Methods. HTLV-IIIB infected ML-3 (myelomonocytic), THP-1 (monoblastic), and U-937 (monocytic) cells at a concentration of 3×10^6 cells/ml were incubated with cytokine at 3 log concentrations for 24-102 hours. Cell viability was assessed by trypan blue exclusion and HIV replication by HIV p24 antigen capture on cell free supernatants of cultured viable cells.

Results. TNF- α had a marked cytolytic effect on HIV infected and uninfected cells at concentrations of 10^{-10} u/ml. No HIV inhibitory effects were seen with any of the cytokines alone or in combination. HIV p24 was significantly increased in ML-3 cells by TNF- α and by GM-CSF and in U-937 cells by GM-CSF alone.

Conclusion. The effect of these cytokines on HIV expression in chronically infected cells appears to be cell specific and may represent differences in viral regulation in cells at different stages of maturation.

W.C.P.87 PRESENCE OF TUMOR NECROSIS FACTOR IN THE CEREBRAL SPINAL FLUID (CSF) OF AIDS PATIENTS WITH HIV ENCEPHALOPATHY

Zelesa, Macek, L.; Janssen, R.; Spira, T.; Fanci, A. S.***; Dubois, R.***; Polks, T. A., Centers For Disease Control, Atlanta, GA, USA; **National Institutes of Health, Bethesda, MD, USA; ***Atlanta Medical Association, Atlanta, GA, USA.

Objective. To assess the presence of Tumor Necrosis Factor- α (TNF) in the CSF of HIV seropositive patients with HIV encephalopathy (HIV-E).
Methods. CSF from 3 patients with HIV-E, 6 AIDS patients without central nervous system (CNS) disease, 5 patients with HIV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP), and 1 HIV seronegative control individual, was tested for the presence of the TNF using the Wehi 16-clone 13 bioassay. Positive samples were confirmed by neutralization with a rabbit antibody to human TNF- α .

Results. TNF was detected in significantly more patients with HIV-E (3/3) than AIDS patients without CNS disease (1/6, p=0.05). There was a trend toward significance comparing presence of TNF in patients with HIV-E (3/3) to HAM/TSP patients (1/5, p=0.07, Fisher's Exact Test, 1-tailed). No TNF was detected in the HIV seronegative control individual.

Conclusion. The current data suggest that detectable TNF levels are present in the CSF of patients with HIV-E but to a much lesser degree in HIV-E patients with no neurological manifestations or in patients with HIV-1 associated neurologic disease.

W.C.P.89 SERUM CAPACITY TO INHIBIT REVERSE TRANSCRIPTASE IN VITRO DISTINGUISHES HIV-1 INFECTION FROM HIV-2 OR HIV INFECTION

Wolfs T.*, Goudimil, Jann*, Goolen J., Schellekens H**., Berin P.***
*Human Retrovirus Laboratory, Amsterdam, the Netherlands, ** Primate Center TNO, Rijswijk, the Netherlands, ***Laboratoire de Virologie, IHRU Bretonneau, Tours, France.

Objective. To study the inhibition of HIV-1 and HIV reverse transcriptase by human and chimp macaque serum positive for HIV-1 or HIV-2/SIV antibodies.

Methods. Inhibition of HIV-1 or HIV reverse transcriptase activity was assayed after incubation with HIV-1 or HIV-2/SIV antibody positive serum.

Results. The domain to which reverse transcriptase inhibiting antibodies were elicited appeared to be highly antigenic. Sixty-seven percent (48/72) of individuals had HIV-1 reverse transcriptase inhibiting (RTI) antibodies one year after seroconversion for HIV-1, 90% (91/102) of HIV-2 antibody positive persons had HIV-RTI antibodies and all four experimentally HIV-infected chimp macaques developed HIV-RTI antibodies. Low cross-reactivity between HIV-1 and HIV-2/SIV-RTI antibodies was observed. Of 10 HIV-1-RTI sera 7 reduced HIV-RTI activity by more than 50% (mean reduction 85% versus 24%). Only 1 of 9 HIV-RTI human sera showed HIV-1-RTI (mean reduction 74% versus 29%). This serum however showed a shared reactivity against both HIV-1 and HIV-2 envelope proteins.

Conclusion. These results indicate that the HIV-1 domain inducing RTI antibodies is antigenically different from the HIV-2/SIV domain.

W.C.P.86 PRESENCE OF HIV-1 IN THE SPERMS OF HIV-SEROPOSITIVE INDIVIDUALS BY DNA-HYBRIDIZATION AND IMMUNOGOLD METHODS

Wagenvoort, J. A., Bessers, O. G. J., Freund, M. J., Condolesi, G. J., Reins, S. B., Weidman, J. A., and Condit, J. A., Departments of Microbiology, Obstetrics and Gynecology, and Medicine - University of Medicine and Dentistry of New Jersey, Camden, New Jersey, USA.

Objective. To explore the role of sperm in the transmission of HIV-1. Semen specimens were collected at weekly intervals from three patients who were seropositive for HIV-1. Semen specimens were washed and pellets were assayed for presence of HIV-1 by electron microscopy, by use of HIV-specific monoclonal antibodies and immunogold labelling and by HIV-specific DNA probes and *in situ* hybridization.

Results. Electron microscopy analysis of sperm showed HIV-1 like particles in the sperm of all 3 specimens. Further evaluation with HIV specific DNA probe and immunogold labelled monoclonal antibodies confirmed the presence of HIV-1 in the sperm of HIV seropositive individuals but their absence in HIV-seronegative individuals.

Conclusion. Presence of HIV-1 in the sperm of HIV-seropositive individuals indicates a potential mechanism for the venereal transmission of HIV by sperm from HIV seropositive individuals to their sexual partners.

W.C.P.88 DETECTION OF UNINTEGRATED VIRAL DNA IN HIV-1 INFECTION: USE OF A RAPID AND EASY PCR METHOD

Lange J., Goudimil J., *Human Retrovirus Laboratory, Amsterdam, the Netherlands, **UMD-New Jersey Medical School, Newark, NJ, USA.

Objective. To study the kinetics of unintegrated viral DNA (UVD) in HIV-1 infected cells *in vitro* and presence of UVD *in vivo* in HIV-1 infected children and in homosexual men.

Methods. UVD was detected by use of the polymerase chain reaction (PCR) in which the long terminal repeat (LTR) is covalently closed circular viral DNA was amplified. The specificity of the amplified sequences was confirmed by Southern blot analysis using an LTR-specific probe and sequencing the primer fragment.

Results. Closed circular viral DNA was detected within one day post-infection in HTLV-IIIB infected Molt-3 cells. Depending on the infecting virus titer, UVD was undetectable for a short period early in infection, but persisted thereafter. Brain and spleen tissues of HIV-1 infected children with HIV-1 associated progressive encephalopathy were analyzed for the presence of UVD. In both tissues high levels of UVD were detected, indicating active infection at both sites. In blood of AIDS-patients UVD could also be detected.

Conclusion. UVD can be detected in HIV-1 infected cells both *in vitro* and *in vivo* by use of the PCR and it may be used as a marker to active infection and disease progression.

W.C.P.90 EXPRESSION OF A POTENTIAL HIV RECEPTOR ON HUMAN GASTROINTESTINAL EPITHELIAL CELLS (GIECs)

Mayer, Mary Pat, Huot, R., Wideman, D., and Martin, D.
The University of Texas Health Science Center at San Antonio, TX, USA.

Objective. To determine if human GIECs express a CD4-related receptor which might allow HIV attachment.

Methods. Immunopassays of tissue sections and early passage cultures of GIECs from human normal GI (small intestine and colon) or human colon cancer (HCC) sources were done using LexA and OKT4 monoclonal antibodies. In addition to an immunoreactive subpopulation of lamina propria lymphocytes in tissue sections, staining was observed at the microvillar surface, or glycolexy, in a subset (2 to 25%) of GIECs in sections or in cell cultures derived from different individuals. Reactivity of well characterized GIECs maintained for 10 or more subcultures, and protein immunoblot detection of 80kd and 106kd proteins verified that carryover of CD4+ lymphoid cells did not explain the immunoreactivity. Furthermore, the established HCC lines tested in these experiments were not immunoreactive.

Conclusions. These observations suggest that GIECs bear CD4-related epitopes, which are associated with the cell surface or mucinous glycolexy. Since such surface molecules could serve as sites for HIV attachment and subsequent viral infection, these data are relevant to virus transmission, gastroenteropathies associated with AIDS or ARC, and the possibility that GIECs may serve as a reservoir for HIV. Support was provided by PHS grant R01 DK40625 and The UT-HSCSA Center for Human Cell Biotechnology.

**Session d'affichage
Poster Session**



**Recherche fondamentale (biomédicale)
Basic Research (Biomedical)**

W.C.P.91 CELL-SPECIFIC CONTROL OF HIV PRODUCTION IN CHRONICALLY INFECTED GLIAL CELLS

Melzer, W., Festl, H., Kleinshöndler, A., Müller-Lentsch, N., Erfm, Volker

*GSG-Abteilung für Molekulare Zellpathologie, D-8042 Neuherberg, **Medizinische Poliklinik der Universität München, D-8000 München, ***Institut für Medizinische Mikrobiologie und Hygiene, D-6000 Wiesbaden, West-Germany.

Objective. Evaluation of HIV regulation in potential virus reservoir cells in the brain (glial cells).

Methods. Establishment of chronically infected glioma cell lines. Measurement of HIV proteins, RNA expression, and production of infectious virus. We established chronically HIV-1 infected glioma cell lines harbouring an integrated HIV genome. The cell lines express structural proteins, which can be detected in the cytoplasm but they release extremely low amounts of infectious virus in comparison to other infected cell types (T-cells, monocytes/macrophages, mesenchymal cells). Furthermore, high amounts of intracellular p27 protein with a molecular weight of 27 kD is produced in these cells.

Conclusion. Chronically infected glial cells control virus production by a cell-specific mechanism using net protein induction and may thus represent a virus reservoir in the brain.

W.C.P.92 NEUTRALIZING AND ENHANCING ANTIBODIES IN DIFFERENT STAGES OF HIV INFECTION

D. Joffe F., Szabo, B., Uhlirly, E., Horvath, A., Fust, G., Baranyi, D., et al.
Inst. Microbiol. Univ. Med. School, Debrecen, ***Nat. Inst. Haematol. Blood Transf. Budapest, **Nat. Inst. Dermat. Venereol., ****Anticorp. Laszlo Hosp. Int. Dis., Budapest, Hungary

Objective. Enhancing antibodies (ENH AB) were reported to be present in the blood of HIV-infected patients and to influence the course of infection. In the present study the incidence of these antibodies were investigated in parallel to that of the neutralizing antibodies (NEU ABS). Heat-inactivating assay on M-1 cells was used for detection of ENH and NEU AB. HIV-seropositive (HIV+) sera were neutralized through 50 ml filters and heat treated (56°C, 30 min). The same sera were tested for NEU and ENH AB after 1 ml mixing with fresh, complement-sufficient (CS) pooled HIV-seronegative serum (CS-serum). Results. The following results were obtained in the 39 serum samples tested:

Group	no sample tested	NEU AB		ENH AB	
		CS-serum	CS-serum	CS-serum	CS-serum
asympt. HIV+	19	19	8	4	0
ARC, AIDS	20	11	0	0	12

Conclusion. These findings support the results of Robinson et al. (1988) on the presence of complement-dependent ENH AB in HIV-infected persons and suggest that their appearance in parallel to the loss of NEU AB may signal a bad prognosis.

W.C.P.93 LOW PLASMA CYSTEINE AND ELEVATED GLUTAMATE LEVELS IN HIV-1 PATIENTS MAY CONTRIBUTE TO LOSS OF T CELL FUNCTIONS.

Brigg, M.J., Frey, K. and Cox, H.-V.
Institute of Immunology and Genetics, German Cancer Research Center, Heidelberg, F.R.G.

Objective. To investigate the hypothesis that the immunological deficiency may be partially the consequence of a virus-induced metabolic disorder. Methods. The plasma glutamate and thiol (cysteine) levels of groups of HIV-1 infected patients with different stages of disease have been studied; and the influence of abnormal extracellular concentrations of glutamate and cysteine on lymphocyte and macrophage functions has been analyzed *in vitro*. Results. HIV-1 infected patients have markedly reduced plasma cysteine and elevated glutamate concentrations. Similar variations of the extracellular cysteine or glutamate concentrations have profound effects on proliferative responses in lymphocyte cultures. Lymphocyte responses are suppressed by cysteine and inhibited by elevated concentrations of glutamate or by its structural analogues quisqualate and N-methyl-D-aspartate (NMDA) but not with kainate. This suggests that glutamate may act on cell surface receptors analogous to the quisqualate and NMDA sensitive excitatory glutamate receptors in the vertebrate central nervous system. Elevated extracellular glutamate levels inhibit also the capacity of macrophages, monocytes and fibroblasts to release cysteine into the extracellular space.

Conclusion. A metabolic defect in HIV-1 infected patients may cause an insufficient supply of cysteine for lymphocyte and may thereby be responsible at least in part for the insufficient immunological reactivity.

W.C.P.94

IDENTIFICATION OF PHENOTYPIC ULTRASTRUCTURES OF LYMPHOCYTES REACTING TO AUTO-ANTIBODIES IN AIDS

Edwards, D., Goren, S. and Steyrolow, H. N., Lapinskas, and Alajalovic, D.

*AIDS Research Center, Biomedico Canada Inc., Canada, **Faculté de Médecine de l'Université de Montréal, ***Général Hospital, ****Général Armand Proppa, Montréal, Québec, Canada. Underscoring the mechanisms of immune suppression and lymphocyte depletion in HIV-positive patients is perhaps central to the understanding of the initiation and the evolution of AIDS. There is general agreement that the etiologic agent of AIDS is HIV but the precise mechanisms by which the virus affects the immune devastation are unknown. Anti-lymphocyte auto-antibodies (Ab) are lympholytic *in vitro* and undoubtedly contribute to the destruction of lymphoid tissues *in vivo*. Present studies aim at determining the specificity of anti-lymphocytes auto-Ab in AIDS.

HIV antigens were identified in peripheral blood lymphocytes (PBL) obtained from 94 patients at different stages of HIV infection using immunofluorescence (IF) and immunoelectron microscopy (IEM) techniques. In vivo studies of the phenotype of HIV-containing lymphocytes by double labelling showed that CD4+ cells are the principal target of the virus. About all infected PBL and approximately 30 percent of uninfected PBL displayed Ab-C1 complexes on the cell surface as demonstrated by IF. Sera from HIV-positive patients contain Ab reacting with cell membranes and membrane structures of PBL from normal subjects, as demonstrated by IEM. Double immunogold labelling showed that the pattern of reaction of serum Ab is different among phenotypic lymphocyte populations and that this pattern changes with the evolution of HIV infection.

The presence of Ig-C1 complexes on a high percentage of HIV-positive or negative PBL suggests that the Ab-C1-mediated lympholysis may represent a major mechanism of lymphatic tissue destruction in AIDS.

W.C.P.95 LONGITUDINAL STUDY OF HIV ANTIBODY RESPONSES OF INFANTS BORN TO SEROPOSITIVE WOMEN IN ZAIRE.

Katzenstein, David; Hendry, R.M.; Sea, W.; Ryder, C.; Brown, C.; Quinn, T.C., et al.
LSE, DV, *Center for Biological Evaluation and Research, FDA and NIAID, NIH, Bethesda, MD, USA, **Proj. SIDA Kinshasa, Zaire

Objective. To determine if neutralizing antibodies (NA) or antibodies on isotype specific Western Blots (IBW) are associated with transmission of HIV from pregnant women to their infants.

Methods. Paired maternal and infant sera were collected at the Mama Yemo Hospital in Kinshasa, Zaire. Sera were obtained every 3 months from 100 infants born to HIV seropositive women. Sera were studied from 2 years based on infant's outcome; healthy at 18 mo. (Op 1), AIDS at 12-18 mo. (Op2). IBW were developed for IgG, IgG 1-4, IgA, or IgM. MA were assessed by inhibition of cytotoxic formation using HIV113.

Results. Maternal sera from both groups reacted strongly with all HIV antigens in IgG blots. Among Op1 infants, 1/8 had anti-HIV IgG Ab and 4/8 developed new IgG Ab. Among Op 2 infants 8/10 had IgM and 9/10 had IgG by 9-12 mo. of age. MA were detected in most maternal sera at titers from 1/10 to 1/128. Significantly, 8/10 Op 2 infants developed MA compared to 1/10 Op 1 infants (p<.05, Fisher's exact test).

Conclusions. Infants with MA and evolving IBW patterns had AIDS by 18 months, although 5/8 healthy infants had IBW suggesting HIV infection. IgM responses to HIV were not observed in the first 6 months of life, even in infants who had other evidence of infection. We did not find a relationship between maternal MA and transmission of infection to infants.

W.C.P.96

NEUTRALIZING ANTIBODY IN SEROPOSITIVE SUBJECTS FROM AFRICA, SOUTH AND NORTH AMERICA AGAINST A DIVERGENT STRAIN OF HIV

Katzenstein, David; Jajic, L.; Lacit, A.; Galvao, B.; Halsey, N.; Quinn, T.C., et al.
LSE, DV, *Center for Biological Evaluation and Research, FDA, Bethesda, MD, **Univ. of Zimbabwe, Harare, Zimbabwe, ***Johns Hopkins School of Pub. Health, Balt., MD, USA, ****Laborat. Brazil

Objective. To assess cross reactivity of neutralizing antibodies (NA) against different isolates of HIV in serum of HIV infected individuals from North and South America and Africa.

Methods. Virus isolate HIV-1118, RF, MN, and 2-2 were tested with sera from Haiti, the U.S., Brazil, Zaire, and Zimbabwe. NA titers of sera were the reciprocal of the serum dilution that decreased the number of syncytia by >50% in Molt-3 cells.

Results. Some of 50 sera from seropositive subjects had MA, while sera from seropositive subjects had NA against HIV1118, HIVRF and HIV2 in 94%, 80%, 56%, and 57% respectively. Asymptomatic subjects (AS) were less likely to have MA than subjects with AIDS or ARC (SP) (SP/AS vs 72/86 SPX for HIV1118 and 56/116 vs 53/70 for HIVRF, p<.016, X²).

Analysis of individual geographic cohorts demonstrated similar geometric mean titers for HIV1118 of highest each isolate, although the GMT were significantly higher against HIV1118 in 60 U.S. sera (1929) than in 40 Zairean (475), 52 Zimbabwean (732) or 50 Haitian (372) sera (p<.05, Student's T).

Conclusion. Sero-specific HIV seropositive subjects have higher titers of NA against HIV compared to AS. NA in seropositive subjects in the Americas and Africa have broadly cross reacting genetically divergent strains of viruses from the U.S., Haiti, and Africa.

Session d'affichage Poster Session



W.C.P.103 A POSSIBLE ROLE OF VIP DEPENDENT NEURONAL SURVIVAL BY gp120 IN AIDS DEMENTIA COMPLEX

Elmehrikh, M., Nandi, J. and Dandekar, S.
Dept. of Microbiology, Tokyo Metropolitan Institute for Neuroscience, 2-6, Minamiohara, Fuchu-shi, Tokyo, Japan

Objective: Reversible intestinal peptide (VIP) has been shown to increase neuronal survival in acute brain cultures (Brennan, J.E., et al., PNAS, 83:1159, 1986), and the amino acid sequence shows some homology with a sequence of the gp120, called peptide-2. Burt et al. have reported that the VIP attenuated the neuronal cell death caused by gp120 in mouse hippocampal cultures (Brennan, J.E., et al., Nature, 335:619, 1988). To determine the isolation of VIP dependent neuronal survival, we studied the effects of VIP and/or peptide-2 on rat brain cultures, and tried to clarify the pathogenesis of AIDS dementia complex.

Methods: Rat brain slices (hippocampus or cerebral cortex) were obtained from 18-19 day old fetal rat. VIP and/or peptide-2 was added to the culture on day 0 or 7. After 12 days, the slices were stained with specific antibodies to neurons or astrocytes, and the survival of neurons was measured.

Results: Addition of 0.1 nM VIP to brain cultures produced a significant increase of neuronal survival. On the other hand, 100 nM peptide-2 decreased the number of neurons. Peptide-2 (100 nM) abrogated the function of VIP (0.1 nM). They did not affect the number of astrocytes. The results suggest that the addition of VIP to brain cultures and antagonizes the VIP-dependent neuronal survival. Finally,

Conclusion: We confirm that VIP is important for neuronal survival in cultures of hippocampus and cerebral cortex of rat. The results suggest that peptide-2 binds to VIP receptors and antagonizes the VIP-dependent neuronal survival. Finally, the gp120 of HIV also blocks VIP-dependent neuronal survival, and the resulting death of neuronal neurons causes the AIDS dementia.

W.C.P.105 VIRAL ANTIGEN STIMULATION OF THE SECRETION OF HUMAN MONOKINES CAPABLE OF REGULATING HIV-1 EXPRESSION

Claude Khatib, A.Y. Hwang, J. Ferris, B. Orenov, J.M. Fauci, A.S. "Georgetown University, Washington, D.C.; "ILR, NIAID, NIH, Bethesda, MD, U.S.A.

Objective: We have previously described model systems for cytokine-induced regulation of HIV-1 in chronically infected T lymphocyte and monocyte lines. Our current objective was to determine whether viral antigens can stimulate human macrophages to secrete monokines capable of upregulating HIV expression in infected cells.

Methods: Chronically HIV-1 infected T cells (ACH-2) or monocytes (U1) were tested for inducibility with monokine-enriched supernatants obtained following stimulation of clonally derived human monocytes with bacterial lipopolysaccharide or purified, inactivated viruses (viral antigens). Induction of HIV expression was monitored by reverse transcriptase activity.

Results: We found that certain herpes group viruses, including cytomegalovirus and Epstein-Barr virus augmented HIV expression by stimulating monokine production. Other herpes viruses, such as herpes simplex virus, varicella zoster virus, and human herpes virus-6 were unable to function in this capacity. When non-herpes group viruses were tested, we found that human adenovirus, hepatitis B virus, and vaccinia virus all failed to stimulate the production of monokines capable of activating HIV in the chronically infected cell lines. Furthermore, HIV-1 can augment its own expression by inducing the secretion of monokines which upregulate HIV expression in the infected cell line. Monokine production mediated by viral antigens was not attributable to contaminating endotoxins.

Conclusion: These studies provide a model to determine whether other opportunistic infections may induce the expression of HIV by indirect mechanisms, such as the stimulation of cytokine production.

W.C.P.107 TNF- α CAN INDUCE THE EXPRESSION OF HIV PROMOTER CHIMERIC TRANSCRIPTS IN AN AUTOCRINE FASHION

Poll-The, J., Kinoshita, K.A., Folks, T.M., Fauci, A.S., ILR, NIAID, NIH Bethesda, MD; Georgetown University, Washington, DC, U.S.A.

Objective: To investigate the hypothesis that tumor necrosis factor alpha (TNF- α) can induce the expression of HIV-1 in T lymphocyte and monocyte cells. Our current objective was to determine whether TNF- α can induce HIV expression in autocrine fashion.

Methods: The T lymphocyte (ACH-2) and monocyte (U1) cell lines are chronically infected with HIV-1, and the constitutive low level expression of HIV can be potently induced (10-2 fold) by reverse transcriptase (RT) treatment with phorbol esters (PMA) or TNF- α . We therefore investigated the possibility that ACH-2 and U1 cells could synthesize and secrete TNF- α (as assessed by a specific Biotinyl kit) and could express TNF- α molecules on the plasma membrane (by immunofluorescent stain and FACS analysis). We also studied the expression of TNF receptors (R) on ACH-2 and U1 cells and on their parental uninfected cell lines in unstimulated and PMA stimulated conditions.

Results: TNF- α is not detectable in supernatants of unstimulated ACH-2 and U1 cells, but significant amounts (150 ng/ml) of TNF- α are present in the supernatants of both cell lines after 24 to 48 h stimulation with PMA 10^{-7} M, in parallel with the expression of HIV. Furthermore, TNF- α is present on the plasma membrane of ACH-2 cells after treatment with PMA. Of interest, PMA stimulation of ACH-2 and U1 cells resulted in the upregulation of TNFR. 2-3 fold whereas the levels of TNFR were found unchanged or downmodulated in the uninfected parental cell lines and were not exposed to PMA. **Conclusion:** TNF- α can act as an autocrine cytokine capable of inducing the upregulation of viral expression in cells of lymphocyte and monocyte origin that chronically carry integrated HIV provirus.

Recherche fondamentale (biomédicale) Basic Research (Biomedical)

W.C.P.104

THE EARLY STAGES OF T LYMPHOCYTE ACTIVATION ARE INITIATED BY HIV-1 STIMULI AND DIFFERENT STAGES OF HIV-1 SPECIFIC P-45^{CAZ} AND P-24^{CAZ} ANTIBODIES. J. PLANET, UCLA Center of Infection, Los Angeles, CA, U.S.A.

Objective: To show the suppressive effect of HIV-1 infection on T lymphocyte proliferation and also the effect of HIV on lymphocyte activation.

Methods: Culture of activated HIV-1 pretreated P-45^{CAZ} stimulated cultures of lymphocytes.

Results: We and others have earlier reported a suppressive effect of a HIV-1 on T lymphocyte proliferation. Here we have extended these studies using different but more potent immunomodulatory preparations of HIV-1, HIV-2, and two different isolates of HIV-1, and showed that these all had a suppressive effect on T lymphocyte proliferation. Further investigation of a preparation of HIV-1 glycoprotein (gp120) showed that the addition of this preparation to cultures of peripheral blood lymphocyte severely decreased the proliferation induced by both CD4⁺ cell membrane and CD4⁺ membrane monoclonal antibodies as well as the response induced by phorbol esters (PMA) or the lymphocyte A23187, whereas the response to different concentrations of PMA (A23187) was almost completely unaffected. Studies of purified CD4⁺ cell membrane showed that the addition of HIV-1 gp120 to these cells inhibited the response to PMA. However, CD4⁺ cells that were not exposed to HIV-1 but were cultured in the presence of HIV-1 gp120 showed that the addition of HIV-1 gp120 to these cells inhibited the response to PMA. This indicates a decrease in the number of receptors expressed. Preliminary experiments showed that the increase in the number of CD4⁺ cells after stimulation with PMA was not inhibited by HIV-1 gp120 and that HIV-1 did not increase an increase in the intracellular Ca²⁺. Studies are in progress to determine the effect of HIV on the intracellular pathways of lymphocyte activation.

Conclusions: The current studies indicate that HIV-1 has a suppressive effect on both CD4⁺ cell membrane and CD4⁺ lymphocytes independent of infection and that this effect occurs in the early days of activation and may be due to the protein levels of CD4⁺. The results with HIV-1 gp120 may propose that the inhibition may also be proteinaceous.

W.C.P.106 EFFICIENT HIV ISOLATION FROM HEALTHY SEROPOSITIVE INDIVIDUALS USING NORMAL MONOCYTE TARGETS:

IMPLICATIONS FOR HIV CD4⁺ CELL SURVIVAL

Mansueti, F.E., Scheinin, S.M., Lane, H.C., Fauci, A.S., ILR, NIAID, NIH, Bethesda, MD, U.S.A.

Objective: To determine the efficiency of viral isolation and *in vivo* cellular source of HIV from peripheral blood mononuclear cells (PBMC) of healthy seropositive individuals. **Methods:** PBMC from healthy, HIV-seropositive individuals were cocultured with either Moloney P14 blast or monocytes obtained by elutriation. Supernatants were assayed for reverse transcriptase activity and p24 antigen. Cells were separated into highly purified lymphocyte and monocyte fractions by rosette and FACS techniques. Polymerase chain reaction (PCR) was used to amplify proviral DNA.

Results: When HIV isolation was attempted onto P14 blast or monocyte targets we found: in 1/23 (4%) patients, HIV could only be isolated by PBMC coculture with P14 blast; in 1/23 (9%) patients, virus could only be isolated when PBMC were cocultured with monocytes and in 5/23 (22%) patients virus could be isolated using both systems. Lymphotropism was performed on five of the seven patients whose viral isolation was accomplished only on monocytes. PBMC from these individuals were fractionated by rosette and FACS techniques (99% purity) and PCR was performed on each fraction. Despite the fact that virus could only be isolated onto monocytes, 4 out of 5 individuals had proviral DNA detectable only in their T cells, and in the other individual in both monocyte and lymphocyte fractions.

Conclusions: In healthy seropositive individuals, HIV could be isolated with greater than 50% efficiency using monocytes as targets as compared to 26% efficiency when using P14 blast targets. In 4 out of 5 patients from whom virus could only be isolated onto monocytes viral DNA could be detected *in vivo* only in T cells. Thus, *in vivo* monocyte tropism does not necessarily indicate *in vivo* monocyte infection with HIV.

W.C.P.108 QUALITATIVE DIFFERENCES IN HIV-1 AND HIV-2 INFECTIONS OF A PANEL OF CD4⁺ T CELL CLONES

W. C. Krawinkel, J. M. Fauci, A. S., ILR, NIAID, NIH Bethesda, MD, U.S.A.

Objective: To investigate the patterns of HIV-1 and HIV-2 infection *in vitro* in a panel of T cell clones expressing comparable amounts of CD4.

Methods: A panel of T cell clones obtained from the CEM-derived A301 cell line. Four clones expressing comparable levels of CD4 were selected from an original panel of 42 because of their differences in response to HIV-1 and HIV-2, as measured by reverse transcriptase activity (RT) released in the culture supernatant and by the kinetics and extent of cytopathic effect (CPE). Cell extracts were made from the four clones and tested for the presence of transcription factors by gel mobility shift assays for NF- κ B and Sp-1. **Results:** Two out of four clones were "fast/high" (peak RT activity 5000-9000 cpm) observed between day 4 and 7 post-infection) and two were "slow/low" (peak RT below 2000 cpm), observed between day 10 and 18 post-infection). HIV-1 and HIV-2 showed similar efficiency of infection in terms of RT and downmodulation of the CD4 molecule. The only evident correlation with the infection patterns described, HIV-1 and HIV-2 showed similar association of infection in terms of RT and downmodulation of the CD4 molecule. The only difference between HIV-1 and HIV-2 was that HIV-2 infection was frequently associated with a second burst of viral replication occurring in the absence of CPE in cells that had already lost the CD4 molecule from the plasma membrane. When cell extracts from the four clones were examined, no differences were noted in terms of binding to Sp-1 specific sequences. On the other hand, only 1 out of 2 "fast/high" responder clones showed detectable binding to NF- κ B.

Conclusions: Significant biological differences were observed among T cell clones expressing comparable levels of CD4 molecules in response to HIV-1 and HIV-2 infection. Different constitutive levels of NF- κ B transcription factor could partially explain these results.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

W.C.P.115 ANEMIA AND LYMPHOPENIA IN HIV INFECTION: RELATION TO SERUM LEVELS OF TUMOR NECROSIS FACTOR- α
Mary, P.J.* and Labevirta, J.**
*Fourth Department of Medicine, University of Helsinki, **Aurore Hospital, Helsinki, Finland

Objective: Hematological abnormalities are common findings in patients with AIDS and AIDS-related complex. However, the underlying causes of the abnormalities are not well understood.

Methods: TNF levels in serum were measured by a double antibody radioimmunoassay in 37 HIV-seropositive subjects.

Results: Significant inverse relationships were found between serum TNF levels and hemoglobin values ($r = -0.83$, $p < 0.001$), as well as between TNF levels and peripheral erythrocyte ($r = -0.78$, $p < 0.001$) and lymphocyte ($r = -0.66$, $p < 0.003$) counts.

Conclusion: Since TNF suppresses the colony formation of erythroid and granulocytic progenitor cells in murine cultures and causes anemia when administered to humans and experimental animals, the demonstrated relationship between TNF and cytopenia in HIV infection may be causal.

W.C.P.117 IMMUNOHISTOCHEMICAL ANALYSIS OF GERMINAL CENTERS (GC) IN RECTAL BIOPSIES OF PATIENTS WITH HIV-1 INFECTION.

Rado, Paul*, Tanner-Rado, K**, Schmidt, H*, Hartmann*, Dietrich*, K.F. Popovic, M**
*Institute for Tropical Diseases, Hamburg, Germany; **A.K. St. Georg, Hamburg, Germany; ***National Cancer Institute, Bethesda, USA.

Objective: To investigate the role of the GC-s of the rectum in the pathogenesis of HIV we studied 33 rectal biopsies from patients with HIV-2 infection.

Methods: Detailed histological and immunohistochemical analyses of the rectal biopsies were performed.

Results: Immunohistochemical reactions revealed gc proteins within the GC-s. The network of follicular dendritic cells was often disrupted. An important characteristic was the decreased numbers of CD4 lymphocytes. A similar decrease was observed in the numbers of Leu7 positive cells. There were increased numbers of CD8 lymphocytes.

Conclusion: Our findings indicate that the GC-s are important reservoirs of HIV. CD4 lymphocytes and macrophages circulating through the GC may become infected with HIV there. We suggest that HIV can persist in the GC of the rectal mucosa for long periods or can be transported to the regional lymph nodes via the lymphatic vessels. The lymphatics then, quite possible serve as thoroughfares for HIV-1.

W.C.P.119 ESTABLISHMENT OF A CELL LINE CHROMOSOMALLY INFECTED BUT NOT TRANSMISSIONALLY FROM AN ANTROPATHIC RESISTIVE SUBJECT.
Tilli, Fausto; Fedorin, M.; Norsetti, A.; Casaccia, L.; Virelli, P. and Barbi, S.*
*Laboratory of Virology, Istituto Superiore di Sanità, Rome, Italy.

Objective: To study a) the latency and the chronicity of HIV-1 infection and b) the control of HIV-1 gene expression.

Methods: PBs from an asymptomatic HIV-1 seropositive and HIV-1 seronegative (Tilli, W.S.) subject were cloned by limiting dilution in presence of IL-2. The past medical history of the subject was characterized by recent-onset LAS (3 years ago) with virus isolation from lymphnodes. Further attempts, even at time of cloning, to re-isolate virus were negative, as determined by antigen capture and reverse transcriptase assays. Cell subset characterization was made using monoclonal antibodies anti-T and - α lymphocytes, monocytes and macrophage membrane antigens.

Results: Two cell clones (UB1, USA) carrying but not expressing the HIV-1 genome were isolated. The two clones have been maintained in culture for 75 months. Both are negative for extracellular virus production. Clone UB4 shows giant cells and an absolute requirement for exogenous IL-2. Cytofluorometric analysis indicated that both clones are not terminally differentiated. PCR-MSA analysis, using SOD, SDC2 HIV-1 gag primers followed by hybridization using oligonucleotide probe specific for gag region, was positive. Preliminary PCR-MSA analysis indicated the absence of active transcription of HIV-1 genome.

Conclusion: Cells with seropositive but not expressed HIV-1 genome are present in an asymptomatic seropositive individual. Further biological, immunological and molecular characterization of these clones is in progress.

W.C.P.116 REPLICATION OF HIV-1 GAG AND POL INTERGENE-ANT
RELATION MUTANTS IN HUMAN CELL LINES
Reisling, Volker*, Zahn, S.* and Sagury, D.,**
*IMM1-Hamburg, FKG, **Universitäts P. St. M. Curie, Paris, France.

Objective: Development of retroviral vectors for human gene transfer requires HIV-1 gene expression vectors with deletions in the gag or pol regions giving rise to a frameshift. All constructs were derived from pC₁, a plasmid containing the complete HIV-1 proviral genome, a hygromycin B gene for selection and the 3'LTR with deletions in the -138 to -40 region. Cells were analysed using immunofluorescence assays (IFA), reverse transcriptase activity (RT), Southern and western blots.

Methods: We have constructed various HIV-1 mutants, twelve containing insertion linkers and twelve with deletions in the gag or pol regions giving rise to a frameshift. All constructs were derived from pC₁, a plasmid containing the complete HIV-1 proviral genome, a hygromycin B gene for selection and the 3'LTR with deletions in the -138 to -40 region. Cells were analysed using immunofluorescence assays (IFA), reverse transcriptase activity (RT), Southern and western blots.

Results: All lymphocyte lines showed more than 60% cells positive when tested, using AIDS patient serum, one, two and five months after transfection. Supernatants were RT negative. When analysed by Western blotting the presence of p17, p24, p51, p55 and gp160 proteins was revealed in two cell lines, p0-89 and a gag deletion mutant. Viral preparations from supernatants are RT negative even when separated by sucrose gradient.

Conclusion: The transfected plasmids are stably transfected and express viral proteins. All cell lines are RT negative but a present we do not know if the 3'LTR deletion is responsible. Two cell lines, that release particles into the supernatant, are WB positive for the pol protein.

W.C.P.118 EVIDENCE FOR INTRAFOLLICULAR VIREMIA IN GERMINAL CENTERS OF LYMPH NODES OF CATS INFECTED WITH FeLV. AN ULTRASTRUCTURAL STUDY.
Tanner-Rado, Klara*, Morona, F**, Schmidt, H**, Rado, P**, K.F. Popovic, M***
*Institute for Tropical Diseases, Hamburg, Germany; **A.K. St. Georg, Hamburg, Germany; ***National Cancer Institute, Bethesda, USA.

Objective: Many cats infected with the feline leukemia virus develop follicular hyperplasia, severe immunodeficiency and die of opportunistic infections, very similar to human infection with HIV. Therefore we used the feline model to investigate the cellular mechanisms of the pathomorphology and pathogenesis.

Methods: Ultrathin sections of 33 lymph nodes among 5 cats infected and 1 control animal were taken 5 or 9 months after inoculation, according to standard methods.

Results: The ultrastructural changes of the very hyperplastic follicles revealed a high concentration of virus particles in the vicinity of follicular dendritic cells (FDC) as shown in HIV-infection. FeLV was found to replicate in different cell types: lymphocytes, plasma cells, macrophages and FDC.

Conclusion: The results suggest that FDC, as antigen trapping cells, capture FeLV. Virions held on FDC infect different target cells. Quite possible that a genomic shift may occur at the time of transmission of the virus to a novel target. Therefore, GC may be one of the anatomic sites where variants with altered cell tropism and pathogenicity may be generated.

W.C.P.120 INCREASED PRODUCTION OF ARABINOSIDE CATABOLITES (PROSTAGLANDIN E₂ AND THROMBOXAN B₂) BY HIV-1 INFECTED HUMAN ADIPOCYTES (VDA) INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS.

Yamamoto-Crua, Margarita; Zabay, J.M.; Longo, N.M.; Gomez, G.A.; Rosell, J.; Galis, H.*
Hospital General "Gregorio Marañón", Madrid, Spain. *Centro de Investigación y Desarrollo del C.I.C.I.C., Barcelona, Spain.

We have analyzed the production of PGs by monocytes from 19 VDA with different clinical manifestations of HIV infection and from 16 healthy normal individuals. HIV-1 seronegative VDA were cultured in the presence of culture supernatants of purified monocytes was performed by high performance liquid chromatography and radioimmunoassay. The results showed that in the AIDS group 21 of 21 patients showed PGs levels (134.4 \pm 108.7 pg/ml) higher than the mean \pm 2 SD values from healthy controls (7321 pg/ml). This group with HIV increased production of PGs by monocytes from AIDS patients induced a marked suppression of IL-2 production. HIV infection may alter the synthesis and secretion of PGs in monocytes which may lead to the immune dysfunction of AIDS.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

W.C.P.121

Des oncogènes co-transfection induisent transactivation de l'HTLV-III
through NF- κ B binding sites.
**FRANCOIS-CRIVELLO, FRANÇOIS, ISHAI, M., BACHTELIERE, F., HANON, H., ALONZI, J.,
DOUTRY, F., WITTELLER, J.-F., FIMONDINO, P., LEROUX, M., BOUTIER, P., PARIS, A., S.B. D'Onofrio,
Molécules Vitales, France.**

Objectif: To ascertain whether p21ras (the product of ras protooncogenes induced during T cell activation) and a G protein with known transduction properties) can induce signals leading to HIV-1 transcription.

Méthode: Human cells of two different tissues, fibroblasts (HRC-5) and astrocytes (U8739G astrocytoma cell lines) were transiently transfected with vectors permitting the expression of the CAT reporter gene under the control of either the whole LTR of HIV-1 (LW-1-3ER) or various subcloned fragments of the LTR. A vector permitting the expression of co-receptor coding for a G21 protein with GTPase II1 mutation was co-transfected with LTR-CAT vectors.

Résultats: Co-transfection of co-receptor consistently resulted in a 2 to 22 fold transactivation of the whole HIV-LTR. We have performed further co-transfection of an HIV-1 infection provirus clone (pNL4-3) in this system, and shows that transcription of the provirus, including the p24 protein function induction, was induced by co-receptor transfection. Deletion of the LTR 126 bp region did not decrease but induced transactivation. The LTR enhancer was shown to be a main responsive element in this system, since a 96 bp fragment containing the enhancer, or a synthetic oligonucleotide with the exact sequence of the enhancer, increased the activity of the LTR 126 bp region. A 20 bp fragment upstream a TK promoter, versus a responsive to rat than the whole LTR.

Conclusion: Our observations are compatible with the hypothesis that endogenous p21 ras, induced during cell activation, participates in HIV-1 gene transcription through transactivation of the HIV enhancer.

W.C.P.123

HIV-1-ASSOCIATED CHANGES IN TRANSMEMBRANE SIGNAL
TRANSDUCTION IN MACROPHAGES
**Suzanne Gaudin and Yvonne R.
University of California, San Diego, CA, USA.**

Objective: Macrophages play an important role in the pathogenesis of AIDS. However, the mechanisms of HIV-1-induced dysfunction in macrophages are not well understood. We hypothesize that the macrophage dysfunction in HIV infection may be a result of a deficit in transmembrane signal transduction. Furthermore, adhesion molecules expressed on macrophage may play an important role in the transmission of HIV infection to CD4+ T cells as well as in inducing transmembrane signaling. The objective is to examine the changes in plasma membrane potential and in intracellular free calcium (Ca^{2+}) in uninfected macrophages (U937) and HIV-infected (937/HIV) macrophages.

Methods: Cells were cultured in the presence or absence of monoclonal antibodies against adhesion molecules, lymphocyte-associated antigen-1 and 3 (LFA-1, LFA-3) and intracellular adhesion molecule-1 (ICAM-1). Plasma membrane potentials were measured with DiOC2 dye and (Ca^{2+}) with Indo-1 dye using FACS.

Results: The membrane potentials of U937 and 937/HIV cells were 120 and 39 mV mean channel numbers respectively. Anti-LFA-1 and anti-LFA-3 induced hyperpolarization of both U937 and 937/HIV cells. In contrast, anti-ICAM-1 decreased (depolarized) membrane potentials of U937 (120 to 40 mV mean channel number), but increased the membrane potential of 937/HIV cells (39 to 60 mV mean channel number). The basal (Ca^{2+}) levels in U937/HIV cells were elevated (100 nM) as compared to U937 cells (90 nM). Anti-LFA-1 induced less increase in (Ca^{2+}) levels in U937/HIV (120 nM) as compared to U937 cells (180 nM).

Conclusions: This study demonstrates a deficit in the transmembrane signal transduction in macrophages infected with HIV, which could be responsible for macrophage dysfunction in AIDS. (Supported by USPHS Grant AI-26456).

W.C.P.125

HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS AS A POTENTIAL
COFACTOR IN HIV-1
**LOUIS, P., ENOEL, B., NEGRO, F., DE ROOCCO,
S.E.S., MARZBAN, P.D., GALLO, R.C., et al. NCI,
Bethesda, MD, Georgetown Univ., Rockville, MD, **Bionetics
Research, Inc., San Diego, U.S.A.**

Objectifs: To investigate the interactions between HIV-6 and HIV-1 in vitro and the potential role of HIV-6 in the pathogenesis and/or disease progression in AIDS.

Méthode: Human peripheral blood mononuclear cells (PBMC) or enriched adherent cells and established cell lines of T lymphocytic or monocytic origin were simultaneously infected in vitro with HIV-6 and HIV-1. Electron microscopy, immunohistochemical analyses and dual-probe *in situ* hybridization were employed to demonstrate dual infection at the single cell level.

Résultats: HIV-6 and HIV-1 can productively infect human CD4+ T lymphocytes of both normal and neoplastic origin, resulting in accelerated viral antigen expression and cellular death. Cells of the monoclonal phagocytic system can also be infected by the two viruses. HIV-6 is a potent transactivator of HIV-1. HIV-6-infected cells can be visualized in AIDS patients blood.

Conclusion: These *in vitro* observations suggest that HIV-6 is particularly suitable candidate as a cofactor in AIDS. Studies are underway to detect dual infected cells in PBMC from HIV-1-infected individuals.

W.C.P.122

CYTOKINE MODULATION OF HIV-REPRODUCTION IN
MONOCYTES/MACROPHAGES
**KUMASHI, THOMAS, ZORR, B. and HABERSMANN, K.-O.
Institute for Clinical and Experimental Virology, Federal Republic of Germany,
Berlin, Hinderburgstrasse 27, 1000 Berlin 46, F.R.G.**

Objective: Reproduction of different primary HIV-isolates (HIV-1/2) at a given multiplicity of infection (m.o.i.) in adherent monocytes/macrophages. Modulation of HIV-1 replication in monocytes/macrophages by cytokines and phorbol ester.

Résultats: All HIV-wildtypes (n=49) isolated from patients by cocultivation with peripheral blood lymphocytes (PBL) lead to our investigations to an infection in monocytes/macrophages. There were gradations regarding the productivity of replication, between low level and productive HIV-infection. The cell of intercurring defective particle will be discussed. Cytokines affected the HIV-replication in monocytes/macrophages in a dose dependent manner. Control cells had a stronger HIV-reproduction with rM-CSF and rGM-CSF especially if the cytokines were applied before HIV-infection. Also rIL-3 enhanced the HIV-replication in a positive manner. Treatment of monocytes/macrophages with phorbol ester (TPA) lead to time-dependent upregulation or activation of HIV-1 replication.

Conclusion: Low level HIV-replication in monocytes/macrophages can be changed to a more productive HIV-infection by different cytokines. Possible meanings about the *in vivo* situation will be discussed.

W.C.P.124

PREVALENCE AND SIGNIFICANCE OF ANTIBODIES TO nef (p27) IN
HIV-1 INFECTION
**CHEN, YUN, PAPPAS, D., BARNETT, R., FINEGOLD, C., HENNING, C. and
Weber, J., Department of Infectious Diseases, Royal Postgraduate Medical
School, London W2, U.K.**

Objectifs: To measure and analyse the humoral immune response to nef (p27) in serial samples from HIV-1 infected subjects.

Méthode: Purified recombinant nef protein derived from 8-001 (T-tropic, 3' proviral) was used as the antigen in a direct, anti-glyceralis ELISA assay. Specificity of the anti-nef response was confirmed with a large battery of HIV-negative sera, and by immunoblotting on HIV and on nef protein. Sera were obtained from serial blots over a six year period from homosexual men and haemophilic patients, and were further assayed for antibody to HIV env and gag proteins, and for HIV p24 antigen.

Résultats: Antibodies to nef appear simultaneously with antibodies to HIV structural proteins at seroconversion in 67% of cases. Only 1/65 seroconverters expressed detectable anti-nef antibodies prior to seroconversion. This subject had anti-nef present 7 month prior to full seroconversion. High initial titres of anti-nef antibody after seroconversion correlated with lack of progression to AIDS.

Conclusion: The expression of the nef protein prior to seroconversion occurs, but is a rare phenomenon (circa 1%). The titre of anti-nef does correlate with progression from disease in haemophilic, suggesting that this negative regulatory protein may slow viral replication *in vivo*.

W.C.P.126

MISE EN EVIDENCE DE SEQUENCES VIRALES HIV
CHEZ DES SUJETS MARIAGES A WESTERN BLOT INDETERMINES
**L. D'ARNO, C. METZGER, J. GUY, J. L. GUY, J. L. GUY, J. L. GUY,
P. KATZ-SHIMONI, D. CALZADILLA, F. GILBERT,
M. Nomsler, Paris.**

*Laboratoire d'Immunologie Appliquée, Centre Mérieux Hospital St-Louis,
CHU de Fort-de-France, l'Institut Pasteur de Paris-France.

Objectif: Le taux de séropositivité HIV est élevé en Martinique, intradépendamment entre autres observés en Guyane et en Afrique, avec un fort taux de western blot indéterminés (0,16 %). La transmission est essentiellement hétérosexuelle (62 %). Le PCR a permis de mettre en évidence des séquences virales HIV-1 chez des hommes séropositifs et des couples sérodiscordants.

Méthode: Les séquences virales HIV-1 ont été recherchées par PCR dans le plasma de séropositifs et de couples sérodiscordants. Les résultats ont été confirmés par sérotypage et par séquençage.

Résultats: Les séquences virales HIV-1 ont été réalisées pour la technique de séquençage et de séquençage. Les résultats ont été confirmés par sérotypage et par séquençage. Les résultats ont été confirmés par sérotypage et par séquençage.

Conclusion: Le PCR a permis de mettre en évidence des séquences virales HIV-1 chez des couples sérodiscordants et chez des couples sérodiscordants. Les résultats ont été confirmés par sérotypage et par séquençage.

Session d'attachage Poster Session



Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

W.C.P.127 HIV ENCEPHALITIS IN ADULTS AND CHILDREN

Rosnay-Vazex, M.C. Curoin, I. Montagier et al. Institut Pasteur, Paris, France.

Objectives: To study Human Immunodeficiency Virus (HIV) encephalitis in adult and children by identifying the HIV infectious virus and determining which additional pathogens are present.

Methods: We have extensively screened from CNS tissue of 43 adult and 6 children AIDS patients for the presence of pathogens using a combination of immunohistological staining and *in situ* hybridization.

Results: A first striking difference between adults and children infected with HIV was the detection of a massive and multifocal HIV encephalitis in 24/83 adult patients, but a failure to detect HIV antigens in 4/6 children who either died with severe and typical AIDS related encephalopathy, 2/6 children with immunologically detectable HIV encephalitis but less severe neurological symptoms. For adults and children, both single and double immunohistological procedures showed that all infected cells had macrophage/microglial cell phenotype, without any HIV antigen expression in astrocytes, neurons, or endothelial cells. The second striking difference between adult and children encephalopathies was the very frequent association with other CNS pathogens in adults, and their absence in infants with severe encephalopathies.

Conclusions: In adults, dementia is associated with multifocal and diffuse HIV replication, but the presence of severe neurological symptoms in infants without evidence of HIV replication in brain macrophages suggests that perinatal, productive viral infection is not required for the pathogenesis of HIV encephalopathy. Opportunistic associated pathogens might play an important role for iatrogenic HIV replication in adult brains.

W.C.P.129 IMMUNE DEFECTS FOR HIV INFECTION IN HLA HOMOZYGOUS (DR5)

Bentwich, Z.J.H.*; Mandel, Z.T.*; Burstein, R.*; Hershkovitz, H.B.*; Haber, T.*; Legor, S.** et al. *A. Ben Ari Institute of Clinical Immunology, **Rita Research Laboratory, Kaplan Hospital, Rehovot, ***Dept. of Pathology, Soroka Medical Center, Beer Sheva, Israel

Objective: To determine the role of immune cofactors to HIV infection. **Methods:** We have studied several immune parameters and functions in a cohort of 1000 male homozygous (DR5) in Israel, 144 of whom were followed for over 4 years and 18 seroconverted during that period.

Results: Elevated levels of serum acid labile α -interferon (aIFN), antibodies to nuclear antigens (Histones, SS-A, SS-B and Cardiolipin) antibodies to HIV, CMV and Chlamydia trachomatis, elevated cellular lymphocytotoxicity, with normal serum levels of tumor necrosis factor (TNF), extremely high inducibility of IFN- γ gene expression upon mitogen stimulation and lower levels of CD4 T cells were all found in a large proportion of HIV sero-negative individuals and preceded HIV infection. Further derangements of several of these immune parameters were observed following sero-conversion and at later stages of HIV infection.

Conclusion: Our studies suggest that immune dysregulation is common among HIV seroconverters. Our studies suggest that immune dysregulation is common among HIV seroconverters. Our studies suggest that immune dysregulation is common among HIV seroconverters.

W.C.P.131 QUANTITATION AND MODULATION OF HIV P24 ANTIGEN CONTENT IN INTESTINAL MUCOSA.

Rita Sahaj, Borwick, A; Kotler, DP
St. Luke's-Roosevelt Hospital Center and Columbia University, New York, NY, USA

Objective: To quantitate HIV replication in the intestine and to determine if viral protein production can be modulated *in vivo*.

Methods: Mucosal biopsies were assayed directly, or incubated *in vitro*. HIV content in homogenates was determined by p24 antigen enzyme ELISA. (Coated). *In vitro* incubation was performed in media containing varying amounts of hydrocortisone (5-2000ng/ml) or progesterone (2-200ng/ml).

Results: HIV p24 was found in 44/65 serum specimens, 18/24 biopsies from jejunum, 24 from ileum, 15 from right colon, 6/10 from left colon, and 7/10/4 from rectum. In several cases, p24 was detected in tissue but not in serum. When calculated by sample weight, tissue p24 was more than 100 times higher than serum concentrations. As compared to control sections (Digital rectum), either 50 ng/ml and 500 ng/ml cortisol significantly depressed p24 content after 48 hours in tissue and sodium in both AIDS and AARC in culture. 50M POE increased p24 content.

Cortisol (N=15)		Progesterone (N=7)	
50ng	500ng	50ng	500ng
860±23	401±9*	370±379	947±21*
		308±106	252±127

*p<0.05, **p<0.02, Mann-Whitney U test p<0.05

Conclusions: HIV p24 expression occurs throughout the GI tract. P24 content is higher in tissue than serum, implying transcellular localization in the gut. Mucosal HIV production can be modulated *in vitro*.

W.C.P.128 BLOCKING OF INFECTIVITY AND IMMUNOSUPPRESSION BY AN HIV ENVELOPE DERIVED SYNTHETIC PEPTIDE

Katze-Hommes, T. F. Kowalski, J. S. W. Whalley, A. B. Bernstein, L. and Morono, W. W. * IDEC Pharmaceuticals Corp., La Jolla, California. ** Department of Laboratory Medicine, University of California School of Medicine, San Francisco.

Objective: We have identified an epitope in the external envelope glycoprotein of HIV-1 that is likely to be involved in the binding of this molecule to its cellular receptor, CD4. Independent studies have confirmed the importance of this region in the HIV-1/CD4 interaction and, in addition, this region may contain an immunosuppressive T cell epitope.

Methods: An 18 amino acid synthetic peptide was synthesized and purified and its ability to block syncytial formation as well as be recognized by antibodies and T cells from HIV infected individuals was determined.

Results: The peptide would inhibit 100% of syncytial formation at a concentration of 100 ng/ml. Only asymptomatic HIV carriers had detectable levels of anti-peptide antibodies that were significantly different from normal, uninfected control subjects. The peptide did not induce proliferative responses in peripheral mononuclear cells from the HIV-seropositive individuals, either in the presence or absence of IL-2. Tetanus toxoid and CMV were used as positive controls in these studies. The peptide was shown to suppress recall antigen (CMV and tetanus toxoid) responses, but not PHA-induced proliferation.

Conclusions: The apparent immunosuppressive properties of this peptide indicate a potential pathogenic role of the HIV envelope in the pathogenesis of infection.

W.C.P.130 HYPOTHESIS: AIDS IS AN AUTOIMMUNE DISEASE CAUSED BY HIV PLUS ALLOGENEIC CELLS

Hutchinson, Geoffrey, W. and Cross, Michael D. University of British Columbia, Vancouver, Canada V6T 1W5

We suggest that the following factors are relevant to AIDS pathogenesis. Firstly, there is complementarity of CD4 and class II MHC. Hence gp120 can be regarded as MHC-mimicking, and the anti-viral immune response may include an anti-class II internal image component. Secondly, immunisation with foreign lymphocytes leads to the production of MHC-mimicking (i.e. MHC-image) antibodies. Since infection with HIV usually occurs coincidentally with exposure to allogeneic lymphocytes, infected individuals are likely to make MHC-mimicking antibodies.

These factors lead to the idea that AIDS is an autoimmune disease, that is triggered by a combination of HIV and allogeneic cells, rather than by HIV alone. These two stimuli produce MHC-image and anti-MHC image immune responses that seem likely to synergize with each other to destabilize the system. We have found anti-collagen antibodies in the sera of many homozygous, both HIV and HIV+, and in the sera of 16/16 homozygous AIDS patients. These antibodies are also found in alloimmune sera, graft versus host disease and lepra. Our results are consistent with AIDS being an autoimmune disease that is provoked by a combination of allogeneic cells and HIV. The theory leads to further experimentally testable predictions, and ideas concerning possible approaches for prevention of the disease. It suggests that vaccines consisting of gp120, gp60 and anti-CD4 may cause AIDS in individuals belonging to high risk groups.

W.C.P.132 CREATION OF A NEW TARGET CELL TYPE FOR HIV-1

Potanyi, Harry Gene; Volaky, D.J.; St. Luke's-Roosevelt Hosp Ctr Columbia University, New York, NY, USA.

Objective: To investigate the dichotomy between productive and nonproductive HIV-1 infection by construction of a hybrid target cell type between T cell and gall cell lines, and by analysis of its susceptibility to HIV-1.

Methods: A constant resistant BMT-1000B clone of the lymphoblastic T cell leukemia line, CEM, was selected and fused to US21MG, a cobain sensitive, HIV resistant astrocytic cell line with polydispersed glycolipid. Fusion products were selected in HAT-medium, which kills the parental cells.

Results: BMT, a hybrid derived from this fusion, was selected for further analysis. Like US21MG, BMT has gall morphology, growing as an adherent monolayer in tissue culture. Like CEM, and unlike US21MG, it displays high amounts of surface membrane CD4. Upon infection with a cytopathic molecular clone of HIV-1, HIV-BMT-A, CEM expresses HIV-1 antigens 5 days after infection, and is killed within 10 days; US21MG expresses approximately 100 fold less HIV-1 than CEM as measured by p24 antigen expression, and is resistant to killing by HIV-1. BMT on infection with HIV-BMT-A displays no cytopathic effects and 100 fold less HIV-1 antigens than CEM.

Conclusions: HIV-BMT-A's cytopathogenicity target cells can be dissociated from their high CD4 display. In this case, factors either i) contributed by the gall parent, or ii) contributed by the T cell parent, and suppressed by the gall parent, determine BMT's response to HIV-1 infection.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

W.C.P.133 HIV DNA IS PRESENT IN A HIGH PERCENTAGE OF PERIPHERAL BLOOD MONONUCLEAR CELLS IN INFECTED INDIVIDUALS

Halla, Kåmø, LeRoux, E. and Spector, S.A.
University of California, San Diego Medical Center, San Diego, California USA

Objective: To determine the percentage of peripheral blood mononuclear cells (PBMCs) containing HIV DNA in infected individuals.

Methods: PBMCs isolated by Ficoll-Hypaque gradient centrifugation were counted by immunocytometry. Cells cell lysates of 10^6 , 10^5 and 10^4 PBMCs were subjected to polymerase chain reaction (PCR) for 35 cycles in the presence of primers SK38 and SK35 obtained from the Cetus Corp. The specific HIV sequence amplified from these lysates were subsequently analyzed by slot blot and Southern blot hybridizations with a specific HIV oligomer probe (SK19) (Cetus Corp).

Results: Using 10% of PCR mixture from 10⁶ PBMCs, specific HIV sequences were detected in 7/9 of patients with AIDS, 5/6 patients with ARC, 4/8 asymptomatic HIV seropositive individuals, and 10/10 HIV seronegative controls. In some of these PCR positive persons, amplified DNA could be detected in 10% of PCR mixtures with only 10 PBMCs, indicating that greater than 10% of PBMCs contain HIV DNA in these infected individuals.

Conclusions: Using *in vitro* amplification of HIV DNA by PCR, we have detected a very high percentage (greater than 10%) of PBMCs containing HIV sequences in seropositive individuals. This reflects a substantially higher percentage of PBMCs primally infected with HIV than previously reported by using the *in situ* hybridization (10⁻⁶-10⁻⁷). These findings may be important in establishing the severe immunologic deficit associated with HIV infection.

W.C.P.135 BLOCKING OF ANTIBODY-ENHANCED HIV-1 INFECTION BY RECOMBINANT SOLUBLE CD4 (rCD4)

Zelma, Highland, Byrn, R.A., 828 Groopman, J.S., New England Deaconess Hospital, Boston, MA U.S.A.

Objective: To test whether rCD4 can block antibody-enhanced HIV-1 infection of Fc γ -receptor (FcR) expressing cells.

Methods: The monocytic cell line, U937 served as an target for HIV-1. HIV strain infection, FcR and CD4 expression were measured by flow cytometry. Virus neutralization tests were performed by mixing dilutions of heat inactivated patient sera with 100TCID₅₀ of HIV-1. After incubation for 1 hr at 4°C, U937 cells were added and infection was monitored by reverse transcriptase activity. High concentrations of patient sera neutralized HIV-1 but a subneutralizing concentration from the same patient enhanced infection. The role of CD4 in this antibody-enhanced infection was tested using rCD4.

Results: Flow cytometry of U937 cells showed that 74% express FcR11 and 97% express CD4. At subneutralizing concentrations (10⁻²-10⁻⁶ dilutions) 5 out of 6 patient sera enhanced viral infection. The enhancement index was 1.2 to 2.18 in comparison with HIV-1 Ab-negative sera. This enhancement of HIV-1 infection was totally blocked by 1 μ g/ml rCD4.

Conclusions: Some HIV-1 Ab-positive human sera can neutralize HIV-1 and at higher dilutions enhance infection. Because rCD4 can block this enhancement, this PCR dependent infection pathway is also CD4 dependent.

W.C.P.137 STRESS MEDIATED INDUCTION OF HIV EXPRESSION FROM A CHRONICALLY INFECTED PROMONOCYTOGENIC CELL LINE

Staley, Sharkey, Fokas, T.M., Fauci, A.S., LR, NIAID, NIH, Bethesda, MD U.S.A.

Objective: To investigate the ability of various cell stressors to induce expression of HIV from a strain of latent or non-replicating HIV-1.

Methods: A chronically HIV-1 infected virus producing promonocytic cell line (U1) derived from infection of U937 cells was exposed to varying doses of UV-C, UV-B, or UV-A. Virus induction was measured by quantification of reverse transcriptase (RT) activity in cultures exposed to heat shock (41.3°C for 1.5 hours) and followed for appearance of RT activity over several days.

Results: A 2-3 fold induction of RT activity over untreated cells was seen at 3-5 days after UV-C and UV-B stimulation. Peak induction was seen over a narrow dose range of 0.75-1.0 mJ/cm² for UV-C and 7.5-9.0 mJ/cm² for UV-B. UV-A, which does not usually cause DNA damage, did not induce HIV expression in this cell line. FPA experiments also revealed a time dependent increase in percent positive cells after UV-C exposure. Decreased cell viability and a temporary growth arrest (suggesting cell stress) were associated with UV doses which induced HIV. Cells exposed to heat shock also showed an increase in RT activity over controls and were followed for appearance of RT activity.

Conclusions: Chronically infected U1 cells can be induced to express HIV by UV irradiation in wavelengths that cause cell stress and by heat shock.

W.C.P.134 PLASMA-ASSOCIATED HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 (HIV) IS A MIXTURE OF PHENOTYPES OF HIV INFECTIONS.

Robertson, W. Washington, Seattle, WA, USA.

Objective: To assess the diversity and time course of HIV plasma viruses and whether the development of plasma viruses correlates with progression of disease.

Methods: We sequentially cultured cell-free HIV from a cohort of CDC class II, III, IVa and IVc patients. Three ml of plasma was removed, passed through a 0.45 micron filter to remove cells, and 2 ml was then added to 10⁷-1.4 day old PHA-stimulated donor peripheral blood mononuclear cells (PBMC) and cultured by a standard anti-lymphocyte procedure.

Results: All 67 sequentially sampled patients had HIV isolated from their initial and all subsequent PBMC specimens. Twenty-five CDC class IVa (AIDS) patients had plasma samples taken at a mean interval of 6 weeks (range 2-12 wk). Plasma viruses were detected in 21 of their first sampling and 21 had HIV re-isolated from the plasma on subsequent sampling. Of the 4 in whom HIV was not initially detected in plasma, 3 had HIV isolated from plasma on a second sampling. Fourteen patients in CDC class II and III (asymptomatic) and 28 in CDC class IVb (ARC) were sequentially sampled at a mean interval of 6 months (range 1-26 months). 14 (74%) of the initially plasma viremic patients remained persistently positive on re-sampling.

Three of 12 CDC class IIb versus 14/12 CDC IVc who were initially plasma HIV negative developed plasma viremia over follow-up (p<0.01). Three of 4 CDC class IIb patients with plasma viremia progressed to more symptomatic clinical disease versus 0/8 without plasma viremia (p=0.04). The CD4-cell count decreased significantly for 6 patients that progressed to plasma viremia (Wilcoxon signed rank p=0.006) as compared to 7 that remained HIV-negative (p=0.88) and 7 that remained seronegative (p=0.11).

Conclusions: Previous cross-sectional studies indicated that the frequency of plasma viremia increased with stage of infection; these data indicate that the frequency of plasma viremia progressed over time, that once it develops it persists and is associated with a decrease in CD4-cell count.

W.C.P.136 HIV-2 SEROCONVERSION IN SENEGAL, WEST AFRICA

Mawya, Sillmon*, Enkai, M., *Obong S.M., Mouton, K.*, Travers, K*, Ester, M*, et al. *Harvard School of Public Health, Boston, MA, USA, ** University of Dakar, Dakar, SENEGAL.

Objective: HIV-2 has been found in high rates in populations of West Africa where as yet high rates of AIDS cases have not been described. This has suggested that HIV-2 may differ in pathogenicity from HIV-1. In order to evaluate this on a population level the rate of seroconversion of the virus is important to determine. Through evaluation of seropositive plasma from a high risk group in Dakar, Senegal, we determined and characterized seroconversion in this population.

Methods: A population of 1300 registered female prostitutes had been followed with serological serially since 1985. All serum samples were evaluated for antibodies to HIV-1 and HIV-2 by immunoblot.

Results: 14 women were found to seroconvert to HIV-2 with 22.6 percent-years of observation. The mean time of observation prior to seroconversion was 17 months. At the time of seroconversion antibodies to the new gene products gp38-40 and gp100 for HIV-2(A05) were readily detected by immunoblot. 14/14 had antibodies to p24(gag), 13/14 to gp96(gp120), 11/14 to gp51(gp41), and 8/14 to p15(gp16). HIV-2 seroconverters were compared to 1100 women (963 percent-years) who remained seronegative. Risk factor analysis showed that seroconverters were significantly older than non-seroconverters (p<0.025). Nationality or years of prostitution were not significant risk factors for seroconversion. None of the seroconverters developed AIDS or related signs. The seroconversion rate was found to be less than 2% per year based on percent-years of observation in this large high risk population.

Conclusions: Seroconversion for HIV-2 appears quite low despite over 10% infection in this high risk population. This suggests slow spread of HIV-2 in contrast to HIV-1. The stability of this virus infection in the absence of AIDS further indicates important biological differences between HIV-2 and HIV-1.

W.C.P.138 ANTI-HISTONE H2B ANTIBODIES IN HIV-SEROPOSITIVE

Maroux, W.J.W.*, Whalley, A.S.*, Leahy, C.*, Rosenberg, J.*, Stricker, R.B.** and McClellan, J.A.**

* IDIC Pharmaceuticals Co., La Jolla, California, ** Laboratory of Microbiology, University of California School of Medicine, San Francisco, California, *** Division of Infectious Diseases, University of California Medical Center, San Diego, California

Objective: The purpose of this study was to quantitatively measure the levels of anti-H2B antibodies in HIV-seropositive individuals to assess whether the prevalence and levels of antibodies correlated with disease status.

Methods: Previous studies carried out in our laboratories have demonstrated the presence of anti-lymphocyte antibodies in individuals with AIDS and at risk for AIDS. These antibodies are specific for a 18 kd antigen present on activated or HIV-infected CD24⁺ T cells. Further studies on the 18 kd antigen have revealed that it is biochemically similar to, and immunologically cross-reactive with, histone H2B.

Results: The prevalence of anti-H2B antibodies in serum specimens tested was as follows: AIDS, 13/38 (34%); ARC, 19/31 (61%); lymphadenopathy syndrome, 41/132 (31%); HIV-seropositive asymptomatic, 3/19 (16%); HIV-seronegative normal controls, 4/20 (20%). The normal range was established as the mean \pm 2 SD of 50 samples in the normal control group. There was only a weak correlation of $r = 0.42$, $p = 0.006$ between serum immunoglobulin levels and titres of anti-H2B antibodies.

Conclusions: Although the prevalence of anti-H2B antibodies was associated with progression of disease, there was no clear relationship between these antibodies and the numbers of circulating CD4 cells.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

Th.C.P.7

PROSPECTIVE STUDY OF NEWBORNS TO HIV SEROPOSITIVE MOTHERS: PROGNOSTIC VALUE OF ANTIGENEMIA AND ANTIBODY WESTERN-BLOT ANALYSIS

Isabelle Christian¹, Myriam MJ², Jeanne C³, Blanche S⁴, Odile C⁵
¹ French HIV Institute in Newborn Collaborative Study Group.
² Hôpital Necker, Paris, France; ³ Hôpital U292, Grenoble-Hôtel, France.

Objective: The results of two virological parameters evaluated at 8 months of age were correlated to the clinical state at the age of 18 months, among 86 children born to HIV seropositive mothers.

Methods: 415 infants have been prospectively followed since birth, in a multicentric French study. Among 200 children born 18 months earlier or more, 86 evaluated in the same laboratory were included in this analysis. HIV antibodies were studied by Western Blot analysis (Diagnostic Pasteur or Dupon de Nemours) and classified into two groups: 1 = negative or inconclusive pattern; 2 = positive pattern, with antibodies to p24 and/or p31 and/or detection of antigens as performed by immunospot assay (Abbott or Diagnostic Pasteur). At 18 months of age the children were classified into two groups according whether they had presented HIV related clinical symptoms or not.

Results: The percentage of children with clinical symptoms is 28 % at 18 months of age. This percentage significantly differs according to positive or negative assignments at 8 months of age (100 % vs 18 % respectively, $p < 10^{-5}$). The same pattern is observed with Western-blot (89 % when positive, vs 11 % when negative or inconclusive, $p < 10^{-5}$). As the two virological parameters were correlated, adjustment has been performed, each of the two factors is associated to the clinical state independently of the other.

Conclusion: The presence of a complete pattern of Western-blot or of a positive assignment at 8 months of age are highly predictive of the appearance of clinical symptoms at 18 months of age or earlier.

Th.C.P.9

THE HIV-1 PROTEINASE IN PERIPHERAL BLOOD MONONUCLEAR CELLS INDUCED BY ANTI-2 DE MICROFILM MONOCLONAL ANTIBODIES.

GERBAUD J., SPAIN C., BERTHIAUX J., VIT F., BERTELIER F. and GERBAUD J.

Unité de Recherches SIDA et les Techniques de Sérologie et Moléculaire (U-322) - Centre de l'Institut de la Santé - 13073 Marseille Cedex 9 - FRANCE

We have recently searched for monoclonal antibodies (mAb) interfering with HIV proteinase. The "in vitro" assays used for the screening were for rapid identification of mAb interfering sites with virus, replication or budding of the virus: most of the anti-2mAb (282) mAb tested strongly delayed HIV-1 proteinase by peripheral blood mononuclear infected cells. Our recent data suggest that anti-2mAb mAb do not inhibit HIV virus state cellular proliferation with this mAb do not prevent HIV-1 proteinase, and therefore interfere rather after virus penetration during the viral replication cycle, either on the replication or the viral particle budding. Preliminary investigations demonstrate that inhibition is efficient if mAb is added to the culture only during the virus first few following infection. However, no inhibition is observed when mAb is added to the cells 8 h after the infection. Finally, anti 2mAb - mAb also delayed virus appearance since infected HIV cells, but has no effect on HIV-1 proteinase by CD4 cells.

Th.C.P.11

ISOLATION OF HIV-2 STRAINS WITH DIFFERENT NEUTRALIZATION PATTERNS USING CELLULAR, MONOCLONAL ANTIBODY AND RIBONUCLEIC ACID POLYMERIZATION ASSAYS.

**Christine J. van der Vliet¹, Thomas A. Schulz², Hilson Mulliken³
 and Robin A. Weiss⁴.** ¹Institute of Cancer Research, Fulham Road, London, UK; ²Vitic Laboratories, MA, USA; ³The Genie.

Objective: To study the variability of HIV-2 isolated from patients with variable neutralization patterns and to understand the implications of this variability on primary sequence and biological phenotype, a neutralization by sera of different origin, cytopathic effect, tropism for T-cells or macrophages.

Methods: Peripheral blood mononuclear cells from HIV-2 positive individuals in 270 patients were cultured with third blood culture and checked weekly for reverse transcriptase activity. HIV-2 strains were isolated from 120 (44%), CD4⁺ 101 (84%), CD37⁺ were used to cultures showing RT-activity or cytopathic effect to obtain pure cultures. These were characterized by Southern Blot, radioimmuno-precipitation assays (RIPA) and sensitivity to neutralizing antibodies. Fragments of the genome generated by PCR were cloned for sequencing.

Results: Among 4 new permanent isolates of HIV-2 made thus far one from an AIDS patient grows rapidly, one from an asymptomatic individual grows slowly, and the remaining two from SAC patients are intermediate. The former was characterized by Southern Blot and RIPA as HIV-2 viruses. Using PCR, regions corresponding to the gag gene and one portion of the env (HIV-2) could be amplified from 11 isolates. HIV-2 (200) gene and from the gag (1741-3343) could only be amplified from 3 and 1 isolates, respectively. This suggests a marked variability in their susceptibility to neutralizing antibodies from HIV-1 and HIV-2 infected subjects.

Conclusions: Four new isolates of HIV-2 differ in their growth properties and susceptibility to neutralizing antibodies. Genome variability is being analyzed.

Th.C.P.8

THREE DIMENSIONAL ELECTRON MICROSCOPY OF HIV-1 INFECTED MACROPHAGES (IN VITRO AND IN VIVO)

Cah, Hana¹, J. Jendry², J. Fleury³, Ph. Grenier⁴, D. Lussery⁵, M. J. Lys, B. J. Sch⁶
¹ Swiss National Center for Research, Center for Electron Microscopy, University of
 Institute for Immunology and Virology, Zürich, and ² Compagnie Genbi, Switzerland.

³ Laboratoire du Traitement du Signal et Instrumentation, Université de Saint-Etienne, et
⁴ Service d'Anatomie-Pathologique, CHU Henri Mondor, Créteil, France.

Objective: Analysis of the 3-D ultrastructure of HIV-1-infected macrophages in vitro and in vivo (bronchoalveolar lavage) and comparison with similar non-infected cells.
Methods: Computer-aided volumetric ultrastructure based on serial sections (20 to 40 nm) containing laser-induced topographical references allows a 3-D reconstruction of entire cells via digital processing of electron microscopy images.

Results: The 3-D analysis offers an improved knowledge of cell ultrastructure and documents the fine cytophotic effects of HIV. The detailed results will be presented on a computer display.

Conclusion: The computer-aided 3-D analysis has potential advantages and proved particularly powerful in the study of HIV-infected cells. The methodology will be useful to delineate new approaches for evaluation of therapeutic agents.

Th.C.P.10

HIV-1 PROTEINASE INHIBITION BY CERCULIN, HIV-1 REPLICASE INHIBITOR, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase², N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase³, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁴, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁵, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁶, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁷, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁸, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁰, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹¹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹², N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹³, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁴, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁵, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁶, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁷, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁸, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²⁰, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²¹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²², N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²³, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²⁴, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²⁵, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²⁶, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²⁷, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²⁸, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²⁹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase³⁰, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase³¹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase³², N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase³³, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase³⁴, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase³⁵, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase³⁶, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase³⁷, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase³⁸, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase³⁹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁴⁰, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁴¹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁴², N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁴³, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁴⁴, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁴⁵, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁴⁶, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁴⁷, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁴⁸, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁴⁹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁵⁰, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁵¹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁵², N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁵³, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁵⁴, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁵⁵, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁵⁶, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁵⁷, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁵⁸, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁵⁹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁶⁰, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁶¹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁶², N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁶³, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁶⁴, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁶⁵, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁶⁶, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁶⁷, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁶⁸, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁶⁹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁷⁰, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁷¹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁷², N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁷³, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁷⁴, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁷⁵, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁷⁶, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁷⁷, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁷⁸, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁷⁹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁸⁰, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁸¹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁸², N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁸³, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁸⁴, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁸⁵, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁸⁶, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁸⁷, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁸⁸, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁸⁹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁹⁰, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁹¹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁹², N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁹³, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁹⁴, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁹⁵, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁹⁶, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁹⁷, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁹⁸, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase⁹⁹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁰⁰, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁰¹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁰², N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁰³, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁰⁴, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁰⁵, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁰⁶, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁰⁷, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁰⁸, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁰⁹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹¹⁰, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹¹¹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹¹², N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹¹³, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹¹⁴, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹¹⁵, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹¹⁶, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹¹⁷, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹¹⁸, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹¹⁹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹²⁰, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹²¹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹²², N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹²³, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹²⁴, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹²⁵, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹²⁶, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹²⁷, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹²⁸, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹²⁹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹³⁰, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹³¹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹³², N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹³³, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹³⁴, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹³⁵, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹³⁶, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹³⁷, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹³⁸, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹³⁹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁴⁰, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁴¹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁴², N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁴³, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁴⁴, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁴⁵, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁴⁶, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁴⁷, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁴⁸, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁴⁹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁵⁰, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁵¹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁵², N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁵³, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁵⁴, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁵⁵, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁵⁶, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁵⁷, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁵⁸, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁵⁹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁶⁰, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁶¹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁶², N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁶³, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁶⁴, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁶⁵, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁶⁶, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁶⁷, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁶⁸, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁶⁹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁷⁰, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁷¹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁷², N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁷³, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁷⁴, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁷⁵, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁷⁶, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁷⁷, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁷⁸, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁷⁹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁸⁰, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁸¹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁸², N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁸³, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁸⁴, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁸⁵, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁸⁶, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁸⁷, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁸⁸, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁸⁹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁹⁰, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁹¹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁹², N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁹³, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁹⁴, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁹⁵, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁹⁶, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁹⁷, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁹⁸, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase¹⁹⁹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²⁰⁰, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²⁰¹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²⁰², N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²⁰³, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²⁰⁴, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²⁰⁵, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²⁰⁶, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²⁰⁷, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²⁰⁸, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²⁰⁹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²¹⁰, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²¹¹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²¹², N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²¹³, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²¹⁴, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²¹⁵, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²¹⁶, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²¹⁷, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²¹⁸, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²¹⁹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²²⁰, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²²¹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²²², N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²²³, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²²⁴, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²²⁵, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²²⁶, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²²⁷, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²²⁸, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²²⁹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²³⁰, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²³¹, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²³², N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²³³, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²³⁴, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²³⁵, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²³⁶, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Keratinase²³⁷, N-ARYL-AMIDES, N-ARYL-AMIDES, N-ARYL-AMIDES, Ker

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

Th.C.P.19 MOLECULAR INTERACTIONS BETWEEN HIV-4 AND HIV-1 IN COINFECTED CD4⁺ T-CELLS LEAD TO INCREASED HIV-1 GENE EXPRESSION

Essaji, Barbara; Lusso, P.; Schaefer, F.; Rappoport, J.; Josephs, S. and Weiss, R.
Laboratory of Tumor Cell Biology, National Cancer Institute, Bethesda, MD, U.S.A.

HIV-4 can superinfect HIV-1 infected human CD4⁺ T-cells, leading to increased and accelerated cell death. HIV-6 infected cells are also capable of stimulating expression of a reporter gene linked to the HIV-1 LTR. Increased HIV-1 LTR transcription is obtained when HIV-6 infected cells are co-transfected with the HIV-1 LTR gene, or when doubly infected cells are used. In fact, sequences necessary for HIV-1 activation by HIV-6 are distinct from those required for the LTR response and map to a region of HIV-1 LTR where nuclear proteins, activated or induced by HIV-6 infection, specifically bind. Increased levels of HIV-1-specific transcripts are seen by *in situ* hybridization in HIV-6/HIV-1 doubly infected cells as compared to HIV-1 HIV-1 infection. These data suggest that since both viruses, HIV-6 and HIV-1, share similar cell tropism, coinfection of CD4⁺ T-cells may play an important role in the progression of HIV-1 infection to AIDS.

Th.C.P.21 ISOLATION OF HIV IN A HIV-1/HIV-2 DUAL SEROCONVERTED CHILD INFECTED WITH TRANSMISSION CHARACTERISTICS WITR PCR

Roussin, Christine; Bergot, M.; Courauval, V.; Bédou, C.; Gassanq, C.; Berhe, P. et al.
Hôpital NECKER-ENFANTS MALADES, Paris, France.

Objective: By means of a seroepidemiological study among 146 patients multitransfused in Paris, we found one dual seroconversion (S1) with HIV-1 and HIV-2. The Wilkeson disease was transfused on a first and unique occasion in April 1984. We have chosen to use the selective DNA amplification technique by polymerase chain-reaction (PCR) to type the proviral sequences, specific for HIV-1 or HIV-2.

Methods: Sers were tested with both type III ELISA, Western-blot (HIV-1 or HIV-2 from Diagnostic Pasteur) and with polymerase chain-reaction (PCR) in a conserved region of the transmembrane protein. Diagnostic Pasteur. Proviral DNA sequences were modified by PCR using primers and probes for HIV-1 (pnl and env regions) for HIV-2 (gag, env and LTR regions).

Results: The serological analysis of patient's sequential sera (from April 1984 to Dec. 1988) using three specific techniques, shows a true double reactivity for both viruses; a simultaneous double seroconversion between April and May 1984; a profound decrease of anti-p24 antibodies between 1984 and 1988 (to remain the titre of HIV-2 antibodies directed against 20% percent at a high level). DNA proviral sequences were detected by PCR for pol and env regions of HIV-1, and for gag and LTR regions of HIV-2. These results were obtained from the different viruses isolated by coculture and from the peripheral lymphocytes of the patient.

Conclusion: This dual positivity obtained by serology and by PCR in a French patient raises the possibility of a dual HIV-1/HIV-2 infection or of an infection by a dual virus containing both HIV-1 and HIV-2 related sequences.

Th.C.P.23 CHARACTERIZATION OF NEF GENES FROM HIV AND HIV-2

Reau, J. L., Bulter, C.V., Dental, M., Deverosters, M.C., New England Regional Primate Research Center, Harvard Medical School, Boston, MA, USA.

Objective: To compare the nucleotide sequences of NEF genes and to examine the function of the NEF gene *in vitro* and *in vivo*.

Methods: Infectious molecular clones of HIV and HIV-2 were subcloned into pLNCX2 and H13 vectors for sequencing and manipulation. DNA sequencing was performed using the primer extended dideoxy method. Genes were mutated by oligonucleotide directed mutagenesis or by restriction site specific mutagenesis. Virus was obtained by transfecting cloned DNA with DMEM dectran. **Results:** Mutations that alter the size and content of NEF are common in infectious molecular clones. The HIV-2NEF gene contains a 3NA in-frame stop signal 93 codons from the initiating AUG predicting a protein product 658 shorter than that of HIV-1NEF. A premature truncation of NEF is also observed in clones HIV-2NEF251 and HIV-2NEF268. HIV-2 encodes a NEF in which a segment of 15 amino acids are different from the other sequenced NEF genes. The introduction of a frameshift mutation that removes 748 of NEF coding sequences in the HIV-1 cloned virus did not affect the ability to replicate in H978 cells. A single nucleotide has been changed in HIV-239 to create a fully open NEF reading frame in this clone with the properties of HIV-239 with open, truncated and intact NEF genes are being compared both *in vitro* cultured cells and in infected macaque monkeys.

Conclusion: Changes that increase NEF expression occur frequently in infectious molecular clones of HIV and HIV-2. These findings are consistent with the proposed role of NEF in mediating repression of viral gene expression. Mutational analysis of the NEF gene is complicated by difficulties in defining the sequence of functional, wild type NEF.

Th.C.P.20 INDUCTION OF HUMAN IMMUNODEFICIENCY VIRUS EXPRESSION BY ULTRAVIOLET LIGHT

Siddiqui, M. Bazz; Tschacher, E.; Valerio, K.; Rosenberg, N.M.; Felner, B.K.; Pavlakis, S.N.; Wang-Su, F.; "Laboratory of Tumor Cell Biology, National Cancer Institute, Bethesda, MD; *Smith, Kline and French, King of Prussia, PA; **BRI-Basic Research Program, National Cancer Institute, Frederick, MD, USA.

Objective: Recent data demonstrate that ultraviolet (UV) light and certain chemical agents activate transcriptional level of HIV-1 LTR-directed gene expression. We have examined effect of UV on activation of HIV-1 promoter in an attempt to elucidate mechanisms by which UV light may induce a latent virus. **Methods:** We have developed several human cell lines clones each containing a distinct form of a stably integrated 100/200 unspliced HIV-1 provirus. Adherent (H1a) and non-adherent (H9) cells expressing HIV-1 constitutively have been used in amplification of virus release after UV irradiation. UV irradiation leads to activation of HIV-1 provirus which is transmissible to CD4⁺ H9 cells. Characteristic syncytial cells and simultaneous virus propagation comparable to wild type were observed as early as two weeks after UV treatment. UV was highly effective for *lat(-)*, but not for *reg(-)* mutants under identical conditions. **Conclusion:** These findings raise the question of whether natural occurrence of UV light might contribute to the pathogenesis of AIDS. We propose that UV radiation of skin might directly or indirectly activate latent virus resident to human epidermal Langerhans cells and/or subepidermal T lymphocytes.

Th.C.P.22 Binding Characteristics of HIV-1 and HIV-2:

Differences in Binding Inhibition by Soluble CD4 and Dextran Sulfate
H. F. Franghili, G. J. Broder, S. J. Beauford, R. J. and Woung, C. M. and Deaton, J. A., Walter Reed Army Institute of Research, Washington, D.C., *DOD COP, NCI, Bethesda, MD., 3 LTRs, NCI, Bethesda, MD., U.S.A.

Objectives: Examine binding characteristics of different HIV-1 and HIV-2 viruses, and binding inhibition by soluble CD4 (sCD4) and dextran sulfate. **Methods:** Viruses (HIV-1: 89BR, HXII, W83-1, HIV-1-Hiig; HIV-2: 2HIV-2gp, HIV-2gp, SH166 clone IV, and HIV-2g) were labeled using 3,6³H uridine, and binding and binding inhibition assays performed on H9 and Molt-3 cells. **Results:** Binding affinities were similar for HIV-1 and HIV-2, but numbers of saturable binding sites varied eight-fold. HIV-2 viruses were much less susceptible to binding inhibition by sCD4, while OKT4 monoclonal antibody and dextran sulfate inhibited binding of HIV-1 and HIV-2 in an identical fashion. These differences may reflect the involvement of accessory cell surface molecules in HIV-2 binding or penetration; however, differences in the structural relationship or the stability of envelope proteins in HIV-1 and HIV-2 is suggested by the presence of differing ratios of sCD4-detectable envelope protein in purified virions and virus-free supernatants from HIV-1 and HIV-2 infected cultures.

Th.C.P.24 *IN SITU* HYBRIDIZATION ANALYSIS OF HIV RNA INDUCTION

IN U1 CELLS TREATED WITH PHORBOL MYRISTATE 13-ACETATE
Russo, H., Malzman, M., Sellers, B., Sanders, A., Laumann, J. and Rosenzmann, Maurice*
*Egan Biotech, Inc., New York, New York, USA, **Cornell University School of Medicine, New York, New York, USA.

Objective: To determine the kinetics of RNA production following activation of latent HIV infection in cellular level using non-nucleolar RNA. **Methods:** Cultures of U1 cells, which contain 2 copies of latent HIV provirus, were treated with 5 ng/ml phorbol myristate acetate (PMA) and maintained in 5-10X10⁶ cells/ml. At various times, the cells were deposited on microscope slides and fixed with ethanol. HIV RNA in the fixed cells was hybridized to a biotinylated DNA probe that contained the entire HIV genome. The hybridized probe was detected using a streptavidin-alkaline phosphatase complex. The assay was completed in 4-5 hours.

Results: In untreated control U1 cultures, 0.5% of the cells expressed detectable levels of HIV RNA. At 24, 48 and 72 hours after exposure to PMA, the fraction of cells expressing detectable levels of HIV RNA increased to 32%, 67% and 60%, respectively. The amount of RNA per cell varied considerably as indicated by the intensity of staining. Unlabeled cultures contained about 4500 cpm/ml of reverse transcriptase activity. The reverse transcriptase activity increased 19, 4.0 and 3.4 fold at 24, 48 and 72 hours after exposure to PMA.

Conclusion: *In situ* hybridization is a more sensitive indicator of HIV induction than reverse transcriptase activity since the extent of induction observed is much greater. Additionally, heterogeneity at the cellular level is revealed. It is used to study HIV induction under other conditions and to evaluate the effect of various inhibitors on HIV expression.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

Th.C.P.31 GENERATION OF HYBRID HUMAN IMMUNODEFICIENCY VIRUSES
SILVERMAN, ALBERTSBERG*, Kalyanaraman, S.; Deuel, S., Jr.; Dwever, S., Jr.; and Jamson-Near, R.; Centers For Disease Control, Retrovirus Atlanta, Ga. USA, Human Retrovirus Department, Abbott Laboratories, Abbott Park, Illinois, USA.

Objective: To investigate the viral determinants underlying tropism and cytopathic effects of HIV, hybrid HIVs were generated.

Methods: Varying 5' or 3' proviral DNA fragments of biologically infectious HIV clones (HIV₂, HIV₂*, HIV₁ III and HIV₁gag₁) were used as substrates for recombination. The proviral 5' or 3' DNA fragments were introduced into cells by calcium phosphate precipitation method and hybrid viruses released from the cells were quantitated by HIV antigen assay.

Results: Truncated HIV₂ DNA with proviral DNA was transfected into human rhabdomyosarcoma cells, HIV₁ released from the cells were quantitated at the end of 3 and 5 days after transfection. Hybrid HIVs with different 5' and 3' ends were generated using the molecular clones. HIVs were infectious upon inoculation into FRLs and their genetic structures were determined by Southern hybridization analysis.

Conclusion: Construction of hybrid HIVs based on compatible restriction enzyme sites present in viral DNA has limitations because of extensive variability between different HIVs. Homologous recombination methodology provides an efficient alternate method for generating hybrid HIVs.

Th.C.P.33 LOCALIZATION OF THE DEFECT IN HIV PROVIRAL DNA BY HOMOLOGOUS RECOMBINATION
SILVERMAN, ALBERTSBERG*, Kalyanaraman, S.; Butler, Jr. D., Jamson-Near, R.; York, D. and De, B.; Centers For Disease Control, Retrovirus Disease Branch, Atlanta, Georgia, USA.

Objective: Homologous recombination methodology was used to localize the defect in a HIV₂ proviral DNA.

Methods: High molecular weight DNA extracted from HIV₂/HIV III cells was cleaved with the $\text{Eco}I$ enzyme and the proviral DNA was molecularly cloned. Clone designated Xba1 was subcloned in a plasmid vector and tested for the virus production by DNA transfection. Reverse transcriptase (RT) and antigen assays were used to quantitate the virus released from the cells transfected with the proviral DNA. Truncated proviral DNAs were generated using standard recombinant DNA techniques.

Results: The proviral clone Xba1 was transfected into human ED cells. Unlike other proviral DNAs, Xba1 DNA transfected cells did not release virus which could be quantitated by RT assay. In cotransfection experiments with HIV ITR-GAT, Xba1 was able to transactivate the HIV ITR-directed expression as other proviral DNAs. Cotransfection of the Xba1 DNA with other truncated proviral DNAs (5' end) was able to increase the virus antigen detected in the medium. 3' end of Xba1 was inactive whereas 5' end was active in cotransfection experiments involving homologous recombination.

Conclusion: The defect in an HIV proviral DNA was localized by using truncated viral DNAs in cotransfection experiments. This approach narrows the region for molecular analysis to identify the nature of the defect.

Th.C.P.35 DISTINCTION BETWEEN HIV-1 AND HIV-2 INFECTION USING ANTIBODY RESPONSE TO ACCESSORY GENE PRODUCTS
Goudim, Jean*, Dekker, T., Boucher, C., De Ronde, A., Deboux, Ch., Metz, F.

*Human Retrovirus Laboratory, Amsterdam, the Netherlands, **Department of Molecular Genetics, Sanofi-Sintelabo, French Laboratories, King of Prussia, PA, USA, ***Laboratoire de Virologie, INSERM, Strasbourg, France.

Objective: To distinguish HIV-1 or HIV-2 infection by using of response to the accessory gene products: tat, rev, vif and vpr.

Methods: Sera of HIV infected individuals from East-Africa and from West-Africa were tested for reactivity with tat, rev, vif and vpr protein expressed in $\text{Eco}I$ by enzyme-linked immunosorbent assay.

Results: Nine (18%) West-African sera had reactivity to HIV-1 accessory gene products relative to 27 (93%) of the East-African sera. Antibodies to the HIV-1 tat, rev and vpr gene products were significantly ($P < 0.0001$) more often present in East-African sera compared to West-African sera. Antibodies to vif and vpr were completely absent from all West-African sera, but also from 33% respectively 55% of the East-African sera.

Conclusion: These results render typing of the infecting HIV strains solely based on HIV-1 accessory gene product reactivity difficult, but reactivity to vif and vpr may also be discriminating power of type-specific serology by seroprevalence.

Th.C.P.32 FACTORS INFLUENCING HOMOLOGOUS RECOMBINATION BETWEEN HIV DNA IN CULTURED HUMAN CELLS
SILVERMAN, ALBERTSBERG*, Kalyanaraman, S.; Jamson-Near, R.; Deuel, S., Jr.; Deuel, S., Jr.; Jamson, D.-W.; Centers For Disease Control, Retrovirus Disease Branch, Centers For Disease Control, Biotechnology and Cell Biology Branch, U.S.A.

Objective: To analyze recombination between HIV DNAs, optimal conditions were determined using DNA transfection in cell cultures.

Methods: Recombinant plasmid substrates were constructed from HIV proviral DNAs (HIV₂, HIV₁gag₁ and HIV₁gag₂). The success of recombination was measured by DNA production of viable hybrid virus. Polymerase chain reaction method was also used to characterize the cross-over junction.

Results: Substrate DNAs were transfected into cells. The process of recombination between HIV DNAs were shown to be dependent on homology between the truncated HIV DNAs and maximum with the concentrations of the DNA 3 ug which above for both single and double cross-over. Human ED cells at a concentration of 1×10^6 showed maximum hybrid virus production.

Conclusion: Optimal conditions for efficient recombination between HIV DNAs were determined. This is a powerful technique to generate hybrid viruses at any region of the genome.

Th.C.P.34 HUMAN ANTIBODIES TO HIV-1 gp160 INHIBIT ATTACHMENT TO CD4
Bak, Nicola*, Thariat, C., Van der Hoek, L., Bock, C., Goudim, J.*

*Human Retrovirus Laboratory, Amsterdam, the Netherlands, **Department of Genetics, Smith Kline-RIT, Rixensart, Belgium.

Objective: To detect the presence in human HIV antibody positive sera of anti-gp160 antibodies inhibiting the binding of HIV-1 gp160 to the extracellular portion of CD4.

Methods: HIV-1 sera of 264 homosexual men, 20 hemophiliacs, 10 v-druggers and 9 HIV-2 antibody positive sera were tested in a competition immunoassay using soluble CD4 (sCD4). Rabbits were immunized with peptides covering the CD4 binding site or with the neutralizing epitope of the HIV-1 strain HTLV-III.

Results: 18 to 50% of the HIV-1 antibody positive sera from the three AIDS risk groups reduced gp160-CD4 binding by more than 80% at a 1:100 dilution, while HIV-2 antibody positive sera tested did not show such activity in our assay.

Attempts to localize the binding site for these gp160-CD4 inhibitor antibodies on the primary sequence of gp120 by using synthetic peptides incorporating the CD4 binding site on gp120 were not successful. Neutralizing antibodies to the V3 domain of gp120 did not inhibit binding of gp160 to CD4.

Conclusion: Antibodies inhibiting the gp160-CD4 binding were highly prevalent among HIV-1 seropositives and not in HIV-2 sera. They emerge at the moment of seroconversion indicating good immunogenic potential of the domain. Presence of antibodies to an HIV-1 gp160 protein involved in CD4 binding did not hamper or prevent disease progression.

Th.C.P.36 EXPRESSION OF HIV-1 AND HIV-2 IMMUNODEFICIENCY VIRUS GENES IN E. COLI USING A SYSTEMIC TESTS
DEUEL, S., Butler, D., Metz, F., Casey, R., Kramer, D., Sapprecht K., AS

*Human Retrovirus Laboratory, North Chicago, Illinois, USA.

Objective: To obtain large amounts of various HIV-1 and HIV-2 gene products using recombinant DNA technology.

Methods: Genes encoding HIV-1 gag, endonuclease, reverse transcriptase, p17, p15, tat, rev, HIV-2 gag and gp160 were molecularly cloned in E. coli . In some instances genes were chemically synthesized using optimized E. coli in order to maximize expression. In order to obtain large amounts of each of the viral proteins, individual genes were expressed in E. coli using vectors with the lambda p1 promoter under the control of a temperature sensitive cI repressor.

Results: Each of the eight genes was successfully expressed in E. coli . The level of expression in each case was greater than 1% of the total E. coli proteins. The HIV proteins could be readily identified in induced E. coli cultures by coomassie blue staining. The antigenicity of recombinant DNA derived proteins was determined by Western blot analysis as well as sandwich enzyme linked immunosorbent assay using sera from virus exposed individuals. However, control sera showed no detectable reactivity. The availability of HIV-1 and HIV-2 proteins could be effectively used to discriminate immune response to either of the viruses.

Conclusions: The HIV-1 and HIV-2 proteins expressed in E. coli at high levels provide a safe, and efficient source to 1) detect virus infection, 2) monitor various stages of the disease and 3) discriminate HIV-1 infection from HIV-2.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

Th.C.P.37 DISCRIMINATION OF HIV-2 INFECTION FROM HIV-1 INFECTION BY WESTERN BLOT AND RADIOIMMUNOPRECIPITATION ANALYSIS (RIPA)

THOMAS J. HOLZNER, R. G. ALLEN, C. A. HEWEN, M. M. KENNEDY, F. P. KINGOLD, D.A. PAUL, and G. J. DAWSON. Experimental Biophysics Research, Dept. 900, Abbott Laboratories, North Chicago, IL, U.S.A.

OBJECTIVE: To evaluate the use of Western blot and SDS-PAGE RIPA to confirm HIV-2 infection and to discriminate the serological response from that seen in HIV-1 infection.

METHODS: Western blot studies using HIV-1 and HIV-2 virus lysates and SDS-PAGE RIPA using 25S-monoclonally labelled cell lysates were used to identify seropositive blood to be repeatedly reactive to a recombinant HIV-1/2 enzyme immunoassay. 126 specimens from the United States, Europe and Western Africa were tested. Antibody reactivity to specific HIV-1 gp120 and gp46 proteins was determined. Confirmation required the detection of antibodies to both HIV-2 env and gp120 proteins.

DISCUSSION: Confirmation required the detection of specific antibodies to env proteins of only one virus type.

RESULTS: Thirty-one seropositive Western Africa and Europe were confirmed by the presence of antibodies to HIV-2 env and gp120 proteins. Twenty specimens had strong antibody responses to HIV-2 env proteins and weak or absent responses to HIV-1 env proteins. Low-level cross-reactivity with HIV-1 gp120 (gp120) and gp46 (gp46) was noted, including 8 (40%) with reactivity to gp120. Eleven HIV-2 confirmed specimens also had antibodies strongly reacting with both HIV-1 gp46 and env proteins suggesting dual infection. Of 95 Western blot positive U.S. specimens, variable cross-reactivity to most HIV-2 proteins was seen but with reactivity to gp120 able to discriminate at but 7 (7.4%) specimens.

Th.C.P.39 HIV POSITIVE SERA IDENTIFIED WITH SYNTHETIC PEPTIDE ANALOGS OF ENV, GAG, TAT, AND REV

Michael Doherty, G. Cummins, A. S. Espy, S. M. and Doherty, R. M. *MORC Special Unit for AIDS Virology, Fairfield Hospital, Fairfield, Victoria, Australia, and *St. Vincent's Institute, Melbourne, Victoria, Australia.

OBJECTIVE: To identify synthetic peptide analogs that are specifically recognized at the earliest time point after immune recognition of infection with HIV.

Methods: Panels of human seronegative, seropositive and seroconverting sera to HIV were screened for their reactivity to peptides derived from conserved regions of gp120, gp41, p17, tat, and rev proteins using an ELISA.

Results: A peptide to the immunodominant region of gp41 was the most sensitive and specific being recognized by almost all HIV positive sera. Antibodies recognizing rev peptides were detected earlier in seroconversion to HIV than those to either a recombinant antigen based commercial ELISA or the various peptides. Peptides derived from p17 were recognized by both HIV-positive and -negative sera. A tat peptide was recognized by 60% of sera, although no correlation with clinical stage of infection was apparent. **Conclusion:** The results of this study determined the utility of using synthetic peptides to serodiagnose HIV infection. In particular, antibodies to gp41 and rev proteins were recognized in peptide ELISA's before reactivity was apparent with other assays.

Th.C.P.41 GROWTH KINETICS OF HIV IN HIV-1 TRANSFORMED CELLS

Klaeren Boshuizen*, G. Peeters, D. A.; Marechal, J. A. and M. J. M. M. *MORC Special Unit for AIDS Virology, *Virology Department, Fairfield Hospital, Melbourne, Victoria, Australia.

OBJECTIVE: To define replication kinetics of HIV-1.

Methods: HIV-1 cells were infected at an MOI of 1. Samples collected serially were then studied for reverse transcriptase activity, viral core antigen, intracellular retroviral infectious virus, viral mRNA and protein, development of CPE, and cell viability.

Results: Three clear phases of infection were observed: an eclipse phase (7-10d) in which progeny virus and CPE were not observed, an exponential phase of particle release (16-20h) coinciding with the development of early CPE, and the production of viral mRNA and proteins; and from 63-82h, extensive CPE and cell death developed, and intracellular mRNA and protein synthesis increased markedly while the amount of infectious virus released remained stable. This appeared to be associated with the accumulation of virus particles in cytoplasmic vacuoles.

Conclusions: The replication of HIV demonstrated several features typical for retroviruses: a lengthy eclipse phase, slow accumulation of virus and low virus yields. A unique feature was the marked increase in virus-specific mRNA and proteins at the time of cell death, after peak production of infectious virus had been reached.

Th.C.P.38 PHENOTYPES OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) WITH THE ENVELOPE ANTIGENS OF VESICULAR STOMATITIS VIRUS (VSV) OR HERPES SIMPLEX VIRUS (HSV)

Zhu, Z.; Gao, S.; and Huang, A. Harvard Medical School, Boston, Massachusetts, U.S.A.

OBJECTIVE: To identify the formation of pseudotypes during coinfection containing HIV genome coated by the envelope antigens of VSV or HSV, designated HIV(VSV) or HIV(HSV), respectively.

Methods: To prepare phenotypic particles of HIV, we infected HIV RF trans-producing 10 cells with VSV (temperature-sensitive (ts) Ots and thermo-labile (ts) 17 mutants or with HSV-1/2 mutant. CD4-negative HeLa cells were used for infection with phenotypic viruses to maintain HIV(HSV) replication. Anti-VSV or anti-HSV antiserum was used to differentiate HIV(VSV) or HIV(HSV) from HIV(HSV). HIV replication was measured by p24 production or syncytium formation in CH210 cells.

Results: Production of p24 in HeLa cells was significantly reduced when phenotypic viruses were treated with anti-VSV. As a control, anti-VSV did not have an effect on HIV(HSV) replication in HeLa cells. The effect of anti-HSV to block down HIV replication can be verified by passing anti-HSV treated particles through CH210 cells.

Conclusions: These observations indicate that phenotypes of HIV(VSV) or HIV(HSV) can be formed during coinfection. This may be a potential mechanism for the broadening of cell tropism of HIV and for the increased spread of HIV in AIDS patients who are also infected with other viruses.

Th.C.P.40 HIV-1 INFECTION OF HUMAN MONOCYTES IS CELLULARLY INITIATED BY ANTISERA TO HIV-1 OR HIV LPS ACTIVATION OF THE CELLS

Oron, S. A.; Katsenelson, I.; Garrow, S. M.; Vial, P.; Webb, D. S.; and Quinlan, G. V. LER, VPI, Center for Biologic Evaluation and Research, FDA, Bethesda, MD, U.S.A.

OBJECTIVE: To assess the motivating effects of HIV specific antibodies and cell activation on the infection of human monocytes by HIV-1 *in vitro*.

Methods: Elutriated peripheral blood monocytes from normal donors cultured for 7 days in GM-CSF/M-CSF-supplemented media were inoculated with 1 of 5 isolates of HIV-1 (IIIB; SF2; 2 clinical isolates from normal lymphocyte cell lines (04515, 043CEM); or a commercial monocytotropic strain. For studies of neutralisation or enhancement, virus was preincubated with sera from normal or HIV-infected donors. To investigate the effect of monocyte activation, cells were pretreated with LPS. Productive virus infection was quantitated by p24 antigen (p24Ag) ELISA and integrated proviral DNA detected by polymerase chain reaction (PCR).

Results: Infection of monocytes was maintained with each virus isolate for 71 days. Virus infection was neutralized (complete inhibition of p24Ag production and failure to detect proviral DNA) by 0/5 HIV antibody positive (HIV Ab+) sera at dilutions of 1:10 to 1:1000. There was no enhancement of p24Ag production by HIV Ab+ sera at dilutions from 1:10 to 1:10,000. Activation of monocytes with LPS resulted in ≥ 100 fold limitation of p24Ag production.

Conclusions: Human monocytes maintained in GM-CSF/M-CSF-media were susceptible to infection by HIV-1 strains characterized as either lymphotropic or monocytotropic. Activated monocytes were resistant to infection. HIV-1 infection of monocytes was neutralized by HIV Ab+ sera.

Th.C.P.42 MONOCLONAL ANTIBODY IDENTIFIES A CONSERVED EPITOPES OF THE HIV-1 ENV2 AND HIV-1 CORE PROTEIN

Glaser, Ching-Hong Henry, E. and Portales, J. S. Division of Blood and Blood Products, CBER, FDA, Bethesda, Maryland, USA

OBJECTIVE: To evaluate the structure and function of HIV core protein.

Methods: BALB/c mice (female, 10 weeks old) were immunized with partially purified HIV-1 protein containing nucleocapsid, nucleocapsid antibodies (NAbs) against HIV-1 were produced by fusing PRODIGAL 651 myeloma cells with the splenocytes from the immunized mice and screened by enzyme-linked immunosorbent assay (ELISA). The positive hybridomas were cloned and the mAbs were screened by Western blot against HIV-1, HIV-2 and HIV-1 proteins.

Results: Three mAbs against HIV-1 proteins were produced. Two of the mAbs, namely CBER-1 & CBER-2, were of IgG1 subclass; they bound to p24 core proteins of HIV-1 but not HIV-2 or HIV-1 in Western blot. The third mAb, CBER-3, was IgM subclass; it recognized p15 of HIV-1 and HIV-2 on Western blot and reacted with both HIV-1 and HIV-2 in ELISA. Comparison of the protein sequence of core proteins shows that a peptide sequence of CBER-2 in HIV-1 is relatively well conserved in HIV-2 and HIV-1.

Further study shows that: CBER-3 exhibited positive response in ELISA on the plates coated with the synthetic peptide, indicating that the mAb may bind to the core proteins at this conserved epitope.

Conclusion: A mAb reactive with HIV-1, HIV-2 and HIV-1 has been produced and its likely binding epitope on the viral proteins identified. The biological activity of this conserved epitope is now under study.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

Th.C.P.43 ROLE OF OLIGOSACCHARIDES ON THE PROCESSING AND MATURATION OF GLYCOPROTEINS FROM HUMAN T-CELL LYMPHOTROPIC RETROVIRUSES

Ed. Badalita¹, R. G. G. Gallo, R. C. ** and Sarngadharan, M. G. ¹Biostatistics Research, Inc., Rockville, MD, *National Cancer Institute, NIH, Bethesda, MD, U.S.A. ²Obierville. To study the effect of oligosaccharide processing on the maturation of glycoproteins from HIV-1 and HIV-2, cells were immunoprecipitated with specific antibodies and the immunoprecipitates were digested by endoglycosidase H. **Methods:** Metabolically labeled viral proteins from infected cells were immunoprecipitated with specific antibodies and the immunoprecipitates were digested by endoglycosidase H. **Results:** The effects of deoxynojirimycin (DNL), deoxymannojirimycin (DMN) and swainsonin on the maturation of HIV-1 glycoproteins were studied in virus-infected cells and the results are summarized below.

Inhibitor	Enzyme Targeted	cleavage of gp160-gp120	Progeny virus
DNL	Glycosidase I	Inhibited	Inhibited
DMN	Mannosidase I	Normal	Inhibited
Swainsonine	Mannosidase II	Normal	No effect

Treatment of HIV-1 cells with DNL did not affect the maturation of gp160, although the protein had different amounts of mannose-rich oligosaccharide cores.
Conclusion: Primary trimming of mannose-rich oligosaccharide cores in HIV-1 glycoprotein is necessary for infectivity of progeny virus but the cleavage of the precursor takes place before trimming of mannose.

Th.C.P.45 A HUMAN MONOCLONAL ANTIBODY AGAINST ENVELOPE GLYCOPROTEIN OF HIV-1 ENHANCES HIV-1 INFECTION *IN VITRO*

W. Edward Robinson, D. S. Ike, D. C. Montefiori, Y. Masuhara, T. Kawamura, W. M. Mitchell, and E. Herz.
¹Dept. of Pathology, Memphis University, Nashville, TN 37232, USA
²Dept. of Medicine, Arizona Cancer Center, University of Arizona, Tucson, AZ 85719, USA; ³Fejny Ltd, Tokyo, Japan

Objective: To evaluate human monoclonal antibodies (HumAbs) for their abilities to enhance HIV-1 infection *in vitro*.
Methods: HumAbs were generated by fusion of P3x63AgU1 cells with lymph node lymphocytes from ARC patients. Protein-A purified HumAbs were assayed for complement-mediated, antibody-dependent enhancement (C-AD) of HIV-1 infection using an MT-2 cell microtiter infection assay.
Results: One HumAb, V10-9, of seven tested was found to mediate C-AD of HIV-1 infection *in vitro*. This IgG₁ recognized gp160, gp120, and gp41 on western blot and enhanced HIV-1 infection to a dilution of >1:17,486 (28 ng/ml). Enhanced infections were characterized by accelerated appearance of HIV-induced cytopathic effect, increased antigen synthesis, increased reverse transcriptase release, and increased progeny virus production. This HumAb did not neutralize HIV-1 in the presence or absence of complement.
Conclusion: The generation of a HumAb that enhances HIV-1 infection but fails to neutralize HIV-1 indicates that at least some neutralizing and enhancing antibodies recognize different epitopes.

Th.C.P.47 EXPANDED HOST RANGE OF HIV ACQUIRED THROUGH MODIFICATION OF GP120

Stefo Debbaghi, Levy, J.A., Cheng-Mayer, C.
Cancer Research Institute, University of California, San Francisco, CA, USA

Objective: To determine what factors control the cellular tropism of HIV.
Method: The host range of HIV obtained by passage through different cell types was determined by infectivity studies. Genomic variations of HIV recovered were assayed by Southern blot analysis and modification of GP120 examined by glycosidase treatment.
Results: HIV-1 isolated through HUT-78 cells vs. peripheral blood mononuclear cells (PBMC) acquired an expanded host range and replicated better in HUT-78 than the virus from PBMC (Table). Restriction analysis showed that the same virus is present in the different cell types. Furthermore, passage of the virus produced from HUT-78 back through PBMC results in HIV with host range properties of the HIV recovered from PBMC. Studies using carboxymethylated and endoglycosidase indicates that the change in cell tropism of HIV-1 could be related to modifications of the gp120.

HIV-1	Source	PBMC	HUT-78	Ac	CMC	DMT	Restriction	Cloning
73	PBMC	+	+	+	+	+	+	+
73	HUT-78	+	+	+	+	+	+	+
645	PBMC	+	+	+	+	+	+	+
645	HUT-78	+	+	+	+	+	+	+

Conclusion: Glycosylation of gp120 may contribute to the heterogeneity of host cell tropism, suggesting that interfering with glycosylation might prevent infection and spread of HIV.

Th.C.P.44 MAPPING OF THE IMMUNOREACTIVE EPTOPIES OF THE HIV-1 ENDOPEPTIDASE PROTEIN BY MEANS OF RECOMBINANT PROTEINS

Cristina Vives-Martin and N. Mesteir-Lanaux
Institut für Medizinische Mikrobiologie und Hygiene, Abt. Virologie, Klinikum der Universität des Saarlandes Homburg/Saar, FRG.

Objective: To define the major immunoreactive part of the HIV-1 endopeptidase protein.
Methods: The complete reading frame of the endopeptidase (HR AA) from HIV-1 and three subdomains representing the N-terminal, central and C-terminal part of the endopeptidase were cloned into the tryptophan regulated expression vector pATH. After expression four fusion proteins of 64 kD, 52 kD, 46 kD and 48 kD, respectively, were obtained and used for the production of specific polyclonal antisera (68 kD recombinant protein) or as antigens in order to map the major immunoreactive part of the HIV-1 endopeptidase part.
Results: 2/3 out of 27 HIV-1 endopeptidase positive sera predominantly reacted with the C-terminal part of the recombinant endopeptidase and only a few also showed a faint reactivity against the N-terminal part in the western blot. In some cases HIV-1 positive sera which did not react against the p31 of HIV-1 infected Mink-bio cells gave a clear reactivity against the C-terminus of the endopeptidase.
Conclusion: The results suggest that the C-terminus contains the immunodominant epitopes of the HIV-1 endopeptidase. Peptide studies on the mapping of distinct epitopes are under investigation. (Supported by the BMFT grant No. FR/12/031817A).

Th.C.P.46 CORRELATION STUDY INVOLVING THE DETECTION OF HIV-1 IN SAMPLES FROM AIDS PATIENTS USING CO-CULTURE, p24 ELISA, AND TAD- AND PCR-MEDIATED HYBRIDIZATION ASSAYS

Cigerci, Thomas*, Gottlieb, J.**, Kichian, D.**, and Davis, G.**, et al.
¹The Salk Institute Microbiology/Industrial Associates, Inc. (SIIA), La Jolla, California 92037, USA. ²Depts. of Medicine and Pathology, UCSF School of Medicine, San Diego, California 92161, USA.

Objective: Correlation study involving the detection of HIV-1 in samples from AIDS patients using co-culture, p24 ELISA, and TAD (transcription-based amplification system)- and PCR (polymerase chain reaction)-mediated hybridization assays.
Methods: A collection of peripheral blood lymphocyte samples which were characterized as: 1) "+" for both co-culture and p24 assays; 2) "-" for both co-culture and p24 assays; 3) "+" for co-culture and "-" for p24 assays; or 4) HIV-1 negative acid sequences using TAD- and PCR-mediated hybridization assays. For TAD or PCR amplification, detection of amplified products was carried out by a variety of methods, including bead-based sandwich hybridization, Northern and Southern blot hybridizations, and solution hybridization.
Results and Conclusion: These experiments have permitted: 1) the results derived from immunological and culture-based assays to be compared to the results derived from amplification-mediated hybridization experiments; and 2) the comparison of PCR- and TAD-mediated hybridization results. Amplification-mediated hybridization assays results derived from individual patients indicate increasing viral nucleic acid concentrations with time, whereas other assay results (p24 and co-culture) appear more variable.

Th.C.P.48 REPLICATION OF HIV-1 IN A VARIETY OF ANIMAL FIBROBLAST CELLS USING PHENOTYPICALLY MIXED VIRAL PARTICLES

Carlson, Madeline; Hoffman, A.; Hardy, D.; Serraninger, J. and Levy, J.A.
Cancer Research Institute, University of California, San Francisco, CA 94143 USA

Objective: To determine whether the inability of HIV to infect animal cells can be abrogated by enveloping the virus in a xenotropic (X-MuLV) or polytropic (PTX) mouse retrovirus coat, and to study variations in intracellular control of HIV replication.
Methods: Phenotypically mixed particles were obtained by superinfecting X-MuLV or HIV-1 chronically infected HUT-78 cell lines with HIV-1. The progeny viruses were inoculated onto a variety of HIV-resistant animal fibroblast and epithelial cells. Their ability to replicate was assessed by reverse transcriptase activity using both ³²P- and ³⁵S-³ labeled cells, by detection of the HIV p24 or HIV-1 antigens (IFA and ELISA tests), the new ³²P- assay and Western blot techniques.
Results: HIV can be enveloped in an MuLV coat and productively infect a wide variety of animal cell types. Differences in level of HIV replication in various cells were observed.
Conclusion: The major block of HIV infection occurs at the cell surface, but an intracellular regulation of the virus can also be present. Phenotypically mixed viruses may be useful for developing an animal model system for AIDS.

Session d'attaché Poster Session



Recherche fondamentale (Biomédecine) Basic Research (Biomedical)

Th. C.P. 49 THE ANTIBODY RESPONSE TO HUMAN IMMUNODEFICIENCY VIRUS: NEUTRALIZATION VS ENHANCEMENT.

Thomas M. Cheney, M.C. and Lewis J.A. Cancer Research Institute, School of Medicine, University of California, San Francisco, CA, U.S.A.

Objective: To examine whether antibody-dependent enhancement of HIV infectivity could explain the apparent lack of protection conferred by neutralizing antibodies *in vivo*, and examine whether the appearance of enhancing antibodies is associated with progression towards AIDS.

Methods: The sera of 17 HIV-infected individuals comprising asymptomatic, AIDC and AIDS patients were tested for neutralization and enhancement against the patients' own (homotypic) HIV isolates as well as against HIV₀₂₃₃, an established strain which exhibits syngamy and a wide host range. Five patients' isolates were also tested for homotypic neutralization/enhancement in macrophages. Moreover, sequential sera of an asymptomatic, an AIDC and an AIDS patient obtained over a three-year period were tested against homotypic isolates obtained at the same time points.

Results: While all sera neutralized HIV₀₂₃₃ only one had such effect on the homotypic isolates, and one asymptomatic, two AIDC and two AIDS patients enhanced their own isolates. In macrophages, four out of five patients sera (comprising one asymptomatic and 3 AIDS patients) enhanced their own isolates. From the sequential study showed that the asymptomatic patient's early and late sera neutralized both early and late homotypic isolates, the AIDC patient's early and late sera enhanced his early but not his late HIV isolates and that the AIDS patient's late sera enhanced his late isolates, while both his early and late sera neutralized his early isolate.

Conclusions: These results suggest that enhancing antibodies might be an indicator of disease progression and underline the need to establish larger groups of infected individuals to assess for such association.

Th. C.P. 50 ARE THERE MULTIPLE STRAINS OF HIV IN AN INFECTED INDIVIDUAL?

Paul L. Cheng-Mayer, C. and Lewis J.A. Cancer Research Institute, University of California, School of Medicine, San Francisco CA 94143 USA

Objective: To determine whether more than one genetically distinct HIV-1 strain can be recovered from an infected individual.

Methods: Culture the peripheral blood mononuclear cells from a clinically healthy individual who had more than four hundred sexual partners in a 12 mo. Co-cultivate these cells with T and B cell lines, peripheral blood macrophages, CD4⁺ lymphocytes and human fibroblasts. Biologically clone each HIV isolate with sequence homology for different cell types including established T and B cell lines, peripheral blood macrophages, CD4⁺ lymphocytes and human fibroblasts. Molecularly probe each HIV isolate in the cell lines selected. Evaluate the biologic, serologic and molecular properties of the various isolates by cellular host range, cytopathic effects, plaque assays and restriction enzyme analyses.

Results: Ten different HIV-1 isolates were obtained by the above techniques from one individual. All were found to grow to high titer in macrophages and only infected the Sup T and HC 8 cell lines. None of them formed plaques in the MTF cell line. No virus isolates traced HJ17-70, Jurland, or HTLV-III₀₂₃₃ cell lines. No differences in recombination patterns among the HIV-1 strains were observed.

Conclusions: All ten virus isolates showed similar biologic and serologic properties. That molecular properties are under study. The results suggest that this healthy individual is infected with one strain of HIV-1. By its substantial growth in peripheral macrophages, HIV recombination may be favored in these cells. The results suggest that serologic disease, such as AIDS, progression and underlines the need to establish larger groups of infected individuals to assess for such association.

Th. C.P. 51 PARAMETERS INVOLVED IN THE CELL FUSION INDUCED BY THE HUMAN IMMUNODEFICIENCY VIRUS

Isabelle Delbecq, and Lewis J.A. Cancer Research Institute, University of California, School of Medicine, San Francisco CA 94143 USA

Objective: To define the parameters involved in HIV-induced fusion.

Methods: Syncytium formation was measured by cell-to-cell and protein synthesis on cells with HIV₀₂₃₃ chronically infected cells. The detection of lymphocyte markers on cells was conducted by FACs analysis. Nucleic acid synthesis and protein synthesis were measured by ³H-labelled thymidine uptake and ³H-labelled leucine incorporation. HIV viral proteins were analyzed by immunodot analysis.

Results: Optimal cell fusion was observed when chronically infected cells and uninfected cells were used at 1:1 to 1:4 ratios. At the 1:1 and 1:2 ratios the CD4 protein levels with the HIV-infected cell line (the CD4 line) despite the fact that it had a 50% expression of the CD4 antigen. Cell clumping and cell fusion were markedly inhibited by D-glucose, D-mannose, D-galactose at 0.5 M and Dextran sulfate at 50 µg/ml. Con A, but not PHA, was capable of blocking cell fusion. An inhibitor of glycosylation, tunicamycin (5 µg/ml), reduced cell fusion in HIV isolate infection and cell to cell fusion. Treatment of uninfected or the infected cells with the metabolic inhibitors, cycloheximide, actinomycin D, and actinomycin D did not affect the efficiency of cell fusion. The proteolytic aspartases, trypsin and aspartyl-chymotrypsin, efficiently prevented cell fusion in HIV acute infection and cell to cell fusion. Subsequent FACs analysis on the Sup T cells treated with tunicamycin indicated that the CD4 protein had not been removed from the cell surface.

Conclusions: HIV induced cell fusion depends on HIV gp120, the expression of the CD4 protein on the surface of uninfected cells, and the presence of sugar moieties particularly D-mannose. Protein and nucleic acid synthesis are not required for the fusion process. The ability to block fusion with tunicamycin without removing the CD4 protein suggests a receptor besides CD4 is required for the fusion event.

Th. C.P. 52 GROWTH OF HIV-1 AND T CELL SUBSETS IN SEQUENTIAL BLOOD SAMPLES TAKEN FROM A HIV-0 PATIENT BEFORE, DURING, AND AFTER INFECTION

Fazlun-Nasir Warfield, D.J. and Sanderlin, K. Centers for Disease Control, Atlanta, GA, USA

Objective: To evaluate the growth of HIV-1 and the T cell subsets of sequential blood samples taken before, during, and after HIV-0 infection.

Method: T lymphocytes from sequential blood samples were: 1) inoculated with varying doses of HIV-1 and measured for virus growth by reverse transcriptase and HIV-1 antigen assay testing; 2) measured for T subset content by flow-cytometry.

Results: Cells taken before and after illness were normal in HIV-1 growth potential and in total T, CD4 and CD8 parameters. Sample taken during infection indicated over 70% loss of ability to be infected with HIV-1, about 35% loss of total T, about 45% loss of CD4, and about 20% loss of CD8. These results also correlated with the presence of HIV-0 antibody and virus. Antibody in the pre-infection sample was 1:10, converted to 1:100 during infection, and by eight months post infection was 1:100. HIV-0 virus was seen only in the two specimens. Four weeks apart, showing T cell depletion.

Conclusions: During this HIV-0 infection, CD4 cell counts and the ability of the patient's lymphocytes to be infected with HIV-1 are both drastically reduced. Both parameters return to normal soon after illness.

Th. C.P. 53 GOLD-LINKED IMMUNO ASSAY (GLIA): A METHOD IN VIRAL DIAGNOSIS

Geeta, Chatterjee, and Robert Koch

Robert Koch-Institute of the Federal Health Administration, Berlin, FEDERAL REPUBLIC OF GERMANY

Objective: To develop a simple, rapid and cheap method in viral diagnosis (i.e. HIV) allowing to identify antibodies in patient sera as well as viral antigen in culture supernatants.

Methods: Infected suspension culture cells are adsorbed to glass slides coated with Poly-L-lysine or streptococcal plates coated with silver blue and fixed mildly. A drop of patient serum is placed on the cell layer. After incubation the serum is washed off and a drop of gold anti-human immunoglobulin conjugate is placed on the cells. After incubation and washing the colloidal gold undergoes silver enhancement and light microscopic evaluation.

Results: The silver enhanced gold colloids lead to a specific gold-brown or black granular staining of virus producing cells or purified virus incubated with serum containing specific antibodies. Likewise, sensitive erythrocytes attached to a glass slide are covered with an antiviral antibody and subsequently treated with immunogold labeling and silver enhancement. The possibilities and limitations of the method in comparison to well established techniques are discussed.

Conclusion: The gold linked immune assay is a simple and rapid method for screening probes (i.e. sera and tissue biopsies) from patients at risk of infection with HIV or other viruses. The method was presented in a lecture, University of Freiburg, 1988. Manuscript in preparation (J. Virol. Methods).

Th. C.P. 54 CHARACTERIZATION OF PROTEINS ASSOCIATED WITH TWO NOVEL RETROVIRUSES ISOLATED FROM AIDS-ASSOCIATED LYMPHOMA TISSUE

No. Valdez, L., Klayman-Sheff, F., Marsh, J. and McDerm, M.

University of California, San Francisco, and San Francisco General Hospital, San Francisco, California, USA

Objective: To characterize the proteins associated with two retroviruses isolated from primary AIDS-associated lymphoma tissue.

Methods: Non-equilibrium two-dimensional SDS-PAGE, limited Sialophenoloxyl V8 protease digestion, exhaustive tryptic peptide fingerprinting.

Results: We purified 27 and 1009 virus particles from culture supernatants by sucrose density equilibrium gradient centrifugation, and analyzed the proteins associated with the purified viruses. Non-equilibrium two-dimensional SDS-PAGE analysis of radiolabelled 277 and 1009 virus particles demonstrated prominent 27kd and 14kd (BLV). The 27 kd protein (D7A) demonstrated peptide homology (by limited Sialophenoloxyl V8 protease digestion and by exhaustive tryptic peptide fingerprinting) with the proteins of BLV, HTLV-1 and HTLV-2, but did not fit with the p24 of HIV-1.

Conclusions: These data support the isolation of these two retroviruses in the subfamily of oncoviruses.

Session d'affichage Poster Session



Recherche fondamentale (Biomédicale) Basic Research (Biomedical)

Th.C.P.61 INHIBITION OF SYNCTIUM FORMATION WITH LECTINS

Hansen, John-Erik, S. Nielsen, C.M., Nielsen, C., Nygaard, P., Mathiesen, L., Mathiesen, J., *Department of Infectious Diseases, Nivardsgade Hospital, Denmark, **State Serum Institute, Copenhagen, Denmark, ***The Protein Laboratory, University of Copenhagen, Denmark.

Objective: To examine the involvement of the glycane of gp120 in binding to the CD4 receptor.

Methods: Ten different lectins were added to HIV-1 III B infected SP2 cells prior to coculture with CEM cells. Incubations were performed in RPMI 1640 with or without competing monosaccharides. Multinucleated giant cells, syncytia, were counted after 4 and 24 hours using phase-contrast microscopy.

Results: The lectins Concanavalin A, Wheat germ agglutinin, Lens culinaris agglutinin and Phytohemagglutinin blocked or inhibited formation of syncytia. This inhibition was reversible with competing monosaccharides. Lectins acted on HIV-1 infected syncytium formation were: PBA-L, GSA-1, GSA-2, UEA-1, HPA, SBA and PBA.

Conclusion: Lectins which bind to either of the four different glycans of gp120 interact with CD4-gp120 binding as evaluated by formation of syncytia.

Th.C.P.63 CO-INFECTION OF HUMAN T-LYMPHOCTIC CELL LINE WITH HIV-1 AND A NEWLY IDENTIFIED VIRUS-LIKE INFECTIOUS AGENT (VIA)

De, Samir, B. Behar, J. B. S.-C. American Registry of Pathology, Dept. of Infectious and Parasitic Diseases, Armed Forces Institute of Pathology, Washington, D.C., USA

Objective: To determine the effects of the VIA (J Trop Med Hyg, Feb. 1989) on HIV-1 infection in a CD4 positive T-cell line.

Methods: A 301 cell line was infected with HIV-1 (SF8 strain) or VIA or both agents simultaneously. At various times after infection, supernatant samples were harvested from all cultures and assayed for reverse transcriptase (RT) activity, HIV antigen, VIA antigen and HIV infectious titer.

Results: Infection by HIV-1 resulted in the production of HIV antigen, RT and the development of large syncytial cells associated with cell death. RT activity was high during the peak of infection, as was the level of antigen, as determined by the antigen capture assay. In contrast, cultures co-infected with both HIV-1 and VIA demonstrated little syncytial formation, yet cytopathogenesis was present, resulting in a sharp decrease in viability. Although little or no RT activity was detected in the culture supernatants, replicons of HIV-1 occurred during co-infection because the HIV antigen level and infectious titer in the supernatants tested were comparable to samples obtained from cultures infected with HIV-1 alone.

Conclusions: (1) During co-infection, despite the fact that VIA expressed the syncytia, cell death occurred. (2) Infectious HIV was produced in the co-infected cultures. (3) Co-infection with VIA masked the identification of RT activity in cultures produced by HIV infection.

Th.C.P.65 Brain and Blood HIV-1 Isolates from the Same Individual have Different Biological Properties

Wain, Carol L., Cheng-Mayor, C., Sato, D., Levy, A., Cancer Research Institute, University of California, San Francisco, CA 94143 USA

OBJECTIVES: To determine whether virus isolates from the brain and blood of the same individual have different biological properties, and are genetically related.

METHODS: Brain and blood specimens, collected from 8 AIDS patients with neurological abnormalities, were co-cultured with CD4-activated normal PBMC. Virus isolates were tested for their ability to grow in established T-cell lines (HUT, CEM, Jurkat, U937, Sup. T) and in primary macrophages. Neutralization assays with performed using autologous and/or heterologous antisera. Genetic relatedness was assessed by restriction enzyme digests and Southern blot analysis.

RESULTS:

Brain/Blood pairs	SIAD	SIAD	SIAD	SIAD	SIAD	SIAD
1	+	+	+	+	+	+
2	+	+	+	+	+	+
3	+	+	+	+	+	+
4	+	+	+	+	+	+
5	+	+	+	+	+	+
6	+	+	+	+	+	+
7	+	+	+	+	+	+
8	+	+	+	+	+	+

No isolates were significantly neutralized. Restriction enzyme fragment patterns of 55 pairs were similar but not identical.

CONCLUSIONS: Brain and blood HIV-1 isolates from the same individual are variants of each other and frequently have different biological properties. This finding suggests that genetic changes in HIV-1 that occur within individuals are critically important because they can lead to variants that can infect and cause pathological effects in different tissues.

Th.C.P.62 ELECTRON MICROSCOPIC EVIDENCE FOR COINFECTION AND REPLICATION OF HERSHPREVUS AND HIV-1 IN THE SAME HUMAN T-CELL

Kucera, L.; Leake, E.; Baban, David; Fyfe, S.; Myrvik, G. Bowman Gray School of Medicine at West Virginia University, Winston-Salem, NC 27103, USA.

Recent data from our laboratory indicated that unstimulated human leukemia cells (Molt-4, Molt-4, CEM-SS) are permissive for both herpes simplex virus type 2 (HSV-2) and human immunodeficiency virus type 1 (HIV-1). Published evidence (Gendelman et al., P.N.A.S. (USA) 81:1939, 1984) indicates that HSV-2 can transactivates HIV-1 long terminal repeat-directed bacterial CAT gene expression. **OBJECTIVES:** We studied the potential interaction of HSV-2 and HIV-1 viruses. **Methods:** At various times after infection with HIV-1 alone or HIV-1 + HSV-2 we harvested CEM-SS cells for analysis by transmission electron microscopy (TEM) and HIV-1 p24 core antigen expression by ELISA. Results indicated that HSV-2 infection of HIV-1 infected cells through the plasma membrane of cells infected with HIV-1 alone or in combination with HSV-2 at 8 days post infection. Also, we observed HIV-1 particles budding into HSV-2 containing cytoplasmic vacuoles. At 10 days after HSV-2 coinfection HIV-1 p24 core antigen synthesis was stimulated 8-fold compared to HIV-1 infected cell control. In contrast, HIV-1 did not affect HSV-2 replication in the coinfecting cells. **Conclusions:** These data provide the first evidence that HSV-1 and HIV-1 can co-infect and simultaneously replicate in the same human T-cell and that HSV-2 may serve as a cofactor in activation of latent HIV-1 infections.

Th.C.P.64 CHEMICAL INDUCERS OF CELL DIFFERENTIATION INHIBIT HIV REPLICATION IN VIVO

Cherif, M.; Khandoukhan, A.; Abshadi, D.***
Vila, Imitator, S.G.*** and Vlach, J.***

*Fondat de Médecine, 75006 Paris, France, **R.I.B. / R.C.I., Laboratory of Cellular and Molecular Biology, Bethesda, Maryland, U.S.A., ***I.I.B. / N.C.I., Laboratory of Tumor Cell Biology, Bethesda, Maryland, U.S.A., ****I.P.L. Laboratories, Barcelona, Spain

Objective: Investigate the effect of Chemical Inducers of Cell Differentiation (CID) on HIV-infected cells.

Methods: Four chemicals known to induce cell differentiation changes in vitro - dimethylsulphoxide, dimethylformamide, pyridine-oxalide and butyric acid - were used for the incubation of two lymphoblastoid cell lines - HDV7 and MOLT 4 - infected with HIV. Their effect was assessed by evaluating the amounts of p24 and RT activity in the Tissue Culture Medium (TCM).

Results: The four compounds used to pre-incubate the lymphoblastoid cells tested failed to prevent viral infection and they also failed to inactivate the virus in vitro. In contrast, they did inhibit viral replication within the infected cells. The observed effect is dose-dependent and transient. HIV-1 replication resumes after the removal of the compounds from the TCM. The infected cells in presence of CID express p24 antigens on their cell surface despite the inhibition of viral replication.

Conclusion: CID had a virostatic effect on HIV-infected cells in vitro. Further studies investigating the in vivo activity are thus warranted.

Th.C.P.66 INHIBITION OF THE MATURATION OF HIV STRUCTURAL PROTEINS BY A PEPTIDE INHIBITOR

Harroberts, L.**, Wilson, S.**, and Oermann, P.C.**(1)

(1) Institut de Recherches sur les Sérovirus et Maladies Associées (I.R.S.M.) - Centre de Recherches sur le SIDA - Institut Pasteur de Paris

(2) Laboratoire - Centre de Montpellier - Rue de St. Pierre - 34293 Montpellier Cedex 9 - France.

The protease encoded by the Human Immunodeficiency Virus (HIV) pol gene, cleaves the gag-pol protein precursor and plays an important role in the viral replication cycle of HIV.

The HIV protease belongs to the family of aspartyl-proteases, as peptidyl or peptidyl-like inhibitors.

Peptide synthetic peptides based on the amino acid sequence of the HIV-1 protease were used to inhibit the protease in vitro.

This specific also inhibited viral production by the CEM cell line, since no reverse transcriptase activity was detected and no viral antigen was revealed by immunofluorescence during several weeks after infection by HIV.

Nevertheless, when the inhibitor peptide was removed from the culture, infectious virus particles were produced after a few days.

These results demonstrate that specific inhibitors of protease can block HIV-1 infections by HIV and provide possible strategies against AIDS.

**Session d'affichage
Poster Session**



**Recherche fondamentale (biomédicale)
Basic Research (Biomedical)**

Th.C.P.67 HIV DOWN-REGULATES ITS CD4 RECEPTOR BY TWO DIFFERENT MECHANISMS

Stropia P., Olivier H., Riviere Y., Montagnier L., Guetters JC., Kloterman D.
Hopital Pit-Salpeatriere, Institut Pasteur, Paris, *Gadon, Strasbourg, France.

Using mAb's and a genomic probe to the CD4 molecule, the HIV receptor, we demonstrated that HIV regulation involved the disappearance of its functional receptor from the cell surface by two distinct mechanisms. First, after being expressed onto the cell surface, HIV envelope glycoprotein CD4, efficiently masking the CD4 epitopes used by the virus to bind its receptor. This phenomenon occurred on the surface of each HIV-infected virus expressing a mutated HIV env gene designed to prevent gp120 release from the cell surface induced a similar gp120 complexes formation. Second, virus replication induced a dramatic reduction of CD4 expression, preventing new CD4 molecules from being synthesized. One possible explanation of this phenomenon could be the negative regulation of CD4 expression by HIV replication. An expression vector containing a reporter gene under the control of a -500 genomic sequence upstream to the CD4 gene transcription start site, which includes the putative CD4 gene promoter, has been constructed to test this hypothesis. Modulation of the reporter gene expression after infection of the cells with various HIV genes expression vectors are currently being analyzed. The possible down-modulation of CD4 expression by HIV is a novel phenomenon which occurs during T-cell maturation and may provide new approaches to study HIV infection. This study may provide new insights in understanding the molecular mechanisms of viral infections.

Th.C.P.68 PRODUCTIVE HIV-1 INFECTION OF HEPATOCELLULAR CARCINOMA CELLS (HCC) LINES *IN VITRO*

Cap. Tsubouchi*, Friedman-Sles, A.K.M., Wang, T.X.H., Li, J.L., Hissballe, R.J., Tucker-Franklin, D.S. and Ho, D.D.*. *New York University Med. Center, NY; **McGill Univ. Med. Center, Montreal, Quebec, Canada.

OBJECTIVE: To determine the *in vitro* susceptibility of HCC lines to infection by different strains of HIV-1.
Methods: Five HCC lines, including CCMC-4371, PLC, Hep3B, HepG2 and HEP7 were inoculated with 3 diverse isolates of HIV-1 (CMV-IIIb, HT, and AL) at multiplicity of infection ranging from 0.002 to 20. HIV-1 expression was monitored by detection of p24 antigen and RT activity in culture supernatants weekly for up to two months, & by immunohistochemical staining, an RNA hybridization, & electrotransfection (ET) performed on the cells at Day 248, 3 & 7 days after virus inoculation. The presence or absence of CD4 on HCC lines was shown by immunofluorescence using anti-CD4 monoclonal antibodies.
RESULTS: Five HCC lines were found to be susceptible to productive infection by three strains of HIV-1 *in vitro*. Expression of HIV-1 p24 lasted for over 100 days and decreased in proportion to the number of viable cells. ET was also found in the cells by RT staining, as were viral RNA by *in situ* hybridization and HIV-1-like particles by EM. Ten supernatant samples were found to be positive for HIV-1 p24 antigen and RT activity was not detected, and range of infectious HIV-1 from culture supernatants with HIV-1 was found to be negative to date. Tests by immunofluorescence, infection, all 5 HCC lines were negative for CD4 expression.
CONCLUSION: CD4-negative HCC lines are productively infectible *in vitro* by HIV-1 via an unknown pathway. Further, the replication of HIV-1 in HCC lines may be incomplete, and HIV-1-like particles found in the HCC lines may represent defective viruses.

Th.C.P.69 QUANTIFICATION AND CELLULAR DISTRIBUTION OF HIV PROVIRAL DNA IN HIV POSITIVE INDIVIDUALS

Simon, J., Pagan, J., Feulner, J., Leigh-Brown, A.J., Bishop, J., and Lamm, G.A., et al.
*University of Edinburgh, *Royal Infirmary, Edinburgh, Scotland, UNITED KINGDOM

A PCR method has been developed that detects individual molecules of HIV DNA in several micrograms of cellular DNA. This has allowed an analysis of the quantity and cellular distribution of HIV-specific DNA in buffy coat samples from seropositive haemophilic patients. Serial dilutions of DNA prepared from buffy coat cells were tested by the PCR and the number of copies of HIV DNA measured. This figure was compared with the proportion of cells containing HIV RNA, obtained by a titration of the buffy coat cells themselves prior to RNA extraction. To corroborate these data, the number of HIV DNA molecules in each of the isolated single cells could be determined by further dilution and retesting of the DNA prepared from each. Results have shown that relatively few buffy coat cells contain HIV-specific DNA, although this is variable between patients and those cells that are positive have a relatively high copy number. Prior cell separation allows a similar analysis to be made on different cell types. Finally, primers spanning the junction on circularization of HIV DNA in the cell can be used to show the configuration of the individual HIV DNA molecules found within each cell.

Th.C.P.70 HIV DNA SEQUENCES DETECTED BY PCR IN SERONEGATIVE, YET ANTIBODY POSITIVE, INDIVIDUALS

Frangou, L., Montagnier, L., Cougnard, V., Chamerat, S., Ragnan, M., URS CHU Necker, Paris, *Hydrobiostat et **Unité d'Oncologie Virus, Institut Pasteur, Paris, ***Diagnostic Pasteur, Marnes la Coquette, ****Service d'Immunologie, Hôpital Salpêtrière, Paris, France.

Objective: To investigate the presence of HIV DNA in seronegative individuals at risk of HIV infection.
Patients: 6 subjects: 2 sexual partners of HIV positive subjects, 2 haemophilic, 2 with lymphomas (one Hodgkin lymphoma 1 NHL). In addition 2 antibody negative patients (1 with T cell lymphoma and 1 sexual partner of a seronegative anti-HIV positive subject) were tested.
Methods: PCR with 40 cycles and 3 sets of primers (Pol and env genes). Anti-env were detected through western-blot using a recombinant env protein (Frangou).
Results: HIV DNA sequences were identified in 5 of the 6 anti-env positive subjects. This included 1/2 haemophilic, 2/2 sexual partner of HIV+, 2/2 NHL lymphomas. In addition HIV DNA scored + in 2/2 anti-env negative subjects with T cell lymphoma and sexual partner.
Conclusion: This study I) indicates the possibility of HIV infections in apparently seronegative yet anti-env positive subjects, 2) will lead to further investigate the potential implications of HIV DNA and anti-env positivity in some subjects with lymphomas.

Th.C.P.71 SEQUENCE ANALYSIS OF A HIGHLY CYTOPATHIC STRAIN OF HIV-1: CORRELATION BETWEEN BIOMOLECULAR AND GENOMIC VARIABILITY

Wills, R., Hill, J., Roberts, C. and Cameron, J. et al.

Units in Edinburgh (EH8) and New Britain (NS) are HIV seropositive individuals who are HIV-1 positive. A highly cytopathic strain of HIV-1 was isolated from a patient with AIDS. This isolate is 10⁶ times more cytopathic and more infectious than the prototype, in order to correlate the high cytopathic properties of this strain with relevant genetic variations we have cloned and sequenced the HIV nucleotides of this isolate and compared the deduced amino acid sequence with those of other isolates. The principal feature which could be deduced from the time analysis of the HIV-1B sequence is that variability is not observed in one particular region but rather spread out all along the gene. The maximum of variability was as expected in the external glycoprotein gene. Representative variants were detected at the same position in other isolates. The region responsible for the binding with the CD4 molecule was highly conserved, but participation of the hypervariable region to a stabilizing effect on the CD4 molecule could not be assumed. Furthermore a small deletion of three amino acids was identified in the C-terminal part of the P24 nucleocapsid protein which could be involved in the cytopathic effect. Alignment of the viral regulatory proteins of HIV-1B and other HIV-1 variants did not show any major differences. It is in the 5' part of the 5' UTR region, which had been proposed as the target for negative regulatory elements where the major variability has been found.

Th.C.P.72 Susceptibility to HIV-1 Infection of a Human B-Lymphoblastoid Cell Line, D27, Transfected with Subgenomic DNA Fragments of EBV, Daefer, Simon, Goldfarb, Matar, Hill, Ted, Akhshi, Sharma, Joseph, Steven, Galahudin, Zakl

*Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA. *Fagarty International Center, National Institutes of Health, Bethesda, Maryland and Hebrew University, Jerusalem, Israel.
We have previously shown that the presence of the EBV genome and active EBV infection in some Burkitt's lymphoma cell lines confer the susceptibility to HIV-1 infection in spite of the absence of surface CD4 receptors in these cells. In the present study we used an EBV genome negative Burkitt's lymphoma B-cell line, D27, transfected with three different subgenomic fragments of EBV expressing the nuclear antigens (EBNA) and EBNA2 and the latent membrane protein (LMP), respectively. Immunofluorescence analysis demonstrated CD4 expression in more than 80% of the EBNA1, EBNA2 and LMP transfected cell lines, whereas the antigen could only be detected in less than 4% of the parental D27 cell line. Unlike the wild type D27 line the three transfected cell lines were found to be susceptible to HIV-1 by both iFA and production of viruses. Northern blotting of poly(A) selected RNA of the four cell lines hybridized to a human CD4 cDNA(p748) demonstrated a 3kb band in all three EBNA1, EBNA2 and LMP transfected cells as well as in the wild type D27 cells. Approximate quantitation indicates equivalent level of T4 mRNA expression in the transfected cell lines as compared to T-cell lines (Hut-78, HP-8).

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

Th.C.P.79 **Dideoxynucleoside Prevent Formation of HIV-1 Provirus During Single Cycle Infection of Macrophages**

James B. Mullis, R.S. Kornbluth, and D.D. Richman.
Departments of Medicine and Pathology, University of California, San Diego, and Veterans Administration Medical Center, San Diego, CA, USA 92161. Dideoxynucleoside (ddI) previously has been shown not to inhibit low level replication of the lymphotropic LAV-1 strain of HIV-1 in primary human macrophages. In contrast, AZT markedly inhibits the replication of a macrophage-tropic strain of HIV-1 (HTM-III_{MAC}) which replicates to high titers (2×10^6 copies/ml) in primary macrophage cultures. The effects of 1 μ M AZT on the replication of this LAV-1 strain in macrophages was examined using a high multiplicity infection. In the absence of AZT infection. At several time points after infection, cells were harvested and viral nucleic acids were assayed by PCR amplification of a conserved HIV-1 sequence. In the presence of AZT, provirus DNA (provirus) could be detected by 12 hours after infection, approximately concurrent with the release of viral p24 antigen into the supernatant. In the presence of AZT, no viral DNA or new p24 antigen was detectable during the five day incubation. AZT infection, approximately concurrent with the release of viral p24 antigen into the supernatant, in the AZT treated cells, viral RNA was continuously present for 48 hours, when it began to decrease steadily during the remainder of the incubation. We conclude that (1) the replicative cycle of this HIV-1 strain in macrophages is approximately 12-24 hours, (2) AZT prevents the formation of HIV-1 provirus in this system, and (3) virion input RNA, in the absence of viral replication, persists in macrophages for more than 48 hours.

Th.C.P.81 **SEQUENCING OF PCR-AMPLIFIED HIV-1 RELATED SEQUENCES FOUND IN THE DNA OF INFECTED FROG, BENTAL, AFRICA**

Moussy, Maurice, J.L.; Becker, J.C.; L'Homme, M. and Montagner, M.

* Unité d'Oncologie Virale, Institut Pasteur, Paris, France; ** Laboratoire de Virologie Moléculaire, Université Paris VII, Paris, France.

Objective. To detect HIV-1 related sequences integrated into the DNA of African Insects and to investigate their nature and origin.
Methods. Classical molecular hybridization techniques were first used for the detection of the considered sequences; i) south-blot, dot-blot, Southern transfers. For the PCR amplification, we designed primer-oligonucleotides in the gag, env and nef genes. The amplified materials were sequenced with the Max-EMBASE[®] and non-biased primers, following the technique of Sanger.
Results and conclusion. Screening of more than 200 insects captured in Central Africa has revealed, using molecular hybridization techniques, the presence of HIV-1 related sequences in the DNA of insects belonging to numerous species. However, HIV-1 PCR generally hybridizes only the EcoRI fragments of 4.5 kb and of 3.5 kb in the insect DNA. This pattern is not in agreement with the restriction map of the described members of the HIV family. We used PCR to amplify these sequences in the gag, env and nef genes. The PCR-amplified DNA was directly sequenced by a new technique using non-biased primers and the Taq-polymerase allowing a higher temperature of reaction, which overcomes the blocks induced by secondary structures of the DNA. Sequence results with evidence of important rearrangements in the env gene, will be presented.

Th.C.P.83 **Multiple Sclerosis and Retrovirus: Screening with retroviral probes of cDNA library constructed with poly A+ RNA from active lesions.**

S. Lefebvre, J. Barrea, S. Charneau, M. Baron.
Laboratoire de Virus Latents, Département de Virologie, Institut Pasteur, Paris, France.

Multiple sclerosis (MS) is a chronic neurologic disease of unknown etiology. The inflammatory demyelinated lesions (plaques) are found in the central nervous system (CNS). Briefly, in MS plaques the oligodendrocytes that are producing the myelin sheath are destroyed leaving naked axons exposed.

One of the best animal models for MS is a demyelinating disease in sheep caused by virus. Virus virus belongs to the retrovirus subfamily of retrovirus and is related to HIV. Recently, another retrovirus was shown to be associated with chronic neurologic disorders. Studies indicated that the oncovirus HTLV-1 has a causal role in tropical spastic paraparesis (TSP) as well as in chronic progressive myelopathy. Attempts were also made to associate HTLV-1 with MS. The results were limited and inconclusive. Since three of the four known human retroviruses can cause neurologic disease, we try to identify retroviral nucleic acid from MS plaques.

RNA was isolated from 10 MS plaques. Purified poly A+ RNA was used to construct a cDNA library in lambdagt10. Low stringency hybridization with specific retroviral probes was used to screen the library for retroviral cDNA clones and topoisomerase. However, these preliminary results will be discussed in regard that they do not exclude the possibility of a new retrovirus.

Th.C.P.80 **IDENTIFICATION OF gp120 FROM HIV BY A "COUPURE" ELISA.**

Aboukhalil, Y., Frickinger, T., and Villacres, M.
Biomedical Center, RM 855, 8-7523 Uppsala, Sweden.

Objective. To develop a sensitive and quantitative test for gp120/gp160 from HIV-1.
Methods. Polyclonal anti gp120 sera were produced by immunizing rabbits with HIV gp120 in Freund's adjuvant. The serum was used as "coupure" antibody. Detection of gp120/gp160 was done by an indirect method using a panel of monoclonal antibodies reacting with gp120 and gp160. The monoclonal antibodies were detected with horse radish peroxidase conjugated rabbit anti mouse antibodies. The monoclonal antibodies were conjugated and attached in our laboratory from spleen cells from mice either immunized with native gp120 or gp160 from vero cells infected with a viraemia virus vector.

Results. We were able to detect gp120/gp160 from cells from different sources with HIV gp120 in culture fluids and HIV infected cells. The detection limit was around 0.5ng. The gp120/gp160 "coupure" ELISA allowed routinely to measure the production of gp120/gp160 in vero cells infected with a viraemia virus vector. The ELISA is also used to determine the yield of gp120 incorporated into 350 experimental/inoculum vaccine. One of the monoclonal antibodies used for the detection of gp120/gp160 recognizes a loop region (aa 303 to 338) and neutralizes the HIV RNA in vitro. The gp120/gp160 "coupure" ELISA we have developed is sensitive with a detection limit of 0.5ng. The ELISA is routinely used for screening of HIV envelope gp120/gp160 content in cell cultures.

Th.C.P.82 **IMPROVED ASSAY FOR DNA-POLYMERIZING ENZYME, BY THE USE OF 3'-NH₂-LIGOCYANURIC TRIPHOSPHATE, ILLUSTRATED BY DIRECT QUANTIFICATION OF HIV-RT ANTIBIOTIC (AR).**

Neuillier M., Karimza A.R., Kallender C.R., J.L. L'Homme, M., B. Baron, M., and J. Barrea, S.
Dept of Molecular Virology, Uppsala University, Box 502, S-751 23 Uppsala, Sweden.

The design of a procedure to synthesize 3'-NH₂-UTRP in one step from 3'-NH₂-UTP, followed by a one-step purification giving an all-over reaction between 30-70% and a 3500 new product within 8 hours is described. The sensitivity and specificity for the 3'-NH₂-UTRP compared to 3'-ATP assays was evaluated with different specimens, including purified recombinant HIV-RT. The 3'-NH₂-UTRP was accepted equally as well as 3'-ATP and depending on enzyme specific a 100-fold increase in assay sensitivity was found when using 3'-NH₂-UTRP at low substrate concentration. Thus the new assay could detect HIV-RT activity from CD 84HD-infected cells, while 0.2610⁶ c.f.u. were needed for detection of purified recombinant HIV-RT. Due to the small HIV-RT amounts necessary for detection, it was possible to quantitate HIV-RT_{ab} without previous purification of immunoglobulin. Analyses of 33 HIV-infected individuals showed that 0.02-0.16% activity corresponded to a 100-fold less immunoglobulin (i.e. all but 21 ng/ml) than earlier reported.... It is concluded that 3'-NH₂-UTRP simplifies the assay, by excluding the need of Triton-precipitation and of scintillation cocktail, and that it is an excellent substrate for improved detection and quantitation of different DNA-synthesizing enzymes, and thus also for their blocking ab.

Th.C.P.84 **A SINGLE TUBE, ONE-STEP PURIFICATION AND ASSAY FOR THE ANALYSIS OF REVERSE TRANSCRIPTASE ACTIVITY (RT) IN CRUDE SPECIMENS AND SOME APPLICATIONS WITH REFERENCE TO HIV.**

Bronckovitz J., Simão, Neuillier M., Barrea, S., Frickinger T., and Kallender C.R.
Dept. of Molecular Virology, and Dept. of Molecular Biology, Uppsala University, Box 502, S-751 23 Uppsala, Sweden.

Based on 3'-NH₂-UTRP as a substrate (see abstract), a further simplified and improved procedure for quantitation of HIV₁ using solid-enclosed template, has been designed. In principle, the assay sample is mixed with a reaction solution containing the radiolabeled substrate and other necessary components, one after the solid-enclosed template is added. Next the reaction proceeds for desired time, whereafter the product is separated from substrate by washing the solid phase with a salt solution. Then the incorporated radioactivity is directly measured in a counter. For the analyses of RT activity in crude specimens, containing disturbing substances or enzymes like DNase, TPase etc, the assay is improved by adding a primary step as follows: the specimen is first added to the solid-enclosed primer template and kept for 10-20 min at 4°C in order to let the RT bind to the template, next the disturbing factors are washed away, whereafter the amount of RT on the solid phase is determined by adding radiolabeled substrate and further proceeding as indicated above. Further, data showing that the assay can be improved by addition of ribonuclease inhibitors and addition of 50% will be given. Analyses using Sepharose or plastic beads as solid phase have been done, and a high recovery of activity from mixtures of recombinant HIV-1 with immunoprecipitated or crude clinical extracts was obtained. Further analysis of clinical specimen are given in abstr. ()

Session d'affichage
Poster SessionRecherche fondamentale (biomédicale)
Basic Research (Biomedical)

Th. C.P.85 CHARACTERIZATION OF AN HIV-2 RELATED VIRUS WITH A SMALLER SIZED ENVELOPE PROTEIN
Kozak, Ruzsa, Roy, M.A., Laurent, A.G., Gesteau, D., Monagnier, L. and Horvathian, A.S.
Unité d'Oncologie Virale, Institut Pasteur, Paris 15, France.

Objectif: A new cytopathic isolate of the human immunodeficiency virus (HIV) related to the HIV-2 strain was isolated (HIV-2 MAN) from peripheral blood lymphocytes of an Ivory Coast patient with AIDS.
Résultat: HIV-2 MAN could be differentiated by its envelope precursor and external glycoprotein which are 20kD molecular weight smaller than those of HIV-2 ROD isolate. Furthermore, the apparent molecular weight of the major core protein of HIV-2 MAN is 27kD instead of 36kD as in HIV-2 ROD isolate. In addition, the product of the *gag* gene which is a characteristic feature of the HIV-2 strain, is 14kD in precursor of HIV-2 MAN compared with 16kD in HIV-2 ROD. In contrast to these, the envelope of HIV-2 MAN is 27kD instead of 36kD as in HIV-2 ROD isolate. It is the case for HIV-2 ROD. In both cases the transmembrane proteins are 36kD and exist as homodimers of 36kD. No RT digestion experiments indicated that the 20kD difference between the two HIV-2 isolates is due to their polyepitopic moiety. Furthermore partial proteolytic with 1% protease gave two distinct polypeptide patterns, thus suggesting the difference between the external envelope proteins of the two HIV-2 isolates are due to their amino-acid composition. Accordingly, polyepitopic raised against HIV-2 ROD envelope do not recognize the corresponding envelope proteins of HIV-2 MAN by immunoblotting and immunoprecipitation assays.
Conclusion: These data illustrate that analysis of viral proteins could be useful for a rapid and an efficient method to characterize new HIV isolates.

Th. C.P.87 INFECTION AND REPLICATION OF HIV-1 IN HUMAN
NEURO-GLIAL AND PERIPHERAL
T-CELL RECEPTOR-MACROPHAGES

REIN, S., WILSON, D., PRINCE, R., GORVING, J.C.

Unité de Neurobiologie INSERM et les Unités de Neurologie Neurochimie (U-322) - Centre de l'Enfermé - 93 231 - 13200 NANTERRE Cedex, France

Objectif: To characterize the site of replication, localization and transmission of HIV in neurons - macrophages (CM).
Résultat: HIV-1 was found by plaque formation, *in vitro* trans-activator (Tat) gene and RNA detection in both CD4+ T-lymphocytes and in CD4+ macrophages (CM) from healthy donors and from infected *in vitro*. Cells were monitored for HIV by reverse transcriptase (RT), electron microscope (EM) and sensitive DNA detection techniques.

Conclusion: HIV virus expression monitored by RT, was never detected in striatum cultures of HLA-B2 microglial cells *in vitro* or *in vivo*. Structures with a sensitive cell line (CM) or normal PM-180 cells, after freezing - thawing the adherent cells, allowed virus detection. Efficient blockage of virus infection on PM-180 was obtained using low concentrations of human HIV neutralization sera and various monoclonal antibodies (mAb) against CM (13B-2). These mAbs directed against different CM epitopes are currently investigated. In the absence of a high amount of viral particles included into immunological vesicles of HLA-B2 while no mAb was present. Furthermore, no neuronal budding has been seen on the same cells. Preliminary results using Western analysis indicated that viral DNA was not incorporated in infected HLA-B2.

Th. C.P.89 EXPRESSION OF VIRAL AND CELLULAR GENES IN CELLS INFECTED BY THE HUMAN IMMUNODEFICIENCY VIRUS, HIV-1, AND THE SIMIAN IMMUNODEFICIENCY VIRUS, SIVmac.
Klein, R., Berman, R.S., Hoenes, R.L., Roy, K.J., Gray, L.J., Kay, M.A., I. Department of Microbiology, University of Washington, Seattle, Washington; Regional Primate Research Center, University of Washington, Y-10 of viral pathogenesis, NCI, Frederick Cancer Research Center, Frederick, Maryland, U.S.A.

The current study was undertaken to define the complex regulatory events occurring *in vivo* in CD4-positive lymphoid cells infected by HIV-1 and SIVmac. Initial efforts were directed at measuring viral and cellular mRNA and protein levels in HIV-infected CD4 cells. Northern blot analysis revealed that viral-specific mRNAs could be detected as early as 2 days after infection of CD4 cells by HIV-1. Maximal accumulation of the major species of viral mRNAs occurred by 5 days post-infection (PI). In accordance with these results, the synthesis of viral-specific proteins was readily detectable at 2 days PI and peaked essentially at 4 and 5 days PI. Immunofluorescence studies showed that >95% of CD4 cells are infected by 4 days PI. Cell viability studies, using trypan blue exclusion, demonstrated that 75% of infected cells were still viable at 4 and 5 days PI. We next examined the effects of HIV-1 infection on cellular mRNA and protein synthesis. The steady state levels of actin and GAPDH mRNAs steadily declined during virus infection with actin mRNA levels down ten-fold by 5 days PI in HIV-1 infected CD4 cells. There was a corresponding progressive decrease in cellular protein synthesis during infection at the time when viral protein synthesis was found to peak. In parallel studies, we examined the kinetics of viral protein synthesis in cells infected by SIVmac. In contrast to the results obtained with HIV-1, little or no viral protein synthesis was detectable in SIV-infected CD4 cells. However, in SIV-infected CD4 cells, high levels of the SIV-specific proteins were detectable by 2 days PI. As was the case in the HIV-1 system, overall levels of cellular protein synthesis declined during infection of CD4 cells. Efforts are in progress to delineate the mechanisms responsible for the decreases in cellular mRNA and protein levels in HIV- and SIV-infected cells.

Th. C.P.86 NEW TESTS USING SYNTHETIC PEPTIDES IN THE DIAGNOSIS AND TYPING OF HIV INFECTIONS IN HUMAN.

MAITIN, Jean-M., BERTHOUD, S., ADDA, O., TSAI, F.C.P., RICHARDSON, C., GOMAS, J.
*CLONATEC 40 Rue de Valenciennes 75008 Paris France
**SYNTO, S.A.R.L. 08020, CA, USA

Objectif: Monoclonal ELISA using 4 synthetic peptides derived from transmembrane glycoprotein of HIV-1 and HIV-2 were optimized. One shows no cross-reactivity (TOTAL HIV Ab (1-2)) and the other one allows to type specifically and HIV-1 and anti-HIV-2 antibodies (TYPING HIV AB (1 or 2)).
Method: The TOTAL HIV Ab assay involves microtiter wells coated with a blend of the two HIV-1 and HIV-2 peptides and the TYPING HIV AB involves microtiter wells coated with HIV-1 peptide only and assays coated with HIV-2 peptide only on the same plate. The duration of the test is 35 minutes long (15 min. serum incubation, 15 min. conjugate incubation and 5 min. color development).
Résultat: In a preliminary study, 302 sera were tested: 191 and HIV sera and 111 negative sera. Among the 191 positive sera: 122 samples are from Europe origin, 47 samples from Africa origin, 13 samples are from HIV-1 and 7 samples are anti-HIV-2 sera (Africa origin). Among the 111 negative sera: 60 samples from Europe origin, 41 samples Africa origin and 4 samples are from HIV-2 sera. The performance of TOTAL HIV AB and TYPING HIV AB are respectively of 99.16 and 99.36 for sensitivity and 100% 100% for specificity. The cross-reactivity of anti-TYPING HIV AB is 1.16 for anti-HIV-1 sera and 0.2% for HIV-2 sera.
Conclusion: These first results show the advantages of ELISA kits using synthetic peptides for detection of HIV antibodies and also to the infectious virus, this is a very important information for epidemiologic studies. We thank Dr. Ph. Poulety.

Th. C.P.88 ZIDOVUDINE SERUM LEVELS AND HALF-LIFE IN PATIENTS ON CHRONIC MAINTENANCE HEMODIALYSIS

Schilling, H.-J., Averhoff, H.
*Universitätsklinikum Hamburg Eppendorf, Hamburg; *Augusta-Viktoria-Krankenhaus, Berlin; FEDERAL REPUBLIC OF GERMANY

Objective: To determine zidovudine serum levels and half-life in HIV patients on chronic maintenance hemodialysis due to renal failure.

Method: Zidovudine serum levels were determined with an HPLC assay at 0, 60, 120 and 180 min. after single dose oral administration and during hemodialysis sessions. 2 patients with HIV-1 infection have entered the study so far. 1 pat. is ready for evaluation, 1 is still under study.

Patient characteristics:

age	sex	HIV risk cause	renal CD4+	p24 other
42	male	unknown	0.51	undetectable
50	male	transfus. IgA nephritis	0.15	>1000 U/ml

None of the patients had impaired hepatic function.
Results: Zidovudine peak levels were reached after 2 h following oral administration of 100-200 mg of AZI. They were within the therapeutic range (1.67 mg/ml). Half-life was not prolonged and was not significantly altered by hemodialysis in the first pat. studied so far. The results of both will be ready for presentation in detail.
Conclusion: Serum half-life of zidovudine may be normal in renal failure and patients on chronic hemodialysis. Delayed and low peak levels may be due to impaired absorption. Because of these results different from the observations of others (Dery et al. 1988) a pretherapeutic assessment of the basic pharmacokinetic parameters seems justified in this setting.

Th. C.P.90 IDENTIFICATION OF HIV-1 PACKAGING SIGNALS

Levy, Andrew; Gottlinger, M.; Haseltine, W.; Sodroski, J.
*Fred Hutchinson Cancer Institute, Harvard Medical School, Boston, MA U.S.A.

Objective: To define regions of the HIV-1 genome required for packaging HIV-1 RNA into virions.

Methods: Deletions in the area 3' to the splice donor and 5' to the *gag* ATG were made using site directed mutagenesis. Virion RNA content was determined by RNA dot-blot analysis.

Results: Deletions of as little as 19 base pairs in this region produced virions which produced abundant viral protein and morphologically normal virions as seen by EM. These virions displayed a characteristic replication defect and packaged virion RNA at an efficiency of 2% of wild-type virion.

Conclusions: A region important for packaging HIV-1 RNA into virions has been defined. Mutation of this region inhibits both cell free and cell to cell viral transmission.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

Th.C.P.91 DIFFERENTIAL INHIBITION OF HIV VARIANTS INDUCED SYNTHESIS FORMATION BY SEROPOSITIVE PHAGOCYTES

Steinhausen, E.; Sempaphanlann, E.; Cahill, O. and Rubinstein, Arvo

Albert Einstein College of Medicine, Bronx, N.Y., U.S.A.

Objective: To assess the ability of sera from HIV seropositive children to inhibit *in vitro* synthesis of HIV-1 and HIV-2 variants.

Methods: Sera were incubated with supernatant from 8-9 cells productively infected either with HIV-1-1118 or -877. The virus-serum mixtures were inoculated into CEM-10 cells plated on poly-D-lysine coated 96-well plates. Syncytia were counted after 3 days incubation at 37°C.

Results: Each serum was initially tested for its ability to inhibit *in vitro* syncytium formation induced by HIV-1118. Four of the sera showed low inhibition (10-20%). Three other samples exhibited intermediate inhibition (40-60%) and the remaining 3 showed high neutralizing activity (80-100%). The same sera were subsequently tested for their ability to inhibit HIV-877 induced syncytium formation. The sera showed equivalent neutralization of both variants. Of the remaining 3 samples, 3 exhibited 2-fold increase in inhibition of 877 whereas the remaining 1 sample did not neutralize 877.

Conclusions: Sera from HIV seropositive children showed inhibition of HIV induced syncytium formation *in vitro*. Sixty percent of the samples showed equivalent neutralization of 2 different HIV-1 variants, whereas significant differences were observed in 40% of the samples. The development of HIV disease has been shown to correlate with the emergence of HIV-1 variants which, *in vitro*, are progressively more cytopathic. Neutralization of a range of HIV strains may be prognostic of improved clinical outcome.

Th.C.P.92 HIV-1 INFECTION OF HUMAN DENDRITIC CELLS: NEW EVIDENCE FOR SILENT INFECTION

Hahné, M.J., Albert, J.J., Verbeek, H.M., and Agt, W.H.

1. Department of Virology, Middelkade Institute and 2. Department of Virology, National Reference Laboratory, Stockholm, Sweden.

OBJECTIVE: To study HIV-1 infection of normal peripheral blood monocytes/macrophages.

METHODS: Monocyte cultures were prepared from untreated blood mononuclear cells (MNC) released by Ficoll-Paque gradient centrifugation. PBCs were cultured in RPMI medium containing 10% HIV negative human serum and 20% FCS. After five days non-adherent cells were discarded. The monocyte cultures were infected with viruses isolated from primary PBC of HIV-1 seropositive individuals. Two months after infection PMA-stimulated normal PBC were added to the monocyte foci in RPMI medium with 10% FCS. Virus infection was monitored by reverse transcriptase (RT) activity and presence of viral antigen (p24). In culture medium, as well as by immunofluorescence (IF) of infected cells.

RESULTS: HIV-1 replication in monocytes was transient and could be detected by antigen assay in 11 cultures and by RT assay only in 2 cultures (of 14). One if virus replication appeared to be short for up to ten months after infection. The presence of virus could be demonstrated in 12 of 18 monocyte cultures by co-cultivation with PMA-stimulated PBC.

CONCLUSION: Our results show that HIV-1 infection of normal monocytes/macrophages can lead to a silent latent infection. Such persistently infected, non-producing cells, may conceivably serve as infection reservoirs in the infected individual and spread infection to other susceptible cells for a long time.

Th.C.P.93 EFFECT OF CALCIUM CHANNEL BLOCKERS ON HIV-1 EXPRESSION IN LYMPHOID CELLS

Harrison, Gary*, Kim, D**, Baltimore, D**, and Hammer, D**

*New England Deaconess Hospital, Boston, MA, U.S.A.

**Whitehead Institute, Cambridge, MA, U.S.A.

Objective: To determine the effect of the calcium channel blockers (CCB's) verapamil (V), diltiazem (D) on the replication of HIV-1 and the expression of the HIV LTR in lymphoid cells.

Methods: CEM cells were exposed to CCB's at 0, 25, 50, and 75 µM for 1 hour before inoculation with HIV-1118 or medium control. Drug concentrations were included in the cultures, which were monitored for RT activity. Fixed cell immunofluorescence (IFA) for p24 antigen, and cell viability. The effect of CCB's on HIV LTR expression was determined by transfection of CEM cells with LTR-chloramphenicol acetyltransferase (CAT) plasmid constructs, exposure to 50 µM V or D for 48 hours, and assay of CAT activity.

Results: Peak RT and p24 IFA+ cells were seen 3-4 days earlier in V and D treated cultures vs controls. I had no effect. Results, day 8 post-infection:

	RT (log ₁₀ copies/ml)	p24+ Cells (%)	Viability (%)
V 75 µM	5.70	83	63
D 75 µM	5.70	82	80
Control	4.22	5	99

HIV LTR-CAT activity was 7 fold at 50 µM induced consistent 5-10-fold increases in CAT activity.

Conclusions: (1) CCB's can markedly enhance HIV-1 replication in lymphoid cells. (2) This effect may be related to activation of the HIV LTR. (3) Agents which affect signal transduction can be used to further our understanding of the control of HIV replication.

Th.C.P.94 A RAPID AND SENSITIVE PLAQUE ASSAY OF HIV-1 ON CR166 CELLS

Zhu, J.-P., Chan, J.-Y., Janda, R.A.,** and Brinkman, Benjamin*

*Children's Hospital, Harvard Medical School, Boston, MA, USA

**Chester Beatty Institute, London, England

Objective: To develop a sensitive and simple assay to measure the infectivity of human immunodeficiency virus (HIV-1).

Methods: A syncytial plaque assay was developed using CR166 cells (kindly supplied by E. Gallo), a CEM lymphocytic line derived from cord blood and superinfected with HIV-1. The cells were adhered to plastic with poly-D-lysine, infected, and overlaid with agarose. After 2-3 days' incubation, agarose gel was added in a 2nd overlay, and syncytial plaques were counted 8 hours later using low-power or dissecting microscopy.

Results: Two strains of HIV-1, 1118 and 877, were tested, and both produced giant cells large enough to be easily recognized as plaques after staining. There was a linear correlation between number of plaques and virus dilution. The sensitivity of the assay was almost identical to that of TIGD5 tests. Plaques were specifically inhibited by neutralizing antibody. Two of 3 new isolates of HIV obtained from pediatric AIDS cases exhibited focused plaques. The assay has been used to determine the neutralizing antibody titres in multiple serum specimens from children with HIV infection.

Conclusion: A plaque assay of HIV-1 on CR166 cells has been developed which rapidly permits the determination of infectivity in untreated and new clinical isolates and quantitation of neutralizing antibodies in human sera. The assay is rapid, sensitive, reproducible, and easy to perform.

Th.C.P.95 PROCESSING AND ASSEMBLY OF HIV-1 CORE ANTIGENS EXPRESSED BY RECOMBINANT VACCINIA VIRUS

Wu, Zhi-Ling¹, Travis, B.M.², Sridhar, P.², Dykers, T.²

Garrison, J.,¹ Drexler, G.²

Objective: To demonstrate processing and assembly of HIV-1 core antigens expressed by recombinant vaccinia virus and to study the effect of viral protease on these processes.

Methods: Recombinant vaccinia viruses have been constructed that contain the gag ORF and varying extents of the pol ORF of HIV-1. Biosynthesis of HIV-1 core antigens was studied by serological assays and the assembly of core structures detected by electron microscopy.

Results: HIV gag antigens are efficiently expressed by all recombinants tested. Recombinants lacking the protease-encoding region direct the synthesis of gag antigen precursor p55 and processing intermediate p40 only. Those containing the protease region direct synthesis of the processed products p24 and p17 as well. Surface fluorescence is detected by anti-p24 MAb in 10-15% of the infected cells and up to 15% of the core antigens synthesized is released into the media. Particles of 100nm diameter are present in recombinant-infected cells, even in the absence of viral protease functions.

Conclusions: HIV-1 core antigens are efficiently expressed and processed by recombinant vaccinia virus infected cells, indicating the presence of viral protease function are successful read-through of the gag and pol ORF. Recombinant-made gag antigens are assembled into viral core-like structures. This process is independent of any other HIV-specific functions, including that of the viral protease.

Th.C.P.96 CHARACTERIZATION OF HIV-1 PROTEINS EXPRESSED BY VACCINIA VIRUS AND E. COLI

Atsushi, Kazumi¹, Kei-ko, A.², Okamoto, T.³, Chiba, Y.⁴

¹Saito, T. and ²Kuroki, M. ³RIKEN Japan, ⁴RIKEN Japan.

* Nippon Zen Co., LTD., Kawasaki, Japan. ** NIH Japan, Tokyo, Japan. *** Natl. Cancer Center Inst., Tokyo, Japan.

Objective: To examine immunogenicity of HIV-1 gag proteins, p17 and p24, and reverse transcriptase (RT) and rF proteins. The DNA fragments representing p17 or p24 of gag protein, RT or rF protein as well as the sequences spanning from gag to rF were expressed both in recombinant E. coli and in recombinant vaccinia virus (RV). These sequences were prepared from a HIV-1 clone pH810 by restriction endonuclease digestion and/or site-directed mutagenesis and inserted into a bacterial expression plasmid pCR80 and vaccinia virus genome. HIV-specific proteins expressed from the recombinants were detected and identified by indirect fluorescence antibody (IFA) and western blot analyses, using polyclonal and monoclonal antibodies against HIV-1 proteins.

Results and conclusion: Expression of the proteins reacted with patients' sera and monoclonal antibodies was observed except for constructs in both RV-infected cells and E. coli transformed with recombinant plasmids. The production of HIV antigens was also demonstrated at the serum sites inoculated with RV by IFA. For preliminary immunological analysis, rabbits were inoculated with RV expressing p17 and serum samples were prepared for specific response for specific response. Indetectable levels of anti-p17 antibodies are not detected so far. Immunogenicity of other RV and E. coli-derived HIV proteins is presently under research.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

Th.C.P.103 SINGLE AMINO ACID SUBSTITUTIONS IDENTIFY AMINO ACIDS CRITICAL FOR RNAse H ACTIVITY IN REPLICATION OF HIV. Repard, Roy, Clancy, E. and Mauchly, T. D. LAM, MAED, National Institutes of Health, Bethesda, MD, U.S.A.

Objective. To identify amino acids in the HIV *gag* gene critical to the function of RNAse H. **Methods.** Site-directed mutagenesis was used to substitute either of two conserved retroviral *gag* amino acids (aspartic acids) in the putative RNAse H domain in a molecularly cloned infectious HIV (pNL4-3). HIV particles produced by SW480 cells following transfection of the mutant DNAs were harvested, evaluated for RT activity and for infectivity on A3201 cells. RT and RNAse H activities of the partially purified mutant RTs expressed in *E. coli* were determined. **Results.** SW480 cells transfected with the mutated pNL4-3 DNAs produced particles with normal protein and RNA content and slightly decreased RT activity. These particles were not infectious. Whereas RT activities of normal and mutant RTs expressed in *E. coli* were essentially the same, the RNAse H activity in mutant RTs was decreased more than 30 fold. **Conclusion.** Two conserved aspartic acid residues in RT are associated with RNAse H function and are critical for infectivity of pNL4-3.

Th.C.P.105 HIV-1 ANTIBODY SCREENING IN 1646 SEROPOS, HEMOPHILIACS, HEMOPHILICS AND BLOOD DONORS IN EDINBURGH, SCOTLAND. Waters, Leslie M.,** Thompson, J.C.,** Hay, P.A.,** Jordan, A.,** Townell, J.,*** Watt, R.,*** Edwards, R.,*** Edwards, R.,***

**Regional Virus Laboratory, City Hospital, EDINBURGH.
***National National Blood Transfusion Service, EDINBURGH.
****Scottish Reference Laboratory, University of Edinburgh.
*****Central Public Health Laboratory, LONDON, UNITED KINGDOM
Objective. To test for HIV-1 antibody titres in three high risk populations and new blood donors in an area where a high proportion of intravenous drug consumers (IUDCs) are HIV-1 positive. **Methods.** HIV-1 antibody tests were performed on sera from 300 IUDCs, 130 blood donor recipients (BDRCs) (100 haemophilic and 30 non haemophilic donors), 503 heterosexual or bisexual men and 500 new blood donors using Duoset HIV 1 ELISA. HIV antibody seropositivity rates in the groups studied were estimated. Confirmatory testing for HIV-1 antibody was by immunofluorescence (IF) against HIV-1 infected cells, particle agglutination assay for HIV-1 (F) (Ria) and immunoblotting. **Results.** 1 of 300 IUDCs, 1 of 130 blood donor recipients, 6 of 153 heterosexual or bisexual men and 1 of 500 new blood donors were positive by ELISA. Confirmatory testing was undertaken on the single positive IUDC and the individual was negative for HIV-1 by particle agglutination test, positive by IF and immunoblotting. This patient (who is HIV-1 antibody negative) may be infected with a retrovirus other than HIV-1 or HIV-2. The single positive haemophilic was of Japanese origin and was possibly infected by Japanese blood or blood products. Results from confirmatory testing are omitted in the single positive blood donor. **Conclusion.** HIV-1 appears in this initial survey not to have significantly infiltrated a population with a high rate of HIV antibody infection, nor in other high risk populations or new blood donors in the same city.

Th.C.P.107 FUSION OF SDGAN IMMUNOPRECIPITATION VIRUS (SIV_{SD}) WITH LIPIDOMES AND ERTHROCYTE GHOSTS. Lopez, Charles,** Alford, D.,** Yang, L.,** Lee, K.-D.,** McGrath, T.,** and Dinglasan, N.,** University of California, San Francisco, CA, USA. and **National Center for Human Research Center, Davis, CA, USA.

We investigated the kinetics of membrane fusion between SIV_{SD} and phospholipid vesicles, and the effects of various parameters on this process. SIV was purified by sucrose gradient and precipitation of cell-free supernatant followed by two sucrose density gradient centrifugations, and labeled with octadecyl rhodamine (B18). Fusion was monitored continuously as an increase of fluorescence intensity resulting from the dilution of the probe into target membranes. Ultrastructural analysis of the virus and fusion products was performed by electron microscopy. Viral fusion was strongly dependent upon the liposome composition. Pure cardiolipin (CL) vesicles fused with the virus at a fifty-fold greater rate than pure dioleoylphosphatidylcholine (DOPC) liposomes. SIV fusion with CL/DOPC (3/7) and phosphatidylserine (PS) vesicles was slower than that with pure CL. Calcium or reduced pH greatly enhanced the rate of SIV-CL fusion but did not affect that of SIV-DOPC fusion. SIV also fused with erythrocyte ghosts, and the rate of fusion increased in the presence of calcium or reduced pH. SIV fusion with model membranes is similar in some aspects to that of other lipid enveloped viruses. Our results indicate that SIV can fuse with biological and model membranes lacking the CD4 receptor. This assay system can be used to test inhibitors of the fusion activity of SIV.

Th.C.P.104 HIV RESISTANCE IN PLASMA OF PATIENTS WITH RETROVIR.

Deleens, J.,** Blanchet, A.,** Tourenq, J.A.,** Leclercq, D.,** Stane, M.,** Loussier, M.,** Wasth, M.,** Jadot, J.A.,** for the Laros HIV Study Group - Laros Institute 87 - 40 de Meuse - 7200 HAININ OISEL - Belgium

Measurement of the viral load in HIV disease is crucial for the management of antiretroviral patients (pts) especially to evaluate their response to current and future therapeutic trials. To assess the HIV production *in vivo*, we have developed an assay measuring directly cell-free virus in plasma. We cultured plasma (sent cells) from 20 HIV pts (10 AIDS and 10 asymptomatic pts) with an 14 cell control before and 3 month after start of AZT therapy (10µg/ml) * 10⁶ aliquots normal. 14 days prior to PMA and IL2 were cultured with 200 µl of HIV plasma or with 10⁶ HIV₉₀ in 12-well coated plates. 14 experiments were serially harvested for 30 days. 1 pt. was tested with an immune capture assay (Immocore). Cell cultures were 100% positive for HIV-1 RNA and antigenemia was absent. 14 patients were:

	before AZT	after AZT	before AZT	after AZT
Plasma culture	10 positive-3 positive	8 positive-3 positive	8 positive-3 positive	2 negative-1 positive
Antigenemia	11 positive-3 positive	7 positive-3 positive	11 positive-3 positive	2 negative-1 positive

These data demonstrate a significant decrease of plasma infectivity under earlier administration of AZT, and suggest that measurement of plasma HIV is a more valuable tool to evaluate the *in vivo* antiviral activity of chemical compounds than pH antigenemia. However, since these 2 parameters are not closely linked they are both useful for the management of HIV asymptomatic individuals.

Th.C.P.106 THE KILLING EFFECT OF 65°C TEMPERATURE ON HIV-1 IN DRIED BLOOD: DECONTAMINATION OF LAB. INSTRUMENTS/EQUIPMENTS. Boradon, Farzadmanesh,* W. Hardig,* K. Qataish,* B. Tappes,* P. Goldenbom,** A. Laak,* John Johns Hopkins Hospital of Hygiene and Public Health, Baltimore, MD. **Mectron-Dickinson, Johnson Laboratories, Towson, MD, U.S.A.

OBJECTIVE: To determine the efficacy of 65°C for inactivation of HIV-1. This information is valuable for industrial settings involved in repairing laboratory instruments/equipments contaminated with human blood. **METHODS:** HIV-1 (250-500 pg/ml) was mixed with normal blood. One tenth of 1 ml HIV-1 inoculated blood was placed on a sterile plastic slide (in duplicate) and air dried at room temperature for 24 hours. Dried blood samples were left in an oven heated to 65°C for 4, 8, 12, 16, 24 and 36 hours (intervals). After the specified time interval, samples were removed and blood was eluted in 5ml of RPMI. A sterile rubber police spatula was used to ensure removal of blood residues. (Slides were used for HIV-1 isolation using cocultivation with PHA-P treated normal PHW⁺ cells (SIIG⁺ cells) in a 125 cell flask in 1:1 containing RPMI culture media and monitored for viral growth. **RESULTS:** HIV-1 was isolated from blood samples not heated at 65°C. However, HIV-1 was not recovered during one month of follow-up from any blood samples that were incubated at 65°C for four hours or more. **CONCLUSIONS:** HIV-1 in dried blood does not survive four hours or more at 65°C. This low and safe temperature therefore could be applied for decontamination of laboratory instrument/equipment contaminated with human blood.

Th.C.P.108 MONOCLONAL ANTIBODIES TO HTLV I AND HTLV II GAG PROTEINS.

Hoffman-Barrett, Cathryn L.,** Bodner, A.J.,** Alexander, S.,** Salaudeen, Z.,** Lipsky, M.,** and Cortman, A.,**

**Hirsch Research Laboratories, Inc. Bethesda, MD

**NCI, National Institute of Cancer, Bethesda, MD.

**National Institute of Health, Bethesda, MD, U.S.A.

Objective. To generate specific and cross-reactive monoclonal antibodies (MoAb) to HTLV I and HTLV II gag proteins. **Methods.** Lymphocytes from Balb/c mice immunized with either HTLV I or HTLV II viruses were fused with NS-1 myeloma cells by the procedure of FCG. ELISA assays were utilized to select cells secreting anti-viral immunoglobulins. Cells were cloned by limiting dilution. ELISA results were confirmed and protein specificity determined by Western Blot and by RIBA. Immunoglobulin subclass was determined by Ouchterlony double diffusion. **Results.** MoAbs isolated from HTLV I immunized mice showed the following reactivities: (1) specificity for HTLV I p19, (2) specificity for HTLV I p24, (3) cross-reactive with HTLV I and HTLV II p24, and (4) cross-reactive with HTLV I p19 and HTLV II p22. The HTLV I p19 specific clone recognizes and cross-reacts with HTLV I p19 and HTLV II p22. The HTLV I p24 specific clone recognizes only p19. MoAbs isolated from HTLV II immunized mice were: (1) specific for HTLV II p22, (2) cross-reactive for HTLV I p19 and HTLV II p22, and (3) cross-reactive for HTLV I and HTLV II p24. All MoAbs were IgG₁ subclass. **Conclusion.** HTLV I and HTLV II p22 share a common epitope. The p19p22 and the p24 proteins of HTLV I and HTLV II have similar and differing antigenic epitopes.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

Th.C.P.109 ADDITIONAL CHARACTERIZATION OF ORIGINAL HUMAN IMMUNODEFICIENCY ISOLATES FROM TWO CONTINENTS. ANT 70 AND ANT 70A
Bart Vandenbroucke, L. Eys, N. Vanden Bessende, B. Van Neerwyn, R.J. De Leyn. Zoogenetica N.V. Antwerpen, Belgium.

Objective: To assess the relationship between isolated ANT 70 and ANT 70A and other HIV and HIV strains and to determine the biological properties of the isolates.
Results: Dot-blot hybridization experiments were performed in order to evaluate the relationships of the isolate ANT 70 to other known human and simian immunodeficiency viruses. Hybridizations were carried out using probes derived from HIV-1 (gp120), HIV-2 (gp120), and ANT 70 (gp120). Under nonstringent conditions, crosshybridization was observed between virus types. However, a clear distinction could be made between ANT 70 and ANT 70A, and other virus types under stringent conditions. Although ANT 70 and ANT 70A have been shown to be indistinguishable by Western blotting or nucleic acid hybridization techniques, biological differences could be demonstrated between the two strains in terms of their preference for certain cell lines.
Conclusions: ANT 70 and ANT 70A differ significantly in their nucleic acid homology from prototype HIV-1 and HIV-2 strains, even in relatively highly conserved regions of the genome. The two isolates are highly related to each other but can be differentiated based on biological properties.

Th.C.P.111 DETECTION OF HIV GENOME IN SERONEGATIVE HOMOSEXUAL MEN
Perrille Nègre¹, Gerald-Jai P...Vonnest, N.-J. Gentili, J...Stuenkel, N.-J. and G...
¹Institute Infectious Disease, Policlinico Umberto I University of Rome, Rome, Italy

Objective. The aim of our investigation was to evaluate the presence of HIV latent infection and HIV genome in peripheral blood mononuclear cells (PBMCs) from 20 asymptomatic homosexual men with multiple sexual partners. All the subjects, non intravenous drug users, were seronegative for anti-HIV antibodies (ELISA test and Western Blot), for HIV antigens and RNA. The 74/70 cells ranged between 0.7% - 2.5%.
Methods. Cytocentrifuged PBMCs were "in situ" hybridized with three probes: 1) the HIV Δ8 plasmid containing the 9 kb full-length viral insert; 2) the pBR322 to reconstituent clone able to recognize both viral RNA and proviral DNA; 3) the pBR322 plasmid lacking viral insert. The probes were tagged by inserting an antigenic sulfone group in cytosine residues and visualized by the sandwich immunohistochemical reaction using a specific monoclonal antibody against the sulfone group and an anti-mouse alkaline phosphatase conjugate antibody (Chemie probe, Organon). The controls were performed by HIV non infected and infected 5 cell culture lines and PBMCs from 20 healthy heterosexual men.
Results. HIV genome sequences were observed in the cytoplasm of mononuclear cells of three subjects as a granular staining and in some cases a mild non clear positivity was found. The HIV genome was observed also in three cases.
Conclusions. Active homosexual and/or bisexual men are at risk of acquiring HIV infections.

Th.C.P.113 Sodium Pentosan Polysulfate (SP-54), an Anti-HIV Agent Also Enhances Lymphocyte Proliferative Activity and Synergism with AZT

HSA Ahmad, Sanyar Nayyar, Teresa A. Galvin, Carl R. Merrill, Llewellyn B. Bigelow¹, Laboratories of Biomedical Genetics and Clinical Brain Research, National Institute of Mental Health, Saint Elizabeths Hospital, Washington, DC U.S.A.

Objective. Sodium pentosan polysulfate (SP-54) was studied for its antiviral activity against HIV-1 and was compared with dextran sulfate (DS) and AZT.
Methods. Drug responses on the production of HIV-1 in normal human peripheral mononuclear cells were tested by reverse transcriptase (RT) assay, p24 antigen test and p24 radioimmunoassay.
Results. More than 90% of virus replication was inhibited with 5.0 mcg/ml of SP-54. Direct inhibitory effect of SP-54 was also observed on the HIV reverse transcriptase reaction in vitro. No toxicity was observed with SP-54 on PMNC cultures. In fact, it had proliferative effect on uninfected PMNC and protective effect on infected PMNC cultures at concentrations of 0.1 to 10.0 mcg/ml. In addition, SP-54 showed profound synergism with AZT. In the presence of 25 and 100 nM AZT, 2.0 mcg/ml of SP-54 reduced HIV-1 replication 110- to 176-fold as compared to 3- to 16-fold decrease in the presence of either drug.
Conclusions. SP-54, owing to its anti-HIV-1 activity, nontoxic nature, lymphocyte proliferative activity and synergism with AZT could prove to be a valuable agent in the chemopreventive intervention of AIDS.

Th.C.P.110 EXPRESSION OF THE GAG-POL GENE PRODUCTS OF HUMAN IMMUNODEFICIENCY VIRUS BY RECOMBINANT VACCINIA VIRUS VECTORS
Shioda, Tatsuo; Hirose, K.; Awada, H.; and Shioda, T.
Institute of Medical Science, University of Tsuyuki, Tsuyuki, Japan.

OBJECTIVE: To understand the molecular mechanisms of virion assembly and processing of the gag precursor. The gag-pol genes of the thymidine kinase gene of vaccinia virus (TK) were inserted into the thymidine kinase gene of CV-1 and 8240 cells infected with the recombinant vaccinia virus (RV) carrying the entire gag-pol region. The precursor gag protein was almost exclusively detected by immunoblot analysis using serum from an AIDS patient. However, in the culture fluids of infected 8240 cells, but not of infected CV-1 cells, we could clearly detect reverse transcriptase (RT) activity, even when the replication of vaccinia virus was suppressed by cytosine arabinoside. The highest RT activity was found at a density of 1.6 x 10⁶ cells and this fraction was revealed by immunoprecipitation with the cleaved gag proteins by immunoblot analysis, suggesting that particles containing the HIV RT and the cleaved gag protein were released from infected 8240 cells. The corresponding fraction prepared from the culture fluids of 8240 cells infected with another RV carrying only the gag gene contained exclusively the uncleaved gag precursor and lacked the RT activity, confirming that the processing of the gag precursor was mediated by the HIV protease encoded in the pol gene. Electron microscopic examination is now under way. **CONCLUSION:** Our results showed that only the gag gene products are sufficient for particle production and suggested that the particle formation is necessary for efficient processing of the gag precursor.

Th.C.P.112 A METHOD FOR QUANTITATING INFECTIOUS HIV PARTICLES

Tilgner, Egon and Grinde, B.
Department of Virology, National Institute of Public Health Oslo, Norway.

Objective. To develop a method for determining the number of infectious HIV particles in various preparations.
Method. M74 cells were incubated with the preparation containing HIV particles for 1 h. The cells were then mixed with a molten solution of agarose in a cell medium. The agarose was placed in the refrigerator for rapid solidification. Extra medium was added on top of the gel and the tubes incubated for four days with one medium change. The gels were then melted by heating, mixed with a salt solution and the cells rescued by centrifugation. After fixing, the cells were stained by immunofluorescence using an anti-HIV antiserum. The relative number of fluorescent cells were counted.
Results and Conclusion. Cultivating the infected cells in an agarose gel prevented the transfer of virus between cells. The number of HIV positive cells after the incubation should therefore reflect the concentration of infectious HIV particles in the original preparation. If the cells had been cultured without a gel, some cells would be expected to prevent antigen due to secondary infection. The present method is faster than traditional plaque assay.

Th.C.P.114 VIRAL GENE EXPRESSION ASSESSED BY PCR IN HIV-1

INFECTED BY HIV-1
Miyatake, T., Ruta, M., Geyer, S.J., Hawthorne, C., Ford and Drug Administration, Bethesda, MD, U.S.A.

Objective. To study early events of viral gene expression in HIV-1 infected cells by a sensitive gene amplification technique, polymerase chain reaction (PCR).
Methods. 89 cells were infected with HIV-1 (10⁶ infectious units/ml). At various times after infection (1, 6, 18, 24, 48, 72 and 144 hr), high molecular weight DNA and RNA were isolated from the cells. DNA and RNA were detected by co-amplification of primer pairs to gag, env, tat and pol regions of the viral genome using PCR. Reverse transcriptase (RT) activity was measured by direct assay of cell culture supernatants.
Results. HIV-1-specific sequences were first detected in genomic DNA of 89 cells 3 hrs. after HIV-1 infection, thereafter, these sequences increased in copy number. Synthesis of viral-specific RNA was detected at 6 hrs. after infection. Extracellular RT activity increased 35-fold, to 0.75 ng/ml T17hr/10⁶ cells 3 and 6 days after infection.
Conclusions. Results indicate that virus-specific DNA became integrated into host genome rapidly after HIV-1 infection, followed several hours later by synthesis of viral RNA's. Release of virus, signalled by increased extracellular RT, was delayed between 3 and 6 days. These results demonstrate that PCR is a useful technique to evaluate early events in replication of HIV-1 in target cells such as lymphocytes and macrophages.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

Th.C.P.115 PURIFICATION AND ANALYSES OF THE HTLV-I ENVELOPE GLYCOPROTEIN gp46 USING AN ANTI-CARBOXYLY-TERMINAL SYNTHETIC PEPTIDE SERUM.

Lilohol, Edik, Nguyen, A., Tu, C., Alexander, S.
Biotech Research Laboratories, Inc., Rockville, MD 20855, USA.

Objective: The objective was to isolate gp46 from HTLV-I transfected HUT102 cells by immunofluorescent chromatography.

Methods: A rabbit antiserum against a synthetic peptide corresponding to the carboxyl-terminus of gp46 (LPPFLSLSPVTLGSSSRK) was prepared and analyzed for reactivity with the native gp46 and precursor gp64 proteins by ELISA, Western blot and RIFA assays. An affinity column was used to purify gp46.

Results: The anti-peptide serum reacted with gp46 with apparent molecular weights of 46,000 on HTLV-I and HTLV-II virus Western blot strips. The specificity of this reaction was established by inhibition with the homologous but not an irrelevant peptide. Removal of N-linked carbohydrates with endoglycosidase F resulted in a decrease in molecular weight from 46,000 to 31,000. RIFA analysis using 13S5 methionine labeled HUT102 cell lysates revealed specific reactivity with the envelope precursor gp64 in addition to a smaller protein of approximately 30,000 daltons. gp46 was purified by immunofluorescent chromatography and shown to be reactive with sera from HTLV-I infected patients as well as monoclonal anti-HTLV-I gp46 antibody but not sera from uninfected individuals or monoclonal anti-HTLV-I gag (p19, p24) antibodies. False reactivity of the gp46 preparation with an antiserum against uninfected T lymphocytes revealed minor contamination with cellular proteins.

Conclusion: HTLV-I gp46 can be purified using an anti-peptide serum in a form suitable for evaluating envelope-antibody ELISA and Western blot assays.

Th.C.P.117 GLOBAL HETEROGENEITY OF HIV-1 ISOLATES IN U-937 CELLS, BOUTERIEUX, FERRAZZI, BOER, S., GELSTONER, R.**, and Fainberg, J.A.

*Lady Davis Institute for Medical Research, Sir Mortimer B. Davis - Jewish General Hospital, Department of Experimental Medicine and **Department of Immunology and Microbiology, McGill University, Montreal, Quebec, Canada.

Clines of U-937 cells were derived from a chronically-infected population by limiting dilution and micro-manipulation. We studied the expression of HIV-1 by immunofluorescence and reverse transcriptase assays in six of these clones. Four of them showed presence of the p24 viral antigen that correlated with normal mRNA expression and reverse transcriptase activity in the supernatants. These virus-containing supernatants were inoculated onto other cell types and were shown to differ in infectiousness. Western blot analysis revealed structural differences at the level of viral antigens which could account for a defect in viral budding and infectivity. The results clearly show heterogeneity of isolates recovered from U-937 clones and raise the question as to whether the expression of HIV-1 is influenced by the innate biological characteristics of these clones.

Th.C.P.119 SIMULTANEOUS DETECTION OF HIV-1 AND HTLV-I INFECTIONS BY CO-AMPLIFICATION USING PCR

Felix, Heltz, Hewitt, I.K., Hawthorne, C.A., and Tostevin, J.C.
Food and Drug Administration, Bethesda, MD, U.S.A.

Objective: To detect in the same PCR reaction, the presence of multiple viral infections.

Methods: Genomic DNA isolated from HIV-1 (89/HTLV-III) or HIV-1 (MC-2) infected cells was used as the template for gene amplification. PCR was performed in the presence of primer pairs to the gag and env genes of HIV-1 and the pol region of HTLV-1 primers were optimized for conditions of equal sensitivity.

Results: PCR performed by co-amplification of the HIV-1 gag and env regions was positive for both gene sequences in 21/21 high risk samples and 0/11 negative controls. In addition PCR performed on mixed genomic DNA (89/HTLV-III and MC-2) resulted in specific detection of each of the amplified targets with comparable sensitivity (20-40 gene copies each). **Conclusion:** Using co-amplification of multiple gene sequences it is possible to simultaneously detect and confirm the presence of HIV-1 in clinical samples. In reconstitution experiments the same method has been used to simultaneously detect HIV-1 and HTLV-1 predicting another clinical application.

Th.C.P.116 BIOLOGICAL HETEROGENEITY AMONG HIV-1 ISOLATES

Moore, Barbara E., Hart, Andrew R., and Clapp, Miles U.
Department of Microbiology, The University of Texas Medical Branch, Galveston, TX 77550 USA.

Objective: To biologically characterize HIV-1 isolates having variable tropism and cytopathogenicity.

Methods: The infection kinetics of 14 independent HIV-1 isolates were monitored in 8 cell lines. Viral replication was characterized with respect to RT activity, p24 production, and cell growth and viability.

Results: In the absence of preexisting transactivator activity, HIV-1 isolates adapted slowly in most cell cultures requiring from 8-14 days to achieve infection in 100% of the cell population. The viruses varied in their tropisms, with the degree of susceptibility of CD4-positive cell lines to infection varying as much as 100,000-fold. One isolate, HIV-1₁, infected the promonocytic cell line, U937, and T cell lines equally well; but it did not readily infect the H9cns neuroblastoma cell line. RT activity was an unreliable measure of viral replication. Some isolates yielded high RT, while others were consistently low. In addition, RT was always low in some cell lines even though high titres of infectious virus were produced. HIV-1 isolates varied in their ability to kill and/or fuse cells, however most isolates killed cells without syncytia formation.

Conclusions: HIV-1 isolates demonstrate considerable heterogeneity in their biological characteristics. Cell specific replication, and CPE within a given cell will be important parameters of virulence. The findings of this study should form a framework from which HIV genome sequence information may eventually be correlated with biological function.

Th.C.P.118 A RAPID, DIRECT ASSAY FOR REVERSE TRANSCRIPTASE ACTIVITY IN HIV-INFECTED CELL CULTURE SUPERNATANTS.

Greer, Sharon J. and Reising, J.S.

Food and Drug Administration, Bethesda, MD, U.S.A.

Objective: To develop a simple, rapid and sensitive assay for reverse transcriptase (RT) activity in HIV-infected cell culture supernatants.

Methods: The RT microassay reported by Miller *et al.* (J Clin Micro. 23:97,1987) was miniaturized and conditions for trapping the ³²P-products on glass fiber and DEAE filter mats were optimized for rapid collection and counting on a liquid scintillation counter. Briefly, 20ul of culture supernatant was transferred directly to a 96-well microtiter plate and virus coats were neutralized with 5ul buffer including 30E plucolase and 0.5E Triton X-100. 25ul containing 5mM ³²P-thymidine triphosphate (TP, 200Ci/mM, NEN), 0.45ul poly(A)oligo(dT)₁₂₋₁₈ (Pharmacia) and 10mM MgCl₂ were added to wells and incubated at 37°C. Reaction products were precipitated with 25mM ZnSO₄ buffer and 10E TBA and transferred to mats using a cell harvester (LKB). Mats were counted in a liquid scintillation counter (Beckman LS 5000TD). **Results:** The RT reaction was linear over a 100-fold range of RT concentrations during a 4h incubation at 37°C. 20ul of supernatant from 10⁶ HIV-1-infected U937 cells incorporated 1:1 pmol TTP/hr, 3.5 times the activity reported in the microtiter. RT activity in supernatant of 10⁷ 89 cells/ml rose 35-fold, to 0.75 pmol TTP/hr, 6 days after infection with approximately 10⁷ infectious units of HIV-1. The procedure of RT measurements in one 96-well plate required about 3 hr, while each additional plate added 20 min to total processing time. **Conclusion:** The procedure described for measuring RT activity in cell culture supernatants does not require isolation or concentration of virus and expresses a simple, sensitive and rapid assay for HIV replication **in vivo**.

Th.C.P.120 VARIABILITY OF HIV-1 COMPUTER ANALYSIS DATA BASE.

Whitcomb, D.L. Division of Biological Laboratories Science.

DAK-SAN, FUJITSU, Ltd., Shinjuku-ku, Tokyo, Jpn.

Objective: The activity of the reverse transcriptase (RT) depends on Mg ions, and the linker strand around RT may be very strong and may force the nucleic acid sequence to have a specific conformation. Some RT. The conformation of the linker strand of the nucleic acid sequence. I analyzed the data base (Los Alamos, 1988) with computer in Quebec.

Methods: The linker strand of the nucleic acid sequence was divided into four groups: New York, WMA, Haiti which contain nt, csk and if, and Africa. The variability was considered within each group, and was considered the constant dependency the variability of the neighborhood of position (N) or pyrimidine (P) or Y) was considered. When only one strain in a group was tested at the same point of the env gene sequence, this mutation was considered to calculate variabilities of aspartate. The variability of an aspartate in a group was defined as:

$$\frac{\text{sum of constant point mutations at the 2nd, 3rd and 4th bases of the aspartate in the group}}{\text{frequency of aspartate in the group}}$$

Results: The USA in the aspartate (ASD), csk and csk were overrepresented in the aspartate which have polarity and the mutation of these amino acids may be very advantageous to escape from the immune system of host. If the methionine coding were mutated, these amino acids may be very advantageous to escape from the immune system of host. The variabilities of ASD and csk were, however, the highest ones in the 64 possible aspartates, but that of csk was of about the average. This was common to the four groups. There were aspartates which showed similar variabilities among the four groups: the csk and csk, and some other aspartates showed distinct variabilities among the four groups. For example, that of csk decreased from the Africa group to the New York group.

Conclusion: These strongly suggest that the variability of the env gene depends on the context of the nucleic acid sequence (therefore on the conformation), and depends on RT of each group.

Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (Biomedical)

Th.C.P.121 DEVELOPMENT OF A NOVEL QUANTITATIVE ASSAY TO STUDY MEMBRANE FUSION MEDIATED BY gp120gp41
Nelson, M.B., Wang, F.-H., Rekoh, D. and Hammarström, M.-L.
Departments of Microbiology, Biochemistry and Oral Biology, State University of New York at Buffalo, Buffalo, N.Y. 14214, U.S.A.

A single vector (pSVX1) expressing the rat, rev and envelope proteins of HIV-1 was used to develop a quantitative fusion assay. This assay is based on the ability of the rat protein to transactivate the HIV LTR. CD4+ cells are transfected with a plasmid (LTR-CAT) in which the LTR is linked to the chloramphenicol acetyl-transferase gene and at the same time CV-1 cells are transfected with pSVX1. Twenty-four hours later these cells are mixed and after an additional twenty-four hours of incubation the cells are harvested, extracted and assayed for CAT activity. If fusion takes place, the rat protein produced in the CV-1 cell is able to transactivate the LTR. This is the only mechanism by which transactivation occurs in this system, since control experiments have ruled out leakage of rat from transfected cells and transactivation by uptake into the CD4+ cells. The sensitivity of this assay permits it to be performed using only a small number of cells in multi-well dishes. This assay has been used to analyze fusion inhibition by specific antisera and peptides.

Th.C.P.123 PURIFIED REVERSE TRANSCRIPTASE (RT) FROM HIV-1, HIV-2 AND EIAV SHARE STRUCTURAL AND IMMUNOLOGICAL PROPERTIES
Devico, Anthony, Copeland, T.**, Crowlson, S.**, Montalero, R.**, Gallo, R.**, and "HIV-1, S.D.S." *Biometric Research, Inc., Rockville, MD, **NIH-PCRP, Frederick, MD, ***La State Univ., Baton Rouge, LA ****MCI, NIH, Bethesda, MD, U.S.A.

Objective: To determine if sequence homology among the RT proteins of the lentiviruses is reflected in common structural and immunologic properties.
Method: A synthetic peptide derived from a C-terminal portion of HIV-1 RT which is conserved in all lentiviral RTs was used to raise rabbit monoclonic sera. Purified IgG was tested for RT inhibitory activity and as immunofluorescent adsorbent to purify RT from HIV-2 and EIAV.
Observations: Anti-peptide IgG directly inhibited RT from HIV-1, HIV-2 and EIAV RT and it provided a good chromatography matrix to purify RT from HIV-2 and EIAV. RT activity was associated with a pair of proteins - p66/p55 for HIV-2 and p66/p51 for EIAV. Sera of HIV-1 infected individuals had anti-RT antibody; EIAV-infected horses did not.
Conclusions: The RTs of HIV-1, HIV-2 and EIAV share structural similarities, being comprised of two associated proteins. However, high immunogenicity seems to be a feature of human lentiviral RTs. The broadly inhibitory nature of the antibody suggests that the peptide sequence represents a portion of the RT active site.

Th.C.P.125 KINETICS OF APPEARANCE AND SPECIFICITY OF NEUTRALIZING ANTIBODIES IN PATIENTS WITH PRIMARY HIV INFECTION

Albert, J.**, Ljunggren, K.**, Nag, K.**, Abrahamson, B.**, Paves, E.**,
*National Bacteriological Laboratory, Stockholm, Sweden.
**Karolinska Institute, Stockholm, Sweden.
***Hungarian Academy of Sciences, Budapest, Hungary.

Objective: To study the appearance of virus neutralizing antibodies in patients with symptomatic primary HIV-1 infection. To establish if these antibodies play a role in elimination of the initial viraemia; to an selection for the development of antigenically distinct HIV-1 strains in the infected individuals.
Methods: Sequential HIV isolates and serum samples were obtained from four patients during and after primary HIV infection. The neutralizing capacity of the sera from one individual was tested against sequential virus isolates from the same and other individuals.

Results: Preliminary results show that HIV neutralizing antibodies develop after HIV infection. The initial antibody response is strain-specific, but declines with time to include several strains.

Conclusions: The results will be important in understanding early events in HIV-1 infection and in vaccine studies.

Th.C.P.122 EXPRESSION AND CHARACTERIZATION OF HIV-1 ENVELOPE PROTEINS SYNTHESIZED FROM A SV40 VECTOR

Hammarström, Björn; Nelson, M.B.; Hammarström, M.-L.; and Rekoh, D.; Departments of Microbiology, Biochemistry and Oral Biology, State University of New York at Buffalo, Buffalo, N.Y. 14214, U.S.A.

We have used a SV40 late replacement vector system to express HIV-1 envelope proteins in COS cells. One construct produces gp160 which is efficiently processed to gp120 and gp41. Fusion assays utilizing transfected cells and CD4 expressing HeLa cells indicate that functional env proteins are inserted into the plasma membrane of the transfected cells. Approximately one third of the gp120 produced is found in the medium. This plasmid was modified to produce a soluble form of gp120 which is efficiently secreted into the culture medium. Other truncated forms of the envelope protein have also been made. We have started a systematic analysis of these proteins with regard to kinetics of cleavage and glycosylation, transport and oligomerization.

Th.C.P.124 CLONING, PRELIMINARY CHARACTERIZATION AND EXPRESSION OF GENIC FRAGMENTS OF A HUMAN HIV-2 ISOLATE (ARTV).
Farkas, David; Van den Heuvelde M.; Vanderschueren, J.; Driver, A.; Juvell, W.; and Highfield P. Wellcome Institute, Banbury, Oxon, OX2 9AT, *Immunogenetics, 65, 2000 Antwerpse, Belgium.

A Belgian AIDS patient, who had never visited Africa, was found to have a Western blot profile consistent with an HIV-2 infection. An HIV-2 (designated ARTV) was isolated from this patient and adapted to culture. An HIV antigen capture test on culture supernatants indicated that this was indeed an HIV type 2 (Vanderhoef, et al., 1988 Eur J Clin Microbiol Infect Dis 7: 816-8).

OBJECTIVE: To clone and sequence this isolate to determine its relationship to the African HIV-2 prototype R00 and to express ARTV3 genes in heterologous systems to obtain reagents for further research.
METHODS: Viral RNA from infected cell cultures was used to prepare cDNA clones either by standard methodology or by the use of PCR technology. Specific gene products were then expressed in prokaryotic (E. coli) and eukaryotic (insect cell) systems and analyzed immunologically.
RESULTS: Clones containing the major genes were obtained and preliminary sequence data has shown that ARTV3 is an HIV-2 isolate and is distinct from HIV-2 R00; the homology is between 70-90% at the amino acid level depending upon the particular gene compared. RT and gp120 polypeptides have been expressed both in E. coli and baculovirus systems and are reactive with anti-HIV-2 sera.
CONCLUSIONS: ARTV3 is an HIV-2 isolate related to but distinct from the African prototype R00. Recombinant viral gene products will be useful as research tools and as potential diagnostic and vaccine reagents.

Th.C.P.126 EVALUATION OF THREE METHODS FOR HIV DETECTION IN CULTURE OF BUCKINGHAMIA PATIENTS
S. S. Ghosh, D. Basak, J. Stewart, C.A. Steel, H.S.S. Ghosh, L. Laitala

*Department of Bacteriology, University of Edinburgh, 2, Department of Microbiology, Royal Infirmary of Edinburgh, 1, MEI Corporation unit, UNITED KINGDOM
*Department of Microbiology, University of Edinburgh, 2, Department of Microbiology, Royal Infirmary of Edinburgh, 1, MEI Corporation unit, UNITED KINGDOM
*Department of Microbiology, University of Edinburgh, 2, Department of Microbiology, Royal Infirmary of Edinburgh, 1, MEI Corporation unit, UNITED KINGDOM

OBJECTIVE: To evaluate 3 methods for HIV detection in cultures in HIV antibody positive hemophilia A patients.
METHODS: PMPs from 40ms of recipient blood were generated on a Ficol-pyrase gradient. The yield of the cells were cultured in RPMI 1640 in the presence of FCS, IL-2 and PHA. On the reacting cells a screening method was used for CD4 cell detection. Half of the generated PMPs from the CD4 negative donor were co-cultured with the cell line C-816 (p24 negative) and the other half were co-cultured with the cell line C-816 (p24 positive) PMPs from a virus HIV negative donor. The cultures were harvested at weekly intervals, supernatants were tested for the presence of p24 antigen using an antigen capture assay (Biorad). The p24 antigen was checked by flow cytometry (Becton Dickinson, Sector Cytometer).
RESULTS: The cytometry showed that the p24 antigen using an antigen capture assay (Biorad). Six out of 15 patients were investigated, 1 has consistently yielded a positive virus culture, 1 has had a positive culture on one occasion and a more than negative over a period of 2 years. The results are presented in the table below.

CD4 Status	Number of patients	Unscreened culture	co-culture of p24 negative PMPs with C-816
II	2	-	2
I	2	-	1
I/2	2	-	1
I/1	1	-	1

CONCLUSIONS: Co-cultivation of CD4+ depleted PMPs is a more sensitive method for HIV detection than simple culture of PMPs and the addition of normal CD4 cell may promote virus detection.
* FCS Fetal calf serum.

Session d'affichage Poster Session



Recherche fondamentale (Biomédecine) Basic Research (Biomedical)

Th.C.P.133 QUANTITATIVE HIV RNAOCCURRANCES.
Maddala, Robert* Foster, A. Carter, C.S.* Burns,
D.L. & The Walter Reed Biodefensives Research Group
Walter Reed Institute of Research, *NSA Technology, Inc.,
Washington, D.C., U.S.A.

Objective: Quantitate the minimum number of patient peripheral blood mononuclear cells (PBMC's) required to isolate HIV in culture.
Methods: PBMC's from 12 untreated HIV seropositive patients were obtained by Ficoll-Hypaque separation of heparinized blood. Serial ten-fold dilution of cells (10^6 to 3×10^2) were inoculated into cultures of H9 and IL-2 stimulated normal donor tissue PBMC's. Culture fluids were monitored weekly for 4 weeks for HIV p24 antigen.
Results:

Initial Seed Size	Minimum # cells for positive
1 - 2	3
3 - 4	10^4 , 10^3 , 10^2
5 - 6	10^4 , 10^3 , 10^2 , 10^1

 HIV was also isolated in cultures from plasma from 5 of the 12 patients (* noted above). Serial exposures of cultures (7 days) in cultures using 3×10^6 patient cells correlated significantly ($p < 0.05$) with a high titer of circulating infectious virus (10^6 and with plasma viremia, and possibly ($p = 0.11$) with stage of illness.
Conclusions: Culture-positive blood HIV PBMC cultures approximately 100 infectious cells per cm³, with a range from 10 to 10,000 infected cells per cm³.

Th.C.P.135 INFECTION OF MESENCHYMAL CELLS WITH HIV-1 IN VITRO

Melzer, W., Knaemlich, A., Pest, H., Schmid, J., Wiser, A., Eder, Volker*
*GSF-Abteilung für Molekulare Zytobiologie, D-8542 Neuherberg, *Medizinische
Poliklinik der Universität München, D-8000 München, West-Germany.

Objective: Infection of mesenchymal cells of different origin (lung, skin, bone) with HIV-1 in vitro.
Methods: Infection of primary cell cultures and permanent cell lines with HIV-1 in vitro. Demonstration of virus infection and production by indirect immunoperoxidase staining (IP), in situ hybridization, reverse transcriptase activity (RT), electron microscopy and virus rescue.
Results: Different human cells of mesenchymal origin (primary skin fibroblasts, fetal lung cells, osteogenic cells) can be infected with HIV-1 in vitro. Especially in lung-derived cells, the infection was more pronounced, could be inhibited by anti-CD4 monoclonal antibodies and resulted in a persistent and productive infection similar to that of T-cells (RT activity, amount of infectious particles).
Conclusions: The productive and persistent infection of mesenchymal cells with HIV-1 indicates another potential virus reservoir in vivo which may contribute to local pathogenesis as for example in the lung (pneumonia).

Th.C.P.137 COMPARISON BETWEEN IMMUNOCYTOCHEMICAL ANALYSIS (ICF) AND IN SITU HYBRIDIZATION (ISH) IN DETECTION OF HIV INFECTION OF MONOCYTE-MACROPHAGES (MΦ).
Cohen, Suzanne; Elbak, T. Thomas, F. Ishaq, S. Olla, J. McGrath, W. San Francisco General Hospital/University of California, San Francisco, CA, California, U.S.A.

Objective: To compare the techniques of ICF and ISH in assessment of proportion of MΦ which contain HIV antigen and HIV RNA respectively.
Methods: MΦ were isolated from (1) peripheral blood (PB) of HIV seropositive donors (n=6) infected in vitro with HIV-1 at multiplicity of one; (2) PB of HIV-infected individuals (n=6). MΦ were stained with Mab directed against HIV p24 (provided by J. Carlson, U.C. Davis) and the proportion of cells expressing HIV was quantitated using an Ortho IIS cytofluorograph. Parallel samples of MΦ were spotted onto slides, fixed and ISH was performed with ³⁵S-labelled full-length HIV-1 RNA gene probe (provided by Chiron, CA). Slides were coded and examined by a blinded observer.
Results: In the 20 samples examined, the proportion of MΦ containing HIV antigen varied from 0-70% and the proportion of cells containing RNA varied from 0.001 - 881. Linear regression analysis showed a strong correlation between the two methods ($r = 0.77$). The calculated relationship between ICF and ISH is: $1 \text{ MΦ HIV positive (ISH)} = 0.8 \text{ ICF MΦ positive (ICF)} - 3.75$.
Conclusions: ICF and ISH correlate well in determining the proportion of MΦ within a population which contains HIV p24 antigen or HIV RNA respectively.

Th.C.P.134 A BROAD-RANGE MUTANT OF HIV WHICH CAN INFECT FIBROBLAST-LIKE CELLS DERIVED FROM HUMAN BRAIN.
Tateuchi, Yasuhiko and Hosono, H.
Gunze University, Maebashi, Gunma, Japan

Objective: It is not understood well what type of cells in the brain and what type of HIV have participated in the development of neurological disorders induced by HIV. In this study, we analyzed a mutant HIV which can infect fibroblast-like cells derived from human brain.
Methods: Fibroblast-like cells (BF cells) were readily cultivated from various types of human brain tumours. A mutant of HIV (HIV(GM-1)) highly infectious not only to T4⁺ T cells, but to BF cells was obtained by infection of BF cells with HIV(GM-1)₁, which is infectious to T4⁺ T cells, but almost not to BF cells. Genomes of HIV(GM-1)₁ and HIV(GM-1)₂ were cloned from DNA of HIV(GM-1)-infected M92-4 and DNA of HIV(GM-1)₁-infected BF cells, respectively. Various recombinant genomes were transfected to M92-4, and recombinant viruses were produced.
Results: Infectivity of recombinant viruses to BF cells were tested. Viruses containing a 2.3 kbp PstI (Pst-3) fragment derived from HIV(GM-1)₁ clones were infectious to BF cells, whereas viruses containing Pst-3 fragment from HIV(GM-1)₂ failed to express HIV-antigens in BF cells. The Pst-3 fragment contains the Pst-3 open reading frame and the Pst-3' region of the sequences of the Pst-3 fragments from the two viruses, we detected three nucleotide mutations.
Conclusions: Differences in infectivities of HIV(GM-1)₁ and HIV(GM-1)₂ to BF cells was coded for by the Pst-3 fragment. Some of the three nucleotide exchanges might determine the host-range differences.

Th.C.P.136 SYNTHETIC SELECTIVE INHIBITORS OF HIV PROTEASE
Micheals, Christopher J., Blumenstein, J.J., Copeland, T.D., Drayton, S.

BI-Basic Research Program, CMC-Friedrich Cancer Research Facility, Frederick, MD, U.S.A.

Retroviral protease, the enzyme which processes viral precursor polyproteins, is essential for virus replication and thus is an attractive target for chemotherapeutic treatment of retrovirus infections. We have designed and synthesized a structurally simple and versatile class of compounds, 1,3-epoxy alcohols, acids, and derivatives, and found several of them to be selective inhibitors of the HIV protease. The effect of these compounds on chemically synthesized HIV protease was conveniently studied by monitoring the cleavage of an antibiotic single peptide bond in a synthetic nonapeptide corresponding to a natural cleavage site in HIV-1 gag precursor polyprotein. The relative inhibitory effects of these compounds have afforded an insight to the structural characteristics which impart activity. Several compounds which inhibited the HIV protease showed negligible inhibitory effect on renin, a related neuronal aspartyl protease. Preliminary studies indicate that some of these synthetic compounds inhibit viral infectivity without substantial cytotoxicity. These compounds represent an entirely novel class of agents against HIV infection. (Research sponsored by the National Cancer Institute, DMS, under contract NO. N01-CO-7412) with Biotech Research, Inc.)

Th.C.P.138 QUANTITATION OF HIV-1 IN PLASMA AND PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMC) OF SEROPOSITIVE PERSONS.
Ho, Bruce J. Alan, M.J. Mowatt, T. Liu, S. UCLA School of Medicine and Cedars-Sinai Medical Center, Los Angeles, CA, U.S.A.

Objective: To quantify the titer of infectious HIV-1 in plasma and PBMC.
Methods: Plasma (2, 10, 40, 200, 1000 uL) and PBMC (2×10^6 to 2×10^7) were cultured with H9 and PM1C from normal donors. Virus titer was measured by suppressive p24 antigen assay weekly for up to 28 days. Infectious titers for plasma and PBMC were expressed as those cultures infective dose (TCID₅₀) per mL and TCID₅₀ per 10^6 cells, respectively.
Results:

	N	Serum p24 (ng/mL)		TCID ₅₀ /mL		PBMC HIV-1 titer (TCID ₅₀ / 10^6 cells)	
		mean	range	mean	range	mean	range
Healthy	12	0	0	0	0	2-50	23
ARC	8	140	434	25-500	196	50-5000	2675
AIDS	19	9-500	1812	5-5000	143	5-5000	1433

Conclusions: (1) Infectious HIV-1 was detected in the plasma of every seropositive person, suggesting that HIV-1 infective activity and not latent (2) Asymptomatic individuals have significantly more virus in plasma than asymptomatic individuals. (3) In 1 mL of blood, asymptomatic persons have approximately 15 TCID₅₀ of HIV-1 in plasma and 25 TCID₅₀ of HIV-1 in mononuclear cells, while ARC and AIDS patients have 165 TCID₅₀ in plasma and 1000 TCID₅₀ in cells. In fact, many asymptomatic patients harbor HIV-1 in 1 in 300 PBMC, which is a 100-fold increase in frequency over that previous reports suggesting that only 1 in 10^4 or 10^5 cells carry virus. (4) This quantitative culture has been successfully applied in patients receiving azidothymidine to demonstrate the in vivo antiviral effect.



Session d'affichage Poster Session



Recherche fondamentale (biomédicale) Basic Research (biomedical)

Th.C.P.139 THE BINDING OF H5A₂g TO HUMAN T4 LYMPHOCYTES INDICATES THE POSSIBILITY OF THE ANTIGEN TO FUNCTION AS OLIGOPEPTIDE ANTIGENIC TO HIV PRIMARY INFECTION OF T4 LYMPHOCYTES.

Leung Seawen-Lai¹

National Research Institute of Health, P.O.Box 1202, Asele Avenue, Ethiopia

Objective: To evaluate if H5A₂g can bind on CD4 receptor of human T4 lymphocytes and to identify if it can function as oligopeptide antigenic to HIV primary infection of T4 lymphocytes.

Methods: H5A₂g positive sera samples, partially purified H5A₂g and highly purified H5A₂g were assayed for H5A₂g reactivity when tested with and without equal volumes of human T4 lymphocytes (2x10⁶ cells) using Oregon diagnostic kit for the detection of HIV-1.

Result: H5A₂g reactivity in the samples gave higher OD reading than tested with the T4 lymphocytes than the same samples tested without the T4 lymphocytes.

Conclusion: H5A₂g can bind on human T4 lymphocytes obviously on the CD4 receptor hence may function as oligopeptide antigenic to HIV primary infection of T4 lymphocytes. The application of oligopeptides of H5A₂g in preventing HIV primary infection of T4 lymphocytes should be investigated in the future.

Additionalles

Additional

Th.C.P.141 HUMAN MONOCLONAL ANTIBODY AGAINST HIV

Shimizu, Etsuko¹, Sasaki, K., Katagiri, K., Kubo, K., Katori, N. and Takayama, K.W.
Kurume University School of Medicine, Kurume, Fukuoka, Japan

Objective: Attemp. were made to produce monoclonal antibodies of human origin against HIV which have neutralizing antibody activity.

Methods: Monoclonal cells from peripheral blood of the patients with hemophilia showing sero-positive to HIV and the healthy sero-negative donors were cultivated with inactivated HIV and GDH antibody on an *in vitro* immunization for 4 days. On day 4, EBV was infected to the culture. After 2 to 3 weeks of cultivation the growth of EBV transformed B cell clusters was observed. Culture supernatant of propagated B cells through cloning procedure was tested for their antibody activity to HIV by using ELISA method, immunofluorescence method, and Western blot procedure.

Result: Series of experiments were performed on the monoclonal cells originated from 2 hemophilia B patients, 1 hemophilia A patient, and 2 healthy donors. Numbers of B cell clones were obtained from a hemophilia B patient in AHC stage, whereas no continuous propagation of B cells were observed on the cells from other donors. Some culture supernatants of the propagated B cell clones showed antibody activity to HIV by ELISA method. However, those positive reactivities have not been reproducible by immunofluorescence or western blot procedure.

Conclusion: A procedure to produce human monoclonal antibody against HIV by EBV transformed B cell method has been partially established. Cloning procedure and screening procedure have to be improved to obtain B cell clones consistently produce human monoclonal antibody to HIV.

Th.C.P.143 DECREASING PRODUCTION OF IgG, IgM, AND IgA ANTIBODIES AGAINST PHENOCYTIC CARININ ANTIGENS IN AIDS PATIENTS

MORSE, L. AND DE WETTING, BERT.

BAKER RD WILHELM, ANNE GRETE POLGREN, CLAUDE EODOP, BO HOFMAN, AND

PHILIPPE MOJUM,***

Stempejers Hospital, ***Statens Serum Institut and ***State University Hospital, Copenhagen, Denmark, ***University Claude Bernard, Lyon, France.

Objective: The study assesses IgG, IgM, and IgA production against major Hemocytin carinin (PC) antigens during the development of AIDS.

Methods: Eight hemocytin AIDS patients were included in the study. Six patients suffered from PC Pneumocystis during the period and two patients had Kaposi's sarcoma. Between 2 and 21 sera per patient were examined for specific antibodies. Twenty-nine healthy volunteers served as controls. The antibodies were assayed by ELISA and western blot using soluble PC-antigens.

Result: All patients, except one, had decreasing antibody level in all immunoglobulin classes. The level of IgG and IgM were in all patients below the level of the normal subjects. However, the IgA level was during the whole period above the level of the normal subjects. Western blot showed changes relative to the major antigenic components with molecular weights of 64,000 and 98,000 Dalton. IgG from normal controls did not react in the 98,000 Dalton antigen reaction. The reaction between the immunoglobulins and the antigenic components disappeared in the following order: IgG64, IgM98 and finally IgG98 or IgA98.

Conclusion: The humoral immunity against PC may serve as a marker for the degree of immunodeficiency in AIDS patients.

Th.C.P.140 ANALYSIS OF A FUNCTIONAL HIV-1 REV GENE Sylvia Paulina, M. Ennemas, and A. Cordonnier, Unité d'oncologie virale, Institut Pasteur, Paris, France

Objective: HIV-1 Rev is required for HIV-1 envelope protein expression. We have begun a functional and structural comparison of the *rev* gene of HIV-2 with that of HIV-1 in order to better understand their mechanism of action.

Results and Methods: We constructed a cDNA library from HIV-2 infected cells and cloned a cDNA encoding the *rev* gene. The sequence of the *rev* cDNA shows that the *rev* gene of HIV-2 is encoded on a message with four exons. The first, from R to the major splice donor, and the second, a 72 bp exon in the *pal* gene, are non-coding. The first coding exon begins between the ATG of the *pal* gene and the ATG of the *rev* gene and ends after the ATG of the *rev* gene. The second coding exon begins near the end of the *env* gene. The HIV-2 *rev* gene product is predicted to share 44% amino acid identity with that of HIV-1. To show that the HIV-2 *rev* cDNA was functional, co-transfections were done with another plasmid that encodes the envelope gene of HIV-2 from a plasmid vector was dependent on co-expression of the HIV-2 *rev* cDNA.

Conclusion: We have cloned a functional cDNA encoding the HIV-2 *rev* gene. The analysis of the specificity of the HIV-2 *rev* product with that of HIV-1 will be useful in defining the target site of the HIV *rev* products.

Th.C.P.142 CHARACTERIZATION OF MONOCLONAL ANTIBODIES REACTIVE WITH DIFFERENT PROTEINS OF HIV-1 - MDK STRAIN.

REISER, S., ROBERT V., VITKOVIC M. and GERMANN, J.-C.

Unité de Génétique Moléculaire, Ins. Pasteur (Unité Associée U-3221) - Centre de Lympho

- et de Cell. Humaines, Paris - FRANCE

To obtain to generate monoclonal antibodies (mAb) specific for the highly expressed strain HIV-1MDK. Until now, 8 mAb have been obtained: 3 mAb have been shown to react with epitopes of 28 (mAb: H1.4.73; H1.5.11.141; or gp120 (mAb: H1.16.74)) shared among several HIV-1 isolates. The 5 other mAb (3 of which react with epitopes of gp120 (mAb: H1.16.74 and H1.16.74) and 2 with an epitope of gp84 (mAb: H1.21.51)) apparently bind specifically HIV-1MDK proteins. Further characterization is in progress to evaluate the biological effects of these reactions on HIV-1 infection.

Th.C.P.144 B-CELL SYSTEM ACTIVATION AND HIV-1 INFECTION

MAHILLI, ALBERTO¹, ZANETTI, R.², VERONESI, M.L.¹, FRANCESCHI, L.²

1-IRCCS, ***; 2-IRCCS, *** and Chiao-Giuliano L.²

¹Institute of Oncology, University of Padova; Dept. of Infectious Diseases, ILSG 21, Padova²; ULSG 36, Mestre² - ITALY.

Objective: To better define B-cell activation during HIV-1 infection.

Methods: Limiting dilution assay of B-cell precursors spontaneously secreting HIV-1-specific and total Ig by absorption of culture supernatants with solid-phase HIV-1; effect of T-cell and monocyte removal, and interleukin addition, on *in vitro* spontaneous Ig synthesis.

Results: *In vitro* spontaneous Ig synthesis did not depend on T-cell presence, while monocyte removal caused a striking fall in spontaneous Ig production. IL-6 presence in culture was essential; antisera against IL-6 strongly reduced spontaneous Ig synthesis, which was partly restored by rIL-6 addition to monocyte-depleted populations. The frequency of B-cell precursors spontaneously producing HIV-1-specific Ab was about 1/3-1/4 of that of spontaneously activated, Ig-secreting precursors. However, after absorption with solid-phase HIV-1, about 30% of total Ig was removed from unstimulated culture supernatants.

Conclusion: HIV-1-specific B-cell activation is a major component of the overall B-cell activation in PB. In part seropositive subjects. This phenomenon can contribute to the virus-induced immune damage, and partly explain the increased frequency of AIDS-associated B-cell malignancies.

Session d'affichage Poster Session



Recherche fondamentale (biomédecine) Basic Research (Biomedical)

Th.C.P.145 FINE STRUCTURE OF INSIDE THE VIRAL ENVELOPE OF THE HIV-1 [John Tashmeh¹, A-W Lademann², W Tamao³, M S Schulz⁴].
¹Central Laboratory for Electron Microscopy, Teikyo University School of Medicine, Tokyo, Japan, ²Institut für Pathologische Anatomie, ³Max-Planck-Gesellschaft, ⁴Harvard University, Boston, MA, U.S.A.

OBJECTIVE: We presented an envelope surface model of HIV-1 using a computer image processor with negatively stained electron micrographs, namely, envelope structure of HIV-1 particle is constructed of 7-7 layers symmetric lamellae and 72 knob(gp120) are stuck into the envelope on the pentamer/hexamer clustering positions. Int. Conf. AIDS, abstract No. 1002, and J. AIDS to press). Our results support the studies presented by Goldbloom et al. In this study we will indicate some structures under the viral envelope.

METHODS: HIV-1 particles were obtained from HIV-producing M9-cells of the HT-lymphocyte line. The HIV-1 particles were negatively stained with 2% phosphotungstic acid (pH 6.6) and then dried in air to obtain well preserved structures.

RESULTS: From the electron microscopic observations following features will be suggested.

1) The core shell has a polyhedral structure.

2) The space between viral envelope and core shell is filled with fibrous structures.

We also show a three dimensional model.

Th.C.P.147 HIV-1 DOES NOT REPLICATE IN HUMAN VAGINAL EPITHELIAL CELL

Sanjour, James, Norrweber, C, and Sobel, J.
Wayne State University, Detroit, MI, USA 48201; Veterans Administration Med. Ctr., Allen Park, MI, USA 48101

OBJECTIVE: To determine the ability of HIV-1 to replicate in human vaginal epithelial cells, a potential cellular target to heterosexual transmission.

METHODS: Vaginal epithelial tissue explants obtained from HIV-seronegative women undergoing hysterectomies were seeded in tissue culture wells for 12 days. Cell-free supernatant from HIV/HTLV-III B-cells was added and adsorbed 2 hr. Explants were washed three times with saline, refed, and examined for morphological changes and supernatant HIV p24 antigen (Abdotest) at times 0, 2, 4, 8, 10, and 18 days following viral inoculation.

RESULTS: No morphological changes were detected for tissue explants inoculated with HIV when compared to uninoculated wells. Growing monolayers consisting of epithelial and/or fibroblasts were observed in all wells, and increased in size regularly. Supernatant p24 antigen levels were negative in all wells at the time points examined.

CONCLUSION: Human vaginal epithelial cell in contact support HIV replication when assessed for up to 18 days following inoculation with a lymphoblastoid-adapted strain of virus. Experiments are in progress to determine whether a macrophage-adapted strain of HIV can infect vaginal tissue explants.

Th.C.P.149 MOLECULAR CHARACTERIZATION OF A DEFECTIVE HUMAN

IMMUNODEFICIENCY VIRUS
M. Inoue, J. A. Hunkler, and E.P. Reddy*
*The Wistar Institute, Philadelphia, PA, USA; *Hospital of the University of Pennsylvania, Philadelphia, PA, U.S.A.

Prologed culture of HD919 cell line, chronically infected with HIV-1, resulted in the emergence of a variant cell line that was found to be defective for virus production. This cell line (M-III) was tested for the production of p24 antigen by ELISA and was found to be negative. Similar negative results were obtained when the cells were analyzed by FACS using monoclonal antibodies to p24. However, these cells were found to produce large quantities of HIV envelope gene product and were found to induce massive apoptosis when cocultured with SUPT-1 cell line which is a CD4+ T-lymphocytic leukemia cell line. Immunoprecipitation analysis of the labeled cell lysates revealed the synthesis of envelope gene products (gp160, gp120). As predicted, there was no synthesis of p24 antigen as well as gag precursor protein, p55. The Southern blotting analysis of the M-III cell DNA revealed the presence of a single proviral genome in cellular DNA. Following digestion with XbaI, which cleaves outside the proviral genome, the DNA was fractionated and cloned into a λ phage vector. A molecular analysis of the proviral genome aimed at understanding the nature of defect will be presented.

Th.C.P.146 SOME OBSERVATIONS ON THE LATEST HIV INFECTION PHASE

Paganella, M., Microni, M., Miceli, M., Rossi, M., Vescovi, H., and Mazzella, L.***
*** Institute Infectious Diseases, ¹Department of Obstetrics I, University of Rome -National Center for Blood Transfusion C.R.I.; ²Ospedale L. Spallanzani, Italy

Objective: To evaluate the latest HIV infection period, from January 1985 to December 1988 six seronegative regular sexual partners of HIV infected subjects have been studied.

Methods: The seronegative diagnosis has been based on the demonstration of the absence of specific serum antigen and antibodies to the viral proteins by EIA and Western Blot tests. The HIV latest infection has been evaluated by "in situ" hybridization on peripheral blood mononuclear cells (PBMC) using an SP 64 plasmid containing the full-length 9 kb viral insert flanked by 10 ribonuclease sites tagged with a sulfone group and visualized by double immunohistochemical antibody reaction. The controls were performed using HIV infected and non-infected 8 x culture cell lines and PBMC from healthy blood donors.

Results: The HIV genome was demonstrated, at first control, in the cytoplasm of mononuclear cells of all the seronegative subjects as a granular staining (kallium phosphatase). Five subjects showed a transient positivity for anti-p 24 and linear for specific HIV antigens. One subject seroconverted three months after first control.

Conclusions: The "in situ" hybridization is a useful technique to recognize HIV infection at very early stage.

Th.C.P.148 EXCRETION OF HUMAN IMMUNODEFICIENCY VIRUS IN BODY FLUIDS

Georday, Mark, Barrett, J., O' Shea, J., Stames, J., Gostowski, J., London, UK; Abbott Diagnostic Division.

OBJECTIVE: To evaluate techniques to assess HIV excretion patterns and specific antibody responses to body fluids.

METHODS: Peripheral blood, semen, saliva and female genital secretions from asymptomatic and symptomatic patients are being examined for infectious virus, viral antigens (EIA and flow cytometry), viral nucleic acid (PCR to follow) and antibodies (EIA and Western Blot).

RESULTS:

Sample	Infectious Virus	Antibodies	IgG	IgA
Saliva	0/31 (0%)	12/31 (38%)	17/31 (54%)	1/31 (3%)
Semen	3/12 (25%)	0/23	29/20 (84%)	11/13 (84%)
Saliva	0/12	0/18	12/23 (52%)	1/12 (8%)
Genital	0/10	0/5	0/5 (0%)	0/10

No positive/was tested

Positive cultures occurred within 3-7 days among asymptomatic and 7-28 days among asymptomatic patients. We have shown that flow cytometry provides an efficient method for analysis of cell populations in blood and female genital secretions; we have not yet detected expression of HIV antigens.

CONCLUSIONS: Infectious virus and viral antigens were detected less frequently in semen and saliva which may reflect the fact that they contain specific antibodies. These fluids probably represent a low risk for transmission of virus. Detection of positive cultures earlier among asymptomatic than among asymptomatic patients suggests higher virus load or rates that replicate more efficiently.

Th.C.P.150 HIV EARLY VIRUS-CELL INTERACTIONS

Greer, Cynthia Beck, A., Georday, M.R., Robert Koch-Institut, Berlin, FEDERAL REPUBLIC OF GERMANY

Objective: HIV infects CD4+ cells, mainly lymphocytes and macrocytes. Two entry mechanisms have been observed in different reports: 1. direct fusion of the viral envelope with the cell membrane, 2. receptor-mediated endocytosis via clathrin coated pits and vesicles.

Methods: Differentiated cells were incubated with purified virus and studied by EM at different time intervals and temperatures with regard to adsorption, fusion mechanisms and penetration of the core. Emission. Since fusion was seen not only within cytoplasmic vesicles but also the cell surface of both lymphocytes and macrophages, virus entry seems to be pH independent. The two layers of the viral envelope and the lipid bilayer of the cellular membranes usually fuse seamlessly within 1-3 min, but occasionally membrane ruptures may also occur, leading to rapid cytopathic effects, i.e. vacuolization and cytolysis. In the course of fusion at the cell surface, the viral envelope glycoprotein gp120 is integrated into the lipid bilayer of the cell membrane, where it can be visualized by immunoelectron microscopy. Free gp120, shed by the mature virus already before attachment to the cell, may also bind to the cell surface and is most frequently found within clathrin coated pits.

Formation of synaptia by cells studied with viral proteins was observed as early as after 1h of incubation with virus. SBL668(HIV-2) Syncytia reach a larger size than HTLV-III (HIV-1) Syncytia.

Conclusion: The rapid entry of HIV into its host cell as well as early cytopathic effects should be considered in attempts to block virus entry or replication.



Publications

Immunologie de base
Basic Immunology

C.513 A NEW EMPLOYED ASSAY FOR NEUTRALIZING ANTIBODIES TO HIV-1
MILLON, G.M.*; FISHER, R.*; POWLER, A.A.**; ARTHUR, L.*
HIV-1

*Program Resources, Inc., MCI-Fredrick Cancer Research Facility, Frederick, MD, USA; **NSA Laboratories, Rockville, MD, USA; *** Division of Cancer Etiology, NCI, Frederick, MD, USA; **** Developmental Therapeutics Program, Division of Cancer Treatment, MCI, Frederick, MD, USA.

Objective. To develop a simple, large-scale assay for the safe and rapid quantitation of antibodies which block HIV-1 infectivity.

Methods. The reduction of a new tetrazolium salt, NTZ, by viable T-lymphoblastoid cells to a soluble formazan was used to quantitate HIV cytopathic effects in a semi-automated 5-day microtiterum procedure for evaluation of neutralizing antibodies. Comparative methodologies included analysis by enzyme assay, quantitation of p24 synthesis, and anti-HIV-1 gp120/gp130 binding tests.

Results. The tetrazolium assay permitted screening large numbers of human and non-human primates sera including selected AIDS patient sera and sera from isocou- vaccinated chimpanzees and rhesus monkeys for antibodies to HIV-1. Sera from goats immunized with HIV gp120/gp130 were also evaluated for specificity of reactivity permitting development of a competition neutralization assay.

Conclusion. The soluble formazan based tetrazolium assay can be employed for large-scale screening of sera from a variety of species for neutralizing antibodies to HIV. This new assay eliminates manipulations associated with other tetrazolium assays and is sensitive enough to permit evaluation of antibody binding specificities. Supported in part by NCI-CA74102

C.514 ANTIBODY DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC) IN RELATION TO CLINICAL PROGRESSION OF HIV-1 ASSOCIATED DISEASES IN HOMOBIOTICITY

Stclair, Anne J., Hoesbelen, J., Mail, L., Steele, N.* Jodan, C.** and Sinclair, A.G.
MRC Clinical Research Centre, Harrow, UK. **MRC Clinical Cytotoxicity Unit, Edinburgh, UK. *Scottish S.S. Regional Blood Transfusion, Middlesbrough, UK.

Objective. Evaluation of the ability of serum samples from a cohort of HIV-1 positive haemophiliacs to mediate ADCC, with study of the relationship of ADCC to clinical state and disease progression.
Method. HIV-1 isolate in the CEM cell line were used as target cells and peripheral blood mononuclear cells from selected normal donors as effector cells*. Comparison of serum samples from 36 HIV-1 positive haemophiliacs infected with the same contaminated factor VIII is described. Titres of antibody mediating HIV-1 specific ADCC are compared with the evolution and clinical stage of HIV-1 associated disease.

Results. Preliminary results show that 7/7 M/CPC patients with non-progressive disease have higher ADCC than 2/2 patients progressing to AIDS. Full results of 30 patients will be presented.
Conclusion. Our preliminary studies as well as those from other groups support a protective function of sera that can mediate HIV-1 specific ADCC. It is confirmed the findings will be of importance in design of HIV vaccines and therapeutic strategies.

*Reference: Stclair, A.J., Hoesbelen, J.H., Mail, L., Chandler, J., Forster S., Crickham, K. and Dalgleish, A.G. (1988) Antibody-dependent cell-mediated cytotoxicity: comparison between HIV-1 and HIV-1 assays. AIDS Journal, 2:465-472.

C.515 ANTISPERM ANTIBODY AS A RISK FACTOR FOR SEXUALLY TRANSMITTED HIV INFECTION
MILIN, Steven S. and Jordan, J.
Cornell University, Ithaca, New York, New York U.S.A.

Objective. To determine whether men with antisperm antibodies in their semen will be more likely than men who are not permitted to sperm to transmit HIV to their sexual partners. Men with a history of STDs and homosexual sex have a high incidence of antisperm antibodies.

Method. Semen from fresh ejaculates were tested for bound antibodies by the immunodiffusion assay. Spermatozoa from sperm cells were purified by ficoll-density gradient centrifugation and CD4 and CD8 T lymphocytes quantitated by immunofluorescence staining using monoclonal antibodies. Interferon gamma (IFN γ) in seminal fluid was measured by ELISA. The ability of sperm with or without bound antibodies to induce IFN γ production or immunosuppress allogeneic mononuclear cells was determined by cocultures.

Results. CD4 cells predominate over CD8 cells in semen from men with antibody-free sperm. In men with antibody-bound sperm there is a selective loss of CD8 cells so that CD4 cells now predominate. IFN γ is present in semen only from men with antibody-bound sperm. Antibody-bound sperm induces IFN γ from allogeneic lymphocytes while antibody-free sperm inhibits allogeneic lymphocyte proliferation.

Conclusion. CD8 cells normally predominate in semen and the male genital tract and sperm are immunocompetent. This inhibits replication of HIV-infected sperm cells. In men with antibodies to sperm, however, CD4 cells predominate in semen and their sperm are IFN γ inducers. This promotes replication of HIV-infected cells in the male and enhances viral infectivity.

C.516 MODULATION DE L'EXPRESSION DE CD4 PAR LE PMA ET INFECTION VIH IN VITRO
MARCHAL, Karim, Bercat, I. et Tourain, J. L.
Faculté de Médecine A. Carrel, INSERM ICM-CNRS URA 117, Lyon, France

Objectif. La liaison de la glycoprotéine 120 (gp120) à la molécule CD4 constitue l'un des événements principaux de l'infection de la cellule par le virus de l'immunodéficience humaine (VIH). Le modulation de l'expression de CD4 in vitro, par le phorbol myristate acétate (PMA), permet d'étudier les conditions d'infectivité de la cellule par le VIH.

Méthodes. Des cellules de lignée lymphoïde 845 sont prétraitées avec PMA (10⁻⁶M pendant 1,5 et 16h. Le phénotype CD4 de ces cellules est analysé en immunofluorescence avant l'infection par VIH in vitro. L'évaluation de l'infection virale est basée sur l'apparition d'un effet cytopathogène (CCP), l'expression intracytoplasmique de l'antigène viral p24 et d'une activité transcriptase inverse ou RT.

Résultats. Les cellules 845 sécrètent, 8 jours de 80%, la molécule CD4 et des conditions de leur infection in vitro par PMA ont été définies. Le traitement des 845 au PMA, pendant 1,5 et 16 h permet une forte réduction de l'expression CD4 associée à une absence d'CCP et de p24 intracytoplasmique. L'activité RT était absente après 1h d'incubation au PMA mais par contre détectable à 5 et 16 h de prétraitement au phorbol.

Conclusion. Ces résultats confirment que l'infectivité in vitro par VIH est associée avec le degré d'expression de la molécule CD4.

C.517 QUANTIFICATION OF HIV-BINDING TO CD4+ CELLS USING FLOW CYTOMETRY

Thiele, Bernhard*, Kunze, R.O.F.*, Gebauer, F., Ramirez, G., Gedenbom, H., Pauf, G., Abt, Vilhelm, Robert Koch-Institut and AIDS-Zentrum, BGM, Berlin.
*Max Planck-Gesellschaft, AG Rheumatologie, Universitätsklinik Erlangen-Nürnberg

The anti-CD4 antibody Leu 3a is able to inhibit HIV-virus binding to its receptor, the CD4-molecule. (Weiss et al., 1984). On fluorochrome-labeled Leu 3a in combination with Scatter-Plot analysis of flow cytometric data gives a good estimate of the average number of CD4 molecules per cell and of the corresponding affinity constants. Such the optimum Leu 3a concentration with the highest sensitivity to sterfing ligands can be used in further experiments. Human peripheral blood lymphocytes were incubated with supernatants of HIV-producing cell lines (Molt 4/B, H9), washed and fixed. The remaining binding capacity for Leu 3a was determined using a calibrated flow cytometer. The decreased fluorescence intensity compared to appropriate controls can be regarded as a measure of gp120 blocked CD4 and intact viruses. Ultraconjugation of HIV containing supernatants makes it possible to distinguish free gp120 from particle-associated glycoprotein and to estimate the content of viruses with ability to bind to cells. In all experiments performed receptor occupation by HIV-virions or their glycoprotein did not exceed 50% of the CD4 molecules which is in good agreement with theoretical considerations

C.518 SPONTANEOUS TMF-ALPHA PRODUCTION BY ALVEOLAR MACROPHAGES AND PERIPHERAL BLOOD MONONUCLEAR FROM PATIENTS WITH AIDS

Crickham, K., Vazir, M., Mitchell, J., and Pritchard, A.,
MRC Clinical Research Centre, Harrow, UK.

Objectives. To assess spontaneous and IFN induced TMF-alpha production by alveolar macrophages (AM) and peripheral blood mononuclear cells (PBMC) with and without IFN (alpha 2) after which supernatants were collected and assayed for TMF-alpha.

Group 1 - HIV positive patients with PCP (20/20)
Group 2 - HIV positive patients without PCP but with bacterial infection (LAC or AIDS) (20/20)
Group 3 - HIV negative patients with negative bacteriology for LAC or AIDS (20/20)

Results. Spontaneous TMF-alpha production was significantly higher in Group 1 patients with PCP compared to Group 2 patients without PCP but with bacterial infection. Spontaneous TMF-alpha production was significantly higher in Group 3 patients with negative bacteriology for LAC or AIDS compared to Group 2 patients without PCP but with bacterial infection.

Figure. are mean values of TMF α expressed as units/ml/10⁶ macrophages. Values lower than the limit of detection of the assay (25 units/ml) were assigned a value of 0.

Conclusion. AIDS patients with Pneumocystis carinii pneumonia, but not bacterial infection, showed increased spontaneous TMF-alpha production.

C.519 INDUCTION OF MAJOR HISTOCOMPATIBILITY (MHC) CLASS II ANTIGEN ON CELLS OF THE DEVELOPING HUMAN PERIPHERAL NERVOUS SYSTEM BY GAMMA-INTERFERON

Micha, A. and Wigdals, E.
Department of Microbiology and Immunology, The Pennsylvania State University College of Medicine, Hershey, PA 17033 USA

Objective: To examine the effect of gamma interferon (γ -IFN) on the level of MHC class II expression on cells isolated from the developing human fetal peripheral nervous system.

Methods: γ -IFN was used to study the induction of MHC class II antigen expression on the surface of cells obtained from dorsal root ganglia (DRG) derived from abnormal human fetal specimens between 13 and 16 weeks gestation. The induction of class II antigen expression by γ -IFN was also examined on U373 glioma cells. Fluorescence-activated flow cytometric analysis was performed on both live and fixed cells utilizing a primary monoclonal antibody specific for the HLA-DR (MHC class II) region-associated bimolecular complex in conjunction with a fluorescein-conjugated anti-mouse secondary monoclonal antibody.

Results: We have demonstrated that between 15 and 25% of human DRG neural cells isolated from abnormal human fetal specimens are HLA-DR antigen positive. However, human fetal DRG neural cells isolated from the same tissue were treated for 48 hr with γ -IFN (10 U/ml), the number of HLA-DR antigen positive cells increased to between 41 and 71%. Kinetic analysis of MHC class II antigen expression in the U373 glioma cell line after treatment with γ -IFN (100 U/ml), demonstrated an increase in the number of HLA-DR antigen-positive cells, reaching a maximum of 68-96% antigen-positive cells within 48 hr after exposure, declining thereafter, but remaining above pre-treatment levels 24 hr later.

Conclusion: γ -IFN enhances MHC class II expression on human fetal DRG neural cells. Future studies will examine the effects of HIV infection, HIV antigens, and factors secreted by HIV-infected cells on MHC class II expression in the developing human nervous system.

C.521 THE EFFECT OF HIV ON THE EXPRESSION OF HLA-DR AND CYTOSOLIC B-2-OXIDASE mRNA IN MONONUCLEAR CELLS

Cheln, C.T. and Henson, J.
Harvard Medical School and Brigham and Women's Hospital, Boston, MA, USA.

Objective: To determine if HIV infection can alter the expression of two DIFFERENT mRNA markers of mononuclear cell activation: 1. HLA-DR—the major histocompatibility antigen responsible for accessory cell function; and 2. Cytosolic B-2 heavy chain (cyt-b-2)—a component of the oxidase system responsible for mononuclear cell respiratory burst activity.

Methods: The HIV-1 strain was used to infect two human promonocytic cell lines, U937 and THP-1. At the time of peak reverse transcriptase activity, cells were divided into the following groups: non-stimulated cells; cells stimulated with 400 U/ml interferon (γ -IFN); and cells stimulated with 100 ng/ml lipopolysaccharide (LPS). Non-infected cells were treated identically and served as controls. After 24 hr, total RNA was extracted, electrophoresed and subjected to Northern blot using probes consisting of cDNA for HLA-DR and for cyt-b-2. An actin probe was used as an internal control.

Results: Expression of HLA-DR and cyt-b-2 mRNAs were decreased in non-stimulated, HIV-infected cells. γ -IFN stimulation resulted in increased levels of HLA-DR and cyt-b-2 mRNAs; however, these levels were diminished in the infected vs. the non-infected cells. LPS had no effect. Actin mRNA was equivalent in all groups and was not affected by either infection or stimulation.

Conclusion: HIV infection caused down-regulation of two markers of mononuclear cell activation at the transcriptional level. These alterations may play an important role in the pathogenesis of cellular immune dysfunction. γ -IFN partially reversed the HIV effects.

C.523 EARLY DEVELOPMENT OF ANTI-HIV IgG

Bahrén, B. Eriksson, P., Frolner, J., Nilner, E., Albert, E., Sandberg, E., and Eriksson, P.
National Bacteriological Laboratory, Stockholm, Sweden. **Ferring AB, Malmo, Sweden. ***South Hospital, Stockholm, Sweden.

Objective: To enhance the early seroreactivity in HIV infection/immunization.

Methods: Non-viral peptides covering the CD4 binding region of HIV were prepared by solid phase synthesis. All peptides were made to contain two cysteine residues in the same position and chemically oxidized. The sulphur bridges formed, restricts the peptides acritically.

Results: All patients ($n=100$) with established HIV-1 infection had an IgG1 response to one (J8-6) of two peptides representing the CD4 binding region. Subclasses IgG2, 3 and 4 appeared in 27, 60 and 33% respectively. In seroconverting persons ($n=10$) IgG1 and IgG2 antibodies to the peptide J8-6 developed within 3-4 weeks and paralleled total anti-viral IgG. The J8-6 sequence represents the C-terminal of the putative gp120 binding region.

Conclusion: The IgG1 seroreactivity of HIV-infected individuals is a chaotically modified peptide representing the CD4 binding region and the early seroconversion stage; primary infection implies a role for this peptide in vaccine development.

C.520 DECREASING ANTIBODY RESPONSES IN ASSOCIATION WITH AIDS

Roederly, B., Michalski, P., Katsanovich, D., McClellan, J.A.,* Sawyer, L.A.,* Wolick, L.C.,* Quintana, J.H.,* et al. *NIH, DV, Center for AIDS Evaluation and Research, FDA, Bethesda, MD, U.S.A. and **UCSD AIDS Core Study, San Diego, CA, U.S.A.

Objective: To identify HIV specific immune responses associated with the development of AIDS in HIV seropositive homosexual men.

Methods: Sera were obtained semi-annually from 20 asymptomatic HIV seropositive men in San Diego, 10 of whom developed AIDS and 10 remained stable. They were studied by quantitative Western Blot (WB) neutralizing antibody (NA) and antibody-dependent-cell-mediated cytotoxicity (ADCC) assays.

Results: Quantitative analysis of the IgG binding to individual proteins and glycoproteins of HIV W-81 demonstrated no differences between the groups at the initial visit. After 3-5 years, there was a significant decrease in antibodies against p24, p31, gp120, and p51 in the group with AIDS compared to the stable subjects ($p < .05$, Mann-Whitney). NA decreased in the AIDS group with AIDS and 2/10 stable subjects. Reciprocal geometric mean titers (GMT) of NA were identical in the two groups at presentation (1:10) subjects with AIDS and 1:100 in the stable group. In the AIDS group 17/20 subjects and there was no difference or change in ADCC titers between the two groups over the study period.

Conclusions: Development of AIDS in initially asymptomatic HIV seropositive homosexual men was associated with a decline in HIV specific antibodies against core antigens and NA but not ADCC or envelope binding antibodies as detected by WB.

C.522 MICROWAVE INDUCED SYNERGY IN HIV1 INFECTION: ACTIVITY OF SPECIFIC ANTIBODIES IN PARFIDIT SALIVA

Zelen, Zdenek, Anonhik, D.,* Pech, P.,* Havel, D.,* Dole, D.L., S.,* Melan, M.J.,* Rana, M.,* Harvard Univ., Boston, MA. *Univ. of Maryland, Baltimore, MD, U.S.A.

Objectives: To look for qualitative and quantitative properties of the specific antibodies in the period saliva of HIV1 infected people.

Methods: Human serum and periodical saliva was collected from 19 HIV1 infected individuals of different clinical stage: CDCII (7), CDCIII (8), CDCIV (3). The immunoglobulin IgA, IgG and IgM were separately diluted from the sera and saliva. The serological techniques used were the western blot, ELISA and neutralization test.

Results: Specific antibodies (Ab) to the HIV1 were found in the sera and saliva of all the people tested. They were found positive to both immunoblotting and ELISA. The immunoblotting revealed Ab to all major HIV1 antigens (env, pol and gag). The predominant Ig class of specific Ab toward env proteins in the serum was IgG, while in the saliva it was IgA class. Moreover IgA antibodies were found by ELISA in 14 of 18 saliva tested, while IgG antibodies were found in only 6 of 12 saliva samples. The level of Ab to the env antigens in the sera and saliva varied widely. Comparing level and class of IgA, we could not find any significant difference between the groups of asymptomatic, CDCII and AIDS affected people. The saliva IgA antibodies to the env proteins reacted more frequently compared to the serum IgA in 11 of 14 samples tested. The relative lower reactivity ranged from 2 to 65 times lower (mean=11). Neutralization assay revealed positive reaction in 3 of 7 sera tested in rather low titers (1:10-1:100). None of the 9 tested saliva nor their respective IgA demonstrated neutralization activity.

Conclusion: The current data revealed: A) Relatively low reactivity of saliva IgA compared to serum IgA. B) Lack of neutralization activity in the HIV1 antibodies of saliva. C) No correlation could be established between antibody reactivity and the 3 CDC HIV1 categories. These findings might suggest that the mucosal immune response in HIV1 infected people is impaired long before any subclinical symptoms of AIDS occur.

C.524 THE IMMUNE RESPONSE TO HIV-1 ENVELOPE PROTEIN IONOLVINS

2078 AIDS AND HIV
Y. Kikuchi, J. P. Ezzamel, M. McCaskey, A. Grondinakis, M. Berman, M.-P. Kieny, P. Sasmontelli, and L. Montagnier, Institut Pasteur, Paris, France, Strasbourg, France.

Objective: HIV protein specific cytotoxic effector cells, present in the peripheral blood of most HIV seropositive donors, have been characterized and shown to be HIV specific. HIV specific cytotoxic effector cells: Phenotypic studies and analysis of antigen processing were used to define these effector cells.

Methods: Recombinant gp120 anchored in the plasma membrane, soluble gp120, or an HIV precursor with deletion of the peptide signal or gp120 with deletion mutations were expressed in vaccinia. Autologous EBV transformed lymphoblastoid cells were infected with these recombinant vaccinia viruses and used as targets for primary cytotoxic effectors present in PBMC of HIV seropositive donors.

Results: The predominant HIV specific cytotoxicity in most HIV donors is mediated by ADCC effectors cells (CD8⁺, CD8⁺, CD8⁺, CD8⁺ and T_H1 cells can be blocked by antibody to human IgM. ADCC effectors cells are able to lyse only target cells that express the proteins on the cell surface as detected by surface immunofluorescence. However, CD8⁺ CTL are able to lyse target cells that do not express the whole env protein on the surface.

Conclusion: In the heterogeneous population of viral antigen specific effector cells in the peripheral blood of HIV seropositive donors, a major cytotoxic activity is HIV specific ADCC. However, in some individuals CTL activity or both ADCC and CTL activities are detectable.



C.525 TUMOR NECROSIS FACTOR (TNF) STIMULATES HIV-1 TRANSCRIPTION IN HUMAN T CELLS
Israel, Nicolas; Naran, U.J.; Alouf, J.J.; Bachelier, F.; Tranchesi-Milazzo, and Virelizier, E.
Institut Pasteur, Immunologie Virale, Paris, France.

Objective: We have examined whether TNF might stimulate HIV-1 transcription and we have analyzed the mechanism involved.
Methods and results: We transfected T_H then cell line (a subclone from Jurkat T cell line) with the plasmid LTR HIV-CAT which contains the HIV-1 LTR sequences upstream of the bacterial CAT gene. CAT activity was consistently increased 2 fold when transfected cells were treated with TNF. Subtransfection was enhanced: more than 20 fold when the RRE region of the LTR (nucleotides +158) was deleted. We have previously shown here that the enhancer (-108, -75) element, previously described to bind NF- κ B, is necessary for activation of the heterologous promoter. However, flanking sequences of this region are important for full transactivation. Using homologous assays, we show that this increased expression is accompanied by the induction or activation of an NF- κ B-like transcription factor. We show also that PMA and PHA have synergistic effects with TNF. Such a synergy was not due to superinduction or activation of this transcription factor and may be due to upregulation of TNF receptors by PMA or PHA.
Conclusion: Since TNF is secreted during most immunological and inflammatory reactions and has been indeed detected in the serum of AIDS patients, our observations suggest a possible role for TNF in the pathogenesis of AIDS through activation of HIV gene transcription.

C.527

C.529 HIGH LEVELS OF CELL-ASSOCIATED IL-1 IN CIRCULATING MONOCYTES FROM HIV-INFECTED INDIVIDUALS
Miles, Laurence; MacFarther-Cavillan, M.; Londe, M. and Kaschnick, R.
Unité d'Immunopathologie, Hôpital Brocauss, Paris, France.

Stimulation of normal monocytes results in transcription of IL-1 α and β genes and accumulation of cell-associated IL-1. Some but not all IL-1 inducers further trigger the extracellular release of IL-1 β . We have examined the production of cell-associated IL-1 *in vivo* and that of cell-associated and extracellular IL-1 *in vitro* in 30 infected individuals and 30 non-infected controls. Cell-associated IL-1 activity assessed using a cytotoxic thymocyte assay was significantly increased in patients with AIDS (80.6 \pm 19 U/ml (mean \pm SEM); n = 14) and HIV oligo-seropositive individuals (32.9 \pm 10.2 U/ml; n = 16) as compared with normals (4.4 \pm 1.6 U/ml; n = 30). Cell-associated levels of IL-1 α and β antigens were also elevated in HIV individuals. Serum-free culture of monocytes from HIV individuals in the absence of IL-1 inducers resulted in spontaneous release of IL-1 activity. IL-1 β and antigen. No IL-1 activity was released by cells from normal individuals cultured under the same conditions. LPS-stimulation of monocytes from HIV patients induced the release of both IL-1 and whereas monocytes from normal individuals exclusively released IL-1 β . However less IL-1 activity was released by LPS-stimulated cells from HIV patients as compared with normals. Thus, HIV-infection is associated with the chronic stimulation of monocytes to produce IL-1 *in vivo* and an alteration in the intracellular pathways regulating the extracellular release of IL-1 α .

646

C.526 HIV-1 AND HIV-2 SPECIFIC IgG SUBCLAS REACTIVITY TO env AND gag PEPTIDES
Holliday, Peg Andrea; Ottens, A.S.; Silver, E.R.; Trojnar, J.***; Norbury, E.S.*** and Labrecq, R.***
National Bacteriological Laboratory, Stockholm, Sweden, **Institut Pasteur de Côte D'Ivoire, Abidjan, Ivory Coast, ***Ferring AB, Malmo, Sweden, ****Karolinska Institute, Stockholm, Sweden

Objective: To evaluate and compare the HIV-1 and -2 specific IgG subclass reactivity to selected peptides.
Methods: Peptides representing five immunodominant regions of the HIV-1 and -2 env and gag proteins were used as antigens in IgG subclass ELISA assays. Sera from HIV-1 and -2 infected individuals were analysed.
Results: IgG was the dominant anti-HIV-1 subclass and was detected in 100% of the sera. The HIV peptides representing gp36-41 elicited the highest frequency of reactivity of all subclasses. The reactivity to the gp120 peptide was mainly restricted to IgG1 or IgG3. A high IgG3 reactivity was also seen directed to peptides representing the putative hypervariable loop region of gp120. Subclass response to peptides representing regions of gp7 and gp5 was restricted to IgG1+4 and IgG1+5 respectively. Sera from HIV-2 infected individuals showed a 90-100% reactivity to the corresponding HIV-2 peptides. Cross-reactivity was more frequent in the HIV-1 group to HIV-2 peptides than vice versa.
Conclusion: Differential restriction of the IgG subclass response was seen to regions of HIV representing the major structure proteins. The IgG3 response to envelop-representing peptides indicates frequent gp120 stimulation and development for neutralization.

C.528 RELATIONSHIPS BETWEEN THE PHYSIOLOGICAL FUNCTION OF CD4 AND ITS ROLE AS THE HIV RECEPTOR
Quarini I. Sattentau*, Merkenhausen, M***, Healey, D., Truneh, A**, Arthos, J**, Sweet, R.**, Beverley, P.C.L.***
The Academic Dept of Cell Medicine, UCMGSM, London, UK
**HTG, ICRF, UCMGSM, London, UK
***Smith, Klein and French Laboratories, King of Prussia, PA, USA

Objectives: To define with the use of monoclonal antibodies (mAb) to CD4 and their anti-idiotypes those sites on the CD4 antigen important in the physiological functions of this molecule in relation to their role in HIV reception.
Methods: The amino acid residues essential for the binding of a number of CD4 mAbs has been determined using forms of the CD4 antigen containing point mutations. These mAbs have also been used to probe the function of the CD4 antigen in terms of its HIV binding capacity and role in T-cell activation.
Results: We have defined those CD4 mAbs which react with residues most similar to the amino acids which gp120 requires for binding. These mAbs are highly effective at inhibiting T-lymphocyte responses to soluble recall antigens and mitogens in a soluble form, but are also capable of enhancing T-cell responses when cross-linked with CD3 mAb.
Conclusions: Antibodies against CD4 which inhibit HIV-induced synapsium formation require residues very similar to those required by gp120 for binding to CD4, and are also highly effective at modulating T-cell activation. We therefore conclude that the regions of CD4 reactive with HIV gp120 are important in the physiological function of CD4.

C.530 SPECIFICITY OF CD4+ T CELLS FROM CHROMOLUNG MACAQUE IMMUNIZED WITH HYBRID HIV P24/7Y VIRUS LIX PARTICLES
Killey, Kingston*, Barrow, A*, Adams, S**, Kingsman, S**, Kingsman, A** and Kitchin, P.**, FIBIG, ICRF, South Mimms, Hertsmere EN8 3QG, UK. **British Biotechnology Limited, Oxford, UK.

Objective: To assess the ability of a novel antigen presenting system to generate T-cell responses to HIV gag proteins in primates.
Methods: Specificity of virus particles of chromolung macaques immunized with recombinant HIV P24 protein expressed in yeast as hybrid P24/7Y virus like particles (VLP). Animals received 3 i.v. injections, at 8 week intervals, of 50 or 200ug of P24/7Y-VLP with or without adjuvant. Proliferative responses of peripheral blood lymphocytes were tested at 2 week intervals.
Results: Lymphocyte proliferative responses to P24/7Y-VLP and control 7Y-VLP were detected in all animals as soon as 2 weeks after immunisation. Responses were significantly greater in animals given the antigen with adjuvant. Lymphocytes from these animals also gave a significant response to recombinant gag alone or to whole HIV. Proliferation and IL-2 release by T-cell lines and clones in response to synthetic peptides from the P24 sequence demonstrated the presence of CD4+ T-cell epitopes on HIV-P24.
Conclusion: Hybrid HIV P24/7Y VLP are a useful antigen presenting system for the generation of proliferative T-cells to HIV gag proteins and have allowed us to identify determinants on P24 recognised by CD4+ T cells from chromolung macaques.

Publications


 Recherche fondamentale (biomédicale)
 Basic Research (Biomedical)

C.543 USE OF AUTOLOGOUS CD4+ T CELLS IN THE ASSAY OF HIV-1-SPECIFIC CYTOTOXIC T CELLS (HIV-CTL)

Magnan, C. and Drouot, J., Department of Medicine, University of Ottawa and Ottawa General Hospital, Ottawa, Ontario, Canada.

Objective. We have reported that the anti-HIV drug zalcitabine (CZP) and dextran sulfate (DS) induce the regeneration, within 3 days, of CD4+ T cells in lectin-stimulated cultures of blood lymphocytes from HIV+ patients. Based on this observation, we describe a method that permits the use of autologous CD4+ T cells as targets in the assay of HIV-specific cytotoxic T cells (HIV-CTL). **Method.** Blood mononuclear cells cultures are started with Con A, IL-2, to which are added CZP or DS (25 µg/ml). On day 3 the CD4+ cells are separated from CD8+ T cells by staining with anti-CD8 (CD8T) antibodies with post-exposure antibody conjugated to magnetic particles and separation of CD8+ T cells using a magnet. The separated cells are cultured for 3 to 4 days in a medium containing IL-2 and CZP or DS (25 µg/ml). A day before the CTL assay, the CD4+ cells are infected *in vitro* with prototype HIV-1 virus and incubated for 18 hours in a medium without anti-HIV drugs. The following day the CTL assay is carried out. **Results.** A systematic analysis of the method demonstrated that the proposed assay is reproducible and reliable. We have used autologous T cells in the cloning of HIV-CTL (3 experiments) and in the study of the HIV-CTL response in 5 HIV+ patients. A more detailed study of patients is now being carried out. **Conclusion.** The method proposed here should be of value in studies of the HIV-CTL response in the clinical as well as the research laboratory.

C.545 A CHEMICALLY SYNTHESIZED 104-MER PEPTIDE OF THE C-TERMINAL HALF OF HIV-1 P24 SUCCESSFULLY USED AS AN HIV INHIBITOR

Ghisoni, L., Baroni, P., Maggi, P., Di T. T., Tosti, G.E., G. M., Ghisoni, W.A. and Oates, A.H.

The London Hospital Medical College, London, UK. *London School of Pharmacy, London, UK.

Objective. To investigate the immunological properties of a chemically synthesized C-terminal half (104 residues) of HIV-1 p24 core protein. **Method.** The 104-mer peptide was prepared using an Applied Biosystems 430-A synthesizer employing t-boc chemistry and used in purified form in the subsequent work. T-cell response was studied by *in vitro* proliferation of antigen-activated splenic cells from mice previously primed with the peptide. Mice and rabbits were immunized subcutaneously with approx 100 µg peptide in Freund's incomplete adjuvant. Murine monoclonal antibodies were made using NS0 myelomas as partner. Antibody activity in sera from HIV-1 haemophilics and experimental animals was tested in ELISA and Western blot with the 104-mer and HIV-1 proteins. **Results.** A dose-dependent proliferative T-cell response in mice was found using the 104-mer as antigen. Antibodies from mice and rabbits reacted strongly with the 104-mer immunogen and also with the HIV p6 protein p24 and p50. Conversely, sera from HIV-1 seropositive humans reacted with the 104-mer. **Conclusion.** The synthetic 104-mer peptide elicited an anti-HIV-1 T- and B-cell response, indicating that some important epitopes are shared between this chemically synthesized molecule and the natural viral p24 protein. Immunologically useful HIV-1 proteins can now be prepared by chemical synthesis.

C.547 CARBOHYDRATE-DEPENDENT EPITOPES OF HIV-1 GP120

Belsand, A., Bissler, L., Bissler, L., and Giesecke, G., Department of Clinical Virology, University of Göttinge, Göttinge, Department of Virology, University of Göttinge, Göttinge, Germany.

Objective. Carbohydrate epitopes may decrease or increase the antigenic activity of viral glycoproteins. We present one half of the molecular weight of the carbohydrate content representing one half of the molecular weight of the six different N-linked oligosaccharides and their N-linked oligosaccharides: one modulating effects on the antigenic activity.

Methods. Secreted gp120 was covalently linked on microtiter plates and exposed to neuraminidase and increasing concentrations of periodate. As a control of sequential removal of peripheral monosaccharides an enzyme-linked lectin assay was used. The alteration in antigenicity, during the neuraminidase/periodate-treatment, was followed in ELISA with a panel of LAV-specific monoclonal antibodies.

Results. Removal of sialic acid and galactose from N-linked oligosaccharides on gp120 resulted in significant increase in antigenic epitopes, in the N-terminal region, previously masked by glycosylation.

Conclusion. Our results demonstrate that some epitopes of gp120 are modulated by the carbohydrate component. This phenomenon might, at least partly, be of importance for the ability of HIV to escape immune reactions.

C.544 CHEMICAL SYNTHESIS OF CHIMERIC PEPTIDES AND PEPTIDES FOR IMMUNOLOGICAL PURPOSES

Manganji, P., Datta, D.T., Trun, G.K., Gibbons, W.A., Baselin, L.R., Gell, S., and Oates, A.H.

* The School of Pharmacy, London, UK.

** The London Hospital Medical College, London, UK.

*** California Institute of Technology, California, USA.

Objective. To chemically synthesize a 104 amino-acid long peptide corresponding to the 273-377 sequence C terminal half of HIV-1 p24, and the hybrid peptides p24 (1-epitope)-limer-*env* (8 epitope) 44 mer and p24 (273-377)-limer-*env* (D-epitope) 136 mer.

Methods. The three polypeptides were synthesized using highly optimized custom protocols on an All-400 synthesizer. Crude peptides were dialyzed and purified by a combination of reverse phase, size exclusion and ion-exchange HPLC. Quality control included amino-acid analysis, protein sequencing, SDS-PAGE and IDP gel chromatography and P24-immunoprecipitation. The synthesis of the 104 mer peptide yielded three grams of crude peptide-*env*. After purification 20% (w/w) of the cleaved peptide was obtained and had a chemical composition which was consistent with the expected amino-acid sequence. Similar yields of homogeneous material were obtained for the chimeric peptides. Immunisation of mice with the peptide and proteins induced antibodies to HIV core and envelope proteins.

Conclusions. This work suggests that the chemical synthesis of long peptides is feasible and may have application in vaccine development.

C.546 MHC CLASS I-III ALLOTYPES IN PATIENTS WITH DISSEMINATED KAPOSI SARCOMA (KS), ARC/WRS, AND IN NORMAL CONTROLS

Gross, F., H. Kriehuber, F. Isel, C. Baudier, H. Kamber, C. Meis, and the ARC-IVIG Study-Group Cologne/Berlin

Dept. of Medical Microbiology, Virology, Internal Medicine II, Dermatology, Pathology, Biostatistics, Univ. of Cologne, 5000, Bad Mendenstrasse, City, St. Marien, Cologne, FRG; Centre Laboratory, Berlin and Bonn, Cologne, FRG.

Objective: Major histocompatibility complex (MHC) class I and II (HLA-A,B,C,DR) associations in HIV-infected patients has been controversial. Of the MHC coded polymorphic components C1, B2, C4A/C4B (MHC class III) allotypes of C2 and C4 have not yet been reported. CA alleles encode for major immunogenetic relevance for their potential differences in virus neutralizing capacity. In the present study 30 ARC/WRS patients from the ARC-IVIG project (Dr. Schappag-Schäfer et al.), 30 patients with disseminated KS, and 160 HIV-negative control individuals were compared for MHC class I to III allotypes.

Methods: All individuals were of West German origin. Diagnosis of ARC and KS (CDC and WHO criteria) was done by clinical and laboratory parameters. MHC testing by standard method: microlymphocytotoxicity assay for HLA-A,B,C,DR, electrophoretic and serologic tests for class III allotypes, Western Blots with poly- and monoclonal antibodies for C4A/B. **Results:** An increase in frequency ($p < 0.05$) was observed between ARC/WRS patients and controls for HLA-B35/CW4, DRW14, a decrease for B18, CW6/DR1. In KS CW6 was more frequent than in ARC/WRS patients. However, values were not significant if corrected for the number of tested antigens. No significant differences were seen between KS and ARC patients or controls for class III allotypes, nor for the previously reported associations e.g. of B2, DR1, and especially DR3, including the DR3-gp120 DRW11, 12.

Conclusions: The results indicate lack of strong MHC-associations with the investigated antigens in West German Caucasoids. The contrast of our data to previous findings for distinct, as well as disseminated KS supports the hypothesis of ethnic dependence of HIV-related diseases.

C.548


**Recherche fondamentale (biomédicale)
Basic Research (Biomedical)**
C.549 MODIFICATION DE LA SECRETION D'INTERLEUKINE 1 PAR L'EXPOSURE SAISONNIERE A L'INFECTION VIH

Domin Brillet*, Roland St. Omeron*, Litane P.
*Clinique Dermatologique - Hôtel Dieu, A. A. Renardes - AIDS UNIT
CROIX DU - FRANCE.

Objectif. Dans la série, la production spontanée d'interleukine 1 (IL1) augmente chez les patients VIH au début de l'infection, puis s'affaiblit au stade SIDA. Dans ce contexte, nous avons voulu vérifier si aux semaines quantitatives des cellules de lymphocytes (L) de l'épiderme s'associaient des modifications de la sécrétion d'interleukine 1 (IL1) épidermique produite normalement par les kératinocytes de ces cellules.


Méthodes. 37 patients VIH (11 au stade II, 10 au stade III et 16), 8 au stade III et 4 au stade IV, ainsi que 5 témoins séro-négatifs ont été étudiés. Les biopsies cutanées ont louches été réalisées au passé simple (free entrance de temps) avec un piquet-aspire au passé simple (coupe) au stade (free). Les techniques d'immunofluorescence indirectes sur coupes complètes avec un anticorps anti-IL1 (Elior et cell UI 1016, Immunotech) et des cellules (free) des témoins (Elior et cell UI 1016, Immunotech) ont été réalisées.

- au stade II et au passé simple de coupe, la sécrétion d'IL1 épidermique est supérieure avec un niveau normal de cellules de lymphocytes.

- au stade III et IV, elle est plus faible mais toujours supérieure à celle des témoins (L = 29,7%).

- au stade III et IV, elle est s'affaiblie avec chute des cellules L (12,3%).

Conclusion. Le travail confirme donc l'importance de l'entretien fonctionnelle du système immunologique noté par la VIH.

C.551

C.553 NATURALLY OCCURRING AUTO-ANTIBODIES TO CD4 AND THE HEC CLASS II MOLECULE IN HIV-DEPLETED INDIVIDUALS

ROBERTA ROBERTI, J. Baker, J. Payne, A.L. Sweet, R.J. Suckoff, J., and the Walter Reed Retrovirus Research Group, Walter Reed Army Medical Center, Washington, D.C., United States of America.
*Smith, Klein and French Laboratories, Philadelphia, Pa., United States of America

The natural ligand for CD4 is the HEC Class II molecule. Antibodies to the CD4 binding site of HIV could theoretically cross-react with HEC Class II as both bind to CD4. Such anti-HIV binding site antibodies could also result in anti-Idiotypic cross-reactive with CD4. Western blots of EDV-transformed B-cells rich in CD4 are demonstrated by a murine monoclonal were prepared. Sera from 25 HIV patients and 5 normal individuals do not exhibit or do so in such low titer as to be of no pathophysiologic relevance. Incubation soluble CD4 was utilized in a direct RIA to determine if antibodies to CD4 are detectable in HIV patients. 3/20 (15%) patients probably demonstrated reactivity compared to 0/5 normal individuals. EDV-transformed B-lymphocytes from patients continued to produce antibody to CD4 *in vitro* as measured by direct RIA and dot-blot. This indicates that a significant anti-CD4 response is present in HIV patients, possibly as a result of an anti-idiotypic response to gp120. These findings may have implications for the therapeutic use of soluble CD4.

C.550 SYNCTYMIUM FORMATION AND DESTRUCTION OF CD4+ BYSTANDER CELLS COCULTURED WITH PRESENTLY HIV-INFECTED T-CELLS, AS DEMONSTRATED BY FLOW CYTOMETRY

Dominique Schols, R. Pauwels, M. Baha, J. Desmet and E. De Clercq
Rage Institute for Medical Research, K.U.Leuven, B-3000 Leuven, Belgium

To investigate cell fusion and giant cell formation following fusion between HIV-1- or HIV-2-infected (HIV-78) cells and uninfected CD4+ MOLT-4 (clone 8) cells, the two cell populations were mixed and cultured at 37°C, stained with the appropriate monoclonal antibodies (mAbs) (FITC- or PE-conjugated), fixed and analyzed by flow cytometry.

At the moment that syncytium formation started, i.e. after 4-6 h incubation, the MOLT-4 cell number began to decrease and after a 24-hr incubation period all MOLT-4 cells had disappeared, as demonstrated with specific mAbs to antigens expressed on either MOLT-4 or HUT-78 cells. The formation of giant cells and the concomitant disappearance of MOLT-4 cells was blocked by OKT4/Leuck mAbs, and several parameters of cell fusion such as fusion index, percent of fusion inhibition and 30 f fusion inhibitory concentration of the mAbs could be accurately determined.

This flow cytometric method can be readily implemented to evaluate any agents for their capacity to block cell-cell fusion and the subsequent destruction of the bystander target cells. Our observations also reveal a mechanism by which a low HIV-infected cells may gradually deplete the pool of uninfected CD4+ cells *in vivo*.

C.552
DETECTION OF gp120 (HIV-1) AND ANTIBODIES TO DEFINED REGIONS OF gp120 IN HUMAN SERUM: CORRELATION WITH HIV-1 IMMUNIZATION

ROBERTA JOHN AND ROBERTING, J.A. (1)

Dept. Vet. Pathology, Glasgow, UK and

(2) Institute of Cancer Research, London, UK

We have developed ELISA-based methods for the detection of the HIV-1 surface glycoprotein gp120 in a subset of sera from HIV-1 infected individuals, and will describe data relating gp120 levels with those of p24 antigen, anti-gp120 antibodies and disease status. In this study, anti-gp120 antibodies are monitored using an extremely sensitive, sensitive and specific ELISA that can use a wide range of sources of gp120 as a capture antigen, including simple unpurified detergent extracts of divergent HIV-1 strains. We have also developed ELISAs that detect serum anti-gp120 antibodies (1) capable of blocking gp120 binding to CD4, and (2) that bind to the type-specific neutralizing loop (387-395). Data will be presented relating levels of these antibodies to neutralisation titres (see below).

Serum	Neutral. titre	Total gp120	Ab	CD4 blocking	Ab	anti-gp120	Ab
3	160	9000	270	250			
2	80	9000	470	300			
3	40	380	35	0			
4	40	900	70	20			
6	320	5700	680	600			
6	160	9000	900	200			

C.554
CELL-MEDIATED LYMPHOBLASTIC RESPONSES BY ADULTS AND CHILDREN TO RECOMBINANT HIV ENVELOPE AND CORE PEPTIDES.

*ROBERTING, M., Moore, T., Hraimel, H., Papageorgiou, N., New York University Medical Center, and Baltimore Hospital Center, New York, U.S.A.

Objectives. To determine if recombinant HIV antigens elicit cell-mediated immune responses in infected adults and children and to compare these responses to those of seronegative individuals.

Methods. Lymphocytes from individuals at risk for HIV infection were cultured with recombinant HIV envelope and core (ENV & COR) antigens, as well as diabetin or staphylococcus (S & TT). These with a stimulation index >> 0 were scored as responsive. The response rate among seronegative adults (N=6) and seronegative adults (N=6) was compared to that of seronegative children (N=6), seropositive children (N=6), and seropositive children (N=6).

RESULTS. POSITIVE RESPONSES TO HIV AND RECALL ANTIGENS (4)

STIMUL	ENV	COR	TT	IT
Infected	3/32 (9)	4/32 (13)	12/28 (43)	20/28 (69)
Uninfected	5/12 (42)	7/12 (58)	9/18 (50)	10/18 (61)
Uninfected	9/28 (32)	12/35 (34)	8/21 (38)	16/31 (52)
Uninfected	7/28 (25)	4/28 (14)	8/28 (29)	24/28 (86)
Uninfected	1/13 (8)	3/13 (23)	8/13 (62)	10/13 (77)

Conclusions: 1) Infected children are as likely to respond to ENV & COR as they are to recall antigens. 2) Infected children & seronegative children are more likely to respond to HIV antigens than are uninfected children (p<0.01). 3) One fourth of high risk seronegative adults respond to HIV envelope antigen, indicating either antigen sensitization or nonspecificity.



C.561

Evaluation of the role of the soluble CD8 and IL2 receptors (IL2R) in patients with Human Immunodeficiency Virus infection. L. Lichtig*, A. Chachona*, V. Molinari*, M. Rosen*, P. Rong*, P. Valadarias* et al. *New York University Medical Center, NY NY 10016, and *T Cell Sciences, Cambridge MA 02139 USA.

Objective: We evaluated the levels of soluble CD8 and IL2 receptors (IL2R) in patients with HIV infection. **Methods:** 63 patients with HIV infection and 7 normal controls were studied. Of these, 21 were seronegative asymptomatic (ASYM), 19 had ARC, 13 had KS and 10 had AIDS with opportunistic infection. In previous studies the T84 protein has been shown to be induced in direct proportion to the level of activation of T84 positive cells. Serum IL2R is a measure of the activated state of IL2R bearing cells. The levels of T84 and IL2R were compared with each other and with levels of plasma P24 antigen and T4/T8 ratio. Soluble CD8 and IL2R were measured using CellFlowTM Immunometry kits from T Cell Sciences. T4/T8 ratios were determined by standard techniques. **Results:** Soluble CD8 levels in plasma of patients with ASYM, KS, ARC, and AIDS were respectively 1029 ± 89, 1454 ± 131, 980 ± 118, and 771 ± 115 while normal controls were 592 ± 60 antibody (Mean ± SD). IL2R levels in serum of patients with ASYM, KS, ARC, and AIDS were respectively 783 ± 98, 970 ± 129, 1011 ± 119, and 1566 ± 157, normal controls were 482 ± 28 antibody. Using flow-cytometric analysis, comparing each patient with normal controls, the majority of low T84 patients were 59% of normal (p < 0.0001). IL2R was higher than T4/T8, T84, and P24 for discriminating ASYM from AIDS (p < 0.0001), ASYM from ARC (p < 0.002) and ARC from AIDS (p < 0.0001). Using a combination of both receptors in each patient group, a formula was derived which predicted between normal and ASYM patients. **Conclusion:** We conclude that there is an increase in soluble CD8 and IL2R in all patients with HIV infection compared to the normal control group. These data suggest that the measurement of levels of IL2R and soluble CD8 in HIV infected patients provide objective and quantitative parameters for clinical researchers studying changes in the immune system in ASYM, ARC, KS and AIDS and may serve as a surrogate marker of disease in ASYM patients.

C.563

CIRCULATING INTERFERON-GAMMA IN HIV-1 INFECTION

Puchs, Distmer, Hausen, A.; Reibnegger, G.; Werner, E.H.; Dierich, M.P. and Wachter, H. University of Innsbruck and Ludwig Boltzmann Institute of AIDS Research, Innsbruck, Austria

Objective: Progressive HIV-1 infection is associated with diminished in vitro production of lymphokines by T-cells upon antigenic and mitogenic stimulation. However, in vivo markers, e.g. neopterin, indicate hyperproduction of certain cytokines.

Methods: We measured serum concentrations of interferon gamma and neopterin in 43 HIV-1 seropositive individuals and 76 seronegative blood donors. A modified radioimmunoassay procedure for detection of interferon gamma was used with a detection limit of 18 U/l.

Results: 22 of the 43 seropositives exhibited increased serum interferon gamma concentrations. There was a significant association between serum interferon gamma concentrations and CDC-stages of the patients. CDC IV-C patients had the highest concentrations. Further, serum interferon gamma and serum neopterin concentrations were significantly correlated.

Conclusion: Circulating interferon gamma is increased in HIV-1 seropositives compared to seronegative blood donors. Diminished in vitro production of interferon gamma by T-lymphocytes on stimulation contrasts the in vivo findings.

C.565

C.562

AN INTERACTIVE RELATIONAL DATABASE FOR HIV AND THE IMMUNE SYSTEM

Rizova, G., Stanley, E. A., Flynn, James H. and Nelson, G. Los Alamos National Laboratory, Los Alamos, New Mexico 87545 USA

Objective: To organize the complex, changing information about HIV and the immune system in a visually oriented, user-friendly, interactive system. **Methods:** We are using HyperCard, an Apple Macintosh to create an interactive reference tool on HIV and the immune system. Information is presented on "cards," each of which contains a diagram and/or short description, as well as "buttons" which link the card to related cards. The "mouse" is used to click a button and move from card to card. For example, from the main card describing macrophages, the user can go to a card on the infection of macrophages and to other related subjects. Comment cards allow researchers to remark on contradictory results, difficulties with experiments, etc. **Results:** We see one of the primary stumbling blocks to an understanding of how the immune system is slowly destroyed by HIV to be the difficulty involved in organizing the information from experiments and studies on HIV and then organize it within the context of the immune system. This continually expanding relational database can be used by newcomers to the field to get up to speed, by AIDS researchers who are not immune system experts to understand the studies on HIV relative to the immune system, and by immune experts to organize the latest information.

Conclusion: This HyperCard system, although still incomplete, will provide AIDS researchers to develop new ways to organize the growing knowledge base. To obtain this experimental program send us three 20/20 microdisks: in return we would like comments on its utility, structure, and content.

C.564

B ENDOPHRIN, A.C.T.H. AND CORTISOL RELATIONSHIP WITH AIDS

LE GASTHER, J. J. and BOUTIER, C. ** TEXIER, F. **, OBER, F. **, MONTAGNER, L. **, LEFEBVRE, J. **, et al. * Institut PASTEUR - PARIS, ** COLLEGE DE FRANCE - PARIS, FRANCE

Objective: Study of B ENDOPHRIN, A.C.T.H., CORTISOL, plasma concentrations in homosexual HIV infected men groups.

Methods: 72 low drug-abuse men, 20-30 years old, 3 homosexual groups: AIDS-25, SERO-+15, SERO-15, one essential HYPOTENSIVE group as CONTROL with 2 blood samples daily (8 am-5 pm).

B endorphin and A.C.T.H. were evaluated by radio-immunoassay and Cortisol by chromatography. Data were analyzed by parametric and non parametric tests.

Results: 1) Both AIDS, SERO- and SERO- showed plasma B ENDOPHRIN/A.C.T.H. ratios were higher than age-matched/ ratio of CONTROL. 2) A low of normal A.C.T.H./TOTAL CORTISOL revealed and relative rise of free CORTISOL level. **Conclusion:** 1) The higher relative level of plasma B ENDOPHRIN suggests a possible role of HIV derived pituitary precursor (DOPC) processing in the role in immunity. 2) The striking normal and neuroendocrine pattern of the 2 homosexual groups SERO- and SERO- (living together) suggest either latest HIV infection in SERO- patients or other causes factor to these two groups. 3) Possibility to link the higher ratio of B ENDOPHRIN to A.C.T.H. as an early sign of HIV infection will be discussed.

C.566

SUPPRESSIVE EFFECTS OF IMMUNODEFICIENCY VIRUSES ON THE IN VITRO STIMULATION OF HUMAN LYMPHOCYTES

Lieber, Johannes; Benita, I.; König, H.; Kurtz, R. Paul-Ehrlich-Institut, Frankfurt am Main, FRG

Objective: Antial retroviruses exert a suppressive effect on the in vitro stimulation of lymphocytes. The equivalent effect of primate immunodeficiency viruses (HIV-1, HIV-2) and human T-cell lymphotropic virus type II (HTLV-II) on the in vitro stimulation of human lymphocytes should be studied and the responsible viral components should be identified.

Methods: In the lymphocyte stimulation assay, PBMCs are incubated with uv irradiated whole virus or with viral components (purified p24 and glycoprotein) and stimulated with PHA. After two days, the ³H-thymidine uptake is measured. After solubilization, viral glycoprotein complexes are isolated by chromatography on lentil lectin and heparin columns.

Results: The most important variable in the lymphocyte stimulation assays is the origin of the human lymphocytes. Depending on the donor a more or less profound inhibition by inactivated HIV-1 can be observed. The extent of inhibition varies between 20% and 80%. However, the effect of HIV-2 and the SIV is very small, often negligible. Purified glycoproteins give the same results.

Conclusion: The inhibitory effect of different immunodeficiency viruses in the lymphocyte stimulation assay may well be due to differences in the pathogenesis of these virus strains. Therefore, it may play a role in the pathogenesis of AIDS. In addition, lymphocytes of different donors are differently susceptible to this effect. Whether this observation can explain, at least in part, the differences in the time course of the disease in different individuals is an area of further investigation.



C.573 LYMPHOCYTE STIMULATION IN ARC/WRS PATIENTS DURING INTRAVENOUS IMMUNOGLOBULIN (IVIG) TREATMENT
H. Krichbaum, G. Metz, Th. Mennig, G. Meisner, and the ARC-IVIG Study-Group Cologne/Berlin
Department of Medical Microbiology, Hygiene, Internal, Medicine II, Dermatology, Rheumatology, Usher, of Cologne, FRG; Central Laboratory, Peter Badt (Food Production Service), Bonn, Federal Republic

Objective: In a randomized, controlled double blind study 15 ARC/WRS patients were compared during 6 months 6g/kg IVIG treatment with 15 placebo treated patients. The protocol has been described elsewhere (cf. Schupp-Bäcker et al.). Our study was aimed at lymphocyte response to T- and B-cell mitogens.
Methods: ³H-thymidine uptake was determined after stimulation with the specific mitogen PHA, PWM, formalinized *S. aureus* - Cowan 1 (SAC), and with the antigens PPD, and Herpes simplex virus (HSV) at the onset, on day 85 and 181; antibodies against HSV were measured by ELISA and CFT. In addition, 30 untreated HIV-negative control individuals were tested.
Results: For T-cell mitogen PHA, T-7-cell mitogen PWM, and B-cell mitogen SAC no differences between the 2 patient groups was observed at day 1, 85 and 181, but stimulation was significantly lower as compared to the control group (p<0.05) on day 1. Lymphocytes of 4 patients and 5 HIV-negative control individuals showed PPD response. All patients had IgG-antibodies against HSV (ELISA). In the IVIG-group 8 patients' lymphocytes responded to HSV at some time during treatment, 13 had positive CFT titres in the placebo group only 3 patients' lymphocytes responded to HSV, 10 had positive CFT titres. Seven HIV-negative individuals showed positive HSV-lymphocyte response, 19 with ELISA/CFT titres.
Conclusions: In spite of some clinical improvement regarding fever and fatigue during IVIG treatment, there was no influence on T-7-cell stimulation by specific mitogens. All patients having experienced HSV infections, lymphocyte reactivity to HSV, although statistically not significant, was predominantly seen in the IVIG-patient group.

C.575 IMMUNO-ADHERENCE OF *MYCOBACTERIUM AVIUM* (M. AVIUM) TO U937 IS ENHANCED BY HIV-1 INFECTION
Bakker, Leendertz, J.; Meitaz, HJ; Van Strijp, JAG; Visser, NM; Eijssels, HJ; Verhaar, J.
Lab. of Microbiology, State University of Utrecht, Utrecht, The Netherlands.

Objective: To investigate the effect of HIV-1 infection on the function of monoclonal phagocytes. In this study, the interaction of uninfected or HIV-1 infected U937 cells with opsonized *M. avium* was compared.
Methods: *M. avium* was directly labeled with FITC, and opsonized with normal human pooled serum (HPS, HIV-negative), or with heat-inactivated HPS. U937 and U937/HIV-1 cells were incubated with opsonized *M. avium*, washed and cell fluorescence was measured using flow-cytometry and fluorescence microscopy.
Results: Flow-cytometry showed a 10-fold (10,7x±5) increase in fluorescence of uninfected U937 with HPS-opsonized *M. avium* as compared to non-opsonized *M. avium*. Heat-inactivation of HPS reversed this effect. Fluorescence using HPS-opsonized *M. avium* was significantly higher with U937/HIV-1 (1,8x±4; p<0.02) than with uninfected U937, while non-opsonized or heated-opsonized *M. avium* showed no difference. Microscopy showed that *M. avium* was attached to the cells. Since the increase was complement dependent, complement receptor (CR1 and CR3) expression on U937 was measured. Both were significantly higher on U937/HIV-1 (1,8x±1 and 1,4x±1 resp.). Inducers of cell-differentiation (PMA, retinoic acid) up-regulated immunoenhancement of cell-adherence of *M. avium* to uninfected U937.
Conclusions: Immunoenhancement of mycobacterium *avium* to U937 is enhanced by HIV-1 infection. This enhancement may be due to upregulation of complement-receptors on U937 induced by HIV-1 infection.

C.577

C.574 "ACTIVE LIPIDS" (AL) IN VITRO: LOSS OF DETECTABLE T- AND B-CELL SURFACE ANTIGEN

Bommer, Johannes R., Matsuecha A., Heinrich B., Pöhl H., Geoböl P.; Universität München, Med Poliklinik, FRG

OBJECTIVE: AL have been shown in vivo to increase the percentage of lymphocytes detectable neither by T- nor B-cell markers "unstained cells" (UNST) (Steedholm 1981). We have investigated if this effect can also be observed in vitro.

METHOD: Blood from patients with AIDS (n=4) and healthy controls (n=3) was incubated without (1) and with (2) a mixture of lipids similar to AL 721 (triglycerides, phosphatidylcholine, phosphatidylethanolamine) for one hour at 37°C. PBMC were stained with anti-CD3, CD4, CD8, CD19 and MLA DR after and prior to incubation with AL and analyzed with two-color flow cytometry.

RESULTS: 2 versus 1 resulted in a significant increase of UNST (mean ±1,7x±0,19) and reduction of all other cells (mean ±0,67-fold ±0,17). In contrast, 2 did not differ significantly from 1 (UNST 0,97fold ±0,13, other subsets 1,03fold ±0,19) when AL incubation was performed after antibody incubation, difference after/prior p<0,01. The effect occurred in all 7 subjects without regard to diagnosis.

CONCLUSION: Our results show that in vitro incubation of lymphocytes with "active lipids" unspecifically lowers detectability of cell surface markers by monoclonals. Physiologic lymphocyte function or virus binding might be altered by AL.

C.578

A HUMAN anti-LIKE PROTEIN: POSSIBLE RELEVANCE IN HIV INFECTION

Stzanski-Fabio, De Santis, C.; Beretta, A.; Gullberg, M. and Ericard, A.B. Dipartimento di Biologia e Diagnostica per la Scienze Mediche, Università di Milano, Italia, Unità for Applied Cell and Molecular Biology, University of Umeå, Sweden.

Objective: To characterize a human env-like protein.
Results: A 45 kDa human lymphocyte activation-associated protein sharing an epitope with env gp120 has been described and named HELP (human env-like protein). Two monoclonal antibodies reactive with HELP have been produced: one of them (M8) is reactive with both the cellular protein and env gp120, the other (L31) binds only the human molecule, but its binding can be inhibited by M8, probably because of steric hindrance. The two Mabs have different effects on lymphocyte functions: M8 inhibits proliferation by antigen presentation whereas L31 inhibits IL-2 production by cross-linked CD3 stimulated lymphocytes. Since HELP acts in negative signalling and an autoimmune response against it induces HIV infection could be deleterious for the patient, we are now searching for M8- or L31-like specificities in sera from infected individuals to evaluate a possible prognostic significance.
Conclusion: HELP is involved in more than one physiological immune function. Autoimmune responses against it are likely to be deleterious to the AIDS patient.

Publications


 Recherche fondamentale (biomédicale)
 Basic Research (Biomedical)

C.585

CHARACTERIZATION OF TANNINS CONTAINING ANTI-HIV ACTIVITY.
 Kikukawa, Robert L.* Cheng, Y. C.* Lee, K.-H.* and Boster, A.L.*
 *Hirsch Research Laboratories, Inc., Rockville, MD 20850, USA.
 *University of North Carolina, Chapel Hill, NC 27599, USA.

Objective: To characterize anti-HIV activity of purified tannins.
Methods: Tannins were purified from commercial tannic acid by chromatography through Sephadex LH-20 and preparative high performance liquid chromatography with reverse phase column. HIV-1 reverse transcriptase was purified by immunoaffinity chromatography. Enzyme activity was measured using poly (A)-oligo (d) U as the template. HIV-1 replication was assayed after infection of H9 lymphocytes. A p24 antigen capture test was used to detect viruses released into culture supernatants after a three day incubation following HIV-1 infection. Drug cytotoxicity was evaluated by cell count after a three day incubation with uninfected H9 cells.
Results: Four new tetrahydroxyquinone acids were isolated which inhibit purified reverse transcriptase by 85-90% at 100 µg/ml and 60-70% at 30 µM. They inhibit HIV-1 replication in H9 lymphocytes by at least 50% at 1.5 µM without cytotoxicity to uninfected H9 cells. Drugs were cytotoxic approximately 50% growth inhibition) at 25-50 µM. Inhibition of HIV-1 replication in H9 cells by tetrahydroxyquinone acid was assayed in the presence of either AZT or ddC. Inhibition by the combination of drugs was additive at all concentrations of AZT and ddC tested.
Conclusion: A new class of plant products which inhibit purified reverse transcriptase and HIV-1 replication *in vitro* has been isolated and characterized.

C.586

TREATMENT OF AIDS ASSOCIATED CRYPTOSPORIDIOSIS WITH HYPER-
 IMMUNE COLONUM FROM COWS VACCINATED WITH CRYPTOSPORIDIUM
 J. Nodji, F. Ma, C.D. Tackes, D. DiJohn, S. Lippert, S. Sahar,
 C. Shieh, St. Vincent's Hosp. & Med. Ctr. of New York, Div. of Maryland, Dept.
 of Medicine, Royal College of Surgeons, New York, N.Y.

Objective: To assess the efficacy of hyperimmune bovine colostrum against
 Cryptosporidiosis in asymptomatic AIDS patients.
Methods: Bovine colostrum was obtained from cows hyperimmunized with Cryptosporidium antigen. 5 AIDS patients with diarrhea and Cryptosporidiosis were
 given the colostrum by continuous infusion via feeding tube in a double blind,
 placebo controlled pilot study. Stool was analyzed for vel. frequency &
 consistency. Quant. cryptosporidial oocysts counts were determined by Cold
 Kinyoun stained smears. Antibody titer of colostrum was assayed by IFA.
Results: Antibody Titer Conc. of Oocyte/ml Stool
 Patient of Colostrum 1st day Last day

A	125:600	1.4 x 10 ⁷	2.2 x 10 ⁶	Improved (2 wks.)
B	13200	8.4 x 10 ⁴	2.0 x 10 ³	Resolved (6 mos.)
E	1200	1.6 x 10 ⁶	1.8 x 10 ⁶	No Change
C	Placebo	2.0 x 10 ⁷	6.0 x 10 ⁶	No Change
F	Placebo	4.2 x 10 ⁶	4.0 x 10 ⁶	No Change

Conclusion: Placebo showed no effect on the diarrhea. Two of three patients
 receiving hyperimmune colostrum showed clinical improvement/resolution
 accompanied by a reduction of oocysts in the stool. The patient receiving the
 hyperimmune colostrum failed to respond. A combination of low antibody titer
 and high oocyst concentration may be responsible. Therefore, higher antibody
 titers may be required for treatment of high oocyst concentration.

C.587

THE EFFECT OF CIGARETTE(S) ON LYMPHOCYTE POPULATIONS IN NORMAL
 AND HIV-1 INFECTED BLOOD.

Wessels, Kenneth* Meyers, D.* Vora, J.* Baker, J.R.*
 ** Henry H Jackson Foundation, Rockville, MD. ***National Naval Medical
 Center, Bethesda, MD. ****Walter Reed Army Medical Center, Washington, DC *

Objective: Measure the effect of varying CD concentrations on lymphocytes in
 whole blood from an uninfected and a Walter Reed Stage 2 HIV patient.
Methods: Separated whole blood samples were exposed in triplicate to 0, 10, 20,
 40, 80 and 160 µg/ml with an oxygen control. Coded, blinded blood samples
 were gently agitated for 18 min. and incubated for 1 hr. at 37 C. Monoclonal
 cells were separated using Ficoll-type density gradients and stained for
 FACS analysis using labeled monoclonal antibodies.
Results: CD had no effect on lymphocyte populations of the uninfected donor
 as numbers of total T cells, CD4, CD8, and T cell subpopulations did not
 change. In contrast, there were marked changes in the lymphocyte popula-
 tions of the HIV positive donor with increasing CD11.

(6.1)	T cells	CD4	CD8	T4/T8	CD positive [†]	CD8 positive [†]	CD4/CD8 [†]
(%)	CD3	CD4	CD8	T	T	T	T
0	8.5	82	34	43	81	13.3	1.8
20	8.6	79	34	41	85	14.9	8.8
40	8.4	82	48	38	1.18	18.3	15.5
80	6.3	83	42	34	1.28	7.8	8.2

Conclusion: Osmotic CD concentrations previously shown to inactivate HIV,
 may alter lymphocyte surface markers in HIV infected patients. Further
 studies are indicated to assess this effect.

C.588

DEC AND PER CAPITA AIDS CASES
 IN THE UNITED STATES

Werner, David* Kirschbaum, D.* Courby, M. AIDS Coalition
 to Unleash Power, New York, New York, USA.

Objective: Administration of the antiretroviral/immunomodulator
 Zidovudine (ZDV) to HIV-1 infected patients has been reported to
 interfere with human immunodeficiency virus (HIV) replication. This
 suggests that ZDV is concentrated in brain tissue. The present
 study examines, on a country-by-country basis, the relationship
 between Zidovudine control programs involving administration of
 ZDV and per capita reported AIDS cases.

Methods: Numbers of known AIDS cases (WHO 2/88) in each of 161
 countries were reported in articles were combined with population
 data to obtain per capita figures for known AIDS cases. The
 countries were listed into 3 subgroups according to their
 status: Group A, no evidence of Zidovudine (ZDV) control;
 Group B, ZDV control program in place; Group C, ZDV control
 program in place but no data on ZDV control program. The
 null hypothesis was that the null hypothesis was that the use of
 ZDV is associated with fewer per capita AIDS cases.

Results: The null hypothesis was rejected (a) when group 2
 (p=0.01) and (b) when group 3 (p=0.005) were compared against
 group 1 (p=0.005).

Conclusion: These preliminary observations suggest that the
 effect of ZDV on HIV infection warrants additional study.

C.589

C.590

WOMEN UNDERREPRESENTED IN AIDS CLINICAL TRIALS

Kelly, John* Kirschbaum, D.* Courby, M. AIDS Coalition
 to Unleash Power, New York, New York, USA.

Objective: To monitor the access of women to experimental AIDS
 treatments in the United States. **Method:** We collected data on women
 enrolled in U.S. Government AIDS clinical trials to identify barriers to
 health care. **Results:** Current Food and Drug Administration (FDA)
 policy restricts access of all patients to experimental treatments for
 AIDS on the theory that many women will prevent patients from
 entering trials. Yet historically, many women have been prohibited from
 participating in clinical trials. Even AIDS, the most HIV drug
 approved in the U.S., has not been adequately tested in women to show
 beneficial as well as adverse reactions as required by the FDA. Although
 in November 1988 women represented 9% of CDC-defined AIDS cases, women at
 all stages of disease comprised only 5.8% of total trial enrollment. In
 February 1987, 142 women were enrolled in AIDS trials; by August 1988
 200 women were enrolled. Over 60% of women in AIDS trials are enrolled
 in AIDS trial 018 which is testing AZV versus AZV in asymptomatic for
 HIV-infected subjects. As of December 1988, 52% of women with AIDS in
 the U.S. were infected through IV drug use. Nationally, 70% of women
 with AIDS are black and Hispanic. Most of these women are poor and have
 access only to public hospitals. **Conclusions:** Government and medical
 establishment policies restrict the access of women to experimental
 treatments. These results imply inadequate drug approval policies, poor
 health care on the local level, and many unvoiced biomedical issues.

Publications


 Recherche fondamentale (biomédicale)
 Basic Research (Biomedical)

C.591

IN VITRO EVALUATION OF EFFECTS OF LP1985 ON HIV INFECTED CELLS, ALONE OR IN ASSOCIATION WITH ANTIVIRALS.

D. G. Klapper, G. M. Clayton, J. D. Miller, G. M. L. Liang, G. C. and Damon, D. L. J.
 (1) Centre de Recherches de Santé des Amér. Commun. à l'Énergie Atomique, Pasteur-Ann. Sures, France. (2) Institut Pasteur, Paris, France.

Objectives: To determine the cellular target of an immune modulator drug, LP1985, in HIV infected PBL and cell lines, and to evaluate potential interactions with antivirals.
Methods: Interactions of LP1985 with thymocyte membrane have been studied by Spin Label Method and competitive assays between monoclonal anti-CD4 antibodies and LP1985 (immunofluorescence). Dose response curves of LP1985 action on HIV Reverse Transcriptase activity have been established (only 10-100 nM). In vitro toxicity of the drug on normal human PBL has been determined. Effects of LP1985 on cell growth and HIV replication has been reported using RT assay on cell culture supernatants. Potential interactions between LP1985 and AZT have been investigated by measurement of toxicity in suspensions of cell cultures which were doublet treated with both drugs at different concentrations.
Results: Biological effects of LP1985, such major interactions with the external part of cell membrane has been demonstrated, and acute cytolysis like the antiviral effect observed in low HIV infected PBL cultures, and the competition with anti-CD4 antibodies seem to amount 100 per cent of healthy donors. No direct and reverse transcriptase effects could be demonstrated for LP1985. Immune modulating concentrations of LP1985 do not exhibit either cellular toxicity or reproductive antiviral effects, as demonstrated in IL2 stimulated HIV infected PBL cultures. However, some inhibition of HIV replication was noted in a cell line of monocyte origin. LP1985 does not interact with antiviral effect of didanosine or zalcitabine. Furthermore, a normal cell growth in cell cultures treated with a 100 per cent antiviral dose of AZT.
Conclusion: LP1985 is an immune modulator drug which cellular target is the cell membrane. A despite the lack of direct antiviral effect, this drug might be used in association with didanosine/zalcitabine, as a complement of the antiviral cellular toxicity.

C.593

BIOCHEMICAL PHARMACOLOGY OF AZT IN HUMAN T-LYMPHOBLASTOID CELLS (CEM).

J. M. Estévez, W. M. Mackinnon, Edward Compton & John S. Holmberg, Children's Hospital of Los Angeles, Los Angeles, CA, U.S.A.

The purpose of this study was to investigate the biochemical pharmacology of AZT and to examine the effect of AZT on nucleoside triphosphate pool in virus-free human T-lymphoid line (CEM) cultured *in vitro*. Although the inhibitory concentration 50% (IC₅₀) of AZT in this cell line averaged 3.90 ± 2.5 μM (n = 3 determinations ± S.D.), the readily obtained plasma concentration of AZT in patients (1 μM) was used in these studies. CEM cells were incubated with 1 μM of [³H]AZT for 24 hr. In 100% and at various times relative to depletion of 10% cells were removed and extracted with perchloric acid for nucleoside and metabolites of AZT. The extract were assayed by HPLC. 54% of cultures for nucleoside, adenosine, deoxy, and triphosphates nucleoside of [³H]AZT. The cellular concentration of AZT ranged from 0.98 to 1.8 μM (mean 1.28 ± 0.3 μM) throughout the 24 hr experiment. The [³H]AZTMP cellular concentrations averaged 1.3 μM at 2 hr and declined gradually to 0.12 μM by 18 hr. The [³H]AZTDP was on average 17.5 ± 11.4 fold lower than the AZTMP, strongly indicating that a rate-limiting step in the activation of AZTMP to AZTDP exists at the AZTMP kinase level. The intracellular [³H]AZTDP pool of 4 hr after initiation of drug treatment at 14.5 nM in CEM cells declined exponentially with a t_{1/2} of 5.3 hr and a t_{1/2} of 18.1 hr. NTP cellular concentrations declined rapidly in the cells after exposure to AZT and by 9 hr reached a nadir of 21.8% CTP, 8.1% UTP, 13.3% ATP and 14.6% GTP, in comparison to control values. Consequently, phosphorylation of AZT to AZTMP and AZTMP to AZTDP declined 2.9- and 2.4-fold, respectively. The depletion of NTP pools may be responsible for the host toxicity that has been observed in patients. The amount of AZT metabolite incorporated into purified DNA peaked at 0.66 pmol/mg of DNA 1 hr after AZT treatment and declined with a t_{1/2} of 12 hr. We conclude that 1 μM AZT is sufficient for activation to the triphosphate which is associated with depletion of NTP pools and is incorporated into DNA.

C.595

DIFFERENTIAL ANTIVIRAL ACTIVITY OF DEKSTAN SULFATE, PENTOSAN POLYSULFATE AND HEPARIN AGAINST HIV-1 (HTLV-III₂) AND HIV-2 (HTLV-III₁)

M. Baba, D. Schmidt, J. Balzarini, J. Dewayer, and B. H. Huisman, K. Institute for Medical Research, E. v. Leuven, B-3000 Leuven, Belgium.

Objectives: Since sulfated polysaccharides interfere with the interaction of the highly variable envelope glycoproteins of HIV with the cellular receptor, we wondered whether these compounds may have differential effects on different HIV-1 and HIV-2 strains.
Methods: Anti-HIV activity was determined 3 days post-infection by a tetra-sulfate stability assay. All HIV strains were used at the same multiplicity of infection and all experiments were done in 96 wells.
Results: 20 ± 3 effective doses (ED₅₀) except for AZT (nM).

	Anti-Human-pulvita	Pentosan-Polysulfate	Heparin
HIV-1(III ₂)	0.0018	0.1	0.1
HIV-2(III ₁)	0.0013	0.05	0.1
HIV-1(III ₁)	0.0018	0.1	0.1

Conclusion: Whereas AZT was equally effective against both HIV-1 and HIV-2, dectan sulfate and pentosan polysulfate were significantly more inhibitory to HIV-2 than HIV-1. Heparin, however, was more inhibitory to HIV-1 than HIV-2. These findings point to a specific interaction of sulfated polysaccharides with the HIV envelope glycoproteins. As pentosan polysulfate is acid and dectan sulfate could be detected in the renal range by using HIV-2(III₂) as the challenge virus, the HIV-2(III₁) system could be used as a bioassay for the detection of these compounds in biological systems.

C.592

INHIBITION OF HIV-1 AND HIV-2 REPLICATION IN FRESH AND CHRONICALLY INFECTED CELLS WITH ANTIVIRAL AGENTS

S. D. Baxby, K. L. F. Farrant, D. G. M. Thornton, A. H. J. Fullen, J. J. Sheahan, S. J. G. and Sarin, P. S.
 (1) University of Toray Cell Biology, National Cancer Institute, Bethesda, Maryland. (2) New Jersey State Department of Health, Trenton, New Jersey, U.S.A.

We have examined and compared the inhibition of HIV-1 and HIV-2 replication in fresh and chronically infected cell cultures by a number of drugs directed towards various stages in the virus life cycle. We have evaluated the effect of these drugs, including AZT, ddC, foscarnet, amphotericin methyl ester (AME) on HIV-1 and HIV-2 replication in freshly infected and chronically infected Molt-3 and H9 cells. It appears that some drugs can inhibit both HIV-1 and HIV-2 replication at similar drug concentrations, whereas others require a higher drug concentration to inhibit HIV-2. Similar differences were observed between the potency of these drugs on freshly infected cells as compared to chronically infected cells. These findings indicate that it may be extremely important to select antiviral agents which are equally active on both freshly infected and chronically infected cells for the treatment of AIDS.

C.594

McGosh, M.P., Hwang, E.M.P., Caldwell, S.H., O'Brien, P., Luk, K.C.M., Linton, R.P., et al.
 *San Francisco General Hospital, San Francisco, California, U.S.A. *Onsite Incorporated, Redwood City, California, U.S.A.

C.596

GLQ223: AN INHIBITOR OF HIV REPLICATION IN ACUTELY AND CHRONICALLY INFECTED T CELLS AND MACROPHAGES

McGosh, M.P., Hwang, E.M.P., Caldwell, S.H., O'Brien, P., Luk, K.C.M., Linton, R.P., et al.
 *San Francisco General Hospital, San Francisco, California, U.S.A. *Onsite Incorporated, Redwood City, California, U.S.A.

OBJECTIVE: To evaluate GLQ223 for ability to inhibit HIV replication in acutely and chronically infected cells and cells of both thymocyte and monocyte/macrophage lineage.
METHODS: GLQ223 is a highly purified dimer derived protein used in crude form, in traditional buffer medium for a variety of clinical indications. GLQ223 was tested for ability to inhibit HIV replication in assays systems employing target cells of both thymocyte and monocyte/macrophage lineage, in acute and chronic infection models. Viral replication in treated cultures labeled with laboratory indicator of HIV was assayed by effects of GLQ223 on cultured cells from HIV-infected donors. Viral replication was monitored by flow cytographic immunofluorescence analysis, antigen capture immunosay of culture supernatant, and northern blot analysis.

RESULTS: GLQ223 showed concentration dependent inhibition of HIV replication in acute infectivity assays with a 50% T cell line as target. Complete inhibition of viral replication was obtained at concentrations of GLQ223 which were one tenth to parallel cultures of uninfected cells. Northern blot analysis showed a selective proportional decrease in the amount of viral RNA compared to levels of a representative cellular RNA species in treated cultures. Treatment of chronically HIV-infected monocyte/macrophage cultures also showed selective inhibition of HIV antigen expression. A single 3 hour exposure of whole blood from HIV-infected donors to GLQ223 was sufficient to prevent the expansion of HIV antigen which occurred upon subsequent culture when the cells were not treated.

CONCLUSION: GLQ223 is a compound with encouragingly to virus anti-HIV activity in both acute and chronic infection, in both T cells and monocyte/macrophages. The mechanism of action is under investigation.




Publications

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

- C.603** **NM-1 IN THE TREATMENT OF AIDS.**
REPORT ON 172 TREATED PATIENTS.
Shafiq-Abadi¹, Larkhan²,***, Nase, M.***, Wayne, J.***,
¹Cairo University, Cairo, Egypt;
²***, ***, *** University of Kinshasa, Kinshasa, Zaïre.

The result of treatment of 172 AIDS patients with NM-1, an antiviral drug, is presented. Twenty AIDS patients were treated with the standard treatment for opportunistic infections and were considered as controls. Patients were monitored for clinical and laboratory changes before, during and after treatment. NM-1 was given in a dose of 0.07 mg/kg body weight, one injection every other day for 10 injections, and every third day for another 10 injections. Of the 172 patients treated with NM-1, 24 died; 6 of cryptococcal meningitis, 8 of electrolyte imbalance from diarrhea, and 10 of Kaposi's sarcoma. Improvement achieved in 148 patients. Follow-up varied from 4 to 14 months. NM-1 showed no side effects except fever after each of the first 3 injections. The patients showed clinical improvement and immunologic restoration to normal. The 20 control patients died within the follow-up period.

C.605



- C.607** **INHIBITION OF HIV REPLICATION BY NYLAN-POLYHYDROGENSULFATE: HOE/BAY 946, A NEW ANTIVIRAL COMPOUND IN CLINICAL TRIAL.**

Lothar Blasser¹, H. Saharoun², J. Wenker³, E. Schinner⁴, H.-D. Schlumberger⁵, H. Rübmann-Wiegmann⁶,
¹Chemothérapeutisches Forschungsinstitut Georg-Spoyler-Haus, Frankfurt, FRG,
²Hoechst AG, Frankfurt, FRG, ***Bayer AG, Wuppertal, FRG.


Objective: HOE/BAY 946, a styrenopy-hydrogenosulfate disodium salt, inhibited HIV-1 and HIV-2 replication and virus-induced cell fusion in lymphocyte cultures at concentrations above 25 µg/ml (4.2 µmol/l) totally. The drug was found to be an inhibitor of the HIV-enzyme reverse transcriptase. Experiments were performed to find out which step of the virus life cycle was inhibited by the drug in the living cell.

Methods: HIV-infection of lymphocytes was detected by determination of syncytia formation, reverse transcriptase activity and antigen release.

Results: 1) An inhibiting effect of the compound for free viruses could not be demonstrated. 2) Lymphocytes incubated with HIV in the presence of 100 µg/ml HOE/BAY 946 followed by the removal of both the drug and unbound virus were found to be infected. Thus, inhibition of virus adhesion to the cells may not be sufficient to avoid further infection. 3) Several experiments showed that the permanent presence of the drug was necessary for its full antiviral activity. 4) Treatment of a permanently HIV-infected monocyte cell resulted in a drastic reduction of virus shedding and points to an additional mode of action. It is discussed that HOE/BAY 946 has an influence on virus assembly or virus release.

Conclusions: Based on the anti-HIV activity of the compound, a clinical pilot study with HOE/BAY 946 was started recently in Germany with AIDS-patients and asymptomatic virus carriers.

C.604



- C.606** **INHIBITION OF EXPRESSION OF NATURAL UAC SUPPRESSOR GLUTAMINE tRNA IN HIV- AND MOLONEY VIRUS-INFECTED HUMAN PB3 CELLS IN VITRO BY AVANAC.**

Müller, Werner E. C., Kuchino, Y., Schröder, W. C.,
¹Institut für Physiologische Chemie, Universität, Duesbergweg, 6500 Mainz, West Germany, ** Biophysics Division, National Cancer Center Research Institute, Chou-ku, Tokyo 106, Japan.

Objective: To study the mode of action of the anti-HIV compound Avanol. **Methods:** Human T cells (HT), infected with HIV-1 and NIH-3T3 cells, infected with Moloney Murine Leukemia Virus (Mo-MuLV) have been used for the studies. **Results:** Avanol is a squariterpenoid hydroquinone, which causes a strong antiviral effect on HIV and Mo-MuLV in vitro. It was found that in HIV- or Mo-MuLV-infected cells a high level of the UAC suppressor glutamine tRNA-UAG is present. In Mo-MuLV-infected cells this tRNA is required for the synthesis of the RNA, coding for the viral proteins; the function of this tRNA in HIV-infected cells is not yet known. Avanol causes at virostatic concentrations a reduction of the virus-induced UAC suppressor tRNA to normal levels. The functional consequence of this event is an inhibition of the processing of the viral polyprotein, very likely due to an inhibition of the readthrough of the Mo-MuLV process gene; in the HIV system the molecular explanation is not yet possible. **Conclusion:** This study demonstrates that an inhibition of HIV production can be achieved also by a selective inhibition of the expression of a cellular gene. Ref.: Müller et al., AIDS Res. Human Retrov. 4, 279 (1988); Kuchino et al., Virology 165, 358 (1988). Supported by grants from the Bundesgesundheitsamt.

C.608

- Hypericin mediates Anti-HIV Effects in Vitro:**
D. M. Stasick¹, P. O. Lavee², W. V. Williams³, D. Lavee⁴, M.I. Greene¹, D. Muroto², Department of Pathology¹, Department of Medicine², University of Pennsylvania, Philadelphia PA, 19104-6082., Department of Pathology and Kaplan Cancer Center³, New York University Medical Center, 550 1st Avenue, New York, NY 10016, The Weizmann Institute of Science, Rehovot 76100, Israel.

Objective: To examine the ability of two aromatic polycyclic dyes hypericin and pseudohypericin to control HIV infection in vitro. **Methods:** Evaluation of syncytia formation, reverse transcriptase activity, viral RNA production, biochemical as well as electron microscopic studies of HIV-1 and HIV-2 have been studied. **Conclusions:** The low in vitro and in vivo toxicity of these compounds, the ability to interfere with infectious virus particle production, the fact that humans have been treated with these compounds with no serious side effects as well as the widespread availability of these agents, suggest further examination of hypericin for future AIDS patient therapeutic regimens may be warranted. **Discussion:** Both HIV-1 and HIV-2 were sensitive to the effects of hypericin. Hypericin possesses at least two different active components and syncytia and blocking of viral infectivity. Morphological examination demonstrates a significant difference in the number of virus particles exhibiting the mature HIV-1 virus phenotype after hypericin treatment. Hypericins does not have direct effects on several commercially available viral reverse transcriptase and viral integrase activities. Studies in our laboratory have demonstrated synergistic anti-viral effects between this class of compounds and other inhibitors of HIV infectivity. Further examination of the mechanism of anti-viral effects of these compounds is in progress.


C.609 EVALUATION OF erythro-9-(2-hydroxy-3-oxo)adenine (EHNA) TREATMENT ON HIV-1 REPLICATION

Yoshitani Sei¹, I. Tsuboi², M.M. Tokuyama³, and Prince K. Arora⁴
¹Laboratory of Neurovirology, NIDDK, National Institutes of Health, Bethesda, MD, U.S.A.
²Department of Immunology, Kurume University School of Medicine, Japan.

Objective: To evaluate the efficacy of EHNA treatment on viral replication in HIV-1 infected cell lines *in vitro*.

Methods: HIV-1 infected or uninfected H9 cell lines were treated with varying concentrations of erythro-9-(2-hydroxy-3-oxo)adenine (EHNA), an inhibitor of the common Adenosine deaminase (ADA) [enzymes/ADA and ADA1-CP]. Several different concentrations of deoxythymidine (dCT) were also added to the cell cultures. Cell viability was assessed by vital dye exclusion. Reverse transcriptase (RT) activity in the supernatants and in the cell lysates was determined by standard RT activity assays. Finally, RT activity in the supernatants was inhibited by assay 9PS in EHNA-treated HIV-1 infected H9 cells, when compared with the untreated but infected H9 cells. There was also a significant decrease in cell viability, but this was reversed following the addition of dCT to these cultures. This combined treatment had an effect on RT activity in the cell lysates, suggesting an inhibition of HIV-1 replication, and release from the infected cultures. This combined treatment was also effective in suppressing HIV-1 release of HIV-1 from infected U937 cells.

Conclusions: The treated treatment with EHNA+CT may be an means of suppressing viral replication in HIV-1 infected cells. Also, since EHNA inhibits adenosine deaminase, HIV-1 release from infected cells may be regulated by purine metabolic pathways.

C.610

CONTROLLED EVALUATION OF THE EFFICACY OF ZIDOVUDINE ON NEUROPSYCHOLOGICAL TEST PERFORMANCE IN GUC GROUP BY HIV INFECTED INDIVIDUALS
 Boudreau, A., Vermeiren, S., Charu, J., Hubert, M., Pature, B., Plamondon, J.
 Psychology Department and Neurology Dept., St. Mary's Hospital, London, ON, CAN.

Objective: To evaluate the effectiveness of Zidovudine in reversing cognitive impairment in GUC Group HIV infected patients and to judge the speed of drug effectiveness.

Methods: Monthly evaluation on a battery of neuropsychological tests was carried out on Zidovudine treated patients (ZID) and control groups: (1) HIV infected GUC patients treated for non-neurological aetiology (N=10) (2) GUC Group HIV patients treated with AZDT (N=10) (3) HIV seronegatives. Tests used included (COWAT), Trail-Making, Mark Flattery, Rey Auditory Verbal Learning and St. Mary's Departmental Hall Attention Task. Multivariate analysis of variance was used to look at change over testing sessions for each of the groups.

Results: On an overall impairment score calculated by summing standardized (z-scores) over the individual tests there was a significant (p<0.05) interaction between group and improvement on testing. This was mainly due to greater initial improvements in the Zidovudine treated group as compared to the other groups. They did not however continue to improve in all cases. Further follow-up is continuing.

Conclusions: Zidovudine does appear to improve overall neuropsychological test performance in those with AIDS. More improvement is seen it is likely to be greatest in the first few months of treatment.

C.611
C.612

ANTI-HIV-1 ACTIVITIES OF SULFATED MONOSACCHARIDES (SMS) AND POLYSACCHARIDES (SPS); THERAPEUTIC STRATEGIES (T1)

Bassey, Umar; Lischner, R.W.; Halligan, G.E.; Shino, N.
 Univ. of Medicine and Dentistry of New Jersey, Camden, NJ; Temple Univ. Sch. of Med. and St. Christopher's Hosp. for Children, Philadelphia, PA, USA.

Objective: To compare the T1 in vitro of anti-HIV SMS and SPS.

Methods: SPS including dextran sulfates (DS) of various mw, heparin, heparin sulfate, chondroitin sulfate (ChS) and heparan pentosan polysulfate, fucoidin, and carrageenan as well as SMS including D-glucosamine 2 sulfate, D-glucosamine 6 sulfate, D-glucosamine 2,6 disulfates and monofucosyl hexasulfate were examined for their direct inhibitory effects on HIV-1 reverse transcriptase, spycyctic formation (SF), and infection of pretreated target cells as well as on partial thromboplastin and prothrombin times.

Results: (1) All of the SPS inhibited HIV reverse transcriptase (25-99%) at 50 µg/ml of the SMS, only glucosamine 6 sulfate had significant anti-SF activity (50%). (2) Spycyctic formation was inhibited by as low as 6 µg of 5% carrageenan, fucoidin and pentosan polysulfate. D-glucosamine 6 sulfate completely inhibited SF at 50 µg/ml. Other SMS had no significant anti-HIV activity at this concentration. (3) All SPS had significant anticoagulant activity, whereas SMS had no anticoagulant activity up to 1 mg/ml concentration except heparin hexasulfate. **Conclusions:** SPS have broader and more consistent anti-HIV activity but POTENTIAL LOW T1 because of anticoagulant activity. SMS, particularly glucose 6 sulfate, have higher *in vitro* T1 and deserve clinical trial.

C.613

BLOCKING OF HIV-1 BINDING SITE BY LECTIN

Hasegawa, Osamu; Reine, R.; Whittle, P.; Lischner, R.
 Temple Univ., University of Medicine and Dentistry of New Jersey -SOM, Camden, NJ, USA; Temple Univ., Philadelphia, PA, USA.

Objective: Blockade of the interaction of HIV-1 gp120 molecule with CD4-ligands is one of the many strategies for blocking HIV-1 infection and possibly cytopathicity. The use of purified lectins, which are specific for one or two sugars, as a blocking agent may provide a rather simple way of HIV-neutralization.

Methods: (1) Sup-T7 cells (CD4+ cell line) were pre-incubated with various lectins, washed, and degree of inhibition of HIV-CD4-ligands (OCT4, OKT4, lectin) was evaluated by flow-cytometry and microscopy. (2) Anti-HIV activation of various lectins was examined by a spycyctic-inhibition assay using Sup-T7 and HIVIIII cells (2Zidov. Dis). (3) Western blot analysis were performed to determine the possible site of binding of the lectins.

Results: (1) Five lectins: VVA, DBA, RAA, WPA and SMA completely or partially blocked the binding sites of HIV-1. (2) VVA, DBA, RAA, WPA, PMA, PMA, ConA, PMA and WPA blocked spycyctic formation. (3) Western blot analysis revealed that two lectins, VVA and PMA have affinity for certain components of HIV-1.

Conclusion: (1) Lectins have specificity for a certain sugar or oligo-saccharide. Therefore, they can be used as a simple agent(s) for "anti-spycyc" which will block the "critical" HIV-CD4 site. (2) Theoretically, such sugars can be used to block HIV-1 from binding to CD4 and has therapeutic potential.

C.614




Publications

- C.627** BACULOVIRUS DIRECTED CELL-SURFACE EXPRESSION AND PURIFICATION OF CD4 IN INSECT CELLS
 Webb, J.C., Felt, P.S., Brumstad, D.R., Saeed, I., Summers, M.D., Nicolson, C.
 *Texas A&M University, College Station, Texas, USA; **Genzyme Corporation, Cottage Station, Texas, USA; ***College of Medicine, Houston, Texas, USA.

Infection by the human immunodeficiency virus (HIV), the causative agent of acquired immune deficiency syndrome (AIDS) is mediated by the binding of the viral envelope glycoprotein, gp120, to CD4, a glycoprotein expressed on the surface of HIV-susceptible cells, most notably T helper lymphocytes (Gautschi and Weiss, 1988). In a recent report, we described the stable insertion of CD4 derived from human lymphocytes into rat blood cells and its interaction with HIV-1 and HIV-1-infected HeLa cells (Nicolas et al., J. Cell Biochem. 33, 234, 1988). The potential use of a CD4-erythrocyte complex as a therapeutic agent for AIDS requires large amounts of CD4 which contains the bicyclic hexamer-spanning region. To do this, we have produced a baculovirus expression vector (Lusick and Summers, 1988) for the abundant production of full-length CD4 in insect cells. We show that the recombinant protein expressed on the surface of insect cells is chemically, immunologically and biologically similar to CD4 expressed in human cells.

C.629



- C.631** CELLULAR PHARMACOLOGY OF 3-AZIDO-2'-3'-DIDEOXY-URIDINE (AZDUI) IN HUMAN PRIMARY CELLS: EVIDENCE OF A NOVEL METABOLITE
 Zhou, Z., Srinivas, R.P.F., Edson, B.F.H., Chu, C.K., Williams, G.L., and Remington, J.P.

Univ. of Alabama at Birmingham, Birmingham, AL, Veterans Admin. Med. Ctr., and Emory Univ., Sch. of Med., Atlanta, GA; Univ. of GA, Athens, GA; and Tibco Biociences, Inc., Alameda, CA, USA*

Objective: To investigate the cellular pharmacology of AZDUI (CS-87) and 3-azido-2'-3'-dideoxythymidine (AZT) in human bone marrow (BM) and peripheral blood mononuclear (PBMC) cells. **Methods:** Human PHA-stimulated PBMC or BM cells (2×10^6 cells/ml) were exposed to 10 μ M (10) AZT or (10) AZDUI from 2 to 16 hrs. The 80% methanol-soluble fraction of the cell lysate was analyzed by HPLC using a Parted 10-SAX column. **Results:** Within 2 hrs AZT-MP accumulated for 80% (87 to 92%) of intracellular metabolites in increased within 48 hrs to 5.2 and 6.1 percent of cells in PBMC and BM cells, respectively. AZDUI-MP accumulated at a slower rate reaching 5 to 10 fold lower levels compared to AZT-MP and represented approximately 50 to 80% of intracellular radioactivity in both PBMC and BM cells at all times. AZDUI-DP represented similar concentrations compared to AZT-DP in both cell systems, while AZDUI-TP had 5-10 fold lower levels than AZT-TP in PBMC cells. In contrast to AZT, an unknown metabolite analogous of AZDUI labeled with AZDUI-MP and DP with a different retention time from AZT-MP and DP in both cell systems. This AZDUI metabolite increased over time and represented as much as 20% of intracellular radioactivity in BM cells following a 48 hr exposure. The metabolite was resistant to 5'-phosphatase, but was a substrate for 5'-phosphodiesterase, yielding AZDUI-MP with the same retention time as the analog, suggesting formation of a AZDUI-5'-diphosphate base. **Conclusions:** The metabolite of AZDUI to AZDUI-DP, hence its primary human cells, especially in BM cells, may contribute to the decreased toxicity of the anti-HIV drug when compared to AZT.

- C.628** ESSAIS CONTRÔLES EN DOUBLE INSU DU LF 1695 CHEZ DES PATIENTS VIH-1
 Livraghi, Jac-Michel, *; Cimet, D.**, Kienast, J.L., **; Touraine, F. **, Touraine, J.L., **
 *Division Hospital E. Herriot, Lyon, France; ** Laboratoire Fournier, Dijon, France; *** Hôpital Neurologique, Lyon, France.

Objectifs: Evaluer et comparer l'efficacité de 2 poologies d'un immunomodulateur, le LF 1695 (Lab. FOURNIER) parmi 38 patients au stade de LPJ ou d'ARC. **Méthodes:** Dans un essai contrôlé randomisé en double insu, 20 patients ont reçu 1 g/jule quotidien de 120 mg de LF 1695, 15 jours par mois pendant 3 mois, puis 1 g/jule de placebo en continu les 3 mois suivants; 18 patients ont reçu une g/jule de placebo 15 jours sur 30 pendant 3 mois puis une g/jule de 120 mg de LF 1695 en continu les 3 mois suivants. Une évaluation clinique et biologique (NF, CD3+, CD4+, CD8+) a été réalisée tous les 3 mois. A la fin de l'étude randomisée, les patients ont été traités par placebo ou LF 1695 en continu ou en discontinuation selon un arbre de décision (variation de +/- 20 % du nombre de CD4+ au cours de l'étude randomisée).

Résultats: La composition des profils de lymphocytes CD4+ au cours de la phase initiale ne montre pas de différence significative entre le groupe placebo et le groupe placebo, seule une tendance vers une augmentation à la fin de l'étude. En revanche, lors du protocole de suivi, le nombre de lymphocytes CD4+ et significativement augmenté parmi les patients traités en discontinuation (de 400 à 200 à 630 à la dernière visite) par rapport aux patients traités en continu (de 411 à 310 à 344 à la dernière visite), ou par rapport aux patients (de 426 à 310 et 376 à la dernière visite). **Conclusions:** Le LF 1695 à la dose de 120 mg par jour, 15 jours par mois, présente un intérêt thérapeutique. Il devra être confirmé dans un nouvel essai randomisé.

C.630

- C.630** IN VITRO ANTI-HIV ACTIVITY OF A NEW CLASS OF POLYMERS.
 Lemelle, Michel; Boyer, B.**, Roque, J.-P.**, Lamly, G.**, Montagnier, L.**, and Lericq, A.***
 *Univ.-Paul Sabatier, Research Center, F-31062 Vilry-Cedex, **Université des Sciences et des Techniques de LangueDoc, 34090 Montpellier-Cedex, France, ***Institut Pasteur, Viral Oncology, Paris, France.

Objective: We have synthesized a new class of polymers and tested their ability to act as HIV inhibitors. **Methods:** We have tested these compounds as HIV replication inhibitors in Molt-4 (T8 cells) and in human peripheral blood lymphocytes (PBMC). We have measured the reduction of cytopathic effect (CPE) induced by HIV-1 (LAI-89 strain) - WT assay, and reduction of reverse transcriptase (RT) activity in supernatants. **Results:** Two polymers PS and PC were active. The EC₅₀ were 1-3 μ g/ml and 2-5 μ g/ml respectively in CDM (1 and 14 days after infection respectively) and the EC₅₀ of PS was 0 μ g/ml in PBMC. The CDM were in all cases superior to 100 μ g/ml. Both products were active when added to the cells 2 h, post infection. In these conditions the EC₅₀ in CDM were 5 and 10 μ g/ml respectively for PS and PC. RT were 2-10 μ g/ml (PS) and when injected i.v. in mice (1 dose), the LD₅₀ were 0.10 mg/kg (PS) and 5 days was well tolerated. **Conclusions:** Our new compounds were active as in vitro HIV inhibitors at doses similar to those reported for clinically used compounds.

- C.632** IMMUNOTOXICOLOGICAL EFFECTS OF BETA-CAROTENE ON T-CELL ACTIVATION MARKERS AND NK CELLS IN HIV INFECTED PATIENTS.
 Stigum, Ronald B., Coombs, R.W., *; Aouf, N.M., *; Freiberg, M., *; Allen, V.**, Dob, C.**, Hirsch, M.J.**, et al.
 *University of Arizona, **Veterans Administration Medical Center, Tucson, Arizona, USA.

Objective: Study the effect of beta-carotene on lymphocytes from patients with AIDS, based on its immunological effects in normal subjects. **Methods:** Eleven HIV infected patients were given 30 mg/day of beta carotene for 4 months. Samples of heparinized peripheral blood were collected prior to, during, and after cessation of supplementation. Changes in the number and percentage of mononuclear cells with various markers were measured with monoclonal antibodies and flow cytometry.

Results: After 3 months of treatment the percentage of cells with markers of NK cells increased significantly (from $3.2 \pm 2.8\%$ to $19.4 \pm 13.6\%$) in HIV infected patients. The percentage of cells expressing CD-28, transferrin receptor, and HLA-Dr antigens was increased from 3.6 ± 4.8 to 16.8 ± 18.3 ; from 3.4 ± 3.1 to 23.2 ± 16.9 ; from 36.5 ± 9.3 to 61.1 ± 13.3 respectively by the treatment of beta-carotene for 3 months in HIV infected patients. No significant changes in T-lymphocytes, T-suppressor or total T-cells were observed during the treatment. Similar changes were seen in the number of these cells with each antigen. The maximum response was reached after 1 month, and had declined since by 4 months of treatment. These results are all qualitatively similar to those previously observed by us in normal subjects. No toxicity attributable to the drug was observed and the effects of cessation of supplementation were also assessed.

Conclusions: Beta-carotene produces an increase in the number of cells with NK markers and markers of activation (CD-28, transferrin receptor). Clinical studies are warranted to assess if these findings will be of clinical benefit in AIDS or AIDS-related diseases. Supported in part by grants from Wallace Centers and NIH AA-08073.

Publications

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

C.633

EFFECT OF p24 ANTIGEN IN AIDS CD4+ T-LYMPHOCYTES WITH NO ZIDOVUDINE AND PROGRESSION TO AIDS

THOMAS¹, GILLI², THOMAS³, NICHOLSON⁴, GARDNER⁵, HARTLOW⁶, ST. THOMAS⁷ HOSPITAL, PHOENIX, AZ; ²UNIVERSITY OF ARIZONA, TUCSON, AZ; ³UNIVERSITY OF ARIZONA, TUCSON, AZ; ⁴UNIVERSITY OF ARIZONA, TUCSON, AZ; ⁵UNIVERSITY OF ARIZONA, TUCSON, AZ; ⁶UNIVERSITY OF ARIZONA, TUCSON, AZ; ⁷UNIVERSITY OF ARIZONA, TUCSON, AZ.

Objective: To study the effect of 1200 and 800 mg zidovudine given in 4 or 12 15 day courses in patients with AIDS CD4+ T-lymphocytes. **Methods:** 36 asymptomatic patients (AIDS CD4+ T-lymphocytes) were randomized to receive either zidovudine or Placebo on a double-blind basis. The results of the first 18 are shown.

Table 1

	No. of patients	Weeks 1-6	Weeks 7-12
A Zidovudine	7	600 mg qds	600 mg bid
B Zidovudine	5	200 mg qds	200 mg qds
C Placebo	3	6 caps qds	2 caps qds
D Placebo	3	3 caps qds	2 caps qds

Mean age was 35 years, average IB at entry 14.5 g/dl (range 11.8-17.0) and median CD4 cell count 800 cells/mm³ (range 100-2000).

Results: The mean percentage reduction of p24 antigen level was 62% (range 37-78%) in group A, 28% (range 8-47%) in group B and 0% in the Placebo groups. Mean percentage reduction of p24 antigen in the combined treatment group was statistically significant ($P=0.01$, Mann-Whitney U test), with no difference between groups A and B. Treatment was well tolerated since few side effects were reported. All patients were followed up for a minimum of 9 months after cessation of therapy. 7 (5 treated, 2 placebo) had continued with zidovudine 250 mg or 500 mg bid and remain well. 7 (5 treated, 2 placebo) have progressed to AIDS or NEC. The remaining 4 patients remain well. Conclusions: Short-term zidovudine given 600 mg and 400 mg bid reduces p24 antigen levels but may not influence progression of disease.

C.635

DEXTRAN SULFATE DECREASES CELL SURFACE GP120, BUT DOES NOT INTERFERE WITH GP120-CD4 INTERACTIONS

CATHAN, L., PHAN, M. and HOGAN, M.A.

Food and Drug Administration, Bethesda, MD, 20895, USA

Objective: Dextran sulfate has been reported to block virus binding to CD4+ cells. To determine if this effect is due to receptor blockade, we examined the effect of dextran sulfate on gp120 to CD4 binding and cell surface gp120 expression.

Methods: GP120 binding to CD4 was measured by incubating recombinant gp120(Genentech) with Meth-4 T-cells followed by monoclonal anti-envelope antibody and fluorescently-labelled goat antibody to mouse Ig. Binding was also measured in an ELISA format by incubating soluble CD4(PharMing) with gp120 coated plates, developing with anti-CD4 monoclonals. The effect of dextran sulfate on cell surface expression of gp120 on HIV-infected cells was quantitated by immunofluorescence and flow cytometry analysis.

Results: Anti-viral concentrations of dextran sulfate from 10µg/ml to 10 mg/ml were without significant effect on gp120-CD4 binding in both cell surface binding and ELISA assays. In contrast, HIV-1 chronically infected cells treated with dextran sulfate show marked decreases in gp120 surface staining, while CD3 remained constant.

Conclusion: Dextran sulfate does not directly block gp120-CD4 interactions. The rapid decrease in the amount of gp120 on the surface of infected cells suggests that the effects of dextran sulfate include the disruption of gp120 cell surface expression resulting in inhibition of synctia formation.

C.637

Effect of the polyene macrolide group of antibiotics on inhibition of human Immunodeficiency Virus (HIV) replication in cell culture

DENNIS, R., BENTLEY, S.R., SHARIF, I., DIANE RUBERTSCHER, I., LEVIN SWIATEK, DANEY K.L. SUN, P. RAN, S. SARIN

New Jersey State Department of Health, Trenton, New Jersey

Objective: The polyene macrolide family of antibiotics contain several potent antiviral compounds and act by binding to a sterol niche in the membrane of cells. They have recently been shown to be effective inhibitors of HIV RNA virus due to the presence of a high cholesterol:phospholipid ratio in this virus. These antibiotics are grouped according to the number of conjugated double bonds in their lipophilic hydrocarbon region. A number of these compounds including the trime, tetraene, pentane, hexane and heptane groups were examined for their cytotoxicity and activity against HIV. Of the compounds tested amphotericin B, its methylated derivative AMB, nystatin and the methylated derivative of amphotericin proved to be effective inhibitors of HIV-1 replication at non-cytotoxic dose levels. The other compounds tested were not active against HIV at non-cytotoxic dose levels. The results show the importance of structural modification as a means of reducing toxicity of current compounds in search for effective compounds for the treatment of AIDS. Current studies show that derivatives of amphotericin B are much less toxic compared to the parent compound without any loss of antiviral activity.

C.634

PULMONARY FUNCTION IN INDIVIDUALS WITH AIDS RECEIVING AZENKIDOLYD PIPROVEDINE (AZ) FOR PNEUMOCYSTIS CARINI

PERINAKA (CI) PHARMACEUTICALS, NEW YORK, N.Y.; KILMARTIN, S.A.; BLAS, A. *Community Research Institute, New York, U.S.A.

Objective: To monitor pulmonary function in 205 patients with AIDS enrolled in a 1-year trial of the doses of AZ for prophylaxis of PCP, which was fully enrolled by 8/2/88. 75.4% of study participants had experienced a prior episode of PCP.

Methods: Pulmonary function tests (PFTs) including measurements of TLC, FEV₁, and FVC, were performed at entry, at 4-6 months, and at 12 months after entry. Spirometry were obtained and physical examinations done at the same time.

Results: 125 patients were tested after 4-6 months (mean = 5.1 months). The mean values for FEV₁ and FVC did not differ at both times, nor were there significant differences in the distributions for both tests when the first repeat set of tests was compared to baseline. The 125 patients showed an increase in mean value on the second test: 73.2% (n=82) of the population showed an improvement in TLC when retested after a mean period of 4.6 months on AZ. The degree of improvement correlated inversely with the time elapsed since diagnosis of a prior episode of PCP. ($r = -0.214$, $p = .047$).

Conclusion: No deterioration in pulmonary function could be shown in this study. Whether AZ hastens improvement in patients who had a mean of 4.6 months at this study.

C.636

Effect of amphotericin B and its methyl ester (AMB) on human immunodeficiency virus infection and phagocytosis in macrophage cultures.

D.K. SUN, B. WOLF, P. RYAN, S.I. SHARIF, J. BROWN, J. ROSEN, C.P. FLESCIA, C.P. SCHIFFER and T.S. BERTIN, U.S.A.

Objective: The antifungal amphotericin B and its methyl ester AMB were tested in the continuous macrophage cell line DM37 for activity against HIV-1. At non-cytotoxic dose levels the expression of HIV-1 was inhibited as shown by the measurement of p24 antigen expression with immunofluorescence. At 10 µg/ml there was complete inhibition of virus activity.

To examine the effect of these drugs on the enhancement of macrophage activity, phagocytosis was measured using primary murine adherent cells. Either Sheep red blood cells, latex or coated with antibody, or listeria monocytogenes were added to the cultures which had been inoculated in the presence of each drug at concentrations of 0.1, 1, and 10 µg/ml. Furtuin was added as a positive control. With both systems a significant increase in phagocytic activity was observed in the presence of AMB and amphotericin B.

Conclusion: These studies suggest that both AMB and amphotericin B could be very useful in the treatment of AIDS due to their inhibition of HIV-1 replication in T cells and macrophages.

These compounds may provide an alternative to AIDS therapies due to their multifunctional cellular activities.

C.638

MECHANISTIC ASSAYS FOR NATURAL PRODUCT ANTI-HIV ACTIVITY

MULLIGAN, JAMES; WATSON, O.K.; KIE, R.W.; OLAHOSKI, R.A.; WARREN, J.; GUSTAFSON, K.F.; BADER, J. and BOYD, M.

*Developmental Therapeutics Program, DCR, Wyngate Research, Inc., NCI-FCRF, Frederick, MD, USA.

Objective: To develop rapid quantitative assays to study the mechanism of action of compounds with anti-HIV activity isolated from natural products.

Methods: Microculture procedures were utilized to define the various steps of HIV infection in T-lymphoblastoid cells. Quantitative readouts of these assays included several novel colorimetric, enzymatic, and fluorescent endpoints. Interactive laser cytometry was also used to study the effects of anti-HIV compounds at the single cell level.

Results: In addition to developing quantitative tetraacetyl and fluorescent assays for the overall cytopathic effects of HIV, microculture assays measuring the effects of compounds on virus/target cell interactions, reverse transcriptase and infectious viral release were also developed. Quantitative measurements of viral antigen expression at the single cell level was accomplished using immunocytofluorescent methods. Antiviral compounds with known mechanisms of action and comparative methodologies were used for assay validation.

Conclusions: Several rapid quantitative assays have been developed and/or modified which allow for the large-scale mechanistic screening and/or analysis of AIDS antiviral activity of natural products. These investigations attempt to determine where in the life cycle of HIV natural products exert their activity. Understanding the mechanism of action of antiviral compounds will aid in the selection and prioritization of novel anti-HIV agents for clinical trials.

Publications

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

C.639

A TRIAL OF AZIDOGLUCOSYL PENTAMIDINE (AP) FOR PROPHYLAXIS OF PNEUMOCYSTIS CARINI PNEUMONIA (PCP) IN AIDS.
Joseph Bilmeser, S.J.; Fieischer, T.; Community Research Initiative, New York, U.S.A.

Objective. To investigate the safety of 100 and 150mg of AP during biweekly to individuals with AIDS, as well as the efficacy of these dosages in the prevention of PCP.

Methods. Eligible participants who had CDC-defined AIDS, were randomized to receive either 100 or 150mg of AP biweekly using the Neupogen randomized 2 numberizer, in a 1-year trial fully enrolled by 6/28/88.

Results. 212 subjects were enrolled, for 191 of whom demographic data was available: 71.5% white, 5.3% black, 11.2% Hispanic, 2.4% women. 63.9% had a prior episode of PCP (mean of 7.6 months before entry). 83.4% were gay/bisexual men, 4.5% intravenous drug users, 1.8% blood transfusion recipients. As of 1/89, 46% had discontinued participation (26.4% voluntary withdrawal, 15.8% non-compliance, 11.3% infectious illness, 25.9% death). AP was well tolerated with no significant side effects, and results of pulmonary function tests (FVC, MLD, FEV1) showed no deleterious effect after a mean of 4.6 months. The number of cases of proven PCP was far less than anticipated for this population.

Conclusion. AP (100 & 150mg) biweekly demonstrated no systemic or localized pulmonary toxicity. The recurrence rate of PCP in those who had experienced a prior episode appeared to be considerably lower than that anticipated for 2nd episode cases.

C.640

A CRITIQUE OF THE U.S. GOVERNMENT AIDS CLINICAL TRIAL PROGRAM
Lynn Lutz; Kirschbaum, D. and Barf, R. AIDS Coalition to Unleash Power, New York, New York, U.S.A.

Objective. To evaluate accessibility of experimental treatments in the AIDS Clinical Trial Group (ACTG) Program to HIV-infected people.
Methods. In January 1989, this program had enrolled over 5,700 subjects in trials at 35 sites and 11 pediatric centers. Government documents related to these trials were reviewed periodically.

Results. There were 24 agents under study and 45 trials open. Twelve trials were closed and 2 completed. There were 12 ACT trials in which 4,625 subjects (80% of total program enrollment) were enrolled. AZT was being tested at many different stages of the disease. There were also 16 trials of AZT in combination with other drugs, with a total program enrollment of 78. Antivirals other than AZT were in 12 preliminary Phase I or pharmacokinetic trials and had enrolled 349 subjects (4% of total program enrollment). Enrollment by sex: Male 94.2%, female 5.8%. Enrollment by race: white 82.94, black 6.94 and Hispanic 8.94. Enrollment by IV drug use history: never used 84.3%, previously used 11.0% and currently using 0.3%.

Conclusion. The main drug tested in the program is AZT alone or in combination. Access to trials testing other antivirals besides AZT or in combination with AZT is very limited. Women, people of color, children, hemophiliacs and prisoners are not represented to the extent that they are HIV-infected. All recently diagnosed people with AIDS have few clinical trial options.

C.641

SPECIFIC INTERACTION OF ADENINETRICARBOXYLIC ACID WITH THE HIV/CD4 RECEPTOR

Dominique Sordet, N. Balm, E. Kowalek, J. Demptier and E. De Clercq
Rega Institute for Medical Research, K.U. Leuven, B-3000 Leuven, Belgium

Considering the essential role of the CD4 receptor in the replicative cycle of HIV, it would seem important to find appropriate marker molecules that specifically interact with the CD4 receptor and thereby block HIV attachment to the cell.

CD4⁺ cells (M1, U-937, peripheral blood lymphocytes and monocytes) were incubated in the presence or absence of the test compounds, stained with various monoclonal antibodies (mAbs), washed, fixed and examined by flow cytometry. To investigate virus-cell binding, HIV cells were exposed to radio-labeled HIV-1 virions in the presence or absence of the test compounds.

The triphosphathene derivative aurtitricarboxylic acid (ATA), but not surin, selectively prevented the binding of (D6TA)Leu3a mAb, and, to a lesser extent, (2E9) mAb to the CD4 receptor of all four cell types at a concentration of 10 µM. The effect was rapid (1 minute), dose-dependent and reversible. It could be neutralized by surin. ATA also prevented the attachment of radio-labeled HIV-1 virions to HIV-1 cells, presumably as the result of its specific binding to the CD4 receptor.

These unusual properties of a small molecule of non-immunological origin may have important implications for the study of CD4, HIV, AIDS pathogenesis, and, possibly, therapy and prophylaxis.

C.642

Biologie moléculaire
Molecular Biology

C.643

VARIABILITE DES SEQUENCES DU VIRUS DU SIDA
F. GARDYETZ, P. BONHOUD, S. HAZOUTI, A.J. VALLERON
INSERM U163, 2 INSERM U163, Institut Pasteur, Paris, France

Objectif. La variabilité génétique du virus du SIDA peut être utilisée comme un outil d'analyse des processus de migration et de sélection quantitative sélective. L'objectif de ce travail est, après avoir conclu statistiquement à la non-homogénéité du taux de substitution par site, de caractériser dans les séquences différents ensembles de régions de haut de substitution proche. Les données utilisées sont les séquences publiées de la protéine de l'enveloppe.

Méthodes. À partir de l'alignement multiple des séquences HIV-1, HIV-2 et SIV, on construit d'abord une séquence consensus avec les acides aminés les plus fréquents à chaque site; on calcule ensuite le taux de substitutions par rapport au consensus le long de la séquence, ceci constituant la fonction de variabilité. Un ensemble de tests statistiques est effectué sur cette fonction afin de vérifier l'existence de régions homogènes.

Résultats. L'analyse statistique a permis de classer l'ensemble des régions en trois groupes de variabilité et de composition nucléotidique (en position 1 des codons) différentes.

Régions

	type	variabilité	variabilité	consensus	nb sites
Longueur en Ac.Am.		33	326	446	818
Longueur (%)		4.0	41.9	54.7	100

Taux moyen (%) de substitutions par site

	type	variabilité	variabilité	consensus	nb sites
Taux en base A/G		65.2	23.7	40.0	27.1
base T/C		84.1	28.7	15.0	19.2
		18.5	18.5	18.5	18.5

Le découpage de la séquence en régions ne se révèle significatif que pour des tailles inférieures à 15 résidus.

Conclusion. L'analyse des séquences à l'aide d'une telle partition constitue une étape nécessaire qui peut être discutée en termes de relation structure-fonction.

C.644

Publications


 Recherche fondamentale (biomédicale)
 Basic Research (Biomedical)

- C.645 DIFFERENCES IN LONG TERMINAL REPEAT ACTIVITY OF TWO HUMAN IMMUNODEFICIENCY VIRUS-1 VARIANTS FROM THE VIRAL STRAIN**
 M. L. Li, G. and Volosky, D.J.
 Molecular Virology Lab, St. Luke's/Roosevelt Hosp, Ctr. and College of Physicians and Surgeons, Columbia University, New York, NY, U.S.A.
- Objective.** To compare transcriptional activity of long terminal repeats (LTR) of different HIV-1 variants.
- Methods.** LTR activity was analyzed by transient chloramphenicol acetyltransferase expression assay or by measuring production of p24 protein.
- Results.** Two HIV-1 variants, derived from a single parental isolate and termed HIV-1₁ and HIV-1₂, differ substantially in their ability to replicate in CD4-positive cells. We show that the LTR of the better-replicating HIV-1₁ virus has a 3-5 fold higher capacity than HIV-1₂ to direct gene expression in T cells. The higher activity of HIV-1₁ LTR is due to a combined effect of two mutations: 1) a point mutation in position -94 (relative to the CAP site), which is located between the two subunits of HIV-1 enhancer 1) a duplication of 24 base pair in positions -128 to -132, which has not been known to be involved in any regulatory mechanism. Presence of these mutations increases the basal level of the LTR-driven gene expression and does not influence the degree of induction caused by the viral tat gene product or by cell activation. Conclusions: HIV-1 LTR is one of the sites which may determine functional heterogeneity of HIV-1.

- C.647 EXPRESSION OF GAP PROTEINS OF HUMAN IMMUNODEFICIENCY VIRUS USING RECOMBINANT ADENO24 VECTORS**
 Katherine L. Molinar-Kramer, Robert Mastroeni, Suresh K. Dheer, Robert B. Franch, Chantal M. Franch, Alan B. Alan B. Davis, and Paul P. Nung, Biotechnology and Microbiology Division, Wyeth-Ayerst Research, P.O. Box 8299, Philadelphia, PA USA 19101-1245.
- To develop Ad24-HIV recombinant adenovirus type 2 vaccine candidates, the gag-pol gene of Human Immunodeficiency Virus was inserted into the Ad24 E3 region. In attempts to generate a new late transcription factor, an oligomer which contained 32 bp of the splice acceptor from the L5 transcription factor was inserted upstream of the gag-pol gene followed by a large E3 deletion and an intact EBV polyadenylation signal. The recombinant adenovirus, Ad24GAGPOL, synthesized gag p55 protein both early and late during infection. Although the protease gene was intact, no protease activity was detectable. The expression of the gag proteins was approximately 500 lower than expression of the hepatitis B virus envelope proteins using Ad24 E3-based vectors. Recent reports suggest that the expression of the gag-pol proteins is positively regulated by the presence of rev. The mechanism will be discussed.

- C.649 CONSTRUCTION OF HIV-1 INTER-ISOLATE RECOMBINANTS**
 York, D.A., Barisano, L.,* Bauer, D.,* Chang-Mayer, Cecilia**,
 Levy, J.M.,* Wain, D.*
- *Chiron Corporation, Emeryville, CA, USA, **University of California- San Francisco, San Francisco, CA, USA.

Objective. Construction of inter-isolate recombinant HIV-1 viruses using molecularly cloned DNA from viruses with distinct biological properties was undertaken to identify the genes determining these specific biological properties.

Methods. The HIV-1 isolates SF-2 and SF-3 differ biologically in their ability to form plaques in the MT-4 cell line (possibly related to their cytopathicity) and their host range. The SF-2 isolate replicates in peripheral blood lymphocytes and CEM-established T-cell lines such as HUT 78 and CEM, whereas the SF-3 isolate additionally replicates in human and baboon peripheral mononuclear cells as well as human fibroblasts such as HOS. By making constructs exchanging specific regions between the two molecularly cloned HIV-1 genomes, it should be possible to follow the biological characteristics. The construction series was transfected into cells and infectious virus was rescued from all combinations for comparison studies.

Results. Biologic assays performed on the recombinant viruses indicate that plasmids in MT-4 cells and cytopathicity segregate with the env-3'orf region of the genome. Host range specificity is being examined.

Conclusions. The env-3'orf region of the HIV genome appears to be directly responsible for the cytopathicity characteristic of the isolate.

- C.646 DELAYED & SLOW EXPRESSION OF HIV-1 RNA & tat PROTEIN DURING INFECTION WITH A NON-CYTOPATHIC HIV-1 VIRUS STRAIN**
 Sakali, Kelli Ma, X-Y Shiang, J. P. and Volosky, D.J.
 St. Luke's/Roosevelt Hospital Center, College of Physicians and Surgeons, Columbia University, New York City, NY, U.S.A.
- Objective:** To study the mechanism of infection with a non-cytopathic isolate of HIV-1.
- Methods.** The non-cytopathic and cytopathic HIV-1 isolates HIV-1₁ and HIV-1₂, respectively, were obtained from the virus-producer CD4/HIV-1/MT cell line by molecular cloning. Virus entry was measured as a function of the virus-cell fusion by the membrane fluorescence dequenching assay. Viral RNA was detected in crude cell lysates with HIV-1 RNA probe from the pol gene. tat and rev proteins, and LTR functions, were tested by CAT assay.
- Results:** HIV-1₁ and HIV-1₂ entered CD4-positive target cells with equal efficiency by virus-cell fusion. The expression of HIV-1₁ genome was delayed and characterized by slow kinetics, resulting in low levels of HIV-1 RNA, structural proteins, and tat protein during the first 7-10 days after virus entry. In contrast, cells infected with the same dose of the cytopathic HIV-1₂ virus began to express high levels of HIV-1 RNA structural proteins and tat protein with a kinetics similar to that of infection; the expression peaked on day 5, followed by complete cell lysis. Both HIV-1₁ and HIV-1₂ viruses replicated well in chronically-infected cells. Conclusions: Our results show that slow kinetics of HIV-1₁ expression during early stages after virus entry is an important determinant in a non-cytopathic infection.

- C.648 ISOELECTRIC FOCUSING OF RECOMBINANT HIV PROTEINS BY ISOELECTRIC FOCUSING.**
 Chant, Albert*, Winkler, E.,* Stafford, A.*, Saaz, J.*, Siaw, M.,* Van Winkle, M.*
 St. Louis, MO. *Beckman Instruments, Inc. 92421, and **SmithKline Beecham, King of Prussia, PA, U.S.A.
- A preparative isoelectric focusing (IEF) method using a commercial available apparatus was applied to the purification of recombinant HIV proteins expressed in E. coli. Proteins representing env, gag and pol domains were extracted from inclusion bodies and initially purified through various sequences of ion-exchange and molecular sieving chromatography. Proteins obtained from the primary purification were desalted and subjected to isoelectric focusing separation. Appropriately solubilized proteins in the presence of various non-ionic surfactants and polylysines were focused at their isoelectric points (pI). Proteins were harvested in fractions after reaching equilibrium. Each fraction was analysed electrophoretically for purity and further identified by western blot using specific monoclonal antibodies. The results of ELISA testing for HIV antibodies using the IEF proteins showed significantly increased activity and specificity. Our work shows that IEF methodology can yield significant quantities of effectively purified recombinant proteins in a simple, efficient and cost effective process.

- C.650 IN VITRO DETECTION OF HIV ANTIBODY IN SERUMEDITHYLSULFIDE BY USING RECOMBINANT ANTIGENIC PEPTIDES**
 Saperstein, P.,* Hwang, J.,* Lewis, M.,* Pittsitt, M.P.,* Berman, C.,* Hershkov, I.*
 * Institute of Biological Research - University of Texas - Dallas
 ** Institute of Biological Research - University of Texas - Dallas

Objective. To validate the data on serum antibodies in seropositive individuals, detecting HIV RNA by polymerase chain reaction (PCR) technique.

Methods. We collected 94 HIV sera and 10 peripheral blood sera from HIV seropositive HIV subjects. The HIV RNA was amplified in the sera and blood by PCR. HIV RNA was amplified by using specific PCR primers. The PCR products were directly used for the PCR. HIV RNA was amplified by using specific PCR primers. The PCR products were directly used for the PCR. HIV RNA was amplified by using specific PCR primers. The PCR products were directly used for the PCR.

Results. The PCR products were directly used for the PCR. HIV RNA was amplified by using specific PCR primers. The PCR products were directly used for the PCR. HIV RNA was amplified by using specific PCR primers. The PCR products were directly used for the PCR.

Conclusions. The absence of prolamellar aggregation in all serum specimens, in the presence of HIV-1 RNA in the blood, and of HIV-1 amplification in the sera, is in accord with the important of detecting through this study. Our results confirm the potential utility of the PCR technique in complementing existing virus isolation procedures as a routine means of determining the presence of HIV in blood cells.


Publications
C.663

EPI TOPE MAPPING OF THE HUMAN IMMUNODEFICIENCY VIRUS *gag* GENE PRODUCTS p24 AND p26 WITH MONOCLONAL ANTIBODIES:
 Brian J. Young, T. Crowl-Hickson, S. J. Swerdlow, S. J. Younger, R. P. and Lockwood, S. A. Biostatistics Research Institute, Rockville, MD, *Organon Teknika Corporation, Durham, NC, USA.

Objective: To map immunogenic domains of HIV-1 p24 and HIV-2 p26 using specific monoclonal antibodies and to define epitopes conserved between the two proteins.

Methods: Overlapping synthetic and recombinant peptides of p24 were prepared and tested for reactivity with each monoclonal antibody (Mab) using ELISA and Western blotting techniques.

Results: Sixteen murine monoclonal antibodies reactive against native viral p24 were also reactive with a full-length recombinant clone of p24 generated from a cDNA library of HIV-1. The Mab map within four discrete regions along the 230 amino acid length of p24:

Mab Group:	(within an open reading frame)
A	264-344
B	244-362
C	143-209
D	133-242

In addition, two of the Mab are cross-reactive with HIV-2 p26. Three of the Mab have proven useful in a sandwich ELISA for the detection of p24 and p26 in sera/plasma from infected patients and cell culture supernatants.

Conclusion: A large variety of epitope specificities are represented by the Mab and this has proven useful for the development of an in vitro assay.

C.665

ENZYME IMMUNOASSAY OF RECOMBINANT HIV PROTEINS.
 Lewis, Stephen, Bofinger, G., Kost, M., Ballard, M. and Lee, H. H. (Rockwell Instruments, Inc., Irvine, CA, U.S.A.)

Three enzyme immunoassays were developed to specifically quantitate & recombinant p17 protein in support of our development of A5U-HIV assay for antibody to HIV.

- Using a direct solid phase sandwich technique, antigen under study was presented in microtiter plate wells and reacted with specific mouse monoclonal antibody (mAb). After incubation in turn with rabbit anti-mouse alk. phos. conjugate and pNPP substrate, antigen was quantitated photometrically at 410 nm.

- In the second method, soluble antigen was studied using a competitive sandwich technique. This assay used precoated control antigens to react simultaneously with antigen specific Mab and the soluble antigen under study. Competition between soluble and bound antigen for Mab generated signal which was inversely correlated with concentration of soluble antigen.

- Finally, a more complex solid phase direct sandwich method was developed which featured the use of 1) avidin/biotin enhancement; 2) Mab to HIV proteins of both G1 and G2 subtypes and 3) rabbit alkaline phosphatase conjugated antibody to the mouse monoclonal subtypes. The competitive assay was needed to speed analysis by alleviating the need to precoat plates with the antigens under test. The multistep avidin/biotin technique was employed when competitive displacement curves were difficult to obtain.

C.667

STUDIES ON THE MECHANISM OF ENHANCEMENT OF HIV-ENVELOPE (ENV) EXPRESSION BY HIV-*tax* GENE USING ADENOVIORAL EXPRESSION VECTORS.
 Dhat, Sheer, Chanda, P., Natar, R., Chodolofsky, S., Nelson, B., Morin, J., Diner, S., Molar-Kramer, K., Luback, M., Mizutani, S., Davis, A., Hunt, P. Biotechnology and Microbiology Division, Hyatt-Ayerst Research, P.O. Box 8299, Philadelphia, PA U.S.A.

The enhanced expression (30-70 fold) of HIV-env gene in human cell line, by co-infection of adeno virus recombinants (A67-*gus* and A67-*gus*) to a good vector system to explore the direct mechanism mediated by HIV-*tax* gene, since other HIV-proviral gene(s) are present in these vectors. By comparing the study levels of mRNA isolated from A67-*gus* and also after co-infection with A67-*gus*, revealed that: 1) the *gus*-specific mRNA(s) present in the cytoplasmic fraction after the co-infection with A67-*gus*, were qualitatively and quantitatively different from that in A67-*gus* recombinant; 2) however, in the nuclear fraction of the above experiment, the *gus*-mRNA(s) showed only a qualitative difference. Addition of actinomycin D, 20 hr post-infection with A67-env for 1-6 hr prior to mRNA extraction, resulted in a significant reduction in the cytoplasmic *gus*-mRNA(s). In a similar experiment, but in presence of *tax*, there was no decrease in the cytoplasmic *gus*-mRNA(s). Using these recombinant adeno virus recombinants is understanding the direct interaction of *tax* on *gus*-mRNA processing will be discussed.

C.664

HIV INFECTION OF THE GASTROINTESTINAL TRACT: COMPARISON OF THE SENSITIVITY OF HYBRIDIZATION AND IMMUNOASSAY

Enler, Donald P., Ecks, P., Cossin, W., Clayton P., Flux CH **, S. L. Blau's Roosevelt Hospital Center, New York; *Lance Hill Hospital, New York; **Laboratory of Immunogenetics, NIH, Bethesda, MD, U.S.A.

Objective: To use hybridization and immunology for detecting evidence of HIV in rectal smears; to compare the results with histopathologic features in the tissue.

Methods: Rectal biopsies from 25 HIV seropositive subjects (19 AIDS, 6 ARC) were examined by RNA in situ hybridization, polymerase chain reaction (PCR), a quantitative p24 ELISA, and p24 immunohistologic stains. Coded sections were examined for specific histologic features.

Results: Positive results were obtained by in situ hybridization in 34%, by PCR in 70%, by quantitative p24 ELISA in 70%, and by p24 immunoperoxidase stains in 80%. Only one AIDS patient was negative by all methods used. In situ RNA hybridization was demonstrated only in lamina propria lymphocytes and macrophages by immunoperoxidase. p24 antigen could be detected in lamina propria lymphocytes and macrophages in 64% of cases. Antigen also could be detected in epithelial cells in 40% and immunohistopathologic features in 26%. There were no correlations between the presence of HIV nucleic acids or tissue p24 content and specific histopathologic features.

Conclusions: Evidence of HIV in rectal smears is common. Of the methods used, in situ hybridization with viral RNA was the most sensitive technique for detecting viruses. PCR was the most sensitive method for detecting viral genes. Methods to detect p24 antigen in mucosal homogenates or in tissue sections also use sensitive means of revealing evidence of HIV infection in the tissues.

C.666

PROTEOLYTIC CLEAVAGE OF THE 66-KD FORM OF THE HIV-1 REVERSE TRANSCRIPTASE.
 Enayati, M., Strydom, P., Hizi, A., Pichantans, S., Bahr, L., Craik, C., Shawalter, S.D., **** and Hughes, S.H., *

BRI-Basic Research Program, **Program Resources, Inc., MCI-Fredrick Cancer Research Facility, Frederick, Maryland, USA, **Sackler School of Medicine, Tel Aviv University, Ramat Aviv, Israel, ***University of California, San Francisco, San Francisco, California, USA.

Objective: We wished to test the ability of viral and non-viral proteases to convert purified 66-kD reverse transcriptase (RT) to the 51-kD form. The 66-kD form of HIV-1 RT and the viral protease were separately purified to homogeneity from two recombinant strains of *E. coli*. Proteolytic cleavage sites on HIV-1 RT were mapped using a battery of monoclonal antibodies that recognize known positions in HIV-1 RT.

Results: Using a viral protease produced in *E. coli* we have been able to react a condition that contains only HIV-1 RT and the protease. However, this poses the question of whether the specificity of cleavage resides in the protease or in the structure of the properly folded 66-kD form of RT. We have found that certain other proteases produce cleavage products closely related to the 51-kD protein produced by the viral protease.

Conclusions: Of the tested proteases, the viral protease most closely reproduces the cleavage event seen in viruses; however, unrelated proteases make similar cleavages suggesting that the structure of the 66-kD form of the RT plays a significant role in defining the site of protease cleavage.

C.668

HIGH LEVEL EXPRESSION OF THE ENVELOPE GLYCOPROTEINS OF THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) USING RECOMBINANT ADENOVIORUS VECTORS.
 Prasad, K., Chanda, P., Natar, R., Wark, Lydia Greenberg, Bruce B. Hanson, Sheer Dhat, Saravada S., Diner, John E. Morin, Catherine L. Molnar-Kramer, Michael D. Luback, Satosh Mizutani, Alan R. Davis, and Paul P. Hunt. Biotechnology and Microbiology Division, Hyatt-Ayerst Research, P.O. Box 8299, Philadelphia, PA, U.S.A.

Recombinant adeno viruses containing either the envelope (env) or the rev (rev/rt) genes of the human immunodeficiency virus type 1 (HIV) were constructed by inserting the genes into a cassette which contained adeno virus major late promoter, tripartite leader containing intervening sequence and the poly(A). The cassette was then inserted between the *gus* and *ITR* region on adeno virus genome. A649 cells infected with the env recombinant virus produced the envelope glycoproteins gp160, gp120, and gp125. HIV envelope gene expression made by the env-adeno virus recombinant can be greatly enhanced (30-70 fold) in A649 cells that were simultaneously infected with the rev-adeno virus recombinant as measured by ELISA, western blotting, and immunoperoxidase staining of infected cells. A double recombinant adeno virus which contains both rev and env genes was also constructed by inserting the rev gene in the deleted E2 region and the env gene in the terminal cassette. This double recombinant virus was able to infect A649 cells in 100% of cells similar to that expressed by cells that were doubly infected with both the env and rev recombinant viruses.

Publications

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

C.675

SELECTION OF PRIMERS OF HUMAN MONOCLONAL FOR THE EXPRESSION OF HUMAN IMMUNODEFICIENCY VIRUS SEQUENCES USING THE POLYMERASE CHAIN REACTION.

Robertson, R. and G. G. Stevenson. *Journal of Virology*, 61: 1966-1970, 1987.
 *Molecular Virology Laboratory, Laboratory Center for Disease Control, National Center for Zoonosis and Vector-borne Diseases, Institut Armand-Frappier, Ville de Québec, Québec, Canada; *Molecular Research Institute, National Research Council of Canada, Montreal, Québec, Canada.

Most of the oligonucleotide primers which have been proposed for the detection of human immunodeficiency virus (HIV) sequences using the polymerase chain reaction (PCR) contain sites known to cause an increase in specificity and sensitivity of the PCR. However, the use of such primers is dependent on the prevalence of the mismatched strains the use of different proportions of false negative results. Our objective was to optimize the design of primers according to their degree of homology to all available HIV sequences. In particular, we have been interested in the design of primers suitable for the amplification of Hind III fragments. Algorithms and computer programs were developed to determine the optimal alignment for the detection of the longest regions of homology within groups of sequences. The results of these algorithms are presented. The longest regions of maximum homology among all complete sequences available for HIV are presented.

Based on this information we identified and synthesized a pair of Hind III restriction primers which allow the PCR reconstruction of specific HIV sequences. The primers were used for the detection of HIV sequences in clinical specimens.

C.676

USE OF A CASSETTE EXPRESSION VECTOR FOR THE EXPRESSION OF HUMAN IMMUNODEFICIENCY VIRUS SEQUENCES IN CHO CELLS

O'Shaughnessy, M.Y. and Campbell-Pineda, D.
 *Bureau of Laboratories and Research Services, Federal Center for AIDS Health Protection Branch, Ottawa, Ontario, Canada; *Centre de Recherches en Virologie, Institut Armand-Frappier, Ville de Québec, Québec, Canada; *Molecular Virology Laboratory, Laboratory Center for Disease Control, National Center for Zoonosis and Vector-borne Diseases, Institut Armand-Frappier, Ville de Québec, Québec, Canada.

Human immunodeficiency virus (HIV) has already been expressed in vitro using different expression systems. We have chosen the pSVcat cassette vector expression system which contains a powerful cytomegalovirus (CMV) promoter to express the entire *gag* in mammalian cells. Our design required the excision of a 2.9 kb *Bst* I fragment of HIV-1 RNA from plasmid pSHIV1. This fragment contains the entire open reading frame in the *gag* region of the genome. The *Bst* I enzyme cuts the genome 1.6 kb before the *gag* stop codon in the *gag* open reading frame. This 2.9 *Bst* I fragment was ligated with a 1.5 kb promoter containing the CMV promoter. The fragments were added. The new *Bst* I fragment was cloned into the EcoRI site in the open reading frame of the insert was in frame with the first ATG after the coding site of the CMV promoter. Cells expressing the HIV-1 *gag* are being tested as target cells for immunoprecipitation assays. Dr. M. Harper (N.I.H., Bethesda, MD) is making available the pSHIVcat construct. He is interested in our work to produce the HIV-1 expression vector system and Dr. H. Melnick's (Institute of Protein Research, Academy of Sciences of the U.S.S.R., Moscow Section) for his kind gift of restriction enzyme *Bst* I.

C.677

SYNTHESIS AND PROCESSING OF HIV RNA IN THE PRESENCE OF ANTIVIRAL AGENTS

Chiu, J.A. and Crumpacker, C.S.
 Beth Israel Hospital/Harvard Medical School, Boston, MA, USA.
Objective. Several antiviral agents inhibit the replication of HIV in vitro. Ribavirin (RBV) has been shown to interfere with post-transcriptional processing in vesicles. We assessed effects of RBV in combination with other antiviral agents on the size and amount of RNA synthesized in infected cells. *Methods.* Cytoplastic (HIV) RNA isolated from HIV infected cells treated with RBV was analyzed by northern blot using a ³²P labelled RNA probe. Virus replication was assayed in cultured lymphocytes using the p24 antigen assay. *Results.* Previous data has shown that RBV treatment of HIV infected T cells suppresses viral protein synthesis and DNA replication (Crumpacker et al. Abstr. Int. Conf. AIDS 1985). Envelope proteins are expressed by 70% in the presence of 20 µg/ml RBV. An HIV *gag* gene probe was used to measure the size and abundance of HIV cytoplasmic RNA isolated from infected cells synthesized in the presence of increasing concentrations of RBV. A marked decrease in the amount of 3.5 kb *gag* RNA occurred with increasing concentrations of RBV. In addition, there was a dramatic increase in the 385 genomic RNA species in RBV treated cells as compared to non-treated cells. When ddA was used in conjunction with RBV, a similar decrease in *gag* specific RNA occurred with only 20% the RBV concentration as when used alone. *Conclusion.* RBV and other drugs may result in altered amount and size of HIV RNA. Direct measurement of viral RNA is useful to study effects of antiviral agents. The combined effects of RBV and other anti-viral agents on transcription and translation of *gag* and *gag* RNA species in vitro, are being studied to better understand the mechanism of action of these agents.

C.678

Blank space reserved for publication details.

C.679

A MOUSE MONOCLONAL ANTIBODY AGAINST THE REV-PROTEIN OF HIV-1

Voll, R., Amann, Christian, Krapp, F., Fleckenstein, B., and Haidich, H.
 Institut für Klinische Immunologie und Rheumatologie der Universität Erlangen-Nürnberg, D-8520 Erlangen, FRG

The rev-protein of immunodeficiency viruses has an important function in structural gene expression. A 9-kilodalton fusion-protein containing the amino-terminal part of the fusionprotein was synthesized in *E. coli*. It was used to raise a rev-specific immune response in mice. A monoclonal anti-rev fusion with the SP2/O cell line stable hybridoma clones were established. Clones were isolated that secreted monoclonal antibodies specifically recognizing the rev part of the fusionprotein. They were identified by ELISA and Western blot. Data demonstrating recognition of the subviral protein and intracellular localization will be presented.

C.680

CHARACTERIZATION OF AN HIV-1 POINT MUTANT BLOCKED IN ENVELOPE GLYCOPROTEIN CLEAVAGE

Pel, B., Galla, R.C., Bell, M.S. Jr.,
 *National Cancer Institute, Bethesda, Maryland, USA
 *Biometric Research Laboratory, Inc., Bethesda, Maryland, USA

The envelope proteins of retroviruses are derived from a polyprotein precursor protein by cleavage adjacent to a cluster of basic amino acids. Site specific autolysis was used to construct a mutant of the human immunodeficiency virus type 1 (HIV-1) in which the arginine residue at the carboxy terminus of the gp120 was changed to a threonine residue. This single substitution was sufficient to abolish all detectable cleavage of the gp120 envelope precursor polyprotein. Immunofluorescence assays showed that gp120 was transported to the surface of transfected CD4+ Hela cells. No envelope proteins of known size could be detected in the media of cells transfected with the mutant virus, suggesting that functional virion release was impaired. Binding of the mutant gp120 to the CD4 receptor molecule was unimpaired. In spite of this and the presence of gp120 on the cell surface, neither growth of virus-transfected CD4+ Hela cells nor cocultivation of transfected cos-1 cells with H9 cells resulted in significant syncytium formation. The data indicate that the carboxy terminal arginine residue of HIV-1 gp120 is necessary for envelope protein cleavage, and suggest that a lack of cleavage inhibits the virus life cycle at the steps of both virus release and membrane fusion.

Publications


 Recherche fondamentale (biomédicale)
 Basic Research (Biomedical)

- C. 661** COMPARISON OF REVERSE TRANSCRIPTASE OF HIV-1, HIV-2 AND SIV
 Lori, Franco*, Achilli, G.**, Cattaneo, E.**, Serin, P. S.,**
 and Barilanti, J.***
 *IGR/CMR, Pavia, Italy, **IRCCS Poli. S. Matteo, Pavia, Italy, ***National
 Cancer Institute, Bethesda, Maryland, USA.

Objective. To compare the structural and biochemical properties of reverse transcriptase of HIV-1, HIV-2 and SIV.

Methods. An activity gel method was used allowing identification of the active components of reverse transcriptase on polyacrylamide gel, after electrophoresis under denaturing conditions.

Results. We have confirmed the presence of three active polypeptides of 166, 68 and 31 kDa in HIV-1 reverse transcriptase (P. Lori et al, AIDS Res. and Hum. Retrov. 4: 393, 1988). A similar three active band pattern was also observed for RT from HIV-2 (with sizes of 176, 75 and 62 kDa) and SIV (with sizes of 175, 70 and 59 kDa). The migration and the band intensity of the high and the low reverse transcriptase forms of HIV-2 and SIV appear to be closer than those of HIV-1.

Conclusion. In all three AIDS related retroviruses a high M_r putative precursor and two lower active peptides of reverse transcriptase are present. The structural properties of reverse transcriptase from HIV-2 and SIV are similar and tend to differ from those of HIV-1.

- C. 663** HIGH LEVEL EXPRESSION OF HIV PROTEASE IN *E. COLI*
 Olsen, R.K.; Rockenbach, S.K.; Tomaselli, A. and Iwashita, Shin-ichi.*
 The Upjohn Company, Kalamazoo, Michigan 49007, USA

We have obtained high level expression of the HIV protease in *E. coli* using the *gag* promoter and a runaway vector. Upon induction of the runaway function to increase plasmid copy number, the protease production results in the accumulation of inclusion bodies. In a pBR322-derived vector, the expression level is greatly decreased. Fusion of the protease to its pro-peptide, to β -galactosidase, or to bovine growth hormone gene only low level accumulation of the product as the fusion form or the auto-processed form. Low level expression was also obtained by fusion of the protease to a *E. coli* signal peptide to expression the protease by secretion.

To monitor expression and to test if the HIV protease made in *E. coli* is active *in vivo*, two truncations of the HIV *gag* protein containing parts of the *p6* region were used as substrates. These *gag* truncations have been expressed to high levels using the *gag* promoter in a pBR322-derived vector. The sequence coding for protease was placed immediately downstream of the *gag* sequence in an open fusion arrangement. Activity of the protease can be directly measured by its ability to cleave the *gag* protein into the product *p6* which is detected by Western analysis.

Inclusion bodies containing HIV protease were dissolved in urea or guanidine-HCl. Upon dilution of the chaotropic agent, the protease is active on synthetic peptide substrates. For comparison, the *E. coli*-derived *gag* truncations are being tested as substrates.

C. 665

- C. 662** BIOPHYSICAL CHARACTERIZATION OF REVERSE TRANSCRIPTASE (RT) FROM HIV
 Schalken, Gerard; Hillebrandt, R.; Kopke, M.L. and Dickerson, R.E.
 Molecular Biology Institute, UCLA, Los Angeles, CA 90024, U.S.A.

Objective. In order to find conditions for the growth of single crystals suitable for x-ray structure analysis, various experimental techniques were applied to characterize the properties of RT in solution, especially with regard to dimerization equilibria.

Method and Results. Protein preparations from *E. coli* cultures carrying a plasmid with the full p66 sequence were analyzed, comparing pure p66 samples with p66-p51 mixtures. Analytical ultracentrifugation shows 2 species at 3.95 and 5.95 in a p66 solution. Chemical crosslinking with Dimethylsuberinate indicates strong dimer-formation in p66-p66 mixtures, and weaker dimer-formation with more higher aggregates in pure p66 samples. FPLC runs on a size-exclusion column give one peak for p66-p66 samples and 2 clearly separated peaks for pure p66. Both peaks show high activity in a specific assay for reverse transcription activity, and yield a single band under denaturing conditions on PAGE with SDS. Fraction of each of these peaks give the corresponding single peak when relectrodesed with respect to concentration.

Conclusion. In solutions of pure p66 RT homodimers coexist with monomeric species in a slow equilibrium. Under similar conditions, mixtures of p61 and p66 form heterodimers with significantly stronger affinity.

- C. 664** A GENE FAMILY WITH HIV-LIKE POTENTIAL REVERSE TRANSCRIPTASE
 Forsythe, Donald; Blum, S.; Sideris, D.P. and Forsythe, M.E.
 Department of Biochemistry, Queen's University, Kingston, Ontario, Canada K7L 3N6

Objectives. To understand the molecular basis by which HIV establishes, maintains and escapes from, latency. To identify genes in T-lymphocytes which regulate, are regulated by, or are coregulated with HIV.

Methods. "Latent" peripheral blood lymphocytes in the G0 phase of the cell cycle were activated by culturing with lectin and cycloheximide for 2h. cDNA libraries enriched for 60S11 switch (60S) genes were screened by differential cDNA hybridization (Forsythe, 1988; *Biochem. Biophys. Res. Comm.* 123: 619-625).

Results. Among the 60S11 switch ones, 60319, is the first identified human homolog of the mouse "activation gene" family (MIP, J. Virol. 61: 1804-1811; *Immuno.* 11: 481-483) and is identical to ID78 (Obara et al. 1986; *J. Biol. Chem.* 261: 885-894). We have identified 3 genes in Lambda Charon 35 libraries which hybridize with 60319 cDNA. Three of these have been restricted mapped and two sequenced. One has the identical sequence to the cDNA. Of particular interest are two sequences in the 3' non-coding region which are conserved in MIP: (1) TTTTGGATTATTTT which differs only by a purine transition from a 3'UTR pal sequence and (ii) GGACTCTTC which differs only by 2 pyrimidine transitions from the NF8-binding HIV 5' enhancer.

Conclusion. We speculate that genes conserved with latency in HIV and in G0 lymphocytes are coregulated by similar interacting factors. (Supported by the American Foundation for AIDS Research)

C. 666

NEEDLE/SYRINGE EXCHANGE SCHEME BASED ON COMMUNITY PHARMACIES, TRONDHEIM, NORWAY
 Hvalstad, Hans-Joel; Jarvold, E. (Hennel); Hvalstad, T.; Trondheim Health Board, Norway

Objective. To evaluate exchange schemes based on community pharmacies and local AIDS clinic during 10 months trial period. Injection equipment could otherwise be purchased by ordinary sales from all pharmacies. The exchange scheme involves exchanging or sold carries a label illustrating the importance of sterile equipment. Together with an introduction to the scheme. No. of syringes sold or exchanged were recorded. Questionnaires were presented to IVDA and pharmacy employees. Results: Total no. of syringes/needles showed no increase during the trial period, while the return rate increased to 19%. Pharmacies reported no conflicts. IVDA reported a positive attitude to the scheme, but showed no significant change in risk behaviour. No significant change in the incidence of HIV and HIV were reported. No syringes were returned to the AIDS clinic. Conclusion: An exchange scheme based on community pharmacies were favoured by IVDA to specialised clinics run by HDN. Only marginal effect on the prevention of HIV and HBV transmission can be expected where syringes are already easily available.


**Pathogénèse
Pathogenesis**
C.705

LYMPHOKINES IN DIFFERENT STAGES OF HIV INFECTION
 Kasaoli, Teresa; Pignera, T.; Quer, J.; Garcia, X.; Caragall, I. and Ocaña, J., I.S. Vall de Hebron, Barcelona, Spain.

HIV causes a progressive loss of CD4 cells and their functions, subsequently IL-2 synthesis is decreased in the disease. Although monocytes are also infected there is no cytotoxicity of these cells, and they were interested to know the synthesis of IL-1 in different stages of this infection and the relation with other lymphokines.

We have measured the synthesis of IL-1, IL-2 and β 2M in 36 HIV-1 drug-naïve in different stages of HIV infection and 10 controls. Lymphokines were produced by PHA cultures stimulated with 10% of 24 h, (IL-1) or PHA/40 h (IL-2 and β 2M) and measured on the supernatants with ELISA and RIA methods respectively. Lymphocyte subsets Ig levels and lymphocyte blastogenic responses to PHA and PWM were also studied in these patients.

IL-1 synthesis is very high until advanced stages of immunodeficiency, and is also high in unstimulated cultures in the first stages of the infection. There is some correlation between these levels and clinical symptoms.

IL-2 and β 2M synthesis decreases more rapidly with the progression of the disease and, together with other immunological parameters, has prognostic value.

Therapeutic protocols to modulate lymphokine synthesis must be taken into consideration to improve clinical conditions of these patients.

C.707

SUPPRESSOR EFFECT OF CELL SUPERNATANTS FROM HIV-0 POSITIVE PATIENTS ON NORMAL LYMPHOCYTE REACTIONS.
 Alvarez, María Elena; Merini, L.; Goico, M.A.; Falcaro, Y.; Diaz, S.A. and Sm., J.

Sección Inmunología Oncológica, Instituto de Investigaciones Neoplasias, Academia Nacional de Medicina, Buenos Aires, Argentina.

Objective: The aim of the study was to determine if ConA can induce an increase of the NK cell activity of HIV-infected subjects (IS) similar to that of normal subjects (NS). Also, we investigated if the factors that normally regulate the NK function, released by cells from IS differ from those released by NS cells.

Methods: We studied 13 IS and 19 NS. Mononuclear cells were incubated with and without ConA (50µg/ml) at 37°C for 18-20h. The cell supernatants (SN) were stored; the cells were stained and the NK activity measured by the 51Cr release assay using K562 cells as target.

Results: The NK function and response to ConA of IS cells were similar to NS cells. In 8 out of 15 cells the normal NK activity, in 5 without ConA suppressed ($p < 0.05$) 3/5 + 24 and 5 with ConA 34/5 + 11. On the contrary, 5 without ConA of normal cells did not modify normal NK activity while 5 with ConA increased the NK function (24/5 + 8).

Conclusion: The results indicate that NK effector cell function of IS does not differ from NS. However, the mononuclear cells from IS spontaneously release NK suppressor factors and although ConA can increase the NK effector function, it can not modify the release of suppressor factors. The altered release of soluble factors in prior to the decrease of the NK activity observed in IS may contribute to the development of opportunistic tumors.

C.709

CHARACTERIZATION OF HUMAN B CELL (H2) AND PROMONOCYTE (H37) AFTER HIV-1 EXPOSURE
 Tomalin, J.G. Deane*, and Priscilla E. Arnes *

*Laboratory of Neurosciences, NIDDK, National Institutes of Health, Bethesda, MD, U.S.A.
 *Department of Neoplastic Diseases, Mount Sinai School of Medicine, New York, NY, U.S.A.

Objective: Comparison of HIV-1 infection kinetics among human B (H2), promonocyte (H37), T-8 hybrid (CD4/74), and T890 cell lines.

Methods: SupT1 (HIV1 susceptible CD4+T7) cells were used to analyze syncytia induction capacity of vesicular cell lines. Reverse transcriptase (RT) activity in the supernatant (sRT) and in the cell lysates (iRT) was determined by standard RT activity assays.

Results: CD4/74 and H9 cells indicated strong syncytia inducing capacity against SupT1 and high extracellular RT (eRT) and H37 exhibited syncytia inducing capacity at 3 days. Intracellular RT (iRT) became detectable at 10-15 days but eRT appeared much later. The syncytia inducing capacity and intracellular RT rate were also observed in chronically infected H9CD4+T890 (H2) and subclone of H37/H9. Further, coculture of H9 with H2/H9 (which exhibit no detectable iRT) showed measurable increase in eRT with significant increase of T-8 double marker hybrid (H9-H2-H9).

Conclusions: Our results suggest that B cells and/or monocytes may acquire fusing capacity against CD4+T7 cells in early stages of the infection, and that these cells to cell interactions may lead to reduction in the number of CD4+T7 cells. Further, since T-8 and T-8 monocyte hybrids may serve as temporal sites for viral replication. These in vitro studies may provide clues to the possible immunopathological roles of HIV-1 infected cells and monocytes and may help in understanding the mechanisms of viral burden on an infected host.

C.706

HIV-2 CHRONIC INFECTION OF PROMONOCYTES (H2)
 Tronchetti, Patricia; Brian J.P.; Baccari C.; Seligson J.M.
 Virology Laboratory, Centre Hospitalier universitaire, Genève, France

Objective: To establish chronic infection in cells of the monocytic progenitor system, with HIV-2 we covered (1) to HIV-1 infection; to study the phenotypic variations throughout the infection.

Methods: We clones of the promonocytic cell line U937, with 30 to 35% of CD4+ cells, respectively, were each infected with HIV-2 HD strain and with HD1 (HD) strain (multiplicity of infection: 10 CD4+ per 10⁶ cells). Cell cultures were studied for > 30 days in terms of cytopathic effect, and presence of p24 and RT activity in the supernatant. The expression of p24 in cells was assessed by immunofluorescence and, when necessary, viral genome detection was carried out with the polymerase chain reaction. Fluorescence was used to measure the expression of CD4. Results data are summarized in the following table.

U 937 & CD4	HIV-2				HD-1			
	01	07	021	042	01	07	021	042
Clon 1	30	0.0	>2.5	>2.5	0.0	0.0	>2.5	>2.5
Clon 2	30	0.0	0.0	>2.5	>2.5	1.2	>2.5	0.0

Although a same amount of virus was used to infect cells, a latent period before the production of p24 by HD1 was only observed with HIV-2. Chronic infection was obtained with HIV-2 without the CD4 percentage, as opposed to HIV-1.

Conclusions: This study showed that, in monocyte cells, there was a difference in the pattern of multiplication between HIV-2 and HIV-1, which seemed to be independent of the amount of CD4 in the case of HIV-2.

C.708

AIDS - PARANETIC INFELIA AND PATHOPHYSIOLOGICAL MECHANISM
 Anbar, Michael* and Sheppard, H.* *Viral and
 Bacterioid Diseases Laboratory, Department of Health Services,
 *California Public Health Foundation, Berkeley, CA, USA.

We propose a model whereby HIV component(s) cause immune dysfunction by mimicry of the physiologic ligands of CD4+ molecules of the Major Histocompatibility Complex (MHC), binding to CD4 molecules and causing lymphocyte activation of a generalized and uncontrolled nature (paranety). The symptoms of mediator disease, autoimmune phenomena, lymphadenopathy and hyperglobulinemia are obvious manifestations of such activation. The energy spent early in HIV infection prior to T cell depletion can be attributed to functional desensitization through this T cell receptor pathway. Continuous activation signals in the form of HIV component(s) finally disrupt T cell homeostasis by the interference with filling of memory cells resulting in clonal selection and net T cell loss (anemia). Thus, HIV disrupts immune function by violating the rules of MHC restriction and the adverse result of this interaction establishes the significance and underlying purpose of MHC restriction.

The model can account for the findings of both AIDS-related-complex and frank AIDS without widespread T cell infection, is consistent with a prolonged "incubation period" and provides a role for antigen specific co-factors. In contrast to immunosuppressive approaches, therapy aimed at suppression of aberrant activation via the CD4 molecule and/or the generation of resting cells may have beneficial effects in HIV disease.

C.710

DETECTION OF CD40CD EXPRESSION ON HIV INFECTED T CELL CULTURES
 M.F. McClane, Lee, T.H.; Ho, S.T.; Wolf, A.A.; Fetter, G.H. III* and Essex, M.* Harvard Univ., Boston, MA USA ** PHLS, Witshire, UK

Objective: The study describes the expression of CD40CD on T cell culture lines at early and chronic stages of infection.

Methods: We examined T cell cultures by the techniques of dual color immunofluorescence flow cytometry, ferritin labelling for electron microscopy visualization and reverse transcriptase for virus expression.

Results: CD4 expressed markers remained depressed at post-infection as predicted previously and into the chronic stages. RT activity and absolute number of virus particles being generated did not significantly influence the surface markers once the culture was infected. CD8 when co-expressed remained demonstrable.

Conclusions: Using quantitative doses of HIV strains we find the variation of expressed membrane markers can be separate elements from cell function and maturation of the virus. We are presently using cytokines in modulating surface marker activation and virus induction.

Publications

Recherche fondamentale (biomédicale)
Basic Research (Biomedical)

- C.711** BIOLOGICAL ROLE OF COCAINE IN THE DEVELOPMENT AND EXPRESSION OF AIDS
HAEGHEBAERT P. FURMAN, L.J.*** Department of Microbiology* and Department of Medicine** University of Medicine and Dentistry of New Jersey, Camden, New Jersey, U.S.A.

Objective. To determine the effect of cocaine on the immune system.
Methods. In order to obtain a better understanding of the effects of cocaine on immune function, inbred male rats were treated daily for ten days with 1.25, 2.5 or 5.0 mg/kg of cocaine. Rats were then immunized with T-helper independent (TI) and T-helper dependent (TD) antigens. Splenic plaque-forming cell (PFC) and serum antibody responses were measured 5 days post-immunization.

Results. The ability of rats treated with cocaine to mount primary PFC and antibody responses to TI were elevated several fold when compared to control animals. The magnitude of the elevation was directly related to the dose of cocaine administered. Antibody responses to TD antigens were increased at lower concentrations of cocaine (1.25 and 2.5 mg/kg) and were suppressed at the higher concentration of the drug (5.0 mg/kg). Exposure of isolated lymphocytes from rats and humans to cocaine *in vitro* did not result in a stimulation of B-cell populations indicating that a metabolite of cocaine or the release of some other host factor(s) was responsible for the observed immunomodulation.

Conclusion. The prevalence of AIDS in substance abusers is very high. It is also well documented that activation of CD4 cells in HIV-1 individuals also activates proviral (latent) stages of AIDS. The present studies provide data to indicate that the immune system is stimulated by cocaine.

- C.713** PRESENCE OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN THE ALVEOLAR MACROPHAGES AND FROM SPERMATOCYTES/LYMPHOCYTES (SAL) AIDS
MARGONEN, OLVIN C. JR., Swanson, R.P., Fross, P.T., Floyd, R., Depts. of Medicine, Pathology and Laboratory Medicine, University of Cincinnati Medical Center, Ohio, U.S.A.

Previous work in our laboratory has shown that HIV can be recovered from the BAL fluid of all patients with AIDS, but has only detected p24 antigen directly in the BAL fluid of a patient with lymphocytic interstitial pneumonia. To determine which cells in the BAL fluid contain the virus, BAL cells were separated into glass adherent (alveolar macrophages) and non-adherent populations and were cultured in random donor peripheral blood mononuclear cell cultures. Five consecutive AIDS patients were cultured and the BAL fluid from all were positive for HIV. Both adherent and non-adherent cells contained HIV, but adherent cell cultures were either positive before non-adherent or had higher levels of p24 antigen on days 6-8. Only one non-adherent patient has been cultured and, in contrast to the AIDS patients, HIV was not recovered. These studies suggest that HIV appears at levels detectable by culture in the bronchoalveolar secretions of HIV infected patients later in the natural history of the infection, and, even though virus can be recovered from both BAL and lymphocytes, it appears to be in higher titer in macrophages. Studies on the effects of HIV infections of AM on macrophage function are underway. Production of tumor necrosis factor (TNF) by HIV infected AM has been evaluated. Spontaneous release of TNF was detected from AM of 2 of 5 AIDS patients, while all 5 released normal amounts of TNF when stimulated with lipopolysaccharide.

- C.715** HIV-1 INFECTION OF HUMAN FETAL THYMOCYTES
JANKA-BATHANY, BACH, V.; BATHANY, W.; RUBINSTEIN, A.; WEISS, I.; and LIPMAN, V.D. Albert Einstein College of Medicine, Bronx, NY, USA

Objective. Since infants with congenital HIV-1 infection are immunocompromised, it is felt appropriate to examine those infected by HIV-1 resulting in immune dysfunction. To examine this hypothesis, normal human thymocytes were established in culture with HIV-1. The potential for this virus to affect thymocytes was determined by measuring ³H/5 and functional assays. Thymocytes were exposed to either infectious or heat-inactivated HIV-1 isolates. The presence of HIV-1 infection was determined by immunocytochemistry, molecular hybridization and an infectious cell center (ICC) assay using the GEM-25 cell line. Treated cultures were analyzed by flow cytometry and functional assays.
Results. Increased thymocytes responded to T_H but not to B-cell associated antigens and were comprised of over 90% double (CD4⁺CD8⁺) positive cells. After 5-7 days in culture, immunocytochemistry revealed the presence of p24 in the HIV-1 exposed cells and the ICC assay was positive. In addition, there was a significant change in the subset ratios of infected cells. Furthermore, thymocyte infection was observed in a dose dependent fashion, upon the titer of the HIV-1 inoculum.
Conclusion. Culture of thymocytes with HIV-1 and the ICC assay of this infection causes significant cytopathology. As a model, this system may permit a better understanding of the pathogenesis of pediatric AIDS. (Supported, in part, by NCI, # 55283, DA 05363, NS 11920, AT 20473, and the Diamond Foundation).

- C.712** CHARACTERISTICS OF HIV-1 IN MONOCYTE-MACROPHAGES
SHIBUI, MITSUO;* GÖTHLUND, M.†; NILSSON, K.†; FENYK, M.* and WÄGELIN, H.†**

*National Institute, Stockholm, Sweden. **Univ. of Uppsala, Uppsala, Sweden.

Objective. To investigate infectivity and localization of HIV in monocyte-macrophages.
Methods. HIV-1-infected producing cells, D897 subclone, T.H.P.1 and T cell lines were by measuring reverse transcriptase activity and the amount of p24. Infectivity of HIV-1 in the solution was determined by infecting HIV-1 sensitive T cells, MT-2 and MOLT-4. Infection of the infected cells was checked by cytopathic effect and amount of p24 in culture supernatant.

Results. Solution obtained by freezing-thawing of monocyte lines showed higher reverse transcriptase activity and larger amount of p24 compared with T cell lines. The solution showed high infectivity to T cell lines.

Conclusion. Monocyte-Macrophage can harbour large amount of infectious virus inside the cells.
 Localization of the virus will be also discussed.

- C.714** POSSIBLE ROLE OF GENETIC, IMMUNOLOGICAL AND VIRAL FACTORS IN THE ACQUISITION AND/OR PROGRESSION OF HIV INFECTION

PURVIS, RAY†; KOSCI, M.A.††; MICHEL, M.†; KIROLO, M.†††; PASSELLI, M.††† and SENSILLA, E.†††

† National Center for Blood Transfusion and Cell Therapy, Hospital for Infectious Diseases, †† Institute Infectious Diseases, University of Rome, Italy

Objective. To evaluate the role of genetic, immunological and viral factors in the acquisition and/or progression of HIV infection.

Methods. Five seronegative regular sexual partners of HIV seropositive subjects and 5 HIV seropositive patients without HIV infection progression (during the last 3 years, were included in our study. We carried out HLA-A,B,C,D,RN antigen phenotyping and surface phenotypes of PBMC; we also performed *in situ* hybridization, P.C.R. and *in vitro* response to recall Ag, PHA and PWM.

Results. A higher frequency of HLA-2 Ag in seronegative and in HIV seropositive subjects without infection progression was found; an increase of CD4⁺ cells in HIV seropositive was also observed. All seronegative subjects were positive *in situ* hybridization and, at performed follow-up, the seronegativity has been lasting for more than one year.

Conclusions. Could HLA-A antigens and CD4⁺ cells play a role in the acquisition and/or progression of HIV infection?

- C.716** AIDS IS A NON-INFECTIOUS "OCCUPATIONAL" SYNDROME
MARRINO LOCA MORELLI,† Instituto de Terapia Plasma y Sindrome Infecciosa de Guatemala, Caracas, D.F., Venezuela

Objective. To find answers to the following questions: a) Is AIDS an infectious disease? b) Can it be considered a sexually transmitted disease? c) Is HIV the etiologic agent? d) What is the prophylaxis for AIDS? e) What is the possible cure for people at high risk for AIDS, with PGL, ABC or AIDS? **Methods.** Three years research conducted through: a) study and analysis of more than 5,000 AIDS research studies; b) study and analysis of the U.S. AIDS cumulative statistical official data during the period 1981-1988; c) study and analysis of clinical aspects and results in groups at high risk; d) study and analysis of the components and properties of the clotting factors and heroin and fecal material; e) analysis of the AIDS epidemiology between industrialized and developing countries. **Results.** These studies have shown that: a) AIDS is a non-infectious syndrome. b) HIV is not the etiologic agent. c) How the cause/effect factors of AIDS made possible the misunderstanding of HIV as the etiologic agent of AIDS. d) What are the causative factors of AIDS.

Conclusions. a) A new postulate for the AIDS pathogenesis: what are the causative factors and how they work. b) A new postulate for AIDS prevention. c) A new postulate for the cure of PGL, ABC, and AIDS.

Publications

C.717

THE COURSE OF IgG REACTIVITY WITH SYNTHETIC PEPTIDES DERIVED FROM HIV-1 GAG AND ENV IN HIV-1 SEROPOSITIVE INDIVIDUALS.

Johan Blomberg (1), Per Johan Klenck (1), Rüdiger Pipkern (2) Bernd Ljungberg (2), Bertil Christenson (2) and Bo Strandberg (2) Section of Virology, Dept Med Microbiol (1), Dept Infect Dis (2) Lund, Sweden, Zentrum f. Molekulare Biologie, Heidelberg/FRG (3)

OBJECTIVE: To evaluate the development of the immune response to epitopes simulated by synthetic peptides during the course of HIV-1 infection.

METHODS: [I₂₅I] with synthetic peptides from HIV-1 gag (1-20, 320-338, 335-355) and env (503-520, 581-599, 583-599, 606-620, 622-627, 658-663) were performed on consecutive sera from 39 HIV seropositive persons. A time period of 0.5 - 5 years was covered. Results were correlated with clinical status.

RESULTS: As previously noted by us, the pattern of reactivity with HIV peptides was individual. However, also a temporal pattern of variability was observed. Antibodies to certain peptides increased rapidly after an acute HIV infection, and then declined rather rapidly. Antibodies to some epitopes varied more, independently of other HIV antibody parameters. Antibodies to env 583-599 were more frequent in asymptomatic individuals than in patients with HIV-related disease. In individuals with more advanced disease, several peptide antibody parameters, both from gag and env, were low. The independent temporal variability among epitopes can be both abandoned and reconstituted during HIV-1 infection. Absorption by antigen, opsonin, also contributes.

C.719

A RAPID AND IMPROVED 2',5'A SYNTHETASE ASSAY BY POLYACRYLAMIDE GEL ELECTROPHORESIS

Henry C. Lee, Mary Beth Hiale, and Dal-Keo Lu.

Department of Pharmacology, The Pennsylvania State University, College of Medicine, Hershey, Pa. 17033, USA

Induction of 2',5'oligoadenylate (2,5A) synthetase activity is an accurate and sensitive parameter for viral infection of mammalian cells. It could be used clinically to monitor circulating interferences. The enzymatic assay ideally involves chromatographic separation of 2,5A, which range from di- to oligomers, from each other and from the unincorporated substrate of radiolabeled ATP. However, this procedure is not done routinely, and the enzymatic activity is measured instead by the amount of radiolabeled AMP incorporated into total 2',5'A. We developed a rapid and improved assay using a 0.3- μ m denaturing 20% polyacrylamide gel to separate the different species of [³²P]-labeled 2,5A from each other, and from the substrate [³²P]ATP. 2,5A species were visualized by autoradiography and the amount of incorporated [³²P] can be quantitated. To confirm the 2',5' linkage of the reaction products, the predominant species which coigrated with a tracer standard was shown to be resistant to 72 Hase but readily digested by phosphodiesterase. The current method is sensitive, fast and can assay a large number of samples simultaneously. Host cells we examined, including human T cell lines CEM and HP, had a low 2,5A synthetase activity. HIV infection of HP cells did not induce this enzymatic activity. This assay will be useful clinically to monitor circulating interferences in AIDS patients before and after therapy.

C.721

TROPICAL SPASTIC PARAPARESIS: SEROLOGIC AND HISTOLOGIC ANALYSIS

Canavaggio, M., Leckie, G.,* Chi, L.,* Madrid, R.E.,**

Lee, Helan,* and Van Gelder, R. Light and Electron Microscopy, *WESBOTE Laboratories, North Chicago, IL, 60064, USA, **SUNY State Center at Brooklyn, Brooklyn, NY

OBJECTIVE: To identify and further characterize by sural nerve biopsies, **MSWSP** in a neurological patient population from New York City.

METHODS: Serum and CSF from 150 patients were assayed for antibodies to HIV-1 by EIA. Repeat biopsies were confirmed by Western blot and SDS-PAGE. Sural Nerve was also performed on paired EIA positive serum and CSF. Sural nerve biopsies were performed on 17 TSP patients; these were analyzed by immunofluorescence, and light and electron microscopy.

RESULTS: 15 patients were HIV-1 seropositive; 12 of these had clinical features of **MSWSP** and all except one (black patient from S. Carolina) originated from the Caribbean. No differences in MB banding patterns were observed in matched serum and CSF. Surprisingly, a sensorimotor peripheral neuropathy was observed in 7 of the TSP patients. Two of the nerve biopsies revealed epineural and endoneurial inflammatory lesions containing plasma cells, but no giant or multinucleated cells. A myelin demyelinating process and abnormal giant axonal mitochondria were observed.

CONCLUSIONS: TSP is prevalent in the U.S. among Caribbean migrants and African-Americans. Repeat biopsies were performed to detect if intrathecal synthesis of anti-HIV-1 Ab was observed when comparing CSF and serum by MB. Nerve biopsies provide one means to assess the role of HIV-1 in the pathogenesis of myelopathy.

Section A

Recherche fondamentale (biomédicale) Basic Research (Biomedical)

C.718

PATHOGENESIS NK DEFICIENCY IN AIDS

Maria Caterina Sirtanni, F. Tagliavini, F. Alati Dept. of Allergy and Clinical Immunology, University of Rome, Rome, Italy.

OBJECTIVE: To give a model explaining NK defect in AIDS.
METHODS: PBMC from AIDS patients were assessed for NK activity on the D1C7 labelled K562 cell line. Cytoxicole tubulin polarization in these conjugates was studied by monoclonal antibodies (wAb) and immunofluorescence. Tubulin is responsible for an effective NK lysis. Results from these experiments were compared with those obtained on PBMC from normal donors, which were treated, before the assays with an anti-CD16 wAb.
RESULTS: NK activity and tubulin polarization were deficient in PBMC from AIDS patients as well as in normal controls, pre-treated with anti-CD16 wAb.
CONCLUSION: Pathogenesis of NK deficiency in AIDS may be explained on the basis of this model, assuming that some HIV-1 env proteins mimic the action of anti-CD16 wAb.

C.720

KINETICS OF HIV INFECTED CELL-TO-CELL FUSION

Graham, Barry and Rowland, J. Vanderbilt University School of Medicine, Nashville, TN, USA.

Objective: To define the mechanism and timing of the cell-to-cell fusion process important in the pathogenesis of AIDS.
Methods: A cytoxic effect assay to measure serum fusion inhibition activity has been developed that utilizes HR23T-HIV as fusion partner and the CD4+ cell line, M12, as target for spycytium formation. Serum is added to wells containing cells in viable culture (Titer A340 - virus control A340 - virus control A340) X 100. The kinetics of the fusion process was investigated by adding a dilution of serum known to have fusion inhibition activity in wells simultaneously, and 15, 30, 60, 90, 120, 180, and 360 minutes after wells were mixed. An equivalent dilution of non-immune serum was added to another series of wells mixed by repeated pipetting at the same intervals. Control wells included non-immune serum without mixing and immune serum with mixing. Assays were done in triplicate. Results: Anti-fusion activity of serum was unchanged when added simultaneously or 15 to 120 minutes after cell mixing. However, at 180 minutes there was a diminished anti-fusion effect and at 360 minutes there was an anti-fusion effect when the assay was terminated at 20 hours. Mechanical disruption of cells retarded the onset of mechanical formation on fusion inhibition was diminished when performed at the 360 minute time point. Non immune serum had no protective effect.
Conclusions: There is a point in the fusion process at which antibody is unable to inhibit syncytium formation. The data suggest that in the fusion process there are evolving cell-to-cell interactions that attain sufficient stability to diminish antibody interference by 6 hours and to resist mechanical disruption by 6 hours.

C.722

HIST IMMNOGLOBULIN MOLECULES ARE ON THE SURFACE OF PHAGOCYTES CARINII

Blumenfeld, Walter and Griffin, J. Melech Veterans Administration Medical Center, University of California, San Francisco, San Francisco, California, U.S.A.

Objective: To define the organ and/or host factors that explain the pathogenesis of P. carinii pneumonia in humans.
Methods: (1) Immunofluorescent labeling of whole organism preparations of P. carinii in bronchoalveolar lavage fluid separated with enzyme-labeled polyclonal and monoclonal antibodies to human immunoglobulins and to P. carinii. (2) Analysis of electrophoretically sedimented components of density gradient-purified P. carinii from human antibodies as well as whole organisms in 3/2 preparations. Monoclonal antibody to the Fab fragment of human IgG also labeled whole organisms. Anti-human IgG, one of the two monoclonal antibodies to the Fc fragment of human IgG, and a monoclonal antibody to P. carinii all labeled a 40k band that was present in (a) purified preparations of P. carinii, (b) 4/4 bronchoalveolar lavage fluid supernatants from patients with (2) and without (3) AIDS, and (c) IgG purified from 2/2 human sera (1 HIV-, 1 HIV+).

Conclusions: A host-derived IgG fragment is present on the surface of P. carinii. Its role in the pathogenesis of P. carinii pneumonia in AIDS is currently unknown. It may conceivably interfere with the ability of an already compromised immune system to clear the organism or recognize it as foreign.


C.723 INFECTION OF MONOCYTES WITH A T CELL TROPIC CLONE OF HIV. Janssens, Jean, S., Foka, T.M., Orensanz, J. and Fauci, A.S. IIR, NIAID, NIH, Bethesda, MD, U.S.A.

Objective: To determine if an HIV clone derived from infected T cells can infect normal human macrophages in vivo.

Methods: The HIV infectious clone (pNL4-3) was developed by combining the 5' GAG-POL region of the NY5 strain construct and the 3' ENV region of the LAV-1 strain construct. The pNL4-3 construct was transfected into SW640 (colony carcinoma) cells, with a subsequent passage onto a T cell tumor line (A31). Elutriated monocytes were infected with the passaged pNL4-3 clone. The monocytes passaged pNL4-3 and original clone were equilibrated by reverse transcriptase levels (RT) and stained onto monocytes and PHA blasts.

Results: The initial passage of pNL4-3 onto elutriated monocytes resulted in RT positivity on day 30 post infection. The culture remained RT positive through day 65 when the experiment was ended. Infection of these cells revealed virus particles budding intracellularly as well as from the plasma membrane. pNL4-3 showed a much greater ability to replicate in PHA blasts than in monocytes. Of particular note, a single passage onto monocyte culture resulted in an increased (3 log infectious units) ability of the virus to replicate in monocytes. In parallel, a 3 log decrease in ability to infect PHA blasts was noted with this single passage HIV.

Conclusions: A T cell tropic HIV clone can infect monocytes. Moreover, a single passage of the clone onto monocytes is sufficient to markedly increase the tropism of the virus for macrophages at the same time as it decreases the tropism for T cells.

C.724 MONOCYTE CHEMOTACTIC ACTIVITY IN THE SUPERNATANTS OF IN VITRO INFECTED HUMAN MACROPHAGES. Jouis L., LAKELINE E., Alieri* and R.S. Melitzer**

*Research Laboratory†, PHARMACOLOGICAL DIVISION, CIBA-GEIGY Ltd. CH-4002 Basel, Switzerland.
**Walter Reed Army Institute of Research, WMAI, WANC, Washington DC 20307 USA.

Macrophages (MΦ) are an important target for HIV infection and probably play a major role in the establishment and propagation of AIDS. Following infection, the virus is found in tissue MΦ and blood monocytes. As present, the mechanism of infection and spreading of HIV in these cells is not known.

We present results that address this issue. Human blood monocytes cultured in presence of 1,000 units of Colony Stimulating Factor-1 (CSF-1) differentiate into macrophages and are permissive to the infection with HIV-1 (ADA strain). Following infection, viral replication with minimal cytopathic effect can be demonstrated. When supernatant from infected MΦ were assayed for their ability to attract freshly isolated non infected blood monocytes, they were found active at levels comparable to the supernatant with optimal concentration of the standard chemotactant F-Met-Leu-Phe. Control supernatants obtained from non infected MΦ did not show this activity. A 48-microwell chemotaxis chamber was used for the measurements. These results can be of relevance to explain the initial rapid spread of the virus from primarily infected MΦ to circulating monocytes.

C.725 DETECTION OF HTLV-1 IN ALVEOLAR LYMPHOCYTES OF PATIENTS WITH TROPICAL SPASTIC PARAPARESIS (TSP) WITH BRONCHOVULVAR LYMPHOMAS.

Claude Desmet†, Coedat J.L.**, Norza N.A., Cabaret†† and Vermet J.C.***
INSERM U 271, Lyon; * Service de Pneumologie, Hôpital, St. Simeon; ** Service de Neurologie, Hôpital La Meynard, France, Montpellier, France.

Objective: To study the type of alveolar cells draining HTLV-1 genome in the TSP patients with bronchovulvar lymphomas.

Methods: After bronchoalveolar washing of TSP patients serologically HTLV-1 associated with bronchovulvar lymphomas, the adherent and non-adherent cells were separated, identified and HTLV-1 genome was detected in the different cell populations.

- by Polymerase Chain Reaction (PCR) after cellular DNA extraction of each cell population.
- by coculture of the two alveolar cell populations with lymphocytes of HTLV-1 seronegative subjects.

Results: PCR was done with two different types of primers in pol and pX regions; HTLV-1 genome was present only in lymphocytes and never in adherent cells. After coculture, we observed immunolabelled TSP cells producing complete HTLV-1 only with the alveolar lymphocytes and never with the alveolar adherent macrophages.

The immunolabelling of TSP cells will be presented and these cell lines will be phenotypically and virologically characterized. The biological properties of the HTLV-1 isolated from alveolar lymphocytes and from peripheral lymphocytes of the same patient will be analysed.

Conclusions: HTLV-1 is detected in alveolar lymphocytes and never in alveolar macrophages of these TSP patients, while in HIV infected patients with bronchovulvar pathogenesis, HIV genome is currently present in the two types of alveolar cells.

C.726 PLASMA VALUES OF FIBRONECTIN (FN) AND ANGIOTENSIN CONVERTING ENZYME (ACE) IN KAPOSI'S SARCOMA (Ks)-RELATED AND CLASSICAL (KS).

Palanis A.† and Korte P.†
† STD Clinic, ** Haematology and *** Biochemistry laboratories, Hôpital Saint-Louis, Paris, France.

Objective: To investigate plasma values of FN and ACE as putative markers of endothelial proliferation in HIV-related and classical Kaposi's sarcoma (KS).
Methods: Plasma FN (ELISA, Stago Lab) and ACE (Radiochemical technique of Rohrbach) were determined in patients with AIDS-related KS, classical KS and the lymphoedematous syndrome (LAS).

RESULTS	FN (ng/ml)	SE	p	ACE (mg/ml/min)±SE	p		
CONTROLS	138	± 28	n=30	12.5	± 3.5	n=20	
LAS	153	± 75	n=18	KS	21.4	± 10.1	n=14
HIV-KS	227	± 80	n=21	CLASSICAL KS	16.9	± 6.1	n=3
				15.9	± 5.5	n=15	

The increase in plasma values of FN is highly significant in both HIV-related and classical KS (P<10⁻³). Plasma Von Willebrand Factor (VWF) gave similar results (Santur J. Invest. Dermatol. 1988; 90, 703). On the other hand, ACE increase is highly significant in LAS patients (p<10⁻³) and moderate in both forms of KS (p<0.01 and p<0.05).

Conclusion: Fibronectin and ACE are both partly released by endothelial cells. They are both, besides VWF, markers of endothelial damage or proliferation in KS. Their prognostic significance in LAS patients remains to be ascertained.

C.727 CD4- CELL HELPER AND SUPPRESSOR FUNCTIONS OF HIV INFECTED PATIENTS

Wetzel, Hol†(1), Bissel, Y.†(2); Schweighofer, Th.†(3); Scheller, G.†(4) and Opelitz, G.†(5).

†(1)Institute of Immunology, University of Heidelberg, and (2)Rehabilitation Hospital and Hematology Center, Metelberg, FR Germany

Objective: To investigate helper and suppressor functions of CD4+ T cells in HIV infected hemophilia patients.

Methods: We assessed T cell functions in 61 hemophilia patients (22 HIV-Group 1; 27 HIV without AIDS; Group 2); 13 ARC/AIDS patients, Group 3). PWM-stimulated allogeneic cocultures of CD4+ T cells and control B cells were evaluated by assessment of immunoglobulin secreting cells (ISC) in a reverse hemolytic plaque assay and by ELISA-determination of IgM and IgG secretion.

Results: We found no significant differences between HIV- patients and controls whereas CD4+ cells of HIV patients showed reduced helper activity for generation of ISC (p<0.01, Group 2; p<0.001, Group 3), IgM (p<0.005, Group 2; p<0.001, Group 3) and IgG secretion (p<0.02, Groups 2,3). CD4+ cell suppressor activity was enhanced with respect to ISC generation (p<0.01, Group 2; p<0.0001, Group 3) and IgM secretion (p<0.02, Groups 2,3). Preliminary data in 38 patients show that autoantibodies against CD4+ cells were associated with CD4+ cell helper defects (p<0.01).

Conclusion: Considering the central role of CD4+ cells in the immune response CD4+ cell dysfunction may play a role in the development of immunodeficiency state of ARC/AIDS patients. CD4+ cell autoantibodies might be involved in the pathogenesis of CD4+ cell helper defects.

C.726	
RESULTS	FN (ng/ml)
CONTROLS	138 ± 28 n=30
LAS	153 ± 75 n=18
HIV-KS	227 ± 80 n=21
CLASSICAL KS	21.4 ± 10.1 n=14
	16.9 ± 6.1 n=3
	15.9 ± 5.5 n=15

Publications



Section A

Recherche fondamentale (biomédicale) Basic Research (Biomedical)

C.753

GROWTH OF HIV IN CELLS FROM VARIOUS DONORS
O. Yamada, T. Matsumoto, H. Saitoh and T. Kurimura,
Department of Virology, Tohoku University School of
Medicine, Yonegi 581, Japan

Peripheral blood mononuclear cell (PBMC) preparations were prepared from 27 individuals and the growth of Japanese HIV isolates, J90/1 and J90/2, in these PBMC preparations was studied. There was significant diversity in infectious virus yield among PBMC preparations. The virus yield did not correlate with the ratio of CD4 lymphocytes in PBMC or growth ability of the cells. In some PBMC preparations, p24 antigen levels did not correlate with infectious virus yield. Mean E-rosette forming cells were used instead of whole PBMC. Similar phenomena were observed, but the production of p24 antigen was much reduced without decrease of infectious virus yield. These results indicate that each individual donor has lymphocytes with capacity to allow the growth of HIV different from others, and that E-rosette forming cell-depleted PBMC produces excess p24 antigen.

C.754

DETECTION BY POLYMERASE CHAIN REACTION OF HIV-1 DNA IN
HOMODUPLEXES, HETEROLOGUES, AND AIDS PATIENTS IN TAIWAN
H. Dou¹, C. T. Chang², M. C. Shiao³, M. C. Lin⁴, Y. C. C.
Kuo⁵, C. H. Chiu⁶ and Kenneth B. S. Chien⁷ National Center Institute, NCH
Taiwan; ²National Taiwan University College of Medicine, Taipei,
Taiwan; ³Center for Venereal Disease Control, Taipei, Taiwan; and
⁴Shanghai Medical College, Shanghai, Taiwan.

Objective: To detect HIV-1 proviral sequences by polymerase chain reaction (PCR) with DNA samples obtained from seropositive Taiwanese subjects.
Methods: Peripheral lymphoid cells from an AIDS patient, an asymptomatic homosexual male, and two hemophiliacs, as well as formalized spleen tissues from two autopsied AIDS patients were tested. The presence of proviral sequence in the Southern blot was detected by specific probes following PCR-amplification procedures. **Results:** All of the 6 samples exhibited a positive reaction when primer pairs from gag region and splI domain of gag region were used. Primer pairs derived from a relatively conserved region of splII domain of gag region also functioned to produce amplified fragments for all samples. However, when primer pairs covering splII through splI domain were used, only four samples gave a definite amplified band, and one yielded a faint band. When primer pairs derived from gag and 3' LTR regions were used, all were negative. The degree of hybridization signal intensity for each of the samples PCR-amplified at gag region did not correlate exactly with those PCR-amplified at various gag regions.
Conclusion: The results suggest that these six samples contain various copy numbers of HIV-1 proviral sequences which exhibit heterogeneity in their gag sequences, divergent from those of HXB-2 clone of HIV-1.

C.755

CONSTRUCTION OF A RECOMBINANT RETROVIRAL INTERFERING PAR-
TICLES CONTAINING A DEFECTIVE HIV-1 GENE
Ferdinando, Maurizio; Taddeo, S.M.L.; Orsacchia, A.; Sabbatini,
L.; Carletti, F.; Veroni, F.; Rossi, G.S.
Laboratory of Virology, Istituto Superiore di Sanità, Rome, Italy.

Objective: By infecting Huc-78 cells with an RT positive supernatant of P81 from an AIDS patient, we have isolated a non-productive HIV-infected cell clone (P17), which exhibits a viral RNA pattern superimposable with that of productive cell clones, and shows resistance to HIV-1 or HIV-2 superinfection. In order to study the phenomenon of viral interference, the whole genome will be transferred in HIV-sensitive cell lines via transfection of a retroviral vector construct in an amphotropic packaging line.

Methods: From an λ gt10 genomic library of P17 clone we have molecularly cloned the whole provirus in pUC-19 and then subcloned it in retroviral vectors bearing the G418 resistance gene such as pL2 (CMV LTR promoter), pS (hyaluronidase kinase promoter) and HIV (SV40 promoter).

Results: The pL2 construct has been transfected in an amphotropic retrovirus containing the provirus originally integrated in P17 clone. More than 30 G418-resistant P4311 clones have been obtained. Indirect IFA analysis using a pool of human positive sera was clearly positive in two P4311 clones also showing an integrated construct by Southern Blot. A more detailed molecular characterization will be discussed.

C.756

Blank area reserved for publication content.

C.757

Blank area reserved for publication content.

C.758

REPLICATION OF A LETHAL VARIANT OF HIV/SIV IN MACAQUE PBMC
IN THE ABSENCE OF EXOGENOUS IL-2 OR ACTIVATION BY MITOGENS
Parks, Patricia; McClure, H.; Anderson, D.
Yerkes Regional Primate Research Center and Department of Pathology, Emory
University, Atlanta, GA, USA.

Objective: To identify mechanisms by which HIV/SIV(PB₁) replicates in and induces proliferation of PBMC from normal macaques and mangabey monkeys.

Methods: Resting or PHA-stimulated PBMC from normal monkeys, chimpanzees or humans were infected with SIV(PB₁) or the parent, HIV/SIV-9; cultures were monitored for RT activity, cell viability, total cell number, percentage of cells expressing the IL-2 receptor, and production of various cytokines.

Results: Infection of PBMC from pithecioid macaques or mangabey, but not from chimpanzees or humans, with HIV/SIV(PB₁) resulted in as much as 5-fold increases in total viable cells. This phenomenon was not observed in parallel cultures infected with the parent HIV/SIV-9. In addition, SIV(PB₁) but not SIV-9, replicated in and induced proliferation of resting macaque PBMC, irrespective of whether exogenous IL-2 was added to the medium. The proliferative response paralleled virus accumulation in culture medium and increases in IL-2 receptors. Experiments are in progress to assess the possible roles of various cellular activation pathways in the proliferative response to SIV(PB₁).

Conclusion: SIV(PB₁) has escaped the requirement that cells be activated before productive infection can occur. Also, the induction of cell proliferation during *in vitro* infection is manifest as lymphoid hyperplasia *in vivo*, leading to the speculation that the gag gene product, which has some sequence homology with and functions similar to p60-*src* and v-Src-*src*, has acquired mutation(s) that render it "oncogenic-like." (PFR 88-00163)

Publications


 Recherche fondamentale (biomédicale)
 Basic Research (Biomedical)

C.765 SCREENING ET TYPAGE HIV-1 ET HIV-2 GRACE A UN TEST RAPIDE 15 MINUTES UTILISANT DES PEPTIDES SYNTHETIQUES (CLONATEC TARGET HIV TEST).

Sylvie Bergeron, Gilles Laroche, S. Bettiger, A. Dangereux, G.M. Gerety-Danet, M. Denis, J. Département Virologie, France, C. Clonatec, Paris, France, Institut Pasteur, Côte d'Ivoire.

Objectif : Evaluation d'un test rapide (3 minutes) utilisant des peptides synthétiques HIV-1 et HIV-2 dérivés de la séquence de la glycoprotéine transmembranaire de chacun des deux virus HIV-1 et HIV-2.

Matériaux et Méthodes : 208 sérums provenant de sujets vivants en Afrique de l'Ouest.

Résultats : L'étude a porté sur 237 sérums provenant de sujets vivants en Afrique de l'Ouest. Les résultats obtenus ont été filtrés à travers une membrane sur laquelle ont été déposés chaque peptide HIV-1 et HIV-2. Après addition du conjugé (anti IgG humaine couplé à la peroxydase) et lavage, on ajoute le substrat (TMB). Le résultat (spot blanc) est visible à l'œil en une minute environ.

Résumé :

WR	TOTAL	HIV-1	PEPTIDES	PEPTIDES	Négatif
1	7	1	HV-2		
2	72	2	1	48	3
1+2	12	12	1	8	3
Non	186	2	-	-	-

Conclusion : Les résultats montrent une bonne sensibilité (HIV-1 : 94% et HIV-2 : 92,5%) et une très bonne spécificité (HIV-1 : 98,6% et HIV-2 : 100%). Ces résultats, très intéressants pour un test rapide, sont encourageants, une augmentation de la sensibilité doit pouvoir être obtenue.

C.767 INFLUENCE OF BLOOD VOLUME AND TEMPERATURE ON HIV CULTURES IN INFANTS AND CHILDREN

Barthelemy, P., Wessely, J.L., Jodar, A.M., Gilchrist, S.A., Sweeney, P., Burke, D.S., the Walter Reed Retrovirus Research Group, Walter Reed Army Medical Center, Walter Reed Army Institute of Research, Washington, D.C., Institute of Research.

Objectif : To determine the influence of blood volume and specimen transport on pediatric HIV cultures.

Méthode : Blood cultures for HIV were obtained with 1-3 cc of heparinized whole blood from 26 patients (PO-9) with an age range of 3 mos. to 31 yrs. Each culture was enveloped with a standard number of the patient's macrophage cells (10⁶) and a lesser number of cells (10⁵) using a modification of the method of D. Gallo, et al. Laboratory personnel were blinded to the patient's age and origin of specimen.

Résultats : Cultures from 9 children were positive and all asymptomatic infants and seropositive children had positive cultures. Eight of 9 had positive cultures with 10⁶ and 10⁵ cells. One child had a positive culture with 10⁶ cells only. Most cultures were positive at 7 days incubation and 7 of 8 were parallel samples were positive at the same time intervals. Six specimens were paraffin sealed (one of heparinized blood) and cultured over 24 hrs. after phlebotomy. Cultures from 3 of these 6 patients were positive. Conclusion : Prompt and reliable diagnosis of HIV infection in infants is a valuable diagnostic tool despite a small volume of blood (1-3ml) and delay between phlebotomy and culture processing.

C.769 HUMAN IMMUNODEFICIENCY VIRUS (HIV) MUTLIPLES IN PRIMARY CULTURES OF HUMAN KUPFFER CELLS

SCHMITT, Marie-Françoise, STEFFAN, A.M., JAECK, D., GENDRAULT, J.L., DE KINK, A., Département de Médecine Générale et Endocrinologie, Faculty of Medicine, U.P., STRASBOURG, FRANCE

OBJECTIVE: Given their localization in the liver sinusoid, the Kupffer cells (KC), which represent the largest reservoir of fixed macrophages in the body, are ready candidates for early infection following a blood transfusion. However, until now, the role of KC in HIV infection has never been studied and no attempt has ever been made to infect KC in culture.

METHOD: Isolation was carried out according to the method we have previously described (Krivt et al., C.R. Acad. Sci. Paris, 1980, 291, 249). The purity of the cell culture attested 90%. Primary cultures of 24- to 72-hour-old KC were infected with HIV 1 (isolate LAV 1 - Rev).

RESULTS: In 3 different experiments syncytia detectable under optical microscopy appeared between 4 and 10 days. Di observations showed typical HIV particles released either in vacuoles or outside the cell as well as characteristic budding figures. Except from the syncytia, no obvious cytopathic effect could be found. Furthermore, a reverse transcriptase activity increasing with the time of infection was demonstrated in the supernatant of the infected KC.

CONCLUSION: Our results, which demonstrate that KC may constitute a target for HIV, suggest that these cells may play a crucial role in the physiopathology of the disease. They may not only constitute a reservoir for the virus but, given that strategic position in the liver lobule, they may also be involved actively in the dissemination of the viruses.

C.766 ABSENCE OF P24 ANTIGEN AND ANTI P24 ANTIBODY DECREASING IN AFRICAN AIDS - COMPARISON BETWEEN EUROPEAN AND WEST AFRICAN POPULATIONS.

Guy Léopold, P.Wainreb***, M.Mouner*, G.M.Gerety-Danet***, F.Bari***, F. Delbecq***, M. Denis** et le sélectio desse des Groupes HIV Linoges France, Institut Pasteur Abidjan Côte d'Ivoire, Virologie CHU Tours France.

Objective : to compare virological pronostic factors (p24 antigenemia, anti p24 antibody titer) in European and west African patients. Materials and Methods : 508 HIV positive patients from Limoges France (106 sera) and Abidjan Côte d'Ivoire (402 sera) were tested for p24 antigenemia by Abbott HIV-1 antigen p24 assay and for anti p24 by recombinant EIA/RIA Abbott.

Virus Area	Cl. Status	Anti p24 % (n)	Ag p24 % (n)	20-50 % positivity	
HIV-1	AF	HEALTHY(146)	7%	91%	9%
	EUR	ARC(10)	20%	80%	20%
HIV-2	AF	HEALTHY(12)	2%	77%	4%
	EUR	ARC(20)	4%	58%	0%
HIV-1/2	AF	HEALTHY(12)	2%	100%	0%
	EUR	ARC(20)	2%	100%	0%

Conclusion : AIDS African patients have higher titers of core antibodies than European individuals. The pronostic value of HIV antigenemia is not the same for seropositive patients in Europe and in west Africa.

C.768 PRIMARY ISOLATION OF HIV FROM LYMPHOCYTES, MONOCYTES, AND MACROPHAGES WITH A PERMANENT T-CELL LINE AS A MODEL TO STUDY VIRUS REPLICATION AND CELL PROTEIN 24 EXPRESSION.

Barthelme, Andreas, Ehrmann, U. and Jahn, G., Institut für Klinische und Molekulare Virologie der Universität Erlangen-Nürnberg, D-8520 Erlangen, FRG.

Objective: To establish a standardized HIV isolation procedure where PMBC can be replaced by a permanent T-cell line in order to study primary HIV replication and transmission of HIV from monocytes/macrophages to T-cells.

Méthode: Under optimal conditions primary HIV isolation gave an overall positive result in 44%. Using the permanent T-cell line SupT1 as the cocultivating system, instead of negative donor PMBC, HIV isolation was positive in 68% of cases. In contrast to SupT1, negative donor PMBC's showed suppressive influence on primary virus isolation in vitro. Direct transmission of HIV from infected patients blood monocytes to SupT1 was observed in 9 out of 20 isolations. However, the monocytes had to be stimulated with CD-3/CF. In one case the virus could be isolated directly from alveolar macrophages to the permanent T-cell line.

Conclusion: SupT1 as a cocultivating system in primary HIV isolation are not as sensitive as PMBC, but revealed to be a good model to study virus replication and cell tropism of HIV wild isolates in vitro.

C.770 PRODUCTIVE INFECTION OF PRIMARY CULTURES OF HUMAN HEPATIC ENDOTHELIAL CELLS (EC) BY HUMAN IMMUNODEFICIENCY VIRUS (HIV).

STEFFAN, Anne-Marie, SCHMITT, M.P., GENDRAULT, J.L., JAECK, D., DE KINK, A., Département de Médecine Générale et Endocrinologie, Faculty of Medicine, U.P., STRASBOURG, FRANCE

OBJECTIVE: The presence of CD 4 antigens on the surface of human liver EC prevents them susceptible to infection by HIV. Hepatic EC were isolated from liver specimens obtained after liver resection in second liver cancer by a method we developed several years ago (Steffan et al., C.R. Acad. Sci. Paris, 1981, 292, 809). The cells were purified by centrifugal elutriation. The well flattened out EC could be easily characterized under SEM by their typical fenestration. RESULTS: Primary cultures of 24-hour-old EC were infected with HIV 1 (isolate LAV 1 - Rev) for 3, 5 and 6 days and processed for SEM and TEM. Under SEM, a great number of virus particles were detected at the plasma membrane as early as 3 days after infection. One or two days later, the number of viruses in close contact with the plasma membrane or in the vicinity of the cell had considerably increased. Moreover, numerous pictures strongly suggestive of virus budding were observed. TEM observations confirmed these results and demonstrated the presence of typical virus particles as well as the different steps of virus budding.

CONCLUSION: These results demonstrate that liver EC in culture may be infected with HIV and are able to produce large amounts of virions. This suggests that the EC could play an important role in the dissemination of HIV particles.

Publications


 Recherche fondamentale (biomédicale)
 Basic Research (Biomedical)

C.771

**A HUMAN MONOCLONAL ANTIBODY AGAINST HIV-1
 TRANSMEMBRANE GLYCOPROTEIN GENERATES
 COMPLEMENT-MEDIATED, ANTIBODY-DEPENDENT
 ENHANCED (C-ADE) OF HIV-1 INFECTION *IN VITRO*.**

W.F. Robinson, Jr., M.K. Gornzy, J.-Y. Xue, D.C. Montefiori¹, W.M. Mitchell¹, and T. Zolla-Pazner²

¹Dept. of Pathology, Vanderbilt University, Nashville, TN USA 37232
²Dept. of Pathology, New York University, New York, NY USA 10016

Neyers Administration Medical Center, New York, NY USA 10010

Objective: To evaluate ten human monoclonal antibodies (mAb) against HIV-1 for their abilities to neutralize or enhance HIV-1 infection *in vitro*

Methods: Ten human hybridoma cell lines producing mAb against HIV-1

were generated *in vitro* by infection of peripheral blood lymphocytes from HIV-1 seropositive subjects with Epstein-Barr virus. All ten IgG were tested in an MT-2 cell microtiter infection assay for HIV-1 neutralizing and enhancing activities.

Results: Of the ten, 4 mAbs reacted with gag protein (gp24) and 6 reacted with env protein (gp41), by radioimmuno-precipitation. None of the mAbs were neutralizing. It was determined that one mAb, 120-16, could enhance HIV-1 infection to a division of 1.648 (approximately 25 ng/ml). This mAb is an IgG₁ which recognizes gp41 and is directed against an immunodominant region of the virus. Enhanced HIV-1 infections were characterized by increased cytopathic effect, reverse transcriptase release, antigen synthesis, and progeny virus production.

Conclusions: Since only 1 of 6 human mAb tested mediated C-ADE of HIV-1 infection *in vitro*, this phenomenon probably depends on recognition of one or more specific epitopes. The epitope(s) can be mapped and should, perhaps, be eliminated from recombinant vaccines.

C.772

**IDENTIFICATION OF PROTEIN INTERMEDIATES IN THE PROCESSING
 OF THE p55 HIV-1 gag PRECURSOR.**

Shaharraz D. Gowde, B.S. Stala, and E.G. Englemann, Stanford University School of Medicine, Palo Alto, CA 94304, USA.

Objective: To analyze the cleavage pathway of the 55 kDa (p55) HIV-1 gag precursor.

Methods: HIV-1 gag proteins isolated from [³H]leucine labeled, recombinant HIV-1/vaccinia virus infected M1 lymphocytes by immunoprecipitation with anti-p24, anti-p17 or anti-p6 antibodies were subjected to one- and two-dimensional SDS-PAGE.

Results: SDS-PAGE analysis revealed that the initial cleavage of the p55 gag precursor gives rise to three processing intermediates (p41, p41 and p39), p41 and p39 proteins contain the p17 and p24 protein segments, and p41 is comprised of p24 and p15 proteins.

Two-dimensional gels, these intermediates as well as the mature p24 and p17 proteins were separated as distinct species. The tryptic acid labeling of the HIV-1 gag proteins revealed that in addition to p55 and p17, the p41 and p39 intermediates, but not p41, are glycosylated, confirming that glycosylation occurs at the N-terminus before cleavage of the p55 precursor.

Conclusion: The glycosylated HIV-1 gag p55 precursor is initially cleaved in a random either at the p17/p24 junction or at two sites between p24 and p15 proteins, resulting in three intermediates which are subsequently cleaved to yield mature gag proteins.

C.773

**EARLY DIAGNOSIS OF HIV INFECTION IN CHILDREN AND NEWBORN
 BY LYMPHOCYTE CULTURES AND DNA/RNA DETECTION IN THE
 POLYMERASE CHAIN REACTION (PCR).**

Basch, Senta¹, Polinger, J.M., Riser, J.M., Chaste, O.***, Bagatell, L*, and Tzipori, C.*

¹ NIDDKM U 271, Lysa; **Newman Hospital, Lysa; *** Rockefeller University, Lysa; **** Elster Hospital, Lysa, Germany.

Objective: In order to diagnose early HIV infection in newborns and children from seropositive mothers, we have looked for HIV in their peripheral blood mononuclear cells (PBMC).

Methods: 14 seropositive children were studied, age one day to 3 years and HIV was detected in lymphocyte cultures by P24 Ag ELISA (Abbott). HIV DNA and RNA in PBMC was demonstrated by PCR.

Results: HIV was isolated from lymphocytes in 5/14 cases (in 2/5 the first day of life). HIV DNA was detected in 13/14 children with two pairs of primers. HIV RNA was found in PBMC in 8/14 cases including the five with a positive HIV culture.

Furthermore HIV RNA was present in 6/8 cases of children with clinical and/or immunological abnormalities but only in 2/8 of those with no clinical or biological changes.

Conclusion: PCR appears as the most sensitive method to diagnose HIV infection anytime after birth. Since HIV RNA detection in isolated children does not correlate with immunological abnormalities and possibility of lymphocyte culture, it is likely that it may also be due to the assessment of active HIV replication and therefore of prognostic value in newborn HIV infection.

C.774

C.776

**HIGH CAPACITY DRUG SCREEN FOR INHIBITORS OF HIV
 TAT TRANSCRIPTION: EFFECT OF INTERFERONS**

Leo Bacheler and Bob Nardone, Medical Products Department, ELDuPore de Neuros and Co. Inc., Experimental Station, Wilmington DE 19800-0400, USA.

Transactivation of the HIV LTR by the virally encoded tat protein is an essential step in virus replication. As such, tat transactivation is an attractive target for antiviral therapy. Transfection of HeLa cells with recombinant DNA plasmids expressing the HIV tat protein and linking EcoRI/beta-galactosidase to the HIV LTR has been used to generate human cell lines which express high levels of *in situ* beta-galactosidase activity from a tat transactivated HIV LTR. One such cell line, 389, expresses sufficient beta galactosidase to allow the detection of the activity from 2000-5000 cells grown in a microtiter well. A high through put, virus free, microtiter format based drug discovery screen has been devised using the 389 cell line, and is being used to search for inhibitors of HIV tat transactivation. Compounds which inhibited HIV tat transactivation of the HIV LTR would be expected to reduce *in situ* beta galactosidase expression in this cell line.

Alpha, beta, and gamma interferons are potent inhibitors of beta galactosidase expression in this assay. In order to differentiate between effects of interferons and other active compounds on tat transactivation and other effects which result in reduced beta-galactosidase expression, we derived a control cell line which expresses significant levels of beta-galactosidase from a different promoter, unrelated to HIV and not subject to transactivation by HIV tat. The effects of interferons and other "nuclear" compounds on the expression of *in situ* beta galactosidase in this control cell line, as well as the effect on transactivation of a second LTR linked indicator gene introduced by transient transfection will be described.

C.775

**COMPARISON OF SINGLE AND DOUBLE-LABELLING OF SLB1 AND MT2
 CELLS IN THE DETECTION OF HTLV-1 ANTIBODIES BY RADIOIMMUNOPRECIPITATION (RIP) AND IN VITRO INFECTION (IVIF).**

Marian T. Sullivan¹, Richard A. Johnson, and D.J. Slamon², ¹American Red Cross, Rockville, MD, USA, ²UCLA School of Medicine, Los Angeles, CA, USA.

OBJECTIVE: To determine if the sensitivity to HTLV-1 antibodies can be enhanced by a double-labelled lysate or infected cells. To evaluate Leu 5 as a substitute for Cys 1 in the labelling of viral antigens. To compare RIPA profiles from MT2 cells to a cell line of non-activator origin (SLB1).

METHODS: Samples known to display varying patterns of antibody reactivity were combined with either ¹²⁵I-Cys 1 labelled MT2 or SLB1 lysate, ¹²⁵I-Leu 5 or ¹²⁵I-Cys 1 labelled SLB1 lysate or ³²P-UTP of both ³²P-Cys 1 and ³²P-Met labelled SLB1 lysate. Antigen-antibody complexes were precipitated by protein A-Sepharose. Pellets were electrophoresed by SDS-PAGE and autoradiographed.

RESULTS: No samples displayed any additional antibody reactivities with Cys-Met than with Cys alone, and there was no observable difference in the intensity of bands. Lanes representing double-label treatment had greater non-specific background. Leu 5 substituted for Cys did not improve the detection of any viral-specific antibodies, despite the fact that Leu 5 is 5 times as common in the coding sequence. Using SLB1 viral products p24, p40, p55, and gp67 were present; MT2 did not produce detectable p40, p41, and gp67 but exhibited p24, p55 and gp68. The representation of viral antibodies in 25 positive samples was 20%/100%, 40%/70%, 65%/25%, and 66%/100%.

CONCLUSION: 1. ¹²⁵I-Cys-labelled-lysate is as effective in the detection of HTLV-1-specific antibodies as is ¹²⁵I-Leu or Cys-Met. 2. The SLB1 cell line provides better detection of anti-p24s than MT2.

Publications


 Recherche fondamentale (biomédicale)
 Basic Research (Biomedical)

C.777 SEROLOGIC ANALYSIS OF PROTEINS ASSOCIATED WITH AND PREVALENCE SEROEPIDEMIOLOGIC STUDIES OF TWO NOVEL RETROVIRUSES ISOLATED FROM AIDS-ASSOCIATED LYMPHOMAS.

No. Virella L., Khayat-Bassif F., Marsh J. and McGinn MS.
 University of California, San Francisco, and San Francisco General Hospital, San Francisco, California, USA.

Objectives: To determine the serologic relationship of the proteins associated with two novel retroviruses, 27F and 10C9, isolated from primary AIDS-associated lymphoma tissue to other known retroviruses, and to determine prevalence of exposure to these viruses in various populations at risk for retroviral infection.

Method: Immunoblot.

Results: Purified 27F, 10C9, HTLV-I (QIVP), and bovine leukemia virus (BLV) proteins were used as antigen sources for immunoblotting. Antibodies raised against 27F/10C9 p27 (candidate major virus core proteins) recognized HTLV-I p24, and antisera raised against HTLV-I envelope proteins recognized 50 kd proteins present in 27F/10C9 virus preparations. A small subset of each had limited reactivity with HTLV-I virus core proteins and BLV envelope proteins (p55G1), and did not react with HIV-1 proteins.

Conclusions: These results demonstrate that the 27F/10C9 viruses are serologically related to oncoviruses, not to leukemia, and provide evidence that exposure to these viruses has occurred in individuals in groups at risk for retroviral infection.

C.779 HIV-SPECIFIC HIV P24 ANTIGEN REACTION DUE TO BACTERIAL CONTAMINATION OF HIV ANTISERA

BARBARA B. PHILIPS, BR. LEWIS, A. J. JAMES, A. M. AND SPYRID. 87*
 *Tulane Medical Center School of Medicine, New Orleans, LA, U.S.A.
 *Tulane Medical Center School of Medicine, New Orleans, LA, U.S.A.

OBJECTIVE: To determine the source of HIV p24 reactivity in a series of tissue culture growth medium (TCM) used as matrix negative control in capture assay. **RESULTS:** A positive antigenic containment in a seronegativity clear TCM was amplified at 37°C for 48 hrs. The culture was reactivated in antigen-capture and the isolate was grown in fresh sterile TCM. P24 antigen reactivity was determined with commercial (Behring) kits in the test prior to and after centrifugation (100g, 30min), and in the filtrate (0.45 µm) centrifuge. P24 reactivity was also evaluated in samples from a culture of *ESCHERICHIA COLI* strains in TCM. P24 specificity test was as per 101 envelope.

RESULTS: The contaminant in the original TCM was identified as *ALCALIGES FACIOLIS*. The centrifugate and filtrate derived from the TCM with the microbial growth had p24 reactivities of 324 and 424 gpa/ml respectively. P24 reactivity of 110 gpa/ml was noted with the centrifugate from TCM with *E. COLI* growth. In specificity reactions with the centrifugate from TCM with *E. COLI* growth, in specificity reactions with the sample from the bacterial culture, no effect on the p24 reactivities associated with the sample from the bacterial culture. **CONCLUSIONS:** false positive HIV p24 reactivity in the antigen-capture assay may be related to microbial growth in test samples. Measurement of p24 antigenemia in samples from HIV-infected patients should be adequately controlled for possible bacterial contamination.

C.781 BIOLOGICAL FACTORS AFFECTING TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS

Robertson JL, Shillington CA, Davidson DJ, & Babus S, Jr
 University of Pittsburgh Medical Center
 Pittsburgh Drug Addiction Study, Pittsburgh, PA
 Biomedical Research Institute of Pittsburgh
 UNIV. OF PITTSBURGH

OBJECTIVE: To examine biological factors which affect heterosexual transmission of HIV, with particular reference to biological markers of infectivity.

RESULTS: Couples were identified whose sex partner (10 male, 2 female) was infected with HIV, and the other partner seronegative. The couples were followed for 12 months. The seronegative partner was exposed to the infected partner by vaginal intercourse. There was no evidence of barrier methods of contraception. All infections were acquired at least once in the 12 month period. In 11 cases, tests were carried out using commercial kits.

RESULTS: Virus was detected in lymphocyte cultures from 5 index cases, of whom 3 (60%) also had p24 antigen. One other index case also showed antigen but no virus. Among their sexual contacts 3 seroconverted during the study period 2 and 6 months after virus was first detected in culture. A third patient also yielded virus on culture and later had evidence of HIV DNA on immunoblotting but 12 months after the original test is still HIV antibody negative. In 2 out of 3 couples where transmission occurred the index patient was antiseronegative and all 3 index cases yielded virus from lymphocyte cultures on one of each occasion. In all 3 cases who showed evidence of seroconversion, virus detection was the earliest marker of infection.

CONCLUSIONS: In all 3 cases who showed evidence of seroconversion, virus detection was the earliest marker of infection. Virus detection in lymphocyte culture during the study period, and the presence of HIV DNA on immunoblotting, p24 seroconversion. Virus isolation was present in all transmitted, p24 seroconversion. The use of p24 antigenemia as an early indicator of infection (before antibody detection) is important, and the implications for subsequent heterosexual spread are discussed.

C.778 BUDDING FEATURES OF DIFFERENT MORPHOLOGIES OF HIV-1 PARTICLES FROM CELL CLONES ISOLATED FROM HIV-1-INFECTED MT-4 CELLS

GOTO Toshiyuki, IUTA M, ZHANG, J, JIWAHITO, S, and KAKAI, H*
 Osaka Medical College, Osaka, Japan, 426, and *University, Osaka, Japan,***Shaanxi Anti-epidemic Station, Xia, China.

Objective: To elucidate the viral maturation process. **RESULTS:** Cell clones were isolated from HIV-1-infected MT-4 cells. Cloned cells were observed by electron microscopy, and immunoelectron microscopy was also carried out using monoclonal antibodies and HIV-1-seropositive serum.

Results: The cell clones produced particles with different kinds of morphologies. Normal particles were produced from the cell surface by a budding process in which crescent-shaped structures first appeared beneath the cell membrane, and subsequently matured to a complete form with an electron dense core just before being released from the cell surface. Doughnut-shaped and teardrop-shaped particles were respectively produced by budding of the crescent shape with double-layers from the cell surface, and by the budding of a teardrop form with an electron dense core from the cell surface.

Conclusion: The morphological maturation of HIV-1 particles appeared to be complete just before their release from the cell surface in several cell clones producing differently shaped particles.

C.780 MACROPHAGE CULTURES DO NOT INCREASE FREQUENCY OF HIV ISOLATION OVER LYMPHOCYTES FROM HEMOPHILIACS

LEONARD BLOOM, RICHARD S. HANSEN, S.R. S. ANDERSON, A. AND HYNOP JR., N.E.
 Tulane University School of Medicine, New Orleans, LA, USA.

OBJECTIVE: To determine whether macrophages (MΦ) of hemophiliacs preferentially harbor HIV, since the frequency of virus isolation from hemophiliacs in many studies is lower than that from infected asymptomatic homosexuals.

Methods: Monocytes and lymphocytes from asymptomatic seropositive hemophiliacs and homosexual controls in PICOI-lysozyme fractionated blood mononuclear cells were separated by adherence to plastic culture dishes and panning of the unattached cells. The MΦ fraction was subjected to complement-mediated lysis with MAb Lea 50 to remove residual T cells. The two populations of cells were cocultured with GM-CSF treated MΦ or PHA-stimulated lymphocytes from seronegative donors. Harvests from the cultures obtained weekly for 4 weeks were tested for p24 by the antigen-capture assay.

Results: Under comparable cultural conditions, HIV recovery from the blood mononuclear cells of 5 homosexual controls and 5 hemophiliacs studied was as shown.

Conclusions: The reported lower frequency of HIV recovery from hemophiliacs is unlikely to be due to the virus being preferentially harbored by the monocytes.

	Monocytes	Lymphocytes
Controls	4/5 (80%)	3/5 (60%)
Hemophiliacs	1/5 (20%)	2/5 (40%)

C.782 EXPRESSION AND TRANSCRIPTION OF HIV PROMOTER IN BACTERIA

Wood, Charles and Kambhosi, F.
 Department of Microbiology, University of Kansas, Lawrence, Kansas, 66045 U.S.A.

Objective: To study the expression and transactivation of HIV long terminal repeats (LTR) in a bacterial system.

Methods: A recombinant plasmid construct of the HIV-LTR linked to an indicator gene, chromosomal acetyl transferase (CAT), was transformed into *E. coli*. The expression and transactivation of the HIV promoter in the presence and absence of tat, was followed by assaying the level of CAT enzyme.

RESULTS: We have demonstrated that HIV-LTR can also function as a promoter in *E. coli*. The HIV-CAT plasmid can express the enzyme efficiently upon transformation into bacteria. The bacterial transcriptional start site was mapped by using base nuclease analysis. HIV-LTR, besides being fully functional in *E. coli*, can also be specifically transactivated by the HIV-tat gene product. Transactivation can be demonstrated by an increase in CAT enzyme activity as well as an increase in the level of CAT mRNA. **Conclusion:** This specific transactivation of HIV-LTR by tat protein in bacteria will provide a useful system to further investigate the specific interaction between the tat protein with the HIV-LTR and the mechanisms used for transactivation.

Publications


 Recherche fondamentale (biomédicale)
 Basic Research (Biomedical)

C.783 IMPORTANCE OF STRUCTURAL ELEMENTS OF HIV GP120 ON CD4-BINDING ABILITY
 Hoshino, Anna¹, Holmseth, A.¹, Flodby, P.¹, Lundberg, L.¹, and Oldeman, P.²
¹Department of Clinical Virology, University of Örebro, Örebro, ²Department of Immunology, Karolinska Institute, Stockholm, Sweden
 Biochemistry and Biophysics, Chalmers University Technology, Örebro, Sweden.

Abstract: The CD4-binding region of HIV gp120 has been mapped to a peptide stretch situated between aa 376 and aa 440. The aim of this study is to identify structures within this region, which are important for the ability of gp120 to bind to the CD4-receptor.

Analysis: Site-directed mutagenesis was used to introduce mutations within the CD4-binding region of gp120. Target structures were 1) cysteines, which are very conserved among HIV-1 isolates, hence indicating that they could be involved in disulfide bonds important for the three-dimensional conformation of the protein; 2) glycosylation sites, which surround the putative binding loop of gp120, thereby maybe protecting the binding region. Mutants were analysed in vitro by detecting a gp120 expression vector, containing the mutant gene, onto CW-1 cells. CD4-binding ability was examined in an *in vitro* assay.

Results: Changing cysteines to a serine resulted in a protein unable to bind to CD4-receptor in the *in vitro* assay. Moreover, the protein had an altered electrophoretic mobility probably due to structural changes in the protein. In conclusion, the ability to bind to CD4-receptor is dependent on the presence of cysteines and glycosylation sites. Cysteine mutation or its caused indirectly by protease.

Conclusions: Cysteines are important for the three-dimensional conformation and hence the biological function of gp120. Our results show that gp120, which has low glycosylation, is extremely sensitive to changes in its conformation, since mutating only two cysteines results in a protein susceptible to protease attack.

C.784 HUMAN IMMUNODEFICIENCY VIRUS (HIV) EXAMINED BY NEGATIVE STAINING: MORPHOLOGY AND ANTIGENICITY.
 Gattell, Ian¹, Barilak, Jane E., and Bartlett, J.S. Department of Virology, Dental Medical and Dental Schools of Guy's and St Thomas', St Vincent & Carsons, London, United Kingdom

negative staining EM has proved less rewarding than thin sectioning in the study of HIV morphology and antigenic structure. This may, in part, be due to the clinical need of HIV with the propagating cell making it difficult to obtain good preparations of isolated virus. However, when HIV-1 infected cells (CD 4-2/CD45) are gently homogenised in a Triton-bead-type classification homogeniser surface located virus is sheared off and can be concentrated by simple differential centrifugation. The particles so obtained are neatly clumped and very little internal morphology is visible. However the greater number of particles isolated make it possible to classify the immature virus particle which contains a spherical, detergent shaped core.

Optimal treatment of the semi-purified virus with a mixture of detergent (Sorbitol 140) and glutaraldehyde both releases and stabilises the 22' outer coat shaped component. Concentrations of both detergent and amount of antigenically reactive cores are available for immun EM. These HIV-2 cores react positively with their corresponding human antibodies giving rise to classical immune complexes. These complexes contain various aberrant forms of the cone shaped core ranging from a sheet like form to classical elongated rods. Their presence within the aggregates establishes that, antigenically, they are similar to, if not identical with, the standard cone shaped internal component. The isolated cores also reacted positively with a mouse monoclonal antibody directed against p16 (HIV-1) which reacts also with p16 (HIV-2).

C.785

C.786 FAILURE TO DETECT HIV-1 PROTEINS AND DNA IN
 ENTOZOAEMA HISTOLYTICA STRAINS ISOLATED FROM
 PATIENTS WITH HIV-1 INFECTION

Chr. C. Meyer¹, G.D. Burchard², F.T. Hufen², D. Berzow¹, H. Schmitz¹

¹Type of Virology, Bernhard-Noke-Institut für Tropische Medizin, Hamburg, F.R.G.

²Clinical Dept., Bernhard-Noke-Institut für Tropische Medizin, Hamburg, F.R.G.

Objective: To detect HIV proteins and proviral HIV DNA in Entamoeba histolytica strains isolated from patients with HIV-1 infection and from E. histolytica cultures fed with HIV-1 infected lymphoblasts. In order to characterize E. histolytica strains from HIV infected patients, it is important to know, whether these strains are HIV-1 positive. To answer this question, we characterized 3 E. histolytica strains isolated from 3 patients with HIV-1 infection and tried to detect E. histolytica cultures (DNA) by using three well known HIV-1 related lymphoblast (LH), human/lymphoblast antigenometry and the polymerase chain reaction for the detection of viral protein and proviral DNA were applied.

Methods: Isolated E. histolytica strains were cultured in TY296 medium, HEM-1 was cultured in TY293 medium.

Immunofluorescence microscopy was applied to detect viral antigenic material in the amoebae.

For the Polymerase Chain Reaction (PCR) DNA was extracted from blood cells and from E. histolytica, both

from HIV-1 infected patients. For the DNA amplification we used different regions of the HIV-1 genome for general detection (gap region: 8K 12, 8K 20/22) and virus region (8K 7a, 8K 8/9) according to the

primer and primer described by Ch et al. Amplification was performed within 30 cycles. DNA was demonstrated at 5'p C.

Results: By immunofluorescence microscopy viral proteins were not detectable neither in the isolated strains nor

in E. histolytica cultures, fed with HIV-1 infected LH cells after two weeks of cultivation. Applying the PCR, we could not find out, that all three primers were positive using the gap (8K 12) and the virus (8K 7a) gene fragments

as a target. However, no proviral DNA could be detected in DNA samples extracted from E. histolytica, isolated

from three patients in the interest E. histolytica cultures.

Conclusion: E. histolytica can be excluded from transmission routes of HIV-1 and occurs also as possible HIV

transmission by E. histolytica is not justified.

C.787

RELATIONSHIP OF OTHER INFECTIONS TO PROGRESSION OF DISEASE
IN HIV INFECTED MEN

Lesch, C., Jentink, Roger, Giorgi, J., English, P., and Cherry, J., University of California at Los Angeles (UCLA) Schools of Public Health and Medicine, Los Angeles, California, U.S.A.

To determine the relationship of other infections to changes in immune status and risk of AIDS, specimens for isolation attempts for CMV, HSV-2, adenovirus, *Streptococcus urealitidis*, and *Mycobacterium hominis* were collected 6 months apart in 222 HIV-1 antibody positive men participating in a cohort study of HIV-1 infection since 1984. Corresponding antibody titers to CMV (IgG and IgM), HSV-2, adenovirus, HSV, *Chlamydia*, HIV, and measles are being determined. At baseline, CMV was isolated from 63% of semen specimens, 5% of urine specimens, 5% of rectal swabs, and 5% of buffy coat cells. Isolation of CMV from semen at the baseline visit was associated with receptive anal intercourse, but not with isolations of HSV, *M. hominis*, U. urealitidis, HIV or adenovirus. The mean number of CD-4 cells and the mean CD-4/CD-8 ratio was significantly lower among HIV antibody positive men who shed CMV in their semen than in men who did not (p<0.005), but there was only a weak correlation between the titer of CMV virus in the semen and number of CD-4 cells. Semen excretion of CMV has persisted for six months in most men with positive cultures at baseline. Rates of isolation of HSV-2, adenovirus, U. urealitidis and *M. hominis* were low. Results of serologic and isolation studies at both visits will be presented in relation to other factors in these men. Implications of the association of low levels of CD-4 cells with isolations of CMV from semen will be discussed.

C.788



C.789

REGULATION OF REPLICATION OF HIV-1.
 Haselme, William. Dana-Farber Cancer Institute, Harvard
 Medical School, Boston, MA USA

Regulated growth of the Human Immune Deficiency Virus Type-1 (HIV-1) is the hallmark of infection with this virus. Prolific replication followed by a prolonged period of controlled replication followed once again by prolific replication is characteristic of most HIV-1 infections. The controlled aspect of the HIV-1 infection represents interactions between the virus and host immune system as well as viral regulatory genes which determine where, when and how much virus will be produced within a particular cell lineage. A systematic discussion of these interactions which occur at the level of control of synthesis and processing of messenger RNA, and of virion assembly and budding, and of the specific infectivity of the viral particle will be presented. Specifically the role of the *zif*, *zra*, *rat*, *rxr* and *raf* genes in the control of viral replication will be explored.

C.790

C.791

C.792

C.793

C.794



C.795


C.796



C.797

C.798

SECTION D



Le SIDA et l'individu
AIDS and the Individual

Séance thématique Specialty Session



Le SIDA et l'individu AIDS and the Individual

Les adolescents (partie 1) Adolescents (Part 1)

M.D.0.7

EPIDEMIOLOGY OF AIDS IN ADOLESCENTS, U.S.A.
Carli, Holmes, Reiser, P., Roper, M.
Centers for Disease Control (CDC), Atlanta, GA, USA

Objective. To describe the epidemiology of AIDS in adolescents in the United States.

Methods. We analyzed demographic features and transmission categories for adolescents (13-19) with AIDS reported to CDC.

Results. Adolescents aged 19 years or younger comprise 0.4% of the total reported AIDS cases; 50% of these cases have been diagnosed since 1986. Most of the adolescent AIDS cases (54%) were reported from 5 states and Puerto Rico and 74% from urban areas with populations greater than 1,000,000 inhabitants. Eighty-two percent of adolescents with AIDS are male and 51% are black or Hispanic. Overall, 54% of cases were attributed to sexual contact or intravenous (IV) drug use, 39% to exposure to blood or blood products and 4% to undetermined exposure. Heterosexual contact was the most frequent route of transmission for females. Accounting for 3% of cases, sexual contact or drug use accounted for 37% of cases for blacks and Hispanics and 40% for whites. The proportion of cases due to sexual contact or IV drug use increased from 10% for 13-14 year olds to 56% for 17-19 year olds.

Conclusions. Although adolescents comprise 1% of all AIDS cases, many adolescents may be at risk for HIV infection now and in the future. Our findings suggest that urban youth, particularly minorities may be at highest risk of exposure to HIV infection. Targeting interventions to adolescents with behaviors that place them at high risk of HIV infection is important. Helping all adolescents to develop safe sexual behaviors and avoiding drug use will have a major impact on the future of the AIDS epidemic.

M.D.0.9

THE SIGNIFICANCE OF THE AIDS PARADOX FOR HOMELESS ADOLESCENTS
Lynch, S., Galanter, Brown, N.C. and Rosenbaum, R.
*University of California, San Francisco, California, USA
**Hospital Universitário Pedro Ernesto, Rio de Janeiro, Brazil

Objective. This paper reviews social epidemiological research on AIDS related attitudes, beliefs, and behaviors among street youth in the Western United States and in Rio de Janeiro, Brazil. This discussion will focus on the risk of HIV infection among street youth in developing countries, within the context of the larger world problem.

Methods. Ethnography and participant observation, structured and unstructured interviews with street youth and service providers in natural and institutional settings in Los Angeles, San Francisco, Seattle and Rio de Janeiro.

Results. While the majority of youth in the United States live above or with their families, Brazilian youth leave their homes because of extreme poverty and familial misery to make what living they can on the streets. Many through prostitution. Street youth in Rio, especially those from the slum areas of favelas, lack the long history of health education in schools, the community, and the media as compared to the United States. They are at risk for HIV infection because of their perception that AIDS is only a homosexual disease, concurrent exposure and discomfort they associate with condom use, and subsequent unprotected sexual activity. Bilingual activity and small intercourses are common among both heterosexual and homosexual street adolescents in Brazil, while cultural beliefs would dictate otherwise.

Conclusions. International collaboration and emergency economic support can assist greatly in the development of education material and outreach to prevent HIV among the growing number of street youth in the developing world.

M.D.0.11

Sex, Drugs and AIDS: Two Innovative Approaches to HIV/AIDS Prevention and Outreach for Minority Adolescents.
Troiano, Adelman*, Ball, J.V.**

*Newark Department of Health, Newark, N.J., USA; **NYC Health and Hospitals Corp., New York, NY & Greater Brooklyn Youth Council, Inc., Brooklyn, NY, USA.

Objective. To provide HIV/AIDS educational and outreach services to minority adolescents and to evaluate the effectiveness of these services and the beliefs concerning sex, drugs and HIV/AIDS through two innovative programs in Newark, New Jersey and Brooklyn, New York.

Methods. The Newark Department of Health program has four components. Three directly involve adolescents which are: (1) a original "Rap Off" contest on sex, drugs and AIDS; (2) a "Street Theater" program in which a professional production company will perform a teen theatre company which will perform an original scripted production on sex, drugs and AIDS for teens; and (3) peer counseling will be provided for adolescents. The fourth component, a professional video production will document the prior 3 components. The Brooklyn-Brownsville program trains 10 peer educators in sexuality, substance abuse, HIV/AIDS information and risk reduction strategies, and improvisational theatre techniques. Peer educators present role plays and skits on sex, drugs and HIV/AIDS to youth groups, organizations, community centers and parent associations. KANB surveys are distributed by both groups.

Results. Initial results indicate that minority adolescents (1) are concerned about their risks of HIV/AIDS; (2) have some AIDS specific knowledge but also have misconceptions and (3) want to help educate their peers regarding HIV/AIDS. Culturally sensitive and relevant HIV/AIDS information for minority adolescents must use innovative approaches to educate them on risks.

M.D.0.8

ADOLESCENTS AT RISK OF HIV INFECTION

Radford, Jagan*, Warren, V.P.* and King, A.*

*Queen's University, Kingston, Ontario, Canada.

Objective. To describe the AIDS-related knowledge and attitudes, and the risk-taking behaviours, of youth who had dropped out of school and lived on the streets of large Canadian cities.

Methods. Over 1,000 "dropouts" and over 700 "street youth" across Canada were interviewed by telephone and face-to-face, respectively. The data were analysed to assess the extent to which they were at risk of HIV infection.

Results. Many of these young people were knowledgeable, yet anxious, about AIDS, intolerance of homosexuality, sexually repressed and highly active sexually, and some of them were using illicit drugs.

Conclusions. The high incidence of unprotected sexual intercourse with numerous partners and the sharing of injection-drug needles indicate that these young people are at risk of HIV infection. Persuading them to abandon behaviours that are integral to their lifestyles will be difficult, but must be attempted.

M.D.0.10

INFECTION WITH HIV AND HIV IN ADOLESCENTS LOGGED IN SECURITY INSTITUTES OF BRASIL
Ribeiro, L.C., Cruz, A. & Almeida, M.C.

*Hospital de Ginecologia, São Paulo, São Paulo, Brazil
**National Directorate for the Promotion of Youth and Family, *Ministério Federal de Administração, **Departamento de Microbiologia, School of Medicine, Saõ Paulo, Saõ Paulo, Brazil.

Objective. To determine the prevalence of infection with HIV and HIV in adolescents lodged in Security Institutes and relate it to different risk factors.

Methods. The sera of all adolescents lodged in 3 national Institutes of Saõ Paulo from October 1987 to July 1988 were studied. In every case there was previous consent of the adolescent, as well as from the entity which legally protects them, to detect anti-HIV and HIV antibodies and to fill in the questionnaire about the risk factors. Anti-HIV and HIV antibodies were studied by ELISA method, anti-HIV were confirmed by Western blot.

Results. 158 adolescents (64 females and 94 males) whose ages ranged between 13 and 20 years were studied. 26.6% were positive for HIV and 26.6% for IgG. When 100% of both cases 13% were HIV positive and 52.9% non-HIV positive while there was a prevalence of 2.3% for HIV and 10.2% for HIV among non-adolescents or non-internation students. Of all the adolescents studied, 14 stated they were non-adolescents of which one was HIV positive and 2.9% positive.

	Number	HIV+	HIV-	Total
IVA	71	39/71 (55%)	32/71 (45%)	71
Non-adolescent or non-IVA	86	2/86 (2.3%)	84/86 (97.7%)	86
TOTAL	158	40/158 (25.4%)	118/158 (74.6%)	158

Conclusion. HIV antibodies were detected in 1/6 and HIV in 1/3 of the adolescent population in Security Institutes. Of the total population 40% used TDAM and this was, by far, the main risk factor found for infection with HIV and HBV.

M.D.0.12

THE DEVELOPMENT OF A STREET BASED OUTREACH PROGRAMME TO REACH YOUTH MALE, FEMALE AND TRANSGENDER, STREET BASED PROSTITUTES IN SYDNEY, AUSTRALIA

Crane, S., Toomey, M., Allen, S., Gold, J., Tarbit, P., Ryan, P., Reddy, P., et al.

Albion Street (AUS), New South Wales, Sydney Australia

Objective. (a) To ascertain the prevalence of HIV infection within a group of street based male, female and transsexual prostitutes; and (b) To develop an intervention programme to minimise transmission of HIV by this group. **Methods.** In November 1985 a mobile outreach bus program was established to provide HIV screening, counselling, education and the provision of free condoms, needles and syringes to street based prostitutes. The programme operates 365 nights a year, early evenings to early mornings in the streets of Sydney's "Red Light" districts. The outreach service is staffed by nurses and counsellors. **Results.** As at December 1988, 213 clients had been screened for HIV. 19 were HIV antibody positive (15 male prostitutes, 1 female prostitute, 3 transsexual prostitutes). 187 had used IV drug, 155 were current users, 17 were HIV antibody positive. Five clients re-screened during the 3 year period. An average of 2,000 condoms and 1,500 needles/syringes are given out per week. This paper will discuss the risk factors associated with the client group and highlight educational issues raised by the seroconversions. **Conclusions.** A street based outreach program is an effective way of minimizing transmission and providing client support who are otherwise disfranchised from existing health services due to, illiteracy, low socio-economic grouping and general alienation from established health services.

Colloque Symposium



Le SIDA et l'individu AIDS and the Individual

Détenus : contraintes et défis Prisoners: Constraints and Challenges

T.D.O.1 RAY IN PRISON - A TEST CASE FOR HUMAN RIGHTS
T. Harding
University Institute of Legal Medicine, Geneva,
Switzerland.

The AIDS epidemic has revealed grave deficiencies in prison health care. Prisoners are a vulnerable group, subject to an authoritarian regime and with little public sympathy. In over half the countries surveyed in a European study, inappropriate management of HIV-infected prisoners was described as routine: segregation, limited access to work places, lack of confidentiality. Compulsory screening of prisoners is also carried out in many countries, and results are frequently communicated to prison administrations without the prisoner's consent or knowledge.

Prisoners have a right to preventive and curative health care on the same level as in the community.

All prisoners should (i) receive adequate information on HIV/AIDS, (ii) be free to request or refuse HIV-testing, after counselling.

(iii) benefit from pre-release education and guidance.

HIV carriers should (i) receive appropriate psychosocial support, (ii) be housed and treated as other prisoners, (iii) benefit from normal parole procedures.

Prisoners with AIDS should (i) receive adequate care, (ii) be considered for early release, (iii) be allowed to die in dignity.

The degree to which prisoners' human rights are respected will demonstrate the authenticity of governmental commitment to human rights promotion in AIDS-related activities.

T.D.O.3 AIDS AND INTRAVENOUS DRUG USERS: THE CHALLENGE FOR THE JAIL ADMINISTRATOR
THOMAS, STEVEN G., DEPARTMENT OF CORRECTION
NEW YORK, NEW YORK

An administrator of a correctional system is confronted with a difficult challenge to provide appropriate AIDS prevention and treatment services to a large number of inmates with a history of IV drug abuse, without compromising the operation of a secure correctional setting.

One 6th of New York City's jail population abuses illicit drugs and/or alcohol regularly, and about 30% of them have used drugs intravenously. Given these extraordinary rates of drug abuse and addiction, an estimated 20% of the inmates are infected with HIV.

The New York City Department of Correction has implemented an extensive range of AIDS and drug prevention and treatment services, which reflects a willingness to respond to this epidemic in a creative and flexible manner. The use of illicit drugs in the jails is prohibited and strict enforcement measures are used to ensure compliance by both staff and inmates. In addition, the Department offers methadone detoxification and methadone maintenance programs for opiate addicts and an array of intervention programs (including acupuncture) for crack/cocaine abusers.

Although significant, the services for intravenous drug users provided by the New York City Correctional system are only as effective as the long-term treatment and other services available in the community. More inmates leave jail and return to the same high-risk activities because no alternative treatment and other preventive services are available.

T.D.O.5

APPROACHES TO THE SEROPOSITIVE PRISONER
Lester, Elizabeth, Medical Director, San Francisco County Jails; University of California, San Francisco, USA

OBJECTIVE To review current practices in the identification and management of seropositive prisoners. To suggest a rational, safe and humane approach.

METHODS A review of current policies in United States correctional facilities of screening and testing inmates for HIV antibody will be undertaken with reference to National Institute of Justice and American Civil Liberties Union surveys. Policies and procedures for special management of identified seropositive prisoners will be reviewed, with the National Institute for the study of segregation. A review of the San Francisco jail policy and procedures will be presented.

RESULTS In the prison environment, limited resources tend to be directed either towards procedures of testing and serological testing, or towards education and counselling. Variables for policies of segregation are frequently correctional rather than medical. Proper correctional classification and supervision of prisoners are essential for a safe prison environment.

CONCLUSIONS The essential information which AIDS education programs impart. HIV infection may be prevented by safe behavior, HIV is not causally transmitted, are contradicted by policies of segregation. Policies should be based upon medical rather than correctional reasoning.

T.D.O.2 RISK BEHAVIOUR IN PRISON: SEXUAL ACTIVITY MEASURED IN PRISON
Crawley, Bruno, Service Médico-psychologique
régional, Lyon (FRANCE), FRANCE.

T.D.O.4 CONSTRAINTS ON IMPLEMENTATION OF PREVENTIVE MEASURES IN PRISON

Bray, P. J., Deputy Director of Prison Medical Services,
England and Wales, Home Office, London.

The factors which influence AIDS prevention strategies for prison systems, and how they are implemented, will be discussed by reference to experience in England and Wales.

The environment.

The population.

Attitudes of prisoners (uninfected and infected) to AIDS/HIV.

Attitudes of staff.

Attitudes and preoccupations of management.

Limits to confidentiality.

Credibility of information and education.

The law and the prison discipline code.

The closed single sex institution.

**Séance thématique
Specialty Session**



**La SIDA et l'individu
AIDS and the Individual**

Recherches sur le comportement (partie 2)

Behavioural Research (Part 2)

T.D.O.6 RECEIVED NEED FOR BEHAVIORAL CHANGE: DETERMINING BARRIER CONCEPTS AT RISK OF HIV INFECTION BY A LONGITUDINAL COHORT OF GAY AND BISEXUAL MEN. **John D. Coates, Richard B. St. O'Neill, Ph.D., James P. B. Rowe, Ph.D., James Coates, Ph.D., Centers for Disease Control, Atlanta, GA., USA.**

Objective: In a longitudinal cohort study of gay and bisexual men, to assess the relationship of perceived need for behavioral change with knowledge, attitudes and beliefs (KAB), and with actual modifications of high-risk sexual behavior.
Methods: A questionnaire assessing HIV risk behavior and KAB was administered to study participants at initial visit and six month intervals. From December 1986 through December 1988, 700 men were enrolled, of whom 226 had returned for at least 3 visits. Subjects were grouped according to their perceived need for change at each of 3 time points, and those falling in the extreme categories (those most to change [MC] versus as need to change [NC]) were selected for analysis. Between group comparisons were made regarding risk-related behaviors and discriminant function analysis was used to determine the discriminating KAB characteristics of each group.
Results: The MC group had 2.7 times as many sexual partners at each time point (p<0.001) and used condom less frequently than did the NC group (p<0.001). Discriminant analysis of KAB successfully classified 80% of subjects into the MC or NC groups. Factors which discriminated MC from NC included lack of perceived validity of education from local gay organizations, difficulty seeing one's need, absence of assertiveness and communication regarding safe sex practices, concern over drug/alcohol use, and need for condom during anal intercourse.
Conclusions: Gay men are able to correctly assess personal risk of HIV infection and it is possible to predict those who need to change their high-risk behavior by assessment of KAB systems. Specific behavioral interventions targeting motivation, communication skills, and coping should address issues that predispose to high-risk sexual behaviors.

T.D.O.8 RISKY SEX RELAPSE: THE NEXT CHALLENGE FOR AIDS PREVENTION PROGRAMS: THE AIDS BEHAVIORAL RESEARCH PROJECT
Estimation: J.J. Gelles, L.J. and McQuaid, L., Center for AIDS Prevention Studies, San Francisco, CA., U.S.A.

Objective: Research on other health-related behaviors such as smoking, drinking and weight loss has shown that initial health behavior change is often followed by relapse. This study was designed to examine the stability of individual behavior change following initial adoption of safe sex as well as psychosocial predictors of relapse.
Method: A sample of 483 gay and bisexual men was followed annually from 1984 to 1987. High risk sex was defined as unprotected anal intercourse with multiple partners. Predictor variables included social support, personal efficacy, sexual self control, knowledge of health guidelines, and openness about one's sexual orientation. These were examined in a multiple logistic regression comparing subjects who relapsed to those who were able to maintain low risk behaviors over time following initial behavior change.
Results: The individual behaviors over time were grouped into the following behavior patterns:

BEHAVIOR PATTERN	PERCENT
Stable low risk throughout the study	50.8%
Changed to and maintained low risk behaviors	29.8%
Relapsed after initial behavior change	19.7%
Stable high risk throughout the study	9.8%

Subjects who relapsed reported lower levels of self efficacy and less social support for safe sex behaviors than did subjects who were able to maintain safe sex behaviors.
Conclusion: It is clear from these data that future AIDS prevention programs need to include relapse prevention components to increase the likelihood that behavior change will be maintained over time. The predictor analysis suggests that it may be beneficial to address social support and self efficacy issues in these interventions.

T.D.O.10 TENSION REDUCTION EXPECTANCIES UNDERLIE THE EFFECT OF ALCOHOL USE ON AIDS-RISK BEHAVIOR AMONG BISEXUAL MALES
Estimation: David L. Reardon, Ph.D., *University of Illinois at Chicago, **University of Alabama at Birmingham, USA

Objective: Alcohol use is associated with AIDS-risk sexual behavior. Also, but "disinhibiting" in the sense underlying this association, but has not been well defined. We found tension reduction expectancies of alcohol effects to be related to risk for substance abuse and sexual risk. We hypothesized that such expectancies would also underlie the sexually disinhibiting effects of alcohol. Our objective was thus to assess the co-occurrence of alcohol and high risk sex, and to examine the role of such expectancies in mediating this relationship.
Methods: A large (n=2600) diverse sample of homosexual men were given an anonymous survey regarding alcohol use, sexual behavior, and psychosocial variables. This was accompanied by a smaller (n=67) in-depth interviewee sample.
Results & Conclusions: 54% of respondents reported some unsafe sex. A majority of these respondents reported alcohol disinhibition, an incident that was independent of "passion" or other factors. Alcohol problems, intoxication rates, alcohol use in sexual contexts, and tension reduction expectancies consistently predicted number of sexual partners and unsafe sexual practices. Tension reduction expectancies were strongly related to alcohol use in sexual contexts, with either habitual or new partners. Finally, alcohol use variables were consistently associated with expectancies in predicting unsafe sex, consistent with the hypothesis. These findings suggest a mechanism of alcohol disinhibition, and an avenue for prevention or intervention.

T.D.O.7 SITUATIONAL FACTORS ASSOCIATED WITH AND RATIONALIZATIONS EMPLOYED TO JUSTIFY UNPROTECTED INTERCOURSE IN GAY MEN
Gold, R., Skinner, M., Grant, D., and Plummer, D.
*Cairns University, Victoria, Australia, **Victoria AIDS Council, Melbourne, Victoria, Australia, ***Monash University, Melbourne, Victoria, Australia**

Objective: Investigate (a) the situational variables that distinguish between sexual encounters in which gay men (n) engaged in (1) abstinent from, unprotected anal intercourse; and (2) the rationalizations these men employ at the time to justify unprotected intercourse.
Methods: Gay men were asked to recall two sexual encounters in the past year one in which they had unprotected intercourse ("unsafe encounter" or UE) and one in which they remained a strong desire to do so the "safe encounter" or SE). For each encounter the respondent was asked when it took place and with whom. Each encounter was then divided into (a) when the "evening" (or morning) etc began; (b) when the respondent met his partner; (c) at the start of sex; (d) during sex. For each of these, the respondent was asked about location, his feelings, alcohol and drug consumption, and whether the question of safe sex was raised. For UE the respondent also identified any rationalizations he used for unprotected intercourse.
Results: Key findings were: (a) For respondents who described both SE and UE (n = 181) the latter was more likely with a lover, the former with a casual partner. (b) With the difference controlled for (100), factors which distinguished UE from SE were in UE there was a greater desire for unprotected sex from the start of the evening, greater feeling of being alert and relaxed by reflex and desiring excitement, greater physical attraction and less communication about safe sex. Consumption of alcohol and drugs did not distinguish UE from SE. (c) Respondents reporting UE (n = 139) employed only risk rationalizations, the most common being the thought that intercourse would take place without ejaculation.
Conclusion: The findings can be used to inform AIDS education strategies.

T.D.O.9 PSYCHOLOGICAL STATUS AND RISK BEHAVIOR IN MEN SEEKING HIV TESTING
Psychologist: Fishman, R.; Perry, S.; Jacobson, B.L. and Ryan, J., Cornell University Medical College, New York, NY, USA

Objective: To examine the hypothesized relationships between HIV risk behavior, psychological variables and effects of HIV testing.
Methods: 154 psychologically asymptomatic gay men voluntarily sought HIV testing and were evaluated with clinical ratings of psychiatric diagnosis (SCID-R), and self-report measures of risk behavior, hardiness, social support, attributional style and distress (Beck Depression, Brief Symptom, and Spillanberg Inventory Inventories). Risk behavior and distress measures were reported 9 weeks after notification and counseling.
Results: 132 subjects (86%) reported no unprotected Anal Sex (UAS) in the 3 week period to HIV testing; of 79 subjects seen 9 weeks later (28 HIV+), 75 continued to abstain from UAS. 23 subjects (14%) engaged in UAS in the month prior to testing; of 11 subjects seen 9 weeks later (27 HIV+), all had abstained from UAS in the past month. Psychological variables and serological status did not distinguish the two behavior groups at either measurement point.
Conclusions: Most participants ceased high risk behavior at least one month prior to HIV testing. This "floor effect" impeded determining the relation between risk behaviors, psychological variables, and effects of HIV testing and counseling. This study documents the need for prospective studies to determine if risk reduction surrounding HIV testing is sustained over time, and low psychological factors and known HIV status predict possible relapse.

T.D.O.11 HIV RISK BEHAVIOR SCREENING: CONCURRENCE BETWEEN ASSESSMENTS THROUGH INTERVIEWS AND QUESTIONNAIRES
Estimation: Roger Levy, James H. Stewart, Ph.D., Centers for Disease Control, Atlanta, Georgia, USA

Objective: To determine level of agreement between assessments by self-administered questionnaire and face-to-face interview, of HIV risk behaviors in two groups and individuals.
Methods: A sample of 336 women attending a family planning clinic responded to the same questions through a self-administered questionnaire and a face-to-face interview, for each HIV interview coded reasons for discrepancies between the two responses were recorded.
Results: 1. Prevalence of HIV risk behaviors in the group, as determined by the two methods were remarkably similar; the maximum difference between the two estimates for any risk behavior was 1.3 percentage points, for the proportion of individuals reporting more than 3 partners in the last 10 years. 2. Individuals' risk behaviors were assessed with less agreement between the two methods; 15 women (4%) reported risk behaviors on the questionnaire which they denied during the interview; 6 women (2%) did the reverse. Also, twice as many women (8%) reported greater numbers of sex partners during the interview compared to those who reported greater numbers on the questionnaire (4%). 3. Discrepancies between assessments did not differ by demographic characteristics.
Conclusions: Prevalence of HIV risk behaviors in a group are similarly assessed by self-administered questionnaires and face-to-face interviews. However, these two methods can yield highly discrepant findings in assessments of individuals' risk behaviors.

Séance thématique Specialty Session



Le SIDA et l'individu AIDS and the individual

Minorités Minorities

T.D.O.12 IDENTIFICATION, RECRUITMENT AND RETENTION OF BLACK AND LATIN COMMUNITY LEADERS IN AIDS PREVENTION RESEARCH

Monica Edwards and Fulvia, Review: Hunter's Point Foundation and Center for AIDS Prevention Studies, University of California-San Francisco, CA, USA.

Multicultural Inquiry and Research on AIDS, Bayview Hunter's Point Foundation and Center for AIDS Prevention Studies, University of California-San Francisco, CA, USA. **Objectives: This presentation examines the issues related to identification, recruitment and retention of Black and Latin community leaders in a research effort designed to evaluate the impact of AIDS education on the AIDS-related activity level of these leaders.

Methods: A list of Black and Latin community leaders in San Francisco was compiled consisting of elected officials, directors and administrators, appointed officials, clergy, and persons who were acknowledged as community leaders by two or more persons of the other categories. Subjects were contacted by letter with a follow-up telephone call to solicit participation. Reasons for not participating were recorded. Those agreeing to participate were randomly assigned to one of two conditions, a four session workshop on AIDS in their respective communities (Black or Latin) or receiving an AIDS information manual. **Results:** Of the 168 leaders identified, 84 (50%) agreed to participate; of those 46 (57%) formally entered the trial, of whom 22 were Black and 24 were Latin. Reasons for non-participation were examined and included: reluctance to be involved with an AIDS activity, "burnout" from AIDS work, has against people with AIDS and reluctance to commit time to the research activity.

Conclusions: While it is widely agreed that increased involvement of Black and Latin community leaders would improve prevention and education activities, this study identified major obstacles to their involvement. Minority community leaders may not see AIDS as a pressing issue and may have biases against people with AIDS. These attitudes require recognition in developing AIDS prevention activities.

T.D.O.14 INVOLVEMENT OF NATIVE HEALTH-CARE PROVIDERS IN DEVELOPING AIDS PREVENTION STRATEGIES FOR NATIVE PEOPLES

Morgan, J., Rekart, M.,* Harris, D.***

*Division of STD Control, British Columbia, Vancouver, British Columbia, **Vancouver Indian Centre Society, Vancouver, British Columbia, Canada

Objective: To develop an AIDS prevention strategy for Native population of the Province of British Columbia.

Methods: A representative Planning Group of Native health-care and human services providers from around the province was convened to develop a proposal for an effective AIDS program for the Native community. A "non-political" approach was taken in choosing Native providers rather than Native policy-makers to develop the program. A strategy was developed through meetings of the Planning Group. Funding, logistical and advisory support was provided by the provincial and federal governments.

Results: Consensus was reached on several general principles to be established as a basis for the strategy. The program would be 1) Native developed, implemented and owned, 2) designed to reach all Natives irrespective of status or place of residence, 3) generic in graphic design while remaining recognizably Native, 4) focused on AIDS while also addressing other forms of social malaise in the Native community and, 5) followed by a sustained AIDS prevention resource. Based on these guidelines a proposal was developed that included videos, posters and pamphlets, community presentations and workshops, and a large conference. **Conclusions:** Giving the task to health-care providers from the Native community is an effective way to develop AIDS prevention strategy for the Native population.

T.D.O.16 REACH OUTREACH PROGRAMS TO AIDS

Dillon, E.J., Barr, Dr. G.**, Perreault, Y.***

Ontario Association of the Deaf, Toronto, Ontario, Canada, *Canadian Hearing Society, Toronto, Ontario, Canada

***AIDS Committee of Toronto, Toronto, Ontario, Canada

Objective: To describe the formation and development of a joint project on AIDS and Deafness established to enable the deaf community to access AIDS information.

Methods: Information gathered during the initial phase of the project revealed: 1) 18,000 profoundly deaf persons in Toronto whose primary language is American Sign Language generally have limited English skills, usually below grade 4 level. Thus, current AIDS materials are inaccessible. 2) AIDS information is passed socially from 1 deaf person to another rather than through mass media. Misconceptions are spread quickly and are extremely difficult to challenge without direct access to deaf social networks. 3) Models of community development used by most AIDS organizations are not appropriate for the deaf community. Evaluation with key deaf leaders led to the restructuring of the project design.

Results: The service delivery model developed is congruent with the structure and needs of the deaf community and utilizes a cross-cultural approach of mediation, advocacy and culture-brokering. 14 deaf men and women from a variety of social groups (deaf gay networks, sports groups, clubs and informal groups based on ethnicity, communication modality and educational background) are trained as paid consultants to provide actual services.

Conclusions: Consistent liaison between the deaf community is critical to the development of a culturally-relevant, cost-effective and efficient AIDS and Deafness Program.

T.D.O.13 AMERICAN INDIANS/ALASKA NATIVES: ARE THEY AT HIGHER RISK OF HIV INFECTION?

Hewitt, Ronald M., Tafaya, T., Beaulieu, L., Green Rush, A. National Native American AIDS Prevention Center, Oakland, CA, USA

Objective: To highlight the risk factors which make American Indians and Alaska Natives particularly vulnerable to HIV infection.

Method: The National Native American AIDS Prevention Center has gathered secondary data from the U.S. Centers for Disease Control on rates of primary and secondary syphilis and gonorrhea and conducted knowledge, attitudes and behavior surveys of Native people in substance abuse programs at national pop-over and other venues; and conducted structured interviews concerning sexual behavior among Native Americans and of Native American people with AIDS.

Results: Sexually transmitted diseases rates are from 2 to 10 times higher for Native Americans in some geographical areas than for the non-Indian population as a whole. Interviews with substance abuse providers, tribal officials and youth indicate a growing but unmeasured problem with intravenous drug use. Although comprehensive sexual behavior research has not yet been done, preliminary findings indicate a higher rate of biennially than among any other American ethnic group.

Conclusions: American Indians/Alaska Natives are at high risk for infection.

T.D.O.15 A VIDEO AIDS PREVENTION TRAINING PROGRAM FOR PEOPLE WHO ARE MENTALLY RETARDED/DEVELOPMENTALLY DISABLED

Samowitz, P., Levy, P., Ph.D., Levy, J., Jacobs, Raymond, Young Adult Institute, New York, N.Y., U.S.A.

Objective: To teach adults who are mentally retarded/developmentally disabled (MR/DD) to better protect themselves from AIDS through the practice of safer sex.

Methods: A video training program with a staff training manual was developed by the Young Adult Institute to change sexual behaviors for people who require a multi-sensory mode of learning due to their impaired learning abilities. Participants who functioned in the mild and moderate range of MR were taught in small groups: 1.What AIDS is; 2.How it is sexually transmitted; 3.How to put on and take off a condom; 4.How to negotiate safer sex when pressured to have unsafe sex.

Results: The video training program was presented to 113 of our clients in small groups. Staff conducted a survey 2 months after their clients were educated, which revealed that 82% of our clients in the mild range of MR retained crucial information taught in the session. Additionally, before the training, our clients were not using condoms. Subsequently, 52% of those clients who are sexually active asked for condoms now being supplied in the program.

Conclusion: This study indicates that people with MR/DD do need protection from AIDS and can learn through education specifically designed for their learning needs.

T.D.O.17 AN AIDS EDUCATION PROGRAM FOR BLACK AND LATINA WOMEN

Fleisher, Jacquelyn M., Rymaszak, M. University of California, Los Angeles, CA, United States

Objective: To test the effects of an AIDS education & prevention program on the knowledge, attitudes & practices of low income Black & Latina women. **Method:** The study used a pretest-posttest nonequivalent control group design with a 2-3 month stretch of the experimental group. The sample consisted of 256 control Black women & 105 control Black women & 101 control Latina women who were clients of the Public Health Foundation Nutrition Program for Women, Infants & Children in Los Angeles. The program consisted of a slide-tape presentation, educational and resource brochures, knowledge, attitudes, sexual & drug use practices were measured using a structured pretest, posttest & retreat that was developed in both English & Spanish languages. Content validity of the questionnaire was established & it was pilot tested on each group. Reliability was determined using Cronbach's alpha.

Results: Using a 2-way repeated measures ANOVA, there were significant differences in pretest-posttest knowledge, attitudes & practices for both racial/ethnic experimental groups that were retained on retreat. Control groups did not show significant pretest-posttest differences. Blacks & Latinas differed on pretest knowledge & attitudes but not practices. Blacks had more knowledge & positive attitudes on pretest. The posttest improvements for both knowledge & attitudes were greater in Latinas than in Blacks. Multiple regression analysis revealed the best predictors of knowledge, positive attitudes & practices.

Conclusions: A didactic audio-visual program can positively affect the knowledge, attitudes & practices of participants that are retained over time.

**Science thématique
Specialty Session**



**Le SIDA et l'individu
AIDS and the Individual**

**Psychologie et sexologie
Psychology and Sexology**

T.D.O.18 THE WORRIED WELL: IDENTIFICATION BY SIMPLE CHECKLIST
Hedge, Barbara¹; Acton, T.²; Miller, D.³ et al.,**
¹St. Mary's Hospital, London, England, ²Westfield Hospital
London, England.

OBJECTIVE: The "Worried Well", who misattribute somatic symptoms to HIV infection despite repeated negative clinical and serological investigations, can benefit more from appropriate coping/life-behaviour intervention than from further medical investigations and reassurance. The development of a checklist to aid identification of the "Worried Well" for alternative intervention is described.

METHODS: Patients presenting to a gynaecology/primary care clinic seeking counselling with respect to anxiety about having contracted HIV infection were scored on items relating to presenting symptoms, style of presentation and psychosocial history. Differences between those accepting the negative results of clinical and serological investigations and those continuing to believe they are infected were examined. A checklist based on these differences was constructed and its ability to predict the "Worried Well" assessed using a further sample of forty similar patients.

RESULTS: The "Worried Well" group was characterized by a number of items, particularly presentation of symptoms and psychosocial history. The checklist developed using these items demonstrated a high predictive ability, high test-retest reliability and good inter-rater reliability.
CONCLUSION: It is possible to identify the "Worried Well" accurately and reliably using a simple checklist. The potential usefulness of early identification is discussed.

T.D.O.20 MODIFICATIONS OF SEXUAL BEHAVIOUR DUE TO AIDS IN
MIDDLE-CLASS HOMOSEXUAL "AT-RISK" POPULATION

Mouton, Jean-Paul (1), Favre, J. (2), Bajou, N. (3), Méraud, C. (2),
Sérand, C. (2).
(1) INSERM Unit #240, Paris, France. (2) French Committee for Health Education (CFES)-
(3) INSERM Unit #31, Marseille, France.

A survey has been carried out in France by CFES in a national sample (n = 1 000, Sept. 1988) of "sexual outpatients": identification of individuals recognizing a priori that they had more than one sexual partner during the last six months was done using a random walk procedure; a questionnaire was then administered to those on their personal interview.

45.9 % of the sample declared use of condoms (10.3 % declaring systematic use); 38.7 % of users were new users of the last six months, mainly motivated by fear of Aids; 33.5 % of sexual outpatients declared that they made some change of sexual behaviour because of Aids but 41.7 % of these only quoted "being more careful in choice of partners" without any condom use. Condom use was significantly more frequent for men (53.3 %) than women (41.6 %) (p < 0.01), and for individuals under 35 years of age.

Multivariate analysis (using logistic regression model) shows that the following factors are the main predictors of condom use in this population: High school level of education [OR = 1.32 - 95% IC = 1.03 - 1.74], being single [OR = 1.42 - 95% IC = 1.10 - 1.83], and [OR for women = 0.64 - 95% IC = 0.49 - 0.83], knowing HIV carrier in personal relations [OR = 2.04 - IC = 1.55 - 2.69], having voluntarily undergone a HIV test [OR = 2.91 - 95% IC = 1.90 - 4.44].

Although interpretation of results is limited by the absence of data on the real degree of exposure to sexual transmission of HIV in such French population of sexual outpatients, conclusions will be drawn for information campaigns about condoms and screening policies.

T.D.O.22 HIV-POSITIVE GAY MEN: SEXUAL DYSFUNCTIONS
Meyer-Rabuhny, Helmo F.L., Berberet, A.A., Gorman, J.M.,
and Goldstein, M., New York, N.Y., USA.

HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute and Columbia University, New York, N.Y., USA.
Objective: To evaluate HIV positive men for sexual functioning expected to be impaired because of the emotional, systemic, and/or neurological effects of HIV disease.

Methods: 120 HIV-positive gay men with no or few symptoms and 80 HIV-negative gay men (all mostly white, middle class, age range 18-59 years) underwent a detailed semi-structured interview, the Sexual Risk Behavior Assessment Schedule (SRBAS-A-RBM-1), Meyer-Rabuhny et al., 1988).

Results: Preliminary analyses show high interindividual variability in frequency and practices of sexual behavior. Two-fifths of the men reported distasteful sexual activities, more than half some degree of negative feelings during sex, and about one-third some degree of sexual erection. As to classical sexual dysfunctions as listed in DSM-III-R, about one-fifth of the men reported the presence of hyposexual sexual desire, two-fifths some degree of erectile failure, one-half some degree of retarded orgasm, one-fifth some degree of premature orgasm, and one-quarter other sexual dysfunctions.

Conclusions: The prevalence of sexual dysfunctions among HIV-positive gay men with no or few symptoms of HIV disease appears to be relatively high.

T.D.D.19

SOCIAL SUPPORT, HIV SYMPTOMS AND DEPRESSION AMONG GAY MEN
Black, Robert; Turner, H.; Cassano, J.; Mandel, J.; and Coates, T.
Center for AIDS Prevention Studies, University of California, San Francisco, California, USA.

Objective: To examine the impact of objective HIV status, knowledge of HIV status and AIDS-related symptomatology on depression among a community sample of gay men and identify which of three types of social support (emotional, informational, practical) most effectively buffered that depression.

Methods: Longitudinal questionnaire data come from 455 gay and bisexual men who participated in 1986 and 1987 waves of the San Francisco Men's Health Study, a population-based sample drawn from the census tracts with the highest AIDS incidence in 1984.

Results: The number of AIDS-related symptoms experienced significantly predicted depression cross-sectionally ($r = .25$) and one year later ($r = .17$). Objective HIV status and knowledge of one's status were not significantly associated with depression. The three types of social support were not significantly associated with depression. The three types of social support were not significantly associated with depression. The three types of social support were not significantly associated with depression. The three types of social support were not significantly associated with depression.

Conclusions: Gay men are at higher risk for depression when they begin to experience AIDS-related symptoms. While all types of social support are associated with reduced depression, informational support may be especially beneficial for those in early stages of disease progression.

T.D.O.21 THE PREVALENCE OF AIDS-RISK RELATED SEXUAL BEHAVIORS AMONG
WHITE, MIDDLE-CLASS, URBAN AMERICAN ADULTS: A SURVEY OF
RESEARCH FROM KANSAS TO THE PRESENT

J.M. Reinisch, Stephen A. Sanders, and M. Zimba Davis
The Kinsey Institute for Research in Sex, Gender, and Reproduction, Indiana University, Bloomington, IN USA

Objective: To provide a comprehensive view of sexual behavior patterns among American men and women, data from recent studies were combined to provide estimates of the prevalence of behaviors implicated in the transmission of Human Immunodeficiency Virus (HIV).

Methods: Drawing from 17 of the most thoughtfully designed scientific investigations and the largest, most comprehensive cross-sectional studies published between 1948 and 1984, we derived estimates of the prevalence of AIDS risk-related behaviors for White, middle-class, minority well-educated, primarily urban Americans between 20 and 50 years of age. These estimates are conservative. They represent weighted means derived by multiplying the results from each of the relevant studies by the sample size, remaining across studies, and dividing this sum by the total number of subjects across all studies.

Results: Results indicate that a substantial proportion of the participants in the studies reviewed had engaged in (a) conventional sexual intercourse, (b) and intercourse, (c) sex with prostitutes, (d) sexual intercourse across nonsexually distant sexual orientation groups, and (e) sexual contacts during visits to cities with a high prevalence of HIV.

Conclusions: Accurate data on sexual behavior and the attitudes related to these behaviors are essential to the development of behavior change programs that to stem the tide of AIDS. In the absence of sufficiently large and unbiased samples, our estimates based on 17 scientific and cross-sectional studies provide important insights into the prevalence of sexual behaviors which place Americans at risk for infection with HIV.

T.D.O.23 CHANGES IN LYMPHOCTY PEHNOTYPE AND FUNCTION IN HIV
SEROPOSITIVE HOMOSEXUAL MEN FOLLOWING THE DEATH OF A PARTNER

Kempy, Margaret, E., Durk, Robert, J., Visccher, B., and Fahny, J.L.,** UCLA Center of Medicine and
UCLA Department of Psychology, Los Angeles, CA, USA

Objective: To determine whether immune parameters relevant to HIV infection were altered in HIV+ homosexual men following the death of an intimate partner. HIV+ homosexual men were studied as a comparison group.

Methods: 25 subjects whose intimate partners had died over the past year were selected from among participants in the UCLA Multi-Center AIDS Cohort Study (MACS). Blood samples drawn prior to and following the death of the partner were compared. Age- and HIV serostatus-matched non-bereaved subjects provided blood samples over an equivalent time period. Immune parameters relevant to HIV progression were evaluated (e.g., CD4 cell levels; measures of immune activation such as the percent of CD8 cells expressing DR).

Results: Preliminary results from phenotypic analyses indicated that there was a significant increase in the percent of CD8 cells expressing DR following the death of the partner among HIV+ subjects; this change over time was not seen in the non-bereaved subjects. This change was also not seen among HIV-

Conclusions: The loss of a partner in HIV seropositive homosexual men was associated with increased evidence of immune activation. This pattern was not seen among the HIV- men who had lost a partner. Immune activation is relevant to progression of HIV infection.



**Séance thématique
Specialty Session**

**Le SIDA et l'individu
AIDS and the Individual**

**Counseling
Counseling**

T.D.O.30 TRAINING INMATES AS HIV PEER SUPPORT COUNSELLORS IN GAOZ
Lynas, M.*; English, L.; McClellan, L.; Cooley, J.; ...
*National Wallace Street AIDS Centre, Sydney
Hospital, Sydney, Australia. **NSW Department Corrective Services.

Objectives: To develop a programme to train inmates as HIV peer support counsellors and establish a network of inmates throughout goals who are available on HIV peer counselling and education.
Methods: Inmates collaborated with HIV workers in the design and implementation of the programme. Topics covered included: counselling and psycho-social issues. Topics were presented by visiting specialists and information delivered in a variety of ways including lectures, group discussions, role plays and videos. The course was evaluated through interviews and by questionnaires.
Results: The evaluation process involved collecting qualitative and quantitative information. Questionnaires were used to compare participants' AIDS knowledge (pre and post) and their attitudes towards AIDS. Results showed that inmates who had attended a higher general AIDS knowledge (p<0.001) and higher positive attitudes scores (p<0.05). As a result of the course, inmates produced an educational play and video on safe needle use for the internal television network of the inmates. They were involved in HIV peer education and counselling of other inmates.
Conclusion: The success of the programme is directly attributable to the active involvement of the inmates in its planning and implementation. The programme demonstrates the practical and economic value in using inmates as HIV peer educators and counsellors in goals.

T.D.O.32 PROBLEMS WITH COUNSELLING UNDEREDUCATED PEOPLE REGARDING HIV-1 SEROLOGIC RESULTS
Rivara, M.*; Adrien, M.*; Boulos, R.*; Halsey, M.*; Abdallah, M.*; Kinsinger, J.*
*Centres for HIV and AIDS, Port-au-Prince, Haiti
*Johns Hopkins University, Baltimore, MD, USA

Objective: To describe the difficulties in counselling undereducated men and women in an impoverished Haitian slum about HIV-1 infections and AIDS.
Methods: Women attending prenatal clinics were tested for HIV-1 by ELISA and WB. Men with signs and symptoms suggestive of HIV-1 infections were tested in an STD clinic. Counseling was provided by physicians and social workers.
Results: Of 1992 women, 49.7% had received no formal education and 75% had attended primary school for 4 or fewer years. Of 14 to 19 year old pregnant women, 68 to 98 have been HIV-1 seropositive each year during 1986 through 1988. Adverse reactions to learning that they were HIV-1 seropositive included destruction of household goods, physical threats to the STD clinic physician, hopelessness, anger, despair, and confusion.
Conclusion: Undereducation, illiteracy, and lack of general information about AIDS in the community make counseling regarding serologic status and the complex aspects of HIV-1 infections very difficult. Adolescent girls are acquiring HIV-1 infections soon after becoming sexually active. Education programs and changes in sexual behavior are urgently needed.

T.D.O.34 SPECIAL PROBLEMS INVOLVED IN COUNSELLING HIV-INFECTED HOMOSEXUALS AND BIPHOBICS
Matschek, Ginter*; Drasch, M.*; Sutar, G.*; Seitz, O.*; Schneider, M.*; Hahn, F.*; Schram, W.*
*Dept. of Psychosomatics at the Psychiatric Hospital, University of Munich, Munich, Federal Republic of Germany.
*Psychosomatic Unit, University of Munich, Munich, Fed. Rep. of Germany.
** Dept. of Semanticsology at the Medical Hospital "Immanuel", University of Munich, Munich, Federal Republic of Germany.

Objective: Descriptive problems involved in counselling of HIV-infected homosexuals and biphobics.
Methods: The coping behaviour of HIV-infected homosexuals and biphobics is descriptively analyzed, resulting from records of over 2000 counselling contacts over a period of 3 years.
Results: It was observed that an important prerequisite for an adequate coping with the HIV-infection (minimizing denial, guiltfeelings, depression, feeling victimized and isolated) is the person's successful coping with his group-specific stress factor: homosexuality or biphobia. For clients who demonstrated a deficiency in this coping ability, sensitive and non-confronting counselling led many cases to greater self-acceptance and more ease in dealing with the HIV-infection.
Conclusion: In counselling HIV-infected homosexuals and biphobics the task is, with a large number of clients, to help them accept themselves as homosexuals or biphobics as well as to cope with the HIV-infection of the partner. But even when it is ignoring the personal and social implications of homosexuality and biphobia is forced confrontation with these issues at the wrong time.

T.D.O.31 OPTIMIZING INNER CITY PRENATAL AIDS COUNSELLING (AC)
Menden, C.; Tarras*, Lischner, R.N.*; Saphel, J.A.*; Olson, M.H.*; Cohen, A.V.*; Steinberg, J.M.*; et al. *Temple Univ., Univ. of Pennsylvania; **Epidemiol Hosp., Philadelphia, Pa, USA.

Objective: To compare the effectiveness of 4 approaches to prenatally sensitive acceptance of preventive AC and HIV antibody testing (ABT), minimize client stress and permit the gathering of risk-behavior data.
Methods: The 4 approaches to AC were pilot-tested in 2 clinics serving predominantly Black and Hispanic women who have an average incidence of perinatal HIV infection of about 0.3% by anonymous umbilical cord blood screening. 1) Of 97 women who received flyers which described AIDS risk activities and offered AC, 29% requested AC and 18% requested ABT. 2) Out of 169 women interviewed directly by a social worker (SW) for consent to join a research program for anonymous risk assessment and ABT, 36% agreed. 3) Out of 42 women interviewed by the SW without prior mention of risk behaviors, 57% requested AC and less decrease was verbalized. 4) Out of 34 additional women approached as in method 3) but asked for verbal presentation to complete an anonymous risk assessment form, 35% requested AC. Regardless of the initial approach, confidential risk-assessment interviews were permitted during post-test AC and the resulting data were more complete than, though sometimes discrepant from, those from anonymous questionnaires.
Conclusion: As proposed by Menden et al. (New Eng J Med 319:1108, 1988), the initial focus in prenatal and perinatal AC should be on the danger of HIV infection to the infant and not on risk behavior. The consensus of observing professionals, soon to be tested, was that this AC would be most effective if conducted as part of multifocus SW or nursing interviews.

T.D.O.33 ARE PATIENTS GETTING THE AIDS EDUCATION THEY WANT FROM THEIR PHYSICIANS?
Richard, Barbara; Magnus, and Costes, T. University of California at San Francisco, San Francisco, California, United States.

Objective: Physicians are positioned in the health care system to counsel patients about risk reduction. We completed a population-based survey of United States residents to find out the extent to which physicians talk to them about AIDS and to assess their desire for AIDS prevention counseling during their medical visits.
Methods: Telephone interviews were conducted in July and August 1988 with 2000 English-speaking, United States adults using a representative national sample generated by random digit dialing. A 75% response rate was achieved.
Results: Only 15% of respondents had talked with their physicians about AIDS, and in most instances (78%) the patient had initiated the discussion. Most respondents (79%) had never been asked by their doctor about their sexual behavior. Among those who had not discussed AIDS with their physician, only 17% did not want such a discussion. Physicians were rated as the most credible source of AIDS prevention information.
Conclusion: AIDS prevention is not routinely discussed by physicians with their patients. Because patients are not aware of such counseling, we suggest additional research to identify barriers to AIDS prevention counseling in the medical encounter and strategies to increase such counseling.
Funded by NIMH & NIDA Center grant #MH4245 and the Universitywide Task Force on AIDS.

T.D.O.35 CONDOM USE AND ASSOCIATED HIV SEROCONVERSION FOLLOWING SEXUAL INTERCOURSE WITH HIGH RISK INDIVIDUALS
Mills, A.*; Bhatnagar, S.*; Bhatnagar, S.*; Haines, E.*; ...
*AIDS Unit, University of California, San Francisco, CA, USA.

Objective: To prospectively determine condom use and subsequent HIV seroconversion following sexual intercourse with high risk individuals. HIV seroconversion was defined as the presence of HIV-1 antibody in the serum. HIV-1 infection was confirmed by Western blot analysis. HIV-1 infection was confirmed by Western blot analysis. HIV-1 infection was confirmed by Western blot analysis.
Methods: 100 individuals were followed up for 12 months. HIV-1 antibody was tested at baseline and at 1, 2, 3, 4, 6, 8, 10, and 12 months. HIV-1 antibody was tested at baseline and at 1, 2, 3, 4, 6, 8, 10, and 12 months. HIV-1 antibody was tested at baseline and at 1, 2, 3, 4, 6, 8, 10, and 12 months.
Results: 100 individuals were followed up for 12 months. HIV-1 antibody was tested at baseline and at 1, 2, 3, 4, 6, 8, 10, and 12 months. HIV-1 antibody was tested at baseline and at 1, 2, 3, 4, 6, 8, 10, and 12 months. HIV-1 antibody was tested at baseline and at 1, 2, 3, 4, 6, 8, 10, and 12 months.
Conclusion: Condom use significantly reduces the seroconversion rate in sexually active individuals. An intensive counselling programme has been shown to increase condom use by 11% of 100% of couples. A practicing attorney was not following during all couple's visits. A significant decrease in seroconversion rate was noted to meet SC and led to seroconversion changes in sexual behavior.

Séance thématique Specialty Session



Le SIDA et l'individu AIDS and the Individual

Les femmes

Women

W.D.O.1 HIV INFECTION AMONG WOMEN ATTENDING WOMEN'S HEALTH CLINICS IN THE UNITED STATES, 1988-89
Primary: Pattillo,¹ Allen, W.R., Goewert, J.,² and State and Local Health Department, Centers for Disease Control, Atlanta, GA, USA

Objective: To evaluate HIV seroprevalence in women attending family planning, prenatal care and abortion clinics in the United States.

Methods: In 1988 and 1989, binned surveys are being conducted in clinics providing services to women of reproductive age. After testing blood for routine purposes, individual identifiers are removed and consecutive sera are tested for antibodies to HIV. Age group, race, ethnicity, and type of clinic will be collected on over 100,000 women from 137 clinics in 30 metropolitan areas.

Results: Preliminary results for 10,164 women in 8 areas indicate that the highest seroprevalence rates are in prenatal and family planning clinic clients in densely populated cities. HIV seroprevalence ranged from 0-6.2% (median 0%) in prenatal, 0-4.3% (median 0%) in family planning and 0-0.16% (median 0.1%) in abortion clinics. Rates were 1.0% in black compared to 0.11% in white and 0% in Hispanic women. Seroprevalence was highest in the 25-29 year age group and lower among adolescent and older women.

Conclusions: These results suggest that HIV seroprevalence rates in women attending family planning, prenatal, and abortion clinics vary, but are generally low. Rates are higher in black women and in more populated areas. Surveillance of HIV seroprevalence in women of reproductive age is essential in directing programs to prevent perinatal and heterosexual transmission and to evaluate the effectiveness of such programs. These programs may need to focus on educating minority and adolescent women.

W.D.O.2 RELATIONSHIP BETWEEN HIV AWARENESS, PARTNER SELECTION CRITERIA, AND EARLY RELATIONSHIP FORMATION IN TWO GROUPS OF SAN FRANCISCO BAR PATRONS

McKusick, Lepp, and Hoff, C.C.
 Department of Medicine, Center for AIDS Prevention Studies, University of California San Francisco, USA.

Objective: To investigate the interaction between awareness of HIV and interpersonal relationship seeking and formation in adult heterosexual women and homosexual men.

Methods: San Francisco bar patrons were chosen, bars being places where awareness of HIV is likely to be high and where a sexual encounter with an HIV antibody seropositive may occur. 50 heterosexual women and 50 homosexuals men filled out questionnaires and were interviewed. Twenty five of each group were in an early relationship and 25 were single. Data was gathered on three HIV aware behavioral strategies: 1) assessment of partner characteristics and behavior, 2) safe sex practices, and 3) determination of HIV antibody status of partner. Additional data was gathered on partner selection and relationship criteria, awareness of AIDS, sexual behavior, and relationship history and satisfaction.

Results: Single heterosexual women were more likely than single homosexual men to assess partner characteristics of potential partners as an HIV avoidance strategy. Homosexual men were more likely than heterosexual women to know their own HIV antibody status and, for those in early relationships, to know the antibody status of the partner. Single homosexual men were also more likely to engage in safe sex practices than single heterosexual women. Those women who practiced safe sex early in relationship formation suspended the practice upon the establishment of trust that their partner was monogamous.

Conclusions: Psychological factors associated with relationship formation can interfere with effective HIV protection strategies, particularly in single heterosexual women.

W.D.O.3

W.D.O.4 GENDER RULES AS BARRIERS TO RISK REDUCTION FOR BLACK WOMEN

Fallone, Mundy, Pullimore, R., Haynes, K. and Cross, S.A.
 Multicultural Inquiry and Research on AIDS of the UICAR Center AIDS Prevention Studies and the Bayview-Hunter's Point Foundation, San Francisco, CA, USA.

Objective: This study was designed to examine gender rules that affect black women in their adoption of risk reduction behaviors. In particular, the study compared drug-using and non-drug-using women's comments about rules for sexual behaviors, drug use, and subordination within relationships.

Method: In order to examine the attitudes, beliefs and practices of women in the drug-using world, we conducted 12 focus groups with 75 black teenage and adult women, drug-users and non-drug-users, representing middle-, working- and uneducated black women residing in Bayview-Hunter's Point, a black ghetto in San Francisco. The focus groups asked women participants to discuss sexual practices and drug-related behaviors.

Results: The women in our focus groups were able to state explicitly what they believed to be the rules of their environment. The rules for behavior reflected an awareness of strict gender roles in which women were subservient to men and had fewer privileges than men. The gender rules varied with age, socioeconomic status and drug use. Of the women who participated, those addicted to crack cocaine appeared to face not only the highest risk for infection with HIV, but also the most severely limited options for behavior change.

Conclusions: Risk reduction must take into account black women's perception of acceptable gender behaviors. To the extent that these rules support subservience to men, women may be limited in their ability to initiate and maintain prevention activities. The degree to which this perception reflects reality, and the corresponding views of black men, deserve further study.

W.D.O.5 BARRIERS TO AIDS INTERVENTIONS AMONG SEXUAL PARTNERS OF HIV DRUG USERS
Smith, Chen, M.P., Frederick, S.P., Sofian, M.P., Stephenson, R.T., De Jureth, OC**
 *Narcotics and Drug Research, Inc., New York, NY, USA; **NY State Div of Substance Abuse Services, New York, NY, USA

Objective: (1) To develop strategies to locate sexual partners (SP) of drug users so they can receive AIDS education and be enrolled in research studies. (2) To determine barriers to sexual partners' participation in these activities.

Method: Under the direction of an ethnographer, a team of outreach workers attempted to locate and recruit SP. Barriers to recruiting SPs were identified through (1) conducting in-depth interviews with SPs who were recruited about the reasons that led to their status and that deterred their friends, and (2) casual feedback between the ethnographer and the outreach workers about what obstacles they discussed in their attempts to recruit SPs.

Results: Most SPs are women. The key barriers to their participation are denial, dependency, social isolation, and opposition from their drug using partners. Many SPs deny their partners' drug use and hope they will eventually stop using drugs. They are emotionally, and sometimes economically, dependent on their drug using partner. Thus, they want to hold on to the relationship, especially if they have children. SPs often contact with friends whom they do not want to have know about their partner's drug use. The drug users do not want the SPs to talk with outsiders about their drug use because they are ashamed of their drug use or because they fear these conversations may give the SPs social support to break the relationship.

Conclusions: Outreach based on ethnography facilitates locating sexual partners and identifying barriers to participation. Efforts to reduce HIV infection of SPs can use network techniques to locate SPs. Ways to overcome dependency, denial, and social isolation of female SPs, and to neutralize their drug using partners' opposition, must be developed. Theoretically promising ideas include group processes and counseling that lead to empowerment and collective identity.

W.D.O.6 CONTRACEPTIVE UTILIZATION AND REPRODUCTIVE DESIRES IN A GROUP OF HIV-POSITIVE WOMEN IN KINSHASA
Hemba, Bassia, E.P.,¹ Duppaigne, A.P.,² Piriel, L.,³ Moore, H.,⁴ ⁵
¹Ryher H.V.,⁶ ⁷Bertrand H.V.,⁸ ⁹Kashala T.D.,¹⁰
¹¹Zaire School of Public Health, Kinshasa, Zaire; ¹²Tulane University, New Orleans, USA; ¹³Beaujeu Cosmeceutic du Zaire, Kinshasa, Zaire; ¹⁴Projet SIDA, Kinshasa, Zaire.

Objective: To determine contraceptive utilization and future reproductive desires of women identified as HIV-positive. Methods: A working population and their spouses were treated for HIV and contraceptive/reproductive data collected.

Results: Fifty-eight (4.3%) of the 1299 women tested were HIV+. Ninety-one % of HIV+ women were married, and 7% currently use modern contraception. No differences in age (33.0/33.2 years), number of children (2.9/4.4) or condom usage (28/12) were found between HIV+ and HIV- women. HIV+ women were significantly more likely to use "rhythm" for contraception (26% vs 9%, p=0.0003). Of HIV+ women, 71% wanted more children within the next 2 years (mean desired family size = 5.2), and 5% were pregnant. A majority of women expressed a desire for more accessible contraception options.

Conclusions: Counseling services for HIV+ women in Kinshasa must be prepared to address the current low level of contraceptive usage and the definite pro-natalist sentiment in the population reflected by the high levels of desired and actual completed fertility.

Séance thématique Specialty Session



Le SIDA et l'individu AIDS and the Individual

Prostitution Prostitution

Th.D.0.7 THE IMPACT OF AN EDUCATIONAL PROGRAM ON HIV INFECTION AMONG PROSTITUTES.

James R. Foret***, A. Tejeda*, J. Alarcón*, J. Piscayo*, and L. Varela**.
**Universidad Nacional Mayor de San Marcos, Lima, Peru.
***The Population Council, New York, New York, USA.

Objective: To determine the impact of a reproductive health program on the prevention of AIDS among registered prostitutes in El Callao, Peru.
Methods: A reproductive health program with an educational component was implemented in a STD clinic serving almost 600 prostitutes. The program's impact is being evaluated through successive surveys, program participation, changes in condom use and lab tests to detect seroconversion to HIV and infection with other STD's.

Results: To date 783 women have participated in program activities, 463 of them consistently, in the average every woman has attended 4 educational sessions. Changes in attitudes towards condoms have taken place. For instance, higher fees for sex when condoms are used are no longer charged, and condoms are now used in oral sex. More women participating in the program know the correct use of condoms (72% VS 52% among those not participating). The demand for condoms has increased from 1,010 in August 1988 to 32,445 in October of 1988. In addition, the demand has remained low with no seroconversion between April and November of 1988. In the same period prevalence of gonorrhoea decreased from 2.75 to 0.175 and candida infections from 85 to 35.

Conclusions: The program has had an impact on the social behavior of prostitutes, reflected mainly in an increased demand for condoms. Low and stable HIV seroconversion risk, and reduction of gonorrhoea and candida infection.

Th.D.0.9 WOMEN WORKING AS PROSTITUTES: PARTICIPATION/CONSENSUS-BASED PLANNING FOR PROVISION OF HIGHER PREVENTION, AIDS REDUCTION, AND SEROPREVALENCE ACTIVITIES

Stephanie P. Clay*, Adam R. E. Gross, M.J.

AIDS Office, Massachusetts Department of Public Health, Boston, MA USA. 02111

Problem: Provision of educational and risk reduction services and seroprevalence studies within the field of women working as prostitutes raises ethical, scientific, and political concerns. Women in general and sex workers in specific have little trust in the "good intentions" of outsiders. Public Health Departments (PHDs) and community-based organizations (CBOs) often lack credibility with prostitutes. Client distrust may lead to difficulty in reaching target populations, low utilization, and biased outcomes.

Model: Participatory/consensus-based planning minimizes conflict and increases cooperation among clients, project staff, and funding agency.

Application: The AIDS Office of MPHV received funding from CDC for a 22-month outreach, education, and risk reduction project for women working as prostitutes to be conducted by a CBO at the site. Consensus groups were formed consisting of AIDS/HIV service providers and women sex workers. Meetings jointly and separately, the groups seek consensus on program design and procedures, sites, hours of operation, and staffing. The providers and the AD staff seek consensus concerning contractual obligations and political concerns.
Conclusion: The participatory/consensus model offers an alternative to traditional planning and design. This model involves clients in a strong voice; CBO's input into issues of local concerns; realization of criminal justice issues; and increased access to technical support and funding. In partnership, this model seeks most needs without sacrifice of client anonymity, ethical considerations, or scientific quality.

Th.D.0.11 EVALUATION OF KEY MESSAGES TO INCREASE THE USE OF CONDOMS IN SEX WORKERS: AN AGRI-EXPERIMENTAL STUDY.

Xaldemaini-Jaak*, Izquierdo J.A.*, Sepúlveda S., Ramah M**.

Quetz** *General Directorate of Epidemiology, Ministry of Health, Mexico.

Objective: To identify and evaluate key messages and channels of distribution of educational strategies in prostitutes in Mexico to rapidly increase the use of condoms.

Methodology: The end goal took place in Toluca, Mexico (border city with California, USA) where approximately 50,000 prostitutes live. A randomly selected survey was undertaken, which investigated sociodemographic characteristics of persons and attitudes, a blood sample for HIV-1 was also drawn. Upon the data of the survey, key messages and adequate channels of distribution were identified. Educational material (posters, tracts, and comics) was pre-evaluated through local media and distributed. The final material was distributed by 15,000 prostitutes, with their active participation. Six months after the first survey, a second survey in a random sample was undertaken to evaluate changes.

Results: Women under study have an average age of 27 years, with a second grade elementary school level. 89% have children, no STD was reported, 87% are afraid of acquiring AIDS, and 10% use condoms. The usage of condoms is set: attractive women, prostitutes for social reasons and mothers worried for their children's health. Key messages were: 1) HIV is a STD; 2) Condom prevents infection; 3) When avoiding sexual transmission, perfect transmission is prevented; 4) Prostitutes who use condoms are responsible mothers. The use of condom increased 88% (incl. oral) after 6 months. The messages transmitted to the population considered to be the educational material. Seroprevalence of infection by HIV-1 was <1.0% in both serosurveys.
Conclusion: The identification of adequate key messages and channels of distribution improves the efficiency of educational programs of AIDS on female sex workers. This strategy must be evaluated in an educational program for prostitutes abroad.

Th.D.0.8 YOUNG MALE PROSTITUTES: SAFE AND UNSAFE SEX AND AIDS KNOWLEDGE

Frank Edelstein*, and Meyer Balthus, M.P.H.
HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute and Columbia University, New York, New York, United States.

Objective: To assess sexual behavior and AIDS awareness in young male prostitutes, a group at particularly great risk for acquiring and disseminating infection with the etiologic agent of AIDS.

Methods: 50 New York male prostitutes (for men), aged 14-27, were recruited by their operating locations (streets or bars and theaters) and systematically interviewed for 2.5 hours using semi-structured instruments to assess demographic, detailed sexual behavior, and knowledge and attitudes about AIDS/HIV.

Results: Preliminary results show an average age of 20.7 years. In erotic fantasy, 50% were predominantly homosexual, 20% bisexual, and 30% predominantly heterosexual. Only one reported being HIV antibody positive. The subject's sexual behavior with their male customers for pay included rates of condom use of 50% with fellatio and 85% with anal intercourse. With their non-paying male partners these rates fell to 25% with fellatio and 50% with anal intercourse, and fell further with their (non-paying) female partners to 21% with fellatio and 12% with vaginal intercourse. The safety of their sexual behavior did not appear to be related to their knowledge and awareness of AIDS/HIV, which was quite high overall. Distances between the street and the bathhouse/hustlers exist, with street hustlers being younger, less knowledgeable about AIDS/HIV, less likely to use condoms with women, and more likely to use drugs.

Conclusion: Male prostitutes' sexual behavior is related (in part) to their 'higher-end activities' with their male customers, where perceived threat is highest, and most unsafe with female partners where perceived threat is lowest. Knowledge of AIDS, while quite high, appears unrelated to awareness of sexual behavior.

Th.D.0.10 THE ACQUISITIVE APPROACH TO JOHN STD/AIDS PREVENTION AND CONTROL IN FEMALE SEX WORKERS: THE DOMINICAN REPUBLIC

Rosario, S.; Suterro, Ernesto; De Moya, I.A.; Velquez, C.

Alcántara, E. PROCTIS, Ministry of Public Health, Santo Domingo, Dominican Republic.

Objective: To describe and analyze the conceptual approach to STD/AIDS prevention in Dominican female sex workers (FSW), as well as the detection, diagnosis and treatment strategies and their results from 1987 to mid 1989.

Methods: On the basis of an agglutinating approach that incorporates FSW law fees selected by their peers to the National Struggle against AIDS, sex workers receive educational preventive training, at least monthly physical exams, laboratory tests and treatment for STD, in 12 new sentinel points in the Dominican Republic. FSW receive 50 condoms gratis in each visit.
Results: As of December 1988, 22,000 medical exams have been delivered to 5,000 FSW; 121 have been treated for syphilis and 111 for gonorrhoea. Out of 3,000 voluntary HIV tests, 2,155 have been seropositive.

Conclusion: Aggressive control of genital ulcer disease (GUD) through joint peer/professional intervention provides an unique opportunity for educating sex workers, detecting STD at an early stage, treating these diseases opportunistically, and reducing the risk of HIV infection.

Th.D.0.12 THE DEVELOPMENT OF VIDEO-INTERVIEWS AS SOME ALTERNATIVES FOR FEMALE SEX WORKERS IN THE DOMINICAN REPUBLIC

Alcántara, E.; Suterro, Ernesto; De Moya, I.A.

PROCTIS, Ministry of Public Health, Santo Domingo, Dominican Republic.

Objective: To describe the approach to HIV seropositive female sex workers (FSW) counseling and provision of training for profitable work alternatives through the Ministry of Public Health and a specialized Catholic Organization of women.

Methods: FSW who voluntarily demand HIV testing and refer seropositive are offered counselling services by State psychologists, who treat these women to the "Marianas Adoradoras", an International Catholic Organization of women specialized in developing work alternatives for female sex workers.

Results: From the start of this program in 1988, 56 HIV positive FSW have been recruited for psychological counselling, social support, and training for low risk work alternatives. Twenty-one of them have been able to support themselves and their children without resuming sex work.

Conclusion: HIV seropositive FSW in the Dominican Republic, when provided with appropriate professional counselling, social support and technical training, can have developed work alternatives capable of providing an income to support themselves and their children without resorting to sex work.

Séance thématique Specialty Session



Le SIDA et l'individu AIDS and the Individual

Consommateurs de drogues par voie intraveineuse (partie 2) Injection Drug Users (Part 2)

Th.D.0.13 DRUG USE TRENDS AMONG PARTICIPANTS IN THE TACOMA BYRNGE EXCHANGE
 HUGH HENDER, D.C. De Sales¹, D. Proctor², T. J. Reed³, B. R. Friedman⁴,
¹Tacoma Pierce County Health Dept., Tacoma, WA, ²Wash. Nat. State Division of Substance Abuse Services, ³Port Defiance AIDS Project, Tacoma, WA, ⁴Harvard and Drug Research, Inc., Boston, MA

OBJECTIVE: To examine the relationship between frequency of drug use and participation in a syringe exchange (SE). One of the arguments against SE programs has been that they will promote drug abuse and that the availability of equipment will cause injecting drug users to inject more often.

METHODS: Retrospective data were collected regarding drug injection frequency on 48 randomly selected SE users, using a standardized interview. Comparisons between the time periods just prior to first using the SE (PRE-SE), and since starting to use the SE (POST-SE) are reported as mean number of times each drug was used per month.

RESULTS: The majority of participants had used the SE for 3 months. Trends show no differences in the frequency of injection of heroin and cocaine between PRE-SE and POST-SE (66 vs. 64), heroin PRE-SE (56 vs. 56), crack PRE-SE (45 vs. 45), POST-SE (45 vs. 45), amphetamine PRE-SE (3.5, POST-SE 3.7, p=0.4). Looking at drug use that did not involve injection, no changes were noted in the use of snuff (heroin PRE-SE 0.01, POST-SE 0.01), snuff (cocaine PRE-SE 0.3, POST-SE 0.4), smoking crack (PRE-SE 0.3, POST-SE 0.8), or in the use of non-injection methadone or marfanin (all p > 0.5). Overall, 50% of SE users report injecting less, 15% the same and 35% inject more frequently since using the exchange. The mean age of SE users is 30, and 4 (9%) had been injecting drug use more than 5 yrs, 11 (23%) age, and 80% first injected more than 5 yrs ago. No other changes were noted during the time since the SE was used.

DISCUSSION: Clearly, the majority of SE users have a long history of drug use, and the availability of clean equipment is not restricting individuals who were once users. No increases were seen on the frequency of use of injected or non-injected substances. The finding that more SE users decreased than increased drug injection is consistent with earlier data from the same and other SE programs, but long-term study is needed to determine trends in drug use with prolonged SE use.

Th.D.0.15 REDUCING HIV TRANSMISSION AMONG RECOVERING FEMALE DRUG USERS
 Robert J. R. Anderson, M.D., Ph.D., Robert C. Gardner, M.D., and Nicholas L. S. ¹Columbia University School of Social Work, New York City, USA, ²Albert Einstein College of Medicine, Bronx, New York, USA

OBJECTIVE: To study the effect of a skills-building approach to reducing rates of HIV transmission among recovering IV drug users. Methods: Drawing on extant research and findings of an earlier descriptive study, the authors developed a multi-session group approach to reducing high risk behavior among a cohort of women enrolled in New York City area clinics. A controlled trial carried out by social workers in drug treatment settings involved random assignment to intervention- or skills-building conditions. Results: Outcome analyses demonstrated that participants in an information-only condition regularly attended in the clinic made fewer gains than skills-building participants in behavior related to HIV transmission. Participants in the skills-building condition were significantly more likely to carry condoms, talk about and initiate discussions around safer sex, and feel comfortable talking about discussing safer sex with IV drug users. Discussion: As follow-up data have not yet been collected, these modest preliminary findings must be viewed with a degree of caution. Nevertheless, ongoing research and support to the viability of skills-building strategies to reduce relapse and AIDS risk associated with recovering drug use.

Th.D.0.17 HIV IN PRISONS: A DESCRIPTION AND EVALUATION OF A PROJECT DESIGNED SPECIFICALLY FOR WORK WITH IVDA'S IN PRISON
 Barbara J. G. Anderson, Muriel Shover, and John S. Sorenson
 Ann Jensen, Dep. of AIDS Prevention, Ohio City Health and Environment Dep. Agency

OBJECTIVES: IVDA's constitute a large proportion of the prison population in Norwegian prisons. There is a need for new methods in preventive and supportive work among inmates. In 1987 the Department of AIDS Prevention employed a doctor, a psychologist, a registered nurse and a pedagogue, two of whom are also active in the prison. The project is a project to answer the following: - How do you give adequate information? - Under what circumstances can change of risk behavior take place? - How do you give adequate psychosocial support in a prison? - How can you best run support groups in a prison? The project works in the four prisons in the Oslo area with a total of 750 inmates.

METHODS: The project is, and is perceived by the inmates as, independent of the regular health service and authorities of the prisons, and information received from the inmates is kept confidential. Notwithstanding this separation from the prison system, contact with, and education of, prison employees has been an essential part of the work. The methods employed with the IVDA's are: - individual counselling, psychological support and medical examinations - counselling of the inmates' social partners - support groups for former IVDA's - take one's own responsibility - information meetings. The methods are continuously evaluated, and the activities give in themselves knowledge about the "anthropology of prison life".

RESULTS: The project has been in contact with 48 hiv positive inmates. This constitutes 20% of the registered hiv positive IVDA's in Norway. A qualitative evaluation of the methods used will be presented at the paper.

Th.D.0.14 THE PREVALENCE OF HIGH RISK SEXUAL BEHAVIOR IN MALE METROPOLITAN IV DRUG USERS
 Linda Gross¹, J. Walters, J.K. Cline², C. Case³,
¹University of California, Santa Cruz, California, U.S.A., ²University of California, San Francisco, California, U.S.A., ³Urban Health Services, San Francisco, California, U.S.A.

OBJECTIVE: To determine the prevalence of high risk sexual behavior in male intravenous drug users (IVDU) who are female sexual partners.

Methods: One hundred forty-nine IVDU's (70 whites and 79 blacks) with stable partners were interviewed in early 1987.

Results: During the previous year, 83% had more than 1 female partner and 31% had 4 or more female partners. The median number of female sexual partners was 3 for whites and 2 for blacks. Eleven percent (16/148) had sexual contact with men, with no significant difference between whites and blacks (7% or 5/70 vs. 14% or 17/120 respectively, p = 1.6). Heterosexual and intercourse were reported by 20% (50/148), with whites more likely than blacks to report this behavior. (ie. 46% (32/70) vs. 20% (24/70) respectively, p = .01). Reports of new sexual contacts between men and women were reported by 17% for the 2 groups of men. Of the 128 men who reported whether their steady female partners injected drugs, 40% (51/128) said their partners were IVDU's. Black men were more likely than whites to report that their partners were IVDU's (54% (57/106) vs. 32% (14/43) (p < .001). Blacks were also more likely than whites to report no enrollment in drug treatment programs during the previous 3 years. (ie. 49% (67/137) vs. 20% (14/70) (p < .01).

Conclusions: This study demonstrates that educational outreach programs in sexual risk reduction are important for both IVDU's and their sexual partners. The need for culturally sensitive programs is particularly important for black IVDU's and their sexual partners in San Francisco.

Th.D.0.16 IMPACT OF AIDS ON MORTALITY AND MORBIDITY AMONG INDIANIZED DRUG USERS (IVDU) IN A REHABILITATION TREATMENT PROGRAM (RMP)
 Richard M. Heron, J. W. Hennessey, M.D., and Robert C. Gardner, M.D., ¹Northwestern Medical Center/Albert Einstein College of Medicine, Evanston, Ill., USA

OBJECTIVE: To assess the impact of the AIDS epidemic on morbidity and mortality in a defined population of IVDU's in a long-term supervised RMP in New York City.

Methods: An unlinked sample in overall and cause-specific deaths (AIDS, liver disease, and medical hospitalizations among IVDU's in a Bronx RMP for 1984-1987). The underlying population each year was used to calculate crude incidence rates.

Results: The underlying population each year ranged from 828 to 8011 median age of the entire population was of 31.6/yr. Population demographics did not differ between study years. Total deaths increased from 13.3/1000 in 1984 to 24.2/1000 in 1987 (p<.001). Deaths from AIDS increased from 3.6 to 14.7/1000 (p<.003), and deaths from bacterial pneumonia/sepsis from 3.4/1000 to 12.6 (p<.001). Deaths from cirrhosis, osteomyelitis, trauma and other causes showed no significant increase or decrease over the five years. AIDS incidence rates from 6/1000 in 1984 to 20.4/1000 in 1987 (p<.001). Year-to-year analysis yielded similar results. Hospitalizations for AIDS, bacterial pneumonia, and endocarditis/sepsis increased from 84.9/1000 in 1986 to 144.9/1000 in 1987, with minimal or no increase in other diagnostic categories.

Conclusions: Results indicate that AIDS has had a profound impact on morbidity and mortality among IVDU's in our RMP, reflected not only in AIDS diagnoses but also in secondary bacterial infections. Data suggest that RMP's may be important sites for targeting clinical services for HIV-infected IVDU's, which will require expansion of existing resources to meet the growing need for AIDS-related care.

Th.D.0.18 AIDS PREVENTION THROUGH THE ORIGINAL JUSTICE SYSTEM (CJS): REFERRAL OF INTRAVENOUS DRUG ABUSERS (IVDA) TO DRUG ABUSE TREATMENT
 Lewald, Carl; Bellini, Robert; Picheno, R.
 National Institute on Drug Abuse, Rockville, MD, USA

OBJECTIVE: To explore the potential contribution of the CJS to AIDS prevention through referral of IVDA to drug abuse treatment.

Methods: Data from a recent study of IVDA admitted to methadone treatment were examined. Original justice and drug abuse treatment literature were reviewed, and relevant experts were contacted.

Results: Drug abuse treatment has proven effective in helping IVDA stop drug injection. In fact, there is an important AIDS prevention strategy. Yet, only 1 in 7 IVDA in the US is in treatment. The CJS provides access to approximately 80% of all arrestees but used illicit drugs at arrest. Rates of CJS involvement among IVDA are high. Yet, only about 20% of IVDA in treatment were CJS-referred. A study of treatment admissions in 5 cities found that 22.1% were CJS-involved, with rates of involvement ranging from 9.3% in New York City to 37.6% in San Antonio. HIV infection rates within each city were similar for CJS-involved and non-CJS-related individuals with no current CJS involvement, suggesting similar rates of HIV infection. Conclusions: The CJS provides an important AIDS prevention strategy. The treatment referral and other AIDS prevention programs. Yet, this resource is underutilized. Potential strategies to improve referral initiatives are high, especially in cities such as New York where HIV rates are high and CJS-involvement is low.

**Colloque
Symposium**

**Le SIDA et l'individu
AIDS and the Individual**
Les femmes des pays en voie de développement : Où commencer? Que faire?
Women in Developing Countries: Where do we start? What can we do?
Th.D.0.19 AIDS AND THE AFRICAN WOMAN: REPRODUCTIVE ISSUES
Muhombwa, Eustace. Muhimbili Medical Centre,
 University of Dar es Salaam, Dar es Salaam, Tanzania.

Th.D.0.20 WOMEN WITH AIDS: ISSUES IN PATIENT CARE
Allen, Susan. Center for Aids Prevention Studies
 University of California at San Francisco, San Francisco, CA
 USA.

Th.D.0.21 WOMEN AS CARE-GIVERS
Kaleeba, Noorino. Kampala, Uganda

Th.D.0.22 THE RESEARCH AGENDA FOR AFRICAN WOMEN
Nahmad, Fatia. Bethesda, Maryland, USA

Th.D.0.23 EDUCATIONAL INTERVENTIONS FOR WOMEN
Ivyoyintono, Rebecca. Uganda

**Session d'affichage
Poster Session**



**Le sida et l'individu
AIDS and the Individual**

M.D.P.19 **ETHNOGRAPHIC AND RISK-REDUCTION PRACTICES OF MALE BAR WORKERS IN BANGLADESH**

DEBAPATI BHATTACHARYA, FRANKLIN P. BATTANARON, M. WEI
DAVID L. KONTZ, Ed. Center for Health Research and Education, Bangkok, Thailand, *Family Health International, North Carolina, USA.

Objective: To determine risk factors for directing intervention programs.
Method: We surveyed 141 male bar workers in 5 bars in Bangkok.
Results: 78% of the men were between 17 and 21 years old and 84% were born outside of Bangkok. 49% were living with friends who worked in similar bars. 31% had only primary school education. 68 were rarely or never exposed to the mass media. 55% had never worked in a bar before. 50% had worked in bars for 2 months or less. 82% had chosen bar work to solve their unemployment problem. 51% were introduced to this job by their friends and 34% by reading job advertisements. Only 50% stayed in the bar longer than 2 months. In the 2 week period prior to the survey, 100% had sex with male customers, 23% with female customers, 13% with non-customer males, and 50% with non-customer females. In the same period the men averaged 5.6 male partners. 53% of the men did not use a condom the last time they had insertive anal sex. The last time the bar worker had receptive anal sex, 43% of the bar workers' insertive partners did not use a condom. 72% had both insertive and receptive anal sex. 55% had used condoms for oral sex. 99% of the men had not used IV drugs in the last 5 months.
Conclusion: The sexual activities of these young men with little education and rural backgrounds place them at high risk for HIV infection. The potential for rapid HIV spread is high because they have sex with both men and women as customers and non-customers.

M.D.P.21

THE IMPACT OF COMMUNITY-BASED BEHAVIORAL GROUP INTERVENTION TO HELP PERSONS REDUCE HIGH-RISK SEXUAL BEHAVIORS
Ellis, Jeffrey A.*; St. Lawrence, J.S.*; Brawfield, T.L.*
Head, N.I.H.;* & Univ. of Mississippi Medical Center, **PL Dept. of Health & Rehab. Services, U.S.A.

Objective: Many individuals still have difficulty implementing and maintaining adequate change in sexual patterns. Behavioral skills training principles can be used to assist persons reduce high-risk behaviors.
Method: In Study 1, 106 men who engaged in risky behavior with multiple partners were randomly divided into experimental and control groups. Experimental subjects participated in 12 group sessions of risk education and self-management, assertion, and cognitive skills training specifically related to sexual risk reduction. In Study 2, a second cohort participated in a similar 6-session program. Behavior change was assessed using multiple self-report, self-monitoring, and sexual assertiveness skill measures. Follow-up data through 24-month postintervention were obtained.
Results: Multivariate analyses revealed significant reductions in occurrence of anal intercourse to near zero levels and greatly increased use of condoms, risk knowledge, and sexual assertiveness behavioral skills as a result of this training. Change was well-maintained even at long-term follow-up and was corroborated by change across the measures.
Conclusions: Behavioral principles derived from other areas of health promotion can be adapted for use in AIDS risk reduction. These findings identify a model to help persons acquire the skills to implement and maintain behavior change recommendations. This model is of practical importance for men clients seen in AIDS prevention programs, health and STD clinics, and schools.

M.D.P.23

PERSISTENCE OF HIGH-RISK SEXUAL BEHAVIOR IN HOMOSEXUAL/BISexual MEN: A MULTI-CENTER STUDY
Doll, Lawrence, Ph.D.; Rabin, G.M.; Douglas, J.M.***
Noon, P.*; Miller, Ph.D.***; Centers for Disease Control, Atlanta, GA; **San Francisco Public Health Dept., ***Denver Disease Control Service; **Newport Brown Clinic, USA**

Objective: To describe and predict high-risk sexual behavior in homosexual men attending 3 STD clinics.
Method: 463 men who engaged in unprotected anal or oral sex in the previous 6 months were interviewed from April-Dec, 1988. Risk was assessed by calculating: 1) absolute % of unprotected anal and total (anal and oral) exposure and 2) ratio of unsafe to total exposures for the 6-month period. Principal component and cluster analyses were used to arrive at groups of men; regression techniques were used to predict levels of risk.
Results: Preliminary cluster analyses identified subgroups: 1) a relatively-closed group (N=22) who self-identified as heterosexual/bisexual; 2) a somewhat-closed group (N=101) of older, self-defined bisexual/homosexuals; 3) a younger, openly-homosexual group (N=109) with male steady partners; 4) an older, openly-homosexual group (N=195) with higher incomes and nonsteady male partners; and 5) a small, openly-homosexual group (N=37) with large numbers of sex partners and higher cigarette and drug use. Regression analyses showed having sex with a steady partner, younger age at first sex, isolation from gay organizations, bisexuality, IV-drug use, and "hustling" were related to higher levels of unprotected exposures.
Conclusions: Relative exposure estimates to have unsafe sex; each subgroup will require targeted education to effect behavioral change.

M.D.P.20

Peer and Partner Influence and Self-confidence as Correlates of AIDS Preventive Behavior (APB) in a Low Prevalence State-
Landis, E.E., Kary JA, Univ North Carolina, Chapel Hill, NC

Objective: To examine the effects of social influence and self-efficacy on APB knowledge and by the self-reported practice for HIV-1 with a partner in a heterosexual sample in a low prevalence state.
Method: Over a 6-month period in a low prevalence state, 1000 men were conducted with 335 adults tested for HIV antibodies at 2 Counseling and Testing Sites in North Carolina. Emphasized were: perceptions of network behavior; respondents' own, as well as peers and partners', beliefs about practicing safer sex; and confidence in the ability to elicit negative social network influences.
Results: In this largely rural state, our sample was 64% black, 32% female, 67% homosexual, 12% IV drug users, 10% positive for HIV-1, with a median age of 26. Almost the entire sample (94%) knew that having only one steady sexual partner would reduce the risk of HIV infection. Over 80% of the men in the past month and believed "safe sex" was "turn off" over 80% (84%) believed their peers also had more than 1 partner while 60% felt "safe sex" was hard to practice "in the heat of passion". Over two-thirds (68%) believed their peers engaged in "unsafe sex" and 62% were not certain they could adopt safer sexual practices. Those who believed their peers and sex partners practiced or encouraged safe sex perceived fewer social barriers to change (10%), reported more preventive behaviors (16%) and were more confident they could change their behavior (33%).
Conclusions: In a heterogeneous but predominantly heterosexual, highly acute population in a low prevalence, rural state, imaginative counseling should try to reinforce perceptions of positive social influences, elicit network barriers, emphasize peer support and enhance self-confidence.

M.D.P.22

PSYCHOLOGICAL AND DEMOGRAPHIC CHARACTERISTICS OF GAY MEN WHO DO OR DO NOT ENGAGE IN UNSAFE SEX
Ellis, Jeffrey A.*; St. Lawrence, J.S.*; Brawfield, T.L.*
Smith, J.J.*; Head, N.I.H.*; Jones, A.L.*; Univ. of Mississippi Medical Center, **PL Dept. of Health & Rehab. Services, U.S.A.;*Newport, U.S.A.**

Objective: To determine differences between gay men who still engage in unprotected anal intercourse, a behavior of particular interest because it is strongly predictive of HIV seroconversion even at low rates of occurrence.
Method: 508 men who patronized 8 gay bars in 3 different American cities (Atlanta, Tampa, & Mobile) completed a survey measure eliciting information on sexual practices over the past 3 months and AIDS risk knowledge, beliefs, and perceived sexual norms. Over 75% of all men entering these bars on survey nights completed the measures.
Results: 17% of the entire sample reported engaging in receptive or insertive unprotected anal intercourse in the preceding 3 months; 87% did not. Multivariate analyses confirmed significant differences (p<.0001) between men who engaged or refrained from this activity. Men who engaged in anal intercourse were more likely to attribute AIDS risk to chlamydia and "powerful other" external factors. They scored lower in AIDS risk knowledge, were younger, and had less education than men who did not engage in the activity. Similar patterns were found regardless of whether subjects were insertive or receptive partners.
Conclusion: Some gay men still engage in high-risk sex. In addition, to continued education, there is a need to stress efficacy themes that one's own behavior (rather than chance or others) determines risk for AIDS. Efforts targeted toward young, less educated gay men are now especially needed.

M.D.P.24

CONDOM USE CAN OCCUR DESPITE USE OF ALCOHOL AND DRUGS
Harrison, Janet, Ph.D.;*Waller, P.*; Bartholow, B.***
Atkins, G.A.*; Jorg, L.***; Centers for Disease Control, Atlanta GA; **Denver Disease Control; ***San Francisco Health Dept.; **Newport Brown Clinic, Chicago IL, USA.**

Objective: To examine the use of alcohol and drugs during high and low risk sexual contacts of homosexual and bisexual men who had engaged in unprotected anal or oral sex during the previous year. Men who had engaged in unprotected anal sex were used to describe the circumstances under which they last engaged in unprotected anal/protected anal sex. Compared the alcohol/drug use of 180 men during their last instance of unprotected anal sex versus their last instance of protected anal sex.
Results: Preliminary analyses (using the McNemar Test for Significance of Change) indicated no significant differences (p>.05) in alcohol/drug use before or during unprotected protected anal sex. Percentage of men using were:

UNPROTECTED/PROTECTED	NO	1-2	3-5	6-10	11-15	16-20	21-30	31-40	41+
ALCOHOL	100	432	302	195	58	21	601		
DRUGS	100	432	302	195	58	21	601		

In response to a question on reasons for not using a condom during alcohol/drug use, only 9.1% listed alcohol/drugs as the major cause.
Conclusion: Among high risk homosexual/bisexual men, alcohol/drug use is associated with sexual behavior in general but not only with unprotected sex. Men can and do use condoms when they are drinking and using drugs. The risk of substance use in high educated gay men are now especially needed, rather than motivating factors.

Session d'affichage Poster Session



Le SIDA et l'individu AIDS and the Individual

M.D.P.37 SEXUAL BEHAVIOUR AND HIV RELATED KNOWLEDGE AMONG A RANDOM SAMPLE OF YOUNG POPULATION OF ITALY.

Marina Giannini, D'Angelo R¹, De Cadedo D², Della Giotta G³, Lino B⁴, Paresi F⁵, et al.
¹ Istituto Superiore di Sanità, Rome, Italy, ² University of Rome, Rome, Italy, ³ Pragma-MRA, Rome, Italy.

Objective: To quantify sexual activity and behaviour and to determine HIV related knowledge.

Methods: A random sample of young population (age 16-30) was selected using a nested sampling procedure. Nine local authorities (Comuni), three each for Northern, Central and Southern Italy and, for each one, one for each of the following population size (10,000-50,000, 50,001-100,000, >100,000) were randomly selected in order to be representative of metropolitan, urban and rural areas. A random sample of individuals was then contacted by the selected local authorities. Each individual was interviewed by the population size of the individual, mentioning the broad scope of the research and the support given by the I.A. to the initiative was sent to the selected individuals. Each individual was then contacted by specially trained interviewers who handed him out a structured questionnaire for self completion. The key questions were asked at first sexual intercourse, number of sexual partners in different periods, use of condoms, knowledge about HIV transmission and use of IV drugs.

Results: 1,450 individuals were contacted. Valid questionnaires were obtained in 1,044, with an overall response rate of 72%. Analysis is not yet completed and will be presented at the Conference.

Conclusions: The good response rate suggests that the population in Italy is prepared to answer questions about their sexual lifestyle.

M.D.P.38 FEE WOMEN FOR SAFER SEX AS A PREDICTOR OF SEXUAL RISK BEHAVIORS IN A SORT OF GAY BAR

Scott, Barbara N., Meyer-Halpern, H.P.L., Green, R.S., Ehrhardt, A.A., and Gorman, J.M.
EIV Center for Clinical and Behavioral Studies, Columbia University, New York State Psychiatric Institute; Columbia University, New York, NY, USA.

Objective: Recent evidence suggests that positive peer norms for safer sex are associated with sexual risk reduction. This study looked at sexual risk behaviors as a function of perceptions of peer norms for safer sex in a sample of gay men. Subjects are primarily white and middle class; target ages: 19-60 years.

Methods: Subjects provided a detailed sexual history, and completed a self-report measure evaluating peer norms regarding safer sex, modeled after Finkelhor's theory of reasoned action.
Results: Preliminary analyses (N=70) indicate that approximately 74% of the cohort engaged in sex with multiple partners. Rates of at least one occasion of unprotected sex were: 56% (receptive anal); 41% (insertive anal); and 80% (vaginal). Subjects' perceptions of peer norms for safer sex were associated with having fewer sex partners (p<.025), with being monogamous (p<.005), with fewer sex occasions (p<.005), and with fewer occasions of unprotected sexual activity, but not with incidence of unprotected insertive or receptive anal activity.

Conclusions: Perceptions of peer norms for safer sex indicate at least some sexual activities, even in a sample of gay men from a highly organized community. Failure of peer norms to predict unprotected passive anal activity may be related to greater incidence of such activity among monogamous men (p<.025).

M.D.P.39 GAY IDENTIFICATION IMPROVES THE EFFECTS OF ALCOHOL USE ON AIDS RISK BEHAVIOR

Robert E. Page, D. Williams, D.J. University of Alabama at Birmingham, University of Illinois at Chicago, USA

Gay males' shift toward safe sex is often attributed to their identification with an active community which promotes safe sex, in contrast to IV drug users. Our data, however, show that many gay males slip from safe sex, and that this is often related to alcohol use. Given the importance of the gay bar, we reasoned that identification with the community, while providing safe sex norms, may also induce risk via exposure to alcohol settings. This process may differ by levels of gay identification.

Objective: To examine the complex relationships among gay identification, involvement in the gay community, alcohol settings, and AIDS risk behavior.

Methods: A structured interview among a sample of 87 gay men from a large urban area.
Results: For all respondents, alcohol use, both by the individual and their primary social network, increased risk for unsafe sex. However, for highly gay identified respondents, alcohol use increased risk behavior via alcohol use in multiple gay settings, and not primarily the bar. In contrast, for low identified respondents, AIDS risk behavior was strongly related to bar-going.
Conclusions: Alcohol continues to be an important risk factor for unsafe sex among gay men. Further, such risk factors operate differently for those with different levels of gay identity. Thus, understanding and/or preventing AIDS risk behavior requires that specific cultural features of the gay community be examined.

Travailleurs de la santé Health Care Workers

M.D.P.41 DECENTRALIZED SERVICES: GLOBAL NETWORK-TYPE APPROACH

POISSON, MARIE, WORMSTEIN, N.K.
AIDS AND TESTING TEAM, QUÉBEC CITY, QC, CANADA

Objective: To make accessible medical and psychosocial services in order to provide persons concerned by HIV infection and AIDS with quality services.

Methods: 1. Setting up of a general practitioner/physician network in the public and private sectors. 2. Selection according to interest, geographical distribution, accessibility and operation methods (confidentiality). 3. Self approach, pre and post-test counseling, coded on-site sampling, medical follow-up, psychological referral. 2. Setting up of a network of psychosocial professionals working in the public and private sectors. 3. Priority interventions: individual consultations, support groups for seropositive persons, case management. 4. Professional expertise: social workers, psychologists, sociologists. 5. Training of medical and psychosocial intervening parties. Information to target groups, interventions among media. Health education. Access to services through Info-Health (24 hr. hot line).

Results: After one year: 1. Staff: 33 physicians, 7 social workers, 2 sociologists, 2 psychologists, 1 nurse, distributed across 18 service points. 2. Achievements: 227 referrals to the medical network by Info-Health, 22 group meetings (seropositive persons), 85 interviews media, 33 presentations (lectures, conferences).
Conclusions: The "network" team is operational. Offered services aim at reaching target groups to help them to reduce their risk factors and to support them in what they are experiencing.

M.D.P.40 KNOWLEDGE, ATTITUDE AND PRACTICE RELATING TO AIDS AMONG A RANDOM SAMPLE OF STUDENTS AT A PARIS UNIVERSITY.

Jean-Marcus, P. Echeverry, V. Massat, F. Sureau, S. Lesieur, et al.
INSERM U263, Université Paris 7, 2, pl. Jussieu, 75251 PARIS, Cedex 05, FRANCE - INSERM Unit, Vigneul, FRANCE

Objective: To provide a database on perception and reaction of beginning university students concerning sexual practices in the AIDS epidemic in order to develop a continuously adapted program of information.

Methods: A 1st IV in the random sample including 471 male and female, 17-22 year old students answered a self-administered anonymous questionnaire, through 140 items, knowledge, attitudes and practice with regard to health in general, sexually transmitted diseases and AIDS.

Results: The response rate was 88%. Less than 5% of questions were unanswered. Questions concerning sexual practices have the same response rate as those concerning knowledge and attitudes. Students are concerned by the quality control of condoms. While 88 % say that they know that condoms, without reference to quality, reduce the risk of getting AIDS, this frequency rises to 82% when the condom proposed has the quality control seal. While 72% of the students actually plan to use condoms, only 49% of questions concerning the practical use of condoms were correctly answered by those students having sexual intercourse and only 40% of students say that they really use it (26% sporadically, 16% systematically). These latter figures do not differ between males and females nor between students with a single sexual partner and those with more than three sexual partners.

Conclusions: A proposed program of information should include a wholly explicit explanation about the practical use of condoms. A pilot program is to be proposed for adoption after discussion with students about specific sensitization and motivation.

M.D.P.42 OVERSTIMATION OF RISK FOR OCCUPATIONAL HIV TRANSMISSION AS A FACTOR IN THE DECISION TO USE CONDOMS

Scott, Barbara N., Meyer-Halpern, H.P., Green, R.S., Ehrhardt, A.A., and Gorman, J.M.
EIV Center for Clinical and Behavioral Studies, Columbia University, New York State Psychiatric Institute; Columbia University, New York, NY, USA.

Objective: To assess the prevalence of gross and exaggerated risk for HIV infection as they potentially function as a factor in the decision to use condoms. The study was conducted in a sample of gay men who were interviewed about their sexual practices and their use of condoms.

Methods: Having questioned by personal staff or apparent best of knowledge about HIV was frequently asked about overestimation because knowledge about occupational risk for HIV was frequently asked about and having studied at a major university. The study was conducted in a sample of gay men who were interviewed about their sexual practices and their use of condoms. The study was conducted in a sample of gay men who were interviewed about their sexual practices and their use of condoms.

Results: A total of 140 gay men were interviewed about their sexual practices and their use of condoms. The study was conducted in a sample of gay men who were interviewed about their sexual practices and their use of condoms.

Conclusions: A proposed program of information should include a wholly explicit explanation about the practical use of condoms. A pilot program is to be proposed for adoption after discussion with students about specific sensitization and motivation.

Session d'affichage Poster Session



Le SIDA et l'individu AIDS and the Individual

M.D.P.43

JOB-RELATED STRESS AMONG HIV-ANTIBODY TEST CONSULTORS
Buss, D. J., Spigel, Susan Liggett, Pagan, S. A., Rhodes, P., **
**California State University, Long Beach, CA, USA

Objective. To assess the stress and level of stress among counseling consultants in July 1987. A questionnaire designed to measure job-related demographic factors was self-administered by 781 (50) of all HIV, and in counseling and testing centers throughout California. Consultants included: respondents ranged to female (82%), white (82%), college educated (77%), and generally scored well on knowledge questions. Gender, education, training or degree, and volunteer versus paid status were not associated with either level of knowledge about HIV/AIDS. Psychosocial factors: 0.18) and stress index (Chronbach's $\alpha = 0.82$). Significant associations ($p < .05$) were observed for: age and knowledge questions (Chronbach's $\alpha = 0.82$); time pressure (Gittelman's $\alpha = 0.82$); and helplessness/optimism scale (Chronbach's $\alpha = 0.82$). Significant associations between levels of stress and counselor age, counselor gender, sexual orientation, and time pressure were observed. Significant associations between stress and stressor were reported by consultants who perceived less control in their work environment ($p < .05$). Age, sex, and education reported stress ($r = 0.22$, $p < .05$). Stress was measured by the S-OSSQ. Significant associations between perceived stress and counseling stressors were reported by consultants who were not target interventions.

M.D.P.44

PRIMARY CARE PHYSICIANS' KNOWLEDGE, ATTITUDES AND WILLINGNESS TO TREAT AIDS PATIENTS

George L. James*, Stoneburner, R., Gemson, D**, Columbus, J.A., and Elinson, J.

*New York City Dept. of Health, **Columbia University, New York, New York

Objective. To examine the relationship between physician knowledge, attitudes, personal characteristics and AIDS prevention and treatment practices. Data were collected from 472 primary care physicians in New York City were taken during 1988 about knowledge, attitudes and clinical practices toward AIDS prevention and treatment.

Methods. Telephone interviews of a representative sample of 472 primary care physicians in New York City were taken during 1988 about knowledge, attitudes and clinical practices toward AIDS prevention and treatment. Thirty-six percent of physicians would refer an HIV patient elsewhere rather than manage alone or in consultation. Stepwise logistic regression analysis estimated the adjusted odds ratios between physician characteristics and willingness to treat AIDS patients shown below.

Characteristic	Adjusted Odds Ratio
Age < 40 years	1.85-2.47
Practice Internal Medicine	2.56
High AIDS Knowledge	1.53-2.42
Liberal Political Orientation	3.22
	1.58-2.51
	1.5-2.65

Physicians' race and attitudes towards homosexuals were not retained in the final logistic model when controlling for variables shown above. Conclusions: Preliminary data suggest that physician age, specialty, level of knowledge and political orientation are associated with willingness to treat AIDS patients.

M.D.P.45

COLLABORATIVE EVALUATION STUDY OF AIDS TRAINING PROGRAMS FOR WOMEN'S HEALTH PROVIDERS

Doherty, M., Coughlin, E.,* Gillette, F.,** Sackel, J.,***
*NYC Dept. of Health, NYC, USA, **Montefiore Medical Center, Bronx, NY, USA, ***NYNY Health Science Center at Brooklyn, NY, USA, ****NY Sexual Health Center, NYC, NY, USA

Objective. To develop, implement and evaluate AIDS training programs for health care providers of inner-city women, so that AIDS education, prevention and counseling can be incorporated into routine women's health services.

Methods. Three NYC teaching hospitals have been selected to conduct training programs for a total of 750 women's health providers using three distinct models: (1) a competency-based, teaching symposia model; (2) a multi-modality model; and (3) a training-of-trainers model. Using a quasi-experimental study method to evaluate training effectiveness, pre- and post-training questionnaires were developed to measure changes in provider knowledge, attitudes and medical practices. As a further assessment of provider training, participants are being asked to report on the AIDS prevention services they receive.

Results. Changes in provider knowledge, attitudes and medical practices before and after the AIDS trainings will be described and analyzed across the three hospitals. Differences in outcome will be reported.

Conclusion. As a result of provider training in AIDS education, prevention and counseling, most women's health providers now incorporate these services into their routine health care. As a next step, it is important to ascertain whether provider training has an effect on the knowledge of AIDS and risk reduction practices among inner-city women who voluntarily seek health care.

M.D.P.46

THE NEEDS OF PERSONS LIVING WITH AIDS
Mena Herr, N.Sc.G.W., C.S.W., Social Services
Advisor, Federal Centre for AIDS, Health and Welfare Canada, Ottawa, Canada

A needs assessment study was conducted across Canada to identify and prioritize the major palliative care needs of persons living with AIDS. A two-part questionnaire was developed to gather both quantitative and qualitative information on eight core issues considered to be critical in the care of AIDS patients. A targeted sampling approach was used to ensure that within four categories of potential respondents, Canadians had with varying amounts of experience in caring for persons living with AIDS were included. The respondents were drawn from every region of the country which included 27 hospitals, 28 palliative care programs, 15 home care/visiting nurse services and 13 community AIDS groups. This presentation will present the results of this study and describe how Canadians who care for persons living with AIDS have spoken about the resources they require to provide an effective and a humane response to this devastating disease. This study has major implications in the development and expansion of Canada's present health care system.

M.D.P.47

THE KNOWLEDGE AND UNDERSTANDING OF HUMAN IMMUNODEFICIENCY VIRAL (HIV) INFECTION AMONG HEALTH CARE WORKERS (HCW) IN TEACHING AND NON-TEACHING HOSPITALS IN JAMAICA.

FRISBY A. OTHMAN, P. Franks

Department of Microbiology, University of the West Indies, Mona, Jamaica, W.I.
The Acquired Immune Deficiency Syndrome (AIDS) is now evolving into a global epidemic affecting a wide cross section of the world's population. Public education on AIDS in Jamaica began in April 1987. No known case of HIV infection in Health Care Workers (HCW) has been reported in Jamaica or in the Commonwealth Caribbean and neither has any study been undertaken to assess the understanding of HIV infections to Health Care Workers in Jamaica.

The aim of this study therefore, was to assess the knowledge and understanding of H.C.W. on HIV transmission and isolation and precision to be instituted for control of HIV infection and also, to ascertain whether any differences in knowledge existed between H.C.W. of teaching and non-teaching hospitals. A total of 650 questionnaires were sent to H.C.W. in four hospitals (2 non-teaching and two teaching), of which 509 were returned, a response rate of 79%. Questions on AIDS transmission via blood transfusion and sexual intercourse and proper disposal of sharps received highest scores (85-100), embracing all groups at both teaching and non-teaching hospitals. The greatest area of misunderstandings and misconceptions were reflected in responses obtained on sharps and needles which received low scores (4-100) for both teaching and non-teaching hospitals.

Our study demonstrated that there was no difference in the knowledge of HIV infection among HCW in teaching and non-teaching hospital, and an urgent need for a comprehensive approach to education of HCW on prevention and control of HIV infection in Jamaica.

M.D.P.48

IMPACT OF AIDS WORKSHOP ON KNOWLEDGE AND ATTITUDES IN HEALTH CARE WORKERS

Charles, Jennifer, Engstrom, M., Shaw, R., Metz, J.
AIDS Training and Information Centre, South Africa Institute for Medical Research, Johannesburg, South Africa

Objective. To determine the state of and change in health care workers (HCW) knowledge and attitude towards HIV infection and AIDS after attending a workshop in 1985. The workshop assessed the national history, transmission and prevention of infection, psycho-social aspects and counselling. The information was presented using a combination of didactic sessions, audio-visual material, role plays, group activities and discussion. 200 participants completed a pre and post-test questionnaire designed to elicit attitudes towards knowledge of the disease. The questionnaires were analysed comparing (1) knowledge before and after the workshop, and (2) the correlation between knowledge and attitude.

Results. Significant differences were found in knowledge and attitudes before and after the workshop. The majority of respondents lacked basic knowledge prior to the workshop. In addition, attitudes changed with more knowledge and anxiety decreased significantly.

Conclusion. The results of this study confirm that workshops promote knowledge, improve attitudes and thereby assist HCW in providing optimal care to patients and disseminating education for prevention of HIV infection and AIDS.

Session d'affichage Poster Session



M.D.P. 49 EXPERIENCE WITH AIDS AMONG 3500 ZAIRIAN HEALTH WORKERS, 1987-1988

Moola, Ndinda, **, Hasiela, K. **, Luusuluira M. **, Bertrand DE **, Kambala TD **, Zaire School of Hygiene, Kinshasa, Zaire
** Tulane University, New Orleans, USA

Objective. To determine the current level of AIDS experience among health workers (HW) throughout Zaire.
Methods. We surveyed 3462 Zairian physicians, nurses, health facility workers, community HW and traditional healers.
Results. A total of 423 reported personally knowing someone with AIDS, and 183 had cared for an AIDS case. Cases were reported from urban and rural areas of all regions. Half of these persons had been informed of AIDS. One-third of persons caring for a patient of his HIV(+) or AIDS status, and 62% favor informing the family. However, only 81 of AIDS cases and 22% of their families were so far informed. These percentages increased greatly between 1987 and 1988, when national policy permitted informing cases of their AIDS status. One-third of respondents favor isolation of AIDS cases, and 3K recommend killing them.
Conclusions. 1) This is the first report suggesting that AIDS can be found throughout Zaire. 2) Patients and families are generally not informed of the AIDS diagnosis. 3) Negative attitudes of HW toward AIDS cases must be addressed to ensure a more positive role of HW in AIDS education activities.

M.D.P. 51 GENERAL PRACTITIONERS AND MANAGEMENT OF HIV INFECTION

Masard, Yvonna, Landman R. **, Fagnan F. **, A. J. Valeron **
INSERM U104, France, ** Services des Maladies Infectieuses, Hôpital Bichat, Paris, France, ** INSERM U240, Paris, France.

Objectives. To survey current practice and attitudes among GPs in relation to the presence of HIV and in relation to the management of HIV infection in asymptomatic, seropositive patients.
Methods. A questionnaire was mailed to all sentinel GPs (N=500) of the French Communicable Diseases Network (1% sample, representative of GPs in France). Questionnaire components included demographic data and attitudes towards HIV screening and follow-up of patients, personal methods for obtaining information about the disease, HIV antibody testing and their strategies for the management of HIV infection.
Results. The response rate was 70%. Within the context of their medical practice, 67% said that they were affected by the subject of HIV infection, while 29% were already caring for an infected individual. 47% of these GPs thought that it was useful for them to follow infected patients. 6% considered these patients to be a normal part of the practice of medicine for a GP. 38% complained that they did not have enough information to do this. 20% of these GPs had reservations about lack of an infected patient's 9% expressed fear of contagion. There was a positive relationship between having reservations about treatment and the perception of the lack of information ($p < 0.05$). 9% of GPs had no systematic routine toward HIV screening and always waited for patients to request the test. HIV testing was systematically proposed by 52% of the GPs in the case of prenatal screening, by 40% for prenatal patients, by 37% for IV drug users, by 30% for homosexual partners.
Conclusion: The better informed a GP is, the more likely he is to have a positive attitude towards prevention and care of HIV infection. HIV testing is more often proposed by GPs when the subject is not a 'prior' at risk (i.e. prenatal or prenatal screening).

M.D.P. 53 ACCESS TO DENTAL CARE IN THE SAN FRANCISCO AIDS BEHAVIORAL RESEARCH COHORT

Griffin, Richard, Maguire, R, Sumner, J, and Coates, T.
University of California, San Francisco, California, San Francisco, United States.

Objective. Press reports in recent years have reported cases of dentists refusing to provide care for HIV infected and HIV infected patients. These reports have raised doubts about whether such patients have full access to dental care. We wished to learn the extent to which a cohort of men with HIV disease or at high risk for HIV disease had used dental treatment.
Methods. The San Francisco AIDS Behavioral Research Cohort were surveyed in November 1988. This group of gay men has been surveyed annually since 1984 to track their reactions to the HIV epidemic. The response rate was approximately 70% (N=336).
Results. Only 5 respondents (1.5%) reported having been rejected from a dental practice in the past 3 years because of their HIV status. Only 16% said they would not inform their dentist if they were HIV positive. Over half (54%) indicated they would freely volunteer the information to their dentist. The remainder said they would disclose their status under certain conditions, e.g. if oral manifestations of the disease were present.
Conclusion. The low prevalence of denial of care suggests that dentists in this community have responded well to the needs of this population. The relative willingness of patients to disclose highly sensitive medical information may be a reflection of the positive response of dentists. It may also reflect stress state and local laws safeguarding confidentiality and prohibiting discrimination and the relatively positive response of San Francisco to the epidemic.
This study was supported by NIMH & NIDA Center grant #49814249.

Le SIDA et l'individu AIDS and the Individual

M.D.P. 50 A RAP SURVEY OF HEALTHCARE WORKERS IN BANGKOK ABOUT AIDS

Thongbun, Prachon, Sittivivat, T. **, and Visuvanond, S. **, Chulalongkorn University Hospital, **Center for AIDS Research, Bangkok, Thailand, Thai Red Cross Society, **National Statistical Office Bangkok

Objectives. To assess the knowledge, attitudes and opinions concerning AIDS among Thai healthcare workers (HCW) in order to find out the basis for their fears and the means to minimize such fears.
Methods. Questionnaire survey was conducted in 274 HCW in 3 hospitals in Bangkok during August-September 1988. Twenty-eight percent of the subjects thought that they have already had some exposure to HIV patients.
Results. Knowledge: Almost a quarter of the HCW admitted that they knew very little about AIDS. The misunderstanding was mainly the risk of HIV transmission with body fluids and the uncertainty about the efficacy of HIV inactivation procedures.
2. Attitudes: More than half of the HCW stated that they rather preferred staying away from HIV patients because of the fear of contracting the disease which they perceived lacked the adequate facility provided by the hospitals.
3. Practices: To make the HCW feel more comfortable in caring for HIV patients, they requested more frequent lectures and information distribution, particularly the measures to prevent nosocomial infection. They also requested free anti-HIV screening for themselves as well as better patient care among Thai healthcare workers (HCW) in order to find out the basis for their fears and the means to minimize such fears.

Conclusion: Results from this study can be used as the background information for every effort to improve the attitude and the quality of patient care in countries where HIV infection just emerges and resources are limited.

M.D.P. 52 WOULD PATIENTS SWITCH PHYSICIANS IF THEIR DOCTOR WERE HIV POSITIVE?

Griffin, Richard, Maguire, R, Hulley, S, and Coates T.
University of California at San Francisco, San Francisco, California, United States.

Objective. To assess patient perceptions of HIV in physicians' offices, including their reactions to physicians with HIV disease for their patients.

Methods. Telephone interviews were conducted in July and August 1988 with 2000 English-speaking, United States adults using a representative national sample generated by random digit dialing. A 73% response rate was achieved. The denominator for the data reported below is all those who received medical care from a physician in the past five years (N=1881; 94% of sample).

Results. Thirty-three percent of the respondents considered it likely that patients could get AIDS from an HIV infected physician. Forty-five percent believed that HIV positive physicians should not be allowed to continue to work (compared to 23% who believed HIV positive school teachers should not work). Fifty-six percent of respondents said they would find another physician if they believed their doctor were HIV positive. Twenty-five percent of the respondents said they would find another physician if they believed their doctor were treating people with HIV disease. Patients who said they would find another physician tended to believe that the virus could be transmitted from an infected physician to patients.
Conclusion: Patients are concerned about the presence of HIV in their doctors' offices but have misconceptions about the likelihood of transmission which should be addressed by public education program.

Supported by NIMH & NIDA #49814249 and the University-wide Task Force on AIDS.

M.D.P. 54 FEAR OF CONTAGION IN HOME HEALTH AIDS:

A COMMUNITY SURVEY

Melchior, Janine Bell, New England Deaconess Hospital, Boston, MA, U.S.A.

Objective: To determine the potential for severity of home health aides (HHA) willing to care for persons with AIDS (PWA) and seropositive persons for their clients.

Methods: A community telephone survey was conducted to the majority of proprietary agencies in our metropolitan area. A total of 21 agencies qualified for the survey. Fully answered the questions. The person in charge of assigning HHAs, usually a nursing supervisor, was asked three questions: 1) Are you having difficulty or do you anticipate having difficulty finding HHAs willing to care for PWA? 2) If yes, why are HHAs refusing to go into the homes of PWA? 3) Would a continuing education program for HHAs on HIV infection be useful to your agency?

Results: Difficulty finding HHAs willing to care is outlined below:

Agency	YES	NO	DON'T KNOW
Responding difficulty	9	2	
Anticipating difficulty	9	2	

Thematic analysis of answers to second question showed a high fear of contagion among HHAs. Contributing factors commonly identified included ethnic and cultural backgrounds of HHA, family pressure, and ignorance. Five of the supervisors felt strongly that education alone was not the answer. The interviews suggested a "kangaroo atmosphere" which either contributed to or ameliorated fear, which coincides with known fear by group anxiety.

Conclusion: Home health agencies may have difficulty meeting increasing needs of PWA's for personal home care due to the cultural, social, as well as educational factors which contribute to fear of contagion among home health aides.

Session d'affichage Poster Session



Le SIDA et l'individu AIDS and the Individual

M.D.P.67

40%-RELATED PROBLEMS FACING GENERAL PRACTITIONERS UPON RELEASE

Edil, Heston, Boston, F. N. and Swetlow, L. S.
F. Institute of Health Services, Belgium and St Scientific College of
General Practitioners in Brussels, Belgium.

In November 1983 a telephone survey was conducted among a representative sample of 175 GPs (12.6% of the total) working in Flanders (Belgium). The items studied were: 1) the proportion of GPs caring for seropositive or Aids patients, the indications for HIV-testing and the reasons later to avoid infection during medical practice. Eight percent of the GPs have at least one Aids seropositive patient and 1.5% the GPs without HIV-testing that for providing this medical care.

Number 12 of physicians asking HIV-test on different indications and number 13 of physicians

informing the patient about the meaning for seropositivity

	within for HIV-test		informing of the patient	
	Medical 12	13	Medical 12	13
physical follow-up	54/105 (51.4)	11/114 (9.7)	41/76 (53.9)	10/103 (9.7)
pregnancy	54/105 (51.4)	11/114 (9.7)	41/76 (53.9)	10/103 (9.7)
STI	54/105 (51.4)	11/114 (9.7)	41/76 (53.9)	10/103 (9.7)
"highly sensitive"	54/105 (51.4)	11/114 (9.7)	41/76 (53.9)	10/103 (9.7)
on the request of the patient	54/105 (51.4)	11/114 (9.7)	41/76 (53.9)	10/103 (9.7)

On the third of the physicians say to have changed their medical practice to avoid infection. Nearly seven percent of them allow either HIV-test or they refuse it. They refuse only a medicine for use during equipment, seven during hair visits 70% of the GPs learn the use of needles and syringes associated with the patient's advice.

Specific training for GPs is needed to be familiar with the needs of consulting seropositive and more informative education is desired to implement the HIV-test in a more appropriate way.

M.D.P.68

EVALUATION DE QUATRE DISPOSITIFS DE PROTECTION DES AIGUILLES USAGES POUR LA PREVENTION DE L'INFECTION HIV CHEZ LES FEMMELES DE SANTE ET PROPOSITION DE CRITERES DE CHOIX

Vismont-Ballemans, P., et al.
Centre Hospitalo-Universitaire, Angers, France ; * Centre Hospitalier,
Bellemeuse, St. Georges, France.

Objectif: Plusieurs dispositifs visant à éviter les piqûres accidentelles des personnels de santé sont aujourd'hui disponibles ; ceux-ci sont très hétérogènes dans leur conception et leur utilisation pratique. Nous avons testé quatre d'entre eux selon des critères rationnels et mesurables. Méthodes: 40 infirmières de 7 services différents de notre CHU ont testé 4 dispositifs couramment utilisés à savoir: Containeur (Sherwood), Sharpsafe (LBA), Acup-sécurité (Amdis) et Securoject (Astrim). Dix critères quantitatifs ou qualitatifs furent cotés: 1) facilité de désinfecter/éliminer l'aiguille et/ou le contenu du contenant; 2) risque de reflux; 3) résistance passive au cisaillement (distorsion, traction...); 4) risque de reflux; 5) résistance passive après usage; 6) acceptabilité sous différents usages (choix de soins, placement...); 7) présence ou non d'un désinfectant; 8) rapport qualité/prix. Résultats: Ils sont globalement satisfaisants pour les 4 dispositifs, mais 1) existe certaines disparités, en particulier pour les critères 3, 4, 5, 6. Discussion: Les critères retenus apparaissent une échelle de méthodologie pour une évaluation objective des différents dispositifs mis sur le marché; 2) ils sont compatibles avec les critères de choix établis dans des protocoles de soins et devraient permettre une acquisition raisonnée fondée sur un ensemble de critères objectifs et quantifiables; 3) convenirait-il d'appliquer ces critères à l'ensemble de l'équipement de soins pour une meilleure utilisation, d'affecter chacun de ces critères d'un coefficient qui tienne à leur importance.

M.D.P.69

MYTHS AND STIGMAS ABOUT AIDS IN HEALTH PERSONNEL IN A LATAMERICAN COUNTRY.

Bernal, M., de la Cruz, Valdeagüero, J.L., Alente, L.J., Granados, M.L., Ramirez, R., Sepúlveda, J.

Central Directorate of Epidemiology, Ministry of Health, Mexico

Objective: To obtain information about knowledge and attitudes of health personnel towards AIDS and the influence of communication media over them.

Methodology: A survey was done in a random sample of 808 health workers (61% (598 doctors and 598 nurses) working in care areas in institutional hospitals in 6 cities in Mexico.

Results: Although most do not identify the disease as produced by HIV (91%), 34% identify it as a disease caused by homosexual intercourse, 19% associate it to casual contact, and 17% to blood donation; more than 80% identify correctly sexual, blood and perinatal transmission and preventive measures. 20% consider that greatest population should be HIV tested. 57% are afraid of being infected, 51% would report an infected person, 80% would feel ashamed if a relative became infected, patient and only 20% would provide financial assistance. 51% would have sexual relations with an infected partner, 67% would refuse taking care of an infected patient and 57% would request another person to do it. 82% consider homosexuality a mental illness, 19% a sin, 60% a sexual aberration; 51% would not have homosexual friends. 40% consider prostitution immoral, 20% a sin and 51% socially condemned. No significant difference was found between attitudes in nurses and doctors. Their contact with information media is adequate, they consider that the messages are of good quality but incomplete.

Conclusions: Health care discordance between having received information and the level of knowledge and attitudes. This was consistent regardless of having received information about AIDS. Information is not enough to modify deeply ingrained attitudes. Educational campaigns must design specific educational strategies that influence social and psychological areas and not only cognitive aspects.

M.D.P.70

HIV-1 KNOWLEDGE, ATTITUDES AND RISK PERCEPTION IN BIOMEDICAL RESEARCH FACILITY EMPLOYEES

Stehman, Rubin, Vlahov, D., Currow, B.,

Johns Hopkins University School of Hygiene and Public Health, Baltimore, MD, USA

Objective: To identify and characterize HIV-1 knowledge, fear and risk perception among employees at a biomedical facility active in AIDS research.

Method: A questionnaire was self-administered by a random sample of 274 employees stratified into occupational groups: 1) custodial/maintenance, 2) clerical/administrative, 3) technical, 4) scientific. Information on potential occupational exposure to HIV-1 was available. The response rate was 64% (n=174). Results: Knowledge scores were high and not significantly different between groups except on a subset of questions dealing with casual

contact. On this section groups 1 and 2 scored significantly lower than groups 3 and 4 (p<0.05). Fear levels were similar across groups; 34% of custodial, 15% of clerical, 26% of technical and 10% of scientific staff reported moderate to high levels of fear. Surprisingly, despite high knowledge levels and wide differing levels of actual risk of exposure, approximately 40% of each occupational group felt themselves to be at occupational risk of HIV-1 infection; approximately 20% of workers assigned their role of infection to 1/10,000 or greater. Conclusion: Although potential actual risk of occupational exposure to HIV-1 varied greatly among a group of research facility workers, similar levels of fear, concern and risk perception were noted. The relatively high levels of fear in low exposure groups may be the result of misunderstandings regarding HIV-1 exposure in the workplace.

M.D.P.71

MEDICAL STUDENTS' KNOWLEDGE AND CONCERNS ABOUT HIV INFECTION

Sklar, J., Lee and Culbert, Arthur

School of Public Health, Harvard School of Medicine, Boston, Mass. U.S.A.

Objective: To examine the knowledge, concerns and attitudes of medical students about HIV, treatment of AIDS patients, and affect on careers.

Method: In May 1988 124 1st year and 103 2nd year medical students at Boston University were surveyed.

Results: All students were knowledgeable about casual, anal/vaginal and drug use transmission of HIV. Approximately 70% of 1st year students reported knowing a great deal about transmission of HIV, risk behaviors, and risk groups. Less than 25% of either year reported knowing a great deal about the legal or ethical obligation to treat AIDS patients, or the cost to patient and society; and less than 10% reported being taught about these issues. Over 50% of both years said you or did not know whether prostitutes, IV drug users, pregnant women, people getting married, and immigrants should be tested for HIV. 85% of 2nd year and 89% of 1st year worried about being infected as medical students, and 60% of 2nd year and 80% of 1st year wanted or were not sure if they should be allowed to refuse to treat AIDS patients. 45% of 2nd year and 27% of 1st year reported that the epidemic will influence their decision to practice clinical medicine.

Conclusions: Medical students' concerns about becoming HIV infected may influence their decision to practice clinical medicine. Their unwillingness to treat AIDS patients, 45% of 2nd year and 27% of 1st year, curricula should address HIV transmission, implications of testing and other AIDS-related policies, and legal, ethical and patient/societal issues.

M.D.P.72

RISK OF OCCUPATIONAL EXPOSURE TO HIV INFECTED BODY FLUIDS AND TRANSMISSION OF HIV-1 AMONG HEALTH CARE WORKERS: A MULTICENTRE STUDY

Ippolito, Giannini, Carrobbi, P., Carosi, G., Ripicco, P., Filini, G., Puro, V., Sanchez, M., Viscusi, D.

The Italian collaborative study group on HIV occupational risk, IRL

Objective: To evaluate the risk of occupational exposure to HIV and other

potentially infected body fluids and the risk of transmission of HIV infection

Method: In Italian hospitals (7840 beds) have been enrolled in a multicentric study on occupational risk of HIV infection. The study is supported, in part, by the Italian Ministry of Health (IDS Project).

All participating hospitals started in March 1985 and 1987. A prospective surveillance of occupational exposures, the risk of exposure, per person/month of work, has been calculated.

Results: In December, 1988, 255 occupational exposures to HIV infected blood or body fluids (parenteral 71.7%, mucous-membrane exposure 28.3%) have been observed on a total of 2220 exposures to potentially contaminated

materials. All HIV exposed to HIV, were prospectively followed and none of them seroconverted after a median follow-up of 13 months (range 2-34 months).

The risk of occupational exposure by occupational group were: nurses 52.1, physicians 28.7, housekeeping 19.8, laboratory technicians 7.3. The risk of seropositivity per person/month of work (on a total of 1465 person/month at risk) was: category was: physician .0066, Nurse .0095, Housekeeping .0004, Laboratory technicians .0011.

Conclusions: Despite massive information, the risk of occupational exposure to HIV contaminated materials continue to be high, but the risk of infection is low.

Session 4/1 Individual Poster Session



Le SIDA et l'individu AIDS and the Individual

M.D.P.73 ADVERSE EXPOSURES TO BLOOD AND BODY FLUIDS AMONG PRACTICING NURSES IN THE UNITED STATES
 Wylie, Mary E., D'Arcy, G., Lawson, N., Wesley, R.* and Janderson, D.K.*. *Clinical Center, N.I.H., Bethesda, MD., U.S.A. **Georgetown University School of Nursing, Washington, D.C., U.S.A.

Objectives: To 1) assess the frequency and intensity of adverse exposures to blood and body fluids and 2) assess the attitudes toward and practices of Universal Precautions (UP) among practicing nurses in the United States.

Methods: Detailed questionnaires requesting demographic data, knowledge and use of infection control procedures, and frequency and types of adverse exposures to blood and body fluids were distributed to certified nurse nurses in the U.S.

Results: 17642503 (60%) returned completed questionnaires. 1562 (88%) of the 1754 respondents provide patient care. Of those providing care, 85% have completed masters level training. With respect to knowledge and use of UP, 65% reported using UP in their practices. Of those not using UP, 40% reported occupational injury with UP, 30% had UP unnecessary, and 79% reported that UP interferes with the patient-nurse relationship. 45% perceive a high risk for occupational infection with hepatitis B virus and 45% perceive a high risk for occupational infection with HIV-1. 49% have received hepatitis B vaccine. Of the 1562, 375 (24%) reported 823 hazardous exposures and 762 (51%) reported 1154 hazardous exposures with blood or amniotic fluid in the past 6 months. **Conclusion:** This national sample of a small, but well-educated population of health-care workers demonstrates a high level of knowledge and use of UP. Although only a small percentage were unfamiliar with UP, almost half do not use UP in practice. These data emphasize the need for effective UP education, stressing both the presence of occupational risk as well as appropriate measures to minimize the risk.

M.D.P.74 THE IMPACT OF AIDS ON HEALTH CARE PROVIDERS: AN ANNOTATED BIBLIOGRAPHY AND SYNTHESIS
 Baskin, J.M., Palmer, Mergley, Taylor, K.M. Physician Behaviour Research Unit, Department of Behavioural Science, University of Toronto, Toronto, Ontario, Canada, M5S 1A8.

To understand further the impact of AIDS on health care providers, the International projects have been conducted by the Global Program on AIDS of the World Health Organization.

(1) Annotated International Bibliography. Drawing on health care and social science literature from around the world, the bibliography will focus on the psychosocial impact of AIDS for the providers of health care on factors associated with this impact, and on the implications of providers' response for the health care system and for quality of care. The bibliography will be based on a theoretical model of health care provider behaviour. Each citation will include a summary and an analytical commentary.

(2) International Survey. Approximately 160 countries will be surveyed to identify: (a) the nature of health care providers in each country who are currently caring for AIDS and seropositive individuals; (b) the major problems faced by these providers; and strategies to deal with them; (c) the settings in which care is being given; (d) the sources of funding; and the role of government in providing care; (e) ongoing research that focuses on the behavioural impact of AIDS on health care providers; (f) services and strategies that will be required in the future and (g) people who are interested in participating in future studies of health care providers and their response to AIDS.

M.D.P.75 THE ROLE OF HOMEMAKER/HOME SUPPORT SERVICES IN AIDS CARE IN CANADA
 Monahan, Kathleen*, Fiets, M.**

* Canadian Council on Homebased Services, Toronto, Ontario, Canada
 ** Family Services Unit, St. Catharines, Ontario, Canada

Objectives: To report the results of the Canadian Council on Homebased Services' AIDS training needs assessment study and describe service care delivery issues in the homebased industry in Canada and Europe.

Methods: Preliminary data from the 1989 C.C.H.S. Study on Homebased Services & Training Needs for AIDS care and from the 8th International Congress of the International Council on Homebased Services (May 7 - 12, 1989) will be presented to identify the issues affecting the delivery of homebased/home support services to persons with HIV/AIDS and their partners/families.

Results: Homebased services to persons with AIDS are now being provided in Europe and Canada through various home care models. Results will be available prior to June, 1989 indicating preferred models, training and support required, client-directed coordination methods, etc.

Conclusion: Participants will increase understanding of factors influencing effectiveness of home support/homebased service for persons with HIV/AIDS in Canada, with similarities to European care models noted.

M.D.P.76 THE DOCTOR-PATIENT RELATIONSHIP:
 IS IT WORKING FOR PEOPLE WITH HIV INFECTION?
 Boland, Michelle and Tomosak, L.

University of California School of Medicine, San Francisco, CA, U.S.A.

Objective: While many articles have been written from the physician's point of view about the doctor-patient relationship, there are few data-based studies from the patient's perspective. The aim of this study is to document the patient's perceptions of their experiences with their health care providers.

Methods: 100 seropositive homosexual men with at least one HIV-related structured interview inquiring about stressors and coping, at 3 time points about 6 months apart.

Results: Data are presented on the frequency and nature of stressful and supportive interactions with HCPs over time in the following areas: (a) communication/information regarding symptoms, treatment, test results, diagnosis, and medical procedures, (b) HCP attitudes about treatment, (c) diagnostic skill, (d) treatment efficacy, (e) hospital stays, (f) clinical trial trials, (g) financial concerns, and (h) appointments. Responses are also tabulated according to type of health care provider and health, as well as diagnostic status of the subject at the time of the interview. Most subjects BCP and/or staff at the clinic, office or hospital however, many also cited doctor-patient relationship stressors and coping changed over time.

Conclusion: A comprehensive understanding of patients' changing needs for information, support, and guidance in the context of the doctor-patient relationship over time and the course of disease will permit HCPs to respond more effectively to these needs or to make appropriate referrals.

M.D.P.77 AIDS/HIV INFECTION: KNOWLEDGE, ATTITUDES, AND BELIEFS OF HEALTH CARE PROVIDERS AND STUDENTS
 Shiu, Diana M.C. and Wong, A.Y.*

*Center for Infectious Diseases and Diseases (CIDDD) at University of California at Los Angeles (UCLA), USA **University of California at Los Angeles (UCLA) School of Dentistry, USA

Objective: To assess the current knowledge, attitudes, and beliefs of dental health faculty and students relative to AIDS/HIV infection as an new high prevalence infectious disease.

Methods: Knowledge of AIDS/HIV infection, attitudes, and beliefs relating to the care of those with AIDS, HIV infection, or at risk were assessed in 100 dental professionals at a school of dentistry in Los Angeles, L.A. 1988. Responses were received from 63 faculty members, 161 practitioners (year 1 and 2), and 175 dental (1 to 4) students were surveyed.

Results: Preliminary data demonstrated AIDS knowledge (measured by 20 items) was generally high, yielding a high mean correct score for all three groups (17.2, 17.5 and 16.9 for the faculty (F), dental students (S), and preclinical students (PC), respectively). However, there were a number of people who incorrectly answered questions related to HIV transmission, such as: from the water supply (25% F, 39% S, 39% PC), food handlers (19% F, 17% S, 21% PC), airborne transmission (29% F, 36% S, 28% PC), and donating blood (59% F, 20% S, 28% PC). Many dental faculty and students had a negative attitude regarding the dental professional's obligation to treat the AIDS/HIV infected individual; contributing to the reluctance by all three groups to treat was the fear of becoming infected and the potential loss of other patients. Although both dental faculty and students felt the AIDS patient had a right to quality dental care (94% F, 92% S, 92% PC), many felt dental professionals should be allowed to refuse care to AIDS patients (64% F, 46% S, 47% PC) and/or refer such individuals (58% F, 54% S, 47% PC). Among the three groups there were 65% F, 61% S, and 61% PC who believed that dental professionals should be 47% of the dental students, 78% of the preclinical, and 77% of the faculty believed their skills to be less than those of dental students. Both faculty and students were more about AIDS/HIV infection and infection control.

Conclusion: Preliminary data suggest that lack of knowledge regarding AIDS transmission, lack of skills, and concerns about the risk of infection may be deterrents to treating AIDS/HIV infected patients. Education in infectious diseases and AIDS/HIV infection, and the development of specific factors to enhance treatment of HIV infected patients by present and future dental health professionals.

M.D.P.78 PHYSICIANS' PERCEPTION OF PERSONAL RISK FROM AIDS (HIV) VIRUS
 Taylor, Kathryn M., Skinner, J.A., Ezdin, J.A., Bellner, W.H.,

Physician Behaviour Research Unit, Department of Behavioural Science, University of Toronto, Toronto, Ontario, Canada, M5S 1A8.

This research reports on physicians' perception of personal risk as a key element in their response to AIDS. In a questionnaire instrument we developed, the Physician AIDS Profile, we surveyed 440 physicians from a variety of specialties. A 1 month follow-up study of 100 physicians from the same specialties. We obtained a 10% (N=267) response rate from the mailed survey.

The concept of personal risk was differentiated into 1. physical risk of contagion and 2. social risk (such as professional burn-out) in caring for HIV positive patients. Separate indices were derived for each type of risk and statistical analyses were conducted. The significant findings included: (1) perceived physical risk was moderately but not highly correlated with perception of social risk (Pearson's $r = .49$, $p < .001$); (2) primary source of income (fee for service vs. salary), not medical specialty, was the most significant demographic variable in predicting physicians' perception of physical and social risk; and (3) perception of social risk tended to decrease as physicians were exposed to more seropositive patients in their practice, whereas there was no relationship between proportion of personal risk and number of seropositive patients. Physicians' perception of personal risk is a key factor in understanding their complex response to AIDS.

Session d'affichage Poster Session



Le SIDA et l'individu AIDS and the Individual

M.D.P.79

PRACTICES AND ATTITUDES OF HEALTH CARE WORKERS (HCW) TOWARDS HIV-INFECTED PATIENTS IN A LARGE ACUTE CARE HOSPITAL.
S. J. "BILLY" McDonald, M. J. Pansky, C. G. Lefort-Jost, J. A. *

* Dalhousie University Faculty of Medicine and Victoria General Hospital
** Victoria General, Nova Scotia Canada

Objective: To determine the attitudes and practices of HCW towards HIV-infected patients (HIV pts) in an 800-bed university hospital.
Methods: A 60-item anonymous questionnaire was distributed to 2,425 HCW Dec. 1988-Jan. 89. Standard demographic data, occupation, compliance with hospital guidelines, knowledge and attitudes about HIV, hepatitis B and serology were assessed.

Results: 1,137 responses (47%) have been analyzed to date. 44% of physicians and 55% of nurses had cared for HIV pts. 54% nurses vs 30% physicians were HCW for blood drawing and placement (p<.001). 77% nurses vs 42% physicians were gloves to move HIV patients from stretcher to bed (p<.001). Both groups thought it was more likely that they could acquire HIV from work-related activities than non-work-activities. Both groups took more inappropriate precautions for HIV pts vs Hep B pts (p<.001). 33% of physicians and 50% of nurses thought they should have the option to refuse care for HIV pts. 80% felt that they should be increased for HIV on admission; 40% felt that hospital staff should be notified; 80% felt HIV (+) staff should not be permitted to give direct patient care.

Conclusions: Despite intensive HIV education in our hospital, significant personal fears and misinformation still exist. Comparison of attitudes toward HepB and HIV suggest some fears are based on attitudes rather than risk.

M.D.P.80

AIDS AND DENTAL HEALTH PROFESSIONALS: KNOWLEDGE, ATTITUDES AND INFECTION CONTROL PRACTICES

S. J. "FRANCIS" Stepien, R. W. Kronenfeld, J. J. Daniel, J. M. * and Jackson, R. ** University of South Carolina School of Dentistry, 100 South Carolina Department of Health and Environmental Control, Columbia, S.C., USA

Objective: To determine the knowledge, attitudes and infection control practices related to AIDS among dental health professionals.

Methods: 584 dentists and dental hygienists responded to a survey. The questionnaire contained 54 multiple choice questions on knowledge, attitudes and infection control practices. Scores for knowledge, attitudes and infection control practices were calculated. Data were analyzed using chi-square tests, two sample t-tests, analysis of variance and Pearson correlation matrix.

Results: Respondents were quite knowledgeable about AIDS and HIV transmission. 75% knew the oral manifestations of AIDS. Dentists had a higher mean knowledge score than dental hygienists. Dental hygienists scored higher on infection control practices than dentists. 57% of the dentists felt safe in treating AIDS patients. Older dentists, dental hygienists had lower levels of knowledge about AIDS and infection control practices. There was no correlation between perceived risks and infection control practices.

Conclusion: Despite their high level of knowledge about AIDS, only 57% of the dentists were willing to treat AIDS patients and 43% perceived that they were at risk for HIV just the other health care workers. Only 64% of the dentists reported they were using gloves. More educational efforts should be aimed at dental professionals with emphasis on allaying their fear of AIDS and improving their infection control practices.

M.D.P.81

A METHOD FOR IMPLEMENTATION OF UNIVERSAL PRECAUTIONS
L. A. Chidister, M. S. F. Nottelbart, P. W. Soffen, J. Fiat, R. E. Hagan & W. H. Miller, Boston, Massachusetts USA

Objective: Develop a method for simple and objective determination of protection required by various blood and body fluid exposures which is recommended by the CDC. A form was designed that allows identification of representative procedures, the types of exposure to potentially infectious materials, and the classification of risk of exposure and type of fluid automatically indicates the barrier protections required.

Task	Exposure Body Fluid		Type	Contamination of Clothing		Risk	Barrier Protection
	Blood	Fluids		High	Low		
	High	Low	Direct	High	Low	High	Low
	High	Low	Indirect	High	Low	High	Low

Body Fluid: High - highly infectious; Low - potential transmission. **Contamination:** High - splash, spillage, contact; Low - contact with surface. **Risk:** High - splash, spillage, contact; Low - contact with surface.

Results: Supervisors used these forms to classify activities in their departments. Thirty-two managers identified an average of 50 tasks. After review, these forms formed the basis of detailed infection control guidelines. They were used for in-service education programs and are maintained at each work area for reference by hospital personnel.
Conclusion: This task worksheet simplified development of standardized barrier techniques. It improved understanding by hospital personnel of the requirements of blood and body fluid precautions, and facilitated compliance with required procedures.

M.D.P.82

A SURVEY OF KNOWLEDGE AND ATTITUDES CONCERNING HIV INFECTION AND AIDS AMONG FACULTY AND STUDENTS

THREE UNITED STATES DENTAL SCHOOLS
J. M. * Jones, S. R. * Robinson, J. W. * Holleran, J. A. ** and
University of Texas Dental School at San Antonio, **University of Texas at
San Antonio, **University of Detroit Mercy, Detroit, Michigan, U.S.A.

Objective: Compare knowledge and attitudes concerning HIV infection and AIDS among dental faculty and students in different U.S. cities. **Methods:** A questionnaire was distributed at 3 dental schools in 3 different cities (Detroit, Houston, and San Antonio). Frequency distribution was determined for all questions. General knowledge scores were obtained and classified.

Knowledge characteristics: personal infection concern, and professional self confidence were determined. **Results:** The 500 survey participants scored a 75% correct response rate although areas of weakness were noted. Faculty and student knowledge was comparable in all areas except for infection control (faculty 64%, students 54%). About half of respondents indicated anti-HIV test was diagnostic for AIDS. Faculty were twice as knowledgeable about agents which inactivate HIV. About 3/4 of respondents felt they should have the right to refuse treatment to a patient with AIDS/ARC and about 50% would refer such patients. All participants expressed a high index of personal infection concern, although the faculty expressed more professional self confidence. **Conclusion:** The majority of participants were reluctant to treat HIV positive and diagnosed AIDS patients as indicated by high response rates concerning referral, although they felt an obligation to treat these patients. The greatest knowledge deficit was use of virucidal chemical disinfectants and universal precautions for contaminated items.

M.D.P.83

HIV-RELATED RISK, WORRY AND BEHAVIOR CHANGES AMONG EMERGENCY MEDICAL WORKERS: PERSONAL AND JOB-RELATED FACTORS
Bolin, T. J. Zimmerman, N. M. Rodriguez, J. Patrono-Rosse, J. University of Miami, Miami, Florida, USA

Objective: To evaluate the relationship in job-related and socially transmitted risks for HIV infection to worry and behavior changes among emergency medical workers.

Methods: A voluntary, anonymous, self-administered questionnaire with 149 items related to HIV infection, job-related functions, sexual practices, and demographic variables was completed by 268 Emergency Medical Technicians, Paramedics, and Firefighters.

Results: 44% perceived themselves to be at high risk for contracting HIV infection through job-related activities and T related to sexual behaviors (paired t=13.60, p<.0001). Perceived job-related risks included needle sticks and negative attitudes toward AIDS patients (p<.01). 73% indicated worry about contracting HIV infection from patients; 51% from sexual activity (paired t=14.24, p<.0001). Predictors of job-related worry included marital status (B=.17, p<.01), worry related to sexual transmission of HIV (B=.28, p<.0001), and self-perceived high occupational risk (B=.24, p<.0001). 80% changed job-related behavior according to recommended CDC infection control guidelines. 6% used condoms regularly. Predictors of job-related behavior changes included a negative attitude toward AIDS patients (B=-.20, p<.01) and worry about contracting HIV infection from patients (B=.21, p<.01).

Conclusions: Among emergency medical workers, perceived job-related risks and HIV infection increased worry to motivate job-related behavior changes. In contrast, perceived sexual-related risks increased worry but minimally motivated sexual behavior changes.

M.D.P.84

ATTITUDES AND PRACTICES OF GENERAL INTERNISTS REGARDING CARE OF PEOPLE WITH HIV INFECTION
R. Haddad-Maxey, M. **, and Phillips B. **
*Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts
**Boston University School of Medicine, Boston, MA, USA

Objective: To understand the attitudes and practices of primary care physicians concerning the care of people with HIV infection.

Methods: We surveyed the members of the Society of General Internal Medicine in 1987. Of 1753 surveys mailed, 75% were returned; 569 respondents indicated they had cared for a subjectively defined HIV patient.

Results: These general internists were asked about their care of people with HIV infection. 89% felt it most appropriate to counsel patients as AIDS risk reduction. 89% felt it most appropriate to evaluate and diagnose HIV infection and 52% felt they should follow people with HIV infection using subspecialty consultations when necessary. Only 6% felt it was most appropriate to refer AIDS patients to a specialist for primary care. They asked what would be effective ways to expand the role of primary care physicians in caring for those with HIV infection. 85% requested education on medical aspects of care. 83% wanted information about community services, and 38% sought help confronting fears and/or negative feeling about high risk individuals. **Conclusion:** Most general internists surveyed feel their role includes providing primary care for people with HIV infection. However, strategies must be developed to provide explicit education and emotional support in order to maximize the role played by these physicians.

Session d'attachage Poster Session



Le SIDA et l'individu AIDS and the Individual

Adolescents (partie 2)

Adolescents (Part 2)

T.D.P.1 MODIFICATIONS OF SEXUAL ACTIVITIES IN THE ERA OF AIDS: A TREND ANALYSIS

Yves-Jean LEBLANC
Gilles St. Laurent, Quebec, Canada; and
University of Calgary, Alberta, Canada.

Objectives: To assess whether sexual conduct of primarily heterosexual 17-21 year olds has changed since 1981 in a direction likely to reduce transmission of HIV.

Methods: Licit sexual history is used to identify trends and reversals of trends evident in responses of 1534 Montreal College students to questionnaires administered in 1981, 1983, 1985 and 1988.

Results: Trends showed decreasing age of first sexual intercourse, increased likelihood of males participating in same-sex sexual activities, likelihood of coital partners, increasing numbers of coital partners at least once use of condoms were identified for 1981 to 1985. In 1988 there is a reversal in the first two trends, and a continuation of the third.

Conclusions: Based on the students surveyed, initiation of risk-related sexual activity was more likely to be postponed and condoms more likely to be used in 1988 than in 1981-1985. There was no change in the incidence of casual sex or reduction in the number of sexual partners reported from 1981 to 1988.

T.D.P.3 SHORT-TERM IMPACT OF AN AIDS EDUCATION CURRICULUM FOR ADOLESCENTS

Blake, S., Timsone, L., and Mikhedon R.
University of Washington, U.S.A.

Objectives: To assess the short-term impact of an AIDS curriculum for adolescents on knowledge, attitudes, and behaviors related to AIDS, and to explore factors associated with change.

Methods: Two junior high schools in an ethnic, suburban community within the Boston metropolitan area participated in a 4-week AIDS education program. A treatment-delayed control group design was employed wherein 1/2 of the students received the educational program in health education classes, and the other 1/2 received no education. Measures of knowledge, attitudes, and behavior were obtained from all students before and after the program.

Results: Chi-square test statistics revealed relatively few baseline differences between students in the treatment and control groups (n=289) prior to the education program in HIV knowledge, attitudes, or behavior. Significant differences were observed following the curriculum with students receiving the program having improved scores on most measures of knowledge, attitudes, and behavior when compared to the control group. Results from further statistical analyses controlling for baseline differences between groups, and baseline scores will be presented.

Conclusions: The relative impact of an AIDS education curriculum on knowledge and attitudes can be demonstrated with junior high school students. Greater difficulty exists in documenting behavior change due to school system constraints, temporal factors, and the expected prevalence of risk behavior at lower ages.

T.D.P.5 CORRELATION BETWEEN 24, 26 AND 29 SERO-CD POSITIVENESS

Zelen, Mueli; Rice, J. and Reart, P.
National Institute of Public Health, Oslo, Norway.

Use of condoms is widely accepted as a "safe-sex" practice. The present study was undertaken to assess the level of understanding of condom behavior in Norwegian adolescents. The material comprised a representative sample of 860 persons in the age group 17 to 19, and a representative sample of 616 data were collected by self-administered questionnaires. The results showed that 68% of the boys, and 68% of the girls had used their sexual partners. For the 17 year-olds, 67% of the 18 year-olds, and 80% of the 19 year-olds. Median age at first intercourse for both sexes, and all age groups were 17. The proportions in the respective age groups who claimed they did not use condoms habitually were 33, 36, and 44%. However, 37% of the boys, and 36% of the girls used condoms at their last sexual intercourse. In order to provide a better understanding of condom behavior, the theory of reasoned action was applied, in which the intention to use condoms at the next intercourse was considered to be a function of attitudes towards use of condoms as well as personal use and subjective norms. Preliminary analysis of the model showed that behavioral beliefs related to the immediate consequences of condom use and the sexual context, and the normative expectations of significant others were the strongest determinants of intention (beta-coefficients 0.20-0.60). There was no relationship between neither intention to use condoms nor actual use of condoms and friends' intention. The theory of reasoned action was found to be a sufficient understanding of intention to use condoms, but further empirical analysis in terms of estimating the full model are forthcoming.

T.D.P.2 SEXUAL BEHAVIOR, CONTRACEPTIVE USE, AND STD HISTORY AMONG INTERCOLLEGE COLLEGE STUDENTS

Janet M. Ralston, S. A. Sanders, M. Zivich-Davis, and C. A. Hess
The Kinsey Institute for Research in Sex, Gender, and Reproduction, Indiana University, Bloomington, IN, U.S.A.

Objectives: To describe the prevalence and frequency of sexual behaviors of college-age university students that place them at increased risk for Human Immunodeficiency Virus (HIV) infection. A questionnaire developed by The Kinsey Institute asked respondents to indicate which of specific sexual behaviors they had engaged in and to report on a number of other factors relevant to HIV transmission.

Results: Data on the sexual histories of 810 self-selected college students, who based on their demographic characteristics appear to be representative of the targeted student population, were obtained. The typical respondent was 22 years old, white, Protestant, politically moderate, and from the Midwest. In reporting on sexual behavior, we consider only those respondents who labeled themselves as currently heterosexual (over 90%) and have experienced penile-vaginal or penile-oral intercourse. Over 80% of the respondents reported use of one or both of these behaviors, while over 20% of the females and 77% of the males reported engaging in heterosexual anal intercourse at least once. Of these self-labeled heterosexual males, 3,399 had engaged in anal intercourse with another male. The average number of one-night stands was 3.75, while the average number of male partners for females was 4.17 and the average number of female partners for males was 3.72. Less than a third of the respondents had used a condom the last time they engaged in male-vaginal or penile-oral intercourse, while close to a quarter had either used no contraception or used the rhythm or withdrawal methods. Approximately one in five respondents had experienced some form of sexually-transmissible disease (STD).

Conclusions: Although the young adults in this sample have been sexually active a relatively short time, they have both engaged in unprotected sexual activity and had multiple sexual partners. Based on 16 behaviors, these findings might be regarded as a conservative estimate of the proportion of young adults in the U.S.A. who engage in sexual activities which place them at risk for STD's, including HIV.

T.D.P.4

SEXUAL BEHAVIOR IN HIGH-RISK ADOLESCENTS
Meyer-Bahlburg, Helmut F.L., Netherem-Borus, M.J., Koopman, C., Emery, J.R., and Hirschman, S.B.
New York State Psychiatric Institute and Columbia University, New York, N.Y., U.S.A.

Objectives: To evaluate sexual behavior in high-risk adolescents and youths who are believed to be at high risk of unprotected sexual activities and HIV infection.

Methods: A detailed semi-structured sexual history interview, the Sexual Risk Behavior Assessment Schedule for Youths (SRBAS-Y): Meyer-Bahlburg et al., 1988) was developed in 3 iterations, extensively piloted, and then administered to 50 males and 50 females in 2 runaway shelters, and to 50 homosexual males in a special agency, all ranging in age from 12-18 years, with an overrepresentation of minorities.

Results: Preliminary analyses showed that 56% of the adolescents engaged in sexual intercourse during the past 3 months prior to evaluation, with significant differences between the 3 groups. Males reported significantly more partners and sexual occasions than females did. Only a small minority of adolescents in either group used condoms at all, and those who did so used condoms inconsistently and infrequently. Gay males were more likely to use condoms (r = .48) they experienced.

Conclusions: These results confirm that runaway adolescents are a high-risk sex group and in need of preventive intervention.

T.D.P.6 THE IMPACT OF FEMALE'S KNOWLEDGE AND CONCERN OF AIDS ON SEXUAL BEHAVIOR AND PREVENTION STRATEGIES

Samuel J. Hamrick, AIDS Prevention Center,
San Francisco, California, U.S.A.

Objectives: To assess the impact of teenager's delinquent behavior and attitudes on their sexual behavior, condom use, and prevention strategies. **Methods:** A survey of 419 high school students (15-19 years old) and representative of all ethnic groups was conducted. The survey included questions on: (1) whether they had ever had sex (181 females and 138 males); (2) whether they had ever used a condom (124 females and 112 males); (3) whether they had ever used a condom (124 females and 112 males); (4) whether they had ever used a condom (124 females and 112 males); (5) whether they had ever used a condom (124 females and 112 males); (6) whether they had ever used a condom (124 females and 112 males); (7) whether they had ever used a condom (124 females and 112 males); (8) whether they had ever used a condom (124 females and 112 males); (9) whether they had ever used a condom (124 females and 112 males); (10) whether they had ever used a condom (124 females and 112 males); (11) whether they had ever used a condom (124 females and 112 males); (12) whether they had ever used a condom (124 females and 112 males); (13) whether they had ever used a condom (124 females and 112 males); (14) whether they had ever used a condom (124 females and 112 males); (15) whether they had ever used a condom (124 females and 112 males); (16) whether they had ever used a condom (124 females and 112 males); (17) whether they had ever used a condom (124 females and 112 males); (18) whether they had ever used a condom (124 females and 112 males); (19) whether they had ever used a condom (124 females and 112 males); (20) whether they had ever used a condom (124 females and 112 males); (21) whether they had ever used a condom (124 females and 112 males); (22) whether they had ever used a condom (124 females and 112 males); (23) whether they had ever used a condom (124 females and 112 males); (24) whether they had ever used a condom (124 females and 112 males); (25) whether they had ever used a condom (124 females and 112 males); (26) whether they had ever used a condom (124 females and 112 males); (27) whether they had ever used a condom (124 females and 112 males); (28) whether they had ever used a condom (124 females and 112 males); (29) whether they had ever used a condom (124 females and 112 males); (30) whether they had ever used a condom (124 females and 112 males); (31) whether they had ever used a condom (124 females and 112 males); (32) whether they had ever used a condom (124 females and 112 males); (33) whether they had ever used a condom (124 females and 112 males); (34) whether they had ever used a condom (124 females and 112 males); (35) whether they had ever used a condom (124 females and 112 males); (36) whether they had ever used a condom (124 females and 112 males); (37) whether they had ever used a condom (124 females and 112 males); (38) whether they had ever used a condom (124 females and 112 males); (39) whether they had ever used a condom (124 females and 112 males); (40) whether they had ever used a condom (124 females and 112 males); (41) whether they had ever used a condom (124 females and 112 males); (42) whether they had ever used a condom (124 females and 112 males); (43) whether they had ever used a condom (124 females and 112 males); (44) whether they had ever used a condom (124 females and 112 males); (45) whether they had ever used a condom (124 females and 112 males); (46) whether they had ever used a condom (124 females and 112 males); (47) whether they had ever used a condom (124 females and 112 males); (48) whether they had ever used a condom (124 females and 112 males); (49) whether they had ever used a condom (124 females and 112 males); (50) whether they had ever used a condom (124 females and 112 males); (51) whether they had ever used a condom (124 females and 112 males); (52) whether they had ever used a condom (124 females and 112 males); (53) whether they had ever used a condom (124 females and 112 males); (54) whether they had ever used a condom (124 females and 112 males); (55) whether they had ever used a condom (124 females and 112 males); (56) whether they had ever used a condom (124 females and 112 males); (57) whether they had ever used a condom (124 females and 112 males); (58) whether they had ever used a condom (124 females and 112 males); (59) whether they had ever used a condom (124 females and 112 males); (60) whether they had ever used a condom (124 females and 112 males); (61) whether they had ever used a condom (124 females and 112 males); (62) whether they had ever used a condom (124 females and 112 males); (63) whether they had ever used a condom (124 females and 112 males); (64) whether they had ever used a condom (124 females and 112 males); (65) whether they had ever used a condom (124 females and 112 males); (66) whether they had ever used a condom (124 females and 112 males); (67) whether they had ever used a condom (124 females and 112 males); (68) whether they had ever used a condom (124 females and 112 males); (69) whether they had ever used a condom (124 females and 112 males); (70) whether they had ever used a condom (124 females and 112 males); (71) whether they had ever used a condom (124 females and 112 males); (72) whether they had ever used a condom (124 females and 112 males); (73) whether they had ever used a condom (124 females and 112 males); (74) whether they had ever used a condom (124 females and 112 males); (75) whether they had ever used a condom (124 females and 112 males); (76) whether they had ever used a condom (124 females and 112 males); (77) whether they had ever used a condom (124 females and 112 males); (78) whether they had ever used a condom (124 females and 112 males); (79) whether they had ever used a condom (124 females and 112 males); (80) whether they had ever used a condom (124 females and 112 males); (81) whether they had ever used a condom (124 females and 112 males); (82) whether they had ever used a condom (124 females and 112 males); (83) whether they had ever used a condom (124 females and 112 males); (84) whether they had ever used a condom (124 females and 112 males); (85) whether they had ever used a condom (124 females and 112 males); (86) whether they had ever used a condom (124 females and 112 males); (87) whether they had ever used a condom (124 females and 112 males); (88) whether they had ever used a condom (124 females and 112 males); (89) whether they had ever used a condom (124 females and 112 males); (90) whether they had ever used a condom (124 females and 112 males); (91) whether they had ever used a condom (124 females and 112 males); (92) whether they had ever used a condom (124 females and 112 males); (93) whether they had ever used a condom (124 females and 112 males); (94) whether they had ever used a condom (124 females and 112 males); (95) whether they had ever used a condom (124 females and 112 males); (96) whether they had ever used a condom (124 females and 112 males); (97) whether they had ever used a condom (124 females and 112 males); (98) whether they had ever used a condom (124 females and 112 males); (99) whether they had ever used a condom (124 females and 112 males); (100) whether they had ever used a condom (124 females and 112 males); (101) whether they had ever used a condom (124 females and 112 males); (102) whether they had ever used a condom (124 females and 112 males); (103) whether they had ever used a condom (124 females and 112 males); (104) whether they had ever used a condom (124 females and 112 males); (105) whether they had ever used a condom (124 females and 112 males); (106) whether they had ever used a condom (124 females and 112 males); (107) whether they had ever used a condom (124 females and 112 males); (108) whether they had ever used a condom (124 females and 112 males); (109) whether they had ever used a condom (124 females and 112 males); (110) whether they had ever used a condom (124 females and 112 males); (111) whether they had ever used a condom (124 females and 112 males); (112) whether they had ever used a condom (124 females and 112 males); (113) whether they had ever used a condom (124 females and 112 males); (114) whether they had ever used a condom (124 females and 112 males); (115) whether they had ever used a condom (124 females and 112 males); (116) whether they had ever used a condom (124 females and 112 males); (117) whether they had ever used a condom (124 females and 112 males); (118) whether they had ever used a condom (124 females and 112 males); (119) whether they had ever used a condom (124 females and 112 males); (120) whether they had ever used a condom (124 females and 112 males); (121) whether they had ever used a condom (124 females and 112 males); (122) whether they had ever used a condom (124 females and 112 males); (123) whether they had ever used a condom (124 females and 112 males); (124) whether they had ever used a condom (124 females and 112 males); (125) whether they had ever used a condom (124 females and 112 males); (126) whether they had ever used a condom (124 females and 112 males); (127) whether they had ever used a condom (124 females and 112 males); (128) whether they had ever used a condom (124 females and 112 males); (129) whether they had ever used a condom (124 females and 112 males); (130) whether they had ever used a condom (124 females and 112 males); (131) whether they had ever used a condom (124 females and 112 males); (132) whether they had ever used a condom (124 females and 112 males); (133) whether they had ever used a condom (124 females and 112 males); (134) whether they had ever used a condom (124 females and 112 males); (135) whether they had ever used a condom (124 females and 112 males); (136) whether they had ever used a condom (124 females and 112 males); (137) whether they had ever used a condom (124 females and 112 males); (138) whether they had ever used a condom (124 females and 112 males); (139) whether they had ever used a condom (124 females and 112 males); (140) whether they had ever used a condom (124 females and 112 males); (141) whether they had ever used a condom (124 females and 112 males); (142) whether they had ever used a condom (124 females and 112 males); (143) whether they had ever used a condom (124 females and 112 males); (144) whether they had ever used a condom (124 females and 112 males); (145) whether they had ever used a condom (124 females and 112 males); (146) whether they had ever used a condom (124 females and 112 males); (147) whether they had ever used a condom (124 females and 112 males); (148) whether they had ever used a condom (124 females and 112 males); (149) whether they had ever used a condom (124 females and 112 males); (150) whether they had ever used a condom (124 females and 112 males); (151) whether they had ever used a condom (124 females and 112 males); (152) whether they had ever used a condom (124 females and 112 males); (153) whether they had ever used a condom (124 females and 112 males); (154) whether they had ever used a condom (124 females and 112 males); (155) whether they had ever used a condom (124 females and 112 males); (156) whether they had ever used a condom (124 females and 112 males); (157) whether they had ever used a condom (124 females and 112 males); (158) whether they had ever used a condom (124 females and 112 males); (159) whether they had ever used a condom (124 females and 112 males); (160) whether they had ever used a condom (124 females and 112 males); (161) whether they had ever used a condom (124 females and 112 males); (162) whether they had ever used a condom (124 females and 112 males); (163) whether they had ever used a condom (124 females and 112 males); (164) whether they had ever used a condom (124 females and 112 males); (165) whether they had ever used a condom (124 females and 112 males); (166) whether they had ever used a condom (124 females and 112 males); (167) whether they had ever used a condom (124 females and 112 males); (168) whether they had ever used a condom (124 females and 112 males); (169) whether they had ever used a condom (124 females and 112 males); (170) whether they had ever used a condom (124 females and 112 males); (171) whether they had ever used a condom (124 females and 112 males); (172) whether they had ever used a condom (124 females and 112 males); (173) whether they had ever used a condom (124 females and 112 males); (174) whether they had ever used a condom (124 females and 112 males); (175) whether they had ever used a condom (124 females and 112 males); (176) whether they had ever used a condom (124 females and 112 males); (177) whether they had ever used a condom (124 females and 112 males); (178) whether they had ever used a condom (124 females and 112 males); (179) whether they had ever used a condom (124 females and 112 males); (180) whether they had ever used a condom (124 females and 112 males); (181) whether they had ever used a condom (124 females and 112 males); (182) whether they had ever used a condom (124 females and 112 males); (183) whether they had ever used a condom (124 females and 112 males); (184) whether they had ever used a condom (124 females and 112 males); (185) whether they had ever used a condom (124 females and 112 males); (186) whether they had ever used a condom (124 females and 112 males); (187) whether they had ever used a condom (124 females and 112 males); (188) whether they had ever used a condom (124 females and 112 males); (189) whether they had ever used a condom (124 females and 112 males); (190) whether they had ever used a condom (124 females and 112 males); (191) whether they had ever used a condom (124 females and 112 males); (192) whether they had ever used a condom (124 females and 112 males); (193) whether they had ever used a condom (124 females and 112 males); (194) whether they had ever used a condom (124 females and 112 males); (195) whether they had ever used a condom (124 females and 112 males); (196) whether they had ever used a condom (124 females and 112 males); (197) whether they had ever used a condom (124 females and 112 males); (198) whether they had ever used a condom (124 females and 112 males); (199) whether they had ever used a condom (124 females and 112 males); (200) whether they had ever used a condom (124 females and 112 males); (201) whether they had ever used a condom (124 females and 112 males); (202) whether they had ever used a condom (124 females and 112 males); (203) whether they had ever used a condom (124 females and 112 males); (204) whether they had ever used a condom (124 females and 112 males); (205) whether they had ever used a condom (124 females and 112 males); (206) whether they had ever used a condom (124 females and 112 males); (207) whether they had ever used a condom (124 females and 112 males); (208) whether they had ever used a condom (124 females and 112 males); (209) whether they had ever used a condom (124 females and 112 males); (210) whether they had ever used a condom (124 females and 112 males); (211) whether they had ever used a condom (124 females and 112 males); (212) whether they had ever used a condom (124 females and 112 males); (213) whether they had ever used a condom (124 females and 112 males); (214) whether they had ever used a condom (124 females and 112 males); (215) whether they had ever used a condom (124 females and 112 males); (216) whether they had ever used a condom (124 females and 112 males); (217) whether they had ever used a condom (124 females and 112 males); (218) whether they had ever used a condom (124 females and 112 males); (219) whether they had ever used a condom (124 females and 112 males); (220) whether they had ever used a condom (124 females and 112 males); (221) whether they had ever used a condom (124 females and 112 males); (222) whether they had ever used a condom (124 females and 112 males); (223) whether they had ever used a condom (124 females and 112 males); (224) whether they had ever used a condom (124 females and 112 males); (225) whether they had ever used a condom (124 females and 112 males); (226) whether they had ever used a condom (124 females and 112 males); (227) whether they had ever used a condom (124 females and 112 males); (228) whether they had ever used a condom (124 females and 112 males); (229) whether they had ever used a condom (124 females and 112 males); (230) whether they had ever used a condom (124 females and 112 males); (231) whether they had ever used a condom (124 females and 112 males); (232) whether they had ever used a condom (124 females and 112 males); (233) whether they had ever used a condom (124 females and 112 males); (234) whether they had ever used a condom (124 females and 112 males); (235) whether they had ever used a condom (124 females and 112 males); (236) whether they had ever used a condom (124 females and 112 males); (237) whether they had ever used a condom (124 females and 112 males); (238) whether they had ever used a condom (124 females and 112 males); (239) whether they had ever used a condom (124 females and 112 males); (240) whether they had ever used a condom (124 females and 112 males); (241) whether they had ever used a condom (124 females and 112 males); (242) whether they had ever used a condom (124 females and 112 males); (243) whether they had ever used a condom (124 females and 112 males); (244) whether they had ever used a condom (124 females and 112 males); (245) whether they had ever used a condom (124 females and 112 males); (246) whether they had ever used a condom (124 females and 112 males); (247) whether they had ever used a condom (124 females and 112 males); (248) whether they had ever used a condom (124 females and 112 males); (249) whether they had ever used a condom (124 females and 112 males); (250) whether they had ever used a condom (124 females and 112 males); (251) whether they had ever used a condom (124 females and 112 males); (252) whether they had ever used a condom (124 females and 112 males); (253) whether they had ever used a condom (124 females and 112 males); (254) whether they had ever used a condom (124 females and 112 males); (255) whether they had ever used a condom (124 females and 112 males); (256) whether they had ever used a condom (124 females and 112 males); (257) whether they had ever used a condom (124 females and 112 males); (258) whether they had ever used a condom (124 females and 112 males); (259) whether they had ever used a condom (124 females and 112 males); (260) whether they had ever used a condom (124 females and 112 males); (261) whether they had ever used a condom (124 females and 112 males); (262) whether they had ever used a condom (124 females and 112 males); (263) whether they had ever used a condom (124 females and 112 males); (264) whether they had ever used a condom (124 females and 112 males); (265) whether they had ever used a condom (124 females and 112 males); (266) whether they had ever used a condom (124 females and 112 males); (267) whether they had ever used a condom (124 females and 112 males); (268) whether they had ever used a condom (124 females and 112 males); (269) whether they had ever used a condom (124 females and 112 males); (270) whether they had ever used a condom (124 females and 112 males); (271) whether they had ever used a condom (124 females and 112 males); (272) whether they had ever used a condom (124 females and 112 males); (273) whether they had ever used a condom (124 females and 112 males); (274) whether they had ever used a condom (124 females and 112 males); (275) whether they had ever used a condom (124 females and 112 males); (276) whether they had ever used a condom (124 females and 112 males); (277) whether they had ever used a condom (124 females and 112 males); (278) whether they had ever used a condom (124 females and 112 males); (279) whether they had ever used a condom (124 females and 112 males); (280) whether they had ever used a condom (124 females and 112 males); (281) whether they had ever used a condom (124 females and 112 males); (282) whether they had ever used a condom (124 females and 112 males); (283) whether they had ever used a condom (124 females and 112 males); (284) whether they had ever used a condom (124 females and 112 males); (285) whether they had ever used a condom (124 females and 112 males); (286) whether they had ever used a condom (124 females and 112 males); (287) whether they had ever used a condom (124 females and 112 males); (288) whether they had ever used a condom (124 females and 112 males); (289) whether they had ever used a condom (124 females and 112 males); (290) whether they had ever used a condom (124 females and 112 males); (291) whether they had ever used a condom (124 females and 112 males); (292) whether they had ever used a condom (124 females and 112 males); (293) whether they had ever used a condom (124 females and 112 males); (294) whether they had ever used a condom (124 females and 112 males); (295) whether they had ever used a condom (124 females and 112 males); (296) whether they had ever used a condom (124 females and 112 males); (297) whether they had ever used a condom (124 females and 112 males); (298) whether they had ever used a condom (124 females and 112 males); (299) whether they had ever used a condom (124 females and 112 males); (300) whether they had ever used a condom (124 females and 112 males); (301) whether they had ever used a condom (124 females and 112 males); (302) whether they had ever used a condom (124 females and 112 males); (303) whether they had ever used a condom (124 females and 112 males); (304) whether they had ever used a condom (124 females and 112 males); (305) whether they had ever used a condom (124 females and 112 males); (306) whether they had ever used a condom (124 females and 112 males); (307) whether they had ever used a condom (124 females and 112 males); (308) whether they had ever used a condom (124 females and 112 males); (309) whether they had ever used a condom (124 females and 112 males); (310) whether they had ever used a condom (124 females and 112 males); (311) whether they had ever used a condom (124 females and 112 males); (312) whether they had ever used a condom (124 females and 112 males); (313) whether they had ever used a condom (124 females and 112 males); (314) whether they had ever used a condom (124 females and 112 males); (315) whether they had ever used a condom (124 females and 112 males); (316) whether they had ever used a condom (124 females and 112 males); (317) whether they had ever used a condom (124 females and 112 males); (318) whether they had ever used a condom (124 females and 112 males); (319) whether they had ever used a condom (124 females and 112 males); (320) whether they had ever used a condom (124 females and 112 males); (321) whether they had ever used a condom (124 females and 112 males); (322) whether they had ever used a condom (124 females and 112 males); (323) whether they had ever used a condom (124 females and 112 males); (324) whether they had ever used a condom (124 females and 112 males); (325) whether they had ever used a condom (124 females and 112 males); (326) whether they had ever used a condom (124 females and 112 males); (327) whether they had ever used a condom (124 females and 112 males); (328) whether they had ever used a condom (124 females and 112 males); (329) whether they had ever used a condom (124 females and 112 males); (330) whether they had ever used a condom (124 females and 112 males); (331) whether they had ever used a condom (124 females and 112 males); (332) whether they had ever used a condom (124 females and 112 males); (333) whether they had ever used a condom (124 females and 112 males); (334) whether they had ever used a condom (124 females and 112 males); (335) whether they had ever used a condom (124 females and 112 males); (336) whether they had ever used a condom (124 females and 112 males); (337) whether they had ever used a condom (124 females and 112 males); (338) whether they had ever used a condom (124 females and 112 males); (339) whether they had ever used a condom (124 females and 112 males); (340) whether they had ever used a condom (124 females and 112 males); (341) whether they had ever used a condom (124 females and 112 males); (342) whether they had ever used a condom (124 females and 112 males); (343) whether they had ever used a condom (124 females and 112 males); (344) whether they had ever used a condom (124 females and 112 males); (345) whether they had ever used a condom (124 females and 112 males); (346) whether they had ever used a condom (124 females and 112 males); (347) whether they had ever used a condom (124 females and 112 males); (348) whether they had ever used a condom (124 females and 112 males); (349) whether they had ever used a condom (124 females and 112 males); (350) whether they had ever used a condom (124 females and 112 males); (351) whether they had ever used a condom (124 females and 112 males); (352) whether they had ever used a condom (124 females and 112 males); (353) whether they had ever used a condom (124 females and 112 males); (354) whether they had ever used a condom (124 females and 112 males); (355) whether they had ever used a condom (124 females and 112 males); (356) whether they had ever used a condom (124 females and 112 males); (357) whether they had ever used a condom (124 females and 112 males); (358) whether they had ever used a condom (124 females and 112 males); (359) whether they had ever used a condom (124 females and 112 males); (360) whether they had ever used a condom (124 females and 112 males); (361) whether they had ever used a condom (124 females and 112 males); (362) whether they had ever used a condom (124 females and 112 males); (363) whether they had ever used a condom (124 females and 112 males); (364) whether they had ever used a condom (124 females and 112 males); (365) whether they had ever used a condom (124 females and 112 males); (366) whether they had ever used a condom (124 females and 112 males); (367) whether they had ever used a condom (124 females and 112 males); (368) whether they had ever used a condom (124 females and 112 males); (369) whether they had ever used a condom (124 females and 112 males); (370) whether they had ever used a condom (124 females and 112 males); (371) whether they had ever used a condom (124 females and 112 males); (372) whether they had ever used a condom (124 females and 112 males); (373) whether they had ever used a condom (124 females and 112 males); (374) whether they had ever used a condom (124 females and 112 males); (375) whether they had ever used a condom (124 females and 112 males); (376) whether they had ever used a condom (124 females and 112 males); (

Session d'affichage Poster Session



Le SIDA et l'individu AIDS and the Individual

T.D.P.7 **TITLE: DEMOGRAPHIC AND HIGH RISK BEHAVIOR STUDY OF INCREASINGLY ADOLESCENTS**

Authors: Morris, R., Hancock, S., Roseman, J., Wu, G., Baker, C.J., and Weikowski, K.A.
 *Juvenile Court Health Services, Los Angeles County, California, USA
 **UCLA Epidemiology Program, Los Angeles County Department of Health, California, USA

OBJECTIVE: To obtain demographic and AIDS high risk data to target and implement educational and research programs among increasingly adolescents.
DESIGN: Interviews to gather data were conducted following a randomized design. This information was computerized (data manager 3 BASE III Plus) and analyzed with the statistical software package PROLOG.

RESULTS: 262 minors, age 16 and 17 were interviewed. 83% were males and 17% were females. 28% were Black, 20% Hispanic and 52% White. Incidence of sexual activity was high. Alcohol consumption during sex was frequent (47%); drug use concomitant with sex activity was 13%. Heroin and cocaine were the most frequently used I.V. drugs. Incidence of IV was 17% with syringes the most common disease article. While awareness about contracting AIDS was high, correct and other precautionary resources were low.

CONCLUSION: Despite the fact that this population reported a 67% attendance to sex education classes, their degree of knowledge and concern about high risk behavior for AIDS was low. Educational programs with peer participation, surveillance studies and emphasis on HIV testing and counseling of high risk individuals will be pursued.

T.D.P.9 **HIV-RELATED KNOWLEDGE, BELIEFS, AND BEHAVIORS AMONG HIGH SCHOOL STUDENTS IN THE UNITED STATES**

Authors: Fagan, D., and School Health Center for Chronic Diseases (SHCCD), San Francisco, San Francisco, California, USA
 *University of California, San Francisco, San Francisco, California, USA
 and Chicago. To describe HIV-related knowledge, beliefs, and behaviors among high school students in cities and states in the United States with the highest cumulative incidence of AIDS and to describe the participation and strategies developed to enable departments of education to collect these data annually.
DESIGN: As part of a unique system of surveys involving participation and cities administered anonymous questionnaires to high school students in 1985. The response rate of schools from each state ranged from 52% to 100%. Results: Many students incorrectly thought HIV infection may be acquired from living blood (range: 27.8%-53.1%), using public toilets (range: 44.4%-64.4%), or having a blood test (range: 48.1%-64.4%). Most students knew IV drug use (range: 54.4%-84.4%), and needle sharing (range: 48.5%-84.4%) can result in HIV infection. High school students from 10% states reported variable rates of IV drug use and needle sharing. 44% of students reported sex partners at least once, and 19.4%-44.6% reported having had sex with sex partners. **CONCLUSIONS:** Implementation of education should implement programs to correct misperceptions about HIV transmission, to reduce behaviors resulting in HIV infection, and to assess periodically whether these misperceptions and behaviors change over time among high school students.

T.D.P.11 **ASSESSING KNOWLEDGE, INDIVIDUAL RISK FACTORS, BELIEFS ABOUT AIDS AND ATTITUDES ABOUT CURRENT CHANGES**

Authors: R.A., Petty, B.A., Frossen, A.C.; Baker, Charles E., and Kroegel, M., Dallas County Health Department, Dallas, Texas, USA

OBJECTIVE: Objectives of study were to 1) determine baseline risk factors and knowledge about AIDS, 2) determine attitudes about AIDS and prevention, and 3) determine attitudes about condom usage among runaway adolescents while at an alternative school. **DESIGN:** A questionnaire was administered to 213 runaways. Upon intake to the school, adolescents (213) were administered a questionnaire about AIDS knowledge, behavior risk factors and prevention information. While at the alternative school, adolescents received 3 to 4 instructional classes about AIDS and prevention information. After the classes the adolescents (102) were given the same questionnaire to determine if the group had improved its knowledge base about AIDS information, and changed attitudes about condom usage. **RESULTS:** Results indicate that of the 213 runaway adolescents (between the ages of 11 and 16), 76% are sexually active, 7% had used intravenous drugs and only 13% stated they always use condoms. Post data results on some knowledge questions indicated significantly larger proportions of correct responses. There are areas where misunderstandings persist, i.e., transmission through blood donation and transfusions. Attitudes about condom usage did not improve and adolescents felt uncomfortable talking about condoms with a partner. **CONCLUSIONS:** Runaway adolescents' behavior puts them at risk for HIV infection and AIDS. Alternative schools provide a setting for exposure to information about AIDS. A change in attitudes toward condom use and a change in condom use require more than classroom exposure to AIDS information.

T.D.P.8 **KNOWLEDGE, ATTITUDES AND BEHAVIOR OF STREET-INVOLVED PEOPLE IN VANCOUVER**

Authors: Michael J. Hanson, I. Loftus, P., STD Control, Ministry of Health, Vancouver, British Columbia, Canada

OBJECTIVE: To assess and describe the knowledge, attitudes and behaviors of street-involved people in Vancouver in relation to AIDS.
DESIGN: In January 1985, sixty-nine street-involved youth answered an anonymous, standardized questionnaire administered on the street by outreach nurses.

RESULTS: Of the 40 males and 29 females interviewed, 93% were 14-29 years old, 53% were Caucasian and 30% Native Indian, 44% lived with lovers or friends and 40% lived alone. The majority supported themselves by prostitution (70%) and/or welfare benefits (48%). Seventy-seven percent felt that AIDS was not as serious as the media said, 40% would use condoms with a new but not a steady partner, 45% felt their chances of catching an STD were low. With regard to drug-taking behavior, 50% had used intravenous drugs within the past year, 72% of these had shared tools and 76% cleaned their needles with bleach. The favorite drugs were cocaine and talwin and rituals. Findings with regard to sexual behavior included the following: 43% had had sex with a homosexual man and 43% with an IVUD; 6 women and 10 men said they were bisexual in their private lives; 85% always shared condoms with "dates" (i.e. customers) but only 28% always used condoms with "lovers" (i.e. steady partners). Their ability to use safe sex having sex or using intravenous drugs was often adversely affected by being drunk or high. **CONCLUSION:** Street involved people in Vancouver remain at highest risk for acquisition and transmission of HIV because of risk behavior in their personal lives.

T.D.P.10 **ETUDIANTS ET SIDA: INTERET D'UNE TYPOLOGIE POUR UNE PREVENTION SPECIFIQUE**

Authors: Failloux T., Larigault J., Lesarrieux A., L'Andrieu H., and Université Paris X à Rouen, Centre de Recherche de l'Enfant et de l'Adolescent (CREA), Paris, France, **Fondation des étudiants de France, Secours, France, CREA, Paris, France, ***Institut Français d'Etudes et d'Analyses (IFE), Paris, France.

OBJECTIF: 1) Décrire étudiants (18-22 ans) de région parisienne, 2) Mesurer les corrélations entre facteurs de risque SIDA et facteurs de risque "supposés", 3) Construire une typologie pour actions préventives spécifiques.

Méthode: 1) Échantillon: 963 étudiants représentatifs (méthode des quotas), 2) Intervention: strict anonyme, février/avril Juin 1985, 3) Auto-questionnaire: 176 items sur représentations, attitudes, comportements, sur sexualité, sida, SIDA, valeurs, informations SIDA, prévention, mesurer l'état des connaissances sur notre société SIDA, facteurs de risque SIDA, 4) Tri à plat, croisées, analyses en composantes principales et typologiques (logiciel SAS). **Résultats:** 1) Parmi tous les nombreux résultats: 50 % sans premier rapport ont utilisé préservatif, 15 % ont pratiqué coïtactus du V.D. 50 % pensent que le préservatif est le moyen le plus sûr pour éviter le V.D. 52 % s'estiment insuffisamment informés sur SIDA, 84 % pensent qu'un sérotest est mieux à faire de les informer, 52 % que l'information doit être faite en Faculté, 2) Cinq facteurs de risque supposés ont été retenus car tous bien corrélés aux facteurs de risque du SIDA, 3) Propose une typologie de dix types associés différemment aux facteurs de risque conduisant à approches préventives particulières d'out "tactis" groupées.

T.D.P.12 **THE RELATIONSHIP OF KNOWLEDGE AND ATTITUDES TOWARD AIDS TO SAFE SEX PRACTICES AMONG RUNAWAY AND SEX WORKERS**

Authors: Rosen, Mary Jane; Salfinger, C.; Koppman, C.; Halperin, C.; Meyer-Illand, R.; Bhatnagar, A.; and HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute and Columbia University, New York, NY, USA

OBJECTIVE: To evaluate the relationship between knowledge of and attitudes towards AIDS and safer sex practices among runaway and sex workers.
DESIGN: Questionnaire assessments of knowledge of transmission, high risk groups, outcomes, prevention strategies, definitions, and HIV testing were collected and separate interviews of sexual behavior during the last three months were conducted with 50 runaway and 30 sex youth in community agencies in New York City.
RESULTS: There was substantially high general knowledge of AIDS (74%) and positive attitudes towards safer sex (74%) across all groups as well as substantial unsafe sex. These high risk youth reported an average of 3 sexual partners and 12 sexual encounters over the last three months, most of which were unprotected by condoms used (89%). General knowledge of AIDS was more highly correlated with condom use ($r = .31$, $p < .05$) and positive attitudes ($r = .36$, $p < .01$) among sex youth than for runaway youth. In addition, general knowledge of AIDS was positively related to the number of partners among sex youth ($r = .31$, $p < .01$), indicating those most at risk knew the most about AIDS.

CONCLUSIONS: Although attitudes towards AIDS, not general knowledge, appears important and potentially effective among those at most risk, sex youth.

Session d'annonce Poster Session



Le SIDA et l'individu AIDS and the Individual

Comportement (partie 2) Behaviour (Part 2)

T.D.P.13

YOUTH IN DETENTION AT HIGH RISK FOR HIV KNOWLEDGE, ATTITUDES AND BEHAVIORS REGARDING CONDOM USAGE.
Thompson, Lizlin; Houston, J.M.; Risner, M.M.; Sweet, D.M.*
Baxter, M.**; Shalowitz, Giv. of California School of Medicine, San Francisco. **San Francisco Dept. of Public Health, San Francisco, CA, U.S.A.

Objective: Because youth who come into contact with the juvenile justice system are typically sexually active, prone to drug experimentation and have high levels of STDs, they are at particularly high risk for HIV infection and transmission. Our aim was to examine their knowledge of how HIV can be transmitted and prevented, and their attitudes and behaviors about condoms.
Methods: 184 juvenile offenders (mean age = 18) at the San Francisco Youth Guidance Center completed anonymous self-report questionnaires. The sample was 50% male and 50% Black, 16% Hispanic, 7% Asian, 0% White, 7% other. Results: Knowledge about HIV prevention was generally high, for example, 80% agreed that using condoms during sex reduces the chances of HIV infection. Further, ability to obtain condoms "very afraid of getting AIDS." On the other hand, 80% said that it would not be difficult at all. There was also evidence of motivation: 71% said they would use condoms more than a problem; 80% said that using condoms during sex reduces the chances of HIV infection. 80% said that using condoms would "really like to have a baby." **Conclusion:** The findings of low intention to use condoms and low usage are disturbing. In view of the high HIV infection rates among youth who have someone in exchange for money, drugs, etc. during the past year. Results here are culturally sensitive HIV education programs aimed at changing attitudes about using condoms are urgently needed for this high risk group.

T.D.P.15

HIV STATUS RELATED TO KNOWLEDGE AND BEHAVIORAL CHANGE
Miller, Kenneth and Patient, Margaret, University of California, San Francisco, U.S.A.

Objective: To assess whether knowledge about AIDS influenced behavior in anti-HIV(+) blood donors, blood recipients, hemophiliacs and their sexual partners as compared to controls.
Methods: A 16 item multiple choice questionnaire and an 11 item behavioral survey were distributed to 238 study participants and their sexual partners 6 to 12 months following standard verbal counseling regarding transmission and prevention of AIDS.
Results: 50/51 (98%) of anti-HIV(+) respondents and their sexual partners, who correctly identified preventive measures, indicated that they used condoms more than half the time; while only 30/313 (7%) of the anti-HIV(-) controls did so. 32/69 (46%) of anti-HIV(+) respondents and their sexual partners identified and practiced health promoting behaviors as compared to 17/405 (3%) of anti-HIV(-) controls. 66/69 (96%) of the anti-HIV(+) respondents avoided sharing unsafe items such as needles, razors, etc. with their partners while an equivalent number of anti-HIV(-) controls (39/115) (90%) evinced similar behavior.
Conclusion: In this sample, generally, knowledge about AIDS prevention was more likely to be translated into behavioral changes by anti-HIV(+) subjects than by those who were anti-HIV(-).

T.D.P.17

PREVALENCE OF GENITAL LESIONS IN A STD CLINIC: SEXUAL BEHAVIOR CHARACTERISTICS
Jacobs, R.; Roberts, T.**; Mosey, B.**; Whittington, N.P.; Whittington, Y.*
University School of Medicine. **Duke Health Department, and West Gate Hospital, Atlanta, GA, USA.

Objective: To determine the prevalence of genital lesions in individuals attending an STD clinic and to evaluate their sexual behaviors.
Methods: During a 15 week period, individuals (>200) making their first visit for a variety of reasons were studied. Those patients with genital lesions were referred to a single clinician for evaluation. The patterns of sexual behavior of these patients were compared to those without lesions.
Results: Patients with genital lesions accounted for 781 (7.5%) visits. Men were more likely than women to present with genital lesions (p<.01) and genital lesion patients were less likely to be referred as a sexual partner (p<.01). Women with genital lesions more often did not use chemical or mechanical barriers for contraception and also gave a history of sexual intercourse (p<.05). Men with genital lesions were less likely to use condoms than men without lesions (p<.01). After lesions were recognized, 24% of the men and 21% of the women continued to have sexual intercourse.
Conclusion: In view of previous findings that genital lesions are associated with an increased risk of HIV transmission, it is important to understand the pattern of sexual behavior of patients with genital lesions. The current evidence for poor use of preventive measures must be addressed.

T.D.P.14

THE NATIONAL STUDY OF HEALTH AND SEXUAL BEHAVIOR
Cain, Virginia B. and Baldwin, M.
National Institute of Child Health and Human Development, NIH, Bethesda, MD, U.S.A.

Objective: To describe the development of a national survey of health and sexual behavior, this is a major undertaking that will provide data to help understand sexual behavior patterns associated with varying degrees of risk with respect to HIV infection and the contexts in which the behaviors are occurring. It will also provide some of the data needed to model the spread of HIV infection, e.g. rates of partner change and sexual behaviors within relationships. Note, of the estimates of HIV infection depend upon estimates of risk behavior derived from the Kinsey studies of the 1940's. While these were landmark studies, the lack of a representative sample and the changes in sexual behavior that are known to have occurred in the past 40 years make them less than useful for current purposes. The present study involves the development of a national survey of sexual behavior that will obtain high quality data on sensitive questions from the general U.S. population and simultaneously being able to accommodate the less frequently occurring high risk behaviors. The development of the survey has included a number of methodological tests designed to determine the most effective means of eliciting accurate information. These include effects of: (1) matching interviewers and respondents on selected demographic characteristics, (2) the location of the interview (in situ or in the lab), (3) telephone vs. door-to-door interviewing including a mail-administered questionnaire and (4) a closed-ended questionnaire vs. an open-ended semi-structured interview.

T.D.P.16

SELF PERCEPTION OF THE RISK OF CONTRACTING AIDS AMONG UNIVERSITY STUDENTS
Dias, M.N.**; Agui, Francisco H.*; Goodson, P.**; Dias, J.*
Vera, E.* and Pinto e Silva, B. Brazil. ** The Population Council, New York, USA. *** CEMDOR, Campinas, SP, Brazil.

Objective: To assess how accurate is the self perception of the risk of contracting AIDS among University students.
Methods: A structured questionnaire on sexual behavior and knowledge about AIDS was mailed to 2009 students of the first two grades of the State University of Campinas, Brazil. Analysis was performed using SPSS PC.
Results: The percentage of students declaring not having risk of AIDS was 71.8%. But, 56.3% of them did not use condoms, 14.1% had anal intercourse and 12.2% of men had homosexual relations. Based on the whole questionnaire, each student was classified as having null, low or high risk. Seventy five per cent of those who classified themselves as having null risk, actually had low or high risk. On the other hand, 77.8% of those who classified themselves as high risk, were low, according to our classification.
Conclusion: Even though the level of knowledge about AIDS is relatively high among University students, there is still a high incidence of misconceptions or classifying which behaviors do actually constitute risk. Further educational activities appear as a high priority.

T.D.P.18

BEHAVIORAL PATTERNS OF BISEXUAL MALES IN THE U.S., 1982
Lever, Janet; Rogers, L.J.; Heron, R.*
Kenmore, D.R.*
*The RAND Corporation, Santa Monica, California, U.S.A.; **Wellesley College, Wellesley, Mass., U.S.A.

Objective: To analyze 1982 survey data on the sexual practices of 7,486 heterosexually bisexual males to better understand the behavioral and reported incidence of HIV infection in that population and their female partners.
Methods: Data from a national survey of 80,324 and female readers of Playboy magazine were examined using analysis of variance techniques. Demographic profiles and sexual behavior patterns were compared among men whose adult sexual behavior was exclusively heterosexual (N=4,082), exclusively homosexual (N=780), predominantly heterosexual (N=4,903), or predominantly homosexual (N=729).
Results: Of 7,486 heterosexually bisexual men, 2,111 described themselves as bisexual, 141 as homosexual, and 5,232 as heterosexual in orientation; 392 were currently married (vs. 44% of heterosexual men) and 391 were currently dating more than one partner. Bisexual men were less concentrated in cities than homosexual men (43% vs. 63%, 38% for heterosexual men). Behavioral bisexuality was associated with increased promiscuity (.43 SD on an index combining no. of partners and 3 other indicators) and increased risk of STIs (18% vs. 10% reporting one or more in past 5 yrs.) compared to exclusively heterosexual men, and with increased use of prostitutes in last five years (33% vs. 19% for exclusively heterosexual or homosexual men).
Conclusions: The behavior reported by this large sample of bisexual men would place them at intermediate risk of HIV infection. Sexual patterns of bisexual men are not representative of the general population.



Session d'affichage Poster Session



Le SIDA et l'individu AIDS and the individual

T.D.P.19 PATTERNING IN THE SEQUENCES OF SEXUAL ACTIVITY BETWEEN MEN AND ITS IMPLICATIONS FOR HIV-1 TRANSMISSION

DETAILED, LONGER AND CONCISE, A.F.M.***, Project SIDA,
*South Bank Polytechnic, London and Univ. of Wales, Cardiff, U.K.

Objective: Until now, analysis has concentrated on individual sexual acts and their role in the transmission of HIV-1. This paper looks at sequences of sexual acts which take place between men in order to discover any **REGULARITY** which might be relevant to transmission.

Methods: Diaries of sexual activity were kept by 170 men who recorded, for each episode or session of sexual activity, where and when it took place; the other people involved (if any); the sequence of acts and other relevant details such as condom use. Diaries were encoded and analysed using a specially written computer programme.

Results: Analysis suggests the existence of 2 patterns or modes of sexual interaction: role-playing and reciprocal. Role-playing keeps the insertions/insertee distinction, while reciprocal action does not, typically involving an alternation of such roles. Role-playing sessions involve fewer individual acts than reciprocal ones ($p < .01$) and are more likely to include anal intercourse ($p < .05$). When anal intercourse does occur in reciprocal sessions, it is less likely to produce orgasm ($p < .001$).

Conclusions: Reciprocity seems to be likely to be safer. Further analysis of the patterns of sexual activity is urged as a means of understanding the context of transmission and as a resource for health education.

T.D.P.20 FACTORS ASSOCIATED WITH SEROPOSITIVITY TO HIV-1 AMONG A NON-CLINIC SAMPLE OF GAY AND BISEXUAL MEN IN LONDON

Busk, A.J.; Davies, J.G.; Conon, A.F.M.***, Kershaw, T.J.*** and Sutherland, S.***, Project SIDA, *South Bank Polytechnic, London; **University of Wales, Cardiff; ***King's College Hospital, London, U.K.; ****Dulwich PMS, London, U.K.

Objective: To describe the relevant characteristics of those found to be HIV antibody positive in a study of homosexually active men.

Methods: As part of a national study, 310 gay and bisexual men in London were recruited using a variety of sampling methods and interviewed in a non-clinic setting. 123 (71.9%) volunteered a sample of blood, which were tested for HIV-1 antibody using the Wellcome competitive assay, with positives confirmed using the Abbott recombinant assay. Interviewees could choose to know the result of the test. Data from the interview were analysed using SPSS 7.0.

Results: Individuals were classified as positive (30, 9.7%), negative (182, 61.3%) and not tested (88, 28.4%). Positives were found to be significantly younger ($p < .05$) and to have had more penetrative sexual partners - 'top's' partners with whom anal intercourse had taken place - ($p < .05$) in the course of their lives. There was no difference between the groups in having had a pop in the mouth prior to interview, but of those who had, positives had a higher proportion of partners who had a pop in the mouth than negatives ($p < .05$). Level of education, current relationship status and degree of disinclination were not significantly different.

Conclusions: The hypothesis that younger gay men are currently more at risk seems supported from these findings.

T.D.P.21 TRENDS IN AIDS KNOWLEDGE, ATTITUDES AND BEHAVIOURS (KAB) IN 18 COUNTRIES, HIGH-RISK SEX GROUPS, FLORIDA

Lieb, Spencer*; Zimmerman, R.S.***; Kuehler, M.***; Lengua, L.M.***; Sims, J.P.*** and Witte, J.J.**, Florida Department of Health and Rehabilitative Services, Tallahassee, Florida, USA, **University of Miami, Coral Gables, Florida, USA, ***Hunter College (CUNY), N.Y., N.Y., USA.

Objective: To compare levels of AIDS KABs in 1987 and 1988 in groups at high risk in a region having 4,000 reported AIDS cases as of 1/1/89.

Methods: A KAB survey was administered anonymously in 1987 (N=1,937) and 1988 (N=1,873) to those sampled non-randomly in 4 south Florida counties. Weights were assigned to each 1988 respondent by race, age, sex, education and distributing agency for comparability with 1987 values.

Results: Knowledge levels of HIV transmission modes were high in both years. A decline in anal intercourse was reported by gay/bisexual men [(1198)=2.7%, $p < .001$]. The percent tested for HIV antibody increased significantly ($p < .005$) for 6 of 7 hierarchical risk groups, 3 of which are shown below.

Condom use increased markedly among 2 of the 3 groups:

Group	1987	1988	1987	1988
	N	% tested for HIV	N	% tested
Gay/bisexual male	451	58%	514	75%
TV drug abuser	202	11%	30*	32
MSM alone	176	43*	118	31**
$p < .00001$				

Conclusion: To the extent that such groups may be 'sentinels' for larger, at-risk populations, these results favor a reduction in HIV transmission.

T.D.P.22 BEHAVIORAL AND PSYCHOSOCIAL PREDICTORS OF COMPLIANCE IN HIV ASYMPTOMATIC AND SEROPOSITIVE PATIENTS IN CLINICAL TRIALS

Condon, Jerome, Jiles, Malcolm, L.***, University of Miami, Miami, Florida, USA; Pringle, L. St. St. University of Miami, Miami, Florida, USA.

Objective: To evaluate and determine factors associated with study compliance among HIV infected patients in clinical drug trials.

Methods: A voluntary, anonymous, self-administered questionnaire consisting of demographic and risk factor information, recreational and non-IDA approved drug use, and sexual practices was completed by patients with asymptomatic or asymptomatic HIV infection participating in clinical drug trials.

Results: Of 150 distributed questionnaires, 120 were completed. The majority of patients not filling out questionnaires were Hispanic. Of the 150 participating patients, 86 had asymptomatic and 34 had asymptomatic HIV disease. A greater study compliance rate was noted among asymptomatic patients than asymptomatic patients as prescribed ($p < .02$).

Conclusions: Asymptomatic patients with HIV infection are generally more likely to be non-compliant with clinical drug trials. Factors associated with recreational drug use, alcohol use and sexual activity must be considered in developing strategies to improve compliance rates of asymptomatic patients in clinical drug trials.

T.D.P.23 MALE HOMOSEXUAL SEXUAL BEHAVIOR IN THE UK 1985-1988

Thomas, APRN Consultant
*Department of Contraceptive Methods, King's College Hospital, London SE5
*South Bank Polytechnic, London SE1
**University of Wales, Cardiff, UNITED KINGDOM

Objective: To monitor changes in male homosexual sexual behaviour in the United Kingdom using a non-clinic sample.

Method: A questionnaire was circulated via the gay press. It was self administered and asked about numbers of sexual partners, changes in sexual behaviour, drug, condom use, HIV antibody status and sexual attitude.

Results: 1292 replies from 1985 and 1200 from 1988 were analysed. The demographic details of both samples were comparable. 60% of men in 1988 had less than 3 sexual partners in the previous 12 months compared with 15% in 1985. The 1988 respondents reported a 50% decrease in both oral and anal sex with casual sexual partners but only 50% used condoms >50% of the time during anal sex. Very little illicit drug use was reported. 18% of the 1988 cohort had been sexually satisfied by another man.

Conclusion: This national survey of sexual behaviour in gay men in the UK is attempting to monitor changes in behaviour as the HIV epidemic of a change towards safer sex but a significant proportion of respondents still have unprotected anal sex. The number of men sexually satisfied is higher than previously reported in similar studies.

This investigation is part of Project SIDA and is funded by the Medical Research Council.

T.D.P.24 A REVIEW OF STUDIES OF BEHAVIORAL RESPONSE TO HIV-ANTIBODY TESTING AMONG GAY MEN

RR (Hempstead) AN Moss, School of Medicine, University of California, San Francisco, San Francisco, CA, USA

Objective: To review changes in annual behavior made by gay men receiving HIV-antibody test results.

Methods: We examined 22 studies of sexual behavior change by groups of gay men from the United States and Western Europe.

Results: A median of 41% of study subjects (range=23-84%) choose to know their HIV-antibody status when made available to them in the context of their research study. Most studies (16/22) have indicated that awareness of infection decreases risk behaviors (anal intercourse and multiple partners) with seropositives showing greater declines than seronegatives. A considerable number of studies (10/22), however, have shown no difference in the seronegativization behavior of subjects.

Conclusion: The behavioral consequences of HIV-antibody test results are not uniform. The reasons are unclear, but a reduction in behaviors which transmit HIV usually ensues. No clear pattern explaining these ambiguous findings is yet apparent. Inappropriate (change) behaviors following notification have not been reported in these groups.

Session d'affichage Poster Session



Le SIDA et l'individu AIDS and the Individual

T.D.P.31 FACTORS ASSOCIATED WITH RECURRING OF UNSAFE SEXUAL PRACTICES IN A COHORT OF GAY MEN PREVIOUSLY ENGAGING IN "SAFE" SEXUAL PRACTICES

William, Scott, S. Rodgers, A. Jaccard, J. J. Hayes, K. T. Frawley Community Health Center, Boston, Massachusetts, Anderson, W.

Objective: To analyze the behavior of gay men who had engaged in "safe" sexual behaviors (SB) for one or more years and assess the predictors of subsequent maintenance of SB.
Methods: Collection of the longitudinal behavioral, attitudinal, clinical and serological data was gathered as part of a natural history of HIV infection of a cohort of initially asymptomatic gay men (n=236) seen in a Boston health center. 254 condom usage if anal intercourse was practiced.

Results: Those maintaining SB were similar in age, smoking and drinking activities, duration of homosexual activity and AB status to those who did not. Those maintaining SB were more likely to have higher levels of "unsafe" sexual behavior on entry to the project as well feeling that behavior change was not beneficial. Non-maintainers increasingly perceived greater barriers to maintaining susceptibility and were less able to differentiate maintainers and non-maintainers.
Conclusions: Health education strategies designed around the Health Belief Model may need to be reassessed in relation to long term maintenance of sexual behavior change.

T.D.P.32 THE ROLE OF PENITENTIARY REFORM AND SOLIDARITY ENHANCEMENT ACTION JAIL DRUGS IN THE PREVENTION OF AIDS IN THE DOMINICAN REPUBLIC

De Moya, E. Antonio; Carías, S.; Rosario, G.; Guerrero, E.; Arrau-Larrocena, R.; García-Alvarez, E. PROCTIS, Ministry of Public Health, Santo Domingo, Dominican Republic.

Objective: To evaluate the approach to AIDS prevention in highly crowded Dominican jails through the inducement of penitentiary reform measures and the enhancement of solidarity networks among inmates.

Methods: AIDS GAP studies were carried out in Dominican jails in November 1987 and February 1989. Ongoing intervention includes attempts to create staff committees, training of health personnel, inmates' group discussion and lecture sessions, group formation and voluntary HIV testing and counseling.

Results: A lag of 14 months in AIDS awareness among inmates as contrasted to the general population has been overcome by the joint pro-professional intervention. Gang sex rates ("maniquis") of youngest prisoners have been reduced to a minimum by inmates' defense committees.

Conclusions: Empowering inmates for self-organized preventive action in prisons both enhances their self-esteem and decreases the transmission potential of HIV among inmates.

T.D.P.33 IMPLICATIONS OF HEALTH BELIEFS FOR AIDS PREVENTION PROGRAMS: THE SAN FRANCISCO MEN'S HEALTH STUDY

Edward, Margolin, J. C.; Coates, T. J.; Stone, G. W. Center for AIDS Prevention Studies, and "Health Psychology, U.C. San Francisco, CA, U.S.A. Fellow, for AIDS Research.

Objective: To examine the relationship between health beliefs and sexual behavior among gay and bisexual men in San Francisco.

Method: This analysis is based on 465 single sexually active gay and bisexual men participating in the San Francisco Men's Health Study (a population-based longitudinal study of single males in San Francisco). Health beliefs specific to HIV infection and AIDS prevention were assessed in 1987. Number of sexual partners and condom use were measured at six and twelve month follow-up. Low risk was defined as mutual monogamy or 100% condom use. High risk was defined as having multiple partners and less than 100% condom use. The longitudinal relationship between the respondent's beliefs and subsequent sexual behaviors was examined using univariate statistical tests.

Results: The longitudinal analysis showed that subjects who perceive safe sex as important in preventing the spread of AIDS and who do not perceive safe sex as pleasure reducing are significantly more likely to report low risk sex during the next twelve months than are those who hold the opposite beliefs. In addition, high risk subjects were significantly more likely to believe that safe sex is unnecessary when two partners have the same serostatus than are low risk subjects. Finally, high risk subjects perceived significantly fewer barriers as transmitting HIV than did low risk subjects.

Conclusions: These results support the hypothesis that health beliefs influence preventive behaviors among gay and bisexual men. AIDS prevention programs may thus benefit from including work on beliefs regarding HIV transmission and safe sex.

T.D.P.34 SEXUAL BEHAVIOR OF EXPATRIATES IN AFRICA

Roosendaal, Hans; de Groot, A.; Balis, S.F.; Lithebe, R.J.; Leentvaar, A.; Kok, J.M.; et al. National Institute of Public Health (RIVM), Bilthoven, The Netherlands.

Objective: To describe sexual behaviour of Dutch expatriates in Africa with respect to risk of HIV infection.

Methods: In the course of a routine medical check Dutch expatriates working in sub-Saharan African countries are asked to complete a self-administered questionnaire on sexual and other risk factors (since 1978) for HIV infection. **Results:** Between Sept. 1987-Dec. 1988 499 men and 531 women entered the study; 278 men and 429 women were married or cohabited; 179 men and 404 were accompanied by their partner during their stay in Africa. Participants were posted in cities and rural areas of all sub-Saharan countries, including those in which prevalence of HIV infection is high. Of participants 22% had heterosexual contact with African partners (NCA): 37% of men and 15% of women. The mean number of sex partners was 5, the median 2, range 1-50. 10% of men and 4% of women had been treated for S.T.D. NCA was associated with a history of S.T.D., being single, and not being accompanied by the partner ($p < 0.001$). Males more often had NCA, independently of the previously mentioned factors ($p < 0.001$). Condom use was infrequent and inconsistent.

Conclusion: Sexual contact with African partners is a frequent occurrence especially among single men; Dutch expatriates run a substantial risk of sexual exposure to HIV.

T.D.P.35 CHANGES IN SEXUAL PRACTICES IN THE SYDNEY AIDS PROJECT:

1985-1989
Tisdall, Brett*, Nicholas T. and Cooper DA*,
NSWRC Special Unit in AIDS Epidemiology and Clinical Research,
University of New South Wales, Sydney, Australia.

Objective: To describe the changes in sexual behaviour in a cohort of homosexual and bisexual men in Sydney, Australia.

Methods: The Sydney AIDS Project is a prospective cohort study of 1057 homosexual and bisexual men enrolled between February 1984 and January 1985. At each six-monthly review visit subjects complete a self-administered questionnaire that examines their sexual practices during the preceding six months.

Results: A decrease in the mean number of sexual partners during the preceding 6 months was reported by both seropositives (22 to 4) and seronegatives (16 to 2) over the first 3 years of observation.

Seropositives reported a reduction in receptive anal intercourse from a mean of 8 to 3 times per month and seronegatives from 4 to 1 per month. There was a similar reduction in all sexual practices. These changes were reflected in a decrease in the seroconversion rate from 4% to 1% which peaked at 4% during early 1985 but remained below 1% in 1988.

Conclusion: These data indicate significant changes in the sexual practices of a large group of homosexual men in Sydney since 1984. These changes are reflected in a decrease in the seroconversion rate for this cohort. An updated analysis of the data, incorporating data to early 1989, will be presented.

T.D.P.36 CHANGE IN SEXUAL BEHAVIOR IN HOMOSEXUALS AT RISK FOR AIDS

Subjunctive, Michael; Joseph, G. D., Jr. University of Michigan, Ann Arbor, Michigan, United States

Objective: To describe longitudinal prevalence and predictors of safe sex among homosexual men at risk for AIDS.

Methods: Detailed behavioral data describing condom usage during receptive and insertive anal sex were collected in the Ongoing sex Questionnaire (OSQ) cohort, beginning in February 1984. Change in behavior between 85 and 89, measured by a six month interval, was the dependent variable. Multivariate, logistic regression models with condom usage, and seronegative/seropositive status were used as predictors.

Results: OSQ data are shown in Table 1. Predictors of behavioral change during receptive vs. insertive anal sex were dissimilar. While HIV serologic status was related to behavioral change in receptive anal practices, seronegative and seropositive status predicted change in insertive anal practices.

	Safe (n=81)	Not Safe (n=141)	Total
	81%	84%	84%
INSERTIVE ANAL SEX:			
Safe (n=91)	149(84)	149(83)	298(73)
Not Safe (n=91)	131(62)	123(42)	254(52)
Total	280(80)	272(58)	552(50)
RECEPTIVE ANAL SEX:			
Safe (n=91)	243(64)	143(64)	386(64)
Not Safe (n=91)	124(44)	83(40)	207(36)
Total	367(64)	226(40)	593(50)

Conclusions: Individual condom usage is not constant over time. Previous reports of behavioral measures change longitudinal condom usage among gay men should be viewed with caution because of such individual fluctuations which are not yet fully understood. Our findings also suggest that serologic status is an important determinant of behavioral change and/or change of partner. Decreasing seroconversion rates might be attributed partly to these processes, rather than the utilization of anal sex or consistent use of condom.

**Session d'affichage
Poster Session**



**Le SIDA et l'individu
AIDS and the individual**

T.D.P.37

TITRE : COMPORTEMENT SEXUEL ET RISQUE D'INFECTION
A. V. I. H. A. SÉNÉGAL

DIPIOT Ousmane*
CARRELLI M**; **WOITE Y**; **PEYRIBEAUD Anne****
*Ministère de la Santé Publique
** CFA/ONS - GENEVE

OBJECTIF : Identifier les comportements sexuels et ses déterminants dans une population de 15 - 49 ans.

METHODOLOGIE : Enquête par interview sur un échantillon national représentatif (sondage par groupes : 2.500 personnes) complétée par observation, interview ethnographiques, focus-group, Conception finale et Éducation faites par équipe pluridisciplinaire. Coordination par Centre National d'Éducation Pour la Santé.

RESULTATS : la recherche a permis d'établir les rapports entre comportements sexuels et données sur l'infection à VIH et les autres M.S.T. Les résultats permettent d'établir une échelle de risque en fonction des comportements et données démographiques (migration et fécondité sexuelle) et persistence de valeurs socio-culturelles (félicité, croyances religieuses) d'une part, estime de perception du risque et prédisposition à adopter un comportement sexual à risque.

CONCLUSION : Ces résultats indiquent les incidences pratiques pour l'orientation, la réflexion et l'évaluation des programmes d'intervention éducative facilitent leur intégration et efficacité.

T.D.P.38

"Pretesting AIDS Health Promotion Materials".

Ballal, Jai*, Kishorewani A**
*World Health Organization, Pacific Promotion Specialist, GPOW, Geneva; **World Health Organization, Health Educator, WHO/OS, Geneva, SWITZERLAND

This presentation will be supported by slides illustrating types of changes made to materials and pretesting sessions with target audience. A poster presentation will be available.

Objectives: 1) To introduce methods for pretesting prototype AIDS health promotion messages and materials designed for culturally diverse target audiences in Africa, Asia, the Pacific and the Caribbean. 2) To present the concepts of developing specific AIDS messages for primary, secondary and tertiary target audiences with the long range goal of behavioral change.

Method: 141 persons working in AIDS health promotion from 34 countries participated in a series of 5 self-reported workshops during 1985-1988. The health education and related variables among a semi-structured sample of gay men in the Richmond metropolitan area. Key variables to be discussed are: gay men's health, perceptions of themselves, self-esteem, and changes in risk-reduction and drug use behaviors.

Results: Initial data were collected in the spring of 1985; follow-up data were collected two years later. A questionnaire was prepared specifically for the study, with the help of focus groups of gay men in the city. The same process was used to modify the original questionnaire before follow-up. A two-stage method was used to distribute questionnaires to potential respondents. A list of distributors, both individuals and organizations, was recruited and trained in contacting gay men and explaining the study. The area distribution network was used for the follow-up, in order to make convenient feasible. Anonymity of respondents was carefully protected, in order to gain participation in this city, where homosexual behavior is a felony offense. The response rate was 45% in 1985 and 67% in 1987. Results: Very few had been tested for HIV infection in 1985, but 47% had been tested by 1987. Thirty-one percent of the 1987 cohort were inferring HIV/AIDS in 1985 and 20% reported "great fear" about their own vulnerability to infection; in 1987, this percentage was about the same (21%). However, more than half of gay men sampled in 1987 had experienced an increase in level of fear when they first heard about AIDS. Changes were noted in sources of information about HIV prevention, AIDS service organizations and the public health department being in attendance. Only a minority reported self-protective behavior in 1985; in 1987, almost everyone reported this behavior.

Conclusions: Gay men in this middle-sized southern city were 3 times as likely to have made sex changes in risk behaviors in 1987 as they were to have done so in 1985. Reported changes were probably sufficient to prevent transmission of the virus to increasing numbers of individuals in the population sampled.

T.D.P.39

BEHAVIORAL INTENTIONS AND OTHER FACTORS INFLUENCING BEHAVIOR CHANGE IN A COHORT OF GAY MEN: A PROSPECTIVE STUDY

Calcutt, Christine*, O'Malley, K.M.*, Higgins, D.L.*; Sheridan, J.S., Galloway, T.L.**, *Centers for Disease Control, Atlanta, Georgia, U.S.A.; **Professional Services, Rockville, MD, U.S.A. ***Denver Disease Control Service, Denver, Colorado U.S.A.

Objectives: To examine the influence of intentions to change unsafe sexual behavior on reported behavior change in a cohort of gay and bisexual men.

Methods: 217 gay and bisexual men completed baseline and six month follow-up questionnaires on their HIV risk behavior, beliefs, attitudes and intentions. A model to predict behavior change from Time 1 (T1) to Time 2 (T2) was developed using variables drawn from social cognitive theories of behavior change.

Results: Behavioral intentions at T1 predict behavior change at T2. Men who reported intentions to decrease the number of occasional partners with whom they had receptive anal intercourse at T1 reported significant decreases at T2 ($p=0.99$, $p<0.05$). Beliefs about normative behavior mediated this relationship. Among men who intended to decrease the number of meeting partners with whom they had anal intercourse, only those who perceived positive norms for this behavior had made significant reductions ($n=234$, $p<0.05$).

Conclusions: Cognitive models of behavior change may help identify predictors of change, and thus be useful in developing risk reduction interventions.

T.D.P.40

AIDS-RELATED BEHAVIOR CHANGE OF GAY MEN IN RICHMOND VA 1985-1988

Bradford, Judith B. and Johnson, D. Virginia Commonwealth University, Richmond, Virginia, USA.

Objectives: To present baseline and follow-up data on AIDS-related behavior change and related variables among a semi-structured sample of gay men in the Richmond metropolitan area. Key variables to be discussed are: gay men's health, perceptions of themselves, self-esteem, and changes in risk-reduction and drug use behaviors.

Method: Initial data were collected in the spring of 1985; follow-up data were collected two years later. A questionnaire was prepared specifically for the study, with the help of focus groups of gay men in the city. The same process was used to modify the original questionnaire before follow-up. A two-stage method was used to distribute questionnaires to potential respondents. A list of distributors, both individuals and organizations, was recruited and trained in contacting gay men and explaining the study. The area distribution network was used for the follow-up, in order to make convenient feasible. Anonymity of respondents was carefully protected, in order to gain participation in this city, where homosexual behavior is a felony offense. The response rate was 45% in 1985 and 67% in 1987. Results: Very few had been tested for HIV infection in 1985, but 47% had been tested by 1987. Thirty-one percent of the 1987 cohort were inferring HIV/AIDS in 1985 and 20% reported "great fear" about their own vulnerability to infection; in 1987, this percentage was about the same (21%). However, more than half of gay men sampled in 1987 had experienced an increase in level of fear when they first heard about AIDS. Changes were noted in sources of information about HIV prevention, AIDS service organizations and the public health department being in attendance. Only a minority reported self-protective behavior in 1985; in 1987, almost everyone reported this behavior.

Conclusions: Gay men in this middle-sized southern city were 3 times as likely to have made sex changes in risk behaviors in 1987 as they were to have done so in 1985. Reported changes were probably sufficient to prevent transmission of the virus to increasing numbers of individuals in the population sampled.

T.D.P.41

SEXUAL BEHAVIOUR CHANGES AMONG MALE SEXUAL CONTACTS OF MEN WITH HIV DISEASE: A 3 YEAR OVERVIEW

Calderazzo, Adriana*, Cohen, K. M., Reid, S. Johnson, G. C., Farwell, V., Fanning, M., Shephard, F., MacPáez, D. University of Toronto, Toronto, Ontario, Canada.

Objectives: To describe the behavior changes which have taken place (over a 3-year period) in a cohort of male sexual contacts of men with HIV disease.

Methods: 264 sexual partners of men with HIV disease were recruited into a retrospective study between July 1984 and July 1985. The cohort has been monitored every three months. Data on sexual activities have been collected through an interviewer-administered questionnaire and comparisons between the first and twelfth follow-up visit have been made.

Results: The cohort has experienced a reduction in the number of sexual contacts from a median of 3.7 (range=1) to a median of 1.1 (range=4). The percentage of men who did not have sex increased from 24% to 51%. The mean number of anonymous partners has dropped from 3.7 to 2.0. High risk sexual activities such as anal insertive and anal receptive have decreased (anal insertive from 68% to 43% and anal receptive 58% to 42%). Only a small number are being exposed to semen in the rectum (14/100) or orally (19/100). The frequency of lower risk activities such as oral insertive and receptive has also decreased; frequency of masturbation with a partner has remained unchanged. 70% of follow-up visits have been made. In anal intercourse, 80% more than 50% of the time.

Conclusions: Overall, the men have reduced both the numbers of sexual partners and the volume of sexual activity. The reduction in volume of sexual activity has been gradual and consistent in trend.

T.D.P.42

PSYCHOLOGICAL AND BEHAVIORAL COMPONENTS OF BELIEF IN ANTIVIRAL STATUS

Antoni, Ernest*, Anton, M. J., Johnson, G. C., Lapeere, A. T., Stribanowski, N. J., Fleisher, M. A. et al.
*University of Miami, FL, USA; **Miami University, Fair Hills, CA, USA

Objectives: This study investigated the relationships of perceived belief in HIV status to sexual and health behaviors, psychological and social variables in healthy gay men at risk for AIDS, prior to their anti-HIV-1 status.

Method: Healthy gay males at risk for AIDS ($n=45$) wishing to know their anti-HIV-1 status participated as part of a longitudinal investigation. At baseline, prior to being informed of their diagnosis, subjects provided behavioral and psychological data including measures of psychological distress, coping, gay history, internalized homophobia, and sexual behaviors. Immune function (serum and saliva) antibody status was also determined. Prior to diagnosis, subjects were classified as belief negative (BN) or belief positive (BP), based on their self-reported anti-HIV-1 status.

Results: Of 17 anti-HIV-1 subjects, 12 (69%) were BP of 25 anti-HIV-1 subjects, 22 (79%) were BN. Thus, 71% of all subjects predicted that anti-HIV-1 status correctly. Controlling for status, CD4+ (T-lymphocyte) cell counts, were significantly higher for BP than for BN subjects. Among all subjects, CD4+ numbers were positively correlated with distress measures of depressive and somatiform thoughts about AIDS. Significantly more intrusive thoughts about AIDS were reported by BP subjects. BP subjects also engaged in more anal insertive and female and reported more receptive anal intercourse partners in the last month, as well as, more female, active intercourse, and analque and greater number of partners for analque and female one year ago. BP subjects reported more gay history, more positive coping, more positive self-esteem, and more self-disclosure about their sexual orientation with family and friends. In BP subjects, internalized homophobia was negatively correlated with being gay and engaged in more self-disclosure about being gay in BP subjects was significantly correlated with decreased intrusive about anti-HIV-1 status.

Conclusions: Self-reported behavioral and psychological as well as actual immunological differences were related to belief in HIV-1 seropositivity. Supported by NIMH, P50MH42455-03.



Session d'affichage Poster Session



Le SIDA et l'individu AIDS and the Individual

T.D.P.43 SAFE AND UNSAFE SEXUAL PRACTICES BY HETEROSEXUAL AND HOMOBISexual MEN: PREDICTING INTENTIONS AND BEHAVIOR

M. C. Smith, M. H. Hirsch, G. G. Catania, Y. Kato, A. and Chavira, A.

University of Queensland

Objectives: To examine, in three groups, the influence of attitude, personal and peer norms, and past behavior on the intention to practice safe or unsafe sexual behavior and on actual behavior at the next sexual encounter.

Methods: Homosexual men and heterosexual men and women (N = 240) were recruited from the Brisbane community to participate in the study. They used (1) their intention to engage in several sexual behaviors and behaviors occurring during sexual encounters, (2) the pleasantness of these practices, and other stress and benefits, (3) their present norms about the behavior, (4) peer norms, (5) norms for significant others, and (6) their past sex role behavior. The behaviors had previously been classified as safe or safer with respect to HIV transmission. At their next sexual encounter, subjects completed a brief questionnaire indicating the behaviors they had engaged in, using the same list as on the initial questionnaire.

Results: On the basis of their intention, subjects were classified as positive, risky, or overly strict behavior. Homosexual men were significantly more likely to practice safe behavior than heterosexual men or women. Multiple regression analyses indicated that attitude was the strongest influence on both intentions and actual behavior for all three groups of subjects, but that attitude towards the behavior also played a significant role. Multivariate analysis of variance explored further differences among the three subject groups, and between subjects practicing safe and unsafe sex, on the influence of attitudes and norms, especially peer norms. These results indicated that peer norms are more influential for heterosexual men, while the best source of norms is the most important normative influence for homosexual men and women.

Conclusions: These results highlight the importance of individual psychological variables in the decision to practice safe or unsafe sex, and thus have strong implications for further education programmes. Much more research must be taken of the influence of past sexual behavior on present practice.

T.D.P.44 PSYCHONEUROIMMUNOLOGICAL RELATIONSHIPS IN MEN WITH AIC

T. M. Johnson, J. G. Solomon, G. P. Jenkins, F. W. Rutter, D. P. Sweet, D. H. Univ. of California San Francisco, Univ. of California Los Angeles, Univ. of California Berkeley, CA, U.S.A.

Objectives: To describe and understand the nature of relationships among psychological, neuropsychological, and immunologic variables in HIV disease. To our knowledge, the interactions of variables in these 3 domains have not been reported for men with HIV spectrum disorders.

Methods: Laboratory immunologic measures were obtained for 103 seropositive homosexual men with at least one HIV-related symptom who were recruited from the UCSF AIDS Clinic, and administered neuropsychological tests and psychological self-report measures. All the measures were obtained at 3 time points, approximately 6 months apart.

Results: Significant correlations were found between measures of anxiety, depression, contentment, fatigue and absolute numbers of T_{H1} cells, and natural killer (NK) cell activity. At Time 1, higher scores on emotional suppression were also significantly correlated with more T_{H1} and T_{H2} and T_{H2} cell numbers, as well as with more NK cell activity. At Time 2 (N = 56), higher scores on suppression of anxiety and unhappiness were significantly correlated with higher numbers of T_{H1} and T_{H2} cells, T_{H2} and T_{H2} and T_{H2} cell activity, and with more NK cell activity. Higher numbers of neuropsychological impairments from mild to marked.

Conclusions: While it is premature to draw conclusions about the implications of psychoneuroimmunologic relationships in HIV disease, our findings suggest that these relationships change with disease progression, and are perhaps best interpreted in the context of immunologic and psychological adaptation to ongoing disease and psychological events.

T.D.P.45 CHANGES IN CONDOM USE AMONG GAY MEN: PREDICTORS AND METHODOLOGICAL ISSUES

Calvin A. Jansz, Colette Y. Bell, R. E. Eys, L. J. Capel, F. J. Turner, H., et al. University of California, San Francisco, Center for AIDS Prevention Studies, California State Office of AIDS, U.S.A.

Objectives: Psychosocial predictors of changes in condom use over time were examined. Sample attrition and repeated measurement effects on changes in condom use in two studies were also examined.

Methods: Respondents were gay men in San Francisco. Study One: a longitudinal sample (N=300; 1984-1987) and cross-sectional samples (N=200 per year; 1985-1987) were randomly selected by random digit dial techniques; Study Two: a longitudinal sample (N=600; 1984-1987) was recruited from bars and bath houses and classified questionnaires. Identical behavioral measures were used across studies (Psychological measures will be described).

Results: Condom use increased significantly over time in all samples. The increase was unrelated to subject attrition or repeated measurement effects (Study 1 & 2). Higher levels of social support and enjoyment of condoms were associated with increased condom use over time (analysis of covariance; Study 2). Health beliefs, alcohol use, and antibody status did not predict changes in condom use.

Conclusions: Prevention programs with gay men should focus on building social support groups and enforcing safe sex practices. Changes in condom use observed in longitudinal studies of gay men are probably unrelated to design features.

T.D.P.40 COPING OF HIV-EXPOSED MEN AND AIDS-PATIENTS

Leiberman, P. J., Brooker, M. J., Newman, G. J., Harver, T. J., Oberlin, R. J., Kaldjian, R. J., University of Erlangen, Medical Clinic I, Medical Clinic III, Dept. of Psychology I, RWG AIDS-Center of Federal Health Administration, Berlin.

Objectives: To assess relationships between psychosocial stress caused by an HIV-infection and different reaction patterns as directly influenced or modified by coping processes.

Methods: Life Quality, Coping, and Social Support Questionnaire and semi-structured interviews, administered to 30 homosexual men and 30 HIV-IV, Walter Reed Stage IV, at least 3 months after diagnosis.

Results: Feelings of psychic (68% negatively affected) and job distress (45%) decreased from high levels after the HIV test to moderate degrees (20% resp. 10%). In order to minimize stress, individuals used differential patterns of coping. Passive cooperation, rationalization, problem-analysis, faculty, activity an diversion were used most frequently. Gay men further preferred perceptual defense and tried to preserve competence, while HIV-IV's were seeking social support. Gay men felt less threatened by HIV than HIV-IV's. Clustering over subjects, we found one group, aged 19 to 28, who at the start of their autonomous life were hit by the diagnosis, and developed a depression, showing high scores in perceptual defense, social withdrawal, self-esteem and psychosomatic reactions. A second group of professionally successful gay men focused on distraction by emphasizing job activity. Conclusions: Coping patterns of HIV-positives are similar to those of cancer patients (cf. Hein 1989). Effectiveness of coping will be discussed.

T.D.P.47 DE NOUVEAUX COMPORTEMENTS PARMIS LES HOMOSEXUELS EN EUROPE : LES CAS DE PARIS ET D'AMSTERDAM.

Algra, T., Berghe (Dr.) J., "prog. M.A.M.", (Ransome (Dr.) K.I.), Kaldjian, R.J.

*Amsterdam Jacks, Amsterdam, Jazzy-Bar, *Santé et Plaisir Gai, Paris, France, *Centre National de la Recherche Scientifique (CNRS), Paris, France.

Objectif: Étudier et de reconnaître l'existence de pratiques sexuelles à moindre risque, ainsi que de diffuser d'informations spécifiques ont une influence sur le changement en profondeur du comportement des homosexuels. Ces renseignements (Jack Off Parties-JOP) seront diffusés simultanément à Paris et Amsterdam et l'étude portera de mieux connaître les pratiques sexuelles des participants en dehors des Jack Off Parties.

Méthodes: Réalisation et diffusion de même questionnaire (60 questions) portant sur: prise de contact avec les JOP, évaluation des JOP, test de détection des anticorps du VIH et révélation, pratiques sexuelles habituelles en dehors des JOP, caractéristiques sociodémographiques des participants.... Questionnaires diffusés lors des JOP de janvier, février et mars 1989 (600 à 800 retours attendus pour les deux villes).

Résumé: La première enquête de ce type avait été réalisée à Paris début 88. Les conclusions, présentées à la Conférence de Stockholm (septembre 1988) 3, indiquent que le plus important des JOP pour diffuser et maintenir de nouveaux comportements sexuels à moindre risque. De même, cette enquête avait fait apparaître trois grands groupes de participants selon l'âge et le statut social. L'étude actuellement en cours devrait valider ces résultats, noter les évolutions, mettre en évidence les différences éventuelles entre deux pays ayant des traditions et des politiques de prévention différentes.

Psychologie et sexologie Psychology and Sexology

T.D.P.48

Session d'affichage Poster Session



Le SIDA et l'individu AIDS and the Individual

T.D.P.49 PSYCHOSOCIAL REACTIONS OF MEN WHO ARE CAREERS FOR HIV-INFECTED PEERS AND MEN WHO ARE HIV-ANTIBODY POSITIVE.

Wiley, Linda, L. Crooks, Leavitt, Walker, R.M.
Psychology Department, University of Waikato, NewSouth Wales, Australia.

Objectifs: (1) To describe and compare the psychosocial reactions of HIV-antibody positive gay men and gay men involved in providing care to their HIV-infected peers in three Australian cities. (2) To contrast these responses to those of two groups of men, one with non HIV-related illness and one with no major illness. (3) To examine the implications these findings have for the development and implementation of counselling and support services for carriers and HIV-infected men.

Méthode: Content analysis which was applied to transcripts of the men's interviews to secure measures of distress, anxiety, depression, anger and helplessness, together with their better experiences of competence and sociability as well as general positive emotion.

Résultats: (1) The psychosocial reactions of gay men showed considerable consistency across the three Australian cities. (2) HIV-antibody positive men and the carriers react differently from both the ill and well men, but their reactions are very similar to each other. (3) HIV-antibody positive men showed the most negative positive men, followed by the experience of anger. Depression is also common for carriers. However, perceived competence is also high for both the antibody positive and carrier groups.

Conclusions: Caring for people with HIV infection can be distressing and demanding. The psychosocial reactions of individual carriers need to be examined in order to develop adequate support structures for them. Methods of counselling and support and with HIV-antibody positive men should be examined when developing interventions for carriers. The perceived competencies resulting from carriers and HIV-infected men suggest these strengths should be fostered in developing counselling.

T.D.P.51 DEFENSE MECHANISMS AND HIV RISK RELATED BEHAVIORS IN SUBSTANCE ABUSERS

Blatt, Richard and Ottensmiller, Genevieve
SUNY Stony Brook Science Center, Brooklyn, N.Y., U.S.A.

Objectifs: The clinical importance of understanding a patient's defensive structure, little attention has been devoted to the role of defense mechanisms in the intrapsychic structure of substance abusers and the relationship of defenses to HIV-related risk behaviors. In this study, substance abusers were administered the Defense Mechanisms Inventory (DMI) and the Risk Behavior Inventory (RBI). The DMI measures five defense categories - Denial Against Object (DAO), Turning Against Self (TAS), Isolation (IS), Projection (PD) and Projection (PD). The RBI elicits demographic and HIV-related risk information such as sexual activities, needle sharing and drug-related risk activities. The sample consisted of 39 substance abusers hospitalized for detoxification from heroin and cocaine addiction. Results showed that despite an absence knowledge fund of AIDS prevention and risk reduction information, the patients reported substantial risk related behaviors on the RBI. Evaluation of the DMI data indicated that the patients scored highest on the RIV defense, followed by PD, DAO and TAS respectively. ISM and ISM, which represent intellectualization and denial defenses, may play a significant role in the interpersonal dynamics of continued involvement in substance abuse and continued HIV-related risk behaviors. Clinical and health education implications of providing treatment services and AIDS prevention information to substance abusers is discussed.

T.D.P.53 ENTENDEMENT PSYCHOLOGIQUE DE L'INFECTION A VIRUS SUR LA RELATION DE COUPLE.

Marijckx, Godefride*, S. Tisserand*, Y. Edelle*
* Département des Maladies Parasitaires et Infectieuses, Unité INSERM 313 (Dr. G. Gentilini), Cx. 75116-Bichat, Paris, France
** Service de Médecine Interne, Maladies Infectieuses et Tropicales (Dr. C. Lafatz), Centre Hospitalier de Villeneuve-St-Georges, France.

L'étude des facteurs psychologiques qui perturbent la relation d'un couple stable a été effectuée auprès de 40 couples séropositifs et SIDA, hospitalisés. A partir d'entrevues semi-directives et de questionnaires auprès du patient et de son partenaire habituel, les auteurs ont trouvé que les facteurs de risque psychologique sont corrélés avec la situation affective et sociale du couple séropositif à l'annonce de la séropositivité ou VIH.

Dans le majorité des couples homo-sexuels et hétérosexuels, la séropositivité est annoncée par le patient au partenaire, alors qu'elle est gardée secrète vis-à-vis des parents (tout au moins au début de l'infection et plus encore vis-à-vis des enfants. Le mode de contamination sexuelle est un réglé-on évoué ou tenu secret dans la relation de couple hétérosexuel (mécanisme de protection du couple, système de loyauté).

On observe une plus grande stabilité de lien dans le couple homo-sexuel. En cas de rupture, la cause de la séropositivité n'est pas le seul motif de rupture. On observe le lien affectif supplée à la réduction notable des pratiques sexuelles, à l'acceptation du sous-groupe des couples dont l'un des partenaires ou les deux sont touchés. Les particularités de ce sous-groupe sont analysées par rapport aux comportements du couple vis-à-vis de la prévention de l'infection par le VIH.

T.D.P.50 PSYCHOLOGICAL INTERVENTIONS IN THE TREATMENT OF PERSONS WITH AIDS, ARC & ASYMPTOMATIC HIV INFECTION.

Wiley, Linda L. Metastorming Inc., Montreal, Quebec, Canada

Objectifs: To report on the use of Neuro-linguistic Programming (NLP) in the treatment of HIV infected persons and the consequent beneficial effects on quality of life and clinical status.

Méthode: The approach is based on psychoneuroimmunology (PNI), the study of the complex bidirectional interactions of consciousness (psychic), brain and central nervous system (neuro), and the body's defense against disease (immunology). The NLP model of human behavior provides a characteristic lens between survivors of AIDS and other life threatening illness. The asymptomatic group participated in a 2 1/2 day workshop, persons with AIDS or ARC were seen individually (from 1 to 16 hours each).

Résultats: The preliminary results (follow-up period of 3 to 24 months) indicate substantial increase in self-perceived quality of life, changes in life style and living/working situations, weight gain, decrease in number and intensity of symptoms and infections, elimination and/or substantial decrease in number and intensity of side effects from drug treatments.

Conclusions: Because of lack of control with respect to other treatments it is not possible to isolate the effects of NLP. Nevertheless, the timing and extent of many changes was impressive and not merely coincidental. Given that it has no harmful side effects, NLP offers an effective strategy in the treatment of AIDS and ARC and in the maintenance of health in asymptomatic HIV-infected persons.

T.D.P.52

PROCESSUS D'ADAPTATION A LA MALADIE DE PERSONNES ATTENTES AU SIDA
Côté, José; Fortin, M.-F. Université de Montréal, Montréal, Québec, Canada.

En raison de l'absence de traitement efficace à ce jour, il paraît essentiel de promouvoir le bien-être des personnes atteintes de SIDA.

Objectif: Décrire le processus d'adaptation à la maladie des personnes atteintes du SIDA.

Méthode: Une étude descriptive de type transversal s'est déroulée dans un Centre hospitalier universitaire de Montréal auprès de 50 sujets, la moitié au stade préinfecté et les autres, au stade précoce d'avancé. Les variables étudiées ont été: les perceptions des sujets vis-à-vis la sévérité des pertes (questionnaire élaboré); leurs stratégies adaptatives (échelle de coping, Billings & Moos, 1984) et l'état psychologique (échelle de bien-être, Kovacs et al., 1985).

Résultats: Les pertes d'ordre physique sont celles perçues le plus sévèrement. I. Les stratégies adaptatives orientées vers la recherche d'information sont celles les plus utilisées. II. La sévérité des pertes détermine l'influence de façon statistiquement significative l'utilisation des stratégies d'évitement. IV. Les sujets qui ont les meilleurs scores de bien-être utilisent davantage des stratégies orientées vers la recherche d'information et ils ont moins recours à des stratégies d'évitement. V. Les sujets qui ont le stade précoce de la maladie perçoivent plus sévèrement les pertes d'ordre social que ceux au stade préinfecté.

Conclusion: Les efforts déployés par les sujets pour composer avec les pertes ont des répercussions profondes sur leur intégrité psychologique.

T.D.P.54

DIFFICULTES IN THE MANAGEMENT OF AIDS PATIENTS AND INFECTED PEOPLE IN BRAZIL
Instituto Lacta Evolucio Lacta, Vila Anália***
*** Divisão Nacional de Doenças Sexualmente Transmissíveis/AIDS - Ministério da Saúde - Brasília, Brazil

Objectifs: To identify the problems health professionals face in dealing with AIDS patients and infected individuals.

The management of AIDS patients and infected individuals in a hospital, out-patient clinics, home care facilities or work place have brought controversial responses from health professionals in Brazil. The main responses were the following: irrational fear, stigma, refusal to provide medical care, ignorance, lack of solidarity and discrimination. These responses brought a crisis on the management of patients on both in-patient and out-patient basis and led us to develop and implement a training course and counseling services. The methodology used in the training was role-play. From 400 health professionals evaluated, 90% (432/480) showed improvement on the level of knowledge, change in perceptions and attitudes towards infected individuals, AIDS patients, and themselves.

**Session d'affichage
Poster Session**



**Le SIDA et l'individu
AIDS and the Individual**

T.D.P.55 PSYCHOLOGICAL CORRELATES OF THE TRANSMISSION AND ACCEPTANCE OF RUMORS ABOUT AIDS

Kimmel, Allen J.
Fitchburg State College, Fitchburg, Massachusetts, U.S.A.

Objective. To identify the emotional and cognitive factors that underlie the transmission and acceptance of widely disseminated rumors about AIDS, and to determine the prevalence and degree of belief in the rumors. Rumors were expected to thrive in an atmosphere of anxiety and uncertainty.
Method. A questionnaire, which listed current rumors about AIDS, was completed by 229 college students. These were designed to explore the relationship between apprehension, doubt, AIDS-related changes in behavior, and rumor-specific anxiety, importance, and uncertainty as correlates of self-reported frequency of rumor transmission and degree of rumor belief.
Results. Stepwise regression analyses revealed that the best predictive variables of frequency of rumor transmission included rumor-specific anxiety and behavior change ($r=.56$, $p<.001$); rumor-specific anxiety, importance, and expectation of AIDS-related personal consequences best predicted belief in rumors ($r=.73$, $p<.001$). Rumor-specific credibility was related to AIDS uncertainty ($r=.30$, $p<.001$) and rumor transmission ($r=.17$, $p<.05$). Overall uncertainty about AIDS transmission was related ($r=.15$, $p<.05$).
Conclusion. Rumor-specific anxiety appears to be the strongest predictor of rumor transmission and credibility. Tendencies to transmit anxiety-provoking rumors are likely to increase AIDS-related behavior change, perhaps to justify the change or reduce post-decisional dissonance. Anxiety-provoking rumors perceived as important and personally consequential are most likely to be believed. Reduction of anxiety in AIDS education campaigns is advised.

T.D.P.57

HELP-SEEKING FOR AIDS-RELATED CONCERNS: A COMPARISON OF GAY MEN WITH VARIOUS HIV DIAGNOSES
Hass, Robert; Cunniff, Michael; Lusk, L. and Coates, T.
Center for AIDS Prevention Studies, University of California, San Francisco, San Francisco, USA

Objective. To examine psychological distress levels and help-seeking patterns among four groups of gay men (AIDS diagnosed, HIV seropositive, HIV seronegative, men unaware of their HIV status) and assess the helpfulness of different sources used (peers, family, professional helpers).
Methods. 574 gay men who participated in the 1987 wave of the AIDS Behavioral Research Project completed questionnaires regarding help-seeking, HIV status, AIDS-related worry, anxiety and depression.
Results. Respondents reported high anxiety and a high degree of help-seeking. Men diagnosed with AIDS and seropositive reported the most AIDS-related worry and were the most likely to seek help. Peers were the most widely sought help-source and perceived to be the most helpful. Help-seekers of peers was correlated with less anxiety and depression. Family members were least likely sought and perceived as least helpful.
Conclusions. Peers were seen as the primary and most effective help-source for gay men confronting the AIDS crisis. Community programs are needed to promote the helping abilities of peers, prevent burn-out among peer helpers and provide alternative help sources for men who lack supportive peer networks.

T.D.P.59 EVIDENCE OF FRANK COGNITIVE IMPAIRMENT AND DEPRESSION AMONGST INDIVIDUALS AWARENESS INDEPENDENTLY OF WALKER REED STAGE

Gibson, William C., Thomas, R.C.**, Carter, C.N.***
*Psychology Service, Walter Reed Medical Center and the Walter Reed Bioregulatory Research Group, Washington, D.C. United States of America
**Infectious Disease Service, Walter Reed Army Medical Center, United States of America.

Objective. To provide descriptive information on levels of depression and global cognitive functioning in HIV positive males at a military medical center.
Method. A retrospective review of psychological test data was conducted. Scores on a standard depression scale (Bard) and cognitive test (Shipley-Hartford) are presented, and these were examined in relation to the patient's stage of infection in the Walter Reed Classification system.
Results. Descriptive data are presented in tables. Of 254 patients, 278 scored in the clinically depressed range, and a frequency analysis of these showed no relation between Walter Reed stage and number of patients with a depressed score. Using a Shipley-Hartford IQ of less than 80 to indicate cognitive decline, 15% of 256 patients evidenced such a change. Frequency analysis revealed no relation between Walter Reed stage and IQ.
Conclusion. Patients in both early and late stage of HIV infection are subject to depression and cognitive impairment, and substantial numbers of patients in all stages had normal scores. Professionals should not assume either normality or dysfunction of a patient's psychological status on the basis of information on stage of infection alone.

T.D.P.56 THE STRESS OF CARING: DIMENSIONS OF STRAIN AMONG INFORMAL AIDS CAREGIVERS

Twiter, Heather University of California, San Francisco, USA

Objective. To identify the dimensions of stress experienced by gay men caring for friends or lovers with AIDS. Methods. Qualitative interviews were conducted with 20 informal caregivers. Interviews were taped, transcribed and analyzed for stress-related content. Structured questionnaires were administered to an additional 30 respondents. Results. Three broad dimensions of stress were identified: 1) Primary Caregiver strains that arise directly out of the demands and responsibilities of the caregiver's role; 2) Secondary Strains that develop in other areas of the caregiver's life because of the intrusion of caregiving demands; and 3) Intrapsychic strain resulting from the caregiver's own fear of contracting AIDS, the attenuation of his social network because of AIDS-related death, and the anticipated loss of an intimate relationship. Several sub-components within each of these general dimensions of stress have been identified. The importance of humanistic benefits for the patient and informal caregiver in often left to contend with a great number of intense stressors. The importance of incorporating the needs of informal caregivers into public health policy is evident.

T.D.P.58 SHORT-TERM MEMORY (STM) CAPACITY DECLINES AS A FUNCTION OF AIDS SEVERITY

Corfian, D; Kellip, JG; Sadler, AR; Wolf, J; Price, RW & Memorial Sloan-Kettering Cancer Center, NY, NY, USA

Objective. To assess STM capacity as a function of clinical severity of ADC. Although memory failure is a frequent complaint in ADC patients the bases for such complaints have yet to be determined.
Methods. STM on a free recall task was examined in a group of 80 patients at various stages of HIV-1 infection. Patients were rated according to cognitive impairment based on a standard neurological history and examination: 50 (unimpaired), 21 (mild) and 18 (moderate to severe). STM capacity was measured by determining the mean number of items recalled from STM in the Auditory Verbal Learning Test (Maugh, HC and Norman, DA. *Psych. Rev.* 85-104, 1965).
Results. STM declined as a function of cognitive impairment ($F(2,88) = 8.30$, $p<.001$). Memory decline was modest in patients with mild impairment (7%). It was more pronounced in patients with moderate or severe impairment (42%). The decrease in STM correlated with other neuropsychological measures of ADC: timed walk ($r=-.34$), grooved pegboard ($r=-.43$), and trail making A and B ($r=-.46$), but not with measures of psychiatric distress.
Conclusions. STM decreases as a function of increased severity of ADC. This decline reflects diminished cognitive capacity but because of the role of attention in STM, it is unclear whether the reported results represent a true memory deficit. The extent to which this decline affects cognitive functioning warrants further investigation.

T.D.P.60 ATYPICAL STYLE AND DEPRESSION IN HIV-RELATED ILLNESS

*Van Gorp, Wilfred**; Preams, D.***; George, L.****
*Department of Psychology, University of California, San Diego, CA, USA
**West Los Angeles VA Medical Center, Los Angeles, CA, USA
***Medical Center, Jackson, R.C., USA

Objective. To examine the influence of self-reported depressed mood in a group of AIC and AIDS patients and the relationship of attributional style to mood state.
Method. Thirty subjects (AIDS, $n=18$; AIC, $n=12$) were administered the following tests: BDI-16, Beck Depression Inventory (BDI), and Attributional Style Questionnaire (ASQ). The subjects were aged from 22-43 with a mean and median of 42 years and a mean education of 14 years.
Results. Internal depressed mood was found for the total sample on both the depression scales of the BDI-16 ($M=11.1$, $SD=4.4$) and the BDI ($M=10.8$, $SD=3.5$). Although both groups reported significant depression on the BDI-16 depression scale (AIDS, $M=9.8$, $SD=4.7$; AIC, $M=11.9$, $SD=4.4$) and ASQ to indicate depressed mood and the BEI (AIDS, $M=5.5$, $SD=4.7$; AIC, $M=5.7$), no significant differences were found between the groups on these measures. A significant positive correlation was found between the ASQ and BDI-16 depression scale ($r=.49$, $p<.05$) and the BEI ($r=.49$, $p<.05$).
Conclusions. Elevated depressed mood was observed in a sample of AIC and AIDS patients and a significant positive relationship was found between internal, stable and global explanations for negative events and self-reported depression. Attributional style may be an important factor in the manifestation of depression among patients presenting with HIV-related symptoms, and the implications of this will be discussed.

Session d'affichage Poster Session



Le SIDA et l'individu AIDS and the Individual

T.D.P.61 HIV-1 PATIENTS' SELF-REPORTED COMPLAINTS OF MEMORY FAILURE AND THEIR RELATIONSHIP TO ACTUAL MEMORY PERFORMANCE
Kellip, John S.; Sadler, AE; Wolf, A; Brew, BJ; Dorfman, D; Price, NR; Stoltz, JJ. Memorial Sloan-Kettering Cancer Center, NY, NY, USA

Objective: To evaluate the relationship between HIV-1 patients self-reported memory complaints and their actual performance on formal tests of memory.
Methods: 123 untreated HIV-1 patients at varying AIDS Dementia Complex stages were evaluated with the Neuro-AIDS Study group neurological history, examination, and neuropsychological battery. Patients also completed a self-report scale of memory complaints (Memory Assessment Clinic, Inc.), which provides scores on two general factors: (1) ability (AM1) to perform a variety of everyday memory tasks and (2) frequency (FRQ) with which lapses in performing such tasks occur.
Results: AM1 and FRQ were strongly correlated with each other ($r = .54, p < .001$), and with the number of memory complaints elicited from neurological history (AM1: $r = .50, p < .001$; FRQ: $r = .50, p < .001$). AM1 score was lower ($t = 3.7, p < .001$) and FRQ score higher ($t = 3.2, p < .002$) in patients with mild to moderate symptoms of ADC. Only the AM1 score was significantly correlated with scores on formal tests of memory (with Verbal Learning, $r = .20, p < .009$; with Visual Retention, $r = .16, p < .08$) or tests with a memory component (with Digit Span, $r = .22, p < .01$). The FRQ factor was most strongly correlated with mood ($r = .51, p < .001$) and general psychiatric symptomatology ($r = .56, p < .001$).
Conclusions: Complaints of impaired memory ability are mildly related to actual decrements in performance. The frequency of reported lapses, however, is strongly related to the intensity of mood/psychiatric disturbance.

T.D.P.63 EMOTIONAL STATES IN RELATION TO IMMUNE FUNCTION IN A GROUP OF MALE SEXUAL CONTACTS OF MEN WITH HIV DISEASE

Authors: Rosenblatt, M.; Casser, R.***; Reed, S.***; MacPhaden, D.***; Johnson, M.***; Panning, M.***; Shephard, D.***
*Women's College Hospital, Toronto; **Department of Preventive Medicine and Biostatistics, University of Toronto; ***Hospital for Sick Children, Toronto; The Toronto Hospital, Toronto, Ontario, Canada.

Objective: To explore the relationship of emotional state and laboratory measures of immune function.
Methods: Men with prior homosexual contact with an individual with HIV-related illness were recruited without regard to emotional state for a study of HIV status, risk behaviour, clinical status, and immune function. 155/161 (96.3%) men without AIDS completed the Profile of Mood States (POMS) for at least one quarterly visit in one year. 6 POMS scales X 12 immune function measures = 72 possible significant (p < .05) correlations.

Results: POMS scale scores did not differ between HIV+ and HIV- men. For HIV+ men, 1 POMS/immune function pair was correlated at visit 1 ($N = 47$) and 2 different pairs were correlated at visit 2 ($N = 62$). For HIV- men, 5 POMS/immune function pairs were correlated at visit 1 ($N = 99$) and 19 pairs were correlated at visit 2 ($N = 72$); unexpectedly, greater emotional distress was associated with better immune function on all correlations.
Conclusion: In this long-term study of homosexual men, greater emotional distress was not associated with deterioration in immune function measures commonly used to monitor progress of HIV infection.

T.D.P.65 HIV INFECTION AND IMMUNOLOGICAL STATES IN ADOLESCENT GAY MEN
David GORSON, Bill LEE, Robert J. HANES
Division of Internal Medicine, Hospital "Thomas Traill" (TTH), Universitat Autonoma de Barcelona, Barcelona, Spain.

Objective: To analyze the role of viral-mediated immunity and viral load in HIV compared to CD4+ to determine if there is any relation between these immunological functions and HIV seropositivity.

Methods: 30 HIV seropositive individuals were tested from January II to December II. 10 seropositive tests were negative. The lower's memory progressive function for the area of visual-spatial reasoning (II spatial) and the III spatial area section for the sensitive memory area ("1" section) in age 10 and II after adjustment at the identification test, patients were tested with the digit span on the III spatial area.

Results: 14/20 (70.0%) of patients had HIV antibodies (HIV tests) and 16/20 (80.0%) had anti-HIV. The HIV test was 10.4% in 10 years and the time of infection was 10.2% in 10.7 months. 10.1% in 10.1% in HIV and 10.1% in 10.1% in HIV. 10.1% had only primary serological level and in 10.4% of such individuals was anti-HIV or anti-HIV. About of other drugs was high. We set significant in each group. 10.1% of the HIV test obtained in 10.1% permits in the area of visual-spatial reasoning. The digit span showed no differences, between the two days of testing, and finding the same conclusion in both seropositive individuals.

Conclusions: There was not significant differences in the visual-spatial reasoning and sensitive memory areas of both seropositive and seronegative individuals. It indicates a decreased visual-spatial reasoning in a 10% of the cases that does not seem related to HIV seropositivity. It seropositive. It is therefore, factors as low serological level, absence of other drug and longer seroconversion intervals could explain these findings.

T.D.P.62 QUALITY OF LIFE OF PERSONS WITH AIDS/ARC.

Donald Ellerman, Health Planning Consultant and Mark Smith, University of Pennsylvania, Philadelphia, PA, USA.

Objective: To document and quantify the effects a diagnosis of AIDS has on one's life.

Methods: All persons diagnosed with either AIDS or ARC (PWA) were surveyed in the metropolitan Philadelphia area. A mail-return survey method resulted in 90 completed surveys of a total documented population of 253 PWAs. The survey was distributed through health care and social service networks.

Results: The survey produced evidence for a cycle of impacts on PWA's of diagnosis leading to illness, to loss of employment, to loss of health insurance, to loss of financial security, and all these to mental stress. Average monthly income declined from \$180 before diagnosis to \$80 afterwards. Health care expenditures (PWA) lives; they spent a mean of 5.9 hours per day on their personal medical care, paperwork and extra hours attending and made an average of 6 visits per month to health care facilities. Overall quality of life is standardized on a scale from 0 to 10 using Spitzer's quality of life index. The mean for PWA is 6.8.

Conclusions: A diagnosis of AIDS leads to significant impacts on employment, finances, mental health, daily living and overall quality of life which can be documented and quantified.

T.D.P.64 IMMUNITY RESPONSE AND HIV INFECTION IN GAY MEN

Alan Corbin, Bill Lee, Robert J. Hanes, J. Hanes
Division of Internal Medicine, Hospital "Thomas Traill" (TTH), Universitat Autonoma de Barcelona, Barcelona, Spain.

Objective: To test the hypothesis that personality disorders are lower risk patients for HIV infection in comparison with other classes (BPD), based on the analysis of personality scales and factors. It is a typical characteristic of BPD.

Methods: 10 seropositive HIV test and 10 female seronegative tests (HIV-). HIV- test (HIV) and HIV- test (HIV) were administered to 10 gay men. HIV- test (HIV) and HIV- test (HIV) were administered to 10 gay men. HIV- test (HIV) and HIV- test (HIV) were administered to 10 gay men. HIV- test (HIV) and HIV- test (HIV) were administered to 10 gay men.

Results: 10/10 (100%) of HIV- test (HIV) and HIV- test (HIV) had anti-HIV. HIV- test (HIV) and HIV- test (HIV) had anti-HIV. HIV- test (HIV) and HIV- test (HIV) had anti-HIV. HIV- test (HIV) and HIV- test (HIV) had anti-HIV. HIV- test (HIV) and HIV- test (HIV) had anti-HIV.

Conclusions: HIV- test (HIV) and HIV- test (HIV) had anti-HIV. HIV- test (HIV) and HIV- test (HIV) had anti-HIV. HIV- test (HIV) and HIV- test (HIV) had anti-HIV. HIV- test (HIV) and HIV- test (HIV) had anti-HIV. HIV- test (HIV) and HIV- test (HIV) had anti-HIV.

T.D.P.66 PSYCHOLOGICAL FACTORS PREDICTING DISTRESS AFTER HIV TESTING
Elizabeth, Barbara Perry, J. Hanes
Cornell University Medical College, New York, NY, USA.

Objective: To identify individuals at risk for distress after HIV testing.

Methods: When 264 physically asymptomatic subjects voluntarily sought HIV serology testing, three hypothesized predictors of distress were assessed: (1) perceived social support (Interpersonal Support Evaluation List, ISEL); (2) attributional style (Attributional Questionnaire, AQ); (3) attributional style (Health Attributional Style Questionnaire, HASQ). Distress was concurrently measured by the Beck Depression Inventory (BDI), State-Trait Anxiety Inventory (STAI, TAI), and Brief Symptom Inventory (BSI). The distress measures were re-administered 9 weeks later, after notification and one of three psychoeducational interventions.

Results: Seronegative correlations (initial) and partial correlations (follow-up) controlling for effects of serological status and intervention:

	Initial (N=264) 283 (N=14)	Follow-up (N=167) 283 (N=14)	
ISEL	-.55	-.44	-.52
AQ	-.59	-.58	-.57
HASQ	-.52	-.54	-.43

For all correlations, $p < .05$. For ISEL, $p < .01$. For AQ, $p < .01$. For HASQ, $p < .01$.

Conclusions: Perception of social support, pessimistic and attributional style were strongly associated with distress before HIV testing and predict distress 9 weeks later. They may be useful assessments to identify patients for preventive psychoeducational interventions.

Session d'affichage Poster Session



Le SIDA et l'individu AIDS and the Individual

T.D.P.73

PSYCHOLOGICAL ASSESSMENT IN AIDS RESEARCH: INTERVIEWER SELECTION, TRAINING, AND MONITORING

Spiegel, M. S.; Galanter, H. P.; Meyer-Bahlburg, H.F.L.*
Berkeley, A.A.*


*MGI Center for Clinical and Behavioral Studies, New York State Psychiatric Institute and Columbia University, New York, NY, USA.

Objective. To describe a program designed to optimize rapport between interviewer and subject and to minimize specific biases in the value-laden and emotionally charged area of assessment.

Method. (1) Interviewer selection; criteria include both general educational requirements and level of comfort in dealing with diverse sexual histories. (2) Desensitization workshops, to familiarize the interviewer with sexual vernacular. (3) Item-by-item review of the sexual instrument. (4) Conducting of audiotaped interviews. (5) Supervised interview practice with staff members. (6) Supervised interview practice with subjects from the target population. (7) In the field: ongoing review of every interview. (8) Monitoring of interviewer style by audiotape-review of every 7th to 10th interview. (9) Weekly group supervision of interviews. (10) Results. Overall, selection of interviewers reduced overall training time. The training program facilitates rapport, self-disclosure, etc. Group sessions enhance interviewer awareness.

Conclusion. Overall quality of psychosocial data is enhanced by interviewer selection and training procedures.

T.D.P.74



T.D.P.76

SELF-LABELLED SEXUAL ORIENTATION AND SEXUAL BEHAVIOR AMONG WOMEN

Ryan, S. and Lerman, J.M. Raleigh and J. Zomba-Davis

The Kinsey Institute for Research in Sex, Gender, and Reproduction, Indiana University, Bloomington, IN, U.S.A.

Objective. To describe the relationship between women's self-labeled sexual orientation and actual sexual behavior both since 1981 and since 1980.

Method. A self-administered sample of 639 men completed a questionnaire specifically designed for this study. The instrument included questions concerning demographics, sexual behavior with both men and women, and both knowledge and opinion regarding AIDS.

Results. The data suggest the self-labeling of sexual orientation among women does not necessarily correlate with actual behavior since age 18 or since 1980. In our sample of 262 women who had themselves labeled as self-labeled of sexual orientation and actual sexual behavior patterns appear to be relatively independent - 75% of those women had had sex with men since age 18 and 49% had done so since 1980. Thirty percent of the Indian women reporting sex with men since 1980 had engaged in public-to-public intercourse. Our data also indicate that the likelihood of engaging in anal intercourse is significantly related to the sexual orientation of a woman's male partner. Among lesbian women in our sample, only 25% of those with heterosexual partners engaged in anal intercourse as compared to 67% of those with known behaviorally bisexual male partners.

Conclusion. The labels "heterosexual" and "homosexual" are often presumed to predict the sex of partners, the types of behavior engaged in and in some cases, the overall frequency of sexual activity. Moreover, once a label has been identified, it is accepted as characterizing an individual's lifetime sexual behavior. Like other non-risk-identified groups in our studies, lesbian women are assumed to be at minimal risk for infection with Human Immunodeficiency Virus (HIV). Although sexual behavior between women may act as a partially cover of transmission, the danger of assuming that lesbian women, for that matter men and women of any particular orientation group, are at minimal risk, lies in the erroneous notion that such group designations impose impermeable barriers to sexual intercourse.

T.D.P.76

SAFER SEX AMONG HOMOSEXUAL MEN: MEANING A MOTIVATION.

DeBruin, James* New, J.F.; Kallisher, J.

Christchurch School of Medicine, Christchurch, New Zealand.

Objective. To study the motivations and meanings of changing sexual practices amongst men who have sex with men. In response to AIDS.

Method. Fifty men were contacted at a gay sauna or through snowball sampling and were interviewed with an unstructured, in-depth approach.

Results. Sexual practices were variable over time and context dependent. Those generally practicing safer sex were characterized by one or more of the following: most strongly identifying themselves as gay; concerned to maintain a healthy life-style; close relationship with someone with HIV infection; concerned for health of others particularly their partners. Those men who tended to participate in "safer" sexual practices included those who were still in the process of "coming out"; saw themselves as sexually inexperienced; lacked social skills or self-confidence to assert their preference for safe sex; younger men who used sex as a means of gaining entry into gay society; older men who were willing to compromise health concerns for sexual availability; men who had broken off a stable relationship and were particularly vulnerable.

Changes to sexual behavior had usually been made at great cost. Often, safer sex represented a major disruption in social life. Some exchange was seen by men as "real sex" and therefore giving it up was a significant loss. It appeared that sex was the most important form of communication between these men. Other forms of fantasy were poorly developed. **CONCLUSIONS.** Consistency in the practice of safer sex depends upon circumstances, characteristics and context. The extent of the sacrifice required should not be underestimated.

T.D.P.77

VARIABLES INFLUENCING CONDOM USE AMONG INTRAVENOUS DRUG USERS

Marcus, Stephen, Shapiro, R.L., Siddons, C., Linton DS*

Nagano and Drug Research Inc., New York, New York, USA

Objective. To determine the knowledge, belief, attitudes, and behaviors related to the use of condoms among 110 IDUs at risk of contracting and/or transmitting HIV through unprotected sexual contact.

Method. 289 IDUs attending 3 methadone maintenance clinics in New York City completed confidential standardized questionnaires during 1987-1988.

Results. AIDS risk factors were: sexual activity in previous month (yes=79%); condom use among sexually active (no use=48%); sexual partner(s) injected drugs in past year (yes=53%); intravenous drug use in previous month (yes=41%); needle-sharing in previous month (yes=59%). Multiple logistic regression was conducted for the sexually active subjects to predict their condom use in the previous month (none vs. some). Condom users scored higher on Acceptability of Condoms, e.g. to believe that condoms did not "cut down" on enjoyment and to be willing to use condoms "if my partner asked me" (Odds Ratio=1.7, 95% CI=1.2, 1.4). Users also scored higher on Receptivity of Partners to Protection, e.g. to believe that their sexual partners would "not be insulted" by requests for condom use or other sexual protections (OR=1.6, 95% CI=1.1, 2.2). Condom users were also more likely to personally know a person with AIDS (OR=1.5, 95% CI=1.2, 2.3) and to be recent entrants to the study (OR=1.6, 95% CI=1.2, 2.0).

Conclusion. IDUs' willingness to use condoms is significantly determined by specific beliefs and attitudes that could be modified by appropriate health education and cognitive-behavioral interventions.

T.D.P.78

SEXUAL BEHAVIOR SURVEY OF BRAZILIAN MEN THAT ARE CLIENTS OF TRANSGESTIVE PROSTITUTES

Piquet, Arley*

*Centro de Referência e Treinamento-AIDS, São Paulo, Brazil

Objective. To elucidate the sexual behavior of men that engage in sexual contact with transvestite prostitutes.

Method. A 20-item questionnaire was applied to 162 men that regularly engaged in sex with transvestites. 150 men were included in the study.

Results. The mean age was 34.01 years, 60% were married or had stable female partners, 3.7% reported homosexual activity in adulthood. None had stable male partners. 97.3% of the subjects identified themselves as heterosexuals and 2.0% as bisexuals. 10% were engaged exclusively in active anal intercourse with the transvestite, 20.67% in passive anal intercourse, and 57.33% in both. 4% did not engage in anal intercourse. 61.3% reported some degree of alcohol or drug use before or during the encounter. 4.6% reported IDU with the transvestite. 94.67% acknowledged the risk for acquiring some form of STD. None thought that they were at risk for AIDS.

Conclusion. This study demonstrates that transvestite prostitution is an important risk factor for heterosexual transmission in Brazil, as well as, the need for developing specific educational programs for heterosexuals including these aspects.

Session d'affichage Poster Session



Le SIDA et l'individu AIDS and the Individual

T.D.P.79 CHILDHOOD GENDER NONCONFORMITY PREDICTS HIV-1 SEROPPOSITIVITY IN HOMOSEXUAL MEN


Richard James Grant, I. Adamson, J. Richman, D. Spence, S. University of California, San Diego, U.S.A.

Objective: To determine whether childhood gender nonconformity (CGN), an important variable in gender identity research) is of value in AIDS research. The central hypothesis is that homosexual men with high CGN become disproportionately seropositive for HIV-1, largely due to high levels of receptive anal intercourse (figures above).

Methods: N = 72 homosexual men have been recruited (23 seropositive and 49 seronegative), and completed the Childhood Gender Identity Scale (CGI). A one-way ANOVA compared seropositivity with CGI scores. Additional analyses used scoring variations.

Results: CGI scores differ significantly by seropositivity status (figures below) ($F = 6.65, df = 71, p < 0.012$). Fisher's LSD, $p < 0.05$, $p < 0.001$, all except one of the men with the higher CGI scores were seropositive.

Conclusions: The association between CGI and seropositivity is so strong at the high end of the CGI distribution that it might not arise merely by way of the hypothesized intermediate variable. Personality variables as well as behavioral ones may be required. Additional analyses are in progress that suggest that CGI may be a good surrogate for receptive anal intercourse experience, and might to some extent mitigate the underreporting of such experience in direct questions. Implications for medicine and sociology will be discussed.



T.D.P.81 CONDOM USE AMONG HETEROSEXUAL MALE IV DRUG USERS IS AFFECTED BY THE NATURE OF SOCIAL RELATIONSHIPS.

Richard James Grant, I. Adamson, J. Richman, D. Spence, S. University of California, San Diego, U.S.A.

Objective: To describe the extent to which male IV drug users in treatment know that condoms reduce HIV transmission risk, contrast knowledge to actual use, and determine whether characteristics of social relationships affect men's condom use with women.

Methods: One hundred fifty-one men recruited from a New York City methadone treatment program in 1986 and 1989 were interviewed with a structured questionnaire in 1987-88.

Results: Of the 150, 137 (91%) had sex with women in the period (mean 23 months) covered by the interview. Of these 137 sexually active men (of whom 2 also had sex with men), 57% (78/137) reported only one sexual partner. While 70% (125/144) knew that condom use can prevent sexual transmission of HIV, only 50% (76/153) of the sexually active men ever used condoms during the interval.

Conclusions: While men's sexual, educational, and number of women partners were not significantly associated with condom use, but the nature of social relationships was. Among the 64 men who lived with a sexual partner, 44% used a condom at some time during the period, compared to 68% of the 71 who did not live with a sexual partner ($p < 0.05$). The relationship remained significant after controlling for number of partners.

Conclusions: Education about condoms is not necessarily sufficient to promote condom use; the nature of social relationships also affects sexual risk reduction. Condom use among men is less frequent in relationships with more complex interdependencies.

T.D.P.83 EVALUATION OF SEXUALITY IN HIV INFECTED PATIENTS BY THE WARTING TEST.

Leopoldo Pineda, Gerardo Nieto, L.D. and Maria de S.C. Garcia & Duke University Medical Center - University of Rio de Janeiro (UFRJ) - Brazil

Objective: To observe possible changes in the sexuality of HIV infected patients by sexual transmission, compared to those infected by blood transfusion.

Methods: 20 HIV infected patients were assessed by a non-directive sociological method, this group including 18 (90%) infected by sexual transmission (heterosexuals and 2 female partners of bisexual men) and 2 (10%) by blood transfusion. The survey test was performed in all infected patients in a manner of a semi-structured interview. Through sociological stimulus the patients develop pictures and comments about the subject, eliciting adequate and non adequate responses in 8 different fields. The sexuality field was specifically evaluated and statistically assessed by Chi-Square Test.

Results: Data are presented in the following table:

SEXUALITY FIELD ALTERNATIVES	SEXUAL TRANSMISSION	BLOOD TRANSMISSION	T	O	A	Z
Observed	18	10	5	41,6	23	
Exp. Observed	6	6	7	38,3	7	

Alterations in the sexuality field observed ranged from difficulty in reacting to sociological stimuli to non adequate responses.

Conclusions: HIV positive individuals (who were) infected by sexual transmission may develop own changes in their conception of sexuality.

T.D.P.80 SEX AND DRUG PRACTICES IN THE ILLEGIT SEX INDUSTRY AS RELATED TO THE SPREAD OF AIDS

William J. Jones, I. Adamson, J. Richman, D. Spence, S. University of California, San Diego, U.S.A.

Objective: To assess the sexual practices of prostitutes and their clients with respect to AIDS transmission.

Methods: Information was collected from a total of 169 seropositive prostitutes contacted on the streets of New York City from 1983 to 1988. (22 in 1983, 43 in 1984, 65 in 1987, and 37 in 1988).

Results: Of 169 seropositive prostitutes, 14 (8.3%) were found by ELISA with confirmation by Western Blot to be positive for HIV-1. Of 22 (13%) of these women who admitted to former or present intravenous drug use, 25% were positive, while among the 147 (87%) women not admitting to intravenous drug use, only 5% were positive. Many of these women reported having lovers who used intravenous drugs.

Conclusions: Information was collected from a total of 169 seropositive prostitutes contacted on the streets of New York City from 1983 to 1988. (22 in 1983, 43 in 1984, 65 in 1987, and 37 in 1988).

Results: Of 169 seropositive prostitutes, 14 (8.3%) were found by ELISA with confirmation by Western Blot to be positive for HIV-1. Of 22 (13%) of these women who admitted to former or present intravenous drug use, 25% were positive, while among the 147 (87%) women not admitting to intravenous drug use, only 5% were positive. Many of these women reported having lovers who used intravenous drugs.

Conclusions: Information was collected from a total of 169 seropositive prostitutes contacted on the streets of New York City from 1983 to 1988. (22 in 1983, 43 in 1984, 65 in 1987, and 37 in 1988).

Results: Of 169 seropositive prostitutes, 14 (8.3%) were found by ELISA with confirmation by Western Blot to be positive for HIV-1. Of 22 (13%) of these women who admitted to former or present intravenous drug use, 25% were positive, while among the 147 (87%) women not admitting to intravenous drug use, only 5% were positive. Many of these women reported having lovers who used intravenous drugs.

Conclusions: Information was collected from a total of 169 seropositive prostitutes contacted on the streets of New York City from 1983 to 1988. (22 in 1983, 43 in 1984, 65 in 1987, and 37 in 1988).

Results: Of 169 seropositive prostitutes, 14 (8.3%) were found by ELISA with confirmation by Western Blot to be positive for HIV-1. Of 22 (13%) of these women who admitted to former or present intravenous drug use, 25% were positive, while among the 147 (87%) women not admitting to intravenous drug use, only 5% were positive. Many of these women reported having lovers who used intravenous drugs.

Conclusions: Information was collected from a total of 169 seropositive prostitutes contacted on the streets of New York City from 1983 to 1988. (22 in 1983, 43 in 1984, 65 in 1987, and 37 in 1988).

Results: Of 169 seropositive prostitutes, 14 (8.3%) were found by ELISA with confirmation by Western Blot to be positive for HIV-1. Of 22 (13%) of these women who admitted to former or present intravenous drug use, 25% were positive, while among the 147 (87%) women not admitting to intravenous drug use, only 5% were positive. Many of these women reported having lovers who used intravenous drugs.

Conclusions: Information was collected from a total of 169 seropositive prostitutes contacted on the streets of New York City from 1983 to 1988. (22 in 1983, 43 in 1984, 65 in 1987, and 37 in 1988).

Results: Of 169 seropositive prostitutes, 14 (8.3%) were found by ELISA with confirmation by Western Blot to be positive for HIV-1. Of 22 (13%) of these women who admitted to former or present intravenous drug use, 25% were positive, while among the 147 (87%) women not admitting to intravenous drug use, only 5% were positive. Many of these women reported having lovers who used intravenous drugs.

Conclusions: Information was collected from a total of 169 seropositive prostitutes contacted on the streets of New York City from 1983 to 1988. (22 in 1983, 43 in 1984, 65 in 1987, and 37 in 1988).

Results: Of 169 seropositive prostitutes, 14 (8.3%) were found by ELISA with confirmation by Western Blot to be positive for HIV-1. Of 22 (13%) of these women who admitted to former or present intravenous drug use, 25% were positive, while among the 147 (87%) women not admitting to intravenous drug use, only 5% were positive. Many of these women reported having lovers who used intravenous drugs.

Conclusions: Information was collected from a total of 169 seropositive prostitutes contacted on the streets of New York City from 1983 to 1988. (22 in 1983, 43 in 1984, 65 in 1987, and 37 in 1988).

Results: Of 169 seropositive prostitutes, 14 (8.3%) were found by ELISA with confirmation by Western Blot to be positive for HIV-1. Of 22 (13%) of these women who admitted to former or present intravenous drug use, 25% were positive, while among the 147 (87%) women not admitting to intravenous drug use, only 5% were positive. Many of these women reported having lovers who used intravenous drugs.

Conclusions: Information was collected from a total of 169 seropositive prostitutes contacted on the streets of New York City from 1983 to 1988. (22 in 1983, 43 in 1984, 65 in 1987, and 37 in 1988).

Results: Of 169 seropositive prostitutes, 14 (8.3%) were found by ELISA with confirmation by Western Blot to be positive for HIV-1. Of 22 (13%) of these women who admitted to former or present intravenous drug use, 25% were positive, while among the 147 (87%) women not admitting to intravenous drug use, only 5% were positive. Many of these women reported having lovers who used intravenous drugs.

Conclusions: Information was collected from a total of 169 seropositive prostitutes contacted on the streets of New York City from 1983 to 1988. (22 in 1983, 43 in 1984, 65 in 1987, and 37 in 1988).

Results: Of 169 seropositive prostitutes, 14 (8.3%) were found by ELISA with confirmation by Western Blot to be positive for HIV-1. Of 22 (13%) of these women who admitted to former or present intravenous drug use, 25% were positive, while among the 147 (87%) women not admitting to intravenous drug use, only 5% were positive. Many of these women reported having lovers who used intravenous drugs.

Conclusions: Information was collected from a total of 169 seropositive prostitutes contacted on the streets of New York City from 1983 to 1988. (22 in 1983, 43 in 1984, 65 in 1987, and 37 in 1988).

Results: Of 169 seropositive prostitutes, 14 (8.3%) were found by ELISA with confirmation by Western Blot to be positive for HIV-1. Of 22 (13%) of these women who admitted to former or present intravenous drug use, 25% were positive, while among the 147 (87%) women not admitting to intravenous drug use, only 5% were positive. Many of these women reported having lovers who used intravenous drugs.

Conclusions: Information was collected from a total of 169 seropositive prostitutes contacted on the streets of New York City from 1983 to 1988. (22 in 1983, 43 in 1984, 65 in 1987, and 37 in 1988).

Session d'affichage Poster Session



Le SIDA et l'individu AIDS and the Individual

W.D.P.7

MANAGEMENT OF PSYCHOLOGICAL DISTRESS: A HOSPITAL-BASED "MUTUAL AID" SUPPORT GROUP FOR HIV POSITIVE MEN

Johns, Jonathan, *Harvard Center for AIDS, New York Hospital-Cornell Medical Center, New York, N. Y., U.S.A.*

Objective: To decrease psychological distress and increase social support and the exchange of medical and treatment information, an inpatient "mutual aid" support group for HIV seropositive men was created.

Methods: A support group consisting of nine seropositive men led by a trained facilitator met for one and one-half hour weekly sessions for one month. In the "mutual aid" support group format two types of support occur: (1) a one-on-one, non-judgmental alliance structured by a facilitator (uses a group therapeutic technique and (2) a peer support model for group-generated topic preference, preparing the group to identify and process self-selected issues at their own pace.

Results: Two forms of self-report ratings were utilized in evaluating the intervention's efficacy. Inpatient, immediate reporting by group members on a weekly basis indicated a general decrease in emotional distress and an increase in social contact. A written assessment after two months of group involvement reported relief, increased adjustment to serostatus, decreased social support, increase in correct knowledge of medical and treatment information and a desire for continued group interaction.

Conclusions: This inpatient format of serostatus support, group therapy and crisis management encourages adjustment to a traumatic psychological event: HIV seropositivity. This group has proven so effective that group members have requested the need for continued sessions beyond the program two week period. This model is being used in the hospital outpatient care setting using trained staff resources while maintaining patient well-being.

W.D.P.8

THE NEED FOR COUNSELLING OF HIV TESTED INDIVIDUALS IN A RURAL POPULATION OF UGANDA

Uganda: Lumbago, A. J.; Kewer, M.*; Konde-Lule, J.***; Namara, N.***; Sanyal, S.***; Mupfema, S.*** AIDS Control Program, Entebbe, Uganda. Uganda: University, N. Y., USA**; Mukereye University, Kamula, Uganda.**

Objective: To determine the demand for HIV serological results among seropositive subjects in a rural Ugandan population.

Method: The Uganda AIDS Control Programme has implemented a longitudinal study of HIV related knowledge and behaviors, and of HIV serological trends in rural Rakai district. A baseline knowledge, attitudes and practices (KAP) and serological survey was conducted on consenting adults in 21 randomly selected rural and 5 trading center clusters. Plans call for repeated KAP and serological survey rounds.

Results: Preliminary results indicate 72% of adult study subjects stated they wished to know their serostatus. 81% knew there is no cure for AIDS, 82% knew of a period of latency between infection and illness, 83% knew of sexual transmission. Survey team members were approached by individuals asking to know their serostatus.

Conclusions: Demand for serological results in this population was high. Baseline knowledge of characteristics of the illness was also high. The information is being used to design a counselling program for survey clusters, which will encourage subjects to learn their results in a confidential and culturally appropriate manner. The special circumstances of seropositive subjects will also be considered in developing counselling in this non-clinical setting. The researchers consider a counselling program essential for program credibility and for the success of repeat visits for data and blood collection.

W.D.P.9

PSYCHOSOCIAL ISSUES PRESENTED BY SELF IDENTIFIED BISEXUAL MEN WITH HIV CONDITIONS

W. Gallo-Silver, S., McCabe, R., Mounthan, J., Rawels, G., Miller, J., & Y. M. Y.

Memorial Sloan-Kettering Cancer Center, New York City, U.S.A.

Objective: To examine the consequences and psychosocial issues confronting bisexual and gay men with HIV conditions.

Methods: A study of 35 HIV positive (30 with AIDS) bisexual men, aged 26-64, who were seen in individual counseling by a social worker as part of standard patient services and 36 gay men with AIDS, aged 24-61, who completed a structured interview with a social work researcher. Data collected from 8/86 to 12/88.

Results: Both groups were similar on educational, racial and religious background and occupational groupings. Groups differed on marital group (53% of bisexuals were currently or previously married compared to 13% of gay men) and parental status (41% of bisexuals had children vs. 3% of gay men). Prior to their learning their HIV status, only 11% of currently married bisexuals told their wives of their bisexuality and only 8% of bisexual fathers had told their children. However, 35% of bisexuals have told family members about their HIV status and 73% of those who have AIDS have told their family. Of the gay men 75% of their immediate family know about their status.

Conclusions: A major task confronting bisexual men is that of the disclosure of their condition and lifestyle. Mental health professionals need to develop specific strategies for assisting them in communication about these issues.

W.D.P.10

PSYCHOSOCIAL ISSUES PRESENTED BY TRANFUSION ASSOCIATED HIV INFECTED ADULTS AND THEIR FAMILIES

W. Gallo-Silver, S., Wise Campbell, R., Mounthan, J., Goldman, J., & Y. M. Y.

Memorial Sloan-Kettering Cancer Center, New York City, U.S.A.

Objective: To identify psychosocial issues of transfusion associated HIV infection in infected adults and their families.

Methods: 15 patients (5 with IDH/AIDS), ages 30-92, transfused for cancer-related treatments (3), cardiovascular surgery (5), trauma (3), other medical conditions (3), sexual contact with a transfused spouse (1). Information drawn from individual, family, and group counseling sessions and team meetings with physicians.

Results: Common themes reported by patients and their families: intense anger with medical community and blood banks; mistrust of health care providers; feelings of victimization, lack of identification with other HIV patient groups and need for control of their medical care. Male patients reported concerns of being labeled homosexual. Fourteen patients and families expressed anger at the gay community and reluctance to utilize community AIDS organizations. Of 8 married couples, 7 have since abstained from sexual relations.

Conclusions: Special circumstances of transfusion associated HIV infection require psychosocial interventions that are specifically designed to diminish feelings of isolation, enhance communication with family, health care professionals and physicians; and provide a way to manage anger and mistrust.

W.D.P.11

A REVIEW OF HIV COUNSELLING IN AN INNER CITY UNIVERSITY HOSPITAL

Harbach, Margaret, *Wilcox, W., Chalmers, R., Johns Hopkins University, Baltimore, MD, USA.*

Objective: To review HIV counselling procedures in an inner city university hospital.

Methods: Review of HIV counselling policy in effect 8/77-1/88 at Johns Hopkins University Hospital. Pre-test counselling and informed consent was the responsibility of the medical staff treating the HIV test. Patients with positive or indeterminate Western blot results were to be referred to the hospital HIV counselor for post-test counselling. No policy is in effect for counselling patients with negative HIV results.

Results: Between September 1987 and January 1988, 4300 HIV tests were performed. Of these, 190(12%) were ELISA and Western blot positive; 47(1%) were ELISA positive and Western blot indeterminate. HIV infection risk factors: 50% intravenous drug use (IVDU), 7% gay/bisexual men, 4% sexual partner of a person at risk, 2% transfusion.

No risk factor was identified in 48% of patients testing positive/indeterminate. Of 157 patients with positive/indeterminate tests, 329 (59%) were referred for post-test counselling. Counseling sessions include basic education re HIV infection, safer sex practices, cleaning IV drug needles, ending with the counselor making a determination what psychologic and/or medical follow-up is necessary. The remaining patients testing HIV+, being followed by either an inpatient service or an outpatient clinic, will likely receive some form of informal counseling from their care provider.

Although most patients testing HIV positive/indeterminate received some post-test counselling, this represents only 30 (29/103%) of patients undergoing HIV testing. **Conclusions:** This HIV test counselling program was effective at reaching most HIV positive/indeterminate patients. Since there was no policy for counselling HIV patients, those at continued risk of infection may not get adequate counselling. HIV counselling should not only be based on test results, but on the patients risk factor as well.

W.D.P.12

COUNSELLING TRAINING - CURRENT NEEDS: AN EVALUATION OF AIDS COUNSELLING TRAINING COURSES LOOKING AT CHANGE AND CONTENT

L. Sherry, A. MacCreaner, J. Green / St Mary's Hospital, National AIDS Counseling Training Unit, London, UNITED KINGDOM

OBJECTIVE: To examine the change/needs for training over time and to assess current course content, demand and efficacy.

METHOD: - Training of health care workers - carried out since 1985. All participants are questioned before and after course. A random sample followed up for 12-18 months after course. This study examines change over time and current course needs.

RESULTS: - AIDS and HIV Counselling training has changed in focus, content and style over time. This is in response to new information, needs, demands and essentially different audiences who require training. A shift has been noted over three years. Initially front line workers were involved. Their needs were informational and they required a validation of counselling need, approach and technique. Counselling has now become accepted and attendees tend to be more entrenched role staff. Training has moved towards skills based training, early anxieties about contact with AIDS and HIV individuals has now been replaced with worries about basic counselling skills. Skills training is more lengthy and the requires active participation. Role play, contracts, group work and the use of video techniques are discussed.

CONCLUSION: - Training demand is high and needs constantly change.

**Session d'affichage
Poster Session**



**Le SIDA et l'individu
AIDS and the Individual**

W.D.P.26 **REPRESENTATIVITY, RETENTION AND COMPLIANCE OF MINORITY PATIENTS AND USER AGREEMENT IN A VA COOPERATIVE STUDY**


Shiboski, M., Hamilton, J., Harrison, P., Brusano, G., and the Cooperative Studies Group on Treatment of AIDS-related Complexes, New York, N.Y., USA

Objective: Minorities and drug abusers (TVA) have under-represented in some HIV treatment studies. We evaluated their recruitment, retention and compliance in a multi-center VA Cooperative Studies trial of AZT vs. placebo for patients with AIDS-related Complexes.
Methods: Demographic characteristics, risk behavior activities and follow-up (F/U) for scheduled visits of the patients were reviewed. Blood samples were analyzed for study drug by HPLC and classified as compliant, non-compliant or indeterminate.
Results: Results are tabulated below: (*p<.01)

RACE OR RISK	PATIENTS	RECRUITED F/U	FURTHER DRUG COMPLIANCE		
			COMP	NON-COMP	INDETERMINATE
White	131	80-2	92	2	6
Non-White	58	75*	93	3	4
MS (nonsexual)	115	83	92	2	7
TVA	32	64*	92	4	5
Blk & TVA	28	78*	91	2	7
MS	5	75	97	3	0
Intersexual	6	85	94	3	3
Unknown	10	78	0	0	8

Conclusion: Minority patients and TVA were significantly less likely to return for scheduled F/U. However, they were compliant with taking study medication. These data should be taken into account in considering them for HIV clinical trials.

W.D.P.26



W.D.P.27 **CLOSE ENCOUNTERS OF AN UNSAFE KNID: RISKY SEXUAL BEHAVIORS AND PREDICTORS AMONG BLACK GAY AND BISEXUAL MEN**

***John L. Pearson,* Robert Phillips,**Joseph Catania,** Thomas Coates,* Center for AIDS Prevention Studies, University of California, San Francisco and Multicultural Institute, Bayview-Hunter's Point Foundation**

***Center for AIDS Prevention Studies, University of California, San Francisco, U.S.A.**

Objective: To determine the current high risk sexual behaviors and predictors of those behaviors in a cross-sectional study of Black gay and bisexual men.
Method: The sample consisted of 50 gay and 50 bisexual Black men recruited in 1988 through gay organizations, gay bath houses, parties, personal referrals and unsolicited volunteers in San Francisco, Oakland and Berkeley, California. All respondents were questioned about their unsafe sexual behaviors (e.g. all and oral unprotected sexual activity within the last month), AIDS knowledge, attitudes and beliefs.

Results: Compared to gay men, Black bisexual men had a higher total number of sexual partners (M= 3.9 vs. 5.7, p<.01), a higher percentage of unsafe sex (50 % vs. 78 %, p<.01), and unsafe sex with other partners (50 % vs. 88 %, p<.05), in using for correlates of unsafe sex for the combined sample, discriminant analysis revealed the following predictor variables significantly discriminated (p<.01) between the respondents who practiced unsafe compared to those who practiced safe sex: self efficacy, enjoyment of sexual activity with partners, close association with persons with AIDS, and media awareness of AIDS.
Conclusion: This study, one of the first to examine sexual behavior and self-reported unsafe sex, reveals high levels of risk behaviors in bisexual men. Preventive studies and culturally appropriate interventions are drastically needed among these minority men at high risk for HIV infection.

W.D.P.28 **DEMOGRAPHIC PROFILES OF SAN FRANCISCO BAY AREA BLACK AND LATIN AIDS DEATHS, 1985 - 1986**

Blumen, R.*, Chin, G., Kiserles, N.**, Toliver, D.**, Fuller, J.**, *Multicultural Institute and Research on AIDS components of the UCSF Center for AIDS Prevention Studies and Bayview-Hunter's Point Foundation. ** UCSF Center for AIDS Prevention Studies, ** Kaiser Foundation Hospital, San Francisco, U.S.A.**

Objective: To obtain demographic data not currently available from AIDS surveillance statistics for planning intervention strategies for Blacks and Latins in five San Francisco Bay Area counties.
Methods: Vital statistics data were used to identify all Black and Latin deaths in 1985 and 1986 with ICD codes consistent with AIDS-related illnesses. Death certificates were then reviewed to confirm AIDS as the cause of death and abstract demographic data. Addresses of decedents were converted to census tracts.

Results: 223 Black and Latin AIDS deaths were identified, 97.7% were male, living primarily in middle-class neighborhoods. 27.8% died in private residences, 33.2% in public housing, and 38.0% in private hospitals. Overall, 31.5% were employed as skilled workers. Blacks in professional and clerical/creative positions were more likely to die in private residences (62.5%) while Latins in those occupations were more likely to die in private hospitals (61.5%). Occupations of most Latins suggest proficiency in English.
Conclusion: In contrast to the underclass profile of minorities with AIDS nationally, data show that, prior to 1985, AIDS was not a disease of disadvantaged Blacks and Latins in the San Francisco Bay Area. These findings are consistent with the nature of the epidemic in San Francisco where, gay men are disproportionately represented among people with AIDS. Active surveillance, incorporating socioeconomic data, such as that available from death certificates, is necessary for planning targeted regional interventions and tracking the epidemic in minority communities.

W.D.P.29 **COMPARISON OF THE KNOWLEDGE, ATTITUDES, AND AIDS-RISK BEHAVIOR OF BLACK AND WHITE COLLEGE STUDENTS IN THE SOUTHEASTERN UNITED STATES**

St. Lawrence, Jesse S., Jr., Jarvis, S.A. *Jackson State University, Jackson, MS, USA

Objective: To compare the knowledge, attitudes, and risk behaviors of black and white college students in a currently low-AIDS prevalence area.
Method: 393 undergraduate students attending 3 state-supported universities in Mississippi completed measures evaluating AIDS-risk knowledge, prejudice toward persons with AIDS, willingness to interact with PMA, and self-reported sexual behavior and substance use for the preceding month. The sample included 211 black and 182 white college and engaging in practices which pose potential HIV-exposure risk. There were no significant racial differences in the frequency and range of sexual activities. Black and white college students were significantly different in substance use patterns with white students reporting use of both legal and illegal substances significantly more often (p<.001), although white students were better informed about practical aspects of AIDS risk (p<.003). Black students reported less prejudicial attitudes toward persons with AIDS (p<.05). There were no significant differences between black and white students' willingness to interact with a person with AIDS or willingness to interact with PMA, and self-reported findings no relationship between students cognitive knowledge of AIDS-risk and the frequency with which they personally engaged in potentially risky practices.
Conclusion: The results confirm the need for prevention efforts targeting college students to reduce their present and future vulnerability to HIV infection.

W.D.P.30 **AIDS: KNOWLEDGE, ATTITUDES AND SEXUAL PRACTICES AMONG HISPANIC IN CHICAGO-RESULTS OF A 1988 CITIZEN SURVEY**

Aldas, L. C., Glicklich, A., Aguilon, O., and Probat, J. *University of Illinois at Chicago, Chicago, Illinois U.S.A.

In 1980 Hispanics represented 6 percent of the U.S. population and currently they account for 15 percent of all U.S. AIDS reported cases.

Objective: To obtain baseline information on Chicago Hispanic AIDS knowledge, attitudes about AIDS transmission, sexual practice and prevention of HIV infection useful for program planning and implementation and for policy formulation.

Method: During the Spring of 1988 400 Hispanic persons 16 years of age and over were interviewed using Random Digit Dialing (RDD) telephone survey.

Results: Most Hispanics have general awareness and basic knowledge about AIDS. However, they have high levels of misinformation about modes of transmission. Many believe that they can contract AIDS through kissing, shared towels or through toilet seats. Younger people and those with high education know more about AIDS. Youth and single people were found to be more at risk for AIDS due to their sexual practices.
Conclusion: There is a gap between what Hispanics know and what they do. They know that AIDS can be prevented with the use of condoms, but most Hispanics do not use them as a mean of protection.

Session d'affichage
Poster Session
W.D.P.49 COMPARISON OF BLACK AND WHITE WOMEN TESTED FOR
HUMAN IMMUNODEFICIENCY VIRUS
Cats, Bonita¹; Simpson, Sharon L.²
¹University of Florida, Gainesville, Florida, U.S.A.

Objective: The primary goal was to develop a profile of women in a low incidence area by examining characteristics of 360 white and 53 black women, self-selected as at risk for HIV infection.

Methods: The women were anonymously recruited and tested at a public health facility in a university town in north central Florida. Differences in risk behaviors, STD history, educational level, safer sexual practices, sources of information regarding AIDS, and level of fear were examined.

Results: The mean educational level for white women was 12 years, for black women 13 years. Using Spearman correlation coefficients, history of hepatitis, IV drug use, sexual partner with HIV infection, and presence of tattoos were significantly associated with seropositivity in the group as a whole. Seropositivity in black women were more likely to have had transfusion, tattoos, and an HIV seropositive partner. Seropositivity in white women was negatively correlated with education. They were also more likely to have had a history of hepatitis, IV drug use or a partner who was a hepatitis C.

Conclusions: Women who come for voluntary testing represent an educated group which may imply that this type testing only reaches a select population, and that women at risk may not be represented. Identified risk factors for women who are seropositive match those found in high risk areas.

W.D.P.51 UNSAFE SEXUAL BEHAVIOR AND HIGHER RISK PARTNERS: CHANGE OVER
TIME IN A PROSPECTIVE STUDY OF WOMEN AT RISK FOR AIDS
Cohen, Judith B., Dorfman, L.E., Kelly, T.A., Rik, M., Garcia, D.A., Wofsy, C.A.
University of California San Francisco, San Francisco, California, USA

Objective: To assess sex and drug use behavior changes in a prospective study of women at risk for HIV infection.

Methods: 270 sexually active women with increased, high risk, or multiple partners were interviewed and tested between 1985 and 1987, and followed up to 18 to 24 months later.

Findings: At entry, 64% reported sexually or possibly unsafe behavior with VDRL, syphilis, or HIV-infected partners. At follow-up, 70% fit the same definition; one had seroconverted. Significantly more women reported changing to lower risk partners than reported changing to lower-risk behaviors.

Partner at Risk and High Risk Behavior	Entry	Follow-up
Partner at Risk and Low Risk Behavior	54%	70%
Low Risk Partner and High Risk Behavior	1%	4%
Low Risk Partner and Low Risk Behavior	14%	20%

Conclusions: Women followed over time have significantly reduced unsafe partnerships but only moderately reduced unsafe behaviors. To the extent that they continue to engage in risky behavior and do not always know their partners' risk, they remain at some risk for HIV infection. Prevention programs for women need to emphasize reduction of risky behavior as the only certain prevention strategy.

W.D.P.53 BEHAVIOR CHANGES TO REDUCE HIV TRANSMISSION RISK IN A
PROSPECTIVE STUDY OF SEROPOSITIVE WOMEN

Frank, Lanning E.; Cohen, J.B.; Lyons, C.A.; Kelly, T.A.; and Wofsy, C.A.
University of California San Francisco, California, USA

Project AWARE has evaluated 1047 women at risk for HIV infection 66 (6%) of whom are seropositive. Of the 40 seropositive who have been followed for at least 12 months, 118 (40%) are VDRL (16.40%) had an HIV infected sexual partner, (4) 12% had a partner at increased risk for HIV infection (3) 5% had no identified sexual partners. Behavior changes include:

Behavior	Entry	6 Mo.	12 Mo.
Number of Women	40	40	24
Avg. No. Sex Partners	5.2	5.1	4.0
% With Fewer Partners	n/a	40	60
% Abstinent	9	22	29
% Tongue Kissing	93	60	67
% Contraception, No Barrier	85	45	54
% Any vaginal Sex, No Condom	75	37	37
% Using Males	42	11	8
% Sharing Needles	40	23	19
% IV Drug Use	40	15	15

Of the 11 women who are still reporting uninfected partners to vaginal secretions, 6 engage only in consensual, 3 have partners who relate to use condoms, and 2 have been unable to disclose their antibody status.

Although many HIV+ women experienced a period of abstinence, most resumed sexual activity but discontinuously reduced sexual and needle-sharing behavior known to transmit HIV to others.

W.D.P.50 COMPARING ESTIMATES OF HIV SEROPREVALENCE IN U.S. WOMEN:
CHILDREARING WOMEN AND MILITARY RECRUIT APPLICANTS.

Massey, Shari¹; Quinn M²; Papapanagos M¹; Novelli Ave¹; Willoughby A¹; AIDS Program, CID, CDC, Washington, DC, USA; ²Wesley, Bethesda, MD, USA.

Objective: To assess bias in estimated HIV seroprevalence rates for U.S. women by comparing rates in female military recruit applicants with those from the Survey in Childbearing Women.

Methods: Since October 1985, female civilian applicants for U.S. military service have been tested for HIV-1 infection. Beginning in October 1987, ongoing, blinded statewide HIV seroprevalence surveys have been conducted in U.S. women delivering live infants.

Results: Statewide prevalence rates among childbearing women were higher than corresponding rates among female military applicants in each of four regions of the U.S. among childbearing women, state-specific rates ranged from 0.025 to 0.045, with corresponding rates from 0.002 to 0.025 in female military applicants. State-specific rates from both surveys were highest in the Northeast, followed by the South, West Central, and West regions. Women who participate in high-risk behaviors such as IV drug use may be less likely to apply for military service. This introduces bias in the population tested and likely produces underestimates of the prevalence of HIV infection among U.S. women. In contrast, the population of women delivering live infants includes women from all risk groups.

Conclusions: Women who participate in high-risk behaviors such as IV drug use may be less likely to apply for military service. This introduces bias in the population tested and likely produces underestimates of the prevalence of HIV infection among U.S. women. In contrast, the population of women delivering live infants includes women from all risk groups. Seroprevalence among childbearing women, however, may be different from that in women who choose not to or are unable to become pregnant or who experience adverse pregnancy outcomes. Data from both surveys, however, though subject to these biases, provide useful information on the prevalence and trends of HIV infection in U.S. women of reproductive age.

W.D.P.52 EMERGING PATTERNS OF DRUG USE, SEXUAL BEHAVIOR, HIV
INFECTIONS AND STDs IN HIGH RISK SAN FRANCISCO AREAS
FROM 1980-1989

Cohen, Judith B., Lyons, C.A., Lusk, G.J.^{1,2}, McConnell, P.A.^{1,2}, Senneker, L.R.^{1,2}, Wofsy, C.A.
¹University of California San Francisco, ²California Prostitution Education Project, San Francisco, California, USA

Objective: To evaluate changes in drug use, sexual behavior and STDs among high risk women and their partners participating in a street-based peer provided prevention research and education program.

Methods: In a three phase ongoing program, 100 women in 1980-87 (T1) and 153 women and 34 male partners (MP) that in 1988-89 (T2) received interviews, counseling, and testing for HIV Ab, HepB, and syphilis infection in San Francisco Bay Area districts known for drug use and prostitution.

Findings: From T1 to T2, HIV infection was unchanged at 8% in women but was 12% among MP. HepB rates were unchanged among women (60%, 60%) but rose 60% for MP. HIV infection was associated with IV drug use among women and MP. Probable acute syphilis (PPH and RPR-TP) was significantly associated with crack cocaine use, younger age, and less condom use, but not with IV drug use or HIV infection.

Conclusions: Ongoing assessment of AIDS risk in these areas indicates two patterns of HIV infection associated with IV drug use, and an ominous new pattern of crack use. Existing prevention programs do not address the problems and needs of people in the latter group.

W.D.P.54 EPIDEMIOLOGICAL, INFECTIOLOGICAL AND IMMUNOLOGICAL
RESULTS FROM THE HIV-AMBULANCE OF THE DEPARTMENT
OF OBSTETRICS AND GYNECOLOGY

Fricks K, Rosael S, Voth H, Hearn G, Meyer am Buchenfeld, H, Knappstein PG, University of Mainz/FEDERAL REPUBLIC OF GERMANY

OBJECTIVE: To examine gynecological problems in HIV infected women in relation to immunological parameters.

METHODS: From 40 HIV-infected female patients, who were tested 25 women were seen every three months. Six months most of them are living outside the cities of the state Rheinland-Pfalz. 12% of them are or have been infected by sexual transmission. Only one third use condoms for cohabitation, another third denies this form of protection. The rest has no sexual intercourse in the moment.

23 pregnancies are known in this group and in 20% of the cases HIV-infection has been discovered during prenatal care. Results: 80 % of the patients had have a recurrent candida infection of the vagina which was detected in culture. Immunologically 75% of the women belong to the stage III (in order to the CDC-classification). Out of this group more than 50% show less than 400 CD 4 cells/ml. A positive result for HIV-1g, anti-p-18 and negative anti-p-24 could be detected in five cases. One of the four women with AIDS died of a rapid growing cervix cancer although treated with radiotherapy.

CONCLUSIONS: Our data provide evidence for the increasing incidence of gynecologic problems in HIV-infected women. From our experience gynecological examination has to be routinely integrated into medical care of HIV-infected women.



**Session d'affichage
Poster Session**

**Le SIDA et l'individu
AIDS and the Individual**

**Consommateurs de drogues par voie intraveineuse (partie 1)
I.V. Drug Users (Part 1)**

W.D.P.61

**CRACK USE AND RISK FOR AIDS AMONG BLACK
ADOLESCENTS**

Bullimore Robert, Ph.D., Fullilove M.T., Bowser B.M., Gross S.A.
*Multinational Inquiry and the University of California, San Francisco & California State and the Bayview-Hunter Point Foundation, San Francisco, CA; S.A.
**California State University at Hayward

Objective: To describe the characteristics of black adolescent crack cocaine users and assess their risk for sexually-transmitted HIV.
Methods: 204 black adolescent crack users in Oakland and San Francisco, California, were surveyed about their use of crack and other drugs, their social partners, their sexually transmitted disease (STD) history, their attitudes toward condoms, their use of condoms, and their use of crack during sexual activity.

Results: 100 respondents (49%) were using crack in combination with sexual activity. Of those mixing crack with sex, 50% reported a history of one or more STDs, as compared with 29% (significant at p<0.05) of those who did not combine sexual activity with crack. A history of gonorrhea was more prevalent among those combining sex with crack (42%) than among those who did not (15%, significant at p<0.01). The prevalence of STD history among those who reported both having sold crack and having combined sexual activity with crack was 92% for females, 48% for males) was much higher than for those who did not combine sex with crack. **Conclusions:** Given the prevalence of a history of STD reported by respondents, particularly among those who have sold crack and among those who combine crack use with sexual activity, the risks for contracting and transmitting HIV in this population appear to be great. Further studies to assess HIV prevalence among crack users and dealers and expanded efforts to develop and test interventions to prevent HIV spread within this population are urgently needed.

W.D.P.63

**THE EFFECT OF A NEEDLE AND SYRINGE EXCHANGE ON A HEROIN-DEPENDENT
RESIDENTIAL UNIT**

Wolk, J.L., Haddad, A., Oleson, J.J.,***
*University of New South Wales, Sydney, Australia. ** St. Vincent's Hospital, Sydney, Australia. ***Albion Street (AIDS) Centre, Sydney Hospital, Sydney, Australia.

Objective: To determine if the location of a needle and syringe exchange adjacent to the methadone maintenance unit was associated with an increase in the use of heroin. **Methods:** A needle and syringe exchange scheme was opened in November 1986 adjacent to an inner city NSW maintenance unit. **Results:** 128 MSU clients who were on the programme continuously 3 months before and 3 months after the introduction of a needle and syringe programme were analysed for heroin use. **Results:** There was no significant increase in the overall proportion of clients who had contaminated urines before and during exchange opening (14.6% established urines before 1986 and 14.9% had clean urines prior to the opening). A proportion of clients (28%) who had clean urines prior to the establishment of the exchange were found to have contaminated urines after it began. However, a comparable proportion of clients (19%) with dirty urines prior to the exchange opening were found to have contaminated urines prior to the exchange opening were found to have clean urines after it opened. **Conclusion:** The increase in availability of sterile needles and syringes adjacent to a drug treatment unit did not appear to adversely affect the proportion of drug free clients in this study. While some clients started using heroin during exchange, others who were using heroin exchange ceased, indicating that factors other than the exchange were influencing heroin use.

W.D.P.65

**A HIV-PREVENTION SYRINGE EXCHANGE PROGRAM IN LUND,
SWEDEN. TWO YEARS OF OBSERVATIONS OF THE ATTENDERS**

Tunving, Kerstin; Andersson, B.; Ljungberg, B**;
Christensson, B*.
*Dept of Paediatrics and Neurochemistry. **Dept of Infectious Disease. University of Lund, Sweden.

In November 1986, a syringe exchange program at the Clinic for Infectious Diseases (General Hospital) in Lund, Sweden, was started. The program gets active support from the local drug treatment facilities. So far no HIV-epidemic has broken out in our region. No negative side-effects have been observed. 804 patients have visited the program. 75 % use centralinums, the rest use heroin. Drug abusers with a small limited abuse, attend the program. 75 % of the visitors are males. The program attracts even those with a hidden abuse, since only half of the attenders have been in contact with local drug treatment facilities. There were no significant differences between these two groups except the fact that a greater proportion of those who used amphetamines were without treatment experiences. In spite of this, we have observed that more drug abusers come to the out-patient clinic and detoxification unit. Most of the clients are below 20. The program does not reach the very young and probably not the most chaotic.

W.D.P.62

**RELATIONSHIP BETWEEN HIV RISK BEHAVIOURS, KNOWLEDGE AND
SENSITIVITY OF SYRINGE INTRAVENOUS DRUG USERS (IVDU)***

Wolk, J.L., Haddad, A., Oleson, J.J., Bullimore R., Gross S.A.,
*Albion Street (AIDS) Centre, Sydney Hospital, Sydney, Australia. **St. Vincent's Hospital, Darlinghurst, Sydney Australia

Objective: To investigate the HIV risk taking behaviours, knowledge, attitudes and HIV serostatus of Sydney intravenous drug users (IVDU)*. **Methods:** On hundred and eighty-one Sydney intravenous drug users both in and out of drug treatment were recruited. An interviewer-administered questionnaire was used to collect information on demographic characteristics, drug-using and sexual behaviour, AIDS knowledge and prison experience. HIV test results were obtained from subjects. **Results:** The mean age was 27 +/-, the HIV ratio 12%, and 77% of the males were heterosexual. The majority injected daily (91%) and shared needles and 91% cleaned their equipment. Condoms were used only by 12% with regular partners but by 12% with casual partners. 77% of the males were prostitutes with their clients. Thirty percent (54/181) had been in prison since 1981 of whom 50% (27/54) had engaged in risk taking behaviours while in custody. Knowledge was satisfactory and perception of risk of HIV infection for IVDU* was high. However perception of personal risk was low. Twelve percent (14/119) subjects had HIV antibodies of whom 7 were homosexual. **Conclusion:** The 9% HIV seroprevalence found in this study can be explained to increase due to the frequency of HIV risk-taking behaviours. The high proportion of HIV positive homosexual IVDU* suggests the need for targeted campaigns for this subgroup.

W.D.P.64

**HIV RISK BEHAVIOURS OF INTRAVENOUS DRUG USERS PRESENTING TO
THE ALBION STREET (AIDS) CENTRE, SYDNEY, AUSTRALIA.**

Wolk, J.L., Oleson, J.J., Bullimore R., Gross S.A.,
*Albion Street (AIDS) Centre, Sydney Hospital, Sydney, Australia.

Objective: To investigate needle sharing behaviour and sexual practices of intravenous drug users (IVDU) presenting to the Albion Street (AIDS) Centre. **Methods:** Detailed medical history, physical examination, intravenous drug use history and sexual behaviour information were collected and computer coded for all clients presenting for HIV diagnosis. Those reporting IV drug use, between March 1985 and March 1988, were included in this analysis. **Results:** 1047 clients presenting during this period reported IV drug use as a risk factor. The mean age was 27 (sd 5.6) years, 747 (71.3%) were male, 292 (27.9%) female and 6 (0.6%) transsexual. 59% of males and 77% of females claimed exclusive heterosexual. 39% reported current intravenous drug use and 87% of the total reported having shared needles and syringes. 10% had worked as prostitutes and the mean monthly number of sexual partners in this sample was 12.45, with 15.4% of males and 4.7% of females being infected. 42.0% of homosexual men were infected compared to 3.8% of male and female heterosexuals. There was a small but significant quarterly increase in the proportion of HIV seropositive heterosexual IVDU during this period. **Conclusions:** The HIV seropositive prevalence of IVDU tested was substantially lower than reported amongst European and 8th American samples and is consistent with the low incidence of IVU AIDS cases reported to Australia (1%, MV 1988). However, evidence of continued risk behaviour indicates the possibility of rapid spread of HIV within this subgroup.

W.D.P.66

**Need Taking and Risk Reduction
Among IV Drug users in A U States**

Wilhelm, Wayne; Altman M. Chasn, D.; Prits R.
University of Illinois at Chicago, Chicago, Illinois, USA

Objective: To examine the AIDS risk behaviors and risk-reduction activities of active IV drug users in Baltimore, Maryland, and El Paso, Texas. **Methods:** This is a multi-site study using quantitative and qualitative methods. Face to face interviews were conducted with intravenous drug users not in treatment. Study participants were recruited using street-based indigenous outreach workers who are also involved in community and educational activities. In addition, telephone interviews were conducted to aid the interpretation of results. **Results:** A total of 110 active IV drug users were interviewed in Baltimore, 619 in Chicago, 139 in Denver, and 92 in El Paso. Different patterns of needle sharing and needle cleaning emerged in each city. Intercity comparisons reveal a complex but identifiable set of associations between various social, demographic, and drug-related variables on the one hand and needle sharing and cleaning behaviors on the other. **Conclusions:** It is concluded that AIDS/IVU education programs must understand and take into account (1) racial/ethnic and regional subcultural differences and (2) the local IV drug practices (i.e. in terms of types drugs used and frequency of injection).

**Session d'affichage
Poster Session**



**Le SIDA et l'individu
AIDS and the Individual**

W.D.P.67 CESSATION OF ALCOHOL AND DRUG USE DISORDERS IN AN HIV SAMPLE
Reisin, Robert B.; Hankin, J.; Williams, J.; Gorman, J.; Ehrhardt, A.

HIV Center for Clinical and Behavioral Studies, NY State Psychiatric Institute and Columbia University, New York, N.Y., U.S.A.

Objective: To assess longitudinal patterns of cessation of abuse of alcohol and other drugs in an HIV community sample.
Methods: 167 gay and bisexual men were assessed at part of a longitudinal study examining predictors of HIV 11-month progression. Structured clinical interviews were conducted to evaluate past and current psychiatric disorders, as well as current levels of depression and anxiety. Self-report measures of personality attributes and life outlook were also collected.

Results: A significant number of our sample reported successful termination of past alcohol and drug abuse and dependence with maintenance of that change (see table below). Many of the men attribute this behavioral change at least in part to their concern about AIDS. They appear to be different on current measures of psychological distress when compared to those men who never had an alcohol or drug use disorder.

	Past Dependence/Abuse*		Current Dependence/Abuse*	
	Alcohol	Drug	Alcohol	Drug
Group (N=118)	24	35	35	35
HIV (N=42)	24	40	75	50
Total (N=167)	48	62	80	85

* percentages refer to cessation of alcohol and drug diagnoses in our subjects.
Application: In a group of men at risk for AIDS we find successful cessation of an addictive substance use that is rarely reported in the alcohol and drug literature.

W.D.P.68 DEMOGRAPHIC, BEHAVIORAL, AND CLINICAL FEATURES OF HIV INFECTION IN NEW YORK CITY AND INTERVIEWING DRUG USERS (IVDU)

Bravo, Lawrence B.; Chu, A.; Menzies, T. and Frawley, B.J.
Behavioral and Treatment Corporation, New York, USA

Objective: To determine the demographic, behavioral, and clinical features of HIV infection.
Methods: Subjects were recruited from patients scheduled for physical examination in drug treatment clinics in NYC. A questionnaire was administered and serum was collected for HIV serology, using ELISA and Western blot techniques. Subjects were categorized using the CDC HIV classification criteria. Data was analyzed using univariate and multivariate analyses.

Results: 167 subjects were interviewed. 61% were HIV infected and anti-HIV was detected in 58% and 43%, respectively, of the population. HIV infection rates for HIV seropositive and HIV seronegative of the CDC classification criteria for HIV-associated conditions. Only behavioral factors (p<.001) and clinical indicators (p<.001) were found to distinguish the HIV infected from the non-infected. Frequent use of IV drugs (p<.016), duration of drug use (p<.005), daily methadone dose (p<.018), and duration of drug treatment enrollment (p<.038) were significantly associated with HIV seropositivity status and CDC HIV stage. **Conclusions:** These findings strongly support aggressive efforts to reduce parenteral drug use and enroll IVUDs into effective drug treatment.

W.D.P.69 NEEDLE SHARING AMONG IVDU'S WHERE NEEDLES ARE AVAILABLE WITHOUT PRESCRIPTION

Sibthorn, Beverly**; Egan**; McClain**R.; Klockner, J.; Gossel**, Oregon Health Division, Portland, Oregon, USA** *Multnomah County Health Division, Portland, Oregon, USA.

Objective: To assess needle sharing among intravenous drug users (IVDU's) in a region where needles are more readily available without prescription.

Methods: Current IVDU's in Portland, Oregon, were questioned about AIDS, drug-use history, and needle-sharing practices using a standardized questionnaire that included both structured and open-ended questions. Sources of recruitment included a correction facility, county health clinic, private welfare organizations and street outreach. Participation was voluntary and confidentiality was assured. Preliminary results are presented below.

Results: Between 12/88 and 2/89, 150 IVDU's were interviewed. Mean age was 28 years; 56% were male. Mean years of IV drug use was 7.5 years. Heroin was the principal drug injected; 23% cocaine for 31%, methamphetamine for 27% and heroin plus cocaine or amphetamines for 17%. Most (85%) had never been in drug treatment. Needles were purchased from pharmacies or other stores by 79% of users. Over half (54%) stated they currently shared needles while shooting drugs. Of those sharing needles, 13% shared only with their sex partners, 39% also shared with other friends, and 46% shared with total strangers. The main reason given for sharing needles was convenience (50%); less than 7% said they shared because of difficulty obtaining needles. Needles were never cleaned by 27%. Needles were cleaned by 2% with bleach and 50% with water. Over 50% of all these IVDU's, including those who shared of needles, knew that sharing could transmit AIDS. Sixty five percent of IVDU's who shared needles assessed their level of AIDS as moderate or high compared with 18% of those who did not share (p<.001 by chi square). **Conclusions:** The ready availability of needles, knowledge of AIDS transmission, and perception of personal risk are not sufficient to prevent needle-sharing among many IVDU's. Education regarding safe needle cleaning may be the most effective intervention among IVDU's who continue to shoot up.

W.D.P.70 SEXUAL RISK FOR HIV TRANSMISSION IN A GAY MALE SUBSTANCE-ABUSING POPULATION

Stall, Ronald** and D'Augelli, University of California San Francisco Center for AIDS Prevention Studies; **HIV St. Services) U.S.A.

Objective: Combining alcohol and/or drugs with sex is associated with sexual behavior that is high-risk for HIV transmission. Gay substance abusers were compared to the general gay population to further test the reasonable hypothesis that high-risk sex and drug use are related.

Methods: Substance abusers entering treatment at 16th St. Services in San Francisco were asked to fill out a self-administered questionnaire on sexual activity, substance use, and AIDS knowledge (n = 108). The comparison sample of gay/bisexual men were recruited in a random digit dial telephone study in San Francisco (Community Oriented Epidemiology Study, 1987, n = 207).

Results: Sexual risk was calculated with a version of the Chicago Multi-Center AIDS Cohort Study (MACS) group's scale. 28.8% of the substance abusers were rated "high-risk" (i.e. anal sex without condoms outside of monogamous relationships), compared to 6.9% in the sex and without injecting AIDS prevention. This was true although the clinical sample was well-informed regarding AIDS prevention, had high levels of educational achievement, and was as likely to be sober as high-risk sex. **Conclusions:** The association between drug/alcohol use and unsafe sex is not a simple one. The proportion of high-risk sex not associated with drug or alcohol abuse in this clinical population suggests that we may be dealing with more than a "demonstration effect". Programs are needed to intervene with substance abusers, and further research on the psychosocial factors contributing to these levels of unsafe sex is needed.

W.D.P.71 ABSENCE OF ANTIBODY TO HIV IN LONG-TERM, SOCIALLY REHABILITATED METHADONE MAINTENANCE PATIENTS

E.A.; Wang, G.; Dreyfus, David R.; Joseph, H.; Crosson, T.S.; Salatis, Beth Lateral Medical Center, New York, NY, USA; ** New York State Division of Hospital Care, New York, NY, USA; *** St. Luke's - Roosevelt Hospital Center, New York, NY, USA

Objective: To determine the prevalence of antibody to HIV in long-term, socially rehabilitated methadone-maintained former heroin addicts in New York City, where 35-60% of active IV heroin addicts are HIV-infected.

Methods: Of the 68 former parenteral heroin addicts in "medical maintenance", 18 (26%) agreed to participate in this study. In medical maintenance, and socially rehabilitated methadone maintenance patients are treated in the offices of primary care physicians, who provide methadone treatment and general medical care (AMA 1988:129:2393). Antibody to HIV (anti-HIV) was determined in all patients by both ELISA (Dupont) and indirect immunofluorescence (Fluoroguard). Hepatitis B surface antigen, antibody and core antibody were determined by ELISA (Abbott).

Results: None of the 58 socially rehabilitated methadone maintenance patients had anti-HIV. One of seven markers of HIV infection were seen in 53 (91%). The duration of methadone maintenance was 16.9 ± 0.3 yr, and the median daily dose was 40mg. 25% of the 58 patients had been on parenteral heroin maintenance for 10.1 ± 1.7 yr, and they had engaged in additional high-risk practices for HIV infection. **Conclusions:** Effective HIV infection. Methadone maintenance treatment can protect parenteral drug abusers from HIV infection.

W.D.P.72 HIV STATUS & RISK BEHAVIOR IN PARTICIPATING AND NON-PARTICIPATING I.V. DRUG PATIENTS IN A COMMUNITY

Schaefer, Heidi R.;**; Melnick, R.;**; Dorus, W.;**; Puchucki, C.;**; Lettino, J.;**; Schaefer, D.;**; Hines Johnson, Illinois, IL, USA; ** Loyola University, Maywood IL, USA.

Objective: To describe differences in rates of HIV infection and risk behaviors between I.V. drug patients who volunteer (n=224) and those who decline (n=25) to participate in a HIV seroprevalence and risk reduction program.

Methods: I.V. drug users seeking drug treatment were screened for willingness to participate. Post-test results revealed significant differences in age (higher in non-participants, p<.020), and number of needle-sharing partners (higher in participants, p<.014). There were no significant differences related to drug choice, length of drug treatment, number of sexually active, number of sexual partners, frequency of sexual activity, or demographic variables. Reasons given for not participating included: not interested in the program (13%); didn't think they were at high risk (12%); didn't want to spend the time (12%); didn't think they were at high risk (12%); previously tested (7%).

Conclusions: Although participants reported more needle-sharing partners, non-participants appear to have a higher frequency of HIV infection. Patients who refused to participate may under-report high-risk behaviors or engage in other high risk behaviors. Voluntary serotyping and education programs may miss some I.V. drug users at high risk for HIV infection.

Session d'affichage Poster Session



Le SIDA et l'individu AIDS and the Individual

Th.D.P.7 THE WOMEN'S CHOICES: A MODEL PEER SUPPORT PROGRAM FOR HIGH RISK HIV INFECTION AND CRACK DRUG USE IN WOMEN.
Mello, A.; DeBruin, Ernest; Welch, B.; Chabon, B.; Finkel, A.; Chalmers, J. The University Medical Center/Albert Einstein College of Medicine, Bronx, N.Y., USA.

Objective: To provide women with a safe and confidential group setting in which to share feelings, thoughts, and information about sexual behavior, drugs and AIDS, and to support behavior change and risk reduction activities.

Method: Groups meet weekly in a methadone clinic or in a Community Health Center. Focus groups, educational lectures, videos and support groups are used to facilitate discussion. Peer leadership is encouraged and participants do outreach work in the community to recruit other women.

Results: The groups have been functioning for one year in which there have been 625 visits from over 100 women. Each weekly group session is attended by an average of 20 women.

Conclusions: The relationship of crack use and sex (especially crack) to high risk sexual behavior is apparent and has led to a "strong peer" ethos in the groups. The group process has contributed to the development of peer counseling, group leaders, and outreach workers from many participating women. In one group with 25 regular participants, 13 (52%) women have entered hospital or detoxity from crack use, four have enrolled in a local community college.

Conclusions: Group based counseling in risk reduction is possible among high risk drug using women through peer support models focusing on reducing drug use.

Th.D.P.9 DIFFERENCES BETWEEN SYMPTOMATIC HIV+ FEMALE & MALE PATIENTS
Bellet, J.; Graham, V.; Hall, L.; Hines, A.; Baselin, J.; and Delavilla, J.; Kings County Hospital Center, Brooklyn, NY, USA

Objective: To compare clinical presentation of female & male patients.
Methods: All 84 female patients seen in the year 1988 (N=86) at the HIV Clinic of a NYC municipal hospital were compared to male controls selected for similar initial visit dates.

Results: Ethnic origins of female patients (Black=8, Italian=16, Hispanic=19, Other=5) were similar to those of males (53,11,21,3). TDM was the largest risk factor for both females & males (41,54), but heterosexual transmission was a larger second risk factor for women (33) than men (4) in this clinic. Both sexes were similar in age (33=3.0 for women, range 19-54; 31=3.7 for men, range 19-55.8), in the average month of time spent in the clinic for men (8 and 8.8 months), in receiving ART (62/52) and in numbers blood dead (13 each). Significantly fewer women than men had a CDC-defined AIDS at their first visit (7/11) or in receiving ART (62/52) and in numbers blood dead (13 each).

Conclusions: Significantly fewer women than men in this clinic had a CDC-defined AIDS diagnosis, suggesting that they seek medical care earlier in the HIV disease process. However, this early intervention on their part results in an inability to receive CDC-AIDS defining economic and social benefits. Alternatively, the natural history of HIV infection may be different in women, with fewer severely immunosuppressed HIV infected women fulfilling CDC-AIDS criteria than men.

Th.D.P.11 COLLEGE WOMEN'S SEXUAL BEHAVIORAL INTENT AND PERCEPTION OF RISK OF HIV INFECTION FOR SELF AND PEERS
Blighter, Donna L.; Sp, J.; Theobald, T.; Summers, D.; and Hauser, J. University of South Carolina School of Public Health, Columbia, South Carolina, USA

Objective: To determine women college students' perceived risk of sexual behavior and their intent to engage in such behaviors with males in long-term and recently-initiated relationships.

Method: 334 randomly-selected female undergraduate students responded to a questionnaire in October 1988 at a major southeastern U.S. university. The questionnaire presented two hypothetical situations, one involving a long-term relationship with a male student and the other involving a recently-initiated relationship. Respondents identified for each situation the sexual behavior in which they and their peers would engage, and rated the level of risk of each behavior. Data were analyzed using paired T-tests.

Results: Preliminary analyses indicate the following significant differences: self and peer perception of risk in the newly-initiated relationship; self perception of risk in both hypothetical situations; self and peer behavioral intent in both hypothetical situations.

Conclusions: It appears that women college students perceived greater risk to themselves than to their peers in both hypothetical situations, even though they predicted lower sexual behavioral intent scores for themselves than for their peers.

Th.D.P.8 THE EXTENT AND IMPACT OF HIV-RELATED DISCRIMINATION IN NEW YORK CITY-A SURVEY OF PWAS AND SERVICE PROVIDERS

Reed, Mitchell, New York City Commission on Human Rights, AIDS Discrimination Unit, New York, N.Y., USA.

Objective: To document the full extent of HIV-related discrimination in New York City.

Methods: A diverse sample of 60 PWAs and 60 AIDS service providers interviewed in standardized format concerning discrimination.

Results: Survey revealed that the scope of actual discrimination experienced by people affected by AIDS extends far beyond areas anti-discrimination laws are designed to remedy.

Conclusions: Local, state and federal anti-discrimination laws must be amended if they are to provide meaningful protections to those who suffer HIV-related discrimination. Further, the social impact of HIV-related discrimination--e.g., of access to public health, social services, education and prevention--is far greater than is generally recognized and must be incorporated into all programs and policy planning.

Th.D.P.10 SELECTED GYNECOLOGIC ISSUES IN WOMEN WITH HIV INFECTION

Anderson, Jean, W.; King, K.; Felder, J.; Hancock, S.; Babcock, K. et al. The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Supported by the Freeman Foundation.

Objective: Describe gynecologic (GYN) variables in women attending an inner-city HIV clinic.

Methods: Retrospective review of available GYN information obtained from 83 HIV-infected women seen between 1987 and 1989.

Results: The mean age was 31.9 years (range 19-58). The racial distribution was: Black=60; Caucasian=18; Other=5. HIV infection risk factors included: IV drug use (10/81) alone=19; heterosexual contact with a high-risk partner only=14; blood transfusion; unknown on denied=17; IVPI and heterosexual contact with a high-risk partner=19. Of 67 patients, 418 had ever been pregnant and 574 of these had 7 living children. Furthermore, 718(19/51) continued to be sexually active; of these 4, 713(51) used no form of contraception and only 39(11/74) used condoms. Abuse history of these women, 181(19/51) became pregnant and 8/10 delivered term infants. History of GYN problems was elicited in 34(11/74). Of 50 women reporting a history of sexually transmitted disease 56 had gonorrhea; 18 syphilis; 10 genital herpes; 14 genital warts.

Active GYN problems of great visit were uncovered in 34%. During the time of review, 37(11/51) women had abnormal GYN exams including a pelvic mass and 10 cases of genital herpes; 19(4/71) Pap smears were abnormal.

Conclusions: Heterosexual activity is a frequent mode of HIV transmission in this population. Unsafe sexual practices and inadequate contraception are prevalent and likely to perpetuate spread of infection. The GYN history and exam were often overlooked, but GYN problems accounted for substantial past and current morbidity in this predominantly inner-city population.

Th.D.P.12 FEMALE SEX PARTNERS OF IV DRUG USERS: A STUDY OF SOCIO-PSYCHOLOGICAL CHARACTERISTICS AND NEEDS

Agapiou, L., Rivers, A.M., Henshaw, C.L., and Corey, A.L. AIDS Research and Education Project, California State University, Long Beach, CA, USA

**School of Social Welfare, University of California, Los Angeles, CA, USA

***Department of Public Health, Long Beach, CA, USA

Objective: To identify and examine the socio-psychological characteristics, needs, and service requirements of non-using female sex partners of IV drug users in Los Angeles County. The data will provide information bases for effective HIV infection prevention education programs and strategies.

Method: Eighty six informants including service providers, law enforcement officers, IV drug users, and sex partners from various ethnic groups were interviewed in-depth. Purposive sampling guided the approach to selecting the key informants. The interview protocols were semi-structured, with both open-ended and objective questions.

Results: The sex partner population is made up of different subpopulations with different characteristics correlated to ethnicity, non-IV substance use, and income and education levels. Commonalities across subpopulations are: low self-esteem, powerlessness, history of abuse, isolation, and low perception of HIV infection risk.

Conclusions: HIV prevention education and intervention programs should be based upon an empowerment model which addresses the psychologies of powerlessness, and is sensitive to cultural and class differences.

Session d'affichage Poster Session



Le SIDA et l'individu
AIDS and the Individual

Th.D.P.13 GENDER DIFFERENCE IN "MATURING OUT" OF INTRAVENOUS DRUG USE Birnbaum, Patrick, Maslow, J., Aldrich, M. Youth Environment Study, Inc., San Francisco, CA, USA

Objective: To specify the proportion of women among different categories of IVDU's, in order to better describe and predict the spread of AIDS.
Methods: Secondary analysis of 3 data sets of IVDU's (reported AIDS cases, drug treatment agency roster, and hospital emergency room admissions) in 3 cities (San Francisco, the Bronx and Chicago), compares the gender ratios at different ages.
Results: In each urban area the proportion of women among IVDU's declines with age. About 1/3rd of IVDU's in their 20's, and 1/4th of those 40 and older are women. On treatment dates, at least half the clients in their early 20's are female, though for older clients the proportion of women IVDU's in treatment increasingly resembles the proportion on other indicators. The declining proportion of women holds for all racial and ethnic groups, though at all ages there are few Hispanic, and especially Mexican American, women.

Conclusions: "Maturing out" cessation of IV drug use for people as they age "occurs" for men and women at different rates. IV drug use is neither permanent nor demands a total commitment overriding all other aspects of life such as raising a family or a desire not to be a criminal. These countervailing forces weigh differently for men than women, so their IV drug careers are markedly different. In the early years, women especially seek out drug treatment to get away from "the life," and by their early 30's, and especially 40's, all indicators show far more women than men have abandoned IV drug use. Substantial ethnic differences in gender roles are evident, though in all groups the risk of AIDS among IVDU's diminishes with age at a faster rate for women than men.

Th.D.P.15 FEMALE FAMILY MEMBERS AS MEDIATORS OF UTILIZATION OF HEALTH AND SOCIAL SERVICES Cristal, Stueha, Schiller, B., Dejewski, E., Hassell, S.; Moran, C.; Beck, P. Rutgers University, New Jersey, United States

Objective: To analyze the degree to which the availability of family members, particularly women, as sources of informal support is related to the utilization of health and social services by the elderly.
Methods: Data from a survey of a population based random sample of living PWAS in New Jersey is analyzed. The sample includes a high number of intravenous drug users, male homosexuals, racial and ethnic minorities and women. An analysis is made of the differential access of these population groupings to informal family support and the reasons and extent of utilization of formal services.
Results: Family members, especially women, are found to be the major source of informal support of PWAS among both IV drug users, homosexuals and women who acquired AIDS through heterosexual transmission. This finding holds true, for Black, American, Hispanic, and white. Support from women family members is demonstrated to be both instrumental and emotional. A significant relationship is demonstrated between high level of support from female family members and a high degree of utilization of health and social services.
Conclusions: There is a relationship between access to informal and formal supports among PWAS.

Th.D.P.17 DETERMINANTS OF SEXUAL RISK REDUCTION IN FEMALE IV DRUG USERS FROM DIVERSE ETHNIC GROUPS Trang, Sahn*, Abadi-Quader, A*, Des Jarlais, DC**, Kouzi, A*, Friedman, SK*

*Narcotic and Drug Research, Inc., N.Y., U.S.A. **New York State Div. of Substance Abuse Services, N.Y., N.Y., U.S.A.

Objective: Female IVDU's are the primary link to perinatal HIV transmission. Their motivation for HIV sexual risk reduction is multifaceted. We examined the reasons and determinants of such efforts in a street sample of active female IVDU's in the lower east side of Manhattan.

Methods: 116 female IVDU's were recruited through street outreach contacts by neighborhood outreach workers. Paid face-to-face structured interviews were conducted to assess HIV-related risk behaviors, beliefs, personal or network experience, and network norms.
Results: 61% of the sample reported initiating any sexual risk reduction behavior (i.e., condom use, abstinence, reduction in number of partners, avoidance of "high risk" partners) since they heard of AIDS. In multiple logistic regression, significant positive predictors included having more than 1 partner during the average month of the past year (p<0.05); having friends who practiced sexual risk reduction (p<0.05); and perceived current (p<0.05) and future (p<0.05) risk of HIV infection. Ethnicity, relationship status, knowing someone with HIV disease, and perceived self-efficacy about being able to carry out risk reduction were not significantly associated with risk reduction behavior.

Conclusions: Elements of both Health Belief and Social Influence theory predict sexual risk reduction behavior in female IVDU's. These results are consistent with the findings of prior studies of drug risk reduction in IVDU's in treatment - which demonstrate that both fear of AIDS and positive social norms (Friedman, et al, 1987) are associated with drug risk reduction behavior. Since both health beliefs and perceived norms are modifiable, these findings have immediate relevance for designing sexual risk reduction interventions.

Th.D.P.14

Th.D.P.16 HIV INFECTION AMONG FEMALES ENTERING NEW YORK STATE PRISONS Smith, Barry*, Hall, L.J., Trumbo, D.P., Landi, L.M., Broadwin, R.M., Noree, D.A.*

*New York State Department of Health, Albany, New York, USA.
**New York State Department of Correctional Services, Albany, New York, USA.

Objective: To determine the prevalence and risk factors for HIV infection among females entering New York State prisons.

Methods: From September 1988 to January 1989, information was extracted from the medical records of 314 consecutive females entering New York State prisons, and their sera were tested in a blinded fashion by ELISA and Western blot for antibodies against HIV.

Results: Of 450 females tested to date, 85 (18.9%) were HIV seropositive. Seropositivity was highest among 30-39 year olds (24.5%) and varied by ethnicity (Black=14.3%, Hispanic=28.9%, White=8.2%) and residence (New York City=23.9%, Upstate=4.1%). Nearly half (46.9%) of the 126 intravenous drug users and one-third (24.8%) of the 69 women with serologic evidence of syphilis were HIV seropositive. Two of 19 pregnant women were seropositive. By logistic regression, seropositivity was associated with intravenous drug use (adj. OR=0.0, p<0.05), Hispanic ethnicity (adj. OR=3.8, p<0.05), black race (adj. OR=2.9, p<0.10), and residence in New York City (adj. OR=7.3, p<0.05).

Conclusion: In New York, nearly one of every five female prison entrants is infected with HIV, primarily due to IV drug use. The association between seropositivity and ethnicity may have resulted from unreported confounding risk factors, such as sex with an unrecognized high-risk partner. Female prisoners are an important group for educational efforts to reduce the risk of transmission to their sexual partners and offspring.

Th.D.P.18 DIFFERENCES IN HIV/AIDS COUNSELLING FOR WOMEN AND FOR MEN

Hutterer, Judith; Blas, P., Oberauer, C.; Opris, M.; Pec, G.; Siggler, F.; Zeman, A.
Österreichische AIDS-Hilfe (Austrian AIDS Foundation) - GdM, Vienna, Austria.

Objective: 1) To find out the differences in the motives of why women and men VISIT HIV/AIDS counselling centre and take an HIV test and 2) to present the varied role of female counsellors when counselling men and women.
Methods: Evaluation of reports of experiences given by the female counsellors of the seven HIV/AIDS counselling centres of the Austrian AIDS Foundation (GdM).

Results: Many women visit the counselling centres to get advice for others. They want to take an HIV test to make sure that they are not dangerous for others. Protection against AIDS is considered - like contraception - as in the first place a matter of women. The wish for an HIV test often has the following functions: to confirm the closeness to the male partner (especially when he is infected), to "liberate" ("permissit") to engage in new relations), to draw a line underneath the past (test result as a proof of purity), to repress the topic AIDS (after a negative result, the topic AIDS is definitely terminated), to lay down a criteria for continuing a relationship (infection through the sexual evaluation of the partner or not). Male clients often try to force a female counsellor to take the role of the "excuse-making woman" and of a "Wailing Wall". Discussion of the effects of these circumstances in the course of the counselling.
Conclusion: The differences between men and women require different concepts for women which take into account their special concerns and desires.

Session d'affichage Poster Session



Le SIDA et l'individu AIDS and the Individual

Th.D.P.25 AIDS AND WOMEN: CHANGE IN SEXUAL BEHAVIOR
By Francisco Richter, D'Theocharis, J. Theusey, J. and Summers, D.
University of South Carolina School of Public Health, Columbia, South Carolina, USA

Objective: To determine the change in sexual behavior of college women with emphasis on their use of effective AIDS risk reduction behavior.
Methods: 334 randomly selected, female undergraduate students in a major university in southeast U.S. responded to an AIDS questionnaire survey for women. Data collected included demographic information, level of sexual activity, change in sexual behavior, knowledge and frequency of use of effective AIDS risk reduction behavior.


Results: The majority of the respondents had high level of knowledge regarding effective AIDS risk reduction behavior. 49.4% reported changes in sexual behavior. Those who claimed to have changed their sexual behavior tend to have been more sexually active. They are more likely to discuss their partners' past sexual experience, and insist their use of condoms. They are also more likely to report using condoms frequently.
Conclusions: Despite the high level of knowledge regarding effective AIDS risk reduction behavior, only half of the respondents reported to have changed their sexual behavior and of whom only 15% claimed to always use condoms.

Th.D.P.27 UPDATE TO THE COMMUNITY RESPONSE ON WOMEN AND AIDS
Saint Cyr-Deje, Women and AIDS Resource Network, Brooklyn, N.Y., U.S.A.

AIDS is the leading cause of death among women aged 25 - 34 years in New York City. Black and Hispanic women account for 85% of all cases. Nationwide AIDS surveillance data indicate that the proportion of women who acquired AIDS through heterosexual contact is increasing (from 12% in 1982 to 30% in 1987). Despite this increase and the projected need for services geared towards women with HIV infection and their families, there has been minimal planning and little systematic response by the public and private sectors or by service providers.

The Women and AIDS Resource Network (WARN) is a not-for-profit agency that has been working to enhance and facilitate access to resources for women and children affected by HIV infection and AIDS. WARN provides information and referral, counseling including crisis intervention, technical assistance to agencies developing services for women, group training and educational presentations is also provided in hopes of empowering women so we can help curve the rising trend of mortality and morbidity statistics among women.

Th.D.P.29



Th.D.P.26 EPIDEMIOLOGY OF WOMEN OF CHILD-BEARING AGE IN TEXAS, USA
Thompson, E. L., Sauer, L. A., Bess, C.M., L. Robinson, R. E. and Harwell, W. L., Jr.
Texas Dept. of Health, Austin, Texas, USA

Objective: To survey women of child-bearing age in Texas for the presence of HIV antibodies.

Methods: 67,816 white blood specimens of women infants received at the Texas Department of Health (TDH) Laboratory for Venereal Disease Screening were tested in a blind test fashion for HIV antibodies. Results: Eighty-three (83) HIV positive women were found among all women tested for an overall prevalence rate of 0.12% (95% confidence interval, .08%-0.17%). When only latex resistant (44,188 women and 81 HIV positive) were considered, the prevalence rate remained essentially the same at 0.18% (95% confidence interval, .07%-0.17%). The HIV positive women were widely dispersed across the state's 124 counties generally consistent with the distribution of the state population. The 2 counties were: (1) Harris County, which has approximately 17.5% of the 1987 estimated Texas population and submitted 20,173 of the samples tested in this survey, and accounted for 47.75% of the HIV positive women for a prevalence rate of 1.04% (95% confidence interval, .64%-1.70%); (2) East Texas which has 7.5% of the state population and accounted for 4.4% of the specimens tested, but only had 1.23% of the HIV positive women for a prevalence rate of 0.20% (95% confidence interval, .05%-0.48%); and (3) For most Texas, which has 8.75% of the state population and accounted for 1.8% of the specimens tested, but had no HIV positive. Ninety percent of 17,148 of the state population and 21.76% of the specimens tested had had at least one of the positive HIV results. When asked about sex of the state population and accounted for 30.4% of the specimens tested, only accounted for 21.0% of the specimens. Statistics were reported for 72,138 of the specimens tested, but only had 14.8% of the HIV positive.

Conclusions: Prevalence of HIV antibodies is generally distributed across Texas women of child-bearing age in a manner similar to the overall population of the state, with the noted exception. However, black women were more likely to be HIV positive in 1988 than either whites or persons of Hispanic origin. Women of Hispanic origin were the least likely to be HIV positive.

Th.D.P.28 MEDICAL-PSYCHOLOGICAL COUNSELLING FOR WOMEN
Friedrich, Monika; Dorn, B.; Rutenzer, G.
Breslau, Poland, G.D.R.

Dermatological Department of Ludwig-Maximilians-University, Munich, FRG

Objective: To determine problems of medical-psychological counselling for women. **Methods:** In our outpatient clinic for sexually transmissible diseases (STD), we have attempted to realize a medical-psychological care system. **Results:** 12.4% (53/429) of medical patients were female. They are younger than men (24.4 vs 35.1 years) and come with special problems in particular with questions concerning contraception and childbirth. Since January 1987 psychosocial counselling was carried out in 3200 cases, 86% of whom were female. 68.6% required information about HIV-infection or antibody tests. 57 women made use of the phone counselling service and 105 wanted to have personal counselling. 33% of women coming to personal counselling were partners or relatives of HIV-infected men. 14.8% of female clients were HIV-infected. **Conclusions:** To the present most of the women require information about HIV-infection. The close cooperation between physician, psychologist and social worker as an integrated team has proved a great benefit for patients and seems to be especially useful for counselling women.

**Consommateurs de drogues par voie intraveineuse (partie 2)
I.V. Drug Users (Part 2)**

Th.D.P.30 RISK-TAKING BEHAVIORS OF INTRAVENOUS DRUG ABUSERS
NOVA Research Company, Bethesda, Maryland, USA 20814

Objective: To describe the needle use and sexual risk behaviors of intravenous drug abusers (IVDA) interviewed in nine large U.S. cities.

Methods: Persons included in this study are 1,669 IVDA who responded to an interviewer-administered questionnaire developed by participants in the National Commission on Drug Abuse.

Results: High-risk practices identified as risk factors included: number of persons sharing needles/borings; using/borrowing used needles, and cleaning needles (with other than bleach). Seventy percent of males and 56% of females reported sharing needles with two or more persons in the past six months. Furthermore, fifty 8% of those male IVDA and 14% of female IVDA had engaged in all three of the identified risk behaviors. Forty-one percent of the total sample reported having visited a "shooting gallery".

Conclusions: Several practices identified as risk-behaviors included type of sex practice (e.g., anal and receptive), number of IVDA sex partners, and condom use. As a group, 16% reported sex having had sex in the past six months and an additional 47% reported having had sex but not with an IVDA. This latter figure represents a potential vector for the transmission of HIV infection outside the IVDA population. Additionally, 49% of the males and 56% of the females reported having engaged in the exchange of sex for money and/or drugs. Twenty-nine percent of both male and female IVDA engaged in sexual activity with one or more IVDA and did not always use a condom, thus increasing their own risk for HIV infection.

Conclusions: Despite efforts to reduce the IVDA population, the danger of continued risk-taking drug behaviors, a large proportion of IVDA continues to put themselves and others at high risk of HIV infection. The NIDA's project should identify interventions that are effective in bringing about risk reducing behavioral change.

Session d'affichage Poster Session



Le SIDA et l'individu AIDS and the Individual

Th.D.P.37 AN AIDS INTERVENTION PROGRAM FOR THE BLACK OUT-OF-TREATMENT INTRAVENOUS DRUG USER

Valente, A., Thomas, A.,* Krupcho, M.,* Johnson, D.,* Freeman, A.,* Bailey, Charles, P.,* Dallas County Health Department, *Dallas Urban League, Dallas, Texas, U.S.A.

Objective: To reach the black out-of-treatment intravenous drug users, develop relationships to promote risk reduction behaviors, promote drug treatment, and improve their access to health care. **Methods:** The intervention in the targeted community is conducted in 4 steps, and includes: 1) involving former and current black IVU's in the outreach effort, 2) establishing a local counseling/testing site, 3) mobilizing assistance from local merchants to distribute intervention materials, and 4) making contact with the black IVU's, offering information regarding AIDS, antibody testing, drug treatment, and providing condoms and bleach kits. Outreach educators visit the target areas regularly, becoming recognizable to the target population. The program has been ongoing for 7 months on a weekly basis in 4 specific sections of the targeted community. Of the 1,500 persons reached, most were black, young adult males, 3,200 condoms, 800 bleach kits, and 420 brochures have been distributed. No merchant has refused to distribute the brochures. Three merchants are distributing bleach kits. Reasons from the community use the local counseling/testing site, and initiates requests to the "AIDS Ladies" for condoms and bleach kits. **Conclusions:** Although black IVU's experience multiple barriers to health care and information, they are receptive to AIDS risk reduction information when educators come to "the streets" and develop relationships with the black IVU's in their own communities.

Th.D.P.39 RISK OF AIDS IN SEROCONVERTER DRUG INJECTORS: A COMPARISON WITH OTHER RISK GROUPS

Deza, Giovanni, Menotti-Ippolito, F., Lazzarini, A.; Zerbini, R.; Agrasano, G.; Prioresi, R.; Sincico, A.; Barbarelli, M.; Dromas, A.; Costantini, R. and Tiscoll, E. (DIRECZ, Italian Multiple Cohort Study on AIDS), AIDS Unit, Dept. Social Medicine (Ministry of Health) and National Institute of Health, Rome, Italy.

Objective: To estimate the risk of developing AIDS from HIV seroconversion in drug injectors and in a group of subjects with sexually acquired HIV infection.

Methods: A multiple cohort study has been conducted to follow subjects for whom the seroconversion period was identified (availability of a negative test preceding the positive confirmed one). Clinical evaluation was performed each 6 months. A modified CDC clinical definition was utilized to classify the clinical stage of patients. The disease progression was analyzed according to actuarial based on Kaplan-Meier survival curves, and differences between groups were assessed by Wilcoxon test. **Results:** 255 subjects who acquired the infection by drug injecting and 122 by sexual contact (46 heterosexual males and 36 heterosexual contacts) were enrolled until October 30, 1988. The estimate of AIDS progression rate by 4 years from seroconversion was respectively 14% in drug injectors and 18% subjects who acquired the infection by sex. **Conclusion:** No statistically significant difference in the risk of developing AIDS was found between drug injectors and the other group.

Th.D.P.41 HIV INFECTION IN INTRAVENOUS DRUG ADDICTS.

Stepniński A., Mazurkiewicz Walentyna, Ochalska B., Cholewa M. Medical Academy Warsaw, Poland

Objective: In the Institute of Venerology, 2075 patients/71.5% of 17,161, 50.5% of 14,674, who were seropositive to narcotic drugs injected intravenously, have been tested for the presence of HIV antibodies in the period from Jan 1986 to Jan 1989. They were patients of detoxification wards and/or patients of drug treatment centers. **Methods:** HIV antibodies were determined by the EIA method, and positive results were confirmed by the Western-blot technique. **Results:** HIV antibodies were found in 21 patients/54 males and 7 females, which accounts for 0.7% of cases. In 1986-1987, all tests were negative. The first positive HIV test was detected in Aug 1988 after testing of 2254 drug addicts. Since Aug 1988 to Jan 1989, 21 cases were positive to HIV antibodies /2.5% of 817 patients studied. This indicates that HIV infection is spreading fast in this population. Infections of drug addicts with HIV represent 7% of total cases of HIV antibody-positive individuals in Poland. **Conclusion:** Intravenous narcotic drug use program should be performed among drug addicts, accompanied with the distribution of free disposable syringes and needles, as well as condoms. Further more, problems related to drug should be covered by special training program for staff of drug treatment centers in Poland.

Th.D.P.38 THE NEEDLE AND SYRINGE EXCHANGE PILOT PROGRAM IN NEW YORK CITY

Edelman, J., Robinson, Gordon, Peck, M., Eaton, C.J. and Joseph, S. New York City Department of Health, New York City, New York, U.S.A.

Objective: To evaluate the first government sponsored needle and syringe exchange pilot program in the United States so as to assess its potential for the control of HIV infection among intravenous drug users. **Methods:** The Needle Exchange Pilot Program of the New York City Department of Health began operation on November 7, 1988. As New York State is one of 11 states which requires prescriptions for the sale of needles and syringes the New York State Commissioner of Health has authorized this pilot study for the purpose of scientific research. In the absence of treatment on demand, the needle exchange program was considered as part of a multiphase approach towards the issue of intravenous drug abuse and AIDS. Current IV drug use by 16 years of age or older consisting of 200,000 persons, rehabilitation program throughout the city are available. A questionnaire is administered periodically for information on needle sharing behavior, in addition to other risk behaviors. Drug treatment referrals and intensive risk-reduction education is provided. Those who take part must return their used injection equipment before they can receive a sterile needle and syringe. One needle and syringe is distributed per encounter. **Results:** Within the first 2 months of operation, 56 persons have enrolled; 19 are men, 37 are women; 24 are black, 28 are Hispanic, 13 are white, and 1 is Native American. The number of participants entered into treatment is 26. **Conclusions:** It has been possible to initiate and continue a pilot needle exchange program in New York City in the context of a "Bridges to Treatment" service program, despite misunderstanding of the program's objectives.

Th.D.P.40 AIDS INCIDENCE AND RISK FACTORS FOR DISEASE PROGRESSION IN A COHORT OF SEROCONVERTER DRUG INJECTORS.

Deza, Giovanni, Menotti-Ippolito, F., Lazzarini, A.; Anagnano, G.; Sincico, A.; Tirrelli, P. et al. (DIRECZ Italian Multiple Cohort Study on AIDS), AIDS Unit, Dept. Social Medicine (Ministry of Health) and National Institute of Health, Rome, Italy.

Objective: To describe the natural history of HIV infection in drug injectors since seroconversion, and to evaluate risk factors associated to disease progression.

Methods: The enrollment criteria were represented by the identification of the seroconversion period (availability of a negative serological test followed by the positive one). Clinical and laboratory evaluation was performed each 6 months. Data collection on demographic and behavioral features was made by means of individual case reports. The disease progression was analyzed according to actuarial based on Kaplan-Meier survival curves. **Results:** 255 subjects fulfilling criteria entered the cohort. Males/females ratio was 41%; mean age was 28 years. The mean period of follow-up until October 30, 1988 was 79 month-period; 13 cases of AIDS occurred up to that date. The actuarial incidence of AIDS was 2.1% by years and 14.5 by four years after seroconversion. The risk of developing increased significantly after two years since seroconversion (Mantel-Cox test).

Conclusions: The duration of exposure to the virus seems to be the main factor in determining the disease progression in seropositive drug injectors.

Th.D.P.42 RISK BEHAVIOR AND ATTITUDES AMONG SEROCONVERTER IV DRUG

Deza, Giovanni, Menotti-Ippolito, F., Lazzarini, A.; Anagnano, G.; Sincico, A.; Tirrelli, P. et al. (DIRECZ Italian Multiple Cohort Study on AIDS), AIDS Unit, Dept. Social Medicine (Ministry of Health) and National Institute of Health, Rome, Italy.

Objective: To describe a study of how knowing IV drug users appraise risks associated with AIDS. **Methods:** The presenters describe findings from structured interviews with 348 seroconverters IV drug users, who were seropositive to narcotic drugs injected intravenously, drug use, and sexual behavior. Structured interview data on Risk, Heroin, and White Anger, and other risk factors were collected in one clinic in New York and Northern New Jersey. **Results:** More than two thirds (68%) admitted to sharing needles in the past and almost a third indicated that they had used needles at least once within the past six months. One in five subjects reported having had sex with an IV drug user on at least six occasions during the past six months. Those who used IV drug in the past six months reported significantly more IV using sexual partners, using sex with heroin, cocaine, crack, speedballing, and greater frequency of crack use. Among 149 males, 68% indicated that they had sex with a woman in treatment more likely to have changed their needle cleaning habits. Current users who reported changing their needle hygiene, were less likely to be sharing needles with women in treatment more likely to have changed their needle after sex than others. About half of respondents claimed to have altered their sexual behavior over the past six months. Persons who had one or more friends die of AIDS were significantly more likely than others to have changed their needle cleaning and sexual behaviors. **Discussion:** Consistent with other findings, these data suggest that past drug use, social attitudes that include sharing, and knowing persons who have died of AIDS, predict favorable behavior changes. Also corroborated with other investigators' data, the descriptive study found that sexual behavior is more difficult to change than many drug related risks.

Session d'affichage Poster Session



Le SIDA et l'individu AIDS and the Individual

Th.D.P.43 AIDS BELIEFS AND BEHAVIOR CHANGE IN MINORITY IV DRUG USERS
Adele Green, M. Greenberg, G. A. Branganstein, Mildred Personalized Nursing Corporation, P.C., Detroit, Michigan, USA

Objective. To identify the IV drug users' (IVDU's) beliefs regarding AIDS and related behaviors.
Methods. Nonprobability sample of IVDU's seen thru the emergency rooms and in the hospitals of 3 inner cities reporting a high incidence of IV drug use and AIDS. Structured interview -- fixed response and open-ended questions.

Results. Interviewed 721 IVDU's: 73.9% male, 26.1% female, 70.1% Black; 19.8% Hispanic, 7.7% White, 2.2% other, 86.9% unemployed. Multiple partners: 92.3% use barbit, 79.4% cocaine, 69.1% speedballs. General knowledge regarding AIDS transmission: 76.6% report drug use, 82.9% report sexual activities, 61.4% report getting information about AIDS from radio or TV, 52.8% report getting from printed media, 75.7% report changing to reduce risk; 71.9% avoid pregnancy, 43.6% stopped or decreased needle sharing, 41.3% use safer sex, 41.8% use needles.
Conclusion. IVDU's report making efforts to change their behaviors to decrease their risk of getting/transmitting AIDS.

Th.D.P.45 THE EPIDEMIOLOGY OF AIDS AMONG NEW YORK STATE PRISON INMATES

Morris Dale*, Thomas, S.*, Nisi, J.*, Smith, P.*, Broadwin, R.**, Maguire, R.***
*New York State Department of Health, Albany, New York, USA
**New York State Department of Correctional Services, Albany, New York, USA

Objective. To describe the epidemiologic characteristics of AIDS among New York State (NYS) prison inmates.
Methods. We analyzed demographic, risk factor, disease and mortality data obtained from medical record reviews of all inmates developing AIDS within the NYS Correctional System from 1981-1988.

Results. Through December 31, 1988, 838 cases of AIDS had been confirmed among inmates in NYS correctional facilities, accounting for 1% of the U.S. and 4% of NYS AIDS cases. Cases increased from 2 in 1981 to 205 in 1987, with an incidence of >450 cases per 100,000 inmates per year since 1983. While most cases (98%) have occurred in males, females have the same high incidence rates (compared to the general population where female rates are 1/8 those of males). Hispanics had the highest incidence rates (2 times other groups) and significantly higher rates of narcotic use and drug related sentences. Intravenous drug use (IVU) was the major risk factor. Six percent of cases have had concurrent tuberculosis and 63% of TB cases since 1985 have had AIDS or HIV infection. HIV seroprevalence has been 17% and 17% among 4000 male and female inmates, respectively. To date, 49% of inmate AIDS cases have died and AIDS now accounts for 70% of inmate deaths.
Conclusion. AIDS is the preeminent health problem among New York State inmates and is primarily related to IV drug use.

Th.D.P.47 SERIAL ACTIVITIES OF IV DRUG USERS WITH MULTIPLE SEX PARTNERS
Michele E. Virginia*, Trapido, S.J.**, Incardini, J.A.***, McBride, D.C.*** and McKay, C.T.***
*Florida International University, Miami, FL, USA; **University of Miami School of Medicine, Miami FL, USA; ***University of Delaware, Newark, DE, USA; ****University of Virginia, Berlin Springs, VA, USA.

Objective. To describe the types of sexual activities of IV drug users who have multiple sex partners and their association with serostatus.
Method. As part of a study which tests two interventions to reduce AIDS among IVUDs, 346 subjects were recruited from drug networks, interviewed and tested for HIV serostatus. Bivariate analyses, using Gamma and Chi-Square values, were conducted to determine the associations.
Results. While about 90% of IV drug users in this sample had multiple sex partners, less than one-fourth admitted to having sex for money and one-sixth had sex to obtain drugs. The type of sex (except for vaginal sex) engaged in with their multiple partners was significantly associated with the number of sex partners and with serostatus, but only when condoms were not used.

Conclusion. The type of sexual activity is an added dimension to be considered for educational prevention information for IV drug users on HIV risk factors.

Th.D.P.44 COCAINE USE AND SEXUALLY TRANSMITTED DISEASES INCLUDING HIV IN BLACK, HISPANIC, AND WHITE COCAINE USERS
Michael R. Hanson*, Rebecca S. DeBruin, M. P. Williams, J. P. Stowers, J. L. Williams, M.D., Health Services Center at Brooklyn, New York, NY, NY, Department of Health, Albany, New York, U.S.A.

Objective: To study the association between cocaine use and sexually transmitted diseases (STD), particularly HIV, in a community with a high prevalence of both cocaine use and HIV disease.
Methods and Results: Between 10/88 and 1/90, 1,170 women birthing at an inner city hospital in New York had otherwise discarded urine coded and stored. Demographic, syphilis serology and HIV risk data was collected from 1028 of these patients. Identifiers removed and codes reassigned corresponding to urines applied. In the latter part of the study 299 patients had blood (remaining after syphilis studies) stored and coded. After all identifiers were removed the urine was analyzed for cocaine, and other drugs. The blood was analyzed for HIV antibody by ELISA and Western blot.
Results: 13.1% of urine had cocaine, cocaine (use) 1.8% seropositive and 1.4% syphilis. 49% of cases denied drug use during pregnancy. 92.3% of patients without cocaine denied intravenous use. 17% of cases had positive syphilis serologies compared to 2.84 (p.R.=7, 1.699C, 1.1-8-12-91) seropositive without cocaine (controls). Among controls 0.784 (1/250) had HIV antibody compared to 9.094 (4%) of cases (p.R.=11, 6.994 C12, 2-3-41). No patient with HIV antibody had other drugs in their urine. One HIV infected case acknowledged intravenous drug use and one HIV infected control was from an endemic country.
Conclusions: 1) Cocaine use among participants in the inner city is epidemic. 2) Preliminary results suggest a link between cocaine use and HIV.

Th.D.P.46 HIV-INFECTION AMONG IV DRUG ABUSERS IN BUENOS AIRES, ARGENTINA
Cahn-Indaco*, Perez JP, Castro A*, Vallejo JM, Hella D*, Marchitelli*, Ramos Aires, Argentina

Objective. To evaluate HIV-infection prevalence and related factors in an IV drug abusers (IVDA) population.

Method. The sera of 538 contemporaneously attending IVDA were studied thru ELISA HIV-1 (Abbott) and reconfirmed thru immunofluorescence. Presence of symptoms, time of addiction and sexual behavior were assessed.

Results. There were 253 men (47.01) and 87.15 women (25.11); 87.15 (294) was under 30 years of age, the average being 23 years old. The time of addiction average was 3.4 years. Seropositivity was found in 204 patients (37.92); 52% of Pt showed 1 or more symptoms (fever >38°C > 1 month, diarrhea > 1 month, weight loss >10% > 1 month, adenopathy, skin lesions, epinoma/gall); 28% of the latter, 771 was HIV+ vs. 211 asymptomatic ones. Positive correlation was found between time of addiction and presence of symptoms (1 year = 121; 3 years = 453), and between the former and seropositivity (60% HIV+ after 3 years; 50% after 4 years). Mono- or bisexual behavior was admitted by 231 of the Pt, which percentage did not significantly alter seropositivity level.

Conclusion. A high proportion of IVDA is HIV+. Time of addiction and presence of symptoms were separately associated to seropositivity while homosexual/bisexual activity didn't involve additional risk for this young group. Greater educational efforts should be made in order to limit the epidemics growth within heterosexual population.

Th.D.P.48 MOBILITY, SEX CITIES, SEX RISK BEHAVIOR, AND HIV STATUS OF IV DRUG USERS

McCoy, Clyde A.*; Chiswood, D.S.*; Page, J.B.*
*University of Miami School of Medicine, Miami, FL, USA.

Objective. To determine the mobility of IVUDs and its relationship to risk behavior and HIV status of more than 400 IVUDs recruited from the streets of the Miami metropolitan area.

Methods. IVUDs have been actively recruited by outreach workers into a centralized assessment center at the medical school at the University of Miami where blood samples and extensive assessments were provided to IVUDs in conjunction with pre and post case counseling. Assessments of sexual, drug taking and other social histories were taken by trained, specialized interviewers. Blood was drawn by a trained phlebotomist, specialized in working with IVUDs.

Results. Of the 541 of IVUDs who traveled outside of their local area, a large majority reported having had sex and a lesser majority indicated that they had shot up with drugs during this mobility. Those having sex, and having said they shot up during this period have a higher rate of seropositivity than those who had less mobility and/or had engaged in fewer risk practices.

Conclusion. There is a potential risk of transmitting the HIV virus from the primary risk heterosexual contacts to other areas as potentially high risk IVUDs travel to other cities.

Session d'affichage Poster Session



Le SIDA et l'individu AIDS and the Individual

Th.D.P.49 GENERATIONAL DIFFERENCES IN HIV RISK BEHAVIOR AND SEROCONVERSION RATES AMONG IVDS

Michelle D.C.,* Inceffari, J.A.,** McCoy, C.B.,***
Chitwood, D.D.,** and McCoy, M.V.,***. *Andrew University, Berry Springs, MS, USA, **University of Delaware, Newark, DE, USA, ***University of Miami School of Medicine, Miami, FL, USA; **Florida International University, Miami, FL, USA.

Objective. To examine generational differences in AIDS risk behavior and seroprevalence rates among IVDS.

Methods. This analysis is part of an AIDS Community Outreach Project funded by the National Institute on Drug Abuse. Over 500 IVDS are in treatment were recruited and interviewed with a focus on needle using and sexual behaviors. Bloods were drawn and analyzed for the presence of HIV antibody using ELISA and Western Blot techniques. Generation was obtained by asking date of birth and categorizing age into three categories: Post baby boomers, those born after 1928; baby boomers, those born 1929-1946 and pre-baby boomers, those born prior to 1946.

Results. Generation differences in risk behaviors and seroprevalence exist. While post baby boomers have drug use patterns and sexual behavior patterns similar to the other generations, they are more likely to clean their needles and have fewer partners. Associated with these behavioral differences is the finding that post baby boomers have a seroprevalence rate of 15.7% compared to 23.7% of the other two generations (significant at the .005 level).

Conclusion. Younger generations of IVDS are more receptive to AIDS prevention strategies and most ready to change high risk behaviors.

Th.D.P.51 COCAINE, MARIJUANA AND ALCOHOL AS RISK FACTORS FOR HIV INFECTION IN SEROCONVERTED INDIVIDUALS: A PILOT STUDY

John D.L.,* Nordstrom, J., Allen, M.,** Boyce, L.,** Specko, P.,** Weinrich, J.,** Mulgrew, C.,** et al.,** UICD AIDS Cohort Study, San Diego State Univ., and University of Calif., San Diego, 1986

Objective. To study the association between use of cocaine, marijuana, alcohol and HIV infection in homosexual men.
Methods. Drug, alcohol, and medical histories were compared in 50 HIV infected (HIV+) homosexual men and 44 HIV uninfected (HIV-) homosexual men, all without a history of intravenous drug use. Sexual histories of 11 HIV+ cases and 11 HIV- controls with were compared for the 7-year period (1978-1984) during which infection occurred and before they were told their HIV status.

Results. Odds ratios and multiple logistic regression analysis revealed a significant association between number of years of cocaine use and HIV seropositivity (p<.01). Odds of being seropositive increased with more prolonged exposure to cocaine (OR=3.7). HIV was weakly associated with levels of marijuana use, but not with levels of alcohol consumption. Analysis of the sexual histories of the sub-sample suggested an association between high-risk sex and levels of cocaine usage.

Cocaine Use	HIV	Total	Odds Ratio (HIV+)	Odds Ratio
0	9	25	1.00	
1-3	16	23	1.00	1.78
4-26	25	37	2.08	3.72

Conclusion. Cocaine, in contrast to alcohol and marijuana, may contribute to risk of HIV infection by promoting risky sexual behaviors.

Th.D.P.53 MODE OF HIV TRANSMISSION AND SEROCONVERTED INTRAVENOUS DRUG USERS IN SEROCONVERTED INDIVIDUALS: A PILOT STUDY

Brown, Lawrence S.; Nemoto, T.; Primm, R.J.; Foster, K.J.; and Chu, A. Addiction Research and Treatment Corporation, New York City, USA.

Objective. To investigate mode of HIV transmission among seroconverted IVDS, especially those on their drug and sexual behaviors.

Methods. A total 641 subjects (218 in '87 and 233 in '88); 627 males and 114 females; 311 HIV+ and 330 HIV- were recruited from methadone clinics in Manhattan and Brooklyn, New York City. After informed consent, a standardized questionnaire was administered by trained interviewers. Also, blood was collected and tested for HIV antibody by ELISA and Western Blot techniques.

Results. The overall HIV infection rate was 60% in 1987 and 52% in 1988. In 1987 and 1988, respectively, 19 of 23 and 23 of 40 subjects, who admitted to a previous HIV seronegative result, were found to test HIV seropositive. These suspected seronegatives significantly differed from subjects who remained seronegative in frequency of sharing needles (p<.01), sharing cookers (p<.02), and use of shooting galleries (p<.05) during the last 5 years. Among 1987 cohort group, all those who remained seronegative stopped sharing needles, but 12 out of 18 subjects who seroconverted still shared needles.

Conclusion. Needle-sharing behaviors continue to be associated with HIV seroconversion among IVDS. More effective education to stop needle sharing among IVDS is needed.

Th.D.P.50 IVDS CHARACTERISTICS ASSOCIATED WITH NEEDLE SHARING

Donald Wallace, Vishov S. Goss, J. Thelma Study, Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, USA.

Objective. Ascertain characteristics associated w/needle sharing in cohort of active IV drug users (IVDU).

Methods. IVDS were recruited for a prospective natural history study of HIV infection from street outreach clinics, hospitals and drug treatment programs. Characteristics were compared among IVDS who reported or denied needle sharing in the preceding 6 months.

Results. Among 441 active IVDU's, 469 (70%) reported sharing needles in the preceding 6 months. Race, sex, age and marital status were not associated with sharing.

	Share + (%)	Share - (%)	P Fisher
Daily user	48	30	<.0010
Cocaine - other drugs	80	91	<.0000
Started before '80	87	85	<.0000
Unemployed at least 1 yr	71	78	<.0100
Pub. assist. for 1 yr	73	72	<.0100
Homeless for a period	50	48	<.0100
Arrest in last ten yrs	82	78	<.0001
Arrest withdrawn	39	39	<.0001
Used gallery	49	11	<.0001

Conclusions. Most currently active IVDS's in this sample (70%) reported sharing needles. The inability to head off serious withdrawal symptoms, more frequent use and economic destitution may be driving forces for needle sharing and gallery use. Multivariate analyses are being carried out.

Th.D.P.52 AIDS-RELATED KNOWLEDGE, ATTITUDES, AND BEHAVIOR IN TREATMENT FACILITY

Milutin, Marzetta,* Coates, R.,* Devesy, P.,** Frankin, T.,** Rankin, J.,** Department of Preventive Medicine and Biostatistics, University of Toronto and **The Addiction Research Foundation, Toronto, Ontario, Canada

Objective. To describe AIDS-related knowledge, attitudes and behavior in a group of Canadian injection drug users (IDUs).

Methods. Over a 3 month period, 90/100 (90%) attending a Toronto treatment facility completed an anonymous, self-administered questionnaire.
Results. Of the 81 male and 29 female respondents, 44% were under 30 and 90% were under 40; 90% were heterosexual; 34% reported more than one sexual partner in the past year, with 12% reporting 10 or more. Most had a drug problem for more than 5 years (50%). The common primary drug was heroin (61%), with 20% being mainly cocaine users. 71% reported needle-sharing within 5 years, 34% within the preceding month. 90% knew that heterosexual spread of AIDS. 84% were personally willing to be tested for HIV and 20% already had been (all were negative). 20% would change their drug use behavior if they received a negative test; 8% their sexual behavior; 15% indicated uncertainty as to how they would deal with a positive test, while a further 12% would consider suicide or resume heavy drug use. Current needle sharers could not be distinguished from former needle sharers on selected demographic, attitudinal, and knowledge variables.

Conclusions. IDUs are sharing needles despite knowledge of the risk. For those testing positive, there may be a risk of self-destructive behaviour. Testing should be done only with excellent counselling and ongoing support.

Th.D.P.54 INPATIENT OUTREACH WITH INTRAVENOUS MINORITY DRUG-USING AIDS PATIENTS: IT CAN BE DONE

Joseph, Deborah; Graham, V.; Kitchens, A. King's County Hospital AIDS Team, Brooklyn, New York, USA.

Objective. To use a group approach to increase coping in a population often thought to be unresponsive, defended, and non-responsive to benefits from such a modality. Purpose(s): 1) educate about diagnosis, services; 2) reduce isolation and depression; 3) bridge to aftercare services; and 4) optimize education and counseling services.

Methods. Large city hospital with daily AIDS census of 65 serves a poor minority community. Patient population in mostly street/room 3-drug/truck users. General nursing staff support adjacently helps motivate patients to attend group. The nurses and a social worker use supportive techniques to facilitate this twice-weekly, voluntary, confidential group.

Results. Group size ranged from 8-13. Patients freely self-disclosed and verbalized. They displayed a capacity to both give and receive support. Patients resolved confidentiality issues through discussion, and without reticence processed themes of stoicism, sexual responsibility, stigmatization, and maintenance of hope. Patients rapidly developed a sense of ownership of the group and acted as outreach to other isolated, non-disclosed patients.

Conclusions. Outreach to expectant concerns that patients would have great difficulty allowing their diagnosis to be revealed among their peers, patients did together to affirm their commonalities to form a constructive camaraderie. The stereotyped image of this population as being incapable of bonding and emotional interdependence is inaccurate. Thus, organized peer support is a necessary part of social work with this population.

Session d'affichage Poster Session



Le SIDA et l'individu AIDS and the Individual

Th.D.P.67 LONG TERM FOLLOW UP OF A COHORT OF DRUG ABUSERS OF THE AREA OF FRUGIO BILLIA (NORTH ITALY)

RES. Ghisla R.A., Vanni F., Tomasi A., Galardi G.F., Divisione Malattie Infettive, Ospedale S. Maria Annunziata, Frugio Billia, Italy.

Objective: To monitor the natural history of the disease in the drug addict and as drug addict.

To assess risk factors and progression in AIDS.

Methods: In May 1985 we began a long-term follow up programme of 106 and ex 106 with HIV infection, who live in the area of Frugio Billia (North Italy). This study is being carried out on about 100 patients thanks to collaboration among the Department of Infectious Diseases, the Rehabilitation Centre of the area and the prison.

We think HIV began to circulate among IVDA in our area in 1980-1985.

170 IVDA HIV with 20 AIDS cases were found out in December 1986. 100 HIV with 30 AIDS cases have been found out up today. The patients are followed with six-monthly check up at Day Hospital, which consist in medical examinations as an serologic, immunologic, and histomorphologic tests.

113 patients HIV infected, in II and III stage of the CD4+ classification, were enrolled from June 1986 to June 1988. 79 of them have completed 3 years of their follow up at least, 9 of them died 3 for the AIDS, 1 the remainder didn't present themselves for the following controls.

In this study we are describing these subjects in their clinical development (according to the classification) and on the ground of some parameters beginning year of the usual drug use, passing months on the street, contracted positive tests for HIV antibodies, total number of injections, number of HIV, HLA-antigen, IgG, positivity of HIV-antigenemia, other risk factors as homosexuality and/or prostitution.

Th.D.P.68 A STUDY COMPARING HIGH HIV-RELATED DEATH AMONG HIV-SEROPOSITIVE IVDA'S WITH DEATH AMONG SERONEGATIVE IVDA'S: THE HIV-PREVALENCE AND THE SERO-CONVERSION RATE AMONG IVDA'S.

Christian Solbach, Peter Kittelsen, Finn Jensen, Oslo City Health and Environment Department, Per Magnus, Norwegian National Institute of Public Health, NORWAY

OBJECTIVES: The Department of AIDS Prevention runs a testing and counselling clinic as well as an out-patient clinic for HIV-positives. The clinics have since the epidemic among IVDA's become known been the most visited testing and counselling facility for IVDA's in Oslo. Between August 1985 and January 1989 approximately 1000 IVDA's have registered at the clinic. The seroprevalence and the sero-conversion rate among the tested IVDA's will be presented. The main objective of the study is to estimate the mortality rate among all 1000 IVDA's registered, and to compare sero-positives and sero-negatives. The mortality rate will be studied with respect to other background factors.

METHODS: The 1000 IVDA's represent between 25000 and 40% of the IVDA population in the Oslo area. All clients at the clinic seek it voluntarily. All information regarding deaths and causes of death are based on statistics obtained from the Central Bureau of Statistics. The viroserological results are based on tests taken at the clinic, or first reported to us by the clients and then confirmed by the department. The causes of death will be presented graphically. Survival analysis utilizing Kaplan-Meier plots will be used to compare the hazard rates of the two groups.

RESULTS AND CONCLUSIONS: Results, statistics and conclusions will be available and presented at the conference.

Th.D.P.69 METHADONE MAINTENANCE IN HIV-INFECTED IV. DRUG ADDICTS - MEDICAL AND PSYCHOSOCIAL EFFECTS

Walter Feyer, P. Baumgart, G. Wiles, L. Kuder, P. Heyen, K. G. Dorst

University of Medicine, University of Wuerzburg, F.R.G.

Objective: to study the effects of methadone maintenance in AIDS-ARC-IV drug addicts on medical, psychological and social parameters.

Methods: open prospective study 30 IV. drug addicts (CDC IV, WR 3-4) were enrolled before and during methadone maintenance. Clinical and labor data, psychological and quality of life parameters and toxicological screening tests were evaluated. The study was based on cooperation between general practitioners, the HIV-outpatient department staff and institutional psychosocial support.

Results: We evaluated data of 30 patients (20 m 10 f) mean age 29,12y, after an average methadone maintenance of 13 (5-24) months. 3 of 30 patients had relapsed; 2 of them only for several weeks. Medical parameters were improved in 20 of 23 patients body-weight, secondary complications due to HIV and drug addiction, infectious/fungal. Psychological parameters were improved in 17 of 23 patients. Stabilization could not be achieved in 4 patients because of ongoing IV. drug addiction of their partners. Drug-delicts stopped in all patients, prostitution in those, who remained in methadone therapy. Positive effects due to quality of life were noticed by all. Change of HIV-stage was observed in only 3 patients, 2 of them after relapse.

Conclusion: chronic HIV-infected IV. drug addicts do benefit from a controlled methadone maintenance. Most of them did stop IV. drug addiction, drug delicts and prostitution as a necessary condition of medical and psychosocial stabilization. Cooperation of all medical and psychosocial institutions is of paramount importance. In addition this stabilization has its place in regard to prevent further spread of HIV-infection.

Th.D.P.70 THE USE OF STERILE SYRINGES AMONG IVDA'S WHO DID NOT UNDERGO INTENSIFIED TREATMENT AT 1986

J. CITERIO, P. HEALTH PRODUCER IS ADMIN.

Marcelo Barron, Juan Carlos P. Banchero, P. Utrera and E. Wallace.

Doctor, Madrid City Center for D.S., Terraza de Arden (Madrid); Doctor, Madrid City Council, see Bureau and Office, Madrid City, SPAIN

Objective: to study the influence of AIDS prevention campaigns message on IV IVDA that had been treated with cisindine, with regard to changing of habits and to permanence.

Methods: Reality-epidemiological inquiry on the present situation of 72 IVDA who were treated with cisindine during 1980-1987, with regard to drug dependence and AIDS risk habits.

Results: 50 IVDA out of the 72 IVDA answered the question: 18 of them were 20-24 years old, 25 were 25-29 years; 47 of them (85%) were males and 5 (9%) females; 82.5% had been IVDA for 9-17 years. The economical level of the group was 49% under the minimum wage. In Jan '88, 18 were unemployed, 5 relapsing periodically and 20 remained 20%. Habits regarding HIV risk infection: 80% have a better health control; 70% have spread out prevention methods; 43% improve alimentacion habits; 58% improve daily hygiene habits. Out of the 26 staying 30, 5 suffering 11 occasionally users and 6 remained daily IVDA. As for the spreading of AIDS control methods, as health workers we point out: 60% bring us our drug addicts to the center; 80% recommend the use of sterile syringes; 5% recommend the use of condoms. None of the 20 IVDA use shared syringes. 2 of them occasionally, and 18 of them use individual syringes.

Conclusion: the above reveals the importance of the detoxification treatment even if there are relapses due to the influence on the subsequent health condition.

Th.D.P.71 SURVEY OF THE METHADONE TREATMENT PROGRAMME OF THE OUTPATIENT CLINIC OF THE VIENNA PSYCHIATRIC UNIVERSITY HOSPITAL

Walter Feyer, Franziska C. O., Fersmann, D.,* Hutterer,

* Fersmann, V.* Gollwitzer-Lobos, K.*

Psychiatric University Hospital, Vienna, Austria, * Osterreichische AIDS-Hilfe (Austrian AIDS Foundation), Vienna, Austria.

Objective: to present a survey of the structure and status of the patients in the programme mentioned above.

Methods: The outpatient clinic mentioned above has been carrying out a methadone detox and maintenance programme since October 1982 and has by now the largest number of patients in Austria. The data presented are results taken from routine documentation.

Results: The following data (average values) concerning the 99 men and 37 women treated were obtained: age at the start of the methadone treatment: 29 years; age at first contact with drugs: 16 years; length of opiate dependency: 12 years; in methadone treatment: 8 months; first methadone dose: 55.25 milligrams; present-day dose: 77.7 milligrams; HIV positive: 44% (75% men, 25% women); polytoxicant addiction of the HIV positive patients at the time of methadone adjustment: 55% (73.3% men, 26.7% women); working profession at the start of methadone treatment: 21.3%, working since methadone substitution: 30.9%; previous convictions (drug abuse offences): 64.7% (73.5% men, 20.5% women); total number of convictions: 18.9% opiate, 5.1% methadone, 0.7% solvent, 3.0% unknown; couples in treatment: 13.2% (both are HIV infected: 33.3%, one partner is HIV infected: 22.2%, both partners are negative: 44.4%).

Conclusion: The programme promotes social and occupational reintegration.

Th.D.P.72 AIDS RELATED BEHAVIOR AND ATTITUDES

AMONG IV DAUROS UNDER IN CARE

A. Eklund, A. Ahlman, C. Sallsten

Department of Psychiatry, Alms University Medical School, Almsna, Greece

Objective: Data presented in this study emphasize an attempt towards the identification of possible factors influencing the low transmission rate (seroprevalence rates lower than 1%) of HIV among Greek IV drug users. Methods: Randomly selected in the visit transactions such as needle and syringe sharing practices and sexual behavior have been investigated in a sample of 127 IV drug users who were in contact with health services. Subjects were additionally asked on the main reasons to which they had resorted to AIDS as well as on their personal beliefs and attitudes related to the risks of infection.

Results and conclusions: Frequent injection frequency, high drug usage, practicing such as sharing of syringes and needles, and sharing of needles, were the major risk factors (75%) while only 37% of them were changed such practices due to the appearance of AIDS. Concerning their sexual behavior the majority (83%) use safety (SR) or even never (81%) condoms during intercourse. From those reporting homosexual contact (20%) the large majority has sexual contacts with both sexes. Half of the population stated not having changed sexual behavior after the appearance of AIDS. Low levels of awareness and sense of responsibility in HIV transmission changes is further confirmed by the high rates of those who believe that it is easy or even totally impossible to be infected by the virus (10%). Moreover respondents expressed the belief that the level of awareness for HIV transmission among subjects in their environment is low to non-existent (80%) and that no change has occurred in behavior (70%). A minority only (30%) considered as main source for the present information on AIDS health professionals, while for the majority (70%) the main source of information were the mass-media and mainly periodical press. Findings are discussed along with implications on the possible reasons of low HIV prevalence among Greek IV drug users. The study was supported by the Greek AIDS implications were discussed. WHO approved study has been used as a basis for the initiation of an ongoing more extensive and continue WHO supported study.

Session d'affichage Poster Session



Le SIDA et l'individu AIDS and the Individual

Th.D.P.79 CLINICAL SYMPTOMS AND MEDICAL HISTORIES OF A COHORT OF IV DRUG USERS: CORRELATION WITH HIV SEROPREVALENCE

Editors: Margot K., Vlahov D., Solomon L., Lindsey A., Chodura N., The ALIVE Study, Johns Hopkins University, Baltimore, MD, U.S.A.
Objective: To ascertain the frequency of clinical symptoms and histories of medical illnesses and their correlation with HIV seroprevalence in a cohort of active IV drug users (IVDU).
Methods: A cohort of active IVUDs were recruited for a prospective study of the natural history of HIV infection from street outreach, STD clinic and STI & drug treatment centers. Persons with AIDS were excluded.
Reported symptoms and medical histories from baseline questionnaires were correlated with HIV serological data (ELISA and Western confirmation).
Results: Overall 441 (84.7%) of 519 participants were HIV seropositive. Significant associations were as follows:

HIV +	HIV -	P-value (Chi-square/Fishers)	
Dyspnea	7.4%	11.6%	0.007
Fatigue	18.9%	22.9%	0.079
Weight loss	28.7%	30.3%	0.007
Oral Thrush	1.8%	4.3%	0.011
Hg. Bacteremia	0.2%	1.4%	0.009
Hg. Endocarditis	0.5%	1.4%	0.063

Histories of the following were associated with HIV status: Bacterial Pneumonia, Tuberculosis, Syphilis, Cirrhosis, Tuberc. of bladder, etc.
Conclusion: Although symptoms associated with AIDS-related events are frequent among active IVUD's who are seronegative, several symptoms are significantly more common in HIV seropositive IVUD's.

Th.D.P.81 THE USE OF A BEHAVIORAL INTERVENTION AS PART OF A RISK REDUCTION STRATEGY AMONG INTRAVENOUS DRUG USERS

Christie, Ang, Daw, M.C.T.
 Department of Clinical Psychology, Consulting Clinic, Ruchill Hospital, Glasgow, UNITED KINGDOM

Objective: To develop a minimal behavioral programme aimed at increasing behavior change towards safer sex and drug use among intravenous drug users (IVDU).

Methods: A booklet was developed following behavioral principles consisting of the following sections: Assessment and feedback; Knowledge test; Drug risk, monitoring and identifying client's own risk situations, using problem solving to find better ways to cope with risk, common risk situations and ways to solve them; Sex risk, choosing partners and using condoms; Identifying risk situations and ways to cope with these; Local information. The format of the booklet is written with local drug users in view. The booklet was developed with the help of groups of clients in residential drug treatment agencies who tested and commented on each section.

Results: A booklet has been developed successfully prior to formal evaluation.
Conclusion: Behavioral interventions offer a great deal to those who wish to change their behavior but have difficulty translating their intentions into practice. So other educational packages offer specific advice on monitoring and altering specific areas of difficulty which lie behind making such changes.

Th.D.P.83 COMPARISON OF SEXUAL BEHAVIORS AMONG WHITE IVUD AND NON-IVUD (MIVUD) HETEROSEXUALS IN SOUTHEASTERN NEW ENGLAND

Meyer, Kenneth; Zierler, S.; Falgout, I.; Lauffer, D.
 New England Behavioral Health Study (NEBHS), Brown University, Providence and Memorial Hospital, Pawtucket, RI, USA.

Objective: To compare sexual behavior and risks of HIV transmission or acquisition of white IVUD and MIVUD in an area where > 1/3 PWAs are IVUD and the prevalence of non-HIV STI is lower than the U.S. average.
Methods: Cross-sectional analysis of in-depth interviews and serologies from the first 175 white enrollees of a community-based prospective study of the heterosexual spread of HIV in New England among self-identified high risk heterosexuals. The full cohort is 813 white.
Results:

	IVUD (%) (n=212)	MIVUD (%) (n=113)
HIV seropositivity	40%	3%
> 1 partner for the past year	61%	21%
> 50 lifetime partners	36%	21%
Sex with an IVUD	61%	21%
History of STD (ever)	45%	30%
Always used condoms for the past year	12%	5%
Never used condoms for the past year	43%	44%

Conclusion: Although IVUDs are more likely to be HIV+ than MIVUD and have sex with other IVUDs, a higher percentage of IVUD always used condoms. Routine condom use was uncommon in both groups. Heterosexual transmission of HIV among white IVUDs was documented. HIV+ IVUD frequently had sex with MIVUD and a subset of HIV+ IVUDs are continuing to place themselves at increased risk for acquiring HIV.

Th.D.P.80 RISK FACTORS FOR TRANSMISSION AND CHANGES IN RISK BEHAVIOUR AMONG IV DRUG ADDICTS (IVDA) IN GENEVA

Robert Claude P., Delgion J., Hirschel B., Pujuguet de Melédine, Div. of Infectious Diseases, University Hospital, and Ermitage Foundation, Geneva, Switzerland, phone 41 22 24 64 18.

Objective: To evaluate risk factors and behaviour with regard to transmission of HIV. Methods: IVDA serum samples were collected since 1983. From 1983 to 1988, IVUDs were interviewed once (223 IVDA), twice (115), and more than twice (30).
Results: Among antiretroviral addicts in an outpatient methadone maintenance program, seroprevalence increased from 7% (5/70) in 1981 to 36% 56/154 in 1988. In 1986-1988, however, 47/88 (53%) of IVDA patients were seropositive.

Table 1 Sharing of needles and syringes (sharers) and non-use of condoms.

Hiv status	before 1987		1987 and 1988	
	sharers*	no condoms	sharers*	no condoms
Seropositive	91% (44/70)	88% (34/56)	5% (2/43)	54% (29/69)
Seronegative	82% (28/34)	50% (46/49)	29% (7/14)	75% (24/32)

*among those still injecting
 10% of men have had sexual relations with homosexuals, and 80% with other IVDA. Among a subgroup of 53 HIV+ IVDA, 31 had a stable sexual partner. Of 18 partners tested, 11 were HIV+, in a sexual transmission was the only probable route of infection.
Conclusion: Among IVDA in Geneva, sharing of needles and syringes has greatly decreased since 1986. However, there remains a potential for sexually transmitted infection. Future preventive strategies aimed at IVDA's must take this into account.

Th.D.P.82 A COMPARATIVE ANALYSIS OF HIV INFECTION AMONG IV DRUG USERS IN TREATMENT AND ON THE STREET

McDory, Clyde L.; Chitwood, D.B.; and Page J.A.*
 *University of Miami School of Medicine, Miami, FL, USA.

Objective: To compare the seroprevalence of HIV among IVUDs in treatment and on the street and to determine the difference in distribution by age and ethnicity/race.

Method: Two separate studies in the Miami metropolitan area have recruited 500 IVUDs respectively from drug treatment programs and from the street. Blood samples were drawn from the clients within the treatment program, or for the street sample at a centralized assessment center at the medical school. Pre and post test counseling were provided in similar fashion to each of the groups as they were given similar assessments of their sex, drug and other histories.

Results: The street population indicates a much higher seropositivity (33%) than the treatment population (13%). Ethnic data indicate no exception, showing more males to be seropositive in treatment (16%) than in the street population (8%). The treatment population is predominantly white (74%), whereas the street population is predominantly black (83%). However, in versus 61 white in the treatment population, 315 black versus 174 white (at the street). Overall, females are of greater seropositivity than males.
Conclusion: It is extremely important to actively recruit and establish prevention and control measures for the street population of IVUDs, as well as for those in treatment because of the potential high risk for transmission of HIV.

Th.D.P.84 PSYCHOEDUCATIONAL GROUP APPROACH TO AIDS PREVENTION WITH DRUG ABUSERS IN RESIDENTIAL TREATMENT: IMPACT 6 MONTHS AFTER INTERVENTION

Sorlessen, James J.; Gibson, D.L.; Reitzman, G.; Dumontet, R.; Costantini, M.; Melrose, J.; et al.
 Center for AIDS Prevention Studies, UC San Francisco, CA USA

Objective: To assess the impact of 6-hour psychoeducational groups on the AIDS knowledge and attitudes of drug abusers completing residential treatment.

Methods: 96 drug abusers in the latter stages of treatment were randomly assigned to receive a 6-hour group protocol or a set of brochures about AIDS. Assessment interviews occurred before randomization, after the intervention, and 6 months after the pre-assessment. Subjects averaged 84% attendance at training. HIV tests were reached for the post-interview, and 81% (of 79 due to data) have been reached for 6-month follow-up. Measures were designed to tap AIDS-related knowledge, risk, perceived threat, response efficacy, self-efficacy, communication skills, and social supports.
Results: There was a significant effect at the post-interview in the expected direction in knowledge of AIDS risk ($p < .006$) and a trend in the expected direction in self-efficacy ($p = .07$). 6 months the knowledge difference had faded, but the differences in perceived self-efficacy had become more pronounced ($p < .02$).

Conclusion: Conducting AIDS education groups in a residential treatment setting can increase participants' knowledge and change some attitudes that put them at risk of acquiring or transmitting HIV. Further research and interventions are needed that are more focused, potent, and long-lasting.



Le SIDA et l'individu
AIDS and the Individual

Session d'affichage
Poster Session

Th.D.P.86 AIDS AND SUBSTANCE USE EDUCATION AND PREVENTION: A COMMITTEE-BASED APPROACH.
Allen, David; Beckman, R. W. and Shyne, G.***
 *Municipality of Metropolitan Toronto, Toronto, Ontario, Canada.
 **Alexandra Park Community Centre, Toronto.
 ***Health Care Consultants (HCC), Toronto, Ontario, Canada.
Objectives: 1. To provide the information and behavioral change skills necessary for prevention of AIDS to substance users. 2. To train workers in effective training techniques for bringing about knowledge and behavior change in substance users. 3. To assure that all those in need have access to bleach and syringe-exchange education programs and related services. 4. To provide advocacy for substance users.
Methods: With personal financing, volunteer labour, donations and the various resources available to community groups, this program initiated AIDS and substance use education (including workshops for workers), provision of bleach-kits, opening of syringe-exchange education programs, and assessed advocacy for substance users. The program relied on community support and networking, free services from health-care and other professionals, and the donation of money, time and supplies from many sources. The key component of this program appeared to be community concern and networking.
Results and Conclusions: Nearly thousand bleach-kits have been distributed through this program. A number of community groups now offer syringe-exchange education programs; a mechanism for formal training of trainers in AIDS care has also been established; general public education on AIDS and substance use is ongoing; advocacy for substance users is increasing in strength. In the absence of government leadership or funding, community groups can effectively provide AIDS education, prevention, and other services if they use networking and shared resources.

Th.D.P.86 MANAGEMENT OF HIV-INFECTED FEMALE IVDA'S
Friedmann*, Schfer, Axel*, Heckmann, Eck*, Schwärtdländer**.**
 *Department Obstetric and Gynecology, Freie Universität Berlin
 ** AIDS Research Center, Bundesgesundheitsamt, FRG
Objective: To evaluate the effects of methadone treatment in a clinical center for Gynecology.
Methods: Maintenance to abstinence by step wise reduction in three different groups of a total collective of 71 women.
 Group 1: 31 HIV-negative pregnant women
 Group 2: 19 HIV-positive pregnant women
 Group 3: 21 HIV-positive non-pregnant women
 Evaluated by clinical documentation and drug tests (salivary). In group 1 39 % reached total abstinence before delivery, in group 2 only 16 % and in group 3 67 % reached total abstinence during period of in- or out-patient care; significant differences were found between in-patient and outpatient care.
Conclusions: Maintenance programs are not very common in the FRG
Results show, that indications of methadone treatment should be very selective. The sources of maintenance - to abstinence depends on very different factors, such as drug status, social support, clinical program, personality, and serology of HIV.

Th.D.P.87

--	--

Counseling
Counseling

Th.D.P.88

CHANGES IN THE SEXUAL BEHAVIOR OF HIV INFECTED PATIENTS PARTICIPATING IN A PCIP PROCESS.
David L. Garcia L., Salame E., Hernandez MP*
 *Division of Epidemiology, Ministry of Health, Mexico
Objective: To induce changes in the sexual behavior and use of condom as a preventive measure of contracting HIV sexual transmission. In a group of HIV seropositive homosexual men.
Methodology: 38 seropositive, homosexual, asymptomatic, unmarried men, aged between 18 and 45 years old requesting psychological support were selected. The individuals were assigned to 3 groups: A (3 months), B (6 months), C (1 year), (60 sessions, 1 x wk). Several psychosocial group techniques, such as interpretation and free association, were used. Killing fantasies, inability to establish total object relations, hostile feelings towards homosexuality, uncertainty of presenting clinical symptomatology and dying were interpreted in group sessions with the purpose of promoting condom use and modifying risky practices. Changes were evaluated at the end of 4 sessions.
Results: The results are presented in the following table:

	GROUP A		GROUP B		GROUP C	
	Pre	Post	Pre	Post	Pre	Post
BEHAVIOURS	No.	No.	No.	No.	No.	No.
Use of condom	0/12	11/12	0/12	12/12	0/12	10/12
Safe Coitus	2/12	2/12	3/12	6/12	6/12	4/12
Hostile feelings for being homosexual	4/12	4/12	6/12	3/12	12/12	3/12
Unpleasant presenting symptomatology	12/12	12/12	12/12	12/12	12/12	12/12

 Groups A and B and 6 months groups were associated with changes in sexual behavior, the one year group structural changes and in the condom's use.

Th.D.P.89

COUNSELLING AND EDUCATION ON AIDS.
Quares, Eleonora Paji, Rendic de Lacerda, M.C., Neman, J.J.L., Lemp, P.P.F., Moore, C.M., Carvacho Melo, L.L. et al.
 *Officer at a Public University Hospital - University of Rio de Janeiro - Brazil.
Objective: To inform people about AIDS transmission/acquisition, prevention, safe sex and the disease.
Method: Psychiatrists, psychologists, social workers and nurses during private sessions at a HIV-1 outpatient unit of our hospital and at conferences in schools, churches, poor communities, bars, industries and other groups; either multiprofessional lectures where all aspects of AIDS are explained or case studies and other exercises with simple language to be easily understood. After the explanation there is an interactive question session when all the remaining doubts are solved.
Results: The most common questions are about oral, anal, vaginal sex, kiss, meninges, mosquito bite, syringe, vaccine, cure, blood transfusion/blood tested, when to find the AIDS test, when to find treatment. It was more difficult to explain, be understood and be accepted: all information about condom/safe sex when talking to male adults. There is a greater concern among women than men about learning how to explain or talk about AIDS with their children. It was difficult to talk openly about sex and drugs with adolescents because teachers and parents are not prepared to cope with sex and drugs subjects.
Conclusions:
 1. Despite being a volunteer work without any support, we are doing our best.
 2. More support should be given for counselling and education on AIDS because they are the only way to stop the AIDS epidemic.
 3. A special attention should be given to adolescents because they are learning about life, love, sex and drugs at this very moment and they have the right to live long.

Th.D.P.90

HIV-AIDS Counselling & Collaborative Project
Gowanlock, Kenneth and Findlay, Joel, Federal Centre For AIDS
 Ottawa; Carballo, Manuel, Global Program on AIDS, World Health Organization, Geneva/SWITZERLAND
 There is a growing need to enhance the availability and quality of counselling for persons with HIV infection, those with AIDS, their families and others affected.
 The Federal Center for AIDS Canada, in collaboration with the WHO/GPA and collaborating Canadian provinces has developed a planning approach for improving, expanding and maximizing existing counselling resources in order to increase the capacity for HIV counselling in any community. This initiative, a world first, examines, defines, and facilitates development of the common elements of counselling needed when dealing with HIV and AIDS. The approach looks not only at a common methodology for such counselling but at necessary co-ordination of existing services for the strengthening and expansion of counselling networks. Implicit in the approach is the enhancement of collaboration between health, social service and community based organizations.
 This presentation will highlight training needs both in the formal health-social service system and in the broader community based non-governmental area, and provides for this training to be put in place.

Publications



Section D

Le SIDA et l'individu AIDS and the Individual

Les adolescents

D.501

EXTRAORDINARY WITHOUT ORDINARY SEXUALITY
Seth L. Baker, Director, Sexuality Division, Calgary Health Services, Calgary, Alberta, Canada

Objective: Education emphasizing negative aspects such as, AIDS, STD's unwanted pregnancy focuses on "extraordinary sexuality". When negative information is stressed, social and behavioral strategies necessary for the integration of information and utilization of preventive actions are missed. PARENTS need to shift from a focus on extraordinary to ordinary sexuality.

Method: The Board of Health approached Calgary School Boards to present PARENTS on the extent of adolescent sexual activity, STD, and ectopic pregnancy. Current piecemeal and optional approach to sexuality education was compared to negative results of sexual activity. The Board of Health recommended that sexuality education programs be mandatory for all students. **Result:** Both school boards accepted the proposal and schools will have a comprehensive, sexuality education curriculum provided to all students by 1990. The Board of Health committed funds to training, inserviceing and support of teachers in the school system. **Conclusion:** In order to promote safer sexual behavior, public health and school officials must ensure that all students receive not only cognitive information about sexuality, but also a comprehensive curriculum that will examine feelings and the behavioral skills in order to practice safer sex techniques. To accomplish this, AIDS education must be placed in the context of comprehensive, compulsory, sexuality education. Public health agencies can have an impact of the decision to provide such education to a community.

D.503

**THE USE OF ONE EFFECTIVE MEDIUM - TELEVISION
TO REACH CANADIAN YOUTH AND PARENTS ABOUT HIV
AND AIDS**

Liebold, Heidi M., Federal Centre for AIDS, Health and Welfare

As a result of the Canada Youth and AIDS Study conducted with 38,000 youth across Canada it was found that a high majority of Canadian youth have received their information about AIDS from television. The Canada Youth and AIDS Study is representative of Canadian youth in grades 7, 9 and 11, first year University/College, Dropouts and street youth. Television as a main source about AIDS was not only prevalent in the in-school population but also those out of school such as dropouts and street youth. In response to this, the Federal Centre for AIDS of Health and Welfare Canada commissioned to undertake three national film productions. Two of these film productions are focused on youth and the third on parents. One of the youth productions will focus on the 12 to 14 year olds and the second on 14 to 16 year olds. The film production for the older population will have an original story and corresponding rock video segment that will be released separately and reinforce the messages of the film production. The parent film will provide parents with the needed information on HIV, AIDS and healthy sexuality but will focus on how parents can effectively communicate this information to their children.

D.505

**LE SIDA EN AFRIQUE CENTRALE - SYSTEMES D'INFORMA-
TION DES PARENTS ET DES ADOLESCENTS**
EVALUATION

• Département de Psychologie et de la Presse, Linguistique, Kinésithérapie, Centre de l'Éducation Nationale, Gombe, Kinshasa, Zaïre

Objectif: Évaluer le synergisme du rôle des médias ainsi que des hommes et des systèmes d'information sur le SIDA parmi les adolescents en Afrique Centrale.
Méthodes: Une enquête par sondage d'opinion relative à la perception du message sur le SIDA était menée parmi 3000 adolescents à Kinshasa (Zaïre) dont une moitié scolarisée et une autre non scolarisée en 1986.

Résultats: L'enquête a montré une l'indice de performance et d'efficacité des messages d'information est très faible. Leur acceptation est insuffisante pour le besoin d'une fonction d'intégration d'une forte proportion des adolescents (34,6%). Les résultats sont significatifs (96,9%) pour les scolarisés en ce qui concerne la perception du message et moins (50%) pour les autres. Cela se traduit aussi au niveau des canaux de communication.

Conclusion: Il faut agir sur un ensemble de reconstructions en vue d'améliorer les systèmes d'information opérationnels sur les perspectives de prévention et de traitement du SIDA, ainsi qu'au rôle des médias. Enfin, des suggestions sont aux variables immédiates à incorporer dans les programmes de santé publique sur le SIDA en Afrique Centrale.

D.502

**TITLE: HIV SEROPREVALENCE AND DEMOGRAPHIC SURVEY OF
INCARCERATED ADOLESCENTS**

Author: Baker, Charles J., Ba, O., Morris, R., Marcott, S., Rosenberg, J., and Schuller, R.

Journal: Court Health Services, Los Angeles County, California, USA

OBJECTIVE: To determine HIV Seroprevalence and I.V. drug abuse factors in adolescent incarcerated within the Juvenile Hall, County of Los Angeles.

METHOD: Blood samples were collected anonymously from 2,005 youngsters. **RESULTS:** The following were recorded: Age, Sex, Race, history of I.V. drug abuse and SGP/SGOT testing.

RESULTS: Only two samples were positive by ELISA and Western blot tests. 90% of the youngsters were between 15 and 17 years of age. 92% of were male. 69% were hispanic. 21% were black and 13% were white. History of I.V. drug abuse were recorded in 24 and 34 received SGP/SGOT tests.

CONCLUSION: HIV Seroprevalence this survey (0.099%) compares favorably with the 0.16 determined 1-1/2 years ago in the same type of population. This prevalence may suggest greater awareness of high risk behavior for AIDS among adolescents.

D.504

**A MODEL-DRIVEN AIDS EDUCATION AND COUNSELLING FOR
ADOLESCENTS IN AN IHO**

Blumenthal, C.J., Mc Schram, S., Mc and Long, G. Mc
Kaiser Permanente Medical Care Program, San Francisco, California and
Los Angeles California, U.S.A.

Objective: Within a pre-paid health plan population of over 5 million members, a targeted intervention model has been developed to identify adolescents at high risk for becoming infected with the AIDS virus.

Method: All health plan members age 12-21 who present for a health care visit by appointment are given a brief questionnaire to be completed in the waiting room before the encounter begins. Highest risk simple, brief questions about sexual activity and other risk behaviors are asked. A rapid review of the completed questionnaire allows the counselor to determine if the adolescent is at risk, no risk, or potentially at risk for AIDS. The questionnaire, once reviewed, is discarded, is not a part of the medical record, but allows a one to one confidential exchange between the teen and counselor. Those adolescents who are identified at risk are referred to a prevention counselor for evaluation of risk behavior, education on AIDS prevention and HIV testing, and most importantly, behavior modification. All adolescents referred to the model for counseling are re-evaluated in several months; behavior and risk taking is reviewed; education is reinforced. Adolescents not at risk are referred to an education component of the model.

Conclusion: Intervention affecting adolescent behavior change may be one of the most definitive methods of preventing high risk adolescents from becoming the next wave of the AIDS epidemic in the 1990's. Information alone is not effective in changing users' risk behavior. Our model of intervention in a nationwide HMO has the potential of changing the behavior of over a million adolescents in the USA.

D.506

**STRENGTHS LIFE EVENTS AND SOCIAL SUPPORT AS PREDICTORS OF
SAFE BEHAVIORS AMONG HERMAN AND GAY YOUTHS**

Rosenberg, Clara and Robinson-Davis, M., Bradley, J., and

Koopman, C., New York State Psychiatric Institute and Columbia University, New York, NY, USA

Objective: To evaluate the effectiveness of stressful life events and social supports as mediators of safe sex behaviors among runaway and gay youth.

Methods: A review of the literature, focus groups, and a chart review in community agencies were used to construct measures of stressful life events and social supports for runaway and gay youths. Test-retest reliability and internal consistency appear high for both measures. Ninety-five runaways and 30 gay youths were interviewed regarding their sexual behavior in the last three months, life events, and social supports.

Results: Runaways have four times the number of stressful life events as Hermans; however, 33% have had a death in the last three months. 12% were physically assaulted, and 20% raped in the last three months. The sexual behaviors of those in the social support network is most highly correlated with the adolescents' unsafe sex and drug use behaviors. Gay youths perceived their parents as less supportive and themselves as needing support more than runaway youths. Neither life events nor social support were significantly correlated with high risk behaviors. **Conclusion:** Life events and social supports may not be the most critical mediators of high risk behaviors among these groups.

Publications



Section A

Le SIDA et l'individu AIDS and the Individual

- D.507** RISK FACTORS ASSOCIATED WITH A HISTORY OF SEXUALLY TRANSMITTED DISEASE AMONG ADOLESCENTS
Diclemente, Ralph, J. Forest, K.**, Wickler, B.***
** University of San Francisco, California, USA
*** Vassar College, Poughkeepsie, New York, USA.

Objective: To identify a profile of risk factors associated with a history of treatment for sexually transmitted disease.
Methods: A national sample of 1,129 college undergraduates, ages 18-23, completed self-administered questionnaires assessing knowledge, attitudes about AIDS, prevalence, type and frequency of sexual behaviors, frequency of condom use and history of treatment for sexually transmitted diseases.
Results: Women and minorities were twice as likely to be treated for an STD compared to males or Caucasians. (Prevalence Ratio (PR) = 2.0, Risk Confidence Limits (CL) = 1.4 - 2.8, P=.007) PR=1.9, CL=1.4 - 2.6, P=.001 (respectively). Unprotected sexual intercourse was also associated with a positive history of STDs (PR=1.3, CL=1.0 - 1.4, P=.09). Students with multiple sex partners and a higher frequency of sexual intercourse were also more likely to have reported medical treatment for an STD (PR=1.7, CL=1.3 - 2.3, P=.003; PR=1.3, CL=1.1 - 1.5, P=.007, respectively).
Conclusion: Identifying adolescents' behaviors which significantly increase the risk of STDs permits development of more effectively targeted education programs.

- D.509** EVALUATION OF A TARGETED AIDS/HIV EDUCATION PROGRAM FOR SECONDARY SCHOOL STUDENTS IN A MIDWINTER CITY METROPOLITAN AREA
Coppola, A. Greg*, Kistner, R.*, Ross, J.*, and Kurwin, M.*
*Marshall University, Huntington, Tennessee, USA

Objective: To evaluate change in AIDS/HIV knowledge level among secondary school students following a targeted education program.
Method: An education program was developed involving a minimum of two hours by trained health teachers. The curriculum stressed HIV modes of transmission and risk reduction measures. 500 students were pre- and post-tested with this intervention. The testing instrument: asked five demographic questions and 15 cognitive questions. Instrument sheets were also coded by health teacher.
Results: There was an overall gain in knowledge with the mean of correct responses increasing by three points on post-test scores as compared to pre-test scores. Sex, race, age, grade level, and residential area did not account for differences in pre- or post-test results. Significant differences in this student knowledge level were found in the post-test by teacher codes; such differences on pre-test results were not significant.
Conclusion: A targeted education program for secondary school students can increase knowledge about AIDS/HIV. Differences in the success of the intervention by classical demographic variables were not significant. Significant differences in the success of the intervention were found in regard to teacher codes. Based on the study results, the curriculum itself successful, however, this success was varied by teacher. Such variation suggests improved teacher training in the delivery of AIDS/HIV education.

- D.511** INTERVENTION MODEL: WORKING WITH GAY AND LESBIAN YOUTH AT RISK FOR HIV INFECTION

Hunter, Joyce MEd, CM

Herrick-Narwin Institute, Inc. New York, New York, USA.

Objective: To develop an effective, comprehensive intervention program for gay and lesbian youth who are at risk for HIV infection and train professionals to work with this population.
Method: The methods used are focus groups for youth, workshops, and community forums. We have worked with over 1,500 youth in the last year and a half. We also conduct semi-structured focus groups (four per week) and one per week for professionals. The young people that we work with are self-identified gays and lesbians. Seventy five percent of these adolescents are minority youth, ages 12-21 (55%).
Results: Development of training manual, printing and publication of articles and brochures.
Conclusions: Materials for this population must be specifically tailored for these adolescents and the professionals who serve them. In contrast to current U.S. providing explicit safer sex practice and guidelines instruction, these materials need to be extremely explicit sexually. Also, these materials need to reflect and acceptance of homosexuality.

- D.508** A COMPARATIVE ANALYSIS OF RISK BEHAVIORS AMONG A SCHOOL-BASED AND JUVENILE DETENTION FACILITY SAMPLES OF ADOLESCENTS IN SAN FRANCISCO, CALIFORNIA
Diclemente, Ralph; Duhan, R.
University of California, San Francisco, California, USA.

Objective: To describe a comparative risk behavior analysis of adolescents residing in a juvenile detention facility (JDC) and a school-based sample.
Methods: Adolescents, ages 14-18, attending high schools in San Francisco (N=802) and incarcerated at a juvenile detention facility (JDC) (N=113) completed identical self-report questionnaires assessing AIDS-related risk behaviors. Surveys were anonymous and completed during the same time-period.
Results: Significant differences in the prevalence of AIDS-RELATED risk behaviors were identified between the two samples. Adolescents at JDC report a higher lifetime prevalence of intravenous drug abuse (12.8% vs 3.7%, P=.003; PR=3.5, CL=1.8-6.7); more than three lifetime sex partners (86.4% vs 51.8%, P=.000; PR=1.7, CL=1.6-1.9); a greater proportion with multiple sex partners in the past year (84.8% vs 46.0%, P=.000; PR=1.8, CL=1.5-2.2); and an earlier age of sex onset (P=.0006).
Conclusion: Adolescents in juvenile detention facilities report a significantly higher prevalence of AIDS-related risk behaviors which substantially increases their risk of acquiring and transmitting HIV infection.

- D.510** KNOWLEDGE OF HIV TRANSMISSION AND ADOLESCENT SEXUAL BEHAVIOR

Wolke, D.**, Ziffer, A.**, Bywater, M.**, Bywater, L.*
*Rollins College, Winter Park, Florida 32789, U.S.A.

Objective: To assess how the knowledge of HIV transmission affects the sexual behavior of the adolescent.
Method: A survey of 210 students, 107 men and 103 women in 9th to 12th grade, was completed. Knowledge of transmission of AIDS, sexual activity, change in sexual behavior, and source of educational information on HIV infection was assessed.
Results: Of the adolescents surveyed, 67% of the men and 40% of the women were sexually active. Of those who knew the routes of HIV transmission, 56% of the men and 34% of the women had changed their sexual behavior. Of those who did not know the routes of HIV transmission, 70% of the men and 42% of the women were sexually active. Only 9% of the men and 12% of the women admitted they lacked accurate information about transmission of HIV infection. A full 60% of those surveyed operate with misinformation. Regardless of sex, sexual behavior, and accuracy of information, radio/television and magazines were reported as the most frequent sources of information about HIV infection. **Conclusion:** Adolescents are participating at alarming rates in high risk sexual behavior. While those most likely to be involved in high risk sexual behaviors are those with inaccurate information, what is disturbing are the numbers who know the risks but fail to alter their sexual behaviors.

- D.512** REPORT OF CMHA'S COMMITTEE ON SERVING CHILDREN AND YOUTH WITH HIV INFECTION IN RESIDENTIAL GROUP CARE.
Ezery, L. Jean*, Anderson, G. M.**, M. J. MD, Horowitz, R.W., Esq., Gitelson, P., Amin, J., East, J.P., et al.
*Child Welfare League of America, D.C. USA

Objective: To address issues of concern to Board members, executives, administrators, clinicians, and care staff and volunteers surrounding the care of children and youth who are emotionally disturbed, infected with HIV, and in need of therapeutic residential group care.
Method: A subcommittee of the Task Force on Children and Youth Infection undertook the challenge of writing a Guide for Residential Group Care Providers. Experts in legal, medical, and psychosocial issues associated with HIV met with experts in providing services to children who not only exhibit behaviors which put them at high risk for HIV infection, but who are also emotionally disturbed and who might have suffered abuse or neglect at the hands of their parents.
Results: The CMHA subcommittee 1) identified issues associated with administration, advocacy, and public policy, program procedures and prevention; 2) identified specific responses to those issues; 3) suggested strategies to achieve them; and 4) practices. **Conclusion:** It is feasible and appropriate to provide care and treatment of HIV-infected children in residential group care.

Publications

Le SIDA et l'individu
AIDS and the Individual**D.531** CHANGES IN SEXUAL BEHAVIOUR OF GAY MEN UNDER THE IMPACT OF AIDS. II

Bochow, Michael; Markert, Stefan
INTERSOZIA, Berlin (West); FEDERAL REPUBLIC OF GERMANY

Objective: To analyze whether further changes in sexual behaviour of gay men are still taking place and whether those already identified in a previous survey (1987) have proved to be stable.

Methods: A questionnaire of 62 questions on different topics relating to sexual behaviour and lifestyle of gay men was circulated by the seven most important gay journals in West Germany in October 1988. The questionnaire is almost identical with the questionnaire distributed for a first investigation in 1987. The 1988 survey is therefore a replication study. The response amounted to 122 questionnaires in 1987 (1987 = 100%).

Results: A preliminary assessment shows a remarkable stability of changes in sexual behaviour of gay men in West Germany. Low risk sex has proved to be accepted by an important majority of gay men. Gay men with a stabled gay identity are also the most successful in coping with the risk of HIV infection.

Conclusion: Efforts in prevention activities targeting specific subgroups of gay men are still to be intensified, namely gay men with a lower level of education and men with covert homosexual activities.

D.533 IMMUNE MODULATION FOLLOWING THE DEATH OF A COHORT: AN ANIMAL MODEL OF PSYCHOLOGICAL STRESS IN AIDS

Yashkovski, Eli; Shalonsky and Prince, E. Aron
Laboratory of Neuroendocrinology, NIDDK, National Institutes of Health, Bethesda, MD, U.S.A.

Objective: The psychological stress, experienced by AIDS patients following the death of their sexual partners or close friends, has been suggested to influence immune functions. An attempt was made in these studies to establish an animal model for this type of psychological stress.

Methods: We examined immune functions among several mouse strains (C57/BL₆, AKR/J and BALB/c) following the death of a cage-mate. Mice were housed in groups of five. At 48 hr intervals, one cohort was killed by cervical dislocation and returned to the home cage. Behavioral responses of the remaining cohorts were noted for 7 hr following each exposure. At the end of four such exposures, natural killer (NK) cell activity was measured in the remaining cohort.

Results: Fighting among the cohorts and biting carcasses were frequently observed in the C57 and AKR but not in the BALB/c mice. Lying carcasses, setting with carcasses were seen more frequently in C57. NK cell activity was significantly suppressed in C57 but not in AKR and BALB/c.

Conclusions: These results suggest that 1) the degree of psychological stress experienced following the death of a cohort differ between different haplotype strains, and 2) such behavioral changes can influence immune functions.

D.535 BEHAVIOUR MODIFICATION STRATEGY IN AIDS PREVENTION

LEWIS, RICHARD; HARRIS, CONSTANCE; AIDS Task Force, I.H.C. Hedley; SOBEL, MD, Health Education, National AIDS Program, Baltimore, BRUNELL, RALPH
Report on an experiment in Baltimore and a discussion on methodology objectives. To promote participative training models for health educators involved in AIDS prevention directed at behavioural change for specific target groups.

To establish the most effective method for each objective and target group.
Method: Theoretical background and practical experience lead to the use of participative methods by the training of health educators in Baltimore. Representatives from different target audiences were trained in information, group work and communication.

RESULTS: Experience indicates a close relationship between the training methods used and the output. Depending on the setting, the degree of personal involvement and the method procedures, changes are obtained in subsequent levels: knowledge, motivation, attitude and behaviour. For example, a lecture or an article provoked a change in knowledge while attitudinal and behavioural change lasted more or less transient. A synthetic table indicating correspondence between method and output is proposed.

CONCLUSIONS: Prevention can be made more effective when methods correspond more to the expected modifications. A differential target audience should also be used for outcome evaluation. The focus of the prevention campaign being behaviour modification, more resources are required for training of trainers, research to devise effective methods and evaluation of the outcome.

D.532 MODIFICATIONS OF AIDSOPREVA AT AN OUTPATIENT CARE UNIT IN RIO DE JANEIRO

BRAGA,
Luigi; Paulo Henrique Pinheiro; Carvalho Neto, L.O.; Sion, F.S.; Moura et al. C.A.

Caffare's Gulinie Hospital, University of Rio de Janeiro (UAC-400) - Brazil.

Objective: To study the etiology and incidence of seronegative manifestations of HIV negative individuals concerned about AIDS who came to the AIDS Outpatient Care Unit at our Hospital (seronegative states and profiles related to AIDS).

Methods: The study comprised 21 HIV negative individuals (17,084) with AIDSOPREVA selects among 130 patients interviewed, from Feb 88 to Dec 88. We performed physical examination, we used non destructive interviews, immunohistologic support and counseling.

Results: Seronegative manifestations related to the serology are shown in the following table:

Serologic And Signs	N	%
Sexual satisfaction	19	90.5
Clapnetis	15	65.2
Low concentration	10	47.6
Insomnia	10	47.6
Headache	8	38.1
Sex Alterations	3	14.3
Fever	1	4.8
Trying Suicide	1	4.8

During immunohistologic sessions it was observed that all the 21 individuals presented a pre-existing sexual conflict, basically comprising latent homosexual impulses, directed to an external object, as AIDS, a seronegative disease. **Conclusions:** A conflictive sexuality can reinforce the fear of AIDS, causing psychiatric states HIV POSITIVE manifestations that can be confused with non specific symptoms of HIV infection. AIDSOPREVA should be considered when elaborating an AIDS prevention campaign.

D.534 RELIABILITY OF DATA COLLECTED ON SEXUAL HISTORIES IN MATRIAN EMBRISMS IN BRAZIL

Molina, Eli's; Loureiro, F. M.
Genetics Health Department, Montreal General Hospital and McGill University, *Intervista de Montreal, Montreal, Quebec, Canada.

Objective: To evaluate test-retest reliability of a questionnaire on sexual histories administered to Brazilians origin.

Methods: Test-retest reliability of the questionnaire was assessed using 18 subjects (11M, 7F), aged 15-70. The median of the interval between the two qualitative administrations was at 15 days with 13.3% of intervals being 28 days or more. French illiterate subjects were asked only 14 questions related to their sexual history. The 27 most sensitive questions were self administered for French literate subjects, the other 7 questions being administered by interview. Kappa statistic was used for the estimate of reliability.

Results: All obtained kappa were significant at the p<0.0001 level. The lowest values were 0.103 and 0.737 for questions on the change of number of sexual sex and homosexual encounters. Six kappa values ranged between 0.800 and 0.900, 8 were zero to the 0.500 to 0.799 range, and perfect agreement (k=1.000) was found for 18 variables. Areas higher than 0.900 were found for: number (k=0.800), prostitute and time (k=0.800), k=0.500) of lifetime sexual partners and for frequency of condom use with these partners (k=0.800).

Conclusions: Sexual histories can reliably be obtained in the Brazilian ethnic minority of Montreal: these questions are self administered or asked orally.

D.536 THE USE OF THREE BIOPSYCHOLOGICAL INTERVENTIONS ON THE STRESS LEVELS AND MOODS FUNCTIONING OF HIV POSITIVE INDIVIDUALS

HAMILTON, Brian; CHU, J.; Duffault, Ethan; *Bellows Hospital/Community Health Project, NY, NY USA, **Smith College School of Social Work, Northampton, MA USA

Objective: On the premise that personality coping styles are a co-factor in disease prognosis, we are assessing the effects of 3 biopsychosocial interventions on the stress levels and mood functioning of HIV patients.

Methods: 10 seropositive patients underwent an intensive 16-week intervention involving Bioenergetic Psychotherapy, Meditation designed to stimulate Thyroxine gland activity & a structured Journal writing program. Each patient received a complete immune profile & biopsychosocial questionnaires at start, mid & end points with 6 month follow-up planned. Results compared to data collected from comparison group not receiving independent variable.

Results: Preliminary data suggest a trend toward enhancement of immune functioning (noting 40% correlations between overall mood profile including anxiety & depression, & most variables as cortisol and immunoglobulin levels. Therapeutic techniques used were successful in patients learning individual stress management-therefore reducing each patient's overall stress levels as measured by through assessment profiles throughout the study.

Conclusion: We anticipate finding a correlation between biopsychosocial interventions designed to promote stress reduction and positive, enhanced immune functioning. We further hope to show how these interventions can be successfully implemented in overall treatment protocols in the functioning of community-based AIDS Assessment Clinic Programs.



Publications

Le SIDA et l'individu
AIDS and the Individual

D.543

OCCUPATIONAL THERAPY ACTIVATION AT A MULTIDISCIPLINARY TEAM TURNED TO AIDS
MOREIRA, C.E.F.A.A.; TANNUS, L.M.N.; LIMA, M.P.J.S.; BELUCCI, S. B. B.
Centro Geriatrico. (CGCI). Campinas. São Paulo, Brazil.

CGCI a philanthropic non governmental entity, multidisciplinary composed by: doctors, psychologists, nurses, dentists, physical education teachers and occupational therapists. Research based on individual attendances of HIV infected clientele from CGCI, ambulatory, hospitable, domiciliary. The clientele belongs to differ ent risk groups at different infection stages. Their ages vary from 13 to 47. Besides the social stigma aggravation, the exacerbation of pre-existing psychological conflicts takes place, determining the Occupational Therapy activation, being the main objective the quality of life improvement, defined from emerging individual needs, like expression and communication, psychological equilibrium maintenance which results in maintenance or improvement of patients cognitive state, and life or death process acceleration. The Occupational Therapist must consider the social-political-economical and cultural context in order to avoid the restriction of therapeutic process. Results will be discussed, in the presentation.

D.545

THE BRITISH SURVEY OF SEXUAL ATTITUDES AND LIFESTYLES - A PILOT STUDY
*G.J. Field, Anne M. Johnson, **K. Wellings, C.

Hodsworth, *G.A. Wadsworth, **R. Anderson, *R.G. and a multidisciplinary team of Medicine, Health Education Authority, Gen. Merv's Hospital Medical School, Imperial College, London, U.K.

Objective: To assess the feasibility of a major national study of sexual attitudes and lifestyles in a random sample of the British population. **Method:** A stratified multi-stage sample of addresses was taken from the Postcode Address File and one person aged between 16 and 59 randomly selected from each address. Respondents were asked about numbers of sexual partners in different life periods, contraception, homosexuality, sexual practices, drug use, prostitute contact and attitudes towards sexual behaviour. Sensitive questions were contained in a self-completion booklet and completed anonymously through the interview. **Results:** From 1,095 eligible addresses, 774 productive interviews were achieved, a response rate of 67%. Preliminary analysis shows that the sample was broadly representative of the population although men were slightly under-represented. There was marked variability in numbers of sexual partners and specific sexual practices. Those in younger cohorts experienced first sexual intercourse earlier and had higher numbers of sexual partners than older cohorts. The proportion of respondents reporting homosexual experience was broadly similar to comparable European studies. **Conclusion:** Good response rates with no serious biases were achieved relative to other surveys of this nature. This pilot study has established a methodology which will be used in a national study of 20,000 individuals.

D.547

SEXUAL BEHAVIOUR AND ITS CHANGE AFTER HAVING KNOWLEDGE ABOUT AIDS
BRASILIAN UNIVERSITARY STUDENTS.
Dias, M.M.**, Adai, Francisco H.**, Goodson, P.***,
Dias, J.L. * and Vitor, A.***

* State University of Campinas, Campinas, SP, Brazil; ** The Population Council, New York, U.S.A.; *** CIBICOP, Campinas, SP, Brazil.

Objective: To assess the incidence of sexual behaviors that constitute risk of contracting AIDS among Brazilian University students and the degree of information about AIDS on this incidence.

Method: A structured questionnaire on sexual behavior and knowledge about AIDS was mailed to 2000 students of the first two grades of the State University of Campinas. Analysis was performed using SPSS PC.

Results: The percentage of respondents was 37.4%. The percentage of students not using condoms, 77.2% before knowing about AIDS, lowered to 45.6%. The incidence of oral and anal sex did not change after knowing about AIDS. The percentage of multiple partners, higher among males, was 70.5% before and 71.6% after receiving information on AIDS. Analyzing the group that had risky behaviors before, 86.5% persisted in anal sex, 56.4% not using condoms and 55.6% continued having multiple partners. **Conclusion:** Knowledge on AIDS did not modify substantially sexual behavior among students. Educational strategies appear as an urgent need.

D.544

TOWARDS IMPROVING CONDOM USE IN A SEXUALLY TRANSMITTED DISEASE CLINIC
Ridley, Jerry; Brynes, D.***

** East Orange Health Department, Newark, N.J., U.S.A.

Objective: To assess patient knowledge about condoms and spermicides in a STD and HIV infection clinic. **Method:** Twenty four patients (22 men, 2 women), mean age 25.8 ± 5.7(SD), were consecutively interviewed at an Inner City STD Clinic. Their knowledge of condoms and spermicides was evaluated through a questionnaire. **Results:** Fifteen (62%) patients knew what the average cost of condoms was. No one respondent could identify any of the spermicidal brands available on the market, also none of the patients used them. Only 2(8%) patients never used condoms, while 19 (79%) patients used condoms only occasionally. Only three patients had preference to a certain condom type. Five (21%) patients reported occasional rupture of condoms while in use. One patient reported his use of vaselins for additional lubrication. **Conclusions:** These results indicate that current counselling methods may need to be modified. One such modification is to provide each counselor with a sampler rack of the available condoms and spermicides in that particular geographic location. This would allow patients to handle each item individually in order to decide which is more appropriate for their needs. Such an approach will improve condom and spermicidal use in this population at high risk for HIV and STD infections.

D.546

THE HIV SUPPORT GROUP: AN ANALYSIS USING DIFFERENT SOCIAL PROBLEM MODELS AND DIFFERENT INSTITUTIONAL SETTINGS
Nesanel, N.D., Jerry Thomas

Bronx AIDS Community Service Project, Director of Education, N.Y.C. American Village, Inc., Health/RVY Coordinator, N.Y.C., U.S.A., Mercy College, Adjunct Professor, N.Y.C. & Bedford Hills Correctional Facility, Internship and Academic Coordinator, N.Y.C.

Objective: To analyze HIV Support Groups in relationship to five social problem models: medical, social discrimination, value conflict, deviant behavior and labelling. To analyze HIV Support Groups at five types of institutions: residential drug treatment community, methadone treatment program, the criminal justice system (local lock-up, state incarceration, the police, the courts, parole and probation), mental health facilities and general hospitals.

Method: Personal observation and study based upon years of experience. **Results:** Differences in HIV Support Groups have been according to what we used to understand them and the type of institutional setting.

Conclusion: To educate, change attitudes and change behavior, we need to consider what kind of model we use and the differences in the types of institutional settings. More study is needed in this subject.

Counseling
Counseling

D.548

A THREE COMPONENT AIDS ATTITUDE SCALE
Tom, Mohammed B. and Varber, A.
Indiana University, Bloomington, Indiana, U.S.A.

Objective: To plan, implement, evaluate and study AIDS education program, development of a valid knowledge test and attitude scale is essential. The purpose of this study was to develop a valid Likert-type test to assess student attitudes towards AIDS and AIDS prevention. The three-component attitude scale consisting of feeling, belief, and intention to act which is known to be an appropriate way of measuring health attitudes was utilized for the above purpose.

Method: By reviewing related literature, a table of specifications consisting of two conceptual areas was developed. A large pool of Likert-type attitude statements related to the table of specifications was developed using a variety of sources. These statements were reviewed by a jury of experts for clarity and content validity. Based on this collective analysis, a preliminary scale with 30 items was constructed. The preliminary instrument is being administered to a representative sample of 50 college students. The collected data will be subjected to Pearson correlation for criterion of internal consistency; t-test for discriminating analysis of the items and external criterion.

Results: As a result of these analyses, 15 of the most discriminating original 30 items on the preliminary instrument will be selected for the final scale. For validation purposes, the finalized scale will be administered to a representative sample of 300 college students in a major university in the United States. The collected data will be analyzed by using univariate and multivariate statistical techniques in order to evaluate scale performance, validity and reliability.



Le SIDA et l'individu AIDS and the Individual

Publications

D.561 A FORMULA FOR ASSESSMENT OF INDIVIDUAL RISK ACTIVITY FOR HIV INFECTION WITH MODIFICATION FOR BEHAVIOR
Berman, Robert L., M.D., Yale University, New Haven, CT., USA

Objective. To develop a method capable of assigning a probability figure to an individual's risk of contracting AIDS, given his or her individual risk factors and sensitive behavior.

Methods. Numerous reports of clinical and epidemiological studies were analyzed to determine the lowest common denominators for risk factors involved in the spread of AIDS.

Results. The probability of an individual contracting AIDS (IRF) is the product of the probabilities of three factors: 1. the transmission efficiency of the activity (TE), 2. the prevalence of HIV in the area to which the contact belongs (AP), 3. the risk group of the contact (RG).

IRF = TE x AP x RG
 This probability can be modified by utilizing the failure probability of each protective measure taken in the encounter, i.e. condoms, testing, etc. Utilizing this formula gives results comparable to the published observation that are available, and allow for predictions when they are not.

Conclusion. The calculated individual risk probability ratio may be a valuable tool to help assess an individual's risk, and help determine the best specific preventive measures to lower his or her risk to acceptable levels for counseling and educational purposes.

D.563 ART THERAPY WITH HIV POSITIVE PATIENTS, MENDING, RESTITUTION AND HEALING
Farmer, Gill M., Art Therapy Section, Walter Reed Army Medical Center, and the Neurotic Research Group, Washington, D.C., United States of America

Objective. To present the importance and value of creative, expressive activities with HIV positive persons.

Methods. Didactic presentation and 20 minute video. The videotape features approximately 150 slides of art productions (by HIV positive military personnel) synchronized to a musical selection which match the primary emotions expressed in the art work. A poem written and read by a patient opens the slide program. One of the musical selections ("The Way We Were") is sung by a patient; others are music found meaningful by the patients themselves. The didactic presentation describes distinctive features in art work of HIV positive persons and the characteristic changes as the disease progresses. Diagnostic value of drawings to screen for major depression, psychosis, suicide risk, and competency will be outlined. Techniques found to be effective are described, with relevant hypotheses from the literature. Preliminary results using imagery followed by drawing to relieve anxiety, reduce pain, or gain insight into problems will be discussed.

Results. The presentation vividly informs how the HIV positive diagnosis and condition is experienced by patients. Effective interventions using art are presented.

Conclusion. It is important to assist patients to find some meaning for their lives, in order to regain a sense of control and self-esteem. Creative art activities allow patients to provide for their own needs for acceptance, life review, mourning and restitution.

D.565 HIV POSITIVE SUPPORT GROUPS - A MODEL OF INTERVENTION
Solomon, Kargu Rosenholtz, SJ James, RJ Santiago, D, and McLaughlin, N., NYC Department of Health, New York, N.Y., AIDS Program Services

Objective. 1. To provide group support for individuals who have tested HIV positive and their partners. 2. To provide barrier free group services to survivors who have tested positive and experience physical, emotional, and social.

Methods. The Department of Health provides professionally facilitated group services for people who tested positive and their partners and for people with AIDS. All groups run weekly and have an on-going, drop-in format. Participation is anonymous, and there are no fees or intake procedures. There is a strong emphasis on self help and leadership training. Peer support, effective communication and feedback are utilized in order to address relevant HIV issues such as safer sex, safer drug use (with an emphasis on drug free behavior) including utilization of 12 step anonymous program (e.g. AA), health promotion and maintenance, patient notification; positive attitude towards self, and control over lives and HIV status.

Conclusions. HIV support groups are effective models of intervention for those who have tested positive, particularly for those who are substance abusers and their sex partners. The groups serve as an appropriate arena to explore risky behavior including obstacles to behavior change, new and creative ideas regarding negotiating and practicing safer sex, partner notification and becoming drug free.

Results. 1. Participants have been helped to deal with the emotional crisis and transition that a positive test result precipitates.

2. Services can provide group education and information that is essential in slowing transmission and possibly progression of AIDS.

3. This model has helped to empower those who are HIV+ to become leaders of supportive groups in other settings, and has provided training for HIV counselors who wish to replicate this model. By enabling them to work with HIV+ individuals and their partners on a long term basis, groups have reduced the burden frequently observed among HIV counselors.

D.562 A TRAINING PROGRAM FOR COMMUNITY CONSULTING COUNSELING AND TESTING
Author: Rosenblatt, S., Fowley, C., Solomon, Kargu, James, R., Bantamberg, E., Schultz, S., New York City Dept. of Health, New York, NY, AIDS Program Services

Objective: To provide nurses, drug counselors, public health educators, social workers, physicians and other health and social service professionals with the skills needed for advising patients/couples about AIDS and conducting counseling related to HIV antibody testing.

Method: A consulting and testing training program was developed to help professionals overcome the barriers to talking about sex, drug, the implications of HIV disease and death. A five-day, 35-hour course, led by two trainers and limited to 12-16 participants, provides complete and up-to-date information about HIV disease, basic counseling techniques, active listening skills, and development of referral resources. The program is run according to the small group genetic model.

Results: There has been an overwhelming demand for this training. From health and other professionals working in prisons, TB and STD clinics, hospital inpatient and out-patient settings, OAS-DYN and Family planning agencies, and drug treatment programs. Requests have found the course extremely helpful, and more felt the need for additional follow-up in view of the emotional intensity of the issues and the limited clinical supervision in the small group genetic model.

Conclusions: A manual containing the complete curriculum of the five-day course has been prepared to be used by agencies in New York City and elsewhere. In addition, the training unit is planning 1/2-day follow-up sessions and 3-day second stage training programs which include case management, case management, refinement of HIV-related counseling skills, sharing of referral resources and more intensive training in such areas as addiction, death and dying and women's issues.

D.564 UTILIZING A FAMILY INTERVENTION MODEL TO PREVENT AIDS WORKER BURNOUT WITH INNER CITY PATIENTS
Walter, Gillian, The Ackerman Institute for Family Therapy, New York, New York, USA

In many large cities the majority of all new AIDS diagnoses are found in inner city families. These families present as drug using, multi-problem families, most of whom sustain more than one loss from HIV infection. The co-occurring of family problems, the stigmatization of AIDS, and the overburdening of AIDS workers negatively affect the way in which these families are perceived and worked with. Furthermore, workers are demoralized by focusing on the individual patient who inevitably dies rather than seeing AIDS as located within a living system whose future he/she can influence. In two years of consultation to pediatric and adult AIDS projects in inner city hospitals, the Ackerman AIDS team has devised a brief, problem-focused model of family intervention which allows the worker and family to concentrate on problems of survival and future planning. In this model intervention identifies family strengths and additive problem-solving capacities. Members of the extended kin system or other natural networks are identified as resources and invited to become a part of the counseling contact. As the worker comes to see the family as a resource, they become colleagues in care instead of entering into the adversarial relationship that feelings of powerlessness generate. David Reiss' illness/family research has shown that when a family can identify or utilize strengths, illness may provide an opportunity for transformation and change.

D.566 BEREAVEMENT ISSUES FOR SURVIVORS OF PERSONS WITH AIDS
Goldman, Kathleen A., Malone, D., Hospice of Central Iowa, Des Moines, Iowa, U.S.A.

Objective. To determine if survivors of a loved one who died of AIDS have a different social and emotional environment in receiving grief.

Method. Personal interview which surveyed what survivors were doing to handle their grief, what resources they had in the community and if they were accomplishing the tasks of grief.

Results. Grief tasks discussed in terms of the social and emotional environment of PWA survivors. These environmental factors appear to interfere with the resolution of three of the four tasks of grief. The results in survivors experience physical and emotional symptoms stemming from unresolved grief.

Conclusions: A structure for a therapeutic group of PWA survivors is proposed. Grief resolution is the primary goal. Specific structured exercises for facilitating the goals of each task of grief are suggested.

Publications

Le SIDA et l'individu
AIDS and the Individual

D.585 "IMVIT" - A PROJECT EMPLOYING FORMER IVDA'S IN HIV PREVENTIVE AND SUPPORT WORK.
Marti Inaba, Rene Ringold, Paer Nestand, Arvion Lien.
Juroun Saetved, Finn Gunnar, Dept. of Aids Prevention, Oslo City Health and Environment Department, NORWAY

OBJECTIVES: There is a need for new approaches in the HIV preventive and supportive work among drug users. This project, established by the Department of Aids Prevention in May 1987, employs, on a full time basis and with normal wages, both social workers and former IVDA's. The aim is to work out new methods utilizing the special expertise the former IVDA's have, in cooperation with professional social workers.

METHODS: - Support groups for HIV positive former IVDA's, run by a former IVDA and a social worker in cooperation. Strictly for persons not in active drug use. Some of the groups are for women only. - Support groups for active drug users. - Individual counselling. - Couple counselling. - Open doors in the day-time, with high tolerance for users under the influence of drugs. - Informal conversation, coffee. - No formal notes taken, informality and confidence stressed. - The project is being evaluated during the spring of 1989.

RESULTS: By January 1989 the project has run 7 support groups, and been in contact with 70-80 HIV positive IVDA's which constitutes approximately 40% of the known HIV positive IVDA's in the Oslo area. A qualitative evaluation of the methods used will be presented in the paper.

D.587 COCAINE USE DURING PREGNANCY: VALIDITY AND ASSOCIATIONS WITH HIV RISK BEHAVIORS
Richard J. Jansky and Ellen J.
HIV Center for Clinical Behavioral Studies, NY Psychiatric Institute and Sergievsky Center, Columbia University, New York, N.Y., U.S.A.

OBJECTIVE: To assess the validity of interview data on cocaine use during pregnancy, and associations between cocaine use and risk behaviors for HIV infection.

Methods: Over 150 women who delivered at a New York City hospital without receiving prenatal care completed a brief structured interview about their use of intravenous drugs, sexual partners at risk of HIV infection, and cocaine use shortly before delivery. The validity of self-reported cocaine use in the period immediately before delivery was evaluated against the results of a urine toxicology screen obtained from the infant at delivery. The association between HIV risk behaviors and cocaine use are studied.

Results: The sensitivity, specificity, and positive and negative predictive values of the interview data on cocaine use are presented. The odds of engaging in behaviors associated with HIV infection are compared for cocaine users and nonusers.

Conclusion: Associations between cocaine use and HIV infection may vary between populations. Within particular settings it may be important to develop means of identifying cocaine users so that they may be counseled appropriately.

D.589 DEMOGRAPHICS, DRUG USE AND SEXUAL BEHAVIOR OF INTRAVENOUS DRUG USERS (IVDU'S) WITH AIDS
Richard J. Jansky, G.R. Kahl, P.J. Palmer, C. Klein, R.S. Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, U.S.A.

OBJECTIVE: Before demographic, drug and sexual behavior of IVDU's with AIDS. **Methods:** Detailed standardized interview of hospitalized AIDS patients.

Results: 112 hospitalized IVDU's with AIDS participated from 10/84-1/89. Demography: male 72%, female 28%; Hispanic 49%, Black 33%, white 14%; mean race/ethnicity 68; mean age 35 years; unemployed 50%; <12 yrs education 4%; income <10,000 71%; supporting 2-3 people 23%. Drug Use: median age last IV use 17 yrs (range 11-39); 97% used IV heroin (for med and/or 9 yrs); 95% IV cocaine (median 3 yrs), 25% other drugs IV. 2 daily IV drug use 62%; "shorting hallway" use 68%; needle sharing 84% (with homosexual men 20%, family members 2%). Other drugs: alcohol 2 daily 35%, marijuana 84%, mood altering drugs 57%, stimulants 2%. Since 1978 only 31% participated in methadone Rx; 41% were incarcerated. Sexual Behavior: All sexually active since 1978; mean of 2.6 sexual partners in year before AIDS dx (median 1); sex with other IVDU 54%, with other AIDS pt 7%, male with other male 17%, female with bisexual male 12%; 17% treated payment for sex.

Conclusion: In addition to many women and poor minorities, the "first wave" of IVDU's with AIDS is characterized by teenage onset of IV drug use, subsequent prolonged, frequent IV drug use, poly substance abuse, infrequent drug treatment and co-existence of high risk drug and sex behaviors. Intervention to reduce transmission should address these complex, interrelated issues.

D.586 A COMPREHENSIVE AIDS PROGRAM IN A METHADONE TREATMENT PROGRAM
Rosa, Brian Maggi, Connolly, G. Cassidy, P.*
New Bedford Area Center for Human Services, Inc., New Bedford, Massachusetts, United States of America.

Our presentation will consist of an explanation of our methadone program and its six core components related to HIV infection. The components to be discussed are: AIDS education, HIV antibody testing, client advocacy, psychotherapy, and community and street outreach.

AIDS education is mandatory to all clients in our methadone treatment program. Three hours of education is provided within the first three months, and a minimum of one hour is provided every three months. HIV antibody testing is offered monthly on a free, voluntary, and confidential basis to all clients and significant others. This is done with pre/post counseling. Case managers can be utilized by all clients to assist with delivery of services (i.e., housing, legal, social, financial, etc.). Weekly one-hour counseling sessions are required of all clients. Within the context of these sessions, AIDS issues are continually addressed. Groups are offered for professional and support staff. Outreach workers actively educate and refer IVDU drug users to community resources. Health, condoms, and educational materials are distributed freely within the community. Our presentation will demonstrate the effectiveness of this program as it relates to knowledge, attitudes, and behavior change.

D.588 OBSERVATIONAL AND INTERVIEWS DATA ON PATTERNS OF INTRAVENOUS DRUG USE AS RELATED TO HIV-1 INFECTION
Doris J. Roney, Clifford, D.B.*, Berlin, P.C.*, Kawa, H.*, Inciardi, J., McBride, D.C.*, and Clyde B. McCoy*,
University of Miami School of Medicine, U.S.A.

Objective: To demonstrate the utility of data collected in the natural habitats of drug users for constructing intervention strategies.

Methods: In a longitudinal study of 230 street-recruited intravenous drug users (IVDU) in Miami, Florida, the investigators include direct observation of needle using behaviors and solicitation of open-ended interviews on needle using behaviors and attitudes.

Results: In "safe houses" settings, compliance with house rules shapes needle using behaviors, an enforcement of house rules are key targets for intervention to prevent HIV infection. Alternative needle practices are apparently sufficiently flexible to allow change within groups of "shooters".

Conclusion: Data resulting from these procedures provide clear guidelines for intervention but pose problems for rigorous research design. Differential influence of participants in networks of IVDUs may affect documentation studies that use random assignment strategies for testing impact of specific interventions.

D.590 SELF-REPORTED NEED FOR TREATMENT AMONG HIV DRUG ABUSERS IN AN HIV-CLINIC
Truher, Per, Johnson, P.O.** and Hagedorn, L.*
*Karolinska Institute, Department of Psychiatry, Huddinge, Sweden.
**Karolinska Institute, Department of Infectious Diseases, Karolinska Hospital, Stockholm, Sweden.

Objective: The aim of the study was to ascertain whether there is a self-experienced need for treatment of drug abuse at a HIV-clinic. **Methods:** A questionnaire was filled out according to the responses of the patients. Patients were asked about present abuse, present treatment and perceived need for treatment.

Results: After 6 months 111 questionnaires were filled out. The mean age was 33 years and 27% reported no contact with a social worker and more than half (54%) reported no present treatment of abuse. One of 117 reporting, 43% abuse heroin, 35% amphetamine, 23% alcohol, 11% benzodiazepines, 9% hashish with poly-drug abuse by 37% and 87% had intravenous drug abuse. 54% had a desire for treatment, waiting methadone treatment. In a majority of the cases (73%), rehab centers (17%), clinics and detoxification (6%).

Conclusion: This study shows that there is a significant self-reported need for treatment with a self-reported preference for methadone treatment. It is very important to improve and increase availability to specific treatment as this is of utmost importance both from individual and epidemiological point of view and necessary to prevent an extensive spread of HIV infection.

Publications

Le SIDA et l'individu
AIDS and the Individual

D.609 NEEDLE-SHARING PATTERNS AS A PREDICTOR OF HIV SEROPREVALENCE AMONG NEW YORK CITY INTRAVENOUS DRUG USERS (IVDU)
See: Kathleen; Brown, L. S.; Prime, S. J.; Memoio, T. A.; Foster, K. Addiction Research and Treatment Corp., New York City, USA.

Objective: To examine the association between patterns of needle-sharing and HIV seroprevalence among IVDU's in NYC.
Methods: Following informed consent, 210 patients, recruited from methadone maintenance clinics in Brooklyn and Manhattan, were administered a standardized questionnaire in 1987. This sample included 152 blacks, 471 Hispanics, and 85 whites, of which 103 were males and 642 were females. Sera were also collected and tested for HIV antibodies via ELISA and Western blot assays.

Results: The overall seroprevalence rate was 60%. Respondents who did NOT clean their needles were more apt to frequent shooting galleries ($p<0.005$). Those who frequently cleaned their needles were more likely to share needles than those who did not ($p<0.001$). Those who shared needles with the same person for at least one year were more likely to be seropositive ($p=0.062$) and less likely to use shooting galleries ($p<0.001$).
Conclusion: This information suggests that interventions directed at reducing usage of shooting galleries, at least, modifying behaviors in shooting galleries may reduce the incidences of HIV transmission associated with needle-sharing.

D.611 BEHAVIORAL RISK FACTORS OF HIGH IMMUNODEFICIENCY VIRUS (HIV) INFECTION AMONG INTRAVENOUS DRUG USERS (IVDU)
See: Memoio, T.; Brown, L.S.; Prime, S.J.; Foster, K.; Cho, A., and Ajuluobu, D. Addiction Research and Treatment Corporation, New York City, USA.

Objective: To investigate behavioral risk factors among IVDU's, especially focusing on their drug and sexual behaviors, and psychological status.
Methods: In 1986, a total 202 subjects: 162 males and 100 females; 107 blacks, 116 Hispanics, and 35 Whites, were recruited from methadone maintenance clinics in Manhattan and Brooklyn, New York City. After informed consent, a standardized questionnaire was administered by trained interviewers. Also, blood was collected and tested for HIV antibody by ELISA and Western blot techniques.
Results: The overall HIV infection rate was 61%. A significant association between age groups and HIV status was found, $p<0.05$. Frequencies of heroin and cocaine use before enrollment were positively correlated, $p<0.01$. After enrollment in the methadone treatment program, the frequencies of using heroin, cocaine, and marijuana were significantly decreased, $p<0.01$. The HIV positive subjects started using heroin significantly earlier in their age ($p<0.01$) and reported significantly larger number of needle sharing partners at shooting galleries ($p<0.02$) than those who were HIV negative.
Conclusion: Methadone maintenance programs may affectively cut the use of heroin, cocaine and marijuana. Also needed are AIDS prevention programs, focusing on younger age groups and behavioral factors, especially.

D.613 HIV INFECTION IN A SEROPRESENTIVE
See: Roberto, T. J.; Nolis R.; Giustol A.; Mey-Jehly C. For N. Service of Infectious Disease, Hospital "Germes tria e Pajol".

Objective: The greater number of IVDU who start detoxification treatment in Spain come from primary assistance programs (Autonomous Barcelona, Barcelona, Spain).
Setting: A first selection of patients tributary of anti-HIV treatment.

Methods: We included 199 heroin abusers (120 males and 79 females), with an age of 25.6 ± 4.3 years and a time of addiction of 66.4 ± 36.5 months, selected from February 27 to July 8th. We analyzed HIV serology (EIA test) and clinical search for physical signs and symptoms related to HIV infection.

Results: 116/135 (74.8%) were IDU, 28/216 (12.9%) were included in group II, 37/216 (17.1%) in group III and 51/216 (23.9%) in group IV. The greater number (40/101) of group IV were included for infectious diseases not definite as AIDS local spread and/or seroprevalence (met. 1/35) for opportunistic infections not previously known and AIDS criteria (serological confirmation).

Conclusion: We observed important clinical disorders corresponding to advanced stages of HIV infection (group III and IV) in the 75% of apparently asymptomatic patients. Efforts must be directed to this group with the aim to stoppage their drug abuse as previous step for anti-HIV treatment.

D.610 PATTERNS OF COCAINE USE AND ITS ASSOCIATION TO HIV SEROPREVALENCE AMONG INTRAVENOUS DRUG USERS (IVDU)
See: Memoio, T.; Brown, L.S.; Prime, S.J.; Cho, A.; Foster, K.; and Ajuluobu, D. Addiction Research and Treatment Corporation, New York City, USA.

Objective: To investigate patterns of cocaine use and its association to HIV infection among IVDU's.
Methods: In 1987, a total 218 participants: average age=33 years, 361 males and 642 females, and 432 blacks, 471 Hispanic, and 85 Whites, were recruited from methadone clinics in Manhattan and Brooklyn, New York City. After informed consent, a standardized questionnaire was administered by trained interviewers. Also, blood was collected and tested for HIV antibody by ELISA and Western blot techniques.

Results: The overall HIV infection rate was 60%. The HIV positive IVDU's significantly more often injected cocaine intravenously ($p<0.005$). Those often smoked cocaine ($p<0.05$) than the HIV negative. Significant intercorrelations ($p<0.01$) were found between frequencies of IV use of cocaine, heroin, and speedball (heroin and cocaine). Multivariate analysis revealed HIV positive IVDU's were older, more frequently used shooting galleries in the last 5 years, were frequently used IV heroin and cocaine, and less frequently skid-popped heroin (all, $p<0.05$).

Conclusion: IV cocaine use was significantly associated with HIV seroprevalence. Also, patterns of drug use (IV, skid popping, and smoking) were differently associated with HIV infection. Research investigating injecting behavior is needed for AIDS prevention.

D.612 'PREVALENCE OF PROSTITUTION' AMONG FEMALE HIV +VE INJECTING DRUG USERS IN GLASGOW AND THE ESTABLISHMENT OF A HEALTH CARE DROP-IN CENTRE.
See: David J Goldberg, A Thomson, ST Green, JA MacIntyre, and R. G. McDonald, CDS(U) & Infectious Diseases Unit, Ruchill Hospital, Glasgow, U.K.

Introduction: Epidemiological studies in the USA and Europe repeatedly confirm that the major risk factor determining if an individual prostitute becomes infected with HIV is not sexual activity but if they are injectors. The 'prevalence of prostitution' among IV known HIV-positive female drug injectors (DIs) (those clearly stating that they had prostituted) attending one ID hospital was found to be 57% (25/37). However, most initiatives looking at HIV-positivity among prostitutes have come across few who inject drugs; this may result from sampling purely from genouirinary medicine (GUM) clinic attenders and could lead to underestimation of seroprevalence. Concern about HIV and the paucity of health care initiatives directed towards drug injecting prostitutes led to the setting-up of a volunteer-run drop-in centre in May'88.

Methods and Results: The centre operates 3 nights weekly (10pm to 1am) in premises near Glasgow's 'red light' areas. It is advertised solely by 'word of mouth'. Referrals are made available. Health care, health education (strengthening prevention) and access to detoxification centres, GUM clinics and contraception (such as long-acting intramuscular medroxyprogesterone acetate) is provided. All women take away a quantity of condoms, including non-lubricated 'Durex Dry' (favoured by some for oral-genital sex). Up to January 1989, 71 female prostitutes had attended, the majority on several occasions. 76% of them were or had been DIs.
Conclusion: It is clear that some HIV-positive drug injectors will prostitute. Prostitutes who are DIs can be contacted through non-statutory initiatives.

D.614 COMPLIANCE OF MEDICAL FOLLOW-UP IN HIV POSITIVE PATIENTS.
See: Corine B., Blaise G., Dupin JM, Whittle RT, HIV Counselling Clinic, Regional Virus Laboratory, City Hospital, Edinburgh, Scotland, H12 6LH, U.K.

OBJECTIVE: To review medical follow-up compliance in HIV positive patients.
METHODS: The City Hospital HIV Counselling Clinic offers confidential, pre-emptive health counselling for self counselling for self counselling for self counselling as follows: injecting drug users (IDU), IDU prescribed/not prescribed

Methadone (IDU+METH), IDU no METH), homosexual/bisexuals (HB/HB), heterosexual (HT), blood and uninfected (UB). Attendance was divided into Regular (REG); Sporadic (SPO) - maximum of 3 attendances; failure to attend (FTA).

RESULTS: To date 1718 people attended (where 271 tested positive for antibodies to HIV. All were offered regular medical review.

	REGULAR (REG)	SPO	FTA	TOTAL	REGULAR (%)	SPO (%)	FTA (%)
IDU	161 (59)	109 (43)	58 (23)	328 (19)	61 (27)	70 (31)	13 (6)
SPO	56 (21)	25 (10)	31 (12)	112 (6)	24 (21)	11 (10)	17 (15)
HT	167 (62)	112 (43)	21 (8)	299 (17)	41 (14)	31 (11)	7 (3)
UB	117 (43)	100 (39)	124 (48)	341 (20)	114 (33)	114 (33)	22 (6)

CONCLUSIONS: Individuals compliance with medical follow-up (including Reg, dental, practical, and financial inaccessibility of hospital, poor public transport, non-availability of child minder, etc.). These results suggest that IDU attendance is no more than for individuals with other original risk factors.



Publications

Le SIDA et l'individu
AIDS and the Individual

- D.615** SAN FRANCISCO SPEEDBALLS: AN ETHNOGRAPHY OF COCAINE AND HEROIN USERS AT HIGH RISK FOR AIDS
BRUNDA, PATRICK; MARZILLI, E.; FELDMAN, H.
Youth Environment Study, Inc., San Francisco, CA, USA.

Objective. To analyze the practice of speedball (combined cocaine and heroin) use in segments of San Francisco's intravenous drug using (IVDU) population.
Methods. Interviews with active IVDUs and Community Health Outreach Workers (CHOWs), coding, analyzing and evaluating this data.
Results. Speedball use is common among IVDUs in San Francisco, particularly among older career heroin addicts. It may involve greater injection frequency than use of heroin alone. A significant portion of people on methadone maintenance continue to inject cocaine, and using a syringe to measure out two doses has been observed. All of these may put speedballers at higher risk for AIDS, in addition to needle sharing.
Conclusions. Focused ethnography can provide answers to questions about specific IVDU behaviors such as speedballing, and this is useful in designing outreach strategies to reduce the spread of AIDS.

- D.617** Support Groups for Drug Users Affected by HIV and AIDS
STANBY, DANIEL; MARSHO, RICCIO, SIVY, YOGAHTI, HANSON
MILITZ, BERNARD; BAWAKAT, A.; DRUGS EDUCATION GROUP
Terrence Higgins Trust, London, England.

Objective. To establish effective support groups in London for drug users affected by HIV/AIDS in order to reduce isolation and poor practices.
Methods. The Drugs Education Group (DEG) is a voluntary body of professionals working in the field of drug misuse which acts as an advisory group to the Terrence Higgins Trust, Europe's largest community-based AIDS organization. The DEG has initiated a number of support groups in London for current, sustained and ex-users affected by HIV. A separate group has been set up for Italian-speaking people not in contact with other drugs/AIDS agencies.
Results. All groups have highlighted the multiple problems facing drug users in deprived inner city areas: lack of access to medical/drug treatment; poverty; isolation; and poor family and peer support. Locating groups in an AIDS organization with access to medical/welfare advice and charitable funds allowed for a swift response to any of these issues. This attracted new members and enhanced the groups' abilities to support, educate and empower. All groups had a policy of not segregating current from ex-users. This did not result in relapse among drug-free members. Several people associated with the groups have "graduated" from facilitated support groups and gone on to initiate their own self-help groups such as Positive Partners and Mainline which are establishing national networks for drug users with HIV.
Conclusion. Support groups for drug users with HIV must be adequately funded and initially facilitated by experienced and motivated people. As such they can play a vital role in health education and in empowering drug users.

- D.619** OUTREACH PROGRAMS IN NORWAY - APPROPRIATE INSTRUMENTS IN NATIONAL HIV/AIDS PREVENTION AMONG DRUG USERS.
Bente Nilssen, Municipal Outreach Program, Oslo, Norway.

Recent research reports an accumulation of HIV-infection among drug users using streets and parks in Oslo city (Norway) as resorts. These groups often withhold from public care, and are not easily reached by the regular health and welfare system.
The main objectives of outreach programs are to seek out and establish contact with drug users who are in need of help and support. Reaching out to these individuals implies an invasion of their "territories". This enforces a constant development of different methods in social work to ensure the stability of the contact with drug users.
An important feature of the municipal outreach programs are the unique chance for social workers and psychologists to establish direct and long-term contact with drug users who live at the streets and are at high risk for HIV-infection and for spreading the HIV-virus.
The outreach program in Oslo provide for syringes and condoms to drug users in order to prevent the use of dirty syringes and participation in unprotected sex. This is perceived as necessary but not sufficient efforts in HIV/AIDS prevention. In the outreach programs most effort is made to bring drug users off the streets and into treatment- and rehabilitation programs to ensure more lasting behavioural changes.

- D.616** Engaging the Client with Histories of Substance Abuse or Mental Illness
BESSLER, CHARMAN; SILVA, CUTTERMAN, S.U.S.A.

Unlike many other ambulatory care settings, the AIDS Stay Treatment of the Village Nursing Home in New York City has succeeded in engaging the client with histories of substance abuse or mental illness. Success in this engagement process is due to a specific set of program policies, including an assumption that some clients may be intensively nurtured before they can pursue any self-empowerment goals such as seeking new housing, entering a drug detoxification program. Further, program policy strictly limits institutional intrusions such as lengthy intake interviews, while providing immediate crisis intervention services -- often within minutes of admission. After admission the client is encouraged to view the program staff as his family, substituting for any dysfunctional street culture, and allowing a wide influence in the client's life.
In summary, immediate responsiveness to client need appears to engage the client with histories of mental illness or substance abuse. This paper should be of interest to all clinicians and administrators working with these difficult groups.

- D.618** SWEDISH AND INTERNATIONAL SYRINGE EXCHANGE PROGRAMMES: EVALUATION AND SWEDISH RECOMMENDATIONS
Erikur Östlin, National Board of Health and Welfare, Stockholm, Sweden.

During 1983 the Swedish Board of Health and Welfare established the syringe exchange programme (SEP) in the Malmö/Land region. Available data from British SEP (Stimnet) in Amsterdam (Blomberg) is also considered in the report. The report also gives a picture of the HIV/AIDS situation in Europe. Swedish IVDA were reached by HIV as late as 1982 and the new waves varied in their infectivity due to the threat of a second wave of HIV spread among Swedish IVDA. Approx. more than 80% of Swedish IVDA have been tested, which gives good baselines for prospective epidemiological studies. Although Sweden as well as British and Amsterdam SEPs have been operating for a short time and have had methodological difficulties, the following conclusions are reached:
a) Drug abuse does not appear to have increased in project areas. Nor has any new recruitment for drug abuse been observed.
b) In the Swedish SEP area there has been no further spread of HIV during the 15-month experimental period. However, it is an open question whether this can be put down to the project.
c) Many of the drug abusers getting in touch with the SEP do not have any current therapeutic contacts. Some establish such after contact with SEP.
d) The educational motivation in the therapeutic work of drug abuse rehabilitation services has not been disrupted by SEP.
e) No drop-outs from treatment have been observed in Sweden.
f) The drug abusers themselves view the activities in a positive light (concern for health).
g) All SEP report certain declines in risk behaviour.
h) The needle exchange ratio varies between 35-100 per cent.
i) The educational opportunities generated by SEP are important.
The following problem areas are discussed in the report:
1. Congruence of drug abusers' and volunteer's views on drug use.
2. Distribution of clean tools to IVDA can be looked upon as an ambiguity at variance with a restrictive drug policy. This problem of two partly opposite goals is thoroughly discussed in the report.

- D.620** THE AIDS VANCOUVER ISLAND STREET OUTREACH PROJECT
Valerie G. Thompson Williams, Judith English,
AIDS Vancouver Island, Victoria, British Columbia, Canada.

Objectives. AIDS Vancouver Island Street Outreach Program investigated the prevalence of high risk behaviours among street youth, sex trade workers, and IVDA's on the streets of Victoria; evaluated their knowledge of and attitudes about HIV/AIDS transmission behaviours and assessed the effectiveness of the street counsellors in reducing high risk behaviours.
Methods. One hundred and one volunteer subjects (48% 15M, age range 14 to 53, 87.0%) responded orally to an AIDS knowledge/risk questionnaire.
Results. Two thirds of the subjects reported engaging in high risk behaviours (vaginal or anal sex without condoms and/or sharing uncleaned injection equipment) in the previous month, despite high knowledge scores (86% correct). The significance of the street counsellors was reflected in the 91.4% of subjects who would use them as a personal crisis support system. Subjects preferred to obtain condoms from street workers more frequently (64%) than from traditional suppliers (18%) and reported using condoms and bleach more frequently.
Conclusions. Significant high risk behaviours exist among the Victoria street youth. A high level of AIDS knowledge was not linked to behavioural risk. Preliminary evidence suggests the street counsellors may be able to reduce high risk behaviour. Future research would investigate this.



Publications

Le SIDA et l'individu
AIDS and the Individual

- D.627** IMPLEMENTATION AND EVALUATION OF UNIVERSAL PRECAUTIONS IN A LARGE COMMUNITY HOSPITAL
Lewison, J.; Altem, J.; Malo-Schniegal, S.; Trifantico, K.; York, E.; Cooper, B. (Hartford Hosp., Hartford, CT, USA)

Objective: To develop and test a model educational training program for the prevention of blood borne diseases in health care settings.
Methods: It has been determined that blood and body fluid precautions be consistently and universally used by health care workers (HCW) for all patients. The concept of "universal precautions" (UP) is a substantial departure from routine, established practices in hospitals and has generated confusion and inaction among HCW, administrators and educators. An educational program was developed for all HCW. Mandatory educational sessions, using video tapes, question and answer periods and a specially prepared brochure, were provided for all employees. A hospital-wide advertising campaign using posters and newsletters throughout the program. Teaching material was being evaluated by post-education tests, follow-up surveys and by direct observations of HCW on the job utilizing "check-blind" methodology. Employee needlestick occurrences and other documented exposure to blood and body fluids will be reviewed. Cost implications of UP will be determined by comparing cost after UP to standard ("disease specific") isolation procedures.
Results: The educational program and evaluation activities are in progress. Employees with difficulty most affected by UP (lab, laboratory, nursing) has refined details and enhanced acceptance. Cost estimates on UP to date exceed \$1.6 million for materials and personnel.
Conclusion: UP implementation can be expensive and disruptive, and should follow thorough planning and preparation.

- D.629** HIV/AIDS PROFESSIONAL EDUCATION: PROGRAM DEVELOPMENT AND EVALUATION FOR PHYSICIANS, NURSES AND SOCIAL WORKERS
Nurys, Patricia S.; Malady, S.; Roffice, J. and Grossman, A. New York University, New York, N.Y., U.S.A.

Objective: To develop and evaluate a comprehensive program of AIDS education for primary care physicians, nurses and social workers.
Methods: A basic core curriculum (e.g. immunology, epidemiology/etiology, opportunistic infections) was developed and has been revised by clinicians and faculty experienced in HIV/AIDS care. Modules developed focus on microbiotics, nutrition, intravenous drug use, medicine, nursing and social work disciplines. Interventions included one- and five-day workshops, conferences, seminars and a lecture series.
Results: Since 1987, over 8,000 health professionals from New York, New Jersey, Connecticut, Puerto Rico and the Virgin Islands have participated. Pre- and post-tests of knowledge, attitudes, anxiety about working with AIDS patients, and satisfaction with the educational programs were administered. Results indicated that participants demonstrated significant increases in knowledge, more positive attitudes, reduced anxiety and high levels of endorsement of the program. Findings varied by participants' prior personal and professional experiences with AIDS, and with geographic location (High/Low incidence areas) and profession.
Conclusion: This program has effectively reached a significant number of health professionals in an area of high AIDS prevalence. It has been favorably received and has impacted on professional behavior. Geographic location, as a factor in the level of education needed to maintain HIV expertise, needs further exploration.

- D.631** DEVELOPMENT AND RESULTS OF A NEEDS ASSESSMENT SURVEY FOR HEALTH CARE PROFESSIONALS AT A HOSPITAL HOSPITAL.
Agnaf, Rajkumar, R.; Gendler, J. and El-Sher, M. A. *Marlin Hospital Center, New York, N.Y., U.S.A.

Objective: To determine attitudinal and/or cultural factors that influence the care administered to HIV-infected patients. This was of particular interest since the HIV-infected population at this institution primarily consists of intravenous drug users (IVDU) and of minorities.
Methods: Informally identified professionals at this institution primarily consisted of patients were stigmatized by the risk factors that cause the disease. As a result of these discussions, we decided to formally assess the attitudes of the health care givers and base our educational approaches on the results. Incorporated into the survey were questions to determine what areas they wanted to learn more about, including behaviors and psychodynamics of homosexuality and I.V. drug abuse. We also included questions regarding the ethnicity of the medical house staff/nursing staff in order to determine if cultural and societal attitudes were influencing attitudes towards the AIDS patients.
Results: The survey was pre-tested among a group of doctors and nurses who cared for the most AIDS patients before implementation. The results of the pre-test indicate strong feelings about the personality and behavior of the IVDU that negatively affected care.
Conclusion: The full results of the survey among medical house staff and nursing staff will be presented.

- D.628** ESTIMATED RISK OF HIV INFECTION AMONG SURGEONS PRACTICING IN THE NEW YORK CITY AREA.
Murray, G.J.; Chiu, S.; and Lowenthal, A.B. New York Medical College, Valhalla, New York, USA.

Objective: To estimate the occupational risk of HIV infection in surgeons.
Methods: Surveys from several hospitals in the New York City area were surveyed by telephone or by mail between July and October 1988 regarding puncture wound injuries occurring within the past 1 year.
Results: 100 (81%) of 110 surgeons contacted by phone and 102 (53%) of 191 contacted by mail agreed to participate. Since there were no significant differences in responses of the 2 groups, the data were combined. 177 (84%) reported at least 1 puncture injury within the past 12 months, with a median of 2 injuries per year. 76% of injuries occurred during surgery with a median injury rate of 4.1/1000 operating room hours. 53% of all injuries involved the index finger of the non-dominant hand. Injury rates were independent of age, sex, type of practice, operative work load, or type of hospital.
Conclusions: If the prevalence of HIV infection in surgical patients is 5% and if the rate of HIV seroconversion per puncture injury is 0.43%, then the average exposure to 30 year cumulative risk of HIV seroconversion per surgeon is 1-2%. This risk could be reduced by approximately 50% if an apparatus were developed to protect just the index finger.

- D.630** USING LEARNING GOALS TO TRAIN HEALTH CARE WORKERS ON

James, Gary
*University of Illinois at Chicago, Chicago, Illinois, U.S.A.

Objective: To help trainers improve health care workers learning in three domains: cognitive, attitude and skills.
Methods: Analyze five observations of over 30 training programs conducted between 1985 and 1988 for multi-discipline health care workers. Program (experiential exercises and small group discussions) were conducted in community settings and health care facilities. Observations included participants' and conductors' comments and written evaluations of training programs.
Results: COGNITIVE LEARNING: 1) "What is believable?" (Health information from credible sources. Acknowledge the unknown. Stress the consistency of use and existing information, development of expanded knowledge base. 2) "How much occupational risk is there?" (Inform on research of HIV exposure vs. infection, compare to other diseases and other risks HIV accept. ATTITUDE: 1) "This disease is scary." Acknowledge fears and concerns of HIV and their families before trying to change them. 2) "People who get HIV are bad people." Challenge personal biases, promote tolerance for differences. 3) "It's not my responsibility to work with these people." Develop and/or reinforce professional ethics. 4) "They can't change their behavior." Reinforce belief in ability of people to change; HIV can adopt universal precautions, change attitudes; persons can change their behaviors. 5) "People like me don't get HIV." Identify and acknowledge HIV personal risk. 6) "This is depressing." Convey hope in scientific research, explore potential of disease to transfuse patients and HIV, reinforce acceptance of HIV's status and spiritual needs. 7) "I don't have it." Reinforce ability of HIV with testing, emphasize adoption of universal precautions, identify relevance of prior skills, provide role models. CONCLUSION: Research is needed to substantiate the community of these learning issues and the value of techniques to provide their resolution.

- D.632** SOURCES OF STRESS AMONG AIDS CAREGIVERS
Mandil, Jeffrey E.; Gendler, J. and El-Sher, M. A. *University of California at San Francisco, Schools of Medicine and Nursing, California, USA;
*Young Adult's Institute, New York, New York, USA.

Objective: To determine common sources of stress among AIDS caregivers.
Methods: Participants in "care for the caregiver" workshops were surveyed by self-administered questionnaire to identify sources of perceived stress in the provision of AIDS care.
Results: Although a wide range of health care providers were targeted by these workshops, physicians chose less frequently than did nurses and mental health professionals to attend. Most commonly cited sources of stress were (1) organizational problems; (2) lack of resources; (3) loss of friends/loved ones; (4) distress associated with death and dying; (5) inability to set limits on work; (6) overidentification with patients; and (7) feelings of helplessness/inadequacy.
Conclusions: AIDS caregivers experience in common several sources of stress in their work. Limitations in organizations' capabilities of responding to the needs of the AIDS crisis are perceived to be as stressful as the emotional demands of patient care.

Le SIDA et l'individu
AIDS and the Individual

- D.639** CARE FOR THE CAREGIVERS - A TRAINING MODEL
 Jacobs, Raymond, Lewis, A., Mandel, J.,
 Yodanis, C. Institute, New York, R.; ** University of
 California, San Francisco, Schools of Medicine and Nursing, U.S.A.

Objective. To develop an educational vehicle which addresses the stress experienced by those who provide AIDS care over time.
Methods. Simple techniques in recreational and drama therapy have been integrated into a workshop format. These techniques are used to facilitate discussions among participants focusing on feelings of sadness and exhaustion, as well as inherent rewards that are related to the AIDS crisis.
Results. A two hour didactic and experiential, insight-oriented workshop which addresses the psychological needs of health care providers who work in AIDS has been developed and used with over 1,000 participants in eight countries. During the course of the workshop, providers learn to recognize sources of stress as well as acknowledge rewards in their work. Participants are able to use these methods and techniques as well as adapt the model from the perspective of their own training and discipline for use in their own professional and paraprofessional settings.
Conclusion. On-going support and care for AIDS caregivers is vital to the process of reaffirmation, commitment to work, and work productivity, in AIDS service delivery systems.

- D.641** UTILIZING MEDICAL STUDENTS IN A UNIVERSITY-BASED COMPREHENSIVE AIDS EDUCATION AND COUNSELING PROGRAM
 Copple, A. Gene*, Schaffner, W. J., Sheets, R., Lindsay, L.,
 Nixon, L.,** and ***
 *Vanderbilt University, Nashville, Tennessee, USA; **University of South Florida, Tampa, Florida, USA; ***University of South Carolina, Columbia, South Carolina, USA

Objective. To successfully involve medical students in the delivery of AIDS/HIV educational and counseling services as part of the academic program.
Methods. First, second, and fourth year medical students at Vanderbilt Medical School were enrolled in the elective course, AIDS Education and Prevention. This course is coordinated through the Vanderbilt AIDS Project and involves a two-day intensive seminar, weekly supervision sessions, and bibliography. The practice section includes curriculum development, providing education programs, and working with symptomatic HIV clients. Course content includes epidemiology, medical and psychosocial aspects of HIV infection, legal and ethical concerns, human sexuality, and counseling and education methods.
Results. 100 medical students have participated in this program since 1985. Student evaluations indicate the program has increased their knowledge of AIDS/HIV, human sexuality, and psychosocial issues. The program has also provided them with practical counseling and patient education methods which will be of value in later practice.
Conclusion. Medical students should be provided with an opportunity to participate in AIDS education and counseling as part of their academic program. Such courses should be focused on practice issues and well supervised.

- D.643** AIDS EDUCATION AND TRAINING FOR HEALTH CARE PROVIDERS IN VIRGINIA
 Hamilton, Lisa*, Bradford, J., and Lewent, L.,
 Medical College of Virginia-Virginia Commonwealth University,
 Richmond, Virginia, United States.

Objective. To plan, implement, and evaluate a program of AIDS education and clinical training tailored to the needs of health care providers throughout Virginia.
Methods. Through cooperation with the Virginia Department of Health and the Mid-Atlantic AIDS National Education and Training Center, a multidisciplinary team of trainers and experts in the care of HIV-infected patients was organized with specialties in infectious disease, psychiatry, social work, substance abuse, nursing, counseling, dentistry, dietetics, epidemiology, and pediatrics. Outreach, publicity, and program planning was accomplished with the assistance of professional organizations and state hospital associations. Free educational programming is available to physicians, counselors, social workers, nurses, prehospital care providers, support staffs, funeral directors, and students in all health fields. A comprehensive baseline needs assessment encompassing knowledge, beliefs, and attitudes was completed by the University's Survey Research Laboratory for physicians, dentists, counselors, nurses, emergency care workers and funeral directors.
Results. Between Jan. 1, 1987, and Dec. 31, 1988, over 15,000 health care workers in Virginia received AIDS education and training tailored to their individual areas of interest and level of need. Serial surveys are planned on a biannual basis to evaluate the effectiveness of the educational intervention, identify program changes needed, and develop target objectives for subsequent years.
Conclusion. A comprehensive AIDS education program can address the needs of health care workers from a wide range of fields. When combined with ongoing needs assessments and evaluation, such a program can be modified to address specific educational needs as these change over time.

- D.640** IMPROVING THE SKILLS OF HEALTH CARE PROVIDERS WHO TEACH
 Doumar, Ann*, Chapman, L.; Kaetz, S.; Mandel, L.*
 *University of Washington, WAH AIDS Education and Training
 Center Program, Seattle, WA.; USA

The University of Washington AIDS Education and Training Center Program (AIDS ETC) was established in 1987 to prepare health care workers to teach others about HIV/AIDS. In addition to content on HIV/AIDS, the program offers instruction using the AIDS TEACHING SKILLS CURRICULUM. This curriculum includes chapters on Creating a Climate for Learning, Curriculum Design and Planning, Teaching Methods, Preparing Visual Aids, Recognizing and Responding to Resistance, Leadership and Training Styles, and Delivery. Each chapter contains lecture material, visual aids and suggested learning activities, each designed to prepare participants to provide effective HIV/AIDS instruction to health care professionals. Approximately one-half of the week-long course is devoted to the AIDS TEACHING SKILLS CURRICULUM and teaching concepts. To date, 250 providers have attended. Examination of the instructor training course is underway. The curriculum package and evaluation results will be displayed during the poster session.

- D.642** RELUCTANCE OF HEALTH CARE WORKERS TO TREAT AIDS PATIENTS - AN ANALYSIS
 Curry, Charles*, Ogden, B.; Johnson, M.P.,
 University of Florida, Gainesville, Florida, USA

Objective. To evaluate association between willingness to work with AIDS patients and knowledge of how AIDS is transmitted, ethical beliefs, and fear of contagion.
Methods. Ninety health professionals were surveyed about their willingness to work with AIDS, their attitudes towards AIDS related ethical issues, and understanding of AIDS epidemiology.
Results: 34.4% of respondents expressed reluctance to work with AIDS patients. This was significantly associated with a belief that working with AIDS increased risk for the disease, a belief that health professionals should have the right to refuse to work with AIDS patients, and an unwillingness to treat homosexuals and J.V. drug abusers. No significant differences were noted between those willing and unwilling to treat AIDS patients with regards to professional status, demographics, understanding of how AIDS is transmitted, compassion for AIDS patients, or agreement with certain basic principles of medical ethics.
Conclusion: Reluctance to treat AIDS appears to be based on irrational fears of contagion rather than ignorance about the epidemiology of the disease or a lack of ethics. AIDS education of health professionals should include strategies to reduce fear and to humanize the AIDS patient.

- D.644** ANALYSE DES COMPORTEMENTS BIOLOGIQUES ET MEDICAUX FACE A LA RELATION SEROPOSITIVITE TOXICOMANIE (ENQUETE DANS LA REGION ILE DE FRANCE)
 Maudin, Claude*, Neumann, C.; Halaud, P.; Labadie, D.; Robin, C.,
 Paris, C.,**

**Association HIV Hôpital de Bigny, 91640, FRANCIS. **DASS ERYV 91000, FRANCE
Objective. Analyser au niveau du Département de l'Essonne, l'implication des Fraticiens dans l'accueil et le suivi des sujets HIV séropositifs et toxico manes. Proposer des solutions aux problèmes rencontrés par nos confrères.
Methods. Association HIV 91 en place le 15 Décembre 88, grâces à une subvention du Ministère de la Santé et à la collaboration de la Direction Départementale de l'Action Sanitaire et Sociale, une enquête adressée aux 2992 Confrères (Médecins et biologistes) de l'Essonne. Un système de gestion de données type 3base (PC compatible II, disque dur File Card 30 Mo western) permet d'évaluer des filières de soins médicaux et d'apprécier les problèmes rencontrés avec les toxicomanes.
Results. Le taux global des réponses est élevé (45 %). Pour le questionnaire Médical 65 % des généralistes et 35 % des spécialistes ont répondu. Parmi eux 45 % suivent des Fraticiens, 30 % des toxicomanes. La fuite du malade et les pathologies intercurrentes sont les difficultés majeures. Pour le questionnaire Biologique 1/4 ne sont pas concernés, 30 % pratiquent le dépistage four positif et le dialogue avec le patient. Une lettre d'informations, Régulière, est soumise par la majorité des Fraticiens.
Conclusion. Une lettre d'informations et des équipes de soins confirmer la nécessité de mettre en oeuvre une action associative et pluridisciplinaire.

Publications

Le SIDA et l'individu
AIDS and the individual

- D.645** MULTIDISCIPLINARY AIDS TEAM ROLE IN NORMALE AND STRESS REDUCTION AMONG HEALTH CARE WORKERS (HOW)
Rabin, M.; O'Neil, R. A.; Collins, K.; Friedland, G.R.; Gordon, L.; Klein, B.S.; et al. Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, U.S.A.

Objective. To describe a multidisciplinary team's role in maintaining morale and reducing stress among AIDS HOWs.

Description. Complexity of AIDS clinical care requires expertise from many disciplines and is associated with HIGH stress. Stressors include: cruelty of AIDS, youth of patients(pts), inadequate social and family resources, issues of confidentiality, discrimination, discomfort with patient life styles, ethical dilemmas, death and dying, unrealistic expectations, fear of infection, sense of isolation, and lack of resources.

Over the past 6 yrs, a multidisciplinary team, initially formed to provide pt care, has functioned to reduce stress and provide support for HOWs. The core team consists of MDs, RNs, RMs joined by psychiatrist, nutritionist, lawyers, and clergy. Functions include: 1. creation of group identity 2. stable leadership 3. frequent meetings to educate, foster trust, optimism, cooperation and communication 4. allow expression of feelings including grief 5. promote cross cultural awareness 6. support research and attendance at professional meetings to enhance personal growth and sense of achievement 7. essential services for patients 8. social events to promote cohesiveness 9. permission to care for oneself as priority.

Conclusion. An AIDS clinical care team can enhance staff morale and reduce stress by formal and informal group mechanisms, but requires commitment to team building and maintenance from the onset.

- D.647** AIDS A HEALTH CARE GIVER'S KNOWLEDGE, ATTITUDES AND INFECTION CONTROL PRACTICES
Katz, J., Fendley, J., McCann, C and Addy, C.
University of South Carolina School of Public Health, Columbia, South Carolina, USA

Objective. To determine the knowledge, attitudes and infection control practices among health care givers.

Methods. 241 health care givers, consisting of registered nurses, licensed practical nurses, nursing assistants and technicians, medical technologists and phlebotomists, responded to an AIDS survey in a South Carolina hospital. Scores for knowledge, attitudes and infection control practices were calculated. Data were analyzed using stepwise regression - one-way ANOVA and Tukey's multiple comparison procedure.

Results. In general, knowledge about AIDS appears to be high among these health care givers. However, they still have fear and increased risk perception concerning AIDS. 32 to 72% of the various study groups believed that they can get AIDS by taking care of AIDS patients. Over 60% of the respondents reported that they would prefer to avoid caring for people with AIDS. Only 51 to 64% of the participants wear gloves at all times.

Conclusions. Although health care givers in this study were quite knowledgeable about AIDS, they exhibited fears and increased perceived risk of acquiring HIV infection. A substantial number did not follow the universal precautions recommended by C.D.C..

- D.649** SUPPORT FOR STAFF ADDRESSING HIV/AIDS ISSUES IN A DRUG REHABILITATION CENTRE.
KEY: Burgess, King's College Hospital, London, U.K.

Objective. To enable staff at a drug rehabilitation centre to identify sources of stress arising from their treatment of clients with HIV/AIDS and to generate management solutions.

Methods. A facilitated support group was set up for all staff, many of whom are themselves management. Eighteen meetings were held over a six month period.

Results. The principal causes of stress were found to be:

- (1) ORGANISATIONAL - poor communications; unneeded operational policies.
- (2) CLINICAL - relating HIV to drug abuse; the need to address death; loss of ability to reassure clients about better health after drugs.
- (3) INDIVIDUAL - feeling de-skilled; fear of infection; feeling isolated; quiet over own past drug use.

Solutions included setting up formal and informal forums to ventilate problems. Attempts were also made to clarify staff roles. A training programme was implemented, both to provide clinical updates and to address counselling issues surrounding death. As a result of the group, staff reported feeling better able to acknowledge and control stress.

Conclusion: Staff support groups can be seen as useful forums for problem solving.

- D.646**

D.646 HIV EXPOSED HEALTH CARE WORKERS AT MSKCC
Carron, Melaine J.; Campbell, S.N.; Blevins, A.; Sobock, K.A.; Wolf, J.R.M. and Armstrong, D.
Memorial Sloan-Kettering Cancer Center, New York, New York, U.S.A.

Objective. To examine compliance of Health Care Workers (HCW) to CDC guidelines for significant exposure (SE) to HIV infected patients.

Methods. All HCW reporting significant exposures (needlestick or mucous membrane) to employee health service between June 1986 and December 1988 were referred to an Infectious Disease nurse for interview and follow-up.

Results. Of the 46 referred 11 refused any follow-up, 20 continued follow-up for one year, 25 reported HIV testing, all were negative. The total number of reported SE including known HIV exposures was 416. He suspect under-reporting of all SE including those involving patients with HIV infection.

Conclusion. Fewer than one-half of HCW who report SE comply with follow-up. Reasons may include: concern for lack of confidentiality, inconvenience, knowledge deficit, and fear of results. A need for education about risks of needlessticks and methods of reducing the number of occurrences is seen. Concerns about confidentiality need to be addressed.

- D.650** NEEDS ASSESSMENT OF STAFF AIDS EDUCATION PROGRAM IN TERTIARY CARE AND INNER CITY COMMUNITY HOSPITAL
Leffels-Greulich, Pearl; Foley, M; Walther, V; Rothenberg, A; MAFAS, M; and EPSTEIN, I.
Mount Sinai School of Medicine, New York, NY, U.S.A.

Objective. To develop an AIDS staff education program in 2 hospitals serving East Harlem, an inner city community: Mount Sinai Hospital, a tertiary care center and North General Hospital, a minority-run community hospital.

Methods. A comprehensive needs assessment was performed at both sites by 2 AIDS Education Coordinators through interviews of staff in selected hospital areas, which serve the targeted high risk population, women of childbearing age. A broad spectrum of health care providers and workers were interviewed ranging from physicians and nurses to social workers and clerks.

Results: Greater than 200 staff were interviewed. Despite more extensive pre-HIV staff training in the tertiary care center, gaps in basic AIDS knowledge were found. Most staff were concerned about their risk of AIDS transmission regardless of their knowledge level. With the stress of working with high risk patients and with the changing role of staff toward education and counseling, there was a great need identified for ongoing staff support. The need for linkages with other AIDS education activities in the hospital and community was noted.

Conclusion. An effective AIDS staff education program requires intensive planning and must be responsive to documented staff needs. Staff knowledge should not be overestimated, and training must go beyond information to staff support. The curriculum will be organized in modules and will be customized to the needs of the particular staff of each hospital area. (This effort was funded by the Alfred P. Sloan Foundation).

Publications

Le SIDA et l'individu
AIDS and the Individual

D.651

A SUPPORT GROUP CAN HELP PRIMARY CAREGIVERS FACE UP TO THE INCREASING IMPACT OF THE HIV EPIDEMIC

Abstract: Harvey, D.S., Frost, J.C.***; Judd, D.; Lee, S.P.; O'Neill, L. HealthCare Associates and the Departments of Medicine, Social Work and Psychiatry, Beth Israel Hospital/Harvard Medical School, Boston, MA. Center for Studies of the Harvard AIDS Institute at Harvard School of Public Health. **The Boston Institute for Psychotherapy, Boston, MA, USA.

Objective: To describe a multidisciplinary support group of health care providers working with people with AIDS in a primary care group practice within a general medical hospital.

Method: A 15 member group of clinical and administrative personnel met with a mental health group facilitator for 15 weeks. The members discussed their personal experiences with HIV infected patients presently in their caseload.

Results: Sessions included both educational and emotional content, focusing upon both personal and professional concerns such as: feelings about and lack of knowledge regarding alternative lifestyles, IV drug use, or cultural differences; ethical and moral concerns raised by treatment decisions; the impact of the rapid growth of information and technology; and their feelings about caring for people their own age or younger with a terminal illness.

Conclusions: Caregivers who had previously felt isolated, overwhelmed by their experience, and worried about the impact of their own emotional experiences expressed feelings of greater support and community, and an increased interest and capacity to care for people with HIV infection.

D.653

EFFECTS OF HIV AND AIDS WORK ON STAFF EMPLOYED IN CARE
A. Clark, S. Werry, J. Hopkins/Infection Institute & George
St Mary's, London, U.K.

Introduction - Staff stress and burnout has been documented. HIV involves health care staff in servicing, caring, counselling and high intensity care. This study assessed the impact on staff, how they cope and to see if coping styles and avenues were predictive of adjustment to stress.

Method - Twenty one staff from front line work in the area of highest incidence in London completed the study investigation. Mean age was 28.6 yrs (range 23-40). Mean work with AIDS/HIV was 16.1 mths. Mean years of qualification was 8.3 years. Staff rated current stress, coping avenues and perceived and experienced stressors.

Results - No subjects were untrained - 29% fairly, 35% moderately and 35% very. All subjects found it desirable to separate work and outside life, yet one fifth were not very effective at doing this. No subjects turned to groups outside the hospital for support. This has important implications for service provision. Low stress subjects attended educational courses whereas high stress subjects did not (mainly used informal support). Emotional courses may provide stress inoculation or may be the choice of support for low stress subjects. Information is a key tool in this area and such groups may be ways of equipping staff or provide a forum for informal networks. Stressors were varied. Although they were associated with the death of a patient and ill patients and relatives, a considerable proportion of stressors were associated with interpersonal and practical issues which could easily be addressed.

D.655

FACTUAL INFORMATION AND A GOOD WAY TO CONTRIBUTE
TO REALISE CARE OBJECTIVES (HOM) EDUCATION
J. Babin, J. Thibaut, J. Félou, J. J. Rimeux, G. J.
Bertoni, J. Boland, J.M. and Renaud, H.
CHU - Sart Tilman, State University of Liège, BELGIUM.

OBJECTIVE: Working with AIDS can induce stress, anxiety and overlook as well as intellectual stimulation. This psychological impact could be linked to the lifestyles associated with AIDS, distress over the youth of the patients, neurological complications and dying patients. Also, individual assessment of HOM remained still anxious about the risk of a nosocomial HIV contamination. It will be interesting to give information about AIDS and lifestyles related to AIDS in order to facilitate the contacts of HOM with patients and, also, to give directives in order to minimize the risk of HIV contamination during professional activity.

RESULTS: Manuscripts with recommendations were provided. However, conclusions were not sufficiently modified. Therefore, on the occasion of the World AIDS Day, we delivered a pictorial information.

CONCLUSIONS: For the first time, we were requested to materials and attitudes regarding AIDS patients.

CONCLUSIONS: Specific informations to HOM are needed to reduce staff's discomfort and to facilitate their work. Specified practical recommendations contribute to a better sense of security. A pictorial information is more attractive than a manuscript and could be a good way to reach this goal.

D.652

DEMI DE LA BEAUTE ET FORMATION DES PROFESSIONNELS DE SANTE
MILHAUD METTETAL - FROBER EUGEMANN - M BARRY - ALFORD
NAPRIAN - ACAT - GALDRES - ACAT - SGAURS - ** ACAT - SGA - FRANCE

Objectif: Analyser dans le cadre de la réhabilitation par le profession de santé les besoins de formation des professionnels de santé. Méthode: enquêtes statistiques des demandes d'information, évaluation des demandes de formation, évaluation de compétences et connaissances des stagiaires en cours de formation, questionnaires.

Resultats:

1) Le rôle de la réhabilitation du patient par le profession de santé est exactement l'attente de la population générale et les évolutions de la corps médical, ce qui est en rapport avec le rôle du professionnel de santé, et une connaissance sérieuse de la maladie, et un meilleur comportement psychologique, et le respect qui très souvent le comporte des situations difficiles à vivre être confronté.

2) Le rôle du corps médical de la population générale, est l'impact de la situation médicale, mais le statut de travail et médecin le conduit à résoudre son problème pour lui-même sans prendre en compte le rôle du patient, et de la famille, et de la personne à faire face avec ses connaissances, sentiment que les traitements ont des effets sur le corps médical par le profession de santé.

3) Le rôle de la famille dans le profession de santé est proportionnel au manque de formation spécifique au problème de santé, et surtout l'absence de connaissances médicales et l'absence de la "grande" presse médicale, surtout au niveau des soins, les conférences ne traitent pas certaines lacunes scientifiques et traitement pas le stress psychologique, la formation continue ne prend pas en compte les problèmes sociaux, pratiques, évaluer correctement par les médecins, les stages médicaux sont encore conduits sur le mode de l'attribution libre, et la technique clinique traditionnelle et psychologique et le vécu.

Conclusion: Seule une conception globale de la formation, intégrant tous les paramètres à long les besoins, et satisfaisant la demande du public général pourra une situation de rupture dans les années à venir.

D.654

COOPERATION BETWEEN PHYSICIAN AND PSYCHOLOGIST:
AIDS - A CALL FOR FREEDOM-ORIENTED SOCIAL TEACHING

Leiberman, R.^{1,2}; Narasim, C.^{1,2}; Palmer, J.²; Porush, U.²; Rosenbaum, M.⁴; Ulich, R.³

University of Erlangen, ¹Medical Clinic III, ²Medical Clinic III/Dept. of Psychology I, ³HIV/AIDS-Center of Federal Health Administration, Berlin, ⁴USA.

Objective: To describe several ways of cooperation between physicians and psychologists caring for HIV-seropositive persons and AIDS-patients.

Methods: 100 physicians and psychologists completed an inventory asking (1) for their experiences with HIV-positive persons and (2) their expectations of the other profession.

Results: 40% of the psychologists and 90% of the physicians had experiences with the treatment of HIV/AIDS-patients. No significant differences were found in both groups' judgements of the importance of counselling patients with regard to their life style, informing them about their prognosis, and teaching them relaxation techniques. Physicians endeavored to talk extensively with their patients, they recognized, however, their own lack in techniques of counselling and psychotherapeutic intervention. Major tasks for psychologists, therefore, would be the training of physicians and other professionals, supervising a/c. them-outreach or helpline groups, offering relaxation and medication courses, and developing psychotherapeutic intervention programs.

Conclusion: HIV/AIDS-patients need special psychosocial care: new forms of cooperation between professionals must be developed in order to minimize stress.

D.656

PSYCHOLOGICAL STRAINS IN A MULTIDISCIPLINARY
TEAM TAKING CARE OF AIDS PATIENTS IN BRAZIL
Eduarda Alencar, G. Guatior, et al.

School of Medicine, Federal University of Rio de Janeiro, Brazil

Objective: To identify and work through, by an experience in group dynamics, the anxieties and conflict tensions felt by a health team treating AIDS patients. **Method:** Investigation was done through the structure of the multidisciplinary team dealing with the group dynamics. Weekly meetings with the research subjects (AIDS, dentist, nurse, nutritionist, social workers), were conducted by two dynamically oriented psychiatrists for one year in a university hospital. All meetings were recorded and an interpretative reading was done.

Results: The anxieties more frequently seen in the group were generated by the therapeutic alliance dealing with transgressive behavior of the patients associated with sexuality and drug addiction, and the fear of contamination. The anxieties identified in the group were shared by the different subjects, and provided the elaboration of more adequate defenses.

Conclusion: AIDS associated death, anxiety, and transgression behavior, intensifies conflict tensions in patient care. The limitation of medical knowledge makes multidisciplinary approach a must in AIDS. The group work was a valid instrument to identify and work on anxieties of health team, to develop the psychotherapeutic function, and to improve integration among the health team.

Publications

Le SIDA et l'individu
AIDS and the Individual

- D.663** **ASSESSING THE IMPACT OF AIDS INTERVENTION PROJECTS**
 Erickson, Barbara and Williamson, Nancy K.*
 *Family Health International, Research Triangle Park, NC, USA.
 Evaluating projects designed to encourage people to engage in behaviors that reduce the risk of AIDS is fairly straightforward. This is not the case if project is designed to prevent HIV transmission. For example, having a control group might make sense scientifically in order to assess what might have occurred without the program, but rarely is this practical with AIDS projects and may consider it to be unethical.
- If incidence is low in the target population, there may be too few cases of transmission over a project's duration to measure its effectiveness. In this instance, multiple indicators can be used, including incidence of other STDs, practice of safe sex or other desirable behaviors, and knowledge and attitudes. If the prevalence is high, there may be little opportunity for the program to have an impact on the infected group. In that intervention may significantly reduce transmission to sexual partners.
- If the focus is on individuals with high risk behaviors (often the most cost-effective public health approach), it may be hard to reach individuals who do not identify themselves as being at risk or do not frequent places where programs can be implemented. Follow up is also difficult especially if the target populations are highly mobile (commercial sex workers, IV drug users, and transportation workers). Finally, it is difficult to ascertain whether participants are practicing safer behaviors. This paper gives examples of these problems and proposed solutions based on planned and ongoing AIDS programs in Africa, Latin America, and Asia.

- D.665** **MARRIAGE, STD AND PROTECTION FROM HIV**
 Clark, Robert P.* and Nahn, Anita C.*
 *U of South Florida, Tampa, FL **US Clinic, Amnsh, Germany
 As the realization that the AIDS epidemic is unlikely to be controlled anytime soon by either a vaccine or a drug treatment, interest in social behaviors that reduce STD rates has increased. The most acceptable sexual behavior occurs with seropositivity, and the relative absence of marriage in the young sexually active black subculture is cited as a contributing cause to the high rate of HIV seropositivity (twice the white rate as shown in the US Military recruit data). US Army studies of syphilis rates done prior to World War II, before the introduction of penicillin, showed that marriage had a protective effect against syphilis.
- To examine the possibility that marriage might serve as a protection against STD's and therefore against infection with HIV, a pilot survey was conducted among US Military personnel. The analysis showed a significant difference between the white enlisted married rate of STD's of 13% and the black enlisted married rate of STD's of 35%, and no significant difference of the latter from black enlisted unmarried rate of STD's of 30%.
- Blacks, married or single, engaged in more risky sexual behaviors than did married whites. This preliminary study suggests that marriage as an institution may not be protective against HIV infection, and that fundamental sexual issues must be addressed with all members of a minority.
- It is of interest to note that in this age of antibiotics and health consciousness, 13% of these white married males have had an STD and must also be considered candidates for HIV infection. Only 30% of white married males met the Judeo-Christian ideal of monogamy.

- D.667** **FOCUS GROUPS AS AN EDUCATIONAL INTERVENTION FOR BLACK GAY MEN**
 Hollinger, George, Jr.* Nays, V. K.,** and Cochran, S.D.**
 *Black C.A.R.E. Project, Los Angeles, United States
 **University of California, Los Angeles, California, United States
 **California State University, Northridge, California, United States
- Objective:** In order to develop effective strategies for AIDS education and prevention efforts with Black gay and bisexual men, information was gathered from diverse groups across the United States.
- Methods:** Six focus groups of 2-5 hours in length, each composed of 8-10 Black gay and bisexual men were conducted in New York, Chicago, Los Angeles, Atlanta, Omaha, and Pittsburgh. Methodology based on marketing and group dynamics was used to assess relevant factors, including language, level of knowledge and culture, involvement in HIV-related behavior.
- Results:** While the initial purpose of the focus groups was to assess information from the subjects, the impact was that of an educational intervention. Participants reported a desire to continue in a group format and to organize similar types of groups. Individuals personally reluctant to become involved in AIDS-related activities appeared motivated to participate because 1) the facilitator did not reside in their city and 2) networks used to organize the groups were so diverse that most members knew few if any of the other participants.
- Conclusion:** Focus groups appear to be a potential model for increasing participation by Black gay and bisexual men in AIDS-related risk reduction.

- D.664** **FACTORS INFLUENCING AIDS RISK PERCEPTION OF BLACK GAY MEN**
 Bush, Jackie B.* Cochran, S.D.** and George Hollinger, Jr.*
 *University of California, Los Angeles, California, United States
 **California State University, Northridge, California, United States
- Objective:** As AIDS continues to disproportionately affect Blacks in the U.S. (CDC, 1988; Nays & Cochran, 1987), it is crucial to determine if their perception of risk is needed to design effective risk reduction interventions. One HIV-at-risk group for whom we have little empirical knowledge of their lifestyles (Cochran & Nays, 1988) are Black gay and bisexual men. The present study is a pretest effort to design an assessment instrument for a national study of HIV-related behavior.
- Methods:** Six focus groups, each composed of 8-10 Black gay and bisexual men, were conducted in New York, Chicago, Los Angeles, Atlanta, Omaha, and Pittsburgh. Methodology based on marketing and group dynamics was used to assess subjects' AIDS knowledge level, perceptions of AIDS infection credibility, and the influence of perceived discrimination on AIDS prevention services utilization.
- Results:** While knowledge of AIDS and its modes of transmission was high, distinctions regarding HIV, medical treatment and protective behaviors were more diffuse and less well understood. Utilization of AIDS preventive services within the White gay community were generally low.
- Conclusion:** Current methods of AIDS education, if they are to be effective must be sensitive to the role that ethnic minority status plays in illness prevention and health care utilization.

- D.666** **A PUBLIC HOSPITAL AND THE AIDS EPIDEMIC IN OAKLAND, CALIFORNIA**
 Edward Allen Seidel; J Veroff; T Hesse. Highland Hospital, Dept. Internal Medicine; Oakland, California. USA
- Objective:** To compare diagnoses, ethnicity, and transmission mode of HIV in 55 patients presenting to a newly formed outpatient seropositivity HIV clinic at Highland Hospital, Oakland, CA, with a similar group already existing for California.
- Methods:** Diagnosis, ethnicity, and risk of all 55 patients (51 males and 4 females) seen in a newly formed seropositivity clinic for HIV infection, are reviewed for the period 3/16/88 through 9/30/88. Pts. were provider or self-referred into the clinic.
- Results:** 64 (84%) of patients had diagnoses of AIDS or ARC, by WHO/ECDC and CDC criteria; and 4 (7%) patients had symptoms of HIV infection. 63% were Black, with AIDS/ARC dx. (n=44)
- | Ethnicity | No. | 1974 | Combined | Total |
|-----------|-----|------|----------|-------|
| Black | 262 | 71 | 242 | 601 |
| White | 112 | -- | 102 | 312 |
| Hispanic | 21 | -- | 12 | 41 |
| Asians | 22 | -- | 2 | 22 |
| Total | 417 | 72 | 356 | 1001 |
- Conclusion:** When compared with existing statistics for California, and the San Francisco Bay Area, this outpatient sample, represents a large proportion of Black individuals, presenting with AIDS or ARC. Heterosexual/bisexual risk, and IVDA are the most common transmission risk factors in this cohort of outpatients seen at Highland Hospital, Oakland, California. USA.

- D.668** **WHERE BOTTOM-UP AND TOP-DOWN APPROACHES MET: THE DEVELOPMENT OF A COMPREHENSIVE AND INTEGRATED HEALTH PROMOTION/AIDS PREVENTION PROGRAM *****
 Koss, David J., Lefkowitz, P., Belvin, K., Barrett, E., Kish, J., Naves, H* and White, C.P., Mount Sinai School of Medicine* NYC, NY, USA, East Harlem Block School** NYC, NY, USA.
- Objective:** The present provides a model for the development of a long-term, dynamic, comprehensive and integrated community based AIDS education/prevention program.
- Methods:** A multi-agency CHO was sought which would provide a strategic program site targeted to the multiple needs of young at-risk families and the schools in which they are served. This program was developed in partnership with a multidisciplinary research team. The process which led to the identification, participation and on-going needs-assessment of The East Harlem Block School, Inc., a multi-agency umbrella organization in a deprived inner-city community, is described.
- Results:** This umbrella organization includes 5 agencies with overlapping memberships -- an alternative educational school, nursery school, 2 day-care programs, a Youth in Action Program for adolescents and a staff of over 100. It thus provides multiple opportunities for programmatic targeting at the various segments (staff, families and students).
- Conclusion:** The case clearly identifies the need for a bottom-up, top-down approach in order to develop an effective, continuous, integrated AIDS education and primary, secondary and tertiary care prevention program. ***Funded by the Aaron Diamond Foundation



Publications

Le SIDA et l'individu
AIDS and the Individual

D.675

BARRIÈRES COGNITIVES-COMPORTEMENTALES DES SUJETS POSITIFS À L'ÉVÉNEMENT

Deputatis, Merg, Jarte, D., Martignolo, P., Vignola, D.,

Service Hospitalier de Diagnostico e Cura "Grande 1" - e Centro di Medicina Comportamentale (Responsabile Prof. G.F. Galimberti), Ospedale di Crema, Milano, ITALIA.

Objectif. Nous avons voulu étudier les aspects psychologiques des sujets positifs à l'ÉVÉNEMENT pour évaluer des programmes de soutien psychosocial.
Méthode. A ce moment nous avons examiné 70 sujets positifs à l'ÉVÉNEMENT avec le Questionnaire Behavioural Assessment-2.0, après nous avoir analysés les données obtenues avec un programme spécifique pour notre entretien. On a considéré comme groupe de contrôle la population (700 sujets) aux localités les plus reculées de l'Italie. On a aussi examiné les données statistiques des résultats avec le test de t de Student. Enfin nous avons évalué la significativité statistique des résultats avec le test de chi carré.

Résultats. On a constaté que moins il a été jugé que le 2% des sujets a des problèmes psychologiques. L'analyse des données nous révèle que 25% de nos cas. Ainsi la dépression a frappé le 2% des patients et il faut remarquer que nos dépressions ont un risque suicidaire très élevé. Le test de la personnalité qui a obtenu le plus grand nombre de fautes (personnalité) a été le psychotique (2% des cas). Il a aussi été constaté que une significativité statistique une plus grande vulnérabilité psychologique et un plus mauvais adaptation social de tes. En conclusion des données. De toute façon nous et le 30% des hommes ont utilisé des drogues. Pour réduire l'usage des drogues, les résultats ont été l'attention centrée après la découverte de la positivité à l'ÉVÉNEMENT utilisé au 5% des t.

Conclusions. Avec un support psychosocial paraît être initié dans le 43% des sujets positifs à l'ÉVÉNEMENT on peut seulement pour des raisons psychologiques mais aussi pour la possibilité relative application au plan psychosociosociologique.

D.677

INFLUENCE OF LOVELESSNESS AND SOCIAL SUPPORT ON THE EFFECTIVENESS OF ABEHAVIORAL INTERVENTION WITH HEALTHY MALES AT RISK FOR AIDS

Bassett, R.C., Laperriere, A., Hanson, G.P., Antoni, M.A.,

Fisher, M.A., and Schrimminger, M.L., et al.,

University of Miami, Miami, FL, USA; *Stanford University, Palo Alto, CA, USA.

Objectif. Increased anxiety and depression have been associated with acquiring a positive diagnosis for the human immunodeficiency virus (HIV). This may serve to further compromise an already vulnerable immune system, resulting in an increased risk for opportunistic infection and worsened disease prognosis. Affective assistance training appears to have a buffering effect on the distress associated with receiving one's anti-HIV-1 status. A reasonable question is whether aspects of being in a group intervention can influence these effects.

Méthode. To investigate this we assessed self-reported lovelessness and social support at three times in the course of the intervention. Healthy gay males (N=64) at risk for the acquired immune deficiency syndrome (AIDS) wishing to know their anti-HIV-1 status participated in this study. Subjects were randomly assigned to meet either control (n=32) or exercise (n=32) groups. The exercise group received 45 min of aerobic training 3 times per week for 10 weeks. All subjects learned their anti-HIV-1 status at week 10 and completed the UCLA Loneliness Inventory and the Social Provisions Scale at baseline and again at weeks 5 and 10. A 2x2 factorial analysis of variance was performed for each of the measures at all of the timepoints.

Résultats. There were no interaction effects between anti-HIV-1 status (vs -) and group (exercise vs control) on either measure at any timepoint. Further, the only significant main effect was at week 5 where the anti-HIV-1 (+) reported greater loneliness than the anti-HIV-1 (-) (F(4,25) = 34.89, F(1, 34) = 26, p < .05).

Conclusions. The overall lack of discrimination among the groups at the various timepoints of the intervention suggests that loneliness and perceived social support have minimal influence in the reduction of psychological distress reported by the intervention with individuals receiving their anti-HIV-1 status. This strengthens the notion that it is the specific intervention, aerobic exercise, per se, rather than merely the effect of being in a group environment-invention which accounts for the salutatory effect reported. Supported by NIMH, P50MH42453-03.

D.679

DEVELOPMENT OF A QUESTIONNAIRE TO DETERMINE KNOWLEDGE, ATTITUDES AND BEHAVIOUR TO HIV INFECTION

Francisco, J. Parga, Sexually Transmitted Disease Control Programme, San Juan, Puerto Rico.

HIV infection has been called by many a behavioral condition. As long as there is no cure or vaccine, the only available method to avoid infection with the Human Immunodeficiency Virus is avoiding the practices employed by persons at increased risk for infection. In order to develop educational campaigns, it is necessary to evaluate the levels of AIDS knowledge and attitudes.

A questionnaire was developed and validated using a group of judges.

Item validity was determined. Then, a pilot study was done using 450 subjects of which 43% were at increased risk for infection by HIV.

A final form of the questionnaire was developed after the pilot study.

The questionnaire is directed to Spanish-speaking subjects.

D.676

SUICIDIAL THOUGHTS AND ACTS IN HIV INFECTION SUSPECTS

Francisco, J. Parga, Sexually Transmitted Disease Control Programme, San Juan, Puerto Rico.

For many persons, infection with human immunodeficiency virus means the immediate development of AIDS and an early death. Suicide becomes a viable alternative to avoid long illness and to obtain control over the situation. In many cases, AIDS will not be developed in years. In order to evaluate the occurrence of suicidal thoughts, 400 subjects were evaluated within 4 categories through the use of a questionnaire: 1) Persons who go to get tested for antibodies against HIV for the first time; 2) Persons who go to receive their results for the first time; 3) Repeat testers and 4) Persons who attend a testing site but do not get tested. Results indicated various patterns related to the persons at increased risk for suicidal thoughts and acts.

D.678

ÉVALUATION DES RÉACTIONS PSYCHOLOGIQUES COMPLEXES CHEZ LES HÉTÉROSEXUELS SEROSOPositifs (ANTI-HIV) ADOPTEUR/QUIES

Becher, Sophie, Pasqua, A., Virelli, M., Du Jardin, P.,

ROCHEFORT, J., GASTELIS, J.

Ligue Régionale Française de Lutte Contre le SIDA - C.H.R.U., Nice, France.

En 1989, le nombre de séropositifs asymptomatiques est estimé en France à 300 000. Les deux régions les plus atteintes par les infections à VIH sont l'Île-de-France et la Provence-Alpes-Côte d'Azur, la proportion d'hétérosexuels exclués est en constante augmentation, tant en ce qui concerne les cas de SIDA avéré (10,3% en France vs 30,0/100) que les porteurs asymptomatiques. Parmi une cohorte de 100 hétérosexuels asymptomatiques, 16 (11 femmes/5 hommes) ont fait l'objet d'un test de dépression (échelle d'Hamilton-Policier), d'un test d'anxiété (échelle T.A.R.D.), d'un test de l'attachement (thème Soral) et d'un entretien semi-directif. 3/16 n'ont aucun symptôme dépressif, 8/16 présentent une dépression mineure, 4/16 ont une dépression légère et 1/16 une dépression grave. Part rapport à l'annonce de la séropositivité, un taux d'anxiété élevé apparaît en général après une période de sidération de durée variable. Ce taux d'anxiété élevé dure jusqu'à 12 mois et lui succède une phase de réorganisation (psychologique et comportementale) où l'anxiété décroît. L'intensité de l'anxiété semble plus marquée chez les hommes et elle augmente nettement après 26 ans dans les deux sexes. Cette anxiété est plus importante dans le rôle relationnel. Lors de l'entretien directif, ce sont les thèmes de préjudice (y compris d'ordre médical), de victime, d'insécurité de la société (cerceur d'information), d'exclusion qui émeuvent le plus fortement. Le test de l'attachement dénote une quête d'équilibre personnel et un besoin d'acceptation par l'entourage.

D.680

LES ATELIERS SUR LES ACTIVITÉS SEXUELLES VIEilles RÉSISTES A SA SANTÉ

Sourdis, Isabelle, Larocque, P.,*

COMITÉ SIDA SIDA Montréal, Montréal, Québec, Canada; **Université du Québec à Montréal, Montréal, Québec, Canada

Objectif. Décrire l'organisation des ateliers et présenter les données évaluatives recueillies de février à mai 1989.

Méthodes. Des groupes de 15 personnes sont formés et animés par un sexologue et un assistant-technique. Les participants sont des hommes ayant eu des contacts sexuels avec d'autres hommes (gais et bisexuels). Ils reçoivent 2 sessions de 3 heures dont les objectifs sont: 1) acquérir des connaissances sur les act. sex. 2) risques réduits; 3) développer des attitudes positives; 4) développer et maintenir de nouveaux comportements et 5) améliorer la qualité de sa vie sexuelle. Le matériel utilisé comprend des dépliants, affiches, vidéos et la distribution d'une trousse. Le questionnaire est distribué au début et à la fin des ateliers. **Résultats.** Les résultats proviennent des questionnaires concernant les objectifs et analysent les connaissances acquises, la modification des act., les cpt., et la place de la sexualité dans la vie personnelle. **Conclusion.** Nécessité de ce type d'intervention, besoin de l'implication des participants. Structurer les act. sex. à risque réduits dans un contexte de nouveaux modes de vie.



Publications

Le SIDA e l'Individuo
AIDS and the Individual

D.687

THE MEDICAL AND EMOTIONAL/SUPPORT NEEDS OF WOMEN WITH HIV
Debbie Thorne* & **Beaulieu, R.*****
 *AIDS Committee of Toronto, Toronto, Ontario, Canada
 **Basic Free Clinic, Toronto, Ontario, Canada

Objectives. To describe the medical needs and psychosocial concerns of women with HIV. To describe a model for support groups for women.
Methods. Initial findings were obtained from 8 members of a support group for women. A further 12 women were given a structured interview.

Results. Qualitative analysis revealed the following issues:

I. **Medical Needs** -- Women reported difficulty in obtaining an accurate diagnosis of HIV infection and immune status. Two-thirds of the women reported increased symptoms specific to their hormonal and reproductive physiology, but only vaginal candidiasis was accepted by physicians as a marker of HIV status.

II. **Emotional Needs** -- Women were more likely to experience shock at diagnosis, and to feel anger at the infecting partner. Isolation within their own support networks and even within the AIDS community was noted. Stress levels increased for those involved in the caregiving of HIV-infected men, those with infected children and those mourning the loss of child-bearing possibilities.

III. **Support Group Issues** -- Despite varying backgrounds, common concerns were found on issues such as reactions to diagnosis, disclosure, relationships with men and the need for improved access to medical and treatment information and services.

Conclusions. That researchers have not fully investigated the medical needs of women with HIV. That support groups for women can be effective, where tailored to their specific needs.

D.689

On being HIV+ positive, European, female, and "non-existent".

Annette Hegge, Copenhagen, Denmark. Positive Women's Support Group, Copenhagen, Denmark

The main topic of this paper will be the situation of HIV-positive women, (non IV drug abusers) in Denmark, and the trials and tribulations of this group in establishing their "help" groups.

The underlying theme of the presentation will be the struggle of this group for recognition in a community which, until quite recently, refused to recognize that heterosexual HIV+ positive people even existed.

The paper will attempt to discuss the social isolation experienced by HIV-positive women in this country, and the attempts made, by means of self-help groups and our own presentations in the media, to break this isolation. The following is an extract from a speech held by the author at WHO's regional office in Copenhagen on World AIDS Day, 1988:
 "To be a Positive woman is incredibly lonely. Heterosexual circles are simply not used to the idea. When I was diagnosed, I contacted the AIDS - Hotline, looking for support and information for women with HIV / AIDS. There was absolutely nothing for us women. Today the situation is not much better... but now we've started our own support group - we're getting stronger".

The paper is based upon the author's own personal experiences as an HIV+ positive woman.

D.691

HOW AND WHY IN LATIN AMERICA: LESSONS FOR THEIR FUTURE

K. SANDRINI, F. STONE

Johns Hopkins University/ABDOCO, U.S.A.

Objectives: To illustrate the importance of developing AIDS prevention interventions targeting non-prostitute women in Latin America.

Methods: An evaluation of existing AIDS prevention programs in Latin America revealed a wide absence of programs targeting women not employed in prostitution. The epidemiology of AIDS amongst the vast majority of HIV positive currently seropositive and at-risk sexually active women was the epidemiology of AIDS in the general population. There were very few cases reported in 1988 occurring among women, suggests that this pattern is likely to persist.

Results: An unmeasured number of women have more than one sexual partner, plan to do so for HIV/AIDS. The fact that so common percentages of men have multiple partners, including female and male prostitutes and other men, also places "heterosexual" female partners at risk. These risks must be understood and addressed. In order to improve prevention interventions in Latin America, the epidemiology of AIDS in the general population must be understood. Researchers tend to ignore that non-prostitute women are also at risk.

Conclusions: Program planners must recognize that non-prostitute women in Latin America are also at risk for HIV/AIDS. Programs are needed to educate them and modify their behavior to reduce their risk of exposure to HIV.

D.688

CLINICAL ASPECTS IN THE FIRST 81 AIDS CASES AMONG WOMEN IN MILAN

Adriano Morfanti Antonelli*, Galli, M., Vignani, G.M.**,**

Vignoli, P., Seracino, A.**, Rizzardi, G.M.** and Valacchi, L.L.**,
 *Infectious Diseases Clinic, and **Infectious Departments, Sacco, Milan, Italy**

Objective. The main risk-factor for AIDS in Italy is IV drug use (IVDU). A considerable number of cases occur in women. Objective of this study is to describe clinical aspects of AIDS in women.

Methods. 478 cases of AIDS (16.4% of total Italian cases) were recorded from 1984 to 1988 in I. Sacco Hospital, Milan. All informations have been collected from clinical records.

Results. 81 out of 478 (16.9%) AIDS cases were diagnosed among women. 46 of them (56.4%) were IVUDU, 16(19.7%) were previous IVUDU (ex-IVUDU), 17(21%) were sexual partners (SP) of anti-HIV pos. men (16/17 recorded from 1987) and 2 (2.4%) were transfused (all before 1985). PCP was significantly more frequent an indicator-disease in SP (10/17) and ex-IVUDU (7/16) than in IVUDU (6/46) (p 0.001 and p 0.01 respectively), while deep fungus (DF) was more frequent in IVUDU (15/46 vs. 3/23, p 0.05). Kaposi's sarcoma (KS) was observed in 7 cases (9.6%) and lymphoma in 2. AIC was present in 6 cases (5/6 IVUDU).

Conclusions. DF have been considered to be more frequent in IVUDU, while ex-IVUDU have clinical course similar to SP. KS is relatively frequent among women.

D.690

RICE BIALS DO GET AIDS: A SUPPORT SYSTEM FOR MIDDLE CLASS WOMEN WITH HIV INFECTION

Nicholas Nussbaum, Paffer, M.,

*Beth Israel Medical Center, New York City, USA

Objective: To present a rationale for and a model of support needs for middle class women in the US: identifying needs, establishing services, and making them available to patients.

In early 1988, two seropositive professional women requested that a supportive network be created for middle class women. Existing support groups focused on IV drug problems and did not meet their needs. At times, attending these groups made them feel even more estranged from other patients. A survey of treatment agencies and individuals showed that a need for this service existed. A support group began meeting twice monthly in August 1988. As of January 1989, 35 women had attended the group or social activities. The problems which have surfaced will be discussed along with the measures taken to address them. Recently services have begun for the husband and boy friends in a separate group. Guidelines for creating similar services in other facilities will be offered.

D.692

PREVALENCE OF ANAL INTERCOURSE IN WOMEN AT A COUNSELING-TESTING SITE

Comolly, Dennis, Brennan, A, Waters, D, Gocke, D,

Robert Wood Johnson Medical Center, New Brunswick, New Jersey, United States of America.

Objective. The high risk of HIV-1 transmission by anal intercourse is well-recognized for homosexual men, but the frequency of this activity in heterosexuals is not well known.

Methods. We questioned 102 consecutive female clients of our HIV counseling and testing service about their participation in anal intercourse and other risk activities using a directed questionnaire. Their ages ranged from 17-46 years. 82 were white, 9 black, 7 Hispanic and 2 Asian.

Results. Twenty-one reported anal intercourse at some time in their life. Eleven reported the frequency to be "occasional", 5 reported varying frequencies as often as once weekly, 1 reported a preference "all the time", and 4 declined to report frequencies. The 6 individuals reporting frequent or preferred anal intercourse also admitted to multiple sexual partners and unprotected sex.

Conclusion. Thus, 21% of an unselected sample of heterosexual women attending an HIV counseling center had experienced anal intercourse at least once. 6% who did so frequently also engaged in other high risk behavior. This study supports the need for health care providers to recognize the frequency of anal intercourse in heterosexuals and to provide topic specific counseling.



Publications

Le SIDA et l'individu
AIDS and the Individual

D.693

EVOLUTION

AMÉRIQUE

SORCABA AMBULATORY AIDS EXPERIENCE WITH PROSTITUTES

SONCALVES, V.L.C. - Dos Anjos, R.M.F. - Ramos, T.F. - Gomes, M.C.O., BRAZIL
Our study has been realized with 54 promiscuous sexual life women, in a period going from January 1986 to November 1988, and among the following was observed:-

1. Median age 26,68 years (14 to 41 years).
2. 24 women have children, and among them 67% have more than 01 and less than 05 children.
3. 28 women (51,85%) mentioned and/or was confirmed that had Transmissible Sexual Disease in some period of their life.
4. 15 women (27,7%) used or are using injectable drugs.
5. 13 women (24,07%) present 8 type Hepatitis positive marking.

From the mentioned 54 women 15(27,7%) presented positive HIV (ELISA recommended method).

1. Median age 23,66X (14 to 31 years).
 2. 07 women have children (median 3,14 children).
 3. 09 women (60%) among the ones of positive HIV, mentioned and/or was confirmed, had some transmissible sexual disease in some period of their life.
 4. 10 women (66,6%) used or are using injectable drugs.
 5. 03 women (20%) present 8 type Hepatitis positive markings.
- None of the said women presented AIDS symptoms.

D.694

LES KINSHOIS FACE AU SIDA: UNE TOPOGRAPHIE DE RISQUE

BUMUCADILLA, M.M. - Wau Engundwe*, Schoepfer, R.G.**, Payenroo Iwera*

* Harvard School of Public Health, Boston, USA; ** Projact COMBIBSIDN, Kinshasa, Zaïre; *** Institut Pédagogique National, Kinshasa, Zaïre.

Objectifs. Les Femmes et enfants sont particulièrement à risque du SIDA en Afrique. Comprendre les causes sociales profondes des risques et des contraintes aux changements de comportements.

Evaluation. Evaluer les risques des Femmes dans des circonstances diverses.

Méthodes. Observations-participantes, entretiens en profondeur et analyse institutionnelle qui lient la macrosociologie au comportement des individus.

Résultats. Une topographie des relations sociales avec leurs circonstances matérielles et psychologiques particulières permet de décrire les risques différenciés des femmes différemment situées dans la société. Il ressort des liens précis démontrant comment les comportements individuels sont médiatisés par les institutions socioculturelles.

Conclusion. Des changements socioculturels qui augmentent les ressources dont disposent les Femmes de toutes les conditions sociales sont nécessaires à la prévention du SIDA chez les femmes et leurs enfants à tout âge.

Mots-clés: risque, Femmes, ressources, changement

D.695

ASIAN WOMEN AND AIDS - RESEARCH ISSUES
Yosh, Shoji*Ozawa, PhD in Anthropology, New Delhi, India

This paper identifies behavioural research issues on Asian women and AIDS. It points out that current information/Education for Health strategies used to educate female prostitutes and women about AIDS are often oblivious to the main problem of women's powerlessness. Research is needed on sex tourism and how it contributes to the vulnerability of women and children to AIDS. Also, more information is needed on the "veil of ignorance" which puts women into a communications "purdah" or seclusion. Even when confronted with health information about sexuality, women may not acknowledge it with a behavioural change as it would violate cultural rules of this communications "veil". Efforts to mobilize women's groups at community level can help to bring women out of this "seclusion", but these efforts have yet to gain widespread support. The paper identifies a number of research/action areas which would help Asian AIDS programmes to support women who are struggling to translate knowledge into behavioural change.

D.696

AGE RELATED KNOWLEDGE AND ATTITUDES IN FEMALE CLINICS OF SELECTED HEALTH DEPARTMENT CLINIC, HOUSTON, TEXAS

Torreson Jr, GENE, MD, PhD, FRCPC, FRCGP, M.D., MPH, M.P.H.

* University of Texas Health Science Ctr, Houston, Texas, U.S.A

** Department of Health and Human Services, City of Houston, Texas, U.S.A

Objectives: To determine AIDS-related knowledge and attitudes in women attending selected city health department clinics in Houston, Texas.

Methods: Between 2/28 and 3/25/88, 95 women attending Family Planning, venereology and sexually transmitted disease (STD) clinics completed an anonymous, self-administered risk assessment questionnaire and a brief knowledge (9 questions) and attitude (4 questions) questionnaire.

Results: Overall, 48% of the questions were answered correctly. Questions concerning means of transmission (parenteral, perinatal, sexual) were known (85% correct), but knowledge of natural history of the disease was limited (43% correct). Women with < 4 years of education did worse (p<0.05) than those with > 4 years; Hispanic women (43% correct) had fewer correct (p<0.05) than blacks (43% correct) or whites (49% correct). Hispanic women who completed the questionnaire in Spanish were especially disadvantaged (37% correct). After adjusting for education by multiple linear regression, ethnic differences remained. Eighty-two percent (82%) of respondents believed an IV-drug partner should "never" use condoms but only 58% indicated their partner would do so.

Conclusion: Overall knowledge was limited in this population. Hispanic women completing the questionnaire in Spanish and women with < 4 years of school were at a distinct disadvantage with respect to knowledge about STD.

D.697

THE SEX INDUSTRY AND THE AIDS DEBATE - Australian Conference

Owens, Cheryl, * Bates, J.*

*Prestitutes Collective of Victoria, Australia.

The Conference aimed at AIDS, to disseminate information to the community and the sex industry and to consolidate and develop the policy required to maintain low infection rates.

Conference participants included a range of sex workers and managements, service providers, administrators and policy makers. Keynote addresses and workshops covered subjects including: testing; education strategies and health and welfare issues. Extensive "special" interest workshops were held (L.A., transsexual workers' issues, condom design).

Speeches and workshop recommendations have been published and widely disseminated. Groups were formed of workers from each state where none previously existed.

(4) An exchange of information occurred and a network established which will effect greater consistency and effectiveness in policy and program development aimed at limiting the spread of HIV in the sex industry.

D.698

CONDOM INSTRUCTIONAL BOOKLET FOR FEMALE SEX WORKERS (An Integrated Project)

Pérez, Bernaldo, Rosario, Santo. PROCTET, Ministry of Public Health, Santo Domingo, Dominican Republic

For the development of a Condom Instructional Booklet nothing was assumed. A study was first made to determine the knowledge, attitudes and beliefs of female sex workers of Santo Domingo, D.R. had in regards to condom use and correct placement steps. Once the workers' beliefs, attitudes and patterns of use with their clients were determined and analyzed, a pilot instructional booklet was designed with a creative focus group of female sex workers and an artist.

This pilot was pre-tested. Results showed very low grasp of key message, "Condom protects against AIDS." Two simplified versions were done and pre-tested again. With the results, a combined final version will be printed in sticker format to be placed in motel, hotel, and brothel rooms.

The whole process and materials will be shown.

Le SIDA et l'individu
AIDS and the IndividualSexology
Sexology**D.699** AFFECTIVE RESPONSE AND HIV SEROPOSITIVITY IN LESBIANISM FROM AFRICA (LMA).

Annex Cecilia, M.; Page J.; Maitre I.; Ponsol J.; Pissot J.
Service of Internal Medicine, Hospital "Gaston Pasteur I. Péri", Université
Antoine de Meville, Marseille, France.

Objective: To evaluate the affective reaction and seropositivity an associated with HIV seropositivity in LMA that potentially acquired HIV infection by sharing medical practices.

Methods: We tested anxiety (STAI-Trait) and depression (Beck's Depression Inventory) in 201 lesbians (104 HIV index and 95 females) studied in a diagnostic unit. From January 21 to December 31, 1988, we tested the first day of admission. Furthermore co-factors as: serotyping (anti-HIV), prison, social status, and daily habits (smoke and alcohol) HIV antibodies were tested by ELISA test.

Results: Being seropositive was the only risk factor. Studying in clinical anatomy other risk factors. (HIV) patients (10.1%) were HIV and (HIV) (18.1%) were not. Differences for seropositivity were in class of medication (14.1% vs 23.2% in a HIV and 13.1% vs 14.1% in HIV) and social status (1.1%) being the seropositive is sex, age, actualizing level, prison, daily habits (smoke and use of other drugs).

Conclusion: Anxiety and depression are frequent in lesbians however but the affective disorders are not related to HIV seropositivity, but the infective results of sharing medical care seem to be influenced by affective disorders.

D.701 CONDOM USE AMONG HOMOSEXUAL MEN

McComb, S.*; Rust, J.**
*City University, London, U.K., **London University, Institute of Education, U.K.

Objective: To investigate condom use during sexual activity and to identify HIV problems associated with the use of condoms.

Methods: A postal questionnaire survey of 262 homosexual men.

Results: It was found that, in spite of the general move by homosexual men towards safer sex practices, half of the men continued to engage in insertive anal intercourse. Almost 90% ejaculated during this activity and of whom one third did not use a condom. Additionally, 90% of those who ejaculated during oral sex did not use a condom. Thirty two percent of those who had used a condom during anal intercourse reported at least one incident of condom breakage. When looked at in terms of frequency of individual condom use, it was found that 1 in 27 condoms break during this activity. Examination of the reasons reported for breakage indicated that physical stress on the condom was almost always thought to be responsible for these incidents.

Conclusion: Given that current condoms have been designed for vaginal use, these results indicate the need for an investigation of a separate specification for homosexual anal intercourse.

Consommateurs de drogues par voie intraveineuse
IV Drug Addicts**D.703** COUNSELLING INTRAVENOUS DRUG ABUSERS ABOUT AIDS AND HIV-TST IN THE OUTPATIENT METHADONE CLINIC

Department of Social Psychiatry University Hospital, Zürich, Switzerland.

Objective: Should the test be recommended to methadone patients and to deal with all patients.

Methods: Therapeutic consultations of 2 centres for drug-addicts were questioned about 97 well-cared for patients.

Results: Disruptive reactions about a positive test were rare. In 2 of the 3 observed cases the positive test was combined with first symptoms of AIDS. Negative as well as positive patients protected themselves an others better and showed increased compliance in medical care after knowing their status. Patients however who had avoided the test changed their behavior less during the period of evaluation despite of numerous public safety campaigns. The severely ill patients tend to deny their situation (often with the help of drugs) most of the time. However at those rare moments when dental breaks down self-aid to despair the need very much an open discussion with a person they can trust.

Discussion: The most important issue is to combine methadone treatment with professional counselling and medical care. Only within a good relationship to the therapist can a normal coexistence of the body and the object relations be established in the former IVDA, which then results in better prevention.

D.700 CONDOM USAGE DECISIONS AMONG GAY MEN

Larkin, Martin¹; Brooks, C.²; Sichel, K.²
¹Stanford College, Menlo Park, U.S.A.
²Memorial Sloan-Kettering Cancer Center, New York City, U.S.A.

Objective: To understand gay men's decisions to use or not use condoms.

Method: Focused interviews.

Results: Analysis of qualitative data from an ongoing study of sexual decision-making among gay men expands our understanding of condom usage within this population. The initial 80 interviews indicate that varying perceptions of the risks associated with insertive and receptive intercourse (anal and oral) highly influence condom usage. Men who believe that condoms prevent transmission of HIV during anal and/or oral intercourse are likely to use condoms. However, men state the following beliefs as reasons for not using condoms during fallatio and anal sex: 1.Receptive anal intercourse without ejaculation or prenasal fluids does not transmit HIV. 2.HIV is not transmitted to the insertive partner during anal intercourse. 3. Condoms are more oral sex without ejaculation or prenasal fluids does not transmit HIV. 4.Receptive oral sex even with ejaculation or prenasal fluids does not transmit HIV because saliva and gastric juices kill the virus. Furthermore, some men decide to abstain from oral and anal intercourse because they believe that condoms decrease erotic pleasure or are ineffective protection against HIV transmission.

D.702 SEXUALITE DES PERSONNES DEVENUS SEROPOSITIVES ANTI-VII

Bachet-Morellet, Sophie¹; Dutey F.²; Motrono G.Vand Trapp O

¹Hôpital NORD-EST ²Hôpital des Sciences, Lyon, France.

Objective: La sexualité des personnes devenues séropositives anti-HIV nous a paru importante à explorer de fait des difficultés nouvelles liées à cet

absence d'aide de référence sur ce thème.

Methods: En 1988, nous avons distribué un questionnaire anonyme à 86 personnes séropositives anti-HIV suivies dans centres spécialisés de Lyon.

Une centaine de questions portait sur leur vie sexuelle, affective, relationnelle, leurs représentations corporelles et leur sexualité.

Résultats: Les résultats montrent que cette population semble vouloir une sexualité sexuelle complexe (3 profils émergeants possibles). Dans les entretiens de la découverte de la séropositivité anti-HIV, l'individu se perçoit comme dévalorisé avec un vécu corporel de mort, de malaise, de transformation irréversible. La sexualité est marquée du fait d'une sidération importante de leur réalité particulièrement chez les homosexuels. Les actes en couple initialement décrits avec chute de la communication dans leur relation à l'autre tandis que 50 à 60 des couples évoluent vers la rupture ou l'isolement relationnel. L'information sur la séropositivité anti-HIV est détournée au maximum unique dans 80 à 85 des cas, et dans 3 des cas à ses partenaires sont multiples.

Conclusion: Cette population semble dans l'attente d'une écoute et d'une reconnaissance de ses difficultés. 30 à 40 % demandent une aide sur le plan sexuel qu'il nous paraît indispensable de proposer, associée au cadre de suivi médical de ces personnes.

D.704 ACCEPTABLE HEALTH CARE FOR IV DRUG USERS

Kiloh, Richard and McCarthy, M. AIDS Coalition to Unleash Power, New York, New York, U.S.A.

Objective: To discuss new case management strategies for HIV-infected IV drug users (IVDU). **Methods:** Interviews with recovering and active addicts, drug treatment professionals, physicians and community based health care workers. **ADAPT. Message:** In evaluating treatment for HIV-infected IVDU, we must consider the following models for treating IV drug use. **Method:** Outreach maintenance programs are characterized by an emphasis on controlling and monitoring the addict rather than on effective treatment of the disease. This strategy is inappropriate for treating HIV infection. The centralized research model has an inadequate treatment capacity and is impossible to meet IVDU. Flexible, community-based treatment, mobile support service units, and outreach programs for IVDU are underfunded, while research programs are designed to increase established funding sources. There is a need to make drug treatment available on demand in combination with health care for HIV infection: an active IVDU who is not dealing with his/her addiction cannot be expected to keep doctor's appointments. Because most IVDU live outside the health care system, they do not have access to preventive treatment for HIV infection. They enter the health care system after they are asymptomatic. IV drug users, routinely handled with prudence and coercion, need to understand informed consent and patients' rights before receiving experimental AIDS therapies. Support services must accompany the HIV test. **Conclusion:** Viable strategies for case management of HIV-infected IVDU should be flexible, community-based, accessible, and together with drug treatment, available on demand.



Le SIDA et l'individu AIDS and the Individual

Publications

D.705 EVALUATION OF A SUPPORT PROJECT FOR IV DRUG USERS WITH AIDS IN AMSTERDAM

DOOR: Frans van den Berke, Jacky Driessens, Anita Meesters
Netherlands Institute of Mental Health, Utrecht, Netherlands

Objective: evaluate effectiveness, feasibility and endurance of a support project for IV drug users with AIDS. **Method:** Often IVUs do not have stable relationships or supportive networks. Contact with family of origin may often be disturbed. Referral from the hospital to the "home" situation can be difficult, because of the absence of a home(life) and/or a supportive network. In Amsterdam a support project for IVUs had been operative since January 1989. The program will be evaluated with respect to feasibility, endurance, effectiveness and client satisfaction, using Goal Attainment Scaling, Problem Oriented Records, and psychiatric interviewing instruments.

Results: The first results of the study will be presented.

D.706 Social characteristics of drug-addicted and non-drug-addicted patients for human immunodeficiency virus.

Authors: Louis J.G. Meeus, Sophia J. Prins, Bart van der Wal, Peter van Tilburg and Antonio Lauri. - Franciscus J. Meelis Institute, Groningen, The Netherlands.

Abstract: Analysis of the different social characteristics in female patients seropositive for human immunodeficiency virus (HIV) and drug-addicted persons.

Methods: Analytic and clinic investigation. Social relations studies of 35 female patients seropositive for human immunodeficiency virus (HIV) and drug-addicted persons.

Results: Comparison of clinical classification of diseases caused by HIV revealed 28 HIV patients to Group II, 40 patients (75,7%) belong to Group III, and three patients (5,4%) belong to Group I.

All of the mentioned patients were drug-dependent.

Age of the mentioned patients ranged from 19 to 47 years. The age of the non-addicted patients ranged from 19 to 47 years.

Of the mentioned patients, 11 (31,4%) were never married (11,7%) and four (11,4%) were married (10,4%). 14 (40,0%) patients had had sexual relations and shared needles with persons infected with AIDS, and 41 (80%) used to have sexual relations with several persons.

Many of the HIV had antecedents of use of more non-transmissible diseases and/or viral hepatitis B.

The serology of HIV was investigated. Concomitantly tests laid out a 100% sensitive. In France three groups of different social characteristics.

In accord with the authors classification, HIV positive patients: A-B-C-D-E-F-G-H-I-J-K-L-M-N-O-P-Q-R-S-T-U-V-W-X-Y-Z.

Group I: 35 patients (70,5%)

Group II: 12 patients (23,8%)

D.707 HIV TRANSMISSION IN SEMI-CLUSTED CONDITIONS OF BRANCHES OF TROPICAL MEDICAL CENTERS

Authors: E. A. Mareschak, N. S. Stetler, L. J. Carvalho, M. S. Lima, M. P. J. S. Belloni, E. S. B. C. Castro Corsini. (CCIL), Campinas, São Paulo, Brazil.

Objective: To analyze transmission of HIV under simulated conditions of absence of hygienic equipment by intravenous drug users.

Methods: In a laboratory setting, hygienic equipment was exposed to HIV (in viral titration). Attempts were made to culture virus in media after eight conditions of exposure.

(1) Uncontaminated needle-syringe left lying for an interval of one minute or one hour after exposure ("floating needle"); (2) A series of needles exposed and left lying for 15 seconds or a minute ("needle stick"); (3) Liquid medium exposed to HIV-contaminated media ("shared syringe"); and (4, 5) separate or incomplete disinfection with bleach and/or water ("disinfection trials"). These separate trials were made under each condition.

Results: HIV was successfully cultured under all three trials each of the "floating needle/syringe" trials, the "needle stick/syringe" trials, and the "disinfection trials with water" conditions. HIV was not cultured from any of the three trials of each of the "floating needle/syringe" trials, the "needle stick/syringe" trials, the "shared syringe", the "disinfection trials with bleach", or the "disinfection trials with water" conditions.

Conclusions: HIV originates from empty, contaminated syringes, or under well-washed conditions, appears to be less dependent. HIV would appear to be viable for a longer period of time as opposed to needles in the interior of hygienic equipment than on the exterior surface. HIV disinfection by bleach rinsing appears to be efficacious; water rinsing does not appear to be effective.

D.708 CONTRIBUTION DE LA PSYCHOLOGIE ET LA PSYCHIATRIE A LA PRISE EN CHARGE INSTITUTIONNELLE ET INDIVIDUELLE DES TOXICOMANES INFECTES PAR LE VIH.

Charles-Nicolas A. * et Condomini J.P. **
*Psychiatre, Mécéc-Directeur du Centre Pierre Nicole, Croix Rouge Française, Paris. **Psychiatre, Mécéc-Consultant au Centre Pierre Nicole, Croix Rouge Française, et Délégué Médical d'ADAPT (Paris).

L'approche phénoménologique temporelle des difficultés psychologiques rencontrées par les toxicomanes confrontés au sida illustre le défaut fondamental que représente l'aspect temporel chronique chez le sujet présentant des conduites addictives toxicomaniales. Les aspects spatiaux et corporels sont étudiés. La clinique analytique permet de mieux appréhender les mécanismes de défense mis en place par le sujet toxicomane séropositif pour le VIH ou déjà en traitement pour le sida. Le concept de la conduite ordinale donne une explication à l'intégration du sida comme une nouvelle conduite de risque chez le toxicomane. Ces deux approches sont complémentaires et dégagent de nouveaux axes psychothérapeutiques en matière de prise en charge institutionnelle et individuelle des toxicomanes infectés par le VIH. Plusieurs cas cliniques de patients suivis pendant deux années minimum sont exposés.

D.709 HIV INFECTION IN I.V. DRUG ABUSERS :

Letts, E.A.; Mareschak, N.; Stetler, L. ; Carvalho, M. S.; Lima, M. P. J. S.; Belloni, E. S. B. ; Castro Corsini, (CCIL), Campinas, São Paulo, Brazil.

Objective: To measure the prevalence of the HIV infection in I.V. drug abuse. (spontaneous request).

Method: The I.V. drug abusers in attendance of CCIL are tested for HIV (E = WB). The patients are oriented by a multidisciplinary education and assistential program and the seronegatives are retested more or less in each 3 month.

Results: 61 I.V. drug abusers, 43 (tested positive with HIV infection) were seropositives between 11 and 35 years of age (32,5% less than 20 years of age) and 42% with less than one years of I.V. 36 patients have been attended drug user. Of from group I, 13 from group II, 14 from group III, 03 from group IV and 05 which have not been classified.

Conclusions: The risk of an acquisition of HIV between I.V. drug abusers is extremely high, where we can see that most of the seropositives an contaminated with less than one years of I.V. drug user.

D.710 AIDS AND PSYCHOSOCIAL TREATMENT

Authors: Irving Huk-Frivate Practice, Calgary Alberta, Canada.

Objective: An exploratory study systematically examined the hypothesis that a specific social work intervention, Heimer's Social Functioning, would provide effective psychosocial care to persons with AIDS. **Methods:** The method employed to test the hypothesis was a single system design, specifically, the ASA model. The study was replicated with seven subjects, five of whom were homosexual males, one a bisexual male and one a female intravenous drug user. Four subjects completed the study, two died and one withdrew because of memory loss. The instruments used to measure needs and response to treatment across the three phases included Heimer's Scale of Social Functioning (Heimer, 1987) and a Self-Anchored Scale specifically designed to measure the person's feelings and perceptions of memory and body images changes. **Results:** Findings revealed that distress permeated all dimensions of the person: physical, emotional, intellectual, social and spiritual. The intervention alleviated perceptions of distress and promoted coping that increased quality of life.

Publications

Le SIDA et l'individu
AIDS and the Individual

Psychology

D.711

USE OF PROPRANOLOL FOR AGITATED BEHAVIOR IN AIDS
SHEINMAN, CARL
St. Vincent's Hospital and Medical Center, New York, USA

Objective: Although AZT is useful for the treatment of HIV encephalopathy, behavioral disturbances in these patients may remain during with this drug. Propranolol has been described to be useful for agitation and other behavioral disturbances associated with Huntington's chorea, a disorder which also affects primarily subcortical structures. Propranolol was used to treat agitation in a patient with AIDS dementia.

Methods: A 29-year-old homosexual male had progressive gait and cognitive impairment over a 3-month period. He became doubly incontinent and confined to bed because of poor balance. After 5 weeks of therapy with oral AZT he became able to ambulate. However, he was hypomanic and disruptive. Incontinence persisted. Propranolol (120 mg in two daily doses) was added to the therapeutic regimen.

Results: Addition of propranolol resulted in marked improvement within 10 days. Incontinence, paranoia and outbursts of agitation disappeared. Propranolol was discontinued after 10 weeks and improvement persisted. The patient continued to take care of himself at home and was fully ambulatory and oriented. A mild attenuation of affect persisted.

Conclusion: This clinical observation suggests a role for propranolol in the treatment of the behavioral disturbances observed with HIV encephalopathy. Experience with a cohort is needed to substantiate this observation.

D.712

Coping With the Psychological Effects of an HIV Infection in Patients in Outpatient
and Inpatient

LEUNG, TERRY, LACROIX, BÉLIS
Université de Montréal, Québec, Québec

Aim: To assess the effectiveness of psychological support services

in the follow-up of various psychological and sociological factors such as drug addiction of female patients with HIV infection and/or their partners, sexual contacts, personality characteristics in their interacting with the illness.

Group studied:

40 of 111 patients with an HIV infection who had special counselling from 1982 to 1983. 63 were interviewed on a volunteer basis.

Method:

Besides the interview a sociological-psychiatric evaluation and behavior analysis were conducted between interview and re-interview treatment.

Results: In the group of drug addicts, we saw counter-productive forms of coping with the illness. This was shown by denial, behavioral which was inappropriate to the illness, extraction of anger and despair.

Conclusions:

The psychological and sociological programs encompassed medical treatment, including a partial substitution program using naltrexone to substitute drug use influences the negative manner in which drug addicts cope with being HIV positive in a positive way.

D.713

ANGER: AN IMPORTANT PSYCHOLOGICAL MEASURE IN HIV DISEASE
LAVY, ELIZABETH, KUPFF, P., JILINS, R., JAYAR, K., STODDARD, A., AND
ANDERSON, J.

Boston University School of Medicine, Boston, MA, USA; **Farnsey Community Health Center, Boston, MA, USA; ***University of Massachusetts, Amherst, MA, USA; ****To establish baseline data for the associations for psychological and immune parameters in a cohort of sexually active gay and bisexual men.

Methods: The first 150 members of a cohort from the FHC were given a battery of psychological measures (including Anger Expression Scale, Hardiness Test, and Profile of Mood States) and had blood drawn for immunological measures (quantitation of CD4 and CD8 subsets, lymphoproliferative assay).

Results: Differences between groups were found for the number and % of CD4 lymphocytes and % of CD8 lymphocytes and the response to the mitogen PHA and ConA using one-way ANOVAs. Surprisingly, the groups did not differ in any of the psychological measures. However, there were intriguing differences in correlations between the groups. The most interesting involved the anger expression scales as indicated in the table below. * p < 0.10, ** p < 0.05

HIV- HIVNA HIV+0		HIV- HIV+0	
Ang-In v CD4	0.22 -0.45* -0.35	Ang-In v CD8	-0.01 0.23 0.78**
Ang-Out v CD4	0.03 -0.29 -0.42	Ang-Out v T4	-0.10 0.42 0.76**
Ang-Out v PHA	-0.06 0.31 -0.85**	Ang-Out v CD8	-0.10 0.41* -0.75**

Conclusions: Both anger-in and anger-out were associated with fewer CD4 and greater CD8 cells in the HIV+ groups. Furthermore, anger-out was associated with lymphocyte function. The expression of anger may be an important variable for longitudinal studies of psychosocial effects in AIDS.

D.715

PSYCHOLOGICAL ASSESSMENT OF MINORITY WOMEN
AT RISK FOR AIDS: A PSYCHOMETRIC PILOT STUDY
KROHNE, GAIL, AND LASTERAS, J.

*University of California, Los Angeles, U.S.A., **University of California, Los Angeles, U.S.A.

Objective: A pilot study to describe the psychometric evaluation of several instruments designed to assess the major stresses experienced, the coping responses used, the factors affecting these responses and psychological outcomes with 70 minority drug abusing and homeless women.

Methods: Reliability, content, convergent and divergent validity was assessed on the following instruments: Inventory of Current Concerns, Coping Scale, Social Support Questionnaire, Profile of Mood States, Social Self Esteem Inventory and Locus of Control Scales.

Results: Factor analysis isolated five dimensions which accounted for 72% of the variance. These dimensions included Emotional Distress, Coping Responses, Social Support Perceived as Useful, Situational Attributions and Personal Attributions. The alpha reliability coefficient for all subscales was .82. Content convergent and divergent validity was established. Contrasting groups analysis on a small sample of low-risk women indicated statistically significant differences in the majority of subscales assessed.

Conclusions: The psychometric investigation of instruments which provide a multidimensional approach to assessing coping and psychological adjustment of minority women at risk for HIV infection can enhance the assurance that subsequent screening interventions are implemented based on reliable and valid information.

D.714

PSYCHOLOGICAL IMPLICATIONS AMONG PATIENTS WHEN RECEIVING ANTI HIV POSITIVE
MARQUES, K.M., FONTANA, M.A., SIOUVEAU, S.G.E., ROSSETI, G., LIMA, M.F.J.S., BELLISSA, S.B.E., AND
CENTRO CORSAI (CCIC), CAMPINAS, SÃO PAULO, BRAZIL

In the holistic vision of the work with patients HIV positive, the Psychology division has been developing a global work that has its aim in the patients emotional stability and better quality of life. This approach, plus a therapy that helped the patient to receive the positive results from HIV test, allowed us the conclusion that when working established stages, there are no reactions such as suicide, psychiatric hearing and deliberate intention to transmit the virus like it is shown by the press. Observed among 82 patients in this case from the initial shock with responses such as effective cry or psychological numbness (emotional blocking), having perceptions interlaced with: improper thoughts, emotions generated by events and fixation of non-resolved situations. Having as reaction continuous anxiety or disphoria and showing as a constant a necessity of affective integration. We also notice that these patients show difficulty to have the correct understand of being an asymptomatic carrying of the virus but by not being sick. These patients when working properly will modify internally their state of shock.

D.716

THE AIDS DEMENTIA COMPLEX (ADC) AND IMPAIRMENTS OF
AMBULATORY ACTIVITY

REILLY, JOHN S., TRYON, W.W., BROW, S.J., SAEGER, A.E., ARONOW, H.A., PRICE, D.A., SIGELIS, J.J., AND
* Memorial Sloan-Kettering Cancer Center, NY, NY, USA; ** Fordham University, Bronx, NY, USA.

Objective: To assess the relationship between symptoms of the AIDS dementia complex (ADC) and decrements in overall ambulatory activity.

Methods: 16 HIV-1 infected patients with early symptoms of the ADC were evaluated with the Neuro-AIDS Study Group neurological history, examination and neuropsychological (NP) battery. Each then wore a 2" x 3" electronic motion detector (Actigraph (TM); Ambulatory Monitoring Inc., Ardsley, NY) on the waist continuously for a period of 7 days. Minute-to-minute recordings of waist movements greater than 0.1 G were obtained.

Results: Subjects with abnormal reflexes and limb incoordination showed lower levels of overall ambulatory activity (1-54, df=14, p=0.7), as did those with marked abnormality of either smooth pursuit or saccadic eye movements (1-27, df=14, p=0.2). The number of these abnormalities correlated significantly with decrements in activity (r=-.60, p=0.1). NP tests assessing speed of planned, coordinated motor movement were also correlated with activity level (time gait, r=-.54; Trail Making A, r=-.52, and B, r=-.55; Grooved Pegboard dominant, r=-.49 non-dominant, r=-.34, p<0.05), but self-ratings of both mood and psychiatric symptomatology were not.

Conclusions: Analysis of this initial sample of ADC patients indicates that activity decreases markedly as motor control becomes impaired. A more detailed analysis of 24-hour variability in activity is currently in progress on a larger sample, to further investigate these relationships.



Le SIDA et l'Individu AIDS and the Individual

Publications

D.717

IMPACT DE L'ATTITUDE DES SOIGNANTS SUR L'ETAT PSYCHOLOGIQUE DES PATIENTS ATTEINTS DU SIDA.

Courcyer, C.*; de Montigny, J.**; Charpentier, S.***
* Infirmière, Hôpital Hôtel-Dieu, Montréal, Québec, Canada;
** Psychologue en pratique privée, Montréal, Québec, Canada;
*** Personne atteinte du sida, Montréal, Québec, Canada.

Dans le but de saisir l'influence des attitudes des soignants sur l'évolution physique et psychologique des sidéens, un échange entre infirmière, psychologue et personne atteinte du sida sera animé autour de la question de la perception, de la signification d'une maladie terminale tant pour les patients que pour les soignants. L'analyse des réactions individuelles et collectives nous permettra d'évaluer l'ampleur des mécanismes de défense contre la peur d'une mort transmissible.

L'approche systématique préconisée vise essentiellement à explorer les besoins de sollicitude, de compassion et de contribution entre soignants et patients dans un processus de sur une maladie terminale et à démontrer les bénéfices secondaires d'une attitude humaniste inscrite dans une approche multi (ou inter) disciplinaire comme soulagement de la douleur globale.

LE SOUTIEN PSYCHOLOGIQUE COMME EXERCICE. VERTADIER, Alain. Association AIDES, Comité de Paris, France.

Objectif: Diminuer l'anxiété en enrichissant la "visualisation positive" des personnes séropositives HIV ou malades.

Méthode: Groupe de six à huit personnes dont deux séropositifs. Chaque réunion comporte exercices et échanges d'expériences entre les participants et feedback.

Exercices: relaxation musculaire et mentale, expression graphique (dessins) et rêve éveillé. Thèmes des exercices : les aspects considérés comme négatifs (la mort, la souffrance, la dépendance physique) et les aspects positifs (la résolution des difficultés physiques, mentales et sociales).

Cette méthode modifie la "vision globale du monde" de la personne, de son environnement à travers les organes des sens, les représentations des rôles dans un entourage (médical, familial ou professionnel), les conceptions sur la maladie, la guérison, la santé. Elle invite chaque participant à découvrir sa force intérieure. Nous appliquons cette technique "vision force".

Résultats: Trois groupes, soit 28 personnes; durée d'appropration de la méthode : 4 séances de 4 heures tous les 15 jours. 25 disent utiliser cette méthode seuls en un an après le début des exercices pour mieux gérer des situations difficiles et ont enseigné cette méthode à d'autres.

Conclusion: Cette une approche peut être caractérisée de "formation" (selon l'formation) Il s'agit d'apprendre quelque chose de nouveau. Conseil : cet apprentissage est accompagné).

D.721

LE COMPORTEMENT SEXUEL A-T-IL CHANGÉ A CAUSE DU SIDA ? ÉTUDE DANS LA POPULATION NORVÉGIE.

Lousballe R. M., Borge R. M., Bekkevold M., Bekkevold R., Hennig G. E., et al. D. Knaaheia. *
* Ecole de Santé Publique, Université de Kinshasa/Zaire
* Tulseve SPSTU, Oslo, Danemark, N. O., U.S.A.

Objectif: Évaluer les changements dans le comportement sexuel à cause du SIDA au Zaire et à étudier le "contexte".

Méthodes: Les répondants ont été sélectionnés informativement vu les difficultés pour avoir l'information sur les habitudes sexuelles d'une personne utilisant les méthodes traditionnelles d'enquête. Les enquêtes ont été conduites dans les différentes couches socio-économiques du pays. Les répondants ont un voisin ou un ami avec qui le cohabite sans avoir connaissance sur son comportement sexuel. À la fin de cohabiter, l'enquêteur note les informations enregistrées par coquer sur un questionnaire à l'issue du répondant.

Résultats: Sur les quelques cas vus, les tendances semblent refléter la situation telle que connue empiriquement dans le parler quotidien des gens. Les filles non-mariées ont tendance de réduire le nombre de partenaires sexuels. Les hommes (marisés et non-mariés) ont tendance de plus en plus des condomes.

Conclusion: Ces résultats préliminaires suggèrent que la population au Zaire est un terrain de changer au comportement sexuelles. Ceci se fait qu'accroître notre optimisme dans le grand combat pour vaincre le fléau du SIDA.

D.718

IMPACT PSYCHOLOGIQUE DU SIDA ET STRATEGIES D'INTERVENTION APRES DES SIDÉENS.

de Montigny, Johanne, M.Ps. Psychologue en pratique privée, Montréal, Québec, Canada et Consultante en psychologie au Comité Sida Aïdes Montréal (CSAM).

Les données cliniques présentées visent à analyser et à évaluer l'impact des réactions psychologiques chez des patients atteints d'une maladie terminale afin de permettre l'élaboration de stratégies d'adaptation à la situation paradoxale de survivre à la menace d'une mort imminente.

Par le biais d'exemples de cas cliniques suivie en bureau privé, à domicile et à l'hôpital, on pourra montrer les méthodes d'approche et élaborer un modèle d'intervention adapté aux étapes évolutives entre le diagnostic, le pronostic et la phase terminale de vie. Il sera question des particularités entre les catégories individuelles et de groupes ainsi que des particularités entre les groupes de personnes atteintes du sida, de personnes séropositives et des proches de ces deux groupes.

Les éléments de contenu tentent de clarifier le rôle du psychologue et l'importance d'autres professionnels et/ou intervenants face à la problématique psychologique du sida.

Sexologie

D.720

SEXUAL DEVELOPMENT AND THE SERO-POSITIVE GAY MALE

Marcotte, Glen* Valentic, M.**

*AIDS Calgary, Calgary, Alberta Canada. **The University of Calgary, Alberta, Canada.

Objective: To describe the impact of sero-conversion upon the sexual development of the gay male. Implications for the involvement of social work are discussed.

Method: A literature review and intensive, unstructured interviews with 3 Western Canadian sero-positive gay males. Additionally, the senior author draws on background knowledge gained while working with an AIDS community group.

Results: The use of the Eriksonian developmental schema and Marcia's identity status model were found to be useful in understanding the concurrence of thanatos and eros. After a positive diagnosis, the sero-converted gay male seeks to resolve these essential forces representing the end and beginning of life. The integrity vs. despair crisis is brought forward into early adulthood. Issues related to identity achievement and intimacy are also discussed.

Conclusion: Sero-conversion impacts seriously on the sexual development of gay males. Social work and other helping professions require knowledge of the gay male's developmental dilemmas as well as the norms of the gay subculture. Dialogue between sero-converted gay males and the social work profession may result in more effective clinical social work service as well as better designed and implemented community-focused services. Social work can take a leading role in destigmatizing and diffusing the health crisis and bridging the private need for confidentiality and the public issue of quarantining.

D.722

FREQUENCY OF SEXUAL INTERCOURSE ACCORDING TO MARITAL STATUS IN THE GENERAL POPULATION.

Per Mønstad, H. Østrem, J.W. Olsen, J.E. Gemeny, L.S. Bakker, Department of Epidemiology, National Institute of Public Health, Oslo, Norway.

Objective: To understand the potential for HIV spread in the general population, empirical data on sexual behavior are needed. We present data on the relative frequency of sexual intercourse in heterosexual relationships with respect to present marital status.

Method: The results are based on responses to a questionnaire on the relative frequency of sexual intercourse in heterosexual relationships with respect to present marital status. A sample of 10,000 Norwegian aged 18 through 60 years. The response rate was 83%. The analysis is restricted to single and married (including cohabiting) subjects reporting heterosexual activity during the past year. The dependent variable is the mean number of intercourse in the past month according to own and his/her partners present marital status, regardless of number of partners.

Results: The mean number of intercourse per month was 4.3 for singles whose last partner also was single (N=408), and 5.0 for the last partner was a married person (N=46). Married subjects with extramarital partners during the past year reports a monthly frequency of 6.7 with spouses (N=279), and 1.7 with extramarital partners when the last partner was single (N=123) and 1.3 when the last partner was married (N=140). Married subjects without extramarital affairs in the past year reports a frequency of 7.0 (N=747). The present data elucidate patterns of sexual activity and may be used as data input in mathematical models for understanding and predicting the HIV-epidemic.



Publications

Le SIDA et l'individu
AIDS and the Individual

D.723

SEXUAL PRACTICES AND HIV INFECTION IN SOME ZAMBIAN PRISONS
Mubumba, J., Simonyo, O., Hira, O., Chifwamba, P. (Zambia, ZWI);
Mukonyandela, M* et al.

*Tropical Diseases Research Centre, Harare, Zambia; **University Teaching Hosp., Lusaka, Zambia; ***Unifomed Services University of Health Sciences, Bethesda.

Objectives: 1. To establish seroprevalence of HIV infection among inmates in 3 urban prisons in Zambia. 2. To study their sexual practices.
Methods: All inmates who had been in prisons for atleast 3 months were enrolled in the study and their clinical, social and sexual information was collected. Serum samples were assessed for HIV-1 antibodies using ELISA (Abbott) and those tested positive were confirmed using Recombigen (Genzyme) and immunofluorescent assay. In Lusaka, rectal smears were taken from prisoners and controls (STD clinic attendees) for gonorrhoeal cultures.
Results: The overall HIV-1 seroprevalence was 256 (16.1%) of 1593 prisoners and 28% were visited among the prisoners.

Prison	HIV prevalence %	Homosexuality %
Mukoboko Makumbo	9.2	13.8
Mukoboko Makumbo	15.2	12.3
Kanfinsa Kabwe	14.8	18.2
Lusaka Central	29.0	4.7
Lusaka Remand	19.8	0.0

The overall prevalence of homosexual activity was in 203 (12.7%) of 1668 inmates. 15 (9.6%) of rectal smears taken from prisoners were positive for gonorrhoeal cultures while none of the smears from control men were positive.
Conclusion: HIV infection is prevalent among inmates in some Zambian prisons and homosexuality exists under deprived sexual conditions.

D.725

ALCOHOL AND HIV DISEASE PROGRESSION IN INTRAVENOUS DRUG
ABUSERS.

Lake-Balmer, C. and Rao, R.S. SERV-Health Science Center, Brooklyn, N.Y.

Alcohol weakens ego controls and is lymphocytotoxic. It might therefore increase the risk of exposure to HIV as well as accelerate disease progression.
Objective: To evaluate the effect of alcohol on the rate of HIV infection and on HIV disease progression.
Methods: Alcohol history evaluated prospectively in 201 IVDA using a questionnaire. Good correlation with CD4 response, acute CRP levels and repeat random interviews. HIV antibody detected by repeat ELISA testing (Abbott).

Results:

	HIV negative	HIV positive	AIDS
n	52	106	42
Age (yr) (SD)	35 (6.7)	35 (6.8)	36 (6.4)
Female	30 (58%)	33 (31%)	13 (31%)
Alcohol			
(40g/d and over)	24 (46.3%)	63 (60.4%)	36 (85.7%)

Alcohol abuse is significantly greater in AIDS than non-AIDS IVDA (p = 0.016; Fisher's exact test). In contrast there is no significant difference in alcohol use between HIV negative and HIV positive patients (p = 0.05).

Conclusion: Alcohol does not significantly increase the risk of HIV exposure but may affect the rate of progression of disease in HIV positive subjects.

D.724


Overview of WHO/UNESCO experience in initiating school health education programmes to prevent AIDS and other STDs.

Keywords: AIDS; School; STD.

*UNESCO Education for the Prevention of AIDS Programme, UNESCO Paris; **World Health Organization, Education Systems Specialist, Health Promotion Unit, Geneva

The National AIDS Plans of developing countries will be analysed with a view of identifying the extent to which they include formal school AIDS education programmes; the dimensions of the problem these programmes are intended to address; and the essential needs, if any, that have been obtained by these programmes up to date.

In parallel with the above study, the AIDS-education materials available at the WHO/UNESCO School AIDS Education Resource Centre (WHOED, Paris), and addressed, in particular, to students, teachers, school authorities, and parents, will be reviewed and a critical and comparative analysis of their approaches to AIDS education content; and teaching/learning strategies and methodologies, will be presented, along with sample illustrative materials.



Le SIDA, la société et le comportement
AIDS, Society and Behaviour

**Colloque
Symposium**

**Le SIDA, la société et le comportement
AIDS, Society and Behaviour**
**Vivre avec le SIDA : le point de vue de personnes atteintes
Living with AIDS: A Person with AIDS Perspective**
M.E.0.1

WOMEN'S ISSUES

Hejlskov, Amanda. Copenhagen, Denmark.**M.E.0.2**

CHILDREN'S ISSUES

Chamness, Barbara. North Cross, GA, USA.**M.E.0.3**

WOMEN'S ISSUES

Waisson, Belinda. Tobinstort, IN, USA.**M.E.0.4**

HOMOPHILIA

Guimarães, Rogério Florio. Brazilian Interdisciplinary AIDS Assoc. Brazil.**M.E.0.5**

AIDS IN THE CARIBBEAN

Sealy, Godfrey. Trinidad and Tobago.**M.E.0.6**

HOMOPHOBIA AND AFRICA

Seabbenis, Peter. Kampala, Uganda.**M.E.0.6.A**

ISOLATION OF PHAs/MEDIA RELATIONS

Bangura, Hassan. Sierra, Leone.

Séance thématique Specialty Session



Le SIDA, la société et le comportement AIDS, Society and Behaviour

Les proches et la famille Close Friends and Family

M.E.O.13 AIDS AND THE FAMILY
Roy, Robert; Miller, R.; Goldman, E.; Johnson, M.; Lee, C.; **Kennedy, J.**
Royal Free Hospital and School of Medicine, London, England.

Objective: To describe the impact of AIDS on families presenting for counselling in a London Teaching Hospital over a four-year period (1986 - 1989).
Method: Families have been interviewed in different hospital units (Thompson, S.T.D., AIDS Counselling, Casualty, Medical Units) over a period of four years. The "Nolan Method" of family therapy has guided the interview approach. Families have been seen at all stages: from the time of diagnosis of an individual; to the period of bereavement. Two thousand interviews have been conducted. Common themes have been recorded.
Results: AIDS is a potentially powerful source of stress on relationships between family members and on the family and other social systems. It exacerbates existing relationship difficulties and leads to new problems over 40 common themes emerged from these interviews. These related to (a) dynamics within the family (20); (b) stresses in the structure of the family (6); (c) problems in the family after someone has died from AIDS (5); and (d) (5); (c) problems in the family and other social systems (10).
Conclusion: AIDS has a profound effect not only on the HIV-infected individual but also on his or her relationships with others. This includes increased stresses within the biological family and the family of affiliation. Counselling approaches which address these may help to reduce psychiatric morbidity in the survivors.

M.E.O.15

THE DEVELOPMENTAL AND FAMILY SERVICES UNIT - A MODEL AIDS PROJECT SERVING ENVIRONMENTALLY DISABLED CHILDREN AND THEIR FAMILIES
Eliason, Karen Green, J.
Albert Einstein College of Medicine, Yeshiva Univ., Bronx, New York, USA

Objective: To assess the developmental needs of HIV infected children to provide rehabilitative and psychosocial services in order to improve the quality of life by optimizing developmental functioning.

Method: This paper describes a model pediatric program that uses a multi-disciplinary team to assess the developmental and psychosocial needs of HIV infected children and their families. The unit includes developmental pediatrician, social workers, psychologist, a medical educator, physician and occupational, physical and language therapists, each of whom perform complete evaluations. The weekly multi-disciplinary conference results in the formulation of an Individual Family Service Plan (IFSP) for each child and his family.

Results: 30 children and their families have been evaluated and are in the program. Family composition were non-traditional and varied. The diagnostic and rehabilitative needs differed as well. The most frequently required services were occupational therapy and psychosocial intervention to increase parental coping skills in handling environmentally disabled, chronically ill children.

Conclusions: Children who are HIV+ are being longer and will have serious deficits. The need to develop services to address the unique developmental and psychosocial needs of these children and their families is paramount.

M.E.O.17

MULTI-PROFESSIONAL EXPERIENCE WITH HIV INFECTED PATIENTS' FAMILIES
MORRIS GROUP IN RIO DE JANEIRO, BRAZIL
Waller, M.A.M.; Cavalcanti, M.L.; Lins, D.F.; Neri, J.A.L.; Lopes, P.A.P.;
Nardi, G.; Lorenço, M.C.; Neri, G. de S., C.A.
Debrife e Saúde Universitária, Universidade de Rio de Janeiro (UNIRIO) - Brazil.

Objectives:

- 1) to inform family members of HIV infected individuals about transmission/prevention and follow up of the patient;
- 2) to give emotional support;
- 3) to stimulate family members and friends to participate in the Social and Health Policies in Brazil.

Methods: Since July 1987 when it started, the study group included psychologists, two social workers and an (RN) doctor that meet weekly for one and half an hour with family members and friends of our patients. During this time period 60 family members and friends of 36 patients were included. Eleven family members continue to participate on the study group even after their patients' death.

Results: Among the 60 family members and friends followed, including those who came exclusively for information, 56 (93%) could meet better with the difficulties of living with an infected person, in 48 (80%) it was observed a clear decrease in the anxiety and depression process. Finally in October 1988, 5 (8%) decided to organize an Association Group of family members of AIDS patients in Rio de Janeiro to discuss and fight against negative situations generated by the AIDS.

Conclusions: The objectives were achieved notwithstanding the numerous social stigmas of AIDS. The preliminary results suggest that it is possible to extend this experience to other hospitals or centers with AIDS care, as happened in 1988 when doctors from other states of Brazil came for training on AIDS care practices on the group and felt the importance of the experience.

M.E.O.14 GAY MEN WITH AIDS: FAMILY OF CHOICE VS. FAMILY OF ORIGIN
Patton, John A.; Walker, G. et al. with Ackerman Institute
for Family Therapy, New York, New York, USA

Objective: A gay man diagnosed with AIDS needs to resolve the disjunction between his gay partnership and friends and his family of origin.
Description: Gay people, in order to establish a gay identity in accord with their sexual orientation, frequently leave their family of origin and sustain long-term cut-offs while establishing a gay family of choice which may or may not include a long-term partnership. When the gay man is diagnosed with AIDS, he often feels a need to resolve this disjunction. His desire or attempt to reconnect to the family of origin may create intense stress as the gay person reenters a world which can retrovise longstanding internalized conflicts. This stress may generate vulnerability to increased illness. The workshop will deal with the delicate balance between forging reconnections and maintaining gay identity in the face of life-threatening illness and will include a discussion of issues of gay identity, sources of work and how values of origin to create bridges between parents and gay children with the gay couples when one partner makes a decision to reconnect with his original family. The area of reconnection requires a high degree of clinical sophistication and extensive knowledge of gay issues. The workshop will analyze the dangers as well as the possibilities for success in reconnection. Videotape excerpts from *Stages of Illness*, an Ackerman AIDS training case, will be used to illustrate themes.
Conclusion: Psychotherapeutic understanding and themes can significantly help in the area of reconnection to family of origin.

M.E.O.16

Effectiveness of a Support Group with Families of HIV Infected Children: A One Year Follow-up
"I Can't Forget", A. Sussman** M. Berthoud** A. Souders*** F. Cascellini** "Kings County Hosp. Bklyn, NY, USA.

**NIH Health Science Center at Brooklyn, Bklyn, NY, USA
***Brooklyn, NY, USA

Objective: To examine the effectiveness of a weekly support group for the caregivers of HIV infected children in 1) reducing social isolation and depression, 2) increasing self esteem and education regarding HIV, and 3) developing a support network.

Method: This report describes the group's development over a 1 year period (6 sessions). 31 families of 36 HIV infected children were invited to attend the weekly support group held in an urban hospital. Participants are referred by staff and by group members. Members include parents, grandparents, and foster parents. Two social workers, a physician assistant and a psychiatric resident facilitate the group while a third social worker leads a children's play group concurrently. Traditional group psychotherapy techniques are utilized.

Results: Groups size ranged from 3 to 15 participants. The average number of participants increased from 8 to 12. Seropositive mothers who acquired HIV behaviorally comprise the largest subgroup. They also attended most frequently. Males failed to attend or remain in the group. Themes such as members' concerns about their health, sexuality and relationships and struggles with being single parents emerged. With time, these women came to focus more on their own emotional struggles and issues and less on more practical concerns of the care of their children. Members attended funerals and visited grieving families at the time of the death of children. They also celebrated the children's birthdays and went on group outings.

Conclusions: A support group for the families of HIV infected children was found to help them cope with the stress and pain of pediatric AIDS. Seropositive mothers demonstrated the greatest need and interest in this intervention. The authors restate their recommendation that this activity be an integral part of comprehensive care.

M.E.O.18

DISCUSSANT:
Horvath, Steven, PWA Coalition, Vancouver
Canada

Coloque Symposium



Le SIDA, la société et le comportement
AIDS, Society and Behaviour

Stratégies innovatrices pour l'éducation des minorités au sujet du SIDA Innovative Strategies for AIDS Education with Minorities

M.E.O.19

SAMU-Stepping AIDS is My Mission-A Minority Adolescent AIDS Education Program.

Carroll, V.J., Assistant Professor of Medicine, University Hospitals of Cleveland, 2074 Abington Road, Cleveland, Ohio 44106. 216-844-3778

SAMU is a two year old minority adolescent AIDS education program. Targeted to predominantly black adolescents at risk, SAMU uses peer pressure to provide a supportive environment to maintain safer behaviors. Founded on volunteerism, SAMU utilizes community persons, black health and paraprofessional professionals, and adolescents to provide AIDS education. Sites are not limited to schools, but rather target adolescents at community centers, detention houses, and Job Corps. Education is provided in a nonjudgmental style, using familiar street terms, as well as black adolescent lingo. Slides of black persons in various stages of HIV infection are also used. In addition to the panel of black PAsas/PNAs/HIV positives who interact with the teens and answer questions. At the end of each session is a social event (dance when permitted), where the SAMU volunteers as well as the disc jockey serve as undercover AIDS educators. By providing free tea, coffee, refreshments and entertainment, SAMU's message is not only to stay safe but to be proud. We believe that our teens are each unique valued individuals. AIDS education in our format is linked to self-respect and empowerment.

M.E.O.20

Triple Jeopardy - Reaching Ethnic and Racial Minority Youth who are Gay - Identified and/or IV Drug Users

Osley, Jacob A., Kent State University
American School Health Association, Kent, Ohio, USA.

American youth are identified as one of the most waves of individuals greatest at risk for HIV infection. Black and Hispanic youth are of special concern regarding increased incidences of HIV infection due to disproportionate HIV antibody seropositivity rates in these racial and ethnic groups. Furthermore, those "minority" youth who are intravenous drug users and/or homosexually active (gay or bisexual) may be at even greater risk because of practices often associated with these identified with reaching either "minority" youth or gay/drug-using youth alone. Very few school-based educational initiatives target such youth in particular.

The American School Health Association has developed strategies to train school-based professionals to prepare for the challenges here-described. This presentation will present some of these strategies.

M.E.O.21

AIDS EDUCATION IN COMMUNITIES OF COLOR: HOW DO WE MAKE A DIFFERENCE

Warren, Elizabeth Lorraine. Babashki, Philadelphia PA, USA.

Those individuals most at risk for HIV infection are also most at risk for a cadre of other maladies which have not as yet been sufficiently addressed in the past by health education. Heart disease, diabetes, hypertension, unplanned adolescent pregnancy infant mortality, all have been addressed in health education targeted toward poor, under educated people of color with very little success. AIDS education can not be successful in altering behavior without defining cultural sensitivity, recognizing cultural mores, consideration of language and cultural/ethnic communications.

A model of education will be presented which incorporates the principals of education blended with the realities of cultural influences. The "how to's" of accessing the community needs, targeting specific populations and developing realistic education and service programs will be highlighted.

M.E.O.22

INTEGRATING HIV/AIDS INFORMATION

INTO SCHOOL HEALTH EDUCATION FOR MINORITY STUDENTS
Warren, Ruben C. Centers for Disease Control

Atlanta, Georgia, U.S.A.
Health education has been taught in the public school system for many years. Unfortunately, strategies to assure relevant and meaningful information have been limited. In fact, such of the school curricula, in general, serve as a barrier rather than an enabler to learning for minority students.

Minority and/or low income students often have limited financial and/or geographical access to health care. Consequently, health issues are low on the priority scale for many of these students. Therefore, innovative models are needed if school health education is expected to influence the knowledge, attitudes, or behaviors of minority students. This presentation focuses on integrating HIV/AIDS information into a health education model for minority students. Emphasis will focus on the students' health goals, other conflicting goals, and competing values and beliefs. Recommendations will be made to assure that the health message are relevant to the total life circumstances of the students. The relationship between knowledge, attitude, and behavior will also be reviewed.

M.E.O.23

AIDS AND MINORITIES: STRATEGIES FOR PREVENTION

Dumphy, James K. Fraser-Hovde, Debra; & Lopez, Mary Louise
RICA Leadership Commission on AIDS, New York, NY, USA

Objective: To pose innovative approaches to reduce AIDS-related risks of poverty, addiction and educational attainment, and therefore the risk of AIDS. **View and structure:** Operations of aid and financial support to municipal hospitals in urban centers overreached by minorities with AIDS. **Development of culturally-sensitive approaches to adolescents to reduce experimentation with "unsafe" sex and drugs:** 1. Focus on the sub of the epidemic of adolescent childbearing age and their infants-with a high-saturation education/prevention campaign. 2. Focus on the IV drug abusing population, the majority of which is Black and Hispanic, and provide new and radical outreach programs. **Message:** Currently, in New York City, the Black Leadership Commission on AIDS has mobilized and now is advising the city, state and federal health systems. **RICA programs are now seeking funding for adolescent outreach and education/prevention centers for African-Americans.** **Conclusion:** The belief is increasing among African-Americans in the U.S. that AIDS was introduced into this community by outside forces in an attempt to kill off the race. This view of biological genocide is a serious barrier to the implementation of AIDS prevention efforts by governmental, health care and educational systems which are not treated by minority communities. The way to correct this situation is to utilize minority leadership in decision-making, correct this situation in direct service. By placing special culturally-sensitive concentration on minority men of childbearing age, their infants, IV drug abusers and adolescents teaching the age of sexual and drug experimentation, prevention can attain some success. Only the full and active participation of minority leaders in all systems can make this possible.

Table ronde Round Table



Le SIDA, la société et le comportement
AIDS, Society and Behaviour

L'entraide : Une stratégie d'adaptation

Self-Help: A Coping Strategy

M.E.O.24 SELF HELP GROUPS AND THE AIDS PATIENTS
HEIDER BLITZKE

Canadian Council on Social Development, Ottawa, Canada.
There is a scarcity of evidence showing the AIDS Community is fully aware of the potentials of the self-help group model in dealing with many personal, emotional and social problems the condition gives rise to. This session will present a range of possibilities the self-help group model offers AIDS patients, their families and their friends.

Also treated will be the gains the AIDS Community can draw from associating with the Self Help Community as well as the contributions the AIDS Community can make to it. The reasons why the AIDS Community does not work closely with the established centers such as Self Help Clearinghouses will be explored.

The work that a number of self help groups with an advocacy agenda will be presented with the view of exploring both the applicability of such an option for AIDS Patients and the strategies groups have used in dealing with specific concerns.

M.E.O.25 SELF-HELP: A PERSONAL PERSPECTIVE
Kowalski, Alex. Vancouver Person's with AIDS Society, Vancouver, Canada

M.E.O.26 THE AIDS PREVENTION CONCEPT OF THE GERMAN AIDS-LIFE CO-OPERATIVE MODEL

Van Schöfeg, Hubert Specht, Deutsche AIDS-Hilfe e.V.
Hennrichstr. 7 - 9, 1000 Berlin 31, West-Germany

Objectives: To describe planning, realization and monitoring by a nationwide working non-governmental organization in the Federal Republic of Germany.
Methods: In 1985 non-governmental groups were founded as AIDS-Hilfen in the form of self-help groups. The distance to governmental health authorities was essential for the access to target groups as gays, i.v. drug users and prostitutes (in the sense of anti-discrimination). Successes in an open and explicit language were published. The motto was "if you have a sexual disease you have to talk about sex and sex can still be fun". The acceptance of different kind of lifestyles is another main rule for the successful work of non-governmental organizations. Deutsche AIDS-Hilfe is the umbrella organization now of 80 local counselling centers which are well accepted by target groups and the general public. **Results:** Continuous discussion, expert meetings and feedback by people with AIDS/HIV and members of target groups led to promising results in risk reduction and social acceptance of people with HIV and AIDS. **Conclusion:** To reach specific target groups you need a specific language especially for discriminated minorities. A non-governmental organization seems to be the best educational partner.

M.E.O.27 THE DIFFICULTIES OF FWA COALITIONS IN PROVIDING SERVICES TO ACTIVE DRUG MISUSERS

Mordant, John. London Lighthouse, United Kingdom.

M.E.O.28 PHYSICIANS SELF SUPPORT GROUP
Chastagnier, Michel/Ville Marie Social Service Centre, Montréal, Québec, Canada.

Under the auspices of Comité SIDA Aids Montréal I have been facilitating for the past 6 months a self-support group for physicians who have a significant proportion of people with AIDS as patients.
I will present the difficulties in getting such a group off the ground and attempting to keep it focused on meeting some of the emotional and educational needs of the participants, issues such as the following will be addressed: the alleged reluctance of physicians to share their feelings; the difficulties in exercising leadership amongst a group of highly autonomous professionals; emotional impacts of having a large practice of people with AIDS.

M.E.O.29 SELF HELP EXPERIENCE IN AFRICA
Anumudu, Nicolas. Ministry of Social Development, Youth and Sports, Social Welfare Division, Owerri, Nigeria.

Table ronde Round Table



Le SIDA, la société et le comportement
AIDS, Society and Behaviour

Services sociaux : expériences et évaluations Social Services: Experiences and Evaluations

T.E.0.1

NEW YORK STATE'S RESPONSE TO AIDS: A ROAD MAP FOR HUMAN SERVICES

PRESENTERS: Cesar A. Perales, Commissioner, NYS Department of Social Services; Barbara J. Sahn, Executive Deputy Commissioner, NYSDSS; Jeffrey L. Carlles, Deputy Commissioner, NYSDSS; Nicholas A. Bagnio, M.D., Director, AIDS Institute, NYS Department of Health; and Dennis P. Kahan, Deputy Director, NYS Division of Substance Abuse Services, New York, NY, U.S.A.

This forum will describe the development and operation of New York State's (NYS) integrated network of health and human services for people with AIDS, and will suggest ways to establish similar interagency systems in other places. Approximately 20,000 AIDS cases were reported to NYS by January 1989, including a growing number of cases among women and children. The overall numbers are expected to rise to 90,000 by 1995, requiring a significant expansion in health and human services. In this forum, representatives of three NYS public agencies will discuss the coordinated human services model that serves the needs of thousands of individuals and families with HIV-1/2. HIV has afflicted a diverse population in NYS. State agencies provide a continuum of care that meets the differing needs of gay men, ID-drug users, individuals and families, women and children, adolescents, minority and non-minority groups, the homeless, urban and rural dwellers. Governor Mario Cuomo's Five Year Plan (to be given to participants) outlines the requirements for case management and provision of medical, non-medical, and substance-abuse services. Panelists will describe the system of Designated AIDS Care Centers; child foster care programs, such as Leake and Watts; health-related facilities for substance-abuse treatment; shelters for homeless people with AIDS, and other programs. They will also highlight unresolved issues and challenges.

T.E.0.3

EVALUATION OF THE SOCIAL SERVICES NEEDS OF HIV-1 POSITIVE WOMEN ENROLLED IN A COHORT STUDY IN KIGALI, RWANDA
Keywords: *Alameda* C**¹, Allen S**², Muhawenimana C**³, Tice J**⁴, Huddle S**⁵, ¹Center for AIDS Prevention Studies, University of California, San Francisco CA USA; ²Norwegian Red Cross, Oslo, Norway; ³Project San Francisco, Kigali, Rwanda.

T.E.0.5

THE SOCIAL IMPACT OF AIDS IN BRAZIL
Keywords: Daniel, Associação Brasileira Interdisciplinar de AIDS, IBO de Janeiro, Brazil

T.E.0.2

COMpte RENDU Et EVALUATION D'UNE EXPERIENCE DE FORMATION DES TRAVAILLEURS SOCIAUX SUR LA SIDA.

DIRECTION GENERALE DE LA SANTE FRANCE.
TOURETTE TURGIS Catherine de l'université Paris et Rouen. France.
BONNEAU Jacqueline de la Direction de l'Action sociale au Ministère de la Solidarité de la Santé et de la Protection sociale, Paris, France.

Historique de cette formation. La place des Programmes de formation dans la campagne de Prévention menée par la France. Le module Théorique et Pédagogique de cette formation. Approche pluridisciplinaire et multipartenaire. Les Contenus (Savoirs Internes et Savoirs Extérieurs). Modalités d'évaluation des stages. Les changements et les raisons des changements introduits dans le processus de formation. Premiers Echécs dans la Dynamique des Groupes. Hypothèses et Interprétations. Demande de formation de la part des Formateurs. Création d'un groupe BALINT pour les Formateurs. Premiers effets sur la dynamique de la Formation.

Premières Théorisations de ces formations. Comparaison d'une expérience conduite en France et dans les Territoires d'Outre-Mer. Phase érogative menée dans les Institutions accueillant des toxicomanes séropositifs. Première Evaluation conduite à partir d'entretiens non-directifs et d'un questionnaire. Les effets pervers de la Formation. Perspectives épistémologiques, théoriques et cliniques.

T.E.0.4

OBSTACLES TO USE OF PUBLIC SOCIAL SERVICES AND WORKERS IN AIDS PREVENTION AND CONTROL PROGRAMMES
Keywords: *Lloyd*, G, Tulane University, New Orleans, LA USA

Objective: To assess potential weaknesses of training workers in the public social services for prevention education and casefinding in AIDS prevention and control programs, and to identify obstacles to such efforts. **Methods:** Informal discussions were held with trainers and supervisors in public social services in six settings-two each in Patterns I, II and III areas. **Results:** Although public social services offer a pool of workers with some degree of training in counseling or education, obstacles and constraints in both developed and developing countries seriously restrict adding roles/functions related to HIV/AIDS. Public social services are almost universally: (a) accorded low status; (b) prone to high personnel turnover; (c) subject to chronic mismatch of service demand and resources; (d) apt to narrowly define problem areas and restrict clientele; (e) operate in rigid hierarchical structures; and (f) vulnerable to political interference. Taken altogether, these variables are powerful obstacles in the way of training and using public social service workers for carrying out additional tasks related to AIDS prevention and control. Additionally, in many places, workers see any AIDS-related activity as intensifying the stigma or low status of their work and resist training. **Conclusions:** Training existing public social service personnel for roles in AIDS prevention and control programs may be more expensive and less effective than recruiting and training personnel in new HIV/AIDS-specific public social service agencies.

T.E.0.6

SOCIAL SERVICES RESPONSE TO AIDS IN QUEBEC
Keywords: *Miriam*, Ville Marie Social Services, Montreal, Quebec, Canada.

**Atelier
Workshop**

**Le SIDA, la société et le comportement
AIDS, Society and Behaviour**
**Empowerment : Réappropriation de la santé, les expériences des personnes atteintes
Empowerment: Reappropriation of Health and Experiences of Persons with AIDS**
T.E.O.7 INTRODUCTION
Lapointe, Bernard.

T.E.O.8 PLUS, AN ORGANIZATION OF BODY POSITIVES IN NORMAN ENCON-
PASSING ALL GROUPS.

Arne N. Huseid, Sylvia Kabbak, the board of Plus and members, Oslo, Norway

Objective: Having an active organization, unlike compared to similar groups throughout the world, we would like to present our ideas, our achievements so far and our methods and aims.

Methods: Positives must fight two major evils, the virus and the difficult ENVIRONMENT. Both evils seem extremely to conquer, but they are related and not impossible. Many people, experts and humanists fight with us, but there are no recipes for either way; towards getting well or creating Justice. Nobody can fight better than positives. In Norway we fight along with the government and we are supported by the official institutions and other organizations. But just as important is our independence. In Plus, positives support each others, we offer alternative treatments, we consider information vital for each individual and we stand forward and exhibit ourselves to show force of will of living - as we also have to fight public fear, prejudice and discrimination.

Results: It is too early to present a complete evaluation. But already we have become an important supplement for each individual member, to the traditional health and social services and to the society. We keep in touch with all primary health stations and hospitals throughout the country. We have 170 members (equals 25 per cent of all registered positives). By June we will be able to present more results.

T.E.O.9 Michel Gallo, AIDES, Fédération Nationale,
Paris, France

T.E.O.10 THE ROLE OF AIDS SERVICE ORGANIZATIONS IN DEVELOPING
PUBLIC HEALTH POLICY AND SERVICES FOR HIV DISEASE.
Hynes, James E.* Philadelphia Department of Public
Health, AIDS Activities Coordinating Office, Philadelphia, Pa.
This presentation will present a model of a large urban
Health Department interfacing with AIDS Service Organizations
(ASOs) in the provision of education and direct services to com-
munities and individuals with HIV disease. These various pro-
grams will include: prevention activities, HIV testing and
counseling, coordination of service delivery, and policy and
planning. The Philadelphia Department of Public Health is
unique. The AIDS Activities Coordinating Office (AACO) is a
comprehensive department defined as a separate entity. All
services mandated under the aegis of public health exists with
AACO (Surveillance, Prevention, Policy and Planning, and Service
Delivery). An additional component, AIDS Agency Services Unit,
combines all of the above functions on a contractual basis
through ASOs. These ASOs serve as active participants in their
role as conduits for effective public health activities within
the local communities. This level of involvement empowers the
larger community to address its own needs rather than through a
select group of bureaucrats defining the community needs. This
presentation will provide a model for ASOs to impact the local
department of health for the enhancement of AIDS resources,
services, and policy development. ASOs who are beginning or
having difficulty with local health authorities will be given a
model to work more effectively with local authorities.

T.E.O.11 INFORMATION FOR EMPOWERMENT
DeLaney, Martin. Project Inform, USA.

T.E.O.12 THE LEARNING ABOUT AIDS PROJECT - A PARTICIPATORY APPROACH TO
HEALTH EDUCATION ABOUT HIV INFECTION AND AIDS
Peter Aggleton, Department of Education, Bristol Polytechnic
Bristol, England

Objectives - To identify a rationale for participatory education about HIV and AIDS and to describe the processes of development, dissemination and evaluation on the Learning about AIDS project.

Methods - The Learning about AIDS project is a national project developing and disseminating innovative health education materials for use in adult education about AIDS. Interim materials were disseminated by the Health Education Authority in 1987, and a considerably enhanced revised package will be published in February 1989. A major dissemination of these materials has commenced in the 16 health regions in England involving health educators and trainers working in the health service, in education, in social services and in the voluntary sector.

This paper will identify a rationale for participatory education based on group work and describe the manner in which learning about AIDS materials were developed. It discusses the value of such an approach in fostering self-empowerment, community development and social change. The dissemination strategy will be described as well as the steps that have been taken to use process and product evaluation to assess the outcomes of the project.

Séance thématique
Specialty Session



Le SIDA, la société et le comportement
AIDS, Society and Behaviour

Rôle des ONG dans la lutte mondiale contre le SIDA
The Role of NGOs in the Global Response to AIDS

W.E.O.7 COMMUNITY ORGANIZATION FOR HIV PREVENTION:
PROGRAMS AND PRIORITIES OF THE CENTERS FOR
DISEASE CONTROL

Callit, K.A., Brown, J.J., Johnson, S.M., et al. *Centers for
Disease Control (CDC), Atlanta, GA, U.S.A.
*United States Conference of Mayors, District of Columbia, U.S.A.

Objectif: To provide financial and technical assistance to
COMMUNITY-based organizations (CBO) to carry out HIV prevention
programs targeted to individuals whose behavior places them at
increased risk.

Méthode: CDC, in cooperation with State and local health
departments, the U.S. Conference of Mayors, national and regional
organizations has begun a financial and technical assistance program
to assist CBO (especially those that represent and serve minority
populations) to plan, implement, and evaluate HIV prevention
activities which meet the needs of local communities. Financial and
technical assistance are provided through closely-monitored CDC
cooperative agreements.

Résumé: Since 1987, over \$50 million has been awarded to more than
200 cities throughout the U.S. for HIV prevention programs and
activities. The U.S. Conference of Mayors has also awarded CDC
funds of over \$2.5 million to 8 CBOs. CDC has begun an additional
program of direct assistance to CBOs in the form of grants aimed
at HIV. Collaboration and coordination among health departments and
private organizations involved in HIV prevention have increased as a
direct result.

CONCLUSIONS: CDC has established several mechanisms for providing
financial and technical assistance to CBOs. The authors will
provide an overview of the national program, report on experience to
date, discuss technical assistance and other needs of community
organizations, and discuss problems and issues relevant to
implementation and evaluation of such programs.

**Séance thématique
Specialty Session**



**Le SIDA, la société et le comportement
AIDS, Society and Behaviour**

**La lutte communautaire contre le SIDA dans les années 1990
The Community-Based Response to AIDS into the 1990s**

W.E.O.8 ROLE OF COMMUNITY BASED ORGANISATIONS IN THE AUSTRALIAN RESPONSE TO AIDS
Whittaker, Bill*

*Australian Federation of AIDS Organisations, Australia

Objective: To discuss the development of the community response to AIDS in Australia, into the achievement and difficulties encountered. Comparisons will be made between the Australian response and initiatives in other countries. The challenges of developing a community response to AIDS in Asian, African and other regional countries using aspects of the Australian model will be examined.

Discussion: Community based AIDS organisations have played a vital role in Australia's response to AIDS. The Australian community response is one of the most successful in the world. Each Australian State has established an AIDS Council, which are volunteer oriented community based organisations. These Councils provide AIDS education, support services and advocacy on key issues. The Australian AIDS Councils have in turn set up a peak body called the Australian Federation of AIDS Organisations. Australia is now at the point where special AIDS education programs and support services for those affected by AIDS are required outside principal cities. This is presenting new challenges for community organizations in overcoming geographical problems and limited human and financial resources.

W.E.O.9 THE COMMUNITY BASED AIDS RESPONSE IN THE 1990's.

Holm, Jim, National Aids Network, Washington, D.C. USA

The community based response in the United States has been unprecedented. Affected communities provide a continuum of services to care for people living with AIDS and to prevent the spread of HIV. Over 650 community based organizations, receiving a mix of private, public, and individual funding, are either registered with or members of the National Aids Network (NAN). NAN's strategic plan for the 1990's includes an assessment of the community based response. NAN believes no single funding source can provide the necessary support. One necessary step is to replace Federal demonstration projects with a long term commitment to funding prevention and care. However, leaders of the community based response must accept greater responsibility for accountability when seeking such funds. As the epidemic becomes more mainstream, leaders ask why we should expand special resources we don't spend for other diseases. If we do not, the U.S. medical system's infrastructure will be overwhelmed. AIDS will force changes of the system.

W.E.O.10 INNOVATIONS IN HEALTH CARE DELIVERY FOR HIV IMPROVED PRACTICES

Reaslow, Judith B.; Horvater, C.; Horner, M.; Dolowak, G.; Hutchings, J.J. Health Resources and Services Administration, Public Health Service, Department of Health and Human Services, Rockville, Maryland, U.S.A.

Objective: To highlight examples of innovative HIV service related programs developed by grantees of the Health Resources and Services Administration (HRSA) of the U.S. Public Health Service (PHS).
Methods: HRSA is the agency within the USPHS responsible for supporting health care delivery programs for various populations with special needs, including those infected by HIV. Among the HIV service grants awarded to date are 21 service demonstration focusing on improved case management, 13 projects focusing on out of hospital care of children with AIDS, 19 projects designed to provide intermediate and long term care facilities for people with AIDS, and 13 training programs which focus on improving the quality of HIV services delivered by health service providers of various disciplines.

Results: Among the above projects, there are examples of innovative service delivery and training approaches which will be highlighted in this presentation. The value of those selected is the potential for replication in other settings.

Conclusion: Optimal use of public funds is achieved when they are applied to the development of unique, community responsive models of health care delivery, and when such models are made available for application in other settings. While each community's needs are unique, lessons learned from these programs can be applied in others.

W.E.O.12 COMPARATIVE STUDY OF COMMUNITY-BASED AIDS SERVICE DELIVERY
Chagnac, Nancy, McGill Centre for Medicine, Ethics and Law, Montreal, Quebec, Canada

Objective: To describe a comparative survey of community-based AIDS service organizations from Sweden, Holland, Denmark, West Germany, Belgium, France, Norway and Canada.
Methods: An analysis grid was developed and utilized for a comparative review, based on interviews and published reports of the operations and structure of these organizations. The analysis grid permitted both lateral and vertical comparison in all dimensions.
Results: The analysis grid included parameters such as organizational structure, budget, sources of financing, epidemiological circumstances, socio-political climate, case load, programme services delivered, target populations, institutional cooperation, developmental changes and decision-making mechanisms.

Similarities include the common circumstances of rapid development and change, in target populations served and basic services offered (some services were restricted to specific groups or were offered in conjunction with those of other organizations).

Critical distinctions occurred in the areas of use of volunteer labour force, membership decisionary powers, executive disciplinary powers, means and levels of financing, cooperation with other AIDS service organizations, legal and social atmosphere, and level of interaction with public institutions.

Conclusions: Community groups operated more effectively if one or more of the following conditions were met:

1. maintenance of close contact with community infrastructure (their community base);
2. close co-operation with already existing health and welfare networks and with community organizations;
3. adequate and diverse funding arrangements;
4. a social climate of acceptance and/or tolerance around such issues as homosexuality, discussing sexuality and drug use.

W.E.O.11 COMMUNITY GROUPS INTO THE 1990's

Mantell, Mary, Network of Voluntary Organizations in Aids and HIV, United Kingdom.

W.E.O.13 DISCUSSION

Pattiel, Freda, Health and Welfare Canada, Ottawa, Canada.

Séance thématique Specialty Session



La SIDA, la société et le comportement AIDS, Society and Behaviour

Le SIDA dans les médias AIDS in the Media

W.E.O.20 MEDIA AIDS EDUCATION: THE BOMBING EFFECT BOMBARDÉ L'ÉDUCATION À L'ÉDUCATION Concordia University, Montreal, Québec, Canada.

Public resistance to AIDS prevention is becoming increasingly apparent, especially among young people. The use of television and mass media campaigning strategies in this psychological resistance.

Methods. A three-year comparative study of TV and film materials from Africa, Australia, W. America and Europe is reported, using traditional programme evaluation techniques and electronic audience research methods recently developed in the media advertising industry.

Results. The most successful campaigns are those which use hard facts about AIDS in a simple and straightforward manner. Advertising campaigns featuring elaborate, symbolic or melodramatic imagery, or dramatization, are perceived as less effective. The use of television advertising can have a temporary effect on establishing public opinion on the urgency of AIDS and the civil rights of infected persons.

Electronic analysis of moment-by-moment audience reactions to materials are reported, attributing the adverse effects of media AIDS education to poor reporting accuracy or ambiguity of its some cases. A few records only, however, of the use of electronic audience research methods in the media advertising industry. Electronic analysis of moment-by-moment audience reactions to materials are reported, attributing the adverse effects of media AIDS education to poor reporting accuracy or ambiguity of its some cases. A few records only, however, of the use of electronic audience research methods in the media advertising industry.

Electronic analysis of moment-by-moment audience reactions to materials are reported, attributing the adverse effects of media AIDS education to poor reporting accuracy or ambiguity of its some cases. A few records only, however, of the use of electronic audience research methods in the media advertising industry.

W.E.O.22 CORRELATION BETWEEN LARGE SCALE MASS MEDIA CAMPAIGNS OF AIDS PREVENTION AND SUBSEQUENT AIDS TESTING BY RISK PRACTICE IN MADRID

Marín, A. Aguilá, J. P. Ballesteros, C. Baranoso, B. Ballesteros, a Journalist, Universidad Complutense, Madrid, & Doctor, Madrid City Council, Spain

Objective. To know the influence of mass media information campaigns on the HIV risk practices in Madrid.

Methods. Descriptive study of the information on AIDS given by 4 Madrid newspapers, 6 radio stations and 2 TV channels during 1985 and 1987. Study of HIV risk practices among 978 TVDS and 488 homosexuals who were treated at a Health Promotion Center of Madrid City Council.

Results. Press information study shows the information was given in different stages, appearing at the beginning of '85 a greater number of articles (5000 increases) with a much more prominent content compared to those at the beginning of '86, much more alarmist and scientific. By the end of '87 it drops to 400. Risk practices among the groups considered slightly decrease during 1987 among homosexuals; but the use of sterile syringes by IVDS increased 75% during the first semester (March and April) and decreased during the last period of 1987. Information on the amount in which the change of habit took place is 80% coincidental during the first months 1987. The reaction of this group to general mass media information has been 00-00.

Conclusion: Our research shows a correlation between the quantity and quality of the information and the abandon of risk practices, thus confirming the great importance of mass media information on AIDS preventive attitude.

W.E.O.24 PERIODIC RISK AND LACK OF REPRESENTATION OF WOMEN'S CHOICES AND DECISIONS IN THE MEDIA PERIODIC RISK AND LACK OF REPRESENTATION OF WOMEN'S CHOICES AND DECISIONS IN THE MEDIA Rosenfeld, Naomi, Women and AIDS Studies, 710 Mac Don Ave., NY, NY 10025 USA

Objective: To assess the lack of representation of women's groups and experts in the media coverage of AIDS, HIV press reports on two issues that particularly affect women—partner notification and serostatus testing—and to assess the extent to which women's voices are heard in the media coverage of AIDS as sources were also reviewed.

Methods: A content analysis of 108 articles in the New York Times, United States and Canada, representing content press coverage. Collected clippings from 4 AIDS newspapers also constitute representation of the opinions of key groups in this legislation included but not enough persons in NYC would presently be included for prevention efforts directed at black and Hispanic women, the mass clippings do not show that any women's or black or Hispanic groups were used to comment on the adequacy of the legislation. Similarly, in articles covering the general lack of awareness of women in transmission trials, papers as diverse as the NY Times and Village Voice presented the women's opinions of AIDS, male physicians that your, identify women are unrepresentative and lacking "credibility and understanding." Being elderly sought so women's reports as sources, these papers stated the story that the three major NY transmission trials administered by women have had no problem recruiting women patients. A People magazine cover story on women and AIDS in which the 6 experts quoted were all white (and 3 male) and which a gay male Times cover story on partner notification which, again, included only men and reports as sources. Challenge: AIDS coverage which depicts almost exclusively or white males as sources results in generally negative content and in factual error. In some instances, press bias has been so severe it has blocked the thorough public discussion needed for policy formation.

W.E.O.21 LES MEDIAS A L'ÉPREUVE DU SIDA / ANALYSE THÉMATIQUE ET COMPARAISON DE LA PRESSE FRANÇAISE ET AMÉRICAINE. THE MEDIA AT THE TEST OF AIDS / THEMATIC ANALYSIS AND COMPARISON OF FRENCH AND AMERICAN PRESS

Chénief, A. M. Depuis le Mal de Naples, la presse occidentale a vu renaître un thème qui d'origine médiatique, celle d'une maladie mortelle, transmissible par le sang et par le sexe.

Le but de la présente étude est d'analyser sur travers des études diachroniques la façon dont la presse française et américaine a traité le SIDA depuis le 1/01/1986 et le 1/06/1984; une comparaison du nombre d'apparition du thème-SIDA dans 4 quotidiens français entre juillet 1983 et juin 1984; un recensement du nombre d'occurrences du SIDA dans 3 hebdomadaires entre 1982 et 1985; - la spécificité de ce "phénomène médiatique SIDA".

Quatre périodes sont détachées depuis la description par le SIDA de la maladie à 81-82; le mystère 83-84; le "parler science" et la grande époque d'immunologie consumer 85 à l'analyse scientifique. Les camps ont une lecture "sociale" du SIDA; 86-87-88; les années de gestion de la réputation comme de la maladie. Sur quelques 290 articles publiés dans 4 quotidiens français et 70 (240) sont exclusivement consacrés au SIDA, relevant le cancer (9,3%), les procédures médicales (10,2%), les traitements (11,1%) ou les données épidémiologiques. Une comparaison avec les données américaines (W.A. Check & Rev. Inf. Dis. 1987 5: 197-200) permet d'établir une constance dans les liens unissant pressé et SIDA.

Conclusion: Cette revue de presse comparative permet de mesurer le chemin

W.E.O.23 THE UK NATIONAL AIDS HEALTH PROMOTION PROGRAMME - RECENT DEVELOPMENTS THE UK NATIONAL AIDS HEALTH PROMOTION PROGRAMME - RECENT DEVELOPMENTS Kaplan, M. Wellington, & P. S. Bagard, S. Health Education Authority, London.

Objective: To describe recent developments and critically review the evolution of the National AIDS Health Promotion Programme in the UK.

Methods: Since 1984, public education efforts have been monitored through consumer research and other public response indicators.

Results: The 1988-87 mass media campaign created high levels of public awareness. But a survey in November 1987 showed significant levels of public anxiety about AIDS, increasing public complacency and so heterosexually behaviour change. A new 1988 campaign was directed at young people and suggested, for the first time, some heterosexual behaviour shift with claimed reductions in casual sex and increased condom usage. The 1989 campaign is aimed at improving the quality of public knowledge, and creating a continuous presence for AIDS issues in the public mind. The UK Programme has evolved substantially over 1986-89, with content and interpersonal approaches have been designed. Target audience specific activities have been developed addressing, for example, homosexual, ethnic minorities, prisoners, people in the workplace, youth and women. To maximize programme outreach, priority is placed on interagency collaboration across the national/local interfaces. Programme development is a dynamic process responding to changing epidemiology and altering socio-cultural perceptions of HIV/AIDS.

W.E.O.25 EVALUATION OF THE NATIONAL AIDS MULTI-MEDIA PUBLIC INFORMATION CAMPAIGN EVALUATION OF THE NATIONAL AIDS MULTI-MEDIA PUBLIC INFORMATION CAMPAIGN Williams, Kenneth L., Dueser, B.D., and Wurdack, P., Centers for Disease Control, Atlanta, Georgia, U.S.A., ** National Center for Health Statistics, Hyattsville, Maryland, U.S.A., *** Ogilvy & Mather Advertising, Atlanta, Georgia, U.S.A.

Objective: To discuss the impact of the U.S. Government's national AIDS public information campaign to inform and educate the American public about AIDS and HIV infection in terms of knowledge, attitudes and beliefs.

Methods: The vast amount and types of HIV/AIDS activities occurring throughout the U.S. makes assessment of a national information campaign very difficult. Methodologies used to assess the impact (i.e., household level) will be presented.

Results: Evidence from the National Center for Health Statistics' monthly Health Interview Survey (approximately 3000 households per month), number calls to the National AIDS Hotline, distribution of educational materials by the National AIDS Clearinghouses, along with other State data will be described. Time correlation between campaign activities such as airing of Campaign PSA's, mailing of the brochure "Understanding AIDS" to all U.S. households, and telephone calls to the National AIDS Hotline will be explored and their impact on the general public will be discussed. There appears to be a correlation between the campaign activities and public knowledge, attitudes and beliefs regarding AIDS. Further studies are required to assess whether the campaign efforts are directly related to these changes.

Séance thématique Specialty Session



Le SIDA, la société et le comportement AIDS, Society and Behaviour

Services de pastoral Pastoral Care

W.E.O.28 PASTORAL CARE IN AIDS MANAGEMENT
Edgar, Allison; Weiss, M.; Campbell, J.D.; Chawwa, T.
The Salvation Army Chikankata Hospital, Harare, Zimb.

Objective: To describe pastoral care as part of integrated AIDS management in the context of home based care and prevention.

Methods: The management of AIDS at Chikankata Hospital has followed a pattern of home based care with hospital intervention where required. Management is described as an integrated approach to the disciplines of clinical care, education, counselling, administration and pastoral care. Implementation of this concept at Chikankata has been progressed through the formation of a multidisciplinary team. The dynamics of the team are discussed with reference to integrated management and then with specific reference to pastoral care.

Results: Pastoral care is presented as a valid and necessary component of care for patients, families and communities affected by AIDS, particularly in the context of African spiritual tradition. After defining pastoral care, its application is described in terms of patient responses, behaviour change, death, and quality of life.

Conclusion: It is proposed that without provision for pastoral care management is incomplete, and that pastoral care can be appropriately implemented through an integrated, multidisciplinary team approach to care and prevention for patients, families and communities.

W.E.O.27 AN EVANGELICAL DENOMINATION RESPONDS TO AIDS
Finger, Reginald, MD, MPH; Malloy, Michael, AGMA*,
Missouri Health Care Fellowship, Kansas City, Missouri, USA
*Christian Counseling Services, Nashville, Tennessee, USA & Association of
Nazarenes in Social Work, Kansas City, Missouri, USA

Objective: To utilize the material, human, and spiritual resources of a religious denomination to deliver compassionate care to those with HIV infection and their families; to educate pastors and laypersons in the church in order to facilitate a scientifically sound and compassionate response to HIV. **Methods:** The evangelical community has often been perceived as holding a judgmental and unsympathetic attitude toward those with HIV, because of the risk behaviors in which many of them have participated. In July 1988, over one hundred local and national leaders of the Church of the Nazarene met in New York state to explore HIV-related issues and to plan for educational outreach to the denomination and for a coordinated compassionate response. This conference is believed to be the first of its kind for an evangelical denomination. Since the conference, an informal network of leaders has been formed to continue the efforts.

Results: As a result of these efforts, the established urban ministries of the Church of the Nazarene in New York, Washington DC, and San Francisco are more effectively serving people with AIDS. Pastors and laypersons across the church are increasingly willing to minister to MSM in the local churches. **Conclusion:** The evangelical community represents a potentially powerful resource for education and human services. The combination of valid medical and epidemiologic information about HIV with a sound theological basis for relating to those with risk behaviors, results in effective compassion.

W.E.O.28 JEWISH LAW, VALUES AND THE SOCIAL ISSUES ARISING FROM HIV DISEASE
Freedman, Benjamin; McGill University and the
Jewish General Hospital, Montreal, Canada

Jewish law (halakha) and associated literature comprises one of the oldest and most developed systems for the analysis of bioethical issues. The method employed proceeds by means of analogical reasoning from controlled values and ethical schemata. The schemata relevant to HIV include the extent and particulars of the duty to guard against infection as relevant to, e.g., blood and body fluid precautions; the commandment of reaching for/visiting the sick ('shilukh cholim') as related to AIDS care and hospices; social and medical confidentiality; prohibitions on "sleazebagging" ('shlut and lashon hora'); and the adjudication of conflict between a duty to aid those in need and the duty to preserve one's own health. Details of these halakic schemata are applied to current difficult social issues raised by HIV disease areas of interest in their own right, and provide a useful contrasting perspective on values and their prioritization.

W.E.O.29 RELIGIOUS LEADERS IN SÃO PAULO BRAZIL JOIN THE AIDS PREVENTION AND CONTROL,
INDUSTRIAL & FERNANDES M.R.;
Centro de Referência e Treinamento em Aids, São Paulo, Brazil.

Objective: To decrease the global impact of HIV infection in the general population through the religious leaders.

Methods: a. Mobilization b. Sensibilization c. Conscientization d. 20 hours training in human sexuality, clinical, epidemiologic, ethical, legal, psycho-social.

Aspects on Aids:

Evaluation: A questionnaire was applied before and after the training course.

Results: The religious leaders of 14 different religious groups decided:

A. To promote information and prevention on AIDS to their communities.

B. Give spiritual support to HIV patients and families.

C. To open houses to take care of HIV patients.

D. Organization of ecumenic events over 2 months for solidarity and non discrimination.

W.E.O.30 BABA'I CONCEPTS TOWARD AIDS PATIENTS AND SOCIETY
Moses, M.; Mosechi, R.; Mungu, M.; *Musa, L. and
*Mwanga, M.

*Department of Medicine, *Mwanga, M. Hospital, *National Spiritual Assembly of the Baha'is of East and West, University of Kinshasa, Kinshasa, Zaïre

Objective: To describe the Baha'i teachings in relation to the AIDS patient and society.

Methods: The AIDS epidemic has caused worldwide concern from religious and secular organizations. In the absence of a unified stance, we reviewed the Baha'i writings to elucidate the Baha'i recommendations.

Results: The Baha'i Faith is an independent religion which believes in the harmony between science and religion - that these two potent forces must go hand-in-hand for the benefit of mankind. It believes in the fundamental unity and solidarity of the human race. It rejects all forms of prejudice and therefore believes that AIDS victims should receive support and compassion without trace of discrimination. It regards marriage as a "fortress of well-being" and encourages the practice of chastity before marriage and fidelity afterwards as a protection to the individual and the society. It requires total abstinence from habit-forming drugs except for medical purposes prescribed by a physician.

Conclusion: As a strong supporter of human solidarity, the Baha'i Faith rejects all forms of prejudice against AIDS' victims. It offers clear teachings which can serve as a protection to the individual and the society. The practice of these principles has the potential to control this epidemic.

W.E.O.31 DISCUSSANT

Piters, Stephen A. Universal fellowship of Metropolitan Community Churches, L.A., USA.

Session d'affichage Poster Session



Le SIDA, la société et le comportement AIDS, Society and Behaviour

Information Information

M.E.P.1 A STRUCTURED EDUCATIONAL SUPPORT GROUP FOR HIV INFECTED INDIVIDUALS

Henry L. Yashavaram, Catherine Tendler, Ruth Skipton-Levy, Melanie Steiner, Ann Stuart

Columbia University School of Public Health - Box 1814 Madison Sq. Station, New York, NY 10032, USA

A six session structured group model for HIV seropositive individuals was developed as part of a randomized control study of newly identified HIV seropositive individuals. 95 individuals have participated with an average of 3-4 per group. Most groups have been heterogeneous with regard to risk factors, age and sex. This psychosocial intervention consists of professionally led group education as well as psychological and social components. Educational content includes information about transmission of the virus as it relates to daily living and sexual practices; medical aspects of HIV infection, health promotion, disease prevention strategies are reviewed. Skills in stress reduction and communication are taught. Individuals share feelings, experiences, and coping strategies.

Groups have decreased the social isolation of HIV positive individuals. Many have developed sufficient cohesiveness to continue as peer support groups. Peer groups seek consultation of professional group leaders as new issues emerge such as changing medical information, illness and death of group members.

M.E.P.2 REPORT FROM A PUBLIC HEALTH PSYCHOSOCIAL CLINIC FOR GAY AND BISEXUAL MEN WITH HIV-RELATED PROBLEMS

Zeppeli, Glenn; Westman, Bo**

*Medical Director and **Clinical Psychologist, Department of Landstinget Psykiatri, Wolmar Yngkullagatan 25, 116 50 Stockholm, Sweden.

Objective. Critical discussion of team formation and team function. Discussion of the need for a clinic aimed especially at gay men. Preliminary analysis of the problems presented by the clients. Tentative evaluation of the therapies and services offered.

Methods. Statistical description of the more than 325 clients. Critical essay on the delicacies and vicissitudes in building a team, forming an agreed philosophy on client work and ascertaining efficiency and cohesion.

Results. The clinic has almost equally served both seropositive and seronegative clients. Recurrent themes in both groups alike and centers often on problems around sexuality and low self esteem. The more sensitive a person is about homosexuality the more liable does he seem to be prone to anxiety. Low esteem is a risk factor for developing (alcohol) abuse which in turn increases the tendency towards risk sexual behavior. There seems to be a strong need for addiction recovery facilities directed towards gay men. Community Building is team based at a gay clientele with HIV-related problems means encountering problems on many levels - yet there are strong motives for specialized clinics with this commission. "Key competence" and tolerant compassion required.

M.E.P.3 AIDS-STIGMA AND ANTI-GAY PREJUDICE: PUBLIC REACTIONS TO AIDS-RELATED POLICIES AND TO GAY MEN IN THE U.S.A.

Markus, Gregory M. and **Glum, E.K.**

Creighton University of Washington, St. Paul, MN, U.S.A.

Objectives. To examine the relationship between attitudes held by the U.S. public toward AIDS-related policies and gay men.

Methods. Two samples were used: 1) 153 adults from 5 U.S. cities who completed written questionnaires; and 2) 859 adults from a subsequent national telephone survey. Responses to a battery of AIDS-policy items were factor analyzed, scales were constructed, and regression analyses conducted to determine the best predictors of AIDS-related policy attitudes.

Results. Two factors consistently emerged for AIDS-policy attitudes. Factor #1 items proposed punitive measures to be taken toward persons with AIDS (e.g., quarantine); this factor includes a strong component of blaming people with AIDS for their condition. Factor #2 consisted of items generally endorsed by public health authorities (e.g., education about safer sex). The factors were uncorrelated in the small sample; in the national sample, they were negatively correlated among Whites, but not correlated among Blacks. Attitudes toward gay men were predictive of scores on both factors, with some analysis suggesting that they react a particularly strong influence on attitudes toward punitive policies.

Conclusion. Attitudes toward AIDS-related policies are multidimensional; ambivalence about AIDS may appear in the form of agreement with punitive as well as constructive public health policies. Influencing U.S. public opinion may require concurrent attempts to reduce anti-gay prejudice.

M.E.P.4 COMMUNICATING AIDS INFORMATION TO HISPANICS: THE IMPORTANCE OF LANGUAGE AND MEDIA PREFERENCE

Hu, Dale J.; Keller, R.H.; Fleming, D.M.**

**Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland, **Stouffer Medical Center, Woodburn, Oregon, Oregon State Health Dept., Portland, Oregon, U.S.A.

Objective. To design an effective AIDS education program for Hispanics in Oregon based on language (Spanish/English) and media preference as well as to increase information on AIDS knowledge and attitudes for Hispanics, the fastest growing minority group in the U.S.

Methods. The first part of the program began in January of 1988 with a survey study of 218 Hispanics from three clinics in Oregon to examine beliefs about AIDS and to determine the principal sources of information access for this population.

Results. Major findings from the study showed that respondents whose primary language was Spanish tended to have fewer information sources and relied relatively more on broadcast media than printed media. Despite recent statewide AIDS education efforts, almost one-half of Spanish-speaking only respondents denied having received AIDS information before. In addition, almost one-half of the sample did not believe or were unsure whether condoms could prevent the transmission of AIDS. Compared to primarily English speakers, respondents whose primary language was Spanish were more likely to believe that AIDS could be casually transmitted and less likely to believe that condoms could prevent transmission.

Conclusion. Based on the results of this study, a culturally and linguistically appropriate media campaign targeted at Hispanics in Oregon was developed and implemented.

M.E.P.5 A GAY - & PROSTITUTE APPROACH TO MENTAL NURSING

Gillian, James, Royal College of Nursing, 10, Cavendish

Square, London, England.

This paper aims to outline the proactive approach required to meet the educational needs to provide the necessary information to those closely involved in the care and training of people with a Mental Handicap both in the community and in residential settings and for the parents and their children - so developing a positive attitude in relation to the many aspects of education and social change required.

There is already a subculture within this field which has developed many stigmatising effects which delay hamper and hinder progress for and colour attitudes to our fellow citizens and to have any further additional labels which may further handicap their chances of being accepted as a full member of society can only disadvantage them further.

The aim of the Society of Mental Handicap Nursing within the Royal College is to provide a format which will help those reading our booklet to promote a positive attitude to the changing needs of those with a Mental Handicap in any setting.

M.E.P.6 EVALUATION OF AIDS EDUCATION PROGRAMS FOR OFFENDERS

Jan, S. Godes, M. Sall*, W. Thelen*, B. Miller**

**Sherman, J. Craig

*Hennepin County Community Health Department and **Hennepin County Office of Planning & Development, Minneapolis, Minnesota, U.S.A.

Objective. 1) To determine AIDS risk and baseline levels of knowledge, attitudes and behaviors for adult and juvenile offenders. 2) To compare offenders' knowledge, attitudes and behavior outcomes after participation in different methods of AIDS education.

Methods. Random assignment of 204 offenders to 1 of 4 methods of AIDS education: printed material only, video only, video and discussion with a nurse educator (NE), and discussion with NE only. Pre and post-tests (knowledge, attitudes and behaviors) and a risk assessment were administered.

Results. The self-reported behavioral assessment showed the target population to be one with considerable risks. A small, but significant increase in knowledge and attitude mean scores occurred from pre to post-test for 3 methods (t-test, p < .05). No significant differences were found between these 3 interventions (ANOVA). Findings from a 3 month follow-up study of changes in behavior after training will be presented.

Conclusion. Although the baseline levels of knowledge about AIDS were higher than expected, adult and juvenile offenders did benefit from receiving AIDS education while in the Correction system. Shifting to a curriculum that focuses on specific techniques for achieving behavior change may have greater potential for success with this special-needs population.

Session d'affichage Poster Session



Le SIDA, la société et le comportement AIDS, Society and Behaviour

M.E.P.7 AN APPLICATION OF SOCIAL MARKETING TO THE DEVELOPMENT OF AIDS EDUCATIONAL MATERIALS.
MARGARET L. BRETHER, GREENWOOD, J.A.; PRINDEBAST, J.T.; MONTVOYA, J.L.
*CENTRE OF ORANGE HARBOR HEALTH AGENCY, GAITHERSBURG, CALIF., U.S.A.
*MONTVOYA, HARBOR, ORANGE, CALIF., U.S.A.

Objective: To develop written materials about AIDS education for persons with limited exposure to formal education and whose primary levels of education are below high school.

Methods: The HEALTH CARE AGENCY FOLLOWED THE PRINCIPLES AND TOOLS OF SOCIAL MARKETING TO DEVELOP A SPANISH LANGUAGE AIDS EDUCATION BOOKLET TARGETED AT THE LATINO MEXICAN/SPANISH SPEAKING POPULATION WITH LITTLE EXPOSURE TO FORMAL EDUCATION. THE FORMAT IS THAT OF A "PITCHBOOK" (SHOW-OPERA COMBO BOOK). THIS FORMAT WAS CHOSEN BECAUSE IT IS CONSISTENT WITH A POPULAR GENRE OF ENTERTAINMENT IN LATIN AMERICA. ALTHOUGH THE MESSAGE WAS DEVELOPED WITH MAXIMUM RELIANCE ON VISUAL CUES AND A MINIMAL RELIANCE ON TEXT, THE WRITING CONTENT IS ESSENTIAL, AND VERY IMPORTANT FOR EDUCATION. THEREFORE, IT WAS DEVELOPED IN A FORM WHICH CAN BE UNDERSTOOD BY INDIVIDUALS WITH NO GREATER EDUCATION LEVELS OF EDUCATION. THE BOOKLET WAS EVALUATED BY FOCUS GROUPS AND A SEPARATE ASSESSMENT OF THE LEVEL OF READING DIFFICULTY WAS CONDUCTED. THE ASSESSMENT OF READING DIFFICULTY WAS FOR DIAGNOSTIC, CAPTIONING AND INSTRUCTIONS.

Results: Focus group results revealed that the booklet has a high degree of comprehension and acceptability in the target population. The dialogue was added to be at the third grade level; the captions at the fourth grade level and the instructions at the sixth grade level.

Conclusions: IT IS SUGGESTED THAT THIS IS A USEFUL METHOD FOR DEVELOPING AIDS EDUCATION MATERIALS THAT ARE APPROPRIATE FOR THE LANGUAGE, EDUCATIONAL, AND CULTURAL CHARACTERISTICS OF PARTICULAR TARGET GROUPS. THE PITCHBOOK IS CURRENTLY BEING USED WITH GREAT SUCCESS IN OUR CLINICS AND AIDS COMMUNITY EDUCATION OUTREACH EFFORTS.

M.E.P.9 AIDS IN THE INNER CITY: A BLACK COMMUNITY ORGANIZATION'S RESPONSE TO THE AIDS EPIDEMIC.
Marilyn-Meléndez, M.D., *University of California, San Francisco and Research on AIDS, Center for AIDS Prevention Studies, University of California, San Francisco, U.S.A.

Objective: To assess the factors which encourage minority community organizations to become involved in AIDS prevention.

Method: A local organization, noted for its involvement in community affairs, including AIDS education and drug abuse services, was asked to participate in the study. The anthropological field methods of participant-observation and in-depth interviewing were used in a study conducted over a period of six months. The researcher worked as a volunteer with the AIDS education unit and developed contacts within the organization and the community.

Findings: The organization's entry into AIDS prevention was aided by three important factors: 1) the organization had a strong central leader who was committed to the community and to AIDS education; 2) the flexible structure of the organization enabled it to respond to problems within the community; and 3) AIDS education could be conducted through existing services provided to drug-using clients.

Conclusions: The initial response to AIDS prevention activities by this organization was facilitated by strong local leadership and concern for community welfare. Secure funding sources were critical in developing building programs. Leadership and funding each effect an organization's response, but may be of critical importance in different times.

M.E.P.11 AIDS EDUCATION IN COMMUNITIES OF COLOR: A PRIVATE-PUBLIC PARTNERSHIP MODEL.
Paula M. Friedman, J. and Bradford, Jr.
*People of Color Against AIDS Network/Sea/King Cty. Hlth Dept., Seattle, WA

Objective: To describe a model for AIDS education in communities of color.

Methods: People of Color Against AIDS Network (POCAN) developed a four level strategy to engage communities of color in AIDS education. Level One is to identify issues in terms that are relevant to, and in the idiom of the community. Level Two is to organize community support from both private and public sectors. Level Three is to mobilize the community to confront AIDS through coalition building. Level Four is to motivate individuals to change behavior via direct education, and advocacy on behalf of these individuals.

Results: The strategy was successfully implemented in communities of color statewide. Issues identification occurred via discussions with community leaders and focus groups. Community support was secured through POCAN's participation in community events, development of culturally specific materials (including a nationally acclaimed comic book for youth of color), and the famous Last Words media campaign, engagement of local and state health departments, and organization of AIDS events including a national conference attended by 350 people. Mobilization of communities was achieved by providing leadership for collaborative education projects taken on by 10 community agencies. Network members are currently being addressed by POCAN and collaborating agencies, who now have credibility in the community.

Conclusion: AIDS communities of color can be achieved by organizing that culminates in the provision of education by indigenous community organizations, with the leadership and oversight of a central agency.

M.E.P.8 USING NATIONAL AND REGIONAL MINORITY ORGANIZATIONS TO PROVIDE CULTURALLY RELEVANT HIV INFORMATION AND EDUCATION IN THE UNITED STATES.
FARANDER, M.; ISHAI, DUNCAN, W.; LANDSAY, B. AND KORNWAG, A.
Centers for Disease Control, Atlanta, Georgia, U.S.A.

Objective: To describe a program for developing and strengthening the participation of national and regional minority organizations in educational efforts to prevent the spread of HIV infection in the U.S. Method: In 1988, the Centers for Disease Control funded 23 national and regional minority organizations to develop culturally relevant information and education projects targeting minorities at risk. Description of programs and preliminary data on their impact and reach, obtained from quarterly reports, will be provided and includes such variables as number of persons reached, changes in knowledge, attitudes and beliefs, and strategies for coordinating activities, coalition building and networking efforts will be discussed.

Results: To date over 900 persons participated in 20 national and local workshops. Preliminary data indicates significant change in knowledge, attitudes and beliefs. Twelve public service announcements using celebrities were developed for TV and theatre audiences. Preliminary figures suggest 87% drop after recall, 78% 3-week recall, and 78% 4-week recall for theatre viewers. Other significant findings and evidence of networking and coalition building among grantees will be presented.

Conclusions: National and regional minority organizations are effective vehicles for providing unique and culturally relevant information and education to minorities in the United States.

M.E.P.10 AIDS EDUCATION PROGRAM FOR NATIVE IMMIGRANTS IN MONTREAL.
Métin, M.; Kervelle, J.; Alchou, A.; Abrevas, M.-J.; Soperol, J.; Bréard, J.; Kervelle, P.; H. H. S. J.
Groupe Natif pour la Prévention du SIDA (GNP-PSA), Montréal, Canada.

As of January 1989, 108 (10%) of the 723 adult cases diagnosed in Québec since 1979 were born in Haiti and 20 of the 30 pediatric AIDS cases in this province were born in Haitian mothers.

Objective: To improve AIDS awareness among the 800 Haitian immigrants in Montreal.

Methods: Because this community was stigmatized in the early years of the AIDS epidemic, our first goal was to mobilize community leaders to support the planning of an AIDS educational program and then to help increase the credibility of the messages. Focus groups were used to formulate french and Creole messages in the fall of 1987. Educational tools included: pamphlets, posters, video, public service announcements in creole radio, TV shows and newsletters. A show response center was also made available.

Results: 4 6 week multi media campaign was organized in the spring of 1988. Four weekly radio shows on AIDS prevention were aired on 2 community radio stations and ads were put in the community newspapers. Educative materials distributed included: 395 pamphlets, 439 buttons, 138 posters (including the GNP-PSA's slogan "Ma Sida, Monnaie au Pain"). Between July and December 1988, 22 (8%) of 269 randomly selected adult Haitians in Montreal reported having participated in an AIDS educational program.

Conclusions: In AIDS education outreach program is now available for a community that until recently was stigmatized. Continued involvement of our community leaders is essential to the success of the program.

M.E.P.12 IMPLEMENTING A CULTURALLY SENSITIVE AIDS PREVENTION PROGRAM FOR HAITIAN IMMIGRANTS IN NEW YORK CITY.
Marilyn Friedman, P. J. Stewart, Y. J. Delcorvis, J.
*AIDS Prevention Center, SUNY-HSC @ Brooklyn, NYC

Objective: To describe the national development of an AIDS Prevention Program for Haitian immigrants in NYC.

Methods: Studies in NYC have shown a high prevalence (64) of HIV infection in recent Haitian immigrants. The Haitian community presents many barriers to AIDS prevention programs including:

1. A history of stigmatization and discrimination.
2. A language impeding the development of printed educational materials;
3. Inadequate access and utilization of medical resources both here and in Haiti;
4. Lack of understanding of concept of prevention of disease;
5. General mistrust of authorities because of both immigration status, and relationships with authority in Haiti.

Results: Components of an effective AIDS Prevention Program should include: 1. HIV counseling and education offered in Creole as a routine part of medical visits when indicated. 2. Active participation by Haitian physicians and community press in educating the population. 3. Unique outreach activities including: videos, skits, and comic books. 4. Public service announcements by TV. 5. Outreach by radio. 6. TV.

Conclusion: In this population the patient's perception of both risk and prevention may be impeded because of multiple barriers. An organized approach must be utilized in order to overcome such problems and increase utilization of appropriate services.

Session d'affichage Poster Session



Le SIDA, la société et le comportement AIDS, Society and Behaviour

M.E.P.13 AIDS KNOWLEDGE, LANGUAGE USE AND RESPONSE TO SPANISH AND ENGLISH MEDIA MESSAGES OF LOW-INCOME HISPANIC-AMERICAN WOMEN IN SOUTH TEXAS.

Meiner, Marc; Hodge, C.; Roberts, A.; Bayas, M. University of Texas Health Science Center, San Antonio TX USA

Objective. To determine the educational relationship between AIDS knowledge, language preference and response to AIDS public radio messages for Hispanic women in South Texas.
Methods. We surveyed 212 women in two predominantly Mexican-American housing projects, employing language of preference for each. Scales were constructed to measure Spanish Language Use (SLU), correct/incorrect knowledge of HIV issues (AK/IAK), risks for HIV (R), recent contact with sexual partners sharing HIV information with children (CK), reported messages from radio (RM), and attitudes toward media messages (OFA).
Results. We found positive correlations between SLU and AK- (p<0.001), AKI and CK (p<0.002), and GK and AKI (p<0.001); and a negative correlation between SLU and AKI (p<0.001). In analysis of media, there was no significant association of RM and SLU (p>0.05) or GK. Of note were positive correlations between AKI and OPA (r=-.33, p<0.006) and OPA and SLU (r=-.31, p<0.03).

Conclusion. Spanish language preference in these Hispanic women was associated with less net AIDS knowledge and greater enthusiasm for specific messages on HIV risks, precautions and testing. The data suggest that Spanish language media is effective in outreach to Hispanic women with less AKI.

M.E.P.15 UTILIZING THE MASS MEDIA TO PROVIDE CULTURALLY RELEVANT HIV EDUCATION TO HISPANIC AMERICANS

Zayas, L. J.; Lopez, R. M.; Montelone, L. M. *Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, Los Angeles, California, U.S.A. **RCET TV/Hispanic Health, Los Angeles, California, U.S.A. ***Sosa and Associates, San Antonio, Texas, U.S.A.

Objective. To present a working model for developing effective, culturally relevant mass media HIV education programs for Hispanics.
Methods. Essential components of the model will be illustrated and its practical application described by tracing the development of three video campaigns (SIDA in AIDS, ALICIA and AMERICA RESPONDE TO AIDS FOR HISPANICS) from initial concept development to production and utilization. Effectiveness of the model was assessed via field tests on stratified samples from the target population, viewer ratings, press coverage, ratings from national experts, number and types of calls to national and local hotlines, and number of requests for the products. A set of principles for developing effective, culturally relevant mass media interventions for minority populations will be provided.
Results. Preliminary analyses of SIDA in AIDS data suggest over 161 increases in volume of calls to the national hotline; press coverage in all major newspapers in the market areas; and overwhelmingly positive ratings from national experts. Viewership ratings were either good or extremely good in 80% of the major markets.
Conclusion. Utilization of this model will increase the effectiveness and reach of mass media efforts targeting Hispanic Americans.

M.E.P.17 THE IMPACT OF MEDIA EVENTS ON PUBLIC INTEREST IN AIDS

Harfield, F. J.; Kay-Kell, L. A.; Wood, Robert* *Seattle-King County Department of Public Health, Seattle WA, U.S.A.

Objective. To assess the impact of major media events on general public concern about AIDS, as to the Seattle-King County, King County, Wash. **Methods.** The Seattle-King County Health Department's AIDS Prevention Project staff an information and referral hotline 50 hours per week. Data are routinely collected on the number of incoming calls, gender of callers and risk level with regard to infection with HIV. We analyzed trends in numbers and types of calls with respect to the following:
Results. Calls to the hotline increased immediately following major media events. In the 3 days following the National Hotline, the number of calls doubled compared with the average number of calls during a comparable time period. We noted increases in requests for antibody testing in low risk sites, and similar peaks after other media events including the release of CDC data on the risk of HIV infection from blood transfusions (May 1987), and national network coverage of the International AIDS Conference, 1987 and 1988. The percentage of calls from females and no risk or low risk individuals also increased following these events.
Conclusion. Major media events have a strong influence on the general public's interest in AIDS, and provide an opportunity for local hotlines to target youth and other vulnerable populations who might not be reached by other campaigns. The Seattle National Hotline was similar to that of a print or electronic media event, indicating a need for further study of the relative effectiveness of a costly, labor intensive education strategy like the National Hotline.

Medias

M.E.P.14 AIDS: THE LANGUAGE, MEDIA, AND PUBLIC RESPONSE

Duffness, Jesse C. Waterloo Regional Health Unit, Kitchener Ontario, Canada.

Objective: To examine the impact of media coverage of AIDS in children papers and magazines, and to ascertain differences in public and media response to AIDS following the Ontario Ministry of Health #7 million dollar "Let's Talk" media education campaign.

Methods: An examination of local print media coverage of AIDS related articles both before and after the Ministry of Health "Let's Talk" campaign. Additional examination of pre-test instruments distributed at AIDS education presentations. A critical examination of the language used by the media in coverage of (a) medical reports, (b) lifestyle articles, and (c) public and private response stories.

Conclusion: The Ministry of Health advertising campaign has had some impact on the general public. However, while many people now believe AIDS cannot be contracted by casual contact, great confusion still exists around transmission and risk categories. Continued education is required, but such education must be targeted at specific audiences if it is to be successful.

M.E.P.16 DEVELOPING A LARGE SCALE AIDS MEDIA CAMPAIGN BY COMBINING PUBLIC AND PRIVATE SECTOR RESOURCES

Nahata, Claudia L.; Fleming, D.; McAllister, R.; Young, O. M. **Oregon Health Division, Portland, Oregon, U.S.A. ***Sosa and Associates, Portland, Oregon, U.S.A.

Objective: To educate the public about AIDS through a statewide media campaign.
Methods: The Oregon Health Division collaborated with two private advertising agencies to produce an AIDS education media campaign. The Division contributed seed money and public health expertise and obtained input and endorsements from political leaders, health care providers, AIDS activists and religious leaders. The private sector donated all creative and production talent and advertising time and space. All material was produced at cost. The campaign's effect was measured by two statewide random digit dialing surveys of 600-800 people each conducted at the beginning and end of the four month campaign.
Results: The campaign was launched in 10/87 by the governor. During the following three months, six T.V. spots were aired 1,532 times; four radio spots were played 3,516 times; 34 newspapers on at least one of six print ads, 120 billboards, 275 bumper and 75 exterior transit ads were placed; and 20,000 bumper stickers and 5,000 copies of 4 posters were distributed. After the campaign, 67% of those polled had seen or heard some of the campaign. Recognition of specific signs or slogans varied between 60% and 87%. People polled after the campaign were more likely to believe that HIV could be transmitted from mother to fetus (78% vs 69%, p<0.01), was likely to believe it safe to have sex with someone who tested negative for AIDS (64% vs 59%, p<0.01) and, among 18-39 year olds, more likely to accept the use of condoms (50% vs 46%, p<0.01). The campaign cost Oregon taxpayers \$70,000. The value of donated private-sector time and services was estimated at one million dollars. Eight national and international awards have been received for the campaign.
Conclusions: Combining public-sector seed money and public health expertise with private-sector talent and resources that are largely dormant is an effective way to mount a large AIDS public information campaign.

M.E.P.18 PERCEIVED RISK OF HIV TRANSMISSION FROM A NONCOUNSELOR RESIDENTIAL POINT WITH AIDS AMONG LAY PEOPLE AND PUBLIC HEALTH SPECIALISTS

Gen Chi, Dept. Biostatistics, Human Med., Nanyang University School of Medicine, Tokyo, Japan.

Objective. To see 1) the magnitude of HIV transmission risk perceived by lay people and public health professionals immediately after mass media exposure that a man with AIDS had contacts with 150 prostitutes and homosexual males prior to the development of the disease and 2) attitude toward preventive policies with alternative measures of varying degrees in comparison with the size of perceived risk.

Methods. Study 1: Questionnaire study was conducted within a week after the news was released on 893 lay people (students, office workers) and 38 public health specialists. Study 2: Questionnaire study on 570 university students regarding the above described risk estimation juxtaposed with their attitudes toward preventive programs.

Results. Study 1: Number of transmission perceived by the lay people was much smaller than that by the specialists (range, 100-893 vs. 0-3).

Study 2: No attitudinal differences between the group with higher estimation and the one with lower estimation.
Conclusion: Lay people tend to overestimate the risk of HIV transmission and may be more vulnerable to the influence of mass media. Bicultural educational messages may be associated with fear and anxiety but not with the presumed magnitude of transmission risk per se.

Session d'affichage Poster Session



Le SIDA, la société et le comportement AIDS, Society and Behaviour

M.E.P.25

THE METRO TORONTO AIDS EDUCATION PROGRAM: A MODEL FOR LOW-RESOURTE MEDICAL TRAINING
PAWLIK, Diana, Dreyer, M., Varley, V., and Siskind S.
 *Municipality of Metropolitan Toronto, Toronto, Ontario, Canada.
OBJECTIVE: 1. To provide all Metro employees with the knowledge and skills necessary to prevent transmission of AIDS to abide by Metro AIDS Policy, Human Rights, Health and other legislation; to practice Universal Precautions for infection control; to cope with the psychological, social, and ethical issues raised by AIDS and similar disorders. 2. To provide all persons serviced by Metro with the knowledge and skills listed above and to ensure a consistently high level of service to Metro residents regardless of their status with respect to the AIDS virus.
Methods: The program has a low budget with minimal staff and resources but Metro has more than 12,000 regular employees alone (including health-care, maintenance, land-fill, and sewage treatment workers), many with low English skills and/or non-English language. Because information alone is not enough to bring about behaviour change, the program uses a small-group (5 or less), interactive lecture/workshop (2-3 hours) depending on need or audience approach. Although it may sound costly, this approach ensures high cost-effectiveness by allowing trainees to break through what is often the reality of AIDS in their own lives, and to discuss concerns. It also allows demonstration of control techniques, discussion of ethical issues specific to each workplace and to each individual, and ensures that each trainee has met a person who they can contact with future questions in a confidential manner.
Results and Conclusions: Program is cost-effective in that many people in very different occupations and with very different language levels can be trained so that both knowledge and behaviour change occurs.

M.E.P.26

EFFECTING BEHAVIOR CHANGE THROUGH POLICY AND TRAINING
Gerberding, Julie Louise, M.D., San Francisco General Hospital, San Francisco, California, U.S.A.
Objective: To assess a hospital's interdepartmental approach to the implementation of Universal Blood and Body Substance Precautions effected staff behavior change.
Methods:
 - Sessions most commonly asked during initial training sessions indicated areas of greatest concern
 - Infection Control Committee observations through hospital rounds and problem-solving consultations
 - Major problem areas identified are then targeted as "the Question of the Week" in week-long multi-educational campaigns for staff
 - Knowledge is measured through pre/post tests in the second training program
Results:
 - Ascertain whether supplies and equipment are available
 - American feedback passed to affected department
 - Ascertain cost increases or decreases due to implementation
 - Knowledge gain from the training will be demonstrated in employee practice
Conclusions:
 - Universal Blood and Body Substance Training transcends the formal program and becomes an on-going, on-site process which is evaluated by changes in staff performance

M.E.P.27

AN EMPLOYER-BASED APPROACH TO AIDS PREVENTION, EDUCATION AND MANAGEMENT
Edwards, William L., Vance, R.D., Sofian, S.L., Anderson, E.S., Washington (State) Employees AIDS Prevention Alliance, Seattle, WA, U.S.A.

Many employers lack comprehensive, current and reliable AIDS-related information to use in the workplace. AIDS prevention and education for the general public is the focus of the most recent by the (Washington) State Governor's Task Force on AIDS. The Seattle-based Washington Employees AIDS Prevention Alliance (WEAPA) is a participatory, private sector response to the need for AIDS/HIV infection preventive education and AIDS-related information in the work environment.

WEAPA has two main goals: 1) the promotion of AIDS/HIV infection preventive education at the workplace, and 2) the provision of AIDS/HIV infection management tools to employers. WEAPA provides educational materials, presentations in AIDS prevention, and technical assistance on legal, benefits, cost, and communication issues related to AIDS. WEAPA is co-sponsored by private and public sector organizations. Participation in WEAPA is through membership (annual fee based on work force size) and includes all employees. After one year of operation, WEAPA has 154 employer members, representing an almost equal cross-section of large (500+ employees), medium (100-500 employees) and small (50 employees) employers. WEAPA's first annual conference, an introduction to AIDS/HIV infection prevention and management for employers, was attended by all members. 31% of the members received technical assistance in developing human resources policy and procedures, managing insurance and benefits programs, and keeping current on legal issues related to AIDS. 30% (60) of members report having employees who self-identify as having AIDS or being HIV positive. WEAPA is an innovative private sector prevention and education model applicable for any metropolitan/occupational area. WEAPA has begun to work with other committees interested in workable AIDS education.

M.E.P.28

AN AIDS EDUCATION INTERVENTION IN A MULTIRACIAL HOTEL
INDOYTH
Chidambaram, Srinivas; Sanyasree, M.; Sher, R.; Metz, J.; AIDS Training and Information Centre, South African Institute for Medical Research, Johannesburg, South Africa.

OBJECTIVE: To formulate, implement and evaluate an AIDS education intervention in a multiracial hotel industry.
METHOD: A three-phase intervention was adopted to create an awareness of AIDS amongst all hotel employees. Firstly, executive management attended an AIDS seminar. Secondly, a multidisciplinary team of professionals visited the different hotel regions to address senior, middle and supervisory management about AIDS, and to plan for preventive education. In the final stage, 30 hotel employees were selected on specific criteria for training. Of these, 20 were black, 10 white, with an even ratio of male to female. Two successive groups of 15 people participated in a five-day training course. The objective of the course was to certify them as AIDS educators so that they could disseminate information to all hotel employees. A follow up to monitor progress is carried out at monthly intervals.
RESULTS: In a period of four months 3317 (138) out of a staff complement of 10319 were informed about AIDS. Surveys and questionnaires reflect increased AIDS knowledge and awareness. Additional research is necessary to evaluate attitude and behaviour change.
CONCLUSION: The success of the intervention to-date results from a cadre of educators who can provide continued in-house information, and also from management commitment to promoting AIDS awareness to all hotel employees eg. common vending machines were installed in all hotels.

M.E.P.29

RESPONDING TO AIDS: TEN PRINCIPLES FOR THE WORKPLACE
LEVIN
Chernin, Catherine, Center for AIDS and Human Resources, New York, NY, USA

In response to current employers and employees about associated policies and programs concerning AIDS, the Centers for AIDS on New York City and Human Resources have developed ten principles to guide business, unions, and other organizations. These principles are:

1. People with AIDS or HIV (Human Immunodeficiency Virus) infection are entitled to the same rights and opportunities as people with any other chronic illness. 2. Employment policies must be nondiscriminatory, comply with federal, state, and local laws and regulations. 3. Employees' policies should be based on the scientific and sociological evidence that people with AIDS or HIV infection do not pose a risk of transmission of the virus to coworkers through ordinary workplace contact. 4. The higher levels of management and unions leadership should unequivocally endorse nondiscriminatory employment policies and educational programs about AIDS. 5. Employers and unions should communicate their support of these policies to workers in a simple, clear, and understandable way. 6. Employers should provide employees with sensitive, accurate, and up-to-date education about risk reduction in their personal lives. 7. Employers have a duty to protect the confidentiality of employees' medical information and to prevent work-related rejection by coworkers of an employee with AIDS or HIV infection, employees and unions should undertake education for all employees about AIDS or HIV infection, employees and unions should ensure that HIV screening is voluntary as part of general pre-employment or workplace physical examinations. 10. In those situations where there is a potential risk of exposure to HIV for employees, in health care, when workers may be exposed to blood or blood products, employers should take specific, clear, and understandable steps to provide the necessary equipment, to reinforce appropriate infection control practices and ensure that they are implemented.

As of February 1, 1988, over 300 companies and non-profit organizations in the United States have publicly endorsed these principles. They serve as a model for other groups concerned with these issues.

M.E.P.30

Workplace AIDS Education: An Evaluation of CDC Employees
Shorrock, Egan, S. Klaid, D. Brownell, D. Schell
Centers for Disease Control (CDC), Atlanta, Georgia, USA

Objectives: To examine the impact of an educational intervention on employees' AIDS knowledge, attitudes, beliefs, risk perceptions, HIV test-seeking and level of comfort working with a person with AIDS or HIV.
Methods: A questionnaire designed to assess these factors was self-administered in a pre-post test design by 583 (93%) of the employees attending a one-hour AIDS education session.
Results: Survey respondents were generally white (81%), married (64.8%), female (60.3%), and college educated (70.2%). Mean age was 41.0 years. Overall, participants' awareness and attitudes about AIDS improved significantly ($p < .01$, $p < .001$). However, many participants reported only modest comfort in working with someone infected with HIV (70%). Accurate AIDS knowledge was modestly predictive of how comfortable people would feel working with someone who is infected. Most of the participants who had already been tested (25.2%), had been tested at blood banks. Although CTIs had not been used in the past, CTIs were reported as a major potential site to visit for testing. Additionally, people remain confused about the safety of the nation's blood supply (40% were incorrect) and what the HIV antibody test shows (50% were incorrect). Respondents rated themselves at low risk (50.4%). Nevertheless, over one-third were single adults and 11 felt that they were at risk or were unsure of their risk.
Conclusions: Continued AIDS education targeting these issues and intensive evaluations of such workplace programs are warranted.

Session d'affichage Poster Session



Le SIDA, la société et le comportement AIDS, Society and Behaviour

M.E.P.31 EDUCATIONAL STRATEGY ON AIDS AT WORKPLACES.
Graciele L. Fernandes, R.T., Abbud, J. R., Adão, V. M., Kakinara, R.
Centro de Referência e Treinamento-Aids, São Paulo, Brasil

Objective: The State of São Paulo, Brazil, is the most industrialized region in South America with approximately 100,000 big companies, and because so many people can be reached at the workplace, one of the primary targets for Aids Education considered by the Department of Education and Training from the Secretary of Health was the workplace.

Methods: Once a month we realized a training course with 20 hours for human resources and health care providers from big companies with the following classes: Epidemiology, Clinical, ethical, legal social and educational aspects on Aids. Evaluation of the training is done with pre and post-test with basic questions due to HIV patient in the workplace.

Results: 408 human resources and health care workers were trained from 149 big companies. 70% of them developed massive campaigns and helped with their own material other smaller companies.

Conclusion: The response of the training course was considered very effective decreasing discrimination and misunderstanding.

M.E.P.33 RESULTS ON THE EFFECTIVENESS OF AN AIDS IN THE WORKPLACE EDUCATION PILOT PROGRAM
Blake, S., Maljer, D., Georgia, A., and Makinson, E.
**American Red Cross, Washington, D.C., U.S.A.

Objective: To assess the short-term impact of an AIDS curriculum in the workplace, and to explore factors associated with knowledge, attitude, and behavior change.

Methods: Pre-post survey results from 1131 employees in six companies were analyzed using paired t-test comparisons and McNemar test statistics to determine the significance of change. Kruskal-Wallis and Chi-square test statistics were used to assess the relationship between change and participant or employer demographic characteristics.

Results: Statistically significant changes ($p < .01$) in knowledge of the mode of transmission, risk perceptions, workplace attitudes toward PWA, spousal and risk reduction behavioral intentions were found. Participant gains following participation were greatest for persons who were less knowledgeable, less confident, less tolerant of PWA, and less likely to engage in prosocial behavior, to communicate about AIDS, or to have done anything previously to reduce their risk for exposure ($p < .05$). Statistically few individual or corporate predictors of change were observed.

Conclusion: Short-term effects of an AIDS education program in the workplace can be demonstrated, particularly for those individuals at greatest need of basic information. Future research and curriculum needs are discussed.

M.E.P.35 MULTI-AGENCY SUPPORT GROUP FOR TRANSFUSION RELATED HIV INFECTION
Stuart, A., Steilen, M. A. and Campbell, S.**
*Columbia University, New York, NY. **Memorial Sloan Kettering Cancer Ctr., New York, NY

Objective: To decrease the isolation of the recipients from their families, to educate patients and their families about HIV infection and to provide a safe environment in which the patients and their families can express their feelings.

Methods: Group was composed of recipients and any of their family members that could/should attend. The contact was for 4 consecutive weekly evening sessions which lasted 90 minutes. Content included fear of infection, anger, frustration, issues of loss of control, shame and grief. Education was very important in this population as they were psychologically sophisticated and grew up in an era in which exposure to infection could result in death.

Results: Group provided a safe environment in which members (age range: 26-75) could share their feelings. These feelings had been denied at home, resulting in family disequilibrium. An ongoing support network was begun.

Conclusion: Important strides were made within this group to restore the homeostasis of the family units. This group model could help others who, because of their beliefs about infections, reinforced by society's fears, are not getting adequate support or medical care.

M.E.P.32 RULES FOR APPROPRIATE CARE AFTER ACCIDENTAL SKIN LESIONS WITH RISK OF EXPOSURE FOR BLOOD BORN INFECTION
Kashraba, Lara, M.D., TSMAN, M.D., Greitt, Tronca, R.N.T.
Department of Epidemiology, National Bacteriological Laboratory, Stockholm, Sweden

Accidental skin lesions in staff handling possibly HIV-infected material often provoke strong feelings of anxiety for an infection. Thus, there is a need for firm rules how to act in order to prevent overreacting and to ensure adequate measures, after several incidents we have formed rules how to advise people in different positions. These rules are divided into four parts each applicable to persons in different roles, summarized as follows:

1. On the spot any blood should be washed away and if bleeding occurs one should try to squeeze out the blood. The exposed person should be brought to the occupational health service together with full details on the suspected nature of the accident.
2. The local safety delegate has to help the person in question to make a report of the accident.
3. The local foreman has to ensure that the exposed person is adequately treated, gets good support, and is taken to the health service, that a complete report is duly written, and that the exposed person's family gets support and advice.
4. If the health service considered must elucidate the circumstances, take all indicated tests, give prophylactic medication, and organize proper follow-up.

Family Family

M.E.P.34 FAMILY THROUGH APPROACH NEW HIV INFECTED CHILDREN
Reisman, Anita and Robinson, A.
Albert Einstein College of Medicine, Bronx, N.Y., U.S.A.

Objective: The index patient with HIV infection identifies a whole family at risk when the mother is infected, possibly the father and at times one or more siblings. The exposure of chronic illnesses paralleled by the acquisition of multiple lesions places a heavy emotional burden on AIDS families. Prior to their HIV infection, these families possess a formidable challenge by the mere fact of their poverty, stigma, rejection, unresolved grief, and poor quality of life.

Method: Clinical observations from case analyses and therapeutic intervention with 45 families at our institution revealed the following: 1) Issues and fears experienced by young adults having their children; 2) Isolation and separation from family members and friends causing the deterioration of couple and family relationships; 3) Full spectrum of emotional illnesses due to loss of loved ones and fear of infecting others; pervasive anxiety related to future prognosis in young adults; 4) Issues related to lack of financial support, sexual involvement, medical outcomes.

Result: Identifying as many family members and friends as possible and eliciting their expert opinion as effective support network, better quality skills and more functional family intervention team. Treating cases outside the family context is ineffective and often detrimental.

Conclusion: In order to dislodge family chaos, sustain family equilibrium, improve compliance and provide families with renewed energy and quality of life, timely and targeted family interventions are crucial to the comprehensive management of HIV infected families.

M.E.P.36 BISEXUAL MEN AND THEIR PARTNER WORKSHOP SESSION
Palmer, William, Research Officer
Gay and Married Men's Association, Melbourne, Victoria, Australia.

Objective: This workshop is designed to explore the issues related to bisexual behaviours in men which may subsequently lead to H.I.V. transmission within the general community. To discuss the research data on which the rationale of the cases is based.

Methods: By examining case histories, to identify a range of sexual and emotional behaviour patterns which may, for a variety of reasons result in H.I.V. infection of men in a primary heterosexual relationship. Such factors as non-cognitive homosexual behaviour, denial of risk behaviour, adolescent type sexual behaviour patterns and unrepresented homosexual experiences will be considered. Emotional barriers to behaviour change and methods to overcome these barriers will be discussed. Factors which risk force positive changes will be presented with the background research information on which they are based.

Results: It is expected that an evolution of emotions and attitudes within the workshop framework will lead to a better understanding of the dilemma routinely faced by men with a bisexual orientation.

Conclusion: By promoting a better understanding of the issues involved in dealing with bisexual behaviour and orientation it is possible to provide more appropriate specialised services to this group of men. The end results at a community level is the protection of the men themselves, their female sexual partners and the children conceived.

Session d'affichage Poster Session



Le SIDA, la société et le comportement AIDS, Society and Behaviour

M.E.P.37 AIDS AND HEMOPHILIA: A COORDINATED EDUCATION, SUPPORT AND PERSONAL CARE PROGRAM. PRELIMINARY REPORT FROM A TWO-YEAR PILOT PROJECT

McDonald, John B., Dawick, Sherry*
*University of Calgary, Calgary, Alberta, Canada. **AIDS Calgary, Calgary, Alberta, Canada.

Objective: To describe results of a two-year, Health and Welfare, Canada funded pilot project in education, support and personal care for persons and families having or at-risk for HIV and AIDS in the Southern Alberta Hemophilia Program.

Methods: The project purpose was to strengthen the education, support and personal care network for people with hemophilia and their families in Southern Alberta. This purpose was addressed through four objectives: (1) an education, support and personal care network, (2) cooperation with Regional Hemophilia Society of the Commonwealth Hemophilia Clinic in establishing resource and information services, (3) scheduling regular updates on specific topic meetings conferences, social and information sessions, (4) conducting hospital staff and public education sessions, and (5) providing limited financial assistance in urgent need areas.

Results: In all five program areas, initial information has been established, support and financial assistance provided. A visible strengthening of the hemophilia community resulted, as well as a regular mechanism for education, support and networking occurred.

Conclusion: Evaluation indicates program with modifications is viable and important. First year provincial funding granted for program continuance.

M.E.P.38 THE HIV-INDANGEROSED/INFECTED CHILD IN THE FOSTER-FAMILY

Schwarz, Gabriele; Hense, A.
Arbeitskreis zur Förderung von Pflegekindern e.V., Berlin, Federal Republic of Germany.

Beside medical specifics of HIV-infection with children as there are - problems in diagnosis of HIV-infection, - course of disease, - mortality rate, - infection of mother in case of pre-/perinatal endangered/infected children, there are also a large number of exceptional psychological and judicial problems.

Psychological aspects of HIV-infection with children resulting for example from: - HIV-infection of members of the family, - preliminary uncertainty about HIV-status of the child, - death of the mother, - sickness of the mother, resulting in temporary or permanent living of the child outside of his home, - change in the person who is in charge of the child, - difficulties between own- and foster-family, - problems with social neighbourhood, - problems with institutions.

Judicial aspects to be considered are: Liability of the foster-family, - law regarding electronic data processing figures, - HIV-testing of applicants for foster and adoption of the child, duty of revelation for example, when the child is attending the kindergarten. The poster shows the subjects concerned as well as their combined effects on each another.

M.E.P.39 WHO SPEAKS FOR THE ABANDONED CHILD BORN WITH HIV? A FOSTER PARENT AND ADOPTIVE PARENT RESPONSE.

Chambers, Sandra A.; McCrellin, Barbara*
*Childlink, Inc., Alhambra, Georgia, USA. **Starcross, Amnopolis, Calif., USA.

Objective: To provide for and address the needs of homeless children born with HIV. From the perspective of the child.

Methods: Childlink and Starcross Community are actively involved in the placement and protection of HIV children. Our position is that each child should have maximum human continuity. We have adopted or are in the process of adopting 7 homeless children with HIV. We offer nationwide support and educational services for prospective foster and adoptive parents. The health and dignity of these children are the primary focus in all our lobbying and advocacy efforts.

Results: By cooperating with existing religious outreach programs as well as governmental and social service agencies foster and adoptive parents have been recruited. Foster care homes have been purchased with private monies and parents provided with the appropriate support to care for infants and children born with HIV. These agencies and parents support spiritually, emotionally and usually the day-to-day stable home environment so desperately needed by these children.

Conclusion: Children with HIV should be mainstreamed and given the opportunity for early bonding with an individual or family. Our responsibility as caring human beings is to do everything possible to give these children the opportunity to equip themselves with the mental and emotional resources to fight off this disease. Personal involvement with our adoptive and foster children are proving the validity of this approach.

M.E.P.40 AIDS ORPHANS IN NEW YORK CITY: PROTECTED MEMBERS AND POLICY DRIVES

Shoond, Chris; Weiss and Aida Steiner, 750 Mac Don. St., NY 10025 USA.

Objective: In the focus on AIDS and prevention, it has been widely overlooked that HIV positive women may not only be HIV-infected (HIV+) but also HIV-infected (HIV-) and may all HIV-infected will be orphaned at a mother's death. Realization of orphaned as expected in NYC are projected and implications for social policy and prevention discussed.

Methods: Assessment was made of the relative numbers of HIV- and HIV+ children under age 18 residing with HIV+ mothers in 3 NYC boroughs with high levels of women's infection:

Neighborhood	% Total HIV-Children HIV-Orphaned	% HIV-Orphaned	% HIV-Orphaned
Manhattan	30	5	7.5%
NY Div-Infected	56	7	12%
Brooklyn	46	25	31%

Results: Mothers infected in drug abuse had more HIV+ children than those infected conventionally but, on average, there were 2 HIV- children per mother in both groups. The NYC Dept. of Health estimates there are between 25,000 and 50,000 total infected women in the city, with large numbers approaching illness. Reducing the women's infection by HIV to allow for older women unlikely to have dependent children, if even HIV of the remaining women develop AIDS, it is estimated they will leave behind between 25,777 and 72,000 living, orphaned children, given an average of two HIV- children per woman.

Discussion: While these results are necessarily based on estimates, they have important implications: 1.) In New York and many US, institutions, efforts to directly contact women about prevention are focused on women in general care. However, with many women clearly having had their children by the time they become infected, such an preventive effort, including partner notification, must be focused on women who are already mothers. 2.) National policy and attention to care for orphans is unique in nations with high levels of female infection. AIDS-infected women simply will not have the resources to care for orphans by themselves.

M.E.P.41 EXPERIENCE QUÉBÉCOISE D'INTERVENTION AUPRES DE FAMILLES A L'ÉCHÉANCE D'HOSPITALISATION DE LEUR PROCHE HOMOSEXUEL ATTEINT DE SIDA

Berthelot, Pierre; Poirier, G.**
**CENTRE DE SERVICES SOCIAUX DE Québec, Services sociaux hospitaliers, Équipe de prévention et de soins Québec, Québec, Canada. ** Centre de services sociaux de Québec, Services sociaux hospitaliers, Hôtel-Dieu de Québec, Québec, Québec, Canada.

Objectif: Présentation d'une expérience québécoise d'intervention auprès de FAMILLES à l'occasion de l'hospitalisation de leur proche homosexuel atteint de SIDA.

Methods: Présentation:

- Su processus d'intervention: utiliser la crise vécue au moment de l'hospitalisation comme moment stratégique d'intervention auprès de la famille; accompagner et normaliser le vécu des membres impliqués de la famille; précéder le non-dit pour rendre explicite l'indicible, pour le normaliser et pour supporter la famille.
- des difficultés rencontrées: entre autres: craintes par la famille du jugement de l'intervenant; difficulté de communication de la famille avec les personnes atteintes; peur du secret.
- les questions qui se posent: le deuil pour la famille et chacun de ses membres? l'utilité de l'accompagnement à cette étape...

M.E.P.42 PROVIDING COMPREHENSIVE SERVICES FOR DEVELOPMENTALLY DISABLED CHILDREN WITH AIDS AND ISSUES

Authors: Phyllis Sumner & Anthony Trunfo
THE CHILDREN'S CENTER - 394 East 53rd Street, Brooklyn, New York 11203, U.S.A.

The Herbert O. Birch Services, with IPE Office of Mental Retardation and Developmental Disabilities and the Children's Hospital Medical Center in Brooklyn, New York operates the first community residence providing comprehensive residential, educational, rehabilitative and medical services for ten developmentally disabled "border babies" with AIDS, aged birth to six years.

One out of six babies in NYC are born with the virus. On any day, there are 20-30 border babies left abandoned in City Hospitals.

Over 93% of children with AIDS show measurable HIV-related System dysfunction such as: impaired motor skills, severe language disorders, significant cognitive deficits and loss of acquired developmental milestones. A variety of residential alternatives and specialized diagnostic and therapeutic interventions must be established to address the special needs of infected children. These services are offered: 1) community residence and respite care, 2) special education day care, 3) daily medical surveillance, 4) foster care placement offering case management, training and supervision of families.

The following significant issues will be discussed: foster care vs. congregate care for children with AIDS, aged birth to six years. (Do you have more than 2 people, or, good care vs. bad care whether congregate or foster?) discrimination toward children with AIDS, their caretakers (what should staff do when they are refused entry into a local apartment with the child(ren)? Helping staff cope with the inevitable loss of children with whom they have established loving ties.

Session d'attachage Poster Session



Le SIDA, la société et le comportement AIDS, Society and Behaviour

La communauté (partie 1) Community (Part 1)

M.E.P.43

ACCESSING, READING AND RESEARCHING HARMED HOMOSEXUAL AND BISEXUAL MEN
Phyllis Williams, Research Officer
Gay and Lesbian News Association, Melbourne, Victoria, Australia

Objective: To establish a model method to contact, educate and research harmed homosexual and bisexual men in the field.

Method: Contact was established, and where possible maintained, using a telephone counselling service in combination with an established peer support group. A wide range of additional services were incorporated into this structure to provide suitable medical and legal assistance as well as additional counselling services to the group. Research information was recorded for all participants in a separate format.

Results: Over one thousand calls have been processed - date and a nature of these calls have been followed up in case studies. A wide range of sexual and social behaviour patterns have been noted and an assessment of safe sex knowledge levels has been noted and an assessment of safe sex knowledge levels seen within this group. Knowledge levels for safe sex and general information on AIDS were significantly lower levels than those generally found within the gay community. Data on factors which influence behaviour modification for this group of men are collected. Factors which contribute towards safe sex behaviour for this group of men were also noted.

Conclusion: Harmed homosexual and bisexual men are difficult to access in the general community, as a result little is known about their sexual and social behaviour patterns. This method of accessing and maintaining contact has been successful. Research results obtained indicate the need for a comprehensive campaign aimed toward educating this particular target group and their female partners.

M.E.P.45

DES PROFESSIONNELLES DE LA SANTÉ ET LA CRÉATION D'UN GROUPE D'INFORMATION À QUÉBEC: l'initiation préalable de la complémentarité des ressources.

LAURENCE CHÉLIEU, agente de recherche, Département de Santé Communautaire de l'Hôpital Ste-Justine, Ville de Québec, Québec.

DAVIDE BÉGIN, président du conseil d'administration de MIESS-Québec.
OBJECTIF: Présenter un modèle de collaboration entre des bénévoles et des professionnels de la santé dans la création d'un mouvement d'information et d'éducation dans la lutte contre le SIDA à Québec (MIESS-Québec).

MÉTHODE: Présentation du processus d'implantation, de définition et d'ajustement des méthodes et des actions qui en découlent. Quelques données sur les résultats d'application après 2 ans de fonctionnement seront également présentées et discutées.

RÉSULTATS: En juin 1986, agreement, dans des rencontres se déroulant dans un contexte d'urgence pour échanger sur les problèmes vécus par les personnes atteintes de la maladie et les difficultés rencontrées par les professionnels de la santé, par exemple, pour avoir accès à certaines cliniques particulièrement touchées. Après quelques rencontres, le comité consistait de la nécessité de former un groupe d'éducation bénévoles. Les objectifs visent l'information, l'éducation à la prévention et le support aux personnes atteintes du SIDA.

CONCLUSION: La collaboration entre bénévoles et professionnels de la santé est possible, ainsi qu'essentielle à MIESS-Québec en fait. La détermination tient en insistant sur la spécificité des rôles de chacun.

M.E.P.47

**THE ESTABLISHMENT AND ADMINISTRATION OF
CASEY HOUSE HOSPICE, TORONTO**

HILMAN MATHEN, Executive Director, Casey House Hospice, Canada.

DOROTHY LEY, Board Member, Casey House Hospice.

Objective: To describe the process of the establishment of Casey House Hospice, and the administrative challenge of AIDS hospice management in the health service environment of Ontario, and the political environment surrounding AIDS, and the psychosocial issues of AIDS.

Method: Oral presentation with slides and overheads.

Results: Overview of success and challenge of a free-standing AIDS hospice.

Conclusion: The need for standards and funding mechanisms to allow the model of the free-standing hospice system, within the context of the Canadian health care system.

M.E.P.44

THE GENESIS AND RAPID DEVELOPMENT OF THE AIDS ACTIVIST MOVEMENT

The Dwight Foundation, New York, U.S.A.

Objective: To describe the rise of AIDS activism, including civil disobedience and direct confrontation as a response to the perceived indifference on the part of medical and government officials resulting in a lagged response to the pandemic.

Methods: The presentation will use video clips, still photos and excerpts from the popular press to trace the history of the AIDS activist movement from its inception in the fall-winter of 1984-87 through June 4, 1989.

Results: The confluence of 3 separate currents: the visual arts community of artists and graphic designers, e.g. the Silence = Death Project; advocates of civil disobedience and direct confrontation, e.g. the Lavender Hill Mob; and documentary and educators, e.g. the Testing the Limits Collective, resulted in the founding of ACT UP (the AIDS Coalition to Unleash Power) and similar organizations. These groups not only produce highly successful demonstrations and confrontations but museum exhibits, speakers bureaus, community outreach, and participation at conferences and conventions at which the medical, economic, or sociological aspects of the AIDS pandemic are discussed.

Conclusion: A new medical/social phenomenon has arisen. An afflicted community refusing to accept a passive role in its treatment is challenging medical and governmental authority to demand an equal voice in deciding its fate.

M.E.P.46

A COMPARATIVE STUDY OF LOCAL AIDS PROGRAMS IN THE UNITED KINGDOM

Fve, M^o, Eugénie Nubani^o Baskley, G^o, Cunningham, M^o

^oHealth Education Authority, London; ^oRoyal College of General Practitioners, London; ^oFaculty of Community Medicine, London; ^oTHE KINGDOM

Objective: To critically appraise the diversity of responses made by locally based AIDS programs to supplement the National UK AIDS Prevention Programme.

Methods: Nine areas (urban/rural, high/low HIV prevalence) were selected. In workshop discussions, guidelines were developed for the construction of case studies and their critical analysis.

Results: Nine case studies illustrating good practice and diverse responses were analysed with respect to, various dimensions including:

- organisational arrangements for local AIDS programmes;
- local and specific preventive initiatives (eg. needle exchange schemes for drug users);
- models of care in the community (eg. multi-disciplinary specialist teams);
- training and education (eg. school programmes).

Conclusion: In tackling similar issues, local initiatives have used varied, but successful approaches, dependent on prevailing socio-political contexts and opportunities. In many instances, AIDS initiatives have provided the opportunity to tackle other health concerns. Re-examination of the study's findings is aimed at influencing the development of good AIDS related practices nationwide in the UK.

M.E.P.48

HOMELESSNESS AND AIDS

Blakeney, Barbara, Mahan, Joan
Long Island Shelter, Boston, Massachusetts, U.S.A.

Objective: To identify and present in an educational format, the dual issues of AIDS and homelessness from the perspectives of the Homeless individual with the diagnosis of HIV infection and the clinicians involved in providing care.

Method: A video, produced by the Nurse's clinic at Long Island Shelter. This video focuses specifically on the special problems associated with being homeless and having HIV infection.

Results: At the present time the majority of homeless people with HIV infection at the shelter share the primary risk factor of intravenous drug abuse. Many of these individuals have been homeless prior to their diagnosis. The video explores the experiences, feelings and responses of four homeless men in various stages of their illness, as well as a series of short discussions from the clinicians involved in their care. Approx length is 30 minutes.

Session d'affichage Poster Session



Le SIDA, la société et le comportement AIDS, Society and Behaviour

M.E.P.49 COMMUNITY COALITION BUILDING AS A MEANS OF IMPROVING SERVICE SYSTEMS FOR PEOPLE WITH HIV INFECTION
Hurtwitz, C., Matheny S., McKeown M., Health Resources and Services Administration, Division of HIV/AIDS, Department of Health and Human Services, Rockville, Maryland, U.S.A.

Objective: AIDS Service Demonstration Projects have been funded to demonstrate the impact of a collaborative coalition of service organizations, coordinated through a case management system, on the continuum of care, comprehensiveness of services, and cost.

Method: To demonstrate that community coalitions can improve patient care and the utilization of unnecessary redundancy of service organizations for PWAs, 21 high AIDS prevalence communities received funds to establish and maintain such coalitions. The cities were selected on the basis of the demographics of the epidemic, the political context and organization of their health care delivery system, and the ability to receive funding. After nearly 2 years in operation, data and experience are available on the relative degree of success of these coalition building efforts.

Results: Factors contributing to the success of coalition efforts include: organizational location of health care and drug abuse services, cohesiveness of groups targeted for services, definition of the historical patterns of health care, cohesiveness of the community, the need for funding resources outside the local community, and the organization formed to receive funding.

Conclusion: While community coalitions can have a positive impact on the quality and cost of services, and innovative strategies can be replicated in other areas, an effective health care delivery system must be tailored to the unique characteristics of a community to insure optimal success.

Services sociaux

Social Services

M.E.P.51 AN ASSESSMENT OF THE PSYCHOSOCIAL NEEDS OF THE HIV ANTIBODY POSITIVE POPULATION USING THE NORTHERN HEALTH AND SOCIAL SERVICE NETWORK.

Chick, Elizabeth, Hodgson, V., Grayson, N.,...
*Catholic AIDS Clinic Montreal, Montreal, Quebec, Canada; **Royal Victoria Hospital, Montreal, Quebec, Canada; ***McGill University, Montreal, Quebec, Canada.

Objective: To describe a research project designed to assess the psychosocial support needs of the HIV antibody positive population of Montreal. Since it is evident to professionals within the health and social service network that the demand for psychosocial services far outstrips the available resources, there is a need for concrete data as to the psychosocial service needs of the HIV antibody positive population. There is presently no concrete data available from the point of view of the affected group. It is hoped that results of the data collection and analysis will enable us to make recommendations to the government with respect to the adequacy or inadequacy of services provided in Montreal.

Method: A questionnaire will be administered to a sample of 300 HIV positive persons attending hospitals and community clinics. The questionnaire will be presented by the physician and trained personnel will be available to answer questions about the patient with assistance.

Results: Some preliminary results of data collected will be presented and discussed.

M.E.P.53 DEVELOPING THE SKILLS OF HOME CARE STAFF IN CARING FOR PEOPLE LIVING WITH AIDS

Cotton Terry, Platt D., London Borough of Hammersmith and Fulham, London W6, U.K.

Objective: To provide a comprehensive package of training and support for staff in order to respond to increasing demand for services and to overcome staff reluctance to work in this area.

Method: After consultation with service managers and Trade Unions to identify key objectives and principal concerns, 1, 2 and 3 day workshops were established to address a range of training techniques. Practical issues have been explored alongside and experiential focus on counselling approaches and personal attitudes. People living with AIDS have provided a major part of the teaching input into the course.

Results: Course evaluations have shown considerable change in attitudes towards HIV and AIDS. The proportion of staff refusing to work in this area has dropped and staff confidence has improved.

Conclusions: Staff training addressing a broad approach to both practical and emotional issues, addressing locally identified staff concerns and incorporating the experience of people living with AIDS can be beneficial in overcoming staff fears and encouraging sympathy with service recipients.

M.E.P.50 A COMMUNITY-BASED AIDS EDUCATION, COUNSELLING AND INFORMATION SERVICE IN THE DISTRICTS OF ADO-21 FOR AFRICA 7
Foster, Geoff, Mutere Provincial Hospital, Mutere, Shabaha

Objective: To establish the Family AIDS Care Trust (FACT), a non-governmental organization with activities carried out by volunteers. FACT is a 100-strong organization which has operated in late 1987 from Mutere churches. Most volunteers were non-medical. In 1988, 40 people completed one of the six 10-hour training courses in AIDS education or counselling which included role-play and community assignments. Funding of \$5000 was raised from many individuals in the community. FACT activities were co-ordinated by a paid secretary.

Results: All information centre, telephone services and window display were set up. Volunteers produced literature, posters and visual aids. Local doctors were consulted. Many patients were referred to FACT for counselling but only 15 attended. Educators used story-telling with appropriate illustrations on flash cards; 70 educational meetings in appropriate facilities etc. were conducted by 25 volunteers. FACT gave support to official agencies responsible for AIDS activities.

Conclusion: Culture and traditional beliefs influence the effectiveness of AIDS programs. Psychological counselling may be inappropriate in African settings. Preventive education using simplified leaflets may be more acceptable and persuasive than mass media campaigns. AIDS prevention programs are feasible in rural communities. FACT's model includes the involvement and training of non-medical appropriate materials and the substitution of other agencies in FACT activities. The program was implemented rapidly with a limited budget and is being extended to other centres. It may be an appropriate model for other African settings.

M.E.P.52 HOSPITALIZED AIDS/ARC PATIENTS PRESENTING DISPOSITION PROBLEMS: IS SIMPLE SOLUTIONS POSSIBLE?

New York, USA.

Objective: To identify demographic/social factors predictive of disposition problems (ALOC) in a large urban hospital. A poor minority community.

Method: Reviewed social work charts for 131 AIDS/ARC patients to identify which demographic/social factors correlated with becoming ALOC. Data for the total group regarding sex, ethnicity, age, risk factor, and degree of family involvement were compared with data for the 24 ALOC patients.

Results:

Factor	N = 131	N = 24	ALOC Group
Male	97	74	12
Female	106	56	50
Black	106	81	22
Hispanic	22	17	93
Other	3	2	-

Of greatest interest is that fully 12 of 31 black females became ALOC. IV-drug-using and heterosexually-infected patients, but not gay males, often became ALOC as well. Age and degree of family involvement had no significant bearing on ALOC status.

Conclusion: The social milieu in which black females acquire HIV disease is a principal factor in their inability to secure proper post-hospital placement. Solutions cannot be simply hospital-based, but must also address broad environmental factors (poverty, racial discrimination, drug abuse, educational parity, and reproductive rights/child placement).

M.E.P.54 ESTIMATING NUMBERS OF PEOPLE LIVING WITH AIDS/HIV INFECTION IN A SMALL URBAN AREA FOR SOCIAL SERVICES PLANNING PURPOSES

Manning, Nicholas
Social Services Department, London Borough of Hammersmith and Fulham, W6, U.K.

Objectives: To develop some planning assumptions about the numbers of people who may be requiring services in a densely populated urban area (population 150,000) with a perceived high incidence of HIV infection. UK National Health Service figures are not available at this level.

Methods: Research was undertaken to ascertain an estimate of the numbers of people living with AIDS, and the numbers unwell with HIV infection, based on the current knowledge of all relevant health and social services agencies operating within the local administrative area. Networking within the voluntary and statutory agencies produced a comprehensive list of all relevant formal and informal agencies and their services. The numbers of people in receipt of each of those services during a three month period was determined. Through extensive liaison, the degree of overlap between groups of services was determined and total estimates of the numbers of residents living with AIDS, and of those unwell with HIV infection, were calculated.

Results: The method produced very considerable co-operation from all participating agencies, and reasonable quantitative estimates were calculated.

Conclusion: A survey of local agencies can produce valuable information about the numbers of people living with AIDS which reflects both the services of the larger agencies and the detailed local knowledge of informal groups and organizations, within a clearly delineated urban area.

Session d'affichage Poster Session



M.E.P.55 ESTABLISHING QUALITY CONTROL TARGETS FOR THE PROVISION OF PERSONAL SOCIAL SERVICES TO PEOPLE LIVING WITH AIDS AND HIV INFECTION

Maning, Nicholas
Social Services Department, London Borough of Hammersmith and Fulham, London W6, UK

Objective: To develop measures of the outcome of an agency's increasing range of personal social services provision as perceived by key groups of service users.

Methods: A consensus approach was employed within a group of practitioners, managers, local agencies, and local residents to identify a series of realistic targets for service delivery by systematically considering the key groups of consumers for whom the agency was providing a service, and the services which the agency could be expected to provide for them. By employing broad definitions of the terms used in the service the Group was able to identify dimensions of the Agency's activities ranging from the provision of information about the agency's services in relation to HIV to Black and Asian residents of its catchment area, to the provision of a consumer's service to people living with HIV infection.

Results: Steps have been taken towards developing a series of realistic targets for the Agency's services along a series of interesting dimensions. The targets will be publicised, along with details of the services, to the Agency in order that monitoring of the extended services can be made public.
Conclusions: Establishing service targets at a time of increasing demand from people living with HIV infection is a feasible exercise, and can successfully appreciate the perspectives of a range of disadvantaged and other interested

M.E.P.56 LOCAL GOVERNMENT PROVISION OF SOCIAL CARE TO PEOPLE LIVING WITH AIDS/HIV INFECTION

Denise Platt, Cotton T., London Borough of Hammersmith and Fulham, London W6, U.K.

Objective: To develop a consultative model of social care provision for residents of an urban local government area with a disproportionately large number of residents living with AIDS.

Methods: Detailed planning systems involving staff at all levels have been explored within an urban Borough to develop a wide range of both practical and emotionally supportive domiciliary and day care services, in co-operation with all other relevant formal and informal organizations. A comprehensive training programme has been established to support the service initiatives.

Results: The London Borough of Hammersmith and Fulham has been able to provide services to over 200 people living with AIDS or otherwise affected with HIV infection. It has gained extensive co-operation from staff and from other agencies working in the field and is recognised as having pioneered many service developments. In particular it is gaining evidence of the confidence of many people living with HIV infection from groups with a traditional antipathy towards statutory welfare services.

Conclusions: An openly participative approach to the planning and development of services enhances co-operation in a sensitive area of provision, and can facilitate access to services for a wide range of individuals and groups.

M.E.P.57 POLITICAL, ATTACK, MEDICAL, COMFORT, PSYCHOLOGICAL DEFENSIBILITIES: FACTS AND EFFECTS OF AIDS POLICES IN BAVARIA, WEST GERMANY

Beatrice Wipperfurth, Jäger, H.M., Hummel, G.M., Weber, U.*
*Institute for Medical Information and Health Services Research/DFG
** AIDS Study Group, Schwabinger Krankenhaus, Munich, FRG

Background: For PWA in Bavaria, the government's tough position in relation to AIDS is contrasted by the high standards of a number of medical institutions providing AIDS care.
Objective: Description of the psychosocial situation and behavioral patterns of persons with AIDS under Bavarian conditions.

Methods: Survey of out-patients assessing medical care and psychosocial support systems; multi-stage sequential reevaluation of AIDS-consulting agencies.
Results: 187 HIV-infected patients (80% homosexual men, 20% WDA, 16% female, 21% in stage II of the WPA classification) were asked about their attitudes towards AIDS-related care. 30% of them used more than one medical institution parallel. Contrary to their needs expressed, a majority of the respondents tended to underestimate psychosocial support systems. Homosexual men and severely ill patients described the care systems in a rather positive way whereas WDA, younger patients and those in earlier stages of disease were more critical of it. Community-based organizations are increasingly forced to perform a tightrope act between the concerns of their (potential) clients and the demands of authorities, between voluntary self-help work and the need for professionalization.
Conclusions: The ambivalence of the Bavarian AIDS situation (politically deterrent, medically attractive) puts psychosocial support for PWA into an important as well as ambiguous position. Four of political (de)institutionalization increases the need for psychological assistance but also acts as a barrier against using the relevant facilities.

M.E.P.59 "WE HAVEN'T DEALT WITH MUCH OF THAT YET": HELPING MEDICAL HEALTH PROVIDERS PREPARE TO WORK WITH HIV-RELATED CLIENTS

Detach, D.* **Quackenbush, Maria,*** **Martin, R.†**, **Schwartz, M.****

*University of California AIDS Health Project, San Francisco; **California Department of Health Services, Office of AIDS

Objective: To address the problems in the HIV incidence areas whose mental health and social service providers (MH/SSP) are not prepared to work with clients with HIV related concerns.

Methods: In six major regional areas of California, MH/SSP have not seen HIV related cases so far, are not familiar with the relevant issues, and may be apprehensive about providing services (or unwilling to do so). Individuals in these areas receiving positive HIV antibody results or dealing with other HIV related issues often have few resources for counseling support. A train-the-trainers project will be described which offers in-depth training to selected providers in regional areas, then provides them go on to train their colleagues on issues related to HIV and mental health.

Results: By May 30, 1988, four three-day trainings will have been provided throughout the state of California; and participants in those trainings will have gone on to train an additional 900 individuals by June 30. Preliminary evaluation of the program's success will be presented. The complete training manual will be available for review.

Conclusions: A program of this type can expand response and contact among MH/SSP, thereby improving the quality of resources for the client population. The program's success will be presented.

Supported in part by a grant from the California State Office of AIDS, contract # 88-94560.

M.E.P.58 HIV INFECTION, AIDS AND MENTAL HEALTH: THE CANADIAN NATIONAL WORKING GROUP'S EXPERIENCE

BOB LANGRISH (in English); **YVES JOHANNES** (in French) and **Members of the National Working Group on HIV Infection, AIDS and Mental Health, Federal Centre for AIDS, Ottawa.**
Hospital: St Paul Hospital/University of Toronto, Toronto, Ontario, Canada
Psychologist, Private Practice, Montreal, Quebec, Canada

Objectives: (1) to provide an evaluation of the state of mental health service delivery in Canada, as it responds to those affected by HIV; (2) to make program recommendations.

The National Working Group on HIV Infection, AIDS and Mental Health convened in December 1985. The 14 members include representatives from across Canada. They encompass social work, nursing, theology, behavioral sciences, research, psychology, psychiatry. The group identified 4 main areas of concern: (1) need for a clear definition of mental health as it applies to persons affected by HIV; (2) identification of "special" groups and the implications for service, education and research; (3) the mental health of health care providers serving people affected by HIV; (4) need for a suitable model of care. The group recommends: a needs assessment be done to determine existing mental health services, models and gaps; mental health care needs of health care providers be determined and program/service developed; centres of excellence to which mental health care workers can go to train be developed; current or proposed legislation regarding HIV infection, that affects the mental health of Canadians be addressed by this working group; methods to encourage research and education into the mental health aspects of HIV infection be developed.

M.E.P.60 SOURCES OF DELAYED HOSPITAL DISCHARGE FOR AIDS PATIENTS

Widman, Mandy Light; D.V.† **Platt, J.J.***
University of Maryland School of Medicine, New Jersey-School of Osteopathic Medicine, Department of Psychiatry, Camden, New Jersey, U.S.A.

Objective: Determine the social/environmental factors contributing to delays in hospital discharge for AIDS patients, rank them in order of importance, and determine if any differences exist by race/ethnicity or sex/race.
Methods: Interviews were conducted at 13 agencies in 5 cities (Baltimore, Boston, New York, San Francisco, Washington, D.C.). Respondents (N=17) were asked to list factors delaying discharge. The Delphi technique, in which respondents individually and without consultation rank the listed barriers, was used to gain consensus over 3 consecutive Delphi rounds. Variation scores were used to rank all items after each round.

Results: An absence of supportive housing and all levels of nursing home beds exacerbated by inappropriate/ inadequate insurance were ranked highest overall. There was, however, variability for IV drug users (IVDU) where the lack of caretakers or caretaker skills was found most important. Great variations in barriers to discharge were also found among the cities.

Conclusions: As treatments for AIDS improve and patients live longer, more attention will have to be paid to their chronic care needs. Understanding the services required by different populations or in specific regions is necessary for effective allocation of resources. For example, hospital discharges for IVDU appear to be blocked after less serious episodes of illness by the absence of skilled support services. In addition, the need for patients to remain hospitalized later in the syndrome's progression due to an absence of supportive housing or nursing home beds, each of these requires that different financial and personnel commitments be made.

Session d'affichage Poster Session



Le SIDA, la société et le comportement AIDS, Society and Behaviour

M.E.P.61

POST-DISCHARGE HOUSING OF HIV INFECTED PATIENTS IN ROME
L. Biondi, R. Ammendino, G. Antonucci, G. Biondi,
L. Spallmann; Hospital for Infectious Diseases, Rome, Italy.

Objective: To determine if homelessness in HIV infected patients is determinant for pressure on infectious disease units and to assess social needs for such patients in terms of suitable post-discharge housing.
Methods: In Italy, departments of infectious disease manage more than 80% of AIDS patients. It has been suggested that the lack of suitable post-discharge housing is a major factor in determining the long stay in hospital after acute care. Presently chronic long term facilities are limited in Rome and extensive home health care is not available. Epidemiological, demographic and social data of 101 AIDS patients and 345 HIV asymptomatic subjects hospitalized from 1981 to 1985 were reviewed. 100% were male, 95% were from Rome. The distribution by risk group of the 146 HIV infected patients (340 males and 90 females) was: intravenous drug addicts (IVDA) 72.6%, homosexual males (HMA) 14.1%, heterosexual contacts 9.4%, ITDA + prostitutes 3.4%, homosexual males + IVDA 3.1%, transfused 1.6%. Out of 101 AIDS cases, 3 patients were females by the family and died in hospital because the lack of social support. 1 want to hospital, 3 were accepted home by parents. Out of 345 subjects with HIV asymptomatic infection, 25 were accepted in a therapeutic community for medicalization program, 9 went to hospital without medical assistance and 9 were accepted by parents.
Conclusions: Systematic and comprehensive services for people with HIV infection must be encouraged through public sector and non professional caregivers. Presented data are relevant for planning size of services and alternate resources.

M.E.P.63

NEEDS ASSESSMENT OF PERSONS WITH AIDS AND HIV
ILLNESS IMPLICATIONS COMMUNITY COORDINATION
SERVICE PLANNING IN A LOW INCIDENCE COMMUNITY
Curtis Richards*, Coleman, D., *Zelinski, D.,
*United Way of Columbus, **Columbus Health Department,
***Metropolitan Human Services Commission, Columbus, Ohio, USA

Objective: To measure the perceptions of local PWAs and HIV positive individuals regarding unmet needs, awareness of existing community services, and the importance of these services to plan community response.
Method: A written survey instrument was designed to collect this information as part of a comprehensive AIDS-planning effort. The survey was developed with the input and support of local PWAs and AIDS service agencies. The instrument was 23 pages, over 120 questions and took 45 minutes to complete. Over 600 surveys were distributed through physicians and direct service agencies; 110 were returned and analyzed. While not a random sample, the results closely resembled the current known incidence of AIDS, ARC, and HIV seropositivity. Responses were both anonymous and confidential. Survey results were compared with a similar survey of service providers.
Results: Respirie care, mental health care, income subsidy, dental care, legal assistance, and patient information were ranked as the greatest unmet needs. Responders were generally uninformed about the availability of existing human services. Most needs (50-75%) were being met by friends and family.
Conclusions: Community planning efforts need to focus on (1) strengthening PWAs' existing networks of informal support systems; (2) ensuring that PWAs can access existing human services.

M.E.P.65

HOSPITAL ILLNESS AND VISITATION PROGRAMS PROVIDE EMOTIONAL SUPPORT, ADVOCACY AND LINKAGE TO COMMUNITY BASED ORGANIZATIONS FOR HOSPITALIZED PWA/PWAR/Cs.
Jan. S. Beigman, D. J. Gendron, S. J. Gendron, M. Michael,
AIDS Project Los Angeles, CA, U.S.A.

Objective: To provide emotional support, advocacy and information regarding community services to PWA/PWAR/Cs hospitalized in Los Angeles County. To provide greater linkage among hospitals serving these clients.
Methods: APLA recruited 87 full time employees from 60 hospitals who, by virtue of their position, have access to provide supportive PWA/PWAR/Cs. Once the illness was identified, APLA recruited and trained 42 volunteers for 13 hospitals to visit hospitalized with AIDS/ARC. Volunteers training includes active listening, hospital protocol and AIDS specific medical and psychosocial information. The hospital illnesses act as resource persons for the volunteers. Hospital illnesses meet quarterly as a group for networking and support. Visitation volunteers meet as a group for supervision and support monthly.
Results: Volunteers provide emotional support, advocacy and information about community and APLA services. Hospital staff report the volunteers to be an asset to patients and staff, particularly in that they are able to spend more time with sicker patients. Information regarding CPTG's leads to more timely linkage to these services. Also, the illness and visitation programs provide opportunities for networking and mutual support for the staff for participating hospitals.
Conclusions: These programs provide an effective model for providing emotional support, advocacy and information regarding community resources to AIDS/ARC patients when they are very vulnerable, i.e., during hospitalization. These programs help these participants alleviate stress/burnout and enable them to maximize scarce resources.

M.E.P.62

DEVELOPING COMPREHENSIVE SERVICES FOR HIV INFECTED INTRAVENOUS DRUG USERS: A GUIDE FOR CASE MANAGERS
Glenn Finkbein, Byron, C.S.M.,
Bronx-Lebanon Hospital, Bronx, New York, U.S.A.

Objective: To develop a system of comprehensive case management that addresses the multiple needs of HIV infected drug users.
Methods: I.V. drug users have numerous problems that complicate medical treatment. These include personality disorders and social problems that lead to noncompliance, failed appointments and physical/emotional suffering. Comprehensive case management requires addressing of concrete needs: system negotiation, counseling, drug treatment, etc. Most important is the development of resources for individuals at all points of the HIV continuum (asymptomatic, ARC, AIDS) via networking, outreach and mutual contacts.
Results: Needs of the IV drug user are identified and discussed in terms of treatment implications, solutions and impact on the patient, significant others, professionals and society. A framework for developing an individualized, comprehensive case management system, including resource development, is offered. **Conclusions:** Case managers that consider all aspects of the patient's treatment while developing additional resources is crucial for the care of HIV infected drug users. A systematic approach ensures inclusion of all factors while simplifying this formidable task for the case manager.

M.E.P.64

COMPREHENSIVE VOLUNTEER PROGRAM FOR PEOPLE WITH AIDS
Sandra Swanson, Miller, S.,
Center for Special Studies, New York Hospital-Cornell Medical Center, New York, N.Y., U.S.A.

Objective: To provide essential medical, practical assistance and to ensure link with professional staff for hospitalized and ambulatory people with AIDS. Through bi-monthly home contact, to reduce the numbers of unnecessary emergency room visits and to increase staff awareness of patient's home situation.
To provide formal support to volunteers to maximize their effectiveness.
Methods: Recruitment and training program which provides volunteers with an intensive, inpatient program taught by professional staff. A volunteer in-patient training program in which 25 patients are visited per week by 15 volunteer carers. An on-going monthly support group led by social worker to assist volunteers with their own coping. A telephone reassurance program in which 184 calls were made on a bi-monthly basis over a three month period to 25 patients by 7 volunteers. Volunteers provided practical and emotional support to 77 applicants and their families during clinic hours. Supervision of the program provided by two clinical social workers. **Results:** Study of 15 hospitalized patients reported their first home visit, fearful and anxious after visits from volunteers as compared to 15 patients not seen by volunteers. Percentage of discharged patients who have volunteers from their inpatient stay kept their first appointments at a higher rate than those who did not have volunteers. Their behavior on first visits was more relaxed and patients were able to more effectively negotiate hospital system. Less frequent visits to the clinic and emergency room by these patients called on a regular basis for non-medical concerns. **Conclusions:** This program has contributed to the effectiveness of self-referral of patients with AIDS. It has provided patients and families with a consistent group of experienced and caring individuals linking them to the professional team. It provides the staff with ongoing reports on vital information on ambulatory patients between visits. The mutual respect and support between volunteers and staff has contributed to the success of this program.

M.E.P.66

THE IMPORTANCE OF THE SOCIAL SERVICE EXPERIENCE AT A UNIVERSITY HOSPITAL IN THE USE OF AIDS TO HIV INFECTED INDIVIDUALS.
MURPHY, JAMES (LINDA LITTLE), MURPHY, E.M.M., OLIVEIRA, E.A. and MERRIS DE SA, C.A., U.S.A.
Griffin & Guthrie Hospital, University of Rio de Janeiro (UNIC-RJ) - Brazil.

Objectives:

- 1) Identify the meaning of AIDS to HIV infected patients, their family members, friends and health care workers.
- 2) To assess the reasons for discrimination of HIV infected individuals.

Methods: The study comprised 170 infected individuals, 73 family members and friends of these individuals and 100 health care workers, from February to December, 1985. They were interviewed by two social workers who used a phenomenological approach and follow-up.

Results: The meaning of "AIDS" and the reasons for discrimination were related to:

	PATIENTS		FAMILY		HEALTH CARE WORKERS	
	N	%	N	%	N	%
Lack of information	133	78	21	29	28	40
Insufficient information	133	78	21	29	28	40
Lack of confidence or information obtained	100	59	16	22	15	21
Difficulty related to sexuality/						
Homosexuality	96	56	17	24	29	42
Difficultly to face women	100	59	16	22	15	21
Lack of medical/health resources	100	59	16	22	15	21
Lack of financial resources	100	59	16	22	15	21
Lack of emotional support	130	76	21	29	25	35
Lack of family support	100	59	16	22	15	21
SOCIAL SERVICE	100	59	16	22	15	21

Conclusions: wherever the educational needs of AIDS to HIV infected individuals and their involvement activities beyond the patient and the disease. We believe in the need to continue to improve the social service experience in the diagnosis, classification and broader utilization of the process.

Session d'affichage Poster Session

M.E.P.67

SOUTHERN HARMATION WOMEN AND CHILDREN HIV DEMONSTRATION PROJECT: SOCIAL SERVICE ISSUES
Patrice Chokler*, K. Andrew*, C. Hulton*, V. Walner**
 Joann Johnson**¹, R. V. K. L., *McGill University, N.Y., N.Y., **Mount Sinai Hospital, N.Y., N.Y., ***Saint Luke Hospital, N.Y., N.Y., U.S.A.

Objective: To increase regional communication and coordination of resources for HIV infected or at risk women and children, and to suggest the provision of health education, social services and clinical care in an area where service delivery and health education efforts are fragmented and there is a documented rise in HIV infection. To identify the service needs experienced and the ethical questions faced by participating women.

Methods: The establishment of a consortium model, funded by Health Resources and Services Administration, Bureau of Maternal and Child Health, includes five voluntary and public agencies, three branches of city government, a State Services Administration, a community based task force of providers and a school of public health, a community based task force of providers and a major clinical research center. The consortium incorporates a social services committee which captures the collective experience of providers with similar populations in varied settings.

Results: Participating agencies have developed a shared set of goals and objectives, a uniform evaluation instrument and a forum in which problem-solving is enhanced.

Conclusion: The model effectively strengthens the group's ability to advocate for increased and augmented services for women and children and to identify helpful approaches to ethical decision-making.

M.E.P.69

SOCIAL SERVICE NEEDS OF PEOPLE WITH AIDS: PERCEPTIONS OF NEED AND COST NEED
Fialama, John* Platte, J.* Nor, V.*
 *Yrums University, Providence, Rhode Island, U.S.A.

Objective: To describe needs for social services as reported by people with AIDS.

Methods: In-person interviews were conducted with 27 clients of the Robert Wood Johnson Foundation's AIDS Health Services Program. Clients were interviewed at site outside the UR. For each of 12 social service needs (e.g., medical, home visiting, support groups, transportation, housing placement, dental care), respondents were asked (1) if they needed that service, (2) how much they needed it, (3) if they received it, and (4) whether services received met their needs.

Results: The highest proportion of responses (49%) expressed a need for dental care, followed by needs for support groups (44%), counseling (41%), and legal advice (40%). Lowest reported needs were for homemakers (13%), meals at home (15%), housing placement (13%), and drug rehabilitation (11%). The most intensely felt, unmet need for housing placement, medical, and drug rehabilitation. Only 21% of those who needed it received dental care; only 38% who needed it got housing placement. Of those receiving services, at least 70% said that their needs were met for each service, with the exception of money for housing (50%). Those who were employed had fewer needs. Compared to gay men, drug users perceived greater need for home nursing and for medical.

Conclusion: Dental care is an often overlooked and unmet need. Needs for housing, although not prevalent, are intense and hard to meet.

M.E.P.71

A MULTI-DISCIPLINARY MODEL FOR DECISION-MAKING AND CASE PLANNING FOR HIV-INFECTED CHILDREN & YOUTH IN CHILD WELFARE AND CHILD PROTECTIVE SERVICES SYSTEMS
Anita J. Burr*, Rose J.J.* Potts, K.** *Child Welfare League of America **Massachusetts Department of Social Services, W. Mass.

Objective: To provide service providers in the public and volunteer sectors a decision-making model to approve or recommend case decisions in order to establish a standard of practice and support the willingness of agencies to serve HIV-infected children in the face of varied fears, e.g. liability.

Methods: CWLA convened administrators from 17 public child welfare agencies to identify problems in mobilizing their bureaucracies to serve HIV-infected children and youth. They identified supporting decisions made as a significant barrier. The Massachusetts Department of Social Services and CWLA proposed and described a multi-disciplinary review team model; CWLA received 289 responses from 250 agencies surveyed re: challenges faced; decisions made; methods used; and conclusions reached; Massachusetts DSS tested and operationalized the model.

Results: Among obstacles agencies face making case planning decisions for infected children are: 1) resistance to serve without assurance of financial contact; 2) conflicting confidentiality and testing policies and beliefs; and 3) liability and risk management concerns.

Conclusions: A multi-disciplinary review team's validation of case-planning decisions speeds agencies' responses.

M.E.P.68

GROUP RESIDENCE AND SCATTERED SITE APARTMENTS AS HOUSING FOR HOMELESS PERSONS WITH AIDS
Diener, Douglas*, Sandler, K. and Noyak, L.*
 *Haley House, New York, NY, USA.

Objective: To provide supportive housing for homeless persons with AIDS.

Methods: A 6 person group residence was established in N.Y.C., supported by government funds and private donations. In addition, 20 scattered site apartments were leased by the sponsoring agency. The 2 programs were separately staffed but concerned needs and problems.

Results: Staffing included social services, nursing, pastoral care and support services. Average length of stay in the group residence was seven months, and eight months in the apartments. About one-third of residents in the group residence pass away in their respective homes cited in the following admission for acute medical care. In the group residence, medical care was provided by referral to hospitals and clinics. In the group residence, 50 persons were served in two years; in the apartment 90 persons were served in three years.

Conclusions: Homeless persons with AIDS are in need of housing. Homeless persons encounter difficulties in providing appropriate support and structure for residents with AIDS psychiatric and behavioral problems. A combination of housing and individual service plans was effective in most cases, but residents who were physically destructive or who threatened the safety of others were referred to various other settings.

Conclusions: Scattered site apartments and group residences both provide appropriate housing for persons with AIDS who do not need medically assisted care.

M.E.P.70

STEP DOWN CARE ACCEPTABILITY IN HOSPITALIZED AIDS PATIENTS
Kozminski, Bruce* Prival, T.* Dayo, M.*, deGroot, David* Wood, R.**
 *University of Washington, Seattle, Washington, U.S.A.
 **AIDS Prevention Project, Seattle, Washington, U.S.A.

Objective: To determine the acceptability of special AIDS residences with skilled nursing ("step down care") among hospitalized persons with AIDS. Patients obtained medical, behavioral, and social services with AIDS during their hospitalizations, and interviewed them regarding the acceptability of step down care as an alternative to a long-term hospital stay or to home care. We also interviewed their doctors, nurses, and social workers regarding appropriateness of such a care setting for such patients.

Results: Of the 100 AIDS patients (all males, mean age 38 yrs), 56 found step down care to be acceptable in concept during their hospital stay (although 21 of these felt home care would be equally as acceptable). Of these 56, 50 social workers (all 3) 9 were discharged to such settings (nursing home and hospices), 6 admitted to the hospital, and 5 went home (with home care). Of the 44 patients who felt step down care was an unacceptable option, the majority (42 or 95%) wanted to receive their care at home (21 wished to stay in the hospital). Of these 44, 11 were considered appropriate for step down care by their caregivers; 9 went home (5 with home care), 1 went to a hospice and 1 died. Of the patients who found step down care acceptable, none went to such settings at discharge or expired in the hospital (15 of 56) than those who did not find step down care acceptable (2 of 44) (7% vs 9%, p=0.01).

Conclusion: Hospitalized persons with AIDS willingly accept their desires for various care settings following hospitalization. A majority feel step down care would be acceptable, but many patients prefer home care.

M.E.P.72

COMMUNITY-BASED CARE FOR PEOPLE WITH HIV DISEASE
Rubin, Howard* and Sacks, R.* Mount Sinai Medical Center, New York, New York

Objective: To develop models for comprehensive community-based care for people with HIV disease (1988).

Methods: We interviewed representatives from AIDS service organizations (ASOs) in New York, San Francisco and Chicago and observed their operation. We called promotional material from ASOs across the USA and examined how they incorporate care of their local communities and of their clientele into viable systems of care.

Results: We describe the basic elements of care which may be necessary for ASOs to develop adequate services for PWAs: 1. The existence of community clinics which can provide primary health care to PWAs and which offer anonymous HIV antibody testing and counseling. 2. A mechanism for recruiting and training volunteers to serve the emotional and practical needs of PWAs, their friends and families. 3. Advice for PWAs concerning their legal rights, appropriate medical care, access to government aid, and experimental protocols. 4. Assistance with housing and food. 5. An AIDS hotline and other educational services. 6. Outreach for intravenous drug users. 7. Coordination of services with local hospitals.

Conclusion: An appreciation of the basic needs of ASOs provides may help local communities develop services which offer competent, humane, and comprehensive care for PWAs.



Session d'affichage Poster Session

Le SIDA, la société et le comportement AIDS, Society and Behaviour

M.E.P.73 THE CHALLENGE OF AIDS IN AN AREA OF SCATTERED POPULATION AND LOW PREVALENCE Tuxton, PAI

Regional Joint AIDS Community Support Centre, 52 Clifton Road, Newcastle upon Tyne NE4 8QJ England.

Our AIDS and HIV figures are "normal" for the U.K. and very much lower than London - 28 AIDS cases and 214 diagnosed as HIV positive. We have encountered serious obstacles in pursuing our aim of developing non-hospital based care. Among the issues I would like to discuss are:

1. Medicalisation of care of people with AIDS.
2. Protective/possessiveness of established carers - largely medical.
3. Lack of confidence of people with AIDS and medical providers in social workers.
4. Non-availability of AIDS as an issue in areas of normal (low) prevalence.
5. Social workers' perception of being de-skilled by HIV and its implications - is this an appropriate or inappropriate response?
6. Training - who and how to target training to social workers when AIDS is seen only in theory as a priority area, and in practice is seen not to be relevant to most social workers in a local authority.
7. Non-availability of substantial, vocal and cohesive groups of people with AIDS.

M.E.P.74 COMPREHENSIVE SOCIAL SERVICE HIV SERVICES PROGRAM AT WALTER REED ARMY MEDICAL CENTER, WASHINGTON, D.C. O'Neill, Robert H., Social Work Service and the Walter Reed Microvirus Research Group, Washington, D.C., United States of America.

Objectif. To identify and describe 20 clinical psychosocial treatment and health care management components utilized in the development and implementation of a comprehensive social service program for HIV infected individuals, family members and health care service providers.

Methods. Twenty psychosocial treatment/intervention procedures and health care management components were developed based upon policy review, problem identification, needs assessment, literature review, patient surveys and research findings. The resulting components were utilized in developing, implementation and providing a comprehensive social service program for HIV infected individuals, family members and a supportive program for staff.

Results. The table below summarizes the 20 components:

- | | | |
|-------------------------------|---------------------------|-------------------------|
| 1. Priority and justification | 8. State-process | 15. Substance-abuse |
| 2. Services and treatment | 9. Self-administration | 16. Role development |
| 3. Process and content | 10. Coping-affect | 17. Management-forensic |
| 4. Rehabilitation | 11. Technology-complexion | 18. Integration |
| 5. Practice and research | 12. Content-contrast | 19. Ousey traces 12/89 |
| 6. Treatment and care | 13. Evolutionary process | 20. Predictions |
| 7. Multidisciplinary | 14. Threshold level | |

Conclusion. A comprehensive HIV retrovirus social service program was developed and implemented based upon 20 psychosocial and management components.

M.E.P.75 CHERCHER UN MILIEU DE VIE: UNE APPROCHE ARCHITECTURALE INNOVANTE

RENÉE, HALLÉ Montréal, P.Q., (Québec, J.***)
* Corporation Héliobus/Héliobus, Montréal, Québec, Canada; ** Héliobus de Montréal, Montréal, Québec, Canada; *** Héliobus Montréal, Montréal, Québec, Canada.

Le milieu d'Héliobus se veut une alternative qui longe sereuse au milieu hospitalier. **OBJECTIF:** créer un milieu de vie pour les personnes atteintes qui soit adapté à leurs besoins. **METHODS:** le projet a été élaboré par une équipe multidisciplinaire composée de médecins, travailleurs sociaux, architectes, administrateurs, personnes atteintes. Le projet a fait l'objet de consultations auprès d'autres groupes ou individus impliqués dans l'intervention auprès des personnes atteintes ou ayant développé un projet établissant un lien de confiance personnelle. Les différences d'opinion de la méthode et les besoins spécifiques y sont traités au 4^e congrès. Le type et la qualité de l'intervention ainsi que les besoins des intervenants ont été clairement établis.

REMARKS: Le choix de vivre en un concept architectural qui réunit une rénovation sur un bâtiment ancien à une construction neuve impliquant d'une préoccupation majeure de créer un milieu de vie répondant aux différents besoins des personnes atteintes:

cadre de vie familial; ancrage dans la communauté; vie communautaire en un même temps qu'intimité; autonomie - semi-autonomie - surveillance; besoin de sécurité et besoin de liberté; alléger - recueillir et communiquer - exprimer; présence continue; soins et support à la vie quotidienne;

aménagement médical léger; activités récréatives et artistiques. **CONCLUSION:** Un concept architectural pourrait pour servir 11 personnes atteintes. L'impact élargi par médias en fonction des besoins et des activités permet de répondre à une variété de situations à différents stades de la maladie.

M.E.P.76 DESCRIPTION ET ÉVALUATION DU SERVICE TÉLÉPHONIQUE INTÉGRÉ DE LA PROVINCE DE QUÉBEC POUR LE SIDA ET LES AUTRES ITS.

Duval, Bernard; Bédard, N.; Fortin, G.; * Unité de recherche-Laval, Québec, Canada; * Centre régional de la Santé et des Services sociaux (CRSSS QJ), Québec, Canada.

Objectif. Analyser le fonctionnement d'un système téléphonique provincial pour les ITS-SIDA intégré à un service général d'informations sur la santé. On a mis sur pied en septembre 1987, un service téléphonique de renseignements sur les maladies transmissibles sexuellement (ITS) qui fonctionne 24 heures par jour et 7 jours par semaine. Le service est bilinéaire et accessible gratuitement pour les 6 millions d'habitants de la province. Appelé INFO-ITS, il est intégré à un système d'information générale sur la santé, INFO-SANTÉ, qui est basé au CRSSS QJ et sert la région immédiate de Québec.

Un échantillon aléatoire de 1157 appels a été analysé à partir des fiches 31,8% des appels. Par comparaison avec les autres ITS, ceux qui appelaient pour parler du SIDA étaient plus souvent des hommes (44,5% contre 36,7%) et moins fréquemment des jeunes de moins de 20 ans (20,8% contre 26,8%).

Parallèlement aux appels concernant le SIDA, 87,5% demandaient de l'information. 18,3% des conseils thérapeutiques et 28,6% une référence à un service clinique. Pour les autres ITS, on observe respectivement 70,7%, 26,2% et 35,4%. **Conclusion.** On constate la pertinence d'un service téléphonique de renseignements sur le SIDA. Le jumelage avec un service d'informations sur la santé permet d'améliorer beaucoup l'accessibilité car le volume d'appels autorise une permanence continue qui serait trop onéreuse autrement.

Session d'affichage Poster Session



Le SIDA, la société et le comportement AIDS, Society and Behaviour

Éducation (partie 1) Education (Part 1)

T.E.P.1

REPORTED LIKELIHOOD OF SEXUAL ACTIVITIES WITH A NEW PARTNER IN A SURVEY OF BAR PATRONS IN A LOCAL GAY COMMUNITY.
Martin, David J., Edwards, C.W., and Geiger, R.***
***AIDS School of Medical Center, Torrance, California, **AIDS Intervention Project, Long Beach, California, USA.

Objective: To survey current sexual activities to determine current and future risk-reduction education needs of the local gay community.
Methods: An exit survey was administered to local gay bar patrons, requesting demographic information, information on participation in local AIDS-education programs, whether or not respondents had been tested for HIV antibodies, test results (if applicable), changes in sexual behavior, number of partners, location(s) where respondents met new partners, and likelihood of various sexual behaviors with and without condoms with a new partner.
Results: Most respondents reported meeting new sexual partners at bars. The following behaviors were relatively unlikely with condoms and likely without condoms: mutual masturbation, receptive oral sex, and insertive oral sex. The following behaviors were rated relatively likely with condoms and unlikely without condoms: insertive anal sex, receptive anal sex, ejaculation inside partner, and receptive anal sex with ejaculation. HIV antibody testing seemed to have no effect on reported likelihood of any behavior, but seropositive men reported that they were less likely to engage in receptive or insertive anal sex than seronegative respondents regardless of condom use.
Conclusion: Gay men reported significant changes in their sexual behavior that appear to substantially reduce the risk for HIV transmission. The relative likelihood of unprotected oral sex in the absence of definitive information regarding its risk suggests that research on the associated reasons for and the risks of this behavior is needed.

T.E.P.3

ADAPTATION OF SAFER-SEX WORKSHOPS FOR GAY AND BISEXUAL MEN IN BARCELONA, SPAIN.

Wohlfeiler, Daniel A., Frutuchy, C., de Blasi, R.,***; Prosepe, A.,*** (University of California, Berkeley, USA); Spain Francisco AIDS Foundation;*** made per Ja Salas, Barcelona;***AIDS Program, Generalitat de Catalunya, Barcelona, Spain.)
Objective: To adapt, conduct and evaluate workshops, originally designed to promote behavior and more change in U.S. gay and bisexual men, for use in Barcelona, Spain.
Methods: Gay for Health, a Barcelona community-based organization, began these workshops in December, 1988, with U.S. and Barcelona facilitators. Publicity was distributed to gay bars, bath houses, bookstores, and through the media.
Results: 31 men attended the two pilot workshops. SEI agreed that the workshop helped them feel more comfortable talking about safer-sex; 79% agreed the workshop helped them believe safer sex could be fun; 79% that the workshop helped them feel more capable of controlling AIDS. At the end of the workshop, participants were asked to list at least three safer-sex activities. 94% of the responses were correct; 33% referred to avoidance of unsafe behaviors. A process evaluation revealed that participants perceived role-players (i.e., negotiating safer sex with a partner) to be less useful than brainstorming (i.e., discussing AIDS and safer sex in large groups).
Conclusion: 1) Interventions targeting gay populations in one culture may be adaptable for use in another; 2) Recording participants' responses provides an excellent source of information on knowledge, attitudes and behavior of the target population.

T.E.P.5

AIDS EDUCATION: USING COMMUNITY TELEVISION TO REACH GAY MEN AND BISEXUALS
Sobota, Michael, AIDS Committee of Thunder Bay, Thunder Bay, Ontario, Canada

Objective: To deliver education about AIDS, particularly about safer sex practices, to gay and bisexual men.
Methods: Utilizing public, community television which included negotiations with television station management, training of volunteer technicians and support staff, designing and producing [content, format, graphics] taping and airing programs including live, on-air phone in sessions.
Results: AIDS education programs commenced on community television from October 1988 through April, 1989. Written feedback [correspondence] and direct contact from phone-in programs indicate viewer interest and positive response. Some controversy concerning language and content with resulting intervention of public officials. Conflict resolved in favour of program continuing to be aired.
Conclusions: Community television is an important media to access difficult to reach targeted populations. Community television can be utilized at little financial cost, if there is a volunteer pool available. Community television relies volunteers from within the gay and lesbian community if they see the project to have real and specific benefit to their brothers and sisters.

T.E.P.2

AIDS-PREVENTION ACTIVITIES TARGETING HOMO-AND BISEXUAL MEN
Michael von Hippel, Deutsche Aids-Hilfe e.V., Mestorfstr.-8
1000 Berlin 31, West-Germany

Objective: The main objective is the fight against the spread of HIV-infections. Homo- and bisexual men are extensively informed. Their collective and individual identity is strengthened. Lifestyles and sexual behavior are accepted and as there is little intervention a considerable prevention effect is achieved. The Safer Sex message is transmitted through existing structures within the gay sub-culture. One-way media as well as interpersonal communication are offered. Apart from an employed staff volunteers and even bartenders are prepared for counselling services. Lapulas are given by gay-swaps. There are no prohibitions neither in words nor in pictures. We confine ourselves to give advice in regard to lifestyles and sexual behavior. Social problems and personal fears are individually treated and anonymously discussed in public. The work is supported by public relations.
Results: The study "CHANGES IN SEXUAL BEHAVIOUR OF GAY MEN UNDER THE IMPACT OF AIDS" (1987), a follow-up study made in 1988 as well as further observations (such as the decrease of rectal gonorrhoea) show that the low-risk sex has proved to be accepted by an important sector of gay men in West-Germany. **Conclusion:** By this prevention strategy the rate of infection has been reduced considerably. It has not been proved that similar results can be achieved by means of official measures.

T.E.P.4

SOURCES OF INFORMATION ON AIDS IN ZAIRE AND IMPLICATIONS FOR PROGRAM PLANNING
Lussabaine R.**, Sorens, Helaine, **, Wassig JE. **, Bertrand WE. **, Bahula T.,**
** Zaire School of Public Health, Kinshasa, Zaire
** Tulane University, New Orleans, USA

Objective: To determine sources of information on AIDS in Zaire and desired sources of communication for the future.
Methods: Two populations were surveyed during 1987-1988: 3500 health workers (HW) of all levels throughout Zaire and 2500 employees and spouses (ES) at a commercial bank in Kinshasa. **Results:** HW have learned about AIDS from radio (59%), written materials (29-38%), television (TV, 28%), courses (12%) and discussions (10%). For ES, sources were radio (51%), TV (43%), written materials (11-25%) and discussions or songs (2%). For HW, mass media and written materials are preferred in urban areas, courses and discussions in rural areas. Among ES, mass media and written materials are preferred by male employees, while their female spouses prefer face to face communication. The preferred language for HW is overwhelmingly French; among ES, male employees prefer French, and female spouses prefer Lingala, the local language in Kinshasa.
Conclusions: AIDS education programs should specifically consider the setting (urban/rural) and the audience (HW, lay population), including different strategies according to sex, educational level, profession and language preference.

T.E.P.6

LES EFFETS D'UNE CAMPAGNE GRAND PUBLIC SUR LES HOMOSEXUELS FRANÇAIS

Michael Pollak, Pierre Boisson**, *CNRS, GSPM, **Gal Pled Hebdo, Paris, France.

Objective: Evaluer les effets de la campagne télévisée "Le SIDA, il ne passera pas par moi" (1987) sur les attitudes et comportements des homosexuels français.

Méthode: Sondage par questionnaire (n=1 500) inséré dans une revue homosexuelle.
Résultats: Bien qu'elle ait réussi à capter l'attention des gays (78% de mouvement du regard), cette campagne est jugée peu claire, floue, peu explicite et "utile pour les autres" plutôt que pour les gays. Les moins de 25 ans sont les seuls qui, grâce à la campagne, ont accéssé leur adaptation sexuelle au risque. Les moins motivés par la campagne sont les classes populaires.

Conclusion: Pour avoir un effet incitateur important sur les homosexuels, la campagne télévisée est arrivée trop tard, avec un message trop limé. Les campagnes grand public, efficaces par les homosexuels dans le groupe d'âge des moins de 25 ans, n'ont pas à toucher les homosexuels des classes populaires. La prévention devra tenir compte de ce phénomène dans des actions de proximité spécifiques.

Session d'affichage Poster Session



Le SIDA, la société et le comportement AIDS, Society and Behaviour

T.E.P.13

FIGHTING AIDS - AN EDUCATIONAL MODEL FOR ARMY UNITS

Scheiner Inc., School of Public Health and Community
Medicine, Hebrew University-Hebrew Medical Faculty, Jerusalem, Israel

Young men and women who serve in the armed forces of their countries are an important target group for AIDS prevention campaigns. Data collected by WHO and the CDC demonstrate clearly that prevalence and incidence of HIV infection are higher in the young adult populations. This data shows as well that AIDS cases in their late 20s or in their 30s, have contracted HIV 5 or 8 years before - while in university/high school or the army.

In some cultures army life is a catalyst for sexual and drug activities that coincide with sexual development and maturity at that age.

As a totalitarian institution (technology every army is in the position to control HIV infection by obligatory education campaigns in its units. In collaboration with the Israeli Defense Forces Medical Corps, a special educational program for AIDS prevention was developed. It was named "Victory AIDS".

The module is a 100 minutes session which based on direct communication between a medical officer/instructor in an army unit and the soldiers of that unit. Fighting AIDS comes in a kit which includes material for the army doctor: a set of cartoon slides, a leaflet for each army personnel.

Since July 1987 this module, officially accepted as the unified program for the IDF, is implemented in all commands. Special training workshops were developed and conducted for army physicians in the various units.

The module was pre-tested in a sample of units across which were the army fall for women and for men/barriers of implementation will be discussed as well.

T.E.P.15

EFFECTIVENESS OF FEAR APPEALS IN AIDS-EDUCATION POSTERS: COMPARISON BY RACE/ETHNICITY, AGE, AND GENDER IN THREE POPULATIONS

Rhodes, Pam; Weibel, J. and O'Leary, M.
AIDS Research & Education Project, California State University, Long Beach, CA, USA

Objective: To investigate the effectiveness of fear appeals in AIDS-education posters. **Methods:** Twenty experimental posters with high-fear pictures depicting severe consequences of AIDS and 20 posters having pictures that were neutral with respect to disease severity were evaluated in terms of their attention value and their perceived effectiveness in motivating people to use condoms. Poster messages were also manipulated experimentally to achieve high and low levels of communicated personal vulnerability and behavioral response efficacy. Subjects were 310 Black, White, Hispanic, and Asian community residents, college students, and intravenous-drug users (IVDU).

Results: Fear level of experimental posters was positively related to their perceived effectiveness in motivating people to use condoms and to their value in attracting attention ($p < .001$). This effect was consistent across the three populations studied, i.e., general community residents, college students, and IVDU. Response efficacy and personal vulnerability of poster messages, and their interactions with fear, were also significant ($p < .05$) but accounted for relatively little treatment variance in comparison with the fear main effect. Age, gender, ethnicity, and population membership were found to moderate responses to high versus low-fear posters to only a small degree.

Conclusions: Findings confirm previous research supporting the effectiveness of fear appeals in persuasive health communications and suggest that fear-oriented posters may be more effective than positive, non-threatening appeals in motivating a broad range of individuals to adopt AIDS risk-reduction practices.

T.E.P.17

PRODUCTION OF HIV PREVENTION OUTREACH ACTIVITIES TARGETING INTERVENING DRUG USERS IN THE UNITED STATES

Levine, J., Johnson, J., and O'Leary, M.
Centers for Disease Control, Atlanta, GA, U.S.A.

Objective: To implement outreach activities targeting intravenous drug users (IVDU) to control the spread of HIV infection through contaminated injection paraphernalia and sexual transmission to partners.

Methods: IVDU are at greatest risk for HIV infection because of their high risk for HIV infection and their high risk for sexual transmission to partners. This project was an empirical data analysis concerning the effectiveness of outreach activities to IVDU. The project was designed to determine which outreach activities were most effective in motivating IVDU to use condoms and to use clean injection paraphernalia. These programs are currently being implemented by the U.S. Conference of Mayors (Community Demographics project) and the U.S. Conference of Mayors (Community Demographics project) and the U.S. Conference of Mayors (Community Demographics project) and the U.S. Conference of Mayors (Community Demographics project).

Results: The project was designed to determine which outreach activities were most effective in motivating IVDU to use condoms and to use clean injection paraphernalia. These programs are currently being implemented by the U.S. Conference of Mayors (Community Demographics project) and the U.S. Conference of Mayors (Community Demographics project).

Conclusions: Through training and provision of technical assistance, CDC - supported outreach activities targeting IVDU and their partners in community-based organizations - has promoted the implementation of HIV prevention outreach activities targeting IVDU and their partners. The results of CDC efforts have shown an increase in the number of outreach programs targeting IVDU and an increase therefore in the numbers of IVDU receiving HIV prevention education.

T.E.P.14

AN ASSESSMENT OF KNOWLEDGE, PERCEIVED RISK AND BELIEFS ABOUT PREVENTION STRATEGIES AMONG NEW YORK STATE RESIDENTS

Winkler, Caroline M.; Glanville, M.H. and Tolson, J.

Objective: To assess knowledge, attitudes and beliefs about AIDS in the general population of New York State. **Methods:** As part of a CDC-sponsored AIDS prevention project, a random digit telephone survey of New York State adults (N=1117) was conducted between May and September 1988. Survey items were adopted from the 1987 National Survey, from Ostrow (1987) or developed by the authors.

Results: The representative sample included 10% Hispanics and 14% blacks and 86% were divided between males and females, single and married, with a mean age of 43. At least 90% of the sample correctly responded to "basic" questions on AIDS, e.g., major modes of transmission; and over 85% discriminated the possibility of HIV transmission through very casual contact, such as shaking hands. A larger proportion of the sample, however, were still believing that HIV could be transmitted through donating or receiving blood, insects, public toilets and being coughed on. While condom use is correctly regarded by 80% of the sample as an effective risk reduction strategy, more than one-third are uninformed or misinformed about diaphragms and spermicides. Educational attainment, race/ethnicity and age are consistently related to accuracy of knowledge on a number of casual transmission and risk reduction effectiveness items. Knowledge of casual transmission and risk reduction effectiveness items appears to be related to the perceived risk of personal exposure and reported behavior change.

Conclusions: Educational campaigns in New York State must address misinformation about casual contact transmission and provide clear messages about the ineffectiveness of diaphragms and spermicides without condoning sex barriers to HIV.

T.E.P.16

COMPUTER-ASSISTED HIV EDUCATION FOR IVDU

Lewis Benjamin P.M.; Algham D.P.M.; Green A.C.
* Spawton House Inc., Woburn MA 01891, * Trinity College, Hartford, CT 06106, U.S.A.

Objective: To develop and evaluate a modular kit program for IVDU's using computer-aided-instruction (CAI) techniques. Course modules are currently being developed at Trinity College. **Methods:** A Macintosh IIx-based software system developed at Trinity College. TSS facilities development and use of mixed-mode courseware without requiring special computing expertise.

Methods: An experimental bi-lingual CAI program was developed and introduced to a sample of intravenous drug users in an urban clinic. Program modules include 1) a simple instructional module; 2) a module describing HIV, HIV transmission, and IVDU; 3) a module describing protective behaviors (needle cleaning and safe sex). TSS provides quantitative utilization information for evaluation purposes.

Results: A Macintosh computer has been dedicated to this CAI application. Staff have been trained in using the modules. Modules on protective behaviors have been completed, planned and released by 57 IVDU's. As reported in client satisfaction surveys, interest in HIV education employing this technology is substantially higher than in HIV education based on formal compliance.

Conclusions: This interdisciplinary merger of computing technology with HIV education objectives shows great promise. For the first time it is possible to develop multi-media, computer-based instructional approaches which place control of learning in the hands of the learner.

T.E.P.18

MARRIED HOMOSEXUAL AND BISEXUAL MEN - THE DEVELOPMENT OF AIDS EDUCATION STRATEGIES AND RESOURCES FOR HEALTHCARE PROFESSIONALS.

Wolmar, John M., Education and Liaison Officer
Gay and Married Men's Assistance Course, Victoria,
Australia. Curriculum Consultant, Ministry of Education,
Victoria, Australia.

Objective: To present the range of strategies employed and resources developed to assist healthcare professionals and workers to make contact with and educate married homosexual and bisexual men.

Methods: Over one thousand married and bisexual men and their needs, concerns and information levels documented. Specific counselling and education strategies have been developed as a result of this information and has been presented in a number of formats to assist healthcare professionals and workers.

Results: The development of a resource kits entitled - Married Homosexual and Bisexual Men and their Partners; Resource Kit for Healthcare Workers; Workshop Kit for Facilitators; a poster - AIDS Special Information for Married Couples and Bisexual Men; and pamphlets - AIDS Special Information for Married Couples and AIDS Special Information for Bisexual Men. These materials are distributed on request.

Discussion: These materials have trialled and reviewed by Healthcare Professionals. Requests for the materials come from all over Australia including the Australian College of Nursing and District Nursing Society, Queensland. Application of current research assists in the development of relevant resources for specific target groups and their support providers.

Session d'affichage Poster Session



Le SIDA, la société et le comportement AIDS, Society and Behaviour

T.E.P.19 DIRECT APPROACH WITH INFORMATION TO BLOOD DONORS AT RISK OF AIDS INCREASES THE SAFETY OF THE BLOOD SUPPLY

Van Der Pijl, Ooms*, Reesink, H.P.
*Med Cross Blood Bank, Amsterdam, The Netherlands.

Objective. To study the effects of more direct approach with information to high-risk blood donors, in order to increase the safety of the blood supply. **Methods.** In January 1988 the risk groups of AIDS in the national information leaflet for blood donors, were defined more strictly. Since July 1988 informed consent, indicating non-involvement in high-risk activities, was required. Rates of withdrawal of high-risk blood donors, related to donation history, risk factors and gender were compared, before and after introduction of the new approaches in information.

period	n	donors at risk n (%)	p value before	proportion of repeat donors	p value after
1987	10,498	167 (1.62)		83 (52)	
Introduction new information leaflet					
1988 (Jan./Feb./Mar)	19,663	96 (0.5)	<0.001	54 (56)	
1988 (Apr./May/June)	30	10 (0.2)		11 (37)	
Introduction informed consent					
1988 (Jul./Dec)	27,310	102 (0.4)	<0.001	85 (83)	<0.001

Conclusions. After the new approaches, a significant increase of withdrawal of high-risk donors was observed. The relative proportion of repeat donors being significantly higher after implementation of informed consent.

T.E.P.21

SMOKING, ATTITUDE A PRACTICE RELIÉ DE BÉNÉFICÉ POPULATION COÛTE PEU POUR LE STRAIN AIDS

Van, J.M.M.J., Van der, A., Rade, S., Van, J.
*M.C., *M.C., *M.C., *M.C., *M.C.

Dep. of Community Health Faculty of Medicine, Atila University, Utrecht

OBJECTIVE. Following a large scale program of information dissemination on AIDS, a 50% survey was conducted to assess and compare perceptions and attitude formation of different population groups in the east side town in The Netherlands.

METHOD. The health of various levels in the community, teachers, students, health workers and politicians were randomly selected and interviewed using structured and unstructured questionnaires.

RESULTS. Information on AIDS reached 90-100% of the population studied. Access to information was (low a combination of health, education and responsibility. Attitudes towards collaboration and participation in control programs including voluntary counselling had very high and AIDS was reported in all groups of society. Health workers were the most informed and well advised behavior change. Use of condom was especially indicated in 50-100% of them, and all condom users were students.

CONCLUSIONS. Combined usage of available media is superior than mass media. Teachers are potential agents of behavior change in low health workers. Overall education and community activities in prevention messages should be considered and be reinforced selectively rather than indiscriminate mass education. Behavior change through mass prevention is velocity with health education films, but requires additional efforts to change their way of life.

T.E.P.23

LA PREVENTION DU SIDA REALISATION ET EVALUATION DANS L'OCÉAN INDIEN

INDONESIA Dilipt, * EFFIAND Bernard, PRADMANA, Patrick
PRABHAKAR, P. * PRABHAKAR, P. * PRABHAKAR, P. * PRABHAKAR, P. * PRABHAKAR, P.
P.P. 1232 - 1974 P. 1232 DEKES (La Réunion)

Ce travail a été effectué dans le cadre associatif de l'A.R.P.S. Les réunions intermédiaires ont eu lieu en décembre 1988 et l'évaluation de l'information cette zone de monde particulièrement dépourvue, le diffusion de l'information peuvent s'expliquer sans réellement que celle d'un N.S.T.

Le but est de former les différents groupes afin de respecter la pluralité ethnique, socio-culturelle, la présence importante dans les îles de l'océan indien. Cette formation tiendra compte des différences de diversos communautés. Les réunions intermédiaires ont eu lieu en décembre 1988 et l'évaluation de l'information cette zone de monde particulièrement dépourvue, le diffusion de l'information peuvent s'expliquer sans réellement que celle d'un N.S.T.

Le problème de réinfection psycho-sociale de personnes atteintes dans un "butils" leur être soutenu.

La réalisation de ces différentes formations de relais et de leur impact sur l'individu sera en place fonction des possibilités locales.

Note: c'est à l'adresse, Association, personnel de santé, formation, Evaluation.

T.E.P.20

EVALUATION OF THE AIDS EDUCATION PROGRAMME IN S.S.M. PRISONS, AUSTRALIA.

John Doolley, Peter, P. N.S.M. Program of Corrective Services, Sydney, Australia.

Objective. To evaluate the AIDS education programme in S.S.M. prisons which aim to disseminate AIDS information, teach prevention strategies and prepare prisoners and staff for the implementation of HIV positive inmates.

Methods. Inquiries were conducted with random samples of prisoners from six S.S.M. prisons. Their knowledge about AIDS, attitudes to AIDS and risk of sexual behavior were assessed using standardized semi-structured interviews. The interviews with prisoners of each S.S.M. prison were also assessed from questionnaire data and from interviews with staff members of each S.S.M. prison. Overall prisoners and staff levels of knowledge about AIDS were low, but educated prisoners had a significantly higher level of knowledge about AIDS. New prisoners were optimistic that the spread of AIDS could be stopped in S.S.M. prisons then staff. Variety of arguments for and against prison AIDS prevention strategies (compulsory testing, segregation or integration of HIV positive inmates in prisons and close medical care) were put forward by both staff and prisoners. Sex prisoners said they had abandoned drug use or sexual relationships or had adopted their partners to reduce the risk of spreading AIDS. However, other prisoners said they continued to engage in behavior that they knew would put them at risk for AIDS.

Conclusion. AIDS education must involve staff and prisoners and staff to continue their knowledge about AIDS. To address this AIDS education must involve staff and prisoners and staff to continue their knowledge about AIDS. To address this AIDS education must involve staff and prisoners and staff to continue their knowledge about AIDS. To address this AIDS education must involve staff and prisoners and staff to continue their knowledge about AIDS.

T.E.P.22

CIS-AIDS ZAGREB: TELEPHONE ENQUIRY SERVICE - TWO YEARS' EXPERIENCE

Gotovac Petar, Lang S., Svjetlicina M., Stritar M., Baklaic T., WOODGATE M.

*Zagreb Institute of Public Health, Zagreb, Yugoslavia
*City Committee for Health and Welfare, Zagreb, Yugoslavia

Objective. Yugoslavia belongs to a group of countries with the lowest cumulative number of AIDS cases (65 AIDS cases as of 23rd Dec. 1988). The AIDS help-line in Zagreb was established with the aim of enabling the general population and health workers to receive information and advice on AIDS or on equal basis. Apart from the telephone line educational activities are also conducted within the CIS-AIDS (Center for Information and Education on AIDS).

Methods. The Center has developed horizontal and vertical communication with related institutions and offers a comprehensive and updated knowledge about AIDS. Public health workers daily answer telephone calls in scheduled time.

Results. Initial frequency of calls, in 1987, was between 50 and 100 per day, gradually decreasing to less than 10 calls/day. An estimated 10% of calls are placed by persons belonging to any of the risk-behaviour groups or otherwise potentially exposed to HIV infection.

Conclusion. Through adequate information and advice HIV infection IS REDUCING the stigmatization of social stigma. The activity of CIS-AIDS represents a new form of health promotion in Zagreb.

T.E.P.24

ESSAI D'UN DIDACTICIEL EN PREVENTION DU SIDA/MTS ADRESSE A'ADOLESCENTS.

Claudet, Richard, Département de santé communautaire, Hôpital général de Montréal, Québec, Canada.

Objectif. Développer un logiciel éducatif interactif en prévention du SIDA et des MTS et l'évaluer dans une école secondaire d'élèves de 15 à 17 ans.

Méthodes. Un logiciel éducatif "Les MTS, c'est facile à éviter", a été conçu et mis à l'essai auprès de 200 élèves de 15e et 16e années. Le programme est composé d'un questionnaire appelé BÉNÉFICÉ portant sur les connaissances et les attitudes face aux MTS et au SIDA et évalue le risque de contracter une MTS. Des informations sous forme de jeux et d'animations sont offertes sur le SIDA, la gonorrhée, la chlamydia et les moyens de se protéger. La gestion informatisée des apprentissages est possible et permet à un intervenant de coder des activités pédagogiques de groupe.

Résultats. Avec un questionnaire de type stratifié il a été démontré que les élèves connaissent le logiciel très viable (4,0/5), très intéressant (4,7/5), très utile (4,5/5) et amusant (4,1/5) et savent parler (4,2/5). On voit aussi que les dix-neuf actifs socialement appréciés davantage le logiciel que ceux qui ne le sont pas. Les commentaires recueillis soulignent l'intérêt pour la facilité d'utilisation, l'aspect interactif du logiciel, l'individualisation de l'enseignement et le respect de l'acceptation.

Conclusion. La détermination d'une note personnelle du risque de contracter une MTS et la possibilité d'analyser les données des élèves ayant utilisé le programme sont des aspects particulièrement intéressants. Ce logiciel est un outil novateur et utile pour la réalisation d'activités éducatives sur le SIDA et les MTS auprès des adolescents.

Session d'affichage Poster Session



Le SIDA, la société et le comportement AIDS, Society and Behaviour

T.E.P.25 LIVE BEYOND YOUR LIMITS Nasaney, Louis* Kolb, Glenn* *Louis L. Hay Educational Institute Santa Monica, Ca., U.S.A.

Objective: To describe how Louis Nasaney has combined medical, holistic, and nutritional techniques to survive AIDS for over six years.

Methods: In addition to medical therapies which have included AZT and Interferon, Mr. Nasaney has also employed alternative techniques such as vitamins, nutrition, meditation, visualization, positive affirmation, and self-love to survive during this time.

Results: Mr. Nasaney has not been ill during this period due to an HIV-related cause. The quality of life has vastly improved since diagnosis.

Conclusion: Medical and alternative techniques combined with loving the self have affected well-being and survival.

T.E.P.27 WHO IS AFFECTED BY AIDS TREATED AS OUTSIDERS; CONSEQUENCE OF MISINFORMATION. Coronado, A., Conde, F., Arredondo, C. S., Gil, E.* Ministry of Health

Objective: The strategy of information based on the relationship of AIDS-death, the diffusion of the concept of groups at risk... has led to the creation of a stereotype of AIDS whose extremely negative social consequences lead to social segregation of the collective social groups susceptible to becoming affected, and to the nihilism and fatalism of those who suffer it.

Conclusion: It is absolutely necessary to change this one way communication code that encourages uncertainty and fear. For a double communication code that simultaneously defines the healthy stages of the syndrome on one hand, and on the other hand the individual and collective behaviour that the individual carrier as well as the non-carrier should adopt at each stage of the illness.

T.E.P.29 THE MALE COUPLE: A CASE STUDY Krusch, Judy Social Work Department, St. Paul's Hospital Vancouver, British Columbia, Canada

Reliable social science research indicates that over 50% of gay men maintain committed, intimate relationships for one to five years. Other studies and clinical reports document relationships between gay male partners lasting from five through fifty years. What is surprising is the number of male couple relationships that manage to survive and endure in the face of institutionalized, social, and internalized homophobia. Gay male relationships lack legal and religious sanctions and are often unsupported by the partners' families.

This presentation will discuss the impact of a diagnosis of HIV infection/AIDS on one male couple and the stresses this created on their relationship. Some of these stresses included: addiction to prescription drugs, disclosure of the illness to others, resurgence of internalized homophobia, concerns with sexual and physical intimacy, depression, financial problems, dementia and a suicide attempt.

Conflict between the couple and the PWA's mother accelerated. Excerpts from an audio tape sent by the PWA's mother graphically depicted her anger, hostility, and homophobia towards her dying son and his lover.

This case study illustrated the multi-dimensional challenges endured by the couple, and how they managed to maintain their relationship when faced with a diagnosis of AIDS.

T.E.P.28 EVALUATION OF THE ITALIAN NATIONAL AIDS INFORMATION CAMPAIGN.

Mazana Giannini, Rosvati V., Greco U., Pisanello M., Zamagni A., Istituto Superiore di Sanità, Rome, Italy, Aversa, Milano, Italy, A. Tesse, Roma, Italy.

Objective: To determine knowledge and beliefs about HIV transmission and prevention; to determine the impact of the national AIDS information campaign.

Methods: A random sample of the general population of Italy was selected using a multistage sampling procedure. The sample was selected in order to be proportional to the general population for sex, age groups, population size, and geographical area. The sampling unit was the local authority and within each of its subjects were randomly selected from telephone directories. Interviews were carried out by phone in the evening, using a structured questionnaire. The key questions were about transmission, prevention, risk categories and information. The interviews were carried-out in 3 stages, early in July 1983 before the starting of the campaign and in October just before the ending.

Results: 2,363 numbers were selected in stage I, interviewed in 1,050 and refusal in 42.3. The figures for stage II were respectively 2,251 contacts, 1,012 interviews (66.4% of attempts) and 44.0% response rate. 37% of the subjects in July and 37.8% in October knew at least the word AIDS. However in October 71% considered AIDS a disease extremely contagious, compared to 57% in July; 60% knew about the sexual transmission of HIV in October and 57% in July. Comparable figures for parenteral transmission were 75% and 37%. A more detailed analysis will be presented at the Conference.

Conclusions: Although the low response rate limits the value of the results it seems that in Italy there is a good general knowledge about AIDS even though more efforts should be made in the area of actual prevention of the spread of the disease.

T.E.P.28 NEEDS OF FAMILY CAREGIVERS OF PERSONS WITH AIDS Cohen, Nancy H. and Wilson, G. Long Beach Health Dept., Long Beach, CA, USA

Objective: To determine the social and educational needs of family members of adult male persons with AIDS (PWAs).

Method: A detailed assessment questionnaire was designed, pre-tested, and administered to 50 family members. In addition, a focus group of bereaved family members was conducted to identify needs associated with terminal stages of AIDS.

Results: Specific needs of the family were related to duration and severity of the PWA's condition. Early in the course of the disease, families wanted information on AIDS transmission and prevention, their own risk, treatments, who to call, and nonsexual depression (theirs and their PWA's), and care resources and skills. Some bereaved caregivers wanted more concrete information about legal issues, preparing for death, funerals, management of religious issues and conflicts, emotional changes to expect, survivor guilt, managing grief, and determining how much information to disclose to whom. After death, a major concern of a significant portion of families was how to most effectively fight AIDS; others wished to retreat from involvement in AIDS. Need for family and social support occurred throughout the process.

Conclusions: In order to most effectively serve their needs, programs targeting family caregivers should be tailored to the stage of HIV infection at which their relative with AIDS curvey from home.

T.E.P.30 AIDS PREVENTION AS COMMUNITY INTERVENTION Urevis, V., Jewell, T., Sennerfeldt, P. and Ohgren, M. The Stockholm Youth Prevention Project, Stockholm, Sweden

Background: Behavioral change requires not only information but also a social environment. This project was designed to address this need through discussion with trusted peers and adults. Stockholm county has around 250,000 teenagers.

Objectives: To make adults who meet teenagers in their everyday life as professionals, privately or as volunteers prepared to discuss and give information on sex and relationships, STD and AIDS.

Method: Through using the existing infrastructure, massive outreach was possible in short time. Partnerships were formed with local authorities and organizations. The project offered training, service, support and follow up. During 2 years 3,500 people were trained: teachers, schoolnurses, youth leaders, priests, social workers, PTA-members etc.

Results: 98% of all schools for 13-20 year olds have sex-education including info on STD and AIDS. Numerous youth clubs have developed discussiongroups on sex and relationships. New youth clinics are established. Local plans are being developed.

Session d'affichage Poster Session



Le SIDA, la société et le comportement AIDS, Society and Behaviour

T.E.P.31 The hiv-epidemic: Attitudes towards public preventive measures in the Norwegian population. **Stein A. P. Kraft**, National Institute of Public Health, Oslo

Several public preventive measures have been debated in Norway in order to combat the hiv-epidemic. Coercion against the so-called risk-groups and hiv-infected persons, different hiv-antibody testing designs, revelation of the identity of hiv-infected persons, and regulation of sexual behavior. Eleven statements were constructed in order to test the attitude structure of these issues in a nationwide interview survey in March 1988 in 1100 Norwegians aged 15 and above. A factor analysis produced three attitudinal dimensions which may be denoted: "Prohibition", "Coercion", and "Restriction". The "Prohibition" dimension was strongest and explained 24.6% of the variance. The "Restriction" dimension explained 20.8% of the variance. The "Coercion" dimension explained 15.7% of the variance. The results indicate that in addition to being associated with factors related to hiv-aids and psychological factors, attitudes towards public preventive hiv-measures is a controversial issue impinging upon the value-attitudinal axis as empirically observed in Norwegian politics.

Political issues Social Policy

T.E.P.33 COMMUNITY PARTICIPATION IN THE DEVELOPMENT OF A FIVE YEAR PLAN ON AIDS/STV. **YORK STATE'S PROCESS AND SIGNIFICANT FINDINGS** **Arnella D'Angelo, Terrence C. McP.H., *AIDS Institute, New York State Department of Health, New York, U.S.A.**

Objective: To describe the process that allowed New York State to incorporate community analysis of AIDS related problems in the Governor's Five Year Plan on AIDS and to summarize significant recommendations.

Method: A series of nine Roundtable discussions were held with health and human service providers, advocacy groups, community based organizations, and persons with HIV infection. Roundtables were charged with identifying AIDS related issues, prioritizing those issues and then developing recommendations. **Results:** A total of eighty recommendations emerged from the Roundtable process. A significant outcome was that separate Roundtables often developed similar recommendations, thereby strengthening these proposals. Included among these common recommendations were: increase access to a wider variety of ongoing training to professionals so they may be sensitive to the needs of different populations; provide services to families; develop and refine educational materials with the targeted community's assistance; increase access to information and clinical trials and identify sources of alternate sites of care.

Conclusion: The Roundtable discussions were a useful means of identifying important issues and proposing specific recommendations. State agency planners gained valuable insight into "Frontline" needs, and community representatives expressed satisfaction with the dialogue that was established.

T.E.P.35 A FEMINIST VIEW OF AIDS: POLICY IMPLICATIONS OF THE SOCIAL CONSTRUCTION OF A DISEASE

Richard R. Ralston, MD, Working Group on Women and AIDS and the Bruce V. Glavin Hospital, Baltimore, MD, USA

Many policy decisions affecting HIV positive women in the US are informed by implicit principles and covert perceptions which obtain to women. In general, differences from men, but may not be consciously available to policy makers. These differences result in prevention principles with limited likelihood of success: i.e. approaches which mirror previously unsuccessful campaigns like our current efforts to decrease the rate of teen pregnancy. These policies may have widespread implications for gender definition, sexual autonomy and reproductive choice among women at risk for infection as well as women, who because of class and race categories frequently used as proxy for risk in the absence of known behavior, disproportionately experience their impact. North American feminist analysis provides a framework to understand these underlying principles and evaluate their policy implications. Feminist experience utilizes concepts like empowerment may provide new directions in policy and prevention.

T.E.P.32 AIDS in Barbados

Prof. E. B. Walton, Chairman, National Advisory Committee on AIDS Barbados

Barbados is a small independent island country in the Southern Caribbean with a population of 250,000. The population is well educated and has good internal and external communications. The island has 400,000 tourist visitors a year, and this is one of the mainstays of its economy.

The first indigenous case of AIDS was reported in late 1984, and the local medical association and the Ministry of Health moved early in 1985 to establish general and health professionals' education and the screening of donated blood. The epidemic has been similar in pattern to that in the West with well and predominantly male homosexuals affected at first, with increasing heterosexual transmission thereafter. The prevalence of the disease is similar to that of the United States.

Aspects of the education programme to send simple direct messages without an extraordinary message of death are described. Evidence is presented that the messages are being reabsorbed, they may have however had high risk individuals to use the blood donation service to obtain testing free and without counselling. The limited evidence obtained is used to direct specific changes in education and practice related to AIDS education, prevention and control.

T.E.P.34 PATIENTS' PREFERENCES FOR LOCUS OF CARE AND FOR ACTIVE TREATMENT: PRELIMINARY RESULTS OF A SURVEILLANCE STUDY

Mrs. Virginia Fleishman, J. Piette, J.*

*Brown University, Providence, Rhode Island, USA.

Objective: To describe preferences of people with AIDS for care at home and for continuing active treatment in the face of severe symptoms.

Methods: Personal interviews were conducted with 257 clients of the Robert Wood Johnson Foundation's AIDS Health Services Program in 9 cities in the US. We assessed patients' preferences for home treatment (e.g., dying at home, being treated at home, being home with unreliable medical care access) and for active treatment in the face of severe symptoms (e.g., constant nausea, incontinence, disfigurement, life support dependence). We compared responses by risk group and by whether the patient had recently been hospitalized. **Results:** Nearly 90% want to die at home; 73% prefer living at home even if city to living in group quarters; and 61% prefer being home even if access to medical care is more complicated than getting therapy in a hospital. Patients' willingness to endure complications of aggressive treatment had 3 clusters: common symptoms, which 55-57% would tolerate; functional dependence and disfigurement, which 31-41% would take; and life support risk group, which only 8-11% would put up with. Only small differences by risk group were observed, and recent hospitalization was unrelated to preferences.

Conclusion: Patients' preferences for home-based care are consistent with social norms and should be considered in program planning. Preference for aggressive treatment varies as a function of the anticipated consequences.

T.E.P.36 The Social Correlates of AIDS Heterozygosity, **Onasme for Onasme**, **Parrell, J.**

*New York University, New York City, NY, USA

Objective: To explore the social correlates of AIDS heterozygosity (negative attitudes toward persons with AIDS) among Americans and to investigate the implications it has for the rights of persons with AIDS and policies directed at persons with AIDS.

Method: Data from the General Social Survey were examined using multiple regression analysis in an effort to determine what were the social correlates of the implications it has for the rights of persons with AIDS and policies directed at persons with AIDS. **Results:** AIDS heterozygosity was not easily explained by the variables traditionally used in social science research. Among the strongest indicators was the overall level of education, but this too was weakened when personal contact issues, such as whether or not AIDS testing should occur before marriage, were introduced.

Conclusion: This investigation has implications for policy makers because it demonstrates that general research, such as programs to reach the most people such as mass mailings or television shows) may not be the best method to do it. It does mean that programs must be designed to address issues that are of concern to the public, but that program designers and policy makers are well advised to study just what they mean by "public."



Session d'affichage Poster Session

Le SIDA, la société et le comportement AIDS, Society and Behaviour

T.E.P.43 Current Utilization of Inpatient Alcohol and Drug Treatment Services in a Cohort of IV Drug Users.
Edelman, Lisa; Frank, R.; Vibash, D.; Colestanto, D.; Cohen, S.
The ALIVE Study. The Johns Hopkins University, Baltimore, MD, USA.

Objective: To determine the current utilization of inpatient drug and alcohol treatment services in a cohort of high risk IV drug users (IVDU) and to correlate current utilization with serostatus.
Methods: A cohort of IVDU, recruited by community outreach, were enrolled in a longitudinal study of HIV infection. Participants were queried concerning their utilization of inpatient drug or alcohol treatment services within the prior six months. Utilization of services was correlated with HIV serostatus.

Results: Among the group of 305 respondents, 23% were HIV seropositive (ELISA and WB confirmed). Twenty-four (18%) had been an inpatient in a drug or alcohol detoxification program within the previous six months. Four (9%) of those in drug or alcohol treatment, versus 50 (23%) not in treatment were seropositive (p < .001).

Conclusion: Although based on a self-selected cohort, these data indicate that the majority of patients in inpatient detoxification are also on limited broadcast community testing programs need extensive resources in order to reach, inform, and motivate populations at risk for HIV infection. Creative strategies are needed in order to maximize limited resources, overcome cultural barriers to research in general, and to deal with the anxieties that people have about HIV testing and research.

T.E.P.44 THE SOFT UNDERBELLY OF RESEARCH: ADMINISTRATIVE AND COST CHALLENGES IN A STUDY OF HETEROSEXUAL HIV TRANSMISSION

Lauter, D.; Kierler, S.; Peisngold, L.; and Mayer, Kenneth.
New England Behavioral Health Study (NEHS), Brown University, Providence and Memorial Hospital, Pawtucket, RI, U.S.A.

Objective: To enroll up to 3000 heterosexual adult volunteers in a cross-sectional seroprevalence study of HIV transmission, and up to 1000 high risk heterosexuals in a prospective cohort study.
Methods: Recruitment, beginning in early 1988, has involved establishing multiple outreach and referral sites at hospital-based HIV clinics, community service agencies, drug and STD treatment facilities, and other agencies serving HIV high risk populations. Publicity efforts have included public service announcements for TV and radio, newspaper ads, brochures, booklets and newsletters. Participants are offered free physicals, counseling, HIV testing which includes risk surveys and "Partner" lymphocyte screening for HIV, persons, and medical and social service referrals, but are not paid.

Results: In the first 16 months, 215 people (109 women and 106 men) have enrolled. In the first 16 months, 215 people (109 women and 106 men) have enrolled. In the first 16 months, 215 people (109 women and 106 men) have enrolled. In the first 16 months, 215 people (109 women and 106 men) have enrolled.

Conclusion: Research and voluntary testing initiatives. Creative strategies are needed in order to maximize limited resources, overcome cultural barriers to research in general, and to deal with the anxieties that people have about HIV testing and research.

T.E.P.45 NEW JERSEY'S SEXUAL BEHAVIOR REASSESSMENT PROGRAM - EVALUATION OF ITS IMPACT ON SEROLOGY RISK

Chandler, R.; Wang, S.; Hamel, J.; Hothorn, B.; Costa, S.
New Jersey State Department of Health, Trenton, New Jersey, USA

Objective: New Jersey received \$5.5 million and subsequently \$996,000 from Congress to provide additional funds for low-income people with HIV infection lacking public assistance, enough to provide for about 175 persons years of AZT (Zalcovir). This study's objective is to determine the characteristics of persons receiving the drug through this program, to compare them with persons receiving the drug through other programs and to determine the effect of AZT on length of life of recipients.

Methods: Confidential serologic data from the serologic program was compared to information from the State AIDS Registry. Demographic and diagnostic variables were matched between two samples: those receiving the drug through the various serologic programs and those on the Registry who were not receiving the drug. In the basis of the Registry, length of life was studied. 504 persons receiving AZT through serologic programs was compared to 3153 persons on the State AIDS Registry.

Conclusions: The demographic profile of the two sample groups were fairly well-matched. However, analysis identified a need for further outreach to black men, who are under-represented in the AZT population as compared to the State AIDS Registry. This study also provides an analysis from a broad public policy perspective that compares existing national literature.

Results: Analysis suggests an effect of AZT on persons on the various serologic programs in terms of increased length of life, when compared to survival time of a comparable sample of individuals from the State AIDS Registry. 73% of AZT recipients were alive at the end of the study period, compared to 50% from the State AIDS Registry sample not receiving AZT through these programs.

T.E.P.46 POLITIQUE D'INFORMATION MUNICIPALE DE LA VILLE DE MONTRÉAL RELATIVE À LA PREVENTION DE LA SIDA

CHATELAIN, J.-M.; DORE, J.-M.; BEAUN, Raymond; GAGNON, de Montréal, Québec, Canada

Objectif: Prévenir la politique municipale de la Ville de Montréal relative à la prévention de la SIDA.

Contexte: La Ville de Montréal a décidé d'intervenir à l'indicateur des quatre rôles qui lui sont dévolus en ses qualités d'employeur, d'entrepreneur de services, de gouvernement municipal et d'agent de planification sociale: 1) traiter la progression de l'épidémie; 2) réduire les conséquences sociales négatives aux personnes atteintes; 3) favoriser l'implémentation des ressources susceptibles de répondre aux besoins exprimés par la maladie.

La Ville l'adoption d'une politique qui identifie clairement les intentions de la Ville par rapport à ces quatre rôles, la Ville entend mettre en oeuvre les six mesures concrètes suivantes:

- 1- planification et diffusion d'un programme d'information pour ses employés;
- 2- planification et diffusion de programmes de formation adaptés à l'usage des employés de première ligne afin qu'ils puissent effectuer leur travail de façon sécuritaire et respectueuse des droits de la clientèle atteinte;
- 3- mettre à la disposition de la population la documentation relative au SIDA et à sa prévention;
- 4- effectuer obligation dans certains établissements publics de mesure de prévention contre le SIDA;
- 5- l'élimination des obstacles à l'établissement des ressources aptes à répondre aux besoins exprimés issues du SIDA;
- 6- la participation à la concertation des différentes actions entreprises sur le territoire de la Ville en vue de contrôler le SIDA.

T.E.P.47 RECENT CHANGES IN SEXUAL BEHAVIOR AMONG MEN IN LOS ANGELES
Frasser, R.; Lewis, C.; Bannenberg, K.; Corey, C.
University of California at Los Angeles, Los Angeles, California, U.S.A.

Objectives: To assess the changes in sexual behavior among homosexual and heterosexual men over a 2-year period.

Methods: Random-digit dialing telephone calls were placed to residences; men ages 18-60 were eligible to be interviewed. Households in census tracts with higher than average rates of reported cases of AIDS were oversampled. Results are weighted to reflect oversampling.

Information on sexual orientation, numbers of sexual partners, and other risk-related behaviors, were gathered for 2 time frames: the past 2 years and the past 3 months.

Results: Significant differences are found between homosexual and heterosexual men in terms of numbers of partners and presence of other risk-related behaviors (over half the homosexual men in the study reported having 4 or more sexual partners in the past 2 years (1986-1988), as compared with less than one quarter of heterosexual men).

Sexual activity and increased rates of reported cases of AIDS were documented for both groups over the past 3 months (March-June 1988), although a higher percentage of homosexual men remained highly sexually active.

T.E.P.48 SCIENCE AS A POLITICAL FORCE: THE CASE OF THE AIDS EPIDEMIC

Smith, Stephen C., Human Rights Campaign Fund, Washington, D.C., USA

Objectives: To draw the lessons of the AIDS crisis for the role of science and scientists in political life.

Methods: The author - who has divided political arguments and strategies for AIDS politics according to scientific advice - will review relevant literature in the history of science.

Results: Most modern political-economic systems claim to be "scientific," and science has greatly reduced the forces that most excite human fears - poverty, violence, and disease - but public understanding of science has not progressed at the same rate.

Scientists are not well represented among policymakers nor in the general public. Thus, the average person, even in "developed" countries today, often responds to their basic fears from superstition or pseudoscience, not scientific thinking.

The public and political responses to the AIDS crisis demonstrates the results: many people are reluctant or unwilling to accept the advice of science on scientific questions - e.g., modes of transmission. Policies may thus be based on an unscientific response to fear, and may be counterproductive.

Not only in addressing the problem at hand, but in developing a scientific outlook on the common challenges of human society. Conclusion: Scientists must become more actively involved in political life and the formulation of policy.

**Session d'atfichage
Poster Session**



**Le SIDA, la société et le comportement
AIDS, Society and Behaviour**

T.E.P.49 THE REFERENCE AND TRAINING CENTER ON AIDS, S&O PAULO, BRAZIL.

Keywords: M. E. L. L.; Teixeira P.R., Dal Bianco, Rosana, Pinto V., Ueda H.

Referencia e Treinamento em Aids, São Paulo, Brazil.

Objective: In February 1985 the secretariat of Health, of S&O Paulo, Brazil created a reference and Training Center in an 8 floor building to bring together the state Aids Prevention and Control Plans. The Center is composed of: The surveillance UNIT, the educational and Training UNIT, a day care hospital, an out patient clinic, a laboratory UNIT, a "central for hospitals beds vacancy and a multiprofessional home care unit.

Methods: A multiprofessional TEAM with experience on Aids since 1983 established the policy of Aids Prevention and Control in the state of São Paulo, and disseminated the information on Surveillance, Education, Patient care to the 63 health regions. Coq culture is being done to all 63 health regions.

Results: 3,000 patients are followed in average/per month in the out patient clinic.

- HIV patients from all state are being followed in 75 different health care units after training.

- 210 health care providers and community leaders were trained in 1985.

Conclusion: the reference and Training Unit Permitted the implementation of the policy Aids Prevention and Control in the State of São Paulo.

T.E.P.50 A STUDY OF NATIONAL AIDS/RIV POLICIES AND PROGRAMMES IN THE 31 COUNTRIES FOR THE EUROPEAN REGION

Keywords: Brigitte, and Weyling, E.*
*World Health Organization, Regional Programme on AIDS, Copenhagen, Denmark

Objective: To describe and evaluate national AIDS/RIV policies and programmes in the European Region and identify strategic lessons for national AIDS/RIV prevention, control and care policies.

Methods: An analytical review, using guidelines of good practice developed by the Global Programme on AIDS, of material from representatives of national governments. Preliminary results substantiated through formal and informal contacts with persons in and outside of government.

Results: National AIDS Committees and other national coordinating mechanisms that are multi-disciplinary and include participation of Non-governmental Organizations initiate AIDS/RIV policies that appear to achieve a greater degree of effectiveness in HIV prevention and securing a continuum of care.

Conclusion: The presence or absence of explicit policy is not necessarily the measure of the effectiveness national AIDS/RIV programmes. Effective policy programmes appear to be strongly influenced by the mechanism by which they are formulated and implemented. As such, and lacking comprehensive measures of HIV seroprevalence, the policy process and application in practice must be evaluated to estimate impact.

T.E.P.51 PROVISION ACCESS TO PROMISING INVESTIGATIONAL DRUGS (I.D.) A MANAGEMENT MODEL FOR "TREATMENT IND"*

Keywords: Feinberg J.; Myers, M.; Oubisi, E.; Roth, D.; AIDS Program, National Institute of Allergy and Infectious Diseases (NIAD), Bethesda, Maryland, USA

One of the primary goals of the AIDS Program, NIAD, is the rapid transfer of new therapeutic advances from the clinical research setting to the community of treating physicians. New federal regulations (42CFR) defined a mechanism for access by any licensed U.S. physician to promising investigational new drugs (IND) that have evidence of safety and preliminary evidence of efficacy in serious of and life-threatening diseases. These "treatment IND" protocols provide access by any licensed U.S. physician to such therapies.

We have employed "treatment INDs" as part of our overall strategy for rational drug development, and have created a successful management model for their design and implementation. The key components of this model, to be discussed in detail, are: (1) establishment of a telephone information capability (hotline), (2) protocol design, (3) physician education, (4) triage and enrollment process, (5) drug distribution system, (6) data capture and retrieval, and (7) analysis of results.

The AIDS Program has sponsored the only 8 such "treatment INDs" for AIDS indications. While each novel therapy for AIDS patients presents unique medical and logistical problems, we have successfully developed a strategy for "treatment INDs" which allow access to new agents and collect data on their use while meeting U.S. regulatory requirements.

T.E.P.52 DISCRIMINATION AGAINST HIV POSITIVE WOMEN BY ABORTION

Keywords: AIDS Discrimination Division, New York, N.Y. City Commission on Human Rights

Objective: To document discrimination against HIV positive women in access to abortions in New York City.

Methods: Test calls were placed to 39 abortion clinics. After an appointment was made for an abortion, the caller revealed that she was HIV positive.

Results: Of 25 clinics surveyed, 16 (64%) would not schedule an abortion for a woman who reveals she is HIV positive.

Conclusion: Many health care professionals who perform abortions in New York City manifest open hostility toward HIV positive female patients and remain poorly educated on the need to use universal infection control precautions, thereby violating various public health and anti-discrimination laws.

T.E.P.53 PSYCHOSOCIAL ADAPTATION AND ECONOMIC CIRCUMSTANCES OF PERSONS WITH AIDS OR ARC

Keywords: Heston, Margaret
Rutgers University, New Brunswick, NJ, USA
*School of Medicine, University of California, San Diego, CA, USA

Objective: To evaluate how persons with AIDS (PWA) and persons with ARC (PWARC) meet their economic needs.

Methods: 50 PWA and 54 PWARC were surveyed in San Diego County, California, between October 1984 and February 1987.

Results: Social and economic impacts of the disease had been profound for both groups. PWARC reported more urgent needs than did PWA. Both groups reported their greatest unmet needs as financial. A majority were no longer employed; 64% of unemployed PWA but only 41% of unemployed PWARC were receiving Social Security disability or SSI, and many unemployed PWARC had little or no income. Most PWARC lacked Medicaid or other health insurance coverage.

Conclusion: Health care and social services systems will be increasingly challenged not only by needs of PWA but by severe unmet economic and medical needs of an even larger population of PWARC.

**Rôle des organismes non-gouvernementaux
The Role of Non-Governmental Organizations**

T.E.P.54 CANADIAN HEMOPHILIA SOCIETY: A PLANNED RESPONSE TO HIV AND AIDS

Keywords: Robert O'Malley, Nana Nera, M.Sc.S.W., C.S.W., Canadian Hemophilia Society, Social Services Advisor, Federal Centre for AIDS, Health and Welfare Canada, Ottawa, Canada

This presentation will describe how a consultative planning process model used by the Canadian Hemophilia Society (CHS) to deal with HIV and AIDS has resulted in an effective response to the crisis.

CHS created a "Task Force on HIV and AIDS" in 1987, comprising of a non-medical and medical group. The four-step planning process followed by these two groups to develop a comprehensive response to the HIV/AIDS catastrophe will be presented and discussed.

The numerous positive effects and substantial results of this well coordinated planning process will be shared at this conference.

Session d'affichage Poster Session



Le SIDA, la société et le comportement AIDS, Society and Behaviour

T.E.P.55

CANADIAN HEMOPHILIA SOCIETY: A NON-GOVERNMENTAL MODEL APPROACH WITH A COLLABORATIVE ORGANIZATION (190)

Mrs. Norma M. Sawyer, R. J. Federal Centre for AIDS, Health and Welfare Canada, Ottawa, ON, Canada

The devastating impact on HIV/AIDS did not make its mark early on to the Canadian Hemophilia Society as an organization. In early 1980, shortly after the Minister of Health and Welfare, Canada, announced its five-year national program, the then National AIDS Centre met with the Canadian Hemophilia Society to analyze the impact of HIV/AIDS on the hemophilia community. The effects of blood products, HIV testing and psycho-social needs of hemophiliacs with hemophilia became of paramount concern.

With the assistance of the Federal Centre for AIDS in July, 1987 both the Canadian Hemophilia Society and the Federal Centre for AIDS used various approaches to meet identified needs of the hemophilia community.

This presentation will not only describe the step-by-step process which led to this collaboration with a non-governmental organization, but will also present the achievements derived from such a partnership. The benefits derived by the Society as an organization; the community members as individuals, families and support groups, as well as the general community; and the benefits derived by a governmental agency in the response to the AIDS crisis will be described.

T.E.P.56

ROLE OF THE UNIVERSITY: EDUCATION, RESEARCH, POLICY AND SERVICE

Bethel Cayton, Cooksey, J.A.*

*University of Illinois at Chicago, Chicago, Illinois, U.S.A.

Objectives: To describe a role for an urban university in AIDS education, research, policy and service.
Methods: The University of Illinois at Chicago appointed an AIDS Advisory Council in 1987 with the charge: encourage AIDS-related instruction and prevention programs; promote research; advise on policy; and develop community outreach. Faculty, students, employees and administrative members developed an organizational plan: identified priorities and carried out the charge through several working groups.

Results/Education: - highest priority; distribution of printed AIDS awareness materials; peer education program for students. Research - information and interest sharing; quarterly research forums combine biologic and social scientists; newsletter listing all AIDS grant programs. Policy - campus level policy; addressing nondiscrimination, no mandatory testing, educational progress; and currency with legislation and scientific guidelines. Service - community outreach and empowerment; forum on AIDS prevention and resources in community groups in the neighboring area.
Conclusions: A university has many technical, leadership and service resources to utilize in developing an institutional response to the AIDS epidemic. These resources may be productively shared with the community.

T.E.P.57

PRIMARY CARE AT A RESIDENCE FOR PERSONS WITH AIDS (PWAA) BALLEE HOUSE, NEW YORK CITY, U.S.A.

Ramon A. Torres, Staats '88*

*St. Vincent's Hospital and Health Center, New York, NY, USA.

*Ballee House (BH), New York, NY, USA.

Objective: To describe a pilot program of onsite primary care at Ballee House (BH), a 14 room residence for persons with AIDS in NYC. The program includes assessment, advocacy, and timely referrals to lead to appropriate interventions.

Methods: A 6 month pilot program was instituted at Ballee House in 7/88 to provide onsite medical consultation to supplement the existing team of nurse practitioners, social workers, substance abuse counselor, and personal care workers. Close association with a local community hospital, SVHC, facilitated referrals for diagnostic procedures, hospitalization and/or specialty clinics.

Results: During the six month period 137 resident contacts by the medical/nursing team led to referrals for outpatient therapy for opportunistic infections, including oral candidiasis, PCP, bronchitis/pneumonia, and soft tissue infections. Many were seen in the SVHC clinic of the BH medical consultant. Familiarity with the physician appeared to encourage compliance with clinic visits and treatment plan. Other referrals were to emergency rooms, psychiatric clinic, specialty clinic, private labs, etc. for transfusions, diagnostic tests, direct admission, or experimental protocols. Inclusion of a physician in the BH team also allowed for administration of intravenous hydration and infusion therapies in conjunction with and supervised by the Visiting Nurse Service of New York, administration of aerosol Pentamidine, laboratory monitoring, supportive care to terminally ill patients, counseling, and crisis intervention.

Conclusions: Onsite primary care in a residential setting, utilizing the team approach, provides for more comprehensive outpatient management of PWAs.

T.E.P.58

AIDS OUTLET FOR EDUCATION (AOE): A BROAD-BASED ORGANIZATION FOR THE COORDINATION OF AIDS EDUCATION, RESEARCH AND PREVENTION SERVICES

Billy, Bruce J.; Ballouck, D.P.; Peterson, J.M.*

*American Disease Control Center, Colorado, U.S.A.

Objective: To coordinate and extend the duplication of efforts by agencies in the state of Colorado involved in AIDS education, information and prevention.

Methods: Beginning in July 1988 with 6 members, AOE had grown to 42 members by December 1988. Members include individuals and organizations, public and private, involved or concerned with AIDS educational activities. They include state and local health departments, community-based service organizations, hospitals, insurance carriers, state and local school districts, blood banks, minority organizations, and family planning groups.

Results: AOE collectively sponsors educational events and maintains a coordinated schedule of home care fairs. In July, 1988, AOE incorporated as a nonprofit educational organization.

Methods: Members meet once a month to share resources and present work completed and planned. AOE has a 13-member working Board of Directors. AOE has coordinated three annual statewide education campaigns. In 1987, AOE received national recognition for its first media fair for the show "DAYS OF THE FIGHT". The coordinated program has been documented for 20th anniversary to a cumulative audience of 100,000 people from October 1988 to November 1989. The data base collects information in 18 states including type, type of audience, and educational media used. Similar, local coalitions have developed as a result of AOE's example, allowing for ongoing regional cooperation and statewide referral.

Conclusions: Given the limited resources available, and the current proliferation of activities involved in AIDS education, AOE has lowered the effective utilization of resources, coordinated among participants, and an effective method for coordination of regional and state activities.

T.E.P.59

IN SUDANESE COLLABORATION WITH THE OIC ET LE PROGRAMME NATIONAL DE LUTTE CONTRE LE SIDA EN L'ONG - LA CONFERENCE CLINIQUE DES LES SIDA (CCLS)

Nabilou Sam J., Labou J.M., Bernoulli B., Lami A.*

* Organisation Mondiale de la Santé (OMS). Programme national de lutte contre le SIDA (ONG), Genève, Suisse; ** Médecine du Monde OMD, Paris, France.

Objectif: dans le cadre d'une action spécifique de formation, développer une collaboration entre l'ONG et l'OMS et inscrire dans les plans nationaux de lutte contre le SIDA deux des pays africains.

Méthodes: A la suite de la signature d'un protocole d'accord entre l'ONG/OMS et Médecine du Monde, six séminaires d'un semaine ont eu lieu, de décembre 87 à novembre 88, dans les pays suivants: Omdurman, Khartoum, Gonder, Addis Abeba, Oua D'Abouja. Organisés par Médecine du Monde, six séminaires ont permis: pour le SIDA de former des fonctionnaires de haut niveau sur le SIDA pour environ 20 à 40 participants dans chaque pays, de sensibiliser le corps médical de ces pays aux stratégies élaborées par l'ONG et les OMS/OMS de lutte contre le SIDA (OCS), d'instituer une commission de la prise en charge des malades et des épidémiologistes.

Résultats: - Le SIDA des six pays sur un total de 215 participants à huit séminaires de responsabilité ont reçu une formation sur le SIDA. - La collaboration triangulaire entre l'ONG/OMS, Médecine du Monde Paris, et les OMS dans les pays a parfaitement fonctionné. - Les séminaires ont permis aux participants de Médecine du Monde d'établir des contacts directs avec l'ONG et les OMS et d'être partiellement responsables de la lutte contre le SIDA dans les pays concernés.

Conclusions: - Les OMS peuvent et doivent s'engager dans les programmes de lutte contre le SIDA élaborés par l'ONG et les OMS. - Cette collaboration dans le cadre de la formation doit continuer et s'étendre à d'autres aspects de la lutte contre le SIDA.

T.E.P.60

A PROPOSAL FOR A PERMANENT INTERNATIONAL FORUM OF NODS WORKING WITH AIDS

Almeida, Wellington*, Braune, F.W.*; Cardoso Jr. R.P., Daniel, R.P.*

* Brazilian Interdisciplinary AIDS Association (AIIA), Rio de Janeiro, Brazil.

Objective: To propose the creation of a permanent international forum (PIF) of NODs related to the AIDS epidemic in order to exchange experiences, articulate activities and progress and increase the effectiveness of each organization.

Methods: A list of all NODs related to the AIDS issue was drawn up and approx. 500 circular letters were sent out by AIIA explaining this proposal to NODs in Latin America, Central America, Caribbe, Europe and USA. It was also suggested that the initial site for this encounter be at the V AIDS CONF. contacts with key persons in various countries were made to compose a steering group to link the proposed forum with Programme Committee and secretariat of the Conference, so that a date and place be set during the event for a first session.

Results: The response to the letters was highly positive, and suggestions were made for a workable timetable for sessions during the Conference.

Conclusions: Many NODs face insurmountable difficulties establishing network activities programs within their respective countries as well as across national boundaries. Amongst them, they are the reality of AIDS at grassroots level, the need to directly involve the general public and community support, the little has been done to tap this potential in fight against AIDS, mostly in the Third World context. The V International AIDS Conference on AIDS offers a unique opportunity in this direction.



Session d'affichage Poster Session

T.E.P.67

SURVEY OF THE CLIENT STRUCTURE OF THE AUSTRIAN AIDS FOUNDATION'S COUNSELLING CENTRE IN VIENNA, JULY 1987-DECEMBER 1988
Hutterer, Judith, Brandstätter, R., Vogl, G., Piribauer, F. J.

Österreichische AIDS-Hilfe (Austrian AIDS Foundation) - ÖAM, Vienna, Austria.

Objective: To give a survey of the composition of the clientele of Austria's most frequented HIV/AIDS counselling centre.

Methods: Evaluation of the 3,600 clients who frequented the Vienna counselling centre of the Österreichische AIDS-Hilfe (ÖAM) between 1 July 1987 and 31 December 1988. This centre is one of seven in a nation-wide network of anonymous and free HIV/AIDS counselling centres operated by the Austrian AIDS Foundation in which teams of psychologists, physicians and social workers offer information and advice, anonymous physical and telephone counselling, psychological help, care and support, and anonymous and free HIV antibody testing.

Results: 643 of these 3,600 clients were men, 365 women; 803 stated that they were heterosexual, 145 homosexual or bisexual; the sexual orientation of 65 was not stated; 67% of the clients declared to have an HIV antibody test, 94% of them tested negative, 5% tested positive. A more detailed presentation concerning factors such as risk behaviour, frequency of visits to the counselling centre, age, etc., will be given at the poster session.

Conclusions: The information and counselling offered by the ÖAM are, to a large extent, accepted both by the general population and by the so-called risk-groups: the ÖAM, however, focusses on the care and support of HIV positive people and Pals.

T.E.P.69

A 40-HOUR TRAINING PROGRAM IN AIDS FOR PUBLIC HIGH SCHOOL TEACHERS

Fernandes, Maria Eugénia¹, Pinel, A., Nardi, M.A.,²
Abud, N.,³ Ising, A.,⁴ Engelse,⁵ J.O.S., São Paulo, Brazil

¹Centre de Referência e Treinamento, ²IOS, ³USO, ⁴USO, ⁵USO, São Paulo, Brazil

Objectives: To train teachers from the public school network on AIDS.

Methods: A 40-hour training program on human sexuality and AIDS was developed by the Education and Training Unit of the Center of Reference and Training in AIDS as a complement to a booklet that would be distributed by the Secretariat of Education of the State of São Paulo to public high schools. The program consisted in 16 hours of human sexuality (gender identity, gender role behavior, sexual orientation, childhood sexuality, adolescent sexuality, anatomy and physiology, condom use), 16 hours of AIDS (biological, psychological and social aspects), and 8 hours of teaching methodology and AIDS. The format included lectures, discussion and audiovisual presentations. A pre and post-test was applied and a subjective evaluation was required from each participant.

Results: 150 teachers were trained in 2 groups. Despite the fact that there was a significant increase in the knowledge about AIDS as seen in the post-test, the majority of the participants did not feel ready to pass the information to colleagues and students.

Conclusion: Training must be followed by a support program.

T.E.P.71

AIDS SERVICE ORGANIZATION: LESSONS FROM STRATEGIC PLANNING AND ORGANIZATIONAL DESIGN

Rector, Richard¹, Waylun, S², Gross S³

¹Health Consultant - AIDS, ²World Health Organization, Regional Programme on AIDS, Copenhagen, Denmark ³World Health Organization, Geneva

Objective: To identify strategies to deal with the evolving organizational and management issues identified by AIDS Service Organizations as priorities.

Methods: Outcome of a meeting of AIDS service organization in Vienna, Austria, 28 February - 3 March 1989. Forty organizations from 23 countries were represented.

Results: The capacity of AIDS service organizations to initiate, fund and manage programs was being reached. Strategic planning and organization design are prerequisites to overcome organizational and management challenges.

Conclusions: AIDS Service Organizations have the technical expertise to provide client services. However, their organizational objectives must be clarified, administrative frameworks delineated and resources better allocated.

Le SIDA, la société et le comportement AIDS, Society and Behaviour

T.E.P.68

RECHERCHE D'UNE STRATEGIE DE COMMUNICATION EFFICACE CONTRE LE SIDA

Ducloux, Bernard, Université Laval, Québec, Canada.

Objectif: Déterminer pourquoi les reportages et les campagnes de communication d'ont pas réussi à changer les comportements des individus dans les pays occidentaux.

Méthode: Comparaison des études sur la mémorisation des messages et les changements de comportement des individus.

Résultats: Un sondage Gallup mondial de janvier 1988 estime que 80% de la population des 40 pays interrogés ont au courant du SIDA. Le taux de mémorisation des campagnes anti-SIDA en 1988 s'éleva à plus de 70%. Mais la crainte d'être contaminé par le virus est de 10% en moyenne. Pourquoi?

1. Le SIDA est la maladie des autres. Les campagnes sont faites pour nous dire comment nous protéger.

2. Les campagnes anti-SIDA sont confrontées aux valeurs religieuses et sociales de chaque société.

3. Toutes les campagnes ont été orientées vers les changements de comportement, ont été de nombreuses années à se réaliser (la cigarette).

4. La résistance aux politiques publiques à parler de sexe.

Conclusion: Les stratégies anti-SIDA ne le SIDA ne sont pas efficaces car on a sauté l'étape de l'information sur le SIDA pour parler des moyens de s'en protéger.

T.E.P.70

AIDS - NEW TYPES OF PUBLIC HEALTH PROGRAMS IN WEST-BERLIN

Anders, Rüdiger, Bergmann, J., Henschel, H., Giese, P.¹

¹Working Group AIDS of the State Department for Health and Social Affairs of the Berlin Institute for Tropical Diseases, Berlin, F.R.G., ²Max von Petten, Berlin, F.R.G.

Objective: How serious are they in the context of AIDS only those measures can be effective which consider and accept individual needs and conditions of the different target groups. Public health institutions therefore have to develop new types of programs based on this principle.

Methods: In West-Berlin 3 programs have been implemented in this sense by support of the Working Group AIDS of the Department for Health and Social Affairs of the Tropical Diseases.

1. Since May 1987 an AIDS Information Program for Schools, carried out by specially trained voluntary groups of teachers (volunteers).

2. since May 1987 a "Prevention Abstinence Program" for prostitutes in danger of infection from clients; as the main method: 100% abstinence with an anti-fall-back group for prostitutes.

3. since Oct. 1987 a Health Information and Counseling Team (1 doctor, 1 psychologist, 1 nurse and 1 social worker) for the staff of local outpatient services.

Results: until Dec. 31, 1988: 1. About 6700 students aged from 13 to 22 were given instructions on sexually and AIDS during normal lessons. Their level of information has considerably increased. 2. About 300 women could be offered employment which would not be subject to sex prostitution voluntarily. The on-call-out service was only to 70%. 3. About 200 staff members of local outpatient services could be instructed and encouraged to accompany patients with HIV and AIDS into their routine of daily practice.

Conclusions: The obvious success of these new types of measures - all of them are accompanied by scientific evaluation studies - indicates the possibility of developing similar target group-linked programs in other big city areas with large numbers of people with HIV and AIDS. Such programs can possibly serve as prototypes for further public health strategies.

T.E.P.72

PLACING EDUCATIONAL INTERVENTIONS WITHIN THE CONTEXT OF COMPREHENSIVE SOCIAL POLICIES TO REDUCE THE SPREAD OF HIV INFECTION.

Reuter, A., Shitka, M., The Hebrew University & Hadassah Faculty of Medicine, Jerusalem, Israel.

Objective: To assess if there are no bio-medical means to either prevent HIV infection or cure AIDS, it is a mistake to assume that the only, or even dominant means available to reduce the risk of HIV infection are educational. Other means which could be used from the basis for a comprehensive social policy are sometimes. These are both of a "Health Promotion" and a "Health Protection" nature, sometimes combining elements of both in one measure. I propose to consider the following measures as examples of the elements that can compose such a policy and to consider their implications and ramifications: 1. the direct and indirect use of medico-economic and socio-economic incentives, among vulnerable groups, to promote early testing and recruitment into preventive programs; 2. lowering economic and social barriers to the use of risk-reducing measures; 3. feeding drug addiction socially as a disease and address it as ill people, rather than criminals, while keeping an authorized drug production and distribution illegal; and, 4. considering and studying different strategies to free or at-cost distribution of injectable drugs under medical supervision, within comprehensive programs, as part of the effort to stem the spread of HIV infection among IV drug users.

Among the implications which I intend to discuss are: possible objections from established social power and professional groups; reactions of organizers; influence on drug addiction and on drug-related crimes; and, the influence on disadvantaged groups.

Session d'affichage Poster Session



Le SIDA, la société et le comportement AIDS, Society and Behaviour

Éducation (partie 2) Education (Part 2)

W.E.P.1

STRUCTURE OF AMERICANS' KNOWLEDGE REGARDING TRANSMISSION OF HIV INFECTION: IMPLICATIONS FOR TARGETED EDUCATION.
Sullivan, Varda, Schell, B.J., Aral, S.O., and Bowen, G.
Centers for Disease Control, Atlanta, GA USA

Objective: To identify racial and ethnic differences in underlying basic conceptual components of knowledge about modes of HIV transmission.
Method: We analyzed responses of 17,699 adults to the AIDS Knowledge and Attitudes Supplement of the 1987 National Health Interview Survey, drawn from a nationally representative sample of households. Underlying components of knowledge about HIV transmission were identified separately for Blacks, Hispanics, and Whites, using principal components analysis.

Results: a) The proportion of correct responses was significantly higher for Whites than Hispanics and Blacks, on some items, such as who was most at risk for AIDS (41%, 51%, 50%, respectively, p<0.05), and transmission via mosquitoes (31%, 24%, 24%, respectively, p<0.05) b) Despite differences in levels of knowledge, similar underlying components, which accounted for the same proportion of total variability, were identified in all three groups. They were: general misconceptions of HIV transmission (explaining 31% of the variability), followed by very risky behaviors (13%), transmission via body fluids (9%), transmission via sex and mosquitoes (7%), and transmission without physical contact with a person with AIDS (7%).

Conclusions: 1) Areas in which Blacks and Hispanics have less knowledge than Whites should be addressed through content specific educational interventions targeted to the group. 2) Future educational messages should be prepared in accordance with the basic conceptual structure underlying cognition of transmission.

W.E.P.3

BIDN, ÉPIDÉMOLOGIE ET CULTURE EN AFRIQUE CENTRALE
BIDN, EPIDEMIOLOGY AND CULTURE IN CENTRAL AFRICA

Dr. Jean-Marie Mouton, Dr. Roger Nkomo, Dr. Raymond Nkomo, Dr. Jean-Marie Mouton

School of Public Health, Boston, USA; ** Institut Démographique National, Kinshasa, Zaïre; ** Institut Démographique National, Kinshasa, Zaïre.

OBJECTIFS: Comprendre la construction culturelle du BIDN et ses relations avec les pratiques sexuelles, la procréation, le mariage et les croyances communes afin de faire face aux contraintes de la prévention.

MÉTHODES: Observation-participative, entretiens en profondeur, récits de vie, lectures bibliographiques, analyses de documents, recherche-action psychosociale.

RÉSULTATS: Des valeurs ancestrales telles le casier de procréer beaucoup d'enfants, des croyances telles les liens entre la sexualité, la santé et la procréation et le caractère des relations sociales entre hommes et femmes, rendent difficile l'adoption du condom ainsi les croyances stables ont une procréation reproductive est déjà dépressive.

CONCLUSIONS: L'ethnographie et la recherche-act qui associe les intérêts à la résolution pratique des problèmes sont indispensables pour comprendre la portée du BIDN et limiter son extension dans la région. Elles démontrent la limitation des méthodes de prévention actuellement employées et suggèrent de nouvelles approches.

Mots-clés: sociologie, couples stables, prévention, méthodologie

W.E.P.5

TITRE : L'INFORMATION ET LA PRÉVENTION DU SIDA
ANALYSE COMPARATIVE DE DEUX PROGRAMMES NATIONAUX D'ÉDUCATION POUR LA SANTÉ EN AFRIQUE CENTRALE ET DE L'EST AFRICAINE

Dr. Denise Hertzog**

** NPS - OMS - GENÈVE

** Directeur de l'Éducation Pour la Santé - SERCAL

et Coordonnateur Programme SIDA Nihilus Centralafricain.

OBJECTIF: Comparer les programmes nationaux en identifiant les similitudes et différences d'approche éducatifs et les résultats obtenus à la phase initiale, afin de proposer les principes directeurs méthodologiques par une action de mobilisation sociale en vue d'un engagement de comportement.

MÉTHODE: Analyse des choix de politique éducative en fonction des contextes socio-culturels, démographiques et organisationnels de ces pays. Analyses des moyens globaux (par 1000 habitants adultes) et distribution par genre cible et par structure organisationnelle.

RÉSULTATS: Avec des objectifs généraux similaires, on constate une grande différence d'approche entre les programmes d'information, la participation de tous les secteurs de planification éprouve ces différences et facilite la mise en oeuvre des programmes. L'information médiatique est toujours limitée par des résistances culturelles religieuses et institutionnelles. Elle ne permet la contextualisation et l'intégration, que renforcée par une stratégie de promotion de santé.

CONCLUSION: C'est à partir de la mobilisation participative qui, progressivement, les activités I.E.C. développées dans les réseaux et services existants dans le secteur santé et, au-delà dans les secteurs de développement et les réseaux actifs-de-la-société

W.E.P.2

AIDS ACTIVISM: A MEANS FOR PRODUCTIVE CHANGE TO PROMOTE CLINICAL RESEARCH AND DRUG DEVELOPMENT.
William B. Mahlum, Veterans Gay and AIDS Activist,
A founding member of the Lavender Hill Mob, the Lavender Hill Education Project and the AIDS Coalition To Unleash Power (ACT UP), U.S.A.

Objective: To explain the positive role individuals can play in defining issues and setting national research agendas to promote a speedier and more humane process to develop drugs for the antiretroviral.

Methods: Through practical experience the presenter will explain the importance of careful development of positions, organizing out-of-classroom, interactive leaflets and the carrying out of sensitive and creative actions. Sample copies of leaflets and press clippings will be made available to those attending this session.

Results: A number of specific victories and failures of AIDS Activists efforts will be discussed.

W.E.P.4

LA SOCIÉTÉ SÉNEGALAISE FACE AU SIDA.

Dr. M. Ndiaye, Dr. M. Sarr, Dr. Fall, Dr. Touré, Dr. B. Ndiaye
Unité de recherches épidémiologiques et statistiques, DAST/Ministère du Plan et de la Coopération, Sénégal.

Objectif: Evaluer la compréhension du SIDA pour une prévention efficace.
Méthode: Enquête à bas et à proche buteaux auprès d'un échantillon de 5000 (5158 et plus)** Les méthodes statistiques de traitement (SPSS) et d'analyse factorielle des correspondances des variables.

Résultats des résultats: ** 12,6 % de la population ont une bonne connaissance de la transmission du virus, les sexes informés l'ont été par les journaux (3,2 % contre 7,2 % par la rumeur publique). Une bonne connaissance semble indiquer des comportements d'évitement du risque. Dans le groupe bien informé, 62,2 % ne s'exposent pas au danger contre 57,8 %, alors que pour les mal informés, les proportions sont de 56,3 % contre 43,7 %. Ces personnes, mal informées, sont peu disponibles au préservatif (64,9 %) et aux mesures préventives générales (51,7 %). Une bonne connaissance de la transmission est corrélée avec les catégories socio-professionnelles : 76,5 % des cadres moyens sont bien ou assez bien informés contre 32,5 % des sans profession.

Conclusion: L'enquête réalisée avant le lancement de la campagne nationale d'information montre que la population de la capitale est globalement mal informée. Les résultats de cette étude devraient permettre la mise en oeuvre d'une politique de prévention plus adaptée tenant compte des contraintes identifiées dans cette étude.

** erreur type réelle inférieure à 1 %. ** Niveau de signification = 5 %

W.E.P.6

Computer Simulation as a Tool to National Problem Awareness.

ASA, Arendal, **Arvidsson, Jose J., Myrvang, M., Vavik, L.,**

University of Applied Sciences, Høgskolen, Norway.

AIDS has given rise to unfamiliar problems. Knowledge of epidemiological facts and interrelations had become less important, for epidemics were supposed to have become a thing of the past, and have just any importance they may once have had for modern society. The appearance of a sexually transmissible disease for which it is hardly likely there will be a cure or a vaccine in the near future came unexpectedly.

Using novel methods we address the crucial problem of educating the public in order to reduce the spread of HIV through behavior change and appropriated measures. It is now possible for any school to have a personal computer (PC). One has in this way access to data processing equipment which only 15 years ago would have served a whole university. The advantage of such computers is that they can rapidly process huge amounts of data and, if the user so decides, carry out simulations of complex situations. Our program, AIDS Information, Modification and Simulation (AIMS), is a user-friendly program for schools and (in an advanced version) for doctors and medical personnel. It offers geographical, demographic and epidemiological facts; the freedom to focus these facts in any way the user chooses; the means of representing them in plastic form; the chance to undertake and explain to others their interrelations, and to represent concretely their abstract significance for individual behavior.

Session d'attachage Poster Session



Le SIDA, la société et le comportement AIDS, Society and Behaviour

W.E.P.13

THE USE OF INDIGENOUS WORKERS FOR AIDS OUTREACH
EDUCATION/PREVENTION
Aster, Rebecca S.
NATIONAL Institute on Drug Abuse, Rockville, Maryland USA

Objective: To present issues and solutions for hiring and training local persons outreach workers.
Methods: By anecdotal information gathered by informal survey with 58 sites around the USA in AIDS funded programs who have hired at least one indigenous outreach workers.
Results: The foundation of 58 AIDS funded outreach research demonstration projects rests on indigenous (ex-addicts) outreach workers to educate and motivate addicts who are not in treatment and their sexual partners to change their AIDS behaviors. Because of their ex-addict background, these outreach workers present a unique challenge to program management in terms of (1) hiring; (2) orientation; and (3) training. In addition, program management must confront ethical issues because of exposure to workers of dangerous drugs, medications, exposure to an atmosphere where the workers are vulnerable to relapse, and helping workers who contract AIDS because of past risky behavior.
Conclusions: All outreach workers need to be aware of these issues and develop policies and strategies which are specific to this population of employees. Suggestions include special attention to job descriptions, the interview and hiring process, time management, development of career ladders and management of staff contamination and anger. Reassignment should also be prepared to help staff develop writing and communication skills.

W.E.P.15

EDUCATION STRATEGIES FOR HEALTH CARE WORKERS AND PRISONERS IN MALES. GEORGE, A.B., WELSH O'LEARY, GARDIFF, WALES AND GRIFFITHS, T.D. WEST GLANMORGAN HEALTH AUTHORITY, SWANSEA, WALES

OBJECTIVE: To describe methods of providing regular updates of information on AIDS to two specifically targeted groups.

METHODS: (1) Health Professionals: a core team with expertise in epidemiology, research, health promotion and nursing was established by professional organizations and a Government Department. The team visits each health authority on a regular basis at approximately six monthly intervals as a "road show". Health care workers from many disciplines attend.

(2) The programme for prisoners is targeted at short-stay young offenders and long-stay adult prisoners. Issues covered are drug abuse, other sexually transmitted diseases and AIDS. The approach has recently been changed to target prisoners just prior to release so as to maximize the impact. This programme is run by a health promotion officer not a multi-disciplinary team.

RESULTS: Several thousand health care workers have participated and demand continues to increase. This programme has run for 2 years, as has that for prisoners.

CONCLUSIONS: A small multi-disciplinary core team is an effective way of regularly updating health care workers. Prisoners require a more intensive approach and the use of a dedicated health promotion officer has been found effective.

W.E.P.17

EVALUATION OF AN EDUCATIONAL PROGRAM
KNOWLEDGE, BELIEFS, ATTITUDES AND BEHAVIOUR
ABOUT AIDS IN THE 147000 AIDC GROUP.

Böhm W., Hochmann W., Hübner B., Seyen R.***
Sen.F.Schäwe-Berlin** *BGA-AIDS-Zentrum *FEDERAL REPUBLIC OF GERMANY
tagl.*WHO/CDC Come Paris, FRANCE

Objective: To assess the KNOWLEDGE, BELIEFS, ATTITUDES AND BEHAVIOUR of 147000 students from 1470 schools in Germany. (Böhm W. 1987) and the optional school program to inform on AIDS by social trained physicians or biologic teachers.
Methods: Knowledge about transmission, risk factors, use of condoms, attitudes, beliefs and former sexual education were collected by a questionnaire with standardized and open questions before(n=770), four weeks(n=572) and six months(Sept.88) after(n=431) the lessons.
Results: After six months there was a higher acceptance of using condoms, and still very high level of information about ways of transmission and risk factors. Coping with fear, confidence, stable partnership, communication and the composition of aids condoms are most important factors to prevent HIV-infection. Only 11% proposed instead of enlightenment, measures of repressive control. Although 90% of the students had sexual education <2% had learned to speak about feelings and emotions related to sexuality. Students would not isolate HIV-persons.
Conclusions: Six months after the AIDS information lesson students still have a high level of AIDS related information and competence. They are interested in more lessons about sexuality and partnership, and about AIDS as a social problem. The approach of "personal prevention" is a necessary measure, which leads to better the preventive information given by the mass media ("massive prevention") and the necessary preventive acting of adolescents.

W.E.P.14

AN INFORMATION, EDUCATION WORKSHOP TO INCREASE CONDOM USE AMONG MALE BAR WORKERS IN BANGKOK
HERASITY SUWITTAI, NODDY RV*, Center for AIDS Research and Education, Bangkok, Thailand; **Festy Health International, North Carolina, USA.

Objective: To evaluate a workshop for increasing condom use among men who work in bars and who are at risk for HIV infection.
Method: We conducted workshops in 3 bars and 2 bars served as controls. The workshop consisted of a play, a video of an interview with that person with AIDS and an informal question and answer period. Free condoms and lubricants were provided in all study bars during the study. We compared knowledge about HIV infection, attitudes about condom use, reported condom use and sexual practices.

Results:

	Pre-workshop	Post-workshop	Survey	Control
Knowledge Score, Mean(Kang) 8.1(3-14)	8.1(3-14)	9.6(5-14)	8.6(3-13)	8.6(3-13)
Attitude Score, Mean(Kang) 4.6(1-6)	4.2(1-6)	4.6(1-6)	4.6(1-6)	4.4(1-6)
Customer used condoms	214	278	474	574
Bar worker asked customer to use a condom	554	444	474	584
Bar worker used condom	424	374	474	524

Pre- vs post-workshop in study: group-1) 1) expect vs control; group post-workshop. **p<.05 pre vs post; survey in control group.
Conclusions: The workshop was able to increase the knowledge about HIV infection but changed attitudes about condom use little. Unexpectedly, condom use increased more in the control than in the experimental group.

W.E.P.16

LES SERVICES À DOMICILE: LA PERSONNE CILIBOISE.
Duroan, Céline; Oursenan, A; Fortin, R.; Gagnon, P.; Chénier, J.-J.
CLICC Méro (Centre local de services communautaires), Québec, Canada

Les services à domicile. Le CLICC Méro est un organisme para-public qui offre des services de soins et de services sociaux courants à sa population. Le CLICC dispose d'un programme de services à domicile que les équipes d'infirmières, physiothérapeutes (auxiliaires familiales, ergothérapeutes, infirmières, infirmières, physiothérapeutes et travailleurs sociaux) visitent des personnes ayant besoin d'aide dans leur milieu de vie. Actuellement, une vingtaine de aidés requièrent ces services. Cette situation représente un défi à la fois personnel, professionnel et organisationnel.
Problèmes identifiés. Les personnes atteintes de SIDA font face à des problèmes d'ordre physique et psychosocial tandis que les intervenants pour leur part, vivent des situations nouvelles, parfois difficiles et stressantes. Ces faits de fait demandent des ajustements à l'organisation fonctionnelle par les équipes d'intervenants habilités à travailler à domicile avec une clientèle âgée et handicapée.
Éléments du modèle d'intervention. Le modèle personnel fait appel à divers éléments et ressources qui ensemble, contribuent à l'amélioration des conditions de vie des aidés et à domicile et à la qualité des services. Ces éléments sont: l'approche globale, les liens avec les ressources médicales et communautaires, la concertation de l'équipe, la formation et le financement.

Conclusion: C'est le personnel d'abord, en tant qu'individu, qui est considéré dans l'approche et c'est la vie et non seulement le maladie qui détermine les interventions. Les six éléments du modèle d'intervention ne doivent pas être examinés séparément mais faisant partie d'un tout. Ils sont indispensables afin de relever le défi de façon optimale et afin de maintenir une plus grande qualité de services auprès de la clientèle aidée.

W.E.P.18

SCHOOL AND COMMUNITY PARTICIPATION IN AIDS EDUCATION
MARK J. ARON, Chairman, AIDS Education Task Force,
Sydney Catholic Education Office, Sydney, Australia.

OBJECTIVE: To develop and implement a comprehensive education program, teaching knowledge, skills and values about AIDS for students aged 5 to 18 years in a large school system, and through teacher education and school-based parent meetings, to reach out to the wider community with AIDS education.

METHODS: During 1987 a comprehensive teaching kit consisting of print and audio visual materials was produced to teach, both about HIV infection, and how to care for people with AIDS. It is a resource-based, interactive approach which not only provides knowledge about AIDS, but also teaches skills (eg communication, decision-making, assertiveness) and values (eg love, respect for human dignity, compassion, hope) in response to the AIDS crisis. In early 1988 implementation of the program began, after a series of intensive 4 hour teacher education sessions ensured that every school had at least one member of staff trained to use the kit to educate their staff, parents, community members and students.

RESULTS: Over 50% of the 200 Sydney Catholic schools began AIDS education using the kit in 1988 for activities including teacher education, community meetings and integrating AIDS education for students into all relevant areas of the curriculum. The success of elementary schools was particularly impressive. There is continuing widespread use of the audio-visual systems and health education in the teaching kit.
CONCLUSIONS: Successful teaching and values education programs about AIDS are essential. Schools can provide AIDS education for the community.

Session d'affichage Poster Session



Le SIDA, la société et le comportement AIDS, Society and Behaviour

W.E.P.19 KNOWLEDGE AND ATTITUDES OF ITALIAN YOUTH ABOUT AIDS
(Co-ordinator: Rosalinda Fresco, R.; Mattioli, G.;
Caldesi, M.; Nio, C.R.)
Dpt. of Biomedicine, University of Pisa, Pisa, Italy.

Objective. To evaluate the effects of educational campaigns about AIDS on the awareness and the perception of the problem by the youth.
Methods. A self-concept questionnaire was administered to 3300 Navy recruits and to 2437 high school students from the city of Pisa.
Results. Fifty percent indicated newspapers and TV television as major sources of information, only 14% the school. The information provided was judged sufficient and easily true, useful and clear; nevertheless most people (90%) requested further information mainly from doctors. On the whole, knowledge about the etiologic agent, mode of transmission and risky behaviour was satisfactory, while clinical symptoms, vehicles of infection and preventive measures appeared less well known. There were, however, marked differences between the two groups in terms of residence: youth from Northern and Central Italy with upper instruction showed a more precise perception of the AIDS problem. Concerning psychological reactions, 60% declared some impact on their social life, but there were again considerable differences among different groups.
Conclusions. The study indicated the need of systematic and continuing results of educational campaigns in order to correct possible errors in information strategies.

W.E.P.21 PEDIATRIC AIDS SOURCEBOOK
Allibonati, Rosalinda, J.A.
National Association of Children's Hospitals
and Related Institutions, Alexandria, Virginia, USA

Objective. To assist hospital and community-based agencies in planning programs of care for children with AIDS and HIV infection.
Methods. Nineteen programs in areas of high incidence of HIV infection providing pediatric care were identified and surveyed. A review of literature and interviews were conducted. Information was then assembled, documented and disseminated.
Results. The sourcebook is a compendium of current principles, plans and interdisciplinary programs that may be used as models of comprehensive care for children in primary, secondary and tertiary health care settings.
Conclusion. Many programs provide care in a variety of ways to HIV infected children. Common factors found include an interdisciplinary team working in a coordinated effort to provide comprehensive, child-centered, family-focused intervention to meet the complex needs of these special children and their families.

W.E.P.23 AIDS INFORMATION IN FRENCH SCHOOLS: AN EXPERIENCE AND A SOCIOLOGICAL VIEW
Bouquet, Françoise; Kalamazoff, M.***; Crispin, S.***;
L'Yvignat, C.; Moreaux, D.; Delamarre, A. et al.
* Unité d'Onco-Hématologie, Hôpital St-Jacques, Paris, France.
** Santé scolaire du Rectorat de Paris, France.
*** Santé scolaire du Rectorat de Créteil, France.

Objective. To evaluate an AIDS information model for youth at school.
Methods. During the school year 1987-88, 4500 students from Paris and suburbs, from 13 to 25 years old received a pilot information. This model was personalized, supported visually by video 8 slides and dramatic but non-formal, e.g. suggesting questions and dialogues among the classes.
Results. 1707 open questionnaires have been answered: 1512 by students who followed the information (mean age = 18; sex ratio = 1/2). 186 by "control" students (mean age = 18; sex ratio = 2/3).
Results. 1/ If the information model improved the students' recognition of risks related to the frequent change of sex partners. 2/ It convinced them that condoms are efficient if of good quality and used correctly. 3/ However, the model did not change their intention (74% in both groups) of using one in a "one-night stand with an unknown partner", as described in the questionnaire. 4/ The model did not change use of existing condoms and mutual respect of each partner.
Conclusion. This information model improves the global understanding of AIDS among the students, without knowing if they will lead to a new behavior, some intentions expressed are encouraging: to refrain from one-night stands, to use a condom also for contraceptive aims to protect the partner whenever there is a doubt about one's own sexual history.

W.E.P.20 PREPARING TEACHERS FOR ADOLESCENT AIDS PREVENTION EDUCATION: YEAR TWO OF THE MASSACHUSETTS TEACHER TRAINING DESIGN

Bevelli, Gerald M.*; Greenston, K. and Rosenfield, S.***
*Massachusetts Department of Education, United States
**Massachusetts Department of Public Health, United States
***Massachusetts Department of Education, United States

Objective: To describe the effectiveness of a split three day teacher training on 1) their knowledge and attitude (related to AIDS), 2) their confidence for doing AIDS education, and 3) the impact of utilizing a Person With AIDS (PWA) in the team training design.
Methods: Fifty-three school districts participated. Changes in knowledge, attitudes and confidence levels were measured by pre-post-testing. Subjective feedback forms measured the effectiveness and utility of the training activities. The initial two day training included basic AIDS information, health behavior change strategies, effective education techniques, human sexuality, and interaction with a PWA. The third day, held 6-8 weeks later, covered grades K-12 learning activities, parent education strategies, and an opportunity to report on the process and progress of their AIDS education efforts within their respective schools and districts.
Results: A total of 210 faculty were trained. Statistically significant gains were noted regarding teaching strategies for working with HIV and AIDS diagnosed students and co-workers, answering questions about HIV transmission, and teaching about AIDS. Regarding the training activities, interacting with a PWA received the highest ranking for personal impact.
Conclusions: The split three day training design, and interacting with a PWA, has proven an effective methodology for increasing AIDS related knowledge and confidence. ~~Methods, results, and conclusions about the use of a PWA in the training design.~~

W.E.P.22 KNOWLEDGE AND ATTITUDE TO AIDS SHOWN BY UGANDAN SCHOOLCHILDREN, BASED ON A NATION-WIDE POSTER COMPETITION
Mueller, Olga*; Labega, J.*; Senoga, J.*
*League of Red Cross and Red Crescent Societies, Geneva, Switzerland
**Uganda Red Cross Society, Kampala, Uganda.

Objective. To determine the knowledge and attitudes of youth in Uganda concerning AIDS-prevention and -patient care after one years education campaign in the country.
Methods. On 1. 12. 1989, World AIDS poster day, Uganda Red Cross carried out a nationwide AIDS poster competition on the themes of AIDS-prevention and -patient care. The contents of the posters have been evaluated.
Results. Out of 6 major cities in Uganda, 20 schools contributed 97 posters. The median age of participants was 14 yrs. 85% mainly described AIDS-prevention as keeping to one partner, whereas only 3% emphasized the use of condoms. 17% insisted mainly on the use of sterile instruments. 100% of the children promoted the importance of caring for AIDS patients, emphasizing close relation, good food and medical care. The main problem, in 6%, was that the carrierstate of HIV infection was not fully understood.
Conclusion. The poster contents reflect the current state of the AIDS education program in urban Uganda. Schoolchildren have good knowledge and a positive attitude about AIDS.

W.E.P.24 AN HIV/AIDS EDUCATION AND TRAINING PROGRAM FOR LAW ENFORCEMENT OFFICERS
Middell, Willem Jaffe, B.*; Fedriche, R.***; Hancock, D.***
*City of Toronto Department of Public Health, Toronto, Ontario, Canada.
**Metropolitan Toronto Police, Toronto, Ontario, Canada.
***Metropolitan Toronto Police, Toronto, Ontario, Canada.

Objective. To give police officers sufficient understanding of HIV transmission and prevention for them to operate confidently and appropriately.
Methods. 10-week training video series and a public health educator (PHU) were developed by police and public health officials for use in an established decentralized police training format. Each session was conducted jointly by a PHU and a police sergeant (Sgt.) and a public health educator (PHU).
Results. From January to June 1988 all uniformed officers D-9600 of the Metro Toronto Police underwent the HIV/AIDS training module. Each of the municipal public health units participated in the sessions conducted within the jurisdiction of the metropolitan area covered by the police. New police procedures were developed within the context of a comprehensive Police Dept. Training Prevalence on Infection Control and the Metro Toronto Corporate Policy on AIDS. Procedures and policies were reviewed by the PHU while the PHU covered the curriculum on AIDS; both could then respond to questions. Prior to the implementation of this program there were numerous complaints from officers about possible HIV exposures and some community incidents. Following implementation there have been no complaints or criticism inside the Force or from the community, and appropriate contact have been maintained when blood-related incidents involving officers have occurred.
Conclusion. A highly organized and cooperative effort between local law enforcement and public health authorities has resulted in a decentralized HIV/AIDS training program that is concise and effective.

**Session d'affichage
Poster Session**

**Le SIDA, la société et le comportement
AIDS, Society and Behaviour**



W.E.P.49 A NATIONAL STRATEGY DESIGNED TO REMOVE BARRIERS IMPEDING THE EFFECTIVE HIV EDUCATION OF YOUTH: FIRST YEAR'S ACHIEVEMENTS

Diane G. O'Neil, Ph.D., Kelly J. Pankler, D.Sc., Pam. J. Kolbe, Ph.D., Division of Adolescent and School Health, Centers for Disease Control, Atlanta, Georgia, USA; Robert A. Hays, Ph.D., Center for Disease Control, Atlanta, Georgia, USA; Robert A. Hays, Ph.D., Center for Disease Control, Atlanta, Georgia, USA

Objective: To describe the first year's achievements of a national strategy designed to overcome major barriers hindering implementation of effective HIV education for youth. **Methods:** In 1984, the Centers for Disease Control (CDC) sponsored 2 national efforts to identify barriers hindering implementation of effective HIV education for youth. Participants identified as major barriers the lack of 1) regional support from national education organizations; 2) educational policies, guidelines, and recommendations; 3) parental involvement and support; and 4) data describing HIV-related knowledge, attitudes, and behaviors among youth. The effectiveness of educational interventions to influence these factors. CDC initiated a national strategy supporting 1) a system of national educational organizations; 2) a system of national educational organizations; 3) a system of national educational organizations; 4) a system of national educational organizations. These education agencies provided effective HIV education for youth. National educational organizations provided national training for educators and 13 regional training organizations provided regional training for educators and 13 state training organizations provided state training for educators and 13 city training organizations provided city training for educators and 13 city training organizations provided city training for educators. **Conclusions:** First year's achievements rapidly reduced the first 3 barriers. This strategy may have applicability in nations that provide national-level support for implementing HIV education for youth.

W.E.P.50 A NATIONAL STRATEGY FOR THE DEVELOPMENT OF PROGRAMS ON SCHOOL HEALTH IN 1974: A NATIONAL STRATEGY FOR THE DEVELOPMENT OF PROGRAMS ON SCHOOL HEALTH IN 1974

Sheffield A.***, Kelly J. Pankler, D.Sc., Jones, J.; Jobb, W.; Martins, J.;***, Division of Adolescent and School Health, Centers for Disease Control, Atlanta, Georgia, USA; Robert A. Hays, Ph.D., Center for Disease Control, Atlanta, Georgia, USA; Robert A. Hays, Ph.D., Center for Disease Control, Atlanta, Georgia, USA; Robert A. Hays, Ph.D., Center for Disease Control, Atlanta, Georgia, USA

Objective: To describe a national model for the development of programs on school health education to prevent the spread of HIV infection. **Methods:** In 1974, the Centers for Disease Control (CDC) began providing technical and financial support to 1 local and 2 state education agencies that had the experience and capacity to help others plan, implement, and evaluate HIV education programs for youth. Each agency provided training for educators and 13 regional training organizations provided regional training for educators and 13 state training organizations provided state training for educators and 13 city training organizations provided city training for educators. **Conclusions:** This national model of educational training and technical support may have applicability in nations that provide national-level support for regional training/demonstration programs.

W.E.P.51 COMPARATIVE RISK PERCEPTIONS AND STD IN TWO DIFFERENT SOCIO-ECONOMIC GROUPS

Owens, Edward, Managosa, J., Aedeago, A., Surocinan, A., and Soyinka, K.

Chiefed, Awolowo University, Ibadan, Nigeria

Objective: To compare the level of awareness, cultural and social practices as well as attitudes to AIDS and STD in two different socio-economic groups with a view of formulating appropriate health education messages for HIV prevention.

Methodology: Pretested and modified questionnaires were administered to 110 randomly selected undergraduates and also to 70% (purposefully) selected individuals of lower socio-economic status. Questions were designed to cover awareness, knowledge, practices on AIDS and STD, sexual habits and preferred modes of receiving health education as well as individual assessment of existing health education material on AIDS.

Results: Undergraduates exhibited more knowledge of symptoms and prevention of AIDS than the rural dwellers. Whereas, the former indulged in higher risk practices than the latter, undergraduates were more acceptable and used by the former than the latter. Undergraduates preferred to learn more about AIDS through electronic media and newspapers while the rural dwellers prefer community health talks.

Conclusions: Health education against AIDS must be targeted to meet needs of different groups. For rural areas with low AIDS prevalence, health education with emphasis on safe sex is important. Campaign against HIV infection ought to be integrated with Primary Health Services.

W.E.P.52 UN EXEMPLE DE COLLABORATION ENTRE MÉDECIN ET JOURNALISTE

FOURCROT, J. ET METTICAT, J. EDLMANN

CHU DE LYON, FRANCE

Objectif: Analyser l'interaction sur le site d'un hebdomadaire destiné aux homosexuels (Qui Plus) notamment par le biais de la page intitulée "Info-Sida" qui paraît deux fois par semaine. **Méthode:** Une collaboration étroite et régulière a été établie avec une association spécialisée sur l'éducation et la prévention du SIDA (A.S.A.) et, en particulier avec le rédacteur en chef associatif. Ce a été d'ailleurs possible de proposer des informations ou de faire établir par le praticien médical, les articles publiés ou de leur être écrits en commun par un journaliste et un médecin au cours d'entrevues individuelles. L'interaction est devenue régulière et a permis de publier des articles de grande qualité et de les rendre plus accessibles à un public plus large.

Conclusions: Une coopération étroite et régulière entre un médecin et un journaliste a permis de publier des articles de grande qualité et de les rendre plus accessibles à un public plus large. Cette collaboration a permis de publier des articles de grande qualité et de les rendre plus accessibles à un public plus large. Cette collaboration a permis de publier des articles de grande qualité et de les rendre plus accessibles à un public plus large.

W.E.P.53 COMPARISON OF AIDS KNOWLEDGE LEVELS AND BEHAVIORS IN SEXUALLY TRANSMITTED DISEASE (STD) CLINIC PATIENTS AND ALTERNATIVE TESTING SITE (ATS) CLIENTS

Day, J.; Dillon, B.; Ross, John; Kancher, L.; Rossman, L.; et al. MA Dept. Public Health, Boston

Objective: To compare levels of AIDS knowledge and behaviors in persons attending selected urban STD and ATS facilities.

Methods: From 7/88 through 10/78, 1,063 (338 ATS, 665 STD) self-administered surveys of AIDS knowledge, behaviors, and demographics were completed. Knowledge scores and behaviors were compared by clinic setting, sex, and race. Demographics for STD respondents (STD) showed greater proportions of males (62% vs. 13%), female (38% vs. 29%), and adolescent patients (19% vs. 28) compared to ATS respondents (ATS).

Results: Bivariate preference was more common in STD than ATS (93% vs. 68%). The groups were similar with respect to sexual partners, history of nonconcurrent STD, needle use, needle sharing, and prior antibody testing. Fewer STD indicated a desire for testing than ATS (45% vs. 97%).

Based on a 10-point scale, ATS rated self-perceived knowledge levels higher than STD (mean score, 4.5 vs. 5.7) and objective evidence of knowledge was greater in ATS for all questions. Among STD, knowledge levels were higher among whites than nonwhites. ATS reported sexual behavior changes (fewer partners, increased condom use) more often than STD (53% vs. 18% and 48% vs. 37%). Reductions in ATS in needle intravenous drug use (19%) were similar to STD (stopped 17%). STD increased needle sharing, 25% vs. 35%.

Conclusion: Compared to ATS (who are test seekers), STD need greater educational and behavior modification efforts to reduce AIDS risk.

W.E.P.54 WHAT KEEPS PHYSICIANS FROM TALKING ABOUT AIDS:

Barriers to AIDS Prevention Education

Alford, Michael W., MD, Kaiser Health Education, Permanente Medical Group, Oakland, California, USA.

The specific aims of this study were:

- 1) To find out if primary care physicians in a large HMO setting were providing AIDS risk reduction information to their patients, and 2) to identify barriers that might prevent them from providing this information.

An anonymous survey was mailed to 650 physicians in a large Northern California Health Maintenance Organization (HMO). A usable return rate of 63% (423/650) was obtained.

Statistically significant differences in the willingness to discuss AIDS with patients were found to exist depending on the physician's perception of the patient's risk for AIDS. Use of Pearson correlation coefficients found that the most often reported barriers of "lack of time," "more important health issues," and "the need for more reliable information" did not correlate as a deterrent to providing health education as much as reported discomfort with initiating discussions of sexual practices or drug use. Chi-square analyses showed differences in providing AIDS prevention education were not statistically significant by age, type of practice, or location (urban or rural) of practice. There were statistically significant differences for sex of the physician, number of AIDS patients in their practice, and knowing someone (friend, relative or colleague) with AIDS.

These findings changed the direction and emphasis of physician education programs and were an essential part of the needs assessment used to develop clinic services to enhance AIDS risk reduction efforts.

**Session d'affichage
Poster Session**



**Le SIDA, la société et le comportement
AIDS, Society and Behaviour**

W.E.P.61 THE JUDICIOUS USE OF HUMOR IN A CONDOM PROMOTION

CAMEROUN
Romney, A.M.; Kelleigh, B.M.; Welch, N.M.; Purdue, T.*
*University of Washington, Seattle, WA, USA; *Northwest
AIDS Foundation, Seattle, WA, USA.

The Northwest AIDS Foundation coordinates social services for people living with HIV/AIDS in the Pacific Northwest United States and sponsors skill-building workshops and mass media campaigns. The Be Well-Equipped media campaign (1987-8) was designed to promote consistent use of lubricants, spermicides and latex condoms. Humor became an integral part of this campaign based upon the belief that taboos about discussing condoms could most easily be abolished through humor. A community-based planning group helped the foundation to develop guidelines for using humor in AIDS prevention messages. Writer/Artist Lynda Barry created a series of condom promotion cartoons with titles such as: "Fascinating Condoms of the Future," "Can This Love Affair Survive?", and a Valentine's Day cartoon called "Born, Not Bought." Comments and testimony from the community was positive regarding this attempt to use humor in promoting safer sex. Guidelines for using humor in AIDS education will be discussed and the artwork for Be Well-Equipped will be displayed.

W.E.P.62 SIDAIDS: A COMPUTERIZED TELEPHONE AIDS INFORMATION & COUNSELLING SERVICE (TELEMA TIC)

Billon, P., Dackiw, S., Kavanagh, K., Champoux, J., Barbeau, T., and Demou, A.
*Communications Canada, Quebec, Canada;
*McGill Centre for Medicine, Ethics and Law, Montreal, Quebec, Canada.

OBJECTIVE: To describe a personalized telematics service providing information and advice on AIDS, accessible by the general public through any telephone (residential or public). Although the computer software and structure of the communications are complex, the service to users is highly user-friendly.
METHOD: A user consults the computer-driven service anonymously using a personal access code. The user can choose to communicate with a counsellor or a computer. The user receives replies to the following service(1) SIDAIDS communication clear and precise information on AIDS; and advice that take into account his or her personal situation(such as sex, marital orientation, etc.).
RESULTS: The equipment, computer programme and data collection are now defined that provide the following service(1) SIDAIDS communication clear and precise information on AIDS to anyone who consults the system about specific questions. This function is similar to the activity of many hotlines with respect to information on AIDS. In many cases, the user receives replies for personalization of the system without oversteering counselling(2) SIDAIDS promotes self assessment by the user or his/her coefficient. In many cases, the assessment involves several steps: each step covers a specific aspect of the individual case and includes educational elements(3) SIDAIDS establishes and maintains a continuing relationship between counselling and education, so as to foster changes in individual behaviour and thereby reduce the risk of contracting AIDS. In this regard, clients with "at risk" behaviour have priority access to the counsellor, and, as far as possible, a user in this category will have access, if he or she wishes, to the same counsellor, call after call(4) SIDAIDS permits a counsellor, at the user's discretion, to have access to all information ever entered by the user(5) SIDAIDS facilitates the collection of epidemiological and behavioural information for subsequent data analysis.
CONCLUSION: Principles are confirmed the feasibility and utility of the SIDAIDS mechanism.

W.E.P.63 Teduzo Gokubi, N. Kasimaini, E. Korosyiki*

THE KINSHASA CAMPAIGN IN HEALTH CITY PROJECT OF ZAMBIA

Sanitary-Epidemiological Station, Wodwa str., 40, 90-046 M66, Politicins of Zambia, Kinshasa, Zambia
OBJECTIVE: To describe the AIDS prevention campaign as one of very important tasks in the healthy city project of M66-Health for All by the year 2000.

METHOD: WHO/Unesco approach and principles for undertaking the health promotion of cities have been adopted. For the health surveillance the main AIDS risk group of about 500 nonorganised adult people has been chosen. They have been taught on AIDS, the healthy attitudes and risk behaviours by the questionnaire study.
RESULTS: The blood service intervention and health education have caused the implementation of AIDS precautionary measures among blood donors and drug abusers. AIDS problem is connected with the improvement of the survey on other groups. The questionnaire survey among adult risk group shows that their knowledge is on the sufficient level but their risk behaviours are unrelated to their knowledge as it is shown in the below table.
Condom use gives Do you use Are condoms Do you examine full security? Yes No Unknown Yes No Yes No Unknown Yes No Unknown
Is a lab? Yes No Unknown
Conclusion: The regular use of condoms should be practised especially by homo/bisexualists. They ought to receive them free.

W.E.P.64 EXTENDING THE ROLE OF AIDS HOTLINES IN AIDS PREVENTION PROGRAMS IN DEVELOPED AND DEVELOPING COUNTRIES

Saunders, Susan G.; Delquist, M.; Stein, J.; Cavanaugh, K.; Kavanagh, K.; Dackiw, S.; Billon, P.; Demou, A.*
*AIDS/CDC Project, The Academy for Educational Development, Washington, D.C.; *Brooklyn AIDS Task Force, New York; *National AIDS Committee, Trinidad and Tobago.

OBJECTIVE: To assess the role and function of AIDS hotlines in developed and developing countries.
METHOD: Literature review and in-depth interviews with key informants and hotline staff in community-based organizations and AIDS programs in the U.S., Mexico, Trinidad and Tobago, and Peru.
RESULTS: AIDS hotlines are an integral component of AIDS prevention programs in the United States, with operations at the community, state, and national level. Hotlines in the U.S. provide information dissemination, referrals, and listening support to callers. Hotlines also track trends in caller concerns, misperceptions, and service needs; and monitor levels of message awareness and recall provided through national information and education initiatives. Comparable programs which provide listening services and referrals are being established in several Latin American and Caribbean countries.
CONCLUSION: Hotlines are an important link in the communication chain to inform and support callers concerned about AIDS and HIV infection. Hotlines are frequently the first point of intake into the AIDS service support system in the U.S. In Trinidad and Tobago the hotline serves primarily as a listening support system, and in Peru it is being used to provide information to callers who are at high risk.

W.E.P.65 KNOWLEDGE AND PERCEIVED RISK OF AIDS AMONG THE LOW POPULATION OF KINSHASA, ZAMBIA

Bertrand, J.; Bakshuwidi, R.; Kinavidi, L.R.*; Balove D.; Kasimaini N. and Chivesa C.*
*University of Washington, WA, USA; *Projet des Services de Reinsertion D'adultes (PRSD), Kinshasa, Zaire.

OBJECTIVE: To measure knowledge of AIDS, level of perceived risk, and factors influencing perceived knowledge and perceived risk.
METHOD: Based on probabilistic sampling, 2085 men and 3661 women of reproductive age were selected for this 1988 survey.
RESULTS: In Kinshasa, 88% men and 96% women have heard of AIDS. Among these, nine in 10 men and women know the four main modes of transmission. Knowledge of specific facts about AIDS is higher among men than women, among the more educated, and among the age group 20-40. Forty-seven percent of men and 62% of women believe they are at no risk of contracting AIDS. Perceived risk was highest among those who had extramarital relations, were more educated, were 20-40, and had seen messages on AIDS through multiple channels. However, knowledge of the specific facts relating to AIDS was not associated with perceived risk.
CONCLUSIONS: Educational efforts have succeeded in informing the public of AIDS and the modes of transmission. Future campaigns should promote greater use of condoms, stress the absence of a vaccine or cure, and focus special efforts on the young, unmarried population that seemingly deny their risk of AIDS.

W.E.P.66 SECONDARY SCHOOL STUDENTS AS AIDS HEALTH PROMOTERS FOR AN ILLITERATE RURAL WEST AFRICAN COUNTRY

Bessell, Brian; Deaby, A.; and Kama, P.
Eastern Province AIDS Committee, Selbywa, Sierra Leone, W. Africa

In rural areas of Africa, where most of the population is illiterate and mass media are not available, AIDS health promotion is often difficult. Literate young people make up a small proportion of the population, but they traditionally bring news and information when they return to their villages. We recruited secondary school students, training them as pretested pamphlets and photovideos to teach villagers about AIDS. The young people used mass posters, radio, creative songs and dramatic presentations. A pilot programme showed that information about AIDS transmission and prevention was successfully conveyed by these means, but that the young people most often shared information with semi-literate people. The materials and training programme were redesigned so that the audience reached would be larger and more varied. Randomly selected villagers were interviewed before the programme and at one week, six weeks, and six months after it. Interviews included questions about programme exposure, AIDS transmission and prevention, sexual practices, and condom use. STD incidence is sexually active age groups in the villages will also be compared with pre-programme data. The programme is being planned Parenthood centres for condoms. We will discuss the design and limitation of our programme, including pretesting, preliminary evaluation, and recommendations as well as our conclusions.

Session d'affichage Poster Session



Le SIDA, la société et le comportement
AIDS, Society and Behaviour

Tendances démographiques, tendances de la fertilité Demography and Fertility Patterns

Th.E.P.1 CONTRACEPTIVE UTILIZATION IN AND OUT OF THE MARITAL SETTING: IMPLICATIONS FOR THE TRANSMISSION OF HIV IN KINSHASA.

Piripiri L., Doupagne A***, Haming JC***, Moore M***, Bertrand ME***, Kasseba TD*
* Zaire School of Health, Kinshasa, Zaire; ** Tulane SPHIT, New Orleans, USA; *** Banque Comre Zaire, Kinshasa, Zaire

Objective: To determine and compare the level of contraceptive utilization in and out of the marital setting.

Methods: A working population in Kinshasa and their spouses were interviewed to obtain contraceptive and sexual histories.

Results: Overall 32% of 1063 monogamously married men (MM) and 47% of 1064 monogamously married women (WM) currently use contraception with their spouse. Condom usage with spouses was 2% in MM and 2% in WM. 12% of MM and 12% of WM used condoms for pregnancy prevention. Thirty-five % of MM and 2% of WM used condoms for contraceptive purposes. 12% of MM and 12% of WM used condoms in EHC was low (13% and infrequent (23% regular use). MM knew that condoms were effective against HIV, and this was associated with condom use in marriage (p<0.002) but not in EHC. Use of condoms in marriage was 4 times higher in men and women with a high educational level in the past year.

Conclusion: The potential for HIV transmission in this population is high, given the prevalence of unprotected extramarital relations. Education and counselling efforts for both family planning and prevention of HIV should take this into account.

Th.E.P.3 RISK FACTORS FOR HIV-2 INFECTION De Zakarias, B.,* Kage, Elinor,* Sjö, T,**, Marne, R.,* Essae, M.,* Mjöberg, S.,* et al. *Harvard School of Public Health, Boston, MA, USA; **University of Dakar, Dakar, Senegal

Objective: To determine the risk factors and hormonal parameters associated with HIV-2 seropositivity in a cohort of prostitutes in West Africa.

Methods: An analysis of 139 registered female prostitutes was performed on a subset of approximately 1100 prostitutes registered at an STD clinic in Dakar, Senegal. The HIV-2 seropositive females in the subset had been matched by age, nationality and years registered in the clinic with seronegative females, yet still were representative of the entire clinic population in age (2 years), nationality distribution and years in the clinic. The matched hormonal parameters were analyzed in relation to HIV-2.

Results: In a subset of 139 prostitutes, as well as in the clinic population, a slightly higher seropositivity rate to HIV-2 was associated with an original nationality outside of Senegal. Also associated with significantly higher seropositivity was the "wobbling" parameter usually seen with the non-Senegalese prostitutes ("Ches else" or "bottle setting"), continuing the above observation.

Interestingly, the seronegative prostitutes in the subset were more likely to have been previously hospitalized and to have a history of transfusion. No association was seen with HIV-2 seropositivity and female circumcision, scarification, tattoos or previous vaccinations, such as BCG. In evaluating the hormonal parameters concerning the prostitutes' children, no difference was noted in seropositives versus seronegatives in the number, health status or interchildhood mortality of their offspring. There was no difference in the age of first sexual encounter between seropositive and seronegative prostitutes. Estimates of the number of lifetime sexual partners, however, was significantly associated with seropositive status.

Conclusion: HIV-2, as with HIV-1, appears to be a sexually transmitted disease. Follow-up of the cohort will provide insight into the epidemiology and risk parameters associated with HIV-2 infection.

Th.E.P.5 CHARACTERISTICS OF MEN IN THE NATIONAL MORTALITY FOLLOWBACK SURVEY WHO DIED OF AIDS Rosen, J.,* Trent, J.** *NATIONAL CENTER for Health Statistics, Hyattsville, Maryland, U.S.A.; **State University of New York, Albany, New York, U.S.A.

Objective: To contrast the social and demographic characteristics, health care access and utilization of men who died of AIDS with those of other men.

Methods: Descriptive statistics are presented for data from a nationally representative sample of adults aged 25 or more who died in the USA in 1986. The sample consists of 18,733 decedents, 284 of whom died of AIDS. The data yields the first population level statistics on many characteristics of men dying from AIDS in the USA.

Results: Men dying from AIDS tended to be younger, were highly educated, and held higher status occupations than other men. They were more likely to suffer discrimination and need help with daily activities. Caregivers of AIDS decedents were less likely to be family members and more likely to be visiting homemakers or nurses. Use of physicians, mental health professionals and hospice care was also greater among men dying from AIDS than others.

Conclusion: The social, demographic and health characteristics of men dying from AIDS are considerably different than those of men dying from other causes. Understanding differences can help in developing programs to assist those who are infected with HIV. The NPHS data can provide information on many characteristics not available from any other source in the USA. As a nationally representative sample, the data can be used for generalizing to the population as a whole.

Th.E.P.2 MODELLING THE SPREAD OF HIV/AIDS AND ITS DEMOGRAPHIC IMPACT: A REVIEW OF APPROACHES

United Nations Population Division Task Force on AIDS** and A. Paloni**
*United Nations Population Division, United Nations, New York 10017;
**University of Wisconsin, Madison, Wisconsin 53706, U.S.A.

Objective: To review models of the demographic impact of AIDS developed by selected authors in light of modelling objectives, data needs, assumptions, algorithms and usefulness for assessing the impact of selected interventions.

Methods: Numerical information is reviewed on the nature of the HIV agent, modes of transmission, duration from infection to AIDS to death, and regional patterns. Current models are reviewed and classified according to their ability to incorporate behavioral, biological and epidemiological elements, and measure the demographic impact of behavioural and other changes.

Conclusions: Models requiring very few parameters are often uninformative from a policy perspective; those requiring many parameters were hampered by insufficient empirical data. Modelling results appear sensitive to assumptions of the shape of the incubation function, time distribution of infectivity, heterogeneity in sexual behaviour, and intervention among population groups.

Conclusions: In spite of shortcomings, models have already helped enhance our understanding of expected short and long-term demographic effects of women development, behaviour changes and blood screening. The extent to which numerical results depend on assumptions of parameter values, distribution functions and model structures is not clear at present. The Population Division Task Force will be further investigating these issues as part of its efforts to synthesize the results of world-wide modelling efforts.

Th.E.P.4 DETERMINANTS OF CONTRACEPTIVE PRACTICES AMONG INTRAVENOUS DRUG USERS IN NEW YORK CITY Aulick, Kenneth D., De Jager, De Fontaine, J. Therese A. Abdul-Quader* *National and Drug Research, Inc., New York, NY, USA **New York State Division of Substance Abuse Services, New York, NY, USA

Objective: To identify factors associated with contraceptive use among IV drug users in New York City.

Methods: Structured interviews with 463 IV drug users resulted through street outreach in New York City produced information about contraceptive AIDS risk behaviors, and socio-demographic characteristics. Analyses used cross-tabular and logistic regression techniques.

Results: Forty-two per cent (15/400) reported current use of contraceptive or other forms of birth control. Thirty-three per cent (13/400) used condoms. Contraception was significantly positively associated with education, stable housing, employment, number of sex partners, currently being in a sexual relationship, being non-Hispanic, and engaging in drug injection risk reduction practices. Contraception model (p<0.05) fit to be greater among younger and non-Hispanic subjects, but was not related to gender, having children, levels of alcohol use, or past psychiatric history. In seropositive logistic regression, the number of sexual partners, current sexual relationship, race, and walking drug related behavior change remains significant. Similarly, for condom use alone, the number of sexual partners, drug injection behavior changes, and involvement in a sexual relationship were significant predictors.

Conclusions: Among IVUDs, there is considerable contraceptive and condom use but not nearly enough to prevent pregnancy. Almost half of the sample practiced at least one form of contraception or birth control as an ongoing method. These findings associating education, working, and consumption are consistent with the findings from general population surveys. Since contraception consisted mostly of barrier methods such as the use of condoms, this should serve to retard HIV spread through heterosexual and potential transmission.

Débatage Testing

Th.E.P.6



**Session d'affichage
Poster Session**

**Le SIDA, la société et le comportement
AIDS, Society and Behaviour**

Th.E.P.7 CENTRE DE DÉPISTAGE ANONYME VOLONTAIRE ET GRATUIT DE MÉDECINS

DU MOEUF, PARIS, FRANCE. **ALEXANDER François** 1 LERAS 3* / MASSE B* / BODOSSA A**
* Médecine du Monde, PARIS, FRANCE.
** Laboratoire BODOSSA, PARIS, FRANCE.

Objectif. En juillet 1987, Médecins du Monde entreprend une action contre la pandémie du SIDA, en créant le premier centre de dépistage anonyme et gratuit du V.I.H. en France. Cette démarche qui a permis d'informer et de sensibiliser les personnes face à l'existence de ce fléau, sera reprise par les pouvoirs publics six mois plus tard.
Méthode. L'équipe est composée de médecins : 30 médecins hospitaliers et 11 infirmiers ; 5 psychologues, 1 infirmier ; 1 porteur d'informations ; 1 assistante sociale. Nos critères sont : l'accessibilité au test, le volontariat, l'anonymat, la confidentialité, la gratuité, et l'information personnalisée avec pour but la prévention. L'épreuve de séropositivité apparaît en dernier prioritaire et le travail de l'équipe psychologique nous semble important.
Résultats. Nous avons dépisté 280 personnes, dont 62% d'hommes, 33% de femmes. Le pourcentage de séropositifs est de 7,5%.

Conclusion. Il nous est apparu important de faire une étude sur le profil des personnes séropositives à partir du questionnaire anonyme et du carton réponse en représentant certains critères : le sexe, l'âge, la catégorie socio-professionnelle, le comportement sexuel, la toxicomanie.

Th.E.P.8 ESTIMATING THE PREVALENCE OF HIGH RISK SEXUAL BEHAVIOR WHICH HAS BEEN TESTED AND COUNSELLED FOR HIV IN 1986. **Johnston** Margaret, Douglas, J., Davidson, A., Denver State Health, Denver, Colorado.

Objective. To estimate the percentage of homosexual and bisexual men (OO) and heterosexual intravenous drug users (HVO) ever tested/counselled for HIV.

Methods. House surveys indicate that about 2% of men aged 18-60 consider themselves homosexual or bisexual (OO) and that are at potential risk of HIV infection. By December, 1986, Denver Public Health had recorded 5,128 HIV testing/counseling visits by OO. Because 0% or more tests than the estimated 4,528 of the Denver's population of 300,000. Because this approach does not account for multiple testing of individuals, we asked all patients waiting initial visits to the Denver Home STD Clinic 1/1/88 - 9/30/88 if they previously had been tested for HIV and recorded the numbers tested during the current visit.

Sexual Patient Group	No. Visits	No. Previously Tested (%)	No. Tested/Counselled Current Visit (%)	Total No. Tested (%)
Male OO	521	18 (3.5%)	286 (54.9%)	347 (66.4%)
Female HVO	275	122 (44.4%)	176 (63.3%)	213 (77.1%)

Conclusion. Based upon a stratified sample of patients attending an STD clinic, we estimate the 10-15% of homosexual men and 40-50% of heterosexual drug users who undergo HIV TC. For OO, 40% more of HIV acceptance decline prevalence of HIV in recent TC volunteers, a 100% increase in HIV AIDS cases of only 12% over 1987, and dramatically falling incidence rates for gonorrhoea, syphilis, and HIV infections after the success of 7 years of public efforts toward safer sexual practices and tests will for eventual control of AIDS in this risk group.

Th.E.P.9

Psychological Impact of Voluntary HIV Antibody Testing
Richard Jacobson, L., Flannery, R., Truong, A., Novick, R., Cornell Medical Center, New York U.S.A.

Objective: To assess prospectively the psychological effects of HIV testing in conjunction with individualized pre-and post-test counseling.
Methods: Stratified because of demographic variables were completed 7 weeks before HIV test notification, immediately before and after notification, and 10 weeks later by 216 seronegative adults (126 gay/bisexual men, 90 HIV drug users, all heterosexuals with suspected HIV-infected partners).

Results: For the 174 seronegative, visual analogue scale (VAS) measures of anxiety and depression fell immediately upon notification compared to scores at entry and immediately before notification (all p < .001), even though men seronegative (SN) had correctly predicted their results. Compared to entry values, their scores on SAS, Beck Depression Inventory (BDI), and State Trait Inventory (STAI) at 10 weeks after notification were all significantly decreased (all p < .05). Immediately after notification, the 40 seropositives had a transient increase in reported depression, but did not have significant decreases in the VAS measure of anxiety. At 10 weeks, after notification and continuing psychoeducational counseling, VAS depression had returned to its baseline. HIV had decreased significantly (p < .002) and VAS anxiety had decreased below its values at entry (p < .05).

Conclusions: HIV serological testing when combined with individualized counseling was emotionally helpful for both seronegative and seropositive research subjects at two months following notification.

Th.E.P.10

HIV ANTIBODY TESTING BY CANADIAN GENERAL PRACTITIONERS AND FAMILY PHYSICIANS
Kimball Thomas *, Sherman, J. *, Buning M. *, University of Ottawa, Ottawa, Ontario, Canada.

Objective. To assess HIV antibody testing by primary care physicians in Canada. **Methods.** A mailed questionnaire survey was used to obtain information from a proportionate, random sample of Canadian general practitioners and family physicians, stratified by geographic region and size of community. Replies, 80.4% of the physicians returned a completed questionnaire. Of the 823 respondents, 754 had ordered at least one HIV AB test in the last two months. Of these 625 physicians, 66% stated that the test was patient-initiated over three-quarters of the time. 11% of physicians received at least one positive result. 24% of physicians always obtained informed consent, 22% never do, 68% always do pretest counseling and 37% never do post-test counseling. Factors identified by logistic regression as being associated with those physicians who always pretest counsel and obtain informed consent include feeling a sense when pretest counseling, feeling concerned about HIV infection in their practice, and conduct routine risk assessment. 28% of all respondents stated they would inform the patient's partner of a positive result without the patient's consent, 22% would sometimes. **Conclusion.** Much of HIV testing is patient initiated. The importance of informed consent, carrying out pretest and post-test counseling needs to be emphasized.

Th.E.P.11

TELEPHONE SCREENING FOR MEN AT RISK OF HIV INFECTION
Lewis C.E. *, Frazee, H. *, Montgomery, E. * University of California at Los Angeles, Los Angeles, California, U.S.A.

Objective: To test the feasibility of conducting telephone interviews with a random sample of men in Los Angeles to determine their engagement in activities placing them at high risk of HIV infection and to assess the effects of feedback on their degree of risk (low/increased) on their follow up of this information.

Methods: Random digit dialing telephone calls were placed to residences; men age 18-60 were asked to participate in a risk-assessment interview. Those determined to be at increased risk were so informed and given a toll-free 800 number to call for further information, counseling, and referral for a free medical evaluation, if indicated.

Results: Seventy-percent of men contacted were interviewed; 1,610 interviews were completed, half in 18 census tracts, with an incidence of 19.2 cases of AIDS per 1,000 men. The rest represented all other areas of Los Angeles. 4.7% of men stated they were homosexual/bisexual. Of heterosexual men, 12.3 had 2+ partners in the past 2 years. Rates of HIV testing were associated with degree of risk. Overall, 14.7% (adjusted for oversampling) of men in Los Angeles had been tested for HIV antibodies. Despite facilitating access to counseling/refs, only 4% of those at risk took advantage of the assistance offered and called the 800 number.

Th.E.P.12

CAMPAIGN DE PROMOTION POUR LE DÉPISTAGE VOLONTAIRE, ANONYME ET GRATUIT A LYON - FRANCE.
SHERBY Bruno, LLOYD M., LYVROUX M. & BAYROUXE J.L.
Médicine du Moede - Lyon, 69001, FRANCE.

L'association Médécine du Monde a réalisé à Lyon du 11 au 26 avril 1988, une campagne d'affichage publicitaire (sur 300 personnes multiples, 50 personnes commencent au 4-11) en plusieurs endroits de la ville, destinée à étudier pour promouvoir le dépistage volontaire, anonyme et gratuit. Le slogan retenu est "Le SIDA, ça se dépiste". Cette campagne a permis de connaître l'opinion d'une cinquantaine de personnes, public et privé, de la ville. Cette campagne consistait les jeunes répondant sur la dernière année laquelle une personne connaissant en sérologie (positive ou négative) est plus motivée pour respecter les mesures de prévention, par rapport à une personne en situation de doute. Dans les six semaines qui ont suivi la campagne d'affichage, 6 800 appels téléphoniques ont été reçus, la fréquentation moyenne de tous les centres a été multipliée par trois. Au cours des consultations de rendez de résultats et d'information, un questionnaire anonyme suggère était proposé aux patients. Le pourcentage de séropositifs dépistés pendant cette période a été plus faible que pendant les mois précédents (54%).

Session d'affichage Poster Session



Th.E.P.13

ANONYMITY BARRIER IN HIV ANTIBODY TESTING
Kochman, J., Harvey, B., and Ellis, James M.
University of Illinois Medical Center, Dept. of Psychiatry and
USCF AIDS Project, San Francisco, California, U.S.A.

Objective: To determine HIV antibody test site client preferences for confidential versus anonymous antibody testing across two collection points: 1987 and 1988.

Methods: In Study 1 (1987) and Study 2 (1988) 417 and 677 consecutive clients (respectively) from the San Francisco HIV Antibody Test Site were surveyed about their preferences for confidential versus anonymous testing prior to receiving their test results.

Results: Study 1. Of the 336 respondents completed of gay men, bisexual men, intravenous drug users (IVDU), and heterosexual contacts with multiple partners, 46% reported they would not have taken the test if anonymity were not guaranteed. An additional 30% said they were not sure whether they would be tested under confidential procedures. Bisexual, gay, and IVDU respondents were significantly more likely to express doubt about utilization of either the anonymous or confidential procedures (p<0.005). Also prior to notification, respondents and seropositive differed in their response to the question (p<0.05) with majority of positive (74%) testing and they were likely to be tested without a guarantee of anonymity. Study 2. Results (N=417) pertain to 1988 preferences for confidential versus anonymous testing. Comparisons across time points, gender, ethnicity, and age will be reported.

Conclusions: Based on 1987 data, the guarantee of anonymity in the testing process was an essential factor leading to utilization of the Antibody Test Site in San Francisco.

Th.E.P.15

PRELIMINARY EVALUATION OF AN ADMISSION, HIV ANTIBODY,
VOLUNTARY SCREENING PROGRAM IN A LARGE PRIVATE HOSPITAL.
Kochman, J., Harvey, B., and Ellis, James M.
The Methodist Hospital, Baylor College of Medicine, Houston, Texas, U.S.A.

Objective: To evaluate an admission, HIV antibody, voluntary screening program in a large (2300 beds), private hospital as to testing compliance, attitudes, positivity rate, cost and confidentiality.

Methods: Data were obtained from The Methodist Hospital (TMH) Infection Services, Virology Laboratory, and from individual patients' medical records. One hundred patients (50 who agreed to and 50 who refused testing) were interviewed.

Results: From 12/18/88 to 1/15/89 there were 3987 patients admitted to TMH: 2115 (53%) agreed to testing, there were 9 (43%) true +, 3 (15%) false +, and 3 (15%) indeterminate results. Of the 9 true +, 6 were admitted for proven or probable HIV-related disease, 1 of 9 patients was known to be in a high-risk category on admission. Informed consent for testing was obtained by admitting personnel, ward clerks, or nurses - seldomly by physicians. The most common reasons to agree to testing were "I wanted to know" (50%) and "I thought it was required" (28%). The most common reasons to refuse testing were "I was not at risk" (68%) and "I was previously tested" (16%). Of the 100 patients interviewed, 82% felt that this screening program was in their best interest and should be continued. Cost of testing was borne by patient insurance or by Medicare DRO payments. No problem with confidentiality was discerned.

Conclusions: An admission, HIV antibody, voluntary screening program can be implemented in a large private hospital with favorable patient opinion and at least moderate patient compliance. If greater patient testing compliance is desired, better education and physician-patient interaction is suggested. In this HIV+ risk population, it is difficult to show that universal admission screening adds to a practical approach to hospital infection control. Although previously unknown HIV+ patients were discovered, the majority could have been predicted by a history of risk factors and this is a significantly more cost-effective method of HIV screening.

Th.E.P.17

CARACTERISTIQUES DES CONSULTANTS D'UN CENTRE DE
DEPISTAGE ANONYME ET OBLIGATOIRE DE L'INFECTION PAR LE VIH,
MONTREAL
Munoz, R., Pilon, G., Charneau, A., Proulx, M., Gagnon, M., Salomon, R.,
Duchon, G., D'Amour, G., Gagnon, F., and Lacour, R.
Université Laval, Québec, Québec, Canada

Objectif: Une enquête a été effectuée pour étudier le profil de la population consultant le centre.
Méthodes: Un questionnaire anonyme est rempli pour chaque sujet, par un médecin, au cours de la consultation. Une prise de sang permet ensuite de pratiquer de manière confidentielle ou anonyme, le sérodiagnostic (dépendant par un test ELISA, et confirmation par un test Western-blot).

Résultats: Du 1^{er} Août au 31 Décembre 1988, sur ses 665 mes effectués, 29 étaient positifs (4,2%). Pour 85% des consultants, il s'agissait d'un premier dépistage. Le sexe ratio homme/femme (94/7) est de 13,1, sans trop de cas de femmes chez les moins de 20 ans (94%-2,1) et chez les plus de 20 ans (94%-11,1) (p<0,001). La tranche d'âge des 20-29 ans prédomine (51%), suivie de celle des 30-39 ans (25%). Les consultants sont le plus souvent célibataires (77%) et hétérosexuels (79%). Les homo-bissexuels utilisent plus souvent les préservatifs (55%) que les hétérosexuels (27%) (p<0,001). Les homosexuels qui résidentent 10% des sujets testés. Les principaux motifs de demande de dépistage sont par voie croisée, appartenance du partenaire actif à un groupe à risque (7%), appartenance du sujet testé à un groupe à risque (22%), soupçon personnel de saur relation sexuelle antérieure (42%). Dans 55% des cas, l'individu est patient à la confidentialité.

Conclusions: Le consultant teste le centre de dépistage d'un homme, jeune, célibataire, hétérosexuel, arrive en général des premiers secours non protégés, ne présentant pas d'autre comportement à risque, et consultant pour la première fois une sérologie par sérum personnel. Ce profil correspond à celui des patients consultant habituellement pour des infections sexuellement transmissibles.

Le SIDA, la société et le comportement AIDS, Society and Behaviour

Th.E.P.14

ASSESSING THE ETHICAL AND POLICY IMPLICATIONS OF TESTING
SURGICAL PATIENTS FOR HIV ANTIBODY IN THE USA
Coppola, L., Goss*
Wanderbilt University, Nashville, Tennessee, USA

Objective: To assess the ethical and policy implications of HIV antibody testing of USA surgical patients in the context of preventing occupational transmission of HIV in surgical settings.
Methods: 1) Review of data concerning: a) HIV occupational transmission in surgery, b) current status of HIV testing technology, and c) rationale advanced for antibody testing of surgical patients; 2) analyze the surgical health care worker and patient relationship regarding policy benefits and policy problems which may be generated by antibody testing in surgical settings.

Results: Review of data suggests that HIV occupational transmission is a non-zero risk, especially when U.S. Centers for Disease Control (USCDC) recommended precautions are routinely followed. The current status of HIV antibody testing technology and c) rationale advanced for antibody testing of surgical patients would generate more difficulties than benefits at the present time. It could also disrupt the normative ethics of the health care relationship and patient relationship. **Conclusions:** Mandatory HIV antibody testing for surgical patients in the USA is not recommended at this time. The routine offering of HIV antibody tests especially if clinically indicated is recommended. Such testing should address counseling needs and patient consent.

Th.E.P.16

EVOLUTION DES MOTIFS DE PRESCRIPTION DE SEROLOGIE VIH EN
MEDICINE GENERALE EN AQUITAINE, FRANCE, 1987-88
Maudou, S., Pommerehne, C., Vignat, C., Duba, F., Tilly, A., Blotman, J.,
Département d'Infectiologie Médicale, Université de Bordeaux II, Bordeaux, France

Objectif: Etude de l'évolution de la prescription de sérologie VIH par les médecins généralistes et des facteurs influençant cette prescription.

Méthodes: Un échantillon représentatif de surveillance épidémiologique par une médecine "sentinella" rapporte sur le région Aquitaine >2.700.000 habitants - à été mis en place en 1986. Depuis octobre 1987, 40 médecins généralistes transmettent des données concernant leurs prescriptions de sérologie VIH.
Résultats: En 15 mois, 566 sérologies VIH ont été prescrites, dont 20 (3,5%) ont été positives (confirmation par Western Blot). Le nombre moyen de prescriptions par médecin et par année a augmenté de 20% (de 0,41 en 1987 à 0,53 en 1988). Dans 40% des cas, le test est prescrit à la demande du patient, et dans 56% des cas à l'initiative du médecin. Ces proportions sont stables au cours du temps. Les demandes de sérologie concernent aussi bien les médecins (22%) que les femmes (68%). On retrouve dans 40% des prescriptions un comportement à risque pour l'infection par le VIH. Dans 10% des cas il s'agit d'hétérosexualité hétérosexuelle, associée ou non à une transaction, dans 3% des cas d'hétérosexualité ou autosexualité de transaction, et dans 25% des cas d'un contact avec des partenaires hétérosexuels multiples ou à risque. Pour 60% des prescriptions, les hommes et 147 femmes, aucun comportement à risque n'est identifiable à l'origine de la demande. Dans ce contexte, la prescription de sérologie à l'occasion d'un examen préopératoire pour 41% des hommes et 38% des femmes, ainsi qu'à l'occasion d'une grossesse pour 41% des femmes. Les seuls autres comportements à risque identifiables, des antécédents de maladies sexuellement transmissibles sont retrouvés dans 12% des cas; une proportion de 18% chez les hommes et de 7% chez les femmes.

Conclusions: La demande de sérologie VIH est presque généralisée libéralement augmentée régulièrement en Aquitaine. Toutefois la stabilité des proportions nous indique que des efforts ne sont pratiquement aucun comportement à risque. Dans ce cas, le médecin est souvent à l'origine de la demande que le patient. Les bilans préopératoires et pré-grossesse sont souvent à l'origine d'une prescription.

Th.E.P.18

CARACTERISTIQUES OF PATIENTS SUBMITTED TO HIV SEROLOGY IN A
CLINIC FOR SEXUALLY TRANSMITTED DISEASE OF DOWNTOWN MONTREAL
Lacour, R., Pilon, G., Charneau, A., Proulx, M., Gagnon, M., Salomon, R.,
Duchon, G., D'Amour, G., Gagnon, F., and Munoz, R.
Université Laval, Québec, Québec, Canada

Objectif: To describe the evolution in time of sex, age, sexual orientation, prevalence of HIV infection in patients submitted to HIV serology in an STD clinic of downtown Montreal. (Clinique L'Actuel)

Méthodes: Les caractéristiques de tous les patients qui ont subi une sérologie VIH ont été rétrospectivement revues; sérologie positive, age, sexe et sexual orientation were recorded.

Résultats: 1.709 patients were submitted to 3027 tests for HIV from November 1987 to December 1988. The global prevalence was 15.8% in this population. The mean age was 30.8 years. The following table presents the time trends:

Séropositivité	Prévalence	% d'hommes	% d'hétérosexuels
2/85	2,3%	10,0%	6,7%
1/87	1,1%	2,0%	10,0%
1/87	2,2%	13,3%	37,7%
2/87	10,2%	23,9%	54,3%
2/88	10,8%	22,9%	49,0%
2/88	10,4%	24,2%	48,8%

Conclusions: As expected, the prevalence of HIV infection in HIV tested individuals decreased at the same time that the proportions of women and of heterosexual individuals increased in that population. However, the increased prevalence noted in summer 2, 1988, might reflect a recent increase of heterosexual transmission in downtown Montreal. This observation has to be confirmed by additional data.

Session d'affichage Poster Session



Le SIDA, la société et le comportement AIDS, Society and Behaviour

Th.E.P.19

ALTERATIONS SOCIO-ECONOMIQUES ET COMPORTEMENTALES DES PERSONNES INFECTÉES PAR HIV.

RENÉE, JACQUES, LÉVELLÉ, MARIE, E.M.M. et MORAIS DE SA, C.A.
Hôpital de la Clinique de la Santé - Orléans - FRANCE

OBJECTIF: Identifier les altérations socio-économiques et comportementales qui sont avec plusieurs Français dans les centres infectés par HIV.

MÉTHODE: L'étude a été réalisée en trois d'évalués les éléments que ont choisi deux des Promoteurs Sociaux de personnes HIV dans la direction de nous à distance, totalisant 100 personnes infectées.

RÉSULTATS: Les altérations plus fréquemment observées, ont été:

SOCIAL	N	%	ECONOMIQUES	N	%	COMPORTEMENTALES	N	%
Moins de 25 ans	170	100	Doucement	61	61	Changement de lieu d'habitation	25	25
Moins de 30 ans	170	100	Difficulté à trouver un logement	49	49	Prise de médicaments	25	25
Professionnels	170	100	Diminution des revenus	59	59	Prise de médicaments	25	25
Qualification	170	100	Changement de métier	59	59	Prise de médicaments	25	25
Discrimination	170	100	Manque d'argent	59	59	Prise de médicaments	25	25

CONCLUSION: Les altérations les plus observées sont à la question de la stigmatisation, de la peur et de la discrimination. Les personnes qui ont subi les autres altérations d'évaluation nous ont permis de traverser d'un accès programme d'éducation, et d'accéder à l'aide sociale, cette dernière puisse être interrompue.

Th.E.P.20

FUNK AND EPIDEMIOLOGY: VIRAL DIALECTICS IN THE SOUL MUSIC OF FUNK

HARRINGTON, Mark; BARR, D.; VASSOUR, R.J.; DANGLER, R.
AIDS Coalition to Unleash Power, New York NY, USA.

Objective: To elucidate the hitherto unexamined impact of the HIV epidemic as depicted in motifs of the seminal work of a major 1980's musician. **Methods:** Analytically listened to, read the lyrics of, danced to and attended concerts containing material from the album "O" THE TIMES and LOWESKY. **Discussion:** "In France, a skinny man died of a big disease with a little name. By chance his girlfriend came across a needle and soon she did the same." "Positively... Have U had your plus sign 2-day? Positivity. Do we mark U present or do we mark U later? ... Where did it come from? What did U have 2 dot? Can U mister? Conclusion: "Hold on 2 your soul, your plus sign 2-day." **Conclusion:** "Hold on 2 your soul, we've got a long way 2 go." [In concert:] "Cross the Line!"

Th.E.P.21

STUDY OF THE PREVALENCE IN A HIV TESTING CENTER

DEFORON, N.M.; MARCHAND-MERIEU, D. and BACHTEL, J.F. *Sandoz-Thalix, D.*
AIDS Reference Laboratory, Université de Liège, Belgium.

Objective: The AIDS Reference Center of the University of Liège has developed a program to evaluate the HIV seroprevalence in relation with motivations of consultants and actual risks of transmission.

Methods: A preliminary interview with the consultant is held with each team member and a confidential epidemiological survey form is filled. Seroprevalence is determined by classical serological methods (EIA, WB).

Results:	Motivation	Percentage	Evaluation of risk	Seroprevalence
to be reassured	multiple heterosexual relationships	44%	none	0%
	homosexual relationships	17%	±	0%
	IV drug users	3.5%	+	1%
	sexual relationship with seropositive professional risk	6%	+	1%
	others	16.5%	±	0%

Conclusion: In Belgium, the seroprevalence rate among blood donors is 2/100,000. In our AIDS Reference Center, this rate is 4/100 among people requiring a HIV test. The rate climbs to 1/9 in the population considered at risk.

Th.E.P.22

PREVALENCE OF ANTI-HIV ANTIBODIES IN PRINISITICE - SOMOGMA (507 PRINCE) - RWANDA

SOMBALES, V.L.C.-Des Anjos, R.M.P.-Gomes, M.C.C.-Ames, T.F.

Prevalence of anti HIV antibodies was investigated in 100 internal patients of CHUVIHO HOSPITAL DE SOMOGMA (507 PRINCE) (Institute of Infectious Diseases) recorded test, in a period going from May 12, to August 20, 1987. All patients were of male gender, their age varied from 16 to 36 years (median = age 36 years). 36% of them of white color and 64% single.

In the epidemiological examination realized later, to select persons with AIDS-risky behavior, we verified:

- 14% of the patients were homosexual or bisexual.
 - 88% of the patients had antecedents of sexual transmissible diseases.
 - 50% of the patients donated or received blood.
 - 28% of patients
 - 03% of the patients were using injectable drugs.
- 5 Seropositives (5%) were encountered, being minimum 23 and maximum 33 years old (median 28 years); four (4) of them were white and single. All presented a risk factor (one or more) for AIDS Virus infection: being 04 homosexuals or bisexuals (two of them were using injectable drugs) and 1 blood receptor, with a total of 2 transfusions.
- For the five (5) HIV (+) patients, one was blood donor, one has been jailed, and 3 admitted that they had transmissible sexual diseases, and in the medical examination, two of them had signals and symptoms related to AIDS.
- After leaving the infirmary, they were sent to health centers, near their houses, for attendance. Only one belonged to our district and died after presenting disseminated sarcoma appearing before AIDS, concomitantly after the diagnostic of the infection by HIV.

Th.E.P.23

PREGNANT ACCEPTABILITY OF HIV SCREENING AMONG

MOUST JAMER, (1), Le Galis C. (1), Pr Héarier R. (2) et Pr Papiernik E. (3)
(1) INSERM Research Unit 240, Paris, France. (2) Obstetrics and Gynecology Port-Royal, Paris, France. (3) Obstetrics and Gynecology Antoine Béclère, Clamart, France.

Since 1987, from HIV screening is systematically proposed, as their first prenatal visit, to all pregnant women attending 9 obstetrical clinics of public hospitals in Paris region (CIVU Census Data, December 1987 and January 1988, a questionnaire in written form was submitted, just before HIV screening proposal, to all women attending two of these clinics: response rate was 97% and 400 questionnaires were analyzed.

Respondents were significantly older (68% between 25 and 35 years of age) and had a higher level of education than the general population of pregnant women in the region (CIVU Census Data).

26-4% declared having already been tested for HIV (43.8% of these tests have been performed during ambulatory prenatal care), 63.7% knew, before attending clinics, about the risk of transmission of HIV from mother to fetus, 92.7% having learned about it through the media, 94.2% believed in such transmission during pregnancy, 29% during delivery, 11.1% through breast feeding, and only 2% by sucking care of child after birth.

20% supported systematic HIV screening proposal during pregnancy. 81% thought that female HIV carriers should reduce to pregnancy, and 80% supported abortion proposal for pregnant HIV carriers.

Among women already tested before attending clinic, 9.5% perceive themselves as being "more than average" at risk for HIV, among women not already tested but having previously thought about testing, 15.5% are in this category only 2.8% among others (p<0.01). It suggests an important effect of reassurance of testing. High acceptability of screening is also revealed by the fact that 70% were ready to financially participate in order to get access to testing.

Th.E.P.24

PSYCHOSOCIAL PREDICTORS OF HIV PEOPLE WHO FAIL TO RETURN FOR THEIR HIV TEST RESULTS

CALNIA, JUANJO; KEYLES, S.; COOPER, T.

University of California, San Francisco, Center for HIV Prevention Studies, U.S.A.

Objective: Although the majority of people who seek HIV antibody testing return for their results, a substantial minority fail to return. An understanding of the barriers to returning for test results is important to HIV prevention efforts that depend on people having knowledge of their HIV antibody status.

Methods: Data were collected from 997 individuals seeking HIV antibody testing at the anonymous test sites in California (98% volunteer rate). Respondents were assessed (self-administered questionnaires) when they came to have their blood drawn and reassessed when they returned for their test results two weeks later.

Results: Twenty-eight percent did not return for results (n=287). Relative to returnees, non-returnees were more likely to be of lower educational level, more anxious about contracting AIDS, less knowledgeable about HIV testing, and more likely to be young transfusion groups did not offer on sexual orientation, gender, race, age, marital status, reasons for seeking testing or knowledge of HIV transmission routes.

Conclusions: Efforts are needed to motivate young transfusion, and those with less education to obtain their test results; more on-site counseling to reduce anxiety and increase knowledge of test results may enhance return rates.

Session d'affichage Poster Session



Le SIDA, la société et le comportement AIDS, Society and Behaviour

Th.EP.31 PRENATAL SCREENING FOR ANTIBODIES TO HIV-1 IN THE U.S. White, Harold, Patterson L., and the Perinatal HIV Screening Study Group, U.S.A.

Objective. To evaluate prenatal (PN) HIV screening in the United States.
Methods. 1) Surveyed all states to determine which had PN HIV legislation.
2) Compared number of marriages from 1/88-4/88 to similar months in previous two years to determine the impact of mandatory PN HIV screening laws in two states. 3) Conducted blinded HIV seroprevalence surveys of marriage license applicants (MLA) using routine PM syphilis serology specimens in 8 areas.
Results. PN HIV legislation has been proposed in 36 states. Mandatory PN screening (started 1/1/88) in Louisiana and Illinois resulted in 142 and 132 fewer marriages and repeat of the Louisiana law (7/88). Blinded surveys of MLA showed prevalence similar to military recruits (prevalence (PRA)).

Area	Rate	MLA % POS (8)	95% C.I.	MLA % POS* Adult ADPRA*
Alabama	11/87-07/88	0.65	0.11-1.00	130
Alameda Co., CA	11/85-08/87	0.64	0.26-1.25	418
Long Beach, CA	03/87-08/87	0.50	0.00-1.08	NA
Connecticut	01/88-08/88	0.23	0.10-0.42	381
Georgia	10/87-10/88	0.23	0.13-0.40	332
Mississippi	02/87-02/88	0.22	0.10-0.31	109
Albuquerque, NM	12/87-06/88	0.18	0.01-1.18	245
Oshkosh	02/87-07/88	0.07	0.02-0.15	0.09

*Age- and sex-adjusted to prevalence per million population (317 years)
Conclusion. HIV antibody prevalence in MLA was as high as 0.64%. Mandatory PN screening resulted in fewer marriages in two states. Voluntary PN screening may be justified in high AIDS incidence areas.

Th.EP.32 THE EFFECT OF MANDATORY AIDS EDUCATION ON VOLUNTARY HIV TESTING IN PRISONS Addington, J., Fleming, D., Knaus, C., McAllister, M., Hoggan, J., Foster, L., *Center for Disease Control, Atlanta, Ga., U.S.A., *Mass Health Division, Portland, Ore., U.S.A., **State Department of Correction, Salem, Ore., U.S.A.

Objective. To assess whether mandatory interactive AIDS education leads to fewer at-risk inmates going to HIV testing and counseling.
Methods. We divided 1477 consecutively admitted inmates into two cohorts by date of admission: the first admitted 5/87-12/87 received only 10 minute videotape on AIDS (no-ED) and the second, admitted 1/88-2/88, received the videotape and a mandatory interactive session with an AIDS counselor (w-ED). All inmates were then offered HIV antibody (HIV AB) testing. HIV AB status for inmates declining testing was determined by testing serum routinely drawn for syphilis serology after personal identifiers had been removed. All were given a 20-item questionnaire (Q) on HIV risk (HCRAI). Results were linked to a questionnaire that assessed the inmate's history of risk behavior administered before admission to prison.

Results. Sixty three percent (927) of all the inmates were at risk for HIV infection defined as being positive for either HBsAg, IV drug use, and/or male homosexual. The cohorts were not different in their proportion of at-risk inmates (62.4% in the first and 63.6% in the second). Nineteen inmates were HIV AB positive (1.3%, 95% confidence limits (CI) 0.7%, 1.9%). Compared to at-risk inmates who did not receive interactive AIDS education, at-risk inmates who received interactive AIDS education were 23% less likely to refuse testing for HIV (79/264 vs. 192/661, p=0.03). IV drug users who received interactive education were 23% less likely to refuse testing than IV drug users who did not receive education (10/107 vs. 10/107, p=0.001). HIV AB testing was 67% less likely to refuse testing than HIV positive inmates who did not receive education (1/7 vs. 1/1).

Conclusion. Providing mandatory interactive AIDS education before offering HIV testing may result in fewer at-risk inmates refusing to be tested and counseled.

Anthropologie Anthropology

Th.EP.33 A REPORT ON A NEWLY DEVELOPED AIDS INTERVENTION PROGRAMME IN MONTRÉAL, QUÉBEC, CANADA

White, Harold, Patterson L., and the Perinatal HIV Screening Study Group, U.S.A.
CLSC Métro (Centre local de services communautaires), Montréal, Québec, Canada

Objective. To develop a comprehensive AIDS program for the population at high risk (HR) in Montreal, Quebec, Canada. HR is defined as those individuals who are sexually active, do not use condoms, and do not use the services of a counseling and medical support, with the objective to examine who, in the community at large, is using the services and to isolate the seroprevalence of this particular population. **Method:** Through a co-ordinated mandate by the Ministry of Health and Social Services and the CLSC Métro (Youth and Women's Clinic), the AIDS Intervention Centre was conceived. A staff of 4 counselors were hired to provide the necessary education and counseling component to this program. In-service education was provided for all support staff, both professional and non professional of CLSC Métro - Youth and Women's Clinic to assure consistency and sensitization. Telephone information, pre and post counseling, psycho-social support, follow-up and referral are provided to all beneficiaries of this program.

Results: Since the initiation of the program, we have tested (to date) 1387 individuals, which shows a seroprevalence rate of 5.4%. This seroprevalence rate is represented exclusively (100%) by the homosexual population.

Conclusion: This particular, comprehensive approach to H.I.V. testing is most commonly utilized by the "worried-well" population, but also reveals a seroprevalence rate consistent with the prevalence rate of homosexual population which is a targeted high-risk group.

Updated statistics available on day of conference.

Th.EP.34 SEXUALITY AND HIV TRANSMISSION IN KAGERA REGION, TANZANIA

White, Harold, Patterson L., and the Perinatal HIV Screening Study Group, U.S.A.
Dr. George E. Jaramba, Faculty of Medicine
P.O. Box 85018 Dar es Salaam Tanzania.

Kagera Region accounts for more than 60% of the total AIDS patients in Tanzania. A sero-survey based on healthy individuals in the area revealed prevalence rates ranging from 21% in urban areas to 10% in the rural area. Transmission of the infection is largely heterosexual. However, no study has ever been carried into the cultural factors governing sexual behaviours of the people in the area. This one year anthropological study is a contribution in that direction. It highlights on the cultural construction of sexuality among the people of Kagera with a view of devising appropriate control measures against AIDS pandemic in the area.

Th.EP.35 SEXUALITÉ ET CONNAISSANCE DE SIDA CHEZ LES LYCÉENS ET LES JEUNES FEMMES DE DAKAR ET BANZIEZ YOUSSEF M'BANGANI GUISSE ET LÉONARD D'ALMEIDA FILIPELA RP. SYSS DAKAR, SENEGAL

OBJECTIFS Les objectifs de cette enquête sur le SIDA visent à déterminer des groupes cibles d'éducation et de connaissance de la maladie, d'identifier les pratiques, habitudes et conduites culturelles autour de la sexualité, la contraception, les MST et le SIDA, participer à la conception de l'information, de participer à la conception et à la réalisation des actions de prévention du SIDA. Les groupes cibles sont ici des individus en activités sexuelles évidentes, des femmes fréquentant des cours de PNE, nombre de 400 en tout et des individus ayant déjà désiré d'activités sexuelles des lycéens (senne) de collèges à Dakar au nombre de 121.

MÉTHODOLOGIE Au questionnaire comprenant la 4 grande thèmes évoqués a été élaboré et complété par des interviews semi-directives individuelles et collectives.

RÉSULTATS: Les résultats de l'enquête montre que la sexualité du niveau de celle de la population cible est très libre; précocité, fréquence des rapports sexuelles, multiconjugalité, recherche de plaisir multiforme. Ceci avec des hommes en rapport avec le niveau d'instruction, la sexe. Utilisation relativement faible des préservatifs ainsi que le multipartenaire encore particulièrement évidente entre un niveau d'information grandissant et des hommes et pratiques sexuelles très peu contrôlées. **CONCLUSION:** L'enquête couvre des pistes pour analyser et créer des instruments d'information plus adaptés et plus conformes aux réalités sociologiques et culturelles.

Th.EP.36 THE ROLE OF HIV DRUG WITHDRAWAL SYMPTOMS AND SMOOTHS ACTIVATION IN AIDS RISK-REDUCTION

Margaret M. Connor, Spectra Systems, Inc., 155 6th St., Westboro, MA 01581 U.S.A.

Objective. To describe the experience of withdrawal within the social context of drug use and HIV-related risk activities. To determine the influence of withdrawal on the continuance of high-risk behavior.
Methods. A 20-item questionnaire was administered to 130 IV-drug using inmates at a methadone maintenance facility, a detoxification unit, and a drug-free residential facility. 152 of those surveyed were followed with a 10-month interview. Self-reported information was amplified with ethnographic observations "on the street."

Results. Interpreting the withdrawal experience in a context of drug use reveals as follows: recovery were complex than that elicited from a clinical diagnosis. The withdrawal experience affects an individual's ability to prevent AIDS transmission. 51% of those sampled who indicated that "it had come to mind that the person they were about to share a needle with might be HIV-infected" did not act on this thought in the form of prevention. Perceived withdrawal, sickness was a prominent reason for not taking preventative action.

Conclusion. Interpreting the withdrawal experience in its actual context can shed light on the meaning, experience and actions taken to alleviate symptoms of withdrawal and some of the barriers to integration of needle cleaning during needle sharing episodes. AIDS outreach education could prove more effective if, as part of the negotiation with active users to prevent needle-sharing practices, withdrawal symptoms were addressed as a problem area.

Session d'affichage Poster Session



Le SIDA, la société et le comportement AIDS, Society and Behaviour

Th.E.P.43 RELIGION AS A TOOL IN PREVENTING THE SPREAD OF HIV IN UGANDA.

MUSABERI, Mohamed* Masaganda Florence**

*Health Educator, AIDS Control Programme, Uganda
**Nantrembe Christian Fellowship, Uganda.

Objective: To describe the success of using religion in preventing the spread of HIV in Uganda.

Methods: Focus groups and direct observation were used in several Christian Church groups in Uganda.
Interviews with AIDS patients were done.
Scientific analysis of information collected reveals how important christianity has been in preventing HIV spread especially in Urban areas.

Conclusion: Christian religion has had a significant impact in the prevention of AIDS in Uganda.

Th.E.P.44 HOW ORGANIZED RELIGION IMPACTS ON THE AIDS PANDEMIC IN PREVENTION, EDUCATION, AND PREJUDICE

Dr. Henry J. Zeiger, Memorial Hospital/Brno University, U.S.A.
The AIDS crisis in two areas: preventing or precluding discrimination against PWAs and those at risk for AIDS.

Methods: An analysis will be made of pertinent statements by prominent clerics ranging from the Pope through television evangelists. Major articles in the religious press will be analyzed. Secular publications will be examined for editorial opinions reflecting a religious influence.

Results: Analysis of pertinent materials shows a condemnation of the so called life styles of the groups at risk for AIDS. Many denominations express the attitude that "they" deserve what "they" get, thus contributing to preclusion for people with the syndrome and those at risk. This attitude has helped to slow governmental and medical responses to the AIDS pandemic, and added immeasurably to the attendant adverse social and economic suffering.

Furthermore, with their narrow, restrictive view of sex the same denominations have blocked efforts to teach safe sex, thus placing at grave risk all those outside of a strict, monogamous, heterosexual marriage.

Conclusion: By not adopting a truly Christian response to those with AIDS, organized religion encourages judgemental, condemnatory reactions, actually exacerbating the adverse medical, social and economic effects of the epidemic.

Sociologie du SIDA Sociology of AIDS

Th.E.P.45 REVELATION OF VOLUNTEERS FOR CONTROL OF THE HIV EPIDEMIC

CHANG, Chien-Ji University of South Florida, Tampa, Florida

A review of US efforts to control epidemics between 1941 and WWII reveals that education, a partially effective drug (arsphenamine), case finding, contact tracing and free treatment were the major control measures. Mass media recruitment, identification followed by involvement in a long treatment program (18 months with arsphenamine) modified behavior sufficiently so that further spread was significantly reduced. We must identify the 1.5 million Americans infected with HIV and embrace them in a social-medical program which will so alter their behavior that transmission of HIV will be significantly reduced. This can best be accomplished by emulating the "buddy" system of San Francisco except that the buddy begins to care for and to advocate for the HIV seropositive person as soon as that person is identified and long before that person is ill, with wary identification there will be several years available for behavior modification through the social-medical-buddy involvement before the HIV positive person becomes highly infectious. By that time the evidence should have been so effective that further transmission rarely occurs. The only practical way to mobilize large numbers of long term dedicated volunteer "buddies" is through the churches. The Christian Church grew explosively from the 2nd to the 4th centuries AD as the Christian cared for the victims of the smallpox and measles epidemics which struck Rome beginning in 165 AD while decessions of the State Religion fled from the ill. Such fearless demonstration by Christians of faith in God and of God's love in the face of terrifying disease attracted an enormous following. We must rekindle Christians of their heritage and convince them to take up this historic and critical role. Such a buddy program combined with widespread testing, contact tracing and free treatment can control HIV in our society.

Th.E.P.47 WHERE ARE PEOPLE IN ENGLAND & WALES DYING FROM AIDS?

Kennedy Ann R.; Eilan G.A.; Porter J.D.W.H.;
PHLS Communicable Disease Surveillance Centre, U.K.

Objectives: To determine 1) Where people with AIDS (PWA) are dying in hospital, at home or hospice; 2) Whether their cause of death was related to where they die and whether these factors are changing with time.

Method: All PWA reported to the Communicable Disease Surveillance Centre by December 1988, were reviewed to ascertain those who had died and on whom there was a matched death entry. Demographic data and cause and place of death information were also collected.

Results: By the end of 1987, 1243 PWA had been diagnosed of whom 362 had matching death entry data. Of these 302 (83.4%) died in hospital, 55(15.2%) at home, and 5(1.4%) in hospice. Of the 60 PWA who died outside hospital, 58 were men, 2 were women, 435 (38/65) were aged 30-40 years; 125 (32/28) of homosexual/bisexual men died in the community compared with 92 (12/11) of injecting drug users and 85 (32/8) of haemophiliacs. Preliminary data for 1988, albeit incomplete, confirms that place of death is changing. Data on cause of death related to place of death will be presented.

Conclusion: National surveillance data has an important role to play in understanding patterns of "terminal" care, which have previously not been recognized and which are of value in highlighting important resource implications.

Th.E.P.46 COMPORTAMENT RELATIU AL SIDA ÎN VILIA DE BUCUREȘTI ÎN TRIMESTRII ÎNCEPUTURII ANULUI 1990

MIHAI, TUDOR Institut de Statistică și Informatică în Medicină, București, România

*Universitatea de Științe și Medicină din București, România; **Fundația Științelor Științelor, Arad, România; ***Institutul de Statistică și Informatică în Medicină, București, România

Obiectiv: Să se prezinte rezultatele unei studii asupra comportamentului sexual în viziunea medicilor din cadrul serviciilor de urgență și de ambulanță în București în perioada 1989-1990.

Metode: S-a realizat o analiză retrospectivă a 100 de cazuri de SIDA în viziunea medicilor din cadrul serviciilor de urgență și de ambulanță în București în perioada 1989-1990. S-a realizat o analiză retrospectivă a 100 de cazuri de SIDA în viziunea medicilor din cadrul serviciilor de urgență și de ambulanță în București în perioada 1989-1990. S-a realizat o analiză retrospectivă a 100 de cazuri de SIDA în viziunea medicilor din cadrul serviciilor de urgență și de ambulanță în București în perioada 1989-1990.

Rezultate: În urma analizei s-a constatat că majoritatea pacienților cu SIDA au fost diagnosticați în viziunea medicilor din cadrul serviciilor de urgență și de ambulanță în București în perioada 1989-1990. S-a constatat că majoritatea pacienților cu SIDA au fost diagnosticați în viziunea medicilor din cadrul serviciilor de urgență și de ambulanță în București în perioada 1989-1990. S-a constatat că majoritatea pacienților cu SIDA au fost diagnosticați în viziunea medicilor din cadrul serviciilor de urgență și de ambulanță în București în perioada 1989-1990.

Concluzii: SIDA este o boală care se transmite prin contact sexual, prin transfuzii de sânge și prin utilizarea de seringi contaminate. Este important să se realizeze o educație de sănătate pentru a preveni răspândirea bolii.

Th.E.P.48 MATRIÈRE DE RISICU ȘI SIDA ÎNtre ÎNTERVENȚIILE SIDA

MIHAI, TUDOR Institut de Statistică și Informatică în Medicină, București, România

*Universitatea de Științe și Medicină din București, România; **Fundația Științelor Științelor, Arad, România; ***Institutul de Statistică și Informatică în Medicină, București, România

Obiectiv: Să se prezinte rezultatele unei studii asupra comportamentului sexual în viziunea medicilor din cadrul serviciilor de urgență și de ambulanță în București în perioada 1989-1990.

Metode: S-a realizat o analiză retrospectivă a 100 de cazuri de SIDA în viziunea medicilor din cadrul serviciilor de urgență și de ambulanță în București în perioada 1989-1990. S-a realizat o analiză retrospectivă a 100 de cazuri de SIDA în viziunea medicilor din cadrul serviciilor de urgență și de ambulanță în București în perioada 1989-1990.

Rezultate: În urma analizei s-a constatat că majoritatea pacienților cu SIDA au fost diagnosticați în viziunea medicilor din cadrul serviciilor de urgență și de ambulanță în București în perioada 1989-1990. S-a constatat că majoritatea pacienților cu SIDA au fost diagnosticați în viziunea medicilor din cadrul serviciilor de urgență și de ambulanță în București în perioada 1989-1990.

Concluzii: SIDA este o boală care se transmite prin contact sexual, prin transfuzii de sânge și prin utilizarea de seringi contaminate. Este important să se realizeze o educație de sănătate pentru a preveni răspândirea bolii.

Session d'affichage Poster Session



Le SIDA, la société et le comportement AIDS, Society and Behaviour

Th.E.P.55 AIDS IN AN AGING SOCIETY: ETHICAL AND PSYCHOLOGICAL CONSIDERATIONS

Schmidt, Robert M.* and Kanan R.B.** *Center for Preventive Medicine and Health Research, San Francisco State University and Pacific Presbyterian Medical Center, San Francisco, California. **Department of Sociology/Antropology, Trenton State College, Trenton, New Jersey, U.S.A.

Objective: To analyze ethical and psychosocial issues of AIDS in an aging society. **Methods:** Health care services and health research funding agencies have not acknowledged similarities between needs of America's aging population and the estimated 1.3 million Americans infected with HIV. Knowledge of individual variation of susceptibility to HIV infection, latency of HIV disease progression, HIV infection of the central nervous system, and lifelike HIV infection in currently asymptomatic individuals is especially applicable to older people. Ethical and psychosocial issues are similar; e.g., aging, homophobia, racism, loss of self-esteem, insurance coverage, access to health benefits and services. **Results:** Currently, 10% of AIDS patients are age 50 years of age; 25% of those are 60 and 4% are 70 years of age. In Europe, 11% of AIDS cases have been reported in persons 50-62 of these are 60 years of age. Ethical issues for persons with health care progress and age of receiving retirement benefits include stigmatization, erratic access to health services, age of qualifying for federal health care programs and age of qualifying for retirement benefits. **Conclusions:** Ethical and psychosocial effects on the older individual with AIDS and the impact of the epidemic on the elderly as a group would benefit from comparative analysis. We suggest appropriate societal responses to the AIDS pandemic and a rapid aging population in Western countries provide a paradigm for health care services and research in the United States.

Th.E.P.57 GUARDIANSHIP STATUS AND SUPPORTIVE RELATIONSHIPS AS CO-DETERMINANTS OF ENROLLMENT OF HIV-POSITIVE CHILDREN IN A PLACEBO-CONTROLLED STUDY

Steinberg, Katherine*; Calwell, T.*; Kambhni, J.*; Hillyough, A.*; Hertzstein, L.* and Subintstein, A.* *Albert Einstein College of Medicine, Bronx, New York. **National Institute of Child Health and Development, Bethesda, Maryland.

Objective: To identify psychosocial factors influencing enrollment of asymptomatic and mildly symptomatic HIV-positive children in a double-blind placebo-controlled intravenous gamma globulin study. **Methods:** Eligibility criteria: non-hemophiliac children under 13 years with CDC Classification P-3a, P-3c (not hypoxic), P-2b, T-2f. Consenting and refusing caregivers were compared re: guardianship and socioeconomic status. Supportive contacts prior to consent or refusal were enumerated. **Results:** Of 38 children eligible, consent for treatment was given for 13.

Guardianship	Consent Given	Consent Withheld	More than 1 prior supportive contact
biologic parent	9 (24%)	6 (18%)	with 9 (69%) consent-adoptive parent
adoptive parent	2 (5%)	1 (3%)	with 9 (69%) consent-
other family member	2 (5%)	4 (11%)	ing caregivers and with 2 (18%) withheld-
father care agency	14 (37%)	14 (37%)	ing.
TOTAL:	13 (34%)	25 (64%)	

 No socioeconomic difference noted between the 2 groups of caregivers. **Conclusions:** Biologic and adoptive parents are most likely to consent to the blinded treatment trial. Other family members are more likely to refuse consent while father agencies are the most reluctant. A supportive relationship with caregivers can positively influence study enrollment.

Th.E.P.59 CHANGES IN SEXUAL BEHAVIOR OF A COHORT OF FEMALE HEALTH CARE WORKERS DURING THE AIDS ERA

Cherry, J.* and DEPTERBERG, P.* *Medical Center, Los Angeles, California, U.S.A. *University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, U.S.A.

Objective: To determine whether health care workers (HCWs) in a university hospital with AIDS patients altered their sexual behavior from 1984 to 1987. **Methods:** As part of a prospective study on assessing the risk of occupational HIV infection, 116 female HCWs at UCLA Medical Center (Los Angeles) were enrolled in 1984 and completed follow-up 3 years later. At each visit HCWs responded to questions including demographic and sexual practices (sexual preference, number of sexual partners/year and number of sexual contacts/month). **Results:** Four sexual partners in 1987 were reported by 23 of 105 respondents whereas 73 had approximately the same number and 10 had more partners (p=02 for fewer partners). Those workers sexually active in 1984 (n=70) decreased their activity by 1.6 contacts per month in 1987 (mean \pm SD: 7.4 \pm 8.6 (1984) vs 5.8 \pm 5.6 (1987), p=.04). Fourteen of 100 HCWs changed sexual preference from male to female (n=5) or male to no sexual partners (n=12) during the 3 years (p=.04 for less male sexual contacts). **Conclusions:** After 3 years of follow-up female HCWs in a large university hospital in Los Angeles reported fewer sexual partners, fewer sexual contacts and less heterosexual activity, this may reflect an increased awareness of risk factors for community-acquired HIV infection.

Th.E.P.56 HEALTH PROFESSIONALS' VIEWS OF SOCIAL DISTANCE FROM PERSONS WITH AIDS AND OTHER CONDITIONS

Cohen, Melissa L.*; Muder, T.* *University of Illinois College of Nursing, Chicago, Illinois, United States.

Objectives: To determine the social distance health professionals feel comfortable putting between themselves and persons with AIDS or other conditions. To determine whether differences in social distance were perceived for persons in various AIDS transmission categories. **Methods:** The pretested instrument was developed using a modified social distance scale after the work of Bogardus and Gentry. It was distributed randomly to nurses, pharmacists, lab technicians and others at two large hospitals, one in a high AIDS prevalence area and one in a lower AIDS prevalence area in a midwestern state. 425 subjects received questionnaires, 219 responses were received for a response rate of 51.5%. **Results:** Respondents perceived the most social distance between themselves and persons with conditions that could be said to be under the voluntary behavioral control of the affected person such as drug resistance, sero-conversion, alcoholic, promiscuous persons, homosexuals, etc.; however, persons with AIDS from unknown sources had more than were virtually equal to homosexuals and bisexuals. No statistically significant differences were detected between those respondents in high/low prevalence areas. **Conclusions:** Those with HIV infection in AIDS or between AIDS and families. White respondents were willing to allow a closer social distance for all disease conditions and AIDS transmission categories except for IVDA's than were non-white respondents. **Conclusions:** Will be reported based on results.

Th.E.P.58 PERINATAL STUDY COMPLIANCE OF HIV-INFECTED WOMEN: SIGNIFICANCE OF RISK FACTORS AS A DETERMINANT

Douglas, Cecilie*; Cabot, T.*; Burt, C.*; Calwell, T.*; Robinson, J.*; Hillough, A.* *Albert Einstein College of Medicine, Bronx, New York. **National Institute for Child and Human Development, Bethesda, Maryland, U.S.A.

Objective: To determine whether specific risk factors influence compliance of HIV-infected women in a Prospective Perinatal Transmission Study. **Methods:** Of 80 women at risk for HIV infection enrolled in a perinatal HIV transmission study over a 3 year period, 45 (56.8%) were HIV-infected at entry, 60 (22/36) carried to term. Risk factors were determined by a structured questionnaire and counseling. They were categorized into 2 primary strata: (1) Past or current intravenous drug use (IVDU), (2) Heterosexual contact with high risk partners. Compliance was defined by the patients' attending drug use, post-partum visits within 6 months of delivery. **Results:** Of the 36 HIV-infected women, 61% (22/36) had histories of intravenous drug use; 39% (14/36) were infected as the result of sexual contact with an HIV-infected partner. 11% (10/94) completed the IVDU, the 14 women infected heterosexually, 11% (10/94) completed. In all cases, aggressive interventions and follow-up methods were employed. **Conclusions:** No significant differences in compliance between the 2 groups was observed. Aggressive interventions and follow-up may normalize differences between the 2 groups.

Th.E.P.60 SOCIAL ASPECTS OF AIDS: AN ANALYSIS OF ATTITUDES AND BEHAVIORS

Dr. Subintstein, A. and P.R. Subintstein, M.D.* *Medical Center, Los Angeles, California, U.S.A. **National Institute of Child Health and Development, Bethesda, Maryland, U.S.A. **Dept. of Medicine, National Medical College, Madras, India.

AIDS in the epidemic of economic, social, political, individual reactions and responses to HIV infection and AIDS. This epidemic of social distance is also viewed a global phenomenon. A public awareness about AIDS grows, as the number of HIV-infected persons and the number of AIDS cases rises steeply during next five years. The impact of AIDS and HIV infection on social and economic development may be critical. The present study is an attempt to analyze the attitudes and responses of AIDS epidemic in the help of perception theories and tools of behavioral analysis, on the origin and prevention of the disease, medical care, public sentiments among AIDS and other sero-negative individuals and psychological attitudes such as guilt, anxiety and depression and stressful reactions. The analysis of findings revealed that the people felt the need for useful therapies and they perceived that the most effective therapy begins to be a sense of well-being born out of a positive attitude towards life. Among urban population AIDS has caused a deep concern in the individual as well as a society whereas in rural areas the awareness of this new disease is negligible or not at all even reached. Among rural population the awareness on the prevalence of local diseases are found to be higher than AIDS. Still a higher percentage of population have no knowledge about the origin. Based on the findings it is felt essential that priority should be heavily laid to mass tv media programs in both urban and rural areas as the most necessary public health measures.

Session d'affichage Poster Session



Le SIDA, la société et le comportement
AIDS, Society and Behaviour

Les arts Arts

Th.E.P.61 OUR LADY OF AIDS: THE TALISMANIC DESIGN OF
SAUND DURAND'S PLAYS FROM "VOICIVE OFFERING"
Miller, James (Professor),
University of Western Ontario, London, Canada.

In 1987 London-based Canadian artist André Durand depicted the Princess of Heaven, the healer Touching American Pua Sunmye Sherman in "Voicive Offering," a large (8'x 12') oil painting in Renaissance style displayed in several British Churches in 1988. The icon includes portraits of saints traditionally associated with plagues and healing miracles (George, Sebastian, Catherine of Genoa) as well as images of doctors, nurses, and gay male PWAs.

Objective: To account for the survival of Renaissance plague iconography in the Age of AIDS; to discuss the healing function of "Voicive Offering" as a magical talisman and to consider the implications of Durand's iconography as a representation of PWAs as martyrs.

Method: A Renaissance iconological approach to Durand's imagery will be adopted to reveal its origins in Florentine theatre (Neoplatonic magic). Slides will be shown.

Conclusions: Western/medical notions of healing tend to flourish during plague-times when faith in the power of the medical and political establishments wanes. Durand's arcane art of healing is comparable to modern 'imaging' therapy.

Th.E.P.63 PRIVATE/PUBLIC SECTOR COOPERATION IN AIDS
EDUCATION

Donner, Ann; C. Bishop; Hillard, P.; Grant, C.;
University of Washington, Seattle, WA, USA; SAFECO
Insurance Companies; Seattle Public Schools; Plays for
Living, New York City, U.S.A.

SAFECO Insurance Companies, based in Seattle, awarded a grant to Plays for Living in early 1988 to develop an AIDS education play for students in Seattle Public Schools. Plays for Living, a New York-based organization with a Seattle office, hired a playwright, Bruce Peyton, to develop the play with a panel of local educators and SAFECO representatives. Like *Life* is a 30-minute dramatic play performed by young professional actors. The performance is the "first act" of the prevention effort. The "second act" occurs when students return to classrooms to discuss the play with trained volunteers using a study guide created for this purpose. The play was performed for 6,300 students (11-14 years) during the 1988/89 school year. The use of live theater was a powerful medium for AIDS education and the involvement of SAFECO increased the perceived legitimacy of the project, contributing to its success. Evaluative comments from students, a description of the play and its development, and recommendations for working with private sector companies will be presented.

Th.E.P.65 THE RURAL THEATRE PROJECT: AIDS EDUCATION IN THE VILLAGES
OF TRINIDAD

Neilson, Michael; Nelly, C.; Jan, R.; Almodi, C.;
AIDS/COM, Washington, D.C.; AIDS Educators, Trinidad and Tobago; New
York, USA; Trinidad and Tobago Red Cross Society; AIDS/COM, Washington, D.C.

Objective: To reach rural populations with an entertaining and educational theatre production that encourages discussion of AIDS prevention and the impact of AIDS on the community. To evaluate the effectiveness of the production and the impact on other Caribbean regions.

Method: An international collaboration developed and financed a communications research project to reach rural communities in Trinidad and Tobago with a popular theatre production that examined the impact of AIDS on a family in which a son who is bisexual contracts and dies of AIDS. A promotional campaign preceded the theatre presentation, an AIDS educator led group following the presentation. Written materials and condoms were distributed and the audiences completed evaluation forms.

Results: More than 700 people in 30 villages viewed the dramatic production during a five week period all located on sites in additional AIDS educational presentations, both in dramatic and written form. Most questioned the meaning of the "AIDS test" and how to avoid AIDS.

Conclusion: AIDS education via popular arts is well-received. This channel provides information in a friendly, non-threatening manner and encourages community discussion of AIDS. Theatre can help Caribbean populations address controversial subjects such as death, sexuality, and modern family life.

Th.E.P.62 Back to Basics/Use of Popular Theatre in AIDS Awareness
Campaigns

Spaulding,
Director of Fieldwork, School of Social Work, University of
Zimbabwe, P.O. Box 66022, Harare,
Harare, Zimbabwe.

Objective: To show how popular theatre can be used effectively as a tool in the AIDS awareness campaign.

Method: The paper seeks to show how popular theatre groups have been used in the campaign against AIDS in Zimbabwe. It examines some of the problems that have been encountered in using popular theatre and indeed what successes have been achieved. The main focus is on the achievements of a theatre group sponsored by a non-governmental organisation called AIDS Counselling Trust (ACT) which the author has been involved with. However, work by other theatre groups is also reviewed.

Results: The paper tries to show that although various approaches have been employed by various organisations to spread the message on AIDS, the message, it would appear, has not fallen on deaf ears. The majority of the people have started to take heed of the warning and change their sex and other habits. This paper argues that the conventional information dissemination methods and tools are often ineffective due to problems of inaccessibility (eg TV, radio, newspapers etc) for the majority of the population, and at times the practical inaccessibility of these media. There is therefore a need to develop fresh and more effective strategies for the campaign. **Conclusion:** In the light of the afore-mentioned problems, some organisations have gone 'back to basics' and introduced popular theatre as the latest weapon in the AIDS awareness drive - with a considerable degree of success.

Th.E.P.64 1989 PARTNERSHIP IN Caring CAREGIVER
CALENDAR

Kochman, Diane A.; Reister, C.; Health Resources and
Services Administration, Public Health Service, Department
of Health and Human Services, Rockville, Maryland, U.S.A.

Objective: A calendar was conceptualized as a visual expression of the message that AIDS is a human health problem worthy of a broad, societal caring response. Its purpose is to promote a partnership of community resources in providing such a caring response. This message was conveyed in a way which balanced hope and reality, and activated viewers, especially the uninformed, to engender a caring attitude and positive response.

Method: Collaboration with major AIDS organizations. Choice of a title which reflects the theme which is reinforced in the text. Each month focused on how different segments of society are responding. Illustrations were commissioned which symbolically and dramatically underscore the human dimension of AIDS and which move beyond stereotypes. Characters were selected from "heroes" in history to reinforce the visual images. Concrete examples of caring responses were developed, and a directory of national and local resources was included. **Results:** The enclosed 1989 calendar has been enthusiastically and practically received. It is being used in medical offices and facilities, in work places, in local state and federal government facilities, in religious organizations, and as a training tool to emphasize a multidisciplinary, "partnership" approach to AIDS care. **Conclusion:** The calendar will be considered for continuation in 1990, potentially as a handbook, and as a vehicle for involvement of the arts in the AIDS epidemic.

Th.E.P.66 PHYSICIAN-PATIENT RELATIONSHIPS IN AIDS DRAMAS
Bakajina, Genev' and Bhatia, R.C.

Johns Hopkins University School of Medicine,
Baltimore, Maryland, USA; Mount Sinai School of Medicine,
New York, New York, USA.

In the spring of 1985 two plays about AIDS, *As Is* by William Hoffman, and *The Normal Heart* by Larry Kramer, opened in New York City. The physician-patient relationships they depict provide insight into how people with AIDS and their friends perceive doctors and understand their relationships. Five nameless physicians function as shadowy, background figures who are unapproachable. They are perceived as expensive, insensitive, and ignorant. At the end of the play when the main character, Rich, is hospitalized with AIDS, a nurse and a janitor interact with him, and physician contact is noticeably absent.

In contrast to *As Is*, *The Normal Heart* portrays a physician, Dr. Ross Brooker, as an emotionally involved caregiver. She is politically aware and empathetic. She symbolizes everybody's vulnerability to disease because she is a victim of polio, who is confined to a wheelchair. In one scene she tells Felix, a major character, about his AIDS diagnosis. In another, she holds him as he dies.

By analyzing these two plays, one may appreciate the contrast between the special closeness Dr. Brooker and Felix share and the distance separating Rich and his doctors.

Session d'affichage Poster Session



Le SIDA, la société et le comportement AIDS, Society and Behaviour

La communauté (partie 2) Community (Part 2)

Th.E.P.67 THE FUNDACION SIDA DE PUERTO RICO EXPERIENCE
SOSD, Doracalberto, EN(C) A. Rodriguez, MS**
A. Nigallioni, MS(C) A. Menaux, MS** Fundacion
Sida de Puerto Rico, 251 University of Puerto Rico, San Juan,
Puerto Rico, U.S.A.

OBJECTIVES: To describe demographic, social and clinical characteristics of persons receiving services.
METHODS: Fundacion SIDA de Puerto Rico was established in 1983 as a volunteer community organization to provide services to persons with HIV infection, their families and significant others. Clients received services in four areas: prevention and education, emotional/practical support, financial aid and advocacy. We reviewed 182 records of clients seen from Oct. 1987 to Jan. 1989 (51% of consultative records).

RESULTS: There were 130 males (71%) and 52 females (29%) seeking services. The majority (53%) were in the age range of 30-39 yrs. Risk factor was known for 156 persons (86%) were homosexual and 76% were either IVDU's or their partners. PWA's accounted for 70%. PWAC 6% and asymptomatic HIV+ 24%. Most persons (91%) were from low socioeconomic background including some imprisoned (2%) and others homeless (6%). A large proportion (41 of 182) showed migration patterns with mainland USA. Close to half (48%) required direct financial aid, as well as emotional support (49%), and advocacy (28%).

CONCLUSION: Persons seeking aid from this community based service organization needed a wide variety of services. Long range goals of similar organizations should include these.

Th.E.P.68 Le Comité sida aide Montréal et ses activités

Langue Française

Directeur/Président générale du CSAM, M.V. (ada), M.A.P. Montréal, QC, Canada.

Le Comité sida aide Montréal fut mis sur pied en septembre 1985, par des intervenants de différents milieux. Depuis sa fondation, le Comité sida aide Montréal n'a cessé de progresser et d'améliorer ses services. Le CSAM est devenu par ses activités un organisme non-gouvernemental complémentaire du réseau de la santé et des services sociaux de la province, particulièrement à Montréal.

Avec l'expertise accumulée, les représentants du CSAM sont souvent appelés à travailler comme consultants dans divers endroits œuvrant dans la lutte contre le sida.

Les objectifs du Comité sida aide Montréal sont d'assurer le support aux personnes atteintes et à leurs proches, d'aider les personnes séropositives et leurs familles et amis; de prévenir et de sensibiliser le public sur la question du sida, sur la manière de se protéger, aider certaines populations dans ses comportements à risque, le CSAM intervient auprès des hautes instances afin que les décideurs aient toutes les informations nécessaires pour mettre de l'avant une politique d'aide et de prévention.

Th.E.P.69 HIV RELATED SERVICES MODEL FOR COMMUNITY SERVICE PROVISION
Rosen, Deborah M., D.,
New York State Department of Health, AIDS Institute,
New York, NY, U.S.A.

Objective: To describe a model for HIV-related community services which include outreach, community education and support services for persons with HIV infection, their partners and families.

Methods: Services are developed thru contracts with not-for-profit organizations throughout New York State. State initiatives are generated on the local level with input from community leaders, local health and human service providers to effectively respond to needs of specific regions/communities. This public/private partnership is strengthened as programs expand and become self-sustaining. The model is based on coordination with other community-based organizations and health and human services systems. Results: Since 1983, 16 community service programs (CSVs) have been developed through the State. Programs are located in urban areas to provide services to a regionally diverse area and hard-to-reach populations are served through volunteer task forces, satellite offices and staff stationed in home service settings.

Conclusions: Advantages of developing regional not-for-profit programs: greater flexibility in designing strategies for HIV prevention and support services which are responsive to regional needs; CSVs play a significant role in HIV related service delivery through identifying needs/gaps in services and coordinating provider resources to fill those gaps. The effectiveness of other health and human services in response to HIV is maintained through coordinating providers, thereby ensuring direct needs are met in an efficient and expeditious manner.

Th.E.P.71 LONDON LIGHTHOUSE - A CONTINUUM OF CARE
C. B. MacGregor, S. Halach, Dr S. Mansfield*,
D. O'Brien*, M. Pipes* et al.
*Management Team, London Lighthouse, London, UK.

Objective: To describe a unique model of care for people with HIV, ARC and AIDS in the London area which is of potential value in all health care planning strategies.

Method: The description of London Lighthouse, a community project, offers a continuum of care for people with HIV. This project has principles of love, respect and non-judgement in the UK. The centre's services are based as defined by people with the virus and on principles of love, respect and non-judgement. The centre's services are based on the London Lighthouse has grown in 3 years to become one of the largest AIDS voluntary organizations in the UK. The centre's services comprise the work of voluntary and statutory agencies. Care and emotional support are provided both in the home and within the centre, by means of counselling, training, health programmes and residential nursing care.

Conclusion: This basic model of integrated and continuous care can be incorporated into planning strategies for other local, national and international projects and could have far reaching consequences not only for people with HIV but also for other types of health care.

Th.E.P.70 CONTRIBUTIONS OF THE INTERNATIONAL GAY COMMUNITY TO AIDS RESEARCH

Falk, Lawrence A., Jr., Verick, W.A., et al. Committee for A Nobel Endeavor, Chicago, Illinois, USA

AIDS was first recognized within the gay community and since then other at-risk groups have been identified. Although the threat of AIDS is world-wide, particularly in developing African nations, early recognition of high density AIDS cases within the gay community provided scientists with a cooperative group of individuals, yielding numerous clinical specimens and essential information on probable transmission modes. The international gay community has played an essential role in advances of knowledge concerning AIDS:

1. Isolations of putative etiologic agent; lymphadenopathy associated virus (LAV), human T-lymphotropic virus type-III (HTLV-III) and AIDS associated virus (ADV), collectively classified as human immunodeficiency virus (HIV) were made from clinical specimens obtained from gay men.
2. In blood samples from gay men expedited development of blood screening assays which have reduced significantly transfusion-associated AIDS.
3. Provided the medical/scientific community with innumerable clinical specimens for immunologic and virologic studies.
4. Participated in clinical studies for safety and efficacy evaluation of potential therapeutic agents.

5. Developed and implemented educational and safe sex programs that have served as models for programs presently in place for other at-risk groups. These contributions of the international gay community will be summarized and reviewed and compared with initial advances in hepatitis B research and vaccine development.

Th.E.P.72 CREER UN MILIEU DE VIE: UNE APPROCHE ARCHITECTURALE NOVATRICE

Séguin, Gilles*, Morisset, R.** Gauthoin, J.***
*Commissariat Régional d'Hygiène, *Hôpital-Dieu de Montréal,
**Atelier Habitat/Urbanisme, Montréal, QC, Canada

OBJECTIF: créer un milieu de vie pour les personnes atteintes qui soit adapté à leurs besoins.

Méthode: le projet a été élaboré par une équipe multidisciplinaire composée de professionnels architectes, administrateurs, personnes atteintes, les individus dans l'intervention auprès des personnes atteintes ou ayant développé un projet similaire en fonction d'autres pathologies. Les différents étages de la maladie et les besoins spécifiques y étant reliés ont été cernés. Le type et le qualité de l'intervention ainsi que les besoins des intervenants ont été clairement établis.

RÉSULTATS: Le choix du site et le concept architectural qui réunit une rénovation sur un bâtiment ancien à une construction neuve témoignent d'une préoccupation majeure de créer un milieu de vie répondant aux différents besoins des personnes atteintes: cadre de vie familial, encadrement dans la communauté, vie communautaire, soins et soutien à la vie quotidienne, connaissance, sécurité et insécurité, silence-neuillisme vs communication-expression, présence continue, soins et soutien à la vie autonome, encadrement médical léger, activités récréatives et artistiques.

CONCLUSION: Un concept architectural polyvalent pour recevoir 11 personnes atteintes, 13 soins répartis par modules en fonction des besoins des intervenants ont été permis de répondre à un mixité de clientèle à différents stades de la maladie.

Session d'affichage Poster Session



Le SIDA, la société et le comportement
AIDS, Society and Behaviour

Éducation (partie 3) Education (Part 3)

Th.E.P.73 THE STOP/AIDS MODEL FOR COMMUNITY CHANGE: ACCEPTABILITY IN A LOW-INCIDENCE AREA FOR AIDS
Baker, Cedric M. Ross, T. J.
New York State AIDS Institute; Albany NY, USA

Objectives: To pilot a San Francisco-based risk reduction model in a low-incidence area for AIDS.

Method: The STOP/AIDS model, which uses the peer-led group meeting as a forum for education and support, appears to have been effective in changing sexual norms in the San Francisco gay community. Gay/bisexual volunteers from a GDU-funded AIDS prevention study were trained in a 20-hour seminar to implement the model in an area where seroprevalence is believed to be low. The trained volunteers recruited STOP/AIDS meeting participants through targeted outreach to gay bars, social networks and the prevention study cohort.

Results: During October through December 1988, 260 gay and bisexual men agreed at outreach activities to be contacted for participation in a local STOP/AIDS meeting. At recruitment, 188 men were scheduled for one of 14 meetings; 86 men (46%) actually attended their scheduled meeting.

Fifty-five meeting participants (63%) expressed interest in becoming STOP/AIDS project volunteers. Attrition rates are comparable to those reported for New York City and San Francisco.

Conclusions: The acceptability of STOP/AIDS at this pilot site suggests that the model may be exported to communities outside the AIDS epicenters. Even where seroprevalence is low, the need for information, emotional support and social action may be high. Studies are now needed to evaluate the effectiveness of the model in motivating sustained behavioral change.

Th.E.P.75 RESOURCES FOR EDUCATING ABOUT MARRIED HOMOSEXUAL AND BISEXUAL MEN - A FACILITATOR'S KIT IN ACTION
Moloney, John W. Education and Liaison Officer
Gay and Lesbian News Association, Melbourne, Victoria, Australia

Objective: To review materials specifically developed to assist in the understanding of the nature bisexual behaviours and H.I.V. transmission, and the significance this has for educating married homosexual men.

Methods: A review of materials contained in the AIDS and Bisexual men and their partners - Facilitator's Kit, analyzing the approaches most appropriate to educating the target group. Exploring the needs of married homosexual men and their partners, and the implications that these have for educating about H.I.V. prevention.

Results: First hand experience at using materials and the implications that these have for educating about the relevance of the content of the content and the strategies in working with or identifying the needs of married homosexual and bisexual men and their partners.

Discussion: The Facilitator's Kit contains workshop resources which provides participants with experiences leading to an understanding of the range of constraints and needs experienced by married homosexual men and the implications that this has for the education about AIDS and the prevention of transmission.

Conclusion: The opportunity to discuss and explore the issues related to bisexuality, enables one to more fully appreciate the needs and concerns of many men in or community who may be at risk of contracting H.I.V.

Th.E.P.74 EDUCATIONAL INTERVENTION IN A COHORT OF HOMO/BISEXUAL MEN TOWARDS A CHANGE IN HIGH RISK BEHAVIOR FOR HIV INFECTION: AN ASSESSMENT OF THE PROCESS AND ITS EFFECTS.
Cabrera, Carlos; Marcial, F. P. De la Vega, E. M.; Torres, E.; Riera, H. M.; Ruiz, de Mend. Trinidad. A. von Humboldt Univ. Berlin. *MEXICO-Centro. Lima, Peru. **AIDS/CN/Agency for Educational Development, Washington, U.S.A.

Objectives: Developing an educational intervention in a cohort of homo/bisexual men in Lima, pursuing an increase in their knowledge about HIV/AIDS and the adoption of safer sexual practices.

Methods: Fifty middle class homo/bisexual men in Lima, Peru, attend a program of three workshops offering general information about HIV/AIDS and negotiating safer sexual practices, through several group dynamics and audiovisual methods. Pre- and post-workshop questionnaires are given to attendees; so are surveys about the workshops themselves. One month after the last workshop, another questionnaire is given. The trial is controlled through comparison with a non-interventive, parallel group.

Results: The program, begun in 1988, is continuing. The results from the first stages show that: (a) the starting knowledge level was high, so it did not rise significantly; (b) the attendees were generally willing to assume promptly behavioral changes towards risk reduction; and (c) the workshop was generally found to be entertaining and of appropriate length. The information appeared to be new and of appropriate complexity, and the audiovisual presentations were well accepted.

Conclusions: This program shows to be welcome and to succeed in producing the desired for behavioral change. The information level, which was already high when the trial began, does not increase significantly.

Th.E.P.76 STD PATIENTS' AND PROSTITUTES' KNOWLEDGE ON AIDS: MODIFICATION OF SEXUAL PRACTICES, AND EDUCATION NEEDS.
Z. Ezidiye, K. J. Fasanjo, G. Ogunseun
Obafemi Awolowo University, Ife-Ife, Nigeria

Objectives: To assess STD patients' and prostitutes' knowledge of AIDS with a view to identifying education needs and to assess if knowledge of HIV-status could influence sexual practices.

Methodology: 50 randomly selected STD patients and 25 prostitutes/whorehouses were interviewed concerning knowledge on AIDS, and sexual practices. HIV-antibody screening was carried out on all and the results were made known to them. Participants were reinterviewed 6 months later concerning their sexual practices after knowledge of HIV-status.

Results: There were serious gaps in knowledge about transmission and prevention in both groups. Majority of STD patients had prostitutes as clients while prostitutes were not discriminatory. Some used condoms regularly. Majority of participants who know that condoms could be used to prevent STD were not sure of its effectiveness in the prevention of AIDS. Over 50% of the prostitutes who screened negative for HIV-antibody responded 6 months later that they now limit on usage of condoms while 20% of STD patients said they now keep to sex normal partner or regularly use condoms.

Conclusions: Identifying various gaps and other areas of education needs could be used to provide effective information needed to design health education strategies. Knowledge of the negative status of HIV-antibody could possibly be used to modify sexual behaviour in high risk groups. Integration of AIDS messages into STD services is recommended.



Le SIDA, la société et le comportement
AIDS, Society and Behaviour

Publications

Éducation
Education

E.501 CULTURAL DIFFERENCES IN AIDS-RELATED ATTITUDES, BELIEFS, AND BEHAVIOR CHANGE
Zimmerman, Rick S.; Stevens, K. A.; Fischl, N.
University of Miami, United States.

Objective: To assess differences among Hispanics, non-Hispanic Whites (Angles), American Blacks, and Caribbean Blacks on AIDS-related attitudes and beliefs and their impact on reported behavior change.
Methods: A subsample of 100 of respondents recruited in primary care and STD Clinics for a high-risk heterosexual transmission study received a 25-minute interview. Group differences were assessed with ANOVA, and correlations assessed relationships with behavior change for each of the 4 groups.
Results: Hispanics were most worried about contracting HIV, Caribbean blacks and Hispanics had the strongest moral associations with AIDS. Angles had the most negative feelings about condom use, and Angles and American Blacks had the most negative feelings about the various groups. American Blacks and Blacks reported the greatest intentions to change sexual behaviors, though there were no differences on reported behavior changes. Different variables predicted reported behavior change for the various groups. American Blacks who believed that the proportion of PMA who were women and heterosexual men was high, those with a positive attitude toward reducing sexual partners, and those who saw HIV as preventable were more likely to reduce risky behavior. Hispanics who had strong moralistic attitudes about AIDS, believed promiscuity was important in sex, and that their friends would approve of increased condom use were more likely to have reported change.
Conclusion: There are important cross-cultural differences in beliefs and attitudes about HIV as well as differences in predictors of behavior change. These results have important implications for public health education.

E.503 FOSTERING PUBLIC-PRIVATE PARTNERSHIPS: The New York City Experience. *Mohr, J.; Macgregor, C.; Hantover, Eliza; Maysa-Coslar, R. J.* New York City Department of Health, New York City.

Objective: To describe the design and outcome of the NYCDOH technical assistance initiative for community based organizations under contract to provide AIDS prevention services.
Methods: During the 12 month fiscal year 1988-89, NYCDOH let 30 contracts with community based organizations for the provision of AIDS education and outreach services. To facilitate the coordination and effectiveness of resultant programs, DOH staff provided technical assistance to the contractors. This assistance included program development, training, evaluation design, coordination of borough and city-wide collaborative efforts, and on-site program review.
Results: Requests for technical assistance in the initial stages of the initiative were administrative in nature, i.e. clarification of fiscal and contractual policies and resources availability. Requests made by organizations later in the year concerned more programmatic issues, i.e. staff training, outreach skills, development of referral sources, and evaluation.
Conclusion: The provision of technical assistance must be responsive to the specific needs of recipients. Several factors influenced need and demand for technical assistance, including geographic density of similar projects; size, age and sophistication of agency; familiarity of agency with contract procedures; and complexity of service scope. Thus, a multi-tiered approach was utilized: 1) organizational development, 2) review and staff development, 3) quality assurance and evaluation, 4) review and expansion.

E.505 SOCIAL IMPACT OF HIV INFECTION IN WOMEN.
Barfield, Robert; Oberlin, C.J.; Stone, University Medical Center, Providence, RI USA.

Objective: To study the impact of HIV infection on the families of affected women. **Methods:** 31 HIV-seropositive women, 34 infected by intravenous drug use (IDU) and 9 by heterosexual transmission (HT), were thoroughly evaluated and assessed for 33-month (mean) in a multidisciplinary evaluation. Several factors influenced need for services observed and family counseling was provided. **Results:** The 31 women (mean age 31) had 31 HIV-infected children, ranging in age from 1 to 20 (mean age 12 years). 5 of the women had no living children. For the remaining 26 women, nuclear family structures consisted intact in only 3 instances (12 of 8 infected via IDU and 1 of 21 via HT). Among the remaining 23 women with children, 5 were widowed as a result of AIDS. 11 were divorced and 8 had never married. In only 7 of the 23 families were all older children living with the affected mother. With all women who lived with one or more children, problems related to child care had a negative impact (e.g., difficulty in keeping satisfactory care appointments) on nuclear health care. **Conclusions:** The societal impact of HIV infection is disproportionately large. Much because of the effects of maternal HIV infection on family structure, and because obligations to children often interfere with health care of the mother. More comprehensive efforts to deal with the medical, social and economic aspects of HIV infection in women are urgently needed.

E.502 COMMUNITY-BASED PROJECTS FOR HIV PREVENTION: TYPES OF ORGANIZATIONS, TARGET POPULATIONS, AND EDUCATIONAL STRATEGIES
Kobehuchner, Robert; Martin, F.A.; Diets, E.J.; West, G.R. Centers for Disease Control, Atlanta GA, USA

Objective: To provide financial support and technical assistance to minority and other community-based HIV prevention projects.
Methods: On January 9, 1989, the Centers for Disease Control (CDC) announced the availability of funds for minority and other community-based HIV prevention projects. These projects will be conducted in coordination with existing community organizations including State and local HIV prevention programs. To July 1989, awards will be made to approximately 75 community-based organizations. The CDC expects a large number of organizations to apply for this funding.
Results: Authors will report on the number and types of organizations applying for funds, the demography and risk groups of the target populations to be addressed, their size, and the amount of funding requested. Authors will summarize the proposed outcomes for these projects and the types of activities designed to contribute to their achievement. Authors will discuss the relative likelihood of the success of these projects based on the quality of their plans and their relationship to models of behavioral change. This information may be useful to community-based organizations in designing more effective proposals for behavioral change.

E.504 THE IMPACT ON CHILDREN WHOSE PARENTS OR LOVED ONES HAVE HIV DISEASE
Seligson, Rebecca; Private Practice, counselor and consultant, Cascade AIDS Project, Portland, Oregon, U.S.A.

Objective: To describe the unique personal, social, and familial issues children face when a parent or adult friend has HIV disease.
Methods: Interviews and counseling sessions with male and female children between the ages of 10-18 years and their parent, relative, or adult friend.
Results: Information gathered indicates that there are unique complexities children and their family members experience. Some of these complexities are: isolation, fear, anger, loss, shame, and a need to hide. These identified issues are greatly intensified because of the stigma paired with HIV disease.
Conclusion: Children who live with or know someone with HIV disease face unique difficulties. It is extremely important to identify and assist these children in breaking the cycle of fear and isolation. Care providers need to help children access their barriers and feelings, introduce accurate information about HIV disease, and connect them with appropriate support systems.

E.506 EVALUATION OF CARE PROVISION TO AIDS PATIENTS AND PSYCHOLOGICAL PROBLEMS OF RELATIVES OF (DECEASED) AIDS PATIENTS
Bloom, Frans M. van den; Koozenburg, Hans Netherlands Institute of Mental Health, Utrecht, Netherlands

Objective: Evaluate hospital and homebased care; inventory of psychological problems and coping mechanisms of relatives. By striving for more hospital and home care, the pressure on the supportsystem (partners, family, friends) will only increase, meaning that the patient's social network will be increasingly confronted with shorter and more frequent episodes of hospitalisation. Relatives of deceased AIDS patients are a valuable source of information with respect to the quality of health care, with respect to the feasibility and adherence of homebased care, to their own need for support and help, burn out, and dealing with the process of becoming ill, dying and death.
Method: Interviews with relatives of 100 deceased AIDS patients (the total number of deceased patients in the Netherlands is 300).
Results: The first results of the study, based on 25 interviews, will be presented.



Publications

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

- E.507** PSYCHOLOGICAL STATUS OF PARTNERS OF HAEMOPHILIACS WITH HIV INFECTION: A CONTROLLED INVESTIGATION.
Kilwein, J., Catalano, J., Bono, A., Gerrard, A., Day, A., and Rizza, J.
- Objectives:** To establish prevalence of psychological problems in partners of HIV haemophiliacs; to compare it with that of the infected partners; to identify the characteristics of those with problems; to assess the need for further psychological intervention.
- Methods:** Partners (n=36) of randomly selected and matched for haemophilia severity HIV (+) (n=17) and HIV (-) patients were studied. Measures included psychiatric status (DSG, FOMS, haemophilia), social adjustment, social functioning, coping (self-esteem, health locus of control, Hardiness).
- Results:** The majority of HIV+ subjects were asymptomatic. All the women with HIV-. Psychological status, coping style and other measures of partners of haemophiliacs were not affected by the men's HIV status. There was a trend suggesting that the women had worse psychological functioning than their partners (whatever the men's HIV status), but this seldom reached statistical significance.
- Conclusions:** Partners of HIV asymptomatic haemophiliacs do not appear to suffer more psychological difficulties than those of HIV+ haemophiliacs. Possible reasons for this are considered, and include their being aware of their partner's HIV status for at least three years, and their prior experience of coping with a chronic condition such as haemophilia.

- E.509** A LONGITUDINAL STUDY EXAMINING THE IMPACT OF AIDS AND HIV ON PATIENTS AND THEIR FAMILIES - RESULTS FROM INDIANA, TEXAS AND NEW YORK STATE DATA.
Charles, John, Bonde, A.E., Hensels, L.F., Owen, J., Sherman King, St. Mary's Hospital, London, UK, IRE, U.K.
- Objectives:** To assess with targeting support for infirmal carers by 1) determining anxiety and depression levels in carers 2) establishing the degree of role, habit and attitudinal changes experienced 3) Identifying factors predictive of positive or negative outcome.
- Methods:** Infirmal carers of PWA's and family caregivers were recruited (N=50). Anxiety and depression questionnaires were given along with the St. Mary's Personality, Behaviour and Cognitive Changes questionnaire. Controls were cancer cases (N=50).
- Results:** Carers' lives are greatly affected by the conditions of their partners. Their work and social lives are severely restricted. Very carers reported positive relationship changes. Social support and satisfaction with social support was significantly correlated with anxiety and depression levels in the carers. (P<0.1). Carers at time one were highly socially oriented, 25% being care workers and depressed than index patients. This in itself did not have a welfare effect on anxiety and depression scores in carers. There was a trend for carers to have higher anxiety scores at time two. Those and distressed at time one and two, had less social contact at retest. A predicted factor of increase in stress levels from time one to time two was the perceived (rather than actual) impact on work, social life etc. Correlations with impact on carers of cancer patients are also presented.
- Conclusions:** The impact of the caring role can be horrendous. However, it is possible to locate factors indicating need for support in carers and the areas in which it should be provided.

E.511

- E.508** THE ROLE OF PEOPLE WITH AIDS. THEIR FAMILIES AND FRIENDS AS HEALTH EDUCATORS IN THE AIDS EPIDEMIC
Innes, R., Becken, P., Paine, G. PEOPLE WITH AIDS AND AIDSWORK, Washington DC U.S.A., *National Association of People with AIDS
- Objectives:** To demonstrate that people with AIDS and their loved ones continue to be effective in AIDS education and prevention efforts; and to explore ways of overcoming cultural, social and political resistance to their participation in that capacity.
- Methods:** A panel will model the effectiveness of the peer education approach. Though peer educator programs have been shown to be most effective in reaching people with health promotion messages, this model frequently encounters community resistance when applied to AIDS prevention. A message with AIDS at a classroom presentation may provide the most effective AIDS prevention message to most audience, school boards and/or parents may resist this. The authors discuss ways of working with community groups to promote use of People with AIDS, their families and friends as AIDS educators.
- Results:** Though health education campaigns have repeatedly shown the value of peer education, there is still much resistance to having individuals known to be infected with HIV appear at public presentations, in classrooms, churches, etc. A panel of HIV-infected people model ways to overcome this resistance, describe people living with HIV infection, and promote not only healthier lifestyles, but also compassion and understanding.
- Conclusion:** People with AIDS/ARC/AB+, their families and friends can be effective spokespersons in AIDS prevention efforts.

- E.510** THE IMPACT OF AN AIDS DIAGNOSIS ON PATIENTS AND THEIR SOCIAL SUPPORT SYSTEMS
Lambert, Richard, Janowski, S.,* Vitek-Sharman, L.** Albany Medical Center, Albany, New York, U.S.A., *Albany Veterans Administration Medical Center, Albany, New York, U.S.A., **State University of New York at Albany, New York
- Objectives:** The primary purpose of this study was to obtain information about the impact of the diagnosis of AIDS on the social support system of persons with AIDS (PWA's).
- Methods:** Qualitative, semi-structured interviews with fifteen PWA's and their primary helpers were completed to obtain thorough and specific descriptive information about the impact of the illness on patients and their social support networks. Computerized analysis of this qualitative data was conducted with the Ethnograph analysis software. Interviews were analyzed according to grounded theory qualitative content methods (Glaser and Strauss, 1967).
- Results:** The PWA's and their primary helpers reported profound effects on their social networks due to the diagnosis of AIDS. The stigma associated with the illness resulted in reduced levels of support for the primary support network, and placed them at higher risk of isolated stress. The diagnosis impacted on the depth and structure of the relationship between the PWA's their primary supporters and their social support network.
- Conclusion:** The needs of the primary support network should be assessed and addressed by the mental health professional.

E.512

- PREVENTION METHODOLOGIES FOR WOMEN AT RISK FOR AIDS**
Altmann, Christine and Flanagan, L.P.
Thomas Jefferson University, Philadelphia, Pennsylvania, U.S.A.
- As part of on-going efforts to prevent HIV infection in women at risk, 42 drug dependent pregnant and post-partum women receiving comprehensive treatment were surveyed. Drug use history revealed that 50% are current or past IV drug users with an average of 12 years of needle sharing; 87% of the subjects reported cessation of needle sharing. The women completed questionnaires detailing their sexual and risk behaviors followed by a 30 minute factual didactic session on AIDS. Questionnaires were repeated two to three weeks after the session. Results revealed that 79% are currently engaged in some risk behavior for HIV infection, such as prostitution, lack of condom use and sexual partners who are IV drug users. Nearly all women (97%) knew that AIDS is spread by sharing needles and 85% knew how to effectively clean needles. All women knew that condoms provide protection during intercourse. The women showed concern about AIDS and 71% feared infection, but did not believe they would catch the disease in spite of their past and/or current high risk behaviors. Didactic sessions had little influence on the subjects' knowledge and behavior since differences in pre and post tests were insignificant. These women are clearly at high risk for exposure to HIV infection, both through sexual and needle sharing behavior. Although this survey revealed some cessation of needle sharing practices, condom use and other safer practices were negligible. Conventional teaching efforts had a limited effect on increasing knowledge or changing behaviors. Therefore, these women clearly remain at risk for future infection in them and their children until IV drug use ceases and sexual behaviors change. As a result of this study, other methodologies are being defined in an effort to prevent HIV infection in women who are involved in high risk behaviors.



Publications

Le SIDA, la société et le comportement
AIDS, Society and Behaviour
E.519 AN ETHNOGRAPHIC STUDY OF THE SEXUAL PRACTICES AND DRUG BEHAVIORS OF INTRAVENOUS DRUG USING MALE PROSTITUTES
 Becker, Kenneth D., * University of Cincinnati, Cincinnati, Ohio, U.S.A.

*Cincinnati Health Department; West Central AIDS Education and Training Center and REACH Program, the National Institute of Drug Abuse (NIDA); Cincinnati, Ohio, U.S.A., ** University of Cincinnati, Cincinnati, Ohio, U.S.A.

Despite a widespread belief that safer sexual practices have been adopted by many gay and bisexual men, little research has been conducted to determine the extent of behavioral change that has occurred among male prostitutes since the appearance of AIDS. Additional knowledge in this area is important to determine what factors might be involved in designing behavioral change programs to influence these individuals to reduce or eliminate their AIDS risk behaviors.

Methods: Ethnographic techniques were employed to gain access to a cohort of 30 male prostitutes over a four year period from 1985-1989. **Results:** Half of this sample had used intravenous drugs at least once. All had practiced unsafe sexual behavior on multiple occasions with different partners. Six of the individuals stating that they had practiced unsafe sex also had knowledge of their own HIV seropositivity. The unsafe sexual behavior continued to the present time and for some of the individuals was reported to be increasing along with IV drug use. **Conclusions:** Effective behavioral change programs are needed to decrease transmission of HIV among male prostitutes and their sexual partners.

E.521 EPIDEMIOLOGICAL VARIABILITY AND HIV TRANSMISSION AMONG LONDON PROSTITUTES
 Heston, London, U.K.

J. S. HAY, M.D., M.Sc., J. S. W. HARGIS, The Prud'homme Clinic, St. Mary's Hospital, London, U.K.

Objective: To assess the influence of geographical mobility in relation to HIV infection among prostitutes seen in London.

Methods: An analysis of geographical mobility among 122 women in the Prud'homme Clinic prostitutes cohort was made in the context of regular inter-city and correlated with HIV status and socio-demographic factors.

Results: Forty women (33%), including 1/23 non-British nationals, have worked abroad since 1979 in a total of 20 countries.

No. Visits	Class of Work				
	Male	Continental	Australia	Far	North
	East	Europe	East	West	America
0	21	22	19	5	5
1	1	1	1	1	1
2	1	1	1	1	1
3	1	1	1	1	1
4	1	1	1	1	1
5	1	1	1	1	1
6	1	1	1	1	1
7	1	1	1	1	1
8	1	1	1	1	1
9	1	1	1	1	1
10	1	1	1	1	1
11	1	1	1	1	1
12	1	1	1	1	1
13	1	1	1	1	1
14	1	1	1	1	1
15	1	1	1	1	1
16	1	1	1	1	1
17	1	1	1	1	1
18	1	1	1	1	1
19	1	1	1	1	1
20	1	1	1	1	1

Those who worked abroad were more likely to work privately or for agencies in London than those who did not (20/40 v 30/82, $p < .001$) none was HIV-1 seropositive. On all but 4 visits abroad, mobility was associated with the more or lesser degree of on-site use.

Conclusion: The London cohort is characterized by high mobility, especially among better paid prostitutes, and the place of work influences the safety of the contact. The potential role of prostitutes as "bridges" between areas of relatively high and low HIV prevalence is not borne out in the London study as travel is not associated with areas of known high prevalence.

E.523 SEXUAL PRACTICES AND HIV RISK FACTORS: THE GEOGRAPHY OF PROSTITUTION IN RIO DE JANEIRO, BRAZIL
 Richard G. Barker, Ph.D.
 Universidade do Estado do Rio de Janeiro

Objective: To differentiate distinct forms of prostitution in Rio de Janeiro, Brazil, and to analyze variations in risk-related sexual behavior.

Methods: Descriptive description, based on in-depth interviews with selected informants, is used to distinguish between different forms of prostitution and to map out the social geography of Rio de Janeiro. Patterns of sexual behavior can be linked to patterns of HIV transmission.

Results: Class and gender emerge as key factors in differentiating distinct forms of prostitution. A distinction is made between female prostitution, transactional prostitution, and male prostitution, which, depending on the class background of the participants, take place in specific areas of the city and can be tied to specific sets of sexual practices. Different types of prostitution in different areas involve distinct patterns of heterosexual, homosexual, and bisexual behavior, as well as distinct patterns of vaginal, oral, and anal intercourse.

Conclusions: Understanding these diverse forms of prostitution is essential to understanding the role of prostitution in the spread of HIV, as well as to developing effective AIDS information materials for individuals who are involved in prostitution.

E.520 CULTURAL CONTEXT OF HIV INFECTION AMONG HOMELESS FAMILIES IN NEW YORK CITY
 Sabatelli, Jim
 Community Health Education, Hunter College and HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute, New York, New York, U.S.A.

Objective: To explore the significance of HIV infection and AIDS among residents of homeless shelters with particular attention to women and children in terms of their own understanding and strategies for prevention.

Methods: Field work, structured interviews, participant observation, discussions with groups and collection of documentation. **Results:** Most people in shelters have heard of AIDS; the exception is those who speak mainly Spanish and live in hotels for the homeless. Most people are aware of the main source of transmission. A clear issue emerges with regard to the limitations to their implementing preventive strategies within the life-style imposed by homelessness and lack of resources.

Conclusions: Prevention, either through individual counselling or mediated through medical care facilities, spreads information but attention to the social and economic situation will be needed for more effective change to be implemented.

E.522 SEXUAL PRACTICES AND CONDOM USE AMONGST MALE PROSTITUTES IN LONDON: DIFFERENCES BETWEEN STREETFORING AND NON-STREETFORING PROSTITUTES
 Johnson, T.V., * Bristol, *Bristol, *Bristol
 *South Bank Polytechnic, London, U.K., **Friends' World College, London, U.K.

Objective: To examine the differences in sexual and other practices relevant to the risk of HIV infection between non-streetworking male prostitutes (non-SFPs), commonly known as "call boys", and streetworking prostitutes (SFPs). **Methods:** Between November 1988 and January 1989, as part of an ethnographic study, 12 non-SFPs, 10 SFPs and 7 clients completed a 2h hour-long structured interview concerning sexual practices, condom and drug use.

Results: Reports from non-SFPs and their clients disagree on the incidence of anal intercourse with their clients is low but is higher with non-paying partners. Moreover, they say that condoms are more likely to be used with clients than with other partners. Their clients, however, report anal intercourse to be common.

According to their self-reports, SFPs are more likely to engage in anal intercourse with their clients than non-SFPs. With non-paying partners, anal and vaginal intercourse is high. They report lower rates of condom use than non-SFPs in both cases.

Conclusions: High risk sexual behavior is more likely between prostitutes and their non-paying partners than with clients. SFPs are more likely than non-SFPs to engage in such behavior with both groups of partners. Differences in the reports suggest that some non-SFPs are more likely to engage in "high risk" activities than others.

E.524 THE RESEARCHER-ADVOCACY MODEL: IN THE STEEL OF PMA'S PSYCHO-SOCIAL SUPPORT AS A FEATURE OF PSYCHOLOGICAL RESEARCH
 Shewley, Sylvia G., Ph.D. Physician Behaviour Unit, University of Toronto, Toronto, Ontario, Canada.

Background: Because fatally ill patients (such as PMA's) participating in psychosocial research require researcher support, I adapted Ocaselli's researcher-advocacy model. This study examines its effectiveness for highly stressed research participants.

Objective: This descriptive paper analyzes the methodological features of SOC research projects with 100% participation rates until respondent's death.

Methods: The adapted model is based on PMA's (1) life expectancy; (2) emotional vulnerability; (3) stress levels. Researcher-advocacy includes: (a) type and frequency of feedback; (b) relationship between the researcher and PMA's social network; (c) the researcher's role vis-à-vis PMA's.

Results: The model provides guidelines to psychosocial AIDS researchers. Research was assessed by PMA's and PMA's as a "humming experience" in the two psychosocial studies reported. Where participation was continuous despite acute disease, stress, and opportunity for non-participation, researcher burnout was limited by the reciprocity of support built into the model.

Conclusions: Literature indicates that PMA's are aware of the potentially de-personalizing features of clinical care. The philosophy, structure and continuity of the researcher-advocacy model may counteract the stress experienced by otherwise socially stigmatized research participants.



Le SIDA, la société et le comportement

AIDS, Society and Behaviour

E.525

DEPRESSION LIQUO-INDUITE DES DEFENSES SOCIALES.

RESUME: LIQUO-INDUITE
UNIVERSITE Paris XII Val de Marne, Créteil, France.

Objectif: Décrire la nature des résistances sociales opposées au changement des pratiques sexuelles.

Méthodes: Enquêtes longitudinales:
- enquête de référence BVA-INSEEM, échantillon 1.000 personnes à risques, septembre 1989
- enquête réalisée auprès de 400 étudiants, Laboratoire de Sciences Sociales appliquées, Université Paris XII Val de Marne, Septembre 1989.
Résultats: La sociabilité française qui souvent oppose le privé et le public voit aujourd'hui s'affaiblir momentanément ses défenses collectives: l'information SIDA transmise par les médias et rationalisée par la santé est l'information considérée en réalité virtuelle, hors du champ de la santé privée, hors sujet pour l'individu, stoppée dans l'espace de la télé-sociabilité et donc sans prise sur le comportement des pratiques sexuelles.

Conclusion: Nécessité d'une information de proximité qui relève du génie social.

E.526

PONTIERS DE RISQUE ET SIDA PARMI LES TROISOMES ESPAGNOLS

USCIBO, IBEROPO, SERRANO, J.M.; ANASTASIOU, J.M.; TORRES, J.;... DE NERVO, J.M.;...
* UNIVERSITAT DE VALÈNCIA, INSTITUT DE NERVO, ESPANA; ** MAJORE DE VIDUA, ESPANA; *** UNIVERSITAT DE VALÈNCIA, INSTITUT DE NERVO, ESPANA; **** UNIVERSITAT DE VALÈNCIA, INSTITUT DE NERVO, ESPANA; ***** UNIVERSITAT DE VALÈNCIA, INSTITUT DE NERVO, ESPANA; ***** UNIVERSITAT DE VALÈNCIA, INSTITUT DE NERVO, ESPANA.

Objectif: Connaître d'une façon scientifique la situation des troisomes espagnols en face du SIDA (après les pratiques de risque). Connaître leur opinion en toutes les matières relatives au risque d'être porteur de VIH ou de développer le sida. Étude détaillée des changements des habitudes, etc. des troisomes espagnols. Étude de l'émergence et du refus social en l'Espagne. Méthode: Enquête d'opinion pour toute l'Espagne. Personne âgée de plus de 14 ans. Proportionnel par sexe des villes de moins de 50.000 habitants et plus de 500.000 habitants. Par régions, sept, huit, etc. Questionnaires: 330 questionnaires et réponses possibles. Résultats: 1.117 réponses valides. Avec une erreur $\pm 3,8$ points de confiance ± 2 (95,3%) et la variance pondérée $\pm 10,5$ SD.

Méthodes: 70% des troisomes ont manifesté ou indirectement manifesté le plaisir d'être en tant qu'adulte. Ils ne peuvent pas répondre: 70% à la fois des relations sexuelles avec 5 personnes différentes. Le motif des hommes a réalisé l'évaluation orales et la moitié des femmes ± 10 points. 40% d'emploi entre méthode anticontraceptive. 40% ou corrélaté par le SIDA au risque d'être infecté. 60% s'injecte de l'héroïne, 40% de la cocaïne. Un 30 seulement utilise le préservatif, et cela 20 en usage de contraceptif par jour.

Conclusion: Face à l'apparition du SIDA, 40% connaît le partage par d'agitation et de seringue. Plus de 20 ne peut pas se détacher des drogues. Également, on a constaté d'être des relations avec des prostituées (LIM) 20% a refusé le risque de contracter. 50% propose de tenter le trafic par quitter la drogue définitivement.

Services sociaux

Social Services

E.527

PSYCHOLOGICAL CONSEQUENCES OF INFORMAL CAREGIVING TO GAY- MEN WITH AIDS. N.Y.: KENNEDY, VICTORIA, M.; KLEBER, C.; SEGAL, J.; ROYCHAK, A.; HERRICK, D. IONIA, NEW-YORK, CANCER CARE, NEW YORK CITY, U.S.A.

Objectif: To understand the psychological consequences of providing informal assistance and care to gay men with AIDS.

Method: Structured individual interview with gay men with AIDS and their primary caregivers.

Results: The main sources of social support and informal assistance to gay men who were diagnosed with AIDS (in the last 12 months) are their friends and lovers, followed by family members. Analyses of the initial interviews with 20 informal caregivers reveals that, even in the early stages of the disease, when the large majority of the AIDS patients were still functioning well, providing care and assistance was seriously impacting on the caregivers' own lives. A substantial minority of caregivers reported experiencing physical strain, financial burdens and employment related burdens. A sizable minority also scored in the clinical range on at least one of two measures of psychological distress (CES-D or Rutter Malaise). There is little evidence of negative coping strategies, in the form of increased substance abuse, at this stage in their caregiving experience. Furthermore, there are indications that, at least within the first year of the patients' illness, caregivers are finding some satisfactions in their role, feeling good about the job they are doing and finding it to be a source of self-esteem.

E.528

THE ESSENTIAL ROLE OF CASE MANAGEMENT AND COMMUNITY SUPPORT FOR HOME TREATMENT OF PERSONS WITH AIDS. RURAL REGION. ILLINOIS, A.; LIEBOW, R.; BARTLET, L.A. DAKA UNIVERSITY MEDICAL CENTER, DURHAM, NORTH CAROLINA, U.S.A.

Objectif: To assess the need for case management and community support services in a largely rural region for the successful treatment of AIDS patients at home.

Methods: Patients (22) who received therapy for an AIDS defining illness were included for analysis. All persons received at least a portion of their therapy at home. A positive outcome was defined as successful medication at home; negative as admission to the hospital or death. **Results:** Six persons received a complete course of therapy at home, while 16 began home while hospitalized and completed their course at home. Diagnoses included PCP (6), cryptococcal disease (6), CMV (5), wasting/syndrome (4) and lymphoma (3). Therapies included IV fluid and medication (17), aerosolized medication (12), and oral antibiotics (3). Support personnel included visiting nurses (7), family members (8), friends and volunteers (26). Positive outcomes occurred in 12, negative in 4 (all deaths) and 6 remain in treatment. Positive outcomes were associated with the availability of in-home care (6), support personnel (19), mean 3 visits weekly and a case manager (7). Four patients chose to discontinue therapy and subsequently died.

Conclusion: Seventy-five percent of our patients with AIDS were successfully treated at home for complex medical illnesses in a largely rural region. Successful treatment was dependent upon the availability of support services and a case manager to coordinate them. Health care policy in all areas must recognize the need for home nursing, volunteer networks, and case managers in caring for patients with AIDS.

E.529

DEVELOPING AN INTEGRATED AND COMPREHENSIVE LOCAL COMMUNITY RESPONSE TO AIDS IN A LOW INCOME COMMUNITY.

CORREY-RICHARD, COLEMAN, D.; ZELINSKI, D**
*United Way of Franklin County, **Columbus Health Department, **Metropolitan Human Services Commission, Columbus, Ohio USA

Objective: To develop an integrated and comprehensive community plan to deal with the problems of AIDS and HIV illness in a low income community. **Method:** A broad-based group of community leaders was convened to provide overall direction to the effort to respond to AIDS. This group included local representatives from government, human services systems, both public and private, and the business, medical, academic, legal and gay communities. Staff support for this effort came from an interdisciplinary team assembled from 8 local human service systems who were loaned to the coalition for 3 months on a part-time basis. Primary data were collected through individually designed surveys of persons with HIV illness, businesses, hospitals, schools, and human service organizations. Secondary data were collected from focus groups of AIDS-related providers. **Results:** The information base developed by the Staff identified local estimates of incidence through 1991, of numbers of people in high risk transmission categories, current need for both education/prevention and treatment/support and current capacity to address those needs. From these, a plan has been developed that specifies needed efforts, the projected 3-year costs and specific implementation strategies.

Conclusions: The conscious development of a broad-based community approach to the problem of AIDS has resulted in a more integrated and positive community dialogue, more effective interagency cooperation and increased community funding.

E.530

A STATEWIDE APPROACH TO LOCAL PUBLIC HEALTH LEADERSHIP IN HIV PREVENTION. LETHBRIDGE, A.; HECKER, K.; BENTLEY, JUDY; MOER, M.; PARKER, J.; MINNESOTA DEPARTMENT OF HEALTH (MDH), MINNEAPOLIS, MN, USA.

Objective: To design a statewide system that enables MN Community Health Services agencies to develop and implement prevention programs. **Methods:** In August 1987, the Commissioner of Health presented expectations for HIV prevention to 47 community health boards; appoint an HIV resource person, establish a local HIV task force, develop HIV policies, provide and coordinate community education and resources. These expectations are consistent with statewide goals for health promotion. The MDH cooperates with community health boards and staff to: fund 7 model projects, provide statewide conferences on HIV epidemiology, policy development, risk assessment and behavior change, staff an HIV Subcommittee of local health and elected officials, and develop a funding proposal to the legislature. **Results:** All 47 community health boards representing 67 counties have appointed a trained HIV resource person. HIV task forces are established in most areas. Community resources are being assessed and coordinated statewide. The subcommittees develop guidelines and recommendations for HIV program development. The state legislature is considering a proposal for formula funds to community health boards. Education and prevention model projects are available.

Conclusion: Local health departments play an important role in organizing community constituencies to prevent HIV transmission. This role is enhanced through cooperative efforts between state and local health departments. This approach has potential value for other state and local health departments.

Publications



Section B

Le SIDA, la société et le comportement AIDS, Society and Behaviour

E.531

A COMMUNITY-BASED APPROACH TO AIDS PREVENTION AND CONTROL

Reinhold M. Muller¹*, Anne Swaby², Janet Vetter³, Frank Noller⁴
¹Senior Medical Consultant, AIDS Consultants, AIDS Section Staff, Public Health Branch, Ontario Ministry of Health, CANADA

The province of Ontario (pop. 9.2 million) has AIDS of the cases of AIDS occurring in Canada. Epidemiologic surveillance since case reporting became mandatory in 1983 has shown that 90% of cases occur as a result of homosexual/bisexual practices. Some gay communities responded by forming local education and support committees. Recognizing the unique position of community-based organizations in the fight against disease transmission, the Ontario Ministry of Health made the decision to fund community-based AIDS education and support programs. With assistance from community activists, guidelines and a formal application form were developed. The main criteria for funding are: a demonstrated need for a program or service that does not duplicate existing services, strong community endorsement of the proposal, fiscal responsibility and the establishment of a voluntary Advisory Board.

The ministry targeted specific groups as priorities for funding. In the first year 10 community-based AIDS groups were funded and one-time grants were given to 5 other organizations mainly for educational purposes.

This paper will describe the evaluation of these programs after one year and show how funding enables these groups (e.g. IV drug users, prostitutes, men, health-care workers, street youth and ethnic and native communities) to assume responsibility for the control of AIDS and HIV infection at the community level.

KEY WORDS: AIDS, community groups, funding

E.533

AN INNER CITY VOLUNTEER PROGRAM UTILIZING COMMUNITY AIDS EDUCATION AS A VEHICLE FOR RECRUITMENT

B. Powell, T. Iversen, L. Cherry, C. Niles, J. Martin, *Street Outreach*
Imperial Health Center, Bronx, New York, U.S.A.

Objective: To describe the effectiveness of community AIDS education as a recruitment vehicle for Project BRWG, an inner city volunteer program.

Methods: This paper describes our work in recruiting volunteers to provide practical and emotional support to persons with AIDS (PWAs) in the Bronx, New York, an area that is predominantly comprised of people from minority backgrounds and low socioeconomic status. This paper describes an AIDS education model which goes into the community to church and social organizations with already established ties to the people who live and work there. Meetings are scheduled for one restaurant of their choice and are convenient for them. Participants receive culturally sensitive AIDS education as well as an introduction into the psychosocial concerns of PWAs. Volunteers currently working with BRWG also share their experiences and the rewards they have received from doing this work. A segment on the Epidemiology of AIDS in the Bronx, which differs somewhat from the national picture is also provided and adds a very real dimension to the role of the practitioner.

Results: Project BRWG has recruited better volunteers who work on a daily basis with PWAs. We have recruited twenty volunteers who are available on a per diem basis as well as four volunteers who act as peer educators of community AIDS education seminars.

Conclusion: People from minority backgrounds and economically depressed circumstances can be utilized as volunteers for persons with AIDS if agency criteria staffs not only the need for volunteer services but also volunteer opportunities are available to them and their role can have an impact on the community in which they live.

E.535

BUILDING A COLLABORATIVE APPROACH TO AIDS PROGRAM PLANNING: THE BOSTON AIDS CONSORTIUM

Leda, Holly, D. J. Nakagawa, Holly, J. Sweeney, J. A. A. The Boston AIDS Consortium, Boston Foundation, Boston, MA, USA

Objective: To develop an organization to facilitate a community-based planning process that involves all interested members of the community concerned with AIDS service, prevention and education programs.

Methods: A working group was convened in the Fall of 1987 to consider the need for a community-based planning organization for the City of Boston that would focus on the ongoing identification needs for new HIV-related services, education and prevention programs as well as the need for additional resources to support ongoing efforts. It was hoped that a consensus approach would foster collaborative efforts among diverse interests in our community.

Results: Since beginning operations in January 1988, over seventy public and private agencies and two-hundred individuals have participated in Consortium efforts. The Consortium operates nine issue specific Task Forces (Hospital Care, Ambulatory Care, Long-term Care, IV Drug Use, Family Networks, Mental Health, Prevention and Education, Housing and Homelessness) which are collaborative activities open to all. In October, the Consortium released its first publication, *Task Forces: A Boston Foundation Report*, which was distributed and presented it to the State as a way of signifying key issues for discussion that had been highlighted as a result of this community process.

Conclusion: The Consortium provides a useful forum for open discussion and planning of AIDS programs in our community.

E.532

HARVET, AIDEN ***; Bernstein, A.*; Ryan, T.*

¹Congregation Sha'ar Zahav, San Francisco, CA, USA
²Kaiser Permanente Medical Center, San Francisco, CA, USA
³University of California, San Francisco, CA, USA

Objective: To describe the design and operational structure of a community based volunteer program operating in an acute care hospital setting.

Methods: This is a volunteer directed and operated program by members of the Sha'ar Zahav, which provides nutritional, psychosocial, and spiritual support to the inpatient and outpatient populations; significant others and hospital staff are included. An interest assessment of congregational membership was performed. The idea was discussed with the Bikur Cholim (Acts of Loving Kindness) Committee at Sha'ar Zahav, a reform Jewish Congregation. We then presented the concept to administration at Kaiser Hospital, and together developed guidelines. A 1.5 hour HIV sensitivity training was offered to participants. Volunteers prepare food at home and meet at the hospital. Psychosocial and spiritual support is provided as necessary. Volunteers deliver food and visit with immobile patients. We provide a classical music and flowers to enhance the party-like atmosphere. Financial assistance is primarily from contributions directed to the program.

Results: The AIDS Branch Program has been instituted and occurs monthly. It is coordinated by community volunteers in cooperation with hospital volunteer, social services, environmental services, and nursing departments. Chaplains and outpatients, with significant others, as well as hospital staff attend regularly.

Conclusions: An ongoing community based brunch program is providing support for people with HIV disease and others, in an acute care hospital setting. It has been recognized as a model in San Francisco, providing a new adjunct service utilizing community resources.

E.534

A COMMUNITY GENERATED AIDS PREVENTION PROGRAM: THE CASE OF CANDEN, NEW JERSEY

Della, Dora A.; Platt, J.J.*; Wolff, C.*; ¹University of Medicine and Dentistry of New Jersey School of Osteopathic Medicine, Camden, NJ 08103. ²Area Health Education Center, Northgate Plaza, Camden, NJ, U.S.A.

Objective: This presentation is a report of the Area Health Education Center (AHEC) community AIDS prevention outreach program. Attempts at controlling the spread of the AIDS epidemic will continue to depend on education and efforts aimed at attitude and behavior change as we search for a vaccine or cure. Change in behavior can, and should, occur at the micro- and meso-level of human interaction. This project is one such effort.

Procedure: Early in 1988, AHEC received CDC funding, through the NJ Health Department, to provide a culturally sensitive AIDS education program in Camden. In developing the outreach approaches which include home visits, church meetings, etc. AHEC sought and received the cooperation of other agencies, church and community leaders. We present data on 393 participants over a 4-month period. **Results:** 60% of participants were female. Age range = 9-89 (mean 47.7) years, 72% were black, 15% were white, 10% were hispanic. 11% of those reached had never been married, while 22.4% are married. Comparison of the pre- and post- intervention global scores on the knowledge, attitude, and beliefs (KAB) questionnaire demonstrate a significant change in scores. Implications of the results are discussed.

E.536

JOINT CASE PLANNING BETWEEN THE HEALTH AUTHORITY, LOCAL AUTHORITY AND VOLUNTARY ORGANIZATION

Mullis G. ¹ Riverside Health Authority, London, England, UK.

²Hammerstein & Palmer Local Authority, London, England, UK.
³Diagnose. To develop case planning provision of services for people who are H.I.V. positive or have A.I.D.S.

Objective: A series of sub-groups were established to report on the following to the Joint Health Authority, by Mrs. Jessica Gray, Secretary, Dept. Public Health, Central Office, Civil Serv. Dept. Health.

Methods: Joint Planning Demos conducted the Social Services Department Planning & Research meeting to undertake a survey to enable the use to build up a picture of the services already available to those with H.I.V. related disease and the number of people requiring the services.

- Results:**
- 1) The recommendations in these reports will act as a basis for health and local authority planning and service provision.
 - 2) A comprehensive directory of local services for professional working with people with H.I.V. disease has been produced.
 - 3) During the last year a team for 2/3 people with H.I.V. disease has been established by a voluntary organization in the borough. The Social Services department facilitates a voluntary support meeting once a week for local authority H.I.V. positive. The Health Authority provides health care to the residents as necessary.
 - 4) Another team is planned for 1989. A project worker for this development has been funded by the Health Authority to facilitate the development of the home and district initiative between the voluntary organization, Local Authority and the Health Authority.

Publications



Le SIDA, la société et le comportement AIDS, Society and Behaviour

E.537 COMMUNITY CAPACITY FOR COPING WITH HIV/AIDS
Miller, Sheila, University College London;
McLain, Keville, Institute, Rockdale, OZ689

Objective: To development strategies to monitor resources and needs affecting community capacity to cope with HIV/AIDS; and to support local efforts to enhance that capacity in specified settings in Africa.
Methods: Longterm and interdisciplinary comparison of different types of community affected by the HIV/AIDS epidemic. Social research methods include ethnographic survey employing local people as interviewers; in-depth case studies of family and household dynamics; focus group discussions and Base Observation diaries to monitor change in community attitudes, organisation and levels of morale. All quantitative data will be stored on computer and a data base and monitor created.
Results: These activities will reveal local networks and support systems, sources and channels of communication and information, and the likely boundaries of social and spiritual interaction and opportunity. The methods will provide a basis for qualitative studies of sexual relationships and **Conclusions:** Studies of risk and general survey research to date have been limited with little reference to general health or questions of community identity and social cohesion. This programme will seek to clarify the balance of economic and affective elements. The systematic comparisons proposed will allow both the methods used and the findings on specific communities to be generalised for wider application.

E.539 AN ELECTRONIC INFORMATION AND EDUCATION SYSTEM ENHANCES COMMUNITY AIDS PROGRAMS
Jamison-Smith, Pearl; **Jensen, James**; **Season, Lauretta**; **Levy, James**
*University of California at Irvine, Orange, CA U.S.A.
**AIDS Coalition to Identify Orange County Needs (ACTION), Irvine, CA U.S.A.

Objective: To demonstrate the effectiveness of electronic communication in writing community activities related to AIDS.
Methods: ACTION was established in 1984 to promote and facilitate education, planning, and coordination of efforts in Orange County. More than 50 agencies are currently involved in ACTION. Monthly meetings did not provide the needed communication in a rapid enough fashion. An electronic mail and conferencing system with up to the minute news, medical information and other data sources was implemented. The system, called AIDS (for AIDS Education and Generalized Information Service), is easily accessible using a low cost terminal, modem and telephone line. Currently, no fees are charged for the service, which is inexpensive to operate.
Results: Participants are able to exchange information and ideas rapidly and accurately. Coordination of inter-organization events and projects is greatly simplified. People are better informed, and the decision making process is accelerated, while decision makers are better informed.
Conclusion: Electronic mail and conferencing systems can be implemented by, and are affordable to, organizations and agencies dealing with AIDS, and a substantial return on investment can be demonstrated.

E.541 SOCIOLOGICAL CO-FACTORS IN THE PROGRESSION AND MORTALITY OF HIV DISEASE: BUREAUCRACY, GRIEF, HOMOPHOBIA AND RACISM.

Harrington, Mark; **Bordowitz, G.**; **McCarthy, M.**; **Alderson, O.**
AIDS Coalition to Unleash Power, New York NY, USA.

Objective: To examine political, economic and social structures in the USA which impede access to health care and drug trials, delaying the combat HIV. **Methods:** Analysis of drug development spending; clinical trials protocols; accurate demographics; hospital and trials contracts and Federal legislation. **Results:** Structural deficits in the US health care delivery system include a 2-class medical system, with inadequate access to care for the poor, the slow pace of clinical trials, poor coordination among bureaucracies and the private sector and the marginalization of groups most affected by HIV. New treatments are too costly for many. Congress has not funded for explicit AIDS education materials. **Conclusion:** The HIV epidemic has made acute the chronic inequities of health care in the USA. Health care delivery must become more equitable. Drug development should be streamlined to take advantage of new techniques and discoveries. Drugs should be provided for those unable to pay. AIDS prevention efforts must be frank and comprehensive. People living with AIDS must participate in all decisions affecting their lives.

E.538 PROBLEMS IN EVALUATING COMMUNITY-BASED AIDS EDUCATION PROGRAMS
Clay, David; **Lyne, P.A.**; **Roberts, S.** and **Thom, G.****
*Sheffield City POLYTECHNIC, Sheffield, England; ** Sheffield Health Authority, Sheffield, England.

The paper reviews the development of evaluation frameworks and the emergence of the linear experiment paradigm, which is currently predominant in the evaluation of health promotion strategies. The limitations of this approach in the field of community-based AIDS education are discussed and the need for alternative evaluation strategies, incorporating concepts of utility and durability, is emphasized.

Drawing on examples from the Sheffield AIDS Education Project, key obstacles to effective evaluation are outlined: epidemiological, sociological, political. The conflicting evaluation requirements of service providers and service planners are identified. The role of the evaluator is examined in relation to contrasting models, of inspector and consultant.

Examples are given of how these problems may be overcome in developing practical evaluation processes, agreed to be relevant at city level and proving applicable elsewhere.

E.540 COMMON BARRIERS: TOWARD AN UNDERSTANDING OF AIDS AND DISABILITY
Saids, James C.

B.C. Coalition of the Disabled, Vancouver, British Columbia, Canada

Objective: To examine how people with disabilities ought to understand AIDS.
Method: Literature review of books and articles on social aspects of AIDS compared with articles about Independent Living Movement. AIDS is examined from medical, legal and gay community perspectives with the intention of suggesting how the disabled community ought to view this disease.
Results: AIDS ought to be considered a disability by people living with other disabilities. Persons with AIDS share many common interests and barriers with the disabled community. The concept of Independent Living, defined as "a process whereby disabled citizens achieve their desired individual lifestyle by assuming responsibility for the development and management of personal and community resources," can be useful in building understanding between these two groups.
Conclusion: Disability may be seen as a combination of physical and social factors. AIDS presents these factors in a unique way. Responses to the disease will add to understanding about self-help, self-care and Independent Living.

E.542 ONE CONCEPT OF SUPPORTED HOUSING FOR PEOPLE WITH AIDS

KELING Michael, St Mungo Community Trust, London W6 U.K.

Objective: To provide home-like, stress-free accommodation for people with AIDS who are in a respite condition, but who need to be near a hospital. Units are for three/four people

Method: To develop 'caring' families, who are grouped around a core person without AIDS. The accommodation provides bed and breakfast and all facilities for ordinary living. Bedrooms have en-suite bathrooms, there is a communal living room. A visitors suite is provided. Support is provided by local government domiciliary care and Health Service Community Nursing/Social Workers and Voluntary Organisations.

Results: Since 1987 6 people have been supported in the houses, of whom three have died. Quality of life has been maintained and enhanced. Support has also been offered to families of people with AIDS.

Conclusion: The First house, set up as an experiment has been successful in terms of appropriate care provision and cost effectiveness. Funding has now been agreed by the local Health Authority to fund a development worker for more projects.



Publications

Le SIDA, la réduction et le comportement AIDS, Society and Behaviour

E.543 THE COMMUNITY CARE AND RESIDENTIAL CARE NEEDS OF PEOPLE WITH AIDS IN CALGARY: REPORT FROM A DELPHI RESEARCH PROJECT

McDonald, John B., *Maratjan, Thom*
*University of Calgary, Calgary, Alberta, Canada; Executive Secretary, Health and Social Services Council, Diocese of Calgary. **Alberta Social Services, Calgary, Alberta, Canada.

Objectives: To present results of a Delphi Study on residential care needs of people with AIDS in Calgary.

Methods: Interviewer-administered questionnaire examined the expert opinion of 19 persons central to AIDS community and residential care in this city of 800,000 people.

Results: While there was some disagreement, significant consensus emerged for generic hospital acute care services, a carefully and confidentially protecting multidisciplinary clinic, and an integrated hospice care service. (Results accepted for publication in the Canadian Journal of Palliative Care.)

Conclusions: Report concludes with series of recommendations for Calgary Community and for involvements of the Roman Catholic Diocese of Calgary.

E.544 REPORTED SKILLS DEFICITS IN THE USE OF CONDOMS IN A SURVEY OF GAY MEN

Maritz, David J.,* Edwards, C.W.,** Rhodes, F.,***, and Corby, R.H.,****
*UCLA School of Medicine, Harbor-UCLA Medical Center, Torrance, California, **AIDS Intervention Project, Long Beach, California, ***California State University, Long Beach, California, ****Department of Public Health, Long Beach, California, USA.

Objective: To determine skills deficits in AIDS risk-reduction efforts among sexually active gay men.

Methods: A total of 425 gay/bisexual men were surveyed concerning their sexual practices at local gay pride events and among entrants at an ongoing AIDS-risk-reduction education program during the summer and fall of 1988, and their responses compared to those of 2,051 gay/bisexual men surveyed at an alternative test site for HIV antibody testing from December 1985 to February, 1987. In addition, they were queried regarding their use of condoms and lubricants used in anal intercourse.

Results: Compared to those surveyed in 1985-1987, gay men surveyed during 1988 reported reductions in the numbers of new sexual partners, and increases in reduced-risk sexual behaviors, including use of reduced-risk alternatives, and condoms for anal sex. Most reported use of appropriate condoms (latex rather than natural), but many reported use of inappropriate lubricants such as hand lotion, petroleum jelly, mineral oil, and vegetable oil, that increase the risk of condom breakage and intercourse.

Conclusion: These results suggest that ongoing efforts at AIDS-risk-reduction education require greater specificity in information regarding condom use, and may require greater specificity in other areas of risk-reduction information.

E.545 THE CHALLENGE OF AIDS IN AN AREA OF SCATTERED POPULATION AND LOW PREVALENCE

Thorn, Paul
Regional Joint AIDS Community Support Centre, 52 Clifton Road, Newcastle upon Tyne NE4 8QJ England.

Our AIDS and HIV figures are "normal" for the U.K. and very much lower than London - 28 AIDS cases and 259 diagnosed as HIV positive. We have encountered serious obstacles in pursuing our aim of developing non-hospital based care. Among the issues I would like to discuss are:

1. Medicalization of care of people with AIDS.
2. Practitioner/management of established careers - largely medical.
3. Lack of confidence of people with AIDS and medical providers in social workers.
4. Non-reality of AIDS as an issue in areas of normal (low) prevalence.
5. Social workers' perception of being de-skilled by HIV and the implications - is this an appropriate or inappropriate response?
6. Training - who and how to target training to social workers when AIDS is seen only in theory as a priority area, and in practice is seen not to be relevant to most social workers in a local authority.
7. Non-availability of substantial, vocal and cohesive groups of people with AIDS.

E.546 MYTHS AND REALITIES OF THE MIGRATION-AIDS RELATIONSHIP: THE CASE OF MEXICAN MIGRATION TO THE UNITED STATES

Wong, Marc*, Compostress, S. and G.***, Mexico, U.S.A.

*El Colegio de Mexico, Mexico City, Mexico, **OHADENA, Mexico City, Mexico.

The concern about the effect that movements across the frontiers (traveling, migration) may have on the dissemination of the HIV has generated a large number of proposals for action which, in general, imply making a test and exhibiting some kind of certificate with the results. However, little has been researched with respect to the actual impact that IMMIGRATION processes have on the dissemination of the HIV. The case of Mexican migration to the United States enables demonstrating the danger of jumping to conclusions. The analysis of the available information allows showing that while certain data confirm the existence of this relationship, other information weakens it.

The paper will include and up-dated analysis of the existing information about AIDS cases in Mexico and their migratory background. To this date, it has been found that some of the Mexican emities (provinces or states) which largely contribute to migration are over-represented in the distribution of AIDS cases in the United States. There is also evidence that the majority of Mexican migration to the United States goes to those states with the highest prevalence of this ailment (California, Texas). Some preventive measures are suggested, as well as lines of action concerning this population group under risk.

E.547 PROJECT REACH: A PEER APPROACH

Wise, Lynn Ann, Apson, J., Stwertown, S., Ryan, P.,

AIDS Administration DDMH, State of Maryland, U.S.A.
Directed to the health is an HIV prevention and risk reduction outreach program targeting youth in a major resort town. This program was designed to reach youth for whom we had little educational and risk reduction messages were really not available.

Being the summer months, the population of these city, a resort town as Maryland's Ocean City, increases from 17,000 to 250,000. Youth, who come to work in the local businesses for the summer for a vacation, account for much of this increase. To reach these young people, three peer educators, ages 19-23, were retained in this resort town for a summer.

Working out of the Ocean City Youth Health Center, these educators provided direct one-to-one outreach to young people on the beach, at private parties and in street corners known to be frequented for drug and/or sex. In addition, they conducted a 16-week AIDS lecture, offered to local businesses employees a large number of young people, established temporary free condom distribution sites, sponsored "Partner Test" events, established and administered an survey. They also acted as project-OT test counselors for the health center.

These three educators made 3,018 direct one-to-one contacts, distributed over 10,000 condoms, and administered 106 test surveys. Nearly percent of the local businesses contacted agreed to make AIDS literature available to their youth employees. Overall condom distribution for the area increased by 20% during the summer months.

E.548 ANDROLOGICAL FEATURES IN HIV1 INFECTED PATIENTS

Brockmeyer, N.H., Mertins, L., Goss, M., University Essen, Dept. of Urology, FRG

We performed complete clinical and laboratory andrological examination in 20 HIV1 infected patients at state MR 3-5 and a minimum Karnovsky index of 0.7. Diagnostic measures included registration of quantity, motility and morphology of spermatozoa, cultural and immunological assessment of microbiological parameters in sperm and serum/plasma of Testosterone, FSH and all patients analysis of spermatozoa and seminal plasma revealed a higher incidence of abnormally shaped and immobilized spermatozoa compared to normal values in our laboratory. The quantity of spermatozoa was diminished only in patients at state MR4 and 5. Zidovudine treatment caused an aggravation of morphological and functional damage and a further diminution of spermatozoa numbers. In spite of remarkable loss of libido no alterations of endocrinological parameters (LH, FSH and Testosterone) were found neither in Zidovudine treated patients nor in patients not receiving the drug. Compared to normal values in our laboratory there was no increase of leucocyte numbers or microbes in seminal plasma. We found, however, in one case a contamination with *Shigella* not accompanied by clinical or laboratory signs of Shigellosis infection in other organ systems.



E.555 WORCESTER LATINO AIDS NETWORK
Sánchez, Luis, Ardino, J., Ortiz-Ortiz, J., Collazo, J.,
Núñez, M., Rodríguez, L., Trillo, J.,
City Health Department; Worcester Area Community Mental Health Center;
AIDS Project Worcester; San Juan Lutheran Church, Worcester,
Massachusetts, USA.

Objective: To develop effective strategies for AIDS education and risk reduction for Latinos using resources within the Latino community.

Methods: Through the efforts of the Worcester City Health Department, community service agencies, and Latino community leaders, a Latino AIDS Network was established. The following areas of need were identified: 1-Education/Prevention through local media, 2-Education/Prevention for high risk groups: 3-Education for Providers: 4-Education/Prevention for children: 5-Support services for HIV infected Latinos and their families.

Results: The following strategies have been implemented in each area of need: 1-A weekly radio program in Spanish with audience participation dealing with issues and AIDS; 2-Outreach in Night Clubs with distribution of educational materials and bleach/cordons; 3-We AIDS curricula in Spanish for bilingual providers that work in these service agencies and a library with videos directed toward minority communities; 4-The Worcester School Department and the Network has developed and translated into Spanish, a High School AIDS Curriculum; 5-A support group for Spanish speaking HIV infected Latinos and concerned others has been established.

Conclusions: A comprehensive AIDS education and risk reduction program directed toward the Latino community was established in the second largest city in New England. This model may be applied to other urban communities.

E.557 DEVELOPING COMMUNITY PARTNERSHIPS FOR AIDS PREVENTION IN AN URBAN LATINO NEIGHBORHOOD: AN ETHNOGRAPHIC EVALUATION
Lazo, Im, Gordoa, R., Esteves, L., Romo, A.,
Soto, J., Freudenberg, R., et al.

* Segundo Year Health Care Center, Brown, N.Y., USA
** Center for Community Action to Prevent AIDS, Hunter College, N.Y., N.Y., USA

Objective: To describe an AIDS prevention project in a Latino community in the US South Bronx.

Methods: Investigators conducted 30 semi-structured interviews with health center staff and leaders of community organizations - schools, churches and housing projects.

Results: Factors contributing to an effective partnership between an AIDS prevention project and community groups included a clearly defined core audience, previous experience working on drug and sex related issues, a participatory planning process, and a project staff sensitive to socio-cultural issues.

Conclusion: An effective partnership can be established between health centers and community organizations to bring AIDS prevention messages to populations at risk of HIV infection.

E.559 THE EPIDEMIC SPREAD OF AIDS LITERATURE AND ITS IMPLICATION FOR THE MANAGEMENT OF THIS CRISIS
Dobbs, Linda M., Bowd School of Medicine, NYC, NY, USA.

Objective: To identify the major gatekeepers and networks that serve the various public concerned with the state of the field and to examine and compare the roles played by these actors in the dissemination of new findings and information regarding AIDS.

Methods: The major gatekeepers examined are 1) communications from the CDC; 2) TIMELINE; 3) the USFV news service; 4) the AIDS clearwatchhouse (AIDS-C); and 5) self-appointed specialized AIDS news service's current awareness summaries. A typology was developed which was used to classify articles which appeared during the past year by study type, coverage, approach, and type of appearance in any of the five datasets.

Results: Multiple examples of the almost simultaneous appearance of these iterative "findings" (in case reports, drug trials, therapeutic interventions, prevention models) in scientific communications, informal networks, the journal literature and mass media were identified. In addition, many examples of instant coiffination of cutting-edge work in progress research findings to widely networked literature were found.

Conclusions: The crisis brought on by the AIDS epidemic, coupled with the speed with which research findings become incorporated into the bibliographic network and into practice, have transcended the stages of assessment and evaluation traditionally required before new knowledge becomes codified. Structures, roles and mechanisms must be created which will allow for the more scientific assessment of findings and reduce the risk of their premature incorporation into practice.

E.556 SEGMENTING THE MARKET OF BLACK GAY MEN FOR AIDS PREVENTION EDUCATION AND RISK REDUCTION

Alford, J., Tabor Tharion Ph.D., * (Phipps Research and Development, San Francisco, CA, USA)

Objective: To develop an analytic model for defining and differentiating between subgroups of Black men who have sex with other men for purposes of segmenting them for AIDS prevention interventions.

Methods: A review of the literature and ethnographic research led to development of a three dimensional matrix that differentiated between subgroups within men, socioeconomic patterns, and communication styles and channels. The matrix isolates 8 Black men who have sex with other men in terms of the extent to which they self-identify as gay, bisexual or heterosexual; the degree to which they are Black-identified in terms of culture, style and attitudes; and their socioeconomic class (as measured by occupation, education, and income).

Results: Subgroups identified to date include Black gay intellectual/lesbian (men who are high on all three dimensions of the model), Black street prostitutes (men who are Black identified, gay identified, and low on the socioeconomic scale), Black street hustlers (men who are Black identified, heterosexually identified, and low socioeconomic), 3-Black homosexual professionals (Black identified, non-gay identified, and mid to upper socioeconomic), gay-identified Black men (or many identification as gay, low to moderate Black identity, mid to upper income).

Conclusions: Black men who have sex with other men are not at risk of AIDS as a result of their behaviors do not all share the same values, do not all engage in the same behaviors, do not get their information from the same sources or find the same sources credible. Given their differences they require different messages delivered through different media.

E.558 COMMUNICATING RISK ABOUT HIV INFECTION

Engel, Fred; Shepherd, R.; Rosenberg, M.; Wilson, R.,* Centers for Disease Control, Atlanta, Georgia, USA

Objective: To describe the problems and processes associated with communicating risk information to a national audience; effectiveness to date.

Methods: The United States Public Health Service has used a variety of vehicles to inform the American public, including persons at high risk, what factors increased risk of exposure to human immunodeficiency virus (HIV) infection, how risk could be reduced, and what situations entailed low or no risk to uninfected persons. These efforts are often complicated by political, social, scientific, and resource constraints. The effectiveness of these efforts is monitored through a continuous, cross-sectional household survey that measures HIV/AIDS knowledge and attitudes in a probability sample of noninstitutionalized adults (18 years and older).

Results: American adult citizens are very knowledgeable about how HIV is transmitted. Knowledge levels are close to true transmission risk factor range from 92% to 98%. Erroneous notions about transmission risks remain disturbingly high, though steady improvement has occurred over the past 18 months.

Conclusion: Translating scientific findings into understandable and believable communications requires equally scientific rigor. Interpretations, once established, are difficult to eradicate.

E.560 CONTENT ANALYSIS OF AIDS EDUCATIONAL MATERIALS IN THE UNITED STATES

Jahan, A., York, P.M., Ed. M.A., Amy Wolf BS*, Peter DeWitt BS*

* The Project Hope Center for Health Affairs, Washington, DC, USA.

Objective: 1) To develop categories based on social learning theory for classifying the content of AIDS educational messages. 2) To describe the distribution of these categories in a representative sample of materials in the US. 3) To profile content patterns of message content and their relationship with types of media. 4) To correlate relative frequency of content with the effectiveness of a panel of AIDS education experts who independently assessed the quality of materials.

Methods: 1000 AIDS educational materials were selected from AIDS Information Resources Database (American Foundation for AIDS Research, 1988). The 4 categories of media are brochures, cards, and inserts (n=100), pamphlets, booklets, and monographs (n=41), posters (n=60), and videos (n=60). The samples are classified by target group including adolescents, drug users, gay/bisexual men, children/adolescents, HIV test-takers/HIV positive, and others. Ratings are performed by two raters; inter-rater reliability is assessed in a separate sample using Cohen's kappa.

Results: The content categories based on social learning theory are: **Attitudinal** including epidemiology, transmission, community resources, testing and legal issues; **Behavioral** - Target and risk group, symptoms, AIDS history, risk behaviors, safe sex, Risk Reduction; **Practical** and **Interpersonal skills**; **Content/Quality** - **Targetable** and **non-targetable**; **Model**, **process**, **verbal** and **AIDS-related terms**; **Outcomes** and **Humanistic**; **Characteristics** and **media**; **Visual**, **nonvisual**, **nonoral** and **oral**. Kappa on 11 **Attitudinal** items in 9 brochures are distributed: 1=0.4, 1=0.6, 1=0.8, 1=1.0. Efforts have been made to improve reliability where deficient. Ratings of the AIDS education experts have been obtained from the American Foundation for AIDS Research.

Conclusions: Categories for classifying the content of AIDS educational materials can be derived from social learning theory. Preliminary results indicate that inter-rater reliability is adequate.



Publications

E.561

INNOVATIVE APPROACHES TO SCHOOL-BASED AIDS EDUCATION
REINHOLD, DAVID L.; FALKER, JAMES W. and WILSON, K. A.

Objective: Training and Research Associates, Santa Cruz, California, U.S.A.
Educating: To describe a national school-based AIDS prevention education teacher training project.

Methods: The Teaching AIDS Training Project, developed by ETR Associates and supported by the U.S. Centers for Disease Control, was designed to increase the number of junior/senior and senior high schools nationwide providing effective AIDS prevention education that is locally determined, consistent with community and family values, and appropriate to curricula needs. In 1988 five Texas sites (Arlington, Austin, El Paso, Harlingen and Houston) were selected to receive training for experienced family life educators with a commitment to school-based education about AIDS. By September 30, 1988, 242 experienced health or family life education teachers received the two-day AIDS Teacher Training, resulting in the implementation of AIDS prevention education for over 8,000 junior and secondary level students. After completing the 2-day training, participants were asked to rate each training activity for usefulness and quality on a Likert-type scale. Mean scores for usefulness of activities ranged from 4.07 to 4.82 and quality of activities ranged from 4.16 to 4.88 (highest possible score was 5). A pre-post instrument was developed to measure participant's knowledge about AIDS, HIV transmission modes, at-risk behaviors, and participants' attitudes towards Persons With AIDS. Mean scores from the pre/posttest showed statistically significant increases in participant knowledge and attitudes.
Conclusions: Positive responses were expressed by training participants underscoring the deep commitment and need for providing direction in how to prevent the spread of HIV/AIDS among youth.

E.563

COMPARISON OF ATTITUDES TO AIDS IN 12 COUNTRIES AMONG THE GENERAL POPULATION
L.C.M. ROZENDIUS
Division of Communicable Transmitted Diseases and AIDS
Ministry of Health-Brazil

In 1987, the Gallup Organization, conducted a survey to look at attitudes in the disease in 12 countries including Brazil.

Objectives of the research were: (1) to know attitudes related to some issues in order to set up priorities, for public education and (2) to draw conclusions about the strategies to be used in the future to prevent the epidemic.

Methods: A questionnaire was developed and carried out through domiciliary visits. In Brazil 1200 persons of both sex were interviewed.

The population sampled was randomized and proportional to the size of the administrative regions.

The questions were related to: "the most urgent health problem facing the country at the present time"; "WUI AIDS risk survey"; "Am I at risk?"; "fear at the office"; "attitude of compassion and solidarity"; "AIDS much only homosexual, IV drug users, hemophiliacs, etc."

Conclusion: The data show, that awareness of AIDS is very high, but also show that people are not taking the steps to change their sexual behavior. Substantial numbers of people in many parts of the world still refuse to work with an infected person and that around the world misconceptions are still common. Finally the research also suggests, that people will be able to deal with AIDS as a disease, since direct information is provided.

E.565

SEXUALITE ET COMPREHENSION DU SIDA CHEZ LES LYCEENS ET LES JEUENES FEMMES DE DAKAR ET BANLIEUE
YOUSSEF M. NARGANE OUISSSE ET LUDOVIC D'ALMEIDA PLURALAL SF.
3334 DAKAR.

OBJECTIFS: Les objectifs de cette enquête sur le SIDA visent à déterminer des groupes cibles, d'évaluer leur état de connaissances et les attitudes d'identification, les pratiques, habitudes et conditions culturelles autour de la sexualité. La connaissance des besoins, des attentes, des perceptions et les besoins de l'information, de participer à la conception et à la réalisation des actions de prévention du SIDA. Les groupes cibles sont ici des individus en activité sexuelle évidente: les femmes fréquentant des centres de PMI nombre de 400 au et des individus ayant reçu des activités éducatives: des lycéennes (jeunes) de collèges à Dakar et nombre de 125.
METHODOLOGIE: Un questionnaire comprenant la 4 grande thèmes envoyés a été élaboré et complété par des interviews semi-directives individuelles et collectives.

RESULTATS: Les résultats de l'enquête montrent la nouveauté du niveau de celle de la population cible sur leur savoir positif, fréquence des pratiques sexuelles, multipartenariat, recherche de plaisir multiples. Ceci est des nuances en rapport avec le niveau d'instruction, le sexe-utilisation relativement faible des préservatifs et le multipartenariat; encore persistant montre le divorce existant entre un niveau d'information grandissant et des moeurs et plus ou moins très peu contrôlées.
CONCLUSIONS: L'implication pour des plans pour améliorer et créer des instruments d'information plus adéquats et plus conformes aux réalités sociologiques et culturelles.

896

E.562

AIDS-RELATED KNOWLEDGE IN A SAMPLE POPULATION FROM A PRIMARILY BLACK, INNER CITY AREA OF THE U.S.A.
BRIKER, JARREN L.; Celentano, D.***; Benedict, A.***; and Sawyer, J.***

***The Johns Hopkins University School of Medicine and **JHU School of Hygiene and Public Health, Baltimore, Maryland, USA.**

Objective: To determine the existing level of AIDS related knowledge in a sample population from an impoverished, primarily black, inner city area of the United States.

Methods: 398 individuals, accessed through a hospital waiting area, were interviewed using a standardized question set developed by the U.S. National Center for Health Statistics.
Results: In our study population, 71% of whom were black and 77% of whom had 10 or fewer years of education, AIDS related knowledge was at least equal to that of the general population in the United States by comparison of results with identical NCHS questionnaires. Specifically, 93% were aware that AIDS is an ultimately fatal illness, 98% knew that the virus can be transmitted by sharing of needles in drug abuse and 96% knew that either homosexual or heterosexual sexual contact may result in transmission. In virtually all AIDS related subject areas exceeding the knowledge level of the sample population was either equivalent to or greater than that known to exist in the general American population.

Conclusions: Efforts to control the HIV epidemic in inner city areas may need to focus much less on increasing simple cognitive awareness, and much more on methods of behavioral modification.

E.564

E.566

ISSUES IN THE SELECTION, TRAINING AND DEPLOYMENT OF AIDS COMMUNITY HEALTH OUTREACH WORKERS: THE SAN FRANCISCO MIDCITY PROJECT

Blernagel, Patrick; Feldman, H.; Knapp, T.; Margolis, E.; Norman, P.
 Youth Environment Study, Inc., San Francisco, CA, USA.

Objective: This 3 year old project was created to intervene in the AIDS epidemic among intravenous drug users (IVDU's) through the use of trained workers (CHOW's) who educate the target groups wherever they can be found.

Methods: The methods of selecting, training and deploying AIDS health outreach workers revolve around a series of issues. Examples of those issues are as follows. Should non-addicted or non-addicted be selected as outreach workers? Are the best training recruits judgmental or non-judgmental about drug use and alternative lifestyles? What perspective works best for CHOW's, psycho-social or socio-historical? How far to go, educator or case worker? Confidentiality a legal and research issue vs confidentiality on the streets. Political and pragmatic considerations in deploying CHOW's.

Results: In the areas where CHOW's have been deployed, their work has had a dramatic impact. An independent survey has shown an increase in needle using hygiene (e.g. cleaning needles between uses with bleach) from 39% in 1986 to over 70% in 1988. The same population reported an increase in the use of condoms from 23% in 1986 to 42% in 1988.
Conclusions: Outreach education has shown great promise in changing the behavior of IVDU's.



Publications

E.567 MAINTAINING AIDS EDUCATION VIA COMMUNITY BASED HOTLINESCassady, M., Miles, T., Spohnhauer, D., Spohnhauer, S.
St. Clare's Hospital and Health Center, New York, New York, U.S.A.

Objective: To evaluate the educational outreach of the volunteer staffed hotline at St. Clare's Hospital, NYC (a comprehensive AIDS Care Facility).

Methods: Training of volunteers by Hospital professionals which includes: 1) interview 2) videotape 3) education 4) study center 5) group support. As a follow-up National Hotline, outreach in National, contiguous states and the local community.

Results: In 1981, the number of calls averaged 500 per week representing a decline of 30% since 1987. The geographical distribution of calls remained the same in 1988 as in 1987. Ninety percent of the calls from New York, 63% from contiguous states (New Jersey, Pennsylvania and Connecticut) and 33% from other states and Puerto Rico. The hotline educating training enables volunteers to disseminate accurate, timely information on AIDS transmission and offer psycho-social support to callers finding hospital professionals from such routine queries.

Conclusions: The decrease of calls are attributed largely to the increasing publicity of AIDS throughout the US-state area and nationally, to the increase of AIDS services and resources. Downstreaming hotline from national to state sponsorship to community health organizations and local hospitals gives the public greater accessibility and options to receive information and referrals. Maintaining volunteers addresses those concerns which allow limited personnel to concentrate their time on effective patient care.

E.568 LET'S TALK! ONTARIO MINISTRY OF HEALTH AIDS HOTLINEShraw, Pamela, Lu, L., Billier, V.***
City of Toronto, Department of Public Health, Toronto, Ontario, Canada, ***University of Toronto, Toronto, Ontario, Canada, ***Street Outreach Services, Toronto, Ontario, Canada.

Objective: To provide telephone service to residents of Ontario as part of the Ministry of Health multi-media AIDS Education Program. **Methods:** A staff of 10 trained operators provide service seven days a week, fourteen hours per day. Callers are provided with 1) information on epidemiology, transmission, prevention of HIV virus 2) crisis counselling, 3) referral to appropriate community resources. **Results:** Major trends in the type of service provided to callers:

Type of Service	Contact	Frequency
Basic Education	Oral sex, casual contact	
Intercourse and general information		87%
Behavioral change re: safer sex		18%
Medical/dental care/support/psycho-social issues		
Health Unit		
Advocacy/legal/complaint		17%

Characteristics of the Caller:
Sex: 34% male 42% female 4% unknown sex
Sexual Preference: 16% same gender 41% bisexual 41% other gender 33% unknown
Age Group: 39% (10-29yrs) 26% (20-29yrs) 16% (20-29yrs) 7% 35 (39yrs) 11% 35 Unknown
Conclusion: The target population (under 39 yrs.) is represented by 80% of callers. An increased awareness of service by 1) non-English speaking, low literacy injection drug use and gay/bisexual population is needed. Expanding the hotline's awareness of AIDS and related services will be essential.

E.571 WAREHO USE GAME: DESIGNED AND CREATED BY MR ARNLEY WAREHO
Nzubei, Sidiem, J.
University of Cape Town, South Africa

Objective and aim: to be simple and informative; to create awareness and educate new sexual attitudes persons about AIDS and prevention in a spirit of competitiveness, the reward being to become "The Grand Master of HEALTH" to change attitudes and behaviour; to create understanding of other religious and traditional beliefs; to create a global spirit of goodwill and cooperation.

Methods: Based on existing tribal games already known in rural and urban areas it was designed to be played in four different ways:

- for the very young player: a very simplified version of draughts;
- for older children a version of snakes and ladders with rewards or admonishment for answering questions correctly or wrongly;
- for sexually active people a more complicated, chess-like game;
- for the general public a game with questions like trivial pursuit.

The board design is a variation of a traditional chess board, with 16 pieces consisting of a hospital, doctors, nurses, nurses (sexually active person or drug pushers hunting to compare sexual partners or drug users), AIDS viruses (carriers) and blood (potentially infected). All four variations can be played by the "captains" of opposing teams on a life-size mat with children at draught pieces. A "referee", for example the Biology teacher or health officer, compares players and outcriers to discuss aspects of the disease and argue against decisions in order to share and improve knowledge. "Live potential" lectures self-study is encouraged from handouts and literary references available at inter-school competitions. **Results:** Enthusiastic response from audience in limited trials.

E.568 DEVELOPING AN AIDS CURRICULUM FOR OUTREACH WORKERSAshley, Rebecca J.
National Institute on Drug Abuse, Rockville, Maryland USA

Objective: To present curriculum content needed to train indigenous outreach workers to educate and motivate addicts to engage in risk reduction behaviors. **Methods:** By anecdotal information gathered by informal survey with 58 sites around the USA which are NIDA funded outreach research demonstration projects. **Results:** An informal survey indicated a myriad of training needs for outreach workers. Primarily, many outreach workers find it difficult to work within the framework of a research project because of the longwinded, field notes and additional paperwork involving number of contacts, type of contacts, etc. that are necessary in such a project. A ranking of training requests from NIDA research demonstration projects indicates the need for skill building in basic outreach strategies. This includes the do's and don'ts of appropriate street outreach contact, troubleshooting situations which will arise while conducting outreach activities, developing rapport building skills, developing and practicing "active listening" etc. Although most of the outreach workers are ex-addicts, many programs indicated a need for workers to understand both the pharmacology and psychosocial aspects of addiction including misuse system impact. **Conclusions:** From this needs assessment a core curriculum consisting of 13 modules was developed and delivered to outreach workers in NIDA funded projects.

E.570 COOPERATIVE LEARNING WITH TEAM PACKS: A ROLE PLAYING PROGRAMFOR AIDS EDUCATION OF ADOLESCENTS
Heston, K.L., Lee D.D., Plummer, P.A., Dorman, S.N., Johnson, Michael P., and Small, J., P.A., Center for Cooperative Learning,
The University of Florida, Gainesville, Florida, USA

Objective: To measure the effectiveness of TEAM PACKS, a self-contained, printed role playing program for AIDS education of 14 to 17 year old high school students.

Methods: TEAM PACKS provide factual information and direct statements, in groups of four with minimal teacher supervision, through a role playing scenario about HIV infection, randomized health checks, received (A) the TEAM PACK, (B) a lecture with matched content, (C) the TEAM PACK and the lecture, or (D) neither intervention. Pre and post tests assessed knowledge and attitudes about AIDS.

Results: Knowledge was significantly improved by each of the three interventions (A, B, or C), as compared to controls (D), attitudes were improved by the combination of TEAM PACK and lecture (see table).

N	KNOWLEDGE				ATTITUDE			
	A	B	C	D	A	B	C	D
67	64	71	72	67	64	71	72	
**	41.9*	29.0*	47.7*	9.5	10.2	10.6	20.4*	11.8

*A of maximum possible improvements = different from control at p<0.05. **Conclusion:** TEAM PACKS, like the lecture, increases cognitive gain. The active involvement of students, promoted by the TEAM PACKS, was essential to effect an attitudinal change. Additional TEAM PACKS dealing with other sexually transmitted diseases should increase the attitudinal change. Whether they will lead to behavioral changes will remain further study.

E.572 AIDS INFORMATION THROUGH CITY WATERBILL DELIVERY IN HOUSTON, TEXAS, USABureau of Epidemiology, Houston Dept. of Health and Human Services, Houston, Texas, USA
Fellitti, Robert L., Bridgewater, S.J., Smith, G. and Shannon, J.

Objective: How to provide written AIDS information in a simple, cost-effective way, to 400,000 people, and in the process, promote other agencies to do the same.

Methods: The City of Houston Public Works Department provides public information on various topics through billing inserts. In order to utilize this distribution method, a question and answer insert was prepared with the most commonly asked questions about AIDS. This insert was written in both English and Spanish at a level of understanding equivalent to eighth-grade reading skills.

Results: In the months of September and October 1987, the AIDS information inserts were included in over 400,000 City waterbills. This was the first mass mailing of AIDS information by the City of Houston to its citizenry. The total cost for this project was \$12,616, for typesetting and printing. No additional postage was required to include this insert.

Conclusions: Other agencies are now interested in trying what the City of Houston has initiated, including Southwestern Bell, Houston Lighting and Power, and Entex Gas Co.

Special thanks to James C. Houghton, M.D., M.P.H., former director of Public Health, and George Crean, City Councilmember, for their direction, support and interest.



Publications

- E.579** **IMPLEMENTACIÓN DE SERVICIOS EDUCATIVOS EN VIVIENDAS DE LOS COMPLEJOS HABITACIONALES (IMPLEMENTATION OF SERVICES IN APARTMENTS)**
Barralera, J., Jarama, J., Uribe, M., Arriaga, J., Gaitaneri, L., Delgado, A., Rodríguez, J.
* Servicio Vasco de Salud Pública, ** Universidad del País Vasco, Leizor, España.

Objectives: Establish a program for the implementation of educational activities (VIE) that are geared to the local situation.
Methods: IMPLEMENTACIÓN: In the Directorate of Centers and the professor responsible of the (VIE) faced the situation actually of the (VIE) and the final objective of the (VIE) was to ensure that the center collected information. RESULTS: periódicos de la Uspide de seral con las personas responsables de cada centro en el momento de las intervenciones con los centros implicados. CONCLUSIONES: El VIE se desarrolló en el mayor número de centros de atención de enfermos de SIDA. **Results:** Durant les sessions de treball (VIE) en els apartaments, s'ha de 2 a 4 a un 75 en els centres de VIE. **Conclusions:** El VIE s'ha desenvolupat amb més èxit en els centres de SIDA. Nos anava pa observar un net progrés de la VIE, la consciència de subjecte i l'atenció a les persones VIH de la part de personal de centres socials i de gestió.
1. L'adaptació de les sessions a les necessitats de cada centre.
2. La comunicació a la direcció de centres i a la persona responsable, avant l'entrada de l'VIE.
3. Fer dels locals comuns, de les associacions i de les persones que s'organitzen al voltant de SIDA.
Conclusions: Nos considerem de gran importància capital la comunicació al Centre (Director, professor responsable de la VIE) i al personal de centres socials i de gestió.
1. L'adaptació de les sessions a les necessitats de cada centre.
2. La comunicació a la direcció de centres i a la persona responsable, avant l'entrada de l'VIE.
3. Fer dels locals comuns, de les associacions i de les persones que s'organitzen al voltant de SIDA.

- E.581** **LEVEL OF KNOWLEDGE REGARDING TRANSMISSION OF THE AIDS VIRUS IN A SAMPLE OF HIGH SCHOOL ADOLESCENTS**
Cohen, Richard, Walter, M., Davis, M., Guterman, E.M., Nichols, J.L., Vaughan, R.D. & Ehrlich, S.A. HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute and Columbia University, New York, New York, USA.

Objective: To describe and compare the level of knowledge regarding casual, IV drug, sexual, blood transfusion, and prenatal transmission of the AIDS virus in a representative sample (N=250).
Setting: A comprehensive cross-sectional questionnaire measuring knowledge, attitudes, and behaviors related to the nature, cause, transmission, and prevention of AIDS was developed and administered during one 45 minute class period in 16 tenth grade classrooms in two suburban high schools.
Results: Preliminary data on 111 students indicate that over 80% of the sample are well informed about IV drug, sexual and prenatal transmission of AIDS. However, students were less well informed about casual transmission and transmission through blood transfusion, with less scores falling to less than 60% correct. New analysis indicates that all items discriminate well in the expected direction between students scoring high and low in overall knowledge.
Conclusions: Even in a middle class high school system that has implemented a mandatory AIDS education curriculum, students maintain modest levels of knowledge of specific areas of AIDS transmission, and show great variability in overall knowledge. This indicates that AIDS prevention education programs need to be tailored to meet the needs of specific student populations, and to focus more on areas such as casual transmission which have major implications for the elimination of AIDS victims.

- E.583** **AIDS EDUCATION FOR FIRST YEAR MEDICAL STUDENTS: A QUASI-EXPERIMENTAL STUDY IN KNOWLEDGE AND ATTITUDE DEVELOPMENT AND RETENTION INVOLVING THREE TEACHING METHODOLOGIES**
Carroll, James L., Wolpe, P.A., J.L.S.A.

Objective: To examine the relationships between AIDS educational methodologies and the development and retention of knowledge and attitudes in first year medical students.
Method: Randomized Pre-post Test Control Group Design utilizing 116 first year medical students from a large urban medical center. A total of six groups were given AIDS education. Two groups received either an experiential, didactic, or audio-visual educational format, while two control groups received no AIDS education.
Results: Data analysis revealed that there were no significant differences in AIDS knowledge or attitude scores with respect to teaching methodology. However, when attitudinal questions were analyzed separately, there were several significant differences in reported comfort levels in working with persons with AIDS. These results indicate that certain teaching methods may be more effective for teaching about AIDS, but that the most effective strategy would be to use a variety of teaching methods. Qualitative data revealed that medical students are feeling afraid and uncomfortable about working with persons with AIDS and that they have a difficult time discussing their feelings.
Conclusions: Much more work is necessary in the area of AIDS education. There is no comprehensive data on how medical students are being prepared to work in the current AIDS epidemic. This study sheds light on this area.

- E.580** **PERCEPTIONS ABOUT PERINATAL AIDS TRANSMISSION AMONG DOMINICAN ADOLESCENTS: KNOWLEDGE AND EMPLOYMENT**
Ojeda, A.; Escalante, John
HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute, New York, New York, U.S.A.

Objectives: Among adolescents in the Dominican Republic, to determine the barriers that must be overcome in order to make effective, a preventive program that emphasizes perinatal transmission of AIDS.
Methods: A series of 30 interviews, individual or small group, among 60 teenagers (36 scholars or students), documents the perceived conditions in which occur, HIV transmission, and perinatal transmission of AIDS.
Results: These were the barriers encountered:
1. Few people mentioned, or appreciated, the role of perinatal transmission.
2. People did not feel themselves at risk. Some expressed disbelief about the presence of AIDS in their country; many considered it a disease confined to homosexual men, Haitians and sex workers.
3. There was considerable objection to using condoms, and many doubted their efficacy in prevention.
4. Mutual monogamy was emphasized; at the same time there was a widely recognized impression that men were "sachs" and not monogamous.
Conclusions: Economic resources (which were not easily available) are required to mount an intensive educational campaign to overcome these barriers. These resources will compete for priority with other recognized health, social and educational needs.

- E.582** **HIV EDUCATION IN A PUBLIC PSYCHIATRIC SYSTEM**
Mullis, Rita; Bennett, M., Jacoby, V., Passafium, N., James, D., Wohlstein, D., Pines

*Department of Mental Health, Boston, MA, USA, **AIDS Action Committee, Boston, MA, USA, ***Boston, MA, USA.
Objective: To demonstrate the effectiveness of small group process in two "train the trainers" models for HIV education in public psychiatric systems.
Methods: To compare and contrast two train the trainer models of HIV education to public psychiatric employees. In the first model, didactic training was the primary method of education. In the second model didactic training was interspersed with small group process.
Results: As measured by evaluation and observation of training participants, the training method that includes small group process, was more favorable than those received for the strictly didactic training.
Conclusion: The more effective method of imparting information to mental health professionals concerning HIV is a curriculum that relies on group process to facilitate the reduction of fear and anxiety associated with AIDS.

- E.584** **"CANADIAN ADOLESCENTS AND AIDS: A SURVEY OF KNOWLEDGE AND ATTITUDES ABOUT AIDS AMONG TEENAGERS VOLUNTEERING IN TORONTO HOSPITALS"**
Lefebvre, Arlette, Reed, S.J., Collins, E., Hogan, T., Snyder, N., University of Toronto, Toronto, Ontario, Canada.

Objective: This study examines the impact of mandatory AIDS education initiated in Ontario Schools during the fall of 1987, on 1000 Canadian and eighty students - 135 females, 45 males, mean age 16.3 years - working as volunteers in 13 Toronto area hospitals. These were surveyed during the summer. In terms of 1) General Health Knowledge, 2) Knowledge about HIV infection, 3) Attitudes towards persons with AIDS and safe sex practices, using both open ended and multiple choice questionnaires.
Results: Knowledge about HIV, but not Attitudes, was found to correlate positively with general health scores. The only variables to correlate significantly with attitude scores were sex (p<0.0001) and rural background (p<0.005) with females and children of Canadian, American and European backgrounds being significantly more positive in their attitudes towards safe sex and persons with AIDS than males and children of Asiatic or Third World countries. Approaching significance were the trends for children of highly educated parents (especially health professionals) to be more negative than children whose parents had not completed high school.
Conclusion: Increased knowledge about HIV does not necessarily guarantee positive attitudinal changes.

Publications

Le SIDA, la société et le comportement
AIDS, Society and Behaviour
E.585 DO SEXUAL PRACTICES IN UNIVERSITY STUDENTS JUSTIFY THE PROMOTION OF CONDOMS?
 IZABELA Antonia, Mendieta M., Valeriano J.L., Sepúlveda J., Townsend J.*

*Instituto de Epidemiología, Ministry of Health, MEXICO. *Instituto Nacional de Estadística y Censos, Mexico

Objective: To describe sexual practices, and knowledge and use of condoms in Mexican university students.

Methods: A survey to determine actual practices regarding the risk of AIDS transmission was carried out in university students in three cities. 8 following resorts and one USA border city. The information was obtained through a questionnaire. 473 men and 430 women were interviewed.

Results: The main results are presented in the following tables.

	SEXUAL ACTIVITY			KNOWLEDGE AND CONDOM USE IN SEXUALLY ACTIVE			
	MALE	FEMALE	P	MALE	FEMALE	P	
AGE (Average)	22	21	NS	Knows condoms	49%	36%	<.001
Sexually active	43%	11%	<.001	Ever used one	39%	16%	NS
Homosexual practices	3.5%	0.5%	NS	Purpose of use:			
Partners (average in the last 6 months)	1.8	0.8	<.001	Family planning	36%	47%	NS
				AIDS prevention	1%	0%	NS

Conclusions: Contrary to expectations prevalent sexual practices in university students justify educational interventions to promote condom use, although it may be thought that Latin American students have less risky practices than students living in industrialized countries. Condom use is now associated to family planning.

E.586 AIDS EDUCATION OF DRUG ADDICTS

 Sorrell S.,* Elton, R.**
 *St. Luke's/Roosevelt Hospital Center, New York, N.Y., USA
 **Montefiore Medical Center, Bronx, New York, USA
 *Presenter

The strategy of risk reduction in substance abusers is dependent on the stage of awareness and recovery of the population. We have shown that the techniques used with a population in methadone maintenance, while similar in form, shows respect to the significant difference of the user on the street, such as bleach to clean their works, or a condom "to protect themselves." This intervention is further distinguished by the need to recognize what phase of drug acquisition and intoxication is being displayed by the client.

This should be contrasted with the needs of the street based interventions that by necessity must be much briefer in duration and be addressed to an immediate interest of the user on the street, such as bleach to clean their works, or a condom "to protect themselves." This intervention is further distinguished by the need to recognize what phase of drug acquisition and intoxication is being displayed by the client.

Notwithstanding the above differences, the similarities of tailoring the materials in a subset, non-judgmental fashion in appropriate language to the audience is paramount in importance. We will present examples of the above intervention in our presentation.

E.587 AIDS KNOWLEDGE AND SOURCES OF INFORMATION ABOUT AIDS AMONG IN DRUG USERS
 McCoy, B.,* McCoy, C.,* McCoy, C.,* Whitwood, D.B.,** and Drapido, E.,** and McKay, C.T.*** *Florida International University, Miami, FL, USA, **University of Miami School of Medicine, Miami, FL, USA, ***

Objective: To describe the distribution by sex and ethnicity/race of sources of AIDS information and to determine the effect of the source of information on AIDS knowledge among IVUDs.

Method: As part of a study which tests two interventions to reduce AIDS among IVUDs, 316 subjects were recruited from drug networks and interviewed. Bivariate analyses were conducted to assess the distribution of information sources and the relationship to AIDS knowledge. Gamma values assess the strength of relationships.

Results: First source was the most likely source of AIDS information used by IVUDs. Information source varied, however, by ethnicity/race and sex and was statistically significant. Each source (TV/radio, print, institutions, personal) was more likely to be the choice of a particular ethnic/racial group. The source of information was also related to the accuracy of knowledge about AIDS. Those who obtain information from individual persons, such as outreach workers and friends, score higher on a knowledge test.

Conclusions: Communications about AIDS should be ethnic/race-specific and sex specific using particular media for each group.

E.588 REACHING HIGH-RISK YOUTH: TRAINING THE PROVIDER

 Popowich, Nancy* (Doctor), L. Rosenfield, C.,** Green, R.***
 *Planned Parenthood, Cambridge, MA, USA, **NIH, Dept. of Health/PHS, Substance Abuse Services, **DHHS AIDS Program, and ***DHHS Addictions and Health Research

Objective: To describe the outcome of a two day intensive training on increasing AIDS knowledge, comfort and skill level in providers working with high-risk youth.

Methods: Three regional trainings for a total of 80 youth intervention program staff took place in the spring of 1988. Youth intervention programs are designed to provide outreach and early intervention services to youth identified with alcohol and drug related problems. The program was planned and implemented with the collaboration of the Dept. of Public Health, Planned Parenthood, community-based agencies and people with AIDS. A safe environment was created by skilled trainers. Role modeling, affective and didactic methods were used. Participants were exposed to issues faced by gay, black and Latino youth from the perspective of members of these communities. Pre, post and follow-up questionnaires were used to measure change in knowledge, comfort and delivery of service.

Results/Conclusion: Preliminary results show significant increase in understanding of AIDS information, in comfort and skill level in addressing issues of sexuality and in comfort and skill level in educating high-risk youth about AIDS and AIDS prevention. Follow-up surveys indicate participants are using the risk reduction and prevention strategies developed during the training.

E.589 POST-TEST DISCOMFORT IN AIDS KNOWLEDGE SCREENING INTERVENTIONS
 DODD, JOHN, PHD, IN A HIGH-RISK AIDS SCREENING INTERVENTION
 Nelson, M.,* J. Beckman, M.D.†, Lipatova, C. (Ch), O'Brien, S.

*Harvard Medical Center/Alburt Einstein College of Medicine, Boston, MA, USA.

Objective: To assess the impact of an educational program on AIDS knowledge among incarcerated IDU's in a New York City detention facility.

Methods: Newly arrested male IDU's were offered a five-session small group AIDS education program as part of a pilot project in 1986-88. Sessions included didactic sessions, role-playing, and printed materials. Participants took self-administered pre-test/post-test true/false pre- and post-tests. Pre- and post-test scores were compared overall, for individuals, by time, and by sociodemographic variables.

Results: Pre- and post-test results were available for 104 inmates, of whom 47 (45%) were black, 46(44%) Hispanic, and 11(11%) white; mean age was 31.7 yrs. 84(81%) had secondary school education or less. Mean percent correct for pre-test was 78%, vs. 88% for post-test (P<0.01), with no significant differences in improvement by race, education, or age. Pre and post-test scores were both 90% correct for those concerning risks of needle-sharing, heterosexual contact, and percutaneous transmission of HIV. Significant post-test improvement (P<0.05, McNemar's test) was seen for items concerning correct anatomy, needle hygiene, percutaneous transmission, and certain needle aspects of AIDS.

Conclusions: Results indicate significant post-test improvement in AIDS knowledge scores among incarcerated IDU's participating in a peer-based AIDS education program, especially regarding prevention behaviors and popular misconceptions about AIDS. Pre-test knowledge was high regarding certain aspects of drug and heterosexual transmission. Data suggest that primary may be stratified advice for targeted AIDS education programs for IDU's, combined with strategies to promote behavior change.

E.590 A COMPARISON OF STUDENTS', TEACHERS', AND SCHOOL BOARD

 PRESIDENTS' KNOWLEDGE AND ATTITUDES ABOUT AIDS
 Huestis, R.C.;* Amos, S.;* Johnson, J.;* Mullins, L.L.;*
 *University of Oklahoma Health Center, Oklahoma City, OK, USA,
 **Case Western Reserve University, Cleveland, OH, USA.

Objective: To determine the level of knowledge about AIDS and attitudes towards persons with AIDS (PWAs) of high school students, teachers, and school board presidents. As most children with AIDS attend public schools, it is important for those who allow children entrance (school board), teachers and administrators, and their peers to have accurate knowledge about AIDS and positive attitudes towards PWAs. In order to design programs to counteract negative public attitudes towards AIDS, it is important to first determine what these misconceptions are. This study explores the knowledge and attitudes of these three groups.

Methods: A previously used knowledge and attitude questionnaire was administered to 10th grade students (n=448), school teachers (n=214), and school board presidents (n=190). The form contained questions about the risk of casual contagion, the meaning of the results of antibody testing, and modes of transmission. The form also contained questions about the subjects' attitudes towards social interactions with persons with AIDS, and whether PWAs should attend public school.

Results: Data will be presented on the three groups' relative knowledge about AIDS and attitudes towards AIDS.

Conclusions: Differences between the groups will be highlighted. Recommendations for educational programs will be made.

Publications

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

E.609 AIDS: DIAGNOSING EDUCATIONAL NEEDS OF HEALTH CARE PROFESSIONALS
 Wright, J.; Fitzgerald, A.; Risi, George; Marier, R.
 Delta Region AIDS Education and Training Center, New Orleans, La., U.S.A.

Objective. To determine health care providers' attitudes toward AIDS education and learning needs in three southern states.
Methods. A written questionnaire was mailed to a random sample of 942 primary care physicians, nurses, infection control practitioners, dentists, dental hygienists and social workers. Additional data was collected from 15 key informant, telephone interviews. AIDS experts in the 3-state region were selected as informants. In addition to statistical analysis of the survey results, the quantitative data was triangulated with qualitative findings from the interview.

Results. An education needs profile within and across professional group categories found that health care professionals and AIDS experts agreed on the importance of AIDS/HIV education but differed on HIV focus. For example, AIDS experts described the need for learning in the psychosocial dimensions of AIDS treatment. Although survey respondents ranked low their current satisfaction level with these issues, psychosocial concerns were not a priority learning need. Instead, knowledge about prevention techniques and high risk groups and profession-specific skills related to AIDS/HIV treatment were more highly rated. Attitudes toward AIDS/HIV infection differed among professional groups as well as their perceived impact on service quality. Implications for educational program based on health providers' learning style preferences and perceived educational needs are discussed.

E.610 TRAINING OF HEALTH CARE PROVIDERS IN SAO PAULO STATE, BRAZIL
 Fernandes, H.E.; Ferreira, A.C.; Grandi, J.L.; Pinto, U.; Del Bianco, F.

Centro de Referência e Treinamento-Aids, Sao Paulo, Brazil

Objective. Training of health care providers to decrease the morbidity and mortality caused by HIV infection in Sao Paulo State.
Methods. 80 hours course, 40 hours of classes and 40 of practice. The program includes the following contents: Epidemiology, virology, pathogenesis, immunology, clinical and laboratory management pediatric Aids, blood bank control, Human sexuality and Educational strategies. We established the same program with 5 clinical multiprofessional team from 5 reference centers in Sao Paulo State. The course evaluation was made using a 15 marks questionnaire two times before and after the course.

Results. 350 Health Care Providers trained in the period between April to December 1988.75% developed local programs for Aids prevention and control.

Conclusion. This is a very effective way of training and demands only a period of 2 weeks.

E.611 A CLINICAL PROGRAM TO TRAIN PHYSICIANS AND PHYSICIAN ASSISTANTS TO PROVIDE OUTPATIENT CARE FOR HIV-INFECTED PATIENTS

Kaiser, Travis, Peters, S. R.; Gales, J. F.; Merritt, S. J.; Lee, F. Y.*
 AIDS Research and Training Center, University of Medicine
 *Department of Medicine, University of Southern California School of Medicine, Los Angeles, California, USA.

Objective. To provide opportunities for PA's with knowledge and skills to manage the complications of HIV infection seen in the outpatient setting, and to increase the number of trained primary care providers caring for HIV-infected patients in the community.

Methods. Physicians and PA's from 3 counties in Southern California receive intensive, 1 week, one-on-one clinical training with a physician specialist in a multidisciplinary, university-affiliated AIDS outpatient clinic. The population includes ethnic minorities (40%), indigent (66%), women (4%), and TOUT's (3%). Additional training is provided in a private physician's office and an STD clinic. Training takes place during the course of patient visits and didactic sessions. Emphasis is on clinical instruction in the context of direct patient care supplemented by a comprehensive syllabus.

Results. Formal evaluation of the program includes exit interviews of the participants and 6 month follow-up. Preliminary data indicate that the trainees' goals are being met by the program.

Conclusion. An intensive, short-term clinical program is effective in modifying clinicians' management of HIV infection.

E.612 EVALUATING AIDS EDUCATION FOR HEALTH PROFESSIONALS

Fearns, James; Harris, V.; Harrison, V.; Harris, R.; Stuebner, J.; Gabel, R.

East Central AIDS Education and Training Center, Columbus, Ohio, USA

The East Central AIDS Education and Training Center (ECATC) has developed a wide range of educational methods and programs to educate health care workers about AIDS. Evaluating the match of educational methods to health care provider needs for AIDS education has been an integral component of ECATC efforts over the last 12 months.

METHODS. The ECATC evaluation effort functions on three levels: 1) **trainee assessment**; 2) **program impact**; and 3) **regional impact**. Methods used to evaluate these included participant assessments of program, program documentation and dissemination surveys, and site visits and interviews.

RESULTS. **Trainee assessment:** 2717 health care professionals completed ECATC program evaluations. Eighty-eight percent of participants indicated favorable responses to: importance/values of training content, improvement of knowledge, quality of presentation and materials, and overall quality of presentation and program. **Program impact:** 16,547 health care professionals participated in ECATC programs, including 3453 physicians; 3813 nurses; 1171 dentists; 2011 allied health; 1933 students; 987 counselors; 71 physician assistants; and 1099 emergency medical technicians. **Regional impact:** 136 key organizations/agencies were contacted in order to establish formal, ongoing linkages; 4000 entries were made in ECATC databases; 3000 newsletters were distributed; and 3000 brochures were distributed. More study is needed in order to determine the long-term impact of such AIDS education and training centers.

E.613 RESULTS FROM 1988 SURVEY OF MICHIGAN STATEWIDE SCHOOL HIV POLICY, STAFF INSERVICE, AND STUDENT EDUCATION
 Hines, Barbara J.; Project Coordinators: Manda Juhnke* AIDS Survey Advisory Committee** * **Michigan Department of Education, Comprehensive Health Services, Lansing, Michigan, USA

Objective. To establish baseline data on the number implementing and quality of Michigan public school policy, staff inservice and student education.

Methods. We AIDS Information Surveys were sent in May, 1988 on HIV program activities for the 1987-88 school year. Districts were asked to report on level activities were sent to 517 superintendents with an 88% return. A 91 item survey on building level activities was sent to 411 middle school principals with a 71% return and also to 613 high school principals with a 73% return. Random verification of survey data was conducted.

Results. Returns showed 74% of the reporting districts had a policy addressing attendance for persons with AIDS. Districts reported 341 had district staff inservice training with principals reporting 41% of the middle and 48% of the high schools had staff inservices. Both the middle and high school principals reported 41% had adopted written routine procedures for blood and other body fluid spills. A district, age appropriate K-12 program for educating students about AIDS occurred in 34% of the reporting districts though less than 10% taught anything in grades K-4, 5% in 5th, and 2% in 6th grade. Planned student AIDS education occurred in 82% of the middle and 78% of the high schools.

Conclusion. Assistance must be provided to school districts on policy issues i.e. confidentiality and handling body fluid spills. More total school staff inservice must occur. Comprehensive health education plan is the most effective.

E.614 THE RELATIONSHIP BETWEEN CONCERN ABOUT AIDS, KNOWLEDGE OF TRANSMISSION, AND BEHAVIOR CHANGE: CORRELATIONS AT THE INDIVIDUAL AND NATIONAL LEVELS
 Nicholson, S. and Horan, R.C.
 AIDS/CDC, Astenberg School of Communication, University of Pennsylvania, Philadelphia, PA, USA.

Objective. To examine correlations between concern about acquiring AIDS, knowledge of transmission, and reported behavior change.

Methods. Correlation coefficients were computed using aggregated data from 34 nations in which the Gallup organization conducted surveys of AIDS related knowledge, attitude and practice. The associations found were compared to results reported from several individual level studies which employed similar questions.

Results. At the national level, concern about acquiring AIDS was associated with belief in transmission by casual contact, a finding similar to several individual level studies that have shown a relationship between low and inaccurate knowledge. Countries with higher levels of reported behavior change had lower levels of accurate knowledge. Lower levels of accurate knowledge were associated with reports of inappropriate behavior change such as avoiding homosexual. Reports of behavior change that involved increasing condom use were associated with concern about getting AIDS, but not with accurate knowledge of transmission. **Conclusion.** Countries in which concern about AIDS was associated with higher levels of reported behavior change had lower levels of accurate knowledge. Lower levels of accurate knowledge were associated with reports of inappropriate behavior change such as avoiding homosexual. Reports of behavior change that involved increasing condom use were associated with concern about getting AIDS, but not with accurate knowledge of transmission.

Conclusion. Countries in which concern about AIDS was associated with higher levels of reported behavior change had lower levels of accurate knowledge. Lower levels of accurate knowledge were associated with reports of inappropriate behavior change such as avoiding homosexual. Reports of behavior change that involved increasing condom use were associated with concern about getting AIDS, but not with accurate knowledge of transmission.



Publications

- E.615** CHANGES IN AIDS-RELATED KNOWLEDGE, ATTITUDES AND BEHAVIOURS OF HIGH SCHOOL STUDENTS IN GREECE
 G. Kotsopoulos, A. Katsiava, T. Kioseoglou, G. Achiladeu, C. and Papapanagoulou, V.
 University of Thessaloniki, Thessaloniki, Greece.

Objective: To estimate the AIDS-related knowledge, attitudes and behaviours of high school students and evaluate factors affecting their changes.

Methods: A questionnaire was developed and administered to a national representative sample of 503 high school students, probing their knowledge about transmission and prevention of HIV, their attitudes and their behaviours about AIDS.

Results: Accurate responses about the main routes of transmission were given by more than 90% of the students. AIDS-related knowledge was associated with age and socioeconomic level. Females were less knowledgeable than males, especially in younger and those living in provincial cities. The level of misinformation was high: 25-70% believed that HIV could be transmitted through usual social contact or by scorpion-ticks. Mass media and newsletters distributed through the electricity bill were the main sources of information. Only 11.6% attended relevant lectures. Changes in sexual behaviour were declared by 28.7% of the students. They were more common in males and in older students. Suggestive measures for containment of the disease were suggested more often by younger and male students. Females and older children requested more information and could more often accept carriers as school-mates.

Conclusion: There is great need of implementing a systematic effective educational school programme to improve AIDS-related knowledge, and decrease misconceptions leading to unacceptable attitudes and behaviours.

- E.617** AIDS INFORMATION AND TEEN-AGERS IN PARIS
 Cartiercher, Ivan*, Demand, F., Bravaud, C. ** Unité d'Oncologie Virale, Institut Pasteur, Paris, France.

Objective: To describe the impact of AIDS information on teen-agers, some of them socially vulnerable.

Methods: 600 students from three secondary schools in the north of Paris, age 13 to 16, have been informed on AIDS in February and March 1988. The sessions were informal, with video and slides. A few weeks later, 35% (sex ratio = 1) responded to a confidential multiple-choice questionnaire. 81% reported no sexual relation, 75% were living in an unfavorable environment: low socio-economic level, and ethno-cultural differences (the majority of North African immigrants and Asian refugees).

Results: 54% felt misinformed before this program. After it, the definition of HIV was better understood (95%) than AIDS (70%). 55% knew the three transmission routes among eight choices. Only AIDS knew that seropositives and asymptomatic carriers are contagious. 61% understood what "seropositive" is. Principles of prevention were well assimilated (89%) but 61% would not wait long enough before having the antibody test. Results in the more vulnerable group were not significantly different.

Conclusion: Appropriate information among teen-agers and vulnerable youth has to be stressed:

- transmission modes, particularly sexual, e.g.: HIV infection can escape notice if asymptomatic infected persons are contagious.
- the 3-6 months delay before testing.
- instructions for condom use (e.g. avoid oil-based lubricants), and the necessity not to change sexual partners.

- E.619** Impact of Mandatory AIDS Education on Ontario Schools, 1987
 Arlette LeFebvre, M.D., F.R.C.P.C., Stanley E. Read, M.D., F.R.C.P., F.R.C.P.C., Nathan Silverberg, Thomas Heagy, M.A., Evan Collins, M.D., F.R.C.P.C.
 Hospital for Sick Children, Toronto, Ontario, Canada

Objective: This study examines the impact of mandatory AIDS Education initiated in Ontario schools during the fall of 1987.

Methods: One hundred and eighty students - 135 females; 45 males; mean age 16 years - were surveyed in 14 schools in two Toronto area hospitals were surveyed during the summer, in terms of 1) general health knowledge, 2) knowledge about HIV infection, 3) attitudes towards persons with AIDS, and safe sex practices, using both open ended and multiple choice questionnaires.

Results: Knowledge about HIV, but not Attitudes, was found to correlate positively with general health scores. The only variables to correlate significantly with attitude scores were sex (p 0.001) and sociocultural background (p 0.005) with females and children of Canadian, American and European backgrounds being significantly more positive in their attitudes towards safe sex and persons with AIDS than males and children of Asiatic or Third world countries. Approaching significance were the trends for children of highly educated parents (especially health professionals) to be more negative than children whose parents had not completed high school.

Conclusion: Increased knowledge about HIV does not necessarily guarantee positive attitudinal changes.

- E.616** VALIDATION OF AN INFORMATICE AND EDUCATIONAL PROGRAM IN TURCANOV'S HIGH SCHOOLS STUDENTS.

Inferno, Annalisa*, Orsini, C.**, Prioli, C.***
 *University of Siena, Siena, Italy **University of Florence, Florence, Italy

Objective: To value the preventive capability of some informative instruments, which are different in modality of creation. **Methods:** The informative validity is assessed by a questionnaire, purposely created. The research has been carried out on statistical sample of students of province of Florence. The first validation has been before the informative program (video-tapes) and the second after it.

Results: With this questionnaire has been possible to verify the efficacy of the message and the modification of behaviour.

Conclusion: We could be able to realize a proper preventive behaviour. Today it constitutes the only form of struggle against the disease.

- E.618** AIDS INFORMATION IN FRENCH YOUTH
 Demand, François
 Unité d'Oncologie Virale, Institut Pasteur, Paris, France.

Introduction: AIDS information is still underdeveloped amongst french youth. NGOs may be incorrectly perceived. Only a minority have benefited from personalized information, mostly at school, given by physicians, school nurses or educators.

Objective: To improve AIDS prevention for the young.

Methods: Among the 10,000 students that I personally informed from June 1987 to October 1988, more than 1500 expressed their opinion through an anonymous questionnaire.

Results: AIDS provokes contradictory attitudes: although they deny any DIRECT threat from the epidemic, the young are bothered and disturbed by the media giving too much heterogeneous information that is sometimes incoherent and polemic. They feel that AIDS will in the short term modify their sexual and social behavior; they are waiting urgently for authentic, more human and explicit information, indispensable for AIDS awareness. To better involve the young in AIDS prevention, new models of information are suggested, e.g. a "second generation information": we need motivated young volunteers, previously trained and informed to convey basic data on AIDS, leading to concrete preventive counseling.

Conclusion: - The more specifically designed information modes given by AIDS to youth leaders to the young, the more efficient the prevention;

- School is one of the best environments to experiment with these models (formal and non-formal);

- personalized information delivered to small groups is necessary to teach them how to use condoms and to recommend to them their use in any new relationship (always of uncertain origin).

- E.620** AIDS KNOWLEDGE, ATTITUDE AND BEHAVIOR PATTERNS AMONG UNIVERSITY STUDENTS IN Ibadan, NIGERIA.

OLADINJI OLUFEMI, Ph.D. M.P.H.
 W.R. BRIDGER M.P.H., University of Ibadan, Nigeria.

This study investigated the knowledge, attitudes and Personal Behavior of University Students related to AIDS. Two hundred and fifty two students from the University of Ibadan randomly selected from eight faculties were surveyed. Results indicated that 50.7% of respondents knew that AIDS is caused by a virus but 77.5% thought the disease could be spread through kissing, hugging or shaking hands and 48.0% believe they cannot have AIDS. Their respondents showed a high degree of aversion to AIDS victims while about a quarter reported having multiple sexual partners in the last five years. The results suggest that well organized, specifically targeted health education programmes are needed for University Students.

E.627

AN INTEGRATED APPROACH TO HIV-RELATED CURRICULUM FOR PHYSICIAN'S ASSISTANT STUDENTS:

Richard Lyons, R.A. and Maza, R.D.

Department of Physician Assistant Studies, The University of Texas Medical Branch, Galveston, Texas, USA.

The Department of Physician's Assistant Studies developed and implemented a curriculum to teach physician's assistant students about the didactic, clinical, and psychosocial aspects of HIV infection. Student attitudes about AIDS and AIDS patients were measured using the Sham-Torner AIDS Attitude Questionnaire at various points in the program curricula. The object of the model curriculum has been not only to make physician's assistants students more knowledgeable about the pathophysiology, diagnosis, and prevention of AIDS diseases but to stimulate an awareness of the psychosocial consequences and implications of HIV infection as well. An integrated methodology was devised for the Junior year curriculum which placed appropriate information in numerous existing courses beginning with the Patient Evaluation II and Problem Solving Techniques, and extending through the Preventive Medicine and Community Health and Human Dynamics III courses. For senior students, the materials were covered in several senior seminars at the end of clinical rotations. Senior students also participated in a 4-week rotation with direct clinical contact with HIV-infected patients. Prior to patient contact, all students are taught basic principles in pathophysiology, diagnosis, and treatment/prevention for care of patients with HIV infections. Results of the attitude survey will be utilized to make adjustments in the program curricula.

E.629

FACTORS PREDICTIVE OF AIDS-HIV KNOWLEDGE AND ATTITUDE AMONG NURSING AND MEDICAL STUDENTS

Joseph, Thomas P., Shinn, M.P., Beckel, M.P., Belden, M.P. and Ish, J.

University of Illinois at Chicago, Chicago, Illinois, The University of California, San Francisco, California, USA.

OBJECTIVE: To identify psychosocial and personal variables that explain negative attitude toward AIDS patients and nursing and medical students. **DESIGN:** A total of 113 nursing students and 118 medical students were surveyed regarding their knowledge and attitude about AIDS. The estimate of knowledge of HIV infection did not differ significantly between nursing and medical students. Students were also surveyed regarding their level of homosexuality, drug use, and indicators of drug use. **SETTING:** The University of Illinois at Chicago and the University of California, San Francisco. **MEASUREMENTS AND MAIN RESULTS:** Knowledge about AIDS was higher in HIV infection than in medical students, although an differences emerged between nursing and medical students in regard to their overall AIDS attitudes, but not a sub-set of it. The majority of students, however, demonstrated low for HIV infection attitude to be negatively associated with age.

Multiple regression analysis was performed to determine what best predicted low attitude of AIDS knowledge, AIDS attitudes, and AIDS attitudes toward patients (measuring a student's willingness to work with AIDS patients), and negative affect (measuring a student's endorsement of negative attitudes responses in regard to a person with AIDS). Predictive variables were entered: response to the regression equation following the forward entry of items from the Comprehensive Social Desirability scale. Results indicated that the best predictor of knowledge, medical information about AIDS was an overall negative attitude towards AIDS. Lack of clinical experience with AIDS, the perception of prevalence of HIV, and homosexuality also significantly added to the prediction of low scores on AIDS knowledge, medical information about AIDS was an overall negative attitude towards AIDS. Homosexuality, an indicator of drug use, and of clinical experience with AIDS patients, high school seniors, and low levels of homosexuality also significantly added to the prediction of negative AIDS attitudes.

The best predictor of both professional knowledge and negative affect was homosexuality. Encouraged this prediction, the use of drug use and low level of clinical experience also significantly added to the prediction of professional knowledge, whereas only an indicator of drug use, and low levels of AIDS knowledge significantly added to the prediction of negative affect. The results of this study suggest that the best predictor of knowledge, medical information about AIDS was that will be additive in changing attitudes. Positive attitude an opportunity essential to the availability of our staff and students about AIDS. The results also suggest that increased experience with AIDS patients, as well as greater familiarity and exposure to the theories of drug use at high risk might help. Attitudes negative AIDS attitudes and reduce positive AIDS patients among future health care givers.

E.631

WORKING WITH AIDS IN THE HEALTH CARE MODEL CURRICULUM FOR REGIONAL TRAINING OF CAREGIVER PROVIDERS

Heister, Michael J., Mack, J., Diller, J.J.

Duke, B., Batters, D., *** Ministry of Health, Trinidad and Tobago, *** Caribbean Epidemiology Centre and the Pan American Health Organization, S.A.

OBJECTIVE: To address the information and training needs of health care providers in the Caribbean regarding AIDS prevention counseling with clients and patients.

DESIGN: Two sets of regional training materials for 40 health care providers from 19 English-speaking countries in the Caribbean led to the development of training guide to be used throughout the region. Components of the training and the guide were tested among focus groups and the pilot trainers were implemented in national workshops as well.

SETTING: Sixty health care professionals from the Caribbean rated the workshops as timely, informative, effective, and valuable to their AIDS prevention efforts. During a four-month period more than 2000 individuals in 18 countries were reached with AIDS prevention counseling messages by these same 40 participants. As a result, a training guide was developed and is currently in use in the field.

CONCLUSION: A train-the-trainer model for disseminating AIDS prevention counseling skills can be effective among health care providers in the Caribbean. A guide to supplement these trainings has been useful in ongoing efforts.

E.628

SELF-SELECTION AMONG PROSPECTIVE HEALTH CARE PROVIDERS AS A FACTOR IN AIDS EDUCATION

John, Margaret B., Forewille, T.J., Bannett, H.B., Hoang, B.A., Zupina, L.J., Dinger, J.

University of California, San Francisco, California, United States

OBJECTIVE: To identify the characteristics of those individuals who seek to take an AIDS education course. In so doing, we sought to determine if self-selection for a study of AIDS education was related to demographic characteristics such as race, gender, marital status, and other factors. **DESIGN:** A cross-sectional study of 1000 health care providers at the University of California, San Francisco (UCSF) were surveyed regarding their demographic characteristics, their race, gender, marital status, and other factors. **SETTING:** UCSF School of Medicine and those sites who did not. **MEASUREMENTS AND MAIN RESULTS:** Data from UCSF analyses indicated that the decision to take an AIDS education course was contingent upon both sex and gender. A statistically significant proportion of women elected to take the course in comparison to men, and a statistically greater proportion of whites elected to take the course in comparison to nonwhite students. The significance of gender and race was not significant with respect to entering professional training. However, when asked to take the course, however, women did not with significantly more enthusiasm than men. The decision to take the course was not significantly related to age, marital status, and other factors. **CONCLUSIONS:** The decision to take an AIDS education course was contingent upon both sex and gender. In addition, with respect to the decision to take the course, there were no significant differences by profession.

CONCLUSIONS: The decision to take an AIDS education course was contingent upon both sex and gender. In addition, with respect to the decision to take the course, there were no significant differences by profession.

E.630

Projet de communication au congrès international sur le SIDA

Les travailleurs sociaux et les représentants

du SIDA au Québec

Maria Conaire, Coimbatore, Pérou

E.P.S.I. (Ecole de Service Social), Clermont, France

Martin, Nicole

L'objet de la communication que nous souhaitons faire est de montrer comment un centre de formation de travailleurs sociaux peut être à l'origine d'un mouvement de sensibilisation sur ce qu'est le SIDA, et cela à partir d'une part de recherches menées par des étudiants et des professionnels, d'autre part de journées d'information et de formation.

partant de ce principe, nous avons proposé un travail qui pouvait s'articuler de la façon suivante :

- une phase d'investigation sur le terrain afin de connaître les réalités + population ciblées + réaction des travailleurs sociaux + ceci grâce à un travail recherche mené l'une par les étudiants, l'autre par les professionnels de la Région.
- une phase d'information + grand public (2 jours) + de travail (6-7) au sein d'une action collective de prévention et d'information dans un lycée. Le tout devant déboucher sur la production d'un document final qui serait pour objectif de aliter le problème de SIDA au QUÉBEC.

Notre souhait est de mobiliser par un travail action-recherche le maximum de professionnels autour du problème du SIDA.

E.632

IMPLEMENTING UNIVERSAL PRECAUTIONS IN A TEACHING HOSPITAL UTILIZING A CASCADE TRAINING METHOD

Hedley, D. and Johnston, Peter C.

Departments of Nursing and Medicine, Veterans Administration Medical Center and The University of California, San Francisco, California, USA

Ours is a 300 bed teaching hospital with 1500 full and part-time employees in a area of high endemicity for HIV infection. The need to introduce concepts of universal precautions provided the means to simultaneously disseminate basic HIV information. This program consisted of the following elements: 1) a core MD/PHN faculty, 2) support of hospital administration, and 3) emphasis of content to accommodate classroom work units. Employees were chosen by supervisors to be trainers based on criteria that selected for teaching potential rather than by professional status within the work unit. Two half-day seminars were attended by 38 trainers from 23 departments. Trainers were then required to hold at least one training session within their work groups. The faculty assisted on individual programs and monitored content in the first 3 months of the program, nearly 750 hospital employees received documented training. As a result, there has been 1) widespread compliance with new infection control procedures, 2) decreased anxiety regarding HIV transmission in the workplace as evidenced by decreased demand upon infection control nursing staff, 3) decreased use of inappropriate barrier protection, and 4) increased demand for Hepatitis B vaccine among high-risk groups. Hospital employees can successfully be taught basic HIV concepts by peers rather than by traditional teachers such as physicians and nurses.


E.633 SEXUALLY TRANSMITTED DISEASES AND THE AIDS EPIDEMIC: POLICY IMPLICATIONS

Author: Reid,^{*} Hessell, D.^{**}
^{*}Family Health International, Triangle Park, North Carolina, U.S.A.
^{**}Research Triangle Institute, Research Triangle Park, North Carolina, U.S.A.

Objective: Describe the policy implications of data showing that STDs increase HIV transmission.

Methods: Computer simulations using two different models of the effect of STDs on HIV transmission were run and the history of successful AIDS control efforts in the United States was reviewed.

Results: Computer simulations suggest that control of STDs will slow the HIV epidemic. If appropriate educational strategies are followed, the epidemic's impact is likely to result in sustained behavior change and a lower incidence of STDs in the population. Additional considerations suggest that STD control should be the priority intervention in developing countries with high rates of STDs.

Conclusions: 1. It is important to use persons with AIDS in health education and STD Programs. 2. STD control should be a priority because (1) behavior change and condom use are generally resisted until late in the course of the epidemic; (2) treatment of STDs is highly sought by high risk groups; and (3) STD treatment facilitates health education of high risk individuals.

E.635 REPORTED KNOWLEDGE, CHANGES IN MID SOUTH TEXAS URBAN RESIDENTS: LONGITUDINAL RESULTS OF AN INTENSIVE HIV INFECTION COEXISTENT INTERVENTION

Author: Christie,^{**} Zylot, P.^{*}; Shomaker, P.^{**}; Hallstar, A.^{*}; O'Conn, R.^{*}; and Reed, C.^{**} ^{*}The University of Texas Health Science Center, Houston, Texas, USA. ^{**}The University of Texas, Austin, Texas, USA. ^{***}Centers for Disease Control, Atlanta, Georgia, USA. ^{****}Texas Department of Health, Austin, Texas, USA.

Objective: To assess the effects of a community intervention on reported knowledge relating to HIV infection.

Methods: Randomly sampled residents of a large Mid South Texas city completed a telephone survey in 1987 (n=603) and one year later (n=207, use sample of respondents). The survey included questions on HIV-related knowledge, attitudes, behavior and sources of information. The intervention included an AIDS hotline, factored communications in the local media, safer sex workshops, counseling and testing, and the passing of an AIDS anti-discrimination ordinance.

Results: Knowledge about transmission of HIV and HIV symptoms increased 6% (p<0.05) and 15.3% (p<0.1) respectively. At baseline, 43.4% cited television as the most influential source of information about AIDS, whereas physicians and health care providers were the most important source a year later (18.8%), followed by television (16.8%), mailings (12.8%), magazines (10.8%) and newspapers (6.8%).

Conclusions: Reported knowledge increased in a cross-section of urban residents after a multi-dimensional community AIDS prevention program. Reported information sources increased in variety which is a key element in successful public health AIDS prevention campaigns.

E.637 AIDS KNOWLEDGE AND ATTITUDES OF STUDENTS FROM A SELECTIVE U.S. GIRLS' PAROCHIAL PREPARATORY SCHOOL. Genser

Author: Genser, S.^{**}; Preston, A.^{**}; Hawkins, K.^{**}
^{*}National Institute on Drug Abuse, Rockville, Maryland, U.S.A.
^{**}Potomac, Maryland, U.S.A.; ^{***}Washington, D.C., U.S.A.

Objective: To trace the early development of AIDS knowledge and attitudes in primary school students in a selective Episcopal girls' preparatory school and compare results to a national sample of adult women.

Methods: Questions covering basic biological facts and attitudes about AIDS were selected from the National Health Interview Survey (NHIS) for 11th Stat). The resulting questionnaire was administered to entire classes in the 5th and 6th grades (ages 10-12) for a total N=72.

Results: In this unusual sample of students, the 50th percentile corresponds to overall aptitude to the 97th national percentile. In the school, 88% of families pay the full annual tuition of over \$8000/yr., 99% of graduates attend selective colleges & there are 16% minority students & 9% foreign nationals.

On the factual questions, the 5th and 6th grade scores are significantly different at 41% & 56% respectively. Patterns of responses reveal areas in which these subjects (4 samples of male students and adults from different studies) show developmental progression.

On the attitudinal questions, the majority of the acquisition of accurate knowledge or beliefs, the rejection of inaccurate knowledge, and the unique sample for a cognitive/developmental theory of the acquisition of AIDS knowledge and beliefs are discussed.

Conclusion: Studies of the early patterns of information acquisition may point to educational efforts to strengthen the often tenuous connection between knowledge and effective prevention.

E.634 AIDS/HIV INFECTION AND OUTREACH PROGRAM FOR HEALTH CARE PROFESSIONALS

Author: De Ma,^{*} Fraser, M.^{*}; Paley, J.^{*}
^{*}Center for Interdisciplinary Research in Immunology and Disease (CIRID) at University of California at Los Angeles (UCLA), USA. ^{**}CIRID at UCLA and UCLA School of Nursing, USA

Objective: To develop a comprehensive AIDS educational program specific to the needs of health care professionals.

Methods: The program is comprised of four components: needs assessment, interventions, follow-up and evaluation. Interventions utilize conferences, lectures, workshops for health professionals. These also include the training of those individuals responsible for the instruction of physicians, medical students, nurses, nursing students, and other medical staff. The use of audiovisual educational tools (AIDS Training Modules/C.R. Levin, MD) is incorporated into the program when appropriate. Collaborations with other medical institutions and organizations promote the implementation of program. Resources materials produced by CIRID at UCLA include the AIDS/HIV Progress Guide for Medical Professionals, Textbook of AIDS, and AIDS/HIV Infection: A Reference Guide for Nursing Professionals. These materials are provided through the AIDS Training Program Guide for Medical Professionals. Textbook of AIDS and evaluation include surveys of AIDS-related needs of nurses, physicians, dentists, and dental students.

Results: Needs assessment has indicated a need for AIDS knowledge and skills by health professionals and a preference for continuing education courses as the method to gain such knowledge. Surveys have shown AIDS related fears to be prevalent among health professionals and students and a decrease in giving health care to the HIV-infected individual. Evaluation has shown that continuing education can bring health care knowledge and attitudes. Data from a one-day AIDS conference for nurses demonstrated that significant pre- and post-conference improvements had occurred in both knowledge and attitudes (p<.05); these were changed in 60% (p<.05) of the participants three months later. In large differences took place in the group with low knowledge of AIDS.

Conclusions: The experience indicates that traditional AIDS education for the health professional relies on addressing their specific concerns using both topical and integrative educational tools. This program has been conducted in several sites (including outside California) and can be adapted to local circumstances.

E.636
E.638 AIDS KNOWLEDGE AMONG UNIVERSITY STUDENTS

Author: Reuter, Buente,^{*} Katz, D.^{**}; Vader, J.P.^{**}; Foxman, B.^{**} et al.
^{*}University of Michigan, Ann Arbor, Michigan, ^{**}Institut Suisse de la Santé Publique, Lausanne, Switzerland.

Objective: To assess AIDS knowledge among students at a large Midwestern university.

Methods: A 24-item questionnaire assessing knowledge of HIV prevalence, transmission, and infectivity was administered by telephone to 216 randomly-selected students at the University of Michigan in March 1988 (response rate 78%). Each student was also asked about socio-demographic characteristics and whether the student was, by self-assessment, "sexually active."

Results: Students are very well-informed about annual transmission of AIDS; more than 90% agreed that condoms are protective and that risk increases with increasing number of partners. However, many still believe AIDS can be transmitted by casual contact; shared eating utensils and toilets were considered unsafe by 30% and 21%, respectively. Age, sex, race and sexual activity are the most important predictors of AIDS knowledge. Knowledge is greater among students aged 21 and older (odds ratio=1.9, 95% confidence interval=1.1-3.4); men (OR=1.7, CI=1-2.9); whites compared to blacks and Hispanic (OR=2, CI=1-3.7); and sexually active students (OR=5.5, CI=2-13.8). Age modifies the relationship between sexual activity and knowledge (OR=9 and 2.1 for young and old students, respectively).

Conclusion: Education efforts directed towards university students need to distinguish more clearly between safe and unsafe activities. Health education should target particular groups - women, younger students, and minorities - that are less knowledgeable.

Publications



- E.639** SURVEY OF COMMUNITY COLLEGE STUDENTS' AIDS KNOWLEDGE, ATTITUDES, AND RISK BEHAVIORS
 Anderson, R.A.,* Freeman, A.C.,* Betty, S.A.,** Tabors, J.,** and Haley, Charles E.,* Dallas County Health Dept., Dallas, TX, USA, **Professional Management Associates, Rockville, MD, USA.

Objectives: To determine the baseline level of AIDS knowledge and attitudes prior to a major media intervention, to provide data for development of curricula, to measure the level of risk-taking behavior. **Methods:** Students in 2 community colleges were asked to complete a 50 question survey during regularly scheduled classes. A seven point Likelihood scale rather than a binary true/false scale was used to measure knowledge of mechanisms of AIDS transmission. **Results:** A total of 420 students completed the survey: 60% female, 30% married, 41% freshmen. The students answered most transmission questions correctly. They might be exposed to HIV in the future by living with an infected person. 33% thought AIDS cases should be quarantined while 58% would attend class with a person with AIDS. 43% of the men with multiple sex partners thought they might be exposed to HIV in the next 5 years. Men were less likely to engage in promiscuous sexual behavior than men (19% vs 4%), but also less likely to use condoms. Other differences emerged when controls were introduced for age, marital status and ethnicity. **Conclusions:** AIDS education program aimed at heterosexual college age students must take into account gender based risk behaviors, attitudes, and knowledge.

- E.641** SEX EDUCATION: AN IMPORTANT ELEMENT OF AIDS EDUCATION
 "Centro de Pesquisas em Planejamento-AIDS, Sao Paulo, Brazil
 Diana Brakley"

Objectives: To describe a sex education curriculum that has been used as part of an AIDS education program in Brazil. **Methods:** A human sexuality curriculum was tested as a part of a training program on AIDS for 9 different groups of professionals: teachers, health care professionals, mental health professionals, social workers, human resource professionals of the private industry, professionals that work with abandoned children, general population, and sexual workers (male, female and transverse prostitutes). The curriculum is divided in four parts: a) Values clarification b) Basic information on human sexuality c) Specific information on human sexuality (AIDS related) and d) Specific strategies for each group depending on their needs and interests. **Results:** Sex education proved to be an important element in preparing the groups for the information on AIDS. This was especially true for the religious leaders (of 17 different religions) and sexual workers. **Conclusions:** a) The lack of knowledge about sexual behavior brings about misconceptions and fears that interfere with the transmission of facts about AIDS. b) Sex education is a necessary element of AIDS education.

- E.643** THE "THREE-FOR-FREE" PROGRAM: A STATISTICAL DENSIFICATION PROGRAM IN HARTFORD, U.S.A.
 Wondolowski, J., Bonaguidi, M.,* Clark, Samuel,** Gidycz, Anne,** Johnson, Pam,** Wiley, Andrew**
 *AIDS Administration, Department of Health, Baltimore, MD, USA **Division of Family Planning, MD Department of Health, Baltimore, MD, USA.

Objectives: Describe key components leading to the successful, rapid expansion of a Statistia Agency program which distributed over 1.6 million condoms annually from over 540 sites sponsored by over 170 agencies. **Methods:** Internal measures and self-administered questionnaires. **Results:** Since 1983 the Maryland State Health Department's Division of Family Planning had the objective of decreasing barriers to condom use by making free condoms available for anonymous pick-up at as many sites as possible. Statistia, in close interagency cooperation with the Administration, the rate of expansion over the last two years has been exponential.

Year	# Condoms Requested	Picked Up	# Dispensers	# Sites
1986	1,750	74	32	32
1987	571,515	52	164	164
1988	1,600,000	25	330	330

* (Provisional) Same reporting for first three quarters of 1989)
Conclusions: The Three-for-Free Program is a highly effective method of expanding access to condoms among high risk populations. With an average annual cost per active client of less than \$10.00 per year, the Three-for-Free program is an effective model for preventive community outreach based on interagency cooperation.

- E.640** A DEVELOPMENTAL APPROACH TO AIDS/IV EDUCATION
 Cooledge, A.,* Sages*, Sheets, R.,* Lindsay, L.,* Harris, V.,** ST, F.,** and Roberts, R.*
 *Vanderbilt University, Nashville, Tennessee, USA, **Harvey Medical College, Nashville, Tennessee, USA, ***University of South Carolina, Columbia, South Carolina, USA

Objectives: To plan and pilot a systematic developmental approach to AIDS/IV education in a variety of settings with different population groups. **Methods:** 1) Analysis of developmental education literature; 2) establish a needs assessment system which can detect population-specific issues of age, core AIDS/IV content for use across settings and populations; 3) design a needs assessment system in four settings with differing population groups (gay males, heterosexual youth in public school, employees of a conservative religious organization, and black participants of an AIDS training session); 4) for each setting, develop a curriculum consisting of the core AIDS/IV content and the specific results of the needs assessment with emphasis placed on the developmental stage of the group's knowledge and attitude towards AIDS/IV; and 5) pilot and evaluate the developed group-specific curricula. **Results:** Sensitivity to group-specific issues increased the motivational level of participants towards AIDS/IV. **Conclusions:** Assessing the group-specific needs of any AIDS/IV education population group, with emphasis on the group's perceptions of need and further development, will increase the likelihood of program success.

- E.642** AIDS Inside and Out: A National Education Programme For Prisoners in England and Wales

GURRAN Len*, GALLWEY J**, CRIGHAM J***, KILGOUR J**, HILLES D****, THORNTON D****

- ** HM Home Office, London England ** Jeddiffe's Infirmary Oxford, England
 *** The Landmark, London England **** Director, Prison Medical Service, London, England
 **** World Health Organisation, Geneva, Switzerland
 ***** Adult Offender Unit, HM Prison Service, London, England

Objective: To describe the design, implementation and evaluation of a national education programme for prisoners in England and Wales on AIDS and HIV.

Method: An advisory committee composed of outside and independent experts on AIDS and HIV and experienced prison staff produced an education package consisting of a 20 minute video, manual for tutors and 2 leaflets. The elements were based on research surveys of inmate fears and attitudes regarding AIDS/HIV. The video film was shot on location in prisons in England and Wales and directly addresses the concerns and fears expressed by prison inmates. **Results:** to be discussed.

- E.644** REVISIONS AND IMPLEMENTATION A.I.D.S. EDUCATION FOR STUDENTS AND THE GENERAL PUBLIC IN A SMALL WESTERN COUNTRY

R.L. Sattler, R.L.J. Jones E. Surin : Richmond County District Health Unit, Ontario, CANADA

Objective: To present factual, objective and representative data to persons at risk in a typical rural West Scottish community. Describe the low incidence and prevalence rates for A.I.D. infection. The degree of promiscuity and illegitimate births observed preceded estimates of high risk behavior with few or no identified A.I.D. cases. A multi-disciplinary committee was formed to represent the target population and the community as a whole; policy and educational programs were designed to represent the most current information available.

Methods: Further review of the population received between three and six hours of intensive material delivered in a multimedia presentation. Currently one hundred and sixty slide III grading stations were targeted for slide hours of class time over a three day period. A standardized protocol was administered to determine the level of knowledge; a standardized self test was administered one year later.

Conclusions: Behavior among the youth of the community appeared to be attracted and subject to intense peer pressure. The presentation of facts, current and relevant data is not enough to alter high risk behavior. A.I.D.s. education as it is presently taught will be ineffective in reducing the incidence of A.I.D. unless behavior is altered. Youth have identified parents and the medical profession as their best source of information however, when tested that information does not alter high risk behavior. We conclude that the approach may be more valid in the context of the society in which we live while preventing, emphasizing, up to date and factual information.



Publications

Le SIDA, la société et le comportement AIDS, Society and Behaviour

E.645

EDUCATING THE PUBLIC ABOUT AIDS IN LIMA, PERU

Luis A. ~~Manuel~~, Saba, Walter###, Varela, Luis###, Payne, Alice###, Peruvian Health Ministry, Lima, Peru, ##Population Council, Mexico, ###The Johns Hopkins University/Population Communication Services, Baltimore, Maryland, USA.

Objective: To develop an AIDS mass media information campaign for the city of Lima, Peru.

Methods: Five steps were followed to develop an information campaign: 1) an audience analysis carried out through focus groups and a survey of 1,900 households; 2) design of 3 TV and 2 radio spots; 3) pre-testing of materials in the target population; 4) production of spots; and, 5) dissemination through TV channels and radio stations.

Results: Audience analysis showed high public awareness about AIDS but a low prevalence of preventative behaviours. Also, great interest on the subject overrode any objections to the use of mass media to promote safer sex, condom use included. Testing of materials showed identification, acceptance and a good comprehension of preventative messages. **Conclusions:** Audience analysis and pre-testing were crucial to determine content and format of the AIDS education campaign.

E.646

ISSUES IN THE EVALUATION OF AIDS EDUCATION PROGRAMS: THE CALIFORNIA EXPERIENCE

Jung, Michael, Moore, M., Forst, M., The USA Institute, San Francisco, California, United States.

Objective: To discuss the results and some of the critical issues in the evaluation of AIDS education programs in California. **Methods:** All 87 of the state-funded community education and prevention programs for fiscal year 1987-88 were evaluated. Interviews were conducted with program directors and key program staff. All relevant educational testing materials were collected and analyzed.

Results: All of the programs met the objectives they had contracted to achieve. Specifically, programs reached the specified number of adult clients and those clients achieved the requisite level of educational competency regarding AIDS transmission and prevention. However, several problems were uncovered that cast doubt on the effectiveness of the programs to alter clients' attitudes and behaviors. These problems related to evaluation design, test construction, test administration, and data analysis.

Conclusion: Most target groups reached by the educational interventions have achieved minimal levels of educational competency about AIDS transmission and prevention, and contracted program objectives were met. The state's program must move beyond emphasis on cognitive knowledge about HIV transmission and prevention and begin to stress interventions concerning, and evaluation based on, attitude and behavior change.

E.647

EDUCATIONAL PROGRAMS ON AIDS - PEOPLE'S REACTION IN DELHI, INDIA. Dr. Neelam Kishore, Health Education Bureau, Dts.General of Health Services, New Delhi, India.

Objective: To study people's reaction to the educational programs on AIDS launched by the Govt. through television, radio and newspapers.

Method: One Hundred Four patients of Sexually Transmitted Diseases and 37 Blood Donors randomly selected from three Govt. Hospitals in Delhi were covered. Only 70 individual, who were exposed to the programs were interviewed with a set of closed and open questions.

Results: Among all channels, television was rated as the most effective to inform the public about the disease. Most of the respondents found it of relevant appropriate, but the duration was considered to be short-lived to comprehend various aspects of the disease. Very few acquired correct knowledge on mode of transmission, incubation period; and symptoms. On the other hand, many of the respondents acquired correct knowledge on preventive measures-avoiding extramarital and homosexual contact. The educational campaign did create fear among the public regarding blood donation. This contributed a disturbing drop in the number of blood donors. The blood donor respondents were frightened for donating blood for the fear of contracting AIDS by sharing common needle used for blood donation.

E.648

AIDS AWARENESS AMONG COLLEGE STUDENTS IN INDIA.

Verma, Shankar and Parul Dhandekar, *Incharge Computer Section, National Institute, Pirbright, Pune, India. **Project Director, ICOR Centre for AIDS Research and Control (CANC), Pune, India.

Objective: To assess knowledge about AIDS among college students of a metropolitan city, Bombay, and a provincial city, Pune, both in Maharashtra state.

Methods: CANC carried out a limited questionnaire survey in October 1988. Anonymity was maintained and questions regarding personal sexual behaviour were avoided. Information was computerized for comparative analysis.

Results: A significantly higher percentage of Bombay students (62%) responded as compared to only 21.3% from Pune (p<0.05). About 77% of Bombay students compared to Pune ones indicated foreign magazines as the major source of information (p<0.01). In contrast, 60% of Pune and 33% of Bombay students had marked Indian newspaper/magazines as a major source (p<0.05). Overall, all students depicted monogamous relationship. However, 51% of Bombay students as compared to 25% of students from Pune were aware of condoms for safe sex (p<0.05). There were a few misconceptions regarding transmission of HIV infection, e.g. 24% of students considered toilet seats to play a role in transmission. There were also several misconceptions concerning transmission through blood transfusion. This and subsequent surveys are presented.

Conclusion: The questionnaire survey though limited, establishes its usefulness in formulating health information programmes and indicates the need for a wider survey in different regions.

E.649

SEXUAL BEHAVIOUR OF UNIVERSITY STUDENTS

RESULTS FROM A PILOT STUDY

H.Laatz*, J. Papp*, F.-D.Goshe*

*FD Dr. H. Laatz, J. Papp, STATION Medizinische Forschungsgemeinschaft mbH, Bismarckstrasse 12, FRG - 8033 Pasing

**Prof. Dr. F.-D. Goshe, Medizinische Poliklinik der Universität München, Paterhoferstrasse 16, FRG - 8000 München 2

As an exact understanding of the actual sexual behaviour of a population is essential for predicting the speed and the direction of the spread of AIDS. In our survey 358 students of medicine and psychology were given a detailed anonymous questionnaire about their sexual activities and attitudes. 84% of the students (307) returned the questionnaire. The results revealed that 19% had more than one sexual partner during the preceding three months. Anal intercourse was reported by 35/307 (11.4%). A large proportion of the students was reluctant to using condoms for various reasons. E.g. 42% (129/307) saw no indication for using condoms although 18 of them had reported sexual contacts to more than one sex partner during the preceding three months including two students who had practiced anal intercourse.

We conclude that more specific concentration on young, sexually active subgroups of the population and their needs is mandatory. Our results indicate that knowledge of even medical students is not sufficiently reflected by avoiding risky sexual behaviour.

E.650

STUDY OF THE ATTITUDES AND INDIVIDUAL FACTORS OF SELECTED EGYPTIAN WOMEN TOWARDS AIDS

*Director The Arab Centre for Fighting Against AIDS, Cairo, Egypt

Objective: This study is to measure cognitive knowledge of selected groups of the Egyptian population about the AIDS problem and to assess the attitudes, if any, of the attitudes and behaviours of the groups studied as a result of their knowledge.

Methods: The AIDS problem and to assess the attitudes, if any, of the attitudes and behaviours of the groups studied as a result of their knowledge. The study included and questioned by five (5) questions, the [1] tested their knowledge and the last 1 to assess any change of the attitudes related to the AIDS transmission. The 100 persons included consisted of females on vice offences, the 2nd group (40 persons) of drug offenders, the 3rd (50 persons) consisted of young university students and the 4th (50 persons) consisted of workers in tourism industry. The common denomination in these groups is that they are particularly vulnerable either because of drug practices or active sexual lives or contact with foreigners.

Results: are outlined the following table.

FACTORS IN SHORT STATEMENT	Mean of the score of the return		Type of the score		Change of practices		Change of attitudes	
	100	0	100	0	100	0	100	0
Number of sexual partners	400	320	80	20	80	20	80	20
Use of condom	600	60	10	90	10	90	10	90
Anal intercourse	500	50	10	90	10	90	10	90
Sexual Intercourse	500	50	10	90	10	90	10	90

n.s. = not significant, * = significant. The study showed that the relatively educated Egyptians are better informed about HIV disease than those less educated who are at even greater risk. In all the groups studied the impact on the change of behaviour is not great. The study showed that selective campaigning targeted at the more vulnerable groups is needed.



Publications

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

- E.657** MILIEU SCHOLAIRE ET PROBLÉMATIQUE DU SIDA
Michèle MANTION, Bruno BONIFACE, Bernard DUMÉZIL**
 ** ASSOCIATION DES JEUNES CONTRE LE SIDA - AJS
 ** UNION DES SOCIÉTÉS ÉTUDIANTES NÉOULTRAIÈRES - U.S.E.N., FRANCE

OBJECTIFS: Connaître les structures officielles de l'Éducation Nationale d'organiser des séances de prévention du SIDA dans les lycées et collèges par des intervenants extérieurs formés pour cela avec un matériel adapté.

MÉTROLOGIE: Après plus de 200 interventions spontanées en 1988, sur les demandes des enseignants, des infirmières scolaires, des parents et des jeunes, avec des documents spécifiques (vidéos et brochures), l'AJS a pu effectuer un travail de pression auprès des autorités de l'Éducation, des parents d'élèves et de la presse pour généraliser ces actions.

RÉSULTATS: La seconde étape est aujourd'hui avancée. Les interventions jusqu'aux écoles, s'officialisent. Les demandes émanent des médecins scolaires, des chefs d'établissement et des autorités locales (rectorats).

CONCLUSION: Les réticences du milieu scolaire et de la communauté éducative à accepter des interventions extérieures ont été levées en douceur par une persuasion basée sur la confiance et la réponse aux besoins exprimés par les jeunes sur leurs demandes.

Les associations ont un rôle précurseur de première importance, tant par la collaboration avec les partenaires que pour la conception des programmes.

- E.658** IMPLEMENTING AIDS EDUCATION INTO THE CURRICULUM IN N. IRELAND
O'Donnell P. James, Kibben M. P. J. UNITED KINGDOM

Objective: To explore the feasibility of joint health and education initiatives to introduce AIDS education into the secondary school sector in N. Ireland. This initiative occurred against a background of a conservative culture, a school system dominated by religious teaching and a reported antagonism towards homosexuality. There were no standardized sex education programmes in schools and in addition N. Ireland is an area with a low level of drug misuse and a low prevalence of HIV infection and AIDS.

Methods: An interdisciplinary approach was adopted in this initiative involving collaboration in a consultative process between health and education sectors, and the formation of a joint team to produce suitable health promotional materials.

Results: Unprecedented attendance for in-service training and use of material occurred in N. Ireland with some 76% of post primary schools in the Eastern Health and Social Services Board having one or more teachers trained in the programme. Further uptake occurred from schools for children with special needs and colleges of further education.

Conclusion: It is possible to implement AIDS schools prevention programmes even in a conservative and unfavourable climate in a population with low prevalence. The programme was successful because of the way in which this was achieved and the vital components of the programme.

- E.659** "AIDS EDUCATION OR PSYCHIATRIC INTERVENTIONS"
Patience Jeteroli, Peyton, L., McGill, C. U.S.A.

Most health care organizations have emphasized the vital importance of AIDS education for the general public. The AIDS policy for inpatient psychiatric units developed by the American Psychiatric Association addresses briefly the topic of AIDS education, recommending appropriate counseling for patients and staff. The rationale for educating psychiatric inpatients includes: eliminating HIV-related risk behaviors reported by psychiatric patients, addressing the needs of the increasing number of patients with AIDS hospitalized on psychiatric units, reducing fears and prejudice among patients and staff, and fulfilling a responsibility as health professionals to provide patients with information about HIV. We are presenting two models of AIDS education that target adult and adolescent psychiatric inpatients. The models are tailored to four psychiatric units affiliated with the University of California, San Francisco. Each unit takes into account patient sociodemographic characteristics, level of psychiatric impairment and HIV-related risk behaviors. Descriptions of clinical interventions for the different models are presented.

- E.660** PERFORMANCE STANDARDS FOR THE DEVELOPMENT AND EVALUATION OF SCHOOL HIV/AIDS EDUCATION CURRICULA FOR ADOLESCENTS
Tarber, William L., and Terabi, Mohamed R. U.S.A.

Objective: Most U.S. schools provide HIV/AIDS instruction for adolescents and either (1) utilize outside curricula, or (2) develop their own curriculum. Performance standards against which current curricula can be evaluated or new curricula can be developed are needed. This paper describes the development of a performance standards checklist.

Methods: Professional literature and health experts were used in developing the performance standards. Particular attention was centered on suggested content and pedagogical approach, including learning and instructional theory. A list of standards or evaluative criteria was generated, and arranged on paper as a checklist.

Results: It was determined that the most ideal curriculum would have both the student and teacher guides. Seventy-two specific performance standards were generated for both guides. The student guide had ten major components: nature of HIV/AIDS, impact of AIDS, HIV transmission, individual HIV prevention, HIV control efforts, learning enhancement, learning domains approach, verbal quality, visual aesthetics, and tone of message. The teacher guide had six major components: HIV/AIDS school education, implementing the curriculum, learning activities, handouts, evaluation, and educator/instructor sources. **Conclusion:** Specific performance standards for school HIV/AIDS education curricula for adolescents can be generated and can assist educators in (1) determining the specific strengths and weaknesses of existing curricula, and (2) developing new curricula. Educators are encouraged to utilize the performance standards checklist for both of these tasks.

- E.661** FACE-TO-FACE: INTERACTING PERSONS WITH AIDS INTO ADOLESCENT AIDS PREVENTION EDUCATION

Cronston, E. A., Tates, R. W., Wright, S. W.

**Massachusetts Department of Education, Quincy, Massachusetts, USA, **Health Care of Southeastern Massachusetts, Abington, Massachusetts, USA

Objective: To enhance the impact of AIDS prevention education efforts on adolescent audiences in public schools.

Methods: Persons with AIDS were recruited, screened, trained and fully integrated into a four-session AIDS prevention education module. Difficulties of community and staff resistance, parental approval, logistics and the limited personal resources of the persons with AIDS involved in the program were addressed. The person with AIDS presentation was preceded by two sessions on basic information and effective education about AIDS, and was followed by one session of emotional feedback from students.

Results: Anecdotal reports from educational faculty indicate that this format powerfully affects the attitudes and awareness of students. This may translate into true behavior change.

Conclusion: This model of AIDS prevention education may be easily replicated by other educational systems with minor modifications.

- E.662** AIDS PREVENTION FOR ADOLESCENTS IN SCHOOL: DO SCHOOL PRINCIPALS PERCEIVE THE NEED?

Guterman, E.M., Walker, Heather J., Beach, G.E., Glantz, M. and Ehrhardt, A.A. HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute & Columbia University, New York, New York, USA

Objective: The long-term goal of the project is to implement and subsequently evaluate an AIDS prevention program in the high schools which will broadly modify the behaviors that place students at risk for acquiring HIV. The school setting maximizes access to the adolescent population, but poses a host of challenges since a good fit between needs of the program and the school must be achieved. To determine the desirability of AIDS education, our first step was to target principals, the prime decision-making group within the schools.

Methods: In June, 1988, an interview containing open-ended and structured items was administered by telephone to principals (or other high ranking school personnel) in Manhattan and Rockland County high schools.

Results: Our surveys indicate that principals view AIDS prevention as a high curriculum priority. There was total consensus that the goals of a school AIDS prevention program should include knowledge, attitudinal change, and drug abstinence goals. There was less agreement regarding the promotion of behavior change related to sexual abstinence and safer sex.

Conclusion: Principals generally concur with the need for an AIDS education program that would target knowledge, attitudes, and behavior. The commitment to AIDS education among teachers, parents, and students will be surveyed next.

Publications

Le SIDA, la société et le comportement
AIDS, Society and Behaviour**E. 663** AIDS AND THE MEANS OF COMMUNICATION: FROM HIGH RISK GROUPS TO HIGH RISK FACTORS; FROM HIGH RISK FACTORS TO AN UNDERSTANDING OF THE VIRUS.

Frederico C. Conde, F., Coronado, A., Gil, E., et al.

Ministry of Health-Spain.

Objective. The manner in which AIDS and the AIDS problem has been put across to the general public has gone through several phases since the discovery of the virus in the early 80's. The major source of information has been the media-scientific world and though the stress has changed from the defining medical-scientific world to the present emphasis on high risk factors, AIDS has been and is still understood in pure epidemiological terms.

Conclusion. This paper analyses these sources of information, their underlying factors and proposes an alternative scientific discourse which would bring clear information on the transmission of the virus, a better understanding of this process and help change the ever increasing "quarantine" mentality towards the people afflicted with AIDS.

E. 664 HEALTH AND MEDICAL APPRENTICESHIP PROGRAM OF AIDS RESEARCH

Clayton Gonzalez, II, War Immunological Network, Los Angeles, California, USA, Treasurer.

Objective. The health and medical apprenticeship program is designed to provide a support network to assist students and community members in the dissemination of AIDS information.

Methods. This group research project will examine technical, social, political and economic aspects of the global HIV epidemic. The goal of the project is to produce a portion of an accurate, current information resource for use by AIDS educators and the general public.

Results. It will provide training and prepare students and community members who are aware of the inner-workings of AIDS research and facilities.

Conclusion. There is a demonstrated need for an apprenticeship program where interested students and community members can learn first-hand the inner workings of research. In this way they will have been trained in many of the fundamentals, as well as exposing them to a field of work in which they have expressed interest. In this way the end product would be dedicated professionals entering the field with prior knowledge and therefore confidence in their ability to meet the needs of AIDS research.

E. 665 EDUCATIONAL AND TRAINING STRATEGIES IN SÃO PAULO STATE, BRAZIL.

Roberto H. L. Eisinger, E. Ferreira A.C.; Grandi J. J. Abad, M. S.

Centro de Referência e Treinamento em Aids - São Paulo, Brazil.

The state of São Paulo, Brazil, has a population of 33 million. From 1980 until December 1988, 3213 AIDS cases were reported to the Health department.

In 1987 was organized the first massive Campaign with 12 million pamphlets, 1.5 million posters, 4,5000 billboards, 100,000 guidelines for infection control, 4 videos for TV, 4 spots for radio.

Apart from the massive programs and Campaigns the Educational and Training UNIT on Aids, from secretary of Health, developed strategies of training health care providers and community leaders in order to be those who will train and inform others.

During 1988 we trained 2100 community leaders to give Aids in information in the front-line.

Conclusion: The person to person information on Aids is most effective way of prevention especially in our region which is full of contrasts of all sorts cultural, educational, economical and Social.

E. 666 EFFECTS OF AN EDUCATIONAL CAMPAIGN TO REDUCE BLOOD TRANSFUSIONS IN CHILDREN IN KINSHASA, ZAIRE

Theresa E. Borch, M.D., M.P.H., *Harvard, B. and *Henn, J.M. Department of Pediatrics, Henn Veno Hospital, **Ministry of Health, Kinshasa, Zaire and *MO, Geneva, Switzerland.

Objective. To evaluate the effectiveness of an educational campaign to reduce the number of blood transfusions and thereby reduce the transmission of AIDS.

Methods. An investigation carried out at the Department of Pediatrics revealed that malaria induced anemia was the major cause of transfusion. Nevertheless, children with a hemoglobin as high as 11 gm had been referred for transfusion to the Satrien Society of Pediatrics, for the faculty and housestaff and guidelines were set. Based on seroepidemiological evaluation, transfusion was reserved for children with a hgb. of less than 5 gm if there were signs of hemolytic anemia. In addition, an HIV screening unit was installed at the blood bank.

Results: Dramatic results followed the campaign. There was a 72% decrease in the number of transfusions from 30,302 in 1986 to 8,531 in 1987 with no increase in mortality. Transmission of other endemic infections such as malaria, cytomegalovirus and hepatitis B were proportionately reduced.

Conclusion: A worldwide educational campaign is required to reduce the number of unnecessary transfusions. This coupled with HIV screening tests prevents the risk of HIV transmission by this route.

E. 667 PATIENT OPINIONS ABOUT DENITISTS AS AIDS EDUCATORS.

Geoffrey Magnus Maguire, B. Sumner J. and Spitzer, S. University of California at San Francisco, California, United States.

Objective. There has been little discussion about whether dentists would be appropriate disseminators of HIV information. We wanted to determine if patients would accept dentists as HIV educators and if they experienced dentists acting in this role as part of their response to the HIV epidemic.

Methods. Telephone interviews were conducted in July and August 1988 with 2000 English-speaking, United States adults, using a representative national sample generated by random digit dialling. The response rate was 79%. The denominator for the data reported below is all those who have received dental care in the past five years (n=1212; 91% of sample).

Results. Only 12% of the respondents had discussed AIDS with their dentist; in 80% of these cases, the conversation was started by the patient rather than the dentist. Twenty-one percent of respondents wanted to discuss AIDS, 49% did not care, and just 30% would prefer not to talk about it. A majority of patients were "very" or "mostly" comfortable with the idea of discussing AIDS (88%) or intravenous drug use (80%) with their dentist, but a minority (45%) felt that way about discussing their sexual behavior. Of those who were willing to discuss AIDS, 35% believed patients themselves should start the conversation; the rest thought the dentist should (33%) or that it did not matter who began the conversation (32%).

Conclusion. These data show that dental patients are willing to see their dentists as information resources concerning HIV. On the topic of sexual behavior, however, patients were more reticent. We believe patients would be more receptive to dentists providing patients with educational information on HIV and suggest that dentists initiate such discussions with patients.

E. 668 A MODEL HIV EDUCATION/PREVENTION PROGRAM FOR A PREPAID HEALTH PLAN

Neil A. M.D., Caseo, W. Ph.D., **Southern California Permanente Medical Group, Harbor City, California, USA. **Kaiser Permanente Medical Care Program, Oakland, California, USA.

The Kaiser Permanente Medical Care Program is a group practice prepaid health plan with approximately five million members in twelve regions of the United States. A three-regional (nation-wide) AIDS committee has been formed to respond to and plan for issues that the AIDS epidemic present to complex health care systems like ours. The Education and Counseling Subcommittee has developed a model program to educate, reduce fear, and overcome denial; to allow our employees, physicians, and members to prevent the transmission of HIV; and to deal most effectively and humanely with the AIDS epidemic.

Three specific populations have been targeted for education and counseling: 1. Kaiser Permanente employees and providers (including physicians). 2. The general patient membership. 3. Patients and employees who practice behaviors that put them at risk for HIV infection.

A four-step process for AIDS prevention in the context of ambulatory health care will be presented:

1. Identifying members who practice high-risk behavior.
2. Providing same day information.
3. Providing risk reduction education.
4. Implementing risk reduction counseling programs aimed at gay and bisexual men, IV drug users and their steady sexual partners, hemophiliacs and their steady sexual partners, adolescents, and the steady sexual partners of anyone who is infected with HIV.



Publications

E.669

EVALUATION OF THE IMPACT OF AIDS EDUCATION
 SWHARTZ, R.L.; SANDERS, R.J.; KRIDER, L.J.; BIANCHI, F.B.
 American Red Cross and Navy Environmental and Preventive
 Medicine Unit, Naples, Italy.

Objective: The potential severity of HIV infection has demanded aggressive intensive and effective educational programs to limit the spread of disease. This study evaluated the level of knowledge concerning HIV transmission factors in a diverse overseas American community, and established a methodology to evaluate which educational activities could result in modification of high risk behavior.

Methods: An educational program was designed to present information on the HIV epidemic. Prior to and immediately following the program, a questionnaire was administered to assess levels of awareness concerning transmission and non-transmission factors for the HIV virus.

Results: The study group (137 predominantly young (20-30 year old) individuals) were all users of the principal transmission factors; however, 70% had significant misconceptions related to the infection and disease process, including blood donation (28%), insect bites (22%), and fingering (32%). Initial data indicate that certain channels of communication are preferred by population subgroups and specific formats are more likely to improve levels of knowledge and actually result in changes in behavior.

Conclusion: While the majority of persons are aware of the transmission factors related to HIV, a significant number of individuals provided misinformation. Educational program must be developed to provide sufficient, comprehensive information targeted to specific groups to result in behavior modification, and evaluated in document effectiveness.

E.671

CORRECT CONDOM USE: AN ASSESSMENT AND INTERVENTION STUDY AMONG SEXUALLY ACTIVE MEN IN TRINIDAD AND TOBAGO,

WOODS, WILLIAM, J.; CLEGGON, F. **; MAHABIR, B. ***; HOLLOWAY, M. **
 *AIDSICON, Washington, D.C.; ** Caribbean Epidemiology Centre, Trinidad and Tobago
 *** Queens Park Counseling Centre and Clinic, Trinidad and Tobago.

Objective: To assess the degree of correct condom use among sexually active heterosexual, bisexual, and homosexual men in Trinidad and Tobago and to compare different approaches to teaching correct use.

Methods: Contact investigators at an urban STD clinic invited 200 male clients to participate voluntarily in a condom use study. Selection based on client availability. An initial assessment of knowledge and use of condoms was followed by 1 of 2 interventions and an immediate post-test. Intervention 1 had the interviewer model correct condom use with a surrogate object and #2 involved providing a brochure with pictorial explanations of condom use procedures.

Results: Study in progress but pilot study indicated men knew basic about putting condoms on but were clear about important ways to avoid condom breakage. Interventions with immediate consultation helped increase skills considerably.

Conclusion: Clients at risk for STD may improve and sustain building for correct condom use. Which teaching intervention proves more effective remains uncertain; this study may help indicate whether mass produced and distributed "how to use condoms" brochures are useful for increasing correct condom use.

E.673

LE CENTRE REGIONAL D'INFORMATION ET DE PREVENTION SIDA (CRIPS), PARIS
 JACQUES, L., DR. JACQUES, L., FRANCE

*CRIPS
 *Observatoire Régional de Santé

Objectif: Centre de conseil pour la prévention du SIDA en Île-de-France destiné aux professionnels de la santé et de l'éducation. Lieu d'échange pour le VII en Europe. Une initiative de Conseil Régional de l'Île-de-France - métropolitaine. A. renseignements, publiques ou privées, métropolitaine sans la région.

1. renseignements par téléphone, documentation sur la prévention (en collaboration avec DCL Belgique) ceux qui sont dans des projets de prévention.

2. Centre des formations pilotes

3. Depuis son ouverture en novembre 1988

4. La documentation représente plus de 1.000 références indexées accessibles à distance et 100 films vidéo.

5. La lecture du CRIPS est adressée directement aux professionnels.

6. des formations pilotes pour des centres de dépistage HIV, éducation préventive universitaires, FFP, policiers, etc.

7. des formations pilotes pour des centres de dépistage HIV, éducation préventive universitaires, FFP, policiers, etc.

8. Le CRIPS est une structure pluri-partite-publique. Lieu de rencontre pour les associations et les professionnels, destiné à favoriser les initiatives et la circulation de l'information.

E.670 CONDOM USE ASSESSMENT AND INTERVENTION STUDY: A NEW TOOL FOR CONDOM PROMOTION

Salish, William*, Paraja, Nayindoo**; *AIDSICON, Washington, D.C.; **AIDSICON, Dominican Republic

Objective: To determine level of correct application and removal of condoms among targeted populations.

Methodology: Using an observation protocol respondents are asked to place on a surrogate object a condom. The researcher, through observation, records data about placement and removal, noting such items as how package opened, whether/how condom unwound, whether condom breaks due to respondent error etc. Observation protocol is followed by brief RAP Survey.

Results: Findings indicate 60% indicate that basic training in the fundamentals of correct placement and removal are required. The materials are developed to encourage condom use.

Conclusion: The materials are developed to encourage condom use, a return to basic knowledge gathering may be called for. The procedures in universal, may require further exploration.

E.672

THE ORIENTATION OF LIFE: THE BASIC GUIDING PRINCIPLES FOR AIDS PREVENTION IN THE DOMINICAN REPUBLIC

De Moya, E., Antonio, Guerrero, E.; Belliard, M; Peña, G.; Garcia, L.; Dominguez, L.
 PRCTC, Ministry of Public Health, Santo Domingo, Dominican Republic.

Objective: To present the ten basic guiding principles for AIDS prevention developed by PRCTC, and to analyze the supporting empirical evidence accumulated from 1985.

Methods: Principles are discussed together with the main supporting findings derived from CAP studies and educational research.

Results: Key principles that have proven effective for AIDS prevention are: 1) Enhance the target-audience's self esteem; 2) Speak to the heart of the targets; 3) Emphasize the value of health, love and life; 4) Increase awareness of one sexual contact infectiousness; 5) Promote a high perception of the preventive value of condom use; 6) Educate the population about other STD; 7) Insist on mother-infant transmission; 8) Keep high levels of perceived threat of AIDS in women and low levels in men; 9) Create awareness of individual responsibility for contagion; 10) Always speak of hope, joy of life and power to control AIDS.

Conclusion: High standards of acceptance and responsiveness to the program - have been reached through an approach that deemphasizes disease and death - while promoting health, love and life.

E.674

WORLD AIDS DAY ACTIVITIES AND THEIR SIGNIFICANCE FOR AIDS PREVENTION IN CATALUNYA

Wölfeliler, Demí* Segura, M** Prouzet, A.** FRANCE

Objective: To Initiate World AIDS Day activities in Catalonia, and determine their significance for future AIDS prevention efforts.

Method: The government, Church, citizens' organizations and mass-media all actively participated in World AIDS Day activities. These included distributing information, releasing balloons to commemorate those who had died of AIDS, a condom party at a gay discotheque, and documentary and feature film premieres at local cinemas. Restaurants, religious and gay media gave extensive coverage with features and scientific articles. Direct advertising was kept to a minimum.

Results: This was the first time a multisectoral AIDS prevention effort took place in Catalonia. Success would have been enhanced by instituting a coordinating team. Potential new community opinion leaders were identified and recruited. By focusing on media coverage, costs were kept low.

Conclusion: World AIDS Day provides an opportunity for education and coalition building among otherwise unaffiliated members of the community. It also serves to identify community participants necessary to maintain high levels of AIDS awareness throughout the year.



Publications

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

- E.675** THE NEED FOR PSYCHOSOCIAL EMPHASIS IN ACADEMIC COURSES ON AIDS
Ziffo, Albert S. and Ziffer, J.*
*Rollins College, Winter Park, Florida 32789, U.S.A.
- Hypothesis:** Although the number of educational programs concerning AIDS has multiplied significantly during the past 3 years, frequently more attention is paid to the epidemiology and clinical aspects of the disease rather than the psychosocial issues which need equal or greater emphasis.
- Method:** To evaluate this premise pre/post tests on attitudes were administered to two groups of students enrolled in one semester, intensive courses on AIDS. One course taught only facts and the other taught facts, values clarification, and attitudinal change of attitudes.
- Results:** The course in which medical and psychosocial aspects of AIDS are emphasized resulted in significant attitudinal change among the students. The post course questionnaires revealed a markedly more ethically responsible and compassionate attitude toward persons with AIDS than existed prior to the course. The course which taught only facts resulted in no statistically significant attitudinal change.
- Conclusion:** If academic courses on AIDS are to be effective in disseminating information and in increasing compassion and reducing biases of students, then the teaching model for such course work must address the psychosocial issues as well as the scientific facts.

- E.676** EVALUATION OF THE HIV SPONSORED TRAINING OF TRAINERS PROGRAM ON AIDS AND THE IV DRUG USER

Ashery, Rebecca S.
National Institute on Drug Abuse, Rockville, Maryland USA

Objective: The purpose of the study was to conduct a follow up evaluation on the HIV train the trainers (TOT) program on how to deliver the HIV/AIDS curriculum to drug treatment personnel.

Methods: A mail questionnaire was sent to participants of 16 TOT workshops conducted for selected individuals from 14 states and the District of Columbia. The self administered questionnaire was designed to assess the usefulness of the training, the extent to which it increased their skills in specific areas and their AIDS training activities since the TOT and additional technical assistance needed from HIV.

Results: Out of 160 respondents 93% indicated that the overall effectiveness of the TOT course was excellent or good. Nearly 75% of the respondents had delivered training in the six months after they had received the TOT. Less than 20% of the respondents followed the HIV curriculum exactly, changing either the time schedule or adding and deleting units.

Conclusion: It was estimated that 16,500 people had received some training by graduates of the HIV TOT workshops. By most factors considered in the survey, the TOT program is considered a success.

- E.677** PAR ANCIEN AND BOOK TACTIC TO REDY WORK

Leslie Ray - St. Mary's Hospital/Johnson Dist. UNITED KINGDOM

Objective: To evaluate the use of film-visual in AIDS campaigns.

Introduction: Four annual film behavior change has little recorded success. The Dist. Health Education Campaign on AIDS used four messages targeted at spread via contaminated needles. Is four annual effective? If not is this because the recipients are not motivated (4 hours greater film would be looked) or is the technique based on disease theory and of limited use (4 hours should be shortened)?

- Method:** 111 subjects (52 consecutive drug dependent (all attendees in the area of highest U.K. HIV incidence & 59 attendees in the same area) had recently used, shared, pre and post exposure to the posters (visual) and television screens (audio-visual) material to monitor activity change. Attitudes, drug using and sexual behaviour and perceived personal risk was monitored.
- Results:** The DVD group were significantly more active than students (p<0.01) as a group. Few messages significantly increased in attitudes (4-3, 10 p<0.001) but had no impact on drug users. Visual and audio-visual material was inconsequential in contributing to the effect. Drug users were less likely to react actively as realists. Likelihood of changing sexual behaviour was low for both groups (4) had multiple sexual partners in the preceding six months). Perceived personal risk was low (25% DV and 20% DV felt at no risk). Few students thought the message was used at times. Both were worried about AIDS (over 3,5 and 4,1 on 7pt scale).
- Conclusion:** Four annual has limited use.

- E.678** REV COUNSELLING AND TESTING IN REDUCED MEDICAL PRACTICE IN NEW JERSEY
Ong, Philip*, Barkan, E., Hyllingstad, A., Preved, J., Oates, S., Pincus, J.

New Jersey State Department of Health, Trenton, New Jersey, USA; *University of Medicine and Health, Lenoirville, TN, USA

Objective: To assess the extent to which HIV counselling and testing rates in private practices, public information concerning the extent to which HIV counselling and testing rates (CS) are being utilized for referrals, and the potential need for continuing medical education related to HIV counselling.

Method: In September 1988, a nine point questionnaire printed on a self-mailing postcard was sent to approximately 10,000 physicians in New Jersey. Of 2,046 responses 2,023 completed surveys were returned for choice errors, transcription, and entered into an IBM data set. All analyses were carried out using SAS.

Results: Physicians indicated that they average only about 40% of post-test counselling themselves, in contrast to about 60% of all other counselling and testing activities. The 597 physicians who reported increasing OR credits on AIDS reported significantly increased counselling activities, with the largest relative increase in post-test counselling. Of these physicians who report practices for counselling and testing, 40% refer to local infectious disease specialists, while only 25% refer to local CS. Barriers, only 1% of respondents could accurately identify their local CS.

Conclusion: The response rate of 20% suggests that the subject matter is considered to be important by a significant segment of the medical community. Very few physicians, however, even in areas with AIDS patients, see a need of the local CS. Having OR credits in AIDS significantly increases personal involvement both in the treatment of AIDS patients and in the provision of pre and post test counselling. Information obtained via this survey is being used to plan future OR credits.

- E.679**

--	--

- E.680** DIFFERENCE D'EFFICACITE DU SOUTIEN ASSURE PAR UN OIL D'ELUX VOLONTAIRES.
LEMOUX, Yves
Association AIDSIS, Comité de Paris, France.

Objectif: Evaluer l'efficacité du travail d'accompagnement dit "en binôme". Il s'agit du soutien assuré par deux volontaires visitant individuellement la personne atteinte de SIDA.

Méthodes: Etude comparative réalisée sur 100 dossiers (période de référence : mars 86 à janvier 89) de suivis en binômes et de suivis individuels.

Répartition : 50% en binômes
50% en individuels

Principales sources d'information : comptes-rendus écrits par les volontaires après chaque contact, témoignages de volontaires et de personnes suivies.

Résultats: Les arrêts de suivi assurés par un seul volontaire ont des raisons non expliquées (autre que le décès du malade ou sa volonté clairement exprimée de l'arrêt de l'aide) sont beaucoup plus nombreux qu'en binôme :
50% des cas en individuel
10% des cas en binôme

Conclusion : Il est nécessaire de développer ce type de prise en charge à deux, afin d'améliorer le service offert d'une part et protéger les volontaires d'autre part. Cette technique de co-responsabilité peut-être également envisagée pour l'animation de groupes de volontaires.

Enfin, le principe du suivi en binôme paraît la meilleure approche en cas de prise en charge de toxicomanes.

Publications

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

E.687

A.I.D.S. THE DEVELOPMENT OF SCHOOL BOARD POLICY ON SENSITIVE ISSUES

Conrad, G. Scott, Adams, S., and Seneff, J.
Lauravert School Board, Duvrney, Laval, Quebec, Canada.

Objective: To present to participants the process the Lauravert School board used in establishing a policy on A.I.D.S.

Methods: To establish a school board policy on A.I.D.S., a committee including medical expertise prepared a document which was subjected to consultation with the parents, community and teacher councils of 19 schools.

Results: The policy, which attempts to teach appropriate behaviour, while respecting individual rights, was accepted by an entire community without rancour, division. The process raised everyone's awareness in a period of relative calm. We are now prepared should an employee or a child acquire A.I.D.S.

Conclusion: The process establishing a policy on A.I.D.S. is in and of itself an education for all involved.

E.688

LESSONS FROM FAILED TRIALS: A COMMUNITY RESPONSE

Edo, James Kirshenbaum, D. and Long, J. AIDS Coalition To Unleash Power, New York, New York, USA.

Objective: To discuss the premeditated controlled clinical trial in an ethical context.

Methods: Specific trials will be presented and the ethical dilemmas faced by subjects will be evaluated.

Discussion: Ethical abuses in trial design have led to slow enrollment, high dropout rates and incomplete data in many HIV drug studies. From an ethical standpoint, participation in a controlled clinical trial is often an HIV-infected person's only way to get a particular treatment. Research protocols must be understood as a form of treatment. U.S. AIDS Clinical Trial Group trials 005, 006 and 010 will be discussed.

E.691

HOMOSEXUALS WHO HOSPITALIZED PATIENTS WITH AIDS-RELATED COMPLEX (ARC)

18 AND 1902 (1982)

Edo, James J. Long, J., Murray, W., Harrington, M., Ed. Vincent's Hospital (1982) and Medical Center, Mt. Sinai Hospital and Medical Center, New York, N.Y., USA.

Objective: To determine the prevalence of homosexuality among hospitalized patients with ARC over a 3-year period in a community hospital in NYC and compare the characteristics of homosexual patients to those of non-homosexual patients with ARC.

Methods: Retrospective review of the medical records of all patients with ARC (n=165) admitted to Mt. Sinai between 1980-1982.

Results: Twenty-four percent of patients with ARC (n=165) were homosexual, i.e. were living in menages or menages, in lieu of admission to the hospital. Homosexual patients had significantly higher rates of intravenous drug use (IVDU), syphilis, tuberculosis (Tb) and bacterial pneumonia (BP), than non-homosexual patients. More homosexual patients signed out (SO) (1980) or were lost to follow-up (LFO) and the majority were discharged to shelters or streets (D/S) (n=84).

	Homosexual No. (%)	Non-homosexual No. (%)	L.Ratio
IVDU	22 (58)	27 (24)	<0.01
BP	13 (34)	11 (9)	<0.01
SO	25 (64)	31 (27)	<0.01
SO&LFO	18 (47)	18 (16)	<0.01
D/S (n=8)	25 (64)	33 (29)	<0.001

Conclusions: Because of a high incidence of IVDU, BP and SO among homosexual patients with ARC, who are likely to progress to full-blown AIDS, homosexuals should be addressed in these patients prior to hospital discharge, in order to halt transmission of HIV through needle sharing or airborne transmission of opportunistic pathogens to shelters or streets.

E.688

IMPLICATIONS OF FAILURES TO DEVELOP COMPREHENSIVE POLICY RE AIDS/RIV

Edo, James Kirshenbaum, D., Adams, S., and Seneff, J. National Minority AIDS Council N.Y.C., N.Y.S., USA.

Objective: To analyze the impact of AIDS as well as problems of poverty as barriers with an Infant Mortality Rate of 19.7 percent of N.Y.C.'s overall 12. As of 1/12/89 59% of the cumulative 18,116 adults are Black, Hispanic, Asian and Native American (N.A.) defined AIDS, and of these cases, 80% of the women are also minority (2,849). Peds cases are 361 of the total 402 with a Black or Hispanic mother.

The probable transmission and risk factor of both adult and peds are drug related. To extrapolate out to the adolescent cases - it is for males 13-19:125 cases, females 13-19: 10 cases. Of the 7 to 10 year incubation rate, today's cases are males 20-29:272, females 20-29:159. NYC Health Dept. estimates of 50,000 HIV+ cases would translate to predict if they are primarily Black and Hispanic and mirror issues of present cases, each will have a majority drug related risk factor, primarily low income and limited education with 1-3 children. Low birth weight and other indicators of poverty status (less than 1% have no refrigerator and no prenatal care prevents information re HIV risk factors). Implications for comprehensive planning for prevention that is class, income, education and culture/race/ethnicity specific are seen in failure to present to cope with 300,000 factor, the presence of 50,000 HIV positive women leaving as orphans from 50,000 to 300,000 healthy, emotionally unstable children.

E.696

AIDS DRUGS AND THE POLITICS OF REGULATION

Edo, James and Harrington, M. AIDS Coalition to Unleash Power, New York, New York, USA.

Objective: To place biomedical and AIDS drugs in the U.S. in the political context.

Methods: An analysis of the U.S. biomedical research budget, specific AIDS-related clinical trial protocols sponsored by the National Institutes of Health and private drug companies and drug regulations as they have been applied to experimental AIDS drugs.

Results: 1) In the U.S., most people with AIDS are from populations that have been historically marginalized, so there has never been broad-based political pressure to fund AIDS research. 2) Scientists do research to advance scientific inquiry; this favors elegant solutions to scientific problems over the development of practical therapies. 3) High-tech companies favor high-tech solutions; i.e. knockout curves and vaccines, which save writing off just about everyone who has AIDS but 4) Regulators only accept data from controlled clinical trials, so a drug proves effective after treating thousands of people on a "compassionate use" basis has been denied marketing approval.

Conclusions: The pragmatic politics of industrial constituencies, the academic politics of basic research, the market politics of drug companies and the bureaucratic politics of the regulators all delay the delivery of effective therapy to people with AIDS.

E.692

TREATMENT 2D0 AND AIDS DRUGS: A BROKEN PROMISE

Edo, James J. Long, J., Murray, W., Harrington, M., Kirshenbaum, D. AIDS Coalition to Unleash Power, New York, New York, USA.

Objective: To evaluate the success of the Food and Drug Administration (FDA)'s Treatment 2D0 program in delivering AIDS-related drugs to HIV-infected people. **Methods:** An analysis of FDA regulations governing Treatment 2D0 (1987) and streamlining drug approval (1988), an evaluation of protocols governing the release of the two AIDS-related drugs available under Treatment 2D0 and interviews with FDA officials.

Results: The FDA's Treatment 2D0 program, codified in June 1987, was designed to make drugs of some proven efficacy available before their marketing approval to people with serious illnesses or life-threatening conditions. Two AIDS-related drugs are available under Treatment 2D0.

The FDA drew the original protocol for zalcitabine as a compassionate use protocol. The drug is less available under the Treatment 2D0 program than it was before it was granted this status. Recent FDA regulations state that Treatment 2D0 bridge the time from the end of a clinical trial to the final decision on marketing approval, which is a severe narrowing of the program's original purpose. **Conclusions:** Treatment 2D0 initially promised the early release of AIDS-related HIV-infected people; however, the program has actually restricted access to promising therapies.



Publications

E.699

SOCIAL WORK STUDENTS' KNOWLEDGE AND ATTITUDES ABOUT AIDS.

Finkel, Barry*, Grosser, Shirley*
*University of Manitoba, Winnipeg, Manitoba, Canada.

Objective: To describe social work students' knowledge and attitudes about AIDS; identify relevant contributors.
Method: Approximately 240 Social Work students completed a survey designed to evaluate their knowledge and attitudes regarding AIDS. A subsample (n = 100) also completed a social distance questionnaire aimed at separating the effects of feelings about homosexuality from feelings about AIDS. This study is the first phase of a broader evaluation of an "Inbound" AIDS education package at the University of Manitoba School of Social Work.
Results: Preliminary results will focus on the level of students' knowledge about AIDS and the nature of their attitudes. The effects of a variety of demographic and contextual variables will be explored.

E.701

Adult Day Health Care as a Service Delivery Model
LEAN RAGON BECE AND LEM MCNALLY

Village Nursing Home AIDS Day Treatment
New York, NY, U.S.A.

Adult Day Health care has long been available as a service delivery model for older adults. This paper will describe the development and application of this service model for a heterogeneous AIDS population at the Village Nursing Home in New York City. Currently serving a client roster of 75, the program provides nutrition, skilled nursing services, psychiatric, psychotherapy, medication monitoring and administration, therapeutic group activities and other alternative therapies.

Costs are under a hundred dollars per day per client, and clients demonstrate marked initial improvements in body weight, grooming and mental status. There are some indications as well that the daily nursing/psychiatric triage of each client is shortening hospitalizations. Further study will be required to determine the program's effect on positive outcomes.

E.703

A HOSPITAL-BASED VOLUNTEER PROGRAM FOR PATIENTS
WITH HIV INFECTION

Bender, Paula, and Susan Paul
Department of Medicine, Veterans Administration Medical Center and The University of California, San Francisco, California, USA

Objective: To describe a hospital-based specialized volunteer program designed to meet the emotional and practical needs of HIV patients.
Methods: Joint effort of Voluntary and Social Work Services with four components: 1) recruitment of hospital employees, federal employees at large, and gay/lesbian community members, 2) selection based on application and group interview processes, 3) training for 15 day training to inform and sensitize volunteers to HIV-related issues, and 4) supervision through individual and group sessions. After "hospital internship," volunteers eligible to work with outpatients.
Results: Volunteers provide necessary emotional/practical support to patients and staff, and aid in bridging communication gaps between patients and staff. Improved continuity of care with volunteers contributing a holistic approach to care.
Conclusions: Volunteers are a necessary component to patient care. Specialized preparation is essential for a successful program. Volunteers aid in decreasing isolation, provide an opportunity to express thoughts and feelings, engender a caring environment, reduce patient stressors, alert staff to daily psychosocial and medical changes, and effectively share the overwhelming burden of care.

E.700

FAILURE TO DISCLOSE AIDS DIAGNOSIS, PSYCHOLOGICAL STRESS
AND THE UTILIZATION OF SERVICES

Schiller, Nina; Crystal, S.; DeJewski, E.; Haase, S.; Merritt, C.
Beth, F.

Rutgers University, New Jersey, United States

Objective: To examine the extent, and consequences of the failure by People with AIDS to disclose their AIDS diagnosis to members of their social support network.

Methods: Data from a survey of a population based random sample of living PWAS in New Jersey is analyzed. The sample includes a high number of intravenous drug users, male homosexuals, racial and ethnic minorities and women. The relationship between this failure to disclose diagnosis and measures of psychological distress, health status and the utilization of informal supports and of formal services is explored.

Results: Failure to disclose diagnosis is found to be widespread. Only a limited number of relatives and friends are told about the diagnosis. The relationship with this attempted network is strengthened. The failure to disclose diagnosis is shown to vary by risk group, gender, and cultural background and to be related to distress but not to the utilization of formal services.

Conclusion: Failure to disclose diagnosis is a significant variable in the analysis of the psychosocial state and coping behavior of PWAS.

E.702

PROJECT OPEN HOME - ATLANTA:
DAILY MEALS FOR PEOPLE WITH AIDS AND ARC.

RENÉE L. HUBERT, PROJECT OPEN HOME, Atlanta, Georgia, U.S.A.

OBJECTIVE: To describe a non-profit community based AIDS/ARC support service devoted to providing meals to persons with HIV infection.
METHOD: Project Open Home - Atlanta, is a non-profit volunteer organization designed to provide nutritionally balanced meals to needy persons with HIV infection. It is a member source of structures recruits the able of volunteers and appeals for funding to Community Organizations, Private Foundations, and Individuals. St. Bartholomew's Episcopal Church provides kitchen, office and storage space for the Project and its volunteers.

Daily operations are handled by a volunteer staff consisting of a project director, kitchen coordinator, secretary and approximately 15-20 volunteers each day who assist in preparation and delivery of meals to clients. Each client receives two meals each day, if the client has no way to heat or store the meals, Project Open Home can loan microwave ovens or refrigerators as needed. Clients are referred by physicians, nurses, social agencies and friends. To qualify for services, clients must express a need for assistance and secure a physician's statement verifying the HIV diagnosis. Assessments are completed on each client to determine special dietary requirements and needs. These needs are addressed when meals are prepared and delivered.

MEALS	5/82	10/82	11/82	12/82
clients served	43	124	108	104
meals prepared	86	248	216	208
volunteers	186	124	186	154

100% rating for service.

CONCLUSION: Many people with AIDS/ARC face difficulties in matters of daily living. Financial obligations often exceed the amount of disability checks. Many face physical wasting, loss of appetite and apathy about eating. Project Open Home Provides nutritionally balanced meals to clients at no charge. Clients enjoy the personal contact when the meals are delivered and look forward to the next day.

E.704

SOCIAL SERVICE WORK RELATED TO AIDS PATIENTS

Morandini, R.J., Lofel, C.J., Ferreira, A.C.J.
Motta, P., and Colombo, A.S., Javei, D.S. From Faculdade Paulista de Medicina, BH/SP.

OBJECTIVE: To give biopsychosocial counseling to assure a better quality of life to the patients.

METHOD: The patients are all with positive HIV results. Nowadays we have 130 patients from July/1988 to Jan/1989. Interviews with the patients and counseling are our means of methodology, reaching that will help clarify their needs.
RESULTS: Characteristics of the patients: 86,28 male, 13,98 female; 18,18 married; 72,88 single; 9,28 others; 81,98 are between 24 and 45 years of age; 57,78 homosexual; 13,04 drug addicts; 10,08 bisexual; 19,38 others. We have observed that through the whole work, the 130 patients presented the following patterns: 49,3% of consciousness, 21,9% of behaviours; 2,88 economic, 3,8% of work, 3,18 family, 12,18 two or more patterns and 3,88 clinical occurrences. From these 130 patients: 59,28 maintain their professional activity; 25,9 are in social security and only 14,6% are inactive.
CONCLUSIONS: The biopsychosocial help, the education process of conscientization, the process of unifying attitudes and diminishing the basic social problems surely lead to maintain the AIDS patients productive and socially integrated.

Publications

Le SIDA, la société et le comportement
AIDS, Society and behaviour

E.711

A NOVEL METHOD FOR BLENDED ROUTINE BLOOD SAMPLES AND DATA COLLECTION PRIOR TO RISK INDETERMINATE INFECTION (RIV) ANTIPOY TESTING FOR UNBLINDED SEROPREVALENCE SURVEYS

Tapert, R.; Brady, C.; KARNES, ROSEMARY; BRACCI, P.; BERARDI, V.; ROSE, J.; U.S. Dept. of Public Health State Laboratory Institute (SLI), Boston, MA, U.S.A.

Objective: To design a system to collect demographic and other data without personal identifiers on routine blood samples for subsequent HIV antibody testing to determine seroprevalence in certain population groups.
Methods: Routine blood samples are submitted to SLI for serologic testing for syphilis (RPR). Data from test requisitions including date, sex, age, race, residence, indication for testing, information on risk behaviors, and reason for clinic visit are entered into a laboratory computer database. After RPR, unused sera are aliquoted into tubes marked only with a sample number in alcohol soluble ink. The sample number permits access to all data extracted from the requisition into the laboratory computer database. A computer program extracts only nondescriptive geographic, risk, and reason for visit variables from the database with STS result. This information is encoded in a bar code label which is applied to the tube. The sample number is then removed with alcohol, blinding the specimen. Blinded samples are placed in tube racks in random order, frozen, and batched for HIV antibody testing. When ready for testing, data from the bar code label are read electronically into a separate computer file with a new sample number, to which the HIV antibody result is assigned.
Results and Conclusions: Information on HIV seroprevalence by age, race, sex, area of residence, risk, reason for visit, and STS result is obtained from routine blood samples with maximum preservation of patient confidentiality.

E.713

ANONYMOUS OR CONFIDENTIAL HIV TESTING AT STD CLINICS

Reider, Gary; LoCaino, J.*; Byrnes D.**. *Saint Michael's Medical Center, **East Orange Health Department, Newark, N.J.

Objective: Should anonymous or confidential testing be the preferred method of testing for HIV infection in STD clinics.

Methods: Over a 7 month period, 340 patients were seen at the STD clinic of an inner city neighborhood. Counselled patients were given the choice of confidential or anonymous HIV testing.

Results: 248 patients were counselled. Only 140 patients accepted HIV-antibody testing. Anonymous testing was chosen by 51% of the patients. In 13 (3%) patients HIV-antibody was positive. Of the 140 patients tested only 28 (20%) called for results of their test. Due to anonymous testing 7 HIV-antibody positive patients could not be traced.

Conclusion: The above data demonstrates that in an STD setting, confidential HIV testing is more appropriate than anonymous testing, since field workers would be able to follow up on positive cases and hence assure the necessary medical follow up care for patients.

E.715

WILLINGNESS TO OBTAIN HIV ANTIBODY TESTING IF RESULTS MUST BE REPORTED RATHER THAN CONDUCTED ANONYMOUSLY

Kaplan, Susan; Calamia, J.; Coates, T. Lo. B. University of California-San Francisco, California.

Objective: To examine, among people who are seeking the HIV antibody test, whether changing the conditions under which testing would be conducted would influence the willingness to obtain testing. This was part of a larger study on the consequences of HIV antibody testing.

Methods: All adults seeking testing at an alternative test site before testing is offered free of charge and anonymously were asked to participate in the larger study (N = 957) by completing self-administered surveys (participation rate = 86%). A random subset of the larger study participants (N = 156) were asked about the conditions under which they would be willing to be tested.

Results: Thirty-nine percent reported that they would avoid testing if it were conducted confidentially rather than anonymously. Sixty percent said that they would avoid testing if the names of seropositives had to be reported to public health officials, but kept confidential or if seropositives had to be reported and contact-tracing would be conducted. There were no significant differences in the proportions of gay/bisexual men versus heterosexual men and women who would consent to testing under the various conditions (76% of those seeking antibody testing were heterosexual).

Conclusions: Previous research has shown positive effects on risk behavior when people voluntarily seek anonymous antibody testing. These findings indicate that many people who otherwise would have sought testing will avoid it if such testing is no longer conducted anonymously.

E.712

THE EPIDEMIOLOGICAL SIGNIFICANCE OF OFF-CITY HIV COUNSELING AND ANTIPOY TESTING AMONG STUDENTS ATTENDING AN URBAN STATE UNIVERSITY

Richway, Michael; Tripp, D., Cincinnati Health Department, Cincinnati, Ohio, United States of America

Objective: To describe HIV infection risk behavior patterns and HIV antibody sero-prevalence rates among students attending a state university having a large urban campus in a city with a moderate HIV infection prevalence rate.

Methods: In cooperation with student campus organizations, free and anonymous HIV antibody counseling and testing was advertised and subsequently made available during a three day period at the University of Cincinnati Student Center. Counseling and testing procedures were identical to those utilized during the past three years at the HIV Counseling Testing Site, Cincinnati Health Department. HIV risk assessment data was recorded on a standard form. Data was then optically scanned and analyzed using the Medical Information Management System (MIMS), an automated data storage and retrieval program.

Results: A program of off-site HIV antibody counseling and testing can be a successful, epidemiological tool in assessing HIV prevalence rates within a well defined population. Although the unprotected sexual activity level is substantial among students on an urban state university campus, HIV prevalence rates reflect moderate nature of this infection prevalence within other community groups.

E.714

SHARING THE NEWS: TRAINING BEGINNING COUNSELORS TO DISCLOSE HIV ANTIBODY TEST RESULTS

Duckworth, Michael; Pies, C.**; Broome, J.*; Deich, D.*; Ramirez, A.**; Japerson, J.**

*University of California AIDS Health Program, San Francisco; ** Education Program Association, Campbell CA; ***California Department of Health Services, Office of AIDS

Objective: To present a training model designed to train beginning HIV antibody counselors how to provide pre- and post-test counseling.

Methods: The UCSF AIDS Health Program, through the alternative test site program in San Francisco, has provided over 4000 antibody test results. The Project has provided training for approximately 1,500 persons on how to provide antibody test counseling. A one-day HIV Antibody Counselor Training course has been developed for this purpose. This presentation will discuss the philosophy of training, some specific training techniques used, and the results of the program and share some of the difficulties encountered.

Results: If three-day trainings will be held throughout the state by 1989, preliminary evaluation of the program's success will be offered. The complete training manual will be available for review.

Conclusions: This carefully planned and proven training program for new HIV antibody test counselors will aid in the provision of pre- and post-test counseling services in HIV antibody test settings.

Supported in part by a grant from the California State Office of AIDS, contract # 88-94679.

E.716

RISK FACTORS AND HIV SEROPREVALENCE IN FEMALE CLINICS OF SELECTED HEALTH DEPARTMENT CLINICS, HOUSTON, TEXAS

Crane, P.; Terhune, P.*; Decker, M.*; Gatta, P.*

HIV/AIDS '84

*University of Health Science Ctr., Houston, Texas, U.S.A.

**Department of Health and Human Services, City of Houston, Texas, U.S.A.

Objective: To determine prevalence of HIV infection and risk factors for HIV infection in women attending selected City Health Department Clinics in Houston, Texas.

Methods: 278 and 48088, a 477 women attending Family Planning, Prenatal and Sexually Transmitted Disease (STD) Clinics completed an anonymous, self-administered risk assessment questionnaire. Of these, 1063 referred themselves for counseling and completed a risk factor interview. Results: 81% (1/25) of the 712 women who were tested for HIV were confirmed HIV seropositive by western blot and 11 (1.2%) had serological test results. Approximately 20% of the women completing the self-administered risk assessment form reported at least one factor that would have made them eligible for HIV testing including self or partner using IV drugs (35), STD within the previous 5 years (15) or bisexual or HIV-infected partner (25). Only 38% of these women referred themselves for counseling and testing. Of the women who were tested, approximately 70% were considered to be at increased risk of HIV infection by virtue of IV drug use or an ongoing relationship with a high risk partner.

Conclusions: Although HIV seroprevalence is relatively low in this self-DETERMINED population, conditions exist for its continued spread. A significant number of women attending these clinics maintain their increased risk.

Publications

Le SIDA, la société et le comportement
AIDS, Society and BehaviourE.717 FAILURE TO RETURN FOR HIV TEST RESULTS: A SECOND LOOK AT
DETERMINANTS

Debrah Bagg, D. Miggins, D. Schell
Centers for Disease Control, Atlanta, Georgia USA

Objective: To assess factors affecting a 50% failure to return rate in an anonymous HIV Counseling and Testing (ACT) site.
Methods: A questionnaire designed to measure the psychosocial, behavioral, and demographic factors found to be predictive of failure to return in past studies, as well as the immediate impact of pre-test counseling, was self-administered by 503 715 clients in DeKalb County, Georgia.
Results: Respondents were male (57%) and female (42%); white (59.4%) and black (29%), generally single (53.3%) heterosexuals (68.1%). Bivariate and multivariate regression analyses showed race to be the single most independently predictive factor in determining failure to return (Chi square=4.9, p<.001). Additionally, race was also a factor in study participation, although those who did not participate in the study had the same return rates as those who did. Significant differences between whites and blacks were also observed.
Conclusion: Test reasons for failure to return included fear of test results (50%) and a low priority on learning results (30%). Serostatus and risk group membership were not significant predictors of failure to return.

Implications: This study suggests failure to return rates are affected by race and counselor variables. Since these variables operate to affect return rates warrants further study.

E.719 RAPID, INSTRUMENT-FREE ASSAYS CAN BE USED IN TANDEM FOR
SCREENING AND CONFIRMATION OF HIV INFECTION.

F. Spelberg, K. Auditor-Hagrupova, W.L. Hayward, R.W. Ryder, J.C. Quinn, Milton S. Jam, et al. The Diabtech Program for Appropriate Technology in Health, Seattle, WA, USA; CDC, Atlanta, GA, USA; Project SIDA, Kinshasa, Zaire; and NIAID, Bethesda, MD, USA.
Objective: Although alternative methods to blood screening by conventional ELISA exist, to date Western blot (WB) remains the accepted confirmation method. This study was to evaluate performance and cost-effectiveness of rapid, instrument-free assays used in tandem for screening and confirmation.
Methods: 3,878 serum samples (5.5% HIV-1 seroprevalence) were collected and tested in each of five different rapid assays, as well as conventional ELISA and WB in Kinshasa, Zaire. The results were analyzed retrospectively to determine the accuracy of a test method which included neither ELISA nor WB.
Results: A testing hierarchy comprised of duplicate screening assays, followed by confirmation in duplicate of all repeatedly reactive specimens, provided perfect accuracy when HIVOCEK (Du Pont) was employed as the screening assay and Serodiv-HIV (Fujirebio) as the confirmatory assay. Compared to the standard method of ELISA screening and confirmation by WB, the rapid method resulted in a cost savings of approx. \$3.00 per positive specimen identified.
Conclusions: The ability to use one rapid assay to confirm the results of another can be expected to facilitate blood screening in developing country transfusion centers, where highly technique-dependent methods such as WB are not appropriate. While a modest cost savings can be realized without compromising accuracy, the major advantages are in the savings of time and labor, and eliminating dependence on capital equipment. However, despite these considerable advantages, the cost per HIV-positive unit identified is still unrealistically high for the majority of developing countries.

E.721 POLICY, LEGISLATION AND RESPONSE; MANDATORY HIV TESTING

D.S. Friedman
Kent E. Elisebach, Medical Director, San Francisco County
Jail; University of California, San Francisco, USA

Objective: To consider policies and legislation regarding mandatory HIV anti-body testing of US prisoners, and to compare and contrast the responses of health care and prisoner advocacy personnel to essentially similar mandates.
Methods: A review of local policies, popular elections and legislative actions mandating HIV screening of prisoners will be presented.
Results: Health care personnel and prisoner advocates have responded to these mandates with varying degrees of enthusiasm or opposition. Mandatory testing necessarily excludes informed consent, confidentiality of results, and often is not tied to counseling and education. In some jurisdictions, health care personnel are required to provide institutional staff with lists of HIV + or "possibly infected" individuals.
Conclusion: Mandatory HIV testing presents challenges to professional norms, standards of care, and to individual rights.

E.718 MULTI-LAB STUDY RESULTS OF A NEW RECOMBINANT ELISA

IMMUNOASSAY FOR ANTIBODIES TO HIV COMPARED AGAINST DUPOUT WESTERN BLOT, E. Baden, M. Vashiliani, M. Scott (Jackson Instruments, Inc. 300 S. Kramer Blvd, Ives, GA 98621); Dr. M. Busch (Civian Memorial Blood Bank, San Francisco, CA); Dr. M. G. Hirsch (U.S. Dept. of Health Services, Berkeley, CA); Dr. K. Thorenstam (Swedish National Institute of Health, Stockholm, Sweden).

The etiologic agent implicated as the probable cause of Acquired Immunodeficiency Syndrome (AIDS) is the Human Immunodeficiency Virus (HIV). The Western Blot™ HIV Reagent Kit is a semi-quantitative assay for the detection & identification of antibodies in human serum or plasma to proteins representing GAG (p18 and p24), GP (gp 120 to gp 160) and POL (p66/31). These antigens are purified recombinant peptides produced by genetic engineering techniques in E. Coli. Individual peptides are reacted in a microtiter plate format.
After incubation of diluted sample (1:100) in the microtiter plates, the plate is developed with alkaline phosphatase conjugated/substrate A reagent at 410/490 nm. Total assay time is less than 6 hours.
The absorbance cutoffs for each peptide was established with 1000 samples. Data, the established criteria of positivity for each, 1440 samples were compared against DuPont Western Blot.

	850	AQ	DUPOUT	POS
NB	1082	16	0	0
DWS	117	116	126	0
POS	0	5	274	0

Buschman recommends that each evaluator establish their own cutoff & criteria of positivity for this research use only product but found excellent results with the stated criteria in correlation to DuPont Western Blot.

E.720 TB SKIN TESTING: A PROTOCOL FOR IMPROVING HEALTH AND
EPIDEMIOLOGICAL INTERVENTION WITH HIV SEROPROTECTIVE INDIVIDUALS

Anderson, P. Frossen, A. Bailey, Charles E. J.

Objective: To improve TB screening of HIV antibody positive clients, improve partner notification efforts, improve assessment of HIV seroprotective individuals, and improve client comprehension and retention of HIV positive counseling messages. **Method:** Offer TB skin test (PPD) at post test counseling session to all individuals testing HIV positive. For those who accept, another counseling session will be offered in conjunction with the appointment to read the skin test. The counseling session could include any of the following: 1.) Assessment of client's medical status including medical comorbidity, 2.) Assessment of clients knowledge and retention of post-test counseling messages and their performance, 3.) Partner notification counseling to enhance, through roleplay, client's willingness and ability to tell sex partner(s) needle-sharing partners they may have been exposed to HIV. Health Dept.'s assistance will be offered on a voluntary and anonymous basis when counselor assesses the need for it or the client requests the service. **Results:** Program will begin February 1, 1989. Results of client assessment of this program will be presented. **Conclusion:** Upon learning their HIV seroprotective status, clients may be anxious and in shock and thus retain a very small percentage of information from the post test counseling session. Discussion of partner notification can also be inappropriate at that time. The TB test provides a health screening as well as a reason for a return visit for additional counseling and assistance with partner notification.

E.722 STD SCREENING AT ALTERNATE HIV TEST SITES?

Thomas Gagliardi, Oscar P. Russel, Dr. Robertson OHS,
Rettelle RW. Dep. Gastroenterology/Medical(GM), Royal

Infirmary, "Communicable Diseases Div., City Hospital, Birmngham, UK.

Objective: In 1985 the City Council funded a seroprevalence study set up as an alternate HIV test site & has now seen 1718 clients (254 were injection drug users [IDU]). A prospective study was set up to assess the need to screen for sexually transmitted diseases(STD) in clients seropositive above HIV.
Method: New clients were offered STD screening, their risk factors for HIV & for concurrent STD(s)/low/high risk were assessed. A comparison was made with those attending GM for an HIV test.

Results: Preliminary results on 605 GM & 110 CDC clients.
GM(155 had HIV test +ve) | No. | gm. STD test | STD Definito. | STD +ve |
No. risk HIV tested | STD +ve | STD test | STD Definito. | STD +ve |
Low 27 9 36 6 4 0 0
High 26 9 35 6 1 2 2
Not Done - - - - - - - - -
Total 53 18 71 13 5 2 2

Conclusion: None of the GM HIV test sites which may imply they do not regard HIV as an STD (one of 2 STD +ve was a partner of 2 STD +ve) Assessed risk in GM(155) was below that of CDC(110) in those HIV seropositive. 9/60 (14%) CDC clients tested STD tests other than HIV, of those (6/32) defined either as negative HIV results. It seems clients' choice of clinic depends on their perceived STD risk. People are reluctant to STD testing at CDC, which has important implications for health education regarding HIV spread.

Publications

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

E.723

PEOPLE ASSOCIATED WITH TESTING THE HIV SCREENING TEST
Yvonne Kiehl, Health Policy Institute*, L. Hofmann*, R. Higgins* Boston Univ. *Mass. Dept. of Public Health/D.P.H.

OBJECTIVE: To determine if those at risk for HIV infection are more likely to obtain a screening test.

METHODS: A statewide anonymous random digit dial telephone survey of 1,223 Massachusetts residents was conducted in October 1987. Information about demographics, attitudes and concerns about AIDS, and risk factors was obtained and examined in relation to whether respondents had been tested or would be willing to be tested for the HIV antibody (AB).

RESULTS: Of 1,223 respondents, 111 (9%) had been tested; all but two had received negative test results. Persons with at least one risk factor were more likely to have received the test than without risk factors (12.1% v. 7%), (p<.05).

RISK FACTOR

RISK FACTOR	NUMBER	% TESTED	% WILLING TO BE TESTED
Gay/MSM + partners	59	14.1	41.1
IV drug users + partners	79	11.1	7.1 (p<.05)
Need recipients + partners	75	23% (p<.05)	47%
Respondents with other sex risks + partners	377	11% (p<.05)	6% (p<.05)

Persons who had not been tested and had at least one risk factor were more willing than those without risk factors to be tested if the test were free and anonymous. (SEI v. 40), (p<.05).

CONCLUSION: Although many of those more likely to have received the screening test, the proportion of respondents with risk factors who had been tested was relatively low. Of those not yet tested, a majority would be willing to be tested. The use of free and anonymous tests may increase the likelihood that individuals at risk will choose to be tested.

E.726

Recruitment of Research Subjects at Risk for AIDS

Authors: Pamela Bellini, M.S.; Barbara Newman, M.A.; Patricia Walter, R.N.; Lawrence Goodenough, M.D., Ph.D.; David Smith, M.D.; Cornell University Medical College, New York, N.Y., U.S.A.

Objective: To test methods for recruiting physically asymptomatic subjects at risk for AIDS into longitudinal psychological studies. Psychological diagnosis, the central public health need, limited prospective clinical data are available regarding the psychological and behavioral effectiveness of being at risk for acquiring or transmitting HIV. Many potential sources of subject pools of confidentiality and see little personal benefit in hazardous studies, findings to date have generally been from self-report measures of subject samples of asymptomatic males. **Methods:** To reduce concerns about confidentiality, our study was conducted in a private residential setting and with an agreement that no information would be given to any third party; further, overall arrangements were made to preclude subjects seeing one another, and contact for follow-up was arranged in accord with subject specifications. To offset the burden of extensive clinical assessments, we provided free periodic HIV testing and individualized counseling by a psychiatric nurse. **Results:** Over 18 months, in depth prospective clinical psychological assessments were obtained on 260 physically asymptomatic subjects who were independently heterogeneous and represented major risk groups: 145 gay/bisexual males, 34 IVU, and 81 heterosexuals with suspected or known infections. Seropositivity rate was 37%, and attrition at 6 months was 29%. **Conclusions:** If confidentiality is absolutely protected and supportive care provided, psychological studies of at-risk populations are feasible; however, in designing and conducting future studies, researchers should consider the additional demands and cost of meeting special requirements posed by the AIDS epidemic.

E.727

REASONS FOR NOT DISCUSSING HIV-ANTIBODY TEST RESULTS TO OTHERS - DATA FROM A COHORT OF SEROPOSITIVE GAY MEN

J. Margolis, J. Bellini, P. Buchheit, & M. Rosen. School of Medicine, University of Illinois, Urbana, Illinois, U.S.A.

Objective: To determine the reasons for not discussing positive HIV-antibody test results to others, in a cohort of gay men.

Methods: 77 seropositive gay men reported reasons why they were concerned about discussing test results to others at 2 weeks, 2, 4 & 12 months following notification, using a questionnaire developed by Handel.

Results: 1 REASONS POST-NOTIFICATION 1 YEAR POST-NOTIFICATION

Fear of Practical Losses	73%	45%
Job	49%	45%
Insurance	43%	87%
Housing	40%	33%
Fear of Relationship Losses		
Love	20%	14%
Sex Partners	20%	14%
Family	27%	41%
Friends	22%	0%
Fear Inge as AIDS Carrier	70%	0%

Conclusions: Potential loss of health insurance, housing and jobs are primary reasons for not wanting to discuss HIV-antibody test results to others. Fears of disturbing close relationships are of less concern. Merits of being perceived as an "AIDS carrier" diminished over the year.

E.724

THE EFFECT OF HIV ANTIBODY TESTING UPON SEXUAL BEHAVIOR, CONCERN ABOUT AIDS AND AIDS RISK COMMUNICATION.
HALL, L. HARRIS, M.D. Shoshul, M.D. Department of Medicine, Los Angeles, California, U.S.A.

Objective: We evaluated the effect of a negative HIV antibody test upon sexual behavior, concern and knowledge about AIDS, and communication with sexual partners (SPs) about AIDS risk.

Methods: 256 heterosexuals attending an urban sexually transmitted disease (STD) clinic entered a randomized trial of HIV testing. All subjects received AIDS education and pre-test counseling, completed a questionnaire, and had blood drawn, then 124 received a "TEST" and post-test counseling; 94 tested negative for HIV. The 122 "NO TEST" subjects were informed of alternative test sites. A follow-up survey was completed 8 weeks later.

Results: Participants had a mean age of 27 years; 68 were male, 84 were female. TEST and NO TEST groups did not differ in baseline number of recent unprotected SPs, in number of inquiries to SPs about AIDS risk or in AIDS knowledge. Follow-up of 78% of subjects revealed a decrease in mean monthly number of unprotected SPs (1.7 to 1.2, p=0.0001), but no difference between TEST and NO TEST groups (p=0.38). TEST subjects however, reported that they were more worried about getting AIDS (p<.05) and asked partners more questions about AIDS risk (p<.001). They were more likely to increase questions about partners about HIV tests (p<.05) and intravenous drug use (p<.001). AIDS knowledge did not differ at follow-up.

Conclusions: In STD clinic subjects who received an educational intervention, HIV testing was associated with increased concern about getting AIDS and more questioning of SPs about AIDS risk, but did not affect knowledge about AIDS or sexual behavior.

E.726

PERCEPTION OF RISK FOR HIV INFECTION AND THE DESIRE FOR HIV TESTING AMONG IVU AND NON-IVU DRUG USERS

Wolke, John, Abidin-Quader, A.M., Preid, C.C., Rockwell, R.M., Fenwick, S.

*Beth Israel Medical Center, New York, N.Y., U.S.A., **Narcotic and Drug Research, Inc., N.Y., U.S.A.

Objective: Since HIV testing is advocated for high risk behavior groups, we examined the perception of risk for HIV infection and the desire for HIV testing among Intravenous (IVU) and Non-Intravenous (Non-IVU) drug users entering a detoxification facility in NYC. **Methods:** A brief survey was administered to 100 substance users applying for detoxification from drug or alcohol. Information was collected concerning their understanding of HIV testing, their perception of their risk for HIV infection and whether they wanted to be tested for HIV. **Results:** N=100, 70 male/30 female, Mean age = 35, 43 Black, 34 Hispanic, 14 White. 17% Non-IVU, 83% IVU. 17% Non-IVU, 83% IVU of heroin or cocaine, 37% Non-IVU (use cocaine, alcohol, or methadone).

1. Awareness of the existence of the HIV Test ----- 60% 39% (p<.05)
2. Cognizant of spectrum of HIV infection from asymptomatic to AIDS 53% 37% vs
3. Believe that their own risk of HIV infection was 5.10% ----- 81% 81% vs
4. Previously HIV tested ----- 44% 19% (p<.05)
5. Wanted to HIV tested during this hospitalization ----- 77% 67%

Verification of self assessed HIV negative status was the reason given by the majority of those who wanted to be tested.

Conclusion: IVU's were more likely to know about HIV testing and were more likely to have been tested. However, IVU's tend to minimize their risk for HIV infection.

E.728

HIV TESTING AT AN ALTERNATE TEST SITE IN NEW YORK CITY.

Rinder, Bruce; Albrecht, Robert; Heward, S. J. and Palmer, Wagh, U. Beth Israel Medical Center, New York, NY, U.S.A.

Objective: To describe the population characteristics of persons presenting for HIV testing at an alternate test site in New York City.

Methods: The Infectious Disease Research Institute Medical Center was designated as an alternate confidential HIV test site in January 1988.

Results: 1000 persons were provided confidential HIV testing. On all persons tested, clinical and demographic information was obtained. HIV serology was performed using the ELISA and was confirmed by the Western Blot method. Post-test counseling was offered to all after receipt of lab results.

Results: Of the 531 persons tested during 1988, 244 were males, 221 were females and 66 were children of high risk mothers. Overall, 1051 (20%) males, 512 (24%) females and 261 (29%) children tested were seropositive. Analysis of data according to risk group for adult males and females is tabulated below:

	1st test				
Male	100	100	100	100	100
Female	100	100	100	100	100
Child	100	100	100	100	100

Conclusions: 1) A heterogeneous population sought testing at our alternate test site during 1988. 2) The majority (68%) of men who presented for testing belonged in conventional risk groups (gay, IVU). 3) In contrast, the majority (70%) of women came for testing because of concerns over their heterosexual relationships.

Publications

- E.729** DISCLOSURE OF HIV-ANTIBODY TEST RESULTS & REACTIONS OF HEALTH PARTNERS, FRIENDS, FAMILY & HEALTH PROFESSIONALS
 T. Magill, J. Buckley, P. Benchetti, M. G. Seal, School of Medicine, University of California, San Francisco, San Francisco, CA, USA.
- Objective:** To investigate to whom HIV-ab test results are disclosed.
Subjects: 107 gay men reported: 113 Persons told results of HIV-ab test and 121 their reactions to HIV-ab test 4 to 12 weeks following notification.
Results: Disclosure to whom HIV-ab test results were disclosed (percentage of those told expressing unfavorable reactions):
- | | 2 WEEKS POST-NOTIFICATION | 1 YEAR POST-NOTIFICATION |
|----------------|---------------------------|--------------------------|
| Persons | Positive | Positive |
| Lower | 313 (121) | 313 (121) |
| SexPartners | 193 (69) | 193 (69) |
| Bestfriend | 161 (58) | 161 (58) |
| Mother | 154 (17) | 154 (17) |
| Father | 125 (14) | 125 (14) |
| Physician | 121 (13) | 121 (13) |
| Bestie | 121 (13) | 121 (13) |
- Conclusions:** About half of lovers and nearly a third of one sex partners were told test results - more widely by negatives than positives. Friends were almost always told and reacted well. Mothers were told less twice as likely to be told a father. Best physicians had been told by one year after notification - but less than a third of dentists. Negatives had favorable reactions to all positives experienced their most unfavorable reactions from dentists and sexual partners.

- E.731** PSYCHOLOGICAL IMPACTS OF INDETERMINATE HIV WESTERN BLOTS.
 Connie Galamb, Vlastos, P.P., Lafferty, W.E., Roberts, P.L., Hirsch, R.W. Univ. of Washington, Seattle, Washington, D.C., U.S.A.
- Objective:** Indeterminate results on Western blots pose a problem for both patients and clinicians due to the lack of consensus on the significance of indeterminate Western blots (IWb). We conducted an ongoing prospective study to characterize anxiety, depression, coping processes, and specific symptoms in 100 patients with IWb.
- Methods:** Thirty-seven individuals with positive HIV ELISAs and IWb were referred from diverse HIV testing sites in Washington state (50% from low and 50% from high-risk groups) and voluntarily participated in a prospective study. Standard instruments were used to measure depression (Beck Depression Inventory), anxiety (Symptom Checklist-90), coping (Ways of Coping Checklist), and the psychological impact of IWb.
- Results:** Seventeen individuals were tested for HIV because of concern over past sexual exposures to heterosexual, 13 heterosexual, 4 because of intravenous drug use, 11 as blood donors, 4 as applicants for the insurance, and 13 in the military reserves. Causes reported considerable anxiety and depression in semi-structured interviews and the Beck and SCL-90 measures. Coping by self-blame and avoidance (denial) were significantly correlated with anxiety (r=.44 and .32, respectively, p<0.05). Inverse HIV events attributed to the IWb included consideration of termination of a first trimester pregnancy, use of the IWb in a custody case, ineligibility for the insurance, marital distress, and the decision to drop out of medical school. Informational needs included explanation of ELISA and Western blot techniques and results, discussion about the low rates of seroconversion in low risk individuals with IWb, possible etiologies other than HIV, and options for further evaluation.
- Conclusions:** Counseling of individuals with IWb should include assessment of anxiety, depression, coping processes, the attributed consequences of IWb, and should provide information about HIV testing techniques and options for further evaluation.

Médias

Media

- E.732** DIGNITY CANADA DIGNITE AIDS PASTORAL CARE PROJECT
 Dignity Canada, Charis, J. and Simon, C.C., National Director, Dignity Canada Dignité, AIDS Committee Chairperson, Dignity Canada Dignité

What is "pastoral care"? It is relevant to people dealing with AIDS? What forms can it take? Who is qualified to administer it? Who is eligible to receive it? These were the fundamental questions asked by the Dignity Canada Dignité AIDS Pastoral Care Project. Furthermore, the Project was interested in determining the scope and nature of pastoral care as an eye to indicating the directions for development of more responsive pastoral care initiatives.

Data was collected by means of a self-administered questionnaire made available across Canada in two languages. The tabulated results indicated wide-ranging answers to the Project's fundamental questions. Answers receiving or wanting to receive pastoral care were not to be limited to persons actively ill with AIDS, but included as well the asymptomatic, the family and friends of the presently and potentially ill, and also AIDS caregivers themselves. Those perceived as "givers" of pastoral care were not only the recognizable representatives of organized religion, but also family, friends and caregivers as well. The forms (both experienced and hoped for) of pastoral care related to AIDS included: one-to-one pastoral care, as well as an development of public policy by religious institutions. The need for persons sensitively informed and specially trained in dealing with AIDS was indicated. And the need for openness to the spiritual dimension, with an array of specific issues* (e.g., pain, suffering, grief) demanding particular focus.

*Top ten resentments/sin/sinfulities on such issues.

Le SIDA, la société et le comportement
 AIDS, Society and Behaviour

- E.730** QUALITY ASSURANCE IN ANTI-HIV TESTING -
 JENNIFER MCGRAW and Polesky, H.F. Memorial Blood Center of Minneapolis, Minneapolis, USA

Objective: To document the high quality of anti-HIV testing performed by LABORATORIES participating in external proficiency testing programs. **Methods:** The College of American Pathologists and the American Association of Blood Banks jointly sponsor a proficiency testing program for laboratories testing for antibody to human immunodeficiency virus (anti-HIV). Panels of 5 samples each are mailed quarterly to approximately 1000 subscribers. Participants are provided with a report summarizing results by test method and report manufacturer.

Results: Over the past 3 years greater than 90% of laboratories reporting ELISA screening methods have correctly identified anti-HIV reactive samples. Reports from laboratories using western blot confirmation methods show a low greater than 95% agreement on reactive samples. Non-reactive samples were correctly identified by greater than 95% of laboratories reporting confirmation testing while those using only ELISA screening tests were more likely to report false positive results. Some variability in sensitivity and/or specificity of both ELISA and western blot test reagents can be documented.

Conclusion: Laboratories participating in external proficiency testing programs maintain a high level of performance. These programs are useful in monitoring the performance of flow comparison with others using similar methods and reagents.

- E.732** HIV: A PRIVATE SECTOR MODEL PROGRAM TO PROMOTE COMMUNITY BASED CLINICAL DRUG TRIALS
 Anderson, Robert L., King, D.**, Lang, C.**, Beaulieu, P.**, Johnson, K., DeLong, J.**,

Methods: The combination of an ongoing monitoring program for HIV seropositive patients, a patient registration system for primary care physicians, and direct advertising in target media reaching high HIV prevalence populations was developed to facilitate registration and subsequent enrollment into IRB-approved clinical trials. Startup funding was provided by a venture capital firm with ongoing support from pharmaceutical sponsors.

Conclusions: A private sector model program has been established in San Francisco to efficiently conduct sponsored clinical trials. This program augments current systems of university-based programs, Community Research Initiative and County Councils, and differs in the use of a dedicated research facility and private funding for startup and ongoing support. Initial response from industry and patients has thus far been favorable.

- E.734** AIDS AND SPIRITUALITY: LIVING IN THE FACE OF DEATH
 Carol L. Huntington, ACM, AICW, University Hospital
 University of Medicine and Dentistry of New Jersey,
 Newark, N.J., Associate Minister, Christ Episcopal Church,
 Teaneck, N.J., U.S.A.

Objective: The AIDS social worker is faced with the dilemma of incorporating spiritual issues into traditional clinical intervention strategies.

Methods: This paper is based on clinical observation gained in social work practice with AIDS patients at University Hospital in Newark, N.J., and pastoral counseling as a professional in the Episcopal Church. Most of my patients are IV drug abusers.

Results: AIDS social workers are in a unique position to address people of faith, courage, and love.

Conclusions: AIDS social workers are in a unique position to address appropriately the needs of a person who presents with a spiritual crisis. This paper examines what is appropriate for the social worker to do, what is not appropriate, and when, to whom, and how to refer. It looks at the positive and negative aspects of spirituality and how social workers can best respond to the statements and questions of faith.

Conclusion: It is in that responsibility that we are most able to help patients seek life in the face of death. Social workers are challenged to confront spirituality, strengthen it and use it therapeutically in social work practice with AIDS patients.



Publications

- E.735** MEDIA MESSAGE (PROTECT YOURSELF AND EACH OTHER)
Smith, Linda; Seaborn, J.; Latrop, L.; Bouvick, D.
Calgary, Health Services, Calgary, Alberta, Canada
- Objective.** Young adults, not associated with a school or institution are a difficult audience to access with health information. Positive messages, about the use of condoms to prevent pregnancy and STD's including AIDS, are particularly important for this age group which has high STD and unwanted pregnancy rates. There are few positive media images on how to use condoms, who purchases them, or how to talk about using them with a partner.
- Methods.** To promote the messages of dual responsibility and need for dual protection against pregnancy and STD including AIDS, four Public Service Announcements (PSAs) were developed (30 seconds each) for television.
- Results.** Approval was received from the telecaster Committee of Canada for use in Public Service Announcements. Four out of five television stations in Calgary area are airing the PSAs. This is the first time a condom has been presented as part of a public health message in Canada.
- Conclusion.** A small outlay of funds (\$15,000.00 Can.) produced a top quality product. One of the four spots won the #1 Public Service Announcement in its category in Canada. Innovative, positive (media) messages including modeling of behavior are conducive to enhancing the knowledge base and preventive practices of the young adult.

- E.737** MEDIA DISTORTIONS OF AIDS: NINE YEARS OF MISPERCEPTION
Scherrie, Michael¹; Vowles, J.²
- ¹ Chair, Media Committee, AIDS Coalition to Unleash Power (ACT UP), New York, N.Y., USA;
² Member, Media Committee, AIDS Coalition to Unleash Power (ACT UP), New York, N.Y., USA; Freelance science writer.

Objective. To present a survey of media coverage of the AIDS epidemic and identify inherent biases and misinformation.

Methods. Both television and print media were analyzed; different reports on the same events were compared; points of view that were not mentioned were highlighted.

Results. While coverage of the scientific aspects of AIDS by the world's media has become more accurate over the course of the epidemic, it still lacks any real attempt to provide adequate social perspectives. The views of people with AIDS are rarely if ever taken into account, and most scientific evidence is taken at face value, with insufficient analysis and context provided. Methods have been created to remedy these problems, and to provide a more accurate and more rounded perspective on the global AIDS epidemic, and the many complex issues that surround it.

Conclusion. A decade of media coverage of the AIDS epidemic shows that balanced and educated reporting is rare.

- E.739** AIDS IN SWISS-NEWSPAPERS: REPORTING OF PREVENTIVE EVENTS AND DESIGNING THE IMAGE OF AIDS
Birncherer B., Richard J.E., Haenni, Dominique¹, Dubois-Arber F., Lehmann Ph.
¹Dpt socio. and Genéve; ²Inst. univ. de méd. sociale et préventive, Lausanne, Suisse.

More than 1500 different newspapers are printed in Switzerland. Since 1986 the Swiss authorities have launched a multimedia campaign under the slogan STOP-AIDS, associated with an important effort of stimulating multipliers such as regional authorities, schools, social and health professionals.

Objectives. Analyses of the 3776 articles about AIDS printed in 445 newspapers between Jan and Oct 1988 have 3 goals: 1. As a source of information about local actions, political facts or decisions, discriminative reactions in the different part of the country. 2. To describe the image of AIDS designed by press. 3. As a database.

Results. The main conclusions are:

- AIDS has been treated as any other topic by the press, but appears much more often and more regularly than the others (media report live every events and news of scientists concerning AIDS).
- The press plays a major role in designing popular beliefs about AIDS.
- Most reported events are not directly related to prevention but still have preventive effects.
- Persons with AIDS take a large place and are presented as "usual" patients who need care and compassion.
- Journalists are generally neutral, but don't take much care of contradictions appearing in or between the agencies' news.

- E.736** NOTES ON MEDIA PORTREYS: WHAT ARE THEY REALLY SAYING?
Birncherer, Joseph R.; Oberlin College, Princeton, N.J., U.S.A.
- Objective:** This study examines several recent Mass Transit Authority (MTC) advertisements for the rhetorical progression of Ideological development around AIDS, many of which have been documented by Ellen Hestor. This paper clarifies the relations between the MTC images and the cultural formations which they, ultimately, refer to. Their use of such tropes as the violation of the 'family', the femme fatale, danger in unexpected places, etc., illustrates the widespread psychic displacements occurring, whose symbols of four prevalent anxieties serve in other contexts.
- Methodology:** The study employs semiotic analysis to reveal these ads' rhetorical structures, while foregrounding the importance of social context in interpreting representation.
- Results:** The study found that these advertisements reinforce an underlying climate of unease which reflects displaced anxieties around AIDS.

- E.738** AIDS AND THE MEXICAN PRESS: IS IT USEFUL AS AN EDUCATIONAL MEANT?
Guzmán, L.; Blanca Encz, Maga, C., and Páez, G.
¹"El Regional" Center for the Documentation and Information about AIDS, CIRID/COAHUILA, MEXICO.
²General Directorate of Epidemiology, Ministry of Health, MEXICO.

Objectives. To analyze the response of the Mexican press to the AIDS epidemic from April to December 1988. This included the role of the Mexican press in educational meant, 370 articles on public opinion response to the educational campaign against AIDS.

Methods. Notes and articles were collected from the eleven most important national daily newspapers. Each role was considered as an analysis unit and quantitative variables were counted and analyzed using a SPSS-PC programme. For the qualitative variables content analysis was used.

Variables studied to know the frequency and the way the Mexican press is dealing with AIDS.

Results. The most relevant results are: 1) the average number of articles was 0.8 per day; 2) the information flow increased after the AIDS official campaign, because of the public opinion response; 3) the social groups that expressed an opinion related to the campaign were: public employees 59.7%, social associations 20.9%, civil associations 11.9%, political parties 5.9%, religious institutions 2.0%, and private organizations 0.5%; 4) in regard to the article content, 2.8% were about transmission; 4.7% about treatment; 18.2% had epidemiological information and 40% about the response of the public to the preventive measures the campaign proposed.

Conclusions. Although articles are being published correctly, the press is not acting as an efficient educational mean. Nevertheless, results show that the public opinion has reacted significantly, and so we consider that special strategies must be design in order to make the press a useful mean. The social discussion in this medium should be considered by the decision makers to orient the following steps of the campaign.

- E.740** Lakeshore School Board's Comprehensive AIDS Model
Shingleton, George; Bell, William
Lakeshore School, Lakeshore, Ontario, Canada

Objectives. To describe the implementation of a comprehensive plan which included the development of a policy, school based plan for high schools, students, professional personnel, for teachers, a community development strategy and a public awareness.

Methods. A report will be presented on the results of the Lakeshore School Board's mandate to develop a policy and an educational plan on AIDS 1987-1988. Correlation with representation from every group organizing fifteen major information seminars, and awareness group assemblies using films, brochures, informative literature, education kits, videos, and awareness and television coverage in the underwriting.

Results. Approximately 1200 employees, 1500 parents, and 4800 high school students were given the opportunity to learn about the deadly disease. AIDS awareness and literature coverage gave the Lakeshore School Board positive publicity to learn about this topic. Students' essays and projects offered encouraging feedback to the teachers and parents; comments were most reassuring that the committee must continue its work.

Conclusions. The Lakeshore School Board has proven that a grassroots venture without funding can have a transforming effect on the attitudes of the community and the general public. The Committee is committed to continue to educate its people about the magnitude of the disease and the prevention and being planned in the context of Family Life/Health sexuality curriculum this year. AIDS organized and planned great strides can be made. These findings will be available for the Committee.



Publications

Le SIDA, la société et le comportement
AIDS, Society and BehaviourMilieu de travail
Workplace

E.741

SIDA ET MEDIA AU SENEGAL.
Dagnelid, Bernard. Université Laval, Québec,
Canada.

Objectif. Connaître l'image que véhiculent les médias sur le SIDA au Sénégal au moment du développement du Programme national à Moyen Terme de lutte contre le SIDA.
Méthode. Analyse des articles parus dans le Soleil de Dakar, au Sénégal, de 1986 à 1988.

Résultats. Entre le moment où le Soleil tirait à la une le 20 février 1986: SIDA: AUCUN CAS AU SENEGAL, et l'article du 4 juin 1988 sur le Soleil faisant état de 64 cas de SIDA recensés au pays, l'analyse de la couverture de presse nous livre les acquiescements suivants:
- Il n'y a pas de SIDA
- Les cas de SIDA viennent d'ailleurs
- Les médias dramatisent
- Le SIDA se développe
- Les premières préconisations sont d'accord bio-médicales
- Le SIDA n'est pas la seule urgence en matière de santé.
- Il faut combattre le SIDA.
- Les dimensions psycho-sociales de la maladie.

Conclusion: L'étude comparative de la couverture de presse du SIDA en France dans le Nouvel Observateur et au Québec dans le Soleil démontre que le pattern sénégalais se retrouve dans tous les pays présentant conscience du développement de la maladie sur leur territoire.

E.742

"Asian women and AIDS - research issues"

submitted by Sana-Yuana Tsou, PhD anthropologist, UNIDA

This paper identifies research issues on "Asian women and AIDS". It points out that current Information/Education for Health strategies need to educate prostitutes and women whose AIDS are often oblivious to the main problem of women and health - women's powerlessness. Sex tourism contributes to the vulnerability of women to AIDS, particularly as many prostitutes are children. At home, women are victims of "batterer cultures" and male standard values which put them in a communications "purdah" or veil. Even when confronted with health information about sexuality, they are not supposed to acknowledge it with a behavioural change such as asking husbands to wear condoms. Efforts to mobilize women at community level can brighten the picture but these have yet to have widespread support. The paper identifies a number of research/practice issues which would help AIDS programs to support women who are struggling to lift this communications "purdah".

E.743

THE EMOTIONAL IMPACT OF NEEDLESTICK INJURIES ON HEALTH CARE WORKERS

Morris, T. MacInnes, M. Strang, G. Schlich, Walter,

Dalhousie University, Victoria General Hospital, Halifax, N.S., Canada

Objective. To determine if a needlestick injury has an adverse emotional impact on health care workers (HCW).

Methods. Self administered questionnaire at the time the employee reported the injury and a supplemental questionnaire was completed two weeks following the injury.

Results. To date 54 HCW's have been enrolled. Seventy-four percent of the injuries involved contaminated needles. Two incidents involved patients with group IV HIV infection and 2 involved patients with hepatitis B. Immediately after the injury 74% felt the risk of developing HIV infection was low. At two weeks following the injury, 48% were worried about developing an infection; 18% had lost sleep due to worry and 5% had a change in appetite. The "feeling" regarding the accident consisted of anxiety - 40%, anger at one's self - 18%, depression - 24. One person had a decrease in sexual activity and another changed her method of contraception to condoms following the injury. Eighty-two percent discussed the accident with co-workers; 53% with his/her spouse; and 5% with their family physician.

Conclusion. The preliminary results of this study indicate that needlestick injuries have a significant emotional impact on health care workers. Our data suggest that occupational health departments, in addition to programs to prevent such injuries, must recognize and deal with the emotional impact of such injuries.

E.744

TITLE: THE WORKPLACE: LARGE ADVANCES FOR SMALL BUSINESSES
Schwartz, Beverly J. Williams,
U. S. CENTER FOR DISEASE CONTROL, Atlanta, Georgia, USA

Objective. This paper identifies and discusses leverage points, motivating factors and program successful in stimulating small businesses to educate employees about the prevention of HIV.

Methods. Needs assessment surveys have been used as the basis for designing education strategies responsive to small business needs and capacities. Professional membership organizations consisting of small business owners were enlisted to assist in the development of program content, structure, and initial implementation of the project's pilot phase.

Results. The program offered unique perspectives and approaches in identifying applications to a multiplicity of organizational structures. Evaluation methodologies for program usage by employers and impact on employee knowledge level and behavior will be discussed.

Conclusion. The worksite must be acknowledged as a vital target area, and utilized as a primary vehicle for communication of adult AIDS education and prevention programs. Indeed, the development of usable programs for this population appears to be a most important step in reaching a large segment of individuals who may effectively be reached only through their place of employment.

E.745

HEALTH PROFESSIONALS' KNOWLEDGE, BELIEFS AND ATTITUDES REGARDING AIDS IN RELATION TO ANOTHER ANXIETY CINDING FOR DEFERRED
University of Illinois at Chicago, U.S.A.

Objective. The AIDS epidemic has caused considerable anxiety among health professionals. Anxiety with high incidence has reported employee loss, absenteeism by medical students of certain hospitals and/or specialities, and high employee stress every three to six years. It is important to be able to discriminate those variables associated with anxiety in order to develop effective workplace responses to reduce stress, improve quality of care and patient care.

Methods. In this study, 536 physicians, nurses and social workers at University of Illinois Medical Center were surveyed and compared to ascertain the relationship between their knowledge, attitudes, and experience concerning AIDS in relation to caring for infected persons. Knowledge about AIDS was measured by self-rated knowledge level, and actual accurate knowledge. Experience included frequency, type, and level of contact with infected persons. Attitude variables included willingness to work on an AIDS unit, treating patients on a special unit, and willingness to treat persons with AIDS. Anxiety included by worry and doubt patients with AIDS, infection through their work, and infecting their families.

Results. Overall, attitudes were stronger indicators of anxiety than was knowledge and/or experience for physicians and social workers. For nurses experience with patients was also significant.

Conclusions. Professional role and responsibility must be addressed in the workplace in conjunction with worries about AIDS in order to facilitate reduced anxiety about caring for patients.

E.746

ATTITUDES OF MEDICAL TECHNOLOGISTS TOWARDS THE ACQUIRED IMMUNODEFICIENCY SYNDROME
Rosen, James W., Penney, K. S., and Gauth, R., Boche
Mimodical Laboratories, Erie, PA, Fairleigh Dickinson
Administration Institute, Rutherford NJ, U.S.A.

Objective. To assess the degree of concern medical technologists have towards the acquired immunodeficiency syndrome. **Methods.** We surveyed attendees at the annual meeting of the NJ Society for Medical Technology held in Liberty Park, New Jersey during April 1988. The survey addressed concerns, attitudes, knowledge and practices of medical technologists with respect to AIDS. Multiple choice questionnaires (281), utilizing a Likert scale, were distributed and a 74% response was obtained.

Results. Of those surveyed, 85.4% have friends or families who expressed concern about working with HIV positive samples; 25.9% are considering leaving the profession because of their fear and/or their "significant other's" fear of acquiring HIV in the laboratory; 45.2% would not have chosen the field of medical technology knowing they would be handling HIV positive samples; 71.0% currently wear gloves after most of the time or always when handling samples. **Conclusion:** We found a high degree of concern about AIDS among technologists. This may be a factor contributing to the current personnel shortage in medical technology.

Publications


Le SIDA, la société et le comportement
AIDS, Society and Behaviour
E.747 AIDS-RELATED KNOWLEDGE, ATTITUDES AND PRACTICES OF GREEK DENTISTS

Antasia Rommelis, Kostasopoulos, J. Konstantinidis, R. and National Center for AIDS, Athens School of Hygiene, Athens Greece

Objective: To estimate knowledge attitudes and practices related to AIDS of dentists in Greece and determine responsible factors.

Methods: An anonymous questionnaire was sent by mail to a randomly selected 10% sample among dentists in Athens. Details about their demographic and scientific background, prophylactic measures during their competition and practical knowledge about AIDS were asked to be completed. Of the 349 who received the questionnaire 71.5% participated in the study.

Results: Of the participated dentists 59.4% were males, 51.5% were less than 40 years old and 18.5% admitted post graduate studies. More female (4.5%) than male (3.7%) of dentists always gloves. The use of gloves and masks was higher in dentists less than 40 years old (8.4% and 34.5% respectively) than in those more than 40 (26.3% and 18.7%). Of the Greek dentist 64.2% disinfected the high speed hand piece after treatment of every patient. Only 38.5% accept the therapy of HIV infected patients while 80.5% were well informed about AIDS.

Conclusion: High proportion of Greek dentists take precautions for themselves and their patients. Are well informed about AIDS but are not willing to therapy HIV infected persons. More education is necessary to improve their practices and behavior.

E.749 AIDS and Refusal to Work: A Canadian Experience

Thompson, Marlene Labour Canada, Ottawa, Ontario, Social Sciences and Health, Ottawa, Ontario, Canada

Objective: To describe the process of assessing refusals to work because of danger, when the danger consisted of a co-worker or client with AIDS.

Methods: Cases of refusal to work because of a co-worker with AIDS, in the Federal jurisdiction are reviewed and the ruling explained. Comparisons are made with cases in other Canadian jurisdictions.

Results: Up till now refusals to work because someone in the workplace has AIDS, have not been upheld.

Conclusion: Fear of contracting AIDS is a potent motivator for refusing to work with someone who has been infected, even when the contact with the infected person is minimal. Dissemination of information about the disease and its spread would prevent many of those incidents.

E.751 RECOMMENDATIONS FOR AN AIDS WORKPLACE POLICY

Ratoff, Lew, Gay Men's Health Clinic, New York, New York, USA

Objective: To provide suggestions for human resources policies for organizations involved in AIDS social services, research and education.

Methods: The role of institutions involved in AIDS services and research in addressing the issues of persons with AIDS in the workplace were considered.

Results: AIDS service and research organizations have the capacity and the responsibility to serve as models for employers in their communities, as well as a responsibility for the well-being of their employees. Demonstrating that persons with AIDS can and do continue to lead productive lives contributes to the creation of communities in which a diagnosed person can live fully. While difficult and costly, attention to AIDS in the workplace has important benefits for affected employees, their co-workers, the organization and the larger community. The involvement of the person with AIDS may enhance the effectiveness and sensitivity of education, research and support services. Most important, fair and effective treatment of HIV-infected employees provides a model of compassion and sensitivity.

Conclusion: Recommendations for establishing a relevant, effective PWA personnel policy include consideration of reasonable accommodations, employee benefits and the availability of support services.

E.748 A MODEL APPROACH FOR LABOR UNIONS AMID THE

HIV EPIDEMIC IN ALAMEDA COUNTY, CALIFORNIA
Informants: Frangou, Swain, E. M., Crane, B. M., Labor and Occupational Health Program (LOHP), University of California at Berkeley; East Bay AIC's Resource Organization; and Service Employees International Union (SEIU) Local 520
 *SEIU Local 616, Oakland, California, USA, **Highland General Hospital (HGH), Oakland, California, USA, ***HIV/AIDS Services Division, Alameda County, California, USA

Objective: To describe a public sector labor union's workplace efforts in directed HIV educational programs and in creating and expanding HIV services in Alameda County, CA.

Methods: SEIU Local 616 has organized a collaborative effort utilizing union, community, and county government resources to educate the county's workforce; to expand HIV clinical services; and to improve access to quality care.

Results: 1) Shop steward training in HIV transmission, occupational safety, and education/prevention. 2) Collaboration with hospital management at Highland General Hospital in training all workers regarding HIV transmission, prevention and workplace safety. 3) Organize a Gay and Lesbian Caucus within local 616 to address HIV and other issues in the workplace. 4) Political action around HIV funding allocations. 5) Establishment of HIV outpatient services at Highland General Hospital.

Conclusions: Labor unions can organize and reinforce workplace education efforts; lobby local government to support comprehensive HIV services; and provide a focus for important gay and lesbian, minority, and community concerns.

E.750 AIDS EDUCATION IN THE WORKPLACE

*Ray-Kell, L., Donner, Ann M. Seattle, King County Department of Public Health, Seattle, WA, USA; **University of Washington, Seattle, WA, USA*

Objective: To educate the King County workforce about AIDS, and to evaluate the effectiveness of this training on knowledge and attitudes.

Methods: As part of a county-wide policy on non-discrimination for people with AIDS (PWA) in the workplace, a voluntary AIDS educational was offered to all county employees on work time. The one hour sessions consisted of an oral presentation, a videotape and a question and answer period. A pre and post test was administered to the first 1000 participants.

Results: Approximately half of the 5000 persons workforce chose to attend one of the 70 presentations given in 1988. In general, those surveyed showed a high degree of basic knowledge about AIDS. For instance, over 91% answered correctly on the pre test that a person risks infection by sharing intravenous drug equipment, that women can pass the virus to male sexual partners, and that an infected pregnant woman can pass the virus to her unborn baby. Areas in which there was less knowledge included: the ability of bleach to kill HIV, the safety of sharing eating utensils with a PWA, the risk of infection from blood transfusions, and the safety of latex condoms compared to natural skin condoms. An average of 39% correctly answered these questions on the pre test. After the presentation, an average of 59% answered correctly. Those who would not work with a PWA decreased from 40% before to 24% after.

Conclusions: A one hour educational can significantly increase knowledge about AIDS and alter attitudes about working with a person with AIDS.

E.752

FEAR OF AIDS IN THE WORKPLACE
S. Francis Goodrich, D. Mathur, S. and Addy, C. University of South Carolina School of Public Health, Columbia, South Carolina, USA

Objective: To determine the level of fear and misconceptions about AIDS in the workplace.

Methods: In a major university in southeast U.S. responded to a university-wide AIDS survey. The measurement instrument used was a questionnaire with questions regarding their general knowledge and personal attitudes related to AIDS. Data on demographic information and job position were also collected. A general knowledge score and an attitude score were calculated for each subject.

Results: 31% were "very concerned" in the situation "being served in a restaurant by a person infected with the virus". 30% were "very concerned" being "near an infected person while they sneeze or cough". 24% were "very concerned" in "using an infected co-worker's personal belongings", and 22% from "drinking from a water fountain used by an infected person". Staff non-supervisors had a higher level of fear and concerns about AIDS.

Conclusions: Fear of AIDS in the workplace exists due to various misconceptions about AIDS. Extensive AIDS education efforts must be conducted to provide facts and to calm down fear and hysteria which may disrupt the workplace.



Publications

E.753 **INTV/AIDS AND INTERNATIONAL ORGANIZATIONS: A STAFF AND DELEGATE HANDBOOK**

Editor: Nancy L. American Red Cross, Los Angeles Chapter, 8700 Wilshire Boulevard, Los Angeles, California 90057, U.S.A.

Objective: To describe the process and present a sample of the result of development of a multinational HIV/AIDS basic education and anti-discrimination pack for use by international organizations.

Working in the Secretariat of the League of Red Cross and Red Crescent Societies in Geneva, and in cooperation with WHO, the author has involved League staff members and staff from other Geneva-headquartered non-governmental organizations to develop an appropriate educational programme for staff members and field delegates in international service.

Results: The resulting pack includes a self-questionnaire, scripted slide presentation, case studies, questions on non-discrimination, interviews with persons undergoing the HIV test in Geneva, resource list, workplace HIV bibliography and the newly-developed League HIV/AIDS policy for the workplace.

Conclusion: League of Red Cross and Red Crescent Societies has a tested programme designed to help staff and delegates work appropriately with HIV issues in their workplaces and prevent HIV/AIDS-related discrimination.

E.754

[Empty table with 10 rows and 1 column]

E.755

[Empty table with 10 rows and 1 column]

E.756

It's Your Job: A Three-Part Plan To Control Infectious Diseases

Miller, Dr. E. Harry
Director of Education, Fredericton, New Brunswick Canada

Objective: To explain how a school system has informed employees of the basic public health principles that govern infectious disease control in schools.

Methods: A sixteen page brochure has been prepared for all school board employees. It provides specific direction under such headings as How Should I Deal With AIDS in the Classroom?, How Can I Protect Myself Against AIDS?, What You Don't Have To Worry About.

The document provides a model for any school system that is concerned about providing accurate information to their employees. The publication has been endorsed by the Canadian Public Health Association. The publication will be available in limited quantity.

E.757

THE SAFE HANDLING OF HIV-POSITIVE BIOLOGICAL FLUIDS IN THE ANALYTICAL CHEMISTRY LABORATORY

P.A. Lewis and D.B. Garcia, Reston Corporation, U.S.A.

Although biological fluids have long been handled in the analytical chemistry laboratory, official guidance relative to their safe handling have only recently been disseminated by the U.S. Occupational Safety and Health Administration (OSHA).

While the possible exposure to biological agents has always been present, greater concern has surfaced as a result of the AIDS epidemic. Further, the need for analytical chemistry laboratories to handle biological samples from AIDS clinical research trials presents a special case since all samples are known to be HIV-positive. Presently there is much reluctance by laboratories capable of conducting drug disposition studies to handle known HIV-positive samples and thus we have designed containment facilities and developed standard operating procedures (SOPs) for these activities. The containment laboratory used for this activity operates under negative pressure and is governed by a series of SOPs. The SOPs address the following activities:

- General work practices, policies, and procedures;
- Packaging and transporting of specimens;
- Receipt and transfer of specimens to sample control;
- Sample log-in and storage;
- Laboratory clean-up, decontamination, and disposal;
- Emergency procedures for surface spills and personal contamination; and
- Decontamination of biological waste.

In addition to the general SOPs above, a safety protocol relative to the specific analytical procedure to be performed is formalized. This protocol focuses on possible hazards peculiar to the analytical procedure.

E.758

THE IMPACT OF AN AIDS EDUCATION PROGRAM IN THE WORKPLACE

University of South Carolina School of Public Health, Columbia, South Carolina, USA.
By: Franciscano, Richter, Mathur, S and Addy, C.

Objective: To measure the effectiveness of an AIDS education program for employees in a university workplace.

Methods: A university-wide AIDS education program was implemented in a major university in southeast U.S. from January-May 1984. 596 employees, grouped according to their job positions, attended two-hour AIDS education sessions conducted by a medical epidemiologist and a health educator. Pre and post test questionnaires, consisting of knowledge and attitude questions, were completed by the participants. Pre and post test scores were calculated for each employee. Data were analyzed using the chi-square test, paired t-test, and ANOVA.

Results: Before the educational program, the mean knowledge score was relatively high. There were misconceptions regarding the cause, cure and transmission of AIDS. Many employees were concerned about getting AIDS in low or no risk situations. After the program, there was statistically significant improvement in both knowledge and attitude scores of the employees.

Conclusion: This AIDS education program in the workplace was found to be effective with improvement in both the knowledge and attitudes about AIDS among the employees.



Publications

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

E.759

Blood Control in Brazil

Jurberg, Claudia; Galvão, Bernardo; Silva, Edmilson*
Oswaldo Cruz Foundation, Rio de Janeiro, Brasil

Objective: To realize an analysis, together the Brazilian authority government, the population and together the press in general, about aids transfusional Brazilian situation. What is the government actuation? The Brazilian press contributed with the elucidation the problem? And the population have conscience the important of voluntary blood donation?
Methods: It is an work of scientific journalism with objective is, through interview with authority government, scientist, technical science, journalist and the population, establish the blood control situation in Brazil, during a period.
Results: A new Brazilian constitution, promulgated in 1988, prohibit a blood sale, but any government measure will be realize. The blood have been selling and the Brazilian population ignore the danger with blood transfusional.

E.761

A MODEL OF COMMUNITY SUPPORT FOR PEOPLE WITH HIV DISEASE
Mergles, E.*; McKenna, P.**; Kohl, J.**; Lemire, L.*; W. Turner, R.*. *Coordinator, AIDS Community Care Montreal (ACCM), ** Administrative Council, ACCM, QMADA

Objective: To provide community based, psychosocial and practical support to people affected by HIV.
Method: Developing, writing and publishing a comprehensive layman's guide to coping with HIV related conditions. Providing one to one support by trained volunteers, counselling, self help support groups, an information library and emergency financial assistance.
Conclusion: This type of support is beneficial and helps people cope both physically and emotionally with HIV related illness.
Results: We maintain an average of twenty clients at a time, indicating a strong need for this type of program.

E.763

DIFFERENCES IN AIDS RISK ASSESSMENT (ARA) COINCIDING BEHAVIORS OF PRIMARY CARE PHYSICIANS IN COSTA RICA AND HARRIS COUNTY, TEXAS

Cavallini, John Velasco, C. Luzz, L., Arrufin, J. and Thornley, J.
 Baylor College of Medicine, Houston, Texas, USA.

Objective: To assess whether there are significant differences in attitudes and ARA/counseling behaviors of Costa Rican and Harris County physicians.
Method: In this study, we obtained responses from 48 Costa Rican physicians at a medical conference to questions we had previously used to assess the ARA/counseling behaviors of physicians in Harris County Community Health Centers. The questionnaires were translated into Spanish by one of the co-authors who attended the meeting. These responses were compared to the responses of 47 primary care physicians from the health centers using the general linear model program of SAS.
Results: Significant differences ($p < 0.05$) were found on 22 of the 43 questions. Costa Rican physicians report being more comfortable asking patients about their sexual preferences and practices and that they counsel patients on how to reduce their risk of AIDS at a substantially greater rate than Harris County physicians. Costa Rican physicians also report feeling more responsible for ARA/counseling.
Conclusions: There are cultural differences in physicians behaviors and attitudes about sexual and drug history taking and counseling which may reflect differences in medical training as well as cultural differences in attitudes about appropriate physicians behavior.

E.760

DEEP REEVALUATION CASE REPORT: THE CASE OF GENICLOVIR
Eliou, James; Long, J.; Harrington, M.; Pomarato, M. AIDS
Coalition to Unleash Power, New York, New York, USA.

Objective: To evaluate flaws in the current drug approval process in the U.S. through analysis of the "genocivir" story.
Methods: An analysis of all the anti-cytomegalovirus (CMV) genocivir protocols, of published data on genocivir and of the minutes of the Food and Drug Administration (FDA)'s Anti-Infective Drug Advisory Committee and interviews with ophthalmologists and people who have CMV. Results: In October 1987, the FDA's Anti-Infective Drug Advisory Committee, ignoring the advice of its two ophthalmologist members, voted to recommend against marketing approval for genocivir to treat CMV retinitis in immune-suppressed people. It did so even though evidence gathered under a "compensatory use" protocol showed genocivir to be as effective as improving CMV retinitis, which is a severe progressive disease that leads to blindness in nearly 100% of untreated patients. The vote, in effect, mandated a controlled clinical trial to establish the drug's efficacy. The trial began in January 1989.
Conclusion: Genocivir, proven effective against CMV retinitis, should have been approved in October 1989. Efficacy trials for a drug that has been proven effective waste resources, put patients at indefensible risk, and limit access to an effective therapy.

E.762

SIDA ET SOCIÉTÉ: RÉFLEXIONS SUR LA PRATIQUE ANTHROPOLOGIQUE INTERNATIONALE
Bismont, Jacques Brunerfat

Introduction: Les réflexions sur la pratique des anthropologues s'inscrivent à la situation critique causée par le développement du SIDA.
Méthode: Observation-participants dans des congrès scientifiques, des séminaires entre collègues et des recherches sur le terrain en tant qu'individu et chef d'équipe.
Résumé: La crise du SIDA offre aux anthropologues un terrain privilégié pour avancer la production des connaissances. On y mène des recherches sur le processus des changements sociaux, les rapports entre la maladie et la société, l'économie politique et les modes et tenter de nouvelles approches méthodologiques. Certains entendent contribuer à la recherche des solutions aux problèmes de prévention. D'autres seient consacrer leurs recherches de base ou d'application, les recherches sur le SIDA présentent une série de contradictions qui soulèvent des problèmes de méthodologie et de responsabilité professionnelles.
Conclusion: La pratique de l'anthropologie est une action sociale par excellence qui met les chercheurs devant des choix parfois difficiles et mène à des réflexions critiques.
Mots-clés: épidémiologie, responsabilité, réflexivité, anthropologie.

E.764

IMPACT OF A SLIDE ASSISTED PRESENTATION ON THE KNOWLEDGE ABOUT HIV-INFECTION IN INSURANCE EMPLOYEES
Eissel, Suzanne, Bismont, Jacques, Long, J., Retouche, A., Harlow, B. and Gossel, P.D. Medizinische Fakultät der Universität

Montreal, Quebec, Canada
Objective: To assess the present knowledge about AIDS in insurance employees and to investigate the effect of a single educational talk.
Method: A questionnaire with 10 questions concerning AIDS was filled in by 192 insurance employees before and after a slide assisted presentation on relevant items of HIV transmission. The results were compared by χ^2 test.
Results: 190 and 185, respectively, of the questionnaires were returned. The percentage of wrong answers before and after (X²) the presentation were 1. You can get AIDS being in the same room with a person with AIDS (1/1) BE. 2. AIDS has been transmitted through sharing office equipment (3/0) BE. 3. The virus which causes AIDS has been transmitted through saliva (5/7) p < 0.001. 4. AIDS is transmitted by sneezing (2/1) p < 0.01. 5. AIDS is an easily transmitted disease (21/8) p < 0.001. 6. There are reports of casual transmission of AIDS to family members who are not sexual partners of people with AIDS (31/3) p < 0.01. 7. People can look and feel healthy and still transmit the virus (10/7) BE. 8. If you inject drugs with your own needle and never share it you cannot get AIDS from shooting drugs (14/7) p < 0.05. 9. You can get AIDS from donating blood (46/16) p < 0.001. 10. There is a vaccine to prevent AIDS (10/10) BE.
Conclusion: There is still a considerable lack of information even among educated middle class people. Slide assisted presentations may have a significant impact on the knowledge about HIV transmission.



Publications

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

E.705 AIDS AS A PROCESS
Cordero, F.; Coronado, A., Arredondo, C., Gil, E.,
Ministry of Health, Spain.

Objective. AIDS is not a unique and irreversible fact, but rather a process in which society as well as the individual can and should participate.
AIDS is a "relatively controllable process" in which the attitude of the subject and society are the key for combating and preventing the possible development of the syndrome, and thus "give time" (a variable fundamental in the process) for science to find more efficient solutions than those that already exist.
Conclusion. AIDS as a process allows us to define the stages and aspects of the disease over which science already has knowledge and answers to those others that are still being investigated, which would permit public opinion to regain its confidence in scientific discourse.

E.706 THE DOUBLE CONTAGIOUSNESS PHENOMENON: FROM SEROPOSITIVITY TO PSYCHOPOSITIVITY
Cordero, F.; Coronado, A., Arredondo, C., Gil, E.,
Ministry of Health, Spain.

Objective. As can be seen from the analysis of the attitudes the population carried out by means of representative surveys, we are confronted by a dual "contagiousness", the most important from the point of view of the development of the disease, which must be fought by science and healthy education. But, on the other hand there also exists the "psycho-social-contagiousness" of fear, of irrational attitudes, that lead to segregation and social racism. Eliminating this phenomenon is fundamental to be able to cope with the disease and develop information campaigns (prevention) which upon now have been the only real means of fighting this problem.
Conclusion. The report develops the concept of "psychopositivity" (fear, rejection, isolation...) as one of the major sources of difficulties in the fight against AIDS. Psychopositivity creates "regression", which leads those affected to turn their backs on the health system, to hide themselves to avoid greater complication, to look for parallel solutions, to not take care of themselves, to abandon the system, all of which are negative for themselves as well as for society.

E.707 ACCEPTANCE AS A PRE-CONDITION FOR AIDS-PREVENTION AMONGST
I.V. DRUG USERS

Dr. Ingo Michels, Deutsche AIDS-Hilfe e.V., Nestorstraße 9-9,
D - 1000 Berlin 31

There is at the moment no data for the prevalence of HIV that is accurate because the necessary scientific and social network is missing. Also there are no uniform standards for the determination of regional differences in respect of the first appearance of HIV, the methods of application of illegal drugs, different needle-sharing practices, varying levels of availability of sterile needles and syringes and condoms, scantest information on the sexual behaviour of i.v.d.u. etc. The existing studies amongst groups in prisons, treatment centers and hospitals indicate an increased incidence which threatens to increase if the necessary preventive measures are not provided and carried out expeditiously. The Deutsche AIDS-Hilfe calls for the de-institutionalization of those affected, the development of low threshold treatment opportunities without therapy and substance demands, subsequent professional support with adequate financing, needle-exchange programs and distribution of condoms (also in prisons). Further no forced testing in the granting of places in drug rehabilitation, controlled substances with methadone for those i.v.d.u. at risk of infection along with those already HIV-infected or suffering from AIDS and the incorporation of a care-dimension for HIV-infected and AIDS-ill persons, d.o. into the existing therapy programs including a possible personal care until death. The Deutsche AIDS-Hilfe calls in answer to the often catastrophic state of health of i.v.d.u., estimated between 80,000 and 100,000 of which probably 30% are already infected. A call which must be followed by a sense of humanity which will defend against alienation and stigmatisation.

E.708

E.709 "EDUCATION ABOUT AIDS" COURSES, VICTORIA, AUSTRALIA
Giles, Ian; Jones, J.; "Glover, D." and Lewis, P.,
Health Promotion Unit, Health Department Victoria, Melbourne, Victoria
Australia, **Social Biology Resources Centre, Melbourne, Victoria, Australia,

Objective. To evaluate the impact and outcomes of a series of 6 day multidisciplinary AIDS education programs designed for health, welfare and educational professionals.
Methods. Various tools have been used to evaluate these courses. These include knowledge and attitude questionnaires as well as in depth interviews with selected course participants.
Results. In the period June 1985 to December 1986 16, 4 day "Education About AIDS" courses have been held in both country and metropolitan regions of Victoria. Over 540 people have completed these courses; the participants coming from a wide range of health, welfare, education and community groups. Knowledge about AIDS has been shown to improve significantly during the duration of the course (approximately 6 weeks) and is maintained at these levels 3 months following completion. Participants report that they are more comfortable and confident in communicating with others on AIDS and issues of sex and sexuality. Course participants have shown skills in undertaking many AIDS initiatives e.g. policy development, educational sessions and community education on employment issues. Participants show a positive attitude to needle sharing, in relation to AIDS related issues. v.g. towards people infected with HIV and IV drug use issues. **Conclusions.** These training programs have been shown to have a major impact on AIDS awareness and prevention activities in the state of Victoria.

E.770 EN MILIEU DE PREVENTION

Uladis Vaidas, World Health Organisation
Regional Office for Europe/Copenhagen-Denmark
Paris, France

-Afin de pouvoir prendre une décision responsable et avertie, nous avons besoin:

- De connaissances sur le comportement sexuel sain qui implique des choix et des responsabilités.
- D'une éducation sexuelle efficace qui est saine, réaliste, pragmatique, non moraliste, éducation qui valide la sexualité comme un aspect positif de la vie, qui réduit la peur, donne des informations claires et honnêtes et qui met l'accent sur les pratiques sûres d'être sexuel et offre des comportements alternatifs à considérer.

- Souligner, dans la transmission des messages efficaces pour les relations sexuelles saines, l'importance du langage utilisé, d'attitude réceptive, de qualifications interpersonnelles et de communication.

- Viser dans les programmes d'enseignement des pratiques sexuelles saines dans toute la communauté des différents groupes de la population, utiliser différents types d'information selon le groupe et préparer des solutions éducatives ou de précautions nécessaires afin de limiter le nombre de personnes infectées et de réduire les conséquences de l'infection.



Publications

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

- E.771** PROBLEMS IN THE INTERFACE BETWEEN THE MEDICAL TREATING SYSTEM AND THE PATIENT/FAMILY SYSTEM
Peter John
The Ackerman Institute for Family Therapy, New York; New York, USA
- Many medical management problems occur in AIDS patients because of poor relationships between patient/family and the medical system (doctors, social workers, nurses, administrators, etc.). The Ackerman AIDS Project, by using psychotherapeutic and educational techniques with many individuals, couples, and families and members of the medical systems, has been able to show improvement in these relationships. For instance, many individuals, families, and health care workers believe the equation AIDS=DEATH. This is in spite of AIDS being seen by the writers and by many members of the medical community as behaving more like a chronic illness. When patients' and families' percepts of AIDS has been psychotherapeutically shifted from FATA, to CHRONIC, they feel and act more hopeful; they are likely to be more compliant to treatment protocols and to take better care of themselves. Normal activities of living can be resumed once the illness is seen in a different perspective. Patients and families often feel empowered to ask more questions of the medical treating system and to be less passive about their illness. To create a shift in perception, we must place emphasis on basic information and education about AIDS. Ignorance and misinformation about the disease, anxiety, isolation, and guilt that surround AIDS make education about everything from testing to treatment essential. It is a time-consuming, repetitive process which requires a high degree of expertise.

- E.773** INNOVATIONS IN AUSTRALIAN NURSING
Barbara Joy
Private Palliative Care Services Pty Ltd, Adelaide, South Australia, Australia.

This paper traces the growth of an Australian nursing innovation: a professional service to meet the needs of those suffering a life threatening illness. Private Palliative Care Services Pty Ltd (PPCS) was created to provide a health care option for individuals wishing to live in ways that are personally meaningful and significant. Professional nurses assessed by PPCS practice as private primary nurse practitioners in meeting the physical, intellectual, emotional and spiritual needs of patients. A key feature of their practice is third party reimbursement from a major private health insurer in the form of a Palliative Care Benefit. The development of the Company required considerable effort and expertise. Professional and political lobbying at a range of levels was necessary to ensure a legitimate place in the health care system along side well established public systems. On going education programs provide support for the palliative care nurses as well as necessary revenue to meet office expenses. Details of Company structure, cost effectiveness and the practicalities of establishing a private nurse practice are discussed. It is believed that the PPCS model of practice holds international potential and interest for nurses.

- E.775** PSYCHOLOGICAL SUPPORT SYSTEM FOR PEOPLE WITH HEMOPHILIA AND HIV IN THE FEDERAL REPUBLIC OF GERMANY

Jan Schäfer, Herbert Specht, Deutsche AIDS-Hilfe e.V., Nestorstr. 8-9, 1000 Berlin 31, West-Germany

Objective: To develop new and practical educational counselling strategies and support systems for hemophiliacs in the FRG. Methods: In cooperation with the Hemophilia Treatment Centres (HTCs) Deutsche AIDS-Hilfe and hemophiliacs with HIV regular meetings were held to design a concept for support system. Results: Although 50-80 of the estimated 8,000 hemophiliacs in West-Germany are HIV-antibody-positive the lack of a non-doctors controlled support system became evident. There is a need for self help groups to talk about social and sexual problems in an open private atmosphere without a doctor's guidance. Conclusion: The hemophilia support system should be utilised from medical treatment centers. The existing network of 80 local AIDS help groups in the Federal Republic can offer the limited number of hemophiliacs the infrastructure for non-therapeutic and interpersonal self-help groups. More data will be presented at the conference.

- E.772** PRIMARY HEALTH CARE FOR HIV-INDUCED HEROINE
Kirschbaum, David; Ely, J. and Long, J. AIDS Coalition to Unleash Power, New York, New York, U.S.A.
- Objective: To discuss the availability of primary care (baseline health care) for HIV-infected people.
Methods: We interviewed physicians, researchers and government officials and analyzed data on trial enrollment and epidemiology.
Results: Our research indicates that there is a two-tiered health care system in the U.S. Some patients with economic resources receive primary care consisting of regular medical visits, AZT and PCP prophylaxis. A second group, economically deprived, receives little or inadequate primary care. Participation in clinical trials is generally restricted to those who have received primary care. We will focus on the obstacles to obtaining treatment in New York City as a specific example. Conclusion: The U.S. government should be meeting a standard of baseline health care for all HIV-infected people, consisting of regular medical visits, AZT and PCP prophylaxis. In addition, the government should rigorously enforce equitable access to trials.

- E.774** Culturally Sensitive Care at Minimal Cost Through In-Home Health Attendant Care.
Shirley L. LPA, APA, CST*, Addison, Constance**
*California State University, Hayward, California, USA, **San Francisco State University, San Francisco, California, USA
- Objective: Providing optimal, culturally sensitive care at minimal cost to People of Color and Others with AIDS.
Methods: Use of in-home, hand-picked and trained home health attendants within a system of comprehensive case management offers cost effective care in a setting where quality care can be assured/insured. An interdisciplinary team consisting of program director, nurse case manager, social worker, home health coordinator and attendants provides a higher morale and more continuity of care than case management where services are "farmed out." Data collection regarding time and costs can also be monitored more effectively when most services are in-home.
Conclusion: As care for AIDS clients becomes increasingly costly and draining, the in-home home health attendant model adds greatly to team spirit while cutting costs so that more clients may be helped. The MBA program, overseen by an interdisciplinary team, is very effective in providing quality, culturally sensitive care to minority AIDS/ARC clients. Results: More clients are seen; costs are minimized; morale is enhanced.
- | Table of Conference | Number of Participants |
|---|------------------------|
| 1 People of Color Conference, Sacramento, CA | 450 |
| 2 Life Foundation, Hawaii | 1500 |
| 3 National AIDS Network, Washington, D.C. | 1500 |
| 4 2nd National Conference on AIDS, San Francisco 1989 | 1500 |
| 5 Centers for Disease Control, Washington, D.C. 1990 | 1500 |
- Monterey, CA

- E.776** DISCRIMINATION OF MALE AND FEMALE PROSTITUTES UNDER THE ASPECTS OF AN INCREASING SOCIAL CONTROL IN THE CONTEXT OF AIDS.

Micela Rippe, Deutsche AIDS-Hilfe e.V., Nestorstr. 8-9, 1000 Berlin 31, West-Germany.

Objective: In order to fight against prejudice prostitution must be prohibited as a normal profession and the health consciousness amongst prostitutes must be clearly shown.

Methods: The experiences of all organizations of Federal prostitutes are to be taken into consideration including the evaluation of existing results on voluntary and compulsory HIV-tests as well as the numerical development of sexual transmitted diseases in the years 1985 to 1987.

Results: Prostitutes cannot be considered a relevant group for the transmission of HIV-infections and further sexual transmitted diseases. Male and female i.v. drug users who get their money for drugs by prostitution do have other living conditions.

Conclusion: A precondition for the stabilization of the health status of prostitutes is the acceptance of prostitution as a profession of one hand and a continuous information and education of the male population about the necessity of safer sex on the other hand.



Le SIDA, la société et le comportement AIDS, Society and Behaviour

E.777

LE SIDA, UN PROBLÈME DE TOUTES
AMÉRIQUES, MÉTRIC : Nougradd, B.
Comité Ciudadano Anti-SIDA de Madrid/SPAN

Objectif. Définir les stratégies des organisations non-gouvernementales et des mouvements sociaux, face à l'information et prévention du SIDA.

Méthodes. Les expériences dérivées des activités quotidiennes du Comité Anti-SIDA de Madrid, à travers les programmes d'information, des conférences, des colloques, des soins directs avec les porteurs, malades et sujets que leur comportement rend vulnérables à l'infection à VIH.

Résultats. Après deux ans de l'expérience acquise après cinq ans d'existence, on a constaté la prise de conscience de la population, les changements d'habitudes, des soins sanitaires plus attentives; mais encore on peut rassembler des situations de discrimination et refus à l'égard de personnes infectées par le VIH ou soupçonnées de l'être.

Conclusions. Les mouvements sociaux contre le SIDA en Espagne ont joué un rôle très important pour éviter la progression du virus et pour assouvir cette maladie comme une simple maladie, sans aucune autre connotation.

E.779

AIDS PATIENTS AND THE USE OF ZIDOVUDINE HIV DRUG THERAPY
IN COMMUNITY CENTERS OF CANADA
Jackson, J. and Fleming M.*
Toronto General Hospital, Toronto, Canada

Objectives. To examine the relationship between patients' involvement with AIDS community organizations and the use of experimental drug therapies obtained outside of the country.

Methods. Semi-structured interviews were carried out with 25 AIDS patients in three major centers in the province of Ontario.

Results. Of the 25 AIDS patients interviewed, 7 are/are have been involved with obtaining experimental HIV drug therapies from outside of Canada. All 7 patients are gay men but only 4 are (or were) actively involved with AIDS community organizations, and 3 are knowledgeable of the activities of such organizations although they are not actively involved. 6 of the 7 patients indicated that their physicians recommended seeking drug therapies from outside of the country, seven of the 25 patients interviewed are gay men who are actively involved with AIDS community organizations. Of these only 4 have obtained drug therapies from outside of the country. One has chosen to be "drug free" against the strong recommendations of their physicians.

Conclusions. There is no necessary relationship between patients' active involvement with AIDS community organizations and obtaining experimental HIV drug therapies from outside of Canada. Preliminary research indicates that a combination of factors including knowledge of AIDS community organizations' activities and physicians' recommendations play a role in determining patients' involvement with such drug therapies.

E.781

PROGRAMME OF ASSISTANCE TO RELATIVES OF PATIENTS CARRIERS OF HIV
IN PORTUGAL. P.F. WELLS, A. BUCHS, M. DE
TANZI, P. E. - Hospital e Maternidade Ceão Piêrro de Pontifícia Universidade Católica de Campinas-S.P.-Brasil.

OBJECTIVE: This programme of assistance to relatives of patients carriers of HIV in the Infectious Disease service of HMC-FUCAMP.

METHOD: We ring of groups of relatives with multidisciplinary team that takes part of physicians, nurses, psychologists and religious, aiming to give support and technical and psychosocial explanations.

RESULTS: 1. For the professional team, the confrontation with relatives diverted responsibilities and alleviated the anxiety that the professional AIDS includes. 2. We succeeded with the patient to the familiar environment, extending the acceptance initially found in the multidisciplinary team. 3. We observed wide interest of the relatives in discussing and assimilating the AIDS question.

CONCLUSION: This meeting results in gains for the relatives, patients and principally for the multidisciplinary team. We think, therefore, that such event could extend to the community in general (Public Health Centers and District Entities).

E.778

MODEL PROGRAM: COLLABORATION OF PRIVATE AND PUBLIC HEALTH
SYSTEMS ON OUTPATIENT SERVICES
LITVINSON, RADIN M.* Rosenthal Susan*, Rosenber,
Ellen*, Ernst, Jerome R.S.P., Bronx-Lehman Hospital Center, *New York
City Department of Health.

Objective. To link two (2) separate health systems centered around AIDS care in the South Bronx.

Methods. The majority of AIDS patients served by Bronx-Lehman Hospital Center are primarily IVDA's and homeless. The hospital has established an active outpatient center to manage these patients after hospital discharge. The Department of Health New York City has begun an active anonymous counseling and testing program for self-referred clients. A testing center has been set up in the same building as the hospital's AIDS clinic. With the opening of this center talks were begun between the Commissioner of Health's staff and hospital's AIDS Team with the goal of presenting duplication of services and thereby, identify gaps in services and the development of needed services.

Results. Close collaboration with Health Department clients who test positive are immediately seen at the hospital's AIDS Clinic for followup medical care. Clinic patients, referred from hospital outpatient centers are referred to City Site for HIV testing and counseling. This program has functioned over six months. Approximately 100 city referred clinic patients have been seen in the hospital clinic and 200 have been found to have reduced immunity.

Conclusion. Close collaboration between private and public sector is working in this linkage in the South Bronx.

E.780

THE STOCKHOLM MODEL - INFORMATION STRATEGIES AND CAMPAINS TO
SUPPORT THE COMMUNITY INTERVENTION WORK.
App. Anna-Martin, Stockholm County Council Aids Prevention Project

Objectives: To let the information unit within an aids prevention project support, facilitate and guide the work with community intervention. A close collaboration between information service and aids prevention work.

Methods: To put an information unit with educated people within a health education project and work close together. The information unit supports the people in the project who work with our four main target groups: young people, health and medical staff, immigrants/refugees and homo- and bisexual men. The information unit leads the project going by giving services through our information centre to all the 5,000 people that we have educated within the project. We provide them with brochures, videos, books, exhibitions. We run seminars to keep their interest on top. We produce a paper "Tajpall". We formulate the messages and advertise in newspapers, local papers and we organize public activities.

Results: To let an information unit work directly within a project makes the projects message more clear and makes the needs of information strategies more clear. The project can very quick get an answer on what is possible to do regarding to information strategy. It also facilitates and guides the long-term work with community intervention work. We have within one and a half year reached 5,000 people which we now provide with all kind of information at our information centre.

E.782

Fluoresc. Prototype, Organizational and
Law Sheet.

Sandwal, Chris. - Shanti Project California, U.S.A.

OBJECTIVE: How to empower human beings with the optimum measure of life while facing life-threatening extinction through AIDS.

METHODS: Shanti Project grew out of the Apollo II mission which put the first man on the moon. Apollo II individually worked at peak performance to exceed all notion of human expectation.

Both Apollo II and Shanti Project evolved experientially without a prototype. At Shanti the experience of AIDS became the teacher while the caregiver and the cared became the pupils.

CONCLUSIONS: What people learned experientially in their quest to go into outer space gave permission to those same people to go into the inner space of human feelings which peaks in the final stage of human maturation, prior to life transition.

RESULTS: Civilization and its institutions attempt to limit the expression of human emotion with the institutions of family, faith and community. In the final analysis it is human emotion which allows people with AIDS to face the saturation of their lives.

Publications

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

Divers

Miscellaneous

E.801

VIDEO FILM SCREENING — ALICIA
Alicia, Rebecca S.

National Institute on Drug Abuse, Rockville, Maryland USA

The National Institute on Drug Abuse announces the availability of a video produced by the Latino Community/ETC in Los Angeles through a NIDA grant with the Georgetown University Child Development Center. Alicia is a dramatic portrayal of a woman who learns that she and her child test positive for the human immunodeficiency virus (HIV). In an emotional scene she confronts her husband about his drug using behavior which caused the HIV infection. The meaning of HIV, AIDS, and modes of transmission are described in a clear, concise manner. The videotape is produced in Spanish. Drug counselors and health professionals can use the videotape to educate Hispanic women and men who are at risk for AIDS because they are sexual partners of intravenous drug abusers or are drug abusers themselves. The videotape comes with a leader's guide and can be used as a "trigger" film to stimulate discussion about AIDS. The videotape is for adult audiences and is not appropriate for school prevention programs. The videotape is 20 minutes long.

E.802

POTENTIAL RISKS OF ULTRAVIOLET RADIATION (UVR) IN HIV INFECTION.
FARIZ, Peter, J., D.O.I., Memorial Hospital, MOONSHIRE, U.K.

OBJECTIVE: To determine the differences in recreational UVR exposure and the knowledge of its effects in HIV seropositive and in those not at risk of HIV in the light of reports that both DNA/UVB radiation are immunosuppressive and that UVR can activate HIV expression.

METHODS: Questionnaires were answered by 58 male homosexuals seropositive for HIV (11 with AIDS or ARC) and 51 controls matched for gender but not from an at risk category for HIV infection. Skin type was assessed from reported response to UVR.

RESULTS: Skin type and mean age did not differ between groups (HIV positive, 26.6 years; controls 24.8 years). HIV positives had significantly greater regular annual or solarium exposure than controls (20.7h vs 6.5h, p<0.05) and greater exposure to natural sunlight sufficient to tan or burn the skin over a 4 year period (11.5 weeks vs 3.3 weeks, p = 0.06).

CONCLUSIONS: Knowledge of the harmful effects of UVR was similarly poor in both groups ("personal health improved": 64% vs 57%; "immunity improved": 71% vs 23%). Only 60% of HIV positive and 53% controls thought UVR exposure could cause skin cancer. 65% of HIV positive also thought UVR exposure could improve the outcome of their HIV infection.

CONCLUSIONS: Knowledge of the harmful (photocarcinogenic and immunosuppressive) effects of UVR is poor. Greater exposure among HIV positive may partly be due to misconceptions that it might improve health and the reduction of HIV infection. HIV positive should be warned to reduce unnecessary UVR exposure in view of the theoretical risks involved.

E.803

INFORMATION, PREVENTION, EDUCATION ETABLIR UNE THEORE PREALABLE
A L'ETABLISSEMENT DES STRATEGIES DE SANTE PUBLIQUE
FERRAZ, J.J. Bello, P. Paris, France

PARC/SA/SDA "Institut Pasteur, Paris, France

OBJECTIF: Affiner et renforcer les actions et les politiques des organismes non gouvernementaux. **METHODE:** Informations détaillées des demandes, analyse permanente des données, suivi, interview. **RESULTATS:** Analyse de la situation française de 1985 à 1989 révèle une évolution: une absence de volonté politique, de moyens et de contrôle dans la prévention du SIDA, un système palliatif fondé sur le médecin, sans évaluation préalable, et évaluation publique des résultats; une certaine généralité entre les causes des formes infectieuses, prévention, succès, formation, et éducation. Une évaluation régulière des demandes formulées et des besoins ne permet pas de définir une stratégie et d'adapter clairement, dans partie information, éducation, et distribute selon une hiérarchie verticale (médecin/patient, parents/médical, professeur/élève, pharmacien/clients, etc.) et d'autre part la prévention, c.à.d. un ensemble de savoirs, de techniques, de comportements, partagés par des individus en situation d'égalité (étudiant, couples, classes scolaires, membres d'associations, groupes sociaux, etc.) Dans ce cadre, la formation et l'évaluation relevant de demande générale de l'information, même si l'évaluation peut utiliser des techniques photographiques tendues sur l'échiquier.

Les difficultés de faire passer effectivement des informations, et contenues une charge cognitive liée à la mort, et des messages de prévention liés à la gestion du plaisir et à la vie, rencontrent de fortes résistances. Elles rattachement à la fois le passage de l'information, et l'acceptation de comportements de prévention, que la réduction des "campagnes de prévention" à la publicité pour les préservatifs ne favorise pas en plus la prise en compte de ces difficultés à penser à l'PARC/SA/SDA affiner son action. Les données se sont après difficiles, et l'efficacité des documents ne des interventions apparaît réduite. **CONCLUSION:** La certification des notions d'évaluation de prévention semble, en France, être un préalable à toute campagne réussie ou stable.

E.806

EDUCATION, INFORMATION, COMMUNICATION

MARY F. OWON, OJO UNICOR, UDAHARA, P.O. BOX 7847, KAMPALA, UGANDA

BACKGROUND

AIDS was identified in Uganda in 1982. The National AIDS Control Programme was formed in 1985. In May 1988 the National School Health Education Programme, Ministry of Education, introduced a Primary Science syllabus with UNICEF assistance with AIDS as one of its topics under STD. This syllabus was designed by an internationalist Panel formed in 1985. A new science in Secondary schools was organized because of the great threat of AIDS to young people in Uganda. Doctors and Educators were identified and trained in each District. From March 1988 the trained teams have been going around schools educating children and the community about AIDS.

METHOD

For each session a talk, illustrated with visual aids is given on History, Statistics, Modes of transmission, Socio-economic implications, Myths and misconceptions, available tests and Prevention of AIDS, followed by a question-answer discussion period.

IMPACT AND CONCLUSIONS

By face-to-face interaction the teams are able to communicate information that the students had not received through other channels and correct misconceptions. It seems that there is a real breakthrough in the fact that many students and the community feel free to discuss sensitive sexual issues openly. Communication between children and parents in the area of education. These were quite improved. By March 1989 the Programme will have introduced in all 24 Districts comprising of 1000 Primary and 600 Secondary Schools. Over 1,000,000 people have been made aware. The School AIDS Education Programme is being very well received throughout the country.

E.804

E.806

KNOWLEDGE, PERCEPTIONS AND ATTITUDES CONCERNING AIDS AMONG UNIVERSITY STUDENTS/STUDENTS FOR AN EDUCATION PROGRAM.
Wesley, J. Lewis, L., "Madame Barbara, Wesley H.", (Paris, Wesley A.), UNIVERSITY HOSPITAL, FEDERAL UNIVERSITY OF RIO DE JANEIRO.

OBJECTIVE: To provide information for health educational program based on real status of knowledge, perceptions and behavior related to AIDS among university students.

METHODS: Four hundred students of the Rio de Janeiro Federal University were interviewed and answered 41 questions each one. To analyze the results, chi-square, t-test and higher correlations were inferred from these questionnaires with stronger associations. Finally, the epidemiological and prognostical profiles were defined and reported.

RESULTS: 65% of students, although aware of transmission and prevention were correctly answered by 75% of all students. There was however a significant increase of students and correct answers about the transmission of HIV by heterosexual active and/or passive direct contact.

CONCLUSIONS: The results of the study showed that the majority of students had a high level of information about AIDS from TV, newspaper, books, scientific reviews and others. The perception of the problem is distorted by a false and fear. Being AIDS a disease related to sexuality and death, students very difficult to deal with in terms of changing habits and behavior. New Educational Program is based on one methodology based on these issues.

Publications

Le SIDA, la société et le comportement
AIDS, Society and Behaviour

E.807

ADOPTION OF CHILDREN FROM HIV POSITIVE WOMEN
CORLETT SANDY*, K SKINNER**, G O'HARA**, S Fowler*, J Mox**
*Health Health Council, Social Work Department, Edinburgh
**Lothian Health Board, Edinburgh

Objective: To describe the placement in adoptive families of children born to HIV positive women.

Methods: Adoptive families were recruited from 2 sources 1) Foster families already caring for a child. All foster parents are informed and prepared to care for a child at risk of HIV, and some volunteered. Their strength of feeling for the child led these families to want to adopt. 2) Adoptive families specifically recruited for children at risk of HIV. All prospective adopters are informed about HIV, and told about children with special needs, including children at risk of HIV. Some families responded.

Results: 4 children have been adopted. All are now HIV negative with good health. Extensive pre- and post-adoption placement includes medical advice, special support group, hygiene advice, practical help, financial stability. Issues are: dealing with the uncertainty of caring for a child who may become ill and die; confidentiality; what to tell the child.

Conclusion: Adoptive families have been found without special advertising for foster parents and prospective adopters. Informing all carers about HIV is crucial. Our experiences have informed development of an HIV screening policy for some child placements. Consideration of relatives as adopters of children whose parents die is a future issue.

E.808

SUPPORTED ACCOMMODATION FOR PEOPLE WITH H.I.V. RELATED ILLNESSES OR A.I.D.S.
(S.A.T.A.)

John Muller*, E. Houghton and P. Davies - Lothian Region Council Social Work Department, Edinburgh.

Objectives: To outline our experience of developing a range of supported accommodation resources within the community.

Methods: Through the use of small regional and housing association properties using a specially negotiated contract between ourselves and the Association. We aim to provide dispersed housing, with support which meets the needs of people with A.I.D.S./A.I.S.S. Most tenancies to date have been shared by two persons, with single rooms. All are furnished to a high standard. A gay couple are to provide lodgings for someone with H.I.V. have also been assessed and accepted as to our scheme. This development was achieved through advertising, public contacts and negotiations with lease plans with individual housing associations, and housing providers. Contact with housing agencies has not had the time. It is achieved as a result of active discrimination for people with A.I.D.S./A.I.S.S. through direct tenancies involving a support agreement and secondly, to relate the use of A.I.D.S./A.I.S.S. For housing agencies and promote good practice.

Since October 1987, we have developed 10 such tenancies, and are offering support to 18 people although we are in the process of negotiating further single tenancies and supported accommodation for single parents and their children. We are working in the main with current or ex-H.I.V. drug users, but in one instance, have a mix of ex-drug user and gay man. The support available is on a rotating basis, and centres on the practical and medical means by which people with A.I.D.S. can remain in the community.

E.809

A COMMUNITY PROGRAM OF COMPREHENSIVE CARE FOR HIV DISEASE
PAYNE, P., FLETCHER, D., **BARNETT, CAROL**, SHAW, J.***
*Goldersboro, **Worlington,***Fairfax County Health Dept.,
Fairfax, Virginia, U.S. RIVERS, VIRGINIA, VIRGINIA, U.S.A.,**
***Community Services Board, Fairfax, Virginia, U.S.A.

Objective: To establish an interdisciplinary community based program for staging and case managing HIV infections which will prolong lives and slow the spread of HIV in the community.

Methods: The Fairfax County human services agencies, i.e., Health Services Board and Social Services have developed a voluntary program to provide education, continuing medical care, and psycho-social support to asymptomatic individuals infected with HIV. Patient sources are from the County's case-finding activities, the substance abuse program, private medical practitioners and hospitals. This program is linked to Fairfax Hospital's HIV Center to provide the broader scope of care required for HIV case management. The program is 2 tiered; tier 1 consists of the County's interagency case management program (CMP) with primarily CDC Group 11 and III. CMP provides every 6 months a social case, mental health, and medical evaluation including HIV p24 antigen and p22 microglobulin assay. As the disease progresses to CDC Group IV, medical case responsibility shifts to tier 2, i.e. the Hospital's HIV Center which also serves the larger medical community.

Results: To date more than 200 cases monthly CDC Group IV have been followed by the medical staff of the Hospital's HIV Center. More than 30 cases have entered CMP during the first 18 months of operation.

Conclusion: We recommend that communities faced with serious drug abuse and/or STD problems consider similar programs.

E.810

The development of community-based AIDS initiatives
CORNE, D., CAMPBELL, M., EISEL, D., HARRIS AND M. HAZELL. THE
"WITCHES" Nightingale Trust (1977), London, England.

Objective: To maintain a strong community based whilst developing, and professionalising the work of non-governmental organisations (NGOs) in response to the AIDS crisis.

Method: TWI is the first UK, and the largest European, NGO concerned solely with TB and AIDS. Services are provided by members of the community for one another. Since 1982, when TWI was founded, increasing numbers of community based initiatives are developing in the UK to access their own community groups.

Results: The most effective health education occurs when community groups provide their own education - this is appropriate to the groups' existing behaviour, acknowledge obstacles to change and presents risk reduction as a positive alternative. This work is based in communities defined by area, institutional groupings or, more commonly, shared characteristics (eg sexuality, gender, age, use of drugs, ethnic groupings). Support services need to be organised according to the person's medical diagnosis, or relationship to the diagnosed person (eg buddies for people with ARC/AIDS, HIV support groups, liver's support groups, family support networks). In community based organisations develop in numbers of clients, staff and volunteers, the services (education and support) must be increasingly professional, but not become distanced or lose their community base. These must complement statutory services rather than replace them.

Conclusion: Community based organisations work on a level with people and by sharing skills and resources with statutory services we can avoid duplication and use our abilities more fully for a comprehensive response to the health crisis.

E.811

STATE OF THE ART MEDICAL CARE FOR AIDS PRISONERS
MELIN, ERIC, SAYFEN, J., BRALOW, C., MONTPELIER MEDICAL
CENTRE, HEALTH SERVICES, QUEBEC, N.Y. USA

Objective: To describe the medical needs of ambulatory AIDS prisoners and the complex policy considerations necessary in managing their care in a prison.

Methods: A 40-man open dermatology for prisoners with CDC defined AIDS was organized for the delivery of prophylactic and medical health services on Rikers Island NYC. Rikers Island houses NYC inmates awaiting trial or who have been sentenced for periods that may vary.

Results: In the first 25 months 61 patients were cared for with a median age of 33 and median duration of diagnosis of AIDS prior to incarceration of 6 months (0-20). Major diseases experienced historically by our patients included: PCP, 4 CNS TOXO, 3 large cell lymphomas, 1 B cell lymphoma, 2 extrapulmonary TB, 1 PML, and 1 cryptococcos meningitis. 8 patients were discharged to the hospital and did not return as of December. 15.7 patients had a history of TB and an additional 10 were PPD positive, 10 had evidence of sputal smear history or screening blood test. A maximal temperature greater than 102 F was observed 3 times per 100 patient-days.

The treatment of AIDS patients in the prison is fraught with conflicting objectives. The prison is a place of confinement and punishment while the physician's role is to heal and to relieve pain. The patient wants to improve his medical condition but also may benefit from appearing rehabilitated when considered for compassionate judicial release. Physicians wish to relieve legitimate pain even if pathology is not demonstrable, but they resist behavior perceived as purely drug seeking in nature.

Conclusions: AIDS patients can live most of the rest of their life in prison. One group's approach to the many challenges of prison AIDS care will be reviewed.

E.812

UN APPROVE INTERPERSONNELLE E LA REDUCTION DES RISQUES
SEXUELS E L'UPTAZIA CENTRALE

AYRES MORGAN, Nils Engdahl, BARNETT, N. Hertz et Brown A. Schopf,
Projet COMBINATION, Kinshasa, Zaïre.

La population adulte de Kinshasa, dans sa grande majorité, n'est âgée que de 19-30 ans. Le SIDA était une maladie fatale, transmise au grand public par relations sexuelles avec des partenaires infectés. Néanmoins, pas de gens à risque fréquents les comportements qui réduisent considérablement l'infection et beaucoup ont vu leur vulnérabilité. Cette conclusion est basée sur des entretiens, auto-évaluations, cultures, cognitives et psychologiques. Elle présente une stratégie qui peut servir différents groupes dans la prévention à grande échelle de la transmission de l'infection.

Basé sur les résultats des recherches ethnographiques, les ateliers furent organisés en utilisant des méthodes d'engagement actif. Les expériences structurées aidèrent les participants à analyser leur situation et à se sentir suffisamment dans les années à venir. Cette méthode de communication peut être utilisée par des organisations gouvernementales, des réseaux d'information, des services de santé et des groupes en conjonction avec des campagnes de communication de masse.

SECTION F



Droit et éthique
Ethics and Law

Colloque Symposium



Droit et éthique Ethics and Law

Vue d'ensemble de la législation sur le SIDA Global Survey of AIDS Legislation

M.F.O.1 THE HUMAN RIGHTS CONTEXT OF AIDS LAW
Justice Michael Kirby, Member, Global Commission on AIDS, Sydney, Australia.

In this paper, the speaker will stress the context of developing human rights jurisprudence within which national and subnational legislation dealing with AIDS and HIV must be developed. This is necessary not only because derogations from such norms diminish the effectiveness of such laws as measures for individual behaviour modification. It is also necessary because such norms are often legally binding on states and are morally binding as providing basic rules to be respected because of the very humanness of the person affected and his or her family and friends. The Global Commission on AIDS in its first report emphasized the necessity for WHO and national programmes and laws on AIDS to be developed with full knowledge of and compliance with universal human rights norms. These include rights to privacy, to establish a family, to move freely in international travel etc. Derogations from such basic rights must be provided by law, be proportional to the risk and limited strictly to what is necessary to prevent the spread of the HIV infection. Measures for public health do not provide a blanket exemption from compliance with basic rules of human rights.

M.F.O.3 STATE AIDS LEGISLATIVE AND POLICY TRENDS 1983-1988
Kane, Mona; Morrill, DM; Ryan, CC; Bridgman, R; and Bewing, L

AIDS Policy Center, Interdepartmental Health Policy Project, The George Washington University, Washington, DC, U.S.A.

Objective: To describe the response of state legislatures to the epidemic from 1983-1988 and to analyze the evolution of state AIDS policy on key issues affecting confidentiality, discrimination and prevention and the delivery of services. **Method:** All bills and laws were collected from all state legislatures from 1983-1988. They were analyzed by category, frequency and content from both a legislative and health policy perspective. **Results:** Since 1983, more than 1,450 bills and 314 laws have been passed by state legislatures. Categories reviewed include: testing, discrimination, confidentiality, health care services, financing, education and public health measures. More legislation has been introduced and passed regarding HIV testing than in any other area with related activity in areas of confidentiality and required disclosure. States are using AIDS to update their public health laws in terms of managing communicable, infectious and sexually transmitted disease. State handicapped laws and new provisions are being used to protect patients and providers from AIDS-related discrimination. Some states are taking a comprehensive approach to managing AIDS through omnibus legislation. A wide range of provisions including criminal penalties, due process for existing quarantine provisions, penalties for anonymous testing and for health care providers are being added. **Conclusion:** Almost all states have passed AIDS legislation. Level of legislative activity does not always correlate with case incidence. Overall, final state actions evidence a measured, balanced, non-partisan response.

M.F.O.5 AIDS IN COURT: IMPORTANT QUEBEC DEVELOPMENTS
Lettellier de St.-Just, Louis, Montreal, Quebec
Canada

M.F.O.2 IMPLEMENTING HIV/AIDS LEGISLATIVE POLICY FOCUSING ON ETHICAL ISSUES IN A NATIONAL HEALTH CARE SYSTEM
Petersen, Matthew; Member, H.C.'s; Sheip, R.*; Storr, R.*; Swahn, R.*; Allan, E.*

*Department of Veterans Affairs, Washington, D.C., USA. **Foundation for Interfaith Research and Ministry, Belaire, Texas, USA.

Objective: To implement sound Federal AIDS legislation focusing on significant ethical issues in the largest health care system in the USA. **Methods:** In May 1988, the President signed Congressional legislation specific to the care of veterans with HIV infection/AIDS in the Veterans Administration. This legislation addresses significant ethical issues well subject to diverse opinion such as privacy and confidentiality of medical records; nondiscrimination in admission and treatment; self-determination; a voluntary testing program which incorporates the principle of justice and resource distribution. Broad policy direction including a system wide consent form has been sent to all health care facilities. A national training program on HIV/AIDS counseling and prevention education has been used as a forum to standardize the information process. **Results:** Two counselors/educators from each facility in the system attend the course. The application of policy is discussed within the framework of ethical considerations every counselor should think about, such as mutual respect within moral pluralism, personal morality and professional limitations, professional duties, honesty in presentation of information; accuracy and consent and confidentiality and the Chorny Issue of spouse/partner notification. **Conclusion:** Despite a lack of moral consensus on some issues, legislation based on ethical issues can be implemented on a national scale.

M.F.O.4 THE LIMITS AND PROSPECTS OF AIDS LEGISLATION IN ANGLOPHONE AFRICA
AMANUEL, ABDOU IDEK, DANAN, SENEKAL.

OBJECTIVE: To survey and analyze the effectiveness of existing AIDS legislation in Anglophone Africa.

METHOD: Content analysis of existing health laws and AIDS legislation.

RESULTS: In most Anglophone African countries, specific legal instruments for dealing with AIDS prevention are lacking. Where AIDS-related laws exist their application to the epidemic of AIDS is weak. The greatest potential for appropriate (i.e. humane) and effective AIDS legislation seems to be in those countries with better organized public health services, greater public awareness of the epidemic, legal sensitivity to the epidemic, and a tradition of human rights legislation.

CONCLUSION: There is an urgent need for effective and appropriate legislation to deal with the prevention of AIDS in Anglophone Africa. Fulfillment of this need will help to significantly reduce the social stigma and criminalization of AIDS and HIV victims.

M.F.O.6 A GLOBAL SURVEY OF AIDS LEGISLATION
Gottlieb, Lawrence O. Harvard University, School
of Public Health, Boston, MA, USA

**Vue d'ensemble de la législation sur le SIDA**
Global Survey of AIDS Legislation**M.F.O.7** A GLOBAL SURVEY OF AIDS LEGISLATIONCURRY, William J. Harvard University, School of
Public Health, Boston, MA, USA.

Table ronde
Round Table

Droit et éthique
Ethics and Law
Points de controverse dans les rapports sur les politiques relatives au SIDA
Points of Controversy between Policy Reports on AIDS
M.F.O.8 POINTS OF CONTROVERSY BETWEEN POLICY REPORTS ON AIDS (INTRODUCTION).
Chrétien, Michel, Montréal, Québec, Canada.

M.F.O.9 POINTS OF CONTROVERSY BETWEEN POLICY REPORTS ON AIDS
Pompidou Alain, Paris, France

M.F.O.10 POINTS OF CONTROVERSY BETWEEN POLICY REPORTS ON AIDS
Ostern, Jung, Ann Arbor, Michigan, USA

M.F.O.11 POINTS OF CONTROVERSY BETWEEN POLICY REPORTS ON AIDS
Matheson, Vivienne, London, United Kingdom

M.F.O.12 POINTS OF CONTROVERSY BETWEEN POLICY REPORTS ON AIDS
 A representative of the MIO, Geneva, Switzerland

M.F.O.13 POINTS OF CONTROVERSY BETWEEN REPORTS ON AIDS
Martin, Jean, Lausanne, Switzerland

M.F.O.13.A POINTS OF CONTROVERSY BETWEEN POLICY REPORTS ON AIDS
Gilmore, Norbert, Montréal, Québec, Canada


Éthique et Injustice sur le plan International
Ethics and International Inequity

M.F.O.14 THE ETHICS OF INTERNATIONAL INEQUITY (OVERVIEW)
Koucher, Bernard. Paris, France.

M.F.O.15 INTERNATIONAL CODES OF RESEARCH ETHICS: SHOULD HUMANISM
 AND HUMANITY BE SUSPENDED DURING THE AIDS EPIDEMIC?
Annan, Chester J. Law, Medicine & Ethics Program, Boston University
 Schools of Medicine and Public Health, Boston, Mass., USA

Objectives: To establish the basis of international codes of research ethics and their relevance to AIDS drug and vaccine research today.

Methods: The basis for the Nuremberg Code and the Helsinki Code will be examined with a view toward establishing the universal principles contained in these Codes are their applicability to research conducted during an epidemic, and research conducted in countries that had not participated in the formulation of these Codes.

Results: Based on this analysis, it is possible to explain the legal and ethical bases of existing international codes of research ethics, including their "natural law" basis which would render their universal applicability. Special attention is properly focused on the principles of self-determination (autonomy) to be safeguarded by informed consent; nonmaleficence, to be safeguarded by adherence to reasonable scientific principles in research design and execution; and justice, to be safeguarded by fairly distributing the risks and benefits of the research.

Conclusion: The AIDS epidemic does not justify a suspension of the codes that safeguard human rights in medical research.

M.F.O.16 LIMITED RESOURCES FOR AIDS
N'Sally, Roxanne. Kinshasa, USA.

M.F.O.17 THE DEARTH OF THERAPEUTIC AGENTS IN DEVELOPING
 COUNTRIES
de Swameer, Cécile. International Development
 Research Centre, Oaker, 06n0gal.

M.F.O.18 OVERCOMING THE NIMBY SYNDROME FOR FACILITIES TO
 CARE FOR HIV INFECTED PEOPLE
Stein, Robert E. Environmental Mediation Inter-
 national, Washington, D.C. USA.

M.F.O.19 A FOCUS ON LATIN AMERICA
Connor, Susan M. Washington, DC, USA

M.F.O.19.A ETHICS AND INEQUITY
Sabbatier, René. London, UK

Colloque
SymposiumDroit et éthique
Ethics and LawLa confidentialité et ses limites
Confidentiality and Its Limits

T.F.O.1 CONFIDENTIALITY AND ITS LIMITS: OVERVIEW OF THE ISSUES.

Closen, Michael L. Chicago, Illinois, USA.

T.F.O.3 THE OPTIMA OF AIDS ON THE DEATH CERTIFICATE

Knox, Michael, B.

Institute of Psychiatry, De Crespigny Park, London SE5, U.K.

Death registration became constitutional law in England and Wales in 1836 and physicians have been urged ever since to accurately record the cause of death. Until the advent of AIDS, more liberal attitudes in society had reduced the stigma of most causes of death as an obstacle to their accurate certification. AIDS or HIV infection will usually appear on the Death Certificate as the condition leading to death or as another associated condition. This has major ramifications for the bereaved and may have particular implications for surviving family members with regard to placement of children in foster homes.

For historical reasons death records in most countries of the world are public documents and provide no safeguard for the privacy of sufferers after death. Patients with AIDS encounter many social and psychological problems and thus the importance of confidentiality has been established in guidelines provided by bodies such as the American and British Medical Associations. In the USA there have been calls to adopt a two part death certificate, mainly for purposes of medicine delay for relatives pending further clinical or autopsy information. However greater privacy would also result with a two part certificate, one of which, without stating cause of death, could be used for the local and civil necessities after death.

T.F.O.5 AIDS AND THE CANADIAN PRIVACY ACT

Orszak, John, Privacy Commissioner of Canada, Ottawa, Ontario, Canada

Significance of the Study. The study described the impact of Canada's Privacy Act on the collection, use and disclosure of AIDS-related information about individuals. The level of confidentiality afforded this information may affect the degree of discrimination experienced by HIV-infected persons and may also affect the rate of spread of HIV infection. The study seeks to strike a balance between individual privacy and the legitimate needs of government to collect, use and disclose some types of AIDS-related personal information.

Methods. The study reviews Canadian government policies and practices for dealing with AIDS-related information about government employees, the general public and government clients (such as immigrants or penitentiary inmates). These policies and practices are assessed against the requirements of the Privacy Act about handling personal information. They are also assessed against the practical need to use some types of AIDS-related personal information to understand the syndrome and to combat the spread of HIV infection. It also addresses privacy concerns relating to HIV antibody testing.

Results. The study recommends measures to regulate the collection, use and disclosure of AIDS-related personal information. The recommendations will be useful for other jurisdictions attempting to strike an appropriate policy on the treatment of AIDS-related personal information.

T.F.O.2 X v Y (1988): WHEN IS CONFIDENTIALITY A LEGAL RIGHT? MORRIS,

JULY LEGAL OFFICER, THE TORONTO HOSPITAL TRUST LEGAL COUNSEL.

UNITED KINGDOM
Objective: To review the legal right of confidentiality to see when it is overridden by the public interest exceptions either to protect others or the freedom of the press.

Methods: When is information legally confidential as opposed to just private? Examination of legislation and case law in the UK. Clinical information identifying people with AIDS in confidential files, NHS (1 Regd) 1974, and the case of X v Y (1988). There is a primary duty to the patient to keep medical information confidential. However, it is legally advisable to breach confidentiality to serve the wider public interest of protecting others. Only when there was a clear infection risk could a doctor be legally liable for failure to disclose.

Conclusion: X v Y (1988) 2 All ER 648, was a English court case concerning two doctors who had AIDS. A newspaper obtained the confidential hospital records identifying the doctors but the court granted an injunction restraining publication. The judge said that the confidentiality of the hospital records was more important than protecting the public from theoretical risks posed by the doctors, and the freedom of the press to publish such information.

T.F.O.4

AIDS AND PRIVACY: RETAINING, RESTRICTING OR
ABANDONING MEDICAL CONFIDENTIALITY?Closen, M. Patricia*, Morissette, J.-P., Gilmore, N.,
Somerville, N.*

*Centre for Medicine, Ethics and Law, McGill University, Montreal, Quebec, Canada.

Confidentiality of HIV/AIDS-related personal information (HIVAPPI) has suffered from: (i) increasingly vacuous content of medical confidentiality in era of institutional medical care; (ii) inability of formal law to control effectively flow of personal information. Further legislative regulation of medical confidentiality therefore unlikely to produce greater protection. Balance should be placed on increasingly articulate soft law (guidelines, policy, protocols) to formulate precise measure of protection accorded particular category of HIVAPPI. Reasons proposed are: a) systemic potential not been exploited, each embodies inherent degree of protection. Measures of protection are: (i) unlimited, providing absolute protection; (ii) anonymous, allowing control exclusively by subject of information; (iii) coded, allowing control by designated individuals only; (iv) partial, necessarily accompanied by stated further measures of protection. Mandatory, exclusive use of these measures of protection in all institutional settings will: concentrate attention on HIVAPPI; prevent reliance on ineffective content of confidentiality; provide courts with precise standards to measure alleged breaches of privacy and damage. Paper suggests application of measures to number of categories of HIVAPPI. Method capable of extension to all personal medical information

T.F.O.6

MEDICAL PRIVACY FOR THE HIV-INFECTED INDIVIDUAL
Hochstetler, Gail, Administrator, AIDS Legal
Referral Panel, San Francisco, CA, USA.

Partial listing of 1988 conferences

I. National AIDS Law Conf., S.F.	400 Participants
II. Nev. Public Health Assoc., Las Vegas	100 Participants
III. University of California, S.F.	1,000 Participants
IV. Concern for Dying, N.Y.	50 Participants

Objective: To explore the lack of confidentiality protections for persons with HIV infection and generally to describe the decline of medical privacy.

Methods: Review of the concept of confidentiality within the physician/patient relationship. Examination of AIDS Legal Referral Panel case studies of health care providers' violation of Calif. confidentiality laws that resulted in injury to the patient. Analysis of limited exceptions to the general rule against disclosure of private medical information, including disclosure (1) after patient consent, (2) to institutional staff, (3) to hospital visitors, (4) to a foreseeable victim of serious harm (Tarasoff), and (5) to others where health laws require.

Results: Despite the strongest confidentiality protections of any US state, examination of pre-1989 California legal cases indicates erosion of medical privacy for HIV infected persons. **Conclusion:** Communications between patient and care provider can no longer be considered confidential.

Colloque
SymposiumDroit et éthique
Ethics and LawÉthique clinique
Clinical Ethics

T.F.O.16

OLIVIER DE CLERMONT
CLINIQUE PÉDIATRIQUE L'ACTUEL, MONTRÉAL
QUÉBEC, CANADA

LE PATIENT DIFFICILE

Cinq prototypes de réactions des patients au diagnostic de séropositivité au VIH ou de SIDA sont abordés. La négation, la manipulation, l'agressivité, la dépression et la panique sont des réactions auxquelles les médecins ont à faire face. La dynamique patient-médecin engendrée par ces réactions est nouvelle à cause en partie du caractère imprévisible de l'évolution des aspects cliniques, psychosociaux et scientifiques reliés au VIH.

Ces réactions forcent désormais à une nouvelle approche du médecin qu'il est urgent de définir pour la survie du médecin et du patient devant l'intolérance sans cesse croissante d'une partie de la société et d'une partie du corps médical face au SIDA.

Devant l'absence de vaccin et de traitement efficaces, la confiance aveugle de la société envers les médecins s'estompe progressivement et tant que les médecins persisteront à se protéger derrière leurs armes thérapeutiques, le regard critique posé sur eux par la société s'accroîtra.

Colloque Symposium



Droit de éthique Ethics and Law

Infection par le VIH, reproduction et fonction parentale HIV Infection, Reproduction and Parenthood

T.F.O.17 Overview of the Issues
Bernard M. Dickens, Faculty of Law and Faculty of Medicine,
University of Toronto, Canada. MSB 203

Key ethical issues in HIV infection and reproduction arise at different stages of pregnancy. They include:

- 1. Initiation of Pregnancy:** Counseling of the HIV-positive woman about risks of pregnancy to her health-directive or non-directive; advice about risks of HIV transmission to fetus; access to reproductive assistance - genetic donation, in vitro fertilization, etc; screening donated gametes/donors for HIV; access to safety of contraceptive sterilization.
- 2. Maintenance of pregnancy:** Access to health services, pre-natal care, etc. for the HIV-positive woman; counseling on continuation/termination of pregnancy.
- 3. Termination of pregnancy:** Access to abortion services and counseling; health care during and after delivery; risk to uninfected child of natural delivery - risk of infection by passage through birth canal-untreated cesarean delivery; post-natal care of HIV-infected child.
- 4. Post-natal Issues:** Prohibition of breast feeding uninfected child - child abuse; foster parent/adoptive parent of infected/uninfected child-confidentiality and the (parental) right to know.

T.F.O.19

SHOULD HIV POSITIVE WOMEN HAVE CHILDREN: AN ETHICAL PERSPECTIVE.
Arora, John D., Montefiore Medical Center - Albert Einstein College of
Medicine, Bronx, New York, USA

In order to halt the perinatal transmission of HIV, advocates of a "public health" model of counseling contend that infected women should be strongly urged not to have children. Advocates of a "genetic counseling" model, on the other hand, argue on moral and practical grounds for a supportive, "non-directive" approach. This paper provides an ethical analysis of these competing claims and perspectives, and offers an alternative counseling model described as "respectful confrontation".

The ethical core of the debate turns on the question whether perinatal transmission of HIV constitutes a "threat" or "harm" to the infected child. This question is approached through an application of the "wrongful life" argument as analogous with other devastating (genetic) diseases (i.e. Sickle, cystic fibrosis). Then the factor of risk and uncertainty is addressed. Is a 25-35% chance of infecting one's child with a potentially lethal virus an unreasonable or irresponsible risk? While acknowledging such cultural diversity in perceptions of childbearing and risk, I note that infecting need not continue such arbitrary perspectives if the well-being of children is threatened.

Finally, the implications of these moral analyses for counseling are explored. I argue that if perinatal infection with HIV constitutes a harm or wrong to the child, and if the risk of transmission is judged to be very high, then "directive" counseling is not necessarily coercive or unethical. However, cultural differences warranting counsel from counsel we might advise this approach. In order to assure future infants from undue suffering we might prefer to cultural differences, I advocate counseling that respects an infected woman's latent preferences for childbearing, that counsel is her at least to save the problem as a genuine moral dilemma, before supporting her final decision.

T.F.O.21

AIDS AND REPRODUCTIVE HEALTH IN THE AFRICAN SETTING

Temu, Borahy, Tanzania.

T.F.O.21A

ETHICAL IMPLICATIONS OF HIV/AIDS AMONG MOTHERS AND CHILDREN IN KENYA.

Ongando, Phillista, Nairobi, Kenya.

T.F.O.18

ETHICAL DILEMMAS IN PEDIATRIC AND MATERNAL AIDS

Mallickozhy, Anne, Wright, A. and Novello, A.

National Institutes of Child Health and Human Development,
National Institutes of Health, Bethesda, Maryland, USA.

Objectives: To describe ethical dilemmas which are specific to pediatric and maternal human immunodeficiency virus (HIV) infection and disease.

Methods: The Secretary of the U.S. Department of Health and Human Services commissioned a major initiative to examine issues pertaining to pediatric and maternal AIDS in the U.S. The departmental experts who participated in this six-month long project identified a number of ethical concerns in this area.

Results: Areas of concern identified included: (1) the participation of infants and children in clinical trials; (2) the participation of women of childbearing age in clinical trials; (3) the right to prepare women of screening for infection; (4) confidentiality issues in testing and treating adolescents; (5) the conduct of clinical trials in pregnant women; (6) delivery of care to hard-to-reach populations.

Conclusion: The AIDS epidemic has generated a number of problems unique to this disease entity.

T.F.O.20

**UNINFECTED CHILDREN OF INFECTED WOMEN - THE
FOSTER CARE DILEMMA**

*Landman, S. - SUN Health Science Center at Brooklyn,
Brooklyn, New York*

HIV infection in women creates a dilemma of the family. Not only is the woman infected, but her newborn is potentially infected, her husband often ill with HIV disease and her health suffering rather severely as a consequence of her illness. As infected women become ill, require hospitalization or die, the necessity of caring for their uninfected children will increase the burden on society and increase the risk of emotional and developmental damage to these children. This problem will be most acute in cities where infected rate (DR) is as numerous (e.g. Newark, NYC, New York City, Burlington (N.C., Baton) These men serve as the caregiver for the infection of women. New York City has an estimated 35,000 infected women each with average of 2 children/year (at time when HIV infection is first diagnosed). This means that over the next several years 70,000 children will be at risk of losing their parents. Often these children become orphans and end up in foster care because they live in single parent homes or the father has already died of AIDS. The foster care system of NYC currently cares for 21,000 children. How the potential addition of thousands or tens of thousands of new children into the foster care system will be handled remains unexplored. The problem is further complicated by social doctrines that place the highest priority on the biological mother's rights over her child and the foster care concept of making decisions "in the best interest of the child". In the social milieu wherein HIV declines "in the next few decades are often in conflict. More attention must be focused on the care of uninfected children of infected women if the social and human damage of the epidemic are to be minimized.

T.F.O.22

HIV INFECTED CHILDREN IN THE COMMUNITY: ETHICAL PROBLEMS

*Medkin, Ruth,
Albert Einstein College of Medicine, Bronx, New York, USA*

Objective: To offer an ethical analysis of emerging problems regarding children with HIV infection in the community. **Methods:** Cases are presented that pose ethical issues of confidentiality, school and pre-school placement, parental rights, and needs of children. Cases are drawn from the ongoing work of a multidisciplinary team established to deliver services to HIV-infected children and their families.

Results: Special problems arise when the need to preserve confidentiality conflicts with the "best interests" of children. Despite negative consequences of "labeling" children with AIDS, identification may be necessary in order for children to be eligible for special services or entitlements. Several potentially conflicting rights are identified: rights of the biological mother, of foster parents, of the HIV-infected child. **Conclusion:** The chief ethical value should be "the best interest of the child," thus requiring subordination, when necessary, of competing values such as confidentiality of HIV information.

**Colloque
Symposium**



**Droit et éthique
Ethics and Law**

**Prévenir la transmission du VIH : les conflits religieux en matière de santé publique
Preventing HIV Transmission: Religious Conflicts in Public Health**

W.F.O.15 "SAVING LIFE AS AN OVERRIDING DEMAND"
(A JEWISH PERSPECTIVE)
W. Gunther Plaut, Toronto, Ontario, Canada

Jews see the source of their moral demands as springing from their relationship with God. While not all Jews agree on what this relationship betokens, there are some common views which may be applied to the subject of the Conference on AIDS:

Life is precious and must be preserved under all circumstances and at all costs. While ordinarily the ends do not sanctify the means and the religious law must not be infringed for otherwise desirable purposes, it is different when it comes to the preservation of life and, by implication, the prevention of pandemic disease.

Prevention of HIV transmission may involve providing means for sexual activity which in itself is frowned upon by much of Jewish tradition. The liberal view (taken by the presenter) holds that the preservation of life must be tantamount, and that all possible support must be given to programs which will prevent people from becoming infected and from infecting others.

W.F.O.16 COMMENTARY
Hollman, David. The United Church of Canada,
Toronto, Ontario, Canada

W.F.O.17 COMMENTARY
de Swaab, Cécile. International Development
Research Centre, Dakar, Sénégal.

Colloque
SymposiumDroit et éthique
Ethics and LawCoercition ou volontarisme? Analyse critique internationale
Coercion or Voluntarism: An International Critical Review

W.F.O.18 COERCITION OR VOLUNTARISM: AN INTERNATIONAL CRITICAL REVIEW

GosEttE, Lawrence, O. Harvard University, School of Public Health, Boston, MA, USA.

W.F.O.19 COERCITION OR VOLUNTARISM: AN INTERNATIONAL CRITICAL REVIEW

Havana, Cuba. Terry-Mallinet, Hector. Ministry of Public Health,

W.F.O.20 BAVARIA: A REVIEW SYMPOSIUM - COERCION OR VOLUNTARISM: AN INTERNATIONAL CRITICAL REVIEW.

Jäger Hans,
AIDS Study Group, Schwabinger Krankenhaus, Munich, FRG.

Of the total of about 2 300 CDC AIDS cases in West Germany 17% have been diagnosed and treated in Bavaria, one of eleven West German states ("Länder"). During the first months of 1987 a package of anti-AIDS regulations ("Bayrischer Maßnahmenkatalog") was decided by the catholic conservative majority within the Bavarian state parliament. Since then Bavaria has had a political and legislative AIDS position that - more in theory than in its practical consequences - contrasted sharply with the other 10 German states, with federal policies, with WHO recommendations and in part with scientific knowledge.

HIV testing in foreigners from non EC countries as well as to civil servants and judges to be hired, coercive stage approval IVU and male and female prostitutes and a 98 % (voluntary) testing rate within prisons were introduced. Counseling, psychosocial treatment facilities and free anonymous testing in every private doctor's office were made available. No mandatory testing or reporting, no large scale screenings were organized. Several cases of criminal justice against HIV positive individuals rose concerns within human rights groups in Bavaria and abroad. Homosexual men and many patients from other risk groups were unnecessarily frightened. Growing mistrust in public health authorities was noted.

No major modes of AIDS prevention was observed. Because of high standard basic research and clinical care especially in Munich, some patients are coming from other states as well as other countries to get treatment here.

W.F.O.21

Sweden: A Review on compulsive treatment, Gunnar Ågren, County Council of Stockholm, Stockholm, Sweden.

Swedish HIV-positive patients can be submitted to compulsive treatment if they don't follow the chief medical officer in the county. This is in accord with the law on control of infectious diseases. The law is, however, very seldom used. In Stockholm a special hospital department with two beds is used for this purpose.

HIV-infected drug addicts are more often treated according to a special law which permits compulsory care of alcohol and drug abusers for a time period up to 6 months. There is a number of special institutions for this kind of treatment. A cohort of 133 compulsory treated drug addicts, 58 of them HIV-positive, has recently been followed up. The results are not encouraging.

W.F.O.22 ETHICAL AND LEGAL ISSUES OF AIDS IN SOUTH AFRICA.
Eichel, Gideon J.,
University of Cape Town, South Africa.

Objective. To analyse existing laws and effects on preventive, educational and health care programmes within an ethical framework.

Methods. Amongst others the Health Act, Sexual Offences Act, Admission of Persons to the Republic of South Africa Act, Media Act, the Medical, Dental and Supplementary Health Services Professions Act were analyzed.

Results. The Sexual Offences Act have a potentially counterproductive effect on homosexual and prostitutes: regarding sexual contact with minors it has the inherent danger of a homophobic backlash and blackmail by male prostitutes over sixteen but under nineteen years of age. Listing AIDS and HIV infection as a communicable disease may dissuade persons with HIV infection of AIDS to seek medical help; it has the positive aspect of empowering the Medical Officers of a Local Authority to take action against a known infected person who persists with irresponsible behaviour. Declaring any foreign passport-holder with AIDS or HIV infection a prohibited person have potentially serious consequences for individuals. Existing health and education laws cause fragmentation of preventive, educational and health care programmes. The Medical, Dental and Supplementary Health Services Professions Act provide mechanisms for investigation of foreign passport-holders and HIV infection as communicable disease and Media Act for investigation of improper media reporting.

Conclusion. Homosexuality and prostitution should be decriminalized; regulations on foreign passport-holders and HIV infection as communicable disease should be reviewed; the identities of persons taking legal action against breach of confidentiality and media exposure should be protected.

W.F.O.23 A HUMAN RIGHTS PERSPECTIVE
Justice Michael Kirby, (Member, Global Commission AIDS), Sydney, Australia.

Law is traditionally bound to a particular territorial jurisdiction. It typically reflects local cultural norms and historical institutions. But AIDS/HIV is international in character. Its global dimension provides an international context for the measures of response. National, subnational and international responses must be considered in the light of the developing jurisprudence of human rights. Not only does this require consideration of local constitutional or other guarantees now typically found in the laws of most societies. It requires compliance with developing international human rights law. This includes law declared by the Universal Declaration of Human Rights and established by such international instruments as the International Covenant on Civil and Political Rights. One function of

WFO - and the Global Commission on AIDS - may be to remind member countries of the provisions of international law on human rights as it affects local responses to the epidemic. As the sorry history of past epidemics demonstrates, human rights are often the first casualties of a challenge such as AIDS.

The thesis of the author is that this time we should do better. Not only is compliance with human rights a legal obligation and a moral requirement. It is also likely to be the only effective way of securing the cooperation of persons and groups most affected by the epidemic.

W.F.O.24 Voir/See page 1059


Séance thématique
Specialty Session
Droit et éthique
Ethics and Law
Discrimination de droits de la personne
Discrimination and Human Rights

Th.F.O.7 DISCRIMINATION REFLECTED IN THE LANGUAGE AND DIAGNOSES OF TARGET HIV CLIENT BY PHYSICIANS
 Notion, Sujet: Schwarzbauw, J. & Wham, J. "Memphis State University, Memphis, Tennessee, United States. "University of Tennessee, Memphis, Tennessee, United States.

The object of this research was to see whether the language of physicians varied with the type of diagnosis they would make for somebody who has been described as having the HIV virus. In addition to questions about how they talked about AIDS, each physician randomly received a one case study vignette. The only difference across vignettes was whether the patient was described as male or female, homosexual or heterosexual, or white or black. Six hundred physicians were randomly sampled.

It was found that physicians discriminated in terms of diagnosis across vignettes. Also, how they talked about AIDS reflected biases. The language of physicians often reflected ethical biases relating to the AIDS problem. For example, out of two hundred and thirty two metaphors reported by general physicians in answer to the question, "AIDS is like _____" some physicians responded with extremely judgmental replies: "AIDS is the wrath of God," "AIDS is the plague brought to us by a minority of aberrant individuals," and "AIDS is poetic justice, almost."

This information is being used to craft educational programs which sensitize physicians and residents to ethical issues inextricably related to AIDS issues.

Th.F.O.8 COMMENTARY

Connor, Susan S. Pan American Health Organization
 World Health Organization, Washington, D.C. USA.

Session d'affichage Poster Session



Droit & éthique
Ethics and Law

Vue d'ensemble de la législation sur le SIDA Global Survey of AIDS Legislation

M.F.P.1 LEGAL PROTECTIONS AGAINST HIV-RELATED DISCRIMINATION IN THE USA: A FIFTY-STATE ANALYSIS

* National Gay Rights Advocates, San Francisco, California, USA

Objective. To determine extent to which U.S. state handicap discrimination laws prohibit HIV-related discrimination in employment, housing, public accommodations, and other areas.

Method. Survey of state human rights agencies in 50 states and Wash., D.C.

Results. Clear majority of state agencies interpret state handicap laws to prohibit discrimination against people with AIDS, AC, and asymptomatic HIV infection, although minority differ (see table below.) Majority also prohibit discrimination against uninfected persons considered "high risk." In addition to differences in statutory interpretation, other gaps exist in protection: 2 states have no handicap discrimination statutes; 3 state laws exclude "communicable diseases" from protection; 2 states prohibit only government discrimination. Although all state laws govern employment, only 38 cover public accommodations, 37 cover housing and 21 cover credit.

State Law Protects:	Yes	No	Unclear
Employment with AIDS	79	8	14
Persons with AC	69	9	24
Asymptomatic HIV persons	60	12	28
Uninfected persons considered "high risk"	55	18	27

Conclusion. Many people with HIV infection are unprotected from discrimination in the USA as a result of inconsistent state laws and policies. Nevertheless, consensus is developing that state handicap discrimination laws prohibit discrimination against people with AIDS, AC, HIV infection,

M.F.P.2 LEGAL AUTHORITY FOR HIV TESTING OF ADOLESCENTS

Keith Richard, Associate Professor, University of Maryland School of Law, Baltimore, Maryland, USA

Objective. To describe the risk of HIV infection in adolescents in the United States and to unravel the varied laws in each state to allow for the voluntary HIV testing and counseling of adolescents without parental consent or notice to parents.

Methods. Analysis of the statutes in each state concerning medical care for minors, venereal and sexually transmitted diseases, emancipation and HIV infection. Analysis of case and constitutional law and the law relating to parental rights.

Results. Evidence in a number of studies points to the potential for a new wave of infection among adolescents in some areas of the United States. Little attention has been devoted to the risk to adolescents in the U.S. and the new laws designed to contain the infection ignore the special problems of adolescents.

Conclusion. Legal authority exists in all jurisdictions in the U.S. for the voluntary testing and counseling of minors but the authority is usually not found in venereal or sexually transmissible disease statutes. The sources of authority differ from state to state and do the requirements of confidentiality and notice to the parents of minor patients. A chart describing the sources of authority and confidentiality requirements in each state is attached.

M.F.P.3 IMPACT OF THE SANITARY REGULATION ON HIV TRANSMISSION IN BLOOD DONATIONS IN GUADALAJARA, MEXICO.

Yolanda Lozano*, Teresa Mendez, S.L.; Jauregui-Nos, M.,* and Soto-Molina.

*Instituto de Patología Infecciosa y Experimental "Dr. Fco. Ruiz Sánchez" de la Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.

In Mexico, since May 1986, the mandatory detection of antibodies anti HIV in blood and its derivatives for the use in humans was legislated, one year later the prohibition of blood trade took effect.

Objective. To compare the impact of the sanitary legislation to mandate screening for HIV antibodies in blood donations in Guadalajara, Mexico.

Methods. An alenary sample was taken from 3228 sera of donors of six public and private blood banks in Guadalajara, between June 1986 and June 1989; 4020 in the first year and 1208 after mandatory; in all the samples the presence of anti HIV antibodies was determined by the ELISA assay and positive ones were confirmed by indirect immunofluorescence and/or western blot.

Results. During the first year, the seroprevalence fluctuated between 2.01 and 30.15% depending on different factors, compared to the second year where the seroprevalence was 0.1%.

Conclusion. It is concluded that the mandatory detection of antibodies anti HIV and the prohibition of blood trade, have been effective factors in decreasing the incidence of HIV in blood donors in Guadalajara, Mexico.

M.F.P.5 CURRENT ISSUES IN DRUG REGULATION IN THE U.S.A.

Malik, Stephen G., Human Rights Campaign Fund, Washington, D.C., USA

Objective. To identify and analyze key issues raised by current proposals to reform the legal regulation in the United States of the sale of drugs for medical treatment.

Methods. The author is an attorney and lobbyist concerned with AIDS policy in the USA, has read a number of legislative and regulatory proposals, reviewed the literature, and attended conferences where these proposals have been discussed.

Results. Current proposals for legal reform of drug regulation have attained new urgency in the public debate as a result of the AIDS crisis. It has been proposed that medical drugs be "de-regulated" by eliminating the efficacy requirement, or the requirement of a doctor's prescription, and related rules of civil liability. It has been proposed that the governmental role of reviewing and certifying drug tests be either eliminated or made purely advisory. It is claimed that de-regulation will make effective drugs more widely available to patients and enhance individual choice. The strongest objection to this claim is that competitive processes will result in "bad" drugs driving "good" drugs out of the market.

Conclusion. Empiric research is needed to establish the benefits and costs of a legal requirement that medical drugs be proven effective before sale.

M.F.P.4 PHYSICIAN BREACH OF PATIENT CONFIDENTIALITY AMONG INDIVIDUALS WITH HIV INFECTION: A PRELIMINARY INVESTIGATION OF TENNESSEE, GEORGIA, AND MISSISSIPPI.

John Whelan*, Robert Novack**

*University of Tennessee, Memphis, Tennessee, USA, **Memphis State University, Memphis, Tennessee, USA

To determine whether the sex, race, or sexual preference of an HIV infected patient influences a physician's decision to breach patient confidentiality, 222 Tennessee primary care physicians were each mailed a questionnaire containing a case study in which an HIV infected patient presented a risk to a third party. Eight different descriptions of the sex, race, and sexual preference of the hypothetical patient were distributed equally among the physicians who were asked to decide whether to maintain confidentiality, notify the health department or inform the patient's partner. Physicians said they would report a black male homosexual to the health department 16.1 (17.50%) times more often than they said they would a black female homosexual. Physicians with increased knowledge of AIDS were 50.4 (28.0, 88.0) times more likely to say they would inform the partners of black homosexuals than those of black homosexuals. These physicians were also significantly more likely to report male homosexuals to the health department than they were female homosexuals. Physicians reporting confidence in their knowledge of AIDS also said they would report male homosexuals to the health department with greater frequency (odds ratio 59.2 (6.0, 581.0) than they would female homosexuals. These physicians were 6.6 (1.4, 50.8) times more likely to say they would inform the partners of black males than they would those of white males. When physicians decide to proceed a third party by breaching an HIV infected patient's confidentiality, they consider the race, sex, and sexual preference of the patient.

M.F.P.6 TRENDS IN AIDS LITIGATION IN THE UNITED STATES - 1983 TO 1989

Bartham, Sara W., and Reiland, V.E. Office of the General Counsel, Centers for Disease Control, Atlanta, Georgia, U.S.A.

Objective. To review published cases involving AIDS litigation to identify current legal issues.

Methods. Over 300 legal actions occurring in the past 6 years (1983 through 1989) were reviewed and categorized. Comparisons were made by category between the earlier cases (1983 to 1986) and the more recent cases (1987 to 1989).

Results. Within certain categories, litigation patterns established prior to 1987 have continued over the last two years, including a significant number of legal actions involving prison-related AIDS, employment discrimination, and sanctions against recalcitrant HIV transmitters. However, new patterns have also emerged since 1986, such as decisions involving appropriate use of the HIV test and decisions disclosing the names of blood donors to transfusion AIDS plaintiffs.

Conclusions. During the past 2 years the number of reported AIDS legal actions has more than doubled the total that were reported during the preceding 4 year interval of 1983-86. Within this rapidly expanding framework, a significant body of AIDS law is now taking shape.



Session d'affichage Poster Session

Droit de éthique Ethics and Law

M.F.P.7 AIDS AND THE COURTS: COMPELLING AND PROTECTING THE DISCLOSURE OF AIDS STATUS
Morissette, Yves-Marie; de Glanville, H. Patrick; McGill Centre for Medicine, Ethics and Law, Montréal, Canada.

Court proceedings, whether civil or criminal, require under certain conditions the compulsory collection and the public disclosure of medical information. An AIDS patient may thus be forced to divulge his status in order to bring or to defend an action, including one not directly related to his illness. This paper discusses the competing legal policies which favour the confidentiality or the disclosure of a person's AIDS status in adversarial systems of procedure. Bearing in mind the desirability of protecting the privacy of AIDS patients, the authors examine (i) basic evidential principles, such as relevance, privilege and confidentiality, (ii) forms of compulsory discovery, including physical examinations and access to medical records, and (iii) the extent to which judicial proceedings and court records are and must remain open to the public. The idea of proportionality is central in this analysis. In most jurisdictions which adopt an adversarial model of procedure, legal rules already in existence allow for a satisfactory resolution of the conflict between the privacy of AIDS patients and the public nature of court proceedings.

M.F.P.9 SIDA : PROBLÈMES ÉTHIQUES POSÉS PAR LA PROTECTION DES DOSSIS DE SANG
D. BÉVÉRIER, CHAMBLÉ, M.P. LARSEN, J. CHAMBLÉ, P. ENEL, J.L. SAN MARCON

Laboratoire Santé Publique, Faculté de Médecine de Marseille, FRANCE

A partir d'une analyse qualitative concernant les aspects éthiques du SIDA, et portant sur 402 articles, notre réflexion s'est arrêtée sur problèmes particuliers posés au Centre de Transfusion Sanguine. Les questions ont été soulevées dès 1983, avec des mesures d'exclusion pour les donneurs présumés à risque; nous faisons une revue des législations des différents pays, en suivant leur évolution depuis l'apparition des tests de dépistage.

Toutes les questions éthiques posées par un dépistage systématique des donneurs sont analysées: anonymat, consentement éclairé, confidentialité ou ce qui concerne les résultats des tests, information des donneurs sur ces résultats... D'autre points concernent la responsabilité des banques de sang en cas de contamination. L'information des receveurs sur les dangers d'une transfusion dans des cas "à risque" ou des dons d'urgence ou de réserve.....

M.F.P.11 AIDS—ETHICAL, LEGAL, SOCIAL, AND ECONOMIC PROBLEMS

Joseph P. Izzo

New York City Council Health Committee Chairman
City Hall, New York, NY, U.S.A.

Objective. Examine the roles of ethical, health law, social and economic factors relating to the HIV epidemic.

Results. Discussion and analysis of the ethical, legal, social, and economic scope of this problem. Our failure to accurately predict the future size, magnitude, and changes in the pattern of the AIDS epidemic may result in the risk of total collapse of the health care system. Without a specific model to predict the future, we are placing our fiscal integrity in jeopardy for if we underestimate the size of the epidemic, we will guarantee that the result will be uncompensated care to all affected by the epidemic.

Conclusion. The establishment of a North American International AIDS HIV data base center would facilitate the collection, analysis, and distribution of HIV data which will encourage close collaborations between medical and epidemiologists and assist the governments of Canada and the United States in taking the most appropriate actions to stem the HIV epidemic.

M.F.P.8 THE CONSEQUENCE OF LEGALISATION OF PROSTITUTION IN VICTORIA
Overs, Cheryl*

* Prostitutes Collective of Victoria, AUSTRALIA

The objective is to explain and analyse the relationship between recent reforms to prostitution legislation in Victoria and changes to the structure of the sex industry with reference to HIV susceptibility of sex workers and clients.
Method. The following structural features of both the legal and illegal sectors of the sex industry will be discussed and compared: demography of participants; testing patterns; results and policy; industrial health and injury compensation; mechanisms for safe work practices and negotiation; policing; health care planning and other regulatory activity. **Conclusion.** Selective criminalisation and regulation of the sex industry may exacerbate the risks it aims to reduce where it simply reworks mistaken conceptual understandings of sex work from old criminal law into modern administrative provisions.

M.F.P.10 COMPELLING SEXUAL COOPERATION: DOES IT REMAIN OR SHOULD PUBLIC HEALTH
BENNETT, JUDITH, McGill Centre for Medicine, Ethics and Law, Montréal, Canada

Objective. To consider whether compulsory sex-reporting of HIV/AIDS facilitates the collection of necessary health and treatment, and the implementation of effective and safe sex practices.

Background. A number of empirical studies of compulsory requirements in public health legislation in Canada, the United States, and the United Kingdom have been conducted.

Results. (1) In the jurisdictions studied, which all have a similar pattern of HIV infection, HIV/AIDS cases have been reported more extensively in their respective countries under public health legislation. (2) This trend has been observed in the case of both men and women. (3) The extent of HIV/AIDS, (4) the way in which the provisions do not meet the specific requirements of public health measures) or too broad (the provisions are more restrictive of rights than is necessary for public health purposes). (5) There is often little or no statutory protection for the confidentiality of information reported.

Conclusions. (1) The lack of uniformity in compulsory requirements indicates uncertainty about the benefits and harms of sex-reporting in achieving the aim of reducing the spread of HIV and obtaining necessary epidemiological data.

(2) Compulsory sex-reporting can affect these aims and cause other harm by (a) discouraging necessary health and treatment, and (b) discouraging participation. One of the reasons why voluntary and non-remunerated sex-reporting may be better achieved by law.

(3) Some of the aims sought to be achieved by compulsory sex-reporting may be better achieved by other, less harmful, means. An empirical investigation of public health, concerning voluntary behavior changes.

(4) Support for individual rights demands that compulsory requirements be defined as narrowly as possible while still achieving the desired public health objective; the majority of requirements studied do not meet this test.

(5) There is an urgent need for HIV/AIDS sex-reporting requirements to be re-evaluated (a) to ensure collection of accurate and uniform data; (b) to protect individual rights to the greatest extent possible; and (c) to avoid obstructing and to maintain the effect of efforts to reduce the spread of HIV.

M.F.P.12 THE IMPACT OF LAW AND POLICY ON NEEDLE EXCHANGE PROGRAMMES IN CANADA
Orkin, A. and Gupta, A.S.

McGill Centre for Medicine, Ethics and Law, Montreal, Quebec, Canada

Objective. To evaluate policy and law as factors impeding public health initiatives aimed at preventing the spread of HIV amongst intravenous drug users in Canada.

Background. Analysis of Canadian policy and legislative approaches to illicit drug use and their impact on the distribution of needles and syringes to those at highest risk of HIV.

Results. The response to illicit drug use in Canada, mirrored and influenced by that of the U.S., is largely incoherent and inconsistent. Outside user legislation in 1988 as an intended result of anti-AIDS risks. Subsequent legislation was also followed by demands for stronger control of illicit drug markets which criminalisation had helped to create. Canadian narcotic legislation since 1981 imposes harsh penalties for possession, trafficking, importation and exportation, but mostly none for use. Treatment legislation has received little emphasis. The general climate is one of harsh societal disapproval of illicit drug use and drug users.

In contrast to the U.S. one Canada lacks legislation prohibiting the possession of needles and syringes or their supply to intravenous drug users. A recent Bill criminalising possession, sale and exportation of needles and syringes to intravenous drug users in Canada, only one pilot program has been established (1989). A conflict is perceived between the increased efforts for programs to prevent the spread of HIV and demands for tougher drug use laws. Increased efforts are required to persuade legislators and the public that these two goals are not incompatible, and that increased syringe distribution is not in contravention of the law.

Conclusions. The climate surrounding illicit drug use in Canada is a substantial obstacle to urgently-needed public health programmes to prevent the spread of HIV. Such programmes in Canada, only one pilot program has been established (1989). A conflict is perceived between the increased efforts for programs to prevent the spread of HIV and demands for tougher drug use laws. Increased efforts are required to persuade legislators and the public that these two goals are not incompatible, and that increased syringe distribution is not in contravention of the law.

Session d'affichage
Poster Session



Droit et éthique
Ethics and Law

M.F.P.13

STATE/LOCAL STRATEGIES TO PREVENT AND RESOLVE HIV-RELATED DISCRIMINATION: FIVE CASE STUDIES

Coauthors: Anne H.**, Sherwood-Faber, J.**, Steele, R.J.***, Karsten, S.L.***, Lorenz, S.T.***, Ritter, J.L.***, [†]Office of the Assistant Secretary for Health, U.S. Public Health Service, Washington, D.C., **Kirch and Davis Associates, Inc., Silver Spring, MD.

Objective: To identify successful processes for preventing and resolving complaints of HIV-related discrimination, and program features affecting replicability.

Methods: Five programs were selected for the study based on the existence of a relevant discrimination statute, availability of program documentation, and program experience. The project team visited all 5 sites (Los Angeles, CA; San Francisco, CA; New York City, NY; Philadelphia, PA; and, Olympia, WA), prepared case-study reports, and a final summary report.

Results: Litigation is rarely necessary to resolve complaints. Most often, discrimination occurs out of fear or ignorance, and interventions utilizing educational, mediation, and advocacy strategies are sufficient and timely. In addition, the programs' enforcement efforts appear to prevent some additional complaints. The programs may also provide technical assistance to persons seeking advice on their rights or obligations under the law.

Conclusion: The wide variety of site features suggests that the essential processes of these programs can be successfully adapted in many settings. Further, the programs' successes in keeping persons in their homes and/or jobs tends to promote private sector involvement in the AIDS issues, and may limit the burden of the AIDS epidemic which is shifted to the public sector.

M.F.P.14

M.F.P.15



Session d'affichage Poster Session



Droit et éthique
Ethics and Law

La confidentialité et ses limites Confidentiality and Its Limits

T.F.P.1 TRIAL OF CHEMO-PROPHYLAXIS OF HIV INFECTION AMONG THE HEALTH-CARE WORKERS' RIGHT-TO-KNOW VISA-VIS THE PATIENT'S RIGHT TO CONFIDENTIALITY

Author: Stanley Korman, Hospital Center, Bronx, NY, USA.

Objective: To evaluate health-care worker's (HCW) rights vis-à-vis patients' rights in relation to possible chemo-prophylaxis of HIV infection in HCW after exposure in the workplace (WP) to HIV infective blood and body fluids (BBF).

Methods: The Burroughs Wellcome Co., makers of zidovudine (AZT), is sponsoring a double-blind, placebo-controlled trial of AZT in the prevention of HIV infection in HCW after WP exposure to BBF of HIV antibody (Ab) positive patients. Animal studies suggest that early AZT treatment is most effective. A rapid reliable slide test is now available to detect HIV Ab in serum.

Results: HCW may join the trial after exposure to known HIV Ab positive BBF by phoning 1-800-HIV-STIX. However, if the Ab status of the patient is unknown, informed consent, to protect patient confidentiality, must be obtained to test the patient's blood for HIV Ab. If consent is denied, and HIV Ab status of the patient is unknown, the HCW may be excluded from the trial.

Conclusion: After exposure of a HCW in the WP, patients who's HIV Ab status is unknown should be tested with the rapid slide test, with or without the patient's consent, since HCW right-to-know of a potentially lethal hazard in the WP and possible subsequent exclusion from the AZT trial supersedes the patient's desire for confidentiality of results of HIV Ab testing.

T.F.P.3 CONFIDENTIALITE ET SIDA. UTILISATION D'UN CODAGE IRREVERSIBLE DE L'IDENTITE

L. THILION, R. SARRUC, C. MANUEL, J.L. SAN MARCO

à Laboratoire de Santé Publique, Faculté de Médecine de Marseille, FRANCE

Objectif: Respecter la stricte anonymat des patients tout en permettant les soins épidémiologiques et économiques nécessaires par le SIDA.

Méthode: Utilisation d'un algorithme codé qui est le résultat d'une formule de calcul irréversible. Il est impossible à partir de ce code de retrouver l'identité du patient, son code. Pourtant la formule de codage est publique et un message suffit à décodifier.

Résultats: Validation de la non réversibilité du codage par le Service Central de la Sécurité des Systèmes d'Information.

Utilisation de ce message d'anonymat par les différents centres d'information de Santé (CISID), de même que par l'organisation responsable de la distribution des produits actifs contre le virus.

Conclusion: Cette méthode est opérationnelle et contribue à la protection de ces données médicales particulièrement confidentielles.

Éthique clinique Clinical Ethics

T.F.P.5 "PERCEPTIONS AND ATTITUDES OF HEALTH CARE WORKERS ON ETHICAL AND SOCIAL ASPECTS OF AIDS IN A DEVELOPING COUNTRY."

Faizal Farhat, B. A. A. Greatt. University of the West Indies

Monica, Kingpin AIDS has raised several controversial and unresolved ethical, social and medical health care problems.

In order to assess the perceptions and attitudes of Jamaican health care workers (HCW) on ethical and social aspects of AIDS, we conducted a survey in 4 Jamaican hospitals between July-August, 1986. 500 Questionnaires were sent to randomly selected members of which 379 were returned before the cut off date. A response rate of 75%. The affirmative responses (A) were tabulated for each category of HCW.

QUESTIONS	Doctors (n=102)	Nurses (n=112)	Hygiene (n=104)	Radiographers (n=102)	Total (n=420)
1. Confidentiality	20	8	9	11	23
2. Routine screening	78	78	55	63	51
3. Identity card	78	84	86	83	83
4. Special isolation hospital for AIDS patients	40	57	59	50	40
5. Sharing waiting room/toilet facilities	70	63	53	52	62
6. Extensive lab tests for seropositivity test	90	59	57	54	71

Our survey demonstrated that HCW do not differ in their perceptions and attitudes as compared with general public. Hence, HCW of developing countries need to be further educated themselves before they can educate the public.

T.F.P.2 CONFIDENTIALITY AND AIDS: A CANADIAN PERSPECTIVE MAGILLIAN, ROBERT M., Barnes, M.E.*

*Ministry of Health, Ontario, Canada

Objective: To explore legal, ethical and public health issues related to balancing the interests of the individual with respect to privacy of personal information, with that of protecting the health of the public.

Methods: The presentation will report the results of inter-provincial consultation and collaboration on such areas as: 1. control of HIV testing facilities; 2. reporting requirements; 3. collection of epidemiological data; 4. contact tracing and counselling; 5. under which circumstances should information be disclosed and to whom. Information will include the results of an invitational conference for providers, patients and the public on these same issues as well as the results of a formal inter-provincial working group.

Results: The consultation has resulted in national agreement on definitions, general principles for HIV testing, basic data to be collected for testing, the role of public health authorities and primary care physicians, and guidelines for the following: i. disclosure of information to protect the interests of the HIV positive persons; ii. disclosure to protect sexual or other contacts; iii. disclosure to protect the public; disclosure to protect patients of HIV positive physician and iv. disclosure to an employer

T.F.P.4 ETHICAL THEORIES APPLIED TO CONFIDENTIALITY IN HIV/AIDS DINA, J. Editor, Union Theological Seminary, New York, NY, U.S.A.

Objective: Protection of confidentiality and prevention of further disease through an

Method: Use of various established theories and models applied to the problems of the prevention and limitation of confidentiality for infectious immunodeficiency Syndrome (AIDS), AIDS Related Complex (ARC), or Human Immunodeficiency Virus (HIV), and the theories and models to the conflict between the medical tradition of absolute confidentiality between clinician and patient and the tradition of disclosing infectious status to others at risk of the presenting patient, allowing these others to make autonomous choices.

This debate, while important for patients who are openly homosexual or intravenous drug abusers, is even more key for the bisexual male, often married, and with children or planning children, whose bisexual preference is not known to his family.

For medical practitioners and the students who work with them, the dilemma is unavoidable. Often these patients belong to a family practice organization. Hence, their wives and other family members of the same group of practitioners, balancing the value of confidentiality for the presenting patient against the value of protecting the health of the other persons also known to the practitioners. Yet, it is a physician or group inform their other patients, will the presenting patients disagree, thereby leaving any choice of their clinicians unhelpful and affecting their behavior?

The paper will include a sample protocol that attempts to apply ethical theories to these problems.

Results: With sustained counseling, most infected patients will voluntarily inform their contacts where they have not done so. Where physicians have done so, these patients have generally not been lost to treatment. There have been some notable and unfortunate exceptions.

Conclusion: Under certain circumstances, it is ethically permissible to break confidentiality, when the direct and immediate result is the probable prevention of disease, and there are no other means to accomplish this goal.

T.F.P.6 A MODEL FOR FACILITATING PHYSICIANS WITH AIDS OF RISK WHEN TREATING PATIENTS WITH AIDS

Franklin, Victor Y., Walker, J., Blake, P.,

San Jose Medical Center, San Jose, CA, U.S.A.

The refusal of physicians to treat patients with AIDS because of fear of infection is a recognized problem. Recently clinicians have proposed models based on strain to encourage physicians to treat patients with AIDS. It is argued that these models will not be widely enough applied and the additional model that recognizes physician self-interests are needed.

Physicians have always shown a mixture of altruism and self-interest, the proportions varying not only from individual to individual, but from one historical era to another. The period when all apparently quackish physicians treated the contagious, it is assumed that is generally held today, based only a century (c. 1800-1900). This was also a period when a high degree of paternalism was inherent in the physician's role and it is argued that the benefits of paternalism, e.g. power, self-interest, and submission, compensate in part for the risk of infection.

Public culture and self-interest are recognized and derive self-interest because they risk their lives daily in the service of others. When a public officer or fire-fighter is injured or dies in the line of duty, he or she is considered a "hero" because the injury or death resulted from the willingness to assume the risks of the job. Being interested and being seen by others as heroes might provide additional justification to some physicians to help compensate for the risk of infection. The first step in helping physicians become a selfless, respectful, emotional and financial, for someone who accompanies in the line of duty. Specific proposals to implement such a model and implications for other health-care workers will be presented.

Session d'affichage Poster Session



Droit et éthique
Ethics and Law

T.F.P.7 **CHRL BIOCETHICS COMMITTEE AND THE ANTI-HIV SCREENING TEST**
Mauritice R. E. *
*Centre Hospitalier de l'Université Laval (CHUL), Québec (QC), Canada; *Chûpital de biotechnique.

Within 16 months, three requests for opinion concerning the use of anti-HIV screening tests were submitted to the CHUL Bioethics Committee by health-care professionals. The first request dealt with accidental infection with HIV among the surgical block staff (1988-91). The second request dealt with routine screening of anti-HIV for all patients undergoing surgery (1989-91). The third request was related to the management of fresh semen in frozen semen stocks for the purpose of heterologous insemination (1988-91).

Objectives: To present: (a) the positions adopted by the Committee; (b) the scientific, legal and ethical considerations that justified these positions; (c) the outcome of these requests for opinion submitted to the Committee.

Method: The method adopted by the Bioethics Committee is as follows: (a) creation of a multidisciplinary task force (medicine, ethics and law) upon reception of the request for opinion; (b) submission of a preliminary paper to the Committee; (c) discussion of and modification to the preliminary paper by the Committee; (d) issue of a unanimous opinion by the Committee.

Results: These opinions are now part of CHUL internal policies regarding the use of the anti-HIV screening test.

Conclusions: 1. The fear of possible accidental contamination by HIV among health-care professionals is very high. 2. Health-care professionals are aware of the ethical dimension in the use of the anti-HIV screening test.

T.F.P.9 **ETHICAL STANDARDS IN THE CONTEXT OF HIV INFECTION**
Nobert Bouché, Ian Schäfer, Deutsche AIDS-Hilfe e.V.
Neustadt, B-9, 1000 Berlin 11, West-Germany

Objective: To determine ethical standards for obtaining medical data.
Methods: The Deutsche AIDS-Hilfe performed several seminars on ethical standards. Participants were people with HIV and AIDS, doctors, health care workers, philosophers etc.

Results: It was found that there is a lack of ethical standards in treatment, counselling and research with people with HIV and AIDS. An ongoing irrational fear of contracting HIV and AIDS is one of the main factors that inhibit people from dealing with HIV infection and AIDS in an objective way. The lack of ethical standards in collecting medical data leads to the misgiving of people with HIV and AIDS that their personal data could be misused and that treatment research is more for the benefit of the researcher and not for the person with HIV and AIDS. **Conclusions:** There is a desperate need for national and international ethical standards for counselling and research. Specific proposals will be presented at the conference.

T.F.P.11 **APPROCHÉ ÉTHIQUE EN PRÉSENCE D'UNE SEVE HÉMOGRAPHIQUE**
MABEL GAGLIARDI, EMIL P.A., DANIEL J.P., REYNER D., LARSEN R.P.,
DAN SIEGEL
*Laboratoire de Saint Pauliens, Faculté de Médecine, Montréal, FRANCE

Objectif et méthode: L'étude hémigraphique présentée a débuté par l'introduction de quatre bandes de bandelettes médiales, CHRL, Biotek et HEM, avec les kits d'analyse (assemblée au no 105) à l'échelle, Droits, Droits de l'homme, Confidentialité, Législation, Jurisprudence. Un total de 412 références ont été listées de 1982 à fin 1987.

Méthode: Après lecture et analyse des publications disponibles et à l'aide de certains (1987), les législations québécoises, CHRL, Biotek et HEM, avec les kits d'analyse recueillies dans les articles ont été répertoriées par thèmes et classées.

La classification qui sera présentée est la suivante:

- 1 - BÉNÉFICES DESTINÉS À PROTÉGER LA SOCIÉTÉ
Nouveaux produits et méthodes d'analyse et traitement, services d'assistance sociale, services groupés, tests de sérologie, application de code criminel, déclarations obligatoires à l'Agence, protection des dons de sang, vaccins et médicaments nouveaux, essais thérapeutiques, information, éducation.
- 2 - BÉNÉFICES DESTINÉS À PROTÉGER L'INDIVIDU
Droits fondamentaux de l'individu : droit à la confidentialité, à l'information et au silence.
Droits citoyens : liberté, droit à l'éducation, au travail, etc...
Droits de l'individu non malade : droits de contacts, sécurité du personnel soignant, des receveurs de sang, etc.

T.F.P.8 **A LEGAL OR ETHICAL DUTY TO WARN: ONE LAST TIME**
North, Richard, Rothenberg, K. Associate
Professor, University of Maryland School of Law,
Baltimore, Maryland, USA.

Objective: To reconcile the moral, institutional, public health and legal principals bearing upon the existence of a duty owed by professionals to warn unsuspecting third parties that a patient or client knowingly places that third party at risk of HIV infection.

Method: Reviewed the medical, ethical, and legal literature concerning the "duty to warn" and summarized the arguments. Evaluated the many proposals for legislation or for legal clarification of the moral dilemma.

Analysis: There are three primary values or goals competing in the debate: confidentiality, the public desire to block the spread of infection and the personal desire to avoid legal liability. These values are irreconcilable in some extraordinary factual circumstances. Law does not resolve these tensions nor should it be relied upon to do so.

Conclusions: Professionals are traditionally entrusted by society to make difficult decisions, distinguishing them from other occupations. On a case-by-case basis, professionals must determine if a warning (or other action) to a person at risk of infection is the highest "good." We propose a framework for making that decision which includes consideration of a professional's risk of legal liability.

T.F.P.10 **SIDA : LES DROITS DES MALADES**
CHRISTEL JOLIVET*, LARSEN R.P.P., EMIL P.A., MABEL G., DAN SIEGEL J.L.*
*Laboratoire de Saint Pauliens, Faculté de Médecine, Montréal, FRANCE

Les relations de santé et de risque associées par le SIDA compromettent au danger éthique par le risque en matière de droits de malade au regard de la relation médecin-patient. **Objectif:** L'information et les soins.

Les défenseurs de la confidentialité protestent et défilent dans l'urgence sans une présentation de la transmission, tout en respectant la dignité des malades.

Les appaats traitent que le niveau de secret médical est le seul moyen de protéger le patient des contacts et pallier l'irresponsabilité de la plupart de ces malades.

Au sujet de droit de malade à l'information, les soins s'appuient sur quatre points principaux: l'accord de sujet par la pratique de test de dépistage, la réalisation de son affecter au malade, l'existence de consentement aux traitements et les modalités d'application des essais thérapeutiques dans le cadre de SIDA.

Quant au droit au soin, il se présente en deux cas: le SIDA, à tel point que les Assemblées Médicales sont sous contraintes de respecter fondamentalement ce principe d'éthique.

Un dialogue de santé s'est ouvert instauré entre défenseurs et détracteurs des droits de malade, entraînant parfois des prises de position excessives.
En fin des années le monde connait ce qu'est à apprendre à vivre avec le SIDA, et les problèmes peuvent être abordés de façon plus constructive.

T.F.P.12 **INFLUENCE OF HIV STATUS ON DECISION MAKING FOR SURVIVAL**
PODREK, DANIELA B. *
*Columbia University School of Nursing, New York, New York, U.S.A.
*Yale University School of Nursing, New Haven, Connecticut, New York, U.S.A.
*Brooklyn College, BROOKLYN, New York, U.S.A.

Objective: To describe the impact of maternal/infant HIV seropositivity on decision making for newborns.

It is clear that current HIV testing in the newborn does not yield results that allow for differentiation between maternal and fetal seropositivity. Newborn HIV status, however, is used by some physicians and nurses to justify treatment/management decisions. It is not always clear that alteration of the management plan based on HIV status is warranted. In addition, parents and parental surrogates (ie foster parents) may alter their decisions based on the HIV status.

Methods: Questionnaires administered to physicians and nurses in three metropolitan New York City neonatal ICUs and interviews with social service child-care workers.

Results/Conclusions: Preliminary data (both formal and anecdotal) indicate a newborn's HIV status influences decision making.

**Session d'affichage
Poster Session****Droit et éthique
Ethics and Law**

T.F.P.13

T.F.P.14

T.F.P.15

**Session d'affichage
Poster Session****Droit et éthique
Ethics and Law****W.F.P.13**

W.F.P.14

W.F.P.15



Session d'affichage Poster Session



Droit et éthique Ethics and Law

Discrimination et droits de la personne Discrimination and Human Rights

Th.F.P.1 AIDS AND ETHICS

Levi, Guido Carlos* & Barroo, Antonio Osério
Lima, A. *
* Hospital do Servidor Público Estadual, São Paulo, Brazil
** Health State Secretary, São Paulo, Brazil

Objective: The authors prepared for the São Paulo Medical Council and the Brazilian Federal Medical Council a resolution regarding many ethical aspects on AIDS. Approved in 1989, it is now the official guideline for Brazilian medical doctors on this matter.

Methods: The subject was divided into six parts: introduction, AIDS and discrimination, relationship between doctors and patients (including patient refusal, respect towards the patient, patient's abandon and confidentiality), AIDS and institutions (including hospitals, blood banks and prisons), AIDS and Occupational Medicine and AIDS and medical research.

Results: A short resume of each of these topics will be presented.

Th.F.P.3 STATE/LOCAL STRATEGIES TO PREVENT AND RESOLVE HIV-RELATED DISCRIMINATION: FIVE CASE STUDIES

Griffin, James H., Starwood-Petrie, L., Siseal, E.J.,**
Kavran, S.E.,** Lorenz, B.W.,** Miller, J.L.,**
Secretary for Health Services, Ontario, Canada
**Aitch and Davis Associates, Inc., Silver Spring, Md. U.S.A.

Objective: To identify successful programs for preventing and resolving complaints of HIV-related discrimination, and program features affecting replicability.

Methods: Five programs were selected for the study based on the existence of a relevant discrimination statute, availability of program documentation, and program experience. The project team visited all 5 sites (Los Angeles, CA; San Francisco, CA; New York City, NY; Philadelphia, PA; and Olympia, WA) prepared case-study reports, and a final summary report.

Results: Litigation is rarely necessary to resolve complaints. Most often, discrimination occurs out of fear or ignorance, and interventions utilizing educational, mediation, and advocacy strategies are sufficient and timely. In addition, the programs' enforcement efforts appear to prevent some additional complaints. The programs may also provide technical assistance to persons seeking advice on their rights or obligations under the law. **Conclusion:** The wide variety of site features suggests that the essential processes of these programs can be successfully adopted in many settings. Further, the programs' successes in keeping persons in their homes and/or jobs tends to promote private sector involvement in the AIDS issue, and may limit the burden of the AIDS epidemic which is shifted to the public sector.

Th.F.P.5 GOVERNMENTS' DUTY TO PROVIDE FINANCIAL ASSISTANCE AND COMPENSATION TO PERSONS WHO HAVE CONTRACTED AIDS INFECTION BY HIV THROUGH BLOOD TRANSFUSIONS AND BLOOD PRODUCTS

Jacques J.M. BODIN, Hennes & Inattlie Law Firm, Montreal, Que.CANADA

Objective: 1) To review Governments' response to the Demands FOR COMPENSATION by individuals who have contracted AIDS INFECTION BY HIV THROUGH BLOOD TRANSFUSIONS AND BLOOD PRODUCTS.

Method: In addition to a brief review of the early history of ETHICAL and LEGAL issues, Reference is made to other countries legal principles and domestic constitutional documents are made to support arguments. Compensation schemes in other countries and their legal bases are also identified. **Results:** The author explains that since certain Governments had not characterized infection too broadly at the outset to those individuals who contracted the disease from contaminated blood. **Conclusion:** Those Governments displayed little interest in the duty of blood supplies in its system or ignored the early demand since it considered the most elementary responsibility in the field of human rights: the right to life and the protection thereof. Such Governments have the duty to compensate hemophiliacs and blood transfusion recipients infected by HIV/AIDS.

Th.F.P.2 L'ETHIQUE DANS LES GROUPES COMMUNAUTAIRES

Sourdis, Isabelle
Centre AIDS Montreal, Montreal, Québec, Canada

Objectif: Décrire l'organisation d'un groupe de travail sur les aspects éthiques dans un organisme communautaire. Les priorités, les méthodes, l'étude des besoins, l'identification des problèmes d'ordre éthique pour un groupe de travail sur l'éthique. Quelles priorités établir? Actions à entreprendre? Objectifs? Qui doit faire partie de ce groupe? Critères? Structure? Fonctionnement?
Méthodes: Elaboration de procédures d'acceptation des projets de recherche. Codes d'éthique interne. Code d'éthique des professionnels et des bénévoles. Positions officielles de l'organisme. Confidentialité.
Conclusion: Possibilité de ce genre de travail pour protéger les droits des personnes affectées par le virus. Voir au respect des individus (personnes atteintes, bénévoles, professionnels). Capacité de regarder objectivement un problème. Travail-réflexion.

Th.F.P.4 EQUALITY RIGHTS FOR PEOPLE WITH AIDS: MANDATORY REPORTING OF HIV INFECTION AND CONTACT TRACING IN ONTARIO

Fleming, William F., B.A., LL.B. (Toronto), D.C. (Paris 1), LL.M. (Columbia); Columbia University School of Law, New York, New York, U.S.A.

Objective: To examine the public health rationale and constitutional implications of (1) the mandatory reporting of HIV infection with identifiers and (2) an active contact tracing program supervised by public health officials (as in the present practice in the Province of Ontario).

Method: Examination of the equality rights provision under s.15 of the Canadian Charter. I present the view that protection for the physically disabled under s.15 extends to HIV-infected individuals. I then examine whether the Ontario program, which prejudicially affects the interests of the physically disabled, can withstand Charter review. **Conclusion:** Because of concerns for confidentiality, the mandatory reporting of HIV infection with identifiers seriously discourages voluntary HIV testing, an essential element in preventing the spread of HIV. Mandatory reporting does not therefore serve the public health objective of controlling HIV. Although mandatory reporting does permit public health officials to enforce a contact tracing program, contact tracing is better performed by private physicians (where warranted) rather than public health officials. Physician-conducted contact tracing (even without the patient's consent) less seriously threatens the need for confidentiality because no state records of HIV infected individuals are maintained. Third parties at risk for HIV infection are thus notified without seriously discouraging individuals from seeking voluntary HIV-tests.

Th.F.P.6 PROVIDING HIGH QUALITY, LOW COST LEGAL SERVICES TO PEOPLE WITH AIDS: A DISCRIMINATION LAW PROJECT

Barnes, Mark and Greenberg, J.
AIDS Law Clinic, Columbia University School of Law, New York, New York, USA

People with AIDS or HIV infection, as well as persons only perceived to have AIDS or HIV infection, have experienced severe discrimination in employment, housing, access to health care and insurance. At the same time, because of indifference or fear-inducement due to medical expenses, persons with AIDS have had very limited access to high quality legal help for their discrimination problems. In September 1988, the Columbia University School of Law formed an AIDS Law Clinic, staffed by two full-time faculty and sixteen students, each of whom devoted half their academic time to the Clinic and received one-half of a semester's course credit for their work. Operating under a special practice order from the local court system that allowed the students to function as formal legal representatives, the Clinic accepted referrals from local AIDS service organizations, local human rights agencies and public interest attorneys. The Clinic provided free legal services to its clients, and by February 1989, it had accepted representation in approximately thirty discrimination cases, with several cases already resolved in favor of clients who otherwise would have lacked any private legal counsel. By using law students as legal representatives, the Clinic has provided high quality, low cost legal services to underserved populations. Also, law students valuable experience in the representation of clients and training in important policy issues. The AIDS Law Clinic can serve as a model for similar clinics at other professional schools.

Session d'affichage Poster Session



Droit et éthique Ethics and Law

Th.F.P.7 AIDS POLICIES OF CANADIAN UNIVERSITIES

Harvey, Donald C.,¹ Blomhette, M.²

¹Canadian Association of University Teachers, Ottawa, Canada.
²Canadian Association of University Teachers, Ottawa, Canada.

Objective: A study of the administrative and ethical policies on AIDS of Canadian universities in regard to their faculty, students and support staff.

Method: by questionnaire and telephone follow-up with university administrators and the local representatives of faculty, students and support staff.

Results: Universities normally regard themselves as leaders in their communities. This research tests whether Canadian universities are acting as leaders in this area. It examines and analyzes on a comparative basis the extent to which Canadian universities have developed policies both to deal with AIDS on the university campus and to educate the university community about AIDS. This involves in the first category such ethical and administrative matters as policies on confidentiality, restriction of access to some or all university facilities and programs, access to insurance programs and the second category the type of program for educating staff and students and the investment therein.

Th.F.P.9 HIV ANT-BODY TESTING: is consent the legal issue?

Harvey, Don, Leah Officer, The Terrence Higgins Trust Legal Centre, U.K.

Objective: To analyze the legal importance of patient consent, and to ask whether it secures the proper use of the antibody test.

Method: Consent is important ethically and professionally. Testing without consent would undermine confidence in public health. Whereas voluntary testing is extremely useful. Positive or negative people can be advised to have safer sex directly by the doctor or clinic. Consent is required under UK law before a patient's blood is tested. Without expressed or implied consent there is no defence to the charge of assault. People tested positively without consent can sue, if, as a result, they lose their insurance, job or accommodation.

Conclusion: Consent is an important legal issue in ensuring the proper administration of the antibody test. How the test is used may be the more important social and legal issue. Agreeing to have a HIV is fast becoming a standard pre-condition to be considered for insurance, a job or work permits in some countries.

This requirement is legal in the UK, should it be?

Th.F.P.11 CATASTROPHIC RIGHTS

Olson, John Frederick, B.C. Civil Liberties Association, Vancouver, British Columbia, Canada

Objective: To define and explore the limits of a special instance of patients' rights in the context of catastrophic illness.

Method: To bring the disciplinary tools of philosophy and law to bear on the task of analyzing the conflicting claims of the catastrophically ill and public health authorities in connection with the specific issue of access to experimental therapies, and the general issue of therapeutic self-determination.

Result: Considerable merit is discovered in the argument of public health policy-makers that important public interests are served by the social control of therapies. In opposition to this result it is discovered that there exists a well-grounded claim, on the part of the catastrophically ill, to an enhanced right to therapeutic self-determination. Specifically, a symmetry between the right to refuse medical treatment (one of the most well-established rights of patients) and the right of the catastrophically ill to access experimental therapies is discovered and explored. When catastrophic rights are carefully balanced against the public interest sought through the governmental control of therapies, it is discovered that they are real, not limited scope.

Conclusion: Regulatory authorities should respond to catastrophic rights by carefully liberalizing access to some experimental therapies.

Th.F.P.8

FORUM FOR CIVIL AND HUMAN RIGHTS SOCIETIES ACTIVE IN AIDS WORK
The B.C. Civil Liberties Association
B.C., CANADA

Objective: To make possible a sharing of information and expertise in the specific areas of concern to governmental and non-governmental bodies concerned with the recognition and protection of individual rights in connection with AIDS.

Methods: To inform most of the human and civil rights bodies in the world - including all ambassadors of every government - of the special focus of the 1989 International Conference on both social and scientific issues, and to encourage their participation in a special forum for rights bodies. The physical planning for such a forum can be organized on the basis of the responses received to the correspondence with these bodies undertaken by the B.C. Civil Liberties Association.

Conclusion: We suspect that many rights bodies would welcome an opportunity to explore together, in the supportive expert context provided by the International Conference, the special difficulties posed for individual rights by AIDS. Regulatory authorities would capitalize on an opportunity to sensitize rights advocates to the substantial public interests that policy makers must responsibly secure as they respond to the special plight of the AIDS person.

Conclusion: The Rights Forum, organized under the aegis of the International Conference, is an important step towards reconciliation of the perspectives of AIDS persons, their advocates, and the governmental authorities who must adjudge their demands.

Th.F.P.10 A BILL OF RIGHTS FOR PERSONS WITH AIDS

Spitzer, Herbert S., Ph.D., Taylor, Clark¹
¹Issues Committee, ACT UP, N.Y., U.S.A.

The objective of this abstract is to describe the elaborating of a Bill of Rights for Persons living with AIDS. Above all else, the medical, political and social rights of Persons with AIDS must be secured in the treatment of this disease. To ensure this objective, a Bill of Rights for PWAs must be drafted, discussed, ratified and promulgated. It will be developed primarily by Persons with AIDS, defined as anyone who is HIV seropositive and/or living with AIDS or ARC. This Bill of Rights will serve as a model to be presented to national legislative bodies, and to the United Nations General Assembly and the World Health Organization; it will contain recommendations for laws that will place the health and care of PWAs in the forefront of setting national and world policies on AIDS. Medical, moral, economic, political and social principles affecting all aspects of AIDS (including but not limited to research, treatment, health care and public policy) will be derived from what is beneficial for persons most effected by AIDS--those having the disease. Any and all claims, be they political, medical, economic, scientific, proprietary or social, conflicting with the principles in the Bill of Rights will be subordinated to the fundamental rights of Persons with AIDS.

Th.F.P.12 THE INFLUENCE OF AIDS ON INDIVIDUAL RIGHTS AND THE DIGNITY OF PEOPLE

Arredondo, C., Conde, F., Coronado, A., Gil, E.,
Ministry of Health, Spain.

Objective: The influence that AIDS is having on the rights of individuals and the dignity of people in the social conception of it is, and the form in which different social groups learn about it has been studied. This has taken account the fact that the repercussions of AIDS go far beyond daily social affairs, and that within society it is reflected as a contagious-incurable-sole-mortal-fact that causes the inevitable physical deterioration and ensuing death, as well as inevitable social segregation.

Conclusion: This report presents research carried out by means of a representative survey of the Spanish population and has clearly shown that information and rational reasoning alone when dealing with AIDS are insufficient to undertake this problem which is strongly rooted in deeper "social fears".

SECTION G



Implications internationales
International Issues



Séance thématique Specialty Session



Implications Internationales International Issues

Le sérodiagnostic Serodiagnosis

M.6.0.1 EVALUATION OF THE PROGRAM FOR PREVENTION AND CONTROL OF BLOOD TRANSMISSION OF HIV (PCPCT) IN MEXICO
Basilla, L., Garcia, L., Dominguez, A., Valdesola, M.,
 "Instituto de Epidemiología y Higiene de Salud, Mexico,"
 "National Center of Blood Transfusion."

Objective: Evaluation of the Program for Prevention and Control of Blood Transmission of HIV (PCPCT) in Mexico.
Method: To design a strategy for the evaluation of donors, blood products and recipients, to measure the impact at short, medium and long term of PCPCT.

Results: The PCPCT in Mexico has been functioning for two years. Infrastructure, legal modifications and political will were required. The initial legal modifications based on an acceptance of 7% of paid donors, were mandatory donation of donors and prohibition of blood commerce. A national network of laboratories (NNL) was created. At present, seroprevalence in donors is 0.01 to 0.08%. 700,000 units of blood are transfused yearly. Main coverage problems are located in rural areas and small hospitals in other areas. Measures taken to face this problem include the adoption of quick tests and the expansion of the NNL. Cases associated to transfusion increase from 2.2% in March, 87 to 11.2% in January, 88.

Conclusions: In those countries where the transmission of HIV associated to transfusion of blood products is important, it constitutes a bridge between hematological and general transfusion. Measures to ensure the quality of blood should be screened, including the prohibition of blood commercialization. The medium term evaluation shows that the measures adopted are still insufficient. It is expected that cases associated to transfusion continue to increase for some years. The adoption of quick techniques and consolidated purchases of reagents will allow the optimization of resources.

M.6.0.3 DETERMINATION OF HIV-1 SEROPREVALENCE IN A COHORT OF 800 INDIVIDUALS IN KINSHASA ZAIRE USING POOLED SERA CONCERNED WITH TESTING OF INDIVIDUAL SERA
Recht, L., Kasi, M., Ndilo, M., Brown, C., Ryser, R.,
 Quinn, T.C., "Projet SIDA, Kinshasa, Zaire," "HIAID, NIH, Bethesda, Maryland."

Objective: To determine the accuracy and cost-effectiveness of testing pooled sera samples compared to testing individual sera samples in establishing seroprevalence of HIV-1 infection in an African population.
Method: Serum samples from 800 persons were tested by ELISA (Orgenon) and repeatedly sensitive samples were analyzed by Western blot (DuPont). 800 pooled sera were made from this population, each containing 100 microliters from 10 different individuals. Pooled samples which were repeatedly tested by ELISA were considered positive.

Results: The seroprevalence as determined by testing 800 individual sera was 2.44% compared to 2.41% (95% CI=2.05 - 2.77%) as determined by testing 800 pooled samples. Of the pooled samples that tested negative (n=27), none contained any positive individual samples. Of the positive pooled samples (n=73), 146 contained 1 positive sample, 16 contained 2 positive samples, 2 contained 3 positive samples and 9 had 4 individual samples. 828 ELISA tests were required to determine seroprevalence using individual sera compared to 973 ELISA tests using pooled sera. To identify each individual positive sample within each positive pool, a total of 2996 tests would be required.

Conclusions: For determination of HIV-1 seroprevalence rates in large population-based surveys, testing of pooled samples appears to be cost-effective, practical and highly accurate.

M.6.0.5 THE USE OF DILUTION TECHNIQUES IN SCREENING FOR HIV-1 AND 2 ANTIBODIES IN WEST AFRICA
Bogdan, A., Njiru, N., Mwanah, C., Okian, B.,**
 Cham, M.,*** and Tedder, R.,****
 *Royal Victoria Hospital, Banjul, The Gambia, **Epidemiology and
 Statistic Unit, Banjul, The Gambia, ***Medical and Health Dept,
 Banjul, The Gambia, ****Middlesex Hospital, London, UK.

Objective: To demonstrate the potential usefulness of a dilution technique in HIV-1 screening in West Africa.

Method: Using a combination of 2 'screening' tests (either an ELISA and a particle agglutination test for HIV-1 or 2 different ELISAs for HIV-1 and Western Blotting), tested sera were categorized as either true HIV positives or HIV false positives. These sera were then diluted with HIV negative serum to 1/200 and retested using competitive ELISAs for HIV-1 and 2.

Results: 58 sera considered HIV positive were tested at dilution 1/200; 51 HIV-1 and 55 remained strongly positive. 59 sera considered to be HIV false positives were tested at dilution 1/400; 55 HIV-1 and all were found to be negative.

Conclusion: In areas where false positive HIV tests are a problem and where financial and technical resources may be limited, retesting diluted ELISA positive sera at dilution may give a reliable indicator of true HIV positivity.

M.6.0.2 A regional perspective of HIV antibody testing in the Americas
M. D. O'Donoghue, J. Finlay, A. Melzer, R. St-John,
F. Scazzari, M. Riccio

Federal Centre for AIDS, Health & Welfare Canada, Ottawa, Ontario, Canada
 The Federal Centre for AIDS, Health and Welfare Canada, and the Pan American Health Organization co-sponsored the first international meeting of directors of national AIDS reference laboratories, Americas Region.

The meeting, intended to assist countries in developing and strengthening the operational and scientific aspects of national HIV screening programs, was held in Toronto, Quebec, in August 1988 and was attended by representatives from 18 countries in the Americas. The meeting was preceded by four workshops at which small groups drafted position papers on: quality assurance, regional seroprevalence, standardization of the immunoblot and indirect immunofluorescence tests and laboratory networks. The papers were considered by the group as a whole, and consensus was achieved around the 4 topic areas.

The Laboratory needs, practices and human resource requirements were assessed by questionnaire. The analyses indicate resource allocation, laboratory facilities, scientific expertise and testing protocols are highly variable within the region. Infrastructure analysis and the resulting adoption of an appropriate network could lead to improved service with a minimum of expenditure within any given country. Development and implementation of a model laboratory network is in progress.

M.6.0.4 A Simple, Rapid, Practical HIV Screening Assay for Developing Country Manufacturing and Use.
Developing COUNTRY MANUFACTURE AND USE.
Herrick, M., Coulter, R., Schaffner, Barbara A.,
Spielberg, F., and Tan, M.R. Program for Appropriate Technology in Health, Seattle, Washington, USA.

Objective: To develop a simple, rapid, inexpensive HIV assay, which can be produced in and used by developing countries. Goals for such a test include a relatively short assay time, reagent stability, equipment independence, and an easily interpretable endpoint.
Method: HIV p24 peptide was immobilized onto polystyrene strips, and incubated with neat sera or whole blood. After a wash step, any bound antibody was detected by exposure to protein A-colloidal gold. The total assay time was less than twenty minutes.

Results: Preliminary data was generated using a panel of 110 specimens. The rapid test was positive on 34/54 Western blot-confirmed HIV sera (sensitivity 100%), but detected only 1/77 normal and 8/87 sera (specificity 98.7%). A positive result could easily be interpreted by a dark red dot of color on the plastic strip. Although the numbers of specimens at present are small, the test method is also accurate when assayed on samples of whole blood. A cost analysis indicated that the expense of materials is very low (less than US \$0.10 per assay).

Conclusions: We have developed an HIV screening assay which appears to be accurate, affordable, and practical. Transfer of this technology for the manufacturing of assay kits in areas proximal to their use will allow many developing countries to extend their screening capability to transfusion centers, primary health care centers, or other areas of urgent need.

M.6.0.6 POOLING OF SERA TO REDUCE COSTS OF HIV-ANTIBODY SCREENING IN BLOOD BANK DONORS FROM BOGOTÁ, COLOMBIA, SOUTH AFRICA
Boshall, J., Jorgé, García Marcela,** Carrero S.,
 Pérez, H.,** and Gaudin M.,**

(*) Instituto Nacional de Salud, Avenida Eldorado Carrero 50, Bogotá, Col.
 (**Red Cross National Bank, Bogotá, Colombia.

Objective: Because Colombia is a country with a relatively low prevalence of HIV antibodies among blood donors, (0.008%) we sought to determine whether donated blood samples could be pooled and then tested in a simple assay without a loss of sensitivity.

Method: A single pool consisting of five serum samples was assayed using six different commercially available antibody kits. One HIV-1 positive specimen taken from a group of self-made serum samples with different graded above seroconversion ELISA reactivities was included in each pool.

Results: We report on our findings using pools of five specimens and compare them with those from individual specimen screening. We assayed 196 pools of 980 serum samples. From 15 to 30% of pools containing low absorbance values positive specimens were missed.

Conclusion: We discourage the pooling of samples by this procedure in order to reduce costs of HIV-screening among blood donors. The best results indicate that 15 or 1.5% of false negative reactions sera will be missed, a figure still unacceptable, even in countries where economical resources are badly needed.



Aspects culturels et sociaux de la sexualité Cultural and Social Perspectives of Sexuality

M.G.0.7 CULTURE, SEX AND SCIENCE: ANTHROPOLOGICAL PERSPECTIVES FOR AIDS PREVENTION AND CARE
de Saldwando, Barbara. Harvard School of Public Health, Boston, MA, USA.

The production of sexual HIV transmission world-wide has led scientists from diverse disciplines and countries to probe the determinants and measures of sexual attitudes and norms. A scientific approach to sexual, because neither investigators nor subjects are free from bias: Culturally based assumptions and values shape personal sexual behavior, and other representations of and responses to the proposed behavior of others. This paper contrasts anthropological with epidemiological approaches to the scientific study of sexual risk behavior. It highlights theory and methods for mapping and evaluating determinants of observable practices (e.g., economic, social and health conditions), and unobservable realities such as perceptions, intentions, values, self-concept and social meaning, all of which are culturally constructed, systematically interrelated, and which often vary by age, gender and social position.

Moreover, sexual risk-reduction strategies promote changes in behavior for selfish reasons. That is, they intersect at least in highly-charged and culturally variable domains: those of sexuality and illness. Since AIDS prevention relies upon voluntary changes in behavior, accounting for perceptions, concepts and meanings in both domains are essential tasks for prevention-oriented research and effective interventions. To analyze such factors in the name of science is unscientific, and it detracts from the real challenge: appreciating culturally-grounded medical work.

M.G.0.8 CULTURAL, SEXUAL AND SOCIAL PERSPECTIVES OF AIDS IN BRAZIL
PINAL, Aletéia

*Centro de Referência e Treinamento-AIDS, São Paulo, Brazil
Brazil, with 140 million inhabitants and US\$ 140 billion in external debt, is a country of contrasts. The State of São Paulo (33 million) contributes 41% of the gross national product and boasts a per capita income of US\$ 3000. Nevertheless, 1,207,696 families (avg. 4 members) earn less than US\$ 60 a month, 10% of the state population is illiterate, 35:1000 is the mortality rate for children under the age of 5, 50% of public elementary school children are malnourished, and the maternal mortality rate is 116 for women between the ages of 15 and 49. Despite of being a rich state, 39,000 cases of Hansen's disease and 16,000 cases of tuberculosis were notified in 1988. As of 1988, 65.4% of the AIDS cases in the nation were from São Paulo (more than 70% from the city of São Paulo). Brazil is the largest Roman Catholic country in the world. However, it has the largest concentration of spiritualism and the city of São Paulo is considered the cultural capital of Pentecostalism. Afro-Brazilian cults are deeply seeded in the culture. Although Brazil gives a touristic image of a sexually permissive country, it is essentially a very conservative one. Sex is still a taboo subject and, even though it may be a source of pleasure, for many it is a way of survival.

M.G.0.9 ADOLESCENT SEXUALITY IN EUROPE
Slikkerveer, L. Institute of Culture and Social studies, University of Leiden, Leiden, The Netherlands.

M.G.0.10 AIDS AND THE SOUTH AFRICAN CULTURE
SANKHOSHE, MUSA, CHRISTIE, G.

THE AIMS CENTRE, SOUTH AFRICAN INSTITUTE FOR MEDICAL RESEARCH (SAIMR), JOHANNESBURG, SOUTH AFRICA

OBJECTIVE To describe how the South African Cultures influences the AIDS epidemic. **METHOD** An action research methodology was used. Data was collected over a sixteen month period from people seeking services from the AIMS Centre (SAIMR). The multi-cultural population consisted of male and female, adolescents and adults, from major cities and towns throughout south Africa, as well as dependent and independent townships. **RESULTS** Two broad aspects of South African culture have been recognized for their influence on AIDS. Firstly, the ideology and practice of apartheid and secondly, that services such as education and counselling are generally imported, decontextualized, non-African and therefore inappropriate for Third World clients. South Africa is a culturally diverse society that requires multicultural rather than monocultural practices. **CONCLUSION** The apartheid system together with a eurocentric theory of human behaviour severely restricts the control and prevention of AIDS in South Africa. It is advocated on helping professionals to be aware of the structural determinants of problems, and also to revolutionize the delivery of AIDS services so as to benefit people from a variety of cultural backgrounds.

M.G.0.11 "Sexuality in Africa: The Role of Cultural Beliefs and Behaviour".

By Violet N. Kimani,
Dept. of Community Health,
University of Nairobi, Kenya.

Abstract.

In this paper sexuality is defined according to age and sex of the participants. Sexuality for men and women?

Examples from a selection of ethnic groups are used to illustrate beliefs and expected behavior. Population discussed include adolescents in schools, colleges and places of work. Spouse both young and not too young are also included.

The influence of social change as that which is brought about by formal education, Christianity and the mass media is considered.

Discussions are centered on the role that a return to traditional beliefs could play to avoid risk behaviour in sexuality.

M.G.0.12 CULTURAL DETERMINANTS OF SEXUALITY IN THE SUDAN
Amm, L. University of Khartoum, Faculty of Medicine, Khartoum, Sudan.

M.G.0.12A SITUATION
Campagnolo, Iona. McMaster International Centre for International Health, Hamilton, Ontario, Canada

Colloque Symposium



Implications Internationales International Issues

Les nourrissons à risque : Le point de vue africain Infants at Risk: An African Perspective

M.G.0.19 INFANT MORBIDITY AND MORTALITY IN UGANDA
A.L. MURDOCK - Dept. of Paediatrics Makerere University,
P.O. Box 7072, Kampala.

OBJECTIVE: To review the causes and rates of infant morbidity & mortality in Uganda from 1985-1988 and to determine the impact of HIV infection on the infant's morbidity & mortality rates in Uganda.

METHOD: A review of literature (data) on the causes and rates of infant morbidity and mortality 1985-1988 in Uganda was made with special reference to a study on the HIV impact.

RESULTS: 1 Year 1985 1984 1985 1986 1987 1988
IME 110 105 106 140 133 98

The leading causes of infant morbidity & mortality still remain mainly infective and preventable diseases as illustrated in a district mortality survey in 1988-respiratory tract infections (RTI) 16% of all deaths, diarrhoea 15%, malaria 10%, measles 10%. In the follow-up study 12.6% of the infants born of HIV positive mothers died before their first birthday as opposed to only 2% of a comparable group of infants of HIV+ve mothers. The causes of mortality among the HIV positive group were failure to thrive 45%, diarrhoea 16%, measles 10%, RTI 5%, meningitis 5%. The only infant who died in the control group died of RTI.

CONCLUSION: 1. The causes of morbidity and mortality in Uganda remain the same i.e. preventable & mainly infective diseases. 2. In recent years the IME in Uganda has generally been declining. 3. HIV infected infants had higher morbidity & mortality rates but overall the HIV infection has not increased the IME in the country.

M.G.0.20 INFANT MORBIDITY AND MORTALITY IN MALINDI.
Datta, Pravilba. University of Malindi, Kenya.

OBJECTIVE: To assess morbidity and mortality in infants of HIV+ mothers. **METHOD:** Systematic follow-up from birth of infants of HIV+ (study) and HIV- (control) mothers.

RESULTS: One hundred and fifty-five study infants and 353 controls have been followed for a mean of 10 (range 0.5 to 38) months. Study infants had more episodes (per 100 infant months of follow-up) of febrile illnesses (14 vs 13, p<0.1), diarrhoea (10 vs 8, p<0.05), cough/CR vs CR, pneumonia (2 vs 1.6, p<0.1), and otitis media (1.8 vs .6, p<0.01). Failure to thrive (FTT) occurred in 31/155 (20%) study infants versus 27/353 (8%) controls (p<0.01). 95% (151/157) study infants and 1/101 (1%) control (p<0.001) were immunized in 7/70 (10%) study infants and 1/101 (1%) control (p<0.001). 95% (151/157) study infants and 2 of 98 control infants, 2 infants from each group had chickenpox. Infant mortality (IM) was higher in the study group 12/155 (7.7%) vs 6/353 (1.7%), p<0.01. Infants of HIV+ mothers with more advanced HIV disease or subsequent death had higher IM, FTT and OM than infants with asymptomatic mothers. **CONCLUSION:** Infants of HIV+ mothers have repeated and severe childhood illness leading to FTT or death. Infants of HIV- asymptomatic mothers are at greater risk of dying, FTT or frequent illness.

M.G.0.21 RISK FACTORS FOR MATERNAL-INFANT TRANSMISSION IN ZAMBIA

Byers, Robert W. Projet SIDA, Kinshasa, Zaïre

M.G.0.22 BREAST MILK AS A RISK FACTOR FOR HIV-1 TRANSMISSION.

Hipa, Subhash

University Teaching Hospital, Lusaka, Zambia.

HIV-1 may be transmitted from an infected mother to her fetus during pregnancy or childbirth or immediate post-partum period. Although virus isolation from cell-free breast milk has been documented, the contribution of breast feeding in latter modality of transmission of HIV-1 has been questioned. There are, however, at least 8 case reports of HIV-1 seronegative women at the time of delivery, who during immediate post-partum period (usually through receipt of HIV-1 infected blood transfusion or drug abuse) got infected. These mothers and their breast-fed children seroconverted. While other routes of transmission could not be excluded in some cases, it was suggested that children were infected through breast milk. In Lusaka, we prospectively followed 16 maternal incident cases and their children for 2 years (mothers and children were p24 and antibodies negative at labor). Mothers acquired HIV-1 through heterosexual route. Subsequently, 3 mothers infected their children who seroconverted at 18, 20, and 22 months of age, respectively. No risk factors other than breast milk were identified. **Conclusion:** The sequential seroconversion of mothers and children is suggestive of possible transmission of the virus through breast milk. Since advantages of breast feeding outweigh the possible risk of HIV-1 transmission, breast feeding may not be discouraged till more information is available.

M.G.0.23 SAFETY AND EFFICACY OF IMMUNIZATIONS WITH LIVE VACCINES,
Edwards, James. University of Medicine, Kingston, Canada.

Objective: To review the safety and efficacy of live oral and bacterial vaccines given to children of HIV+ mothers.

Methods: Review of vaccination complications following BCG, oral polio vaccine (OPV) and measles vaccine used in the perinatal HIV transmission study in Kenya.

Results: BCG: Although 6 HIV-infected infants have been reported with respiratory disease and/or lymphadenitis following BCG vaccination, neither have occurred in 120 infants of HIV+ mothers given BCG in this study. Failure to respond to PPD testing occurred in 28/60 (20%) study vs 28/62 (45%) control infants (p<0.02) (OR=2.8); 95%CI=1.13-7.19). OPV: Polio did not develop in either infant or family members following administration to 137 infants of HIV+ mothers. Short and long term anti-polio antibody testing is not yet completed. Measles: 61 infants of HIV+ mothers have received measles vaccine without sequelae; 1/8 had protective antibody production vs 10/15 controls tested to date. Measles developed in 7/70 (10%) study infants vs 1/101 (1%) controls (p<0.004; OR=1.1; 95%CI=1.3-81.0) prior to vaccination. One of 61 study and 2/98 control infants developed measles despite vaccination.

Conclusion: Complications from live vaccines are rare in infants of HIV+ mothers. Continued BCG use should be reserved for areas of high tuberculosis risk. In developing countries, OPV is not contraindicated. Significant HIV presence in an area may hamper existing control measures. A more efficacious measles vaccine which can be safely given to infants prior to 9 months of age is needed.

M.G.0.24

**Atelier
Workshop**

**Implications Internationales
International Issues**
**Atelier régional : Afrique orientale
Regional Workshop: East Africa**
M.G.O.31

IMPACT ON THE HEALTH CARE SYSTEM
Over, Head, Washington, D.C. USA

M.G.O.33 The Impact of HIV on the Laboratory in Developing Countries

John Shao - Muhlabili Medical Centre, Dar es Salaam, Tanzania
Most blood tests currently available in the markets for AIDS screening in the laboratory measure antibodies against human immunodeficiency virus (HIV). There are no tests so far developed that are one hundred percent perfect. Under ideal laboratory conditions both ELISA and Western blot are capable of achieving greater than 99% sensitivity and specificity. Screening of blood samples in Africa have caused problems concerning false and negative results. Besides there is a burning issue of stability of testing materials under difficult conditions. Further more the tests must be easy to perform and need without high and expensive technology unaffordable by most laboratories in developing countries. There is an urgent need to evaluate the performance of tests in field conditions.

M.G.O.35

M.G.O.32

CASE STUDY: SOCIAL ECONOMIC IMPACT OF AIDS IN A HOME
ELIZABETH N. NGUGI
UNIVERSITY OF WAIKATO, DEPT. OF COMMUNITY HEALTH

In July 1987 a young man in his early twenties went abroad for higher learning. He had been tested for HIV antibodies before departure and found negative. Ten months later he came back with AIDS and was hospitalized, improved and discharged home. Parent (mother) took compassionate leave to care for him. This presentation sets to show the changes the family had to make and how they coped with effects of the young man in that community.

The young man stayed at home for about a month where I visited him twice a week. Counselling was seen as an element of support. He was then readmitted and died a week after admission.

This case study would have been impossible without kind permission and inherent co-operation from the parent (names and photographs withheld on request).

M.G.O.34

AIDS AND COMMUNITY BASED CARE
Kalemba, Moririne, Kampala, Uganda

M.G.O.36

Séance thématique Specialty Session



Implications Internationales International Issues

Risques de prévention Risks and Prevention

T.G.0.7

SOME CORRELATES OF PERCEIVED VULNERABILITY TO HIV INFECTION IN SIX LATIN

Authors: Ceballos, M.**, Alvarez, A.**, Tavel, S.**, Vermeulen, J.**, Institute of Biostatistics, University of Chile, St. Bernardo, Chile. Belec, M.**, Rodriguez, J.**, Center for Studies in Public Health, World Health Organization, Geneva, Switzerland.

Objective: To investigate factors of personal behavior on perceived vulnerability to HIV infection by providing an answer to the following question: what are the socio-demographic, sociologic, attitudes and practice variables that differentiate the minority of respondents who regard themselves as likely to get AIDS from those who do not?

Design: Using the data obtained through a large-scale RAB survey in St. Louis, Chile 13 per cent of respondents were found to be concerned about their personal vulnerability to HIV infection. These were compared with those respondents who do not have such knowledge about HIV infection. The variables considered as potential risk factors were: age, sex, residential status, religious, educational, marital status, self-esteem, knowledge, attitudes, beliefs and practices.

Results: Of the large number of variables considered only a few indicated statistically significant differences between the two groups. While none of the observed differences are in the expected direction, most others are not. Thus, perceived personal vulnerability seems to be only partially related to most objective measures of risk appears as age, sex, residential status and sexual activity.

Conclusions: These findings should be taken into account in developing IEC campaigns on AIDS.

T.G.0.8

THE CHALLENGE OF ADOPTING RISKY PRACTICES IN WELL INFORMED GAY MEN.

Authors: Alarcon, Sepulveda P., Valenzuela J.L., Ramon M., Ramos R. Division of Epidemiology, Ministry of Health, MEXICO. Hastings, J. Objective: To describe the process of production of graphic educational material, and its possible impact on the promotion of condom use in a gay men with a high level of knowledge about AIDS in Mexico. Methods: With knowledge, attitudes and practices data about AIDS and its preventive measures in gay and bisexual men from Guadalajara City, Mexico (St. 87 and May 98), a sociodemographic and educative needs profiles were done. Different concepts were tested through focus groups in the population. With the chosen concepts, 2 posters, 2 condom wallets and 1 comic were done and distributed in July 98. In centers where gay men meet (saunas, bars, etc) by staff members with the collaboration of gay community. Another survey was carried out after the distribution of the material in August. The messages included in the condom wallet are that AIDS is an STD, prevention and detection of condom and addresses of reference centers. These messages were distributed through five different projects: 1) to casual contacts and 2) to stable couples, according to the selected design. Results: Since the first survey, an appropriate level of knowledge of the principal variables was higher than 80%, messages of reference were not included, although there are still some gaps. The prevalence of condom use was increased slightly, whereas it is noted that the change is higher between the second and third survey when controlled by having removed the graphic material.

Prevalence of condom use 1987 - 1988		Condom use by detection of material	
Sex	Age	Sex	Age
Men	25	Men	25
Men	35	Men	35
Men	45	Men	45
Men	55	Men	55
Men	65	Men	65
Men	75	Men	75
Men	85	Men	85
Men	95	Men	95

Conclusions: It is particularly complex the design of educational material for well informed groups with educative attitudes towards prevention but with high prevalence of risk practices. The challenge in gay and bisexual men is exactly the case. Perhaps the only way to modify high risk practices is with the combination of the design of focused educational material with adequate channels of distribution.

T.G.0.9

MASSIVE CAMPAIGN FOR AIDS EDUCATION, ACHIEVEMENTS AND PROBLEMS
Buenos Aires, 1989. Traverso J.F., Valenzuela J.L., Munniching R.,
Toussaint J.**,
Institute of Epidemiology, Ministry of Health, MEXICO.
Population Council

Objective: To describe the principal achievements and problems of the mass media AIDS prevention campaign.
Methods: The educational campaign through mass media in Mexico began in April 1987. In September, 1987 and May, 1988, 4 surveys to determine the knowledge about AIDS in general population were carried out in 6 cities in Mexico. Simultaneously, an analysis of press contents was undertaken.

Results: The first and second surveys showed 91% and 80% identification of sexual transmission mechanisms (90, 90% and 94% identified blood, and 88% and 89% parental; 7% and 7% identified AIDS as a disease to which everybody is susceptible; 81% and 80% identified it as an infectious disease and 77% and 80% identified AIDS as preventable. Myths about transmission are still frequent, although there is a decreasing trend, e.g. 30% and 31% think HIV can be transmitted through casual contact. Condom use was stable, 20% and 32% referred having ever used a condom. The knowledge of AIDS prevention through the use of condoms increased from 61% to 77%. Critiques arising from different groups condemned the use of the word "condom" believing that the "promotion of condom would increase sexual freedom, promiscuity, prostitution and male homosexuality". Some other groups requested that the campaign "should be more aggressive" in its contents. This discussion, however, positioned the condom on the top of people's mind.
Conclusions: Mass media campaigns directed to general population, do not modify practices (nor may not preventive), however, they are useful to create proper perception of the magnitude of AIDS and decrease myths and stigmatization. These campaigns may influence decision-makers to support programs for AIDS prevention.

T.G.0.10

AN INTERNATIONALLY ADAPTABLE AIDS PREVENTION PROGRAM FOR

YOUTH
Youn, Wendy**, Menton, S.**, Vally, R.**, and Renaud, L.**,
Adolescent Alliance, Los Angeles, CA, USA. **Adolescent Alliance** Centre for
SEX (AACS), Paris, France, **Association des Antistes Centre for SEX,
Paris, France.

Objective: To set up a volunteer-based AIDS education program where trained young people speak directly to their peers in academic settings
In school AIDS transmission and prevention. Methods: Adolescents and young adults are recruited through announcements on national television shows and publications targeting the youth. After an intensive training on basic AIDS information and communication skills, the young speakers lead small group discussions with comparably aged youth, the issues of how HIV is transmitted and how to protect oneself from HIV exposure are emphasized. All AIDS-related concerns are addressed. **Results:** With the use of video films and AIDS informational brochures targeting teenagers and parents, thousands of junior and senior high school students in France have shown an increase in AIDS knowledge and prevention as evaluated by a pre/post-attitude questionnaire. Parents have an active role in the educational program as well. **Conclusions:** The AIDS program, adapted from the Adolescent Alliance Project Education Program in the USA, is culturally sensitive to the needs and AIDS-associated concerns of youth in France and can be applied to other countries in the world. The international model is inexpensive and easy to implement and evaluate.

T.G.0.11

ADOPTION OF SAFER SEXUAL BEHAVIOR BY AN HIV HIGH RISK GROUP
OF BAR HAD
Watt, M., Aida C.,** Serge P.,** Siro J.,** Bouchay Helen C.,** Blandford G.,** et al.

Objective: To study the adoption of safer sexual behaviour by a group of bar and restaurant workers at high risk of HIV infection in Bar de Salinas, Venezuela.
Methods: After recognizing the rapid rise in HIV infection survey measurements and bar workers in Bar de Salinas where the prevalence rose among female workers increased from 20.4 in 1986 to 45.4 in 1989 (prevalence in males were 38 in 1986 and 53.8 in 1989) efforts were made to request health education, individualized counselling and free provision of condoms to the group.

Results: 366 workers (156 male and 210 female) out of 637 (240 male, 397 female) originally enrolled in the study were available for follow-up after 3 months. 263(69%) of the workers had not adopted any sexual behaviour change due to the theme of AIDS. 101(40.3%) had had only one sex partner, 131(31%) had stopped having sex, 40(12.7%) were using condoms all the time and 122(46.9%) had reduced the frequency of changing sex partners. The prevalence of utilization of condoms increased from 29.19 to 67.14 during the 3 months of follow-up. 245(46.6%) of the workers considered a policy of 3 condoms per week to be adequate. 96(21.1%) explained no condom at all while 46(10.1%) did not use any condom.

Conclusions: Intensive health education and counselling with provision of condoms have a good chance of success in reducing the rapid spread of HIV infection among groups of individuals engaging in high risk sexual behaviour in developing countries.

T.G.0.12

THEORY AND PRACTICE IN PROMOTION OF SAFE BLOOD
IN KAMPALA, UGANDA. Katabaha, F., Coutinho, S.,** and Sanyang, P.,
Nakasero Blood Bank, Ministry of Health, Uganda.

Objective: For the past two years, it has been policy to screen all donated blood for anti-HIV before transfusion. In November 1988, the Ministry of Health and European Development Fund joint project of an all volunteer blood bank in Kampala started operation.

Methods: Prospective donors get information, both verbal and written, concerning the transmission of HIV-1. Blood is given anonymously, but one week later the donor can use a code to request the test result. Each sample is tested by a first generation EIA method (Vironostika, Organon). Positives are confirmed by a competitive inhibition EIA (Uniform Anti-HIV-1, Organon). Negative sera are retested by EIA using synthetic peptides as antigen (Biochrom, Inc.). Donors with confirmed positive tests have a second sample checked before getting a definitive result. **Results:** During the first three months we have found: 1. Positive results in 91 of donors. 2. Donors informed of positive results. With accurate information, donors make appropriate behaviour decisions. 3. Some donated blood sero to obtain an HIV-1 antibody test. **Conclusion:** The implications for blood bank policy in Uganda will be discussed.

**Séance thématique
Specialty Session**



**Implications Internationales
International Issues**

**Prévalence (partie 2)
Prevalence (Part 2)**

T.G.0.19 PROGRESSIVE INCREASE IN HIV-1 SEROPREVALENCE IN PREGNANT HAITIAN WOMEN: 1984 THROUGH 1985
Rouquié, Réginald*, Halsey, M., Holt, E**
Quinn, C**, Huff, R., Brutus, J**
**Centers for Health and Development, Port-au-Prince, Haiti;
*Johns Hopkins University, Baltimore, MD, USA

Objective: To determine changes in HIV-1 seroprevalence in pregnant Haitian women residing in a perinatal clinic in a perinatal unit were screened by HIV-1 ELISA and confirmed by WB. Prior studies have demonstrated that heterosexual contact is the predominant mode of transmission.

Results:	1984	1985	1986	Total
Number Screened	1245	2009	1074	4328
% HIV-1 Positive	8.88	9.98	10.53	9.78

Increases were most notable in the 20 to 34 year age groups. 1986 seroprevalence by age: 14-19 yrs (9.3%), 20-24 yrs (11.5%), 25-29 yrs (11.3%), 30-34 yrs (9.1%), 35-39 yrs (4.0%), 40+ yrs (5.3%). The seroprevalence rate (16.7%) in 1986 was in women in their third pregnancy, but 6% or more of women pregnant for the first time were HIV-1 seropositive each year. **Conclusions:** Many women are becoming infected soon after becoming sexually active and transmission rates remain high. A control program is urgently needed.

T.G.0.20 HIV-1 IN HOSPITALIZED HAITIAN PEDIATRIC AND ADULT PATIENTS
Adrien, Marcio*, Boulog, M*, Louis, A*, Joseph, P*, Kissinger, P*, Halsey, M., Holt, E**
**Centers for Health and Development, Port-au-Prince, Haiti,
*Johns Hopkins University, Baltimore, MD, USA

Objective: To determine the HIV-1 seropositivity rate and related symptoms of hospitalized patients in an urban primary care hospital.

Methods: All patients admitted to the general pediatric and adult wards were screened anonymously for HIV-1.

Results: Of 177 adult admissions, 37(21%) were HIV-1 seropositive. Of 372 pediatric admissions, 44(11.8%) had HIV-1 antibodies in their sera and 45(13.5%) of 333 of their mothers were HIV-1 seropositive. Although higher rates of HIV-1 seropositivity were observed in children with gastroenteritis (12.8%), weight loss (11.9%), and/or rash (18.2%), significant (p<0.05) associations with HIV-1 seropositivity were observed only with cough and pneumonia (29.2%). Since 71% of the children were < 1 year of age, the presence of maternal antibodies could not be ruled out. Two HIV-1 seropositive children 11 and 13 years of age who had not had transfusions were identified. **Conclusions:** High percentages of pediatric and adult patients requiring hospitalization in this population are infected with HIV-1 and have a mother with HIV-1 infection. Pneumonia may be a predictor of HIV-1 seropositivity.

T.G.0.21 PREVALENCE OF HIV-1 AND HTLV-II IN GONAIVES, HAITI
Boulog, Réginald*, Halsey, M., Quinn, C**, Zertour, J**, Labrun F**, Halsey, M**, Holt, E**
**Centers for Health and Development, Port-au-Prince, Haiti **Family Health International, Research Triangle Park, NC, USA **Johns Hopkins University, Baltimore, MD, USA

Objective: To determine the prevalence of HIV-1 and HTLV-II infection in a semi-urban area outside of Port-au-Prince.

Methods: Between April and November 1985 a total of 1863 men and women aged 15-45 obtaining medical services at 2 health centers in Gonaives, Haiti, were recruited to participate in this study. Serum specimens were collected from each participant and information on demographic characteristics and selected risk factors for HIV-1 and HTLV-II infection was obtained using a brief structured questionnaire. Serum specimens were tested for antibody to HIV-1 and HTLV-II by ELISA, and repeatedly positive samples were confirmed by Western blot.

Results: Preliminary results indicate the prevalence of Western blot confirmed HIV-1 antibody to be 9%. Additional results on the prevalence of HTLV-II infection and on the prevalence of co-infection will be presented. **Conclusions:** Two seroprevalence studies have been conducted outside of Port-au-Prince, the capital. These results indicate that the prevalence of HIV-1 infection is high in Gonaives, a semi-urban area northwest of Port-au-Prince. Appropriate educational interventions to reduce the spread of HIV-1 infection and additional research to better define risk factors important in this population are needed.

Key words: HIV-1; HTLV-II; Haiti; prevalence; risk factors

T.G.0.22 RISING PREVALENCE OF ANTIBODIES AGAINST HUMAN IMMUNODEFICIENCY VIRUS (HIV-1) IN WESTERN HANGARU, INDIA
K. SANCHEZ, National Institute of Virology, Pune, India.

Until recent years HIV infection was considered a rare event in India. In 1982, 3/855 paid blood donors from Pune were seropositive and in 1984, 3/495 were positive. From Bombay, a single sero was positive in the 4th quarter of 1987, since then 33 have been found positive. All were males; from a STD clinic in Pune, a single sample of blood was positive in 1987, while in 1988 there were 28 seropositives. From Gomay, a single sample was positive in 1st quarter of 1987, by the end of 1988 there were 56 positives, 46 being males and 10 females. Of the 449 sera collected from female prostitutes in Pune between 1985-87, only two were seropositive. From Bombay, 3 were found positive in the 2nd half of 1986, by the end of 1988, there were 78 positives, 62 in the last quarter. Among hospitalized patients (total 370) in a Pune hospital, only one of 863 tested was positive, which was from a group of 292 patients of tuberculosis. From Bombay, 1 out of 15 tuberculous and 2 out of 70 cases of chronic renal failure were seropositive, obviously due to transfusion. The limited serosurveys from Bombay, Pune and some other cities in Western India indicate that the HIV infection is spreading rapidly in the urban areas among the prostitutes and their clients (as evidenced by the progressive rise in seropositivity in STD clinics) and paid blood donors. The current status warrants wider serosurveys to assess the spread of infection and immediate implementation of anti-epidemic measures.

T.G.0.23 SECOND SEROPREVALENCE SURVEY AMONG BANGKOK'S INTRAVENOUS DRUG ABUSERS (IVDA)
S. Vaisidharn*, K. Sombhat*, K. Plangrungsri*, P. Akaravivorn*, R. Wright*, K. Choo-panya*, Bangkok Metropolitan Administration, Piv. Div., Min. Pub. Hlth, INDIA

Objective: To (1) determine prevalence and (2) risk factors for HIV infection and (3) measure behavioral change in an estimated population of 15,000 registered drug abusers in Bangkok.

Methods: Each of 15000 registered drug abusers in Sept. 1985, a 100% sample of detoxifiants was asked to consent to an interview with a social worker and give a blood sample. **Results:** Among 15000 interviewed, no one refused, 44% were HIV+ up from 16% in February. Significant risk factors emerging from multivariate analysis were equipment sharing (OR: 6.95(2.1-2.4) and hand job of being arrested in 1980, OR: 2.0(1.2-2.8). We examined responses to behavior one month before interview compared to 4 months before test. Equipment sharing declined from 60% (sharing with 4+ people from 23 to 18%), condom use among those sexually active was low (7%), and exchanged HIV+ and IVDA claimed to clean their equipment; the methods they used remained ineffective.

Conclusions: HIV infection was being increasing 1 point per month among Thai IVDA in 1986. Widespread injection equipment sharing is a key risk factor. There is no sign in mid-1986 that IVDA are changing their sharing, needle, or condom using behavior in response to intervention programs.

T.G.0.24 AIDS IN PAPUA NEW GUINEA - HETEROSEXUAL TRANSMISSION AND SOME IMPORTANT LOCAL CONSIDERATIONS
Makin, Gilbert, Currie, B., Morde, P., and Pyakala, T. Department of Health Papua New Guinea.

The first positive HIV antibody result reported to the Department of Health in Papua New Guinea (PNG) was from June 1987. The first confirmed AIDS case was reported in April 1988. By the end of 1988 there were 10 confirmed AIDS cases. The first 5 were expatriate males with P. carinii pneumonia, 1 homosexual, 1 bisexual. The other 5 were PNG nationals, aged 18-27 years, and all had died by late 1988. Of these 5 there were 3 females and 2 males who had had heterosexual partners and 1 operator who was bisexual. Four cases fulfilled the criteria for HIV wasting syndrome ("AIDS disease"), and 1 had retroviral HIV antibodies in the indicator disease. Candidiasis and skin lesions were also evident in some cases. HIV infection was documented in the regular female sexual partners of the 2 male rationales. Intravenous drug abuse is virtually unknown in PNG, but the reported incidence of STD has risen alarmingly in the last 10 years. In particular ulcerative disease from syphilis and chancroid is common. The importance of traditional sexwork and sexification remains unclear, as does that of ritual homosexuality which is confined to limited areas. Multiple use of single syringes still occurs throughout the country. Our preliminary data together with the high prevalence of tuberculosis suggest that the PNG AIDS epidemic is likely to follow the African pattern, with heterosexual spread and p. t. being presenting with wasting and tuberculosis.

**Séance thématique
Specialty Session**



**Implications Internationales
International Issues**

**Perspectives mondiales
Global Perspectives**

W.G.0.13 AIDS AND RESTRICTIONS ON IMMIGRATION AND TRAVEL: U.S. POLICY AND ITS RATIONALE.
Roeder, Richard E.*; Whitaker, Rupert E.**
 *Northwestern University and Boston, Boston, U.S.A., **Boston University and Tufts New England Medical Center, Boston, U.S.A.

Objective. To evaluate the efficacy of the U.S. government's policy of including immigrants with AIDS and HIV infection. **Methods.** WHO data on AIDS were used to obtain estimates of the prevalence of HIV infection for those countries reporting in February, 1988. These estimates, along with data on the volume (and country of origin) of immigrants entering the U.S., were used to examine the outcome of mass HIV antibody testing of applicants for immigrant status. The study examines the adequacy of ELISA and Western blot tests as measures of HIV infection, particularly with a view to border controls as a means of controlling the spread of AIDS. **Results.** The proportion of test results that are false varies according to the prevalence of HIV infection in the population being tested. Thus applicants from "high-risk" areas are more likely to produce false negative results, while immigrants from "low-risk" areas are more likely to produce false positive results. The policy of excluding seropositives from the U.S. will therefore be ineffective, but will affect applicants from certain areas more severely than others. **Conclusion.** Attempts to contain the AIDS epidemic in the U.S. by exercising border controls will not only be ineffective, but also counter-productive as other countries will respond by imposing controls upon U.S. citizens.

W.G.0.14 COMPARISON OF NATIONAL AIDS STRATEGIES IN AUSTRALIA AND CANADA.
Dunn, Margaret
 McGill Centre for Medicine, Ethics and Law, Montreal, Quebec, Canada.

OBJECTIVE - To delineate a policy framework and examine the development and implementation of National AIDS strategies in Australia and Canada with attention to consultation, policy directions, resource allocation, time frame, consistency and comprehensiveness. **METHOD** - A review of the evolving social, political and legal positions dealing with HIV infection in Australia and Canada based on interviews and published reports. **RESULTS** - Issues include: 1) The accepted basic principles which underlie the process of policy formulation. 2) The areas and limits of responsibility that are drawn. 3) The ethical issues that are addressed, both overtly and covertly. 4) The identifications of those groups whose input is crucial. 5) The guidelines adopted for resource allocation. 6) The nature of arrangements. 7) Research priorities in biomedical, behavioral and social research. 8) The homogeneity of the national response. **Conclusion** - Despite similar health care systems and national disease profiles, critical differences between the two countries have occurred in the timing of the response, the extent of involvement of all relevant groups, the emphasis on and effect of prevention strategies and the extent to which national policies have addressed ethical issues. The characteristics of a recommended national strategy are outlined, drawing on the strengths, and weaknesses of the two countries.

W.G.0.15 THE EPIDEMIOLOGICAL SURVEILLANCE SYSTEM FOR AIDS IN BRAZIL - CRITICAL ASSESSMENT
Rodrigues-Latt, Chequer, P., Bagnawell, M., Coutinho, E., et al.
 *Ministry of Health-National Division of STD/AIDS, Brasília, Brazil, **Oswaldo Cruz Foundation/Ministry of Health, Rio de Janeiro, Brazil.

Objective. To present methodological and operational aspects of the National AIDS Epidemiological Surveillance System. Critical assessment of the components of the system and presentation of the new epidemiological surveillance unit, updated surveillance. **Methods.** Qualitative and quantitative evaluation of the National AIDS Epidemiological Surveillance System using the current report form, standardized nationwide, which contains demographic data, on opportunistic diseases, results of laboratory tests and side effects. **Results.** The National AIDS Epidemiological Surveillance System was implemented in 1985 and since then has been progressively expanding its coverage and operational capacity. It is organized hierarchically, and its various levels of activities are defined. The data is organized and processed by epidemiological work, generating monthly feedback by means of national and state epidemiological bulletins. The reported form currently used may be considered satisfactory according to a study made in this paper. The new form to be presented will allow for the proposed new case definition based on the serological profile observed in research carried out by the National Division of STD/AIDS with the support of CDC-USA, and ongoing observations. The flow and quality of the data may be improved by the mechanisms proposed in this paper. The under-reporting cases can be reduced by its quantification, identification of bottlenecks, and the optimization and rationalization of procedures. **Conclusions.** The National Epidemiological Surveillance System is wide-ranging and is in the implementation phase. The retrospective review of consecutive years from 1985 up to its setting-up has been no important aspect in the development of the epidemiological profile of AIDS in Brazil. The proposed new form is expected to make the System more operationally responsive and enable better knowledge of the epidemiological profile of AIDS. The flow of data, can be optimized and consequently lead to an improvement in the processing and analysis of the System. In addition, the system will provide guidelines for evaluation of the National Surveillance System.

W.G.0.16 FUNCTIONAL AND DYSFUNCTIONAL AIDS PREVENTION PROGRAMS IN LATIN AMERICA AND THE CARIBBEAN
Fernando H. Zarzarán, Laurence F. Zaslauer, Gloria Nogueira, Evely Lombardo, and Ronald K. St. John
 Pan American Health Organization, Washington, D.C., U.S.A.
 Global Program on AIDS, World Health Organization, Geneva, Switzerland

Objective: To assess the functional/dysfunctional status of AIDS prevention programs in Latin America and the Caribbean (LAC) from a managerial perspective. **Method:** Following WHO guidelines, we assessed the structure of national AIDS programs as well as their efficiency or capacity to implement planned activities (activities completed/activities programmed). **Results:** As of 1 January 1989 all of the 36 PAHO Member Countries had a national AIDS prevention focus. However, the structure and functions of the national AIDS prevention programs varied greatly among countries at comparable stages of the epidemic. For example, of the twenty Latin American national programs ten were considered to be using resources more rapidly and more efficiently than the rest. Eight of these ten countries had a full-time manager devoted exclusively to the AIDS/STD program. These countries showed evidence of "strong" governmental political and financial commitment to the AIDS prevention effort (e.g. composition of the AIDS commission, internal funding, legislation, and active search for external bilateral or multilateral support). In contrast, these two factors were present in only two of the ten less active programs. **Conclusions:** Our preliminary data seem to indicate that certain program characteristics may predict the efficiency with which national programs are implemented.

W.G.0.17 STRATEGIES OF THE EC'S AIDS PROGRAMME FOR DEVELOPING COUNTRIES TO CONTROL SEXUALLY TRANSMITTED HIV INFECTIONS: DISCUSSION OF PROGRAMME IMPLEMENTATION AND MAIN RESULTS
LEADER: LAYNE, RD, PhD Van Dam, C.J., MD, RHC
 European Economic Community AIDS Control Programme/Developing Countries.

Sexual transmission is by far the most important way for HIV infection to spread. All STDs are behaviourally correlated and follow the same risk behaviour patterns, namely multiple or infected sexual partners. Risk workers persistently focusing of intervention efforts. Therefore the basic approach of the EC's AIDS Programme has been to place AIDS within the context of other STDs. Main activities and issues are : focused information campaigns, organisation of adequate training, confidentiality, use of STDs as indicators as well as for evaluation of intervention, adequate management of genital ulcers and other STDs and strengthening of STD and AIDS programmes. All activities have been undertaken in collaboration with WHO. Against this background we will present the first results of programme implementation, operational research and evaluation. A quick assessment method for STDs and AIDS has been developed. The epidemiological recovery issues and resources availableity have been analysed and discussed in view of sustainability and resource allocation. Applicability, feasibility and impact will be analyzed for a few examples of interventions in specialised STD clinics or integrated in primary health care facilities.

W.G.0.18 NATIONAL AIDS PROGRAMME: PROGRESS ACHIEVED AND OPPORTUNITIES FOR FURTHER DEVELOPMENT
Sherris, Dennis; Newn, Jovanett, World Health Organization, Global Programme on AIDS, Geneva, Switzerland

The global collaboration against AIDS increased considerably in 1988 as Governments were seeking to respond to the worldwide spread of the HIV epidemic by establishing policies and undertaking aggressive programs. Of 183 countries and territories in the world, 163 had, as of 1 February 1989, sought a technical collaboration with the World Health Organization's Global Programme on AIDS, of which 153 had already received a technical collaboration. Of those, 118 countries had completed or were implementing a short-term prevention and control plan, while 51 had established on a 3- to 5-year medium-term programme. Of those, 27 were able to mobilize resources through pleading meetings (Table 1). The status of the global reaction to AIDS will be reviewed. Collaboration and cooperation within and between countries will be assessed and current issues encountered in improving programme performance will be discussed.

WHO GLOBAL PROGRAMME ON AIDS - NATIONAL PROGRAMME SUPPORT - 1 FEBRUARY 1989

Region	Collaboration	Technical	Short-term	Medium-term	Resources
	Number	Number	Number	Number	Million
Americas	45	44	44	44	10
Africa	42	42	42	30	13
S.E. Asia	11	11	11	11	-
East. Med.	23	20	20	20	-
Europe	31	20	20	4	-
West. Med.	26	18	18	18	-
TOTAL	187	163	152	118	27

**Atelier
Workshop**

**Implications Internationales
International Issues**
Atelier régional : Afrique occidentale
Regional Workshop: West Africa

W.G.O.31 THE HIV PROBLEMS IN WEST AFRICA FEMI SOYINKA,
OSAFUNMI ANGLLOW UNIVERSITY, ILE-IFE, NIGERIA.
Various studies in West Africa have shown that the prevalence of HIV and AIDS vary significantly from country to country. Even though data arising from countries are inadequate there are indications that HIV poses a threat to West Africa. The most frequently studied groups are prostitutes, STD patients and blood donors where prevalence rates are high. Parenteral transmission of HIV is also reaching alarming dimensions. Blood Transfusion induced AIDS - especially among sicklers, cultural related HIV transmission (e.g. medicinal tattoos, traditional blood letting, and polygamous practices) have not been adequately addressed in West Africa. The emergence of HIV-2 in West Africa around 1985 has generated a lot of scientific and political controversies. HIV-2 may be more prevalent in many West African countries than hitherto recorded. A better understanding of the clinical and immunological implication of infection through HIV-2 is needed through systematic epidemiological and clinico-pathological research. Clinical cases of HIV-1 infection do not differ much in West Africa, from other countries. The prevalence of particular pathogens might make for the differences. Clinical oriented surveillance is more needed in African countries where lack of laboratory facilities, and financial limitations prevail. Operational problems in respect of HIV research include scarce resources, and inadequate flow of information among African researchers. International effort can maintain the information flow to developing countries. AIDS programs should be integrated into existing health care organisations such as the MCH, NHC and STD. What is essentially important about AIDS in Africa is the severity of the problems and the failure to accept ship.

W.G.O.32
POVERTY, WOMEN AND AIDS

Twumasi, Patrick A., Department of Sociology,
University of Ghana, Legon, Ghana

W.G.O.33
PEDIATRIC AIDS

Meeguayee, Janet. Department of Child Health
University of Ghana Medical School, Accra, Ghana.

W.G.O.34
AIDS AND OTHER STDs

Kapite, Rita. Département de médecine interne,
Hôpital Mama Yemo, Kinshasa, Zaire.

W.G.O.35
PROSTITUTION AND AIDS

Sack, Moussa. Dakar, Sénégal.

W.G.O.36
BLOOD BANK SERVICE AND AIDS

Diakhofa, Iqbal. Centre National de Transfusion
Sanguine, Dakar, Sénégal.

**Séance thématique
Specialty Session**



**Implications Internationales
International Issues**

**SIDA et tuberculose
AIDS and Tuberculosis**

Th.6.0.1

AIDS AND TUBERCULOSIS (TB) IN THE USA
From: **M. Wiley, Hayward;** & **Ciesielski, C. Berelman, R. Pyers, J. Klich, A. Galt**
Centers for Disease Control (CDC), Atlanta, GA, USA

Objective: To compare AIDS patients with and without TB and identify risk factors for TB in AIDS patients.
Methods: Using logistic regression, we analyzed all AIDS cases reported to CDC from September 1, 1987 (when the CDC AIDS case definition was revised to include extrapulmonary TB) with lab evidence for HIV through January 5, 1989. **Results:** Of 40,366 AIDS cases, 1001 (2.5%) had extrapulmonary TB. TB was diagnosed definitively in 893, presumably in 100. AIDS patients with TB (AIDS/TB) did not differ by age from AIDS patients without TB. AIDS/TB occurred 3.1% of female AIDS patients vs 2.6% for males (<0.001). TB was reported in 1.3% of whites with AIDS, 1.7% of blacks, and 1.8% of Hispanics (<0.001). Of AIDS patients, 771 (3.1%) of US origin had TB, compared to 20 (7.3%) Mexicans, and 77 (13.0%) patients with AIDS. TB was reported in 4.4% of heterosexual intravenous drug users with AIDS, 1.4% of homo/bisexual men, and 5.4% of those with heterosexual contact as their AIDS risk factor (<0.001). In 33% of AIDS/TB patients, TB was the sole opportunistic infection (OI) reported; the most common additional OI was *Pneumocystis carinii* pneumonia. **Conclusion:** The 2.5% of TB in US AIDS patients should be considered an underdiagnosis, because pulmonary TB is not counted in the case definition and because disease occurring after the initial diagnosis of AIDS may not be reported. Significant variations in TB rates are associated with sex, race, national origin, and risk group. TB needs to be considered in all AIDS patients, particularly those with pneumonia.

Th.6.0.3

TUBERCULOSIS AND AIDS: OUR EXPERIENCE
From: **Hernandez J, Arizola I, Gonzalez Montaner J, Abate Z, de Souza J, Campuzano A, Cortez J and Basso G.**
AIDS Unit and Tuberculoz Division, Hospital de Niños, Buenos Aires, Argentina. **OBJECTIVE:** Determine the prevalence of TB as an opportunistic infection in the seropositive of the Injuria and the low incidence of the mycobacteria in patients with HIV infection in Argentina. **METHODS:** Between January 1986 and July 1986 we studied 17 patients with TB among TB patients with AIDS/6 were males and 1 was female). Age rang 15 to 45 years. There were 5 heterosexual (30%), 3 homosexual (18%), 1 bisexual and 1 was a hemophiliac with multiple blood transfusions. All of them were HIV serology by ELISA and WESTERN-BLOT POSITIVE. **RESULTS:** In 2 patients there were diffuse pulmonary infiltrates; 1 with pulmonary cavities, 1 with pleural effusions (1 of them with ascites), 3 with peripheral adenopathy (1 of them mediastinal involvement) and 1 pericardial and meningeal involvement. In 5 we obtain culture positive for *M. tuberculosis* (3 from sputum from seropositive, 1 bronchial washing, 1 pleural effusion and 1 blood culture) and in 5 we have histopathological result compatible adenopathic biopsias and 1 pleural biopsy) These patients responded to specific treatment (INH, RIF, 5 did and 3 are in treatment. We have not had typical epidemiology. The TB lesions in our patients are of atypical characteristics but of greater extension and cavitation than with non-AIDS patients. **CONCLUSIONS:** TB were founded in 21% of AIDS patients as an opportunistic infection. We have not had atypical epidemiology. In this context of whatever opinion of acid-fast bacilli must be considered as tuberculosis and treated as such. The TB lesions are greater extension and cavitation than with non-AIDS patients.

Th.6.0.5

A STUDY OF HIV INFECTION IN ASSOCIATION WITH TUBERCULOSIS
PATIENTS IN A TUBERCULOSIS DISEASE HOSPITAL (TDR) MARRONI, DANIEL E. KIRDOU, S.N. Gauthan*, P. Nune**
*Senior Medical Officer, TDR; **Physician, TDR.
*Tuberculosis Disease Hospital, MARRONI, KENYA
OBJECTIVE: Assess prevalence of HIV infection and associated complications in TDR patients seen in I.D.U. between January 1987 - June 1988.
Method: A total of 100 HIV seropositive patients by Western Blot and western blot confirmation when available and various aspects of HIV positive patients compared with randomly selected seronegatives seroposited by age and sex.
Results: 100 HIV seropositives were seen. Extrapulmonary disease was TB in HIV was against 9.38 in HIV one and normally despite effective chemotherapy was threefold in seropositives by the end of the 3rd month of treatment. There was no association between HIV positivity and drug resistant strains. The incidence of severe drug reaction in HIV seropositives was about five fold.
HIV Related complications

comp	yes	no	HIV related complications	yes	no
Diarrhoea	38	1	Herpes zoster	3	0
Wt. loss on chemotherapy	56	4	Mental confusion	4	0
Oral thrush	40	1	Severe drug reaction	1	0
Pleuritic dermatitis	17	1	Kaposi's sarcoma	1	0
Generalized lymphopathy	1	1	Chicken pox	1	0
Allergic drug reaction	27	6			

Conclusion: Tuberculosis control programme in Kenya is facing serious challenge due rising HIV infection

Th.6.0.2

**EFFECT OF TUBERCULOSIS INFECTION AT A TUBING
RESISTION CENTER IN BURELIMBA, MOZAMBIQUE**

Objective: 1- to identify possible changes in the prevalence and incidence of AIDS due to the introduction of the new TB infection criteria in the public surveillance system. 2- to determine the effect of the new criteria upon the surveillance criteria. 3- to describe the epidemiology over surveillance in the new definition.
Methods: Data from the surveillance registry of patients were used. The registry automatically collects information on all patients with HIV registered in Cahitanga, covering a population of about 4 million km, with using a hospital based active surveillance system. The HIV test case definition criteria were introduced by surveillance systems in January 1988.
Results: In 1- to identify possible changes in the prevalence and incidence of AIDS due to the introduction of the new TB infection criteria in the public surveillance system. 2- to determine the effect of the new criteria upon the surveillance criteria. 3- to describe the epidemiology over surveillance in the new definition.
Methods: Data from the surveillance registry of patients were used. The registry automatically collects information on all patients with HIV registered in Cahitanga, covering a population of about 4 million km, with using a hospital based active surveillance system. The HIV test case definition criteria were introduced by surveillance systems in January 1988.
RESULTS:

SEX	RESISTIBLE TB	ALL AIDS	NO RESISTIBLE TB	NO AIDS	RESISTIBLE TBLY AIDS
Male	28 (74.0)	18 (45.0)	18 (45.0)	18 (45.0)	18 (45.0)
Female	20 (51.0)	18 (45.0)	18 (45.0)	18 (45.0)	18 (45.0)
Total	48 (121.0)	36 (90.0)	36 (90.0)	36 (90.0)	36 (90.0)
Male	18 (45.0)	18 (45.0)	18 (45.0)	18 (45.0)	18 (45.0)
Female	10 (25.0)	18 (45.0)	18 (45.0)	18 (45.0)	18 (45.0)
Total	28 (74.0)	36 (90.0)	36 (90.0)	36 (90.0)	36 (90.0)

Conclusion: To evaluate the impact of the new definition criteria if it increases or less incidence or prevalence of TB in patients with HIV infection. The impact of the new definition criteria on the surveillance system is being studied. The criteria will probably be more sensitive to TB in men between 25 and 35 years old.

Th.6.0.4

THE IMPACT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) ON TUBERCULOSIS IN ZAMBIA: A CROSS-SECTIONAL STUDY
ELIACK, AIDOO*, MARRONI, DANIEL E. KIRDOU, S.N. Gauthan*, P. Nune**
*Senior Medical Officer, TDR; **Physician, TDR.
*Tuberculosis Disease Hospital, MARRONI, KENYA
*University of Zimbabwe, Harare, Zimbabwe
*Ministry of Health, Lusaka, Zambia
*London School of Hygiene and Tropical Medicine, London, UK.
OBJECTIVE: To study the impact of HIV on tuberculosis in Zambia.
METHOD: From November 1988 to January 1989 we have carried out a study of 300 patients on anti-tuberculous therapy in Lusaka, to be compared with smaller samples from 2 rural centres. The prevalence of HIV antibody detected by Western-blot ELISA and confirmed by Rappart. among these patients is compared with that found in age- and sex-matched blood donors.
RESULTS: Preliminary results on the first 100 patients are as follows:
Site of tuberculosis (number of patients) (seropositivity %)

Confirmed pulmonary	60	30	0
Suspected pulmonary	64	58	0
Pleural	31	25	0
Pericardial	8	8	0
Lymph node	8	8	0
Other	1	1	0

When the study code is broken further data analyses will be available.
DISCUSSION: Tuberculosis is emerging as the major bacterial pathogen in patients infected with HIV in Central Africa. It is both common and treatable. But high questions arise regarding the management of tuberculosis when it occurs in association with HIV. Current data from this study will be presented including at guiding further investigations of these issues.

Th.6.0.6

ASSOCIATION OF TUBERCULOSIS AND HIV INFECTION IN ZIMBABWE
MARRONI, DANIEL E. KIRDOU, S.N. Gauthan*, P. Nune**
*Senior Medical Officer, TDR; **Physician, TDR.
*Tuberculosis Disease Hospital, MARRONI, KENYA
OBJECTIVE: To determine the seroprevalence of HIV in TB patients. **METHOD:** To compare the features of TB in seropositive and seronegative patients. **RESULTS:** From July to December 1988, all patients diagnosed as TB in the Harare City TB Unit were studied. Full clinical assessment and HIV testing using ELISA, in some cases confirmed by Western Blot, was performed. **RESULTS:** 195 clinical TB diagnoses were confirmed. 100 (51%) were seropositive, 195 diagnosed clinically. HIV serology was obtained on 403 (90%).
403a.

Sex	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403b.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403c.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403d.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403e.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403f.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403g.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403h.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403i.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403j.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403k.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403l.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403m.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403n.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403o.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403p.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403q.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403r.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403s.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403t.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403u.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403v.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403w.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403x.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403y.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403z.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403aa.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403ab.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403ac.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403ad.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403ae.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403af.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403ag.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403ah.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403ai.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403aj.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403ak.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403al.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403am.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403an.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403ao.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403ap.

Site of TB	3-15 years	16-40 years	40 years Total	
52% (n=29)	12% (n=7)	43% (n=243)	17% (n=14)	33.7% (n=403)

100% 15 year old females
HIV-positivity by sex in 16-40 age group: Men 43% (n=173), Women 43% (n=70)
403aq.

Colloque Symposium



Implications Internationales International Issues

Recherches sur la sexualité humaine Human Sexuality Research

Th.6.0.7 "Reliability and Validity Issues in the Assessment of Sexual Behavior."

Catania, Joseph A., Ph.D.
University of California, San Francisco
San Francisco, California, USA

An unprecedented number of human sexuality studies have been initiated in response to the AIDS epidemic. Unfortunately, methodological developments in the field of sex research have been slow in meeting the demands of AIDS investigations focusing on the diverse populations at risk for HIV (e.g., adolescents, gay men, IV-drug users, ethnic minorities, elderly transsexuals). This paper reviews and integrates literature on research bias in sex research. The relevance of past methodological findings for AIDS behavioral research is discussed and recommendations are made to guide future investigations on sexual behavior in the area of AIDS.

Th.6.0.8

SEXUALITY RESEARCH IN ZAIRE

Lusaka/Lira, Nkomoji, Kinshasa, Zaire

Th.6.0.9 SEXUALITY RESEARCH CONCERNING STD AND AIDS IN THAILAND

Veraval Kilivilai, Jean Barry
Chulalongkorn University, Bangkok, Thailand

Object: To examine status of research on sexuality concerning sexually transmitted diseases and AIDS in Thailand and recommended areas of research needs.

Method: Compilation of bibliography. Review of available literature and existing data.

Results: Systematic research on human sexuality in Thailand was primarily carried out during the past two decades. Most of earlier research was done in relation to contraceptives and birth control. Later, clinical STD research and research on premarital sex of adolescents received most attention. Research efforts have covered areas: sexual behaviours, marriage, sex education, knowledge, attitude and beliefs concerning sex and sexual health. Inquiry of EAP among adolescents on sexual experience and STD is rather thorough, however, among adults is limited and fragmented.

Conclusion: Research in Thailand covers vast areas but not uniformly. Needed are psychosocial studies on sexuality including description of sexual behaviour and cultural traditions among various groups of the total population.

Th.6.0.10 SEXUALITY RESEARCH IN BRAZIL PineJ. Arletty*

*Centro de Referência e Treinamento-AIDS, São Paulo Brazil

Brazil is usually associated to Carnival (Mardi-Gras), music, Latin lovers and half-naked "mulatas" that crowd the beaches in Copacabana. But the true Brazil is more than the apparent sexual permissiveness of less than 10% of the population, its size, as well as its economic situation and mixed racial and cultural origins, being about a unique and complex country of fascinating contrasts. "Active" and "passive" sexual behavior have a greater significance in the general population than the concepts of heterosexuality, bisexuality and homosexuality. Sex plays an important role in the Afro-Brazilian cults that are widely practiced by Brazilians. Women are expected to be submissive to men. Transvestite prostitution is an important form of prostitution. Homosexuality is still considered a form of disease or a sin. Sex can be practiced for procreation, recreation or survival. Research in sexuality has to have the flexibility to distinguish the difference between sexual and sensuous behavior which, in Brazil, have distinct meanings.

Th.6.0.11 RESEARCH ON HUMAN SEXUALITY IN AN AFRICAN AFRICA Adrian Lawrence A.*

*WHO Programme on AIDS, WHO, Geneva, Switzerland

Objective: The presentation provides a sociocultural framework within which African sexuality and the risk of HIV infection can be investigated.

Method: Ethnographic materials and some preliminary findings from WHO-supported national. However, serological instability expresses the reproductive sexual network to the wider recreational network. The concepts of beauty, crime and sexual obligations are passed on from one generation to another within the framework of puberty rites and at fertility-related festivals. Sexuality in old age is influenced by the socio-economic independence of both sexes at the end of the female reproductive cycle and tends to involve younger persons. Education, migration and urbanisation erode traditional sexual norms. Clustering of young adults, mostly males, in urban centres and on plantations produces a compensatory inflow of females who provide them with a range of domestic, commercial and sexual services on a regular or ad hoc basis. Implications for HIV transmission are stressed.

Conclusion: A systematic research agenda is needed to increase our understanding of the social dynamics of heterosexual transmission and control of HIV/AIDS in Africa.

Th.6.0.12

Séance thématique Specialty Session



Implications Internationales International Issues

MTS et facteurs de risque STD and Risk Factors

Th. G.O.25 PROSPECTIVE STUDIES ON HIV INFECTION OF PROSTITUTES IN THE PHILIPPINES
Hayes, Corina¹; Maelonio, C.²; Padre, L.³; Basaca-Sevilla, V.⁴; Andrada, A.⁵; Tzipora, G.⁶; et al.
¹U.S. Naval Medical Research Unit #2, Manila; ²Ugillipino Department of Health, Manila; and ³The City Health Office, Cilegong, Republic of the Philippines.

Objective. Describe the epidemiology of new HIV infections occurring in prostitutes over a 4-year period.

Methods. Hospitality girls working in bars and night clubs frequently engage in prostitution in the Philippines. We have prospectively sampled populations of these women in several towns to determine HIV incidence based on seroconversions. In addition, other women who entered the study populations and started working between bleeding intervals were tested. HIV positive women have been interviewed and examined clinically at 1-month intervals to verify their diagnosis.

Results. HIV seroconversions have been documented in 14 of 12,615 prostitutes for an incidence rate of 0.9/1000 person years. An additional 12 HIV positives were detected among 25,673 women who entered the target population between bleedings. The number of new HIV positives detected each year appears to be decreasing. Only minor signs and symptoms that are probably HIV related have been detected after an average follow-up of 17 months.

Conclusion. This study documents a low rate of HIV spread among the prostitute populations sampled. Based on interview data, this may be attributable to certain sexual behavior characteristics and to the absence of IV drug use.

Th. G.O.27 MALE CIRCUMCISION IN EASTERN AND SOUTHERN AFRICA: ASSOCIATION WITH HIV SEROPREVALENCE

Tomar, Barbara¹; Plummer, F.A.²; Nwadi, A.K.³; Nwawo-Nwala, J.O.⁴.
¹International Development Research Centre, Nairobi, Kenya; ²University of Nairobi, Nairobi, Kenya; ³University of Nairobi, Nairobi, Kenya; ⁴University of Nairobi, Nairobi, Kenya.

OBJECTIVE. To investigate the association between male circumcision and the geographical pattern of HIV infection in eastern and southern Africa.

DESIGN. Several cross-sectional and prospective studies have shown uncircumcised men to be at higher risk of HIV infection compared to circumcised men. We searched an entomological data base to ascertain the practice of male circumcision among major ethnic groups in eastern and southern Africa and reviewed population-based HIV seroprevalence data.

RESULTS. Approximately 12% of the male population in Kenya (2 major ethnic groups/20) is uncircumcised, as compared to 60% in Tanzania (13/29), 60% in Zambia (17/29), 90% in Uganda (12/13), and 90% in Zimbabwe (18/19). A preliminary review of published and unpublished data yielded population-based HIV seroprevalence data from over 30 areas in the region, which were divided into low, moderate and high HIV prevalence. Ethnic groups in high and moderate prevalence areas were more likely to be uncircumcised compared to those groups in low prevalence areas.

CONCLUSIONS. Preliminary findings suggest that the geographical patterns of HIV seroprevalence are consistent with the hypothesis that uncircumcised men are at higher risk of acquiring HIV infection. Further studies examining the relationship between male circumcision and the risk of acquiring HIV infection are recommended.

Th. G.O.29 CONDOM USE AND KNOWLEDGE IN GENERAL POPULATION, FEMALE PROSTITUTES AND GAY AND BISEXUAL MEN

Itzaja, J.A.¹; Prada, L.¹; Valdesolo, J.¹; Sepulveda, J.¹

¹Department of Epidemiology, Ministry of Health, Mexico

Objective. To compare knowledge and use of condom in general population, prostitutes and homo and bisexual men.

Methods. A survey was done in 6 cities in Mexico during May, 1988. A questionnaire was applied individually to general population (n=101), female prostitutes (n=78) and homo and bisexual men (n=78); a condom was shown to investigate visual recognition and condom use practices.

	Knowledge and use of condom.			Frequency of use of condom			
	Known	Used last m.	Used last 6m.	Always	Half of the time	Never	
Gen.pop.	78%	6%	10%	Gen. pop.	5%	5%	90%
Home.	86%	29%	43%	Home.	29%	14%	57%
Prost.	94%	82%	89%	Prost.	38%	20%	42%

A significant difference existed between every group. The use of condom is less frequent in gay men than in prostitutes although that knowledge is similar. The use of condom is more frequent in gay men than in general population which is explained by their risky practices.

Th. G.O.26 STATUT SEROLOGIQUE D'UNE POPULATION DE PROSTITUES EXCUBAÏENNES EXPOSÉES AUX HIV ET HIV2 AU BURKINA FASO

Sangaré, Lyman¹; Kanki, P.²; Soudré, R.³; Tiendrébogo, H.⁴; M'Boop, S. ⁵; Ezzou, A.⁶; et al.

¹Hopital A. Le Dantec, Dakar, Sénégal; ²Hopital Yağudo Ouedogo, Ouagadougou, Burkina Faso; ³Hopital School of Public Health, Boston, Massachusetts, États-Unis.

Objectif. Déterminer l'évolution de la séroprévalence dans une population de prostituées doublement exposées à HIV1 et HIV2.

Méthode. En 1986, une première étude séroépidémiologique a permis de rechercher par Western blot et RPA, la présence d'Ac anti-HIV1 et anti-HIV2 dans 303 sérum de prostituées.

En 1987, une étude similaire a porté sur 261 sérum de prostituées. Parmi celles-ci, certaines de la première enquête ont été retrouvées.

Résultats. Les séroprévalences rapportées ont été respectivement de:
Année Total exam. HIV1 HIV2
1986 308 8.8% 14.6% 5.8%
1987 268 14.9% 5.6% 4.8%

Parmi les prostituées réexaminées lors de la seconde enquête (N=14), nous avons observé 35% de séroconversion avec 21.4% pour le HIV1 et 14.3% pour le HIV2. Par ailleurs, dans ce même groupe nous avons noté l'apparition de double profil chez 7.0% des prostituées enregistrement indiquées par le HIV2.

Conclusion. Ces différents résultats montrent une importante circulation du HIV1 qui tend à se substituer au HIV2. La poursuite de ce travail permettra de préciser les conditions de reverses des cas de double infection à HIV1 et HIV2.

Th. G.O.28 FACTORS ASSOCIATED WITH PREVALENT HIV-1 INFECTION IN FREGUENT WOMEN IN MALAYSIA

Chaiyapong J., Miové E., Dalabatta G., Niotti P., Lioha N., Alfred J., Shah

¹Queen Elizabeth Central Hospital, Singapore, Malawi; and ²Johns Hopkins School of Hygiene and Public Health, Baltimore, MD, USA.

Objective. To determine factors associated with prevalent HIV-1 infection in frequent women in Malawi.

Methods. 247 consecutive women who presented to the antenatal clinic at the QCH during December 1988 were tested for HIV-1 antibody and had their charts reviewed. Antisero testing was done by ELISA with Western blot confirmation. Informed consent was obtained from each participant. Variables that were analyzed included age, trimester at presentation, gravidity, occupation, VWS, history of TB, STD, transfusions, spontaneous abortion, still birth, prematurity, and neonatal death.

Results. 48 of the 247 (19%) women were seropositive for HIV-1. Reactive VWS was significantly associated with HIV-1 seropositive status (OR = 18, p=0.02). 37 of the 104 women who had had prior pregnancies were HIV-1 seropositive. History of spontaneous abortion in this group was of borderline significance (OR = 14, p=0.06). None of the other variables was significantly associated with HIV-1 infection.

Conclusions. This cross-sectional analysis shows that reactive VWS should raise one's index of suspicion regarding HIV-1 seroreactivity. Also, HIV-1 infection may play a role in fetal wastage.

Th. G.O.30 COMPARISON BETWEEN RISK PRACTICES IN FEMALE PROSTITUTES AND GAY AND BISEXUAL MEN

Itzaja, J.A.¹; Prada, L.¹; Valdesolo, J.¹; Sepulveda, J.¹

¹Department of Epidemiology, Ministry of Health, Mexico

Objective. To determine the prevalence of risky sexual practices in female prostitutes and gay and bisexual men in Mexico.

Methods. A survey was done in Guadalajara, Tijuana, Monterrey, Acapulco, Mérida, and Mexico City in May, 1988. A questionnaire was applied individually to female prostitutes and gay and bisexual men, investigating the frequency of risky sexual practices.

Results.

Sexual practices	Prostitutes		Gay and bisexual men	
	Always	Half of the time	Always	Half of the time
1	81%	1%	4	18%
2	0.6%	0.5%	7%	17%
3	2%	0%	20%	12%
4	16%	16%	22%	12%

Frequency of sexual contact in prostitutes was: vaginal: 80% always, 15% half of the time, 5% never; anal: 30% always, 1% half of the time, 4% never; oral: 32% in gay and bisexual men, frequency of same deposit was: insertive: 49% always, 12% half of the time, 30% never; receptive: 42% always, 18% half of the time and 37% never; oral: receptive: 9% always, 95% half of the time, and 3% never.

Conclusions. Although HIV prevalence in gay and bisexual men ranges from 2% to 30% and is less than 1% in prostitutes, the high levels of risk in sexual practices stress on the need of strengthening educative efforts directed to these groups.

**Atelier
Workshop**

**Implications Internationales
International Issues**
**Atelier régional : Amérique Latine
Regional Workshop: Latin America**
Th.G.O.37

MEXICAN EXPERIENCE ON INTERRELATIONSHIP BETWEEN
EPIDEMIOLOGY AND EDUCATION ON AIDS
Valdespino, José-Luis, Mexico.

Th.G.O.38

CLINICAL-EPIDEMIOLOGICAL CHARACTERISTICS OF AIDS
CASES IN ARGENTINA
Cahn, Pedro, Hospital Fernandez, Buenos Aires
Argentina.

Th.G.O.39

DEVELOPMENT OF AIDS PROGRAMMES FOR HISPANIC
COMMUNITIES IN THE USA
Pina, Arletty, Centre for Reference and Training
in AIDS, Sao Paulo, Brazil.

Th.G.O.40

AIDS EDUCATIONAL PROGRAMMES IN SAO PAULO, BRAZIL
Legos Fernandes, Maria Eugenia, State Department
of Health, Sao Paulo, Brazil.

Th.G.O.41

AIDS IN PROSTITUTES: EXPERIENCE IN THE DOMINICAN
REPUBLIC
Guerrero, Ernesto, AIDS and STD Control Programme
(PROCTS), Santo Domingo, Dominican Republic.

Th.G.O.42

AIDS: A CARIBBEAN PERSPECTIVE
Narain, Jai P., Caribbean Epidemiology Centre,
Port of Spain, Trinidad, W.I.

Atelier Workshop



Implications Internationales
International Issues

Atelier régional : Antilles Regional Workshop: Caribbean

Th.G.O.43 EPIDEMIOLOGY OF AIDS IN THE BAHAMAS 1982-1989

Olofin-Barko Kumbeth, Aymee F. Bain R, Miller M.L., Gomez F, Ministry of Health, Nassau Bahamas.

OBJECTIVE To describe the AIDS epidemic in The Bahamas during the period August 1985 - March 1989.

METHOD Information from notifications of AIDS patients and contact tracing HIV testing and blood donor screening were analyzed.

RESULTS Three hundred and eight cases of AIDS were reported over a period of 44 months. The incidence rate per 100,000 rose from 16 in 1985 to 38 in 1988. Ten of the 24 inhabited islands have been affected. Fifty-five (17.8%) cases occurred in children. The proportion of cases due to perinatal transmission has varied from 27.7% in 1985 to 7.7% in 1989. Heterosexual transmission accounts for 59% of cases, homosexual 21, bisexual 8%. Among the adults 34% were free born, 66% were contact partners. The fatality rate is 30.6%. The number of HIV infected individuals identified has increased from 20 in 1985 to 419 in 1989 with a cumulative total of 310. Of the 10,369 units of blood screened during this period, 48 (0.46%) were found to be positive for HIV infection.

CONCLUSION There has been a rapid increase of AIDS and HIV infection in The Bahamas. The proportion due to perinatal transmission though high, has shown a significant decrease. The predominant mode of transmission is heterosexual. Cocaine abuse has contributed to the spread of HIV infection.

Th.G.O.44

AIDS IN THE DOMINICAN REPUBLIC: INTERVENTIONS AMONG PERSONS WITH HIGH-RISK BEHAVIOUR
Surrero, Ernesto. Santo Domingo, Republica

Dominiqana.

Th.G.O.45 SITUATION EPIDEMIOLOGIQUE DU SIDA EN GUYANE FRANÇAISE - DE VIENNE - F.D.A.S.S. de Guyane - Médecin Inspecteur de Santé.

avec la collaboration des membres du Comité SIDA Guyane.

131 cas de SIDA ont été recensés entre 1987 et 1988 dans une population estimée à environ 100.000 habitants.

Dans ce département français la transmission hétérosexuelle du VIH est prédominante.

14 cas pédiatriques cumulés montrent la transmission materno foetale correspondant à plus de 10% des patients atteints du SIDA.

Les infections opportunistes sont majoritairement dans les manifestations cliniques aigus que le syndrome de l'homme à l'été recensé que chez deux patients.

94 de ces malades sont à ce jour décédés.

Th.G.O.46

STRATEGIES FOR PREVENTION AND CONTROL OF AIDS IN
HAITI

Timothee, Gabriel. CARE PWR Haiti, Port-au-Prince

Haiti.

Th.G.O.47 AIDS EDUCATIONAL STRATEGIES AND ETHNIC DIVERSITY IN SURINAME del Prado, Ruben F.

*"National AIDS Program" of the Bureau of Public Health,
Paramaribo, Suriname, Sur. Am.*

In the 18th century, Suriname (then also known as Dutch Guiana) had a prosperous plantation economy, based on the labour of African slaves. To counteract the manpower shortage after the abolition of slavery in 1843, the immigration of indentured labourers from British India began in 1873, followed by a similar movement of Javanese from the Dutch East Indies. The multi-ethnic, multi-cultural, multi-religious, multi-lingual society which now comprises the Republic of Suriname has no clear manifestations for any health education program. The official language is Dutch, but Surinamese Hindustani, Javanese, Chinese, several Amerindian and Bushinagro (Wayana) languages, and a vernacular comparable to Creole, Surinamese, are widely spoken. None so far as to other Caribbean countries the official language is only "official" in the true sense of the word. Although AIDS education faces the usual dilemma as anywhere in the world, we meet this extra challenge of racial ethnic diversity in a nation without a common tie. The first classified case of HIV infection dates back to 1982, and Suriname has since seen 36 people with clinical HIV infection (AIDS) out of a total of 41 known to be HIV infected. Though we do not have an approximation of the total number of HIV infected in Suriname, we believe that the number of clinical cases is as close to reality as possible, with an estimated 400,000 inhabitants, Suriname lags behind its neighbouring countries in regard to the number of people with AIDS. It is a dismal thought, but we may only be lagging behind the wave of a substantial outbreak of HIV related diseases. A delay which we may (hypothetically) attribute, in part, to our special socio-demographic make-up. HIV specific norms concerning human sexuality. But these very same cultural norms, in their diversity, could very well impede our AIDS education efforts.

Th.G.O.48 CHALLENGES IN DEALING WITH THE AIDS EPIDEMIC IN JEREMO WHY? WHO Muhlestein

Minister of Health, National AIDS Program, Republic of Trinidad and Tobago

Objective: To discuss the socio-cultural factors influencing programme activities as we

respond to the AIDS epidemic in Trinidad and Tobago.

Method: A case study will be based on the current reports of the Ministry

of Health. (Annual reports will be based on the minimum data of reported cases among

health workers, transmission of HIV has been identified as the main mode of spread, as seen

in clinical trials of 39 cases of AIDS over period 1983 - October 1989 (prevalence 20.7%,

homosexual 34.9% and bisexual 30.2%). Blood screening for HIV was initiated in 1985.

A national appointed National AIDS Committee was established in 1987. Efforts to control

AIDS are channelled through public education, training of health care workers,

community and social support services and community participation. One of the major

challenges appear to be the need for focused, sustained interest and willingness to address

the problem of HIV infection/AIDS in the real context of social and economic power and

authority, at community and institutional levels. To the extent and time we are engaged in

program to provide of services or treatment at institutional level for persons with AIDS,

we must be prepared to identify and manage persons for HIV testing for the world will

depend on us to reduce the problem. There is need to increase the cadre of personnel

who address the behavior change or provide counsel and support for clients and families.

Conclusion: Although the AIDS Control Programme has been implemented in Trinidad and Tobago

since 1987, there are some serious concerns which must be addressed, both at individual,

community and institutional levels.

Session of affichage
Poster Session



Implications Internationales
International Issues

M.G.P.13 STUDY OF HIV-1, HIV-2, AND HTLV-I IN FEMALE PROSTITUTES IN BRAZIL
 Correa, Eduardo,*; Datta, R.***; Sisson, D.***; Aboulafia, D.***; Li, X.L.***; and Ho, D.P.*** School of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil; University of California at Los Angeles (UCLA), Los Angeles, California, U.S.A. **Cedars-Sinai Medical Center, Los Angeles, California, U.S.A.

Objective: To investigate human retroviruses, seroprevalence, and transmission patterns in female prostitutes in Brazil.
Methods: A total of 187 prostitutes were studied in 2 states: 101 in Brehim in Rio de Janeiro (34 females [LCP], 77 middle- [MCP], and 47 upper-class prostitutes [UCP]) and 86 prostitutes in Brehim and other brothels in rural areas (RAP). Sera and a questionnaire with information on demographics and practices associated with AIDS were obtained. HIV-1, HIV-2, and HTLV-I were tested by ELISA, immunoblot and radioimmunoprecipitation assay.
Results: HIV-1 was found only in LCP in Rio (9%). HIV-2 was not found. HTLV-I was found in MCP (4%) and LCP (8%) in Rio, and in RAP (1%). Less than 20% of prostitutes used IV drug use; none of HIV infected LCP were IV drug users. Illiteracy was noticed in 20% of LCP, but none in UCP. Median number of different partners/week was 20 for MCP and MCP, 48 for UCP, and 10 for RAP. Linear analysis identified significance in several variables studied.
Conclusion: HIV-1 was prevalent only in LCP. IV drug use was not a significant pattern of HIV transmission in prostitutes in Brazil. HTLV-I is present also in rural areas in Brazil.

M.G.P.14 SEROPREVALENCE OF HIV-1, HIV-2, AND HTLV-I IN BRAZILIAN BIRURAL RALES
 Correa, Eduardo,*; Datta, R.***; Sisson, D.***; Aboulafia, D.***; Li, X.L.***; and Ho, D.P.*** School of Medicine, Federal University of Rio de Janeiro, Brazil; **University of California at Los Angeles (UCLA), U.S.A. ***Cedars Sinai Medical Center, Los Angeles, California, U.S.A.

Objective: To study the seroprevalence of HIV-1, HIV-2, and HTLV-I in birural areas from Rio de Janeiro, and their role in the retroviral transmission to the heterosexual community in Brazil.
Methods: Fifty eight birural males, recruited in gay bars and clubs were interviewed for demographic information and practices related to retroviral transmission. Sera were tested for antibodies against HIV-1, HIV-2, and HTLV-I by ELISA, and confirmed by immunoblots and radioimmunoprecipitation assays.
Results: One female was 20% for HIV-1 and 7% for HIV-2 and confirmed by immunoblots and radioimmunoprecipitation assays. Median number of partners/month was 19 (prostitutes) and 4 (non prostitutes). 50% of the sexual partners were men and 50% women. current IV drug use was reported. Multivariate analysis of different variables, was done using log linear models.
Conclusion: The studied birural males have a high HIV-1 and HTLV-I seroprevalence, and may be an important bridge for HIV infection between the homosexual and heterosexual communities in Brazil.

M.G.P.15 SEROPREVALENCE OF HIV-1 IN EMERGENCY ROOM PATIENTS IN BRAZIL
 Correa, Eduardo,*; Lourenco, R.***; Lima, R.***; Huang L.***; Viana, R.***; Nogueira, C.*** School of Medicine, Federal University of Rio de Janeiro (UFRJ), Brazil; **UFRJ Hospital, Rio de Janeiro, Brazil.

Objective: To study seroprevalence and routes of HIV-1 transmission in emergency room patients.
Methods: 103 patients were recruited in the adult emergency room of the UFRJ Hospital. Information on demographics and practices related to HIV transmission was obtained by a questionnaire. HIV-1 antibodies were tested by ELISA and confirmed by immunoblot.
Results: Fifty one percent of participants were male (50) and 49% female (53); they were white (52%), black (23%) and mixed(25%); median age was years 45.5 for M and 33.1 for F. 20% had blood transfusions, 87% were heterosexual; median number of partners/month was 1.60 and 1.19; 22% of M had contact with prostitutes in the past 10 years. Sexually transmitted diseases were seen in 38% M and 12% F. 90% of sexually active single people (M/F) used condoms. Three (2%) subjects, 2 M and 1 F, had antibodies to HIV-1. All were heterosexual, without contact with HIV infected individuals, IV drug use, or blood transfusions. Significance of the variables collected was determined by log linear models.
Conclusion: HIV-1 is reaching non risk population for AIDS in Brazil. Preventive measures to avoid HIV infection are not widely used by the population studied.

M.G.P.16 HIV-2 INFECTION IN PRENATAL WOMEN IN GUINEA-BISSAU
 Andersson, Per-Ake; Dias, F. J.; Teixeira Goudaby, J. M.; Nacur, A.***; Biserfeld, G.***. Laboratório Nacional de Saúde Pública, Guinea-Bissau and National Microbiological Laboratory, Stockholm, Sweden.

Objective: To determine the prevalence of HIV-2 infection among antenatal women in various regions of Guinea Bissau and the route of vertical transmission of the infection.
Methods: Sera from prenatal women in the capital Bissau and in 5 regional capitals and sera from children of seropositive mothers were tested by HIV-2G6699 ELISA. Positive sera were confirmed by Western blot.
Results: 6.9% of 1992 women in Bissau were HIV-2 seropositive. The HIV-2 seroprevalence ranged from 3.1 to 13.2% among women from various parts of the city. The seropositivity rate increased with age from 2.5% in women less than 17 years old to 13.4% in women older than 33 years. In the 5 regional capitals the seropositivity rates were 2.1% (5/237), 3.6% (9/253), 7.0 (18/258), 3.4% (5/145) and 3.6% (7/195). All of 9 children of seropositive mothers followed up for more than 12 months after birth were seronegative.
Conclusion: The seropositivity rate among prenatal women varied considerably between different parts of the capital and between different regions. Follow-up of additional children which is in progress will allow conclusions about the vertical transmission rate.

M.G.P.17 CHILEAN NATIONAL HIV LABORATORY NETWORK
 Sanchez, D., Muñoz, G., Vera, L., Soto, O. National Public Health Institute, Santiago, Chile

Objective: To establish the usefulness of a national laboratory network on HIV diagnosis and to show results obtained at the national HIV reference center.
Methods: A questionnaire was sent and according to its results, laboratories were classified in different levels, depending on their implementation. Training and resources were provided to the laboratories.
Results: Only one national HIV reference center was established and all doubtful or positive specimens must be sent for confirmation.
Conclusion: The network is composed of 46 public and 23 private blood bank and laboratories in which HIV antibodies detection is performed with a monthly average of 20,000 blood donors.
Conclusion: This national laboratory network allows proficiency laboratory evaluation and sets a base of limited resources, securing an acceptable quality standard diagnosis.

M.G.P.18 HIV-1 SEROPREVALENCE IN RURAL FAIR
 Hanco, Jala J.; Green, S. J.; Cutting, M.*** and Crawford, M.***. Univ. of Edinburgh, Edinburgh, Scotland, **Institute Medical, Evangelische, Klempe, Zurich.

Objective: To determine the seroprevalence of HIV-1 in a rural area, in Fair.
Methods: As part of an ongoing perinatal study, based at a rural reference hospital 220 km s.w. of Kinshasa, 1485 pregnant women were screened for antibodies to HIV-1. Screening was by Abbott Recombinant HIV-1 EIA, confirmed by Molecogen HIV Monoclonal VII 52/55 ELSIA. 1000 blood donors were screened with the Cambridge Bioscience Latex Agglutination (IA) test, with EIA confirmation.
Results - Pregnant women: 46/1485 (3.2%) HIV-1 antibody positive (HIV+). If women from distant large towns are excluded there were 41/1422 (2.9%) HIV+. Age varied from 14 to 48 years, with mean 26 yrs for both HIV+ and HIV- women. HIV- women were more often monogamously married; HIV+ women, single (p<0.01). Mean parity (3) was the same for both groups. Educational level of both HIV+ women and their partners was higher (p<0.025, p<0.1 respectively). Women who were partners of chauffeurs or small business-owners were twice as likely to be seropositive. Blood donors: 55 positive by IA, 21/1000 (2.1%) confirmed HIV+ with ELSIA. The false positive rate for the latex test was 1.6% (n=61).
Conclusion: The prevalence of HIV-1 infection in two asymptomatic adult groups in this rural area of Fair is 2.9% of pregnant women and 2.1% of blood donors.

Session d'affichage Poster Session



Implications Internationales International Issues

Aspects cliniques (partie 2) Clinical Features (Part 2)

Th.G.P.1 HIV AND HTLV-I INFECTION AMONG HOMOSEXUAL AND BISEXUAL MEN IN KINGSTON, JAMAICA
 Murphy, Edward L.; Gibbs, W.H.M.; Figueroa, J.P.; Bain, R.; LaGrande, L.; Cranston, B.; and Blattner, W.A.P.
 *National Cancer Institute, Bethesda, MD; *Univ. of the W. Indies, Kingston, Jamaica; **Min. of Health, Kingston, Jamaica

Objective: To evaluate prevalence and risk factors for infection with HIV and HTLV-I in Jamaican homosexual men.
Methods: From 8/85 through 1/86, 125 homosexual or bisexual men had ELISA/Western blot for HIV/HTLV-I and questionnaire data.
Results: 15 men (12%) were seropositive for HIV and 6 (5%) for HTLV-I; one man had possible co-infection with HIV and HTLV-I. Sexual contact with men in the U.S.A. was common, and was weakly associated with HIV infection (p=0.11). The median number of homosexual partners was 12 per year (range 0-135) and a greater number of partners per year was associated with HIV seropositivity (p<0.01). Lymphadenopathy was identified in several HIV seropositives. For HTLV-I there were no obvious risk factors identified, and age-adjusted seroprevalence was not significantly higher than that of heterosexual men.
Conclusions: HIV appears to have entered this population via sexual contact with foreign men and spread efficiently among men with a greater number of sexual partners. The frequency of bisexuality (65/125 men) and the 11% HIV prevalence in bisexual men suggest that secondary infection of female sexual partners may occur.

Th.G.P.3 HIV INFECTION AMONG PROSTITUTES AND TRANSEXUITES IN BRAZIL
 80k., FRANCISCO, Hideo, Liza, J. N.; Abreu, U. B. S.; Monteiro, D. T.; Pavan, M. H. P.; Pedro, R. J. et al.
 UNICAMP, Campinas, Sao Paulo, Brazil.

During 1988 HIV testing was done among prostitutes and transvestites who spontaneously reported to a health clinic located in the prostitution area in Campinas, southeastern Brazil. Tests were performed using the ELISA (recombinant DNA) antibody assay and Western-Blot (WB) antibody assay. One hundred and two individuals were tested: 218 were male and 79% female. The age ranged from 14 to 56 years but 61% were 20 to 29 years old. Most (78%) were prostitutes, 19% male homosexuals and 3% male bisexuals. Among the prostitutes 15% reported IV drug use. The first 48 individuals were tested by ELISA (2 samples) and WB; 35.7% had antibodies by both methods and 64.3% did not have antibodies by both methods, showing a sensitivity and predictive value of 100% for the ELISA test when compared to the WB test in this high risk population. The 48 remaining patients were tested only through ELISA. The overall prevalence of HIV antibody positive individuals in the population studied was 21.5%.

Th.G.P.5 PREVENTIVE INTERVENTION FOR HIV IN STD CLINICS IN ZAMBIA.
 Nerva, Subhashi; Matsuda, J.*
 *University Teaching Hospital, Lusaka, Zambia.

Zambia is the only sub-Saharan African nation with a STD control programme. It was launched in 1980 and expanded to include a network of STD clinics providing standardized treatment, contact tracing, counselling and surveillance. The male:female attendance ratio has improved from 3:1 in 1980 to 2:1 in 1987. The programme in screening and treatment programme introduced in 1984 has reduced seroprevalence of syphilis in pregnant women in Lusaka from 11.8% in 1983 to 6.0% in 1987. With high seroprevalence of HIV among STD attendees, it is simple, easily accessible target population where health education, counselling and condom promotion can be highly successful in reducing HIV transmission.
Conclusion: Other nations based on this model programme to establish similar programmes and introduce preventive intervention for HIV.

Th.G.P.2 RISK FACTORS FOR HTLV-I INFECTION IN PREGNANT HAITIAN WOMEN
 Buff, Andria*; Hot, E.*; Wiktor, S**; Boulos, R***; Battner, W**;

Jesey, M, et al.
 *Johns Hopkins University, Baltimore, MD; **National Cancer Institute, Bethesda, MD; ***Centers for Health and Development, Port-au-Prince, Haiti

Objective: To identify factors associated with HTLV-I infections in pregnant Haitian women.
Methods: Pregnant Haitian women were screened for HTLV-I, (ELISA and WB) HIV-1, and syphilis.
Results: Of 2070 women, 894 (43%) were seropositive for HTLV-I. Seroprevalence rates increased with age from 2.3% in women 14-19 years old to 8.4% in women over 24 years old. Regression analysis revealed independent associations with alcohol consumption (OR = 5.2, 95%CI = 1.23, 22), HIV-1 seropositivity (OR = 3.7, 95% CI = 2.1, 6.8), smoking (OR = 2.1, 95%CI = 1.0, 4.2), and age > 34 years (OR = 2.0, 95% CI = 1.1, 3.9). HTLV-I seropositivity did not differ from seronegative women in marital, educational, or socioeconomic status, syphilis serology or prior use of family planning. Other potential risk factors, IV drug use and transfusions, are not prevalent in this population.
Conclusion: The increasing seroprevalence rates with age and the association with HIV-1 seropositivity suggest that HTLV-I is transmitted through sexual contact in this population. As our studies of HIV-1 risk factors also demonstrated, an association exists between seropositivity and smoking. We have undertaken additional studies in this population to determine the basis of this association.

Th.G.P.4 MERCHANT SEAMEN: A RISK POPULATION FOR HIV INFECTION?
 Corralo, Malcom; Jerez, R. and Gasanovic, D.
 University of Valparaiso, Valparaiso, Chile.

In Valparaiso (principal port of Chile) 3/90 HIV infected people had been heterosexual merchant seamen, 2 of them had transmitted the infection to their wives.

Objective: To determine if merchant seamen could be a risk group for HIV infection and a factor in the propagation to the female population in Chile.
Methods: After informed consent was obtained a questionnaire was administered to 452 healthy seamen with at least 1 year of international travels. Simultaneously blood was drawn for HIV Ab and HIV Ag determination (Organon).
Results: The mean age was 36.7 years, 70.9% had medium or high level social literacy. In the last five years, 64.6% had frequently travelled abroad. During this period 7.3% had undergone surgical procedures, 1.3% had received blood transfusion, 35.2% injections, and 31.0% tattoos. 100% of the subjects declared heterosexual, 70.3% were married, 65.6% admitted multiple sexual intercourse predominantly with prostitutes of South America (Ecuador, Peru, Brazil) and Europe (UK, FRG) and 22.3% other S.A. Only 3.5% used condoms. Marital status and education were not significantly associated with risk sexual behaviour and use of condoms. HIV antibody and HIV antigen were not detected in 442 and 249 serum samples tested.
Conclusion: HIV infection was not demonstrated in this study, however, the high frequency of sexual contact with different foreign prostitutes may be a risk factor for this group and their female partners in Chile.

Facteurs de risque liés aux MTS (partie 2) STD Risk Factors (Part 2)

Th.G.P.6 DETECTION OF HIV-1 FROM FILTER PAPER BY PCR
 PCR-VALENCE CHAIN REACTION (PCR-VALENCE)
 Stanton, Craig; Kotler, B.; Malher, R.; Kiani, P.; Essex, M.
 Harvard School of Public Health, Harvard University, Boston, USA.

Objective: To determine the suitability of collecting whole blood specimens on filter paper for HIV-1 DNA detection by PCR.
 Dried blood on HIV-1 seropositive mothers may carry and HIV-1 antibodies which may have been transferred across placenta.
 At present, one must either HIV by co-cultivation or demonstrate viral DNA to determine the actual infection of the newborn. PCR is a newly developed method which enables detection of a minute amount of DNA.
Methods: Blood from known HIV-1 seropositive patients and known controls was collected by heparin spotting Whatman #3 filter paper, approximately 1 cm in diameter. The papers were kept in plastic bags at room temperature for 4-6 weeks. DNA was extracted by digestion with SDS and proteinase K followed by phenol-chloroform extraction and ethanol precipitation. Papers were resuspended in 100 µl TE buffer. 2.5 µl of the DNA suspension was then used for DNA amplification by PCR. PCR was performed using HIV-1 specific primers for the gag, env, and LTR regions. The PCR product was dot-blotted and hybridized with pCR labelled probes of these three regions. Results were compared to HIV-1 DNA isolated from rectal tissue cultures.
Results: We performed PCR amplification of DNA extracted from whole blood collected on filter paper from HIV-1 seropositive patients. Using this technique we have been able to detect the presence of HIV-1 DNA in many quantities of blood.
Conclusion: Detection of HIV-1 by PCR, from whole blood collected on filter paper can be performed effectively. The method can facilitate diagnosis of HIV-1 in situations where (1) storage of blood may be logistically difficult, ie. in developing countries, and/or (2) when amount of blood available is very small, i.e. in newborns.

**Session d'affichage
Poster Session**



**Implications Internationales
International Issues**

**Épidémiologie
Epidemiology**

W.G.P.25

MALE SEROPREVALENCE AND AIDR. PRESENT STATUS AND PERSPECTIVES IN MEXICO

Dávalos M.C., Barasa J.M., Velázquez A.T., Magas C., Ornelas O.

Univ. de Guadalajara, Jalisco, Mexico; Univ. de México, Mexico

Objective: To define sexual practices and HIV infection prevalence in bisexual men who attend an HIV detection center in Mexico City. **Methods:** A survey which included HIV test was done in 1978 homosexual and bisexual men who attended an HIV detection center in Mexico City from January to December, 1988. **Results:** 740 men (44%) declared having had sexual relations exclusively with men (0, 945 (28%) with men and women (80) 84% of homosexual men had at least one sexual partner during the last 6 months (M4), 813 (96%) of bisexual men had at least one sexual partner during the last 6 months (M4), of these, 373 (46%) had only male sexual partners during the last six months (M4), 116 (14%) had only female sexual partners during the last 6 months (M4) and 355 (46%) had both male and female sexual partners during the last 6 months (M4). The HIV prevalence was as follows: 10, 20% (M4), 27%, 10% (M4), 20%, 10% (M4), 20%, 10% (M4). Seroprevalence was 21%, 9% of seropositive subjects were in clinical stage I, 12% were in II, none in III. HIV infection was serotyped in 49% of seropositive subjects. The percentage of stable heterosexual partner was 6% (M4) to 47% (M4), and 60% with women. Frequency of stable heterosexual partner was most frequent in Stage I (20%), Stage II (18%), Stage III (18%), and Stage IV (18%). Positive test results (M4) were associated with HIV infection in all groups. **Conclusions:** Heterosexual and bisexual men attending counseling sessions that in other cultures and has modified the epidemiological pattern of HIV infection. Results show that bisexual practices are frequent, risk practices associated to HIV seropositivity are similar to the ones described in heterosexual. While heterosexual practices constitute protective factors for bisexual men, they represent a risk of transmission to their heterosexual partners.

W.G.P.26

HTLV-1 SEROPREVALENCE INCREASED AMONG THOSE LIVING AT LOW ALTITUDE IN JAMAICA

Murphy, Edward J., Maloney, E., Figueroa, J.P., Gibbs, W.W.,

Univ. of Kingston, Jamaica; Univ. of Cranston, R.I.; Blair, W.A., National Cancer Institute, Bethesda, MD, Univ. of Health, Kingston, Jamaica, **Univ. of the W. Indies, Kingston, Jamaica.

Objective: To determine demographic and geographic determinants of Human T-lymphotropic virus Type I (HTLV-1) seroprevalence in Jamaica, an endemic island. **Methods:** During 1985 and 1986, we measured HTLV-1 antibodies using ELISA and Western blot in 13,000 Jamaican workers. **Results:** HTLV-1 seroprevalence was strongly age- and sex-dependent, rising from 1.8% (ages 10-13) to 5.0% (ages over 70) in men and from 2.0% (ages 10-13) to 10.4% (ages over 70) in women. Women were more likely to be seropositive than men (adjusted odds ratio = 2.23). Black men had marginally higher HTLV-1 seroprevalence (M-H chi square = 0.06), but black women had equivalent prevalence to women of other races. Current residence at altitudes of less than 1000 feet (p = .003) and birthplace outside of the Kingston metropolitan area (when only p = .001) were significant risk factors for HTLV-1 seropositivity, after stratification by age and gender. **CONCLUSION:** Older age, female gender, and black race are known risk factors for HTLV-1 infection in endemic areas. Higher HTLV-1 prevalence in those residing at low elevation suggests transmission by an environmental vector - e.g., by arthropods.

W.G.P.27

HIV SEROPREVALENCE SURVEY AMONG HIGH RISK FEMALES AT MOMBASA, KENYA

Muga, G. S. G., Adoo, S. T., Mwachiro, E. S., Njenga, E. S.

Kenya Medical Research Institute; Ministry of Health; Public Health Department of Mombasa Municipality

Objective: To assess the prevalence and distribution of HIV infection among female prostitutes at Mombasa. **Method:** 260 high risk female workers living in bars and soliciting for men in bars and in Mombasa streets plus women known to entertain men in their homes in certain parts of Mombasa town were sampled using cluster method and recruited into the study. The women were asked to report to Communicable Diseases Control department at Guyoni, Mombasa. While at the Guyoni clinic, verbal consent was taken. 5 ml of blood samples were collected from the women and blood sera was later separated at Coast General Hospital Laboratory, Mombasa and Enzyme Linked Immunosorbent Assay (ELISA) test using enzyme linked anti-HIV was done. A written questionnaire was administered by asking the study subjects questions and filling in forms. **Results:** 144/260 (55.4%) women were seropositive for HIV; 80/366 (21.8%) were positive for syphilis; 32/366 (8.7%) positive for both HIV and syphilis; 48/366 (13.1%) were positive for syphilis alone and 112/366 (30.6%) HIV alone. **Conclusion:** The HIV infection among high risk females in Mombasa is definitely high and there is urgent need to organize counselling sessions for the patients.

W.G.P.28

PREVALENCE OF HIV-1 ANTIBODY IN STD PATIENTS.

Hein, Kefauver, Babson, D., Davis, M., Zwi, D., and Kabeta, T.

Armed Forces Hospital, Adis Ababa, Ethiopia; National Research Institute of Health, Adis Ababa, Ethiopia.

Objective: To determine the prevalence of HIV-1 antibodies in patients with STDs attending one of the clinics in Adis Ababa, Ethiopia. **Methods:** Sera from 500 consecutive STD patients (496 male and 4 female) were examined for the presence of HIV-1 antibodies. The serological tests were carried out by ELISA (Walloco) and confirmed by Western Blot (Biorad). **Results:** Of the 500 tested 60 (12%) were HIV-1 antibody positive. The prevalence of HIV-1 antibodies varied with the type of STD:

STD	No. of patients	HIV-1-Ab %	
Gonorrhoea	194	17	8.8
Chancroid	85	16	18.8
Non-gonococcal urethritis	117	5	4.3
Lymphogranuloma venereum	21	3	14.3

Conclusion: The prevalence of HIV-1 infection among STD patients is 12%. This infection rate is higher than that of blood donors (1.6%) but lower than figures for prostitutes in Adis Ababa (18.8%).

W.G.P.29

HIV-1 PREVALENCE IN RAIBOBI SEROTYPED POPULATIONS.

Mwera-Achola, Jackson O. A., Datta, R. P., Wanyaki, P.,

O'Gara, L. J., Smith, A. K., Smith, P., Wanyaki, P.,

University of Nairobi, Nairobi, Kenya; Kenya Medical Research Institute, Nairobi, Kenya; Nairobi City Commission, Nairobi, Kenya; University of Manitoba, Winnipeg, Manitoba, Canada.

Objective: To monitor the rate of change in HIV-1 in at-risk populations since the onset of the epidemic at the beginning of the decade. **Methods:** Data arising from all the studies related to sexually transmitted diseases (STD) and HIV conducted among men and women attending an STD clinic, pregnant women and a cohort of prostitute living in one geographically defined area of Nairobi. **Results:** HIV seropositivity (HIV+) rates increased from 0 to 24% in STD clinic patients, with the largest increase occurring in men with abnormal. Among prostitutes, the HIV+ increased from 1% to 80%. HIV+ in pregnant women increased from 0 to 3.7%. **Conclusion:** HIV infection rate is spreading most rapidly in the Nairobi populations with the highest sexual activity. A slow but steady increase in prevalence of HIV+ in pregnant women suggests substantial spread to the general population.

W.G.P.30

HIV ANTIBODY TESTING AT AN ALTERNATIVE HEALTH CARE SITE IN KENYA

Wanyaki, P., O'Gara, L. J., Smith, A. K., Smith, P., Wanyaki, P.,

University of Nairobi, Nairobi, Kenya; Kenya Medical Research Institute, Nairobi, Kenya; Nairobi City Commission, Nairobi, Kenya; University of Manitoba, Winnipeg, Manitoba, Canada.

Objective: To determine the prevalence of HIV-1 antibodies in patients with STDs attending one of the clinics in Adis Ababa, Ethiopia. **Methods:** The AIDS Control and Prevention Center in Nairobi, Kenya provided anonymous and confidential HIV antibody test for patients with STDs attending the clinic. **Results:** To the end of November 1988, a total of 7,793 individuals agreed to have their HIV antibody and appropriate counseling was given. **Conclusion:** HIV seropositivity testing and counseling was found to be seropositive.

Risk Group	Total	Positive	No. (%)
Sex partner	100	10	10
Male heterosexual partner	244	11	4.5
Non-Chinese	244	11	4.5
Metropolitan	244	11	4.5
IV drug abuser	212	0	0
Non-Chinese	212	0	0
Metropolitan	212	0	0

Conclusion: A total of 128 individuals requested HIV antibody testing because of various forms of contact with known HIV-infected individuals and only one homosexual partner of an HIV case was found to be seropositive.

Form of contact	Sex partner	No. tested	No. (%)
Sex partner	100	10	10
Male heterosexual partner	244	11	4.5
Non-Chinese	244	11	4.5
Metropolitan	244	11	4.5
Health care worker	84	0	0
Sexual/household contact	24	0	0

Follow up: HIV antibody tests were performed for 82 seropositive homosexual and 263 heterosexual after a median period of 8.7 months (0.9-31.8) and 1.1 months (0.3-32) respectively and only one homosexual showed HIV seropositivity after 8 months. **Conclusion:** The prevalence of HIV-1 infection in a sample of homosexual in Hong Kong is higher than that in non-Chinese. The prevalence in the heterosexual population is below 0.05%.

Session d'affichage Poster Session



W.G.P.7

THE IMPACT OF HIV INFECTION ON CHILD SURVIVAL IN AFRICA
Yalowitz, Linda A.***, Morris, J.R. & May, P.O.***
*U.S. Agency for International Development, Washington, DC,
USA, ** U.S. Bureau of the Census, Washington, DC, USA.

Objective. To estimate infant HIV infection prevalence and infant mortality rates associated with transmission of HIV, and to compare these figures with estimates of overall infant mortality and child survival rates.
Methods. HIV seroprevalence data from pregnant women living in 16 countries in East, Central, and West Africa are used to estimate HIV infection prevalence and HIV-attributable mortality rates in infants, assuming 25-60% vertical HIV transmission; and infant mortality of 20-25% among infected offspring. Estimates are compared with U.S. overall infant mortality rates.
Results. The results for East African capital cities are:

City	HIV Prevalence in Infants	HIV-Attributable Infant Mortality Rate	Overall Infant Mortality Rate
Nairobi	0.1-0.6	7.2	75.000
Litenge	2.4-3.7	5-14	150
Mogoto	0.3-0.6	2-2	141
San Jo Salvan	0.2-0.2	2-2	106
Kampala	6.0-16.3	15-38	103

The estimated infection prevalence in Africa is Central and West Africa ranges from 0.1-11%; the HIV-attributable infant mortality rates from <1-27%.
Conclusion. These estimates show that infection-transmitted infection having a low impact of overall infant mortality in some areas but a major impact in others. However, the later mortality of HIV-infected children who survive infancy may have a substantial impact on child survival rates.

W.G.P.9

CORRELATION OF HYPERGAMMOGLOBULINEMIA WITH ASYMPTOMATIC AND SYMPTOMATIC HIV INFECTION IN A COHORT OF AFRICAN INFANTS
Munyaho, G., Kiser, K., Nya, T., Mwalili, S., Njau, J., Baheta, C., Brown, F., Reid, S., Kinshasa, Zaire; Centers for Disease Control, Atlanta, Georgia, USA

Objectives. To examine the relationship between hypergammaglobulinemia and HIV infection in a large prospective cohort of African children.
Methods. 473 children born to HIV-infected women and 597 children born to uninfected and postpartum uninfected women have been followed prospectively since birth. Quantitative immunoglobulin (IgM, IgG, IgA) assays at 9 months age are being compared with serologic and clinical markers of HIV.
Results. Being perinatally HIV antibody (second 12 months) as laboratory evidence of HIV infection, and of clinical signs by the WHO criteria as suggestive of symptomatic infection, mean immunoglobulin levels are shown.

	IgG	IgM	IgA
Asymptomatic, persistently HIV ab+	28	1939	163
Asymptomatic, HIV ab-, mother HIV+	4	1372	112
Symptomatic, HIV ab+, mother HIV+	12	2132	236
Asymptomatic, HIV ab-, mother HIV+	157	1056	128
Asymptomatic, HIV ab-, mother HIV-	224	1030	102

Of children born to HIV-mothers (many still with other infections or malnourished), 17% had total IgG1500; of children born to HIV-mothers, 20% of uninfected children and 90% of infected children had total Ig1500.
Conclusion. High IgG were a sensitive marker of HIV infection even before symptom onset, and were uncommon in children ill with other infections.

W.G.P.11

UPDATE ON THE TRANSITION FROM HOMOSEXUAL TO HETEROSEXUAL AIDS IN TRINIDAD AND TOBAGO
Farley Cleburns*, K. Batio***, C. Diaz**, M. Francis**, B. Hall**, C. Bartholomew.

The University of the West Indies, Port of Spain, Trinidad
**The Caribbean Epidemiology Centre, Port of Spain, Trinidad
***Trinidad and Tobago (pop. 1.2 million) reported 289 cases of AIDS up to December 31, 1989 (185,000). The first case was recognized in 1983 and all 27 cases in 1983-84 were in homosexual/bisexual men. In 1985 there were 5 cases of heterosexual AIDS and 33 cases in homosexual/bisexuals. However, while there was only a 2 fold increase in homosexual/bisexual cases over the following three years, to 61 cases in 1988, there was a 12 fold increase to 66 cases among heterosexual AIDS cases and in 1989 there were more heterosexual than homosexual/bisexual cases of AIDS (66 vs 61). Notably, there has been a rapid increase of AIDS among women so that while in 1985 there were only 4 cases there was a 10 fold increase to 42 cases in 1989 during which interval there was only a 2 fold increase among men (36 vs 106). In 1989/90 all the cases of AIDS in women were infected by bisexual men. Intravenous drug abuse is not practiced in Trinidad and Tobago and transfuse associated AIDS accounted for only 7 cases (1.8%). On the other hand, 36% of the homosexual/bisexual cases were in bisexual men.
Trinidad, therefore, serves as a model of the potential for transition from homosexual/bisexual to heterosexual AIDS, initially through bisexual activity and without the added risk factor of IV drug abuse.

Implications Internationales International Issues

W.G.P.8

THE NATURAL HISTORY OF HIV INFECTION IN TWIN PAIRS BORN TO HIV-POSITIVE IN UGANDA
Merrill, Bruce P.***, Nya, M.***, Mwalili, S.***, Kinshasa, Zaire; University of New Orleans, USA; **CDC, AIDS Program

Objectives. To describe the clinical and serologic progression in pairs of twins. Nine "case" twin pairs born to HIV women and 10 "control" pairs born to HIV-negative women have been followed for the 18 month post-partum period. Blood drawn at 18 and 36 months was tested for HIV. All episodes of illness through age 18 months were recorded.
Results. Five case and 9 control pairs survived the first year of life.

Case pairs	HIV Serology	Clinical
Pair 1	11/18 Mo/No	11/18 Mo/No
Pair 2	11/18 Mo/No	11/18 Mo/No
Pair 3	11/18 Mo/No	11/18 Mo/No
Pair 4	11/18 Mo/No	11/18 Mo/No
Pair 5	11/18 Mo/No	11/18 Mo/No
Pair 6	11/18 Mo/No	11/18 Mo/No
Pair 7	11/18 Mo/No	11/18 Mo/No
Pair 8	11/18 Mo/No	11/18 Mo/No
Pair 9	11/18 Mo/No	11/18 Mo/No
Pair 10	11/18 Mo/No	11/18 Mo/No

Chorioamnionitis was diagnosed in the placenta from the dizygotic pair 1. In addition, twins were breastfed while twin 2 refused to breastfeed.
Conclusions. The discordant serologic and clinical pictures seen in these twin pairs suggest that environmental and genetic factors, environment and genetics, variations in HIV natural history can be documented.

W.G.P.10

INFECTION PAR HIV DANS LES 5 MATERNITES DE BAZAULE (R.D.CONGO):
FACTEURS DE RISQUE MATERNELS ET CARACTERISTIQUES DES NOUVEAUX-NEES
Munyaho, G., Kiser, K., Nya, T., Mwalili, S., Njau, J., Baheta, C., Brown, F., Reid, S., Kinshasa, Zaire; Centers for Disease Control, Atlanta, Georgia, USA

Objectives. To describe the relationship between hypergammaglobulinemia and HIV infection in a large prospective cohort of African children.
Methods. 473 children born to HIV-infected women and 597 children born to uninfected and postpartum uninfected women have been followed prospectively since birth. Quantitative immunoglobulin (IgM, IgG, IgA) assays at 9 months age are being compared with serologic and clinical markers of HIV.
Results. Being perinatally HIV antibody (second 12 months) as laboratory evidence of HIV infection, and of clinical signs by the WHO criteria as suggestive of symptomatic infection, mean immunoglobulin levels are shown.

	IgG	IgM	IgA
Asymptomatic, persistently HIV ab+	28	1939	163
Asymptomatic, HIV ab-, mother HIV+	4	1372	112
Symptomatic, HIV ab+, mother HIV+	12	2132	236
Asymptomatic, HIV ab-, mother HIV+	157	1056	128
Asymptomatic, HIV ab-, mother HIV-	224	1030	102

Of children born to HIV-mothers (many still with other infections or malnourished), 17% had total IgG1500; of children born to HIV-mothers, 20% of uninfected children and 90% of infected children had total Ig1500.
Conclusion. High IgG were a sensitive marker of HIV infection even before symptom onset, and were uncommon in children ill with other infections.

W.G.P.12

CLINICAL MANIFESTATIONS OF AIDS IN QUITO, ECUADOR
Singerberg, Roy*, Sempiternal, R.*** and Morera, M.***, Ministry of Public Health, Quito, Ecuador. **Catholic Univ., Guayaquil, Ecuador

Objective. To evaluate the clinical manifestations of AIDS in Quito, Ecuador, in order to plan appropriate management of further AIDS patients and add further information to the global picture of AIDS.

Methods. A review clinical data of all AIDS patients in Quito until June, 88, via chart review and personal contacts with patients and their physicians.
Results. As of June, 1988, only 10 patients had presented with clinical criteria for AIDS in Quito. (pop. approx. 1 million). (By Jan. 10, 1989 there were 20 AIDS cases in Quito, 40 in Guayaquil (pop. approx. 2 million) and a total of 41 in Ecuador (pop. approx. 10 million). The 10 AIDS patients were young (20-40 yrs. 98%), male (89%) Ecuadorian citizens (68%) infected via homosexual (42%) or heterosexual (20%) contact, IV drug abuse (20%), or blood transfusions (20%). They were infected in the US (90%) or Germany (10%). "SILM DISSEAS" (wasting caused by HIV) was present in 90%, with the wasting accompanied by chronic diarrhea in 78%, and by chronic fever and debility in 20%. Pulmonary disease was less frequent (42%), with no known cases of P. carinii pneumonia, but with one death due to untreated pneumonia. Other conditions included skin disease (60%), hepatobiliary disease (40%), Candida esophagitis (40%) and neurological manifestations (40%). Mean time from first symptoms to death in 7 patients was 8 months. All AIDS patients are alive 12 and 2 months after first symptoms of AIDS, with the 10th lost to follow-up.
Conclusions. "SILM DISSEAS" (wasting due to HIV) is an extreme condition rapidly fatal manifestation of AIDS in Quito, Ecuador. Other common diseases in AIDS are also present, but with very little P. carinii pneumonia.

Session d'affichage Poster Session



Implications Internationales International Issues

Aspects cliniques (Part 1) Clinical Features (Part 1)

W.G.P.1 HIV, HVL1-Delta-HEAT AND T_HCELL DEFICIENCY IN TWO RURAL AFRICAN AREAS: de Lalla Fausto, Rizzardi G., Pallini P.L., Ahmed L., Santos D. and Verga G. Sava Hospital, Genoa, Italy.

Objective: To compare the seroprevalence of HIV, HIV-Delta agent and T_H cell infections in the rural populations living in North Uganda (NU) and in Central Burundi (CB).
Methods: Sera collected in March-October 1988 (Uganda) (RIBA method) and in June-October 1987 (Burundi) were stored at -20°C until tested for HIV₁/HIV₂ (RIBA method) and anti-HIV antibodies (ELISA and IFA) and screened for ophtalmic using the T_H cell haemagglutination (T_HHA) test (80%). Samples showing reactivity against HIV p 24 and p 41 (or p 100) in NU were considered as anti-HIV positive. HIV₂ positive sera were also tested for anti-delta antibodies (RIA method).
Results: The 309 sera collected in NU were obtained from 289 outpatients (174 patients and 115 soldiers) and 20 patients (DO 18 and 19) clinically suspected of being AIDS cases). In CB, sera were drawn from 20 healthy individuals and 27 hospitalised (all with clinical diagnosis of AIDS) patients (204 males and 104 females) were adult (age range: 14-60). In Uganda people 63.5% of anti-HIV positive and 25.5% of anti-HIV negative patients were found to be T_HHA-positive respectively (p < 0.01) for IgG; the corresponding figures were 21.4% and 1.8% respectively (p < 0.001). As for full blown AIDS, T_HHA positivity was 62.5% and 25.5% in NU and CB respectively. No association was seen, on the contrary, found in both areas between either anti-HIV or T_HHA positivity and seropositivity for delta hepatitis serological markers (p > 0.01).
Conclusion: This study confirms the association between seropositivity for HIV and T_H cell (T_HHA), suggesting common patterns of transmission. It also shows no correlation between either anti-HIV or T_HHA positivity and markers for delta hepatitis in two rural African areas.

W.G.P.3 A TWO-YEARS EXPERIENCE IN HIV-POSITIVE PATIENTS IN HOSPITAL DE CLINICAS DE PORTO ALÉGRIE (BRASIL).
Spritz, Eduardo; Krawfick, M. Lucia, M.A. Hospital de Clinicas de Porto Alegre, Rio Grande do Sul, Brasil. Universidade Federal do Rio Grande do Sul, Brasil.

Objective: Describe HIV-positive patients in Hospital de Clinicas de Porto Alegre (HCPA) experience in HIV-positive patients according to risk groups.
Methods: It was reviewed 185 registers of HIV-positive patients who were at HCPA during January 1988 till December 1989.
Results: There were 173 men and 13 women. Among risk groups: 74 (40%) were homosexual men; 75 (40.5%), bisexuals men; 10 (5.4%), with compulsive disorders; 8 (4.3%), drug addicts; 8 (4.3%), had multiple transfusions; 6 (3.3%), bisexuals and drug addicts; 16 (7%), heterosexuals (14 women and 2 men), all with genital lesions.
Conclusion: As in other countries, the greatest group are the homosexual and bisexual men with 85% of the sample. As a whole group, those who received transfusion (blood disorders and multiple transfusions) have 10% of the sample. Drug addicts, as a risk group are not so numerous as in other countries. Although our sample is not so large, it appears that heterosexual contamination occurs only in individuals with genital lesions.

W.G.P.5 ABOUT MONITORING OF HIV-SPREAD IN A DEVELOPING COUNTRY

BORRACCHINI R. *, RICHTER C. **, BACHOF F. *
* Institut für Sozialmedizin der Freien Universität Berlin, Hirtzfelder 18, D-10005 Berlin 33
** Diakonissenanstalt, D-2800 Bremen, FEDERAL REPUBLIC OF GERMANY

Objective: To determine the actual AIDS-risks and introduce prevention efforts with the means of a primary health care system.

Methods: Since 1986, HIV-spread was monitored in an African district hospital. HIV-testing was done in patients with possibly HIV-related disease, such as syphilis (serum treponem), intravenous STDs, or spumant-positive TB. In the present population of disease helped to give early evidence of prevalence-estimates. In the general population, "risk-groups" were contacted, infection-risks were traced.

Results: A rise of antibodies and spumant-positive TB was stated in the area. No rise of "serum treponem" was found. In young adults with syphilis, a high coincidence with HIV-infection was found.

Conclusion: Syphilis e.g. - easy to diagnose even by health workers - could become an "indicator disease" for HIV-spread without HIV-testing. This requires a broader monitoring of such diseases in areas not yet AIDS-afflicted. With such a "basic monitoring", regional HIV-spread could be determined and prevention-efforts could be focused.

W.G.P.2 MARQUEURS DES RETROVIRUS (HIV ET HTLV-I) ET DU VIRUS DE L'HEPATITE B CHEZ LES LEPREUX AU CONGO.
A. Houe-Vicqour*, E. Sandoz-Gosselin*, G. Lelondré*, M. Verdier**, M. Mounier**, Francis Dohin**, *Institut supérieur des sciences de la santé, Brazzaville, Congo ; **Département de Virologie CHU Dujovyer, Limoges, France.

Objectif: Déterminer la prévalence des marqueurs HIV, HTLV-I et HBV chez les lépreux et dans des populations témoins au Congo. Comparer les marqueurs HBV en fonction du statut sérologique HIV dans les deux groupes.

Méthode: En 1988 un total de 809 patients à 318 lépreux et 482 témoins ont été soumis à un prélèvement de sérum dans 2 zones du Congo.
Méthodes: Dépistage HIV par ELISA (Abbott recombinant HIV-EIA), HTLV-I par immunofluorescence indirecte ; confirmation par Western Blot (BiaPac Lab Blast I et II, Diagnostica Pasteur pour HIV ; avec souche HUT 102 pour HTLV-I). Les marqueurs HBV : Ag HBs, anti-HBc, AgHBe, AgHBe, anti-delta par Abbott EIA. Résultats: Globalement, les prévalences sont respectivement pour les témoins et les lépreux de 3,2% et 3,8% pour HIV, de 1,9% et 1,7% pour HTLV-I et de 5,6% et 7,2% pour l'Ag HBs.

En fonction des zones géographiques, de très fortes variations sont observées allant pour HIV de 0,7% à 8,3% chez les témoins et de 1,9% à 10,2% chez les lépreux. Chez ces malades, la prévalence HTLV-I va de 0,2% à 23,8%. Les paramètres HBV sont analysés en fonction de la séropositivité HIV et HTLV-I. Conclusion: Il y a pas de différence statistique entre les prévalences HIV chez les lépreux et les témoins, ni entre les formes polaires de lépre à l'existe pas de différence de "profil" sérologiques HIV entre séropositifs et séro-négatifs. En revanche, les lépreux sont significativement plus infectés par le HTLV-I que les témoins.

W.G.P.4 A SERUM FOR UNRECOGNIZED HIV INFECTION IN A SPECIAL STD CLINIC IN KENYA.
Alphaj, Rashid*, Bahadani, K. **
*Department of Public Health, Ministry of Public Health, Kenait.
**Department of Microbiology, Faculty of Medicine, Kenait University, Kenait.

A three month survey for the presence of unrecognized HIV was conducted August through October 1989, on a total population of 3123 STD exposed patients and voluntary presymptomatic counsees who presented themselves for standard STD testing. Of this total, 104 were selected (30%) for HIV testing by methods of ELISA, and when required, Western Blot. The sample group was classified according to sex, marital status, occupation, age group, nationality (Kenya or non-Kenyan), and sexual history.

The sample group represented travelling to total of 27 different countries within the previous six months and were queried on their sexual history, including heterosexual/homosexual encounters and homosexual/sexual/sexual history. Clinical diagnosis was also recorded.

No HIV infection could be identified in the sample, which otherwise would appear to be a group at higher risk. One explanation may be that the group is not characterized by repeated sexual exposure and hence were HIV drug addicts or users.

W.G.P.6 AIDS ASSOCIATED ENDING INFECTIOUS DISEASES IN MADRID
GARRA, L. Morales R*, Falcón M, Bezo E*, Mora J., Veldesque J., Saldana P.,
**Direccion de Epidemiologia, Ministry of Health, Mexico

Objective: To define the characteristics, epidemiological distribution and clinical evolution of AIDS associated endemic infections.

Methods: Information was taken from registries notified to the General Directorate of Epidemiology between January 1981 and October 1989.

Results: Clinical information was available from 881 patients (87% men and 89% between 25 and 45 years of age). Data on reported diseases at time of initial AIDS diagnosis are: P. carinii pneumonia (PCP) 7% (n=60); other infections 79% (n=452); Kaposi's sarcoma (KS) 5% (n=28) and infections (215, 24%) were: tuberculosis (71,8%), pneumococci (n=81), cryptococcosis (10,1%), histoplasmosis (9,1%), blastomycosis (8,2%). Pathogens identified once were T. gondii; 1. 2nd, C. trachomatis, A. lumbricoides, P. malariae. Enteroptorogones represented 7% of all observed infections. Chronological, regional, transmission categories, and prognostic differences were distinguished. Endemic infections are associated with an increasing number of AIDS patients as the epidemic evolves in rural areas, to heterosexuals and to lower socioeconomic levels. Prophylaxis and treatment probabilities should be explored.

Session d'affichage Poster Session



Implications Internationales International Issues

T.G.P.19 SMALL PARTICLE PERMEABILITY OF USED VERSUS
UNUSED SURGICAL RUBBER GLOVES
Goldstein, Andrew; Stokes, K.; Yoshihara,
P.; Arya, S.C.,
Spitoco, Inc., Beaverton, Oregon, USA

Introduction. Surgical latex rubber gloves are repeatedly re-used in many third world countries after being washed and sterilized. A study was conducted to determine whether used and unused surgical rubber gloves are permeable to particles the size of HIV-1.

Methods. Surgical gloves were obtained from several medical facilities in New Delhi, India as well as the United States. Samples of the glove palm, back and fingers were used as barriers to 0.1 micron fluorescent, polystyrene beads. The rubber was subjected to a stretching protocol designed to mimic actual use conditions.

Results. The likelihood of transmission of particles through the latex rubber samples was dependent upon frequency of stretching, exposure time and condition of the rubber.

3 OF SAMPLES SHOWING PARTICLE TRANSMISSION

GLOVE SAMPLE	WITH STRETCHING	WITHOUT STRETCHING
Unused (India)	45	4
Used (India)	100	34
Unused (USA)	0	0

Discussion/Conclusions. Re-used surgical rubber gloves are more porous to virus sized particles compared with unused gloves. Anti-microbial contaminants in latex may affect the viability of virus particle transmission.

T.G.P.21 ADAPTING US/AFRICA EXPERIENTIAL EXERCISE INTO AIDS PREVENTION
COUNSELLING TRAINING IN DEVELOPING COUNTRIES
JO DOPPEL, A DEBATA*, & CHIRONGWA**

*HISCOM, Washington DC; **Lana Fee Research Project, Maposoa, Sierra Leone; ***AIDS Programme, Harare, Zimbabwe

Objective. To demonstrate that there are cultural sensitive and effective methods for adapting Western experiential exercises into AIDS prevention counselling training in developing countries.

Methods. This paper outlines some of the "Western stereotypes about people from developing countries and their relationship to others describe how such experiential exercises are role playing, leading and/or use death through guided visualization, and stimulating safer sex practices such as non-contraceptives with one another have been adapted into training in developing countries.

Results. Evaluation forms completed by AIDS prevention counselling trainees participating in developing country courses indicate that many of the adaptations have been highly effective. Improvements have been made as a result of the evaluation, though there is still much to be learned.

Conclusions. Many of the skills required for an effective AIDS prevention counselor can be enhanced through culturally sensitive adaptation of some of the experiential exercises developed in the West. Other skills, however, require development of culturally specific in-country methods.

T.G.P.23 AIDS AND ADOLESCENT: A PRELIMINARY STUDY OF YOUTHS'
PERCEPTION OF AIDS & DISEASE: NIGERIA EXPERIENCE
(SOLA YOUTH FORUMS, DR. DMS.),
UNIVERSITY OF IBB, IBB, NIGERIA

SUMMARY: Without doubt AIDS is a serious infection which has been associated with promiscuity and homosexuality. In Nigeria in spite of the mass campaign, the incidence of the disease is still reported to be on the increase. Hence, this study is designed to find out the perception of Nigerian urban youths of the disease, especially those related to health behaviour. In order to know what alternative strategies to employ with regard to prevention.

Objective: To identify the perception and attitude of Nigerian youths to AIDS disease.

Methods: A random sample of 100 Nigerian youths were selected from various parts of Ibb, representing 40 male and 60 female. Questions related to AIDS were asked by 2 interviewers.

Results: The result showed that inputs of the heavy campaign on AIDS, many Nigerian youths still did not regard AIDS as a serious disease. A large proportion considered it as a capitalist's ploy to down grade humanity and to ridicule the people of the 3rd world.

T.G.P.20 A STUDY ON HIV-1 INFECTION AMONG HEMOPHILIACS IN IRAN.
Bazari, Rezaei*, Nayfeh*, J., "Jabali",** and Kaydani, H.***
*Iranian Blood Transfusion Service, Tehran, Iran.
**Iranian Hemophilia Clinic, Tehran, Iran.
***Iranian Hemophilia Center, Tehran, Iran.

Objective. An HIV-1 seroprevalence study was conducted on 368 hemophiliacs found to be the only group exposed to HIV, among the high-risk groups studied in Iran so far.

Methods. HIV-1 antigen and antibodies were tested by ELISA (Recombinant HIV-1, Envirocon and HIV-Antigen, ITH, Abbott Diagnostic, U.S.A.

Immunoprecipitation Anti-HIV-1-antibody, Mahring Institute, W.Germany)

Results. 184(69/368) of the patients studied were found seropositive, i.e. 204(62/265) hemophilia A patients, 18(6/50) hemophilia B patients and only 24(3/23) of patients suffering from other bleeding disorders such as von Willebrand, platelet dysfunction and fibrinogenopathy. All the anti-HIV positive patients were positive for anti-PT4 and anti-CP4 and all but one with full-blown AIDS were negative for HIV antigen. The anti-HIV negative hemophiliacs were also tested for HIV antigens for possibility of recent infection, but none were found positive. The highest incidence of HIV infection was found in the sexually active group of 20-40 years.

However, no transmission was detected when all family members of 15 anti-HIV positive patients were examined.

Conclusion. Follow-up studies on hemophiliacs patients and screening of their families followed by provision of necessary information and counselling as well as control of imported clotting factor concentrates would be most important in the prevention and control of AIDS in Iran.

T.G.P.22 Prevention Counseling: Integrating Concepts and Techniques in
all AIDS Prevention Strategies
D. Stone*, N. Kalishba**, V. Orias***

*Jones Hopkins University/AIDSCOM, **The Support Organization (TASO) in Uganda, ***Department of Health/Division of Health Manpower Development and Training Service, Republic of the Philippines, U.S.A.

Objective: Since counseling is one of the only strategies to support behavior change in HIV prevention, it is imperative that health care providers, educators, and others are provided with training in counselling concepts and techniques. The authors describe various means of incorporating counselling training within cultural settings.

Methods: Using "Train-the-Trainer" Modules, health care providers, educators, and volunteers are being trained in basic prevention counselling concepts and techniques. Emphasis is placed on helping providers cope with client feelings raised by HIV infection (either real or imagined), as well as on helping providers focus on high risk behavior of their clients.

Results: Although counselling for behavior change is a new concept, techniques are being adapted in various cultures to provide support. By working with governments and non-governmental organizations within each country, people are being trained to provide their clients accurate information on HIV infection, to assess their own risk, and to cope with anxiety and fear.

Conclusion: Whether HIV prevalence is high or low, providing prevention counselling skills to educators, health care providers, or others is essential. Working within local and cultural parameters prevention counselling proves to be a successful method in helping people change high-risk behavior.

T.G.P.24 HIV/AIDS-RELATED TRAVEL AND MIGRATION RESTRICTIONS
DORIS M. MERRITT and Orlin A. Adler
McGill Centre for Medicine, Ethics and Law, Montreal, Quebec, Canada.

OBJECTIVE: To identify trends in national regulation and/or quarantine restricting travel and migration by those with HIV infection or AIDS.

METHOD: A comparative analysis of reports and data from multiple sources including national governments and non-governmental reports and a survey by questionnaire of all foreign representatives in Canada, and a review of applicable international law.

RESULTS: While some countries have adopted deliberate policies of non-restriction of visitors and temporary and permanent residents, over 20 others have policies that discriminate against travellers and migrants with HIV infection or AIDS through mandatory HIV screening, exclusion and/or deportation. Examples of extreme responses are the mass deportation of seropositive permanent resident workers, and exclusion of persons found during border searches to be carrying syringes/needles (AZT).

CONCLUSIONS: Mobility and travel are affirmed values in international law and practice, although states enjoy the unfettered right to admit and exclude foreign nationals. The World Health Organization has advised HIV/AIDS-related travel restrictions are "ineffective, impractical and wasteful". A disturbing trend is emerging, however, in which a significant number of countries have applied HIV/AIDS-related travel restrictions. The implications of such restrictions may impede global efforts to respond effectively to HIV/AIDS.

**Session d'arrachage
Poster Session**



**Implications Internationales
International Issues**

T.G.P.13 **Contraceptive Social Marketing Principles: Promoting Condom Use in Uganda and Tanzania for AIDS Prevention**
G. Stone*, D. Levy**, S. Saunders***
*Johns Hopkins University/AIDSCOM, **Academy for Educational Development/SOMDC, ***Academy for Educational Development/AIDSCOM, U.S.A.
Objective: To apply contraceptive social marketing techniques in promoting condom use for AIDS prevention.
Method: Social marketing techniques are being used in developing condom promotion programs for AIDS prevention in Uganda and Tanzania. They are used to enhance the perceived value and desirability of condoms through branding strategies, audience segmentation, and pricing strategies. Distribution and trade considerations are being addressed, and condoms are being distributed through "AIDS in the Workplace" projects in Uganda & Tanzania.
Results: Using GSM strategies for promotion of condoms for AIDS prevention and Tanzania appears to show an increase in condom acceptability and purchase.
Conclusion: AIDS prevention has stimulated the market for condoms in both Uganda and Tanzania. It appears that condom social marketing for protection from HIV infection may overcome substantial barriers usually found in condom use.

T.G.P.15 **EDUCATION AND LAW: THE CONTROL OF TRANSMISSIBLE DISEASES THROUGH THE CONTROL OF GOSSIP, IGNORANCE, AND DISCRIMINATION**
Traub, Kit, University of Georgia, Athens, Georgia, U.S.A.
Objective: To recall lessons from the history of the control of transmissible diseases and present effective, ethical, and scientific alternatives for the control of AIDS.
Methods: Review controls once applied to leprosy, plague, and syphilis, recognizes their recurrence in the AIDS disease, and present alternative ways of thinking about diseases, particularly AIDS.
Results: The current generation has an opportunity to confront AIDS, a fear-some "plague," without adopting dehumanizing rules as in the past with other transmissible diseases. Futile and ineffective gestures accumulate, producing great social damage without alleviating the causes or effects of AIDS. To keep our human perspective, we must first avoid referring to "AIDS Victims," speaking instead of "people with AIDS." Next, we must employ methods of disease control that are simultaneously effective, ethical, and scientific. Both the WHO and the Council of Europe have adopted enlightened, informed guidelines for avoiding discrimination in relation to HIV-infected people and people with AIDS. These efforts have been met by both support and resistance.
Conclusion: Ignorance, fear, and short-term political responses to the AIDS problem are counter-productive to the efforts to control the spread of AIDS. Alternative approaches are demonstrably more effective, while simultaneously preserving the human rights of infected persons and society generally.

T.G.P.17 **INTERNATIONAL AIDS PROGRAMS AT THE NATIONAL INSTITUTE OF HEALTH**
Bridgford, Kenneth*, Hamburg, M., Schambra, P., Whitescarver, J., Faulstich, A., National Institutes of Health, Bethesda, MD., U.S.A.
The presentation will include an overview of NIH International AIDS programs amounting to over \$18 million annually. Three programs will be emphasized. The first, the National Institute of Allergy and Infectious Diseases program of International Collaboration in AIDS Research, contributes to international health by strengthening scientific linkages between U.S. and foreign investigators in areas with major health problems due to HIV.
The second, the Fogarty International Center (FIC) program of International Postdoctoral Research Training Grants in AIDS, supports collaborative research and training involving American and foreign scientists in the epidemiology, diagnosis, prevention, and treatment of AIDS.
The third, FIC's International Training Grants in Epidemiology Related to AIDS, increases the capability of scientists in developing countries to conduct epidemiologic research related to AIDS and to carry out clinical trials and behavioral intervention prevention research. Establishment of an International Network for AIDS Research and Training will also be described.

T.G.P.14 **FOLLOW-UP OF GROUPS AT RISK FOR HIV INFECTION**
Lima, M.B., Jr., Lima, J.N., Abreu, M.B., Aoki, F.F., Goncalves, M. and Pedro, R.J.
UNICAMP, Campinas, Sao Paulo, Brazil.
An HIV counselling/testing service was created in June 1988 at UNICAMP with three main objectives: a) provide an alternative free HIV testing site coupled with pre and post test counselling; b) set up a longitudinal serologic surveillance to determine the rate of annual seroconversion rate among high risk groups; c) give the blood bank support on confirmatory testing of anti-HIV positive blood donors. Testing is done by an ELISA (recombinant DNA) assay; if positive, a second blood sample is tested by ELISA; if positive, a Western blot test is done for confirmation. If a high risk person tests negative, counselling is emphasized and a 6 month follow-up testing is planned. Up to now 167 persons have been tested; 122 positive by at least one ELISA assay.

RISK	NO. TESTED	NO. POSITIVE (%)
HIV & BISEXUAL MEN	49	6 (12%)
IV DRUG USERS	42	18 (43%)
SEX WITH HIGH RISK PERSON	17	1 (6%)
SEX WITH INFECTED PERSON	8	0 (0%)
NO HIV SEROPHILIC TRANSFUSIONS	8	0 (0%)
NONE OF THE ABOVE RISK GROUPS	44	6 (14%)

* no seropositives were seen at our service

T.G.P.16 **TRAINING HEALTH WORKERS IN ZAMBIA FOR HIV INFECTION**
A. Nyanhoro*, K. Kalumba*, M. Kelly**, A. Chingoma***, *University of Malawi, School of Medicine, Blantyre, Malawi
**Ministry of Health, Harare, Zimbabwe.
Health workers are increasingly having to inform patients that they are HIV infected or are suffering from an HIV-related illness, yet they rarely have experience or training in counselling; rather, their approach tends to be highly directive, allowing large gaps of only one-way communication. The use of a World Health Organization training manual is described, in a course consisting of one month intensive orientation and role-playing exercises, project work carried out after return-to-normal duties, over a period of four weeks, and a further intensive de-briefing and training session lasting three days. Although not all physicians and nurses are able to acquire the necessary skills in this kind of brief, concentrated training, a sufficiently large cadre has been created to form a series of nuclei in various institutions, for the further "snowballing" of the training programme in other areas of the country.

T.G.P.18 **DEVELOPMENT OF THE AIDS EPIDEMIC IN SOUTH AFRICA**
Simpson B, Martin SM, Dorn S, Spence S, Hays S*, Padoyevos DM*, Nelson SW**
*Medical Research Council AIDS Virus Research Unit, National Institute for Virology, Sewdoring, South Africa, **Johnannesburg City Health Department.
The seroprevalence of AIDS in South Africa represents an almost unique model of the interaction of type 1 (Western) and type 2 (African) patterns of AIDS and the dynamics of the epidemic are thus of considerable interest. Data on HIV seroprevalence obtained from a number of sentinel populations and AIDS cases reported voluntarily to the Advisory Group on AIDS have been used to construct a composite of the epidemiology of AIDS in South Africa. Analysis AIDS data to the end of 1988 still reveals a predominantly type 1 pattern with 73% of 166 reported South African cases occurring among white male homosexuals, compared to 14% heterosexuals and 2% paediatric cases. Seroprevalence data however, indicates a significant and rapidly developing epidemic of HIV infection in the black African heterosexual population, which may soon overtake the type 1 pattern contrasting the AIDS profile presently. Thus, while no South African black STD clinic attenders were HIV positive in 1986/87 (Trans Roy Soc Trop Med Hyg 1987; 81: 874-875), at the end of 1988, 1.3% of 1174 black female STD attenders 0.3% of 1395 family planning attenders and 0.1% of 1726 new blood donors (first half of 1988), were confirmed HIV seropositive. In the white population type 1 is still the predominant epidemiological pattern, with low seroprevalence in the general heterosexual population (2 of 738 male heterosexual STD clinic attenders being seropositive while no female STD attenders family planning clinic attenders were positive and also only 0.03% and 0.007% of male and female new white blood donors respectively).

Session d'affichage Poster Session



Implications Internationales International Issues

T.G.P.7

DETAILED ESTIMATES OF THE CURRENT AND FUTURE EXTENT OF THE HIV/AIDS PANDEMIC IN SUB-SAHARAN AFRICA

SAHAR, P., J. Chin, J. J., Leung, S. M., Basseloni, L. G. 3rd

* World Health Organisation, Geneva, Switzerland
* WHO Regional Office for Africa, Brazzaville, Congo

Objective: To provide country-specific estimates and projections of HIV/AIDS in sub-Saharan countries for public health planning.

Methods: An AIDS projection model based on estimates of HIV seroprevalence and the annual progression rate from infection to AIDS was used.

Results: From the country-specific estimates, we estimate overall in 1987 that there were about 70,000 new AIDS cases in sub-Saharan Africa for a cumulative total since 1980 of about 100,000 cases in adults, and close to 40,000 in children. Approximately 2.1 million individuals are estimated cumulatively to have been infected with HIV in sub-Saharan Africa since 1980. By 1992, we estimate that there will have been a cumulative total of 600,000 AIDS cases in adults and 200,000 cases in children. In 1992 alone, we estimate that there will be about 250,000 new AIDS cases. This is more than the cumulative total number of AIDS cases in sub-Saharan countries to 1987.

Conclusion: Over the next 4-5 years, we estimate that there will be at least a 10-fold increase in AIDS burden in each of the countries in sub-Saharan Africa.

T.G.P.9

PLANNING A NATIONAL STRATEGY ON AIDS AND INJECTION DRUG USE: LESSONS FROM THE LITERATURE

McLellan, Betty; Kinsler, K. Federal Centre for AIDS, Health Protection Branch, Ottawa, Ontario, Canada.

Objective: To demonstrate how the literature can contribute to the development of a national strategy on AIDS and injection drug use.

Methods: The presentation will be based on an assessment of the literature (bibliographies will be made available) and specific illustrations from the Canadian experience.

Results: As of January 1989 in Canada, only 8% of a total of 2,337 identified AIDS cases were attributed solely to injection drug use. The prevalence of HIV infection among Canadian injection drug users is not yet known but early studies suggest that currently it is relatively low. The literature offers many lessons for a country that might be tempted to think it will escape the "second wave" epidemic. Needle-sharing emerges as a widespread cross-cultural phenomenon. Data describing rapidly increasing seroprevalence among injection drug users in Edinburgh, New York and Honolulu signal an urgent need to acquire baseline data and to recognize that any window of opportunity will soon close. Published material testifies to the complexity of the problem and the need for collaborative, multidisciplinary prevention programs. Risk reduction strategies can form the basis of a partnership between public health and addiction services. The effectiveness of interventions remains unproven, demonstrating the importance of conducting pilot studies with strong program evaluation protocols.

Conclusion: Canada is developing a national strategy to reduce HIV infection among injection drug users emphasizing collaboration, research and innovative program evaluation.

T.G.P.11

ELABORATION D'UNE STRATEGIE DE PREVENTION DU SIDA ADAPTEE AU MILIEU DE LA PROSTITUTION ORGANISEE A COTONOU, BENIN.

Verheide, Ronald* et Monseiro, Bruno **

*Université de Montréal, Belgique; **Université de Cotonou, Bénin.

Objectif: Elaborer un message et des modalités de prévention du SIDA adaptés aux caractéristiques socio-culturelles des prostituées de Cotonou, Bénin.

Méthode: Nous avons procédé à Cotonou à une enquête comprenant entre autres des entretiens individuels avec 61 prostituées. Le repérage de tous les immeubles où vivent et travaillent, au moins 4 prostituées, et des entretiens avec 5 vendeurs de condoms.

Résultats: La prostitution organisée, à Cotonou, est le fait de 600 à 800 femmes qui habitent et travaillent à plusieurs dans un même immeuble. Une stratégie de prévention adaptée à ce milieu doit tenir compte notamment des aspects suivants: (1) méconnaissance des risques réels d'infection, croyance en l'efficacité préventive de médicaments et des toilettes intimes, et ignorance de ce qu'est un préservatif et de la manière de l'utiliser; (2) une forte défiance lors du premier contact se transforme en grande réceptivité à l'entrevue à été menée avec tact et chaleur; et de préférence par une femme; (3) 2% des prostituées ont des clients; (4) la sollicité qui est sollicitée les prostituées habitent et travaillent sous un même toit peut être utilement exploitée; (5) la collaboration des vendeurs et d'ex-prostituées a été aisée et souhaitable; et (6) les préservatifs, dont le coût est prohibitif, doivent être accessibles aisément et à faible prix.

T.G.P.8

CONTROL OF TRANSFUSION RELATED TRANSMISSION OF HIV INJECTION STRATEGIES OF THE EC'S AIDS PRO

GRANDE FOR DEVELOPING COUNTRIES
VAN DER, C. J., MD, RBC; AMAT, T. MD; FRANGEN, L. MD, PhD
European Economic Community - AIDS Control Programme/Developing Countries, Belgium

Various strategies to reduce the incidence of transfusion related HIV transmission have been developed. These vary from exclusion of high risk behaviour donors and a reduction of the number of transfusions to screening of donated blood for anti-HIV antibodies. A number of these are being implemented with support from the AIDS Task Force of the EC in various countries in Africa, Latin America and the Caribbean. A choice for a particular strategy or combination of strategies must be made on the basis of an estimate of the costs and expected benefits of such an intervention. This is a function of the prevalence of HIV infection among the population, the existing infrastructure and capability of the health care system, including blood-transfusion services, and the cost of these interventions. Although screening of donated blood is a technical possibility, presently the cost of universal screening is prohibitive in many developing countries. The development of new tests however will influence strategy options. A preliminary analysis of various interventions in different countries is presented.

T.G.P.10

MEDIUM TERM PLAN FOR THE CONTROL OF AIDS IN CAMEROON-AFRICA: OCTOBER 1988-SEPTEMBER 1993.

Edje, Felix, L. Kapono**

*Chief of AIDS Control Service, **President of the National AIDS Committee, Ministry of Health, Yaounde, Cameroon.

Cameroon has a population of 10 millions and is located in Central Africa. It has borders with Togo, Central African Republic, Congo, Gabon and Equatorial Guinea.

Data from surveys of the general population of provincial towns in the age group 15-64 show HIV 1 seropositivity rates between 0.3 and 0.8 (less 0.1 in prostitutes up to 7% have been found positive). A total of 72 AIDS patients have been notified, including 5 pediatric cases.

The government has recognized that the AIDS epidemic poses a serious threat to the economic and social development of the country and has decided to give priority to combatting AIDS. A National Programme on AIDS has been approved, based on the global strategies as developed by WHO, with the participation of UNICEF, PHEC, EC, France, West-Germany and Canada.

A range of activities for the prevention and control of AIDS, integrated in the health care services of Cameroon, have already been initiated. The National Programme on AIDS has seven major components: (1) mass public information and education (1) blood screening establishment and rehabilitation of blood transfusion services (2) protection of the public health workers and children (4) establishment of an effective national surveillance system (5) drugs for treatment of STD and AIDS cases (6) operational research (7) training and orientation of health workers.

T.G.P.12

THE IMPORTANCE OF QUALITATIVE RESEARCH IN DEVELOPING OPERATIONS RESEARCH PROTOCOLS/STRATEGIES FOR GAY AND BI-SEXUAL MEN IN THE DOMINICAN REPUBLIC

Barra, Michael*, Paraja, Reynaldo**,

*Porter/Novell/ADCON, **ADCON, Dominican Republic

Objective: To determine to what extent research protocols and strategies must diversify to reach significant subgroups of gay and bisexual men in order to impact on sexual behavior.

Methods: Focus groups, individual in-depth interviews and USAID structured surveys at meeting places (bars, discos, bordellos, coffee shops) were conducted. Options with regard to language, sexual practices, social circumstances and others were explored.

Results: Initial findings indicate that there does not exist a homogeneous group of individuals or groups responsible for conducting RAQ surveys or other necessary research among these populations will need to carefully assess and understand the presence of heterosexuality is not necessary homogeneous.

Session d'affichage Poster Session



Implications Internationales International Issues

Th.G.P.7

LIASON ENTRE LA DENSITE OPTIQUE EN ELISA ET LE RESULTAT DU WESTERN BLOT CHEZ LES DONNEURS DE SANG DE BRAZAVILLE (Congo)
M. NGA, H. NGANGA, P. N'PAPA, A. ITOU-NGAPOVO, N. COPIER, F. Yala, M. GAZILLIAT - CHU de Brazzaville, Hôpital Salyvérien, Paris, France, *CHU de Brazzaville, Congo.

Il existe au Congo un taux d'environ 40% de sérums positifs en ELISA et douze au western blot (WB) car contenant des anticorps anti-cœur, le plus souvent positif après une séro-gé.
Nous avons tenté de trouver une liaison entre la densité optique en ELISA et le résultat en WB.
Le réactif utilisé est ELAVIA Pasteur dans lequel le seul positif est de 0,300. Cette étude a été faite sur 130 sérums et a donné les résultats suivants :

	0,300 (C1)	0,100 (C2)
Western blot négatif	76	4
Western blot p24 positif	55	9
Western blot positif	3	81

Cette distribution diffère de façon très hautement significative de celle qui aurait été obtenue par un test (Chi carré = 162, p < 0,001).
Si nous considérons les sérums p24 positifs, l'odeur négative est de 163 (de 76 à 361). On peut donc définir la positivité en ELAVIA par un OD supérieure à 1, afin d'"écarter" les réactifs de western blot.

Th.G.P.9

MODIFIED WESTERN BLOT ASSAYS FOR HIV INFECTION
R. L. HARRIS and S. J. SHELTON, Department of Immunopathology, Postgraduate Institute of Medical Education and Research, Chandigarh 160 012 INDIA

Six thousand sera were screened for HIV infection as a sero-surveillance exercise at the P.C.T.M.E.R., Chandigarh, one of the national surveillance centers. The overall positivity rate was 3% by ELISA. Western blot assay is the acid test for confirming a diagnosis of HIV infection but the cost of WB kit is prohibitive. It was thus imperative to evolve a sero-economical system in developing countries. In the present study various reaction systems were tried: a) Protein A labelled to peroxidase, b) a three step procedure using anti-human rabbit and anti-rabbit labelled to peroxidase, c) an equivalent of a PAP system in tissues. It was found that results obtained with these reagents were comparable to those of avidin/biotin reagents supplied along with the kit. The strips stored at 4°C for 12-18 months gave satisfactory results. The background was minimum with protein A.
Thus with indigenously raised antisera and protein A conjugated peroxidase effective time and cost of WB can be reduced substantially. The system can be applied to cases with strong clinical suspicion. The Dupont kit may be reserved for borderline cases.

Th.G.P.11

BLINDED BY SCIENCE: DRUG AND THE CONFLICT BETWEEN "CLEAN DATA" AND HUMAN HEALTH CARE
Harrington, Mark; Wiley, K.; Eiso, J. AIDS Coalition to Unleash Power, New York NY, USA.

Objective: To use the trajectory of DRUG (Ganciclovir) through the regulatory maze to exemplify problems impeding drug approval and up-to-date health care. Methods: We contacted Syntex Corp., negotiated with FDA and NIAID, read the protocols for the controlled "delayed treatment" treatment IND and compassionate use protocols, and talked with ophthalmologists, community physicians and parents with DRUG infection. Discussion: DRUG is effective in over 80% of those treated for CMV infection, and is approved in 4 European countries. Because the data were derived from a compassionate, uncontrolled trial, FDA rejected Syntex' 1987 NDA application, instituting instead 3 interlocking trials, under which 40 persons would be untreated until progression of retinitis. Here, demands for data derived from "adequate and well-controlled trials" superseded concern for the 20% of PMA's endorped by CMV. Conclusion: Provision must be made for accepting evidence of efficacy when thousands have responded well to a therapy and when there is no approved alternative. "Clean data" modalities must be modified during the AIDS pandemic to speed effective drugs to those at risk.

Th.G.P.8

RAPID METHOD FOR DETECTION OF HIV1 AND HIV2 INFECTIONS
EVALUATION OF SENSITIVITY AND SPECIFICITY

C. CHU*, Daniel Zaldívar, E. Perez-Tellería*
* Hospital Niza de Aragon, San Sebastian, SPAIN

Objective: Evaluation of sensitivity and specificity of a rapid test (HIV CLONATEC) in the diagnosis of HIV1 and HIV2 infections by comparison with ELISA methods and western blots.

Methods: This rapid HIV test (CLONATEC/TECH) is an immunofluorescence device which involves synthetic peptides (SYNTRKO) as antigens to detect anti-HIV1 and anti-HIV2 antibodies.

Results: 484 sera from intravenous drug addicts were tested in the rapid test. 272 samples are positive for anti-HIV1 antibodies in ELISA (Vironostika anti-HIV ELI - ORGANON / ELAVIA Ac-Ab-AE 1 - PASTEUR) and 212 samples are negative (ORGANON). 271 are positive in the rapid test with the HIV1 peptide (sensitivity of 99,6 % for the HIV1) positive. 493 sera from the same source were tested for the presence of anti-HIV2 antibodies: 314 are negative, 19 are unreactive and 76 are positive in the ELAVIA Ac-Ab-AE 1 (PASTEUR) for HIV2. All these sera were tested by anti-HIV1, specific and anti-positive sera in the HIV2 ELISA are positive for anti-HIV1 antibodies in the two HIV1 ELISA. 34 sera among the 76 positive were tested by western blot (Diagnostics TM Immunoblot Assay (DBI) and Lab kit (PASTEUR) for HIV2). All these sera were tested by anti-HIV1, specific and no reaction was observed against reagent (pp 150) present in the HIV2 blot. All three sera are positive in the rapid test with the HIV2 peptide. These results show the great specificity of the HIV2 peptide in the rapid test.

Conclusion: 484 sera from a high risk population were compared in two ELISA tests, in the Target test and confirmed by western blot. The sensitivity of the rapid test is 99,6 % and specificity is 100 %.

Th.G.P.10

FDA REFORM: AN ACTIVIST PERSPECTIVE ON THE NEED FOR LEGAL AND REGULATORY CHANGE.

Harrington, Mark; Eiso, J.; McCarthy, M.; Long, J.; Kirshenbaum, D.E. AIDS Coalition to Unleash Power, New York NY, USA.

Objective: To propose methods of removing regulatory and legal obstacles to faster drug trials and wider access to experimental treatments. Methods: Analysis of protocols, budgets, subject demographics, oversight hearings and discussions with officials. Discussion: Drug approval in the USA takes 8-10 years, longer than many PMA's can expect to live. Current drug approval standards lag behind advances in biotechnology, statistics modeling, toxicology, immunology and virology, and patient advocacy. FDA oversight: Inadequate until the FDA stage, is often arbitrary and restrictive. Companies conduct poorly designed trials wasting of time and lives. Few people cannot participate in clinical trials due to lack of third party reimbursement. Conclusion: FDA must redefine toxicity standards and efficacy endpoints flexible enough to allow for growing knowledge of HIV disease. FDA staff must be expanded to cope with new responsibilities. Members of the AIDS community and ethicists must participate in IIR's and FDA advisory review committees. Health care, and not simply "pure data" must become an acknowledged part of the trials system.

Th.G.P.12

NEIGHAND: WHO AIDS Research and Reference Reagent Program, Stacy, Stuart*, Moul, L. and Milman, G. ERCT* and Pathogenesis Branch, AIDS Program, NIAID, NIH, Bethesda, Maryland, USA.

The National Institutes of Health AIDS Research and Reference Reagent Program (Reagent) in Bethesda, Maryland is one of three collaborating centers established by the World Health Organization Global Programme on AIDS to facilitate the exchange of reagents needed for biochemical research on AIDS related retroviruses. The repository distributes samples of reagents, virus isolates, and antibodies to qualified investigators worldwide, whose research relates to AIDS. Currently available materials include:

- * Antibodies: Polyclonal and Monoclonal
- * Cloned Proteins
- * Expression Systems/Cloned cDNA
- * Isolated and Unisolated Cells
- * Virus Isolates
- * Biologicals, Chemicals and Drugs

The repository relies heavily on requests from individual laboratories. Scientists who wish to contribute to the program should contact the Principal Investigator regarding suitability and other requirements of substances. Contributions will be cited in the reagent catalog as the source and acknowledged in publications by the recipient. Contributions may also receive reports on the requests for their reagents. The repository encourages collaborative relationships between reagent users and laboratory techniques. Future plans include the distribution of standardized protocols. For further information contact Dr. Stacy by telephone at 301-964-0245 or FAX 301-762-4170.



**Session d'affichage
Poster Session**

**Implications Internationales
International Issues**

Th.G.P.13 PHASE-I STUDY OF RECOMBINANT PEPTIDE CORRESPONDING TO THE GP17 TRANSMEMBRANE PROTEIN OF THE HIV-1 VIRUS COUPLED TO PFCCL.

Detlev Harberg; Schwander, B.; Hansen, D.M.; Lewin, B.M.; Schneider, J.M. **Helmholtz-Institut für Experimentelle Medizin, Clin. Dept., Hamburg, Germany**; **Wolfgang Knebel**, Cambridge, Mass., USA.

Objective: Animal experiments demonstrated that both polypeptides coupled to PFCCL can produce a T-independent immune response in route mice. The T-independent response engendered only antibodies. Antibodies directed at appropriate HIV epitopes could possibly block an ongoing infection of newly born T-cells with the virus as well as inhibit the formation of synchia between infected and healthy cells.

Methods: F-46 as a recombinant peptide equivalent to conserved regions of the gp17 of HIV-1 coupled to PFCCL in order to evaluate the toxicity and tolerance of this recombinant peptide. A phase-I study was performed in 18 patients with AIDS with different numbers of T-cells. Peptide was injected intramuscularly with either 0.1 mg of 0.3 mg. Four patients were boosted later on twice with a time interval of 4 weeks, one patient could be boosted only once. The patients were monitored carefully by laboratory and clinical examinations and antibodies were measured at days 0, 7, 14, 21, and 28. Patients 3, 4, and 12 after injection.

Results: All patients tolerated the injections well without any significant side effects. The serological as well as clinical examinations did not show any signs of toxicity. There was a significant increase in antibodies against the peptide after the first injection with significant fall during the first four weeks. Details of the antibody response of all patients including the boosted patients will be presented after the conference.

Th.G.P.14 AFRICAN HIV EDUCATION MOBILIZED THROUGH A PUBLIC-PRIVATE WORKSHOP

Wilson Lillard; Elder, H.M.; Hart, R. **Oregon Health Division, Portland, OR, USA**; **Merry Pettis** Memorial Veterans Hospital, Los Linda, CA, USA; **Loma Linda University, Loma Linda, CA, USA**

OBJECTIVE: To help health care professionals in Africa develop locally based HIV education programs (LBEPS).

Methods: A church with its US university and local mission hospital sponsored 2 workshops in Malawi in cooperation with the Government of Malawi, the Private Health Association of Malawi, and MKD. Presentations described goals necessary to control HIV spread. Working in small heterogeneous, interdisciplinary, groups, 200 participants from 15 African countries identified problems and developed solutions. These were combined into a document to be used in LBEPS.

Results: The broad sponsorship provided wide acceptability of the workshop to many different groups including various mission organizations and health workers. The diversity of participants resulted in stronger, more realistic plans for patient counseling, home care, public health measures, and HIV education. Evaluation showed participants considered this workshop "Africa" because the proceedings and conclusions were by and for Africans. Not expected to make changes in their practices based on the workshop. **Conclusion:** The model of private-public cooperative effort utilizing national health workers to describe and resolve problems can facilitate LBEPS and may be broadly applicable.

Th.G.P.15 THE ROLE OF FEMALE PROSTITUTION IN THE HETEROSEXUAL AIDS EPIDEMIC IN SOUTH AFRICA

Schabir Buzzi, PhD; Martin PJ, Smith AN; Lyons SF; **Friedrichsen DM**; Naidoo S. **Medical Research Council Research Unit, National Institute for Virology, Sandringham, South Africa**; **Johannesburg City Health Department, South Africa**

Many studies in Central and East Africa have confirmed the pivotal role of female prostitutes in the establishment, maintenance and expansion of pattern 2 (African) AIDS. In South Africa, until the latter part of 1987, no cases of AIDS were reported in the black population, while in the white population three cases observed in 1982 had risen to 48 (predominantly male homosexuals) at the end of 1987. Since the end of 1987 the number of cases in black South Africans (all heterosexuals of both sexes) has risen sharply to 24 by mid-January 1989 and the role of prostitution women in the development of this epidemic is confirmed by seroprevalence studies carried out in a number of sentinel colonies - e.g. among STD attenders, 1,788 of females were positive as at December 1988 in contrast to nil of the same population at the end of 1986/87 (Trans Roy Soc Trop Med Hyg 1987, 81: 874-875); male STD attenders had a somewhat lower prevalence of 0.4%. The female:male dominance was also seen in other cohorts and even in black blood donor populations - 0.15 versus 0.048 respectively. The reproductive rate (Ro) of the heterosexual epidemic is, to a major extent, influenced by the characteristics of this core of prostitution females and control measures need to be focussed on abating this core. Identification of prostitute populations in developing societies is far more difficult than in developed countries and licensing measures for control are virtually impossible because of the poor definition and transience of this population.

**Epidémiologie
Epidemiology**

Th.G.P.16 ATTITUDES EXPLAINING DESERTION AND FAILURE OF CONDOMS IN GAY MEN

RAFAEL ANTONIO, BARBARA P. VALDESPINO A., SEPULVEDA S. **Division of Epidemiology, University of Health, Mexico**

OBJECTIVE: To describe the attitudes that may explain dropping condom use or refusing to use condoms.

Methods: In September 1988, a survey to determine knowledge, attitudes, and practices related to AIDS and condom use was carried out in gay men in the second largest city in Mexico. Data about attitudes were collected through agreement or disagreement of several statements about condom use. The comparison groups were the never users (non users), user but not correct users (misusers), and correct users of condoms (users).

RESULTS: Main results are shown in the next table.

STATEMENTS	NEVER USERS (%)	MISUSERS (%)	USERS (%)
Problems at sex are the main cause of condom.	30%	40%	<50%
Condoms take away the sensation.	30%	40%	<50%
You never will reject you if you use a condom.	30%	40%	<50%
Condoms are appropriate for gay men.	60%	74%	<80%
Condoms must be part of sexual routine.	60%	74%	<80%
Condoms frequently break or don't fit.	60%	74%	<80%
Condom use is not effective to prevent AIDS.	60%	74%	<80%
Condom use makes your partner feel you are AIDS.	60%	74%	<80%
If you suggest to use a condom partner feel depression.	70%	82%	<85%
There is AIDS in Mexico.	70%	82%	<85%

Conclusions: The reasons for desertion may be explained as follows: "breakers" are not convinced of the preventive effectiveness of condoms use, or that partners may think that if they propose the use of a condom it means they might have AIDS, either a condom breaks when they are used, or the other hand, the "non users" are more likely to use the risk than using always a condom, that he has taken away the sensation of the moment and that partners reject them when a condom is proposed. Continuity in condom use starts when the user feels that condoms are part of sexual life.

Th.G.P.17 HIV INFECTION IN PREGNANT WOMEN AND THEIR INFANTS IN ARGENTINA

Carla Amador; Orrego JM, Pignodovilla A, Rickard, H. **Hospital Fernández, Academia Nacional de Medicina, Hospital Militar, Buenos Aires, Argentina**

Objective: To present the first communication on HIV perinatal transmission in Argentina.

Methods: A total of 19 HIV-reactive mothers (HIV-Mo) was studied through HIA, HIV-1 and Immunofluorescence in 1988. Their children (Chi) were studied also thru EMWACRI and HIV-1 Antigen Abbott(Ac). Birth characteristics, Apgar index and weight were assessed, and clinical and serological follow-up of Chi was made thru periods of 5 to 18 months (m). Also, 2 Chi from heterophilic father and HIV-Mo, which births took place at another center, were studied.

Results: In 1988, 19 pregnant HIV-Mo were attended. HIV-Mo risk factors were: TWK17 HIV-VDR partner, 2; Age (3) 21 years old. Obstetric outcome: abortion; 1 premature birth and dead fetus(1); vaginal birth; 15; cesarean section; 4(21.5%). Birth weight (2,282 g, general population: 3,300 gr). Gestational age (32) 39 weeks. Apgar index (1) 8 (m); 5 (m); (mean): 1-2.9; 5-10 (0). Chi dropped out of 18 (Chi); HIV-1 Ac at birth; AG: 17(-) and 1(0); this one had a HIV outcome. Five (Chi) were HIV-DM; and 1, HIV-DM; Ten Chi were followed up from 5 to 18 m. The HIV-1 Ac showed seroconversion at 18 (m) (CRS-AG), and clinical signs at present. Three cases turned negative at 8, 9 and 16 m, respectively. HIV-1 Ac was positive at 2 out of 7 Chi with clinical signs, and 6 were DM-DM; and 3, DM-DM.

Conclusion: HIV perinatal transmission is a problem, even in countries with few AIDS cases. HIV infection did not alter the obstetric or neonatological features of this population. EMWACRI and AG did not help identify infected Chi.

Th.G.P.18 AIDS SURVEILLANCE AND PREVENTION IN UGANDA

Dr. Samuel Ouma; Berkley S. P., Fr. **Naamur W.***** **Sutherland D.*****

An review is made of the current status of the AIDS epidemic in Uganda following the establishment of a national AIDS Control Programme in 1987. A single surveillance reporting system was established to follow progression of the disease. By Dec. 1988, 17,000 cases had been reported. In 1988, 478 were reported, 536 females. The doubling time of cases was 3.5 months. The age distribution shows over 50% are between 40 yrs, about 10% < 20 yrs, only 11% cases have been reported between 5 - 14 yrs. The mean age for males was older than females (56.6 versus 24.4 yrs vs.).

A national survey yielded a similar pattern, but with a younger mean age. Sentinel surveys to monitor risk factors for seroconversion and future disease trends and progression.

The review shows heterosexual transmission is responsible for over 80% of cases, vertical, maternal, transmission about 10% and blood transfusion about 10%. Risk factors in transmission are discussed and increased. The role of sexual partners and sexually transmitted diseases are important amplifiers of transmission. The relative risk (odds ratio) increases proportionately to increased number of past sexual partners. The social cultural complications in disseminating health education are also reviewed.

Director Uganda National AIDS Control Programme.

**Session d'affichage
Poster Session****Implications Internationales
International Issues**

Th. G.P.31

Th. G.P.32



Publications

Implications Internationales
International IssuesDivers
Miscellaneous

G.501 CURRENT STATUS OF HIV INFECTION IN TAIWAN

Cheng-Hsin Chuang, Department of Health, Taiwan, ROC

Objective. To control the transmission of AIDS, this study has been conducted to investigate the status of human immunodeficiency virus (HIV) infection in Taiwan.

Methods. A total of 706,246 serum samples from 9 risk groups of acquired immunodeficiency syndrome (AIDS) were tested for HIV antibody, using mainly enzyme-linked immunosorbent assay (ELISA) and Western blot. Results: Among 1,188 homosexuals, 23 were positive (2.79%); 6 full-blown AIDS patients; 2 AIDS-related complex (ARC); 2 HIV seronegativity; 4 persistent generalized lymphadenopathy (PGL); 19 asymptomatic carriers. Among 526 hemophiliacs, 40 were positive (7.6%), of whom two developed full-blown AIDS. One asymptomatic homosexual HIV carrier donated four bags of blood which resulted in a seropositive patient. In general, antibody titers were higher in asymptomatic HIV-carriers. PGL and ARC than those detected in patients with full-blown AIDS. Conclusion. The conclusion is that AIDS has invaded Taiwan, but the prevalence of the HIV infection is presently low. In the interim, active community efforts are needed to achieve future success in AIDS control.

G.503

Dr. G.S. Geshki CDC EDG1¹
Dr. F.H. Maske MDH National AIDS Co-ordinator²
Dr. G.G. Mbugua CHR EDG1¹
Mr. H. Muthami NAC EDG1¹

1. Kenya Medical Research Institute, P. O. Box 54840, NAIROBI - Kenya
2. Ministry of Health, P. O. Box 30018, NAIROBI - Kenya

Since 1984 when the first case of AIDS was reported in Kenya more than 3000 cases of AIDS have been diagnosed in this country. The MIF rate is about 1% and the age distribution shows a bimodal characteristic with a small peak between ages 0 and 5 and a large peak between ages 15 and 30. The prominent clinical presentation is weight loss, prolonged diarrhoea, chest infections, candidiasis and kaposi's sarcoma. Recent surveys in selected large towns of Kenya have demonstrated high seroprevalence rates ranging from 12% to 24% among sexually promiscuous women. Samples taken from sexually active and promiscuous males in some of the towns have shown prevalence of about a third of the rates in corresponding females. Possible reasons for this distribution and implications for intervention measures will be discussed.

G.505

AIDS IN THE CONTEXT OF PRIMARY HEALTH STRATEGY.
BETS, C. (Lagos)*, Carrington, Carmen**
*Nigeria Against STD's (U.L.A.C.E.T.S.) U.S.A.

Objective. Demonstrate impact of the AIDS epidemic on primary health and community organization and participation.

Methods. Trends of the AIDS epidemic are compared with governmental and nongovernmental responses in Latin America. Their impact on primary health and community organization is discussed.

Results. The AIDS epidemic is being characterized by successive waves of transmission among certain risk groups. Health authorities have been under pressure by the scientific community and the general public to implement strategies targeted at specific risk groups involved. Major efforts have been in health education, with emphasis put on disseminating "knowledge" about AIDS and (2) behavior modification. The crisis of health education strategies becomes evident when transmission begins to occur among relatively stable heterosexual populations. In these groups it is situations of risk (i.e., sexual exposure to an infected individual) rather than behaviors of risk that are major determining factors of AIDS transmission. Here, effective responses depend on (1) primary health system and (2) level of community organization and participation.

Conclusion. Responses to the AIDS epidemic have usually weakened already insufficient primary health resources crucial not only for WHO's general health goals, but for the forthcoming waves of the AIDS epidemic.

G.502

DEVELOPMENT OF AN HIV/AIDS SURVEILLANCE SYSTEM
Sax, Ronald; Cann, J. Department of Health, Bermuda Government, Hamilton, Bermuda.


Objective. To develop an accurate and comprehensive system of surveillance and follow-up for AIDS cases and HIV sero-positive tests.

Methods. Although Bermuda (approx. 57,000 population) is a small jurisdiction with a single acute care hospital and HIV testing facility, reporting of HIV/AIDS from physicians has not been complete. To ensure accurate surveillance, a detailed reporting scheme was developed based on regular communication between public health, hospital and laboratory staff. A computerized data base utilizing a personal computer and commercial spreadsheet software was developed to track all HIV sero-positive individuals and AIDS cases.

Results. Organization of the surveillance scheme has ensured that all diagnosed HIV/AIDS cases are reported to the Health Department for recording and follow-up. A Nurse Epidemiologist provides counseling for all newly diagnosed AIDS patients and pre- and post-HIV test counseling provided by Health Department clinic staff. The accuracy of tracking and analysis has been improved through the development of the computerized HIV/AIDS data base.

Conclusions. A comprehensive surveillance system for HIV/AIDS can be developed utilizing currently available staff and resources by stressing effective communication between the public health department, acute care hospital and laboratory facility. A data base to provide accurate statistics for analysis and follow-up can be developed at low cost using proprietary software and a personal computer.

G.504



G.506

MOLECULAR ETIOLOGY OF AIDS: AN ANALYSIS OF EPIDEMIOLOGICAL AND GENETICAL ASPECTS

J. Sambamurti¹, P.T.A. Subramanian²

¹Dept. of Geography, Madurai Kamaraj University, Madurai-625002, India.

²Dept. of Medicine, Madurai Medical College, Madurai-625002, India.

AIDS emerged as a major general health problem globally refers to the last fatal stage of HIV infection. The ecological spectrum of AIDS may be understood in five stages and the ecological changes associated with AIDS makes it difficult to identify since it constantly changes or modifies its nature most along with genetic coding of the cells without making changes in its basic biology. The present study is an attempt to analyze epidemiological aspects with reference to spatial distribution and variation based on analyzing the ecological trends. The epidemiological situation revealed that AIDS has already claimed 1,24,114 cases and in which North America has registered 71,343 cases followed by Europe with 12,414 cases. Of the total number of 26225 AIDS cases reported from 125 countries, 89% of the cases were from United States in September, 1987. The analysis of AIDS cases reported by 6-month period from 1977 to 1987 revealed that 70% of the cases were from Americas followed by Europe (18.37%), Africa (14.4%), Oceania (1.05%) and Asia (0.27%). It can also be reported that between 500,000 and 3 million new AIDS cases will emerge from persons already infected with HIV. Statistical methods like ratio and percentage measure have been used to explain the ecological situations of AIDS in different countries and with this epidemiological analysis is presented.


G.513 The Constitution of the Organization of the African Union-OAU and AIDS

R.A.N.M. MAFAGO*

*Charge de Laboratoires, SCC-SIDA, St. Louis.

 The African struggle against AIDS means fundamentally:

- * Improve the living conditions of the Africans.

The improvement phase of the African standard of living may only be attained by the advent of a system of democratic parity, appropriate to the mentality of the People of this Continent.

 A democracy for Africa, a Continent which is essentially underdeveloped, is only possible in framework of the PanAfricanist Congress-PAN-C which is the social-judicial manifestation of the organization of the African Union-OAU,

- * and which contains four popular power branches:
 1. the PanAfrican Legislative Council;
 2. the Community Financial Audit;
 3. the Constitutional Community Court;
 4. the PanAfrican Executive Council.

G.515 EPIDEMIOLOGICAL FINDINGS OF HIV INFECTION AMONG WOMEN FROM SAO PAULO-BRAZIL.

FERRERIA A. Lopes*, J. Fernandes M. Acceturi C. Pinto W.†

 1. Paulista School of Medicine-Infectious Diseases Unit, São Paulo.
 2. Reference Center for AIDS. Out-patient care Unit, SP, Brazil.

Objective: To evaluate the extension of HIV infection of women in São Paulo state.

Methods: Among the women (10 years old) registered in two out-patient care Units from Jan 84 to Jan 89 a sample of 611 were studied. The test used was ELISA and confirmed by W.1.1. technique. The seroprevalence of HIV infection among the sexual partners, IV drug abusers and blood transfusion receipts was determined. Other epidemiological aspects will be analyzed.

Results: Seroprevalence of HIV antibody in those groups

Sexual Partners	HIV POS	HIV NEG	TOTAL
110000	78	422	500
110000	169	212	381
TOTAL	247	634	881

Conclusion: Many epidemiological aspects of HIV infection in women will be emphasized in this study. One of the most important is that among the IV drug abusers the seroprevalence was higher than in the sexual partners (33%)

G.517 VERTICAL TRANSMISSION OF HIV-2; LACK OF EVIDENCE

Bynalden, Birgit Bak*, Hejlskov, N., Mølbak, K.* and Aaby, M.*

*Statens Serum Institut, Copenhagen, Denmark. **University of Copenhagen, Copenhagen, Denmark.

Objective: To investigate the occurrence of vertical transmission of HIV-2.

Material and Methods: In a 3-year longitudinal cross-sectional community study from Guinea-Bissau based to investigate the epidemiology of cryptosporidiosis in children and their families, 113 mothers and their 143 children less than one year of age were tested for HIV-2 antibodies in order to elucidate the frequency of vertical transmission. Blood samples were tested for HIV-2 antibodies by indirect ELISA; positive results were confirmed by WB.

Results: Of the 113 mothers, 11 were found to be HIV-2 antibody positive. Two of the eleven children born of positive mothers were found to be HIV-2 positive. One was tested positive at 3 1/2 months of age and was lost to follow-up, the other was positive at 5 months but turned negative at 8 months of age. The remaining 9 children were repeatedly negative. No children born of HIV-2 negative mothers were found to be HIV-2 positive.

Conclusion: Vertical transmission of HIV-2 in Guinea-Bissau seems rare.

Maternal antibodies apparently disappear before 8 months of age.

G.514 IMPACT OF COMPUTER SCIENCE ON AIDS RESEARCH

General Objective: World Immunological Network Project Foundation, Los Angeles, CA, USA.

OBJECTIVE: To demonstrate the effort of learn and computer transmitted data on the dissemination of AIDS information among researchers and practitioners on the international level.

METHODS: Using Laser Disk and AIDS-Stack technology, and international data base, utilizing Diversified Network Applications (DNA) an AIDS research and treatment has been created for use by researchers and clinicians worldwide.

RESULTS: The Laser Disk and AIDS Stack methods of data collection increase the speed, timeliness and availability of the latest information on AIDS, avoiding duplication of efforts, fragmentation of locale and unnecessary expenditure of scarce resources.

CONCLUSION: There is a demonstrable need for centralizing information on AIDS to develop a cohesive, widely accessible body of data that is readily updated and revised. The computerized network of information enables researchers and clinicians to track epidemiological trends, exchange ideas on treatment protocol and document research results. The database also has applications in the educational arena where universities, clinics and nonprofit groups are involved in teaching the community about AIDS.

G.516 PREVALENCE OF POSTNATAL ANTI HIV ANTIBODIES IN THE STATE OF JALISCO, MEXICO.

Alvarez-Gallardo, Eduardo*, Torres-Mendoza, S.*; Vázquez-Rizo, J.*; Rivas-Suárez, R. P. and Valero-Luque, I. M.*

*Instituto de Patología Infecciosa y Experimental "Dr. Fco. Ruiz Sánchez" de la Universidad de Guadalajara, Jalisco, México. **Departamento de Medicina Forense, Procuraduría Federal de Justicia del Estado de Jalisco, México.

Objective: To know the prevalence of postnatal anti HIV antibodies in corpse of unknown origin in the state of Jalisco, Mexico, and to determine the risk factor for health workers that are in contact with them.

Methods: Randomized samples of 87 corpses of unknown origin were taken from 2556 necropsies, during the year of 1988. At the beginning of each necropsy a sample of 5 cc of blood was taken from the thoracic cavity, to which ELISA assay was practiced, and confirmed by Indirect Immunofluorescence assay (IFA) and/or Western Blot (WB).

Results: The seropositivity obtained and corroborated by IFA and/or WB assay in HIV study, was 1.03% (one case), that belonged to a 30 years old male corpse, apparently from the USA, his death cause was medical intoxication, and in the necropsy there was also data of homosexuality. The health workers risk factor in Guadalajara, from being in contact with corpses of unknown origin HIV positive, is 1.03% and it increases to 25% with foreigners.

Conclusion: In our country the prevention rules should be increased in health workers in contact with corpses of unknown origin specially with foreigners, and probably with homosexuals.

G.518 HIV-1 ANTIBODIES IN BRAZILIAN PRISONERS

Costine, Antonio*, Peixoto, Z.*; Hernandez, R.; Lacouture, C.†; Lopez, L. and Mendes, M.*

Nicola Paviستا de Medicina, São Paulo, Brasil.

Objective: to measure the HIV-1 infection prevalence among male Brazilian prisoners.

Methods: The presence of HIV-1 antibodies was investigated in serum samples from 923 volunteers from a prison located at the inner-city area of São Paulo, obtained during April and May, 1988. They were clinically well at the time of blood collection. The serum samples were analyzed by indirect ELISA using a whole-virus preparation (VIR200® HIV-1 ELISA; Biotecro-Sulcilac), recombinant viral proteins (89 M405, Indurabio) and the synthetic peptide IgGMYKICR200 corresponding to a segment of gp120 from each test kit. Escola Paulista de Medicina.

Results: By using the three distinct serological methods, the prevalence of HIV-1 antibodies was 12.56% (115/923). This result may reflect the actual HIV-1 infection prevalence among the individuals within that prison, since some prisoners with risk factors denied to enroll in the study. False positive reactions due to antibodies to B cell line proteins were not observed.

Conclusion: The high prevalence of HIV-1 infection among Brazilian prison

HIV-1, as occurs in other countries, is mostly due to homosexual and drug-sharing exposures.



Publications

G.519 ASSENCE OF HIV-1 AND HIV-2 INFECTION IN AFRICAN TRIBES, 1960-72
 Schindler, J.; Jones, S.; Balala, R.; Reed, J. and Mufson, M.
 Marshall University, Huntington, WV, U.S.A.

Objective. To examine sera for HIV-1 and HIV-2 antibodies collected in Africa in the Pre-AIDS era.
Methods. 155 sera from Africa were collected as part of a respiratory epidemiological study from 2 tribes: 60 Mano (Liberia); 84 Korokore (Sierra Leone); and 15 Turkana (Kenya). These sera were tested for HIV-1 (Abbott HIV-1 EIA, Biotech/Diagnost), HIV-1 Western Blot (WB) and HIV-2 (Subout HIV-2 WB) antibodies.

Tribe	Number Positive or Indeterminate (%) / Number Tested (N)			
	HIV-1		HIV-2	
	ELISA	WB	ELISA	WB
Turkana	9/15 (60)	11/15 (73)	0/15	0/15
Mano	41/60 (68)	46/60 (77)	0/60	32/53 (62)
Korokore	56/96 (57)	33/93 (36)	0/83	15/45 (33)
Total	106/159 (66)	90/158 (57)	0/108	52/108 (48)

The frequency of positive EIA increased with age but indeterminate Western blot (WB) to HIV-1 or 2 did not increase with age. The most common bands detected by HIV-1 WB were p24, (70%) and p17(20%). HIV-2 WB detected bands to p66 (43%) and gp41(14%) but indigmantly to p24 (3%).

Conclusion: No HIV-1 or HIV-2 infected persons were found in this retrospective study. Significant differences in patterns of HIV-1 and HIV-2 WB occurred.

G.521 TRANSMISSION OF HIV INFECTION THROUGH BREAST MILK
 Sami Solomon*, Sodhar, N. S., Sundararaman, S., Anuraj, A.,
 S. P. Thangavelu**

* Madras Medical College, Madras, India. ** Post Graduate Institute of Basic Medical Sciences, Madras, India.


Objective. Can breast feeding transmit HIV infection from HIV seroreactive mothers to their children?

Methods. With a view to assess the possibility of perinatal transmission of HIV infection from seroreactive mothers to children besides vertical transmission, 19 HIV seroreactive prostitutes (both by ELISA and Western Blot) and their children were analysed. Group A mothers (2) were asked not to breast feed their children and the latter remained seronegative till 10 months of follow-up. Group B mothers (3) who could not be stopped from breast feeding their children transmitted HIV infection as evidenced by appearance of HIV antibodies in them by 6th, 7th and 8th month after birth. Group C mothers (14) who had breast fed all their children could be analysed only retrospectively. They revealed interesting patterns. The details would be presented.

Conclusion. The high rate of HIV transmission through breast feeding is highlighted.

G.520 HIV INFECTION AMONG DUTCH EXPATRIATES WORKING IN AFRICA
 Houweling, H.M.A.; Van den Akker, E. P.; De Groot, A. J.; Smits, S. P.; Kijlstra, R. J.; Leentvaar, A. J. et al.
 * National Institute of Public Health (RIVM), Bilthoven, The Netherlands.

Objective. To study the prevalence of HIV infection and related risk factors among Dutch expatriates working in sub-Saharan Africa.
Methods. In the course of a routine medical check expatriates who have been posted in sub-Saharan Africa for at least 6 months since 1978 are asked to give a vial of blood and to complete a self-administered questionnaire on sexual, occupational and other risk factors for HIV infection.
Results. Among 1230 participants posted in 39 African countries (Sept. 1987-Dec. 1988) Western risk factors were relatively rare: 18 men (2.8%) were homo/bisexual, 2 men and 1 woman had used i.v. drugs. However, 71 men (10.2%) and 20 women (3.2%) had been treated for S.T.D. Risk factors in Africa included sex with African partners (37% of men, 15% of women; mean 3, range 1-150). Condom use was infrequent and inconsistent. The majority of medical doctors (81%) and nurses (69%) and 32% of nurses had suffered needle stick accidents (mean 1, range 1-150). Four participants were found to be infected (seroprevalence: 0.3%, 95%CI: 0.01-0.7%). 2 men and 2 women: 1 woman had sex with a bisexual man, all 4 had sex with African partners and had been treated for S.T.D., 1 had an African partner and 1 was born in Africa, no one had occupational exposure to HIV.
Conclusion. Despite high prevalence of risk factors HIV infection is rare among a non-selected group of expatriates working in sub-Saharan Africa.



Répercussions économiques du SIDA

The Economic Impact of AIDS



Séance thématique Specialty Session



Répercussions économiques du SIDA The Economic Impact of AIDS

Aperçu et coûts de la prévention et de l'éducation Overview Plus Costs of Prevention and Education

M.H.O.1

OVERVIEW

Duchet, Margaret. McGill Centre for Medicine, Ethics and Law, Canada

M.H.O.2

COST OF MEDIAN-TERM AIDS PREVENTION AND CONTROL PROGRAMMES IN SUB-SAHARAN AFRICA

Dreyer, Neil; Collins, L.*; Tarranto, D.*; Lamborg, J.L.**; Gemen, U.**; Phillips, M.***, et al.
*World Health Organization, Geneva, Switzerland, **The World Health Organization, DC, USA, ***University of Geneva, Geneva, Switzerland, ****London School of Hygiene and Tropical Medicine, London, UK.

The globally agreed strategy for AIDS prevention and control calls for the formulation of comprehensive median-term plans which describe the policies, strategies and activities around which government, non-governmental and international agencies will focus their collaboration. Governments and the international community need to know the level of resources required to implement these plans. As very little published data exists on the real costs of implementing AIDS programmes, a study was made by the World Health Organization and the World Bank of budgeted costs of 12 median-term programmes formulated in Sub-Saharan Africa.

The study initially described the main features of the first year budgets and then explored the relationship between cost and several country characteristics with the intention of using this both to predict likely future costs and to extrapolate costs to other countries in the region. This paper provides a discussion of the rationale, the methodology and the results of the study. It points to the need to develop uniform costing guidelines, to collect retrospective expenditure data and to undertake preliminary cost-effectiveness analyses of elements of the plan.

M.H.O.3

COSTS OF AIDS EDUCATION

Fingberg, Harvey. Harvard School of Public Health, Harvard University, Boston, MA, USA.

M.H.O.4

HIV SCREENING AMONG POTENTIAL IMMIGRANTS: A COST/BENEFIT ANALYSIS

Brown, Ronald; M Gilmore, JD Ph.D.; M. Gaudin, A. Dutschak, SA Grover; *McGill University, Montreal, Quebec, Canada, **Queen's University, Kingston, Ontario, Canada.

Objective: To assess the economic impact of HIV screening among potential immigrants to Canada on the national health care system and Canadian community.

Method: We developed an economic model based on current international HIV seroprevalence data, Canadian immigration statistics, disease progression estimates and the projected costs of HIV screening and treating AIDS patients.

Results: Estimating that 139,034 immigrants enter Canada in 1988, between 269 and 471 are likely to be HIV carriers. Screening would lead to the exclusion of between 264 and 566 persons including false positive results. The estimated total cost of screening every immigrant ranges between \$1.7 million and \$4.0 million. The present value (discounted at 7.5 percent) of the medical costs for 48 percent of the HIV carriers who will develop AIDS between 1988 and 1997, ranges between \$6.5 million and \$21.0 million. However, the limited net benefit associated with screening may be significantly offset by additional administrative costs to immigration, loss of desirable applicants, and Foreign Income.

Conclusion: The cost/benefit of HIV screening for potential immigrants remains uncertain given the associated costs which have not yet been determined.

M.H.O.5

COST-EFFECTIVENESS OF HIV SCREENING AMONG PREGNANT WOMEN IN PARIS HOSPITALS

La Caille, Catherine; Oti, Moust J. (1), Colucci, Paris-Tours d'Etude de la transmission HIV périnatale (Paris-Tours Study Group on Perinatal Transmission HIV) (2) INSERM U246, Paris, France

An epidemiologic multicentre study (coordinated by "Centre d'Histopathologie Périnatale", Paris and Service de Virologie, Hôpital Necker, Tours) about perinatal transmission of HIV is currently carried out in Paris region. In this context, between August 1987 and February 1988, HIV screening was systematically proposed to all pregnant women attending in 6 obstetrical clinics in the region (97,820; 2,140 have already been tested for HIV out of 475 known HIV+). Among the 1,660 tests of pregnant women who have never been screened, 18 were discovered HIV+ (total prevalence = 6.95 10⁻³). Under the assumptions of ELISA sensibility (98.5 - 99.2%) and specificity (98.1 - 99.1%) the average cost per additional pregnant woman HIV+ discovered in clinic varies from 2 640 to 6 650.

As women, before being screened, had to answer a questionnaire about risk factors, non-systematic screening based on such factors can be avoided. In this case, only 12.9% of pregnant women would have been tested, the total prevalence would have been 3.6% and the average cost per HIV+ discovered 1 120. With regard to the 3 additional HIV+ pregnant women discovered by systematic screening (compared to non-systematic one), the cost per supplementary HIV+ woman found (average cost) is 2 810.

For the next 6 months of the screening program (February - August 1988, n = 7,750), similar calculations lead to an average cost of \$ 7,360 - 28,800 for systematic screening (6 pregnant women discovered HIV+); and of \$ 1,620 for non-systematic screening (15% of at-risk population, total prevalence 7%).

Results suggest that cost-effectiveness of HIV screening among pregnant women in hospitals is, in fact, highly dependent of efficiency of screening practices in other sectors of prenatal care especially obstetrical medicine (between August 1987 and 1988, the % of women already tested before attending obstetrical clinics varied from 22 to 32%).

M.H.O.6

THE ROLE OF COMMUNITY-BASED ORGANIZATIONS IN CONTAINING THE COSTS OF THE AIDS EPIDEMIC

Smith, Mack D., University of Pennsylvania, Philadelphia, PA, USA

National AIDS efforts have 3 general components: prevention, health and social services, and creation of a supportive social environment. All three are expensive and rapidly-growing financial outlays.

Community-based AIDS service organizations (CSOs), including organizations of Persons With AIDS, have been in the forefront of education and service delivery in the U. S.

One study estimated the value of volunteer services by one CSO in New York to cost over 2 million dollars for 187 slots. A number of areas of work can benefit economically from CSO efforts:

AREA	MECHANISM OF COST REDUCTION
Medical services	Early discharge, home support
Education	Training of volunteers
Client's trials	Publicity, recruitment, retention
Public disputes	Community education, dispute mediation
Prevention	Community education to reduce HIV transmission

CSOs depend on relative fringe government and private support, and their volunteers face fatigue and burnout. In addition, the changing face of the epidemic in the U.S. - particularly the rise in the numbers of minorities and drug-users with AIDS - may make it more difficult to rely on unpaid volunteers. Support for the CSOs themselves is arguably a cost-effective investment for hard-pressed public agencies.

**Séance thématique
Specialty Session**



**Repercussions économiques du SIDA
The Economic Impact of AIDS**

**Planning of gestion
Planning/Management**

T.H.O.1

WORK DISABILITY AMONG AIDS CLINIC PATIENTS
Creswell, Ruth M.; Tolleter, H.; McIndler, J.; Kuhl, S.; and Pison, M. University of California, San Francisco, California, USA.

Objective: To describe the incidence, prevalence and predictors of work disability among 61 randomly selected AIDS clinic patients.

Methods: A cross-sectional study of medical and work histories which utilized a structured interview survey instrument.

Results: Fifty-nine (97%) of the respondents reported symptoms which are associated with HIV-related illness. Fifty-three (88%) worked prior to onset of symptoms. The mean time between onset of symptoms and interview was 2.3 years. Twenty-seven of the 53 (51%) stopped working during the period of time between onset of symptoms and interview. (51%) during year 1, (20%) during year 2, 30% during year 3, and 31% during year 4. Among the 26 who remained working, the mean work week declined only slightly to 35 hrs. Among the 53 who worked prior to onset of symptoms, hours worked per week declined 52% to a mean of 19. Given the youth of the study population (mean age = 35 years), and assuming that no additional work disability cases occur before retirement at age 65, 62% of the 40 year productive life span (DLS) of this population would be lost. However, assuming that a 10% disability incidence rate continues, the loss would be 48%.

Conclusion: This group of AIDS clinic patients experienced a 51% work disability rate within 3 years of the onset of symptoms. Since hours per week declined only slightly among those continuing to work, most of the lost productivity was due to a complete cessation of work. The incidence of work disability is estimated to result in the loss of 48-62% in the working life of this population.

T.H.O.2

FIVE YEAR AIDS PLANNING PROCESS AT A HEALTH MAINTENANCE ORGANIZATION
Anderson, Elizabeth S.; Thompson, R.L., M.D.; and Berry, W.J. Group Health Cooperative of Puget Sound, Seattle, Washington, U.S.A.

Objective: To provide a basis for resource allocation and planning decisions. Group Health Cooperative (GHC), a large HMO, completed a five-year (1981-1985) service planning process. **Methods:** GHC identified multiple areas where it had AIDS-related responsibilities and issues; and as a provider and coordinating health care services; preventive education; developing and administering insurance packages; as an employer; utilizing clinical and management information systems; and as a partner in community-wide projects. A multidisciplinary planning team gathered data; identified policy issues and resource needs, and forecast future impact. The team used the HMO's data systems and CDC's AIDS case-reporting methodologies to predict future AIDS cases and outcomes.

Results: By year 5 (1985), GHC predicted a 50% increase in AIDS cases. The PWAs, unevenly distributed over the HMO's service area. The direct medical costs of treating PWAs are estimated at \$12.0 million annually. To meet legal mandates and clinical needs over 1989-1991, the PWAs will cause a major impact on future planning for hospital beds, staff, inpatient and outpatient beds, and ancillary services. To meet legal mandates and clinical needs over 1989-1991, the PWAs will increase 3 to 10 times to over 25,000 employees each year, requiring significant additional staff resources. Staff training needs in infection control, clinical management, and case management were identified. A system to coordinate the case and support services for PWAs across settings is needed. Strong ties to community-based AIDS efforts (e.g. prevention and care) and low case rates are factors shown to be useful to health care and the community. The planning team set directions for design and administration of the de IDMO's "benefits package" to support care and treatment of PWAs and other patients with chronic and reduce adverse selection problems. **Conclusions:** Long term service planning provides HMO's with information to allocate resources needed for adequate AIDS treatment, case management, and prevention services, future bed and staffing levels; training; and benefits administration.

T.H.O.3

UTILIZATION OF COMMUNITY-BASED AND HOSPITAL CARE FOR PERSONS WITH AIDS IN SAN FRANCISCO, 1980-85
Stern, Adam L.; Chen, R.; Udell, J.; Frazier, V.; Lifson, A.; Hernandez, M.; Williams, M.; Riddle, R.; Gorman, G. Department of Public Health, San Francisco, CA, USA.

Objective: To assess utilization of community-based and hospital care for persons with AIDS in San Francisco.

Methods: We defined 8 distinct care settings for PWAs and surveyed care providers to determine average daily census of PWAs in each setting during January 1980 and January 1989. Utilization was calculated as a percentage of living persons with AIDS in San Francisco, adjusted for reporting delays.

Results: Of the 2,859 living PWAs in San Francisco in January 1989, 82.2% were living at home without healthcare, 7.8% were receiving healthcare, 4.4% were in residential settings with social service support, 3.8% were in acute care hospitals, 0.5% were in skilled nursing facilities, 0.5% were in mental hospitals, 0.5% were in substance abuse treatment, and 0.2% were in mental health treatment. The distribution of living PWAs in these settings did not significantly change from January 1988 (2,042 living PWAs) to January 1989.

Conclusions: On an average day, most PWAs in San Francisco (82.2%) are currently living at home without healthcare. Only 3.8% of living PWAs are in acute care hospitals. The remaining group of PWAs receive home care or are served in a variety of community-based care settings. As the number of living PWAs in San Francisco is expected to rise to 6,200 by 1992, utilization patterns at all care settings will be critical for health care planning purposes.

T.H.O.4

ASSESSING THE COST OF AIDS TO BOTH PATIENTS AND THE HEALTH CARE INSTITUTION
Pittman-Indiana, M.J.; Miller, D.; Sowa, P.F. San Francisco General Hospital, San Francisco, California and *San Francisco Office of Public Health, San Francisco, California

Objective: To describe and document the cost of AIDS to San Francisco General Hospital.

Methods: The authors review patient medical records to assess a base line of services provided. These services are compared to individual workload monitors (i.e., nurse activity tool; medical record tasks; medical social worker/client hours). The cost is further evaluated by looking at internal service department workload related to HIV patient care. The cost to the hospital in staff hours, materials, supplies and equipment is compared with other overall hospital costs. The cost of AIDS is also considered as an opportunity cost and the authors attempt to quantify the programs which have least support or resources while the hospital staff have directed their efforts to AIDS.

Results: The review of medical records and departmental monitors clearly show that key hospital services are disproportionately involved in HIV care and that those services are typically not part of the billing documents. The paper describes a model that each health care institution can use in evaluating the cost of AIDS care.

Conclusions: The cost of AIDS care must be evaluated from the impact on the individual patient as well as the cost to a health care institution. This paper attempts to quantify these departmental expenses. It also raises the question of the eventual cost to our health care workers. Although this issue is not quantified, it is a crucial factor in assessing the real cost of AIDS.

T.H.O.5

PUBLICALLY-FUNDED COSTS OF COMMUNITY-BASED EDUCATIONAL PROGRAMS BY RISK CATEGORY IN SAN FRANCISCO
Evans, Patricia L.; Herrington, M.; Rutherford, D.W.; Amery, J.W.; Conne, D.; Nguyen, B.; Amery, A.; Wieringer, D.; Department of Public Health, San Francisco, CA USA

Objective: To evaluate publicly-funded costs of community-based AIDS prevention/education program by risk category.

Methods: We reviewed 5 community-based state and city) for the 12-month period July 1987 through June 1988 and categorized funding for 11 community-based organizations (CBOs) according to target populations. We determined per capita expenditures using estimated sizes of specific risk groups. **Results:** Total public funding for the 12-month period was US\$5,751,579. Of this amount, \$1,111,127 (20%) was subcontracted to 11 CBOs according to the following target populations:

Home/bisexual men (including IVUDs)	Total Funding(\$1000)	Per Capita
IVUD	\$1,009 (30%)	\$17.35
Heterosexual*	897 (27%)	74.76
General Public	474 (14%)	4.82
Provider Education	520 (16%)	1.31
GENERAL	125 (4%)	16.60
TOTAL	\$3,311	5.72

*Defined as heterosexual partner of an intravenous drug user or bisexual man or heterosexual with 2 or more partners in last year or no sexual contact with any partner. **Conclusions:** San Francisco's comprehensive educational program includes \$2,360,217(72%) of community-based funding targeted towards high-risk groups and \$30,911(28%) towards the general public and provider education.

T.H.O.6

COMMUNITY-BASED FINANCING IN AIDS: CBO AS MODEL
Stern, Adam L.; Department of Public Health, San Francisco, CA USA

Objective: To demonstrate how community-based costs can represent a successful alternative model for the design and conduct of clinical research in AIDS, expanding the number of study participants and increasing compliance (including minorities and group members) and incorporating the perspective of patients in the research.

Methods: The CBO is organized and approved by the New York State Department of Health to sponsor the longitudinal, multi-center study of seropositive AIDS/HIV seroconverters conducted in a community setting by qualified physicians in cooperation with informed volunteers. Subjects recruited from their neighborhoods throughout the field of AIDS.

Results: Although the CBO has been in existence for little more than one year, it already has 200 approved clinical trials fully approved and underway, as well as 4 other important research studies under way. In addition, the CBO has an informal monitoring project of substance, the results of which will be reported at the 1989 International Conference on AIDS in Seattle. The CBO has also prepared a report submitted for publication on the underactive surveillance in AIDS of low risk levels. Both reports represent evidence of the CBO's ability to collect data to evaluate the effectiveness of its programs. We are prepared to present the procedures for development of research networks from independent support, financial success, and general conduct of based research conducted in an AIDS center.



**Séance thématique
Specialty Session**

**Repercussions économiques du SIDA
The Economic Impact of AIDS**

**Financement et assurances
Financing and Insurance**

W.H.O.7

**EMPIRE BLUE CROSS AND BLUE SHIELD:
THE FIRST 7500 AIDS CASES**

Responsible: Jan, Padgug, Robert,
Empire Blue Cross and Blue Shield, New York City, USA

Objectives: To describe the experience of Empire Blue Cross and Blue Shield with its first 7500 AIDS cases, and to draw conclusions regarding health insurance coverage, costs per case and trends in types and sites of treatment.

Methods: Presentation of Empire's policies regarding insurance coverage for AIDS followed by statistical analyses of hospital and medical claims data for persons with AIDS insured by Empire.

Results: Lifetime health care costs for persons with AIDS covered by Empire are approximately \$60,000 per case, significantly below many early cost estimates. Costs have been stable through the course of the epidemic because of a decline in inpatient utilization.

Conclusion: Costs for the treatment of persons with AIDS are manageable, even when the number of cases is large and there is easy access to health care providers. Results should be useful for private insurers, governmental bodies, and other institutions concerned with trends in costs and with insurance coverage issues.

W.H.O.9

**THE COST OF HIV-RELATED HEALTH INSURANCE CLAIMS
IN THE UNITED STATES**

Responsible: Charles, Health Insurance Association of America, U.S.A.

Objectives: To present data on the cost of health and disability insurance claims related to the HIV epidemic for 1978 and 1987. (Data for 1988 may be available by the time of the conference.)
Methods: Each year since 1986, the Health Insurance Association of America and the American Council of Life Insurance have surveyed their members to collect data on claims related to HIV illness. Although not all HIV-related claims are identified, this survey provides the best estimate currently available of the HIV-related costs paid by insurance companies.

Results: The percentage of claims related to HIV illness is small, but increasing rapidly. There is wide variation in impact among companies, with a substantial number of companies experiencing no HIV-related claims, while others report more than 4 percent of claims related to HIV illness.

W.H.O.8

**HEALTH INSURANCE INDUSTRY MODELING OF THE
EPIDEMIC IN THE UNITED STATES**
Responsible: Dinius, J.**, Health Insurance Association of America, *Atlanta Life and Casualty, U.S.A.

Objectives: To present the results of a model developed jointly by the Health Insurance Association of America and the American Council of Life Insurance.

Methods: A joint committee of the two trade associations developed a model for forecasting AIDS cases and claims costs through the year 2000, using a range of scenarios. This presentation discusses the assumptions, methodology and results of this modeling effort.

W.H.O.10

ANALYSIS OF AID ASSISTANCE PROVIDED BY A PRIVATE HOSPITAL

Responsible: Claxton, M.; Houtis, J.; Nelson, J.; St. Clare's Hospital and Health Center, New York, NY, U.S.A.

Objective: To identify gaps in third party coverage of AID

Methods: Analyzed free distribution of AID during six months at St. Clare's Hospital, NY, to various financial classifications in relation to: 1) date Retrovir available for purchase; 2) dates of various stages of progression of governmental AID Drug Assistance Program (ADAP); 3) date assistance effective to individuals; 4) date patient first aware of assistance.

Results: Seventy-three patients were given 45,868 AID capsules, cost approx. \$74,765. Breakdown of capsule distribution as follows: Medicaid eligible, patient not notified by govt.; 241. ADAP eligible, no action taken by Fed. Govt.; 51. ADAP eligible, application not available; 161. ADAP eligible, program not implemented; 51. Covered by private insurance, unable to afford out-of-pocket outlay; 131.

Conclusions: Non-governmental agencies must be aware of bureaucratic delays in providing governmental assistance for new drugs and that patients are often unable to meet out-of-pocket expenses necessary with private third party coverage. These agencies must implement mechanisms to ensure interim assistance is available.

W.H.O.11

**NATIONAL SURVEY OF STATE SPENDING FOR AIDS PROGRAM
ACTIVITIES**

Responsible: Ryan, C.C.; Krutz, R.M.*; and Merritt, D.M*,
Richard, J., Madson, S.* and Parvill, K.W.*
*Intergovernmental Health Policy Project/The George Washington University,
Public Health Foundation, *National Association of State Budget Officers,
Washington, D.C. U.S.A.

Objective: To report on findings from a 50-state survey of 1989 state appropriations for AIDS (funding (non-Medicaid) across all state departments and by program area. Methods: A pre-conference questionnaire was distributed to a Governor's designated sample of state budget officers and health officials, with assistance from related organizations. Results: Preliminary survey results show that states are appropriating funds to a variety of state agencies besides health, including those in corrections and education. Total state-only funding (non-federal) for AIDS has increased by at least a third from the previous fiscal year. Almost four-fifths of the states have appropriated funds from their own general revenues. Those with no state funding continue to rely on federal grants primarily for public health activities. AIDS has changed the source of support for public health activities, with the private sector directly funding service programs sponsored by state and local governments. The findings document the shift in AIDS funding for specific program activities and demonstrate the amount of state and federal funds passed through to local governments and community based organizations. Conclusions: Federal funding will continue to influence how states fund their own health. States are using state funds to develop model programs for service delivery, planning and outreach to special populations.

W.H.O.12

**FINANCING THE MEDICAL COST OF THE HIV EPIDEMIC
IN THE UNITED STATES: A POLICY REVIEW**

Responsible: Barry, J.; Saaga GPN*; Thorpe KEE; Pinsherg WPN*,
* Center for Policy and Education, Harvard AIDS Institute, Harvard School of Public Health,
** Department of Health and Hospitals, Boston, MA, U.S.A.

Objective: To review strategies to provide access to care to people with HIV infection in a country without universal health insurance.

Methods: We use explicit criteria to evaluate use of policy options to provide increased access to care for those with HIV infection in the United States. The options include: Use of state risk pools and provider malpractice, employer mandates, and expansion of public financing programs, Medicaid and Medicare.

Results: The complex health care needs of persons with HIV infection highlight inadequacies in our fragmented health care financing systems and raise serious questions concerning how best to pay for care. While the total cost of caring for an individual with AIDS is similar to the cost of caring for those with other catastrophic illnesses, these costs do have a significant impact on both affected individuals and regions of the country that have been hard hit by the epidemic.

Conclusions: We recommend approaches to broaden the available continuum of care through improved financing mechanisms. In order to provide more universal access to care, we recommend changes that will extend eligibility for private insurance among the previously unemployed, extend Medicaid and Medicaid coverage, and establish state funds for the uninsured.

Session d'affichage Poster Session



Repercussions économiques du SIDA The Economic Impact of AIDS

M.H.P.7

THE CONTRIBUTION OF PCP TO TRENDS IN AIDS HOSPITAL DISCHARGES AND AVERAGE LENGTHS OF STAY.

Stevens, Sandra R.; Struchiner, F.; Rutherford, G.;

Basket, L.*; Hays, R.*; Department of Public Health, San Francisco, CA; *West Bay Hospital Conference, San Mateo, CA, USA.

Objective: To evaluate the contribution of *Pneumocystis carinii* pneumonia (PCP) to declining average lengths of stay (ALOS) and decreasing average daily census (ADC) of hospitalized AIDS patients in the San Francisco Metropolitan Statistical Service Area (MSA).

Methods: We compared acute hospital discharges and average lengths of stay (ALOS) for AIDS patients discharged with a primary diagnosis of PCP and those discharged with other AIDS-related diagnoses from 1984-1987. Discharge data included are non-Federal acute-care hospitals in San Francisco, San Mateo, and Marin Counties.

Results: The contribution of PCP to all AIDS discharges did not change from 1984 and 1987 but the ALOS of patients with PCP decreased more rapidly than ALOS patients without PCP.

	1984	1985	1986	1987
Discharges, % PCP	30.3	35.8	32.3	34.1
ALOS, PCP	16.2	12.9	13.7	12.3
ALOS, non-PCP	10.6	11.6	11.5	9.8

Conclusions: The decreasing ALOS and ADC for hospitalized AIDS patients in San Francisco MSA can be primarily accounted for by shorter ALOS for PCP patients.

M.H.P.8

COSTS OF HOSPITAL CARE FOR PATIENTS WITH HIV INFECTIONS

Boroff, Jan C.C.; Jager, J.C.; Geels, R.M.A.;

Long, J.L.C.; Misch, C.F.; University Hospital Utrecht, The Netherlands and *National Institute of Public Health and Environmental Protection, The Netherlands.

The implications of AIDS for health care are unknown. Precise data on the utilization of health care facilities and the related costs, and efficiency and effectiveness of hospital care are not available, mainly due to the absence of suitable methods for registration of demographic, medical and financial data of individual patients in hospitals. For this reason we developed a system which enables a detailed collection and analysis of data. The application of this system to six patients with HIV infections treated in our hospital between January 1, 1987 and July 1, 1988 showed that the mean yearly costs of in- and out-patient treatment of a patient with AIDS (CDC IV) were \$ 20,000; those of treatment of patients with other HIV infections (CDC I-III) ranged from \$ 1,700 to 2,500. Comparison of the mean costs for patients who died in that period with those of patients who did not, revealed that patients deceased because of AIDS would have costed \$ 40,000 yearly and those with AIDS who were alive at July 1, 1988 \$ 15,000. These figures only concern costs of hospital care for these patients. Other costs, such as those of procedures for prevention of HIV transmission, are not included. In the time of the conference the data will be updated. In addition, underlying diagnostic activities and treatment patterns will be described.

M.H.P.9

HOSPITAL USE BY A POPULATION-BASED COHORT OF AIDS PATIENTS

Hudson, James J.; Mosenifar, K.; Klockner, R.; Bennett, D.; Fleming, D.

Oregon Health Division, Portland, Oregon, U.S.A.

Objective: To accurately determine statewide hospital use among AIDS patients by following all cases in a statewide, population-based cohort.

Methods: We follow all AIDS cases identified by active AIDS surveillance in Oregon who remain in the state for follow-up medical care. At six month intervals, we review each patient's medical record and abstract information about every hospitalization requiring at least an overnight stay.

Results: Records were available for 381 (94%) of the 407 Oregon AIDS cases diagnosed between 1/181 and 6/30/87. During the cumulative 3,965 case-months of follow-up, there were 103 hospitalizations. 83% of all ICU days occurred within the first 6 months of diagnosis. Among all patients, the median number of days spent in the hospital during the year following diagnosis has remained constant at between 7 and 8 from pre-1983 through 1986. By 12/88, 240 (63%) of the 381 patients had died. The total hospital days among cases that had died averaged 80. This total was unaltered to length of survival after diagnosis by linear regression (total hospital days for those surviving 1-3 months, 26 days; 4-6 months, 23 days; 7-9 months, 19 days; 10-12 months, 20 days; 13-18 months, 22 days; 19-24 months, 25 days; more than 24 months, 34 days). The percent of time spent in the hospital was inversely associated with length of survival (1-6 months, 53%; 7-12 months, 42%; > 12 months, 5% ; p<0.001 by linear regression).

Conclusions: In this cohort of AIDS patients, hospital use has been constant over time. Admissions have been short and relatively infrequent. Contrary to expectations, increased length of survival has been associated with more hospital-free days rather than more hospitalizations.

M.H.P.10

OUTPATIENT TREATMENT OF AIDS: A VIABLE ALTERNATIVE TO DECREASED HOSPITAL CARE COSTS

Lichten, Richard; Malmgren, P.; Mizolzi, A.; Bertoni, J.A.; Dale

University Medical Center, Durham, North Carolina, U.S.A.

OBJECTIVE: To compare the per diem charge of inpatient vs. outpatient treatment of AIDS patients with an opportunistic infection.

METHOD: Twelve patients were grouped according to opportunistic infection with a classification of inpatient/outpatient, PCP (1 inpatient/7 outpatient), P22 (1 inpatient/2 outpatient), wasting (1 inpatient/7 outpatient), lymphoma (1 inpatient/1 outpatient), toxoplasmosis (1 inpatient/1 outpatient). Hospital days and inpatient charges per admission, and outpatient charges and charges per visit were collected over eight months. Average inpatient and outpatient per diem were calculated. The additional patients will be added as charges are posted and billed.

RESULTS: Average inpatient per diem for PCP was \$1023 ± 18 hospital days. Average out-patient per diem was \$117 ± 33 clinic for home health visits. CPK averaged a \$615 inpatient per diem ± 113 hospital days. Outpatient averaged 30 clinic for home health visits per diem of \$242. Average inpatient per diem for wasting was \$699 ± 31 hospital days. Out-patient cases averaged 17.5 clinic for home health visits at \$147 average per diem. Lymphoma was \$911 inpatient per diem ± 37 hospital days. Outpatient was \$214 per diem ± 34 clinic for home health visits. Toxoplasmosis averaged a \$584 per diem ± 8 hospital days. Outpatient averaged \$83 per diem ± 6 clinic for home health visits.

CONCLUSION: Our data show that individuals with complications of AIDS have very different clinic costs and per diem charges at home and in the hospital. Preliminary data strongly suggest that outpatient therapy for these complications can be administered, per diem charges can be substantially reduced. These preliminary findings warrant further study, and have profound implications for health care policy development.

M.H.P.11

LA FRAUDAZIONE OSPEDALIERA: LE VIE AL VINCO DE

NEOLOGICHE ANCHE IN UN

OSPEDALE DI UN PAESE SVILUPPATO

Chenot, D.; Chelvar, P.;

Ministère de la Santé, de la Famille et de la Protection Sociale, Paris, France *Direction du Plan - Assistance Publique de Paris, Paris, France

OBJECTIVE: Mesurer un jour double l'activité hospitalière liée aux patients infectés par le VIH et au suivi l'évolution des cas.

Methodes: Une enquête nationale transversale semestrielle recense "un jour double" les patients déjà connus comme infectés par le VIH) en fonction de leur statut de la semaine 22 en fonction du type de recours aux soins.

RESULTS: 11 patients recensés asymptomatiques forme sérologique SIDA précoce

9 décembre 1987 1 280 335 378 405

6 Juin 1988 1 280 335 378 405

De décembre 1987 à Juin 1988 l'augmentation totale des cas présents est de 56. Elle porte sur les SIDA sévères (2 202), les formes sévères restées stables et les formes asymptomatiques diagnostiquées de 135. La diffusion des malades sur le plan géographique est très faible (70% des malades concentrés aux deux régions de la Champagne-Normandie, reste stable). Deux malades sur trois sont hospitalisés (80% des SIDA) les autres sont en soins ambulatoires.

L'évolution observée porte sur l'hospitalisation de jour (45% des formes sévères), 84% des patients ont recours aux services de médecine générale et de spécialités médicales.

Conclusion: La répétition structurelle de cette enquête fournit d'importantes informations pour apprécier l'impact de la typologie de soins par le statut de l'infection à VIH et adapter les structures de soins en fonction de son évolution.

M.H.P.12

MEDICAL CHARGES AND HEALTH CARE UTILIZATION FOR PRIVATELY INSURED PATIENTS WITH HIV DISEASE IN CALIFORNIA

Ortiz, Mag.; Brown, RB; Meach, S.J. and Hanks, J.

University of California, San Francisco, USA; Kaiser Foundation Health Plan, Eureka with Blue Cross of California, Oakland, California, USA; Blue Cross of California, Oakland, California, U.S.A.

OBJECTIVE: To develop methods for identifying patients with HIV disease through insurance billing codes and to describe their need and estimated lifetime charges and distribution of health services utilization.

Methods: A major claims file of Blue Cross of California was reviewed for HIV diagnosis from 1984 to 1988. Charges and utilization were analyzed for those with specific HIV diagnostic codes and for those with presumed HIV manifestations including specific signs, symptoms, and laboratory criteria. Kaplan-Meier lifetime cost estimates were also generated for all diagnostic groups except AIDS.

RESULTS: Of the 274 subjects identified, most were men (93%); 57% were male. Mean follow-up was 31 months, with 68% alive at study completion. Forty-three had PCP. Mean charges were \$19,000 for services to \$52,000 for those who died. The deceased were in hospital 3 times longer than survivors (29 days v. 10 days); their estimated lifetime charges were \$79,000. Among all patients, hospital charges represented 67% of the total bill. Among those hospitalized, the highest charges were room and board. Among those not hospitalized, the highest charges were inpatient PCP, pharmacy charges increased from 9% for those diagnosed in 1984 to 20% for those diagnosed in 1987. Among the deceased, 11% of total charges occurred in the last 6 months of life, 66% within the last 3 months. Inpatient variables associated with higher medical charges for all patients included: death, PCP diagnosis, length of follow-up, and hospital days. Last year of follow-up was associated with higher charges.

Conclusions: Identifying persons with HIV disease through insurance billing systems and estimating potentially needed in hospital based reports or those relying on patient recall. We report charges comprehensively low for survivors. Due to the long survival period of HIV disease, the impact of the importance of reporting completed or true lifetime charges (true diagnosis used death rather than observed charges which include patients still alive). Unlike prior results from California, significant differences in charges are not explained exclusively by different hospitalizations patterns or care.

**Session d'Affichage
Poster Session**



**Repercussions économiques de SIDA
The Economic Impact of AIDS**

T.H.P.7

**SCATTER AND VERSUS CLUSTER HIV TREATMENT OF AIDS
IMPACTS.** *Clair D. Strain J., Faba R., Sacks S.*
The Mount Saint School of Medicine, NYC, USA.

Objective: The Presidential AIDS Commission commented on the need to compile data from dedicated AIDS units and those using scattered placement with regard to quality of care and outcome. Many hospitals are converting beds to an AIDS unit to meet the needs of cost and benefit analysis. This preliminary study describes the outcome and charges of AIDS Unit (Cluster) and Scatter HIV Impact.

Methods/Results: Cluster (n=23) versus Scatter (n=27) patients were studied over the Mount Saint Hospital in NYC using the Utilization Information Service database over a 3 month period. Cluster patients were more likely than Scatter inpatients to be female (74.6%), have more comorbidities (p<.01), stay 225 (range 100-300) hospital (p<.01), and have higher charges (p<.05) (mean: \$9,422 vs \$6,493), and services - \$9,976 vs \$7,720). No differences in age, race, insurance, number of previous hospitalizations, completed infections, death rate, and discharge how were observed.

Conclusion: This preliminary study observed a significantly prolonged hospital stay and increased charges for Cluster patients compared to Scatter patients. Without significant differences in mortality and disability, home, Postoperative, and non-effectiveness studies of Scatter vs. Cluster units are required.

T.H.P.8

The Economic Impact of Early Intervention in HIV Disease
Patric Amos, Sharon D.F., Siegel N.M., Franks P., Lee P., Montefiore Med Ctr, Bronx, NY, USA, *Muhlbach, Chapel Hill, USA, Montefiore, CA, San Francisco, USA*

Objective: To assess the economic impact of providing early intervention services in HIV disease.

Methods: The prerequisites of an early intervention strategy were assessed. The number of individuals requiring early intervention was determined for New York, San Francisco, and the United States. The economic costs for requisite services, including HIV-antibody testing; serologic monitoring; counseling; drug treatment; and primary medical care were estimated. Results: Median estimated costs of early intervention beginning each year 1980-1991 (expenditures in millions of dollars)

	1988	1989	1990	1991
United States	4,078	3,070	3,602	3,200
New York City	627	595	567	531
San Francisco	66	82	75	67

Conclusion: There is a "window of opportunity" for effective early intervention in HIV disease because the majority of infected individuals are approaching the asymptomatic phase of illness. Planning for its implementation should begin immediately.

T.H.P.9

PATIENT PREFERENCE AND SATISFACTION WITH AIDS SERVICES

*Fitzsimons-Indiano, Margi; Miller, D.; Hernandez, S.; Resse, A.**

Department of Public Health, San Francisco, CA USA - *University of California, San Francisco, U.S.A.

Objective: To evaluate the accessibility and quality of services available to persons with HIV infection in San Francisco in order to plan for future needs.

Methods: The authors will utilize a questionnaire and follow-up phone interviews with a sample of persons receiving one or more HIV-related services in San Francisco. Recruitment of persons to respond to the questionnaire will be 1) persons utilizing services at SFHC or other Department of Public Health service sites including substance abuse programs serving PWAs, will be asked to volunteer and 2) an ad will be placed in local newspapers. The initial questionnaire will be closed-ended questions pertaining to prior utilization of services, housing and support, perceived gaps of problems with services, preferred type of service provider, source of insurance/payments, socio-economic data, and level of disability. The survey will be pretested with both providers and persons with HIV infections.

Results: Discussions about the long term needs of PWAs for planning purposes has indicated that the patient's opinion may vary from that of the patient. In some cases we believe that this may be due to a lack of information about the service and its availability. Some services have not been successful due to a lack of support from the person with AIDS.

Conclusion: In order to meet the needs of PWAs in the future in San Francisco, it is necessary to gather the direct input from persons utilizing the services. This information will ensure a responsive system of care.

T.H.P.10

HOSPITAL COSTS AND DRG REIMBURSEMENT FOR HIV ADISSIONS.

Ellis, Zilber, Heide, D., Perez, G. Johnson, E.S., Perez, E. Saint Michael's Medical Center, Newark, New Jersey, U.S.A.*

Objective: To determine impact of DRG system and admitting charges on hospital reimbursement for HIV admissions.

Methods: Retrospective review of 1987 admissions coded as HIV disease. Total admissions listed as self-payers studied in detail as well as admitting service.

Results: Total of 326 patients comprised 403 admissions. Of these, 310 were listed as self-payers. 70% of admissions were to the Infectious Disease Service. Of the 110 self-payers, 643 not able to reimburse the hospital. This resulted in a \$331,423 loss to the hospital. Only 13% of the Infectious Disease Service admissions with a Case Management System failed to reimburse as opposed to a 33% rate in the Medical Service group. Most of these latter admissions were emergency in nature.

Conclusion: Although losses occurred in the self-payer category, these can be minimized by prior infectious diseases and Case Manager involvement with a decrease in emergency type admissions.

T.H.P.11

SHIFTING TOWARDS AMBULATORY CARE OF AIDS PATIENTS - LESSONS FROM THE PCP EPIDEMIC.

Lange, J., Hershberg, R., Mahesh, L. and Ruedi, A. AIDS Research Program, St. Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.

OBJECTIVE: To describe the successful shift towards ambulatory care of patients with AIDS-related PCP. **METHODS:** Data was obtained from the Health Department and the Metropolitan Laboratory Services records at St. Paul's Hospital (SPH). The following variables were collected on a quarterly basis for 2 year period ending March 31, 1987.

1. Number of AIDS-related PCP cases diagnosed
2. Number of AIDS-related PCP cases admitted to hospital
3. Length of hospital stay of AIDS-related PCP cases.

RESULTS: The number of PCP cases diagnosed at SPH increased steadily from the from the 2nd quarter of 1986 (56/2) to the 3rd quarter of 1987 (17/3). Over 17.3% cases. Hospital utilization for PCP cases followed the same pattern (from 273 to 276 hospital days). At this time, a major effort was undertaken to encourage a shift towards ambulatory care of AIDS patients. This was generally facilitated by the opening of an HIV dedicated ambulatory care facility in mid May 1987 and specifically in the use of PCP, by the introduction of a new antipneumococcal, the wider use of PCP prophylaxis and the availability of hospitalization. Although SPH continued to care for over 70% of all AIDS cases in the province, the number of PCP cases admitted at 22 per quarter. Approximately 20% of them were successfully treated on an outpatient basis while the rest required hospitalization for varying periods of time. As a consequence, the hospital bed occupancy for the last 3 quarters of the study, dropped from 220 to 200 per quarter. Average length of stay per diagnosed case of PCP also decreased from 16.6 days (86/7) to 17/7 (for the period to 11:20 days for the last 3 quarters of the study).

CONCLUSIONS: The present study demonstrates the feasibility for implementation of ambulatory care programs for specific groups of AIDS patients. This lesson from the PCP epidemic should be expanded to aid in the shift towards ambulatory care of AIDS patients.

T.H.P.12

HEALTH CARE COSTS OF CLASS 4 REVA CRT IN HOME SETTING

Anderson, Kathleen G.; Shelds, A.; Reva, T.; Mehler, M. Ch. Y.; Thompson, L.L.
Group Health Cooperative of Puget Sound, Seattle, Washington, U.S.A.

Objective: To identify the health care costs and service utilization patterns with CDC Class 4 HIV conditions from January 1987 to June 1988 at Group Health Cooperative (GHC), an HMO with comprehensive medical coverage.

Methods: A database tracking utilization and revenue costs was used to identify all patients in a sample of 13 homosexual/bisexual males (age 38 mean) with CDC Class 4 HIV disease from January 1987 to June 1988. 86% (71) had an AIDS diagnosis; 14% (12) had other Class 4 HIV conditions. All 83 had a total of 1177 contacts with the health care system. 89% (77) received AZT all or part of the time. Results were compared to age and sex matched control sample randomly selected from all GHC enrollees.

Results: GHC's estimated annual costs for all services are \$211,139/person. In the AIDS sample, \$640 for the control sample and \$1,032/person for all GHC enrollees. In the HIV sample, costs were 55% inpatient, 7% primary care, 16% specialty care, 15% outpatient pharmacy, 4% laboratory, and 5% other. Assuming a survival range of 18 to 24 months, a range of diagnosis-to-death costs for PWAs is estimated at \$31,700 to \$42,200. Average length of hospital stay was 10.5 days (with a mean of 140 days) comparable to the Washington State average of 11 days. GHC's primary care MD's manage HIV cases with specialty consultation when needed. Primary care visits are 11 times greater than in controls. Eight specialties (infectious disease, pulmonary, oncology, radiology, therapy, dermatology, ophthalmology, E.R. medicine, and surgery) were utilized to a greater extent than primary care.

Conclusions: Accurate information about the costs of AIDS care and utilization profiles are powerful tools for HMOs and hospitals to use in budgeting manpower and bed projections and long range planning, particularly when coupled with estimates of future caseloads.

* Reported by post to the National AIDS Director, Department of Health, Ottawa, Canada.

**Session d'affichage
Poster Session**



**Reperçussions économiques du SIDA
The Economic Impact of AIDS**

T.H.P.19 **MEETING THE NEEDS?**
Cooper, Jonathan, Director of Programmes, United Kingdom, Haemophilia Society, WINDLE KINGDOM

Objectives: To assess the needs of people living with HIV and examine financial provision made by the State for individuals and their carers.

Method: The weekly living costs of people with symptomatic HIV infection were assessed. An investigation of need compared to existing state benefits was made. Benefits examined were income related, non-contributory and non-contributory based.

Results: Personal needs per week for single person living with AIDS under 25 years old, on top of regular living costs = 65.22 Pounds.

Income Related Benefits Available:
Income Support - 13.05 Pounds
Non-Income Related Benefits Available:

Mobility Allowance: 23.05 Pounds
Attendance Allowance: (Lower rate) 22.00 Pounds
Invalid Carer Allowance: 24.75 Pounds
Invalidity Benefit: 41.15 Pounds

Severe Disablement Allowance 24.73 Pounds
Conclusion: The only benefits in the U.K. applicable to meeting the needs of people with symptomatic HIV infection is the 13.05 Pounds Disability Premium. This premium is only available to those with no or virtually no income. As well as being inadequate the premium also has a qualification period

T.H.P.20 **ACCESS TO INSURANCE AND PERCEIVED DISCRIMINATION BY HOMOSEXUAL MEN**
Kane, Nancy, Johns Hopkins University, Baltimore, Maryland, U.S.A.

Objective: 1) To compare access to health life and disability insurance among homosexual men who are seropositive, seropositive or have AIDS; 2) to compare perceived discrimination in employment and in medical/dental treatment.

Methods: Self-administered questionnaires were distributed to Baltimore and Los Angeles MACS participants between October 1987 and December 1988. Questionnaires also were distributed to supplemental samples of AIDS and subacute patients (the latter as a comparison group) at the Johns Hopkins Hospital.

Results: Analysis of the first 288 of 1900 subjects revealed the following results:
Baltimore N=1,448 Los Angeles N=100 % HIV+ AIDS

Has any health insurance
or Medicaid

90%	80%	100%	90%	90%	70%
-----	-----	------	-----	-----	-----

Was asked about previous HIV testing or required to be tested by insurance company

4%	6%	-	2%	5%	10%
----	----	---	----	----	-----

Asked about health insurance
type for being gay

3%	12%	-	8%	10%	11%
----	-----	---	----	-----	-----

Discriminated by a doctor or dentist

4%	9%	-	0%	10%	30%
----	----	---	----	-----	-----

Conclusions: Persons with AIDS are more likely than seropositive or seronegative persons to be uninsured, to have been turned down for health insurance and to have been refused medical or dental treatment. Seropositive perceive more discrimination by doctors and dentists than do seronegatives.

T.H.P.21 **COSTS OF HOSPITALIZATION FOR AIDS PATIENTS AT A COMMUNITY HOSPITAL IN CONNECTICUT**
Lynn, Robert W., Medford, G and Costanzo, R. St. Francis Hospital and Medical Center, Hartford, Connecticut, U.S.A.

Object: To determine the cost of in-patient care for patients with AIDS (PWA) at community teaching hospital in the northeastern United States in fiscal year (FY) 1988.

Methods: All PWA admitted are known to the Infectious Disease department. Detailed billing records of all PWA admitted from 10/1/87 to 9/30/88 were obtained from accounting department.

Results: 51 PWA had 108 admissions. The average length of stay (ALOS) per admission was 13.7 days. (The ALOS for all 23122 admissions in FY 1988 was 7.5 days).

The cost for PWA was \$379,462 - \$8,143/admission or \$17,744/PWA/year. The largest cost was for room, \$473,199, and includes \$11,480 for 10 admissions totaling 210 days as in ICU. Laboratory costs were \$126,782.

The total reimbursement received was \$434,140 for a loss of \$44,331 - a loss of \$412/admission or \$8727/PWA/year. Reimbursement sources are shown:

Source	No.	Payments	Per/diem	Loss
State Welfare	64	124,208.66	2097.79	36,173.28
City Welfare	17	62,086.66	3653.36	61,404.33
Insurance	20	31,968.25	8090.09	24,031.56
Self Pay	3	21,094.63	7068.21	(8,957.79) gain
FMGO	4	54,307.00	13,626.75	1,246.26

Conclusions: As the number of indigent PWA increases the financial burden on community hospitals will become unbearable unless more money is allocated for patient care and more out-patient facilities are developed.

T.H.P.22 **HOW DO PERSONS WITH SYMPTOMATIC HIV DISEASE FINANCE THEIR CARE IN TEXAS**
Crane, Martha, "Infectious D", Miles A*, Jarolim L*, 30365SD 75474

*University of Texas Health Science Center at Houston, Texas, U.S.A.
**Southwest Texas University, San Marcos, Texas, U.S.A.

Objective: To determine utilization of medical and social services and payment by persons with HIV infection in the State of Texas.

Methods: An anonymous self-administered survey of HIV-infected persons in selected urban areas of Texas was undertaken in fall 1988 at the request of the State Legislative Task Force on AIDS. Participants identified through physicians, AIDS service organizations and other care providers were given surveys that were mailed back either to the investigators or the Task Force office. Forty percent (40%) of those distributed were returned.

Results: Respondents included 71 asymptomatic (65), 81 symptomatic (53) and 287 AIDS patients. All AIDS patients had seen a physician at least once in the three months prior to the survey (avg 7.0 visits) and 41% had been hospitalized. There was heavy utilization of dentists and various counseling services. Between the time of first HIV-related diagnosis and the survey, the proportion of employed AIDS patients decreased (from 83% to 23%); as did the proportion with private insurance (from 60 to 41%); the proportion relying on public and indigent care exclusively increased (from 8 to 21% and from 5 to 21% respectively). Of AIDS respondents, 33% had spent all their savings on their illness and 44% were unable to pay for prescription drugs. A similar pattern was present for 53 respondents.

Conclusions: As illness progresses, an increasing proportion of once prosperous persons are forced on the indigent care system in Texas.

T.H.P.23 **HEALTH INSURANCE STATUS AND THE UTILIZATION OF HEALTH SERVICES BY A COHORT OF IV DRUG USERS**
Bolton, Lisa, Frank R, Coleman D, Vishaw B, Cobb S, The ALIVE Study, The Johns Hopkins School of Hygiene and Public Health, Baltimore MD, USA

Objective: To identify the patterns of health service utilization and the financing of outpatient health care services in a population of HIV positive and negative IV drug users (IVDU).

Methods: A cohort of IVDU, recruited into a natural history study of HIV infection were interviewed to determine the type of health services used, and the means of financing these services. Persons with AIDS were excluded from recruitment. Correlations between HIV serostatus and type of insurance were examined.

Results: Among the first group of 805 respondents, 84 (21%) were HIV positive (HIV+ and 80 confirmation). Forty-three percent of the study population had at least 1 outpatient visit within the past six months.

Sixty-three percent of these visits were hospital based. Nine percent had a hospital admission. Presently 88% of the population is covered by Medicaid. Medicaid coverage did not vary by serostatus.

Conclusions: The numbers of HIV positive IVDU who do not have insurance suggests additional planning for an increasing Medicaid population if indicators. Further, this population's preference for using hospital based facilities, frequently emergency rooms, will continue to burden these facilities and be costly to the system.

T.H.P.24 **THE SHARE OF AIDS MEDICAL CARE COSTS PAID BY PRIVATE INSURANCE IN THE UNITED STATES**
Katz, Charles, Health Insurance Association of America, U.S.A.

Objective: To assess the merit of alternative sources of data on the distribution of AIDS medical costs among various payers in the United States.

Methods: The most widely cited estimates of payer shares were those developed by Andrus, et al, based on surveys of public and teaching hospitals, and estimates of the Medicaid share developed by the Health Care Financing Administration. However, data from the National Hospital Discharge Survey, and data from local hospital associations appear to conflict with these widely cited estimates. This presentation reviews the strengths and weaknesses of all of these data, in an effort to identify the best estimate of payer share and the degree of uncertainty attached to it.

Session d'affichage Poster Session



Répercussions économiques du SIDA The Economic Impact of AIDS

Pays en voie de développement Developing Countries

W.H.P.1 COSTS OF TREATING AIDS PATIENTS IN AFRICA
Makins, Mary; Wong, H. Abt Associates Inc.,
Washington, DC, United States.

Objective. To assess the direct costs of treating AIDS patients in Africa and to determine patterns of treatment of the disease.

Methods. A methodology has been developed to estimate the direct costs of treating AIDS patients at selected health care facilities in African countries and to obtain information about the indirect costs of the disease to the patient population. Such retrospective studies have the advantage of being fast and inexpensive compared to prospective studies, and will provide important baseline data as a foundation upon which future studies can be built. Data will be collected on initial and subsequent diagnosis, number of visits and admissions to health facilities, length of stay for admissions, and costs of providing health services in the facilities. This information will be obtained from patient records, salary histories, and investigation at health care delivery sites. A questionnaire will be administered to the sample population to estimate the costs to the patients of treating the disease outside of the health care facilities, including charge per visit, charge per hospital stay, and charges for drugs.

Results. Information will document the magnitude and incidence of the costs required to treat the disease.

Conclusion. Such a methodology will help decision makers to weigh the costs of treating the disease against the costs of treating other patients; to develop cost effective treatment protocols; and to prepare for the anticipated growth of the epidemic.

W.H.P.3 DIRECT MEDICAL COSTS OF AIDS IN LATIN AMERICA AND THE CARIBBEAN: MORE COST-EFFECTIVE MODELS
George Gagliardi, Y. Koum*, F. Zaccaria**, D. Shepard***,
S. Zetomayor*, San Juan AIDS Institute, San Juan, Puerto Rico **Harvard Institute for International Development, Cambridge, MA ***Pan American Health Organization, Washington, DC ****Harvard School of Public Health, Boston, MA, U.S.A.

Objective. To describe, compare and analyze the estimates of the direct medical costs of AIDS patients available to present in Puerto Rico, Dominican Republic, Mexico, Costa Rica, Brazil and Argentina, and to analyze the policy issues related to the respective health care delivery systems.

Methods. A compilation and comparison of all costs related to out-patient and in-patient care for AIDS patients available from official sources of the six countries, was followed by an analysis of how these costs related to the respective systems for financing and delivery of medical care.

Results. The availability of different types of services varied among countries. Length of hospital stay, costs per patient per year and share of hospital cost in the total cost of services, when comparable, were significantly higher in those places where treatment was mainly hospital-based and a comprehensive approach was not available.

Conclusion. A comprehensive system of health care including ambulatory, extended, home and hospice care provides a more cost-effective approach to the management of AIDS patients and may be applied in other LDC nations. Cooperation among nations to share their experiences in developing cost-effective models to contain the costs of AIDS and to maximize the utilization of available resources should be promoted.

W.H.P.5 Economic Analysis of AIDS in Puerto Rico
José J. Alameda-Lezand*, Alfredo González-Nortea**
Assistant Professor of University of Puerto Rico at Mayaguez,
*Professor of University of Puerto Rico at Mayaguez

The authors attempted to assess AIDS epidemic from the economic point of view. Specifically, they determined whether the economic burden of the disease is heavy. It should be pointed out that Puerto Rico depicts high levels of AIDS prevalence rate as compared with other Latin American island Republics during the fifty states. The ratio between the Latin American countries only Brazil) surpassed the number of cases per million inhabitants in Puerto Rico.

The estimated economic costs consist in two main categories: Direct costs and indirect (implicit costs). The direct costs include medical care and research & education expenditures. Indirect costs include the income losses due to illness and disability (morbidity) as well as present values of future earnings lost by premature death (mortality).

A striking result from the study is that the main economic impact of AIDS between 1981 to 1988 is due to indirect costs rather than direct costs. The former accounted for over 80 percent of total estimated economic costs. The reason for this high indirect costs is attributed to the fact that most of the victims of AIDS are young persons. In 1988, 72 percent of AIDS victims are in 20 to 39 year age bracket, and thereby, in their most potentially productive years. The average age for AIDS victims is 24 years. Finally, the authors forecasted economic costs for the fiscal years 1989 to 1992 using a discount rate of 5 percent.

W.H.P.2 HEALTH-CARE COST OF AIDS AT A HOSPITAL IN CANTON TAIWAN
ANAN, HANJIN-Hsiangse, P. Hsuife, J. H. Odean, R. Antolin, J. J. Aorta, et al.
Hospital Rostrer Belcora del Pao-Lao Palmas-Spain.

Objective. To evaluate health-care burden of AIDS and AIDS-related conditions on our Hospital.

Methods. Review of clinical records of HIV-infected patients admitted to Hospital or attended at the outdoor clinic from Jan-1987 until Nov, 1988.

Results. Number of HIV-infected: 144. Number of AIDS cases: 20.
Duplication time of AIDS cases: 8 months. AIDS cases dead: 17 (35%)
Main risk-factor for AIDS: Male homo-bisexuality (50%), and parenteral drug abuse (20%). Main opportunistic infections: PCP (30%), PJP (30%) and candidal oesophagitis (36%).

Number of AIDS-related admissions: 182. Mean delay from admission to definite diagnosis of suspected infections: 13 days. Mean length of hospitalization: 13 days. Number of invasive procedures per admission: 1.4 (surgery: 0.40, or endoscopy) cost per admission: \$13,000 pesos (720 US\$).

Conclusion. AIDS cases are rapidly increasing in our Hospital area. Our AIDS cases are mainly homo-bisexual males and parenteral drug abuse. Tuberculosis is a leading opportunistic infection in our AIDS patients. It is necessary a plan for reducing pre-diagnostic time, length of hospitalization and health-care cost.

W.H.P.4 COMPARATIVE COSTS OF AIDS CARE IN PUBLIC AND PRIVATE SETTINGS
Kopari, L. J.; Shepard, D.; Rieak, K. J.; Rieak, J. L.***; Smith, S.; Varney, J. A.
**Harvard Institute for International Development, Cambridge, MA, USA,
***University of Puerto Rico Medical School, San Juan, PR.

Objective. To identify the cost advantages of public and private settings for AIDS patient care more cost-effective.

Methods. We assessed retrospectively the cost of AIDS care in 34 consecutive episodes of hospitalization in a private hospital and 245 in a public hospital in San Juan, P.R. in 1987-88. This area has many characteristics of a middle-income developing area. Types, amounts, and unit costs of services were abstracted from medical records and cost reports using identical protocols.

Results. The average length of stay was 16.4 days in the private hospital and 17.5 days in the public hospital. The cost per day averaged \$200 in the private hospital and \$140 in the public hospital. Patterns of care appeared similar. In 1988, however, after private management and incentives had been introduced in the public hospital, the average cost per day was reduced to \$190.

Conclusions. The private hospital appeared to provide care more efficiently through a lower daily rate, earlier discharge, and more efficient use of skilled services. Good management can improve the efficiency of care of patients with AIDS.

W.H.P.6 THE ECONOMIC AND SOCIAL IMPLICATIONS OF AIDS IN AN AFRICAN SETTING
Mwambi, Patrick, Mwenya, N., Kabonjo, L., M'kololo, K. and M'wambi, Jaine

**Department of Pathology, New York Hospital, and *Ministry of Health, Kenya.

Objective. To evaluate the economic and social impact on families of children with AIDS.

Methods. We reviewed the economic status of 84 families of children with symptomatic AIDS admitted to a state subsidized teaching hospital and the social interaction of the community toward the afflicted family.

Results. 39 percent were low education employees, 42 were unemployed and 3 had already died. The average hospitalization was 24 days with 23% mortality. A single hospitalization was 4 times and funeral expenses 11 times the average monthly income. Those who were employed received assistance from their employers for medical expenses and burial, however, when expenses were supported by the family. African tradition requires a dignified and respectful funeral which entails considerable expense. The unemployed depended on family and friends for financial assistance. The most remarkable observation was the community's response to the afflicted and their families. A world process was observed: the community was tolerant and accepting of AIDS patients; extended families, friends and neighbors gave an abundance of moral support and contributed toward the medical care costs and funeral expenses.

Conclusion. The AIDS epidemic has placed a financial burden on the society. In the face of economic crisis, Africans continue to show a strong social solidarity, acceptance and goodwill towards AIDS patients and their families. In the case of Kenya, the community contributes toward the funeral expenses.

Session d'affichage Poster Session



Répercussions économiques du SIDA The Economic Impact of AIDS

Méthodologie des coûts Costing Methodology

W.H.P.7

HOW COST-ANALYSIS UTILIZES INFORMATION
Murray, Sheila, MD, BSc, J. Johnston, J. Gosselin, BV, G. Davis, BSc(Ed)***, *Harvard Medical School, Boston, U.S., **McGill, St. L. Health Sciences Center, Boston, U.S., ***Health Costs Model Development, Boston, U.S., USA

OBJECTIVE: To provide a means (anatomically) (Viral) case management system utilizing personal computer(PC) in the healthcare setting.
METHOD: Perinatal Research Hospital(PRH) is the largest medical provider for all isolated patients in Dallas County, TX, with an active caseload of 500 patients out of 1500 total. There are three major components to the data collection system: clinical, accounting and AIDS Registry. The AIDS clinic utilizes 4 clinics (A in a local area network to maternal clinic) and research data. The Maternal Services Department maintains data on a single AIDS PC on all HIV related hospitalizations. The Hospital Inpatient Service Department utilizes its admission computer to report HIV related data to the incident of service (investigations, charges and collection).
RESULTS: An clinic database secure and sensitive patient data to enhance treatment, medical insurance and research. It also serves as a real-time report of practice immediate access to data for telephone consults and interviews with community healthcare providers. Retrieving the maintainers' facilities/organizations to track total service utilization by age section.
CONCLUSIONS: Attainment of quality case assessment through an enhanced information system. Total cost reduction through data analysis/forecasting of costs, clinical treatment and collection of epidemiological information. This system is utilized by Administration, Nursing Management, Clinicians, Quality Assurance, Infection Control, Business Services and Public Relations.

W.H.P.9

SOCIO-ECONOMIC MODELS TO ASSESS THE ECONOMIC IMPACT OF HIV INFECTION
Kahn, John
McGill Centre for Medicine, Ethics and Law, Montreal, Quebec, Canada.

Objective: To propose two comprehensive models that could be applied in the assessment on an international scale of the economic impact of HIV infection.
Method: A review and comparative analysis was carried out of existing literature on the economic impact of HIV infection, drawn from four countries (Canada, U.S., Australia and U.K.).
Results: The literature varied considerably with respect to its acknowledgment of the ways in which costs might be affected by:
1) **Geographic Differences:** local, regional and international, e.g. with respect to incidence and prevention, modes of transmission and manifestation of pathology.
2) **The Effects of Change:** e.g. in disease definition, in treatment and diagnosis, in health care system, funding and utilization, and in the availability of human and natural resources.
3) **Other factors:** e.g. absence of an explicit conceptual framework, models and methodologies. This lack of explicitness limited meaningful comparability.
Conclusions: Two comprehensive models are defined:
Model 1: The Order of Costs: This model delineates three 'orders' of costs: First Order (Medical Costs, Care and Containment); Second Order Costs: foregone earnings, household services, labour and expertise, research, construction and property; Third Order Costs: 'psycho-social-cultural'.
Model 2: The Cascade Effect: This model delineates seven 'levels' of cost: individual, immediate support system, community, institutional, government, society, and international. The possible advantages or disadvantages relating to the development and use of a standardized, international approach in determining economic impact of HIV infection will be discussed.

W.H.P.11

FINANCIAL BURDEN OF FINANCING OF HIV TREATMENT
Mullaly, Julia* MD Department of Health and Mental Hygiene, Baltimore, MD U.S.A.

Objective: The financial burden of HIV treatment is shared among Federal, State, and private payers. It has been difficult to assess, however, the distribution of this burden among payers during the course of the AIDS epidemic. This paper applies a novel HIV information system to measure temporary, long-term, and community-based HIV-related treatment across payers. **Methods:** Institution and community-based services used by 1,300 Maryland residents with AIDS diagnosed between 1985-1989 were retrospectively tracked to information system made up of longitudinal, person-based files served as the basis of this study. The system links HIV registry, vital statistics, hospital and community-based services, and insurance claims records to measure the nature, value, and costs of AIDS treatment during the period between diagnosis and death. **Results:** Volume of AIDS treatment, associated costs, and payer mix are examined during the course of illness. Inflation-adjusted costs, charges, bills, and payments made by Federal and State payers are measured. Unreimbursed services generated by the difference between charges, bills, and payments are estimated. The proportional distribution of the financial burden of HIV-related treatment and level of reimbursement provided by public and private payers is reported for the 5-year period studied. **Probability of shifting from private to public financing is estimated, and shifts from State to Federal assistance categorized during the course of illness. Factors associated with shifts in payer, insurance characteristics and risk group, are also discussed. Conclusions:** Findings of this study are useful to policy makers and health insurers in projecting the financial impact of the AIDS epidemic.

W.H.P.8

DIRECT COSTS AND FINANCING OF HIV TREATMENT AND COMMUNITY-BASED TREATMENT
Mullaly, Julia*

MD Department of Health and Mental Hygiene, Baltimore, MD, U.S.A.
Objective: The economic impact of HIV on the U.S.A. health care system has been difficult to measure. This paper applies a novel, automated HIV information system to measure and direct costs of HIV-related treatment across providers and payers. **Methods:** Institution and community-based services used by 1,300 Maryland residents with HIV infection during the period between 1985-1989 were retrospectively studied. An automated information system made up of longitudinal, person-based files served as the basis of this study. The system links HIV registry, vital statistics, hospital, long term and chronic care, and community-based services, and public and private health insurance claims records to measure the nature, value, and costs of service use associated with HIV treatment during the period between diagnosis and death. **Results:** HIV-related costs are estimated for treatment of AIDS and AIDS. Inflation-adjusted average lifetime, annual, and per visit costs, as well as components of costs, are reported. Trends and the difference between costs, charges, and payments are described, as well as shifts in payment source during the course of illness. Factors including socio-demographic characteristics, transmission group, survival time, and case and service-use are also discussed. **Conclusions:** Findings of this study are useful to policy makers at the local, State, and Federal levels in planning services and financing required to meet the needs of persons with HIV disease.

W.H.P.10

HIV INFECTED HOSPITAL PATIENTS IN NEW YORK STATE (NYS): THE CREATION OF LONGITUDINAL INFORMATION FROM A HOSPITAL DISCHARGE DATA SET
Kaufman, GI, Orabau, JC, Norick, L, Yan, Y, Schmidt, E
New York State Department of Health, Albany, NY, USA

Objective: To obtain longitudinal information regarding HIV infected patients in NYS acute care hospitals, useful for describing HIV related acute care needs.
Methods: Identified medical records of patients discharged from NYS acute care hospitals between January 1, 1983 and October 1, 1987, which contained a diagnosis of HIV infection (86,864) were linked into a longitudinal file (HLVLF) of patient specific cases (25,000). The records do not contain explicit personal identifiers, so linkage was accomplished using hospital code, medical record number, sex, date of birth, address, and payer identification codes.
Results: A validation study utilizing 1985 Medicaid discharge information indicated: the HLVLF cases contained 85% (SE±2.2%) of the expected discharge; the number of HIVLF cases was too large by 10% (SE±2.2%) due to a failure to link all the discharges to the appropriate cases.
The number of new HIV patients (HIV infection identified for the first time), entering the acute care system increased monotonically on a quarterly basis from 1984 through 1986. In the first quarter of 1984, 421 new HIV patients utilized the acute care system, as compared to 1899 in the last quarter of 1986. During the first year of acute care, new HIV patients in 1984 or 1985 exhibited an average of 1.6 admissions, and a mean total of 30 inpatient days. During this first year, patients with multiple stays had longer first and last stays as compared to intervening stays. As the number of stays increased the period between stays decreased and the length of stays of each admission decreased. **Conclusions:** The HLVLF is of sufficient quality to be useful for estimating acute care resources required to respond to the HIV epidemic.

W.H.P.12

A PROJECTION FUNCTION APPROACH TO ESTIMATING THE ASSUMED ASSOCIATED IMPACT OF AIDS
Mullaly, Julia*

MD, BSc, PhD, Department of Health and Mental Hygiene, Baltimore, MD, U.S.A.
Dell, David, PhD, Center for Health Services Research, University of California, Los Angeles**Harvard University, California.

OBJECTIVE: To combine demographic projections of the HIV epidemic's impact on population size and structure with economic projections of impact on gross domestic product (GDP) in order to estimate the epidemic's impact on per capita GDP.
Methods: Based on previous modeling of the population dynamics of the disease by one of the author's and on appropriate projection functions for sub-Saharan Africa which incorporates measures of human capital, the paper estimates the future course of both the GDP and the population under a variety of alternative assumptions. Sensitivity analysis is performed with respect to the size of the epidemic and with respect to the amount of human capital assumed to be affected individuals.
Results: Results are presented for the epidemic's impact on GDP growth rates and GDP per capita and compared with those of a naive model using a constant growth rate per HIV-infected person. The discounted present value of losses due to the infection of a single individual with HIV are estimated under several disease rates.
Conclusions: The AIDS epidemic is affecting most negatively certain sub-Saharan African countries that are already experiencing slow or negative rates of per capita GDP growth. This paper estimates the degree to which the AIDS epidemic can exacerbate the growth problems of the most severely affected economies.

Session d'attaché Poster Session



Résumés économiques du SIDA The Economic Impact of AIDS

W.H.P.13

A REGIONAL-AREA MODEL FOR THE ANALYSIS OF THE ECONOMIC IMPACT OF AIDS IN SUB-SAHARA AFRICA

Author: P. Gervais, L.M. Dyer, M.***
*Northwestern University, Boston, Massachusetts; **Harvard University,
North and South, Washington, D.C.

Objective: This study presents an internally consistent view of the sectoral-macroeconomic repercussions of the epidemic on the labor market, on the production sectors and hence on the entire economy of a "typical" sub-Saharan African country.
Method: The study characterizes the AIDS endemic as a shock to the supply of labor of several (12) categories in several different productive sectors of a "typical" sub-Saharan African country. The study uses a complete regional multiplier model order to represent this shock, and the effects will be reported to the various sectors and the flexibility of this system along in adjusting to such shocks, and it will be possible to predict the internally consistent effects.
Results: The study estimates the effect on sectoral-macroeconomic performance of 12 different situations regarding the distribution of the epidemic across skill categories of labor. The paper identifies the critical role of AIDS epidemic in each general equilibrium method. This study uses in this paper five substantially different estimates of the macroeconomic impact, then would the sectoral-multiplier equilibrium method. Results are presented for the epidemic's impact on such macroeconomic aggregates as current account balances as well as for total GDP.
Conclusion: Because the study shows that aggregate macroeconomic impact of the epidemic can be considered to be severely affected African country, expenditures on domestically effective preventive measures are justified. Furthermore, the study shows to what degree such policies of source prevention strategies of AIDS may have a more beneficial effect on macroeconomic performance than others.

W.H.P.15

DECLINE OF AIDS INCIDENCE IN KENYA

L.N. MUTHARI* DR. N.K. AGATA, **DR. G.S. GACHIEI, **DR. G.O. MBOGUA
*KENYA MEDICAL RESEARCH INSTITUTE NAIROBI, KENYA
**KENYATA NATIONAL HOSPITAL NAIROBI, KENYA.

Objective: To reduce and control the spread of HIV infection in Kenya.
AIDS: By August 1988, 2378 cases of AIDS had been reported cumulatively by all the Health Facilities in Kenya. Data from three provinces that have been reporting consistently over a period of 18 months were compared with national figures - Graphical plots, linear trends and predictive models were fitted to the data.
Results: The rate of change for the national figures over the 18-month period show an increasing trend. But comparing 1987 and 1988 there is a definite drop in the number of the new cases reported. At the province, a significant improvement observed in 1987, but the curves had asymptotic tendencies in 1988.

If the 1987-8 rate of change was sustained over 1988-9 the predictive models show a slight increase in the number of cases in Nairobi (425 in 1988 to 509.22 in 1989); a drop in Kwana (208 in 1988 to 142 + 24 in 1989); and a drop also at Coast (208 in 1988 to 85.2 + 24 in 1989).

Conclusion: The National figures are likely to stabilize or drop after the provision of testing kits, for HIV in all the district Health facilities (currently 30/41) and the current campaign against AIDS.

W.H.P.17

A MODEL FOR EVALUATION OF UNKNOWN FRESH HIV-INFECTED PERSONS
M. HALLIN, Anders Brattler, M.
National Bacteriological Laboratory, Stockholm, Sweden

Objective: Evaluation of the extent of unknown HIV-infected persons in Sweden and a method used for this purpose.

Methods: Use of information collected by two report systems in Sweden concerning HIV: 1) Reports of HIV-infected persons (coded) initiated in 1985; 2) Reports of cases fulfilling criteria for AIDS since 1983.

Results: Of 228 AIDS cases diagnosed in 1985 to 1988 (22, 51, 68 and 87 cases in respective year), 59, 37, 25 and 311 were diagnosed during the four respective years in connection with the first HIV test, i.e., within 3 months of the test. However, there were considerable variations in different groups. In 1988, all hemophiliacs and IV drug users and the majority of the blood transfusion recipients had been known as seropositive for more than a year before the AIDS diagnosis while those infected heterosexually or homosexually 12 respectively 20% were diagnosed as seropositive in connection with the AIDS diagnosis. Several of these persons were people coming directly from abroad.

Conclusion: The findings indicate that among hemophiliacs, blood transfusion recipients and IV drug users few of those infected in the early 80ies are not yet detected. However, heterosexually or heterosexually infected in the early 80ies, a number of individuals have not yet been tested for HIV antibody status. A further extension of this kind may contribute to the estimation of unknown HIV-infected persons.

Modélisation mathématique et prévisions Mathematical Modelling and Predictions

W.H.P.14

THE SOCIOCULTURAL AND ECONOMIC IMPACT OF AIDS ON SOCIETY

BOOK, Frans M. van den Dijk, Jager, JCM*, Reining, BP*
*Netherlands Institute of Public Health, **National Institute of Public Health and Environmental Protection, The Netherlands.

Objective: Investigation and analysis of the present and (possible and predicted) future situation(s) of the three mutually dependent AIDS-epidemics: the infection with HIV, the AIDS epidemic and the epidemic of reactions and answers -social, cultural, economic and political- to the AIDS and HIV epidemics.

Methods: A scenario-project can be separated into three components: -definition of the existing situation (basis analysis) by means of description and interpretation of the three AIDS epidemics as they exist at present -the development of a number of future perspectives, as an alternative of the present situation

-scientific research into a series of events that could lead to the future perspective with an indication of connecting pathways

Scientific research makes use of data already collected
Results: A differentiation is made into three aspects: epidemiological aspects; economic aspects; sociocultural aspects. A model for the description of the course and the scope of the HIV epidemic is conceived. This model, has the epidemiological aspects as reference point. The epidemiological aspects will serve as basis and background for the determination and assessment of the influence of the AIDS and HIV epidemic on society.

W.H.P.16

THE USE OF RANDOM GRAPHS IN MODELLING THE TRANSMISSION DYNAMICS OF HIV-INFECTION

Philippe Beaudouin P. Bob, T. Kijger
Rahabji Ri Yvicki, Stockholm, S-14030 Stockholm 1, FRO

Objective: To develop a mathematical model for the spreading of sexually transmitted diseases being able to account for the characteristic features of HIV-infection. This model mathematically resembles standard models studied so far to compare simulations based on this approach to data with seroprevalence results in the case of AIDS.

Methods: Based on two concepts: a random graph, representing the mesh of sexual contacts inside a society, and a discrete time stochastic process, describing the spread of infection on the graph, the model incorporates specific assumptions through specifications on the structure of graphs and on the dynamical process. Probabilistic and combinatorial methods lead to algebraic tractable model structures, while direct computer simulations deal with realistic scenarios.

Results: Even, the general basis of the modelling approach is described, it is shown how a variety of important details can be incorporated, and how it relates to standard epidemiological models; it is discussed how it may be used in public health planning to predict the effects of certain prevention strategies, a problem which can only be solved by a model capable of handling internal balances.

Conclusion: This new approach to the epidemiology of sexually transmitted diseases leads to predictions different from standard epidemiological models; it is versatile enough to account for the particularities of HIV and it allows for a detailed description of the dynamics of the transmission process; it will be extensively adapted, in its specific application, to reflect the actual state of knowledge about the epidemiology of AIDS.

W.H.P.18

HIV Carriers: Non-Infectious Initial Interval Shows up Spread of Virus
GONZALES, Jose J.,* Davidson, P.,** Mos, C.E.,***
and Koch, M.C.,****

*A&A, N-4185, Arundel, N.M.V., Bergen, N-5000 Bergen, **AAH, N-4601 Kristiansund, Norway, ***VAC, S-546 00 Karlsborg, Sweden.

Where the HIV is sexually transmitted, an increasing number of cases have been observed with a seroconversion latency period lasting 1 to 3 years and longer. In young HIV carriers, these appear to be initially non-infectious or very slightly infectious. Transmission of the HIV through transfusions of seronegative blood have shown, however, that seronegative HIV carriers become viraemic before seroconversion. Recent evidence suggests that the degree of infectiousness increases with the duration and progress of the infection.

Mathematical models show that a non-infectious initial interval causes a surprisingly long delay in the spread of the HIV, and thus a slowing down of the epidemic. During a temporary phase which can last for many years, depending on the length of this interval, the incidence of HIV carriers remains low; it appears as if the disease is spreading in a less infectious form. Our models take into account heterogeneous sexual behavior, import and export of persons and infections, and variable patterns of infectiousness. Sensitivity analyses show that the non-infectious initial interval has a considerable influence on the dynamics of the spread of the HIV.

Session d'affichage Poster Session



Répercussions économiques du SIDA The Economic Impact of AIDS

Affectation des ressources Resource Allocation

Th.H.1.P.1 AFFECTATION DES RESSOURCES MONÉTAIRES (C-3AM)
Lise Lefebvre, Directrice générale, Comité SIDA Aïe Montréal,
Montréal, QC, Canada.

Objectif: Faire part aux congressistes de la distribution des ressources financières attribuées par les différents paliers gouvernementaux aux organismes sans but lucratif au Québec en matière de SIDA.

Méthode:

- Exposition/conférence
a) distribution gouvernement fédéral
b) gouvernement provincial
c) autres ressources
d) répartition interne

Résumé: Les services offerts selon les arguments obtenus tout en étant respectueux de la mission et des objectifs de l'organisme.

Conclusion: Évaluation du rendement selon les ressources financières pour 1983-1989.

Th.H.1.P.2 THE ECONOMIC IMPACT OF AIDS: A PATIENT PERSPECTIVE
Jackson, Leslie and Parfitt, M.A.
Victoria General Hospital, Victoria, Canada

Objective: To examine the economic impact of AIDS on the patient population. **Methods:** Semi-structured interviews were carried out with 25 AIDS patients in three different centers in Ontario - Toronto, London and Ottawa.

Results: Approximately one-half of the patients interviewed have been negatively impacted upon economically because of their health status. These patients tend to be in their twenties or early thirties and have not had well established careers or jobs. In most cases, those who have experienced a negative economic impact have been fired from their fulltime jobs because of their health status, or have been forced to quit because of poor health. In order to survive economically, they rely on social assistance (welfare, U.S.C. or family benefits), financial assistance from their family and/or spouse. Some have worked when their health permits and when such work is available. Few have worked since they have experienced a drastic reduction in income tend to be in their late thirties or older who have, or have had, well established careers or jobs. For these AIDS patients, withdrawing from the work force either temporarily or permanently has meant relying on social leave or disability plans (the latter typically purchased through employers), and their income has only been reduced slightly, if at all.

Conclusions: The economic impact of AIDS varies across the patient population. Not all AIDS patients experience a negative economic impact because of their health status, but those who have tend to be younger patients who have not had well established careers or jobs.

Th.H.1.P.3 DISTRIBUTION AND CHARACTERISTICS OF AIDS HOSPITALIZATIONS IN THE U.S., 1980-87

Wald, K., Ball, Ph.D.,* and Barbara J. Turner, M.D.,**
* National Center for Health Statistics Research, CDC/MS, Rockville, MD, USA;
** Thomas Jefferson Medical College, Philadelphia, PA, USA

Objective: To investigate the characteristics of AIDS hospitalizations in 1980-87 in a large, nationally representative sample of U.S. hospitals.

Methods: The Hospital Cost and Utilization Project collects over 2 million discharge abstracts per year from a sample of 4000 short-term community hospitals across the U.S. AIDS discharges have been selected based on the presence of an AIDS diagnosis or PCP. Both patient and hospital characteristics are analyzed to provide a national view of AIDS.

Results: In 1980, adult AIDS discharges (26320 from 156 hospitals) were concentrated in the west (39%) and the northeast (36%), in urban areas (88%), and in larger than average (over 400 beds), private not-for-profit (68%), and teaching (88%) facilities. On average, length of stay and total charges were highest in the northeast (17 days, \$1204), but charge per day, a measure of service intensity, was highest in the west (1992). AIDS discharges were most often covered by private insurance (54% versus 43% for all discharges) but were twice as likely to be covered by Medicaid (23% versus 11%). 63% of AIDS discharges reported Medicare coverage.

Conclusions: For policymaking at a national level, the view of AIDS must be expanded beyond New York and California. Substantial variations in patient characteristics and resource use are found when a large number of AIDS discharges from across the U.S. are considered.

Th.H.1.P.4 THE ECONOMIC IMPACT OF AIDS ON THE HEALTH CARE SYSTEM IN SWITZERLAND

Murphy, M., Pedergnani, lic.oec., University of St. Gall.

Objective: To estimate the impact of all direct costs due to HIV infection and AIDS on the Swiss health care system according to the data collected by applying current epidemiologic projections (com. 12,000 in 1991).

Methods: Analysis of medical and financial records of AIDS patients (79 of all Swiss cases), of governmental subsidies and of other direct costs.

Results: Personal costs were far lower than overall governmental costs. This will change radically until 1995. Estimated lifetime costs were 74,000 Sfrs. per AIDS patient (including outpatient treatment). Health care insurances will have generated such excesses among policyholders, paid typically only 50 percent of all medical costs, the remaining costs consisted almost entirely of increased hospital deficits that were covered by taxes.

Direct Costs (in million Sfrs.)

	1986	1987	1988	1989
Personal Costs	6.0	8.0	12.0	80.0
Governmental Costs	18.0	26.0	48.0	50.0
Total Direct Costs	24.0	46.6	60.0	275.0

Among nonpatients costs, there had been expenditures for prevention & information (186512) and care (198210), screening (70,070), HIV testing (4,0 12.5), research (2,0 10.0) and other expenditures (1,5; 8.1). By comparison, the impact of alcoholism (3.14) and rheumatism (5.38) on the health care system today is still far higher than the estimated impact of AIDS (1.01) in 1995. The number of hospital beds required is low and will remain low (1000 beds in 1995 or 1.0% of all acute care hospital beds).

Conclusion: With cumulative 3,500 (12,000) AIDS cases expected until 1991 (1995), AIDS will have only minor resource implications on the health care system and will create the health care insurers only negligibly.

Th.H.1.P.5 HOSPITAL UTILIZATION AND HOSPITAL EXPENDITURES FOR PATIENTS WITH HIV DIAGNOSES, UNITED STATES, 1984-1987

Mary Weing and Olivia Gene Kozak, National Center for Health Statistics, Hyattsville, Maryland, USA

Objective: To present a national overview of hospital utilization and expenditures and the changes found over the period 1984-1987.

Methods: The data are from the National Hospital Discharge Survey (NHDS) and are collected from the medical records of a sample of patients in a national sample of over 400 short-stay general and specialty hospitals. For the 4-year period, 1984-1987, there were over 700 records with an HIV diagnosis. Estimates of annual hospital expenditures were computed using data on hospital expense per day from the American Hospital Association.

Results: Approximately 24 million dollars were expended by short-stay hospitals in the care of HIV patients in the years 1986-87. HIV patients spent almost 1.4 million days in hospitals in 1986-87, compared to half a million days in 1984-85. The increased number of days was due to growth in the number of hospitalizations: 10,000 in 1984, 23,000 in 1985, 37,000 in 1986 and 49,000 in 1987. The average length of stay for HIV patients remained at about 2-2½ times the average for all patients (15.9 days vs. 6.4 days for all patients in 1987). In 1986-87, public sources, primarily Medicaid, were expected to provide payment for 40 percent of hospital days for HIV patients, compared to 25 percent in 1984-85.

Conclusion: Hospital use and costs for HIV patients with HIV diagnoses are growing rapidly in the United States. Public funds are supporting an increasing proportion of hospital costs.

Th.H.1.P.6 Impact of Hospitalized, I.V. disease in a low incidence area

G.H. Taylor, L.V. Medianski
University of Alberta, Edmonton, CANADA

Object: With 6% of the Canadian total of HIV diagnosed AIDS cases Alberta is a low incidence area. To determine the impact on and distribution of I.V. disease within the 6 active treatment hospitals within the city of Edmonton, a medical records search was undertaken.

Method: Medical records analysis using ICD diagnosis indexes and ICD-9-CM codes 795.8, 279.19, 279.3 and 042.0 - 042.9 extracted hospital admissions and days of stay for all Edmonton hospitals 1980 through 1988. Data for 1988 was extrapolated to year end from available information.

Results:

	1985	1986	1987	1988*	Total	Full Edmonton days	Bed days
1 (UW)	31	334	767	1512	2640	80X	29
2	40	32	182	120	466	12X	29
3	0	0	7	27	34	1X	12
4	0	60	6	4	70	2X	14
5	0	37	14	0	51	1.25X	14
6	0	0	0	70	70	2X	29
Total	71	463	1006	1663	3303	99.25X	100X

Whereas provincially between 1985-88 there was a 180% growth in annual AIDS incidence, in Edmonton gross incidence grew 138%; 75% of bed use by identified HIV patients was for AIDS.

Conclusion: Even in a low incidence area such as ours, impact of HIV disease has grown considerably. Growth in diagnosed AIDS cases has greatly underrepresented growth in in-patient days. Reasons for and consequences of the maldistribution of impact needs to be explored.

Session d'affichage Poster Session



Répercussions économiques du SIDA The Economic Impact of AIDS

Th.H.P.7 A SYSTEMIC APPROACH TO AIDS (ECONOMIC AND SOCIAL) IMPACT ANALYSIS

Dr. BOUNYA-EPEE, Samuel Ph.D. The University of Yaounde, Cameroon

Our aim in this study was to construct indicators leading to a coherent planning (indirect) system by which to reveal obstacles to world distribution of AIDS funds can be worked by reading off these relative marginal efficiency rates in allocating mean to ends at all levels of hierarchical and functional autonomy (individual-nation-society-world), then the direct method of experimenting with and intended behavior or logical action constraints can be used as best method at solving the crucial problem of modern man or modern society ought for survival from a less and less complex or cooperative environment.

Th.H.P.9 LABOR PRODUCTIVITY LOSSES TO NEVADA'S AND THE AMERICAN ECONOMY RESULTING FROM PNEUMONIA DEATHS DUE TO AIDS

Chandra A. Vaidya, M.D., University of Nevada, Las Vegas, Las Vegas, Nevada, U.S.A.

Objective. To determine the labor productivity losses to Nevada's and the American economy resulting from pneumo and death of persons with AIDS reported in Nevada during the years 1987 and 1988. **Methods.** The past and future income losses were individually calculated for each individual in the population (N=709) based upon date of birth, sex, race, age at AIDS diagnosis, month and year of AIDS diagnosis, occupation and annual income. Past income loss was defined as the period between the date of diagnosis and December 31, 1988 and was determined by calculating the partial salary for the year of diagnosis if diagnosed in 1986. For those diagnosed in 1987 the partial salary for 1987 was added to the projected 1988 salary. Upon determination of each individual's work life expectancy future income losses were calculated by multiplying the 1988 annual income by a growth factor of 1.4% for each year of the remaining work life. **Results.** The labor productivity loss to Nevada's and the American economy in past and future income adjusted for inflation for all (N=709) AIDS cases reported in Nevada during 1987 and 1988 was \$301,929,724. Past income loss was \$4,654,398 and future income loss was \$301,275,326. In constant 1988 dollars the total lost income is \$117,567,218. **Conclusion.** AIDS is having a serious impact upon the productivity of the labor force in Nevada and the United States. Billions of dollars will be lost to the American economy over the next few years as a result of the premature disability and death of persons with AIDS.

Th.H.P.11 Medical Consumption of HIV positive outpatients in London: an analysis in terms of gravity level

Y. THOMAS, J. LA. BUCKLER & C. COTTEAU P.

Laboratoire d'Economie sociale 90 Rue de Tolbiac 75013 Paris cedex 13 France
The aim of the study was to estimate the structure of the medical consumption of patients with HIV infection according to their seriousness level, irrespective or AIDS status or the prognosis.
This study was conducted in Paris and Lyon. During 1985-110 patients (50% men) were recruited and filled up a questionnaire that was given in ambulatory consultations or at the general practitioners. After acceptance by the patient, the specialist or general practitioner noted the seriousness level on the back of the questionnaire according to a check list (four cases). The questionnaire included: the number of ambulatory consultations (general practitioner and specialist), the cost of drugs and biological examinations, the number of stays at hospital and some items about the professional life.

The main results are: there is a significant difference between the structure of the consumption of the retrospective AIDS patients. This effect is an accumulation effect, non substitution one (e.g. from 1.3 to 4.5 G.P. consultations for 3 months, and from 230 to 670 FF for the drugs). In the beginning of the disease, the G.P. are autonomous or their prescriptions while they are primarily with hospital specialists when their patients fall in AIDS disease.

There is no effect of the participation to a therapeutic trial in terms of consumption outside of hospital because expensive drugs are given only by hospital.
Most of the patients included in the sample are working (80% of retrospective and 25% of AIDS patients). There is a low economic loss consumption (2.7).
The direct cost of care outside hospital (according to the Social Security prices) is: 1.790 FF (average) \$ 100 for a retrospective patient (1 G.P. and 2 stays at hospital); for AIDS patients, the direct cost is 8.734 (\$ 1400, 516 FF paid, by the patient)

Th.H.P.8

THE CANADIAN AIDS RESEARCH CONTRIBUTION: A CRITIQUE
Ronald Allan R. Department of Internal Medicine, University of Medicine, Winnipeg, Manitoba, Canada

Canadians are becoming involved in the international effort to control the spread of HIV, and to understand the biology of the agent and the host response to it. This is evident by a number of parameters including the number of abstracts at the International Symposia from 1983(1) through 1989 (over 40), and the major contributions to the world literature. In 1989-90, almost 2% of the total Canadian research effort or 10-15 million dollars will be allocated to AIDS research. What is this purchasing? What are the priorities for the future?

All AIDS researchers in Canada have been circulated with a questionnaire to identify Canadian contributions and determine future directions. The questionnaires are being collated. It is intended that this exercise will determine how AIDS researchers in Canada evaluate the contributions made to the direction and quality of leadership of the Canadian AIDS research effort, and priorities required for the future. This is a constructive critique with some guidelines intended to determine where we wish to be and how we plan to get there.

Th.H.P.10 STUDY ON CONSUMPTION OF CARE OF HIV-POSITIVE PATIENTS

Bo R Nilsson*, Knut Liljén**, Harry Malmgren*** et al.

* Department of Cancer Epidemiology, Karolinska Hospital, Stockholm, Sweden
** National Bacteriological Laboratory, *** National Swedish Board of Health and Welfare, Stockholm, SWEDEN

Objective. A follow-up study to estimate the consumption of institutional and non-institutional care of patients with HIV/AIDS and to study the changes in consumption over time.

Method. Two random samples of HIV/AIDS patients reported to the REGION wide register of National Bact. Lab. before 1986-07-01 (1st sample) and after 1986-07-01 (2nd sample) were drawn.

Conclusion. The consumption of institutional and non-institutional care for HIV/AIDS patients can be estimated. When forecasting the need of care, the results from the studies can be served as a basis of facts.

Results. The follow-up study (the 2nd sample) is going to be reported preliminary in June, 1989 and compared with the first one. Parts of results from that study show that the estimated yearly number of days of institutional care for AIDS patients was 178 per patient. For patients without developed AIDS, the corresponding number was 5.9 per patient. The estimated, yearly number of non-institutional care for AIDS patients was 17.1 per patient; 6.0 for HIV patients.

Th.H.P.12 COMPARATIVE AND COST-EFFECTIVE APPROACH TO THE MANAGEMENT OF AIDS PATIENTS IN AN OUTPATIENT CARE FACILITY: THE RESULTS OF A PATIENT SURVEY.

SMITH, Bill, Seaworth, Jeannette. San Juan AIDS Institute, May, PR

A general survey was conducted in May, 1988, to determine the status in the world with the present number of AIDS cases reported by population density and the status of the management of the population. The survey began on May 2, 1988; the cumulative number of AIDS cases in San Juan will be between 50,000 and 60,000. The survey included the management of 1,911 patients. Also, it was estimated that 55% of the cases reported to Puerto Rico belong to the first 500 cases. The San Juan Department of Health developed a policy statement entitled "AIDS care in San Juan" which explicitly encouraged the cooperation of public and private sectors in the provision of health care. Following this policy, a cost-effective approach to the management of AIDS patients in private corporations formed in December 1988. Resources from the municipality under a contract to provide services, and its main purpose is to offer alternatives to locating and substituting care in ambulatory care or preventive measures and reduce the costs of inpatient care.

As part of its main functions, the Institute provides ambulatory care at its main facilities, located in a three floor of a municipal local health center, which provides care to ambulatory and inpatient patients, other than AIDS patients. Last year, 1,719 patients were evaluated and treated as ambulatory care. 40 patients were picked up in the street, and 400 were picked up in the street. Ambulatory services included: medical assistance and patient's education of services being offered. Final results include a 81% (14,562) of satisfaction regarding the quality of service and a 75% (14,562) of satisfaction regarding the quality of service. The San Juan AIDS Institute (SAII) realized personnel as qualified or slightly qualified in the AIDS field. The SAII has been visited the Institute and more than half of retrospective drug addicts in groups were picked up in the street. The SAII has been visited by the staff of this study are indicative, that in spite of social stigma of high risk groups, the San Juan AIDS Institute has succeeded in providing cost effective, high level care to AIDS patients in San Juan.

Session d'affichage Poster Session



Répercussions économiques du SIDA The Economic Impact of AIDS

Th.H.P.19 PEAK PREVALENCE OF HIV IN NAMBIAN TEENAGERS

Legassie, G. J.; Joghret, J.J. J.; Schutte, C.N.J. J.; Taylor, H.B. & Schneider, C. J.

1. Department of Microbiology, Medunsa, Pretoria, South Africa
2. Department of Microbiology, University of Stellenbosch, South Africa
3. RIDIT, MEC, Durban, South Africa
4. Department of Medical Virology, University of Pretoria, South Africa

Objective. To determine the prevalence of HIV-1 and HIV-2 antibodies in a series of 700 serum specimens collected in the east Caprivai area of Namibia. **Methods.** Elisa (Elavia and Du Pont) and Western blot techniques were used to investigate and confirm respectively the prevalence of antibodies to HIV-1 and HIV-2.

Results. Half of the HIV-1 positive specimens were from teenagers and younger. A significant difference in HIV-1 positivity between the two Elisa tests was found (4.25 by Elavia, 5.65 by Pastour). On confirmation by Western blot, a false positivity rate of approximately 50% for both Elisa tests was demonstrated. No HIV-2 positives were confirmed although 15 of 704 (2.1%) HIV-2 Elavia positives were detected. Four false negative results were obtained (4/704) (0.6%). **Conclusion.** In contrast to other countries, Namibian teenagers form the target group of HIV-1 positive individuals. The high degree of false positivity suggests the presence of cross reacting antigens in this area. The detection of false negatives indicates the need for more careful evaluation of test results.

Th.H.P.21 HIV-1 INFECTION IN SEXUALLY ACTIVE AND HIV-1 INFECTED SUBJECTS IN THE PHILIPPINES

Delia Ramos, E.M. Palencia, S.V. Mwanani, C. Lam, J.M., Cepellin Department of Health Research Institute for Tropical Medicine, Philippines

Objective. To determine the prevalence of HIV-1 infection among subjects at risk for or with HIV infection.

Methods. Sera were collected from subjects in Metro Manila being surveyed for HIV-1 antibodies and HIV infected subjects under follow-up. Testing for HIV-1 was performed with particle agglutination (PA) and Western Blot (WB) methods. HIV-1 antibodies were detected with PA and immunofluorescence tests.

Results. A total of 196 samples were tested for antibodies to HIV-1 and HIV-2. The age range was 18-57 years; sex were female; originally from different islands; and with many sex partners from other countries. 60/196 samples showed no antibodies to both HIV-1 and HIV-2 on screening tests. 11 HIV negative samples had HIV-1 antibodies on the screening test. 18 tests were negative in 5 sera retested in 5. Repeat WB studies in another laboratory showed no antibodies in the latter samples. Among the 23 HIV-1 seroreactive samples, no antibodies to HIV-2 were seen on PA screening. There were no positive WB tests.

Conclusion. HIV-1 antibodies do not appear to be prevalent among the subjects studied. Further studies are needed to determine the significance of indeterminate WB results. However, additional serological surveys are necessary to establish the prevalence of HIV-1 among other population groups.

Th.H.P.23 HIV-1 INFECTION IN HETEROSEXUAL POPULATION: PARADOX OR CONCLUSION OF INFORMATION?

Cahn, Doreen P. H.; Drinberg, M.; Boumas, M. P.

Machini, O. P. Hospital Fernández, #1189A, Academia Nacional de Medicina, Buenos Aires, Argentina.

Objective. To perform a comparative analysis of the prevalence of HIV-reactive subjects on 2 populations (one with HIV-reactive individuals reported contact (PI) and the other with multiple sexual partners (P2) unknown HIV serology. **Methods.** A total of 269 patients (P1) without a history of homosexuality, IVDA, transfusion or transfusion was studied (P1-18 men/90, 56 women/0/14; P2: 106 M, 49 W-151 Pt.). Sera were assayed through ELISA HIV-1 Abbott and confirmed through immunofluorescence and/or Western Blot.

Results. Table 1 shows seroprevalence data.

	N = n		W = n		P1 W's partners were as follows:	
	No HIV-1	% HIV-1	No HIV-1	% HIV-1	No HIV-1	% HIV-1
P1	18	-	96	12	5	1
P2	151	11	49	7	14	6
TOTAL	124	11	9	145	13	5
					16	16
					31	5
					14	16

Conclusion. Heterosexual transmission is also confirmed in this population, where it shows a slight preponderance of M over W. When comparison of HIV-1+ risk group, no significant differences were found among their female partners. It is not clear whether P1 has seroprevalence levels higher than those of P2, a paradox that could be due to possible concealment of past epidemiological risk. This fact must be explained through subsequent studies.

Th.H.P.20 AIDS AND MIGRATION IN JALISCO, MEXICO: THEIR RELATION WITH RISK FACTORS.

Diaz-Santana, David & Colla, M. A.

- Consejo Estatal para la prevención del SIDA en Jalisco.
- Instituto Estatal de Salud Pública, U.de G., Guadalajara, Jalisco, México.

OBJECTIVE: To describe migration background in the 250 AIDS patients reported in Jalisco, Mexico, up to December 31, 1988, and its relation to risk factors.

METHODS: Information supplied by the reports of AIDS cases in Jalisco. Analyses focused on travel to foreign countries and high risk practices.

RESULTS: Of the 250 case reported, approximately 50% traveled to foreign countries. Analyzing by sex and sexual habits the percentage modifies significantly.

CONCLUSION: A strong association was found with males and travel to foreign countries, this is stronger in homosexual, at the beginning of the epidemic this relation was more frequent.

Th.H.P.22 NIVEAU DE CONTAMINATION DES ENFANTS A PROTEINE URINE CHIMIQUE

AGUIAR-SANTANA, J. M., MONTE, L., RODRIGUEZ, P., BARRERA, J.

- * Servicio de pediatria y unidades infectadas Hospital A. SIDA, Puerto RICO, CHIMO
- ** Davis & Associates, Inc. Puerto RICO, CHIMO
- *** Hospital Serrano, P.R. CHIMO

OBJECTIF: Déterminer le mode de contamination des enfants hospitalisés pour SIDA dans le service de pédiatrie de Puerto Rico après un épisode de contamination de leur mère.

METHODS: Tous les enfants atteints de SIDA hospitalisés au CHIMO au 30/06/1988 ont fait l'objet d'une enquête, d'un examen clinique et d'une sérologie VIH, de la mère et de l'enfant. L'immunogramme a défini :

- 1) les caractéristiques de la naissance, à domicile et en maternité, les conditions néonatales, le nombre d'hospitalisations et de transfusions aux 18 premiers mois de vie, l'absence d'infection bactérienne, virale ou fongique, les antécédents de transfusion sanguine, de consommation de produits de sang, de médication, le mode d'allaitement et l'existence d'un contact avec des sujets de VIH dans la famille.

RESULTS: Les modes de contamination ont été analysés chez 15 enfants. 4/15 ont contracté le VIH après 19/8/88 par une contamination ; 1/15 ont contracté le VIH après, soit 11/88, non transfusé, dont la mère est séropositive, un examen des facteurs de risque des épisodes d'infection ont permis d'un meilleur contrôle d'hygiène, préventive, vaccinale, curative, etc.

CONCLUSION: L'importance de la contamination par infection cutanée a conduit à une révision des attitudes pré-conception vis-à-vis du plasma et des sérum, à une formation du personnel de santé et à l'organisation d'un programme d'éducation sanitaire.

Th.H.P.24 TYPOLOGY, BEHAVIOR, BISEXUALITY AND HIV INFECTION OF HOMOSEXUAL MEN OF COSTA RICA, 1985-1988

RASA, LAMONGGOL, KANTHA, G. J. Madala, J.; Mata, S. A. *IRISA, University of Costa Rica, San Pedro, Costa Rica.

Objective. A cohort was established to study risk factors and incidence of HIV-infection.

Methods. Healthy homosexual volunteers participated. Confidentiality, informed consent, and freedom to withdraw from the study at any time was assured. Each man was interviewed and tested by an ELISA and confirmed with Western blot. Three of five "types" of homosexual men in the country were represented: openly "gay" and "cryptic" (not publicly gay) (80-87); "male prostitutes" (80-93); and "homosexuals in prison" (80-81).

Results. 1) HIV infection remains confined to the gay and cryptic men (11% HIV-positive). Very few infections have been recorded in male prostitutes or in men in prison. 2) Bisexuality: 13 per cent of gays and cryptic men, and 30 per cent of male prostitutes said they were bisexual. 3) HIV infection by sexual preference: 12 per cent of initially homosexual and 9 per cent of bisexuals were infected. 4) Behavior was similar in all "types", but differences in intensity and occurrence of sexual practice varied.

Conclusion. Our epidemic follows 1985 (Costa Rica); 120 women had heterosexually acquired AIDS appeared in 1988 (4% total). The presence of HIV in many bisexual men forecasts an increase of AIDS in women in the near future.



W.B.O.45A PEPTIDE T PHASE I STUDY: NEUROPSYCHIATRIC RESULTS
Goodwin, F.K.*; Bridges, P.L.*; Hoeseltine, P.N.R.*; Baton, E.*; and Parker, E.L.*
*National Institute of Mental Health, Bethesda, MD.,
*University of Southern California, Los Angeles, CA., U.S.A.

Objective: To evaluate the toxicity and possible response measures to Peptide T (D-ala¹-peptide-T-²⁸-amide), a homologue of VIP and gp-120, and gp-120 receptor blocker.
Methods: In this ongoing study, 4 AIDS and 5 ARC patients received escalating fixed IV doses of Peptide T (1.08-18mg/kg/day) or intranasal (25 mg/day) without other antivirals. Baseline/repeat neurotoxicity measures were taken.
Results: Pruritis in 1 patient led to early drug withdrawal. No neurotoxicity was observed. Individual responses to neuropsychologic testing varied from -0.3 to +1.5 S.D. increments across the 12 week testing period with variable decrements after drug withdrawal. Immuno/virologic drug responses were seen in as many as 8/9 patients. Cognitive neuromotor benefit and reduction of HIV constitutional symptoms on drug were greatest in those patients with immuno/virologic improvement.
Conclusion: Peptide T was well tolerated for 12 weeks, with increases in body weight and well-being noted. Preliminary results indicate that these measures and immuno/virologic tests may be useful efficacy parameters for Phase II testing of Peptide T.


W.F.O.24 ETHICAL AND POLICY ISSUES POSED BY THE USE OF COERCION TO COMBAT THE SPREAD OF HIV INFECTION
Beyer, Ronald; Columbia University, School of Public Health, New York, NY, USA.

From the beginning of the AIDS epidemic there have been calls for the use of the State's power to quarantine to halt the spread of the lethal infection. But because it was quickly established that HIV infection was not casually transmitted the wholesaler's stance on isolation was deemed unnecessary from a public health point of view, contrary to the principles of ethics that require respect for freedom, and undesirable from a public policy perspective. Troubling, however, was the question of how to respond to infected individuals who continued to act in ways that posed a threat to unsuspecting sexual or needle sharing partners. This has been the dilemma of those committed to a 'voluntaristic' approach to controlling AIDS. There is, however, one national model of AIDS control that rejects the premises of voluntarism and that has determined that all HIV infected individuals must be isolated to prevent the possibility of behavioral transmission. The Cuban model stands as a bold and disturbing example of the exercise of public health powers to the exclusion of all other social values. This presentation will discuss the Cuban challenge and drawing on the experience of the United States, Sweden, Bavaria and South Africa analyze its relevance to other nations.

The.O.6A BLEACHMAN: A SUPER-HERO TEACHES AIDS PREVENTION
Pappas, Liz*¹; Durazzo, R.*; Repella, A. J.*²
¹San Francisco AIDS Foundation, San Francisco, CA., USA;
²Mid-City Consortium to Combat AIDS, San Francisco, CA., USA

Objective: To educate IVUDs about the risk of HIV transmission and the effectiveness of using bleach to clean hypodermic syringes. To motivate IVUDs to adopt safe needle using and sexual behaviors to limit the spread of HIV.
Methods: A super-hero character was developed with extensive use of focus groups and field testing. BLEACHMAN appears in posters, brochures, billboards, hot cards, newspaper ads, television commercials, and on t-shirts. He also appears live (in an 8 foot super-hero costume with a bleach bottle for a head) and leads regular street outreach efforts. On the streets, accompanied by t-shirt wearing volunteers, BLEACHMAN talks to IVUDs and distributes bleach and condoms. BLEACHMAN has attracted the attention of IVUDs and their partners as well as extensive coverage in the media.
Results: 8% of 165 randomly selected IVUDs have been reached by this AIDS prevention campaign. Of the IVUDs who acknowledged sharing needles (80% of the total group) 87.7% reported they were more likely to use bleach to clean their needles as a result of their exposure to BLEACHMAN.
Conclusion: The ability to reach IVUDs indicates the effectiveness of this combined grass-roots and media strategy. BLEACHMAN represents a unique interactive approach to AIDS prevention. This is the first time IVUDs have had a hero who cares about their well being and they have responded with appropriate knowledge and behavior changes. AIDS prevention campaigns aimed at IVUDs can be effective if they are non-threatening and respectful of the target population.

SECTION I



Audiovisual
Audiovisual



11:00 - 12:30



Session vidéo

Video session

Le Counseling Counselling

- 11:00 Introduction: Ken Morrison
- 11:10 M.I.V.1 **"TALKING ABOUT AIDS"**
Vidéo de/Video by:
British Medical Association
Foundation for AIDS
Année/Year: 1988
- 11:33 M.I.V.2 **"PRE AND POST HIV TEST"**
(en français, Rwanda), (in French, Rwanda)
Vidéo de/Video by:
Suzan Muska
Norwegian Red Cross
Année/Year: 1989

Le counseling est devenu un élément capital dans les traitements médicaux ou le dépistage d'anticorps reliés au SIDA. L'intervenant doit aider les personnes atteintes à comprendre l'infection par le VIH, ses modes de transmission et ses possibilités de traitement; il doit aussi les aider à faire face à leur situation tout en abordant les problèmes de la confidentialité, des droits, des responsabilités et du consentement éclairé. Ces deux films vidéo destinés à la formation de consultants (le premier en anglais, le deuxième en français) ont été choisis parmi plusieurs autres propositions sur le sujet.

Counselling has become a vital element in AIDS-related medical treatment or antibody testing. As well as helping people understand HIV infection, transmission routes and treatment possibilities, the care provider must help people to cope with their situation while addressing issues such as confidentiality, rights, responsibilities and informed consent. These two videos for counsellor training (the first in English, the second in French) were chosen from many submissions on the subject.

14:00 - 15:30

Session vidéo
Video Session

La Sexualité, la politique et l'histoire Sex, Politics and History

- 14:00 Introduction: Andy Fabo
- 14:04 M.I.V.3 **"ARE WE GOING BACKWARD"**
Vidéo de/Video by:
David Tuff
Année/Year: 1987
- 14:14 M.I.V.4 **"PROSTITUTES RISK & AIDS"**
Vidéo de/Video by:
GMHC
Année/Year: 1988
- 14:39 M.I.V.5 **"THEY ARE LOST TO VISION ALTOGETHER"**
Vidéo de/Video by:
Tom Kalin
Année/Year: 1989
- 14:52 M.I.V.6 **"REFRAMING AIDS"**
Vidéo de/Video by:
Pretibhe Parmar
Année/Year: 1988

La vidéo offre toute une panoplie de méthodes pour poser un regard historique et analytique sur le sujet. Ce groupe éclectique d'artistes et de militants du monde des arts aborde les problèmes de la sexualité, de l'orientation sexuelle, du racisme, du sexisme, de la politique de la santé, de diverses phobies reliées au SIDA, des stéréotypes et de la considération du SIDA comme une catastrophe idéologique. Ces films vont de l'analyse visuelle à l'analyse textuelle en essayant de comprendre comment s'articule le discours sur le SIDA.

Video offers the use of a myriad of historical and analytical methods. This diverse grouping of artists and aesthetic activists touches on issues of sexuality, sexual orientation, racism, sexism, politics of health, various AIDS-related phobias, stereotyping and confronting AIDS as an ideological catastrophe. It ranges from visual to textual analysis attempting to understand the construction of AIDS discourse.

16:00 - 17:30

Session vidéo
Video Session

Les Femmes et le SIDA Women and AIDS

- 16:00 Introduction: Colette Lachance
- 16:14 M.I.V.7 **"SAFE SEX SLUT"**
Vidéo de/Video by:
Scarlot Harlot
Année/Year: 1988
- 16:17 M.I.V.8 **"CORI: A STRUGGLE FOR LIFE"**
Vidéo de/Video by:
Nina Sobell
Année/Year: 1989
- 16:35 M.I.V.9 **"DOCTORS, LIARS & WOMEN"**
Vidéo de/Video by:
Carlomusto, Maggenti
Année/Year: 1988
- 16:58 M.I.V.10 **"JULIE"**
Vidéo de/Video by:
Seth Levin
Année/Year: 1989
- 17:08 M.I.V.11 **"LE SIDA ET LE MILIEU DU TRAVAIL"**
Vidéo de/Video by:
Kate Wardrop,
ACSP, CTC.
Année/Year: 1988

Mères, filles, amantes, travailleuses, lesbiennes, malades, militantes, prostituées, soignantes : les femmes sont vues de multiples manières à travers le prisme du SIDA. Ces films s'attaquent à la marginalisation des femmes sous divers angles. Chacun dépeint les luttes particulières des femmes face au SIDA et à l'infection par le VIH.

Mothers, daughters, lovers, workers, lesbians, patients, activists, prostitutes and caregivers: women are depicted in many ways in relationship to AIDS. From various viewpoints, these videos challenge the marginalization of women. Each depicts the special struggles which women face in relation to AIDS and HIV infection.

11:00 - 12:30

Session vidéo
Video Session

**L'autodétermination des personnes
atteintes
PWA Power**

- 11:00 Introduction: Une Personne Atteinte
A PWA
- 11:04 T.I.V.1 **"MEREDITH A YOUNG MOTHER WITH AIDS"**
Vidéo de/Video by:
Edan Programs
Année/Year: 1988
- 11:24 T.I.V.2 **"ROBERT MARSHALL"**
Vidéo de/Video by:
Stuart Marshall
Année/Year: 1989
- 11:34 T.I.V.3 **"LIVING WITH HIV"**
Vidéo de/Video by:
Nicke Johansen
Année/Year:
- 11:54 T.I.V.4 **"SURVIVAL OF THE DELIRIOUS"**
Vidéo de/Video by:
Michael Balsler,
Andy Fabo
Année/Year: 1988
- 12:08 T.I.V.5 **"WORK YOUR BODY"**
Vidéo de/Video by:
GMHC
Année/Year: 1988
La prise en charge de soi-même est devenue essentielle pour vivre avec le SIDA. Ces films scrutent la vie d'hommes et de femmes porteurs du VIH et examinent d'autres moyens de faire face aux dangers de l'affaiblissement du système immunitaire et à une société hostile. Films des États-Unis, de Suède, de Grande-Bretagne et du Canada.
Self empowerment has become the key to living with AIDS. These videos investigate the lives of those affected by HIV infection and examine alternative means of coping with the hazards of a weakened immune system and a hostile society. Presentations from the United States, Sweden, Britain and Canada.

14:00 - 15:30


 Session vidéo
 Video Session

La discrimination
Discrimination

- 14:00 Introduction: Tom Waugh
- 14:05 T.I.V.6 **"ONE OF OUR OWN"**
 Vidéo de/Video by:
 G.T. Rogers
 Année/Year: 1987
- 14:35 T.I.V.7 **"WHEN THE FAMILY GETS AIDS"**
 Vidéo de/Video by:
 Slawomir Grunberg
 Année/Year: 1988
- 15:03 T.I.V.8 **"THE 2nd EPIDEMIC"**
 Vidéo de/Video by:
 Amber Hollibaugh
 Année/Year: 1988

Trois films, trois situations, trois techniques visuelles : illustration du SIDA au travail et des dilemmes qui en découlent, un regard personnel sur une famille aux prises avec une infection par le VIH et une analyse documentaire des effets négatifs de la réaction de la société au SIDA. Ces documents offrent une vision éclairante des problèmes inhérents à un monde dominé par la peur et les préjugés et présentent les diverses manières dont des personnes atteintes font face à ces difficultés.

Three videos, three situations and three visual techniques: 2 dramatizations of AIDS in the workplace and resulting dilemmas, a personal look at a family dealing with HIV infection, and a documentary analysis of the negative effects of society's response to AIDS. Each gives an insightful look at the problems inherent in a world of fear and prejudice and the various ways by which PWAs cope with these difficulties.

16:00 - 17:30

Session vidéo
Video Session
Programmation française
French Programming

- 16:00 Introduction: Colette Lachance
- 16:04 T.I.V.9 **"OÙ EST PASSÉ STÉPHANE"**
Vidéo de/Video by:
Dr. Didier Jayle
Mutualité Française
Année/Year: 1987
- 16:08 T.I.V.10 **"UNE VIE INCURABLE" (EXTRAIT)**
Vidéo de/Video by:
Robert Blais
Année/Year: 1988
- 16:18 T.I.V.11 **"REPORTAGE SUR JACQUES UNE PERSONNE ATTEINTE DU SIDA"**
Vidéo de/Video by:
Année/Year: 1988
- 16:27 T.I.V.12 **"UN MONDE UNI CONTRE LE SIDA"**
Vidéo de/Video by: OMS/WHO
Année/Year: 1988
- 16:48 T.I.V.13 **"VIRUS, QUEL VIRUS?"**
Vidéo de/Video by:
Fabrice Rouleau
Année/Year: 1987
- 17:05 T.I.V.14 **"FAITS DIVERS"**
Vidéo de/Video by:
Quentin Van De Velde
Année/Year:
Les films de France, de Belgique, de Suisse et du Québec traitent de multiples aspects du SIDA, des campagnes d'information pour les jeunes au contexte international du SIDA, avec des reportages très personnels.
Presentations from France, Belgium, Switzerland and Quebec, these videos address many aspects of AIDS ranging from general information for youth, the international context of AIDS, to very personal accounts.



11:00 - 12:30

Session vidéo
Video Session

La Perte et le deuil
Loss and Mourning

- 11:00 Introduction: Andy Fabo
- 11:11 W.I.V.1 **"MILDRED PEARSON; WHEN YOU LOVE A PERSON"**
Vidéo de/Video by:
Yannick Durand
Année/Year: 1988
- 11:20 W.I.V.2 **"THE INAUGURAL DISPLAY OF THE NAMES QUILT"**
Vidéo de/Video by:
David Thompson
Année/Year: 1988
- 11:36 W.I.V.3 **"DANNY"**
Vidéo de/Video by:
Stashu Kybartas
Année/Year: 1987
- 11:56 W.I.V.4 **"A PLAGUE HAS SWEPT MY CITY"**
Vidéo de/Video by:
Emjay Wilson
Année/Year: 1987
- 11:59 W.I.V.5 **"GAB"**
Vidéo de/Video by:
Ann Moriyasu
Année/Year: 1986
- 12:11 W.I.V.6 **"A"**
Vidéo de/Video by:
Andre Burke
Année/Year: 1986
- 12:19 W.I.V.7 **"THIS IS NOT AN AIDS ADVERTISEMENT"**
Vidéo de/Video by:
Isaac Julien
Année/Year: 1987
Vivre la perte d'un être cher. Ces films vont de l'hommage à l'élogie -- douleur collective et peine individuelle, douleur vécue dans les familles traditionnelles et dans d'autres qui le sont moins.
Dealing with the loss of a loved one. These tapes range from tributes to elegies, from collective to individual grief and from alternative family to traditional family grieving.



14:00 - 15:30

Session vidéo
Video Session

**Le Militantisme et la résistance
culturelle**
Activism and Cultural Resistance

- 14:00 Introduction: John Greyson
- 14:03 W.I.V.8 **"THE ADS EPIDEMIC"**
Vidéo de/Video by:
John Greyson
Année/Year: 1987
- 14:08 W.I.V.9 **"SNOW JOB"**
Vidéo de/Video by:
Barbara Hammer
Année/Year: 1986
- 14:16 W.I.V.10 **"WE'RE NOT REPUBLICANS"**
Vidéo de/Video by:
Bob Huff
Année/Year: 1988
- 14:30 W.I.V.11 **"STIFF SHEETS"**
Vidéo de/Video by:
John Goss
Année/Year: 1989
- 14:49 W.I.V.12 **"ANOTHER MAN"**
Vidéo de/Video by:
Youth Against Monsters
Année/Year: 1988
- 14:54 W.I.V.13 **"TESTING THE LIMITS NEW YORK part 1"**
Vidéo de/Video by:
Testing the Limits Collective
Année/Year: 1988
- 15:20 W.I.V.14 **"SPREAD THE WORLD"**
Vidéo de/Video by:
Aboriginal Medical Service
Redfern Co-Operative ltd.
Année/Year:

Le militantisme artistique et la résistance culturelle face au SIDA ont entraîné une prolifération de films et de vidéos. Cette séance en présente parmi les meilleurs. Des défilés de mode provocateurs aux vidéos musicaux subversifs, de la désobéissance civile à l'analyse critique des médias, les stratégies esthétiques illustrées prouvent qu'il ne faut pas seulement réinventer la politique du SIDA mais aussi le langage du SIDA.

Aesthetic activism and cultural resistance in response to AIDS has meant a proliferation of videos. This session is a sampling of some of the best. From guerrilla fashion shows to subversive music videos, from civil disobedience to media deconstruction, the aesthetic strategies illustrated show that not just the politics of AIDS but the politics of language related to AIDS needs to be reinvented.

16:00 - 17:30

Session vidéo
Video Session

Les clips Clips

16:00 Introduction: René Lavoie

16:15 W.I.V.15

Clips télévisés du monde entier
Television spots from around the world

Les campagnes de prévention restent le principal moyen d'informer le grand public. Beaucoup d'organismes, gouvernementaux et communautaires, ont essayé d'intervenir en utilisant les techniques médiatiques existantes comme les messages télévisés d'intérêt public ou des clips spécialisés pour les lieux publics.

Ces clips sont réservés ou conservateurs, explicites ou hilarants, réactionnaires ou fascinants. Ils sont juxtaposés à dessein pour amener le public à choisir activement entre la peur et la prise en charge de soi.

Prevention campaigns remain the primary means of getting information to the general public. Many organizations, both government and community-based, have tried to intervene using existing media techniques such as Television Public Service Announcements (PSA's) or community-specific shorts intended for use in public venues.

These clips vary from coy to conservative, explicit to hilarious, reactionary to riveting. They are purposefully juxtaposed to force the audience to actively participate in choosing between promotion of fear or of empowerment.

11:00 - 12:30

Session vidéo
Video Session
Programme international-espagnol
Spanish International Programme

- 11:00 Introduction: Dr. Guy Loneran
- 11:03 Th.I.V.1 **"PUPPETS AGAINST AIDS"**
 Vidéo de/Video by:
 Gary Friedman,
 African Research and Educational Puppetry Programme
 Année/Year: 1989
- 11:08 Th.I.V.2 **"SIDA UN PROBLEMA DE TODOS"**
 Vidéo de/Video by:
 Daniel Villalobos
 Année/Year: 1988
- 11:38 Th.I.V.3 **"OJOS QUE NO VEN"**
 Vidéo de/Video by:
 Latino AIDS Project
 Instituto Familiar de la Raza
 Année/Year: 1987
- Trois voies pour l'éducation communautaire et l'éducation des jeunes. D'Afrique du Sud, un film vidéo qui dépeint l'emploi de marionnettes géantes pour décrire le SIDA. Du Chili, un film gouvernemental d'information sur le SIDA et sur la transmission du VIH mettant en scène des jeunes et un médecin. Des États-Unis, la transposition du SIDA sur le petit écran dans des téléromans explorant les relations sociales au sein de la communauté latino-américaine.
- Three alternatives to community and youth education. From southern Africa, a video depicting the use of oversized puppets to describe AIDS. From Chile, a state informational video on AIDS and HIV transmission with youth and a doctor. From the United States, the dramatization of AIDS by the use of soap opera/ tele novella exploring the social intricacies of the latino community.



14:00 - 15:30

Session vidéo
Video Session

Le personnel soignant
Care givers

- 14:00 Introduction: James Miller
- 14:04 Th.I.V.4 **"WITH LOVING ARMS"**
Vidéo de/Video by:
Child Welfare League of America
Année/Year: 1989
- 14:22 Th.I.V.5 **"FINDING OUR WAY TOGETHER"**
Vidéo de/Video by:
Mark Dworkin,
John Mitsud,
American Red Cross
Année/Year: 1989
- 14:50 Th.I.V.6 **"NURSING AND AIDS--COMMUNITY CARE"**
Vidéo de/Video by:
Année/Year: 1988
- 15:00 Th.I.V.7 **"THE INSIDE STORY"**
Vidéo de/Video by:
Lynn Coward,
Royal Victoria Hospital
Année/Year:

Les intervenants sociaux ont besoin de formation, de conseils et de soutien dans l'aide qu'ils apportent aux personnes atteintes du SIDA. Ces films évoquent le rôle des parents d'accueil, des familles, de la communauté homosexuelle et lesbienne, de tous ceux qui dispensent des soins palliatifs, des infirmiers et infirmières et de divers bénévoles qui racontent comment ils ont vécu la réaction de la société au SIDA.

Care providers need training, guidance and support when caring for people with AIDS. These videos depict the role of foster parents, families, the gay and lesbian community, palliative care workers, nurses and various volunteers telling their stories about society's response to AIDS.

16:00 - 17:30

Session vidéo
Video Session

La Prévention Prevention

- 16:00 Introduction: Ken Morrison
- 16:05 Th.I.V.8 **"THE BEST DEFENSE"**
Vidéo de/Video by:
Deborah Shames
Année/Year: 1988
- 16:10 Th.I.V.9 **"WORK SAFE PLAY SAFE"**
Vidéo de/Video by:
Jessica Douglas Henry
Année/Year: 1988
- 16:30 Th.I.V.10 **"SOMETHING FIERCE"**
Vidéo de/Video by:
GMHC
Année/Year: 1989
- 16:50 Th.I.V.11 **"ON GUARD"**
Vidéo de/Video by:
Deborah Shames
Année/Year: 1988
- 17:13 Th.I.V.12 **"AIDS-WISE, NO LIES"**
Vidéo de/Video by:
David Current,
Anne Ruthledge
Année/Year: 1988

La prévention reste le noyau fondamental de toute intervention contre le SIDA. Puisant dans le déluge de films vidéos proposés, cette séance présente un aperçu général des techniques de prévention mises en oeuvre pour de nombreux groupes cibles : toxicomanes, travailleurs du secteur de la santé et des services sociaux, personnels paramédicaux, prostituées, homosexuels et jeunes.

The nucleus of AIDS work remains prevention. From the deluge of videos submitted on the subject, this session provides an overview of prevention techniques for many target groups: drug users, health care workers, paramedics, prostitutes, gay men and youth.

Principaux
commanditaires

Major Sponsors

Le Ministère de la Santé nationale et du Bien-être social est responsable des questions relatives à la promotion et au maintien de la santé, à la sécurité sociale et au bien-être social des Canadiens qui relèvent du Parlement du Canada. Des exemples de ses responsabilités sont l'application des lois touchant à la santé, à la sécurité sociale et au bien-être social des Canadiens; la conduite d'enquêtes et de recherches dans les domaines de la santé publique et du bien-être social; les services d'information sur les conditions et les pratiques sanitaires; les services de santé pour les Indiens et les Inuits, les habitants du Yukon et des Territoires du Nord-Ouest, les fonctionnaires fédéraux, les immigrants et le personnel de l'aviation civile; la coopération et la coordination avec les gouvernements provinciaux sur les questions de santé, de sécurité sociale et de bien-être social; et la collecte, la publication et la diffusion d'informations sur la santé, la sécurité sociale et le bien-être social.

Une importante partie des efforts que déploie le Ministère pour préserver et améliorer la santé et le bien-être social de tous les Canadiens exige la collaboration avec les autorités provinciales et territoriales. La nécessité de mener des activités conjointes dans certains secteurs découle de la division constitutionnelle des responsabilités et de l'existence de programmes fédéraux dont l'objet est d'aider les provinces et les territoires à assurer leurs propres programmes de services sanitaires et sociaux.

Les responsabilités et les activités du Ministère sont concentrées dans les principaux secteurs suivants : la sécurité du revenu pour les particuliers et les familles; les services sociaux de base, particulièrement pour les Canadiens défavorisés sur le plan socio-économique; l'universalité d'accès à des services de santé adéquats pour tous les Canadiens; la protection contre la maladie et les risques liés à l'environnement; la promotion de modes de vie sains; l'essor, l'encouragement et le développement de la condition physique et du sport amateur.

Les principales stratégies par lesquelles le Ministère s'acquitte de ses responsabilités sont les suivantes : transferts aux particuliers, transferts aux gouvernements provinciaux et territoriaux (sans oublier les groupes autochtones), recherche, réglementation et surveillance, services directs à des groupes particuliers, consultation, conseils, information et promotion.

Une brève description des divers programmes suit :

Services et promotion de la santé : Ce Programme assure un appui financier et technique aux provinces et territoires au titre des services de santé assurés et de certains services complémentaires de santé. Il encourage également l'adoption et la conservation de saines habitudes de vie, et stimule la recherche en santé publique.

Services sociaux : Ce Programme contribue à assurer de l'aide sociale et des services sociaux aux personnes qui n'ont pas les moyens financiers de satisfaire leurs besoins fondamentaux, ou qui, en raison de circonstances sur le plan social, sont exposés à la pauvreté, à l'isolement ou à la dépendance.

Services médicaux : Ce Programme assure des services de santé à plusieurs groupes de clients. Les principales activités s'adressent aux Indiens inscrits et aux Inuits de tout le pays, ainsi qu'à tous les habitants du Yukon et des Territoires du Nord-Ouest. Des services de santé sont également fournis aux fonctionnaires fédéraux, aux immigrants, aux résidents temporaires, aux voyageurs internationaux, au personnel de l'aviation civile, aux personnes physiquement handicapées et aux victimes de catastrophes.

Protection de la santé : Ce Programme vise à éliminer les risques pour la santé liés à des facteurs environnementaux, naturels ou artificiels, pouvant être cause de maladies et de décès prématurés. Les principales activités portent sur l'évaluation et le contrôle de la qualité et de la sécurité des aliments, ainsi que de la sécurité et de l'efficacité des médicaments et des appareils médicaux; l'identification et l'évaluation des risques liés au milieu; la surveillance des maladies; et la fourniture de services de laboratoire spécialisés.

Sécurité du revenu : Ce Programme a pour but de maintenir et d'améliorer la sécurité du revenu des Canadiens. Trois grands programmes de sécurité du revenu sont administrés : le Régime de pensions du Canada, la Sécurité de la vieillesse et des Allocations familiales. Un programme d'évaluation de l'invalidité est également appliqué dans le cadre de la Loi de l'impôt sur le revenu.

Condition physique et Sport amateur : Ce Programme contribue à améliorer la condition physique des Canadiens et à promouvoir l'excellence dans le sport amateur canadien sur les plans national et international.

Administration centrale : Ce Programme fournit au Ministère des services de direction et de gestion.

Health and Welfare Canada

The Department of National Health and Welfare is responsible for matters related to the promotion and preservation of the health, social security and social welfare of the people of Canada over which the Parliament of Canada has jurisdiction. Major examples of these responsibilities include administration of legislation relating to the health, social security, and welfare of the people of Canada; investigation and research into public health and welfare; information services relating to health conditions and practices; health services for Indian and Inuit people, residents of the Yukon and Northwest Territories, federal government employees, immigrants and civil aviation personnel; cooperation and coordination with provincial governments on matters of health, social security and welfare; and collection, publication and distribution of information relating to health, social security and welfare.

A significant amount of Departmental activity involves collaboration with provincial and territorial authorities in efforts to preserve and improve the health and social well-being of all Canadians. The need for joint activity in certain areas arises from the constitutional division of responsibilities and the existence of federal programs which assist provinces and territories to maintain their own health and social service programs.

Departmental responsibilities and activities are focused on the following principal objectives: income security for individuals and families; essential social services, particularly for socially and economically disadvantaged Canadians; universal access for all Canadians to quality health services; protection against disease and environmental hazards; promotion of healthy lifestyles; promotion, encouragement and development of fitness and amateur sport.

The major strategies through which the Department carries out its responsibilities are: transfers to individuals, transfers to provincial and territorial governments and to native groups, research, regulation and surveillance, direct service to specific groups, advice, consultation, information and promotion.

Following is a brief description of the various programs:

Health Services and Promotion: This Program provides financial and technical support to the provinces and territories for insured health care services and certain extended health care services. The Program also promotes the adoption and maintenance of healthy lifestyles and fosters public health research.

Social Services: This Program supports the provision of social assistance and services to persons whose economic circumstances are inadequate to meet their basic needs or whose social circumstances expose them to risk of poverty, isolation or dependency.

Medical Services: This Program provides health services to several client groups. The major activities are directed towards registered Indians and Inuit throughout Canada and residents of the Yukon and Northwest Territories. Clients also include federal public servants, immigrants and temporary residents, international travellers, civil aviation personnel, the physically handicapped and disaster victims.

Health Protection: This Program endeavors to eliminate health hazards associated with the natural and man-made environments that lead to illness and untimely death. Principal activities include: assessment and control of the quality and safety of food, and safety and effectiveness of drugs and medical devices; the identification and assessment of environmental hazards; the surveillance of diseases; and the provision of specialized laboratory services.

Income Security: This Program is responsible for maintaining and improving the income security of the people of Canada. It administers three major income security programs: The Canada Pension Plan, Old Age Security and Family Allowances. It also assists in the administration of the Income Tax Act through a disability certification.

Fitness and Amateur Sport: This Program contributes to the increased fitness of Canadians and the promotion of excellence in domestic and international amateur sport by Canadians.

Departmental Administration: This Program provides executive direction and management services to the Department.

ACDI

Créée en 1968, l'Agence canadienne de développement international (ACDI) est l'organisme du gouvernement fédéral responsable de la gestion d'environ 75 % de l'aide publique au développement accordée par le Canada aux pays en développement.

Depuis 1987, l'ACDI participe à la lutte contre le SIDA dans le monde en appuyant le Programme mondial de lutte contre le SIDA (PMLS) de l'Organisation mondiale de la santé ainsi que les programmes nationaux de lutte contre le SIDA. L'ACDI estime que les efforts déployés pour lutter contre le SIDA dans les pays en développement devraient également permettre d'améliorer et de renforcer les systèmes de soins de santé primaires établis dans ces pays.

L'aide de l'ACDI vise principalement à soutenir les cinq stratégies communes à la plupart des programmes nationaux de lutte contre le SIDA, notamment : le contrôle épidémiologique; la prévention contre la transmission de la maladie par relations sexuelles, par la transfusion sanguine ou autres produits sanguins, ou encore pendant la période périnatale; et la réduction des effets du SIDA sur les individus et sur la société.

À l'intérieur de ce cadre d'intervention très large, l'ACDI a apporté son soutien à la réalisation d'enquêtes sur la connaissance du SIDA, sur les attitudes à son égard et sur les pratiques sexuelles; à diverses initiatives en matière d'information, d'éducation et de communication; à la lutte contre les maladies transmises sexuellement; aux traitements palliatifs; aux services de conseils aux personnes infectées et à leurs partenaires; à la protection des réserves nationales de sang; au perfectionnement du personnel de laboratoire et des méthodes de diagnostic. Les compétences des universités canadiennes, d'autres organismes gouvernementaux et des organisations non gouvernementales ont rendu possible la mise en place d'un bon nombre de ces activités et continueront à favoriser la réalisation d'autres initiatives de ce genre.

Les engagements financiers de l'Agence en matière de lutte contre le SIDA, atteignent actuellement plus de \$45 millions. L'ACDI est l'un des plus importants donateurs au PMLS, lui ayant fourni la somme totale de \$14,5 millions de 1987 à 1989.

À travers ses programmes bilatéraux, l'ACDI appui des programmes pluriannuels dans de nombreux pays d'Afrique, des Antilles et de l'Amérique latine, dans le cadre de leurs programmes nationaux de lutte contre le SIDA. Ainsi, l'ACDI s'est engagée à verser \$6,3 millions à l'Afrique anglophone et \$22,8 millions à l'Afrique francophone : ces sommes permettront la réalisation de différents projets, dont la préparation d'une brochure d'information en portugais qui sera distribuée au Mozambique ainsi que d'un programme intensif de huit ans, mis en oeuvre en Afrique francophone. Les interventions réalisées dans le cadre de ce programme seront concentrées dans les domaines de l'information, de l'éducation, de la communication, du perfectionnement des ressources humaines, de l'épidémiologie et des études en anthropologie.

En Amérique latine et aux Antilles, l'ACDI a accordé \$3,2 millions pour l'exécution de programmes régionaux et nationaux de lutte contre le SIDA.

D'autre part, la Direction générale des Programmes spéciaux de l'ACDI a affecté \$1,4 million à la réalisation de trois projets de lutte et d'information administrés par des organisations non gouvernementales. Dans le cadre de ces projets, on préconise l'utilisation d'une bande dessinée conçue à l'intention des enfants de la rue ainsi que celle de documents d'information que distribuera la Fédération internationale de planning familial.

D'autres projets sont actuellement à l'étude et il est à prévoir que la contribution de l'ACDI à l'effort international de lutte contre le SIDA augmentera à la faveur de la naissance de nouvelles initiatives et de la mise en place de nouveaux programmes nationaux de lutte contre le SIDA.

CIDA

Created in 1968, the Canadian International Development Agency (CIDA) is the federal government agency responsible for approximately 75 per cent of Canada's official development assistance to developing countries.

Since 1987, CIDA has contributed to the global fight against AIDS by supporting the World Health Organization's Global Program on AIDS (GPA), and national AIDS control programs. The Agency sees AIDS-control efforts as opportunities to complement and strengthen existing primary health care systems in developing countries.

CIDA's assistance primarily supports five basic strategies common to most national AIDS control programs: epidemiological surveillance; prevention of sexual transmission; prevention of transmission through blood and blood products; prevention of perinatal transmission; and reduction of the impact of AIDS on the individual and society.

Within these broad approaches, CIDA has supported surveys of AIDS knowledge, attitudes concerning AIDS and sexual practices; information, education and communication initiatives; control of sexually transmitted diseases; palliative care; counselling of infected individuals and their partners; protection of national blood supplies; and upgrading of laboratory personnel and diagnostic procedures. The expertise of Canadian universities, other government agencies, and non-governmental organizations has been instrumental in many of these endeavors, and will contribute to future initiatives.

The Agency's spending commitments on AIDS control projects now total over 45\$ million. CIDA is among the largest donors to the GPA, having contributed a total of \$14.5 million from 1987 to 1989.

Through the bilateral channel, CIDA supports multi-year programs in many African, Caribbean and Latin American countries, within the context of their national AIDS control programs. CIDA has committed \$6.3 million in Anglophone Africa, and \$22.8 million in Francophone Africa. Projects range from the preparation of an AIDS information pamphlet in Portuguese for distribution in Mozambique, to an eight-year intensive project in Francophone Africa, focusing on information, education, communication, human resource training, epidemiology, and anthropological studies.

In Latin America and the Caribbean, CIDA has designated \$3.2 million for sub-regional and national AIDS control programs.

Through the Special Programs Branch, \$1.4 million has been allocated to three projects administered by non-governmental organizations involving AIDS control or information. These projects include an instructional cartoon for street children, and support for the dissemination of information by the international Planned Parenthood Federation.

A number of additional projects are in the discussion phase, and CIDA's contribution to international AIDS programming is expected to increase as new initiatives and more national programs develop.

Le CRDI est une société d'État créée par le Parlement du Canada en 1970. La mission du CRDI consiste à favoriser le développement du Tiers-Monde par la recherche et des activités connexes.

Par "développement", le CRDI désigne le processus d'évolution sociale et économique constant en vertu duquel les habitants d'un pays parviennent à déterminer quels changements ils devraient apporter à leur société et comment effectuer ceux-ci. Pour cela, les pays en développement doivent participer à la prise de décision sur un pied d'égalité avec les autres pays et doivent profiter pleinement des conséquences du changement. Cette forme de développement permet aux habitants du Tiers Monde d'améliorer leurs conditions de vie sans pour autant sacrifier leur dignité et le respect d'eux-mêmes.

Le CRDI est convaincu que cette forme de développement est plus susceptible de se manifester quand une population mange à sa faim, est en bonne santé, manifeste un esprit d'indépendance, est fière de ses réalisations, respecte les droits d'autrui et voit les autres respecter les siens. C'est pourquoi elle parraine les recherches destinées à faire naître ces conditions.

Objectifs

Le but principal poursuivi par le CRDI est de soutenir la recherche pertinente au développement et dont les résultats probables faciliteraient les activités dans ce domaine. Le Centre s'intéresse particulièrement aux projets qui se concentrent sur les problèmes liés à la pauvreté.

En deuxième lieu, il vise à consolider les capacités de recherche des pays en développement. Comme il préconise une intégration suffisante de ses activités, le Centre prend grand soin de rattacher l'aide qu'il prodigue en formation aux projets et aux programmes de recherche qu'il soutient.

Son troisième objectif est de promouvoir la diffusion, la vulgarisation et l'application des résultats des projets qu'il parraine.

Un quatrième objectif consiste à établir des liens entre les scientifiques des pays en développement et à aider ceux-ci à avoir accès aux résultats des travaux poursuivis un peu partout dans le monde.

Pour y parvenir, le CRDI finance des groupes et des établissements de recherche dans les pays en développement et soutient des réseaux et des organismes régionaux dans le Tiers Monde. Ainsi, il espère créer un noyau de chercheurs dans chaque pays et favoriser le développement de réseaux de personnes et d'établissements qui disposeront des ressources nécessaires à la réalisation des projets de recherche et à l'exploitation de leurs résultats.

Depuis 1970, le CRDI a ainsi contribué à plus de 3 500 projets auxquels participent au-delà de 10 000 scientifiques de 900 établissements répartis dans plus de 100 pays.

Bureaux

Le CRDI compte sept bureaux—le siège social, à Ottawa, et six bureaux desservant diverses régions des pays en développement : Bogota, Colombie; Le Caire, Égypte; Dakar, Sénégal; New Delhi, Inde; Nairobi, Kenya; Singapour.

Pour de plus amples renseignements sur le CRDI et les projets subventionnés par le CRDI dans les pays en développement, veuillez vous adresser à :

Louise Behan (613) 598-0564 ou Diane Hardy (613) 598-0570

Agentes de relations avec les médias

CRDI

B.P. 8500

Ottawa (Ont.)

K1G 3H9

IDRC is a public corporation created by the Parliament of Canada in 1970. IDRC's mission is to contribute to development in the Third World through research and activities which support research.

IDRC uses the term "development" to mean a continuing process of social and economic change in which people have the power and ability to decide what changes to make in society, and how to make them. They must be able to participate equally in these decisions, and to share fully in the results of change. This kind of development makes people's lives materially better and encourages a sense of dignity and self-respect.

IDRC believes that this kind of development is most likely to happen when people eat properly, are healthy, have a sense of independence, are proud of their achievements, respect the rights of others and have their rights respected. It supports research which tries to foster these conditions.

Objectives

IDRC's main objective is to support research relevant to development and whose likely results could be used in development work. The Centre is especially concerned with research on the problems of poverty.

A second objective is to build up the research capacity and capability of developing countries. Since it wants its activities to be relatively well-integrated, the Centre very carefully links most of its support of training to research projects and programs it supports.

A third objective is to promote the diffusion, popularization and application of the results of the research which the Centre supports.

A fourth objective is to develop links among developing country researchers, and to provide them access to the results of world-wide research.

To achieve these objectives, IDRC funds research groups and institutions in developing countries, and provides some support to regional networks and institutions in the Third World. This support is designed to build a corps of researchers in each country, and to help develop the networks of people and institutions which provide the services needed to get research done and to use its results.

IDRC has supported more than 3,500 projects involving over 10,000 researchers in 900 institutions in more than 100 countries.

Offices

IDRC has its headquarters in Ottawa plus six regional bureaus to service particular regions of the developing world: Bogota, Colombia; Cairo, Egypt; Dakar, Sénégal; New Delhi, India; Nairobi, Kenya; Singapore.

For more information on IDRC or IDRC-funded projects in the developing world, contact:

Louise Behan (613) 598-0564 or Diane Hardy (613) 598-0570

Media Relations Officers

IDRC

P.O. Box 8500

Ottawa (Ont.)

K1G 3H9

Qu'est-ce que l'OMS?

L'Organisation mondiale de la Santé (OMS), institution spécialisée des Nations Unies créée en 1948, a 166 états membres. Elle agit en tant qu'autorité directrice et coordonnatrice, dans le domaine de la santé, des travaux ayant un caractère international. Les organes directeurs de l'OMS sont l'Assemblée mondiale de la Santé, "parlement" de la santé publique qui se réunit deux semaines par an, et le Conseil Exécutif, composé de 31 experts de la santé qui se réunissent deux fois par an.

Le secrétariat de l'OMS comprend environ 5 000 spécialistes opérant dans plus de 100 pays. Quelques-uns d'entre eux travaillent au siège de Genève et collaborent avec six bureaux régionaux en Afrique, dans les Amériques, en Méditerranée orientale, en Europe, en Asie du Sud-Est et dans le Pacifique occidental.

Les états membres contribuent directement au budget ordinaire de l'OMS—plus de 300 millions US \$ par an—et des contributions volontaires additionnelles, qui doublent pratiquement le budget de fonctionnement, financent des programmes spéciaux tels que le SIDA, la reproduction humaine, les maladies diarrhéiques et la recherche concernant les maladies tropicales.

La "Santé pour Tous" est le principal but de santé sociale que se sont fixés les gouvernements et l'OMS pour les décennies à venir. De nombreuses organisations non gouvernementales apportent leur appui et les individus sont encouragés à "s'aider eux-mêmes". La "Santé pour Tous" a été définie par l'Assemblée mondiale de la Santé comme "un niveau de santé qui permette aux gens de mener une vie socialement et économiquement productive".

Sous la tutelle impartiale de l'OMS, les pays ont au cours des 40 dernières années combattu ensemble les fléaux de l'humanité. Un exemple en est la variole, la première maladie mortelle jamais éradiquée de la surface du globe. L'OMS s'est maintenant engagée à éradiquer la poliomyélite, qui paralyse encore quelque 275 000 enfants chaque année. Grâce au programme de l'OMS de lutte contre la cécité des rivières, des millions d'enfants d'Afrique de l'Ouest ne deviendront plus aveugles. En 10 ans, le pourcentage des enfants vaccinés contre six maladies mortelles est passé de 5 à plus de 50%. À ce jour, plus de 100 gouvernements ont adopté la liste modèle de l'OMS des 200 médicaments considérés comme essentiels.

Les succès sont nombreux, mais les défis restent impressionnants. Des millions de gens sont encore pris dans un cercle vicieux de pauvreté, de malnutrition et de maladie et n'ont pas accès aux soins médicaux, à une eau saine et à des systèmes d'élimination des déchets. La pandémie de SIDA exigera pendant de nombreuses années une mobilisation mondiale. Pour relever ces défis, l'OMS souligne que l'engagement politique et la participation des populations seront des facteurs essentiels.

The World Health Organization (WHO), a specialized agency of the UN created in 1948, has 166 Member States. Its mandate is to act as the directing and coordinating authority on international health work. The two governing bodies of WHO are the World Health Assembly—a public health “parliament” which meets for two weeks every year—and the Executive Board, composed of 31 health experts who meet twice a year.

The Secretariat of WHO comprises some 5,000 specialists working in more than 100 countries. Of these, about 1,500 work at the headquarters in Geneva and there are six Regional Offices in Africa, the Americas, the Eastern Mediterranean, Europe, South-East Asia and the Western Pacific.

Member States contribute directly to the WHO regular budget—over US \$ 300 million per year—and additional voluntary contributions, which virtually double the working budget, support special programmes such as AIDS, human reproduction, diarrhoeal disease control and tropical disease research.

“Health for All” is the main social health target of governments and WHO for the coming decades. Valuable support to achieve this goal comes from numerous nongovernmental organizations, and much emphasis is placed on helping individuals to help themselves. Successive World Health Assemblies have defined “Health for All” as “a level of health that will permit people to lead a socially and economically productive life.”

Under the “neutral umbrella” of WHO, countries have, over the past 40 years, cooperated to combat together the scourges of humanity. An example is smallpox, the first killer disease ever to be eradicated from the world. Now WHO aims at eradicating polio, which still cripples about 275,000 children every year. As result of WHO’s river blindness control programme, millions of children in West Africa no longer risk going blind. Immunization coverage of children against six killer diseases—measles, tuberculosis, whooping cough, tetanus, polio and diphtheria has increased from 5% to over 50% in 10 years. To date, more than 100 governments have adopted the WHO model list of 200 drugs considered essential for good medical practice.

The list of achievements is very long but the challenges that remain are daunting. Millions of people are still trapped in a vicious cycle of poverty, malnutrition and disease, and have no access to medical care, clean water and safe waste disposal. The AIDS pandemic will require a global mobilization for many years to come. To meet these challenges, WHO underlines that the vital factors will be political commitment and people’s involvement.

Le Québec s'est doté d'un premier plan d'action sur le SIDA en 1987. Un groupe de travail, formé d'experts et de professionnels, a alors été constitué afin de fournir des éléments de réponse sur les questions éthiques et légales, la prévention, les soins, les aspects psychosociaux et la recherche.

La synthèse de ces travaux est devenue la principale source d'information à la base de la deuxième phase du plan d'action lancé par la Ministre de la Santé et des Services sociaux à l'occasion de la Journée mondiale du SIDA, le 1^{er} décembre 1988. Cette phase II comporte des mesures regroupées dans plusieurs champs d'activités avec prédominance de la prévention.

La prévention, par l'information et l'éducation, demeure encore le moyen le plus efficace de lutte contre le SIDA. Le Québec a identifié plus particulièrement quatre clientèles auprès desquelles devront s'articuler les efforts: la population en général, le milieu scolaire et la jeunesse, les personnes susceptibles de contracter le SIDA et celles avec lesquelles elles ont été en contact, et enfin certains groupes-cibles.

Le plan prévoit aussi des mécanismes d'information et de support pour toute personne désireuse de connaître sa situation par rapport au SIDA, des services de dépistage et de counseling, des subventions à des organismes communautaires pour des fins de support et d'entraide, des modalités pour la surveillance épidémiologique et des mécanismes de surveillance éthique relativement aux enquêtes de séroprévalence. Par ailleurs, des activités de formation et d'information sont prévues pour le personnel du réseau de la santé et des services sociaux, qui regroupe plus de 900 établissements.

En matière de soins hospitaliers, le plan d'action prévoit l'accessibilité à des services dans l'ensemble des centres hospitaliers québécois ainsi que la mise en place d'unités SIDA d'un maximum de 20 lits.

Pour les services complémentaires, l'orientation qui a été développée consiste à répondre aux attentes des malades qui souhaitent demeurer le plus possible dans leur milieu de vie ou dans un contexte qui lui ressemble. Ainsi, des projets pilotes de maisons d'hébergement ou de familles d'accueil spéciales et un programme de soins et d'aide à domicile sont mis en place.

L'évolution rapide de la maladie et l'état précaire des connaissances sur ce sujet nécessitent un accroissement des efforts en matière de recherche. Des fonds seront donc investis dans le développement de la recherche psychosociale et biomédicale et dans le perfectionnement des chercheurs.

Enfin, toutes les interventions seront l'objet d'une coordination et d'une évaluation visant à mesurer leur pertinence eut égard aux objectifs visés et aux résultats escomptés.

SANDOZ

SANDOZ Ltd., dont le siège social est situé à Bâle en Suisse, emploie plus de 43 000 personnes dans le monde entier dans des domaines aussi divers que la recherche et le développement, la fabrication de produits pharmaceutiques, chimiques et de matières colorantes, la nutrition et les produits agricoles.

Les recherches effectuées par Sandoz touchent cinq domaines de la médecine : neurologie, cardiologie, endocrinologie, immunologie et dermatologie. Cette entreprise investit, à l'échelle mondiale, plus de 700 \$ millions par an dans la recherche fondamentale et la recherche clinique. Les spécialités pharmaceutiques Sandoz comprennent des produits tels que le Parlodel (bromocriptine) et le Sandimmune (cyclosporine) qui représentent de grands progrès scientifiques. Ce dernier produit, en particulier, a ouvert la voie à la transplantation et à la maîtrise du système immunologique.

Sandoz contribue aux travaux de recherche des professionnels de la santé en parrainant des colloques sur la science et la médecine. Depuis plus d'un siècle, des hommes et des femmes chez Sandoz ont participé activement à une véritable révolution sociale. Grâce à leur esprit innovateur et leur désir de partager leurs connaissances scientifiques, leurs travaux ont permis des améliorations importantes dans les sciences médicales et la santé. C'est ainsi que certains médicaments les plus remarquables du XX^e siècle sont des produits provenant de la recherche entreprise par Sandoz.

Sandoz Ltd., with headquarters in Bâle, Switzerland, employs over 43,000 people around the world in research, development and manufacture of pharmaceuticals, chemicals and dye stuffs, nutrition and agricultural products.

SANDOZ directs its medical research into five main areas; Neurology, Cardiology, Endocrinology, Immunology, and Dermatology. The company invests more than \$700 million annually in basic and clinical research worldwide. SANDOZ medications include such breakthrough products as Parlodel (bromocriptine) and Sandimmune (cyclosporine). The discovery of Sandimmune has opened the road to organ transplantation and, ultimately, to control of the immune system.

SANDOZ contributes to the work of the health care community through the sponsorship of medical and scientific education forums. In fact, some of the most notable and advanced medications of the 20th Century are products of Sandoz research. For over a century now, the men and women of Sandoz have been active participants in a veritable social revolution. Through their spirit of innovation and desire to share knowledge, their endeavors have contributed to major improvements in medical science and human health.

Chaque année, la Société canadienne de la Croix-Rouge vient en aide à un Canadien sur six. Elle dessert la population à partir de plus de 1 000 postes non officiels, 608 sections, 10 bureaux divisionnaires provinciaux et territoriaux, et 17 centres de transfusion sanguine au Canada. C'est le siège social à Ottawa qui est responsable du Programme du sang et des Services internationaux, et qui coordonne 16 services de santé et d'action communautaire au pays. Toujours au siège social, le Laboratoire central constitue le centre de consultation du système canadien de transfusion sanguine et veille à l'élaboration et au respect des normes établies à l'égard du sang et des produits sanguins. La Société canadienne de la Croix-Rouge désire remercier la "Vancouver PWA Society" et le Comité des personnes atteintes du virus de l'immunodéficience humaine (CPAVIH) du Comité SIDA Aide Montréal (CSAM), pour leur aide au centre d'accueil et de repos pour les personnes atteintes du SIDA.

The Canadian Red Cross Society touches the lives of one in six Canadians every year. Its services are delivered through more than 1,000 informal units, 608 branches, 10 provincial/territorial divisions, and 17 blood centres across Canada. The National Office in Ottawa is responsible for the national blood program and international services, and co-ordinates 16 health and community initiatives across the country. The National Office includes the NRL (National Reference Laboratory), the reference centre for the national blood system, developing and monitoring the standards and quality of blood and blood products. The Canadian Red Cross Society gratefully acknowledges the assistance of the Vancouver PWA Society and the PWA Committee of CSAM (Comité SIDA Aide Montréal) in the operation of the PWA Rest and Welcome Centre.

**Société canadienne
de la Croix Rouge**
Red Cross Society

**L'Industrie des
assurances de
personnes au
Canada**

**The Life and
Health Insurance
Companies in
Canada**

Cent soixante-cinq sociétés d'assurance-vie offrent leurs services aux Canadiens. En coordonnant ses efforts et en allouant des ressources financières, l'industrie canadienne des assurances de personnes est en mesure d'apporter une aide importante à la lutte contre le SIDA et de faire ainsi preuve d'initiative dans ce domaine.

En 1987, elle a mis sur pied un Groupe de travail des chefs de direction sur les projets concernant le SIDA pour faire face à la menace que constitue cette maladie dévastatrice pour l'industrie et l'ensemble de la société.

Le plus sûr moyen d'enrayer la propagation du SIDA étant la prévention, l'objectif principal des projets parrainés par l'industrie est donc l'information, en particulier celle diffusée en milieu de travail et auprès des jeunes. L'industrie a financé un certain nombre de projets à cet égard et est constamment à la recherche d'autres projets dignes d'intérêt.

Canadians are served by 165 active life insurance companies. Through collective action and funding, the life and health insurance companies in Canada have the opportunity to make a significant contribution to the fight against AIDS and to show leadership on this issue in this country.

In 1987, the life and health insurance industry formed a CEO Task Force on AIDS Projects in response to the threat this devastating disease poses to business and to society.

The life and health insurance companies in Canada consider prevention the one sure way to curb the spread of AIDS. Therefore, the primary focus for industry-sponsored projects is on education, especially among young people and in the workplace. The industry has funded a number of projects in this area and is continually seeking other projects appropriate for consideration.

One of the companies that make up AKZO's Pharma Division, ORGANON TEKNIKA focuses its activities on the R&D, manufacturing and marketing of high-tech products for hospitals, blood banks and laboratories.

From its headquarters in Turnhout, Belgium, ORGANON TEKNIKA serves a worldwide market via 40 local companies in all important geographical regions and production sites in the Netherlands, Ireland and the United States of America.

ORGANON TEKNIKA provides a range of HIV diagnostics for a range of applications. The latest contributions to the diagnosis, monitoring or confirmation, of HIV-infection are VIRONOSTIKA ANTI-HIV UNI-FORM (compatible with testing procedures for HBsAg and anti-HBc),

VIRONOSTIKA HIV antigen, VIRONOSTIKA anti-Core and VIRONOSTIKA anti-ENV, which will be introduced at the V International Conference on AIDS together with HIV-LIA. Accomplishments diagnostic system, which also includes for instance the HEPANOSTIKA line of HAV and HBV assays and an extensive series of modern tests and dedicated equipment for still other viral, bacterial, parasital and endocrinological parameters.

With more than 25 years of experience in the field—including the invention of worldwide accepted standards like ELISA—ORGANON TEKNIKA has become a trendsetter in the systematizing of diagnostic praxis.

Index

Indexes

Index des auteurs Authors' Index

A

- A Povo, C.**
Th.B.P.377
- Aaby, P.**
Th.B.P.166, T.G.P.31, G.517
- Abad, S.**
M.B.P.59
- Abascal, L.**
T.E.P.76
- Abascal, Luis**
D.669
- Abdessa, S.**
M.A.P.13
- Abdessa, V.**
M.B.P.248
- Abbate, E.**
Th.G.O.3
- Abbatte, E.**
B.536
- Abbatte, E. A.**
A.515
- Abbott, R.**
W.B.P.166
- Abboud, C. S.**
G.509
- Abbud, N.**
M.E.P.31, W.E.P.37, E.610
- Abbud, N. M.**
E.665
- Abdul-Quader, A.**
Th.D.O.6, Th.D.P.17,
Th.E.P.4, E.726
- Abdul-Quader, Abu**
Th.D.P.64
- Abdullah, Tariq H.**
Th.B.P.304
- Abdurahman, M.**
T.A.P.102
- Abe, T.**
W.B.P.311
- Abel, C.**
T.B.P.136
- Abel, S. N.**
Th.B.P.350
- Abelhauser, A.**
W.A.P.88
- Abella, E.**
Th.A.P.22, M.B.P.251
- Abellard, M.**
T.D.O.32
- Abels, R.**
M.B.P.328
- Abeni, D.**
T.A.P.5, A.527, W.E.P.45,
E.622
- Abenia, M. C.**
Th.D.O.12
- Abisogun, B.**
M.B.P.314
- Abissey, A. S.**
B.535
- Abita, J. P.**
C.591
- Abiteboul, Dominique**
D.622
- Ablashi, D.**
Th.C.P.64, Th.C.P.72, C.740
- Abos Navarro, Josep**
Th.B.P.193
- Aboud, M.**
T.C.P.119
- Aboulafia, D.**
M.G.P.12, M.G.P.13,
M.G.P.14, M.G.P.20
- Aboulafia, David M.**
Th.A.P.8
- Aboulker, Jean-Pierre**
W.B.P.302, Th.B.P.149
- Abrahamsson, B.**
Th.C.P.125
- Abramowitz, A.**
W.D.P.74, Th.D.P.33,
Th.D.P.34
- Abrams, D.**
A.626, T.B.P.312
- Abrams, D. I.**
T.B.O.3, T.B.P.76, M.H.P.2
- Abrams, Donald I.**
W.B.P.247, W.B.P.315
- Abrams, K.**
W.C.P.10
- Abreu, E. A. V.**
M.B.P.162
- Abreu, W. B.**
M.B.P.93, T.G.P.14, Th.G.P.3
- Abreu-Larancuenti, L.**
T.D.P.32
- Abud, N.**
T.E.P.69
- Abulafia, O.**
Th.D.P.60
- Accetturi, C.**
B.539, Th.G.P.26, G.515
- Accetturi, C. A.**
M.B.P.263, Th.B.P.38,
Th.B.P.63
- Accetturi, Conceição A.**
M.B.P.266, T.B.P.356
- Accurso, V.**
M.B.P.248
- Accetturi, C. A.**
M.B.P.279
- Aceves-Casillas, P.**
M.B.P.69
- Achik, G.**
B.517, C.681
- Achladas, C.**
E.615
- Achour, Ammar**
M.C.P.30
- Achterhof, L.**
E.651
- Acosta, A.**
W.H.P.2
- Acres, B.**
W.C.O.33
- Acton, T.**
T.D.O.16
- Acuna, G.**
W.A.P.118
- Adachi, A.**
M.C.O.25
- Adal, G.**
T.A.P.102
- Adam, Zennan E.**
T.E.P.21
- Adamkiewicz, V. W.**
B.564
- Adams, H. G.**
M.H.P.14
- Adams, I.**
Th.B.P.114, T.D.P.25
- Adams, M.**
W.C.P.65
- Adams, P.**
T.C.P.27
- Adams, R.**
Th.D.O.9
- Adams, S.**
E.687
- Adams, S. E.**
M.C.P.34, M.C.P.35, C.530
- Adams-MacKie, B. A.**
C.622
- Adamski, M.**
Th.C.O.24
- Adamsons, K.**
M.B.P.28
- Adao, V. M.**
M.E.P.31
- Adatia, A.**
M.B.P.157, T.B.P.350,
T.B.P.359
- Adaw, S.**
W.G.P.27
- Adda, D.**
Th.C.P.86
- Addy, C.**
D.647, E.752, E.758
- Adekunle, Lola Vivian**
T.G.P.23
- Adeniyi-Jones, Samuel R.**
T.C.P.136
- Adeokun, L. A.**
M.G.O.18
- Adeokun, Lawrence**
Th.G.O.11
- Ades, A.**
W.A.O.9
- Ades, A. E.**
Th.A.O.3, Th.A.O.4
- Adetugbo, A.**
W.E.P.51
- Adib, S. Maurice**
T.D.P.36
- Adinolfi, A.**
E.528
- Adinolfi, Anthony J.**
D.670
- Adinolfi, T.**
M.H.P.10
- Adjorlolo, G.**
T.B.O.10
- Adler, J. J.**
W.A.P.16
- Adler, Karl E.**
Th.B.O.10
- Adler, M. W.**
T.A.O.9
- Adler, W.**
M.C.P.14
- Adler-Storzh, K.**
Th.B.P.330
- Adrados del Llano, M.**
B.647
- Adrien, A.**
M.D.P.65
- Adrien, Alex**
M.D.P.33, D.534, M.E.P.10,
Th.E.P.26
- Adrien, M.**
W.A.P.7, T.D.O.32
- Adrien, Mario**
T.G.O.20
- Adu-Krow, W.**
E.653
- Advani, M.**
T.B.P.210
- Aeberhard, F.**
D.575, W.E.P.27
- Aeberhard, François**
Th.E.P.7
- Aebischer, M. L.**
M.G.P.9
- Aepinus, Christian**
C.679
- Afessa, B.**
M.B.P.238
- Afessa, Bekele**
M.B.P.201
- Afonso, C.**
W.E.O.16
- Agarossi, A.**
M.B.P.56
- Agata, N. N.**
W.H.P.15
- Agbalika, F. A.**
W.B.P.106, B.619
- Aggarwal, S. K.**
M.C.P.64

- Aggleton, P. J.
M.P.2
- Aggleton, Peter J.
T.E.O.12
- Agins, Bruce D.
A.590, W.B.P.64
- Agius, G.
C.733
- Agius, Gérard
M.A.O.14, M.C.P.28, C.702
- Agnelli, F.
W.B.P.205
- Agnoletto, V.
E.790, E.814
- Agosti, J. M.
W.C.P.97
- Agosti, Jan M.
M.C.P.101
- Agostini, Carlo
Th.B.P.78, Th.B.P.79
- Agrafiotis, Demosthenis
E.654
- Agrawal, Krishna C.
M.C.P.64
- Agrawal, Sudhir
M.C.P.80
- Agren, Gunnar
W.F.O.21
- Agresti, M. G.
M.B.O.46, M.B.P.92,
W.B.P.370
- Aguado, I.
W.B.P.165
- Aguillon, O.
W.D.P.30
- Agut, H.
Th.B.P.219
- Agut, Henri
Th.B.P.235, B.547
- Agy, M.
Th.C.P.89
- Ahern, S.
T.C.P.86
- Ahlgren, D. J.
T.E.P.16
- Ahlgren, David J.
T.A.O.38, Th.A.P.56
- Ahluwalia, G. S.
W.B.P.275
- Ahmad, Nafees
T.C.P.102
- Ahmed, E. A.
M.B.P.341
- Aho, S.
M.B.P.88, T.B.P.304
- Aldoo, Akwasi
M.F.O.4
- AIDS Community
Demonstration Projects
M.D.P.32
- Aluti, F.
B.643, T.C.P.41, C.718
- Ajaniku, I.
T.A.P.100
- Ajdukovic, D.
Th.B.P.356, Th.B.P.366,
B.564, W.C.P.94
- Ajuluchukwu, D.
T.A.P.49, A.550, D.610, D.611
- Ajuwon, B.
Th.E.P.38
- Akabutu, J.
Th.B.P.28
- Akarasewi, P.
W.D.P.73, T.G.O.23, W.G.P.19
- Akatani, K.
W.B.P.298
- Akerblom, L.
M.C.P.26
- Åkerblom, L.
C.547
- Akerblom, Lennart S.
M.C.P.10, Th.C.P.80
- Åkerlund, B.
Th.B.P.88
- Akil, B.
M.B.P.45, M.B.P.285, T.B.P.10
- Akil, Bisher
M.B.P.286, T.B.P.286
- Akins, C.
T.G.O.11
- Akins, R.
Th.B.O.59
- Akman, J. S.
E.665
- Akoun, G.
B.559, B.589
- Akpan, Sandra
D.631
- Al-Qubati, Y.
T.B.O.9
- Alam, M.
Th.C.P.138
- Alameda-Lozada, José I.
W.H.P.5
- Alan, Diana L.
W.D.P.34
- Alan, Diana Lynne
T.D.P.82
- Alanis, L.
M.D.P.69
- Alarcon, J.
Th.D.O.7
- Alarcón, Jorge
Th.H.P.17
- Alary, Michel
M.A.O.21, Th.E.P.18
- Albano, A.
M.B.P.44
- Albeck, M.
W.B.P.320, T.C.P.142
- Albert, J.
W.B.P.147, M.C.O.9,
W.C.P.141, Th.C.P.92, C.523
- Albert, Jan
Th.C.P.125
- Albertini, A.
M.A.P.78
- Albertoni, F.
T.A.P.113
- Albrecht, G.
E.745
- Albrecht, K.
C.694
- Alcalde, X.
W.B.P.120
- Alcami, J.
C.525
- Alcantara, R.
Th.D.O.10
- Alcindor, A.
M.E.P.10
- Aldavert, L.
D.671
- Alderson, O.
E.541
- Aldrich, M.
Th.A.P.68
- Aldrich, M. R.
Th.D.P.13
- Aledori, L. M.
W.A.P.61
- Aledori, Louis M.
Th.B.O.38
- Aleksijevic, A.
T.C.P.43
- Alemi, F.
T.H.P.4
- Alessi, E.
A.545, M.B.P.50
- Alevizou, S.
Th.D.P.72
- Alexander, H.
W.B.P.245
- Alexander, L.
M.A.P.2
- Alexander, Linda L.
M.D.P.17
- Alexander, S.
Th.A.O.34, T.B.P.237,
Th.C.P.25, Th.C.P.108,
Th.C.P.115
- Alexander, V.
T.E.P.40
- Alexander, W. A.
E.553
- Alfaro, C.
T.E.P.37
- Alfonsi, E.
Th.B.O.20
- Alford, D. R.
Th.C.P.107
- Alger, L.
W.A.P.47, M.B.P.12
- Algra, Y.
T.D.P.47
- Ali, Kaiser
Th.B.P.20
- Ali, S. K.
W.B.O.27
- Alizon, M.
T.C.P.97
- Allain, J. P.
M.A.O.33
- Allain, J.-P.
T.B.P.93, W.B.P.139
- Allam, S.
M.C.P.146
- Allan, Davis J.
T.B.P.303
- Allan, J. D.
Th.B.O.5, W.B.P.328
- Allan, M.
M.B.P.175, Th.B.P.328
- Allard, R.
M.D.P.64
- Allribitten, Dorothy J.
W.E.P.21
- Allen, B. J.
Th.B.P.298
- Allen, D.
W.D.O.1, W.D.P.24
- Allen, David M.
T.A.O.10
- Allen, F.
T.B.P.167
- Allen, R.
W.B.P.71
- Allen, R. A.
M.F.O.2
- Allen, R. G.
Th.C.P.37
- Allen, Robert
W.B.O.16a
- Allen, Robert E.
W.A.P.26
- Allen, S.
W.B.P.353, T.E.O.3
- Allen, Susan
Th.D.O.20
- Allen, V.
C.632
- Allerton, Micheal W.
W.E.P.54
- Almedal, C.
T.E.O.3, Th.E.P.65
- Almeida, J. D.
C.784
- Almeida, Manuel José M.
M.G.P.2
- Almeida, Matos, M.G.
M.B.P.82
- Almeida, W.
T.E.P.64
- Almeida, Walter
T.E.P.60
- Alom Poveda, J.
Th.B.P.193

- Alonso, P.
T.G.P.32
- Alowalsh, Rashed
W.G.P.4
- Alsn, D. L.
M.D.O.12
- Alter, H.
A.534, W.B.P.154
- Alter, M. J.
T.A.P.26
- Alteri, E.
C.724
- Altes, J.
M.B.P.97
- Althoff, P. H.
M.B.P.265, M.B.P.270
- Althoff, Peter-Henning
Th.B.O.42
- Altholz, J.
M.A.P.51
- Altman, N. L.
W.D.P.66
- Altman, R.
W.A.O.7, Th.A.O.23
- Altmann, M.
Th.A.P.73
- Alton, K.
M.C.P.52
- Alvarado, R.
Th.B.P.228
- Alvarez, H. L.
T.B.P.193
- Alwood, K.
Th.A.P.100, M.B.O.35,
Th.D.P.24
- Alwood, Karla
W.B.P.52
- Amaana, A.
T.A.P.11
- Amadori, A.
T.B.P.244
- Amadori, Alberto
Th.C.P.144
- Amama, A. B.
M.E.O.8
- Amaral, L.
M.A.P.10, Th.A.P.4
- Amaro, F.
W.E.P.76
- Amaro, Fausto
Th.E.P.46
- Amat Cortadillas, T.
T.G.P.8
- Amat, M. L.
M.E.P.10
- Ambuel, B.
E.590
- Ameisen, J. C.
Th.B.P.178
- Ameisen, Jean-Claude
Th.C.O.6
- Ametson, J. C.
Th.B.P.10
- Amer, H.
M.G.P.22
- Amecua, C.
W.D.P.37
- Amicucci, P.
M.C.P.39
- Amiel, C.
C.541
- Amiel, Corinne
T.C.P.44, T.C.P.45
- Amirault, C.
W.C.P.77
- Ammar, A.
M.A.P.80, W.B.P.69
- Amory, J.
M.H.P.6
- Amory, J. W.
T.H.O.5
- Amory, J.W.
T.E.P.41
- Ampel, N. M.
C.632
- Ampel, Neil M.
M.B.P.46
- Amrheim, C.
M.C.P.37
- Amsel, Z.
T.A.P.40
- Anabitarite, H.
A.544, Th.D.P.19, Th.E.P.46,
E.515, E.526, M.H.P.21
- Anabitarite, Héctor
T.E.P.73, E.777
- Anabwani, G.
Th.B.O.39
- Anand, Raj
Th.F.O.1
- Anand, Rita
Th.C.P.113
- Anantha Subramaniam, L.
Th.G.P.24
- Anarella, Joseph P.
T.E.P.33
- Anastasi, A. M.
Th.C.P.99
- Anastos, K.
B.507
- Anastos, Kathryn
B.507
- Ancelle-Park, R.
M.A.O.24, Th.A.O.20, T.A.P.98
- Ancelle-Park, R. A.
M.A.O.7, W.H.P.22
- Ancelle-Park, Rosemary
W.A.P.15, A.537
- Andary, M.
Th.B.P.113
- Andersen, J.
W.C.P.29
- Andersen, D.
A.624, M.C.O.13, M.C.P.98
- Andersen, D. C.
T.C.O.42, W.C.P.15, C.758
- Anderson, D. J.
A.623, A.625
- Anderson, Daniel C.
W.C.O.45
- Anderson, David W.
Th.A.P.31
- Anderson, E.
Th.A.P.112, E.684
- Anderson, E. J.
M.H.O.16
- Anderson, E. L.
M.C.P.32
- Anderson, E. S.
M.E.P.27
- Anderson, Elizabeth S.
T.H.O.2, T.H.P.12
- Anderson, J.
M.A.O.4, M.B.P.10, Th.D.P.24
- Anderson, J. E.
M.A.O.2, M.D.P.1
- Anderson, Jean R.
Th.D.P.10
- Anderson, M. D.
Th.D.P.43
- Anderson, P.
T.A.P.21, W.A.P.39, E.720
- Anderson, R.
M.A.P.99, Th.A.P.84, A.822
- Anderson, R. E.
A.583
- Anderson, R. M.
T.A.O.40, Th.A.P.75, A.524,
D.545, T.H.O.16
- Anderson, Robert E.
Th.B.O.29, T.B.P.85,
Th.B.P.144, E.732
- Anderson, Roy
Th.A.O.2
- Anderson, V.
T.B.P.370, Th.B.P.372, B.580,
Th.E.O.9
- Anderson, V. M.
D.512
- Anderson, Virginia M.
B.583
- Anderson, W. F.
Th.C.O.11
- Andersson, B.
W.D.P.65, Th.D.P.36
- Andes, A.
C.780
- Andes, W. Abe
Th.B.P.19, Th.B.P.311
- Andiman, Warren A.
T.B.P.228
- Andrada, A.
Th.G.O.25
- Andrada-Serpa, Maria-José
M.A.P.53
- Andrade Perez, M.
E.806
- Andrade, D.
C.745
- Andrade-Arzabe, R.
Th.B.P.228, G.512
- André, C.
Th.B.P.189
- Andreasson, P. -A.
Th.C.P.8
- Andreasson, P. A.
T.B.P.104
- Andreasson, Per-Ake
M.C.P.16
- Andreesen, R.
C.823
- Andreu, A.
A.589
- Andreu, P.
A.572
- Andreu, R.
M.E.P.67
- Andrés, A.
T.B.P.18
- Andrés, E.
M.B.O.45
- Andrés, Laurie
W.B.P.238
- Andrés, R.
W.E.P.70
- Andrés, Roxanne M.
T.H.P.17
- Andrés, S.
M.B.P.141, M.B.P.142,
T.B.P.344
- Andrés, W.
T.C.P.80
- Andriamampihantona, E.
M.G.P.7
- Andrieu, J. M.
M.B.P.51, W.B.P.302,
W.B.P.355, Th.B.P.143,
Th.C.P.104
- Andrieu, Jean-Marie
Th.C.O.39
- Andriolo, Mario
D.633
- Andriolo, Mario, Jr.
Th.B.P.350
- Andronico, F.
C.567
- Andrulis, Dennis P.
M.H.P.18
- Andrus, Jon K.
Th.E.P.32
- Andrzejewski, C.
Th.B.P.126
- Aneja, R.
Th.C.P.36
- Anema, J. T.
W.B.O.35
- Angarano, G.
Th.D.P.39, Th.D.P.40
- Angeloff, Luben G.
M.C.P.140
- Angeloni, P.
M.A.P.8, M.A.P.36, T.B.P.341

- Angeloni, U.
M.A.P.8
- Angeloni, V.
M.G.P.9
Th.G.O.32
- Angus, P.
Th.G.O.32
- Ankrah, E. Maxine
M.G.O.15, W.G.P.32
Th.G.P.19
- Annas, George J.
M.F.O.15
- Annin, Burt J.
D.512, Th.E.O.S, M.E.P.71
- Ansari, A.
T.C.O.42, W.C.O.45, W.C.P.15
- Anselmo, A.
T.A.P.108, Th.B.P.13
- Anselmo, W.
W.B.P.309
- Anthony, J. C.
T.A.P.44, T.A.P.45, W.A.P.90
- Anthony, T.
M.E.P.42
- Antinori, A.
M.B.P.230, Th.B.P.96,
Th.B.P.99
- Antinori, Andrea
M.B.P.229, Th.B.P.72
- Antinori, S.
M.B.P.216
- Antipa, L.
W.C.P.18
- Antolin, J.
W.H.P.2
- Antonelli, G.
M.C.P.39
- Antonello, O.
M.B.P.171
- Antoni, M. H.
T.D.P.42, D.677, D.681
- Antoniskis, D.
M.B.O.49, W.B.O.5,
W.B.P.312
- Antoniskis, Diana
M.B.P.45, W.B.P.24
- Antonucci, G.
W.B.P.16, Th.B.P.220,
M.E.P.61
- Antunes, F.
M.A.P.77, Th.B.P.123
- Anumudu, Nicolas
M.E.O.29
- Anzala, Aggrey
Th.A.O.25
- Anzén, B.
W.A.O.10
- Aoki, F. H.
M.B.P.93, T.G.P.14
- Aoki, Francisco H.
T.D.P.16, D.547, Th.G.P.3
- Aoki, T.
C.750
- Apisoock, Chantawipa
T.G.O.15
- Aprilli, G.
M.B.P.171
- Apson, J.
E.547
- Aral, S. O.
W.E.P.1
- Aral, Sevgi O.
T.D.O.11
- Aranda-Anzaldo, A.
Th.C.P.64
- Araneta, M. R. G.
W.A.P.16
- Araneta, Maria Rosario G.
W.A.P.11
- Arano, M.
B.605
- Arasteh, K.
M.B.P.120, Th.B.P.45
- Arasteh, Keikawus
T.B.P.28
- Araujo, M. F.
M.B.P.40
- Arbaje, M.
M.E.O.11
- ARC-IVIG-Study-Group
Cologne/Berne
W.B.P.291, C.573
- Arca, M.
E.622
- Arcá, M.
T.A.P.5, A.526, A.527
- Archambault, M. P.
T.B.P.273
- Archibald, D.
Th.B.P.171, C.522
- Archibald, David W.
T.B.P.238, M.C.P.37
- Archibusacci, C.
Th.B.P.72
- Archinard, P.
Th.C.P.75
- Arcla, J.
T.B.P.8
- Arcidiacono, I.
W.B.P.365
- Arday, David R.
W.B.P.225
- Ardito, F.
Th.B.P.72
- Arditti, D.
M.C.P.11
- Arella, M.
C.675, C.676
- Arendt, Gabriele
Th.B.P.265
- Arendt, V.
W.A.O.19
- Arens, Max
B.553
- Arenson, C.
E.512
- Arenzana-Seisdedos, F.
C.525
- Arenzana-Seisdedos,
Fernando
W.C.P.121
- Argirova, Radka
W.B.F.178
- Argov, S.
W.C.P.129
- Argueles, L.
W.D.P.57
- Arguelles, L.
T.E.P.15
- Argüelles, Lourdes
Th.D.P.12
- Argyroudis, E.
Th.H.P.15
- Arici, C.
M.A.P.95
- Arici, Claudio
W.B.P.352
- Arico, Maurizio
T.B.P.264
- Arida, Elie N.
T.C.P.148
- Ariens, J.
W.B.P.96
- Aristegui, J.
E.579
- Armando, E.
B.513
- Armas, Portela
W.H.P.2
- Armbruster, Christine
M.B.P.213
- Armenakas, N.
M.B.P.274
- Armengaud, M.
Th.C.O.39
- Armenian, H.
W.A.P.40
- Armignacco, O.
W.B.P.16, Th.B.P.220,
M.E.P.61
- Armitage, G.
W.C.P.32
- Armstrong, D.
A.548, W.B.O.39, T.B.P.53,
W.B.P.312, W.B.P.374,
M.C.P.151, D.648
- Armstrong, J.
W.A.P.41, M.H.P.23
- Armstrong, J. A.
M.B.P.355, W.B.P.303
- Armstrong, M. Y. K.
Th.A.P.7Anebon, M.
W.A.O.10
- Arneson, C.
M.B.P.315
- Arnett, G.
M.C.P.65
- Arno, P.
T.H.P.16
- Arno, Peter S.
T.H.P.8
- Arnold, B.
M.C.P.55
- Arnold, Wendy
T.D.O.28, T.G.O.10
- Aronow, H. A.
W.B.P.255, Th.B.P.249
- Aronow, Howard
Th.B.P.257
- Arora, P. K.
C.605, C.709, D.533
- Arora, Sunil K.
Th.G.P.9
- Arras, John D.
T.F.O.19
- Arras, Marcella
Th.B.P.158
- Arredondo Miguel, Carmen
M.E.P.22, E.663, Th.F.P.12
- Arredondo, C.
A.544, T.E.P.27, E.765, E.766
- Arrizabalaga, C.
W.B.P.66
- Arrizabalaga, J.
W.A.P.75, T.B.P.278,
W.B.P.66, Th.B.P.55, B.601
- Arroyo, A.
B.583
- Arroyo, Ramon A.
Th.B.P.141
- Arruda, E. N.
M.B.P.266
- Arseanian, Sergey G.
T.B.P.91
- Arthos, J.
W.C.O.12, C.528
- Arthur, K.
M.A.P.71, W.B.P.258
- Arthur, L.
C.513
- Arthur, L. O.
Th.B.P.177, M.C.P.38
- Artigas, Juan
Th.B.O.22, M.B.P.95,
W.C.P.60
- Artioli, A.
M.B.P.65
- Aruffo, J.
W.D.P.5, E.763
- Aruffo, John
W.D.P.35
- Arulraj, A.
G.521
- Arvin, A.
B.526
- Arvin, A. M.
W.B.O.2
- Arvin, T.
M.C.P.102
- Arva, S. C.
T.G.P.19

- Arya, Suresh K.
T.C.P.127
- Asato, N.
W.C.O.8
- Ascher, M.
M.A.P.99, Th.A.P.40, E.718
- Ascher, M. S.
T.B.P.359
- Ascher, Michael S.
W.C.P.145, C.708
- Ashery, Rebecca S.
D.582, W.E.P.13, E.568,
E.676, E.800, E.801
- Ashman, M.
Th.B.P.223
- Ashmun, R.
M.C.P.120
- Asjö, B.
M.C.O.9, T.C.O.3, T.C.O.28
- Åsjö, B.
Th.C.P.92
- Askew, Mark J.
W.E.P.18
- Aslanivatan, E.
M.D.P.5
- Asma, L.D.
M.G.O.12
- Asnis, G.
W.B.P.214
- Asp, Anna-Karin
T.E.P.76, E.780
- Aspa Marco, Francisco J.
M.B.P.212, M.B.P.214,
Th.B.P.77
- Ass. Teachers in Gen. Med.
E.607
- Assal, G.
Th.B.P.212
- Assan, D.
T.B.P.319
- Assan, R.
T.B.P.319
- Assaykeen, T.
M.B.P.48
- Assoa, A.
M.G.P.25
- Astarloa, L.
D.686, D.706, Th.G.O.3,
Th.G.P.17
- Astarloa, L. N.
A.586
- Asthagiri, R. B.
Th.G.P.24
- Astua, M.
B.511
- Astua, M. C.
Th.B.P.14
- Atassi, H.
M.C.P.20
- Atassi, M. Z.
M.C.P.20
- Atchison, R.
Th.A.P.95
- Athanassopoulos, A.
T.C.P.139, Th.C.P.27
- Atthey, T. W.
W.A.P.101
- Atikala, L.
T.B.P.107, W.B.P.156
- Atkhen, P.
M.A.P.25
- Atkinson, Amy R.
T.B.P.101
- Atkinson, J.
T.B.P.260, Th.D.P.24
- Atkinson, J. C.
Th.B.P.363
- Atkinson, J. H.
W.B.P.230, Th.B.P.195,
Th.B.P.262, T.D.P.79
- Atkinson, J. Hampton
W.B.P.223, W.B.P.233
- Atkinson, V.
M.E.P.51
- Atkinson, W.
T.A.P.33, W.B.P.8
- Atkinson, William
T.A.P.50
- Atkinson, William L.
B.519
- Attas, H. A.
W.E.P.55
- Aubert, A.
M.C.P.2
- Aubert, C.
M.C.O.30
- Auckenthaler, R.
Th.B.P.58
- Audifore-Hargreaves, K.
E.719
- Audoin, J.
M.A.O.16
- August, Sharon M.
T.D.P.42
- Auguste, U.
Th.G.O.51
- Auleb, Ann W.
W.E.P.34
- Aultman, Kathryn S.
T.G.P.1
- Auroux, M.
T.A.P.92, W.C.P.100
- Austin, A. A.
W.B.P.330
- Autran, B.
Th.B.P.149
- Autran, Brigitte
M.B.P.42, T.C.P.25
- Auza, J.
Th.B.P.228
- Averdunk, R.
Th.C.P.88
- Averous, S.
M.A.P.46, A.574, T.B.P.90
- Avila, C.
W.G.P.24
- Avilez, F.
T.B.P.349
- Aviliez, F.
M.A.P.82, M.A.P.86
- Avio, C.M.
W.E.P.19
- Avonts, Dirk
M.A.P.66, M.D.P.67
- Avramis, V.
T.B.P.46
- Avramis, Vassilios I.
C.593
- Aw, D.
C.781
- Awerbuch, T.
Th.A.P.81, A.507, W.H.P.24
- Axel, R.
W.C.O.12
- Axthelm, M. L.
W.C.P.147
- Aya, G. M.
M.B.P.91
- Ayanian, J.
M.B.P.200
- Aye, M. T.
T.B.P.306
- Ayehunie, Seyoum
M.A.P.79
- Ayhunie, S.
T.A.P.102
- Aylmer, F.
Th.G.O.43
- Ayre, Steven G.
W.C.P.24
- Ayres, Laura
M.A.P.82, M.A.P.86
- Ayroza, Galvao
T.A.P.17
- Azevedo Pereira, J. M.
A.511, M.G.P.2
- Azevedo, M.
T.B.P.336
- Aziz, D.
M.C.O.11, W.C.O.28
- B**
- B.C. Civil Liberties Ass.,
Th.F.P.8
- Ba, M.
W.E.P.4
- Ba, O.
E.798
- Baba, M.
Th.C.O.20, C.550, C.595,
C.621, C.641
- Baba, Masanori
M.C.P.75
- Babe, L.
M.C.P.84, C.666
- Babin, F.
M.A.O.41, T.A.P.22, A.569,
A.572, A.633, M.B.P.59,
- Babiuch, L.
M.A.P.69
- Baca, L.
M.C.O.20
- Baccard, J. P.
C.706
- Baccard, M.
B.530
- Baccard-Longere, M.
T.B.P.231
- Bacchetti, P.
T.A.O.11, T.A.O.31,
M.A.P.100, T.A.P.47,
Th.A.P.24, A.526, T.B.P.312,
W.B.P.196, W.C.P.38, E.727,
E.729
- Bach, Michael C.
M.B.P.247
- Bachelor, L.
Th.C.O.26
- Bachelor, L. T.
T.C.P.83
- Bachelor, Lee T.
C.776
- Bachelerie, F.
W.C.P.121, C.525
- Bachelerie, Françoise
Th.C.O.23
- Bachelet, J. F.
Th.E.P.21
- Bachetti, P.
Th.A.P.102, W.B.P.231
- Bachmann, P.
M.A.P.43
- Back, A.
W.B.P.162
- Back, Nicole K. T.
Th.C.P.34
- Back, S.
M.A.P.67, W.A.P.9
- Bäcker, U.
M.B.P.64, M.B.P.148,
T.B.P.360
- Backer, V.
T.B.P.59
- Bacon, Marion
W.E.P.25
- Badl, Nsanga
T.B.P.205
- Badilla, J.
Th.H.P.24
- Baena Mendo, N.
M.B.P.212
- Baende, E.
M.B.O.17, M.B.P.31,
W.G.O.1, T.H.O.9
- Baer, J.
W.B.P.271
- Baez, M.
W.B.P.306
- Bagasra, O.
T.B.P.225

- Bagasra, Omar**
 A.631, T.C.P.99
Baggaley, Jonathan P.
 W.E.O.20
Baginski I.
 C.773
Baglioni, P.
 M.B.P.256
Bagnall, H.
 T.B.P.260
Bagolini, A.
 M.B.P.230
Bahlman, William R.
 W.E.P.2
Bahraoui, E.
 M.C.O.3, M.C.P.31, Th.C.P.1,
 C.674
Bahraoui, Elmoustafa
 T.C.P.42
Bahraoui, M.
 T.C.P.76
Bahro, M.
 W.B.P.50
Bai, X. Q.
 W.C.P.64
Bai, Xin-Qing
 C.536
Baker, M.
 C.696
Bailey, J. M.
 T.C.O.2
Bailey, P.
 Th.H.P.29
Bailey, Richard W.
 T.C.P.47
Bailey, V.
 W.D.P.79
Bain, B.
 Th.G.P.1
Bain, R.
 Th.A.P.120, Th.G.O.43
Baine, R.
 Th.C.P.32
Baird, S. M.
 T.C.O.44
Bais, P.
 A.563
Bajos, N.
 T.D.O.20
Baker, C.
 M.D.P.5, T.D.P.7, E.797
Baker, Charles J.
 D.502
Baker, Edward L.
 Th.A.P.44
Baker, J.
 T.C.P.66, C.553, C.587
Baker, James L.
 E.562
Baker, L.
 W.F.P.10
Baker, L. A.
 E.595
Baker, M.
 T.E.P.41
Bakker, E.
 M.B.P.162, T.B.P.355,
 W.B.P.171
Bakker, Leendert J.
 C.575
Bakker, M.
 W.C.P.44, C.732
Bakketeig, L. S.
 W.A.P.103, Th.A.P.59
Baklaic, B. Z.
 T.E.P.22
Bakshi, S.
 M.B.O.44
Bakutuwidi, M.
 W.E.P.65
Bala, M.
 M.H.P.6
Balachandran, R.
 W.C.O.10, Th.C.O.28,
 Th.C.P.14
Balanon, Angelita B.
 W.D.P.60
Balanzat, J.
 M.B.P.97
Balasubramanian, P.
 C.555
Balbaryski, M.
 W.B.P.382
Baldeb, S.
 M.D.P.12
Baldi, A.
 M.B.P.228
Baldwin, G.
 M.C.P.100
Baldwin, P.
 W.E.P.43
Baldwin, W.
 T.D.P.14, D.523
Balende, J. D.
 Th.H.P.22
Balfé, P.
 T.C.P.124
Balfé, P. B.
 T.C.P.92
Balfé, Peter B.
 C.659
Balfour, H.
 W.B.P.312
Balfour, H. H. Jr.
 Th.B.O.6, T.B.P.348
Balian, P.
 M.A.O.40
Balian, P.
 Th.D.P.35
Balint, J. P.
 T.B.P.287
Ball, J. K.
 W.A.P.33
Ball, Judy K.
 M.H.O.8, Th.H.P.3
Ball, M. D.
 M.B.P.183
Ballard, C.
 M.B.P.325
Ballardini, B. G.
 T.B.P.383
Ballen, Penny J.
 M.B.P.143, T.B.P.270
Balling, J.
 T.H.O.12
Balling, J. D.
 T.H.O.10
Balloul, H.
 T.B.P.195
Balotta, C.
 M.B.P.354
Balotta, Claudia
 M.B.P.267
Balowa, D.
 W.E.P.65
Balthazar, J. Hector
 M.E.O.24
Baltimore, D.
 W.C.O.35, Th.C.P.93
Baltzarini, J.
 M.C.P.75, C.595
Baltzarini, Jan M.
 Th.C.O.20, M.C.P.76
Balzer, Thomas
 W.B.P.33
Bamgbose, J.
 W.E.P.51
Bamji, M.
 M.B.O.44, T.B.P.147,
 T.B.P.154, T.B.P.168,
 T.B.P.285
Banapour, B.
 T.C.P.134
Banarjee, Kaylan
 T.G.O.22
Banatvala, J. E.
 M.A.P.58, Th.C.P.148, C.784
Banekowich, F.
 W.B.P.98
Bangura, Hassan
 M.E.O.6a
Bánhegyi, D.
 Th.B.P.139, W.C.P.92
Bánhegyi, Dénes
 T.B.P.302
Bankowski, M.
 Th.B.P.111
Bankowski, Matthew J.
 T.B.P.80
Banks, S.
 D.607
Banks, Susan
 D.608
Bannie, F.
 M.B.P.323
Banura, C.
 B.581
Bao, D.
 M.H.P.24
Baracat, E.
 D.617
Baran, A. J.
 M.C.P.124
Barata, R.
 T.B.P.356
Barateau, V. B.
 W.B.P.106, B.619
Barba, G.
 M.B.P.137
Barbacci, M.
 Th.D.P.10
Barbacci, Marguerite
 M.B.P.5, M.B.P.10, W.D.P.11
Barbara, J.
 M.B.P.155
Barbarini, G.
 M.B.P.232, W.B.P.186,
 Th.B.P.272, Th.B.P.299
Barbarini, Giorgio
 T.A.P.56, B.545
Barbaro, Daniel
 W.B.P.304
Barbaru, Daniel J.
 Th.B.P.71
Barber-Madden, R.
 E.653
Barbier, F.
 Th.B.P.147
Barbieri, D. D.
 A.554
Barchi, E.
 M.B.P.358
Barchi, J. J.
 M.C.P.107
Barcia, M. J.
 B.801
Bardoux, C.
 T.A.P.82
Barrelli, A.
 Th.C.P.144
Barrelli, B. A.
 T.B.P.363
Barett, Y.
 Th.C.P.148
Bargal, E.
 W.E.P.35
Bargstedt, C.
 T.E.P.70
Baribeau, T.
 W.E.P.62
Barin, F.
 M.A.P.15, M.B.P.1,
 W.B.P.109, W.C.P.89,
 Th.C.P.36, Th.C.P.75, C.732,
 C.766, W.G.P.22
Bariu, Francis
 T.G.O.1
Barker, S. S.
 Th.A.P.11

- Barlet, P.**
 Th.D.P.31
Barlow, D.
 C.633
Barlow, David
 M.A.P.58
Barlow, M. A.
 M.C.P.97
Barnard, A. L.
 C.530
Barnes F.
 T.D.O.26
Barnes, A. K.
 W.C.O.30
Barnes, M. E.
 T.F.P.2
Barnes, Mark
 W.E.O.18, Th.F.P.6
Barnes, Rosemary
 T.D.P.63
Barnes, S.
 M.B.P.201, M.B.P.238
Barnes, Sandra E.
 T.B.P.237
Barnet, J.
 Th.E.O.4
Barnett, J.
 M.B.P.186
Barnhart, J.
 M.B.O.50
Barnhart, J. L.
 M.A.P.111
Barnhart, L.
 W.A.P.27
Barnwell, M.
 A.827
Baron, P. A.
 M.C.P.131
Baronchelli, C.
 B.565
Barone, V. J.
 W.E.P.38
Barquet, L.
 M.B.P.327, M.B.P.373,
 Th.G.P.22
Barr, D.
 Th.E.P.20
Barr, P.
 M.C.P.84
Barr, W.
 W.B.P.180
Barrat, J.
 M.B.P.32
Barré-Sinoussi, F.
 M.C.O.30, Th.C.O.47,
 T.C.P.39, T.C.P.40,
 M.C.P.144, Th.C.P.78
Barré-Sinoussi, F. B. S.
 W.C.P.128
Barré-Sinoussi, F. C.
 M.C.P.7
Barré-Sinoussi, François
 T.C.O.41
- Barreiro, G.**
 M.B.P.369, T.B.P.164, B.600
Barrera, J. M.
 A.618, T.B.P.202, W.B.P.101
Barrera, José
 M.A.P.104
Barreto, J. A. X.
 M.B.P.327, Th.G.P.22
Barreto, Jorge A. X.
 M.B.P.373
Barrett, E.
 D.668, T.E.P.10
Barrett, N.
 T.C.P.38
Barriga, Angulo G.
 W.B.P.168
Barros, A. O. L.
 Th.F.P.1
Barry, David
 Th.B.O.50
Barry, Martial
 W.E.P.4
Barry, P.
 T.C.P.78
Barth, A.
 W.B.P.48
Barthels, M.
 Th.B.P.12
Bartholomew, C.
 W.G.P.11
Bartholomew, Courtenay
 Th.A.P.23, M.B.P.296,
 M.G.O.30
Bartholomeyczik, S.U.
 E.550
Bartholow, B.
 T.D.O.6, M.D.P.24
Bartholow, Bradford N.
 E.708
Bartlett, J.
 W.B.P.3, B.555
Bartlett, J. A.
 W.B.O.12, M.B.P.237,
 W.B.P.15, W.B.P.330, D.670,
 E.628, M.H.P.10
Bartlett, J. G.
 W.B.P.7
Bartlett, John A.
 W.B.P.325
Bartlett, K.
 W.B.P.62
Bartlett, M. S.
 M.B.O.13, M.C.P.46
Bartnof, H.
 E.800, E.629
Bartnof, H. S.
 M.D.P.42, E.599, E.628
Bartnof, Harvey
 W.E.O.19
Bartnof, Harvey S.
 M.D.P.85
Bartok, A.
 M.B.P.325, T.B.P.8
- Bartolomé, J.**
 M.B.P.221, M.B.P.246,
 W.B.P.145
Bartolozzi, D.
 T.B.P.100
Barton, Simon E.
 M.B.P.115
Bartos, V.
 Th.B.P.228
Baruchel, Sylvain S.
 T.B.P.261
Bary, M.
 Th.B.P.22
Basaca-Sevilla, V.
 T.B.P.377, Th.G.O.25
Basañez, R.
 Th.G.P.16
Basch, C. E.
 E.662
Bascialla, A.
 Th.B.P.136
Baseler, M.
 M.C.O.10, W.C.O.39,
 T.C.P.33, W.C.P.62
Baseler, Michael
 Th.B.P.167
Bash, M.
 T.B.P.176
Basílio de Oliveira, C. A.
 M.B.P.109, M.B.P.223,
 M.B.P.257, B.563
Basilio, C. A.
 M.B.P.136, T.B.P.369, C.700,
 C.763
Baskerville, A.
 W.C.P.7, C.502
Baskett, L.
 M.H.P.7
Baskin, G.
 W.C.P.147
Baskin, G. B.
 W.C.P.30
Bass, S.
 W.A.P.68, W.B.P.221
Bassett, D.
 Th.G.P.27, Th.G.P.28
Bassett, M.
 M.B.P.289
Bassetti, D.
 M.B.P.217, Th.B.P.213
Bassi, B. P.
 T.B.P.363
Bastien, A.
 A.614, Th.D.P.9
Bastien, Arnaud
 M.E.P.12
Bastien, R.
 W.E.P.11
Bastos, V.
 E.785
Batalia, J.
 T.A.O.3
- Batalia, Juan**
 W.A.P.78
Bateman, N.
 T.B.P.67, T.B.P.79
Bateman, N. T.
 T.B.P.57, C.633
Bates, F.
 Th.E.P.33
Bates, J.
 D.697
Bates, J. H.
 Th.B.P.62
Bates, Julie
 W.D.O.13
Batista, L.
 M.B.P.44
Batki, S. L.
 Th.D.O.5
Batra, K.
 M.B.P.337
Batra, K. K.
 M.B.P.345
Battan, R.
 M.B.P.72
Battan, R. C.
 Th.B.P.41
Battagay, Manuel M.
 M.A.P.88
Batterman, A.
 M.B.P.189
Battjes, R.
 T.A.P.49, Th.A.P.18
Battjes, Robert J.
 T.A.P.39, T.A.P.40,
 Th.D.O.18, D.599
Battoo, K.
 Th.A.P.23, W.G.P.11
Bauch, S.
 W.A.P.2
Baudry, O.
 T.E.P.66
Bauer, D.
 C.649
Bauer, H.
 T.B.P.316
Bauer, P. G.
 C.700
Bauer, Pierre G.
 M.B.P.136, C.763
Bauer, S.
 M.A.P.10
Bauer, Stanley
 Th.A.P.4, T.F.P.1
Baughman, L.
 W.A.O.23
Baughman, R. P.
 M.B.P.73, C.713
Baughman, Robert P.
 T.B.P.9
Bauketig, L. S.
 D.722
Baulieu, J. L.
 W.C.P.1

- Baum, B. J.
Th.B.P.353
- Baum, Gregory
W.F.O.10
- Baumann, Reinhard
W.B.P.328
- Baumgart, P.
W.B.P.318
- Baumgarten, K.
M.B.P.148
- Baumgartner, A.
Th.A.P.107, T.B.P.226
- Baumzart, P.
Th.D.P.69
- Baur, Andreas
C.788
- Baur, S.
M.B.P.60
- Bawdon, R.
T.B.P.46
- Baxter, M.
T.D.O.29, T.D.P.13
- Bayer, Hubert,
B.542
- Bayer, R.
T.F.O.13
- Bayer, Ronald
W.F.O.24
- Bayer, T.
M.D.P.85
- Bayes, Ramon
D.598, D.571
- Bayle, J.
M.B.P.250
- Baylo, A.
W.B.P.101
- Bazex, J.
M.A.P.46, A.574, T.B.P.90
- Bazillou, M.
M.A.O.14
- Beach, R.
Th.B.P.313, Th.B.P.314
- Beach, R. S.
Th.B.P.310
- Beach, Richard
Th.B.O.40
- Beach, Richard S.
Th.B.P.306
- Beall, G.
W.B.P.124, Th.B.P.307
- Beall, G. N.
W.B.P.337
- Beardsell, J.
M.H.P.1
- Beardsley, M.
M.A.P.20
- Beatrice, S.
A.554, M.B.P.184, W.B.P.88,
T.D.P.80
- Beatson, D.
W.B.P.74, Th.C.P.126
- Beaucaire, G.
W.B.P.248
- Beaucaire, Gilles
T.B.P.282, T.B.P.288
- Beauchard, Jacques
E.525
- Beaulieu, L.
T.D.O.13, W.D.P.32
- Beaulieu, R.
W.B.P.43
- Beaumont, A.
Th.B.P.280
- Beausoleil, E.
T.G.P.3
- Beausoleil, E. G.
T.G.P.7
- Bebenroth, D.
T.A.O.17, Th.A.P.15
- Bebermeyer, R.
M.D.P.82
- Becherer, Paul R.
M.A.P.45
- Bechtel, L. J.
Th.B.O.10
- Beck, A.
Th.B.P.154, Th.C.P.150
- Beck, Andreas
Th.A.P.29
- Beck, E. J.
M.A.P.57
- Beck, K.
Th.B.P.307
- Beck, P.
Th.D.P.15, E.700
- Beck, S.
E.508
- Becker, J.
Th.B.P.218, Th.B.P.278
- Becker, J. L.
Th.C.P.81
- Becker, J. T.
W.B.O.45, Th.B.P.202
- Becker, James T.
W.B.P.221, W.B.P.226,
W.B.P.236
- Becker, M.
W.B.P.295
- Beckford, Ursula
Th.B.O.56, T.B.P.332
- Beckstein, David L.
W.E.P.7
- Bédard, L.
W.A.O.14
- Bédard, N.
M.E.P.78
- Bedarids, G.
Th.B.P.86
- Bedell, G.
B.575, B.595
- Bedjabaga, L.
W.B.P.107
- Bednarik, D. P.
T.C.O.14
- Bedossa, A.
Th.E.P.7
- Becker, Carolyn G.
D.528, T.E.P.14, Th.E.P.73
- Beery, W. L.
F.H.O.2
- Beery, William L.
M.E.P.27
- Beese, Jackie
M.B.O.8
- Beese, Jacqueline Y.
W.B.P.383
- Beeson, L.
E.539
- Begemann, F.
M.B.P.234
- Begley, K.
A.581
- Begley, Kim
T.D.O.30
- Behbehani, K.
W.G.P.4
- Behets, F.
M.A.O.35, T.B.P.107, B.625,
T.D.O.35, W.G.P.9
- Behets, Frieda
W.B.P.156, M.G.O.3
- Beidas, Sary O.
A.590, D.544, E.713
- Beil, J.
T.A.P.78, T.A.P.79
- Beisell, J.
E.710
- Bejarano, E.
T.B.P.289
- Bek, B.
Th.B.P.172
- Bekesi, J. G.
Th.B.P.276, Th.B.P.285, C.709
- Bekesi, J. George
Th.B.P.84, Th.B.P.95,
Th.B.P.182
- Bekure, D.
W.G.P.28
- Belcher, L. O.
E.709
- Beldjord, K.
M.B.P.61
- Belec, L.
M.B.P.185, T.C.P.22,
Th.E.P.52
- Belec, Laurent
Th.B.P.209
- Bellan, B.
Th.A.P.9, Th.A.P.10
- Bellilovsky, C.
W.C.P.72
- Bellilovsky, C.
M.B.P.350
- Bell, C.
Th.B.P.28
- Bell, D.
Th.A.P.47
- Bell, K.
Th.B.P.261
- Bell, K. J.
M.E.P.6
- Bellean, B.
M.C.P.83
- Bellean, Bernard
T.C.O.1
- Belletti, G.
B.587
- Belli, L.
W.G.P.18
- Belliard, M.
E.672, M.G.O.25
- Bellin, Eran Y.
E.811
- Belling, G.
D.664
- Belling, George Jr
D.667
- Bellingham, K.
W.E.P.40
- Bellini, F.
W.B.P.111
- Bellobuono, A.
M.A.O.11
- Bellucci, S. B.
Th.B.P.337
- Bellucci, Silvia B.
D.543
- Bellucci, Silvia B. B.
D.709, D.714
- Belman, A.
M.B.O.41, T.B.P.184, B.573
- Belman, Anita L.
T.B.P.174
- Belohradsky, B. H.
T.B.P.163, T.B.P.208
- Belschner, Wilfried
W.A.P.110
- Belshe, R.
Th.C.O.33, M.C.P.23, G.519
- Belshe, R. B.
Th.C.O.32, M.C.P.32
- Belshe, Robert B.
Th.A.P.88
- Belsky-Barr, D.
W.B.P.180
- Beltran, Eugenio D.
E.638
- Beltran, E.
Th.E.P.30
- Beltz, G. A.
B.635, M.C.P.2, C.540, C.690
- Belville, R.
D.668, T.E.P.10
- Belzberg, A.
T.B.O.29, T.B.P.270
- Ben-Levi, Joseph M.
E.736
- Ben-Porath, Edna
T.A.P.81
- Benamouzig, R.
M.A.P.24, A.543

- Benard, I.**
 C.516
Bender, A.
 M.B.P.330
Bender, J.
 W.B.P.363
Bender, P.
 E.703
Bendick, C.
 C.546
Bendinelli, M.
 W.E.P.19
Bene, M. C.
 T.C.P.44, T.C.P.45
Benedetti, J.
 W.H.P.26
Benedict, A.
 E.562
Benedik, B.
 D.687
Benelli, M.
 W.B.P.128
Benenson, A. S.
 T.B.P.339
Benetucci, J. A.
 A.586
Benetucci, Jorge A.
 W.D.P.56, D.686, Th.G.O.3
Benga, E.
 M.B.P.183
Benge, Mark A.
 W.H.O.10
Benhamou, J. P.
 M.B.P.362
Beniak, J.
 D.660
Beniak, Judy
 E.630
Benish, J. B.
 Th.C.P.63
Benitez Fuentes, Jesús V.
 W.B.P.97
Benitez, J.
 B.602
Benitez, Raúl
 Th.H.P.12
Benito-García, A.
 M.A.P.82
Benjamin, Y.
 T.B.P.256
Bennett, C. L.
 T.H.P.18
Bennett, Charles L.
 M.B.P.376, M.H.O.17,
 M.H.P.17
Bennett, D.
 M.A.O.22, W.B.P.273, D.724,
 M.H.P.9
Bennett, Diane E.
 W.E.P.66
Bennett, J. A.
 M.B.P.303
Bennett, M.
 W.B.P.245, E.582
Bennetti, R. L.
 M.H.O.17, T.H.P.18
Bennett, Thaddeus A.
 Th.E.P.42
Benoit, M.
 M.A.P.23
Benson, C.
 W.B.P.313, Th.B.P.90
Benson, E. M.
 Th.B.P.230
Benson, Elizabeth M.
 Th.B.P.296
Benson, J.
 Th.C.P.32
Benson, M. F.
 W.B.O.36
Benton, J.
 Th.B.P.126
Benstrup, K. L.
 E.570
Bentwich, Z. H.
 M.A.P.59
Bentwich, Zvi H.
 W.C.O.29, W.C.P.129
Benzen I.
 T.E.P.12
Benveniste, R.
 W.C.P.10
Benveniste, R. E.
 Th.C.P.89
Beral, V.
 M.A.O.30, W.A.P.17
Berardi, V.
 E.711
Bercite, P.
 Th.C.P.21
Berenstein, A.
 E.532
Beresniak, A.
 A.557
Beretta, A.
 C.578
Bergamaschi, D.
 T.B.O.12, M.G.O.26,
 W.G.O.15, M.G.P.1
Bergamaschi, Denise
 Th.G.O.50
Berge, P.
 M.B.P.141, T.B.P.344
Berger, B. F.
 C.699
Berger, C.
 W.B.P.76
Berger, E. A.
 M.C.P.89
Berger, Edward A.
 Th.C.O.12
Berger, J.
 Th.B.P.223, Th.B.P.240
Berger, Joseph R.
 M.A.P.90, W.B.P.51,
 W.B.P.56, Th.B.P.263
Berger, R. E.
 B.578
Bergeron L.
 M.C.O.22
Bergeron, M.
 Th.B.P.360, B.621
Berges, O.
 T.D.P.47
Berglund, O.
 B.576
Bergman, D
 M.E.P.65
Bergmann, C.
 T.E.P.33
Bergner, D.
 M.C.P.56
Bergonzoli, S.
 Th.B.O.20
Berinati, William E.
 W.B.P.377
Berk, A.
 M.B.P.204
Berkeley, Seth
 Th.G.O.14
Berkelman, R.
 T.A.O.27, W.A.O.17,
 Th.A.O.11, Th.B.P.44,
 Th.G.O.1
Berkelman, R. L.
 M.A.O.30, T.A.O.4, W.A.O.16,
 T.A.P.63, W.A.P.17, W.A.P.29
Berkelman, Ruth L.
 W.A.O.13
Berkley, S. F.
 Th.G.P.18
Berkower, I.
 C.736
Berlie, H. C.
 Th.B.P.124
Berlin, F.
 W.B.P.189, B.608
Berman, Caryn
 D.630, T.E.P.56
Berman, Stuart M.
 A.542
Bernal, A.
 Th.C.P.74
Bernal, Antonio
 M.B.P.236
Bernal, M.
 M.A.O.9, T.A.P.44
Bernard, E.
 M.B.P.207, T.B.P.33
Bernard, Edward M.
 T.B.P.53
Bernard, Evelyn
 M.B.P.252
Bernard, J.
 M.C.P.48, W.C.P.3, C.762
Bernardi, D.
 W.C.P.110
Bernatowicz, A.
 Th.C.P.102
Berns, D.
 W.A.O.8, T.A.P.53, W.A.P.9
Berns, D. S.
 M.A.O.18
Bernstein, A.
 M.C.P.145
Bernstein, G. S.
 D.686
Bernstein, L.
 T.B.P.233, W.C.P.49,
 Th.E.P.57
Bernstein-Singer, M.
 M.B.O.48, M.B.P.366,
 W.C.P.49
Berntorp, E.
 Th.B.P.15
Beroli, A. M.
 M.A.P.80
Berquist, L.
 W.C.P.128
Berrebi, A.
 T.B.P.187
Berrebi, Alain
 M.B.P.25, M.B.P.26
Berretta, A.
 A.510
Berriche, S.
 T.C.P.131
Berrisford, C.
 T.B.P.332
Berry, Alison J.
 A.546
Berry, C. F.
 M.C.P.32
Berry, D.
 W.B.P.267
Berry, K.
 Th.E.O.1
Berson, A. M.
 Th.B.P.341
Bertaglia, A.
 D.623
Bertazzoli, Rita de Cassia
 Th.B.P.337
Bertazzoni, U.
 M.B.P.358
Bertazzoni, Umberto
 C.681
Berthaud, M.
 M.B.O.2, W.D.P.58, M.E.O.16
Berthelot, Pierre
 M.E.P.41
Berthier, Anne-Marie
 Th.B.P.10
Bertho, J. M.
 W.B.P.281
Berti, C.
 W.E.O.18

- Bertoli, A. M.
W.B.P.69
- Bertoni, G.
W.B.O.34, M.B.P.227
- Bertozzi, S.
T.H.O.8
- Bertrand, J. T.
W.E.P.65
- Bertrand, M. A.
Th.B.P.100, W.E.P.32
- Bertrand, W. E.
M.G.O.16
- Bertrand, W. E.
Th.B.P.267, M.D.O.3,
M.D.O.17, W.D.O.6,
M.D.P.49, D.721, W.G.P.20
- Bertrand, W. E.
T.E.P.4, Th.E.P.1
- Berzofsky, J. A.
W.C.O.25, M.C.P.30
- Berzow, D.
W.B.P.104, C.786
- Berzow, Dirk D.
T.C.P.150
- Beshkov, D.
W.B.P.178
- Besly, O.
Th.E.P.65
- Bess, J. W.
Th.B.P.177
- Bess, Julian W., Jr.
M.C.P.38
- Beth-Giraldo, E.
Th.B.P.16, W.C.P.47,
W.C.P.51
- Betscher, S.
D.678
- Bettinger, S.
Th.C.P.86, C.765
- Bettinger, Stéphane
T.B.P.128
- Betts, Claude D.
G.505
- Betts, R.
M.D.P.21
- Betts, S.
W.D.P.29
- Beuscart, C.
Th.B.P.178
- Beuscart, Claude
Th.B.P.105
- Beveridge, S.
E.822
- Beverley, P.
T.C.P.141
- Beverley, P. C. L.
T.C.P.14, C.538
- Bevilacqua, M.
M.B.P.267
- Beyer, L.
T.B.P.213
- Bez, G.
M.H.O.12, M.H.P.19
- Bez, Gabriel
M.H.P.15
- Bhalla, R.
Th.B.O.28, W.B.P.91,
Th.B.P.233
- Bhandari, A.
M.B.P.286
- Bhat, B.
C.647, C.668
- Bhat, Bheem M.
C.687
- Bhat, G.
W.A.P.50
- Bhat, G. J.
Th.G.P.30
- Bhat, K.
M.B.P.218
- Bhayana, V.
W.D.P.20, Th.D.P.56
- Bhikhabhai, R.
W.B.P.147, Th.C.P.84
- Bhimani, G. V.
T.D.P.84
- Bialek, R.
W.B.P.235
- Bialer, P.
T.F.P.6
- Bialer, Philip A.
D.624
- Biancalana, M. L. N.
W.B.P.31
- Biancalana, Maria Lucia
Th.B.P.40, B.522
- Bianchi, U.
M.B.P.16
- Bianco, C.
M.B.P.152
- Biasioli, B.
Th.H.P.25
- Biberfeld, G.
T.B.P.104, B.548, W.C.P.141,
Th.C.P.6, T.G.O.11, M.G.P.16
- Biberfeld, Peter
Th.C.O.9, W.C.P.54, W.C.P.67
- Bibler, M.
M.B.P.178
- Bielefeld, P.
M.B.P.88, T.B.P.304
- Biendo, M.
W.B.P.151
- Bieniek, B.
W.B.P.278
- Bienvenu, E.
M.D.P.18, Th.G.P.23
- Bienze, U.
W.A.P.53
- Bienze, U. et al.
Th.B.P.275
- Bierling, P.
T.B.P.273
- Bierman, M.
W.A.P.81
- Biernacki, P.
Th.D.P.82
- Biernacki, Patrick
Th.A.P.68, Th.D.P.13, D.615,
W.E.P.9, E.566
- Biernes, D. L.
D.683, D.684
- Biesert, Lothar
C.607
- Bigbee, L.
M.A.P.11
- Biggar, R. J.
M.A.O.45, T.A.O.35,
Th.A.P.77, C.702
- Biggar, Robert J.
Th.A.O.22, Th.A.P.89
- Bigler, W.
W.A.P.1
- Biglino, A.
W.B.P.144
- Biglino, Alberto
M.B.P.353
- Biglione, J.
W.A.P.22, A.582, M.G.P.29
- Bignon, J. D.
Th.B.P.149
- Bigot, J. M.
M.B.P.196, Th.B.P.254, B.559
- Bihari, Bernard
M.C.P.59, M.C.P.62, C.619,
T.D.P.51
- Bilini
M.E.O.33
- Bilello, John A.
M.C.P.53
- Bilheimer, Linda
Th.H.O.3
- Billon, P.
W.E.P.62
- Bimamisana, B.
W.B.P.316
- Bincsik, A.
T.B.P.45
- Binder, Wayne
E.728
- Bingham, J.
W.B.O.3
- Bini, A.
A.510
- Bini, T.
M.B.P.351
- Biniek, R.
T.B.P.381, W.B.P.50
- Binyingo, M.
T.B.P.181
- Birch, F.
T.A.P.29, T.A.P.35
- Birch-Limberger, K. A.
W.C.O.43
- Birch-Limberger, Karen A.
T.C.P.2
- Birchmeier, B.
E.739
- Bird, A. G.
M.A.P.92, Th.B.P.164
- Biritwum, R.
T.G.P.3
- Biron, F.
T.B.P.288
- Birx, D. L.
Th.B.P.120, T.C.P.28
- Birx, Deborah L.
Th.B.P.155
- Biryahwah, B.
T.B.P.358, W.B.P.117
- Bisaillon, Denise A.
D.636
- Bishagara, K.
T.H.O.9
- Bishberg, E.
T.E.P.45
- Bishop, C.
Th.E.P.63
- Bishop, J. O.
T.C.P.92, Th.C.P.69, C.659
- Bisset, C.
T.A.P.51
- Bisset, C.M.
E.722
- Bisset, Catherine M.
M.A.P.47, D.614
- Bisson, L.
W.A.O.4
- Bissonnier, M.
Th.C.P.78
- Bitran, J. D.
M.C.P.116
- Bitterlich, G.
T.C.P.68
- Bixler, R.
M.A.P.20
- Björner, J.
A.579
- Blaas, P.
Th.D.P.18, T.E.P.67
- Blaauw, Bernard B.
W.B.P.71
- Black, F.
W.B.P.125
- Black, Finn T.
Th.B.P.106
- Black, J.
T.B.P.22
- Black, John R.
T.B.P.30
- Black, M.
B.574
- Black, W.
Th.E.P.25
- Blackie, Steve
Th.B.P.52
- Blacklow, N.
W.B.P.240, W.B.P.246
- Blackwelder, W. C.
A.622

- Blackwell, J.**
 M.B.O.26
Blagojevic, N.
 Th.B.P.298
Blahd, W.
 Th.B.P.259
Blain, E.
 T.E.P.46
Blair, Edward D.
 T.C.P.101
Blair, M.
 M.H.P.25
Blair, S.
 M.B.P.47, Th.B.P.49, B.529
Blake, Susan M.
 T.D.P.3, M.E.P.33
Blakeney, Barbara
 M.E.P.48
Blanc, A.
 W.A.P.88
Blanc, A. P.
 T.B.P.277, T.B.P.305
Blanc, Sylvie
 T.B.F.231
Blanca, I.
 Th.B.P.101
Blanchard, P.
 Th.A.P.65
Blanchard, Philippe
 W.H.P.16
Blanche, S.
 M.B.O.3, M.B.O.39,
 T.B.P.170, Th.C.P.7, W.D.P.16
Blanchette, M.
 Th.F.7
Blanchette, V.
 Th.B.P.5
Blanchette, Victor S.
 Th.B.P.18
Blanford, D. L.
 M.C.P.132
Blaney, N.
 Th.A.P.97
Blankenship, Evetyn M.
 W.D.P.1
Blankenship, K. D.
 W.B.P.325
Blasky, Terry
 Th.B.O.52
Blattner, W.
 Th.A.P.23, B.636, M.G.P.3,
 Th.G.P.2
Blattner, W. A.
 M.A.O.45, Th.A.O.22,
 Th.A.P.118, Th.B.P.177,
 T.C.O.19
Blattner, William A.
 M.C.O.7
Blau, A.
 C.634
Blaxhult, Anders
 W.H.P.17
Blevins, A.
 D.648
Blini, Mirella
 M.B.P.227
Blinov, V.
 T.C.P.144
Blivise, N.
 C.629
Block, A.
 Th.B.P.44, Th.G.O.1
Blomberg, J.
 W.C.P.98
Blomberg, Jonas
 C.717
Blomberg, Patty S.
 W.B.P.63
Blondon, J.
 M.B.P.55
Bloom, Jeff A.
 W.B.P.378
Blough, Herbert
 M.C.P.106
Blower, Sally M.
 T.A.O.40
Blum, S.
 T.A.P.71, W.A.P.32, A.615,
 C.684
Blumenfeld, Walter
 C.722
Blumenstein, J. J.
 Th.C.P.136
Blynn, N.
 M.B.P.345
Blystad, Hans
 C.686
Blythe, S. P.
 A.524
Blythe, Steve P.
 Th.A.P.57, A.522
Boardway, K.
 T.C.P.72
Bobo, John W.
 T.D.O.9
Boccellari, A.
 W.B.P.193, W.B.P.197,
 W.B.P.198, W.B.P.231,
 W.B.P.234
Boccon-Gibod, Liliane A.
 T.B.P.155
Bochow, Michael
 D.531
Bockstahler, L. E.
 M.A.P.114
Bocsson, P.
 T.E.P.6
Bodey, G. P.
 M.B.P.129
Bodjeva, E.
 W.B.P.178
Bodner, A.
 M.A.O.17
Bodner, A. J.
 Th.C.P.106, C.585, C.622
Bodsworth, Nell J.
 M.B.P.222, W.B.P.369
Bodwell, C. E.
 Th.B.P.305
Bocchat, N. L.
 Th.B.P.37
Boegel, M.
 T.C.P.150
Boert, Elio
 W.B.P.357
Boespflug, O.
 W.C.P.113
Bogner, J. R.
 W.B.P.92, Th.B.P.244, B.516,
 E.764
Bogner, Johannes R.
 M.B.P.64, Th.B.P.168, C.574,
 W.D.P.3
Bohlin, A. B.
 W.A.P.52
Bohlin, Ann-Britt
 W.A.O.10
Böhm, W.
 M.D.P.36
Boillot, C.
 W.B.P.366
Boisaubin, E.
 Th.E.P.15
Boisson, P.
 T.A.P.19
Boivin, D.
 A.547
Boivin, J. F.
 M.D.P.33, Th.E.P.26
Boix, J.
 M.B.P.240, M.B.P.245
Boiziau, J.
 C.662
Bolan, G.
 W.B.P.54, M.D.P.23,
 M.D.P.28, M.D.P.30,
 W.D.P.82, D.557, E.706
Boland, M.
 T.B.P.258
Bolao, F.
 M.B.P.43, M.B.P.176,
 Th.B.P.327
Boldt, Kristi L.
 Th.B.P.67
Boles, J.
 W.A.P.38
Bolger, F.
 Th.B.P.196
Bolmstedt, A.
 C.783
Bolmstedt, Anders J. G.
 C.547
Bolognesi, D.
 M.C.O.17, W.C.O.18,
 Th.C.O.50
Bolognesi, D. P.
 T.B.P.207, W.B.P.330,
 T.C.O.33, M.C.P.22, T.C.P.32
Bolon, T.
 M.D.P.83
Bolton, V.
 M.C.P.50
Bolz, A.
 M.B.P.76
Bolz, G. F.
 W.H.P.16
Bolz, Georg F.
 Th.A.P.65
Bona, C.
 T.C.P.70
Bonaccorso, C.
 M.B.P.94
Bonadies, G.
 W.B.P.362
Bonariva, Benjamin
 T.C.P.57
Bond, A.
 Th.B.P.31, E.507
Bond, G.
 M.D.O.1
Bond, J.
 M.D.O.18
Bond, Lydia S.
 W.E.P.33
Bond, S.
 M.D.O.18
Bond, V.
 T.A.P.6
Bonetti, A.
 W.B.P.321
Bonetti, M.
 T.B.P.269, B.565
Boneu, B.
 Th.B.P.9
Bonfim de Lima, Dirce
 M.B.P.231, W.B.P.39
Bongaarts, J.
 T.A.P.86
Bonhomme, M. G.
 T.G.O.21
Bonhomme, P.
 D.878
Boniface, B.
 E.657
Bonilla, J.
 C.566
Bonin, D.
 M.B.P.43
Bonk, G.
 W.C.P.60
Bonneau, J.
 T.E.O.2
Bonneen, E.
 W.B.P.309
Bonner, M.
 W.B.P.360
Bonnez, W.
 M.C.P.8
Bonnyns, M.
 M.B.P.272

- Bono, G.
M.B.O.34, Th.B.P.281
- Bonsel, G.
D.578
- Bontemini, L.
Th.B.P.213
- Bouvini, V.
T.E.P.26
- Boone, E.
T.B.P.281
- Boone, E. J.
T.C.P.69
- Booraem, C. D.
W.A.P.111
- Bor, R.
W.D.P.19, E.602
- Bor, Robert
D.549, M.E.O.13
- Borchard, F.
M.B.P.100
- Borcich, A.
M.B.P.135, M.C.O.27,
W.C.F.131
- Borderi, M.
W.A.P.43, W.B.P.338
- Bordi, E.
W.B.P.16
- Bordowitz, G.
E.541
- Borges, F.
W.G.O.23
- Borghetti, A. G.
Th.C.P.4
- Borghi, Vanni
T.B.P.235
- Borgia, P.
W.E.P.45, E.622
- Borgognoni, L.
C.571
- Borissenko, L.
C.649
- Borkowsky, W.
Th.A.P.15, M.B.P.20
- Borkowsky, William
C.554
- Borleffs, Jan C. C.
D.578, M.H.P.8
- Bornemann, Reinhard
T.A.P.28, W.G.P.5
- Boros, F.
Th.B.P.84
- Borowsky, C.
M.B.O.20
- Borras, F.
T.H.O.10
- Borras, S.
T.H.O.12
- Borri, A.
Th.C.P.144
- Borsetti, A.
W.C.P.119
- Bortolotti, Flavia
D.583, D.623
- Borucki, Michael J.
W.B.P.323, Th.B.P.273
- Borucki, S. J.
Th.B.P.273
- Bosch, A.
A.504, Th.G.O.2
- Boschini, A.
T.A.P.116
- Boshell, Jorge
M.G.O.6
- Bossio, Luis E.
D.552
- Bosson, D.
M.B.P.271
- Boswell, N.
Th.B.P.102
- Boswell, R. N.
M.A.P.13, Th.B.P.135,
Th.B.P.141, Th.B.P.229,
Th.B.P.230
- Boswell, R. Neal
Th.B.P.102, Th.B.P.126
- Botas, J.
Th.B.P.123
- Botas, Julio
M.A.P.77
- Botcherby, M.
M.B.P.292
- Bottari, G.
M.B.P.232, Th.B.P.299
- Bottiger, B.
W.C.P.141
- Böttiger, Blenda
Th.C.P.8
- Böttiger, M.
W.A.O.10, W.H.P.17
- Böttiger, Margareta
W.A.O.29
- Böttinger, C.
Th.B.P.334
- Botvin, G.
Th.D.P.42
- Bouall, R.
M.H.P.4
- Bouchard, André
M.D.P.41
- Bouchard, I.
M.A.O.40, M.A.P.25, A.543,
Th.D.P.35, D.601
- Bouchard, Isabelle
M.A.P.24
- Bouche, P.
Th.B.P.196
- Boucher, C.
W.B.P.109, Th.C.P.35
- Boucher, Charles A. B.
, T.C.P.73
- Boucher, François D.
W.B.O.2
- Boucher, M.
T.B.P.243
- Boucher, Marc
M.B.P.17
- Boucher, V.
Th.C.P.78
- Boucrant, J.
Th.C.P.9
- Boudinat, Douglas F.
M.C.P.98
- Boudou, P.
M.B.P.269
- Boue, F.
T.C.P.39
- Boué, F.
W.A.P.88, T.B.P.380, T.C.P.40
- Boughton, W.
Th.B.P.53
- Bouhasin, J. D.
T.B.P.253
- Boulay, Fabrice
A.571, M.H.O.12, M.H.P.19
- Boulerice, F.
T.C.P.112
- Boulerice, F. B.
Th.C.P.77
- Boulerice, François
Th.C.P.117
- Boulos, R.
T.A.O.18, T.D.O.32, T.G.O.20,
T.G.O.21, Th.G.O.51,
Th.G.P.2
- Boulos, Reginald
W.A.P.7, T.G.O.19
- Boulton, Mary
M.D.P.15
- Bounya-Épée, Samuel
Th.H.P.7
- Bouquety, J. C.
T.B.P.191, W.G.O.28
- Bour, S.
T.C.P.112, Th.C.P.117
- Bour, Stephan
Th.C.P.77
- Bourdoux, P.
M.B.P.272
- Bourin, P.
M.B.P.269, Th.B.P.160,
Th.B.P.162
- Bouza, E.
T.B.P.294
- Bouzas, M. B.
W.A.P.22, Th.B.P.13, B.513,
Th.H.P.23
- Bouzas, María Belén
T.A.P.108, T.B.P.340,
Th.B.P.3, Th.B.P.4, Th.B.P.24
- Bova, C.
W.B.P.240
- Bove, G.
M.E.P.61
- Bowcock, B.
W.B.P.153
- Bowcock, S.
W.C.P.124
- Bowen, B.
M.H.P.12
- Bowen, G. S.
M.A.P.55, M.A.P.75,
W.A.P.109, T.D.O.11, D.806,
W.E.O.7, T.E.P.74, W.E.P.1
- Bowen, Stephen G.
A.533
- Bowlby A.
E.531
- Bowleg, I.
M.F.O.3
- Bowlin, T.
M.C.P.117
- Bowser, B. P.
W.D.P.61
- Boxaca, M.
W.B.P.382, M.D.O.10, D.866,
W.G.P.21
- Boxaca, Martha C.
W.G.P.18
- Boyd, D.
E.785
- Boyd, M. R.
C.513
- Boye, C. B.
T.G.P.28
- Boye, C. S.
M.A.P.19
- Boyer, B.
C.630
- Boyer, Beth A.
C.519
- Boyer, C.
T.D.O.27
- Boyer, Véronique
T.C.P.59
- Boyle, D.
W.B.P.5
- Boyle, K. E.
M.C.P.127
- Boylan, C. T.
M.B.P.285, Th.C.P.10, T.B.P.61
- Boylston, A. W.
Th.B.P.328
- Bozeman, L.
Th.B.P.93
- Bozzette, S.
M.B.P.300, W.B.P.11
- Bozzette, Samuel A.
T.B.P.8, T.B.P.12, W.B.P.9
- Bozzi, A.
T.B.P.361
- Brabant, M.
T.A.P.59
- Bracci, P.
M.A.O.26, E.711
- Brackmann, H. H.
M.A.O.12, T.A.P.107,
T.A.P.110, W.B.O.26,
W.B.P.170
- Bradbeer, C.
T.B.P.79, Th.C.P.148
- Bradbeer, C. S.
M.A.P.58

- Bradbeer, Caroline S.**
 M.B.P.58
Braddick, M.
 W.A.P.65, Th.B.O.39,
 Th.G.O.52, M.G.P.27
Braddock, M.
 T.C.P.137
Braddock, Martin
 T.C.P.103
Bradey, P. F.
 W.B.P.123
Bradford, B. B.
 T.B.P.152
Bradford, Judith B.
 T.D.F.40
Bradley, J.
 D.506
Bradley, O.
 W.B.P.271
Bradshaw, S. A.
 D.545
Brady, J. P.
 Th.E.P.39
Braeck, F.
 T.B.P.291
Brahic, M.
 Th.C.P.83
Braithwaite, C.
 M.H.O.18
Brajtburg, Janina M.
 M.C.P.141
Braman, G. B.
 Th.A.P.118
Braman, V.
 C.690
Brancato, L.
 Th.B.P.116, C.655
Brancato, Lenore J.
 W.B.O.17
Branchini, M. L.
 M.B.P.93
Brandao-Mello, C. E.
 W.B.P.266
Brandao-Mello, Carlos
 Eduardo
 M.B.P.112, M.B.P.223
Brandenburg, N. A.
 W.A.P.18
Brandon, D.
 W.A.O.7, D.518
Brandstaetter, R.
 T.E.P.67
Brandt, J.
 W.B.P.227
Brandtzaeg, P.
 W.C.F.78
Brankovan, Vera
 M.C.P.128
Bransford, J.
 D.643
Brant, R.
 Th.A.P.37
Brasfield, T. L.
 M.D.P.21, M.D.P.22
Brasilio de Oliveira, C. A.
 T.B.P.365
Braslow, C.
 E.811
Braslow, Judith B.
 W.E.O.10
Brassel, J. H.
 W.B.P.177
Brasseur, R.
 T.C.P.107
Brathwaite, W.
 M.A.P.68
Bratos, M. A.
 M.A.P.21
Bratt, G.
 B.576
Bratt, J.
 Th.O.11
Braun, B.
 W.B.P.95, W.B.P.134
Braun, M.
 M.A.P.27
Braun, M. Miles
 Th.G.O.1, M.G.P.24
Braun, R. W.
 M.B.O.24
Braun-Falco, O.
 M.B.P.187, M.B.P.365,
 Th.D.P.28
Braune Wilk, F.
 T.E.P.60
Braunstein, Mildred S.
 Th.D.P.43
Bravard, C.
 E.617
Bravo, E.
 T.A.P.8, M.G.O.27, W.G.P.6
Bravo, F. P.
 B.531
Bray, F.
 C.564
Bray, J. L.
 Th.A.O.26
Bray, R. A.
 T.C.P.71
Brea de Cabral, M.
 T.D.P.89
Bréchet, C.
 M.B.O.6, M.B.P.1, T.C.O.40,
 Th.C.P.21, Th.C.P.70, C.660
Brechet, Jeanne-Marie
 B.515
Bredberg Raden, U.
 T.G.O.11
Brede, H. D.
 M.B.P.105
Breden, K.
 T.B.P.181
Bredesen, D.
 T.B.P.177, Th.B.P.375
Bredesen, D. E.
 Th.B.O.19, Th.B.P.205
Breen, Elizabeth C.
 T.C.P.19
Breen, R.
 E.588
Bregman, G.
 M.D.P.26
Breiling, M. K.
 Th.A.P.95
Bremer, J. W.
 T.B.P.117, T.B.P.122
Bremer, James W.
 T.B.P.121
Bren, B. J.
 Th.B.P.376
Brendstrup, E.
 A.518
Brennan, A.
 D.692
Brennan, Cynthia
 A.602
Brennan, P. F.
 W.B.P.376
Brenneman, D. E.
 M.C.P.92
Brenner, B.
 T.C.P.79
Bres, P.
 T.G.P.3
Bresson-Hadni, S.
 B.520
Brette, R.
 W.B.P.229, W.B.P.232
Brette, R. P.
 T.A.O.14, M.A.P.47,
 M.A.P.92, M.A.P.105,
 M.B.P.3, T.B.P.5, T.B.P.271,
 W.B.P.317, W.B.P.371,
 Th.B.P.164, D.614, E.722
Brette, Raymond P.
 T.A.P.51, W.B.O.3
Brettler, D.
 W.B.O.25
Brettler, D. B.
 T.A.P.109, Th.B.P.34
Bretton, R.
 M.G.P.24
Breuer, Nancy, L.
 E.753
Brew, B. J.
 Th.B.O.24, M.B.P.101,
 W.B.P.194, W.B.P.255,
 W.B.P.256, W.B.P.259,
 Th.B.P.197, Th.B.P.232,
 Th.B.P.257, W.C.P.45,
 W.C.P.84, D.716
Brew, Bruce J.
 T.B.P.299, W.B.P.91,
 Th.B.P.199, Th.B.P.227,
 Th.B.P.233, Th.B.P.249
Brewer, F.
 M.A.P.26
Brewer, J.
 M.B.P.80
Brewster, T.
 Th.D.P.61
Brey, R.
 Th.B.P.141
Brey, R. L.
 Th.B.P.229, Th.B.P.230
Brian, E. L.
 M.C.P.82
Bricaire, F.
 M.B.P.179, T.B.P.319
Brickman, A.
 W.B.P.162
Brickner, P. W.
 M.A.P.51, E.691
Bricolo, R.
 T.A.P.30, D.594
Bricout, F. B.
 W.B.P.36
Bridbord, Kenneth
 T.G.P.17
Bridge, P.
 Th.B.P.295
Bridge, T. P.
 W.B.P.286, Th.B.P.277, B.566
Bridge, T. Peter
 W.B.O.45a
Bridgeham, B.
 M.F.O.3
Bridges, C.
 Th.B.O.41
Bridgewater, S.
 E.572
Bridwell, M.
 T.A.P.16
Brieger, W.
 E.620
Briendo, M.
 A.568
Briggs, M.
 W.A.O.9
Bril, T.
 M.B.P.271
Brinchmann, Jan E.
 T.C.P.20
Brion, J. P.
 T.B.P.282, C.706
Brion, Jean-Paul
 Th.B.P.251, Th.B.P.282
Brito Lyra, L. C.
 M.B.P.257
Britton, Carolyn B.
 Th.B.P.224, Th.B.P.237
Britton, Patti O.
 E.561
Britz, J.
 M.B.O.26
Brizuela, L.
 A.520
Brnolic, B.
 Th.B.P.222

- Broaddus, R.**
 M.A.P.27, Th.D.P.16,
 Th.D.P.45
Broadhead, R. S.
 W.E.P.9
Broadhurst, K.
 C.538
Brockmeyer, N.
 W.B.P.50, Th.B.P.185
Brockmeyer, N. H.
 M.B.P.335, T.B.P.381,
 W.B.P.324, E.548
Broder, S.
 Th.B.O.4, W.B.P.275,
 W.B.P.327, W.B.P.329,
 Th.C.O.13, Th.C.O.17,
 Th.C.O.19, M.C.P.49,
 M.C.P.135, M.C.P.137,
 Th.C.P.22
Broderick, Bonnie
 Th.B.P.318
Brodie, A.
 T.C.O.42
Brodie, B.
 T.A.O.31, T.A.P.47, T.A.P.94,
 Th.A.P.102
Brodie, H.
 W.C.P.80
Brodin, M.
 T.E.P.37
Brodine, Stephanie K.
 Th.A.P.28
Brodth, Hans-Reinhard
 M.A.P.103, Th.A.P.96
Brodth, R.
 Th.B.P.59, Th.B.P.60
Brody, O.
 E.711
Broliden, P. A.
 Th.A.P.113, T.C.P.55,
 Th.C.P.97, C.523
Broliden, Per Anders
 C.526
Bron, Christophe R.
 Th.C.P.8
Bronfman, Mario
 E.546
Bronson, Joanne J.
 M.C.P.74
Bronstein, Irena
 W.B.P.149
Brooke
 M.E.O.33
Brookman, J.
 E.714
Brookmeyer, R.
 Th.A.P.77
Brooks, C.
 D.700
Brooks, S.
 A.638
Brookshire, D.
 M.B.P.383
- Brossard, A.**
 M.B.P.1
Brossard, Y.
 M.A.P.15, M.B.P.32
Brothers, T. A.
 T.B.P.126, T.B.P.127
Broussard, D. R.
 C.627
Brousseau, R.
 C.675
Brouwers, P.
 M.B.O.43, T.B.P.248
Brouwers, Pim
 T.B.P.179, Th.B.P.208
Brown, A.
 M.D.O.14
Brown, C.
 W.B.P.156, W.C.P.95,
 T.D.O.35, M.G.O.3
Brown, Christopher
 T.B.P.107, Th.B.P.186,
 Th.B.P.239
Brown, Christopher C.
 Th.B.P.166
Brown, D.
 W.B.P.332
Brown, G. R.
 W.B.P.228
Brown, J.
 M.B.P.273
Brown, James W.
 E.745
Brown, L. S.
 T.A.P.40, T.A.P.54, D.607,
 D.608, D.609, D.610, D.611
Brown, Larry K.
 W.E.P.36
Brown, Lawrence S.
 T.A.P.49, A.550, W.D.P.68,
 Th.D.P.53
Brown, M., F.
 C.561
Brown, N.
 C.704
Brown, R. C.
 M.D.O.9
Brown, Tim
 Th.A.P.51
Brown, V.
 W.D.P.57
Brown, Y.M.
 E.596
Brown, Z.
 M.B.P.9
Browne, K.
 M.H.P.16
Brownell, D.
 M.E.P.30
Bru, F.
 A.569
Bru, Francisco
 T.A.P.22
- Bruck, C.**
 Th.C.P.34
Brucker, G.
 Th.H.P.11
Bruckner-Tuderman, L.
 Th.A.P.107
Brudney, Karen
 Th.B.P.69
Brugnetti, Anne
 A.531
Brühwiler, J.
 M.A.P.88, W.B.P.72
Brühwiler, Johannes
 Th.B.O.27
Bruisten, J.
 W.B.P.157
Brunner-Korvenkontio, H.
 Th.A.P.2, A.509
Brunner-Korvenkontio, H. K.
 B.552
Brun Vezinet, F.
 T.B.P.340, Th.B.P.3
Brun, J.
 Th.B.P.365
Brun-Vézinet, F.
 Th.B.O.54, M.B.P.343,
 M.B.P.346, T.B.P.109,
 T.B.P.195, W.B.P.107,
 Th.B.P.21, B.629, Th.C.P.131,
 C.660, C.745
Brundage, J.
 Th.A.O.34, M.A.P.2, M.A.P.3,
 M.A.P.4, M.A.P.17, W.A.P.31,
 W.A.P.66
Brundage, J. F.
 M.A.O.1, M.A.O.3, M.A.P.1,
 Th.A.P.103, W.B.P.225
Brundage, John F.
 M.A.O.6
Bruneau, Julie
 T.A.P.59
Brunet, J. B.
 M.A.O.7, W.A.P.15, W.A.P.25,
 A.537, W.H.P.22, A.571
Brunet, L. B.
 Th.H.P.22
Brunet, P.
 Th.B.P.219
Brunetti, G.
 W.B.P.21
Bruninx, G.
 D.655
Brunkhorst, R.
 M.B.P.280
Brunkhorst, U.
 M.B.P.299, T.B.P.14,
 M.C.P.143
Brunkhorst, Ulrike
 M.B.P.280, Th.B.P.12
Brunner, C.
 B.503
Brunner, D. P.
 T.C.P.108
- Brunner, S.**
 Th.B.P.96, T.C.P.88
Brunton, J.
 W.B.P.176
Bussels, B.
 M.C.P.139
Brust, J. C. M.
 Th.B.P.188
Brust, S.
 T.B.P.104, W.B.P.93, B.562,
 B.624
Brust, Stefan
 B.618
Brustia, R.
 Th.B.P.243
Brustus, J. R.
 T.A.O.18, T.G.O.19,
 Th.G.O.51
Brustus, Jean-Robert
 T.D.O.32
Bruun, L. S.
 W.C.P.25
Bruzki, C.
 W.B.O.42, Th.B.P.192
Bryant, M. L.
 T.C.P.121
Bryant, P.
 W.B.P.293
Bryden, Philip L.
 E.577
Brys, L.
 Th.C.P.109
Brysk, L.
 Th.B.P.195, Th.D.P.51
Bryson, Y.
 T.A.P.65, T.B.P.161
Bschor, F.
 T.A.P.28, W.G.P.5
Bschor, Friedrich
 T.A.P.60
Buc, H.
 M.C.P.106
Buchala, C. M.
 A.554
Buchanan, D.
 Th.D.P.56
Buchanan, K. B.
 Th.B.P.26
Buchbinder, A.
 T.C.O.13, W.C.O.32
Buchbinder, S. P.
 T.A.O.32, M.A.P.111,
 Th.A.P.86
Buchbinder, Susan P.
 M.B.P.224
Buchet, P.
 M.H.O.12
Buchner, B. K.
 M.B.P.174
Buchovsky, Gregorio
 W.B.P.306
Buck, T.
 T.B.P.104

- Buckheit, R. W.**
A.599
- Buckler-White, A.**
T.C.P.94
- Buckley, G.**
M.E.P.46
- Bucquet, D.**
A.570
- Budens, R.**
Th.B.P.117
- Budka, Herbert**
Th.B.P.248
- Budzyn, C.**
Th.B.P.167
- Buehler, J.**
W.A.O.15, Th.A.O.12,
T.A.P.37, Th.B.P.44
- Buehler, J. W.**
T.A.O.4, W.A.P.35
- Buehler, James W.**
W.A.O.16, W.A.P.29
- Bueno, C.**
M.B.P.172
- Bueno, R.**
W.A.P.4
- Bueti, C.**
M.B.P.7, T.B.P.184, Th.E.P.58
- Buff, E. E.**
M.A.P.6
- Buff, K.**
C.598
- Buffet-Janvresse, C.**
T.B.P.382
- Bugard, M.**
T.B.P.283
- Bugingo, G.**
M.B.P.188
- Buhrich, N.**
D.560
- Bulimovici-Klein, E.**
A.620, W.B.P.80, B.554
- Bulisson, G.**
W.C.P.139
- Bulisson, M.**
M.B.P.61, M.B.P.88, T.B.P.304
- Buko, A.**
W.B.P.137
- Bulatao, R.**
T.H.O.15, W.H.P.12
- Bûlau, P.**
W.B.O.42, Th.B.P.192
- Bulcavage, L.**
Th.B.P.307
- Bulger, P.**
T.C.P.1
- Bulkin, Wilma**
D.645
- Builard, W.**
C.665
- Bullian, P.**
M.A.O.38
- Bulwachter, L. A.**
A.588
- Bunde-Birouste, A.**
T.D.P.88, D.516
- Bundow, D.**
Th.B.O.28, W.B.P.374
- Bunin, J. R.**
M.A.O.3
- Buning, E. C.**
T.A.O.21
- Buning, Ernst C.**
T.A.P.82
- Bunker, John F.**
W.E.O.14
- Bunn, R. J.**
W.B.P.272
- Buntinx, F.**
M.D.P.67
- Buolos, R.**
Th.B.P.368
- Buonagurio, D.**
W.B.P.122
- Buonaguro, Franco M.**
W.C.P.51
- Buono, D.**
Th.D.P.78
- Buonocore, S.**
W.B.P.361
- Burans, J.**
W.B.P.152
- Burchard, G. D.**
C.786
- Burchett, S.**
M.B.P.9
- Burchett, Sandra K.**
T.B.P.234
- Burckhardt, Johann J.**
M.A.P.43
- Burczak, J.**
Th.A.O.29
- Bureau, Cécile**
W.E.P.16
- Bureau, J. F.**
Th.C.P.83
- Burgard, M.**
Th.C.P.21
- Burger, H.**
W.C.P.55
- Burger, R. A.**
C.512
- Burgess, Mary P. J.**
T.D.P.26, D.649
- Burgisser, P.**
Th.B.P.180
- Burk, R. D.**
Th.A.P.104
- Burke, D.**
M.A.O.6, Th.A.O.34, M.A.P.3,
M.A.P.4, W.A.P.66,
Th.B.O.57, Th.B.P.7,
Th.B.P.155, Th.B.P.264,
M.C.O.15, T.C.P.128
- Burke, D. S.**
M.A.O.1, Th.A.O.10,
T.B.P.112, Th.B.P.120,
Th.B.P.146, T.C.P.28,
T.C.P.29
- Burke, Donald S.**
Th.A.P.93
- Burke, G.**
Th.D.P.81
- Burke, G. M. D**
E.684
- Burke, M.**
Th.B.P.118
- Burke, Michael**
T.A.P.2
- Burke, O. S.**
Th.C.P.133
- Burke, S.**
C.767
- Burkel, A.**
W.B.P.305
- Burnemann, R.**
T.A.P.60
- Burns, D.**
E.695
- Burns, N. R.**
M.C.P.34, M.C.P.35
- Burns, S. M.**
M.A.P.47, T.A.P.51, M.B.P.3
- Burns, Sheila M.**
T.B.P.5, Th.C.P.105
- Burns, W. H.**
T.B.P.285
- Burny, A.**
T.C.P.107
- Burr, R.**
W.E.O.1
- Burrell, Peter G.**
M.A.P.28, M.E.P.7
- Burris, J.**
D.647
- Burstein, A. M.**
T.B.P.342
- Burstein, R.**
M.A.P.59, W.C.P.129
- Burton, J. E.**
E.644
- Bury, A.**
W.B.P.196
- Bury, J. A.**
W.E.P.32
- Busalacchi, Mary**
T.B.P.325
- Busch, D.**
T.B.O.3
- Busch, M.**
M.A.P.30, M.A.P.107,
M.B.O.27, M.B.P.169,
Th.B.P.144, E.718
- Busch, Michael**
M.B.P.150
- Busch, Michael P.**
M.A.O.10, M.B.P.172,
T.B.P.347
- Büscher, P.**
W.B.P.105
- Bush, T.**
W.A.O.2, W.A.O.17, M.A.P.35
- Bush, T. J.**
W.A.P.18, T.A.P.85, W.D.P.48
- Busher, J. T.**
M.H.P.14
- Busing, N.**
Th.E.P.10
- Buskard, N. A.**
M.B.P.143
- Bussi, P.**
T.C.P.100, W.C.P.40
- Busso, M.**
M.B.P.353
- Busso, M. E.**
M.C.P.86, M.C.P.87
- Butler, D., Jr.**
Th.C.P.33
- Butler, C. A.**
T.B.P.185
- Butler, C. V.**
Th.C.P.23
- Butler, K.**
T.B.P.247
- Butler, R.**
M.A.P.109
- Büttler-Brunner, E.**
M.A.P.43
- Butman, B.**
T.B.P.102
- Butman, Bryan T.**
C.663
- Buttler, M.**
T.D.P.89
- Büttner, M.**
Th.B.P.98, Th.B.P.122
- Butto, S.**
W.B.P.146
- Butz, Arlene M.**
B.588
- Butzin, C.**
Th.B.P.102, Th.B.P.136
- Butzin, C. A.**
Th.B.P.229, Th.B.P.230
- Buys, L.**
T.B.P.323
- Buzas, J.**
W.B.P.312
- Buzby, Bruce R.**
W.H.P.25
- Buzón, L.**
Th.B.P.268
- Buzy, J. M.**
M.C.P.92
- Bye, L.**
T.D.P.45
- Byers, R.**
M.A.P.35, M.D.P.23, Th.G.O.1
- Byers, R. H.**
M.A.O.46, T.A.O.36
- Byers, T.**
Th.A.P.76

- Bykovsky, A. F.
C.760
- Byrn, R.
W.C.O.35, W.C.P.78
- Byrn, R. A.
T.C.O.18, W.C.P.135
- Byrne, M.
M.B.P.292
- Byrne, W. R.
W.C.P.80
- Byrnes, B. D.
D.544, E.713
- Byrnes, D.
A.580
- Byrnes, John J.
M.C.P.99
- Bystritsky, A.
C.584
- Bywater, L.
D.510
- Bywater, M.
D.510
- C**
- C.M.A. (Canadian Medical Association)
T.F.O.11
- Cabanas, D. K.
T.C.P.18
- Cabanis, E. A.
M.B.P.196
- Cabat, T.
M.B.P.7, Th.E.P.58
- Cabée, A. E.
M.B.P.196, Th.B.P.254
- Cabot, T.
M.B.O.41, T.B.P.174
- Cabotin, P. P.
B.530
- Cabral, A. J. R.
Th.G.P.22
- Cáceres, C. F.
D.582
- Caceres, Carlos F.
Th.E.P.74
- Cadena, N.
W.A.P.113
- Cadeo, G. P.
M.A.P.78, B.585
- Cadoré, J. L.
W.C.P.71
- Cadranel, J.
W.B.P.25
- Cadrobbi, P.
M.D.F.72, D.583, D.623
- Caffrey, B.
T.B.P.160
- Caggese, L.
T.A.P.111, M.B.P.133,
Th.B.P.194
- Cahbon, B.
Th.D.P.7
- Cahill, K.
W.A.O.22, W.E.O.7
- Cahill, Kathy
M.A.P.55, M.A.P.75
- Cahill, M.
Th.B.P.132
- Cahill, O.
Th.C.P.91
- Cahn, F.
M.D.O.18, T.B.P.139,
T.B.P.140, Th.G.P.17
- Cahn, Pedro
Th.G.O.38
- Cahn, Pedro E.
Th.B.P.207, Th.B.P.328,
Th.D.P.46, Th.H.P.23
- Cai, B.
Th.A.P.42
- Cain, Virginia S.
T.D.P.14, D.523
- Cairns, C. J.
T.B.P.34
- Cairolí, Silvano
W.B.P.186
- Cajot, Angela
Th.B.P.322
- Cajozzo, A.
M.B.P.248
- Calabrese, Leonard H.
M.B.P.261
- Calabro, M. L.
W.C.P.110
- Calamusa, A.
W.E.P.19
- Calder, Barbara L.
E.596
- Calderón, E.
B.640
- Calderon, W.
M.B.O.34, Th.B.O.20, B.545
- Calderwood, M.
T.D.P.73
- Caldwell, S. E.
C.596
- Calelo, M.
M.D.O.10, W.D.P.56
- Cales-Quist, D.
T.A.P.12, Th.A.P.30
- Cales-Quist, D. C. Q.
W.C.P.126
- Calev, A.
B.595
- Cali, Ann
W.G.O.10
- Caligaris, S.
B.585
- Call, J.
D.671
- Callaert, S.
M.C.P.57
- Callahan, L.
C.635
- Callan, M.
D.645
- Callan, W. J.
M.A.P.7
- Calonghi, G. F.
T.B.P.74, Th.D.P.67
- Calsyn, D. A.
W.D.P.85
- Calsyn, Donald A.
Th.D.P.77
- Calvetti, T.
B.592, Th.E.P.57
- Calvetti, Theresa A.
T.B.P.184, T.B.P.233, B.573
- Calvert, C.
B.556
- Calvetti, T.
Th.E.P.58
- Calzavara, L.
M.A.P.97, Th.B.P.373, B.603,
T.D.P.63
- Calzavara, L. M.
Th.A.O.27, M.A.P.113
- Calzavara, Liviana
T.A.P.69, T.D.P.41
- Camara, C. S.
B.532
- Camargo, Irani
W.E.P.37
- Cambié, G.
Th.B.P.86
- Camen, U.
M.H.O.2
- Camerini, David
W.C.O.15, T.C.P.125
- Cameron, D. W.
M.A.P.110, T.A.P.88,
T.B.P.306
- Cameron, D. William
T.A.P.91, Th.G.O.36,
Th.G.P.29
- Cameron, G.
W.E.P.12
- Cameron, Miriam L.
W.B.P.3
- Campagnolo, Iona
M.G.O.12a
- Campbell, C.
M.B.P.81
- Campbell, D.
T.B.P.87, E.810
- Campbell, I. D.
W.B.P.265
- Campbell, I.D.
W.E.O.26
- Campbell, J. R.
M.E.P.23
- Campbell, S.
M.D.O.13, M.D.P.57,
M.D.P.89, M.E.P.35, W.E.P.73
- Campbell, S. W.
A.548, W.B.O.39, D.648
- Campbell, Scott
M.D.O.16, M.D.P.56, D.626,
T.E.P.39, Th.E.P.29
- Campestri, R.
Th.B.P.4, Th.B.P.24,
Th.G.P.21
- Campillo, M.
T.A.P.114
- Campione-Piccardo, J.
C.676
- Campione-Piccardo, José
C.675
- Camporiando, M. P.
B.597
- Campos de Magalhães, M.
M.B.P.257
- Campos, D. L.
W.G.P.15
- Campos, J.
T.B.P.230
- Campos, J. M.
T.B.P.241, W.B.P.78
- Camposortega, S.
E.546
- Camus, F.
T.B.P.4
- Camus, Françoise
T.B.O.2
- Canas Ferreira, W.
T.B.P.343
- Canas-Ferreira, Wanda
T.B.P.357
- Canavaggio, M.
C.721
- Canavaggio, Michel
Th.A.P.112
- Cancellieri, F.
M.E.O.16
- Candido, A.
Th.B.P.96
- Cane, R.
T.B.P.31
- Canick, J. P.
W.B.O.44
- Canick, Jonathan P.
W.B.P.199
- Canilh, M.
Th.B.P.359
- Carnivet, Martine
Th.C.P.48
- Cann, J. W.
G.502
- Cannat, A.
M.B.P.131, W.B.P.32,
W.B.P.138, W.B.P.167
- Canneson, G.
M.B.P.197
- Cannon, G.
M.C.P.62
- Cannon, L.
W.A.P.46, W.B.P.224
- Cannon, R.
T.A.P.119

- Cannon, R. O.
Th.B.P.173
- Cannon, Robert O.
Th.A.O.18
- Cantin, E.
Th.C.O.22
- Cantisano, A. L.
B.533
- Canton, P.
T.C.P.44, T.C.P.45, C.541
- Cantor, Kenneth P.
Th.A.P.18
- Cao, Y.
W.B.P.142
- Cao, Y. Z.
M.C.P.78
- Cao, Yunzhen
W.B.P.159, Th.C.P.68
- Caouette, J.
T.A.P.80
- Capdevila, A.
Th.G.P.17
- Capel, P.
M.B.P.253
- Capell, F.
T.D.P.45
- Capellan, J.
T.B.P.377
- Capellan, J. M.
Th.H.P.21
- Capobianchi, M. R.
M.C.P.39
- Capobianco, K.
W.B.P.48
- Capon, D.
Th.C.O.14, M.C.P.129
- Capon, Daniel J.
Th.C.O.15
- Caprilli, F.
M.A.P.48, Th.B.P.361
- Caprih, F. C.
Th.C.P.111
- Capron, A.
Th.B.P.178, Th.C.O.6
- Capron, F.
B.615
- Capsoni, F.
E.790, E.814
- Caquet, R.
T.B.P.310
- Caragol, I.
T.B.P.214
- Caramazza, R.
M.B.P.228
- Caramello, P.
M.B.P.194
- Caraux, Jean
W.B.P.301
- Carballo, M.
T.D.P.37, Th.D.P.90, D.575,
M.E.O.31, M.G.O.18, T.G.O.7
- Carballo-Diequez, Alex
D.603
- Carboni, A.
A.526
- Cárcaba, V.
W.B.O.37, T.B.P.274,
Th.B.P.89
- Card, R.
W.B.O.27, Th.B.P.20
- Cardenas, C.
M.D.P.3
- Cardno, T.
T.B.P.89
- Cardo, D.
W.G.P.13
- Cardon, B.
M.B.P.268, T.B.P.283,
T.B.P.307
- Cardona, L.
Th.B.P.42
- Cardoso, Gisela
W.B.P.203
- Cardoso, J.
M.A.P.86
- Cardoso, R., Jr.
T.E.P.60, T.E.P.64
- Carducci, Annalaura A.
W.E.P.19
- Caredda, Francesco
M.B.P.216
- Carette, M. F.
B.559
- Carey, R. F.
W.A.P.101
- Carey, V.
W.A.P.67, Th.A.P.85
- Cargill, V. A.
M.E.O.19
- Cargnet, A.
D.674
- Cargnet, Antonietta
M.B.P.215, M.B.P.361
- Carias, S.
T.D.P.32
- Carini, C.
T.C.P.41
- Cariti, G.
M.B.P.219
- Carito, M.
W.A.P.30
- Carles, J.
A.502
- Carles, M.
M.B.P.252
- Carlin, G.
Th.B.P.88
- Carlini, F.
M.C.P.105
- Carlisle, M.
T.A.P.57, W.A.P.104
- Carlo, D. J.
Th.C.O.46
- Carlo, S.
T.B.P.75
- Carlson, J. R.
Th.A.P.7, M.C.P.50,
W.C.P.23, C.746
- Carlson, James R.
W.B.P.169, C.510
- Carlsson, A.
W.B.P.83
- Carmack, B.
A.626
- Carne, B.
A.568
- Carne, Bernard
M.B.P.91, T.B.P.19,
W.B.P.151
- Carminati, G.
A.545
- Carminati, Guido
M.B.P.59
- Carmona Gonçalves, Vilma
Lucia
D.693, Th.E.P.22
- Carnahan, C.
Th.E.P.42
- Carnaíba, D.
M.B.P.40
- Carne, X.
T.B.P.294
- Carneiro, A.
M.B.P.102
- Carney, P. G.
M.A.P.114
- Caron, F.
W.E.P.42
- Carosi, G.
M.D.P.72
- Carosi, Giampiero
M.A.P.78, M.B.P.16, B.585
- Carovano, K.
D.552, W.E.P.64
- Carovano, Kathryn
W.E.P.57
- Carovano, Kathryn
D.691
- Carpenter, C.
Th.D.P.83
- Carpenter, C. C. J.
A.825
- Carpenter, Charles C. J.
T.B.P.95, Th.D.P.2, E.505
- Carples, J. L.
T.E.O.1
- Carr, D.
M.B.P.290
- Carr, P. G.
E.553
- Carr, Susan E.
M.B.P.310
- Carreño, V.
M.B.P.221, M.B.P.242,
M.B.P.246, T.B.P.216,
W.B.P.145
- Carrer, M.
W.G.O.2
- Carrer, M. T.
W.A.P.48
- Carretta, M.
D.583
- Carrick, Richard V.
M.E.P.63, E.529
- Carrière, Dominique
Th.B.P.113
- Carrington, C. C.
G.505
- Carrodegas, J.
M.B.P.27
- Carroll, Janell L.
E.583
- Carrow, E. W.
M.C.P.36, Th.C.P.40
- Carrow, Emily W.
T.C.P.69
- Carrow, M.
W.B.O.39, M.B.P.207
- Carrow, Melanie J.
D.648
- Carsel, M.
Th.G.P.20
- Carson, S.
T.D.P.18
- Carswell, John W.
A.617
- Cartacheff, I.
E.617
- Carter, C.
B.627
- Carter, J.
Th.B.P.304
- Carter, L.
W.A.P.44
- Carter, R. A.
A.589
- Carter, Susan R.
M.B.P.305
- Cartier, F.
W.B.P.75
- Carton, H.
B.637
- Carton, J. A.
W.B.O.37, T.B.P.274,
Th.B.P.69
- Carton, O.
M.C.P.57
- Carton, J. C.
Th.B.P.140
- Cartier, M.
T.A.O.8
- Cartwright, T.
G.662
- Carvajal, F.
M.B.P.129
- Carvalho Neto, L. D.
W.D.P.38, D.532
- Carvalho Neto, Lahire D.
M.E.O.17
- Carvalho, C.
M.A.P.77, Th.B.P.123

- Carvalho, E. C.
M.D.P.61
- Carvalho, L. D.
T.D.P.83
- Carvalho, M. B.
M.B.P.167, D.709
- Carvalho, M. C. S.
B.522
- Carvalho, Maria Inez
Linhares
T.E.P.65
- Carvalho Silva, A.
D.550
- Carvela, A.
M.A.P.80
- Carvell, A.
T.A.O.9
- Carwein, Vicky L.
W.B.P.267, Th.H.P.9
- Casabona, Jordi
M.A.P.52, T.A.P.114, A.504,
M.B.P.137, Th.G.O.2
- Casadei, A.
M.B.P.118
- Casado, C.
T.B.P.172
- Casado, Concepcion
T.B.P.92
- Casado, Deborah
T.H.P.2
- Casali, P.
Th.C.P.3
- Casals, A.
M.B.P.251, B.509
- Casanova, D.
Th.G.P.4
- Casanova, P.
M.B.P.29, M.B.P.130,
W.D.P.77
- Casaneuva, E.
M.D.O.10
- Casari, S.
B.585
- Casariago, Z.
Th.B.P.326
- Casariago, Zulema
M.B.O.16
- Casasnovas, C.
Th.B.P.128, Th.B.P.129,
Th.B.P.364
- Cascone, G.
Th.B.P.2
- Case, P.
M.D.O.5, Th.D.O.4,
Th.D.O.14, Th.D.P.73
- Casella, S.
T.B.P.178
- Caselli, D.
T.B.P.264
- Casey, J.
Th.C.P.26
- Casillas, V.M.
W.E.P.37
- Casiro, A.
M.B.O.16, Th.B.P.207,
Th.B.P.326, Th.D.P.46
- Casiro, A. D.
Th.H.P.23
- Casiro, Arnaldo D.
Th.G.P.17
- Casoli, Claudio
M.B.P.353
- Casoo, R.
W.G.P.18
- Caspari, G.
M.A.P.40
- Caspe, W.
T.B.P.160
- Casriel, C.
W.D.O.10, Th.D.P.75
- Cassidy, C. M.
M.D.O.4
- Cassidy, D.
M.A.O.22
- Cassidy, P. F.
D.586
- Cassinat, B.
W.B.P.364
- Cassola, G.
W.B.P.346
- Cassone, A.
M.B.P.92
- Cassuto, J. P.
M.A.P.37, A.531, T.B.P.20,
W.B.P.366, Th.B.P.364,
B.524, D.678
- Cassuto, J.P.
M.B.P.255
- Cassuto, Jill-Patrice
Th.B.P.128, Th.B.P.129
- Cassuto-Viguier, E.
M.A.P.37
- Castagna, A.
Th.B.P.245
- Castel, J.
M.A.O.21, Th.E.P.18
- Castelli, F.
M.B.P.16
- Castelli, G.
M.B.P.258
- Castello, A.
M.B.P.258
- Castello, T.
A.586
- Castello-Branco, L.R.
T.E.P.65
- Castets, M.
M.A.O.14, C.702
- Castilho, E.
T.B.O.12, M.G.O.26,
W.G.O.15, Th.G.O.50
- Castilho, E. A.
T.A.P.117, W.A.P.70, B.638,
M.G.P.4
- Castilho, Euclides
M.G.P.1
- Castilho, Euclides A.
M.G.P.6
- Castilho, M.
B.525
- Castillo, Inmaculada
M.B.P.221, M.B.P.242,
M.B.P.246, T.B.P.216,
W.B.P.145
- Castillo, R.
W.B.P.101
- Castillo, T. N.
W.B.P.168
- Castillo-Chavez, C.
A.522, A.605
- Castricriono, Santana
B.566
- Castro, A.
T.B.P.162, W.B.P.28
- Castro, Blesila A.
W.C.P.26
- Castro, C. C.
Th.B.P.114
- Castro, F. P., Jr.
D.524
- Castro, K. L.
T.A.P.15
- Castro, M.L.
M.E.O.9
- Catalan, F.
Th.B.O.55, T.B.P.113,
T.B.P.120
- Catalan, José
Th.B.P.31, E.507
- Catania, J.
T.D.O.19, T.D.O.25, M.D.P.3,
T.D.P.57, E.715
- Catania, J. A.
W.D.P.27
- Catania, Joseph A.
M.D.P.4, T.D.P.45, Th.E.P.24,
Th.G.O.7
- Cataudella, Mary
E.567
- Cates, W.
W.A.O.22, A.533
- Cattaneo, E.
B.517, C.681
- Cattelan, C.
T.B.P.178
- Caubarrere, I.
C.725
- Caubel, Patrick
M.B.P.55
- Cauda, Roberto
M.C.O.32
- Caudie, C.
Th.B.P.247
- Caudie, Christiane
Th.B.P.147, Th.B.P.365
- Caumartin, S.
T.D.P.67
- Caumartin, Susan
T.D.P.67
- Caumes, E.
W.B.P.49
- Caun, K.
W.C.P.98
- Causey, D.
M.B.O.49, M.B.P.123
- Causey, Dennis M.
M.B.P.283, M.B.P.379,
W.B.P.358
- Cavagnoli, K.
M.B.P.167
- Cavalcante R.
T.D.O.28
- Cavalcante, N.
B.639
- Cavalcanti, A.
M.B.P.102
- Cavelier, Annick
M.A.O.24
- Cayemites, Michel
W.G.O.39
- Cayla, J. A.
W.A.P.78
- Cayla, Joan-Arthur
T.A.O.3
- Cazco, V.
T.D.P.85
- Cdn Zidovudine Collab.
Grp.
W.B.P.356
- Ceccarelli, L.
W.C.P.119
- Cecchini, G.A.
W.E.P.37
- Cedenho, A.
M.B.P.266
- Celentano, D.
T.E.P.43, E.562, T.H.P.23
- Celentano, D. D.
T.A.P.45, W.A.P.90
- Celentano, David D.
T.A.P.44
- Celis, A.
Th.H.P.20
- Cellini, Mauro
M.B.P.228
- Cellule «SIDA» du
CHU-Franche-Comté
Th.B.P.100
- Celton, J. L. C.
Th.B.P.140
- Celum, Connie L.
B.551, E.731
- Cendorogio, Miguel Neto
M.B.P.279
- Center, D. M.
T.C.P.15
- Cerney, M.
B.630
- Cernuschi, M.
Th.B.P.348
- Cerutti, P. G.
W.B.P.186

- Cervera, C.
M.B.P.280
- César, D.
M.A.O.29, Th.A.O.30
- César, M.
M.A.O.29
- Cesari, D.
M.B.P.350, W.C.P.72
- Chaava, T.
W.E.O.26
- Chablani, V.
T.B.P.156
- Chabon, B.
Th.D.P.6
- Chachkes, Ester
M.E.P.67
- Chachoua, A.
C.561
- Chadwick, E. G.
T.B.P.224
- Chaiken, M.
T.C.P.106
- Chalkin, M. A.
W.C.O.12
- Chain, R.
A.549
- Chaison, Richard
M.B.O.30
- Chaisson, R.
Th.A.P.24, M.B.P.5, M.B.P.10,
Th.D.P.24, M.H.P.13
- Chaisson, R. E.
T.B.P.11, B.555
- Chakrabarti, Lisa A.
W.C.P.34
- Chakroun, Mohamed
M.B.P.226
- Chalhoub, E.
W.B.P.359
- Chalifour, R.
W.B.P.110
- Chaloupka, K.
T.B.P.234, W.C.P.134
- Chan, M. K.
M.D.P.12, M.G.O.5, T.G.P.30
- Chamaret, S.
Th.A.P.116, Th.B.P.10,
W.C.O.46, Th.C.O.8,
Th.C.P.70
- Chamberlain, M.
C.572
- Chamberland, M. E.
T.A.P.85, W.D.P.48
- Chamberland, Mary E.
W.A.O.2, W.A.O.15
- Chambers, A.
T.C.P.103
- Chambers, H.
T.B.P.270
- Chambrin, V.
M.B.P.2, M.B.P.34
- Chamness, Barbara
M.E.O.2
- Chamness, Barbara A.
M.E.P.39
- Chamow, S.
Th.C.O.15
- Chamow, S. M.
Th.C.O.13
- Champalimaud, J.
T.B.P.357
- Champoux, L.
W.E.P.62
- Chams, Vida
Th.C.O.5
- Chan, E.
W.B.P.95
- Chan, L.
Th.A.P.117
- Chan, M. S.
M.A.P.6
- Chan, Maria
W.B.P.78
- Chan, R.
M.B.O.33
- Chan, S.
Th.E.O.4
- Chan, Wendy
Th.B.P.5
- Chan, Y. Y.
T.A.P.120
- Chan-Thim, J.
T.B.P.97
- Chanda, P.
C.647, C.667
- Chanda, Pranab K.
C.668
- Chandler, L. K.
E.709
- Chandler, S.
T.C.P.18
- Chandon, B.
Th.B.P.293
- Chandwani, Sulachni
M.B.P.20
- Chang, H. G.
W.D.P.15
- Chang, H. R.
Th.B.P.58
- Chang, Kenneth S.S.
C.754
- Chang, P.
Th.C.O.22
- Chang, R. D.
T.C.P.51
- Chanh, T.
M.C.O.32
- Chanin, E.
T.B.P.75
- Chanock, Stephen
B.584
- Chapigina, S.
T.C.P.144
- Chapman, B. D.
D.616
- Chapman, L.
D.640
- Chappey, Colombe
C.643
- Chapuis, F.
W.C.O.9
- Charakchieva, R.
B.614
- Charest, J.
T.B.P.151
- Charles-Nichols, A.
D.708
- Charpentier, S.
D.717
- Charrel, J.
T.F.O.7, M.F.P.9, T.F.P.11,
W.F.P.4
- Charrel, Y.
T.F.P.10
- Charubala, R.
M.C.P.136
- Chase, E.
T.A.P.67
- Chasterie, A.
T.A.P.25, A.635
- Chasterie, C.A.
Th.E.P.17
- Chasnoff, I.
T.B.P.206
- Chast, F.
M.C.P.57
- Chateauvert, Michel
M.E.O.28
- Chatis, Pamela A.
C.677
- Chaudhary, V. K.
Th.C.O.12
- Chaudhuri, K.
M.B.P.139
- Chaunu, M.
Th.B.P.196
- Chaunu, M.-P.
Th.B.O.21
- Chaussoy, D.
W.B.P.248
- Chauvin, A.
T.D.P.49
- Chavanet, Pascal
M.B.P.88, T.B.P.304
- Chave, Jean-Philippe
Th.B.P.212, Th.B.P.319
- Chaves, Ricardo L.
M.B.P.44
- Chavis, M.
E.534
- Chavkin, W.
T.E.P.40
- Chaze, S.
W.E.P.5, Th.E.P.52
- Cheatham-Speth, D.
Th.B.P.119
- Checola, R.
T.B.P.160
- Checola, R. T.
W.A.P.5
- Checota, T.
T.B.P.159
- Cheeseman, S.
M.B.P.332, W.B.P.240
- Cheeseman, Sarah H.
W.B.P.246
- Cheimey, I.
B.644
- Cheingsong-Popov,
Rachanee
W.C.P.98, W.C.P.124
- Chela, Clement M.
W.B.P.265
- Chen, Albert
C.648
- Chen, I.
Th.A.P.21
- Chen, I. S. Y.
T.C.O.16
- Chen, K.
W.B.P.85
- Chen, L.
A.619, M.D.P.63, D.634,
Th.H.P.26
- Chen, R.
Th.O.3
- Chen, S.
Th.C.P.94
- Chen, Steve
Th.C.P.38
- Chencnier, N.
T.C.P.67, W.C.P.5, W.C.P.20
- Chene D. G.
D.591
- Chene, D.
M.A.P.50, W.D.P.66
- Chene, G.
W.A.P.60
- Chenet-Monte, Céléste
M.B.P.168, Th.B.P.178
- Cheng, C. M.
C.651
- Cheng, Y.-C.
C.585
- Cheng-Mayer, C.
Th.C.P.47, Th.C.P.49,
Th.C.P.50, Th.C.P.65
- Cheng-Mayer, Cecilia
W.C.O.37, T.C.P.104, C.649
- Cheng-Meyer, C.
M.C.O.1
- Chensong-Popov, R.
M.C.P.91
- Chequer, P.
W.G.O.15, Th.G.O.50,
M.G.P.1
- Chequer, Pedro
T.B.O.12, M.G.O.26
- Cherchi, M.
Th.B.P.150

- Chermann, J.-C.
Th.B.P.83, Th.C.O.27,
M.G.P.144
- Chermann, J. C.
T.C.P.91, Th.C.P.9,
Th.C.P.86, Th.C.P.71,
Th.C.P.87, Th.C.P.142
- Chernesky, M. C.
B.556
- Cherney, C.
M.B.P.69
- Chernoff, D.
T.B.P.25, Th.B.P.247
- Chernoff, David N.
M.B.P.193
- Cherry, J.
A.540, M.B.P.110, C.787,
Th.E.P.59
- Cherry, L.
E.533
- Chervenak, J. L.
Th.D.P.4
- Chesney, M.
M.D.P.6
- Chesney, P.
W.C.P.18
- Chetwynd, Jane
T.D.P.76
- Cheung, E.
T.C.P.139
- Cheung, Tony W.
M.B.P.198, M.B.P.297,
W.B.P.269
- Chevalier, J.
M.H.P.11
- Chevalier, T.
M.H.P.4
- Chevallier, P.
Th.B.P.169
- Chevallier, Philippe
M.G.P.7
- Chevarley, F. M.
W.A.O.16
- Chevarley, Frances M.
W.A.P.35
- Cheynier, D.
W.G.O.3, Th.G.O.54
- Cheynier, R.
T.C.O.28, T.C.P.77, W.C.P.20
- Chhay, H.
W.C.P.77
- Chi, L.
C.721
- Chi, Y.
Th.P.12
- Chia, J. K. S.
T.C.P.34
- Chiama, M.
M.B.P.227
- Chiang, C. S.
T.C.P.49
- Chiang, J.
W.B.O.38
- Chiarello, L.
T.A.P.80
- Chiasson, M.
T.A.P.89, W.A.P.34
- Chiasson, M. A.
M.A.O.34, M.A.P.67, W.A.P.84
- Chiasson, Mary Ann
T.A.P.112
- Chiasson, R.
W.D.P.11
- Chiba, J.
Th.C.P.96
- Chiba, Joe
W.C.P.37
- Chidekel, J.
T.D.P.22
- Chidiac, C.
T.B.P.282
- Chidiac, Christian
W.B.P.248
- Chieco Bianchi, L. et al.
T.B.P.165
- Chieco-Bianchi, L.
Th.B.P.225, W.C.P.110,
Th.C.P.144
- Chief, Ajisefinni S. O.
M.C.P.150
- Chierchi, M.
T.C.P.41
- Chierchini, P.
T.A.P.5, A.527
- Chieze, F.
Th.B.P.219
- Child, C. C.
W.B.P.247
- Chimfwembe, E.
M.A.O.42, D.723
- Chimfwembe, Evelyn C.
Th.P.144
- Chin, J.
Th.A.O.14, W.G.O.25, T.G.P.7
- Chingono, A.
T.G.P.16
- Chingono, R.
T.G.P.21
- Chinn, J.
W.C.P.10
- Chintu, C.
Th.A.O.5
- Chiodera, A.
M.B.P.16
- Chiodi, Francesca
Th.C.P.97
- Chiodo, F.
T.A.O.19, W.A.P.43,
M.B.P.118, M.B.P.226,
M.B.P.256, T.B.P.330
- Chiodo, Francesco
W.B.P.338
- Chiphangwi, J.
Th.G.O.28, G.507
- Chipuka, L.
M.B.P.149, T.B.P.337
- Chirgwin, K.
W.B.P.367
- Chirgwin, K. D.
Th.B.P.50
- Chirgwin, Keith
M.B.P.57
- Chirlianni, A.
T.A.P.115, W.B.P.362
- Chiribosa, R.
M.G.P.19
- Chirinian, S.
Th.C.P.83
- Chirmule, N.
T.C.P.53
- Chirwa, B.U.
Th.H.P.13
- Chirwas, C.
W.E.P.65
- Chisemba, C.
Th.G.P.30
- Chiswick, A.
W.B.P.232
- Chiswick, Ann
W.B.P.229
- Chitwood, D. D.
T.A.P.48, B.527, Th.D.P.48,
Th.D.P.49, Th.D.P.82, D.588,
D.592, D.605, E.587
- Chitwood, Dale D.
M.A.P.38, W.A.P.89
- Chiu, F. C.
W.C.P.61
- Chiu, J.
T.B.P.12, W.B.P.9, W.B.P.11,
W.B.P.24
- Chiu, Joseph
M.B.P.300
- Chlebowski, Rowan T.
Th.B.P.307
- Chloupka, K.
W.C.P.112
- Chmiel, J.
M.A.O.48, W.A.P.64,
W.A.P.67, W.A.P.68,
W.A.P.69, W.B.P.164,
Th.E.P.30
- Chmiel, Joann S.
Th.A.P.85
- Cholodofsky, S.
C.667
- Chomyc, S.
Th.B.P.67
- Chong, Pele
T.C.P.16
- Choopanya, K.
Th.D.O.1, W.D.P.73,
T.G.O.23, W.G.P.19
- Choquet, O.
M.H.P.11
- Chossegros, Philippe
Th.D.P.31
- Chou, J.
M.C.P.110
- Chou, T. C.
M.C.P.97, M.C.P.128,
M.C.P.131
- Chou, Ting-Chao
M.C.P.110
- Choudtury, N.
W.A.P.90
- Choudhury, Shankar
T.G.O.27
- Chout, R.
Th.A.O.30, Th.A.P.30
- Chout, Roger
T.A.P.12
- Choutet, P.
A.636, W.C.P.1
- Chow, J.
B.582
- Chow, Jean
M.B.P.371, T.B.P.156
- Chowdhury, M.
B.573
- Chowdhury, N.
T.A.P.58, Th.D.P.79
- Chrétien, Michel
M.F.O.8
- Christakis, Nicholas A.
W.F.O.2
- Christensen, K.
Th.B.O.46
- Christenson, P.
Th.E.P.59
- Christensson, B.
C.717, W.D.P.65, Th.D.P.36
- Christie, G.
W.E.P.28
- Christie, Grania M.
M.D.P.48, M.E.P.28, W.E.P.56
- Christie, I.
M.A.P.58
- Christopher, S.
Th.A.P.54
- Chrysomilides, Sonia A.
Th.B.P.379
- Chrystie, Ian L.
C.784
- Chu, A.
A.550, W.D.P.68, Th.D.P.53,
D.608, D.610, D.611
- Chu, A. E.
T.B.P.125, T.B.P.137,
T.B.P.138
- Chu, Alvin
D.607
- Chu, C. K.
Th.C.O.21, M.C.P.54,
M.C.P.98, M.C.P.115, C.625,
C.631
- Chu, F. N.
Th.B.P.95, Th.B.P.182
- Chu, G.
T.A.O.7

- Chu, G. T. S.
 W.D.P.28
 Chua, J.
 T.B.P.311
 Chuang, C. Y.
 C.754
 Chuang, Cheng H.
 G.501
 Chumdermpadetsuk, S.
 T.B.P.221
 Chun, P. K.
 T.B.P.137, T.B.P.138
 Chun, Peter K.
 T.B.P.125
 Chung, Y.
 M.C.P.100
 Church, D.
 M.B.P.165, M.B.P.241
 Church, J.
 T.A.P.65, T.B.P.161,
 T.B.P.260, C.610, E.598
 Church, J. A.
 M.B.P.317, T.B.P.257,
 W.B.P.204, E.509
 Church, John A.
 M.D.P.92
 Church, Joseph A.
 T.B.P.213, B.579
 Churchus, R.
 W.B.O.3
 Chwalow, J.
 M.D.P.40
 Chwaya, H. M.
 W.E.P.55, E.652
 Ciacci, D.
 W.A.P.30
 Ciacco, Marie I.
 Th.B.P.46
 Ciaffoni, S.
 A.536, M.B.P.171
 Ciberi, C.
 W.B.P.69
 Ciccomascio, F.
 A.510
 Cichutek, Klaus
 C.696
 Ciciani, R.
 Th.B.P.256
 Cicognani, A.
 W.B.P.340
 Ciesielski, C.
 Th.G.O.1
 Ciesielski, Carol A.
 Th.B.P.44
 Cihak, W.
 W.C.P.43
 Cilla, G.
 W.A.P.75, Th.G.P.8
 Cilleruelo, Jose
 B.600
 Cilleruelo, M. J.
 M.B.P.369, T.B.P.164,
 T.B.P.255
 Cimoch, P. J.
 T.B.P.315
 Cinque, P.
 M.B.P.336, M.B.P.351
 Cintron, M.
 W.H.O.10
 Ciraru-Vignerone, Nicole
 B.503
 Ciravegna, B.
 T.B.P.252
 Cisterna, R.
 T.B.P.294
 Citterio, R.
 E.790, E.814
 Claessens, C.
 T.B.P.217
 Clair, B.
 W.B.P.35
 Clapham, P.R.
 Th.C.O.41
 Clarbour, J.
 M.B.P.122
 Clarenbach, P.
 W.B.O.42, Th.B.P.192
 Clarisse, O.
 C.773
 Clark, Charles F.
 D.665, Th.E.P.45
 Clark, David
 E.538
 Clark, E. A.
 W.C.P.33
 Clark, Edward A.
 T.C.P.10
 Clark, Elizabeth
 M.E.P.51
 Clark, G.
 Th.D.P.73
 Clark, Ray, P.
 W.B.P.242
 Clark, Rebecca A.
 W.B.P.8, W.B.P.18
 Clark, S.
 B.627, E.643
 Clark, W.
 M.C.P.148, W.D.P.74,
 Th.D.P.33, Th.D.P.34
 Clark, W. S.
 T.A.O.36
 Clarke, K.
 Th.H.P.29
 Clarke, S.
 T.B.P.65
 Clarke, S. E.
 T.A.P.4
 Clarkson, S.
 T.C.O.21
 Clauseul, Genevieve M.
 G.514
 Claus, J.
 Th.B.P.208
 Clausen, L.
 M.A.P.83
 Clauvel, J. P.
 W.B.P.25, M.B.P.249,
 M.B.P.295, Th.B.P.336
 Clavel, F.
 W.C.P.108
 Clavel, François
 T.C.P.97, Th.C.P.103
 Clavel, L.
 T.B.P.261
 Claverie, J. M.
 M.C.P.7
 Clauseul, Genevieve
 E.664
 Clauseul, Geneviève M.
 M.E.P.24
 Clayette, P.
 C.591
 Clayman, B.
 M.C.P.12
 Claypoole, K.
 Th.B.P.270
 Clayton, J.
 C.664
 Clayton, J.
 Th.F.P.14
 Clegborn, F.
 Th.A.P.23, M.B.P.296, E.671,
 M.G.O.30
 Clegborn, Farley
 W.G.P.11
 Clemens, R.
 Th.B.P.119
 Clement, Jean-Marie
 T.C.P.116
 Clement, M.
 M.A.P.31, T.A.P.76, W.C.P.88
 Clement, M. J.
 W.B.P.54
 Clements, J.
 W.C.P.17
 Clements, M.
 Th.C.O.33
 Clements, M. I.
 T.B.P.123, M.C.P.14
 Clerget-Rasslain, B.
 M.C.O.3, Th.C.P.1
 Clerget-Rasslain, B.
 C.674
 Clerici, M.
 Th.B.P.91
 Cleveland, P. H.
 Th.C.P.29
 Clifford, David B.
 Th.B.P.269
 Clifford, M.
 T.G.P.2
 Cline, M.
 W.H.O.14, M.H.P.2
 Closen, Michael L.
 T.F.O.1
 Clotet, B.
 W.A.P.55, Th.A.P.19,
 Th.A.P.22, T.B.P.294,
 Th.D.P.57
 Clotet, Bonaventura
 A.502, M.B.P.103, M.B.P.240,
 M.B.P.245, M.B.P.251,
 T.B.P.308, W.B.P.22,
 Th.B.P.148, Th.B.P.234, B.509
 Clouse, K.
 W.C.P.107
 Clouse, K. A.
 Th.C.O.12
 Clouse, Kathleen
 W.C.P.105
 Cloutier, Richard
 T.E.P.24
 Cloyd, M. W.
 T.C.P.54, Th.C.P.116
 Clumeck, N.
 T.A.P.119, W.A.P.49,
 M.B.P.356, Th.B.P.43,
 Th.B.P.345, D.526
 Clumeck, Nathan
 W.A.O.19, W.B.O.14,
 M.B.P.253, M.B.P.271,
 M.B.P.272
 Cluzan, S. C.
 W.A.P.25
 Coares, T.
 Th.E.P.24
 Coates, A. R. M.
 M.C.P.41, C.544, C.545
 Coates, Anthony R. M.
 M.C.P.40
 Coates, R.
 Th.B.O.26, M.B.P.349,
 Th.B.P.373, B.603, M.D.P.58,
 T.D.P.41, T.D.P.63, Th.D.P.52
 Coates, R. A.
 T.A.O.33, T.A.P.69, Th.A.P.37
 Coates, Randall A.
 Th.A.O.27, M.A.P.97,
 M.A.P.113
 Coates, T.
 T.B.P.213, T.D.O.19,
 T.D.O.25, T.D.O.33, M.D.P.3,
 M.D.P.4, M.D.P.52, M.D.P.53,
 T.D.P.45, T.D.P.57, E.715
 Coates, T. J.
 W.A.P.31, T.D.O.8, M.D.P.31,
 T.D.P.33, W.D.P.27
 Coates, Thomas J.
 M.A.O.49, W.A.O.27,
 W.B.O.40
 Coats, Bonnie
 W.D.P.49
 Coats, Michael
 Th.B.P.264
 Cocchi, F.
 M.B.P.354, T.B.P.212
 Cochran, M.
 Th.C.O.48

- Cochran, Nancy A.
M.C.P.72
- Cochran, S. D.
W.D.P.36, D.684, D.667
- Cochran, Susan D.
W.D.P.22
- Cochrane, K.
Th.D.P.8, Th.D.P.7
- Cockerell, C. J.
M.B.P.36
- Cockerell, G. C.
W.C.P.4
- Codini, G.
W.A.P.30
- Coello, M.
Th.H.P.29
- Coen, Massimo
M.B.P.94
- Coffin, E. T.
Th.B.P.163
- Coffman, Hugh L.
W.B.P.183
- Coffman, J.
T.B.P.12
- Coget, A.
Th.B.P.105
- Cogniaux, J.
C.742
- Cogo, F.
T.B.P.186
- Cohen, A. R.
Th.A.O.28
- Cohen, A. W.
T.D.O.31
- Cohen, B.
Th.B.P.200, Th.B.P.202,
Th.B.P.278, Th.B.P.283,
Th.B.P.375
- Cohen, B. A.
Th.B.P.218
- Cohen, C. J.
T.B.P.68
- Cohen, C. S.
M.A.P.57
- Cohen, D.
M.B.O.40
- Cohen, D. S.
T.B.P.182
- Cohen, Eric
W.C.O.34
- Cohen, Eric A.
T.C.O.49
- Cohen, Felissa L.
Th.E.P.28, Th.E.P.56
- Cohen, H.
T.A.P.24, M.B.O.41
- Cohen, J. B.
W.D.P.52, W.D.P.53
- Cohen, J. S.
Th.C.O.19
- Cohen, Jeffrey Allen
Th.B.P.190
- Cohen, Judith B.
W.D.P.51
- Cohen, Lucie
T.C.P.118
- Cohen, M.
A.562, W.B.P.260
- Cohen, N.
M.A.P.34, M.B.P.161
- Cohen, R. L.
E.589
- Cohen, Sarale
T.B.P.183
- Cohen, Stuart H.
M.C.P.50
- Cohen, T.
A.511, M.G.P.2
- Cohen, W.
Th.B.P.270
- Cohn, D.
T.B.P.43, W.B.P.182,
W.B.P.345, T.D.P.27,
Th.D.P.81
- Cohn, D. L.
M.A.P.54, T.A.P.83, T.D.P.39
- Cohn, David L.
M.A.P.78, T.A.P.52, T.D.O.6
- Cohn, Jonathan
W.B.P.353
- Cohn, P.
W.E.O.17
- Cohn, S.
M.A.P.98, T.A.P.45,
Th.D.P.24, Th.D.P.50,
T.E.P.43, T.H.P.23
- Colffier, B.
T.B.P.280
- Coignet, M. C.
Th.E.P.7
- Colan, D.
T.B.P.146
- Colangehi, V.
T.A.O.19
- Colao, M. G.
Th.B.P.203
- Colburn, Kathleen A.
D.566
- Coldiron, B. M.
Th.B.P.71
- Cole, C. A.
T.B.P.124
- Cole, Curtis
W.F.P.10
- Cole, Nanette L.
T.A.P.73
- Cole, V.
M.A.P.76
- Colebunders, B.
W.B.P.12
- Colebunders, R.
M.B.O.38, T.B.O.10,
T.B.P.108, T.B.P.116,
Th.B.P.211, Th.B.P.346,
W.G.O.1
- Colebunders, R. L.
Th.B.O.30
- Coleman, D.
E.529
- Coleman, D. A.
M.E.P.63
- Coleman, P.
T.B.P.124, M.E.O.12,
M.E.P.20
- Coles, F.
T.A.P.80
- Colgate, S. A.
Th.A.P.66
- Colgate, Stirling A.
T.A.O.39
- Colin, J. N.
M.B.P.343, M.B.P.344
- Coll, A. M.
M.B.P.183, M.B.P.195
- Coll, Awa Marie
B.641
- Collandre, H.
B.547
- Collazo, J.
E.555
- Collier, A.
C.570
- Collier, A. C.
W.C.P.112, W.C.P.134
- Collier, Ann C.
Th.B.P.270, M.C.P.11
- Collier, M.
W.B.P.166
- Colligan-Levine, P.
Th.F.P.14
- Collins, B.
M.H.O.16
- Collins, E.
E.584, E.619
- Collins, J. M.
T.B.P.295
- Collins, J. V.
A.601
- Collins, S.
W.B.P.347
- Collinson, A. R.
M.C.P.72
- Collis, L.
M.H.O.2
- Collman, Ronald G.
Th.C.P.101
- Colmeiro, A.
Th.B.P.69
- Colombo, A. L.
E.704
- Colombo, C.
A.559
- Colombo, M.
T.A.P.116, A.516, M.C.P.43
- Colombotos, J.
M.D.P.44
- Colomo, C.
T.A.P.22, A.633, E.813
- Colomo-Gomez, Concepcion
M.A.O.41
- Colonna, A.
B.550
- Coltin, Kathryn L.
M.H.O.14, T.H.P.1
- Comeau, L.
Th.F.P.14
- Comella, B.
T.B.P.130, W.D.P.80
- Comella, Brianne
W.D.P.81
- Comella, Brianne R.
D.598
- Comenford, Mary
T.A.P.46
- Comer, S.
T.C.P.106
- Comerford, M.
M.A.P.38, W.A.P.89
- Comida, J.
W.C.P.86
- Comité AZT
M.B.P.347
- Comiombani, J.
C.570
- Commenges, D.
W.A.P.50
- Compaas, R.
W.C.P.79
- Compton, C.
T.B.P.118
- Conant Sloane, Beverlie
Th.E.O.1
- Conant, F. P.
T.A.P.86
- Conant, M.
M.H.P.25
- Conant, Marcus A.
T.B.P.290
- Concia, E.
Th.B.P.213
- Conde, F.
M.E.P.22, T.E.P.27, E.663,
Th.F.P.12
- Conde, Fernando
E.766, E.766
- Condini, A.
T.B.P.178
- Conducci, D.
Th.B.P.305, W.C.P.86
- Cone, L. A.
W.A.P.77, W.B.P.279
- Cone, Lawrence A.
M.B.P.204, Th.B.P.53
- Confalonieri, F.
Th.B.P.82
- Confalonieri, Franco
Th.B.P.191
- Conklin, J.
M.B.P.235

- Conklin, R.
M.B.P.235
- Conklin, R. H.
M.C.P.60
- Conley, L.
W.A.O.2, W.A.O.15
- Conley, Lois J.
T.A.P.85
- Conlon, Christopher P.
M.B.P.236
- Conlon, R.
D.606
- Conly, J.
T.B.P.111, M.C.P.147,
M.H.P.26
- Conly, John M.
M.H.P.16
- Connelly, G. M.
Th.B.P.328
- Connelly, M.
M.C.P.120
- Connelly, Mark C.
W.B.P.130
- Conner, Edward M.
T.B.P.162
- Connolly, C. M.
D.586
- Connolly, Doris
D.692
- Connolly, G. M.
M.H.P.3
- Connolly, Gerard M.
W.B.P.46, W.B.P.47
- Connor, E.
M.B.P.19, M.B.P.29, T.B.P.268
- Connor, E. M.
T.B.P.259
- Connor, Susan S.
Th.F.O.8, M.F.0.19
- Connors, Margaret
E.595
- Connors, Margaret M.
W.A.P.106, Th.E.O.17,
Th.E.P.36
- Conolly, L.
T.D.O.30
- Conolly, Lisa
T.E.P.20
- Conrad, A.
W.B.P.124
- Conrardy, M.
W.D.P.39
- Conrod, G. Scott
E.687
- Constance, P.
T.A.O.34, W.D.P.92
- Constantine, N.
M.A.P.79, M.G.P.22
- Constantine, N. T.
A.515, Th.C.P.57
- Constantine, Niel T.
B.538
- Conte, John E.
T.B.P.25, T.B.P.72
- Conti, E.
M.B.P.56
- Conti, M.
M.B.P.56, T.B.P.201
- Conti, S.
T.A.P.38
- Contreras, B.
T.B.P.245
- Contreras, Gerardo G.
A.576
- Contreras, M.
M.B.P.155
- Contreras, M.C.
Th.E.P.48, E.515
- Contu, L.
A.634, T.B.P.292, Th.B.P.158
- Conviser, R.
T.E.P.45
- Conway, B.
Th.B.O.10
- Conway, Brian
A.600
- Conway, G. A.
T.A.P.67
- Conway, George A.
T.A.P.61, W.A.P.23, A.519
- Conway, J.
Th.B.P.8, E.696
- Cook, D.
Th.A.P.38, W.B.P.172,
Th.E.P.25
- Cook, M. K.
T.B.P.271
- Cooke, K.
A.605
- Cooke, M.
C.618
- Cooksey, J.
E.745
- Cooksey, J. A.
T.E.P.56
- Cooley, Philip C.
Th.A.P.54, Th.A.P.78
- Cooley, Timothy P.
T.B.P.297
- Coombs, B.
Th.B.P.270
- Coombs, R.
T.B.P.234, M.C.P.11,
M.C.P.101
- Coombs, R. W.
M.B.P.140, T.B.P.93, B.551
- Coombs, Robert W.
W.C.P.112, W.C.P.134
- Cooney, D. A.
Th.C.O.17, M.C.P.107
- Cooney, Elizabeth L.
Th.C.O.34
- Coop. Dialysis Study Group
T.A.P.27
- Coop. Needlestick Surv.
Grp.
W.A.O.1
- Cooper, A.
W.B.P.140
- Cooper, B.
D.627
- Cooper, D.
M.B.P.278
- Cooper, D. A.
W.B.P.350, W.B.P.369,
Th.B.P.266, Th.B.P.296,
Th.B.P.369, Th.B.P.370,
T.C.P.123, T.D.P.35, W.D.P.89
- Cooper, E. R.
B.591
- Cooper, Edward H.
W.B.P.81
- Cooper, Ellen C.
W.B.O.47, M.C.P.61
- Cooper, Ellen R.
T.B.P.150
- Cooper, Jonanthan P.
T.H.P.19
- Cooper, L. Z.
A.820, W.B.P.80
- Cooper, R. W.
M.C.O.5, T.C.P.100, W.C.P.40
- Cooper, S.
M.A.P.76
- Copeland, T.
Th.C.P.123
- Copeland, T. D.
Th.C.P.136
- Copello, Gene A.
D.529, D.641, Th.E.P.14,
E.640
- Copin, N.
A.588, W.B.P.151, Th.G.P.7,
G.511
- Corbeau, P.
Th.B.P.97, Th.C.O.27
- Corbeau, Pierre
Th.C.P.9
- Corby, N. H.
Th.D.P.12, W.E.P.59, E.544
- Corby, Nancy H.
T.A.P.42, T.E.P.28
- Corda, L.
M.A.P.78
- Cordell, R.
M.B.P.172
- Cordero, R.
Th.B.P.14, B.511
- Cordery, M.
C.653
- Cordery, Mark
Th.C.P.148
- Cordes, Michael
Th.B.P.260
- Cordiali-Fei, P. C. F.
Th.C.P.111
- Cordier, Geneviève
W.C.P.71
- Cordonnier, A.
Th.C.P.140, C.524
- Cordonnier, Agnès M.
W.C.O.14
- Cordonnier, J. P.
M.D.P.91, D.513, D.569,
Th.E.O.14, W.E.P.44
- Cordonnier, Jean-Pierre
D.709
- Corey, C.
T.E.P.47
- Corey, L.
T.A.P.119, T.B.P.234,
Th.C.O.34, M.C.P.11,
M.C.P.101, W.C.P.97,
W.C.P.112, W.C.P.134,
Th.C.P.89, W.H.P.26
- Corkery, K.
T.B.O.3
- Corless, Inge B.
A.599
- Corlett, Sandy
E.807
- Corman, M.
M.D.P.4
- Cormier, N.
M.C.P.16
- Cornblath, D. R.
Th.B.P.206
- Cornejo, Mónica
Th.G.F.4
- Cornet, Bernard J. P. G.
C.742
- Cornu, P.
Th.B.P.258
- Cornuet, P.
C.597
- Coronado Luengo, Alonso
T.E.P.27
- Coronado, A.
A.544, M.E.P.22, E.663,
E.765, E.766, Th.F.P.12
- Coronesi, M.
Th.C.P.5, C.740
- Corrah, T.
T.B.P.362, B.612
- Corral, R.
Th.B.P.4
- Corrales, J.
W.B.P.306
- Correa Lima, M. B.
M.B.P.223
- Correa-Lima, Mário B.
W.B.P.266
- Corrigan, A.
Th.C.P.108
- Corrigan, Alice J.
C.622
- Côrte-Real, R.
M.A.P.18

- Cortes, Eduardo
W.C.P.85
- Cortes, Eduardo J. B.
M.G.P.12, M.G.P.13,
M.G.F.14, M.G.P.15, M.G.P.20
- Cortes, H.
W.B.P.5
- Corwin, A. L.
Th.A.P.28
- Cory, J. M.
T.B.P.83, T.B.P.313
- Cory, Joan M.
T.B.P.84
- Coscina, Antonio
G.518
- Cosin, J.
T.B.P.294
- Cossette, Michèle
Th.B.P.301
- Costa, A. M.
T.B.P.330
- Costa, A. M. M.
Th.B.P.37
- Costa, C.
T.B.P.357
- Costa, D.
D.671
- Costa, F.
M.A.P.8, M.G.P.9
- Costa, S.
W.A.O.7, T.A.P.78, T.A.P.79,
T.E.P.45, E.678
- Costagliola, Dominique
Th.A.P.61
- Costantini, M.
T.B.P.272, Th.D.P.84
- Costanzi, G.
Th.B.O.14
- Costanzo, R. M.
T.H.P.21
- Coste, J.
Th.A.P.3
- Costello, C.
T.B.P.326
- Costello, R.
W.B.P.90
- Costigliola, P.
W.A.P.43, M.B.P.116,
M.B.P.228, M.B.P.256,
T.B.P.330, W.B.P.338
- Costigliola, Paolo
T.A.O.19
- Costil, J.
T.B.P.155
- Cot, M.
Th.C.P.55
- Cot, M.-C.
Th.A.P.108
- Cot, Marie-Camille
B.629, Th.C.P.78
- Côté, José K.
T.D.P.52
- Côté, L.
Th.B.P.224, Th.B.P.237
- Côté, S.
Th.E.P.18
- Cotton, D.
T.B.P.7, T.B.P.296, W.B.P.252
- Cotton, D. J.
T.B.P.68
- Cotton, M.
W.E.O.2
- Cotton, T.M.
M.E.P.56
- Cotton, Terry M.
M.E.P.53
- Cottone, James A.
Th.B.P.354, M.D.P.82
- Couch, K. W.
M.D.P.16
- Couch, R.
Th.B.P.104
- Couderc, L. J.
C.725
- Coughlin, Richard T.
T.C.P.1
- Coulaud, J. P.
M.B.P.225, T.B.P.113
- Coulaud, Jean-Pierre
T.B.P.27
- Couloudon, J.
M.E.P.75
- Coulson, A. H.
D.685
- Coulter, M.
M.G.O.4
- Coumaros, G.
T.C.P.43
- Coupal, L.
W.A.P.79, A.609, M.H.O.7
- Courgnaud, V.
T.B.P.106, T.C.O.40,
Th.C.P.21, Th.C.P.70,
Th.C.P.131
- Courgnaud, Valérie
M.B.P.1, C.660
- Cournos, F.
W.B.P.209
- Courouce, A. M.
M.A.P.102, M.A.P.116,
Th.A.P.3, M.B.P.151, B.629,
B.644
- Courouce, Anne-Marie
M.A.P.33, M.A.P.85
- Courpotin, C.
M.B.O.5, T.B.P.155, T.B.P.195
- Courtress, J.
W.B.P.308
- Courtneay, Audrey V.
T.E.P.63
- Courval, J. M.
T.A.O.40
- Cousineau, Léa
T.E.P.46
- Coussement, A.
M.B.P.255
- Coutinho R. A.
W.A.P.36
- Coutinho, R.
M.A.O.47, M.B.P.362
- Coutinho, R. A.
T.A.O.13, T.A.O.21,
M.A.P.112, T.A.P.14,
T.A.P.20, T.A.P.36, T.A.P.82,
W.A.P.107, Th.A.P.55,
T.D.P.72
- Coutinho, Roel A.
W.D.O.9
- Coutinho, S.
T.G.O.12
- Couto-Fernandez, J. C.
T.B.P.99, W.G.P.15
- Couto-Fernandez, José
Carlos
C.743
- Coutoudon, J.
Th.E.P.72
- Coutts, N. A.
T.B.P.246, B.590
- Couturier, E.
W.A.P.15, A.537
- Coverdale, J.
W.D.P.5, W.D.P.35
- Coverdale, John H.
E.763
- Cowan, D.
M.A.P.17
- Cowan, David N.
W.A.O.3, M.A.P.1
- Cowan, F. M.
M.A.P.105, E.722
- Cowan, Frances M.
M.B.P.3, W.B.P.317,
W.B.P.371
- Cowan, J.
T.A.P.16
- Cowan, M.
M.B.P.24
- Cowan, Morton J.
T.B.P.227
- Cowing, M.
W.B.P.249, W.B.P.250
- Cox, C. P.
E.589
- Cox, Patricia
W.B.P.337
- Coxon, A. M. P.
T.D.P.23
- Coxon, A. P. M.
A.594, T.D.P.19, T.D.P.20
- Coxon, Anthony P. M.
D.529
- Coye, Molly J.
T.A.P.79, W.A.P.19,
W.B.P.293, E.678
- Coyne, P.
B.550
- Cozen, Wendy
W.A.P.9
- Cozens, R. M.
M.C.P.81, W.C.P.6
- Cozon, G.
W.C.P.71
- Cozzani, S.
T.B.P.166
- Crabbe, C.
B.617
- Craib, K.
T.A.P.89
- Craib, K. J. P.
M.A.O.26, W.A.P.57,
Th.A.P.33, W.D.P.92
- Craib, Kevin J. P.
W.A.P.58
- Craig, J. L.
M.E.P.6
- Craik, C.
M.C.P.84, C.666
- Cranage, M. P.
W.C.F.7
- Cranage, Martin P.
C.502
- Crandies, Sheila
W.E.O.16
- Crane, Martin M.
D.696, E.716, T.H.P.22
- Cranfield, M.
M.G.P.18
- Cranfield, Steven S.
D.617
- Cranston, B.
W.G.P.26, Th.G.P.1
- Cranston, K.
W.E.P.20
- Cranston, Kevin C.
E.661
- Craske, John
W.B.P.186
- Cravanis, A.
C.597
- Craven, A.
W.E.P.25
- Craven, D.
T.B.P.130, W.D.P.81
- Craven, D. E.
W.D.P.80
- Cravioto, M. L.
M.D.P.69
- Crawford, J. H.
Th.B.P.62
- Creagh-Kirk, Terri H.
W.B.O.45
- Crection, K. W.
M.B.P.146
- Creger, J.
T.A.O.7
- Crespin, S.
W.E.P.23
- Crespo, J. D.
A.520

- Crétien, J.
Th.B.P.64
- Crevon, M. C.
Th.B.P.92
- Crimet, D.
C.628
- Crisler, J.
W.B.P.184
- Criss, V. C.
T.B.P.241
- Critchley, S.
Th.A.O.33
- Crivellaro, C.
D.583
- Crocchiolo, Paolo
W.B.P.365, Th.B.P.86,
W.E.P.55
- Crofts, N.
T.A.P.37
- Crombleholme, W.
M.B.P.33, M.B.P.54, T.B.P.198
- Cromwell, Gale G.
W.B.P.274
- Cronin, K.
Th.B.P.249
- Cronin, K. C.
W.C.P.45
- Cronin, W.
M.B.P.135, M.C.O.27, C.664
- Cronin, William
M.B.P.191
- Cronin, William J.
M.B.P.274, T.C.P.62
- Crooks, Levinia
T.D.P.49
- Cross, B.
E.748
- Crossman, C.
T.E.P.8
- Crout, F. V.
M.B.P.170
- Crovari, P.
W.B.P.346
- Crowe, S.
W.C.P.42, C.670
- Crowe, Suzanne M.
M.C.P.109, Th.C.P.137
- Croxson, T. S.
W.D.P.71
- Croxson, T. Scott
W.B.P.150
- Cruaud, P.
Th.B.P.124
- Cruccu, V.
W.A.P.30, Th.B.P.82,
Th.B.P.191
- Cruikshank, W. W.
T.C.P.15
- Crumpacker, C.
W.B.P.252
- Crumpacker, C. S.
C.677
- Crumpacker, Clyde S.
T.B.P.296
- Crush-Stanton S.
C.663
- Cruz, C.
T.A.P.61
- Cruz, O.
T.D.P.85
- Crysler, Carl
M.C.P.127
- Crystal, S.
E.700
- Crystal, Stephen
Th.D.P.15, T.E.P.53
- Cudd, A. N.
M.C.P.102
- Cuff, P.
Th.B.P.312
- Culbert, A.
M.D.P.71
- Cullen, Bryan R.
T.C.O.9
- Culp, J.
T.C.P.106
- Culpepper-Morgan, J. A.
Th.B.O.37
- Cumberland, W.
Th.B.O.25
- Cumming, S.
T.C.O.35, Th.C.P.39
- Cummins, B.
D.814
- Cumont, M. C.
W.C.P.127
- Cuneo, W.
E.688
- Cuneo-Crovari, Piera
W.B.P.346
- Cunha Teles, Louise
W.E.P.76
- Cuninghame, D.
M.E.P.46
- Cunningham, A.
W.B.P.153
- Cunningham, A. L.
W.C.O.23, T.C.P.6,
T.C.P.123, W.C.P.27
- Cunningham, E. L.
M.E.P.19
- Cunningham, Ineke
M.E.P.19
- Cunningham, Philip H.
W.B.P.140
- Cunnon, S.
A.506
- Curbow, B. A.
M.D.P.70
- Currell, N.
T.B.P.214
- Curless, R.
M.B.O.40
- Curless, R. G.
T.B.P.182
- Curran, J.
T.A.O.27
- Curran, L.
T.D.P.68, T.D.P.69
- Curran, Len
E.642
- Curran, William
M.F.O.7
- Currey, Charles J.
D.642
- Currie, B.
T.G.O.24
- Currie, D.
T.B.P.31
- Currie, J. N.
Th.B.P.296
- Currie, Jon N.
Th.B.P.290
- Curry, N.
Th.B.P.53
- Curry, T. F.
Th.A.P.71
- Curvin, M.
D.509
- Cusik, P.
W.C.P.38
- Cusini, M.
A.545, M.B.P.50, M.B.P.384
- Cuthbert, Melinda
W.D.O.16
- Cuthbert, Melinda A.
T.E.O.17, Th.H.O.4
- Cuthbert, R. F. G.
W.B.P.74
- Cuthbert, R. J. G.
Th.C.P.126
- Cutting, W. A. M.
M.G.P.18
- Cvitanic, M.
M.H.O.17
- Cvitanic, Marilyn
T.H.P.18
- Cynnnon, Marcie L.
M.D.O.6
- Cyr, H.
M.H.P.27
- Cyr, W. Howard
M.A.P.114
- Czajkowski, J.
W.A.P.52
- D
- D'Abbraccio, M.
T.A.P.115
- D'Agay, M. F.
Th.B.P.336
- D'Agostino, F.
Th.B.P.86
- D'Almeida, L.
Th.B.P.377, M.D.P.18, E.565
- D'Almeida, P.
Th.E.P.35, E.798
- D'Almeida, L.
Th.G.P.23
- D'Andrea, L.
Th.B.P.339
- D'Angelo, K.
T.A.P.32
- D'Angelo, Lawrence J.
M.D.P.10
- D'Arcangelo, E.
M.D.P.37
- D'Arminio Monforte, A.
W.B.O.34, M.B.P.216,
M.B.P.227
- D'Arminio Monforte,
Antonella
W.B.P.200
- D'Arminio Monforte, F.
T.B.P.212
- D'Auriol, L.
W.C.P.126, W.C.P.139
- D'Avola, G.
W.B.P.186
- D'Costa, L.
T.A.P.87
- D'Costa, L. J.
T.A.P.88, T.A.P.91,
Th.G.O.36, W.G.P.29,
Th.G.P.29
- D'Elia, R.
T.B.P.165
- D'Hallivillée, P.
M.A.P.24
- D'Hallivillée, R.
D.601
- D'Offizi, G.
T.A.P.103, A.567
- D'Souza, I.
T.B.P.106
- Da Bouza, J. H.
A.586, Th.G.O.3
- Da Silva, M.
M.B.P.274
- Daar, Eric S.
T.C.P.34
- Dab, W.
E.673
- Dabis, F.
Th.E.P.16
- Dabis, François
W.A.P.60
- Dadaglio, G.
T.C.P.67, T.C.P.76
- Daefler, S.
T.C.O.31, Th.C.P.72
- Dagenais, Bernard
T.E.P.68, E.741
- Dago, A.
T.B.O.8
- Daguet, G. L.
Th.B.P.124
- Daldouh, M. A.
Th.B.P.50

- Daigh, D.
T.B.P.176
- Dailey, L.
D.661
- Daily, I.
W.E.P.49
- Daily, Lisa A.
W.E.P.50
- Dal Corso, M.
T.A.P.50
- Daley, T.
T.B.P.160
- Dalgleish, A. G.
Th.C.O.41, T.C.P.11, C.514
- Dalgleish, Angus
Th.C.O.43
- Dallabetta, G.
Th.G.O.28, G.507
- Dallas, A. B. C.
M.B.P.149
- Dallot, A.
W.B.P.49
- Dalloul, A. H.
W.B.P.281
- Dalloul, Ali H.
W.B.P.284
- Dalton, J.
Th.B.P.116
- Damato, J.
Th.A.O.34, Th.B.O.57
- Damato, J. D.
Th.B.P.146
- Dambreville, M.
Th.B.P.70
- Damet, G.
T.B.P.116, M.G.P.24
- Damiano, F.
Th.B.P.72
- Danagoro, J. P.
Th.E.P.52
- Danahy, R.
M.G.P.22
- Danforth, S.
T.B.P.95, Th.D.P.2, E.505
- Daniel, H.
T.E.P.60, T.E.P.64
- Daniel, J.
M.D.P.80
- Daniel, L.
W.C.O.21
- Daniel, M. D.
M.C.P.47, Th.C.P.23,
Th.C.P.68
- Daniel, Muthiah
W.C.O.48
- Daniel, V.
C.727
- Daniel, Volker
Th.B.P.142, C.727
- Daniell, F. D.
E.669
- Daniell, Fredric D.
A.506
- Danila, R.
T.A.O.28, T.A.P.43
- Danila, Richard N.
M.A.P.70, M.A.P.72
- Danis, M.
T.B.P.13
- Dannemann, B. R.
W.B.P.24
- Dannenberg, Andrew L.
W.A.P.31
- Danner, S. A.
Th.B.O.38, M.B.P.121,
Th.B.P.210
- Danner, Sven A.
M.B.P.283
- Danos, O.
T.C.P.97
- Danozzo, M.
W.C.P.110
- Dansky, S.
M.D.P.62
- Dantas, A.
W.E.P.76, Th.E.P.46
- Danton, C.
E.656
- Darban, Hamid R.
C.511
- Darby, G.
T.C.O.7
- Darby, G. K.
T.C.O.4
- Darke, P. L.
M.C.O.23
- Darke, S.
W.D.P.64
- Darragh, M.
W.B.P.287
- Darrow, W.
W.A.P.38
- Darrow, W. W.
T.A.O.36, E.550
- Das, Prakash C.
M.B.P.153, T.B.P.131,
T.B.P.354
- Dascal, André
M.B.P.359, T.B.P.97
- Dassey, David E.
M.H.O.18
- Dataaha, P.
T.G.O.12
- Datema, R.
M.C.P.128
- Datry, A.
T.B.P.19, W.B.P.25
- Datry, Annick
T.B.P.13, B.546
- Datta, P.
Th.B.P.324, M.G.P.27,
W.G.P.29
- Datta, Pratibha
M.G.O.20, W.A.P.65
- Datta, Pratibha P.
Th.G.O.52
- Dattel, B. J.
M.B.F.54
- Dattel, Bonnie J.
M.B.P.33, T.B.P.198
- Daul, C.
Th.B.P.19
- Daum, F.
B.580
- Dauphinais, R. M.
A.529
- Dautry, F.
W.C.P.121
- Davachi, Farzin
T.B.P.188, B.646, W.E.O.30,
E.666, Th.G.O.33, W.H.P.6
- Davachi, N.
W.E.O.30
- Davenny, K.
Th.A.P.101, T.B.P.173
- Davenny, Katherine
M.B.P.8
- Davey, R.
W.B.P.335
- Davey, R. T.
M.B.P.128
- Davey, Richard T.
Th.B.P.179
- Davey, V.
W.B.P.322
- Davey, Victoria
Th.B.O.43
- Davey, W. A.
M.E.P.25
- David, H.
Th.B.P.124
- David, M.
T.B.P.277
- David, O.
B.540
- Davidson, P.
Th.A.P.53, A.560, A.561,
W.H.P.18, W.H.P.20
- Davidson, A.
W.B.P.345, Th.D.P.61,
Th.E.P.8
- Davidson, Bruce L.
M.A.O.39
- Davidson, J.
T.A.P.51
- Davidson, M.
W.B.P.5
- Davidson, R.
Th.B.P.117, E.678
- Davidson, S. J.
C.781
- Davidson, Susan J.
T.A.O.14
- Davies, D.
M.C.P.91
- Davies, E. T.
Th.B.P.127
- Davies, P.
T.D.P.23
- Davies, P. L.
E.806
- Davies, P. M.
D.529
- Davies, Peter M.
A.594, T.D.P.19, T.D.P.20,
E.522
- Davis, A.
W.B.P.193, W.B.P.197,
W.B.P.198, W.B.P.231,
W.B.P.234
- Davis, B.
T.B.P.196
- Davis, E.
T.B.P.220, T.B.P.238
- Davis, F.
W.D.P.70
- Davis, G. R.
Th.C.P.46
- Davis, H.
Th.G.O.51
- Davis, I.
A.827, W.B.P.245
- Davis, Iris L.
A.828, W.B.P.307
- Davis, Jeffrey P.
M.A.P.22
- Davis, M. G.
T.C.P.101
- Davoli, Gerald W.
W.E.P.20
- Davydov, V.
T.B.P.233
- Dawson, C.
T.C.P.36
- Dawson, D.
W.A.O.26
- Dawson, D. A.
E.550
- Dawson, D. D.
W.E.O.25
- Dawson, G.
M.A.P.108, W.B.P.71,
T.C.P.72
- Dawson, G. J.
Th.C.P.37
- Dawson, J.
M.D.P.15
- Dax, E. M.
T.A.P.13
- Day, A.
Th.B.P.31, E.507
- Day, E.
M.C.P.17
- Day, J.
M.A.O.25, T.A.O.2, T.A.P.74,
Th.A.P.98, W.E.P.53
- Day, Jacqueline
Th.B.P.195
- Day, N.
M.D.P.14
- Day, N. A.
E.791

- Day, Noel A.
M.E.O.34, T.E.P.7, E.556
- Day, S.E.
E.521
- Dazza, M. C.
M.B.P.382, Th.C.P.131, C.660
- Dazza, Marie-Christine
M.B.P.348
- De Almeida, M.
T.A.P.92
- De Andres, R.
Th.D.P.19, Th.E.P.48, E.515,
E.526
- De Andrés, Rafael
A.578, A.575
- De Baetselier, P.
T.C.P.149
- De Bernardo, Robert L.
D.561
- De Biasi, R.
Th.B.P.16
- De Blai, R.
T.E.P.3
- De Bracco, M. M. de E.
Th.B.P.362
- De Bruyn, J.
Th.B.P.55
- De Buen, L.
T.B.P.289
- De Buysscher, R.
W.E.P.71
- De Candido, D.
M.D.F.37
- De Caprariis, P. J.
W.D.P.4
- De Caprariis, Pascal J.
M.D.P.82
- De Carvalho, M. C. S.
T.B.P.317
- De Cataldo, F.
W.B.O.11, M.B.P.294,
T.B.P.272, C.729
- De Clercq, E.
Th.C.O.20, M.C.P.75,
M.C.P.76, M.C.P.93, C.550,
C.595, C.621, C.641
- De Cock, K.
T.B.O.8, T.B.O.10, T.B.P.116,
W.B.P.113, M.G.P.24
- De Cock, Kevin M.
W.G.O.27
- De Crescenzo, G.
M.B.P.92
- De Dona, D. D.
T.B.P.363
- De Filippes, P.
M.D.O.1
- De Gans, J.
Th.B.P.210
- De Gans, Jan
M.B.P.121, M.B.P.134,
W.B.P.2
- De Girolami, U.
W.B.O.18
- De Goede, R. E. Y.
M.C.O.8, W.C.P.46
- De Gramont, A.
T.B.F.279
- De Grave, A.
T.D.P.34, G.520
- De Gruttola, Victor G.
Th.A.P.63
- De Hovitz, J.
W.B.P.367
- De Jager, M. H.
T.C.F.73
- De Jong, Jean-Jacques
W.C.P.56
- De La Cruz, F.
M.B.P.373
- De La Cruz, F. V.
M.B.P.327
- De La Cruz, Fernando V.
Th.G.P.22
- De La Vega, A.
M.B.P.27
- De La Vega, E.
W.E.P.64, Th.E.P.74
- De La Vega, R.
Th.B.P.228
- De Lacerda, M. C.
M.B.P.74
- De Lalla, Fausto
W.G.P.1
- De Leys, R. J.
T.C.P.149, C.672
- De Leys, Robert J.
Th.C.P.109, C.761
- De Longis, P.
T.A.P.113
- De Luis, A.
M.B.P.67, M.B.P.98,
M.B.P.260, T.B.P.289,
W.B.P.28, Th.B.P.57
- De Mayo, E.
T.B.P.100
- De Maria, Andrea
T.B.P.252
- De Marquez, M.
Th.B.P.101
- De Martin, C.
W.E.P.48
- De Martini, Rodney J.
Th.E.P.41
- De Matteis, M.
Th.B.P.128, Th.B.P.364
- De Meis, A.
M.A.O.39
- De Meis, C.
M.A.P.53
- De Mendonça, J. S.
T.B.P.317
- De Mercato, R.
M.A.P.48
- De Montigny, J.
M.E.P.58
- De Montigny, Johanne
D.717, D.718
- De Moya, E.
W.A.P.94
- De Moya, E. A.
Th.D.O.10, Th.D.O.12,
M.G.O.25
- De Moya, E. Antonio
T.D.P.32, T.D.P.89, E.672
- De Moya, R. A.
M.E.O.11
- De Negri, Berengere
E.793
- De Noronha, C. M. C.
W.C.O.31
- De Paula, L.
W.G.O.15
- De Piccioto, C.
T.B.O.2
- De Rienzo, B.
T.B.P.235, Th.B.P.339
- De Rinaldis, M. L.
T.B.P.361, C.747
- De Ronde, A.
M.B.O.23, Th.C.P.35
- De Rossi, A.
M.B.P.324, T.B.P.165,
Th.B.P.225
- De Rossi, Anita
T.B.P.244, W.C.P.110
- De Rossi, G.
B.518
- De Salab, R.
M.B.P.132, M.B.P.368,
T.B.P.283
- De Salamanca, R. E.
M.B.P.107
- De Santis, C.
C.578
- De Seljls, A.
T.B.P.251
- De Silverstro, G.
D.623
- De Stefano, G.
T.A.P.113
- De Sweemer, Cécile
M.F.O.17, W.F.O.17
- De Tafur, Matilde
W.E.P.48
- De Tezanos Pinto, M.
Th.B.P.13, Th.G.P.21
- De Tezanos-Pinto, M.
B.513
- De Thé, Guy
T.B.P.158
- De Truchis, P.
M.B.P.225
- De Vincenzi, Isabelle
Th.A.O.20, T.A.P.98
- De Vries, A. H.
T.B.P.131, T.B.P.354
- De Vroome, E.
D.673
- De Vroome, E. M. M.
M.A.P.112, T.A.P.20,
W.A.P.36
- De Vroome, Ernest
W.A.P.97
- De Wis, S.
M.B.P.271
- De Wit, Stéphane
M.B.P.356, Th.B.P.43,
Th.B.P.345
- De Wolf, F.
M.A.P.112, M.B.O.23,
M.B.P.352, Th.B.P.87,
M.C.O.8, T.C.P.73, W.C.P.44,
T.D.P.72
- De Wolf, Frank
M.A.O.47
- De Zalduando, B.
Th.E.P.3
- De, B.
Th.A.O.33, Th.C.P.33
- De, B. K.
W.C.P.4, Th.C.P.30
- De, Barun K.
Th.B.O.11
- De-Thé, G.
T.B.P.368
- Deagle, R.
Th.E.P.20
- Dean, H.
W.A.P.8
- Dearmas, L.
M.B.P.329
- Debliez, C.
D.644
- DeBoeck, H.
C.581
- Debord, T.
T.B.P.309
- Debouck, C.
M.B.O.23, T.C.P.73, Th.C.P.35
- Debouck, Christine M.
T.C.O.11
- Debré, M.
W.D.P.16
- Debre, F.
M.B.P.42, T.C.P.25
- Debré, F.
W.B.P.281, W.B.P.284,
W.B.P.302
- Debs, R. J.
W.A.P.39
- Décary, F.
M.A.P.29
- Decazes, Jean M.
T.B.P.25, W.B.P.29
- DeCecco, J.
M.H.P.24
- Decker, Scott R.
M.C.P.126

- Decker, W. D.
T.C.P.126, Th.C.P.132
- Deckman, I.
T.C.O.11
- DeCock, K.
Th.B.P.346
- Decourt, J. L.
C.672
- Dedera, Douglas
T.C.O.46, Th.C.P.12
- Deen, K. C.
W.C.O.12
- Defillipes, P.
E.560
- DeFilippes, P.
W.E.P.29
- Defourny, J.
Th.E.P.21
- DeGasperi, R.
M.C.P.51
- Degenhardt, S.
W.B.P.291
- DeGenova, V.
W.B.P.270
- Deglon, J. J.
Th.D.P.80
- Degner L.
M.D.P.46
- DeGroff, C.
B.593, M.E.P.70
- DeGrutola, V.
Th.A.P.80
- DeHovitz, J.
M.B.P.57, Th.D.P.9, M.E.P.12
- DeHovitz, Jack A.
A.614
- Delbel, M. R.
T.C.P.108
- Delbis, L.
Th.B.P.101
- Deicas, A.
T.B.P.264
- Delcher, H.
M.B.P.280, M.B.P.299,
T.B.P.14, T.B.P.334,
Th.B.P.12, M.C.P.143
- Deicken, R.
W.C.P.69
- Deinhardt, F.
T.B.P.360, C.624, W.G.O.29
- Deitch, D.
M.E.P.99, E.714
- Dejace, Pierre M. J. T.
T.B.P.528
- Dejarlais, Don C.
W.D.O.10
- Dejowski, E.
Th.D.P.15, E.700
- Dekegel, D.
C.742
- Dekker, T.
Th.C.P.35
- Del Arco Galan, C.
T.B.P.293
- Del Bianco, R.
W.B.P.21, T.E.P.49, E.610
- Del Bianco, Rosana
M.B.P.40
- Del Junco, G.
M.B.P.235
- Del Junco, G. W.
M.B.P.377
- Del Mistro, A.
T.B.P.186, T.B.P.244
- Del Moral, A.
T.B.P.215
- Del Prado, Ruben
Th.G.O.47
- Del Rio, C.
Th.C.O.38
- Del Rio, Carlos
M.B.P.290
- Del Valle, C.
M.B.P.141, M.B.P.142,
M.B.P.152, T.B.P.344
- Del Venthal, H.
W.B.P.144
- Dela Torre, A.
W.C.P.17
- Delacour, T.
T.B.F.4
- Delacoux, R.
Th.B.P.280
- Delage, G.
M.B.P.17, T.B.P.243
- Delagneau, Jean-François
Th.A.P.108, B.617
- Delamater, A.
W.E.P.23
- Delaney, Martin
T.E.O.11
- Delaporte, E.
Th.B.O.54, W.B.P.107,
T.C.P.100, W.C.P.40
- Delaporte, Eric
M.A.O.16
- Delassus, S.
W.C.P.20
- Deleage, J.
E.732
- Delestre, L.
C.591
- Deletoille, P.
T.B.P.13
- Deleuze, J.
M.B.P.350, W.C.P.72
- Defraissy, J. F.
T.B.P.380, T.B.P.273,
T.B.P.92
- Defraissy, Jean-François
W.A.P.88, M.B.P.2, M.B.P.34,
T.C.P.39, T.C.P.40
- Delgado, S.
A.585
- Delgado, A.
E.579
- Delgrance, F.
W.G.O.23
- Delisle, M. B.
T.S.P.187
- Delke, I.
Th.D.P.44
- Della Guista, G.
M.D.P.37
- Della Negra de Paula,
Marinella
T.B.P.194, T.B.P.196,
T.B.P.199
- Dellamonica, P.
M.B.P.252, Th.B.P.128,
Th.B.P.129
- Dellamonica, Pierre
M.A.P.37, T.B.P.33,
Th.B.P.364
- Delleplane, C.
Th.B.P.207
- DeLong, P. A.
Th.C.O.16, W.C.P.75
- Delord, B.
T.B.P.115, T.B.P.245
- Deloria, M. A.
Th.A.P.100
- DeLuca, A.
T.B.P.15, W.B.P.42
- DeLuca, P.
W.B.P.42
- Dembitzer, F.
T.B.P.29
- Dembitzer, R.
T.B.P.29
- Dembo, M.
Th.C.P.100
- Demby, A.
W.E.P.66, T.G.P.21
- Demeleumesster. R.
Th.A.P.30
- Demeulemester, R.
T.A.P.12
- Demuytyn, B.
T.B.P.279
- Deng, P.
A.619, Th.H.P.26
- Dengelegi, L.
Th.D.P.76
- Deniaud, François
W.E.P.23, E.617, E.618
- Denis, F.
T.A.P.12, Th.A.P.112,
T.B.O.9, T.B.P.382,
W.B.P.108, B.523, C.765,
C.766, T.G.P.29
- Denis, François
A.587, W.G.P.8
- Denis, J.L.
W.E.P.11
- Denis, M.
T.B.P.1, T.B.P.4
- Denis, Michel
B.559, B.569
- Denisenko, Bela
Anatolyevna
A.586
- Denisova, A. B.
T.B.P.342
- Denning, David W.,
W.B.P.10
- Dennis, Macy W.
W.C.P.142
- Denny, T.
T.B.P.182
- Denny, Thomas N.
M.B.P.19
- Dentale, N.
W.A.P.43
- Deppermann, K. M.
W.B.P.33, W.B.P.372
- Deppner, M. D.
B.599
- Der, S.
W.C.P.83
- Derby, S.
T.A.O.22
- Derdevesis, T.
E.615
- Deren, S.
A.586
- Deresinski, S. C.
T.B.O.5
- Derivianaki, A.
Th.A.P.27
- Derix, M. M. A.
Th.B.P.210
- Derks, J.
D.705
- DeRocco, S.
W.C.P.125
- DeRossi, A.
T.C.O.13
- Derrner, M.
W.B.P.14
- Derse, D.
Th.C.P.27
- Des Jarlais, D.
T.A.P.54
- Des Jarlais, D. C.
T.A.O.12, T.A.P.48, W.D.O.5,
W.E.P.68, Th.D.O.3,
Th.D.O.13, T.D.P.81,
Th.D.P.17, Th.D.P.64,
Th.D.P.74, Th.E.P.4, T.G.P.5
- Des Jarlais, Don C.
T.A.O.20, Th.D.O.6, Th.D.P.75
- Desai, S.
Th.C.P.36
- Desai, S. M.
Th.C.P.31
- DeSantis, R. D.
Th.C.P.99
- Deschamps, M. M.
Th.B.F.70

- Deschamps, Marie-Marcelle**
 M.B.P.6
Descout, R.
 W.E.P.62
Desgranges, C.
 T.C.P.59
Desgranges, Claude M. F.
 C.725
DeShazo, R. D.
 Th.B.P.19
DesJardins, D.
 Th.D.P.60
Desmet, P.
 W.B.P.4, W.B.P.13
Desmond, Gerald M.
 T.H.O.13
Desmond, S.
 Th.A.P.83, W.B.O.19
Desmyter, J.
 C.550, C.595, C.641
Desmyter, Jan
 B.637
DeSouza, M.
 M.B.P.345
Desportes, I.
 W.C.P.3
Desportes, Isabelle
 M.C.P.119
Desroches, A.
 W.B.P.271
Desrosiers, R.
 W.C.O.48, M.C.P.16,
 M.C.P.47, W.C.P.9
Desrosiers, R. C.
 Th.C.P.23, Th.C.P.58
Destree, A.
 M.C.P.47
Detels, R.
 T.A.O.29, Th.A.O.17,
 M.A.P.101, W.A.P.62,
 W.A.P.64, W.A.P.67, A.540,
 Th.B.O.25, M.B.P.380,
 T.C.P.46, M.G.P.12
Detels, Roger
 C.787
Detruchis, P.
 M.B.P.249
Deutsch, A.
 M.H.O.4
Deutsch, G.
 T.B.P.130, Th.B.P.315,
 Th.B.P.316
Devarajan, S.
 W.H.P.13
Devare, S. G.
 Th.C.P.31
Devare, Sushil G.
 T.C.P.72, Th.C.P.36
Devash, Y.
 C.671
Devash, Yair
 M.C.P.25
Devaux, C.
 Th.C.P.9
Devaux, Christian
 Th.C.P.142
Devenyi, P.
 Th.D.P.52
DeVico, Anthony L.
 Th.C.P.123
Devilchabrolle, A.
 Th.B.P.235
Devine, J.
 C.619
Devine, K.
 M.C.P.70
Devine, O. J.
 T.A.O.37, W.A.O.16,
 W.A.P.29, Th.A.P.79
Devine, Owen
 E.550
Devine, Owen J.
 T.A.P.83
DeVries, A. H.
 M.B.P.153
Dew, M. A.
 W.B.P.221, W.B.P.226,
 W.B.P.236
Dew, Mary-Amanda
 Th.B.P.32
Deyo, R. A.
 B.593, M.E.P.70
Deziel, P.
 T.B.P.69
Dhawan, Subhash
 Th.C.P.3
Dheer, S.
 C.668
Dheer, S. K.
 C.647
Dhillon, G.
 M.D.P.73
Di Costanzo, B.
 M.B.P.185
Di Costanzo, D.
 Th.B.P.209
Di Fazio, F. P.
 Th.B.P.1
Di Ferdinando, George T., Jr.
 W.D.P.15
Di Franco, Matthew J.
 W.B.P.76
Di Giandomenico, G.
 M.B.P.96
Di Giovanni, Cleto
 W.B.P.213, B.608
Di John, David
 T.B.P.262
Di Lenardo, L.
 M.B.P.14
Di Marco, P.
 M.C.P.39
Di Maria, H.
 T.B.P.195
Di Maria, Hugo
 M.B.O.5
Di Perri, G.
 M.B.P.217
Di Pietro, M.
 Th.B.P.330, Th.B.P.343
Di Pietro, Massimo
 T.B.P.100, Th.B.P.203
Di Rienzo, A. M.
 M.C.P.105
Di Sora, F.
 M.B.P.199
Di Vittis A.T.
 W.D.P.21
Di, S.
 C.522
Diaby, L.
 T.B.O.8, W.G.O.27
Diakhaté, L.
 T.B.P.105, W.B.P.100
Diakhoté, Lamina
 W.G.O.36
Diallo, K.
 T.G.P.28
Diallo, P.
 T.G.P.28
Diamond, G.
 M.B.O.41, T.B.P.174
Dianzani, Ferdinando
 M.C.P.39
Dias, F.
 Th.B.P.156, M.G.P.16,
 T.G.P.31
Dias, M. B. S.
 M.B.P.93
Dias, M. Beatriz S.
 T.G.P.14
Dias, M. G.
 M.B.P.291
Dias, R. S.
 M.B.P.263
Dias-Carneiro, L. A.
 W.G.P.15
Diaz Lestren, M.
 A.586
Diaz, C.
 M.B.P.27
Diaz, C.
 Th.A.P.23, W.G.P.11
Diaz, Clemente
 W.G.O.2
Diaz, F.
 Th.H.P.25
Diaz, J.
 T.D.P.16, D.547
Diaz, M. M.
 T.D.P.16, D.547
Diaz, Ricardo Sobie
 B.525
Diaz-Mitoma, Francisco
 M.A.P.87
Diaz-Santana, David
 Th.H.P.20
Dibba, Sekou
 W.E.P.8
DiCarlo, F.
 T.B.P.259
Dick, Bruce
 E.514
Dickens, Bernard
 T.F.O.17
Dickenson, E.
 W.G.P.24
Dickerson, R. E.
 C.682
Dickey, D.
 W.B.O.10
Dickinson, G.
 M.A.O.28, W.A.P.72
Dickman, P. S.
 T.B.P.3
Dickmeiss, E.
 T.A.O.30, W.B.P.290
Dickmeyer, M.
 M.B.P.207, T.B.P.53
Diclemente, Ralph J.
 T.D.P.91, T.D.P.92, D.507,
 D.508
Dideriksen, P.
 D.670, M.H.P.10
Dideriksen, Patricia W.
 E.528
Didier, J.-M.
 Th.B.P.100
Didierjean, L.
 Th.B.P.131
Didiez, Nelson
 M.E.O.11
Diebold, D. J.
 C.699
Dieck, E.
 W.D.P.23
Diehl, D. W.
 M.D.P.29
Diehr, P.
 M.D.P.35
Dienemann, D.
 W.B.O.20
Dieng, M. T.
 T.B.P.373
Dierich, M.
 W.B.P.96
Dierich, M. P.
 T.C.P.12, T.C.P.68, C.563
Diese, M.
 W.B.P.316, C.603
Dieterich, D.
 M.B.P.127
Dieterich, Douglas T.
 M.B.P.116
Diétrich, D.
 W.B.P.159
Diétrich, M.
 T.B.P.39, T.B.P.40, W.B.P.89,
 W.B.P.297

- Dietrich, Manfred**
W.B.P.277
- Dietrich, R.**
Th.C.O.24, Th.D.P.73
- Dietz, E.**
E.502
- Diez, R. A.**
C.707
- DiFerdinando, G.**
M.A.P.27
- DiFerdinando, George T.**
T.H.P.5
- Diferdinando, George T. Jr.**
M.A.P.71, W.B.P.258
- Dighiero, G.**
W.C.O.6, T.C.P.35
- DiGiovanna, T.**
W.A.O.4, Th.A.P.12, T.G.P.4
- DiJohn, D.**
C.586
- Dikov, I.**
B.613
- Dikov, Ivan**
B.614
- Dillard, T.**
B.550
- Dilley, J.**
E.631
- Dilley, James W.**
W.B.P.193, W.B.P.197,
W.B.P.196, W.B.P.231,
W.B.P.234, Th.E.P.13
- Dillon, B.**
W.E.P.53
- Dillon, S.**
M.B.P.57
- Dilworth, S.**
C.767
- Dimitrikakis, M.**
T.B.P.311
- Dimitrov, D. H.**
T.B.P.148
- Dina, D.**
W.C.O.49, T.C.P.104, C.649
- Dinarello, C.**
W.C.P.77, W.C.P.78
- Dindinaud, G.**
M.A.O.14, C.702
- Ding, D.**
W.D.P.79
- Dingwall, C.**
T.C.O.29, T.C.P.93
- Dinh Xuan, A. T.**
W.B.O.22
- Dinius, J.**
W.H.O.8
- Dinyarian, P.**
Th.B.P.354
- Diodato, S.**
W.A.P.59
- Dion, M.**
T.C.P.98, W.C.P.82
- Dionne, G.**
W.B.P.110, W.B.P.111
- Diop, A. G.**
Th.B.P.377
- Diop, B. M.**
M.B.P.195, B.641
- Diot, P.**
W.C.P.1
- Diouf, G.**
M.A.P.19, M.B.P.195, B.641
- Diouf, O.**
W.E.P.5
- Diouf, Ousmane**
T.D.P.37, M.E.O.7
- DiPasquale, L.**
T.B.P.55
- Diquet, Bertrand**
M.S.P.343
- DiSalvo, A. F.**
T.B.P.333
- Dittel, B. N.**
T.C.P.71
- Dixit, D.**
T.C.O.1
- Dixon, John**
Th.F.P.11
- Dixon, W. J.**
Th.A.P.43
- Dixson, A. L.**
T.C.P.100
- Djedje, M.**
M.B.P.373
- Djelebova, J.**
B.614
- Dobberstein, J.**
W.H.P.23
- Döbell, H.**
Th.B.P.231
- Dobkin, J.**
Th.B.P.68, Th.B.P.188
- Dobkin, Jay F.**
M.B.P.71
- Dobko, Theresa**
D.687
- Doco-Lecompte, T.**
W.B.P.29
- Doctor, L.**
E.588
- Dodd, C.**
Th.B.P.347
- Dodd, Caroline L.**
Th.B.P.340
- Dodd, Roger Y.**
M.A.P.29
- Doë, B.**
W.C.P.8
- Doerr, H. W.**
T.A.P.10
- Doerr, Hans**
C.569
- Doerr, M.**
T.B.P.114
- Doganov, B.**
B.613
- Doherty, G.**
Th.B.P.370
- Doherty, R.**
T.C.O.35, Th.C.P.39
- Doherty, R. R.**
Th.C.P.41
- Dohin, E.**
M.B.P.117, M.B.P.119
- Doi, Hirofumi**
Th.C.P.120
- Doi, P.**
M.B.O.45
- Doinel, C.**
M.A.P.102, M.B.P.269
- Doinel, Christian**
M.A.P.106, Th.B.P.160,
- Dolan, K.**
W.A.P.108
- Dolcini, P.**
M.D.P.4
- Dolecek, M.**
W.E.O.10
- Dollin, R.**
M.C.P.8, M.C.P.130
- Dollin, Raphael**
Th.C.O.33
- Dolitsky, D.**
M.B.P.116
- Dolivo, Nicolas**
Th.B.P.180
- Doll, I.**
M.D.P.28, E.708
- Doll, I. S.**
M.A.O.27, T.A.O.32,
M.A.P.111, W.A.P.46,
M.D.P.24
- Doll, Lynda**
M.D.P.23
- Doll, Lynda S.**
M.D.O.2
- Dollard-Pavlis, Sheila H.**
M.B.P.306
- Dols, C.**
C.632
- Dols, C. L.**
M.B.P.46
- Dombret, H.**
T.B.P.280
- Dominguez, J.**
A.585, B.515
- Dominguez, J. L.**
M.G.O.1
- Dominguez, José-Luis**
T.B.P.335
- Dominguez, L.**
T.D.P.89, E.672, M.G.O.25
- Dominguez, M.**
A.532, M.B.P.240, T.B.P.308,
W.B.P.22, Th.B.P.148
- Don, P. C.**
M.B.P.189
- Donahue, James G.**
M.B.P.161
- Donahue, P. R.**
M.C.O.12
- Donahue, Peter R.**
W.C.O.31
- Donatucci, L.**
Th.B.O.3
- Donati, R.**
Th.B.P.297
- Dondero, T.**
M.A.P.5, W.D.P.24
- Dondero, T. J.**
M.A.O.2, M.A.O.5, M.D.P.1
- Dondero, Timothy**
Th.A.O.1
- Dondero, Timothy J.**
M.A.O.4
- Done, P.**
E.642
- Donegan, C.**
M.A.P.57
- Donegan, E.**
T.A.P.105
- Donegan, Elizabeth A.**
T.A.P.106
- Donelli, G.**
Th.B.P.252
- Donker, G.**
Th.C.O.27
- Donnenberg, Albert D.**
T.B.P.285, W.B.P.319
- Donnenburg, A.**
M.B.P.51
- Donoghue, M. C.**
W.A.P.108
- Donot, Antoine M.**
A.532
- Donovan, B. J.**
M.B.P.222
- Donovan, Richard M.**
W.B.P.123
- Dooneief, G.**
Th.B.P.261
- Doppagne, A.**
B.623, M.D.O.3, W.D.O.6,
M.D.P.13, Th.E.P.1, W.G.P.20
- Doré, L.**
T.E.P.46
- Doré, M. F.**
B.615
- Dorfman, D.**
W.B.P.259, T.D.P.58, T.D.P.61
- Dorfman, L. E.**
W.D.P.51
- Dorfman, T.**
M.C.O.22
- Dörlemann, A.**
W.B.P.89, W.B.P.297
- Dörlemann, Alois**
T.B.P.39

- Dorlette, J.**
 Th.A.O.30
Dorman, S. M.
 E.570
Dormong, D.
 W.B.P.282
Dormont, D.
 M.B.O.5, T.B.P.195,
 T.B.P.309, W.B.P.320, B.557,
 M.C.P.4, M.C.P.7
Dormont, Dominique
 W.C.O.46, C.591
Dormont, J.
 T.C.P.39
Dorn, B.
 Th.D.P.28
Dornan, D.
 W.B.P.218
Dornan, Douglas H.
 M.E.P.68
Dörner, D.
 A.560, W.H.P.20
Dorner, F.
 T.C.P.38
Dorsett, B. D.
 T.C.P.62
Dorst, K. G.
 W.B.P.318, Th.D.P.69
Dorw, W.
 Th.A.P.1, W.B.P.268,
 W.D.P.72
Dorwin, S.
 W.B.P.137
Dos Anjos, R. M.
 D.693
Dos Anjos, R. M. P.
 D.584, Th.E.P.22
Dosik, Harvey
 Th.A.P.25, Th.A.P.26
Dosquet, P.
 M.B.P.249
Dotson, T.
 Th.D.P.60
Douard, D.
 T.B.P.245
Dougherty, C.
 D.692
Douglas, B.
 W.A.P.58, W.D.P.92
Douglas, Bruce
 T.A.O.34
Douglas, C.
 M.B.P.7, T.B.P.174
Douglas, Cecilia
 Th.E.P.58
Douglas, D.
 Th.D.O.1
Douglas, J.
 T.A.P.52, Th.A.P.16,
 M.D.P.23, E.708
Douglas, J. M.
 M.A.P.54, T.A.P.83, Th.E.P.8
Douglas, S.
 Th.C.P.101
Douglas, S. D.
 T.B.P.87
Douhovnikova, T.
 B.614
Douidar, S. M.
 M.B.P.341
Dournon, E.
 M.B.P.347, M.B.P.348
Dournon, Eric
 W.B.P.344
Douville, Helene
 M.B.O.34
Dove, S. B.
 M.D.P.82
Dow, M. G.
 M.D.P.69
Dow, M. G. T.
 Th.D.P.81
Dow, S. W.
 W.C.P.13
Dowd, P.
 M.B.P.324
Dowdle, G.
 M.E.P.37
Dowell, Scott E.
 M.B.P.233
Downer, A.
 W.E.P.43
Downer, Ann
 E.750
Downer, Ann E.
 D.640, W.E.P.61, Th.E.P.63
Downie, Jean C.
 W.B.P.153
Downing, More
 Th.D.P.73
Downing, R.
 T.B.P.358
Downing, R. G.
 W.B.P.117
Downs, Angela M.
 M.A.O.7, W.H.P.22
Drabick, Joseph J.
 B.550, C.553
Dragavon, J.
 W.C.P.112
Drager, Nick
 M.H.O.2
Drakatos, A.
 T.A.P.32
Drake, J.
 Th.B.P.23
Draper, D.
 M.H.P.17
Dray, F.
 Th.B.P.241
Dray, Fernand
 W.B.P.82
Dreikhausen, U.
 T.B.P.334
Dreno, Brigitte
 C.549
Dretler, R. H.
 M.B.P.247
Drew, L.
 D.707
Drew, Lawrence W.
 W.C.P.80
Drew, W. Lawrence
 M.H.P.25
Drewes, A.
 B.510
Drexler, E.
 Th.B.P.174
Drexler, M.
 W.B.O.44
Dreyer, G.
 W.C.O.11
Dreyfuss, J.
 M.E.P.10
Driessen, A.
 D.705
Driscoll, John S.
 M.C.P.107
Driver, A.
 Th.C.P.124
Drobacheff, C.
 Th.B.P.100
Dröge, W. A. M.
 T.D.P.47
Dröge, Wulf
 W.C.P.93
Drony, S.
 T.B.P.305
Drooker, Nancy
 E.588
Drotman, D. P.
 A.621
Drouet, L.
 C.726
Drouin, J.
 Th.B.O.48, C.543
Drucker, E.
 Th.D.O.2, Th.D.O.16,
 M.D.P.45, Th.D.P.1
Drucker, Ernest
 W.A.P.32, A.604, Th.D.P.6,
 Th.D.P.7, E.533
Drucker, J.
 W.G.O.3
Drummond, J.
 Th.A.P.24, B.636
Drummond, J. E.
 Th.A.O.26, M.C.P.38
Drummond, J. T.
 Th.A.P.118
Drummond, James E.
 Th.B.P.177
Drury, F.
 M.C.P.62
Drusano, G.
 W.D.P.25
Drusano, George L.
 M.C.P.94
Dryden, P. J.
 B.505
Drysdale, C. M.
 T.C.O.50, T.C.P.139
Du, B.
 T.C.P.51
Dube, G.
 W.G.O.19
Dubé, Manon F.
 W.C.P.22
Dubeaux, D.
 C.591
Dubessy, Bruno
 Th.E.P.12
Dubin, N.
 T.A.P.24
Dublanchet, A.
 A.552, B.557, M.G.P.26
Dubois, G. C.
 M.B.O.22
Dubois, R.
 W.C.P.87
Dubois-Arber, F.
 W.A.P.117, E.739
Dubois-Arber, Françoise F.
 D.636
Dubois-Arber, Françoise H.
 W.A.P.116
Dubouch, P.
 W.C.P.3
Ducati, A.
 Th.B.P.297
Ducasse, M.
 E.576
Ducesse, M.
 E.575
Duchange, N.
 T.C.P.78
Ducharme, Todd
 Th.F.O.3
Duchateau, J.
 W.A.P.49
Duckett, Margaret
 W.E.P.62, W.G.O.14,
 T.G.P.24, M.H.O.1
Ducos, J.
 M.B.P.131, W.B.P.32,
 Th.B.P.97
Ducos, Jacques
 W.B.P.167
Dudley, J.
 W.A.P.64, Th.A.P.100,
 Th.B.P.288, Th.B.P.294
Dufault, E.
 D.536
Duffaud, B.
 T.E.P.23
Duffhues, Josee C.
 M.E.P.14
Duffie, Anne
 Th.D.P.32, M.F.P.12

- Dugan, T.
T.A.O.17, T.A.P.101
- Duh, E.
T.C.O.12, W.C.P.108
- Dujardin, P.
M.B.P.255, T.B.P.20, B.524,
D.678
- Duke, B.
W.E.P.64, E.574, E.575, E.576
- Duke, Beulah
Th.G.O.48
- Duke, Sharen I.
M.D.P.45
- Dullège, A. M.
M.B.O.3, M.B.O.39, W.D.P.16
- Dullège, Anne-Marie S.
T.B.P.170
- Dumois, A.
T.E.P.40
- Dumontet, R.
Th.D.O.5, Th.D.P.84
- Dumpson, James R.
M.E.O.23
- DuNah, R.
T.D.P.91, D.508
- Duncan, Carlton
W.E.P.49
- Duncan, R. J. S.
Th.B.O.56, T.B.P.332
- Duncan, W.
M.E.P.8
- Duncanson, Frederick P.
M.B.P.189, T.B.P.37
- Dundas, E.
W.E.P.34
- Duneton, P.
Th.B.P.219, Th.B.P.235
- Dunham, N.
A.639
- Dunlop, N.
T.C.O.22
- Dunning, A.
M.B.P.283
- Dunphy, C.
W.D.P.6
- Duperval, R.
M.E.P.10
- Duperval, Raymond
A.547
- Dupla, J. M. L.
M.B.P.370, B.848, M.C.P.71
- Dupon, M.
T.A.P.25, A.635, M.B.P.254
- Dupont, B.
Th.C.O.39
- Duport, J.-M.
C.697
- Dupree, John D.
T.E.P.82, E.508, T.G.P.21
- Duquesnoy, R.
M.A.P.101
- Durancan, A.
W.E.P.16
- Durand, J. P.
M.A.O.16
- Durand, S.
T.B.P.28
- Durant, J.
M.B.P.252, T.B.P.33
- Durazzo, R.
Th.E.O.6
- Durbano, F.
W.B.P.219
- Durbec, J. P.
T.D.O.20
- Durbin, Meg A.
M.D.P.6, M.H.P.12
- Durda, P.
Th.C.O.25
- Durda, Paul J.
Th.C.O.26
- Durkin, M. M.
M.C.P.46
- Durnan, Richard J.
E.605
- Durosini, A.
W.E.P.51
- Durrain, R.
T.D.O.23
- Durrbach, A.
M.H.P.4
- Duschl, D.
M.B.O.26
- Duse, M.
B.585
- Dussaix, Elisabeth
T.A.P.92
- Dutarrie, H.
C.549
- Dutey, P.
D.702
- Duthely, M.
M.B.P.23
- Duval, Bernard
M.E.P.76
- Duwez, B.
E.657
- Duyckaerts, C.
Th.B.P.258
- Duynstee, S.
A.638
- Duzgues, N.
M.B.P.190, W.C.O.40
- Düzgünes, N.
Th.C.P.107
- Dwek, R. A.
M.C.O.18
- Dworkin, Joan E.
E.745
- Dwyer, R. J.
W.B.P.111, Th.B.P.371
- Dyer Chamberlain, M.
Th.E.O.1
- Dyke, A. M.
E.580
- Dykers, T.
Th.C.P.95
- Dykes, J.
D.560
- Dyner, Toby S.
W.B.P.363
- D'Arminio Monforte,
Antonella
D.688, M.G.P.13, M.G.P.14,
M.G.P.20
- E**
- Eaker, E. D.
Th.A.O.15
- Eakin, J. E.
M.D.P.78
- Eakin, J. M.
M.D.P.74
- Eakin, J. K.
Th.E.P.53
- Earl, P.
W.C.O.41
- Earl, Patricia L.
T.C.O.34
- Earp, J. A.
M.D.P.20
- East Bay AIDS Response
Org. (E.B.A.R.O.)
E.748
- Easter, M.
Th.B.P.179
- Eaton, C.
Th.D.P.38
- Eaton, E.
W.B.O.45, Th.B.P.277
- Ebbeling, W. L.
Th.B.P.115
- Ebener, U.
T.B.P.257
- Eberle, J.
T.B.P.380, C.624, W.G.O.29
- Eberle, Josef
M.B.P.148
- Ebikili, B.
M.B.P.91
- Eble, B.
M.A.O.10
- Ebrahim, Shahul Hameed
Th.H.P.30
- Eby, Charles L.
W.H.O.8, W.H.O.9, T.H.P.24,
T.H.P.26, T.H.P.27
- Echevarria, P.
M.D.P.40
- Echeverría de Pérez, Gloria
Th.B.P.101
- Echeverria, Juncal
E.579
- Echols, R.
T.B.P.88
- Eck, H.-P.
W.C.P.93
- Eck, M.
Th.D.P.86
- Eckel, R. H.
T.B.P.295
- Eckert, D.
T.B.P.41
- Eckler, L.
Th.C.O.29
- Economidou, J.
W.B.P.348, Th.B.P.17
- Eddy, J.
W.B.O.43, T.B.P.179,
T.B.P.247, T.B.P.248,
Th.B.P.89
- Ede, A.
T.D.P.43
- Edel, Y.
T.D.P.53
- Edel, Yves
W.B.P.207
- Edelman, Andrew S.
T.C.P.74
- Edelmann, F.
D.652, W.E.P.52, T.H.P.14
- Edelmann, Frédéric
Th.E.O.7, E.856, E.803
- Edelson, R.
W.B.P.76
- Edelstein, Howard E.
Th.B.P.279
- Ederly, I.
T.C.O.27
- Edgington, T. S.
W.C.P.97
- Eddi, B.
T.B.P.366, W.B.P.156
- Edison, R.
M.B.P.33, M.B.P.54, W.C.P.38
- Edison, R. J.
T.B.O.26
- Edlin, Brian R.
M.C.P.116
- Edmondson, S.
T.B.P.85
- Edmonson, Paul F.
W.C.P.12
- Edo, S.
T.A.P.56
- Edward, T.
T.D.P.17
- Edwards, C.W.
T.E.P.1, E.544
- Edwards, J.
T.B.P.227
- Edwards, Richard K.
W.G.O.13
- Edwards, T.
T.A.P.118
- Eede, M.
E.810
- Eeflinck Schattenkerk,
J. K. M.
W.B.P.2

- Efantis, J.
M.B.P.23
- Egan, R. J.
B.551
- Egan, V.
W.B.P.229
- Egan, Vincent G.
W.B.P.232
- Egboga, A.
T.B.P.362, B.612, T.G.P.32
- Eggerding, F.
T.B.O.1
- Egoria, M. J.
M.C.P.94
- Ehlers, P.
M.B.P.162, T.B.P.355
- Elm, I.
Th.A.P.29, W.B.P.84,
Th.B.P.153
- Ehrhardt, A.
T.D.P.12, W.F.P.2
- Ehrhardt, A. A.
T.B.P.192, T.D.O.22,
M.D.P.38, T.D.P.4, T.D.P.28,
T.D.P.73, W.D.P.67, E.662
- Ehrlich, G.
T.A.P.32, Th.B.P.199, C.741
- Ehrlich, G. D.
W.B.P.119
- Ehrmann, U.
C.768
- Ehrnst, Annela C.
W.A.P.52
- Eibi, M. M.
T.C.P.38
- Eichberg, J.
W.C.O.27, Th.C.O.30,
T.C.P.1, W.C.P.58
- Eichberg, J. W.
W.C.P.26, W.C.P.28
- Eichberg, Jorg W.
M.C.O.26, T.C.O.26
- Eichmann, A.
M.D.P.25
- Eiden, L.
T.C.P.90
- Eiden, Lee E.
W.C.O.16
- Eigenrauch, H.
W.B.P.252
- Eiger, R.
Th.E.O.3
- Eigler, J.
M.B.P.35
- Eigo, J.
W.B.P.249, E.772, Th.G.P.10,
Th.G.P.11
- Eigo, James
W.B.P.250, E.689, E.690,
E.692, E.760
- Elibott, D.
W.C.P.55
- Einbäupl, K.
Th.B.P.244
- Einloth, M.
T.B.P.247
- Eiros, J. M.
M.A.P.21
- Elsdorfer, C.
W.B.P.190, Th.B.P.313
- Eiseman, J. L.
M.C.P.53
- Eisenbach, G.
M.B.P.280
- Eisenhandler, J.
M.H.O.9
- Eisenhandler, Jon
W.H.O.7
- Eisenstein, E.
M.D.O.9
- Eitelbach, Florian
M.B.P.11, M.B.P.18
- Eke, T.
Th.E.O.3, E.621
- Ekman, M.
Th.C.O.9, W.C.P.67
- Ekstrand, M.
M.A.O.49, W.A.O.27,
W.B.O.40
- Ekstrand, Maria L.
T.D.O.8, M.D.P.31, T.D.P.33
- El Amad, Z.
M.A.O.10
- El Tonsi, Hani
W.E.P.74
- El-Bassel, N.
Th.D.O.15, Th.D.P.42
- El-Dabi, M.
M.G.P.5
- El-Sadr, W.
M.B.P.273, W.B.P.373, D.603,
D.631
- Elango, R.
T.G.P.6
- Elashoff, J. D.
Th.A.P.43
- Elbeik, T.
M.C.P.109, Th.C.P.137
- Eldeik, Tarek
C.670
- Eldert, G.
M.A.P.40
- Elder, H.
Th.G.P.14
- Elford, J.
M.A.P.96, W.B.O.28
- Elghouzi, M. H.
M.B.P.151
- Elgo, J.
W.B.P.257
- Elaszewicz, M.
Th.B.P.11
- Elaszewicz, Muriel
M.B.O.36, M.B.P.32, T.B.P.71
- Elie, R.
M.A.O.29
- Elie, Robert
Th.A.O.30
- Elifson, Kirk
W.A.P.38
- Elinson, J.
M.D.P.44
- Elion, R.
E.586
- Elizalde, B.
T.A.O.280
- Ellam, G. A.
T.A.P.4, Th.E.P.47
- Ellaurie, Maadava
B.592
- Ellenberg, Susan S.
M.C.P.45
- Ellerbrock, Tedd V.
W.D.P.48
- Ellerman, Donald
T.D.P.62
- Elliott, Alison M.
Th.G.O.4
- Elliott, J. C.
W.C.P.14
- Ellmer, R. M.
T.D.O.29, T.D.P.13
- Elmer, J. J.
T.C.P.9
- Elmrodt, A.
T.A.P.92
- Elmrodt, Axel
W.C.P.100
- Elmendorf, Edward
Th.H.O.1
- Elmquist, W. F.
W.B.O.4
- Elmslie, K.
T.A.P.69, Th.A.P.39,
W.D.P.20, T.G.P.9
- Elmslie, Kimberly D.
Th.A.P.46, W.D.P.59
- Elmslie, Thomas J.
Th.E.P.10
- Elonga, S.
T.B.P.181
- Elovaara, Irina
Th.B.P.242
- Elovich, Richard
D.704
- Elsing, C.
M.B.P.100, Th.B.P.265
- Elsing, Christoph
T.B.P.17
- Elsmlie, K.
A.591
- Emanuele, T.
W.H.P.7
- Emanuele, Tom E.
M.B.P.307, M.B.P.311
- Embree, J. E.
W.A.P.65, Th.G.O.52
- Embree, Joanne
M.G.O.23
- Embree, Joanne E.
M.G.P.27
- Eme, D.
M.B.P.61
- Emerman, M.
W.C.O.14, T.C.P.114,
T.C.P.115, Th.C.P.140, C.524
- Emery, L. J.
D.512, Th.E.O.9, M.E.P.71
- Emery, V. C.
Th.B.P.22
- Emilie, D.
Th.B.P.92
- Emini, E.
W.C.O.18
- Emini, Emilio A.
Th.C.O.30
- Emmanuel, J.
Th.A.P.5
- Empfield, Maureen
W.B.P.209
- Emslie, J.
Th.A.P.115
- Emslie, J. A.
Th.D.P.3, D.612
- Ena, Javier
M.B.P.107
- Ench, Y.
Th.B.P.23
- Enders, Sheila R.
W.F.P.1
- Endert, E.
Th.B.O.38
- Endow, R.
M.B.P.169
- Enekel, S.e
T.B.P.257
- Enel, P.
A.557, M.F.P.9, T.F.P.10,
T.F.P.11
- Enel, Patricia
T.F.O.7, W.F.P.4
- Enekel, S.
T.B.P.218
- Engel, Jeffrey P.
M.B.P.51
- Engel, R.
M.A.O.5
- Engel, Robert R.
T.A.O.6
- Engel, S. D.
T.D.P.81
- Engels, B.
Th.O.8
- Engelhard, P.
M.E.O.32
- Engelman, P.
M.B.P.2, M.B.P.34

- Engeter, M.
 T.D.P.46
 Engh, Marit
 D.585
 Englard, A.
 M.B.P.360
 Engleman, E. G.
 T.C.O.38, C.772
 Englert, M. D.
 W.A.P.95
 English, Judith
 D.620
 English, P.
 W.A.P.64, M.B.P.110, C.787
 Englund, J.
 M.B.P.51
 Enochs, Micheal D.
 M.A.P.73
 Enrico, A.
 T.B.P.114
 Ensoli, B.
 W.C.P.54, W.C.P.125
 Ensoli, Barbara
 W.C.P.48, Th.C.P.19
 Ensoli, Fabrizio
 B.643
 Enthus, Anne K.
 T.D.P.50
 Enzensberger, R.
 T.A.P.10, C.569
 Eppolito, L.
 T.B.P.62, T.B.P.63
 Epstein, I.
 D.650
 Epstein, J.
 M.A.O.33, W.B.P.154,
 W.C.O.27
 Epstein, J. S.
 T.B.P.232, Th.B.P.109,
 Th.C.P.42, Th.C.P.114,
 Th.C.P.118, Th.C.P.119
 Epstein, Jay
 M.B.P.333
 Epstein, Joel B.
 M.B.O.21
 Epstein, L.
 T.B.P.259, W.C.P.44,
 W.C.P.88
 Epstein, L. G.
 W.C.P.30
 Eqa, F.
 M.A.O.28
 Eramova, E. U.
 W.A.O.5
 Ercilla, Guadalupe
 W.B.P.101
 Ercilla, M. G.
 T.B.P.202
 Erckenbrecht, J. F.
 M.B.P.100, T.B.P.17
 Erfle, V.
 C.567, C.598
 Erfle, Volker
 M.C.P.33, W.C.P.91,
 Th.C.P.135
 Eric, K.
 Th.D.P.6, Th.D.P.7
 Erice, Alejo
 Th.B.P.288
 Erickson, Beth
 M.A.P.68
 Erickson, J.
 M.C.P.65
 Erickson-Viitanen,
 Susan K.
 T.C.P.130, C.671
 Eriksson, B.
 A.579
 Eriksson, B. F. H.
 M.C.P.55, C.631
 Eriksson, Bertil F, H.
 M.C.P.54
 Eriksson, Bo
 Th.A.P.69
 Eriksson, S. L.
 M.C.P.26
 Erlandsen, S. L.
 W.B.P.289
 Erlich, K.
 C.504
 Erling, A.
 W.C.P.31
 Ermann, M.
 T.D.O.34
 Ernsberg, I.
 T.C.O.29
 Ernsberg, I.
 T.C.P.93
 Ernst M.D., J.
 E.778
 Ernst, J.
 Th.A.P.4, B.507
 Ernst, Jerome
 Th.B.O.16
 Ernst, Jerome A.
 M.A.P.10, T.B.P.55
 Ernst, M.
 Th.B.P.329
 Errante, I.
 M.B.P.133
 Errante, Isabella
 T.A.P.111
 Errasfa, M.
 W.B.P.82
 Erskine, D.
 T.B.P.64
 Ervik, R.
 Th.D.O.17
 Ervolino L.
 T.D.P.54
 Ervolino L. A.
 D.550
 Ervolino Neto, J.
 D.550
 Esbivel, G.
 W.B.P.306
 Escaich, S.
 Th.B.P.169
 Escaich, Sonia
 C.773
 Escalona, J.
 Th.B.P.121
 Eskander, Gamal S.
 A.589
 Eskild, Anne
 M.A.P.91, Th.D.P.63
 Español, Teresa
 T.B.P.214, C.705
 Espina, B.
 M.B.P.366
 Espinar, B. E.
 T.B.P.286
 Espinosa, G.
 Th.G.O.25
 Espinoza, P.
 M.A.P.24
 Espinoza, Pierre
 M.A.O.40, M.A.P.25, A.543,
 Th.D.P.35, D.601, Th.F.O.6
 Espiscopio, P.
 M.D.P.72
 Esposito, A.
 W.A.O.28
 Esposito, A. J.
 M.B.P.310
 Esposito, Roberto
 Th.B.P.348
 Esser, R.
 Th.C.O.24
 Essex, M.
 M.A.O.15, M.B.P.200, B.633,
 T.C.O.17, T.C.P.29,
 W.C.P.136, Th.G.C.P.18, C.710,
 Th.E.P.3, Th.G.O.26,
 T.G.P.27, T.G.P.29,
 W.G.P.22, Th.G.P.6
 Essex, Myron
 T.C.O.23
 Essien, Etim
 M.B.P.158
 Essien, Etim M.
 M.B.P.156
 Estany, C.
 W.A.P.55
 Estebanez, P.
 Th.D.P.70
 Esteban, J. I.
 A.534
 Estebanez, P.
 M.A.O.41, E.813
 Estebanez, Pilar
 W.E.O.22
 Estebanez, R.
 W.E.O.22
 Esteve, E. G.
 M.B.P.237
 Estevez, María E.
 C.707
 Estournel, J. L.
 D.569, Th.E.P.12
 Estournel, Jean-Luc
 D.513
 Estreich, S.
 Th.B.P.374
 Eto, Kotaro
 Th.B.P.130
 Ettinger, P.
 E.696
 Etzaniz, P.
 W.A.P.75
 Etzioni, A.
 T.A.P.81
 Euler, P.
 M.A.O.12, T.A.P.107,
 T.A.P.110, W.B.P.170
 European Collaborative
 Study
 Th.A.O.3, Th.A.O.4, M.B.O.1
 Evans, D. M.
 W.E.P.60
 Evans, G.
 Th.B.P.259, B.568, T.D.P.60
 Evans, G. A.
 Th.B.P.67
 Evans, M.
 T.A.P.65, T.B.P.161
 Evans, P.
 M.E.O.34
 Evans, Patricia E.
 Th.O.5
 Evans, R. E.
 M.A.P.60
 Evatt, B.
 T.C.P.82
 Evatt, B. L.
 B.549
 Evatt, Bruce
 Th.B.O.31
 Even, P.
 Th.B.P.143
 Everaere, S.
 Th.B.P.241
 Eversley, Rani B.
 W.D.P.45, W.D.P.46, D.683,
 D.684
 Evjen, L.
 C.686
 Ewert, D. P.
 M.B.P.68
 Ewing, D. J.
 Th.B.P.291
 Ewing, W.
 M.A.P.67
 Ewing, W. E.
 W.A.P.34, W.A.P.84
 Exner, T. M.
 T.D.P.4
 Exner, Theresa M.
 M.D.P.38, T.D.P.28

- Eyer, S.
M.D.P.57, W.E.P.73
- Eyer-Silva, W.
W.A.P.70, M.B.P.257,
Th.B.P.66, B.532
- Eyer-Silva, W. A.
W.A.P.51, M.B.P.291
- Eyster, E. M.
T.B.P.84
- Eyster, Elaine M.
T.B.P.82
- Eyster, M. E.
Th.A.O.26, T.B.P.83,
T.B.P.313
- Eyster, M. Elaine
W.B.P.70
- Ezzati, T.
Th.A.O.13
- F**
- Fabricius, Eva-Maria
M.B.P.52
- Fagan, R.
M.D.P.43
- Fagnani, F.
M.D.P.51, M.H.O.13
- Fahay, B. J.
M.D.P.88
- Fahney, J. L.
W.A.P.62, Th.B.O.25,
T.C.P.46, W.C.P.104,
T.D.O.23, E.634
- Fahrenheim, E.
T.B.P.208
- Fahrner, Eva-Maria
W.D.P.86
- Falis, M. C.
T.H.P.7
- Fahs, Marianne
M.H.O.9
- Fahy-Chandon, B.
Th.B.P.292
- Fainboim, Hugo
A.586
- Fairchild, P.
W.B.P.246
- Fairchild, Patrick G.
W.B.P.240
- Falron, Y.
M.B.P.340, Th.B.P.103,
Th.B.P.145, D.855
- Fajardo, A.
M.B.P.23
- Fakhry, R.
W.A.P.79, A.609, M.H.O.7
- Falchetti, M.
T.B.P.269, B.565
- Falco, I.
M.A.P.10
- Falcone, N.
W.B.P.328
- Falletti, R. L.
W.A.P.20
- Falk, A. D.
T.B.P.182
- Falk, L.
M.A.P.108, W.B.P.71,
T.B.P.80, W.B.P.139
- Falk, Lawrence A.
Th.E.P.70
- Falk, S.
M.B.P.210
- Falkenbach, Albrecht
M.B.P.265, M.B.P.270
- Falkowski, C.
T.A.P.43
- Fall, H.
T.B.P.46
- Fall, L.
W.E.P.4
- Falletti, R. L.
M.A.P.73, T.A.P.73
- Falletti, Robert L.
E.572
- Fallon, R. J.
W.B.O.7
- Falloon, J.
T.B.P.247
- Falutz, J.
W.A.P.79, A.609, M.B.O.47,
W.B.O.8, M.B.P.367,
T.B.P.54, B.606, M.H.O.7
- Falutz, Julian M.
Th.B.P.315, Th.B.P.316
- Fang, C.
Th.A.O.29
- Fang, Chyang T.
Th.B.O.59
- Fanning, C.
M.D.P.79
- Fanning, M.
M.B.O.47, T.B.O.35, W.B.O.1,
W.B.O.8, Th.B.O.26,
T.B.P.314, W.B.P.351, B.603,
B.606, M.D.P.58, T.D.P.41
- Fanning, M. M.
E.779, Th.H.P.2
- Fanning, Mary M.
W.B.O.6, W.B.O.36,
M.B.P.349, M.B.P.367
- Fanning, T.
M.H.O.11
- Fantoni, M.
Th.B.P.72
- Farber, A.
W.D.P.40
- Farber, B. F.
M.B.P.4
- Farber, B. F. F.
T.B.P.35
- Farber, C. M.
M.B.P.367
- Farber, Claire-Michèle
Th.B.P.55
- Farcet, J. P.
M.B.P.296, T.B.P.280
- Farewell, V.
Th.A.O.27, M.A.P.97,
M.A.P.113, Th.B.P.373,
T.D.P.41
- Farewell, Vernon
T.A.O.33
- Fargnoli, K.
W.C.P.35
- Farley, T.
T.A.O.8
- Farrar, G. H.
C.710
- Farrays, J.
M.B.P.230
- Farrow, C.
M.A.P.115
- Farzadegan, H.
T.B.P.123, Th.B.P.238,
Th.B.P.368, B.555, M.C.P.85
- Farzadegan, Homayoun
Th.A.P.92, A.616, T.B.P.98,
Th.C.P.106
- Fass, R.
T.C.P.27
- Fass, R. J.
T.B.P.30
- Fassin, D.
M.B.P.117, B.546
- Fast, Judith E.
D.541
- Fätkenheuer, G.
W.B.P.291
- Faty/Ndieye, C.
M.B.P.183
- Fauci, A.
Th.B.P.239
- Fauci, A. S.
Th.B.O.43, W.B.P.322,
W.B.P.335, M.C.O.10,
M.C.O.28, W.C.O.39,
W.C.O.41, W.C.P.59,
W.C.P.62, W.C.P.87,
W.C.P.105, W.C.P.106,
W.C.P.107, W.C.P.108,
W.C.P.109, W.C.P.137,
C.723, T.G.P.17
- Fauci, Anthony S.
Th.C.O.44
- Faucomnier, B.
W.B.P.75
- Faulkner, A.
D.530
- Faundes, A.
D.547
- Faure, G.
T.C.P.44, T.C.P.45, C.541
- Faust, J.
T.B.P.167
- Fauvel, M.
M.B.P.17, T.A.P.59,
Th.B.P.371
- Fauvel, Micheline
T.B.P.217, T.B.P.243
- Fauvele, F.
M.C.P.57
- Fauzi, A. S.
T.C.O.12
- Favero, J.
W.B.P.138
- Favero, Martin S.
T.A.P.26
- Favier, V.
W.C.O.6, W.C.P.65, Th.C.P.4
- Favoretto, A. C. O.
Th.B.P.189
- Fay, M.
T.B.P.4
- Fay, Oscar
W.A.P.22, A.582, M.G.O.29,
M.G.P.29
- Faye/Ndao, M. A.
M.B.P.183, M.B.P.196, B.641
- Fayer, R.
W.B.P.45
- Fayne, T.
T.D.P.22
- Fayol, V.
Th.D.P.31
- Fazely, F.
M.C.P.51
- Fedelli, Franco
M.B.P.113
- Federico, G.
M.B.P.229
- Federico, M.
W.C.P.119, W.E.P.24
- Federico, Maurizio M.
M.C.P.105, C.755
- Federman, L.
D.706
- Feeeny, F.
T.A.P.52
- Feeeny, Frances
Th.D.P.61
- Feeeny, K.B.
E.746
- Feeeny, L. A.
T.C.P.61
- Féguoux, S.
M.B.P.225
- Fehrs, Laura J.
W.A.O.11, Th.A.P.76
- Feigal, D.
M.B.P.166, T.B.P.25,
W.B.P.270
- Feigal, D. W.
M.B.O.20, T.B.O.26, T.B.P.76,
T.B.P.78, Th.B.P.320,
Th.B.P.340
- Feigal, David
M.B.O.19
- Feigal, David W.
M.A.P.31, T.A.P.76

- Feigal, E.
M.B.P.288
- Feigal, Ellen G.
Th.A.P.24, C.704
- Feljó, N.
T.E.P.85
- Felik, D.
Th.B.P.350
- Feinberg, J.
T.B.O.26, M.B.P.123,
W.B.P.22, T.B.P.30, T.B.P.46,
W.B.P.331, T.E.P.51
- Feinberg, Judith
T.B.O.28
- Feiner, C.
D.589
- Feingold, A.
T.B.P.173
- Feingold, A. R.
W.B.P.60
- Feingold, Anat R.
Th.A.P.104
- Feingold, L.
T.A.P.96, T.A.P.97, T.D.P.71,
Th.D.P.83, T.E.P.44
- Feizi, Ten
M.C.O.4
- Fekadu, D.
T.E.P.21
- Felber, B. K.
W.C.O.22, T.C.P.139
- Felber, Barbara K.
T.C.O.50, Th.C.P.27
- Felber, S.
W.B.P.341
- Feldblum, Paul J.
M.A.O.37
- Felder, C.
E.561
- Feldes, O.
Th.B.P.367
- Feldman, D.
M.D.O.4
- Feldman, Douglas A.
M.E.O.35
- Feldman, H. W.
D.615, E.566
- Feldman, Harvey W.
Th.D.P.82
- Feldman, I.
E.684, M.H.O.16
- Feldman, J.
Th.D.P.44
- Feldman, R.
T.B.P.70
- Feteke, G.
W.B.P.64
- Felgenhauer, K.
Th.B.P.246
- Feliciano, H.
M.A.P.77, Th.B.P.123
- Felippo, M.
Th.B.P.362
- Felix, D. H.
Th.B.P.137
- Felix, R.
Th.B.O.23, Th.B.P.260
- Feller-Dansokho, E.
M.B.P.183, M.B.P.195, B.641
- Felming, David W.
A.551
- Felisch, F.
W.D.P.61
- Felten, A.
W.B.P.305
- Fenger, Terry W.
M.C.P.23
- Fenn, Shannon C.
W.A.P.1
- Fenouillet, E.
M.C.O.3, Th.C.O.5, Th.C.P.1,
C.674
- Fenster, Gail M.
D.563
- Fensterstheib, M.
W.A.O.28
- Fenyo, E. M.
T.C.O.50
- Fenyó, E. M.
Th.C.P.92, Th.C.P.97,
Th.C.P.125, C.712, C.752
- Fenyó, E.-M.
W.B.P.147
- Fenyó, Eva M.
M.C.O.9
- Feorino, Paul M.
Th.C.P.52
- Ferbas, J.
T.C.P.26
- Ferchal, F.
Th.A.P.119, W.B.P.106, B.619
- Feremans, W.
M.B.P.253
- Ferentinou, D.
W.C.P.140
- Ferguson, D. D.
Th.B.P.201
- Ferguson, R. S.
T.B.P.56, T.B.P.77
- Fermosel, J.
T.B.P.172, T.B.P.215
- Fernández-Cruz, Eduardo P.
Th.B.P.121, Th.B.P.184,
W.C.P.120
- Fernandes da Silva, O.
M.B.P.231
- Fernandes, M. E.
M.B.P.108, W.E.O.29,
W.E.P.31, Th.G.P.26, G.515
- Fernandes, M. M.
M.B.P.74
- Fernandes, M.E.L.
W.E.P.37
- Fernandes, Maria Eugénia
E.610, E.665
- Fernandes, Maria Eugénia
L.
T.E.P.49, T.E.P.69
- Fernandes, Maria Eugénia
Lemos
Th.G.O.40
- Fernandez, A.
Th.B.P.184
- Fernández, E.
W.A.P.22, A.582, M.G.P.29
- Fernandez, Francisco
W.B.P.191, W.B.P.195
- Fernandez, I.
W.B.P.206
- Fernández, J.
T.B.P.293
- Fernández, J. L.
A.556
- Fernández, J. M.
M.B.P.260
- Fernandez, M. Isabel
M.E.P.8, M.E.P.15
- Fernandez, N.
W.B.P.382
- Fernandez-Rubio, H.
E.707
- Fernez, P.
Th.B.P.132, Th.B.P.359
- Fernie, B.
T.B.P.123, M.C.P.3,
W.C.P.105
- Ferns, R. Bridget
Th.C.P.59
- Ferrari, G.
W.B.P.357
- Ferrari, P.
Th.B.P.129
- Ferraro, G.
Th.B.P.136
- Ferraro, Robert
Th.B.P.312
- Ferraz, M. L.
B.525
- Ferrazin, A.
T.B.P.252
- Ferrazzi, D.
T.A.P.111, A.503, M.B.P.384,
W.B.P.208
- Ferrazzi, Mario
T.B.P.361, C.747
- Ferreira, A. C.
E.610, E.665, E.704
- Ferreira, Ana Carolina I.
Th.G.P.26
- Ferreira, Ana-Carolina
M.B.P.108, G.515
- Ferreira, J.
E.799
- Ferreira, L. E. M.
D.638
- Ferreira, M. O.
A.512
- Ferreira, R. P.
D.604, E.781
- Ferrer Le Coeur, Françoise
Th.B.P.11
- Ferrera, C.
T.B.P.129, B.578
- Ferriani, R.
W.C.P.78
- Ferris, Andrea L.
C.666
- Ferron, P.
M.B.P.23
- Ferry, R.
E.673
- Festi, H.
W.C.P.91, Th.C.P.135
- Fetro, J.
E.561
- Fiaccadori, F.
M.B.P.358
- Fiala, M.
M.B.P.204, Th.B.P.53
- Fiala, Milan
W.B.P.279
- Fialho, F.
M.B.P.136, M.B.P.281,
T.B.P.369, B.563, C.763
- Ficarra, G.
Th.B.P.341
- Ficarra, Giuseppe
Th.B.P.330, Th.B.P.343, C.571
- Ficarrotto, T. J.
M.D.P.42, E.628
- Ficarrotto, Thomas J.
E.599, E.600, E.629
- Ficher, L. L.
W.C.O.43
- Fico, R.
W.B.P.139
- Fidelia, A.
Th.A.P.15
- Field, E. J.
D.545
- Fieldhouse, S.
B.627
- Fields, M.
W.A.P.82
- Fierz, W.
W.B.P.72, Th.B.P.81
- Fierz, Walter
T.B.P.86
- Fiet, J.
M.B.P.269
- Fietz M.
M.D.P.75
- Fife, K. H.
T.C.P.82
- Figuera, T.
T.B.P.214, C.705
- Figueredo, I.
M.B.P.107
- Figueron, J. P.
W.G.P.26, Th.G.P.1

- Fikrig, S.
T.B.P.180
- Filgueiras, A.
M.E.O.9
- Fillon, Lionel G.
T.C.P.56
- Filipowsky, M. E.
C.682
- Filippi, C.
W.B.P.365, Th.B.P.86
- Filastre, J. P.
M.B.P.344
- Fillet, G.
M.B.P.340
- Filson, M.
Th.O.1
- Finaud, Michael
M.B.P.39, M.B.P.130
- Finaud, Michael J.P.
W.D.P.77
- Finazzi, M. G.
M.A.P.95, W.B.P.352
- Finberg, R.
Th.C.O.49
- Finch-Manzagoi, S.
T.C.P.61
- Findlay, J.
Th.D.P.90
- Fine, A.
T.B.P.150
- Fine, R. L.
M.C.P.42
- Fine, Richard H.
E.683
- Fineberg, H. V.
Th.A.P.70, W.H.O.12
- Fineberg, Harvey
M.H.O.3
- Finger, Reginald F.
W.E.O.27
- Finkelstein, E.
W.B.P.211
- Finlay, J.
M.G.O.2
- Finn, M.
W.A.P.2, D.660
- Finnegan, L.
W.D.P.43
- Finnegan, L. P.
M.B.P.30
- Finnegan, Loretta P.
D.600, E.512
- Finzi, G.
M.D.P.72
- Fiocca, R.
M.B.P.232
- Fiorelli, V.
B.643
- Fipps, Donald R.
Th.A.O.34
- Firpo, R.
E.797
- Fisch, Alain
M.D.P.68
- Fischer, G.
T.B.P.176, T.C.P.66
- Fischer, Harald E.
B.831
- Fischl, M.
M.B.P.287, T.B.P.69, E.501
- Fischl, Margaret
T.B.O.13
- Fischl, Margaret A.
M.B.P.329, T.B.P.331
- Fiser, R.
T.E.P.42
- Fish, D.
W.B.P.287
- Fish, Falk
M.B.O.25
- Fishback, Lorraine M.
W.A.O.23
- Fisher, Evelyn J.
W.B.P.86
- Fisher, M.
M.C.P.9
- Fisher, R.
T.C.P.76
- Fisher, R. A.
Th.C.O.16
- Fisher, W.
T.E.P.8
- Fishman, B.
W.B.P.210, T.D.O.9, Th.E.P.9
- Fishman, Baruch
T.D.P.66
- Fitt, Sarah
W.B.P.272
- Fitzgerald, A.
E.608, E.609
- FitzGerald, D. J.
Th.C.O.12
- Fitzgerald, P. M. D.
M.C.O.23
- Fitzpatrick, R.
M.D.P.15
- Fitzsimmons, M. J.
D.685
- Fiume, A.
W.A.P.63
- Flamand, L.
M.C.P.29
- Flambolc, Leo
T.B.P.58
- Flaminio-Zola, G.
W.C.P.3
- Flanagan, William F.
Th.F.P.4
- Flannery, J.
W.B.P.378
- Flaskerud, J. H.
E.634
- Flaskerud, Jacquelyn H.
T.D.O.17
- Flatov, U.
M.C.P.95
- Fleckenstein, B.
T.C.O.45, C.679
- Fletcher, M. A.
M.A.P.90
- Fleet G. W. J.
M.C.O.18
- Flegenheimer, W.
D.624
- Flegenheimer, Walter V.
T.F.P.6
- Flegg, P. J.
W.B.P.317, W.B.P.371,
Th.B.P.164
- Flegg, Peter J.
M.A.P.92, M.A.P.105,
T.B.P.271, E.802
- Fleischer, T. I.
C.602, C.619, C.634, C.639
- Fleishman, J. A.
T.E.P.34
- Fleishman, John A.
M.E.P.69
- Fleming, D.
M.E.P.4, M.E.P.16, Th.E.P.32
- Fleming, David W.
M.A.O.22, W.B.P.273,
W.D.P.69, M.H.P.9
- Fleming, S. C.
Th.B.O.41, Th.B.P.317
- Fletcher, C.
M.B.P.51
- Fletcher, M.
W.B.P.360
- Fletcher, M. A.
Th.A.P.97, W.B.P.56,
W.B.P.190, Th.B.P.223,
Th.B.P.240, Th.B.P.263,
Th.B.P.313, T.D.P.42, D.677,
D.681
- Fletcher, M. J. F.
W.B.P.356
- Fletcher, Mary A.
M.B.P.144, W.B.P.181,
Th.B.P.159
- Fletcher, P.
D.660
- Fleury, H.
W.B.P.282
- Fleury, Hervé J. A.
T.B.P.115, T.B.P.245,
M.G.P.21
- Fleury, J.
Th.C.P.8
- Flexner, C.
T.C.P.2
- Flik, J.
T.B.P.334
- Floch, Jean-Jacques
W.B.P.14, B.599
- Floody, P.
C.783
- Flomenberg, N.
W.B.P.369, W.B.P.374
- Flomenberg, P.
Th.B.P.8
- Flores, A.
Th.A.P.22
- Flores, M. V.
M.G.O.6
- Flori, Y. A.
Th.H.P.11
- Floris, C.
T.B.P.292
- Flowers, J. V.
W.A.P.111
- Flowers, T. S.
M.B.P.170
- Floyd, R.
C.713
- Flux, A.
E.795
- Flux, R.
E.795
- Flynn, F.
Th.B.P.259
- Flynn, N.
T.B.P.379, W.B.P.63,
M.C.P.113, W.D.P.79,
Th.D.P.55, W.F.P.1
- Flynn, N. M.
M.B.P.337
- Flynn, Neil
W.A.P.118
- Flynn, Neil M.
W.B.P.263
- Flynt, J. W.
W.A.O.23
- Focaccia, R.
M.A.P.84
- Focht, J.
W.A.O.23
- Fofana, O.
A.577
- Fogel, K.
W.B.P.210
- Foley, M.
D.650
- Foley, P.
T.C.P.8, W.C.P.27
- Folks, T.
T.C.O.12, Th.C.P.30
- Folks, T. M.
W.C.P.41, W.C.P.59,
W.C.P.87, W.C.P.107,
W.C.P.137, C.723
- Follansbee, S.
M.B.P.48
- Folstein, M.
W.B.P.227
- Fomekong, E.
M.B.P.99
- Fong, K. L. L.
M.C.P.127

- Fong, S.
Th.A.P.110
- Fonseca, M. A.
W.B.P.266
- Foraine, C.
Th.B.P.113
- Fontana, M. A. S.
D.714
- Fontelos, P.
M.B.P.369, T.B.P.255, B.600
- Fontelos, Pablo
T.B.P.164
- Fontenay, F.
Th.E.O.7
- Fontenay, Frank
W.E.P.52
- Forbes, J.
W.D.P.80
- Forbes, M. A.
W.B.P.81
- Ford, G.
W.C.O.32
- Ford, H.
M.C.P.107
- Ford, W.
A.528, W.B.P.53, Th.D.P.58
- Ford, Wesley L.
M.A.P.74
- Fordyce, E. J.
D.659
- Fordyce, J.
W.D.P.60
- Fordyce, James E.
M.D.P.44
- Fordyce-Baum, M.
Th.B.P.314
- Fordyce-Baum, M. K.
Th.B.O.40, Th.B.P.306
- Fordyce-Baum, Marianna K.
Th.B.P.310
- Foreit, J.
E.787
- Foreit, James R.
Th.D.O.7
- Forest, C.
D.717
- Foresti, V.
Th.B.P.191
- Foresti, Valeriano
M.B.P.206, W.D.P.84
- Forjaz Lacerda, Maria José
W.B.O.21
- Forlenza, S.
A.590, W.B.P.64
- Forman, L. J.
C.711
- Fornasini, M.
D.696
- Fornataro, K.
E.760
- Forni, F.
T.B.P.252
- Forno, B.
M.B.P.353
- Forrest, D.
M.B.O.33
- Forrest, J.
M.B.P.303
- Forrest, K.
T.D.P.92, D.507
- Forrester, C.
T.B.P.2, T.B.P.15, W.B.P.336,
Th.B.P.380
- Forrester, W. R.
W.A.P.119
- Forsberg, A.
Th.B.P.34
- Forsberg, Ann D.
T.A.P.109
- Forsdyke, Donald R.
C.684
- Forsdyke, R. E.
C.684
- Forsgren, M.
W.A.O.10, W.B.P.129
- Forst, M.
E.646
- Forster, G. E.
Th.B.P.574
- Förster, H.
Th.B.O.42, M.B.P.270
- Forster, S. M.
M.B.P.262, M.B.P.292
- Forsythe, Alan B.
Th.A.P.43
- Fortier, R.
W.E.P.16
- Fortin, C.
M.E.P.76
- Fortin, M.
T.D.P.52
- Fortner, C.
A.546
- Fortney, Judith A.
T.G.O.21
- Fortún, J.
Th.B.P.268
- Fortuny, Claudia
T.B.P.202
- Foss, Brian M.
D.588
- Foss, L. A.
M.A.P.7
- Fossati, I.
M.C.P.20
- Foster, Geoff
M.E.P.50
- Foster, K.
Th.D.P.53, D.609, D.610,
D.611
- Foster, L.
M.A.O.22, Th.E.P.32
- Fotopoulos, S. S.
T.B.P.129
- Foucault, C.
B.629
- Foucault-Fretz, Catherine
T.G.P.29
- Fouchard, Jan
M.D.P.55
- Fouchard, M.
M.C.P.119
- Foulques, H.
M.B.P.55
- Foung, Steven K.H.
M.B.P.173
- Fountouli, P.
M.A.P.80
- Four Minorities Councils
D.660
- Fournel, J. J.
T.G.P.28
- Fournie, A.
M.B.P.26
- Fournier, S.
T.B.O.31
- Fourrier, A.
Th.B.P.105
- Foutty, L. L.
T.B.P.3
- Fowler, A.
Th.A.P.93, M.C.O.15,
N.C.O.20, Th.C.P.133, C.513,
C.767
- Fowler, Arnold K.
T.B.P.112
- Fowler, C. J.
Th.B.P.287
- Fowler, S.
E.807
- Fowley, C.
D.562
- Fox, C. H.
C.684
- Fox, E.
B.538
- Fox, Emile
A.515
- Fox, L.
W.D.P.28
- Fox, Phillip C.
Th.B.P.363
- Fox, R.
M.A.O.44, T.A.O.29,
W.A.P.40, W.A.P.69,
Th.A.P.91, A.622, M.B.O.35,
W.B.P.52, W.B.P.236
- Fox, Robin
D.537
- Foxman, B.
E.638
- Foy, C.
M.D.O.18
- Foy, D.
Th.A.P.47
- Foy, K.
W.C.P.33, Th.C.P.89
- Foz, M.
W.A.P.71, Th.A.P.19, A.556,
Th.B.P.336, Th.D.P.57, D.613
- Fracchia, J.
M.B.P.274
- Fraga, J.
T.B.P.293
- Fraga, L. F. P.
B.531
- Fragua, H.
W.B.P.304
- Frame, J. D.
T.A.P.13
- Frame, P. T.
M.B.P.73, T.B.P.9, C.713
- Francavilla, E.
Th.C.P.144, D.583, D.623
- France, B.
Th.E.O.3, E.621
- Frances, A.
W.B.P.210, T.D.P.66, Th.E.P.9
- Frances, M.
B.648
- Franceschi, S.
M.A.O.38, D.526
- Franchi, M.
D.706
- Franchini, E.
W.B.P.357
- Franchini, G.
W.C.P.35, Th.C.P.22
- Franciotta, D.
Th.B.P.243
- Francis, C.
M.B.P.273
- Francis, Donald P.
M.A.O.19, W.A.O.28
- Francis, H.
B.625
- Francis, H. L.
Th.B.O.30
- Francis, M.
W.G.P.11
- Francis, N.
M.B.P.244, M.B.P.326
- Francisci, D.
Th.B.P.252
- Franco, A.
M.B.P.277
- François, E.
B.644
- François-Gérard,
Christiane
B.623
- Frank, B.
W.D.O.10
- Frank, John W.
Th.A.P.37
- Frank, R.
T.E.P.43, T.H.P.23
- Franke, G.
W.B.P.187

- Franke, Katherine M.**
T.E.P.52
Frankel, Harvey
E.699
Franklin, T.
Th.D.P.52
Franks, P.
T.H.P.8
Fransen, L.
T.A.P.3, T.G.P.8
Fransen, Lieve
W.G.O.17
Fransham, Alfred
Th.B.P.276
Franzman, M.
M.B.P.79
Frasca, M.
W.E.P.19
Fraser, R. D.
M.H.O.4
Fraser-Howze, D.
M.E.O.23
Frazier, I. H.
W.A.P.44
Frazier, O.
M.A.P.34, M.B.P.161
Frazier, Y.
T.H.O.3
Frederick, T.
T.A.P.85
Frederick, Toni
T.B.P.161
Frederick, W.
M.B.P.201, M.B.P.238,
T.B.P.237
Frederickson, T.
M.C.P.53
Frederiksen, K.
T.G.P.31
Freedberg, Kenneth A.
T.B.P.88
Freedman, Benjamin
W.E.O.28, E.697, W.F.O.5
Freedman, P.
A.614, M.E.P.12
Freeman, A.
T.A.P.21, W.A.P.39,
W.A.P.81, M.D.P.29,
Th.D.P.37, E.720
Freeman, A. C.
M.A.P.120, T.D.P.11, E.551,
E.639
Freeman, B.
M.B.P.325
Freeman, D.
B.568
Freeman, D. B.
T.D.P.80
Freeman, G.
W.D.P.65
Freeman, G. Jr.
Th.D.P.77
Freeman, H.
T.E.P.47, Th.E.P.11
Freeman, T.
Th.B.P.102
Freese, U. K.
M.B.O.18
Frei, P. C.
Th.B.P.180
Freire, C.
B.639
Freire, S. V.
B.508
French, C. K.
Th.B.P.338
French, J.
Th.A.O.23, E.678
French, S.
E.783
Frenetich, S.
W.B.P.161
Frenkel, L. M.
M.A.P.12
Frenkel, Lawrence D.
T.B.P.169
Frenkl, T.
W.B.P.122
Frenkl, Tatyana
A.629
Fresneda, A.
M.B.P.59
Freund, H.-J.
Th.B.P.265
Freund, K.
Th.B.O.22
Freund, M.
T.C.P.99, W.C.P.86
Frey, H.
W.C.P.93
Friberger, T.
M.C.P.26
Fridberger, T.
Th.C.P.80
Fridland, Arnold
M.C.P.120
Fried, C.
E.726
Fried, P.
M.B.P.189
Friedland, G. H.
Th.A.O.24, Th.A.O.32,
Th.D.O.2, Th.D.P.59,
Th.D.P.78, D.589, D.645
Friedland, Gerald H.
Th.A.P.101
Friedland, R.
M.B.P.69
Friedman
Th.D.P.86
Friedman, F.
M.A.P.56
Friedman, H.
Th.B.P.223, W.C.P.76,
Th.C.P.101
Friedman, H. B.
A.622
Friedman, R. M.
T.C.P.58
Friedman, S.
A.598
Friedman, S. R.
T.A.O.20, T.A.P.48, W.D.O.5,
Th.D.O.6, Th.D.O.13,
T.D.P.81, Th.D.P.17,
Th.D.P.64
Friedman, S. F.
Th.E.P.4
Friedman, S. R.
W.D.O.10, Th.D.P.66,
Th.D.P.75, W.E.P.68, T.G.P.5
Friedman, Samuel R.
T.A.O.12, Th.D.O.3
Friedman-Kien, A.
W.B.P.76, W.B.P.142
Friedman-Kien, A. E.
W.B.P.159, Th.C.P.68
Friedman-Kien, Alvin E.
M.B.P.36
Friedmann, W.
M.B.P.21
Friedmann, Wolfgang
W.C.P.53
Friedrich-Jänicke, B.
B.521
Friese, Klaus
W.D.P.54, Th.D.P.23
Frigerio, L.
E.790, E.814
Frigieri, G.
T.B.P.235
Frisby, H. F.
M.A.P.22
Fritsch, P.
W.B.P.341
Fritz, G.K.
W.E.P.36
Fritz, R. B.
W.D.P.66
Fröschl, Monika
M.B.P.187, M.B.P.365,
Th.D.P.28
Frösner, G. G.
Th.B.P.181
Frösner, Gert G.
T.A.P.64, Th.A.P.36
Frossard, F.A.M.
Th.E.P.17
Frost, Andra R.
T.B.P.230
Frost, J. C.
D.651
Frottier, J.
M.B.O.36, W.B.P.35,
W.B.P.320, Th.B.P.11
Frutchey, C.
T.E.P.3
Frutchey, Chuck
E.686
Fry, C.
M.B.P.308
Froland, S.
T.C.P.146, W.C.P.73
Froland, S. S.
Th.B.P.215
Fuchs, D.
M.A.O.45
Fuchs, Dietmar
W.B.P.79, C.563
Fuchs, Edward J.
B.555
Fuel, H.
B.516
Füel, H. S.
W.B.P.92, Th.B.P.168, C.574
Fuessl, H.
W.D.P.3
Füssl, Hermann S.
E.764
Fuger, J.
E.649
Fujimaki, M.
M.A.P.42
Fujimaki, Michio
W.B.P.292
Fukasawa, M.
M.C.O.5, M.C.O.6, M.C.O.25
Fukushima, M.
M.C.P.144
Fullen, J.
C.592, C.620
Fullilove, M.
T.D.O.12
Fullilove, M. T.
W.D.P.61
Fullilove, Mindy
M.E.P.9
Fullilove, Mindy T.
W.D.O.4
Fullilove, R.
W.D.P.28
Fullilove, R. E.
W.D.O.4
Fullilove, R. F.
W.D.P.27
Fullilove, Robert E.
W.D.P.61
Fullwood, Catlin P.
M.E.P.11
Fulop, G.
M.H.O.9
Fulop, George
T.H.P.7
Fultz, D. N.
M.C.P.44
Fultz, P.
T.C.O.42, W.C.O.45,
W.C.P.15, W.C.P.58,
Th.C.P.58

- Fultz, P. N.
W.C.O.47
- Fultz, P. W.
T.C.O.40
- Fultz, Patricia N.
M.C.O.13, W.C.O.49, C.758
- Funk, Carole
W.C.P.19
- Furlone, M.
Th.B.P.243
- Furness, J. N.
C.869, C.764
- Furtado, C.
M.A.P.82
- Furth, P.
Th.B.P.171, C.522
- Fusco, F.
M.B.P.189
- Füst, G.
T.B.P.96, Th.B.P.139,
M.C.P.146, W.C.P.92
- Füst, G. Y.
T.B.P.302
- Füst, George
T.C.P.141
- Futterman, Donna
T.B.P.258
- Fuzibet, J. G.
A.531, M.B.P.250, B.524
- G**
- G. Rodriguez, M. C.
W.B.P.339
- G.E.C.S.A.
M.B.P.254
- G.R.S.N.T.S.
Th.A.P.3
- Gabel, L.
E.612
- Gahiano, C.
B.540
- Gahiano, Clara,
W.B.P.144
- Gabuzda, Dana H.
W.C.P.17
- Gachhi, G. S.
W.G.P.27, G.503, W.H.P.15
- Gadelle, S.
W.B.P.158, B.617, B.629
- Gadler, Hakan
W.C.P.84
- Gafa, S.
M.B.P.113
- Gafa, Sergio
M.B.P.65, M.B.P.363
- Gafa, Sergio
T.B.P.74, Th.D.P.67
- Gagliani, J. N.
M.B.P.46
- Gagliardi, L.
W.B.O.34
- Gaglioti, D.
Th.B.P.330, Th.B.P.343
- Gaglioti, M.
C.571
- Gagnon, C.
W.E.P.18
- Gagnon, S.
M.B.P.329, T.B.P.331
- Gaiera, G.
M.B.P.216
- Gaifuba, Jonathan K.
M.E.O.8
- Gail, M. H.
T.A.O.35, W.A.P.61
- Gail, Mitchell H.
Th.A.P.77
- Gaines, H.
W.B.P.129
- Gairin, J. E.
T.C.P.109
- Gairin, Jean-Édouard
C.856
- Galt, M. J.
T.C.O.29, T.C.P.93
- Gallo, Michel
T.E.O.9
- Gala, Costanzo
W.B.P.215, W.B.P.219,
Th.B.P.297
- Gallanaud, P.
Th.B.P.92, T.C.P.39, T.C.P.40
- Gallavotti, C.
M.D.P.32, T.D.P.27
- Galavotti, Christine
T.D.P.39, W.D.P.37,
W.E.P.58, E.635
- Galbán, Enrique
W.A.P.86
- Gale, M. J.
T.C.P.10, W.C.P.33
- Galezzi, R. L.
M.B.P.364
- Galegov, G.
T.C.P.145
- Galgani, S.
W.B.P.16, Th.B.P.220,
Th.B.P.255, Th.B.P.256
- Galibert, F.
W.C.P.139
- Galibert, F. G.
W.C.P.126
- Galinder, J.
W.A.P.22, A.582, M.G.P.29
- Gallagher, M.
M.D.O.18
- Gallais, H.
B.629
- Gallardo, M.
M.B.P.101
- Gallatin, W. M.
T.C.P.10
- Galli, M.
M.B.P.267, T.B.P.212, C.729,
D.688
- Galli, Massimo
W.A.P.30, W.B.O.11,
M.B.P.354, T.B.P.212
- Gallis, H.
W.B.P.3
- Gallis, H. A.
W.B.P.15
- Gallo, J. M.
M.C.P.98
- Gallo, Paolo
Th.B.P.225
- Gallo, R.
M.A.O.17, T.C.O.22,
Th.C.O.9, W.C.P.125,
Th.C.P.123
- Gallo, R. C.
W.C.O.32, Th.C.O.11,
M.C.P.1, M.C.P.30, M.C.P.48,
T.C.P.38, T.C.P.127,
W.C.P.47, W.C.P.48,
W.C.P.54, W.C.P.67,
Th.C.P.43, C.680, C.762
- Gallo, Robert C.
T.C.O.10
- Gallo-Silver, Les L.
W.D.P.9, W.D.P.10
- Gallois, C.
T.D.P.43
- Gallopp, Ruth M.
M.D.P.58
- Gallwey, J.
T.C.P.23, E.642
- Galphin, J.
T.C.P.83
- Galpin, J.
Th.B.O.3
- Galpin, J. E.
M.B.P.328
- Galpin, S.
M.C.P.70
- Galvao, B.
W.C.P.98, E.759
- Galvao-Castro, B.
T.B.P.99, Th.B.P.74, C.743,
W.G.P.15
- Galvin, J. P.
T.B.P.137, T.B.P.138
- Galzagorry, G.
T.B.P.290
- Gama-Sosa, M. A.
Th.C.O.49, M.C.P.51
- Gamba, G.
Th.B.P.2
- Gamba, Gabriella
Th.B.P.1
- Gambacorta, M.
T.B.P.272
- Gamble, W. B.
W.A.O.20, W.A.P.87
- Gambrell, A. E.
T.E.P.74
- Ganfield, Mong-Ching
C.572
- Gangadharam, Pattisapu
R. J.
M.B.P.190, Th.B.P.61,
Th.B.P.62
- Gangemi, J. D.
W.C.P.6
- Gangemi, J. David
M.C.P.81
- Ganguly, M. E.
W.B.P.177
- Gann, D.
Th.D.P.73
- Gansbacher, B.
W.B.P.374
- Garabedyan, C.
T.B.P.277
- Garbanzadeh, D.
Th.A.P.99
- Garber, G.
T.B.P.306
- Garber, G. E.
T.C.P.56
- Garbutt, J. M.
Th.A.P.37
- García Aguado, C.
B.847
- García Gurutzarri, A.
T.A.O.23
- García Polo, I.
M.B.P.212
- García Saiz, A.
A.576, T.B.P.92, T.B.P.229
- García Suárez, José
B.802
- García, D. B.
E.757
- García, D. R.
W.D.P.51
- García, G.
E.716
- García, J.
W.B.P.97, T.C.P.122, W.G.O.2
- García, J. G.
W.B.P.36
- García, L.
Th.A.P.80, Th.D.P.88
- García, Lourdes
M.D.P.69, W.G.P.8, W.G.P.25
- García, M.
T.B.P.164, T.B.P.255, B.600,
M.G.O.6
- García, M. E.
A.505
- García, M. L.
T.A.P.8, Th.D.O.11, M.G.O.1,
M.G.O.27, G.510
- García, N.
M.B.P.371
- García, T.
T.A.P.114

- García, X.
T.B.P.214, C.705
- García, Z.
W.B.O.37
- García-Alvarez, R.
T.D.F.32
- García-Montes, M.
Th.B.P.184
- García-Foto, Iluminada
T.B.P.293
- García-Reinoso, C.
M.B.P.242
- García-Saez, A.
T.A.P.22
- García-Sáiz, Alfredo A.
Th.C.P.74
- García-Soto, M.
T.A.O.22
- García-Tunon, M.
M.A.P.9
- Gard, E.
W.C.P.35
- Gard, E. A.
W.C.O.32
- Garde, C.
W.A.P.75, T.B.P.278,
W.B.P.66, Th.B.P.65, B.601
- Gardini, G.
M.B.P.113
- Gardner, L. I.
W.B.P.225
- Gardner, Lytt I.
M.A.P.3
- Gardner, M. B.
Th.C.O.45
- Gardom, J. C.
D.606
- Gardom, Jessica
W.A.P.109
- Garell, D. C.
M.B.P.313
- Garewal, H. S.
C.632
- Garfinkle, J.
M.H.P.17
- Gargantini, L.
M.B.P.294, T.B.P.272, C.729
- Garib, J.
T.H.O.10, T.H.O.12
- Garib, Jorge
W.H.P.3
- Garin, J. P.
T.B.P.47
- Garland, Frank C.
M.A.P.11
- Garlick, R. L.
C.687
- Garner, J.
M.A.P.30
- Garner, Jane
M.A.P.107
- Garner, L.
M.A.O.6
- Garnier, J. L.
T.B.P.47, W.B.P.55
- Garou, A.
T.B.P.27
- Garrigues, J.
Th.C.P.95
- Garris, Ivelisse
M.G.O.25
- Garrison, C.
D.647
- Garrison, L.
M.C.P.14
- Garrison, Leslie
T.B.P.123, M.C.P.12
- Garrod, A.
Th.B.P.31, E.507
- Gartner, S.
W.C.O.7, Th.C.O.42, M.C.P.42
- Garvey, B.
W.B.O.27
- Garvey, D.
Th.B.P.20
- Garzon, S.
Th.B.P.356, B.564, W.C.P.94
- Gasione, P.
Th.B.P.48
- Gasparini, M.
Th.B.P.194
- Gasparini, P.
C.850
- Gasper, P. W.
W.C.P.142
- Gasper, Peter W.
W.C.P.13
- Gastanguay, Claude
W.H.O.1
- Gastaud, J. A.
W.B.P.302
- Gaston, I.
C.596
- Gatell, J.
Th.B.P.193
- Gatell, J. M.
M.A.P.104, W.A.P.78, A.618,
T.B.P.294, W.B.P.40,
W.B.P.101, B.610
- Gatell, José M.
W.A.P.55, M.B.O.37
- Gates, J.
E.611
- Gath, L.
W.B.P.260
- Gathe, J. C., Jr.
M.C.P.60
- Gathe, J. Jr.
M.B.P.377
- Gathof, B.
M.B.P.64, M.B.P.148
- Gathof, Birgit E.
T.B.P.360
- Gathof, G.
T.B.P.360
- Gathua, S. N.
Th.G.O.5
- Gattegno, L.
M.C.O.3
- Gattegno, Liliane
C.674
- Gatti, G.
M.B.P.75
- Gatti, H.
M.G.O.29
- Gauch, R.
E.746
- Gaudebout, C.
M.B.P.348, T.B.P.49
- Gauderack, G.
T.C.P.20, T.C.P.146
- Gaulier, A.
Th.B.P.336
- Gaumer, R.
Th.A.P.49
- Gaur, S.
T.B.P.169
- Gaut, P.
Th.B.O.6
- Gauthier, D.
M.H.P.19
- Gavosto, F.
Th.C.O.40
- Gaye, A.
T.B.O.9
- Gaye, I.
T.B.P.362, B.612, T.G.P.32
- Gayet, C.
Th.B.P.9, Th.B.P.21
- Gayet-Mengelle, C.
M.A.P.46, A.574, T.B.P.219,
T.B.P.222, T.B.P.242
- Gayle, H.
A.604, T.B.P.157, M.D.P.10,
Th.D.P.1
- Gayle, Helene D.
M.A.P.9, M.D.O.7
- Gayle, Jacob A.
M.E.O.20
- Gaynor, S.
T.A.P.105
- Gaynor, Suzanne M.
M.B.P.141, M.B.P.142,
M.B.P.152, T.B.P.344
- Gazengel, C.
Th.C.P.21
- Gazzard, B.
M.B.P.81, M.B.P.264,
T.B.P.328, W.B.P.242,
M.H.P.3
- Gazzard, B. G.
T.B.O.30, M.B.P.115,
M.B.P.122, M.B.P.175,
M.B.P.209, T.B.P.64,
T.B.P.66, W.B.P.17,
W.B.P.46, W.B.P.47,
W.B.P.314, Th.B.P.328
- Geaga, J.
W.B.P.363
- Gebauer, F.
C.517
- Gebrehiwot, B.
M.A.P.79
- Gebreselassie, Lakew
Th.C.P.139
- Geelen, J.
W.C.P.88, W.C.P.89
- Geels, R. M. A.
D.578, M.H.P.8
- Geiger, W.
T.E.P.1
- Geit, M.
M.B.P.374
- Gejer, M.
G.515
- Geiderblom, H.
Th.B.P.342, C.517
- Gelderblom, H. R.
Th.C.P.53, Th.C.P.150
- Gelezinnas, R.
T.C.P.110, Th.C.P.117
- Gelezinnas, Romas
T.C.P.112
- Gelfer, M.
W.A.P.120
- Gelman, Karen
W.B.O.30
- Gelmon, K.
M.B.O.47, W.B.O.1, W.B.O.8,
W.B.O.8, M.B.P.367,
W.B.P.351, B.606
- Gelmon, Karen
Th.A.P.33
- Gelmon, S. B.
E.624
- Gemmill, I.
W.E.O.1
- Gemmill, Robert H.
M.E.P.74
- Gemson, D.
M.D.P.44
- Gendelman, H.
T.B.P.112, M.C.O.15,
W.C.P.63, C.741
- Gendelman, H. E.
M.C.P.131, T.C.P.30
- Gendelman, Howard E.
M.C.O.20
- Gendrait, J. L.
C.769, C.770
- Gendron, S.
M.A.P.23, Th.A.P.39
- Genesca, J.
W.B.P.122
- Genesca, Juan
A.534, W.B.P.154
- Genetet, G. B.
B.535
- Genetet, N.
W.B.P.75
- Géniaux, G. M.
Th.E.P.17

- Gennaro, M.
B.587
- Genoulaz, O.
M.B.P.61, T.B.P.231
- Genova, F.
M.B.P.133
- Genser, J.
E.681
- Genser, S.
E.637, E.637
- Genser, S.
E.681
- Gentile, Patricia
W.B.P.245
- Gentili, E. G.
Th.C.P.111
- Gentilini, M.
M.A.P.119, M.B.P.117,
M.B.P.119, T.B.P.13,
T.B.P.41, Th.B.P.219, B.546,
Th.C.O.39, Th.G.P.7, G.511
- Gentsch, Jon R.
T.B.P.87
- Gentschew, G.
Th.B.P.334
- Geoffroy, L.
M.H.P.4
- George H.
D.653
- George, A.
M.E.P.33
- George, Alan Michael
W.E.P.15
- George, J.
W.B.P.160
- George, James R.
M.B.P.163, T.B.P.119
- George, L.
T.D.P.60
- George, R.
W.A.O.12, W.B.P.112,
W.B.P.174
- Georges, A. J.
M.B.P.185, Th.B.P.209,
T.C.O.41, T.C.P.22
- Georges, Alain J.
T.B.P.191, W.G.O.28
- Georges, Alain Jean
Th.E.P.52
- Georges-Courbot, M. C.
T.C.O.41, T.C.P.22, Th.C.P.78
- Georgopolou, S. A.
W.B.P.342
- Georgopolou, O.
W.C.P.140
- Georgopolou, Stamatina
A.
A.612
- Georgoulas, Vassilis
M.A.P.80, Th.A.P.27,
W.B.P.69, B.620, C.535, C.597
- Gérard, H.
C.541
- Gérard, M.
M.B.P.263
- Gerard, M.
M.B.P.366, Th.B.P.43
- Gerbase, Antonio C.
E.799
- Gerbase, C.
E.799
- Gerberding, Julie Louise
M.D.O.14, M.E.P.28
- Gerbert, B.
D.833
- Gerbert, Barbara
T.D.O.33, M.D.P.52,
M.D.P.53, E.667
- Gerdelman, R.
T.B.P.14
- Gerdol, D.
M.A.O.38
- GERICCO
A.636
- Gerin, J.
M.C.P.3
- Germain, Céline
M.E.P.75, Th.E.P.72
- Gerna, G.
M.B.P.114
- Gerna, Giuseppe
M.B.O.31
- Gerniers, Marie-Madeleine
Th.H.P.18
- Gerrity, E. T.
E.665
- Gershman, K.
M.C.P.14
- Gershon, Robyn R. M.
M.D.P.70
- Gershy-Damet, G. M.
A.567, W.B.P.108, C.765,
C.766
- Gershy-Damet, Guy-Michel
M.G.P.25
- Gerstoft, J.
T.A.O.30, Th.B.O.46,
W.D.P.55
- Gervais, A.
T.B.P.54
- Gesemann, Michael
Th.B.P.185
- Getchell, J. P.
T.B.P.333
- Getson, P.
T.B.P.157, M.D.P.10
- Gettie, A.
Th.C.O.45
- Getty, Grace E.
D.539
- Geyer, C.
Th.B.P.264
- Geyer, S. J.
Th.C.P.114
- Geyer, Sharon J.
Th.C.P.118
- Gharakhanian, S.
M.B.P.132, T.B.P.283,
T.B.P.307
- Gharakhanian, Shahin
M.B.P.306
- Ghazzeouli, I.
M.C.P.74
- Ghesquiere, W.
T.B.P.42
- Ghetie, V.
Th.C.O.14
- Ghetie, Victor
M.C.P.129
- Ghidinelli, M.
Th.H.P.25
- Ghirardini, A.
T.B.P.345
- Ghmassia, J.-C.
B.561
- Ghori, N.
Th.B.P.61
- Giachello, Aida L.
W.D.P.30
- Giacobbì, D.
M.B.P.194
- Gialeraki, A.
M.A.P.88, W.B.P.348,
Th.B.P.17
- Gianguasaro, F.
M.B.P.118
- Gianguande, P. L. F.
W.B.P.349
- Gianna, M. C.
D.540
- Giannelli, F.
A.503
- Giannini, V.
Th.B.O.14
- Giaquinto, C.
T.B.P.244
- Giaquinto, Carlo
M.B.P.114, M.B.P.324,
T.B.P.166
- Gibbon, J.
T.C.P.10
- Gibbons, W. A.
M.C.P.40, M.C.P.41, C.544,
C.545
- Gibbs, C. J.
Th.C.O.46, M.C.P.13
- Gibbs, J.
Th.A.P.119
- Gibbs, W. N.
W.G.P.28, Th.G.P.1
- Gibes, J.
M.B.P.164
- Gibson, D. R.
Th.D.O.5, Th.D.P.84
- Gibson, David R.
T.A.O.22
- Gibson, P. M.
M.D.P.30
- Gibson, Paul M.
W.D.P.82, D.557
- Gibson, Paul W.
D.519
- Gibson, W. P.
D.557
- Gidlund, M.
C.712
- Giesecke, J.
W.A.O.24
- Gigase, P. L.
T.B.P.135
- Gil Aguado, Antonio
M.C.P.71
- Gil, A.
M.B.P.370, W.B.P.338, B.648
- Gil, E.
M.E.P.22, T.E.P.27, E.663,
E.765, E.766, Th.F.P.12
- Gil, M. P.
W.B.P.101
- Gil, R.
W.A.P.86
- Gilada, Ishwarprasad S.
T.D.P.84, Th.G.P.25
- Gilcher, Ronald O.
E.709
- Gill, J.
W.B.P.351
- Gill, M. John
M.B.P.165, M.B.P.241
- Gill, O. Noel
T.A.P.4
- Gill, P.
M.B.P.174, T.B.P.286,
W.B.P.172, T.C.P.17
- Gill, P. S.
Th.A.P.11, M.B.O.48,
W.C.P.49
- Gill, Parkash S.
M.B.P.366
- Gill, S.
C.833
- Gilles, K.
Th.A.P.83
- Gillette, E. L.
W.C.P.142
- Gillette, P.
M.D.P.45
- Gillies, P. A.
W.E.P.39
- Gillies, Pamela A.
W.E.P.40
- Gilljam, G.
Th.C.P.26
- Gilman, T. M.
T.B.P.61, T.B.P.82
- Gilman, T. T.
T.B.P.63
- Gilmore, N.
W.A.P.79, A.809, T.F.O.4,
T.F.O.11, M.F.P.7, M.H.O.4,
M.H.O.7

- Gilmore, Norbert
M.F.O.13a
- Gilmour, Jacqueline E. M.
M.C.P.34
- Gilson, I.
T.B.P.325
- Gilson, Ian
M.B.P.188
- Gimeno, J. M.
T.B.P.308, W.B.P.22,
Th.B.P.148
- Ginestà, C.
Th.B.P.335
- Ginestà, C.
W.A.P.71, Th.D.P.57, D.613
- Gingeras, T.
T.C.P.129
- Gingeras, Thomas R.
Th.C.P.46
- Ginsberg, Michele M.
M.A.P.82
- Ginsburgh, Charles L.
C.698
- Gioia, G. A.
W.B.P.183
- Gioia, K.
T.B.P.253
- Giordano, Michael
M.G.P.3
- Giorgi, J.
A.540, M.B.P.110, C.787
- Giorgi, J. V.
Th.A.P.94, T.C.P.31
- Giorgi, Janis V.
M.C.P.24
- Giovanetti, Anna
M.A.O.11
- Gir, Elucir
M.D.P.61, M.D.P.87
- Giraldes, P.
M.G.P.8
- Giraldi, D.
A.538
- Giraldo, G.
W.C.P.51
- Girardo, Gaetano
Th.B.P.16, W.C.P.47
- Girard, B.
W.B.O.18, M.B.P.119
- Girard, M.
M.B.P.151, M.B.P.362,
M.C.P.31, T.C.P.77
- Girard, Marc
W.C.O.17
- Girard, Marc P.
Th.C.O.47
- Girard, P. M.
T.B.O.2, T.B.P.4, T.B.P.27
- Girard, Pierre-Marie
T.B.P.23, T.B.P.49
- Girke, W.
Th.B.P.275
- Giroto, S.
T.B.P.185
- Giroud, M.
T.B.P.231
- Gisselbrecht, C.
M.B.P.295, T.B.P.280
- Gissmann, L.
M.B.O.18
- Gitelson, P.
D.512
- Gitterman, S. R.
M.C.P.94
- Giudici, M.
W.C.P.50
- Giudici, M. G.
M.B.P.113, M.B.P.363,
T.B.P.74, Th.D.P.67
- Giuliani, G.
M.B.P.194
- Giuliani, M.
M.A.P.48
- Gjerset, George F.
M.B.P.145
- Gladis, M.
E.581, E.662
- Glancy, T. P.
M.C.P.46
- Glaser, Jordan B.
T.A.P.32, A.613, M.B.P.37,
W.B.P.119
- Glaspay, J.
M.C.P.52, M.C.P.100
- Glass, M.
M.C.P.27
- Glass, S.
T.A.P.93, T.A.P.100
- Glasser, D.
Th.A.O.18, M.A.P.68
- Glatt, A. E.
Th.B.P.50
- Glauser, M. P.
Th.B.P.212, Th.B.P.319
- Gleason-Morgan, Deborah
T.B.P.280
- Glebatis, D.
W.A.O.8
- Glenn, H. Patrick
T.F.O.A, M.F.P.7
- Glick-Schiller, Nina K.
E.700
- Glicksman, M.
Th.B.P.269
- Glidden, D.
W.A.P.82
- Glied, Sherry
W.H.O.18
- Glode, M.
W.B.P.246
- Glover, L.
D.571
- Glück, Dorothee
M.A.P.40
- Gluck, Michael E.
M.H.P.13
- Gluckman, J. C.
W.C.O.9, T.C.P.42, Th.C.P.1,
C.674, T.G.P.28
- Gluckman, J.-C.
Th.C.O.5, Th.C.O.47,
Th.C.P.67
- Gluckman, Jean-Claude
M.C.O.3, M.C.P.31
- Gluckstein, D.
T.B.P.12
- Glunt, E. K.
M.E.P.3
- Glusic, W.
Th.A.P.112
- Gluska, T.
Th.D.P.41
- Gnaore, Emmanuel
T.B.O.8
- Gober, B.
T.C.P.44
- Gochros, Harvey L.
D.580
- Gochros, Jean S.
D.558
- Gocke, D.
D.692
- Gocke, D. J.
Th.B.P.125
- Godeau, R. E.
M.D.P.59
- Godes, Jan R.
M.E.P.6
- Godfrey, B.
W.C.P.76, Th.C.P.101
- Godfried, M. H.
Th.B.O.38
- Godin, G.
M.D.P.11, M.D.P.27
- Godin, Norman J.
M.C.P.149
- Godkin, M. A.
M.D.P.8
- Gody, M.
T.B.P.368
- Goebel, F.
C.598
- Goebel, F. D.
W.B.P.235, C.574, W.D.P.3,
E.784
- Goebel, F.-D.
M.B.P.64, Th.B.P.168, B.516
- Goebel, Frank D.
W.B.P.92, Th.B.P.244, E.649
- Goede, H.
D.535
- Goedert, J.
Th.A.P.18, M.B.O.2,
M.B.O.42, T.B.P.82, W.B.P.70
- Goedert, J. J.
M.A.O.45, T.A.O.35,
Th.A.O.22, W.A.P.51,
Th.A.P.77, T.B.P.185
- Goedert, James
Th.B.O.34
- Goedert, James J.
Th.A.O.6, Th.A.O.28
- Goeffray, Anne
M.B.P.265
- Goehhegan, C.
M.D.P.28
- Goetz, R.
W.B.P.222
- Goetz, R. R., Jr.
T.D.O.22
- Goetz, E.
M.B.P.193
- Goff, M. R.
W.B.P.242
- Gogu, S. R.
M.C.P.64
- Goh, Beng T.
Th.B.P.374
- Gohchi, K.
W.B.P.311
- Golcoa, M. A.
C.707
- Goicochea, P. G.
M.E.P.20
- Gola, T.
T.A.P.56
- Gold, J.
M.A.P.65, A.581, M.B.P.278,
W.B.P.374, Th.B.P.298,
W.D.P.62
- Gold, J. M. W.
M.B.P.207, W.D.P.10
- Gold, J. W. M.
A.548, W.B.P.309, M.C.P.131,
D.648
- Gold, Jonathan W. M.
W.B.O.39
- Gold, Julian
T.B.P.298, Th.B.P.358,
M.D.O.12, W.D.P.54
- Gold, R.
T.D.O.7
- Goldberg, D. J.
W.B.O.7, Th.D.P.3, W.F.P.8
- Goldberg, David J.
Th.A.P.115, Th.D.P.55, D.612
- Goldberg, J.
M.H.O.14, T.H.P.1
- Goldblum, Natan
Th.C.P.72
- Golden, J.
T.B.P.25
- Golden, S.
Th.B.P.308, Th.B.P.381
- Goldensbaum, M.
M.A.O.8, M.A.P.1, M.A.P.17,
W.B.P.225

- Goldenbaum, P.**
 Th.C.P.106
- Goldenberg, R.**
 E.809
- Goldie, R.**
 M.B.P.315
- Golding, B.**
 W.C.P.57
- Golding, H.**
 T.C.P.48
- Golding, Hana**
 Th.C.O.2, W.C.P.57
- Golding, Simon M.**
 D.625
- Goldmacher, V. S.**
 M.C.P.72
- Goldman, A.**
 E.643
- Goldman, E.**
 M.A.P.41, M.E.O.13
- Goldman, H.**
 W.C.P.64
- Goldmeyer, D.**
 W.B.P.58, W.B.P.59
- Goldring, S.**
 T.C.O.18
- Goldschmidt, C.**
 T.C.P.123
- Goldsmith, D.**
 T.A.O.12, Th.D.P.85, W.E.P.68
- Goldstein, A. L.**
 W.B.P.141
- Goldstein, A. S.**
 W.B.P.128
- Goldstein, Allan L.**
 M.C.P.13
- Goldstein, Andrew S.**
 T.G.P.19
- Goldstein, E.**
 W.B.P.123, M.C.P.113
- Goldstein, J.**
 M.B.P.190
- Goldstein, M.**
 Th.A.P.25, Th.A.P.26
- Goldstein, S.**
 W.B.P.192
- Goldstone, Irene**
 M.B.O.7
- Goldstone, Irene L.**
 T.H.P.13
- Goldwurm, G. F.**
 W.B.P.206
- Goliav, C.**
 M.A.P.66
- Goller, Ian E.**
 E.769
- Golodner, M.**
 T.B.P.194
- Golombok, Susan E.**
 D.701
- Golub, Efrim E.**
 C.645
- Golubjatnikov, R.**
 M.A.P.22
- Gomatos, Peter John**
 M.C.O.15
- Gomes, C.**
 W.E.O.18
- Gomes, M. C. O.**
 D.584, D.693, Th.E.P.22
- Gomez Carrillo, M.**
 W.B.P.382, W.G.P.18
- Gómez, A.**
 D.706
- Gomez, C.**
 Th.B.P.284
- Gomez, E.**
 W.H.P.2
- Gomez, G.**
 W.C.P.120
- Gomez, M. Perry**
 Th.A.P.120
- Gomez, P.**
 Th.G.O.43
- Gomez-Carrillo, M.**
 D.686
- Gomperts, E.**
 Th.B.P.33, C.593
- Gomperts, E. D.**
 T.B.P.267
- Gomperts, Edward D.**
 A.565
- Gonçales, N.**
 T.G.P.14
- Gonçalves, R. S.**
 T.G.P.25
- Gonçalves, V. L. C.**
 D.584
- Gonda, M.**
 M.C.O.16
- Gonzalez, G.**
 T.E.P.65
- Gonstorek, J.**
 D.555
- Gonzaga, A. L.**
 M.B.P.112, M.B.P.223
- Gonzales, G.**
 W.B.P.283
- Gonzales, J.**
 Th.C.O.36
- Gonzales-Scarano, F.**
 W.C.P.70
- Gonzalez Gonzalez, A.**
 Th.B.P.77
- Gonzalez Montaner, J.**
 Th.G.O.3
- Gonzalez, A.**
 M.B.P.286, M.C.P.71
- Gonzalez, B.**
 Th.B.P.121, Th.B.P.184
- González, J. J.**
 A.560, A.561, W.H.P.20
- Gonzalez, José J.**
 Th.A.P.53, A.513, W.E.P.6,
 W.H.P.18
- Gonzalez-Canali, Gustavo**
 T.B.P.279
- Gonzalez-Clemente, J. M.**
 M.B.O.37
- Gonzalez-Lahoz, Juan Maria**
 B.647
- González-Martinez, A.**
 W.H.P.5
- Gonzalez-Scarano, F.**
 W.C.P.76
- Good, R. A.**
 Th.B.P.138
- Goode, L.**
 M.B.P.19, M.B.P.29
- Goodfriend, N.**
 D.552
- Goodman, D. L.**
 Th.B.P.115
- Goodson, P.**
 T.D.P.16, D.547
- Goodwin, F. K.**
 W.B.O.45, W.B.P.286, B.566
- Goodwin, G.**
 W.B.P.229, W.B.P.232
- Goodwin, S. D.**
 T.B.P.318
- Goos, M.**
 M.B.P.335, T.B.P.361,
 W.B.P.324
- Gor, D.**
 A.601
- Gorbea, Hector F.**
 A.505
- Gorbea, R. M. C.**
 T.B.P.193
- Gorczyca, Kenneth C.**
 A.626
- Gordin, Fred M.**
 M.B.P.104
- Gordon, B.**
 W.B.O.45
- Gordon, J. B.**
 M.B.P.306
- Gordon, K.**
 Th.D.O.15
- Gordon, L.**
 D.645
- Gordon, Mark R.**
 C.508
- Gordon, P.**
 W.C.P.74
- Gore, Ira**
 Th.C.P.132
- Gorfinkle, K.**
 W.B.P.332
- Gorin, I.**
 M.B.P.350, W.C.P.72
- Gorman, J.**
 W.B.O.41, T.B.P.192,
 Th.B.P.261, D.603, W.F.P.2
- Gorman, J. G.**
 W.D.P.67
- Gorman, J. M.**
 T.D.O.22, M.D.P.38, T.D.P.28
- Gorman, Jack M.**
 W.B.P.229
- Gorman, M.**
 W.A.O.28
- Gorman, R.**
 W.B.P.287
- Gorna, Robin V.**
 E.810
- Gornitsky, M.**
 T.C.P.79
- Gorny, M.**
 T.C.O.33
- Gorny, M. K.**
 T.A.O.38, T.C.P.7, T.C.P.70,
 C.771
- Gorse, G. J.**
 M.C.P.32
- Gorse, Geoffrey J.**
 Th.C.O.32
- Górski, Tadeusz**
 W.E.P.63
- Gorter, R.**
 T.A.O.11, A.525
- Gorter, Robert**
 Th.A.P.102
- Gosselin, G.**
 M.C.P.93
- Gossman, E.**
 M.B.P.148
- Gostin, Lawrence O.**
 M.F.O.6, W.F.O.18
- Gosting, Larry H.**
 T.B.P.124
- Goto, Toshiyuki**
 C.778
- Gotovac, Petar**
 T.E.P.22
- Gottesleben, A.**
 W.B.P.297
- Gottfried, T.**
 W.B.P.143
- Gottfried, Toby**
 W.B.P.142
- Gottlieb, A. A.**
 Th.B.O.47
- Gottlieb, J.**
 M.D.P.3
- Gottlieb, Marise S.**
 Th.B.O.47
- Gottlieb, Michael S.**
 Th.B.O.3
- Gottlinger, H.**
 Th.C.P.90
- Gottstein, A.**
 Th.A.P.96, W.B.P.334
- Gotzuso, E.**
 Th.E.P.74
- Götze, G.**
 W.B.P.297
- Goubau, P.**
 B.637

- Goudeau, A.
M.B.P.1
- Goudeau, Alain M.
M.A.P.15
- Goudsmit, J.
M.A.O.47, M.A.P.112,
T.A.P.20, M.B.O.23,
M.B.P.332, T.B.P.96,
W.B.P.109, Th.B.P.210,
M.C.O.8, T.C.O.22, W.C.P.46,
W.C.P.56, W.C.P.88,
Th.C.P.34
- Goudsmit, Jaap
W.C.P.44, W.C.P.89,
Th.C.P.35, C.732
- Goudsmith, J.
T.C.P.73
- Gould, J.
M.A.O.22, W.D.P.69
- Gouveia, S. G. E.
D.714
- Govindarajan, A. G.
W.B.P.142, W.B.P.143
- Govindarajan, S.
M.B.P.218
- Govoni, L.
Th.B.P.295
- Gowanlock, Gweneth
Th.D.P.90
- Gowda, S. D.
C.772
- Goyer, P. F.
W.B.P.213
- Gr. de Travail Rétrovirus
de la S.N.T.S
M.A.P.33
- Grabau, J. C.
W.H.P.10
- Graca, M. H. P.
T.B.P.190, B.532, B.534,
B.638
- Grace, A. G.
T.E.P.16
- Grace, John W.
T.F.O.5
- Grace, S. A.
Th.C.P.40
- Grace, William C.
T.D.P.59, E.594
- Grade, M.
D.632, E.600, E.629
- Grade, M. M.
M.D.P.85, E.599
- Grade, Margaret M.
M.D.P.42, E.628
- Grady, G. F.
M.A.P.14
- Grafman, J.
Th.B.P.295
- Graham, B.
Th.C.O.33
- Graham, Barney S.
M.C.P.19, W.C.P.144, C.720
- Graham, C.
W.C.P.80
- Graham, F. L.
M.C.P.21
- Graham, V.
Th.D.P.9, Th.D.P.54
- Granat, C.
Th.E.P.83
- Granati, Lucia
B.518
- Grandi, J. L.
M.B.P.108, E.610, E.665,
Th.G.P.26, G.515
- Grandi, Joao Luis
M.E.P.31
- Grandinetti, T.
M.B.P.146
- Grangeiro, A. D.
D.540
- Granier, C.
T.C.P.42
- Grant, Christine M.
W.A.O.7, T.A.P.78, W.B.P.61
- Grant, I.
W.B.P.223, W.B.P.233,
W.B.P.254, Th.B.P.195,
T.D.P.79
- Grant, Igor
W.B.P.230, Th.B.P.262
- Grant, J. M.
A.538
- Grant, M. D.
W.C.P.130
- Grant, Michael D.
T.C.P.60
- Grant, Peter J.
T.D.O.7
- Grant, S.
W.B.P.283
- Grassi, Fabio
C.578
- Grässmann, W.
M.A.P.40
- Gratz, E.
B.574
- Graus Ribas, F.
Th.B.P.193
- Graves, F.
A.598
- Graves, F. L.
W.E.P.68
- Gravier, Bruno
T.D.O.2
- Gray, F.
Th.B.P.253
- Gray, Graciela
T.B.P.152
- Gray, J.
W.B.P.314
- Gray, J. A.
W.B.P.317, W.B.P.371
- Graybill, D.
E.793
- Grayson, N.
M.E.P.51
- Greatbatch, Wilson
Th.A.P.60
- Greaves, W. L.
E.553
- Greco, D.
M.B.O.46, M.B.P.92,
Th.B.P.344, T.E.P.26,
W.G.P.13
- Greco, Dirceu B.
Th.B.P.114, Th.B.P.170,
T.D.P.25
- Greco, M.
M.B.P.20
- Greco, M. A.
B.580, B.583
- Greco, M. Alba
T.B.P.370, Th.B.P.372
- Greder, Brigitte
T.E.P.50
- Green Rush, A.
T.D.O.13, W.D.P.32
- Green, F. A.
W.F.P.8
- Green, J.
W.B.P.204, M.D.P.92,
W.D.P.12, D.573, E.509,
M.H.O.16
- Green, Jesse
Th.A.P.82, M.H.O.10,
M.H.P.5, T.H.P.16
- Green, John
D.572
- Green, Miriam
T.E.O.6
- Green, S.
D.512
- Green, S. R.
M.G.P.18
- Green, S. T.
Th.D.P.55
- Green, Stephen T.
W.B.O.7, Th.D.P.3, W.F.P.8
- Green, T. L.
Th.B.P.346
- Green, W.
M.B.P.201
- Greenberg, Alan E.
W.A.P.12, W.G.O.7
- Greenberg, B.
M.A.P.67
- Greenberg, D. M.
Th.F.P.6
- Greenberg, L.
C.668
- Greenberg, M.
W.B.P.325
- Greenberg, P.
Th.C.O.34
- Greenberg, S.
Th.B.P.104, Th.C.O.33
- Greenblatt, R.
Th.C.O.36, M.D.P.3, M.D.P.4
- Greenblatt, R. M.
T.H.O.1
- Greenblatt, Ruth M.
T.D.O.25
- Greene, A. W.
W.A.P.12
- Greene, J. B.
M.E.P.23
- Greene, M. I.
W.C.O.25, C.608
- Greene, S. I.
T.B.O.5
- Greenfield, S.
M.H.P.17
- Greenhalgh, J. B.
M.A.P.94
- Greenhalgh, John B.
M.A.P.89
- Greenspan, D.
M.B.O.19, Th.B.P.323,
Th.B.P.340, Th.B.P.347
- Greenspan, Deborah
M.B.O.20, Th.B.P.320
- Greenspan, J.
W.C.P.32
- Greenspan, J. S.
Th.A.P.24, M.B.O.18,
M.B.O.19, M.B.O.20,
Th.B.P.320, Th.B.P.323,
Th.B.P.340, Th.B.P.351, C.704
- Greenwood, B.
T.B.P.362, B.612
- Greenwood, J. R.
M.A.P.28, M.E.P.7
- Greer, D.
W.B.P.8, W.B.P.18, Th.B.P.42
- Greer, K.
M.H.P.26
- Greer, Pedro Jr.
M.A.O.28
- Grespan, J. S.
Th.B.P.346
- Gregersen J.-P.
C.697
- Gregersen, Jens-Peter
M.C.P.44
- Gregersen, P. K.
C.655
- Gregg, Robert A.
T.B.P.232
- Grégoire, M.
W.B.P.30
- Gregory, B.
T.A.P.6
- Gregory, G.
T.B.P.75
- Gregory, T.
Th.C.O.14, Th.C.O.15
- Greitz, Y.
M.E.P.32

- Grella, P. V.**
 M.B.P.14
Gremillet, P.
 Th.C.P.8
Greengard, G.
 Th.E.P.52
Grewe, Carola
 Th.C.P.53, Th.C.P.150
Grey, E.
 E.536
Grieco, M. H.
 A.620, M.B.P.360, W.B.P.80,
 W.B.P.315, M.C.P.142
Grier, P.
 M.B.P.314
Griffin, C.
 T.B.P.141
Griffin, C. W.
 T.B.P.142, T.B.P.143
Griffin, G. B.
 Th.B.P.287
Griffin, G. E.
 Th.B.O.41, Th.B.P.317
Griffiss, J. M.
 C.722
Griffith, B.
 W.C.O.8
Griffith, P.
 T.E.P.11
Griffiths, C.
 W.E.P.15
Griffiths, J. M.
 M.C.P.35
Griffiths, P. D.
 M.A.P.41, M.A.P.96, W.B.O.28
Griffiths, Paul D.
 Th.B.P.22
Griffiths, R. K. G.
 W.D.P.41, D.682, T.E.P.38
Griggs, L.
 M.D.O.12
Grigsby, M.
 M.B.P.238
Grilia, M.
 Th.B.P.258
Grillner, L.
 W.B.P.129
Grillner, Lena
 W.B.P.114
Grillo, A.
 Th.B.P.76
Grillo, L.
 Th.B.O.14
Grillo, L. R.
 W.B.P.16
Grimaldi, L.
 Th.B.P.245
Grimfeld, A.
 T.B.P.155
Grimm, G.
 T.A.P.28
Grimshaw, J.
 W.E.O.3, E.642
Grinberg, N.
 M.B.O.16, Th.B.P.326
Grinberg, N. S.
 Th.H.P.23
Grinde, B.
 Th.C.P.112
Grinde, K.
 E.669
Gringeri, A.
 M.A.P.44, T.A.P.116,
 T.B.P.345
Gringeri, Alessandro
 A.516
Gristein, S.
 Th.B.P.4
Grippa, A.
 Th.B.P.203
Griscelli, C.
 M.B.O.39, T.B.P.170,
 Th.C.P.7, W.D.P.16
Griscelli, Claude
 T.O.20
Grizzi, Francesco M.
 M.B.P.96, Th.B.P.76
Grob, P.
 T.B.P.86, Th.B.P.81
Grob, F. J.
 Th.B.O.27
Grohmann, S.
 Th.B.P.283, Th.B.P.375
Gromisch, D. S.
 T.B.P.147, T.B.P.168,
 T.B.P.265
Grondin, M.
 Th.D.P.92
Grondin, Mary
 D.553
Grononna, C.
 Th.B.P.82
Gronowitz, J. Simon
 W.B.P.147, Th.C.P.82,
 Th.C.P.84
Groopman, J.
 Th.B.O.5, T.B.P.303,
 W.C.O.36, W.C.P.77,
 W.C.P.78
Groopman, J. E.
 W.B.P.328, T.C.O.18,
 M.C.P.135
Grosch-Würmer, I.
 M.B.P.11
Grosch-Würmer, Ilse
 T.B.P.378
Grose, R.
 T.E.P.71
Grose, Robert N.
 W.E.O.6
Groseclose, S. L.
 Th.A.O.18
Groschen, S.
 Th.B.O.44
Gross, M.
 Th.D.O.9, D.579
Gross, S. A.
 W.D.O.4, W.D.P.61
Grossberg, H.
 T.B.P.284
Grosse, G.
 Th.B.O.22, M.B.P.95,
 M.B.P.120, T.B.P.375,
 W.C.P.60
Grosser, S.
 E.699
Grossi, P.
 M.B.O.31, M.B.O.34,
 M.B.P.75, M.B.P.114
Grossman, A.
 D.629
Grossman, J. I.
 W.A.P.105
Grosvenor, M.
 Th.B.P.307
Grosz, J.
 M.E.O.15
Groth, A.
 Th.B.P.342
Groth, E.
 B.582
**Groupe d'épidémiologie
 clinique (GECSA)**
 W.A.P.80
**Groupe d'épidémiologie
 clinique (GECSA)**
 T.A.P.25, A.635
**Groupe de Travail
 Rétrovirus de la SNTS**
 M.A.P.85
**Groupe Rennais de
 recherche sur le SIDA**
 Th.B.P.10
Grove, T.
 T.C.P.49
Grover, S.
 M.H.O.4
Grover, Steven A.
 W.A.P.79, A.609, M.H.O.7
Grovit, C.
 Th.A.P.92, T.B.P.98
Grove, G.
 W.B.O.27, Th.B.P.7, Th.B.P.20
Gruda, I.
 M.C.P.141
Gruen, R. S.
 M.D.P.38, T.D.P.28
Gruen, Rhoda S.
 T.D.P.73
Gruffydd-Jones, T. J.
 W.C.P.143
Grundt, J. E.
 Th.B.P.22
Grunow, R.
 T.C.P.150
Gruters, R.
 Th.C.O.1
Gryllis, Chrissy
 T.C.P.79
Grønnesby, J. K.
 W.A.P.103, Th.A.P.59, D.722
Grønningseter, Arne
 Th.E.O.11
Gschmitt, F.
 W.B.P.98
Guagnino, L.
 A.582, M.G.P.29
Gualandi, G.
 W.B.P.340
Guareschi, G.
 M.B.P.206, Th.B.P.82,
 W.D.P.84
Guariento, A.
 W.B.P.338
Guarner, J.
 M.B.P.290
Guarner, Jeannette
 M.B.P.62, Th.C.O.38
Guatelli, J.
 Th.C.P.46
Guatelli, John C.
 T.C.P.129
Gubertini, G.
 M.B.P.215, M.B.P.361
Gubish, E.
 T.E.P.61
Gudelin, Marie-Ange
 T.D.P.53
Gudeman, V.
 T.C.P.31
Guder, W.
 M.B.P.35
Gudiol, F.
 M.B.P.43, M.B.P.176,
 Th.B.P.327
Guedet, P.
 M.B.P.383
Guedj, Roger
 M.C.P.93
Gueguen, Monique
 B.535
Guerin, M. C.
 B.561
Guerini, S.
 T.A.P.56
Guerra, C. C. C.
 M.B.P.167
Guerra, L.
 T.D.P.85
Guerreiro, M. D.
 A.512
Guerrero, E.
 T.D.P.92, T.D.P.89, M.E.O.11,
 E.672, M.G.O.25
Guerrero, Ernesto
 W.A.P.94, Th.D.O.10,
 Th.D.O.12, Th.G.O.41,
 Th.G.O.44
Guertler, L.
 T.B.P.349
Guertler, Lutz
 W.G.O.29

- Guétard, D.**
 T.A.P.92, W.C.O.6, Th.C.P.1,
 Th.C.P.4, Th.C.P.85
- Guétard, D.**
 W.B.P.82, W.C.O.46
- Guétard, Denise**
 W.C.P.86, C.583
- Gueye, A.**
 M.A.P.117, W.G.O.20
- Gugel, E.**
 W.C.P.16
- Guglielmo, B. J.**
 M.B.P.234
- Guida, B.**
 W.B.P.346, Th.B.P.51
- Guidugli, R.**
 A.554
- Gulbeneuc, C.**
 Th.A.P.99
- Guillemot, D.**
 T.D.P.88, D.516
- Guillon, J.-M.**
 M.B.P.42, T.C.P.25
- Guimaraes, C. D.**
 T.E.P.60
- Guimaraes, Carmen D.**
 T.E.P.64
- Guimaraes, M. D. C.**
 W.A.P.70, T.B.P.190,
 M.G.P.4, M.G.P.6
- Guimaraes-Dias, M.**
 Th.B.P.66, D.638
- Guimares, Rogério Fiaro**
 M.E.O.4
- Guinan, J.**
 W.D.P.34
- Guinan, J. J.**
 Th.B.P.358, T.D.P.82,
 W.D.P.63, W.D.P.64
- Guinan, James**
 M.A.P.65
- Guindo, A.**
 A.577
- Guiraud, M.**
 T.B.P.373
- Guisharo, L.**
 E.517
- Guisse, Y. M.**
 E.565
- Guisse, Y. Mb.**
 M.D.P.18, Th.E.P.35
- Guisse, Y. N.**
 Th.G.P.23
- Guisth'au, G. O.**
 B.535
- Guisthau, O.**
 W.B.P.75
- Gulakowski, R.**
 C.638
- Guldager, H.**
 T.B.P.24
- Gulizia, R. J.**
 T.C.O.44
- Gullberg, M.**
 C.578
- Gumbly-Smith, D.**
 A.637
- Gumm, R. A.**
 W.A.O.20
- Güngör, T.**
 T.B.P.218, T.B.P.257
- Gunn-Mota, R.**
 W.E.P.7
- Gunnarsson, J.A.**
 W.E.O.15
- Guo, H.**
 C.754
- Guo, Hong-Guang**
 C.680
- Gupta, A.**
 M.B.O.44, M.B.P.371,
 T.B.P.156
- Gupta, Anil**
 T.B.P.254
- Gupta, Asha**
 B.582
- Gupta, P.**
 Th.A.P.92, T.B.P.98,
 W.C.O.10, T.C.P.5, T.C.P.26
- Gupta, Phalguni**
 T.B.P.114, Th.C.O.28,
 M.C.P.133, Th.C.P.14
- Gupta, Sudhir**
 W.C.P.123
- Gupta, Sunetra**
 A.524
- Gurbindo Gutierrez, M. D.**
 T.B.P.172, T.B.P.229
- Gurbindo, Gutierrez**
 W.A.P.4, M.B.P.277
- Gurbindo, Gutierrez M.D.**
 T.B.P.215
- Gurney, M.**
 C.759
- Gürtler, L.**
 T.B.P.360
- Gürtler, Lutz**
 C.624
- Gust, I. D.**
 T.B.P.311
- Gustafson, K.**
 C.638
- Gustafsson, B.**
 T.E.P.76
- Gutbrau, P.**
 Th.H.P.11
- Gutfreund, Klaus**
 Th.B.P.119
- Guthrie, Anne M.**
 M.F.P.13, Th.F.P.3
- Guthrie, C.**
 Th.A.P.115
- Gutierrez, C.**
 E.579
- Gutierrez, R.**
 T.C.P.72
- Gutierrez-Lobos, K.**
 Th.D.P.71
- Gutshall, L.**
 C.671
- Gutterman, E. M.**
 E.581, E.682
- Gutterman, L.**
 D.616
- Gutzwiller, F.**
 W.A.P.117, M.D.P.25, D.636
- Guy, B.**
 Th.C.O.6, M.C.P.31
- Guy, Bruno**
 W.C.O.33
- Guyader, M.**
 T.C.P.115
- Guydish, J.**
 M.D.P.31, W.D.P.74
- Guydish, Joseph R.**
 Th.D.P.33, Th.D.P.34
- Guzmán, L.**
 E.738
- Guzman, M.**
 M.G.O.6
- Gwinn, M.**
 Th.A.O.12, W.D.P.50
- Gwinn, Marta**
 Th.A.O.11, W.D.P.24
- Gyorkey, F.**
 T.B.P.148
- H**
- H'Moud, T.**
 B.589
- Haabeim, L. R.**
 M.C.P.40, C.544
- Haabeim, Lars R.**
 C.545
- Haas, H.**
 D.596
- Haas, Henriette S.**
 D.703
- Haas, Jennifer S.**
 W.B.P.54
- Haas, S.**
 T.B.P.218, T.B.P.257
- Haase, David A.**
 T.B.P.42
- Habermann, R.**
 Th.B.P.45
- Habermehl, K.-O.**
 T.A.P.9, T.B.P.378, T.C.P.37,
 W.C.P.66, W.C.P.122
- Habeshaw, J. A.**
 T.C.P.11, C.514
- Habibi, B.**
 M.B.P.151
- Hachmann, Monika**
 W.D.P.23, T.E.P.70
- Hachouel, M.**
 W.C.P.100
- Hada, M.**
 M.A.P.42, W.B.P.292
- Hadchouel, M.**
 T.A.P.92
- Haddad, L. R.**
 W.B.P.266
- Haddad, Wadad**
 E.770
- Hadderingh, Roel J.**
 M.B.P.203, Th.B.P.349
- Haddon, W.**
 M.A.O.17
- Haden, Bill H.**
 E.718
- Hadler, James L.**
 T.A.O.8
- Hadler, S. C. et al.**
 M.B.P.224
- Hadley, D.**
 W.B.P.82, E.632
- Hadley, W. K.**
 T.B.P.11
- Haefner-Cavallion**
 T.C.P.3
- Haefner-Cavallion, N.**
 C.529
- Haepfy, S.**
 T.C.P.93
- Hafez, S.**
 W.E.P.74
- Hafez, E. S. E.**
 B.501, B.502, C.651, C.682
- Hagan, H.**
 T.A.O.20, Th.D.P.74
- Hagan, Hollis C.**
 Th.D.O.13
- Hagard, S.**
 W.E.O.23
- Hagerty, Cornelia A.**
 B.506
- Haggarty, B. S.**
 Th.C.O.25
- Hague, R. A.**
 T.B.P.211
- Hague, Rosemary A.**
 T.B.P.246, B.590
- Hahn, B.**
 M.C.O.7, W.C.P.79
- Hahn, B. H.**
 T.C.O.19, T.C.P.126,
 W.C.P.84, Th.C.P.132
- Hahn, Beatrice H.**
 T.C.O.20
- Hahn, T.**
 W.C.P.129
- Haidl, S.**
 T.B.P.58
- Haight, V.**
 W.B.P.143
- Haignere, C.**
 T.D.P.12
- Haignere, Clara**
 D.506

- Haigwood, N.
W.C.P.8
- Haigwood, Nancy L.
Th.C.0.31
- Hains, B.
T.C.P.99
- Haislip, A. M.
W.C.O.47
- Hakulinen, J.
A.509
- Hales, M.
W.B.P.349, Th.B.P.355
- Haley, Charles
T.D.P.11
- Haley, Charles E.
M.A.P.120, T.A.P.21,
W.A.P.39, W.A.P.81,
Th.A.P.48, M.D.P.29,
Th.D.P.37, E.551, E.552,
E.639, E.720
- Halliburton, B.
T.D.P.22
- Halligen, G.
T.C.P.99
- Hall, J. Y.
M.D.O.11
- Hall, L.
Th.D.P.9
- Hall, Thomas L.
A.639
- Hall, W.
T.C.P.53
- Hall, W. W.
M.B.P.4
- Hall, William W.
Th.C.P.5
- Halligen, G. E.
C.612
- Hallman, David
W.F.O.16
- Halloran, Mary E.
Th.A.P.41, W.D.P.83
- Halsey, N.
W.A.P.7, M.B.P.31,
Th.B.P.368, W.C.P.96,
T.D.O.32, T.G.O.19,
T.G.O.29, T.G.O.21,
Th.G.O.61, Th.G.P.2
- Halsey, Neal A.
T.A.O.18
- Ham, J.
Th.D.P.5
- Hamb, A.
A.562, W.B.P.260
- Hamblyn, Julie C.
M.F.P.10
- Hambraeus, Lars
M.E.P.32
- Hamburg, M.
T.G.P.17
- Hamel, D.
C.522
- Hammerschlak, N.
D.709
- Hammerschlak, Nelson
B.S.P.167
- Hamidi, C.
W.H.O.17
- Hamidi, Cyrus
T.A.P.68, T.A.P.77, A.530
- Hamil, J.
T.D.P.60
- Hamill, D.
Th.A.P.54, Th.A.P.78, E.633
- Hamilton, Brian R.
D.536
- Hamilton, J.
W.D.P.25
- Hamilton, J. R.
W.B.P.10
- Hamilton, John
T.B.P.118
- Hamilton, R.
Th.B.O.29
- Hamm, B.
W.B.P.33
- Hammar, Lena
M.C.P.26, Th.C.P.26
- Hammarskjöld, Björn P.
Th.C.P.122
- Hammarskjöld, M.-L.
T.C.O.6, T.C.P.81,
Th.C.P.121, Th.C.P.122
- Hammarskjöld,
Marie-Louise
T.C.P.80, T.C.P.133
- Hammek, R.
T.B.P.109
- Hammel, G.
T.B.P.301, M.E.P.57, E.606
- Hammer, Glenn S.
T.B.P.29
- Hammer, S.
Th.C.P.93
- Hammerle, Christoph H. F.
W.C.P.32
- Hammerschlak, N.
W.B.P.116
- Hammett, Theodore M.
M.F.P.4
- Hammond, Gregory W.
W.D.P.20, Th.D.P.56
- Hampf, H.
T.B.P.349
- Hampf, Hartmut
T.G.O.5
- Han, Y.
W.H.P.10
- Hanafi, L.
E.687
- Hanan, E. P.
M.E.P.66
- Hanan, J. L. L.
W.D.P.38, Th.D.P.89,
M.E.O.17
- Hanan, Janete L. L.
Th.E.P.19, E.591,
- Hanchard, B.
B.639
- Hancock, D.
W.E.P.24
- Hand, I. L.
W.A.P.5
- Hand, L.
T.B.P.159
- Handsfield, H.
Th.B.P.270
- Handsfield, H. H.
W.C.P.112
- Handsfield, H. Hunter
M.A.P.81
- Handsfield, Hunter
Th.A.O.9
- Handsher, R.
Th.B.P.118
- Handzel, Z. T.
W.C.P.129
- Handzel, Zeev T.
M.A.P.59
- Hanff, P.
T.B.P.7
- Hankins, C. A.
M.A.P.39, M.B.P.17,
M.D.P.33, Th.E.P.26
- Hankins, Catherine A.
M.A.P.23, Th.A.P.39
- Hann, W.
Th.A.O.34
- Hanna, Z.
M.C.O.11, W.C.O.28
- Hanna, Zaher
T.C.P.138
- Hannan, Thomas
C.601
- Hannema, H. I.
T.D.P.47
- Hannen, Tom
T.H.O.6
- Hannon, A.
E.643
- Hannon, H.
W.A.O.12, W.B.P.175
- Hannon, Harry W.
W.B.P.174
- Hansell, S.
Th.D.P.15, E.700
- Hansen, John-Erik S.
Th.C.P.60, Th.C.P.61
- Hansen, T. N.
T.B.P.236
- Hanson, C.
Th.A.P.90, T.B.P.175
- Hanson, C. V.
Th.C.O.45
- Hanson, I.
M.B.P.305, T.B.P.148
- Hanson, I. C.
T.B.P.236
- Hanson, I. Celine
T.B.P.266
- Hanson, L. H.
W.B.P.10
- Hanson, M.
Th.B.P.348
- Hanson, Margaret
E.730
- Hanson, Peter J. V.
A.601
- Hansson, B. G.
W.B.P.280
- Hansson, L. O.
Th.B.P.226
- Harada, S.
Th.C.P.28
- Harada, Shinji
W.C.O.38
- Harawitz, S.
E.728
- Harbison, Mary A.
Th.C.P.93
- Harbour, D. A.
W.C.P.143
- Hardefelt, M.
W.C.P.65
- Hardie, John
E.801
- Hardikar, S.
D.986, E.716
- Hardin, M.
D.506
- Harding, Timothy
T.D.O.1
- Hardy, Ann M.
W.A.O.26, W.E.P.31
- Hardy, D.
M.B.P.123, Th.C.P.248
- Hardy, Daniel B.
Th.A.P.7
- Hardy, Iain R.
M.G.P.18
- Hardy, J.
T.B.P.132
- Hardy, W.
W.A.P.40, Th.A.P.92,
Th.B.P.199, Th.B.P.249,
Th.C.P.106
- Hardy, W. D.
W.B.P.254
- Hardy, W. David
T.B.P.46
- Harelimana, Fidele
M.B.P.188
- Hargous, M. L.
W.B.P.364
- Hargreaves, F. D.
T.B.P.211, T.B.P.246,
Th.C.P.105
- Harismides, M.
T.B.P.75
- Harkavy, J.
W.B.P.214

- Harnie, S.
M.B.P.271
- Harnish, D. G.
T.B.P.110
- Haroche, G.
M.D.P.68
- Harouse, J. M.
W.C.P.70
- Harouse, Janet M.
W.C.P.76
- Harper, Mary, E.
T.C.P.18
- Harper, R. G.
M.B.P.4
- Harrer, T.
T.D.P.46
- Harrer, Thomas
W.A.P.53, M.C.P.56
- Harrington, M.
E.690, E.692, E.760
- Harrington, Mark
W.B.P.257, Th.E.P.20, E.541,
Th.G.P.10, Th.G.P.11,
T.H.P.15
- Harris, Allen
E.532
- Harris, D.
E.810
- Harris, Dai
T.F.O.2, Th.F.P.9, W.H.O.4
- Harris, J.
W.A.P.40, W.D.P.81
- Harris, J. R.
W.A.P.98, T.G.P.1, W.G.P.7
- Harris, J. R. W.
M.B.P.326, W.B.P.58,
W.B.P.59, E.521
- Harris, M.
M.B.P.122
- Harris, N.
M.A.P.81, T.A.P.57,
W.A.P.104, Th.B.P.141
- Harris, N. L.
Th.C.O.7
- Harris, N. V.
W.A.P.6
- Harris, Richard L.
Th.E.P.15
- Harris, S.
T.B.P.70
- Harris, V.
M.B.P.320, E.612, E.640
- Harrison, J.
W.B.P.57, M.D.P.28
- Harrison, J. S.
M.A.O.27
- Harrison, Janet S.
M.D.P.24
- Harrison, L.
B.627
- Harrison, M.
W.B.P.185, M.H.P.22
- Harrison, M. J. G.
Th.B.P.287
- Harrison, V.
E.612
- Harrold, L.
M.F.P.4
- Hart, A. R.
Th.C.P.116
- Hart, Clyde E.
T.C.P.83
- Hart, D.
W.B.P.164
- Hart, G.
M.D.P.15
- Hart, Graham J.
T.A.O.9
- Hart, L.
W.B.P.123
- Hart, R.
Th.G.P.14
- Hart, S.
Th.C.O.35
- Hartel, D.
Th.A.P.101
- Hartel, D.
Th.A.O.24, Th.A.O.32,
M.B.P.8, Th.D.O.16, Th.D.P.78
- Hartel, Diana
Th.D.O.2, Th.D.P.59
- Hartfield, K.
M.E.P.11
- Hartfield, K. A.
M.E.P.17
- Hartgers, Christina
T.A.O.21
- Hartigan, P.
T.B.P.118, W.D.P.25
- Hartigan, P. M.
M.B.P.104
- Hartie, H. T.
C.749
- Hartley, T. M.
W.C.P.4
- Hartley, Trudie M.
Th.B.P.173
- Hartman, N. R.
Th.B.O.4
- Hartman, Neil R.
W.B.P.275
- Hartmann, M. G.
W.C.P.117
- Hartquist, C.
Th.E.P.41
- Harvell, I.
B.595
- Harvey, R. L.
M.B.P.147
- Harwell, J.
W.A.P.82
- Harzic, M.
B.561
- Hasan, Mohamed A. E.
E.650
- Hasegawa, A.
M.C.O.5
- Haseltine, W.
M.C.O.22, T.C.O.49,
W.C.O.34, Th.C.P.90
- Haseltine, William
W.C.O.3
- Haseltine, William A.
C.789
- Hasford, J.
M.D.P.66, E.607
- Haslund, I.
W.A.P.81
- Hasner, A.
T.A.P.2, Th.B.P.118
- Hassan, N.
Th.C.P.101
- Hassan, Rashidah Lorraine
M.E.O.21
- Hasselvedt, Viggo H.
A.607
- Hassig, E. E.
M.D.P.49
- Hassig, S.
M.A.O.35, B.625, T.D.O.35,
W.G.O.4, W.G.P.9, T.H.O.8
- Hassig, S. E.
M.D.O.3, M.D.O.17, M.D.P.13,
T.E.P.4, W.G.P.20,
- Hassig, Susan E.
T.B.P.204, W.D.O.6,
W.E.P.65, Th.E.P.1, W.G.P.8,
T.H.O.9
- Hastings, J.
W.C.P.76
- Hatch, W.
W.C.P.81, C.715, C.741
- Hathaway, J.
Th.F.O.3
- Hattori, Y.
M.C.P.5
- Hatzakis, A.
Th.B.P.17
- Hatzakis, Angelos
M.A.P.89, M.A.P.109,
W.C.P.140
- Hauer, L. B.
M.B.P.33, M.B.P.54, T.B.P.198
- Haughton, K. A.
E.808
- Haus, E.
W.C.P.81
- Hausen, A.
W.B.P.79, C.563
- Hausler, R.
Th.B.P.280
- Hausler, William J.
T.B.P.333
- Hausner, M. A.
T.C.P.31
- Hausser, D.
W.A.P.116, D.636
- Hausser, Dominique
W.A.P.117, E.739
- Hauw, J.-J.
W.B.O.18, Th.B.P.250
- Hauw, Jean-Jacques
Th.B.O.21, Th.B.P.258
- Havassy, B. E.
Th.E.P.13
- Havens, Jennifer F.
W.B.P.211
- Haverkos, Harry W.
A.621, E.637, E.681
- Hawk, H.
M.B.P.365
- Hawkes, C.
Th.B.O.45
- Hawkins, D.
M.B.P.209, T.B.P.66,
T.B.P.326, W.B.P.17,
W.B.P.201
- Hawkins, D. A.
M.B.P.115, M.B.P.262,
W.B.P.47, M.H.P.3
- Haworth, A.
T.G.P.16
- Hawthorne, C.
M.B.P.333
- Hawthorne, C. A.
W.C.O.27, Th.C.P.114,
Th.C.P.119
- Hay, Phillip E.
W.B.P.58, W.B.P.59
- Hayami, M.
M.C.O.5, W.C.P.2
- Hayami, Masanori
M.C.O.5, M.C.O.25, T.C.O.25
- Hayashi, S.
Th.C.O.13, M.C.P.135
- Hayden, C. H.
W.A.P.109
- Hayes, B. J.
Th.D.O.9
- Hayes, C.
T.B.P.377
- Hayes, Curtis G.
W.B.P.152, Th.G.O.25
- Hayes, K.
M.B.P.124, M.C.P.68,
M.C.P.69
- Hayes, M. M.
C.738
- Hayes-Cozier, R.
M.A.O.43, E.503
- Hayman, C. L.
M.D.P.1
- Haynes, J.
T.C.P.16
- Haynes, K.
W.D.O.4
- Haynes, Katherine
W.D.P.28
- Haynes, M.
T.E.P.11

- Hays, Robert
T.D.O.19
- Hays, Robert B.
T.D.P.57
- Hayward, Rodney A.
W.B.P.251
- Haywood, M. D.
T.B.P.121
- Hazan, U.
W.C.P.121
- Hazan, Uriel
C.859
- Hazan, V.
C.825
- Hazard, Mabel W.
D.861
- Hazell, M.
E.810
- Hazout, S. H.
C.643
- Healey, D.
C.528
- Healey, Donald G.
C.538
- Healton, C.
M.E.P.87
- Heaphy, S.
T.C.O.29
- Hearn, T. L.
T.B.P.142, T.B.P.143
- Hearn, Thomas L.
T.B.P.141
- Hearst, N.
W.A.P.24, W.D.P.74,
W.G.O.24
- Hearst, Norman G.
T.A.O.7
- Heath, C. W.
T.A.P.81
- Heath-Chiozzi, Margo E.
T.B.P.7, W.B.P.252
- Heaton, R.
W.B.P.182
- Heaton, R. K.
W.B.P.223, W.B.P.230,
W.B.P.233, Th.B.P.195,
Th.B.P.262
- Hébert, Martin
T.F.O.8
- Heckert, K. A.
E.530, E.695
- Heckert, Karen A.
D.538, D.660
- Heckmann, W.
M.D.P.36, Th.D.P.86
- Heckmann, Wolfgang
E.792
- Hedaya, M. A.
Th.B.P.198, Th.B.P.204
- Hedaya, Mohsen A.
W.B.O.4, M.B.P.339
- Hedderman, M.
T.A.P.67
- Hedderman, Michael
M.E.P.85
- Hedge, Barbara
T.D.O.18, D.571
- Heegaard, P.
Th.C.P.60, Th.C.P.61
- Heffner-Barrett, Cathy L.
Th.C.P.108
- Heffron, P.
A.830
- Heffron, Phyllis B.
W.A.P.112
- Heffron, P.
M.D.P.63, D.634
- Heifer, H.
Th.B.P.265
- Heggs, Amanda
W.D.O.14, D.689, M.E.O.1
- Heter, J.
T.A.O.26
- Heimdal, A.
B.576
- Heimer, J.
T.C.P.80
- Heim, K.
T.D.O.27
- Heinrich, B.
W.D.P.3
- Heinrich, B.
M.B.P.64, W.B.P.92,
Th.B.P.168, Th.B.P.244,
B.516, C.574, E.764
- Heinrikson, R. L.
T.C.P.85
- Heins, B.
W.C.P.86, C.612, C.613
- Heinz, F. X.
W.B.P.99
- Heinze-Lacey, B.
T.A.P.74, Th.A.P.98
- Heinze-Lacey, Beverly
T.A.O.2
- Heirich, M.
W.B.P.67
- Heise, W.
Th.B.O.22, M.B.P.95,
Th.B.P.28, Th.B.P.260,
W.C.P.60
- Heise, Walter
M.B.P.120, T.B.P.375,
Th.B.P.45
- Heise-Quatiere, J.
M.H.P.26
- Heise-Quatiere J. M.
M.C.P.147
- Heisig, V.
T.C.O.15
- Heisig, Volker
W.C.P.116
- Heitzmann, C.
Th.D.P.84
- Helal, H.
M.A.O.24
- Helbert, M.
M.B.P.244, C.610
- Heldge, D.
T.H.P.10
- Helenor, R.
T.A.P.12
- Helfrich, R.
C.694
- Helgaodottir, Hildur
M.B.P.321
- Helgerson, S. D.
A.519
- Helgmann, Larry
Th.E.P.2
- Helina, A.
T.E.P.21
- Heller, J. S.
M.B.P.140, M.B.P.164
- Heller, Todd D.
W.B.P.38
- Hellingner, Fred J.
W.H.O.15
- Hellings, J. A.
W.B.P.96, W.B.P.126,
W.B.P.132
- Helm, E. B.
M.A.P.103, Th.A.P.96,
M.B.P.76, M.B.P.210,
T.B.P.73, W.B.P.334,
Th.B.P.59, Th.B.P.60,
Th.B.P.334
- Helm, M.
W.A.O.9
- Helm, E. B.
T.A.O.15
- Helmstadter, C.
W.B.O.42, Th.B.P.192
- Helquist, M.
W.E.P.57, W.E.P.64, E.576
- Helquist, Michael
Th.E.P.65, E.574, E.575,
E.597, E.631, E.671
- Hemme, A.
M.E.P.38
- Hemming, Anna M.
C.783
- Heus, G. M.
Th.B.P.303
- Henderson, B. E.
Th.B.O.44
- Henderson, David K.
M.D.P.73, M.D.P.88
- Henderson, J.
W.D.P.39
- Henderson, J. F.
M.C.P.73
- Henderson, R.
T.D.P.90
- Hendrick, B. B.
Th.B.P.163
- Hendricks, M.
Th.B.P.208
- Hendricks, R.
T.C.P.28
- Hendricksen, C.
B.555
- Hendricks, C.
M.A.P.49
- Hendrix, C. W.
T.B.P.295
- Hendrix, Craig W.
M.C.P.85
- Hendrix, J.
T.B.P.82, W.B.P.343
- Hendrix, L. E.
M.B.P.290, Th.C.O.38
- Hendry, R. M.
M.C.P.36, T.C.P.69, W.C.P.95
- Hendry, R. Michael
C.520
- Heneman, C.
W.A.P.2
- Hengster, P.
T.C.P.12, T.C.P.68
- Hénin, D.
Th.B.O.21, Th.B.P.258,
W.C.P.100
- Hénin, Dominique
W.B.O.18, Th.B.P.196,
Th.B.P.250
- Henin, H. D.
C.699
- Henin, Y.
M.C.P.104, T.C.P.116, C.658
- Henke-Quinn, W.
W.A.O.28
- Henkes, H.
Th.B.P.260, Th.B.P.274
- Henkes, Hans
Th.B.O.23
- Henneman, C.
W.A.O.11
- Hennin, Y.
M.C.P.4
- Henrion, G.
T.B.P.113
- Henrion, R.
M.A.P.15, Th.E.P.23
- Henrivaux, P.
M.B.P.340, Th.B.P.103
- Henrivaux, Philippe
Th.B.P.145, D.655
- Henry, K.
M.A.P.70, M.A.P.72,
M.B.P.85, M.D.O.13,
M.D.O.16, M.D.P.56, D.555,
D.626, T.E.P.39, Th.E.P.29
- Henry, Keith
M.D.P.57, M.D.P.89, W.E.P.73
- Henry, S.
Th.B.P.109, Th.C.P.42
- Henry, W. K.
W.B.P.315
- Hensley, G.
W.B.P.51

- Hensley, R.
Th.B.P.102
- Herb, Alice
Th.F.02
- Herb, F.
Th.D.04
- Herberman, R. B.
W.C.O.10
- Herbert, B.
Th.D.P.10
- Herbert, Barbara L. A.
T.E.P.35
- Herbert, Daniel
T.E.O.5
- Hercot, R.
D.655
- Herd, D.
T.B.P.66
- Herdewijn, P.
M.C.P.76
- Herek, Gregory M.
M.E.P.3
- Herman, Bruce A.
W.A.P.101
- Herman, C.
M.B.O.35, Th.B.P.238,
Th.B.P.271
- Herman, W. A.
W.A.P.101
- Hermann, Claudia
T.D.P.46, D.654
- Hermans, P.
W.A.O.19
- Hermida, J. M.
Th.B.P.268
- Hermoso, A.
A.615
- Hernandez Sampelayo, T.
T.B.P.215
- Hernández, Eugenia
A.618
- Hernandez, H.
W.B.P.115, G.518
- Hernandez, M.
T.G.P.27, W.G.P.24
- Hernandez, S.
T.H.O.4, M.H.P.6
- Hernandez, Sandra R.
M.H.P.7
- Hernandez-Sampelayo, T.
T.B.P.229
- Hernandez-Sampelayo,
Teresa
T.B.P.172
- Hernier, B.
M.B.P.288, Th.C.O.35
- Hernier, Brian G.
Th.C.O.37
- Herne, H.
M.B.P.25
- Herne, P.
M.B.P.26
- Herns, M. V.
Th.B.P.287
- Herns, Mary V.
W.B.P.185
- Herpin, B.
Th.B.O.43
- Herranen, A.
T.B.P.128
- Herrera, C.
M.G.P.19
- Herrera, J.
W.A.P.4
- Herrera, L.
W.B.P.97, B.602
- Herrera, L. R.
W.B.P.168
- Herrick, M.
M.G.O.4
- Herrin, R.
E.612
- Herring, M.
T.H.O.5
- Herring, N.
M.A.O.5
- Hershe, E.
W.B.P.287, Th.C.O.4,
T.C.P.75, W.C.P.19
- Hershler, R.
Th.A.P.33
- Hershman, D.
Th.B.P.276
- Hershman, K.
Th.A.P.25
- Hertz, R.
T.D.P.18
- Hery, C.
W.C.P.113
- Herzberg, M.
M.B.O.25
- Heseltine, P.
E.732
- Heseltine, P. N. R.
W.B.O.45, Th.B.P.277
- Heseltine, Peter
W.B.P.286
- Hess, G.
M.B.P.220, Th.B.P.119,
W.D.P.54, Th.D.P.23
- Hess, J.
W.C.P.17
- Hesselink, J.
Th.B.P.262
- Hesseltine, P.
M.B.P.300
- Hesselton, Ruthann M.
M.C.P.17
- Hessol, N. A.
T.A.O.32, W.A.P.46,
Th.A.P.86, M.B.P.224
- Hessol, Nancy A.
M.A.O.27, M.A.P.111
- Hethcote, Herbert W.
Th.A.P.52
- Hewitt, P.
M.B.P.155
- Hewlett, I.
W.B.P.154
- Hewlett, I. K.
M.B.P.333, Th.C.P.119
- Hewlett, Indira K.
M.A.O.33, W.C.O.27,
Th.C.P.114
- Heyderman, E.
M.B.P.58
- Heyer, David M.
W.B.O.19
- Heyes, M.
W.B.P.194, Th.B.P.227
- Heyes, Melvyn P.
Th.B.P.232
- Heyman, R.
T.B.P.18
- Heymann, David
T.A.O.41
- Heymsfield, S.
Th.B.P.312
- Heynes, C. A.
Th.C.P.37
- Heyward, W.
T.B.O.10, T.B.P.119,
W.G.O.27, Th.G.O.1
- Heyward, W. L.
E.719
- Heyward, W. M.
Th.A.P.109
- Heyward, William L.
W.B.P.113
- Hickey, T.
M.A.P.11
- Hicks, J.
Th.B.P.323
- Hidalgo, J.
T.A.P.68, T.A.P.77
- Hidalgo, Julia
Th.B.P.216, W.H.O.17,
W.H.P.8, W.H.P.11
- Hidvégi, T.
Th.B.P.139
- Higgins, D. L.
T.D.P.27, T.D.P.39, E.717
- Higgins, Donna L.
M.D.P.32
- Higgs, J.
Th.B.P.141
- High, K.
M.B.P.332
- Highfield, P. E.
Th.C.P.124
- Higuchi, M. H.
B.512
- Hilberg, Charles F.
M.B.O.26
- Hildebrandt, D.
T.A.P.112
- Hilfenhaus, J.
M.C.P.44
- Hilgartner, M.
Th.B.P.8
- Hilgartner, M. W.
Th.A.O.26
- Hill, C. A.
T.D.P.2
- Hill, D.
W.A.O.11
- Hill, Deirdre A.
M.A.P.12
- Hill, E.
M.B.P.47
- Hill, F.
W.B.P.314, T.C.P.105
- Hill, F. G. H.
W.B.P.87
- Hill, Joseph A.
A.625
- Hillard, P.
Th.E.P.63
- Hiller, Klaus F.
M.B.P.60
- Hillier, W.
E.569
- Hillman, K.
Th.C.O.2, W.C.P.57
- Hills, D.
T.B.P.64
- Hillmarsdottir, I.
T.B.P.13
- Hillsor, D.
Th.H.P.30
- Hilton, M.
T.B.P.52, W.B.P.343
- Hinderer, W.
W.B.P.94
- Hindin, R. H.
W.A.P.12
- Hindin, Rita H.
T.A.P.70, T.A.P.71
- Hines, A.
T.H.P.22
- Hines, S.
W.A.P.47, M.B.P.12,
T.B.P.210, T.B.P.238
- Hing, M.
T.C.P.123
- Hingson, R.
E.723
- Hingson, Ralph W.
T.D.O.24
- Hinkin, C.
B.559
- Hinkula, J.
T.C.P.65
- Hinman, A. R.
A.533
- Hintz, E.
M.H.P.18
- Hipp, S.
M.A.P.71
- Hippolithe, R.
M.A.O.29

- Hira, S.
T.B.P.337, D.723, M.G.P.23
- Hira, S. K.
M.A.O.37, M.A.O.42,
Th.G.P.30
- Hira, Subhash
Th.G.O.16
- Hira, Subhash K.
Th.A.O.5, W.A.P.50,
W.A.P.54, T.B.P.371,
M.G.O.22, Th.G.P.5
- Hirai, K.
Th.C.P.56
- Hiramani, A. B.
E.647
- Hirano, T.
T.C.P.19
- Hirel, Ph.-Hervé
C.662
- Hirots, G.
C.562
- Hirose, K.
Th.C.P.110
- Hirsch, A.
T.B.P.26
- Hirsch, I.
T.C.P.91
- Hirsch, M.
Th.C.P.13
- Hirsch, M. S.
A.600, Th.B.O.10, M.C.P.97
- Hirsch, R.
M.H.P.24
- Hirsch, V.
W.C.P.12
- Hirsch, V. M.
W.C.O.30, W.C.O.50
- Hirsch, Vanessa M.
T.C.O.43
- Hirschel, B.
Th.B.P.58, Th.B.P.280,
Th.D.P.80
- Hirschkorn, D.
T.B.P.85
- Hirschman, S. Z.
T.B.P.29
- Hirschorn, E.
E.728
- Hiscott, J.
T.C.P.118
- Hitchcock, M. J. M.
M.C.P.74, M.C.P.96
- Hite, E.
W.A.P.113
- Hitimana, D. G.
T.B.P.374, W.G.O.6
- Hittleman, Joan
M.B.O.42, T.B.P.180
- HIV Blood Donor Study
Group
M.D.O.2
- HIV Newborn Coll. Study
Grp.
Th.C.P.7
- HIV Subcommittee
E.530
- Hivert, P.
Th.B.P.11
- Hizi, A.
C.666
- Ho, D.
M.G.P.14, M.G.P.20
- Ho, D. D.
Th.B.O.8, M.B.P.140,
W.B.P.159, M.C.P.24,
T.C.P.34, M.G.P.12, M.G.P.13
- Ho, David D.
Th.C.P.138
- Ho, Hsu-Tso
M.C.P.96
- Ho, M.
W.A.P.41, Th.A.P.95,
M.B.P.338, M.B.P.355,
T.B.P.114, W.B.P.303,
M.C.P.133
- Ho, Y. F.
W.G.P.30
- Hochkeppel, H.
M.C.P.81
- Hochlowski, J.
C.694
- Hockenberry, Clint
T.F.O.6, Th.F.P.13
- Hodges, T.
T.B.P.303
- Hoegsberg, Bente
Th.D.P.60
- Hoff, C. C.
W.D.O.2
- Hoff, R.
W.A.O.12, M.A.P.14,
W.B.P.136
- Hoff, R. A.
W.D.P.80
- Hoff, Rodney
T.B.P.150
- Hoffenbach, A.
W.C.P.5
- Hoffenbach, Agnès
T.C.P.67, T.C.P.78
- Höfken, G.
W.B.P.33
- Hoffken, Gert
W.B.P.278, W.B.P.372
- Hoffman, A.
Th.C.P.48
- Hoffman, M.
T.A.P.2
- Hoffman, P.
T.C.P.10
- Hoffman, X.
D.602
- Hoffmann, G. W.
T.C.P.60
- Hoffmann, Geoffrey W.
W.C.P.130
- Hoffmeister-Barcellos, S.
T.B.P.113
- Hofner, L. K.
T.B.P.339
- Hofman, Florence M.
T.C.P.17
- Hofmann, B.
W.A.P.62, Th.C.P.143
- Hofmann, Bo
Th.B.O.25, W.C.P.104
- Hofmann, W.
M.B.P.35
- Hofnung, M.
T.C.P.116
- Hogan, T.
E.584, E.619
- Hogan, V.
T.B.P.359
- Hogarh, S.
D.617
- Hoggan, M. D.
M.C.P.95
- Hoke, G. M.
Th.C.P.43
- Holbrook, D.
T.E.P.58
- Holcenberg, J. S.
C.593
- Holcombe, Hilda R.
W.C.P.39
- Holden, W.
B.574
- Holder, L.
W.A.P.113
- Holding-Cobham, M.
W.G.P.26
- Holford, T. R.
M.A.P.93
- Hollán, S. R.
T.B.P.96, M.C.P.146
- Holland, B.
Th.A.O.23, M.B.P.29
- Holland, H. K.
T.B.P.285, W.B.P.319
- Holland, P.
M.A.P.30
- Holland, P. .
W.B.P.150
- Holland, R.
W.B.P.270
- Holland, Steven M.
Th.B.O.30
- Hollander H.
M.A.P.31
- Hollander, H.
T.A.P.76, M.B.O.20,
W.B.O.44, M.B.P.193,
M.B.P.334, T.B.P.25,
Th.B.P.340, Th.C.O.36,
T.C.P.61, T.H.O.1
- Hollander, Harry
M.B.O.50
- Hollerer, E.
Th.D.P.71
- Hollinger, F. B.
T.B.P.121
- Hollinger, F. Blaine
T.B.P.117, T.B.P.122,
T.B.P.148
- Hollis, S. L.
W.A.O.20, W.A.P.87
- Holloway, W.
T.B.P.45
- Holm, Jim
W.E.O.9
- Holman, R. C.
W.B.O.23
- Holman, S.
T.B.P.240, W.D.P.58
- Holmberg, J.
Th.A.P.28
- Holmberg, S.
T.A.P.119
- Holmberg, S. D.
M.A.O.30, Th.A.P.87, B.549
- Holmberg, S. H.
Th.A.O.16
- Holmberg, Scott D.
M.A.O.46
- Holmberg, V.
W.B.P.83
- Holme, P.
T.B.P.7
- Holmes, E.
C.510
- Holmes, J.
T.E.P.14
- Holmes, K.
M.B.P.53
- Holmes, K. K.
B.551, E.731
- Holmes, R.
M.A.O.28
- Holmes, Valerie F.
B.611
- Holmes, W. S.
Th.A.P.60
- Holody, T.
T.B.P.102
- Holt, E.
T.A.O.18, T.G.O.19, Th.G.P.2
- Holt, E. A.
M.B.P.233
- Holt, Elisabeth
Th.G.O.51
- Holt, W.
E.740
- Holton, D.
Th.C.O.3
- Holton, Donna
M.A.P.110
- Holtzman, D.
M.A.P.6

- Holtzman, Deborah
W.A.P.18
- Holzemer, S.
C.834, C.639
- Holzemer, Stephen P.
M.B.P.301, M.B.P.303
- Holzer, Timothy J.
Th.C.P.37
- Holzman, R.
T.A.O.17, W.B.P.134,
W.B.P.353
- Holzman, R. S.
M.B.P.70, M.B.P.77, T.B.P.46
- Holzmann, H.
M.B.P.365
- Horn, R.
Th.C.O.49
- Houmes, Mirjam J. T.
Th.B.O.38
- Homsy, J. J.
M.C.O.1
- Homsy, Jacques
T.C.O.21, Th.C.P.49
- Honda, M.
Th.B.P.83
- Honderlick, P.
B.503
- Honderlick, P. H.
W.B.P.106, B.619
- Honey, J.
T.A.P.72, W.A.P.82,
W.A.P.104
- Honeycutt, H.
M.A.P.73
- Hong, Barry A.
M.B.P.383, T.B.P.384
- Honjo, S.
W.C.P.2
- Honma, H.
E.625
- Honnen, W.
Th.B.P.8
- Honnen, W. J.
T.C.P.70
- Honoré, C.
Th.B.O.54, W.B.P.107,
T.C.P.100, W.C.P.40
- Hood, H. V.
M.D.P.22
- Hood, M. V.
M.D.P.21
- Hook, E.
M.B.O.35, W.B.P.52
- Hook, E. W.
T.B.P.127
- Hook, III, E. W.
Th.A.O.18, M.A.P.68
- Hooley, J.
Th.C.O.2
- Hooper, E. Y.
W.A.P.23, A.519
- Hooton, T.
A.602
- Hoover, D.
M.C.O.15
- Hoover, E. A.
M.C.O.12, W.C.O.13,
W.C.O.31
- Hooykaas, Crista
T.A.P.14
- Hopewell, P.
T.B.O.26
- Hopewell, P. C.
T.B.O.27, T.B.P.11
- Hopewell, Phil
M.B.O.12
- Hopkins, Karen
M.E.O.15
- Hopkins, S.
M.A.P.61, W.A.P.82
- Hopkins, S. G.
W.A.P.6
- Hopkins, Sharon G.
T.A.P.72, W.A.P.104,
M.H.O.15
- Hoppenjans, W. B.
M.B.P.178
- Hopper, Cheridad
W.C.P.143
- Hopsicker, J.
Th.B.O.8
- Horai, P.
W.B.P.125
- Horai, Peter
T.C.O.37
- Horan, Hubert J.
D.591
- Horan, J.
Th.E.P.32
- Horman, J. T.
A.530
- Horn, J.
M.B.P.10, T.D.P.76, Th.D.P.10
- Horn, Janet
Th.D.P.24
- Horn, William F.
Th.B.P.302
- Hornor, June
A.630
- Hornor, M.
W.E.O.10
- Hornor, M. J.
W.A.P.112
- Hornik, R.C.
E.614
- Horning, L.
B.550
- Hornaung, R.
Th.A.P.111
- Horowitz, R. M.
D.512, Th.E.O.9
- Horsburgh, C. R.
T.A.O.36, Th.A.O.16,
Th.A.P.42, T.C.P.82
- Horsburgh, C. Robert
Th.A.O.32, B.549
- Horsburgh, C. P., Jr.
Th.A.P.114
- Horsburgh, Robert C., Jr.
Th.A.P.87
- Horton, A.
M.B.P.318
- Horton, Jacqueline A.
M.A.P.2
- Horváth, A.
W.C.P.92
- Hosein, B.
M.B.P.152
- Hoshino, H.
M.C.P.121, Th.C.P.134
- Hosokawa, R.
M.D.O.10
- Hospedales, J.
Th.G.P.27, Th.G.P.28
- Hossain, M. Z.
Th.D.P.20, Th.E.P.76
- Hosseini, M.
T.B.P.129
- Hostetler, Karl Y.
Th.C.O.18
- Hostetter, C.
W.E.O.10, M.E.P.49,
Th.E.P.64, Th.P.3
- Hoth, D.
T.B.O.28, T.E.P.51
- Hoht, Daniel
W.B.O.50
- Hough, G.
W.B.P.218, M.E.P.68
- Houle, L.
W.B.P.360
- Houle, Linda
W.B.P.356
- Houlihan, C.
B.526
- Houston, S.
M.A.P.87, M.B.P.289,
Th.B.P.217, Th.G.O.6
- Houston, Stan
Th.A.P.5
- Houston-Hamilton, A.
M.E.O.34, T.E.P.7
- Houston-Hamilton,
Amanda M.
E.791
- Houvardis, S.
E.769
- Houweling, H.
A.593
- Houweling, Hans
T.D.P.34, G.520
- Houweling, J.
M.A.O.47
- Hovanessian, A. G.
T.C.O.36, Th.C.P.85
- Hovanessian, Ara G.
T.C.O.5
- Howard, John J.
A.538
- Howard, R.
W.B.P.153
- Howell, D. A.
M.B.P.247
- Howell, Embry M.
W.E.P.70
- Howells, J.
A.617
- Hower, Barbara J.
E.615, E.696
- Howland, K.
T.C.P.23
- Hoxie, J.
M.C.O.20, M.C.O.21,
W.C.O.12
- Hoxie, J. A.
T.C.O.20, W.C.O.25,
Th.C.P.149, C.653
- Hoxie, James A.
Th.C.O.25
- Hoxie, N. J.
M.A.P.22
- Hoy, J.
T.B.P.44
- Hoy, Jennifer F.
M.B.P.124, T.B.P.311
- Hoyle, P. C.
M.C.P.61
- Hoyos, M.
T.E.P.32
- Hrushesky, W.
W.C.P.81
- Hsia, Karen
W.C.P.133
- Hsieh, F.
T.C.O.32
- Hsieh, H. C.
C.740
- Hsu, M.-Y.
W.B.P.124
- Hu, Dale J.
M.E.P.4
- Hu, S.-T.
T.C.P.143
- Hu, S. L.
Th.C.O.34, M.C.P.11
- Hu, Shiu-Lok
W.C.P.10, Th.C.P.95
- Hu, W.
T.C.O.46, T.C.P.95
- Hu, Y. W.
C.764
- Huang, A. S.
Th.C.P.38
- Huang, D. P.
Th.B.O.12, M.C.P.9
- Huang, Karen H. C.
M.D.O.5
- Huang, L.
M.G.P.15
- Huang, M.
Th.B.P.333, T.C.P.51

- Huang, Ming
M.C.O.11, W.C.O.28
- Huang, W.
A.605, M.B.P.241
- Huang, X.-L.
W.B.P.303
- Huang, Y. X.
Th.C.P.68
- Huang, Z.
M.B.P.11, M.B.P.18
- Huber, Felix
D.596
- Hubert, B. H.
W.A.P.25
- Hubsch, B.
W.C.P.69
- Hubner, K.
W.C.O.25
- Huchet, J.
M.A.P.15
- Hudes, E.
M.H.P.12
- Hudson, R. A.
T.D.P.11, E.639
- Huebsch, L.
T.C.P.56
- Huebsch, Lothar
T.B.P.306
- Huet, T.
W.C.P.40
- Hufert, F. T.
C.786
- Huff, J.
M.B.O.26
- Huff, R.
W.B.P.249, C.640
- Huffman, P.
A.514
- Hufnagle, G.
C.685
- Hughes, A.
T.G.P.30
- Hughes, Andrew S. B.
M.G.O.5
- Hughes, V.
T.B.P.196, T.B.P.199
- Huguet, M.-P.
M.B.P.151, W.B.P.32,
W.B.P.138, W.B.P.167,
Th.B.P.97
- Huhtala, M.-L.
W.B.P.102
- Hui, H.
T.C.O.20, W.C.P.79
- Hui, J. O.
T.C.P.85
- Huisman, H.
M.B.P.162, T.B.P.355,
Th.C.P.55
- Huisman, J.
W.B.P.157
- Huisman, J. G.
M.C.O.8, W.C.P.46
- Hulin, M.
D.583
- Hulin, Marg
Th.D.P.92
- Hull, B.
Th.A.P.23, W.G.P.11
- Hull, H. F.
Th.A.P.76
- Hulley, S.
M.D.P.52, T.E.O.3
- Hulman, S.
A.521, W.B.P.273, M.H.P.9
- Hulstaert, F.
Th.B.P.166
- Hummel, Robert F.
D.518, T.E.P.45, E.707
- Hung, C.-H.
M.C.P.2, C.690
- Hung, Chung-Ho
B.635
- Hung, D. S.
C.511
- Hunger, J.
Th.B.P.280
- Hunold, F.
Th.G.O.42, M.B.P.265
- Hanpou-Wusu, O. O.
D.542
- Hunt, A. J.
T.D.P.20
- Hunt, D.
W.D.P.57
- Hunt, J.
T.C.P.72
- Hunter, A. P.
Th.D.P.91
- Hunter, Andrew P.
D.662
- Hunter, DeLoris James L.
E.553
- Hunter, J.
W.B.P.196, T.D.P.90
- Hunter, Joyce
D.511
- Huntington, Carol L.
E.734
- Hunzelmann, N.
D.654
- Huo, R. J.
W.C.P.90
- Huprikar, J.
W.B.P.164
- Huroux, J. M.
Th.B.P.235, B.547
- Hurley, Patricia M.
D.829
- Hurtlich, M.
T.A.P.72
- Husayni, H.
T.C.P.29
- Huscroft, S.
T.D.P.7, D.502, E.797
- Huscroft, Susan
M.D.P.5
- Husdal, Arne N.
T.E.O.8
- Huskins, K.
T.C.P.46
- Huskins, K. R.
C.669, C.764
- Hussey, J.
Th.D.P.11, Th.D.P.25, E.549
- Hustad, T.
C.686
- Huszi, H. C.
E.590
- Hutchings, J.
W.E.O.10
- Hutner, G.
T.D.O.34, Th.D.P.28
- Hutterer, J.
W.B.P.98
- Hutterer, Judith
Th.D.P.18, Th.D.P.71,
T.E.P.67
- Hutto, C.
Th.A.O.8, T.B.P.166
- Hutton, N.
T.B.P.229, T.B.P.256, B.586
- Huygen, K.
Th.B.P.103, Th.B.P.145
- Hwang, K.
W.G.O.16, T.C.P.90
- Hwang, K. M.
C.596
- Hwang, Michael Yi-shuh
C.750
- Hyams, K. C.
M.G.P.5
- Hylland, R.
T.B.P.54
- Hyman, F.
E.532
- Hyman, J.
T.B.P.102
- Hyman, J. M.
T.A.O.39, Th.A.P.71, C.562
- Hyman, James M.
Th.A.P.66, C.562
- Hymes, James P.
T.E.O.10
- Hynes, J.
W.E.P.25
- Hynes, Patrick
T.D.O.4
- Hyslop, H.
W.B.P.8
- Hyslop, N.
W.B.P.18
- Hyslop, N. E.
T.B.P.328, C.779, C.780
- Højlyng, N.
G.517
- Iannello, P.
W.C.O.37
- Iatrakis, George
Th.H.P.15
- Icardi, G. C.
W.B.P.346
- Iezza, A.
W.B.P.60
- Igata, A.
Th.A.O.31, Th.A.P.17
- Iglehart, J. D.
W.B.O.12
- Iglesias, J.
Th.B.O.23
- Iglesias, J. R.
W.B.P.34
- Ikegami, H.
W.B.P.285, M.C.P.148
- Ikegami, Nobuko
W.B.P.298
- Ikematsu, S.
M.A.P.42, W.B.P.292
- Ikenchi, K.
W.G.O.35
- Ikeuchi, Kenji
T.C.O.18
- Ikuta, K.
C.778
- Ikuta, Kazuyoshi
Th.C.P.56
- Ilaria, G.
W.D.P.7
- Ilei, G.
M.C.P.146
- Ileman, M. L.
T.B.P.290
- Ilingworth, Patricia
W.F.P.5
- Ilunga, N.
Th.G.O.32
- Imagawa, D.
Th.A.P.92, W.B.P.124,
W.C.P.111
- Imai, H.
Th.C.P.56
- Imbach, J. L.
M.C.P.93
- Imbarrato, Anna Maria
E.616
- Imbert, J.-C.
W.B.P.320, T.E.P.66
- Imperato, P.
M.G.O.30
- Imperiale, D.
M.B.P.56
- Impey, A.
C.779
- Imrie, A.
W.B.P.140
- Imrie, Allison A.
Th.B.P.369, Th.B.P.370

- Inada, Y.
W.B.P.80, W.B.P.285,
M.C.P.142, M.C.P.148
- Inagaki, M.
W.B.P.292
- Inciardi, J.
M.C.P.113, D.588
- Inciardi, J. A.
B.527, Th.D.P.47, Th.D.P.49
- Inciardi, James A.
D.592
- Indiveri, F.
B.587
- Indyk, Debbie
D.688, T.E.P.10, Th.E.P.50,
E.559
- Inglese, E.
T.E.P.69
- Inglesi, E. A.
E.665
- Inglesi, Elisabeth
W.E.O.29
- Inglis, J. M.
T.A.P.51, D.614
- Ingraham, L.
Th.B.P.277
- Ingraham, Loring J.
B.586
- Ingram, Fred
D.677
- Innocenti, Patricia
C.706
- Inoue, M.
Th.C.O.25, C.653
- Inoue, Masahiro
Th.C.P.149
- Insbiengmay, P.
W.C.P.104
- Int'l AIDS Inutiol Study
Group
W.B.P.301
- Inui, T. S.
B.593, M.E.P.70, E.731
- Invernizzi, R.
Th.B.P.1
- Ioachim, H. L.
M.B.P.191, T.C.P.62
- Ioannidi, E.
E.654
- Iosub, S.
T.B.P.154
- Iosub, Silvia
T.B.P.147, T.B.P.168,
T.B.P.265
- Ippoliti, G. B.
Th.B.P.1
- Ippolito, G.
M.A.P.36, T.B.P.341
- Ippolito, Giuseppe
M.A.P.8, W.B.P.16, M.D.P.72,
M.E.P.61,
- Iramain, Carlos A.
D.597
- Ireland-Gill, A.
T.B.P.286
- Iribarren, J. A.
W.A.P.75, T.B.P.278,
W.B.P.66, Th.B.P.65,
- Irish, T.
E.629
- Ironsone, G.
W.B.P.181, Th.B.P.159,
T.D.P.42, D.677, D.681
- Irreguible, D.
M.B.P.98
- Irungu, G. M.
T.A.P.91
- Isaacs, G.
T.E.O.15
- Isabella, L.
D.674
- Isacchi, G.
B.518
- Isahakia, M.
M.C.O.6
- Isensee, J.
E.695
- Ishida, T.
W.C.P.21, W.C.P.37
- Ishida, Takuo
W.C.P.36
- Ishtikawa, K.
W.C.P.2
- Ismael, C.
T.B.P.384, B.534, W.G.P.14
- Ismael, Carla
M.B.P.109, M.B.P.291
- Israel, G.
B.557
- Israel, N.
Th.C.O.23, W.C.P.121
- Israel, Nicole N.
C.525
- Israel, R.
W.B.P.328
- Israel-Biet, D.
Th.B.P.143, Th.C.P.104
- Israni, P.
A.627
- Issi, M.
Th.B.P.136
- Issler, A. C.
T.E.P.69
- Itescu, S.
W.B.O.17
- Itescu, Silviu
Th.B.P.116, C.655
- Ito, S.
C.710
- Itoua-N'Gaporo, A.
W.G.P.2
- Itoua-Ngaporo, A.
M.B.P.91, T.B.P.19, Th.G.P.7,
G.511
- Itri, V.
M.C.P.18
- Ittelet, D.
C.762
- Iuric, D.
D.675
- Iuzzolino, P.
M.B.P.217
- Ivanoff, L.
M.C.O.21
- Ivanov, V. S.
W.B.P.191
- Ivanova, V.
W.B.P.178
- Ivantic, K.
T.B.P.325
- Ivanus, Lidia
M.B.O.10
- Iversen, A. E.
W.A.P.111
- Ivo-Dos-Santos, J.
C.743
- Ivo-Dos-Santos, Jairo
T.B.P.99, W.G.P.15
- Iwakoshi, K.
T.D.P.7
- Iwasaki, T.
W.C.P.103
- Iyer, N.
W.C.O.21, Th.C.P.62
- Izaguirre, C. A.
T.C.P.66
- Izaguirre, Carlos A.
Th.B.O.48, C.543
- Izazola, J. A.
Th.D.O.11, M.D.P.69,
M.G.O.27, T.G.O.9, G.510
- Izazola, Jose Antonio
E.585
- Izazola, José Antonio
Th.G.O.29
- Izazola, Jose-Antonio
T.G.O.8, Th.G.P.16
- Izazoula, José Antonio
Th.G.O.30
- Izzia, K.
Th.B.P.221, Th.B.P.267
- Izzo, C. M.
W.B.P.361
- J**
- Jabbari, B.
Th.B.P.264
- Jablonski, E. G.
W.B.P.149
- Jacas, C.
T.D.P.64, T.D.P.65, D.699
- Jackson, E.
W.A.P.92
- Jackson, G. G.
T.B.P.246
- Jackson, J.
E.707
- Jackson, J. Brooks
Th.B.O.8, T.B.P.348
- Jackson, K.
M.D.P.80
- Jackson, Lois A.
E.779, Th.H.P.2
- Jackson, M.
T.E.P.53
- Jackson, Rudolph E.
T.E.P.11
- Jackson, Susan
T.C.P.64
- Jacob G. S.
M.C.O.18
- Jacob, K. S.
M.B.P.381
- Jacobs, A.
W.B.P.132
- Jacobs, B.
T.A.P.118, T.D.P.17
- Jacobs, J.
W.B.P.211
- Jacobs, Jonathan
M.B.P.322, T.B.P.300,
M.E.P.64
- Jacobs, Jonathan L.
W.D.P.7
- Jacobs, R.
T.D.O.15, D.632, D.639
- Jacobs, Raymond M.
T.D.O.15, D.639
- Jacobsberg, L.
W.B.P.180, T.D.O.9,
T.D.P.66, Th.E.P.9, E.725
- Jacobsberg, Lawrence B.
W.B.P.210
- Jacobsen, Paul B.
W.B.P.332
- Jacobson, Kathleen L.
M.D.P.75
- Jacobson, L.
E.584
- Jacobson, M. S.
M.B.P.138
- Jacobson, Mark A.
M.B.P.123, M.B.P.166,
T.B.P.312, M.C.P.111
- Jacobson, Susan J.
M.B.P.205
- Jacobus, D.
T.B.O.4, M.B.P.192
- Jacoby, R.
Th.B.P.269
- Jacoby, V.
E.582
- Jacomé, C.
Th.C.P.7
- Jacques, C.
E.593
- Jacquette, G.
Th.B.P.188
- Jacquez, J. A.
Th.A.P.64

- Jadresic, Danitza
W.B.F.201
- Jaeck, D.
C.769, C.770
- Jaeger, H.
M.E.P.57
- Jaeger, Hans
E.606
- Jaeger, Helmut
Th.H.P.27
- Jaenel, G.
T.C.O.45
- Jaffarian, C.
W.B.P.240, W.B.P.246
- Jaffe, H.
M.A.O.34, W.A.O.2, T.A.P.112
- Jaffe, H. W.
M.A.O.30, M.A.O.46,
T.A.O.32, Th.A.P.87, B.549
- Jager, C.
W.H.P.14
- Jäger, H.
W.B.O.9, T.B.P.301
- Jäger, Hans
W.B.P.187, W.F.O.20
- Jager, J. C.
Th.A.P.55, A.593, D.578,
M.H.P.8
- Jagodzinski, L.
Th.B.O.12
- Jahan, M. S.
A.589
- Jahavarian, K.
M.C.P.25
- Jahn, G.
W.C.P.116, C.768
- Jain, R.
D.628
- Jain, S.
W.A.P.118, Th.D.P.55,
W.F.P.1
- Jain, Sunita
W.D.P.79
- Jaitch, K. O.
M.D.P.12, T.G.P.30
- Jaiyeoba, D. A.
Th.E.P.38
- Jakschik, A.
Th.B.P.99, Th.B.P.60
- Jalali, S.
T.G.P.20
- Jalick-Toth, C.
T.H.P.27
- Jałnoos, Y.
T.C.O.49
- Jamal, S.
Th.C.O.41
- James, D.
B.504, E.582
- James, E.
Th.E.O.4
- James, Gillian
M.E.P.5
- James, R.
D.562, D.565
- James, William S.
M.C.P.77
- Jamison, D.
Th.O.15, W.H.P.12
- Jasmin, H. R.
T.A.O.24
- Jang, M.
M.D.P.14
- Jang, Micheal
E.646
- Janier, Michel
W.B.P.48, B.530, C.726
- Janini, M.
T.B.P.194, T.B.P.196,
T.B.P.199
- Janitschke, K.
B.521
- Jankowski, S.
E.510
- Janney, A.
C.779
- Janney, K.
T.B.P.87
- Jannoon-Nasr, J.
Th.C.P.31
- Jannoun-Nasr, R.
Th.C.P.32, Th.C.P.33
- Janoff, Edward
Th.B.P.94, Th.B.P.175
- Janosy, G.
M.A.P.96, W.B.O.28
- Janot, C.
B.629
- Janowitz, Barbara
D.663, E.785, Th.H.P.29
- Jansà, J. M.
T.A.O.3, W.A.P.78
- Janssen, F.
W.B.P.49
- Janssen, R.
Th.A.P.17, B.566, W.C.P.87,
Th.C.P.30
- Janssen, R. S.
W.B.P.224
- Janssen, Robert S.
M.A.O.31, Th.A.O.31
- Janssens, A.
M.B.P.253
- Janvier, Blainde
Th.C.P.75
- Jaramillo, L. S.
M.G.O.6
- Jardine, L.
Th.P.22
- Jari, L.
M.B.P.197
- Jaroni, A. N.
Th.A.P.74
- Jarstrand, Connie
Th.B.P.88
- Jarvill, M.
Th.C.P.124
- Jarzem, Peter
Th.B.P.7
- Jasmin, C.
W.B.P.69
- Jasmin, C.
C.535
- Jason, J.
T.C.P.82
- Jason, J. M.
Th.A.P.87, B.549
- Jasperson, J.
E.714
- Jassy, C.
M.B.O.24
- Jauregui-Rios, M. L.
M.F.P.3, M.G.P.10, W.G.P.23
- Jautzke, G.
W.B.O.20, M.B.P.125
- Javaherian, K.
W.C.O.18, Th.C.O.50,
M.C.P.22
- Javaherian, Kashi
M.C.P.6
- Javanni, J.
M.C.P.91
- Javanni, Jean
Th.E.O.14, W.E.P.44
- Jayle, D.
T.D.P.88, D.516, W.E.P.27,
W.E.P.32, E.673
- Jean, B.
M.A.P.39
- Jeansson, S.
T.C.O.37
- Jeffers, J.
W.D.P.78
- Jefferson, Frances A.
E.748
- Jeffrey, Kelly A.
M.D.P.21
- Jeffries, D. J.
A.601, M.C.P.70
- Jemison, J.
E.539
- Jemison-Smith, Pearl
E.539
- Jenaer, M. C.
M.C.P.139
- Jendls, J.
Th.C.P.8
- Jenkins, S.
T.D.P.44
- Jennens, I. D.
M.B.P.124
- Jennings, M.
T.C.O.41, Th.C.O.45,
M.C.P.50, Th.C.P.78, C.510
- Jennings, M. B.
W.C.P.23, C.748
- Jennings, Myra B.
W.C.P.18
- Jensen, B. L.
T.A.O.30
- Jensen, Brigitte Nybo
T.B.P.59
- Jensen, F.
Th.D.O.17, Th.D.P.68, D.585
- Jensen, F. C.
Th.C.O.46
- Jensen, Peter C.
W.B.P.62, W.C.P.69, E.632
- Jeremias, J.
C.515
- Jeremy, R. J.
M.B.P.24
- Jerez, R.
Th.G.P.4
- Jernigan, T.
Th.B.P.262
- Jesencky, K.
W.E.P.71
- Jestin, C.
A.571
- Jestin, Christine M.
A.539, M.H.P.11
- Jesus, V. C.
A.549
- Jett, B.
W.B.P.154
- Jett, M.
M.C.P.124
- Jevtovic, D.
Th.B.P.222
- Jewell, N.
T.A.P.95, Th.B.P.144
- Jewett, A.
T.C.P.57
- Jimenez Gonzalez-Adleo,
M. L.
M.B.P.212, M.B.P.214,
Th.B.P.77
- Jimenez, C.
M.B.P.214
- Jimenez, D.
M.A.P.50
- Jimenez, E.
M.B.P.11, M.B.P.18, W.G.O.2
- Jimenez, Eleanor
W.A.P.48
- Jimenez, P.
W.H.P.2
- Jimenez, R.
T.B.P.202
- Jinadu, M. K.
Th.E.P.38
- Jingu, K.
T.D.O.35
- Jingu, M.
W.D.P.2
- Job-Splra, N.
W.A.P.100
- Jobin, J.
Th.F.P.15

- Jochens, R.
Th.B.O.23, Th.B.P.260
- Jockusch, J. D.
T.B.P.56, T.B.P.77, W.B.P.347
- Jockush, J.
W.H.P.7
- Johannes, P.
A.519
- Johansen, Hanne R.
T.C.P.106
- Johansson, B.
T.B.P.81
- John, I.
W.E.O.18
- John, J. K.
M.B.P.381
- John, R.
Th.E.P.65
- John, T. J.
M.B.P.381
- Johns, D. G.
Th.B.O.4, W.B.P.275,
Th.C.O.17
- Johnson
W.D.O.12
- Johnson, A. M.
T.A.O.9
- Johnson, Anne M.
D.545
- Johnson, C.
T.H.P.22
- Johnson, D.
Th.D.P.37
- Johnson, E. S.
T.B.P.2, T.B.P.15, W.B.P.336,
T.H.P.10
- Johnson, G.
Th.B.P.303, T.G.P.4
- Johnson, J.
W.A.P.47, T.B.P.238, B.574,
M.E.P.67, E.590
- Johnson, J. K.
Th.A.O.27, M.A.P.113,
T.D.P.41
- Johnson, J. M.
M.C.P.125
- Johnson, J. P.
M.B.P.12, T.B.P.262,
T.B.P.283
- Johnson, John L.
T.C.P.9
- Johnson, John P.
T.B.P.210, T.B.P.220
- Johnson, Jr. W. D.
Th.G.O.49, M.G.P.3
- Johnson, K.
M.B.P.349, T.D.P.63, E.732
- Johnson, M.
A.528, T.B.P.65, T.D.P.40,
W.D.P.19, M.E.O.13
- Johnson, M. P.
D.642
- Johnson, Margaret A.
T.C.P.8
- Johnson, Michael P.
T.B.P.318, E.570
- Johnson, N.
W.B.P.85
- Johnson, P.
M.C.P.67
- Johnson, P. D.
Th.A.P.71
- Johnson, P. R.
T.C.O.43, W.C.O.30
- Johnson, Philip R.
W.C.O.59
- Johnson, Pierre-Marc
Th.H.O.2
- Johnson, R.
Th.B.P.295, W.E.O.7
- Johnson, R. D.
T.E.P.74
- Johnson, R. J.
.A.P.62
- Johnson, S.
M.B.P.85
- Johnson, Sandra M.
Th.B.P.303
- Johnson, Sylvia S.
T.G.P.18
- Johnson, Victoria Anne
M.C.P.97
- Johnson, W.
M.A.P.50
- Johnson, W. D., Jr.
M.B.P.6, Th.B.P.70
- Johnson, Warren
W.G.O.11
- Johnson, Warren D.
W.G.O.8
- Johnsson, E.
Th.D.P.36
- Johnsson, H.
Th.B.P.6
- Johnston, B.
T.B.P.268
- Johnston, B. L.
T.B.P.42
- Johnston, B. Lynn
W.B.P.381
- Johnston, Margaret I.
M.C.P.58, M.C.P.123
- Johnston, P.
M.C.P.122, E.643
- Jolicoeur, P.
M.C.O.11, W.C.O.28,
T.C.P.138
- Jollo, Y.
T.B.P.277
- Joller, Peter W.
Th.B.P.110, Th.B.P.133, B.622
- Joller-Jemelka, H.
Th.B.O.27
- Joller-Jemelka, H. I.
Th.B.P.110, Th.B.P.133, B.622
- Jolly, D. H.
W.D.P.1
- Joly, P.
M.B.P.42, T.C.P.25
- Jonas, C. R.
E.533
- Jonckheer, Tjij
T.B.P.197
- Jondal, M.
Th.A.P.113, T.C.P.55,
Th.C.P.97
- Jones, A. B. S.
W.D.P.51
- Jones, Barbara J.
T.D.P.87
- Jones, Donna S.
M.A.P.35
- Jones, F. R.
T.B.P.287, W.B.P.310
- Jones, G.
T.A.P.51
- Jones, G. A.
W.B.O.3
- Jones, J.
T.D.P.9, W.E.P.49, W.E.P.50,
E.769
- Jones, J. L.
W.A.P.87
- Jones, Jeffrey L.
W.A.O.20
- Jones, K.
T.C.P.78
- Jones, L. T.
D.537
- Jones, M. E.
M.A.P.92, M.A.P.105,
T.B.P.271, W.B.P.317,
T.C.P.52
- Jones, Stephen T.
D.606
- Jones, T.
T.A.O.10
- Jones, T. S.
W.A.P.109, W.A.P.119,
T.E.P.17
- Jong, J. T. L.
M.H.P.8
- Jonhson, R. J.
T.A.P.62
- Jonkheer, Tjij
T.B.P.251
- Jonsen, Albert
T.F.O.12
- Joos, B.
M.C.P.83
- Jorbeck, Hans J. A.
A.517
- Jordahl, L.
M.A.O.28
- Jordan A.
Th.C.P.105
- Joseberg, H.
M.B.P.126
- Joseph H.
W.D.P.71
- Joseph, A. E. A.
Th.B.O.41
- Joseph, F.
T.G.O.20
- Joseph, H.
E.574, E.575, E.576
- Joseph, Herman
W.D.P.78
- Joseph, J.
M.A.O.48, Th.E.P.30
- Joseph, J. A.
W.B.P.1
- Joseph, J. C.
T.D.P.67
- Joseph, J. G.
T.D.P.36
- Joseph, J. M.
T.B.P.333
- Joseph, M.
D.603
- Joseph, S.
M.C.P.1, Th.D.P.38
- Josepher, H.
M.A.P.20
- Josephs, S.
T.B.P.241, W.B.P.78,
T.C.O.31, T.C.P.136,
- Josephs, S. J.
T.B.P.157
- Josephsen, Knud
Th.E.O.10
- Joshi, N. N.
W.B.P.241
- Joshi, Sadhna
M.C.P.145
- Joshi, Vijay V.
T.B.P.269
- Josse, R.
M.A.O.16
- Jost, Jean-Paul
Th.E.P.17
- Jou, A.
M.B.P.240, M.B.P.245,
T.B.P.308, W.B.P.22,
Th.B.P.148,
- Jouault, T.
W.C.O.9, Th.C.O.5
- Joubert, J.
Th.F.P.15
- Joubert, J. J.
Th.H.P.19
- Jourdain, G.
W.G.P.10
- Jourdan, A.
D.652, E.656, T.H.P.14
- Joy, D.
M.D.P.24
- Joy, Dan M.
M.D.P.28

- Joy, K.
M.B.P.311
- Joyner, M.
B.539
- Jubault, C.
W.C.P.1
- Jubb, W.
W.E.P.50
- Jubb, W.H.
E.613
- Judd, D.
D.651
- Judson, F.
M.A.P.76, T.A.P.52, T.D.O.6
- Judson, Franklin N.
M.A.P.54, T.A.P.83, Th.E.P.38
- Jue, S.
M.E.P.65
- Jui, J.
A.521
- Julander, I.
T.B.P.372
- Juliana, Patti L.
W.D.P.43
- Julien, T.
W.B.P.93
- Julien, Anne-Marie
M.B.P.151
- Junca, J.
M.B.P.251
- June, B. A.
C.559
- Junge-Hülsing, B.
Th.B.P.244
- Jurado da Silva, E.
M.B.P.231, W.B.P.39
- Jurado, H.
M.G.O.28
- Jurberg, Claudia
E.759
- Jurica, K.
Th.B.O.1
- Jurriaans, Suzanne
W.C.P.88
- Just, Gudrun
Th.B.P.334
- Justement, J.
W.C.P.107
- Justement, Jesse S.
C.723
- Juszczyk, Jacek R.
T.A.P.7
- Juvall, I.
Th.E.O.5
- Juvall, T.
T.E.P.30
- K**
- Kabagabo, U.
T.B.P.161, W.G.O.1,
Th.G.O.34
- Kabena, M.
B.646
- Kabeya, C.
Th.H.P.27
- Kabeya, C. M.
T.B.P.105, W.B.P.100
- Kabeya, M.
Th.H.P.18
- Kabongo, L.
T.B.P.188, Th.G.O.33,
W.H.P.6
- Kaboth, W.
W.B.O.9
- Kaboto, M.
M.B.O.38
- Kacian, D. L.
T.C.P.18
- Kadakia, A.
W.C.P.80
- Kadende, P.
W.B.P.14, B.599
- Kadiot, A.
Th.B.O.55
- Kaetz, S.
D.640
- Kafmann, E.
Th.B.P.245
- Kägi, Martin Kurt
Th.B.P.81
- Kahi, L.
T.B.P.101
- Kahl, P.
Th.B.P.381, D.589
- Kahn, B.
T.B.O.1
- Kahn, E.
T.B.P.370, Th.B.P.372, B.590
- Kahn, J.
W.B.O.19, T.B.P.303
- Kahn, J. O.
T.B.P.284
- Kahn, James O.
Th.B.O.5, W.C.P.42
- Kahn, Joan
W.H.P.9
- Kahotwa, M.
M.B.O.17, W.B.P.12
- Kairam, Ram
M.B.O.44
- Kajdacsy-Balla, A.
A.631
- Kakera, K.
T.E.P.61
- Kakihara, R.
M.E.P.31
- Kakimoto, D.
M.D.P.6
- Kakishita, E. K.
B.512
- Kalainov, D.
W.A.O.4
- Kalamaridès, M.
W.E.P.23
- Kalambayi, Kayembe
W.B.P.4
- Kalbakki, S.
T.E.O.8
- Kalden, J.
C.679
- Kalden, J. R.
W.A.P.53, M.C.P.56, T.D.P.46
- Kalebic, T.
M.C.O.28
- Kalechman, Y.
T.C.P.142
- Kaleeba, N.
T.G.P.22
- Kaleeba, Noerime
Th.D.O.21, M.G.O.34
- Kalengayi, M.
W.G.O.30
- Kalengayi, M. M.
Th.G.O.32
- Kales, Christopher P.
M.B.P.70, M.B.P.77
- Kalichman, A. O.
D.540
- Kalinowska, B.
T.A.P.7
- Käll, K.
W.D.P.76
- Källander, C. F. R.
W.B.P.147, Th.C.P.82,
Th.C.P.84
- Kallinikos, G.
W.A.P.37
- Kalombo, Kitoto K.
Th.E.O.3, E.621
- Kaltenbach, K. A.
M.B.P.30, D.600
- Kalter, D. Chester
W.C.P.63
- Kaltwasser, Gustavo
B.539
- Kalumba, K.
T.G.P.16
- Kalyanaraman, S.
Th.C.P.31, Th.C.P.32,
Th.C.P.33
- Kalyanaraman, V.
W.C.O.16
- Kalyanaraman, V. S.
Th.A.P.31, M.C.P.1, T.C.P.53
- Kamanga, J.
M.A.O.57, W.A.P.50, W.A.P.54
- Kamara, P.
W.E.P.66
- Kambara, A. M.
Th.B.P.38
- Kambou, Gerard
Th.O.17, W.H.P.13
- Kamenga, M.
E.621, W.G.O.26
- Kamenga, Munkolenkole
T.D.O.35, M.G.O.17
- Kamieniak, H.
W.E.P.63
- Kaminkova, J.
Th.C.P.127
- Kaminski, Z.
Th.B.P.46
- Kammerer, B. L.
W.B.P.183
- Kampen, D.
W.B.O.43, Th.B.P.284,
Th.B.P.286
- Kamps, B. S.
M.A.P.103, T.A.P.110
- Kamps, Bernd S.
M.A.O.12, T.A.P.107,
W.B.O.26, W.B.P.170
- Kamradt, T.
M.A.O.12, T.A.P.107,
W.B.O.26, W.B.P.170
- Kamradt, T. G. A.
T.A.P.110
- Kan, Nancy
C.719
- Kanai, M.
M.C.P.79
- Kanda, P.
M.C.O.32
- Kane, Assane
T.B.P.373
- Kane, N.
D.588
- Kaneko, Y.
C.750
- Kang, C. Y.
T.C.O.31, C.764
- Kang, M.
M.C.P.117
- Kangas, Lenn W.
W.A.P.98
- Kanki, M.
Th.G.P.6
- Kanki, P.
M.A.O.13, M.B.P.200,
W.G.O.30, Th.G.O.26,
W.G.P.22
- Kanki, P. J.
C.540, T.G.P.27, W.G.P.24
- Kanki, Phyllis
Th.E.P.5, T.G.O.3
- Kanki, Phyllis J.
M.A.O.15, W.C.P.136
- Kann, L.
W.E.P.49
- Kann, Laura
T.D.P.9
- Kannagi, M.
W.C.O.38
- Kanouse, D.
M.B.P.376
- Kanouse, David E.
T.D.P.18
- Kantanen, M. L.
Th.A.P.2, A.509

- Kantanen, Marja-Leena**
B.552
- Kantor, Elizabeth**
T.D.O.5, E.721
- Kanu, J. M.**
W.G.P.16
- Kapembwa, M.**
T.B.P.34
- Kapembwa, Moses S.**
Th.B.O.41, Th.B.P.317
- Kapila, Mukesh**
W.E.O.23, M.E.P.46
- Kapila, R.**
M.A.P.16, A.553, A.563,
Th.B.P.48
- Kapita, B.**
M.B.O.17, Th.B.O.30,
Th.B.P.211, W.G.O.26,
T.H.O.9
- Kapita, Bila**
W.B.P.12, W.B.P.359,
W.G.O.34
- Kaplan, C.**
W.B.P.287
- Kaplan, J.**
A.613, Th.C.P.30
- Kaplan, J. C.**
Th.B.O.10
- Kaplan, J. E.**
W.B.P.224, Th.B.P.173
- Kaplan, Jonathan E.**
Th.A.P.17
- Kaplan, L.**
Th.C.O.37
- Kaplan, L. A.**
Th.B.O.5, W.C.P.42
- Kaplan, Lawrence D.**
M.B.P.288, T.B.P.284
- Kaplan, M.**
A.558, W.B.P.333, B.595
- Kaplan, M. H.**
Th.C.P.5
- Kaplan, Marcy E.**
M.B.P.313, M.B.P.317
- Kaplan, Margaret T.**
B.575
- Kaplan, Mark H.**
M.B.P.4, T.B.P.35, C.740
- Kaplowitz, L.**
A.546
- Kaplowitz, Lisa G.**
D.643
- Kappes, J. C.**
T.C.O.20
- Kappes, John C.**
T.C.P.126
- Kappes, R.**
M.A.O.25
- Kappes, Rosemarie A.**
E.711
- Kapsalis, A.**
W.B.P.95, W.B.P.135
- Kaptue, L.**
Th.A.O.19, W.D.P.87,
Th.D.P.22, W.G.O.21,
T.G.P.10
- Kaptue, L. N.**
A.573
- Kaptue, Lazare N.**
M.B.P.99
- Kaptue-Noche, L.**
T.A.P.1
- Karabulut, Nigahus**
M.B.P.69
- Karacostas, Velissarios**
Th.C.P.130
- Karafoulidou, A.**
M.A.P.89, W.B.P.348
- Karafoulidou, Anastasia**
Th.B.P.17
- Karahunga, C.**
M.B.O.38
- Karam, Marc**
T.G.P.3
- Karavassik, B.**
T.B.P.183
- Karbowiak, B.**
Th.A.P.29
- Kargbo, T. K.**
W.G.P.16
- Karhunen, P. J.**
B.552
- Karim, R.**
W.B.P.226
- Kariuki, H.**
Th.B.P.324
- Karjalainen, Klaus E.**
T.C.P.96
- Karlsson, A.**
Th.C.P.6
- Karlstrom, A. R.**
Th.C.P.62
- Karn, J.**
T.C.O.29, T.C.P.93
- Karol, C. N.**
M.C.P.60
- Karon, J.**
M.A.O.8, W.A.O.13, Th.A.O.12
- Karon, J. M.**
T.A.O.4, T.A.P.83
- Karon, John M.**
T.A.O.37, Th.A.P.79
- Karp, Mitchell**
Th.D.P.8
- Karpas, A.**
T.C.P.105
- Karpas, Abraham**
W.B.P.314, M.C.O.18
- Karpf, M. T.**
W.H.P.7
- Karsten, S. E.**
M.F.P.13, Th.F.P.3
- Kasai, M.**
M.G.O.3
- Kasali, M.**
Th.H.P.18
- Kasen, Stephanie**
E.581
- Kashala, Oscar**
W.G.O.30
- Kashala, T. D.**
Th.B.P.221, M.D.O.3,
M.D.O.17, W.D.O.6,
M.D.P.13, M.D.P.49, D.721,
T.E.P.A, M.G.O.16, W.G.P.20
- Kashamuka, M.**
T.B.P.204, W.G.P.8
- Kashunchi, F.**
C.782
- Kashima, Y.**
T.D.P.43
- Kashiwagi, N.**
M.B.P.165
- Kashkin, J.**
Th.E.P.57
- Kaslow, R.**
M.A.O.44
- Kaslow, R. A.**
T.A.O.29, Th.A.O.17
- Kaslow, Richard A.**
M.A.P.101, Th.A.P.100
- Kaslow, Richard S.**
A.622
- Kasper, J.**
Th.B.P.167
- Kass, Nancy E.**
T.H.P.20
- Kasswara, J.**
W.E.O.17
- Kataaha, P. K.**
T.B.P.189
- Katabira, E.**
Th.G.O.35
- Katabira, E. T.**
T.B.O.11
- Katagiri, K.**
Th.C.P.141
- Katanzaga-Lahaye, A.**
M.E.O.36
- Kater, C. E.**
M.B.P.283
- Kathalia, S.**
M.B.P.47, W.B.P.280
- Katims, Jefferson J.**
Th.B.P.285
- Katlama, C.**
T.B.P.13, Th.B.P.235,
Th.B.P.250, B.546, W.C.P.100
- Katlama, Christine**
M.B.P.117, M.B.P.119,
Th.B.P.219
- Katner, Harold P.**
M.D.P.16, M.D.P.59
- Kato, S.**
Th.C.P.56, C.778
- Katoff, Lew S.**
E.751
- Katongole-Mbidde, E.**
W.C.P.47, W.C.P.51
- Katongole-Mbidde, Edward**
B.581
- Katsivo, M. N.**
W.G.O.22
- Katsouyanni, K.**
M.A.P.89, M.A.P.109
- Katsoufrakis, Peter J.**
E.611
- Katz, D.**
T.B.O.28
- Katz, D. J.**
E.539
- Katz, Deborah G.**
T.E.P.51
- Katz, M.**
T.C.O.27
- Katz, Michael G.**
Th.C.P.89
- Katzenstein, D. A.**
T.C.P.69, C.520
- Katzenstein, David A.**
W.C.P.95, W.C.P.96,
Th.C.P.40
- Kauffman, C. L.**
M.B.P.49
- Kauffman, Carole K.**
W.E.O.2
- Kaufman, G.**
W.B.P.258, T.H.P.5
- Kaufman, G. I.**
W.H.P.10
- Kaul, A.**
M.B.O.44, T.B.P.156, B.582
- Kaul, Ruby K.**
E.794
- Kaunath, T.**
W.C.P.66
- Kaunath, Thomas**
W.C.P.122
- Kaushal, J. A.**
C.622
- Kavanangh-McHugh, A.**
T.B.P.256
- Kawamura, T.**
T.C.P.75, Th.C.P.45
- Kawamura, Takashi**
Th.C.O.4
- Kawwaff, O.**
T.B.P.37
- Kay, John W. D.**
M.B.P.170
- Kayembe, K.**
Th.B.P.211, Th.B.P.221,
Th.B.P.287
- Kayembe, K. A. L.**
Th.B.P.221, Th.B.P.267
- Kayembe, Kalambayi**
W.B.P.13, Th.H.P.16
- Kayembe, M.**
Th.G.O.32

- Kayhani, M.
T.G.P.20
- Kayser, L. C.
M.A.O.43
- Kazadi, K.
B.637
- Kazatchkine, M. D.
T.G.P.3, G.529
- Kazazi, F.
W.C.O.23, W.C.P.27
- Kazazi, Farhad
T.C.P.8
- Kearns, W. E.
A.597
- Keasler, J.
Th.D.P.58
- Keatings, M.
M.D.P.58
- Kebede, T.
W.G.P.28
- Keddle, E.
Th.D.P.55
- Keddle, Elise M.
C.746
- Keefe, C.
D.579
- Keefer, Michael C.
M.C.P.8
- Keegan, J.
D.530
- Keelin, D. R.
W.B.P.133
- Keeling, Michael
E.542
- Keeling, R.
M.A.P.9
- Kefene, Hailu
W.G.P.28
- Keffelew, A.
T.A.O.11, T.A.P.47
- Kegeles, M.
Th.E.P.24
- Kegeles, S.
T.D.O.25, M.D.P.4
- Kegeles, S. M.
W.A.O.27
- Kegeles, Susan M.
M.D.P.3, E.715
- Kehe, J.
M.B.O.42
- Keiding, N.
M.D.P.85
- Kelip, J. G.
Th.B.O.24, T.B.P.239,
W.B.P.255, W.B.P.256,
W.B.P.259, T.D.P.58
- Kelip, John G.
W.B.P.194, Th.B.P.376,
T.D.P.61, D.716
- Keintz, R. M.
W.H.O.11
- Kelen, G. D.
T.B.P.126, T.B.P.127
- Kelen, Gabor D.
W.A.O.4, Th.A.P.12, T.G.P.4
- Kelleher, J.
T.D.P.76
- Kelleigh, B.
W.E.P.61
- Keller, G. H.
M.C.P.9
- Keller, George H.
Th.B.O.12
- Keller, J.
Th.D.P.10
- Keller, R.
M.E.P.4
- Kelley, D.
M.B.P.281
- Kelley, J. A.
W.B.P.275
- Kelley, K. F.
Th.A.P.104
- Kelley, Patrick W.
M.A.P.4
- Kellihier, J.
C.741
- Kellogg, D.
Th.A.P.110, Th.B.O.7
- Kelly, Ann
M.B.P.308, W.B.P.379
- Kelly, Chester J.
W.A.O.25
- Kelly, J.
W.A.P.10, A.584, M.B.P.241,
M.B.P.276, T.B.P.51,
T.B.P.324, W.B.P.68,
W.D.P.40
- Kelly, Jeffrey A.
M.D.P.22
- Kelly, L.
M.B.P.87
- Kelly, M.
T.G.P.16
- Kelly, Patricia J.
Th.D.P.9
- Kelly, Paul J.
W.D.P.17
- Kelly, T. J.
W.D.P.51, W.D.P.53
- Kelner, M. J.
M.D.P.78, Th.E.P.53
- Kelner, Merrijoy
M.D.P.74
- Kemeny, Margaret E.
T.D.O.23
- Kemp, B.
T.C.O.35, Th.C.P.39
- Kenen, R. H.
Th.E.P.55
- Kengeya-Kayondo, Jane
Frances
T.A.P.11
- Kennard, C.
Th.B.P.374
- Kennedy, Ann R.
Th.E.P.47
- Kennedy, C.
W.B.P.331
- Kennedy, D. H.
W.B.O.7, Th.D.P.3, D.612
- Kennedy, M. J.
T.A.P.104, W.A.P.93
- Kennedy, M. M.
Th.C.P.37
- Kennedy, P.
T.B.O.1, T.B.P.276
- Kennedy, Peter S.
B.588
- Kennedy, R.
M.C.O.32
- Kenny, Colin
M.A.P.57
- Kenny, Frank T.
W.A.P.76
- Kensil, Charlotte R.
M.C.P.2
- Keogh, Pauline M.
T.E.O.3
- Kermani, V.
W.A.P.77
- Kern, E. R.
M.C.P.74
- Kern, P.
W.B.P.89, Th.B.P.329
- Kerndt, P.
W.A.O.11, W.A.O.13,
M.A.P.74, A.528, W.B.P.53
- Kerndt, P. R.
M.A.P.12, T.A.P.67, M.B.P.68
- Kerndt, Peter R.
Th.D.P.58
- Kernen, R.
T.B.P.226
- Kernoff, P.
Th.B.P.22, M.E.O.13
- Kernoff, P. B. A.
M.A.P.41, M.A.P.96,
W.B.O.28, T.B.P.275,
W.B.P.349, Th.B.P.355
- Kerouedan, D.
M.A.P.119, B.547
- Kerr, G.
T.D.O.16
- Kerschner, J. H.
W.B.P.149
- Kertzner, R.
W.B.P.222
- Kertzner, Robert
W.F.P.2
- Kesarwala, H.
T.B.P.169
- Kesavalu, L.
M.B.P.190, Th.B.P.61
- Kessinger, J. M.
T.B.O.5
- Kessler, C. M.
W.A.P.61
- Kessler, D.
M.B.P.141, M.B.P.142,
T.B.P.344
- Kessler, H.
T.B.P.250, W.B.P.313,
Th.B.P.50, Th.B.P.91
- Kessler, H. A.
T.B.P.83, T.B.P.313, T.C.P.21
- Kessler, J.
C.741
- Kessler, R.
T.D.P.67
- Kessler, Ronald C.
M.A.O.48
- Kestelyn, P.
T.B.P.374
- Kestelyn, Philippe G.
T.B.P.203
- Kestens, Luc
T.B.P.135
- Kestler III, Harry W.
Th.C.P.23
- Kestler, H.
W.C.P.9
- Kestler, H. W.
Th.C.P.58
- Ketchum, S.
T.B.P.93
- Keur, W.
W.B.P.132
- Keusch, G. T. K.
W.C.P.102
- Kevy, S. V.
M.B.P.138
- Kewa-Ilunga, Wa Bilond
D.505
- Keyes, C.
W.A.P.10, M.B.P.276,
M.B.P.319, W.D.P.40
- Keyes, Craig
A.584
- Keyes, Craig W.
T.B.P.51, T.B.P.324, W.B.P.68
- Keyes, M.
A.808, W.E.P.70, M.H.O.11,
T.H.P.17
- Khazzaz, R.
Th.A.O.31, Th.C.P.30
- Khazzaz, R. F.
Th.A.O.32, Th.B.P.173
- Khazzaz, Rima F.
Th.A.O.33, Th.A.P.16
- Khai, Paul
Th.B.P.308
- Khalil, K.
T.C.P.59
- Khan, A.
M.B.P.101
- Khan, Sabih R.
W.B.P.241
- Khshaba, S.
M.G.P.22

- Khatib, O. J.
W.E.P.55, E.652
- Khayam-Bashi, F.
M.B.P.288, Th.C.O.37,
Th.C.P.54, C.777
- Khayam-Bashi, Hassan
W.B.P.85
- Khondi
Th.B.O.30
- Khorlin, A.
T.C.P.145
- Khouiri, E.
W.D.O.10, Th.D.P.75
- Khuong, M. A.
M.B.P.249
- Khuzale, Rula F.R.
Th.C.P.102
- Kibuga, Daniel K.
Th.G.O.5
- Kidd, P. G.
M.C.P.101
- Kidd, S.
M.E.P.30, T.H.O.1
- Kieber, T.
W.C.P.128
- Kiefer, H.
T.C.P.96
- Kiefer, R.
W.D.P.74
- Kielp, J.
Th.B.P.197
- Kielp, J. G.
Th.B.P.257
- Kieny, M. P.
W.C.O.33, W.C.O.44,
Th.C.O.47, T.C.P.77,
W.C.P.5, C.524
- Kienzler, J. L.
W.B.P.282, C.628
- Kiernan, Rosemary E.
Th.C.P.41
- Kiguli, S.
W.A.P.56, T.B.P.189
- Kilbane, M. P. J.
E.658
- Kilborn, J.
W.B.P.86
- Kilbourne, B.
M.A.P.9
- Kilbourne, Barbara W.
W.A.O.18
- Kilduff, J.
C.669
- Kilgour, J.
E.642
- Kilkuskie, R. E.
C.622
- Kilkuskie, Robert E.
C.585
- Killian, H.
B.504
- Killinger, Joyce F.
W.A.P.61
- Kilpatrick, D.
B.590
- Kim, Helen
Th.C.P.16
- Kim, M.
T.B.P.159
- Kim, M. H.
W.A.P.5
- Kim, S.
Th.C.P.93
- Kim, Sunyoung
W.C.O.35
- Kimani, V.
M.G.O.11
- Kimball, T. J.
W.A.P.6
- Kimble, Vesta
E.723
- Kimmel, Allan J.
T.D.P.55
- Kimura, Satoshi
M.B.P.63
- Kimura-Kuroda, Junko
W.C.P.103
- Kinavwidl, L. N.
W.E.P.65
- Kind, C.
T.B.P.226
- Kindervater, G.
M.A.P.103, Th.A.P.96
- Kindt, T. J.
W.C.P.16, C.508
- Kindt, Thomas J.
W.C.P.41
- King, A. J. C.
M.D.O.8
- King, Alison B.
Th.B.P.300
- King, D.
E.732
- King, J.
M.B.P.337, M.C.P.113
- King, M. C.
Th.A.P.83
- King, Michael B.
W.B.P.212, T.F.O.3
- King, N.
W.C.O.48, M.C.P.16
- King, N. W.
W.C.P.147
- King, R.
Th.D.P.10
- King, S. M.
M.B.P.315
- Kingsley, L.
M.A.O.44, Th.A.O.17,
M.A.P.101, W.A.P.67,
W.A.P.68, W.A.P.69,
W.B.P.221, W.B.P.226,
W.B.P.236
- Kingsley, L. A.
Th.A.P.95, W.B.O.24
- Kingsley, Lawrence A.
W.A.P.41
- Kingsman, A. J.
M.C.P.34, M.C.P.35,
T.C.P.103, T.C.P.137
- Kingsman, A. S.
C.530
- Kingsman, S. M.
M.C.P.34, T.C.P.103,
T.C.P.137, C.530
- Kinloch de Loes, Sabine
Th.B.P.131
- Kinnell, Hilary R.
W.D.P.41, D.682, T.E.P.38
- Kinney, Evlin L.
M.B.P.282, M.B.P.284
- Kinoshita, T.
W.B.P.311
- Kinter, A.
M.C.P.95, W.C.P.107
- Kintora, Audrey
W.C.P.59
- Kinuthia, D. M. W.
M.B.P.160, Th.E.P.39
- Kioseglou, G.
E.615
- Kipke, Michele D.
T.D.O.27
- Kirby, C.
M.A.P.55, M.A.P.75
- Kirby, J.
A.533
- Kirby, Justice Michael
M.F.O.1, W.F.O.23
- Kirch, P.
B.542
- Kirihara, J.
M.C.P.109, C.670
- Kirkley, J. E.
M.C.P.13
- Kirkpatrick, D. V.
Th.B.P.304
- Kirn, A.
C.789, C.770
- Kirpach, P.
T.B.P.109
- Kirsch, Gorm D.
M.B.P.304
- Kirschenbaum, D.
C.590, C.640, E.689, E.692
- Kirschenbaum, D. Z.
W.B.P.257, Th.G.P.10,
T.H.P.15
- Kirschenbaum, David Z.
E.772
- Kirschfink, M.
Th.B.P.139
- Kirschner, R. J.
C.687
- Kirsetter, M.
M.B.O.36, W.B.P.284,
W.B.P.296
- Kirsetter, Myriam
W.B.P.305
- Kiser, R.
C.638
- Kiser, R. F.
C.513
- Kishimoto, T.
T.C.P.19
- Kissing, P.
T.D.O.32, T.G.O.20
- Kisumbi, N.
Th.B.P.324
- Kitamura, K.
Th.B.P.83
- Kitamura, T.
B.605, M.C.P.108, M.C.P.134
- Kitchen, Lynn W.
C.588
- Kitchen, V.
W.B.P.59
- Kitchen, Valerie S.
M.B.P.244
- Kitchens, A.
Th.D.P.9, Th.D.P.54
- Kitchin, P.
C.502
- Kitchin, P. A.
C.530
- Kitchin, Peter
W.C.P.7
- Kitembo
M.E.O.33
- Kitonyi, G. W.
M.B.P.160
- Kittelson, P.
Th.D.P.68
- Kitzis, M. D.
T.B.P.26
- Kiviat, N.
M.B.P.53
- Kivuvu, M.
Th.A.O.21, T.A.P.90, W.A.P.96
- Kizer, K. W.
M.A.P.64
- Kizito, A.
B.581
- Klassen, Robert J. L.
W.C.P.99
- Klapholz, A.
M.B.P.90
- Klapps, P.
T.E.P.70
- Klasse, P. J.
C.717
- Klatzmann, D.
Th.C.O.5, Th.C.P.67
- Klauke, S.
M.B.P.265
- Klauke, S.
Th.B.O.42, M.B.P.270
- Kleiber, Dieter
B.609

- Kleiman, Mark A. R.
E.694
- Klein, Ami
W.C.P.74
- Klein, C.
B.542, Th.D.P.23
- Klein, E.
M.C.P.62
- Klein, K.
Th.B.P.98, T.C.P.88
- Klein, M.
Th.B.P.373, T.C.P.16
- Klein, N. C.
T.B.P.37
- Klein, R.
Th.A.P.101
- Klein, R. S.
Th.A.O.24, Th.A.O.32,
Th.A.P.104, Th.B.P.331,
Th.B.P.352, Th.D.P.59,
Th.D.P.78, D.589, D.645
- Kleinbaum, D.
Th.A.O.15
- Kleiner, M.
A.613
- Kleinman, A.
M.G.O.7
- Kleinschmidt, A.
M.C.P.33, W.C.P.91,
Th.C.P.135
- Kleinschmidt, Andrea
Th.B.P.181
- Kletecka, C.
W.D.P.9, E.527
- Kletler, Ron
M.B.P.24
- Kleyn, J.
T.A.P.57
- Kleyn, Jeanne E.
T.E.P.42
- Kilmas, N.
M.A.P.90, W.B.P.56,
W.B.P.181, Th.B.P.263, D.681
- Kilmas, N. G.
W.A.P.72, Th.B.P.159
- Kilmas, Nancy C.
Th.A.P.97, Th.B.P.223
- Kilmas, Nancy G.
Th.B.P.240
- Klímek, J.
W.B.P.238, D.627
- Klimes, I.
M.B.P.304, Th.B.P.31, E.507
- Klimkait, T.
T.C.O.47
- Klimkait, Thomas
W.C.O.38
- Kline, J.
D.587
- Kline, J. K.
B.577
- Kline, R.
M.A.O.39, M.B.P.5,
Th.B.P.188
- Kline, Richard L.
T.B.P.126, T.B.P.127
- Klobe, L.
T.D.P.9
- Klockner, R.
M.A.O.22, W.B.P.273,
W.D.P.69, M.H.P.9
- Kloser, P.
M.A.P.16, Th.B.P.48
- Kloser, Patricia C.
A.563
- Klotman, M.
T.C.P.136
- Klotman, Mary E.
T.C.O.13
- Klutchi, M.
T.C.P.84
- Knapp, P.
D.713
- Knapp, T.
Th.D.P.62, E.566
- Knapstein, G.
W.D.P.54, Th.D.P.23
- Knechten, Heribert
T.B.P.291
- Knicker, S.
W.B.P.134
- Knickman, J.
A.639
- Knigge, K.
W.B.P.120
- Knigge, K. M.
W.B.P.121
- Knigge, Kevin M.
W.B.P.95
- Knight, R.
B.550
- Knight, Susan
T.B.P.110
- Knight, V.
M.C.P.124
- Knirsch, A. K.
W.B.P.1
- Knobel, Gideon J.
E.571, W.F.O.22
- Knoop, M.-T.
Th.C.P.10
- Knox, C.
Th.E.P.32
- Knox, Kristine A.
C.557
- Knox, Michael D.
M.D.P.60
- Knupp, C.
M.C.P.130
- Knutsen, A. P.
Th.B.P.112
- Knutsen, Alan P.
T.B.P.253
- Ko, R. J.
W.B.P.81
- Ko, Richard J.
W.B.O.5
- Ko, Y. C.
C.754
- Kobayashi, Joyce S.
W.B.P.182
- Kobayashi, T.
W.C.P.36, W.C.P.37
- Kobb, K. E.
W.C.P.28
- Koblin, B.
T.A.P.35
- Koblin, Beryl A.
T.A.P.29
- Kobrinisky, N.
W.B.O.27, Th.B.P.20
- Kobuch, W. E.
M.B.P.26
- Koch, C.
Th.C.P.143
- Koch, G. G.
M.A.O.23
- Koch, J.
Th.B.P.183
- Koch, M. A.
Th.A.P.29, W.B.P.331,
W.H.P.23
- Koch, M. G.
Th.A.P.53, W.H.P.18
- Koch, Michael
C.750
- Koch, Michael G.
A.550, A.561, E.784, W.H.P.20
- Koch, S.
T.B.P.378
- Koch, Thomas K.
T.B.P.177
- Kochanek, K. D.
W.A.P.35
- Kochen, Michael M.
M.D.P.66, E.607
- Kociba, G.
M.C.P.69
- Kocka, F.
Th.B.P.49, B.529
- Kocsis, A.
E.598
- Kocsis, A. E.
M.D.P.92, E.509
- Kocsis, Agnes E.
W.B.P.204, C.610
- Kocurek, K.
Th.A.P.102, T.B.P.312
- Kocurek, Kathryn M.
A.525
- Koda, R. T.
T.B.P.61
- Koda, R. I.
W.B.O.5
- Kodama, T.
W.C.P.9
- Koeffler, J. P.
W.C.P.85
- Koehl, C.
T.C.P.43
- Koenig, B.
E.500, E.629
- Koenig, B. A.
M.D.P.85, E.599, E.628
- Koenig, S.
W.C.O.39
- Koenig, Scott
W.C.O.41
- Koenig, T.
W.B.P.189, W.B.P.220
- Koerner, D.
M.A.P.40
- Koerper, M.
T.B.P.177
- Koester, S.
Th.D.P.81
- Koff, Wayne C.
M.C.P.3
- Koffi, K.
M.G.P.25
- Koffmann, D.
M.G.O.29
- Kohen, M.
Th.A.P.25
- Kohler, A.
Th.B.P.280
- Kohler, C.
C.541
- Kohlhoff, A.
T.E.P.70
- Kohmescher, R. N.
W.E.O.7
- Kohmescher, Robert N.
E.592
- Köhn, H.
M.B.P.213
- Köhn, R.
M.A.O.27, W.D.P.82
- Kohn, Robert
M.D.P.30
- Kohn, S.
T.E.P.40
- Koike, K.
M.A.P.42
- Koistinen, J.
Th.A.P.2
- Koistinen, Jukka
M.B.P.159
- Kojima, A.
Th.C.P.96
- Kok, P. W.
T.D.P.34
- Kokkevi, A.
Th.D.P.72
- Kolakathis, A.
Th.D.P.76
- Koib, G. R.
T.E.P.25

- Kolbe, L.
W.E.P.49, W.E.P.50
- Koleis, J.
M.A.P.76, T.A.P.52
- Kolesnitchenko, V.
M.C.P.28, C.733
- Koller, S.
Th.B.P.380
- Koller-Campert, K.
Th.B.P.59
- Koller-Lampert, Karin
Th.B.P.60
- Konde-Lule, J.
W.D.P.8, M.G.O.14
- Konde-Lule, Joseph K.
M.G.O.13
- Kondraske, G. V.
Th.B.P.282
- Kong, L.
M.C.O.7
- Kong, Lilly I.
T.C.O.19
- König, H.
C.566
- Könneke, J.
Th.B.P.275
- Konno, Akihro
W.C.P.21
- Konstantinidis, R.
E.654, E.747
- Kontio, S.
W.B.P.102
- Kontopoulou-Griva, I.
B.544
- Koopman, C.
T.D.P.4, T.D.P.12, D.506
- Koopman, Cheryl
T.D.P.90
- Koopman, James S.
Th.A.P.84
- Koot, A.
B.510
- Kopka, M. L.
C.682
- Kopolo, Olive
M.B.O.9
- Köppen, Stefan
M.B.P.331
- Koralnik, Igor
Th.B.P.280
- Korber, B.
Th.G.P.6
- Korber, Bette
W.G.P.22
- Korczyński, E.
W.E.P.63
- Koren, G.
Th.B.P.5
- Korkolainen, Mirja
W.B.P.102
- Kornaszewski, Wacław
W.B.P.276
- Kornbluth, R. S.
Th.C.P.79
- Kornbluth, Richard S.
Th.C.P.29
- Kornfeld, Hardy
T.C.P.15
- Korniewicz, Denise M.
T.D.P.70, M.H.P.27
- Kornilova, M.
T.C.P.145
- Kosecoff, J.
M.B.P.376
- Kosia, Andrew
W.G.P.16
- Kosseim, M. L.
T.A.P.91
- Kossyphidou, J.
E.747
- Kočeva, R.
B.614
- Kotler, D.
W.B.O.38, T.C.P.64
- Kotler, D. P.
W.B.P.38, Th.B.P.312,
M.C.O.27, W.C.P.131
- Kotler, Donald P.
W.B.O.29, Th.B.O.37,
M.B.P.135, C.664
- Kotloff, Karen L.
T.A.P.16, T.B.P.263
- Kotsianopoulou, M.
W.A.P.37
- Koucher, Bernard
M.F.O.14
- Koumare, B.
W.E.P.71
- Koup, R. A.
T.B.P.209
- Koup, Richard A.
T.C.P.24
- Kouri, Y.
T.H.O.12, W.H.P.3
- Kouri, Y. Z.
M.C.P.78
- Kouri, Yamil
T.H.O.10, W.H.P.4
- Kourilsky, F.
Th.C.P.9
- Kourilsky, P.
M.C.P.7
- Kourouma, Hamadou
W.H.O.2
- Kourouma, K.
T.G.P.28
- Kourounis, G.
Th.H.P.15
- Kouzesek, V.
W.B.O.36
- Kouzi, A.
Th.D.O.6, Th.D.P.17
- Kouzi, A. C.
Th.D.P.84
- Kouzi, Anthony C.
Th.E.P.4
- Kovacs, A.
T.A.P.65, T.B.P.161
- Kovacs, J. A.
Th.B.O.43, T.B.P.6
- Kovacs, Joseph A.
W.B.P.335
- Kovacs, R.
T.A.P.13
- Kowalski, Alex
M.E.O.25
- Kowalski, M.
M.C.O.22
- Koyada, R.
M.B.P.185
- Koyama, T. K.
B.512
- Koyanagi, Y.
T.C.O.16
- Kozak, L. J.
Th.H.P.5
- Kozhich, A.
T.C.P.144
- Kozhich, Alexander T.
W.B.P.131
- Kraft, P.
T.D.P.5, T.E.P.31
- Králl, G.
T.C.P.141
- Krämer, Alexander
M.A.O.45
- Kramer, D.
Th.C.P.36
- Krampf, W.
T.A.O.31, M.A.P.100
- Krane, S.
Th.C.P.13
- Kranzler, S.
Th.B.P.224, Th.B.P.237
- Krapf, F.
C.679
- Krasinski, K.
T.A.O.17, T.A.P.24, M.B.P.20,
M.B.P.70, C.554
- Krasinski, Keith
Th.A.P.15
- Krasnik, A.
A.518, A.579, M.D.P.55
- Krasnovsky, F.
M.D.P.6
- Krasser, R.
Th.B.P.153, Th.B.P.154
- Kraus, E.
T.A.P.109
- Kraus, Elissa M.
Th.B.P.34
- Kraus, G.
C.696
- Kraus, J. L.
T.C.O.1
- Kravitz, R. K.
W.B.P.251
- Krayevsky, A.
T.C.P.145
- Krčňák, V.
Th.C.P.127
- Krebs, J.
Th.A.P.109, W.B.P.113,
M.G.P.24
- Krebs, J. W.
T.B.O.7
- Krebs, John W.
T.G.P.25
- Kreeck, M. J.
T.A.P.48, A.550
- Kreider, D.
T.A.P.13
- Kreiss, J.
Th.A.O.25, W.A.P.65,
Th.G.O.52, M.G.P.27
- Kreiss, J. K.
T.A.P.88, B.536
- Kreiss, Joan
M.A.O.36, M.B.P.53
- Krell, P.
W.C.P.69
- Krenc, C.
W.B.P.135
- Kreniske, John
Th.E.O.15, E.580
- Krepcho, M.
Th.D.P.37
- Krepcho, M. A.
T.D.P.11, E.552
- Kress, Y.
W.C.P.61
- Kreuz, W.
A.606, T.B.P.200, T.B.P.218,
T.B.P.250
- Kreuz, Wolfhart
T.B.P.257
- Krickeberg, H.
C.546, C.573
- Kriebel, P.
M.C.O.20
- Krieger, John N.
B.578
- Krieger, M. S.
B.578
- Krieger, Monica S.
T.B.P.129
- Krings, M.
Th.E.P.21
- Krishnan, Vijaya L.
C.518
- Kristunas, E. P.
A.529
- Kristensen, J. H.
D.559
- Kritski, A. L.
Th.B.P.37
- Kritski, Afranio Lineu
Th.B.P.74

- Krochmal, E.**
 B.634
Kroger, F.
 W.D.P.44
Kroger, Fred
 E.588
Kroliczak, Alice
 W.D.P.33
Kronauer, C.
 Th.B.P.81
Kronawitter, U.
 W.D.P.3
Krone, W.
 W.C.P.56
Kronenberger, H.
 M.B.P.210
Kronenfeld, J.
 M.D.P.80
Kronfeld, M.
 T.B.P.336, W.B.P.48,
 Th.B.P.36, Th.B.P.39, W.G.P.3
Kronfeld, Matias
 M.B.P.102, W.B.P.20,
 W.B.P.41, Th.B.P.47
Kroon, S.
 W.B.P.280, W.D.P.55
Krowka, J.
 W.C.P.128
Krowka, John F.
 W.C.O.40, T.C.P.13
Krown, S. E.
 T.B.P.299
Krown, Susan E.
 Th.B.O.28, W.B.P.309,
 W.B.P.374
Krueckl, Judy G.
 T.E.P.29
Krueger, L.
 M.D.P.35, W.D.P.6
Kruger, S.
 Th.B.P.307
Krüger, T.
 Th.A.P.65, W.H.P.16
Krulik, M.
 T.B.P.279
Krumholz, H. M.
 M.B.P.375
Krupka, U.
 B.618
Krupka, Udo
 W.B.P.93, B.562, B.624
Krust, B.
 T.C.O.5, T.C.O.36
Krust, Bernard
 Th.C.P.85
Krutzsch, H.
 M.C.P.95
Kruzich, A.
 M.H.O.15
Krvavac, Sukrija
 M.C.P.138
Krystossek, Heinz
 M.B.P.125
- Kubacki, V. B.**
 W.B.P.315
Kubaneck, B.
 M.A.P.40
Kubicki, S.
 Th.B.P.274, Th.B.P.275
Kubota, H.
 Th.A.O.31, Th.A.P.17
Kucera, L.
 Th.C.P.62
Kucera, Louis S.
 W.C.O.21
Kuchino, Y.
 C.606
Kucik, S.
 T.B.P.224
Kueberuwa, S.
 W.C.P.35
Kuechler, M.
 T.D.P.21
Kuehn, J. E.
 M.B.O.24
Kuhls, T.
 M.B.P.110, Th.E.P.59
Kuhn A. C.
 D.665
Kühnel, H.
 Th.C.O.24
Kuhns, M.
 T.B.P.80, Th.B.P.111
Kuiken, C.
 W.A.P.36, W.C.P.44
Kukaine, R. A.
 T.B.P.342
Kukhanova, M.
 T.C.P.145
Kulaga, H.
 W.C.P.41
Kulaga, Henrietta
 W.C.P.16
Kuller, L.
 W.C.P.33
Kumar, A. M.
 W.B.P.190
Kumar, Mahendra
 W.B.P.190
Kumar, P.
 T.C.O.20, W.C.P.79
Kumar, R.
 T.B.P.82
Kunches, L.
 M.A.O.25, W.D.P.81, W.E.P.53
Kunches, Lauren M.
 Th.A.P.98, D.579
Kung, H. -S.
 M.C.P.66
Kung, J.
 W.B.P.142
Kung, P.
 C.561
Kunita, N.
 M.C.P.79
- Kunsch, C.**
 C.749
Kunsch, Charles
 M.C.O.31, M.C.O.31
Kunst, Robert P.
 E.708
Kunz, Christian
 W.B.P.99
Kunze, R. O. F.
 W.B.P.84, Th.B.P.153,
 Th.B.P.154, Th.B.P.172,
 Th.B.P.332, Th.B.P.342, C.517
Küpçü, Zaruhi
 T.C.P.38
Kupfer, U.
 W.B.P.318, Th.D.P.89
Kupper, L.
 Th.A.P.35
Kurashima, Y.
 M.C.P.108
Kurata, T.
 W.C.P.37, Th.C.P.96
Kurimura, T.
 C.753
Kurth, R.
 C.686, C.696
Kurtz, R.
 W.A.P.92
Kurz, T.
 D.703
Kusakabe, H.
 W.C.P.111
Kuster, H.
 M.C.P.83
Kuvin, L.
 M.H.O.14
Kuykendall, J.
 M.B.P.309
Kvalem, I. L.
 W.A.P.103, D.722
Kvarness, Ragnar
 Th.D.O.17
Kvinesdal, B.
 A.518, W.D.P.55
Kvinesdal, B. B.
 Th.B.P.156, T.G.P.31
Kvinesdal, Birgit Bak
 A.523, W.C.P.25, G.517
Kvitash, V. I.
 W.B.P.77, T.D.P.29
Kwarinooqi, A.
 M.E.P.8
Kwok, S.
 Th.A.P.110, A.616, Th.B.O.8,
 T.B.P.348, T.C.O.28
Kwok, Shirley Y.
 Th.B.O.7
Kyle, B.
 T.B.P.129
Kyllingstad, A.
 E.678
Kynaston, A.
 M.A.P.47
- L**
L'Age, M.
 M.B.P.120, T.B.P.28,
 T.B.P.375, Th.B.P.45
L'Age-Stehr, J.
 A.560, T.C.P.65, W.H.P.20,
L'Huilier, J. P.
 B.589
L.P.M.I.
 A.539
Lab, M.
 B.520
Labayle, D.
 D.644
Laberge, C.
 Th.A.P.39
**Labor & Occupational
 Health Program, UCB**
 E.748
Labrousse, Françoise
 Th.B.P.143
Lacasa, C.
 M.A.P.52
Lacassin, F.
 T.B.P.71
Lacaud, G.
 T.C.P.77
Lacerda, M. C. R.
 M.B.P.109
Lacey, J.
 E.539
Lachance, Colette
 M.E.P.45
Lachance, J.
 W.E.P.16
Lachapelle, L.
 M.C.P.29
LaCharité, Christopher
 M.D.P.81
Lackner, A.
 W.C.P.32
Lacoste, D.
 T.A.P.25, A.635, M.B.P.254
Lacouture, C.
 G.518
LaCouture, R.
 M.B.P.70
Lacouture, Yves
 T.B.P.89
Lacroix, Martial
 W.B.P.110, W.B.P.111,
 Th.B.P.371
Lacut, J. Y.
 T.B.P.282
Ladd, Holly D.
 E.535
Ladhoff, A. M.
 Th.C.P.145
Ladné, P.
 Th.C.O.22
Lafaix, C.
 A.562, B.557

- Lafferty, W.
T.A.P.72
- Lafferty, W. E.
B.551, E.731
- Lafferty, William E.
W.A.P.82
- Lafon, S.
W.B.O.2
- Lafontant, G.
T.B.O.8
- Lafuente, C.
G.512
- Laga, M.
M.A.O.32, M.A.P.49,
M.A.P.66, T.A.P.90,
W.A.P.96, T.B.P.108,
T.B.P.366
- Laga, Marie
Th.A.O.21
- LaGamma, D.
Th.F.O.2
- Lagarde, N.
T.B.P.191
- Lagrenade, L.
Th.G.P.1
- Lagüe, J.
W.E.P.11
- Lähdevirta, J.
Th.B.P.242, W.C.P.114
- Lahrer, M. P.
T.F.P.11
- Lal, Patrick K.
M.C.P.118
- Lai, S.
T.B.P.166
- Laio, P.
A.813
- Lairmore, M.
Th.A.O.32, Th.A.O.33,
Th.A.P.16, Th.A.P.31
- Lairmore, M. D.
Th.B.P.173
- Lairmore, Michael D.
W.C.P.4, Th.C.P.30
- Laitila, V.
Th.A.O.29
- Lake, D.
Th.C.O.4, Th.C.P.45
- Lake, Douglas
T.C.P.75
- Lake, E.
T.E.P.42
- Lake-Bakaar, G.
M.B.P.218, D.725
- Lallemant, M.
M.B.O.6, W.G.O.3
- Lallemant, Marc
Th.G.O.54, W.G.P.10
- Lallemant-Le Coeur, S.
M.B.O.6, Th.G.O.54, W.G.P.10
- Lallemant-Le Coeur, Sophie
W.G.O.3
- LaLota, Marlene
M.A.P.6
- Lam, W. Y.
W.G.P.30
- Lamarre, L.
W.B.P.30
- Lamaty, G.
C.630
- Lamb, G. A.
Th.A.O.16, Th.A.P.42
- Lambert, D.M.
W.C.O.11
- Lambert, J.
M.D.P.27
- Lambert, John S.
M.C.P.130
- Lamberto, Barbara
W.E.P.60
- Lambin, P.
M.A.P.102, M.A.P.106,
Th.A.P.116, W.B.P.368
- Lamboray, J. L.
M.H.O.2
- Lamerson, C. L.
W.C.P.68
- Lami, G.
T.B.P.235, Th.B.P.339
- Lamothe, F.
T.A.P.59
- Lamoureux, G.
Th.B.P.366
- Lampinen, T.
M.A.P.50
- Lampson, Judith
D.827
- Lampety, P. R.
T.B.P.133
- Lana Braga Costa, R.
M.B.P.231
- Lancastre, F.
T.B.P.1
- Lancee, W. J.
M.D.P.58
- Lanckriet, C.
T.B.P.191
- Lancôt, Lise
Th.H.P.1
- Lancôt, Lise L.
Th.E.P.68
- Landay, A.
Th.B.O.58, T.B.P.80,
T.B.P.83, T.B.P.206,
T.B.P.313
- Landay, A. L.
Th.B.P.111, T.C.P.21,
T.C.P.71, C.558
- Landay, Alan L.
T.B.P.224, Th.B.P.90,
Th.B.P.91
- Landers, D. V.
M.B.P.33
- Landers, S.
D.579
- Landesman, S.
T.A.O.5, M.B.O.42, T.B.P.240,
W.B.P.367, W.D.P.58,
Th.D.P.60
- Landesman, S. H.
Th.A.O.6, M.B.P.57, Th.B.P.50
- Landesman, Sheldon
T.F.O.20
- Landi, L. A.
T.E.P.59
- Landis, R.
W.E.P.41
- Landis, Suzanne E.
M.A.O.23, M.D.P.20
- Landman, R.
T.B.O.2, T.B.P.46, M.D.P.51,
M.H.O.13
- Landonio, G.
W.B.O.11, M.B.P.294
- Landonio, Giuseppe
T.B.P.272, C.729
- Landry, M.
W.C.O.8
- Landry, Yves
M.A.P.39
- Landthaler, M.
M.B.P.187, M.B.P.365
- Lane, C.
T.B.P.281, Th.F.P.14
- Lane, Clifford
W.C.O.20
- Lane, H.
M.B.P.128
- Lane, H. C.
Th.B.O.43, M.B.P.333,
W.B.P.322, W.B.P.335,
Th.B.P.179, M.C.O.10,
W.C.O.39, W.C.P.62,
W.C.P.106, M.D.P.88
- LaNeve, D.
W.C.P.55
- Lang, J. M.
W.B.P.282
- Lang, Jean-Marie
W.B.P.296, T.C.P.43
- Lang, L. S.
T.E.P.22
- Lang, M. C.
T.C.O.41
- Lang, Onnie S.
T.B.O.5
- Lang, S.
M.D.P.31
- Lang, Sabine
T.C.O.45
- Lang, W.
Th.A.P.84, W.B.P.363,
Th.B.P.144, E.732
- Lang, William
M.A.P.99, A.583
- Lange, J.
M.A.O.47, T.B.P.96,
Th.B.P.87, W.C.P.88
- Lange, J. M. A.
Th.B.P.210, W.C.P.46,
W.C.P.99
- Lange, Joep M. A.
M.B.O.23, M.B.P.362,
W.B.P.109
- Lange, M.
W.B.P.285, M.C.P.148
- Lange, Michael
A.650, W.B.P.80, B.554
- Lange, N.
Th.A.P.83
- Lange, W. Robert
T.A.P.13
- Langer, L. M.
T.D.P.21
- Langford, A.
W.B.O.20
- Langford, Angelika
W.B.P.84, Th.B.P.332,
Th.B.P.342
- Langley, C.
M.B.P.84
- Langlois, A.
Th.C.O.29, M.C.P.6
- Langlois, A. J.
A.599
- Laenza, P.
A.510
- Laenza, T.
W.B.P.357
- Lanzarini, P.
T.B.P.264
- Lanzoni, G.
M.B.P.96
- Laperriere, A.
W.B.P.181, Th.B.P.159,
T.D.P.42, D.677
- Laperriere, Arthur R.
D.881
- Laperriere, G.
W.A.P.72
- Lapointe, B. J.
T.D.P.30
- Lapointe, Bernard
T.E.O.7
- Lapointe, N.
Th.A.P.39, M.B.P.17,
T.B.P.151, T.B.P.217,
T.B.P.243, W.C.P.94
- Lapointe, S.
W.B.P.30
- Laporte, A.
Th.A.P.61, A.571
- Laporte, Anne
W.A.P.25
- Laporte, Jean-Philippe
W.B.P.283, W.B.P.320
- Laqueur, P.
A.628, W.B.P.245
- Laqueur, Peter A.
M.B.P.314

- Laquidara, Karen A.**
 E.510
Larder, B. A.
 T.C.O.4
Larder, Brendan A.
 T.C.O.7
Large, K.
 W.B.P.9
Larher, M. P.
 T.F.O.7, M.F.P.9, T.F.P.10,
 W.F.P.4
Larimore, M.
 Th.B.P.199
Laroche, Eddy
 W.A.P.16
Laroche, F. L.
 D.680
Laroche, R.
 W.B.P.14, B.599
LaRosa, G.
 W.C.O.18
Larouze, B.
 M.B.O.6, W.G.O.3, W.G.P.10,
 Th.C.P.04
Larsen, Charles E.
 Th.C.P.107
Larsen, M.
 M.A.P.15
Larsen, R.
 W.B.P.9
Larsen, R. A.
 M.B.P.45
Larsen, Robert A.
 W.B.P.11
Larsen, S. A.
 W.B.P.54
Larson, D. B.
 Th.B.P.216
Larson, E.
 B.586, M.H.P.27
Larsson, J.
 Th.D.P.21
Lasfargues, G.
 M.B.O.5
Lassegue, A.
 Th.A.O.30
Lassegue, Alex
 M.A.O.29
Lathey, Janet L.
 W.C.P.97
Lathrop, L.
 E.735
Latif, A.
 Th.A.P.5, W.C.P.96
Latif, A. S.
 Th.B.P.214, Th.B.P.217
Latif, Ahmad
 Th.G.O.15
Latif, Ahmed S.
 M.B.P.289
Latorre, X.
 W.B.P.40
- Latrelle, J.**
 W.B.P.43
Letteman, Nadine H.
 E.778
Lau, Allan S.
 W.C.P.82, W.C.P.83
Lau, L.
 W.H.P.12
Laubenstein, H. P.
 Th.B.P.122
Laubenstein, Linda J.
 M.E.P.23
Laude, M.
 T.C.P.3, C.529
Lauffer, D.
 T.A.P.96, T.A.P.97, T.D.P.71,
 Th.D.P.83, T.E.P.44
Laug, W.
 B.579
Laughlin, M.
 W.C.P.70
Laughlin, M. A.
 W.C.P.76
Laughlin, Mark A.
 W.C.P.70
Lauchon, B.
 M.H.P.27
Launay, D.
 Th.C.P.8
Laurance, J.
 Th.C.P.24
Laure, F.
 M.B.P.1, Th.B.P.10, T.C.O.40,
 C.680
Lauré, Françoise
 Th.C.P.70
Laurence, Jeffrey
 T.B.O.34
Laurent, A. G.
 T.C.O.5, T.C.O.38, Th.C.P.85
Laurian, Y.
 M.A.O.33
Laurie, K. E.
 T.B.P.110
Laurindo, L.
 D.540
Lauritzen, E.
 T.A.O.30
Lauritzen, Edgar
 W.B.P.125
Lauro, A.
 T.A.P.33
Laussecq, S.
 T.A.P.105
Laussucq, Suzanne
 W.A.P.84
Lautenberger, James A.
 M.B.O.22
Lauwers, G. Y.
 M.B.P.191
Laux, L.
 M.D.O.15, E.763
- Laux, Lila**
 W.D.P.5
Lavaysière, R.
 M.B.P.196, Th.B.P.254
Lavelle, G. C.
 M.C.P.125
Lavenhar, M. A.
 T.A.P.66
Lavenhar, Marvin A.
 A.551
Laverda, A. M.
 T.B.P.178
Laverda, Anna Maria
 T.B.P.186
Lavie, D.
 C.608
Lavie, G.
 M.C.P.18, C.608, C.626
Lavie, Gad
 C.501
Laviens, L.
 M.D.P.62, W.D.P.4
Lavilla, M. P.
 M.B.P.370, B.648
Lavilla, P.
 W.B.P.339, M.C.P.71
Lavoie, G.
 W.A.P.15
LaVoie, L.
 Th.B.P.240
Lavoie, Michel
 M.D.P.11
Law, W.
 W.B.O.43, Th.B.P.284,
 Th.B.P.286
Lawrence, A. G.
 M.B.P.262
Lawrence, David W.
 T.A.P.33
Lawrence, R.
 T.B.P.262
Lawrie, J. M.
 M.C.P.126
Lawson, L.
 T.B.O.29, T.B.P.54, T.H.P.11
Lawson, L. M.
 Th.B.P.52
Layne, A.
 C.553
Layne, S. P.
 T.A.O.39, Th.A.P.66
Layne, Scott P.
 Th.C.P.100
Lazanas, M.
 M.B.P.179
Lazaro, A.
 M.B.P.59
Lazartigues, A. L.
 T.D.P.10
Lazartigues, Alain A.
 T.D.P.86
Lazarus, L.
 M.D.P.6
- Lazzins, Janis K.**
 W.C.P.6, C.724
Lazo, C.
 Th.H.P.21
Lazzarin, A.
 W.B.O.11, W.B.O.34,
 T.B.P.23, W.B.P.146,
 W.B.P.200, W.B.P.215,
 Th.C.O.40, M.C.P.103, C.729,
 Th.D.P.39, Th.D.P.40, D.526
Lazzarin, Adriano
 M.B.P.336, M.B.P.351
Le Fichoux, Y.
 T.B.P.33, W.B.P.44
Le Foche, L.
 T.A.P.113, A.568
Le Gales, C.
 Th.E.P.23
Le Gales, Catherine
 M.H.O.5
Le Gunno, Bernard M.
 Th.B.P.151
Le Hoang, P.
 W.B.O.18, M.B.P.117,
 M.B.P.119
Le Pape, A.
 W.C.P.1
Le Port, C.
 W.B.P.26
Le, P.
 Th.B.O.59
Le, T.
 W.B.O.1, W.B.O.8, B.606
Le, T. N.
 W.A.P.57
Leach, C.
 C.787
Leach, Charles T.
 A.540, M.B.P.110, Th.E.P.59
Leach, R.
 A.519
Leadbetter, G.
 Th.C.P.105
Leader, M.
 M.C.O.20
Leahy, C.
 W.C.P.138
Leake, E.
 Th.C.P.62
Leal, M.
 W.B.P.9, W.B.P.165, B.640
Leal, M. A.
 W.B.P.11
Leary, J. J.
 W.C.O.11
Lebas, J.
 T.B.P.71, W.B.P.283,
 Th.B.P.11, Th.B.P.241,
 W.E.P.27, Th.E.P.7
Lebas, J. F.
 Th.B.P.282
Lebas, Jacques
 D.575, T.E.P.66

- Lebas, L. J.**
T.E.P.59
Leblanc, A.
B.844
LeBlanc, E.
W.C.P.133
Leblanc, J. F.
T.C.P.118
Lebour, V.
Th.D.P.35, D.601
Lebovits, A. H.
M.B.P.202
Lebovitz, V.
T.B.P.300, W.D.P.7
Lebras, P.
T.B.P.310
Lebret-Lerolle, D.
M.B.P.197
Lebrun, F.
T.G.O.21
Lecatsas, Gersimos
Th.H.P.19
Leckie, G.
C.721
Leclercq, P.
Th.B.P.251, Th.B.P.282
Lecocq, J.-P.
Th.C.O.47
Lecompte, T.
T.B.P.23
Lecomte, J.
T.B.P.217
Ledbetter, J. A.
W.C.P.58
Ledergerber, B.
M.A.P.88, Th.B.O.27,
T.B.P.50, W.B.P.72
Lederman, M.
M.B.P.84
Ledford, D. K.
Th.B.P.138
Lee, C.
T.B.P.65, Th.B.P.22, B.505,
M.E.O.13
Lee, C. A.
T.B.P.275, W.B.P.349,
Th.B.P.355, W.D.P.19
Lee, Christine A.
Th.B.O.35
Lee, Christine Ann
M.A.P.41, M.A.P.96, W.B.O.28
Lee, D.
W.B.P.166
Lee, D. D.
E.570
Lee, F.
T.A.P.118, T.A.P.119,
M.B.P.346, T.B.P.223,
Th.B.P.93
Lee, H.
Th.A.O.33, Th.A.P.10,
Th.A.P.13, Th.A.P.20,
Th.B.O.59, B.583
Lee, H.
B.636
Lee, Helen
Th.A.O.29, Th.A.P.21,
Th.A.P.119, B.630, B.634,
C.721
Lee, K.
M.C.P.100
Lee, K. D.
Th.C.P.107
Lee, K.-H.
C.585
Lee, M.
M.A.P.12, Th.A.P.92,
W.C.P.111
Lee, N. C.
Th.A.O.15
Lee, P. R.
T.H.P.8
Lee, P. V.
E.611
Lee, S.
D.651
Lee, S.-W.
T.C.P.126
Lee, S. H.
T.A.P.120
Lee, S. J.
T.C.P.89
Lee, Shirley J.
W.B.P.264
Lee, Stephanie L.
T.B.F.116
Lee, T. H.
Th.A.P.31, T.C.O.17,
T.C.P.29, Th.C.P.18, C.710
Lee, Tun-Hou
T.C.P.51
Lee, W. R.
T.C.P.51
Lee, Y. H.
W.G.P.30
Leedom, J. M.
M.B.O.49, W.B.O.5, M.B.P.45,
M.B.P.83, W.B.P.24,
W.B.P.286, W.B.P.358
Leentvaar, A.
T.D.P.34, G.520
Leentvaar-Kuijpers, A.
T.A.P.82
Leeper, Mary Ann
W.D.P.39
Leete, J.
Th.A.O.29, Th.A.P.49,
Th.B.O.59
Lefebvre, A. M. L.
E.584
Lefebvre, Arlette M. L.
E.584, E.619
Lefebvre, Suzie
Th.C.P.83
Lefkowitz, L. B. Jr.
W.B.P.239
Lefkowitz, Mathew
M.B.P.202
Lefkowitz, P.
D.688, T.E.P.10
Lefkowitz-Korenblit, Pearl
D.650
Lefort-Jost, S.
M.D.P.79
Lefranc, J. P.
M.B.P.55
Lefrère, J. J.
M.A.P.106, W.B.P.368,
Th.B.P.160, Th.B.P.162
Lefrère, Jean-Jacques
M.A.P.102, Th.A.P.116,
Th.B.P.140, T.G.P.131
Legay Vermelho, L.
E.806
Léger, J.-M.
Th.B.O.21, Th.B.P.196
Legg, William G. W.
Th.G.O.6
Leggott, P.
Th.B.P.347
Legoaster, Jacqueline
C.564
Lehman, J.
T.B.P.88
Lehman, J. S.
T.A.P.54
Lehman, J. Stan
W.A.P.21
Lehman, P.
Th.G.P.20
Lehmann, P.
W.A.P.116, W.A.P.117
Lehmann, Ph.
D.636, E.739
Lehr, L.
T.C.P.43
Lehrman, S.
T.C.O.42
Leibel, J.
T.A.P.104, W.A.P.93, A.628,
W.B.P.307
Leiberich, P.
T.D.P.46, D.654
Leibowitch, J.
M.B.P.350, B.558, Th.C.P.98
Leibowitch, Jacques
W.C.P.72
Leidl, Reiner
W.H.O.16
Leigh Brown, Andrew J.
T.C.P.124
Leigh, M.
Th.A.P.82, M.H.O.10, M.H.P.5
Leigh-Brown, A. J.
T.C.P.92, Th.C.P.69, C.669
Leik, R. K.
Th.E.P.54
Leikola, J.
Th.A.P.2
Leinikki, P.
B.552
Leinikki, Pauli O.
Th.A.P.2, A.609
Leite, C. T. C.
W.B.P.266
Leite, E. A.
D.709
Leite, Jane Te Luzia
M.E.P.66
Leithner, A.
E.530
Leitman, Paul
Th.B.P.51
Lekas, P.
M.C.P.55, M.C.P.111,
Th.C.P.137
Lelie, N.
M.B.P.162, W.B.P.171,
Th.C.P.55
Lema, Valentino M.
W.E.P.72
Lemagnen, J.
C.564
Lemaigre, G.
Th.B.P.92
Lemaire, Jean-Marie
Th.A.P.3
Lemaître, Marc M. A.
C.630
Lemarie, E.
W.C.P.1
LeMay, M. D.
T.B.P.150, T.B.P.249
Lemay, Mireille D.
B.591
Leme, S. S. T.
W.B.P.21
Lemire, A.
E.761
Lemke, A. L.
M.D.P.22
Lemoine, C.
Th.B.P.19
Lemon, S. M.
M.A.P.45
Lemos, Ricardo S.
C.780
Lemoux, Yvon
E.680
Lemp, G.
T.E.P.7
Lemp, G. F.
T.A.O.36, M.A.P.60,
M.A.P.84, W.A.P.24,
W.A.P.27, W.A.P.80,
Th.B.P.201, M.D.P.26
Lemp, George F.
W.A.P.14, W.B.P.354
Lemp, J. F.
M.C.P.44
Lenahan, G.
M.B.P.193

- Lendvay, J.
T.B.P.302
- Lennick, Michael
C.540
- Lennox, J.
B.550
- Lenoir, L. G.
C.899
- Lenox, T. H.
M.B.P.189, T.B.P.37
- Lentino, J.
W.B.P.268, W.D.P.72
- Lentino, Joseph R.
Th.A.P.1
- Lenzner, U.
Th.B.P.329
- Leombruno, C.
T.B.P.254
- Leon, Antonio
T.D.P.85
- Leon, C.
M.B.P.286
- Léonard, G.
A.587, C.785, W.G.P.2
- Léonard, Guy
W.B.P.108, C.786
- Leonard, J. M.
T.C.P.94
- Leonard, Noelle R.
B.595
- Leoni, G. C.
Th.B.P.56
- Leoro, G.
M.G.O.28
- Leoro-Monroy, Galo
M.G.P.19
- Leoung, G.
T.B.P.30
- Leoung, Gifford S.
T.B.O.3, T.B.P.76, T.B.P.78
- Lepage, P.
T.B.P.203
- Lepage, Philippe
T.B.P.374, Th.B.P.187, B.543,
W.G.O.8
- Lepeu, G.
T.B.P.288
- Lepicier, R.
M.E.P.15
- Lepine, D.
T.B.P.106, T.B.P.314,
W.B.P.161
- Lépine, M.
A.547
- Lepont, F.
M.D.P.40
- Lepont, C.
M.B.P.179, M.B.P.226,
T.B.P.319
- Lepont, C. L.
W.B.P.36
- Lepont, J. L.
W.B.P.36
- Leprière, A.
T.B.O.2, T.B.P.49
- Lerche, B.
T.B.P.59
- Lerche, N.
T.C.O.39, W.C.P.18
- Lerche, N. W.
W.C.P.23, W.C.P.26
- Leroy, J.
T.B.P.382
- Leroy, O.
W.B.P.248, Th.B.P.105
- Lerro, M.
M.A.P.120, E.551
- Lertora, J. J. L.
M.C.P.64
- Lesieur, C.
B.617
- Lesieur, S.
T.A.P.75, M.D.P.40
- Leslie, N.
T.B.P.355
- Lesniak, L.
D.643
- Lesser, M.
W.B.P.333
- Letellier de St-Just, Louis
M.F.O.5
- Letellier, L.
T.F.O.6
- LeTourneau, J.
Th.A.P.76
- Letterst, C.
M.C.P.123
- Leturcq, D. J.
M.C.P.15
- Leturcq, Didier J.
M.C.P.67
- Letvin, N. L.
W.C.O.42, W.C.P.75
- Letvin, Norman L.
Th.C.O.16
- Letwin, B.
Th.B.O.6
- Letz, R. E.
Th.B.P.276
- Letzel, H.
E.649
- Leukefeld, C. G.
Th.D.O.18
- Leukefeld, C. J.
D.599
- Leung, F. Y.
W.G.P.30
- Leung, L.
W.D.P.36
- Levacher, Maryse
M.B.P.347, Th.B.P.166
- Levadoux, M.
M.G.P.21
- Leveque, D.
D.513
- Leveques, Dominique
D.569
- Lever, Andrew M. L.
Th.C.P.50
- Lever, J.
T.D.P.18
- Levey, D. I.
M.B.P.87
- Levi, G. C.
W.B.P.31, Th.B.P.40, B.522
- Levi, Guido Carlos
T.B.P.317, Th.F.P.1
- Levillain, R.
M.B.P.41, Th.B.P.253
- Levin, B.W.
T.F.P.12
- Levin, C.
W.B.P.306
- Levin, S. A.
A.605
- Levine, A. M.
M.B.O.48, M.B.P.366,
W.C.P.49
- Levine, Alexandra M.
Th.B.O.44
- Levine, C.
W.F.O.7
- Levine, Carol
M.E.P.29, E.513, T.F.O.13
- Levine, Carole
W.F.O.8
- Levine, James D.
W.B.P.328
- Levine, Martin
D.700
- Levine, Martin P.
Th.E.P.51
- Levine, P. H.
Th.A.P.26, W.B.O.25
- Levine, P. H.
M.A.O.23
- Levine, Robert
W.F.O.1
- Levine, Robert J.
W.B.O.51
- Levine, Stuart H.
C.584
- Levinstein, R.
M.A.P.59
- Levitt, N.
T.B.O.29
- Levitt, Nirvair
T.H.P.11
- Levy, A.
W.A.P.88
- Levy, C. S.
M.B.P.49
- Levy, D.
T.G.P.13
- Levy, E.
W.B.P.73
- Levy, Elinor M.
D.713
- Levy, H. B.
Th.B.O.45
- Levy, J.
T.B.P.197, C.649, T.D.O.15
- Levy, J. A.
T.C.O.21, T.C.O.32, W.C.O.5,
W.C.O.37, T.C.P.104,
T.C.P.132, W.C.P.26,
Th.C.P.47, Th.C.P.50,
Th.C.P.49, Th.C.P.50,
Th.C.P.51, Th.C.P.65
- Levy, J. K.
W.B.P.191, W.B.P.195
- Levy, Jack
W.A.P.49
- Levy, Jay A.
M.C.O.1
- Levy, M.
M.D.P.64
- Levy, P.
T.D.O.15
- Levy, Robert M.
Th.B.P.283, C.759, Th.B.P.375
- Levy, S.
T.C.P.43
- Lewandowski, C.
Th.A.P.9
- Lewi, D.
B.839
- Lewi, D. S.
M.B.P.266, B.525, E.704
- Lewi, David Salomao
M.B.P.263
- Lewinski, C.
A.629
- Lewis, A.
D.632, D.639
- Lewis, B.
T.A.P.29
- Lewis, B. F.
W.A.P.106, Th.A.P.56, E.595
- Lewis, Benjamin F.
T.A.P.35, T.E.P.16, W.E.P.12
- Lewis, C.
T.E.P.47
- Lewis, C. E.K.
Th.E.P.11
- Lewis, D. E.
T.C.P.47
- Lewis, Diane K.
Th.D.O.14
- Lewis, Dorothy E.
M.C.P.20, M.C.P.124
- Lewis, E.
T.B.P.177
- Lewis, Edwin M.
Th.B.P.205
- Lewis, F.
M.B.P.244
- Lewis, I.
D.542
- Lewis, J.
T.A.P.118

- Lewis, J. A.**
 Th.C.O.30
Lewis, K.
 W.D.P.43
Lewis, N.
 T.B.O.4, M.B.P.192, T.C.P.80
Lewis, P. A.
 E.757
Lewis, S.
 W.B.P.174, W.B.P.175
Lewis, Stephen J.
 C.865
Lewis, Y.
 E.769
Lewis, V. M.
 A.514
Ley, D.
 M.E.P.47
Li, D.
 E.787
Li, G.
 M.C.P.126, C.645
Li, H.
 W.C.O.24
Li, K.
 T.B.P.156, B.582
Li, P. C. K.
 T.A.P.120
Li, Patrick C. K.
 W.G.P.30
Li, S.
 Th.B.P.104
Li, X. L.
 W.B.P.159, Th.C.P.68,
 M.G.P.12, M.G.P.13,
 M.G.P.14, M.G.P.20
Li, Y.
 W.B.P.177, W.C.P.9,
 Th.C.P.23
Li, Yen
 Th.C.P.58
Liambi, A.
 M.G.O.17
Liang, Chi-Ming
 Th.B.P.109, Th.C.P.42
Liang, K. Y.
 W.A.P.69
Liang, L.
 Th.B.P.104
Lieberman, B.
 E.725
Libonatti, O.
 M.D.O.10, W.G.P.18
Libonatti, Osvaldo V.
 B.548
Lichtiger, B.
 B.631
Lida, H.
 Th.B.P.336
Lidman, K.
 W.A.O.10, Th.H.P.10
Lieb, L.
 T.B.P.167
Lieb, L. E.
 Th.A.P.50
Lieb, Loren E.
 T.A.P.67, M.B.P.68
Lieb, S.
 M.A.P.6
Lieb, Spencer
 T.D.P.21
Liebes, Leonard
 C.561
Liebman, H. A.
 T.B.P.297
Liekweg, Richard J.
 M.H.P.10
Liekweg, R.
 E.828
Lien, A.
 D.985
Liepold, Heidi M.
 D.503
Liepold, M.
 T.D.P.87
Liesnard, Corrinne A.
 M.B.P.357
Lietman, P. S.
 T.B.P.295, M.C.P.85
Lifschitz, Marta
 T.B.P.175
Lifshitz, M.
 W.B.P.177
Lifson, A.
 M.B.O.50, W.B.P.162, T.H.O.3
Lifson, A. R.
 M.A.O.27, T.A.O.32,
 M.A.P.111, M.B.P.224
Lifson, Alan R.
 W.A.P.46, Th.A.P.86, Th.B.O.9
Lifson, J.
 W.C.O.16, T.C.P.90
Lifson, J. D.
 C.596
Light, D.W.
 M.E.P.60
Lightfoote, Marilyn M.
 T.C.O.2
Ligthelm, R. J.
 T.D.P.34, G.520
Likimani, Sopiato
 Th.B.P.346
Likitnukul, S.
 T.B.P.221
Lile, C. C.
 C.669
Lillehoj, E.
 Th.C.P.25
Lillehoj, Erik
 Th.C.P.115
Lim, S. C.
 W.D.P.19
Lim, Seng Gee
 T.B.P.275, W.B.P.349,
 Th.B.P.355
Lim, W. L.
 T.A.P.120
Lima, C. O.
 A.554
Lima, J. N.
 M.B.P.93, T.G.P.14, Th.G.P.3
Lima, M.
 M.G.P.15
Lima, M. P.
 Th.B.P.337, D.543
Lima, M. P. J. S.
 D.709, D.714
Lima, Maria Patelli P.S.
 D.504, E.781
Lin, H. C.
 C.754
Lin, M.
 B.542
Lin-Greenberg, A.
 Th.A.O.23
Linard, Françoise
 W.B.P.380
Lincoln, P.
 T.B.P.45
Lindan, Christina P.
 W.A.P.24
Linde, R.
 D.713
Linder, C. R.
 M.C.O.24
Lindgren, S.
 W.A.P.52
Lindhardt, B. ø.
 T.A.O.30, W.B.P.125
Lindhölm, Merete M.
 W.E.P.38
Lindner, L.
 Th.B.P.26, Th.B.P.28
Lindsay, A.
 Th.D.P.79
Lindsay, L.
 E.640, D.641
Lindsey, B.
 M.E.P.8
Lindvig, K.
 M.B.P.259
Linhares, D.
 M.A.P.53
Link, B.
 C.555
Linn, L.S.
 E.724
Linnemann, Calvin C. Jr.
 C.713
Linsk, Nathan L.
 M.D.P.63, D.634
Lint, T. F.
 C.568
Liomba, N. G.
 W.G.O.29, Th.G.O.28, G.507
Liou, M.
 T.E.P.62
Lipka, J.
 Th.A.P.110, M.B.P.173
Lippke, J. A.
 Th.B.P.338
Lipschik, G.
Lipschik, G. Y.
 T.B.P.16
Lipscomb, J.
 Th.O.11
Lipschultz, Steven E.
 T.B.P.146
Lipshutz, C.
 E.589
Lipsky, M.
 Th.C.P.108
Lipton, D. S.
 W.A.P.106, T.D.P.77
Lisa, Joseph F.
 M.F.P.11
Lisandre, H. L.
 T.D.P.10, T.D.P.86
Lischner, H. W.
 A.631, C.612, C.613, T.D.O.31
Lischner, Harold W.
 T.B.P.225
Lischner, W.
 T.C.P.99
Lischwe, M. A.
 C.572
Liseo, B.
 M.D.P.37
Lisker, A.
 A.599
Liskin, L.
 M.E.O.12
Lisse, I.
 Th.B.P.156
Lissen, E.
 W.B.P.165, B.640
Litoux, P.
 C.549
Littell, C.
 M.D.O.14
Litterst, Charles
 M.C.P.122
Liu, D.
 C.719
Liu, D. J.
 W.B.P.133
Liu, J.
 Th.C.O.3
Liu, P.
 M.C.P.117
Liu, Q. L.
 Th.B.P.356, Th.B.P.366
Liu, S.
 Th.C.P.138
Liu, T.
 Th.C.O.16, M.C.P.72
Liu, Wu-Tse
 T.C.P.143

- Livartowski, J.
 W.C.O.46
 Livesey, J. F.
 W.C.P.82
 Livingston, Gary L.
 W.E.P.43
 Livrozet, C.
 W.E.P.23
 Livrozet, J. M.
 W.B.P.55, W.B.P.296,
 Th.B.P.147, Th.B.P.247,
 Th.B.P.365, Th.E.P.12
 Livrozet, Jean-Michel
 T.B.P.47, C.628
 Lizard, G.
 C.591
 Lizioli, A.
 W.B.P.365, Th.B.P.86
 Ljungberg, B.
 C.717, W.D.P.85, Th.D.P.36
 Ljunggren, K.
 Th.A.P.113, M.C.P.10,
 Th.C.P.97, Th.C.P.125
 Ljunggren, Kristina
 T.C.P.55
 Liana, T.
 Th.C.P.72
 Llistar, R.
 T.D.P.64, T.D.P.65, D.699
 Llorente, R.
 T.B.P.274, Th.B.P.69
 Lloyd, G.
 A.617
 Lloyd, Gary A.
 T.E.O.4
 Lo, B.
 E.715
 Lo, E.
 W.B.P.56
 Lo, S.-C.
 Th.C.P.63, C.738
 Lobo, I. M. F.
 W.B.P.31
 Loche, M.
 Th.C.O.6
 Lockett, G. J.
 W.D.P.52
 Lockey, R. F.
 Th.B.P.138
 Lockhart, A.
 W.B.O.22
 Lockwood, D.
 C.663
 Lockwood, Don E.
 T.B.P.102
 LoConte, J.
 A.580
 LoConte, J. L.
 E.713
 Lode, H.
 W.B.P.278
 Loeb, I.
 Th.B.P.345
- Loeffelhoelz, M.
 M.C.P.50
 Loewen, N.
 M.D.P.73
 Lofti, C. J.
 E.704
 Loftus, P.
 T.D.P.8
 Lofy, L.
 Th.A.P.12
 Logan, D.
 W.B.P.128
 Logan, K. A.
 M.C.P.126
 Logan, R.
 M.B.P.244
 Logerot, H.
 M.H.O.12, M.H.P.19
 Loh, J. P.
 M.B.P.341
 Lokiec, P.
 M.B.P.88
 Lomami, L.
 W.G.O.30
 Lombardo, J.
 A.563
 Lombardo, Joseph M.
 M.A.P.16
 Lomvardias, Stylianos
 M.B.P.177, B.560, B.616
 London, J.
 M.C.O.30
 Long, I.
 W.B.P.250, W.B.P.257,
 E.689, E.692, E.760, E.772,
 Th.G.P.10
 Long, Iris
 W.B.P.249, C.590, C.640
 Long, O.
 D.504
 Longiaru, M.
 A.629, W.B.P.122
 Longini, Ira M. Jr
 T.A.O.36
 Longini, T. M. Jr.
 Th.A.P.67
 Longinovic, D.
 T.A.P.75
 Longo, L.
 T.B.P.356, W.B.P.115,
 M.G.P.8, G.518
 Longo, N.
 Th.B.P.184, W.C.P.120
 Longo, P. H.
 Th.D.P.89
 Longo, P. H. P.
 M.E.O.17
 Longo, Paulo H. P.
 T.D.P.83, W.D.P.38, D.532
 Longshore, D.
 W.E.P.33
 Longshore, S. L.
 W.A.P.87
- Longshore, S. T.
 W.A.O.20
 Looney, D. J.
 Th.C.O.11
 Looney, D. L.
 Th.C.O.13
 Looney, David J.
 M.C.O.21, Th.C.P.22
 Lopalco, Lucia
 A.510
 Lopes, G. S.
 M.B.P.74, M.B.P.281,
 T.B.P.365
 Lopez Elzaurdia, C.
 M.B.P.214
 Lopez Gomez, J. M.
 M.B.P.277
 Lopez, C. A.
 M.A.O.46
 Lopez, L.
 W.G.O.2
 Lopez, L. A.
 W.A.P.48
 Lopez, M. L.
 M.E.O.23
 Lopez, O.
 W.G.O.44
 Lopez, S.
 T.A.P.55
 Lopez-Anaya, A.
 M.B.P.13, M.B.P.15, M.B.P.22
 Lopez-Botet, M.
 Th.B.P.77
 Lopez-Correa, R.
 W.G.O.2
 Lopez-Juarez, A.
 Th.E.O.6a
 Lops, R.
 M.A.P.18
 Lord, C. I.
 W.C.O.42
 Lord, E.
 Th.D.P.16
 Lord, S.
 M.B.P.143
 Lore, V.
 M.D.P.28
 Lorenzo, R. et al.
 T.S.P.159
 Lorentsen, Kevin J.
 T.B.P.295
 Lorenz, B. F.
 M.F.P.13, Th.F.P.3
 Lorenzetti, T. M.
 D.604
 Lori, F.
 C.681
 Loring, K.
 T.G.P.4
 Los, A. P. M.
 E.651
 Losilla, J. M.
 D.671
- Lososky, G. A.
 T.B.P.283
 Loubeyre, J.-L.
 A.543
 Loue, S.
 Th.D.P.51
 Louie, B.
 W.B.P.162
 Louie, Leslie G.
 Th.A.P.83
 Louis, A.
 T.G.O.20
 Loukaka, J. C.
 G.511
 Lounsberry, G.
 W.D.P.26
 Lourea, D.
 M.H.P.24
 Lourenco, M. H.
 M.A.P.84, A.512
 Lourenco, M. H.
 M.G.P.2
 Lourenco, Maria Helena
 A.511
 Lourenco, R.
 M.G.P.15
 Louras, L.
 T.B.O.12
 Loures, L. A.
 W.G.P.14
 Loures, Luiz
 W.G.P.13
 Loustaud, V.
 B.523
 Louvet, C.
 T.B.P.279
 Love, E.
 W.B.P.166
 Love, W. C.
 W.B.O.7
 Loveday, Clive
 Th.C.P.128
 Loveless, Mark O.
 W.B.P.288
 Lovelle-Drache, J.
 T.A.O.22
 Low, L.
 W.C.O.23
 Lowder, J.
 Th.B.P.166
 Lowe, D.
 T.C.O.4
 Lowenfels, A. B.
 D.628
 Lowenstein, W.
 W.B.P.355
 Lowenstein, L. J.
 W.C.P.147
 Löwer, J.
 T.C.P.12
 Löwer, Johannes
 C.566

- Lowery, S.
M.B.P.346
- Lowinson, J. H. L.
W.D.P.43
- Lowry, P.
Th.A.P.47
- Loy, A.
T.B.P.252
- Loysee, J.
M.A.O.24
- Lozada-Nur, F.
M.B.O.21, Th.B.P.341
- Lozada-Nur, Francina I.
Th.B.P.333
- Lozat, R.
Th.E.P.12
- Lu, B.
A.619, Th.H.P.26
- Lu, Wei
Th.C.P.104
- Lu, Xiaopin
T.C.P.81
- Lu, Y. C.
T.C.O.49
- Luabeya, M.
Th.B.P.211
- Luabeya, Mesu'a-Kabwa
Th.B.P.221, Th.B.P.267
- Lubaki, N.
Th.B.P.166, Th.B.P.239
- Luban, N.
T.B.P.230, M.D.P.10
- Luban, Naomi L. C.
T.B.P.157, T.B.P.241
- Lubega, J.
W.E.P.22
- Lubega, Juliet
W.E.O.5
- Lubega, M.
W.G.P.32
- Lucá Moretti, Maurizio
C.716
- Lucas, C. R.
M.B.P.124, T.B.P.44,
T.B.P.311
- Lucas, M.
T.B.P.376
- Lucas, S. B.
M.B.P.236
- Lucas, Susan, E.
W.E.O.4
- Luce, J.
E.683
- Luce, J. M.
T.B.O.27
- Lucey, D.
Th.B.P.126
- Lucey, D. R.
M.A.P.13, Th.B.P.230
- Lucey, Daniel R.
Th.B.P.135
- Lucht, Erik
B.576
- Lucia, P. A.
W.C.O.37
- Luciw, Paul
W.C.O.2
- Luciw, Paul A.
T.C.P.78, T.C.P.134
- Ludlam, C.
C.514
- Ludlam, C. A.
Th.C.P.89, Th.C.P.126
- Ludlam, Christopher A.
W.B.P.74
- Ludwig, W.-D.
W.B.P.278, W.B.P.372
- Luelmo, S.
W.G.O.16
- Lüer, W.
Th.B.P.231
- Lüer, Wilfried
Th.B.P.246
- Lueth, R.
T.A.P.60
- Luethy, R.
Th.A.P.111
- Luginbuhl, L.
B.584
- Lugoboni, F.
T.A.P.30, D.594
- Lujan, Manuel E.
M.E.P.20, E.645, E.787
- Luk, K. C.
C.596
- Lukas, H.
M.D.P.9, E.705
- Lüke, W.
Th.B.P.231
- Lum, L. L. O.
E.569
- Lumer, G.
A.532
- Lumey, L. H.
A.593
- Luna, Cajetan G.
M.D.O.9
- Lunardi-Iskandar, Y.
C.535
- Lundberg, L.
C.783
- Lundervold, A. J.
Th.B.P.215
- Lundgren, Bettina
T.B.P.6
- Lundgren, Jens D.
T.B.P.32
- Lundin Kvalen, I.
Th.D.P.63
- Lundin, K.
M.C.P.10
- Lundren, J. D.
Th.B.P.80
- Lunney, S.
T.D.P.87
- Luño, J.
M.B.P.277
- Luo, N.
W.A.P.50, Th.G.O.4
- Luo, N. P.
M.B.P.236, M.B.P.372,
W.G.O.5
- Luo, Nkandu P.
M.B.P.149, T.B.P.337
- Lupia, R. H.
M.C.P.84
- Lurhuma, Z.
M.C.P.48
- Lurhuma, Z.
W.B.P.276, W.B.P.316, C.603
- Lusakulira N.
T.E.P.4
- Lusakulira, N.
M.D.O.17, M.D.P.13,
M.D.P.49, D.721, M.G.O.16
- Lusakulira, Namagosi
Th.G.O.8
- Lusso, P.
Th.C.P.19
- Lusso, Paolo
W.C.P.125
- Luta, Martin
Th.B.O.39
- Luten, I.
M.B.P.371
- Lutete, K.
W.B.P.276
- Lüthy, R.
M.A.P.88, Th.B.O.27,
T.B.P.50, T.B.P.88, W.B.P.72,
W.B.P.321, M.C.P.83
- Lutz, R.
M.B.P.60, T.B.P.163,
T.B.P.208
- Luzi, G.
A.567, Th.B.P.150
- Luzi, Giuseppe
T.A.P.103
- Luzuriaga, Katherine F.
T.B.P.209
- Luzzati, Roberto
M.B.P.171, M.B.P.217,
Th.B.P.213
- Luzzati, Roberto R.
A.536
- Lvovich, A. V.
Th.C.P.77
- Lwanga, S.
Th.A.O.14, T.G.P.7
- Lwegaba, Anthony
W.D.P.8
- Lwihula, George K.
Th.E.P.34
- Ly, T. D.
Th.B.O.55, T.B.P.113,
T.B.P.120
- Lybanon, J.I.
Th.B.P.311
- Lyden, M.
M.B.P.312
- Lyerly, H. K.
W.B.P.330
- Lyerly, W. H.
M.G.P.11
- Lyman, W. D.
W.C.P.43, C.715
- Lyman, William D.
W.C.P.81
- Lynch, A.
A.563
- Lynch, J. M.
Th.B.P.290, Th.B.P.296
- Lynch, R.
M.B.P.204
- Lynch, Y.
W.B.P.381
- Lyne, P.
E.538
- Lyonnet, F. et al.
W.B.P.364
- Lyons, B. A.
E.627
- Lyons, C. A.
W.D.P.53
- Lyons, Catherine
W.D.P.52
- Lyons, M.
W.C.O.24
- Lyons, Robert W.
A.529, T.H.P.21
- Lyons, S.
T.D.O.30
- Lyons, S. F.
T.G.P.18, Th.G.P.15
- Lyons, Susan F.
M.A.P.83
- LymphoMed Consortium
Investig.
T.B.P.78
- Lyras, A.
C.536
- Lystad, A.
A.607
- Lytle, C. D.
M.A.P.114
- Lytle, D.
M.H.P.27

M

- M'Boup, S.
M.A.O.15, M.A.P.117,
T.A.P.3, T.B.P.133,
T.B.P.133, T.B.P.373,
W.C.P.136, Th.E.P.3,
W.G.O.20, Th.G.O.26,
Th.G.O.31, T.G.P.27,
T.G.P.29, W.G.P.22

- M'Boup, Souleymane**
M.A.P.19, T.B.P.105,
W.B.P.100, M.E.O.10,
T.G.P.28
- M'Pele, P.**
M.A.P.119, B.547, D.515,
Th.G.P.7
- M'Pele, Pierre**
G.511
- Ma, P.**
C.586
- Ma, Pearl**
M.B.O.32, M.B.P.38
- Ma, X.-Y.**
C.646
- Maayan, S.**
W.C.P.136
- Maboshe, M.**
D.723
- Maboshe, Mwendaweli N.**
M.A.O.42
- Mac Donald, S.**
M.D.P.79
- Macanca, R.**
T.B.P.371
- MacAuley, C.**
M.C.P.63
- Maccahruni, A.**
T.B.P.264, B.545
- MacCallum, L.**
M.B.P.3
- MacCallum, L. R.**
M.A.P.92, M.A.P.105,
T.B.P.271, W.B.P.317,
W.B.P.371, Th.B.P.164
- Macchia, G.**
M.B.P.199
- MacMacCreamer, A.**
W.D.P.12
- MacDonald, G.**
W.E.P.57
- MacDonald, K.**
M.A.P.70, M.A.P.72, T.B.P.348
- MacDonald, Kristine L.**
T.A.O.26, T.A.P.43
- MacDonell, K.**
Th.A.P.85, M.B.P.86
- MacFadden, D.**
M.A.P.57, M.A.P.113,
Th.B.P.373, T.D.P.63
- MacFadden, D. K.**
W.A.P.76
- MacFadden, Douglas K.**
T.B.P.321
- MacGregor, H.**
Th.E.P.71
- Macguire, J.**
M.B.P.200
- Mach, Nicolas**
Th.B.P.58
- Mach, Otakar**
Th.C.P.127
- Machado, I. Z.**
B.508
- Machado, J. A.**
W.S.P.97, B.902
- Machela, Alfred**
T.G.O.14
- Macher, A.**
W.A.P.112, A.630
- Macias, J.**
W.D.P.56
- Macias, José R.**
D.706
- MacIntosh, N.O.**
E.743
- Mackay, S. Rae, III**
W.H.P.26
- Mackenzie, Betsy**
T.G.P.9
- MacKenzie, Malcom R.**
T.C.O.39
- MacKey, J.**
M.C.P.16
- Mackinlay, L.**
T.B.P.332
- Mackin, E. J.**
W.G.P.16
- Macklin, Ruth**
T.F.O.22
- Macks, J.**
E.631
- MacLean, H.**
M.B.P.124
- MacMillan, Robert M.**
T.F.P.2
- MacPhail, L.**
Th.B.P.320
- Macuacua, R.**
W.A.P.54
- Macwacwa**
T.B.P.337
- Madarnas, P.**
W.C.P.22
- Madaule, P.**
T.C.P.59, C.656
- Madaule, Pascal**
T.C.P.109
- Madde, C. R.**
E.774
- Madden S.**
W.H.O.11
- Madden, G. M.**
A.529, T.H.P.21
- Madden, Gayle M.**
T.A.P.23
- Maddon, P.J.**
Th.C.O.41
- Maddon, Paul**
T.C.O.8
- Madeira, E. P.**
M.B.P.281
- Madejón, A.**
M.B.P.221
- Madera, I.**
M.D.P.62
- Madera, Inez**
W.D.P.4
- Madhavan, S.**
M.B.P.8, Th.G.O.49
- Madoulet, C.**
C.827
- Madrid, R. E.**
C.721
- Madsen, Kirsten K.**
D.559
- Madsen, Paul Christian**
T.E.P.12
- Madureira, R.**
W.B.O.21
- Madzouka, J.**
A.568
- Maeda, H.**
M.C.P.5
- Maeda, Y.**
M.C.P.5
- Maerki, S.**
M.H.P.12
- Mafama, Nkumu wa Ngale**
B.A.B
G.513
- Magalhaes, M. C.**
D.638
- Magana, J.R.**
M.E.P.7
- Magder, L. S.**
T.D.O.11
- Magee, T.**
B.B.O.1
- Maggio, C. M.**
T.B.P.320
- Magid, M.**
T.B.P.370, Th.B.P.372, B.580
- Magier, M. R.**
T.C.P.52
- Magis, C.**
E.738, W.G.P.25
- Magis, Carlos L.**
T.A.P.8
- Magnani, G.**
M.B.P.358
- Magnus, P.**
M.A.P.91, W.A.P.103,
Th.A.P.69, Th.D.P.68
- Magnus, Per**
D.722
- Magnusson, A.**
Th.C.O.9
- Magruder, Charles D.**
A.514, D.554
- Maguire, B.**
M.A.P.27, T.D.O.33,
M.D.P.52, M.D.P.53, D.633,
E.667
- Magura, S.**
W.D.P.78
- Magura, Stephen**
M.A.P.20, W.A.P.105,
T.D.P.77
- Maha, M.**
W.B.O.2
- Mahabir, B.**
E.671
- Mahabir, J.**
Th.G.P.28
- Mahabir, S.**
Th.G.P.27
- Mahart, M.**
Th.G.O.6
- Mahawar, S.**
Th.B.O.19, Th.B.P.205
- Mahmud, Fatia**
Th.D.O.22
- Mahnovski, V.**
T.B.P.370, Th.B.P.372
- Mahon, R.**
A.636
- Mahoney, Kevin J.**
Th.D.P.39
- Mahoney, M. A.**
W.B.O.23
- Mahony, J.**
B.556
- Mai, D.**
W.B.P.308
- Mai, S.**
T.C.P.106
- Maiga, M. K.**
A.577
- Maiga, Y.**
C.745
- Maingi, A. M.**
Th.G.P.29
- Maintz, C.**
W.B.O.26
- Maio, G.**
W.B.P.361
- Maison, Belinda**
M.E.O.3
- Maisonnet, G.**
T.A.P.93
- Maisonneuve, P.**
B.561
- Maitha, G.**
T.A.P.87, T.B.P.338, B.536
- Maitha, G. M.**
T.A.P.91, Th.G.O.36
- Maitra, R. K.**
T.C.P.102
- Maltski, T.**
T.B.P.136
- Majewski, S.**
W.B.P.128
- Major, C.**
T.B.P.106, W.B.P.176, B.603
- Major, C. J.**
T.A.P.6
- Major, Carol J.**
T.B.P.145, W.B.P.127

- Makadon, Harvey J.**
M.D.P.84, D.851, W.H.O.12
- Makadon, J.**
E.535
- Makarewicz, L.**
T.A.O.2, T.A.P.74, Th.A.P.98
- Maki, M.**
M.D.O.16, M.D.P.56,
Th.E.P.29
- Makinen, M.**
T.H.O.7
- Makinen, Marty**
W.H.P.1
- Makinodan, R.**
T.D.P.3, M.E.P.33
- Maknis, P.**
W.B.P.348
- Makuch, R.**
Th.B.O.1
- Malach, S.**
Th.E.P.71
- Malach, Stephanie**
W.E.O.3
- Malafef, P.**
W.C.P.27
- Malama, M.**
W.E.O.26
- Malamud, P.**
D.644
- Malau, Clement**
T.G.O.24
- Malaviya, A. N.**
M.B.P.139
- Malazdrewicz, R.**
W.D.P.20, Th.D.P.58
- Malchiodi Albedi, F.**
Th.B.P.252
- Maldarelli, F.**
T.C.O.47
- Malek, Adel N. A.**
M.B.P.372, W.G.O.5
- Malele, B.**
M.A.O.35
- Malena, D.**
D.566
- Malena, M.**
A.536, M.B.P.171, M.B.P.217,
Th.B.P.213
- Malefa, R.**
T.B.P.381
- Malessa, R.**
W.B.P.50
- Malfitano, A.**
M.B.P.258, M.B.P.298, B.545
- Malfon, P.**
T.B.P.310, T.B.P.380
- Malgady, R.**
D.623
- Malinowski, J.**
T.C.O.11
- Maliszewski, M. L.**
M.C.P.132
- Malkin, A.**
W.C.P.74
- Malkin, J. E.**
M.D.P.68
- Malkin, Jean E.**
T.E.P.59
- Malkin, Jean-Elie**
M.G.P.28
- Mallet, J.**
T.B.P.304
- Malliaraki-Pinetidou, E.**
M.A.P.80, Th.A.P.27, B.620
- Malliarakis, N.**
B.620
- Mallolas, J.**
M.A.P.104, M.B.O.37
- Mallolas, Josep**
W.B.P.40
- Mallow, C.**
M.B.P.4
- Malloy, M.**
W.E.O.27
- Malloy, R.**
D.617
- Malm, K.**
M.C.P.26
- Malmquist, Harriet E.**
Th.H.P.10
- Malo-Schlegel, S.**
D.627
- Malone, Joseph L.**
Th.B.P.163
- Maloney, E.**
W.C.P.26
- Maloo, R.**
Th.A.P.26
- Malouf, Renée**
Th.B.P.188
- Malphanov, A. D.**
A.588
- Maltez, F.**
Th.B.P.363
- Maltzman, W.**
Th.C.P.24
- Malysk, L.**
T.H.P.11
- Mamadou, T.**
M.G.P.24
- Mamane, M.G.**
Th.E.P.17
- Mammano, F.**
T.B.P.244
- Manak, M.**
Th.B.O.12, T.B.P.237
- Manak, Mark M.**
M.C.P.9
- Manalioto, C.**
T.B.P.377, Th.G.O.25
- Manca, M.**
T.B.P.139, T.B.P.140,
Th.G.P.21
- Manca, V.**
Th.B.P.339
- Mancini, Maryline**
M.C.P.4
- Mancini, Silvana, S.**
E.704
- Mancuso, Salvatrice**
M.B.P.248
- Mandalaki, T.**
M.A.P.89, M.A.P.109
- Mandalaki, Tiitika**
W.B.P.348
- Mandalya, Kishorchandra**
W.C.P.27
- Mandel, J.**
Th.A.P.68, Th.B.P.33,
T.D.O.19, D.639
- Mandel, J. S.**
M.D.P.42, Th.D.P.13
- Mandel, Jeffrey S.**
D.632
- Mandel, L.**
D.640
- Mandelkern, M.**
Th.B.P.259
- Mandell, W.**
W.A.P.90, M.B.P.71
- Mandell, Wallace**
Th.D.P.50
- Mandelli, F.**
B.518
- Mandrand, B.**
Th.C.P.75
- Mandy, Francis**
Th.B.P.360, Th.B.P.361,
B.621, C.676
- Manfredi, J.**
T.C.P.130
- Manfredi, R.**
W.B.P.338
- Mangone, C.**
Th.B.P.207
- Mangrola, U.**
Th.A.O.5
- Mani, S.**
M.A.P.51, E.691
- Maniez, M.**
Th.B.P.178
- Manischewitz, J.**
M.B.P.128, Th.C.O.2,
W.C.P.57
- Manji, F.**
Th.B.P.325
- Mankikar, S.**
T.B.P.350
- Mankikar, Sadanand**
M.B.P.157, T.B.P.359
- Manlan, L. K.**
T.B.P.388
- Mann, A.**
Th.A.P.119
- Mann, Dean L.**
W.C.O.7
- Mann, J.**
Th.A.O.14, W.G.O.25,
T.G.P.3, T.G.P.7
- Mann, J. M.**
W.E.O.6, W.G.O.18
- Mann, K. A.**
Th.C.O.31
- Mann, T.**
B.634
- Mannek, K.**
M.G.O.5
- Mannella, E.**
M.A.P.8, C.714
- Mannella, E. M.**
Th.C.P.146, C.739, C.747
- Mannella, Emilio**
M.A.P.36, T.B.P.341
- Mannhalter, J. W.**
T.C.P.38
- Manning, Nicholas P.**
M.E.P.54, M.E.P.55
- Manns, Angela**
B.636
- Mannucci, P. M.**
A.516, T.B.P.345
- Mannucci, Pier**
M.A.P.44
- Manoff, S.**
W.A.P.1, M.D.O.7
- Manoka, A. T.**
Th.A.O.21, T.A.P.90, W.A.P.96
- Mansaray, N. M.**
W.G.P.16
- Mansell, P.**
M.B.P.66, M.B.P.129
- Mansell, P. W. A.**
W.B.P.191
- Mansfield, S.**
W.E.O.3
- Mansfield, S. J.**
M.D.P.86, Th.E.P.71
- Mansi, M.**
A.545, M.B.P.50, Th.B.P.297
- Mansinho, K.**
T.B.P.357
- Mansour, I.**
M.B.P.269, Th.B.P.160,
Th.B.P.162
- Mantelli, Johanne E.**
W.D.P.21
- Mantelli, Mary**
W.E.O.11
- Mantero-Atienza, E.**
Th.B.O.40, Th.B.P.306,
Th.B.P.310
- Mantero-Atienza, Emilio**
Th.B.P.313, Th.B.P.314
- Manton, S.**
T.G.O.10
- Manton, Stéphane**
E.657
- Manucci, Pierre**
Th.B.O.32

- Manuel, C.
T.F.O.7, T.F.P.3, W.F.P.4
- Manuel, Catherine
M.F.P.9, T.F.F.10, T.F.P.11
- Manzano, C.
W.E.O.22
- Manzara, S.
Th.B.P.99
- Manzila, T.
T.B.P.204, W.G.O.4,
Th.G.O.34, W.G.P.8, W.G.P.9
- Manzila, Tarande
W.G.O.1
- Manzillo, Elio
W.B.P.361
- Manzillo, G.
W.B.P.361
- Manzou, L.
T.D.P.8
- Maquire, B.
Th.D.P.45
- Maradona, J. A.
W.B.O.37, T.B.P.274,
Th.B.P.69
- Marasca, Giuseppe
W.A.P.63, M.D.P.37, T.E.P.26
- Marcelhin, F.
M.B.P.362
- Marchand, M.
Th.E.P.18
- Marchand, Sophie
A.636
- Marchand-Gonod, N.
W.B.P.207
- Marche, C.
W.B.P.23, W.B.P.25,
W.B.P.26, W.B.P.35
- Marchesi, M.
Th.B.P.245
- Marchetto, Sylvie S.
Th.C.P.66
- Marchisio, P.
W.B.P.200
- Marchitelli, C.
W.A.P.63
- Marciani, D. J.
B.635, M.C.P.2, T.C.P.1
- Marciniack, A. M.
W.A.P.25
- Marcolini, S.
Th.C.P.99
- Marcotte, Glen J.
D.720
- Marcoux, J. A.
A.547
- Marcus, Joseph C.
T.B.P.185
- Marcus, Ruthanne
W.A.O.1, T.A.P.27
- Marcus-Sekura, Carol J.
T.C.P.84
- Marder, Karen
Th.B.P.261
- Marecki, M.
T.B.P.254
- Margalith, D.
Th.B.P.319
- Margalith, Miriam
W.B.P.73
- Margaritte, C.
M.C.P.30
- Margo, Glen E.
M.D.O.4
- Margolese, Ellen
E.761
- Margolese, R.
T.C.P.79
- Margolick, J.
M.A.O.9, Th.A.P.91,
Th.A.P.94, Th.B.P.238
- Margolick, J. B.
M.C.P.85
- Margolick, Joseph B.
M.A.P.98, C.542
- Margolis, E.
Th.D.P.82, D.615, E.566
- Mari, D.
M.C.P.43
- Maria, V. A. J.
Th.B.P.107
- Mariani, G.
T.B.P.345
- Mariani, L.
C.707
- Marichal, Bernard J.
M.C.P.139
- Marichez, M.
M.B.P.41
- Marier, R.
B.504, E.608, E.609
- Marietti, G.
Th.B.P.344
- Marin, Barbara
D.658
- Marin, G.
D.658
- Marinacci, G.
T.A.O.19
- Mariner, Wendy
W.F.O.4
- Marino, S.
M.D.P.81
- Mariotti, M.
T.C.P.131
- Mariscal, F.
Th.E.P.74
- Mariscal, J.
E.512
- Marius, P.
M.B.P.72
- Markakis, C.
Th.B.P.17
- Markert, S.
D.531
- Markey, S. P.
Th.B.P.232
- Markham, P.
W.C.P.125
- Markham, Phillip D.
W.C.O.32, W.C.P.35
- Markowitz, N.
Th.A.P.10, W.B.P.86
- Marks, S.
W.B.P.271
- Markson, L.
T.H.P.4
- Markson, Leona
A.608
- Markson, W.
C.593
- Marland, M. K. I.
A.517
- Marlink, R.
M.A.O.15, W.B.P.76,
W.C.P.136, Th.E.P.3,
T.G.P.27, Th.G.P.6
- Marlink, Richard
M.B.P.200
- Marlink, Richard G.
M.A.O.13
- Marmor, Michael
T.A.P.24
- Marone, Piero
M.B.P.75
- Marotta, T.
E.556
- Marowa, E.
Th.G.O.6
- Marques, Luiz Paulo José
M.B.P.74, M.B.P.281,
T.B.P.366
- Marques, M. M.
D.714
- Marquez, V. E.
M.C.P.107
- Marra, C.
Th.B.P.270
- Marranghello, L.
A.555
- Marrari, M.
M.A.P.101
- Marrie, T.
W.B.P.381
- Marrie, T. J.
T.B.P.42, E.743
- Marries, G.
T.B.P.268
- Marriott, T.
M.H.P.23
- Marsella, R.
T.B.P.366
- Marsh, J.
Th.C.P.54, C.777
- Marshall, Douglas
Th.B.P.230
- Marshall, Douglas W.
Th.B.P.229
- Marshall, G.
B.579
- Marshall, J. A.
Th.C.P.41
- Marshall, K.
W.B.P.245
- Marshall, T. David
T.F.O.9
- Marsters, S.
Th.C.O.15
- Martas, M.
D.650
- Marte, C.
W.A.P.10, A.584, M.B.P.319,
T.B.P.51, T.B.P.324,
W.B.P.68, W.D.P.40
- Marte, Carola
M.B.P.276
- Martel, R.
M.C.P.63
- Martel, Robert F.
E.644
- Martelli, B.
W.A.P.112, A.630
- Martelli, P.
W.A.P.59
- Martens, M.
T.C.P.78, T.C.P.134
- Marti, N.
Th.B.P.57
- Martich, F. A.
E.502
- Martin, A.
Th.B.P.232, Th.B.P.264,
M.C.P.92, T.H.O.11
- Martin, Alex
W.B.O.43, Th.B.P.284,
Th.B.P.286
- Martin, D.
T.G.P.18, Th.G.P.15
- Martin, D. W.
W.C.P.90
- Martin, David J.
T.E.P.1, E.544
- Martin, E.
Th.B.P.279
- Martin, Isabelle, M. G.
T.C.P.107
- Martin, J.
T.B.P.128, W.B.P.286, E.533,
W.F.P.3
- Martin, J. C.
M.C.P.74
- Martin, J. M.
W.H.P.2
- Martin, Jacqueline
Th.B.P.26
- Martin, Jacques
Th.C.P.86
- Martin, Jean
M.F.O.13
- Martin, L. N.
W.C.P.30
- Martin, M.
W.B.P.337, E.691

- Martin, M. A.
T.C.O.47, W.C.O.38, T.C.P.94
- Martin, Malcolm
T.C.O.24
- Martin, Olivia S.
W.B.P.137
- Martin, P. M. V.
Th.B.P.209
- Martin, Paul M.
T.C.P.22
- Martin, R.
M.E.P.59
- Martin, Rita A.
E.582
- Martin, Steven R.
T.B.P.249
- Martin, T.
D.616
- Martin, W.
T.B.P.379
- Martindale, J.
W.E.P.50
- Martinez Fernandez, R.
B.647
- Martinez Peralta, L.
W.D.P.56, W.G.P.21
- Martinez Vazquez, J. M.
C.705
- Martinez Vázquez, J. M.
M.B.P.260
- Martinez, A.
A.623, A.625, W.E.O.22
- Martinez, C., Jr.
M.E.P.13
- Martinez, J. M.
W.B.P.28
- Martinez, M. F.
M.B.P.221
- Martinez, M. G.
M.B.P.242, M.B.P.246,
W.B.P.145
- Martinez, R.
Th.B.P.23, W.E.P.48
- Martinez-Barrios, Juan
Carlos
Th.D.P.70
- Martinez-Maza, O.
T.C.P.19
- Martinez-Vázquez, J. M.
M.B.P.67, M.B.P.98,
T.B.P.289, Th.B.P.57
- Martini, S.
W.B.P.215, W.B.P.219,
Th.B.P.297
- Martnot, M.
M.B.P.362
- Martins, C. N.
A.549
- Martins, F. S. V.
A.549
- Martlew, V.
W.B.P.166
- Martorana, M. C.
M.G.P.9
- Martorano, A.
W.B.P.121
- Martucci, F.
Th.B.P.16
- Marty, Laurent
E.516
- Marty, P.
W.B.P.44
- Maruyama, I.
C.582
- Marx, P.
T.C.O.39, T.C.P.134
- Marx, P. A.
C.760
- März, W.
M.B.P.270
- Marzouk, J.
Th.B.P.368
- Mas, S.
Th.C.P.131
- Masafumi, Akao
W.B.P.42
- Mascagni, P.
M.C.P.40, M.C.P.41, C.545
- Mascagni, Paolo
C.544
- Masci, J.
T.B.O.6, T.B.P.48
- Masci, Joseph R.
W.B.P.6
- Mascola, L.
W.A.P.2, T.B.P.161
- Mascola, Laurene
T.A.P.65
- Masdeu, J. C.
Th.B.P.285
- Mascrati, R.
M.B.P.298, Th.B.P.243
- Masina, Marco
T.B.P.330
- Masini, V.
W.A.P.63
- Masison, V. G.
T.C.P.1
- Masler, D.S.
E.605
- Mason Beck, Leah
E.701
- Mason, B.
C.667, C.668
- Mason, Gregory R.
T.B.P.3
- Mason, P.
Th.B.P.182, Th.B.P.276
- Mason, Patrick J.
E.590
- Masquelier, B.
T.B.P.115
- Massa, B.
W.B.P.382
- Massari, F. E.
W.C.P.106
- Massari, Ferdinand
W.C.P.109
- Massari, V.
M.D.P.40
- Massari, Véronique
M.D.P.51, M.H.O.13
- Masse, B.
Th.E.P.7
- Massey, J.
Th.A.O.13, T.A.P.78, T.A.P.79
- Massin-Cochereau, I.
M.B.P.117
- Massina, William C.
D.616
- Masrip, P.
T.B.P.282
- Massironi, E.
T.B.P.201
- Massironi, M.
M.B.P.227
- Masterson, Andrew
T.A.O.5
- Mastrangelo, F.
D.675
- Mastroeni, R.
C.647
- Mastrucci, M.
T.B.P.153
- Mastrucci, M. T.
T.B.P.162, T.B.P.166
- Masuda, T.
W.C.O.38
- Masuda, Takao
Th.C.P.28
- Masubo, Y.
T.C.P.75, Th.C.P.45
- Masur, H.
M.B.P.128, T.B.P.16,
W.B.P.322
- Masur, Henry
T.B.O.23
- Mata, E.
Th.H.P.24
- Mata, Leonardo J.
A.555, A.603, Th.H.P.24
- Matar, P.
D.706
- Matear, P.
T.C.P.14
- Matela, B.
T.B.P.205, W.G.O.4
- Matheny, S.
M.E.P.49, T.H.P.3
- Matheny, S. L.
Th.B.P.302
- Mather, S. H.
W.A.P.26, M.F.O.2
- Matheron, S.
M.B.P.348, W.B.P.23,
W.B.P.26, W.B.P.344,
Th.C.P.131, D.622
- Matheron, Sophie
M.B.P.225, M.B.P.249,
T.B.P.195
- Mathes, L. E.
M.C.P.68
- Mathes, Lawrence E.
M.C.P.69
- Mathes, L. A.
E.603
- Mathew, S.
T.G.P.6
- Mathews, W. C.
M.B.P.376, W.B.P.254,
M.H.P.17
- Mathez, D.
W.C.P.72
- Mathez, Dominique
M.B.P.350, B.558, Th.C.P.98
- Mathews, T.
W.C.O.18
- Mathias, T.
W.G.O.23
- Mathiesen, L.
M.B.P.79, T.B.P.24, T.B.P.59,
W.B.P.27, Th.B.P.253,
Th.C.P.60, Th.C.P.61,
W.D.P.55
- Mathieu, M.
M.B.P.164
- Mathieu-Boué, Anne
T.B.P.310, T.B.P.380
- Mathijs, J. M.
T.C.P.6, T.C.P.123, W.C.P.27
- Mathov, J.
T.A.P.108, T.B.P.340,
Th.B.P.3, Th.B.P.24
- Mathur, S.
E.782, E.758
- Mathur-Wagh, U.
E.728
- Mathys, J. M.
W.C.O.23
- Matida, A.
Th.B.P.74
- Matondo P.
Th.G.P.5
- Matos-Almeida, M. J.
A.511
- Matsiota, P.
C.583
- Matsuda, Juzo
W.B.P.311
- Matsuda, K.
Th.B.P.83
- Matsuda, M.
Th.C.P.18
- Matsuda, Shunji
C.712
- Matsuda, Zene
Th.C.P.18
- Matsukura, Makoto
Th.C.O.19

- Matsumoto, T.**
 C.753
Matsumura, S.
 W.C.P.21
Matsuno, S.
 B.605
Matsushita, S.
 W.C.O.38, Th.C.O.30
Matsushita, Shuzo
 M.C.P.5
Matteelli, G.
 W.E.P.19
Matter, A.
 M.C.P.81
Matthews, G. W.
 Th.F.O.4
Matthews, Gene W.
 M.F.P.6
Matthews, J.
 Th.C.O.50
Matthews, T.
 M.C.O.7, Th.C.O.26,
 Th.C.O.29, M.C.P.6
Matthews, T. J.
 T.C.P.49
Matthey, C.
 W.D.P.23
Matthiessen, L.
 W.B.P.23, W.B.P.26
Matilla, E.
 Th.A.P.2
Matuschke, A.
 M.B.P.64, W.B.P.92,
 Th.B.P.168, Th.B.P.161,
 Th.B.P.244, C.574, W.D.P.3,
 E.764
Matuschke, Alexander D.
 B.516
Mauch, H.
 Th.B.P.54, Th.B.P.73
Mauchard, D.
 Th.E.P.21
Maudru, T. D.
 Th.C.P.103
Maufl, G.
 Th.B.P.134, C.546, C.573
Mauji, Firoze
 Th.A.P.62
Maul, D.
 T.C.O.39
Maurel, H.
 M.D.P.91, D.513, D.569,
 Th.E.O.14, W.E.P.44
Maurice, C.
 T.B.P.277
Maurice, S.
 Th.E.P.16
Maury, C. P. J.
 W.C.P.114, W.C.P.115
Maury, W.
 W.C.P.59
Maury, W. J.
 T.C.O.12
Mawson, S. J.
 W.B.P.87
Mazelier, Horst-Günter
 T.A.P.9
Maxfield, L.
 C.510
Maxwell, R.
 M.A.P.28
May, K.
 M.B.P.312
May, R. M.
 T.A.O.40
May, T.
 T.C.P.44, T.C.P.45
May, Thierry
 C.541
Mayaud, C.
 M.B.P.42, T.B.P.1, B.559,
 B.589, T.C.P.25
Mayaux, J. F.
 C.862
Mayaux, M. J.
 M.B.O.3, Th.C.P.7
Mayebana, N.
 T.B.P.188, Th.G.O.33,
 W.H.P.6
Mayer, Felix
 W.B.P.98
Mayer, K.
 A.623, A.625, M.B.P.168,
 M.B.P.200, W.B.P.71, D.713
Mayer, K. H.
 Th.A.O.16, Th.A.P.42,
 T.B.P.70, T.B.P.95, T.D.P.31
Mayer, Kenneth H.
 M.A.P.108, T.A.P.96,
 T.A.P.97, T.D.P.71,
 Th.D.P.83, T.E.P.44
Mayer, Vlastimil
 Th.B.P.367
Mayers, D.
 M.A.P.11, C.587
Mayers, D. L.
 Th.B.P.163
Mayers, Douglas L.
 W.A.P.73, Th.B.P.115
Mayers, Marguerite M.
 T.B.P.173
Mays, A.
 M.B.P.318
Mayeux, R.
 W.B.P.222, Th.B.P.261
Mayhew, Miriam
 M.E.P.47
Maynard, M.
 M.A.O.26
Maynard, Pat
 M.B.O.11
Mayner, R.
 T.B.P.232
Mayon-White, R.
 M.B.P.304
Mayordome, J.-C.
 M.B.P.39
Mayorga, Ruben
 W.B.P.23, W.B.P.36
Mayrand, D.
 Th.B.P.356
Mays, V. M.
 W.D.P.22, D.667
Mays, Vickie M.
 W.D.P.36, D.664
Mazumder, A.
 T.C.P.17
Mazurkiewicz, W.
 M.A.P.69
Mazurkiewicz, Walentyna
 Th.D.P.41
Mazza, C.
 M.A.P.84
Mazzanti, P.
 M.C.P.103
Mazzara, G.
 M.C.P.16, M.C.P.17, T.C.P.24
Mazzara, G. P.
 M.C.P.47
Mazzi, R.
 A.536, Th.B.P.213
Mazzotta, F.
 T.B.P.100, Th.B.P.203
Mbanga, M.
 W.E.O.30
Mbitsi, A.
 M.B.P.91
Mbougou-Kimpolo, N.
 Th.H.P.22
Mboup, S.
 T.A.P.3, T.B.P.133,
 T.B.P.373, W.G.O.20,
 Th.G.O.31, T.G.P.29
Mboussa, J.
 T.B.P.19
Mboyi, L.
 W.G.O.19
Mbu, M.
 W.D.P.2
Mbugun, G.
 W.G.P.27
Mbugua, G. G.
 G.503, W.H.P.15
Mbula, M.
 W.B.P.276
Mbuyi, Kashama
 W.D.P.2
Mc Auliffe, V.
 C.561
Mc Callum, L.
 T.D.P.82
McAdam, K.
 Th.G.O.4
McAllister, A.
 W.D.P.37, W.E.P.58, E.635
McAllister, R.
 W.D.P.69, M.E.P.16,
 Th.E.P.32
McAllister, R.
 W.B.P.185
McAllister, Ruth H.
 Th.B.P.287
McArthur, C. L.
 Th.B.P.290, Th.B.P.296
McArthur, J.
 W.B.P.227, Th.B.P.200
McArthur, J. C.
 M.B.O.35, W.B.O.45,
 Th.B.P.202, Th.B.P.271,
 Th.B.P.288
McArthur, J. H.
 W.B.P.52, Th.B.P.238
McArthur, Jane M.
 E.808
McArthur, Julie H.
 M.B.O.35
McArthur, Justin C.
 Th.B.P.218, Th.B.P.238
McAtee, N.
 W.B.P.327, W.B.P.329
McBride, D. C.
 Th.D.P.47, D.588, D.592
McBride, Duane C.
 Th.D.P.49
McCabe, A.
 W.D.P.9
McCabe, D.
 C.671
McCaffrey, R. P.
 T.B.P.297
McCall, O.
 C.698
McCalla, S.
 Th.D.P.44
McCallum, L.
 T.D.O.30, W.D.P.34, D.560
McCamish, Malcolm
 T.D.P.43
McCandless, L.
 W.B.P.263
McCann, M.
 T.D.P.22
McCarroll, T.
 M.E.P.39
McCarthy, M.
 M.A.P.90, M.A.P.115,
 W.B.P.56, Th.B.P.263, C.590,
 D.704, E.541, E.692,
 Th.G.P.10
McCarthy, Michael C.
 M.G.P.5
McCarthy, P.
 E.605
McCarthy, S.
 M.C.P.52
McCartney-Francis, Nancy L.
 T.C.P.117
McChesney, M.
 C.524

- McClean, J.
 M.D.P.15
 McClung, R.
 W.E.P.70
 McClure H.
 M.C.P.98
 McClure, H.
 M.C.O.19, W.C.O.49
 McClure, H. M.
 W.C.O.45, W.C.P.147, C.758
 McClure, Harold M.
 T.C.O.42, W.C.P.15
 McClure, Myra O.
 M.C.P.91, Th.C.P.10
 McClure, Wilma M.
 Th.B.P.28
 McClutchan, J. A.
 T.C.P.50
 McCombie, S.C.
 E.614
 McConnell W.
 W.E.P.25
 McConnell, P. A.
 W.D.P.52
 McCormack, W.
 M.B.P.57
 McCormick, Anna
 W.A.P.28
 McCormick, Wayne C.
 B.593, M.E.P.70
 McCoy, C. B.
 M.A.P.38, T.A.P.46,
 W.A.P.89, B.527, Th.D.P.49,
 D.592, D.605, E.587
 McCoy, Clyde B.
 Th.D.P.48, Th.D.P.82
 McCoy, E.
 Th.D.P.17, Th.D.P.64
 McCoy, H. V.
 B.527, Th.D.P.49, D.605
 McCoy, Virginia H.
 Th.D.P.47, E.587
 McCray, Eugene
 M.A.O.20
 McCreaner, Alana
 D.572, D.573
 McCrimmon, M.
 Th.D.P.85
 McCrow, L.
 T.B.P.95
 McCuan, R.
 W.D.F.37, E.635
 McCulloch, B.
 Th.B.P.360
 McCusker, J.
 M.A.P.106, T.A.P.29,
 T.A.P.35, T.D.P.31, D.713,
 W.E.P.12
 McCutchan, A.
 C.531
 McCutchan, Allen J.
 Th.D.P.51
 McCutchan, F.
 T.C.P.128
 McCutchan, J.
 Th.B.P.195
 McCutchan, J. A.
 M.B.P.300, T.B.P.8, W.B.P.9,
 W.B.P.11, W.B.P.24,
 W.B.P.223, W.C.P.230,
 W.B.P.233, W.C.P.138,
 C.520, T.D.P.79
 McCutchan, J. Allen
 M.B.P.325
 McDermott, C.
 T.B.O.28
 McDonald, J.
 Th.B.P.28
 McDonald, John R.
 M.E.P.37, E.543
 McDonough, S. H.
 T.C.P.18
 McDougall, S.
 T.C.P.36
 McDougall, J. Steven
 Th.C.O.41
 McEvoy, M. B.
 D.625
 McFarland, L.
 T.A.P.50, B.519
 McFarland, Louise
 W.A.P.8
 McGee, F.
 E.531
 McGee, Jull S.
 M.C.P.15
 McGee, S.
 W.B.P.174
 McGee, Susan A.
 W.B.P.175
 McGhee, B.
 A.629
 McGill, C.
 E.659
 McGillivray, G. M.
 M.A.P.83
 McGinn, J.
 A.613
 McGinty, E.
 T.B.P.78
 McGivern, T. M.
 Th.B.P.350
 McGough, J.
 W.A.P.104
 McGough, J. P.
 T.A.P.57
 McGowan, J.
 M.C.P.58, M.C.P.122,
 M.C.P.123
 McGowan, K.
 M.B.P.205
 McGrath, M.
 Th.C.O.35, Th.C.P.137,
 C.670, C.704
 McGrath, M. S.
 M.B.P.288, Th.C.O.37,
 M.C.P.55, M.C.P.109,
 M.C.P.111, Th.C.P.54, C.596,
 C.777
 McGraw, T.
 T.C.P.134, Th.C.P.107
 McGregor, J. R.
 Th.A.P.74
 McGriff, E.
 D.629
 McGuigan, Chris
 M.C.P.70
 McHugh, J.
 B.586
 McIntosh, K.
 T.B.P.146, T.B.P.249, B.584
 McIntosh, Kenneth
 Th.C.P.94
 McKay, C. Y.
 Th.D.P.47, E.587
 McKeating J.
 C.732
 McKeating, J. A.
 C.552
 McKeever, B. M.
 M.C.O.23
 McKegney, F. P.
 W.B.P.214, W.B.P.216,
 W.B.P.217
 McKenna, P.
 E.781
 McKenzie, S.
 T.C.P.24
 McKinley, G.
 M.B.P.360, W.B.P.285
 McKinley, G. F.
 M.C.P.142
 McKinney, N.
 Th.A.P.110
 McKinney, R. E.
 T.B.P.207
 McKinnon, J.
 D.603, W.F.P.2
 Mckirran, D.J.
 M.D.P.39
 Mckirran, David J.
 T.D.O.10
 McKusick, L.
 T.D.O.8, T.D.P.57
 McKusick, Leon
 W.A.P.91, C.618, W.D.O.2
 McLane, M.
 W.B.P.76
 McLane, M. F.
 C.922, C.710
 McLaren C.
 M.C.P.130
 McLarena, C.
 T.B.P.297
 McLaughlin, B.
 T.B.P.106, T.B.P.145,
 W.B.P.127, B.603
 McLaughlin, Bernadette
 T.A.P.6
 McLaughlin, Bernadette J.
 W.B.P.176
 McLaughlin, M.
 T.A.P.89
 McLaughlin, Magaret M.
 A.615
 McLaws, Mary-Louise
 W.D.P.89
 McLellan, Iain
 T.D.P.36
 McLeod, A.
 W.H.P.1, T.H.P.13
 McLeod, W. A.
 T.A.O.34, W.A.P.58,
 M.B.O.21, M.B.O.33, W.D.P.92
 McLoughlin, R.
 W.D.P.80
 McLoughlin, S.
 D.565
 McLullich, Archie
 W.F.O.11
 McMahon, D. K.
 W.B.P.303
 McMahon, Deborah
 M.B.P.355
 McMahon, J.
 B.607
 McMahon, J. R.
 M.E.P.48
 McMahon, James
 C.638
 McManus, N.
 M.C.P.109, Th.C.P.137
 McManus, T.
 Th.B.P.127
 McManus, T. J.
 T.A.P.55, A.594, W.B.P.272,
 T.D.P.20
 McManus, Thomas J.
 T.D.P.23
 McMaster, J.
 T.H.O.1
 McMeeking, A.
 W.B.P.353, W.B.P.375
 McMenamin, D.
 M.E.P.49, T.H.P.3
 McMenamin, Diane M.
 Th.E.P.64
 McMichael, A. J.
 T.C.P.23
 McMillan, C.
 M.A.P.45
 McMillan, C. W.
 T.C.P.49
 McMillan, G.
 Th.B.P.300
 McMurdo, H.
 Th.C.O.3
 McMurtry, L.
 M.B.P.311

- McNally, L.
E.704
- McNamara, A.
T.B.P.80, Th.B.P.111
- McNearney, Terry
T.C.P.122
- McNeil, J.
M.A.O.6, M.A.P.17, W.A.P.31
- McNeil, J. G.
M.A.O.3, Th.A.O.10,
Th.A.P.103
- McNeil, John G.
M.A.O.1
- McPhee, D. A.
Th.C.P.41
- McPhee, Dale A.
T.G.O.35, Th.C.P.39
- McPherson, R.
B.537
- McQuade, T. J.
T.C.P.108
- McQuie, H.
Th.D.P.73
- McQuilan, G.
M.A.O.17
- McQuilan, Geraldine M.
Th.A.O.13
- McRae, Brian J.
W.B.P.139
- McSharry, James J.
T.B.P.88
- McShine, R. L.
M.B.P.153, T.B.P.131,
T.B.P.354
- MDiaye, M.
M.E.O.10
- Meagher, N.
W.B.O.10
- Meakin, R.
T.A.O.11, T.A.P.47, T.A.P.94,
A.525
- Mearns, D.
T.D.O.14
- Meaux, A.
Th.E.P.67
- Mecelis, R. L.
M.B.P.40
- Medina, H.
E.546
- Medley, Graham F.
Th.A.P.75
- Medoff, G.
M.C.P.141
- Medrano, M. J.
A.575, A.578
- Meek, T.
T.C.O.11, W.C.O.11
- Meeker, T.
M.B.P.288, Th.C.O.37
- Meer, J.
T.B.P.247
- Mehaffey, W.
Th.A.P.20
- Meheus, André
Th.G.O.17
- Mehring, M.
Th.P.12
- Mehryar, A.
M.E.O.31
- Mehryar, A. H.
T.G.O.7
- Meichsner, C.
Th.C.O.24
- Meichsner, Christoph
C.623
- Meideros, E. A. S.
T.B.P.317
- Meier, W.
M.C.P.72
- Meier-Sydow, J.
M.B.P.210
- Meigel, W.
M.B.P.234, Th.B.P.329
- Meignan, F.
W.B.P.55
- Meini, M.
M.A.P.63, T.A.P.111
- Meisenholder, Janice Bell
M.D.P.54
- Melte, M.
T.B.P.368
- Melancon, H.
W.B.P.358
- Mélançon, M.-J.
T.F.P.7
- Melcher, G.
Th.B.P.135
- Melcher, G. P.
M.A.P.13
- Melder, Robert J.
W.C.O.10
- Meléndez, Guerrero Loyda
T.C.P.36
- Melese-d'Hospital, I.
T.A.O.22, Th.D.P.84
- Melgar, M.L.
G.512
- Melia, E.
M.B.P.318
- Melico-Silvestre, Antonio
M.A.P.18
- Mellado, J. M.
B.500
- Mellado, M. J.
T.B.P.164
- Mellado, Maria José
M.B.P.369, T.B.P.255
- Melberg, G.
Th.D.P.21
- Mellert, W.
Th.B.P.181, M.C.P.33,
W.C.P.91, Th.C.P.135, C.598
- Mellors, John W.
W.C.O.8
- Melmed, R.
W.A.P.62
- Melnick, J. L.
T.B.P.145
- Meloen, R.
W.C.P.56, C.732
- Meltzer, A.
M.G.O.2
- Meltzer, M.
T.B.P.112, C.724
- Meltzer, M. S.
T.C.P.30, W.C.P.63
- Melús, R.
W.A.P.71, Th.B.P.335, D.613
- Melville, R.
M.B.P.278
- Melzi d'Eril, G. L.
Th.B.P.243
- Meme, J. S.
M.B.P.160, Th.E.P.39
- Ménard, C.
T.D.O.20
- Menares, Juan
M.D.P.40
- Menarguez, J.
Th.B.P.121
- Mendelson, J.
T.B.P.97
- Mendes Costa, C.
Th.C.P.8
- Mendes, N.
W.B.P.115, B.639, G.518
- Mendes, N. F.
T.B.P.358
- Mendes, Nelson
M.G.P.8
- Mendes, W. S.
Th.B.P.40, B.522
- Mendez, H.
Th.A.O.6, M.B.O.2, M.B.O.42,
T.B.P.180, T.B.P.185,
W.D.P.58
- Mendez, Hermann
T.B.P.240
- Mendez, P. J.
Th.H.P.25
- Mendez, Theresa C.
T.D.O.31
- Mendonça, J. S.
Th.B.P.40, B.522
- Mendonça, Joao S.
W.B.P.31
- Mendonça, M.
W.B.P.21
- Menéndez, J.
W.A.P.86
- Menendez-Bergad, B.
W.A.P.32
- Menniti-Ippolito, F.
M.B.O.46, W.B.P.370,
Th.D.P.39, Th.D.P.40
- Menor, J.
Th.D.P.19, E.526
- Meraviglia, P.
M.B.P.215, M.B.P.361, D.674
- Mercuro, L.
W.C.P.74
- Mercuro, Louis
M.C.P.112
- Mercurio, V.
A.566
- Merigan, T.
Th.B.P.30
- Merigan, Tom
T.B.O.14
- Merino, M. L.
M.G.O.28, M.G.P.19
- Meriwether, C.
Th.C.P.147
- Meriwether, R. A.
W.D.P.1
- Merksenslaker, M.
C.528
- Merlini, R.
B.585
- Merodio, C.
A.572, A.633
- Merrill, D. P.
M.C.P.97
- Merrill, Joseph M.
M.O.15
- Merritt, D. M.
M.F.O.3, W.H.O.11
- Merritt, J.
Th.B.O.29
- Mertens, T.
C.673
- Mertins, L.
M.B.P.335, T.B.P.381,
W.B.P.324
- Mertins, S.
Th.B.P.89
- Merton, Vanessa
W.F.O.7
- Mertz, S.
E.611
- Meruelo, D.
M.C.P.18, C.501
- Meruelo, Daniel
C.626
- Merveille, J.
M.E.P.10
- Merz, W.
W.B.P.7
- Merzel, C.
Th.D.P.15, E.700
- Meshorer, A.
W.C.O.29
- Mesquita, Roberto P.
C.700
- Messele, T.
M.A.P.79
- Messiah, A.
T.B.P.170
- Messiah, Antoine C. D.
A.570
- Messing, K.
W.A.P.53, W.D.P.23, T.E.P.70

- Messinger, Delphi**
C.762
- Metcalf, B.**
W.C.O.11
- Metcalf, J.**
T.B.P.281, Th.B.P.179
- Metcalf, J. A.**
Th.B.O.43, W.B.P.322
- Metcalfe, J.**
M.B.P.333
- Metroka, Craig E.**
T.B.O.4, M.B.P.128,
M.B.P.192
- Mettetal, J.-F.**
A.570, W.B.P.368, W.E.P.52,
Th.E.D.7, E.656, E.803
- Mettetal, Jean-Florian**
D.652, T.H.P.14
- Metz, J.**
M.D.P.48, M.E.P.28, W.E.P.56
- Meyer zum Büschenfelde,
K. H.**
M.B.P.220, W.D.P.54,
T.C.P.86, Th.D.P.23
- Meyer, A.**
T.B.P.39, W.F.P.7
- Meyer, Andreas**
T.B.P.40
- Meyer, C. G.**
T.C.P.150
- Meyer, Christian G.**
W.B.P.104, C.786
- Meyer, D.**
M.B.P.2, M.B.P.34
- Meyer, E.**
W.A.P.53
- Meyer, I.**
W.B.P.209
- Meyer, M.**
M.A.P.59, T.C.O.21, Th.C.P.49
- Meyer, P.**
W.B.P.69
- Meyer, W. A.**
Th.B.O.2, T.B.P.101
- Meyer-Bahlburg**
T.D.P.12
- Meyer-Bahlburg, H. F. L.**
Th.D.O.8, M.D.P.38, T.D.P.28,
T.D.P.73
- Meyer-Bahlburg, Heino F.
L.**
T.D.O.22, T.D.P.4
- Meyer-Glauner, W.**
A.501
- Meyerhans, Andreas**
T.C.O.28
- Meyohas, M. C.**
M.B.P.32, M.B.P.226,
W.B.P.283, Th.B.P.160,
T.E.P.66, M.B.O.36, T.B.P.71,
Th.B.P.11
- Mezin, M.**
Th.B.P.251
- Mezzaroma, I.**
T.A.P.103, A.567, Th.B.P.150,
B.643
- Mezzelani, Paolo**
T.A.P.30, C.650, D.594
- Mezzenzana, M. A.**
M.B.P.215, M.B.P.361, D.674
- Mhalu, F.**
T.B.P.104
- Mhalu, Fred S.**
T.G.O.11
- Mhalu, S.**
B.548
- Mian, M. A.**
M.C.P.86
- Miceli, M.**
M.A.P.36, T.B.P.341, C.714
- Miceli, M. M.**
Th.C.P.146, C.739
- Michaels, J.**
W.C.P.30
- Michailov, M. V.**
T.B.P.91
- Michaud, Jean**
W.B.O.32
- Micheau, M.**
T.B.P.245
- Michejda, Christopher J.**
Th.C.P.138
- Michel, A.**
Th.E.O.14, W.E.P.44
- Michel, André**
M.D.P.91
- Michel, F.**
T.C.P.67
- Michel, Frédérique**
T.C.P.77, W.C.P.5
- Michel, M. L.**
M.C.P.4
- Michel, S.**
M.D.P.36
- Michel, Sigrid**
W.E.P.17
- Michela, J.L.**
E.581
- Michalet, C.**
W.B.P.75
- Michelton, Harry**
A.581
- Michelone, G.**
T.B.P.264
- Michels, B.**
Th.B.O.42, M.B.P.265
- Michels, Ingo**
E.767
- Michon, C.**
T.B.P.49, W.B.P.344
- Mickler, S.**
T.D.P.92, D.507
- Micouac, M.**
Th.B.P.251, Th.B.P.282
- Middelhoff, Monique**
Th.E.O.2
- Midgley, J.**
M.B.P.81
- Midthun, K.**
T.B.P.123, M.C.P.12
- Midthun, Karen**
M.C.P.14
- Miedema, F.**
Th.B.P.87, M.C.O.8,
Th.C.O.1, W.C.P.46, W.C.P.56
- Miedzinski, L.**
Th.B.P.67
- Miedzinski, L. J.**
Th.H.P.6
- Miedzinski, Lilly J.**
T.B.P.38
- Miele, M. E.**
C.719
- Mielke, M.**
T.B.P.378, W.B.P.278,
W.B.P.372
- Mielle, A.**
D.604, E.781
- Migley, J.**
M.B.P.175, Th.B.P.328
- Migliorati, C. A.**
Th.B.P.341
- Miguët, J. P.**
B.520
- Miguez, L. A.**
M.B.P.291, B.563, D.638
- Mihalik, R.**
T.C.P.141
- Mihály, I.**
T.B.P.302
- Mijch, A. M.**
T.B.P.311
- Miljch, Anne M.**
T.B.P.44
- Milki, K.**
M.C.O.6
- Miki, J.**
W.A.P.21, Th.D.P.16,
Th.D.P.45
- Mikovits, J.**
T.C.P.33
- Mikovits, Judy A.**
M.C.O.16
- Miksza, L.**
Th.A.P.90
- Mikulecky, M.**
Th.B.P.367
- Milan, Fiala**
W.A.P.77
- Milazzo, F.**
Th.B.O.14
- Milbradt, R.**
M.B.P.111, M.B.P.180,
M.B.P.276, T.B.P.316
- Milchan, R.**
W.C.P.129
- Mildvan, Donna**
W.B.P.312
- Miles, Steven A.**
M.C.P.52, M.C.P.100
- Miles, T.**
E.567
- Milich, D.**
M.C.P.15
- Milla, F.**
M.B.P.251
- Miller R.**
D.549
- Miller, Barry W.**
E.756
- Miller, C.**
M.B.P.85, Th.C.O.45, M.D.P.1
- Miller, D.**
T.D.O.18, E.642, E.683,
T.H.O.4, Th.P.9
- Miller, E.**
T.A.P.4, Th.B.P.200,
Th.B.P.289
- Miller, E. N.**
W.B.O.45, Th.B.P.202,
Th.B.P.218
- Miller, Eric N.**
Th.B.P.278, Th.B.P.288,
Th.B.P.294
- Miller, G. C.**
W.B.P.294
- Miller, J.**
T.D.O.25
- Miller, J. P.**
Th.B.P.269
- Miller, James L.**
Th.E.P.81
- Miller, Kenneth P.**
T.D.P.15
- Miller, L.**
Th.B.P.190
- Miller, Laurel A.**
T.B.P.43, W.B.P.345
- Miller, M.**
M.A.P.11
- Miller, M.L.**
Th.G.O.43
- Miller, N.**
T.A.P.70, M.C.O.17
- Miller, R.**
M.A.P.3, M.A.P.4, Th.C.O.37,
M.D.P.63, D.634, M.E.O.13
- Miller, R. N.**
M.A.P.1
- Miller, R. D.**
M.E.P.6
- Miller, Richard A.**
Th.C.O.35
- Miller, Riva**
M.B.P.155, W.D.P.19, E.602
- Miller, S.**
W.D.P.7, M.E.P.64
- Miller, S. D.**
W.D.P.47, T.E.O.15
- Miller, Steven D.**
T.B.P.60

- Miller, Timothy E.
W.A.P.111
- Miller, Veronica E.
M.C.O.29
- Mills, E. L.
C.536
- Mills, J.
M.B.P.48, M.B.P.123,
T.B.P.236, W.B.P.270, B.526,
M.C.P.109, Th.C.P.137, C.670
- Mills, John
C.504
- Mills, Kingston H. G.
C.530
- Millson, Margaret E.
Th.D.P.52
- Milman, G.
Th.G.P.12
- Milo, D.
T.B.P.100
- Milovanovic, A.
Th.B.O.55, T.B.P.120
- Milpied, B.
C.549
- Milpied-Homsli, B.
W.B.P.302
- Mindell, William
W.E.P.24, E.593, E.783
- Minder, C.
T.A.O.6
- Mindry, D.
W.B.P.192
- Mingle, J.
T.B.P.133
- Mingle, Julius
T.B.P.351
- Minkoff, H.
T.B.P.240
- Minkoff, Howard L.
Th.D.P.44
- Minlangu, M.
W.B.P.359
- Minnella, A.
M.B.P.229, M.B.P.230
- Minola, E.
M.A.P.95, W.B.P.352
- Minoli, L.
M.B.O.31, Th.B.P.272
- Minoli, Lorenzo
M.B.P.114, M.B.P.258,
M.B.P.298, Th.B.P.243,
Th.B.P.281
- Minor, R.
D.707
- Miotti, P.
Th.G.O.28, G.507
- Mir, N.
T.B.P.328
- Mirabile, M.
W.B.P.159, Th.C.P.68
- Miraglia, E.
Th.B.P.16
- Miro Meda, J.
Th.B.P.193
- Miro, J. M.
M.A.P.104, W.A.P.55,
M.B.O.37, W.B.P.40
- Miro, José Maria
B.610
- Miroló, M.
T.B.P.341, C.714
- Miroló, M. M.
Th.C.P.146, C.739
- Mirra, S.
W.C.O.45
- Mirsky, A. F.
B.566
- Mirza, N.
Th.G.O.53
- Missmahl, M.
M.C.P.56
- Mitamura, K.
M.B.P.63
- Mitchell, C.
Th.A.O.8
- Mitchell, D.
C.518
- Mitchell, M.
T.B.P.7
- Mitchell, Margaret C.
E.740
- Mitchell, S.
T.B.P.105, T.B.P.134,
T.B.P.351, W.B.P.100,
W.B.P.173
- Mitchell, Sheila W.
T.B.P.133
- Mitchell, T. F.
W.B.P.247
- Mitchell, W.
Th.C.O.4, M.C.P.19
- Mitchell, W. M.
W.C.O.26, Th.C.P.45,
Th.C.P.129, C.771
- Mitchell, William M.
W.B.P.239
- Mitra, I.
W.B.P.143
- Mitsuhata, K. T.
M.B.P.317
- Mitsuya, H.
Th.C.O.15, Th.C.O.17,
M.C.P.107, Th.C.P.22
- Mitsuya, Hiroaki
Th.C.O.13, M.C.P.135
- Mitsuyasu, R.
Th.B.P.63, Th.B.P.236,
T.C.P.57
- Mitsuyasu, R. T.
Th.A.P.8, M.C.P.52, W.C.P.85
- Mittal, K.
M.B.P.20
- Mittal, M.
M.A.O.23
- Mitten, C. M.
T.B.P.138
- Miura, T.
M.C.O.5, M.C.O.25
- Mivumbi, N.
T.E.P.81
- Miyake, S.
Th.C.P.55
- Miyano, K.
M.C.P.79
- Miyasaki, S.
Th.B.P.320
- Miyasaki, Shelley H.
Th.B.P.323
- Miyoshi, I.
W.C.P.4
- Mizawa, H.
M.B.P.167
- Mizerek-Erhart, A.
T.C.P.61
- Mizrachi, Y.
Th.C.P.16, Th.C.P.17
- Mizrachi, Yaffa
Th.C.P.15
- Mizukami, Tamio
M.C.P.89
- Moatti, J. P.
M.H.O.5
- Moatti, Jean-Paul
T.D.O.20, Th.E.P.23
- Mobarak, A. B.
Th.H.P.28
- Mobrandt, L.
W.D.P.88
- Mockler, R. W.
E.684
- Modai, J.
W.B.P.29
- Modesitt, S.
W.B.P.273, M.H.P.9
- Modesitt, S. K.
A.521
- Modest, E.
W.C.O.21
- Modlin, J.
T.B.P.256
- Modlin, J. F.
W.B.O.2, T.B.P.239
- Modliszewski, A.
W.B.P.239, W.C.O.26
- Moe, C. E.
Th.A.P.53, W.H.P.18
- Moelling, K.
Th.C.P.10
- Moen, M. E.
D.660, E.530
- Moen, Michael E.
E.695
- Moens, E.
T.B.P.251
- Moestrup, T.
W.B.P.280
- Mofenson, L.
Th.A.P.98, W.E.P.53, E.723
- Mofenson, Lynne M.
M.A.P.14
- Moglia, Arrigo
Th.B.O.20
- Mohammad, H. K.
M.B.P.334
- Mohammad, S. S.
Th.P.21
- Mohan, D.
A.620
- Mohar, A.
Th.A.P.81
- Mohar, Alejandro
Th.A.P.80
- Mohilef, E.
W.B.P.53
- Mohla, C.
T.B.P.230, T.B.P.241
- Mohler, J.
T.B.P.26
- Mohr, E.
Th.B.P.208
- Mohri, H.
M.B.P.63
- Moien, Mary
Th.H.P.5
- Moini, S.
M.F.P.4
- Moiok, M. C.
M.A.P.83
- Mojon, M.
T.B.P.47, Th.C.P.143
- Mok, J.
E.807
- Mok, J. Y. Q.
T.B.P.246, B.590
- Mok, Jacqueline Y. Q.
T.B.P.211
- Mokwa, K.
W.A.P.96
- Molbak, K.
Th.B.P.156
- Molenaar, John W.
T.E.P.18, Th.E.P.75
- Molgaard, C.
Th.D.P.51
- Molina, Jean-Michel
W.C.P.77, W.C.P.78
- Molinari, J. A.
M.D.P.82
- Moling, O.
Th.B.P.245
- Moller, B.
Th.B.P.106
- Molnar-Kimber, Katherine L.
C.647
- Momose, D.
M.C.P.108
- Mompradé, B.
T.E.P.73, E.777

- Monaco, M.**
 W.C.P.51
- Moncany, Maurice L. J.**
 Th.C.P.81
- Mondain, V.**
 M.B.P.282, T.B.P.33
- Mondia, P.**
 T.G.O.24
- Mondragon, M.**
 E.585, T.G.O.9
- Monfardini, S.**
 Th.C.O.40, M.C.P.103,
 W.G.P.50
- Mongalo, G.**
 W.G.O.16
- Montardo, Nicola**
 Th.B.P.339
- Moniaci, D.**
 Th.B.P.344
- Monical, C.**
 Th.B.P.146
- Monji, N.**
 T.B.P.124
- Monnier, J.**
 T.A.P.32
- Monnig, Regina L.**
 M.B.P.320
- Monny-Lobe, M.**
 A.573, W.E.P.71
- Monny-Lobe, Marcel**
 Th.A.O.19, W.D.P.87,
 Th.D.P.22, W.G.O.21
- Monplaisir, N.**
 Th.A.P.30, B.630
- Monplaisir, N. M.**
 W.C.P.126
- Monplaisir, Nicole**
 W.C.P.139
- Monsuez, J.**
 M.B.P.323
- Monsuez, J.-J.**
 M.B.P.282, M.B.P.284
- Montagnier, L.**
 W.B.P.82, Th.B.P.10,
 M.C.O.3, M.C.O.13, T.C.O.5,
 T.C.O.36, T.C.O.40, W.C.O.8,
 W.C.O.9, W.C.O.14,
 W.C.O.44, W.C.O.46,
 M.C.P.29, M.C.P.104,
 M.C.P.106, T.C.P.42,
 T.C.P.115, T.C.P.116,
 W.C.P.85, W.C.P.113,
 W.C.P.127, Th.C.P.1,
 Th.C.P.4, Th.C.P.87,
 Th.C.P.70, Th.C.P.81,
 Th.C.P.85, C.564, C.630,
 C.658
- Montagnier, Luc**
 M.C.O.14
- Montalbán, J.**
 M.B.P.260
- Montana, J. P.**
 T.B.P.124
- Montaner, J.**
 W.B.O.6, M.B.P.349,
 M.B.P.367
- Montaner, J. S. G.**
 W.A.P.57, M.B.O.47,
 T.B.O.35, W.B.O.1,
 W.B.P.351, Th.B.P.52,
 M.H.P.1, T.H.P.11
- Montaner, Julio**
 M.B.O.15
- Montaner, Julio S. G.**
 T.B.O.29, W.B.O.8, T.B.P.54,
 B.666
- Montani, N.**
 Th.B.P.2
- Montano, B. Lily**
 T.A.P.82
- Monte, M.**
 W.B.P.43
- Montealegre, L.**
 M.E.P.15
- Montecucco, C. M.**
 Th.B.P.2
- Montefiori, D.**
 M.C.P.19
- Montefiori, D. C.**
 W.B.P.239, Th.C.P.45,
 Th.C.P.129, C.771
- Montefiori, David C.**
 W.C.O.26, M.C.P.136
- Monteiro, B.**
 T.G.P.11
- Monteiro, D. T.**
 Th.G.P.3
- Montelaro, R.**
 Th.C.P.123
- Montella, Francesco**
 M.B.P.199
- Montero, C.**
 Th.B.P.14, B.511
- Montgomery, A. B.**
 T.B.O.3, T.B.P.76, T.B.P.78
- Montgomery, A. Bruce**
 T.B.O.26
- Montgomery, Kathleen**
 T.E.P.47
- Montgomery, Kathleen E.**
 Th.E.P.11
- Montgomery, N.**
 A.590
- Montiel, F.**
 B.539
- Montoya, R.**
 M.E.P.7
- Montreuil, A.**
 W.B.P.269
- Monzon, Ofelia T.**
 T.B.P.377, Th.H.P.21
- Moody, A. H.**
 M.B.P.236
- Moody, Dewey J.**
 T.C.P.61
- Moody, R. C.**
 M.A.P.7
- Moon, Martha W.**
 T.B.P.70
- Mooney, Terry**
 W.G.O.38
- Moore, Barbara E.**
 Th.C.P.116
- Moore, C.**
 M.B.P.155
- Moore, D.**
 W.A.P.112, A.630
- Moore, D. F.**
 Th.B.P.302
- Moore, G. K.**
 Th.C.O.31
- Moore, H.**
 M.B.P.304
- Moore, J. L.**
 Th.A.P.114, T.C.P.21
- Moore, John P.**
 C.582
- Moore, M.**
 Th.E.P.1, M.B.O.50, T.C.O.11,
 W.D.O.6, E.646
- Moore, Melinda**
 M.D.O.3, M.D.O.17, M.D.P.13,
 M.D.P.49, D.721, T.E.P.4,
 M.G.O.16, W.G.P.20
- Moore, Melinda K.**
 M.D.P.14
- Moore, T.**
 Th.A.P.15
- Moore, T. H.**
 C.554
- Moore, Teri**
 E.774
- Mor, V.**
 M.E.P.69
- Mor, Vincent**
 T.E.P.34
- Mora, C.**
 Th.C.O.46
- Morace, G.**
 Th.B.P.99
- Morais de Sá, C. A.**
 W.A.P.51, T.B.O.7, W.A.P.70,
 M.E.O.17, M.B.P.109,
 M.B.P.182, M.B.P.291,
 T.B.P.190, T.B.P.369, B.563,
 B.638, Th.E.P.19, T.D.P.83,
 W.D.P.38, D.532, M.E.P.66,
 E.591
- Morais de Sá, Carlos Alberto**
 M.B.P.257, Th.B.P.66, B.532,
 B.533, B.534, D.638
- Morais de Sá, W.**
 T.A.P.117
- Moraleda, G.**
 M.B.P.246
- Morales, A.**
 W.B.P.78
- Morales, C.**
 T.B.P.335, W.B.P.179, B.515
- Morales, Catalina**
 A.585
- Morales, Edward S.**
 T.D.O.12
- Morales, J.**
 Th.B.O.45
- Morales, L.**
 M.B.P.28
- Morales, R.**
 E.555
- Morales, R. A.**
 W.G.P.6
- Moran, John S.**
 T.A.O.24
- Moran, Patricia A.**
 W.C.P.58
- Morandi, C.**
 C.650
- Morcamp, D.**
 T.B.P.382
- Mordant, John**
 M.E.O.27
- Mordenti, J.**
 Th.C.O.15
- Morea, J.**
 Th.B.O.55, W.G.O.27
- Morea, D.**
 W.E.P.23
- Morecki, R.**
 B.580
- Morein, B.**
 M.C.P.10, M.C.P.26
- Moreira, C. E.**
 D.543
- Moreira, P.**
 M.B.P.231
- Morél, B.**
 M.H.P.11
- Morél, P.**
 W.B.P.49, B.530, C.726
- Moreno Ceida, V.**
 B.647
- Moreno, A.**
 T.A.P.93, T.A.P.100, W.B.P.40
- Moreno, J.**
 W.G.P.12
- Moreno, J.D.**
 T.F.P.12
- Moreno, Jose N.**
 T.B.P.220
- Moreno, M.**
 T.B.P.335
- Moreno, Sylvia A.**
 W.H.P.7
- Morera, J.**
 M.B.P.103
- Morféldt, Jan-Olof**
 D.574
- Morféldt-Månson, L.**
 M.C.O.9

- Morfheldt-Manson, R. Linda**
T.B.P.372
- Morgado, A.**
Th.B.P.363
- Morgan, A.**
W.B.P.307
- Morgan, Allyah**
A.827
- Morgan, B.**
W.B.P.271
- Morgan, C.**
W.A.O.23
- Morgan, J.**
Th.B.P.19
- Morgan, J. E.**
T.B.P.329
- Morgan, R.**
Th.A.P.97, M.B.O.40,
Th.B.O.40, W.B.P.190,
Th.B.P.306, Th.B.P.310,
Th.B.P.313
- Morgan, Richard A.**
Th.C.O.11
- Mori, K.**
W.B.P.292, Th.C.O.19
- Mori, P. G.**
W.B.P.357
- Moriarty, A. M.**
M.C.P.15
- Moriarty, R.**
T.B.P.176
- Morice, A.**
T.C.P.75
- Moriceau, M.**
T.B.P.305
- Morikawa, S.**
B.605, M.C.P.108, M.C.P.134
- Morin, J.**
C.867
- Morin, Nicole**
E.630
- Morin, S.**
W.A.P.91
- Moris, J.**
Th.B.P.69
- Morisset, R.**
T.B.O.31, M.C.P.112,
W.B.P.30, M.E.P.75,
Th.E.P.72, Th.F.P.15
- Morissette, M. R.**
M.D.P.41
- Morissette, Michel R.**
T.F.P.7
- Morissette, Y.-M.**
T.F.O.4, M.F.P.7
- Moriya, T. M.**
M.D.P.61, M.D.P.87
- Morlat, Philippe**
T.A.P.25, A.635, M.B.P.254
- Morlet, A.**
M.A.P.65, A.581, Th.B.P.358,
W.D.P.62, W.D.P.64
- Mornex, J. F.**
W.C.P.171
- Moro, M.**
W.A.P.4
- Moroni, M.**
M.B.P.287, M.B.P.354
- Moroso, G.**
M.B.O.2, W.D.P.58
- Morrey, John D.**
C.512
- Morris, J. G.**
T.B.P.263
- Morris, L.**
E.785
- Morris, R.**
M.D.P.5, D.502, E.797
- Morris, Robert**
T.D.P.7
- Morris, Scott K.**
M.B.P.237
- Morris-Smith, J.**
M.A.P.41
- Morrison, A.**
E.809
- Morrison, C.**
W.E.P.12
- Morrison, Cliff**
Th.H.O.5
- Morrison, J.**
W.A.P.34
- Morrison, Ken A.**
W.E.O.12
- Morriss, R.**
W.B.P.227
- Morrow, C. D.**
T.C.P.126
- Morrow, John W.**
W.C.P.128, W.C.P.138
- Morse, D.**
T.A.P.80, W.A.P.21,
W.D.P.15, Th.D.P.16
- Morse, Dale L.**
M.A.P.27, Th.D.P.45
- Morse, Gene D.**
M.B.P.342
- Morton, W. R.**
W.C.10, Th.C.P.89
- Morton, William R.**
W.C.P.33
- Mosca, J.**
T.C.P.128
- Mosca, Joseph D.**
T.C.O.14
- Moscato, M. L.**
M.B.O.3
- Moschese, V.**
Th.A.P.113, T.C.P.55
- Moscoso, R.**
M.B.P.27
- Moses, H.**
M.B.P.381
- Moses, Stephen**
Th.G.O.27
- Moshe-Sterk, T.**
W.B.P.171
- Mosier, D.**
M.B.P.110, W.C.P.19
- Mosier, Donald E.**
T.C.O.44
- Moskie, S.**
T.H.P.25
- Moskowitz, L.**
W.B.P.51
- Mosley, James W.**
Th.A.P.32
- Mosnaim, A. D.**
W.C.P.24
- Mosqueira, C.**
W.B.P.179
- Moss, A.**
T.A.P.94, M.B.O.19,
W.B.P.198, W.B.P.231,
W.C.P.38, Th.O.4
- Moss, A. R.**
M.A.P.100, T.A.P.47,
Th.A.P.102, A.525, T.B.P.312,
W.B.P.54, T.D.P.24, E.727,
E.729
- Moss, Andrew R.**
T.A.O.11, T.A.O.31
- Moss, B.**
T.C.O.34, W.C.O.41,
W.C.O.43, Th.C.O.12,
M.C.P.36, M.C.P.69,
Th.C.P.130
- Moss, G.**
T.A.P.87
- Moss, Gregory B.**
T.A.P.88, B.536
- Moss, H.**
M.B.O.43, T.B.P.179
- Moss, Howard A.**
T.B.P.248
- Moss, P.**
M.D.P.23, M.D.P.24, E.708
- Moss, R. T.**
T.C.P.2
- Moss, V. W.**
M.A.P.57
- Mossalayi, Djavad**
W.B.P.281
- Mossalayi, M. D.**
W.B.P.284
- Mostertz, P.**
M.B.P.120, T.B.P.375
- Motta, M.**
W.G.P.3
- Motta, P. R.**
M.B.P.263, E.704
- Motz, M.**
W.B.P.94, W.B.P.118,
Th.C.P.2, Th.C.P.73
- Mouanga-Yidika, G.**
T.B.P.19
- Moudgil, T.**
Th.C.P.138
- Mouillot, L.**
M.A.P.118
- Mouillot, Laurence**
B.644
- Moulton, J.**
E.727, E.729
- Moulton, J. M.**
T.D.O.29, T.D.P.13, Th.E.P.13
- Mounier, M.**
B.523, C.766, W.G.P.2
- Mounlaila, K.**
T.B.P.47
- Moura, E. M. M.**
Th.D.P.89, M.E.O.17,
M.E.P.66, Th.E.P.19, E.591
- Moura, M. C.**
T.B.P.376
- Mous, J.**
Th.B.P.231
- Mouton, Y.**
T.B.P.288, W.B.P.248,
W.B.P.282, Th.B.P.105,
Th.C.O.6
- Mouton, Yves**
Th.B.O.13, Th.B.P.178
- Moxey, R.**
T.D.P.17
- Moxuam, J.**
W.B.P.272
- Moye, J.**
E.711
- Moye, John**
M.A.O.25, W.E.P.53
- Moyer, Mary Pat**
W.C.P.90
- Moyle, G.**
M.B.P.122
- Moynihan, R.**
W.D.P.9, W.D.P.10, E.527
- Mozes, E.**
W.C.O.29
- Moizzi, F.**
M.A.O.11
- Mpele, P.**
T.B.P.19, W.B.P.151,
W.G.P.10
- Mposo, Ntumbanzondo**
Th.H.O.8
- Mrfizi, B.**
W.B.P.14
- Msellati, P.**
M.B.P.254
- Msimanga, S.**
W.G.O.19
- Muchnik, G.**
T.A.P.108, M.B.O.16,
T.B.P.139, T.B.P.340,
Th.B.P.3, Th.B.P.24,
Th.B.P.207, Th.B.P.326,
Th.D.P.46, M.G.O.29,
Th.G.P.21, Th.H.P.23
- Muchnik, G. R.**
W.A.P.22, Th.B.P.4

- Muchnik, Guillermo
A.520, T.B.P.140, Th.B.P.13,
Th.B.P.382, B.513
- Mudro, R.
Th.E.P.56
- Mueke, F. M.
W.G.P.27
- Mueke, F. N.
G.503
- Mueller, K. B.
T.B.P.253
- Mueller, N.
Th.A.P.14, B.633
- Mueller, O.
W.E.O.5
- Mueller, Olaf
W.E.P.22
- Mueller-Lantzsch, N.
Th.C.P.44
- Muenchau, D. D.
Th.CO.11
- Muerelo, D.
C.608
- Mufson, M.
G.519
- Muga Bustamante, Roberto
W.A.P.71, Th.B.P.335,
T.D.P.84, D.613
- Muga, R.
M.A.P.81, Th.A.P.19, A.556,
T.D.P.65, Th.D.P.57, D.699
- Mugaruka, Z.
M.B.O.17
- Mugerwa, Roy D.
Th.G.O.35
- Muggeo, C.
A.558, W.B.P.333
- Muggia, F.
M.B.O.48
- Muggiasca, Maria-Luisa
M.B.P.56, T.B.P.201
- Muhawenimana, C.
T.E.O.3
- Muhondwa, Eustace
Th.D.O.19
- Muir, H.
T.B.P.141, T.B.P.142
- Muir, H. W.
T.B.P.143
- Muir, L.
C.514
- Muirhead, L.
W.A.P.8, B.504
- Mukaj, R.
W.C.P.2
- Mukelabai, K.
M.B.P.372, W.G.O.5,
Th.G.P.30
- Mukherjee, M.
T.G.F.8
- Mukunyandela, M.
T.B.P.144, D.723
- Mulai, T.
T.E.P.21
- Mulandi, T. N.
W.H.P.15
- Mulder, J.
M.B.P.352
- Mulder, J. W.
W.C.P.99
- Muldoon, R.
M.B.P.47
- Mulhall, Brian P.
W.A.P.44, B.627
- Muligande, G.
Th.G.P.20
- Mullan, R. J.
Th.A.P.44
- Mullaney, S.
Th.CO.49, W.C.P.29
- Mulleady, G.
D.617
- Mullen, M.
W.B.P.5
- Mullen, M. P.
M.B.P.89
- Müller, Fredrik
T.C.P.146, W.C.P.73
- Müller, K.
M.B.P.47, Th.B.P.49
- Müller, R.
W.A.P.3, T.B.P.73
- Müller, Ruth
Th.B.P.59
- Müller, W. E. G.
Th.B.P.58, Th.B.P.122,
T.C.P.88
- Müller, Werner E. G.
W.B.P.163, C.606, C.654
- Müller-Lantzsch, N.
W.C.P.91
- Mulligan, L.
Th.A.P.46
- Mulligan, M.
T.B.P.352
- Mulligan, Mark J.
W.C.P.79
- Mullins, J. I.
T.C.O.30, W.C.O.13,
W.C.O.31, W.C.P.12
- Mullins, James I.
M.C.O.12
- Mullins, L. L.
E.590
- Multare, S.
W.D.P.56
- Multare, Salvador
W.C.P.21
- Mulumba, M. P.
Th.H.P.16
- Muma, R. D.
E.627
- Munday, P.
M.B.P.292
- Mundy, T.
T.E.P.183
- Mundy, Thomas M.
T.B.P.167
- Mungieri, A.
W.B.P.12
- Munhoz, R.
D.540
- Munis, J. R.
Th.C.P.29
- Munis, James R.
Th.C.P.79
- Munio, E.
W.B.P.173
- Muniz, R.
W.H.O.10
- Muñoz, A.
T.A.O.29, M.A.O.44,
M.A.P.26, M.A.P.34,
M.A.P.98, T.A.P.45,
Th.A.P.85, Th.A.P.91
- Muñoz, Alvaro
W.A.P.67, W.A.P.68,
Th.A.P.94
- Muñoz, G.
M.G.P.17
- Muñoz, J. A.
W.B.O.37
- Muñoz, L.
T.B.P.172, T.B.P.229,
Th.C.P.74
- Muñoz-Baroja, I.
Th.B.P.65
- Mupate, E.
W.G.P.27
- Mupediswa, Rodreck S.
Th.E.P.62
- Mura, H.
M.B.P.294
- Muratori, S.
M.B.P.50, M.B.P.384
- Muratori, Simona
A.545
- Murayama, T.
T.C.P.5
- Murayama, Tsugiya
T.C.P.4
- Murbach, Ruth
W.F.P.9
- Murdock, P.
W.E.O.25
- Murphy, M.
T.E.P.74
- Murphy-Corb, M.
M.C.O.12, T.C.O.43,
W.C.P.12, W.C.P.30
- Murphy, D.
M.A.P.71, W.D.P.15
- Murphy, Dano B.
C.736
- Murphy, E.
Th.A.P.24, B.636
- Murphy, Edward L.
W.G.P.26, Th.G.P.1
- Murphy, F. K.
Th.A.P.48, M.B.P.233
- Murphy, R.
M.A.O.17, Th.A.O.17,
M.B.P.86, T.B.P.30, T.B.P.31,
Th.B.P.283, Th.B.P.309
- Murphy, Robert
W.B.P.313
- Murphy, V.
A.602
- Murray, C.
B.588
- Murray, P. A.
Th.B.P.338, Th.B.P.351
- Musagara, Muhammed
Th.E.P.43
- Musch, C. K.
M.H.P.8
- Musgrave, S.
T.B.P.358, W.D.P.8, M.G.O.14
- Mussa, M.
Th.B.P.211, Th.B.P.221,
Th.B.P.267
- Muthami, L. N.
W.G.O.22, W.H.P.15
- Muthami, N.
G.503
- Muther, J.
T.B.P.223
- Muthuswamy, P.
Th.B.P.49, B.529
- Mutul, L.
Th.G.P.12
- Mvula, M.
W.G.O.4, Th.G.O.34
- Mwale, C.
Th.A.O.5, W.A.P.50
- Mwansa, N.
Th.A.O.5
- Mwendapole, Rosemary M.
M.G.P.28
- Mwendasilumba, D.
T.B.P.371
- Mwile, Abraham
T.B.P.353
- Mworozi, E.
W.A.P.56
- Mworozi, E. A.
M.G.O.19
- Mworozi, Edison A.
T.B.P.189
- Mwungura, G.
T.A.P.90
- Myers, P.
M.B.P.261
- Myers, Gerald
M.C.O.24
- Myers, L. E.
T.B.P.121
- Myers, M.
T.B.O.28, T.E.P.51

- Myers, M. H.
Th.D.P.30
- Myers, T.
W.A.P.92
- Myrtveit, M.
A.513, W.E.P.6
- Myrvik, Q.
Th.C.P.62
- Melbak, K.
T.G.P.31, G.517
- N**
- N'Doye
M.A.O.13
- N'Doye, I.
T.G.P.26
- N'Galy, B.
T.B.P.166, Th.E.O.3, E.621,
E.666, M.G.O.17, Th.G.O.33,
W.H.P.5
- N'Galy, Bosenge
M.F.O.16, W.G.O.26
- N'Go, N.
A.552
- N.Y.C.D.H. AIDS Sur. Unit
T.A.P.70, T.A.P.71
- Naamara, W.
T.A.P.11, W.D.P.8, M.G.O.14,
Th.G.P.18
- Naber, D.
W.B.P.235
- Nadai, V.
M.C.P.83
- Nadal, J. M.
M.H.P.11
- Nagashima, K.
Th.C.P.5
- Nagata, S.
W.C.P.37
- Nagelkerke, N.
Th.A.P.62
- Nagode, L.
M.C.P.68
- Naguat, A.
M.B.O.40
- Nagy, K.
Th.C.P.125
- Nagy, Károly
Th.B.P.174, T.C.P.140
- Nahass, G.
Th.B.P.125
- Näher, Helmut
M.B.O.18
- Nahlen, Bernard
A.528
- Nahmias, A.
W.A.P.7, T.D.P.17
- Nahmias, A. J.
T.A.P.118
- Nahmias, André J.
T.A.P.119, M.B.P.346,
T.B.P.223, Th.B.P.93
- Naidoo, S.
T.G.P.18, Th.G.P.15
- Naidu, Y.
W.C.P.9
- Naidu, Y. M.
Th.C.P.58
- Naillia, M.
D.659
- Naini, A.
Th.B.P.224, Th.B.P.237
- Nair, P.
T.B.P.210, T.B.P.220,
T.B.P.238, T.B.P.263, B.574
- Nair, P. N. M.
A.629
- Nair, Prasanna
W.A.P.47
- Nájera, R.
A.578, T.B.P.92, Th.C.P.74
- Najjar, D.
M.E.P.33
- Najjar, M.
W.A.P.42
- Najman, A.
W.B.P.283, W.B.P.320
- Nakagawa, A.
M.B.P.63
- Nakai, M.
C.778
- Nakae, C.
W.B.P.115
- Nakajima, G.
Th.E.P.66
- Nakamura, M.
E.785
- Nakamura, R. M.
D.685
- Nakamura, S.
W.C.P.48, W.C.P.54
- Nakane, H.
M.C.P.144
- Nakashima, H.
M.C.P.75
- Nakashima, Hideki
C.621
- Namaara, W.
A.617
- Namaganda, F.
Th.E.P.43
- Nantele, K.
M.A.O.35
- Napiórkowska, T.
M.A.P.69
- Napols, A. J.
Th.E.O.6
- Nappi, G.
Th.B.P.281
- Nara, P.
M.C.O.7, Th.C.O.29,
T.C.P.90, C.513
- Nara, P. L.
Th.C.O.30, M.C.P.66
- Nara, Peter L.
T.C.O.22, C.741
- Narain, J.
E.574
- Narain, Jai P.
Th.G.O.42, Th.G.P.27,
Th.G.P.28
- Narciso, P.
Th.B.O.14, M.B.P.106,
Th.B.P.56, Th.B.P.220, B.597
- Nardella, M. L.
W.B.P.365
- Nardi, M.A.
T.E.P.69
- Nardolillo, J.
M.A.P.29
- Nardone, B.
C.776
- Narer, J.
Th.A.O.17
- Nariotti, M.
Th.A.P.116
- Narkunas, J.
M.A.P.9
- Narkunas, John P.
T.A.P.15
- Naruszewicz-Iesiuk, D.
T.A.P.7
- Närvinen, A.
W.B.P.102
- Nascimento, M. F. A.
M.B.P.44
- Nash, M.
W.B.P.270
- Nash, R.
Th.B.P.268
- Nasr, M.
M.C.P.115, M.C.P.122
- Nassaney, Louie
T.E.P.25
- Nassar, N.
W.A.P.118
- Nassig, S. E.
M.G.O.16
- Nassor, H.S.
E.652
- Nastala, C. L.
T.C.P.32
- Natali, C.
W.B.P.214, W.B.P.217
- Natarajan, T.
E.543
- Nathanson, Vivienne
M.F.O.11
- Nathwani, D.
W.B.O.7
- Natori, H.
Th.C.P.141
- Natuk, R.
C.647, C.667, C.668
- NaucIér, A.
M.G.P.16, Th.C.P.6
- Naudin, Claude A.
D.644
- Nault, P.
W.D.P.59
- Nault, Penny L.
A.591
- Navarette, Maria-Soledad
T.B.P.307
- Navarret, N.
A.582, M.G.P.29
- Navarrete, C.
W.B.O.17
- Navarro, A.
W.B.P.203
- Navarro, C.
M.B.P.273
- Navarro, F.
G.512
- Navarro, M. D.
B.640
- Navarro, R.
M.E.P.21
- Navarro-Carola, E.
T.B.P.279
- Nave, R.
M.A.P.59
- Navia, Manuel A.
M.C.O.23
- Navio, D.
T.B.P.202
- Navy Retroviral Study
Group
M.A.P.11
- Naylor, C. W.
M.C.P.13
- Naylor, P. H.
M.C.P.13
- Naylor, Paul H.
W.B.P.141
- Nayyar, S.
Th.C.P.113
- Nazar, A.
W.G.P.24
- Nazarali, S.
T.B.P.38
- Ndabaneze, E.
W.B.P.14
- Ndiaye, B.
T.B.P.373
- Ndibisheye, N.
Th.G.P.20
- Nditu, M.
M.A.O.35, M.G.O.3
- Ndinya-Achola, J.
M.A.O.36, Th.A.O.25,
T.A.P.87, W.A.P.65,
- Ndinya-Achola, J. O.
T.A.O.25, M.A.P.110,
T.A.P.88, B.536,
- Ndinya-Achola, Jacksoniah
O.
W.G.P.29

- Ndoko, K.
T.B.P.188, Th.G.O.33,
W.H.P.6
- Ndovi, E.
Th.G.O.28, G.507
- Ndoye, I.
M.A.P.117, T.A.P.3, T.D.P.37,
M.E.O.7, W.G.O.20
- Ndoye, Ibra I.
Th.G.O.31
- Ndungwa, C. M.
T.B.P.189
- Ndumbe, P.
T.A.P.1
- Ndumu, J.
T.B.P.358, M.G.O.14
- Ndumu, J. R.
T.A.P.11
- Neaigus, A.
W.E.P.68
- Neal, D.
Th.B.P.201
- Neal, D. P.
W.A.P.14, W.A.P.80,
W.B.P.354
- Neegayee, Janet
W.G.O.33
- Neemeh, J. A.
W.B.P.43
- Neeguaye, A.
W.E.P.71
- Negre, M.
A.531
- Negro, F.
W.C.P.125
- Nehm, K.
T.B.P.28, T.B.P.375,
Th.B.P.45
- Neibart, E. P.
T.B.P.29
- Neihart, Robert E.
M.B.P.80
- Neil, J.
Th.B.P.28
- Neill, P.
M.B.P.289, Th.G.O.6
- Neilsen, I. O.
B.578
- Neilsen, T. L.
Th.B.P.80
- Neisson-Vernant, Claudine
Th.A.P.30
- Neisson-Vernant, C. N. V.
W.C.P.128
- Nelson, A.
Th.B.P.186
- Nelson, Ann Marie
T.B.P.366, Th.G.O.32
- Nelson, G.
C.562, T.D.P.9
- Nelson, J.
M.B.P.129
- Nelson, J. A.
W.C.P.97, C.531
- Nelson, Kenrad E.
M.A.O.9, M.A.P.34, T.A.P.58,
W.B.P.7.
- Nelson, M.
T.B.O.30
- Nelson, M. B.
Th.C.P.122
- Nelson, M. Bud
Th.C.P.121
- Nelson, Mark R.
M.B.P.209, W.B.P.17
- Nelson, P.
Th.D.P.66
- Nelson, Robert P.
Th.B.P.138
- Nemeth, G.F.
E.519
- Nemoto, T.
T.A.P.49, W.D.P.68,
Th.D.P.53, D.607, D.608,
D.609
- Nemoto, Tooru
D.100, D611
- Nera, Nena M.
Th.B.P.27, Th.B.P.35,
Th.B.P.46, T.E.P.54,
- Nesdoly, C.
W.B.O.10
- Nesheim, S.
M.B.P.346, T.B.P.223,
Th.B.P.93
- Neshund, V. S.
M.F.P.6
- Neshund, Veria S.
Th.F.O.4
- Nessel, Jerry T.
D.546
- Nesset, J. K.
Th.B.P.318
- Nestande, P.
D.585
- Nestor, S.
D.519
- Nestoridou, A.
W.A.P.37
- Neto, P.
T.B.P.376
- Neugebauer, R.
W.B.O.41, W.B.P.244
- Neumann, C.
D.644
- Neumann, Jeanne E.
C.764
- Neumann, P.
T.B.P.106
- Neumann, Peter W.
Th.C.O.48
- Neumüller, M.
W.B.P.147, Th.C.P.82,
Th.C.P.84
- Neuvent, C.
Th.C.P.71
- Newbury, J.
M.B.P.309
- Newell, M. L.
Th.A.O.3
- Newell, Marie-Louise
Th.A.O.4
- Newell, Mark E.
M.B.P.122
- Newell, Murray C.
W.E.P.42
- Newlett, C.
T.B.P.12
- Newman, B.
Th.A.P.83
- Newman, F.
Th.C.O.32
- Newman, H.
D.668
- Newman, J.
E.761
- Newman, S.
T.B.P.85, W.B.P.185
- Newman, S. P.
Th.B.P.287
- Newmeyer, J.
Th.D.P.34
- Newmeyer, John A.
D.707
- Newsome, Glenn S.
M.B.P.208
- Newstein, M.
T.C.P.113
- Newstetter, A.
W.D.P.46, D.683, D.684
- Ng, T. W.
Th.O.16
- Ng, Timothy
M.H.P.1
- Ng, V. L.
T.B.P.11
- Ng, Valerie L.
Th.C.P.54, C.777
- Ngalala, K.
W.G.O.30
- Ngaly, B.
M.B.O.17
- Ngandu, K.
M.G.O.17
- Ngirabakunzi
M.E.O.33
- Ngole, K.
T.B.P.188, Th.G.O.33
- Ngiolet, A.
M.B.P.91
- Ngoy, T.
M.G.O.17
- Ngu, K.
A.573
- Ngugi, E.
M.A.O.36, M.A.P.110,
M.B.P.53
- Ngugi, E. N.
T.A.O.25
- Ngugi, Elizabeth
M.G.O.32
- Nguma, J.K.
E.604
- Nguyen Tan Lung, R.
B.503
- Nguyen, B.
Th.O.5
- Nguyen, B. H.
M.A.P.60
- Nguyen, M.
B.630
- Nguyen, N.
Th.C.P.115
- Nguyen-Ba, N.
T.C.O.1
- NIAID AIDS Vaccine
Evaluation Group
T.B.P.123, M.C.P.12
- NIAID AIDS Vaccine
Program
M.C.P.32, Th.C.O.32
- Nicholas, A.
T.A.P.70
- Nicholas, P.
T.B.O.6, T.B.P.48, W.B.P.86
- Nicholas, T.
T.D.P.35
- Nichols, D.
W.D.P.87, Th.D.P.22,
W.G.O.21
- Nichols, David L.
Th.B.O.58
- Nichols, Douglas J.
W.E.P.71
- Nichols, Larry
W.B.O.33
- Nichols, Larry C.
T.B.P.22
- Nichols, Margaret
T.A.P.104, W.A.P.93
- Nichols, S.
Th.D.O.15, Th.D.P.42
- Nichols, Stuart E.
D.690
- Nicholson, J.
T.C.P.36
- Nicol, Isabelle
W.C.P.3
- Nicolas-Randegger, Joëlle
Th.P.22
- Nicolau, Claude
M.C.P.102
- Nicolli, N. F.
T.B.P.363
- Nicolosi, Alfredo
T.A.P.41
- Niederman, T. M. J.
T.C.P.120
- Niedobitek, F.
Th.B.O.22, W.C.P.60

- Niedrig, Matthias**
 T.C.P.65
Niedzwiecki, D.
 W.B.O.39, Th.B.O.28
Nielsen, C.
 Th.C.P.60, Th.C.P.61
Nielsen, C. M.
 W.C.P.25, Th.C.P.60,
 Th.C.P.61
Nielsen, J.
 Th.C.P.60, Th.C.P.61
Nielsen, J. O.
 T.B.P.24
Nielsen, Peder B.
 Th.C.P.143
Nielsen, T.
 T.B.P.32
Nielsen, T. L.
 T.B.P.59
Nielsen, Thyge Lynghej
 M.B.P.259, T.B.P.24
Niemeck, U.
 W.D.P.86
Niemeyer, B. L.
 T.A.P.61
Niese, D.
 M.A.O.12, T.A.P.107,
 W.B.O.26, W.B.P.170
Niese, Dettel
 T.A.P.110
Nigaglioni, A.
 Th.E.P.67
Nigam, V. N.
 W.C.P.22
Nightingale, S.
 Th.B.P.117
Nightingale, S. D.
 M.B.P.78, W.B.P.347
Nightingale, Stephen D.
 T.B.P.56, T.B.P.77
Nigrisoli, E.
 M.B.P.113
Nigro, M.
 M.B.O.34
Nijs, P.
 C.761
Nikolaeva, I. A.
 T.B.P.91
Niland, Joyce C.
 Th.B.P.108
Niles, C.
 E.633
Nilsen, B.
 Th.D.P.63
Nilsen, Bente
 D.619
Nilsen, Ø
 M.A.P.91, A.607
Nilsson, B.
 T.B.P.372
Nilsson, B. R.
 Th.H.P.10
Nilsson, K.
 C.712
Nilsson, L.
 C.760
Nimorwicz, P.
 Th.B.P.32
Ninane, J.
 W.A.P.49, T.B.P.197
Nirigara, B.
 T.E.P.62
Nisato, D.
 Th.C.P.66
Nisda
 T.A.P.41
Nishanian, P.
 W.A.P.62, T.C.P.57,
 W.C.P.104, W.C.P.111
Nishanian, Parung G.
 T.C.P.46
Nishanin, P. G.
 M.C.P.24
Nishida, Yasuharu
 B.512
Nishitani, H.
 Th.A.O.31, Th.A.P.17
Niven, P.
 M.B.P.19
Nixon, Douglas F.
 T.C.P.23
Nixon, L.
 D.641
Njie, A. B. H.
 M.D.P.12
Njie, R.
 M.G.O.5
Nkowane, B.
 T.G.P.3
Nkumbi, S.
 W.G.P.32
Noble, L. M.
 W.A.P.5, T.B.P.159
Noba, E.
 T.D.P.85
Noce, S.
 T.A.P.115, W.B.P.362
Noël, B.
 Th.A.P.116, T.C.P.131
Noël, Grégoire
 W.B.P.30
Noël, Luc
 B.561
Noel-Connor, J.
 W.B.P.373, D.631
Nogueira, C.
 M.G.P.15
Noguera, E.
 A.544, M.H.P.21
Noguerado Asensio, A.
 T.B.P.293
Noguerado, A.
 M.B.P.214
Nokta, M. A.
 T.B.P.322
Nokta, Mostafa A.
 M.B.P.341
Nolan, Kathleen
 W.F.O.8, W.F.P.6
Nondo, Hassan S.
 E.682
Nonoyama, M.
 M.C.P.118
Noone, S.
 T.A.P.35
Nooney, Kay
 T.D.P.68
Norat, Y.
 A.614, M.E.P.12
Noraz, N.
 C.725
Norbeck, D. W.
 M.C.P.135
Norbeck, Daniel
 M.C.P.65
Norbiato, G.
 M.B.P.267
Norcross, M.
 T.C.P.117
Norcross, Michael A.
 C.635
Norcross-Nechay, K.
 Th.B.P.273
Nord, C. E.
 B.578
Nord, J.
 M.B.P.38
Nord, Jill A.
 C.586
Norkrans, G.
 Th.B.O.46, Th.C.P.97
Norman, P.
 E.556
Noronha, F.
 W.C.P.118
Norry, E.
 C.526, C.752
Norris, B.
 A.627, W.B.P.307
North, Marie-Louise
 M.A.P.118
North, Richard L.
 M.F.P.2, T.F.P.8
Norton, I.
 W.B.P.182
Norton, Robert W.
 Th.F.O.7
Norwood, Chris
 W.E.O.24, M.E.P.40
Nosari, A.
 T.B.P.272, C.729
Nosari, A. M.
 W.B.O.11, M.B.P.294
Notcze, M.
 T.B.P.174
Notkins, A. L.
 Th.C.P.3
Noto, R.
 T.B.P.154
Nottebart-Finn, S.
 M.D.P.81
Nottet, H. S.
 C.575
Novak, D.
 A.506
Novak, J.
 M.C.P.3
Novati, R.
 T.B.P.201, T.B.P.212,
 W.B.P.200
Novati, Roberto
 W.B.O.34
Novella, Antonia
 M.H.P.20
Novello, A.
 W.A.O.12, Th.A.O.11,
 Th.A.O.12, W.D.P.50,
 T.F.O.18
Novello, Antonia C.
 E.682
Noventa, F.
 D.583
Novick, A.
 Th.E.P.9
Novick, David M.
 T.A.P.48, M.B.P.243,
 W.D.P.71
Novick, Lloyd F.
 W.A.O.8, W.H.P.10
Novis Pereira, S. A.
 Th.B.P.189
Novoa, L. I.
 W.B.P.67, B.602
Nowicki, C.
 T.E.P.74
Nozyce, Molly
 M.B.O.41
Nsa, W.
 T.B.P.204, T.B.P.205, B.625,
 W.C.P.96, W.G.P.8,
Nsa, Wato
 W.G.O.4, Th.G.O.34
Nseka, K.
 Th.H.P.27
Nseka, M.
 E.666
Nsengumuremyi, F.
 T.B.P.374, W.G.O.6
Nshimbi, R.
 M.B.P.149, T.B.P.337
Nsiangana, Z.
 T.B.P.396
Nsuami, M.
 T.B.P.205
Nsubuga, P.
 Th.G.O.35
Ntabe, H. M.
 W.G.O.29
Nugent, Joy
 E.773

- Nugeyre, M. T.
M.C.G.30
- Numazaki, K.
C.536
- Numazaki, Kei
W.C.P.64
- Nunan, T.
T.B.P.57, T.B.P.67, T.B.P.79
- Nunna, P.
Th.G.O.4
- Nunna, P. P.
Th.G.O.5
- Nusinoff-Lehrmann, S.
M.B.O.50
- Nussbaum, J.
M.B.P.300
- Nussbaum, J. M.
W.B.P.24
- Nussbaum, Joseph
M.B.O.49
- Nutinsky, C.
Th.B.P.305
- Nyamathi, A. M.
T.D.O.17
- Nyamathi, Adeline
D.715
- Nyamongo, J.
T.B.P.134
- Nyamongo, Jackton A.
W.B.P.173
- Nyamuryekunge, K.
E.604
- NYC Perinatal HIV Study
Group
Th.A.O.7
- NYC Perinatal HIV TCSS
M.B.O.4
- Nye, Keith E.
C.673
- Nyengele, M. N.
D.505
- Nygren, Anders G.
C.752
- Nyonyintono, Rebecca
Th.D.O.23
- Nyuma, E.
T.A.P.1
- Nyst, M.
W.B.P.359
- Nzaramba, D.
Th.G.P.20
- Nzila, N.
M.A.O.32, Th.A.O.21,
T.B.P.107, T.B.P.366, W.D.P.2
- Nzila, Nzilambi
T.A.P.90, W.A.P.96
- Nzingoula, S.
W.G.O.3, Th.G.O.54
- Nzuzi, N.
Th.E.O.3
- O**
- O'Boyle, K.
W.B.P.309
- O'Brien, S.
M.B.P.155
- O'Brien, U.
W.E.O.3, Th.E.P.71
- O'Brien, William A.
T.C.O.16
- O'Connell, C. A.
W.B.P.130
- O'Connell, J. J.
B.506
- O'Connor, J. I.
M.C.P.142
- O'Connor, T.
M.C.P.70
- O'Dell, V.
D.575
- O'Doherty, M.
T.B.P.57, Th.B.P.355
- O'Doherty, Michael
T.B.P.67
- O'Doherty, Michael J.
T.B.P.79
- O'Donnell, Fiona M.
E.658
- O'Dowd, M. A.
D.645
- O'Dowd, Mary Alice
W.B.P.214, W.B.P.216,
W.B.P.217
- O'Gara, Chloe
W.E.P.41
- O'Hara, G.
E.607
- O'Keefe, C.
M.B.P.4
- O'Malley, P. M.
W.A.P.46, Th.B.O.9,
M.B.P.224
- O'Marro, S.
M.C.P.133
- O'Meara, D.
M.G.P.30
- O'Neil, C. E.
T.B.P.328
- O'Neill, K.
T.B.P.210
- O'Neill, C.
T.B.P.223
- O'Neill, R.
Th.B.P.35, E.783
- O'Neill, S. F.
D.651
- O'Neill, R.
T.E.P.54
- O'Reilly, K.
T.A.P.21, T.D.O.6, M.D.P.35,
T.E.P.17
- O'Reilly, K. R.
M.D.P.32, T.D.P.39
- O'Reilly, Kevin R.
T.D.P.27
- O'Shaughnessy, M.
M.A.P.23, W.B.P.172,
W.B.P.351
- O'Shaughnessy, M. V.
M.A.O.26, Th.A.P.46,
W.B.P.127, Th.B.P.360,
Th.B.P.361, B.621
- O'Shaughnessy, Michael V.
T.B.O.33, T.B.P.106,
T.B.P.314, W.B.P.161,
M.G.O.2
- O'Shea, S.
Th.C.P.148
- O'Sullivan, Anna
W.E.P.39
- O'Sullivan, Mary J.
M.B.P.23
- O'Sullivan, S. M.
T.B.P.127
- Oates, J. K.
W.B.P.314
- Oberauer, C.
Th.D.P.18
- Oberst, R.
W.B.P.152
- Ocaña, I.
W.A.P.55, C.705
- Ocaña, Inmaculada
M.B.P.67, M.B.P.98,
M.B.P.260, T.B.P.289,
- Ochelska, B.
Th.D.P.41
- Ochsendorf, F. R.
M.B.P.111, T.B.P.316
- Ochsendorf, Falk R.
M.B.P.180, M.B.P.275
- Octávio, F.
A.511
- Odaka, N.
W.A.P.40
- Odaka, Nancy J.
Th.A.P.91
- Oddieifson, S.
T.A.O.2, Th.A.P.98
- Oddieifson, Stephanie
T.A.P.74
- Odehour, K.
Th.A.P.109, T.B.P.119,
W.B.P.113, Th.B.P.346,
- Odehour, Koudou
T.B.O.10
- Odemouri, K.
Th.B.O.55
- Odewald, J.
W.A.P.3, W.B.P.334
- Oduonwo, B. D.
D.542
- Oduor, D.
T.A.P.91
- Oelman, B.
M.G.O.5
- Oelman, Bruce J.
M.D.P.12, T.G.P.30
- Oette, D.
W.B.P.329
- Ofuso-Barko, K.
Th.A.P.120
- Ofuso-Barko, Kenneth
Th.G.O.43
- Ogden, B.
D.642
- Ognibene, F. P.
T.B.P.16
- Ognjan, A.
Th.A.P.9, Th.A.P.10
- Ognjanov, M.
B.613
- Ogris, M.
Th.D.P.18
- Oh, P. S.
Th.C.P.29
- OHFOM
D.601
- Ohgren, M.
Th.E.O.5, T.E.P.30
- Oh, Gen
M.E.P.18
- Ohlsson-Wilhelm, Betsy M.
T.B.P.83, T.B.P.313
- Ohlsson-Wilhelm, B. M.
T.B.P.84
- Ohnishi, M.
M.B.P.165
- Ohnota, Hideki
M.C.P.108
- Ohta, Yoshihiro
M.C.O.6, W.C.P.2
- Ojiwya, A.
T.B.P.358
- Okamoto, T.
Th.C.P.96
- Okarma, T. B.
T.C.P.61
- Okleberry, K. M.
C.512
- Oksenhendler, E.
M.B.P.249, M.B.P.323,
Th.B.P.336
- Oksenhendler, Eric
M.B.P.295, T.B.P.273,
T.B.P.280, W.B.P.25,
- Okubo, Susumu
Th.B.P.25
- Okuda, T.
W.C.P.11
- Okware, Ikwara S.
Th.G.P.18
- Oladepo, Oladimeji O.
E.620
- Olbrich, E.
T.D.P.46, D.654
- Oldenburg, B.
W.D.P.89

- Oldfield, E. C.
Th.A.P.28
- Oldstone, M. B. A.
W.C.P.97, C.531
- Oleske, J.
M.B.P.29, T.B.P.162,
T.B.P.258
- Oleske, J.
M.B.P.19
- Oleske, J. M.
T.B.P.259
- Oligiati, Marco
T.A.P.34
- Olin, Robert
W.D.O.7, W.D.P.76, D.618
- Oliva, G.E.
D.519
- Oliveira, A. V.
M.B.P.281, T.B.P.365
- Oliveira, C. A. B.
B.534
- Oliveira, D. P.
M.B.P.109, Th.B.P.86, B.533
- Oliveira, E. I.
T.D.P.25
- Oliveira, E. R.
M.E.P.66
- Oliveira, R. L.
C.700
- Oliver, C.
T.B.P.298
- Oliver, Christopher
Th.B.P.298
- Oliver, J.
M.B.P.38, M.B.P.184
- Olivier, C.
Th.E.P.18
- Olivier, Clément
T.F.O.16
- Olivier, R.
Th.C.P.87
- Oliviera, M. R.
T.D.P.25
- Olo, Christine L.
Th.B.P.295
- Olmsted, R. A.
W.C.O.50
- Olmsted, Robert A.
W.C.O.30
- Olofsson, S.
C.547, C.783
- Olopoenia, L.
M.B.P.201, M.B.P.238,
T.B.P.237
- Olsen, C.
M.B.P.83
- Olsen, M. K.
C.683
- Olshen, R.
W.B.P.230
- Olson, B.
T.B.P.228
- Olson, J.
M.B.P.342
- Olson, M. M.
T.D.O.31
- Olivier, René
W.C.O.9
- Omar, Bagasra
W.C.P.86, C.612, C.613,
C.711
- Omar, M.
Th.B.P.132, Th.B.P.359
- Omeñaca, F.
W.A.P.4, T.B.P.216
- Omi, J.
E.503
- Onayemi, O.
Th.D.P.20, Th.E.P.76
- Ong, Kenneth R.
M.C.P.142
- Ono, Katsuhiko
M.C.P.144
- Onorato, I.
T.A.O.10, M.A.P.74,
W.B.P.53, W.D.O.1
- Onorato, I. M.
M.A.O.20
- Onorato, Ida M.
M.A.P.5, W.A.P.119
- Onyango, Philista
T.F.O.21
- Opelz, G.
Th.B.P.142, C.727
- Operskatski, Eva A.
Th.A.P.105
- Opheim, K.
M.B.P.332
- Opheim, K., Coombs, R.
M.B.P.9
- Oppenheimer, G.
M.H.O.10
- Oppermann, A.
T.A.O.5
- Opravil, Milos
T.B.P.50
- Oravec, R.
T.B.P.336
- Orazem Favoretto, C.
W.B.P.39
- Orchi, N.
T.A.P.5, A.526
- Orcutt, V.
W.B.P.347
- Orcutt, V. L.
Th.B.P.71
- Orduña, A.
M.A.P.21
- Orecchia, A.
C.755
- Orenstein, J.
W.C.O.36, W.C.P.63, C.723
- Orenstein, Jan Marc
W.B.O.38
- Oreste, P. L.
Th.B.P.194
- Oreste, Fierinigi
M.B.P.294
- Orgad, Shlomit
Th.G.P.6
- Orgnero, Irene
D.710
- Orholm, Marianne K.
Th.B.P.80
- Orias, V.
T.G.P.22
- Orinda, V.
Th.E.P.39
- Oriol, L.
Th.G.O.49
- Orkin, A.
Th.D.P.32, M.F.P.12, T.G.P.24
- Orkin, Andrew
M.G.P.30
- Oriandi, M.
Th.D.P.42
- Oriando, Giorgio
B.587
- Oriloff, G.
Th.C.O.41
- Orme, R.
M.B.P.178
- Ornelas, C.
W.G.P.25
- Ornelas, G.
T.A.P.8, W.D.P.14, G.510
- Ornelas, H. G.
M.D.P.7
- Oron, M.
T.C.P.142
- Orosz, C.
T.C.P.27
- Oroszlan, S.
T.C.P.135, Th.C.P.123,
Th.C.P.136
- Oroszlan, Stephen
M.C.P.66
- Orozco, M.
T.B.P.335
- Orr, K.
W.A.P.92
- Orrett, F. A.
T.F.P.5
- Orrett, Fitzroy A.
M.D.P.47
- Orsini, C.
E.616
- Orso, M.
M.A.P.63, T.A.P.111
- Ortiz de LejaRazu, Raúl
M.A.P.21
- Ortiz, C.
A.633, E.813
- Ortiz, Carmen
A.589
- Ortiz, M.
W.C.O.8
- Ortiz-Ortiz, L.
E.555
- Ortmann, C.
M.B.P.211, W.B.P.19
- Ortona, I.
M.B.P.229, Th.B.P.99,
M.C.O.32
- Ory-Lavollée, L.
M.B.P.343
- Osachoff, J.
W.B.O.6, Th.B.O.26,
M.B.P.349
- Osame, M.
Th.A.O.31, Th.A.P.17, B.630,
B.634
- Osborn, June
M.F.O.10
- Osel-Kwasi, O.
T.B.P.351
- Osmond, D.
T.A.O.11, T.A.O.31
- Osmond, Dennis
M.A.P.100
- Ossari, S.
W.B.P.107
- Oster, C.
W.A.P.86, Th.A.P.93,
M.B.P.104, T.B.P.112,
- Oster, C. N.
T.D.P.59
- Osterholm, M.
T.A.O.26, M.A.P.70,
M.A.P.72, T.A.P.43
- Ostrove, J. M.
W.C.P.105
- Ostrow, D.
M.A.O.48
- Ostrow, David G.
W.A.P.115, W.B.P.67,
Th.E.P.30
- Oswald, B. J.
M.C.P.54
- Oswald, H.
M.D.P.9, E.705
- Otake, Toru
M.C.P.79
- Oth, D.
M.C.P.29
- Othman, A.
W.E.F.55
- Otis, Joanne
M.D.P.27
- Ottenthal, C.
W.A.P.82
- Ottomanello, G.
M.C.P.62, T.D.P.51
- Ottuso, P.
M.B.P.72
- Ou, C. Y.
Th.A.P.87, Th.A.P.109,
T.B.P.162, B.549
- Ou, C.-Y.
T.A.P.105, T.C.P.21, T.C.P.83

- Ou, Chin-Yih
Th.A.P.114, T.C.P.82
- Ouatara, A.
A.573, T.B.P.158
- Ouatara, A. S.
C.526
- Ouatara, Antoine
T.B.P.368
- Ouatara, S.
M.G.P.25
- Ouellet, L.
M.A.P.50
- Ouka, M.
W.C.P.139
- Oulton, S. A.
W.C.P.142
- Ouma, S. O.
M.G.O.15
- Oura, Y. O.
B.512
- Outerovitch, D.
C.682
- Ouvry, O.
W.B.P.207
- Over, M.
W.H.P.13
- Over, Mead
M.G.O.31, T.H.O.15, W.H.P.12
- Overbaugh, J.
M.C.O.12, W.C.O.31,
W.C.P.13, W.C.P.33
- Overbaugh, Julie
W.C.O.13
- Overby, G.
M.B.O.19, M.B.O.20,
Th.B.P.320, Th.B.P.340
- Overholt, C.
Th.B.O.12
- Overs, C.
D.682
- Overs, Cheryl
D.697
- Overs, Cheryl M.
Th.D.P.91, M.F.P.8
- Overton, H.
M.D.P.17
- Österberg, I.
W.E.O.15
- Owen, S.
T.B.O.30
- Owen, S. L.
W.B.P.47
- Owen-O'Dowd, J. M.
W.D.P.1
- Owor, Mary F.
E.805
- Oxtoby, M.
W.A.P.9, M.B.P.19, M.B.P.29,
T.B.P.162, T.B.P.167
- Oxtoby, Margaret J.
W.A.O.17, W.G.P.9
- Oyaizu, N.
Th.C.P.5
- Oyaizu, Naoki
T.C.P.83
- Oyewo, Edward A.
W.E.P.51
- Ozden, J.
M.C.O.30
- P**
- Paalman, M.
W.A.P.97, D.673
- Paalman, Maria E.
W.F.P.7
- Pablos-Mendez, A.
M.B.P.72, M.B.P.89, Th.B.P.41
- Pacheco E. Silva, A.
M.B.P.279
- Pacheco, M. A.
Th.B.P.228, G.512
- Pacheco, R. G.
M.B.P.291
- Pachucki, C.
W.D.P.72
- Pachucki, C. T.
Th.A.P.1
- Pachucki, Constance T.
W.B.P.268
- Paci, P.
T.B.P.100, Th.B.P.203,
Th.B.P.343
- Padayachee, G. N.
T.G.P.18, Th.G.P.15
- Padayachee, G.N.
W.E.P.28
- Padgett, M.
W.C.O.16, T.C.P.90
- Padgug, A.
W.H.O.7
- Padian, N.
W.A.O.28, T.A.P.100
- Padian, Nancy S.
T.A.O.16, T.A.P.93, T.A.P.94
- Padilla Ortega, M. B.
M.B.P.212, M.B.P.214
- Padre, L.
Th.G.O.25
- Padrón, G.
W.B.P.97, B.602
- Pagano, J. S.
M.C.P.82
- Page, C.
T.B.P.57, T.B.P.67, T.B.P.79
- Page, J. B.
Th.D.P.48, Th.D.P.82
- Page, J. Bryan
D.588
- Pagels, William R.
T.B.P.137, T.B.P.138
- Pagerols, X.
M.B.P.176, Th.B.P.327
- Paggi, G.
M.B.P.194
- Pagni, S.
Th.B.P.225
- Pagnucco, G.
M.B.P.298
- Pahlisa, A.
M.B.P.67
- Pahwa, S.
T.B.P.254, T.C.P.53
- Pailieux, T. P.
T.D.P.10, T.D.P.86
- Paiva, A.
W.B.P.115
- Paiva, J. D.
Th.B.P.123
- Paiva, S. A.
W.E.P.37
- Pal, R.
C.680
- Pal, Ranajit
Th.C.P.43
- Palacio, J. J.
W.B.O.37
- Palacios, F.
C.707
- Palacios, M.
M.G.O.27, W.G.P.6
- Palacios, M. M.
M.D.P.7
- Palacios, O.
Th.H.P.17
- Paladin, F. J. E.
Th.H.P.21
- Palangié, A.
C.726
- Palefsky, Joel
Th.C.O.36
- Paleniecek, John G.
W.A.P.40
- Palermo, S.
T.B.P.75
- Palestine, A.
M.B.P.128
- Palestro, G.
M.B.P.194
- Paley, M. D.
D.511
- Palha de Sousa, C.
M.B.P.373
- Palha de Sousa, C. A. D.
Th.G.P.22
- Palha de Sousa, Cesar A. D.
M.B.P.327
- Palker, T.
B.634
- Pall, L.
M.A.P.90, W.B.P.56,
Th.B.P.263
- Pallares, R.
M.B.P.176
- Pallavicini, F.
Th.B.P.96
- Palloni, A.
Th.E.P.2
- Palmer, R. W. H.
W.A.O.14, W.A.P.83
- Palmer, S.
M.A.P.58, M.B.P.315
- Palmer, William A.
M.E.P.36, M.E.P.43
- Pálóczy, K.
T.C.P.141
- Palomba, E.
W.B.P.144
- Palomba, Elvira,
B.540
- Paltiel, Freda
W.E.O.13
- Pampazzo, M.
T.B.P.166
- Pan, A.
M.B.P.298
- Pan, Li-Zhen
Th.C.P.50
- Panagiotidi, C.
W.C.P.98, W.C.P.124
- Pancheo, S.
Th.C.O.3
- Pane, J.
Th.B.O.9
- Panicali, D.
T.B.P.209, M.C.P.17, T.C.P.24
- Panicali, Dennis L.
M.C.P.16, M.C.P.47
- Panlilio, Adela
Th.A.P.47
- Pannoung, Wattana
T.B.P.221
- Pannhorst, J.
M.B.P.331
- Pantaleo, Giuseppe
W.C.O.39
- Panu-Mpabi, M.
D.505
- Panzeri, M.
W.B.P.365
- Paolucci, S. L.
W.B.P.226
- Papa, D.
B.587
- Papa, F.
Th.B.P.124
- Papadakis, M. A.
M.D.P.85
- Papadopoulos, A. I.
A.612
- Papadopoulos, Antonios I.
T.B.P.342
- Papadopoulos, Nicholas
W.B.P.90
- Papadopoulos, T.
T.B.P.87
- Papaevangelou, G.
W.A.P.37, E.747
- Papaevangelou, G. I.
W.B.P.342

- Papaevangélou, George
E.615
- Papaevangélou, V.
C.554, E.615
- Papas, T. S.
M.B.O.22
- Pape, J.
M.G.P.3
- Pape, J. W.
M.B.P.6, Th.B.P.70
- Pape, Jean
W.G.O.9
- Pape, Jean W.
Th.G.O.49
- Papetti, C.
T.A.P.103, A.567, Th.B.P.150
- Pappugr, R.
M.H.O.9
- Papiernik, E.
Th.E.P.23
- Papillon, Françoise
Th.B.P.64
- Pappaioanou, M.
M.A.O.4, Th.A.O.11, M.A.P.5,
W.B.P.174, W.D.P.50
- Pappaioanou, Marguerite
W.A.O.12, Th.A.O.12
- Pappas, Les G.
Th.E.O.6
- Papsidero, L.
T.C.P.33
- Pâquet, C.
T.B.P.151
- Paquin, C.
Th.E.P.33
- Paquin, N.
T.H.P.3
- Paquot, E.
W.G.O.1
- Para, M.
T.C.P.27
- Paradis, G.
W.A.P.42
- Paradis, H.
T.A.O.6
- Paradis, T. J.
T.C.P.2
- Paradise, M.
M.C.P.101
- Paras, M.
M.B.O.31
- Paraja, R.
E.670, T.G.P.12
- Paraja, Reynaldo
D.698
- Parakh, Bharat S.
C.555
- Parellada, N.
T.A.O.3, W.A.P.78
- Parenti, D. M.
Th.B.O.2, W.B.P.308
- Parga, Francisco J.
D.676, D.679
- Parga, J.
W.A.P.32
- Parides, M. K.
E.589
- Parikh, K.
Th.B.P.61
- Parimi, Prabhakar
T.F.P.5
- Parish, C.
W.C.O.23
- Parish, Kathy L.
Th.B.P.33
- "Paris-Tours" Study Group
M.H.O.5
- Parisi, A.
W.B.P.186, Th.B.P.272,
Th.B.P.281, B.545
- Parisio, E.
M.B.P.206, Th.B.P.191,
W.D.P.84
- Park, L.
Th.B.P.278
- Park, Lawrence
W.A.P.69
- Park, Y.
T.B.P.174
- Parker, David
T.C.P.86, Th.C.P.124
- Parker, E. S.
W.B.O.45
- Parker, Elizabeth S.
Th.B.P.277
- Parker, F.
C.682
- Parker, J.
M.B.P.173, E.530
- Parker, J. B.
M.A.P.7
- Parker, M. A.
Th.A.O.23
- Parker, Richard G.
E.523
- Parker-Martin, Jeanne
W.B.O.16
- Parkhede, U.
W.B.P.99, W.B.P.109,
W.B.P.114
- Parkin, N.
T.C.O.27
- Parkin, Neil T.
T.C.P.87
- Parkhill, L.
M.B.P.373
- Parks, E. S.
Th.C.P.132
- Parks, James M.
M.B.P.78
- Parks, R.
W.C.P.69
- Parks, W. P.
Th.A.O.8, M.B.O.40,
T.B.P.152, T.B.P.153,
T.B.P.166, T.B.P.182
- Parmley, R.
Th.B.P.23
- Parnet-Mathieu, F.
M.B.P.32
- Paroski, P.
T.A.P.104, W.A.P.93, A.628,
W.B.P.307
- Parquin, F.
T.B.P.1, B.589
- Parra, F.
M.A.O.28
- Parra, N.
W.A.O.9
- Parra, O.
M.B.P.103
- Parravicini, C. V.
M.B.P.216, W.C.O.9, Th.C.O.9
- Parravicini, C. V.
W.C.P.67
- Parris, N.
Th.E.P.59
- Parrish, C.
Th.A.P.47
- Parrot, A.
T.B.P.1
- Parrott, C. M.
T.C.P.94
- Parry, J.
T.A.O.9
- Parry, R. V.
M.B.P.140
- Partridge, J. C.
Th.C.P.59
- Pascal, A.
M.H.O.17, T.H.P.18
- Pascual, I.
T.A.P.22, A.569, E.813
- Pascual, J.
T.D.P.64
- Pascual, P.
D.699
- Pascual, P.
T.D.P.65
- Pass, C.
W.A.P.42
- Pass, Carol L.
T.D.P.30
- Pass, K. G.
M.A.O.18
- Passikoff, N.
E.582
- Passos, R. H.
W.B.P.39
- Passos, R. M.
W.G.P.15
- Pastan, I.
Th.C.O.12
- Pastor, C.
Th.B.P.234
- Patarroyo, M.
T.C.O.3
- Patashnik, B.
T.A.P.29
- Patel, D. K.
B.591
- Paterlini, Patricia
M.B.O.6
- Patey, Olivier
A.552, B.557
- Pathak, R.
T.B.P.233
- Pathouli, Christina
B.544
- Patient Managers
T.D.P.15
- Patrick, S.
D.659
- Patrizi, A.
T.B.P.330
- Patron-Reese, Janie
T.D.P.22
- Patrone-Reese, J.
M.B.P.329, M.D.P.83
- Pattanayak, S.
T.G.O.28
- Patten, John T.
M.E.O.14, E.771
- Patterson, H.
E.710
- Patti, J.
W.A.P.1
- Patton, J. S.
T.C.P.7
- Patzner, E.
M.C.P.129
- Pau, Chou-Pong
W.B.P.112
- Pau, F. M.
M.B.P.106, Th.B.P.255
- Paul, D.
B.558, Th.C.P.98
- Paul, D. A.
M.A.O.39, Th.C.P.37
- Paul, David B.
Th.B.P.111
- Paul, J. P.
W.D.P.70
- Paul, M.
Th.B.P.233
- Paul, Morris O.
M.B.P.101
- Pauli, G.
Th.A.P.29, Th.B.P.153,
Th.B.P.154, Th.B.P.172,
Th.B.P.183, T.C.P.66, C.517
- Paulino, U. H. M.
Th.B.P.114, T.D.P.25
- Paulli, M.
M.B.P.232
- Paulous, Sylvie
Th.C.P.140
- Pausen, R. H.
D.651
- Pautson, Yama J.
T.B.P.61

- Pauluzzi, S.
Th.B.P.252
- Pautrat, G.
Th.C.P.87
- Pauwels, P.
M.B.O.38, Th.H.P.18
- Pauwels, R.
Th.C.O.20, M.C.P.75, C.550,
C.641
- Pauwels, Rudi
C.585
- Pauza, C. David
M.C.O.19
- Pavan, M. H. P.
Th.G.P.3
- Pavliakis, G. N.
T.G.O.50, Th.C.P.20,
Th.C.P.27
- Pavliakis, George N.
W.C.O.22, T.C.P.139
- Pavri, Khorsheed M.
T.C.P.147, E.648, T.G.O.26
- Pavuk, N.
T.C.O.35
- Pawel, B.
M.A.P.16
- Pawlowski, J. M.
W.B.P.133
- Pawlowski, W.
D.576
- Paxton, H.
Th.B.O.2
- Payanzo, N.
W.D.P.90, D.894, W.E.P.3
- Paye, S.
Th.B.O.56
- Payne, A.
E.645, E.787
- Payne, F.
E.809
- Payne, J.
Th.H.P.26
- Payne, S. F.
W.A.P.14, W.A.P.24,
W.B.P.354
- Payne, Susan F.
W.A.P.13, W.A.P.80, M.D.P.26
- Pazin, G. J.
M.B.P.355
- Pazin, George J.
M.B.P.338, W.B.P.303
- Peabody, B.
B.645
- Peake, J. D.
W.B.P.356
- Peakman, Mark
Th.B.P.127
- Pean, Claude
Th.B.P.70
- Pearce, F. M.
W.D.P.18
- Pearl, L. H.
Th.C.P.10
- Pearlstein, G.
T.B.P.296, W.B.P.252
- Pearsall, N. N.
Th.G.P.30
- Pearson, James A.
E.612
- Pearson, Andrew P.
M.C.P.132
- Pec, B.
Th.D.P.18
- Peckham, C.
W.A.O.9
- Peckham, C. S.
Th.A.O.4
- Peckham, Catherine
Th.A.O.3, M.B.O.1, T.B.O.17
- Peddecoord, K. Michael
T.B.P.339
- Peden, Keith
T.C.P.114, T.C.P.115
- Pedergranna, Maurice R. H.
Th.H.P.4
- Pedersen, C.
M.B.P.259, T.B.P.24,
T.B.P.32, T.B.P.103
- Pedersen, Court
T.A.O.30, Th.B.O.46
- Pedersen, N.
Th.C.O.45, T.C.P.134
- Pederson, Court
W.B.O.31
- Pediconi, A. M.
M.B.P.206, Th.B.P.82,
W.D.P.84
- Pedro, R. J.
T.G.P.14, Th.G.P.3
- Pedro, Rogerio J.
M.B.P.93
- Pedrol, E.
M.B.O.37
- Pedroza-Martins, Livia
W.C.P.20
- Peters, D.
T.B.P.135
- Peters, M.
M.A.P.49, C.745
- Peters, M. P.
M.A.O.16
- Peters, Martine
Th.B.O.54, W.B.P.107,
T.C.P.100, W.C.P.40
- Petoom, F.
M.B.O.27
- Petoom, Frans F.
E.710
- Pegge, John V.
T.E.O.15
- Pehrson, P. O.
D.590
- Peiperl, L.
M.B.P.166
- Peixinho, Z.
M.B.P.279, M.G.P.8, G.518
- Peixinho, Zulma
W.B.P.115
- Peixoto, C. A.
Th.B.P.189
- Pejsach, M.
E.608
- Pekovic, D. D.
Th.B.P.356, Th.B.P.366
- Pekovic, Drasko D.
B.564, W.C.P.94
- Pela, Ona A.
E.534, W.G.P.17
- Pele, G.
T.D.P.47
- Pelel, P.
M.B.O.6
- Pelfinf, Andrew
D.568
- Pellegrin, J.-L.
T.A.P.26, W.A.P.60,
M.B.P.254
- Pellegrino, F.
Th.B.P.339
- Pelligrino, M. G.
M.C.P.126
- Pelosse, B.
M.B.P.226
- Pelton, S. I.
T.B.P.150, B.591
- Peluyera, L.
E.555
- Peña, C.
E.672, M.G.O.25
- Penaloza, D.
M.A.P.73
- Penaud, D.
B.559
- Penkower, L.
W.B.P.221
- Penney, C. L.
W.B.P.111
- Pennington R.
W.B.P.120
- Pennington, R. M.
W.B.P.121
- Penso, D.
W.A.P.88
- Penttilä, A.
B.552
- Pepin, J.
T.A.P.87
- Pepin, Jacques
T.G.P.32
- Peppler, M.
E.708
- Perales, Cesar A.
T.E.O.1
- Perard, D. P.
T.D.P.96
- Pérand, Dominique D.
T.D.P.10
- Percivalle, E.
M.B.O.31, M.B.P.114
- Perdices, M.
Th.B.P.290
- Perdices, Michael
Th.B.P.266
- Perdue, R.
Th.B.P.116
- Peredo, L. V. M.
T.B.P.193, W.B.P.168
- Pereira, A.
M.A.P.18
- Pereira, C. A. P.
M.B.P.279
- Pereira, M. E. A.
W.C.P.102
- Pereira, Rosemarie
M.C.O.30
- Perel, Y.
T.B.P.245
- Peress, N.
W.C.P.55
- Perez Alvarez, L.
A.576, T.B.P.172
- Perez García, R.
M.B.P.277
- Perez Rguez, Gustavo
T.B.P.193
- Perez, Alvarez Lucia
T.B.P.229
- Pérez, E.
M.D.P.64
- Perez, E.
Th.B.P.380, T.H.P.10
- Perez, G.
T.B.P.2, T.B.P.15, W.B.P.42,
W.B.P.336, Th.B.P.380,
T.H.P.10
- Pérez, H.
M.B.O.16, T.B.P.139,
Th.B.P.207
- Perez, H.
Th.B.P.326, Th.D.P.46
- Perez, H. M.
Th.H.P.23
- Perez, I.
W.A.P.48
- Perez, J.
W.D.P.78
- Perez, M. A.
A.549, T.B.P.364, W.G.P.14
- Pérez, M. L.
M.B.P.369, T.B.P.255
- Perez, Teresa
A.572, A.633
- Perez, Victor L.
W.C.P.87
- Perez-Agosto, R.
W.A.P.32
- Pérez-Bianco, R.
T.A.P.108, T.B.P.139,
T.B.P.140, Th.B.P.4,
Th.B.P.13, Th.B.P.24,
Th.B.P.362, B.513, Th.G.P.21

- Pérez-Trallero, E.
Th.B.P.65
- Perez-Trallero, E.
Th.G.P.8
- Pergami, A.
W.B.P.215, W.B.P.219
- Peri, J. M.
D.595
- Perine, P.
Th.A.O.5, W.A.P.50,
W.A.P.54, D.723
- Perine, P. L.
M.A.O.42, T.B.P.371
- Perine, Peter L.
Th.G.P.30
- Perkins, C. I.
M.A.P.64
- Perkins, C. J.
T.B.P.297
- Perkins, H.
M.A.O.10, M.A.P.30,
M.A.P.107, T.A.P.105,
M.B.P.150, M.B.P.169
- Pert, S.
W.E.O.23
- Perlado, E.
M.A.P.21
- Perlino, C.
Th.A.P.47
- Perlman, D. C.
D.624
- Perlman, D. C.
M.B.P.87, Th.F.P.14
- Perlman, David C.
M.B.P.90
- Pernet M.
D.622
- Perno, C. F.
W.B.P.327, M.C.P.137
- Perno, Carlo-Federico
Th.C.O.17, M.C.P.49
- Pero, Robert T.
Th.A.O.10
- Perol, M.
Th.A.P.119
- Perol, Y. P.
W.B.P.106, B.619
- Perrault, Roger A.
T.B.P.350
- Perreault, Michel
Th.E.O.18
- Perreault, Y.
T.D.O.16
- Perricone, R.
M.B.P.248
- Perriens, J.
W.B.P.12, Th.B.P.165,
Th.B.P.239, Th.H.O.9,
Th.H.P.18, Th.H.P.27
- Perriens, Joseph H.
M.B.O.17, M.B.O.38,
Th.B.P.211
- Perrin, L. H.
M.A.P.43
- Perrin, M.
T.B.P.71
- Pirro, C.
W.B.P.235
- Perroni, Luigi
T.A.P.113, A.566
- Perronne, C.
T.B.P.27, W.B.P.344
- Perronne, Christian M.
M.B.P.179, T.B.P.319
- Perry, L.M.
É.602
- Perry, S.
W.B.P.210, T.D.O.9,
T.D.P.66, É.725
- Perry, Samuel
W.B.P.180
- Perry, Samuel W.
Th.E.P.9
- Pers, C.
W.B.P.27
- Persson, P. O.
W.B.P.114
- Pert, Candace B.
M.C.P.92
- Perton, L.
W.B.P.205
- Perucci, Carlo A.
T.A.P.5, A.526, A.527, É.622
- Perucci, Carlo Alberto
W.E.P.45
- Perumal, V. K.
Th.B.P.61, Th.B.P.62
- Peruzzi, W.
T.B.P.31
- Pesce, A.
A.531, M.B.P.250, T.B.P.20,
W.B.P.366, D.678
- Pesce, A. M.
T.A.P.103, A.567, Th.B.P.150
- Pesce, Alain
W.B.P.44, B.524
- Peterman, T.
Th.B.P.30
- Peterman, T. A.
T.A.O.24
- Peterman, Thomas A.
M.A.O.30, W.A.P.17
- Peters, B.
C.557, C.610
- Peters, B. S.
Th.B.P.303
- Peters, Barry S.
M.B.P.239, M.B.P.326
- Peters, M.
W.B.P.300
- Peters, Malte
W.B.P.299, Th.B.P.73
- Peters, N.
T.A.P.54
- Peters, R.
Th.B.O.44, Th.C.O.46
- Petersen, C.
W.B.P.125
- Petersen, D.
Th.B.O.12, M.C.P.9
- Petersen, E.
Th.C.O.4, T.C.P.75, W.C.P.19
- Petersen, H.
T.A.P.84
- Petersen, Heidi M.
T.A.P.100
- Petersen, L.
M.A.O.4, T.A.P.37, W.D.P.24,
Th.E.P.31
- Petersen, L. R.
A.519, M.D.P.1
- Petersen, Lyle R.
M.A.O.5, M.A.P.32
- Peterson, C. M.
Th.B.P.106
- Peterson, Denton R.
Th.A.P.73
- Peterson, Eskild A.
W.B.P.287
- Peterson, H. B.
Th.A.O.15
- Peterson, John L.
W.D.P.27
- Peterson, K.
W.B.P.345
- Peterson, L.
T.A.O.8, M.A.P.5
- Peterson, M.
T.E.P.58
- Peterson, M. R.
W.A.P.25
- Peterson, Marvelu R.
M.F.O.2
- Peterson, P. L.
T.D.O.10
- Peterson, Peggy L.
M.D.P.39
- Peterson, W. R.
W.B.P.123
- Petinelli, C.
W.B.P.315
- Petit, F.
M.H.O.12, M.H.P.15, M.H.P.19
- Petitgirard, A.
T.D.P.37, M.E.O.7
- Petitgirard, Anne
W.E.P.5
- Petrén, A. L.
W.C.P.67
- Petri, M.
W.B.P.372
- Petric, M.
Th.B.P.5
- Petricciani, J.
W.B.O.48
- Petrillo, V.
W.B.P.48
- Petronini, P. G.
Th.C.P.4
- Petryshyn, R.
T.C.O.27
- Pettersson, B.
Th.D.P.21
- Pettersson, Elisabeth
Th.D.P.21
- Petteti, G.
T.C.P.66
- Petteyway, S. R.
T.C.P.83
- Petteyway, Stephen R.
W.C.O.11
- Pettiti, D.
Th.D.O.4
- Petty, A.
T.A.P.21, W.A.P.39
- Petty, B. A.
M.D.P.23, T.D.P.11, É.562,
É.639
- Petty, B. G.
T.B.P.295, M.C.P.85
- Petz, W. J.
W.D.P.1
- Petzoldt, D.
M.B.O.18
- Peuchmaur, Michel
Th.B.P.92
- Peudenier, S.
W.C.P.113
- Peugeot, Renée L.
W.B.P.65, É.702
- Peutherer, J. F.
Th.C.P.69, C.781
- Peynet, J.
T.B.P.273
- Peysser, N.
T.A.P.54
- Pezzella, M.
T.B.P.341, T.B.P.361, B.518,
C.714
- Pezzella, M. P.
C.747
- Pezzella, Mario
Th.C.P.99, Th.C.P.111,
Th.C.P.146, C.739
- Pezzotti, P.
M.B.O.46, W.B.P.370,
M.D.P.37
- Pfeifer, W.
M.B.P.374
- Pfersmann, D.
Th.D.P.71
- Pfersmann, V.
Th.D.P.71
- Pfister, J.
M.A.P.22
- Pfleiderer, W.
M.C.P.136
- Pflugshaupt, R.
M.A.P.109

- Phair, J.
M.A.O.48, Th.A.P.85,
Th.A.P.94, M.B.P.86,
Th.B.P.90, Th.E.P.30
- Phair, John P.
M.A.O.44, M.B.P.380,
W.B.P.164
- Phalen, J.
W.E.P.12
- Phaneuf, D.
T.B.O.31, W.B.P.43,
M.C.P.112
- Phanuphak, P.
M.D.P.19
- Phanuphak, P.
T.B.P.221
- Phanuphak, Praphan
M.D.P.50, T.G.O.25
- Phelan, M.
C.635
- Phelps, A.
T.A.P.73
- Phelps, Ann F.
W.A.P.20
- Philippe, N.
C.773
- Phillips, P.
M.D.O.18
- Phillips, A. N.
M.A.P.96, W.B.O.28
- Phillips, I.
Th.H.P.17
- Phillips, M.
M.H.O.2
- Phillips, R.
T.A.P.49, A.550
- Phillips, R. S.
M.D.P.84
- Phillips, S.
M.B.P.163, W.B.P.160
- Philogene, G.
W.B.P.332
- Phokabye, G.
E.517
- Piaggese, A.
Th.B.P.291
- Pial, G.
W.E.O.21
- Pialoux, Gilles
M.B.P.362
- Piantadosi, C.
W.C.O.21
- Piazza, G.
Th.B.P.220
- Piazza, M.
T.A.P.115, W.B.P.362
- Piazza, Paolo A.
W.C.P.28
- Piazzoli, M.
T.E.P.26
- Pibarat, M.-L.
A.571
- Picard, D. B.
Th.A.P.99
- Picard, O.
T.B.O.71, M.C.P.48, T.E.P.66
- Picchio, G.
T.A.P.108, T.B.P.140,
T.B.P.340, Th.B.P.3
- Piccinno, M. G.
Th.B.P.225
- Picciotto, L.
T.A.P.115, W.B.P.362
- Piccirilli, R.
M.B.O.27
- Pichler, W.
W.B.P.118
- Pichuantes, S.
C.666
- Pichuantes, Sergio
M.C.P.84
- Pickers, R. W.
T.A.P.39, T.A.P.40,
Th.D.O.18, D.599
- Pickering, John
Th.A.P.50
- Piedimonte, Giuseppe
Th.C.P.4
- Pierce, P.
M.B.P.268, Th.B.P.208, B.537
- Pierce, P. F.
M.B.P.208, C.738
- Pierone, G.
W.B.P.6
- Pierone, Gerald
T.B.O.8, T.B.P.48
- Pierre, C.
T.B.P.251
- Piersantelli, N.
W.B.P.346
- Piersantelli, Nicoló
Th.B.P.51
- Pierson, R. N.
Th.B.O.37
- Pies, C.
M.B.P.318, E.714
- Pieters, Stephen A.
W.E.O.31
- Pietersz, R.
T.B.P.323
- Piette, J.
M.E.P.69
- Piette, J. D.
T.E.P.34
- Piette, John D.
A.559
- Pignatti, P. F.
C.650
- Pigorini, F.
M.B.P.106, Th.B.P.255
- Piguët, J. D.
Th.B.P.58
- Pikora, C.
T.C.P.24
- Pileri, Stefano
M.B.P.256
- Pimpinelli, N.
C.571
- Pinching, A.
C.610
- Pinching, A. J.
M.B.P.244, M.B.P.236,
M.B.P.239, M.B.P.326,
Th.B.P.303, Th.B.P.317,
C.518, C.557, C.673
- Pincus Strom, Diane
M.E.P.62
- Pincus, D.
T.B.P.154
- Pinczowski, H.
T.B.P.317
- Pindborg, J. J.
Th.B.P.324, Th.B.P.325
- Pine, P.
T.H.P.17
- Pineda, Juan A.
W.B.P.165, B.640
- Pineda, L.
Th.G.O.29
- Pinel, A.
T.E.P.69
- Pinel, Arletty
T.D.P.78, E.641, M.G.O.8,
Th.G.O.10, Th.G.O.39
- Pingel, S.
Th.C.P.102
- Pinna, R.
W.B.O.34
- Pintado, V.
M.B.P.370, W.B.P.339, B.648
- Pinter, Abraham
Th.B.P.3, T.C.P.70
- Pinter, E.
T.A.P.103, A.567, Th.B.P.150
- Pinto e Silva, J. L.
T.D.P.16
- Pinto, F.
Th.B.P.203
- Pinto, L. A.
Th.B.P.107
- Pinto, V.
T.E.P.49
- Pinto, W.
E.610, W.G.P.13, Th.G.P.26,
G.515
- Pinto, W. P.
G.509
- Pintus, A.
Th.B.P.158
- Pintus, Aldo
A.634
- Ploger, J. C.
M.B.P.344
- Piot, D.
M.B.P.235
- Piot, Didier F.
M.B.P.377
- Piot, P.
Th.A.O.21, Th.G.O.53,
M.A.P.49, M.A.P.86, T.B.P.94,
T.B.P.106, T.B.P.251
- Piot, Peter
M.A.O.32, T.G.O.2
- Piotrow, Phyllis T.
M.E.O.12
- Pipes, M.
Th.E.P.71
- Pipkorn, R.
C.717
- Piras, S.
A.634, Th.B.P.158
- Piribauer, F.
T.E.P.67
- Piripiri, L.
M.D.O.3, W.D.O.6, Th.E.P.1,
W.G.P.20
- Pirkle, S.
C.779
- Piro, S.
Th.B.P.158
- Pirozolo, F. P.
W.B.P.195
- Piscoya, J.
Th.D.O.7
- Pissarro, B.
T.E.P.37
- Pista, A.
M.A.P.82, M.A.P.86
- Pitt, J.
M.B.O.44
- Pitta-Alvarez, A.
T.B.P.37
- Pitaluga, S.
T.B.P.16
- Pitman-Lindeman, Mary
A.
T.H.O.4, T.H.P.9
- Pitzus, F.
A.634
- Pivar, Iona L.
T.B.P.329
- Pivnick, A.
Th.D.P.6, Th.D.P.7
- Pizzigallo, E.
M.B.P.229
- Pizzo, P.
M.B.O.43, T.B.P.179,
T.B.P.248, Th.B.P.89
- Pizzo, Philip A.
T.B.P.247
- Pizzocolo, G.
M.A.P.78
- Plaeger-Marshall, Susan F.
T.C.P.31
- Plaisier, A.
W.B.P.171, B.510
- Planas, I.
M.A.P.104
- Planas, P.
T.D.P.64, T.D.P.65, D.699

- Planes, A.
M.B.P.87
- Plangsringarm, K.
T.G.O.23
- Plank, C.
M.B.P.342
- Plascencia, Rosalina
T.G.O.16
- Plascencia, A.
T.A.O.3, W.A.P.78
- Plata, F.
M.B.P.42, T.C.P.25, T.C.P.67,
T.C.P.76, T.C.P.77, W.C.P.5,
W.C.P.20
- Platt, D.
M.E.P.53
- Platt, Denise
M.E.P.56
- Platt, J.J.
M.E.P.60, E.534
- Platt, R.
M.D.P.81
- Plattner, J.
M.C.P.65, M.C.P.135
- Platz, W.
T.A.P.60
- Plaut, Rabbi Gunther
W.F.O.15
- Pleak, Richard R.
Th.D.O.8
- Plebani, A.
M.B.P.227, M.B.P.324
- Plettenberg, A.
W.B.P.99
- Plettenberg, Andreas
M.B.P.234, Th.B.P.329
- Plotchev, K.
B.514
- Plotchev, Kamen
B.613
- Plotnikoff, Nicholas P.
W.B.P.294
- Plouffe, J. F.
T.B.P.30
- Ploumidis, G. M.
A.612, W.B.P.342
- Pluda, J. M.
Th.B.O.4, W.B.P.327,
M.C.P.137
- Pluda, James M.
W.B.P.329
- Plum, Georg
C.546, C.573
- Plummer, D.
T.D.O.7
- Plummer, F.
M.A.O.36, Th.A.O.25,
M.B.P.53, Th.B.P.325,
Th.G.O.53, M.G.P.27
- Plummer, F. A.
M.A.P.110, T.A.P.88,
W.A.P.65, Th.A.P.62, B.536,
Th.G.O.27, Th.G.O.36,
- Th.G.O.52, W.G.P.29,
Th.G.P.29
- Plummer, Francis A.
T.A.O.25, T.A.P.87
- Pluskwa, D.
W.E.P.32
- Poblete, Rita
M.S.P.287
- Pocidalo, J. J.
M.B.P.347, Th.B.P.166
- Poco de Voto, J.
Th.D.P.35
- Podlasek, S.
B.537
- Podzamecz, D.
W.A.P.55
- Podzamecz, Daniel
M.B.P.43, M.B.P.176,
- Th.B.P.327
- Poehler, D.
W.E.P.49
- Pohl, P.
W.B.P.341
- Pohle, H. D.
W.B.O.20, M.B.P.211,
W.B.P.19, W.B.P.299,
Th.B.P.246
- Pohle, H.-D.
M.B.P.125, M.B.P.331,
T.B.P.21, W.B.P.34,
W.B.P.84, W.B.P.300,
Th.B.P.54, Th.B.P.73,
Th.B.P.332, Th.B.P.342
- Pohlman, Hans
M.B.P.35
- Pohlod, D.
Th.A.P.9, Th.A.P.10
- Poiesz, B.
T.A.P.32, Th.B.P.199
- Poiesz, B. J.
W.B.P.119
- Poinsard, R.
M.A.O.24
- Poirier, G.
M.E.P.41
- Poisson, M.
T.B.O.31
- Pokapanichwong, W.
W.D.P.73, W.G.P.19
- Pokapanichwong, Waranee
Th.D.O.1
- Pokrowsky, Alexis
D.724
- Pokrowsky, Andrey G.
T.C.P.144
- Pokrowsky, V. V.
W.A.O.5
- Polacek, I.
Th.B.P.323
- Polansky, Jerrold
E.659
- Polas, P. A.
M.C.P.69
- Polensky, H.
W.B.P.150
- Polesky, H. F.
E.730
- Poletti, V.
Th.B.P.76, Th.B.P.78,
Th.B.P.79
- Poli, G.
W.C.P.59, W.C.P.109
- Poli, Guido
W.C.P.106, W.C.P.107,
W.C.P.108
- Polis, M.
W.B.P.335
- Polis, Michael A.
M.B.P.128
- Polish, L.
Th.B.P.190
- Polisoto, D.
T.C.P.81
- Politch, J.
A.623
- Politch, J. A.
A.625
- Polk, B. F.
M.A.P.26, M.A.P.34,
M.B.P.161
- Polkington, G. R.
M.B.P.204
- Pollack, S.
T.A.P.81
- Poliak, Michael
T.A.P.19, T.D.P.47, T.E.O.13,
T.E.P.16
- Pollard, R. B.
M.B.P.341, T.B.P.322,
W.B.P.323, Th.B.P.273
- Pollard, Richard B.
E.627
- Poller, D. E.
T.B.P.135
- Pollet, D.
Th.B.O.54
- Pollet, D. E.
W.B.P.105
- Pollock, L.
T.B.P.232
- Pollono, A. M.
M.B.P.353
- Polo de Voto, J.
M.A.P.24, M.A.P.25, D.601
- Polo Rodriguez, R.
B.647
- Polonis, V.
T.C.P.28
- Polonis, Victoria
T.C.P.29
- Polisky, B.
M.B.P.123, W.B.P.332
- Polisky, Bruce
M.C.P.131
- Polter, S.
M.D.P.34
- Polychronaki, H.
M.A.P.89, W.C.P.140
- Poma, G.
M.B.P.258
- Pombo, V.
M.A.P.18
- Pomerantz, R.
M.A.P.1, M.A.P.4, Th.C.O.26
- Pomerantz, S.
T.B.P.379, W.B.P.263
- Pompidou, Alain
T.B.O.15, M.F.O.9
- Ponchio, L.
Th.B.P.1, Th.B.P.2
- Pons, J. C.
M.B.P.2, M.B.P.34
- Pontani, D.
W.B.P.293, C.592, C.620
- Pontani, Dennis R.
C.636, C.637
- Ponton, L.
E.659
- Pontonnier, G.
M.B.P.25
- Ponis, K.
M.E.P.71
- Poole, Lauren E.
W.D.P.53
- Poon, M. C.
M.B.P.165, Th.B.P.7
- Poon, Man-Chiu
W.O.27
- Poore, P.
W.E.O.4
- Poos, M. J. J. C.
Th.A.P.55, M.H.P.8
- Popesco, M.
T.B.P.301
- Popesco, Matei A.
W.B.O.9
- Popescu, B.
W.B.P.306
- Popovic, M.
W.C.O.7, Th.C.O.42,
M.C.P.42, W.C.P.117
- Poppe, P. O.
W.A.P.109, D.606
- Poretz, D.
E.809
- Porres, J. C.
M.B.P.221, M.B.P.242,
M.B.P.246, W.B.P.145
- Porsch, U.
D.654
- Portaels, F.
Th.B.P.58
- Porte, P.
M.A.O.16
- Portegies, P.
M.B.P.121, M.B.P.134,
W.B.P.2
- Portegies, Peter
Th.B.P.210

- Porter, A.
T.B.O.8, T.B.O.10, T.B.P.116,
W.G.O.27
- Porter, B.
M.D.O.4
- Porter, J. D. H.
T.A.P.4
- Porter, J.D.H.
Th.E.P.47
- Porter, K.
T.A.P.4
- Porter, L.
Th.B.O.59
- Porteus, D.
M.B.P.166
- Portmore, A.
M.B.P.342
- Porto, A.
M.G.P.8
- Ports, Suki T.
E.688
- Porwancher, R.
M.B.P.69
- Porwit, A.
Th.C.O.9, W.C.P.57
- Poser, S.
Th.B.P.246
- Poshyachinda, V.
T.G.O.25
- Poss, M.
W.C.O.13
- Poss, M. L.
W.C.P.13
- Poss, M.L.
M.C.O.12
- Potamianou, A.
W.B.P.348
- Potash, Mary Jane
W.C.P.132
- Pottage, J.
W.B.P.313
- Pottathil, R.
A.629
- Potter, Bill D.
M.H.P.23
- Potter, F.
T.E.P.20
- Pottier, Bernard
W.H.O.5
- Potts, Malcolm D.
E.623
- Poulin, Louise
T.C.P.132
- Poulsen, A. G.
Th.C.P.143
- Poulsen, Anne-Grethe
Th.B.P.156, T.G.P.31
- Poulter, L. W.
T.C.P.8
- Poumerol, G.
A.635, Th.E.P.16
- Pounders, S. M.
M.B.P.78, T.B.P.56, T.B.P.77
- Pounders, Steven M.
W.B.P.347
- Pousson, Rachel A.
Th.D.P.54, M.E.P.52
- Poust, B.
E.533
- Poutiainen, E.
Th.B.P.242
- Powderly, Kathleen E.
T.F.P.12
- Powderly, W.
T.B.P.384
- Powel-Griner, Eve E.
Th.E.P.5
- Powell, D.
W.C.O.41
- Power, M.
W.B.P.315
- Praats, Christ'1
M.A.P.49
- Prabhakar P.
M.D.P.47
- Prabhala, R. H.
C.632
- Praça, C. L.
Th.B.P.114
- Pradinaud, R.
M.G.P.21
- Pradinaud, Roger A.
M.B.P.181
- Prado, P. S.
M.B.P.40, W.B.P.21
- Prager, M.
D.690
- Prajs, E.
T.B.P.305
- Prasad, S.
T.C.P.81
- Prati, E.
M.B.P.16
- Pratt, R.
M.B.P.309
- Pratt-Lowe, E.
T.C.P.78
- Prazuck, T.
M.G.P.26
- Preiksaitis, J.
M.A.P.87
- Preite, P. A.
M.B.P.199
- Prellner, T.
T.B.P.58
- Premkumar, Reddy E.
C.653
- Prendergast, T. J.
M.A.P.28
- Prendergast, T.J.
M.E.P.7
- Prensky, Wolf
W.B.P.177
- Presslich, O.
Th.D.P.71
- Pressma, D.
Th.E.O.9
- Prestileo, T.
W.A.P.63
- Preston, A.
E.637
- Preston, B.
W.E.P.70
- Pretet, S.
M.A.O.24
- Prevec, L. A.
M.C.P.21
- Price, R. W.
Th.B.P.199, Th.B.O.24,
M.B.P.101, T.B.P.289,
W.B.P.91, W.B.P.194,
W.B.P.255, W.B.P.256,
W.B.P.259, Th.B.P.227,
Th.B.P.232.
- Price, Richard W.
W.B.P.331, Th.B.P.197,
W.C.P.45
- Price, William A.
Th.B.P.30
- Priebe, Bruce A.
W.B.P.253
- Prieels, F.
Th.B.P.345
- Priel, Esther
T.C.P.119
- Prieto, Cecilia
T.B.P.236
- Prieto, E.
T.B.P.343, T.B.P.357
- Prihoda, T.
M.E.P.13
- Primi, C.
E.616
- Primm, B. J.
T.A.P.49, W.D.P.68,
Th.D.P.53, D.607, D.608,
D.609, D.610, D.611
- Prince, A. M.
W.C.O.27
- Prince, Harry E.
T.C.P.63
- Pringle, L.
T.D.P.22
- Pristerá, Raffaele
Th.B.P.245
- Prober, C. G.
W.B.O.2
- Probst, J.
W.D.P.30
- Proctor, T. V.
Th.B.P.271
- Procupet, A.
T.E.P.3, E.674
- Proença, R.
Th.B.P.363
- Profy, A.
Th.C.O.50, M.C.P.6
- Profy, A. T.
M.C.P.25
- Profy, Albert T.
Th.C.O.29
- Pronovost, R.
M.D.P.27
- Propersi, A. F.
M.B.P.199
- Prose, Neil S.
T.B.P.149
- Proulx, Andrée L.
W.B.P.148
- Provansal, P.
T.E.P.23
- Provesana, M. M.
T.B.P.132
- Prozorovsky, L.
W.B.P.120
- Prozorovsky, L. A.
W.B.P.121
- Prum, Bernard
Th.A.P.99
- Pruyne, P. T.
Th.C.O.31
- Przedborski, S.
M.B.P.357
- Psallidopoulos, M.
Th.B.P.167, Th.B.P.179
- Psallidopoulos, M. C.
W.C.P.62
- Psallidopoulos, Miltiades
M.C.O.10
- Psarra, K.
Th.B.P.17
- Psychoyos, A.
C.597
- Ptáčcinski, R. J.
M.B.P.338
- Pudney, Jeffrey
A.624
- Puech, F.
M.C.P.93
- Puel, J.
M.B.P.25, M.B.P.26,
T.B.P.109, T.B.P.187,
Th.B.P.9, Th.B.P.21
- Puel, J. M. L.
M.A.P.46, A.574, T.B.P.219,
T.B.P.242, W.B.P.155
- Puel, Jacqueline M. L.
T.B.P.90, T.B.P.222, B.541
- Pueschel, K.
T.A.P.60
- Pugh, Bradley L.
W.A.P.95
- Pugliese, A.
M.B.P.353, W.B.P.144
- Pulik, Marc
M.B.P.197, Th.B.P.336
- Puisatelli, L.
M.A.P.94, W.B.P.340
- Pulvirenti, J.
B.529

- Pumarola, T.**
A.618
- Puppo, F.**
B.587
- Purcell, R. H.**
W.C.O.30, W.C.O.50
- Purchase, D.**
T.A.O.20, Th.D.O.13
- Purchase, David**
Th.D.F.74
- Purdue, T.**
W.E.P.61
- Purifoy, Dorothy J.**
T.G.O.4
- Purnell, P. C.**
E.791
- Purnell, S.**
Th.D.O.5
- Puro, V.**
M.D.P.72
- Purpura, Maria**
C.714
- Pursley, C.**
T.A.P.61
- Putkonen, Per**
W.C.P.141
- Putnam, D.**
T.A.P.80
- Putney, S.**
M.C.P.6, M.G.P.22
- Putney, S. D.**
Th.C.O.30
- Putney, Scott**
W.C.O.18
- Putney, Scott D.**
Th.C.O.50
- Putzi, R.**
W.B.P.321
- Puyuelo, T.**
A.616
- Pyakalyia, T.**
T.G.O.24
- Pye, M.**
M.E.P.46
- Pyle, S. W.**
M.C.P.38, T.C.P.15
- Pyne, C. K.**
M.C.P.119
- Q**
- Qatsha, K.**
T.B.P.98, Th.C.P.106
- Quackenbush, Marcia J.**
M.B.P.318, M.E.P.59,
W.E.P.48, E.714
- Quackenbush, S. L.**
W.C.O.31
- Qualls, C.**
T.A.O.39
- Qualls, K. J.**
M.C.P.125
- Quatiere, Louis F.**
T.B.P.111, M.C.P.147
- Quaranta, J. F.**
M.A.P.37, A.531, W.B.P.366,
Th.B.P.128, Th.B.P.129,
Th.B.P.364
- Quart, Arthur M.**
Th.B.P.331, Th.B.P.352
- Quattromani, F. L.**
A.514, D.564
- Queener, S. F.**
M.C.P.46
- Queener, Sherry F.**
M.B.O.13
- Queiroz, A.**
W.B.P.203, D.656
- Queiroz, W.**
T.B.P.194, T.B.P.196,
T.B.P.199
- Quer, J.**
T.B.P.214, C.705
- Quero, S.**
B.559
- Quiller, C. B.**
W.A.P.87
- Quincy, C.**
Th.B.P.247, Th.B.P.365
- Quincy, C. P.**
Th.B.P.147
- Quinhos, E. P.**
T.A.P.117, B.638, T.G.P.25,
W.G.P.14
- Quinhos, Eleonora**
Th.D.P.89
- Quinhos, Eleonora P.**
M.B.P.182, T.B.P.364,
T.B.P.369, B.531, B.563
- Quinn, C.**
M.B.P.205, W.B.P.45
- Quinn, T.**
T.A.P.16, Th.A.P.12, M.B.P.5,
M.B.P.31, Th.B.P.165, B.565,
T.G.O.19
- Quinn, T. C.**
M.A.O.39, T.A.O.18,
Th.A.O.18, W.A.P.7,
T.B.P.107, T.B.P.126,
T.B.P.127, W.B.P.156,
Th.B.O.30, Th.B.O.186,
Th.B.P.239, W.C.P.95, E.719,
M.G.O.3, T.G.O.21
- Quinnan, G., Jr.**
T.B.P.281
- Quinnan, G. V., Jr.**
M.C.P.36, T.C.P.69,
W.C.P.96, Th.C.P.40, C.520
- Quintero, Y.**
A.572
- Quirino, T.**
M.B.P.94
- Quirk, John F.**
W.D.P.18
- Quirk, Mark E.**
M.D.P.8
- Quiroga, M.**
T.C.P.104
- Quivey, J. M.**
Th.B.P.341
- R**
- Raasch, R.**
M.B.P.332
- Raben, A.**
W.C.O.21
- Raben, David**
Th.C.P.62
- Rabesandratana, H.**
W.B.P.138, Th.B.P.113
- Rabian-Herzog, C.**
C.570
- Rabine, C.**
D.644
- Rabkin, J.**
W.B.O.41
- Rabkin, J. G.**
T.B.P.192, W.B.P.244,
W.D.P.67
- Raboud, J.**
Th.A.O.27, M.A.P.97
- Rabson, A.**
W.C.P.108
- Rabson, Arnold B.**
T.C.O.12, M.C.P.95, T.C.P.94
- Raburn, T.**
M.B.P.305
- Rachid de Lacerda, M. C.**
T.A.P.117, W.A.P.70,
M.B.P.182, B.531, Th.D.P.89,
M.E.O.17
- Rachlis, A.**
W.B.O.36, T.B.P.54
- Rachlis, Anita R.**
W.B.P.360
- Racines, A.**
M.G.O.28
- Racz, P.**
W.C.P.118
- Rácz, Paul**
W.C.P.117, Th.C.O.8
- Kademacher T. W.**
M.C.O.18
- Rader, Alison D.**
W.E.O.26
- Radford, Joyce L.**
M.D.O.8
- Radinger, H.**
W.B.P.295
- Rae, D.I.**
E.596
- Raevsky, C.**
W.A.O.21
- Raevsky, Catherine**
W.A.P.85
- Ragni, M. V.**
Th.B.P.32
- Ragni, Margaret V.**
W.B.O.24
- Ragone, V.**
M.C.P.62
- Rahimtoola, S. H.**
M.B.P.286
- Rahman, A.**
W.A.P.41
- Rahman, Abid**
Th.A.P.95
- Rahmin, M.**
M.B.P.116
- Raineri, Ines**
Th.A.P.111
- Raininko, R.**
Th.B.P.242
- Raimon, P.-M.**
E.656
- Raise, E.**
M.B.P.96
- Raise, Enzo**
M.A.P.94, W.B.P.340
- Raise, G.**
M.A.P.94
- Raiteri, R.**
Th.B.P.344
- Raja, D. V. P.**
W.F.O.14
- Rajkumar, S.**
Th.E.O.13
- Ralin, Peter L.**
T.E.P.58
- Ramah, M.**
Th.D.O.11, Th.E.P.74,
T.G.O.8, Th.G.P.16
- Ramah, M. L.**
W.E.P.30
- Ramah, Michael L. E.**
T.G.P.12
- Rambaua, P.**
W.D.P.77
- Ramcharitar, S.**
W.C.P.74
- Ramella, M.**
A.520
- Ramey, J. W.**
W.H.P.25
- Ramey, W.**
W.B.P.80
- Ramirez, A.**
W.D.P.37, E.714
- Ramirez, E.**
Th.H.P.24
- Ramirez, G.**
C.517
- Ramirez, L.**
M.A.P.67
- Ramirez, L. L.**
W.A.P.11
- Ramirez, R.**
Th.B.P.101
- Ramis, C. M.**
A.627

- Ramis, I.
W.C.P.120
- Ramos Filho, C. F.
T.B.P.364, W.G.P.14
- Ramos Filho, Celso F.
A.549, T.B.O.7
- Ramos Filho, Thyroso
D.584
- Ramos, M.
T.G.O.8
- Ramos, M. J.
W.E.O.16
- Ramos, S.
T.E.P.60, T.E.P.64
- Ramos, Silvia
W.E.O.16
- Ramos, T.
D.693, Th.E.P.22
- Rams, T. E.
Th.B.P.350
- Ramsden, B. M.
Th.B.P.290, Th.B.P.296
- Ramsey, J.
E.535
- Ramsey, Keith M.
T.C.P.54
- Ramstedt, G.
W.E.O.15
- Randell, R.
W.B.P.150
- Rangan, S. R. S.
M.C.P.64, C.779, C.780
- Rangel, F.
W.G.P.13
- Rangel, G.
E.738
- Ranger, S.
T.B.P.349, T.B.P.382,
W.B.P.106, C.702
- Ranger, Sylvie
C.765
- Rango, N. A.
T.E.O.1
- Rango, Nicholas
M.H.O.16
- Rango, Nicholas A.
Th.E.P.69, E.684
- Ranieri, Sergio
T.B.P.363
- Rankin, J.
Th.D.P.52
- Rao, N. A.
M.B.P.379
- Rao, R. S.
D.725
- Rao, S. M.
T.B.P.117
- Raouit, D.
B.628
- Raphael, M.
Th.B.O.21, M.B.P.295,
Th.C.O.39, Th.C.P.70
- Raphael, Martine
C.699
- Raphael, N.
T.B.P.280
- Raphael, S. A.
T.B.P.225, T.D.O.31
- Rapp, F.
T.B.P.83, T.B.P.84, T.B.P.313
- Rappaport, E.
W.A.O.7
- Rappaport, J.
Th.C.P.19
- Rappaport, Jay F.
T.C.O.31, T.C.P.69
- Rappocciolo, G.
T.C.P.26
- Rarick, M.
M.B.P.366
- Rarick, M. U.
M.B.P.45
- Rarick, Mark U.
M.B.O.48, W.C.P.49
- Rarrick, M.
T.C.P.17
- Rashbaum, W.
C.715
- Rasheed, Suraiya
Th.A.P.11, C.703
- Rashid, A. S.
Th.H.P.28
- Rasokat, H.
W.B.P.291, C.546
- Rastrelli, M.
M.A.P.63
- Rastrelli, Mario
A.503
- Ratimahirana, H.
Th.E.O.21
- Ratner, L.
T.B.P.384, T.C.O.46,
T.C.P.122, Th.C.P.12
- Ratner, Lee
M.C.P.90, T.C.P.95,
T.C.P.120, T.C.P.121
- Rattan, B.
M.B.P.89
- Rauch, K. J.
M.A.O.2
- Rausch, D.
W.C.O.16
- Rausch, Dianne M.
T.C.P.90
- Rautenberg, E.
T.A.P.71, W.D.P.60
- Rautenberg, E. L.
W.A.P.12, T.E.P.41
- Rautenberg, Ellen
M.A.O.43, E.503
- Rautenberg, R.
D.582
- Ravasi, L.
M.B.P.56
- Raveis, V.
W.D.P.9, W.D.P.10
- Raveis, Victoria H.
E.527
- Raviglione, M.
W.B.P.5
- Raviglione, Mario C.
M.B.P.72, M.B.P.89, Th.B.P.41
- Ravina, A.
Th.B.P.343
- Ravina, J. H.
E.503
- Ravipati, M.
T.B.P.254
- Ravisse, P.
T.B.P.191
- Rawal, Bhupat
M.B.P.169
- Ray, B.
W.C.P.14
- Ray, C. G.
Th.H.P.9
- Ray, C. S.
Th.G.O.6
- Ray-Keil, L.
M.E.P.17, E.750
- Rayfield, M.
T.B.P.116, T.B.P.119,
W.B.P.113
- Rayfield, Mark A.
Th.A.P.109
- Raymond, R.
M.E.P.45
- Rayner, M.
Th.C.O.26
- Rayon, D.
D.516, W.E.P.27
- Razuididin, M.
M.C.O.16
- Re, M. C.
T.A.O.19, W.A.P.43
- Re, O.
M.D.P.5, T.D.P.7, D.502, E.796
- Read, J.
G.519
- Read, J. A.
T.B.P.5
- Read, S.
W.B.P.176, Th.B.P.5, T.D.P.63
- Read, S. E.
Th.A.O.27, M.A.P.97,
M.A.P.113, W.B.O.36,
W.C.P.83, T.D.P.41, E.584,
E.619
- Read, Stanley E.
Th.B.O.26, M.B.P.315,
Th.B.P.373, B.603, W.C.O.24
- Reade-Christopher, S.
Th.A.P.78
- Reagan, K.
C.671
- Reagan, K. J.
C.764
- Reagan, Kevin J.
C.669
- Reale, M. T.
M.B.P.336
- Reback, C. J.
Th.D.P.12
- Rebus, S.
C.781
- Rebus, Selma
Th.C.P.126
- Recchia, O.
M.B.P.199
- Recker, D.
W.C.P.16, W.C.P.41
- Rector, Richard
T.E.P.71
- Redding, K. L.
M.C.P.60
- Reddy, E. P.
Th.C.O.25, Th.C.P.149
- Reddy, M. M.
M.B.P.360, M.C.P.142
- Reddy, Mohan M.
M.B.P.360
- Redfield, R.
Th.A.P.93, Th.B.P.155,
M.C.O.21, T.C.P.128,
Th.C.P.22
- Redfield, R. R.
T.B.P.112, Th.B.P.120,
T.C.P.28, T.C.P.29
- Redfield, Robert
T.B.O.22, Th.C.P.133
- Redfield, Robert R.
W.A.P.66
- Redd, C.
W.B.P.17, W.D.P.37,
W.E.P.58, E.635
- Red, Christie M.
Th.D.P.26
- Reed, D.
T.B.P.137
- Reed, David E.
T.B.P.287
- Reed, S.
W.C.P.63
- Rees, Malcolm S.
W.H.P.19
- Reesink, H.
M.B.P.162, T.B.P.355,
W.B.P.157, W.B.P.158,
W.B.P.171, Th.C.P.55,
T.E.P.19
- Reesink, H. W.
T.B.P.323
- Reesink, Heuk W.
B.510
- Reeves, J. P.
M.B.P.174
- Reff, V.
W.A.P.81
- Reff, V. J.
Th.A.P.48

- Regenbrecht, Marlies**
 E.749
Regeniter, A.
 M.B.P.105
Regnard, J.
 W.B.O.22
Régnier, C.
 Th.B.P.9, Th.B.P.21
Rehle, T.
 W.G.O.29, Th.H.P.27
Rehmet, S.
 T.A.O.15, W.A.P.3, T.B.P.73
Rehmet, Sybille
 A.606, T.B.P.200
Reibnegger, G.
 W.B.F.79, C.583
Reichard, P. A.
 Th.B.P.332
Reichart, P. A.
 W.B.P.84
Reichenbach, N. L.
 M.C.P.136
Reichert, S.
 M.B.P.283
Reichman, L.
 Th.B.P.48
Reichman, R. C.
 M.B.P.342, M.C.P.8,
 M.C.P.130
Reid, D.
 Th.A.P.115
Reid, P.
 M.B.P.322, W.D.P.7
Reid, Stewart
 M.B.O.33
Reid, T.
 T.A.O.20, Th.D.O.13,
 Th.D.P.74
Reif, S.
 T.A.P.15
Reimann, K. A.
 Th.C.O.16
Reimer, C.
 Th.B.P.93
Rein, R.
 Th.E.P.9
Reina, S.
 W.C.O.32
Reining, Priscilla
 T.A.P.86
Reinis, M.
 Th.C.P.127
Reinisch, J. M.
 T.D.P.75
Reinisch, J. M.
 T.D.O.21
Reinisch, June M.
 T.D.P.2, Th.E.P.37
Reinking, D. P.
 W.H.P.14
Reinyang, Ivar
 Th.B.P.215
Reir, D.
 T.A.O.28
Reis, Myriam
 T.B.P.328
Reisbeck, Günter
 T.D.O.34
Reiser, J.
 D.654
Reisinger, E.
 T.B.P.39, Th.B.P.329
Reisinger, Emil C.
 W.B.P.89, W.B.P.297
Reisler, R.
 M.A.O.8
Reiss, Ira L.
 Th.E.P.54
Reiss, P.
 M.B.O.23
Reiter, William M.
 T.B.P.315
Reitz, B.
 M.B.P.161
Reitz, M. S.
 C.630
Reka, S.
 M.B.P.135, C.664
Reka, Safak
 M.C.O.27, W.C.P.131
Rekacewicz, I.
 W.B.P.264
Rekart, M.
 W.A.P.120, T.D.O.14
Rekart, Michael L.
 M.A.P.115, T.A.P.84,
 Th.A.P.38, A.535, T.D.P.8,
 Th.E.O.A, Th.E.P.25
Rekosh, D.
 T.C.O.6, T.C.P.80, T.C.P.81,
 Th.C.P.121, Th.C.P.122
Remien, Robert H.
 W.B.O.41, T.B.P.192,
 W.B.P.244, W.D.P.67
Remington, Jack S.
 M.B.O.28
Remis, R. S.
 W.A.P.83
Remis, Robert
 T.A.O.1
Remis, Robert S.
 W.A.O.14, W.A.P.42
Remold, H.
 C.521
Renard, C. A.
 W.B.P.82
Renaud, D.
 E.571
Renaud, L.
 T.G.O.10
Renaud, M.
 D.655
Renaud, M. A.
 M.B.P.138
René, E.
 M.H.P.4
René, P.
 T.B.P.97
Rennelsen, K.
 W.B.P.163
Rennels, M. B.
 T.B.P.262
Rentier, B.
 B.623
Renzullo, Philip O.
 M.A.O.3, Th.A.P.103
Repaske, R.
 Th.C.P.103
Repke, J.
 M.B.P.5
Repo, H.
 W.C.P.114
Rescaldani, R.
 W.B.P.102
Resnick, L.
 M.A.P.90, Th.B.P.263
Resnick, Lionel
 M.C.P.86, M.C.P.87
Retel, O.
 T.A.P.75
Retta, S. M.
 W.A.P.101
Reuben, J.
 B.531
Reuben, James M.
 Th.B.P.104
Reuter, P.
 W.B.P.163
Reux, I.
 Th.B.P.250
Réveuil, B.
 M.C.P.119
Revello, M. G.
 M.B.O.31, M.B.P.114
Revesz, K.
 Th.B.P.8
Reviron, D.
 M.F.P.9, T.F.P.11, W.F.P.4
Revis, T.
 T.H.P.12
Rex, R.
 T.A.P.60
Rey, C.
 W.B.P.165, B.640
Rey, F.
 Th.C.P.9
Rey, Françoise
 Th.C.O.27
Rey, J.
 M.G.O.29
Rey, M. A.
 T.C.O.5, Th.C.P.85
Rey, Marie-Anne
 T.C.O.38
Rey-Joly, C.
 W.A.P.71, Th.B.P.335,
 Th.D.P.57, D.613
Reyes, C. N.
 W.A.P.48
Reyes, J.
 T.B.P.153
Reyes, M.
 M.E.P.13
Reynaud, C.
 W.E.P.27
Reynes, J.
 M.B.P.131, T.B.P.288,
 W.B.P.167, Th.B.P.97
Reynes, Jacques
 W.B.P.32
Rezvan, Hourii
 T.G.P.20
Rezza, G.
 M.A.P.48, W.B.P.146,
 Th.C.O.40, E.622
Rezza, Giovanni
 W.D.O.8, Th.D.P.39,
 Th.D.P.40
Rhame, F.
 M.B.P.85
Rhame, Frank S.
 W.B.P.289, W.C.P.81
Rhoads, J.
 Th.E.P.155
Rhoads, Joanne
 Th.B.P.120, T.C.P.28
Rhodes, A. R.
 M.C.P.77
Rhodes, F.
 T.A.P.42, M.D.P.43,
 W.E.P.59, E.544
Rhodes, Fen
 T.E.P.15
Rhodes, Tim J.
 M.D.O.18
Ribas, J. L.
 W.C.O.45
Ribas, Jorge L.
 W.C.P.147
Ribble, D.
 M.B.P.276, T.B.P.51,
 T.B.P.324, W.B.P.68
Ribble, Denise J.
 W.A.P.10, W.D.O.15,
 W.D.P.40
Ribero, S. A.
 Th.B.P.38
Ribero, Sandra A.
 Th.B.P.63
Ribera, A.
 M.A.P.81, Th.A.P.19,
 Th.A.P.22, A.556, M.B.P.245
Ricalde, A. L.
 T.B.P.267
Ricard, Dominique
 T.G.P.29
Ricart, I.
 M.B.P.43
Ricardi, R.
 Th.B.P.330, C.571

- Ricchetti, M.**
M.C.P.106
- Ricchi, E.**
T.A.O.19, M.B.P.228,
M.B.P.256, T.B.P.330,
W.B.P.338
- Ricchi, Ennio**
W.A.P.43, M.B.P.118
- Riccio, M.**
W.B.P.201, D.617
- Rice, J.**
M.B.P.383, T.B.P.384
- Rich, Kenneth C.**
T.B.P.206
- Richard, C.**
M.A.P.23
- Richard, D.**
M.B.P.151
- Richard, H.**
D.516
- Richard, J. E.**
E.739
- Richards, M.**
W.B.P.192
- Richardson, A.**
T.D.P.38
- Richardson, C.**
T.B.P.128, Th.C.P.86
- Richardson, D.**
M.B.P.12
- Richardson, Mark**
M.C.P.35
- Richland, J.**
W.H.O.11
- Richman, B. L.**
W.D.P.71
- Richman, D.**
M.B.P.325, T.B.P.8,
T.C.P.129, Th.C.P.46, C.531,
T.D.P.79
- Richman, D. D.**
W.B.P.11, W.B.P.254,
T.C.O.7, Th.C.O.18, T.C.P.50,
Th.C.P.29, Th.C.P.79
- Richman, Douglas**
T.B.O.16
- Richter, C.**
W.G.P.5
- Richter, D.**
Th.D.P.25, E.549, E.752,
E.758
- Richter, Donna L.**
Th.D.P.11
- Rickard, E.**
T.B.P.140, Th.B.P.13,
Th.B.P.362, B.513, Th.G.P.17
- Rickard, Ema**
T.B.P.139, Th.G.P.21
- Ricketti, A.**
M.B.P.69
- Rickman, William J.**
Th.B.P.146
- Rico, Blanca**
E.738
- Ridolfo, A. L.**
M.B.P.364, T.B.P.212
- Riecken, E. O.**
W.B.P.33
- Riedel, Roif R.**
W.B.O.42, Th.B.P.192
- Rieder, H.**
T.B.P.301
- Rienzo, B. A.**
E.570
- Riepe, Micaela**
E.776
- Riera, M.**
M.B.P.97
- Riera, N.**
Th.B.P.362
- Rifai, N.**
W.B.P.78
- Rifat, S.**
T.B.P.87
- Riggin, C. H.**
M.B.P.168, W.B.P.148,
Th.B.P.176
- Rika, M.**
W.D.P.51
- Riley, Diane M.**
Th.D.P.85, M.E.P.25
- Riley, J.**
W.B.P.263
- Rimon, N.**
T.A.P.81
- Rinaldi, E.**
W.G.P.1
- Rinaldi, J. E.**
W.A.P.101
- Rinaldo, C.**
T.A.O.29, Th.A.P.94, A.616,
M.B.P.380, T.B.P.98,
T.B.P.114, W.B.P.73,
Th.C.O.28
- Rinaldo, C. R.**
W.A.P.41, Th.A.P.95,
W.B.P.303, W.C.O.10,
M.C.P.133, T.C.P.4, T.C.P.5,
Th.C.P.14
- Rinaldo, Charles R.**
T.C.P.26
- Ringdal, A.**
D.585
- Ringenberg, Roy A.**
M.G.O.28, W.G.P.12
- Ringler, D.**
W.C.O.48
- Ringler, D. J.**
W.C.P.75
- Rio, B.**
M.B.P.323
- Riodja, L. S.**
T.B.P.365
- Rion, P.**
T.A.P.61
- Riordan, N.**
T.A.O.7
- Riordan, N. M.**
W.D.P.28
- Rios, Z.**
Th.B.P.101
- Ritpich, Stefan J.**
W.B.P.376
- Rise, J.**
T.D.P.5
- Rise, Jostein**
T.E.P.31
- Risek, J. E.**
W.H.P.4
- Risek, R.**
W.H.P.4
- Risi, G.**
T.A.P.33
- Risi, George F.**
Th.A.P.49, B.504, E.608,
E.609
- Rissi, A. C.**
Th.B.P.337
- Rissi, R. C.**
Th.B.P.337
- Ritchey, Michael G.**
E.712
- Ritchie, N.**
M.G.O.2
- Rittenhouse, J.**
C.694
- Ritter, D.**
W.C.P.79
- Ritter, J.**
C.773, Th.D.P.31, M.G.P.7
- Ritter, J. L.**
M.F.P.13, Th.F.P.3
- Ritter, Jacques**
Th.B.P.169
- Ritterband, M.**
M.A.P.119, M.B.O.25
- Ritz, L.**
T.A.P.40
- Rivas-Souza, M.**
G.516
- Rivasi, P.**
M.B.P.65
- Rivera, J.**
M.A.O.34
- Rivera, Y.**
E.552
- Rivero, A. M.**
Th.D.P.12
- Rivers, E.**
Th.A.P.9
- Rivière, Y.**
M.C.P.4, W.C.O.14, Th.C.P.67
- Rivière, Yves**
W.C.O.44, C.524
- Rizza, C.**
Th.B.P.31, T.C.P.23, E.507
- Rizzardini, G.**
M.B.P.94, D.688, W.G.P.1
- Rizzi, M.**
W.B.P.362
- Rizzi, Marco**
M.A.P.95
- Roata, C.**
A.536, M.B.P.171
- Robb, Merlin L.**
T.C.P.66, C.767
- Robbin, J. E.**
Th.A.P.50
- Robbins, K.**
T.C.P.82
- Robbins, P. B.**
W.C.P.105
- Robbins, R. L.**
Th.A.P.114
- Robert, A.**
T.B.P.187, Th.B.P.9,
Th.B.P.21
- Robert, Claude F.**
Th.D.P.80
- Robert, Jean**
T.F.O.15, W.G.O.40
- Robert, V.**
Th.C.P.142
- Robert-Guroff, M.**
W.C.P.35
- Roberts, M.**
T.C.P.119
- Roberts, B.**
E.538
- Roberts, C. A.**
Th.B.O.56
- Roberts, C. R.**
T.C.P.101
- Roberts, Chester R.**
Th.B.O.57
- Roberts, J.**
M.C.P.8
- Roberts, J. J. K.**
W.D.P.75
- Roberts, James W.**
M.B.P.273
- Roberts, M.**
E.640
- Roberts, Michael**
T.C.P.135
- Roberts, P.**
M.A.O.36
- Roberts, P. L.**
E.731
- Roberts, Richard B.**
Th.B.O.1, M.C.P.88
- Robertson, D.H.H.**
E.722
- Robertson, J. R.**
T.A.O.14, T.A.P.31,
Th.B.P.164, C.781, W.D.P.75
- Robertson, K. J.**
T.B.P.56
- Robertson, L.**
Th.B.P.279

- Robeson, L.
T.A.P.78
- Robey, A. F.
T.C.P.48
- Robey, G.
W.B.P.134, W.B.P.137, C.608
- Robins, D. S.
W.B.P.288
- Robins, J. M.
Th.A.P.41
- Robins, James
Th.A.P.72
- Robinson, E.
Th.C.O.4, M.C.P.19
- Robinson, James E.
Th.C.O.3
- Robinson, P. A.
W.B.P.1
- Robinson, T. W.
E.522
- Robinson, W. E., Jr.
W.B.P.239, W.C.O.28
- Robinson, W. Edward
Th.C.P.45, Th.C.P.129, C.771
- Robottom, B.
M.B.P.309
- Roboz, J. P.
Th.B.P.84
- Robson, I.
M.C.P.145
- Roca, V.
M.B.P.107
- Rocco, R.
W.A.P.51
- Rocha, M. D. C.
D.804, E.781
- Rochemaure, J.
B.615
- Rochet-Rossello, Sophie
D.702
- Rocino, A.
Th.B.P.16
- Rockenbach, S. K.
C.683
- Rockwell, R.
T.D.P.81, E.728
- Roddy, R. E.
M.D.P.19, W.E.P.14
- Rodgers, B.
T.C.P.86
- Rodgers, P.
W.A.P.10, M.B.P.276,
M.B.P.319, T.B.P.51,
T.B.P.324, W.B.P.68,
W.B.P.375
- Rodi, C.
M.C.P.90
- Rodier, G.
B.538
- Rodriguez, G.
D.518
- Rodriguez, G. A.
W.B.P.31, Th.B.P.40
- Rodriguez, José F.
W.B.P.237
- Rodriguez, L.
T.B.O.12, W.B.P.237,
T.D.P.54, M.G.O.26,
Th.G.O.50, M.G.P.1, W.G.P.13
- Rodriguez, L. G. M.
T.B.O.7, T.D.O.28
- Rodriguez, Lair
W.G.O.15
- Rodriguez, Lair G. M.
E.583, E.603, W.G.O.23
- Rodriguez, S. R.
E.785
- Rodriguez, C.
T.B.P.194, T.B.P.196,
T.B.P.199
- Rodriguez, E.
Th.D.P.75
- Rodriguez, G.
M.D.P.82, Th.E.O.6a, E.707
- Rodriguez, H.
E.684
- Rodriguez, J.
W.B.P.207
- Rodriguez, Cassandra
T.B.P.69
- Rodriguez, M.
M.D.P.83
- Rodriguez, M.
Th.E.P.87
- Rodriguez, S. J.
M.B.P.66, M.B.P.129,
W.B.P.37
- Rodriguez, V.
M.C.P.1
- Rodriguez-Arrondo, F.
B.801
- Rodriguez-Torres, A.
M.A.P.21
- Rodriguez-Trias, Helen
T.E.P.40
- Rogan, A.
M.E.P.13
- Roger, P. M.
T.B.P.33
- Rogers, A.
T.A.P.77
- Rogers, M.
W.A.O.17, Th.A.O.11,
M.A.P.35, M.B.P.8, T.B.P.173,
M.D.O.7
- Rogers, M. F.
W.A.O.18, W.D.P.48
- Rogers, Martha
T.B.O.19
- Rogers, Martha F.
M.B.O.4
- Rogers, W.
M.H.P.17
- Rogers, W. H.
T.D.P.18
- Roger, Jean Philippe
T.B.P.382
- Röger, G.
W.B.P.19, Th.B.P.246
- Rognier-Aetherhard, F.
W.B.P.207
- Rogolsky, E.
T.B.P.82, T.B.P.63
- Rohl, M.
E.761
- Rollides, Emmanuel
Th.B.P.89
- Rojanapithayakorn, W.
T.G.O.25
- Rojas De Couville, E.
D.519
- Rojas, J. M.
Th.C.P.74
- Roja-Pieszczyński, M.
W.C.P.22
- Roland, Michelle
C.617
- Roland, Michelle E.
M.D.P.76
- Rolfs, A.
W.B.P.33
- Rollag, H.
T.C.P.146
- Rolland, M.-R.
T.B.P.187
- Roller, T.
W.B.O.43, Th.B.P.286
- Rolston, Kenneth V. I.
M.B.P.66, M.B.P.129,
W.B.P.37
- Romagnoli, P.
C.571
- Romagosa, V.
M.B.P.43
- Romaguera, J.
M.B.P.27, M.B.P.28
- Roman, J. V.
M.B.P.170
- Romano, F.
Th.A.P.14, W.C.P.47
- Romanowski, B.
M.A.P.87
- Romeo, R.
A.516, M.C.P.43
- Romero, C.
Th.G.O.30
- Romero, J.
W.B.P.28
- Romero, M.
A.585, T.B.P.335
- Romero, N.
B.515
- Romette, A.
B.628
- Romeu, A.
Th.B.P.327
- Romeu, J.
Th.B.P.234, B.509
- Romieu, I.
M.A.O.13, M.A.O.15
- Romieu, Isabelle
Th.A.P.81, T.G.P.27
- Romijn, J. A.
Th.B.O.38
- Romines, C.
Th.B.O.57
- Rompalo, A.
Th.A.O.18
- Rompalo, A. M.
M.A.P.68
- Ronald, A. R.
T.A.O.25, Th.G.O.27,
Th.G.O.36, W.G.P.29,
Th.G.P.29
- Ronald, Allan R.
W.B.O.46, Th.H.P.8
- Ronchi, P.
M.B.P.338
- Rondanelli, E. G.
Th.B.P.272
- Roodman, S. T.
Th.B.P.112, W.C.P.52
- Rooke, R.
T.B.O.35
- Rooke, Ronald
T.C.P.111
- Roos, M.
M.A.P.112
- Roos, Marijke T. L.
Th.B.P.87
- Roosjen, J. L.
Th.E.O.2
- Roosenburg, H.
E.506
- Ropchan, J.
Th.B.P.259
- Roque, J. P.
C.630
- Roquin, H.
M.A.P.106, Th.B.P.182
- Rosa, M. D.
M.C.P.72
- Rosario, S.
W.A.P.94, Th.D.O.10,
Th.D.O.12, T.D.P.32, D.686,
M.E.O.11
- Rosci, M. A.
M.B.P.106, Th.B.P.255,
Th.B.P.256, C.714
- Rosci, M. A. R.
Th.C.P.146, C.739
- Rose, A.
Th.B.P.298, Th.E.P.41
- Rose, D.
D.688, T.E.P.10
- Rose, David N.
Th.A.P.45
- Rose, Loree V.
W.E.P.67

- Rose, T.
W.A.O.11, M.A.P.74,
Th.D.P.58, D.528, D.666,
Th.E.P.73
- Rose, Thanne P.
W.B.P.53
- Roseholo, J.
W.C.P.120
- Roseman, J.
M.D.P.5, T.D.P.7, D.502
- Rosen, C.
T.C.P.87
- Rosen, F. M.
D.577
- Rosen, J.
C.636
- Rosenbaum, J.
T.D.P.60
- Rosenbaum, W.
T.B.P.307
- Rosenberg, J.
W.C.P.138
- Rosenberg, M.
Th.C.P.20, E.558
- Rosenberg, P. S.
M.A.O.45, W.A.P.61,
Th.A.P.77
- Rosenberg, Philip S.
T.A.O.35
- Rosenblatt, H. M.
T.B.P.268
- Rosenblatt, J.
Th.A.P.21
- Rosenblum, A.
T.A.O.12, W.D.O.10,
W.D.P.78, Th.D.P.75
- Rosenblum, M.
Th.B.P.375, W.C.P.45,
W.C.P.84
- Rosenblum, M. R.
Th.B.P.249
- Rosenbrook, W.
M.C.P.65
- Rosendahl, C.
T.B.P.208, T.B.P.250
- Rosendahl, Carla
T.B.P.163
- Rosenfeld, S.
W.E.P.20, E.588
- Rosenheim, M.
M.B.P.119, T.B.P.41,
W.B.P.151, Th.B.P.196,
B.546, B.547, G.511
- Rosenheim, Michel
M.A.P.119, Th.G.P.7
- Rosenheim, Michel H.
B.642
- Rosenman, Julie
E.797
- Rosenstrauss, Maurice J.
Th.C.P.24
- Rosenthal, Eric
T.E.O.16
- Rosenthal, Jonathan H.
M.B.P.84
- Rosenthal, K. L.
T.B.P.110
- Rosenthal, Kenneth L.
M.C.P.21
- Rosenthal, S.
D.562, D.565, E.778
- Roser, M. A.
W.B.P.133
- Rosol-Donoghue, J.
T.B.P.7
- Rosonakis, Judith
D.556
- Ross, E.
T.A.O.31, M.A.P.100,
Th.A.P.102
- Ross, Jennifer
D.556
- Ross, K.
M.C.P.6
- Ross, Lawrence A.
T.B.P.287
- Ross, Paul A.
T.H.P.29
- Ross, S.
D.509
- Rossi, E.
M.B.P.217
- Rossi, G.
D.714
- Rossi, G. B.
W.B.P.146, M.C.P.105,
W.C.P.119, C.755
- Rossi, J.
M.B.P.39, Th.C.O.22
- Rossi, J. J.
W.B.P.319
- Rossi, L.
Th.D.O.11, W.D.P.14
- Rossi, Luisa
Th.D.P.88
- Rossi, P.
T.C.P.55
- Rossi, Paolo L.
Th.A.P.113
- Rossier, J.
C.656
- Rossler, J. P.
T.C.P.109
- Rossini, M.
W.B.P.215, W.B.P.219
- Rossol, S.
Th.B.P.119, Th.B.P.122,
T.C.P.88, W.D.P.54, Th.D.P.23
- Rosol, Siegbert
M.B.P.220, Th.B.P.98
- Rostapshov, V. M.
T.B.P.91
- Rota, T.
Th.C.P.13
- Rote, K.
W.B.P.137
- Rote, Kevin V.
W.B.P.134
- Rotenberg, E.
E.778
- Roth, D.
W.E.O.19
- Rothbard, J.
T.C.P.23
- Rothberg, L. R.
Th.B.P.90
- Rothenberg, A.
D.650
- Rothenberg, K.
T.F.P.8
- Rotheram-Borus, M. J.
T.D.P.4, T.D.P.90, D.506
- Rotheram-Borus, Mary
Jane
T.D.P.12
- Rothman, P.
T.B.P.62, T.B.P.63
- Rothspan, S.
W.D.P.22
- Rotkiewicz, L.
E.707
- Rotterdam, H.
W.B.O.38, M.B.P.116
- Rotterdam, Heidrun
M.B.P.127, M.B.P.293
- Rouaix, F.
W.C.O.46
- Roudot, F.
W.B.P.364
- Roué, René
T.B.P.309, W.B.P.282
- Rougeot, C.
C.584
- Rougeot, Catherine
Th.B.P.241
- Rouger, P.
M.A.P.106, Th.B.P.162
- Rouger, P. R.
Th.B.P.140
- Roul, C.
M.B.P.250, M.B.P.252
- Roumeliotou, A. N.
A.612, W.B.P.342
- Roumeliotou, Anastasia
W.A.P.37, E.747
- Rousseau, A.
T.B.P.219, T.B.P.222,
T.B.P.242
- Rousseau, S.
B.628
- Roustang, I.
Th.D.P.35
- Routy, J.-P.
T.B.P.277, T.B.P.305,
W.B.P.43
- Rouveix, B.
M.B.P.347
- Roux, Patricia
T.B.P.1, T.B.P.4
- Rouzoux, C.
A.570, M.B.O.3, M.B.O.39,
T.B.P.170, T.B.P.283,
W.B.P.368, W.G.P.10
- Rouzoux, Christine
T.B.O.32, Th.C.P.7, Th.C.P.21
- Rovnak, J.
W.C.P.4
- Rowe, Bill
T.E.P.8
- Rowe, C.
W.A.P.92
- Rowe, Ian F.
M.B.P.282
- Rowe, Mona J.
M.F.O.3, W.H.O.11
- Rowe, S.
T.B.P.256
- Rowell, R.
W.D.P.32
- Rowell, Ronald M.
T.D.O.13
- Rowland, J.
M.C.P.19, C.720
- Rowley, Jane T. F.
T.H.O.16
- Roy, A.
Th.B.P.14, B.511
- Roy, Charles M.
Th.B.P.29, E.733
- Roy, D.
Th.A.P.39
- Roy, D. J.
Th.F.P.15
- Roy, David J.
T.F.O.10
- Roy, Denis
W.A.P.83
- Roy, Sophie
T.C.O.27
- Royal, W. R.
Th.B.P.271
- Royal, Walter
Th.B.P.206
- Royce, R.
Th.A.P.90, A.583
- Royce, Rachel A.
Th.A.P.84, Th.B.P.75
- Roze, C.
M.H.P.4
- Rozenbaum, W.
Th.A.P.99, M.B.P.348,
M.B.P.368, T.B.P.27,
T.B.P.307, W.B.P.344
- Rozenbaum, Willy
T.B.O.25, M.B.P.132,
T.B.P.283
- Rua, M.
M.A.O.41
- Rua-Figueroa, M.
T.A.P.22
- Ruane, P.
Th.B.P.292, Th.B.P.293

- Ruane, P. J.**
Th.B.P.296
- Rubin, H. R.**
W.B.P.254
- Rubin, Howard C.**
M.E.P.72, Th.E.P.66
- Rubin, Robert H.**
W.B.P.1
- Rubini, N. P. M.**
T.A.P.117, W.A.P.51, B.533
- Rubini, Norma P. M.**
T.B.P.190
- Rubinow, D.**
Th.B.P.232, Th.B.P.295
- Rubinstein, A.**
M.B.O.41, T.B.P.184,
T.B.P.233, B.573, B.592,
W.C.P.43, C.715, M.E.P.34,
Th.E.P.57, Th.E.P.58
- Rubinstein, Arye**
M.B.P.7, Th.C.P.91
- Rubinstein, D.**
T.B.P.55
- Rubinstein, E. M.**
A.529
- Rubinstein, J.**
W.C.O.29
- Rubinstein, P.**
M.A.P.93
- Rübsamen-Waigmann, H.**
M.B.P.105, W.B.P.300, C.607,
C.623
- Rübsamen-Waigmann, Helga**
Th.C.O.24
- Rucker, Ronn D.**
E.519
- Ruebottom, B. Ann**
B.505
- Rueda, R. M.**
A.632
- Ruedy, J.**
M.B.O.33, T.B.O.29, W.B.O.6,
W.B.O.8, M.B.P.349,
M.B.P.367, T.B.P.314,
Th.B.P.52, T.H.P.11, T.H.P.13
- Ruedy, John**
M.B.O.47, W.B.O.1, Th.B.O.49
- Ruf, B.**
W.B.O.20, Th.B.O.23,
M.B.P.125, M.B.P.331,
W.B.P.299, Th.B.P.54,
Th.B.P.73, Th.B.P.274
- Ruf, Bernhard**
T.B.P.21, W.B.P.34,
W.B.P.300
- Ruff, A.**
T.A.O.18, W.A.P.7, T.G.O.19
- Ruff, Andrea J.**
T.B.P.256, Th.B.P.368,
Th.G.P.2
- Ruff, M. R.**
M.C.P.92
- Ruffault, Annick**
W.B.P.75
- Ruffault, A.**
B.535
- Ruffilli, M. P.**
M.P.92
- Ruga, E.**
T.B.P.186
- Rugg, D.**
M.D.P.43
- Rugg, Deborah L.**
M.E.P.30, E.717
- Ruis, J.**
M.B.P.103
- Ruitenberg, E. J.**
Th.A.P.55
- Ruiz, A.**
M.A.P.87
- Ruiz, I.**
T.B.P.289, W.B.P.28,
Th.B.P.57
- Ruiz, J.**
W.A.P.4
- Ruiz-Moreno, M.**
T.B.P.216
- Rukarangira, Nkera**
M.E.O.33, E.812
- Rukarangira, W. N.**
D.894, W.E.F.3
- Rukarangira, Wa Nkera**
W.D.P.90
- Rullan, J.**
Th.O.10
- Rumben, J.**
M.G.O.28
- Rumi, M. G.**
A.516
- Rumi, Mariagrazia**
M.C.P.43
- Ruminjo, I.**
M.A.O.36
- Rumley, R. L.**
M.H.P.14
- Rumsey, C.**
M.B.P.24, T.B.P.227
- Run, G. H. F. Y.**
M.B.P.68
- Rundell, James R.**
W.B.P.228
- Rupprecht, K.**
Th.C.P.36
- Ruprecht, Ruth M.**
Th.C.O.49, M.C.P.51,
W.C.P.29
- Ruscetti, F.**
M.C.O.16
- Ruscetti, Francis W.**
T.C.P.33
- Rusche, J.**
T.C.O.31, Th.C.O.50,
M.C.P.25
- Rusche, J. R.**
M.C.O.21
- Rusk, C.**
M.A.O.48
- Russell, D. H.**
Th.B.P.138
- Russi, E.**
Th.B.P.81
- Russi, M. B.**
T.B.O.27
- Russo, H.**
Th.C.P.24
- Russo, J. P.**
E.595
- Russo, R.**
W.B.P.215, W.B.P.219
- Rust, J.**
D.701
- Rust, Michael G.**
M.B.P.210
- Rustembegovic A.**
M.C.P.138
- Ruta, M.**
Th.C.P.114
- Ruta, Martin**
Th.C.P.119
- Rutherford, G.**
W.A.O.13, M.B.O.19, T.E.P.7,
T.H.O.3, M.H.P.6, M.H.P.7
- Rutherford, G. W.**
W.A.P.14
- Rutherford, G. W.**
M.A.O.27, M.A.O.46,
M.A.P.60, M.A.P.64,
M.A.P.111, W.A.P.13,
W.A.P.14, W.A.P.24,
W.A.P.46, W.A.P.80,
Th.A.P.50, Th.A.P.86,
Th.B.O.9, M.B.P.224,
W.B.P.354, Th.B.P.201,
M.D.P.26, T.E.P.41, T.H.O.5
- Rutherford, George W.**
T.A.O.32, W.A.P.27
- Ruysschaert, J.-M.**
T.C.P.107, C.742
- Rwakakara, E. A.**
M.G.O.13
- Ryan, A. B.**
Th.A.P.28
- Ryan, C. C.**
M.F.O.3, W.H.O.11
- Ryan, Caitlin**
Th.E.O.12
- Ryan, J.**
T.A.P.78, T.A.P.79, W.A.P.19,
W.B.P.210, W.C.O.8, T.D.O.9
- Ryan, P.**
E.547
- Ryan, William J.**
D.551
- Rybojad, M.**
W.B.P.49
- Ryder, C.**
W.C.P.95
- Ryder, R.**
M.A.O.32, Th.A.O.21,
T.A.P.90, W.A.P.96,
T.B.P.107, T.B.P.108,
T.B.P.204, T.B.P.205,
W.B.P.359, Th.B.P.186,
T.D.O.35, W.D.P.2, M.G.O.3,
W.G.O.1, W.G.O.4,
W.G.O.26, Th.G.O.34,
W.G.P.8, W.G.P.9, T.H.O.8,
Th.H.P.27
- Ryder, R. W.**
E.719, M.G.O.17, T.H.O.9,
Th.E.P.1
- Ryder, Robert**
T.B.P.181, B.625
- Ryder, Robert W.**
M.A.O.35, M.B.P.31
- Ryder, Robin**
M.G.O.21
- Ryder, T. B.**
T.C.P.18
- Rymo, L.**
T.C.O.37
- S**
- S.E.I.I.U. Local 250**
E.748
- Saad, W. P.**
A.547
- Saah, A.**
W.A.P.67, W.A.P.68, A.616,
M.B.P.380, T.B.P.98,
W.B.P.52, W.B.P.73,
Th.B.P.202, Th.B.P.238,
Th.B.P.368, Th.C.P.106, C.542
- Saah, A. J.**
M.D.P.88
- Saah, Alfred J.**
T.A.O.29, Th.G.O.28, G.507
- Saalfeld, Catherine G.**
M.E.P.21
- Saatvedt, J.**
D.585
- Saba, W. P.**
E.645
- Sabatier, J. M.**
M.C.P.31, T.C.P.42
- Sabbaj, Steffanie**
T.C.P.27
- Sabbatani, S.**
M.A.P.94, A.510, Th.B.P.76,
W.C.P.50
- Sabbatani, Sergio**
Th.H.P.25
- Sabbatier, Renée**
M.F.O.20
- Sabelli, C.**
A.520
- Sable, R.**
W.B.P.260

- Sabogal, F.
M.D.P.26
- Sabot, B. J.
T.E.O.1
- Sabourin, L.
M.B.P.174
- Sacchi, Giuseppe
T.B.P.269, B.565
- Sacchi, F.
M.B.P.75, M.B.P.258,
M.B.P.298
- Sacharski, Eileen
T.B.P.154
- Sachs, K.
M.B.P.164
- Sackett-Lundeen, L.
W.C.P.81
- Sackoff, Judith
D.587
- Sacks, H.
W.B.P.312, M.D.P.45, M.H.O.9
- Sacks, H. S.
Th.A.P.45, T.B.P.29,
W.B.P.88, M.E.P.72, T.H.P.7
- Sacks, Henry S.
W.F.P.3
- Sadaie, Reza M.
Th.C.P.20
- Sadeghi, H.
C.674
- Sader, H.
M.B.P.263
- Sader, H. S.
B.525
- Sadler, A.
Th.B.P.197
- Sadler, A. E.
Th.B.O.24, T.B.P.299,
W.B.P.194, W.B.P.255,
Th.B.P.267, Th.B.P.376,
T.D.P.58, T.D.P.61, D.716
- Sadler, Abigail E.
W.B.P.256, W.B.P.259
- Sadoff, J.
C.553
- Sadok, S.
W.E.P.69
- Safrin, Sharon
M.B.P.48, M.B.P.54, B.526
- Safyer, S.
E.811
- Sagawa, Kimitaka
Th.C.P.141
- Sager, P.
M.B.P.286
- Saggio, I.
M.C.P.105, C.755
- Sahner, D.
C.586
- Saikumar, C.
Th.G.P.24
- Saimot, A. G.
T.B.O.2, M.B.P.225, T.B.P.49,
W.B.P.35
- Saimot, Adrien G.
W.B.P.26
- Saini, S. S.
W.C.P.68
- Saint Cyr-Delpe,
Th.D.P.27
- Saint-Marc, Thierry
W.B.P.55, Th.B.P.247
- Saint-Paul, B.
B.561
- Saint-Paul, M. C.
W.B.P.44
- Sainte-Marie, D.
M.B.P.181
- Sakai, Koji
C.646
- Sakaoka, R.
C.753
- Sakata, K.
Th.C.P.141
- Sakellaropoulos, G.
Th.H.P.15
- Sakuntanaga, Pratom
W.D.O.11
- Sakuragi, J.
M.C.O.6
- Sala, H.
M.B.P.103
- Salahuddin, Z.
Th.C.P.72, Th.C.P.108
- Salahuddin, Z. S.
W.C.P.48, W.C.P.54,
Th.C.P.64, C.740
- Salame, E.
Th.D.P.28
- Salame, Elisa
W.D.P.14
- Salamon, Roger
Th.E.P.16
- Salamon, R.
Th.E.P.17
- Salas, Ana
M.B.P.97
- Salas, T.
C.676, Th.G.O.2
- Salaun, D.
Th.C.P.87
- Salaün, J. J.
M.C.P.48
- Salavecz, V.
T.B.P.96
- Salazar, A.
M.C.P.92
- Salazar, A. M.
W.B.O.43, Th.B.P.284,
Th.B.P.284, Th.B.P.286
- Salazar, Andres M.
Th.B.O.45
- Salazar-Gonzalez, J. F.
T.C.P.19
- Salem, N.
D.538
- Salerno-Gonçalves, R.
B.638
- Salin, J.
M.H.O.12, M.H.P.19
- Salinas, P.
Th.C.O.29
- Salinas, R.
M.A.P.52, T.A.P.114
- Saliu, I.
M.B.P.156, M.B.P.158
- Salk, J.
Th.B.O.44, Th.C.O.46
- Sall, Richard K.
M.B.P.49
- Salla, R.
Th.A.O.19, A.573, W.D.P.87,
Th.D.P.22, W.G.O.21
- Salla, Roger
T.G.P.10
- Salmaso, Stefania
T.A.P.38
- Salmon, C.
Th.B.P.160
- Salmon, D.
M.B.P.179, W.B.P.23
- Salmon, Dominique
W.B.P.36
- Salmon, Patrick
Th.C.P.67
- Salomao, R.
T.B.P.356
- Salomon, N.
M.B.P.90
- Salsitz, E. A.
W.D.P.71
- Salto, C.
D.595
- Saltzman, B. R.
M.B.P.90
- Saltzman, Brian R.
M.B.P.87, Th.F.P.14
- Saltzman, S.
M.A.P.108, A.623, W.B.P.71
- Saltzman, Scott P.
T.D.P.31
- Salvador, J.
T.B.P.356
- Salvaggio, L.
T.B.P.201
- Salwen, M.
Th.D.P.44
- Salyer, P.
Th.E.P.15
- Salzberger, B.
W.B.P.291
- Salzman, N. P.
M.C.O.10, W.C.P.62
- Saman, Eric
W.B.P.105, T.C.P.149, C.672
- Samb, A.
T.G.P.26
- Samb, N.
T.A.P.3
- Samb, N. D.
M.A.P.19
- Sambuc, R.
A.557, T.F.P.3
- Sambula, Sorina E.
D.659
- Samoszuk, M.
Th.C.O.35
- Samowitz, P.
T.D.O.15
- Sampietro, C.
Th.B.P.136
- Sampietro, Carmen
C.556
- Sampietro, S.
M.C.P.43
- Sample, S.
M.B.P.193
- Sampson, G.
T.A.P.104, W.A.P.93
- Sampson, James M.
T.B.P.36
- Sams, R.
M.C.P.68, M.C.P.69
- Samson, J.
M.B.P.17, T.B.P.217,
T.B.P.243
- Samson, Johanne
T.B.P.151
- Samson, S.
M.A.P.107, M.B.P.150
- Samson, Susan
M.A.P.30
- Samsonoff, C.
T.A.P.53
- Samuel, K. P.
M.B.O.22
- Samuel, M.
T.A.O.6
- Samuels, Jonathan E.
T.B.P.52, W.B.P.343
- Samuelson, Agneta B.
W.B.P.129
- Samundi Sankari,
Selvamani
Th.G.P.24
- San Giovanni, D.
W.B.P.197
- San Marco, J. L.
A.557, T.F.O.7, M.F.P.9,
T.F.P.3, T.F.P.10, W.F.P.4
- San Roman, F.
T.B.P.274
- Sanbartolomeo, P.
T.A.P.56
- Sanchez, C.
M.A.P.104, T.B.P.202
- Sanchez, D.
M.A.P.73
- Sanchez, E.
M.A.P.52, T.D.P.85

- Sanchez, Gerardo F.
M.G.P.17
- Sanchez, J. L.
A.514, D.554
- Sanchez, L. R.
W.D.P.52
- Sanchez, Luis A.
E.555
- Sanchez, M.
T.A.P.24, M.G.P.19
- Sanchez-Madrid, F.
Th.B.P.77
- Sanchez-Palmino, S.
Th.C.P.74
- Sand Petersen, C.
Th.B.O.46
- Sandachiev, L.
T.C.P.144
- Sandala, M. L.
M.A.O.42
- Sandblom, Anita
W.E.O.15
- Sande, Merle
M.B.O.29
- Sanders, S.
Th.A.P.81
- Sanderlin, K.
Th.C.P.52
- Sanders, C.
Th.A.P.49
- Sanders, P.
T.B.P.146
- Sanders, S. A.
T.D.P.2, Th.E.P.37
- Sanders, Stephanie A.
T.D.O.21, T.D.P.75
- Sanderson, F.
M.A.P.37
- Sanderson, R.
A.506, E.669
- Sandfort, T. G. M.
W.A.P.97
- Sandfort, Theo G. M.
D.673
- Sandland, A. M.
M.B.P.124
- Sandlin, G.
M.D.P.26
- Sandoz-Tronca, C.
M.B.P.41, Th.B.P.253,
Th.B.P.254
- Sandrini, G.
Th.B.O.20
- Sands, James C.
E.540
- Sandshöv, E.
C.523
- Sandström, E.
Th.B.O.46, W.B.P.114
- Sandström, Eric
W.B.P.83
- Saneyoshi, Y.
Th.B.P.130
- Sangare, A.
Th.A.P.112, A.587, T.B.O.9,
W.B.P.108, C.765
- Sangare, L.
T.G.P.26
- Sangare, Lasanna
Th.G.O.26
- Sangskaphisarn, R.
Th.C.P.91
- Sangwan, I.
T.C.P.81
- Sanhadji, Kamel
C.516
- Saniel, M. C.
T.B.P.377
- Sanjana, Veeraf M.
W.B.P.5
- Sanjuan, A.
Th.A.P.108
- Sankale, J. -L.
M.A.P.117, T.B.P.105,
W.B.P.100, T.G.O.4,
W.G.O.20
- Sankary, Timothy M.
W.A.O.30, B.596, T.D.P.6
- Sannerud, K.
Th.B.O.8
- Sano, M.
W.B.P.192
- Sansom, Eva I.
W.B.P.243
- Sansonetti, P.
W.C.O.44, T.C.P.67
- Santamaría, J. M.
T.B.P.278
- Santiago, D.
D.565
- Santiago, S.
T.B.P.331
- Santo, I.
M.A.P.86
- Santoro, A.
M.B.P.219
- Santoro, D.
W.G.P.1
- Santos, G. H.
T.B.P.285
- Santos, G. W.
W.B.P.305
- Santos Gil, I.
T.B.P.253, Th.B.P.77
- Santos Pinto, A.
T.B.P.357, T.B.P.343
- Santos, O.
M.B.P.74, M.B.P.281,
T.B.P.365
- Santos-Ferreira, M. O.
A.511, M.G.P.2
- Santos-Ferreira, Maria
Odette
M.A.P.84
- Sanusi, Sahid
M.B.P.238
- Sanvodal, Chris
E.782
- Sanz, M. P.
M.B.P.212
- Saracchini, S.
W.A.P.59
- Saracco, A.
D.688
- Saracco, Alberto
M.A.P.48, T.A.P.99
- Saral, R.
T.B.P.285, W.B.P.319
- Sarantakos, G.
E.806
- Saravolatz, L.
W.B.P.86
- Saravolatz, Louis D.
Th.A.P.9, Th.A.P.10
- Sardet, A.
T.B.P.155
- Sarfati, C.
W.B.P.25
- Sarin, P.
Th.B.O.45
- Sarin, P. H.
W.B.P.141
- Sarin, P. S.
M.C.P.13, M.C.P.80, C.592,
C.636, C.637, C.681
- Sarin, Prem S.
C.620
- Sarin, V.
T.C.P.72
- Sarna, S.
T.A.P.18, Th.A.P.34
- Sarnagadharan, M. G.
M.C.P.1, Th.C.P.43,
Th.C.P.123
- Sarov, B.
W.B.P.73
- Sarov, I.
W.B.P.73
- Sarr, I.
W.E.P.4
- Sarracchini, S.
M.C.P.103
- Sarrazin, C.
T.B.P.305
- Sarthou, J. L.
Th.B.P.151
- Sarver, N.
M.C.P.58
- Sasic, M.
Th.B.P.222
- Sass, J.
C.648
- Sasse, H.
T.A.P.38
- Sassoli, V.
W.B.P.206
- Sassou-Guesseau, E.
T.B.O.9, W.G.P.2
- Sastro, J.
M.A.O.41, A.633, Th.D.P.19,
Th.E.P.48, E.515, E.528
- Sata, T.
Th.C.P.96
- Sathe, Sadhana S.
Th.B.P.48
- Satinger, Y.
T.A.P.81
- Satirakorn, N.
M.D.P.19
- Sato, Paul
T.G.P.7
- Sattentau, Q.
C.538
- Sattentau, Quentin J.
C.528
- Sattler, F.
T.B.P.12, T.B.P.22
- Sattler, F. R.
T.B.O.26, W.B.O.5, E.611
- Satyadeo, M.
W.B.P.60
- Satz, P.
W.B.P.221, W.B.P.226,
Th.B.P.200, Th.B.P.288,
Th.B.P.289, Th.B.P.294, B.588
- Satzinger, Walter
M.E.P.57
- Sauer, S.
T.B.P.250
- Sauerwein, H. P.
Th.B.O.38
- Saunders, A.
Th.C.P.24
- Saunders, C. A.
T.B.P.297
- Saunders, E.
E.678
- Saunders, L. D.
W.A.P.27
- Saunders, S.
E.575, T.G.P.13
- Saunders, Susan G.
W.E.P.30, W.E.P.84, E.576
- Saunier, J. F.
B.599
- Saurat, J.-H.
Th.B.P.151
- Saurin, W.
B.558
- Sauvageon-Martre, Hélène
M.B.P.323, M.C.P.57
- Savage, Donald C.
Th.F.P.7
- Savdie, E.
M.B.P.278
- Savoia, A.
C.650
- Sawada, H.
Th.C.P.110

- Sawchuk, R. J.
W.B.O.4, M.B.P.336,
Th.B.P.204
- Sawchuk, Ronald J.
Th.B.P.198
- Sawyer, L. A.
T.C.P.69, C.520
- Sawyer, Leigh A.
T.B.P.281
- Sawyer, T. K.
T.C.P.85
- Sax, Ronald J.
G.502
- Saxinger, C.
Th.A.P.31, M.B.P.201
- Saxinger, Carl
M.A.O.17
- Saxon, A. J.
Th.D.P.77
- Saxon, Andrew J.
W.D.P.85
- Saykin, Andrew J.
W.B.P.224
- Sayre, J.
W.B.P.279
- Sazdovitch, V.
Th.B.P.250, Th.B.P.258
- Scadden, D.
T.C.O.18, W.C.P.78
- Scaggiante, R.
D.623
- Scalia, Vito
M.B.P.174
- Scally, M. J.
Th.A.P.44
- Scalzi, A.
T.B.P.269
- Scandella, C.
W.C.P.8
- Scapini, R.
W.B.P.21
- Scapini, R. L.
G.509
- Scarsella, A.
T.B.P.62, T.B.P.63
- Scarth, J.
T.A.O.25
- Scevola, Daniel
M.B.P.232, Th.B.P.299
- Schaaff, D.
Th.A.P.1, W.B.P.268,
W.D.P.72
- Schable, Charles A.
W.B.P.160
- Schachter, F.
Th.C.P.19
- Schachter, J.
T.D.O.25
- Schaefer, M.
Th.A.P.1, W.B.P.268
- Schaefer, Melodie R.
W.D.F.72
- Schaefer, U.
T.B.P.28
- Schaeffler, Barbara A.
M.G.O.4
- Schaerf, F.
Th.B.P.216
- Schaerf, F. W.
W.B.P.236
- Schaerf, Frederick W.
W.B.P.189, W.B.P.220,
W.B.P.227
- Schäfer, A.
M.B.P.18, T.B.P.378,
W.C.P.53, D.712
- Schäfer, Axel
M.B.P.21, Th.D.P.86
- Schäfer, Ian
T.F.P.9, M.E.O.26, E.775
- Schaffner, W.
D.641
- Schalken, J. J.
W.B.P.126, W.B.P.132
- Schalla, W.
T.B.P.141
- Schalla, W. O.
T.B.P.142
- Schalla, William O.
T.B.P.143
- Schambra, P. E.
T.G.P.17
- Schatz, Benjamin H.
T.E.O.14, M.F.P.1
- Schechter, M.
T.B.O.29, M.H.P.1
- Schechter, M. T.
M.A.O.26, T.A.O.34, T.A.P.69,
W.A.P.58, Th.A.P.33,
W.D.P.92
- Schechter, Martin
W.A.O.6
- Schechter, Mauro
C.568
- Schechter, Martin T.
W.A.P.57
- Schechter, W.
M.D.O.14
- Schedel, I.
M.B.P.280, M.B.P.299,
T.B.P.14, Th.B.P.12
- Schedel, Ingolf
T.B.P.334
- Schedel, J.
M.C.P.143
- Scheffel, James W.
W.B.P.135
- Scheib, R.
M.B.P.205
- Scheib, Rochelle
W.B.P.271
- Scheidtger, C.
Th.A.P.111
- Schellekens, H.
W.C.P.89
- Schellekens, P. T. A.
Th.B.P.87, Th.C.O.1
- Schenker, Inon
T.E.P.13, W.E.P.47
- Scherer, P. B.
M.B.P.303
- Scherer, W.
M.B.P.211
- Scheuler, W.
Th.B.P.275
- Schewe, S.
Th.B.P.181
- Schiantarelli, Clara
M.A.P.63, Th.B.P.194
- Schiattone, M. L.
M.A.P.94, W.B.P.340
- Schiavini, D.
T.B.P.90, T.B.P.219,
W.B.P.155, B.541
- Schick, Uta
W.B.P.235
- Schieck, E.
W.A.P.3
- Schieken, L. S.
T.B.P.262
- Schiff, M. J.
T.B.P.35
- Schiff, Robert
M.B.O.27
- Schiffedecker, E.
Th.B.O.42, M.B.P.265
- Schiffman, G.
M.B.P.37
- Schiller, N.
Th.D.P.15
- Schilling, Robert F.
Th.D.O.15, Th.D.P.42
- Schiltz, M. A.
T.A.P.19
- Schimpf, K.
Th.B.P.142, C.727
- Schinsia, N.
W.E.P.55
- Schinsia, Nicola
T.B.P.345, T.B.P.346
- Schinazi, R. F.
Th.C.O.21, M.C.P.54,
M.C.P.98, M.C.P.115, C.631
- Schinazi, Raymond F.
M.C.P.55
- Schindler, J.
Th.B.O.6
- Schindler, S.E.
W.E.O.7
- Schindler, Stephen E.
T.E.P.74
- Schindzielorz, A.
Th.A.P.88
- Schindzielorz, Andrew H.
G.519
- Schiozawa, C.
M.B.P.165
- Schirm, J.
W.B.P.35
- Schluge, S. P.
Th.D.P.42
- Schliedt, M.
W.C.P.32
- Schliedt, Morten
Th.B.P.347
- Schlacht, I.
T.A.P.111, M.B.P.133,
M.B.P.384, W.B.P.208,
Th.B.P.194
- Schlageter, M. H.
M.B.O.5
- Schliamm, H.
W.B.P.353, W.B.P.375
- Schlech, W. F.
T.B.P.42
- Schlech, Walter F.
Th.A.O.28, W.B.O.10,
T.B.P.268, M.D.P.79, E.743
- Schlenzig, Celia A.
T.B.P.301
- Schüttgen, R.
W.H.P.23
- Schlumberger, H.-D.
C.607, C.623
- Schmal, M. R.
T.B.P.132
- Schmelzer, S.
Th.B.P.332
- Schmid, G.
A.615
- Schmid, I.
M.C.P.24
- Schmidt, D.
M.B.P.35
- Schmidt, E.
W.H.P.10
- Schmidt, H.
W.C.P.117, W.C.P.118
- Schmidt, J.
Th.C.P.135
- Schmidt, Kirsten
A.518
- Schmidt, L.
W.B.P.98
- Schmidt, R.
M.E.P.16
- Schmidt, R. M.
Th.B.P.378, C.617
- Schmidt, Robert M.
W.B.P.77, T.D.P.29, D.524,
W.E.P.26, Th.E.P.55
- Schmidtmayerová, H.
Th.B.P.367
- Schmitt, A.
W.A.P.60
- Schmitt, H. J.
T.B.P.53
- Schmitt, J. M.
M.D.P.88

- Schmitt, M. P.
C.770
- Schmitt, Marie-Paule
C.769
- Schmitt, H.
W.B.P.104, T.C.P.150, C.786
- Schneck, M.
T.B.P.162
- Schneeberger C.
D.622
- Schneeberger, Claudie
M.B.P.316
- Schneider, C.
T.B.P.28
- Schneider, D. J.
A.551
- Schneider, D. Jean
T.A.P.66
- Schneider, J.
T.C.P.96
- Schneider, M.
M.B.P.210
- Schneider, M. M.
T.D.O.34
- Schneider, W.
T.C.P.110
- Schneiderman, N.
W.B.P.181, Th.B.P.159,
T.D.P.42, D.877, D.681
- Schnell, D.
M.E.P.30, E.717
- Schnell, D. J.
W.E.P.1
- Schnellbach, M.
Th.B.P.334
- Schneuwis, K. E.
T.A.P.110
- Schnittman, S.
M.C.O.10
- Schnittman, S. M.
W.C.P.106
- Schnittman, Steven M.
W.C.P.62
- Schnizlein-Bick, Carol T.
T.C.P.52
- Schnurbus, Ralf
Th.B.P.275
- Schochetman, G.
Th.A.P.109, Th.A.P.114,
M.B.P.163, T.B.P.119,
W.B.P.112, W.B.P.113,
W.B.P.160, T.C.P.21, T.C.P.82
- Schochetman, Gerald
T.B.O.36
- Schoel, G.
Th.E.P.33
- Schoen, B.
T.B.P.349
- Schoenbach, V. J.
M.A.O.23
- Schoenbaum, E.
W.B.P.209
- Schoenbaum, E. E.
Th.A.O.24, Th.A.P.101, A.604,
M.B.P.8, T.B.P.173, Th.D.O.2,
Th.D.P.1, Th.D.P.59,
Th.D.P.78
- Schoepf, B. G.
W.D.P.90, D.694, E.812
- Schoepf, Brooks, G.
W.E.P.3, Th.E.P.40, E.762
- Schoepf, C.
Th.E.P.40
- Schöfer, H.
M.B.P.180, M.B.P.275
- Schöfer, Helmut
M.B.P.111, T.B.P.316
- Scholl, D. R.
M.C.P.50
- Schols, D.
Th.C.O.20, M.C.P.75, C.595
- Schols, Dominique
C.550, C.641
- Scholz, D.
Th.C.P.145
- Scholz, G.
Th.B.P.274
- Schooley, R. T.
A.600, W.C.O.43
- Schooley, Robert T.
Th.B.O.6
- Schooley, T. J.
T.C.P.2
- Schörner, W.
Th.B.O.23
- Schoub, B. D.
M.A.P.83, T.G.P.18
- Schoub, Barry David
Th.G.P.15
- Schoumacher, M.
W.A.O.19
- Schrage, H.
W.B.P.209
- Schrager, L. K.
Th.A.P.104
- Schrager, Lewis K.
D.589
- Schram, N.
B.510, D.504
- Schram, Neil
E.688
- Schramm, Carl
W.H.O.3
- Schramm, W.
M.B.P.35, T.D.O.34
- Schrappé-Bäcker, Matthias
W.B.P.291
- Schreiber, M.A.
E.764
- Schrier, Rachel D.
C.531
- Schrinner, E.
C.607, C.623
- Schrode, J.
Th.A.O.29
- Schröder, H. C.
C.606, C.654, W.B.P.163,
Th.B.P.122
- Schröder, K.-H.
Th.B.P.73
- Schroer, D.
Th.A.P.1
- Schuerman, L.
T.B.P.158
- Schull, Diane E.
M.B.P.302
- Schuller, E.
Th.B.P.209, Th.B.P.235
- Schulman, Sam
Th.B.P.6, Th.B.P.15
- Schulof, R. S.
W.B.P.308
- Schulof, Richard S.
Th.B.O.2
- Schulten, Engelbert
Th.B.P.321
- Schultz, Alan M.
M.C.P.27
- Schultz, B.
D.502
- Schultz, S.
M.A.O.34, T.A.P.70,
T.A.P.112, W.A.P.11,
W.A.P.84, W.B.P.57,
Th.D.P.38, D.562
- Schultz, S. J.
W.A.P.12
- Schultz, Peter
C.682
- Schulz, B.
M.C.P.102
- Schulz, Susan Lloyd
M.D.P.43
- Schulz, T.
T.C.P.12, T.C.P.68
- Schulz, T. F.
Th.C.P.10
- Schulz, Thomas F.
Th.C.P.11
- Schulze, W.
W.B.P.95
- Schulze-Werninghaus, G.
Th.B.P.59
- Schumacher, R.
W.B.P.136
- Schumann, J.
W.D.P.85
- Schumann, L. A.
M.B.P.13, M.B.P.15, M.B.P.22
- Schüpbach, Jörg
T.B.P.226, Th.A.P.107
- Schürmann, D.
T.B.P.21, W.B.P.300,
Th.B.P.73
- Schürmann, Dirk
W.B.O.20, Th.B.P.54
- Schuster, D.
Th.B.P.181
- Schutte, C. H. J.
Th.H.P.19
- Schuyler, M.
M.B.P.318, M.E.P.59
- Schwadron, R.
M.B.P.159
- Schwaitsberg, S.
M.B.P.205
- Schwalbach, J. F. L.
Th.G.P.22
- Schwander, S.
T.B.P.39, W.B.P.89,
W.B.P.297
- Schwartländer, B.
M.B.P.21, W.C.P.53,
Th.D.P.86
- Schwartländer, Bernhard
W.A.P.74, Th.B.P.172,
Th.B.P.183, W.H.P.23
- Schwartz, Beverly
E.744
- Schwartz, L.
W.A.P.77
- Schwartz, M.
W.B.P.91, Th.B.P.233
- Schwartz, O.
T.C.P.116, C.658
- Schwartz, Olivier
M.C.P.104
- Schwartz, P.
M.B.P.305
- Schwartz, S.
T.C.O.50, T.C.P.139
- Schwartz, T.
T.B.P.150
- Schwartz, Y.
M.A.P.119
- Schwartzbaum, J.
Th.F.O.7
- Schwartzter, Thomas A.
Th.B.P.125
- Schwarz, Gabriele
M.E.P.38
- Schwarz, W.
M.C.P.56
- Schweighoffer, T.
C.727
- Schwendemann, G.
W.B.P.50
- Schwenzfeier, E. M.
M.D.P.9
- Schwets, N.
Th.B.P.28
- Sciandra, M.
M.B.P.363
- Scimeca, S.
M.B.P.72
- Scltovsky, Anne A.
W.H.O.14, M.H.P.2
- Scofield, V. L.
M.C.O.29

- Scolari, N.**
 M.B.P.206, Th.B.P.191,
 W.D.P.84
Scolaro, M. J.
 B.589
Scolaro, Michael J.
 T.B.O.1, T.B.P.278
Scolfaro, C.
 M.B.P.219
Scott, C.
 W.A.O.4, M.C.P.22
Scott, Daniel
 W.C.O.6, T.C.P.35
Scott, Daniel A.
 Th.C.P.57
Scott, E.
 C.542
Scott, G.
 T.B.P.152
Scott, G. B.
 T.B.P.182
Scott, Gordon R.
 Th.B.P.291
Scott, Gwendolyn B.
 Th.A.O.8, M.B.O.40,
 T.B.O.21, T.B.P.153,
 T.B.P.166
Scott, M.
 C.665, E.718
Scott, R.
 D.861
Scott, R. J.
 W.C.P.142
Scribailo, Steven
 M.E.O.18
Scrobhaci, M. L.
 C.726
Scudder, R.
 T.B.P.169
Seaborn, J.
 E.735
Seadi, C.
 T.B.P.336
Seage, G.
 T.A.O.2, T.A.P.74
Seage, G. R.
 W.H.O.12
Seage, George R.
 Th.A.O.16, Th.A.P.42
Seals, J.
 C.690
Sealy, Godfrey
 M.E.O.5
Seaman, J. D.
 M.B.P.301, C.602, C.619
Seaman, T.
 M.C.P.23
Sears, B.
 Th.B.P.308
Sears, Barry
 Th.B.P.361
Sebbowa, R.
 W.E.O.5
- Seck, Moussa**
 M.E.O.32, W.G.O.35
Seed, B.
 T.C.P.125, C.697
Seeman, R.
 Th.C.O.2
Sefu, L.
 W.E.O.30
Segal, J.
 W.D.P.9, E.527
Segal, S.
 T.C.P.119
Segondy, M.
 M.B.P.131
Segura, A.
 A.504, M.B.P.137, E.674,
 Th.G.O.2
Sehgal, P.
 W.C.O.48
Sehgal, S.
 Th.G.P.9
Sei, Y.
 Th.B.P.182
Sei, Yoshitatsu
 C.609, C.709, D.533
Seibert, D.
 W.A.P.113, A.562
Seidel, E.
 E.748
Seidel, Edward A.
 D.666
Seiden, Dena J.
 T.F.P.4
Seiden, S.
 W.A.P.47, T.B.P.210
Seidl, O.
 T.D.O.34
Seidl, Siegfried
 W.B.P.103
Seidlin, M.
 T.A.P.101, M.C.P.130
Seidlin, Mindell
 T.A.O.17
Seldman, R.
 W.C.P.55
Seifert, M. H.
 M.B.P.262
Seiffert, U. B.
 M.B.P.105
Seifu, M.
 W.G.P.28
Seigneurin, J. M.
 T.B.P.231, C.706
Seigneurin, Jean-Marie
 M.B.P.61
Seitz, S. T.
 Th.A.P.71
Seki, Jun-ichi
 M.C.P.121
Sekla, L.
 M.C.P.27
Selfridge, C.
 T.D.P.12
- Selibórska, Z.**
 Th.D.P.41
Seligmann, M.
 T.B.P.273, C.570
Selik, R.
 W.D.P.24
Selik, Richard M.
 T.A.O.4, T.A.P.37
Selka, L.
 Th.D.P.56
Seli, R. A.
 W.E.P.29
Sell, R. L.
 M.D.O.1, E.560
Seller, L.
 T.B.P.235
Sellers, B.
 Th.C.P.24
Selnes, O.
 Th.B.P.200
Selnes, O. A.
 Th.B.P.206, Th.B.P.218,
 Th.B.P.278, Th.B.P.288
Selnes, Ola A.
 W.B.O.45, Th.B.P.202,
 Th.B.P.271
Seltzer, M.
 T.B.P.53
Seltzer, Michael S.
 T.H.P.25
Selwyn, P.
 Th.A.P.101, T.B.P.173
Selwyn, P. A.
 M.B.P.8, Th.D.O.2, Th.D.P.59
Selwyn, Peter A.
 Th.A.O.24, W.B.P.60,
 Th.D.O.16, Th.D.P.78, E.589
Semands, D.
 Th.E.P.15
Semenzato, G.
 Th.B.P.78, Th.B.P.79
Sempala, S.
 T.B.P.358
Sempértegui, R.
 W.G.P.12
Sen, L.
 C.707
Sena, Armando
 Th.B.P.363
Sena, V.
 Th.B.P.363
Senaldi, G.
 Th.B.P.127
Senderowicz, A.
 W.B.P.285
Senge, P.
 T.G.O.11
Sengupta, D. N.
 T.C.P.98
Senie, Ruby T.
 Th.A.C.15
Senior, J. M.
 M.C.P.35
- Senk, C.**
 M.B.P.23
Senn, D. E.
 T.B.P.101
Senn, H. P.
 Th.A.P.111
Sennerfeldt, P.
 Th.E.O.5, T.E.P.30
Senneville, E.
 W.B.P.248
Senoga, J.
 W.E.O.5, W.E.P.22
Sensenbrenner, L. L.
 M.B.P.147
Sepetjan, M.
 Th.B.P.169, Th.D.P.31, A.548
Sepiashvili, R. I.
 W.B.P.262
Sepkowitz, Kent
 A.548, M.B.P.207
Septimus, Anita
 M.E.P.34
Sepúlveda, J.
 Th.A.P.80, Th.A.P.81,
 W.B.P.179, Th.D.O.11,
 M.D.P.69, W.D.P.14, E.585,
 M.G.O.27, T.G.O.8,
 Th.G.O.29, Th.G.O.30,
 W.G.P.6, W.G.P.25, Th.G.P.16
Sepúlveda, Jaime
 M.G.O.1, T.G.O.9, W.G.P.24,
 G.510
Séréni, D.
 M.B.P.2, M.B.P.34
Sereno, A. B.
 T.B.O.7, T.B.P.364, T.G.P.25
Serfaty, Annie
 T.E.P.37
Sernatinger, J.
 Th.C.P.48
Seroconverters' Registry
 Group
 Th.A.P.89
Seroconverters' Working
 Group
 Th.A.O.22
Serra, E.
 M.B.P.67
Serra, M. S.
 M.B.P.182
Serraino, D.
 W.A.P.59, D.526
Serraino, Diego
 M.A.O.38
Serrand, C.
 T.D.O.20
Serrano, Yolanda
 Th.D.P.66, W.D.O.12
Serre, A.
 W.B.P.32, W.B.P.138,
 W.B.P.167, Th.B.P.113
Serre, Arlette
 Th.B.P.97

- Serwadda, D.
Th.B.P.317, W.C.P.47,
W.D.P.8
- Serwadda, David
M.G.O.14
- Serwonska, M.
M.B.P.193
- Sestak, Phil
M.A.O.26
- Seth, P.
M.B.P.139
- Seth, Pradeep
T.G.P.6
- Sethi, N.
M.B.P.71
- Seto, D.
Th.C.P.65
- Seto, Deborah
Th.C.P.47
- Sette, P.
M.B.P.106, Th.B.P.56, B.597
- Settlage, R.
M.A.P.12
- Settle, J.
A.546
- Severin, J.
W.B.P.134
- Severo, L.
M.B.P.102
- Severo, R.
Th.B.P.66
- Sewankambo, N.
Th.B.P.317, Th.G.O.35
- Seyfried, H.
T.A.P.7
- Seyfried, W.
T.B.P.384, Th.B.P.269
- Seynhaeve, V.
T.B.P.158
- Seyrer, Yann
M.D.P.36
- SF County Community
Consortium
T.B.P.76
- Shacks, S. J.
E.583
- Shaddock, Phillip P.
T.C.P.49
- Shafer, R.
W.B.P.367
- Shafer, Robert W.
Th.B.P.50
- Shafii, A.
T.B.P.2
- Shafik, A.
W.B.P.316
- Shafik, Ahmed
C.603
- Shafik, Hasnaa M.
T.B.P.322
- Shafran, S.
M.H.P.16
- Shah, B.
T.D.P.84
- Shah, J.
W.B.P.42
- Shah, K.
T.B.P.156, B.582
- Shah, Pramod M.
M.B.P.76
- Shah, V. J.
W.B.P.150
- Shahabuddin, M.
Th.C.P.16
- Shahied, S.
W.A.O.7, W.B.P.293
- Shahied, S. I.
C.592, C.620, C.636, C.637
- Shaira-Nahor, Orit
T.C.P.48
- Shakrani, S.
E.613
- Shalit, F.
T.C.P.142
- Shalit, P.
A.602
- Shalwitz, J.
T.D.O.29, T.D.P.13
- Shandera, Wayne X.
W.A.P.45
- Shandilya, L.
T.B.P.225
- Shands, J. W. Jr.
T.B.P.318
- Shank, Peter R.
T.C.P.113
- Shanks, D.
T.B.P.176
- Shanley, J.
C.504
- Shanmuganandan, S.
M.D.P.90, Th.E.P.60,
M.G.P.31, G.506
- Shannon, J.
E.572
- Shannon, W.
M.C.P.65
- Shannon, William M.
M.C.P.125
- Shanson, D.
M.B.P.81, W.B.P.17
- Shao, J.
T.G.O.11
- Shao, John
M.G.O.33
- Shapiro, B.
T.B.P.31
- Shapiro, J. L.
W.A.P.105, T.D.P.77
- Shapiro, M.
T.A.P.45, M.D.P.78
- Shapiro, M. K.
W.B.P.251
- Shapiro, M.F.
E.724
- Shapiro, S.
M.C.P.83
- Shapshak, P.
W.B.P.124
- Sharer, Leroy R.
W.C.P.30
- Sharma, D.
W.C.P.49
- Sharma, N.
E.647
- Sharma, R.
Th.B.P.311
- Sharp, Erica S.
M.A.P.17
- Sharp, Victoria L.
T.B.P.18
- Sharpton, Thomas
T.B.P.327
- Sharrett, Carol S.
E.809
- Shaunak, S.
M.B.P.237
- Shaunak, Sunil
W.B.O.12
- Shaw, G.
M.C.O.7
- Shaw, G. M.
T.C.O.19, T.C.O.20,
T.C.P.126, W.C.P.84
- Shaw, J. F.
W.B.P.60
- She, Y. J.
M.B.P.127
- Shearer, G.
Th.B.P.91
- Shearer, G. M.
W.C.P.57
- Shearer, R. J.
Th.B.P.27, T.E.P.55
- Shearer, W.
T.B.P.148
- Shearer, W. T.
T.B.P.175, T.B.P.236,
T.B.P.266
- Shearman, J.
Th.E.P.10
- Sheba, F.
M.G.P.22
- Sheehan, M.
M.B.P.338
- Sheets, R.
D.509, D.641, E.640
- Sheffield, A.
W.E.P.50
- Shefner, A.
W.B.P.57
- Sheid, E. E.
T.B.P.110
- Shelp, E.
M.F.O.2
- Shelp, Earl
W.F.O.9
- Shelton, B.
Th.A.P.35
- Shelton, J.
W.E.P.41
- Shelton, J. D.
W.A.P.98
- Shen, M. C.
C.754
- Shenkman, Carl
D.711
- Shenson, D.
T.H.P.8
- Shepard, D.
W.H.P.3
- Shepard, D. S.
Th.A.P.70, W.H.P.4
- Shepard, Donald S.
T.H.O.12
- Shepard, H. W.
Th.B.O.44
- Shepard, M.
W.D.P.44
- Shepherd, M.
E.558
- Shepp, David H.
A.556, W.B.P.333
- Sheppard, H.
M.A.P.99, W.C.P.145, C.708
- Sheppard, H. W.
Th.A.P.86
- Sheppard, Haynes W.
Th.A.P.40, Th.A.P.90
- Sheps, S. B.
Th.A.P.33
- Sher, R.
M.E.P.28, M.D.P.48, W.E.P.58
- Sher, Ruben
Th.B.P.161, W.E.P.28
- Sherer, Renslow
W.A.P.113, A.562, M.B.P.47,
M.B.P.260, Th.B.P.49, B.529
- Sheridan, J.
M.D.P.32, T.D.P.27, T.D.P.39
- Sheridan, K.
W.B.O.45
- Sherlock, Christopher H.
W.B.P.172
- Sherman, R. E.
M.E.P.5
- Sherr, Lorraine
W.D.P.12, D.653, Th.E.P.27,
E.677
- Sherring, A.
Th.B.P.361
- Shervington, W.
D.661
- Sherwin, S.
Th.B.O.5, T.B.P.303,
M.C.P.101
- Sherwin, S. A.
M.C.P.137
- Sherwood-Fabre, L.
M.F.P.13, Th.F.P.3

- Sheu, M.
T.C.P.33
- Shevaller, A. F.
T.B.P.91
- Shevchuk, M.
M.B.P.274
- Sheyka, K.
Th.D.P.85
- Shibata, R.
M.C.O.25
- Shiboski, S.
T.A.O.16, M.A.P.99, T.A.P.93,
A.583, Th.B.O.29, Th.B.P.144
- Shiboski, Stephen C.
T.A.P.95
- Shibuta, H.
Th.C.P.110
- Shields, A.
T.H.P.12
- Shields, J.
B.504
- Shields, M.
W.B.O.5
- Shif, B. A.
T.B.P.342
- Shih, J.
A.534, W.B.P.154
- Shih, J. W. K.
C.736, C.738
- Shih, James W.
W.B.P.122
- Shillito, E.
Th.B.P.330
- Shimada, K.
M.B.P.63
- Shimida, N.
M.C.P.121
- Shimizu, Hiroyuki
M.C.P.134
- Shimonaka, H.
M.C.P.79
- Shin, Diana M.
M.D.P.77, E.634
- Shinaberry, R.
T.B.P.220
- Shioda, Tatsuo
Th.C.P.110
- Shipton-Levy, R.
M.E.P.1
- Shiratsuchi, H.
T.C.P.9
- Shivakumar, A.
C.698
- Shneck, Mary
M.B.P.29
- Shoaib, Ibrahim M.
W.E.P.75
- Shockley, Robert K.
T.B.P.136
- Shoemaker, P.
W.E.P.58, E.635
- Sholinsky, P.
T.A.P.40
- Shore, Jacques M.
Th.F.P.5
- Short, R.
B.627
- Shorty, V.
Th.A.P.21
- Showalter, S. D.
M.B.O.22, T.C.P.119, C.666
- Striver, J.
A.521
- Starckshall, Ronny A.
A.507, A.508, T.E.P.72,
W.E.P.35, W.H.P.24
- Shtun, Pamela
E.569
- Shulman, G.
Th.A.O.33
- Shultz, J.
M.A.P.70, T.A.P.43, D.538,
E.695
- Shuster, J.
W.C.P.8
- Shyamala, G.
T.C.P.110
- Sia, D. Y.
M.C.P.40, T.C.P.16, C.544,
C.545
- Sia, Dwo Yuan
M.C.P.41
- Siangkanga, Z.
W.B.P.265
- Sias, J.
W.C.P.58
- Slaw, M.
C.749
- Sibanda, S.
W.G.O.19
- Sibley, K.
E.551
- Sibthorpe, B.
W.D.P.69
- Siby, E.
Th.G.O.31
- Siby, G.
M.A.P.19
- Siby, T.
M.A.O.13, M.A.O.15,
Th.E.P.3, T.G.P.26
- Siby, Tidiane
M.A.P.117, W.G.O.20
- Siccardi, A.
C.578
- Siccardi, Antonio
C.567
- Siddiqi, Q.
W.A.P.105, T.D.P.77
- Sideris, D. P.
C.684
- Sidhu, G.
M.B.P.293
- Sidtis, J.
T.B.P.299
- Sidtis, J. J.
W.B.P.194, W.B.P.256,
W.B.P.259, W.B.P.331,
Th.B.P.197, Th.B.P.257,
Th.B.P.376, T.D.P.61, D.716
- Sidtis, John J.
Th.B.O.24, W.B.P.255,
T.D.P.58
- Sidwell, R. W.
C.512
- Siebel, E.
C.546
- Siede, W. H.
M.B.P.105
- Siegel, F.
M.B.P.297
- Siegel, B.
W.F.P.1
- Siegel, Bary J.
T.B.P.379
- Siegel, D.
M.D.P.6
- Siegel, Joanna E.
Th.A.P.70
- Siegel, K.
D.700, E.527
- Siegel, N. F.
T.H.P.8
- Siegel, R.
W.C.O.49
- Siegenthaler, W.
M.A.P.88, T.B.P.50,
W.B.P.321, M.C.P.83
- Siever, D.
C.749
- Sifris, D.
T.B.P.60
- Sifris, Dennis
W.D.P.47
- Sigal, I. S.
M.C.O.23
- Signorile, Michael
E.737
- Signorini, D. J. H.
M.B.P.109
- Signorini, D. J. H. P.
T.B.P.190, B.534
- Signorini, Dario J. H. P.
W.A.P.51
- Sigurnjak, R.
T.H.P.11
- Silberman, E.
Th.A.P.25, Th.A.P.26
- Sileoni, S.
M.G.O.29
- Silva A.
T.D.P.54
- Silva, A. E.
B.525
- Silva, C. L. P.
G.509
- Silva, E.
E.759
- Silva, G.
D.616
- Silva, M. A.
M.B.P.223, W.B.P.266
- Silva, R.
Th.B.P.37
- Silva, T. J.
T.B.P.228
- Silveira B.
T.D.O.28
- Silver, Sylvia
E.655
- Silverman, R. H.
T.C.P.98
- Silverman, S.
Th.B.P.333
- Silverman, Sol, Jr.
Th.B.P.341
- Silvertson, D.
E.547
- Simader, R.
M.B.P.374
- Simard, C.
M.C.O.11, W.C.O.28
- Simberkoff, M.
T.B.P.118
- Simberkoff, Michael
W.D.P.25
- Similowski, T.
B.546
- Similowski, Thomas
W.B.O.22
- Simmer, Robert L.
C.694
- Simmonds, P.
C.659
- Simmonds, Peter
T.C.P.92, Th.C.P.69
- Simms, C.
W.A.P.85
- Simoës Barbosa, Regina
Helena
E.806
- Simon, C. P.
Th.A.P.64
- Simon, F.
M.B.P.343, T.B.P.340,
Th.B.P.3
- Simon, François
T.B.P.109, Th.C.P.131, C.745
- Simon, G. L.
Th.B.O.2, W.B.P.308
- Simon, R. E. C.
E.733
- Simonds, Anita
T.B.P.85
- Simoneau, J.
Th.A.P.97, W.B.P.181
- Simonetti, J. P.
M.B.P.112
- Simonetti, S. R. R.
M.B.P.112

- Simonnet, F.
M.G.P.26
 Simonsen, J. N.
M.A.P.110
 Simooya, O.
D.723
 Simooya, O. O.
M.A.O.42
 Simor, A.
W.B.P.196
 Simpkins, H.
W.B.P.119
 Simpson, B. J.
T.B.P.228
 Simpson, David M.
M.B.P.330
 Simpson, M.
M.A.P.70, M.A.P.72, D.555
 Simpson, S. H.
W.D.P.49
 Sims, J.
W.A.P.18, T.D.P.21
 Simurda, M. C.
T.C.P.133
 Sinangli, F.
Th.C.P.15, C.646
 Sinangli, Faruk
Th.C.P.17
 Sinclair, Anne L.
C.514
 Sinclair, M.
M.B.P.143
 Sinclair, Rebecca
E.504
 Sinet, M.
Th.G.O.54
 Sinforiani, E.
Th.B.P.281
 Singer, E.
Th.B.P.292, Th.B.P.293
 Singer, E. J.
Th.B.P.236
 Singh, B.
T.C.P.13
 Singh, S.
M.B.P.264
 Singh, Surinder
M.D.P.86, M.H.P.3
 Singh, T.
W.A.P.34
 Singh, T. P.
T.A.P.71
 Singh, Y. N.
M.B.P.139
 Singlas, Eric
M.B.P.344
 Sinicco, A.
W.C.P.50, Th.D.P.39,
Th.D.P.40
 Sinicco, Alessandro
M.B.P.194, M.B.P.219,
Th.B.P.344
 Sinnadorai, G.
W.B.P.141
 Sinuk, V.
E.593
 Sion, F. S.
W.A.P.51, M.B.P.136,
M.B.P.182, M.B.P.257,
T.B.P.190, T.B.P.369, B.532,
B.533, C.700, C.763, D.532,
T.G.P.25, Th.B.P.66
 Sion, Fernando S.
T.A.P.117, W.A.P.70, B.638
 Siopathis, M. R.
T.B.P.191, W.G.O.28
 Sioufi, Habib A.
M.B.P.138
 Sirchia, G.
M.A.O.11
 Sire, J.
Th.C.P.71
 Sire, Josephine
T.C.P.91
 Sirera, G.
A.502, M.B.P.240, M.B.P.245,
M.B.P.251, T.B.P.308,
W.B.P.22, Th.B.P.148,
Th.B.P.234, B.509
 Sirianni, Maria Caterina
C.718
 Sirivichayakul, S.
T.B.P.221
 Sitima, J.
M.B.P.289
 Sittitral, V.
M.D.P.50
 Sittitral, Werarit
M.D.P.19, W.E.P.14, Th.G.O.9
 Sivertson, K.
Th.A.P.12, T.G.P.4
 Sivery, B.
Th.B.P.105, Th.B.P.178
 Sivile, E.
Th.H.P.13
 Siyambango, J.
M.B.P.149, T.B.P.337
 Sjoblom, I.
C.547
 Skahan, Kenneth J.
M.B.P.73
 Skaletski, B.
W.C.P.24
 Skelly, R.
A.506
 Skelly, Regina R.
E.669
 Skidmore, Carol A.
T.A.P.31, C.781, W.D.P.75
 Skidmore, Susan J.
W.B.P.87
 Skiles, P. V.
Th.C.O.31
 Skillman, Donald R.
T.C.P.30
 Skinhej, P.
T.B.P.59, W.B.P.290
 Skinner, H. A.
M.D.P.78
 Skinner, K.
E.807
 Skinner, M.
T.D.O.7
 Skinner, Michael A.
T.C.O.29, T.C.P.93
 Skjaervold, K.
C.686
 Skogstad, M.
Th.D.O.17
 Skolnick, P.
D.533
 Skolnik, Paul R.
Th.C.P.13
 Skörde, J.
T.B.P.375, Th.B.P.45
 Skotnicki, A.
W.B.P.276
 Skoutelis, Athanasios
M.B.P.86, T.B.P.31
 Skovera, F.
T.B.P.180
 Skovron, M. L.
W.B.O.17
 Slade, B.
T.B.P.223
 Slade, H.
T.B.P.254, T.C.P.53
 Slamon, D.
Th.A.P.31, M.G.P.12,
M.G.P.13, M.G.P.14, M.G.P.20
 Slamon, D. J.
Th.A.P.6, C.775
 Slavin, M.
T.B.P.44
 Sligh, J.
W.C.P.52
 Sligh, J. C.
W.C.P.146
 Sligh, Julie M.
Th.B.P.112
 Slikkerveer, L.
M.G.O.9
 Slim, Jihad
T.B.P.2, T.B.P.15, W.B.P.42,
W.B.P.336, Th.B.P.380,
T.H.P.10
 Slivkowski, M.
W.B.P.119
 Sloan, L.
B.595
 Sloan, V.
W.B.P.343
 Sloan, W.
W.D.P.79
 Sloggett, J.
M.E.P.25
 Slots, J.
Th.B.P.350
 Slutkin, Gary
W.G.O.25
 Small, C. B.
T.B.P.52, W.B.P.343,
Th.B.P.351, Th.B.P.352
 Small, J.
W.C.P.17
 Small, P. A. Jr.
E.570
 Smereck, G. A. D.
Th.D.P.43
 Smialek, J.
M.B.O.26
 Smiley, M. L.
A.569
 Smit Sibinga, C. T.
M.B.P.153, T.B.P.131,
T.B.P.354, E.651
 Smit, J.
T.C.O.22
 Smit, L.
C.732
 Smith, A.
M.B.P.346, T.C.P.80
 Smith, A. L.
M.B.P.15
 Smith, A. N.
M.A.P.83, Th.G.P.15
 Smith, Alan
T.C.O.6
 Smith, C. A.
T.A.P.23, A.529
 Smith, C. D.
M.C.P.89
 Smith, Camilla M.
M.C.P.73
 Smith, D.
M.B.P.122, T.C.P.31, D.696,
E.716
 Smith, D. E.
M.B.P.209, W.B.P.17
 Smith, Don
T.B.P.54
 Smith, Don E.
T.B.O.30, M.B.P.175,
T.B.P.66, Th.B.P.328
 Smith, Donald G.
M.B.P.312
 Smith, Else
M.B.P.79, W.B.P.27, W.C.P.55
 Smith, G.
T.B.P.232, Th.B.P.104,
Th.C.O.48, M.C.P.12,
M.C.P.14, E.572
 Smith, George W.
Th.E.P.49
 Smith, H.
Th.A.P.5
 Smith, J.
W.B.O.1
 Smith, J. E.
M.D.P.22

- Smith, J. R. M.
M.B.O.47
- Smith, J. W.
E.709
- Smith, J.W.
M.B.O.13
- Smith, James R.
A.538, M.B.P.292
- Smith, James W.
M.C.P.46
- Smith, L.
T.B.P.153
- Smith, Linda L.
D.501, E.735
- Smith, M.
A.558, W.B.P.333
- Smith, M. D.
T.D.P.62
- Smith, M. U.
M.D.P.59
- Smith, M. V.
M.D.P.16
- Smith, Marilyn S.
M.C.P.82
- Smith, Mark
M.H.O.6
- Smith, Mark D.
E.696
- Smith, P.
W.A.P.21, W.B.O.38,
Th.D.P.45
- Smith, P. C.
D.588
- Smith, P. D.
Th.B.P.94, Th.B.P.175
- Smith, Perry F.
T.A.P.80, Th.D.P.16
- Smith, Phillip D.
W.C.P.68
- Smith, S.
W.H.P.4
- Smith, Stephen C.
T.E.P.46, M.F.P.5
- Smith, T.
M.B.P.247
- Smith, T. J.
M.C.P.132
- Smith, W.
E.597
- Smith, W. A.
W.E.P.30
- Smith, William A.
E.670
- Smits, S. P.
T.D.P.34, G.520
- Smolka, H.
T.B.P.45
- Smothers, K.
M.B.P.319
- Smyly, V.
D.519
- Snart, R. S.
M.C.P.28
- Snart, Ronald S.
T.C.O.15, C.733
- Snee, Thomas H.
M.B.P.309
- Sneed, L.
C.627
- Snell, Cudore L.
W.D.P.31
- Sneller, V.-P.
M.G.P.11
- Sniffen, J.
M.D.P.81
- Sninsky, J.
A.616, Th.B.O.8, B.551,
T.C.O.28
- Sninsky, J. J.
Th.B.O.7, W.B.P.119
- Sninsky, John J.
Th.A.P.110
- Snippe, H.
C.575
- Sno, H.
M.B.P.382
- Snodgrass, W. R.
M.B.P.341
- Snow, S.
M.B.P.186
- Snyder, Frederick R.
Th.D.P.30
- Snyder, Harry W.
W.B.P.310
- Snyder, N.
E.584, E.619
- Snyder, T. L.
Th.C.P.132
- Sobeck, K. A.
D.648
- Sobet, A.
Th.B.P.241, M.D.P.91,
Th.E.O.14, W.E.P.44
- Sobet, Alain T.
W.B.P.364
- Sobel, J.
Th.C.P.147
- Sobesky, G.
Th.A.P.30
- Sobol, R. W., Jr.
M.C.P.136
- Sobota, Michael
T.E.P.5
- Sochnev, A. M.
T.B.P.342
- Sodroski, J.
W.C.O.34, Th.C.P.90
- Sodroski, Joseph G.
M.C.O.22
- Soehn, M.
T.B.P.579
- Soeiro, R.
W.C.P.61, C.715
- Soeiro, Ruy
W.C.P.43
- Sofian, N. S.
M.E.P.27
- Sohlberg, Christian
Th.D.P.68
- Sohlberg, E.
M.A.P.81
- Sohlberg, E. H.
W.A.P.6
- Sohler, M. P.
Th.S.P.189
- Sohmer, P.
Th.B.O.9
- Sojo, Diana J.
M.B.P.59
- Sokal, David C.
Th.A.P.35, E.633
- Solanki, D.
W.B.P.177
- Sölder, Brigitte
T.C.P.12, T.C.P.68
- Soler, Carmen
W.B.P.179
- Solinger, Alan M.
M.B.P.178
- Solis, I.
M.A.O.43
- Solomon, G.
W.B.O.17
- Solomon, G. F.
T.D.P.44, M.A.O.49
- Solomon, Karen
D.562, D.565
- Solomon, L.
T.A.P.58, W.A.P.90,
Th.B.P.206, Th.D.P.79
- Solomon, Liza
T.E.P.43, T.H.P.23
- Solomon, S.
Th.E.O.13, Th.G.P.24
- Solomon, Suniti
G.521
- Soloway, B.
B.507
- Solver, E.
C.526
- Somaini, B.
T.A.O.6
- Somerville, M.
T.F.O.4, M.F.P.7
- Somerville, Margaret A.
T.F.O.11
- Sommadossi, J. P.
M.C.P.54
- Sommadossi, Jean-Pierre
C.631
- Somme, G.
T.B.P.128
- Somme, G.
Th.C.P.86
- Sommereijns, B.
M.B.P.356, Th.B.P.43
- Somorin, A. O.
D.542
- Somorin, J. E.
D.542
- Somse, P.
W.E.P.5, Th.E.P.52, W.G.O.28
- Sonchai, W.
T.G.O.23
- Soncuya, E.
W.B.P.162
- Sondag-Thull, D.
E.623
- Sondag-Thull, Danielle
Th.E.P.21
- Sone, C.
M.B.P.287
- Sonenberg, N.
T.C.O.27, T.C.P.87
- Sonigo, P.
M.C.O.13, T.C.O.41,
W.C.P.34, C.660
- Sonigo, P. S.
C.643
- Sonigo, Pierre
T.C.O.40
- Sonnabend, J. A.
A.620
- Sonnabend, Joseph
C.602, C.634, C.639
- Sonneborn, H.-H.
W.B.P.94, W.B.P.118
- Sonnega, J.
E.562
- Sonnenberg, M.
B.529
- Sönnenborg, A.
W.A.P.52, Th.B.P.88
- Sönnenborg, Anders B.
T.B.P.81, Th.B.P.226
- Sonnenrgård, Ulla
E.592
- Sonoda, S.
B.630, C.582
- Soo, W.
Th.B.O.3
- Soon-Young, Yoon
E.742
- Soraggi, C.
T.B.P.194, T.B.P.196
- Sorelli, S.
D.603
- Sorensen, J.
T.A.O.7
- Sorensen, James L.
Th.D.O.5, Th.D.P.84
- Sorensen, J.
T.A.O.22, Th.D.P.34
- Soriano, E.
M.B.O.37, W.B.P.40
- Soriano, V.
Th.A.P.19
- Soriano, Vincent
M.A.P.81, Th.A.P.22, A.556
- Sorio, R.
M.C.P.103

- Soro, B. N.
M.G.P.25
- Sorrei, Stephen
E.586
- Sorrelli, T. C.
T.C.P.5
- Sorro, B.
A.587
- Sors, H.
Th.B.P.143
- Soscia, F.
T.A.P.113, A.566, E.622
- Soskolne, Colin L.
Th.A.P.74, W.H.P.21
- Soskolne, Varda
W.E.P.1
- Sotheran, J. L.
T.D.P.81
- Sothern, R.
W.C.P.81
- Soto, G.
M.G.P.17
- Soto, Isa
E.557
- Soto, J.
T.A.P.59
- Soto, J. C.
M.A.P.39
- Soto, Julio C.
M.D.P.64
- Soto-Sanchez, E.
M.F.P.3
- Sotomayor, J.
Th.J.10, Th.H.P.12
- Souche, S.
T.C.P.59
- Soudeyns, H.
T.B.O.35, M.C.P.63
- Soudeyns, Hugo
T.C.P.110
- Soudré, R.
Th.G.O.26
- Soudrey, R.
T.B.P.119
- Soulimane, Abdelkrim
W.E.P.69
- Sourdif, Isabelle
D.880, Th.F.P.2
- Sousa, A.
Th.B.P.383
- Sousa, R.
T.B.P.343
- Souterand, Yves
W.H.O.13
- Soutschek, Erwin
Th.C.P.73
- Soutschek, Erwin
Th.C.P.2
- Soutschek-Bauer, E.
W.B.P.94, W.B.P.118
- Souza, Alicia Navarro
D.656
- Souza, L.
M.C.P.52, M.C.P.100
- Souza, M.
M.G.O.8
- Sow, A.
M.A.P.19, M.B.P.195, B.641,
M.E.O.10
- Sow, P. G.
M.E.O.10
- Sowa, P.
E.683
- Sowa, P. E.
T.H.P.9
- Sowder, Barbara J.
W.D.P.57
- Soyinka, F.
Th.D.P.20, W.E.P.51,
Th.E.P.76
- Soyinka, Femi
W.G.O.31
- Spacey, B.
W.B.P.321
- Spacey, B. E. M.
W.B.O.3
- Spadea, T.
T.A.P.5, A.526
- Spanakis, E.
B.620, C.535
- Spångberg, L.
D.590
- Spanish Grp. Study
Infection Drug Addicts
B.610
- Späth, Peter J.
Th.B.P.134
- Spaulding, D.
C.698
- Spear, G. et al.
Th.B.P.90
- Spear, G. T.
Th.B.P.111
- Spear, Gregory T.
T.C.P.21, T.C.P.71, C.558
- Spears, Alice
W.B.P.367
- Spechko, P.
Th.D.P.51
- Spechko, Phyllis
B.645
- Specht, N.
M.E.O.28, E.775
- Specht, Norbert
T.F.P.9
- Spector, D. H.
T.C.O.44
- Spector, S.
T.B.P.8, T.B.P.296,
Th.B.P.223, T.D.P.79
- Spector, S. A.
T.C.O.44, W.C.P.133
- Spedini, G.
M.G.P.9
- Speich, R.
T.B.P.50, Th.B.P.81
- Spellberg, F.
M.G.O.4
- Spence, C. J.
T.B.P.96
- Spence, Christopher
Th.E.P.71
- Spence, R. P.
Th.C.P.59
- Spencer, Brenda E.
W.A.P.100
- Spencer, L.
D.530
- Spencer, N.
W.A.P.85
- Spencer, Nancy E.
W.A.O.21
- Sperling, Rhoda S.
M.A.P.56
- Spicehandler, D.
E.567
- Spiegel, L.
W.F.P.10
- Spiegel, R.
Th.A.P.16
- Spielberg, F.
E.719
- Spiers, Herbert R.
Th.F.P.10
- Spiga, L.
Th.B.P.78, Th.B.P.78,
Th.B.P.79
- Spiliotopoulou, J.
B.544
- Spina, Celsa A.
T.C.P.50
- Spina, M.
M.B.P.248
- Spinazzola, F.
Th.B.P.56
- Spinelli, J.
M.B.O.21
- Spira, A.
W.A.P.100
- Spira, B.
T.B.P.97
- Spira, T.
Th.B.P.93, W.C.P.87
- Spira, T. J.
W.B.P.79, W.B.P.224
- Spire, B.
T.C.P.91, Th.C.P.71
- Spiritos, M.
Th.C.O.25
- Spitzer, R. L.
T.B.P.192
- Spitzer, S.
E.667
- Spivack, H. B.
W.D.P.21
- Spoiden, A.
W.E.P.32
- Sportaza, L.
T.C.P.118
- Spouge, J. L.
Th.C.P.100
- Sprecher, S.
W.A.P.49
- Sprehn, G. C.
W.B.P.224
- Sprenger, Herman G.
W.B.O.35
- Sprengers, Erik D.
W.B.P.96, W.B.P.126
- Spriggs, D. R.
M.C.P.45
- Springer, J. P.
M.C.O.23
- Sprinz, E.
M.B.P.102, T.B.P.336,
W.B.P.20, W.B.P.41,
Th.B.P.47
- Sprinz, Eduardo
W.B.P.48, Th.B.P.36,
Th.B.P.39, W.G.P.3
- Spruston, B.
T.B.P.270
- Spuhler, T.
T.A.O.8
- Sredni, B.
W.B.P.283, T.C.P.142
- Sridhar, N.
G.521
- Sridhar, P.
Th.C.P.95
- Srinivasan, A.
Th.B.O.11
- Srinivasan, Alagarsamy
Th.C.P.31, Th.C.P.32,
Th.C.P.33
- Ssebjenja, Peter
M.E.O.6, T.G.O.13
- Ssenyonga, P.
T.G.O.12
- St-John, R.
M.G.O.2
- St-John, Ronald K.
T.G.P.2
- St-Louis, Michael E.
M.D.P.1
- St-Pierre, S.
M.A.P.23
- St. Arnaud, J.
Th.B.P.300
- St. Clair, D.
W.B.P.222
- St. Clair, R.
W.B.P.229
- St. John, R.
W.E.P.33, W.G.O.16
- St. Lawrence, J. S.
M.D.P.21, M.D.P.22
- St. Lawrence, Janet S.
W.D.P.29

- St. Louis, M.
M.A.O.4, M.A.P.10, M.A.P.16,
W.D.P.24
- St. Louis, M. E.
W.A.P.23
- St. Louis, Michael E.
M.A.O.2
- St. Louis, M.
Th.A.P.16
- Staats, J.
T.E.P.57
- Staats, Joanne
W.B.P.218
- Stable, C.
M.B.P.279
- Stablein, D.
M.C.P.3
- Stafford, A.
C.648
- Stage, T.
E.809
- Stagni, G.
Th.B.P.252
- Stahl, J. P.
Th.B.P.251, Th.B.P.282
- Stahl, C.
T.B.P.144
- Staib, F.
M.B.P.95
- Stall, R.
T.D.P.45
- Stall, R. D.
M.A.O.49, W.A.O.27, T.D.O.8
- Stall, Ronald D.
W.D.P.70
- Stallard, Anna
Th.D.P.81
- Stallard, V.
M.C.P.47
- Staller, J.
W.B.P.120
- Staller, J. M.
W.B.P.121
- Stallings, E.
M.D.P.10
- Stallmann, D.
M.B.P.187, M.B.P.365
- Stamateou, J.
T.B.P.234
- Stamatos, N.
M.C.O.15
- Stambuk, Drago
M.B.P.264, T.B.P.326
- Stammers, D.
T.C.O.4
- Standiford, H. C.
M.C.P.94
- Stanley, B.
T.C.P.14
- Stanley, E. A.
T.A.O.39, Th.A.P.66, C.562
- Stanley, Elizabeth Ann
Th.A.P.71
- Stanley, M.
Th.B.O.9
- Stanley, S. D.
T.C.O.33, M.C.P.22, T.C.P.32
- Stanley, Samuel D.
M.C.O.17
- Stanley, Sharilyn
W.C.P.137
- Stanton, G. J.
T.C.P.54
- Stapinski, A.
T.A.P.7, Th.D.P.41
- Staples, D. J.
T.C.P.85
- Stapleton, D.
T.C.O.35
- Starcher, T.
M.A.O.31
- Starcich, R.
M.B.P.358
- Starkey, D.
W.B.P.52, Th.B.P.218
- Staser, J. A.
W.B.P.133
- Staszewski, A.
Th.B.P.80
- Staszewski, S.
M.A.P.103, T.A.P.10,
Th.A.P.96, A.606, T.B.P.200
- Staszewski, Schlomo
T.A.O.15, W.A.P.3, T.B.P.73,
W.B.P.334
- Stauber, M.
M.B.P.60
- Stávale, J. N.
Th.B.P.38
- Ste-Marie, L.
M.D.P.65
- Steffens, J.
B.534
- Steet, C. M.
W.B.P.74, Th.C.P.126
- Steele, J.
T.B.P.64
- Steele, M.
C.514
- Steele, R. J.
M.F.P.13, Th.F.P.3
- Steenbergen, G.
Th.G.O.4
- Steenman, G.
T.C.P.22
- Stefani, H. A. V.
T.B.P.317
- Stefani, H. N.
W.B.P.31, Th.B.P.40
- Stefanis, C.
Th.D.P.72
- Steffan, A. M.
C.769
- Steffan, Anne-Marie
C.770
- Steffe, Erika
M.B.P.337
- Steffe, Erika M.
M.C.P.113
- Steffen, Robert
M.D.P.25
- Stegagno, M.
M.A.P.8
- Steger, K.
T.B.P.130, W.D.P.81
- Steger, Kathy A.
W.D.P.80
- Stehn, S.
T.C.P.46
- Stehney, M.
W.D.P.4
- Stehr-Green, J.
M.A.O.31, W.A.O.13
- Stehr-Green, Jeanette K.
T.A.O.27, W.B.O.23
- Steibold, M.
M.B.P.95
- Stellen, M.
M.E.P.1
- Steimer, K.
W.C.O.49, W.C.P.8
- Steimer, K. S.
T.C.O.38, W.C.O.40,
Th.C.O.31
- Stein, A. C.
T.A.O.38, Th.A.P.56
- Stein, Barry S.
T.C.O.38, C.772
- Stein, J.
W.E.P.84, E.575, E.576, E.597
- Stein, Robert E.
M.F.O.18
- Stein, S.
M.A.P.24
- Stein, T. Peter
Th.B.P.305
- Stein, Z. A.
T.A.O.40
- Stein, Zena A.
B.577, E.653
- Steinberg, F.
T.D.O.31
- Steinberg, Katherine E.
Th.E.P.57
- Steinberg, W.
W.B.O.38
- Steinhauer, E.
T.B.P.233, Th.C.P.91
- Steinkeller, E.
A.517
- Steinlen, M.
M.E.P.35
- Stelbrink, Hans-Jürgen
Th.C.P.88
- Stellini, R.
T.B.P.269, B.565
- Stempel, Robert R.
T.D.P.24, E.727, E.729
- Stenger, R. J.
M.B.P.243
- Stephens, Clay P.
Th.D.O.9
- Stephens, D.
Th.C.O.22
- Stephens, J.
W.B.P.95
- Stephenson, J.
E.612
- Stepherson, B.
W.D.O.5
- Stephy, E.
M.B.P.345
- Steplight, N.
M.D.P.80
- Stergiou, G. D.
A.612, W.B.P.342
- Sterk, C.
Th.D.O.3
- Sterk, Claire E.
M.D.O.5
- Sterkel, C.
M.B.P.96
- Sterling, C.
W.C.P.102
- Stern, A.
M.H.P.7
- Stern, Adam C.
Th.O.3, M.H.P.6
- Stern, H. A.
W.A.P.109
- Stern, L. S.
A.604, Th.D.P.1
- Stern, M.
W.B.P.355, Th.C.P.104
- Stern, M. D.
W.B.P.110, W.B.P.111,
M.C.P.83
- Stern, Michael
Th.B.P.351
- Stern, P.
D.539
- Stern, Susan A.
Th.G.P.12
- Stern, Y.
W.B.P.222
- Stern, Yankov
W.B.P.192
- Sterzycki, Roman Z.
M.C.P.114
- Stevens, A. M.
Th.E.P.27
- Stevens, C.
W.A.P.34
- Stevens, C. E.
Th.A.P.13
- Stevens, Cladd E.
M.A.P.93
- Stevens, D. A.
T.B.O.5, W.B.P.10

- Stevens, P.
A.521
- Stevens, R.
W.A.P.9, T.B.P.88, T.B.P.240,
Th.B.P.167, Th.D.P.44
- Stevens, R. A.
E.501
- Stevens, Roy W.
M.A.O.16, T.A.P.53
- Stevenson, B.
E.517
- Stevko, B.
Th.B.O.58
- Stewart, J.
Th.C.P.126
- Stewart, J. L.
M.B.P.140
- Stewart, James L.
T.B.P.93
- Stibu, L.
Th.B.P.186
- Stiepan, D.
T.A.O.26
- Stigum, H.
W.A.P.103, D.722
- Stigum, Hein
Th.A.P.59
- Stiles, J.
W.D.P.4
- Stille, W.
T.A.O.15, W.A.P.3, A.606,
Th.B.O.15, M.B.P.76,
T.B.P.73, T.B.P.200,
T.B.P.316, W.B.P.334,
Th.B.P.334
- Stimmel, K.-H.
T.B.P.73
- Stimson, Gerry V.
W.A.P.108
- Stine, K.
M.C.O.17
- Stine, K. C.
T.C.P.32
- Stites, D. P.
W.C.O.40, T.C.P.13, T.D.P.44
- Stitt, Frank W.
W.A.P.72
- Stoddard, A.
M.A.P.108, D.713
- Stoddard, A. M.
T.D.P.31
- Stoebner, P.
Th.B.P.251
- Stoehr, A.
M.B.P.234
- Stögerer, M.
Th.D.P.18
- Stokes, K.
T.G.P.19
- Stoller, E.J.
D.519
- Stome, R.
T.B.P.154
- Stone, C.
M.A.P.65
- Stone, Dace
D.576, W.E.O.17, T.G.P.13,
T.G.P.22
- Stone, F.
D.691
- Stone, G.
T.D.P.33
- Stone, J.
T.H.P.2
- Stone, K. M.
T.A.O.24
- Stone, R. K.
T.B.P.147, T.B.P.168,
T.B.P.265
- Stoneburner, R.
M.D.P.44, W.D.P.60, D.659
- Stoneburner, R. L.
M.A.O.34, T.A.P.112,
W.A.P.16, W.A.P.84, W.B.P.57
- Stoneburner, Rand L.
W.A.P.34
- Stool, E.
M.B.P.235
- Stool, E. W.
M.B.P.377, M.C.P.60
- Storch, G. A.
B.553
- Stororum, J.
M.B.P.382
- Stott, E.
C.502
- Stott, E. J.
W.C.P.7
- Stournaras, C.
C.597
- Stout, L. N.
M.F.O.2
- Stout, R. L.
T.B.P.129
- Stover, E.
B.566
- Strachaz, F.
M.H.P.7
- Strain, J.
M.H.O.9
- Strain, J. J.
T.H.P.7
- Stramer, S.
T.B.P.348
- Stramer, Susan L.
M.B.P.140, M.B.P.164
- Strand, C. L.
W.B.P.150
- Strandberg, B.
C.760
- Strannegard, Ö.
T.B.P.81, W.B.P.129,
Th.B.P.226
- Strantz, I.
Th.D.P.58
- Strapinski, A.
M.A.P.69
- Stratigos, J.
W.C.P.140
- Strawczyński, H.
Th.B.P.7
- Strelb, K.
W.C.O.36
- Strelb, Klaus
T.C.O.47
- Streckert, H. J.
Th.C.P.102
- Streeter, M.
B.539
- Streeter, N.
M.E.P.84
- Streicher, H. Z.
Th.C.P.3
- Streight, R.
E.743
- Stricker, M.
M.D.P.25
- Stricker, R.
M.C.O.13
- Stricker, R. B.
W.C.P.138
- Stricker, Raphael B.
Th.O.19, W.C.O.47
- Strickler, J.
T.C.O.11
- Stricof, R.
W.A.O.8
- Strine, P. W.
Th.A.P.44
- Stritof, S. M.
T.E.P.22
- Strohmeier, G.
M.B.P.100, T.B.P.17
- Strom, R.
T.B.P.361
- Stroobant, A.
A.595
- Strossell, Maurizio
Th.B.P.272
- Stroud, F.
D.661
- Stroup, S.
M.E.P.65
- Struchiner, C.
M.G.P.6
- Struchiner, C. J.
Th.A.P.41, W.D.P.63
- Struchiner, Claudio
M.G.P.4
- Strunc, G.
T.A.P.6
- Strunin, L.
T.D.O.24
- Strunin, Lee
M.D.P.71
- Struthers, C.
T.A.O.33
- Strykowski, H.
W.C.P.94
- Strykowski, H.
B.564
- Stuart, A.
M.E.P.1
- Stuart, Ann
M.E.P.35
- Stuart, Marla L.
Th.A.P.106
- Stüber, D.
Th.B.P.231
- Study Group
T.B.P.282, T.B.P.288
- Stull, Charles
A.596
- Sturchio, E.
Th.C.P.99
- Sturchio, E. S.
Th.C.P.111, C.747
- Sturm, D.
M.B.P.87
- Stute, R.
M.B.P.148
- Stuver, S. O.
Th.A.P.14
- Styer, C.
W.S.P.337
- Stylianou, J.
E.654
- Suarez, C.
W.C.P.81
- Suarez, E. C.
D.670
- Suarez, L.
Th.D.P.26
- Subha,
Th.E.O.13
- Subramanian, S.
Th.G.P.24
- Subramanian, P. T. K.
Th.E.P.60, M.D.P.90,
M.G.P.31, G.506
- Succi, Menezes Regina C.
G.509
- Sudberg, L.
A.613
- Suehiro, S.
C.582
- Suess, K. U.
M.D.P.9
- Suffredini, A. F.
T.B.P.16
- Sufian, M.
T.A.O.12, A.598, W.D.O.5,
Th.D.O.3, Th.D.P.66
- Sufian, Meryll
W.E.P.68
- Sugita, K.
W.C.P.111
- Sugiyama, H.
M.B.P.63

- Suhadolnik, R. J.
M.C.P.136
- Suhartono, H.
C.607
- Suleiman, G.
T.A.P.17, T.B.P.194
- Suleiman, J.
T.A.P.17
- Sulis, E.
Th.B.P.158
- Sulis, Effasio
T.B.P.292
- Sulis, M. L.
T.B.P.292
- Sullam, Paul
E.703
- Sullam, Paul M.
M.B.P.375
- Sullemann, J.
M.B.P.40
- Sullivan, J.
T.A.P.29, T.A.P.35, M.C.P.17,
T.C.P.24
- Sullivan, J. L.
T.A.P.109, T.B.P.209
- Sullivan, John
M.C.O.2
- Sullivan, John L.
W.B.O.25
- Sullivan, K.
M.A.P.73
- Sullivan, M. T.
M.B.P.146
- Sullivan, Marian T.
C.775
- Sullivan, Timothy J.
Th.B.P.117
- Sulzberger, Judith
W.B.P.285
- Sum, Shirley Y. W.
Th.A.P.117
- Sumaya, Ciro V.
Th.B.P.23
- Summers, D.
Th.D.P.11, Th.D.P.25, E.549
- Summers, M. D.
C.627
- Sumser, J.
M.D.P.53, D.633, E.667
- Sun, D.
W.B.P.293, M.C.P.37
- Sun, D. K.
M.C.P.80, C.620
- Sun, D. K. L.
C.636, C.637
- Sun, Daisy K. L.
C.592
- Sun, Di
Th.B.P.171
- Sun, Nora C.J.
W.B.P.124
- Sundaraman, S.
G.521
- Sundaraman,
Swaminathan
Th.E.O.13
- Sunderland, A.
M.B.O.2, M.E.O.16
- Sunderland, Ann
W.D.P.58
- Sundet, J. M.
Th.A.P.59, D.722
- Sundet, Jon Martin
W.A.P.103
- Sunkara, Prasad S.
M.C.P.117
- Sunstrom, James C.
M.B.P.147, Th.C.P.147
- Surick, Iona W.
T.A.P.89
- Susser, Ida
E.520
- Susser, Phyllis L.
M.E.P.42
- Sussman, A.
M.E.O.16
- Sutherland, L.
M.B.P.241
- Sutherland, S.
A.594, W.B.P.81, T.D.P.20
- Sutherland, Sheena
T.A.P.55
- Sutherland, W. D.
Th.G.P.18
- Sutton, L.
M.H.P.24
- Suurmeyer, T.
E.651
- Suvakovic, V.
Th.B.P.222
- Suvorova, Z. K.
W.B.P.131
- Suzan, Marie
Th.C.P.87
- Svennecke, B.
Th.D.P.21
- Svennerholm, B.
T.C.O.37
- Svensen, S.
Th.D.O.17
- Sverha, S.
E.605
- Sverha, S. K.
M.F.O.2
- Svirskia, Regina V.
T.B.P.342
- Svtjetlicic, S. M.
T.E.P.22
- Swales, Thomas P.
T.B.P.182
- Swan, D.
Th.C.P.32
- Swanda, R.
W.B.P.180
- Swanevelde, C.
Th.H.P.19
- Swanson, Cheryl Elaine
W.B.P.350
- Swanson, P.
Th.A.P.21, B.636
- Swanstrom, R.
T.C.P.130
- Swantee, C.
W.B.P.176
- Swarthout, David B.
D.555
- Swash, M.
Th.B.P.374
- Swatzei, C.
M.A.P.28
- Sweat, M.
W.A.P.38
- Sweedish Study Grp. on
Contact Tracing
W.A.O.24
- Sweeney, P.
T.A.O.10
- Sweeney, P. A.
M.A.O.20
- Sweeney, Patricia A.
W.D.O.1
- Sweet, D. M.
W.B.O.44, W.B.P.199,
T.D.P.13, T.D.P.44
- Sweet, R.
C.528, C.553
- Sweet, R. L.
M.B.P.33, M.B.P.54, T.B.P.198
- Sweet, Raymond W.
W.C.O.12
- Sweetlove, P.
M.D.P.67
- Sweha, A.
W.A.P.118, W.D.P.79
- Swenson, B.
W.C.O.49
- Swenson, C. L.
M.C.P.69
- Swenson, Cheryl L.
M.C.P.68
- Swenson, P. D.
M.A.P.61
- Swerdlow, B.
C.663
- Swiatek, G.
C.637
- Swinney, R. S.
M.B.P.285, T.B.P.10
- Swiss Clin. Task Force on
AIDS
W.B.P.326
- Swiss Group for Clinical
Studies on AIDS
Th.B.P.322
- Sy, A.
W.E.P.4
- Sy, E. R.
T.B.P.55
- Sy, F.
Th.D.P.11, D.641, E.640
- Sy, Francisco
D.647
- Sy, Francisco S.
M.D.P.80, Th.D.P.25, E.549,
E.752, E.758
- Sy, M. T. A.
Th.G.O.31
- Sydov, M.
T.C.P.16
- Sylvestre, D.
W.B.P.380
- Synder, H. W.
T.B.P.287
- Syndulko, K.
Th.B.P.236, Th.B.P.292,
Th.B.P.293
- Syu, W. J.
T.C.P.51
- Szabó, B.
W.C.P.92
- Szapocznik, J.
W.B.P.190
- Szebeni, János
M.C.P.42, T.C.P.58
- Szegedi, G.
T.C.P.140
- Szeleányi, J.
M.C.P.146
- Szewczyk, L.
M.B.P.315
- Szmelcman, S.
T.C.P.116
- Sztejn, M. B.
Th.B.O.2
- Sztejn, Marcelo B.
W.B.P.308
- Szterling, L.
M.B.P.167, D.709
- Szeberg, Björn B.S.
W.B.P.290
- T**
- T'So, P. O. P.
M.C.P.85
- Tabak, I.
M.B.P.323
- Tabori, J.
E.650
- Taburet, A. M.
M.B.P.344
- Taccami, L.
A.566
- Tacconi, F.
B.545
- Tachibana, N.
Th.A.P.14
- Tachibana, Nobuyoshi
B.633
- Tackett, C.
T.A.P.16, M.C.P.37

- Tacket, C. O.
C.586
- Tackett, C.
Th.C.O.33
- Taddeo, B. M. R.
M.C.P.105, C.755
- Tadessa, M.
T.A.P.102
- Tadler, M. B.
W.B.P.130
- Taelman, H.
T.B.P.251
- Taerk, G.
M.D.P.58
- Tafuya, T.
T.D.O.13
- Tafuya, Terry
W.D.P.32
- Tager, I. B.
M.B.P.375
- Tagliaferrri, F.
C.718
- Tai, C.
Th.C.P.115
- Tai, Chang-Chih
Th.C.P.25
- Tailan, B.
T.B.P.20, W.B.P.44,
W.B.P.366, B.524
- Tailan, Bruno
M.B.P.250
- Taitt, Branford
W.G.O.37
- Takahashi, H.
W.B.P.292
- Takahashi, Ichiro
Th.C.P.145
- Takahashi, K.
M.C.P.121
- Takama, M.
Th.C.P.145
- Takasaki, Tomohiko
W.C.P.111
- Takatsuki, K.
W.C.O.38, M.C.P.5
- Takayama, H.
M.C.P.118
- Takeda, Augusta K.
T.B.P.132
- Takeoka, Yuichi
C.582
- Takeuchi, T.
M.C.P.121
- Takeuchi, Yasuhiro
Th.C.P.134
- Takita, T.
M.C.P.121
- Tai, M.
T.D.P.36, T.D.P.67
- Talae, N.
T.B.P.65
- Talavera, J. C.
A.534
- Talavera, W.
M.C.P.123
- Talberg, J.
B.535, B.534, D.638
- Taleb, M.
W.E.P.69
- Tallet, S.
M.B.P.347, Th.B.P.166
- Tam, Janice Y.
M.B.P.334
- Tam, M.
M.G.O.4
- Tam, Milton R.
E.719
- Tamalet, C.
M.B.P.130
- Tamalet, Catherine
B.628
- Tamalet, J.
B.628
- Tamburini, Mario
W.B.P.117
- Tamburrini, E.
M.B.P.229
- Tamburrini, Enrica
M.B.P.230, Th.B.P.96,
Th.B.P.99
- Tame, J.M.
T.E.P.65
- Tammus, L. M.
D.543
- Tamura, S.
W.C.P.37
- Tanaka, K.
W.C.P.43
- Tanaka, Kathryn E.
C.715
- Tang, Alan L.
C.633
- Tang, L.
B.635
- Tang, Shen-Bei
Th.C.P.51
- Tanibata, P. R.
D.604, E.781
- Taniguchi, A.
W.C.P.36
- Tanjies, T.
M.C.P.113
- Tanneau, F.
W.C.O.44, C.524
- Tannenbaum, M.
M.B.P.274
- Tanner, C.
Th.A.P.20
- Tanzi, E.
M.C.P.43
- Tao, Pei-zhen
B.626
- Tapia, Roberto C.
T.H.O.11
- Taranta, A.
M.B.P.89
- Tarantini, K.
M.C.P.123
- Tarantini, M.
M.B.P.16
- Tarantola, D.
W.G.O.25, M.H.O.2
- Tarantola, Daniel
Th.G.O.19
- Tarantola, Daniel J. M.
W.G.O.18
- Tarantola, T. D.
T.E.P.59
- Tardalo, F.
Th.D.P.66
- Tardieu, M.
T.B.P.170
- Tardieu, Marc
M.B.O.39, W.C.P.113
- Tardio, J.
Th.B.P.121
- Tarkington, A.
M.D.O.14
- Tarocchi, Angiolo
E.814, E.790
- Taroyan, S.
T.G.P.20
- Tarpley, Gary
T.C.P.109
- Tarpley, W. G.
C.687
- Tarras, S.
M.B.P.329
- Tartaglione, T.
M.B.P.9
- Tartaglione, Teresa
M.B.P.332
- Taruscio, Domenica
Th.B.P.252
- Tarussova, Natalya
T.C.P.145
- Taskov, H.
B.613
- Tate, R.
W.D.P.20, Th.D.P.56
- Tateno, M.
T.C.O.21
- Tatsumi, M.
Th.C.P.142
- Tauris, P.
Th.B.P.106
- Tavares, I.
M.A.P.77, W.B.O.21
- Tavares, Luis
Th.B.P.123
- Taveres, J.
T.D.O.20
- Tavolato, B.
Th.B.P.225
- Tawil, O.
M.G.O.18, T.G.O.7
- Taylor Castillo, Mayra
Lizeth
B.511
- Taylor, C.
M.A.P.28, M.B.P.342,
Th.F.P.10
- Taylor, Clark L.
M.H.P.24
- Taylor, D.
T.E.P.7, W.G.P.19
- Taylor, D. N.
Th.B.P.285
- Taylor, E.
M.A.P.26, Th.A.P.20
- Taylor, E. W.
Th.C.O.21
- Taylor, Ethan Will
C.625
- Taylor, G.
T.B.P.38, Th.B.P.67
- Taylor, Geoffrey D.
Th.H.P.6
- Taylor, J.
W.A.P.68
- Taylor, J. M. G.
W.A.P.62
- Taylor, K. M.
M.D.P.74
- Taylor, Kathryn M.
M.D.P.78, Th.E.P.53
- Taylor, L.
Th.B.P.14
- Taylor, M. B.
Th.H.P.19
- Taylor, M. E.
T.C.O.19
- Taylor, P.
M.C.P.117
- Taylor, P. E.
M.A.P.93
- Taylor, Patricia E.
Th.A.P.13
- Taylor, R.
T.B.P.141
- Taylor, R. N.
T.B.P.143
- Taylor, Roger
T.B.P.142
- Taylor, S. E.
T.D.O.23
- Taylor, T.
M.B.P.258
- Taylor-Robinson, D.
M.B.P.292
- Tecson-Tumana, F.
A.553
- Tedde, A.
T.B.P.292
- Tedder, R.
M.B.P.149
- Tedder, R. S.
T.B.P.332, Th.C.P.59,
Th.C.P.128, M.G.O.5
- Tedder, Richard S.
W.A.O.9

- Tee, D. E. H.
Th.B.P.127
- Teglbjærg, Lars
W.B.P.280
- Teglbjærg, Lars L. S.
T.B.P.103
- Tegtmeler, G.
Th.A.P.119, M.B.O.27
- Tellet, F.
M.B.P.197
- Tellet-Thiebaud, F.
M.B.P.197
- Teixeira Goudiaby, J. M.
M.G.P.16
- Teixeira, E.
B.532
- Teixeira, G. B.
M.B.P.74
- Teixeira, Paulo
D.540
- Tejada, A.
Th.D.O.7, Th.H.P.17
- Tekaia, F.
C.564
- Teles, L.
Th.E.P.46
- Teles, L. C.
A.512
- Tello, O.
A.575, A.578
- Telzak, E.
T.A.P.112
- Telzak, E. E.
M.B.P.207, W.B.P.57
- Telzak, Edward E.
M.A.O.34
- Tembo, G.
M.A.O.37, W.A.P.54, Th.G.O.4
- Tembo, George S.
M.G.P.23
- Temelso, T.
W.A.P.80
- Temmerman, M.
Th.B.P.324
- Temmerman, Marleen
Th.G.O.53
- Temoshok, L.
T.B.P.329, W.B.P.199,
M.D.P.76
- Temoshok, Lydia
W.B.O.44, T.D.O.29,
T.D.P.13, T.D.P.44
- Tempesta, R.
M.B.P.243
- Temu, Dorothy
T.F.O.21
- Ten Kate, R. W.
Th.B.P.321
- Ten Kortenaar, P.
W.B.P.96
- Ten Veen, J.
T.B.P.323
- Tendler, C.
M.E.P.1
- Tenner-Racz, K.
W.C.P.117
- Tenner-Racz, Klara
W.C.P.118
- Tenneriello, T.
E.533
- Tenscher, K.
M.B.O.24
- Tepper, B.
Th.C.P.106
- Teppo, A. M.
W.C.P.114, W.C.P.115
- Terpstra, F. G.
Th.C.O.1
- Terragna, A.
M.B.P.324, T.B.P.252
- Terry, H.
W.A.P.86
- Terry, P.
M.A.P.57
- Terry, R.
W.B.P.122
- Terry-Mollinet, Hector
W.F.O.19
- Tersmette, M.
W.B.P.157, W.C.P.56
- Tersmette, Matthijs
M.C.O.8, W.C.P.46
- Terstege, Klaus
Th.B.P.274
- Terwilliger, E.
W.C.O.34, T.C.O.49
- Terzi, R.
M.B.P.351
- Tessitore, J. H.
W.B.P.328
- Testa, J.
M.B.P.185
- Testa, S.
Th.B.P.1
- Testa, Sofia
Th.B.P.2
- Tetanye, Ekoe
T.A.P.1
- Teixeira, P.R.
T.E.P.49
- Thager, G. K.
W.B.P.7
- Thakur, V.
T.D.P.84
- Thaler, H.
W.B.P.256
- Thaler, H. T.
Th.B.O.24
- Thampatty, P.
Th.C.O.28, Th.C.P.14
- Thara, F.
Th.E.O.13
- Thaul, S. J.
M.H.O.8
- The commissioner's Task
Forse on AIDS
E.695
- The, T. H.
W.B.O.35
- Thea, Donald
W.C.P.102
- Thelen, V.M.
M.E.P.8
- Theobald, S.
C.745
- Theocharis, T.
Th.D.P.11, Th.D.P.25, E.549
- Theodoropoulou, M.
B.620, C.597
- Therrell, B. L. Jr.
Th.D.P.26
- Theunissen, H. J.
W.B.P.96
- Thiagarajan, S. P.
G.521
- Thiam, D.
T.B.P.105, W.B.P.100
- Thibierge, M.
M.B.P.196, Th.B.P.254
- Thibodeau, Lise
M.C.P.29
- Thielan, B. J.
T.C.P.122
- Thiele, B.
Th.A.P.29
- Thiele, Bernhard
Th.B.P.153, Th.B.P.154, C.517
- Thimothé, Gabriel A.
W.G.P.31
- Thin, R. N.
M.A.P.58, C.633
- Thion, I.
M.A.O.13, M.A.P.117,
W.G.O.20, Th.G.O.31
- Thioux, C.
D.655
- Thiriart, C.
Th.C.P.34
- Thirion, X.
T.F.P.11
- Thirion, Xavier
T.F.P.3
- Thomas, A.
Th.D.P.37
- Thomas, G.
M.B.P.371
- Thomas, J.
T.A.P.43, Th.B.P.33
- Thomas, P.
W.A.O.13, T.A.P.70, T.A.P.71,
W.A.P.9, T.B.P.370
- Thomas, P. A.
W.A.P.11, W.A.P.12,
Th.B.P.372
- Thomas, Pauline A.
Th.A.O.7
- Thomas, R.
W.A.P.102, W.B.P.329
- Thomas, R. J.
Th.A.P.28
- Thomas, R. V.
Th.B.O.4, W.B.P.327,
M.C.P.137
- Thomas, Réjean
W.E.P.11
- Thomas, S.
T.B.P.67, T.B.P.79
- Thomas, Simon H. L.
T.B.P.57
- Thomas, Steven G.
T.D.O.3
- Thompkins, J.
Th.B.O.3
- Thompkins, Jennifer E.
M.B.P.328
- Thompson Williams, V. G.
D.620
- Thompson, B. B.
C.625
- Thompson, C.
W.B.P.201
- Thompson, Carolyn
E.722
- Thompson, E. G.
Th.D.P.26
- Thompson, Ian L.
M.B.P.278
- Thompson, Imani P.
T.E.P.17
- Thompson, Jerrol C.
A.553
- Thompson, L.
T.B.P.331, W.B.P.182
- Thompson, R. L.
Th.O.2, T.H.P.12
- Thompson, S.
M.B.P.346
- Thoms, G.
E.538
- Thomsen, Donald L.
T.H.P.28
- Thomson, A.
Th.D.P.3, D.612
- Thomson, M.
M.B.P.132
- Thomson-Honnobier, G.
T.C.O.32
- Thorlie, I. D.
W.G.P.16
- Thorn, R. M.
Th.A.P.118, B.635
- Thorn, Richard M.
C.690
- Thornby, J.
M.D.O.15, W.D.P.5, E.763
- Thornton, A.
C.620
- Thornton, A. H.
C.592

- Thornton, C.**
 Th.A.P.5, M.B.P.289
Thornton, Charles A.
 Th.B.P.214, Th.B.P.217
Thornton, David
 T.D.P.69
Thornton, G. B.
 M.C.P.15, M.C.P.67
Thorpe, A.
 T.B.P.160
Thorpe, K. E.
 W.H.O.12
Thorsby, E.
 T.C.P.20
Thorstenson, R.
 W.C.P.141, E.718
Thorstenson, Rigmor
 T.B.P.104
Thraenhart, O.
 Th.B.P.185
Thresher, R.
 M.C.P.82
Thuillard, F.
 Th.B.P.212
Thurn, J.R.
 Th.E.P.29
Thurn, Joseph R.
 M.B.P.85, M.D.O.13
Thys, R.
 W.B.P.139
Thyss, A.
 M.B.P.295
Tice, J.
 T.E.O.3
Tielman, R. A. P.
 W.A.P.97, D.673
Tielman, Robert A.P.
 M.D.P.34, Th.E.O.16
Tiendrebeogo, H.
 M.G.P.26
Tiendrebéogo, H.
 Th.G.O.26
Tierney, A.
 M.B.P.135
Tierney, A. R.
 Th.B.O.37, W.B.P.38,
 Th.B.P.312
Tierney, M. R.
 Th.B.O.6
Tierno, P. M.
 M.B.P.36
Tiessens, G.
 M.B.P.121, M.B.P.134,
 W.B.P.2
Tijmstra, T.
 E.651
Till, M. A.
 M.C.P.129, T.C.P.7
Till, Mark A.
 Th.C.O.14
Tillery, S.
 W.C.P.18
Tilley, S. A.
 T.C.P.70
Tilly, B.
 Th.E.P.16
Tilson, H.
 M.B.O.45
Timm, H.
 M.B.P.120, M.B.P.125
Timmerman, Arthur
 W.B.P.116
Timothée, Gabriel
 Th.G.O.46
Timperi, R.
 M.A.O.25, E.711
Timsit, F.
 B.530
Tindall, Brett D.
 T.D.P.35
Tinelli, Marco
 B.517
Ting, R. C.
 Th.C.P.25
Ting, R. C. Y.
 C.750
Tiollais, P.
 W.C.P.34
Tirado, J.
 T.B.P.137, T.B.P.138
Tirelli, U.
 M.A.P.48, W.A.P.59,
 Th.D.P.38, Th.D.P.40, D.526
Tirelli, Umberto
 Th.C.O.40, M.C.P.103,
 W.C.P.50
Tirelli, V.
 M.A.O.38
Tisdale, M.
 T.C.O.4
Tishman, E.
 T.D.P.3
Tisne, B.
 T.B.P.309
Tisseron, S.
 T.D.P.53
Titti, F.
 W.B.P.146
Titti, Fausto F.
 W.C.P.119
Titti, M.
 B.518
Tivey, Bob
 W.E.P.10
Tjøtta, Enok
 Th.C.P.112
Toba, H.
 T.C.P.9
Tobey, E.
 W.D.P.15
Tobin, Ellis H.
 C.521
Tobin, F.
 M.H.P.22
Toboz, J. P.
 Th.B.P.95
Todak, G.
 W.B.P.192, Th.B.P.261,
 W.F.P.2
Todini, G.
 W.E.P.45
Toigeiro, S. M. G. P.
 Th.B.P.63
Tokiyoshi, S.
 M.C.P.5
Tokugawa, D.
 W.D.P.28
Toledano, S.
 T.B.P.261
Tolosa Sarro, E.
 Th.B.P.193
Tolson, K.
 W.B.P.240, W.B.P.246
Toma, Emil
 M.B.O.14, T.B.O.31
Tomasi, L.
 E.799
Tomasi, T.
 Th.B.P.282
Tomasik, Z.
 T.B.P.226
Tomasselli, A.
 C.683
Tomasselli, Alfredo G.
 T.C.P.85
Tomford, W. W.
 A.600
Tomich, C.-S. C.
 T.C.P.85
Tomich, Che-Shen C.
 C.683, C.687
Tomita, M.
 M.B.P.303
Tomoda, I.
 W.C.P.21, W.C.P.36
Tompkins, M.
 W.C.P.39
Tompkins, W.
 W.C.P.39
Tondreau, S.
 T.B.P.102
Tonduangou, K.
 Th.H.P.15
Tonjas, T.
 M.B.P.345
Tonjes, T.
 M.B.P.337
Tonnesen, G.
 W.B.P.336
Toomey, Kathleen E.
 W.A.O.22, W.D.P.26
Toomey, M.
 M.D.O.12
Tooth, G. K.
 C.545
Tor Aguilera, Jordi
 Th.A.P.19, T.D.P.65,
 Th.D.P.57, D.699
Tor, J.
 M.A.P.81, T.A.P.114,
 W.A.P.71, Th.A.P.22, A.502,
 A.504, A.566, B.509
 M.B.P.240, T.B.P.308,
 Th.B.P.148, Th.B.P.335,
 T.D.P.64, D.613
Torabi, M. R.
 E.680
Torabi, Mohamad R.
 D.549
Toraker, Per O.
 D.580
Torelli, G.
 T.B.P.235
Tormey, M. P.
 M.B.P.68
Tornaghi, R.
 W.B.P.200
Tornero, P.
 T.B.P.215
Tornesello, M. L.
 W.C.P.51
Toro, L.
 Th.B.O.45, T.C.P.66, C.567
Toro-Alfonso, José R.
 Th.E.P.67
Torpey, David J.
 T.C.P.5
Torquato, S.
 Th.D.P.76
Torre, Donato
 Th.B.P.136
Torre, T. D.
 C.556
Torrebadella, M.
 M.B.P.98
Tórrés, G. F.
 T.B.P.193
Torres, J.
 M.B.P.28, Th.D.P.19,
 T.E.P.73, Th.E.P.48, E.515,
 E.526
Torres, José
 A.544, M.H.P.21
Torres, L.
 Th.D.P.66
Torres, M. Cristina
 D.550
Torres, R.
 W.B.P.60
Torres, Ramon A.
 M.A.P.51, T.B.P.75, T.E.P.57,
 E.691
Torres, Y.
 W.B.P.165
Torres-Anjel, Manuel J.
 A.532, W.C.P.14
Torres-Mendoza, B.
 M.F.P.3, G.516

- Torres-Mendoza, B. M.**
 W.G.P.23
Torres-Mendoza, Blanca
 M.G.P.10
Torrey, Barbara B.
 T.B.P.352
Torstensson, R.
 B.548
Tortolero, S.
 D.696, E.716, Th.P.22
Tortorano, A. M.
 M.B.P.94
Tosi, P. F.
 C.627
Tosini, G.
 B.597
Tosswell, J.
 Th.C.P.105
Tostes, M.
 W.B.P.203
Tosteson, A. N. A.
 T.B.P.68
Tóth F.
 W.C.P.92
Toth, G.
 M.C.P.41
Toth, G. K.
 M.C.P.40, C.544
Toubert, M. E.
 M.B.O.5
Touraine, F.
 Th.B.P.147, Th.B.P.149,
 Th.B.P.247, Th.B.P.365, C.628
Touraine, J. L.
 T.B.P.47, W.B.P.55,
 W.B.P.296, Th.B.P.147,
 C.516, C.628
Tourani, J. M.
 Th.B.P.143, Th.C.O.39,
 Th.C.P.104
Tourani, Jean-Marc
 W.B.P.355
Toure, O.
 W.E.P.4
Tourette-Turgis, Catherine
 T.E.O.2
Tourigny, Sylvie C.
 E.524
Tourtelotte, W. W.
 W.A.P.77
Tourtellotte, Wallace W.
 Th.B.P.236, Th.B.P.292,
 Th.B.P.293
Tousignant, Y.
 M.D.P.33, D.534, Th.E.P.26
Tousignant, Yves
 M.D.P.65
Toussaint, M.
 M.B.P.284
Tovey, G.
 W.B.P.46
- Tovo, P.**
 M.B.P.324
Tovo, P. A.
 W.B.P.144, B.540
Towsend, J.
 E.585, T.G.O.9
Toy, P. T. C. Y.
 M.B.P.166
Tozzi, V.
 Th.B.P.56, Th.B.P.256, B.597
Trachtenberg, A. I.
 T.A.O.7
Tradati, C.
 E.790, E.814
Tradati, F.
 T.A.P.116
Tracén, Bente
 T.D.P.5
Traficanti, K.
 D.627
Trahan, B.
 W.A.P.8
Trainin, Ze'ev
 C.522
Tramont, E.
 W.A.P.66, Th.B.P.155
Tramont, E. C.
 T.D.P.59
Transfusion Safety Study Group
 T.A.P.106, Th.A.P.32,
 Th.A.P.105, Th.A.P.106,
 Th.B.P.108, M.B.P.144,
 M.B.P.145
Traore, A.
 T.B.P.373
Traore, Bougary
 T.B.P.41
Traoré, E.
 M.G.P.26
Traore, M.
 M.G.P.25
Traore, S.
 A.577
Trapido, E. J.
 M.A.P.38, T.A.P.46,
 W.A.P.89, Th.D.P.47, E.587
Trapido, Edward J.
 B.527, D.605
Traub, Kit
 T.G.P.15
Traugott, M.
 W.A.P.115
Tranunner, A.
 T.C.P.96
Travers, K.
 W.C.P.136
Travis, B. M.
 W.C.P.10, Th.C.P.95
Travis, William D.
 T.B.P.16
Traylor, D.
 W.B.P.135
- Treisman, M. S.**
 M.B.P.39
Tremblay, M.
 T.B.O.35, T.C.P.111
Tremblay, Michel
 Th.C.P.76
Trenti, K.
 Th.E.5
Trentin, L.
 Th.B.P.78, Th.B.P.79
Trépo, C.
 A.550, Th.B.P.169, Th.D.P.31,
 C.773, D.702
Treston, C. S.
 T.B.P.225
Trevisanello, C.
 B.522
Tribe, D.
 T.C.P.130, C.671
Tribe, D. E.
 C.572
Trica, A.
 A.520
Trichopoulou, E.
 W.A.P.37
Tricoche, M.
 W.C.P.61
Tricoire, J.
 M.B.P.25, M.B.P.26, T.B.P.222
Tricoire, Joëlle
 T.B.P.187, Th.B.P.9,
 Th.B.P.21
Trigg, H. L.
 T.A.P.48
Trillo, S.
 E.555
Trinkler, P.
 Th.B.P.153, Th.B.P.154
Triomphe, Annie
 Th.H.P.11
Tripathy, Srikanth Prasad
 M.B.P.139
Tripp, D.
 E.712
Tripp, J. N.
 M.D.P.16
Tristram, Michael
 T.C.P.105
Tritch, R.
 T.C.P.130, C.572
Trojnar, J.
 C.523, C.526
Trompeter, R. S.
 M.A.P.41
Troncoso, I.
 M.E.O.11
Troonen, Hugo
 T.B.P.249
Trost, D.
 M.B.P.121, M.B.P.134
Trophilme, D.
 W.B.P.35
- Tropnes, J.**
 M.B.P.314
Troshev, O.
 W.B.P.178
Tross, S.
 A.598, Th.D.O.8, Th.D.P.60,
 Th.D.P.64, Th.E.P.4
Tross, Susan
 Th.D.P.17
Trost, R.
 M.A.P.16
Trotot, Pierre M.
 M.B.P.41, M.B.P.196,
 Th.B.P.253, Th.B.P.254
Troussier, Thierry
 D.527, T.E.P.23
Troutman, Adewale
 M.D.O.11
Trowbridge, D.
 T.C.P.122
Troxler, S.
 T.A.P.50, B.519
Truckenmiller, M. E.
 W.C.P.41
Trujillo, J. R.
 M.B.P.377
Truman, B.
 M.A.P.27, Th.D.P.16,
 Th.P.45
Truman, Benedict I.
 T.A.P.54
Trunch, A.
 C.528
Truscia, D.
 M.B.P.14
Tryon, W. W.
 D.716
Tsagadigui, J. G.
 Th.A.O.19
Tsai, C. C.
 Th.B.P.112
Tsai, Cheng C.
 W.C.P.52, W.C.P.146
Tsai, P. K.
 T.B.P.128, Th.C.P.86
Tsai, W.-P.
 M.C.P.86
Tsang, P. H.
 Th.B.P.95, Th.B.P.182
Tschachler, E.
 Th.C.P.20, C.680
Tschechne, B.
 M.B.P.280, T.B.P.14,
 Th.B.P.12
Tschechne, Barbara
 M.B.P.259, M.C.P.143
Tshiamala, K.
 W.B.P.316
Tshikuka, J. G.
 W.C.P.14
Tsouliarakis, K.
 W.D.P.26

- Tsoukala, C.
M.A.P.109
- Tsoukas, C.
W.A.P.79, A.609, W.B.O.6,
M.B.P.359, M.B.P.367,
T.B.P.89, T.B.P.314,
Th.B.P.7, Th.B.P.20, B.606,
M.H.O.7
- Tsoukas, C. M.
Th.B.P.315, Th.B.P.130, C.609
- Tsoukas, Chris M.
Th.B.O.33
- Tsuboi, I.
Th.B.P.85, Th.B.P.130, C.609
- Tsubota, Hiroshi
W.C.O.42
- Tsuda, K.
B.633
- Tsui, P.
A.562
- Tsujimoto, H.
M.C.O.5, W.C.P.2
- Tsung, L.
Th.A.P.85, W.B.P.164
- Tubiana, N.
Th.B.P.149
- Tuchs Schmidt, J.
M.B.P.285, T.B.P.10
- Tucker, R. M.
T.B.O.5, W.B.P.10
- Tudiver, Fred G.
W.A.P.92
- Tudor, G.
C.653
- Tukei, P.
W.B.P.173
- Tukei, P. M.
T.B.P.133
- Tukei, Peter M.
T.B.P.134
- Tulin, S.
B.568
- Tulliez, T. M.
C.699
- Tullio Cataldo, Pietro
T.A.P.115, W.B.P.362
- Tumbarello, M.
M.C.O.32
- Tumietto, F.
M.B.P.256
- Tung, C. -S.
M.C.O.24
- Tunving, Kerstin
W.D.P.65, Th.D.P.36
- Tural, C.
A.502, M.B.P.245,
Th.B.P.234, B.509
- Turbitt, P.
A.581, M.D.O.12
- Turbitt, Patrick
D.580
- Turcotte, R.
Th.B.P.366
- Turett, G.
T.B.P.48
- Turlia, M.
Th.B.P.281
- Turner, B. J.
A.608, Th.H.P.3
- Turner, Barbara J.
W.A.P.33, M.H.O.11, T.H.P.4
- Turner, H.
T.D.O.19, T.D.P.45
- Turner, Heather A.
T.D.P.56
- Turner, J.
W.B.O.10
- Turner, R.
E.761
- Turno, R.
T.B.P.292
- Turnock, B. J.
W.A.O.25
- Turpen, T. J.
M.B.P.328
- Turriziani, O.
M.C.P.39
- Tuzza, A.
M.B.P.65, M.B.P.113,
M.B.P.363, T.B.P.74,
Th.D.P.87
- Twumasi, Patrick A.
W.G.O.32
- Tyler, G.
M.E.P.16
- Tyler, D.
M.C.O.17
- Tyler, D. S.
W.B.O.12, T.B.P.207,
W.B.P.325, W.B.P.330
- Tyler, Douglas S.
T.C.O.33, T.C.P.32
- Tyms, A.
M.C.P.117
- Tyndale, Eleanor
T.D.P.1
- Tyrrell, D. L. J.
M.A.P.87
- Tyson, Pat
M.E.P.73, E.545
- Tyson, R. L.
C.689
- Tzipori, S.
C.586
- U**
- Uberti Foppa, C.
M.B.P.354, M.B.P.336,
Th.B.P.348
- Udall, L.
T.H.O.3
- Udall, Linda M.
T.E.P.41
- Udem, S.
W.C.P.43
- Udofia, O.
W.G.O.24
- Ueba, N.
M.C.P.79
- Ugokwe, C.
M.B.P.371
- Uherová, P.
Th.B.P.367
- Uhr, J. W.
Th.C.O.14, M.C.P.129, T.C.P.7
- Ujhelyi, E.
T.B.P.302, T.C.P.141
- Ujhelyi, Eszter
T.B.P.96, Th.B.P.139,
M.C.P.146, W.C.P.92
- Ulrich, P.
M.A.O.10, T.B.P.227
- Ulrich, R.
M.C.P.20
- Umedaly, H.
M.B.O.33
- Un-eklabh, T.
T.G.O.25
- Unadkat, Jashvant D.
M.B.P.13, M.B.P.15, M.B.P.22
- Ungar, Beth L. P.
W.B.P.45
- Unge, T.
Th.C.P.84
- Unger, E. R.
M.B.P.62, Th.C.O.38
- Unger, M.
M.B.P.11, M.B.P.18
- Ungerfels, S.
Th.D.P.21
- Unité de transplantation
hépatique
B.520
- Unkelbach, U.
M.B.P.270
- Unkelbach, U. M. E.
M.B.P.105
- Unkeless, J. C.
Th.B.P.84
- Upadhyay, Gopalakrishna K.
D.577
- Updike, M.
Th.B.P.206
- Upton, Kim
T.D.O.16
- Uranga Imaz, F.
Th.G.P.17
- Urba, W.
Th.B.P.167
- Urcelay, A.
T.A.O.23
- Urcuyo, L.
M.B.P.314
- Urbe, E.
T.A.P.8
- Urbe, Patricia Estela
M.D.P.7
- Uriwiti, V.
T.E.P.76
- Urnovitz, H.
W.B.P.142
- Urnovitz, Howard B.
W.B.P.143
- Ursing, B.
C.717
- Uruturi, M.
E.579
- Urwitz, Viveka
W.D.P.88, Th.E.O.5, T.E.P.30
- US Army R. R. G.
W.A.P.66
- Ushijima, H.
M.C.P.108, M.C.P.134
- Ushijima, Hiroshi
B.605
- Usieto, R.
A.544, M.H.P.21
- Usieto, Ricardo R.
Th.D.P.19, Th.E.P.48, E.515,
E.526
- Usieto, R.
T.E.P.73
- Ussery, Fred M.
W.C.P.60
- Uttamchandani, R.
M.B.P.329, T.B.P.331
- V**
- V. Eiff, M.
W.B.P.318
- V. Eiff, U. M.
Th.D.P.69
- V. Sydow, M.
W.B.P.129
- Vacalis, D.
W.E.P.58
- Vacarelli, J.
E.785
- Vaccaro, K. K.
Th.B.P.338
- Vaccher, E.
M.A.O.38, W.A.P.59,
T.C.O.40, W.C.P.50
- Vacek, Z.
Th.C.P.127
- Vacherot, B.
M.B.P.226
- Vader, J. P.
E.638
- Vago, L.
M.B.P.216
- Vago, T.
M.B.P.267
- Vahey, Mary Anne T.
T.C.P.128
- Vahine, A.
W.B.P.109, T.C.O.37
- Vaidya, K.
M.B.P.177, B.560, B.616

- Vaillant, V.
M.A.O.14, C.702
- Vaira, D.
B.823
- Valadez, J.
A.555, A.603
- Valainis, G.
T.B.P.328, W.B.P.8, W.B.P.18
- Valainis, Gregory T.
Th.B.P.42
- Valanne, L.
Th.B.P.242
- Valdarchi, C.
T.B.P.345, T.B.P.346
- Valderrabano, F.
M.B.P.277
- Valderrama, R.
C.721
- Valdes, M.
D.608
- Valdespino, G. J. L.
M.D.P.7
- Valdespino, J. L.
T.A.P.8, Th.A.P.80,
Th.A.P.81, W.B.P.179,
M.D.P.68, E.585, M.G.O.9,
T.G.O.8, T.G.O.9, Th.G.O.29,
Th.G.O.30, W.G.P.8,
W.G.P.25, Th.G.P.16, G.510
- Valdespino, Jose Luis
Th.D.O.11
- Valdespino, José-Luis
M.G.O.27, Th.G.O.37
- Valdiserri, R. O.
T.B.P.143
- Valencia, M. E.
M.C.P.71
- Valencia, M. Eulalia
M.B.P.370, W.B.P.339, B.648
- Valencia-Gutierrez, N.
G.516
- Valenti, A. J.
M.B.P.247
- Valentich, M.
D.720
- Valentin, A.
T.C.P.140
- Valentin, Antonio
T.C.O.3, Th.C.P.92
- Valentine, F.
T.B.P.296, C.561
- Valentine, F. T.
C.568
- Valentine, Fred
M.C.P.18
- Valentine, J.
Th.D.P.37
- Valentine, J. A.
M.A.P.120
- Valerie, K.
Th.C.P.20
- Valoux, R. M.
W.C.P.113
- Vallbona, C.
W.D.P.5, W.D.P.35, E.763
- Valle, H. A.
M.B.P.136, T.B.P.369, B.563,
C.763
- Valle, M.
M.B.P.219
- Valle, Sirikka-Liisa
T.A.P.18, Th.A.P.34
- Valleix, D.
B.523
- Vallejo, N.
Th.D.P.46
- Vallero, A. J.
T.A.P.75, Th.A.P.61, C.643,
M.D.O.1, M.D.P.51, M.H.O.13
- Vallero, Linda A.
W.G.P.7
- Vallespi, T.
M.B.P.98
- Vallhonnrat, E.
A.578, T.B.P.92
- Valls, V.
M.B.P.107
- Valsecchi, L.
M.B.P.361, D.674
- Valtier, S.
Th.B.P.126
- Van Aerschoot, A.
Th.C.O.20
- Van Beuzekom, M.
T.D.P.72
- Van Brunshot, A.
M.C.P.145
- Van Casteren, V.
A.595
- Van Dam, C. J.
W.G.O.17
- Van Dam, Johannes C.
T.G.P.8
- Van de Laar, M. J. W.
Th.A.P.50
- Van de Perre, P.
T.B.P.203, T.B.P.374, B.543,
W.G.O.6
- Van de Velde, L.
T.A.P.3
- Van den Akker, R.
G.520
- Van den Berg-Wolf, M.
T.B.P.323
- Van den Boom, Frans M.
M.B.P.382, D.705, W.H.P.14,
E.506
- Van den Bruene, M.
M.A.P.66
- Van den Hoek, Anneke
T.A.O.13, W.A.P.107
- Van den Hoek, J. A. R.
T.A.P.26
- Van der Brought, B.
W.B.P.105
- Van der Does, Tibo
T.E.P.51
- Van der Groen, G.
C.761, T.B.P.94, T.B.P.108,
T.B.P.135, W.B.P.105
- Van der Hoek, L.
Th.C.P.34
- Van der Horst, C.
Th.A.P.54, Th.A.P.78,
M.B.P.332
- Van der Meulen, F. W.
Th.B.P.349
- Van der Noordaa, J.
M.A.O.47
- Van der Pijlt, J.
T.A.P.14
- Van der Poel, C.
T.E.P.19
- Van der Poel, Cees L.
M.B.P.162, T.B.P.355,
W.B.P.157, W.B.P.158,
W.B.P.171, Th.C.P.55
- Van der Veen, F.
Th.G.O.31
- Van der Veen, Fred
T.A.P.3
- Van der Waal, I.
Th.B.P.321
- Van Dervent, Nancy L.
M.E.P.1
- Van Die, Huib
T.D.P.72
- Van Doornum, G. J. J.
T.A.P.14
- Van Druten, Hans
Th.A.P.55
- Van Dyck, E.
M.A.O.32
- Van Goethem, C.
T.B.P.374
- Van Gorp, W.
Th.B.P.294
- Van Gorp, Wilfred
T.D.P.60
- Van Gorp, Wilfred G.
Th.B.P.259, Th.B.P.289, B.568
- Van Griensven, Godfried J. P.
M.A.P.112, T.A.P.20,
W.A.P.36
- Van Haastrecht, H. J. A.
T.A.O.13, W.A.P.107
- Van Haastrecht, Harry J. A.
T.A.P.36
- Van Heuverswijn, H.
Th.B.O.54, C.672
- Van Heuverswyn, H.
T.C.P.149, Th.C.P.109, C.761
- Van Ketel, R. J.
W.B.P.2
- Van Lier, R. A. W.
Th.C.O.1
- Van Loo, B.
M.A.O.12, T.A.P.107,
W.B.O.26, W.B.P.170
- Van Noesel, C. J. M.
Th.C.O.1
- Van Patten, H.
T.A.O.27
- Van Raden, M. J.
M.A.P.101
- Van Raden, Mark J.
Th.A.O.17
- Van Riel, F.
Th.B.O.40, Th.B.P.306,
Th.B.P.310, Th.B.P.313,
Th.B.P.314
- Van Rietschoten, J.
T.C.P.42
- Van Roey, P.
Th.C.O.21, C.625
- Van Royen, P.
M.A.P.49
- Van Sprang, R.
W.B.P.96, W.B.P.126
- Van Strijp, J. A. G.
C.575
- Van Treuren, R.
Th.E.O.1
- Van Vooren, J. P.
Th.B.P.55
- Van Weick, U.
A.560, A.561, W.H.P.20
- Van Winkle, M.
C.648, C.665, E.718
- Vanags, R.
C.698
- Vance, R. D.
M.E.P.27
- Vand der Linden, M. M. D.
T.A.P.14
- Vandasová, J.
Th.C.P.127
- Vanden Haesevelde, M.
C.672, Th.C.P.109,
Th.C.P.124
- Vandenbranden, M.
T.C.P.107, C.742
- Vandenbruaene, M.
T.B.P.135
- Vander Heyden, N.
T.C.O.46, M.C.P.90, T.C.P.95,
Th.C.P.12
- Vanderborght, B.
Th.C.P.109, Th.C.P.124,
C.672, C.761
- Vanderburg, Douglas G.
W.B.P.202
- Vandercam, B.
Th.B.P.132, Th.B.P.359
- Vanderveken, Mark R.
W.E.P.32
- Vandeveld, D.
M.B.P.253

- Vanhems, Philippe**
 B.520
- Vanichseni, S.**
 Th.D.O.1, W.D.P.73, W.G.P.19
- Vanichseni, Suphak**
 T.G.O.23
- Vanish, V.**
 M.A.P.94, M.B.P.96,
 W.B.P.340
- VanRaden, M. J.**
 Th.A.P.100
- Varas, F.**
 T.B.P.216
- Vardinon, N.**
 T.A.P.2
- Vardinon, Nurit**
 Th.B.P.118
- Varela, J. M.**
 A.576, T.B.P.92, T.B.P.229
- Varela, L.**
 Th.D.O.7, Th.H.P.17
- Varela, L. R.**
 M.E.P.20, E.645
- Varela, Luis R.**
 Th.E.O.8a
- Varghese, T.**
 M.B.P.139
- Varley, S.**
 M.E.P.25
- Várnai, F.**
 T.B.P.302
- Varnier, O.**
 M.B.P.351
- Varnier, O. E.**
 W.B.P.357
- Vartdal, F.**
 T.C.P.20
- Vas, S.**
 W.B.O.36
- Vasconcellos, A. C.**
 M.A.P.53
- Vaseghi, M.**
 M.B.P.132, M.B.P.368
- Vasilev, T.**
 B.613
- Vasilonkaitis, V.**
 W.C.P.148
- Vaslin, Bruno**
 M.C.P.7
- Vasquez, J. J.**
 M.C.P.71
- Vasquez, M.**
 M.B.P.293
- Vassalos, C.**
 W.B.P.332
- Vassilopoulos-Kada, H.**
 W.G.P.140
- Vasudevachari, V.**
 Th.B.P.179
- Vaughan, R.D.**
 E.581
- Vavik, L.**
 A.513, W.E.P.6
- Vayuvegula, B.**
 W.C.P.123
- Vazeux, R.**
 W.B.O.18, T.B.P.309,
 Th.B.P.250, Th.B.P.253,
 T.C.P.114, W.C.P.100
- Vazeux, Rosemay**
 W.C.P.127
- Vazquez, J. J.**
 W.B.P.339
- Vazquez, W.**
 B.573
- Vazquez-Rizo, J.**
 G.516
- Vazquez-Valls, E.**
 M.G.P.10, G.516
- Vazquez-Valls, Eduardo**
 M.F.P.3, W.G.P.23
- Vazquezra, R.**
 Th.E.P.20
- Vearnals, S.**
 C.610
- Vearnals, S. F.**
 W.B.P.204, M.D.P.92, E.509
- Vearnals, Simon F.**
 E.598
- Veber, F.**
 W.D.P.16
- Vecchi, D.**
 E.603
- Veda, M.**
 T.E.P.49
- Vedat, S.**
 Th.B.P.52
- Vedrenne, C.**
 W.B.P.26
- Veerasukont, B.**
 M.D.P.50
- Vega, C.**
 T.B.O.31
- Vejlsgaard, G. L.**
 W.B.P.125
- Velandia, Manuel**
 T.G.O.17
- Vella, S.**
 M.B.P.92
- Vella, Stefano**
 M.B.O.46, W.B.P.370
- Velleca, W.**
 M.B.P.163
- Velly, R.**
 T.G.O.10
- Vendreit, J.-P.**
 W.B.P.32, W.B.P.167,
 Th.B.P.97, Th.B.P.113
- Vendrell, Jean-Pierre**
 M.B.P.131, W.B.P.138
- Venet, A.**
 Th.C.P.104
- Venetta, T.**
 C.663
- Venkatesan, S.**
 T.C.P.102
- Ventura, G.**
 Th.B.P.72
- Venturini, L.**
 T.A.P.30, C.650, D.594
- Venzon, D.**
 Th.B.P.89
- Vera, L.**
 M.G.P.17
- Vera, S.**
 T.D.P.16, D.547
- Verani, P.**
 W.C.P.119, C.755
- Verani, Paola**
 W.B.P.146
- Veranni, P.**
 M.A.P.52
- Verbeke, Ronald**
 M.E.O.36, T.G.P.11
- Verber, F.**
 M.B.O.3
- Vercauteren, G.**
 M.A.P.66, W.B.P.105,
 Th.B.P.24, B.625
- Vercauteren, Gaby**
 T.B.P.94, T.B.P.108
- Verdier, M.**
 T.A.P.12, Th.A.P.112, A.587,
 W.B.P.108, W.G.P.2
- Verdier, Mireille**
 T.B.O.9
- Verga, G.**
 W.G.P.1
- Vergani, D.**
 Th.B.P.127, D.675
- Vergeront, J. M.**
 M.A.P.22
- Vergne, A.**
 Th.B.P.247, Th.B.P.365
- Verhoef, J.**
 C.575
- Verhoeven-Lespagnard, L.**
 A.532
- Verick, W.A.**
 Th.E.P.70
- Verjee, S.**
 W.H.P.4
- Verma, I. C.**
 T.G.P.6
- Verma, S.P.**
 E.648
- Vermund, S. H.**
 W.A.P.32, Th.A.P.104, A.604
- Vernant, J. C.**
 W.C.P.139, C.725
- Vernazza, P.**
 Th.B.P.319
- Vernazza, Pietro L.**
 M.B.P.364
- Verolini, D.**
 W.E.O.19
- Veronesi, F.**
 C.680
- Veronesi, R.**
 M.A.P.84
- Verreschi, I. T. N.**
 M.B.P.266
- Verri, A. P.**
 W.B.P.186
- Verstær, A.**
 T.A.P.82
- Vertadier, Alain**
 D.719
- Vestergaard, B. F.**
 W.B.P.280
- Vetter, N.**
 M.B.P.213
- Vezzani, F.**
 M.B.P.65, M.B.P.363,
 T.B.P.74, Th.D.P.67
- Vial, P.**
 Th.C.P.40
- Vianello, L.**
 M.A.O.11, Th.B.P.297
- Vianna, R.**
 M.G.P.15
- Vicente, P.**
 T.B.P.274
- Vich, J.**
 Th.C.P.64
- Vicini, Maria Assunta**
 D.674
- Vickroy, B.**
 T.C.P.106
- Victor, J.**
 E.531
- Victor, C.**
 Th.E.P.27
- Victorino, Rui**
 A.512
- Victorino, Rui M. M.**
 T.B.P.376, Th.B.P.107
- Vidal, R.**
 Th.B.P.57
- Vidal-Trecan, G.**
 M.H.P.11
- Videbak, R.**
 M.B.P.259
- Videka-Sherman, L.**
 E.510
- Viederman, M.**
 W.B.P.211
- Vieira, J. G.**
 M.B.P.266
- Vienne, Patricia**
 Th.G.O.45
- Viero, F.**
 T.B.P.178
- Vignò, P.**
 D.688, M.B.P.215
- Vigevani, G. M.**
 D.688
- Vigie Groupe**
 M.B.P.343
- Viglianti, Gregory A.**
 T.C.O.30

- Vignou, Dominique
M.B.P.154
- Vigo, B.
A.503
- Vilhanen, P.
T.C.P.130
- Viker, S.
Th.E.P.59
- Viladomiu, L.
A.534
- Vildé, J. L.
A.539, M.B.P.179, T.B.P.319
- Vildé, J.-L. V.
W.B.P.36
- Villa, A.
M.B.P.206, Th.B.P.191,
W.D.P.84
- Villa, Antonio
Th.B.P.82
- Villa, M. R.
M.A.P.63, M.B.P.133,
Th.B.P.194
- Villacres, M.
M.C.P.10, Th.C.P.80
- Villalonga, C.
M.B.P.97
- Villamarzo, Y.
Th.A.P.114
- Villarreal, S.
W.E.P.46
- Villegas, R.
W.B.P.22
- Villette, J. M.
C.726
- Villette, Jean-Marie
M.B.P.269
- Villota, J.
M.B.P.369, T.B.P.164,
T.B.P.255, B.600
- Viminde, N.
E.621
- Vinco, R.
M.C.P.125
- Vincellette, J.
T.A.P.59
- Vincent, J.
T.C.P.66, C.767
- Vincent, Judy
T.B.P.176
- Vincent-Ballereau, F.
M.D.P.68
- Vincenti, O.
M.B.P.32
- Viney, L.
T.D.P.49
- Vinga-Martins, Cristina
Th.C.P.44
- Vinitsky, Stephen J.
B.607
- Vinti, H.
M.B.P.250, W.B.P.44,
W.B.P.366, B.524, D.678
- Vinti, Henri
T.B.P.20
- Virani, Nzeera A.
T.B.P.11
- Viravaidhya, Meechal
Th.G.O.20
- Virehizer, J. L.
Th.C.O.23, W.C.P.121, C.525,
C.658
- Virta, A.
Th.B.P.242
- Virtue, L.
Th.B.P.368
- Viscidi, R.
M.C.P.12
- Visco, Giuseppe
Th.B.O.14, M.B.P.106,
Th.B.P.56, Th.P.220,
Th.B.P.255, Th.B.P.256, B.597
- Visconti, A.
W.B.P.102
- Visconti, E.
M.D.P.62
- Visintainer, A. M.
Th.H.P.25
- Visintine, R.
M.A.O.6
- Visona, K. A.
B.511
- Visona, Kirsten A.
Th.B.P.14
- Visscher, B.
M.A.O.44, A.540, A.622,
Th.B.P.278, Th.B.P.288,
Th.B.P.289, Th.B.P.294,
T.D.O.23
- Visscher, Barbara R.
W.A.F.64, Th.B.P.200
- Visser, C.
M.B.P.283
- Visser, E.
W.B.P.375
- Visser, M. R.
C.575
- Vitaliano, P. P.
E.731
- Vitetta, E. S.
Th.C.O.14, M.C.P.129, T.C.P.7
- Vitkovik, Ljubisa
M.C.O.28
- Vitores, P.
Th.D.P.70
- Vitoria, M. A. A.
Th.B.P.114, T.D.P.25
- Vittecoq, D.
Th.A.P.116, T.C.P.131
- Vittecoq, Daniel
W.B.P.368
- Vivar, P.
A.572
- Vivares, C.
Th.E.P.16
- Viviani, M. A.
M.B.P.94
- Vivinus, M.
M.A.P.37, Th.B.P.128,
Th.B.P.129, Th.B.P.364
- Viza, Dimitri
Th.C.P.84
- Vlahov, D.
M.A.O.9, M.A.P.98, T.A.P.44,
T.A.P.48, T.A.P.58,
Th.B.P.206, Th.B.P.271,
M.D.P.70, Th.D.P.50,
Th.D.P.79, T.E.P.43, T.H.P.23
- Vlahov, David
M.A.P.26, T.A.P.45,
W.A.P.90, Th.A.P.20
- Vlami, A.
Th.B.P.201
- Vlekke, A. B. J.
W.C.P.99
- Vocks, M.
T.B.P.378
- Vocks-Hauk, Mechthild
T.B.P.250
- Vodegel, P.
W.B.P.132
- Vodopija, V. M.
T.E.P.22
- Voelcker, J.
E.737
- Voeller, Bruce
W.A.P.99, D.685
- Voevodin, A.
Th.B.P.174
- Vogelhut, J.
B.586
- Vogler, M.
T.A.O.17, W.B.P.353
- Vogler, Mary A.
T.A.P.101
- Vogt, G.
M.C.P.4, T.E.P.67
- Vogt, M.
Th.A.P.111, T.B.P.86,
W.B.P.72
- Vogt, Markus W.
M.C.P.83
- Vohito, J. A.
W.G.O.28
- Vohito, M. D.
W.G.O.28
- Vohito, M. Dieudonné
M.B.P.185
- Vohra, S.
M.A.P.114
- Volberding, P.
A.637, W.B.O.19, T.B.P.303,
W.C.P.42, D.526, E.626
- Volberding, P. A.
M.A.P.31, T.A.P.76, Th.B.O.5,
M.B.P.166, T.B.P.284
- Volberding, Paul
W.B.O.15
- Volberding, Paul A.
W.B.P.270, W.C.P.38
- Volcan, K.
E.561
- Voll, R.
C.679
- Volonterio, Alberto
M.B.P.133
- Voloshin, O. N.
T.B.P.91
- Volpe, S.
M.B.P.37
- Volpini, V.
Th.B.P.256
- Volquez, C.
Th.D.O.10
- Voisky, D. J.
M.C.P.126, W.C.P.132,
Th.C.P.15, Th.C.P.16,
Th.C.P.17, C.645, C.646
- Volstein, M.
W.B.P.355
- Voltolin, L.
W.B.O.11
- Von Baehr, R.
T.C.P.150
- Von Briesen, H.
C.623
- Von Brückel, Michael
T.E.P.2
- Von dem Borne, A. E. G.
W.C.P.99
- Von Knebel Doebertz, C.
M.B.O.18
- Von Roenn, J.
M.B.P.86, W.B.P.313,
Th.B.P.283, Th.B.P.375
- Von Roenn, Jamie H.
Th.B.P.309
- Von Salisch, Maria
M.D.P.9, E.705
- Von Stedingk, L. V.
Th.B.P.225
- Von Zeipel, M. G. Claes
M.E.P.2
- Vonesch, N.
Th.C.P.99
- Vonesch, N. V.
Th.C.P.111, Th.C.P.146,
C.739, C.747
- Vonsover, Ami
T.C.P.142
- Vornhagen, Rolf
W.B.P.94, W.B.P.118
- Voth, R.
M.B.P.220, Th.B.P.98,
Th.B.P.119, W.D.P.54
- Voth, Rike
Th.B.P.122
- Voth, Rila
T.C.P.88
- Vowels, J. M.
M.A.O.43

- Voyta, J. C.
W.B.P.149
- Vrehen, H.
D.578
- Vuillecard, E.
Th.B.P.209
- Vuillier, F.
W.C.O.6, T.C.P.35
- Vuillier, J.
Th.B.P.100
- Vuitton, D.
B.520
- Vuitton, Dominique A.
Th.B.P.100
- Vujcic, K. K.
C.520
- Vujcic, K. L.
T.C.P.48
- Vujcic, L.
W.C.P.96
- Vuillier-Le Normand, B.
W.B.P.82
- Vyakarnam, Anna
T.C.P.14
- Vyas, G.
M.A.O.10, M.B.P.169,
T.B.P.227
- W**
- Wachtel, Renee C.
B.574
- Wachter, H.
W.B.P.79, T.C.P.12, T.C.P.68,
C.563
- Wachter, Robert M.
T.B.O.27
- Wade, D.
Th.B.P.53
- Wadhawan, D.
W.A.P.54
- Wadsworth, J.
D.545
- Wagmen, R.
Th.C.P.2, Th.C.P.73
- Wagner, B.
W.B.P.231
- Wagner, G.
M.B.P.11, M.B.P.18
- Wagner, K. F.
W.A.P.73, Th.B.P.115,
Th.B.P.183
- Wagner, Kenneth F.
C.587
- Wagner, Norbert
W.B.P.295
- Wahl, L. M.
M.C.P.42, T.C.P.58,
W.C.P.68, Th.C.P.3
- Wahl, S. M.
Th.B.P.94, Th.B.P.175,
M.C.P.42, T.C.P.58, W.C.P.68
- Wahn, V.
T.B.P.250
- Wahren, B.
Th.A.P.113, T.C.P.55,
T.C.P.65, C.526
- Wahren, Britta
C.523
- Wain-Hobson, S.
T.C.O.28, W.C.P.5, W.C.P.20
- Wain-Hobson, Simon
W.C.O.4
- Wainberg, J.
T.B.P.314
- Wainberg, M.
T.B.P.97, T.C.P.79, W.C.P.74
- Wainberg, M. A.
M.B.P.359, M.C.P.112,
T.C.P.110, T.C.P.111,
T.C.P.112, W.C.P.64,
Th.C.P.76, Th.C.P.117, C.536
- Wainberg, M. A. W.
Th.C.P.77
- Wainberg, Mark A.
W.A.P.102, T.B.O.35,
W.B.P.351, M.C.P.63
- Waivers, Leo E.
M.H.P.14
- Waiyaki, P.
T.A.O.25, Th.A.O.25,
M.B.P.53, W.G.P.29
- Wakamarsu, P. K.
M.B.P.68
- Waked, M.
B.615
- Waldner, A.
M.B.P.88, T.B.P.304
- Walger, Peter
W.B.P.316
- Walker, A.
M.E.O.14
- Walker, B. D.
T.C.P.2
- Walker, Bruce D.
W.C.O.43
- Walker, C.
M.C.O.1
- Walker, Christopher M.
T.C.O.32
- Walker, E. B.
T.C.P.52
- Walker, Gillian E. M.
D.564
- Walker, L. C.
T.C.P.11
- Walker, M.
A.638, T.D.P.49
- Walker, R.
Th.C.P.101
- Walker, S.
D.661
- Wali, R.
Th.D.P.70
- Wallace, J. I.
Th.B.P.285
- Wallace, B.
E.514
- Wallace, E. M.
T.A.P.62
- Wallace, Evelyn M.
E.531
- Wallace, J.
Th.B.P.276
- Wallace, J. I.
Th.B.P.95, Th.B.P.182
- Wallace, Joyce I.
A.564, M.B.P.184, W.B.P.88,
T.D.P.80
- Wallack, J.
D.624, T.F.P.6
- Waller, C. M.
W.C.O.5
- Wallman, Sandra
E.537
- Wallon, C.
T.C.P.39, T.C.P.40
- Walrond, Errol R.
T.E.P.32
- Walsh, K.
E.686
- Walsh, T.
Th.B.P.89
- Walter Reed Retroviral
Research Group
M.A.P.17, Th.A.P.93
- Walter, Emmanuel B.
T.B.P.207
- Walter, H.J.
E.581
- Walter, Heather J.
E.662
- Walter, P.
E.725
- Walter, V.
M.E.P.67
- Walters, David J.
W.E.O.1
- Walther, V.
D.650
- Walu, E.
W.D.P.90, D.694, W.E.P.3
- Walzer, Peter
Th.D.P.89
- Wamola, I.
Th.A.O.25, Th.G.O.63
- Wampler, K.
M.E.P.68
- Wane, J.
W.B.P.316
- Wang G.
W.D.P.71
- Wang, E.
Th.B.P.5
- Wang, F.-N.
C.651
- Wang, J.
Th.B.O.37
- Wang, M.
Th.C.P.13
- Wang, P.
W.B.P.196
- Wang, Richard Yuan-Hu
C.738
- Wang, S.-R.
T.C.P.143
- Wang, S. S.
W.B.P.141
- Wang, Yanfeng
Th.B.P.204
- Wann, F.
M.A.P.1, M.A.P.4, W.B.P.225
- Wann, Z. F.
M.A.O.1
- Wansbrough-Jones, M. H.
T.B.P.24
- Wanzala, Peter
T.B.P.338, Th.B.P.324,
Th.B.P.325
- Wapner, R. J.
D.600
- Wara, D.
Th.B.P.347
- Ward, D.
W.B.P.45
- Ward, D. J.
M.B.P.208
- Ward, Douglas J.
M.B.P.378
- Ward, Helen
E.521
- Ward, J.
M.A.P.30, M.A.P.107,
M.B.P.150, T.B.P.167,
T.B.P.183
- Ward, John W.
M.A.O.8, T.A.P.105
- Ward, T. T.
Th.B.P.300
- Wardlaw, L.
T.B.O.3, T.B.P.76
- Wardrop, K.
W.E.O.1
- Warfield, D.
Th.C.P.52
- Warner, G. L.
Th.A.P.118
- Warren, H.
W.C.O.23
- Warren, J.
C.638
- Warren, R. P.
C.512
- Warren, Rueben C.
M.E.O.22
- Warren, W. K.
M.D.O.8
- Warrior, R.
Th.B.P.311

- Warstedt, K.
 W.C.P.141
- Warwick, Ian
 M.D.P.2
- Washington, I.
 W.C.P.105
- Washizu, T.
 W.C.P.21, W.C.P.36
- Waskin, H.
 M.B.P.237, W.B.P.3
- Waskin, Hetty Anne
 W.B.P.15
- Wasmuth, J.
 T.C.P.83
- Wasser, Shari C.
 W.D.P.50
- Wasserheit, J. N.
 M.A.P.68
- Wasserman, E.
 T.B.P.147, T.B.P.168,
 T.B.P.265
- Wasserman, S.
 T.A.P.16
- Wasserman, W.
 Th.D.O.2, Th.D.O.16
- Wassif, O. M.
 Th.H.P.28
- Wassif, Samir Mohamed
 Th.H.P.28
- Watanabe, Kazuhito
 M.C.P.148
- Watanabe, M.
 Th.C.O.16
- Watanabe, Mamoru
 W.C.P.75
- Waterman, S.
 M.A.P.74, A.528
- Waters, D.
 T.C.O.19, T.C.O.22
- Waters, D.
 B.636
- Waters, D. J.
 Th.B.P.177
- Waters, David J.
 Th.A.P.118
- Watkins, S.
 M.B.P.12
- Watson, A.
 Th.C.O.34
- Watson, H.
 Th.D.P.85
- Watson, R. R.
 C.511
- Watson, Ronald R.
 C.632
- Watson, T.
 W.H.O.10
- Watson-Williams, E. John
 T.G.O.12
- Watters, J.
 M.D.O.5
- Watters, J. K.
 Th.A.P.70, Th.D.O.14
- Watters, John K.
 Th.A.P.67, Th.D.O.4
- Watts, Douglas M.
 M.G.P.22
- Watts, H.
 W.A.P.6
- Watts, Heather
 M.B.P.9
- Watts, J.
 D.560
- Watts, L.
 M.B.P.314
- Wauters, C.
 T.C.P.149
- Wautier, J. L.
 B.503
- Wawer, M.
 W.D.P.8
- Wawer, M. J.
 M.G.O.14
- Wawer, Maria J.
 W.A.P.114
- Waweru, Samuel E. N.
 M.B.P.160
- Waxdal, M. L. J.
 Th.B.P.146
- Way, P.
 T.A.P.86, T.B.P.352
- Way, P. O.
 Th.A.P.71, W.G.P.7
- Way, Peter O.
 M.G.P.11
- Wayling, S.
 T.E.P.50, T.E.P.71
- Wayne, J.
 C.603
- Weatherley, B.
 W.B.O.3
- Weaver, M. S.
 T.A.O.34, W.A.P.58, T.C.P.60
- Webb, D.
 W.A.P.118
- Webb, D. S.
 Th.C.P.40
- Webb, Farrell J.
 T.E.P.36
- Webb, Nancy R.
 C.627
- Webber, M. P.
 A.604
- Webber, Mayris P.
 Th.D.P.1
- Weber, D. J.
 M.A.O.23
- Weber, Günter
 T.B.P.14
- Weber, J.
 M.C.P.91, W.C.P.98,
 W.C.P.124, T.D.P.81
- Weber, J. N.
 Th.C.P.128
- Weber, John
 Th.D.P.76, E.726
- Weber, R.
 T.B.P.50
- Weber, Rainer
 W.B.P.72, W.B.P.321
- Weber, Thomas
 Th.B.P.231
- Weber, U.
 M.E.P.57
- Webster, A. A.
 Th.B.P.22
- Webster, Claudia L.
 M.E.P.16
- Webster, Eddie
 Th.O.14
- Wee Ekweera, E.
 M.D.P.19
- Weeger, M.
 T.C.O.45
- Weeks, D.
 W.E.O.17
- Weeks, S.
 Th.A.P.49
- Weeramunda, J.
 M.E.O.31, M.G.O.18, T.G.O.7
- Weg, I.
 M.B.P.198
- Wegerich, B.
 A.606, T.B.P.200, T.B.P.218,
 T.B.P.257
- Weiblen, B.
 T.B.P.130
- Weiblen, Barbara
 W.B.P.136
- Weidman, J.
 W.C.P.86
- Weigelt, W.
 T.C.P.65
- Weil-Halpern, Françoise
 W.D.P.16
- Weibauer, F.
 M.G.P.19
- Weiler, Pamela H.
 E.725
- Weimer, R.
 Th.B.P.142
- Weinbreck, P.
 B.523, C.766
- Weiner, David B.
 W.C.O.25, C.608
- Weiner, H.
 T.D.O.23
- Weiner, L.
 T.B.P.248
- Weiner, M.
 W.C.P.69
- Weiner, Marc
 M.E.P.13
- Weiner, S.
 W.D.P.43
- Weiner, S. M.
 D.600
- Weiner, Susan M.
 M.B.P.30
- Weingart, Z.
 W.B.P.247
- Weingart-Jesse, Brigitte
 D.712
- Weinhold, K.
 A.599, T.B.P.118, M.C.O.17,
 Th.C.O.28
- Weinhold, K. J.
 T.B.P.207, W.B.P.325,
 T.C.O.33, T.C.P.32
- Weinhold, Kent J.
 W.B.P.330, M.C.P.22
- Weinke, Thomas
 M.B.P.211, W.B.P.19, B.521
- Weirich, J.
 W.B.P.223, W.B.P.230,
 W.B.P.233, Th.B.P.262,
 Th.D.P.51
- Weirich, James D.
 T.D.P.79
- Weinstein, J. N.
 T.C.P.58
- Weinstein, M.
 M.E.P.9
- Weinstein, M. C.
 Th.A.P.70
- Weinstein, R. A.
 M.C.P.116
- Weinstock, A.
 W.B.P.209
- Weintraub, P. et al.
 T.B.P.177
- Weintrub, P.
 M.B.P.24, T.B.P.198,
 T.B.P.227
- Weisberg, M. S.
 M.E.P.23
- Weisbrode, S. E.
 M.C.P.68
- Weise, Lynne Ann
 E.547
- Weisenfeld, D.
 M.A.P.13
- Weiser, Barbara
 W.C.P.55
- Weisfuse, I. B.
 W.A.P.11
- Weisfuse, Isaac B.
 W.A.P.9, M.A.P.57
- Weislow, O.
 C.638
- Weislow, Owen S.
 C.513
- Weisman, Henry W.
 W.B.P.205
- Weisman, Joel D.
 T.B.P.82, T.B.P.83
- Weisman, Z.
 W.C.O.29
- Weiss, Carol D.
 Th.C.P.65
- Weiss, Joanne L.
 E.624

- Weiss, L.**
 T.A.P.24
Weiss, Laurence
 T.C.P.3, C.529
Weiss, R.
 T.B.P.18
Weiss, R. A.
 M.C.P.91, Th.C.P.11,
 Th.C.P.94
Weiss, Rachelle A.
 W.B.P.120, W.B.P.121
Weiss, Robin
Weiss, S. H.
 Th.A.P.18, Th.C.P.132
Weiss, Stanley H.
 Th.A.O.23, Th.D.P.4
Weiss, Susan
 W.B.P.375
Weiss, T.
 W.B.P.143
Weissberg, M.
 M.F.P.4
Weissenbacher, M.
 W.D.P.56, D.686, W.G.P.18,
 W.G.P.21
Weissenbacher, Mercedes
C.
 W.B.P.382, M.D.O.10
Weissman, G.
 W.D.P.43, W.D.P.57
Weissman, H.
 W.B.P.269
Weits, J.
 W.B.O.35
Weitzman, S.
 Th.B.P.309
Welch, N.
 W.E.P.61
Weller, I.
 W.B.P.185, T.C.P.14
Weller, I. V. D.
 Th.C.P.128
Weller, P.
 M.D.P.23, M.D.P.24
Weller, R.
 T.C.P.86
Wellings, K.
 D.545, W.E.O.23
Wellings, Kaye A.
 D.530
Wells, C. L.
 W.B.P.289
Wells, Carole J.
 T.B.P.34
Wells, D.
 D.518, E.707
Wells, J. D.
 T.G.P.1
Wells, James A.
 M.D.O.1, W.E.P.29, E.560
Wells, M. A.
 M.C.P.36
- Welsch, Gregory M.**
 T.S.P.239
Welzl, G.
 B.516
Wenger, Neil S.
 E.724
Weniger, B. G.
 T.B.O.7, T.B.P.364, T.G.P.25
Weniger, Bruce G.
 W.G.P.14
Wente, S.
 M.D.O.15
Wentworth, Peggy A.
 W.C.P.8
Werdegar, D.
 Th.O.5
Wermuth, Laurie A.
 Th.D.P.5
Werneck, E. B.
 Th.B.P.37
Werner, A.
 C.696
Werner, E. R.
 W.B.P.79, C.563
Wescott, S. L.
 M.C.P.3
Wesley, A.
 T.B.P.177
Wesley, A. M.
 Th.B.O.19, Th.B.P.205
Wesley, R.
 M.D.P.73
Weslowski, V.
 M.H.P.18
West, G. R.
 A.533
West, Gary R.
 W.E.O.7
West, R.
 E.562
Westblom, T. Ulf
 M.C.P.32
Wester, M.
 W.B.P.157
Westervelt, P.
 T.C.P.122
Westin, E.
 T.B.P.58
Westman H.G.
 M.E.P.2
Weston, P.
 T.B.P.332
Westphal-Christensen,
Birgit
 A.579
Westwood, John T.
 E.693
Wetherall, N.
 W.C.P.144
Wetherall, Neal T.
 W.C.P.31
Wethers, J.
 T.B.P.240
- Wethers, J. A.**
 M.A.O.18, T.A.P.53
Wexler, H. K.
 M.A.P.20
Whalen, D. P.
 T.E.O.1
Whalen, L. R.
 W.C.P.13
Whaling, S. M.
 M.C.P.116
Whalley, A.
 W.C.P.128
Whalley, A. S.
 W.C.P.198
Whalley, H.
 W.B.P.137
Wheat, J.
 Th.F.O.7
Wheeler, D. W.
 W.C.P.13
Whelan, J.
 T.B.P.42
Whitacre, C.
 T.C.P.27
Whitaker, R. E. D.
 W.G.O.13
Whitaker, Rupert E. D.
 Th.A.P.58
Whitby, D.
 M.C.P.91, Th.C.P.11
White, C. R.
 M.A.O.2
White, Carol R.
 Th.E.P.31
White, E. L.
 M.C.P.126
White, G.
 M.A.P.45
White, G. C.
 T.C.P.49
White, L. O.
 T.B.P.34
White, M.
 T.B.P.136
White, N.
 M.H.P.23
White, Nick D.
 M.H.P.22
Whitelaw, J.
 M.B.P.3, T.B.P.211
Whitelaw, J. M.
 M.A.P.82, M.A.P.105
Whitelaw, James A.
 Th.B.P.164
Whitescarver, J.
 T.G.P.17
Whiteside, T. L.
 W.C.O.10
Whittaker, Bill H.
 W.E.O.8
Whittaker, S.
 W.D.P.85, Th.D.P.77
- Whittemore, N. B.**
 M.B.P.157, T.B.P.369
Whittington, N. P.
 T.D.P.17
Whittington, W.
 Th.A.P.16
Whittington, W. L.
 T.A.P.118, T.D.P.17
Whittle, H.
 T.B.P.362, B.612, Th.C.P.11,
 T.G.P.30, T.G.P.32
Whittle, P.
 C.613
Whitbalsman, Charles J.
 D.504
Wideman, D. A.
 W.C.P.90
Widman, Mindy
 M.E.P.60
Wielb, W. W.
 D.591
Wielb, W.
 Th.B.O.58
Wielb, Wayne W.
 M.A.P.50, W.D.P.66
Wieland, Ulrike
 M.B.O.24
Wielk, C.
 E.684
Wiesner, D.
 W.B.P.135
Wigdahl, B.
 M.C.O.31, M.C.O.31, C.519
Wigdahl, Brian
 C.749
Wightman, S.
 T.B.P.384
Wigzell, H.
 B.548, C.523, C.712
Wiik, Flavio Braune
 M.E.O.9
Wiktor, S.
 Th.G.P.2
Wilber, J.
 Th.A.P.85, T.B.P.312,
 W.B.P.85
Wilber, Judith C.
 W.B.P.162
Wilde, A.
 C.540, C.690
Wilder, M.
 W.A.P.1
Wilensky, G. R.
 M.D.O.1
Wiley, A.
 E.643
Wiley, C. A.
 C.531
Wiley, J.
 Th.A.P.40
Wiley, K.
 Th.G.P.11

- Wilfert, C.**
 T.B.P.207
Wilke, G.
 W.B.P.318, Th.D.P.89
Wilkes, M. S.
 A.615
Wilkins, A.
 T.B.P.362, B.612
Wilkins, H. A.
 M.D.P.12, T.G.P.30, T.G.P.32
Wilks, David
 T.C.P.11
Wilks, R.
 B.636
Will, A.
 E.580
Willame, J. C.
 M.B.O.38
Willard, K.
 Th.A.P.73
Willems, B.
 C.761
Willenbrig, K.
 T.E.P.39
Willenbring, K.
 M.D.P.56, M.D.P.57,
 M.D.P.89, D.626, W.E.P.73,
 Th.E.P.29
Willer, A.
 Th.C.P.135
Willer, Andreas
 C.598
Willford, D.
 T.C.P.10
Williams, A. E.
 C.775
Williams, Alan E.
 M.B.P.146
Williams, Ann B.
 W.D.P.42
Williams, Bryan
 T.C.P.98
Williams, C.
 Th.B.P.351
Williams, Dan K.
 E.554
Williams, Ekanem E.
 W.G.O.24
Williams, G.
 M.C.P.54, C.631
Williams, H.
 Th.C.P.128
Williams, Ivetta Y.
 W.B.P.373
Williams, J.
 W.B.O.41, W.B.O.43,
 W.B.P.222, Th.B.P.284,
 Th.B.P.286
Williams, J. B. W.
 T.B.P.192, W.B.P.244,
 W.D.P.67
Williams, J. L.
 D.554
Williams, K. G.
 T.B.P.271
Williams, K.R.
 E.744
Williams, Kenneth R.
 W.D.P.44, W.E.O.25
Williams, L.
 Th.A.P.25, Th.A.P.26,
 W.B.P.313, Th.B.P.304,
 Th.B.P.309
Williams, M. D.
 W.B.P.87
Williams, M. T.
 W.C.P.80
Williams, N.
 W.A.P.19
Williams, P.
 B.573, M.H.P.23
Williams, S.
 W.B.P.128
Williams, W. U.
 C.608
Williams, W. V.
 W.C.O.25
Williamson, Donald E.
 M.A.P.7
Williamson, J. D.
 M.C.P.70
Williamson, N. E.
 D.663
Wilson J.
 D.549
Willits, D. L.
 T.A.P.109
Willoughby, A.
 W.A.O.12, Th.A.O.6,
 Th.A.O.11, M.B.O.42,
 T.B.P.185, W.D.P.50,
 Th.E.P.57, Th.E.P.58, E.682
Willoughby, Anne
 M.B.O.2
Willoughby, Anne D.
 T.F.O.16
Willoughby, B.
 M.A.O.26, T.A.O.34,
 W.A.P.57, W.A.P.58,
 W.B.O.13, M.H.P.1
Willoughby, Brian
 W.D.P.92
Wills, C.
 M.B.P.309
Wils, Christine Joan
 E.536
Willy, M.
 M.D.P.73
Wilson, A.
 Th.H.P.22
Wilson, A. J.
 T.B.P.132
Wilson, B.
 W.B.P.201
Wilson, C.
 W.A.P.13, T.B.P.234
Wilson, D.
 W.G.O.19
Wilson, D. B.
 W.A.P.73, Th.B.P.163,
 T.C.O.44
Wilson, D. E.
 Th.B.O.3
Wilson, David J.
 W.G.O.19
Wilson, E.
 M.B.O.48
Wilson, G.
 M.B.P.239, T.B.P.175,
 T.E.P.28
Wilson, J.
 Th.A.P.76
Wilson, Jacquelyn
 E.517
Wilson, M. J.
 M.A.P.60
Wilson, Mary J.
 M.A.P.84, Th.B.P.201
Wilson, R.
 W.E.P.31, E.558
Wilson, V.
 M.B.P.296
Wilson, W.
 T.C.P.103, W.D.P.11
Wilson, Wilma
 T.C.P.137
Winchester, R.
 W.B.O.17, Th.B.P.116, C.655
Wing, L.
 Th.C.O.35, W.C.P.128
Winger, E.
 M.A.P.100, W.C.P.38
Wingi, M.
 W.E.O.30
Winiarski, Mark G.
 D.602
Winkelmann, P.
 T.B.P.334
Winkelstein, A.
 M.B.P.355
Winkelstein, W.
 M.A.P.99, Th.B.O.29,
 Th.B.P.144
Winkelstein, W., Jr.
 Th.A.P.84, Th.B.P.75
Winkler, I.
 C.607
Winkler, J. R.
 Th.B.P.351
Winkler, James R.
 Th.B.P.338
Winship, A.
 M.B.P.337
Winslow, B. J.
 M.C.P.67
Winslow, D. L.
 M.B.P.247
Winslow, Dean L.
 T.B.P.45
Winslow, E.
 C.648
Winter, H. S.
 T.B.P.249
Winter, M.
 Th.B.P.355
Wintergerst, U.
 T.B.P.163, T.B.P.250
Wintergest, Uwe
 T.B.P.208
Winters, D.
 D.692
Wintfeld, N.
 Th.A.P.82, M.H.P.5
Wirthlin, M.
 W.C.P.32
Wirtz, K.
 Th.B.P.192, W.B.O.42
Wise-Campbell, S.
 W.D.P.10
Wishart, M.
 W.D.P.78
Wisner-Carlson, B.
 W.B.P.189, W.B.P.220
Wisniewski, C.
 Th.A.P.20
Wisniewski, Ted L.
 Th.P.6
Withum, D. G.
 M.A.P.6
Witkin, Steven S.
 C.515
Witte, J.
 W.A.P.1
Witte, J. J.
 W.A.P.18, T.D.P.21
Wittek, Alec E.
 M.C.P.36
Wittenberg, E.
 A.639
Wiviott, Lory D.
 W.C.O.5
Wiznia, A.
 M.B.P.7
Wiznia, Andrew
 W.A.P.5, T.S.P.159, T.B.P.160
Wodak, Alex D.
 W.D.P.62, W.D.P.63
Woerner, A.
 T.C.P.84
Wofsy, C.
 T.A.P.94, T.A.P.100
Wofsy, C. B.
 T.B.P.196, W.D.P.51,
 W.D.P.52, W.D.P.53
Wofsy, D.
 C.504
Wofsy, J.
 D.666
Wohlfleiter, Daniel A.
 T.E.P.3, E.674
Wojtkowsky, M.
 M.C.O.22

- Wójtowicz, U.**
 M.A.P.69
Wolber, V.
 M.B.O.24
Wolbert, J.
 W.A.P.10, M.B.P.276,
 T.B.P.51, T.B.P.324,
 W.B.P.68, W.D.P.40
Wolbert, Jerry
 M.B.F.319
Wolf, A.
 C.710, T.D.P.61
Wolf, B.
 T.A.P.28, W.B.P.293,
 M.C.P.56, C.636
Wolf, F.
 W.A.O.21, W.A.P.85
Wolf, H.
 W.B.P.94, W.B.P.118,
 Th.C.P.2
Wolf, L.
 Th.B.P.376, T.D.P.58
Wolf, M.
 W.B.P.263
Wolf, W.
 Th.B.P.197
Wolfe, D.
 M.B.P.330
Wolfe, Hannah
 T.A.P.47
Wolff, A.
 Th.B.P.353
Wolff, C.
 E.534
Wolff, H.
 A.624
Wolff, Hans
 A.623
Wolff, M.
 T.B.P.27, W.B.P.23
Wolfs, T.
 W.C.P.89
Wolfs, T. F. W.
 T.C.P.73
Wolinsky, S.
 A.616, W.B.P.112, C.759
Wolitski, R. J.
 T.A.P.42, T.E.P.15
Wolitski, Richard J.
 W.E.P.59
Wolk, D.
 Th.D.P.46
Wolk, J.
 W.D.P.62
Wolk, J. S.
 W.D.P.63
Wolpe, F. R.
 E.583
Wolters, P.
 T.B.P.179, T.B.P.248
Wolters, Pamela L.
 M.B.O.43
Wong, A. Y.
 M.D.P.77
Wong, D. M.
 C.738
Wong, Dennis M.
 Th.C.P.63
Wong, H.
 W.H.P.1
Wong, Holly
 Th.O.7
Wong, I.
 W.C.P.64
Wong, Roberta J.
 A.637, E.626
Wong, V. K.
 T.B.P.267
Wong-Staal, F.
 M.C.O.21, T.C.O.13,
 T.C.O.31, Th.C.O.11,
 Th.C.O.13, T.C.P.89,
 W.C.P.48, Th.C.P.19,
 Th.C.P.20, Th.C.P.22
Wong-Staal, Flossie
 W.C.O.1
Woo, Stephen
 M.E.P.58
Woo, Stephen K. C.
 W.B.P.196, W.B.P.261
Wood, Charles
 C.782
Wood, D.
 Th.E.P.42
Wood, L.
 W.C.O.41
Wood, R.
 T.B.P.141, B.593, T.D.P.27,
 M.E.P.70, M.H.O.15
Wood, Robert D.
 M.B.P.285, T.B.P.10
Wood, Robert W.
 T.A.P.57, W.A.P.6, M.D.P.35,
 W.D.P.6, M.E.P.17
Woodard, D. R.
 M.B.P.204, Th.B.P.53
Woodbury, N. E.
 Th.A.P.50
Woodring, H.
 E.626
Woods, Joycelyn Sue
 T.G.P.5
Woods, W.
 Th.D.P.33, Th.D.P.34, E.671
Woods, William J.
 W.D.P.74
Woodward, N.
 T.A.O.9
Woody, J.
 M.A.P.79, M.G.P.5
Wooley, Dawn P.
 W.C.P.9
Woon, M. D.
 W.C.P.52, W.C.P.146
Worm, A. M.
 A.523
Wormser, G. P.
 T.B.P.37
Wormser, Gary P.
 D.628
Worth, D.
 Th.D.P.6, Th.D.P.7
Worth, H.
 T.B.P.17
Wortman, Jay
 W.A.P.120, T.D.O.14
Wortzman, G.
 W.B.P.196
Wozf, H.
 Th.C.P.73
Wray, David
 Th.B.P.137
Wright, A.
 Th.A.O.12, E.682, T.F.O.18,
 M.H.P.20
Wright, B.
 E.861
Wright, D. N.
 Th.B.P.138
Wright, E.
 E.608, E.609
Wright, E. J.
 M.D.P.63, D.634
Wright, Lester N.
 Th.G.P.14
Wright, N.
 Th.D.O.1
Wright, N. H.
 T.G.O.23
Wright, Nicholas H.
 W.D.P.73, W.G.P.19
Wright, P.
 M.C.P.19
Wright, S.
 W.B.P.225
Wroblewski, S.
 E.582
WRRR Group
 Th.A.O.10
Wu, Albert W.
 W.B.P.254
Wu, Ping
 W.B.P.133
Wu, Y. T.
 M.C.P.118
Wulff, K.
 Th.B.P.19
Wunderli, W.
 T.B.P.226
Wunderlich, Gary W.
 E.843
Wyand, M.
 W.C.O.48
Wybran, J.
 W.B.P.294
Wykoff, R. F.
 W.A.O.20
Wykoff, Randolph F.
 W.A.P.87
Wywendale, Bart
 D.555
X
Xanthoudakism, S.
 T.C.P.118
Xu, J.-Y.
 C.771
Y
Yacob, E.
 T.E.P.21
Yaffe, B.
 W.E.P.24
Yagello, M.
 Th.C.O.47, M.C.P.31
Yajko, D.
 T.B.P.11
Yala, F.
 W.B.P.151, Th.G.P.7
Yala, Fiddle
 A.568
Yamada, F. T.
 T.B.P.132
Yamada, O.
 C.753
Yamamoto, H.
 M.C.P.134
Yamamoto, J. K.
 W.C.O.30
Yamamoto, Janet K.
 W.C.P.11
Yamamoto, N.
 C.621
Yamashita, H. K.
 Th.B.P.63
Yamashita, Helio K.
 Th.B.P.38
Yan, Dongyou
 A.619, Th.H.P.26
Yancovitz, S.
 Th.D.P.76
Yang, H.
 M.C.P.96
Yao, J. S.
 T.A.P.67
Yao, X. K.
 C.703
Yao, Y. T.
 B.535
Yap, P. L.
 T.B.P.5, T.B.P.211,
 T.B.P.246, B.590, Th.C.P.105
Yap, S. L.
 Th.A.P.17
Yarber, W. L.
 D.548

- Yarber, William L.**
 E.660
Yarchoan, R.
 W.B.P.275, W.B.P.329,
 Th.C.O.17, M.C.F.49
Yarchoan, Robert
 Th.B.O.4, W.B.P.327,
 M.C.P.137
Yashiki, S.
 C.582
Yastrebova, O.
 T.C.P.144
Yasuda, Atsushi
 Th.C.P.96
Yasui, K.
 W.C.P.103
Yasunaga, K.
 Th.B.P.25
Yates, R.
 E.661
Yawn, D.
 M.A.P.34
Yeager, D.
 T.A.P.79
Yeager, Henry J.
 M.E.P.44, Th.E.P.44
Yee, J.
 W.C.P.18
Yee, J. L.
 Th.A.P.7, W.B.P.169
Yee, JoAnn L.
 W.C.P.23
Yee, Kathleen
 D.509
Yeh, C.-K.
 Th.B.P.353
Yellin, Edward
 Th.O.1
Yemaneberhan, T.
 T.A.P.102
Yenebat, A.
 T.E.P.21
Yeoh, E. K.
 T.A.P.120, W.G.P.30
Yernault, J. C.
 Th.B.P.55
Yetter, R. A.
 M.C.P.53
Yim, D.
 T.C.P.34
Yogev, R.
 T.B.P.224
Yokota, Yasuko
 Th.B.P.83
Yokoyama, M. M.
 Th.B.P.130, Th.C.P.141, C.609
Yokoyama, Mitchell Mitsuo
 Th.B.P.85
Yonekura, M. L.
 M.A.P.12
Yoon, J. J.
 W.A.P.5, T.B.P.159
- Yoon, Soon-Young**
 D.695
Yorifuji, H.
 M.A.P.42
York, D.
 Th.C.P.33, C.649
York, E.
 D.627
Yosef, O.
 T.C.P.119
Yoshida, M.
 B.633
Yoshida, O.
 C.621
Yoshihara, P.
 T.G.P.19
Yoshihara, Paul H.
 W.B.P.128
Yostioka, H.
 Th.B.P.130
Yoshioka, K.
 W.B.P.298
Youle, M.
 W.B.P.242, W.B.P.314
Youle, M. S.
 M.B.P.262
Youle, Mike
 M.B.P.81
Youmans, M. G.
 C.622
Young, A.
 T.B.P.263
Young, E. H.
 M.D.P.16
Young, L.
 M.B.P.300, Th.C.P.107
Young, M.
 M.B.P.150, T.B.P.237,
 W.B.P.198, Th.B.P.208
Young, Mary A.
 M.B.P.268, B.537
Young, R. A.
 W.C.O.43
Young, S.
 T.E.P.45
Young, S. R.
 W.B.P.61
Youngbar, P.
 T.B.P.102, C.663
Youngman, G.
 M.D.P.63, D.634
Yu, Xiao-Fang
 T.C.O.17
Yuen-Boyer, Marlene
 Th.E.P.33
Yunoki, M.
 Th.C.P.56
Yust, I.
 T.A.P.2, Th.B.P.118
- Z**
Zabay, J. M.
 Th.B.P.121, Th.B.P.184,
 W.C.P.120
Zabriskie, J.
 W.C.O.24
Zacarias, F.
 W.E.P.33, M.G.O.2, W.H.P.3
Zacarias, F. R. K.
 T.G.P.2
Zacarias, Fernando R. K.
 W.G.O.16
Zacchello, F.
 T.B.P.186, T.B.P.244
Zachar, V.
 Th.B.P.367, T.C.P.91
Zacharias, Fernando
 T.B.O.24
Zack, J.
 Th.A.P.21
Zackin, R. A.
 Th.B.O.47
Zackut, V.
 Th.B.P.118
Zagury, D.
 T.C.O.15, M.C.P.28,
 M.C.P.30, T.C.P.59, W.C.P.3,
 W.C.P.116, C.733, C.762
Zagury, Daniel
 W.C.O.19, M.C.P.48
Zagury, J. F.
 M.A.O.14, T.C.O.15,
 M.C.P.28, C.733
Zaia, J. A.
 W.B.P.319
Zaia, John A.
 Th.C.O.22
Zaiss, C.
 T.C.O.39
Zajac, R.
 Th.B.P.135
Zajac, R. A.
 Th.B.P.229
Zajac, Robert A.
 M.A.P.13
Zamarchi, R.
 Th.C.P.144
Zambelli, A.
 M.B.P.232, Th.B.P.299
Zambello, R.
 Th.B.P.78, Th.B.P.79
Zamecnik, P. C.
 M.C.P.80
Zamora, L.
 T.B.P.216
Zamperetti, Marco
 M.B.P.384
Zamperetti, Marco M.
 W.B.P.206, W.B.P.208, D.675
Zampieri, A.
 W.A.P.3, T.E.P.26
- Zampini, L.**
 W.A.P.30
Zampiron, M.
 T.B.P.178
Zanchetta, N.
 M.B.P.215, M.B.P.361,
 T.B.P.201, W.B.P.200
Zandri, C.
 Th.B.O.20
Zanella, A.
 M.A.O.11
Zanetti, A.
 A.516
Zanetti, Alessandro
 T.A.P.116
Zangerle, Robert
 W.B.P.341
Zanini, R.
 A.566
Zapico, R. M.
 M.B.P.370
Zarate, M.
 W.G.P.21
Zarate, S.
 D.686
Zarling, J.
 Th.C.O.34
Zarling, J. M.
 W.C.P.58
Zavattoni, M.
 M.B.P.114
Zavos, M.
 Th.F.P.13
Zawadsky, S.
 C.767
Zazayokwe, M.
 M.D.P.48, M.E.P.28,
 W.E.P.28, W.E.P.56
Zazayokwe, Musa
 M.C.O.10
Zazoun, L.
 M.B.P.132, M.B.P.225,
 M.B.P.226
Zbitnew, A.
 T.B.P.111, M.C.P.147
Zbitnew, Audrey
 M.H.P.26
Zhylot, P.
 W.E.P.58, E.635
Zeballos, Roberto
 B.639
Zech, F.
 Th.B.P.132, Th.B.P.359
Zegans, L.
 E.600
Zegans, L. S.
 M.D.P.42, M.D.P.85, E.599,
 E.628
Zeger, S.
 W.A.P.69, Th.A.P.100,
 W.B.P.226
Zehender, G.
 T.A.P.116

- Zeider, N. S.**
 W.C.P.142
Zeigler, J. L.
 E.628
Zeigler, W.
 B.635
Zeira, F.
 M.B.P.359
Zeira, Michael
 W.C.P.135
Zekeng, L.
 Th.A.O.19, M.B.P.99,
 W.D.P.87, Th.D.P.22,
 W.G.O.21
Zekeng, Leopold
 A.573
Zeli, P. L.
 W.G.P.1
Zelinski, D.
 M.E.P.63, E.529
Zemel, E.
 M.B.P.164
Zenagui, D.
 Th.B.P.132, Th.B.P.359
Zener, Karl
 W.D.P.13
Zerboni, R.
 A.545, M.B.P.50, M.B.P.384
Zerial, A.
 C.630
Zerjav, Sonja
 Th.B.P.222
Zesche, Achim
 A.501
Zessler, L.
 W.G.O.18
Zettlmeissl, Gerd W.
 C.697
Zeugin, P.
 W.A.P.116
Zewdie, D.
 M.A.P.79, W.G.P.28
Zewdie, Debrework
 T.A.P.102
Zhang, J. J.
 C.778
Zhang, P.-F.
 T.C.P.84
Zhang, Y.-H.
 Th.C.F.121
Zhao, J. Q.
 W.C.P.85
Zheng, J.
 T.C.P.17
Zhou, J. T.
 C.703
Zhou, Z.
 C.631
Zhu, Z.
 Th.C.P.38, Th.C.P.94
Zidovetzki, Raphael
 C.581
Ziegler, A.
 T.E.O.16
Ziegler, J.
 M.A.P.31, T.A.P.76
Ziegler, J. L.
 M.D.P.42, M.D.P.85
Zielen, S.
 T.B.P.218
Zielinski, M.
 T.E.P.14
Ziamba-Davis, M.
 T.D.O.21, T.D.P.2, T.D.P.75,
 Th.E.P.37
Zierler, S.
 T.A.P.96, T.A.P.97, T.D.P.71,
 Th.D.P.83, T.E.P.44
Ziffer, A.
 D.510
Ziffer, Albert M.
 E.675
Ziffer, J.
 E.675
Ziffer, Judith M.
 D.510
Zimmerman, P. L.
 M.B.P.379
Zimmerman, R. S.
 T.D.P.21
Zimmerman, Rick S.
 M.D.P.83, E.501
Zimony, I.
 Th.B.P.139
Zissis, G.
 W.A.P.49
Zoffmann, H.
 A.518
Zolla-Pazner, S.
 T.C.O.33, Th.C.O.10,
 T.C.P.70, T.C.P.74, C.771
Zolla-Pazner, Susan
 T.C.P.7
Zon, G.
 Th.C.O.19
Zoon, K.
 T.B.P.281
Zornitta, M.
 W.B.P.203
Zorr, B.
 W.B.P.278, W.B.P.372,
 W.C.P.122
Zorr, Bernd
 T.C.P.37, W.C.P.66
Zorrilla, C.
 M.B.P.27
Zorrilla, Carmen D.
 M.S.P.28
Zorzi, F.
 T.B.P.269, B.565
Zowall, Hanna
 M.H.O.4
Zuberbuehler, D.
 C.637
Zubero, Z.
 T.B.P.278
Zubia, I.
 T.A.O.23
Zucker-Franklin, D.
 M.B.P.36, Th.C.P.68
Zucker-Franklin, Dorothea
 M.C.P.78
Zulacia, D.D
 T.A.O.23
Zulaica, D.
 W.A.P.75, T.B.P.278,
 W.B.P.66, Th.B.P.65, B.601,
 E.579
Zulaica, Daniel D.
 Th.G.P.8
Zunwalt, Sally A.
 Th.B.P.378
Zunich, K.
 W.B.P.335
Zunich, Kathryn M.
 W.B.P.322
Zunzunegui, M. V.
 M.A.O.41, E.813
Zwart, G.
 W.C.P.44
Zweig, M.
 M.B.O.22, Th.D.P.38
Zweig, Michele S.
 W.B.P.57
Zwi, Anthony B.
 A.597

Index vidéo
Video Index

- Aboriginal Medical Service**
 W.I.V.14
Balsler, Michael and Andy Fabo
 T.I.V.4
Blais, Robert
 T.I.V.10
British Medical Association
Foundation for AIDS
 M.I.V.1
Burke, Andre
 W.I.V.6
Carlomusto, Maggenti
 M.I.V.9
Child Welfare League of America
 Th.I.V.4
Coward, Lynn
 Th.I.V.7
Current, David and Anne Ruthledge
 Th.I.V.12
Douglas Henry, Jessica
 Th.I.V.9
Durand, Yannick
 W.I.V.1
Dworkin, Mark and John Mitsud
 Th.I.V.5
Edan Programs
 T.I.V.1
Friedman, Gary
 Th.I.V.1
GMHC
 M.I.V.4, T.I.V.5, Th.I.V.10
Goss, John
 W.I.V.11
Greyson, John
 W.I.V.8
Grunberg, Slawomir
 T.I.V.7
Hammer, Barbara
 W.I.V.9
Harlot, Scarlot
 M.I.V.7
Hollibaugh, Amber
 T.I.V.8
Huff, Bob
 W.I.V.10
Jayle, Dôlier (Jr.)
 T.I.V.9
Johanssen, Nicke
 T.I.V.3
- Julien, Isaac**
 W.I.V.7
Kalin, Tom
 M.I.V.5
Kybartas, Stashu
 W.I.V.3
Latino AIDS Project
 Th.I.V.3
Levin, Seth
 M.I.V.10
Marshall, Stuart
 T.I.V.2
Moriyasu, Ann
 W.I.V.5
Muska, Suzan
 M.I.V.2
OMS/WHO
 T.I.V.12
Parmar, Pretfbbe
 M.I.V.6
Rogers, G.T.
 T.I.V.6
Rouleau, Fabrice
 T.I.V.13
Shames, Deborah
 Th.I.V.8, Th.I.V.11
Sobell, Nina
 M.I.V.8
Testing the Limits Collective
 W.I.V.13
Thompson, David
 W.I.V.2
Tuff, David
 M.I.V.3
Van De Velde, Quentin
 T.I.V.14
Villalobos, Daniel
 Th.I.V.2
Wardrop, Kate
 M.I.V.11
Wilson, Emjay
 W.I.V.4
Youth Against Monsters
 W.I.V.12

Index des mots clés

Keyword Index

- ABORTION**
W.A.O.10, W.A.P.11, M.B.P.7, M.B.P.10, M.B.P.18, M.B.P.25, M.B.P.32, W.D.P.58, T.H.P.1, T.E.P.52, T.G.P.31
- ACUTE INFECTION**
W.A.P.33, M.B.P.63, M.B.P.85, M.B.P.194, M.B.P.199, T.B.P.318, B.523
- ACYCLOVIR**
M.B.P.47, M.B.P.48, M.B.P.49, M.B.P.51, M.B.P.52, M.B.P.88, M.B.P.126, M.B.P.130, M.B.P.178, T.P.304, W.B.P.321, Th.B.P.343, B.526
- ADENOSINE DEAMINASE**
M.B.P.107, M.B.P.358, T.P.361, Th.B.P.85, Th.B.P.130, Th.B.P.234, B.540
- ADENOVIRUS**
W.B.P.36
- ADJUVANT**
M.C.P.38, C.742
- ADVERSE DRUG REACTIONS**
T.B.O.2, W.B.O.45, M.B.P.88, T.B.P.288, T.B.P.317, T.B.P.319, T.B.P.320, W.B.P.297, Th.B.P.117, Th.B.P.277, B.601, B.647, Th.C.O.21, M.C.P.130
see also individual drugs
- ADOLESCENTS**
M.A.O.41, W.A.O.8, W.A.O.18, W.A.P.116, M.D.O.7, M.D.O.8, M.D.O.9, M.D.O.10, M.D.O.11, T.D.O.24, T.D.O.25, T.D.O.29, M.D.P.1, M.D.P.3, M.D.P.4, M.D.P.5, M.D.P.7, M.D.P.8, M.D.P.10, T.D.P.1, T.D.P.2, T.D.P.4, T.D.P.6, T.D.P.7, T.D.P.11, T.D.P.12, T.D.P.13, T.D.P.86, T.D.P.90, T.D.P.91, T.D.P.92, W.D.P.22, W.D.P.61, Th.D.P.11, Th.D.P.25, Th.D.P.63, D.502, D.506, D.507, D.508, D.510, D.511, D.512, D.620, M.E.O.9, T.E.P.24, W.E.P.37, E.662, E.794, M.F.P.2, T.G.P.23
- ADOPTION**
M.E.P.39, M.E.P.40, W.E.P.74, Th.E.P.57, E.807
- ADRENAL GLAND DISEASE**
M.B.P.263, M.B.P.265, M.B.P.268, M.B.P.269, M.B.P.271, T.B.P.154
- AFRICAN COUNTRIES**
see Geographical aspects
- AGE**
M.A.O.31, Th.A.O.8, Th.A.O.26, Th.A.O.32, M.A.P.89, W.A.P.17, W.A.P.67, Th.A.P.36, Th.A.P.71, A.565, M.B.P.323, T.B.P.147, T.B.P.168, Th.B.P.19, W.G.O.2, W.G.O.29
- AIDS POLICY**
see Public policy
- AIDS-RELATED COMPLEX (ARC)**
M.A.P.94, W.A.P.54, W.A.P.76, W.B.O.12, Th.B.O.3, Th.B.O.44, Th.B.O.47, M.B.P.72, M.B.P.92, M.B.P.94, M.B.P.96, M.B.P.194, M.B.P.230, M.B.P.256, M.B.P.343, M.B.P.347, M.B.P.356, M.B.P.364, T.B.P.75, T.B.P.118, T.B.P.201, T.B.P.303, T.B.P.326, T.B.P.363, W.B.P.76, W.B.P.77, W.B.P.192, W.B.P.212, W.B.P.279, W.B.P.291, W.B.P.304, W.B.P.312, W.B.P.314, W.B.P.337, W.B.P.342, W.B.P.350, W.B.P.372, Th.B.P.41, Th.B.P.124, Th.B.P.158, Th.B.P.272, Th.B.P.308, B.597, M.C.O.9, M.C.O.27, M.C.P.94, M.C.P.101, M.C.P.130, M.C.P.148, C.546, C.561, C.573, D.524, E.691
- AIDS SERVICE ORGANIZATIONS (ASO)**
W.E.O.10, W.E.O.12, Th.G.P.12, H.O.15, Th.O.3, Th.O.5, Th.H.O.4, T.H.P.2, Th.H.P.1
- AL 721**
W.B.P.312, C.557, C.574
- ALANINE AMINOTRANSFERASE**
M.B.P.222
- ALCOHOL AND PROGNOSIS**
A.631, Th.B.P.68, M.D.P.24, D.725
- ALTERNATIVE PATHWAY**
Th.B.P.139
- ALTERNATIVE THERAPIES**
W.B.P.292, W.B.P.377, Th.B.P.304, Th.B.P.380, E.782, Th.H.P.13
- AMIKACIN**
M.B.P.190, Th.B.P.61
- AMINO ACIDS**
Th.B.O.42, W.B.P.194, Th.B.P.227
- 3' AMINONUCLEOSIDES**
M.C.P.90
- AMOXICILLIN**
W.B.P.58
- AMPHOTERICIN B**
M.B.P.78, M.B.P.79, M.B.P.80, M.B.P.94, W.B.P.1, W.B.P.7, W.B.P.8, W.B.P.11, W.B.P.12, W.B.P.19, W.B.P.21, W.B.P.22, W.B.P.293, M.C.P.79, M.C.P.141, C.636, C.637
- AMPHOTERICIN B METHYL ESTER**
W.B.P.293, C.636, C.637
- AMPLIGEN**
W.B.P.303, M.C.P.85, M.C.P.142
- ANAL SEX**
see Transmission
- ANIMAL MODELS**
baboon
W.C.P.1, W.C.P.26, C.502
cat
W.C.O.30, M.C.P.69, W.C.P.11, W.C.P.14, W.C.P.36, W.C.P.37, W.C.P.39, W.C.P.142, W.C.P.143
- chimpanzee
T.C.O.22, W.C.O.15, W.C.O.27, W.C.O.49, Th.C.O.30, Th.C.O.46, Th.C.O.47, M.C.P.13, M.C.P.31, M.C.P.44, T.C.P.1, T.C.P.125, W.C.P.28, W.C.P.40, W.C.P.58, C.741, C.782
- gibbon
T.C.P.100, W.C.P.3
- macaque
M.B.P.15, T.C.O.42, W.C.O.45, W.C.O.47, W.C.O.48, W.C.O.50, M.C.P.45, M.C.P.47, T.C.P.134, W.C.P.7, W.C.P.15, W.C.P.18, W.C.P.28, W.C.P.33, W.C.P.35, W.C.P.141, W.C.P.147, Th.C.P.58, Th.C.P.78, C.502, C.530, C.758
- mico
W.B.P.289, T.C.O.44, W.C.O.28, W.C.O.29, M.C.P.21, M.C.P.53, M.C.P.140, W.C.P.6, W.C.P.20, W.C.P.22, M.C.P.29, W.C.P.31, W.C.P.144, W.C.P.146, Th.C.P.102, Th.C.P.108, Th.C.P.150, C.501, C.511, C.512, D.533
- rabbit
Th.B.P.198, Th.B.P.204, W.C.O.32, M.C.P.17, M.C.P.44, M.C.P.57, W.C.P.4, W.C.P.16, W.C.P.41, Th.C.P.96, C.608
- other
A.632, T.C.O.43, W.C.O.46, Th.C.O.16, M.C.P.46, M.C.P.98, M.C.P.127, T.C.P.125, W.C.P.2, W.C.P.8, W.C.P.33, W.C.P.145
- ANONYMITY**
M.A.O.3, M.A.O.24, M.A.P.60, M.P.71, Th.A.P.39, A.523, D.696, Th.E.P.13, Th.E.P.17, E.713, E.715, W.G.P.30
- ANTABUSE**
see Imintolil
- ANTAGONISM**
Th.C.O.21, M.C.P.39, M.C.P.110, M.C.P.115, Th.C.P.139
- ANTHROPOLOGY**
T.A.P.86, M.B.P.23, B.555, M.E.O.31, M.E.O.35, W.E.P.3, Th.E.P.34, Th.E.P.49, E.516, E.517, E.519, E.782, Th.G.P.25
- ANTICARDIOLIPIN ANTIBODY (ACA)**
M.B.P.253, Th.B.P.141
- ANTI-HIV COMPOUNDS**
see specific compounds
- ANTIBODIES**
anti-synovial
Th.B.P.170, M.C.P.19, M.C.P.20, T.C.P.126, W.C.P.79, Th.C.P.9, C.550, C.720
atypical
W.B.P.176
neutralizing
W.B.O.25, M.B.P.138, W.B.P.159, Th.B.P.8, Th.B.P.182, Th.B.P.185, B.553, M.C.O.21, T.C.O.39, W.C.O.38, Th.C.O.27, Th.C.O.28, Th.C.O.30, Th.C.O.34, Th.C.O.48, M.C.P.5, M.C.P.6, M.C.P.19, M.C.P.22, M.C.P.23, M.C.P.24, M.C.P.47, M.C.P.67, T.C.P.13, T.C.P.22, T.C.P.33, T.C.P.37, T.C.P.55, T.C.P.59,

- T.C.P.89, W.C.P.44, W.C.P.92, W.C.P.95, W.C.P.96, W.C.P.111, W.C.P.135, Th.C.P.11, Th.C.P.40, Th.C.P.48, Th.C.P.91, Th.C.P.97, Th.C.P.125, C.510, C.515, C.520, C.522, C.526, C.552, C.732, C.736
- patterns**
T.B.P.5, W.B.P.105, Th.B.P.123, B.542, M.C.P.12, T.C.P.1, T.C.P.39, Th.C.P.91
- saliva**
W.B.P.156, Th.B.P.137, Th.B.P.171, Th.B.P.344, M.C.P.37, T.C.P.64
- see Monoclonal antibodies**
- specific**
Th.B.O.59, M.B.P.105, M.B.P.131, M.B.P.167, M.B.P.327, T.B.P.105, T.B.P.120, T.B.P.213, T.B.P.219, T.B.P.229, T.B.P.242, T.B.P.342, W.B.P.32, W.B.P.120, W.B.P.127, W.B.P.144, W.B.P.155, W.B.P.178, Th.B.P.97, Th.B.P.117, Th.B.P.171, Th.B.P.175, B.541, Th.C.O.35, M.C.P.40, T.C.P.29, W.C.P.98, W.C.P.124, Th.C.P.127, Th.C.P.128, C.515, C.775
- other**
M.B.O.26, M.B.P.168, M.B.P.253, T.B.P.11, T.B.P.124, T.B.P.137, T.B.P.223, W.B.P.146, W.B.P.147, W.B.P.160, Th.B.P.2, Th.B.P.131, Th.B.P.141, Th.B.P.175, Th.B.P.176, Th.B.P.181, Th.B.P.231, Th.B.P.235, B.578, B.628, Th.C.O.35, M.C.P.24, M.C.P.67, T.C.P.19, T.C.P.28, T.C.P.60, Th.C.P.148, C.538, C.553, C.558, C.573, C.586, C.697, C.722
- ANTIBODY DEPENDENT CYTOTOXICITY (ADCC)**
W.B.O.25, M.B.P.359, T.B.P.207, T.B.P.209, Th.B.P.239, W.C.O.17, T.C.O.33, Th.C.O.32, M.C.P.14, T.C.P.4, T.C.P.24, T.C.P.32, T.C.P.35, T.C.P.55, T.C.P.57, T.C.P.69, T.C.P.71, Th.C.P.97, C.514, C.524
- ANTIBODY DEPENDENT ENHANCEMENT**
Th.B.O.1, T.C.O.21, W.C.P.135, Th.C.P.45, Th.C.P.49, Th.C.P.129, C.771
- ANTIBODY RESPONSE**
M.B.O.23, M.B.O.24, M.B.P.348, T.B.P.209, W.B.P.32, M.B.P.71, W.B.P.138, W.B.P.167, Th.B.P.93, Th.B.P.95, Th.B.P.97, Th.B.P.104, Th.B.P.137, Th.B.P.171, Th.B.P.182, Th.B.P.370, Th.C.O.6, T.C.P.1, T.C.P.25, Th.C.P.143, C.520, C.523, W.G.O.29
- ANTIBODY TESTS**
see Serologic tests
- ANTI-INTERFERON IMMUNOGLOBULIN**
Th.B.P.133
- ANTI-LEU-3A**
Th.B.P.166, T.C.P.11, Th.C.P.129
- ANTISENSE NUCLEIC ACIDS**
M.C.P.58, M.C.P.77, M.C.P.80, M.C.P.105, M.C.P.145
- ANTIVIRAL**
see specific compounds
- APHTHOUS ULCER**
M.B.P.247
- ARC**
see AIDS-related complex
- ARSENICALS**
M.C.P.133
- ART THERAPY**
W.B.P.243, B.645, D.563, D.639
- ARTHRITIS**
W.B.O.17, M.B.P.261, M.B.P.262, M.B.P.363
- ARTIFICIAL INSEMINATION**
T.A.P.92, B.501
- AS 101**
W.B.P.283, W.B.P.320, T.C.P.142
- ASIAN COUNTRIES**
see Geographical aspects
- ASO**
see AIDS service organizations
- ASPERGILLOSIS**
M.B.P.90, M.B.P.95
- ASSAYS**
see Serologic tests
- ASTROCYTE**
Th.B.P.252
- ASYMPTOMATIC STAGES**
see Progression
- ATTITUDES**
see Survey
- AUTOIMMUNE PHENOMENA**
Th.B.O.19, M.B.P.171, M.B.P.247, M.B.P.253, M.B.P.271, Th.B.P.126, Th.B.P.142, Th.B.P.364, W.C.O.29, W.C.O.47, Th.C.O.5, T.C.P.60, T.C.P.62, T.C.P.147, W.C.P.57, W.C.P.94, W.C.P.99, W.C.P.130, W.C.P.138, C.553, C.578, C.727
- AUTONOMY**
T.E.P.34, Th.E.P.72, W.F.P.5
- AUTONOMIC NEUROPATHY**
Th.B.P.190, Th.B.P.191, Th.B.P.291
- AUTOPSY**
A.554, M.B.P.109, M.B.P.136, M.B.P.201, M.B.P.216, M.B.P.265, M.B.P.273, T.B.P.267, W.B.P.26, Th.B.P.253, B.534, B.552, B.563, B.565, W.C.P.84, G.516
- AVAROL**
C.606
- AZIDOTHYMINIDE**
see Zidovudine
- AZIDOURIDINE (AZDU, CS-87)**
M.C.P.54, M.C.P.98, C.631
- AZT**
see Zidovudine
- B LYMPHOCYTES**
Th.A.P.86, A.515, Th.B.O.26, M.B.P.288, M.B.P.294, T.B.P.215, T.B.P.218, T.B.P.233, W.B.P.138, W.B.P.167, Th.B.P.101, Th.B.P.106, Th.B.P.166, Th.B.P.223, Th.B.P.225, Th.B.P.242, Th.B.P.384, T.C.P.19, T.C.P.40, T.C.P.74, T.C.P.149, Th.C.P.73, Th.C.P.14, Th.C.P.72, Th.C.P.76, Th.C.P.144, C.703
- B-THALASSEMIA**
T.A.P.1
- BACTERIAL INFECTIONS**
M.B.P.36, M.B.P.39, M.B.P.70, M.B.P.71, M.B.P.73, M.B.P.74, M.B.P.75, M.B.P.76, M.B.P.77, M.B.P.84, M.B.P.86, M.B.P.87, M.B.P.88, M.B.P.100, M.B.P.371, T.B.P.199, T.B.P.262, B.522, B.600, Th.D.O.4
- BEHAVIOUR**
see Health care personnel
see Intravenous drug users
see methods of measurement
M.B.O.43, T.B.P.248, Th.B.P.68, D.534
see Serologic tests
see also Sexual behaviour
- BENZALKONIUM CHLORIDE**
W.A.P.102, T.B.P.113
- BEREAPEMENT**
D.566, M.E.P.42
- BETA CAROTENE**
C.632
- BETA-2-MICROGLOBULIN**
M.A.P.100, A.531, A.583, M.B.O.5, Th.B.O.25, Th.B.O.27, Th.B.O.28, M.B.P.337, M.B.P.360, T.B.P.312, W.B.P.72, W.B.P.74, W.B.P.76, W.B.P.78, W.B.P.81, W.B.P.83, W.B.P.85, W.B.P.86, W.B.P.92, Th.B.P.161, Th.B.P.185, Th.B.P.199, Th.B.P.222, Th.B.P.226, Th.B.P.233, Th.B.P.244, Th.B.P.358, Th.B.P.365, Th.B.P.367, W.C.P.38, Th.C.P.9
- BIOCHEMICAL ABNORMALITIES**
C.654
- BIOLOGICAL RESPONSE MODIFIERS (BRM)**
W.B.P.282, T.C.P.4, Th.C.P.64
- BISEXUALS, PREVALENCE**
M.B.P.224, M.D.P.31, Th.E.P.8, E.708, W.G.P.25, Th.G.P.1, Th.H.P.24
see also Sexual behaviour
- BLASTOCYSTIS HOMINIS**
M.B.P.237, M.B.P.238, W.B.P.37, W.B.P.46
- BLOOD BANKS**
M.A.P.33, M.A.P.85, M.A.P.118, A.577, M.B.P.139, M.B.P.151, M.B.P.155, M.B.P.161, M.B.P.162, T.B.P.183, T.B.P.344, T.B.P.352, T.B.P.355, T.B.P.359, T.B.P.360, Th.B.P.21, M.D.O.2, Th.E.P.70, M.F.P.3, M.F.P.9, T.G.O.12, W.G.O.28
- BLOOD COAGULATION**
M.B.P.65, M.B.P.282
- BLOOD DONORS**
M.A.O.5, M.A.O.10, M.A.O.11, Th.A.O.29, Th.A.O.33, M.A.P.29, M.A.P.30, M.A.P.31, M.A.P.32, M.A.P.36, M.A.P.37, M.A.P.38, M.A.P.39, M.A.P.40, M.A.P.43, Th.A.P.2

- Th.A.P.13, Th.A.P.27, Th.A.P.30, Th.A.P.31, Th.A.P.32, Th.A.P.106, A.502, A.511, A.527, A.549, M.B.P.137, M.B.P.141, M.B.P.142, M.B.P.143, M.B.P.143, M.B.P.144, M.B.P.146, M.B.P.148, M.B.P.149, M.B.P.150, M.B.P.151, M.B.P.152, M.B.P.153, M.B.P.154, M.B.P.155, M.B.P.156, M.B.P.159, M.B.P.182, M.B.P.184, M.B.P.189, T.B.P.344, T.B.P.347, T.B.P.348, T.B.P.350, T.B.P.352, T.B.P.354, T.B.P.355, T.B.P.359, T.B.P.360, T.B.P.368, W.B.P.157, W.B.P.158, B.515, B.525, B.634, T.C.P.63, Th.C.P.132, T.D.P.15, T.E.P.19, E.709, E.710, M.G.O.1, M.G.O.29, W.G.O.26, M.G.P.17, M.G.P.18, M.G.P.19, M.G.P.29, Th.G.P.7, G.511
- BLOOD FLOW**
Th.S.P.255
- BONE MARROW**
M.B.P.248, M.B.P.251, M.B.P.257, M.B.P.258, M.B.P.367, T.B.P.289, T.B.P.270, T.B.P.285, T.B.P.323, W.B.P.124, W.B.P.319, Th.B.P.96, M.C.P.98, M.C.P.103, M.C.P.145, T.C.P.17, T.C.P.146, W.C.P.75, C.631
- BOWEN'S DISEASE (ANAL)**
M.B.P.191
- BRAIN**
see Central nervous system
- BREASTFEEDING**
Th.A.O.5, W.A.P.51, W.A.P.56, M.B.O.3, T.B.P.193, Th.B.P.368, W.G.O.1, G.521, M.H.O.8, Th.H.O.8
- BRONCHO-AVEOLAR LAVAGE**
M.B.P.73, M.B.P.115, M.B.P.130, M.B.P.210, M.B.P.214, T.B.P.2, T.B.P.3, T.B.P.8, T.B.P.9, T.B.P.13, T.B.P.15, T.B.P.25, T.B.P.26, T.B.P.155, Th.B.P.77, Th.B.P.81, C.518, C.713
- BURNOUT**
see Health care personnel
- CACHEXIA**
Th.B.O.37, Th.B.O.38, Th.B.P.305, Th.B.P.309, Th.B.P.312, W.C.P.83, W.C.P.114, W.C.P.115
- CAEV**
see *Caprine arthritis encephalitis virus*
- CALCIUM CHANNEL BLOCKERS**
Th.C.P.93, C.673
- CAMPAIGN**
see Programme
- CANCERS**
Th.A.P.105, W.B.O.19, M.B.P.59, M.B.P.186, M.B.P.274, M.B.P.292, M.B.P.293, T.B.P.259, T.B.P.261, T.B.P.291, B.631, Th.C.O.36, W.C.P.49, W.C.P.51, W.C.P.148
- CANDIDA**
M.B.O.17, M.B.O.18, M.B.P.85, M.B.P.96, M.B.P.175, M.B.P.178, M.B.P.240, M.B.P.245, M.B.P.365, T.B.P.188, T.B.P.265, W.B.P.348, Th.B.P.99, Th.B.P.137, Th.B.P.319, Th.B.P.320, Th.B.P.321, Th.B.P.322, Th.B.P.323, Th.B.P.326, Th.B.P.328, Th.B.P.329, Th.B.P.334, Th.B.P.335, Th.B.P.337, Th.B.P.346, Th.B.P.348, Th.B.P.355, B.591, M.C.P.71, M.C.P.143
- CAPRINE ARTHRITIS ENCEPHALITIS VIRUS (CAEV)**
M.C.O.24, M.C.P.122
- CARBOVIR**
M.C.P.125
- CAREGIVERS, NONFAMILY**
M.B.P.315, T.D.P.49, T.D.P.56, D.639, M.E.O.17, W.E.O.3, Th.E.P.71, E.527, E.771
see also Family; Health care personnel
- CASE CONTROL STUDIES**
M.A.O.3, T.A.O.34, M.A.P.90, W.A.P.31, Th.A.P.41, Th.A.P.95, Th.A.P.103, B.642, W.D.P.92
- CASE DEFINITION**
see Diagnostic criteria
see also Progression
- CASE MANAGEMENT**
A.627, M.B.P.301, M.B.P.302, M.B.P.378, T.B.P.382, W.B.P.44, W.B.P.162, W.B.P.284, B.523, W.E.O.10, M.E.P.27, M.E.P.49, M.E.P.62, M.E.P.71, Th.E.P.49, E.528, E.624, E.684, T.G.P.4, M.H.O.7, W.H.O.8, W.H.O.9, M.H.P.3, M.H.P.4, M.H.P.7, M.H.P.15, M.H.P.19, T.H.P.5, T.H.P.7, T.H.P.10, T.H.P.27, W.H.P.7
- CASTANOSPERMINE (CAS)**
Th.B.O.48, M.C.P.117, W.C.P.29, C.543
- CATHETERS**
M.B.P.72, M.B.P.83, M.B.P.84, M.B.P.85, M.B.P.86, M.B.P.87, M.B.P.89, T.B.P.258, T.B.P.260
- CATIONS**
T.C.P.148
- CD4 LYMPHOCYTES**
M.A.O.45, M.A.O.47, M.A.P.41, M.A.P.96, M.A.P.98, M.A.P.106, W.A.P.77, Th.A.P.80, Th.A.P.91, Th.A.P.92, Th.A.P.101, A.583, A.631, M.B.O.4, T.B.O.4, Th.B.O.1, Th.B.O.43, Th.B.O.45, M.B.P.2, M.B.P.61, M.B.P.103, M.B.P.110, M.B.P.111, M.B.P.145, M.B.P.175, M.B.P.180, M.B.P.192, M.B.P.220, M.B.P.232, M.B.P.245, M.B.P.299, M.B.P.355, M.B.P.374, M.B.P.380, T.B.P.85, T.B.P.86, T.B.P.89, T.B.P.95, T.B.P.118, T.B.P.153, T.B.P.166, T.B.P.198, T.B.P.215, T.B.P.253, T.B.P.277, T.B.P.309, T.B.P.315, W.B.P.70, W.B.P.72, W.B.P.79, W.B.P.82, W.B.P.86, W.B.P.281, W.B.P.291, W.B.P.302, W.B.P.305, W.B.P.307, W.B.P.324, W.B.P.325, W.B.P.329, W.B.P.334, W.B.P.338, W.B.P.355, W.B.P.361, W.B.P.366, W.B.P.368, Th.B.P.9, Th.B.P.15, Th.B.P.17, Th.B.P.20, Th.B.P.25, Th.B.P.40, Th.B.P.56, Th.B.P.77, Th.B.P.80, Th.B.P.83, Th.B.P.87, Th.B.P.102, Th.B.P.108, Th.B.P.113, Th.B.P.115, Th.B.P.116, Th.B.P.118, Th.B.P.119, Th.B.P.135, Th.B.P.143, Th.B.P.149, Th.B.P.147, Th.B.P.148, Th.B.P.149, Th.B.P.153, Th.B.P.154, Th.B.P.155, Th.B.P.158, Th.B.P.159, Th.B.P.161, Th.B.P.164, Th.B.P.166, Th.B.P.167, Th.B.P.168, Th.B.P.181, Th.B.P.185, Th.B.P.238, Th.B.P.265, Th.B.P.315, Th.B.P.329, Th.B.P.343, Th.B.P.344, Th.B.P.347, Th.B.P.351, Th.B.P.358, Th.B.P.359, Th.B.P.365, B.512, B.556, B.576, B.613, B.621, B.639, W.C.O.22, W.C.O.26, W.C.O.47, M.C.P.56, M.C.P.124, M.C.P.133, M.C.P.137, T.C.P.5, T.C.P.10, T.C.P.44, T.C.P.45, T.C.P.63, T.C.P.66, T.C.P.74, W.C.P.5, W.C.P.58, W.C.P.65, W.C.P.71, W.C.P.80, W.C.P.82, W.C.P.93, W.C.P.108, W.C.P.125, W.C.P.133, W.C.P.138, W.C.P.144, Th.C.P.4, Th.C.P.16, Th.C.P.19, Th.C.P.89, Th.C.P.101, Th.C.P.139, C.504, C.528, C.530, C.531, C.543, C.556, C.568, C.708, C.710, C.711, C.720, C.727, C.753
- CD4**
anti-idiotype antibodies
T.B.P.86, T.B.P.334, W.B.P.69, Th.B.P.142, Th.B.P.158, C.538, C.553
binding
T.C.O.34, W.C.O.12, W.C.O.14, W.C.O.16, W.C.O.25, Th.C.O.12, Th.C.O.31, Th.C.O.46, T.C.P.106, W.C.P.66, W.C.P.128, Th.C.P.1, Th.C.P.34, Th.C.P.100, C.517, C.523, C.528, C.552, C.574, C.697, C.752
circadian
M.B.P.269
molecule
M.C.O.29, W.C.O.15, Th.C.O.2, Th.C.O.25, M.C.P.20, M.C.P.89, M.C.P.102, T.C.P.6, T.C.P.11, T.C.P.15, T.C.P.56, T.C.P.125, W.C.P.27, W.C.P.76, W.C.P.132, Th.C.P.13, Th.C.P.61, Th.C.P.67, C.538, C.535, C.641, C.687, C.706, C.783
peptides
W.C.O.16, T.C.P.90
soluble
Th.B.O.5, Th.B.O.8, W.C.O.14, Th.C.O.5, Th.C.O.16, M.C.P.102, T.C.P.20, T.C.P.116, Th.C.P.34, Th.C.P.100
synthesis
Th.B.O.48, Th.B.P.107, Th.B.P.118, T.C.P.112, Th.C.P.67, C.516
other
T.B.P.195, T.B.P.334, W.B.P.365, Th.B.P.86, B.543, W.C.O.15, Th.C.O.27, M.C.P.22, M.C.P.102, T.C.P.138, Th.C.P.113, Th.C.P.138, C.515, C.528, C.542, C.550, C.567, C.613, C.749
- CDS CELLS**
M.A.O.45, M.A.P.98, M.A.P.99, M.A.P.106, W.A.P.77, Th.A.P.91, A.631, M.B.O.4, W.B.O.25, Th.B.O.1, M.B.P.210, M.B.P.220, M.B.P.299, M.B.P.354,

- M.B.P.356, M.B.P.360, T.B.P.86,
T.B.P.209, W.B.P.307, Th.B.P.77,
Th.B.P.87, Th.B.P.95, Th.B.P.103,
Th.B.P.113, Th.B.P.116, Th.B.P.144,
Th.B.P.148, Th.B.P.149, Th.B.P.153,
Th.B.P.154, Th.B.P.158, Th.B.P.159,
Th.B.P.162, Th.B.P.164, Th.B.P.166,
Th.B.P.185, Th.B.P.329, B.512, B.613,
B.621, B.639, T.C.O.32, W.C.O.5,
W.C.O.39, W.C.O.41, W.C.O.42,
W.C.O.44, M.C.P.30, M.C.P.56, T.C.P.5,
T.C.P.25, T.C.P.31, T.C.P.44, T.C.P.45,
T.C.P.47, T.C.P.50, T.C.P.61, T.C.P.63,
T.C.P.67, T.C.P.76, T.C.P.141, T.C.P.148,
W.C.P.5, W.C.P.65, Th.C.P.101,
Th.C.P.126, C.524, C.531, C.541, C.561,
C.655, C.710
- suppressor cells**
T.C.O.32, W.C.O.5
M.B.P.42, W.B.P.294, W.C.O.41,
Th.C.O.1, W.C.P.58
- CELL ENTRY**
W.C.O.25, Th.C.O.26, Th.C.P.15,
Th.C.P.17, Th.C.P.150, C.517, Th.G.P.8
- CELL MARKERS**
T.B.P.8, Th.B.P.77, Th.B.P.153,
Th.B.P.154, Th.B.P.332, B.621, M.C.O.30,
T.C.O.3, Th.C.O.1, T.C.P.14, T.C.P.15,
T.C.P.45, T.C.P.50, T.C.P.52, T.C.P.141,
C.524, C.546, C.573, C.587, C.632, C.655,
C.714, C.718
- CELL METABOLISM, PURINES**
C.673
- CELL TROPISM**
Th.C.O.24, T.C.P.104, W.C.P.106,
Th.C.P.47, Th.C.P.65, Th.C.P.72,
Th.C.P.116, C.649, C.723, C.768
- CELLULAR DIFFERENTIATION**
W.C.O.9, T.C.P.112, W.C.P.107, Th.C.P.64
- CENTRAL NERVOUS SYSTEM (CNS)**
dementia
W.B.O.43, Th.B.O.24, M.B.P.101,
T.B.P.299, W.B.P.91, W.B.P.182,
W.B.P.193, W.B.P.194, W.B.P.218,
W.B.P.229, W.B.P.231, W.B.P.232,
W.B.P.234, W.B.P.255, W.B.P.256,
W.B.P.259, W.B.P.306, W.B.P.331,
Th.B.P.188, Th.B.P.193, Th.B.P.195,
Th.B.P.197, Th.B.P.205, Th.B.P.206,
Th.B.P.210, Th.B.P.211, Th.B.P.215,
Th.B.P.221, Th.B.P.227, Th.B.P.232,
Th.B.P.233, Th.B.P.250, Th.B.P.253,
Th.B.P.257, Th.B.P.259, Th.B.P.267,
Th.B.P.269, Th.B.P.272, Th.B.P.274,
Th.B.P.279, Th.B.P.281, Th.B.P.284,
Th.B.P.286, Th.B.P.288, Th.B.P.289,
Th.B.P.295, Th.B.P.296, B.568, B.611,
W.C.P.45, W.C.P.69, W.C.P.84,
W.C.P.103, T.D.P.58, D.716
- diagnosis**
W.A.P.75, Th.A.P.5, M.B.O.33, M.B.O.36,
M.B.O.38, Th.B.O.20, M.B.P.382,
T.B.P.176, W.B.P.181, W.B.P.229,
Th.B.P.201, Th.B.P.213, Th.B.P.217,
Th.B.P.221, Th.B.P.244, Th.B.P.254,
Th.B.P.255, Th.B.P.264, Th.B.P.267,
Th.B.P.278, Th.B.P.279, Th.B.P.280,
W.C.P.14, W.C.P.45, W.C.P.112,
W.C.P.127
- evaluation, biopsy**
W.B.O.18, Th.B.O.21, Th.B.P.250,
Th.B.P.263, B.565, W.C.P.43, C.763
- evaluation, cerebrospinal fluid**
M.B.O.44, W.B.O.2, M.B.P.88, M.B.P.101,
W.B.P.55, W.B.P.91, W.B.P.194,
Th.B.P.193, Th.B.P.198, Th.B.P.204,
Th.B.P.222, Th.B.P.223, Th.B.P.225,
Th.B.P.226, Th.B.P.227, Th.B.P.232,
Th.B.P.236, Th.B.P.237, Th.B.P.238,
Th.B.P.242, Th.B.P.245, Th.B.P.270,
Th.B.P.383, Th.B.P.365, W.C.P.67CNS
- evaluation, electroencephalography**
W.B.O.42, T.B.P.187, Th.B.P.192,
Th.B.P.265, Th.B.P.272, Th.B.P.273,
Th.B.P.274, Th.B.P.275, Th.B.P.280,
Th.B.P.281
- evaluation, histopathology**
W.B.O.18, Th.B.O.21, Th.B.O.22,
T.B.P.67, W.B.P.60, Th.B.P.194,
Th.B.P.248, Th.B.P.252, Th.B.P.258,
W.C.P.14, W.C.P.45, W.C.P.53, W.C.P.60,
W.C.P.67, W.C.P.103
- evaluation, multimodal evoked**
M.B.O.44, W.B.O.44, W.B.P.193,
W.B.P.232, Th.B.P.265, Th.B.P.280,
Th.B.P.287, Th.B.P.293, Th.B.P.297
- evaluation, neurological**
M.A.P.90, M.B.O.39, M.B.O.40, W.B.O.42,
W.B.O.45, Th.B.O.19, Th.B.O.24,
M.B.P.118, M.B.P.134, T.B.P.174,
T.B.P.179, T.B.P.182, T.B.P.183,
T.B.P.185, W.B.P.28, W.B.P.58,
W.B.P.183, W.B.P.185, W.B.P.186,
W.B.P.198, W.B.P.224, W.B.P.227,
W.B.P.231, W.B.P.232, W.B.P.255,
W.B.P.256, W.B.P.259, W.B.P.297,
Th.B.P.188, Th.B.P.189, Th.B.P.192,
Th.B.P.197, Th.B.P.202, Th.B.P.203,
Th.B.P.205, Th.B.P.206, Th.B.P.207,
Th.B.P.212, Th.B.P.220, Th.B.P.239,
Th.B.P.240, Th.B.P.242, Th.B.P.257,
Th.B.P.269, Th.B.P.261, Th.B.P.263,
Th.B.P.266, Th.B.P.268, Th.B.P.269,
Th.B.P.270, Th.B.P.276, Th.B.P.277,
Th.B.P.278, Th.B.P.280, Th.B.P.285,
Th.B.P.286, Th.B.P.287, Th.B.P.288,
Th.B.P.289, Th.B.P.290, Th.B.P.292,
Th.B.P.295, Th.B.P.377, B.568, B.573,
B.575, B.645, W.C.P.61, W.C.P.65,
Th.C.P.134, T.D.P.44, T.D.P.65, T.D.P.72,
D.716
- evaluation, psychometric**
W.B.O.42, W.B.O.44, W.B.O.45,
T.B.P.175, W.B.P.182, W.B.P.185,
W.B.P.186, W.B.P.192, W.B.P.193,
W.B.P.196, W.B.P.204, W.B.P.210,
W.B.P.224, W.B.P.225, W.B.P.227,
W.B.P.230, W.B.P.231, W.B.P.234,
W.B.P.235, W.B.P.261, Th.B.P.31,
Th.B.P.192, Th.B.P.197, Th.B.P.202,
Th.B.P.207, Th.B.P.208, Th.B.P.219,
Th.B.P.242, Th.B.P.257, Th.B.P.265,
- Th.B.P.266, Th.B.P.269, Th.B.P.275,
Th.B.P.278, Th.B.P.279, Th.B.P.280,
Th.B.P.281, Th.B.P.284, Th.B.P.286,
Th.B.P.292, Th.B.P.295, Th.B.P.376,
B.566, T.D.P.59, T.D.P.61, D.715
- evaluation, radiological**
Th.B.O.23, M.B.P.196, W.B.P.242,
Th.B.P.242, Th.B.P.255, Th.B.P.256,
Th.B.P.257, Th.B.P.258, Th.B.P.262,
Th.B.P.265, Th.B.P.280, Th.B.P.282
- evaluation, viral isolate**
T.B.P.148, T.B.P.187, Th.B.P.222,
Th.B.P.246, W.C.P.13, W.C.P.45,
W.C.P.70, W.C.P.113, Th.C.P.113, C.763
- HIV-2 infection**
T.B.P.382
- other**
M.A.O.31, M.B.O.36, M.B.O.37, M.B.O.42,
W.B.O.45a, M.B.P.63, M.B.P.102,
M.B.P.198, M.B.P.264, W.B.P.26,
W.B.P.29, W.B.P.33, W.B.P.34, W.B.P.51,
W.B.P.219, M.B.P.165, Th.B.P.217,
Th.B.P.260, Th.B.P.267, Th.B.P.277,
Th.B.P.375, B.574, B.595, M.C.P.107,
W.C.P.24, W.C.P.91, W.C.P.112, C.759,
T.D.P.50
- see also* Cerebrospinal fluid;
Computerized tomography; Magnetic
resonance
- CEREBROSPINAL FLUID (CSF)**
M.B.O.35, M.B.P.134, W.B.P.4, W.B.P.8,
W.B.P.14, W.B.P.21, W.B.P.50, W.B.P.51,
W.B.P.55, W.B.P.58, Th.B.P.165,
Th.B.P.196, Th.B.P.210, Th.B.P.214,
Th.B.P.219, Th.B.P.224, Th.B.P.228,
Th.B.P.229, Th.B.P.231, Th.B.P.234,
Th.B.P.235, Th.B.P.238, Th.B.P.241,
Th.B.P.243, Th.B.P.244, Th.B.P.246,
Th.B.P.247, Th.B.P.363, B.573, B.628,
M.C.P.92, W.C.P.42, Th.C.P.97, C.721
- CERVICAL NEOPLASIA**
M.B.P.53, M.B.P.56, M.B.P.60, M.B.P.292
- CHAGA'S DISEASE (TRYPANOSOMA CRUZI)**
M.B.P.102, Th.B.P.4
- CHELATING AGENTS**
T.C.P.148
- CHEMOTAXIS**
Th.B.P.89, C.556, C.724
- CHEST X-RAY**
M.B.P.106, M.B.P.212, T.B.P.15,
T.B.P.379, Th.B.P.38, Th.B.P.56, B.532,
B.559
- CHILDREN**
see Breastfeeding
clinical presentation
M.B.O.1, M.B.O.39, M.B.P.227, T.B.P.146,
T.B.P.150, T.B.P.156, Th.B.P.158,
T.B.P.161, T.B.P.168, T.B.P.169,
T.B.P.174, T.B.P.181, T.B.P.187,
T.B.P.188, T.B.P.190, T.B.P.191,
T.B.P.196, T.B.P.199, Th.B.P.203,
T.B.P.211, T.B.P.259, T.B.P.262,
T.B.P.263, T.B.P.264, T.B.P.265,

- T.B.P.266, T.B.P.374, T.B.P.378, W.B.P.382, B.583, B.586, B.600, W.G.O.2, W.G.O.4, Th.G.O.33, Th.G.O.34, Th.G.O.51, G.509
- diagnosis**
W.A.P.5, A.572, A.633, M.B.P.1, T.B.P.149, T.B.P.155, T.B.P.159, T.B.P.166, T.B.P.211, T.B.P.216, T.B.P.217, T.B.P.223, T.B.P.225, T.B.P.227, T.B.P.228, T.B.P.230, T.B.P.233, T.B.P.234, T.B.P.236, T.B.P.237, T.B.P.238, T.B.P.243, T.B.P.244, T.B.P.260, W.B.P.136, W.B.P.174, W.B.P.200, T.C.P.55, T.C.P.66, Th.C.P.21, C.767, C.773, Th.G.O.34
- foster care**
M.E.P.38, M.E.P.39, M.E.P.42, Th.E.P.57, E.807
- group care**
M.B.P.318, D.512, M.E.O.16, M.E.P.42, E.579
- hemophilia**
M.A.P.41, T.B.P.253, T.B.P.257, W.B.P.87, W.B.P.296, Th.B.P.5, Th.B.P.9, Th.B.P.18, Th.B.P.20, Th.B.P.21, Th.B.P.29, D.556
- HIV antigen**
M.B.O.5, M.B.P.372, T.B.P.228, T.B.P.230, T.B.P.237, T.B.P.261, W.B.P.87, W.B.P.382, B.573, B.592, W.F.P.3
- immunological**
Th.A.O.4, Th.A.O.7, W.A.P.49, M.B.O.1, M.B.O.4, T.B.P.151, T.B.P.161, T.B.P.163, T.B.P.172, T.B.P.184, T.B.P.206, T.B.P.208, T.B.P.209, T.B.P.211, T.B.P.212, T.B.P.213, T.B.P.215, T.B.P.218, T.B.P.224, T.B.P.229, T.B.P.246, T.B.P.254, W.B.P.78, Th.B.P.89, Th.B.P.372, B.573, B.586, B.625, T.C.P.66, W.C.P.95, Th.C.P.91, C.554, M.G.P.28, W.G.P.9
- neonates**
M.A.O.18, W.A.O.7, W.A.O.10, Th.A.O.5, Th.A.O.6, Th.A.O.8, M.A.P.6, W.A.P.1, W.A.P.5, W.A.P.47, W.A.P.50, W.A.P.51, Th.A.P.113, M.B.P.40, W.B.O.2, M.B.P.12, M.B.P.13, M.B.P.15, M.B.P.17, M.B.P.26, T.B.P.115, T.B.P.148, T.B.P.152, T.B.P.154, T.B.P.159, T.B.P.160, T.B.P.162, T.B.P.163, T.B.P.167, T.B.P.173, T.B.P.176, T.B.P.200, T.B.P.206, T.B.P.210, T.B.P.219, T.B.P.220, T.B.P.221, T.B.P.222, T.B.P.223, T.B.P.224, T.B.P.226, T.B.P.229, T.B.P.235, T.B.P.236, T.B.P.238, T.B.P.239, T.B.P.243, T.B.P.257, T.B.P.378, B.540, B.573, B.574, B.577, B.590, M.C.O.31, M.C.O.31, T.C.P.122, C.749, T.F.P.12, Th.G.O.53, W.G.P.10
- neurological**
M.B.O.40, M.B.O.41, M.B.O.42, M.B.O.44, M.B.P.24, T.B.P.148, T.B.P.174, T.B.P.175, T.B.P.176, T.B.P.177, T.B.P.179, T.B.P.180, T.B.P.182, T.B.P.184, T.B.P.185, T.B.P.186, T.B.P.187, T.B.P.248, W.B.P.183, B.574, B.575, W.C.P.61, W.C.P.127
- pathology**
T.B.P.267, T.B.P.370, Th.B.P.324, Th.B.P.372, B.580, W.C.O.45
- prevalence**
M.A.O.18, T.A.O.40, Th.A.O.7, Th.A.O.11, M.A.P.14, T.A.P.1, T.A.P.65, W.A.P.1, W.A.P.9, W.A.P.47, Th.A.P.15, A.572, A.633, Th.B.O.39, M.B.P.160, T.B.P.157, T.B.P.165, T.B.P.190, W.B.P.174, Th.B.P.325, Th.G.P.27
- prevention**
M.B.P.17, M.B.P.314, B.600, W.D.P.43, M.E.P.67, W.E.P.46, E.520, E.682
- prognosis**
M.B.O.11, M.B.O.5, M.B.O.39, T.B.P.147, T.B.P.170, T.B.P.205, T.B.P.228, T.B.P.241, T.B.P.245, T.B.P.265, B.592, Th.C.P.7, W.G.O.5, W.G.O.6, Th.G.O.49, Th.G.O.52, W.G.P.7
- progression**
M.A.P.14, W.A.P.4, W.A.P.50, M.B.O.1, M.B.O.2, M.B.O.44, T.B.P.153, T.B.P.163, T.B.P.165, T.B.P.169, T.B.P.170, T.B.P.174, T.B.P.190, T.B.P.193, T.B.P.197, T.B.P.210, T.B.P.234, T.B.P.254, W.B.P.382, Th.B.P.20, B.574, B.575, Th.C.P.7, W.G.O.4, Th.G.O.54
- psychology**
M.B.O.41, M.B.P.305, M.B.P.317, T.B.P.175, T.B.P.178, T.B.P.183, W.B.P.183, B.595, M.E.O.16, M.E.P.42, E.504
- sexual abuse**
M.D.P.7, T.D.P.71
- social impact**
M.B.P.313, M.B.P.314, T.B.P.378, M.E.O.16, W.H.P.6
- see Transmission, vertical**
- treatment**
M.B.P.323, T.B.P.247, T.B.P.261, B.575, B.579, B.584, B.591, B.600, M.E.O.15, Th.E.O.9, M.E.P.34, M.E.P.67, M.E.P.71, W.E.P.21, Th.E.P.57, E.682
- twins**
W.G.P.8
- vaccination**
M.B.P.372, W.G.O.3, M.G.P.27
- other**
W.A.O.18, M.A.P.25, W.A.P.48, Th.B.O.39, M.B.P.26, M.B.P.315, T.B.P.164, T.B.P.194, T.B.P.204, T.B.P.207, T.B.P.249, T.B.P.256, T.B.P.258, T.B.P.260, C.715, T.D.P.79, W.D.P.16, Th.D.P.27, D.556, E.666, T.F.O.18, Th.H.P.22
- CHINESE HERBAL EXTRACTS**
B.596
see also Alternative therapies
- CHLOROQUINE**
M.C.P.66, M.C.P.119
- CHURCH SUPPORT**
W.E.O.26, W.E.O.27, W.E.O.29, Th.E.P.41, Th.E.P.43, Th.E.P.45, E.532, E.534, E.674, E.733, E.734
- CIRCUMCISION**
T.A.P.86, T.A.P.89, Th.G.O.27
- CLASSIFICATION**
see Diagnostic criteria
- CLINICAL TRIALS, METHODOLOGY**
M.B.O.47, M.B.P.50, M.B.P.104, M.B.P.301, M.B.P.303, T.B.P.56, T.B.P.72, T.B.P.201, T.B.P.359, W.B.P.68, W.B.P.247, W.B.P.249, W.B.P.250, W.B.P.258, W.B.P.270, W.B.P.286, W.B.P.296, W.B.P.299, W.B.P.300, W.B.P.309, W.B.P.374, B.556, M.C.P.11, M.C.P.13, M.C.P.14, M.C.P.52, M.C.P.59, M.C.P.62, M.C.P.85, M.C.P.94, M.C.P.101, Th.C.P.106, Th.C.P.141, C.590, C.601, C.603, C.607, C.618, C.619, C.628, C.639, C.840, D.711, E.889, E.690, E.711, E.732, T.F.O.13, W.F.O.5, W.F.O.6, W.F.O.7, T.F.P.1, W.F.P.1, W.F.P.2, W.F.P.3, M.G.O.3, W.H.P.26
see also individual drugs
- CLOTTING FACTORS**
M.B.P.250, M.B.P.252, M.B.P.253, Th.B.P.6, Th.B.P.10, Th.B.P.21, W.C.P.97
- CMV INFECTIONS**
see Cytomegalovirus
- CNS**
see Central nervous system
- CO2 LASER**
T.B.P.349
- COCCIDIOIDOMYCOSIS**
M.B.P.45, M.B.P.46
- COFACTORS**
M.A.O.16, M.A.O.29, M.A.O.32, M.A.O.34, M.A.O.46, M.A.O.48, M.A.O.49, Th.A.O.6, Th.A.O.10, Th.A.O.17, Th.A.O.26, M.A.P.21, M.A.P.71, M.A.P.87, M.A.P.89, M.A.P.90, M.A.P.91, M.A.P.92, M.A.P.93, M.A.P.95, M.A.P.109, M.A.P.110, M.A.P.111, M.A.P.112, M.A.P.113, T.A.P.81, T.A.P.91, T.A.P.119, W.A.P.65, W.A.P.77, Th.A.P.23, Th.A.P.72, Th.A.P.100, Th.A.P.103, A.508, A.516, A.540, A.565, A.566, A.567, A.615, A.620, A.621, A.631, W.B.O.10, M.B.P.110, T.B.P.151, W.B.P.190, W.B.P.239, Th.B.P.63, Th.B.P.150, Th.B.P.315, Th.B.P.316, B.519, B.521, B.547, W.C.P.80, W.C.P.125, W.C.P.129, Th.C.P.19, C.740, C.747, D.713, E.688, Th.G.P.2, G.509
- COHORT STUDIES**
M.A.O.27, M.A.O.45, M.A.O.48, T.A.O.19, T.A.O.31, Th.A.O.3, Th.A.O.16, Th.A.O.24, M.A.P.34, M.A.P.87, M.A.P.93, M.A.P.105, M.A.P.108, M.A.P.110, M.A.P.111, M.A.P.112, T.A.P.31, T.A.P.58, T.A.P.104, T.A.P.107, W.A.P.30, W.A.P.45, W.A.P.50, W.A.P.54, W.A.P.55, W.A.P.59, W.A.P.65, W.A.P.71, W.A.P.74, W.A.P.75, W.A.P.80, W.A.P.93, Th.A.P.41, Th.A.P.86, Th.A.P.92, Th.A.P.105, A.548, M.B.O.45, T.B.O.27, W.B.O.24, W.B.O.26, W.B.O.28, W.B.O.41, W.B.O.45, M.B.P.29, M.B.P.42, M.B.P.196, M.B.P.254, T.B.P.162,

- T.B.P.204, T.B.P.207, W.B.P.71, W.B.P.112, W.B.P.181, W.B.P.201, W.B.P.211, W.B.P.224, W.B.P.270, W.B.P.273, Th.B.P.16, Th.B.P.22, Th.B.P.75, Th.B.P.95, Th.B.P.183, Th.B.P.195, Th.B.P.200, Th.B.P.202, Th.B.P.218, Th.B.P.281, Th.B.P.276, Th.B.P.278, Th.B.P.287, Th.B.P.288, Th.B.P.324, Th.B.P.373, B.555, B.633, W.C.P.98, C.787, T.D.O.6, T.D.P.35, T.D.P.39, T.D.P.67, Th.D.P.39, Th.D.P.40, Th.D.P.57, Th.D.P.78, Th.D.P.79, T.E.P.43, Th.E.P.73, M.G.O.28, T.G.O.11, Th.G.O.54, M.G.P.3, T.G.P.6, Th.G.P.4, Th.H.P.17
- CONFECTION**
Th.A.O.23, M.A.P.18, M.A.P.79, M.A.P.80, M.A.P.81, M.A.P.93, T.A.P.29, W.A.P.3, W.A.P.40, Th.A.P.18, Th.A.P.23, Th.A.P.30, Th.A.P.109, A.552, A.573, A.586, A.615, A.620, T.B.O.10, Th.B.O.58, M.B.P.19, M.B.P.78, M.B.P.110, M.B.P.371, T.B.P.266, W.B.P.98, W.B.P.112, Th.B.P.68, Th.B.P.70, Th.B.P.351, B.519, B.529, B.610, W.C.P.47, W.C.P.80, Th.C.P.5, Th.C.P.105, C.787, Th.D.P.4, T.G.O.21, Th.G.O.26, M.G.P.3, M.G.P.23, T.G.P.28, W.G.P.6
- COLCHICINE**
W.C.O.24
- COLD AGGLUTININS**
M.B.P.64
- COLONY STIMULATING FACTORS**
M.B.P.63, T.B.P.284, W.B.P.328, Th.B.P.213, W.C.P.109
- COMMUNITY-BASED ORGANIZATIONS**
M.A.P.75, T.A.P.67, W.A.P.82, A.598, A.627, M.B.P.301, M.B.P.303, M.B.P.304, M.B.P.213, T.B.P.18, W.B.P.67, W.B.P.247, W.B.P.250, W.B.P.283, C.601, M.D.P.21, Th.D.P.27, Th.D.P.73, D.704, M.E.O.24, W.E.O.5, W.E.O.8, Th.E.O.18, M.E.P.7, M.E.P.8, M.E.P.9, M.E.P.11, M.E.P.16, M.E.P.49, M.E.P.50, M.E.P.57, M.E.P.63, M.E.P.67, M.E.P.72, T.E.P.3, T.E.P.5, T.E.P.10, T.E.P.40, T.E.P.41, T.E.P.56, W.E.P.16, Th.E.P.33, Th.E.P.68, Th.E.P.69, Th.E.P.72, E.502, E.503, E.529, E.530, E.531, E.536, E.538, E.537, E.538, E.539, E.541, E.557, E.567, E.674, E.695, E.696, E.702, E.732, E.740, E.761, E.778, E.779, E.809, E.810, Th.F.P.2, T.H.P.15
- COMPLEMENT**
Th.P.127, Th.P.134, Th.B.P.139, Th.B.P.191, T.C.P.12, T.C.P.68, C.558
- COMPLEMENT-DEPENDENT ENHANCEMENT**
M.B.P.45, W.B.P.239, W.C.O.26, M.C.P.19, W.C.P.92, W.C.P.94, Th.C.P.129, C.575, C.771
- COMPLEMENT FACTORS**
Th.B.P.139
- COMPUTERIZED TOMOGRAPHY (CT)**
M.B.O.44, M.B.P.41, Th.B.P.255, Th.B.P.283, B.569
- COMPUTERS**
data base
T.A.P.9, T.A.P.72, T.A.P.75, W.A.P.72, A.569, A.637, W.B.P.376, Th.C.P.120, C.582, W.E.P.6, W.E.P.32, W.E.P.62, E.539, E.712, T.F.P.11, T.G.P.3, T.G.P.5, G.502, G.514, W.H.P.26
- management
C.582, G.514
- see Model
- neurology
Th.B.P.294
- CONDOMS**
effectiveness
M.A.O.37, T.A.O.13, T.A.O.25, M.A.P.114, T.A.P.107, W.A.P.95, W.A.P.99, W.A.P.101, A.544, T.D.O.36, W.D.P.39, W.D.P.87, D.685, T.E.P.14, W.E.P.30, Th.E.P.54, E.597, E.670, E.671, M.H.P.21, M.H.P.22, M.H.P.23, M.H.P.24, M.H.P.25
- use by gay men
T.A.P.19, T.D.O.7, M.D.P.15, M.D.P.24, T.D.P.45, W.D.P.89, W.D.P.92, D.700, D.701, T.E.P.1, T.E.P.12, W.E.P.7, E.544, T.G.O.8, Th.G.O.29, Th.G.P.16
- use by general population
T.A.O.24, W.A.P.94, W.A.P.95, W.A.P.98, W.A.P.100, W.A.P.103, T.D.P.5, W.D.P.88, D.526, W.E.O.1, T.E.P.23, T.E.P.61, W.E.P.61, W.E.P.63, W.E.P.65, Th.E.P.1, Th.E.P.39, Th.E.P.46, E.547, E.670, Th.G.O.29
- use by heterosexuals
Th.A.O.15, T.A.P.14, W.A.P.97, T.D.O.35, T.D.P.81, E.735
- use by intravenous drug users
T.A.P.44, T.A.P.111, T.D.P.77, T.D.P.81, Th.E.P.4
- use by prostitutes
M.A.P.117, T.A.P.14, W.A.P.96, Th.D.O.7, Th.D.O.8, Th.D.O.11, W.D.P.87, D.682, D.698, W.E.P.14, E.522, W.G.O.20, W.G.O.23, Th.G.O.29
- use by students
M.D.P.27, T.D.P.5, T.D.P.11, Th.E.O.6a, Th.E.P.35, E.565, W.F.O.14
- other
W.A.P.100, Th.B.P.30, Th.B.P.33, T.D.O.24, T.D.O.25, M.D.P.4, T.D.P.4, T.D.P.11, T.D.P.13, T.D.P.91, D.544, T.E.P.21, E.643, T.G.P.13
- CONFIDENTIALITY**
T.A.P.75, W.A.P.84, M.D.P.66, M.E.P.29, E.711, E.725, T.F.O.2, T.F.O.3, T.F.O.4, T.F.O.5, T.F.O.6, T.F.O.7, T.F.O.11, M.F.P.6, M.F.P.7, T.F.P.1, T.F.P.2, T.F.P.3, T.F.P.4, T.F.P.8, T.F.P.10
- CONSENT (INFORMED)**
T.E.P.19, Th.E.P.10, E.720, T.F.O.11, M.F.P.2, Th.F.P.9
- CONTACT TRACING**
see Partner notification
- CONTRACEPTION**
see Family planning
- CONTROL GROUPS**
M.A.O.46, M.A.P.21, M.A.P.87, W.A.P.95, Th.A.P.4, Th.A.P.105, Th.A.P.107, A.620, W.B.P.301, B.643, Th.D.P.92, E.785, W.F.O.7
- COOMB'S TEST**
M.B.P.64
- COPING**
W.B.P.199, W.B.P.207, T.D.P.46, T.D.P.50, W.D.P.17, Th.D.P.54, D.536, D.540, D.683, E.537
- CORTICOSTEROIDS**
T.B.O.29, M.B.P.90, M.B.P.263, M.B.P.265, M.B.P.267, M.B.P.271, M.B.P.278, T.B.P.24, T.B.P.35, T.B.P.278, T.B.P.309, Th.B.P.333, B.509, B.583, M.C.P.55, T.C.P.110, W.C.P.131, C.564
- COST**
direct
W.E.O.12, M.H.O.13, Th.O.11, Th.O.12, W.H.P.1, W.H.P.3, W.H.P.5, W.H.P.8, Th.H.P.4, Th.H.P.8
- health care
M.A.P.75, A.608, M.B.P.310, W.B.P.265, W.B.P.271, D.561, T.E.O.14, T.E.O.17, T.E.P.41, E.701, E.706, M.F.O.18, W.G.P.13, M.H.O.13, M.H.O.14, M.H.O.17, Th.O.4, Th.O.8, W.H.O.7, W.H.O.8, W.H.O.9, W.H.O.14, W.H.O.16, M.H.P.2, M.H.P.12, M.H.P.13, T.H.P.6, T.H.P.17, T.H.P.19, T.H.P.20, T.H.P.22, T.H.P.24, T.H.P.27
- hospital care
M.B.P.302, W.B.P.253, M.F.O.18, W.G.P.13, M.H.O.7, M.H.O.8, M.H.O.9, M.H.O.11, M.H.O.12, M.H.O.17, Th.O.9, Th.O.10, M.H.P.1, M.H.P.3, M.H.P.4, M.H.P.5, M.H.P.7, M.H.P.8, M.H.P.9, M.H.P.10, M.H.P.11, M.H.P.14, M.H.P.15, M.H.P.16, M.H.P.17, M.H.P.18, M.H.P.19, T.H.P.5, T.H.P.7, T.H.P.10, T.H.P.11, T.H.P.16, T.H.P.21, W.H.P.2, W.H.P.4, W.H.P.10, Th.H.P.3, Th.H.P.5, Th.H.P.6
- indirect
Th.O.11, Th.O.12, W.H.P.5, Th.H.P.4
- projection
T.B.68, Th.H.16
- research
W.A.O.21, M.B.P.336, M.B.P.351, T.B.P.100, T.B.P.202, T.B.P.234, W.B.P.71, W.B.P.280, Th.B.P.184, Th.B.P.187, Th.B.P.367, B.555, B.638, M.C.P.118, Th.C.P.7, Th.C.P.104, T.E.P.44, E.690, E.725
- see Screening
- society
W.A.P.27, M.E.P.49, T.G.P.9, W.G.P.13
- treatment
Th.B.P.216, T.E.P.45, Th.O.8, W.H.O.10, M.H.P.1, M.H.P.2, M.H.P.4, M.H.P.13, M.H.P.15, M.H.P.19, T.H.P.11, T.H.P.15

CO-TRIMOXAZOLE

T.B.O.30, M.B.P.82, T.B.P.23, T.B.P.34, T.B.P.41

COUNSELLING

M.A.O.43, T.A.O.22, M.A.P.59, W.A.P.120, Th.A.P.25, M.B.P.155, M.D.O.3, M.D.O.12, T.D.O.19, T.D.O.31, T.D.O.32, T.D.O.33, T.D.O.34, M.D.P.8, M.D.P.13, M.D.P.17, M.D.P.21, M.D.P.22, M.D.P.41, M.D.P.43, M.D.P.50, M.D.P.82, M.D.P.91, T.D.P.49, T.D.P.55, T.D.P.57, W.D.P.1, W.D.P.3, W.D.P.4, W.D.P.5, W.D.P.8, W.D.P.11, W.D.P.12, W.D.P.16, W.D.P.19, W.D.P.20, W.D.P.54, W.D.P.81, Th.D.P.2, Th.D.P.18, Th.D.P.28, Th.D.P.96, D.501, D.504, D.549, D.550, D.551, D.552, D.553, D.555, D.556, D.557, D.559, D.562, D.572, D.573, D.574, D.575, D.576, D.596, D.597, D.598, D.641, D.680, D.703, D.718, D.720, D.721, M.E.O.13, Th.E.O.2, T.E.P.18, T.E.P.40, W.E.P.62, Th.E.P.28, Th.E.P.32, E.602, E.683, E.712, E.725, T.F.O.19, T.G.P.21, T.G.P.22

CR1

W.B.P.285

CROSS-REACTIVITY

W.B.P.96, W.B.P.151, Th.B.P.180, Th.C.P.55

CRYPTOCOCCUS

M.B.P.91, M.B.P.96, M.B.P.282, W.B.P.1, W.B.P.2, W.B.P.3, W.B.P.4, W.B.P.5, W.B.P.6, W.B.P.7, W.B.P.8, W.B.P.9, W.B.P.10, W.B.P.11, W.B.P.12, W.B.P.13, W.B.P.14, W.B.P.15, W.B.P.16, W.B.P.17, W.B.P.18, W.B.P.19, W.B.P.20, W.B.P.21, W.B.P.22, B.519, B.599, M.C.P.141

CRYPTOSPORIDIUM

Th.B.O.41, M.B.P.83, M.B.P.110, M.B.P.233, T.B.P.196, W.B.P.38, W.B.P.39, W.B.P.45, W.B.P.46, W.B.P.47, W.B.P.48, B.523, W.C.P.102, C.586

CS-87

see Azidouridine

CSF

see Cerebrospinal fluid

CULTURAL PRACTICES

T.A.P.86, W.D.P.90, D.519, M.E.O.32, Th.E.O.15, M.E.P.8, W.E.P.3, W.E.P.72, Th.E.P.34, Th.E.P.37, Th.E.P.38, E.501, E.736, E.742, T.G.P.22, W.G.P.31, Th.G.P.25

CULTURE

B cells

M.B.P.131, T.B.P.82, W.B.P.32, W.B.P.138, W.B.P.167, Th.B.P.97, Th.B.P.104, Th.B.P.105, B.547, W.C.P.44, Th.C.P.14, Th.C.P.78, C.703, C.709, C.761

biopsy

T.B.P.81, T.B.P.114, T.B.P.244, W.B.P.163, T.C.O.7, W.C.O.22, M.C.P.23, M.C.P.33, Th.C.P.112, Th.C.P.114, Th.C.P.118, C.510, C.638, C.750, C.761

bone marrow

B.516, M.C.P.132, T.C.P.17

CD4 enriched

T.C.O.7

endothelium

C.726, C.770

growth characteristics

T.B.P.98, T.C.P.63, W.C.P.48

monitor

M.C.P.75

monocytes, macrophages

T.B.P.112, T.B.P.117, W.B.P.293, Th.B.P.96, M.C.O.28, T.C.O.22, Th.C.O.14, M.C.P.131, W.C.P.16, W.C.P.84, C.596, C.768, C.769

neutral cell

M.C.O.26, Th.C.O.23, M.C.P.92, W.C.P.64, W.C.P.70, W.C.P.76, W.C.P.113, W.C.P.132, Th.C.P.15, Th.C.P.16, Th.C.P.30

plaque

W.B.P.138, Th.C.P.26, Th.C.P.94

promonocytes

T.C.P.110, T.C.P.112, Th.C.P.117

thymic cell

C.715

T cells

T.B.P.112, T.B.P.224, W.B.P.284, Th.B.P.105, W.C.O.39, W.C.O.43, M.C.P.22, M.C.P.131, T.C.P.47, T.C.P.68, T.C.P.110, W.C.P.28, W.C.P.55, Th.C.P.52, Th.C.P.126, C.596, C.709, C.710, C.768

other

M.B.P.45, M.B.P.73, M.B.P.125, T.B.P.118, Th.B.P.57, M.C.P.124, T.C.P.88, T.C.P.106, W.C.P.52, W.C.P.54, W.C.P.51, Th.C.P.48, Th.C.P.68, Th.C.P.104, Th.C.P.133, C.767

see also Isolates; Strains

CYCLOSPORINE

W.B.P.302, M.C.P.139

CYSTEINE

W.C.P.93

CYTOKINES

T.B.P.226, Th.B.P.223, T.C.O.12, W.C.O.8, M.C.P.52, M.C.P.100, T.C.P.14, T.C.P.19, T.C.P.30, T.C.P.146, T.C.P.147, W.C.P.27, W.C.P.48, W.C.P.59, W.C.P.82, W.C.P.83, W.C.P.85, W.C.P.105, W.C.P.122, Th.C.P.14, Th.C.P.29, Th.C.P.144

CYTOMEGALOVIRUS (CMV)

clinical presentation
A.540, M.B.P.116, M.B.P.118, M.B.P.121, M.B.P.134, M.B.P.135

diagnosis

M.B.P.115, M.B.P.124, M.B.P.127, M.B.P.131, T.B.P.8

pneumonitis

M.B.P.115, M.B.P.125, M.B.P.130, M.B.P.136, M.B.P.211

retinitis

W.B.O.18, W.B.O.34, W.B.O.35, W.B.O.38, M.B.P.117, M.B.P.119, M.B.P.122, M.B.P.123, M.B.P.124, M.B.P.128, M.B.P.129, M.B.P.132,

M.B.P.229, M.B.P.230, T.B.P.251, M.C.P.57, M.C.P.60, E.760, Th.G.P.11

other

W.A.P.77, M.B.P.88, M.B.P.114, M.B.P.116, M.B.P.120, M.B.P.121, M.B.P.128, M.B.P.129, M.B.P.192, M.B.P.208, W.B.P.33, W.B.P.36, W.B.P.39, Th.B.P.22, Th.B.P.25, M.C.P.65, M.C.P.74, T.C.P.78, W.C.P.68, C.504, C.676, Th.G.P.11

CYTOPATHIC EFFECT

M.C.O.22, W.C.O.15, M.C.P.87, T.C.P.56, T.C.P.80, T.C.P.95, T.C.P.96, T.C.P.104, T.C.P.125, W.C.P.39, W.C.P.58, Th.C.P.12, Th.C.P.41, Th.C.P.51, Th.C.P.91, Th.C.P.150, C.536, C.568, C.649, C.709, C.712

CYTOPENIA

M.B.P.248, M.B.P.257, T.B.P.284, W.B.P.43, C.568

CYTOTOXICITY, HIV

M.B.P.42, W.B.P.294, W.B.P.300, Th.B.P.78, B.578, W.C.O.31, W.C.O.42, W.C.O.43, Th.C.O.34, T.C.P.2, T.C.P.32, T.C.P.57, T.C.P.146, C.524, C.543

DAPSONE

T.B.O.4, T.B.O.5, T.B.P.44, T.B.P.75

DEATH CERTIFICATES

T.A.O.5, T.A.O.7, T.A.P.82, T.A.P.63, T.A.P.70, T.A.P.71, W.A.P.27, W.A.P.31, W.A.P.35, W.A.P.82, T.F.O.3

DEATHS

W.A.O.16, W.A.O.18, W.A.P.30, W.A.P.32, M.B.P.201, Th.B.13
see also Mortality

DEFECTIVE PARTICLES

Th.C.P.56, Th.C.P.149

DELIRIUM

W.B.P.220

DEMMENTIA

see Central nervous system

DEMYELINIZATION

M.B.P.280

DENTISTS

see Health care personnel
see also Oral

DEVELOPING COUNTRIES

M.A.P.119, W.A.P.96, D.695, D.724, T.E.P.62, T.E.P.63, W.E.P.33, W.E.P.41, W.E.P.72, W.G.O.17, W.G.O.25, M.G.P.21, M.G.P.31, T.G.P.8, T.G.P.21, W.G.P.5, W.H.P.3, Th.H.P.29
see also Geographical aspects

DEXTAN SULFATE

Th.B.O.48, T.B.P.295, W.B.P.289, W.B.P.315, W.B.P.324, M.C.P.75, M.C.P.87, Th.C.P.22, C.543, C.595, C.621, C.635

DFMO

T.B.P.27, T.B.P.29

DHEA (EL-10)

M.B.P.269, C.602

DIAGNOSTIC CRITERIA

T.A.O.2, T.A.O.3, T.A.O.4, T.A.O.5,
T.A.O.25, T.A.P.71, T.A.P.77, T.A.P.78,
T.A.P.79, T.A.P.80, T.A.P.115, W.A.P.4,
W.A.P.28, Th.A.P.43, Th.A.P.84, A.537,
A.567, A.571, A.575, A.578, Th.B.O.7,
M.B.P.40, M.B.P.195, M.B.P.199,
T.B.P.107, T.B.P.135, T.B.P.202, T.B.P.225,
T.B.P.362, T.B.P.364, W.B.P.46,
W.B.P.49, W.B.P.89, W.B.P.179,
Th.B.P.33, Th.B.P.114, Th.B.P.124,
Th.B.P.170, Th.B.P.235, Th.B.P.288,
B.542, B.581, B.602, B.630, B.637, B.639,
B.641, T.C.P.72, T.C.P.131, W.C.P.87,
W.C.P.88, Th.C.P.35, Th.C.P.148, C.675,
C.764, Th.D.P.9, Th.D.P.78, D.711, E.809,
Th.G.O.2, Th.G.O.34, W.G.P.12, Th.G.P.6,
Th.G.P.7, Th.H.P.4, W.H.P.21

see also Progression

DIARRHEA**diagnosis**

W.B.O.38, M.B.P.236, M.B.P.238,
M.B.P.239, T.B.P.263, T.B.P.376,
W.B.P.36, W.B.P.39, W.B.P.39, W.B.P.42,
W.B.P.289, Th.B.P.317, B.546, M.C.O.27,
T.C.P.123, W.G.O.5

treatment

M.B.P.237, W.B.P.43, W.B.P.45,
W.B.P.47, Th.B.P.39, Th.B.P.300,
M.C.P.112, Th.G.O.49

DIDEOXYADENOSINE (DDA)

W.B.P.275, M.C.P.86, T.C.P.145

DIDEOXYCYTIDINE (DDC)

Th.B.O.3, T.B.P.247, W.B.P.327,
M.C.P.99, M.C.P.126, C.609

DIDEOXYINOSINE (DDI)

Th.B.O.4, T.B.P.297, W.B.P.275,
M.C.P.86, M.C.P.128, M.C.P.130

DIDEOPYRIMIDINE

M.C.P.107

DIET

Th.B.P.300, Th.B.P.301, Th.B.P.307,
Th.B.P.308, Th.B.P.379, Th.B.P.381, E.702

DIETHYL CARBAMAZINE

C.588

DIETHYL DITHIO CARBAMATE

see Imithiol

DIPYRIDAMOLES

M.C.P.42

DISABLED PERSONS

T.D.O.15, T.D.O.16, W.D.P.23, D.616,
M.E.O.15, M.E.P.5, M.E.P.42, M.E.P.59,
E.551, E.791

DISCLOSURE

E.700, E.714, T.F.O.2, T.F.O.3, T.F.O.4,
T.F.O.5, T.F.O.6, M.F.P.1, M.F.P.7,
T.F.P.1, T.F.P.2, T.F.P.8, T.F.P.4

DISCRIMINATION

Th.D.P.8, W.E.O.18, M.E.P.21, M.E.P.66,
T.E.P.27, T.E.P.36, T.E.P.52, Th.E.P.44,
E.577, E.693, E.790, E.814, Th.F.O.3,
Th.F.O.7, M.F.P.1, M.F.P.8, Th.F.P.3,
Th.F.P.6, W.G.O.13, Th.P.20

DISINFECTATION

W.A.P.102, W.A.P.104, A.599, A.600,
A.601, Th.B.P.354, M.C.P.140, D.707

DISULFRAM

W.B.P.307, C.619

DNA ANALOGUES

Th.C.O.20, M.C.P.65, M.C.P.70, M.C.P.73,
M.C.P.76, T.C.P.145

D-PENICILLAMINE

W.B.P.278

DRIED BLOOD SPOT

M.B.P.170, W.B.P.174, W.B.P.175

DRUG EXPERIMENTATION

M.B.O.36, M.B.P.300, M.B.P.366,
T.B.P.25, T.B.P.295, W.B.P.275,
W.B.P.306, W.B.P.313, Th.B.P.69, B.608,
T.C.O.1, W.C.O.23, Th.C.O.19, Th.C.O.21,
M.C.P.63, M.C.P.115, M.C.P.121,
M.C.P.124, M.C.P.127, M.C.P.129,
M.C.P.131, W.C.P.19, C.585, C.596,
C.597, C.612, C.630, C.746

DRUG INTERACTIONS

W.B.P.371

DRUG REGULATION

W.B.P.249, M.C.P.61, T.E.O.14, T.E.P.51,
E.626, E.692, E.697, E.732, E.760, E.779,
T.F.O.13, W.F.O.5, M.F.P.5, Th.F.P.11,
Th.G.P.10, Th.G.P.11

DRUG USE

see Intravenous drug users

see Nitrite Inhalants

see Substance abuse

D4T

M.C.P.76, M.C.P.96, M.C.P.114, M.C.P.128

DTC

see Imithiol

DYSAUTONOMIA

T.B.P.376

EBV

see Epstein-Barr virus

ECONOMIC IMPACT

T.E.P.53, M.F.P.11, Th.F.P.5, M.H.O.2,
M.H.O.4, M.H.O.10, Th.H.O.1, Th.O.4,
Th.O.7, Th.H.O.8, Th.O.9, Th.O.11,
Th.O.13, W.H.O.12, W.H.O.15, M.H.P.20,
Th.H.P.8, Th.H.P.8, Th.H.P.16, W.H.P.6,
W.H.P.9, Th.H.P.2, Th.H.P.4, Th.H.P.7

see also Cost

EDUCATION**adolescents**

W.A.P.110, Th.B.P.26, M.D.O.11,
T.D.O.26, T.D.O.27, T.D.O.28, T.D.O.30,
M.D.P.2, T.D.P.3, T.D.P.7, T.D.P.89,
T.D.P.87, T.D.P.88, T.D.P.89, D.503,
D.504, D.505, D.513, D.516, D.518, D.519,
D.569, M.E.O.10, Th.E.O.2, Th.E.O.5,
Th.E.O.8a, T.E.P.12, T.E.P.13, T.E.P.24,
T.E.P.30, T.E.P.70, W.E.P.17, W.E.P.18,
W.E.P.23, W.E.P.35, W.E.P.36, W.E.P.39,
W.E.P.40, W.E.P.42, W.E.P.47, W.E.P.48,
W.E.P.49, W.E.P.74, E.584, E.588, E.617,
E.618, E.621, E.655, E.657, E.660, E.661,
E.681, E.795, E.797, T.G.O.10

college

T.A.P.16, A.557, M.D.P.2, M.D.P.16,
M.D.P.40, M.D.P.71, T.D.P.10, T.D.P.55,
D.671, Th.E.O.1, T.E.P.56, W.E.P.28,
W.E.P.34, W.E.P.51, W.E.P.75, E.585,
E.620, E.638, E.639, E.648, E.655, E.675,
E.699

elementary school

T.B.P.160, Th.B.P.195, B.595, T.E.P.69,
W.E.P.22, W.E.P.38, W.E.P.43, W.E.P.46,
E.579, E.604, E.613, E.652, E.698

evaluation

W.A.O.28, W.A.P.59, W.A.P.111, A.506,
Th.D.O.11, M.D.P.8, M.D.P.9, M.D.P.1,
M.D.P.21, T.D.P.31, T.D.P.36, W.D.P.21,
W.D.P.26, W.D.P.37, D.548, D.579, D.633,
D.658, M.E.O.7, M.E.O.8, M.E.O.12,
W.E.O.22, Th.E.O.1, M.E.P.17, M.E.P.19,
M.E.P.28, T.E.P.2, T.E.P.15, T.E.P.26,
T.E.P.37, T.E.P.58, T.E.P.67, T.E.P.69,
T.E.P.72, W.E.P.4, W.E.P.5, W.E.P.12,
W.E.P.17, W.E.P.18, W.E.P.19, W.E.P.23,
W.E.P.34, W.E.P.40, W.E.P.42, W.E.P.49,
W.E.P.50, W.E.P.52, W.E.P.57, W.E.P.60,
W.E.P.61, W.E.P.66, Th.E.P.63, E.512,
E.531, E.538, E.552, E.567, E.681, E.682,
E.583, E.584, E.586, E.611, E.612, E.627,
E.633, E.646, E.647, E.650, E.656, E.660,
E.665, E.669, E.675, E.738, E.750, E.770,
E.792, W.F.P.5

gay/bisexual

W.A.P.118, W.D.P.21, M.E.P.36,
M.E.P.43, T.E.P.2, T.E.P.3, T.E.P.5,
W.E.P.8, T.E.P.18, W.E.P.7, W.E.P.10,
Th.E.P.73, Th.E.P.74, Th.E.P.75, T.G.O.8

general public

T.D.P.84, Th.D.P.21, D.559, T.E.O.12,
W.E.O.1, W.E.O.2, W.E.O.20, W.E.O.23,
W.E.O.25, Th.E.O.3, Th.E.O.11,
Th.O.18, M.E.P.14, M.E.P.16, M.E.P.25,
T.E.P.10, T.E.P.14, T.E.P.27, T.E.P.58,
T.E.P.59, T.E.P.76, W.E.P.1, W.E.P.6,
W.E.P.8, W.E.P.27, W.E.P.28, W.E.P.58,
W.E.P.62, W.E.P.65, Th.E.P.40

W.E.P.42, Th.E.P.64, E.534, E.547,
E.558, E.560, E.571, E.572, E.577, E.580,
E.593, E.614, E.630, E.635, E.645, E.646,
E.663, E.664, E.685, E.687, E.740, E.780,
E.793, E.795, E.798, E.803, T.G.O.9

high school

W.A.P.110, M.D.P.6, M.D.P.9, M.D.P.36,
T.D.P.9, D.501, D.509, Th.E.O.1,
M.E.P.46, T.E.P.69, W.E.P.25, W.E.P.45,
Th.E.P.35, E.655, E.570, E.581, E.613,
E.615, E.616, E.619, E.644, E.652, E.658,
E.662, E.668, E.698, E.740, E.758

intravenous drug users

W.A.P.118, W.D.P.57, W.D.P.81,
Th.D.P.66, Th.D.P.75, Th.D.P.76,
T.E.P.16, W.E.P.12, W.E.P.68, Th.E.P.4,
E.512, E.586, E.589

minority

T.D.O.17, W.D.P.32, M.E.P.8, M.E.P.10,
M.E.P.11, M.E.P.12, M.E.P.13, T.E.P.11,
T.E.P.74, W.E.P.1, W.E.P.56, W.E.P.58,
E.501, E.517, E.532, E.555, E.597, E.638,
E.696

- police
W.E.P.24
- workplace
Th.B.P.354, D.523, D.662, W.E.O.14,
W.E.O.15, W.E.O.16, W.E.O.19, M.E.P.27,
M.E.P.28, M.E.P.29, M.E.P.30, M.E.P.31,
M.E.P.32, M.E.P.33, W.E.P.14, E.592,
E.687, E.744, E.748, E.750, E.752, E.753,
E.758, E.764, T.G.O.11, T.H.P.29
- other
M.A.O.26, A.507, A.508, M.B.P.143,
M.B.P.307, M.B.P.316, W.B.P.206,
W.B.P.238, M.D.O.2, T.D.O.15, T.D.O.33,
T.D.O.7, M.D.P.17, M.D.P.22, M.D.P.25,
T.D.P.26, T.D.P.38, W.D.P.42, Th.D.P.20,
Th.D.P.84, Th.D.P.85, D.503, D.547,
D.548, D.571, D.575, D.629, D.641, D.662,
D.668, D.695, D.698, D.724, W.E.O.17,
W.E.O.29, Th.E.O.6a, Th.E.O.6, M.E.P.1,
M.E.P.5, M.E.P.6, M.E.P.7, M.E.P.35,
M.E.P.37, M.E.P.50, T.E.P.22, T.E.P.62,
T.E.P.73, W.E.P.11, W.E.P.20, W.E.P.29,
W.E.P.66, W.E.P.67, Th.E.P.32,
Th.E.P.62, Th.E.P.66, E.508, E.551,
E.561, E.640, E.641, E.642, E.653, E.659,
E.668, E.771, E.791, W.G.O.19, W.G.P.17
- EEG
see Electroencephalography
- EHNA
C.609
- ELDERLY
W.A.P.13, A.553, M.B.P.323, T.B.P.20,
Th.B.P.261, Th.E.P.55
- ELECTROENCEPHALOGRAPHY
Th.B.O.20, Th.B.P.273
- ELECTRON MICROSCOPY
M.B.P.136, Th.B.P.251, M.C.O.31,
M.C.O.31, T.C.P.126, Th.C.P.8, Th.C.P.62,
Th.C.P.150, C.778, C.784
- ELISPOT (ENZYME-LINKED
IMMUNOSPOT)
M.B.P.346, T.B.P.223
- EMPLOYMENT
W.E.O.14, W.E.O.16, W.E.O.17,
W.E.O.18, W.E.O.19, M.E.P.23, E.749,
E.751, E.790, E.814, Th.F.O.4, M.F.P.8,
M.G.O.30, Th.H.P.9
- ENDOCARDITIS
see Heart
- ENDOCRINE
M.B.P.264, M.B.P.272, W.B.P.189,
W.B.P.190, Th.B.P.138, Th.B.P.241,
B.608, W.C.P.81, E.548
- ENDOSCOPY
M.B.P.234, M.B.P.245, M.B.P.247,
T.B.P.2, W.B.P.39, Th.B.P.336, B.546
- ENKEPHALIN
W.B.P.294, Th.B.P.241
- ENTERIC PATHOGENS
amoeba
C.786
Salmonella
M.B.P.66, M.B.P.67, M.B.P.69, T.B.P.317,
B.516, B.522
- other
M.B.P.236, M.B.P.239, W.B.P.35,
W.B.P.39, W.B.P.41
- EOSINOPHILIA
T.B.P.328
- EPIDEMIOLOGICAL METHODS
M.A.O.3, T.A.O.26, T.A.O.35, T.A.O.37,
Th.A.O.15, Th.A.O.16, M.A.P.64, T.A.P.36,
T.A.P.62, W.A.P.5, W.A.P.14, W.A.P.18,
W.A.P.35, W.A.P.81, Th.A.P.37,
Th.A.P.34, Th.A.P.35, Th.A.P.37,
Th.A.P.39, Th.A.P.41, Th.A.P.42,
Th.A.P.43, Th.A.P.45, Th.A.P.61,
Th.A.P.72, Th.A.P.77, Th.A.P.78,
Th.A.P.79, Th.A.P.82, Th.A.P.114, A.526,
A.605, M.B.P.46, M.B.P.162, T.B.P.344,
T.B.P.364, W.B.P.266, Th.B.P.64,
Th.B.P.201, B.577, T.D.O.11, T.D.P.73,
D.534, D.545, D.587, D.603, M.F.P.10,
W.H.P.19
- EPITOPe ANALYSIS
core
T.C.P.33
env
Th.A.P.113, W.B.P.102, M.C.O.21,
T.C.O.37, W.C.O.41, Th.C.O.3, Th.C.O.29,
Th.C.O.47, Th.C.O.50, M.C.P.6, M.C.P.21,
M.C.P.22, M.C.P.24, M.C.P.26, M.C.P.28,
M.C.P.30, T.C.P.13, T.C.P.24, T.C.P.29,
T.C.P.51, T.C.P.59, T.C.P.70, T.C.P.76,
T.C.P.109, W.C.P.4, W.C.P.57,
W.C.P.128, Th.C.P.37, Th.C.P.67,
Th.C.P.127, C.547, C.656, C.717, C.732,
C.736, C.752, C.783
- esp.
W.B.P.141, T.C.O.6, Th.C.O.47, M.C.P.7,
M.C.P.15, M.C.P.21, M.C.P.28, M.C.P.40,
M.C.P.41, M.C.P.146, T.C.P.16, T.C.P.23,
T.C.P.85, T.C.P.73, T.C.P.84, T.C.P.109,
T.C.P.149, Th.C.P.37, Th.C.P.39,
Th.C.P.42, Th.C.P.59, Th.C.P.75,
Th.C.P.102, Th.C.P.108, C.545, C.555,
C.663, C.717
- multiple genes
W.C.O.40, T.C.P.37, T.C.P.42, T.C.P.72,
C.784
- psl
T.C.O.6, W.C.O.43, T.C.P.109, W.C.P.89,
Th.C.P.34, Th.C.P.44, Th.C.P.103
- EPSTEIN-BARR VIRUS (EBV)
M.A.P.87, Th.A.P.95, M.B.O.18, M.B.P.61,
M.B.P.62, M.B.P.68, M.B.P.244,
M.B.P.288, T.B.P.264, Th.B.P.23,
Th.B.P.25, Th.B.P.330, B.582, Th.C.O.38,
T.C.P.2, Th.C.P.72
- EQUINE INFECTIOUS ANEMIA
VIRUS
M.C.O.24, T.C.P.119, T.C.P.135,
Th.C.P.123
- ERYTHROCYTE SEDIMENTATION
RATE (ESR)
W.B.P.86
- ERYTHROMYCIN
T.B.P.39
- ERYTHROPOIETIN (EPO)
M.B.O.48, M.B.P.328
- ESR
see Erythrocyte sedimentation rate
- ETHICS
W.B.O.23, M.B.P.23, W.B.P.378, C.590,
C.640, W.E.O.28, T.E.P.23, Th.E.P.14,
Th.E.P.49, E.563, E.689, E.725, E.762,
M.F.O.2, T.F.O.2, T.F.O.4, T.F.O.7,
T.F.O.11, T.F.O.13, T.F.O.18, T.F.O.19,
W.F.O.5, W.F.O.8, W.F.O.7, W.F.O.22,
Th.F.O.6, M.F.P.5, M.F.P.7, M.F.P.9,
M.F.P.11, T.F.P.2, T.F.P.4, T.F.P.5,
T.F.P.6, T.F.P.7, T.F.P.8, T.F.P.9,
T.F.P.10, T.F.P.11, W.F.P.1, W.F.P.2,
W.F.P.3, W.F.P.5, W.F.P.6, W.F.P.9,
W.F.P.10, Th.F.P.1, Th.F.P.2, Th.F.P.4,
Th.F.P.5, Th.F.P.8, Th.F.P.9
- ETIOLOGY, HYPOTHESES
M.A.O.30, M.A.O.32, W.A.P.17, A.621,
W.B.P.42, Th.C.O.38, W.C.P.51, C.781
- EUROPE
see Geographical aspects
- EVOLUTION
M.A.P.24, W.B.O.6, W.B.O.25, W.B.O.44,
M.B.P.16, M.B.P.32, M.B.P.199,
M.B.P.348, M.B.P.352, M.B.P.370,
T.B.P.100, T.B.P.162, T.B.P.164,
T.B.P.169, T.B.P.170, T.B.P.202,
T.B.P.269, T.B.P.363, W.B.P.139,
W.B.P.304, W.B.P.344, W.B.P.346,
Th.B.P.52, Th.B.P.102, Th.B.P.147,
Th.B.P.181, Th.B.P.202, Th.B.P.247,
Th.B.P.299, Th.B.P.367, B.520, T.C.O.22,
T.C.O.28, W.C.O.49, T.C.P.82, W.C.P.44,
W.C.P.147, Th.C.P.58, M.G.O.27, T.G.O.19
- EXERCISE, OXIMETRY
T.B.O.2, W.B.O.22, M.B.P.206, M.B.P.213,
T.B.P.17, T.B.P.56, T.B.P.286, W.B.P.68,
B.508, D.681
- EXPRESSION VECTOR
B.602, T.C.O.6, T.C.O.11, T.C.O.28,
T.C.O.45, W.C.O.14, Th.C.O.11,
Th.C.O.33, M.C.P.21, M.C.P.31, M.C.P.34,
M.C.P.35, T.C.P.80, T.C.P.81, T.C.P.84,
T.C.P.85, T.C.P.86, T.C.P.97, T.C.P.101,
T.C.P.102, T.C.P.108, T.C.P.109,
T.C.P.116, T.C.P.130, T.C.P.133,
T.C.P.136, T.C.P.137, T.C.P.138,
W.C.P.17, W.C.P.116, Th.C.P.2,
Th.C.P.18, Th.C.P.20, Th.C.P.36,
Th.C.P.121, Th.C.P.122, Th.C.P.124,
C.540, C.572, C.647, C.648, C.656, C.667,
C.668, C.670, C.671, C.676, C.679, C.683,
C.687, C.694, C.698, C.782
- EYES
W.B.O.18, M.B.P.225, M.B.P.226,
M.B.P.227, M.B.P.228, M.B.P.379,
T.B.P.205, T.B.P.232, Th.B.P.290,
Th.B.P.296, B.552
- FAMILY, IMPACT ON
M.B.P.305, M.B.P.313, M.B.P.317,
W.B.P.207, W.B.P.383, Th.B.P.29,
W.D.P.10, W.D.P.18, Th.D.P.90, D.523,
D.556, D.564, D.639, M.E.O.13, M.E.O.15,

- M.E.O.16, M.E.O.17, M.E.O.24, Th.E.O.13,
 M.E.P.34, M.E.P.35, M.E.P.41, M.E.P.74,
 T.E.P.28, T.E.P.29, Th.E.P.41, Th.E.P.75,
 E.505, E.506, E.513, E.527, E.771, E.781,
 W.G.P.32, W.H.P.8
- FAMILY PLANNING**
 W.A.O.11, W.A.P.114, M.B.P.7, T.B.P.300,
 W.B.P.261, B.502, W.D.O.6, M.D.P.3,
 T.D.P.2, W.D.P.46, D.683, D.684, D.696,
 M.E.O.12, Th.E.O.6a, T.E.P.40, W.E.P.74,
 E.546, E.716
- FANSIDAR**
 M.B.P.235, T.B.P.21, T.B.P.46, T.B.P.47,
 W.B.P.33, W.B.P.33
- FC RECEPTORS**
 T.C.O.21, T.C.P.5, T.C.P.36, T.C.P.41,
 T.C.P.140, W.C.P.135
- FEBRILE EPISODES**
 M.B.P.39, M.B.P.97, M.B.P.251,
 M.B.P.257, W.B.P.17
- FELINE IMMUNODEFICIENCY VIRUS (FIV)**
 W.C.P.14, W.C.P.21, W.C.P.36, W.C.P.143
- FELINE LEUKEMIA VIRUS (FELV)**
 W.C.O.13, W.C.O.31, M.C.P.2, M.C.P.68,
 M.C.P.69, W.C.P.11, W.C.P.13, W.C.P.37,
 W.C.P.39, W.C.P.118, W.C.P.142
- FIBRONECTIN**
 Th.B.P.136
- FINANCING**
 A.533, W.E.O.7, T.E.P.74, E.690,
 W.H.O.4, W.H.O.11, W.H.O.12, M.H.P.18,
 Th.P.3, Th.P.6, Th.P.10, Th.P.16,
 Th.P.17, Th.P.20, Th.P.21, Th.P.22,
 Th.P.24, Th.P.25, W.H.P.11
see also Cost
- FLOW CYTOMETRY**
 T.B.P.87, Th.B.P.360, Th.B.P.361, B.621
- FLUCONAZOLE**
 M.B.P.79, M.B.P.92, M.B.P.96, W.B.P.1,
 W.B.P.5, W.B.P.7, W.B.P.9, W.B.P.12,
 W.B.P.13, W.B.P.14, Th.B.P.319,
 Th.B.P.322, Th.B.P.334, Th.B.P.348,
 Th.B.P.355, B.599, M.C.P.71, M.C.P.143
- FLUOROTHYIMIDINE (FLT)**
 M.C.P.114
- FOSCARNET**
 W.B.O.36, M.B.P.47, M.B.P.48, M.B.P.49,
 M.B.P.117, M.B.P.119, M.B.P.122,
 M.B.P.123, M.B.P.128, M.B.P.133,
 T.C.O.2, M.C.P.60, M.C.P.109
- GALLUM IMAGING**
 M.B.P.43, M.B.P.106, M.B.P.213,
 T.B.P.15, Th.B.P.51
- GAMMA GLOBULIN**
see Intravenous immunoglobulin administration
- GANCICLOVIR**
 M.B.O.49, W.B.O.34, W.B.O.35,
 M.B.P.114, M.B.P.116, M.B.P.120,
 M.B.P.121, M.B.P.122, M.B.P.124,
 M.B.P.129, M.B.P.130, M.B.P.132,
 M.C.P.57, E.692, E.760, Th.G.P.11
- GASTROENTERITIS**
 M.B.P.66, M.B.P.68, M.B.P.129,
 M.B.P.241, W.B.P.37, W.B.P.40, W.G.O.5
- GAY MEN**
drugs
 W.A.P.58, W.B.P.197, T.D.O.10, M.D.P.24,
 M.D.P.39, T.D.P.42, W.D.P.67, Th.D.P.51
see Education
ethnic groups
 W.A.P.67, W.A.P.68, D.664, D.667, E.517,
 E.556, Th.G.P.25
geographic
 W.A.O.13, M.A.P.69, T.A.P.22, W.A.P.67,
 W.A.P.68, Th.A.P.50, A.559, A.603, C.754,
 Th.H.P.24
immunology
 W.A.P.44, W.A.P.69, Th.A.P.92, A.540,
 A.616, A.620, M.B.O.35, M.B.P.103,
 W.B.P.54, W.B.P.80, W.B.P.181,
 W.B.P.195, Th.B.P.119, Th.B.P.148,
 Th.B.P.159, Th.B.P.183, Th.B.P.238,
 B.627, T.C.P.52, W.C.P.129, T.D.O.23
media
 W.E.O.25, T.E.P.3, T.E.P.6, T.E.P.12,
 W.E.P.10, W.E.P.32, W.E.P.52
neurology
 M.B.O.35, Th.B.P.189, Th.B.P.219,
 Th.B.P.220, Th.B.P.238, W.C.P.112,
 Th.E.P.51
neuropsychology
 W.B.O.45, T.B.P.192, W.B.P.180,
 W.B.P.192, W.B.P.195, W.B.P.197,
 W.B.P.198, W.B.P.224, W.B.P.230,
 W.B.P.233, W.B.P.236, Th.B.P.31,
 Th.B.P.200, Th.B.P.218, Th.B.P.261,
 Th.B.P.262, Th.B.P.270, C.610, D.661
personal integrity
 W.B.P.199, W.B.P.233, T.D.P.30
politics
 T.E.O.16, T.E.O.17, M.E.P.44, W.E.P.2,
 E.686, E.748
prevalence
 M.A.O.27, M.A.P.73, M.A.P.84, T.A.P.19,
 T.A.P.22, W.A.P.34, W.A.P.37, W.A.P.38,
 W.A.P.39, W.A.P.42, W.A.P.74, Th.A.P.24,
 Th.A.P.52, A.594, W.B.O.9, M.B.P.137,
 W.B.P.184, T.D.P.26, T.D.P.79, Th.E.P.8,
 Th.E.P.46, Th.E.P.70, E.623, E.708,
 M.G.P.12, M.G.P.29, Th.G.P.1
prevention
 M.A.P.120, W.A.P.44, T.D.O.10, M.D.P.29,
 M.D.P.32, M.D.P.39, T.D.P.27, T.D.P.31,
 T.D.P.36, W.D.P.82, D.555, T.E.O.15,
 Th.E.O.16, T.E.P.2, Th.E.P.70, E.695,
 E.799
prognosis
 A.559, A.622, W.B.P.181
progression
 M.A.O.27, M.A.O.44, M.A.O.46, T.A.O.31,
 T.A.O.32, M.A.P.88, M.A.P.93, M.A.P.108,
 M.A.P.111, M.A.P.112, W.A.P.53,
 W.A.P.57, W.A.P.64, W.A.P.68, W.A.P.74,
 Th.A.P.86, Th.A.P.94, A.545, A.548,
 M.B.P.293, Th.B.P.373, T.D.O.23,
 T.D.P.63, W.G.P.11, W.G.P.23
- psychosocial*
 W.A.O.27, T.A.P.18, W.A.P.91, W.B.O.40,
 W.B.O.41, M.B.P.312, M.B.P.321,
 W.B.P.181, W.B.P.215, W.B.P.226,
 W.B.P.244, T.D.O.19, W.D.O.2, M.D.P.22,
 T.D.P.24, T.D.P.42, T.D.P.45, T.D.P.57,
 T.D.P.67, T.D.P.76, Th.D.P.88, D.524,
 D.528, D.681, D.720, M.E.O.14, M.E.P.2,
 M.E.P.3, Th.E.P.50, Th.E.P.51, E.540,
 E.727
sexconversion
 M.A.O.26, Th.A.O.17, T.A.P.21, T.A.P.22,
 W.A.P.41, W.A.P.43, W.A.P.44, W.A.P.58,
 W.A.P.68, W.A.P.74, Th.A.P.94,
 Th.A.P.95, T.B.P.83, W.B.P.54, W.B.P.73,
 Th.B.P.373, B.603, M.C.O.8, Th.C.P.111,
 D.720
see Sexual behaviour
subgroups
 M.A.O.44, W.A.P.67, W.B.P.221,
 Th.B.P.184, Th.C.P.105, T.D.P.28,
 T.E.P.6, M.E.P.7, Th.E.P.30, E.556,
 T.G.P.12
symptoms
 T.A.O.32, M.B.P.244, W.B.P.55,
 W.B.P.180, Th.B.P.345
other
 W.A.P.27, Th.A.P.29, Th.A.P.33,
 M.B.O.33, W.B.O.11, Th.C.O.2, M.B.P.116,
 M.B.P.191, M.B.P.223, M.B.P.224,
 W.B.P.52, W.B.P.58, B.521, B.606, C.564,
 C.716, T.D.O.6, T.D.O.34, M.D.P.35,
 M.D.P.38, T.D.P.29, T.D.P.40, T.D.P.58,
 W.D.P.9, D.511, D.539, D.662, D.677,
 D.700, M.E.O.14
- GENE PRODUCTS**
 26kD
 Th.A.P.83
biochemical synthesis and processing
 T.C.O.38, M.C.P.1, Th.C.P.43, Th.C.P.73,
 C.656, C.772
core proteins
 M.B.P.357, T.B.P.96, T.B.P.246,
 W.B.P.116, W.B.P.143, Th.B.P.109,
 Th.B.P.171, Th.B.P.370, W.C.O.44,
 M.C.P.13, T.C.P.65, T.C.P.135,
 Th.C.P.145, C.520, C.545, C.554, C.633,
 C.736
endonuclease
 T.C.P.109, Th.C.P.44
env
 M.B.O.22, T.B.P.81, T.B.P.87, T.B.P.96,
 W.B.P.116, W.B.P.122, W.B.P.148,
 T.C.O.19, T.C.O.20, T.C.O.34, T.C.O.36,
 T.C.O.37, T.C.O.38, W.C.O.13, W.C.O.31,
 Th.C.O.34, Th.C.O.48, M.C.P.1, M.C.P.4,
 M.C.P.10, M.C.P.16, M.C.P.19, M.C.P.40,
 M.C.P.51, M.C.P.134, T.C.P.2, T.C.P.24,
 T.C.P.39, T.C.P.49, T.C.P.53, T.C.P.86,
 T.C.P.122, T.C.P.144, W.C.P.8, W.C.P.9,
 W.C.P.10, W.C.P.112, W.C.P.34, W.C.P.79,
 Th.C.P.6, Th.C.P.12, Th.C.P.36,
 Th.C.P.43, Th.C.P.80, Th.C.P.115,
 Th.C.P.122, Th.C.P.149, C.526, C.536,
 C.540, C.554, C.572, C.643, C.653, C.687,
 C.688, C.676, C.717

rag
 T.B.P.81, T.B.P.82, T.B.P.106, W.B.P.75,
 W.B.P.167, B.620, T.C.O.5, T.C.O.20,
 M.C.P.7, M.C.P.15, M.C.P.16, T.C.P.16,
 T.C.P.49, T.C.P.121, T.C.P.130,
 T.C.P.144, W.C.P.116, Th.C.P.10,
 Th.C.P.36, Th.C.P.95, Th.C.P.110,
 Th.C.P.130, C.526, C.544, C.647, C.663,
 C.671, C.717, C.772

HIV
 M.B.O.23, T.B.P.91, B.602, W.C.O.44,
 C.531

see HIV antigen

net

M.B.O.24, W.B.P.146, W.B.P.158,
 Th.B.P.178, W.C.O.35, W.C.O.37,
 W.C.O.44, Th.C.O.6, Th.C.O.23, T.C.P.42,
 T.C.P.102, W.C.P.5, W.C.P.124,
 Th.C.P.39, Th.C.P.70, Th.C.P.99

pol

T.B.P.106, W.B.P.75, W.B.P.126,
 W.C.O.44, T.C.P.49, T.C.P.137,
 W.C.P.116, Th.C.P.23, Th.C.P.95,
 Th.C.P.110, Th.C.P.130, C.683

see Protase

see Regulation

rev

T.C.O.30, M.C.P.51, T.C.P.81, T.C.P.114,
 Th.C.P.27, Th.C.P.140, C.646, C.668,
 C.679

tat

M.B.O.24, T.C.O.28, T.C.O.29, T.C.O.30,
 M.C.P.51, T.C.P.89, T.C.P.93, T.C.P.103,
 T.C.P.113, C.782

vif

M.B.O.24, Th.C.O.6

vpr

T.C.O.17, T.C.O.45, T.C.O.46, Th.C.O.6,
 Th.C.P.35

vpr

T.C.O.47, W.C.O.34, W.C.O.36,
 T.C.P.144, Th.C.P.18, Th.C.P.35

vpx

T.C.O.17, T.C.P.95, T.C.P.115, T.C.P.126

other

T.B.P.340, Th.C.P.36

GENERAL POPULATION,

PREVALENCE

M.A.O.2, M.A.O.4, M.A.O.5, M.A.O.17,
 W.A.O.30, M.A.P.1, M.A.P.3, M.A.P.7,
 M.A.P.8, M.A.P.9, M.A.P.13, M.A.P.32,
 M.A.P.36, M.A.P.40, M.A.P.43, M.A.P.83,
 M.A.P.70, M.A.P.74, M.A.P.82, T.A.P.6,
 T.A.P.11, T.A.P.12, T.A.P.24, T.A.P.120,
 W.A.P.56, Th.A.P.67, Th.A.P.76,
 Th.A.P.88, A.501, A.512, A.514, A.518,
 A.519, A.521, A.534, A.590, A.595,
 T.B.P.350, W.B.P.153, W.B.P.220,
 W.D.P.48, M.E.P.54, Th.E.P.18, E.515,
 E.545, M.G.O.2, M.G.O.17, M.G.O.30,
 W.G.O.26, M.G.P.4, M.G.P.5, M.G.P.10,
 M.G.P.22, T.G.P.2, T.G.P.30, W.G.P.3,
 W.G.P.29, Th.G.P.30, G.511, G.512,
 T.H.O.18, W.H.P.17, W.H.P.23, Th.H.P.19

GENOME

LTR

T.C.O.14, T.C.P.78, T.C.P.91, T.C.P.105,
 W.C.P.17, W.C.P.88, Th.C.P.31,
 Th.C.P.32, Th.C.P.33, C.645, C.658,
 C.672, C.733, C.782

new gene

T.C.O.49, T.C.P.83, T.C.P.104, T.C.P.143,
 C.649

GENOMIC DIVERSITY

C.643

GEOGRAPHICAL ASPECTS, AFRICA

Africa, general

M.A.O.16, M.A.O.32, T.A.P.86, W.A.P.114,
 M.B.O.6, M.B.O.17, T.B.O.9, Th.B.O.55,
 M.B.P.185, T.B.P.94, T.B.P.191,
 T.B.P.197, T.B.P.352, W.B.P.14,
 W.B.P.107, W.B.P.109, W.B.P.276,
 Th.B.P.132, Th.B.P.209, B.599, B.823,
 B.837, T.D.P.34, D.505, D.575, W.E.O.26,
 T.E.P.59, W.E.P.55, W.E.P.56, W.E.P.71,
 W.E.P.72, E.537, M.F.O.4, Th.G.O.6,
 Th.G.O.27, Th.G.O.34, Th.G.O.53,
 M.G.P.11, T.G.P.7, W.G.P.1, W.G.P.7,
 W.G.P.9, G.513, G.519, G.520, M.H.O.2,
 T.H.O.16, W.H.P.1, Th.H.P.19

Algeria

W.E.P.69

Angola

A.511, M.G.P.2

Burkina Faso

Th.G.O.26, M.G.P.26

Cameroon

Th.A.O.19, T.A.P.1, A.573, M.B.P.99,
 W.D.P.87, Th.D.P.22, W.G.O.21, M.G.P.9,
 T.G.P.10

Central African Republic

B.641, T.C.O.41, M.C.P.139, W.E.P.3,
 W.E.P.5, Th.E.P.52, W.G.O.28, Th.G.O.54

Congo

A.568, M.B.P.91, T.B.P.19, W.B.P.151,
 B.642, Th.G.O.54, T.G.P.3, W.G.P.2,
 W.G.P.10, Th.G.P.7, G.511, Th.H.P.22

East Africa

A.515

Egypt

W.E.P.75, E.650, M.G.P.22, Th.H.P.28

Ethiopia

M.A.P.79, T.A.P.102, T.E.P.21

Gambia

M.D.P.12, W.E.P.8, M.G.O.5, T.G.P.30,
 T.G.P.32

Ghana

A.829

Guinea Bissau

M.B.P.82, T.B.P.357, T.B.P.357, M.G.P.16,
 T.G.P.28, Th.H.P.25

Ivory Coast

Th.A.P.112, A.587, T.B.O.8, T.B.O.10,
 T.B.P.158, W.B.P.113, Th.B.P.346,
 Th.C.P.131, W.G.O.27, M.G.P.24

Kenya

T.A.O.25, Th.A.O.25, M.A.P.110, T.A.P.87,
 T.A.P.88, T.A.P.91, W.A.P.65, Th.B.O.39,
 M.B.P.53, M.B.P.160, T.B.P.108,
 T.B.P.133, T.B.P.134, B.536, Th.E.P.39,

W.G.O.22, Th.G.O.5, Th.G.O.52,
 W.G.P.27, W.G.P.29, Th.G.P.29, G.503,
 W.H.P.15

Madagascar

M.G.P.7

Malawi

W.G.O.29, Th.G.O.28, Th.G.P.14, G.507

Mali

A.577

Mozambique

M.B.P.327, M.B.P.373, Th.G.P.22

Nigeria

M.B.P.156, M.B.P.158, M.C.P.150, D.542,
 Th.E.P.38, Th.E.P.76, E.620, W.G.O.24,
 T.G.P.23

Rwanda

M.B.P.188, T.E.O.3, Th.G.P.20

Senegal

M.A.O.15, M.A.P.19, M.A.P.117, T.A.P.3,
 T.B.P.105, W.B.P.100, Th.B.P.377,
 W.E.P.136, M.D.P.18, T.D.P.37, M.E.O.32,
 W.E.P.4, Th.E.P.45, E.665, E.741, E.798,
 W.G.O.20, T.G.P.26, T.G.P.29, Th.G.P.23

Sierra Leone

W.G.P.16

South Africa

M.A.P.83, W.D.P.47, T.E.O.15, W.E.P.26,
 W.F.O.22, M.G.P.30, T.G.P.18, Th.G.P.15

Sudan

M.G.P.5

Tanzania

Th.E.P.34, E.604, E.652, T.G.O.11,
 T.G.P.13

Uganda

T.A.P.11, W.A.P.56, A.617, T.B.O.11,
 T.B.P.189, Th.B.P.302, Th.B.P.317,
 W.D.P.8, M.E.O.8, W.E.O.5, W.E.O.17,
 W.E.P.22, Th.E.P.43, E.805, M.G.O.13,
 M.G.O.14, M.G.O.15, T.G.O.12, T.G.P.13,
 W.G.P.32, Th.G.P.18, Th.G.P.19

West Africa

A.556, T.B.P.343, T.B.P.251, T.B.P.262,
 W.B.P.108, B.E.10, Th.C.O.24, C.766,
 M.D.P.12, M.G.O.10, W.E.P.5, W.E.P.66,
 Th.E.P.3, T.G.P.11

Zaire

M.A.O.35, Th.A.O.21, T.A.P.90, W.A.P.96,
 M.B.O.38, Th.B.O.30, M.B.P.31,
 T.B.P.107, T.B.P.108, T.B.P.181,
 T.B.P.189, T.B.P.205, T.B.P.396,
 W.B.P.359, Th.B.P.186, Th.B.P.211,
 Th.B.P.221, Th.B.P.229, Th.B.P.267,
 M.D.O.3, M.D.O.17, T.D.O.35, W.D.O.6,
 M.D.P.13, M.D.P.49, W.D.P.2, W.D.P.90,
 D.694, D.721, M.E.O.33, M.E.O.36,
 Th.E.O.3, T.E.P.4, T.E.P.61, W.E.P.65,
 Th.E.P.1, Th.E.P.40, E.621, E.666, E.812,
 M.G.O.3, M.G.O.16, M.G.O.17, W.G.O.1,
 W.G.O.4, W.G.O.26, W.G.O.30,
 Th.G.O.32, M.G.P.18, W.G.P.8, W.G.P.20,
 Th.O.7, Th.O.8, Th.O.9, W.H.P.6,
 Th.H.P.16, Th.H.P.27

Zambia

M.A.O.37, M.A.O.42, Th.A.O.5, W.A.P.50,
 W.A.P.54, M.B.P.149, M.B.P.236,
 T.B.P.144, T.B.P.337, T.B.P.371,
 W.B.P.265, D.723, W.G.O.5, Th.G.O.4,

- M.G.P.23, M.G.P.28, T.G.P.16, Th.G.P.5, Th.G.P.30, Th.H.P.13
- Zimbabwe
Th.A.P.5, M.B.P.289, Th.B.P.214, Th.B.P.217, M.E.P.50, Th.E.P.82, W.G.O.19, Th.G.O.6
- GEOGRAPHICAL ASPECTS, ASIA**
- China
A.619, B.596, Th.H.P.26
- Hong Kong
T.A.P.120, W.G.P.30, Th.H.P.30
- India
M.B.P.139, M.B.P.381, Th.O.13, Th.E.P.60, E.648, W.F.O.14, T.G.O.22, T.G.P.6
- Japan
M.A.P.42, Th.A.P.14, Th.A.P.28, C.753
- New Guinea
Th.A.P.7, T.G.O.24
- Philippines
T.B.P.377, W.B.P.152, Th.G.O.25, Th.H.P.21
- Sri Lanka
M.E.O.31, M.G.O.18, T.G.O.7
- Taiwan
C.754, G.501
- Thailand
Th.D.O.1, M.D.P.19, M.D.P.50, W.E.P.14, T.G.O.23, W.G.P.19
- GEOGRAPHICAL ASPECTS, AUSTRALIA**
- T.D.P.49, W.D.P.62, W.D.P.64, D.697, W.E.O.9, T.E.P.20, E.769, E.773, M.F.P.8, W.G.O.14
- GEOGRAPHICAL ASPECTS, CARIBBEAN**
- Bahamas
Th.A.P.120
- Barbados
T.E.P.32
- Bermuda
G.502
- Caribbean, general
E.575, E.576, E.631, E.653, Th.G.P.27, Th.G.P.28
- Cuba
W.A.P.86
- Dominican Republic
W.A.P.94, Th.D.O.10, Th.D.O.12, T.D.P.89, M.E.O.11, Th.E.O.15, E.580, E.670, E.672, M.G.O.25, T.G.P.12
- Haiti
M.A.O.29, Th.A.O.30, W.A.P.7, T.B.P.182, T.B.P.185, T.D.O.32, M.D.P.33, D.534, M.E.O.11, M.E.P.10, M.E.P.12, Th.E.P.26, T.G.O.19, T.G.O.20, T.G.O.21, Th.G.O.49, Th.G.O.51, M.G.P.3, W.G.P.31, Th.G.P.2
- Jamaica
B.836, M.D.P.47, T.F.P.5, W.G.P.26, Th.G.P.1
- Martinique
T.A.P.12, Th.A.P.30, W.C.P.126
- Puerto Rico
W.A.P.32, W.A.P.48, A.505, M.B.P.27, D.597, M.E.P.19, Th.E.P.67, W.G.O.2, T.H.O.10, T.H.O.12, W.H.P.4, W.H.P.5, Th.H.P.12
- Trinidad
Th.A.P.23, M.B.P.296, Th.E.P.65, E.574, E.671, W.G.11
- GEOGRAPHICAL ASPECTS, CENTRAL AMERICA**
- Costa Rica
A.555, A.603, Th.B.P.14, B.511, E.763, Th.H.P.24
- Mexico
T.A.P.8, Th.A.P.80, Th.A.P.81, A.585, T.B.P.193, T.B.P.335, W.B.P.168, B.515, Th.D.O.11, M.D.P.7, M.D.P.69, E.585, E.738, M.F.P.3, M.G.O.1, M.G.O.27, T.G.O.8, T.G.O.9, Th.G.O.29, Th.G.O.30, M.G.P.10, W.G.P.6, W.G.P.23, W.G.P.24, W.G.P.25, Th.G.P.16, G.510, G.516, T.H.O.11, Th.H.P.20
- Panama
E.658
- GEOGRAPHICAL ASPECTS, EUROPE**
- Belgium
M.A.P.49, M.A.P.86, A.532, T.B.P.94, T.B.P.108, T.B.P.197, M.D.P.67
- Bulgaria
B.613, B.614
- Denmark
Th.A.P.69, M.B.P.79, W.B.P.27, W.D.P.55, D.559, D.689, Th.E.O.10, W.E.P.38, T.G.P.31
- Europe
M.A.O.7, Th.A.O.20, T.A.P.98, W.A.P.15, A.537, Th.B.P.132, B.620, T.E.P.50, W.H.P.22
- Finland
T.A.P.18, Th.A.P.2, A.509, M.B.P.159
- France
M.A.O.24, M.A.O.40, M.A.P.25, M.A.P.44, M.A.P.46, M.A.P.106, T.A.P.19, Th.A.P.3, Th.A.P.116, A.539, A.552, A.557, A.574, A.635, T.B.P.20, M.D.O.1, T.D.O.20, T.D.P.47, Th.D.P.31, Th.D.P.95, D.569, T.E.O.2, W.E.O.21, Th.E.O.7, T.E.P.37, W.E.P.23, Th.E.P.12, Th.E.P.17, E.516, E.617, E.618, E.673, T.F.O.7, M.H.O.5, M.H.O.13, Th.H.P.11
- French Overseas Territories
M.A.O.14, T.E.O.2, T.E.P.23, M.G.P.21
- Greece
Th.A.P.27, W.B.P.342, Th.D.P.72, E.615, E.654, E.747
- Italy
M.A.O.38, T.A.O.19, M.A.P.8, M.A.P.36, M.A.P.44, M.A.P.48, M.A.P.78, T.A.P.30, T.A.P.38, T.A.P.41, W.A.P.30, W.A.P.43, W.A.P.63, A.536, A.545, A.566, A.567, A.634, M.B.P.92, T.B.P.74, T.B.P.100, T.B.P.178, T.B.P.345, T.B.P.346, Th.B.P.51, Th.C.O.40, W.C.P.50, M.D.P.37, Th.D.P.67, D.623, D.688, M.E.P.61, T.E.P.26, W.E.P.19, W.E.P.45, E.616, E.622, E.790, E.814
- Netherlands
T.A.O.21, T.A.P.14, T.A.P.82, W.A.P.97, A.593, M.B.P.162, M.D.P.34, T.D.P.47, D.705, Th.E.O.2, E.506
- Norway
M.A.P.91, W.A.P.103, Th.A.P.59, A.607, M.B.P.308, T.D.P.5, D.619, T.E.O.8, T.E.P.31
- Paris
M.B.P.154, Th.B.P.64, M.D.P.40, Th.E.P.23
- Poland
M.A.P.69, T.A.P.7, Th.D.P.41, W.E.P.63
- Portugal
M.A.P.18, M.A.P.77, M.A.P.82, M.A.P.86, W.E.P.76, Th.E.P.46
- Scotland
T.A.O.14, M.A.P.47, M.A.P.92, M.A.P.105, T.A.P.51, Th.A.P.115, Th.D.P.3, Th.D.P.55, D.612, W.F.P.8
- Spain
M.A.O.41, T.A.O.3, T.A.O.23, M.A.P.52, M.A.P.81, M.A.P.104, T.A.P.22, T.A.P.114, W.A.P.55, W.A.P.71, W.A.P.75, W.A.P.78, Th.A.P.19, Th.A.P.22, A.534, A.556, A.575, A.576, A.578, W.B.O.37, M.B.P.97, M.B.P.137, M.B.P.240, W.B.P.28, W.E.P.40, Th.B.P.57, Th.B.P.527, B.610, B.647, Th.D.P.19, D.671, W.E.O.22, M.E.P.22, T.E.P.3, T.E.P.27, T.E.P.73, Th.E.P.48, E.515, E.526, E.579, E.674, E.765, E.766, E.777, E.813, W.H.P.2
- Sweden
W.A.O.10, Th.A.P.69, Th.A.P.113, W.D.P.65, W.D.P.76, W.D.P.88, Th.D.P.36, D.618, D.669, W.E.O.15, M.E.P.2, T.E.P.30, T.E.P.76, E.780, E.784
- Switzerland
M.A.P.43, W.A.P.116, W.A.P.117, W.A.P.120, Th.A.P.111, Th.D.P.71, Th.D.P.90, D.636, E.739, M.H.P.18, Th.H.P.4
- United Kingdom
W.A.O.9, M.A.P.57, T.A.P.31, Th.A.P.75, A.538, A.594, A.597, W.B.P.383, Th.B.P.317, M.D.O.1, M.D.O.18, M.D.P.15, T.D.P.20, T.D.P.23, T.D.P.68, D.529, D.625, D.682, T.E.O.12, W.E.O.3, W.E.O.23, M.E.P.46, M.E.P.73, T.E.P.38, Th.E.P.47, Th.E.P.71, E.521, E.522, E.538, E.642, E.658, E.802, T.F.O.2, Th.F.P.9, W.H.O.4, M.H.P.3, T.H.P.19
- USSR
W.A.O.5, A.588
- West Germany
M.A.P.44, M.A.P.103, T.A.P.9, T.A.P.10, T.A.P.60, T.A.P.64, Th.A.P.29, Th.A.P.65, Th.A.P.96, W.B.O.26, Th.B.P.59, Th.B.P.60, Th.B.P.73, Th.B.P.183, C.546, M.D.P.9, W.D.P.23, M.E.P.57, T.E.P.2, E.606, E.607, E.705, E.767, E.775, E.776, E.792, T.F.P.9, W.H.P.23
- Yugoslavia
T.E.P.22
- GEOGRAPHICAL ASPECTS, MIDDLE EAST**
- Iran
T.G.P.20

Israel
M.A.P.59, T.A.P.2, A.508, W.E.P.47

Kuwait
W.G.P.4

GEOGRAPHICAL ASPECTS, NORTH AMERICA

Alaska
W.A.P.23, A.519

California
A.528, A.565, W.B.P.263, Th.B.P.195, M.D.P.6, M.D.P.14, D.666, E.646, E.748, Th.P.17

Canada
Th.A.O.27, M.A.P.97, M.A.P.113, M.A.P.115, T.A.P.6, T.A.P.69, T.A.P.84, Th.A.P.37, Th.A.P.38, Th.A.P.46, A.535, A.591, M.B.O.47, W.B.O.10, W.B.O.27, M.B.P.157, T.B.P.54, T.B.P.106, T.B.P.359, W.B.P.241, Th.B.P.18, Th.B.P.28, Th.P.52, M.D.P.58, M.D.P.75, T.D.P.8, W.D.P.56, Th.D.P.32, D.583, Th.E.O.4, M.E.P.37, M.E.P.58, T.E.P.55, Th.E.P.10, Th.E.P.25, E.531, E.543, E.589, E.584, E.644, E.693, E.749, E.783, T.F.O.5, M.F.P.4, M.F.P.12, T.F.P.2, T.F.P.7, W.F.P.9, Th.F.P.7, W.G.O.14, T.G.P.24, M.H.P.16, W.H.P.21, Th.H.P.6

Chicago
W.B.P.260, W.D.P.30, D.591

Los Angeles
M.A.P.12, M.A.P.74, T.A.P.85, T.A.P.87, W.A.P.2, M.B.P.68, M.B.P.113, T.B.P.161, T.E.P.47, W.E.P.70, Th.E.P.11, M.H.O.17, M.H.P.5

Miami
M.A.O.28, W.A.P.1, D.592, W.E.P.70, E.706

Minneapolis/St. Paul
T.A.O.26, M.A.P.72, T.A.P.43

Montreal
T.A.P.59, M.D.P.33, M.D.P.64, D.534, M.E.P.10, M.E.P.51, T.E.P.46, W.E.P.16, Th.E.P.18, Th.E.P.26, Th.E.P.33, Th.E.P.68, Th.E.P.72

New York City
M.A.O.34, M.A.O.43, T.A.O.12, M.A.P.10, M.A.P.51, M.A.P.67, T.A.P.48, T.A.P.54, T.A.P.70, T.A.P.71, T.A.P.89, T.A.P.112, W.A.P.5, W.A.P.9, W.A.P.11, W.A.P.12, W.A.P.16, W.A.P.21, W.A.P.32, W.A.P.34, W.A.P.84, Th.A.P.4, Th.A.P.13, Th.A.P.25, Th.A.P.26, Th.A.P.32, A.550, A.564, A.615, W.B.O.41, M.B.P.141, T.B.P.344, W.B.P.209, W.B.P.249, W.B.P.343, Th.B.P.50, Th.B.P.261, Th.C.P.5, Th.D.O.16, M.D.P.45, W.D.P.60, W.D.P.68, Th.D.P.1, Th.D.P.6, Th.D.P.7, Th.D.P.8, Th.D.P.38, Th.D.P.59, Th.D.P.64, D.607, D.609, D.628, D.725, M.E.P.12, M.E.P.40, M.E.P.67, T.E.P.41, T.E.P.52, T.E.P.57, W.E.P.70, Th.E.P.4, Th.E.P.51, E.503, E.520, E.557, E.612, E.686, E.691, E.728, E.736, E.772, E.778, Th.F.P.6, M.H.O.16

New York State
M.A.P.71, A.588, M.B.P.57, T.B.P.52, W.B.P.258, W.D.P.15, Th.D.P.16,

Th.D.P.45, T.E.P.14, T.E.P.33, T.E.P.40, E.684, M.H.O.11, T.H.P.5, W.H.P.10

Ontario
Th.D.P.52, M.E.P.25, M.E.P.47, W.E.P.10, W.E.P.24, W.E.P.25, Th.E.P.49, E.619, Th.F.P.4

Quebec Province
M.A.O.21, W.A.O.14, W.A.P.83, A.547, M.E.P.41, M.E.P.45, W.E.P.11

San Francisco
M.A.O.49, T.A.O.7, W.A.O.27, M.A.P.64, W.A.P.13, W.A.P.14, W.A.P.24, W.A.P.46, W.A.P.80, W.A.P.91, Th.A.P.32, Th.A.P.90, A.637, W.B.O.19, M.B.P.150, W.B.P.202, W.B.P.354, Th.B.P.75, Th.B.P.201, T.D.O.12, Th.D.O.4, Th.D.O.5, M.D.P.31, M.D.P.53, T.D.P.33, W.D.P.28, W.D.P.52, Th.D.P.5, Th.D.P.33, Th.D.P.34, D.615, D.658, T.E.P.7, T.E.P.41, W.E.P.70, Th.E.P.73, E.566, Th.O.3, Th.O.5, W.H.O.14, M.H.P.5, M.H.P.6

USA
M.A.O.2, M.A.O.17, T.A.O.27, T.A.O.37, W.A.O.1, W.A.O.15, W.A.O.16, W.A.O.17, W.A.O.18, Th.A.O.18, Th.A.O.23, Th.A.O.29, M.A.P.3, M.A.P.9, M.A.P.50, M.A.P.55, M.A.P.75, T.A.P.15, T.A.P.27, T.A.P.37, T.A.P.50, T.A.P.66, T.A.P.85, T.A.P.96, T.A.P.97, W.A.P.26, W.A.P.29, W.A.P.38, W.A.P.64, W.A.P.81, W.A.P.109, Th.A.P.16, Th.A.P.20, Th.A.P.21, Th.A.P.44, Th.A.P.49, A.533, A.551, A.553, A.559, A.603, A.608, A.639, W.B.O.24, M.B.P.23, M.B.P.29, M.B.P.200, T.B.P.70, T.B.P.162, W.B.P.15, W.B.P.61, W.B.P.267, Th.B.P.44, Th.B.P.216, B.519, B.574, B.634, M.D.O.1, M.D.O.7, M.D.O.13, T.D.O.13, T.D.O.21, W.D.O.1, M.D.P.1, M.D.P.56, M.D.P.59, T.D.P.9, T.D.P.18, T.D.P.21, T.D.P.40, W.D.P.24, W.D.P.29, W.D.P.32, W.D.P.33, W.D.P.37, W.D.P.49, W.D.P.50, W.D.P.56, Th.D.P.26, Th.D.P.74, D.509, D.518, D.537, D.643, T.E.O.14, T.E.O.16, W.E.O.14, W.E.O.21, M.E.P.3, M.E.P.13, M.E.P.21, M.E.P.72, M.E.P.74, T.E.P.11, T.E.P.17, T.E.P.36, T.E.P.42, T.E.P.74, W.E.P.1, W.E.P.43, W.E.P.60, Th.E.P.14, Th.E.P.15, Th.E.P.29, Th.E.P.31, E.634, E.635, E.651, E.554, E.558, E.560, E.562, E.572, E.608, E.613, E.628, E.535, E.655, E.702, E.709, M.F.O.2, M.F.O.3, T.F.O.18, Th.F.O.2, Th.F.O.4, M.F.P.1, M.F.P.4, M.F.P.5, M.F.P.6, Th.F.P.3, Th.G.O.1, T.G.P.1, M.H.O.8, W.H.O.8, W.H.O.9, W.H.O.15, Th.P.22, Th.P.24, W.H.P.21, W.H.P.23, Th.H.P.5, Th.H.P.9

GEOGRAPHICAL ASPECTS, SOUTH AMERICA

Argentina
W.A.P.22, A.520, A.582, W.B.P.382, Th.B.P.4, B.513, M.G.O.29, M.G.P.29, Th.G.P.17, Th.G.P.21

Brazil
M.A.P.84, T.A.P.117, W.A.P.70, A.549, T.B.O.7, T.B.O.12, M.B.P.279, T.B.P.194, T.B.P.196, W.B.P.20, W.B.P.48,

W.B.P.116, W.B.P.237, Th.B.P.36, Th.B.P.39, Th.B.P.47, Th.B.P.63, B.525, T.D.O.28, T.D.P.25, T.D.P.54, T.D.P.78, T.D.P.83, W.D.P.38, Th.D.P.89, D.532, D.547, D.604, D.655, D.709, M.E.O.9, M.E.O.17, W.E.O.29, M.E.P.31, M.E.P.66, T.E.P.69, W.E.P.37, Th.E.P.19, E.591, E.603, E.641, E.739, E.781, E.785, E.799, Th.F.P.1, M.G.O.26, W.G.O.15, W.G.O.23, Th.G.O.50, M.G.P.1, M.G.P.4, M.G.P.6, M.G.P.8, M.G.P.12, M.G.P.13, M.G.P.14, M.G.P.15, M.G.P.20, T.G.P.14, W.G.P.3, W.G.P.15, Th.G.P.3, Th.G.P.26, G.518

Buenos Aires
A.586, M.B.O.16, Th.B.P.3, M.D.O.10, W.D.P.56, Th.D.P.46, W.G.P.18, W.G.P.21

Chile
M.G.P.17, Th.G.P.4

Colombia
W.E.P.48, M.G.O.6

Ecuador
T.D.P.85, M.G.O.28, M.G.P.19, W.G.P.12

Peru
D.552, M.E.P.20, E.645, E.787, Th.H.P.17

Rio de Janeiro
M.A.P.53, W.A.P.51, M.B.P.109, M.B.P.182, M.B.P.257, T.B.P.190, T.B.P.384, Th.B.P.66, Th.B.P.74, B.532, B.534, M.E.O.9, W.E.O.16, T.E.P.64, T.E.P.65, E.523, T.G.P.25

Sao Paulo
T.A.P.17, A.554, M.B.P.44, M.B.P.108, T.B.P.356, D.540, W.E.O.29, T.E.P.49, Th.E.P.22, E.610, E.665, G.515

South America, General
M.B.P.181, D.691

Surinam
D.535

see also Developing countries; Gay men; Intravenous drug users; Prostitutes

GLOVES

A.538, E.601, E.746, E.747, T.G.P.19, M.H.P.26, M.H.P.27
see also Health care personnel

GLYCOPEPTIDES

Th.C.O.31, M.C.P.104

GLYCOSYLATION INHIBITORS

W.C.O.26, M.C.P.134, Th.C.P.43, Th.C.P.47

GLYCYRRHIZIN

W.B.P.298

GM-CSF

Th.B.O.45, T.B.P.284, T.B.P.299, T.B.P.331, W.B.P.305, W.B.P.309, W.B.P.328, W.B.P.329, T.C.O.16, Th.C.O.17, M.C.P.103, W.C.P.42, W.C.P.85, W.C.P.109, W.C.P.122

GONADOTROPINS

M.B.P.286

GP 120

activation
A.535, Th.B.P.96, M.C.P.22

binding
T.C.O.34, T.C.O.35, W.G.O.12, W.C.O.16, W.C.O.38, Th.C.O.14, Th.C.O.26, M.C.P.4,

T.C.P.48, W.C.P.56, W.C.P.66, W.C.P.90, W.C.P.128, Th.C.P.1, Th.C.P.34, Th.C.P.100, Th.C.P.121, C.618, C.523, C.513, C.636, C.674, C.680, C.752, C.783
defective
 C.680
glycoylation
 M.C.P.26, Th.C.P.1, Th.C.P.47, Th.C.P.80, Th.C.P.81, Th.C.P.122, C.547, C.783, D.630
human monoclonal
 W.B.P.70, T.C.P.150
suppression
 Th.B.P.101, M.C.O.21, T.C.P.15, C.635
other
 T.B.P.104, T.B.P.207, T.B.P.240, W.B.P.111, Th.B.P.231, T.C.O.22, Th.C.O.31, M.C.P.25, M.C.P.35, M.C.P.38, M.C.P.72, M.C.P.92, T.C.P.29, T.C.P.106, W.C.P.8, W.C.P.44, C.552, C.578, C.760
GP 41
 T.B.P.104, T.B.P.106, W.B.P.71, W.B.P.99, W.B.P.111, W.B.P.118, W.B.P.144, Th.B.P.99, Th.B.P.101, B.548, B.582, B.592, M.C.O.22, M.C.O.32, T.C.O.33, T.C.O.34, T.C.O.35, T.C.O.37, M.C.P.35, M.C.P.36, M.C.P.146, T.C.P.70, T.C.P.107, T.C.P.150, W.C.P.157, W.C.P.98, Th.C.P.89, Th.C.P.78, Th.C.P.100, Th.C.P.122, C.567, C.656
see also Epitope analysis
GROUP SUPPORT
 M.B.P.317, W.B.P.207, T.D.O.30, M.D.P.20, Th.D.P.37, M.E.O.17, M.E.O.24, M.E.P.35, Th.E.P.73, E.516, E.540
GUILLAIN-BARRE SYNDROME
 Th.B.P.214
GYNECOLOGY
 Th.A.P.104, M.B.P.55, M.B.P.58, M.B.P.59, M.B.P.276, M.B.P.292, T.B.P.366, Th.C.P.26, W.D.P.54, Th.D.P.10, D.712
HAIR LOSS
 M.B.P.364
HBV
see Hepatitis B virus
HDV
see Hepatitis delta virus
HEALTH BELIEFS
 M.B.P.320, W.B.P.271, Th.B.P.314, B.508, M.D.O.5, M.D.P.36, T.D.P.12, T.D.P.33, T.D.P.39, D.652, Th.E.P.52, T.G.P.15
HEALTH CARE, COST
see Cost
HEALTH CARE ORGANIZATION
 A.597, M.B.P.302, M.B.P.318, M.B.P.376, W.B.P.61, W.B.P.238, W.B.P.245, W.B.P.248, W.B.P.253, W.B.P.257, W.B.P.260, W.B.P.262, W.B.P.271, Th.B.P.216, B.507, Th.D.P.92, D.600, D.661, W.E.O.10, M.E.P.47, M.E.P.49, M.E.P.55, M.E.P.56, M.E.P.75, W.E.P.70, Th.E.P.69, E.506, E.596, E.772, W.G.P.5, Th.G.P.10, G.505, T.H.P.13

HEALTH CARE PERSONNEL

behaviour
 W.A.O.4, W.B.P.63, W.B.P.245, Th.B.P.33, Th.B.P.234, Th.B.P.354, M.D.O.16, M.D.O.17, M.D.O.18, M.D.P.42, M.D.P.46, M.D.P.83, M.D.P.54, M.D.P.57, M.D.P.60, M.D.P.61, M.D.P.65, M.D.P.69, M.D.P.74, M.D.P.76, M.D.P.79, M.D.P.81, M.D.P.83, M.D.P.84, M.D.P.87, M.D.P.89, T.D.P.54, W.D.P.5, D.624, D.631, D.638, D.642, D.647, D.648, D.652, D.717, T.E.O.4, M.E.P.26, M.E.P.41, M.E.P.44, M.E.P.53, M.E.P.56, T.E.P.39, W.E.P.2, W.E.P.54, Th.E.P.16, Th.E.P.53, Th.E.P.56, Th.E.P.59, E.546, E.594, E.596, E.605, E.608, E.734, E.745, E.763, T.F.P.5, W.F.P.1, M.G.O.16
dentists
 A.520, M.D.P.53, M.D.P.64, M.D.P.77, M.D.P.80, T.D.P.25, D.633, E.601, E.667, E.693, E.729, E.747
needle sticks
 Th.A.P.45, Th.A.P.48, A.503, M.D.P.68, E.743
nurses
 M.A.P.115, M.B.P.304, M.B.P.306, M.B.P.307, M.B.P.308, M.B.P.309, M.B.P.310, M.B.P.311, M.B.P.312, M.B.P.316, M.B.P.319, M.B.P.320, M.B.P.322, W.B.P.65, W.B.P.218, W.B.P.248, W.B.P.376, Th.B.P.35, M.D.O.16, M.D.P.56, M.D.P.61, M.D.P.87, D.626, M.E.P.58, W.E.P.25, W.E.P.76, Th.E.P.56, E.596, E.598, E.745, E.773
physicians
 M.A.O.21, W.A.P.120, A.626, M.B.P.308, M.B.P.319, T.B.P.36, T.B.P.384, W.B.P.64, W.B.P.237, W.B.P.249, W.B.P.251, W.B.P.264, Th.B.P.35, M.D.P.41, M.D.P.44, M.D.P.51, M.D.P.57, M.D.P.59, M.D.P.66, M.D.P.67, M.D.P.78, M.D.P.84, M.D.P.86, M.D.P.89, W.D.P.5, Th.D.P.92, D.614, D.625, D.628, D.644, D.654, M.E.O.28, Th.E.O.10, M.E.P.45, M.E.P.58, T.E.P.39, W.E.P.73, W.E.P.76, Th.E.P.16, Th.E.P.53, E.606, E.622, E.678, E.683, E.745, E.811, Th.F.O.7, T.F.F.6, Th.F.P.1
prevalence
 W.A.O.3, A.517
risks to
 W.A.O.1, W.A.O.2, W.A.O.4, Th.A.P.9, Th.A.P.46, Th.A.P.47, Th.A.P.48, Th.A.P.49, A.503, A.517, A.618, M.B.P.308, M.D.O.14, M.D.O.17, M.D.P.62, M.D.P.68, M.D.P.72, M.D.P.88, D.623, D.627, D.628, M.E.P.29, M.E.P.32, E.632, E.743, E.746, E.757, T.F.P.1, T.F.P.7, T.G.P.19, M.H.P.27
stress
 A.639, M.D.P.43, M.D.P.56, D.564, D.582, D.632, D.639, D.653, D.656, M.E.P.58, M.E.P.65, E.509, E.596, E.596, E.605, E.629, E.743, E.745, E.746
training
 W.A.P.112, A.630, A.639, M.B.P.320, M.B.P.322, W.B.P.63, W.B.P.237, W.B.P.251, W.B.P.251, W.B.P.376,

Th.B.P.314, M.D.O.13, M.D.O.15, M.D.O.16, M.D.O.18, T.D.O.33, M.D.P.42, M.D.P.45, M.D.P.47, M.D.P.48, M.D.P.49, M.D.P.50, M.D.P.55, M.D.P.56, M.D.P.57, M.D.P.58, M.D.P.59, M.D.P.62, M.D.P.63, M.D.P.67, M.D.P.69, M.D.P.81, M.D.P.85, M.D.P.89, M.D.P.92, W.D.P.12, D.550, D.552, D.553, D.582, D.622, D.625, D.626, D.629, D.630, D.633, D.634, D.635, D.638, D.640, D.643, D.650, D.655, M.E.O.34, T.E.O.2, T.E.O.4, M.E.P.24, M.E.P.26, M.E.P.31, M.E.P.32, M.E.P.33, M.E.P.36, M.E.P.59, W.E.P.74, T.E.P.18, W.E.P.6, W.E.P.9, W.E.P.13, W.E.P.15, W.E.P.21, W.E.P.50, W.E.P.54, W.E.P.55, W.E.P.60, Th.E.P.41, E.545, E.546, E.568, E.582, E.583, E.594, E.595, E.596, E.597, E.598, E.599, E.600, E.602, E.603, E.603, E.605, E.606, E.606, E.607, E.608, E.609, E.610, E.611, E.612, E.624, E.627, E.628, E.629, E.630, E.631, E.632, E.634, E.664, E.668, E.673, E.676, E.678, E.683, E.699, E.714, E.753, E.769, E.793, M.G.O.16, T.G.P.16, T.G.P.22, Th.G.P.4
other
 M.B.P.313, M.B.P.314, M.B.P.376, W.B.P.272, M.D.P.71, M.D.P.73, M.D.P.74, M.D.P.90, D.526, D.636, D.645, D.649, D.651, M.E.P.46, W.E.P.15, M.H.P.26
HEALTH MAINTENANCE ORGANIZATION (HMO)
 D.504, E.668, M.H.O.14, T.H.O.2, T.H.P.1, Th.P.2, T.H.P.12
HEART
endocarditis
 M.B.P.282, M.B.P.287, Th.D.O.4
myocarditis
 M.B.P.273, M.B.P.282, M.B.P.284, T.B.P.146
other
 M.B.P.65, M.B.P.259, M.B.P.282, M.B.P.283, M.B.P.284, M.B.P.285, M.B.P.286, T.B.P.256, B.633, B.634
HEAT TREATED FACTOR VIII
 M.B.P.65
HEMATOLOGICAL ABNORMALITIES
 Th.A.P.94, M.B.P.160, M.B.P.171, M.B.P.249, M.B.P.250, M.B.P.325, M.B.P.336, T.P.239, W.B.P.124, W.B.P.303, W.C.P.38, W.C.P.115, C.702
HEMATOPOIESIS
 T.B.P.268
HEMODIALYSIS
 T.A.P.26, T.A.P.27, A.613, M.B.P.277, M.B.P.344, T.B.P.356, Th.C.P.88
HEMOPHILIA
see Children coinfections
 M.A.P.42, W.B.O.28, M.B.P.63, Th.B.P.7, Th.B.P.10, Th.B.P.22, Th.B.P.23, Th.B.P.25, Th.B.P.355
education
 Th.B.P.26, M.E.P.37

- epidemiology**
W.B.O.27, W.B.P.283, Th.B.P.14,
Th.B.P.16, T.E.P.54
- immunology**
M.A.P.45, W.B.O.25, M.B.P.145,
T.B.P.110, W.B.P.87, W.B.P.311,
Th.B.P.1, Th.B.P.2, Th.B.P.8, Th.B.P.10,
Th.B.P.16, Th.B.P.142, Th.B.P.362, B.512,
B.518, T.C.P.141
- neurology**
W.B.O.42, T.B.P.177, Th.B.P.192
- prevalence**
M.A.P.44, T.A.P.64, A.565, T.B.P.345,
Th.B.P.3, Th.B.P.24, T.G.P.20
- prevention**
Th.B.P.30, T.E.P.54, T.E.P.55
- prognosis**
W.B.O.23, W.B.O.26, W.B.O.28, W.C.P.124
- progression**
Th.A.O.26, M.A.P.96, W.B.O.26,
M.B.P.145, T.B.P.345, W.B.P.74,
W.B.P.298, W.B.P.348, Th.B.P.11,
Th.B.P.12, Th.B.P.13, Th.B.P.15,
Th.B.P.192, C.514
- psychosocial**
W.B.P.383, Th.B.P.11, Th.B.P.17,
Th.B.P.26, Th.B.P.27, Th.B.P.28,
Th.B.P.29, Th.B.P.31, Th.B.P.32,
Th.B.P.33, Th.B.P.35, E.507, E.775, E.783
- seroconversion**
M.A.O.12, M.A.P.41, M.A.P.109, W.A.P.61,
W.B.O.24, W.B.O.28, Th.B.P.15,
Th.B.P.17, Th.B.P.34, Th.B.P.311, B.511,
B.513, Th.C.P.69
- sexual transmission**
M.A.O.33, T.A.P.107, T.A.P.108,
T.A.P.109, T.A.P.110, T.B.P.84, Th.B.P.30,
Th.B.P.33, Th.B.P.34, Th.G.P.21
- zidovudine metabolism**
M.B.P.342, T.B.P.177, T.B.P.253,
W.B.P.348, W.B.P.349
- other**
W.A.P.61, Th.B.O.8, M.B.P.35, M.B.P.112,
M.B.P.223, T.B.P.109, T.B.P.275,
W.B.P.70, W.B.P.357, Th.B.P.4, Th.B.P.6,
Th.B.P.19, Th.B.P.174, B.511, Th.C.P.69,
Th.C.P.105, Th.C.P.126, C.716, C.727,
C.754, C.780, T.D.O.34, T.D.P.15
- HEPARIN**
C.595
- HEPATITIS B VIRUS (HBV)**
M.A.O.40, M.A.P.18, M.A.P.45, T.A.P.29,
T.A.P.59, T.A.P.76, T.A.P.82, T.A.P.83,
W.A.P.7, A.511, A.521, A.550, A.582,
A.586, M.B.P.112, M.B.P.113, M.B.P.215,
M.B.P.216, M.B.P.217, M.B.P.219,
M.B.P.220, M.B.P.222, M.B.P.223,
M.B.P.224, M.B.P.246, M.B.P.262,
T.B.P.132, T.B.P.309, T.B.P.343,
T.B.P.368, B.525, M.C.P.4, M.C.P.15,
M.C.P.43, Th.C.P.139, C.747, D.583,
W.G.O.29, W.G.O.30, M.G.P.5, W.G.P.1,
W.G.P.2
- HEPATITIS B VACCINATION**
M.A.P.45, Th.A.P.91, A.550, Th.B.P.5,
Th.B.P.119, D.583
- HEPATITIS DELTA VIRUS (HDV)**
W.A.P.22, A.586, M.B.P.112, M.B.P.215,
M.B.P.216, M.B.P.218, M.B.P.221,
T.B.P.368, W.G.P.1
- HEPATITIS, NON-A, NON-B**
M.B.P.242
- HEROIN**
T.D.P.64, T.D.P.65, D.608, E.694,
W.G.P.22
see also Intravenous drug users
- HERPES VIRUSES**
M.A.O.46, T.A.P.119, W.A.P.7, W.A.P.41,
W.A.P.54, Th.A.P.100, M.B.P.47,
M.B.P.48, M.B.P.49, M.B.P.50, M.B.P.51,
M.B.P.52, M.B.P.133, M.B.P.176,
M.B.P.178, M.B.P.179, M.B.P.275,
T.B.P.188, W.B.P.268, B.526, B.547,
M.C.P.17, M.C.P.65, M.C.P.81, T.C.P.6,
W.C.P.47, Th.C.P.38, Th.C.P.62, C.504,
C.704, C.740, W.G.P.5
- HETEROSEXUAL**
hemophilia
T.A.P.108, Th.G.P.21
prevalence
W.A.O.14, W.A.O.15, Th.A.O.5, M.A.P.5,
M.A.P.7, M.A.P.8, M.A.P.58, M.A.P.61,
M.A.P.65, M.A.P.66, T.A.P.4, T.A.P.14,
T.A.P.14, W.A.P.21, Th.A.P.27,
Th.A.P.38, Th.A.P.53, A.501, A.556,
A.558, A.614, A.617, M.B.P.137, B.620,
B.623, W.G.P.18, Th.G.P.28, Th.H.P.23
prevention
M.A.O.37, T.A.P.100, W.A.P.118,
W.D.P.41, W.D.P.43, W.F.P.10
prognosis
T.A.P.103, W.G.P.24
progression
T.A.P.93, Th.A.P.53, A.546, M.G.P.1,
W.G.P.11
see Sexual behaviour
see Transmission
other
W.A.P.29, Th.A.P.59, Th.B.P.352, T.C.P.52
- HGP-30**
W.B.P.141, M.C.P.13
- HIGH RISK GROUPS, COMBINED**
M.A.O.28, M.A.O.29, M.A.O.30, T.A.O.4,
T.A.O.17, W.A.O.29, Th.A.O.30, M.A.P.54,
M.A.P.60, M.A.P.63, M.A.P.70, M.A.P.72,
M.A.P.82, T.A.P.2, T.A.P.5, T.A.P.7,
T.A.P.8, T.A.P.63, T.A.P.70, T.A.P.81,
T.A.P.83, T.A.P.97, W.A.P.13, W.A.P.18,
W.A.P.19, W.A.P.25, W.A.P.26, W.A.P.55,
W.A.P.78, Th.A.P.5, Th.A.P.12, Th.A.P.22,
Th.A.P.40, Th.A.P.97, Th.A.P.116, A.504,
A.508, A.514, A.526, A.534, A.539, A.547,
A.619, W.B.P.223, Th.B.P.179,
Th.B.P.186, B.634, B.643, M.C.P.9,
T.D.P.21, D.544, M.E.O.32, W.E.O.7,
W.E.O.23, M.E.P.57, T.E.P.73, Th.E.P.70,
E.516, E.683, E.644, E.725, E.813,
Th.G.O.30, M.G.P.11, M.G.P.23,
M.G.P.29, T.G.P.14, W.G.P.30, Th.G.P.26,
G.501, Th.H.P.30
- see also* Gay men; Hemophilia;
Intravenous drug users
- HISTOPATHOLOGY**
Th.A.P.104, W.B.O.20, M.B.P.38,
M.B.P.45, M.B.P.221, M.B.P.241,
M.B.P.243, M.B.P.258, M.B.P.265,
M.B.P.295, T.B.P.16, T.B.P.156,
T.B.P.269, Th.B.P.248, Th.B.P.252,
Th.B.P.332, Th.B.P.339, Th.B.P.342,
B.583, T.C.P.123, T.C.P.125, W.C.P.21,
W.C.P.30, W.C.P.32, C.571, C.664, C.699,
Th.G.O.32
- HISTOPLASMOSES**
M.B.P.78, M.B.P.79, M.B.P.80, M.B.P.81,
M.B.P.82, B.560
- HISTORICAL ANALOGIES**
Th.E.P.37, Th.E.P.45, M.G.P.21
- HIV ANTIGEMIA**
M.A.O.47, Th.A.O.4, M.A.P.94, M.A.P.99,
Th.B.P.85, Th.A.P.92, M.B.P.348,
T.B.P.90, T.B.P.283, W.B.P.280,
W.B.P.365, Th.B.P.66
- HIV ANTIGEN**
assay
Th.A.P.117, M.B.O.25, M.B.O.27,
Th.B.O.9, Th.B.O.12, Th.B.O.59,
M.B.P.147, M.B.P.148, M.B.P.170,
T.B.P.81, T.B.P.93, Th.B.P.94, T.B.P.99,
T.B.P.101, T.B.P.131, T.B.P.132,
T.B.P.133, T.B.P.134, T.B.P.136,
T.B.P.144, T.B.P.230, T.B.P.339,
T.B.P.349, T.B.P.351, W.B.P.93,
W.B.P.94, W.B.P.99, W.B.P.103,
W.B.P.104, W.B.P.105, W.B.P.109,
W.B.P.110, W.B.P.111, W.B.P.112,
W.B.P.113, W.B.P.120, W.B.P.121,
W.B.P.128, W.B.P.135, W.B.P.137,
W.B.P.140, W.B.P.142, W.B.P.143,
W.B.P.149, W.B.P.158, W.B.P.161,
W.B.P.166, W.B.P.171, Th.B.P.111,
Th.B.P.124, Th.B.P.174, Th.B.P.177,
Th.B.P.180, Th.B.P.181, Th.B.P.369,
Th.B.P.370, Th.B.P.371, B.518, B.618,
B.624, M.C.P.17, T.C.P.10, T.C.P.32,
W.C.P.89, Th.C.P.35, Th.C.P.46, C.764,
C.779, M.G.O.5, Th.G.P.3
- brain
Th.B.P.248, Th.B.P.250
- children
W.A.P.52, M.B.P.200, T.B.P.165, T.B.P.244
- core protein, *see* Gene products
- flow cytometry
M.B.P.144, M.B.P.348, T.B.P.83, T.B.P.94,
T.B.P.97, T.B.P.88, T.B.P.89, T.B.P.313,
Th.B.P.108, Th.B.P.112, Th.B.P.142,
Th.B.P.147, Th.B.P.151, Th.B.P.240,
B.505, C.519, C.710
see Cp 120
- immune complexes
M.C.P.142
- infectivity
Th.A.P.106, T.B.P.90, T.C.O.35, T.C.P.32,
W.C.P.90, C.750
- monitor
W.B.P.254, Th.C.P.148

- pregnancy**
M.B.P.4, M.B.P.6, M.B.P.7, M.B.P.17,
M.B.P.20, M.B.P.32, T.B.P.165, T.B.P.195,
B.846
- prognosis**
Th.A.P.108, T.B.P.103, W.B.P.77,
W.B.P.288, Th.B.P.163, Th.B.P.186,
Th.B.P.291
- seroconversion**
M.A.O.35, Th.B.O.58, M.B.P.6, T.B.P.244,
T.B.P.354, W.B.P.97, Th.B.P.14,
Th.B.P.370, B.535
- standardization**
W.B.P.254
- zidovudine**
M.B.P.361, M.B.P.370, W.B.P.339,
W.B.P.342
- other**
M.B.P.195, M.B.P.219, M.B.P.277,
M.B.P.327, M.B.P.373, T.B.P.92,
T.B.P.115, T.B.P.315, Th.B.P.235,
M.C.P.84, W.C.P.145, C.585, C.683,
C.708, Th.P.15
- HIV-IMMUNOGEN**
Th.B.O.44, W.C.P.8, C.558
- HIV-ISCOM**
Th.C.O.50, Th.C.P.80
- HIV-SPECIFIC ACTIVE
IMMUNOTHERAPY (HSAI)**
T.C.P.7
- HIV-2**
disease
A.573, M.B.P.82, T.B.P.109, T.B.P.357,
T.B.P.382, W.B.P.99, Th.B.P.21,
Th.B.P.156, B.812, B.841, W.C.O.46,
W.C.P.3, W.C.P.141, C.540, M.G.O.5,
T.G.P.27
- serologic tests**
M.A.O.13, M.A.P.77, M.A.P.79, M.A.P.83,
M.A.P.84, M.A.P.85, T.A.P.10, Th.A.P.108,
A.509, A.511, A.512, A.568, A.634, A.634,
T.B.O.8, T.B.O.10, Th.B.O.54, Th.B.O.55,
Th.B.O.56, Th.B.O.58, M.B.P.327,
M.B.P.373, T.B.P.99, T.B.P.104,
T.B.P.105, T.B.P.109, T.B.P.116,
T.B.P.116, T.B.P.119, T.B.P.119,
T.B.P.120, T.B.P.123, T.B.P.137,
T.B.P.349, T.B.P.382, W.B.P.93,
W.B.P.93, W.B.P.94, W.B.P.95, W.B.P.96,
W.B.P.100, W.B.P.101, W.B.P.102,
W.B.P.102, W.B.P.103, W.B.P.104,
W.B.P.105, W.B.P.107, W.B.P.108,
W.B.P.109, W.B.P.110, W.B.P.111,
W.B.P.112, W.B.P.113, W.B.P.114,
W.B.P.120, W.B.P.121, Th.B.P.110, B.535,
B.538, B.562, B.602, B.618, B.618, B.619,
B.624, B.624, B.629, B.644, W.C.P.99,
Th.C.P.21, Th.C.P.26, Th.C.P.37,
Th.C.P.131, C.745, C.764, C.785,
T.G.O.21, W.G.O.27, Th.G.O.26, M.G.P.2,
M.G.P.12, M.G.P.13, M.G.P.24, T.G.P.25,
T.G.P.29, T.G.P.30, T.G.P.31, T.G.P.32,
W.G.P.22, G.S.17, Th.H.P.19
- seroprevalence**
M.A.O.14, M.A.O.15, M.A.P.52, M.A.P.77,
M.A.P.78, Th.A.P.30, A.576, B.634,
- M.B.P.158, M.B.P.200, T.B.P.106,
Th.B.P.3, W.C.P.136, Th.E.P.3, M.G.P.16,
T.G.P.26, T.G.P.28, Th.H.P.25
- other**
M.A.P.77, M.B.P.195, T.B.P.340,
T.B.P.373, W.B.P.98, Th.B.P.151,
T.C.O.20, T.C.O.36, T.C.O.43, W.C.O.14,
Th.C.O.24, M.C.P.29, M.C.P.84, M.C.P.91,
M.C.P.135, T.C.P.23, T.C.P.37, T.C.P.95,
T.C.P.115, T.C.P.126, T.C.P.127,
W.C.P.26, W.C.P.35, W.C.P.79,
W.C.P.108, Th.C.P.6, Th.C.P.22,
Th.C.P.23, Th.C.P.36, Th.C.P.58,
Th.C.P.75, Th.C.P.123, Th.C.P.124,
Th.C.P.140, C.526, C.595, C.598, C.608,
C.660, C.669, C.681, C.694, C.706, C.732
- HLA**
M.A.P.101, M.B.P.187, M.B.P.347,
T.B.P.342, Th.B.P.91, Th.B.P.116,
Th.B.P.372, B.500, M.C.P.20, T.C.P.26,
C.519, C.546, C.655, C.708, C.714
- expression**
W.B.O.17, M.B.P.296, Th.B.P.102,
Th.B.P.351, Th.C.P.13, C.521
- HMO**
see Health maintenance organization
- HOE/BAY 946**
C.607
- HOME CARE**
A.581, Th.B.O.37, M.B.P.304, M.B.P.307,
M.B.P.310, M.B.P.311, T.B.P.52,
T.B.P.300, T.B.P.325, W.B.P.64,
W.B.P.65, W.B.P.66, W.B.P.67,
W.B.P.265, W.B.P.376, Th.B.P.27, B.506,
B.507, B.593, M.D.P.75, W.E.O.26,
M.E.P.53, M.E.P.56, T.E.P.34, E.506,
E.526, E.774, E.808, W.G.P.13
- HOMELESSNESS**
M.A.O.28, M.A.P.50, M.A.P.51, W.B.P.209,
W.B.P.218, B.506, M.D.O.9, T.D.P.11,
Th.D.P.17, Th.D.P.65, D.506, D.820,
M.E.O.9, M.E.P.48, M.E.P.61, M.E.P.68,
E.820, E.691
- HOMOSEXUALS**
see Gay men
see Lesbians
- HORMONES**
W.B.P.189, T.C.O.15, C.564, C.602
- HOSPICE CARE**
M.B.P.302, M.B.P.304, W.B.P.67,
W.B.P.248, W.B.P.253, W.B.P.260,
W.B.P.263, W.B.P.265, W.B.P.377,
W.B.P.378, B.593, M.E.P.47, M.E.P.60,
Th.E.P.72, E.542, E.543, M.F.O.18
- HOSPITAL COST**
see Cost
- HOSPITALS**
M.A.P.16, T.A.P.72, T.A.P.73, W.A.P.72,
W.A.P.79, Th.A.P.9, Th.G.P.47, Th.A.P.49,
A.547, A.551, A.571, A.581, A.635,
T.B.O.11, M.B.P.70, M.B.P.302,
M.B.P.384, W.B.P.238, W.B.P.260,
W.B.P.265, W.B.P.273, W.B.P.353,
W.B.P.380, M.D.O.13, M.D.P.47,
- W.D.P.11, D.827, T.E.P.66, W.E.P.31,
E.506, E.703, E.748, T.F.P.7, T.G.O.20,
T.H.P.13
- HOT-LINE**
Th.E.O.2, M.E.P.17, T.E.P.22, W.E.P.62,
W.E.P.84, Th.E.P.11, E.567, E.569, E.574,
E.575, E.576
- HPA-23**
M.C.P.68
- HSV-2**
see Herpes viruses
- HTLV-II**
disease
Th.A.P.12, M.B.P.161, Th.B.P.199,
Th.B.P.249, B.537
- serologic tests**
Th.A.O.33, Th.A.P.2, Th.A.P.7, Th.A.P.24,
Th.A.P.26, Th.A.P.29, Th.A.P.31,
Th.A.P.110, Th.A.P.117, Th.A.P.118,
Th.A.P.119, A.510, A.629, T.B.O.8,
T.B.O.10, Th.B.O.59, M.B.P.19,
M.B.P.161, M.B.P.173, T.B.P.107,
T.B.P.108, T.B.P.128, T.B.P.365,
W.B.P.119, W.B.P.122, W.B.P.128,
W.B.P.130, W.B.P.140, W.B.P.140,
W.B.P.152, Th.B.P.173, Th.B.P.176,
Th.B.P.223, B.518, B.538, B.551,
Th.C.P.25, Th.C.P.27, Th.C.P.105, C.690,
C.702, C.721, C.775, T.G.O.21, W.G.O.27,
M.G.P.2, M.G.P.3, M.G.P.5, M.G.P.12,
M.G.P.13, M.G.P.20, M.G.P.24, T.G.P.29,
T.G.P.30, T.G.P.32, W.G.P.2, W.G.P.26
- seroprevalence**
M.A.O.14, M.A.O.16, M.A.O.18, M.A.O.39,
Th.A.O.29, Th.A.O.30, Th.A.O.32,
Th.A.O.34, M.A.P.62, T.A.P.32, Th.A.P.1,
Th.A.P.3, Th.A.P.4, Th.A.P.5, Th.A.P.7,
Th.A.P.8, Th.A.P.11, Th.A.P.12, Th.A.P.20,
Th.A.P.22, Th.A.P.28, Th.A.P.26,
Th.A.P.27, Th.A.P.28, Th.A.P.32,
Th.A.P.112, A.576, T.B.P.107, W.B.P.119,
Th.B.P.24, Th.B.P.25, Th.B.P.173, B.630,
B.631, B.633, B.634, W.C.P.4, M.G.P.14,
Th.G.P.2, Th.H.P.21
- other**
M.A.P.42, Th.A.P.25, Th.A.P.119, A.587,
Th.B.O.11, M.B.P.144, W.C.P.139,
Th.C.P.3, Th.C.P.30, Th.C.P.42,
Th.C.P.43, Th.C.P.108, Th.C.P.115,
Th.C.P.119, Th.C.P.132, C.572, C.725
- HTLV-II**
M.A.O.18, Th.A.O.33, T.A.P.32, T.A.P.53,
Th.A.P.21, Th.A.P.32, Th.A.P.110,
Th.B.O.11, B.634, Th.C.P.5, Th.C.P.108,
Th.C.P.132, C.702
- HUMAN HERPES VIRUS 6 (HHV-6)**
W.C.P.125, Th.C.P.19, Th.C.P.52,
Th.C.P.57, C.704, T.F.P.10
- HUMAN PAPILLOMA VIRUS (HPV)**
Th.A.P.104, M.B.O.18, M.B.P.53,
M.B.P.55, M.B.P.56, M.B.P.60, M.B.P.186,
M.B.P.191, M.B.P.292, Th.C.O.36,
W.C.P.51, W.C.P.53

HUMAN RIGHTS

E.577, E.693, T.F.P.9, W.F.P.1, Th.F.P.5, Th.F.P.8, Th.F.P.11, Th.F.P.12

HYBRIDIZATION

Th.B.O.10, M.B.P.62, M.B.P.127, T.B.P.80, T.B.P.110, W.B.P.123, W.B.P.124, W.B.P.149, Th.B.P.111, Th.B.P.338, T.C.O.19, Th.C.O.29, Th.C.O.36, M.C.P.50, M.C.P.126, T.C.P.123, W.C.P.43, W.C.P.55, W.C.P.67, W.C.P.86, W.C.P.127, Th.C.P.19, Th.C.P.24, Th.C.P.33, Th.C.P.83, Th.C.P.111, Th.C.P.137, Th.C.P.146, C.664, C.733, C.739, C.749

HYDROCOTYLE ASIATICA

M.C.P.95

HYPERICIN

M.C.P.16, C.501, C.608, C.626

HYPERTRIGLYCERIDEMIA

M.B.P.270

HYPONATREMIA

M.B.P.271

IEC

see Information-Education-Communication

IL-1

W.B.P.277, Th.B.P.96, M.C.O.27, M.C.P.29, T.C.P.3, W.C.P.77, W.C.P.78, C.529, C.549, C.705

IL-2

T.B.P.214, T.B.P.236, W.B.P.47, W.B.P.276, W.B.P.281, W.B.P.288, W.B.P.306, W.B.P.325, W.B.P.330, W.B.P.335, Th.B.P.91, Th.B.P.92, Th.B.P.353, T.C.P.4, T.C.P.53, T.C.P.54, T.C.P.61, T.C.P.71, W.C.P.39, C.535, C.705

IL-2 RECEPTOR

M.B.P.355, W.B.P.69, W.B.P.277, W.B.P.294, W.C.O.10, T.C.P.53, C.535

soluble

Th.B.O.25, M.B.P.354, T.B.P.212, Th.B.P.83, T.C.P.43, C.561

IL-6

T.C.P.19, Th.C.P.144

IMMUNOASSAY

M.B.O.23, Th.B.O.12, Th.B.O.54, Th.B.O.59, M.B.P.11, M.B.P.18, M.B.P.127, M.B.P.157, M.B.P.167, M.B.P.169, M.B.P.172, M.B.P.173, M.B.P.174, M.B.P.331, M.B.P.345, T.B.P.7, T.B.P.14, T.B.P.89, T.B.P.94, T.B.P.97, T.B.P.102, T.B.P.105, T.B.P.114, T.B.P.120, T.B.P.123, T.B.P.124, T.B.P.129, T.B.P.135, T.B.P.136, T.B.P.140, T.B.P.172, T.B.P.219, T.B.P.229, T.B.P.240, T.B.P.339, T.B.P.340, T.B.P.342, T.B.P.349, T.B.P.358, W.B.P.85, W.B.P.95, W.B.P.100, W.B.P.103, W.B.P.105, W.B.P.106, W.B.P.110, W.B.P.111, W.B.P.117, W.B.P.121, W.B.P.126, W.B.P.133, W.B.P.134, W.B.P.135, W.B.P.136, W.B.P.140, W.B.P.145,

W.B.P.150, W.B.P.155, W.B.P.164, W.B.P.168, W.B.P.170, Th.B.P.112, Th.B.P.113, Th.B.P.173, Th.B.P.369, Th.B.P.371, B.536, B.539, B.541, B.548, B.608, B.638, M.C.O.27, T.C.O.5, Th.C.O.26, M.C.P.15, M.C.P.17, M.C.P.25, M.C.P.33, M.C.P.36, M.C.P.47, T.C.P.10, T.C.P.27, T.C.P.36, T.C.P.37, T.C.P.39, T.C.P.42, T.C.P.51, T.C.P.52, T.C.P.72, W.C.P.14, W.C.P.112, W.C.P.114, W.C.P.119, W.C.P.126, W.C.P.127, W.C.P.131, Th.C.P.5, Th.C.P.6, Th.C.P.13, Th.C.P.20, Th.C.P.25, Th.C.P.39, Th.C.P.53, Th.C.P.85, Th.C.P.86, Th.C.P.111, Th.C.P.121, Th.C.P.138, Th.C.P.143, C.510, C.542, C.583, C.664, C.665, C.690, C.720, C.739, C.747, C.761, M.G.O.4, Th.G.P.7, Th.G.P.9

IMMUNOGLOBULINS**IgA**

Th.A.O.8, M.B.P.278, T.B.P.226, W.B.P.73, W.B.P.136, Th.B.P.6, Th.B.P.94, Th.B.P.123, Th.B.P.132, Th.B.P.161, Th.B.P.174, Th.B.P.175, Th.B.P.344, M.C.P.37, T.C.P.22, T.C.P.64, C.522

IgD

Th.B.P.128

IgE

M.B.P.193, T.B.P.215, Th.B.P.135, Th.B.P.143

IgG subclass

M.B.O.4, M.B.P.140, M.B.P.167, T.B.P.153, T.B.P.166, T.B.P.210, T.B.P.218, T.B.P.220, T.B.P.231, T.B.P.233, W.B.P.50, W.B.P.103, W.B.P.116, W.B.P.133, W.B.P.136, Th.B.P.6, Th.B.P.55, Th.B.P.94, Th.B.P.101, Th.B.P.123, Th.B.P.132, Th.B.P.140, Th.B.P.172, Th.B.P.174, Th.B.P.223, Th.B.P.225, Th.B.P.230, Th.B.P.247, Th.B.P.363, Th.B.P.368, B.512, B.625, B.628, T.C.O.39, Th.C.O.4, M.C.P.89, T.C.P.22, T.C.P.75, W.C.P.73, C.520, C.526, C.697, C.717, C.761, W.G.O.6, W.G.P.9

IgM

T.B.P.210, T.B.P.217, T.B.P.220, T.B.P.221, T.B.P.222, T.B.P.226, T.B.P.231, T.B.P.232, T.B.P.236, T.B.P.242, W.B.P.131, W.B.P.133, W.B.P.136, W.B.P.220, Th.B.P.6, Th.B.P.94, Th.B.P.123, Th.B.P.151, Th.B.P.176, B.625, W.G.O.6

IMMUNE COMPLEXES

T.B.P.96, T.B.P.287, M.B.P.68, W.B.P.285, Th.B.P.125, Th.B.P.127, Th.B.P.134, Th.B.P.136, Th.B.P.151, Th.B.P.191, T.C.P.46

IMMUNIZATION

M.B.P.31, M.B.P.37, M.B.P.224, W.B.P.314, Th.B.P.118, Th.B.P.119, W.C.O.49, Th.C.O.46, M.C.P.7, W.C.P.8

IMMUNOADHESION

T.B.P.287, Th.C.O.15

IMMUNOMODULATION

Th.B.O.25, M.B.P.34, T.B.P.206, T.B.P.214, T.B.P.315, W.B.P.190, W.B.P.221, W.B.P.276, W.B.P.279, W.B.P.294, W.B.P.296, W.B.P.307, W.B.P.310, W.B.P.313, Th.B.P.1, Th.B.P.19, Th.B.P.91, Th.B.P.100, Th.B.P.162, Th.B.P.359, B.596, T.C.P.30, T.C.P.142, W.C.P.91, W.C.P.144, C.511, C.512, C.588, C.591, C.619, C.628, C.632, C.711, T.D.P.29

IMMUNOPATHOLOGY

Th.A.P.58, Th.A.P.97, W.B.O.20, M.B.P.193, T.B.P.6, Th.B.P.43, Th.B.P.129, Th.B.P.151, Th.B.P.156, Th.B.P.171, Th.B.P.225, Th.B.P.226, Th.B.P.342, Th.B.P.351

IMMUNOSUPPRESSION

mechanism

Th.B.P.94, Th.B.P.118, Th.B.P.156, Th.B.P.315, Th.B.P.316, B.550, W.C.P.97, C.566, C.707, C.722

serum

M.A.P.101

other

Th.A.P.98, M.B.P.21, M.B.P.261, M.B.P.279, T.B.P.309, B.543, B.588, M.C.P.43, W.C.P.22, W.C.P.104

IMMUNOTHERAPY

T.B.P.285, W.B.P.46, Th.B.P.133, B.579, M.C.P.139, W.C.P.19

IMMUNOTOXIN

Th.C.O.14, M.C.P.129, T.C.P.7

IMPLANTABLE INFUSION PORTS (IAC)

T.B.P.258, W.B.P.381

IMREG-1

Th.B.O.47, W.B.P.279

IMTHIOL

W.B.P.277, W.B.P.281, W.B.P.284, W.B.P.287, W.B.P.296, W.B.P.297, W.B.P.301, W.B.P.305, W.C.P.19

INACTIVATION

A.601, Th.B.O.44, M.B.P.147, W.B.P.163, Th.B.P.353, M.C.P.66, M.C.P.147, T.C.P.77, Th.C.P.136, C.586, C.582, C.598, C.746

INCIDENCE

M.A.O.1, M.A.O.6, M.A.O.27, M.A.O.44, T.A.O.27, T.A.O.37, W.A.O.13, Th.A.O.12, Th.A.O.27, M.A.P.11, M.A.P.76, M.A.P.95, T.A.P.5, T.A.P.20, T.A.P.82, T.A.P.83, T.A.P.91, T.A.P.113, W.A.P.15, W.A.P.19, W.A.P.24, W.A.P.55, W.A.P.64, Th.A.P.35, Th.A.P.36, Th.A.P.76, A.526, A.530, A.537, A.548, A.551, A.555, A.603, A.636, M.B.P.91, M.B.P.166, M.B.P.380, T.B.P.19, W.B.P.26, W.B.P.40, W.B.P.48, W.B.P.267, Th.B.P.83, Th.B.P.364, B.529, W.G.O.27, W.G.P.5, Th.G.P.24, G.507, G.519, W.H.P.15, Th.H.P.17, W.H.P.19

INCUBATION TIME

M.A.O.7, W.A.P.25, Th.A.P.36, Th.A.P.60, Th.A.P.61, Th.A.P.62, Th.A.P.75,

- Th.A.P.77, Th.A.P.87, A.561, T.B.P.361, W.H.P.20
- INFECTION, PRIMARY**
T.A.O.30, M.B.P.38, M.B.P.184, M.B.P.262, T.B.P.372, B.557, B.610, M.C.O.15, T.C.O.13, W.C.O.6, W.C.O.7, M.C.P.66, M.C.P.119, W.C.P.15, W.C.P.64, Th.C.P.72, C.517, C.786
- INFECTIVITY, ACTIVATION**
T.A.O.15, T.A.O.38, M.A.P.29, Th.A.P.53, A.601, M.B.P.169, Th.B.P.356, W.C.O.7, W.C.O.33, T.C.P.12, T.C.P.34, T.C.P.78, W.C.P.59, W.C.P.63, W.C.P.105, W.C.P.107, W.C.P.137, Th.C.P.77, C.516, C.578, C.712, D.107, W.H.P.18
- INFORMATION-EDUCATION-COMMUNICATION (IEC)**
M.A.O.22, M.A.O.43, T.A.O.22, T.A.O.23, W.A.O.23, W.A.O.27, M.A.P.20, M.A.P.115, M.A.P.117, T.A.P.96, W.A.P.2, W.A.P.87, W.A.P.110, W.A.P.113, W.A.P.117, W.A.P.118, W.A.P.120, A.506, A.557, W.B.P.267, M.D.P.45, T.D.P.35, W.D.P.66, Th.E.O.7, W.E.P.15, E.569, E.677, E.803, W.G.P.30, Th.G.P.5, Th.G.P.29, Th.H.P.29
- INFORMATION SYSTEMS**
T.A.O.27, T.A.P.25, T.A.P.71, T.A.P.75, W.A.P.60, W.A.P.82, W.A.P.119, Th.A.P.50, A.591, W.B.P.376, B.577, W.C.O.5, T.E.P.60, W.E.P.29, Th.E.P.50, E.588, E.539, E.576, Th.G.P.12, M.H.O.12, W.H.O.11, W.H.O.16, W.H.O.17, M.H.P.8, M.H.P.11, M.H.P.18, M.H.P.19, Th.H.P.12, W.H.P.7, W.H.P.8, W.H.P.10, W.H.P.11, W.H.P.26, Th.H.P.3
- INSULIN**
W.C.P.24
- INSURANCE**
W.H.O.4, W.H.O.7, W.H.O.8, W.H.O.9, W.H.O.10, M.H.P.12, T.H.P.16, T.H.P.17, T.H.P.20, T.H.P.23, T.H.P.24, T.H.P.26, T.H.P.27
- INTEGRATED CARE MODEL**
W.A.P.112, A.630, W.B.P.62, W.B.P.377, T.E.O.1, E.701, T.H.O.3, Th.O.10, Th.P.6
- INTERFERON**
acid labile
Th.B.P.122, T.C.P.58
- alpha
Th.B.O.43, Th.B.O.46, M.B.P.333, M.B.P.353, T.B.P.275, T.B.P.279, T.B.P.281, T.B.P.282, T.B.P.283, T.B.P.288, T.B.P.289, T.B.P.331, W.B.P.75, W.B.P.321, W.B.P.322, W.B.P.326, W.B.P.374, Th.B.P.99, Th.B.P.103, Th.B.P.122, Th.B.P.133, Th.B.P.145, B.587, M.C.P.81, M.C.P.82, M.C.P.97, M.C.P.109, T.C.P.26, T.C.P.54, T.C.P.68, T.C.P.88, T.C.P.98, W.C.P.29, W.C.P.82, W.C.P.83
- beta
Th.B.O.45, M.B.P.341, T.B.P.291, T.B.P.322, T.B.P.381, W.B.P.323, T.C.P.54, T.C.P.71, T.C.P.118
- gamma
T.B.P.214, W.B.P.79, Th.B.P.103, Th.B.P.145, W.C.O.8, M.C.P.101, W.C.P.85, C.519, C.521, C.563, C.705
other
Th.B.O.28, Th.B.O.29, W.C.P.276, M.C.P.116, T.C.P.14, C.515, C.719, C.776
- INTESTINE**
W.B.O.38, Th.B.O.41, M.B.P.120, M.B.P.135, M.B.P.232, M.B.P.234, T.B.P.375, W.B.P.38, Th.B.P.175, M.C.O.27, T.C.P.123, W.C.P.90, W.C.P.131, C.664
- INTRAVENOUS DRUG USERS (IVDU)**
alcohol
T.B.P.94, A.532, M.B.P.56, Th.B.P.58, Th.C.P.132, Th.D.O.14, T.D.P.51, W.D.P.67, W.D.P.70, Th.D.P.7, D.725
behaviour
M.A.O.9, T.A.O.8, T.A.O.9, T.A.O.14, M.A.P.38, M.A.P.50, T.A.P.30, T.A.P.31, T.A.P.33, T.A.P.38, T.A.P.39, T.A.P.42, T.A.P.44, T.A.P.45, T.A.P.46, T.A.P.49, T.A.P.55, W.A.P.89, W.A.P.90, W.A.P.104, W.A.P.106, W.A.P.107, W.A.P.108, Th.A.P.64, Th.A.P.70, M.B.P.30, W.B.P.246, Th.B.P.69, W.D.O.4, Th.D.O.3, Th.D.O.5, Th.D.O.6, M.D.P.26, T.D.P.71, W.D.P.25, W.D.P.51, W.D.P.52, W.D.P.55, W.D.P.57, W.D.P.62, W.D.P.63, W.D.P.64, W.D.P.66, W.D.P.67, W.D.P.68, W.D.P.69, W.D.P.72, W.D.P.73, W.D.P.74, W.D.P.75, W.D.P.76, W.D.P.77, W.D.P.79, W.D.P.80, W.D.P.82, Th.D.P.30, Th.D.P.31, Th.D.P.35, Th.D.P.42, Th.D.P.43, Th.D.P.48, Th.D.P.49, Th.D.P.52, Th.D.P.53, Th.D.P.55, Th.D.P.59, Th.D.P.60, Th.D.P.62, Th.D.P.63, Th.D.P.70, Th.D.P.75, Th.D.P.77, Th.D.P.80, Th.D.P.81, Th.D.P.84, D.591, D.592, D.594, D.607, D.609, D.610, D.611, D.615, D.620, D.704, D.708, D.712, Th.E.O.17, M.E.P.62, T.E.P.38, W.E.P.9, W.E.P.68, Th.E.P.36, E.526, E.566, E.677, E.694, E.726, E.767, T.G.O.23, W.G.P.19, T.H.P.23
geographical
T.A.O.12, T.A.P.97, T.A.P.99, T.A.P.43, T.A.P.46, T.A.P.50, T.A.P.57, Th.A.P.19, A.539, W.D.P.68, Th.D.P.48, D.688, T.G.O.23, W.G.P.19
- HIV-2
M.A.P.81, M.G.P.7
- HTLV-I
Th.A.O.23, Th.A.O.32, T.A.P.53, Th.A.P.10, Th.A.P.24, Th.A.P.29, Th.B.O.58, Th.C.P.105, M.G.P.7
- immunology
T.A.O.14, M.A.P.94, T.A.P.41, Th.A.P.97, Th.A.P.101, T.B.P.330, W.B.P.289, Th.B.P.82, Th.B.P.121, Th.B.P.148, Th.B.P.164, Th.B.P.191, Th.B.P.335, M.C.P.43, W.C.P.120, C.729
- methadone
T.A.O.8, Th.A.O.24, T.A.P.34, T.A.P.49, T.A.P.54, T.A.P.82, W.A.P.105, A.525, M.B.P.8, W.B.P.60, Th.D.O.2, Th.D.O.5, Th.D.O.16, W.D.P.63, W.D.P.71, W.D.P.78, Th.D.P.58, Th.D.P.69, Th.D.P.71, Th.D.P.86, D.586, D.590, D.594, D.596, D.600, D.703
needle-syringe exchange
T.A.O.9, T.A.O.20, T.A.O.21, T.A.P.33, T.A.P.45, T.A.P.47, W.A.P.89, W.A.P.104, W.A.P.106, W.A.P.108, Th.A.P.56, Th.A.P.111, C.686, Th.D.D.13, W.D.P.63, W.D.P.65, W.D.P.69, Th.D.P.92, Th.D.P.94, Th.D.P.96, Th.D.P.98, Th.D.P.42, Th.D.P.50, Th.D.P.71, Th.D.P.74, Th.D.P.77, D.601, D.609, D.618, D.607, Th.E.O.17, M.E.P.46, T.E.P.17, E.694, M.F.P.12, W.F.P.6, T.G.P.9
pregnancy
W.A.P.47, M.B.P.14, M.B.P.24, M.B.P.26, T.B.P.159, T.B.P.173, D.600, E.512
prevalence
T.A.O.8, T.A.O.10, T.A.O.12, M.A.P.5, M.A.P.26, M.A.P.73, T.A.P.29, T.A.P.30, T.A.P.31, T.A.P.32, T.A.P.33, T.A.P.34, T.A.P.35, T.A.P.36, T.A.P.38, T.A.P.41, T.A.P.42, T.A.P.43, T.A.P.83, T.A.P.54, T.A.P.55, T.A.P.56, T.A.P.57, T.A.P.58, T.A.P.59, T.A.P.60, T.A.P.114, T.A.P.115, Th.A.P.11, Th.A.P.10, Th.A.P.18, Th.A.P.19, Th.A.P.21, A.505, A.529, A.550, A.566, A.576, A.613, W.B.O.9, M.B.P.137, W.B.P.268, B.509, Th.D.P.41, Th.D.P.46, Th.D.P.49, Th.D.P.56, Th.D.P.58, Th.D.P.67, Th.D.P.68, Th.D.P.79, Th.D.P.82, D.584, D.590, D.597, D.608, D.609, D.610, D.709, M.G.O.26, M.G.P.29, W.G.P.18
prevention
M.A.O.9, T.A.O.8, T.A.O.22, M.A.P.20, T.A.P.28, T.A.P.34, T.A.P.42, T.A.P.56, W.A.P.88, W.A.P.89, W.A.P.105, W.A.P.109, Th.A.P.73, T.B.P.52, B.609, M.D.O.5, Th.D.O.15, T.D.P.26, W.D.P.78, W.D.P.83, W.D.P.86, Th.D.P.96, Th.D.P.97, Th.D.P.98, Th.D.P.43, Th.D.P.66, Th.D.P.80, Th.D.P.81, Th.D.P.85, D.583, D.585, D.586, D.588, D.596, D.599, D.606, D.619, D.663, D.707, Th.E.O.6, Th.E.O.17, T.E.P.17, T.E.P.43, W.E.P.68, E.586, E.587, E.694, E.695, E.799, E.800, E.801
prognosis
W.A.P.78, W.B.P.268, Th.C.O.40, W.C.P.50, T.E.P.43, E.587
protection
Th.O.24, M.A.P.92, M.A.P.98, M.A.P.105, W.A.P.59, W.A.P.63, W.A.P.71, W.A.P.75, Th.A.P.73, Th.A.P.102, A.516, A.536, M.B.P.293, W.B.P.88, W.B.P.229, Th.B.P.121, Th.B.P.184, Th.D.P.39, Th.D.P.40, Th.D.P.75, D.583, D.603
psychological
T.A.P.30, W.B.P.215, Th.B.P.271, Th.D.P.69, D.577, D.602, Th.E.O.17, Th.E.P.36, E.734

- see Sexual behaviour**
- subgroups**
M.A.P.23, T.A.P.37, T.A.P.40, T.A.P.48,
T.A.P.49, T.A.P.52, T.A.P.57, Th.B.P.331,
Th.D.P.17, D.589, E.586
- support**
T.A.P.34, A.598, W.D.P.86, O.577, D.585,
D.602, D.617, D.705, D.708, T.E.P.42
- symptoms**
M.B.P.55, M.B.P.113, M.B.P.177,
T.B.P.272, W.B.P.186, Th.B.P.201, B.611,
W.D.P.68, Th.E.P.36
- testing**
T.A.O.9, T.A.O.11, Th.A.P.10, M.B.P.206,
M.B.P.218, T.B.P.130, T.B.P.185,
W.B.P.288, Th.B.P.164, Th.B.P.206,
Th.B.P.271, W.D.P.72, W.D.P.80,
W.D.P.81, D.703, E.726, E.767
- treatment**
T.A.O.10, T.A.O.11, T.A.P.30, T.A.P.47,
T.A.P.52, W.A.P.104, W.B.O.3, W.B.O.11,
M.B.P.282, M.B.P.363, T.B.P.74,
W.B.P.246, W.B.P.317, W.B.P.336,
W.B.P.348, W.B.P.352, W.B.P.367,
W.B.P.378, W.B.P.371, B.587, B.607,
Th.D.O.18, W.D.P.76, W.D.P.77,
Th.D.P.82, D.590, D.599, D.600, D.606,
D.613, D.649, D.704, M.E.P.62, T.E.P.42,
W.E.P.9
- other**
W.A.P.30, Th.A.P.10, Th.A.P.18,
Th.A.P.68, M.B.P.94, M.B.P.243,
M.B.P.248, M.B.P.273, M.B.P.277,
M.B.P.287, W.B.P.81, W.B.P.217,
W.B.P.232, W.B.P.240, Th.B.P.186,
Th.B.P.220, B.509, B.527, B.565, B.610,
Th.C.P.5, C.705, C.716, W.D.O.1,
Th.D.O.1, Th.D.O.4, T.D.P.64, T.D.P.65,
T.D.P.80, W.D.P.42, W.D.P.84, Th.D.P.3,
Th.D.P.5, Th.D.P.13, Th.D.P.54,
Th.D.P.57, Th.D.P.61, Th.D.P.65,
Th.D.P.67, Th.D.P.68, Th.D.P.72,
Th.D.P.78, D.595, D.603, D.605, D.612,
D.616, D.666, D.699, Th.E.P.36, Th.F.O.6
- INTRAVENOUS IMMUNOGLOBULIN
ADMINISTRATION**
T.B.P.163, T.B.P.257, T.B.P.275,
W.B.P.291, W.B.P.295, Th.B.P.134, B.517,
B.579
- IDO-DEOXYURIDINE (IDUR)**
T.B.P.111, W.B.P.147
- ISCOM**
see HIV-iscom
- ISOLATE**
African
W.C.P.96, Th.C.P.131, C.745, C.762
- Brazil**
C.743
- Cameroon**
Th.C.P.109
- HIV-2**
T.C.P.105
- SIV**
W.C.P.2, W.C.P.40
- other**
T.C.O.7, T.C.O.28, W.C.O.30, M.C.P.25,
T.C.P.76, T.C.P.82, T.C.P.128, W.C.P.96,
Th.C.P.77, C.672
- ISOLATION**
plasma
T.B.P.111, T.B.P.115, T.B.P.245,
Th.C.P.131, Th.C.P.138
- other**
A.624, T.B.P.117, W.B.P.351, Th.B.P.37,
M.C.O.7, M.C.O.8, T.C.O.50, W.C.P.46,
W.C.P.106, W.C.P.134, Th.C.P.65,
Th.C.P.125, C.649, C.768, C.780, C.781
- ISOSPORA BELLI**
T.B.P.196, W.B.P.313, Th.B.P.47
- ISOPRINOSINE**
Th.B.O.2, Th.B.O.46, W.B.P.280,
W.B.P.288, W.B.P.290, W.B.P.304,
W.B.P.308
- ITRACONAZOLE**
M.B.P.81, M.B.P.82, M.B.P.175,
M.B.P.340, W.B.P.2, W.B.P.10, Th.B.P.328
- IVDU**
see Intravenous drug users
- JUSTICE**
Th.D.O.18, D.599, W.F.P.9
- KAB**
see Knowledge-attitude-behaviour
- KAPLAN-MEIER ANALYSIS**
T.A.O.32, Th.A.O.22, W.A.P.14, W.A.P.57,
W.A.P.78, W.A.P.80, W.A.P.81, W.A.P.82,
A.548, W.B.O.39, W.B.P.333
- KAPOSI'S SARCOMA**
children
T.B.P.191, T.B.P.259, B.581
- epidemiology**
M.A.O.30, A.821, W.B.O.19, M.B.P.297,
T.B.P.375, Th.B.P.337, M.G.P.1
- histopathology**
M.B.P.136
- immunology**
M.B.P.296, T.B.P.287, W.C.P.47,
W.C.P.48, W.C.P.140
- survival/HIV antigen**
W.B.O.23, M.B.P.291, M.B.P.299,
W.C.P.38
- tissue culture**
W.C.P.54
- treatment IFN**
Th.B.O.28, M.B.P.333, M.B.P.368,
T.B.P.281, T.B.P.282, T.B.P.283,
T.B.P.286, T.B.P.289, T.B.P.291,
T.B.P.292, T.B.P.293, T.B.P.331,
T.B.P.381, W.B.P.374
- other**
M.B.O.21, W.B.O.22, M.B.P.180,
M.B.P.188, M.B.P.234, M.B.P.274,
M.B.P.289, M.B.P.368, T.B.P.286,
T.B.P.290, T.B.P.375, W.B.P.242,
W.B.P.335, Th.B.P.138, Th.B.P.167,
Th.B.P.340, Th.B.P.341, Th.B.P.349,
Th.B.P.381, B.530, B.559, B.589, B.615,
Th.C.O.40, M.C.P.103, T.C.P.147,
W.C.P.50, W.C.P.52, W.C.P.146, C.546,
C.573, C.700, C.726
- KETOCONAZOLE**
M.B.P.80, M.B.P.81, M.B.P.175,
M.B.P.240, W.B.P.22, Th.B.P.328,
Th.B.P.348, B.591
- KIDNEY**
W.B.O.4, M.B.P.35, M.B.P.74, M.B.P.249,
M.B.P.271, M.B.P.278, M.B.P.279,
M.B.P.280, M.B.P.281, T.B.P.264,
T.B.P.385
- KNOWLEDGE**
see Survey
- KNOWLEDGE-ATTITUDE-
BEHAVIOUR (KAB)**
M.A.O.22, T.A.O.20, T.A.P.94, W.A.P.36,
W.A.P.92, W.A.P.97, W.A.P.99,
W.A.P.110, W.A.P.111, A.513, A.542,
A.564, A.579, T.D.P.27, T.D.P.30,
T.D.P.34, T.D.P.36, T.E.P.22, E.501,
E.682, E.677, E.758, M.G.O.13, T.G.P.11
- LABORATORY TESTS, ROUTINE**
M.B.P.138, W.B.P.77, W.B.P.88, B.624
- L-ACETYL CARNITINE**
Th.B.P.234
- LACTATE DEHYDROGENASE (LDH)**
M.B.P.105, T.B.P.17, B.537
- LANGERHANS CELLS**
W.C.P.32, C.549
- LASER THERAPY**
W.C.P.148, C.587
- LATENCY**
cell line
Th.C.P.16
- regulation**
T.C.P.102, Th.C.P.16, C.684
- reservoir**
M.C.O.10, M.C.O.16, W.C.P.117, C.769
- signal**
T.G.P.24
- other**
Th.A.P.116, T.B.P.361, Th.C.P.111,
Th.C.P.146
- LAW**
A.554, Th.D.P.8, T.E.O.15, W.E.O.18,
M.E.P.29, M.E.P.38, T.E.P.29, E.513,
E.540, T.F.O.6, W.F.O.22, Th.F.O.3,
M.F.P.2, M.F.P.5, M.F.P.7, M.F.P.11,
M.F.P.12, W.F.P.9, Th.F.P.10, M.G.O.1
- LDH**
see Lactate dehydrogenase
- LECTINS**
W.B.P.163, T.C.P.31, W.C.P.102,
Th.C.P.40, Th.C.P.80, Th.C.P.81, C.813,
C.674, C.707
- LEGAL ASSISTANCE**
Th.F.O.2, Th.F.P.6, Th.F.P.13, Th.F.P.14
- LEGISLATION**
Th.D.P.32, W.E.P.43, Th.E.P.31, E.577,
E.780, E.814, M.F.O.2, M.F.O.3, M.F.O.4,
T.F.O.2, T.F.O.5, Th.F.O.4, M.F.P.1,
M.F.P.3, M.F.P.9, Th.F.P.3
- LENGTH OF STAY (LOS)**
M.E.P.80, M.H.O.11, M.H.P.3, M.H.P.5,
M.H.P.6, M.H.P.7, M.H.P.14, Th.H.P.3

- LENTINAN**
W.B.P.311
- LEISHMANIASIS**
M.B.P.97, M.B.P.98, M.B.P.99, M.B.P.100,
W.B.P.44, B.546, W.C.P.63
- LEPROSY**
A.587, T.B.O.9, Th.B.P.70
- LESBIANS**
W.A.P.10, T.D.P.75, D.511
- LEUKEMIA**
M.B.P.298, T.B.P.261, B.631
- LFI695**
W.B.P.282, C.591
- LFA-1**
W.C.O.42, T.C.P.44
- LIP**
T.B.P.152, T.B.P.197, B.582, C.713
- LIPIDS**
Th.B.O.41, M.B.P.270, T.B.P.34,
W.B.P.82, Th.B.P.2, Th.B.P.88,
Th.B.P.124, W.G.O.21, M.C.P.124,
T.C.P.107, W.C.P.74, Th.C.P.107, C.574,
C.581, C.742
- LIPOSOSES**
M.B.O.26, M.B.P.170, W.C.O.40
- LITIGATION**
Th.F.O.4, M.F.P.6
- LIVER**
M.B.P.216, M.B.P.223, M.B.P.231,
M.B.P.243, M.B.P.323, M.B.P.332,
M.B.P.335, M.B.P.362, T.B.P.249,
Th.B.P.40, Th.B.P.372, B.580, Th.C.P.68,
C.769, C.770
- LOS**
see Length of stay
- LUNG**
see Cytomegalovirus
diagnosis
W.B.O.37, M.B.P.41, M.B.P.103,
M.B.P.206, M.B.P.211, M.B.P.213,
T.B.P.13, T.B.P.155, T.B.P.379, W.B.P.3,
W.B.P.18, W.B.P.25, Th.B.P.76, C.541,
C.725, Th.G.O.2
symptoms
W.E.O.22, M.B.P.42, M.B.P.71, M.B.P.73,
M.B.P.201, M.B.P.205, M.B.P.207,
M.B.P.209, T.B.P.10, T.B.P.199,
T.B.P.286, W.B.P.23, Th.B.P.78,
Th.B.P.79, Th.B.P.80, B.537, B.559,
B.589, B.615, T.C.P.8, W.C.P.71, C.541,
W.D.P.84
see also *Pneumocystis carinii*
Pneumonia; Pneumonitis
- LYMPH NODES**
A.583, M.B.P.43, M.B.P.254, M.B.P.265,
M.B.P.296, T.B.P.152, T.B.P.369,
Th.B.P.71, Th.B.P.92, Th.B.P.103,
Th.B.P.324, Th.B.P.325, Th.B.P.336,
B.518, W.C.P.73, W.C.P.118, Th.G.O.35
histopathology
W.B.O.21, M.B.P.44, M.B.P.232,
Th.B.P.121, W.C.P.67, W.C.P.73,
W.C.P.117
- LYMPHOCYTES**
see CD4, CD8
- LYMPHOMA**
W.A.P.14, W.A.P.17, W.B.O.19, W.B.O.20,
W.B.O.21, M.B.P.288, M.B.P.290,
M.B.P.295, T.B.P.259, T.B.P.264,
T.B.P.280, T.B.P.284, W.B.P.319,
Th.B.P.336, B.565, B.588, Th.C.O.35,
Th.C.O.37, Th.C.O.39, Th.C.O.40,
M.C.P.103, W.C.P.42, W.C.P.50,
Th.C.P.54, Th.C.P.86, C.699, C.703,
C.704, C.777
Hodgkin's
W.B.O.20, M.B.P.290, B.631, Th.C.O.38,
M.C.P.103
- LYMPHOTOXIN**
B.631
- MACROPHAGES**
Th.B.O.22, W.B.P.79, W.B.P.293,
W.B.P.326, Th.B.P.79, Th.B.P.96,
Th.B.P.99, Th.B.P.366, Th.B.P.372,
M.C.O.19, T.C.O.16, W.C.O.7, W.C.O.8,
W.C.O.9, Th.C.O.18, Th.C.O.24, M.C.P.42,
M.C.P.49, M.C.P.109, M.C.P.135, T.C.P.5,
T.C.P.6, T.C.P.8, T.C.P.17, T.C.P.34,
T.C.P.58, T.C.P.86, T.C.P.140, T.C.P.146,
W.C.P.6, W.C.P.17, W.C.P.27, W.C.P.55,
W.C.P.60, W.C.P.63, W.C.P.64, W.C.P.66,
W.C.P.68, W.C.P.71, W.C.P.77, W.C.P.78,
W.C.P.93, W.C.P.100, W.C.P.105,
W.C.P.122, W.C.P.123, Th.C.P.8,
Th.C.P.29, Th.C.P.79, Th.C.P.87,
Th.C.P.92, Th.C.P.101, Th.C.P.137, C.541,
C.549, C.575, C.623, C.636, C.670, C.712,
C.713, C.724, C.741, C.769, C.780
- MAGNETIC RESONANCE IMAGING (MRI)**
Th.B.O.23, M.B.P.196, Th.B.P.253,
Th.B.P.254, Th.B.P.255, Th.B.P.256,
Th.B.P.260, Th.B.P.262, Th.B.P.270,
Th.B.P.282, Th.B.P.283, W.C.P.69, C.581
- MAJOR HISTOCOMPATIBILITY COMPLEX ANTIGENS**
M.C.P.30, W.C.P.130
- MALARIA**
W.B.P.151, W.B.P.152, E.666, M.G.P.28
- MANNITOL**
Th.B.P.204
- MATHEMATICAL MODEL**
see Model
- MEASLES**
M.G.P.27
- MEDIA**
A.557, T.D.O.15, D.503, D.698, W.E.O.1,
W.E.O.20, W.E.O.21, W.E.O.22,
W.E.O.23, W.E.O.24, Th.E.O.3, Th.E.O.6,
M.E.P.4, M.E.P.6, M.E.P.7, M.E.P.13,
M.E.P.14, M.E.P.15, M.E.P.16, M.E.P.17,
M.E.P.18, M.E.P.19, M.E.P.20, M.E.P.21,
M.E.P.22, M.E.P.44, M.E.P.48, M.E.P.59,
T.E.P.4, T.E.P.5, T.E.P.16, T.E.P.21,
T.E.P.23, T.E.P.56, T.E.P.68, W.E.P.2,
W.E.P.4, W.E.P.11, W.E.P.19, W.E.P.21,
W.E.P.25, W.E.P.27, W.E.P.28, W.E.P.29,
W.E.P.30, W.E.P.52, W.E.P.58, W.E.P.64,
Th.E.P.12, Th.E.P.20, Th.E.P.32,
Th.E.P.37, Th.E.P.62, Th.E.P.63,
Th.E.P.64, Th.E.P.65, Th.E.P.66, E.558,
E.559, E.571, E.574, E.575, E.576, E.587,
E.593, E.635, E.640, E.644, E.645, E.647,
E.648, E.673, E.674, E.675, E.732, E.735,
E.736, E.737, E.738, E.739, E.741, E.787,
E.799, E.800, E.801, W.F.P.7, T.G.O.9
- MEGESTOL**
T.B.P.298, Th.B.P.309
- MEMBRANE PROTEIN INHIBITORS**
W.C.P.123
- MENINGOENCEPHALITIS**
M.A.O.31, M.B.O.36, Th.B.O.22,
M.B.P.118, T.B.P.48, T.B.P.176, W.B.P.4,
W.B.P.5, W.B.P.11, W.B.P.15, W.B.P.16,
W.B.P.22, W.B.P.24, W.B.P.27, W.B.P.31,
Th.B.P.205, Th.B.P.250, Th.B.P.258,
Th.B.P.375, B.599
- MEROYANINE 540 (MC 540)**
M.B.P.147
- METHADONE**
see Intravenous drug users
- METHISOPROLOL**
M.B.O.39
- MHC**
see Major histocompatibility complex
- MIGRATION**
W.A.O.30, T.A.P.15, T.A.P.46, T.A.P.51,
A.528, A.589, M.E.O.11, M.E.P.12,
M.E.P.13, E.546, E.552, W.F.O.22,
W.G.O.13, T.G.P.24, M.H.O.4, Th.H.P.20,
Th.H.P.25
- MILITARY**
M.A.O.1, M.A.O.3, M.A.O.6, Th.A.O.10,
Th.A.O.34, M.A.P.1, M.A.P.2, M.A.P.3,
M.A.P.4, M.A.P.11, M.A.P.13, M.A.P.17,
W.A.P.31, W.A.P.66, W.A.P.73, Th.A.P.28,
Th.A.P.103, A.525, W.B.P.225, W.B.P.312,
Th.B.P.229, Th.B.P.230, M.D.P.17,
W.D.P.50, T.E.P.13
- MINORITIES**
T.A.O.7, T.A.O.10, W.A.O.26, M.A.P.17,
M.A.P.55, M.A.P.61, M.A.P.73, M.A.P.74,
T.A.P.35, T.A.P.48, T.A.P.93, W.A.P.1,
W.A.P.19, W.A.P.23, W.A.P.113, Th.A.P.4,
Th.A.P.25, Th.A.P.26, A.553, A.589,
A.628, W.B.P.249, W.B.P.343, C.640,
M.D.O.11, T.D.O.12, T.D.O.17, W.D.O.4,
M.D.P.3, M.D.P.26, M.D.P.33, W.D.P.21,
W.D.P.22, W.D.P.24, W.D.P.25, W.D.P.27,
W.D.P.28, W.D.P.29, W.D.P.30, W.D.P.33,
W.D.P.35, W.D.P.36, W.D.P.37, W.D.P.45,
W.D.P.49, W.D.P.61, Th.D.P.33,
Th.D.P.37, Th.D.P.43, Th.D.P.54, D.502,
D.658, D.659, D.660, D.661, D.666, D.669,
D.684, D.715, M.E.O.34, T.E.O.17,
M.E.P.4, M.E.P.7, M.E.P.8, M.E.P.9,
M.E.P.10, M.E.P.15, M.E.P.55, T.E.P.7,
T.E.P.23, T.E.P.26, E.501, E.502, E.553,
E.554, E.557, E.582, E.688, E.690, E.774,
E.800, E.801, Th.F.O.2

MITOGEN

M.B.P.355, T.B.P.151, T.B.P.208,
T.B.P.214, T.B.P.315, W.B.P.286,
W.B.P.288, W.B.P.290, Th.B.P.103,
Th.B.P.105, Th.B.P.106, Th.B.P.315,
Th.B.P.316

MM-1

W.B.P.316, C.603

MOMLY

M.C.P.95, T.C.P.119, C.606

MODEL

see Animal models
computer

T.A.O.12, T.A.O.38, T.A.O.39, T.A.P.75,
T.A.P.95, W.A.P.72, W.A.P.74, Th.A.P.43,
Th.A.P.50, Th.A.P.51, Th.A.P.52,
Th.A.P.54, Th.A.P.56, Th.A.P.58,
Th.A.P.59, Th.A.P.63, Th.A.P.65,
Th.A.P.70, Th.A.P.71, Th.A.P.72,
Th.A.P.73, Th.A.P.87, A.513, A.560,
A.570, M.C.P.110, M.C.P.122, W.C.P.97,
C.675, E.633, W.H.P.19, W.H.P.20,
W.H.P.23

mathematical

M.A.O.1, M.A.O.4, M.A.O.45, M.A.O.48,
T.A.O.6, T.A.O.12, T.A.O.20, T.A.O.30,
T.A.O.36, T.A.O.37, T.A.O.39, T.A.O.40,
M.A.P.112, T.A.P.95, W.A.P.57, W.A.P.69,
Th.A.P.35, Th.A.P.37, Th.A.P.43,
Th.A.P.45, Th.A.P.53, Th.A.P.54,
Th.A.P.55, Th.A.P.57, Th.A.P.60,
Th.A.P.62, Th.A.P.63, Th.A.P.64,
Th.A.P.65, Th.A.P.68, Th.A.P.67,
Th.A.P.69, Th.A.P.70, Th.A.P.71,
Th.A.P.74, Th.A.P.75, Th.A.P.78,
Th.A.P.79, Th.A.P.87, Th.A.P.103, A.507,
A.513, A.522, A.524, A.555, A.561, A.605,
A.609, C.625, D.561, M.E.P.15, Th.E.P.2,
M.G.P.4, M.G.P.6, M.G.P.20, G.506,
Th.O.16, W.H.P.16, W.H.P.18, W.H.P.19,
W.H.P.24, W.H.P.25

MONOCLONAL ANTIBODIES**envy**

W.B.P.107, M.C.P.5, T.C.P.59, T.C.P.75,
Th.C.P.25, Th.C.P.45, C.567, C.771

egg

T.B.P.80, T.B.P.97, W.B.P.126, Th.C.O.4,
T.C.P.84, T.C.P.146, Th.C.P.42,
Th.C.P.59, Th.C.P.75, Th.C.P.108, C.663

human

M.B.P.18, Th.B.P.129, B.544, T.C.O.33,
Th.C.O.4, T.C.P.7, T.C.P.75, T.C.P.150,
Th.C.P.99, Th.C.P.141

neutralizing

T.C.O.3, W.C.O.38, Th.C.O.26, M.C.P.49,
T.C.P.75

other

M.B.P.165, T.B.P.11, W.B.P.130,
W.B.P.132, Th.B.P.109, Th.C.O.1,
Th.C.O.37, T.C.P.33, Th.C.P.99,
Th.C.P.142, C.668, C.679, C.749

MONOCYTES

W.A.P.14, M.B.P.267, T.B.P.117,
T.B.P.224, W.B.P.69, W.B.P.82,
W.B.P.261, W.B.P.264, Th.B.P.90,
Th.B.P.91, Th.B.P.94, Th.B.P.98,

Th.B.P.99, Th.B.P.100, Th.B.P.361,
Th.B.P.366, B.558, M.C.O.15, M.C.O.16,
M.C.O.17, M.C.O.19, M.C.O.20, T.C.O.3,
W.C.O.9, W.C.O.10, W.C.O.22, Th.C.O.18,
M.C.P.42, M.C.P.49, M.C.P.55, M.C.P.109,
M.C.P.112, M.C.P.119, M.C.P.135,
T.C.P.3, T.C.P.6, T.C.P.9, T.C.P.21,
T.C.P.30, T.C.P.36, T.C.P.56, T.C.P.57,
T.C.P.58, T.C.P.112, T.C.P.117,
T.C.P.122, T.C.P.146, W.C.P.59,
W.C.P.68, W.C.P.75, W.C.P.77, W.C.P.78,
W.C.P.106, W.C.P.107, W.C.P.109,
W.C.P.120, W.C.P.122, W.C.P.135,
W.C.P.137, Th.C.P.3, Th.C.P.13,
Th.C.P.40, Th.C.P.77, Th.C.P.87,
Th.C.P.92, Th.C.P.101, Th.C.P.137, C.518,
C.521, C.523, C.523, C.670, C.706, C.709,
C.712, C.723, C.724

MORTALITY

W.A.O.16, W.A.O.18, T.A.P.60, T.A.P.63,
W.A.P.16, W.A.P.27, W.A.P.28, W.A.P.29,
W.A.P.30, W.A.P.31, W.A.P.32, W.A.P.33,
W.A.P.34, W.A.P.79, Th.A.P.98, A.563,
A.584, A.609, A.613, M.B.O.38, T.B.O.8,
M.B.P.209, T.B.P.147, T.B.P.156,
T.B.P.169, T.B.P.266, Th.B.P.48,
Th.D.O.18, W.D.P.4, W.D.P.28, Th.D.P.68,
D.533, Th.E.P.5, Th.E.P.47, Th.G.O.49,
Th.G.O.52, W.G.P.7

MULTIPLE SCLEROSIS

W.B.P.227, Th.C.P.83

MULV

W.C.O.28, Th.C.O.49, M.C.P.53,
M.C.P.74, M.C.P.95, W.C.P.29, Th.C.P.48

MURINE AIDS

W.C.O.29, M.C.P.81, W.C.P.6

MUTATION

M.C.O.7, Th.C.O.2, M.C.P.1, W.C.P.116,
Th.C.P.2, Th.C.P.74, Th.C.P.120,
Th.C.P.149, C.680

MYCOBACTERIAL INFECTIONS**tubercular**

M.A.O.29, T.A.O.3, M.A.P.27, W.A.P.16,
Th.A.P.98, M.B.O.38, T.B.O.12, W.B.O.21,
W.B.O.37, M.B.P.64, M.B.P.107,
M.B.P.177, M.B.P.231, M.B.P.282,
M.B.P.372, M.B.P.373, M.B.P.374,
T.B.P.199, W.B.P.274, Th.B.P.36,
Th.B.P.37, Th.B.P.38, Th.B.P.39,
Th.B.P.40, Th.B.P.41, Th.B.P.43,
Th.B.P.44, Th.B.P.45, Th.B.P.46,
Th.B.P.50, Th.B.P.51, Th.B.P.52,
Th.B.P.53, Th.B.P.54, Th.B.P.55,
Th.B.P.56, Th.B.P.57, Th.B.P.59,
Th.B.P.63, Th.B.P.64, Th.B.P.65,
Th.B.P.66, Th.B.P.67, Th.B.P.68,
Th.B.P.69, Th.B.P.72, Th.B.P.74,
Th.B.P.124, Th.B.P.234, Th.B.P.366,
B.532, B.563, T.G.O.24, W.G.O.3,
Th.G.O.1, Th.G.O.2, Th.G.O.3, Th.G.O.4,
Th.G.O.5, Th.G.O.6, M.G.P.24, M.G.P.25,
M.G.P.26

non-tubercular, MAIC

Th.A.P.98, M.B.P.64, M.B.P.190,
M.B.P.192, M.B.P.211, M.B.P.300,

W.B.P.43, W.B.P.336, Th.B.P.45,
Th.B.P.48, Th.B.P.53, Th.B.P.54,
Th.B.P.55, Th.B.P.58, Th.B.P.60,
Th.B.P.61, Th.B.P.62, Th.B.P.71,
Th.B.P.72, Th.B.P.73, T.C.P.9

non-tubercular, others

Th.B.P.42, Th.B.P.45, Th.B.P.47,
Th.B.P.49, Th.B.P.58, Th.B.P.245, B.516,
C.575

MYELOPATHY

Th.A.O.31, Th.A.P.17, M.B.P.121,
W.B.P.51, Th.B.P.194, Th.B.P.199,
Th.B.P.217, Th.B.P.249, W.C.P.55,
W.C.P.60, C.721

MYOCARDITIS**see Heart****MYOPATHY**

M.B.P.239, M.B.P.262, M.B.P.326,
M.B.P.329, M.B.P.330, T.B.P.327

NALTREXONE**M.C.P.82****NATIONAL AIDS PROGRAMME****see Public policy****NATIONAL POLICY****see Public policy****NATIVE GROUPS**

T.A.P.67, W.A.P.23, A.519, M.D.O.4,
T.D.O.13, T.D.O.14, W.D.P.26, W.D.P.32,
Th.D.P.61

NATURAL CYTOTOXICITY**NK**

M.B.P.42, M.B.P.347, Th.B.P.78,
Th.B.P.159, Th.B.P.160, Th.B.P.168,
W.C.O.6, M.C.P.14, M.C.P.149, T.C.P.26,
T.C.P.35, T.C.P.54, T.C.P.71, C.542,
C.632, C.707, C.718

LAK

M.C.O.32, W.C.O.10

NATURAL HISTORY**see Progression****NEONATES****see Children****NEEDLE-SYRINGE EXCHANGE****see Intravenous drug users****NEEDLE STICKS****see Health care personnel****NEOPTERIN**

Th.B.O.25, Th.B.O.27, Th.B.O.28,
M.B.P.360, T.B.P.225, W.B.P.72,
W.B.P.74, W.B.P.76, W.B.P.79, W.B.P.83,
W.B.P.89, W.B.P.91, W.B.P.92,
W.B.P.305, W.B.P.365, Th.B.P.86,
Th.B.P.226, Th.B.P.244, Th.B.P.329,
Th.B.P.327, Th.B.P.353, C.563

NERVOUS SYSTEM, PERIPHERAL

Th.B.O.19, Th.B.O.20, Th.B.O.21,
M.B.P.118, M.B.P.134, M.B.P.260,
T.B.P.177, T.B.P.247, Th.B.P.196,
Th.B.P.199, Th.B.P.205, Th.B.P.209,
Th.B.P.227, Th.B.P.251, Th.B.P.375,
M.C.O.31, M.C.O.31, C.519, C.721, C.749

NEUROLOGY*see* Central nervous system**NEUTROTROPIN**

C.582

NEUTROPENIAM.B.O.49, T.B.P.213, T.B.P.299,
T.B.P.305, T.B.P.308, W.B.P.309,
W.B.P.328, Th.B.P.140, Th.B.P.333**NEUTROPHILS**T.B.P.3, W.B.P.311, Th.B.P.84, Th.B.P.88,
Th.B.P.100, M.C.P.100, T.C.P.21,
W.C.P.99, C.586**NEW INFECTIOUS AGENTS**

W.C.P.40, Th.C.P.54, Th.C.P.63, C.777

NITRITE INHALANTS

Th.A.O.16, A.621

NITROPHENOL DERIVATIVES

C.583

NOCARDIA ASTEROIDES

M.B.P.204

NONGOVERNMENTAL ORGANIZATIONS (NGO)Th.A.P.89, T.D.O.16, D.634, M.E.O.26,
W.E.O.1, W.E.O.2, W.E.O.4, W.E.O.5,
W.E.O.6, W.E.O.27, T.E.P.12, T.E.P.50,
T.E.P.65, T.E.P.89, T.E.P.80, Th.E.P.68,
E.514, E.656, E.746, E.803, E.810,
Th.F.P.7, Th.F.H.P.8, T.G.P.5, T.G.P.10,
G.505, Th.H.O.4, T.H.P.29**NONOXINOL-9**

M.A.O.36

NUCLEOSIDE ANALOGUES*see* specific compounds**NUCLEOSIDE DIMERS**

M.C.P.50, M.C.P.135

NURSES*see* Health care personnel**NUTRITION**Th.B.O.39, Th.B.O.40, Th.B.P.298,
Th.B.P.299, Th.B.P.301, Th.B.P.302,
Th.B.P.303, Th.B.P.306, Th.B.P.307,
Th.B.P.310, Th.B.P.311, Th.B.P.312,
Th.B.P.313, Th.B.P.314, Th.B.P.318,
Th.B.P.378, Th.B.P.379, Th.B.P.380,
B.800, E.702, E.706**OCCUPATIONAL THERAPY**

D.543

2, 5 OLIGOADENYLATES

M.C.P.136, C.719

OLIGOCLONAL IMMUNOGLOBULINS

W.B.P.90

OLIGOSACCHARIDES

M.C.P.91, Th.C.P.12, C.613

ONCOGENEST.B.P.177, T.C.P.112, T.C.P.143, C.703,
C.704**ON-LINE COLUMN-A ADSORPTION**

T.B.P.276

OPPORTUNISTIC INFECTIONSA.563, A.632, T.B.O.4, W.B.O.39,
Th.B.O.43, M.B.P.77, M.B.P.78, M.B.P.92,M.B.P.94, M.B.P.95, M.B.P.109,
M.B.P.111, M.B.P.180, M.B.P.237,
M.B.P.252, M.B.P.280, M.B.P.291,
M.B.P.297, M.B.P.299, T.B.P.73,
T.B.P.88, T.B.P.298, T.B.P.377, W.B.P.3,
W.B.P.16, W.B.P.44, W.B.P.75,
W.B.P.273, W.B.P.279, W.B.P.316,
W.B.P.338, W.B.P.349, W.B.P.358,
W.B.P.366, Th.B.P.48, Th.B.P.53,
Th.B.P.65, Th.B.P.72, Th.B.P.78,
Th.B.P.246, Th.B.P.250, Th.B.P.299,
Th.B.P.323, B.519, B.615, M.C.P.60,
M.C.P.138, W.C.P.53, Th.C.P.143, C.586,
C.634, C.639, C.786, Th.G.O.3*see also* specific organisms**OPSONIZATION**

Th.B.P.136

ORAL FLORA

M.B.P.245, Th.B.P.350, Th.B.P.356, B.564

ORAL MANIFESTATIONSM.B.O.16, M.B.O.17, M.B.O.21,
M.B.P.176, M.B.P.240, T.B.P.292,
T.B.P.321, W.B.P.94, Th.B.P.321,
Th.B.P.322, Th.B.P.323, Th.B.P.324,
Th.B.P.325, Th.B.P.329, Th.B.P.330,
Th.B.P.331, Th.B.P.332, Th.B.P.333,
Th.B.P.334, Th.B.P.337, Th.B.P.338,
Th.B.P.340, Th.B.P.341, Th.B.P.342,
Th.B.P.344, Th.B.P.345, Th.B.P.347,
Th.B.P.350, Th.B.P.351, Th.B.P.352,
Th.B.P.355, B.564, B.576*hairly leukoplakia*M.B.O.18, M.B.O.19, M.B.O.20,
M.B.P.111, M.B.P.244, M.B.P.365,
Th.B.P.320, Th.B.P.321, Th.B.P.327,
Th.B.P.339, Th.B.P.340, Th.B.P.343,
Th.B.P.346, C.571**ORAL SEX***see* Transmission
see also Sexual behaviour**ORGANIC GOLD**

M.C.P.106

OTORHINOLARYNGOLOGY

M.B.P.72

OUT OF HOSPITAL CAREA.584, W.B.P.84, W.B.P.67, B.593,
M.D.P.91, Th.E.O.14, M.E.P.52, M.E.P.61,
M.E.P.68, M.E.P.70, M.E.P.73, M.E.P.75,
W.E.P.44, E.545, E.701, E.707, E.808,
M.H.O.15, M.H.O.16, M.H.O.17, Th.O.3,
Th.O.10, M.H.P.6, M.H.P.14, T.H.P.11,
T.H.P.14**OUT PATIENT CARE**M.A.O.5, M.A.O.14, T.A.P.24, T.A.P.72,
W.A.P.10, A.569, A.572, A.584, A.585,
A.633, A.637, M.B.P.319, W.B.P.61,
W.B.P.62, W.B.P.67, W.B.P.261,
W.B.P.264, W.B.P.317, W.B.P.379,
Th.B.P.318, B.506, B.545, W.D.P.16,
Th.D.P.71, M.E.P.60, T.E.P.57, T.E.P.65,
T.E.P.70, E.678, E.778, Th.G.P.26,
M.H.O.18, M.H.P.10, Th.P.23**OZONE**

M.H.P.23

P24 ANTIGEN/ANTIBODYM.A.P.41, M.A.P.90, M.A.P.100,
M.A.P.108, W.A.P.49, Th.A.P.67, A.565,
Th.B.O.2, Th.B.O.3, Th.B.O.54, M.B.P.2,
M.B.P.25, M.B.P.101, M.B.P.135,
M.B.P.147, M.B.P.148, M.B.P.153,
M.B.P.175, M.B.P.299, M.B.P.336,
M.B.P.337, M.B.P.340, M.B.P.351,
M.B.P.352, M.B.P.363, Th.B.P.83, T.B.P.84,
T.B.P.88, T.B.P.90, T.B.P.94, T.B.P.95,
T.B.P.97, T.B.P.98, Th.P.102, T.B.P.118,
T.B.P.121, T.B.P.151, T.B.P.172,
T.B.P.220, T.B.P.222, T.B.P.229,
T.B.P.229, T.B.P.237, T.B.P.242,
T.B.P.246, T.B.P.247, T.B.P.311,
T.B.P.313, T.B.P.314, T.B.P.336,
T.B.P.347, W.B.P.70, W.B.P.71, W.B.P.75,
W.A.O.87, W.B.P.109, W.B.P.121,
W.B.P.132, W.B.P.133, W.B.P.134,
W.B.P.137, W.B.P.139, W.B.P.141,
W.B.P.155, W.B.P.157, W.B.P.158,
W.B.P.200, W.B.P.252, W.B.P.278,
W.B.P.282, W.B.P.286, W.B.P.315,
W.B.P.321, W.B.P.324, W.B.P.325,
W.B.P.329, W.B.P.365, W.B.P.368,
Th.B.P.8, Th.B.P.9, Th.B.P.17, Th.B.P.80,
Th.B.P.86, Th.B.P.101, Th.B.P.111,
Th.B.P.125, Th.B.P.143, Th.B.P.165,
Th.B.P.169, Th.B.P.177, Th.B.P.182,
Th.B.P.186, Th.B.P.247, Th.B.P.263,
Th.B.P.367, B.542, B.553, B.555, B.561,
B.603, B.622, B.638, T.C.O.33, W.C.O.24,
M.C.P.34, M.C.P.112, M.C.P.116,
M.C.P.124, M.C.P.125, M.C.P.135,
M.C.P.146, T.C.P.149, W.C.P.4, W.C.P.42,
W.C.P.85, Th.C.P.46, Th.C.P.138, C.585,
C.597, C.633, C.669, C.698, C.712, C.730,
C.753, C.766**PALLIATIVE CARE**M.B.P.202, W.B.P.64, W.B.P.66,
W.B.P.378, Th.B.P.27, B.505**PANCREAS**

M.B.P.233, M.B.P.235, Th.B.P.317

PARACOCCHIDIOIDOMYCOSIS

M.B.P.93

PARASITES

M.B.P.91, T.B.P.1, W.B.P.30, B.521

PARENTERAL NUTRITION

Th.B.O.37

PARENTS*see* Family**PAROTITIS**

Th.B.P.947, B.582, B.583

PARTNER NOTIFICATIONM.A.O.33, T.A.O.33, W.A.O.19, W.A.O.20,
W.A.O.21, W.A.O.22, W.A.O.23,
W.A.O.24, M.A.P.97, W.A.P.84, W.A.P.85,
W.A.P.86, W.A.P.87, T.D.O.29, W.D.P.1,
Th.D.P.4, W.E.O.24, E.724, E.729,
W.H.P.24**PASSIVE IMMUNOTHERAPY**T.B.P.5, W.B.P.45, T.C.O.39, W.C.O.27,
W.G.O.6

- PBL**
see Peripheral blood lymphocytes
- PCP**
see *Pneumocystis carinii* pneumonia
- PEDIATRIC**
see Children
- PEER SUPPORT**
see Group support
- PELVIC INFLAMMATORY DISEASE (PID)**
M.A.P.56, M.B.P.54
- PENICILLIN, BENZATHINE**
W.B.P.59
- PENICILLUM MARNEFFI**
M.B.P.94
- PENTAMIDINE**
T.B.O.3, T.B.O.26, T.B.O.30, M.B.P.233, M.B.P.235, M.B.P.286, M.B.P.377, T.B.P.32, T.B.P.37, T.B.P.38, T.B.P.44, T.B.P.45, T.B.P.51, T.B.P.60, T.B.P.65, T.B.P.70, T.B.P.72, T.B.P.73, T.B.P.78, T.B.P.319
inhaled
T.B.O.1, T.B.O.2, M.B.P.208, M.B.P.378, T.B.P.21, T.B.P.23, T.B.P.25, T.B.P.28, T.B.P.33, T.B.P.40, T.B.P.49, T.B.P.50, T.B.P.52, T.B.P.53, T.B.P.54, T.B.P.55, T.B.P.56, T.B.P.57, T.B.P.58, T.B.P.59, T.B.P.61, T.B.P.62, T.B.P.63, T.B.P.64, T.B.P.65, T.B.P.66, T.B.P.67, T.B.P.68, T.B.P.69, T.B.P.71, T.B.P.74, T.B.P.75, T.B.P.76, T.B.P.77, T.B.P.79, T.B.P.324, T.B.P.379, B.607, W.C.P.1, C.634, C.639
- PENTOSAN-POLYSULFATE**
W.B.P.299, W.B.P.300
- PEPTIDE T**
W.B.O.45a, W.B.P.286, M.C.P.92
- PEPTIDES**
recombinant
Th.B.O.54, Th.B.O.55, Th.B.O.56, T.B.P.91, T.B.P.103, T.B.P.119, T.B.P.120, T.B.P.231, T.B.P.332, T.B.P.349, W.B.P.94, W.B.P.95, W.B.P.97, W.B.P.106, W.B.P.118, W.B.P.120, W.B.P.121, W.B.P.125, W.B.P.127, W.B.P.133, W.B.P.134, W.B.P.137, W.B.P.166, W.B.P.169, W.B.P.171, W.B.P.172, Th.B.P.110, Th.B.P.169, Th.B.P.231, B.587, B.619, M.C.O.25, T.C.O.31, T.C.P.48, Th.C.P.2, Th.C.P.44, Th.C.P.73, C.554, C.648, C.665, C.690, C.694, C.697
- synthetic**
Th.B.O.9, Th.B.O.54, M.B.P.167, T.B.P.82, T.B.P.104, T.B.P.128, T.B.P.129, W.B.P.96, W.B.P.101, W.B.P.103, W.B.P.109, W.B.P.110, W.B.P.114, W.B.P.115, W.B.P.125, W.B.P.126, W.B.P.131, W.B.P.144, Th.B.P.110, Th.B.P.172, Th.B.P.371, B.535, B.548, B.562, M.C.O.32, T.C.O.11, T.C.O.35, W.C.O.40, M.C.P.6, M.C.P.7, M.C.P.41, T.C.P.16, T.C.P.23, T.C.P.48, T.C.P.76, T.C.P.144, W.C.P.98, Th.C.P.39, Th.C.P.55, Th.C.P.59, Th.C.P.78, Th.C.P.102, Th.C.P.127, C.523, C.544, C.545, C.555, C.745, C.765
- PERCEPTION OF RISK**
see Risk
- PERIPHERAL BLOOD LYMPHOCYTES (PBL)**
Th.B.O.10, M.B.P.131, M.B.P.165, M.B.P.246, T.B.P.88, T.B.P.95, T.B.P.110, W.B.P.32, W.B.P.145, W.B.P.167, Th.B.P.81, Th.B.P.97, Th.B.P.98, Th.B.P.149, Th.B.P.153, Th.B.P.165, Th.B.P.167, B.544, B.564, T.C.O.44, M.C.P.9, T.C.P.26, W.C.P.94, C.738
- PERSONS WITH AIDS (PWA)**
M.D.O.2, M.D.P.86, W.D.P.3, W.D.P.25, W.D.P.54, Th.D.P.24, D.558, D.583, D.578, D.670, D.706, M.E.O.14, M.E.O.26, M.E.P.57, M.E.P.83, T.E.P.53, E.524, E.700, Th.F.F.10, Th.F.F.13
- PERSONS WITH ARC (PWARC)**
M.B.P.104, W.B.P.346, T.E.P.53
- PHAGOCYTES**
W.B.P.293, Th.B.P.100
- PHORBOL ESTER (TPA)**
T.B.P.111, Th.C.P.24
- PHOSPHATIDYLCHOLINE**
C.598
- PHYLOGENETIC**
M.C.O.5
- PHYSICAL EXERCISE**
T.B.P.301
- PHYSICIANS**
see Health care personnel
- PID**
see Pelvic inflammatory disease
- PLACEBO CONTROLS**
M.B.O.46, Th.B.O.43, Th.B.O.46, Th.B.O.47, M.B.P.352, T.B.P.294, T.B.P.304, W.B.P.282, W.B.P.290, W.B.P.302, W.B.P.308, W.B.P.313, W.B.P.331, M.C.P.142, W.F.O.5, W.F.O.6, W.F.O.7, W.F.P.3
- PLACENTA**
M.B.P.11, M.B.P.18, M.B.P.20
- PMEA**
M.C.P.69, M.C.P.74, M.C.P.81
- PML**
M.B.P.134, W.B.P.311, Th.B.P.89, Th.B.P.362, M.C.P.118, Th.C.P.113
- PNEUMOCYSTIS CARINII**
PNEUMONIA (PCP)
diagnosis
A.584, M.B.P.209, M.B.P.211, M.B.P.377, M.B.P.380, T.B.P.2, T.B.P.3, T.B.P.4, T.B.P.7, T.B.P.8, T.B.P.11, T.B.P.12, T.B.P.13, T.B.P.14, T.B.P.15, T.B.P.20, T.B.P.26, T.B.P.42, T.B.P.155, T.B.P.266, W.B.P.72, Th.B.P.81, B.559, B.616
- prognosis
M.B.P.207, M.B.P.375, T.B.P.18, T.B.P.24, T.B.P.31, T.B.P.32, T.B.P.43, T.B.P.50, T.B.P.156, Th.B.P.52
- prophylaxis
T.B.O.1, T.B.O.3, T.B.O.4, T.B.O.5, T.B.O.6, M.B.P.208, M.B.P.378, T.B.P.5, T.B.P.21, T.B.P.32, T.B.P.43, T.B.P.44, T.B.P.45, T.B.P.46, T.B.P.47, T.B.P.48, T.B.P.49, T.B.P.50, T.B.P.51, T.B.P.52, T.B.P.53, T.B.P.54, T.B.P.56, T.B.P.58, T.B.P.59, T.B.P.60, T.B.P.62, T.B.P.63, T.B.P.66, T.B.P.68, T.B.P.69, T.B.P.70, T.B.P.71, T.B.P.73, T.B.P.74, T.B.P.75, T.B.P.76, T.B.P.78, T.B.P.324, T.B.P.379, W.B.P.285, B.607, M.C.P.46, T.H.P.15
- treatment
T.B.O.2, T.B.O.26, T.B.O.28, T.B.O.29, T.B.O.30, T.B.O.31, M.B.P.205, M.B.P.376, T.B.P.5, T.B.P.22, T.B.P.23, T.B.P.24, T.B.P.25, T.B.P.26, T.B.P.27, T.B.P.28, T.B.P.29, T.B.P.30, T.B.P.31, T.B.P.32, T.B.P.33, T.B.P.34, T.B.P.35, T.B.P.36, T.B.P.37, T.B.P.38, T.B.P.39, T.B.P.40, T.B.P.41, T.B.P.42, T.B.P.61, T.B.P.64, T.B.P.72, T.B.P.316, T.B.P.319, W.B.P.273, W.B.P.285, B.647, C.634, C.639
- other
T.B.O.27, M.B.P.192, M.B.P.205, M.B.P.207, M.B.P.210, M.B.P.240, M.B.P.284, M.B.P.295, M.B.P.296, M.B.P.299, M.B.P.376, T.B.P.1, T.B.P.6, T.B.P.9, T.B.P.10, T.B.P.16, T.B.P.17, T.B.P.19, T.B.P.153, T.B.P.199, W.B.P.28, W.B.P.193, Th.B.P.340, B.637, C.518, C.722
- PNEUMONIA**
see individual organisms
- PNEUMONITIS**
M.B.P.106, M.B.P.115, M.B.P.210, M.B.P.212, M.B.P.214, M.B.P.297, T.B.P.316, Th.B.P.76, Th.B.P.77, B.582, B.615
- PNEUMOTHORAX**
M.B.P.205, M.B.P.207, M.B.P.208, T.B.P.76
- POLIO VACCINE**
HYPERIMMUNIZATION
Th.B.P.118
- POLYMERASE CHAIN REACTION (PCR)**
Th.A.P.109, Th.A.P.110, Th.A.P.111, M.B.O.6, Th.B.O.7, Th.B.O.8, Th.B.O.9, Th.B.O.10, Th.B.O.11, Th.B.O.12, M.B.P.1, M.B.P.333, T.B.P.80, T.B.P.81, T.B.P.82, T.B.P.110, T.B.P.227, T.B.P.235, W.B.P.157, W.B.P.319, Th.B.P.111, Th.B.P.179, B.549, B.623, B.643, M.C.O.10, T.C.O.13, T.C.O.14, T.C.O.40, T.C.O.50, M.C.P.9, M.C.P.28, T.C.P.10, T.C.P.21, T.C.P.82, T.C.P.92, T.C.P.131, T.C.P.143, W.C.P.33, W.C.P.41, W.C.P.43, W.C.P.62, W.C.P.84, W.C.P.88, W.C.P.119, W.C.P.126, W.C.P.133, W.C.P.139, Th.C.P.21,

- Th.C.P.89, Th.C.P.70, Th.C.P.81,
Th.C.P.114, Th.C.P.119, Th.C.P.148,
C.650, C.659, C.660, C.675, C.725, C.733,
C.739, C.741, C.754, C.759, C.773,
Th.C.P.6
- POVERTY**
W.B.P.343, M.D.P.1, Th.F.O.2, M.G.O.17
- PREGNANCY**
HIV prevalence
W.A.O.7, W.A.O.8, W.A.O.12, M.A.P.6,
W.A.P.7, Th.A.P.15, M.B.P.3, M.B.P.5,
M.B.P.6, M.B.P.10, M.B.P.16, M.B.P.19,
M.B.P.23, M.B.P.25, M.B.P.27, M.B.P.28,
M.B.P.33, T.B.P.201, T.B.P.343, B.503,
B.504, W.D.P.50, M.G.P.8, W.G.P.10
- progression
M.B.P.21
see Serologic tests
see also Children; Breastfeeding;
Transmission; Zidovudine
- PREVALENCE**
see Bistaxials
see Children
see Gay men
see General population
see Geographical aspects
see Hemophilia
see Heterosexuals
see Intravenous drug users
methodology
M.A.O.4, Th.A.O.12, W.A.P.29, W.A.P.119,
Th.A.P.34, Th.A.P.35, Th.A.P.78,
T.B.P.347, W.B.P.213, Th.E.P.18
see Pregnancy
see Prisoners
see Prostitutes
other
M.A.P.59, T.A.P.17, T.A.P.26, Th.A.P.16,
W.B.P.209, W.D.P.34, M.G.O.29
see also Serologic tests
- PREVENTION**
see Children
evaluation
M.A.O.27, W.A.O.21, W.A.O.29, M.A.P.15,
M.A.P.70, M.A.P.76, T.A.P.104, W.A.P.93,
W.A.P.105, W.A.P.111, W.A.P.113,
W.A.P.119, A.557, M.B.P.117, Th.D.O.18,
M.D.P.32, M.D.P.36, W.D.P.52, W.D.P.57,
W.D.P.65, Th.D.P.30, D.531, D.557,
D.665, W.E.O.7, T.E.P.35, T.E.P.64,
W.E.P.19, Th.E.P.43, E.502, E.561, E.770,
W.F.F.5, T.G.O.10, W.G.O.17, Th.G.O.31,
T.G.P.8, Th.G.P.29, M.H.P.27, Th.H.P.27
see Gay men
see Hemophilia
see Heterosexuals
see Intravenous drug users
see Prisoners
see Prostitutes
other
M.A.P.2, M.A.P.115, W.A.P.2, W.A.P.120,
Th.A.P.44, A.533, A.570, M.B.P.316,
T.B.P.55, W.B.P.66, W.B.P.206,
W.B.P.265, W.B.P.276, W.B.P.355,
T.C.O.39, T.D.O.14, T.D.O.16, Th.D.O.10,
T.D.P.6, T.D.P.69, W.D.P.23, W.D.P.45,
W.D.P.46, D.516, D.627, D.660, D.668,
D.669, D.683, D.684, D.691, E.546, E.555,
T.G.P.21, T.G.P.22, Th.G.P.5, Th.H.P.30
- PRISONERS**
prevalence
M.A.O.39, M.A.O.40, M.A.O.41, M.A.P.18,
M.A.P.19, M.A.P.21, M.A.P.22, M.A.P.24,
M.A.P.25, M.A.P.26, M.A.P.27, M.A.P.28,
Th.A.P.20, Th.A.P.56, A.532, A.613,
T.D.P.7, W.D.P.76, Th.D.P.16, Th.D.P.31,
Th.D.P.45, D.723, M.E.P.6, M.F.P.4, G.518
- prevention
M.A.O.38, M.A.O.43, M.A.P.20, Th.A.P.56,
A.532, T.D.O.30, Th.D.O.17, T.D.P.32,
W.D.P.78, M.E.P.6, T.E.P.20, W.E.P.37,
W.E.P.67, Th.E.P.32, E.589, E.642, E.797
- other
M.A.O.40, M.A.P.23, M.B.P.69, T.B.P.18,
T.D.P.13, T.D.P.68, D.502, W.E.P.15,
E.693, E.811, Th.F.O.6, M.F.P.6
- PROBENICID**
W.B.O.4, W.B.P.58, Th.B.P.198
- PRODUCTIVITY**
T.H.O.1, T.H.O.13, M.H.P.20, Th.H.P.2
- PROGNOSIS**
see Beta-2-microglobulin
CD4 lymphocytes
T.A.O.29, M.A.P.99, M.A.P.100,
M.A.P.102, M.B.P.356, Th.B.P.163,
W.C.P.38
see Children
see Gay men
see Hemophilia
see Heterosexuals
see P24 antigen/antibody
see Intravenous drug users
laboratory markers
T.A.O.29, T.A.O.34, M.A.P.37, M.A.P.88,
M.A.P.96, M.A.P.102, W.A.P.58, W.A.P.62,
A.531, A.540, A.583, A.622, Th.B.O.29,
M.B.P.140, M.B.P.165, M.B.P.192,
M.B.P.197, M.B.P.356, M.B.P.357,
T.B.P.50, T.B.P.103, T.B.P.172, T.B.P.211,
T.B.P.222, T.B.P.240, T.B.P.311
T.B.P.323, W.B.P.70, W.B.P.72, W.B.P.77,
W.B.P.83, W.B.P.86, W.B.P.90, W.B.P.92,
W.B.P.118, W.B.P.139, W.B.P.141,
Th.B.P.170, Th.B.P.17, Th.B.P.81,
Th.B.P.84, Th.B.P.87, Th.B.P.97,
Th.B.P.107, Th.B.P.143, Th.B.P.144,
Th.B.P.161, Th.B.P.163, Th.B.P.168,
Th.B.P.169, Th.B.P.183, Th.B.P.195,
Th.B.P.251, Th.B.P.310, B.561, B.585,
B.626, W.C.P.92, T.D.P.29, W.G.P.9
see Neopterin
other
M.A.P.102, A.609, A.622, M.B.P.198,
M.B.P.288, T.B.P.269, T.B.P.372, W.B.P.4,
W.B.P.344, Th.C.O.28, W.C.P.98, C.766,
T.H.F.4
- PROGRAMME EVALUATION**
T.A.O.6, T.A.O.20, T.A.O.21, T.A.O.24,
W.A.O.11, W.A.O.23, W.A.O.24,
W.A.O.25, W.A.O.28, M.A.P.20, M.A.P.55,
M.A.P.62, M.A.P.70, T.A.P.82, W.A.P.88,
W.A.P.96, W.A.P.106, W.A.P.107,
W.A.P.108, W.A.P.114, W.A.P.117, A.577,
A.579, A.591, T.B.P.339, W.B.P.241,
C.57, T.D.P.14, T.D.P.85, W.D.P.44,
D.516, D.619, W.E.O.23, W.E.P.4,
W.E.P.5, E.647, M.F.O.2, M.G.O.2,
W.G.O.13, W.G.O.18, M.G.P.17, T.G.P.9,
T.G.P.10, T.G.P.17, Th.G.P.14, Th.P.15,
Th.H.P.8
- PROGRESSION**
energy
M.A.P.53, Th.B.P.155, T.C.P.60,
W.C.P.134, C.708
anti-HIV antibodies
M.A.O.47, T.A.O.34, M.A.P.95, W.A.P.54,
W.A.P.80, W.A.P.114, W.A.P.117, A.599,
T.B.P.99, A.510, A.638, Th.B.P.70,
Th.B.P.187, T.C.P.69
asymptomatic stages
M.A.O.29, M.A.P.88, M.A.P.102,
M.A.P.106, Th.A.P.86, W.B.O.45,
Th.B.O.2, Th.B.O.40, Th.B.O.43,
Th.B.O.46, M.B.P.105, M.B.P.245,
M.B.P.367, W.B.P.56, W.B.P.146,
W.B.P.165, W.B.P.180, W.B.P.186,
W.B.P.198, W.B.P.201, W.B.P.298,
W.B.P.302, W.B.P.362, Th.B.P.50,
Th.B.P.90, Th.B.P.93, Th.P.105,
Th.P.120, Th.B.P.139, Th.B.P.140,
Th.B.P.203, Th.B.P.240, Th.B.P.263,
Th.B.P.264, Th.B.P.265, Th.B.P.271,
Th.B.P.287, Th.B.P.290, Th.B.P.298,
Th.B.P.321, Th.B.P.326, Th.B.P.367,
W.G.P.9
CDC stages
M.B.P.295, T.B.P.294, W.B.P.83,
W.B.P.86, Th.B.P.166, Th.B.P.282,
Th.B.P.270, T.C.P.73
see Children
see Gay men
see Hemophilia
see Heterosexuals
see Intravenous drug users
laboratory parameters
T.A.O.31, T.A.O.34, T.A.O.38, Th.A.O.10,
M.A.P.92, M.A.P.97, M.A.P.98, M.A.P.101,
M.A.P.103, M.A.P.104, M.A.P.105,
M.A.P.106, M.A.P.107, M.A.P.108,
W.A.P.53, W.A.P.58, W.A.P.86, W.A.P.75,
W.A.P.79, Th.A.P.84, Th.A.P.86,
Th.A.P.93, Th.A.P.99, Th.A.P.100,
Th.A.P.102, A.612, M.B.O.18, M.B.O.23,
M.B.O.50, M.B.P.35, M.B.P.105,
M.B.P.254, M.B.P.258, T.B.P.304,
T.B.P.336, W.B.P.73, W.B.P.74, W.B.P.76,
W.B.P.77, W.B.P.79, W.B.P.80, W.B.P.87,
W.B.P.91, W.B.P.341, Th.B.P.75

- Th.B.P.80, Th.B.P.90, Th.B.P.114,
Th.B.P.133, Th.B.P.142, Th.B.P.145,
Th.B.P.185, Th.B.P.189, Th.B.P.189,
Th.B.P.181, Th.B.P.187, Th.B.P.222,
Th.B.P.233, Th.B.P.236, Th.B.P.243,
Th.B.P.245, Th.B.P.310, Th.B.P.313,
B.520, B.554, M.C.O.9, M.C.P.50,
T.C.P.50, T.C.P.67, W.C.P.56, W.C.P.72,
W.C.P.80, C.714, W.G.O.6, T.G.P.25,
W.H.P.18
- see Pregnancy**
- Water Reed stage**
M.A.P.13, W.A.P.86, W.A.P.73, Th.A.P.93,
W.B.P.239, Th.B.P.126, T.C.P.29,
T.C.P.49, T.C.P.88, T.D.P.59
- other**
T.A.O.30, T.A.O.33, Th.A.O.25, Th.A.O.27,
M.A.P.102, M.A.P.110, M.A.P.113,
W.A.P.57, M.A.P.63, W.A.P.70, Th.A.P.83,
Th.A.P.103, A.553, Th.B.O.38, M.B.P.8,
M.B.P.14, M.B.P.29, M.B.P.34, T.B.P.357,
T.B.P.372, W.B.P.146, W.B.P.291,
Th.B.P.49, Th.B.P.127, Th.B.P.182, B.641,
M.C.O.7, W.C.P.46, W.C.P.99, W.C.P.134,
Th.C.P.74, W.D.P.40, Th.D.P.39, D.725
- PROJECTION**
T.A.O.35, T.A.O.36, T.A.O.37, T.A.O.39,
Th.A.O.11, Th.A.O.22, M.A.P.67,
M.A.P.87, M.A.P.89, M.A.P.96, T.A.P.62,
W.A.P.34, Th.A.P.50, Th.A.P.52,
Th.A.P.54, Th.A.P.57, Th.A.P.60,
Th.A.P.61, Th.A.P.63, Th.A.P.67,
Th.A.P.68, Th.A.P.69, Th.A.P.71,
Th.A.P.74, Th.A.P.75, Th.A.P.76,
Th.A.P.77, Th.A.P.79, Th.A.P.80,
Th.A.P.81, Th.A.P.82, A.519, A.524,
A.550, A.551, A.553, A.605, B.593,
Th.E.P.2, M.G.O.29, T.G.P.7, M.H.O.2,
M.H.O.10, M.H.O.18, Th.O.2, W.H.O.15,
Th.P.12, W.H.P.17, W.H.P.19, W.H.P.20,
W.H.P.22, W.H.P.25, Th.H.P.7
- PROLACTIN (PRL)**
Th.B.P.138
- PROLIFERATIVE RESPONSE**
Th.B.P.107, W.C.O.38, W.C.O.40,
Th.C.O.1, M.C.P.8, M.C.P.56, M.C.P.79,
T.C.P.14, T.C.P.27, T.C.P.38, T.C.P.62,
T.C.P.74, T.C.P.77, W.C.P.104, C.535,
C.545, C.554, C.557, C.566, C.711, C.758
- PROMISCUITY**
see Cultural practices
see Sexual behaviour
- PROSTAGLANDINS**
W.B.P.281, Th.B.P.98, W.C.P.120,
W.C.P.131
- PROSTITUTES**
clients
M.A.O.35, W.A.O.30, M.A.P.47, M.A.P.48,
M.A.P.49, A.617, T.D.P.78, T.D.P.80,
W.D.P.41, W.G.O.23, M.G.P.5, Th.G.P.15
see Condoms
geographic
M.A.O.13, M.A.O.15, M.A.P.110, T.A.P.90,
E.521, E.523, W.G.O.24, W.G.P.27,
Th.H.P.17
- intravenous drug users**
M.A.P.28, M.A.P.52, W.B.P.53, Th.D.P.65,
D.682, D.693, E.519
- male**
W.A.P.38, Th.D.O.8, M.D.P.19, W.D.P.31,
M.E.O.31, W.E.P.14, E.519, E.522,
W.F.O.22, M.G.P.20
- prevalence**
Th.A.O.21, Th.A.O.25, M.A.P.28,
M.A.P.46, M.A.P.52, M.A.P.84, A.564,
A.574, W.C.P.136, M.D.O.12, Th.D.O.11,
Th.D.P.23, D.612, D.693, Th.E.P.3, E.523,
W.G.O.26, Th.G.O.25, Th.G.O.26,
M.G.P.13, T.G.P.32, W.G.P.21, W.G.P.27
- prevention**
M.A.O.36, T.A.O.25, M.A.P.117, W.A.P.96,
W.A.P.118, M.D.O.12, Th.D.O.7, Th.D.O.9,
Th.D.O.11, Th.D.O.12, W.D.P.41,
Th.D.P.20, Th.D.P.21, Th.D.P.22,
Th.D.P.66, Th.D.P.91, D.697, T.E.P.70,
W.E.P.71, E.523, E.776, W.G.O.19,
W.G.O.20, W.G.O.21, W.G.O.23,
T.G.P.11, Th.H.P.29
- other**
W.B.P.53, T.B.P.366, Th.B.P.324,
W.C.P.79, Th.D.O.10, T.D.P.80, Th.D.P.3,
Th.D.P.19, D.620, D.682, Th.E.P.78,
E.523, M.F.P.8, W.F.P.6
- PROTEASE**
W.B.P.137, M.G.O.23, T.C.O.11, M.C.P.84,
T.C.P.73, T.C.P.85, T.C.P.130, T.C.P.135,
Th.C.P.4, Th.C.P.10, Th.C.P.66,
Th.C.P.73, Th.C.P.136, C.662, C.666,
C.683, C.694
- PROTEIN KINASE C**
W.C.O.21, T.C.P.98, W.C.P.27, W.C.P.59,
W.C.P.104
- PSEUDOTYPES**
Th.C.P.48
- PSYCHIATRY**
W.B.O.40, W.B.O.41, W.B.O.43,
W.B.O.45a, M.B.P.306, M.B.P.381,
M.B.P.382, M.B.P.383, M.B.P.384,
W.B.P.182, W.B.P.185, W.B.P.191,
W.B.P.201, W.B.P.202, W.B.P.203,
W.B.P.205, W.B.P.206, W.B.P.208,
W.B.P.209, W.B.P.210, W.B.P.211,
W.B.P.212, W.B.P.213, W.B.P.214,
W.B.P.215, W.B.P.216, W.B.P.217,
W.B.P.218, W.B.P.220, W.B.P.223,
W.B.P.224, W.B.P.226, W.B.P.228,
W.B.P.231, W.B.P.236, W.B.P.261,
W.B.P.380, Th.B.P.32, Th.B.P.188,
Th.B.P.217, Th.B.P.221, Th.B.P.267,
Th.B.P.284, Th.B.P.286, Th.B.P.377,
C.584, T.D.P.84, T.D.P.86, D.675, E.659
- PSYCHOIMMUNOLOGIC**
T.B.P.301, W.B.P.68, W.B.P.190,
W.B.P.222, Th.B.P.292, T.D.P.29,
T.D.P.51, D.533, D.675, D.713
- PSYCHOMETRIC**
W.A.O.28, M.B.O.41, W.B.O.43,
W.B.P.185, W.B.P.187, W.B.P.255,
W.B.P.256, W.B.P.259, B.566, T.D.P.30,
T.D.P.51, T.D.P.58, T.D.P.59, D.708, D.713
- see Also Central nervous system**
- PSYCHOSOCIAL**
M.A.O.48, M.A.O.49, Th.A.P.64, A.638,
W.B.O.44, M.B.P.155, M.B.P.306,
T.B.P.300, W.B.P.63, W.B.P.66,
W.B.P.187, W.B.P.199, W.B.P.203,
W.B.P.205, W.B.P.212, W.B.P.219,
W.B.P.269, W.B.P.382, Th.B.P.318, B.595,
M.D.O.2, T.D.O.8, T.D.O.9, W.D.O.2,
M.D.P.41, M.D.P.46, M.D.P.91, T.D.P.22,
T.D.P.44, T.D.P.48, T.D.P.52, T.D.P.53,
T.D.P.60, T.D.P.66, T.D.P.68, T.D.P.70,
T.D.P.72, W.D.P.7, W.D.P.10, W.D.P.17,
W.D.P.31, W.D.P.35, W.D.P.58, D.506,
D.527, D.532, D.551, D.560, D.578, D.600,
D.635, D.638, D.661, D.670, D.674, D.675,
D.678, D.681, D.687, D.689, D.710, D.712,
D.714, D.718, W.E.O.12, W.E.O.15,
Th.E.O.13, M.E.P.2, M.E.P.34, M.E.P.36,
M.E.P.47, M.E.P.57, M.E.P.74, M.E.P.75,
W.E.P.44, Th.E.P.24, E.524, E.527, E.541,
E.675, E.700, E.704, E.761, E.766, E.609
- PSYCHOTHERAPY**
A.581, W.B.P.207, W.B.P.243, W.B.P.261,
W.B.P.380, B.608, W.D.P.14, W.D.P.17,
Th.D.P.88, E.536, D.558, D.577, D.586,
D.654, D.708, D.710, D.719
- PUBLIC POLICY**
W.A.O.7, W.A.O.22, W.A.P.115, A.506,
A.579, A.593, A.597, W.B.P.241,
W.B.P.267, Th.B.P.216, M.C.P.123,
M.D.P.63, Th.D.P.74, M.D.P.67, T.E.O.1,
T.E.O.10, T.E.O.14, T.E.O.15, T.E.O.16,
T.E.O.17, W.E.O.8, W.E.O.25, Th.E.O.7,
Th.E.O.9, M.E.P.3, M.E.P.11, M.E.P.24,
T.E.P.11, T.E.P.21, T.E.P.33, T.E.P.35,
T.E.P.36, T.E.P.37, T.E.P.40, T.E.P.41,
T.E.P.45, T.E.P.46, T.E.P.48, T.E.P.49,
T.E.P.70, T.E.P.72, Th.E.P.68, E.530,
E.536, E.577, E.613, E.633, E.682, E.695,
E.696, E.698, E.721, E.767, E.784,
M.F.O.3, T.F.O.7, M.F.P.10, M.F.P.12,
T.F.P.2, Th.F.P.3, Th.F.P.4, Th.F.P.5,
Th.F.P.9, Th.F.P.10, Th.F.P.11, M.G.O.14,
W.G.O.14, W.G.O.15, W.G.O.25, T.G.P.1,
Th.P.18, G.505, G.510, M.H.O.2,
M.H.O.4, M.H.O.5, M.H.O.8, M.H.O.9,
M.H.O.10, M.H.O.11, M.H.O.16, M.H.O.18,
Th.O.4, Th.O.5, Th.O.13, W.H.O.4,
W.H.O.11, W.H.O.12, W.H.O.15, Th.H.O.4,
M.H.P.10, M.H.P.20, Th.P.3, Th.P.5,
Th.P.6, Th.P.8, Th.P.9, Th.P.11,
Th.P.14, Th.P.19, Th.P.20, W.H.P.8,
W.H.P.11, Th.H.P.1, Th.H.P.3, Th.H.P.4,
Th.H.P.5
- PUROMYCIN**
M.C.P.90
- PWA**
see Persons with AIDS
- PWARC**
see Persons with ARC
- PYRIMETHAMINE-SULFADOXINE**
T.B.P.43, T.B.P.46, W.B.P.34

QUALITY OF LIFE

M.B.P.28, M.B.P.307, M.B.P.311,
T.B.P.300, W.B.P.66, W.B.P.262,
Th.B.P.318, T.D.P.50, T.D.P.52, T.D.P.62,
W.D.P.9, W.D.P.13, D.543, D.577, D.578,
T.E.P.25, T.E.P.53

QUINOLIZINE

M.C.P.108

QUINOLONES

M.B.P.89, Th.B.P.232, M.C.P.147, C.624

RADIATION, ULTRAVIOLET

W.A.P.117, W.B.P.82, W.C.P.70,
Th.C.P.20, E.802

RECOMBINANT SOLUBLE CD4

(RCD4)

Th.B.O.6, T.B.P.303, M.C.O.15, T.C.O.18,
Th.C.O.5, Th.C.O.11, Th.C.O.13,
Th.C.O.14, Th.C.O.15, Th.C.O.16,
M.C.P.49, M.C.P.89, M.C.P.97, M.C.P.127,
M.C.P.129, M.C.P.137, T.C.P.96,
T.C.P.116, W.C.P.135, Th.C.P.22, C.627

linked toxin

Th.C.O.12, M.C.P.72

REGIONAL

see Geographical aspects

REGULATION

by cellular factor

T.B.P.322, T.C.P.20, T.C.P.83, T.C.P.101,
T.C.P.113, T.C.P.117, T.C.P.118,
T.C.P.133, W.C.P.17, W.C.P.91,
W.C.P.105, W.C.P.121, Th.C.P.15,
Th.C.P.29

herpes viruses

T.C.P.78

LTR

M.C.O.24, M.C.O.31, M.C.O.31, T.C.O.12,
T.C.O.14, T.C.O.15, T.C.O.16, T.C.O.30,
W.C.O.22, Th.C.O.23, T.C.P.91, T.C.P.94,
T.C.P.101, T.C.P.103, T.C.P.118,
T.C.P.120, T.C.P.133, T.C.P.136,
W.C.P.121, Th.C.P.19, Th.C.P.20,
Th.C.P.71, Th.C.P.93, C.525, C.646,
C.658, C.670

nef

W.C.O.33, W.C.O.37, Th.C.O.25,
M.C.P.31, T.C.P.120, T.C.P.127,
T.C.P.129, T.C.P.132, T.C.P.139,
W.C.P.91, Th.C.P.23

Pol

T.C.P.137

REV

T.C.P.80, T.C.P.81, T.C.P.102, T.C.P.114,
T.C.P.127, T.C.P.129, T.C.P.139,
Th.C.P.140, C.647, C.667

TAR

T.C.O.27, T.C.O.29, T.C.O.31, T.C.P.93,
T.C.P.136

TAT

T.C.O.29, T.C.O.31, T.C.P.83, T.C.P.87,
T.C.P.89, T.C.P.93, T.C.P.94, T.C.P.101,
T.C.P.103, T.C.P.127, T.C.P.129,
T.C.P.139, C.645, C.646, C.776, C.782

other

W.B.P.241, T.C.O.13, T.C.O.15, T.C.O.45,
W.C.O.5, T.C.P.104, W.C.P.121,
Th.C.P.67, C.606, C.646, C.649, C.789

REITER'S SYNDROME

W.B.O.17

RELATED DISEASES

see AIDS-related complex

see Sexually transmitted disease

RELIGION AND MORALITY

M.E.O.11, W.E.O.27, W.E.O.28, W.E.O.30,
T.E.P.29, Th.E.P.40, Th.E.P.41, Th.E.P.42,
Th.E.P.44, Th.E.P.61, E.733, E.734,
W.F.O.14

REPLICATION

assembly

T.C.O.6, W.C.O.36, T.C.P.99, Th.C.P.90

endocytosis

Th.C.P.150

env processing

M.C.P.146, Th.C.P.122

high molecular weight RNA

T.C.P.129

kinetics

T.C.P.144, W.C.P.70, Th.C.P.27,
Th.C.P.41, Th.C.P.89, Th.C.P.93,
Th.C.P.116, C.743

recombination

B.561, M.C.O.19, T.C.O.19, Th.C.P.28,
Th.C.P.31, Th.C.P.32, Th.C.P.33,
Th.C.P.56, C.703

small nuclear RNAs

M.C.P.78, T.C.P.80

syncytia

M.C.O.8, T.C.O.20, Th.C.O.2, Th.C.O.4,
M.C.P.1, M.C.P.75, M.C.P.147, W.C.P.46,
Th.C.P.61, Th.C.P.63, Th.C.P.116,
Th.C.P.150, C.550, C.582, C.743, C.750

other

T.B.P.118, T.B.P.314, W.B.P.146,
W.B.P.357, B.547, M.C.O.19, T.C.O.47,
W.C.O.9, W.C.O.24, W.C.O.36, W.C.O.37,
Th.C.O.17, Th.C.O.19, M.C.P.39,
M.C.P.112, M.C.P.121, T.C.P.20,
T.C.P.104, T.C.P.110, T.C.P.119,
T.C.P.145, W.C.P.108, W.C.P.118,
W.C.P.144, Th.C.P.64, Th.C.P.90,
Th.C.P.147, C.585, C.597, C.789

REPORTING

T.A.O.3, T.A.O.5, T.A.O.6, T.A.O.7,
T.A.O.26, T.A.O.27, W.A.O.13, T.A.P.9,
T.A.P.25, T.A.P.61, T.A.P.64, T.A.P.66,
T.A.P.68, T.A.P.69, T.A.P.70, T.A.P.72,
T.A.P.73, T.A.P.74, T.A.P.77, T.A.P.78,
W.A.P.15, W.A.P.60, Th.A.P.115, A.530,
A.551, A.590, T.D.O.11, M.F.P.19, E.559,
E.738, T.F.O.11, M.F.P.10, Th.E.P.4,
Th.C.P.18, W.H.P.15, W.H.P.17, W.H.P.22

REPRODUCTION

Th.B.P.277

RESEARCH PRIORITIES

M.C.P.61, M.G.P.23

RESOURCE ALLOCATION

T.A.P.3, A.504, W.B.P.63, W.B.P.241,
W.B.P.262, M.F.P.69, T.E.P.58, T.E.P.71,

Th.E.P.67, E.531, T.F.O.11, W.G.O.17,
T.G.P.4, M.H.O.8, M.H.O.15, M.H.O.16,
Th.O.2, Th.O.5, Th.O.9, Th.O.11,
W.H.O.11, Th.H.O.4, Th.H.P.1, Th.H.P.9,
Th.H.P.18, Th.H.P.26

RESUSCITATION

A.599, T.B.P.31, T.B.P.294, T.F.O.19

RETINITIS

M.B.P.52, M.B.P.225, M.B.P.228,
M.B.P.229, M.B.P.230

RETINOL BINDING

Th.B.P.306

RETROVIR

see Zidovudine

RETROVIRUSES (OTHER THAN HIV)

see under specific viruses

REVERSE TRANSCRIPTASE

M.B.P.336, T.B.P.110, W.B.P.118,
W.B.P.147, Th.B.P.184, M.C.O.31,
M.C.O.31, T.C.O.2, T.C.O.4, W.C.O.24,
W.C.O.43, Th.C.O.9, M.C.P.76,
M.C.P.106, M.C.P.108, M.C.P.115,
M.C.P.118, M.C.P.125, T.C.P.108,
T.C.P.126, W.C.P.146, W.C.P.111,
Th.C.P.2, Th.C.P.82, Th.C.P.84,
Th.C.P.103, Th.C.P.116, Th.C.P.118,
Th.C.P.120, Th.C.P.123, Th.C.P.128,
C.585, C.597, C.624, C.666, C.672, C.681,
C.682

RHODOTRULA RUBRA

M.B.P.83

RIBAVIRIN

Th.A.P.43, Th.B.O.1, Th.B.O.2, T.B.P.294,
T.B.P.296, T.B.P.302, M.C.P.88, C.677

RIBOZYMES

Th.C.O.22, M.C.P.58

RISK FACTORS

see Intravenous drug users

see Sexual behaviour

see Transmission

RISK, PERCEPTION

T.A.O.22, W.A.P.51, W.A.P.91, A.570,
M.B.P.4, M.B.P.142, M.D.O.15, Th.D.O.8,
M.D.P.52, M.D.P.64, M.D.P.82, M.D.P.83,
M.D.P.64, M.D.P.78, T.D.P.7, T.D.P.16,
T.D.P.27, T.D.P.51, W.D.P.69, W.D.P.92,
Th.D.P.5, Th.D.P.8, Th.D.P.11, D.595,
D.624, D.631, D.636, D.664, D.671
W.E.O.19, M.E.P.18, M.E.P.33, W.E.P.40,
W.E.P.65, E.501, E.716, E.724, E.749,
E.785, E.802, T.F.P.5, T.F.P.6, T.F.P.7,
T.F.P.9, T.F.P.10, Th.F.P.12, T.G.O.7,
M.G.P.31, T.G.P.23

RISK (PREDICTORS OF HIV

INFECTION)

M.A.O.3, M.A.O.8, M.A.O.21, M.A.O.32,
M.A.O.41, T.A.O.14, T.A.O.17, T.A.O.19,
Th.A.O.16, Th.A.O.20, Th.A.O.21,
Th.A.O.23, M.A.P.1, M.A.P.4, M.A.P.12,
M.A.P.15, M.A.P.23, M.A.P.48, M.A.P.57,
M.A.P.66, T.A.P.9, T.A.P.10, T.A.P.12,
T.A.P.18, T.A.P.20, T.A.P.24, T.A.P.43,
T.A.P.45, T.A.P.50, T.A.P.85, T.A.P.87,
T.A.P.96, T.A.P.98, T.A.P.99, T.A.P.103,

- T.A.P.105, T.A.P.110, T.A.P.112,
T.A.P.118, T.A.P.119, T.A.P.120, W.A.P.3,
W.A.P.4, W.A.P.6, W.A.P.8, W.A.P.12,
W.A.P.36, W.A.P.37, W.A.P.38, W.A.P.43,
W.A.P.48, W.A.P.107, Th.A.P.20,
Th.A.P.45, Th.A.P.66, A.513, A.562,
A.580, A.587, A.615, A.637, M.B.O.20,
M.B.P.5, M.B.P.23, M.B.P.28, M.B.P.33,
M.B.P.54, M.B.P.141, M.B.P.150,
M.B.P.276, T.B.P.217, T.B.P.352,
W.B.P.53, W.B.P.223, W.B.P.266,
W.B.P.270, M.D.O.4, M.C.P.111, C.515,
M.D.O.1, M.D.O.10, T.D.O.9, T.D.O.13,
Th.D.O.14, M.D.P.25, M.D.P.35, T.D.P.20,
T.D.P.51, T.D.P.67, T.D.P.71, W.D.P.5,
W.D.P.56, W.D.P.70, W.D.P.92, Th.D.P.1,
Th.D.P.2, Th.D.P.31, Th.D.P.48,
Th.D.P.49, Th.D.P.51, Th.D.P.60,
Th.D.P.63, Th.D.P.65, D.508, D.511,
D.541, D.561, D.587, D.611, D.620,
Th.E.P.21, E.558, T.F.O.19, Th.G.O.53,
W.G.P.3, G.509, W.H.P.23, Th.H.P.19,
Th.H.P.20, Th.H.P.24
- RNASE H**
Th.C.P.103
- ROTAVIRUS**
W.B.P.42, W.B.P.42
- ROXITHROMYCIN**
W.B.P.29
- SAFER SEX**
see Sexual behaviour
- SAFETY, HEALTH CARE**
see Health care personnel
- SALIVA**
T.A.O.9, Th.B.P.347, Th.B.P.353, B.564,
C.522
- SCHONLEIN-HENOCH PURPURA**
M.B.P.278
- SCHOOLS**
see Education
- SCLEROTHERAPY**
M.B.P.206
- SCREENING, COST**
W.A.O.25, W.A.P.2, A.532, T.B.P.132,
T.B.P.133, T.B.P.134, T.B.P.136,
T.B.P.137, T.B.P.138, T.B.P.140,
T.B.P.351, W.B.P.156, B.560, T.E.P.44,
Th.E.P.17, Th.E.P.23, E.719, M.G.O.3,
M.G.O.4, M.H.O.4, M.H.O.5, Th.H.O.7,
W.H.P.1
see also Serologic tests
- SELENIUM**
T.B.P.256, Th.B.P.310
- SELF-HELP**
M.A.P.20, D.590, M.E.O.26, E.779
- SEMEN**
T.A.P.92, W.A.P.102, A.623, A.624, B.501,
B.578, M.C.O.29, W.C.O.29, T.C.P.22,
T.C.P.99, W.C.P.86, C.515, C.651, C.652,
C.787
see also Isolation
- SEPTIC ARTHRITIS**
Th.B.P.7
- SEROCONVERSION**
M.A.O.1, M.A.O.26, M.A.O.34, T.A.O.11,
Th.A.O.5, Th.A.O.10, Th.A.O.21, M.A.P.11,
M.A.P.29, M.A.P.34, T.A.P.21, T.A.P.28,
T.A.P.41, T.A.P.56, T.A.P.109, T.A.P.115,
T.A.P.116, W.A.P.46, W.A.P.59, W.A.P.61,
W.A.P.68, W.A.P.71, Th.A.P.25,
Th.A.P.67, Th.A.P.94, Th.A.P.95,
Th.A.P.96, Th.A.P.119, A.503, A.612,
A.618, M.B.P.140, M.B.P.148, M.B.P.152,
M.B.P.154, M.B.P.174, M.B.P.349,
T.B.P.90, T.B.P.93, T.B.P.232, T.B.P.237,
T.B.P.354, W.B.P.97, W.B.P.106,
W.B.P.125, W.B.P.127, W.B.P.129,
W.B.P.163, W.B.P.162, W.B.P.165,
W.B.P.341, Th.B.P.20, Th.B.P.53,
Th.B.P.176, Th.B.P.178, Th.B.P.179,
Th.B.P.288, Th.B.P.370, Th.B.P.371,
B.515, B.538, B.617, B.619, B.633, B.636,
M.C.P.9, T.C.P.49, W.C.P.4, W.C.P.41,
W.C.P.129, W.C.P.143, Th.C.P.21,
Th.C.P.70, C.781, Th.D.P.53, Th.D.P.59,
Th.D.P.68, M.G.O.27, T.G.O.20,
Th.G.O.25, Th.G.O.36, W.H.P.18
- SEROLOGIC TESTS**
attitudes
T.A.P.2, T.A.P.18, A.523, A.619, A.638,
T.B.P.145, T.B.P.160, T.B.P.359,
W.B.P.252, M.D.P.51, D.526, D.635,
Th.E.P.7, Th.E.P.10, Th.E.P.12, Th.E.P.15,
Th.E.P.17, Th.E.P.26, Th.E.P.27,
Th.E.P.30, E.550, E.717, E.722, E.723,
E.727, E.731
behaviour
W.A.O.26, T.A.P.101, A.523, M.B.P.142,
B.627, T.D.P.24, T.D.P.47, M.E.P.51,
Th.E.P.8, Th.E.P.9, Th.E.P.18, Th.E.P.29,
Th.E.P.30, E.708, E.715, E.717, E.723,
E.724
blood banks
M.A.O.11, M.A.P.33, M.A.P.36, M.A.P.40,
M.A.P.85, Th.A.P.13, A.502, A.527,
M.B.P.139, M.B.P.141, M.B.P.152,
M.B.P.154, M.B.P.157, M.B.P.167,
T.B.P.132, T.B.P.133, T.B.P.134,
T.B.P.350, T.B.P.351, T.B.P.354,
W.B.P.154, W.B.P.157, B.510, B.515,
B.605, E.710, E.719, M.F.P.9, M.G.O.6,
Th.H.P.18
comparisons
M.A.P.67, M.A.P.71, M.A.P.83, M.A.P.100,
M.A.P.119, T.A.P.13, T.A.P.79, T.A.P.81,
M.P.11, Th.A.P.1, Th.A.P.7, Th.A.P.24,
Th.A.P.38, Th.A.P.40, Th.A.P.107,
Th.A.P.108, Th.A.P.110, Th.A.P.112,
Th.A.P.117, A.568, A.617, A.623, A.629,
M.B.O.26, M.B.O.27, T.B.O.9, Th.B.O.9,
Th.B.O.10, Th.B.O.56, Th.B.O.57,
M.B.P.40, M.B.P.163, M.B.P.164,
M.B.P.168, M.B.P.170, M.B.P.172,
M.B.P.173, M.B.P.357, T.B.P.11, T.B.P.92,
T.B.P.101, T.B.P.102, T.B.P.104,
T.B.P.108, T.B.P.116, T.B.P.119,
T.B.P.121, T.B.P.126, T.B.P.127,
T.B.P.130, T.B.P.131, T.B.P.135,
T.B.P.137, T.B.P.141, T.B.P.142,
T.B.P.143, T.B.P.144, T.B.P.230,
- T.B.P.231, T.B.P.232, T.B.P.243,
T.B.P.337, T.B.P.338, T.B.P.348,
W.B.P.100, W.B.P.101, W.B.P.102,
W.B.P.104, W.B.P.108, W.B.P.112,
W.B.P.113, W.B.P.114, W.B.P.116,
W.B.P.117, W.B.P.129, W.B.P.131,
W.B.P.138, W.B.P.143, W.B.P.150,
W.B.P.156, W.B.P.159, W.B.P.160,
W.B.P.166, W.B.P.168, W.B.P.171,
W.B.P.172, W.B.P.173, W.B.P.174,
W.B.P.179, Th.B.P.110, Th.B.P.128,
Th.B.P.169, Th.B.P.170, Th.B.P.176,
Th.B.P.338, Th.B.P.365, Th.B.P.369,
B.536, B.539, B.549, B.561, B.563, B.566,
B.603, B.605, B.617, B.618, B.624, B.629,
B.635, B.642, M.C.P.100, M.C.P.111,
T.C.P.46, W.C.P.59, Th.C.P.37, Th.C.P.46,
Th.C.P.55, Th.C.P.86, C.569, W.D.P.49,
Th.E.P.7, Th.E.P.21, Th.E.P.25, Th.E.P.28,
E.710, E.718, E.719, E.730, E.731,
W.G.P.1, W.G.P.15, Th.G.P.9, Th.H.P.18
counseling
M.A.P.55, M.A.P.56, M.A.P.75, M.A.P.76,
M.B.P.155, B.554, T.D.O.18, W.D.P.15,
T.E.O.10, Th.E.P.9, Th.E.P.10, Th.E.P.29,
E.678, E.712, E.717, E.720, M.G.O.17
ethical and legal aspects
M.B.P.152, B.552, Th.E.P.14, Th.E.P.29,
T.F.O.13
evaluation
W.A.O.9, Th.A.O.10, Th.A.O.14,
M.A.P.118, T.A.P.81, T.A.P.108, Th.A.P.2,
Th.A.P.88, Th.A.P.107, Th.A.P.108,
Th.A.P.116, Th.A.P.118, A.509, A.512,
A.534, A.552, A.593, M.B.O.25, M.B.O.27,
Th.B.O.9, Th.B.O.59, M.B.P.99,
M.B.P.107, M.B.P.153, M.B.P.170,
M.B.P.218, M.B.P.361, T.B.P.82, T.B.P.97,
T.B.P.100, T.B.P.113, T.B.P.120,
T.B.P.123, T.B.P.125, T.B.P.126,
T.B.P.127, T.B.P.131, T.B.P.141,
T.B.P.142, T.B.P.144, T.B.P.145,
T.B.P.201, T.B.P.221, T.B.P.233,
T.B.P.241, T.B.P.242, T.B.P.332,
T.B.P.333, T.B.P.335, T.B.P.336,
T.B.P.339, T.B.P.342, T.B.P.347, W.B.P.6,
W.B.P.17, W.B.P.97, W.B.P.100,
W.B.P.102, W.B.P.103, W.B.P.113,
W.B.P.129, W.B.P.147, W.B.P.153,
W.B.P.154, W.B.P.161, W.B.P.162,
W.B.P.169, W.B.P.170, W.B.P.171,
W.B.P.172, W.B.P.175, W.B.P.177,
W.B.P.178, W.P.200, Th.B.P.112,
Th.B.P.123, Th.B.P.149, B.542, B.548,
B.549, B.550, B.551, B.554, B.556, B.557,
B.561, B.578, B.619, B.623, B.635, B.636,
B.640, B.644, M.C.P.100, Th.C.P.80,
Th.C.P.104, C.519, C.589, C.622, C.765,
C.778, Th.E.P.24, Th.E.P.21, Th.E.P.31,
E.709, E.730, E.731, M.G.O.5, W.G.P.15,
Th.G.P.7, Th.G.P.8, Th.G.P.9, Th.H.P.18
see HIV-2
see HTLV-I
in hospitals
T.A.O.5, M.A.P.10, M.A.P.16, T.A.P.23,
W.A.P.8, Th.A.P.9, Th.A.P.12, A.521,
A.529, A.558, A.562, T.B.P.126,

- T.B.P.127, T.B.P.144, B.510, T.H.E.P.15, Th.E.P.28, T.G.O.20, M.G.P.15
- mandatory**
 M.A.O.1, W.A.O.25, W.B.P.228, T.E.P.56, W.E.P.76, Th.E.P.91, E.721
- pregnancy and perinatal**
 T.A.O.18, W.A.O.8, W.A.O.9, W.A.O.11, W.A.O.12, M.A.P.6, M.A.P.8, M.A.P.12, M.A.P.15, W.A.P.2, W.A.P.8, W.A.P.8, W.A.P.11, W.A.P.52, Th.A.P.39, M.B.P.2, M.B.P.5, M.B.P.8, M.B.P.12, M.B.P.14, M.B.P.25, M.B.P.29, M.B.P.30, M.B.P.31, M.B.P.34, T.B.P.160, T.B.P.195, T.B.P.198, T.B.P.202, T.B.P.212, T.B.P.217, T.B.P.220, T.B.P.221, T.B.P.238, T.B.P.343, Th.B.P.34, B.503, B.504, B.585, W.D.P.58, Th.E.P.16, Th.E.P.23, Th.E.P.27, E.716, T.G.O.19, W.G.O.26, W.G.O.30, W.G.O.30, Th.G.O.28, Th.G.O.51, M.G.P.16, M.G.P.18, Th.G.P.2, G.507
- premarital**
 W.A.O.25, Th.E.P.16, Th.E.P.31, W.F.P.4
- prisoners**
 M.A.O.42, M.A.P.19, M.A.P.21, M.A.P.23, D.723, Th.E.P.32, E.721
- psychology**
 A.638, T.B.P.160, T.B.P.192, W.B.P.192, W.B.P.194, W.D.P.29, W.B.P.228, D.714, M.E.P.51, Th.E.P.9, Th.E.P.24, E.729
- saliva antibodies**
 T.B.P.238, W.B.P.156, T.C.P.64
- STD clinics**
 M.A.O.20, M.A.O.22, M.A.O.23, M.A.O.25, Th.A.O.18, M.A.P.54, M.A.P.57, M.A.P.58, M.A.P.61, M.A.P.62, M.A.P.66, M.A.P.67, M.A.P.68, M.A.P.69, M.A.P.72, M.A.P.73, M.A.P.74, Th.A.P.86, Th.A.P.3, Th.A.P.52, Th.A.P.89, Th.A.P.112, Th.A.P.118, Th.A.P.16, A.523, A.528, A.580, A.614, M.D.P.28, M.D.P.30, W.D.P.82, D.557, W.E.P.53, Th.E.P.8, Th.E.P.18, Th.E.P.25, Th.E.P.28, E.713, E.716, E.724, T.G.O.22, Th.G.O.31, Th.G.O.35, T.G.P.18, W.G.P.4, W.G.P.28, W.G.P.29, Th.G.P.5
- other**
 M.A.O.6, M.A.O.14, M.A.O.17, M.A.O.21, M.A.O.28, T.A.O.5, Th.A.O.19, M.A.P.2, M.A.P.4, M.A.P.9, M.A.P.22, M.A.P.48, M.A.P.60, M.A.P.104, T.A.P.6, T.A.P.16, T.A.P.17, T.A.P.27, T.A.P.38, W.A.P.3, W.A.P.87, Th.A.P.34, Th.A.P.37, Th.A.P.96, A.501, A.511, A.514, A.515, A.518, A.520, A.525, A.584, A.585, A.629, M.B.P.5, M.B.P.125, M.B.P.145, M.B.P.149, M.B.P.174, T.B.P.138, T.B.P.333, T.B.P.336, T.B.P.341, T.B.P.357, W.B.P.56, W.B.P.90, W.B.P.115, W.B.P.148, W.B.P.173, W.B.P.176, Th.B.P.85, Th.B.P.114, Th.B.P.154, Th.B.P.175, Th.B.P.231, Th.B.P.236, Th.B.P.271, B.511, B.617, B.622, B.643, W.C.O.47, Th.C.O.46, W.C.P.23, Th.C.O.128, C.766, M.D.O.6, T.D.O.9, M.D.P.10, W.D.P.8, Th.D.P.63, D.586, Th.E.O.4, W.E.P.31, Th.E.P.7, Th.E.P.13, Th.E.P.25, E.714, E.728, E.783, M.G.P.22, M.G.P.25, T.G.P.10, W.G.P.2, W.G.P.30, Th.G.P.26, Th.G.P.30, G.501, G.503, G.512, G.515
- SEROVERSION**
 W.A.P.45, A.616, T.B.P.240, W.B.P.54, W.B.P.176, T.C.P.134, C.502, W.D.P.6
- SEROTONIN**
 W.B.P.194, Th.B.P.224, Th.B.P.237
- SERUM ENHANCING FACTORS**
 see Antibody-dependent enhancement
 see Complement-dependent enhancement
- SERVICE UTILIZATION**
 M.A.O.24, M.A.P.59, W.A.P.98, A.504, A.506, A.597, A.608, A.627, A.628, B.607, Th.D.P.15, M.E.P.55, M.E.P.56, E.541, T.G.P.4, M.H.O.9, M.H.O.11, M.H.O.17, Th.O.2, M.H.P.1, M.H.P.2, M.H.P.9, M.H.P.11, M.H.P.12, M.H.P.17, T.H.P.3, T.H.P.7, T.H.P.8, T.H.P.9, T.H.P.12, Th.H.P.3, Th.H.P.5, Th.H.P.10, Th.H.P.11
- SEXUAL BEHAVIOUR**
 analysis of risks
 T.A.O.16, T.A.O.40, W.A.O.27, M.A.P.47, T.A.P.83, T.A.P.105, T.A.P.117, W.A.P.40, W.A.P.45, W.A.P.91, W.A.P.116, Th.A.P.52, Th.A.P.57, A.507, A.522, A.524, M.B.O.19, M.B.P.28, T.B.P.341, T.D.O.8, T.D.O.21, T.D.O.29, W.D.O.1, W.D.O.4, M.D.P.3, M.D.P.4, M.D.P.5, M.D.P.19, M.D.P.23, M.D.P.25, M.D.P.26, M.D.P.28, M.D.P.30, M.D.P.83, T.D.P.1, T.D.P.6, T.D.P.17, T.D.P.18, T.D.P.19, T.D.P.28, T.D.P.37, T.D.P.75, T.D.P.80, T.D.P.82, T.D.P.92, W.D.P.90, W.D.P.96, W.D.P.46, W.D.P.51, W.D.P.52, W.D.P.70, W.D.P.92, Th.D.P.3, Th.D.P.6, Th.D.P.17, Th.D.P.19, Th.D.P.23, Th.D.P.25, Th.D.P.30, Th.D.P.53, Th.D.P.57, Th.D.P.60, Th.D.P.83, D.507, D.510, D.518, D.527, D.529, D.547, D.580, D.665, D.666, D.673, D.702, D.723, D.723, M.E.O.32, W.E.P.31, Th.E.P.11, Th.E.P.37, Th.E.P.48, Th.E.P.54, E.515, E.522, E.651, E.612, W.G.O.22, W.G.O.24, Th.G.O.30, W.G.P.11, W.G.P.20, Th.G.P.15, Th.G.P.23, G.520, W.H.P.24
- and testing**
 M.A.O.22, M.A.P.21, T.A.P.8, Th.B.P.178, T.D.O.11, E.712
- bisexuals**
 M.A.P.76, M.A.P.120, T.A.P.21, T.A.P.58, T.A.P.113, W.A.P.24, W.A.P.39, W.A.P.92, T.D.O.8, W.D.O.6, M.D.P.23, M.D.P.28, M.D.P.31, T.D.P.18, T.D.P.20, T.D.P.33, T.D.P.35, T.D.P.38, W.D.P.9, W.D.P.27, W.D.P.89, D.528, D.555, D.713, M.E.P.36, M.E.P.43, W.E.P.7, Th.E.P.48, Th.E.P.74, Th.E.P.75, E.544, M.G.P.14
- gay men**
 M.A.O.42, Th.A.O.16, M.A.P.76, M.A.P.120, T.A.P.20, T.A.P.21, T.A.P.58, T.A.P.84, W.A.P.24, W.A.P.36, W.A.P.39, W.A.P.42, W.A.P.44, W.A.P.69, W.A.P.92, Th.A.P.33, Th.A.P.42, A.524, A.570, Th.B.P.178, B.627, Th.C.O.36, T.D.O.22, M.D.P.15, M.D.P.22, M.D.P.23, M.D.P.28, M.D.P.34, M.D.P.38, T.D.P.4, T.D.P.12, T.D.P.33, T.D.P.35, T.D.P.36, T.D.P.39, T.D.P.42, T.D.P.43, T.D.P.47, W.D.P.3, W.D.P.27, W.D.P.70, W.D.P.89, W.D.P.92, Th.D.P.88, D.528, D.529, D.531, D.555, D.701, D.713, Th.E.O.16, M.E.P.2, T.E.P.1, T.E.P.6, T.E.P.8, T.E.P.29, T.E.P.47, W.E.P.7, Th.E.P.48, Th.E.P.74, Th.E.P.75, E.517, E.544
- heterosexuals**
 T.A.O.16, W.A.O.19, M.A.P.107, T.A.P.14, T.A.P.40, T.A.P.84, T.A.P.91, T.A.P.94, T.A.P.97, T.A.P.100, T.A.P.101, T.A.P.105, T.A.P.106, T.A.P.112, W.A.P.18, W.A.P.21, Th.A.P.11, Th.A.P.59, A.604, A.635, M.B.P.28, M.B.P.141, B.557, M.D.O.3, T.D.O.20, Th.D.O.14, M.D.P.13, T.D.P.1, T.D.P.2, T.D.P.34, T.D.P.43, T.O.P.7, W.D.P.53, W.D.P.55, W.D.P.83, W.D.P.90, Th.D.P.21, Th.D.P.83, D.541, D.678, D.721, D.722, T.E.P.47, Th.G.P.4, Th.G.P.29
- intravenous drug users**
 T.A.O.13, T.A.P.31, T.A.P.40, T.A.P.47, T.A.P.112, T.A.P.113, W.A.P.88, Th.A.P.64, Th.A.P.101, M.B.P.27, W.D.O.5, Th.D.O.5, Th.D.O.15, T.D.P.77, W.D.P.82, W.D.P.84, W.D.O.15, W.D.P.85, Th.D.P.8, Th.D.P.12, Th.D.P.42, Th.D.P.47, Th.D.P.64, Th.D.P.65, Th.D.P.83, D.589, D.597, D.601, T.E.P.17, T.E.P.38, Th.E.P.4
- safer sex**
 M.A.O.22, M.A.O.37, M.A.P.47, M.A.P.120, T.A.P.76, W.A.P.44, W.A.P.93, W.A.P.100, W.A.P.116, A.570, A.636, M.B.P.4, W.B.P.178, M.D.O.4, T.D.O.8, T.D.O.20, W.D.O.2, M.D.P.21, M.D.P.27, M.D.P.38, T.D.P.31, T.D.P.36, T.D.P.43, T.D.P.76, T.D.P.83, T.D.P.91, W.D.P.57, Th.D.P.81, Th.D.P.89, D.551, M.E.O.10, M.E.O.33, Th.E.O.16, M.E.P.43, T.E.P.1, T.E.P.3, T.E.P.6, T.E.P.8, T.E.P.12, T.E.P.21, W.E.P.5, W.E.P.10, W.E.P.71, W.E.P.72, Th.E.P.39, Th.E.P.73, E.519, E.525, E.544, E.619, E.653, E.724, T.G.O.8, T.G.O.11
- seropositive partners**
 T.A.O.16, T.A.O.17, W.A.O.19, W.A.O.22, M.A.P.107, T.A.P.88, T.A.P.90, T.A.P.95, T.A.P.98, T.A.P.104, T.A.P.109, T.A.P.114, W.A.P.40, W.A.P.93, Th.A.P.1, Th.A.P.71, W.B.P.367, Th.B.P.33, Th.B.P.34, C.739, T.D.O.35, T.D.P.41, T.D.P.83, W.D.P.2, Th.D.P.4, D.571, D.576, D.686, T.E.P.29
- other**
 A.515, M.D.O.1, Th.E.P.22, E.649
 see also Prostitutes; Transmission
- SEXUAL DYSFUNCTION**
 W.B.P.189, B.608, T.D.O.22, E.548
- SEXUALLY TRANSMITTED DISEASES (STD)**
 M.A.O.23, M.A.O.34, Th.A.O.17, Th.A.O.21, M.A.P.53, M.A.P.90, T.A.P.32,

- T.A.P.58, T.A.P.76, T.A.P.83, T.A.P.84, T.A.P.87, T.A.P.91, T.A.P.102, T.A.P.118, T.A.P.119, W.A.P.37, W.A.P.39, W.A.P.45, W.A.P.85, Th.A.P.16, Th.A.P.51, Th.A.P.100, A.506, M.B.P.57, M.B.P.146, M.B.P.181, W.B.P.51, W.B.P.53, W.B.P.56, B.557, W.C.P.86, T.D.O.25, T.D.P.2, T.D.P.17, W.D.P.3, W.D.P.15, W.D.P.20, W.D.P.52, W.D.P.55, Th.D.P.23, Th.D.P.44, D.507, D.659, D.693, D.696, T.E.P.24, E.716, E.722, E.735, Th.G.O.36, Th.G.O.53, M.G.P.2, W.G.P.16, Th.G.P.18, W.G.P.21, W.G.P.28, Th.G.P.5, Th.G.P.24
- SHO-SAIKO-TOH**
W.B.P.292, M.C.P.144, M.C.P.148
- SIAMIAN D-TYPE RETROVIRUS**
T.C.O.39, W.C.P.32, W.C.P.52, W.C.P.146, W.C.P.147
- SINUSITIS**
M.B.P.203
- SIV**
M.C.O.5, M.C.O.6, M.C.O.25, T.C.O.17, T.C.O.30, T.C.O.36, T.C.O.40, T.C.O.41, T.C.O.42, T.C.O.43, T.C.O.45, W.C.O.12, W.C.O.42, W.C.O.45, M.C.O.50, M.C.P.16, M.C.P.33, M.C.P.45, M.C.P.47, T.C.P.10, T.C.P.190, T.C.P.115, T.C.P.134, W.C.P.7, W.C.P.9, W.C.P.10, W.C.P.12, W.C.P.15, W.C.P.18, W.C.P.23, W.C.P.25, W.C.P.30, W.C.P.33, W.C.P.34, W.C.P.75, W.C.P.89, Th.C.P.23, Th.C.P.58, Th.C.P.78, Th.C.P.89, Th.C.P.107, C.502, C.510, C.540, C.681, C.696, C.746, C.758
- SJOGREN'S SYNDROME**
Th.B.P.116
- SKIN DISEASES**
epithelioid angiomatosis
M.B.P.36
herpes zoster
M.B.P.176, M.B.P.178, M.B.P.188, Th.G.O.35, W.G.P.24
psoriasis
Th.A.P.107, W.B.O.17, M.B.P.187, M.B.P.365, T.B.P.330, B.530
Steven Johnson's syndrome
T.B.P.43
other
M.B.P.111, M.B.P.176, M.B.P.177, M.B.P.180, M.B.P.181, M.B.P.182, M.B.P.183, M.B.P.184, M.B.P.185, M.B.P.186, M.B.P.188, T.B.P.149, T.B.P.282, T.B.P.299, T.B.P.316, T.B.P.371, T.B.P.372, T.B.P.373, W.B.P.49, W.B.P.297, Th.B.P.71, Th.B.P.328, B.530, B.594
- SKIN TESTS**
DTH
W.B.P.274, W.B.P.279, Th.B.P.82, Th.B.P.114, Th.B.P.115, W.C.P.97, W.C.P.145
other
B.639, B.639
- SMOKING**
T.A.O.18, Th.B.P.75
- SMS 201-995**
C.612
- SOCIAL IMPACT**
M.B.P.305, W.B.P.215, B.607, W.D.P.67, D.543, Th.E.O.13, Th.E.P.19, E.510, M.F.P.8, M.F.P.11, T.F.P.5, Th.F.P.12, M.G.P.30, T.G.P.13, T.G.P.15, W.H.P.14
- SOCIAL SUPPORT**
W.B.O.40, M.B.P.311, W.B.P.64, W.B.P.219, W.B.P.238, W.B.P.262, B.595, B.646, C.618, M.D.P.46, D.575, D.677, D.690, M.E.O.17, T.E.O.1, M.E.P.64, M.E.P.65, M.E.P.69, E.510, E.532, E.533
- SOCIOECONOMIC MODELS**
Th.E.O.14, W.H.O.8, W.H.O.9, W.H.O.16, W.H.O.17, Th.P.27, W.H.P.9, W.H.P.14
- SOCIOECONOMIC STATUS**
M.A.O.41, T.A.O.18, M.A.P.53, W.A.P.1, W.A.P.25, M.D.P.29, W.D.P.60, D.690, Th.E.O.15, M.E.P.13, W.E.P.51, Th.E.P.5, Th.E.P.19, E.637, W.G.O.22, M.G.P.18, W.G.P.20
- SOMATOSTATIN**
W.B.P.43
- SOMATOSTATIN ANALOG**
M.C.P.112
- SPECIMEN BANK**
Th.E.P.70
- SPERMICIDES**
M.A.O.38, M.A.O.37, Th.A.O.15, W.A.P.102, D.544, T.E.P.61
- SPINAL CORD**
W.C.P.55
- SPLEEN**
W.B.O.12, M.B.P.377, T.B.P.272, T.B.P.273, T.B.P.275, B.524
- S-POLYSACCHARIDES**
W.C.O.23
- STAFF STRESS**
see Health care personnel
- STAGES**
see Progression
- STAPHYLOCOCCUS AUREUS**
M.B.P.72, M.B.P.287
- STD**
see Sexually transmitted diseases
- STIGMA**
A.554, D.631, M.E.P.3, Th.E.P.44, E.504, E.554, T.F.O.3, T.F.P.9
- STRAIN VARIATION**
Th.A.P.114, M.C.O.6, M.C.O.9, M.C.O.20, T.C.O.37, T.C.O.41, Th.C.O.28, M.C.P.87, T.C.P.91, T.C.P.111, T.C.P.122, T.C.P.124, W.C.P.96, Th.C.P.11, Th.C.P.17, Th.C.P.50, Th.C.P.71, Th.C.P.74, Th.C.P.76, Th.C.P.85, Th.C.P.91, Th.C.P.120, Th.C.P.125, C.643, C.659, C.696, M.F.P.3
- STRAINS, VIRULENCE**
T.C.P.94, T.C.P.134, W.C.P.2, W.C.P.7, Th.C.P.100, Th.C.P.116, Th.C.P.117, C.646
- STREET KIDS**
see Adolescents
- STREPTOMYCIN**
Th.B.P.61
- SUBSTANCE ABUSE (NON-INTRAVENOUS)**
M.A.P.56, T.A.P.32, T.A.P.48, A.516, M.B.P.256, W.B.P.197, W.B.P.210, W.B.P.217, Th.B.P.331, Th.B.P.380, C.711, W.D.O.4, M.D.P.24, T.D.P.51, W.D.P.61, W.D.P.82, Th.D.P.83, Th.D.P.84, Th.D.P.75, Th.D.P.85, D.587, D.604, D.706, E.726
see also Alcohol; Intravenous drug users; Nitrite inhalants
- SUGAR ANALOGUES**
M.C.O.18, M.C.P.93, M.C.P.134, M.C.P.141, Th.C.P.43
- SUGAR**
see Oligosaccharides
- SUCIDE**
A.554, M.B.P.383, W.B.P.214, D.676
- SULPHATED COMPOUNDS**
M.C.P.75, M.C.P.75, M.C.P.79, C.595, C.607, C.623
- SUPPORT GROUPS**
M.B.P.317, M.B.P.381, Th.B.P.35, C.617, M.D.P.52, W.D.P.7, W.D.P.18, Th.D.P.7, Th.D.P.54, D.546, D.554, D.565, D.568, D.571, D.576, D.588, D.602, D.617, D.645, D.649, D.651, D.687, D.704, D.720, M.E.O.16, M.E.O.28, W.E.O.6, M.E.P.1, M.E.P.51, W.E.P.16, Th.E.P.33, E.809, Th.F.PP.203, T.B.P.273, W.B.P.381, Th.B.P.349, B.531
- SURVEILLANCE**
M.A.O.5, M.A.O.6, M.A.O.11, M.A.O.21, T.A.O.6, T.A.O.8, T.A.O.10, T.A.O.26, T.A.O.27, W.A.O.1, W.A.O.2, W.A.O.14, W.A.O.17, W.A.O.29, Th.A.O.11, W.A.O.12, Th.A.O.14, M.A.P.2, M.A.P.3, M.A.P.4, M.A.P.10, M.A.P.16, M.A.P.17, M.A.P.61, M.A.P.64, M.A.P.117, T.A.P.5, T.A.P.25, T.A.P.35, T.A.P.37, T.A.P.56, T.A.P.61, T.A.P.65, T.A.P.66, T.A.P.68, T.A.P.69, T.A.P.70, T.A.P.71, T.A.P.72, T.A.P.75, T.A.P.77, T.A.P.79, T.A.P.80, W.A.P.4, W.A.P.10, W.A.P.12, W.A.P.15, W.A.P.18, W.A.P.20, W.A.P.25, W.A.P.28, W.A.P.29, W.A.P.35, W.A.P.50, W.A.P.63, W.A.P.86, W.A.P.119, Th.A.P.76, Th.A.P.115, Th.A.P.120, A.526, A.530, A.535, A.537, A.547, A.551, A.567, A.569, A.575, A.578, A.588, A.590, A.591, A.595, A.607, A.619, A.635, T.B.P.157, T.B.P.346, T.B.P.384, W.B.P.155, Th.B.P.44, B.541, B.533, B.546, W.G.O.13, W.G.O.25, T.G.P.2, Th.G.P.18, Th.G.P.28, G.502, W.H.P.15, Th.H.P.26

SURVEY

attitudes and knowledge
 W.A.O.20, W.A.O.26, W.A.O.27,
 W.A.O.28, M.A.P.53, M.A.P.60, T.A.P.19,
 W.A.P.85, W.A.P.91, W.A.P.97,
 W.A.P.115, W.A.P.117, Th.A.P.33, A.512,
 A.566, A.588, A.626, M.B.P.309, T.B.P.36,
 W.B.P.251, Th.B.P.30, C.618, M.D.O.3,
 M.D.O.8, M.D.O.11, M.D.O.13, M.D.O.15,
 M.D.O.16, T.D.O.24, T.D.O.29, Th.D.O.1,
 M.D.P.2, M.D.P.5, M.D.P.6, M.D.P.11,
 M.D.P.12, M.D.P.13, M.D.P.14, M.D.P.16,
 M.D.P.17, M.D.P.18, M.D.P.20, M.D.P.26,
 M.D.P.27, M.D.P.30, M.D.P.32, M.D.P.33,
 M.D.P.35, M.D.P.37, M.D.P.40, M.D.P.42,
 M.D.P.44, M.D.P.50, M.D.P.52, M.D.P.54,
 M.D.P.55, M.D.P.56, M.D.P.57, M.D.P.58,
 M.D.P.59, M.D.P.60, M.D.P.64, M.D.P.65,
 M.D.P.66, M.D.P.69, M.D.P.70, M.D.P.71,
 M.D.P.77, M.D.P.78, M.D.P.80, M.D.P.82,
 M.D.P.84, M.D.P.86, M.D.P.89, M.D.P.90,
 T.D.P.7, T.D.P.8, T.D.P.9, T.D.P.10,
 T.D.P.11, T.D.P.13, T.D.P.13, T.D.P.15,
 T.D.P.19, T.D.P.21, T.D.P.25, T.D.P.40,
 T.D.P.50, T.D.P.55, T.D.P.85, T.D.P.90,
 W.D.P.6, W.D.P.18, W.D.P.21, W.D.P.29,
 W.D.P.30, W.D.P.31, W.D.P.35, W.D.P.43,
 W.D.P.47, W.D.P.60, W.D.P.62, Th.D.P.8,
 Th.D.P.19, Th.D.P.20, Th.D.P.52,
 Th.D.P.72, Th.D.P.76, Th.D.P.80,
 Th.D.P.92, D.510, D.528, D.527, D.530,
 D.538, D.542, D.544, D.545, D.590, D.595,
 D.605, D.625, D.626, D.642, D.647, D.659,
 D.671, D.678, D.680, D.682, D.684, D.696,
 M.E.O.33, M.E.O.36, T.E.O.2, W.E.O.25,
 Th.E.O.3, Th.E.O.17, M.E.P.3, M.E.P.4,
 M.E.P.14, M.E.P.18, M.E.P.30, M.E.P.33,
 M.E.P.43, M.E.P.63, M.E.P.66, M.E.P.70,
 T.E.P.1, T.E.P.6, T.E.P.7, T.E.P.14,
 T.E.P.20, T.E.P.21, T.E.P.26, T.E.P.31,
 T.E.P.34, T.E.P.36, T.E.P.39, T.E.P.47,
 W.E.P.1, W.E.P.10, W.E.P.11, W.E.P.12,
 W.E.P.14, W.E.P.17, W.E.P.19, W.E.P.22,
 W.E.P.31, W.E.P.38, W.E.P.49, W.E.P.51,
 W.E.P.53, W.E.P.58, W.E.P.59, W.E.P.63,
 W.E.P.65, W.E.P.68, W.E.P.69, W.E.P.73,
 W.E.P.75, W.E.P.76, Th.E.P.10,
 Th.E.P.11, Th.E.P.13, Th.E.P.27,
 Th.E.P.28, Th.E.P.35, Th.E.P.39,
 Th.E.P.46, Th.E.P.48, Th.E.P.53,
 Th.E.P.56, Th.E.P.59, Th.E.P.74,
 Th.E.P.76, E.504, E.515, E.525, E.526,
 E.543, E.549, E.552, E.553, E.562, E.563,
 E.565, E.570, E.580, E.581, E.584, E.587,
 E.590, E.595, E.599, E.600, E.606, E.607,
 E.608, E.609, E.614, E.619, E.620, E.621,
 E.622, E.627, E.629, E.635, E.637, E.638,
 E.639, E.642, E.644, E.648, E.649, E.651,
 E.652, E.653, E.654, E.662, E.667, E.669,
 E.676, E.681, E.699, E.704, E.705, E.723,
 E.726, E.745, E.746, E.747, E.752, E.763,
 E.764, E.766, E.769, E.772, E.785, E.787,
 E.794, Th.F.O.7, W.F.P.1, W.F.P.3,
 Th.F.P.7, Th.F.P.14, M.G.O.13, M.G.O.14,
 M.G.O.18, W.G.O.21, W.G.O.27,
 Th.G.P.16, Th.G.P.20, Th.H.P.29,
 Th.H.P.30

methodology

Th.A.O.13, Th.A.O.14, T.A.P.26,
 Th.A.P.39, T.B.P.358, W.B.P.61,
 W.B.P.240, W.B.P.270, M.D.O.8,
 T.D.O.11, M.D.P.37, M.D.P.52, M.D.P.65,
 T.D.P.90, W.D.P.73, D.537, D.587, D.588,
 D.679, M.E.O.36, Th.E.P.50, E.614, E.648,
 E.661, E.711, T.F.O.13, W.F.O.7, Th.P.28

SURVIVAL

T.A.O.36, M.A.P.91, M.A.P.108, W.A.P.34,
 W.A.P.85, W.A.P.75, W.A.P.77, W.A.P.78,
 W.A.P.80, W.A.P.81, W.A.P.82, W.A.P.83,
 A.550, A.563, A.608, M.B.O.45, M.B.O.46,
 T.B.O.11, T.B.O.27, W.B.O.39, T.B.P.18,
 T.B.P.31, T.B.P.77, W.B.P.333,
 W.B.P.337, W.B.P.345, W.B.P.347,
 W.B.P.352, W.B.P.354, W.B.P.358,
 W.B.P.363, W.B.P.366, Th.B.P.48,
 Th.B.P.63, T.E.P.25, W.G.O.2, Th.P.4,
 Th.H.P.16

SURVIVORS

T.B.P.77, D.566

SUSCEPTIBILITY

Th.A.P.83, Th.B.P.366

SYNERGY

M.C.P.42, M.C.P.55, M.C.P.87, M.C.P.97,
 M.C.P.110, M.C.P.128, C.620

SYNTHETASE, 2-5A

Th.B.O.26

SYPHILIS

Th.A.O.18, M.A.P.18, M.A.P.56, M.A.P.71,
 M.A.P.90, T.A.P.90, W.A.P.7, W.A.P.45,
 W.A.P.84, A.543, M.B.O.33, M.B.O.34,
 M.B.O.35, T.B.P.371, W.B.P.49, W.B.P.50,
 W.B.P.51, W.B.P.52, W.B.P.53, W.B.P.54,
 W.B.P.55, W.B.P.56, W.B.P.57, W.B.P.58,
 W.B.P.59, M.C.P.133, Th.G.O.28,
 T.G.P.32, W.G.P.1

see also Sexually transmitted diseases

SYSTEMIC LUPUS

ERYTHEMATOSUS

Th.B.P.180

T CELLS, UNSPECIFIED

M.B.P.8, M.B.P.220, T.B.P.86, T.B.P.208,
 W.B.P.76, W.B.P.316, Th.B.P.121,
 Th.B.P.156, Th.B.P.158, Th.B.P.163,
 Th.B.P.167, Th.B.P.240, B.621

see also CD4, CD8

TARGET CELLS

B.558, M.C.O.17, M.C.O.29, T.C.O.18,
 W.O.C.8, T.C.P.8, T.C.P.99, T.C.P.123,
 T.C.P.143, W.C.P.39, W.C.P.90,
 W.C.P.91, W.C.P.100, W.C.P.106,
 W.C.P.117, W.C.P.132, Th.C.P.17,
 Th.C.P.101, Th.C.P.134, Th.C.P.135,
 C.596, C.598

TEARS

Th.B.P.130

TEENAGERS

see Adolescents

TERMINAL CARE

see Palliative care

TESTING

see Serologic tests

TESTIS/EPIDIDYMIS

W.C.P.100

THERMOGRAPHY

W.B.P.242

THROMBOCYTOPENIA

M.A.P.88, M.B.O.49, W.B.O.7, W.B.O.8,
 W.B.O.9, W.B.O.10, W.B.O.11, W.B.O.12,
 M.B.P.248, M.B.P.249, T.B.P.269,
 T.B.P.270, T.B.P.271, T.B.P.272,
 T.B.P.273, T.B.P.274, T.B.P.275,
 T.B.P.276, T.B.P.277, T.B.P.278,
 T.B.P.308, W.B.P.310, W.B.P.349, B.509,
 B.516, B.518, B.584, B.606, M.C.P.78,
 W.C.P.99, C.729

THROMBOTIC

THROMBOCYTOPENIC PURPURA

(TTP)

B.579

THYMOPENTIN

C.556

THYMIDINE KINASE

W.B.P.92

THYMUS

T.B.P.370, M.C.O.30, W.C.P.110, C.715

TOLERANCE

Th.B.O.8, T.B.P.255, T.B.P.310,
 T.B.P.320, W.B.P.30, B.597, W.E.O.12,
 M.F.O.18

TOXOPLASMA

M.B.O.36, M.B.O.37, M.B.P.225,
 M.B.P.226, M.B.P.264, T.B.P.47, T.B.P.48,
 W.B.P.23, W.B.P.24, W.B.P.25, W.B.P.26,
 W.B.P.27, W.B.P.28, W.B.P.29, W.B.P.30,
 W.B.P.31, W.B.P.32, W.B.P.33, W.B.P.34,
 W.B.P.35, Th.B.P.205, Th.B.P.213,
 Th.B.P.246, B.563, W.C.P.63, C.763

TRAINING

see Health care personnel

TRANSFUSIONS

M.A.O.7, M.A.O.10, M.A.P.31, M.A.P.34,
 M.A.P.107, Th.A.P.60, Th.A.P.105,
 M.B.P.158, M.B.P.166, M.B.P.277,
 T.B.P.167, T.B.P.323, T.B.P.324,
 T.B.P.325, T.B.P.344, T.B.P.346,
 T.B.P.353, T.B.P.356, T.B.P.360,
 W.B.P.85, W.B.P.285, W.B.P.345,
 W.B.P.375, B.636, Th.H.P.27

see also Blood banks

TRANSGENES

W.C.P.22, C.670

TRANSIENT SEROPOSITIVITY

T.B.P.164

TRANSMISSION

anal sex

T.A.P.117, Th.A.P.55, A.569, B.627, D.692

blood products

MA.O.7, MA.O.8, MA.O.10, Th.A.O.19,
Th.A.O.31, MA.P.21, MA.P.33, MA.P.35,
MA.P.37, MA.P.39, MA.P.44, MA.P.107,
TAP.106, Th.A.P.81, M.B.P.150,
M.B.P.151, M.B.P.154, M.B.P.160,
M.B.P.161, M.B.P.169, M.B.P.369,
T.B.P.193, T.B.P.194, Th.B.P.199, B.517,
Th.C.P.21, T.D.P.83, W.D.P.10, T.E.P.19,
E.623, E.666, E.683, T.G.P.8, Th.H.P.22

dynamics

MA.O.23, T.A.O.13, T.A.O.15, T.A.O.16,
W.A.O.5, M.A.P.21, T.A.P.83, T.A.P.93,
T.A.P.94, T.A.P.95, T.A.P.116, W.A.P.3,
W.A.P.12, W.A.P.20, Th.A.P.52,
Th.A.P.54, Th.A.P.65, Th.A.P.73, A.515,
A.524, A.605, A.635, T.B.P.194, T.G.O.24,
T.G.P.18, Th.G.P.18, Th.H.P.30,
W.H.P.16, W.H.P.18, Th.H.P.22, Th.H.P.23

intravenous drug users

MA.O.38, TAP.39, TAP.51, TAP.56,
TAP.111, WAP.21, WAP.88,
Th.A.P.19, Th.A.P.55, Th.A.P.73, A.543,
Th.D.P.53, Th.D.P.55, E.623, E.800,
E.801, Th.G.O.50

occupational

W.A.O.1, W.A.O.2, M.A.P.32, Th.A.P.44,
Th.A.P.47, Th.A.P.48, A.503, A.618,
M.B.P.138, M.C.O.7, M.D.P.42, M.D.P.72,
M.D.P.88, E.521, E.683, E.752, E.757,
M.F.P.8

organ transplants

B.520

prophylaxis

M.B.P.214, B.585, M.H.P.26

vaginal sex

MA.O.33, T.A.O.14, T.A.O.15, T.A.O.19,
Th.A.O.15, Th.A.O.19, M.A.P.58, T.A.P.3,
T.A.P.4, T.A.P.87, T.A.P.103, T.A.P.105,
T.A.P.108, T.A.P.110, T.A.P.111,
T.A.P.115, WAP.21, Th.A.P.55, A.507,
A.543, A.569, A.606, M.B.P.57, T.B.P.200,
B.502, T.C.P.99, Th.C.P.147, C.652,
W.D.P.36, W.D.P.41, W.D.P.53,
Th.E.P.34, E.521, E.623, M.G.P.21,
Th.H.P.23

vertical (including perinatal)

W.A.O.10, W.A.O.17, Th.A.O.3, Th.A.O.4,
Th.A.O.6, Th.A.O.7, Th.A.O.8, Th.A.O.19,
M.A.P.25, W.A.P.47, W.A.P.49, W.A.P.50,
W.A.P.51, Th.A.P.15, A.542, A.604, A.606,
M.B.O.1, M.B.O.2, M.B.O.3, M.B.O.4,
M.B.O.5, M.B.O.6, M.B.O.40, M.B.O.42,
W.B.O.2, M.B.P.1, M.B.P.2, M.B.P.10,
M.B.P.12, M.B.P.17, M.B.P.20, M.B.P.24,
M.B.P.26, M.B.P.33, M.B.P.318,
T.B.P.115, T.B.P.162, T.B.P.163,
T.B.P.165, T.B.P.166, T.B.P.167,
T.B.P.173, T.B.P.174, T.B.P.178,
T.B.P.181, T.B.P.182, T.B.P.184,
T.B.P.185, T.B.P.186, T.B.P.189,
T.B.P.193, T.B.P.194, T.B.P.195,
T.B.P.196, T.B.P.200, T.B.P.201,
T.B.P.202, T.B.P.204, T.B.P.205,
T.B.P.208, T.B.P.209, T.B.P.210,
T.B.P.211, T.B.P.214, T.B.P.221,
T.B.P.227, T.B.P.229, T.B.P.233,

T.B.P.235, T.B.P.237, T.B.P.239,
T.B.P.240, T.B.P.242, T.B.P.244,
T.B.P.245, T.B.P.249, T.B.P.257,
T.B.P.264, T.B.P.362, T.B.P.378,
W.B.P.382, B.503, B.540, B.575, B.585,
B.586, B.590, B.512, B.625, B.646,
T.C.P.55, T.C.P.100, W.C.P.16, W.C.P.25,
W.C.P.95, Th.C.P.7, W.D.P.43, W.E.P.74,
Th.E.P.23, Th.E.P.58, E.800, T.F.O.18,
T.F.O.19, T.F.P.12, W.F.P.6, M.G.O.26,
W.G.O.1, W.G.O.2, W.G.O.3, W.G.O.4,
Th.G.O.34, Th.G.O.50, Th.G.O.52,
Th.G.O.53, Th.G.O.54, M.G.P.9, M.G.P.27,
T.G.P.31, W.G.P.8, Th.G.P.17, Th.G.P.27,
G.517, Th.H.P.22

other

W.A.O.5, Th.A.O.17, Th.A.O.20, M.A.P.51,
TAP.13, TAP.17, TAP.27, TAP.85,
TAP.92, TAP.96, TAP.98, W.A.P.4,
W.A.P.39, W.A.P.48, W.A.P.52, Th.A.P.66,
A.533, A.602, M.B.O.3, M.B.P.1, T.B.P.19,
T.B.P.164, W.B.P.266, Th.B.P.338, B.501,
B.502, B.557, M.C.O.29, W.C.P.86,
W.C.P.100, Th.C.P.81, C.651, C.781,
T.D.P.83, D.725, T.E.P.14, W.G.P.29,
W.H.P.22

see also Breastfeeding; Sexual behaviour;
Health care personnel

TRANSPLANTATION

M.B.P.279, T.B.P.38, T.B.P.285,
W.B.P.319, B.520, W.C.P.31

TRANSVESTITES

T.A.P.17

TREATMENT COSTS

see Costs

TRIMETHOPRIM-
SULFAMETHOXAZOLE

T.B.O.4, T.B.O.6, T.B.O.26, T.B.P.26,
T.B.P.32, T.B.P.33, T.B.P.34, T.B.P.37,
T.B.P.44, T.B.P.68, T.B.P.69, T.B.P.316,
T.B.P.318, T.B.P.320, T.B.P.324,
Th.B.P.117, B.584, B.601, B.647

TRIMETREXATE

T.B.O.28

TROPICAL SPASTIC PARAPARESIS
(TSP)

Th.A.O.31, C.725

TUBERCULOSIS

see Mycobacterial infections

TUMOUR NECROSIS FACTOR

A.820, Th.B.O.30, Th.B.P.79, Th.B.P.98,
M.C.O.28, T.C.O.12, W.C.O.8, M.C.P.101,
T.C.P.14, T.C.P.34, T.C.P.40, W.C.P.68,
W.C.P.77, W.C.P.78, W.C.P.82, W.C.P.83,
W.C.P.85, W.C.P.87, W.C.P.107,
W.C.P.114, W.C.P.115, Th.C.P.29, C.518,
C.525, C.713

TUMOURS

M.B.P.284, T.B.P.259, Th.C.O.40,
W.C.P.22, W.C.P.50, W.C.P.53, C.511,
C.702

ULCERS

MA.O.35, TAP.102, M.B.P.50, M.B.P.57,
M.B.P.177, M.B.P.244, M.B.P.275

ULTRASONOGRAPHY

M.B.P.17, M.B.P.255, M.B.P.259,
T.B.P.146, B.533

ULTRASTRUCTURE

M.B.P.136, W.B.P.123, Th.B.P.251,
W.C.P.118, C.700, C.784, C.784

URINE

M.B.P.35, M.B.P.74, M.B.P.267,
M.B.P.274, M.B.P.339, W.B.P.9, W.B.P.11,
C.650

URINE ANTIBODIES

W.B.P.142, W.B.P.159

UTILIZATION PATTERNS

M.H.O.14, Th.O.3, Wh.O.14, M.H.P.5,
M.H.P.6, M.H.P.18, Th.P.1, Th.P.23

VACCINE

chimpanzee

M.C.O.26

development methodology

M.C.P.32, M.C.P.34, M.C.P.35, M.C.P.48,
M.C.P.149, C.923, C.742

evaluation

M.C.P.3, M.C.P.8, M.C.P.11, M.C.P.12,
M.C.P.14, M.C.P.24, M.C.P.27, M.C.P.45,
M.C.P.48, W.C.P.11

FeLV

M.C.P.2

gp 120

Th.C.O.33, M.C.P.12, M.C.P.14

idiotypic

MA.O.13, M.C.O.26

peptides

M.C.O.26, M.C.P.13, C.544

rENV

Th.B.P.104, Th.C.O.32, Th.C.O.48,Th.C.O.50, M.C.P.8, M.C.P.36, M.C.P.37

rGAG

T.C.P.77, W.C.P.5

rhesus

Th.C.O.45, Th.C.O.48

SiV

W.C.O.48, Th.C.O.45, M.C.P.27

Ty:HiV

T.A.P.18, C.530

vaccinia recombinants

M.C.O.26, T.C.O.34, W.C.O.14,
Th.C.O.34, Th.C.O.47, M.C.P.10,
M.C.P.11, M.C.P.16, M.C.P.17, M.C.P.23,
M.C.P.26, M.C.P.31, M.C.P.36, M.C.P.47,
T.C.P.2, T.C.P.5, T.C.P.24, W.C.P.5,
W.C.P.10, W.C.P.79, Th.C.P.95,
Th.C.P.96, Th.C.P.110, Th.C.P.130, C.524

volunteers

Th.A.P.88, D.559, D.580, W.E.O.12, E.702
whole HIV

Th.C.O.46, M.C.P.44

other

Th.B.O.44, Th.B.P.104, Th.B.P.120,
M.C.O.26, Th.C.O.49, W.C.P.11, W.G.O.3

see also Peptides

VAGINAL SECRETION

W.A.P.102, A.625, T.B.P.113

- VAGINAL SEX**
see Transmission
- VASCULAR LESIONS**
M.B.P.82
- VINBLASTINE**
M.B.O.21, M.B.P.368, T.B.P.290, Th.B.P.341
- VIRAL INTERFERENCE**
C.755
- VIRAL MORPHOLOGY**
M.C.O.23, T.C.O.4, Th.C.O.21, T.C.P.70, Th.C.P.145, C.780, C.778
- VIRUS-LIKE INFECTIOUS AGENTS (VLIAs)**
C.738
- VISNA**
W.C.P.71
- VITAMIN B12**
Th.B.O.40, Th.B.O.41, M.B.P.325, T.B.P.307, T.D.O.11
- VITAMIN D3**
Th.C.P.13
- VLIA**
see Virus-like infectious agents
- VOLUNTEERS**
M.A.O.24, M.A.O.25, W.A.O.11, M.A.P.22, M.A.P.82, M.A.P.88, Th.A.P.38, W.D.P.80, Th.C.O.38, M.C.P.32, W.E.O.3, M.E.P.45, M.E.P.64, M.E.P.65, T.E.P.63, T.E.P.66, Th.E.P.45, Th.E.P.69, Th.E.P.71, E.532, E.533, E.536, E.680, E.703, E.761, E.809, M.G.P.10, Th.G.P.3, Th.P.2
- WEIGHT LOSS**
see Cachexia
- WOMEN**
M.A.O.18, M.A.O.36, T.A.O.15, T.A.O.40, Th.A.O.12, Th.A.O.25, M.A.P.2, M.A.P.5, M.A.P.6, M.A.P.8, M.A.P.15, M.A.P.23, M.A.P.28, T.A.P.28, T.A.P.40, T.A.P.47, T.A.P.93, T.A.P.105, T.A.P.108, W.A.P.3, W.A.P.6, W.A.P.8, W.A.P.10, W.A.P.11, W.A.P.56, W.A.P.65, Th.A.P.11, Th.A.P.39, A.507, A.512, A.542, A.546, A.558, A.563, A.606, A.625, M.B.P.29, M.B.P.59, M.B.P.108, M.B.P.276, M.B.P.282, M.B.P.297, T.B.P.95, T.B.P.113, C.590, T.D.O.17, T.D.O.25, W.D.O.1, W.D.O.2, W.D.O.4, W.D.O.6, Th.D.O.8, Th.D.O.10, Th.D.O.15, M.D.P.4, T.D.P.18, T.D.P.75, W.D.P.16, W.D.P.20, W.D.P.38, W.D.P.40, W.D.P.42, W.D.P.44, W.D.P.47, W.D.P.48, W.D.P.49, W.D.P.50, W.D.P.51, W.D.P.53, W.D.P.54, W.D.P.55, W.D.P.56, W.D.P.57, W.D.P.59, W.D.P.60, W.D.P.90, Th.D.P.1, Th.D.P.2, Th.D.P.3, Th.D.P.5, Th.D.P.6, Th.D.P.7, Th.D.P.9, Th.D.P.10, Th.D.P.11, Th.D.P.12, Th.D.P.13, Th.D.P.15, Th.D.P.16, Th.D.P.17, Th.D.P.18, Th.D.P.24, Th.D.P.25, Th.D.P.26, Th.D.P.27, Th.D.P.28, Th.D.P.60, Th.D.P.86, D.541, D.587, D.612, D.683, D.687, D.688, D.689, D.690, D.691, D.692, D.694, D.696, D.696, D.706, D.715, T.E.O.3, W.E.O.24, M.E.P.40, M.E.P.67, T.E.P.35, T.E.P.52, W.E.P.41, Th.E.P.59, Th.E.P.59, E.505, E.512, E.520, E.549, E.742, W.F.P.8, W.G.O.22, Th.G.P.19, Th.G.P.24, Th.G.P.26, G.515, M.H.P.25, Th.H.P.15, Th.H.P.21, Th.H.P.23
- ZIDOVUDINE**
acyclovir
M.B.O.46, M.B.O.50, M.B.P.47, M.B.P.352, W.B.P.318, W.B.P.321, W.B.P.350
anemia
M.B.O.48, M.B.P.328, M.B.P.358, T.B.P.268, T.B.P.306, T.B.P.308, T.B.P.324, T.B.P.325, W.B.P.338, W.B.P.356, W.B.P.368, W.B.P.375, B.648
behaviour
W.B.O.9, M.B.P.354, W.B.P.317, W.B.P.332, W.B.P.373, C.610, W.D.P.19, W.D.P.77
brain
W.B.P.24, W.B.P.255, W.B.P.341, Th.B.P.194, W.C.P.24
children
M.B.O.43, W.B.O.2, M.B.P.324, M.B.P.369, T.B.P.247, T.B.P.248, T.B.P.250, T.B.P.251, T.B.P.252, T.B.P.253, T.B.P.254, T.B.P.255, W.B.P.183
cytomegalovirus
M.B.P.116, M.B.P.128
combined treatments
W.B.O.4, W.B.O.5, M.B.P.128, M.B.P.338, M.B.P.340, M.B.P.341, M.B.P.368, T.B.P.43, T.B.P.46, T.B.P.46, T.B.P.77, T.B.P.257, T.B.P.278, T.B.P.291, T.B.P.322, T.B.P.381, W.B.P.319, W.B.P.319, W.B.P.320, W.B.P.322, W.B.P.323, W.B.P.324, W.B.P.327, W.B.P.329, W.B.P.330, W.B.P.335, W.B.P.374, Th.B.P.309, M.C.P.52, M.C.P.113, M.C.P.116, M.C.P.125, C.557, C.592, C.620
cyclic adenosine
M.B.P.358
d/d
Th.B.O.4, C.592, C.620
dose
M.B.P.324, M.B.P.342, T.B.P.306, T.B.P.326, W.B.P.326, W.B.P.345, W.B.P.346, W.B.P.351, W.B.P.362, M.C.P.83, Th.C.P.98, C.633
economy
W.H.O.10, M.H.P.1, M.H.P.2
foscarnet
W.H.O.12, M.B.P.47, M.B.P.128, C.592, C.620
hepatitis B virus
M.B.P.362
IFN
M.B.P.353, T.B.P.279, T.B.P.381, W.B.P.321, W.B.P.322, W.B.P.323, W.B.P.326, M.C.P.97
in asymptomatic disease
T.A.P.115, M.B.O.50, W.B.O.1, M.B.P.346, M.B.P.352, W.B.P.322, W.B.P.325, W.B.P.332, W.B.P.368
- in vitro
M.B.P.353, Th.B.P.106, T.C.O.7, M.C.P.42, M.C.P.50, M.C.P.55, M.C.P.87, M.C.P.96, M.C.P.114, T.C.P.3, T.C.P.58, Th.C.P.79, Th.C.P.98, C.570, C.593, C.621
- ITP**
T.B.P.270, T.B.P.271, T.B.P.273, T.B.P.306
- intravenous drug users**
M.B.P.361, W.B.P.336, W.B.P.373, Th.B.P.164
Kaposi's sarcoma
M.B.P.365, T.B.P.279, T.B.P.291, T.B.P.293, T.B.P.331, T.B.P.380, W.B.P.326, W.B.P.359
kinetics
W.B.O.1, W.B.O.2, W.B.O.3, W.B.O.4, W.B.O.5, M.B.P.9, M.B.P.13, M.B.P.15, M.B.P.22, M.B.P.323, M.B.P.324, M.B.P.331, M.B.P.332, M.B.P.334, M.B.P.338, M.B.P.340, M.B.P.341, M.B.P.343, M.B.P.344, Th.B.P.198, Th.B.P.204, M.C.P.54, M.C.P.64, M.C.P.94, M.C.P.98, W.C.P.81, Th.C.P.88
levels
W.B.O.4, M.B.P.331, M.B.P.336, M.B.P.337, M.B.P.339, M.B.P.342, M.B.P.344, M.B.P.345, W.B.P.360, Th.B.P.204, Th.C.P.88
mechanism
M.B.P.345, B.582, Th.C.O.21, M.C.P.120, Th.C.P.79
monitor
Th.A.P.72, Th.B.O.26, M.B.P.346, T.B.P.313, W.B.P.332, W.B.P.337, W.B.P.354, W.B.P.363, M.C.P.126, T.C.P.67, Th.C.P.138, T.E.P.45
neurology
T.B.P.248, T.B.P.299, W.B.P.255, W.B.P.331, Th.B.P.197, Th.B.P.210, Th.B.P.215, Th.B.P.218, Th.B.P.268, Th.B.P.278, C.610
Pneumocystis carinii pneumonia
T.B.P.73, W.B.P.347
Pneumocystis carinii pneumonia suppression
W.B.P.358
pregnancy
M.B.P.9, M.B.P.13, M.B.P.15, M.B.P.22
quality of life
T.B.P.325, T.B.P.329, W.B.P.167, W.B.P.337, W.B.P.360, W.B.P.384, C.633, D.674
resistance
M.B.P.350, M.C.P.50, T.C.P.111, Th.C.P.74, Th.C.P.76
semen
T.C.P.28, E.548
side effects
Th.A.P.45, M.B.O.47, M.B.O.49, M.B.O.50, W.B.O.6, M.B.P.37, M.B.P.189, M.B.P.235, M.B.P.239, M.B.P.325, M.B.P.326, M.B.P.329, M.B.P.330, M.B.P.335, M.B.P.337, M.B.P.363, M.B.P.364, M.B.P.367, T.B.P.249, T.B.P.253, T.B.P.268, T.B.P.277, T.B.P.305, T.B.P.307, T.B.P.308, T.B.P.310, T.B.P.314, T.B.P.315, T.B.P.321,

T.B.P.322, T.B.P.326, T.B.P.327,
 T.B.P.329, W.B.P.326, W.B.P.328,
 W.B.P.334, W.B.P.337, W.B.P.338,
 W.B.P.342, W.B.P.345, W.B.P.349,
 W.B.P.355, W.B.P.356, W.B.P.358,
 W.B.P.359, W.B.P.361, W.B.P.362,
 W.B.P.363, W.B.P.369, Th.B.P.307, B.601,
 B.648, M.C.P.53, M.C.P.64, C.610

Toxoplasma

W.B.P.24

other

W.A.P.57, M.B.O.45, T.B.O.6, W.B.O.7,
 W.B.O.8, W.B.O.9, Th.B.O.26, M.B.P.104,
 M.B.P.235, M.B.P.342, M.B.P.346,
 M.B.P.347, M.B.P.348, M.B.P.351,
 M.B.P.355, M.B.P.356, M.B.P.359,
 M.B.P.360, M.B.P.363, M.B.P.364,
 M.B.P.365, M.B.P.370, T.B.P.49, T.B.P.74,
 T.B.P.274, T.B.P.285, T.B.P.311,
 T.B.P.312, T.B.P.323, T.B.P.328,
 W.B.P.155, W.B.P.333, W.B.P.338,
 W.B.P.339, W.B.P.340, W.B.P.343,
 W.B.P.344, W.B.P.352, W.B.P.353,
 W.B.P.355, W.B.P.357, W.B.P.360,
 W.B.P.364, W.B.P.365, W.B.P.366,
 W.B.P.367, W.B.P.369, W.B.P.370,
 W.B.P.371, W.B.P.372, W.B.P.373,
 Th.B.P.71, Th.B.P.115, Th.B.P.145,
 Th.B.P.194, Th.B.P.195, Th.B.P.308,
 B.597, B.606, T.C.O.42, Th.C.O.17,
 Th.C.O.18, M.C.P.53, M.C.P.70,
 M.C.P.109, M.C.P.132, W.C.P.29, C.512,
 C.584, C.618, C.640, W.F.P.9

ZINC

Th.B.P.303, Th.B.P.310, Th.B.P.315,
 M.C.P.56

ZOONOSIS

A.626, A.632, Th.B.P.316



Sous le patronage:
du Centre de recherches
pour le développement
international
de Santé et Bien-être social
Canada
de l'Organisation Mondiale
de la Santé

Sponsored by:
International Development
Research Centre
Health and Welfare Canada
World Health Organisation